P00001606T0076|0 9|Comparison
P00001606T0076|14 33|alkaline phosphatases
P00001606T0076|37 50|5-nucleotidase
P00008171T0000|13 19|aspects
P00008171T0000|30 47|hyperbilirubinemia
P00008997A0472|25 32|function
P00008997A0472|33 39|CSF PCO2
P00008997A0472|101 108|controls
P00008997A0472|140 144|slope
P00010943A0733|0 9|Flurazepam
P00010943A0733|87 94|practice
P00010943A0733|105 109|night
P00012653T0045|14 19|agents
P00013683A0210|18 27|CO2 removal
P00013683A0210|40 52|CO2 production
P00013683A0210|67 77|ventilation
P00015731A0090|11 24|administration
P00015731A0090|27 31|mg/kg
P00015731A0090|42 60|anhydrase inhibitors
P00015731A0090|61 73|acetazolamide
P00015731A0090|74 86|methazolamide
P00015731A0090|87 102|dichlorphenamide
P00015731A0090|103 111|sulthiame
P00015731A0090|177 184|increase
P00015731A0090|193 196|p CO2
P00015731A0090|199 206|decrease
P00015731A0090|223 227|blood
P00022143T0000|13 17|study
P00022143T0000|20 30|etoperidone
P00022143T0000|44 49|rabbit
P00023348A0601|10 15|polyps
P00024600A0522|11 26|HMG dosage regimen
P00024600A0522|44 53|advantages
P00024600A0522|86 98|dosage regimen
P00025557A0100|7 16|CO2 content
P00025557A0100|33 39|animals
P00025557A0100|59 68|body weight
P00027739T0000|0 28|Serum gamma glutamyltransferase
P00027739T0000|34 42|diagnosis
P00027739T0000|45 56|liver disease
P00027739T0000|59 64|cattle
P00027967A0207|2 9|contrast
P00027967A0207|19 30|HI antibodies
P00027967A0207|55 59|onset
P00027967A0207|62 68|illness
P00027967A0207|79 86|patients
P00027967A0207|95 103|formation
P00027967A0207|122 131|antibodies
P00027967A0207|146 151|levels
P00027967A0207|170 174|onset
P00027967A0207|176 182|illness
P00029555A0861|7 15|exception
P00029555A0861|18 27|virus assay
P00029555A0861|31 42|quantitation
P00029555A0861|48 54|methods
P00029555A0861|101 133|shellfish microbiology laboratories
P00029953T0045|0 14|Characteristics
P00029953T0045|17 30|lipase activity
P00030183T0000|0 7|Takayasu
P00030183T0000|9 15|disease
P00030183T0000|16 26|association
P00030183T0000|31 36|HLA-B5
P00030937A0119|15 47|alkaline phosphatase concentrations
P00030937A0119|72 79|subjects
P00033873T0001|0 26|Gamma glutamyl transpeptidase
P00033873T0001|33 40|activity
P00033873T0001|52 56|fluid
P00034935A0545|0 7|Patients
P00034935A0545|12 20|Parkinson
P00034935A0545|22 28|disease
P00034935A0545|50 58|incidence
P00034935A0545|61 69|psychoses
P00034935A0545|76 88|drug treatment
P00038408T0000|9 19|stimulation
P00038408T0000|29 47|alpha-autoreceptors
P00038408T0000|57 65|treatment
P00038408T0000|70 85|alpha-methyldopa
P00039271T0000|12 17|action
P00039271T0000|20 27|diazepam
P00039271T0000|49 59|application
P00041512T0067|0 8|Abstracts
P00048373A0377|0 6|Removal
P00048373A0377|32 37|mucoas
P00048373A0377|60 66|absence
P00048373A0377|77 86|epithelium
P00050628A0202|17 26|gammopathy
P00050628A0202|41 45|serum
P00050628A0202|49 56|patients
P00050628A0202|72 82|proteinuria
P00050628A0202|94 100|patient
P00052597T0000|0 6|Studies
P00052597T0000|9 23|immunoglobulin E
P00052597T0000|27 32|impact
P00052597T0000|36 42|sojourn
P00052597T0000|47 60|Professor Dan H.
P00054900A0226|10 23|reaction stains
P00054900A0226|49 56|esterase
P00055040A0000|3 14|out-patients
P00055040A0000|19 36|pustulosis palmaris
P00055040A0000|70 87|immunofluorescence
P00055040A0000|90 98|technique
P00055040A0000|102 111|deposition
P00055040A0000|114 123|fibrinogen
P00055040A0000|135 153|degradation products
P00055040A0000|154 163|FR-antigen
P00055040A0000|225 232|fraction
P00055040A0000|237 248|cryoglobulin
P00055040A0000|256 271|plasma fibrinogen
P00055040A0000|277 281|blood
P00056837A0000|5 21|mediastinoscopies
P00056837A0000|73 83|operability
P00056837A0000|96 104|carcinoma
P00056901A0308|1 7|mixture
P00056901A0308|15 21|albumin
P00056901A0308|28 47|hydroxy-ethyl-starch
P00056901A0308|57 64|solution
P00056901A0308|68 75|dilution
P00060529A0695|12 23|control group
P00060529A0695|27 42|acquisition-rate
P00060529A0695|75 85|0acteriuria
P00060529A0695|98 103|figure
P00060529A0695|115 124|percentage
P00060529A0695|127 131|women
P00060529A0695|144 161|practice population
P00061478T0000|4 16|complications
P00061478T0000|19 33|catheterisation
P00061478T0000|48 56|nutrition
P00063680T0000|8 16|diagnosis
P00063680T0000|19 31|galactosaemia
P00064414A1098|0 4|Sings
P00064414A1098|36 49|erythropoiesis
P00066874T0000|21 47|fluid alpha fetoprotein levels
P00066874T0000|61 73|contamination
P00066874T0000|83 87|blood
P00066874T0000|88 94|results
P00066874T0000|99 108|experiment
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|16 24|diagnosis
P00072928T0000|27 42|haemochromatosis
P00073344A0367|3 10|subjects
P00073344A0367|14 35|phytomitogen reactivity
P00073344A0367|41 51|lymphocytes
P00073344A0367|68 76|treatment
P00074758T0000|0 7|Patients
P00074758T0000|18 31|hypothyroidism
P00083846T0000|0 6|Albumin
P00083846T0000|16 24|AMP levels
P00083846T0000|37 42|fluids
P00083846T0000|48 52|child
P00084275T0063|0 6|Preface
P00086313A0000|11 17|strains
P00086313A0000|20 31|Legionnaires
P00086313A0000|32 46|disease bacteria
P00086313A0000|87 92|groups
P00086313A0000|98 102|basis
P00086313A0000|105 112|findings
P00086313A0000|142 156|antibody testing
P00088391A0181|10 19|hand factor
P00088391A0181|22 29|activity
P00088391A0181|43 59|coumarin treatment
P00088391A0181|64 69|factor
P00088391A0181|72 78|antigen
P00089778A0000|3 15|concentration
P00089778A0000|18 37|alpha 2-macroglobulin
P00089778A0000|38 55|alpha 1-antitrypsin
P00089778A0000|56 66|plasminogen
P00089778A0000|67 79|C3-complement
P00089778A0000|80 108|fibrinogen degradation products
P00089778A0000|129 136|activity
P00089778A0000|159 164|humour
P00089778A0000|168 172|serum
P00089778A0000|181 188|patients
P00089778A0000|193 197|Fuchs
P00089778A0000|209 217|dystrophy
P00089778A0000|220 227|patients
P00089778A0000|251 258|cataract
P00089778A0000|290 305|cataract patients
P00092689A0352|13 20|patients
P00092689A0352|35 39|times
P00094639A0313|0 7|Prazosin
P00094639A0313|27 32|volume
P00094639A0313|43 50|patients
P00096241A0087|29 35|courses
P00096241A0087|40 45|groups
P00096241A0087|78 83|values
P00096241A0087|116 122|infants
P00096241A0087|130 134|weeks
P00096241A0087|146 156|term infants
P00097989A0106|13 20|analysis
P00097989A0106|23 36|treatment plans
P00097989A0106|42 49|patients
P00100540T0000|0 17|Aspirin intolerance
P00100540T0000|27 40|susceptibility
P00100540T0000|43 65|platelet cyclo-oxygenase
P00100540T0000|68 77|inhibition
P00100540T0000|80 86|aspirin
P00100791A0425|5 11|results
P00100791A0425|24 40|cynomolgus monkeys
P00100791A0425|87 99|rhesus monkeys
P00100791A0425|126 132|effects
P00100791A0425|135 144|norcocaine
P00101300A0257|2 6|cases
P00101300A0257|29 35|cancers
P00101300A0257|67 74|followup
P00101300A0257|75 79|years
P00101300A0257|88 92|years
P00101300A0257|95 100|months
P00105401A0635|3 8|effect
P00105401A0635|40 51|interference
P00105401A0635|54 74|thyroid hormone binding
P00105401A0635|126 138|clearance rate
P00105401A0635|140 154|thyroid hormones
P00105401A0635|173 183|maintenance
P00105401A0635|186 204|premedication levels
P00105903A0288|10 17|research
P00105903A0288|30 40|possibility
P00105903A0288|45 62|polyethylene glycol
P00111174A0351|26 35|properties
P00111174A0351|45 51|neurons
P00111174A0351|71 77|neurons
P00111174A0351|90 96|stimuli
P00111174A0351|111 117|neurons
P00111174A0351|141 147|stimuli
P00111174A0351|149 155|neurons
P00111174A0351|173 179|stimuli
P00112627A0542|0 12|Pentobarbital
P00112627A0542|24 28|mg/kg
P00112627A0542|44 54|combination
P00112627A0542|74 78|doses
P00112627A0542|81 93|normeperidine
P00112627A0542|98 102|mg/kg
P00112627A0542|103 113|anileridine
P00112627A0542|116 120|mg/kg
P00112627A0542|121 132|alphaprodine
P00112627A0542|135 139|mg/kg
P00112627A0542|143 150|fentanyl
P00112627A0542|154 158|mg/kg
P00113657A0628|0 5|Pb foil
P00113657A0628|10 14|gcm-2
P00113657A0628|37 47|improvement
P00114144A0189|28 32|study
P00114144A0189|56 69|result emphasis
P00114144A0189|85 94|hypotheses
P00114144A0189|114 125|similarities
P00114144A0189|138 159|glycogen storage disease
P00114144A0189|159 166|Andersen
P00114144A0189|168 174|disease
P00114144A0189|216 227|enzyme defect
P00115974A0576|3 8|groups
P00117748T0000|0 11|Erythromycin
P00117748T0000|15 35|clindamycin resistance
P00117748T0000|38 63|Corynebacterium diphtheriae
P00117748T0000|68 78|skin lesions
P00118044A0000|14 26|displacements
P00118044A0000|29 34|monkey
P00118044A0000|36 40|wrist
P00118044A0000|58 62|peaks
P00118044A0000|65 72|activity
P00118044A0000|73 79|terms M1
P00118044A0000|87 93|M3 peaks
P00118044A0000|111 121|EMG activity
P00118044A0000|136 142|muscles
P00118810T0001|9 15|disease
P00119339A0400|6 11|animal
P00119339A0400|74 86|T. cruzi stocks
P00119339A0400|91 96|strain
P00119339A0400|112 122|myocarditis
P00119339A0400|135 146|degeneration
P00119339A0400|150 156|lesions
P00119339A0400|162 171|oesophagus
P00122718A0500|3 10|majority
P00122718A0500|13 20|MRF units
P00122718A0500|86 93|activity
P00122718A0500|119 126|behavior
P00129659T0000|0 10|Variability
P00129659T0000|24 31|syndrome
P00129659T0000|31 40|trisomy-21
P00129659T0000|60 73|sex differences
P00131739T0001|18 24|indices
P00131739T0001|35 45|populations
P00131739T0001|48 57|Uzbekistan
P00133214T0064|3 10|concepts
P00133214T0064|26 33|function
P00136175A1137|3 13|maintenance
P00136175A1137|44 50|density
P00136175A1137|67 72|amount
P00136175A1137|75 82|exercise
P00136175A1137|99 106|exercise
P00136175A1137|142 152|enlargement
P00137671A0896|5 16|observations
P00137671A0896|50 59|VIII-ratio
P00137671A0896|76 84|indicator
P00137671A0896|100 110|coagulation
P00139624A0318|5 9|hours
P00139624A0318|18 31|administration
P00139624A0318|34 43|colchicine
P00139624A0318|47 69|serum ceruloplasmin level
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|19 30|pregnenolone
P00139827A0000|31 42|progesterone
P00139827A0000|43 64|dehydroepiandrosterone
P00139827A0000|72 88|alpha-hydroxy-DHA
P00139827A0000|88 94|estriol
P00139827A0000|98 105|cortisol
P00139827A0000|122 126|total
P00139827A0000|141 146|plasma
P00139827A0000|164 169|course
P00139827A0000|185 192|delivery
P00142718A0156|9 16|patients
P00142718A0156|40 46|changes
P00142718A0156|68 77|metastases
P00142718A0156|93 102|99mTc-EHDP
P00142718A0156|115 130|chest radiographs
P00146327A0147|3 10|majority
P00146327A0147|13 18|tumors
P00146327A0147|37 44|cavities
P00146327A0147|64 73|incidences
P00146327A0147|92 97|larynx
P00146327A0147|98 104|trachea
P00146327A0147|108 118|stem bronchi
P00149899T0001|0 9|Prediction
P00149899T0001|15 19|times
P00149899T0001|29 39|development
P00150066A0100|11 20|fibrinogen
P00150066A0100|33 43|coagulation
P00150066A0100|52 59|thrombin
P00150066A0554|16 27|haemorrhages
P00150066A0554|35 44|prostheses
P00154430A0906|3 19|Southern technique
P00154430A0906|35 46|localization
P00154430A0906|52 57|region
P00154430A0906|73 85|transcription
P00154430A0906|109 116|fragment
P00155973A0387|26 31|limits
P00155973A0387|43 48|errors
P00155973A0387|77 82|system
P00155973A0387|113 138|carbon dioxide concentration
P00155973A0387|204 215|gas flow rates
P00155973A0387|222 226|min-1
P00155973A0387|233 237|range
P00155973A0387|240 256|minute ventilation
P00155973A0387|261 265|min-1
P00159600A0871|59 68|compliance
P00159600A0871|94 102|ventricle
P00159600A0871|127 131|shift
P00159600A0871|151 155|curve
P00163384A0000|3 9|carcass
P00163384A0000|29 43|Bubo virginianus
P00163384A0000|78 84|Ontario
P00163384A0000|100 107|necropsy
P00167544A0067|27 41|microdissection
P00167544A0067|64 70|regions
P00167544A0067|111 128|electron microscopy
P00167544A0067|156 179|surface specimen technique
P00168176A0000|0 6|Patulin
P00168176A0000|22 39|apple butter samples
P00168176A0000|44 55|ethyl acetate
P00168176A0000|62 68|extract
P00168176A0000|83 97|silica gel column
P00168176A0000|116 122|acetate
P00168176A0000|132 137|eluant
P00168431T0000|0 18|Steroid glucuronides
P00168431T0000|29 33|fluid
P00172199A0270|3 8|matrix
P00172199A0270|23 30|clusters
P00172199A0270|50 59|morphology
P00172199A0270|74 83|appearance
P00172199A0270|100 114|cross striations
P00173860A0475|0 9|Riboflavin
P00173860A0475|25 34|percentage
P00173860A0475|54 60|animals
P00173860A0475|80 96|excretion patterns
P00173860A0475|114 122|magnitude
P00173860A0475|128 139|disturbances
P00173860A0475|142 152|elimination
P00173860A0475|178 182|acids
P00176742T0000|0 10|Polyglactin
P00176742T0000|14 29|suture absorption
P00176742T0000|52 58|enzymes
P00183063A0300|3 11|incidence
P00183063A0300|14 26|DNCB reactions
P00183063A0300|44 48|Stage
P00183063A0300|54 60|cancers
P00183063A0300|63 70|patinets
P00183063A0300|95 99|Stage
P00183063A0300|102 107|cancer
P00183063A0300|110 117|patients
P00183063A0300|134 141|patients
P00183063A0300|169 173|Stage
P00183063A0300|177 182|cancer
P00188387A0975|0 6|Studies
P00188387A0975|9 20|lipoproteins
P00188387A0975|42 49|children
P00188387A0975|54 61|families
P00188387A0975|92 103|heart disease
P00193088A0196|18 25|subjects
P00193088A0196|36 45|Metyrapone
P00193088A0196|52 60|responses
P00193587T0000|0 12|EEG theta waves
P00193587T0000|29 37|phenomena
P00193587T0000|39 44|review
P00193587T0000|48 55|analysis
P00196255A0000|0 14|REM dream content
P00196255A0000|27 36|categories
P00196255A0000|61 69|influence
P00196255A0000|79 88|hemisphere
P00196255A0000|113 125|verbalization
P00196255A0000|135 144|hemisphere
P00196255A0000|149 153|music
P00196255A0000|161 168|salience
P00196255A0000|169 179|bizarreness
P00198510T0000|0 10|Innervation
P00198510T0000|23 31|diaphragm
P00198510T0000|37 42|locust
P00198510T0000|43 59|Locusta migratoria
P00199012T0000|7 18|ACTH syndrome
P00199012T0000|31 46|thyroid carcinoma
P00201881A0487|9 15|finding
P00201881A0487|26 32|studies
P00201881A0487|45 55|correlation
P00201881A0487|63 68|PI ACTH
P00201881A0487|72 82|MSH contents
P00205074A0000|7 22|hypophosphatemia
P00205074A0000|55 61|rickets
P00209664A0836|10 20|correlation
P00209664A0836|28 34|serum LH
P00209664A0836|53 59|bone age
P00209664A0836|66 73|age group
P00209664A0836|94 104|correlation
P00209664A0836|131 147|parallel phenomena
P00210220X0000|9 22|neurochemistry
P00210220X0000|34 38|drugs
P00211881A0602|0 6|Efforts
P00211881A0602|29 34|amount
P00211881A0602|54 66|kidney lesions
P00211881A0602|119 124|action
P00216939T0001|0 5|Effect
P00216939T0001|8 15|succimer
P00216939T0001|21 29|intensity
P00216939T0001|45 70|acid dehydrogenase reactions
P00216939T0001|76 80|brain
P00216939T0001|109 116|chloride
P00219533T0001|0 11|Distribution
P00219533T0001|15 26|correlations
P00219533T0001|29 42|serum uric-acid
P00219533T0001|59 69|populations
P00219533T0001|89 93|women
P00219565A0172|3 11|incidence
P00219565A0172|14 30|hepatitis B antigen
P00219565A0172|40 50|transfusion
P00219674A0000|0 13|Technetium-99m
P00219674A0000|22 34|pyrophosphate
P00219674A0000|45 55|scintigrams
P00219674A0000|89 96|patients
P00219674A0000|106 110|weeks
P00219674A0000|111 115|range
P00219674A0000|142 151|infarction
P00221136A0984|8 17|phenomenon
P00221136A0984|39 44|humans
P00221725A0523|3 9|decline
P00221725A0523|15 22|activity
P00221725A0523|25 41|cytochrome oxidase
P00221725A0523|42 51|peroxidase
P00221725A0523|60 71|lipid content
P00221725A0523|84 94|neutrophils
P00221725A0523|109 116|decrease
P00221725A0523|132 139|activity
P00222102A0227|0 8|Treatment
P00222102A0227|12 19|patients
P00222102A0227|24 51|pseudohypoparathyroidism type
P00222102A0227|57 67|vitamin-D-3
P00222102A0227|72 99|alpha-Hydroxycholecalciferol
P00222102A0227|134 141|response
P00222102A0227|146 151|regard
P00222102A0227|157 169|normalisation
P00222102A0227|172 184|serum-calcium
P00222827A0000|0 6|Workers
P00222827A0000|11 21|sensitivity
P00222827A0000|31 42|diisocyanate
P00222827A0000|57 61|depth
P00222827A0000|65 71|attempt
P00222827A0000|83 92|mechanisms
P00222827A0000|104 118|hyperreactivity
P00224013A0661|28 33|groups
P00224013A0661|45 51|hypoxia
P00224013A0661|55 61|limb VO2
P00224013A0661|90 94|group
P00224013A0661|114 123|beta-Block
P00224013A0661|168 177|resistance
P00224013A0661|188 194|hypoxia
P00224013A0661|237 247|utilization
P00224013A0661|257 264|delivery
P00224013A0661|283 292|comparison
P00224013A0661|318 333|extraction ratios
P00224013A0661|349 356|pressure
P00224013A0661|401 425|beta-Vasodilator receptors
P00224013A0661|460 473|vasodilatation
P00224013A0661|489 495|hypoxia
P00225352T0000|21 31|alterations
P00225352T0000|37 46|metabolism
P00225352T0000|52 60|vitamin D3
P00225352T0000|81 88|rat liver
P00227393T0000|0 9|Modulation
P00227393T0000|12 45|25-hydroxyvitamin D3-24-hydroxylase
P00227393T0000|48 60|aminophylline
P00227393T0000|62 95|cytochrome P-450 monooxygenase system
P00227610A1593|11 18|respects
P00227610A1593|29 35|DBP mRNA
P00227610A1593|52 61|messengers
P00227610A1593|73 86|polyoma viruses
P00231555T0001|0 5|Effect
P00231555T0001|46 61|combination drugs
P00231555T0001|83 100|cortisol production
P00232354A0286|0 8|Serum ACTH
P00232354A0286|24 30|insulin
P00232354A0286|34 43|metyrapone
P00232456T0000|0 6|Anatomy
P00232456T0000|20 31|gene products
P00232456T0000|64 75|tumor viruses
P00232456T0000|86 93|leukemia
P00232456T0000|97 105|carcinoma
P00232456T0000|106 113|evidence
P00232456T0000|121 125|class
P00232456T0000|140 144|genes
P00234206T0000|0 7|Bertioga
P00234206T0000|8 17|Guama group
P00234206T0000|21 27|Anhembi
P00234206T0000|28 42|Bunyamwera group
P00234206T0000|49 59|arboviruses
P00234206T0000|70 77|Sao Paulo
P00234206T0000|78 83|Brazil
P00234264A0164|0 34|Gamma glutamyl transpeptidase activity
P00234264A0164|53 57|times
P00234264A0164|77 81|limit
P00234264A0164|84 91|children
P00234264A0164|103 113|aminopyrine
P00234264A0164|120 124|weeks
P00239014A0000|26 31|method
P00239014A0000|38 50|determination
P00239014A0000|92 102|blood plasma
P00239169T0000|0 23|Dopamine receptor blockade
P00239169T0000|30 41|neuroleptics
P00239169T0000|59 63|study
P00240518A0000|18 26|procedure
P00240518A0000|33 45|determination
P00240518A0000|51 75|fungicide 5-fluorocytosine
P00240518A0000|78 82|serum
P00242427T0001|3 7|field
P00242427T0001|10 15|stress
P00242427T0001|32 36|nurse
P00254537T0000|5 13|graduates
P00254537T0000|25 29|types
P00254537T0000|32 39|programs
P00254537T0000|49 59|state boards
P00261981A0434|17 33|serum somatomedin A
P00261981A0434|77 83|litters
P00264240A1843|3 11|sequences
P00264240A1843|24 39|X. borealis oocyte
P00264240A1843|50 56|5S genes
P00264240A1843|85 92|residues
P00264240A1843|112 120|T clusters
P00264240A1843|143 148|region
P00264240A1843|151 169|X. laevis oocyte 5S DNA
P00265964A0562|4 12|mechanism
P00265964A0562|34 46|grain boundary
P00267764A0651|4 9|report
P00267764A0651|30 36|reasons
P00267764A0651|40 56|treatment failures
P00267764A0651|73 82|philosophy
P00267764A0651|91 100|management
P00294502T0001|0 8|Diagnosis
P00294502T0001|12 28|treatment planning
P00294502T0001|31 37|Class II
P00294502T0001|38 45|division
P00300314A0132|16 25|infections
P00300314A0132|26 30|fever
P00300314A0132|53 73|degrees F. granulocytes
P00300314A0132|94 108|hospitalization
P00300314A0132|112 120|drug death
P00300314A0132|132 139|patients
P00300314A0132|144 160|calcium leucovorin
P00300314A0132|167 171|mg/m2
P00300314A0132|198 209|methotrexate
P00300314A0132|221 235|treatment cycles
P00303189A0247|26 30|drugs
P00303189A0247|37 43|patient
P00303189A0247|45 58|serum chemistry
P00303189A0247|79 86|efficacy
P00303189A0247|122 128|process
P00304240A0369|19 23|tests
P00304240A0369|43 50|presence
P00304240A0369|66 72|disease
P00304310A0000|3 11|end-stage
P00304310A0000|26 30|phase
P00304310A0000|54 64|retinopathy
P00304310A0000|76 88|stabilization
P00304310A0000|91 96|vision
P00304310A0000|104 110|periods
P00304806A0760|5 9|basis
P00304806A0760|12 36|serum alpha1AT quantitation
P00304806A0760|44 50|infants
P00304806A0760|72 77|groups
P00304806A0760|105 118|concentrations
P00313766A0666|2 9|patients
P00313766A0666|52 61|depression
P00313766A0666|64 71|function
P00313766A0666|80 86|control
P00313766A0666|86 90|range
P00316723A0558|0 6|Changes
P00316723A0558|9 18|body weight
P00316723A0558|31 38|behavior
P00321261A0104|10 17|response
P00321261A0104|20 34|prostaglandin E2
P00321261A0104|44 63|prostaglandin F2alpha
P00321261A0104|103 108|routes
P00321261A0104|136 141|phases
P00321261A0104|156 160|cycle
P00321261A0104|188 192|women
P00330364A0132|1 5|total
P00330364A0132|10 19|BCG strains
P00330364A0132|43 49|strains
P00330364A0132|62 69|cultures
P00330364A0132|88 92|batch
P00330364A0132|93 99|strains
P00330364A0132|112 120|abscesses
P00330364A0132|123 130|children
P00330364A0132|136 150|BCG-vaccination
P00330364A0132|155 161|strains
P00330364A0132|171 175|cases
P00330364A0132|181 195|BCG-vaccination
P00330364A0132|201 207|strains
P00330364A0132|227 238|laboratories
P00331128A0000|4 9|levels
P00331128A0000|12 26|serum calcitonin
P00331128A0000|38 45|patients
P00331128A0000|62 68|failure
P00331936T0000|0 8|Detection
P00331936T0000|26 35|antibodies
P00331936T0000|44 78|immunoperoxidase antiglobulin technic
P00336354A0543|3 10|response
P00336354A0543|13 19|serum GH
P00336354A0543|22 37|arginine infusion
P00336354A0543|73 84|hypoglycemia
P00336547A0000|3 15|mortality rate
P00336547A0000|36 43|features
P00336547A0000|46 63|Nocardia asteroides
P00336547A0000|67 96|Nocardia brasiliensis infections
P00336547A0000|138 150|C3H/eB origins
P00336547A0000|215 226|mouse strains
P00336547A0000|232 240|C57/BL/6J
P00336547A0000|241 255|New Zealand Black
P00336547A0000|256 261|BALB/c
P00336547A0000|262 268|CBA/LAC
P00336547A0000|272 277|C3H/eB
P00337102T0058|0 7|Williams
P00337102T0058|9 14|August
P00339289T0049|18 25|isotopes
P00339289T0049|30 38|chemistry
P00339289T0049|41 48|proteins
P00340692T0033|0 7|Emeritus
P00340692T0033|8 35|John Henri Roosegaarde Bisschop
P00342623A0228|9 16|vaccines
P00342623A0228|20 38|whole-virus vaccines
P00342623A0228|49 60|type B antigen
P00342623A0228|87 96|reactivity
P00350465T0000|9 17|diagnosis
P00350465T0000|34 42|disorders
P00352569A0000|7 18|oxygen supply
P00352569A0000|30 44|blood parameters
P00352569A0000|69 73|rates
P00352569A0000|83 87|mg/kg
P00352569A0000|103 111|endotoxin
P00354315T0000|7 17|dysfunction
P00354315T0000|20 27|patients
P00354315T0000|32 51|ataxia telangiectasia
P00358945A0225|10 15|period
P00358945A0225|18 26|treatment
P00358945A0225|63 67|weeks
P00361059T0000|1 5|study
P00361059T0000|22 29|efficacy
P00361059T0000|32 53|diflucortolone valerate
P00361059T0000|56 64|% ointment
P00361059T0000|68 87|clobetasol propionate
P00361059T0000|91 99|% ointment
P00361340A0529|9 17|phenomena
P00361340A0529|29 42|osteodystrophy
P00361340A0529|65 82|vitamin D deficiency
P00361340A0529|91 99|condition
P00361340A0529|100 109|deficiency
P00361340A0529|112 140|1,25-dihydroxycholecalciferol
P00361340A0529|155 166|significance
P00361340A0529|185 203|hyperparathyroidism
P00361340A0529|211 217|failure
P00369397A0280|13 20|LH levels
P00369397A0280|44 50|addicts
P00369397A0280|56 70|GnRH stimulation
P00369397A0280|74 80|addicts
P00369397A0280|89 96|LH values
P00369397A0280|134 141|controls
P00369683T0000|0 9|Adriamycin
P00369683T0000|10 19|comparison
P00369683T0000|29 36|schedule
P00369683T0000|48 55|schedule
P00369683T0000|61 69|treatment
P00369683T0000|72 83|breast cancer
P00377466A0188|9 16|controls
P00377466A0188|30 36|hormone
P00377466A0188|41 66|follicle stimulating hormone
P00377466A0188|71 79|prolactin
P00377466A0188|85 94|oestradiol
P00377466A0188|98 109|progesterone
P00377466A0188|115 126|testosterone
P00377466A0188|134 142|catabolic
P00377466A0188|145 156|healing phase
P00377466A0188|163 169|disease
P00378492A0475|0 11|Renin studies
P00378492A0475|37 44|patients
P00378492A0475|51 62|control group
P00378492A0475|67 76|recipients
P00378492A0475|87 95|elevation
P00378492A0475|98 116|plasma renin activity
P00378492A0475|122 143|plasma aldosterone level
P00378492A0475|199 212|artery stenosis
P00378735A0000|19 23|trial
P00378735A0000|40 47|patients
P00378735A0000|68 72|fever
P00378735A0000|81 85|blood
P00378735A0000|89 101|marrow culture
P00378735A0000|112 122|amoxycillin
P00378735A0000|126 139|dosage schedule
P00378735A0000|190 204|chloramphenicol
P00378735A0000|207 212|regard
P00378735A0000|226 244|temperature response
P00378735A0000|250 256|respect
P00378735A0000|259 266|carriers
P00378735A0000|270 281|relapse rates
P00381783T0000|0 29|Bone marrow transplantation-1979
P00383169A0000|6 12|article
P00383169A0000|24 30|actions
P00383169A0000|45 60|dopamine receptor
P00383169A0000|72 77|agents
P00383169A0000|78 88|apomorphine
P00383169A0000|95 105|derivatives
P00383169A0000|106 114|piribedil
P00383169A0000|115 134|rye-ergot derivatives
P00383169A0000|152 156|basis
P00383169A0000|193 202|properties
P00384744T0000|23 34|hypofunction
P00385457A0187|7 16|inhibition
P00385457A0187|19 24|pepsin
P00385457A0187|39 43|juice
P00385457A0187|69 77|influence
P00385457A0187|83 89|healing
P00385457A0187|100 104|ulcer
P00386251A0899|3 19|IDF standard method
P00386251A0899|26 34|detection
P00386251A0899|37 46|penicillin
P00386251A0899|74 82|detection
P00386251A0899|84 103|sulphonamide residues
P00390932T0001|8 15|antigens
P00393598A0198|3 8|course
P00393598A0198|11 24|endotoxin fever
P00397806T0039|4 16|Algerian cases
P00401521A0138|11 17|percent
P00401521A0138|20 27|patients
P00401521A0138|39 49|ticarcillin
P00401676A0414|18 24|staging
P00401676A0414|35 42|patients
P00401676A0414|71 82|radiotherapy
P00406585T0001|8 17|hematology
P00409927A0570|0 7|Neomycin
P00409927A0570|32 44|staphylococci
P00409927A0570|65 76|streptococci
P00409927A0570|125 133|organisms
P00411465A0142|26 32|section
P00411465A0142|51 60|trabeculae
P00411465A0142|66 72|contact
P00411465A0142|85 92|cavities
P00413854A0958|0 6|Changes
P00413854A0958|9 18|tissue PCO2
P00413854A0958|86 90|blood
P00414575T0000|10 19|evaluation
P00414575T0000|27 33|calculi
P00415543A0320|0 10|Recognition
P00415543A0320|13 21|emphysema
P00415543A0320|33 43|radiographs
P00415543A0320|56 62|quality
P00415543A0320|90 94|films
P00415543A0320|97 101|films
P00415543A0320|106 113|patients
P00415543A0320|132 142|lung disease
P00416758T0001|0 8|Isolation
P00416758T0001|11 28|T. gambiense strains
P00416758T0001|31 35|Zaire
P00416758T0001|44 53|adaptation
P00416758T0001|56 72|laboratory animals
P00417166T0000|15 21|profile
P00417166T0000|24 33|clonazepam
P00417166T0000|36 48|rhesus monkeys
P00417301T0001|11 20|mechanisms
P00417301T0001|30 40|brucellosis
P00417301T0001|43 48|humans
P00418341T0000|10 19|adaptation
P00418341T0000|30 34|parts
P00420460A0291|2 9|patients
P00420460A0291|34 46|drug treatment
P00420460A0291|47 76|log baseline plasma renin activity
P00420460A0291|80 85|change
P00420460A0291|92 104|blood pressure
P00423649A0259|5 14|techniques
P00423649A0259|33 38|people
P00423649A0259|46 50|years
P00423649A0259|56 60|claim
P00423649A0259|78 87|innovation
P00423649A0259|94 99|regard
P00425547A0000|2 9|patients
P00425547A0000|21 33|osteomyelitis
P00425547A0000|93 102|cephalexin
P00425547A0000|113 117|weeks
P00427715A0000|1 5|total
P00427715A0000|10 17|patients
P00427715A0000|22 28|Hodgkin
P00427715A0000|30 36|disease
P00427715A0000|54 62|diaphragm
P00427715A0000|63 68|Stages
P00427715A0000|97 112|radiation therapy
P00427715A0000|122 131|University
P00427715A0000|134 140|Florida
P00429151T0000|26 37|practitioner
P00429151T0000|62 72|Glasgow area
P00429893A0000|22 26|array
P00429893A0000|30 40|round window
P00429893A0000|49 60|implantation
P00429893A0000|78 83|system
P00429893A0000|110 121|scala tympani
P00429893A0000|126 132|minimum
P00429893A0000|135 140|trauma
P00429893A0000|164 174|stimulation
P00429949A0000|17 39|World Health Organization
P00429949A0000|44 58|Expert Committee
P00429949A0000|61 85|Biological Standardization
P00429949A0000|89 99|preparation
P00429949A0000|107 115|prolactin
P00429949A0000|118 125|ampoules
P00429949A0000|160 192|International Reference Preparation
P00429949A0000|205 213|prolactin
P00429949A0000|216 226|immunoassay
P00430889T0001|15 22|fistulas
P00431832T0001|0 15|Plasma ion changes
P00431832T0001|24 28|blood
P00431832T0001|42 61|beta receptor blockers
P00432615A0541|10 20|differences
P00432615A0541|46 55|literature
P00432615A0541|56 76|heterophile antibodies
P00432615A0541|90 102|gammaglobulin
P00432615A0541|133 144|interference
P00432615A0541|150 163|Sephadex system
P00435187T0000|13 24|flowers bloom
P00437749A0242|7 25|treatment modalities
P00437749A0242|42 48|context
P00437749A0242|54 63|psychology
P00437749A0242|75 84|physiology
P00439618T0001|0 15|Lethal Tachmalcor
P00439618T0001|16 29|diethylamino-2
P00439618T0001|29 41|hydroxypropyl
P00439618T0001|41 48|ajmaline
P00439618T0001|49 57|poisoning
P00439618T0001|60 68|childhood
P00439716T0001|20 29|evaluation
P00439716T0001|32 48|blood flow velocity
P00439716T0001|67 73|fistula
P00445259T0000|0 25|Serum ferritin concentration
P00445259T0000|29 48|bone marrow iron stores
P00445720A0263|11 26|pressure gradient
P00445720A0263|46 54|ventricle
P00445720A0263|65 70|atrium
P00445720A0263|89 120|high-fidelity pressure transducers
P00450367T0000|12 16|trail
P00450367T0000|26 37|hysterectomy
P00450367T0000|38 49|hysterectomy
P00450367T0000|61 66|radium
P00450367T0000|77 82|radium
P00450367T0000|87 98|hysterectomy
P00450367T0000|101 105|stage
P00450367T0000|118 126|carcinoma
P00450559A0269|5 9|basis
P00450559A0269|13 19|patient
P00450559A0269|21 26|report
P00450559A0269|42 50|Clinitemp
P00450559A0269|78 85|accuracy
P00450559A0269|92 102|thermometer
P00450760T0001|0 15|Cryoglobulinemia
P00450760T0001|18 24|Raynaud
P00450760T0001|26 33|syndrome
P00451192A0248|38 52|computer program
P00451192A0248|82 86|curve
P00451192A0248|101 120|LV region-of-interest
P00453780A0430|15 30|serum IgA response
P00453780A0430|44 60|patient population
P00453780A0430|100 105|tissue
P00453780A0430|138 143|source
P00454780A0340|0 17|Ultimate strengthes
P00454780A0340|36 51|cast cobalt alloys
P00454780A0340|59 72|titanium alloys
P00454780A0340|102 113|fatigue limit
P00454780A0340|117 125|corrosion
P00456424A0000|3 9|effects
P00456424A0000|26 34|injection
P00456424A0000|35 40|i.c.i.
P00456424A0000|43 51|clonidine
P00456424A0000|53 65|microgram kg-1
P00456424A0000|68 80|blood pressure
P00456424A0000|84 92|heart rate
P00456424A0000|115 121|rabbits
P00456424A0000|137 144|catheter
P00456424A0000|150 162|cisterna magna
P00463973A0000|0 13|Platelet number
P00463973A0000|17 24|life span
P00463973A0000|48 56|trimester
P00463973A0000|59 67|pregnancy
P00463973A0000|72 76|women
P00463973A0000|126 132|infants
P00463973A0000|138 142|women
P00463973A0000|147 153|infants
P00463973A0000|166 177|birth weights
P00464387A1185|6 17|measurements
P00464387A1185|25 32|serum IgE
P00464387A1185|51 55|index
P00464387A1185|58 72|disease activity
P00465223A0373|6 13|patients
P00465223A0373|17 34|difference betweent
P00465223A0373|50 55|values
P00465223A0373|58 64|delta PU
P00465223A0373|68 74|delta PM
P00465681A0000|9 31|hemoglobin concentration
P00465681A0000|46 53|increase
P00465681A0000|75 84|blood serum
P00465681A0000|110 123|oxygen pressure
P00465681A0000|155 159|state
P00465681A0000|177 181|state
P00465829T0000|0 5|Nernst
P00465829T0000|6 26|Planck analog equations
P00465829T0000|40 52|state membrane
P00465829T0000|61 70|potentials
P00473229T0000|0 6|Effects
P00473229T0000|9 25|methylene chloride
P00473229T0000|26 40|trichloroethane
P00473229T0000|41 57|trichloroethylene
P00473229T0000|58 76|tetrachloroethylene
P00473229T0000|80 86|toluene
P00473229T0000|92 102|development
P00473229T0000|105 116|chick embryos
P00473249T0000|0 5|Effect
P00473249T0000|24 37|administration
P00473249T0000|40 52|streptolysin O
P00473249T0000|58 77|electroencephalogram
P00473249T0000|80 86|rabbits
P00474064A0205|6 14|situation
P00474064A0205|18 36|convlusion threshold
P00474064A0205|44 53|substances
P00474064A0205|65 73|pethidine
P00474064A0205|76 86|mg.kg-1 I.V.
P00474064A0205|87 97|piritramide
P00474064A0205|100 107|morphine
P00474064A0205|111 123|phenoperidine
P00474064A0205|134 141|fentanyl
P00474064A0205|142 151|sufentanil
P00476020T0000|3 14|biochemistry
P00476020T0000|25 29|fluid
P00476020T0000|43 48|growth
P00476572A0139|23 28|lesion
P00476572A0139|91 95|cases
P00476572A0139|109 120|radiodensity
P00476572A0139|122 126|cases
P00477794T0000|0 6|Effects
P00477794T0000|26 35|tractotomy
P00477794T0000|41 56|response patterns
P00477794T0000|59 65|neurons
P00477794T0000|81 97|nuclei principalis
P00477794T0000|101 106|oralis
P00478714T0000|0 7|Efficacy
P00478714T0000|32 54|alcohol treatment program
P00479222A0682|0 9|Resistance
P00479222A0682|35 45|environment
P00479222A0682|65 73|retention
P00479222A0682|86 95|properties
P00479222A0682|101 114|immersion times
P00479222A0682|137 141|fluid
P00479222A0682|152 159|degrees C
P00479222A0682|175 179|years
P00479246T0000|28 40|osteomyelitis
P00481612A1121|23 31|receptors
P00481612A1121|58 66|ventricle
P00481612A1121|102 107|action
P00481612A1121|110 117|fentanyl
P00483716A0366|43 49|carotid
P00483716A0366|58 70|carotid artery
P00483716A0366|98 108|anastomosis
P00484177A0242|4 13|expression
P00484177A0242|23 40|laminar flow regimen
P00484177A0242|47 56|expiration
P00484177A0242|70 76|CT value
P00484177A0242|84 88|range
P00485615A0935|21 29|existence
P00485615A0935|52 57|crisis
P00485615A0935|69 74|entity
P00485615A0935|90 99|importance
P00485615A0935|117 124|syndrome
P00485615A0935|127 131|order
P00485615A0935|142 151|occurrence
P00485615A0935|159 170|pancreatitis
P00485615A0935|177 187|performance
P00485615A0935|222 228|surgery
P00488534A0308|2 9|addition
P00488534A0308|22 48|Treatment X Strain interaction
P00488534A0308|66 82|defecation numbers
P00488534A0308|113 118|MR rats
P00488534A0308|147 152|MR rats
P00490336A0181|5 22|conduction velocity
P00490336A0181|43 47|m/sec
P00490336A0181|48 53|group C
P00493818A0422|3 10|failures
P00493818A0422|34 51|patient intolerance
P00493818A0422|113 118|months
P00493818A0422|122 130|insertion
P00494659A0391|15 25|metabolites
P00494659A0391|30 44|3-carboxyphenyl
P00494659A0391|45 73|hydroxymethyl-2-oxazolidinone
P00494659A0391|78 88|glucuronide
P00494659A0391|91 100|toloxatone
P00495097A0663|5 19|characteristics
P00495097A0663|42 49|activity
P00495097A0663|63 76|fiber synthesis
P00495097A0663|83 88|matrix
P00495097A0663|101 106|tissue
P00497494A0112|3 13|ventilation
P00497494A0112|32 36|PACO2
P00499588T0000|0 21|Carbohydrate metabolism
P00499588T0000|28 39|semen profile
P00499588T0000|40 46|glucose
P00499588T0000|47 53|insulin
P00499588T0000|57 68|sperm studies
P00503336A0285|51 57|attacks
P00503336A0285|64 68|fever
P00503336A0285|76 81|levels
P00503336A0285|84 102|alkaline phosphatase
P00503336A0285|106 118|transaminases
P00503336A0285|124 128|serum
P00503336A0285|142 149|findings
P00503336A0285|165 173|diagnosis
P00506559A0000|12 29|inhalation toxicity
P00506559A0000|32 39|furfural
P00506559A0000|64 71|hamsters
P00506649T0000|0 6|Changes
P00506649T0000|19 40|serum protein components
P00506649T0000|58 63|stress
P00509703A0581|5 15|differences
P00509703A0581|54 62|textbooks
P00510341T0036|1 5|study
P00510341T0036|11 20|E.O.R.T.C.
P00512215A0000|10 14|study
P00512215A0000|26 35|dependence
P00512215A0000|38 56|difference tone level
P00512215A0000|59 63|f2-f1
P00512215A0000|77 86|parameters
P00512215A0000|100 104|input
P00512215A0000|109 113|f2/f1
P00513284A0000|13 23|preparation
P00513284A0000|26 36|doxycycline
P00513284A0000|43 52|Vibramycin
P00513284A0000|52 57|Pfizer
P00513284A0000|71 82|tetracycline
P00513284A0000|106 117|drip infusion
P00513284A0000|122 127|series
P00513284A0000|130 134|study
P00513284A0000|140 154|pediatrics field
P00513284A0000|161 167|results
P00513284A0000|219 233|glucose solution
P00513284A0000|236 240|mg/kg
P00513284A1255|24 35|DOTC infusion
P00513284A1255|35 49|laboratory tests
P00513284A1255|53 57|liver
P00513284A1255|66 74|functions
P00513284A1255|78 82|blood
P00516545T0001|10 24|characteristics
P00516545T0001|30 48|erythrocyte membrane
P00516545T0001|49 69|peroxidation processes
P00516545T0001|84 91|function
P00516545T0001|94 101|children
P00516545T0001|113 130|glomerulonephritis
P00517890A0468|10 14|route
P00517890A0468|37 48|transmission
P00517890A0468|51 60|hepatitis A
P00517890A0468|71 76|levels
P00517890A0468|79 102|hepatitis A virus excretion
P00517890A0468|117 121|onset
P00517890A0468|124 131|jaundice
P00519173A0126|5 12|patients
P00519173A0126|29 36|evidence
P00519173A0126|39 50|oesophagitis
P00521732T0000|7 15|excretion
P00521732T0000|18 25|oestrone
P00521732T0000|26 42|oestradiol-17 beta
P00521732T0000|46 53|oestriol
P00521732T0000|56 66|pregnancies
P00521732T0000|80 106|steroid sulphatase deficiency
P00524451A0136|22 38|locomotor activity
P00524451A0136|64 68|death
P00524451A0136|72 82|amphetamine
P00524451A0136|90 97|toxicity
P00524451A0136|107 119|hexobarbitone
P00524451A0136|144 152|depletion
P00524451A0136|154 167|catecholamines
P00524451A0136|179 184|organs
P00528144T0000|13 23|transferrin
P00528144T0000|28 33|uptake
P00528144T0000|36 42|gallium
P00528144T0000|45 54|tumor cells
P00534613A0000|0 10|Irradiation
P00534613A0000|18 31|blood platelets
P00534613A0000|61 67|ability
P00534613A0000|69 77|aggregate
P00534613A0000|83 91|challenge
P00534613A0000|96 103|collagen
P00535520A0239|11 20|exceptions
P00535520A0239|24 29|method
P00535520A0239|74 88|cholangiography
P00540707A0255|24 30|results
P00540707A0255|44 50|account
P00540707A0255|58 70|complications
P00540707A0255|100 104|cases
P00540707A0255|108 122|tip displacement
P00540707A0255|126 139|pouch haematoma
P00540707A0255|163 169|Authors
P00540707A0255|188 193|method
P00540707A0255|202 209|approach
P00540707A0255|213 227|PMK implantation
P00540707A0255|257 269|vena cephalica
P00541752A1032|7 20|determinations
P00541752A1032|38 44|samples
P00541752A1032|47 52|plasma
P00541752A1032|68 73|adults
P00541752A1032|76 82|October
P00541752A1032|86 91|values
P00541752A1032|126 130|ng/ml
P00550399A0615|15 20|causes
P00550399A0615|23 27|death
P00550399A0615|50 55|groups
P00553858A0000|8 12|Grice
P00553858A0000|14 22|operation
P00553858A0000|44 48|world
P00553858A0000|61 67|account
P00553858A0000|89 98|literature
P00553858A0000|108 119|publications
P00553858A0000|131 139|technique
P00553858A0000|157 161|terms
P00553858A0000|188 197|principles
P00553858A0000|208 216|operation
P00555492A1034|3 9|changes
P00555492A1034|40 48|blood flow
P00555492A1034|72 80|injection
P00555492A1034|83 92|cimetidine
P00555492A1034|103 111|injection
P00555492A1034|151 163|blood pressure
P00555495T0000|0 4|Study
P00555495T0000|7 22|re-establishment
P00555495T0000|25 33|ovulation
P00555495T0000|39 49|termination
P00555495T0000|65 73|treatment
P00555495T0000|87 99|re-appearance
P00555495T0000|102 110|ovulation
P00555495T0000|116 123|abortion
P00555495T0000|136 143|delivery
P00555583T0000|0 15|Pharmacokinetics
P00555583T0000|18 30|Carbamazepine
P00555583T0000|39 44|review
P00557559A0170|5 13|compounds
P00557559A0170|20 24|alpha
P00557559A0170|46 71|N-methylnitrone 1,4-dioxide
P00557559A0170|89 93|agent
P00557559A0170|142 150|organisms
P00564032A0724|0 6|Changes
P00564032A0724|14 20|content
P00564032A0724|54 63|mechanisms
P00564032A0724|70 77|pressure
P00564032A0724|103 107|gland
P00564943A0444|0 5|Calves
P00564943A0444|9 16|MCT-milk
P00564943A0444|38 53|blood cholesterol
P00564943A0444|58 63|calves
P00564943A0444|72 79|SBO-milk
P00565136T0000|7 15|mortality
P00565136T0000|33 42|inhalation
P00565136T0000|49 53|doses
P00565136T0000|62 67|SO2Cl2
P00565314A0293|0 9|Guinea pigs
P00569989A0239|5 23|halothane anesthesia
P00569989A0239|27 46|flow pneumocardiogram
P00569989A0239|75 102|acceleration pneumocardiogram
P00569989A0239|103 108|dPn/dt
P00569989A0239|129 133|apnea
P00569989A0239|151 166|pneumotachograph
P00574222T0000|7 14|kindling
P00574222T0000|15 26|implications
P00574222T0000|30 40|development
P00574222T0000|50 59|prostheses
P00574956A0304|17 26|stereotypy
P00574956A0304|118 128|equilibrium
P00574956A0304|164 170|systems
P00574956A0304|196 203|dopamine
P00574956A0304|226 236|development
P00574956A0304|253 265|manifestation
P00575231A0422|11 25|cystometrograms
P00575231A0422|42 61|detrusor contractions
P00577440A0298|5 12|duodenum
P00577440A0298|64 85|3H-alpha-acetyldigoxin
P00578648T0048|10 16|effects
P00578648T0048|34 47|administration
P00580106T0000|0 8|Treatment
P00580106T0000|11 16|Graves
P00580106T0000|17 23|disease
P00580151A0706|61 72|testosterone
P00580151A0706|83 92|se-T levels
P00580151A0706|108 112|range
P00580151A0706|116 126|convenience
P00580151A0706|132 138|patient
P00580151A0706|184 190|effects
P00580151A0706|200 204|doses
P00583004A0445|10 33|1,8-dihydroxy-9-anthrone
P00583004A0445|34 59|1,8,9-triacetoxyanthracene
P00583004A0445|63 86|1,8-diacetoxy-9-anthrone
P00583004A0445|115 121|lesions
P00583004A0445|141 153|inflammations
P00583522T0001|30 37|problems
P00583522T0001|52 63|inflammation
P00587791T0054|0 6|Nursing
P00587791T0054|9 16|patients
P00587791T0054|34 41|diseases
P00589073A0000|15 43|plasma prolactin concentrations
P00589073A0000|46 52|samples
P00589073A0000|85 89|phase
P00589073A0000|100 106|control
P00589073A0000|107 111|women
P00589073A0000|125 129|group
P00589073A0000|134 141|patients
P00589073A0000|160 166|history
P00589073A0000|169 179|infertility
P00590594T0000|7 25|allotransplantation
P00592887T0000|8 15|reaction
P00592887T0000|18 33|Patent Blue Violet
P00592887T0000|40 51|lymphography
P00593119T0001|0 8|Screening
P00593119T0001|11 24|asthma patients
P00593119T0001|27 39|determination
P00593119T0001|52 64|comprehension
P00593119T0001|66 73|spectrum
P00593119T0001|91 103|IgE antibodies
P00594466T0001|3 11|induction
P00594466T0001|14 21|seizures
P00594466T0001|24 33|Papio papio
P00594466T0001|43 54|allylglycine
P00594466T0001|64 74|combination
P00594466T0001|97 107|stimulation
P00594617A0192|18 28|correlation
P00594617A0192|47 54|presence
P00594617A0192|69 87|degradation products
P00594617A0192|99 107|incidence
P00594617A0192|109 119|nephropathy
P00594617A0192|128 140|insufficiency
P00594617A0192|159 166|presence
P00594617A0192|175 182|monomers
P00594617A0192|183 187|Godal
P00594617A0192|189 212|ethanol-gelification test
P00594617A0192|228 232|signs
P00594617A0192|245 251|disease
P00594617A0192|252 256|fever
P00597715A0256|0 8|One-third
P00597715A0256|23 33|azoospermia
P00597715A0256|40 51|sperm density
P00597715A0256|80 91|FSH elevation
P00597715A0256|98 107|experience
P00597715A0256|127 132|others
P00597715A0256|154 162|prognosis
P00598012A0174|2 21|girls prolactin levels
P00598012A0174|28 32|stage
P00598012A0174|51 58|menarche
P00598012A0174|76 81|change
P00598012A0174|83 97|prolactin levels
P00599601A0260|37 46|procedures
P00599601A0260|64 75|pinealectomy
P00599601A0260|104 114|alterations
P00599601A0260|132 141|physiology
P00600943T0001|1 5|cases
P00600943T0001|13 31|lymphomononucleosis
P00601401A0181|6 23|hemoglobin solution
P00601401A0181|46 53|affinity
P00601401A0181|57 62|oxygen
P00601401A0181|70 79|Bohr effect
P00601401A0181|95 118|delta log Po2/delta pH ratio
P00602622A0362|9 20|ulcer therapy
P00602622A0362|25 32|atropine
P00602622A0362|36 42|Vikalin
P00602622A0362|43 47|Roter
P00602622A0362|80 88|reduction
P00602622A0362|113 120|activity
P00602702A0309|5 11|patient
P00602702A0309|22 29|diarrhea
P00602702A0309|33 52|estriol concentration
P00602702A0309|55 59|serum
P00602702A0309|84 91|function
P00602702A0309|108 127|estriol concentration
P00602702A0309|148 155|diarrhea
P00603783A0647|0 10|Serum levels
P00603783A0647|56 63|findings
P00603783A0647|69 86|observers IgA levels
P00606849T0000|20 31|heart disease
P00606849T0000|41 53|thromboxane A2
P00606849T0000|56 62|rabbits
P00614915T0001|0 9|Vitrectomy
P00614915T0001|18 29|traumatology
P00616575A0000|10 20|sensitivity
P00616575A0000|34 48|brain structures
P00616575A0000|54 59|action
P00616575A0000|79 83|field
P00616575A0000|86 99|decimeter waves
P00616575A0000|119 131|investigation
P00616575A0000|138 149|unit activity
P00617815A0215|12 25|L-R differences
P00618078A0367|1 8|decrease
P00618078A0367|14 29|lysozyme activity
P00618078A0367|54 64|improvement
P00618078A0367|79 88|meningitis
P00619305A0759|18 23|groups
P00619305A0759|47 55|dimension
P00619305A0759|69 78|dimensions
P00619782A0058|28 32|backs
P00619782A0058|34 43|volunteers
P00619782A0058|56 63|exposure
P00619782A0058|74 93|ultraviolet radiation
P00619948A0000|4 10|effects
P00619948A0000|19 26|subjects
P00619948A0000|48 54|Motival
P00619948A0000|57 62|tablet
P00619948A0000|73 84|fluphenazine
P00619948A0000|95 107|nortriptyline
P00619948A0000|136 144|variation
P00619948A0000|149 160|reaction time
P00619948A0000|160 168|heart rate
P00619948A0000|169 181|blood pressure
P00619948A0000|196 201|scales
P00619948A0000|205 213|alertness
P00619948A0000|214 220|anxiety
P00619948A0000|221 227|tension
P00619948A0000|228 237|detachment
P00619948A0000|241 250|depression
P00619948A0000|274 281|diazepam
P00619948A0000|300 306|placebo
P00619948A0000|307 317|propranolol
P00621626T0000|0 12|Stress effects
P00621626T0000|15 36|affiliation preferences
P00621626T0000|42 49|subjects
P00621626T0000|84 98|behavior pattern
P00622556A0111|16 23|collagen
P00622556A0111|30 35|tissue
P00622556A0111|64 69|tendon
P00623361A0221|0 6|Smoking
P00623361A0221|28 39|contribution
P00623361A0221|51 61|dysfunction
P00626014T0001|3 11|malignity
P00626014T0001|20 26|lentigo
P00627039T0000|0 10|Elimination
P00627039T0000|13 22|bagassosis
P00627039T0000|25 63|Louisiana paper manufacturing plant workers
P00627129A0944|5 13|responses
P00627129A0944|30 35|others
P00627129A0944|45 52|subjects
P00627129A0944|65 74|conditions
P00627129A0944|115 120|effect
P00627129A0944|123 131|labetalol
P00627129A0944|155 162|blockade
P00627129A0944|174 191|beta-adrenoceptors
P00627202T0000|0 8|Diuretics
P00627202T0000|22 33|pharmacology
P00628990A0000|5 12|patients
P00628990A0000|33 37|units
P00628990A0000|63 76|reconstruction
P00628990A0000|86 104|ureteroureterostomy
P00628990A0000|119 138|ureteroneocystostomy
P00628990A0000|172 183|ureterostomy
P00630713T0000|0 9|Evaluation
P00630713T0000|15 39|Du Pont aca ammonia procedure
P00633909A0000|18 25|patients
P00633909A0000|26 31|scores
P00633909A0000|34 39|Rotter
P00633909A0000|41 62|Internal-External Locus
P00633909A0000|65 76|Control Scale
P00633909A0000|96 104|treatment
P00633909A0000|133 140|patients
P00633909A0000|169 175|control
P00635143T0001|0 5|Action
P00635143T0001|8 19|strontium-90
P00635143T0001|23 30|metaphos
P00635143T0001|33 46|Cyprinus carpio
P00635194A0093|0 12|Kodak XV-2 film
P00635194A0093|65 80|dose distribution
P00636526T0033|0 8|Diagnosis
P00636526T0033|24 32|diagnosis
P00637637T0000|11 17|factors
P00637637T0000|27 45|plasma renin activity
P00637637T0000|57 68|hypertension
P00639410T0000|0 8|Cortisone
P00639410T0000|16 26|bone changes
P00639410T0000|33 40|response
P00639410T0000|43 61|lipid clearing agents
P00640584A0250|16 24|principle
P00640584A0250|45 53|stability
P00641395A0441|4 15|blood samples
P00641395A0441|18 25|patients
P00641395A0441|30 47|hyperbilirubinemia
P00641395A0441|66 76|measurement
P00641395A0441|90 100|fluorimeter
P00641395A0441|126 131|levels
P00641395A0441|150 165|extraction method
P00644314T0000|7 22|hypersensitivity
P00644314T0000|30 36|effects
P00644314T0000|46 60|anticoagulation
P00644539A0783|17 26|inhalation
P00644539A0783|40 45|saline
P00644539A0783|109 115|subject
P00644539A0783|114 122|reactions
P00644539A0783|128 140|test solutions
P00646023T0058|12 18|studies
P00646023T0058|21 34|virus excretion
P00646023T0058|51 62|transmission
P00646193T0000|0 6|Potency
P00646193T0000|9 17|enflurane
P00646193T0000|26 35|comparison
P00646193T0000|39 47|halothane
P00646193T0000|51 60|isoflurane
P00656008T0000|0 9|Prevention
P00656008T0000|17 32|paraquat toxicity
P00656008T0000|43 61|superoxide dismutase
P00657551T0000|0 10|Measurement
P00657551T0000|13 31|magnesium absorption
P00657551T0000|59 64|tracer
P00659962T0000|16 34|riboflavin excretion
P00659962T0000|53 65|acid ingestion
P00663166A0000|12 22|angiography
P00663166A0000|37 47|body imaging
P00663166A0000|83 94|particulates
P00663166A0000|128 135|shunting
P00663166A0000|138 145|patients
P00663166A0000|150 171|patent ductus arteriosus
P00663166A0000|181 201|Eisenmenger physiology
P00664320T0000|7 15|detectors
P00664320T0000|32 38|pathway
P00665053A0276|40 44|06a6b
P00665053A0276|68 81|group affection
P00665214A0374|3 8|method
P00665214A0374|45 54|physiology
P00665214A0374|65 69|cycle
P00665336A0908|45 59|EEG-information
P00668122A0414|0 7|Analysis
P00668122A0414|10 29|liver biopsy specimens
P00668122A0414|34 41|patients
P00668122A0414|46 54|hepatitis
P00668122A0414|67 75|variation
P00668122A0414|81 95|mean iron content
P00668122A0414|101 122|liver ferritin molecules
P00669800A0579|44 52|infection
P00669800A0579|56 60|males
P00676416A0320|23 27|years
P00676416A0320|43 55|liver biopsies
P00676790T0000|0 16|Angiotensin effect
P00676790T0000|27 32|kidney
P00681550A0000|0 6|Procion
P00681550A0000|51 64|auditory fibers
P00681550A0000|67 74|goldfish
P00681550A0000|92 103|relationship
P00681550A0000|114 125|response type
P00681550A0000|133 138|fibers
P00681550A0000|155 165|termination
P00681550A0000|178 183|macula
P00681571T0028|10 17|findings
P00681571T0028|23 31|epidermis
P00681571T0028|54 74|eccrine sweat duct units
P00682762T0001|0 17|Silicosis mortality
P00685922A0451|26 35|strictures
P00686836A0000|0 6|Pentane
P00686836A0000|10 15|ethane
P00686836A0000|32 48|lipid peroxidation
P00686836A0000|69 85|gas chromatography
P00686836A0000|88 100|breath samples
P00686836A0000|116 120|weeks
P00686836A0000|121 127|vitamin
P00686836A0000|171 187|IU vitamin E acetate
P00693987T0001|0 13|Thromboplastic
P00693987T0001|29 36|activity
P00693987T0001|42 46|blood
P00693987T0001|52 65|administration
P00693987T0001|68 77|intralipid
P00693987T0001|89 95|history
P00693987T0001|107 116|infarction
P00696680A0000|3 9|authors
P00696680A0000|36 43|findings
P00696680A0000|50 54|cases
P00696680A0000|62 66|women
P00696680A0000|71 87|rhabdomyosarcomas
P00696680A0000|107 117|endometrium
P00696680A0000|120 125|cervix
P00696858A0000|3 8|effect
P00696858A0000|22 36|porcine secretin
P00696858A0000|39 47|endocrine
P00696858A0000|69 77|secretion
P00696858A0000|116 130|porcine pancreas
P00701144T0000|9 16|analysis
P00701144T0000|30 38|lens power
P00701144T0000|56 65|emmetropia
P00701144T0000|66 72|results
P00701144T0000|78 85|implants
P00701462A0722|0 14|Urine antibodies
P00701462A0722|47 51|cases
P00702773A0327|0 9|Althoug RBF
P00702773A0327|34 40|therapy
P00702773A0327|75 80|change
P00702773A0327|103 108|output
P00703350A0418|0 11|99mTc phytate
P00703350A0418|12 23|198Au colloid
P00703350A0418|27 31|99mTc
P00703350A0418|40 46|sulfide
P00703932A0000|3 10|patients
P00703932A0000|15 32|glomerulonephritis
P00703932A0000|35 45|association
P00703932A0000|69 73|shunt
P00703932A0000|99 103|modes
P00703932A0000|106 112|therapy
P00704675A0199|35 41|bronchi
P00704675A0199|48 58|bifurcation
P00704675A0199|92 101|inhalation
P00704675A0199|132 138|trachea
P00710217T0001|8 12|cysts
P00710217T0001|18 25|hip joint
P00710372A0302|22 32|dysfunction
P00710372A0302|62 69|function
P00710372A0302|82 93|GH deficiency
P00710372A0302|125 132|features
P00712117A0521|6 13|outbreak
P00712117A0521|16 25|influenza A
P00712117A0521|51 58|February
P00712117A0521|72 80|A/Texas/1
P00712117A0521|87 91|virus
P00712117A0521|93 99|variant
P00712117A0521|105 116|A/Victoria/3
P00712117A0521|118 126|prototpye
P00713525A0268|7 15|decreases
P00713525A0268|21 35|disfluency rates
P00713525A0268|38 47|stutterers
P00713525A0268|69 80|presentation
P00713525A0268|91 103|stimulus words
P00713525A0268|138 142|model
P00715180T0074|0 5|Effect
P00715180T0074|25 35|alterations
P00715180T0074|43 52|inhalation
P00715180T0074|55 81|plutonium-239 dioxide aerosol
P00715753A0241|2 22|biopsies CK-MB fraction
P00715753A0241|55 71|total-CPK activity
P00715753A0241|85 91|muscles
P00715753A0241|103 111|% fraction
P00715753A0241|114 118|CK-MB
P00716366T0001|0 4|Value
P00716366T0001|7 19|determination
P00716366T0001|22 50|alkaline phosphatase isoenzymes
P00716366T0001|66 74|diagnosis
P00716366T0001|88 95|jaundice
P00716366T0001|106 119|liver cirrhosis
P00722298A0619|8 15|analysis
P00722298A0619|18 25|variance
P00722298A0619|56 60|women
P00722298A0619|63 73|differences
P00722298A0619|93 98|groups
P00722298A0619|102 116|field dependence
P00722298A0619|123 134|significance
P00722298A0619|157 163|females
P00722298A0619|170 175|famale
P00722298A0619|196 200|field
P00722298A0619|235 240|groups
P00722298A0619|253 257|males
P00722652A0118|11 33|2nd-generation schizonts
P00722652A0118|47 54|diameter
P00722652A0118|67 76|micrometer
P00722652A0118|101 107|surface
P00722652A0118|113 117|cecum
P00725257A0452|13 21|pD2 values
P00725336T0000|0 32|Newcastle disease virus surveillance
P00725336T0000|35 42|Hong Kong
P00725336T0000|61 67|poultry
P00725534A0888|29 37|challenge
P00725534A0888|40 47|M. leprae
P00725534A0888|53 60|antigens
P00725534A0888|66 79|IgA immunocytes
P00725534A0888|95 104|epithelium
P00725534A0888|121 129|tolerance
P00725534A0888|139 151|IgA deficiency
P00725534A0888|173 179|atrophy
P00725534A0888|195 199|villi
P00725534A0888|205 212|patients
P00725534A0888|228 234|leprosy
P00725752T0001|0 8|Treatment
P00725752T0001|11 22|hypertension
P00725752T0001|28 38|combination
P00725752T0001|54 74|beta receptor blockader
P00725752T0001|75 81|obsidan
P00725752T0001|88 98|vasodilator
P00725752T0001|99 106|apressin
P00726581T0122|0 5|Orthop
P00728718T0000|0 13|Thyroid disease
P00728718T0000|17 25|pregnancy
P00729003A1182|0 7|Residues
P00729003A1182|19 29|transcripts
P00729003A1182|32 39|splicing
P00733067A0188|10 15|reflux
P00733067A0188|35 40|number
P00733067A0188|51 55|steps
P00733067A0188|89 95|section
P00733067A0188|108 112|stump
P00733067A0188|128 139|construction
P00733067A0188|145 155|anastomosis
P00733067A0188|175 182|creation
P00733067A0188|200 210|valve system
P00733067A0188|226 236|anastomosis
P00733067A0188|239 256|spiral introflexion
P00733067A0188|262 267|mucosa
P00733067A0188|283 290|stitches
P00733067A0188|325 329|lumen
P00736376A0371|6 10|stage
P00736376A0371|26 34|mortality
P00736376A0371|42 49|ischemia
P00736376A0371|74 80|urgency
P00736376A0371|86 94|operation
P00736376A0371|100 104|skill
P00737422A0832|0 8|Pathogens
P00737422A0832|44 50|bacilli
P00737422A0832|74 79|member
P00737422A0832|82 86|staff
P00737422A0832|94 100|numbers
P00737422A0832|131 137|numbers
P00737422A0832|142 149|patients
P00740409A0000|3 16|histochemistry
P00740409A0000|20 33|ultrastructure
P00740409A0000|45 62|cerebellar deposits
P00740409A0000|74 78|Tonge
P00741476A0000|11 15|woman
P00741476A0000|24 41|Ergotamine Tartrate
P00741476A0000|45 50|mg p.d.
P00741476A0000|75 82|abortion
P00741476A0000|88 92|birth
P00743335T0001|0 12|Reaction times
P00743335T0001|42 48|stimuli
P00743335T0001|51 59|diabetics
P00745775A0170|12 19|patients
P00745775A0170|45 57|arteriography
P00745775A0170|88 100|complications
P00745775A0170|110 118|injection
P00745775A0170|121 129|Urografin
P00747722A0486|29 36|reaction
P00747722A0486|41 51|B1 injection
P00747722A0486|53 57|Phase
P00747722A0486|71 79|injection
P00747722A0486|99 108|parameters
P00748978T0000|0 17|Serum relaxin levels
P00748978T0000|20 34|prostaglandin E2
P00748978T0000|42 50|abortions
P00753237A0000|20 29|phenomenon
P00753237A0000|35 39|level
P00753237A0000|77 86|body weight
P00753237A0000|109 117|outsentry
P00753237A0000|152 158|Plantar
P00753237A0000|169 178|ulceration
P00753237A0000|195 205|combination
P00753237A0000|207 219|INSENSITIVITY
P00753237A0000|223 231|TRAUMATIS
P00753237A0000|239 245|patient
P00753237A0000|255 264|body weight
P00753237A0000|265 274|traumatism
P00753237A0000|275 281|effects
P00753237A0000|304 310|process
P00753237A0000|333 347|PNEUMATIC INSOLE
P00753237A0000|376 386|compression
P00753237A0000|423 431|attrition
P00753237A0000|441 456|blood circulation
P00753237A0000|474 484|prophylaxis
P00755245A0000|0 5|Effect
P00755245A0000|8 16|indoramin
P00755245A0000|24 28|doses
P00755245A0000|41 53|vasomotor loci
P00755245A0000|70 79|chloralose
P00755245A0000|124 128|sites
P00755671A0485|13 19|heparin
P00755671A0485|39 58|recalcification times
P00755671A0485|65 75|development
P00755671A0485|100 108|hematomas
P00755869A0216|0 21|Contingency contracting
P00755869A0216|29 35|clients
P00755869A0216|44 61|parents/caregivers
P00755869A0216|78 89|consequences
P00755869A0216|98 112|self-monitoring
P00755869A0216|127 132|intake
P00755869A0216|133 142|weight loss
P00755869A0216|146 153|exercise
P00756511T0036|0 8|Dietetics
P00756511T0036|11 19|childhood
P00756511T0036|31 38|diabetes
P00757244A0000|3 9|results
P00757244A0000|25 29|study
P00757244A0000|48 56|membranes
P00757244A0000|62 70|placentas
P00759049A0185|3 13|micromethod
P00759049A0185|18 30|microcuvettes
P00759049A0185|45 53|ferrozine
P00759049A0185|60 87|bathophenanthroline chromogen
P00759400T0000|0 16|Platelet serotonin
P00759400T0000|41 46|factor
P00759400T0000|47 52|plasma
P00759400T0000|65 72|patients
P00762763A0253|10 18|incidence
P00762763A0253|46 51|births
P00764737X0000|3 15|vigilance task
P00764737X0000|22 32|measurement
P00764737X0000|46 53|deficits
P00767155T0001|3 10|December
P00767155T0001|16 21|revolt
P00767155T0001|24 29|Moscow
P00767155T0001|47 55|personnel
P00767161A0837|11 19|increases
P00767161A0837|26 45|serum E2 concentration
P00767161A0837|54 58|pg/ml
P00767161A0837|75 79|hours
P00767161A0837|85 98|administration
P00767161A0837|113 117|hours
P00768220X0000|3 11|motor unit
P00771729X0000|17 22|system
P00771729X0000|28 37|variations
P00771729X0000|40 48|responses
P00771729X0000|51 58|hormones
P00775582T0000|10 19|properties
P00775582T0000|22 30|sumithion
P00779272T0001|11 17|studies
P00779272T0001|20 29|antibodies
P00779272T0001|44 48|virus
P00779272T0001|61 73|mononucleosis
P00780639X0000|16 22|antigen
P00780639X0000|28 37|procedures
P00780639X0000|48 57|evaluation
P00792847A0000|21 42|antilymphocyte globulin
P00792847A0000|74 78|agent
P00792847A0000|80 85|humans
P00799988A0554|5 9|basis
P00799988A0554|19 36|assessment patients
P00799988A0554|61 70|preference
P00799988A0554|74 83|imipramine
P00799988A0554|96 102|placebo
P00799988A0554|115 121|therapy
P00803867A0315|0 7|Patients
P00803867A0315|40 45|groups
P00803867A0315|64 69|cancer
P00803867A0315|81 86|cancer
P00803867A0315|97 104|patients
P00803867A0315|121 127|disease
P00803867A0315|139 144|months
P00806295A0193|0 9|Absorption
P00806295A0193|48 57|absorption
P00806295A0193|99 106|subjects
P00807356T0001|30 37|activity
P00807356T0001|40 59|hydroxy-9 ellipticine
P00808266T0000|0 7|Advances
P00808266T0000|13 22|management
P00808266T0000|36 41|cancer
P00808266T0000|42 57|radiation therapy
P00808898A0000|34 40|patient
P00808898A0000|72 78|failure
P00811852T0001|8 19|satisfaction
P00811852T0001|22 28|nursing
P00811852T0001|31 39|encounter
P00811852T0001|60 67|patients
P00812183T0000|10 23|transfer factor
P00818380A0239|10 15|factor
P00818380A0239|30 42|antibody tests
P00818380A0239|68 76|reactions
P00818380A0239|79 89|gold therapy
P00818380A0239|127 137|populations
P00819176T0001|3 8|effect
P00819176T0001|22 29|pressure
P00819176T0001|35 50|swimming activity
P00819176T0001|71 79|crustacea
P00819176T0001|80 99|Anomalocera patersoni
P00819176T0001|100 119|Pontella mediterranea
P00819176T0001|120 139|Labidocera wollastoni
P00821833A0000|4 9|report
P00821833A0000|20 27|analysis
P00821833A0000|38 47|repertoire
P00821833A0000|50 62|howler monkeys
P00821833A0000|63 78|Alouatta palliata
P00821833A0000|94 103|field study
P00821833A0000|118 123|Panama
P00822611A0467|10 15|number
P00822611A0467|18 25|patients
P00822611A0467|57 63|persons
P00822611A0467|76 88|binephrectomy
P00823087A0608|0 7|Deflunia
P00823087A0608|28 35|patients
P00827364A0000|4 13|instrument
P00827364A0000|32 48|freeze-fracturing
P00827364A0000|61 68|material
P00827364A0000|71 75|ultra
P00827364A0000|80 85|vacuum
P00830568A0000|20 28|secretion
P00830568A0000|39 51|emptying rates
P00830568A0000|61 68|test meal
P00830568A0000|96 102|persons
P00830568A0000|104 111|patients
P00830568A0000|124 134|gastrectomy
P00830568A0000|139 156|gastroduodenostomy
P00830568A0000|157 162|STG-BI
P00830568A0000|169 185|gastrojejunostomy
P00830568A0000|186 192|STG-BII
P00830568A0000|198 205|patients
P00830568A0000|217 224|vagotomy
P00830568A0000|228 239|pyloroplasty
P00832096T0000|8 24|calcium metabolism
P00832096T0000|41 51|sarcoidosis
P00833472A0907|15 21|patient
P00833472A0907|34 43|gallstones
P00833472A0907|53 63|institution
P00833472A0907|66 75|colestipol
P00833472A0907|76 85|saturation
P00833472A0907|88 102|gallbladder bile
P00833472A0907|107 117|cholesterol
P00836637A0000|11 20|experiment
P00836637A0000|63 77|music-listening
P00836637A0000|89 98|reinforcer
P00836637A0000|109 129|arithmetic performance
P00836637A0000|132 142|EMR children
P00836637A0000|168 180|reinforcement
P00836637A0000|192 201|preference
P00836637A0000|209 218|reinforcer
P00837262A0000|3 16|responsiveness
P00837262A0000|25 30|cortex
P00837262A0000|46 55|colliculus
P00837262A0000|93 104|conditioning
P00837262A0000|115 125|stimulation
P00837262A0000|129 134|rabbit
P00837811A0675|1 9|diagnosis
P00837811A0675|46 50|signs
P00837811A0675|56 83|fluid gamma globulin elevations
P00837811A0675|87 99|abnormalities
P00837811A0675|120 126|testing
P00838152A0863|12 30|mean temperature rise
P00838152A0863|44 51|degrees C
P00838152A0863|58 65|degrees C
P00838152A0863|71 79|selection
P00838152A0863|104 116|disappearance
P00838152A0863|127 140|qualifications
P00838152A0863|146 158|triplet groups
P00838152A0863|168 179|predominance
P00838152A0863|194 207|qualifications
P00838152A0863|218 223|groups
P00839378A0649|11 15|Viso V
P00839378A0649|21 28|RDS group
P00839378A0649|39 46|increase
P00839378A0649|54 69|airway resistance
P00839378A0649|84 90|disease
P00839378A0649|98 104|therapy
P00842406A0771|16 20|tests
P00842406A0771|60 81|visuomotor coordination
P00842406A0771|84 98|recognition task
P00842522T0000|18 27|intubation
P00842522T0000|33 42|management
P00842522T0000|76 84|emphysema
P00843232A0100|3 12|background
P00843232A0100|47 52|factor
P00843232A0100|59 67|character
P00843232A0100|70 75|lesion
P00843232A0100|81 90|epithelium
P00843670T0000|3 7|sense
P00846559A0000|6 12|strains
P00846559A0000|15 26|Fusarium poae
P00846559A0000|30 47|F. sporotrichioides
P00846559A0000|55 62|U.S.S.R.
P00846559A0000|67 73|strains
P00846559A0000|81 87|species
P00846559A0000|96 116|F. sporotrichioides var
P00846559A0000|141 150|tricinctum
P00846559A0000|155 160|U.S.A.
P00846559A0000|164 169|France
P00846559A0000|195 202|capacity
P00846559A0000|210 217|T-2 toxin
P00847967T0000|37 46|tomography
P00847967T0000|56 63|medicine
P00851041A0000|10 14|study
P00851041A0000|19 26|patients
P00851041A0000|31 37|Ebstein
P00851041A0000|39 45|anomaly
P00851286A0375|0 5|Deaths
P00851286A0375|15 19|hours
P00851286A0375|25 44|copper concentrations
P00851286A0375|70 74|signs
P00851286A0375|76 83|distress
P00851286A0375|125 129|hours
P00851286A0375|142 146|death
P00857024A0888|0 9|Recurrence
P00857024A0888|12 24|bladder tumors
P00857024A0888|42 46|cases
P00857024A0888|76 90|properdin levels
P00857024A0888|107 112|median
P00863184T0043|0 9|Adaptation
P00863184T0043|24 39|transport maximum
P00863773T0000|0 6|Dangers
P00863773T0000|16 33|live-virus vaccines
P00866577A0579|0 8|Treatment
P00866577A0579|13 19|heparin
P00866577A0579|20 40|plasminogen activators
P00866577A0579|60 65|agents
P00866577A0579|95 102|function
P00866577A0579|121 127|patient
P00866577A0579|157 163|therapy
P00868301A0043|2 21|diethyl ether solution
P00868301A0043|43 74|2-benzylidenamio-1-phenylpropane
P00868301A0043|83 95|retention time
P00868301A0043|102 108|minutes
P00868301A0043|117 125|condition
P00868903A0000|0 7|Amikacin
P00868903A0000|20 28|treatment
P00868903A0000|53 62|infections
P00868903A0000|67 74|patients
P00870859A0121|50 56|account
P00870859A0121|61 69|direction
P00870859A0121|72 84|recirculation
P00870859A0121|107 112|factor
P00871237A0601|6 13|activity
P00871237A0601|20 26|patient
P00871237A0601|36 41|angina
P00872442T0000|0 9|Estimation
P00872442T0000|12 20|L-alanine
P00872442T0000|23 27|serum
P00872442T0000|30 35|plasma
P00872442T0000|44 66|LKB reaction rate analyser
P00872922A0204|3 7|acids
P00872922A0204|22 31|hydrolysis
P00872922A0204|50 55|esters
P00872922A0204|81 88|activity
P00874942T0000|12 21|amnionitis
P00874942T0000|25 35|prematurity
P00874942T0000|48 53|report
P00875778T0000|0 9|Evaluation
P00875778T0000|18 38|Gravigard IUCD inserter
P00876722T0000|9 18|meningitis
P00876722T0000|30 36|abscess
P00876722T0000|47 52|septum
P00877857A0763|0 11|Serum amylase
P00877857A0763|39 46|CU/100 ml
P00877857A0763|55 62|serum FFA
P00877857A0763|68 76|mEq/liter
P00879329A0176|5 22|control preparation
P00879329A0176|29 34|weight
P00879329A0176|78 85|pressure
P00879329A0176|115 121|colloid
P00879329A0176|127 134|pressure
P00879329A0176|140 145|plasma
P00879829A0564|0 6|Infants
P00879829A0564|26 30|hours
P00879829A0564|61 73|birth asphyxia
P00879829A0564|102 108|symptom
P00879829A0564|121 126|apnoea
P00881630A0000|16 22|effects
P00881630A0000|28 38|snake venoms
P00881630A0000|39 44|N. naja
P00881630A0000|48 59|A. piscivorus
P00881630A0000|79 84|Factor
P00881630A0000|88 102|Phospholipase-A
P00881630A0000|103 111|compounds
P00881630A0000|124 129|N. naja
P00881630A0000|135 139|venom
P00881630A0000|167 182|cremaster vessels
P00885562A0281|17 26|components
P00885562A0281|28 42|cartilage matrix
P00885562A0281|46 54|depletion
P00885562A0281|78 91|osteoarthrosis
P00885562A0281|93 98|method
P00885562A0281|120 131|GAG synthesis
P00885562A0281|134 140|culture
P00890028A0507|3 14|length scales
P00890028A0507|20 29|turbulence
P00890028A0507|50 63|Reynolds number
P00890028A0507|76 85|macroscale
P00890028A0507|104 119|Taylor microscale
P00890028A0507|140 155|Kolmogoroff scale
P00891370A0000|15 26|arteriograms
P00891370A0000|32 36|limbs
P00891370A0000|52 66|xeroradiography
P00891370A0000|83 91|injection
P00891370A0000|94 108|contrast-medium
P00891370A0000|115 121|arm vein
P00891370A0000|140 147|patients
P00892353A0686|2 12|hypotension
P00892353A0686|23 30|patients
P00892353A0686|35 41|toxemia
P00892353A0686|54 58|fever
P00892353A0686|68 76|degrees C.
P00898500A0246|17 26|secretions
P00898500A0246|31 38|patients
P00898500A0246|62 74|mites skin test
P00898500A0246|145 163|IgE antibody activity
P00898500A0246|164 168|mites
P00903772A0359|0 7|Wherever
P00903772A0359|22 44|conditioning stimulation
P00903772A0359|49 61|modifications
P00903772A0359|78 86|ischaemia
P00909114A0000|0 17|Diallylnitrosamine
P00909114A0000|34 45|nitrosamines
P00909114A0000|75 83|neoplasms
P00909114A0000|103 111|incidence
P00909114A0000|124 134|tract tumors
P00909114A0000|149 156|hamsters
P00909114A0000|186 190|doses
P00909114A0000|195 202|compound
P00910823A0196|27 36|conditions
P00910823A0196|52 61|blood gases
P00910823A0196|66 72|uterine
P00910823A0196|84 93|blood flows
P00911590T0000|12 20|responses
P00911590T0000|23 32|antagonism
P00911590T0000|35 49|bocurarine block
P00911590T0000|54 80|atropine-neostigmine mixture
P00911590T0000|83 90|children
P00913623A0242|3 11|mechanism
P00913623A0242|24 32|molecules
P00913623A0242|42 54|diphosphonate
P00913623A0242|89 101|pyrophosphate
P00913623A0242|114 124|capillaries
P00913623A0242|136 151|passive diffusion
P00915090A0536|22 30|injection
P00915090A0536|42 47|Tc-99m
P00915090A0536|70 75|testis
P00915090A0536|78 83|number
P00915090A0536|86 94|sperm hads
P00915090A0536|112 118|control
P00916099A0000|0 16|Self-emasculation
P00916099A0000|22 30|end result
P00916099A0000|53 60|disorder
P00916099A0000|91 99|treatment
P00917572T0001|0 10|Possibility
P00917572T0001|27 32|method
P00917572T0001|36 44|detection
P00917572T0001|47 60|hypothyroidism
P00917721A0484|4 11|analysis
P00917721A0484|31 38|evidence
P00917721A0484|52 70|presleep suggestions
P00917721A0484|93 104|dream content
P00918556A0000|3 12|prevalence
P00918556A0000|15 38|hepatitis B surface antigen
P00918556A0000|39 43|HBsAg
P00918556A0000|47 54|anti-HBs
P00918556A0000|95 120|radio-immunoassay technique
P00918556A0000|124 129|series
P00918556A0000|132 139|patients
P00918556A0000|151 163|liver diseases
P00918965A0728|18 25|patients
P00918965A0728|46 52|failure
P00918965A0728|72 82|ventilation
P00918965A0728|90 101|componenents
P00918965A0728|116 120|shunt
P00918965A0728|124 131|parallel
P00920381T0000|16 23|glycogen
P00920381T0000|43 51|injection
P00921032T0000|10 19|evaluation
P00921032T0000|22 31|mibolerone
P00921032T0000|43 48|Beagle
P00921911A0159|0 5|Levels
P00921911A0159|71 76|labour
P00921911A0159|86 95|dilatation
P00921911A0159|124 128|onset
P00921911A0159|130 135|labour
P00926272A0000|13 17|cause
P00926272A0000|25 37|deterioration
P00926272A0000|62 68|patient
P00926272A0000|96 101|reflux
P00926604A0504|0 10|Propranolol
P00926604A0504|11 17|Inderal
P00926604A0504|68 76|apparatus
P00926604A0504|81 85|heart
P00926604A0504|97 107|development
P00926604A0504|130 135|effect
P00926604A0504|149 153|doses
P00926604A0504|156 168|strophanthin K
P00926604A0504|198 207|myocardium
P00926751A0000|6 12|studies
P00926751A0000|25 33|rat larynx
P00926751A0000|49 53|organ
P00926751A0000|59 68|evaluation
P00926751A0000|71 79|irritancy
P00926751A0000|89 97|materials
P00927633T0001|8 15|electron
P00927633T0001|27 40|investigations
P00927633T0001|46 54|formation
P00927633T0001|57 64|Reissner
P00927633T0001|66 70|fiber
P00927633T0001|73 84|Rattus rattus
P00928529T0001|0 14|Feeding behavior
P00928529T0001|25 34|body weight
P00928529T0001|38 55|hibernation rhythms
P00928529T0001|66 73|hamsters
P00928529T0001|109 115|bundles
P00929418T0001|11 38|infectious-disease specialist
P00929418T0001|64 72|incidence
P00929418T0001|87 94|diseases
P00930947A0629|13 28|drug interactions
P00930947A0629|41 46|effect
P00930947A0629|49 58|probenecid
P00930947A0629|66 74|secretion
P00930947A0629|115 120|effect
P00930947A0629|128 132|drugs
P00930947A0629|159 164|effect
P00931089T0001|11 16|arrest
P00931089T0001|22 34|operating room
P00932738A0116|11 23|blood pressure
P00932738A0116|38 54|C02 responsiveness
P00932738A0116|89 94|levels
P00932817A0499|0 9|Iodine-123
P00932817A0499|52 69|pinhole collimators
P00932817A0499|89 97|MTF values
P00932817A0499|125 129|99mTc
P00933251T0000|7 16|meningioma
P00933251T0000|19 24|plaque
P00933251T0000|49 56|ear tumor
P00935526A0000|3 14|difficulties
P00935526A0000|24 37|prostaglandins
P00935526A0000|54 67|chromatography
P00935526A0000|92 102|sensitivity
P00935526A0000|159 168|resolution
P00935526A0000|179 185|columns
P00938594A0149|2 10|cessation
P00938594A0149|13 26|steroid therapy
P00938594A0149|30 36|patient
P00938594A0149|61 74|manifestations
P00938594A0149|89 104|osteoarthropathy
P00938594A0149|129 146|laboratory features
P00938594A0149|158 166|arthritis
P00941050T0000|3 8|effect
P00941050T0000|19 40|procainamide absorption
P00947327A0000|12 17|survey
P00947327A0000|23 31|situation
P00947327A0000|44 53|resistance
P00947327A0000|59 64|region
P00947327A0000|75 81|Bavaria
P00947327A0000|110 117|activity
P00947327A0000|121 136|sulfamethoxazole
P00947327A0000|142 153|trimethoprim
P00947327A0000|158 168|combination
P00947327A0000|187 197|antibiotics
P00947327A0000|217 222|agents
P00947327A0000|226 232|results
P00947327A0000|235 239|tests
P00947327A0000|250 260|combination
P00947327A0000|288 300|sulfanilamide
P00947327A0000|300 310|sulfamoxole
P00947327A0000|314 326|2,4-diamino-5
P00947327A0000|326 348|3,4,5-trimethoxy-benzyl
P00947327A0000|348 357|pyrimidine
P00947327A0000|358 369|trimethoprim
P00947327A0000|373 377|ratio
P00947327A0000|391 395|Nevin
P00947327A0000|395 403|Supristol
P00947327A0000|424 428|tests
P00947327A0000|433 439|TMP/SMZ
P00947834X0000|0 6|RESULTS
P00947834X0000|12 20|IgE levels
P00947834X0000|28 35|tendency
P00951909X0001|12 23|loop syndrome
P00951909X0001|43 48|author
P00951909X0001|50 56|opinion
P00951909X0001|61 69|diagnosis
P00951909X0001|83 94|loop syndrome
P00951909X0001|118 125|patients
P00951909X0001|137 158|Billroth-II gastrectomy
P00952734T0000|0 5|Letter
P00952734T0000|20 25|damage
P00952734T0000|38 42|cause
P00952734T0000|62 72|elastolysis
P00952734T0000|76 84|cutis laxa
P00954819A1041|33 40|recovery
P00954819A1041|60 67|function
P00954819A1041|73 84|intoxication
P00954819A1041|89 93|Soman
P00954819A1041|96 100|Sarin
P00954819A1041|121 126|return
P00954819A1041|129 140|AChE activity
P00956364A0138|0 12|Batch cultures
P00956364A0138|15 30|S. mutans serotype
P00956364A0138|46 51|growth
P00956364A0138|54 60|MSB agar
P00956554A0414|4 10|samples
P00956554A0414|13 17|serum
P00956554A0414|44 63|solid-phase allergens
P00956554A0414|70 79|reactivity
P00956554A0414|94 106|IgE antibodies
P00958550T0001|0 5|Crisis
P00958550T0001|22 30|community
P00958550T0001|38 44|Britain
P00959656A0250|8 12|women
P00959656A0250|33 38|levels
P00959656A0250|40 51|antithrombin
P00961711T0000|0 16|Hematology problem
P00961711T0000|22 26|month
P00962222A0633|22 31|variations
P00962222A0633|34 45|heme turnover
P00962222A0633|58 64|changes
P00962222A0633|67 92|erythrocyte characteristics
P00962222A0633|102 118|progesterone phase
P00962277T0000|0 12|Haemodilution
P00962277T0000|30 35|bypass
P00962277T0000|42 59|gelatine derivative
P00962277T0000|63 69|priming
P00964758T0001|14 25|plasmacytoma
P00964758T0001|31 42|parotid gland
P00968181A0264|12 17|calves
P00968181A0264|31 38|immunity
P00968181A0264|57 65|challenge
P00968181A0264|91 99|infection
P00970320A0000|3 13|performance
P00970320A0000|33 60|chemical cartridge respirators
P00970320A0000|92 101|conditions
P00970320A0000|104 116|copper smelter
P00970488A0105|22 29|increase
P00970488A0105|39 48|DA turnover
P00970488A0105|51 59|indicator
P00970488A0105|66 71|degree
P00970488A0105|74 91|DA receptor blocking
P00970488A0105|142 147|effect
P00970488A0105|150 161|neuroleptics
P00970488A0105|168 178|development
P00970488A0105|198 205|symptoms
P00970839A0118|0 11|Rainbow trout
P00970839A0118|39 47|trout farm
P00970839A0118|61 65|water
P00970839A0118|69 75|feeding
P00970839A0118|90 96|pellets
P00970839A0118|104 108|weeks
P00974901A0080|0 10|Stimulation
P00974901A0080|13 30|macrophage function
P00974901A0080|39 62|Bordetella pertussis cells
P00974901A0080|86 91|effect
P00974901A0080|105 118|susceptibility
P00975314T0001|7 17|amenorrhoea
P00975314T0001|56 64|karyotype
P00975314T0001|83 96|gonadoblastoma
P00975540T0000|14 20|methods
P00975540T0000|31 39|chemistry
P00975540T0000|40 50|application
P00975540T0000|53 71|mass fragmentography
P00975540T0000|74 94|high-accuracy analyses
P00980255T0000|0 10|Application
P00980255T0000|16 38|2-deoxy-D-glucose method
P00980255T0000|44 51|coupling
P00980255T0000|62 71|metabolism
P00980255T0000|75 83|blood flow
P00984209A0614|0 17|Serum gastrin levels
P00984209A0614|38 42|group
P00984209A0614|50 85|background serum gastrin concentrations
P00984209A0614|113 123|V&P patients
P00984209A0614|128 138|V&A patients
P00984209A0614|152 156|study
P00985110T0001|8 18|projections
P00985110T0001|31 37|portion
P00985110T0001|43 49|putamen
P00985110T0001|81 87|regions
P00985110T0001|106 111|cortex
P00985276A0000|0 8|Preflight
P00985276A0000|9 16|inflight
P00985276A0000|20 50|postflight exercise response tests
P00985276A0000|69 78|astronauts
P00985276A0000|90 102|Skylab mission
P00985276A0000|103 108|Skylab
P00985276A0000|122 131|evaluation
P00985276A0000|146 155|adaptation
P00985276A0000|167 180|weightlessness
P00985279A0493|17 40|hemoglobin concentrations
P00985279A0493|84 89|groups
P00985279A0493|92 99|CO2 group
P00985279A0493|116 123|decrease
P00986800A0325|3 10|Cu values
P00986800A0325|26 31|organs
P00986800A0325|55 69|saturation level
P00986800A0325|73 83|mug Cu/g diet
P00986800A0325|91 99|exception
P00986800A0325|105 110|values
P00986800A0325|114 119|body Cu
P00986800A0325|162 169|delivery
P00986925A0002|3 8|effect
P00986925A0002|11 20|calcitonin
P00986925A0002|27 32|amount
P00986925A0002|35 41|calcium
P00986925A0002|53 64|pentagastrin
P00986925A0002|68 75|glucagon
P00986925A0002|78 106|plasma 47Ca radioactivity curves
P00986925A0002|109 116|subjects
P00987649T0001|0 4|State
P00987649T0001|18 26|disorders
P00987649T0001|48 54|rhythms
P00987649T0001|67 77|hypokinesia
P00988572A0000|0 12|Oxygen tension
P00988572A0000|23 34|lymph vessels
P00988572A0000|46 59|rabbit hind limb
P00988572A0000|96 102|chamber
P00988572A0000|120 146|catheter-tip oxygen electrode
P00988572A0000|178 183|source
P00988572A0000|185 190|oxygen
P00988572A0000|196 200|lymph
P00989973A0000|3 10|response
P00989973A0000|16 36|plasma fibrinogen level
P00989973A0000|55 63|injection
P00989973A0000|66 75|turpentine
P00989973A0000|95 103|injection
P00989973A0000|106 114|endotoxin
P00989973A0000|134 140|rabbits
P00989973A0000|146 152|rabbits
P00989973A0000|196 203|busulfan
P00992316A0178|21 34|pressure curves
P00992316A0178|49 58|activities
P00992316A0178|100 107|criteria
P00992316A0178|127 135|gravidity
P00993176A0066|5 13|myoglobin
P00993176A0066|35 44|hemoglobin
P00993176A0066|49 60|heme pigments
P00993176A0066|78 84|portion
P00993176A0066|90 96|extract
P00993176A0066|115 124|hemoglobin
P00993176A0066|137 148|2SO4 solution
P00996272A0397|16 22|sources
P00996272A0397|25 29|error
P00996272A0397|39 49|variability
P00996272A0397|62 74|investigation
P00996272A0397|101 112|instructions
P00999494A0000|3 10|patients
P00999494A0000|18 26|diagnosis
P00999494A0000|34 38|mania
P00999494A0000|58 62|doses
P00999494A0000|91 106|agent propranolol
P01000378T0000|0 5|Effect
P01000378T0000|8 13|trauma
P01000378T0000|16 29|plasma glucagon
P01000378T0000|33 53|insulin concentrations
P01000378T0000|56 60|sheep
P01003819A0498|16 26|nomogram one
P01003819A0498|39 48|refraction
P01003819A0498|53 62|axis length
P01003819A0498|66 81|corneal curvature
P01004298A0744|4 13|up-grading
P01004298A0744|24 28|score
P01004298A0744|34 44|CA component
P01004298A0744|72 79|students
P01004298A0744|83 88|scores
P01004298A0744|101 105|level
P01009451A0728|10 17|controls
P01009451A0728|29 35|OCS rats
P01009451A0728|75 83|reduction
P01009451A0728|89 100|nocturnality
P01009451A0728|103 110|drinking
P01009739T0001|0 5|Effect
P01009739T0001|8 19|indomethacin
P01009739T0001|30 40|circulation
P01009739T0001|41 46|effect
P01009841T0001|4 14|innervation
P01009841T0001|21 26|fibers
P01009841T0001|29 40|trunk muscles
P01009841T0001|43 55|lamprey larvae
P01012640T0001|7 21|characteristics
P01012640T0001|24 33|eye changes
P01012640T0001|36 43|patients
P01012640T0001|48 63|pheochromocytoma
P01012640T0001|73 78|Sipple
P01012640T0001|80 87|syndrome
P01012904A0333|13 30|interference effect
P01012904A0333|59 69|populations
P01012904A0333|82 91|Stroop test
P01012904A0333|122 127|sample
P01012904A0333|141 146|format
P01019207A0232|30 39|conditions
P01019207A0232|47 56|dependence
P01019207A0232|73 83|betaI% value
P01019207A0232|100 104|range
P01019207A0232|111 123|mug ruscogenin
P01021091T0000|3 11|influence
P01021091T0000|24 29|nerves
P01021091T0000|35 42|response
P01021091T0000|45 56|blood vessels
P01021091T0000|62 70|rabbit ear
P01021091T0000|96 106|vasopressin
P01021091T0000|107 117|Octapressin
P01035457A0623|5 10|tumour
P01035457A0623|20 34|nipple discharge
P01035457A0623|45 54|importance
P01035457A0623|61 69|diagnosis
P01035457A0623|73 81|treatment
P01036714A0072|0 6|Studies
P01036714A0072|36 42|changes
P01036714A0072|66 72|animals
P01036714A0072|81 90|chrysotile
P01036714A0072|100 107|increase
P01036714A0072|123 136|cell population
P01036714A0072|158 163|levels
P01044338A0240|8 19|measurements
P01044338A0240|22 39|temperature changes
P01044338A0240|43 51|estimates
P01044338A0240|57 63|heating
P01047417T0000|7 31|National Health Dis-service
P01047895T0001|2 10|criticism
P01047895T0001|13 23|patient care
P01047895T0001|57 61|value
P01047895T0001|75 82|Patients
P01047895T0001|83 91|criticism
P01047895T0001|113 123|patient care
P01048020T0000|0 7|Critique
P01048020T0000|21 27|Effects
P01048020T0000|30 40|Test Anxiety
P01048020T0000|44 58|Credit/No Credit
P01048020T0000|61 77|A-F Grade Condition
P01048020T0000|112 128|Course Information
P01048968A0152|5 11|studies
P01048968A0152|28 35|majority
P01048968A0152|44 56|staphylococci
P01048968A0152|72 82|penicillin G
P01048968A0152|83 94|erythromycin
P01048968A0152|106 119|beta-lactamase
P01050144A0297|15 22|decrease
P01050144A0297|28 33|number
P01050144A0297|36 42|strains
P01050144A0297|65 75|antibiotics
P01050144A0297|99 105|strains
P01050144A0297|111 120|83A complex
P01050400T0000|0 10|Improvement
P01050400T0000|13 30|nursing instruction
P01050400T0000|53 61|discharge
P01050400T0000|86 92|infants
P01057137A0192|2 11|difference
P01057137A0192|25 37|acceptability
P01057137A0192|69 74|groups
P01064124A0560|11 20|subsurface
P01064124A0560|42 47|lesion
P01064124A0560|64 72|specimens
P01067493A0119|16 22|pattern
P01067493A0119|28 32|women
P01067493A0119|51 57|percent
P01067493A0119|78 84|methods
P01071715A0903|16 24|technique
P01071715A0903|36 58|blood pressure recordings
P01078982A0227|52 67|cyclophosphamide
P01078982A0227|69 90|antilymphocyte globulin
P01078982A0227|96 104|treatment
P01078982A0227|108 124|ALG administration
P01078982A0227|141 146|dosage
P01078982A0227|149 164|cyclophosphamide
P01080374A0709|0 7|Evidence
P01080374A0709|23 27|Leber
P01080374A0709|37 53|aneurysm retinitis
P01080374A0709|68 73|entity
P01080374A0709|93 97|Coats
P01080374A0709|97 103|disease
P01081904A0198|22 29|catheter
P01081904A0198|42 49|patients
P01081904A0198|59 79|pull-out arteriography
P01081904A0198|110 117|symptoms
P01082726A0248|3 11|influence
P01082726A0248|21 25|pupil
P01082726A0248|31 38|response
P01082726A0248|44 49|DC-ERG
P01082833A0000|34 38|agent
P01082833A0000|39 44|Y-8004
P01082833A0000|65 74|inhibition
P01082833A0000|82 93|indomethacin
P01082833A0000|128 135|response
P01082833A0000|153 160|erythema
P01082833A0000|163 172|guinea pigs
P01082833A0000|173 188|carrageenin edema
P01082833A0000|220 228|pleuritis
P01082833A0000|250 260|peritonitis
P01083321X0000|2 7|stands
P01083321X0000|17 25|dominance
P01083321X0000|48 59|subalpine fir
P01083321X0000|96 100|rates
P01083321X0000|115 126|productivity
P01083321X0000|132 137|stands
P01083321X0000|158 162|years
P01083375T0000|0 17|Alpha-1 antitrypsin
P01083375T0000|27 44|childhood cirrhosis
P01083784T0000|0 23|Lymphocyte subpopulations
P01083784T0000|24 31|serum IgE
P01083784T0000|40 55|eosinophil counts
P01083784T0000|58 65|patients
P01083784T0000|79 84|asthma
P01084413A0271|1 5|range
P01084413A0271|25 36|measurements
P01087288T0000|1 10|comparison
P01087288T0000|35 43|estimates
P01087288T0000|46 58|radiation dose
P01087288T0000|61 68|patients
P01087288T0000|80 89|iodine-131
P01087288T0000|93 108|thyroid carcinoma
P01088654T0001|0 8|Technique
P01088654T0001|28 35|ceramics
P01090210A0417|11 22|lung capacity
P01090210A0417|40 47|capacity
P01090210A0417|59 64|volume
P01090210A0417|93 109|mean closing volume
P01090210A0417|113 122|lung volume
P01090210A0417|136 141|volume
P01090210A0417|149 153|phase
P01090210A0417|190 194|cm H20
P01090210A0417|213 226|airway pressure
P01090210A0417|227 237|differences
P01090210A0417|241 245|cm H20
P01092248T0000|7 12|status
P01092248T0000|15 28|zinc deficiency
P01092248T0000|34 45|pathogenesis
P01092248T0000|92 100|disorders
P01093055T0000|0 6|Calcium
P01093055T0000|10 29|phosphorus metabolism
P01093055T0000|39 44|uremia
P01093845A0208|0 12|Modern studies
P01093845A0208|26 36|Delta-9-THC
P01093845A0208|46 56|voluntaries
P01093845A0208|72 81|comparison
P01093845A0208|91 98|identity
P01093845A0208|104 116|modifications
P01093845A0208|125 132|cannabis
P01093845A0208|137 141|sleep
P01093845A0208|145 149|dream
P01093847A0000|13 18|action
P01093847A0000|21 44|tropatepine hydrochloride
P01093847A0000|66 72|effects
P01093847A0000|82 93|neuroleptics
P01093847A0000|126 131|states
P01096741X0000|10 15|growth
P01096741X0000|29 35|animals
P01096741X0000|54 66|chickpea haulm
P01096741X0000|82 96|supplementation
P01097100A0217|3 10|patients
P01097100A0217|30 37|regimens
P01098179A0167|0 6|Results
P01098179A0167|44 55|preparations
P01098179A0167|75 91|dissolution curves
P01098179A0167|104 109|assays
P01098179A0167|125 139|chloramphenicol
P01098179A0167|154 160|release
P01098179A0167|169 176|activity
P01098179A0167|181 186|creams
P01098179A0167|205 213|ointments
P01098592A0567|0 8|IgG levels
P01098592A0567|45 51|samples
P01098592A0567|85 89|onset
P01099693T0000|0 5|Letter
P01099693T0000|6 17|Perspectives
P01099693T0000|20 44|bone marrow transplantation
P01101272T0000|0 9|Assessment
P01101272T0000|15 29|carcinogenicity
P01101272T0000|45 53|sweetners
P01101272T0000|56 65|Cyclamates
P01101272T0000|69 83|cyclohexylamine
P01103390A0149|13 21|behaviour
P01103390A0149|55 64|occurrence
P01103390A0149|70 76|animals
P01103390A0149|86 90|phase
P01103390A0149|102 109|increase
P01103390A0149|115 125|parasitemia
P01107226A0808|8 20|amphotericin B
P01107226A0808|37 41|feces
P01107226A0808|85 98|mg/ml dose level
P01113908A0475|15 22|increase
P01113908A0475|30 40|transferrin
P01113908A0475|52 57|tablet
P01113908A0475|60 65|values
P01113908A0475|91 100|experiment
P01116254A0000|20 33|administration
P01116254A0000|47 59|concentration
P01116254A0000|62 79|tracer thallium-201
P01116254A0000|80 91|potassium-43
P01116254A0000|95 105|rubidium-81
P01116254A0000|128 135|thallium
P01116254A0000|158 170|concentration
P01116254A0000|176 185|myocardium
P01116254A0000|209 217|potassium
P01116254A0000|228 235|rubidium
P01116254A0000|239 245|minutes
P01116466A0185|0 17|Thromboplastin time
P01116466A0185|25 42|thromboplastin time
P01116466A0185|43 54|thrombin time
P01116466A0185|69 74|fibrin
P01116466A0185|75 88|clot retraction
P01116466A0185|92 106|clotting factors
P01116466A0185|129 141|platelet count
P01118293A0150|19 24|notion
P01118293A0150|28 38|suppression
P01118293A0150|41 46|images
P01118293A0150|62 68|rivalry
P01119586A0337|0 18|Glycogen utilization
P01119586A0337|34 45|tissue levels
P01119586A0337|48 64|creatine phosphate
P01119586A0337|73 79|lactate
P01119586A0337|99 104|hearts
P01119658A0000|3 9|records
P01119658A0000|53 60|patients
P01119658A0000|73 85|cell carcinoma
P01119658A0000|95 100|cavity
P01119658A0000|101 110|oropharynx
P01119658A0000|123 128|larynx
P01119658A0000|132 142|hypopharynx
P01119658A0000|175 193|lymph node metastases
P01119658A0000|231 243|neck treatment
P01119658A0000|260 275|radiation therapy
P01122015A0467|32 37|values
P01122015A0467|44 50|mumol/1
P01122015A0467|55 62|mg/100 ml
P01122015A0467|69 75|mumol/1
P01122015A0467|80 87|mg/100 ml
P01123658A0000|3 9|authors
P01123658A0000|21 29|technique
P01123658A0000|47 56|tomography
P01123658A0000|62 66|spine
P01123658A0000|83 93|description
P01123658A0000|104 110|anatomy
P01123658A0000|128 132|spine
P01123658A0000|147 152|sacrum
P01124944A0830|15 22|attitude
P01124944A0830|27 37|protein diet
P01125117A0183|22 28|attacks
P01125117A0183|40 46|attacks
P01125117A0183|77 83|changes
P01125117A0183|114 119|groups
P01128985A0000|27 32|method
P01128985A0000|76 82|periods
P01128985A0000|85 89|apnea
P01128985A0000|101 108|patients
P01130186A0568|21 27|patient
P01130186A0568|47 60|insulin release
P01130186A0568|63 70|response
P01130186A0568|73 83|tolbutamide
P01130531A0224|0 15|Nerve stimulation
P01130531A0224|22 29|cycles/s
P01130531A0224|57 66|reductions
P01130531A0224|75 82|decrease
P01130531A0224|86 92|percent
P01130531A0224|116 124|frequency
P01131946T0001|0 5|Effect
P01131946T0001|8 16|ingestion
P01131946T0001|19 28|Norbiogest
P01131946T0001|47 52|period
P01131946T0001|65 70|organs
P01138215T0001|8 16|infection
P01138215T0001|21 29|treatment
P01138215T0001|32 40|fractures
P01138330A0204|6 12|pouches
P01138330A0204|29 37|solutions
P01138330A0204|42 46|% Na C1
P01138330A0204|50 53|N HC1
P01138330A0204|55 62|% glucose
P01138330A0204|64 68|% NaC1
P01138330A0204|73 80|% peptone
P01138330A0204|89 98|% solutions
P01138330A0204|101 121|acetylcholine chloride
P01140184A0342|0 14|Liver microsomes
P01140184A0342|49 70|epoxide hydrase activity
P01140184A0342|106 113|capacity
P01140184A0342|115 129|liver microsomes
P01141114A0188|30 37|increase
P01141114A0188|88 97|degrees C-v
P01141114A0188|100 105|Pv-CO2
P01141114A0188|130 136|effects
P01141114A0188|154 164|temperature
P01145884T0028|33 37|study
P01147436T0000|11 33|Burkitt Lymphoma Registry
P01147436T0000|35 48|progress report
P01147502T0000|0 9|Vitrectomy
P01147502T0000|27 42|instrument system
P01148868A0284|12 24|clearance rate
P01148868A0284|27 38|progesterone
P01148868A0284|54 58|1/day
P01150658A0683|4 11|sequence
P01150658A0683|55 61|hormone
P01150658A0683|62 67|Sairam
P01156631A0658|3 31|mean plasma sodium concentration
P01156631A0658|55 60|mEq/kg
P01156631A0658|74 82|treatment
P01156631A0658|114 122|treatment
P01156631A0658|140 145|mEq/kg
P01156814T0000|0 8|Editorial
P01156814T0000|17 23|heparin
P01156814T0000|30 39|prevention
P01156814T0000|48 68|thromboembolic disease
P01157191A0536|13 22|dose levels
P01157191A0536|27 41|sodium saccharin
P01157191A0536|45 59|sodium cyclamate
P01157191A0536|76 86|carcinogens
P01157191A0536|109 122|bladder tumours
P01157191A0536|153 159|tumours
P01157191A0536|185 189|weeks
P01157614T0000|0 6|Effects
P01157614T0000|19 26|salience
P01157614T0000|32 52|matrix task performance
P01157614T0000|74 81|children
P01158512T0000|19 31|dehydrogenase
P01158512T0000|32 37|G-6-PD
P01158512T0000|38 47|deficiency
P01158838A0438|46 53|flow rate
P01158838A0438|59 64|ml/min
P01159822A0353|12 20|epithelia
P01159822A0353|39 45|animals
P01159822A0353|70 83|ultrastructure
P01159822A0353|90 102|invaginations
P01159822A0353|126 133|increase
P01159822A0353|137 142|number
P01159822A0353|154 162|lysosomes
P01159822A0353|181 186|bodies
P01159822A0353|199 205|numbers
P01159822A0353|234 241|granules
P01168607A0672|10 23|administration
P01168607A0672|37 44|vitamins
P01168607A0672|86 100|prothrombin time
P01168607A0672|104 116|serum vitamins
P01168607A0672|126 134|intervals
P01168908A0000|0 14|Prostaglandins F
P01168908A0000|54 59|artery
P01168908A0000|68 77|vein plasma
P01168908A0000|97 103|tissues
P01168908A0000|113 117|times
P01168908A0000|140 144|cycle
P01168908A0000|172 195|plasma progesterone levels
P01168956A0552|46 55|weight gain
P01168956A0552|64 74|sensitivity
P01168956A0552|80 87|placenta
P01168956A0552|123 143|maximum weight decrease
P01168956A0552|149 153|organ
P01170143A0247|0 5|Groups
P01170143A0247|26 35|saline mice
P01170143A0247|70 79|conditions
P01170143A0247|99 107|cylinders
P01171020A0711|3 9|effects
P01171020A0711|26 46|nucleus accumbens septi
P01171935A0313|3 12|appearance
P01171935A0313|25 41|movement disorders
P01171935A0313|44 49|humans
P01171935A0313|76 83|levodopa
P01171935A0313|85 95|amphetamine
P01171935A0313|102 114|manifestation
P01171935A0313|135 165|dopamine receptor site sensitivity
P01171935A0313|175 182|striatum
P01172734T0035|0 10|Association
P01172917T0000|0 5|Letter
P01172917T0000|6 26|Lactose tolerance tests
P01172917T0000|30 38|predictor
P01172917T0000|41 53|milk tolerance
P01174873T0000|0 13|Retinoblastoma
P01174873T0000|15 19|study
P01174873T0000|29 35|history
P01174873T0000|39 47|prognosis
P01174873T0000|53 57|cases
P01176905A0094|10 18|melatonin
P01176905A0094|19 32|serum melatonin
P01176905A0094|42 49|mid-dark
P01176905A0094|58 66|mid-light
P01178637T0001|0 14|Atherosclerosis
P01185956A0722|3 9|authors
P01185956A0722|33 52|Doppler-cardiography
P01185956A0722|85 91|changes
P01185956A0722|97 108|stroke volume
P01186344A0303|3 12|attainment
P01186344A0303|21 28|maturity
P01186344A0303|31 35|terms
P01186344A0303|53 67|characteristics
P01186344A0303|71 80|production
P01186344A0303|83 93|spermatozoa
P01186344A0303|125 131|pattern
P01186344A0303|135 141|release
P01186344A0303|152 161|end-points
P01186344A0303|179 185|process
P01190120A0832|11 22|% lengthening
P01190120A0832|35 52|thromboplastin time
P01190120A0832|69 73|hours
P01190120A0832|76 82|storage
P01190251A0335|0 6|Caution
P01190251A0335|50 60|lymphograms
P01191955A0077|38 49|incompetence
P01191955A0077|74 80|varices
P01191955A0077|105 110|reflux
P01191964A0000|5 10|groups
P01191964A0000|13 20|patients
P01191964A0000|44 56|thyroidectomy
P01191964A0000|60 65|Graves
P01191964A0000|67 73|disease
P01191964A0000|91 96|goitre
P01191964A0000|120 125|goitre
P01191964A0000|132 136|years
P01191964A0000|159 172|serum thyroxine
P01191964A0000|178 182|level
P01191964A0000|212 220|subgroups
P01191964A0000|226 230|basis
P01191964A0000|249 278|serum thyrotrophin concentration
P01193458T0001|7 24|isotope cystography
P01193458T0001|33 47|Tc sulfur colloid
P01193458T0001|51 59|detection
P01193458T0001|63 71|follow-up
P01193458T0001|89 94|reflux
P01193770T0000|0 11|Air ion action
P01193770T0000|14 21|bacteria
P01194673A0652|2 9|evidence
P01194673A0652|36 46|chemography
P01201977T0000|3 16|interpretation
P01201977T0000|29 45|disc sensitivities
P01202616A0466|9 21|retransfusion
P01202616A0466|43 48|lining
P01202616A0466|90 102|lamina propria
P01202616A0466|139 144|detail
P01206772T0000|1 5|study
P01206772T0000|8 18|chromosomes
P01206772T0000|21 31|lymphocytes
P01206772T0000|36 43|patients
P01206772T0000|55 64|hycanthone
P01206896T0001|0 14|Characteristics
P01206896T0001|17 26|anesthesia
P01206896T0001|30 42|resuscitation
P01206896T0001|45 64|emergency lung surgery
P01208811T0001|0 4|Study
P01208811T0001|26 30|state
P01208811T0001|33 45|plutonium-239
P01208811T0001|49 75|citrate solution-blood system
P01209618A0409|0 9|Tobramycin
P01209618A0409|39 44|effect
P01209618A0409|47 55|dibecacin
P01209618A0409|78 95|potentiating effect
P01209618A0409|100 105|action
P01209618A0409|108 121|d-tubocurarine
P01211754A0192|20 24|cases
P01211754A0192|29 37|operation
P01211754A0192|60 70|improvement
P01211754A0192|74 81|patients
P01211754A0192|116 123|deafness
P01215067A0000|21 30|resistance
P01215067A0000|49 53|fluid
P01215067A0000|67 71|means
P01215067A0000|74 86|conductometry
P01215067A0000|91 95|cases
P01215067A0000|98 116|meningitis purulenta
P01215067A0000|119 123|cases
P01215067A0000|126 141|meningitis serosa
P01215067A0000|144 148|cases
P01215067A0000|151 162|encephalitis
P01215067A0000|177 184|subjects
P01217450A0295|2 18|Chemical occlusion
P01217450A0295|52 56|block
P01224116A0576|17 24|patients
P01224116A0576|34 53|serum immunoglobulins
P01224116A0576|73 77|Russe
P01224116A0576|77 81|Busey
P01224116A0576|85 91|Barbeau
P01224116A0576|127 132|family
P01225339A0590|17 26|occlusions
P01225339A0590|51 60|infarction
P01228258A0000|13 23|preparation
P01228258A0000|24 29|OK-432
P01228258A0000|53 57|agent
P01228258A0000|70 77|patients
P01228258A0000|90 95|cancer
P01228258A0000|98 108|combination
P01228258A0000|113 123|Mitomycin-C
P01228258A0000|133 151|Cytosine arabinoside
P01228882A0437|10 20|correlation
P01228882A0437|46 59|concentrations
P01228882A0437|62 79|CSF immunoglobulins
P01228882A0437|83 88|degree
P01228882A0437|112 119|response
P01228882A0437|134 142|component
P01228882A0437|162 169|diseases
P01233561T0001|8 16|lactation
P01235347T0001|12 25|cardiotoxicity
P01235347T0001|28 37|adriamycin
P01236224T0001|8 16|pathology
P01237206A0199|0 12|Demonstration
P01237206A0199|18 22|agent
P01237206A0199|54 60|day p.i.
P01237206A0199|80 86|methods
P01237206A0199|87 91|Stamp
P01237206A0199|95 110|auramine staining
P01237206A0199|122 138|antibody technique
P01237206A0199|142 156|Coxiella content
P01237206A0199|172 180|titration
P01241437A0152|3 10|patients
P01241437A0152|27 32|groups
P01241437A0152|42 46|NLA II
P01241437A0152|60 69|nalorphine
P01241437A0152|70 77|morphine
P01241437A0152|80 86|Micoren
P01241588A1470|3 13|alterations
P01241588A1470|25 36|5-HIAA levels
P01241588A1470|45 51|regions
P01241588A1470|57 61|brain
P01241588A1470|70 79|conditions
P01241588A1470|110 122|neurotoxicity
P01241588A1470|153 160|neurones
P01241866A0682|3 10|increase
P01241866A0682|13 28|leukocyte-counts
P01241866A0682|42 55|administration
P01241866A0682|58 62|serum
P01241866A0682|75 80|rabbit
P01241866A0682|87 93|phase-2
P01242636A0678|3 9|results
P01242636A0678|55 60|system
P01242636A0678|81 98|beryllium retention
P01243628A0286|6 10|cases
P01243628A0286|23 30|exposure
P01243628A0286|37 41|level
P01243628A0286|44 65|blood carboxyhemoglobin
P01244236A1122|3 9|results
P01244236A1122|40 48|blood flow
P01244236A1122|78 87|resistance
P01244236A1122|101 109|gestation
P01244236A1122|120 127|increase
P01244236A1122|138 143|number
P01244236A1122|146 152|vessels
P01244236A1122|165 183|vasomotor reactivity
P01244236A1122|197 204|increase
P01244236A1122|215 220|amount
P01244236A1122|229 234|muscle
P01244236A1122|243 251|thickness
P01244236A1122|254 259|muscle
P01244236A1122|272 278|vessels
P01245162A0262|0 8|Reduction
P01245162A0262|11 16|dosage
P01245162A0262|31 40|taste sense
P01245162A0262|110 127|transaminase levels
P01246210A0648|3 14|calcium ratio
P01246210A0648|14 22|mean ratio
P01246210A0648|79 83|women
P01247475A0000|5 13|diagnosis
P01247475A0000|16 29|retinoblastoma
P01247475A0000|67 72|growth
P01247475A0000|83 95|deterioration
P01247475A0000|101 107|outlook
P01248124A0281|5 15|cholesterol
P01248124A0281|37 42|fluids
P01248124A0281|63 68|stages
P01248124A0281|71 79|gestation
P01249198A1097|3 23|serum FT3 concentration
P01249198A1097|51 56|ranges
P01249198A1097|65 73|pregnancy
P01249198A1097|78 88|GTD patients
P01249198A1097|104 118|hyperthyroidism
P01252223A0347|3 9|authors
P01252223A0347|37 45|pugnacity
P01252223A0347|60 76|trait correlations
P01252223A0347|91 98|contrast
P01252223A0347|101 105|Winch
P01252223A0347|107 115|principle
P01252223A0347|125 139|complementarity
P01253191T0000|12 45|phase-plane technique representation
P01253191T0000|54 69|action potentials
P01256410T0001|1 10|activities
P01256410T0001|16 21|factor
P01256410T0001|24 31|molecule
P01256410T0001|44 49|infant
P01259027A0416|3 9|concept
P01259027A0416|22 36|identifiability
P01259027A0416|53 60|analysis
P01259027A0416|77 91|model parameters
P01259027A0416|170 178|procedure
P01259027A0416|187 195|extension
P01259027A0416|202 208|concept
P01259027A0416|241 248|approach
P01259027A0416|266 278|design problem
P01261005A0711|28 36|variation
P01261005A0711|40 50|differences
P01261005A0711|53 63|performance
P01261005A0711|77 84|bandpass
P01261005A0711|92 117|bandpass spectrophotometers
P01262596T0000|11 20|compromise
P01264640T0028|17 22|Saigon
P01265443A0159|10 16|glucose
P01265443A0159|45 63|Heidenhain pouch dogs
P01265443A0159|81 90|inhibition
P01265443A0159|113 125|acid secretion
P01265443A0159|133 137|pouch
P01265443A0159|148 154|stomach
P01265443A0159|172 177|saline
P01265443A0159|183 188|effect
P01265887T0001|8 26|factor VIII inhibitor
P01265887T0001|43 50|patients
P01267446A0210|0 15|Biohydrogenation
P01272816A0000|3 7|study
P01272816A0000|10 26|calcium metabolism
P01272816A0000|44 51|children
P01272816A0000|69 76|controls
P01272816A0000|86 99|administration
P01272816A0000|136 145|absorption
P01275335A0158|10 15|agents
P01275335A0158|35 39|semen
P01275335A0158|68 72|phase
P01275541A0405|21 31|CPK activity
P01275541A0405|45 52|newborns
P01275541A0405|86 94|dystrophy
P01275541A0405|119 123|weeks
P01275541A0405|129 136|delivery
P01276105A0313|2 9|contrast
P01276105A0313|13 27|insulin response
P01276105A0313|56 60|value
P01276105A0313|82 91|puerperium
P01278251A0000|3 9|authors
P01278251A0000|19 25|results
P01278251A0000|29 34|series
P01278251A0000|50 54|tests
P01278251A0000|73 81|materials
P01278251A0000|82 93|polyethylene
P01278251A0000|107 126|tetraphenylbutadiene
P01278251A0000|161 170|sensitizer
P01278251A0000|200 208|materials
P01279197T0000|10 17|analysis
P01279197T0000|28 41|homology region
P01279197T0000|44 66|Mason-Pfizer monkey virus
P01279197T0000|76 96|saturation mutagenesis
P01279352A0297|31 50|bp sequence GGGGAGGAGG
P01279352A0473|7 14|extracts
P01279352A0473|50 58|cell lines
P01279352A0473|59 68|mouse brain
P01279352A0473|72 81|mouse liver
P01279352A0473|89 96|proteins
P01279352A0473|131 142|PAL sequences
P01279352A0473|156 163|proteins
P01279352A0473|180 194|target sequences
P01279352A1197|22 29|promoter
P01279352A1197|45 50|tissue
P01279352A1197|59 64|manner
P01279352A1197|71 81|development
P01279352A1197|111 124|promoter region
P01279352A1197|133 162|beta-galactosidase reporter gene
P01279374A0396|30 34|genes
P01279374A0396|62 72|suppressors
P01279374A0396|106 115|truncation
P01279374A0396|118 123|PET122
P01279696A0862|8 14|studies
P01279696A0862|24 31|Hisanaga
P01279696A0862|36 43|Kusubata
P01279696A0862|47 53|Okumura
P01279696A0862|58 66|Kishimoto
P01280413T0001|0 8|Treatment
P01280413T0001|12 19|staining
P01280413T0001|22 27|smears
P01280413T0001|31 38|sections
P01280413T0001|42 50|detection
P01280413T0001|53 66|microorganisms
P01280807A0575|20 43|MetRS/CAU operator complex
P01280807A0575|48 61|order magnitude
P01280807A0575|81 104|ThrRS/CGU operator complex
P01281322A0604|18 29|relationship
P01281322A0604|51 68|percent area density
P01281322A0604|77 82|muscle
P01281322A0604|89 101|percent change
P01281322A0604|115 122|flow rate
P01281472T0000|0 5|Rabbit
P01281472T0000|14 29|muscle glycogenin
P01281771T0000|0 15|Characterization
P01281771T0000|40 50|cytokeratin
P01281771T0000|58 74|expression pattern
P01282014A0275|0 6|Animals
P01282014A0275|19 23|DSP-4
P01282014A0275|51 63|motor recovery
P01282014A0275|79 89|saline group
P01282638A0934|3 17|prophylactic use
P01282638A0934|23 32|medication
P01282638A0934|36 43|patients
P01282638A0934|68 72|cycle
P01282638A0934|75 86|chemotherapy
P01282638A0934|89 97|agreement
P01282638A0934|105 113|estimates
P01282638A0934|135 149|health care costs
P01282638A0934|166 172|quality
P01282638A0934|188 195|patients
P01282638A0934|207 218|continuation
P01282638A0934|233 240|schedule
P01282638A0934|248 259|interruption
P01282638A0934|278 291|life expectancy
P01282638A0934|297 303|patient
P01284032A0213|27 34|infusion
P01284032A0213|48 61|concentrations
P01284595A0102|3 11|isolation
P01284595A0102|37 50|identification
P01284595A0102|55 65|Y-231 cosmid
P01284595A0102|87 95|sequences
P01284595A0102|95 104|HTF islands
P01284595A0102|115 120|insert
P01284828T0001|0 25|Tissue plasminogen activator
P01284828T0001|29 37|inhibitor
P01284828T0001|46 55|parameters
P01284828T0001|58 69|fibrinolysis
P01284828T0001|72 76|blood
P01284828T0001|79 86|patients
P01284828T0001|102 112|hypertrophy
P01284828T0001|118 125|prostate
P01285009A0000|0 13|Gene constructs
P01285009A0000|31 43|growth hormone
P01285009A0000|82 89|sequence
P01285009A0000|90 109|mouse metallothionein
P01285009A0000|120 134|thymidine kinase
P01285009A0000|139 156|rat cholecystokinin
P01285009A0000|164 180|chicken beta-actin
P01285009A0000|210 218|cytoplasm
P01285009A0000|229 238|medaka eggs
P01285009A0000|245 253|micropyle
P01285358A0396|0 11|Serum gastrin
P01285358A0396|15 23|AFP levels
P01285358A0396|34 42|evolution
P01285358A0396|65 72|interest
P01285358A0396|84 89|course
P01285358A0396|95 101|disease
P01285554T0000|0 8|Prospects
P01285554T0000|31 37|systems
P01285807A0365|79 86|infusion
P01285807A0365|96 100|PaCO2
P01286732A0572|6 17|hepatomegaly
P01286732A0572|25 33|elevation
P01286732A0572|36 42|enzymes
P01286732A0572|70 79|proportion
P01286732A0572|82 89|patients
P01286732A0572|90 100|involvement
P01286732A0572|103 107|liver
P01286732A0572|122 130|hepatitis
P01286732A0572|133 149|liver cell necrosis
P01286732A0572|171 182|complication
P01286732A0572|185 203|P. falciparum malaria
P01287197A0761|11 15|group
P01287197A0761|26 33|decrease
P01287197A0761|36 50|plasma potassium
P01287197A0761|61 70|salbutamol
P01287197A0761|104 109|mmol/l
P01287197A0761|125 129|group
P01287197A0761|137 145|decrement
P01287197A0761|179 184|mmol/l
P01292230A0283|6 10|drugs
P01292230A0283|44 50|filling
P01294345A0591|25 35|improvement
P01294345A0591|44 57|administration
P01294345A0591|60 68|Bromergon
P01294345A0591|82 89|symptoms
P01294345A0591|104 119|overreactiveness
P01294345A0591|128 142|prolactin levels
P01294345A0591|156 162|tension
P01294345A0591|163 167|edema
P01294345A0591|168 177|weight gain
P01294345A0591|181 196|breast tenderness
P01295373A0651|3 11|magnitude
P01295373A0651|22 29|response
P01295373A0651|46 56|% baseline RL
P01295500A0366|9 16|patients
P01295500A0366|47 53|Attacks
P01295500A0366|88 95|Deficits
P01296815A0059|45 53|LD78 gamma
P01296815A0059|58 73|sequence analysis
P01296815A0059|98 107|pseudogene
P01297332A0983|4 11|analysis
P01297332A0983|25 37|consideration
P01297332A0983|85 89|genes
P01297332A0983|99 106|proposal
P01297332A0983|117 133|consensus sequence
P01297332A0983|160 166|element
P01297332T0000|10 17|analysis
P01297332T0000|21 31|DNA sequence
P01297332T0000|49 62|gene expression
P01297332T0000|68 76|cell cycle
P01298173A0153|10 16|history
P01298173A0153|24 30|lesions
P01298173A0153|43 52|efficiency
P01298173A0153|67 76|treatments
P01298173A0153|98 109|chemotherapy
P01298173A0153|109 116|survival
P01298173A0153|125 129|death
P01298173A0153|144 153|modalities
P01298173A0153|165 171|measure
P01298398A0461|3 8|method
P01298398A0461|25 37|determination
P01298398A0461|40 55|nadolol racemate A
P01298398A0461|59 64|change
P01298398A0461|73 88|phase composition
P01299489A0788|20 24|study
P01299489A0788|39 46|evidence
P01299489A0788|52 57|effect
P01299489A0788|60 74|supplementation
P01299489A0788|85 95|performance
P01299489A0788|99 106|athletes
P01300914A1066|5 11|absence
P01300914A1066|26 33|criteria
P01300914A1066|73 83|variability
P01300914A1066|85 91|results
P01300914A1066|104 110|dangers
P01300914A1066|127 132|biopsy
P01300914A1066|171 175|walls
P01300914A1066|179 187|diagnosis
P01300914A1066|221 229|existence
P01300914A1066|252 259|criteria
P01300914A1066|271 281|arrhythmias
P01300914A1066|336 342|feature
P01300914A1066|353 358|degree
P01300914A1066|361 371|sensitivity
P01300914A1066|384 394|stimulation
P01300914A1066|395 402|exercise
P01300914A1066|406 414|existence
P01300914A1066|421 430|potentials
P01300914A1066|440 455|amplification ECG
P01300914A1066|502 512|sensitivity
P01300914A1066|523 527|froms
P01300914A1066|598 612|RV abnormalities
P01300914A1066|670 677|vaulting
P01300914A1066|682 687|stasis
P01301171A0979|6 10|cases
P01301171A0979|14 21|enhancer
P01301171A0979|34 54|c-myc bearing sequences
P01301171A0979|57 66|chromosome
P01302765A0999|5 14|components
P01302765A0999|110 119|components
P01304515A0178|11 17|results
P01304515A0178|34 45|control group
P01304515A0178|54 63|volunteers
P01304809T0001|3 7|years
P01304809T0001|10 18|dentistry
P01304809T0001|24 50|Friedrich Schiller University
P01309244A0798|3 8|target
P01309244A0798|25 33|positions
P01309244A0798|66 76|orientation
P01309244A0798|87 95|cell types
P01309244A0798|99 105|species
P01309244A0798|114 120|context
P01309244A0798|136 143|promoter
P01309587A0715|11 25|transactivation
P01309587A0715|31 43|BMRF1 promoter
P01309587A0715|49 66|Z/c-myb combination
P01309587A0715|89 95|binding
P01309587A0715|101 108|Z protein
P01309587A0715|118 129|c-myb protein
P01309593A0095|3 17|UCR core sequence
P01309593A0095|18 26|CGCCATTTT
P01309593A0095|50 55|factor
P01309593A0095|75 84|regulation
P01309593A0095|87 106|MuLV promoter activity
P01309593A1092|5 11|studies
P01309593A1092|20 24|UCRBP
P01309593A1092|39 50|target motifs
P01309593A1092|73 80|UCR motif
P01309593A1092|100 114|virus P5 promoter
P01309593A1092|118 125|elements
P01309593A1092|131 149|immunoglobulin light
P01309593A1092|164 168|genes
P01309593A1092|177 184|elements
P01309593A1092|196 207|protein genes
P01309815A0972|11 24|scr1-1 mutation
P01309815A0972|38 54|signal recognition
P01309815A0972|70 75|arrest
P01309815A0972|95 105|maintenance
P01309815A0972|121 126|arrest
P01309815A0972|129 140|AEP synthesis
P01309860A0559|11 19|sequences
P01309860A0559|31 45|integration site
P01309860A0559|60 68|% identity
P01309860A0559|78 86|sequences
P01309860A0559|101 113|mouse L1 family
P01309860A0559|142 150|sequences
P01309894A0807|4 8|Rep78
P01309894A0807|12 16|Rep68
P01309894A0807|31 41|AAV sequence
P01309894A0807|57 66|nucleotide
P01309910A0428|0 25|Nucleotide sequence analysis
P01309910A0428|49 55|protein
P01309910A0428|74 85|CREB2 protein
P01310154A0879|5 11|results
P01310154A0879|44 52|mutations
P01310154A0879|72 86|transrepression
P01310154A0879|89 98|FBR protein
P01310154A0879|124 132|mutations
P01310154A0879|163 181|protein modification
P01310154A0879|187 200|gene regulation
P01310154A0879|203 212|FBR protein
P01310178A0876|3 27|JS78 mutation changes Gln243
P01310178A0876|40 49|amber codon
P01310178A0876|65 74|production
P01310178A0876|108 118|polypeptide
P01310178A0876|151 156|domain
P01310178A0876|159 183|host transcription shut-off
P01310879A0000|1 16|patient suffering
P01310879A0000|39 54|thrombocytopenia
P01310879A0000|69 85|arteriothromboses
P01310879A0000|98 104|failure
P01310879A0000|110 118|treatment
P01310879A0000|131 137|heparin
P01310899A0339|12 28|receptor structure
P01310899A0339|64 69|domain
P01310899A0339|88 106|transmembrane domain
P01310899A0339|131 158|serine/threonine kinase domain
P01310935T0000|10 14|UbcD1
P01310935T0000|59 64|enzyme
P01310935T0000|84 101|protein degradation
P01312005A0600|0 7|Analysis
P01312005A0600|26 33|mt genome
P01312005A0600|63 70|cleavage
P01312005A0600|72 81|chick mtDNA
P01312005A0600|130 140|target sites
P01312005A0600|176 180|tract
P01312005A0600|224 233|structures
P01312005A0600|250 254|bases
P01312005A0600|278 283|origin
P01312005A0600|290 300|replication
P01313715A0461|21 25|study
P01313715A0461|42 52|feasibility
P01313715A0461|55 64|retrovirus
P01313715A0461|73 82|expression
P01313715A0461|85 92|rp47phox
P01313715A0461|131 139|cell lines
P01313715A0461|157 161|virus
P01313715A0461|173 192|B-lymphocyte cell line
P01313715A0461|193 199|EBV-BCL
P01313715A0461|229 238|CGD patient
P01313846A0850|0 9|Comparison
P01313846A0850|17 33|sequence databanks
P01313846A0850|42 48|Tactile
P01313846A0850|52 57|member
P01313846A0850|63 91|immunoglobulin gene superfamily
P01313846A0850|96 105|similarity
P01313846A0850|128 143|melanoma Ag MUC-18
P01313846A0850|144 150|members
P01313846A0850|172 179|Ag family
P01313846A0850|183 200|poliovirus receptor
P01313846A0850|213 232|cell adhesion molecule
P01313894A1179|14 20|pattern
P01313894A1179|23 29|results
P01313894A1179|45 51|respect
P01313894A1179|54 72|LMP2B mRNA expression
P01313894A1179|77 87|transcripts
P01313894A1179|110 115|subset
P01313894A1179|118 123|tumors
P01313894A1179|146 151|levels
P01313909A0526|3 12|phenotypes
P01313909A0526|18 36|ICP0 nonsense mutants
P01313909A0526|79 83|virus
P01313909A0526|115 122|sequence
P01313909A0526|140 153|nonsense mutant
P01313909A0526|180 188|phenotype
P01314457T0000|0 7|Analysis
P01314457T0000|10 27|nucleotide sequence
P01314457T0000|51 68|herpesvirus saimiri
P01314457T0000|73 77|L-DNA
P01314457T0000|84 95|conservation
P01314457T0000|105 116|organization
P01314457T0000|144 148|virus
P01314841A0724|0 8|Treatment
P01314841A0724|13 18|MK-801
P01314841A0724|27 42|burst suppression
P01314841A0724|80 83|mm Hg
P01314841A0724|101 108|pressure
P01314953A1266|2 9|contrast
P01314953A1266|10 36|gel mobility shift experiments
P01314953A1266|80 85|domain
P01314953A1266|91 103|hap3 mutations
P01314953A1266|113 121|complexes
P01315706A0000|8 22|differentiation
P01315706A0000|42 61|adenovirus E1a protein
P01315706A0000|67 85|rat L6 muscle cell line
P01316125A0176|3 12|experiment
P01316125A0176|50 57|radicals
P01316125A0176|135 141|ability
P01316125A0382|3 8|points
P01316125A0382|44 49|damage
P01316125A0382|97 104|radicals
P01316125A0382|146 151|second
P01316125A0382|178 183|damage
P01316125A0382|239 244|damage
P01316125A0382|270 274|yield
P01316461A1083|23 31|S2 protein
P01316461A1083|44 51|peptides
P01316461A1083|131 136|horses
P01316461A1083|158 165|evidence
P01316461A1083|168 177|expression
P01316461A1083|184 190|protein
P01316461A1083|201 207|animals
P01316476A0842|13 25|TATA sequences
P01316476A0842|73 82|start sites
P01316476A1428|67 75|induction
P01316476A1428|76 80|genes
P01316476A1428|107 115|induction
P01316680A0643|16 21|IR5 ORF
P01316680A0643|24 28|EHV-1
P01316680A0643|39 46|sequence
P01316680A0643|51 60|amino acids
P01316680A0643|61 73|CAYWCCLGHAFAC
P01316680A0643|88 92|match
P01316680A0643|98 121|consensus zinc finger motif
P01316680A0643|122 137|C-X2-4-C-X2-15-C
P01316680A0643|137 144|H-X2-4-C
P01316900A0000|3 13|DNA sequence
P01316900A0000|19 40|sulfate activation locus
P01316903A0296|27 39|RNA polymerase
P01316903A1040|0 15|RNA polymerase IIA
P01316903A1040|53 61|complexes
P01316903A1040|64 72|reactions
P01316903A1040|83 93|input enzyme
P01316903A1040|97 112|RNA polymerase IIA
P01317376A0981|0 19|Fructokinase activity
P01317376A0981|45 53|Z. mobilis
P01317376A0981|64 71|fructose
P01317376A0981|81 87|glucose
P01317376A0981|108 115|increase
P01317376A0981|118 130|frk mRNA levels
P01318310A0000|0 14|Plasma membranes
P01318310A0000|25 29|cells
P01318310A0000|41 57|affinity receptors
P01318310A0000|65 82|density lipoprotein
P01318310A0000|107 113|removal
P01318310A0000|134 144|cholesterol
P01318739A0410|15 33|patients vincristine
P01318739A0410|47 56|teniposide
P01318739A0410|57 61|VM-26
P01318739A0410|67 79|neurotoxicity
P01320255A0795|5 11|results
P01320255A0795|39 45|element
P01320255A0795|73 82|L1 sequence
P01320255A0795|96 108|factor binding
P01320255A0795|114 120|element
P01320255A0795|144 156|transcription
P01320640A0336|0 9|Tumor cells
P01320640A0336|53 59|enolase
P01320640A0336|60 66|insulin
P01320640A0336|67 74|glucagon
P01321277A0342|79 102|chicken embryo fibroblasts
P01321277A0342|105 126|spindle shape morphology
P01321277A0664|36 43|deletion
P01321277A0664|79 84|domain
P01321280A0494|11 16|number
P01321280A0494|20 25|nature
P01321280A0494|38 51|E7 gene products
P01321280A0494|79 83|cells
P01321280A0494|95 124|immunoprecipitation experiments
P01321280A0494|129 136|antisera
P01321280A0494|165 171|BPV-1 E6
P01321280A0494|175 190|E7 fusion proteins
P01321332A0970|9 26|transfection assays
P01321332A0970|37 41|site A
P01321332A0970|88 102|transactivation
P01321332A0970|107 115|apoAI gene
P01321332A0970|121 128|promoter
P01321332A0970|136 153|hepatoma HepG2 cells
P01321332A0970|159 166|presence
P01321332A0970|184 198|transactivation
P01321332A0970|221 227|amounts
P01321332A0970|243 247|ARP-1
P01321336A0000|3 16|enhancer region
P01321336A0000|30 42|leukemia virus
P01321336A0000|53 73|sequence motif ACAGATGG
P01321336A0731|3 16|splice variants
P01321336A0731|19 26|ALF1 cDNA
P01321336A0731|57 65|insertion
P01321336A0731|83 90|proteins
P01321336A0731|102 111|amino acids
P01321337A0318|15 23|component
P01321337A0318|72 81|properties
P01321337A0318|89 95|ability
P01321337A0318|102 106|45Ca2
P01321337A0318|146 152|subunit
P01321337A0318|163 173|calcineurin
P01321337A0318|194 202|antiserum
P01321337A0318|222 232|calcineurin
P01321337A1161|26 37|MATa cna1 cna2
P01321337A1161|44 50|mutants
P01321337A1161|51 65|MATa cnb1 mutants
P01321337A1161|86 92|ability
P01321337A1161|126 137|growth arrest
P01324172A0880|0 9|Antibodies
P01324172A0880|29 35|protein
P01324172A0880|52 63|mitochondria
P01324385A0329|0 6|METHODS
P01324385A0329|7 19|IgG antibodies
P01324385A0329|22 26|HHV-6
P01324385A0329|27 40|anti-HHV-6-IgG
P01324385A0329|65 82|immunofluorescence
P01324385A0329|96 107|seronegative
P01324385A0329|127 131|HIV-1
P01324385A0329|147 151|stage
P01324385A0329|161 165|IV-C1
P01324385A0329|193 200|subjects
P01324385A0329|215 226|control group
P01324404A0813|21 36|activation domain
P01324404A0813|60 66|regions
P01324404A0813|93 108|carboxyl terminus
P01324404A0813|114 129|HNF-3 beta protein
P01324404A0813|130 139|amino acids
P01324404A1208|0 8|HNF-3 beta
P01324404A1208|23 31|sequences
P01324404A1208|50 55|region
P01324404A1208|75 89|transactivation
P01324404A1208|93 98|region
P01324404A1208|101 108|activity
P01324404A1208|120 132|participation
P01324404A1208|138 155|region II-III domain
P01324406A1250|8 12|roles
P01324406A1250|29 54|ATPase/DNA helicase activity
P01324406A1250|56 64|DNA repair
P01324406A1250|73 83|maintenance
P01324406A1250|95 99|rates
P01324406A1250|102 112|instability
P01324406A1250|131 139|sequences
P01324639T0000|0 15|Susceptibilities
P01324639T0000|43 49|bacilli
P01324639T0000|52 62|amoxicillin
P01324639T0000|63 77|amoxicillin-BRL
P01324639T0000|83 105|amoxicillin-clavulanate
P01324639T0000|106 117|temafloxacin
P01324639T0000|121 131|clindamycin
P01325221A0870|10 15|arrest
P01325221A0870|18 27|DU249 cells
P01325221A0870|46 54|detection
P01325221A0870|76 84|MBP kinase
P01325221A0870|104 115|p41 MAP kinase
P01325221A0870|133 146|chromatography
P01325386A0766|3 16|hit1-1 mutation
P01325386A0766|24 29|defect
P01325386A0766|32 40|synthesis
P01325386A0766|49 64|heat shock protein
P01326329A0703|6 19|base pair region
P01326329A0703|44 50|CAP site
P01326329A0703|88 94|TATA box
P01326329A0703|100 107|presence
P01326329A0703|110 118|sequences
P01326329A0703|128 134|GC boxes
P01326329A0703|135 144|CACCC boxes
P01326329A0703|145 154|CCAAT boxes
P01326329A0703|155 170|activator protein
P01326329A0703|178 182|sites
P01326329A0703|189 218|glucocorticoid response elements
P01326329A0703|241 259|AMP response elements
P01326557T0000|0 6|Cloning
P01326557T0000|17 25|structure
P01326557T0000|28 35|neurocan
P01326557T0000|72 101|chondroitin sulfate proteoglycan
P01326557T0000|104 108|brain
P01327280A0000|25 34|chloralose
P01327280A0000|37 43|changes
P01327280A0000|77 90|cord dorsal horn
P01327280A0000|128 137|electrodes
P01327758A0000|0 10|Replication
P01327758A0000|19 34|papillomavirus-1
P01327758A0000|35 39|BPV-1
P01327758A0000|61 72|gene products
P01327758A0000|75 83|E1 protein
P01327758A0000|101 109|E2 protein
P01327967A0668|11 22|inactivation
P01327967A0668|44 54|sensitivity
P01327967A0668|69 95|agent methylmethane sulfonate
P01327967A0668|105 115|requirement
P01327967A0668|119 124|serine
P01327967A0668|132 142|metabolites
P01328197A0985|5 12|findings
P01328197A0985|27 60|MAP kinase activator/MAP kinase system
P01328197A0985|79 88|components
P01328197A0985|91 119|ras signal transduction pathways
P01328219A1397|0 5|NSCL-1
P01328219A1397|26 31|number
P01328219A1397|39 47|cell lines
P01328681A0149|17 24|proteins
P01328681A0149|47 66|c-myc hyperexpression
P01328681A0149|88 100|transcription
P01328681A0149|107 116|activities
P01328681A0149|130 137|proteins
P01328681A0149|167 176|inhibition
P01328681A0149|179 194|protein synthesis
P01328681A0348|0 6|Ruddell
P01328854T0000|7 15|MEF-2 site
P01328854T0000|42 48|element
P01328854T0000|60 72|transcription
P01328854T0000|93 99|subunit
P01328854T0000|110 135|phosphoglycerate mutase gene
P01328854T0000|156 166|muscle cells
P01328884T0000|0 17|Truncation variants
P01328884T0000|20 27|peptides
P01328884T0000|40 47|MHC class
P01328884T0000|50 58|molecules
P01328884T0000|66 79|sequence motifs
P01329039A0239|11 24|E-box consensus
P01329039A0239|45 50|CANNTG
P01329039A0239|62 72|nucleotides
P01329039A0239|85 91|E-boxes
P01329039A0239|106 110|genes
P01329039A0239|129 136|proteins
P01329039A0951|0 17|Intermediate levels
P01329039A0951|20 31|gene activity
P01329039A0951|47 58|TnI enhancers
P01329039A0951|69 75|E-boxes
P01329039A0951|99 107|E-box site
P01329039A0951|116 129|Ig kappa E2 E-box
P01330077A0000|0 17|T-cell receptor beta
P01330077A0000|18 24|TCR beta
P01330077A0000|25 42|gene rearrangements
P01330077A0000|63 68|B-cell
P01330077A0000|87 95|leukemias
P01330309A1134|3 14|CANNTG motifs
P01330309A1134|39 60|myogenin fusion proteins
P01330309A1134|77 84|proteins
P01330309A1134|94 101|extracts
P01330309A1134|114 121|myotubes
P01330975T0000|10 23|polyneuropathy
P01330975T0000|46 52|myeloma
P01331057A0000|24 28|COX12
P01331057A0000|48 57|subunit VIb
P01331057A0000|82 99|cytochrome c oxidase
P01331060A0768|3 11|structure
P01331060A0768|17 32|calcineurin A gene
P01331060A0768|48 57|comparison
P01331060A0768|73 85|cDNA sequences
P01331086T0000|8 23|promoter elements
P01331086T0000|32 56|cytochrome c oxidase subunit
P01331086T0000|92 100|ets motifs
P01331086T0000|122 141|transcription factors
P01331292A1425|22 30|instances
P01331292A1425|43 57|oligonucleotide
P01331292A1425|64 70|repeats
P01331292A1425|77 82|region
P01331292A1425|99 105|variola
P01331292A1425|108 120|vaccinia virus
P01331501A0397|28 35|peptides
P01331501A0397|60 68|sequences
P01331501A0397|92 102|interaction
P01331501A0397|112 118|cyclin A
P01331516A0103|5 11|mutants
P01331516A0103|26 48|3T6 mouse fibroblast cells
P01331516A0103|83 87|virus
P01331516A0103|90 111|coinfection experiments
P01331516A0103|114 124|C2 myoblasts
P01332589A0666|15 22|compound
P01332589A0666|40 48|organisms
P01332589A0666|78 85|S. aureus
P01332589A0666|124 136|micrograms/ml
P01332964A0247|10 17|promoter
P01332964A0247|23 33|RII beta gene
P01332964A0247|68 75|elements
P01333035T0000|0 6|Mapping
P01333035T0000|10 39|cAMP receptor protein contact site
P01333035T0000|45 56|alpha subunit
P01333035T0000|74 86|RNA polymerase
P01333047A0404|23 34|growth factor
P01333047A0404|53 75|growth factor stimulation
P01333047A0404|97 101|cells
P01333047A0404|109 123|phosphorylation
P01333047A0404|126 135|Nck protein
P01333047A0404|138 145|tyrosine
P01333047A0404|146 151|serine
P01333047A0404|155 171|threonine residues
P01333053A0110|6 14|mechanism
P01333053A0110|22 56|steroid hydroxylase gene transcription
P01333053A0110|80 85|cortex
P01333053A0110|106 119|peptide hormone
P01333125A0000|1 11|combination
P01333125A0000|25 40|sequence analysis
P01333125A0000|57 63|methods
P01333125A0000|74 85|conservation
P01333125A0000|96 112|structure elements
P01333125A0000|131 136|region
P01333125A0000|149 161|enteroviruses
P01333125A0000|164 175|rhinoviruses
P01333317A1008|8 13|region
P01333317A1008|58 64|protein
P01333317A1008|84 89|factor
P01333317A1008|92 96|PRF-I
P01334428A1102|19 28|substrates
P01334428A1102|38 44|peptide
P01334428A1102|83 96|mumol min-1 mg-1
P01334428A1102|110 123|mumol min-1 mg-1
P01334493A0289|28 32|sHGFr
P01334493A0289|47 54|affinity
P01334493A0289|100 107|receptor
P01334518T0000|0 9|Strategies
P01334518T0000|13 26|blood screening
P01334518T0000|33 47|hepatitis C virus
P01334518T0000|62 82|immunodeficiency virus
P01334518T0000|89 98|risk groups
P01337142A2043|12 44|glycoprotein alpha-subunit promoter
P01337142A2043|71 76|GH4 rat
P01337142A2043|85 89|cells
P01337142A2043|106 113|ABSTRACT
P01337142A2043|128 132|WORDS
P01338867A0503|0 9|Comparison
P01338867A0503|33 39|results
P01338867A0503|48 56|treatment
P01338867A0503|70 79|antagonist
P01338867A0503|111 118|blockade
P01338867A0503|131 143|fatiguability
P01338867A0503|152 157|extent
P01338867A0503|169 178|activation
P01338867A0503|187 192|system
P01339125A0153|0 16|Laboratory studies
P01339125A0153|35 39|teeth
P01339125A0153|61 65|teeth
P01339125A0153|82 91|dentifrice
P01339125A0153|107 112|enamel
P01339125A0153|115 125|bleach teeth
P01339373T0000|0 8|Structure
P01339373T0000|12 21|expression
P01339373T0000|35 53|Arabidopsis thaliana
P01339373T0000|62 68|protein
P01339373T0000|78 94|SNF1 protein kinase
P01339391A0000|34 39|region
P01339391A0000|42 60|DNA surrounding HRAS1
P01339468A0272|3 13|ORF1 protein
P01339468A0272|55 77|potexvirus RNA replicases
P01339468A0272|93 100|proteins
P01339468A0272|108 116|analogues
P01339468A0272|125 129|potex
P01339468A0272|154 161|proteins
P01339773A0000|1 5|total
P01339773A0000|11 18|patients
P01339773A0000|34 39|groups
P01339773A0000|64 72|diagnosis
P01339773A0000|93 103|capnography
P01339773A0000|104 113|spirometry
P01339773A0000|126 133|analysis
P01339773A0778|3 15|relationships
P01339773A0778|33 41|pressures
P01339773A0778|74 82|gradients
P01339773A0778|103 110|increase
P01339773A0778|116 141|ventilation-perfusion ratio
P01339815A1545|13 24|correlations
P01339815A1545|27 33|peak VO2
P01339815A1545|57 61|tests
P01340470A0000|13 23|protein gene
P01340470A0000|66 84|RNA recognition motif
P01340470A0000|89 95|Arg-Ser
P01340470A0000|104 109|domain
P01341119A0450|4 18|research studies
P01341119A0450|42 47|tumors
P01341119A0450|60 68|ingestion
P01341119A0450|71 82|H2 inhibitors
P01341119A0450|86 98|others antacid
P01346262A0377|12 16|study
P01346262A0377|27 41|protein profiles
P01346262A0377|53 68|S. entomophila UC9
P01346262A0377|132 138|protein
P01346262A0377|175 181|protein
P01346534T0000|0 15|Characterization
P01346534T0000|21 27|regulon
P01346534T0000|71 77|protein
P01347476T0000|0 6|Mapping
P01347476T0000|12 25|mouse ornithine
P01347476T0000|47 60|sequence family
P01347664A1026|4 11|mutation
P01347664A1026|42 47|levels
P01347664A1026|50 56|CAD mRNA
P01347664A1026|60 66|protein
P01347664A1026|72 77|mutant
P01347908T0000|3 11|rationale
P01347908T0000|37 47|stimulation
P01347908T0000|50 57|patients
P01347908T0000|62 70|Parkinson
P01347908T0000|72 78|disease
P01347944A0964|10 16|studies
P01347944A0964|37 58|homeodomain binding site
P01347944A0964|61 68|sequence
P01347944A0964|91 100|regulation
P01348504A0757|7 29|pol alpha-primase complex
P01348504A0757|67 74|distance
P01348508A0313|16 24|positions
P01348508A0313|32 38|introns
P01348508A0313|58 67|comparison
P01348508A0313|75 79|genes
P01348508A0313|111 120|activities
P01348508A0313|135 144|literature
P01348508A0313|151 158|TGM1 gene
P01348508A0313|208 214|introns
P01348590A0000|16 23|analysis
P01348590A0000|38 42|cases
P01348590A0000|55 62|lymphoma
P01348590A0000|68 73|cohort
P01348590A0000|92 99|patients
P01348590A0000|103 107|stage
P01348590A0000|110 120|HIV-disease
P01348590A0000|148 156|diagnosis
P01348590A0000|182 187|agents
P01348590A0000|189 200|radiotherapy
P01348590A0000|219 225|outcome
P01349705T0000|0 6|Effects
P01349705T0000|9 15|dioxins
P01349705T0000|18 32|thyroid function
P01349705T0000|42 47|babies
P01349837T0000|0 9|cDNA clones
P01349837T0000|18 36|Arabidopsis thaliana
P01349837T0000|40 46|Zea mays
P01349837T0000|60 74|chaperonin HSP60
P01349837T0000|78 91|gene expression
P01349837T0000|98 112|seed germination
P01349837T0000|116 124|heat shock
P01350780A0184|0 26|Amino acid sequence comparison
P01350780A0184|46 53|homology
P01350780A0184|64 68|yeast
P01350780A0184|87 107|gamma-glutamyl kinases
P01350780A0184|123 129|lengths
P01350932A1123|17 29|glycosylation
P01350932A1123|45 54|C-terminus
P01350932A1123|60 80|N-glycosylation sequon
P01350932A1123|81 91|Asn-Cys-Ser
P01350932A1123|118 133|disulphide bridge
P01352113A0002|17 22|events
P01352113A0002|37 51|nitrogen dioxide
P01352113A0002|56 63|exposure
P01352113A0002|95 109|inhalation model
P01352113A0002|133 140|measures
P01352113A0231|12 18|effects
P01352113A0231|61 77|NO2 concentrations
P01352113A0231|100 105|ppm NO2
P01352113A0231|110 117|mg m-3 NO2
P01352113A0231|121 133|exposure times
P01353478T0000|0 10|Interaction
P01353478T0000|13 17|H-2Eb
P01353478T0000|24 41|IAP retrotransposon
P01353478T0000|47 65|A20/2J B cell lymphoma
P01354506T0000|24 31|diseases
P01354506T0000|38 45|advances
P01354506T0000|51 63|understanding
P01354506T0000|66 77|cytogenetics
P01354506T0000|78 91|histopathology
P01354506T0000|102 108|history
P01357190A0726|7 15|exception
P01357190A0726|18 24|mutants
P01357190A0726|38 57|membrane anchor domain
P01357190A0726|72 84|glycoproteins
P01357190A0726|96 102|ability
P01357190A0726|110 115|fusion
P01357190A0726|129 133|cells
P01357528A0084|3 16|subunit protein
P01357528A0084|19 23|curli
P01357528A0084|48 60|amino terminus
P01357528A0084|63 68|SEF-17
P01357528A0084|72 85|subunit protein
P01357528A0084|103 110|fimbriae
P01357528A0084|139 146|strain 3b
P01357528A0084|166 171|fibres
P01357528A0084|182 186|class
P01357528A0084|189 205|surface organelles
P01357528A0084|208 221|enterobacteria
P01358190A0654|0 11|Substitution
P01358190A0654|17 28|DR1 beta chain
P01358190A0654|33 41|H-2E beta k
P01358190A0654|64 74|recognition
P01358190A0654|74 95|alpha chain substitution
P01358190A0654|110 115|effect
P01358592A0752|22 28|pathway
P01358592A0752|57 64|cell fate
P01358592A0752|89 93|state
P01358592A0752|114 119|region
P01358592A0752|125 130|embryo
P01358758A0000|9 15|portion
P01358758A0000|21 35|rat insulin I gene
P01358758A0000|60 75|sequence elements
P01358758A0000|86 97|FLAT elements
P01358758A0000|114 124|combination
P01358758A0000|177 184|enhancer
P01358880A0251|10 26|amino acid sequence
P01358880A0251|37 45|% identity
P01358880A0251|64 87|transglutaminase sequence
P01359588A0375|4 14|computation
P01359588A0375|37 43|network
P01359588A0375|73 80|elements
P01360180A0513|8 14|efforts
P01360180A0513|35 47|baculoviruses
P01360180A0513|68 73|kinase
P01360180A0513|87 98|recombinants
P01360180A0513|123 128|kinase
P01360180A0513|143 148|domain
P01360180A0513|151 158|mutation
P01360180A1568|26 41|P68 amino terminus
P01360180A1568|81 85|dsRNA
P01360180A1568|121 130|properties
P01360180A1568|134 152|reporter gene product
P01360294A0000|4 9|August
P01360294A0000|16 22|October
P01360294A0000|44 48|women
P01360294A0000|56 63|subjects
P01360294A0000|79 84|levels
P01360294A0000|87 92|plasma
P01360294A0000|103 114|antithrombin
P01360294A0000|123 130|activity
P01363080A0710|6 11|acuity
P01363080A0710|37 43|changes
P01363080A0710|56 60|error
P01363080A0710|69 80|sulfonamides
P01363080A0710|94 111|agent metronidazole
P01363080A0710|120 128|diuretics
P01363080A0710|140 158|anhydrase inhibitors
P01363166T0001|0 14|Currents aspects
P01363166T0001|17 37|H2 receptor antagonists
P01363166T0001|43 51|treatment
P01363166T0001|54 59|ulcers
P01364100A0377|2 9|addition
P01364100A0377|17 34|subrepeat structure
P01370281A0461|0 9|Sequencing
P01370281A0461|30 41|reading frame
P01370281A0461|57 63|protein
P01370446A0818|5 9|sites
P01370446A0818|26 54|keratan sulfate attachment sites
P01371181A0688|13 20|plasmids
P01371181A0688|26 35|pLS1 family
P01371181A0688|36 40|pE194
P01371181A0688|41 47|pADB201
P01371181A0688|57 61|share
P01371181A0688|84 98|characteristics
P01371181A0688|105 114|regulation
P01371181A0688|122 132|copy numbers
P01371272A1167|0 11|Perturbation
P01371272A1167|14 22|dNTP pools
P01371272A1167|38 55|frameshift fidelity
P01371272A1167|72 94|yeast DNA polymerase alpha
P01371275T0000|12 21|expression
P01371275T0000|30 36|subunit
P01371275T0000|51 56|ATPase
P01371275T0000|64 70|tissues
P01371413A0742|2 9|addition
P01371413A0742|13 22|hGCSFR gene
P01371413A0742|50 69|Southern blot analysis
P01371413A0742|75 92|segregation pattern
P01371413A0742|96 100|panel
P01371413A0742|103 124|rodent-human hybrid DNAs
P01371413A0742|145 153|cDNA probe
P01371863A0000|55 64|gene family
P01371863A0000|70 96|protozoan parasite Leishmania
P01372365A1202|6 10|sites
P01372365A1202|39 52|concentrations
P01372365A1202|70 76|sites %T
P01372365A1202|103 112|conditions
P01372456A0426|0 7|Necrosis
P01372456A0426|24 33|TA infusion
P01372456A0426|46 51|extent
P01372456A0426|80 86|animals
P01372456A0426|104 112|% necrosis
P01372802A1481|2 8|summary
P01372802A1481|12 19|segments
P01372802A1481|39 55|amino acid residues
P01372802A1481|111 118|epitopes
P01372802A1481|152 162|C3 fragments
P01372802A1481|187 205|fluid-phase fragment
P01372802A1481|216 223|segments
P01372802A1481|232 239|residues
P01372802A1481|273 280|epitopes
P01372802A1481|352 360|fragments
P01372802A1481|365 371|protein
P01372900A0448|5 9|exons
P01372900A0448|29 33|exons
P01372900A0448|61 77|amino acid residues
P01372900A0448|87 108|alpha s1-casein variant A
P01372900A1017|37 48|organization
P01372900A1017|54 88|goat alpha s1-casein transcription unit
P01372900A1017|100 133|polymerase chain reaction experiments
P01373374A0735|0 9|Homodimers
P01373374A0735|20 27|proteins
P01373374A0735|52 61|G-box motif
P01373374A0735|75 85|GBF3 binding
P01373374A0735|115 122|sequence
P01374331A0636|46 54|start site
P01374331A0636|63 80|nuclease S1 analysis
P01374392A0341|3 20|hydrophobicity plot
P01374392A0341|23 27|NHE-3
P01374392A0341|49 53|NHE-1
P01374392A0341|57 61|NHE-2
P01374398A0951|10 27|translation protein
P01374398A0951|83 102|amino acid composition
P01374398A0951|143 159|amino acid residues
P01374688A0471|4 8|group
P01374688A0471|19 23|ml/kg
P01374688A0471|32 45|% pentafraction
P01374688A0471|46 57|% pentastarch
P01374688A0471|60 65|plasma
P01374688A0471|77 81|hours
P01374688A0471|92 106|micrograms/kg/0
P01374688A0471|108 111|hr E.
P01375224A0152|21 28|evidence
P01375224A0152|41 45|v-Crk
P01375224A0152|55 68|transformation
P01375224A0152|71 94|chicken embryo fibroblasts
P01375224A0152|111 118|activity
P01375224A0152|129 136|proteins
P01375224A0152|147 162|growth regulation
P01375913A0484|31 49|DNA oligonucleotides
P01375913A0484|51 62|U14 snRNA gene
P01375913A0484|92 118|T7 RNA polymerase promoter site
P01375913A0484|139 145|plasmid
P01376319T0000|9 18|pseudogene
P01376319T0000|23 27|mouse
P01376319T0000|44 69|mannose 6-phosphate receptor
P01377696A0000|3 7|chick
P01377696A0000|23 52|surface glycoprotein neurofascin
P01377696A0000|73 78|growth
P01377696A0000|82 94|fasciculation
P01377696A0000|107 137|antibody perturbation experiments
P01377764A0309|3 11|carcinoma
P01377764A0309|34 43|epithelium
P01377764A0309|59 63|layer
P01377764A0309|86 90|layer
P01377818A0468|2 9|addition
P01377818A0468|10 18|C/EBP beta
P01377818A0468|22 31|C/EBP gamma
P01377818A0468|78 87|C/EBP alpha
P01377962A1012|2 9|contrast
P01377962A1012|10 20|tobacco GS-2
P01377962A1012|33 40|subunits
P01377962A1012|63 68|organs
P01378052A0594|16 22|acoXABC
P01378052A0594|34 38|types
P01378052A0594|41 49|sequences
P01378052A0594|68 75|symmetry
P01378052A0594|133 141|sequences
P01378052A0594|169 186|activator sequences
P01378127A0841|11 17|effects
P01378127A0841|23 39|calcium supplement
P01378127A0841|42 58|calcium antagonist
P01378127A0841|94 102|responses
P01378431A0202|18 22|M.-Y.
P01378431A0202|19 33|Vallejo-Ramirez
P01378431A0202|38 43|Inouye
P01378431A0202|50 55|Inouye
P01378506A0884|15 33|full-deletion mutant
P01378506A0884|47 51|block
P01378506A0884|54 65|virus release
P01378506A0884|96 108|virus assembly
P01378526A0535|29 45|FK506 plasma levels
P01378526A0535|66 75|appearance
P01378526A0535|82 87|effect
P01379032A0495|6 12|percent
P01379032A0495|15 22|patients
P01379032A0495|40 47|steroids
P01379032A0495|61 71|steroid dose
P01379032A0495|77 81|group
P01379032A0495|93 100|steroids
P01379032A0495|113 122|prednisone
P01379150A0996|4 14|cibenzoline
P01379150A0996|42 46|agent
P01379150A0996|77 83|profile
P01379150A0996|112 116|class
P01379150A0996|118 122|drugs
P01379150A0996|125 132|patients
P01379150A0996|142 148|therapy
P01379150A0996|156 170|risk arrhythmias
P01380062A0097|0 7|T antigen
P01380062A0097|45 55|T lymphocyte
P01380062A0097|61 79|recognition epitopes
P01380062A0097|86 92|targets
P01380062A0097|96 107|CTL clones Y-1
P01380076A0165|3 8|method
P01380076A0165|32 37|column
P01380076A0165|42 60|paired-ion technique
P01380076A0165|71 84|docusate sodium
P01380076A0165|94 103|components
P01380454A0451|24 37|protein product
P01380454A0451|43 51|ref-1 gene
P01380454A0451|65 82|DNA binding activity
P01380454A0451|85 103|Fos-Jun heterodimers
P01380454A0451|104 120|Jun-Jun homodimers
P01380454A0451|124 143|Hela cell AP-1 proteins
P01380454A0451|170 189|transcription factors
P01380454A0451|199 207|NF-kappa B
P01380454A0451|216 222|members
P01380454A0451|227 240|ATF/CREB family
P01380716A0174|9 15|tissues
P01380716A0174|40 45|molars
P01380716A0174|77 90|calcium hydrate
P01380825A0622|0 19|Northern blot analyses
P01380825A0622|51 55|mRNAs
P01380825A0622|96 102|tissues
P01380825A0622|127 133|protein
P01380825A0622|164 171|function
P01383690A1023|3 14|ARG SH2 domain
P01383690A1023|38 45|affinity
P01383690A1023|107 118|ABL SH2 domain
P01383695A0100|12 25|EBV B-cell clone
P01383695A0100|26 30|E29.1
P01383695A0100|53 58|embryo
P01383695A0100|75 82|IgM kappa
P01383695A0100|86 94|IgM lambda
P01384040A1043|17 26|activation
P01384040A1043|46 52|regions
P01384040A1043|80 90|orientation
P01384040A1043|118 122|pCF10
P01384165A0000|21 26|effect
P01384165A0000|30 36|omentum
P01384165A0000|50 64|vascularization
P01384165A0000|70 76|trachea
P01384165A0000|82 93|regeneration
P01384165A0000|106 115|epithelium
P01384165A0000|130 134|stage
P01384165A0000|144 159|tracheal grafting
P01384229A0175|46 55|chicken ICS
P01384229A0175|57 71|oligonucleotide
P01384229A0175|91 99|sequences
P01384229A0175|105 113|BF-IV gene
P01384229A0175|148 153|copies
P01384229A0175|163 178|herpes TK promoter
P01384229A0175|193 224|chloramphenicol acetyl transferase
P01384229A0175|236 242|pBLCAT2
P01385462A0151|103 119|acid determination
P01385462A0151|131 143|determination
P01385462A0151|149 158|monoamines
P01386210A0293|45 51|therapy
P01386210A0293|54 62|treatment
P01386210A0293|71 80|depression
P01386210A0293|103 119|GM2 gangliosidosis
P01386897A0000|0 4|Entry
P01386897A0000|7 16|yeast cells
P01386897A0000|31 39|cell cycle
P01386897A0000|40 44|Start
P01386897A0000|65 75|CDC28 kinase
P01386897A0000|104 110|cyclins
P01387105A0933|7 26|Southern blot analyses
P01387105A0933|38 46|backcross
P01387105A0933|79 85|strains
P01387105A0933|95 105|cell hybrids
P01387105A0933|136 141|cyclin
P01387105A0933|151 159|sequences
P01387105A0933|170 182|loci Cycb1-rs1
P01387105A0933|185 193|Cycb1-rs9
P01387105A0933|206 221|mouse chromosomes
P01388160A1102|5 18|residue Glu-381
P01388160A1102|56 62|residue
P01388160A1102|69 82|epsilon peptide
P01388160A1102|106 120|peptide sequence
P01388160A1102|139 145|choices
P01388160A1102|148 154|Ser-106
P01388160A1102|155 161|Ser-107
P01388160A1102|164 170|Ser-108
P01389362T0000|0 8|Porcelain
P01389362T0000|17 28|bond strength
P01389362T0000|34 47|dentin adhesive
P01389573A1071|18 25|quotient
P01389573A1071|30 39|difference
P01389573A1071|62 72|measurement
P01389585A0825|18 27|Scotchbond
P01389585A0825|32 50|Prisma Universal Bond
P01389585A0825|73 92|dentine bonding agents
P01389585A0825|95 100|choice
P01391001A0583|26 38|yeasts species
P01391001A0583|40 44|total
P01391001A0583|67 75|ATB method
P01391001A0583|98 104|methods
P01392012A0228|19 29|vasopressin
P01392012A0228|33 47|oxytocin content
P01392012A0228|63 75|pressor effect
P01392012A0228|85 92|Dekanski
P01392012A0228|108 115|activity
P01392012A0228|132 140|van Dongen
P01392277A0000|0 7|Comments
P01392277A0000|28 33|status
P01392277A0000|36 46|regulations
P01392277A0000|57 61|water
P01392277A0000|64 76|swimming pools
P01392277A0000|80 84|baths
P01392277A0000|91 100|connection
P01392277A0000|108 121|KOK regulations
P01392277A0000|145 152|standard
P01392358A0389|4 8|reply
P01392358A0389|20 35|telephone contact
P01392358A0389|38 47|home visits
P01394200A0592|3 16|treatment group
P01394200A0592|33 48|T-cell activation
P01394200A0592|62 72|lymphopenia
P01394200A0592|84 103|rebound lymphocytosis
P01394200A0592|107 118|upregulation
P01394200A0592|124 140|subset markers CD25
P01394200A0592|141 151|interleukin
P01394200A0592|153 160|receptor
P01394200A0592|164 169|CD45RO
P01394200A0592|178 182|cells
P01394655A0615b|0 13|Urease activity
P01394655A0615b|25 30|amount
P01394655A0615b|33 49|ammonia production
P01394655A0615b|105 122|Jack bean meal urease
P01395755A1023|23 33|differences
P01395755A1023|65 71|methods
P01395755A1023|83 94|oxygen uptake
P01395755A1023|101 106|ml/min
P01395755A1023|115 120|ml/min
P01395755A1023|130 143|oxygen delivery
P01395755A1023|150 155|ml/min
P01395755A1023|165 170|ml/min
P01395755A1023|190 195|output
P01395755A1023|202 206|L/min
P01395755A1023|216 220|L/min
P01396432A0388|13 17|range
P01396432A0388|29 37|functions
P01396432A0388|60 66|seizure
P01396432A0388|81 90|assessment
P01396432A0388|93 109|memory performance
P01396444A0934|3 13|experiments
P01396444A0934|29 39|micromilieu
P01396444A0934|45 51|alveoli
P01396444A0934|58 66|condition
P01396444A0934|96 111|activation states
P01396444A0934|127 134|activity
P01396444A0934|162 167|degree
P01396444A0934|170 177|recovery
P01396572A0320|21 32|plasmid pUC19
P01396572A0320|73 84|plasmid pUC19
P01396572A0320|103 107|dG-dC
P01396572A0320|107 113|segment
P01396572A0320|119 124|Z-form
P01396572A0320|139 148|competitor
P01396583A0204|1 11|cDNA library
P01396583A0204|14 24|tumour cells
P01396583A0204|42 52|interleukin
P01396583A0204|67 71|probe
P01396592A1113|3 13|experiments
P01396592A1113|28 34|SCL gene
P01396592A1113|41 46|target
P01396592A1113|62 86|transcription factor GATA-1
P01396592A1113|97 110|SCL gene product
P01396592A1113|128 136|regulator
P01396592A1113|148 162|differentiation
P01396601A0986|2 9|contrast
P01396601A0986|20 26|domains
P01396601A0986|29 34|Sec12p
P01396601A0986|35 39|Stl1p
P01396601A0986|43 47|Stl2p
P01396601A0986|98 105|homology
P01398068A0948|0 8|Complexes
P01398068A0948|37 42|his175
P01398068A0948|45 50|his273
P01398068A0948|57 67|p53 proteins
P01398068A0948|98 111|RGC DNA sequence
P01398071A0526|5 15|temperature
P01398071A0526|33 39|strains
P01398071A0526|57 64|extracts
P01398071A0526|76 87|BRF1 activity
P01398071A0526|119 126|activity
P01398071A0526|129 142|RNA polymerases
P01398073A0986|5 11|results
P01398073A0986|54 65|TFIID protein
P01398073A0986|89 99|stimulation
P01398073A0986|109 125|activation domains
P01398073A0986|143 150|promoter
P01398074A0697|3 14|gene sequence
P01398074A0697|56 63|yeast RNA
P01398074A0697|76 101|RNase MRP enzyme preparations
P01398074A1081|3 17|RNase MRP RNA gene
P01398074A1081|41 51|replacement
P01398074A1081|84 92|viability
P01398074A1081|128 135|RNase MRP
P01398098A0770|0 17|Clone pSRc200 hybrid
P01398098A0770|49 59|translation
P01398098A0770|74 84|polypeptide
P01398104A0834|9 15|results
P01398104A0834|16 20|CBF-A
P01398104A0834|29 35|CArG box
P01398104A0834|36 40|ssDNA
P01398104A0834|55 61|protein
P01398104A0834|96 101|factor
P01398106A0754|0 7|Cleavage
P01398106A0754|27 32|enzyme
P01398106A0754|33 38|I-CreI
P01398106A0754|64 82|intron insertion site
P01398106A0754|106 111|bottom
P01398106A0754|111 117|strands
P01398106A0754|160 168|overhangs
P01398106A0754|173 181|OH termini
P01398140A0488|15 27|Xenopus U7 gene
P01398140A0488|62 67|motifs
P01398140A0488|127 134|location
P01399206A0375|3 9|results
P01399206A0375|24 30|reports
P01399206A0375|35 55|collagenase inhibitors
P01399206A0375|78 93|blister formation
P01399206A0375|115 134|epidermolysis bullosa
P01400217T0000|10 17|analysis
P01400217T0000|29 61|IncP alpha plasmid transfer genes traF
P01400217T0000|74 84|involvement
P01400217T0000|94 109|phage sensitivity
P01400396A1265|3 10|promoter
P01400396A1265|35 47|phorbol esters
P01400396A1265|97 106|activation
P01400396A1265|109 126|protein kinase C beta
P01400401A0065|2 7|humans
P01400401A0065|12 31|AMP deaminase variants
P01400401A0065|41 46|muscle
P01400401A0065|49 53|liver
P01400401A0065|64 74|erythrocyte
P01400401A0065|94 100|variety
P01400401A0065|130 137|criteria
P01400401A0854|0 18|Western blot analyses
P01400401A0854|40 55|immunoreactivity
P01400401A0854|75 82|extracts
P01400401A0854|106 115|expression
P01400401A0854|128 136|AMPD3 cDNA
P01400775A0435|5 11|results
P01400775A0435|37 49|N-methylation
P01400775A0435|52 61|salsolinol
P01400775A0435|66 83|N-methylsalsolinol
P01400775A0435|95 99|brain
P01402647A0114|0 11|DR1 molecules
P01402647A0114|43 51|cell lines
P01402647A0114|80 95|peptide sequences
P01402647A0114|110 121|phage surface
P01403222A0391|4 10|article
P01403222A0391|47 51|woman
P01403222A0391|74 86|blood donation
P01403222A0391|102 112|transfusion
P01403391T0000|7 16|hepatitis B
P01403391T0000|34 41|children
P01404401A0740|9 21|ATPase cluster
P01404401A0740|29 41|reading frames
P01404401A0740|84 98|chloroplast gene
P01404612A0303|75 82|proteins
P01404612A0303|94 110|vaccine candidates
P01406630A0545|0 8|Alignment
P01406630A0545|22 30|sequences
P01406630A0545|50 66|consensus sequence
P01406630A0545|70 76|binding
P01406630A0545|114 121|proteins
P01406630A0545|136 150|binding analysis
P01406630A0545|164 175|DNA sequences
P01406630A0545|184 202|sequence specificity
P01406630A0545|208 215|proteins
P01406630A0965|31 41|kappa B motif
P01406630A0965|67 73|binding
P01406630A0965|78 84|respect
P01406630A0965|95 101|protein
P01406630A0965|112 118|binding
P01406630A0965|150 165|NF-kappa B complex
P01406656A1075|14 18|clone
P01406656A1075|38 47|mouse alpha
P01406656A1075|118 123|levels
P01406656A1075|122 132|fibroblasts
P01406677A0000|23 37|control elements
P01406677A0000|67 76|expression
P01406677A0000|87 99|myoglobin gene
P01406677A0000|121 128|analysis
P01406677A0000|139 147|sequences
P01406677A0000|148 166|nucleotide positions
P01406677A0000|203 211|start site
P01406677A0000|228 241|luciferase gene
P01406688A0898|0 17|Sequencing analysis
P01406688A0898|34 44|rap1t allele
P01406688A0898|54 69|nonsense mutation
P01406688A0898|85 90|region
P01406688A0898|98 107|amino acids
P01406703A1435|12 28|Y1 cell cDNA library
P01406703A1435|47 52|region
P01406703A1435|58 65|H-2RIIBP
P01406703A1435|73 91|hormone receptor cDNA
P01406703A1435|150 154|cells
P01407286A0427|0 6|Autopsy
P01407286A0427|23 30|survival
P01407286A0427|48 52|cells
P01407286A0427|61 71|integration
P01407286A0427|79 83|brain
P01407286A0427|101 106|traces
P01407286A0427|135 142|reaction
P01407286A0427|146 164|tyrosine hydroxylase
P01408090A0572|3 11|technique
P01408090A0572|17 32|TEE visualization
P01408090A0572|54 61|arteries
P01408137A0974|3 10|sequence
P01408137A0974|17 22|region
P01408137A0974|32 41|G+C content
P01408137A0974|102 110|mRNA start
P01408137A0974|110 113|% G+C
P01408219A0670|10 17|patients
P01408219A0670|43 58|lymph-adenopathy
P01408219A0670|67 75|nontender
P01408219A0670|87 91|nodes
P01408219A0670|102 109|analysis
P01408219A0670|126 136|hyperplasia
P01408474A0531|0 12|PaO2 threshold
P01408474A0531|35 44|indwelling
P01408474A0531|47 60|sensor catheter
P01409581A0206|36 40|v-ets
P01409581A0206|69 76|factor PU
P01409643A0618|7 26|lambda gt11 expression
P01409643A0618|38 53|oligonucleotides
P01409643A0618|77 97|immunodeficiency virus
P01409643A0618|99 109|TATA element
P01409643A0618|121 134|identification
P01409643A0618|146 152|protein
P01409643A0618|208 218|TATA element
P01409643A0618|227 232|factor
P01410071T0000|0 10|Blood levels
P01410071T0000|13 21|melatonin
P01410071T0000|22 30|serotonin
P01410071T0000|31 38|cortisol
P01410071T0000|42 50|prolactin
P01410071T0000|53 60|relation
P01410071T0000|75 80|rhythm
P01410071T0000|83 105|platelet serotonin uptake
P01413984A0737|18 23|effect
P01413984A0737|29 45|FA supplementation
P01413984A0737|53 63|cholesterol
P01413984A0737|64 77|HDL cholesterol
P01413984A0737|78 91|LDL cholesterol
P01413984A0737|92 96|apo A1
P01413984A0737|101 105|HbA1C
P01413984A0737|105 111|glucose
P01413984A0737|112 121|fibrinogen
P01413984A0737|122 131|factor VIII
P01413984A0737|132 143|antithrombin
P01413984A0737|147 175|plasminogen activator inhibitor
P01413984A0737|176 201|tissue plasminogen activator
P01413984A0737|205 236|von Willebrand factor concentration
P01413984A0737|276 288|blood pressure
P01414219A0319|10 19|volunteers
P01414219A0319|42 52|differences
P01414219A0319|60 83|peak plasma concentrations
P01414219A0319|97 109|concentration
P01418272A1072|6 10|ng/mL
P01418272A1072|16 21|cutoff
P01418272A1072|25 35|sensitivity
P01418494T0000|8 13|spikes
P01418494T0000|26 33|function
P01418542A0000|3 8|effect
P01418542A0000|11 16|sodium
P01418542A0000|19 36|beta-glycyrrhetate
P01418542A0000|56 65|arrhythmia
P01418834A0987|11 28|hematocrit decrease
P01418834A0987|76 88|blood pressure
P01418834A0987|119 122|mm Hg
P01418860A0797|3 9|effects
P01418860A0797|12 20|diltiazem
P01418860A0797|47 58|potentiation
P01418860A0797|73 81|diltiazem
P01418860A0797|110 114|cases
P01418860A0797|137 145|diltiazem
P01418860A0797|163 184|calcium channel blockade
P01418860A0797|204 215|interactions
P01419945A1386|0 11|Localization
P01419945A1386|25 30|plexus
P01419945A1386|38 52|nerve stimulator
P01419945A1386|76 87|interscalene
P01419945A1386|114 118|sites
P01420177A1065|0 11|Substitution
P01420177A1065|20 24|Val33
P01420177A1065|34 38|Gly28
P01420177A1065|66 73|residues
P01420177A1065|78 91|protein kinases
P01420177A1065|102 107|enzyme
P01420177A1065|132 139|activity
P01420223T0000|0 11|Significance
P01420223T0000|17 26|biopsy site
P01420223T0000|32 52|latissimus dorsi muscle
P01420223T0000|56 66|fiber typing
P01420363A0818|13 19|AP1 site
P01420363A0818|33 37|motif
P01420363A0818|47 60|c-Fos/c-Jun AP1
P01420363A0818|94 103|competitor
P01420363A0818|107 113|binding
P01420363A0818|123 132|AP1 factors
P01420363A0818|138 149|consensus TRE
P01420363A0818|155 162|addition
P01420363A0818|170 176|factors
P01420363A0818|202 213|consensus TRE
P01420363T0000|0 10|Involvement
P01420363T0000|21 36|PEA3 binding sites
P01420363T0000|41 50|regulation
P01420363T0000|59 73|tissue inhibitor
P01420363T0000|76 95|metalloproteinases-1
P01420363T0000|96 101|TIMP-1
P01420363T0000|102 114|transcription
P01420579A0292|5 21|serum neutralizing
P01420579A0292|26 33|antibody
P01420579A0292|41 46|calves
P01420579A0292|81 90|SN antibody
P01420579A0292|90 94|month
P01420579A0292|126 136|vaccination
P01421145A1190|0 12|Fractionation
P01421145A1190|27 34|extracts
P01421145A1190|37 65|heparin-agarose chromatography
P01421145A1190|79 84|PCAT-1
P01421145A1190|102 109|extracts
P01421145A1190|135 144|leaf tissue
P01421390T0000|11 15|trial
P01421390T0000|74 79|factor
P01421390T0000|90 104|body irradiation
P01421390T0000|114 125|chemotherapy
P01421390T0000|139 163|bone marrow transplantation
P01421390T0000|185 192|leukemia
P01421390T0000|204 211|lymphoma
P01421609A1067|58 63|trauma
P01421609A1067|112 118|support
P01422265A0263|3 20|IgG subclass profile
P01422265A0263|32 45|coeliac disease
P01422265A0263|76 83|controls
P01422265A0263|134 142|magnitude
P01422265A0263|154 170|subclass responses
P01422265A0263|187 201|coeliac patients
P01423454A0309|0 10|Examination
P01423454A0309|40 51|contribution
P01423454A0309|71 79|diagnosis
P01423454A0309|87 96|vasculitis
P01423454A0309|106 114|indicator
P01423454A0309|120 127|activity
P01423454A0309|133 139|disease
P01423454A0309|152 164|effectiveness
P01423454A0309|184 192|treatment
P01423738A0639|21 32|pinealectomy
P01423738A0639|69 75|rabbits
P01423738A0639|104 115|deceleration
P01423738A0639|121 127|rhythms
P01423738A0639|128 139|mean delta tau
P01424674A0000|11 20|pemphigoid
P01424674A0000|43 49|disease
P01424674A0000|84 96|cicatrization
P01425653T0000|3 9|effects
P01425653T0000|15 20|levels
P01425653T0000|23 39|caffeine ingestion
P01425653T0000|60 76|oxygen consumption
P01425653T0000|88 92|women
P01425921A1286|17 24|features
P01425921A1286|38 53|amino acid changes
P01425921A1286|70 83|lysine deletion
P01425921A1286|102 118|consensus sequence
P01425921A1286|152 157|region
P01426635A0496|9 15|profile
P01426635A0496|18 22|ZFH-2
P01426635A0496|80 88|serotonin
P01426635A0496|90 104|dopamine neurons
P01427034A0440|9 15|introns
P01427034A0440|42 53|protein genes
P01427034A0440|89 96|S13 genes
P01427034A0440|119 130|DNA sequences
P01427034A0440|146 151|length
P01427034A0440|162 168|introns
P01427457A0000|32 36|trial
P01427457A0000|50 57|efficacy
P01427457A0000|99 112|calcium heparin
P01427457A0000|126 138|sodium heparin
P01427457A0000|144 152|treatment
P01427457A0000|172 181|thrombosis
P01428490A0671|10 19|prevalence
P01428490A0671|30 39|pet allergy
P01428490A0671|47 51|cough
P01428490A0671|52 57|wheeze
P01428490A0671|58 64|attacks
P01428490A0671|67 75|shortness
P01428490A0671|78 83|breath
P01428490A0671|115 120|asthma
P01428490A0671|131 138|children
P01428513A0440|44 50|persons
P01429596A1669|5 9|basis
P01429596A1669|23 32|properties
P01429596A1669|54 66|hemagglutinin
P01429596A1669|87 120|18K agglutination-aggregation factor
P01429596A1669|121 127|18K-LAF
P01429624A0328|3 7|shift
P01429624A0328|26 36|temperature
P01429624A0328|63 68|guanyl
P01429624A0328|88 95|activity
P01429624A0328|98 112|adenylylcyclase
P01429724A0664|40 45|domain
P01429724A0664|47 51|Nmt1p
P01429724A0664|68 72|Ile59
P01429724A0664|73 77|Phe96
P01429724A0664|81 86|Gly451
P01429724A0664|87 92|Leu455
P01429740A1065|39 49|presequence
P01429740A1065|70 75|domain
P01429740A1065|92 96|exons
P01429740A1065|122 127|E2 gene
P01429768T0000|5 22|neutrophil response
P01429768T0000|35 42|exposure
P01429768T0000|63 67|alloy
P01429836A0457|0 9|Disruption
P01429836A0457|12 23|microtubules
P01429836A0457|39 46|fidelity
P01429836A0457|49 56|kinetics
P01429836A0457|67 80|protein sorting
P01429836A0457|95 107|Vps1p function
P01429836A0457|124 135|microtubules
P01429836A1205|15 19|Vps1p
P01429836A1205|46 51|domain
P01429836A1205|74 87|protein sorting
P01429836A1205|99 103|cells
P01431380A0244|14 26|field research
P01431380A0244|30 38|tick fauna
P01431380A0244|106 110|ticks
P01431380A0244|115 121|vectors
P01431380A0244|145 160|group rickettsiae
P01431380A0244|167 174|antibody
P01431380A0244|200 212|tick emulsions
P01431380A0244|212 219|findings
P01431380A0244|222 232|rickettsiae
P01431380A0244|243 253|patient sera
P01431380A0244|283 290|antibody
P01431380A0244|304 317|hemolymph cells
P01431380A0244|323 327|ticks
P01431380A0244|331 338|electron
P01431380A0244|352 363|observations
P01431380A0244|389 394|organs
P01431380A0244|414 418|gland
P01431380A0244|421 425|ticks
P01431602A0229|9 14|method
P01431602A0229|18 22|macro
P01431602A0229|23 27|assay
P01431602A0229|32 47|sensitivity range
P01431602A0229|57 76|micrograms phosphorus
P01431602A0229|88 103|microliters HClO4
P01431809T0000|0 17|Nucleotide sequence
P01431809T0000|36 43|analysis
P01431809T0000|49 62|polyhedrin gene
P01431809T0000|65 80|Spodoptera exigua
P01431809T0000|88 104|polyhedrosis virus
P01432453T0000|0 9|Validation
P01432453T0000|21 27|systems
P01432453T0000|28 43|system definition
P01433391A0594|3 13|consequence
P01433391A0594|20 26|rearing
P01433391A0594|39 45|density
P01433391A0594|56 62|neurons
P01433391A0594|99 103|value
P01433391A0594|127 133|kittens
P01433502A1163|5 11|results
P01433502A1163|32 36|class
P01433502A1163|38 53|enhancer activity
P01433502A1163|72 76|cells
P01433502A1163|111 116|levels
P01433502A1163|137 142|factor
P01433502A1163|160 168|repressor
P01433524A0788|7 12|domain
P01433524A0788|38 47|amino acids
P01433524A0788|92 101|activities
P01435698A0000|2 6|order
P01435698A0000|23 40|blood compatibility
P01435698A0000|53 61|vein graft
P01435698A0000|67 73|changes
P01435698A0000|75 86|prostacyclin
P01435698A0000|93 102|production
P01435698A0000|111 120|harvesting
P01435698A0000|132 143|implantation
P01436261A0145|0 25|Subcutaneous administration
P01436261A0145|31 50|somatostatin analogue
P01436261A0145|51 60|octreotide
P01436261A0145|64 73|micrograms
P01436261A0145|105 115|improvement
P01436261A0145|118 126|diarrhoea
P01436261A0145|130 142|disappearance
P01436261A0145|151 162|incontinence
P01436261A0145|178 193|calcitonin levels
P01437562A0462|8 17|antibodies
P01437562A0462|30 36|protein
P01437562A0462|39 46|extracts
P01437562A0462|49 61|C.fasciculata
P01437562A0462|63 71|agreement
P01437562A0462|101 118|nucleotide sequence
P01438287T0000|14 27|vaccinia vector
P01438287T0000|59 63|genes
P01441120T0000|18 25|minerals
P01441818T0001|0 13|Interferon type
P01441818T0001|27 39|body reactions
P01441818T0001|56 74|Klebsiella infection
P01443047A0773|7 13|changes
P01443047A0773|29 49|differentiation status
P01443047A0773|64 74|association
P01443047A0773|79 94|Id-SCL expression
P01443745T0000|11 21|interaction
P01443745T0000|33 42|anesthesia
P01443745T0000|46 53|sedation
P01443745T0000|58 66|midazolam
P01443748A1190|3 10|pressure
P01443748A1190|25 30|atm abs
P01443748A1190|42 53|excitability
P01443748A1190|59 66|tadpoles
P01443748A1190|127 135|movements
P01446132A0328|3 13|air embolism
P01446132A0328|36 41|filter
P01446132A0328|61 72|complication
P01446828A1088|4 9|region
P01446828A1088|26 46|consensus binding sites
P01446828A1088|77 84|proteins
P01446828A1088|95 99|LF-A1
P01446828A1088|104 108|NF-A2
P01446828A1088|111 115|NF-E1
P01447189A1546|23 31|RNK-Met-1
P01447189A1546|34 47|serine protease
P01447189A1546|58 65|activity
P01447189A1546|86 93|granules
P01447189A1546|109 119|lymphocytes
P01447189T0000|0 11|Purification
P01447189T0000|15 21|cloning
P01447189T0000|30 43|serine protease
P01447189T0000|44 52|RNK-Met-1
P01447189T0000|60 67|granules
P01447189T0000|83 100|killer cell leukemia
P01448107A0361|24 36|GCN2 mutations
P01448107A0361|47 58|derepression
P01448107A0361|61 74|GCN4 expression
P01448107A0361|80 86|absence
P01448107A0361|89 107|amino acid starvation
P01448806A0135|0 13|Administration
P01448806A0135|16 28|growth hormone
P01448806A0135|42 47|growth
P01448806A0135|61 74|bone maturation
P01448917A0775|0 10|Comparisons
P01448917A0775|27 42|amino acid residue
P01448917A0775|47 65|sequence information
P01448917A0775|80 86|CPMV RNA
P01448917A0775|88 95|sequence
P01448917A0775|109 116|sequence
P01448917A0775|122 141|clover mottle virus RNA
P01448917A0775|154 161|CPSMV RNA
P01448917A0775|200 207|proteins
P01448917A0775|210 227|proteinase cofactor
P01448917A0775|241 248|helicase
P01448917A0775|259 265|protein
P01448917A0775|283 295|24K proteinase
P01448917A0775|311 320|polymerase
P01448917A0775|335 347|cleavage sites
P01448932T0000|0 41|Rice dwarf phytoreovirus segment S12 transcript
P01449183A0795|2 9|addition
P01449183A0795|13 19|utility
P01449183A0795|29 44|transferrin assay
P01449183A0795|49 57|diagnosis
P01449183A0795|73 85|fluid otorrhea
P01449301A0710|0 15|Cold cardioplegia
P01449301A0710|35 38|mm Hg
P01449301A0710|46 52|minutes
P01449301A0710|57 61|hours
P01450815A0337|3 10|addition
P01450815A0337|13 23|diatrizoate
P01450815A0337|63 68|change
P01450815A0337|116 123|increase
P01450815A0337|151 158|decrease
P01451771A0619|12 19|analyses
P01451771A0619|27 41|family variables
P01451771A0619|96 113|components analysis
P01451771A0619|137 151|scaling analysis
P01451771A0619|173 184|health scores
P01451771A0619|187 194|husbands
P01451771A0619|201 205|wives
P01452037A0000|13 17|genes
P01452037A0000|26 64|glyceraldehyde-3-phosphate dehydrogenase
P01452037A0000|65 69|GAPDH
P01452037A0000|88 93|kinase
P01452037A0000|123 146|triosephosphate isomerase
P01452037A0000|164 187|Bacillus megaterium DSM319
P01452037A0000|204 214|gene cluster
P01452037A0000|215 223|gap operon
P01452037A0000|226 240|complementation
P01452037A0000|260 273|gap amber mutant
P01452584T0000|21 29|exotoxin A
P01452584T0000|41 51|retardation
P01452584T0000|53 64|wound healing
P01452584T0000|72 84|Lindberg Award
P01452703A0782|0 16|Laboratory studies
P01452703A0782|131 136|bodies
P01452703A0782|151 159|ELISA kits
P01452703A0782|193 198|bodies
P01454518A0336|10 21|significance
P01454518A0336|29 35|domains
P01454518A0336|61 72|conservation
P01454518A0336|87 93|homolog
P01454518A0336|135 158|stringency hybridizations
P01454518A0336|175 180|probes
P01454518A0336|191 199|ERCC3 cDNA
P01454819A0000|0 20|Mono-ADP-ribosylation
P01454819A0000|34 45|modification
P01454819A0000|48 55|proteins
P01454819A0000|64 94|arginine ADP-ribosyltransferases
P01454819A0000|128 137|hydrolases
P01454819A0000|170 178|reactions
P01454819A0000|182 202|ADP-ribosylation cycle
P01456888A0074|7 12|reason
P01456888A0074|16 23|particle
P01456888A0074|31 38|capacity
P01456888A0074|41 51|derivatives
P01456888A0074|57 66|HIV-1 group
P01456888A0074|75 91|core antigen p55 gag
P01456888A0074|131 147|expression systems
P01456888A0074|159 166|bacteria
P01456888A0074|167 174|vaccinia
P01456888A0074|178 190|baculoviruses
P01456888A0074|223 236|core protein p55
P01456888A0074|257 264|sequence
P01456888A0074|277 304|myristylation consensus signal
P01457380A0000|3 11|tramtrack
P01457380A0000|57 64|proteins
P01457380A0000|81 88|splicing
P01457380A0000|101 113|ttk transcript
P01457695T0000a|0 6|Removal
P01457695T0000a|9 27|beta 2-microglobulin
P01457695T0000a|30 41|hemodialysis
P01457695T0000a|45 58|hemofiltration
P01457695T0000b|0 6|Removal
P01457695T0000b|9 27|beta 2-microglobulin
P01457695T0000b|30 41|hemodialysis
P01457695T0000b|45 58|hemofiltration
P01458170A0155|0 9|Adapromine
P01458170A0155|32 39|decrease
P01458170A0155|45 53|amplitude
P01458170A0155|84 97|theta-activity
P01458170A0155|99 110|power spectra
P01458170A0155|126 131|cortex
P01458170A0155|134 142|hippocamp
P01458170A0155|149 156|increase
P01458170A0155|164 175|wave activity
P01458170A0155|188 192|range
P01458170A0155|202 207|cortex
P01458170A0155|211 219|hippocamp
P01459447A0484|5 13|sequences
P01459447A0484|28 32|clone
P01459447A0484|47 51|genes
P01459447A0484|57 61|yeast
P01459447A0484|69 75|library
P01459451A0478|18 31|antirepression
P01459451A0478|51 56|factor
P01459451A0478|67 82|co-antirepressor
P01459451A0478|122 128|embryos
P01459885A0705|15 34|haloperidol treatment
P01459885A0705|41 47|changes
P01459885A0705|63 67|delta
P01459885A0705|82 89|increase
P01459885A0705|92 96|alpha
P01459885A0705|102 109|decrease
P01459921A0000|36 51|Hampshire wethers
P01459921A0000|77 86|experiment
P01459921A0000|105 123|linoleoyl methionine
P01459921A0000|127 142|calcium linoleate
P01459921A0000|188 192|acids
P01459921A0000|192 196|C18:2
P01459921A0000|197 202|cis C18
P01460054A0478|9 13|ICSBP
P01460054A0478|45 54|amino acids
P01460054A0478|108 123|DNA binding domain
P01460054A0478|153 165|amino terminus
P01460054A0968|9 13|ICSBP
P01460054A0968|65 72|activity
P01460054A0968|88 92|genes
P01460054A0968|108 112|cells
P01460772T0001|16 25|hepatitis C
P01460772T0001|36 49|hypothyroidism
P01460772T0001|66 84|interferon treatment
P01462786T0000|0 20|Dynamic decision making
P01462786T0000|26 32|control
P01462786T0000|35 48|complex systems
P01464329T0000|19 25|protein
P01464329T0000|45 51|regions
P01464329T0000|61 79|prophase chromosomes
P01464606A0344|10 16|amounts
P01464606A0344|19 23|alpha
P01464606A0344|32 39|integrin
P01464606A0344|60 64|cells
P01464606A0344|67 80|chromatography
P01464606A0344|83 99|detergent extracts
P01464606A0344|103 113|fibronectin
P01464606A0344|126 147|fragment affinity column
P01464606A0344|151 157|elution
P01467088T0075|0 8|Abstracts
P01467828A0542|5 11|results
P01467828A0542|29 39|involvement
P01467828A0542|52 65|opioid peptides
P01467828A0542|78 84|effects
P01467828A0542|100 108|ischaemia
P01467828A0542|112 122|reperfusion
P01467828A0542|139 147|receptors
P01467828A0542|161 170|antagonism
P01468625A0282|8 14|library
P01468625A0282|24 32|HIS3 cDNAs
P01468625A0282|48 56|frequency
P01468625A0282|83 87|cases
P01468625A0282|128 133|manner
P01468625A1080|31 35|times
P01468625A1080|49 53|times
P01469042A0355|5 14|CENP-B gene
P01469042A0355|37 43|species
P01469042A0355|47 57|CENP-B boxes
P01469042A0355|72 98|mouse centromere satellite DNA
P01469042A0355|104 112|satellite
P01469042A0355|145 155|interaction
P01469042A0355|191 208|centromere function
P01469047A1606|14 20|portion
P01469047A1606|26 35|tail domain
P01469047A1606|50 55|shares
P01469047A1606|56 81|% amino acid sequence identity
P01469047A1606|93 99|protein
P01469047A1606|104 113|mouse brain
P01469047A1606|135 151|acid decarboxylase
P01470243A0871|12 19|subgroup
P01470243A0871|71 79|reduction
P01470243A0871|90 98|mortality
P01470243A0871|104 109|months
P01470243A0871|138 145|increase
P01470243A0871|146 157|independence
P01470243A0871|195 203|reduction
P01470243A0871|206 214|viscosity
P01470243A0871|217 221|means
P01470243A0871|224 236|haemodilution
P01470243A0871|241 247|albumin
P01470243A0871|257 271|viscosity effect
P01470243A0871|290 294|group
P01470741T0062|0 11|Distribution
P01470741T0062|36 41|course
P01471602A0362|22 29|benefits
P01471602A0362|31 50|bile acid sequestrants
P01471602A0362|72 76|acids
P01471602A0362|102 110|coenzyme A
P01471602A0362|111 117|HMG-CoA
P01471602A0362|118 136|reductase inhibitors
P01471602A0362|140 147|probucol
P01471602A0362|195 204|approaches
P01471602A0362|211 221|conjunction
P01471602A0362|229 233|drugs
P01473196A1016|19 30|reabsorption
P01473196A1016|51 59|clearance
P01473207A0582|20 27|findings
P01473207A0582|33 40|placenta
P01473207A0582|45 57|prematuration
P01473207A0582|61 70|hypoplasia
P01473234A1001|0 10|Green pepper
P01473234A1001|65 77|acid formation
P01474990A0000|8 12|clone
P01474990A0000|13 17|pTt21
P01474990A0000|68 78|Trypanosoma
P01474990A0000|83 97|trypomastigotes
P01474990A0000|142 148|library
P01474990A0000|153 166|trypomastigote
P01474990A0000|170 185|epimastigote cDNA
P01475381T0001|0 10|Brucellosis
P01476376T0000|0 4|Assay
P01476376T0000|26 31|urease
P01476376T0000|53 60|pH-meter
P01477021A0394|0 6|RESULTS
P01477021A0394|12 19|AGA group
P01477021A0394|40 66|serum prolactin concentration
P01477021A0394|93 101|gestation
P01478672A0795|3 12|phage clone
P01478672A0795|22 29|junction
P01478672A0795|37 53|alpha satellite DNA
P01478672A0795|79 86|sequence
P01480183A0000|11 16|region
P01480183A0000|27 41|lactoferrin gene
P01480183A0000|79 85|library
P01480183A1689|21 30|mechanisms
P01480183A1689|36 49|estrogen action
P01480183A1689|63 87|lactoferrin gene expression
P01480183A1689|101 105|mouse
P01480470A0323|0 5|BiP670
P01480470A0323|26 34|ionophore
P01480470A0323|50 59|activities
P01482912A0617|16 34|registration updates
P01482912A0617|39 48|HL7 message
P01482912A0617|61 76|data dependencies
P01482912A0617|79 83|rules
P01482912A0617|89 97|interface
P01482912A0617|103 120|relational database
P01483755A0000|8 28|resonance spectroscopy
P01483755A0000|37 43|imaging
P01483755A0000|69 78|techniques
P01483755A0000|84 88|study
P01483755A0000|99 108|metabolism
P01483755A0000|117 125|structure
P01483755A0000|128 133|muscle
P01483771A1335|40 45|change
P01483771A1335|47 71|plasma epinephrine response
P01485648A0000|27 31|value
P01485648A0000|51 68|Pharmacia CAP System
P01485648A0000|68 89|Pharmacia Diagnostics AB
P01485648A0000|90 96|Uppsala
P01485648A0000|97 102|Sweden
P01485648A0000|121 131|measurement
P01485648A0000|151 163|IgE antibodies
P01485648A0000|166 175|comparison
P01485648A0000|189 194|groups
P01485648A0000|196 203|patients
P01486836A0774|0 7|Patients
P01486836A0774|28 38|differences
P01486836A0774|40 48|attention
P01486836A0774|49 69|visuomotor performance
P01486836A0774|92 110|discrimination tasks
P01486836A0774|118 138|visuomotor performance
P01486836A0774|177 187|differences
P01487144A0505|14 24|gene segment
P01487144A0505|38 44|mu m poly
P01487144A0505|47 53|signals
P01487144A0505|89 96|sequence
P01487144A0505|104 126|transcription terminator
P01487144A0505|133 144|myeloma cells
P01487144A0505|148 163|L cell fibroblasts
P01490493A0416|17 27|examination
P01490493A0416|39 54|serum cholesterol
P01490493A0416|60 64|lipid
P01490493A0416|68 85|triglyceride levels
P01492463T0001|0 4|Alena
P01492463T0001|8 12|nurse
P01492463T0001|15 20|Prague
P01492463T0001|38 42|wages
P01492463T0001|62 66|ocean
P01493864A0619|0 14|Dopamine neurons
P01493864A0619|17 24|subjects
P01493864A0619|37 42|6-OHDA
P01493864A0619|58 70|pre-treatment
P01493864A0619|75 83|GBR-12909
P01495069A0392|53 57|value
P01495069A0392|79 88|percentage
P01496348A0000|0 5|Caries
P01496348A0000|9 20|parodontitis
P01496348A0000|47 54|diseases
P01496348A0000|57 63|mankind
P01496784A0939|3 9|results
P01496784A0939|16 20|study
P01496784A0939|36 51|strongyloidiasis
P01496784A0939|58 62|cause
P01496784A0939|71 75|death
P01497582A0593|12 16|group
P01497582A0593|19 27|disorders
P01497582A0593|30 38|pregnancy
P01497582A0593|49 55|effects
P01497582A0593|58 67|infections
P01497582A0593|73 78|mother
P01497582A0593|86 94|pathogens
P01497582A0593|116 121|embryo
P01497582A0593|127 134|placenta
P01498607A0000|9 27|nucleotide sequences
P01498607A0000|28 32|boxes
P01498607A0000|58 71|responsiveness
P01498607A0000|77 107|parsley chalcone synthase promoter
P01499213A0185|47 56|ochronosis
P01499213A0185|67 86|hyperextension injury
P01499213A0185|92 96|spine
P01499213A0185|118 125|fracture
P01499213A0185|143 156|L2-L3 disk space
P01499616A0136|7 15|blood flow
P01499616A0136|27 34|foreskin
P01499616A0136|99 107|induction
P01499616A0136|108 117|anesthesia
P01499616A0136|172 183|foreskin flap
P01502157A0000|0 4|ME1a1
P01502157A0000|25 41|factor binding site
P01502157A0000|60 66|c-MYC P1
P01502157A0000|70 99|P2 transcription initiation sites
P01502157A0000|113 122|P2 activity
P01504178T0000|13 17|years
P01504178T0000|20 29|prevention
P01504178T0000|38 44|country
P01504178T0000|45 53|visionary
P01504178T0000|54 60|complex
P01504853A0299|38 51|mating behavior
P01504853A0299|60 66|species
P01505488A0231|22 29|patients
P01505488A0231|55 60|period
P01505488A0231|64 69|August
P01505516A0928|31 36|lysine
P01505516A0928|48 54|alanine
P01505516A0928|57 69|valine residue
P01505516A0928|77 85|formation
P01505516A0928|104 109|dimers
P01506705A0282|6 14|V-A bypass
P01506705A0282|15 26|hemodynamics
P01506746A0476|0 18|Greater rupture force
P01509798A0520|2 8|rest AFF
P01511231A0085|17 29|smoking habits
P01511231A0085|32 40|relapsers
P01511231A0085|64 84|smoking cessation trial
P01511231A0085|89 96|nicotine
P01511231A0085|99 112|placebo patches
P01511950T0000|0 7|Exposure
P01511950T0000|10 24|hepatitis B virus
P01511950T0000|37 46|population
P01511950T0000|49 56|Hisayama
P01511950T0000|57 61|Japan
P01511950T0000|62 73|significance
P01511950T0000|84 91|antibody
P01511950T0000|94 117|hepatitis B surface antigen
P01511950T0000|127 136|population
P01512259A0867|19 28|phenomenon
P01512259A0867|60 72|cysteine motif
P01512259A0867|96 100|times
P01512259A0867|103 109|Dfurin2
P01512259A0867|140 144|furin
P01512654A0503|23 31|phosphate
P01512654A0503|39 53|saline injection
P01512654A0503|75 87|KLH challenges
P01512654A0503|121 134|threshold level
P01512654A0503|148 154|latency
P01512941A0000|44 55|levofloxacin
P01512941A0000|62 68|DR-3355
P01512941A0000|98 107|comparison
P01512941A0000|112 124|ciprofloxacin
P01512941A0000|131 139|ofloxacin
P01512941A0000|148 158|norfloxacin
P01513114A1133|7 27|serum creatinine levels
P01513114A1133|82 89|ABSTRACT
P01513114A1133|104 108|WORDS
P01513213A0231|0 15|Model predictions
P01513213A0231|22 27|accord
P01513213A0231|44 61|survival experience
P01513213A0231|64 68|women
P01513213A0231|74 81|HIP trial
P01513213A0231|92 100|exception
P01513213A0231|103 107|women
P01513213A0231|113 117|years
P01513213A0231|125 131|HIP data
P01513213A0231|141 148|survival
P01516427T0000|23 32|tomography
P01516427T0000|38 46|diagnosis
P01516427T0000|56 67|tuberculosis
P01516829A0113|37 48|SNF6 function
P01516829A0113|80 89|activation
P01516829A0113|117 123|complex
P01516829A0460|10 18|LexA-GAL4
P01516829A0460|33 46|fusion proteins
P01516829A0460|89 98|activation
P01516829A0460|98 108|target genes
P01516829A0460|132 144|lexA operators
P01518396T0000|0 7|George T.
P01518833A0397|1 21|lambda gt10 cDNA library
P01518833A0397|65 70|leaves
P01518833A0397|70 76|spinach
P01518849A0165|23 33|destruction
P01518849A0165|46 59|microorganisms
P01518849A0165|95 108|protein elastin
P01518849A0165|131 140|activities
P01518849A0165|150 184|alpha 1-proteinase inhibitor complexes
P01518849A0165|188 202|elastin peptides
P01518926T0000|8 13|topics
P01518926T0000|25 39|ultrasonography
P01522699A0092|0 6|Methods
P01522699A0092|29 34|recall
P01522699A0092|35 45|menu weights
P01522699A0092|49 62|recipe analysis
P01523111A0769|0 6|Factors
P01523111A0769|21 29|afterdrop
P01523111A0769|57 67|temperature
P01523111A0769|84 91|body mass
P01524549A0241|4 15|GH deficiency
P01524549A0241|33 38|growth
P01524549A0241|55 61|stature
P01524549A0241|72 81|occurrence
P01524549A0241|89 95|puberty
P01524549A0241|98 108|association
P01524549A0241|113 124|GH deficiency
P01524549A0241|153 161|GH therapy
P01525153A0359|2 9|contrast
P01525153A0359|12 17|T2AG3T
P01525153A0359|22 26|T2G4T
P01525153A0359|51 67|monomer structures
P01525153A0359|80 99|K cation concentration
P01525153A0359|130 136|Gilbert
P01525966T0000|25 30|stones
P01526658A0454|58 62|cells
P01526658A0454|66 74|cell lines
P01526658A0454|90 98|B lineages
P01526690T0000|18 23|action
P01526690T0000|26 33|warfarin
P01526690T0000|36 46|lymphocytes
P01527020A0511|11 19|junctions
P01527020A0511|33 59|rat AdoMet decarboxylase genes
P01527020A0511|75 83|positions
P01527020A0511|94 98|exons
P01527020A0511|144 150|rat gene
P01529530T0000|24 37|gene expression
P01529530T0000|38 45|evidence
P01529530T0000|59 64|effect
P01529530T0000|67 73|ouabain
P01529530T0000|76 85|activation
P01529530T0000|91 115|ISGF3 transcription complex
P01531086A0127|18 29|reading frame
P01531086A0127|34 43|amino acids
P01531086A0127|68 74|protein
P01531214A0885|24 29|RP-170
P01531214A0885|74 87|administration
P01531632A0000|11 18|proteins
P01531632A0000|34 42|nucleolus
P01531632A0000|72 79|proteins
P01531632A0000|80 88|nucleolin
P01531632A0000|89 99|fibrillarin
P01531632A0000|139 143|motif
P01531632A0000|145 153|GAR domain
P01531632A0000|167 173|glycine
P01531632A0000|177 192|arginine residues
P01532229A1264|8 12|study
P01532229A1264|21 28|evidence
P01532229A1264|49 54|factor
P01532229A1264|55 59|HF-1a
P01532229A1264|64 75|muscle factor
P01532229A1264|76 80|HF-1b
P01532229A1264|80 84|MEF-2
P01532229A1264|115 121|pathway
P01532229A1264|140 149|expression
P01532229A1264|170 180|muscle cells
P01532796A0107|0 8|Mutations
P01532796A0107|51 58|assembly
P01532796A0107|73 77|alpha
P01532796A0107|80 91|beta subunits
P01532796A0107|106 117|mitochondria
P01532796A0107|128 137|aggregates
P01532796A0107|138 145|Ackerman
P01532914A0067|0 6|Expense
P01532914A0067|23 40|hepatitis B vaccines
P01532914A0067|62 73|immunization
P01532914A0067|104 111|strategy
P01532914A0067|122 128|studies
P01533760T0000|0 25|Estrogen replacement therapy
P01533760T0000|37 48|breast cancer
P01533760T0000|48 54|results
P01533760T0000|60 72|meta-analyses
P01535242A0557|9 14|FDC-P1
P01535242A0557|14 21|MAC cells
P01535242A0557|26 31|growth
P01535242A0557|34 38|M-CSF
P01535242A0557|41 46|GM-CSF
P01535242A0557|65 75|degradation
P01535242A0557|78 86|c-fms mRNA
P01535242A0557|102 116|factor switching
P01536153A0574|28 37|difference
P01536153A0574|43 52|prevalence
P01536153A0574|73 80|symptoms
P01536153A0574|88 104|animal food workers
P01536153A0574|128 136|skin tests
P01536153A0574|154 162|fish flour
P01536153A0574|209 215|dyspnea
P01536575A1213|12 18|finding
P01536575A1213|25 32|presence
P01536575A1213|35 42|position
P01536575A1213|64 69|dioxin
P01536575A1213|80 86|element
P01536575A1213|88 95|sequence
P01536575A1213|122 130|induction
P01536575A1213|133 145|transcription
P01536575A1213|151 171|cytochrome P450IA1 gene
P01536575A1213|172 177|CYPIA1
P01536575A1213|186 190|genes
P01536575A1213|201 225|detoxification/activation
P01536575A1213|246 257|hydrocarbons
P01537334A0507|17 25|TRP-2 maps
P01537334A0507|27 41|mouse chromosome
P01537334A0507|49 54|region
P01537334A0507|60 82|coat colour mutation slaty
P01537845A0571|20 30|c-myb clones
P01537845A0571|33 38|change
P01537845A0571|52 73|c-myb gene transcription
P01537845A0571|75 87|mRNA stability
P01537845A0571|108 116|cell cycle
P01538401A1244|3 26|base-pair oligonucleotide
P01538401A1244|35 45|nucleotides
P01538401A1244|60 67|S RNA gene
P01538401A1244|100 106|binding
P01538401A1244|118 123|latter
P01538401A1244|157 168|DNA fragments
P01538403A1058|11 24|reconstitution
P01538403A1058|50 71|transcription complexes
P01538403A1058|83 98|protein fractions
P01538403A1058|121 125|TFIID
P01538403A1058|164 179|complex formation
P01538403A1058|185 203|H5 promoter mutations
P01538403A1058|214 221|TATA-box
P01539996A0588|1 10|comparison
P01539996A0588|16 32|amino acid sequence
P01539996A0588|38 57|T. thermophilus enzyme
P01539996A0588|86 91|enzyme
P01539996A0588|111 120|similarity
P01539996A0588|125 136|conservation
P01539996A0588|142 151|Ser residue
P01539996A0588|193 198|enzyme
P01539996A0588|218 225|sequence
P01539996A0588|235 242|presence
P01539996A0588|253 260|residues
P01539996A0588|266 274|C terminus
P01539996A0588|280 299|T. thermophilus enzyme
P01541556A1040|13 21|palmitate
P01541556A1040|54 60|protein
P01541556A1040|72 88|lipid modification
P01541556A1040|100 112|Cys-22 residue
P01541577A0000|2 10|volunteer
P01541577A0000|37 54|volunteer hearing Ss
P01541577A0000|59 74|Stanford Hypnotic
P01541577A0000|83 87|Scale
P01541577A0000|96 101|Morgan
P01542565A0220|6 22|tobacco L12 protein
P01542565A0220|27 44|% amino acid identity
P01542565A0220|58 70|protein L7/L12
P01542565T0000|35 44|protein L12
P01542565T0000|47 62|Nicotiana tabacum
P01542565T0000|63 78|characterization
P01542565T0000|87 93|protein
P01542565T0000|97 105|isolation
P01542565T0000|109 124|sequence analysis
P01542565T0000|127 136|cDNA clones
P01542565T0000|159 167|precursor
P01542667A0125|17 25|IFN-gamma
P01542667A0125|62 76|enhancer element
P01542667A0125|107 114|activity
P01542667A0125|135 144|expression
P01542686A0000|9 15|cloning
P01542686A0000|21 40|polypeptide component
P01542686A0000|62 84|p75 nucleoprotein complex
P01542686A0000|99 106|identity
P01542686A0000|125 131|subunit
P01542686A0000|133 142|NF-kappa B.
P01542730A1982|40 45|pacing
P01542730A1982|55 61|patient
P01542730A1982|88 98|development
P01542730A1982|100 106|AV block
P01542730A1982|110 118|DDD pacing
P01542730A1982|145 151|support
P01542730A1982|185 196|dual-chamber
P01542730A1982|203 209|devices
P01542730A1982|233 238|number
P01542730A1982|246 253|patients
P01542730A1982|301 308|ABSTRACT
P01542730A1982|323 327|WORDS
P01543909A0787|30 38|K562 cells
P01543909A0787|54 58|clone
P01543909A0787|115 129|characteristics
P01543909A0787|142 151|pseudogene
P01543909A0787|200 214|ferritin subunit
P01544854A0699|5 9|drugs
P01544854A0699|28 36|WR-168643
P01544854A0699|47 55|protector
P01544918A1240|0 15|Characterization
P01544918A1240|23 31|R subunits
P01544918A1240|39 71|8-azido-cAMP photoaffinity labeling
P01544918A1240|75 90|immunoreactivity
P01544918A1240|127 139|mobility shift
P01544918A1240|142 154|sodium dodecyl
P01544918A1240|177 194|gel electrophoresis
P01544918A1240|195 202|SDS-PAGE
P01544918A1240|212 223|subunit sizes
P01544918A1240|226 232|RII beta
P01544918A1240|251 271|RII alpha dephosphoform
P01544918A1240|289 295|RI alpha
P01544928A1252|0 9|Comparison
P01544928A1252|22 32|DNA sequence
P01544928A1252|59 63|mRNAs
P01544928A1252|82 92|transcripts
P01544928A1252|117 124|splicing
P01544928A1252|136 143|pre-mRNA
P01544928A1252|156 168|cassette model
P01545523A0000|14 28|quantifications
P01545523A0000|48 55|testings
P01545523A0000|77 83|protein
P01545523A0000|93 98|factor
P01545523A0000|102 118|antistreptolysin O
P01545787A0345|14 21|enhancer
P01545787A0345|30 34|sites
P01545787A0345|71 75|DNase
P01545787A0345|77 86|footprints
P01545787A0345|87 92|NFAT-1
P01545787A0345|96 102|NFIL-2B
P01545792A0000|10 27|myosin light chain-2
P01545792A0000|28 32|MLC-2
P01545792A0000|33 44|gene promoter
P01545792A0000|89 97|sequences
P01545792A0000|118 127|regulation
P01545792A0000|133 142|expression
P01545792A0492|0 18|Deletion mutagenesis
P01545792A0492|43 50|elements
P01545792A0492|75 84|regulation
P01545792A0492|87 108|MLC-2 gene transcription
P01545797A0587|0 18|Disruption mutations
P01545797A0587|43 50|SLK1 gene
P01545797A0587|71 77|mutants
P01545797A0587|90 97|degrees C
P01545797A0587|105 109|cells
P01545797A0587|128 136|degrees C.
P01545806T0000|19 26|analysis
P01545806T0000|32 36|yeast
P01545806T0000|49 72|recombination genes REC102
P01545806T0000|76 86|REC107/MER2
P01545818A0696|40 47|proteins
P01545818A0696|59 66|v-Src SH2
P01545818A0696|92 96|v-Src
P01545818A0696|116 125|Rat-2 cells
P01545818A0696|136 142|binding
P01545818A0696|160 173|v-Src SH2 domain
P01546522A0000|0 7|Probable
P01546522A0000|29 47|leukoencephalopathy
P01546522A0000|70 74|basis
P01546522A0000|84 90|picture
P01546522A0000|102 117|resonance imaging
P01546522A0000|150 158|remission
P01546522A0000|173 180|lymphoma
P01547775A1024|37 48|significance
P01547775A1024|53 62|frameshift
P01547775A1024|76 83|position
P01547775A1024|155 167|PLRV replicase
P01547775A1024|171 198|ORF2a/ORF2b transframe protein
P01547787A0548|0 19|Proprotein processing
P01547942A0120|31 48|dimerization domain
P01547942A0120|48 58|zipper probe
P01547942A0120|76 80|clone
P01547942A0120|112 118|protein
P01547942A0120|119 125|CHOP-10
P01547957A1083|16 39|oligodeoxyribonucleotide
P01547957A1083|65 74|aa sequence
P01547957A1083|116 121|region
P01547957A1083|131 137|portion
P01547957A1083|178 183|genome
P01547957A1083|196 206|DNA fragment
P01547957A1083|224 246|polymerase chain reaction
P01547957A1083|278 286|substrate
P01548756A1102|9 21|hybridization
P01548756A1102|24 28|EHS-1
P01548756A1102|74 82|EHS-1 loci
P01548756A1102|111 121|band pattern
P01548756A1102|123 135|chimpanzee DNA
P01548756A1102|146 150|locus
P01548756A1102|153 167|rhesus monkey DNA
P01548891A0635|3 7|level
P01548891A0635|38 44|hormone
P01548891A0635|50 57|patients
P01548891A0635|62 77|thyroid carcinoma
P01548891A0635|100 107|patients
P01548891A0635|115 130|thyroid carcinoma
P01549118A0000|3 40|Caenorhabditis elegans vitellogenin genes
P01549118A0000|58 62|stage
P01549118A0000|80 89|regulation
P01549118A0000|122 143|hermaphrodite intestine
P01549123A0480|3 10|MET4 gene
P01549123A0480|26 33|sequence
P01549123A0480|55 61|protein
P01549123A0480|74 79|family
P01549123A0480|106 115|activators
P01549125A0140|3 11|functions
P01549125A0140|22 29|portions
P01549125A0140|35 41|insulin
P01549125A0140|51 65|beta GK promoters
P01549125A0140|92 101|expression
P01549125A0140|105 120|DNA binding assays
P01549129A0356|21 27|domains
P01549129A0356|75 86|interactions
P01549129A0356|108 118|functioning
P01549346A0000|3 20|c-Ets-1 oncoprotein
P01549346A0000|24 45|transcription activator
P01549465A0122|8 33|transactivation experiments
P01549465A0122|52 61|amino acids
P01549465A0122|76 81|region
P01549465A0122|132 145|discrimination
P01551176A0000|0 7|GR63178A
P01551176A0000|24 31|analogue
P01551176A0000|34 44|mitoquidone
P01551176A0000|57 70|pyrroloquinone
P01551568A1476|0 19|Marker rescue analysis
P01551568A1476|54 60|segment
P01551568A1476|82 90|Rif domain
P01551898A1084|4 9|vector
P01551898A1084|28 32|yeast
P01551898A1084|63 72|expression
P01551898A1084|90 96|protein
P01551898A1084|99 104|levels
P01551898A1084|118 127|LAPP/liter
P01551898A1084|129 141|culture medium
P01551910A0313|0 18|Competition analysis
P01551910A0313|21 51|gel mobility shift electrophoresis
P01551910A0313|80 90|interaction
P01551910A0313|117 136|transcription factors
P01551910A0978|4 11|DNA motif
P01551910A0978|43 50|sequence
P01552052A0139|0 8|OBJECTIVE
P01552052A0139|12 16|study
P01552052A0139|44 52|frequency
P01552052A0139|55 65|alterations
P01552052A0139|68 82|serum creatinine
P01552052A0139|85 92|patients
P01552052A0139|97 105|psoriasis
P01552052A0139|116 124|mg/kg/day
P01552052A0139|127 138|cyclosporine
P01552457T0000|0 22|Intrapocket chemotherapy
P01552457T0000|30 42|periodontitis
P01552457T0000|70 75|insert
P01552457T0000|86 94|ofloxacin
P01552457T0000|95 99|PT-01
P01552662A0398|15 23|blood flow
P01552662A0398|28 32|probe
P01552662A0398|69 74|artery
P01552853A1377|5 15|temperature
P01552853A1377|46 54|induction
P01552853A1377|59 68|yop regulon
P01553407T0000|0 7|Problems
P01553407T0000|51 64|risk assessment
P01554334A0000|20 35|gamma-interferon
P01554334A0000|36 44|IFN-gamma
P01554334A0000|45 55|assay system
P01554334A0000|62 70|diagnosis
P01554334A0000|79 90|tuberculosis
P01554334A0000|93 98|cattle
P01554334A0000|129 137|Committee
P01554334A0000|140 150|Agriculture
P01554334A0000|161 169|Australia
P01555556A0565|0 13|Control Tmuscle
P01555556A0565|25 32|degrees C
P01555556A0565|37 45|control Wi
P01555556A0565|66 71|W.kg-1
P01556068A0000|3 29|Klebsiella aerogenes gene maoA
P01556068A0000|50 58|synthesis
P01556068A0000|61 76|monoamine oxidase
P01556068A0000|89 96|tyramine
P01556068A0000|110 118|compounds
P01556068A0000|130 139|catabolite
P01556068A0000|143 163|ammonium ion repression
P01556111A0241|12 18|regions
P01556111A0241|24 30|plasmid
P01557217A0272|33 39|lesions
P01557217A0272|72 76|h p.i.
P01557411A1282|12 18|D1A gene
P01557411A1282|31 38|category
P01557411A1282|65 69|genes
P01557411A1282|95 103|promoters
P01558942A1369|7 18|observations
P01558942A1369|49 53|genes
P01559209T0000|0 12|Preceptorship
P01559209T0000|15 25|CNS students
P01559209T0000|39 43|study
P01560021A0379|21 25|basis
P01560021A0379|32 42|differences
P01560021A0379|63 78|brain AE3 variants
P01560021A0379|108 114|rat gene
P01560774A0885|16 23|fragment
P01560774A0885|61 68|fliA gene
P01562659A0676|0 10|Institution
P01562659A0676|45 58|administration
P01562659A0676|61 73|amphotericin B
P01562659A0676|107 120|administration
P01562659A0676|123 135|dexamethasone
P01562659A0676|152 161|situations
P01562659A0676|172 182|association
P01562659A0676|185 193|C. immitis
P01562659A0676|198 210|CNS vasculitis
P01562659A0676|213 224|encephalitis
P01562659A0676|263 274|confirmation
P01562659A0676|277 294|C. immitis infection
P01563343A0548|0 11|Lac operators
P01563343A0548|37 45|positions
P01563343A0548|55 65|CAB promoter
P01563343A0548|82 88|plasmid
P01563343A0548|98 104|control
P01563635T0000|0 13|Overproduction
P01563635T0000|14 25|purification
P01563635T0000|29 44|characterization
P01563635T0000|47 70|M.HinfI methyltransferase
P01563635T0000|76 89|deletion mutant
P01564653A0307|7 15|companies
P01565093A0179|4 8|March
P01565093A0179|17 23|October
P01565093A0179|35 41|persons
P01565093A0179|67 81|blood lead levels
P01565093A0179|96 103|hospital
P01565093A0179|133 157|disease surveillance system
P01565093A0179|173 189|Alabama Department
P01565093A0179|192 203|Public Health
P01565882A0737|14 20|changes
P01565882A0737|23 38|perfusion defects
P01565882A0737|55 63|ReI images
P01565882A0737|86 90|types
P01565882A0737|98 112|perfusion defect
P01565882A0737|117 123|RD image
P01565882A0737|141 145|image
P01565882A0737|172 180|subgroups
P01565882A0737|186 200|perfusion defect
P01565882A0737|248 254|RD image
P01567649A0139|17 23|infants
P01567649A0139|45 54|hemorrhage
P01567649A0139|90 94|palsy
P01567649A0139|115 124|evaluation
P01567649A0139|132 138|infancy
P01568960A1129|9 17|mechanism
P01568960A1129|40 47|pressure
P01568960A1129|67 72|output
P01568960A1129|82 90|blood flow
P01568960A1129|95 107|corner vessels
P01568960A1129|126 136|VA/Q regions
P01569015A0120|14 18|FRAME
P01569015A0120|19 26|analysis
P01569015A0120|51 63|reading frames
P01569015A0120|80 88|direction
P01569015A0120|107 115|direction
P01569102A0708|0 5|Domain
P01569102A0708|31 41|LDL receptor
P01569102A0708|57 63|repeats
P01569102A0708|75 86|conservation
P01569102A0708|104 112|cysteines
P01569344A0404|6 11|cities
P01569344A0404|21 30|prevalence
P01569344A0404|68 80|New Orleans age
P01569344A0404|95 113|HTLV-I/II prevalence
P01569344A0404|146 154|Baltimore
P01569581A0482|13 20|evidence
P01569581A0482|25 29|model
P01569581A0482|65 75|nucleotides
P01569581A0482|92 101|start codon
P01569581A0482|120 128|base-pair
P01569581A0482|136 162|translation initiation region
P01569581A0482|183 212|translation initiation frequency
P01569584A0672|0 16|Hybridization data
P01569584A0672|29 33|6F6.2
P01569584A0672|72 84|m6F6 cDNA clone
P01569584A0672|92 96|6F6.1
P01569584A0672|99 103|6F6.3
P01569584A0672|109 113|6F6.2
P01569584A0672|136 140|genes
P01569945A0529|3 10|SEN1 gene
P01569945A0529|37 48|reading frame
P01569945A0529|75 81|protein
P01572549A0000|0 21|Protein tyrosine kinases
P01572549A0000|46 52|control
P01572549A0000|54 63|cell growth
P01572549A0000|66 71|virtue
P01572549A0000|87 96|appearance
P01572549A0000|99 106|products
P01572549A0000|119 127|oncogenes
P01572549A0000|143 159|signal transducers
P01572549A0000|165 185|growth factor receptors
P01572549A0000|188 197|components
P01573270A0000|3 8|IA4 mAb
P01573270A0000|28 33|series
P01573270A0000|36 45|antibodies
P01573270A0000|54 63|BALB/c mice
P01573270A0000|69 80|immunization
P01573270A0000|89 96|HLA class
P01573270A0000|128 133|killer
P01573270A0000|149 167|EBV-B lymphocyte line
P01577056A0178|35 39|study
P01577056A0178|43 50|subjects
P01577056A0178|59 70|theophylline
P01577056A0178|72 78|mg.kg-1
P01577056A0178|91 100|omeprazole
P01577056A0178|125 131|placebo
P01577056A0178|139 145|periods
P01577056A0178|171 183|washout period
P01577740A1111|0 14|Primer extension
P01577740A1111|18 25|mung bean
P01577740A1111|29 45|S1 nuclease mapping
P01577740A1111|63 90|transcription initiation sites
P01577740A1111|112 127|Northern analyses
P01577819A0709|10 29|PRP-precursor alleles
P01577819A0709|59 64|number
P01577819A0709|67 73|repeats
P01577819A0709|76 83|domain C.
P01579472A1018|16 30|enhancer element
P01579472A1018|35 40|region
P01579472A1018|75 80|manner
P01579537A0000|11 15|years
P01579537A0000|38 51|botulinum toxin
P01579537A0000|58 67|neurotoxin
P01580738T0001|0 8|Allagille
P01580738T0001|10 17|syndrome
P01580738T0001|41 47|ascites
P01581409A0398|0 10|Sensitivity
P01581409A0398|14 24|specificity
P01581409A0398|45 62|Pharmacia CAP System
P01581409A0398|69 84|DPC AlaSTAT System
P01581409A0398|87 96|comparison
P01581409A0398|101 107|results
P01581577A1186|0 4|PSI-G
P01581577A1186|8 12|PSI-K
P01581577A1186|37 51|gene duplication
P01581965A0388|5 14|C-terminus
P01581965A0388|20 26|protein
P01581965A0388|30 35|domain
P01581965A0388|48 56|sequences
P01581965A0388|85 118|breakpoint cluster region gene product
P01581965A0388|119 128|n-chimerin
P01581965A0388|132 137|rho GAP
P01581965A0388|179 189|GAP activity
P01581965A0388|197 203|GTPases
P01582413A0192|13 23|mutagenesis
P01582413A0192|39 46|clusters
P01582413A0192|54 63|amino acids
P01582413A0192|85 90|region
P01582413A0192|108 114|helices
P01582413A0192|135 140|domain
P01582413A0192|173 182|DNA binding
P01582413A0192|186 207|hetero-oligomerization
P01582413A0759|0 11|Dimerization
P01582413A0759|14 18|Myf-5
P01582413A0759|51 60|protein E12
P01582413A0759|80 87|affinity
P01582413A0759|113 127|transactivation
P01582413A0759|142 151|DNA binding
P01582500A0178|12 22|rhythmicity
P01582500A0178|25 29|sleep
P01583819A0377|33 39|filters
P01583819A0377|69 80|Simson method
P01584812T0000|15 24|expression
P01584812T0000|32 40|structure
P01584812T0000|55 66|localization
P01584812T0000|100 124|transcription factor NGFI-C
P01585014A0000|2 11|experiment
P01585014A0000|23 29|effects
P01585014A0000|32 40|treatment
P01585014A0000|45 57|gonadotrophin
P01585014A0000|67 73|hormone
P01585014A0000|77 90|micrograms GnRH
P01585014A0000|109 132|progestagen sponge removal
P01585014A0000|132 137|season
P01585014A0000|140 148|treatment
P01585014A0000|149 154|autumn
P01585014A0000|157 162|spring
P01585014A0000|166 171|effect
P01585014A0000|198 207|lupin grain
P01585014A0000|210 215|autumn
P01585014A0000|255 267|sponge removal
P01585014A0000|279 287|ovulation
P01585014A0000|298 307|Merino ewes
P01585014A0000|326 336|combination
P01585014A0000|356 377|mare serum gonadotrophin
P01585014A0000|388 415|mg follicle stimulating hormone
P01585014A0000|415 419|FSH-P
P01586901A0000|9 20|interactions
P01586901A0000|43 50|patients
P01586901A0000|68 78|medications
P01586901A0000|86 90|drugs
P01586901A0000|117 122|window
P01587267A1144|3 14|sequence data
P01587267A1144|33 46|interpretation
P01587267A1144|52 56|X-ray
P01587267A1144|73 81|structure
P01587267A1144|87 92|enzyme
P01587267A1144|99 105|cloning
P01587267A1144|109 118|expression
P01587267A1144|168 178|mutagenesis
P01587763A0402|5 19|body irradiation
P01587763A0402|61 66|scheme
P01587763A0402|71 79|fractions
P01588270A1029|1 9|reduction
P01588270A1029|12 24|blood pressure
P01588270A1029|55 59|study
P01588315A0356|0 5|AgMNPV
P01588315A0356|9 31|Orgyia pseudotsugata MNPV
P01588315A0356|32 37|OpMNPV
P01588315A0356|50 54|terms
P01588315A0356|57 73|promoter structure
P01588315A0356|77 86|polyhedrin
P01588315A0356|94 101|sequence
P01588315A0356|108 121|polyhedrin gene
P01588315A0356|128 134|viruses
P01588315A0356|167 175|direction
P01588315A0356|178 185|relation
P01588913A0000|37 44|dnaA gene
P01588913A0000|82 94|transcription
P01588913A0000|128 135|P. putida
P01588961A0000|21 29|yeast gene
P01588961A0000|42 48|removal
P01588961A0000|62 70|sequences
P01588961A0000|88 95|families
P01588961A0000|128 136|pre-tRNAs
P01588963A1153|10 19|antibodies
P01588963A1153|41 50|conditions
P01588963A1153|76 87|Cdc25 protein
P01588965A0000|0 15|GCR1 gene function
P01588965A0000|49 62|gene expression
P01589576A0170|3 13|decay curves
P01589576A0170|16 38|chlorophyll fluorescence
P01589576A0170|46 58|superposition
P01589576A0170|87 96|components
P01589576A0170|101 113|time constants
P01592545A0726|20 32|blood pressure
P01592545A0726|39 45|average
P01592545A0726|54 61|patients
P01592545A0726|124 131|patients
P01594554A0845|5 11|results
P01594554A0845|32 36|roles
P01594554A0845|49 65|trypsin inhibitors
P01594554A0845|95 109|feedback control
P01594554A0845|130 137|function
P01596007A0908|10 15|events
P01596007A0908|30 35|Stages
P01596007A0908|57 66|proportion
P01596007A0908|82 93|gamma OH study
P01596007A0908|117 130|control studies
P01596007A0908|185 191|gamma OH
P01596007A0908|245 252|ABSTRACT
P01596007A0908|267 271|WORDS
P01597170A0000|5 11|rabbits
P01597170A0000|32 39|mg/m3 Co2
P01597170A0000|42 46|CoCl2
P01597170A0000|57 64|mg/m3 Cr3
P01597170A0000|75 81|group Co
P01597170A0000|99 106|mg/m3 Co2
P01597170A0000|106 112|group Co
P01597170A0000|136 147|control group
P01597170A0000|151 156|months
P01597170A0000|158 166|days/week
P01597170A0000|171 176|hr/day
P01597272A0077|2 6|women
P01597272A0077|22 30|methadone
P01597272A0077|40 57|withdrawal symptoms
P01597462A0457|0 9|Disruption
P01597462A0457|26 30|CDC14
P01600531A0483|35 49|phosphocreatine
P01600531A0483|62 73|control group
P01601181A0842|3 16|60A transcripts
P01601181A0842|20 26|protein
P01601181A0842|48 52|onset
P01601181A0842|55 66|gastrulation
P01601181A0842|81 88|mesoderm
P01601181A0842|103 110|germ band
P01601869A1389|7 13|segment
P01601869A1389|27 32|region
P01601869A1389|56 60|E-box
P01601869A1389|103 108|region
P01601869A1389|147 156|activation
P01601869A1389|172 185|BC3H1 myoblasts
P01603088A1121|5 11|results
P01603088A1121|72 81|activation
P01603088A1121|84 93|repression
P01603088A1121|114 119|manner
P01605038T0001|0 8|Influence
P01605038T0001|17 26|regulation
P01605038T0001|44 50|effects
P01607223A0000|6 19|investigations
P01607223A0000|45 60|release technique
P01607223A0000|69 73|pulse
P01607223A0000|76 85|laser light
P01607223A0000|96 102|release
P01607223A0000|145 153|liposomes
P01607223A0000|177 187|vasculature
P01608239T0001|13 20|barriers
P01611699A0000|5 25|pyridoxine derivatives
P01611699A0000|54 61|stem bark
P01611699A0000|64 88|Albizzia julibrissin DURAZZ
P01612085A0624|3 21|serum erythropoietin
P01612085A0624|27 40|concentrations
P01612085A0624|48 58|triathletes
P01612085A0624|63 68|U.ml-1
P01612085A0624|108 122|distance runners
P01612085A0624|127 132|U.ml-1
P01613640A0158|3 18|coating materials
P01613640A0158|23 32|poloxamine
P01613640A0158|36 45|poloxamine
P01613640A0158|49 58|poloxamine
P01613640A0158|63 71|poloxamer
P01615049A0000|3 8|eating
P01615049A0000|12 27|drinking patterns
P01615049A0000|35 39|goats
P01615049A0000|43 47|ad lib
P01615049A0000|60 69|h light/12 h
P01615049A0000|74 78|cycle
P01615182A0206|10 14|study
P01615182A0206|28 38|improvement
P01615182A0206|41 57|sputum amoxycillin
P01615182A0206|58 62|amoxy
P01615182A0206|63 68|levels
P01615182A0206|74 90|combination tablet
P01615182A0206|91 95|amoxy
P01615182A0206|107 117|bromhexeine
P01615182A0206|153 157|amoxy
P01615493A0408|9 16|activity
P01615493A0408|19 31|antigen levels
P01615493A0408|65 72|daughter
P01615493A0408|91 96|levels
P01615493A0975|0 9|Argatroban
P01615493A0975|42 51|conditions
P01615493A0975|69 78|inhibition
P01615493A0975|81 96|thrombin activity
P01615493A0975|99 103|sites
P01615493A0975|114 123|wall damage
P01616475A0756|5 11|results
P01616475A0756|32 39|validity
P01616475A0756|50 63|CP/NCA patients
P01616475A0756|74 81|patients
P01616475A0756|86 98|family history
P01616475A0756|101 113|panic disorder
P01616475A0756|123 130|patients
P01616475A0756|149 173|panic disorder presentation
P01617242T0000|0 13|FDA regulations
P01617242T0000|17 29|growth factors
P01617242T0000|40 47|products
P01617776A0343|27 32|system
P01617776A0343|50 60|arrhythmias
P01617776A0343|74 83|infarction
P01617776A0343|112 122|innervation
P01617776A0343|128 132|heart
P01617776A0343|179 184|system
P01617776A0343|186 192|reentry
P01617776A0343|204 208|heart
P01617776A0343|221 230|infarction
P01617801A0088|0 5|DESIGN
P01617801A0088|6 21|Serum aldosterone
P01617801A0088|25 43|plasma renin activity
P01617801A0088|56 61|supine
P01617801A0088|79 85|minutes
P01617801A0088|95 103|captopril
P01618027A1108|13 23|transcripts
P01618027A1108|68 74|profile
P01618027A1108|104 114|E10 fragment
P01618027A1108|131 136|probes
P01618027A1108|148 156|remainder
P01618027A1108|168 173|region
P01618243T0000|11 27|amine pressor tests
P01618243T0000|37 46|volunteers
P01618256A0521|28 40|concentration
P01618256A0521|52 58|regimen
P01618256A0521|61 74|micrograms.l-1
P01618256A0521|109 114|regime
P01618256A0521|116 129|micrograms.l-1
P01619114A0383|11 15|study
P01619114A0383|19 29|performance
P01619114A0383|69 87|Mini Speech Processor
P01619642A0131|4 10|parents
P01620118A0470|11 18|proteins
P01620118A0470|30 36|ability
P01620118A0470|59 63|kappa
P01620118A0470|89 98|activation
P01620118A0470|109 129|immunodeficiency virus
P01620118A0470|142 147|repeat
P01620118A0470|179 185|chicken
P01620118A0470|194 198|cells
P01620129A0417|20 30|interaction
P01620129A0417|40 51|factor HiNF-D
P01620129A0417|71 85|promoter element
P01620129A0417|91 102|H4-FO108 gene
P01620129A0417|105 113|cell cycle
P01620129A0417|138 142|cells
P01620610A1070|2 11|conclusion
P01620610A1070|46 63|expression problems
P01620610A1070|101 106|vector
P01620610A1070|127 135|mutations
P01620610A1070|159 167|sequences
P01620610A1070|186 197|MTI subregion
P01620781A0611|15 22|subjects
P01620781A0611|41 49|sequences
P01620781A0611|66 72|control
P01620781A0611|78 82|words
P01620781A0611|121 128|reversal
P01620781A0611|140 146|stimuli
P01620781A0611|167 174|position
P01620781A0611|181 188|sequence
P01620781A0611|193 199|members
P01620781A0611|209 213|class
P01621584A0183|0 5|UF-021
P01621584A0183|16 23|solution
P01621584A0183|69 75|rabbits
P01621584A0183|94 105|IOP reduction
P01621584A0183|136 142|IOP rise
P01623900A0670|5 17|blood pressure
P01623900A0670|34 41|activity
P01623900A0670|52 58|changes
P01623900A0670|64 75|plasma levels
P01623900A0670|86 94|excretion
P01623900A0670|97 110|norepinephrine
P01623900A0670|134 140|Pl group
P01623900A0670|164 169|supine
P01623900A0670|189 202|blood pressures
P01623900A0670|229 247|norepinephrine level
P01623900A0670|260 282|norepinephrine excretion
P01623900A0670|304 308|month
P01623900A0670|311 326|dF administration
P01624425A0907|9 15|protein
P01624425A0907|37 43|mutants
P01624425A0907|48 60|substitutions
P01624425A0907|66 84|consensus amino acids
P01624425A0907|101 109|azido-ATP
P01625131A0452|14 19|biopsy
P01625131A0452|27 35|stoma site
P01625131A0452|64 72|rejection
P01625527A0000|5 24|blood serotonin levels
P01625527A0000|44 55|control group
P01625527A0000|68 72|group
P01625527A0000|86 100|failure patients
P01625527A0000|117 132|treatment regimen
P01625527A0000|148 156|treatment
P01625527A0000|163 186|maintenance haemodialysis
P01625527A0000|205 219|transplantation
P01626372T0000|0 6|Tissues
P01626372T0000|10 17|exudates
P01626372T0000|35 43|thymidine
P01626372T0000|47 52|growth
P01626372T0000|64 71|bacteria
P01626372T0000|77 84|presence
P01626372T0000|97 102|levels
P01626372T0000|105 133|trimethoprim-sulfamethoxazole
P01626430A1112|3 12|homologies
P01626430A1112|20 24|RAD16
P01626430A1112|25 29|RAD54
P01626430A1112|87 91|yeast
P01626430A1112|94 108|Drosophila genes
P01626440A0449|6 25|application solutions
P01626440A0449|28 50|instrument disinfectants
P01626631A0557|5 16|Rett syndrome
P01626631A0557|43 54|disturbances
P01626631A0557|60 68|brain stem
P01626631A0557|121 126|system
P01626631A0557|143 151|elevation
P01626631A0557|166 170|level
P01627106A0320|10 19|experiment
P01627106A0320|32 58|nitrofurazone administration
P01627106A0320|62 83|S. enteritidis challenge
P01627106A0320|107 117|differences
P01627106A0320|135 152|isolation frequency
P01627828A0475|2 10|agreement
P01627828A0475|27 34|blotting
P01627828A0475|37 44|mouse DNA
P01627828A0475|49 57|SmN probes
P01627828A0475|65 69|bands
P01627828A0475|101 110|pseudogene
P01627828A0475|154 160|SmN gene
P01627830A0000|3 7|cDNAs
P01627830A0000|16 29|casein kinase-1
P01627830A0000|51 66|yeast cDNA library
P01628201A0824|0 12|Incidence rate
P01628201A0824|69 75|minimum
P01628201A0824|89 96|datasets
P01628806A1347|11 27|sequence variation
P01628806A1347|104 117|helicase region
P01628904A0386|8 16|screening
P01628904A0386|25 29|clone
P01628904A0386|42 49|kilobase
P01628904A0386|54 59|insert
P01629768A0131|0 6|Lesions
P01629768A0131|17 33|pressure injection
P01629768A0131|93 109|glass micropipette
P01630454A0635|11 15|dA-dT
P01630454A0635|15 20|region
P01630454A0635|42 50|regulator
P01630454A0635|53 72|Act1 promoter activity
P01630455A0448|13 19|protein
P01630455A0448|26 36|NFIL-1 beta A
P01630455A0448|37 43|NF beta A
P01630455A0448|76 86|DNA sequence
P01630455A0448|115 126|TATA box motif
P01630455A0448|150 162|IL-1 beta genes
P01630569A0605|7 19|amphotericin B
P01630569A0605|28 36|remission
P01630569A0605|41 45|tumor
P01631229T0000|0 11|Cutis aplasia
P01633435A0743|3 7|DRF-2
P01633435A0743|15 21|protein
P01633435A0743|25 39|characteristics
P01633435A0743|84 89|factor
P01633435A0743|90 94|MEF-2
P01633435A0743|95 100|Buskin
P01633435A0743|104 111|Hauschka
P01633435A0743|116 122|Gossett
P01633816A0667|12 16|clone
P01633816A0667|22 34|EcoRI fragment
P01633816A0667|56 60|exons
P01633816A0667|85 90|region
P01633816A0667|95 101|opn gene
P01633816A0667|135 143|start site
P01633816A0667|156 178|primer extension analysis
P01633816A0667|182 198|S1 nuclease mapping
P01634308A0191|0 24|Cardiovascular risk factors
P01634308A0191|51 60|techniques
P01634400A1101|0 14|Production costs
P01634400A1101|37 45|operating
P01634400A1101|53 73|replacement stock costs
P01634464A0163|9 15|patient
P01634464A0163|26 43|factor VII inhibitor
P01634464A0163|55 62|reaction
P01634464A0163|65 88|penicillin administration
P01634464A0163|108 118|haemorrhage
P01634861A1336|8 15|contrast
P01634861A1336|32 51|oxygen debt hypothesis
P01634861A1336|70 79|oxygen debt
P01634861A1336|83 98|lactate clearance
P01636339A0200|0 6|Account
P01636339A0200|39 46|elements
P01636339A0200|52 57|smears
P01636339A0200|70 74|mucus
P01636339A0200|89 96|crystals
P01636339A0200|97 108|pollen grains
P01636339A0200|116 124|fragments
P01636339A0200|128 132|fungi
P01636714A0845|3 9|results
P01636714A0845|40 44|areas
P01636714A0845|58 62|liver
P01636714A0845|67 72|cortex
P01636714A0845|73 78|spleen
P01636714A0845|97 102|serosa
P01637758A0532|2 9|addition
P01637758A0532|18 27|proportion
P01637758A0532|30 34|women
P01637758A0532|48 52|group
P01637758A0532|65 74|dilatation
P01637758A0532|105 115|examination
P01637758A0532|120 129|labour ward
P01639092A0776|0 4|Lewis
P01639724A0452|1 12|control group
P01639724A0452|19 23|women
P01639724A0452|34 38|years
P01639724A0452|44 57|contraceptives
P01639724A0452|58 68|Nordette-28
P01639724A0452|87 91|times
P01639724A0452|99 107|pill cycle
P01640778A0485|20 25|method
P01640778A0485|34 41|MLPA test
P01640778A0485|76 84|screening
P01641628A0869|3 12|modalities
P01641628A0869|21 35|reference values
P01641628A0869|49 56|subjects
P01641628A0869|68 73|groups
P01641628A0869|100 105|points
P01641628A0869|108 115|research
P01641628A0869|156 170|reference values
P01642060A0471|11 21|application
P01642060A0471|44 57|Phthalocyanine
P01642060A0471|73 80|patients
P01642060A0471|111 119|carcinoma
P01642060A0471|120 126|FIGO III
P01643943A0300|11 27|lung cancer tissues
P01644751A0590|8 19|reading frame
P01644751A0590|67 82|sequence analysis
P01644751A0590|100 114|msgB gene product
P01644796A0374|6 10|study
P01644796A0374|51 55|furin
P01644796A0374|74 79|medium
P01644796A0374|87 91|cells
P01644814A0068|3 7|virus
P01644814A0068|22 28|protein
P01644814A0068|55 69|immortalization
P01644814A0068|71 76|T cells
P01644821A1259|7 14|butyrate
P01644821A1259|57 67|CAT activity
P01644821A1259|70 80|fusion genes
P01644821A1259|99 107|sequences
P01644821A1259|145 153|sequences
P01644821A1259|177 183|regions
P01644821A1259|189 198|PSG1-I gene
P01644821A1259|213 228|butyrate response
P01644831A0824|2 12|examination
P01644831A0824|29 44|carboxyl terminus
P01644831A0824|56 61|NGFI-B
P01644831A0824|77 84|activity
P01644831A0824|99 108|accordance
P01644831A0824|125 133|receptors
P01644831A0824|134 140|mutants
P01644831A0824|148 155|portions
P01644831A0824|161 176|carboxyl terminus
P01644831A0824|196 203|activity
P01645902A1462|15 21|results
P01645902A1462|43 47|locus
P01645902A1462|87 92|region
P01645902A1462|103 110|portions
P01645902A1462|129 133|genes
P01645902A1462|142 152|syn mutation
P01645902A1462|169 178|expression
P01645902A1462|181 188|activity
P01645905A0341|0 12|Nucleoprotein
P01645905A0341|42 54|vaccinia virus
P01645905A0341|121 131|degradation
P01645905A0341|134 143|C-terminus
P01645905A0341|160 176|breakdown products
P01646157A0414|28 51|alpha-GalNAc cDNA sequence
P01646157A0414|87 96|nucleotide
P01646157A0414|109 125|amino acid homology
P01646157A0414|163 182|alpha-galactosidase A
P01646157A0414|182 191|alpha-Gal A
P01646487A0874|0 7|Patients
P01646487A0874|23 30|activity
P01646487A0874|51 58|decrease
P01646487A0874|63 69|content
P01646487A0874|93 104|B lymphocytes
P01646487A0874|116 123|activity
P01646487A0874|126 136|neutrophils
P01646487A0874|149 156|patients
P01646487A0874|181 188|activity
P01646753A0336|3 8|reason
P01646753A0336|20 24|oxide
P01646753A0336|39 54|hydroxyl radicals
P01646753A0336|88 104|reduction proceeds
P01646753A0336|171 177|N2O/N2O
P01647070A0232|9 20|JCV T antigens
P01647070A0232|36 46|SV40 origins
P01647070A0232|48 61|DNA replication
P01647656A0000|3 10|relation
P01647656A0000|43 50|receptor
P01647656A0000|73 80|function
P01647656A0000|94 101|patients
P01647656A0000|112 116|years
P01647656A0000|130 145|LV volume overload
P01647656A0000|170 182|regurgitation
P01647813A0512|9 18|transcript
P01647813A0512|41 47|protein
P01647813A0512|52 61|complexity
P01647813A0512|127 133|control
P01647813A0512|135 144|expression
P01648142A1170|2 9|patients
P01648142A1170|21 27|disease
P01648142A1170|31 38|survival
P01648142A1170|89 96|survival
P01648142A1170|101 106|CAV arm
P01648142A1170|120 127|survival
P01648142A1170|132 136|PE arm
P01648530A0000|13 19|M region
P01648530A0000|40 46|Xenopus
P01648530A0000|54 70|actin gene promoter
P01648530A0000|111 120|expression
P01648530A0000|131 159|actin-beta-globin reporter gene
P01649173A0160|2 9|addition
P01649173A0160|51 60|attenuator
P01649173A0160|72 82|nucleotides
P01649173A0160|109 130|transcription start site
P01649173A0160|138 147|attenuator
P01649173A0160|148 157|attenuator
P01649173A0160|169 179|nucleotides
P01649318A0734|0 5|EBNA-2
P01649318A0734|22 32|CD23 element
P01649318A0734|76 125|herpes simplex virus TK promoter transcription start site
P01649318A1222|5 15|experiments
P01649318A1222|49 63|cell DNA fragment
P01649318A1222|78 85|evidence
P01649318A1222|90 95|EBNA-2
P01649318A1222|110 122|transcription
P01649318A1222|125 133|cell genes
P01649539T0000|0 13|Plasma vitamin E
P01649539T0000|19 24|lipids
P01649539T0000|28 48|myeloperoxidase levels
P01649539T0000|61 67|surgery
P01649835A0822|27 37|PBR/IBP cDNA
P01649835A0822|42 51|COS-7 cells
P01649835A0822|71 78|increase
P01649835A0822|84 90|density
P01649835A0822|97 104|affinity
P01649835A0822|117 128|binding sites
P01649835A0822|142 149|affinity
P01649835A0822|153 160|Ro5-4864
P01650524A0837|10 14|phase
P01650524A0837|34 45|permeability
P01650524A0837|61 66|cavity
P01650524A0837|70 83|LTB4 production
P01650524A0837|118 140|5-LO inhibitors phenidone
P01650524A0837|140 144|BW A4C
P01650524A0837|145 150|A63162
P01650524A0837|173 185|dexamethasone
P01650524A0837|187 196|colchicine
P01650557T0000|10 16|results
P01650557T0000|22 43|latex agglutination test
P01650557T0000|49 58|assessment
P01650557T0000|61 89|cytomegalovirus antibody status
P01650557T0000|99 114|transplant donors
P01651232A0152|36 50|uridine residues
P01651232A0152|76 82|mixture
P01651232A0152|93 100|thio-UTP
P01651918A0000|40 52|cDNA fragments
P01651918A0000|80 96|amino acid sequence
P01651918A0000|99 127|rat testis fructose-6-phosphate
P01651918A0000|128 133|kinase
P01651918A0000|133 142|fructose-2
P01651918A0000|143 156|bisphosphatase
P01652372A0153|30 47|localization signal
P01652372A0153|102 106|entry
P01652372A0153|120 126|protein
P01652515A0379|2 9|contrast
P01652515A0379|22 30|deviation
P01652515A0379|34 54|avoidance conditioning
P01652515A0379|62 72|haloperidol
P01652515A0379|86 100|microinjections
P01652515A0379|128 132|level
P01652515A0379|141 151|neostriatum
P01652755A1492|18 40|transfection experiments
P01652755A1492|43 51|HeLa cells
P01652755A1492|52 65|overexpression
P01652755A1492|78 116|retinoblastoma susceptibility gene product
P01652755A1492|169 173|c-fos
P01652755A1492|184 193|beta-actin
P01652755A1492|205 213|promoters
P01652755A1492|281 289|promoters
P01653173A0619|4 13|repression
P01653173A0619|32 38|binding
P01653173A0619|89 107|P105 promoter TATA box
P01653173A0619|127 139|preincubation
P01653173A0619|145 170|HPV-18 P105 promoter template
P01653173A0619|185 191|extract
P01653173A0619|203 211|formation
P01653173A0619|217 236|preinitiation complex
P01653236A0895|21 31|association
P01653236A0895|41 62|glucocorticoid receptor
P01653236A0895|65 70|L cells
P01653236A0895|93 114|glucocorticoid receptor
P01653236A0895|124 140|hamster ovary cells
P01653238A1062|11 47|12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1062|53 68|response elements
P01653238A1062|91 95|sites
P01653238A1062|102 124|transcription factor AP-1
P01653238A1062|129 145|consensus sequence
P01653238A1062|161 176|growth factor beta
P01653238A1062|178 185|TGF-beta
P01653238A1062|197 203|element
P01653238A1062|218 231|promoter region
P01653238A1715|8 15|TGF-beta
P01653238A1715|39 48|activities
P01653238A1715|60 65|enzyme
P01653918A0286|32 39|pressure
P01653918A0286|56 61|cornea
P01653918A0286|70 76|corneas
P01653918A0286|80 87|strength
P01653918A0286|105 124|corneal pain threshold
P01654349A0327|0 9|Feed intake
P01654349A0327|40 60|NaHCO3 supplementation
P01654349A0327|135 140|NaHCO3
P01655126T0000|0 18|Extraction procedure
P01655126T0000|25 35|measurement
P01655126T0000|38 54|butyltin compounds
P01655126T0000|67 73|tissues
P01655126T0000|79 85|toluene
P01655126T0000|94 102|tropolone
P01655713A0294|6 10|study
P01655713A0294|24 29|region
P01655713A0294|68 76|phenotype
P01655713A0294|79 84|strain
P01655713A0294|126 133|mutation
P01656220T0000|55 67|leukemia cells
P01656220T0000|79 100|receptor tyrosine kinase
P01656221A1319|0 8|Alignment
P01656221A1319|14 31|amino acid sequences
P01656221A1319|43 49|Tyr-766
P01656221A1319|67 73|regions
P01656221A1319|81 85|FGFRs
P01656221A1319|103 118|tyrosine residues
P01656221A1319|129 135|members
P01656221A1319|141 150|FGFR family
P01656235A0946|22 28|element
P01656235A0946|46 53|analysis
P01656235A0946|62 67|region
P01656235A0946|81 90|CCAAT motif
P01656675A0236|0 16|Capnography curves
P01656675A0236|21 31|HVS patients
P01656675A0236|41 48|patients
P01656675A0236|67 76|complaints
P01656675A0236|89 96|controls
P01657246A0325|3 29|transcription initiation site
P01657249A1019|50 55|chains
P01657249A1019|120 136|region determinant
P01657249A1019|141 148|VH4-HV2a
P01657415A0837|0 13|Intron K1 cox1.2
P01657415A0837|57 64|location
P01657415A0837|67 74|K. lactis
P01657594A0472|23 29|mutants
P01657594A0472|39 59|complementation groups
P01657969A1420|7 17|alterations
P01657969A1420|47 58|interactions
P01657969A1420|76 97|amino acid substitutions
P01657969A1420|122 127|change
P01657969A1420|133 138|enzyme
P01657969A1420|156 172|calmodulin binding
P01658356A1369|3 9|results
P01658356A1369|19 30|coexpression
P01658356A1369|55 64|generation
P01658356A1369|67 82|FeLV recombinants
P01658356A1369|87 92|FeLV-C
P01658356A1369|117 129|3201B cell line
P01658356A1369|161 166|levels
P01658356A1369|192 196|mRNAs
P01658356T0000|0 12|Recombination
P01658356T0000|26 47|leukemia virus subgroup B
P01658356T0000|66 76|env elements
P01658356T0000|102 111|activities
P01658356T0000|117 123|viruses
P01658375A0854|3 21|nucleotide sequences
P01658375A0854|45 51|introns
P01658375A0854|77 87|transcripts
P01658375A0854|118 122|genes
P01658375A0854|141 150|difference
P01658375A0854|169 177|LAT intron
P01658375A0854|195 213|consensus sequence GT
P01658468A0123|8 13|months
P01658468A0123|26 34|isolation
P01658468A0123|37 47|C. kutscheri
P01658468A0123|59 64|cavity
P01658468A0123|65 72|hamsters
P01658468A0123|92 99|attempts
P01658468A0123|110 116|culture
P01658468A0123|144 148|sites
P01658741A1047|3 10|strategy
P01658741A1047|36 44|kilobases
P01658741A1047|47 64|nucleotide sequence
P01658741A1047|99 103|locus
P01659685T0000|14 22|promoters
P01659685T0000|44 50|regions
P01659685T0000|59 73|Dd ras expression
P01659685T0000|76 88|Dictyostelium
P01660486A1756|3 9|results
P01660486A1756|39 46|cell type
P01660486A1756|47 60|gene cotransfer
P01660486A1756|66 89|aminoglycoside resistance
P01660486A1756|103 108|marker
P01660486A1756|145 161|control mechanisms
P01660486A1756|171 180|PKC pathway
P01660486A1756|190 199|activation
P01660486A1756|202 215|gene expression
P01660925T0000|0 15|Transfer RNA genes
P01660925T0000|20 42|Dictyostelium discoideum
P01660925T0000|80 87|elements
P01660925T0000|98 111|consensus boxes
P01660925T0000|131 137|regions
P01661369A0825|21 29|strE genes
P01661369A0825|50 55|probes
P01661369A0825|71 78|presence
P01661369A0825|93 100|capacity
P01661369A0825|117 124|moieties
P01662609A0398|6 10|genes
P01662609A0398|18 29|polypeptides
P01662609A0398|35 44|amino acids
P01662609A0398|45 51|M.HgiCI
P01662609A0398|57 66|amino acids
P01662609A0398|67 73|R.HgiCI
P01662794A0640|0 9|Expression
P01662794A0640|15 21|wt1 gene
P01662794A0640|34 45|transfection
P01662794A0640|48 57|COS-1 cells
P01662794A0640|69 78|kDa protein
P01662794A0640|146 153|antisera
P01662807A1182|3 8|factor
P01662807A1182|24 33|TR promoter
P01662807A1182|51 65|SV40 chromosomes
P01662807A1182|81 89|infection
P01662884A1029|0 11|Temafloxacin
P01662884A1029|15 22|mg b.i.d.
P01662884A1029|79 87|treatment
P01662884A1029|106 116|prostatitis
P01664192A1577|16 22|effects
P01664192A1577|42 49|ED90 dose
P01664192A1577|52 61|vecuronium
P01669611A0142|3 9|patient
P01669611A0142|24 28|fever
P01669611A0142|47 54|aneurysm
P01669611A0142|60 64|aorta
P01669611A0142|71 85|pleuropneumonia
P01669611A0142|99 106|diseases
P01671675A0483|12 21|clone pKB11
P01671675A0483|50 59|cDNA insert
P01671675A0483|69 75|pCAD142
P01671675A0483|100 119|hybridization methods
P01671675A0483|122 137|sequence analysis
P01671675A0483|164 175|cDNA sequence
P01671675A0483|182 189|amino end
P01671675A0483|195 208|CAD polypeptide
P01671675A0905|4 13|conclusion
P01671675A0905|28 51|Northern blotting analysis
P01671675A0905|65 70|region
P01671675A0905|73 79|CAD gene
P01673220A0578|11 19|isolation
P01673220A0578|32 41|cDNA clones
P01673220A0578|68 77|bol3 allele
P01674177T0001|0 18|Histamine-2 blockade
P01674177T0001|21 29|psoriasis
P01674242A0358|3 11|clearance
P01674242A0358|77 88|erythromycin
P01674242A0358|88 101|troleandomycin
P01674242A0358|102 122|triacetyloleandomycin
P01674242A0358|123 135|roxithromycin
P01674242A0358|136 143|enoxacin
P01674242A0358|144 156|ciprofloxacin
P01674242A0358|157 166|pefloxacin
P01674242A0358|167 177|norfloxacin
P01674242A0358|178 186|ofloxacin
P01674242A0358|202 207|T-3262
P01674242A0358|223 232|cimetidine
P01674242A0358|232 241|etintidine
P01674242A0358|242 252|propranolol
P01674242A0358|253 261|verapamil
P01674242A0358|262 270|diltiazem
P01674242A0358|271 280|nifedipine
P01674242A0358|281 290|furosemide
P01674242A0358|291 299|frusemide
P01674242A0358|320 325|agents
P01674242A0358|326 335|viloxazine
P01674242A0358|336 346|allopurinol
P01674242A0358|347 357|ticlopidine
P01674242A0358|358 369|idrocilamide
P01674242A0358|370 382|thiabendazole
P01674242A0358|383 392|disulfiram
P01674242A0358|393 401|influenza
P01674242A0358|405 419|BCG-vaccination
P01674242A0358|420 429|interferon
P01674242A0358|433 440|caffeine
P01674242A0358|441 457|half-life increase
P01674369A0417|16 22|element
P01674369A0417|53 67|restriction site
P01674369A0417|75 81|cloning
P01674662A0000|33 45|heroin addicts
P01674662A0000|64 70|disease
P01674662A0000|104 118|lymphadenopathy
P01674662A0000|139 143|study
P01674662A0000|161 171|progression
P01674662A0000|187 193|complex
P01674662A0000|219 225|factors
P01674662A0000|244 252|relevance
P01674817A0862|2 9|homology
P01674817A0862|25 29|RNA14
P01674817A0862|33 37|RNA15
P01674817A0862|47 51|RNA14
P01674817A0862|60 67|proteins
P01674817A0862|79 87|data banks
P01674817T0000|0 8|Mutations
P01674817T0000|14 23|yeast RNA14
P01674817T0000|27 36|RNA15 genes
P01674817T0000|55 67|mRNA decay rate
P01674817T0000|68 83|sequence analysis
P01674817T0000|104 109|domain
P01674817T0000|115 126|RNA15 protein
P01675154T0000|10 19|infarction
P01675154T0000|22 29|patients
P01675154T0000|42 54|bypass surgery
P01675424A0991|15 24|difference
P01675424A0991|41 52|H-NR sequence
P01675424A0991|53 62|comparison
P01675424A0991|65 80|NADH-NR sequences
P01675424A0991|102 119|pyridine nucleotide
P01675637T0033|7 25|amino acid difference
P01675637T0033|41 46|region
P01675637T0033|73 80|activity
P01675637T0033|84 105|receptor dimer formation
P01675763A1389|6 13|benefits
P01675763A1389|25 32|children
P01675763A1389|62 66|liter
P01675763A1389|68 72|entry
P01678287A1308|15 37|Antp TATAA binding protein
P01678287A1308|78 82|cells
P01678287A1308|100 111|homeobox gene
P01678287A1308|159 166|function
P01678287A1308|185 189|cells
P01678392A0648|4 20|% confidence values
P01678392A0648|32 37|change
P01678392A0648|68 78|variability
P01678392A0648|97 105|cmH2O l-1 s
P01679068A0000|8 14|infants
P01679068A0000|27 35|care units
P01679068A0000|53 57|value
P01679068A0000|57 61|range
P01679068A0000|125 131|strains
P01679068A0000|149 158|Klebsiella
P01679068A0000|161 175|Enterobacter spp
P01679124A1368|11 17|studies
P01679124A1368|45 56|ChAT activity
P01679124A1368|61 66|dorsal
P01679124A1368|77 86|hippocampi
P01679124A1368|97 103|animals
P01679124A1368|121 126|levels
P01679124A1368|129 142|norepinephrine
P01679124A1368|152 168|dorsal hippocampus
P01679124A1368|170 182|MS/HSI animals
P01679124A1368|215 222|ABSTRACT
P01679124A1368|237 241|WORDS
P01679749A1171|3 14|localization
P01679749A1171|21 37|proteoglycan locus
P01679749A1171|48 53|genome
P01679749A1171|60 71|availability
P01679749A1171|77 81|RFLPs
P01679749A1171|92 96|tools
P01679749A1171|106 112|studies
P01679749A1171|120 127|diseases
P01679749A1171|136 156|HSPG2 proteoglycan gene
P01681075A0429|13 31|dobutamine injection
P01681075A0429|47 65|pimobendan injection
P01681075A0429|68 77|myocardium
P01681075A0429|98 110|determination
P01681075A0429|116 127|tissue levels
P01681075A0429|130 140|metabolites
P01681075A0429|143 148|energy
P01681075A0429|152 173|carbohydrate metabolism
P01682484A0680|14 21|stenosis
P01682484A0680|27 34|contrary
P01682484A0680|48 57|procaterol
P01682484A0680|116 126|dysfunction
P01682484A0680|141 147|LCX flow
P01682484A0680|154 165|hemodynamics
P01682484A0680|176 192|lactate metabolism
P01682509A0539|13 20|evidence
P01682509A0539|32 43|proteins IE86
P01682509A0539|90 95|HIV LTR
P01682509A0539|97 106|T-cell line
P01682509A0539|107 112|HUT-78
P01682542A0690|3 9|country
P01682542A0690|22 34|HIV prevalence
P01682542A0690|43 50|strategy
P01682542A0690|70 77|location
P01682542A0690|81 91|counselling
P01682542A0690|117 127|individuals
P01684791A0000|13 19|element
P01684791A0000|29 54|glucocorticoid inducibility
P01684791A0000|60 89|chicken glutamine synthetase gene
P01686909A0299|10 17|increase
P01686909A0299|27 35|excretion
P01686909A0299|65 75|elimination
P01686909A0299|78 86|bretylium
P01686909A0299|116 121|kidney
P01687050T0000|10 14|value
P01687050T0000|30 49|fluid immunoglobulin G
P01687050T0000|78 85|diseases
P01688841A0430|0 9|Expression
P01688841A0430|15 19|genes
P01688841A0430|94 106|regulator virF
P01688972A0803|39 45|patient
P01690703A0285|0 9|Venkatesan
P01690728A1166|3 10|presence
P01690728A1166|35 49|mRNA transcripts
P01690728A1166|56 68|kilobase pairs
P01690728A1166|80 90|fibroblasts
P01690728A1166|100 124|Northern blot hybridization
P01690728A1166|125 149|S1 nuclease protection assay
P01690728A1166|156 178|polymerase chain reaction
P01690812A0000|42 46|units
P01690812A0000|98 101|S RNA
P01690812A0000|111 124|gene insertions
P01691184A0995|0 4|Gap b3
P01691184A0995|18 34|polypeptide chains
P01691184A0995|80 95|cleavage products
P01691184A0995|106 119|disulfide bonds
P01691184A0995|125 140|precursor protein
P01692135A0783|10 33|rtFc gamma R alpha cDNA clone
P01692135A0783|76 80|mRNAs
P01692135A0783|92 103|CRNK-16 cells
P01692135A0783|124 130|Fc gamma
P01692135A0783|140 150|mRNA species
P01692135A0783|170 174|mouse
P01692135A0783|182 192|killer cells
P01692837A0390|4 8|genes
P01692837A0390|22 26|exons
P01692837A0390|30 36|introns
P01692837A0390|67 72|region
P01692837A0390|76 88|kilobase pairs
P01692837A0390|126 134|kilobases
P01692962A0980|6 15|expression
P01692962A0980|29 33|alpha
P01692962A0980|35 46|s polypeptide
P01692962A0980|56 67|hamster ovary
P01692962A0980|73 77|cells
P01692962A0980|104 116|cAMP synthesis
P01692962A0980|134 154|protein kinase activity
P01694009A0112|57 62|region
P01694009A0112|77 90|signal sequence
P01694009A0112|96 106|polypeptide
P01694014A0716|0 8|Treatment
P01694014A0716|23 36|cell lines HL-60
P01694014A0716|50 78|phorbol 12-myristate 13-acetate
P01694014A0716|110 115|levels
P01694014A0716|119 133|RNA hybridizable
P01694014A0716|136 143|LD78 cDNA
P01694280A0000|22 36|ventriculoscope
P01694280A0000|40 50|observation
P01694280A0000|56 65|ventricles
P01694280A0000|74 81|cisterns
P01694525A0000|0 22|Isopenicillin N isomerase
P01694525A0000|23 31|epimerase
P01694525A0000|81 97|amino acid sequence
P01694525A0000|103 112|N-terminus
P01695098A1116|0 7|Serum IgG
P01695098A1116|31 38|patients
P01695116A0078|3 9|patient
P01695116A0078|35 43|remission
P01695116A0078|65 76|chemotherapy
P01695116A0078|93 98|months
P01695314A0762|6 10|mg/dl
P01695314A0762|15 27|glucose levels
P01695314T0000|0 18|Platelet aggregation
P01695314T0000|31 37|control
P01695314T0000|54 79|calcium antagonist treatment
P01695314T0000|90 105|diabetes mellitus
P01695322A0000|0 4|Wnt-1
P01695322A0000|5 9|int-1
P01695322A0000|21 28|oncogene
P01695322A0000|45 53|insertion
P01695322A0000|74 78|mouse
P01695322A0000|85 94|tumor virus
P01695378A1406|0 8|Induction
P01695378A1406|11 16|Jurkat
P01695378A1406|25 30|T cells
P01695378A1406|35 63|phorbol 12-myristate 13-acetate
P01695378A1406|67 75|ionomycin
P01695378A1406|91 95|level
P01695378A1406|98 105|FKBP mRNA
P01695905A0480|0 8|GLUT5 mRNA
P01695905A0480|29 34|levels
P01695905A0480|42 50|intestine
P01695905A0480|65 70|levels
P01695905A0480|73 78|kidney
P01695905A0480|87 92|muscle
P01695905A0480|96 108|adipose tissue
P01697611A0738|20 25|tumors
P01697611A0738|61 67|growths
P01697683T0000|0 13|Identification
P01697683T0000|17 32|characterization
P01697683T0000|38 45|promoter
P01697683T0000|52 65|cytotactin gene
P01697928A1214|21 36|sequence homology
P01697928A1214|48 53|region
P01697928A1214|56 60|Ly-6E
P01697928A1214|78 86|consensus
P01697928A1214|114 128|response element
P01697928A1214|195 204|alpha/beta
P01697928A1214|225 233|promoters
P01698761A1059|15 31|DNA rearrangements
P01698761A1059|43 48|region
P01698761A1059|65 71|repeats
P01698761A1059|99 105|histone
P01698761A1059|113 121|structure
P01698761A1059|151 157|strains
P01698761A1059|161 170|conversion
P01698761A1059|178 183|mucoid
P01698761A1059|198 206|phenotype
P01699944A1538|5 11|results
P01699944A1538|57 78|CArG box binding proteins
P01699944A1538|115 129|promoter element
P01699944A1538|148 158|alpha-actin
P01699944A1538|161 170|c-fos genes
P01700272A0838|0 14|Polyadenylation
P01700272A0838|17 21|B4 RNA
P01700272A0838|48 57|maturation
P01700272A0838|72 79|residues
P01700272A0838|91 96|number
P01700272A0838|123 133|recruitment
P01701088A1335|0 11|Co-existence
P01701088A1335|29 36|elements
P01701088A1335|46 53|elements
P01701088A1335|63 73|AP-2 element
P01701088A1335|76 83|CCAAT box
P01702361A0621|8 14|studies
P01702361A0621|17 22|agents
P01702361A0621|34 50|collagen synthesis
P01702361A0621|54 63|deposition
P01702361A0621|85 106|angiogenesis inhibitors
P01702426A0196|16 21|region
P01702426A0196|60 69|regulation
P01702426A0196|74 83|expression
P01702426A0196|135 150|acid synthase gene
P01702426A1006|11 20|cDNA clones
P01702426A1006|64 94|lambda-ZAP goose liver cDNA library
P01702426A1006|121 128|fragment
P01702426A1006|145 152|DNA clone
P01702432A1296|0 23|Northern blotting analysis
P01702432A1296|37 46|expression
P01702432A1296|52 56|genes
P01702432A1296|77 82|clones
P01702432A1296|95 106|pollen tissue
P01702972A0613|7 23|cDNA hybridization
P01702972A0613|33 40|DNA blots
P01702972A0613|56 64|subfamily
P01702972A0613|67 76|G0S19 genes
P01702972A0613|83 90|patterns
P01702972A0613|93 97|bands
P01702972A0613|115 119|cDNAs
P01702972A0613|129 137|G0S30 cDNA
P01702972A0613|163 167|genes
P01703335T0000|19 27|disorders
P01703335T0000|40 56|immunosuppression
P01703335T0000|75 86|observations
P01703335T0000|94 113|transplant population
P01703632T0000|13 22|suppressor
P01703632T0000|44 54|polypeptide
P01703632T0000|58 64|regions
P01703632T0000|92 99|proteins
P01707659A0458|57 63|HLA-5.4
P01707659A0458|70 83|chimpanzee gene
P01707800A0354|11 34|N13-N20 interpeak interval
P01707800A0354|61 73|parallel shift
P01707800A0354|80 84|peaks
P01707800A0354|95 108|conduction time
P01707800A0354|121 134|onset latencies
P01708098A0922|18 40|complex DNA binding assays
P01708098A0922|42 47|series
P01708098A0922|61 85|alpha promoter DNA sequences
P01708098A0922|101 109|basepairs
P01708098A0922|151 160|control GRE
P01708098A0922|171 178|receptor
P01708771A1215|0 20|Sequence determination
P01708771A1215|31 38|peptides
P01708771A1215|52 57|Asn120
P01708771A1215|72 76|Asn65
P01708771A1215|80 85|Asn109
P01708771A1215|104 112|molecules
P01708771A1215|121 126|others
P01708771A1215|130 134|Asn72
P01708774A0203|3 13|DNA sequence
P01708774A0203|24 35|AP-1 activity
P01708774A0203|59 72|promoter region
P01709486A0000|9 16|mutation
P01709486A0000|48 61|proto-oncogene
P01709486A0000|61 65|c-kit
P01709933T0000|0 8|Isolation
P01709933T0000|12 27|characterization
P01709933T0000|59 69|polypeptide
P01709933T0000|95 100|statin
P01710766A0349|3 10|proteins
P01710766A0349|22 29|presence
P01710766A0349|32 38|absence
P01710766A0349|55 62|sequence
P01710766A0349|72 90|amino acids C terminal
P01710766A0349|109 123|initiation codon
P01710768A1172|3 9|results
P01710768A1172|25 33|existence
P01710768A1172|36 44|sequences
P01710768A1172|86 92|pattern
P01710768A1172|109 118|expression
P01710768A1172|124 133|HLA-B7 gene
P01710768A1172|140 146|ability
P01710768A1172|170 184|gamma interferon
P01710979T0000|11 20|SH3 domains
P01710979T0000|22 28|pp60src
P01710979T0000|41 51|association
P01710979T0000|56 63|tyrosine
P01710979T0000|78 89|proteins p130
P01711041A0348|5 10|clones
P01711041A0348|71 83|C5 alpha-chain
P01711041A0348|95 104|beta-chain
P01711041A0962|3 15|C5 alpha-chain
P01711041A0962|30 38|kilobases
P01711041A0962|51 55|exons
P01711041A0962|59 68|beta-chain
P01711041A0962|83 91|kilobases
P01711041A0962|104 108|exons
P01711048T0000|12 19|mutation
P01711048T0000|29 36|position
P01711048T0000|38 43|intron
P01711048T0000|51 59|pro-alpha
P01711048T0000|67 72|COL1A2
P01711048T0000|90 100|RNA splicing
P01711048T0000|110 131|osteogenesis imperfecta
P01712296A0157|3 21|nucleotide sequences
P01712296A0157|29 33|genes
P01712296A0157|50 58|positions
P01712296A0157|75 94|amino acid differences
P01713213A0000|3 9|protein
P01713213A0000|24 31|sequence
P01713213A0000|42 66|pim-1 proto-oncogene shares
P01713213A0000|76 83|homology
P01713213A0000|93 122|serine/threonine protein kinases
P01713213A0000|137 147|Pim-1 enzyme
P01713213A0000|182 210|protein tyrosine kinase activity
P01713213A0488|17 25|pim-1 cDNA
P01713213A0488|54 66|vector pGEX-2T
P01713213A0488|73 84|Pim-1 protein
P01713213A0488|97 109|fusion product
P01713213A0488|123 146|glutathione S-transferase
P01714322A0969|4 9|report
P01714322A0969|44 50|kDa hsps
P01714322A0969|53 57|maize
P01714322A0969|61 68|products
P01714322A0969|90 94|genes
P01714358A0990|5 18|kDa polypeptide
P01714358A0990|55 77|wheat etioplast membranes
P01714358A0990|82 89|gamma 32P
P01714452A0559|0 7|Homology
P01714452A0559|20 26|protein
P01714452A0559|48 59|repeat domain
P01714452A0559|72 83|conservation
P01714452A0559|86 92|serines
P01714452A0559|96 105|threonines
P01714452A0559|114 118|sites
P01714452A0559|129 150|carbohydrate attachment
P01714902A0221|2 9|addition
P01714902A0221|39 82|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
P01714902A0221|88 98|cell surface
P01714902A0221|99 105|CD3 zeta
P01714902A0221|129 151|interleukin-2 production
P01714902A0221|157 170|TCR stimulation
P01714902A0221|188 212|histocompatibility complex
P01715593A0838|4 14|desipramine
P01715593A0838|38 56|fluoxetine injection
P01715593A0838|56 66|brain levels
P01715593A0838|69 79|desipramine
P01715975A0885|8 14|effects
P01715975A0885|58 62|cells
P01716292A0000|10 17|analysis
P01716292A0000|26 32|regions
P01716292A0000|35 41|HLA-DR1
P01716292A0000|53 72|T cell allorecognition
P01716292A0000|93 98|series
P01716292A0000|112 120|cell lines
P01716292A0000|134 141|products
P01716292A0000|155 159|DRB/H
P01716292A0000|160 166|Eb genes
P01716292A0000|183 189|DR alpha
P01716292A0000|192 200|H-2E alpha
P01716629A0000|15 24|cDNA clones
P01716629A0000|52 76|matrix glycoprotein undulin
P01717718A1255|11 24|point mutations
P01717718A1255|30 44|Gag-Pol PR domain
P01717718A1255|54 63|activation
P01717718A1255|117 128|conformation
P01717718A1255|132 139|PR domain
P01717718A1255|142 148|Gag-Pol
P01717718A1255|151 162|prerequisite
P01717718A1255|166 175|activation
P01717833A1223|3 22|alpha inhibin promoter
P01717833A1223|63 71|forskolin
P01717833A1223|73 86|granulosa cells
P01717833A1223|103 113|CREB protein
P01717833T0000|0 9|Regulation
P01717833T0000|15 30|alpha inhibin gene
P01717833T0000|39 47|adenosine
P01717833T0000|49 61|monophosphate
P01717833T0000|67 78|transfection
P01717833T0000|83 99|rat granulosa cells
P01717925A0477|0 9|Comparison
P01717925A0477|15 33|nucleotide sequences
P01717925A0477|76 93|sequence similarity
P01717925A0477|132 137|region
P01717994T0000|0 6|Cloning
P01717994T0000|42 47|kinase
P01717994T0000|49 63|complementation
P01717994T0000|74 78|yeast
P01717994T0000|84 91|mutation
P01718043A0384|2 9|patients
P01718043A0384|14 26|osteomyelitis
P01718043A0384|35 41|empyema
P01718043A0384|48 58|PMN elastase
P01718043A0384|62 72|sensitivity
P01718043A0384|120 147|erythrocyte sedimentation rate
P01718043A0384|147 157|sensitivity
P01718983A1640|4 10|Hession
P01718983A1640|24 32|Griffiths
P01718983A1640|34 39|Tizard
P01718983A1640|43 48|Newman
P01718983A1640|52 60|Chi-Rosso
P01719684A0494|8 14|results
P01719684A0494|26 33|increase
P01719684A0494|52 60|receptors
P01719684A0494|69 76|prostate
P01719684A0494|145 161|sphincter function
P01720555A1087|25 36|B2 transcript
P01720555A1087|54 66|alfalfa organs
P01720843A1506|5 11|results
P01720843A1506|27 41|sulfhydryl group
P01720843A1506|51 61|angiotensin
P01720843A1506|72 87|enzyme inhibitors
P01720843A1506|106 111|effect
P01720843A1506|127 146|nitrovasodilator EDRF
P01721261T0000|0 15|Pharmacokinetics
P01721261T0000|27 44|transplant patients
P01721884A0962|26 30|match
P01721884A0962|43 48|region
P01721884A0962|72 84|ribonuclease H
P01721884A0962|85 90|RNase H
P01721884A0962|91 96|domain
P01721884A0962|123 128|region
P01721884A0962|157 169|investigators
P01721884A0962|183 188|RNase H
P01721884A0962|209 216|helices O
P01721884A0962|237 243|helices
P01721884A0962|255 276|RNase H crystal structure
P01722319A0849|0 7|Analysis
P01722319A0849|20 36|amino acid sequence
P01722319A0849|49 61|CHIP28 protein
P01722319A0849|89 95|domains
P01722319A0849|117 136|N-glycosylation sites
P01722319A0849|159 166|C termini
P01722479A0302|14 27|concentrations
P01722479A0302|39 49|sensitivity
P01722479A0302|61 71|specificity
P01723619A0766|18 28|F absorption
P01723619A0766|45 64|plasma F concentration
P01723619A0766|90 97|emptying
P01723619A0766|110 116|passage
P01723619A0766|134 142|intestine
P01723619A0766|152 157|factor
P01723619A0766|165 175|F absorption
P01723962A0165|3 10|activity
P01723962A0165|13 23|serum lipase
P01723962A0165|27 33|amylase
P01723962A0165|73 79|maximum
P01723962A0165|91 99|injection
P01723962A0165|101 105|Na-Tc
P01724982A0237|41 49|HCV EIA kit
P01724982A0237|50 59|Abbott Lab.
P01724982A0237|60 71|North Chicago
P01725547A0354|0 8|Diltiazem
P01725547A0354|31 38|increase
P01725547A0354|51 58|diameter
P01725547A0354|86 94|blood flow
P01725622A0292|8 18|transfusion
P01725622A0292|30 46|platelet increment
P01725622A0292|51 55|Gpt/l
P01726211A0502|5 15|risk factors
P01726211A0502|33 38|groups
P01726211A0502|44 49|vessel
P01726211A0502|62 68|factors
P01726211A0502|82 87|action
P01726211A0502|96 102|factors
P01726631T0001|0 11|Epidemiology
P01726631T0001|15 24|prevention
P01726631T0001|27 44|hospital infections
P01726631T0001|50 64|Local Health Unit
P01726631T0001|67 73|Sassari
P01726631T0001|74 80|profile
P01726631T0001|92 101|resistance
P01726631T0001|118 123|agents
P01726631T0001|131 135|usage
P01727488A1146|17 21|cDNAs
P01727488A1146|36 46|stimulation
P01727488A1146|82 95|gene expression
P01727494A0000|0 12|Vaccinia virus
P01727494A0000|26 34|immunogen
P01727494A0000|40 45|nature
P01727494A0000|48 57|VV proteins
P01727494A0000|71 80|activation
P01727494A0000|92 99|response
P01730412T0000|15 21|domains
P01730412T0000|24 34|interaction
P01730412T0000|39 43|c-Myc
P01730747A0205|19 24|S phase
P01730747A0205|24 29|Reilly
P01731107A0928|0 12|Substitutions
P01731107A0928|25 29|bases
P01731107A0928|44 52|ICR2 motif
P01731107A0928|60 65|levels
P01731107A0928|68 82|pRNA replication
P01731107A0928|109 119|maintenance
P01731107A0928|141 149|structure
P01731107A0928|163 168|strand
P01731107A0928|179 184|genome
P01731933T0000a|5 29|coordination domain mutants
P01731933T0000a|31 36|T4 gene
P01731933T0000a|39 45|protein
P01731933T0000b|5 29|coordination domain mutants
P01731933T0000b|31 36|T4 gene
P01731933T0000b|39 45|protein
P01731979A1408|3 19|tissue specificity
P01731979A1408|22 35|gene expression
P01731979A1408|79 107|CaMV 35S domain B enhancer element
P01732033A0000|3 17|pathophysiology
P01732033A0000|29 38|management
P01732033A0000|46 56|brain injury
P01732033A0000|59 65|infancy
P01732033A0000|69 77|childhood
P01732033A0000|109 119|brain injury
P01732033A0000|123 127|model
P01732736A1076|0 10|Transcripts
P01732736A1076|22 35|POU-domain gene
P01732736A1076|36 41|Oct-25
P01732736A1076|58 63|levels
P01732736A1076|66 72|oocytes
P01732736A1076|81 87|embryos
P01732736A1076|129 140|gastrulation
P01732752A0156|11 16|B cells
P01732752A0156|20 26|Abelson
P01732752A0156|33 40|leukemia
P01732752A0156|58 72|pre-B-cell lines
P01732752A0156|73 78|LT mRNA
P01733105A0127|3 8|genome
P01733105A0127|11 22|Thogoto virus
P01733105A0127|35 42|segments
P01733105A0127|68 75|sense RNA
P01733358A0240|5 10|tumors
P01733358A0240|39 44|groups
P01733358A0240|46 56|cystadenoma
P01733358A0240|59 76|cystadenocarcinoma
P01733358A0240|85 98|adenocarcinoma
P01733358A0240|102 116|mucin production
P01734020A1318|0 13|Immunostaining
P01734020A1318|16 20|cells
P01734020A1318|41 50|constructs
P01734020A1318|102 108|mutants
P01734020A1318|124 129|nuclei
P01734020A1318|146 153|PKC alpha
P01734283A0817|27 38|RAP74 protein
P01734283A0817|51 59|HeLa cells
P01734283A0817|102 119|translation product
P01734283A0817|134 138|RAP30
P01734570T0000|0 6|Effects
P01734570T0000|9 39|thromboxane synthetase inhibition
P01734570T0000|68 77|resistance
P01734570T0000|101 113|translocation
P01734570T0000|123 134|porcine model
P01735347A0482|20 25|insult
P01735347A0482|51 59|treatment
P01735347A0482|85 96|plasma lipase
P01735347A0482|102 112|development
P01735347A0482|115 121|ascites
P01735347A0482|127 135|extension
P01735347A0482|151 158|necrosis
P01735447A0271|20 27|molecule
P01735447A0271|65 73|precursor
P01735447A0271|74 90|pre-super-pro-PrB
P01735447A0271|103 114|sec61 mutants
P01735447A0271|119 131|translocation
P01735447A0271|150 158|reticulum
P01735447A0833|7 25|active-site mutation
P01735447A0833|46 55|processing
P01735447A0833|81 89|precursor
P01735447A0833|106 115|kDa pro-PrB
P01735447A0833|131 139|reticulum
P01735721A0185|12 28|amino acid sequence
P01735721A0185|39 47|% identity
P01735721A0185|56 86|Bacillus stearothermophilus TyrTS
P01735721A0185|91 99|% identity
P01735721A0185|114 118|TyrTS
P01735721A0185|124 131|identity
P01735721A0185|148 166|B. subtilis TyrTS gene
P01736093A0731|14 24|CAT activity
P01736093A0731|52 60|sequences
P01736093A0731|74 81|promoter
P01736093A0731|97 106|CCAAT boxes
P01736093A0731|138 150|constructions
P01736651A0104|7 11|Women
P01736651A0104|12 18|Infants
P01736651A0104|22 36|Children clinics
P01736651A0104|39 49|Minneapolis
P01736651A0104|50 54|Minn.
P01736844T0000|0 11|Testosterone
P01736844T0000|16 27|testosterone
P01736844T0000|64 75|testosterone
P01736844T0000|83 95|androgen index
P01736844T0000|101 123|testosterone measurement
P01736844T0000|161 168|function
P01736844T0000|180 187|epilepsy
P01737741A0000|0 9|BACKGROUND
P01737741A0000|13 25|effectiveness
P01737741A0000|28 53|monoamine oxidase inhibitors
P01737741A0000|54 58|MAOIs
P01737741A0000|79 88|depression
P01737741A0000|128 132|study
P01737789A0800|22 31|breakpoint
P01737789A0800|52 58|repeats
P01737789A0800|64 81|acceptor splice site
P01737789A0800|92 123|down-stream alpha-delta breakpoint
P01737789A0800|146 151|intron
P01738470A0441|0 7|Patients
P01738470A0441|20 24|PDDAT
P01738470A0441|48 56|positions
P01738470A0441|71 75|order
P01738470A0441|86 102|recognition memory
P01738653T0014|9 13|bones
P01738936A0292|3 10|patients
P01738936A0292|14 28|plasma C-peptide
P01738936A0292|72 79|analysis
P01739439A0257|0 6|Complex
P01739439A0257|17 26|discharges
P01739439A0257|41 47|muscles
P01739439A0257|50 56|mdx mice
P01739439A0257|62 68|complex
P01739439A0257|79 88|discharges
P01739439A0257|96 108|abnormalities
P01739439A0257|123 129|muscles
P01739439A0257|138 148|control mice
P01739956A0638|0 9|Management
P01739956A0638|32 45|calcium channel
P01739956A0638|53 57|drugs
P01739956A0638|60 65|type IC
P01739956A0638|80 84|drugs
P01740121A0136|14 20|problem
P01740121A0136|40 44|Kex2p
P01740121A0136|53 90|baculovirus/insect cell expression system
P01740437A0851|14 24|core protein
P01740437A0851|30 49|liver HSPG preparation
P01740437A0851|74 81|antibody
P01740437A0851|122 127|domain
P01740437A0851|130 140|fibroglycan
P01740448A1735|14 33|transmembrane regions
P01740448A1735|71 88|amino acid stretches
P01740448A1735|130 135|region
P01740448A1735|163 172|attachment
P01740448A1735|175 184|precursors
P01740448A1735|187 195|membranes
P01740682A0703|0 7|Toxicity
P01740682A0703|33 38|emesis
P01740682A0703|48 55|patients
P01740682A0703|64 70|courses
P01740682A0703|70 79|leukopenia
P01740682A0703|82 104|World Health Organization
P01740682A0703|108 112|grade
P01740682A0703|126 133|patients
P01740682A0703|142 148|courses
P01740682A0703|151 166|thrombocytopenia
P01740682A0703|176 183|patients
P01740682A0703|191 197|courses
P01742341A0499|4 8|study
P01742341A0499|35 42|reaction
P01742341A0499|64 77|transportation
P01742341A0499|87 94|stressor
P01742341A0499|98 107|Beagle dogs
P01742606A0000|1 23|mouse brain beta-spectrin
P01742606A0000|52 78|lambda Gt11 expression library
P01742606A0000|85 92|antibody
P01742606A0000|125 147|kDa spectrin beta-subunit
P01742879A0471|0 6|RESULTS
P01742879A0471|7 24|Plasma AVP responses
P01742879A0471|34 44|stimulation
P01742879A0471|59 68|inhibition
P01742879A0471|71 78|drinking
P01742879A0471|91 98|patients
P01742879A0471|113 125|water drinking
P01744039A0511|3 11|fragments
P01744039A0511|18 23|region
P01744039A0511|39 61|polymerase chain reaction
P01744039A0511|75 92|gel electrophoresis
P01744039A0511|114 137|conformation polymorphism
P01744042A1355|3 12|csbA fusion
P01744042A1355|55 59|phase
P01744042A1355|62 66|cells
P01744042A1355|74 83|Luria broth
P01744042A1355|94 101|% glucose
P01744042A1355|107 116|% glutamine
P01744119A0757|3 13|constraints
P01744119A0757|16 42|primase recognition sequences
P01744119A0757|43 73|nucleotide substrate requirements
P01744119A0757|80 86|effects
P01744119A0757|99 106|proteins
P01744119A0757|109 136|oligoribonucleotide synthesis
P01744119A0757|155 161|protein
P01744119A0757|182 190|templates
P01744119A0757|200 207|sequence
P01747972T0000|12 18|therapy
P01747972T0000|40 55|artery dissection
P01748067A0000|12 16|trial
P01748067A0000|45 52|patients
P01748067A0000|73 77|years
P01748067A0000|79 83|women
P01748067A0000|97 101|years
P01748067A0000|131 141|replacement
P01748067A0000|176 184|arthritis
P01748067A0000|187 194|fracture
P01748067A0000|211 215|femur
P01748194A0767|8 14|lesions
P01748194A0767|34 45|hemisections
P01748194A0767|80 87|recovery
P01748194A0767|122 136|cord transection
P01748287T0000|16 23|proteins
P01748287T0000|35 44|properties
P01748287T0000|67 73|targets
P01748292A0000|14 18|cDNAs
P01748292A0000|39 58|G protein alpha subunit
P01748292A0000|62 67|tomato
P01748292A0000|68 89|Lycopersicon esculentum
P01748630A0125|0 22|Growth factor stimulation
P01748630A0125|25 29|cells
P01748630A0125|39 53|phosphorylation
P01748630A0125|59 63|c-Myc
P01748630A0125|79 94|activation domain
P01748630A0125|97 101|Ser62
P01748630A0125|121 126|region
P01748630A0125|153 159|members
P01748630A0125|165 173|Myc family
P01748630A0125|174 180|Alvarez
P01748630A0125|185 193|Northwood
P01748630A0125|199 206|Gonzalez
P01751163A0000|3 9|authors
P01751163A0000|22 30|potential
P01751163A0000|44 56|complications
P01751163A0000|68 79|implantation
P01751163A0000|100 105|device
P01751163A0000|106 117|Sarns/3M-VAD
P01751163A0000|124 129|calves
P01751255A0529|7 12|output
P01751255A0529|61 69|MBBF group
P01751970A0209|0 16|Amino acid residues
P01751970A0209|47 54|sequence
P01751970A0209|71 78|residues
P01752441A0000|15 24|activation
P01752441A0000|30 44|HIV-1 Tat protein
P01752441A0000|61 68|residues
P01752441A0000|74 91|hexanucleotide loop
P01752441A0000|95 112|trinucleotide bulge
P01752441A0000|118 141|TAR RNA stem-loop structure
P01752441A0000|164 169|leader
P01752441A0000|180 190|transcripts
P01752792A0000|22 29|evidence
P01752792A0000|35 40|coding
P01752792A0000|53 67|time differences
P01752792A0000|81 87|stimuli
P01752792A0000|97 103|neurons
P01752792A0000|117 122|cortex
P01752792A0000|137 146|albino rats
P01753317A0879|5 11|results
P01753317A0879|53 63|combination
P01753317A0879|84 96|bone formation
P01753317A0879|118 128|bone defects
P01754381A0000|27 42|characterization
P01754381A0000|55 68|DNA polymerases
P01754381A0000|71 82|trypanosomes
P01754381A0000|118 127|expression
P01754381A0000|133 143|Trypanosoma
P01754381A0000|144 154|Trypanozoon
P01754381A0000|187 204|DNA polymerase alpha
P01754381A0000|219 226|pol alpha
P01756195A1117|2 9|addition
P01756195A1117|30 37|increase
P01756195A1117|65 78|concentrations
P01756539A0354|9 20|hypertension
P01756539A0354|50 58|narrowing
P01756539A0354|69 77|condition
P01756539A0354|101 110|infarction
P01757341A0591|3 16|volume fraction
P01757341A0591|24 33|number/mm2
P01757341A0591|42 52|capillaries
P01757341A0591|90 94|brain
P01757341A0591|124 142|alkaline phosphatase
P01758750A0000|0 13|Airway pressure
P01758750A0000|17 23|air flow
P01758750A0000|63 70|children
P01758750A0000|73 79|variety
P01758750A0000|82 92|ventilators
P01759282A0000|0 5|Issues
P01759282A0000|8 19|distribution
P01759282A0000|29 34|energy
P01759282A0000|49 54|object
P01759282A0000|63 80|contact interaction
P01759282A0000|97 102|impact
P01759282A0000|118 125|position
P01759282A0000|128 139|biomechanics
P01760166A0963|0 9|CONCLUSION
P01760166A0963|36 45|septum site
P01760166A0963|80 89|finger site
P01760166A0963|103 110|patients
P01761736A0158|0 8|Diltiazem
P01761736A0158|26 38|body clearance
P01761736A0158|61 66|mL/min
P01761736A0158|96 115|elimination half-life
P01761736A0158|137 141|hours
P01761736A0158|158 167|antipyrine
P01761736A0158|177 183|changes
P01761736A0158|186 191|volume
P01761736A0158|194 205|distribution
P01762053A0557|3 10|granules
P01762053A0557|26 33|material
P01762053A0557|53 57|space
P01762053A0557|73 81|particles
P01762914A1218|8 18|uPA promoter
P01762914A1218|49 56|elements
P01762914A1218|85 104|translation start site
P01762917A0615|21 25|Gly69
P01762917A0615|57 72|TGEK tetrapeptide
P01762917A0615|73 78|finger
P01762917A0615|83 88|TFIIIA
P01762917A0615|110 119|DNA binding
P01763106A0070|16 23|behavior
P01763106A0070|48 57|locomotion
P01763106A0070|82 92|test session
P01764899A0399|3 7|model
P01764899A0399|32 37|effect
P01764899A0399|40 56|water fluoridation
P01764899A0399|59 74|caries prevalence
P01764899A0399|95 100|caries
P01764899A0399|114 124|cavity level
P01765095A0680|0 34|12-O-Tetradecanoylphorbol 13-acetate
P01765095A0680|73 82|expression
P01765095A0680|85 89|mRNAs
P01765095A0680|110 123|regulators CMD1
P01765095A0680|127 134|myogenin
P01765266A0000|2 14|Xenopus laevis
P01765266A0000|35 57|elongation factor 1-alpha
P01765266A0000|64 73|EF-1 alpha O
P01765266A0000|91 96|oocyte
P01765266A0000|109 115|oocytes
P01765266A0000|124 130|embryos
P01765269A0308|5 11|introns
P01765269A0308|23 27|class
P01765269A0308|37 51|pre-mRNA introns
P01765269A0308|73 90|consensus sequences
P01765269A0308|105 112|features
P01765375A0290|33 40|rat cells
P01765375A0290|52 64|clathrin clone
P01765375A0290|73 83|transcripts
P01765375A0290|156 161|weight
P01765375A0290|165 172|clathrin
P01765375A0290|178 182|chain
P01765386A0305|6 11|report
P01765386A0305|25 35|DNA sequence
P01765386A0305|106 114|junctions
P01765407A0866|5 12|exposure
P01765407A0866|17 25|mg DMEA/m3
P01765407A0866|52 70|plasma concentration
P01765407A0866|77 88|postexposure
P01765407A0866|96 104|excretion
P01765407A0866|110 116|mumol/l
P01765407A0866|122 139|mmol/mol creatinine
P01766666A0788|0 9|Antibodies
P01766666A0788|29 35|rNFIL-6
P01766666A0788|42 63|nucleoprotein complexes
P01766666A0788|84 88|sites
P01766666A0788|102 112|interaction
P01766666A0788|127 133|factors
P01766876A0000|1 6|method
P01766876A0000|38 43|events
P01766876A0000|58 66|chain gene
P01766876A0000|79 91|co-conversion
P01766876A0000|94 104|co-exchange
P01766876A0000|108 120|point mutation
P01766876A0000|136 141|marker
P01766876A0000|154 170|replacement vector
P01766999A0000|10 17|activity
P01766999A0000|20 49|allergen extract Ambrosia elatior
P01766999A0000|72 81|volunteers
P01766999A0000|104 111|allergen
P01767060A0000|4 8|study
P01767060A0000|35 53|c-DDP administration
P01767060A0000|71 82|radiotherapy
P01767060A0000|96 104|frequency
P01767060A0000|108 115|duration
P01767060A0000|127 135|responses
P01767060A0000|144 151|survival
P01767060A0000|154 161|patients
P01767060A0000|189 194|stages
P01767060A0000|205 214|carcinomas
P01767592A0682|22 30|sequences
P01767592A0682|34 51|DNA binding proteins
P01767592A0682|77 82|region
P01767592A0682|84 120|HAP2/HAP3 consensus recognition sequence
P01767592A0682|123 136|nucleotide-154
P01767592A0682|141 172|BAF1 consensus recognition sequence
P01767592A0682|175 188|nucleotide-136
P01767899A0136|6 21|thrombocytopenia
P01767899A0136|22 30|depletion
P01767899A0136|33 47|serum fibrinogen
P01767899A0136|60 70|prothrombin
P01767899A0136|90 107|thromboplastin time
P01767899A0136|136 142|minutes
P01767899A0136|159 170|envenomation
P01768648A0853|12 21|properties
P01768648A0853|24 41|LexA fusion proteins
P01768648A0853|52 63|dimerization
P01768648A0853|81 87|domains
P01769189A0000|0 10|Plasma lipid
P01769189A0000|14 32|lipoprotein profiles
P01769189A0000|60 66|runners
P01769189A0000|85 89|years
P01769189A0000|103 118|training distance
P01769189A0000|122 129|km week-1
P01769189A0000|130 135|VO2max
P01769189A0000|140 150|ml kg-1 min-1
P01769189A0000|185 189|women
P01769189A0000|202 206|years
P01769189A0000|220 225|VO2max
P01769189A0000|228 238|ml kg-1 min-1
P01769919A0393|8 22|threshold shifts
P01769919A0393|52 68|brainstem response
P01770651T0001|22 31|evaluation
P01770651T0001|34 52|equilibrium dialysis
P01770651T0001|53 74|radioimmunoassay system
P01770651T0001|78 88|measurement
P01770651T0001|91 95|serum
P01770651T0001|100 108|thyroxine
P01771593A1152|33 40|decrease
P01771593A1232|14 19|adults
P01771593A1232|21 25|weeks
P01771593A1232|40 48|genitalia
P01771593A1232|61 69|offspring
P01771959A0442|11 26|ejection fraction
P01771959A0442|79 86|function
P01771959A0442|120 128|deviation
P01771959A0442|166 173|segments
P01771959A0442|193 201|deviation
P01772201T0001|12 18|patient
P01772201T0001|34 45|subjectivity
P01772201T0001|50 55|period
P01772341A0852|33 41|treatment
P01772341A0852|46 75|thromboxane synthetase inhibitor
P01772341A0852|80 108|thromboxane receptor antagonist
P01772341A0852|124 133|protection
P01772341A0852|141 159|digoxin intoxication
P01772341A0852|174 178|agent
P01774062A0257|12 17|A148A7
P01774062A0257|31 43|HLA-DQA1 locus
P01774062A0257|54 60|Y3/Ring
P01774062A0257|62 66|locus
P01774062A0257|105 112|YAC B1D12
P01774063A0161|13 29|backcross analysis
P01774063A0161|35 41|progeny
P01774063A0161|53 59|matings
P01774063A0161|62 80|C57BL/6J x Mus spretus
P01774063A0161|86 97|C57BL/6J mice
P01774063A0161|113 130|thrombospondin gene
P01774063A0161|157 161|Actcl
P01774063A0161|169 175|B2M loci
P01774063A0161|183 192|chromosome
P01774093T0000|13 19|outcome
P01774093T0000|43 71|Chlamydia trachomatis infection
P01774093T0000|73 81|pregnancy
P01774822A0289|23 30|computer
P01774822A0289|39 58|LV time-density curves
P01774822A0289|87 91|cycle
P01776306A0572|9 15|patient
P01776715A0489|2 6|delay
P01776715A0489|25 38|centrifugation
P01776715A0489|45 55|measurement
P01776715A0489|87 99|equilibration
P01776715A0489|103 108|sample
P01776715A0489|114 123|gas mixture
P01776715A0489|164 174|measurement
P01777841A0744|11 20|mechanisms
P01777841A0744|31 41|differences
P01777841A0744|56 62|effects
P01777841A0744|67 72|muscle
P01777841A0744|85 93|afferents
P01777841A0744|96 101|adults
P01777841A0744|105 112|neonates
P01779299A0000|20 30|alterations
P01779299A0000|41 49|cockroach
P01779299A0000|50 67|Periplaneta brunnea
P01779299A0000|83 97|acanthocephalan
P01779299A0000|98 121|Moniliformis moniliformis
P01779433A0694|8 14|finding
P01779433A0694|27 41|Alu family repeat
P01779433A0694|47 54|junction
P01779433A0694|73 78|block I
P01779433A0694|82 89|homology
P01779433A0694|103 107|alpha
P01779433A0694|131 136|rhesus
P01779433A0694|165 179|Alu family repeat
P01779433A0694|202 209|position
P01779433A0694|230 238|insertion
P01779433A0694|251 265|Alu family repeat
P01779433A0694|299 313|Alu family repeat
P01779769A0000|3 10|sequence
P01779769A0000|16 29|repressor locus
P01779769A0000|38 49|Streptomyces
P01779769A0000|58 62|phage
P01779769A0000|63 68|phi C31
P01779769A0000|102 113|reading frame
P01779769A0000|125 134|kDa protein
P01780235A0094|3 11|EPO levels
P01780235A0094|41 51|transfusion
P01780235A0094|90 100|transfusion
P01781923A0744|16 26|sensitivity
P01781923A0744|51 63|concentration
P01781923A0744|88 95|righting
P01781923A0744|144 171|barbiturate brain distribution
P01781923A0744|173 183|elimination
P01781923A0744|192 196|lines
P01782424A0278|3 11|existence
P01782424A0278|14 36|threshold concentrations
P01782424A0278|54 62|phenomena
P01782424A0278|93 101|sentinels
P01782669A0496|29 40|temperatures
P01782669A0496|46 53|addition
P01782669A0496|56 61|A23187
P01782982A0155|0 9|Felodipine
P01782982A0155|24 35|baseline FEV1
P01782982A0155|72 77|effect
P01782982A0155|82 90|histamine
P01782982A0155|106 124|bronchoconstriction
P01783088A1136|10 17|patients
P01783088A1136|33 39|disease
P01783088A1136|43 51|mast cells
P01783088A1136|77 86|hyaluronan
P01783088A1136|108 121|micrograms.l-1
P01783088A1136|125 135|fibronectin
P01783088A1136|159 172|micrograms.l-1
P01783088A1136|195 202|patients
P01783088A1136|225 231|disease
P01783088A1136|279 286|ABSTRACT
P01783088A1136|301 305|WORDS
P01783375A1066|3 9|mapping
P01783375A1066|30 40|involvement
P01783375A1066|78 86|disorders
P01783375A1066|115 138|translocation breakpoints
P01784589A0000|43 63|5-HT2 receptor activity
P01784589A0000|80 87|behavior
P01785749A0695|5 11|changes
P01785749A0695|36 40|group
P01785749A0695|48 55|children
P01785749A0695|68 73|weight
P01786094T0001|7 14|contents
P01786094T0001|23 28|copper
P01787085A0331|10 20|experiments
P01787085A0331|38 48|control rats
P01787085A0331|61 67|colloid
P01788002T0001|0 13|Magnetotherapy
P01788002T0001|16 25|hepatitis A
P01788002T0001|34 41|children
P01791363A0208|5 11|results
P01791363A0208|35 42|patients
P01791363A0208|69 75|sutures
P01791363A0208|86 92|testing
P01791754T0000|10 17|analysis
P01791754T0000|54 61|features
P01791754T0000|76 90|secretion signal
P01791754T0000|108 117|haemolysin
P01792580A0198|5 15|blood donors
P01792580A0198|21 28|Republic
P01792580A0198|31 36|Serbia
P01792580A0198|50 55|number
P01792580A0198|58 71|blood donations
P01792580A0198|75 84|percentage
P01792580A0198|93 98|donors
P01792580A0198|132 141|percentage
P01792580A0198|148 158|blood donors
P01792914T0000|14 20|relapse
P01792914T0000|23 39|childhood leukemia
P01797459A0103|0 9|Mycoplasma
P01797459A0103|45 49|fluid
P01797459A0103|56 62|patient
P01797467A0000|0 4|RU486
P01797467A0000|18 28|combination
P01797467A0000|61 71|termination
P01797467A0000|74 82|pregnancy
P01798407A1011|3 10|presence
P01798407A1011|18 30|abnormalities
P01798407A1011|37 44|patients
P01798407A1011|58 67|hypothesis
P01798407A1011|75 80|cortex
P01798407A1011|133 138|origin
P01798407A1011|143 158|laughing seizures
P01804671A1001|20 25|values
P01804671A1001|28 32|QS/QC
P01804671A1001|36 42|results
P01804671A1001|92 100|air spaces
P01804671A1001|140 172|ventilation/perfusion distribution
P01804671A1001|189 195|gas data
P01804671A1001|200 205|CDCSF6
P01804671A1001|216 223|ml.min-1
P01804671A1001|264 269|mmHg-1
P01806314A0322|4 8|cells
P01806314A0322|40 46|markers
P01806314A0322|76 83|antibody
P01806314A0322|91 101|muscle actin
P01808049A0262|0 14|CT abnormalities
P01808049A0262|22 31|term babies
P01808049A0262|40 49|hemorrhage
P01808049A0262|86 96|hypodensity
P01808049A0262|130 140|hypodensity
P01808049A0262|142 151|hemorrhage
P01808049A0262|168 174|atrophy
P01808136T0000|3 9|effects
P01808136T0000|12 24|contrast media
P01808136T0000|27 46|coagulation factor XII
P01808602A0000|9 16|patients
P01808602A0000|38 49|hypertension
P01808602A0000|53 59|effects
P01808602A0000|68 86|nifedipine treatment
P01808602A0000|89 93|serum
P01808602A0000|112 120|excretion
P01808829A0510|14 28|brain congestion
P01808829A0510|73 83|hemorrhages
P01809854A0106|0 7|Examples
P01809854A0106|20 27|subjects
P01809854A0106|40 53|research design
P01809854A0106|64 82|consensus statements
P01809854A0106|90 102|meta-analysis
P01810108A0000|4 16|phase slug flow
P01810108A0000|24 36|heat exchanger
P01810108A0000|57 68|inactivation
P01810108A0000|71 91|Listeria monocytogenes
P01810154A0491|7 14|children
P01811243A0000|0 7|Regional
P01811243A0000|16 24|blood flow
P01811243A0000|31 42|measurements
P01811243A0000|56 62|ratings
P01811243A0000|96 103|patients
P01811243A0000|118 122|years
P01811243A0000|142 146|years
P01811243A0000|160 164|study
P01811243A0000|191 197|ratings
P01811243A0000|212 224|rCBF technique
P01811948A0289|12 16|study
P01811948A0289|58 64|element
P01811948A0289|88 103|LpS1 beta promoter
P01811948A0289|109 116|sequence
P01811948A0289|141 151|cis-element
P01812102A0101|10 21|study reports
P01812102A0101|43 51|responses
P01812102A0101|54 68|pattern reversal
P01812102A0101|69 73|VEP-P
P01812102A0101|84 92|trimester
P01812102A0101|101 105|women
P01812102A0101|109 115|changes
P01812102A0101|118 124|latency
P01812102A0101|127 136|NPN complex
P01812102A0101|158 166|responses
P01812102A0101|183 187|state
P01812690A0475|44 49|growth
P01814182A0000|9 13|doses
P01814182A0000|16 34|15-methyl-PGF2 alpha
P01814182A0000|63 72|luteolysis
P01814182A0000|75 81|oestrus
P01814182A0000|85 91|heifers
P01814182A0000|98 107|treatments
P01814182A0000|132 136|cycle
P01816655T0000|0 5|Review
P01816655T0000|11 20|literature
P01816655T0000|24 29|report
P01817497A0715|0 9|Resolution
P01817497A0715|25 33|asymmetry
P01817497A0715|40 47|decrease
P01817497A0715|50 55|Delta T
P01817497A0715|109 118|population
P01822581A0533|5 13|instances
P01822581A0533|25 40|alcohol responses
P01822581A0533|71 77|reading
P01822581A0533|81 95|microgram/100ml
P01822581A0533|99 111|breath samples
P01822995T0000|0 24|Maize rbcS promoter activity
P01822995T0000|34 49|sequence elements
P01822995T0000|60 77|dicot rbcS promoters
P01823520A0183|0 11|Measurements
P01823520A0183|35 61|haematofluorometer Buchler ZF
P01823520A0183|92 107|haematocrit value
P01823524A0238|19 24|number
P01823524A0238|27 34|examples
P01823524A0238|61 67|variety
P01823524A0238|71 80|complexity
P01823524A0238|91 98|exposure
P01823524A0238|129 135|factors
P01823524A0238|152 160|influence
P01823524A0238|178 188|differences
P01823524A0238|191 204|susceptibility
P01823524A0238|207 225|xenobiotics toxicity
P01824713A0964|3 15|12S E1A product
P01824713A0964|32 42|TRE sequence
P01824713A0964|46 59|cotransfection
P01824713A0964|64 68|c-jun
P01824713A0964|92 102|stimulation
P01824944A0988|5 13|treatment
P01824944A0988|18 28|tunicamycin
P01824944A0988|32 44|transfectants
P01824944A0988|73 84|polypeptides
P01825027T0000|7 15|yeast gene
P01825027T0000|26 45|peroxisome biogenesis
P01825027T0000|54 59|member
P01825027T0000|68 73|family
P01825027T0000|84 90|ATPases
P01826003A0694|16 24|base pairs
P01826003A0694|44 50|members
P01826003A0694|55 63|SIG family
P01826003A0694|67 76|beta TG gene
P01826003A0694|91 95|exons
P01826043A0431|3 31|pp90rsk-protein kinase activity
P01826043A0431|44 53|rsk-kinase
P01826043A0431|90 120|signal transducing protein kinases
P01826043A0431|149 162|protein kinases
P01826043A0431|163 169|members
P01826043A0431|175 194|protein kinase C family
P01826043A0431|215 228|protein kinases
P01827068T0000|5 10|GATA-3
P01827068T0000|30 48|transcription factor
P01827068T0000|65 74|expression
P01827068T0000|80 101|T cell receptor alpha gene
P01827203A0136|18 37|transcription factors
P01827203A0136|43 50|proteins
P01827203A0136|64 69|dimers
P01828248A0189|14 24|UvrA protein
P01828248A0189|41 51|UvrB protein
P01828248A0189|65 74|activities
P01828248A0189|81 88|solution
P01828248A0189|94 104|association
P01828248A0189|122 133|UvrAB complex
P01828248A0189|143 158|helicase activity
P01829060A0649|3 12|ED30 values
P01829060A0649|26 30|mg/kg
P01829060A0649|56 61|values
P01829060A0649|64 73|nifedipine
P01829060A0649|88 92|mg/kg
P01829460A0329|0 23|Southwestern blot analysis
P01829460A0329|44 57|phosphoprotein
P01829460A0329|68 80|kappa B element
P01830114A1587|15 20|effect
P01830114A1587|45 50|levels
P01830114A1587|52 64|P4 transcripts
P01830114A1587|77 89|amplification
P01830114A1587|92 105|gene copy number
P01830114A1587|112 120|integrity
P01830114A1587|134 140|repeats
P01830928A0361|21 37|microtubule motors
P01830928A0361|41 47|dyneins
P01830928A0361|66 76|superfamily
P01830928A0361|95 102|proteins
P01830928A0361|115 131|attachment domains
P01832019A0265|59 65|animals
P01832019A0265|79 83|weeks
P01832152A0000|3 33|incompatibility group W plasmid pSa
P01832152A0000|44 79|Agrobacterium tumefaciens oncogenicity
P01832152A0902|22 33|start signals
P01832197T0001|0 6|Imaging
P01832197T0001|9 26|D2 dopamine receptor
P01833185A0547|3 19|Thr161Val mutation
P01833185A0547|33 41|phenotype
P01833185A0547|47 58|fission yeast
P01833185A0547|88 98|replacement
P01833185A0547|101 106|Thr161
P01833185A0547|145 159|phosphorylation
P01833185A0547|165 178|uncoordination
P01833185A0547|181 187|mitosis
P01833185A0547|199 209|cytokinesis
P01833637A0531|3 11|abundance
P01833637A0531|14 24|transcripts
P01833637A0531|45 49|genes
P01833637A0531|63 69|cdc68-1
P01833637A0531|76 80|cells
P01833637A0531|86 93|transfer
P01833637A0531|110 120|temperature
P01833637A0531|136 145|transcript
P01833637A0531|153 161|HSP82 gene
P01833637A0531|182 188|fashion
P01833716A0990|0 11|Deregulation
P01833716A0990|19 28|expression
P01833716A0990|53 66|transformation
P01833716A0990|81 95|HTLV-1 infection
P01837787T0000|9 18|Mov-34 gene
P01837787T0000|46 57|organization
P01837842A1410|29 45|protein components
P01837842A1410|59 75|gel shift complexes
P01839414T0000|3 10|spectrum
P01839414T0000|45 53|neoplasms
P01839414T0000|56 60|Sabah
P01840513A1019|29 37|SL-2 cells
P01840513A1019|38 48|pCAT plasmid
P01840513A1019|78 83|region
P01840513A1019|102 109|increase
P01840513A1019|112 151|chloramphenicol acetyltransferase activity
P01840513A1019|157 165|induction
P01840513A1019|190 201|8-bromo-cAMP
P01840608A0823|3 12|N-terminus
P01840608A0823|26 37|reading frame
P01840608A0823|91 117|amino acid sequence comparison
P01840711A0000|3 11|RNA genome
P01840711A0000|14 19|rabbit
P01840711A0000|31 42|disease virus
P01840902A1089|25 30|system
P01840902A1089|56 61|plants
P01840902A1089|94 111|transport machinery
P01840902A1089|123 130|monocots
P01840902A1089|134 139|dicots
P01842498A0000|6 14|cDNA clone
P01842498A0000|49 61|hybridization
P01842498A0000|64 74|cDNA library
P01842498A0000|77 94|phytohemagglutinin
P01842498A0000|99 114|phorbol myristate
P01842498A0000|132 142|Jurkat cells
P01842498A0000|160 170|cDNA library
P01842498A0000|197 212|blood lymphocytes
P01842867A0696|2 11|conclusion
P01842867A0696|28 46|regeneration ability
P01842867A0696|66 71|injury
P01842867A0696|82 87|mucosa
P01844017A0410|20 31|relationship
P01844017A0410|50 91|glucose-6-phosphatase dehydrogenase activity
P01844017A0410|96 108|vitamin E level
P01844017A0410|126 133|duration
P01844017A0410|135 143|poisoning
P01844017A0410|148 160|sodium nitrite
P01844878A0000|1 6|vector
P01844878A0000|43 68|neomycin phosphotransferase
P01844878A0000|92 108|promoter sequences
P01844878A0000|134 145|DNA fragments
P01844982A0324|0 5|Chagas
P01844982A0324|6 12|disease
P01844982A0324|21 33|leishmaniasis
P01844982A0324|46 51|factor
P01844982A0324|52 66|schistosomiasis
P01844982A0324|77 82|factor
P01844982A0324|92 99|controls
P01845829A0158|8 15|analysis
P01845829A0158|26 33|sequence
P01845829A0158|69 75|domains
P01845829A0158|102 108|factors
P01845829A0158|123 132|brain cells
P01845885A1003|66 72|protein
P01845885A1003|76 85|amino acids
P01845885A1003|96 101|family
P01845885A1003|104 111|proteins
P01845885A1003|186 216|UL26 transcription initiation site
P01845885A1003|238 262|methionine initiation codon
P01845885A1003|272 279|position
P01845899A0000|19 23|virus
P01845899A0000|29 35|rep gene
P01845899A0000|46 53|proteins
P01845899A0000|54 58|Rep78
P01845899A0000|59 63|Rep68
P01845899A0000|64 68|Rep52
P01845899A0000|72 76|Rep40
P01845899A0000|88 104|AAV DNA replication
P01845899A0000|108 124|AAV gene regulation
P01846206A0665|7 12|region
P01846206A0665|28 33|CMV dbp
P01846206A0665|46 56|replication
P01846206A0665|68 73|assays
P01846489A1119|34 47|protease domain
P01846489A1119|65 79|protease domains
P01846491A0459|18 26|positions
P01846491A0459|32 38|VV genes
P01846491A0459|39 56|genus Orthopoxvirus
P01846491A0459|109 127|genus Leporipoxvirus
P01846491A0459|136 156|complex rearrangements
P01846491A0459|169 174|genome
P01846491A0459|192 198|viruses
P01846491A0459|216 225|divergence
P01846491A0459|237 244|ancestor
P01846803A0688|4 9|result
P01846803A0688|22 36|phosphorylation
P01846803A0688|67 87|p34cdc2 kinase activity
P01846803A0688|101 108|location
P01846803A0688|115 122|residues
P01846803A0688|140 153|ATP binding site
P01846803A0688|159 164|kinase
P01847464A0856|12 26|cotransfections
P01847464A0856|28 42|pFRTK-CAT target
P01847464A0856|67 71|sites
P01847464A0856|79 87|EBV origin
P01847464A0856|90 107|plasmid replication
P01847464A0856|108 112|ori-P
P01847464A0856|149 166|EBNA-1 construction
P01847464A0856|167 176|amino acids
P01847464A0856|201 205|c-myc
P01847464A0856|213 230|localization signal
P01847665A1079|3 10|findings
P01847665A1079|44 48|genes
P01847665A1079|56 68|PDGF receptors
P01847665A1079|71 81|glioma cells
P01847665A1079|96 102|concert
P01847665A1079|112 116|genes
P01847665A1079|120 129|expression
P01847665A1079|163 169|program
P01847665A1079|178 193|glia cell lineages
P01848300A0910|10 17|evidence
P01848300A0910|51 68|peptide utilization
P01848871A0392|4 8|study
P01848871A0392|18 27|hypothesis
P01848871A0392|32 44|sodium channel
P01848871A0392|53 57|drugs
P01848871A0392|83 91|potential
P01848871A0392|105 119|amplitude signal
P01848871A0392|120 126|portion
P01848871A0392|147 156|QRS complex
P01848871A0392|164 175|prolongation
P01848871A0392|185 193|potential
P01848871A0392|212 218|slowing
P01848871A0392|232 242|tachycardia
P01849509T0000|0 13|Identification
P01849509T0000|17 34|nucleotide sequence
P01849509T0000|37 75|Rhizobium meliloti insertion sequence ISRm3
P01849509T0000|76 85|similarity
P01849509T0000|104 114|transposase
P01849509T0000|124 128|ISRm3
P01849509T0000|166 170|IS256
P01849509T0000|174 201|Thiobacillus ferrooxidans IST2
P01849675A0167|14 25|relationship
P01849675A0167|33 39|viruses
P01849675A0167|51 61|DNA sequence
P01849734A1063|8 25|PR55 beta transcript
P01849734A1063|57 62|levels
P01849734A1063|67 79|neuroblastoma
P01849734A1063|87 100|cell line LA-N-1
P01849734A1063|104 108|level
P01849734A1063|145 153|cell lines
P01850096A0662|0 11|Heterodimers
P01850096A0662|14 21|myogenin
P01850096A0662|64 82|restriction fragment
P01850096A0662|116 120|start
P01850096A0662|130 153|alpha-actin transcription
P01850105A1093|3 9|effects
P01850105A1093|12 16|c-myc
P01850105A1093|50 54|c-myc
P01850105A1093|65 79|differentiation
P01850105A1093|108 116|regulator
P01850105A1093|118 138|muscle differentiation
P01850127A0000|6 16|association
P01850127A0000|19 25|U2 snRNP
P01850127A0000|33 51|branchpoint sequence
P01850127A0000|63 71|pre-mRNAs
P01850127A0000|80 86|binding
P01850127A0000|99 105|protein
P01850127A0000|111 129|polypyrimidine tract
P01850893A0286|17 26|antibodies
P01850893A0286|49 55|rabbits
P01850893A0286|72 76|farms
P01851386T0092|10 28|Lung Cancer Task Force
P01851386T0092|29 35|FONICAP
P01851527T0000|3 18|promoter activity
P01851527T0000|38 74|Alzheimer beta-amyloid precursor protein
P01851527T0000|95 100|blocks
P01851527T0000|110 118|sequences
P01851862A0273|0 18|Nucleotide sequences
P01851862A0273|29 35|env gene
P01851862A0273|49 53|SFV-1
P01851876A0129|4 10|element
P01851876A0129|28 37|EMBL3 mouse
P01851876A0129|45 51|library
P01852438A0928|3 11|MVV-value
P01852438A0928|31 35|level
P01852438A0928|54 60|percent
P01852603A0000|12 26|DNA repair mutant
P01852603A0000|33 44|fission yeast
P01852603A0000|101 109|radiation
P01853796T0000|0 5|Review
P01853796T0000|6 18|deterioration
P01853796T0000|21 36|glucose tolerance
P01853796T0000|57 73|insulin resistance
P01854339A0221|4 9|region
P01854339A0221|21 38|sequence similarity
P01854339A0221|56 73|consensus promoters
P01854339A0221|93 101|sequences
P01854339A0221|115 120|levels
P01854339A0221|123 132|expression
P01855255T0000|9 18|initiation
P01855255T0000|21 27|mitosis
P01855255T0000|30 34|yeast
P01855255T0000|63 68|GTPase
P01856021A0577|3 8|method
P01856021A0577|34 43|laboratory
P01856021A0577|79 87|procedure
P01856021A0577|103 109|control
P01856021A0577|124 131|exposure
P01856021A0577|134 140|toluene
P01856021A0577|147 152|xylene
P01857143A0351|3 9|patient
P01857143A0351|37 47|skin lesions
P01857143A0351|58 66|diagnosis
P01857143A0351|69 81|myelofibrosis
P01857326A0160|0 9|Oculus-500
P01857326A0160|13 17|group
P01857326A0160|24 46|resolution imaging boards
P01857326A0160|59 64|IBM-AT
P01857326A0160|77 85|computers
P01860846A0663|38 62|tumor necrosis factor-alpha
P01860846A0663|83 105|MARCKS gene transcription
P01860846A0663|129 148|leukemia cell line HL60
P01861034A0798|5 13|resection
P01861034A0798|27 34|fragment
P01861034A0798|46 56|contact area
P01861034A0798|60 67|pressure
P01861034A0798|86 101|scaphoid fragment
P01861188A0000|0 10|Plate luting
P01861188A0000|12 20|technique
P01861188A0000|77 81|plate
P01861188A0000|111 120|screw heads
P01861188A0000|126 130|plate
P01861188A0000|143 151|stability
P01861188A0000|162 169|fixation
P01861188A0000|220 224|bones
P01861188A0000|243 253|osteotomies
P01861188A0000|277 297|ASIF compression plates
P01862027A0212|5 12|features
P01862027A0212|42 50|diagnosis
P01862027A0212|53 76|Rothmund-Thomson syndrome
P01862455T0000|0 14|Thyroid lymphoma
P01862455T0000|21 30|management
P01863768A0649|3 9|protein
P01863768A0649|19 24|ORF113
P01863768A0649|47 52|domain
P01863887A0174|0 15|Space limitations
P01863887A0174|35 40|review
P01863887A0174|54 68|pharmaceuticals
P01863887A0174|75 91|tissue plasminogen
P01863887A0174|102 110|substance
P01863887A0174|111 118|hormones
P01863887A0174|123 129|thyroid
P01863887A0174|130 136|insulin
P01863887A0174|137 149|growth hormone
P01863887A0174|150 163|erythropoietin
P01863887A0174|164 178|clotting factors
P01863887A0174|182 194|blood products
P01864510A0946|0 7|Dd PK1 RNA
P01864510A0946|28 37|starvation
P01864510A0946|59 63|cells
P01864821A0000|10 14|forms
P01864821A0000|23 33|cell disease
P01864821A0000|48 54|feature
P01864821A0000|67 77|globin chain
P01864821A0000|94 103|conditions
P01864821A0000|110 116|hypoxia
P01864821A0000|129 136|sickling
P01864821A0000|142 151|blood cells
P01864821A0000|155 165|obstruction
P01864821A0000|168 179|blood vessels
P01864837A1029|10 18|structure
P01864837A1029|35 42|proteins
P01864837A1029|52 60|% homology
P01864837A1029|71 85|mouse contrapsin
P01864837A1029|88 95|contrast
P01864837A1029|102 110|% homology
P01864837A1029|121 147|rat alpha 1-protease inhibitor
P01865010A0000|0 7|Patterns
P01865010A0000|10 20|connections
P01865010A0000|45 55|integration
P01865010A0000|103 109|tracers
P01865010A0000|110 120|Fluoro-Gold
P01865010A0000|124 132|diamidino
P01865010A0000|149 154|manner
P01865010A0000|175 189|representations
P01865010A0000|212 219|auditory
P01865010A0000|233 238|cortex
P01867069A0000|5 12|CD-1 mice
P01867069A0000|34 49|% nicotine sulfate
P01867069A0000|131 136|effect
P01867069A0000|139 149|development
P01867069A0000|167 172|molars
P01869565A1254|27 39|transcription
P01869565A1254|42 58|translation system
P01869565A1254|73 83|ADH promoter
P01869907A2146|3 21|across-fiber pattern
P01869907A2146|27 35|responses
P01869907A2146|47 59|NaCl solutions
P01869907A2146|124 131|ABSTRACT
P01869907A2146|146 150|WORDS
P01869968A0000|8 27|radioactivity content
P01869968A0000|47 60|administration
P01869968A0000|63 67|HMPAO
P01869968A0000|80 87|subjects
P01869968A0673|6 23|regression analysis
P01869968A0673|51 56|result
P01869968A0673|68 76|clearance
P01869968A0673|77 81|HMPAO
P01869968A0673|129 140|significance
P01870194A0302|5 29|immunodeficiency virus type
P01870194A0302|31 35|HIV-1
P01870194A0302|81 91|homogeneity
P01870428A0677|0 9|Thigh girth
P01870428A0677|42 47|HDL2-C
P01870428A0677|63 77|LDL particle size
P01870428A0677|82 86|women
P01870500A0276|0 12|Contributions
P01870500A0276|17 21|pairs
P01870500A0276|24 29|source
P01870500A0276|33 52|target volume elements
P01870500A0276|68 74|S values
P01870500A0276|85 89|tumor
P01870500A0276|125 133|host organ
P01870500A0276|156 160|tumor
P01870500A0276|183 191|host organ
P01870500A0276|199 216|reciprocity theorem
P01871033A0434|0 4|Tests
P01871033A0434|24 33|impression
P01871033A0434|39 43|force
P01871033A0434|71 90|laboratory simulation
P01871033A0434|98 111|clearing cement
P01871033A0434|115 127|testing cement
P01871033A0434|149 154|method
P01871135A0295|24 35|reading frame
P01871135A0295|59 65|protein
P01871135A0295|70 79|amino acids
P01871135A0295|112 118|protein
P01871135A0295|121 129|% identity
P01871135A0295|132 150|rat liver glucokinase
P01871971A0836|0 7|Analysis
P01871971A0836|15 21|mutants
P01871971A0836|47 55|NFIII/OCT
P01871971A0836|57 67|binding site
P01871971A0836|81 88|ATF motif
P01871971A0836|119 124|growth
P01872856A0277|0 7|Recovery
P01872856A0277|34 38|urine
P01872856A0277|45 50|faeces
P01872856A0277|92 104|radioactivity
P01872856A0277|104 108|liver
P01872856A0277|112 117|testis
P01872856A0277|130 137|recovery
P01872856A0277|155 161|animals
P01873999A0000|47 57|model system
P01873999A0000|104 110|details
P01873999A0000|113 126|gene expression
P01873999A0000|133 148|secretion process
P01873999A0000|167 176|production
P01873999A0000|190 197|proteins
P01873999A0000|216 223|interest
P01874195A0139|23 32|GH receptor
P01874195A0139|43 47|liver
P01874195A0139|58 75|sequence similarity
P01874195A0139|78 86|receptors
P01874195A0139|96 123|signal transduction mechanisms
P01874195A0139|164 185|tyrosine kinase activity
P01874752A0948|41 58|conditions cdc2/p58
P01874752A0948|62 69|cdc2/p62
P01874752A0948|84 94|differences
P01874752A0948|111 118|activity
P01875922A0770|0 15|Mutation analysis
P01875922A0770|34 41|segments
P01875922A0770|60 65|region
P01875922A0770|95 100|effect
P01876836T0000|0 13|Identification
P01876836T0000|37 44|subunits
P01876836T0000|46 61|GA binding protein
P01878489A0959|12 19|response
P01878489A0959|22 32|neutrophils
P01878489A0959|36 44|monocytes
P01878489A0959|66 74|magnitude
P01878489A0959|80 99|NADPH oxidase activity
P01878489A0959|124 134|neutrophils
P01878489A0959|141 149|monocytes
P01878755A0496|5 9|ileum
P01878755A0496|10 20|enterotoxin
P01878755A0496|40 52|disappearance
P01878755A0496|81 95|blood appearance
P01878755A0496|113 123|chloroquine
P01881595A0476|0 7|Formalin
P01881595A0476|21 25|SNO NS
P01881595A0476|29 39|NnS neurones
P01881595A0476|60 69|NS neurones
P01881595A0476|93 97|phase
P01881595A0476|99 106|activity
P01881595A0476|112 122|NnS neurones
P01881595A0476|149 154|phases
P01881671T0001|0 5|Uptake
P01881671T0001|8 16|ofloxacin
P01882240A0526|17 25|attention
P01882240A0526|33 38|issues
P01882240A0526|65 71|quality
P01882240A0526|74 81|research
P01882240A0526|97 105|behaviors
P01882240A0526|112 122|communities
P01882386A0000|3 15|effectiveness
P01882386A0000|18 36|alpha-mercapto-beta
P01882386A0000|36 42|2-furyl
P01882386A0000|63 98|N-benzyl-N-dithiocarboxy-D-glucamine
P01882386A0000|108 118|combination
P01882386A0000|123 134|mobilization
P01882386A0000|138 146|excretion
P01883992A0922|5 11|results
P01883992A0922|23 28|beta-1
P01883992A0922|65 73|regulator
P01883992A0922|79 88|expression
P01883992A0922|94 106|beta-zein gene
P01883992A0922|119 132|maize endosperm
P01884435A0088|4 8|study
P01884435A0088|20 26|effects
P01884435A0088|29 39|hypovolemia
P01884435A0088|67 82|ptH distributions
P01884435A0088|92 102|tissue sites
P01884435A0088|136 149|microelectrode
P01884435A0088|174 185|measurements
P01884998A1135|3 9|members
P01884998A1135|42 54|transcription
P01884998A1135|59 67|promoters
P01885006A0995|3 9|domains
P01885006A0995|20 34|superactivation
P01885006A0995|46 51|subset
P01885006A0995|88 97|activation
P01885613A1298|0 10|Information
P01885613A1298|31 39|sequences
P01885613A1298|50 56|studies
P01885613A1298|62 71|regulation
P01885613A1298|77 84|pro alpha
P01885613A1298|87 98|collagen gene
P01885752A0198|0 19|Chlamydia trachomatis
P01885752A0198|23 39|Chlamydia psittaci
P01885752A0198|57 72|methanol fixation
P01885915A0000|13 22|infections
P01885915A0000|27 37|bacteraemia
P01885915A0000|43 62|Pasteurella multocida
P01885915A0000|77 88|endocarditis
P01885915A0000|103 115|P. haemolytica
P01886043A0380|21 27|complex
P01886043A0380|61 66|effect
P01886043A0380|70 79|solubility
P01886043A0380|132 140|molecules
P01886043A0380|147 164|inclusion complexes
P01886368A0000|0 14|PO2 measurements
P01886368A0000|36 60|recess type microelectrodes
P01886368A0000|83 91|nerve head
P01886368A0000|111 118|normoxia
P01886368A0000|121 129|hyperoxia
P01886774A0000|24 30|domains
P01886774A0000|53 66|Echerichia coli
P01886774A0000|69 84|characterization
P01886774A0000|87 96|DNA binding
P01886774A0000|102 116|octamer sequence
P01888896A0505|1 14|deletion series
P01888896A0505|29 34|region
P01888896A0505|49 56|position
P01888896A0505|95 108|initiation site
P01888896A0505|141 147|tobacco
P01889753A0441|3 12|nucleotide
P01889753A0441|17 25|sequences
P01889753A0441|30 34|exons
P01889753A0441|46 55|boundaries
P01889753A0441|75 81|regions
P01890362A0305|7 14|patients
P01890362A0305|37 52|eye complications
P01890362A0305|58 64|leprosy
P01890362A0305|67 74|patients
P01890362A0305|99 103|years
P01890989A1392|30 37|elements
P01890989A1392|54 70|estrogen induction
P01890989A1392|80 84|genes
P01890989A1392|87 94|chickens
P01890989A1392|98 107|amphibians
P01892680A0907|0 7|Toxicity
P01892680A0907|27 34|regimens
P01892680A0907|43 50|sedation
P01892680A0907|75 78|arm B
P01893195A0000|21 27|monkeys
P01893195A0000|34 41|hamsters
P01893195A0000|59 65|authors
P01893195A0000|85 94|properties
P01893195A0000|101 114|virus Issyk-Kul
P01893927A0704|22 29|pressure
P01893927A0704|32 52|phenylephrine infusion
P01893927A0704|55 60|levels
P01893927A0704|114 123|reductions
P01893927A0704|131 136|output
P01895358A0000|0 5|Limits
P01895358A0000|8 21|energy turnover
P01895358A0000|24 31|relation
P01895358A0000|42 52|performance
P01895358A0000|68 72|terms
P01895358A0000|88 92|limit
P01895358A0000|93 99|changes
P01895358A0000|107 123|training programme
P01895358A0000|140 152|energy balance
P01895358A0000|164 177|energy turnover
P01895370A0199|12 21|reductions
P01895370A0199|45 50|trough
P01895370A0199|51 56|points
P01895370A0199|61 92|maximum shifted-frequency envelope
P01895370A0199|99 106|parallel
P01895370A0199|116 122|fashion
P01895384A0746|3 16|IE0 gene product
P01895384A0746|38 48|IE1 promoter
P01895384A0746|64 73|expression
P01895384A0746|84 91|promoter
P01895393A0745|8 16|promoters
P01895393A0745|28 34|TATA box
P01895393A0745|40 46|absence
P01895393A0745|49 56|Sp1 sites
P01895393A0745|59 66|Sp1 sites
P01895393A0745|72 78|absence
P01895393A0745|82 88|TATA box
P01895393A0745|123 135|RNA polymerase
P01895393A0745|139 146|promoter
P01895555T0001|0 9|Evaluation
P01895555T0001|27 34|function
P01895555T0001|61 67|imaging
P01895555T0001|72 82|Tc-99m-MIBI
P01896777T0000|0 15|Ivermectin uptake
P01896777T0000|19 30|distribution
P01896777T0000|36 41|plasma
P01896777T0000|45 50|tissue
P01896777T0000|71 78|patients
P01896777T0000|91 108|Onchocerca volvulus
P01897515A0348|0 22|Bone marrow abnormalities
P01897515A0348|25 31|Hodgkin
P01897515A0348|33 39|disease
P01897515A0348|64 76|understanding
P01897515A0348|94 103|mechanisms
P01897515A0348|121 126|anemia
P01898113A0265|10 19|uptake rate
P01898113A0265|29 41|clearance rate
P01898113A0265|68 79|SWA killifish
P01898164A0839|32 37|repair
P01898164A0839|65 69|group
P01898164A0839|72 78|infants
P01898164A0839|116 134|aorta diameter ratios
P01898164A0839|134 144|arch indices
P01898928A0260|0 23|DNA hybridization analysis
P01898928A0260|64 68|cells
P01898928A0260|89 96|DNA locus
P01898928A0260|126 132|fur gene
P01899209A0883|0 8|Increases
P01899209A0883|14 26|perfusate PCO2
P01899209A0883|38 47|perfusate H
P01899209A0883|72 80|decreases
P01899209A0883|97 109|contractility
P01899209A0883|113 129|oxygen consumption
P01899287A0726|0 9|Expression
P01899287A0726|13 21|cell cycle
P01899287A0726|48 56|RNA levels
P01899287A0726|116 120|cells
P01899409T0000a|0 11|Determinants
P01899409T0000a|23 31|ischaemia
P01899409T0000a|35 61|revascularisation procedures
P01899409T0000a|67 78|thrombolysis
P01899409T0000a|94 119|tissue plasminogen activator
P01899409T0000a|137 145|occlusion
P01899846A0862|12 25|rbcL-rbcS locus
P01899846A0862|64 72|condition
P01899846A0862|92 97|growth
P01900194T0000|0 11|Relationship
P01900194T0000|32 55|NADH-ubiquinone reductase
P01900194T0000|81 91|hydrogenase
P01901405A0694|0 7|Analysis
P01901405A0694|10 23|mRNA expression
P01901405A0694|33 38|AT-BP1
P01901405A0694|42 47|AT-BP2
P01901405A0694|68 74|tissues
P01901443A0297|11 18|patients
P01901443A0297|28 47|maintenance valproate
P01901443A0297|69 78|hepatitis C
P01901443A0297|111 120|hepatitis C
P01901443A0297|149 157|steatosis
P01901443A0297|179 185|O stains
P01901664T0064|1 5|cases
P01901859A0000|0 6|UDP-Gal
P01901859A0000|6 12|Gal beta
P01901859A0000|16 27|4GlcNAc alpha
P01901859A0000|31 53|3-galactosyltransferase
P01901859A0000|65 83|glycosyltransferase
P01901859A0000|108 114|variety
P01901859A0000|126 132|species
P01901859A0000|147 155|exception
P01901859A0000|172 186|Old World monkeys
P01901946A0243|10 24|oligonucleotide
P01901946A0243|38 48|SRE sequence
P01901946A0243|56 77|mouse c-fos gene promoter
P01901946A0243|118 122|probe
P01901946A0243|129 146|mobility shift assay
P01901946A0243|150 161|Southwestern
P01901946A0243|162 172|DNA-protein
P01901946A0243|173 180|blotting
P01901946A0243|212 233|affinity chromatography
P01901950T0000|0 19|Sequence requirements
P01901950T0000|32 50|transcription arrest
P01901950T0000|65 70|intron
P01901950T0000|76 89|mouse c-fos gene
P01903404A0688|15 30|ejection fraction
P01903404A0688|70 76|studies
P01903404A0688|98 103|artery
P01903404A0688|107 112|patent
P01903404A0688|151 157|changes
P01903404A0688|185 200|ejection fraction
P01903404A0688|226 240|perfusion status
P01903841A0125|8 21|lysine residues
P01903841A0125|34 43|spermidine
P01903841A0125|50 57|hypusine
P01903841A0125|76 87|modification
P01903841A0125|96 101|eIF-5A
P01903841A1449|3 25|plasmid shuffle technique
P01903841A1449|90 96|failure
P01903841A1449|100 109|yeast cells
P01904154A0164|17 30|identification
P01904154A0164|33 48|characterization
P01904154A0164|51 61|transcripts
P01904154A0164|69 74|Ig loci
P01904154A0164|94 106|understanding
P01904154A0164|112 135|gene rearrangement process
P01904437A0000|0 12|Transcription
P01904437A0000|18 25|metH gene
P01904437A0000|93 107|metR gene product
P01904437A0000|109 125|DNA binding protein
P01904546A0671|0 9|Disruption
P01904546A0671|26 33|AAR1 gene
P01904546A0671|36 40|alpha
P01904546A0671|44 55|a/alpha cells
P01904546A0671|77 85|phenotype
P01904546A0671|92 106|a/alpha diploids
P01905199A0210|3 8|effect
P01905199A0210|11 18|ICRF-187
P01905199A0210|24 40|antitumor response
P01905199A0210|53 63|combination
P01905199A0210|100 104|order
P01905199A0210|111 121|alterations
P01905199A0210|138 142|index
P01905199A0210|168 184|modality treatment
P01905517A1076|41 48|features
P01905517A1076|54 70|sequence data bases
P01905517A1076|86 95|homologies
P01906111A1295|4 8|study
P01906111A1295|38 44|regimen
P01906111A1295|92 97|marrow
P01906111A1295|113 127|toxicity profile
P01906166A0119|0 10|Mitomycin-C
P01906166A0119|25 32|necrosis
P01906166A0119|36 45|ulceration
P01906166A0119|92 98|tissues
P01906166A0119|109 126|drug administration
P01906509A0072|6 10|study
P01906509A0072|34 39|region
P01906509A0072|50 60|nidogen gene
P01906692A0321|0 12|INTERVENTIONS
P01906692A0321|13 20|Patients
P01906692A0321|29 33|rt-PA
P01906692A0321|34 40|heparin
P01906692A0321|44 50|aspirin
P01907265A0670|23 28|result
P01907265A0670|47 59|endonucleases
P01907265A0670|70 80|cell extract
P01907265A0670|108 126|DNA cleavage activity
P01907941A0275|12 22|I kappa B beta
P01907941A0275|29 40|I kappa B alpha
P01907941A0275|57 63|binding
P01907941A0275|76 85|kappa B site
P01909027A0922|0 15|Sequence analysis
P01909027A0922|30 45|DNA binding domain
P01909027A0922|62 69|homology
P01909027A0922|91 114|fork head DNA binding domain
P01909027A0922|143 157|protein fork head
P01909027A0922|162 167|family
P01909027A0922|170 179|hepatocyte
P01909027A0922|187 193|factors
P01909027A0922|194 198|HNF-3
P01909621A0119|18 29|hemodialyses
P01909621A0119|49 56|lithemia
P01909621A0119|67 72|ranges
P01909960A0134|11 19|injection
P01909960A0134|36 40|mg/kg
P01909960A0134|52 64|noradrenaline
P01909960A0134|69 80|biosynthesis
P01909960A0134|106 118|concentration
P01909960A0134|120 134|normetanephrine
P01909960A0134|156 163|NA levels
P01910505A0000|6 21|wuzi yanzong pills
P01910505A0000|42 47|effect
P01910505A0000|50 65|cyclophosphamide
P01910505A0000|73 82|leukopenia
P01911767T0000|0 8|Mutations
P01911767T0000|19 25|subunit
P01911767T0000|28 58|ribulosebisphosphate carboxylase
P01911767T0000|65 78|subunit binding
P01911767T0000|82 90|catalysis
P01913955A0177|13 19|changes
P01913955A0177|34 39|artery
P01913955A0177|60 67|increase
P01913955A0177|70 75|number
P01913955A0177|86 91|artery
P01913955A0177|105 119|muscularization
P01913955A0177|122 135|precursor cells
P01913955A0177|136 144|pericytes
P01913955A0177|160 164|cells
P01913955A0177|231 240|muscle cell
P01913955A0177|274 284|hypertrophy
P01913955A0177|287 297|hyperplasia
P01913955A0177|306 316|muscle cells
P01913955A0177|325 336|accumulation
P01913955A0177|345 350|amount
P01913955A0177|353 360|collagen
P01913955A0177|381 388|collagen
P01915580A0889|5 11|results
P01915580A0889|23 28|NZ-107
P01915580A0889|53 61|treatment
P01915580A0889|72 77|asthma
P01915580A0889|98 112|airway responses
P01915580A0889|116 136|airway hyperreactivity
P01916168A0969|2 6|study
P01916168A0969|11 33|correlation coefficients
P01916168A0969|44 59|ISO2 measurements
P01916168A0969|73 83|ulcer margin
P01916168A0969|106 111|mucosa
P01916168A0969|115 123|delta ISO2
P01916168A0969|148 155|observer
P01916168A0969|172 179|learners
P01916405A0242|9 23|mucosa tattooing
P01916405A0242|26 32|persons
P01916405A0242|61 68|aerosols
P01916405A0242|86 90|forms
P01916405A0242|107 114|diseases
P01916405A0242|113 118|stages
P01916632A0431|8 17|production
P01917943A0621a|0 15|Sequence analysis
P01917943A0621a|21 25|sMtCK
P01917943A0621a|41 49|sequences
P01917943A0621a|65 72|TATAA box
P01917943A0621a|84 92|base pairs
P01917943A0621a|103 125|transfection experiments
P01917943A0621a|147 156|expression
P01917943A0621a|167 174|plasmids
P01917943A0621a|182 221|chloramphenicol acetyltransferase reporter
P01917943A0621b|0 15|Sequence analysis
P01917943A0621b|21 25|sMtCK
P01917943A0621b|41 49|sequences
P01917943A0621b|65 72|TATAA box
P01917943A0621b|84 92|base pairs
P01917943A0621b|103 125|transfection experiments
P01917943A0621b|147 156|expression
P01917943A0621b|167 174|plasmids
P01917943A0621b|182 221|chloramphenicol acetyltransferase reporter
P01917962A0152|3 13|cDNA segment
P01917962A0152|28 73|immunoglobulin gene recombination signal sequences
P01917962A0152|83 93|cDNA segment
P01917962A0152|114 124|IL-2R L chain
P01917962A0152|156 162|control
P01917962A0152|168 179|SV40 promoter
P01918010A0000|0 16|Lipoprotein lipase
P01918010A0000|26 31|enzyme
P01918010A0000|39 59|lipoprotein metabolism
P01918010A0000|71 77|pattern
P01918010A0000|80 89|regulation
P01918010A0000|108 117|expression
P01918010A1730|0 7|Deletion
P01918010A1730|21 39|octanucleotide motif
P01918010A1730|47 53|plasmid
P01918010A1730|71 78|fragment
P01918010A1730|84 94|LPL promoter
P01918010A1730|112 120|% decrease
P01918010A1730|126 130|level
P01918010A1730|133 142|expression
P01918010A1730|156 171|3T3-L1 adipocytes
P01918010A1730|175 190|HepG2 hepatocytes
P01918070A0281|13 19|binding
P01918070A0281|30 44|T3 receptor alpha
P01918070A0281|45 52|T3R alpha
P01918070A0281|106 114|mutations
P01918070A0281|120 126|rGH T3RE
P01918070A0281|159 165|potency
P01918070A0281|180 186|changes
P01918070A0281|189 198|T3R binding
P01918073A0150|0 9|Comparison
P01918073A0150|34 61|TnIcardiac amino acid sequences
P01918073A0150|71 82|TnI sequences
P01918073A0150|100 107|presence
P01918073A0150|122 138|extension sequence
P01918073A0150|152 190|protein kinase A phosphorylation target site
P01918073A0150|216 222|segment
P01918073A0150|250 256|feature
P01918073A0150|304 313|divergence
P01918073A0150|346 354|troponin C
P01918073A0150|366 377|site sequence
P01918073A0150|400 409|adaptation
P01918073A0150|441 450|TnIcardiac
P01918073A0150|457 473|actin/TnC-binding
P01918073A0150|474 494|actomyosin-inhibitory
P01918073A0150|495 500|domain
P01918073A0150|517 534|sequence divergence
P01918073A0150|548 566|TnIcardiac sequences
P01918073A0150|579 585|absence
P01918073A0150|589 612|protein kinase C target site
P01918073A0150|637 643|feature
P01918073A0150|653 659|mammals
P01919831T0000|11 28|management casebook
P01921463T0000|2 17|ASSEMBLER routine
P01921463T0000|35 41|display
P01921463T0000|45 53|averaging
P01921463T0000|81 93|microcomputer
P01922082A0149|0 9|Expression
P01922082A0149|15 30|mouse TSH beta gene
P01922082A0149|61 65|mRNAs
P01922082A0149|92 97|region
P01922734T0000|0 10|Habituation
P01922734T0000|31 37|neurons
P01922734T0000|49 53|snail
P01922734T0000|66 76|stimulation
P01922739A0336|33 38|number
P01922739A0336|40 51|fluctuations
P01922739A0336|76 85|directions
P01922739A0336|110 118|amplitude
P01922739A0336|124 129|course
P01922739A0336|154 162|operation
P01922739A0336|196 201|values
P01922739A0336|232 238|average
P01922739A0336|240 249|electrodes
P01922739A0336|264 268|level
P01922739A0336|274 282|dura mater
P01922739A0336|294 299|values
P01922739A0336|302 311|electrodes
P01922739A0336|326 330|level
P01922739A0336|336 343|pia mater
P01923167A0000|0 25|Blood flow velocity waveforms
P01923167A0000|46 63|Doppler examination
P01923167A0000|82 88|carotid
P01923167A0000|106 113|arteries
P01923167A0000|147 151|route
P01923167A0000|176 183|approach
P01923628T0001|12 19|analysis
P01923628T0001|32 44|flow cytometry
P01923628T0001|65 72|findings
P01923628T0001|77 81|cases
P01923628T0001|91 97|myxomas
P01923766A0485|0 15|Sequence analysis
P01923766A0485|30 37|addition
P01923766A0485|54 60|variant
P01923766A0485|69 79|mRNA species
P01923766A0485|106 113|splicing
P01923766A0485|128 136|exclusion
P01923766A0485|156 166|nucleotides
P01923803A0609|0 7|Position
P01923803A0609|14 23|isoleucine
P01923803A0609|37 57|SsoL12 protein sequence
P01923803A0609|67 74|AUA codon
P01923985A0111|0 7|Symptoms
P01923985A0111|16 21|action
P01923985A0111|24 41|mastocyte mediators
P01924315A0158|5 9|yeast
P01924315A0158|33 44|copper levels
P01924315A0158|54 60|control
P01924315A0158|68 72|level
P01924315A0158|75 88|SOD1 expression
P01924920A0115|10 16|samples
P01924920A0115|17 28|Mobiluncus SP
P01924920A0115|55 66|Gram staining
P01924920A0115|83 95|microorganism
P01924920A0115|108 114|agar RLK
P01924920A0115|127 136|atmosphere
P01925092A0000|8 20|investigators
P01925092A0000|48 52|blood
P01925092A0000|63 68|retina
P01925092A0000|100 107|meshwork
P01925092A0304|11 15|hours
P01925092A0304|24 30|animals
P01925092A0304|57 65|treatment
P01925092A0304|73 82|micrograms
P01925092A0304|85 110|tissue plasminogen activator
P01925092A0304|121 126|volume
P01925092A0304|140 145|saline
P01927421A0181|16 27|examinations
P01927421A0181|55 63|nystagmus
P01927421A0181|77 85|nystagmus
P01927421A0181|96 104|nystagmus
P01927845A0107|8 17|morphology
P01927845A0107|23 29|lesions
P01927845A0107|58 66|disorders
P01927845A0107|67 71|Bowen
P01927845A0107|73 79|disease
P01928923A0000|0 11|Equine amnion
P01928923A0000|19 37|yeast cell derivative
P01928923A0000|85 99|wound medicament
P01928923A0000|117 125|treatment
P01928923A0000|139 144|wounds
P01928923A0000|156 162|portion
P01928923A0000|168 172|limbs
P01928923A0000|175 180|horses
P01930470A0337|21 29|incidence
P01930470A0337|58 76|American Association
P01930470A0337|78 87|Blood Banks
P01930470A0337|105 111|testing
P01930470A0337|142 148|markers
P01930470A0337|161 165|units
P01930470A0337|168 172|blood
P01930660T0000|12 23|growth factor
P01930660T0000|25 29|IGF-1
P01930660T0000|36 43|patients
P01931966A0490|0 5|Fusion
P01931966A0490|8 16|ubiquitin
P01931966A0490|19 24|pADPRP
P01931966A0490|37 41|yield
P01931966A0490|44 49|pADPRP
P01931966A0490|96 101|enzyme
P01932650A0435|2 6|group
P01932650A0435|10 17|patients
P01932650A0435|49 61|drainage blood
P01932650A0435|70 74|hours
P01932650A0435|80 88|operation
P01932650A0435|94 106|concentration
P01932695A1155|3 13|suppression
P01932695A1155|45 59|expression assay
P01932695A1155|79 94|barley endosperms
P01933614A0406|3 8|effect
P01933614A0406|11 26|salmon calcitonin
P01933614A0406|32 36|spray
P01933614A0406|39 43|women
P01933614A0406|59 70|osteoporosis
P01934378A1219|8 36|muscle metaboreceptor responses
P01934378A1219|50 61|heart failure
P01934378T0000|8 44|muscle metaboreceptor exercise responses
P01934378T0000|60 71|heart failure
P01936213T0000|0 9|Evaluation
P01936213T0000|25 34|drug effect
P01936213T0000|37 52|membrane fluidity
P01936348A0155|3 14|examinations
P01936348A0155|33 38|groups
P01936348A0155|48 55|AmF/SnF2
P01936997A0795|0 16|RNA gel retardation
P01936997A0795|20 38|competition analyses
P01936997A0795|51 64|TRP-185 binding
P01936997A0795|89 107|TAR RNA loop sequences
P01937790A0292|3 9|vaccine
P01937790A0292|45 52|children
P01937790A0292|56 61|adults
P01937989A0383|4 9|groups
P01937989A0383|31 39|induction
P01938178T0000|0 11|Applications
P01938178T0000|31 38|analysis
P01939131A0871|3 11|construct
P01939131A0871|29 34|BW2001
P01939131A0871|35 40|xth-11
P01939131A0871|41 45|nfo-2
P01939131A0871|46 56|strain cells
P01939199A0588|16 20|TFIID
P01939199A0588|39 51|transcription
P01939199A0588|73 80|extracts
P01939199A0588|106 118|TFIID fraction
P01939199A0588|123 131|HeLa cells
P01939199A0588|153 157|level
P01939199A0588|160 172|transcription
P01939827A0150|10 21|pretreatment
P01939827A0150|42 58|oxide surface layer
P01939827A0150|62 75|titanium powder
P01939827A0150|96 108|precipitation
P01939827A0150|113 121|solutions
P01939827A0150|133 143|mmol/L CaCl2
P01939827A0150|145 156|mmol/L KH2PO4
P01939827A0150|159 169|mmol/L Hepes
P01939827A0150|188 200|precipitation
P01939827A0150|214 222|solutions
P01939827A0150|236 246|mmol/L CaCl2
P01939827A0150|250 261|mmol/L KH2PO4
P01939827A0150|264 274|mmol/L Hepes
P01939827A0150|286 294|degrees C.
P01939878A0765|14 27|solidification
P01939878A0765|58 63|casein
P01939878A0765|107 114|patients
P01939878A0765|135 141|acidity
P01939899A2043|7 11|model
P01939899A2043|42 48|account
P01939899A2043|54 60|effects
P01939899A2043|70 78|variables
P01939899A2043|81 86|number
P01939899A2043|89 93|tones
P01939899A2043|97 102|amount
P01939899A2043|105 116|perturbation
P01939899A2043|142 149|ABSTRACT
P01939899A2043|164 168|WORDS
P01939906A0233|4 17|generalization
P01939906A0233|69 80|cost function
P01939906A0233|96 106|search space
P01939906A0233|112 122|environment
P01939906A0233|126 131|source
P01939906A0233|144 152|solutions
P01939906A0233|158 169|wave equation
P01939906A0233|192 209|optimization method
P01939906A0233|221 238|parameter landscape
P01939906A0233|251 257|minimum
P01939906A0233|263 274|cost function
P01942033T0000|0 12|Determination
P01942033T0000|17 28|RNA structure
P01942033T0000|39 56|splicing inhibition
P01943184A1050|11 15|cells
P01943184A1050|26 35|University
P01943184A1050|38 54|Wisconsin solution
P01943184A1050|63 68|trypan
P01943184A1050|87 92|% cells
P01945430A0660|11 19|technique
P01945430A0660|59 66|ear fluid
P01945430A0660|80 88|procedure
P01945430A0660|103 116|labyrinthotomy
P01945430A0660|127 141|neuroma suspects
P01947449A0191|3 8|effect
P01947449A0191|11 29|diffusion limitation
P01947449A0191|45 49|terms
P01947449A0191|55 59|ratio
P01947449A0191|62 81|uptake/O2 requirement
P01947449A0191|83 90|fraction
P01947449A0191|143 153|requirement
P01947449A0191|156 165|unit volume
P01947449A1082|1 19|Diffusion limitation
P01947449A1082|38 46|model sets
P01947449A1082|59 74|requirement value
P01947449A1082|116 126|requirement
P01947449A1082|160 165|models
P01947449A1082|184 199|cylinder diameter
P01948783A0000|19 24|effect
P01948783A0000|27 33|Estulic
P01948783A0000|62 67|period
P01948783A0000|85 92|patients
P01952827A0215|16 22|seizure
P01952827A0215|25 31|patient
P01952827A0215|47 56|test phrase
P01954355A0997|0 17|Monitoring patients
P01954355A0997|27 34|leukemia
P01954355A0997|47 55|TNF levels
P01954355A0997|76 81|course
P01954355A0997|84 90|disease
P01954355A0997|108 113|causes
P01954355A0997|123 130|episodes
P01954835A0000|0 21|Echinococcus granulosus
P01954835A0000|47 64|aspiration cytology
P01954835A0000|68 75|lung cyst
P01954835A0000|92 97|female
P01954835A0000|107 114|Missouri
P01956285A0000|3 10|sequence
P01956285A0000|30 40|nucleotides
P01956285A0000|56 63|bet genes
P01956285A0000|109 137|choline-glycine betaine pathway
P01956491A0095|6 14|treatment
P01956491A0095|17 29|amphotericin B
P01956491A0095|31 39|mg/kg/day
P01956491A0095|77 90|filtration rate
P01956491A0095|113 121|clearance
P01956491A0095|124 142|creatinine clearance
P01956491A0095|164 169|ml/min
P01956491A0095|184 193|comparison
P01956491A0095|238 243|ml/min
P01958368A0556|0 8|Evolution
P01958368A0556|11 17|lesions
P01958368A0556|49 59|progression
P01958368A0556|75 80|stages
P01958368A0556|86 110|vitelliform classification
P01958821T0000|8 29|fluorescence microscopy
P01958821T0000|38 48|cell biology
P01960974A0000|0 6|Toluene
P01960974A0000|12 19|chemical
P01960974A0000|43 47|cases
P01960974A0000|65 72|solvents
P01961213A0150|20 29|HCB-levels
P01961213A0150|41 50|breast milk
P01961213A0150|64 68|years
P01961747A0000|1 29|herpesvirus proteinase activity
P01961747A0000|88 93|enzyme
P01961747A0000|97 110|substrate genes
P01961747A0000|122 139|transfection assays
P01961996A0522|0 5|Adult H
P01961996A0522|37 46|preference
P01961996A0522|64 74|opportunity
P01963419A0501|7 25|silver liquid chamber
P01963419A0501|47 56|MeV protons
P01963419A0501|59 63|water
P01963419A0501|111 115|alpha
P01963419A0501|112 122|13N reaction
P01963419A0501|129 139|fluoride ion
P01963419A0501|153 163|18F reaction
P01963438T0000|13 28|electron transfer
P01963438T0000|31 41|cytochrome c
P01963438T0000|55 65|polypyrrole
P01963438T0000|69 77|methylene
P01963438T0000|82 96|polypyrrole film
P01963438T0000|105 114|electrodes
P01963858T0001|9 18|activation
P01963858T0001|21 39|adrenaline secretion
P01963858T0001|59 73|neuroglycopenia
P01963858T0001|84 96|microdialysis
P01964989A0145|0 13|Urine specimens
P01964989A0145|30 42|phencyclidine
P01964989A0145|103 112|9-THC-COOH
P01964989A0145|130 143|sodium chloride
P01964989A0145|144 149|bleach
P01964989A0145|150 156|vinegar
P01964989A0145|157 174|potassium hydroxide
P01964989A0145|187 196|2-propanol
P01964989A0145|199 205|ammonia
P01967130A0645|12 23|pair EFIA cDNA
P01967130A0645|41 51|acid protein
P01967130A0645|103 120|DNA binding proteins
P01968043A0908|20 29|cDNA clones
P01968043A0908|55 60|insert
P01968043A0908|61 66|pASB-1
P01968043A0908|85 96|orientations
P01968156T0000|0 18|Dose standardisation
P01968156T0000|21 34|botulinum toxin
P01968224A0119|3 16|coding sequence
P01968224A0119|35 52|residue polypeptide
P01968224A0119|81 86|intron
P01968224A0119|91 99|base pairs
P01968224A0119|128 144|amino acid sequence
P01968224A0119|194 209|PCNA polypeptides
P01968224A0119|227 233|repeats
P01968224A0119|236 242|leucine
P01968224A0119|258 263|region
P01970560A1024|13 19|fusions
P01970560A1024|41 47|regions
P01970560A1024|114 123|chromosome
P01970560A1024|142 165|beta-Galactosidase assays
P01970560A1024|182 191|regulation
P01970560A1024|194 212|aroF-lacZ expression
P01970560A1024|234 246|TyrR repressor
P01970560A1024|270 278|operators
P01970560A1024|285 293|organisms
P01970560A1024|308 317|efficiency
P01970801A0925|25 29|genes
P01970801A0925|88 92|group
P01970801A0925|106 115|chromosome
P01970801A0925|148 157|chromosome
P01970801A0925|164 168|mouse
P01970926A0000|6 14|exercise K
P01970926A0000|40 45|muscle
P01970926A0000|49 55|plasma K
P01970926A0000|56 73|concentration rises
P01970984A0668|9 17|treatment
P01970984A0668|18 37|serum estradiol levels
P01970984A0668|50 56|groups E
P01970984A0668|73 79|group C.
P01971191A1271|32 38|agonist
P01971191A1271|39 51|isoproterenol
P01971191A1271|61 69|influence
P01971191A1271|80 90|capacitance
P01971191A1271|93 103|liver volume
P01971191A1271|128 144|outflow resistance
P01971191A1271|156 161|agents
P01971191A1271|168 176|histamine
P01972379T0042|0 10|DNA sequence
P01972379T0042|14 22|evolution
P01972379T0042|28 36|CPS domain
P01972379T0042|48 54|hamster
P01972379T0042|70 79|protein CAD
P01973384A0206|28 39|binding sites
P01973384A0206|70 76|ability
P01973384A0206|86 98|transcription
P01973384A0206|123 129|embryos
P01974550A0362|33 52|hexamethonium bromide
P01974550A0362|53 59|mg/kg iv
P01974550A0362|60 77|ipratropium bromide
P01974550A0362|81 94|microgram/kg iv
P01974550A0362|95 106|indomethacin
P01974550A0362|108 114|mg/kg iv
P01974550A0362|130 136|% saline
P01974876A1051|15 51|restriction fragment length polymorphism
P01974876A1051|87 97|individuals
P01974876A1051|105 115|enzyme BglII
P01975157A0836|10 23|transformation
P01975157A0836|46 52|results
P01975428A0151|0 8|Telomeres
P01975428A0151|26 32|fusions
P01975428A0151|50 60|degradation
P01975428A0151|86 96|DNA molecule
P01975428A0151|110 117|function
P01975428A0151|120 131|cell division
P01976638A1135|36 41|region
P01976638A1135|64 72|sequences
P01977585A0222|9 14|enzyme
P01977585A0222|63 67|cells
P01977585A0222|106 113|subunits
P01977585A0222|134 146|protein kinase
P01977856A1036|4 8|study
P01977856A1036|21 25|BSPMs
P01977856A1036|40 49|assessment
P01977856A1036|59 63|terms
P01977856A1036|65 73|diagnosis
P01977856A1036|74 81|location
P01977856A1036|85 90|extent
P01977856A1036|103 109|infarct
P01978834A0076|7 35|abomasum lambda gt11 cDNA library
P01978834A0076|62 69|antibody
P01978834A0076|86 112|rabbit H,K-ATPase beta subunit
P01978857A0504|16 32|laboratory testing
P01978857A0504|41 50|monitoring
P01978857A0504|53 65|CD4 cell counts
P01982061A0615|9 15|TATA box
P01982061A0615|50 76|transcription initiation site
P01982061T0000|0 15|Characterization
P01982061T0000|54 67|hamster CAD gene
P01982190T0001|5 13|cirrhosis
P01982190T0001|21 28|modality
P01982190T0001|34 42|evolution
P01982190T0001|50 58|hepatitis
P01982997A1104|0 10|Examination
P01982997A1104|28 56|transcription factor expression
P01982997A1104|66 75|MDI regimen
P01982997A1104|119 128|expression
P01982997A1104|130 138|c-Jun mRNA
P01982997A1104|162 171|expression
P01982997A1104|174 178|c-Fos
P01982997A1104|182 191|Jun-B mRNAs
P01983026A0483|8 16|heart rate
P01983026A0483|29 36|pressure
P01983026A0483|47 52|degree
P01983026A0483|64 73|intubation
P01983026A0483|85 100|CA concentrations
P01983026A0483|121 131|study period
P01984665T0000|0 9|Processing
P01984665T0000|10 18|secretion
P01984665T0000|22 37|immunoreactivity
P01984665T0000|40 46|carboxy
P01984665T0000|66 94|dengue-2 virus envelope proteins
P01984665T0000|112 116|cells
P01984665T0000|130 142|baculoviruses
P01985301T0000|8 14|therapy
P01985301T0000|19 24|MK-801
P01985301T0000|28 37|nimodipine
P01985301T0000|41 50|protection
P01985301T0000|61 71|brain damage
P01985920A0156|7 15|screening
P01985920A0156|19 37|rat liver cDNA library
P01985920A0156|44 63|oligonucleotide probe
P01985920A0156|78 99|rat SCP2 protein sequence
P01985920A0156|118 130|pair cDNA clone
P01985920A0156|151 169|SCP2 protein sequence
P01985920T0000|0 6|Cloning
P01985920T0000|7 16|expression
P01985920T0000|20 37|nucleotide sequence
P01985920T0000|40 67|rat liver sterol carrier protein
P01985920T0000|69 73|cDNAs
P01985924A0554|3 10|addition
P01985924A0554|24 30|complex
P01985924A0554|59 66|subunits
P01985924A0554|86 95|holoenzyme
P01985924A0554|109 122|chromatography
P01985924A0554|128 135|presence
P01985924A0554|169 186|initiation activity
P01985924A0554|195 199|delta
P01986225A0250|15 28|identification
P01986225A0250|41 52|fission yeast
P01986241A0117|0 8|Induction
P01986241A0117|20 34|ACE1 gene product
P01986241A0117|55 59|sites
P01986241A0117|65 78|promoter region
P01986241A0117|84 91|CUP1 gene
P01986254A0452|0 21|Gel mobility shift assays
P01986254A0452|37 43|E6 motif
P01986254A0452|68 74|complex
P01986254A0452|77 84|addition
P01986254A0452|115 120|T cells
P01986254A0452|123 131|HeLa cells
P01986360A0000|5 10|clones
P01986360A0000|19 57|interferon response element binding factors
P01986360A0000|79 114|mouse fibroblast lambda gt11 cDNA library
P01986360A0000|145 150|trimer
P01986360A0000|155 159|mouse
P01986360A0000|161 213|oligoadenylate synthetase gene interferon response element
P01986360A0000|217 221|probe
P01988041A0281|3 10|sequence
P01988041A0281|17 22|clones
P01988041A0281|55 70|BAL cDNA structure
P01989561A0100|3 13|application
P01989561A0100|21 31|instruments
P01989561A0100|38 46|occlusion
P01989561A0100|61 65|aorta
P01989561A0100|80 95|perfusion cannula
P01989561A0100|135 139|heart
P01989561A0100|174 180|venting
P01989999A0000|16 25|synthetase
P01989999A0000|30 46|L-aspartate ligase
P01989999A0000|86 103|purine biosynthesis
P01989999A0000|127 136|conversion
P01990254A0791|0 16|Immunophenotyping
P01990254A0791|23 27|cases
P01990254A0791|50 59|cell origin
P01990254A0791|75 84|cell origin
P01990266A0678|11 32|UV cross-linking studies
P01990266A0678|46 50|UHF-1
P01990266A0678|71 78|mobility
P01990266A0678|81 93|sodium dodecyl
P01990266A0678|166 173|proteins
P01990266A0678|186 193|promoter
P01991521A0481|3 9|results
P01991521A0481|23 32|conclusion
P01991521A0481|57 64|activity
P01991521A0481|77 85|G4 content
P01991521A0481|108 114|muscles
P01992459A0000|11 21|interaction
P01992459A0000|47 53|element
P01992459A0000|64 88|immunodeficiency virus mRNA
P01992459A0000|97 114|Rev response element
P01992459A0000|133 142|protein Rev
P01992459A0000|165 174|regulation
P01992459A0000|180 185|export
P01992459A0000|225 231|nucleus
P01992459A0000|236 244|cytoplasm
P01992742A0000|13 19|records
P01992742A0000|25 32|patients
P01992742A0000|42 49|neuritis
P01992742A0000|74 79|period
P01992953A0247|7 12|levels
P01992953A0247|23 33|abnormality
P01992953A0247|71 81|specificity
P01992953A0247|112 119|patients
P01992953T0000|0 22|Alanine aminotransferase
P01992953T0000|33 40|practice
P01993181T0000|0 25|Nucleotide sequence analysis
P01993181T0000|48 76|PpG7 salicylate hydroxylase gene
P01993181T0000|97 102|region
P01993656A1860|6 13|ARF cDNAs
P01993656A1860|69 75|guanine
P01993656A1860|94 101|proteins
P01995951A0000|15 20|repeat
P01995951A0000|36 56|immunodeficiency virus
P01995951A0000|81 85|sites
P01995951A0000|106 114|factor Sp1
P01996312A0454|47 66|lambda gt11 cDNA clones
P01996312A0454|91 100|Dd kinase-2
P01997465A0276|17 23|changes
P01997465A0276|37 43|alveoli
P01997465A0276|46 50|septa
P01997465A0276|59 73|collagen content
P01997465A0276|84 88|weeks
P01997465A0276|94 104|irradiation
P01999035A0383|8 16|follow-up
P01999035A0383|37 44|interval
P01999035A0383|50 54|years
P01999035A0383|57 66|Caerphilly
P01999035A0383|73 77|years
P01999035A0383|80 88|Speedwell
P01999035A0383|97 105|IHD events
P01999999T0001|9 16|luxation
P01999999T0001|26 31|injury
P01999999T0001|60 68|treatment
P02000093A0794|0 8|Landsberg
P02001033A1907|2 8|summary
P02001033A1907|25 38|concentrations
P02001033A1907|39 48|desflurane
P02001033A1907|52 61|isoflurane
P02001033A1907|88 94|effects
P02001033A1907|107 113|absence
P02001033A1907|116 120|drugs
P02001033A1907|141 148|reflexes
P02001033A1907|149 158|desflurane
P02001033A1907|183 190|activity
P02001033A1907|206 213|decrease
P02001033A1907|224 231|pressure
P02002051A0276|15 23|isolation
P02002051A0276|38 46|cDNA clone
P02002051A0276|77 83|isoform
P02002051A0276|95 103|C-subunit
P02002051T0000|0 11|Isoform C beta
P02002051T0000|48 54|subunit
P02002051T0000|70 82|protein kinase
P02002511A0637|7 18|applications
P02002511A0637|21 33|PB-PK modeling
P02002511A0637|49 56|problems
P02002511A0637|75 82|examples
P02004521A0266|0 7|Patients
P02004521A0266|27 41|CT abnormalities
P02004521A0266|68 74|disease
P02004705A0686|3 14|cdr1 sequence
P02004705A0686|38 47|amino acids
P02004705A0686|63 70|fragment
P02004705A0686|82 88|product
P02005547A0121|15 27|understanding
P02005547A0121|49 56|pathways
P02005547A0121|90 100|development
P02005547A0121|115 132|hyperbilirubinemia
P02005547A0121|149 156|jaundice
P02005547A0121|160 171|practitioner
P02005547A0121|200 205|family
P02005547A0121|221 225|child
P02005547A0121|227 233|illness
P02006558A0000|0 21|Displacement thresholds
P02006558A0000|34 38|sites
P02006558A0000|55 60|vision
P02007045A0092|3 9|authors
P02007045A0092|42 51|irrigation
P02007045A0092|54 62|brain cyst
P02007045A0092|101 108|distress
P02008982A0463|0 4|ELISA
P02008982A0463|20 31|contribution
P02008982A0463|37 45|diagnosis
P02008982A0463|48 59|tuberculosis
P02008982A0463|75 85|sputum smear
P02010912A0366|6 10|paper
P02010912A0366|28 32|study
P02010912A0366|38 46|structure
P02010912A0366|74 89|MalT binding sites
P02010912A0366|121 125|pulAp
P02010912A0366|129 142|pulCp promoters
P02011924A0729|15 20|number
P02011924A0729|23 30|patients
P02011924A0729|36 40|basis
P02011924A0729|47 52|report
P02011924A0729|72 77|MU/day
P02011924A0729|80 88|alpha-IFN
P02011924A0729|101 109|treatment
P02011924A0729|113 120|patients
P02011924A0729|130 141|cell leukemia
P02012097T0000|10 21|fluctuations
P02012097T0000|32 42|parasitemia
P02012097T0000|45 71|Plasmodium falciparum malaria
P02012789A0051|10 22|family history
P02014928T0000|12 17|asthma
P02014928T0000|21 39|rhinoconjunctivitis
P02014928T0000|44 53|inhalation
P02014928T0000|73 90|serum albumin powder
P02015921A0523|8 18|subdivision
P02015921A0523|21 31|Category pN1
P02015921A0523|42 51|metastasis
P02015921A0523|83 87|nodes
P02016053A0752|0 27|Amino acid sequence comparisons
P02016053A0752|33 43|E74A protein
P02016053A0752|76 81|region
P02016053A0752|99 115|amino acid residues
P02016053A0752|165 182|DNA binding activity
P02016769A0720|22 30|strengths
P02016769A0720|36 44|promoters
P02016769A0720|67 74|contexts
P02017159A0646|0 5|Grasso
P02017271A0502|6 11|months
P02017271A0502|20 30|improvement
P02017271A0502|33 40|strength
P02017271A0502|72 79|patients
P02017271A0502|94 101|controls
P02017414A0307|15 23|asymptote
P02017414A0307|42 49|Line RBC2
P02017414A0307|57 62|Line F.
P02019572A0000|13 24|DNA sequences
P02019572A0000|44 53|expression
P02019572A0000|59 80|rat liver pyruvate kinase
P02019572A0000|85 89|genes
P02019572A0000|91 96|series
P02019572A0000|99 108|constructs
P02019572A0000|119 163|chloramphenicol acetyltransferase reporter genes
P02019572A0000|188 196|fragments
P02019572A0000|206 214|base pairs
P02019572A0000|236 246|gene cap site
P02019572A0000|273 282|expression
P02019572A0000|288 299|introduction
P02019572A0000|304 321|hepatoma HepG2 cells
P02019572A0000|322 335|rat hepatocytes
P02019572A0000|345 351|culture
P02019572A0000|352 364|fibroblast LTK
P02019572A0000|365 369|cells
P02019572A0000|378 387|C2C12 cells
P02019572A0000|391 398|CHO cells
P02020082A0356|3 13|disturbance
P02020082A0356|25 35|gas exchange
P02020082A0356|55 59|value
P02020082A0356|62 66|AaDO2
P02020082A0356|96 106|dysfunction
P02020082A0356|110 114|AaDO2
P02020082A0356|131 142|relationship
P02020082A0356|166 175|parameters
P02020082A0356|188 197|difference
P02020082A0356|205 217|plasma colloid
P02020082A0356|225 232|pressure
P02020314A1290|14 36|micrograms/kg/day GM-CSF
P02020314A1290|46 53|severity
P02020314A1290|56 66|neutropenia
P02020314A1290|70 85|thrombocytopenia
P02020314A1290|91 130|carboplatin-cyclophosphamide chemotherapy
P02020314A1290|158 169|chemotherapy
P02020314A1290|180 185|cancer
P02020314A1290|191 196|future
P02021630A1104|5 15|differences
P02021630A1104|47 58|interactions
P02021630A1104|69 75|protein
P02021630A1104|93 106|guanine N7 sites
P02021630A1104|116 121|groove
P02021630A1104|132 142|alterations
P02021630A1104|144 172|DNA phosphodiester conformation
P02021630A1104|182 195|protein binding
P02022188A0112|11 18|analysis
P02022188A0112|38 47|BJ1 protein
P02022188A0112|64 74|nucleosomes
P02022188A0112|92 100|chromatin
P02022188A0112|103 108|agents
P02022188A0112|161 181|mobility group proteins
P02022188A1463|17 28|gene products
P02022188A1463|38 46|chromatin
P02022188A1463|81 94|order structure
P02022188A1463|98 109|prerequisite
P02022188A1463|123 136|gene expression
P02022920A0334|3 15|C4BP alpha gene
P02022920A0334|44 52|exon codes
P02022920A0334|67 77|nucleotides
P02023097A0000|8 32|immunodeficiency virus type
P02023097A0000|34 38|HIV-1
P02023097A0000|39 48|Rev protein
P02023097A0000|79 87|regulator
P02023097A0000|105 118|gene expression
P02023097A0000|134 149|virus replication
P02023421A0343|7 19|proliferation
P02023421A0343|22 32|fibroblasts
P02023421A0343|36 52|collagen synthesis
P02023421A0343|63 70|increase
P02023421A0343|83 90|strength
P02023421A0343|101 106|effect
P02023421A0343|109 120|wound healing
P02023421A0343|167 172|agents
P02023904A0120|3 10|CDC7 gene
P02023904A0120|25 33|AUG codons
P02023904A0120|44 64|translation start sites
P02023904A0120|93 100|proteins
P02024252A0000|9 13|years
P02024252A0000|22 26|total
P02024252A0000|32 38|persons
P02024252A0000|47 64|disability pensions
P02024252A0000|70 81|municipality
P02024252A0000|84 92|Nordreisa
P02024252A0000|103 108|Norway
P02024488A0506|9 23|Jurkat cell lines
P02024488A0506|34 40|nef gene
P02024488A0506|52 62|CMV promoter
P02024488A0506|68 75|HIV-1 LTR
P02024488A0506|90 100|coselection
P02024488A0506|104 121|neomycin resistance
P02024625A0202|0 10|Differences
P02024625A0202|24 35|presentation
P02024625A0202|47 56|appearance
P02024625A0202|65 69|cases
P02024625A0202|85 96|similarities
P02024625A0202|113 120|features
P02024791A0582|0 11|MEASUREMENTS
P02024791A0582|15 25|MAIN RESULTS
P02024791A0582|32 37|groups
P02024791A0582|51 55|entry
P02024791A0582|63 67|study
P02024791A0582|81 96|FEV1 measurements
P02024791A0582|101 111|L atropine/0
P02024791A0582|114 128|L metaproterenol
P02024816A0521|7 11|ELISA
P02024816A0521|33 40|protein A
P02024816A0521|71 87|pneumonia patients
P02025515A0979|35 43|doses/day
P02026144A0741|8 14|control
P02026144A0741|17 29|GUS expression
P02026144A0741|68 76|sequences
P02026144A0741|131 140|domain UAS1
P02026147A0000|15 24|calmodulin
P02026147A0000|37 49|protein kinase
P02026147A0000|49 57|CaM kinase
P02026147A0000|65 69|yeast
P02026147A0000|97 106|properties
P02026147A0000|133 142|CaM kinases
P02026461A0760|6 10|cases
P02026461A0760|42 52|individuals
P02026461A0760|76 80|panel
P02026461A0760|83 88|probes
P02026491A0399|3 10|patients
P02026491A0399|30 36|effects
P02026491A0399|61 67|seizure
P02027839A0250|3 9|muscles
P02027839A0250|25 29|group
P02027839A0250|65 70|values
P02027839A0250|82 88|density
P02027839A0250|92 100|capillary
P02027839A0250|103 112|fiber ratio
P02027839A0250|149 156|distance
P02027839A0250|179 183|group
P02028125A0101|3 12|prevalence
P02028125A0101|28 36|infection
P02028125A0101|51 62|AIDS patients
P02028125A0101|69 79|probability
P02028125A0101|89 102|tumour response
P02028125A0101|112 124|cancer therapy
P02028125A0101|154 161|examples
P02028125A0101|168 176|functions
P02029468A0296|0 21|Serum TNF concentrations
P02029468A0296|36 44|diagnosis
P02029468A0296|75 89|reference limits
P02030910A0000|7 12|clones
P02030910A0000|33 40|ETS1 gene
P02030910A0000|84 95|organization
P02030910A1070|0 30|Polymerase chain reaction analysis
P02030910A1070|33 40|ETS1 cDNA
P02030910A1070|67 74|products
P02030910A1070|96 103|splicing
P02033038A0309|23 36|E3 polypeptides
P02033038A0309|41 45|bands
P02033038A0309|69 74|pellet
P02033038A0309|130 137|fraction
P02033062A1169|6 21|promotor function
P02033062A1169|30 34|genes
P02033062A1169|57 65|fragments
P02033062A1169|68 79|chicken IGF-I
P02033062A1169|108 122|reporter plasmid
P02034655A1224|3 7|alpha
P02034655A1224|24 29|region
P02034655A1224|37 44|promoter
P02034655A1224|47 64|transfection assays
P02034655T0000|0 15|Characterization
P02034655T0000|21 25|alpha
P02034655T0000|27 46|integrin gene promoter
P02034669A0293|13 22|transcript
P02034669A0293|41 47|tissues
P02034669A0293|56 65|expression
P02034669A0293|115 120|system
P02034676A0267|3 12|homologues
P02034676A0267|18 30|rhombotin gene
P02035805T0000|0 25|Angina haemorrhagica bullosa
P02035805T0000|44 54|obstruction
P02036066A0000|13 19|effects
P02036066A0000|31 39|perfusion
P02036066A0000|57 90|hemoglobin polyoxyethylene conjugate
P02036066A0000|96 103|solution
P02036066A0000|112 119|function
P02036066A0000|130 138|rat hearts
P02038293A0919|0 9|Conclusion
P02038293A0919|10 21|inlet type VSD
P02038293A0919|39 45|type TOF
P02038293A0919|58 65|features
P02038293A0919|87 92|bundle
P02038293A0919|126 135|VSD closure
P02038326A0538|3 18|gcd2-503 mutation
P02038326A0538|40 45|runoff
P02038326A0538|46 57|accumulation
P02038326A0538|82 88|couples
P02038326A0538|91 102|accumulation
P02038326A0538|120 127|subunits
P02038326A0538|140 166|translation initiation factor
P02038326A0538|168 177|eIF-2 alpha
P02038326A0538|180 195|43S-48S particles
P02038326A0538|206 210|shift
P02038326A0538|227 237|temperature
P02038784A0317|5 12|patients
P02038784A0317|30 36|failure
P02041088A1053|12 27|enhancer activity
P02041088A1053|37 51|reporter plasmid
P02041088A1053|103 146|reporter chloramphenicol acetyltransferase gene
P02041088A1053|154 160|control
P02041088A1053|179 189|39K promoter
P02044785A0000|17 30|adenocarcinoma
P02044785A0000|40 54|retroperitoneal
P02044950A0258|8 30|polymerase chain reaction
P02044950A0258|44 53|U6 RNA genes
P02044950A0258|58 66|organisms
P02044975A0380|8 13|volume
P02044975A0380|91 102|instillation
P02044975A0380|128 138|application
P02044975A0380|142 147|volume
P02045366A1149|0 21|Hydrophobicity analysis
P02045366A1149|47 62|KlaB polypeptides
P02045366A1149|92 106|KlaC polypeptide
P02045366A1149|155 161|domains
P02045524A0000|15 26|availability
P02045524A0000|52 57|agents
P02045524A0000|70 87|Drug Administration
P02045524A0000|97 105|mid-1970s
P02045524A0000|130 136|ratings
P02045524A0000|157 161|drugs
P02045524A0000|172 183|end-of-phase
P02045524A0000|186 196|conferences
P02045524A0000|201 212|drug sponsors
P02045809A0331|2 9|contrast
P02045809A0331|17 21|rates
P02045809A0331|24 43|B. sphaericus products
P02045809A0331|44 51|ABG-6184
P02045809A0331|61 66|powder
P02045809A0331|70 74|BSP-2
P02045809A0331|83 93|concentrate
P02045809A0331|115 123|reduction
P02046202A0625|3 11|remainder
P02046202A0625|25 38|IgA nephropathy
P02047597A0149|22 29|vulvitis
P02047597A0149|47 60|field condition
P02047597A0149|64 71|bacteria
P02047597A0149|106 112|strains
P02052544A0641|14 26|DNA polymerase
P02052544A0641|29 35|complex
P02052544A0641|60 65|dpb2-1
P02052544A0641|72 76|cells
P02052544A0641|98 110|DNA polymerase
P02052544A0641|113 119|complex
P02052544A0641|162 172|replication
P02052592A0000|44 51|products
P02052592A0000|66 72|changes
P02052592A0000|75 86|bone turnover
P02052592A0000|106 116|development
P02052592A0000|133 144|osteoporosis
P02052592A0000|159 165|effects
P02052592A0000|168 179|oophorectomy
P02052592A0000|193 211|estrogen replacement
P02052592A0000|228 236|secretion
P02052592A0000|239 249|interleukin
P02052592A0000|260 283|tumor necrosis factor alpha
P02052592A0000|283 291|TNF-alpha
P02052592A0000|300 317|phytohemagglutinin
P02052592A0000|327 335|secretion
P02052592A0000|378 383|factor
P02052592A0000|384 389|GM-CSF
P02052592A0000|404 408|blood
P02052592A0000|420 424|cells
P02053289A0701|15 27|nt differences
P02053289A0701|58 63|groups
P02053289A0701|83 95|nt differences
P02053289A0701|114 120|strains
P02054754A0919|11 20|principles
P02054754A0919|31 40|management
P02054754A0919|65 75|Sandostatin
P02054754A0919|83 90|patients
P02054754A0919|100 108|disorders
P02055484A0538|9 19|PCR products
P02055484A0538|29 37|mutations
P02056553T0000|11 15|shock
P02056553T0000|28 40|translocation
P02056553T0000|44 53|swine model
P02060052A0954|25 30|levels
P02060052A0954|32 37|oxygen
P02060052A0954|42 49|radicals
P02060052A0954|65 75|hepatocytes
P02060052A0954|79 90|mitochondria
P02061282A0447|3 10|sequence
P02061282A0447|16 27|pMxL1 plasmid
P02061282A0447|51 56|region
P02061282A0447|79 84|repeat
P02061282A0447|98 108|orientation
P02061282A0447|121 129|pilin gene
P02061282A0447|135 140|middle
P02061282A0447|146 170|recombination junction site
P02061333A0784|2 9|evidence
P02061333A0784|16 23|presence
P02061333A0784|26 32|introns
P02061333A0784|42 49|acvA gene
P02061333A1359|5 16|observations
P02061333A1359|32 41|occurrence
P02061333A1359|52 85|phosphopantetheine-attachment sites
P02061333A1359|98 113|thioesterase site
P02061333A1359|130 138|reference
P02061333A1359|144 159|reaction sequence
P02061333A1359|169 178|production
P02061333A1359|184 196|ACV tripeptide
P02062116A0688|0 8|Pargyline
P02062116A0688|10 34|monoamine oxidase inhibitor
P02062933A0738|12 17|choice
P02062933A0738|34 39|female
P02062933A0738|74 89|flutamide females
P02062933A0738|96 103|controls
P02062933A0738|120 126|partner
P02064119A1172|18 26|responses
P02064119A1172|41 45|L/min
P02064119A1172|45 49|% SaO2
P02064119A1172|55 63|relatives
P02064119A1172|77 81|L/min
P02064119A1172|81 85|% SaO2
P02064119A1172|98 105|subjects
P02064119A1172|136 143|ABSTRACT
P02064119A1172|158 162|WORDS
P02065022A0747|9 17|deletions
P02065022A0747|36 41|region
P02065022A0747|61 80|transforming activity
P02065022A0747|102 109|deletion
P02065022A0747|122 127|region
P02065022A0747|133 138|effect
P02066246A0258|43 47|files
P02066246A0258|52 78|Massachusetts Cancer Registry
P02066246A0258|82 86|cases
P02068085A1273|13 20|evidence
P02068085A1273|43 49|element
P02068085A1273|64 69|region
P02068085A1273|89 106|activation sequence
P02069738A0000|1 6|method
P02069738A0000|22 36|stimulus control
P02069738A0000|39 45|ethanol
P02069873X0000|0 8|Mechanism
P02069873X0000|11 20|activation
P02069873X0000|26 41|vav protooncogene
P02069873X0000|63 67|locus
P02069873X0000|105 109|cells
P02069873X0000|125 130|origin
P02069873X0000|148 169|differentiation lineage
P02070227T0000|11 21|cell seeding
P02072238T0000|0 15|Menetrier disease
P02072238T0000|19 23|child
P02072798A0330|16 28|stabilization
P02072798A0330|40 46|therapy
P02072798A0330|61 66|chance
P02072798A0330|73 77|ulcer
P02073222A0269|11 18|patients
P02073222A0269|19 32|amitriptyline n
P02073222A0269|36 47|moclobemide n
P02073222A0269|66 77|week protocol
P02073222A0269|111 120|conditions
P02075876A0408|3 19|stimulus threshold
P02075876A0408|49 57|variation
P02075876A0408|61 69|amplitude
P02075876T0001|0 7|Analysis
P02075876T0001|28 35|response
P02075876T0001|43 50|relation
P02075876T0001|68 74|pathway
P02076620A0548|11 32|plasma fibrinogen levels
P02076620A0548|78 83|effect
P02076620A0548|84 94|gemfibrozil
P02076620T0000|0 10|Gemfibrozil
P02076620T0000|28 35|patients
P02076620T0000|58 64|disease
P02076620T0000|81 87|actions
P02076816T0000|18 24|pathway
P02076816T0000|28 45|sporulation control
P02076816T0000|82 107|IME1 transcript accumulation
P02077560T0000|26 34|profiling
P02077560T0000|36 51|safety assessment
P02078080T0040|3 13|application
P02078080T0040|16 25|Madagascar
P02078080T0040|26 35|advantages
P02078080T0040|39 51|disadvantages
P02078570A0287|5 9|cases
P02078570A0287|20 29|expression
P02078570A0287|49 57|integrins
P02079811A0407|3 9|authors
P02079811A0407|29 36|efficacy
P02079811A0407|39 44|EMB AZS
P02079811A0407|56 60|ulcer
P02079811A0407|66 74|operation
P02079811A0407|80 86|stomach
P02079811A0407|100 104|level
P02079811A0407|107 120|acid production
P02079811A0407|148 155|bleeding
P02080902A0183|2 10|adulthood
P02080902A0183|56 72|avoidance response
P02080902A0183|84 91|controls
P02081463A0110|16 25|regulation
P02081463A0110|28 43|Spec gene activity
P02081463A0110|47 52|region
P02081463A0110|62 66|Spec1
P02081463A0110|82 95|initiation site
P02081463A0110|110 114|sites
P02081463A0110|128 138|interaction
P02083199A1175|0 20|Phosphopeptide mapping
P02083199A1175|36 59|autophosphorylation sites
P02083199A1175|70 76|EGFR-IC
P02083230A0938|10 17|sequence
P02083230A0938|34 46|signal peptide
P02083230A0938|75 96|amino acid residue domain
P02083230A0938|102 121|N-glycosylation sites
P02083230A0938|136 141|domain
P02083230A0938|156 161|domain
P02083230A0938|166 175|amino acids
P02083253A1512|3 23|TCF-1 alpha binding site
P02083253A1512|42 65|TCR alpha enhancer activity
P02083253A1512|91 98|extracts
P02083253A1512|103 108|Jurkat
P02083253A1512|115 123|HeLa cells
P02083253A1512|138 147|TCF-1 alpha
P02083253A1512|166 184|transcription factor
P02083546A0000|18 23|method
P02083546A0000|54 59|uptake
P02083546A0000|95 104|amine oxime
P02083546A0000|105 115|99mTc-HMPAO
P02083546A0000|137 159|photon emission tomograms
P02083546A0000|171 178|subjects
P02083546A0000|181 188|patients
P02083546A0000|193 201|Alzheimer
P02083546A0000|203 209|disease
P02083546A0000|212 219|patients
P02083546A0000|224 231|dementia
P02083546A0000|241 248|lobe type
P02083546A0000|253 260|patients
P02083546A0000|265 272|dementia
P02083546A0000|277 295|motor neurone disease
P02088781A0653|3 9|results
P02088781A0653|30 34|level
P02088781A0653|63 74|density units
P02088781A0653|78 86|influence
P02088781A0653|102 109|accuracy
P02088781A0653|115 121|absence
P02088781A0653|127 138|compensation
P02089054A0121|28 48|liquid-solid partition
P02089054A0121|54 61|extracts
P02089054A0121|104 109|column
P02089054A0121|124 133|conditions
P02089054A0121|165 174|UV detector
P02091890A0614|6 10|model
P02091890A0614|11 21|eltoprazine
P02091890A0614|60 66|profile
P02091890A0614|77 86|aggression
P02091890A0614|98 108|interaction
P02091890A0614|112 122|exploration
P02091890A0614|153 162|inactivity
P02091890A0614|164 170|measure
P02091890A0614|174 181|sedation
P02092131T0000|4 9|method
P02092131T0000|23 30|transfer
P02092131T0000|40 55|hypersensitivity
P02092131T0000|66 79|transfer factor
P02093033T0001|0 5|Effect
P02093033T0001|27 33|effects
P02093033T0001|36 48|plutonium-239
P02093033T0001|49 67|hexachlorobutadiene
P02093033T0001|71 87|tributyl phosphate
P02093033T0001|93 103|thymus gland
P02093741A0211|0 13|Data collection
P02093741A0211|26 38|query language
P02093741A0211|42 53|data analysis
P02093741A0211|112 118|MAXITAB
P02093741A0211|147 163|analysis technique
P02093888A0293|0 4|ARPIA
P02093888A0293|83 91|computers
P02094221A0247|0 7|Diuresis
P02094221A0247|29 36|drinking
P02094257T0000|10 14|value
P02094257T0000|17 42|adenosine deaminase activity
P02094257T0000|56 64|effusions
P02095150T0000|7 22|strain adaptation
P02095150T0000|33 46|hip replacement
P02095150T0000|48 57|comparison
P02095150T0000|77 94|ingrowth components
P02095150T0000|97 103|canines
P02099622A1046|0 19|Immuno-cytochemistry
P02099622A1046|25 32|antisera
P02099622A1046|40 58|Campylobacter jejuni
P02099622A1046|80 87|staining
P02099622A1046|107 111|cells
P02099622A1046|141 149|organisms
P02099622A1046|157 165|structure
P02099622A1046|176 191|Campylobacter spp
P02102823A0492|0 17|Promoter activities
P02102823A0492|36 53|beta-glucuronidase
P02102823A0492|57 82|neomycin phosphotransferase
P02102823A0492|85 103|reporter gene systems
P02102831A1282|4 10|regions
P02102831A1282|21 37|soybean actin genes
P02102831A1282|56 63|features
P02102831A1282|77 83|repeats
P02102831A1282|90 98|stretches
P02103140A1088|9 16|patients
P02103140A1088|36 42|failure
P02103140A1088|54 59|grafts
P02103140A1088|105 110|grafts
P02103140A1088|145 161|retransplantation
P02103403A0149|2 8|patient
P02103403A0149|13 19|history
P02103403A0149|28 40|alcohol intake
P02103403A0149|52 57|intake
P02103403A0149|71 75|drugs
P02103403A0149|79 86|steroids
P02105497A1092|14 23|comparison
P02105497A1092|26 43|amino acid sequences
P02105497A1092|48 60|HSP70 proteins
P02105497A1092|67 73|species
P02105497A1092|86 93|BiP genes
P02105497A1092|106 113|ancestor
P02105497A1092|136 145|HSP70 genes
P02105497A1092|163 172|eukaryotes
P02106287A0478|0 11|Spore inocula
P02106287A0478|26 31|coupon
P02106287A0478|45 50|0.5-in
P02107073A0584|7 20|overexpression
P02107073A0584|39 51|STE18 proteins
P02107073A0584|74 90|pheromone response
P02107073A0584|95 108|overexpression
P02107073A0584|122 129|presence
P02107073A0584|140 145|levels
P02107073A0584|148 152|STE18
P02107548A0727|7 23|transcription-PCR
P02107548A0727|37 41|clone
P02107548A0727|100 106|homolog
P02107548A0727|105 110|psi ARF
P02109544A0000|22 29|benefits
P02109544A0000|31 44|screening tests
P02109544A0000|48 67|Chlamydia trachomatis
P02109544A0000|80 84|males
P02109544A0000|97 117|decision analysis model
P02109544A0000|132 165|leukocyte esterase urine dipstick test
P02109544A0000|170 176|culture
P02109544A0000|204 211|antibody
P02109544A0000|227 232|option
P02109544A0000|236 244|screening
P02109544A0000|247 255|treatment
P02110145T0000|0 9|Sequencing
P02110145T0000|54 59|enzyme
P02110145T0000|69 79|Bacteroides
P02110145T0000|87 93|TAL2480
P02110145T0000|107 116|similarity
P02110145T0000|133 160|Bacillus cereus beta-lactamase
P02110148A0423|9 23|HindIII fragment
P02110148A0423|39 57|DNA sequence analysis
P02110148A0423|90 109|B. subtilis IF2 protein
P02110148A0423|137 144|sequence
P02110148A0423|168 172|probe
P02110148A0423|175 179|clone
P02110148A0423|217 224|fragment
P02111015A0574|16 25|amino acids
P02111015A0574|58 63|domain
P02111015A0574|82 99|sequence similarity
P02111015A0574|115 132|IFN response factors
P02111015A0574|133 137|IRF-1
P02111015A0574|141 145|IRF-2
P02113015A0295|8 15|seizures
P02113015A0295|33 41|pregnancy
P02113174A0064|10 16|protein
P02113174A0064|26 36|zinc fingers
P02113174A0064|56 77|transcription factor Sp1
P02113174A0957|0 6|Krox-24
P02113174A0957|51 59|activator
P02113455A0207|18 28|variability
P02113455A0207|34 43|parameters
P02113455A0207|55 67|consideration
P02113455A0207|97 111|threshold levels
P02113699A0372|3 10|patients
P02113699A0372|27 35|subgroups
P02113699A0372|42 49|patients
P02113699A0372|64 68|spots
P02113699A0372|94 101|patients
P02113699A0372|112 116|spots
P02113699A0372|146 153|patients
P02113699A0372|165 169|spots
P02113901A0000|20 26|changes
P02113901A0000|38 48|normocapnia
P02113901A0000|89 95|tension
P02113901A0000|132 141|difference
P02115111T0000|0 9|Expression
P02115111T0000|10 27|nucleotide sequence
P02115111T0000|41 48|analysis
P02115111T0000|58 70|reading frames
P02115111T0000|76 88|nif gene region
P02115111T0000|91 100|Anabaena sp
P02115111T0000|122 134|strain PCC7120
P02115115A1053|31 40|suggestion
P02115115A1053|45 49|sites
P02115115A1053|65 71|CAR1 URS
P02115115A1053|98 104|regions
P02115115A1053|124 133|yeast genes
P02115116A1137|3 9|results
P02115116A1137|22 34|sequence match
P02115116A1137|42 50|enhancers
P02115116A1137|61 76|promoter elements
P02115118A0565|37 46|smg p25A GDI
P02115118A0565|57 69|sodium dodecyl
P02115118A0565|92 109|gel electrophoresis
P02115118A0565|113 153|sucrose density gradient ultracentrifugation
P02115121A0000|0 11|Yeast mutants
P02115121A0000|25 51|pet complementation group G104
P02115121A0000|86 106|dehydrogenase activity
P02115121A0000|110 115|result
P02115121A0000|118 126|mutations
P02115121A0000|132 160|dihydrolipoyl transsuccinylase
P02115121A0000|166 174|component
P02115121A0000|179 185|complex
P02115122A0562|8 15|residues
P02115122A0562|27 36|repression
P02115122A0562|68 77|amino acids
P02115122A0562|80 84|c-Fos
P02115122A0562|90 94|v-Fos
P02115122A0562|108 118|truncations
P02115122A0562|121 125|c-Fos
P02115572A1323|17 33|V lambda pseudogene
P02115572A1323|40 49|psi V lambda
P02115572A1323|69 82|U266 lambda gene
P02115889A0436|6 10|paper
P02115889A0436|28 36|structure
P02115889A0436|53 59|Gx alpha
P02115889A0436|79 87|kilobases
P02116071A0000|14 18|study
P02116071A0000|43 55|stage children
P02116071A0000|68 74|potency
P02116071A0000|92 119|type hypersensitivity reaction
P02116071A0000|122 129|exposure
P02116071A0000|136 142|antigen
P02116071A0000|152 156|titer
P02116071A0000|216 222|attacks
P02116071A0000|233 241|reduction
P02116071A0000|247 252|amount
P02116071A0000|259 265|antigen
P02116071A0000|289 297|reduction
P02116071A0000|302 307|amount
P02116537A1237|5 13|influence
P02116537A1237|32 45|concentrations
P02117799T0000a|8 21|orthoclone OKT3
P02117799T0000a|24 34|prophylaxis
P02117799T0000a|37 45|rejection
P02117799T0000a|49 57|induction
P02117799T0000a|67 77|nonfunction
P02117799T0000a|80 100|kidney transplantation
P02117799T0000b|8 21|orthoclone OKT3
P02117799T0000b|24 34|prophylaxis
P02117799T0000b|37 45|rejection
P02117799T0000b|49 57|induction
P02117799T0000b|67 77|nonfunction
P02117799T0000b|80 100|kidney transplantation
P02118519A0516|31 45|consensus motifs
P02118519A0516|78 86|positions
P02118519A0516|92 96|genes
P02118519A0516|103 127|nerve growth factor receptor
P02118519A0516|140 159|neurofilament protein
P02118525A0737|2 9|addition
P02118525A0737|22 29|fragment
P02118525A0737|35 45|CCK promoter
P02118525A0737|70 77|enhancer
P02118525A0737|96 108|transcription
P02118525A0737|116 156|herpes simplex virus thymidine kinase promoter
P02118525A0737|160 167|position
P02118525A0737|194 199|manner
P02118612A0629|6 12|minutes
P02118612A0629|15 29|supine restraint
P02118612A0629|39 57|DOPAC concentrations
P02118612A0629|69 76|eminence
P02118612A0629|124 131|exposure
P02118612A0629|133 137|ether
P02118612A0629|150 155|effect
P02119530T0000|0 8|Influence
P02119530T0000|11 29|metoprolol treatment
P02119530T0000|48 57|activation
P02119530T0000|60 71|fibrinolysis
P02119626A0471|8 12|scars
P02119626A0471|48 57|dimensions
P02119946T0000|8 16|dysphagia
P02119946T0000|27 37|care setting
P02119946T0000|40 51|introduction
P02120707A0594|18 23|assays
P02120707A0594|53 60|proteins
P02120707A0594|77 85|V elements
P02120707A0594|105 131|HLA-DRA X-box oligonucleotide
P02120833A0000|2 8|Denmark
P02120833A0000|16 20|cases
P02120833A0000|45 57|hepatitis NANB
P02120833A0000|58 65|TAH-NANB
P02120833A0000|111 115|units
P02121371T0000|3 10|NF1 locus
P02121371T0000|19 25|protein
P02121371T0000|64 79|yeast IRA proteins
P02122454A1042|8 18|replacement
P02122454A1042|21 26|Phe-62
P02122454A1042|56 66|determinant
P02122454A1042|71 76|lambda
P02122454A1042|83 87|chain
P02122454A1042|122 130|transport
P02122454A1042|137 144|molecule
P02123029A0478|7 13|isotype
P02123029A0478|16 33|Raja immunoglobulin
P02123029A0478|39 48|chain genes
P02123029A0478|76 92|spleen cDNA library
P02123029A0478|107 112|Raja VH
P02123029A0478|128 133|probes
P02123029A0478|160 166|regions
P02123029A0478|179 185|isotype
P02123293A0227|0 4|Petko
P02123295A0645|0 9|Disruption
P02123295A0645|36 44|phenotype
P02123300T0000|41 46|factor
P02123300T0000|47 52|factor
P02123300T0000|62 70|treatment
P02123300T0000|73 84|hemophilia A.
P02123300T0000|96 115|Factor VIII Study Group
P02123466A0272|9 15|members
P02123466A0272|22 27|family
P02123466A0272|40 44|motif
P02123466A0272|63 68|domain
P02123466A0272|115 124|DNA binding
P02123467A0811|11 20|expression
P02123467A0811|26 33|promoter
P02123467A0811|67 71|cells
P02123467A0811|80 84|MyoD1
P02123467A0811|122 126|sites
P02123467A0811|149 156|presence
P02123467A0811|186 190|MyoD1
P02123820A0000|0 6|Effects
P02123820A0000|19 34|monoamine oxidase
P02123820A0000|41 49|inhibitor
P02123820A0000|49 58|clorgyline
P02123820A0000|69 82|MAO-B inhibitor
P02123820A0000|83 90|deprenyl
P02123820A0000|108 119|MAO inhibitor
P02123820A0000|120 128|nialamide
P02123820A0000|164 173|aggression
P02123875A0223|20 27|features
P02123875A0223|30 37|residues
P02123875A0223|49 56|c-region
P02123875A0223|73 80|fidelity
P02123875A0223|84 93|efficiency
P02123875A0223|96 118|signal peptidase cleavage
P02123875A0223|143 155|translocation
P02123875A0223|171 192|amino acid substitutions
P02123875A0223|200 211|COOH terminus
P02123875A0223|242 254|substitutions
P02123875A0223|259 269|NH2 terminus
P02123875A0223|281 286|region
P02123875A0223|290 299|+1 position
P02123875A0223|303 307|model
P02123875A0223|336 343|delta pro
P02123875A0223|343 349|apoA-II
P02123877A1452|20 24|c-fos
P02123877A1452|28 37|egr-1 mRNAs
P02123877A1452|60 65|levels
P02123877A1452|78 87|liver cells
P02123877A1452|88 92|fos-B
P02123877A1452|93 97|fra-1
P02123877A1452|101 105|egr-2
P02123877A1452|129 135|factors
P02123877A1452|138 145|addition
P02123877A1452|151 169|serum response factor
P02123877A1452|186 195|regulation
P02123877A1452|213 225|gene induction
P02124433A0235|5 12|patients
P02124433A0235|16 20|cases
P02124433A0235|33 43|description
P02124433A0235|46 52|patient
P02124433A0235|54 63|background
P02124433A0235|77 82|Group A
P02124433A0235|83 89|surgery
P02124433A0235|102 113|chemotherapy
P02124433A0235|115 119|cases
P02124433A0235|120 125|group B
P02124433A0235|126 132|surgery
P02124433A0235|147 152|OK-432
P02124433A0235|157 174|immunochemotherapy
P02124433A0235|180 185|group C
P02124433A0235|186 192|surgery
P02124710A0193|10 17|proteins
P02124710A0193|30 34|c-fos
P02124710A0193|38 56|c-jun protooncogenes
P02124710A0193|78 96|proliferation period
P02124710A0193|99 128|osteoblast phenotype development
P02124710A1624|4 8|model
P02124710A1624|29 35|binding
P02124710A1624|41 54|Fos-Jun complex
P02124710A1624|59 66|AP-1 site
P02124710A1624|72 80|type alpha
P02124710A1624|82 97|collagen promoter
P02125016A0145|17 22|agents
P02125016A0145|36 46|SOS response
P02125153A0410|16 22|relapse
P02125153A0410|32 40|treatment
P02125153A0410|52 56|years
P02125153A0410|101 110|Z5 patients
P02125153A0410|110 118|organisms
P02125153A0410|130 141|streptomycin
P02125153A0410|145 153|isoniazid
P02126417A0408|5 12|controls
P02126417A0408|65 79|control subjects
P02126417A0408|105 114|hemisphere
P02126417A0408|114 122|advantage
P02126504A0602|10 22|Rh-antibodies
P02126504A0602|47 55|mechanism
P02126504A0602|77 85|Rh-system
P02129338A0568|10 26|amino acid sequence
P02129338A0568|41 48|homology
P02129338A0568|63 96|alga Scenedemus obliquus plastocyanin
P02131652A0883|13 37|serum gastrin concentration
P02131652A0883|58 63|ng.l-1
P02131652A0883|86 99|gastrin release
P02131652A0883|100 107|AUC0-120
P02131652A0883|130 138|ng.l-1 min
P02131652A0883|156 161|VTP-HM
P02131652A0883|171 177|VTP-Cas
P02131666A0483|15 19|group
P02131666A0483|33 50|examinees class II/2
P02131666A0483|62 70|anomalies
P02131902A0000|4 8|study
P02131902A0000|33 40|location
P02131902A0000|81 90|transducer
P02131902A0000|131 139|ventricle
P02132636A0188|0 7|Subjects
P02132636A0188|25 38|schizophrenics
P02132636A0188|52 65|DST suppressors
P02132636A0188|70 83|nonsuppressors
P02133731A1572|43 47|1/TPC
P02133731A1572|88 100|control levels
P02135343A0131|6 12|article
P02135343A0131|34 43|percentage
P02135343A0131|52 60|occlusion
P02135343A0131|67 78|distribution
P02135343A0131|81 92|maloclusions
P02135343A0131|122 133|relationship
P02135343A0131|150 154|archs
P02135343A0131|167 186|ANGLE3 classification
P02135536A0621|15 19|ratio
P02135536A0621|21 33|brush abrasion
P02135536A0621|66 73|strength
P02135536A0621|103 110|hardness
P02135536A0621|118 132|water absorption
P02135536A0621|136 149|micrograms/mm3
P02135536A0621|160 179|expansion coefficient
P02135536A0621|187 195|degrees C.
P02137704A0000|15 19|group
P02137704A0000|40 47|patients
P02137704A0000|65 72|strength
P02137704A0000|75 85|association
P02137704A0000|100 124|blood pressure measurements
P02137704A0000|156 168|blood pressure
P02137704A0000|191 197|morning
P02137704A0000|204 216|blood pressure
P02137704A0000|225 235|office visit
P02137704A0000|243 255|blood pressure
P02137704A0000|266 276|office visit
P02137704A0000|284 296|blood pressure
P02137704A0000|324 330|indices
P02137704A0000|352 368|target organ damage
P02137704A0000|379 386|diameter
P02137704A0000|416 423|diameter
P02137704A0000|432 444|wall thickness
P02137704A0000|453 465|wall thickness
P02137704A0000|474 486|wall thickness
P02137704A0000|511 519|mass index
P02137704A0000|530 547|wall thickness/left
P02137704A0000|568 580|diameter ratio
P02138707A0198|38 64|lambda gt11 expression library
P02138707A0198|71 81|protein mXBP
P02138707A0198|95 102|sequence
P02138707A0198|136 140|class
P02138707A0198|147 185|histocompatibility complex A alpha gene X box
P02138707A0198|196 215|transcription element
P02138707A0198|234 238|class
P02138707A0198|241 245|genes
P02138915A1060|3 9|p36 gene
P02138915A1060|27 32|length
P02138915A1060|45 52|sequence
P02138915A1060|125 132|ABSTRACT
P02138915A1060|147 151|WORDS
P02138992A0911|17 25|treatment
P02138992A0911|55 60|tumors
P02138992A0911|80 91|modification
P02138992A0911|123 130|approach
P02139473A1603|88 104|Fur concentrations
P02139473A1603|124 129|region
P02139473A1603|161 182|Shine-Dalgarno sequence
P02139891A0532|8 15|promoter
P02139891A0532|52 64|activators EIA
P02139891A0532|88 95|elements
P02139891A0532|96 104|TAGA motif
P02139891A0532|119 125|TATA box
P02139891A0532|129 137|EIIF sites
P02139891A0532|157 167|orientation
P02139891A0532|173 184|ATF/CREB site
P02141425A0175|15 32|fingertip-to-floor
P02141425A0175|39 44|method
P02141425A0175|44 51|patients
P02141425A0175|60 64|stool
P02141425A0175|85 96|measurements
P02141425A0175|109 116|patients
P02141425A0175|137 141|floor
P02141425A0175|158 162|level
P02141425A0175|168 172|floor
P02142240A0506|13 23|differences
P02142240A0506|37 49|response rates
P02142240A0506|64 76|concentration
P02142240A0506|79 95|estrogen receptors
P02142240A0506|98 105|presence
P02142240A0506|108 127|progesteron receptors
P02142240A0506|134 138|group
P02142240A0506|141 148|patients
P02142486A0367|0 10|Teicoplanin
P02142486A0367|47 51|fever
P02142486A0367|74 84|bacteraemia
P02142486A0367|92 100|one-third
P02142486A0367|108 112|cases
P02142921T0000|11 47|hormone-releasing hormone analog therapy
P02142921T0000|57 63|fibroid
P02142921T0000|64 71|analysis
P02142921T0000|74 80|results
P02142921T0000|93 101|buserelin
P02142921T0000|129 137|goserelin
P02142921T0000|174 178|depot
P02142955A0248|2 12|Experiments
P02142955A0248|18 24|infants
P02142955A0248|29 34|adults
P02142955A0248|60 66|objects
P02142955A0248|72 76|basis
P02142955A0248|87 96|appearance
P02142955A0248|125 133|exemplars
P02142955A0248|139 144|delays
P02142993A0176|11 17|picture
P02142993A0176|23 29|disease
P02142993A0176|81 93|leishmaniasis
P02142993A0176|102 110|L. tropica
P02142993A0176|132 139|patterns
P02142993A0176|148 157|L. infantum
P02142993A0176|176 182|pattern
P02142993A0176|196 201|France
P02143023A0729|18 32|octamer elements
P02143023A0729|38 53|adenovirus genome
P02143023A0729|82 94|transcription
P02143023A0729|103 117|octamer elements
P02143023A0729|136 150|repeat sequences
P02143186A0867|2 11|comparison
P02143186A0867|21 27|introns
P02143186A0867|62 67|intron
P02143186A0867|83 88|region
P02143186A0867|99 104|intron
P02143186A0867|120 131|coding region
P02143186A1306|0 19|Northern blot analysis
P02143186A1306|33 40|AHA2 mRNA
P02143186A1306|101 106|levels
P02143186A1306|108 117|root tissue
P02143186A1306|132 142|shoot tissue
P02143768T0000|0 8|Impaction
P02143768T0000|11 25|gastrostomy tube
P02143961A0400|4 18|antidepressants
P02143961A0400|30 42|pain threshold
P02143961A0400|55 66|pretreatment
P02143961A0400|94 102|analgesia
P02144558A1022|1 15|needs assessment
P02144558A1022|23 30|families
P02144610A1306|0 7|TCR alpha
P02144610A1306|11 28|beta gene expression
P02144610A1306|59 64|T-cell
P02144610A1306|71 78|proteins
P02144610A1306|88 92|T beta
P02144610A1306|94 100|element
P02144610A1306|122 132|AMP response
P02144610A1306|147 154|proteins
P02144610A1306|176 181|T alpha
P02144610A1306|183 189|element
P02144610A1306|200 215|TCR alpha enhancer
P02144610A1306|222 235|decamer element
P02144610A1306|251 256|number
P02144610A1306|273 288|TCR beta promoters
P02145195A0253|4 12|stem-loop
P02145195A0253|32 40|structure
P02145195A0253|46 52|species
P02145195A0253|84 94|binding site
P02145195A0253|98 107|Sm proteins
P02145268A0746|10 27|nucleotide sequence
P02145268A0746|42 50|sequences
P02145268A0746|57 63|analogy
P02145268A0746|69 80|organization
P02145268A0746|93 105|collagen genes
P02145268A0746|144 153|COL3A1 gene
P02145268A1454|5 10|losses
P02145268A1454|24 33|resistance
P02145268A1454|36 49|EDS-IV collagen
P02145268A1454|52 66|cyanogen bromide
P02145268A1454|79 98|collagenase digestion
P02146266A0000|13 33|BamHI-HindIII fragment
P02146266A0000|51 93|Neurospora crassa CuZn superoxide dismutase gene
P02146266A0000|110 114|sod-1
P02146266A0000|138 144|library
P02146266A0000|160 185|deoxyoligonucleotide probes
P02146266A0000|213 237|N. crassa amino acid sequence
P02146495A0706|8 15|peptides
P02146495A0706|55 60|region
P02146495A0706|83 101|leucine zipper domain
P02146495A0706|113 118|dimers
P02147223A1047|2 9|contrast
P02147223A1047|28 40|c-fos promoter
P02147223A1047|99 107|PC12 cells
P02147422A0000|51 68|U1-70K snRNP protein
P02148219A0508|19 28|hypothesis
P02148219A0508|62 66|facts
P02148219A0508|77 84|rigidity
P02148219A0508|94 101|extensor
P02148219A0508|105 110|flexor
P02148219A0508|128 134|muscles
P02148291A0173|25 43|HSE oligonucleotides
P02148291A0173|49 53|types
P02148291A0173|56 61|clones
P02148291A0173|75 91|HSE binding domains
P02148291A0173|109 141|tomato lambda gt11 expression library
P02148291A0173|154 162|screening
P02148508A0374|0 4|Fluid
P02148508A1478|3 9|results
P02148508A1478|33 41|principle
P02148508A1478|57 64|patients
P02148508A1478|98 105|patterns
P02148799A0000|3 9|nmr gene
P02148799A0000|49 70|nitrogen control circuit
P02148799A0000|72 87|Neurospora crassa
P02148799A0000|123 127|genes
P02148799A0000|138 147|expression
P02148799A0000|176 180|genes
P02148799A0000|186 192|circuit
P02149487A0348|4 35|days dexamethasone suppression test
P02149487A0348|51 62|% suppression
P02149487A0348|65 95|dehydroepiandrosterone-sulphate
P02149487A0348|115 123|reduction
P02149487A0348|125 136|testosterone
P02149487A0348|140 160|androstenedione levels
P02149566A0478|3 7|ratio
P02149566A0478|10 18|P-31 NMR-S
P02149566A0478|35 44|phosphates
P02149566A0478|51 65|phosphocreatine
P02149566A0478|103 112|LVH baboons
P02149570T0000|9 16|necrosis
P02149570T0000|31 48|protein S deficiency
P02150473T0067|8 12|study
P02151229A0000|0 7|Regional
P02151229A0000|16 24|blood flow
P02151229A0000|41 72|N-isopropyl-123I-iodoamphetamine
P02151229A0000|90 97|emission
P02151229A0000|106 115|tomography
P02151229A0000|128 135|patients
P02151229A0000|159 174|diabetes mellitus
P02151229A0000|175 179|NIDDM
P02151229A0000|196 200|years
P02151229A0000|207 226|fasting plasma glucose
P02151229A0000|230 235|mmol/L
P02151229A0000|252 259|subjects
P02151229A0000|264 268|years
P02151229A0000|272 277|mmol/L
P02151229A0921|0 15|Mean ROI-A/B ratio
P02151229A0921|42 46|group
P02151229A0921|97 101|group
P02153243A0965|37 43|product
P02153243A0965|48 56|int-2 gene
P02153243A0965|76 103|fibroblast growth factor family
P02153243A0965|119 124|factor
P02153243A0965|148 153|tumors
P02153683A1579|4 9|result
P02153683A1579|31 39|complexes
P02153683A1579|55 61|ankyrin
P02153683A1579|65 70|fodrin
P02153683A1579|81 90|uvomorulin
P02153683A1579|98 103|ATPase
P02153977A0364|5 9|genes
P02153977A0364|32 36|hours
P02153977A0364|42 51|initiation
P02153977A0364|54 64|development
P02153977A0364|70 74|mRNAs
P02153977A0364|117 127|culmination
P02154467A0709|3 12|PC2 protein
P02154467A0709|27 36|similarity
P02154467A0709|64 71|sequence
P02154467A0709|82 97|furin gene product
P02154467A0709|137 144|molecule
P02154474A1504|20 28|sequences
P02154474A1504|39 56|cAMP responsiveness
P02154474A1504|77 84|P-450scc
P02154474A1504|109 118|P-450 genes
P02154599A0382|6 10|study
P02154599A0382|17 28|footprinting
P02154599A0382|32 59|gel mobility retardation assays
P02154599A0382|94 110|Zta fusion proteins
P02154599A0382|141 146|motifs
P02154599T0000|3 19|zta transactivator
P02154599T0000|30 38|induction
P02154599T0000|46 64|cycle gene expression
P02154599T0000|93 103|lymphocytes
P02154599T0000|124 131|ZRE sites
P02154599T0000|133 146|target promoter
P02154599T0000|150 164|enhancer regions
P02154602A0092|12 18|homolog
P02154602A0092|24 37|mouse Mx protein
P02154602A0092|48 57|resistance
P02154602A0092|60 73|influenza virus
P02154686A0185|0 8|Fragments
P02154686A0185|34 45|repeat region
P02154686A0185|49 56|enhancer
P02154686A0185|65 69|virus
P02154686A0185|96 122|beta-galactosidase synthesis
P02154686A0185|131 139|fragments
P02154686A0185|147 172|polyomavirus enhancer region
P02154686A0185|191 196|levels
P02154885A0153|3 7|sites
P02154885A0153|19 29|mutagenesis
P02154885A0153|30 37|residues
P02154885A0153|79 91|loop structure
P02154885A0153|112 131|substrate recognition
P02154885A0153|137 142|enzyme
P02155017A1106|11 18|benefits
P02155017A1106|21 30|LMW heparin
P02155017A1106|38 46|frequency
P02155017A1106|49 56|bleeding
P02155017A1106|57 67|alleviation
P02155017A1106|70 89|hypertriglyceridemia
P02155017A1106|137 153|observation period
P02155017A1106|163 171|incidence
P02155017A1106|185 197|complications
P02155017A1106|207 214|dialyses
P02156828A0164|10 26|amino acid sequence
P02156828A0164|29 35|destrin
P02156828A0164|41 48|residues
P02156828A0164|90 96|cofilin
P02156828A0164|142 148|protein
P02157067A0610|0 6|Summers
P02157067A0610|7 14|Virology
P02157141A0923|16 23|T antigen
P02157141A0923|29 36|presence
P02157141A0923|39 51|topoisomerase
P02157141A0923|87 95|sequences
P02157141A0923|152 158|changes
P02157141A0923|189 197|base pairs
P02157764A1115|1 15|rabbit antiserum
P02157764A1115|42 48|peptide
P02157764A1115|76 82|portion
P02157764A1115|104 115|cDNA sequence
P02157882T0000|0 11|Conservation
P02157882T0000|14 21|function
P02157882T0000|65 72|proteins
P02157882T0000|74 87|transformation
P02157882T0000|99 103|cells
P02158099A0487|11 30|cotransfection assays
P02158099A0487|36 50|Chang liver cells
P02158099A0487|58 63|pM1 DNA
P02158099A0487|96 101|effect
P02158099A0487|107 116|expression
P02158099A0487|122 143|pSV2CAT reporter plasmid
P02158927A0000|19 28|nucleotide
P02158927A0000|33 40|sequence
P02158927A0000|51 60|COR segment
P02158927A0000|77 83|cluster
P02158927A0000|89 93|genes
P02158927A0000|146 156|chromosome X
P02158927A0000|155 159|yeast
P02159470A1432|8 14|binding
P02159470A1432|20 33|protein factors
P02159470A1432|39 43|sites
P02159470A1432|62 72|Mt sequences
P02159470A1432|112 121|regulation
P02159470A1432|126 138|transcription
P02159470A1432|148 152|genes
P02159470A1432|161 168|subunits
P02159470A1432|205 219|phosphorylation
P02159559A0779|21 32|interference
P02159559A0779|48 63|DNA amplification
P02160502A0471|2 29|recombination signal sequences
P02160502A0471|58 75|recombination point
P02160622A0000|18 27|properties
P02160622A0000|43 52|tail-flick
P02160622A0000|56 69|hot-plate tests
P02160622A0000|76 87|motor effects
P02160622A0000|118 147|benzodiazepine agonist midazolam
P02160622A0000|158 168|combination
P02160622A0000|173 180|morphine
P02160955A0899|0 9|Constructs
P02160955A0899|27 32|AATAAA
P02160955A0899|46 51|region
P02160955A0899|74 82|distances
P02162049A0291|13 17|issue
P02162049A0291|30 36|factor Y
P02162049A0291|66 76|DNA sequence
P02162103A0000|23 27|cDNAs
P02162103A0000|59 72|phosphoprotein
P02162103A0000|81 97|parainfluenza type
P02162103A0000|98 102|virus
P02162103A0000|103 107|PIV-2
P02162103A0000|131 139|cDNA clone
P02162103A0000|163 173|nucleotides
P02162103A0000|175 180|length
P02162103A0000|227 239|reading frames
P02162103A0000|246 253|proteins
P02162103A0000|265 274|amino acids
P02162467A0311|10 23|cytR expression
P02162467A0311|51 61|CytR protein
P02162467A0311|88 102|cAMP/CAP complex
P02162754A0339|15 19|sites
P02162754A0339|30 46|amino acid sequence
P02162754A0339|52 81|3T3-L1 adipocyte insulin receptor
P02162754A0339|87 91|mouse
P02162754A0801|11 18|turnover
P02162754A0801|23 37|phosphoryl group
P02162754A0801|56 67|accumulation
P02162754A0801|95 112|signal transmission
P02162754A0801|120 127|receptor
P02162754A0801|133 155|glucose-transport system
P02162835A0989|17 36|sequence similarities
P02162835A0989|60 71|architecture
P02162835A0989|80 95|heme binding sites
P02162835A0989|102 118|copper binding site
P02162835A0989|126 132|enzymes
P02163347A0472|3 14|cDNA sequence
P02163347A0472|30 41|reading frame
P02163347A0472|61 77|amino acid sequence
P02163347A0472|118 127|amino acids
P02163347A0472|137 148|ets-1 protein
P02163382A0169|17 28|O7-LPS region
P02163382A0169|43 56|cosmids pJHCV31
P02163382A0169|60 66|pJHCV32
P02163382A0169|84 104|transposon mutagenesis
P02163382A0169|109 116|Tn3HoHo1
P02163382A0169|142 150|lac operon
P02163382A0169|195 201|fusions
P02163382A0169|205 222|target DNA sequences
P02163394T0000|3 10|sacT gene
P02163394T0000|24 34|sacPA operon
P02163394T0000|37 58|Bacillus subtilis shares
P02163394T0000|65 72|homology
P02163394T0000|92 106|antiterminators
P02164585A0416|3 13|TraD protein
P02164585A0416|48 54|regions
P02164585A0416|95 100|region
P02164585A0814|3 16|protein product
P02164585A0814|44 50|tra gene
P02164585A0814|84 93|amino acids
P02164585A0814|108 114|alanine
P02164585A0814|118 124|leucine
P02164588A0266|13 19|HN genes
P02164588A0266|55 62|residues
P02164588A0266|86 91|domain
P02164588A0266|123 130|assembly
P02164588A0266|146 154|transport
P02164588A0266|160 173|HN glycoprotein
P02164604A0399|3 9|studies
P02164604A0399|21 28|findings
P02164604A0399|43 63|E2 transactivation gene
P02164604A0399|87 95|promoters
P02164604A1574|11 18|analysis
P02164604A1574|24 33|E2 proteins
P02164604A1574|50 58|cell lines
P02164604A1574|76 87|BPV-1 mutants
P02164604A1574|104 117|acceptor mutant
P02164604A1574|137 141|modes
P02164604A1574|144 155|E2 expression
P02164637A0515|0 9|Disruption
P02164637A0515|15 22|IRA2 gene
P02164637A0515|43 53|sensitivity
P02164637A0515|56 64|heat shock
P02164637A0515|68 85|nitrogen starvation
P02164637A0515|88 105|sporulation defects
P02164637A0515|112 122|suppression
P02164637A0515|128 136|lethality
P02164637A0515|142 152|cdc25 mutant
P02165181A0299|4 9|cohort
P02165181A0299|12 19|patients
P02165181A0299|36 40|basis
P02165181A0299|51 55|stage
P02165589A0000|54 58|2C1-3
P02165589A0000|69 75|portion
P02165589A0000|81 92|X-chromosome
P02165589A0000|101 106|member
P02165589A0000|127 152|hormone receptor superfamily
P02165589A0888|1 7|portion
P02165589A0888|10 17|Region II
P02165589A0888|47 62|c-jun oncoprotein
P02165589A0888|63 75|leucine zipper
P02165589A0888|115 136|heterodimerization site
P02165589A0888|154 168|fos oncoproteins
P02166040A0385|18 25|vanadate
P02166040A0385|38 59|PEPCK gene transcription
P02166040A0385|61 66|series
P02166040A0385|77 81|genes
P02166040A0385|99 107|deletions
P02166040A0385|128 148|carboxykinase promoter
P02166040A0385|190 194|genes
P02166040A0385|220 237|phosphotransferase
P02166040A0385|245 276|chloramphenicol acetyltransferase
P02166040A0385|293 305|hepatoma cells
P02166040A0385|316 322|methods
P02166040A0385|324 332|infection
P02166040A0385|338 344|Moloney
P02166040A0385|351 358|leukemia
P02166040A0385|370 379|retrovirus
P02166040A0385|381 392|transfection
P02166040A0385|402 410|selection
P02166040A0385|414 426|neo expression
P02166040A0385|439 448|expression
P02166040A0385|451 483|chloroamphenicol acetyltransferase
P02166416A0419|3 11|diagnosis
P02166416A0419|21 32|tuberculosis
P02166416A0419|82 87|origin
P02166825A0198|2 6|order
P02166825A0198|34 41|elements
P02166825A0198|47 54|promoter
P02166825A0198|98 104|signals
P02166825A0198|105 110|number
P02166825A0198|113 129|promoter mutations
P02166825A0198|177 185|mutations
P02166825A0198|200 213|promoter region
P02167321T0000|1 8|DNA motif
P02167321T0000|36 42|element
P02167321T0000|60 77|activator protein-2
P02167321T0000|101 143|tissue-type plasminogen activator gene promoter
P02167321T0000|159 168|expression
P02167321T0000|178 187|activation
P02167321T0000|190 201|phorbol ester
P02167467T0000|3 16|26S rRNA binding
P02167467T0000|26 42|protein equivalent
P02167467T0000|54 63|protein L11
P02167467T0000|94 98|genes
P02167784A0109|15 22|subjects
P02167784A0109|136 149|CO2 measurement
P02168640A0268|11 22|correlations
P02168640A0268|42 48|changes
P02168640A0268|59 66|response
P02168640A0268|76 83|presence
P02168640A0268|109 120|disturbances
P02168640A0268|130 135|ground
P02168640A0268|149 157|disorders
P02169887A0360|3 13|transcripts
P02169887A0360|56 67|capstructure
P02169887A0360|83 90|EMCV-RNA
P02169887A0360|101 105|mRNAs
P02169887A0360|123 132|initiation
P02170687A0000|3 15|E6/E7 promoter
P02170687A0000|33 48|papillomaviruses
P02170687A0000|65 74|expression
P02170687A0000|85 101|transforming genes
P02172672T0001|9 19|Goodpasture
P02172672T0001|20 27|syndrome
P02173399A0333|23 30|controls
P02173399A0333|45 50|blocks
P02173399A0333|63 79|tissue radiographs
P02173399A0333|104 114|specificity
P02173399A0333|120 130|sensitivity
P02173405A0270|13 23|abnormality
P02173405A0270|49 54|period
P02173405A0270|76 89|calcifications
P02174105A1232|19 26|analysis
P02174105A1232|36 44|rat organs
P02174105A1232|55 62|staining
P02174105A1232|75 79|cells
P02174427A1574|4 10|strains
P02174427A1574|51 63|carbon sources
P02174427A1574|100 142|ubiquinol-cytochrome c oxidoreductase activity
P02174861A0736|0 9|Regulation
P02174861A0736|28 37|V. cholerae
P02174861A0736|62 66|level
P02174861A0736|105 112|sequence
P02174861A0736|117 124|vicinity
P02174861A0736|130 137|promoter
P02174861A0736|168 172|sites
P02174974A0000|0 12|Transcription
P02174974A0000|23 28|operon
P02174974A0000|56 62|enzymes
P02174974A0000|68 77|TOL plasmid
P02174974A0000|113 127|xylR gene product
P02174974A0000|133 140|presence
P02174974A0000|143 150|m-xylene
P02175433A0575|31 46|beta A-globin gene
P02175433A0575|65 82|Ylp vector sequences
P02175433A0575|95 100|copies
P02175908A0805|9 17|mutations
P02175908A0805|50 63|Ulysses element
P02175908A0805|74 78|locus
P02175908A0805|115 121|element
P02175908A0805|144 151|mutation
P02176021T0000|0 12|Determination
P02176021T0000|15 20|diquat
P02176021T0000|33 41|materials
P02176021T0000|44 76|electron spin resonance spectroscopy
P02176152A0896|45 52|activity
P02176152A0896|55 66|reporter gene
P02176152A0896|93 106|AP1 binding site
P02176152A0896|116 128|HSV tk promoter
P02176209A0954|33 39|CBF DNAs
P02176209A0954|59 80|gel retardation patterns
P02176209A0954|82 89|extracts
P02176209A0954|95 101|variety
P02176209A0954|113 121|cell types
P02176232T0001|0 10|Risk factors
P02176232T0001|22 41|lymph nodes metastasis
P02176232T0001|44 53|lung cancer
P02176232T0001|58 62|stage
P02176822A0000|15 27|protein kinase
P02176822A0000|59 63|lyase
P02176822A0000|65 72|peptide B
P02176822A0000|78 82|sites
P02176822A0000|96 104|threonine
P02176822A0000|106 111|serine
P02176822A0000|124 132|inhibitor
P02176822A0000|145 151|residue
P02176822A0000|155 170|glycogen synthase
P02176822A0000|173 177|sites
P02179052A1044|27 42|sequence families
P02179052A1044|63 68|system
P02179052A1044|84 103|sequence interactions
P02179052A1044|117 125|evolution
P02179188A1223|22 36|motile responses
P02179188A1223|59 66|presence
P02179188A1223|69 81|dinitrophenol
P02179188A1223|84 97|cytochalasin B.
P02179815A0582|6 13|p59v-rel
P02179815A0582|29 35|protein
P02179815A0582|51 68|immunofluorescence
P02179815A0582|78 85|p68c-rel
P02179815A0582|136 144|cytoplasm
P02179815A0582|151 155|cells
P02179815A0582|169 176|sequence
P02179815A0582|179 186|p68c-rel
P02179815A0582|225 232|sequence
P02179815A0582|272 279|p59v-rel
P02180935A0535|7 17|experiments
P02180935A0535|59 74|precursor protein
P02180935A0535|88 97|HL-60 cells
P02180935A0535|128 169|chondroitin sulfate proteoglycan intermediate
P02181760A0311|0 8|Blood flow
P02181760A0311|12 19|velocity
P02181760A0311|33 49|Doppler ultrasound
P02181760A0311|74 81|diastole
P02181760A0311|105 113|direction
P02181760A0311|116 134|cotyledon resistance
P02182240A0355|1 5|total
P02182240A0355|11 18|patients
P02182240A0355|27 38|anistreplase
P02182240A0355|53 59|heparin
P02182240A0355|71 76|period
P02182240A0355|102 106|onset
P02182240A0355|108 115|symptoms
P02182323A0121|14 24|transcripts
P02182323A0121|90 105|growth conditions
P02182323A0121|104 111|degrees C
P02182323A0121|142 147|region
P02182618A0168|3 18|promoter activity
P02182618A0168|42 51|expression
P02182618A0168|55 86|chloramphenicol acetyltransferase
P02182618A0168|118 132|deletion mutants
P02182618A0168|144 149|region
P02183467A0668|33 38|region
P02183467A0668|65 72|location
P02183467A0668|85 94|similarity
P02183467A0668|124 128|genes
P02183467A0668|154 165|lentiviruses
P02183467A0668|224 228|exons
P02183467A0668|234 238|genes
P02185140A0000|26 33|14DM gene
P02185140A0000|42 65|cytochrome P450 lanosterol
P02185140A0000|68 84|alpha-demethylase
P02185140A0000|128 134|strains
P02185140A0000|142 148|control
P02185140A0000|174 200|yeast transcription promoters
P02185140A0000|201 205|pADC1
P02185140A0000|212 216|pPHO5
P02185140A0000|227 233|control
P02185140A0000|242 249|promoter
P02185250A0726|0 10|Truncations
P02185250A0726|28 37|amino acids
P02185250A0726|74 90|reticulum membrane
P02185250A0726|94 106|translocation
P02187091A0721|17 26|resistance
P02187091A0721|40 55|ejection fraction
P02187091A0721|86 101|relaxation period
P02187871T0000|3 11|ANB1 locus
P02187871T0000|47 84|protein synthesis initiation factor eIF-4D
P02188096A0955|3 14|contribution
P02188096A0955|30 43|splicing events
P02188096A0955|46 60|c-myb expression
P02188096A0955|70 82|c-myb function
P02188168A0000|0 8|Serum beta
P02188168A0000|24 29|levels
P02188168A0000|30 37|beta-2-M
P02188168A0000|54 64|drug addicts
P02188168A0000|85 92|carriers
P02188168A0000|99 113|HIV-1 antibodies
P02188168A0000|127 134|carriers
P02188168A0000|160 174|lymphadenopathy
P02188168A0000|175 180|P.G.L.
P02188168A0000|186 190|serum
P02188168A0000|199 206|patients
P02188168A0000|232 240|community
P02188168A0000|252 256|years
P02190122A0633|4 15|emancipation
P02190122A0633|21 27|ability
P02190122A0633|50 58|influence
P02190122A0633|76 85|motivation
P02190122A0633|96 104|regulator
P02190122A0633|107 112|mating
P02190122A0633|115 122|primates
P02190134A0572|2 8|therapy
P02190134A0572|28 38|progression
P02190134A0572|44 50|disease
P02190134A0572|66 74|exception
P02190134A0572|77 106|laser photocoagulation treatment
P02190134A0572|140 148|membranes
P02190134A0572|153 159|attempt
P02190134A0572|167 179|complications
P02190134A0572|192 202|hemorrhages
P02194273A0913|8 27|hyperimmune globulins
P02194273A0913|30 38|pathogens
P02194273A0913|56 65|influenzae
P02194273A0913|69 81|Streptococcus
P02194972T0000|11 17|effects
P02194972T0000|20 28|cefpirome
P02194972T0000|55 64|infections
P02194972T0000|68 87|Enterococcus faecalis
P02195025T0000|0 9|Regulation
P02195025T0000|12 20|yeast LEU2
P02195715A0143|10 20|individuals
P02195715A0143|35 50|purpura fulminans
P02195715A0143|53 60|newborns
P02195715A0143|73 79|protein
P02195715A0143|91 101|individuals
P02195715A0143|131 140|thrombosis
P02195715A0143|152 159|embolism
P02195715T0000|8 13|stroke
P02195715T0000|19 36|protein C deficiency
P02196176A0749|0 4|TREB7
P02196176A0749|8 13|TREB36
P02196176A0749|31 37|repeats
P02196176A0749|52 56|TREB5
P02196176A0749|78 83|repeat
P02196311A1034|5 11|results
P02196311A1034|24 29|KE X 3/W
P02196311A1034|45 51|regimen
P02196311A1034|64 80|antitumor immunity
P02196450A0870|0 7|Analysis
P02196450A0870|17 31|deletion mutants
P02196450A0870|48 67|sequence requirements
P02196450A0870|71 77|binding
P02196450A0870|133 141|Q activity
P02196450A0870|190 197|function
P02196450A0870|219 226|promoter
P02196565A0606|22 28|factor I
P02196565A0606|34 70|repressor/activator site binding protein
P02196565A0606|76 86|translation
P02196565A0606|94 99|factor
P02196565A0606|121 129|activator
P02196565A0606|131 148|MAT alpha expression
P02196565A0606|199 211|GRFI/RAP1/TUF
P02196565A0606|230 242|gal11 mutation
P02196565T0000|0 16|Yeast Gal11 protein
P02196565T0000|43 58|activation signal
P02196565T0000|84 90|factors
P02196565T0000|117 174|factor I/repressor/activator site binding protein 1/translation
P02196565T0000|182 187|factor
P02198259A0685|0 7|Deletion
P02198259A0685|57 62|codons
P02198259A0685|93 104|reading frame
P02198259A0685|116 124|initiator
P02198259A0685|144 151|activity
P02198289A0436|12 19|peptides
P02198289A0436|33 42|amino acids
P02198289A0436|69 78|amino acids
P02198289A0436|91 96|dimers
P02198289A0436|99 106|solution
P02198289A0436|135 139|dimer
P02199311A0620|7 27|transcription extracts
P02199311A0620|32 42|ret1-1 cells
P02199311A0620|73 103|transcription termination signals
P02199311A0620|117 125|RET1 cells
P02199311A0620|132 138|variety
P02199311A0620|141 153|tRNA templates
P02200150A1381|7 14|patients
P02200150A1381|20 27|decision
P02200150A1381|84 93|oncologist
P02200150A1381|93 102|geneticist
P02200150A1381|103 113|pathologist
P02200150A1381|114 128|psychotherapist
P02200150A1381|132 145|plastic surgeon
P02200315A0278|8 26|IgM antibody activity
P02200315A0278|53 60|dilution
P02200315A0278|63 67|serum
P02200315A0278|70 75|plates
P02200315A0278|86 95|A60 antigen
P02200736A1003|5 11|factors
P02200736A1003|47 55|molecules
P02200736A1003|92 104|CACCTGTC motif
P02200736A1003|112 120|sequences
P02201770A0188|10 19|flea larvae
P02201770A0188|23 40|genus Anomiopsyllus
P02201770A0188|41 55|Anomiopsyllinae
P02201770A0188|56 69|Anomiopsyllini
P02201770A0188|107 112|adults
P02201901A0229|22 29|antibody
P02201901A0229|58 68|SSN6 protein
P02201905A1004|11 17|results
P02201905A1004|31 41|ABFI protein
P02201905A1004|49 59|RAP1 protein
P02201905A1004|65 73|sequences
P02201905A1004|109 118|regulation
P02201905A1004|121 134|gene expression
P02202496T0000|8 16|nutrition
P02202496T0000|24 29|horses
P02203672A1542|22 35|cytocentrifuge
P02204029A0184|0 20|RNase protection assays
P02204029A0184|68 76|direction
P02204029A0184|77 81|N-ras
P02204029A0184|114 122|base pairs
P02204029A0184|133 137|point
P02204029A0184|150 162|transcription
P02204621T0000|0 8|Isolation
P02204621T0000|33 38|mutant
P02204621T0000|52 77|tRNA nucleotidyltransferase
P02204621T0000|81 87|cloning
P02204621T0000|107 132|tRNA nucleotidyltransferase
P02204621T0000|137 141|yeast
P02204623A0000|3 21|juxtamembrane region
P02204623A0000|27 41|insulin receptor
P02204623A0000|46 57|beta-subunit
P02204623A0000|83 96|tyrosyl residue
P02204623A0000|97 102|Tyr960
P02204623A0000|139 160|tyrosyl phosphorylation
P02204623A0000|177 186|substrates
P02204623A0000|207 215|responses
P02204623A0000|216 220|White
P02204623A0000|227 236|Livingston
P02204623A0000|242 247|Backer
P02204623A0000|253 258|Lauris
P02204623A0000|274 280|Ullrich
P02204625A1130|18 22|group
P02204625A1130|24 28|genes
P02204625A1130|34 40|members
P02204625A1130|64 71|response
P02204625A1130|74 80|insulin
P02204625A1130|89 96|mitogens
P02204810A1080|4 9|region
P02204810A1080|36 45|expression
P02206430A0197|24 34|environment
P02206430A0197|43 49|mothers
P02206430A0197|73 77|level
P02206430A0197|80 89|DA turnover
P02206789A0002|3 10|efficacy
P02206789A0002|14 19|safety
P02206789A0002|40 61|anaesthetic preparation
P02206789A0002|69 79|amethocaine
P02206789A0002|122 132|environment
P02206858A0000|10 17|protein C
P02206858A0000|22 31|deficiency
P02206858A0000|46 53|siblings
P02206858A0000|90 98|diagnoses
P02206858A0000|125 129|years
P02208762A0228|3 13|grandfather
P02208762A0228|20 32|granddaughter
P02208762A0228|40 47|microtia
P02208762A0228|57 63|atresia
P02208762A0228|74 81|daughter
P02208762A0228|118 123|meatus
P02208762A0228|135 144|appendages
P02209237A0239|22 29|shunting
P02209237A0239|52 56|cases
P02209237A0239|80 87|scanning
P02209237A0239|92 100|99mTc-MAA
P02209237A0239|122 126|cause
P02209237A0239|129 136|cyanosis
P02209237A0239|139 152|liver cirrhosis
P02209243A0237|10 16|protein
P02209243A0237|17 28|serum albumin
P02209243A0237|63 73|improvement
P02209540A1362|41 53|transcription
P02209540A1362|62 66|genes
P02209605A0510|10 17|sequence
P02209605A0510|21 28|MSAS gene
P02209605A0510|61 72|reading frame
P02209605A0510|83 89|protein
P02209605A0510|96 105|amino acids
P02209811T0000|11 20|peroxidase
P02209811T0000|24 41|permeability marker
P02209811T0000|51 59|rat caudal
P02209811T0000|63 75|iliac arteries
P02212540A0473|19 31|wall specimens
P02212540A0473|60 65|ulcers
P02212540A0473|100 114|light microscopy
P02212540A0473|120 149|transmission electron microscopy
P02213566A0000|3 9|effects
P02213566A0000|12 22|coenzyme Q10
P02213566A0000|31 39|captopril
P02213566A0000|51 58|capacity
P02213566A0000|59 70|hemodynamics
P02213566A0000|74 81|survival
P02213566A0000|144 153|infarction
P02217307T0000|0 7|Evidence
P02217307T0000|23 33|alterations
P02217307T0000|46 51|rhythm
P02217307T0000|62 77|emptying response
P02217741T0001|3 15|interrelation
P02217741T0001|21 26|levels
P02217741T0001|29 43|glucocorticoids
P02217741T0001|47 53|insulin
P02217741T0001|59 63|blood
P02217741T0001|76 82|animals
P02218094A0395|16 21|tissue
P02218094A0395|24 31|transfer
P02218094A0395|54 64|utilization
P02219751A0517|9 16|saccades
P02219751A0517|64 68|basis
P02219751A0517|70 74|speed
P02220102A0271|0 8|Incidence
P02220102A0271|26 30|grade
P02220102A0271|37 46|hygiene und
P02220102A0271|58 64|disease
P02220304A0501|3 7|study
P02220304A0501|28 32|Alcoy
P02220304A0501|35 52|medium MS risk region
P02220304A0501|67 72|thesis
P02220304A0501|75 80|Kurzke
P02220304A0501|93 99|MS areas
P02220304A0501|128 141|MS distribution
P02220304A0501|152 157|Europe
P02223652A0939|4 24|antithrombin unit basis
P02223773A0000|0 34|Chick brain actin depolymerizing factor
P02223773A0000|49 55|protein
P02223773A0000|65 78|actin filaments
P02223773A0000|87 99|actin monomers
P02223928T0069|7 16|experience
P02223928T0069|22 37|serotonin agonist
P02225687A0546|0 16|Comprehensive care
P02225687A0546|22 28|patient
P02225687A0546|44 52|teratogen
P02225687A0546|67 76|discussion
P02225687A0546|97 106|procedures
P02225687A0546|115 140|pregnancy management options
P02227438A0492|0 22|Primer extension analysis
P02227438A0492|26 38|RNA sequencing
P02227438A0492|58 80|transcription start point
P02227438A0492|83 92|rat ODC mRNA
P02227438A0492|124 131|A residue
P02227438A0492|136 145|start codon
P02228615A0974|29 52|distribution coefficients
P02228615A0974|69 89|desorption experiments
P02228615A0974|92 101|indication
P02228615A0974|119 127|formation
P02228615A0974|130 148|metal-oxyhydroxides
P02228615A0974|160 167|reaction
P02229068A0156|0 13|Gene constructs
P02229068A0156|58 65|env genes
P02229068A0156|88 97|COS-1 cells
P02229068A0156|100 113|precursor SU-TM
P02229068A0156|114 118|gp160
P02229068A0156|152 157|gp120 x
P02229068A0156|171 180|rev protein
P02229072A1012|4 15|growth arrest
P02229072A1012|43 48|medium
P02229072A1012|56 65|conditions
P02229072A1012|76 80|cells
P02229072A1012|112 121|metabolism
P02229282A0454|0 7|Patients
P02229282A0454|22 35|serum TNF levels
P02229282A0454|57 77|serum T3 concentrations
P02229282A0454|109 114|levels
P02229541T0000|0 4|Giant
P02229541T0000|15 23|carcinoma
P02229541T0000|24 29|report
P02229541T0000|33 38|review
P02229541T0000|44 53|literature
P02231162T0000|7 13|studies
P02231162T0000|26 33|movement
P02231162T0000|43 54|tooth contact
P02231479A0585|4 9|parent
P02231479A0585|49 56|daughter
P02231479A0585|67 79|conversations
P02231479A0585|98 109|conversation
P02231479A0585|123 134|task activity
P02233626T0000|32 39|symptoms
P02233626T0000|63 79|strabismus surgery
P02233680A1115|5 11|results
P02233680A1115|41 48|elements
P02233680A1115|73 79|control
P02233680A1115|85 106|HaG3-A helianthinin gene
P02233680A1115|135 140|region
P02233715A0914|3 11|induction
P02233715A0914|14 30|pseudorabies virus
P02233715A0914|35 47|IL-6 construct
P02233715A0914|61 71|IL-6 TATA box
P02233715A0914|78 89|RNA start site
P02233715A0914|90 98|initiator
P02233715A0914|104 110|element
P02233715A0914|120 128|MRE region
P02233715A0914|157 164|presence
P02233729A1065|4 12|mutations
P02233729A1065|41 46|manner
P02233729A1065|65 74|startpoint
P02233729A1065|90 104|Dhfr transcripts
P02233729A1065|126 134|abundance
P02233729A1065|148 162|Dhfr transcripts
P02234345A0215|8 15|cyst wall
P02234345A0215|53 62|epithelium
P02234731A0503|14 18|class
P02234731A0503|29 34|smears
P02234731A0503|55 66|inflammation
P02234731A0503|86 93|findings
P02234731A0503|96 106|condylomata
P02234731A0503|118 126|dysplasia
P02236002A0958|4 10|mammals
P02236002A0958|23 41|nucleotide diversity
P02236002A0958|58 66|junctions
P02236002A0958|80 88|diversity
P02236002A0958|99 106|elements
P02236002A0958|109 127|chicken TCR beta cDNAs
P02236022A0000|3 20|protooncogene c-myb
P02236022A0000|36 54|transcription factor
P02236022A0000|91 96|manner
P02236022A0000|113 125|transcription
P02236022A0000|151 155|genes
P02236060A1671|0 11|Modification
P02236060A1671|24 31|compound
P02236060A1671|53 58|amount
P02236060A1671|95 101|protein
P02236064A1178|0 17|S6 kinase activation
P02236064A1178|26 37|displacement
P02236064A1178|54 60|segment
P02236064A1178|106 120|phosphorylation
P02236276T0000|54 58|naris
P02236276T0000|72 76|odors
P02237431A0000|0 9|Expression
P02237431A0000|20 32|T cell receptor
P02237431A0000|38 46|alpha gene
P02237431A0000|91 98|enhancer
P02237431A0000|114 122|kilobases
P02237431A0000|133 149|C alpha gene segment
P02237431A0833|3 18|Ets-1 binding site
P02237431A0833|51 56|region
P02237431A0833|70 75|T alpha
P02241742A0766|17 26|resistance
P02241742A0766|37 46|reductions
P02241892A0681|0 10|Utilization
P02241892A0681|24 45|polyadenylation signals
P02241892A0681|88 92|mRNAs
P02241892A0681|124 129|length
P02241892A0681|149 155|regions
P02242222T0000|12 18|address
P02243093A0000|5 27|T-cell leukemia virus type
P02243093A0000|29 34|HTLV-I
P02243093A0000|56 62|protein
P02243093A0000|83 95|transcription
P02243093A0000|121 127|repeats
P02243093A0000|131 138|U3 region
P02243386A0113|26 31|serial
P02243386A0113|41 48|passages
P02243386A0113|62 66|DI RNA
P02243386A0113|66 70|DIssF
P02243386A0113|101 107|virions
P02246362T0000|3 23|Jenkins Activity Survey
P02246362T0000|48 55|evidence
P02246362T0000|87 92|traits
P02246447A0460|8 15|evidence
P02246447A0460|28 43|regression slopes
P02246447A0460|70 81|portion sizes
P02246447A0460|93 102|food groups
P02246447A0460|111 118|r2 values
P02246447A0460|133 144|portion sizes
P02246803A0692|3 8|result
P02246803A0692|37 45|TTD method
P02246803A0692|108 113|output
P02247069A0261|3 10|TUP1 gene
P02247069A0261|25 30|screen
P02247069A0261|34 38|genes
P02247069A0261|51 60|mating type
P02247072A0794|3 25|SUP44 suppressor mutation
P02247072A0794|37 42|region
P02247072A0794|48 54|protein
P02247072A0794|80 88|positions
P02247072A0794|91 101|alterations
P02247072A0794|112 123|ram mutations
P02247081A0223|13 22|disruption
P02247081A0223|28 37|VPS34 locus
P02247081A0223|70 81|growth defect
P02247081A0223|99 107|VPS34 gene
P02247081A0223|132 137|growth
P02247081A0223|152 169|growth temperatures
P02247924A0078|31 37|abscess
P02247924A0078|48 60|amphotericin B
P02247924A0078|64 74|nephrectomy
P02248732A1113|37 47|haloperidol
P02248732A1113|67 74|increase
P02248732A1113|80 89|firing rate
P02248732A1113|92 98|LC cells
P02248732A1113|140 147|turnover
P02248732A1113|165 176|DOPAC changes
P02249872A1051|4 14|interaction
P02249872A1051|30 34|range
P02249872A1051|41 50|parameters
P02249872A1051|54 66|charge density
P02249872A1051|85 94|microC/cm2
P02249872A1051|101 106|charge
P02249872A1051|110 114|phase
P02249872A1051|135 140|microC
P02249872A1051|144 148|phase
P02250919A0404|0 10|Perceptions
P02250919A0404|13 32|illness intrusiveness
P02250919A0404|64 74|muscle cramp
P02250919A0404|78 93|headache symptoms
P02250919A0404|117 135|assessment intervals
P02250919A0404|152 163|muscle cramps
P02250919A0404|166 174|headaches
P02251119A0319|0 6|Results
P02251119A0319|34 41|presence
P02251119A0319|70 76|regions
P02251119A0319|92 98|introns
P02251119A0319|110 114|mouse
P02251119A0319|122 139|hsc70 heat shock gene
P02252891T0000|13 19|protein
P02252891T0000|36 46|interleukin
P02252891T0000|48 58|stimulation
P02252891T0000|88 92|sites
P02252891T0000|114 118|sites
P02252953A0300|19 23|girls
P02252953A0300|47 54|EAT score
P02252953A0300|76 80|girls
P02252953A0300|99 105|mothers
P02252953A0300|107 120|susceptibility
P02252953A0300|139 145|effects
P02252953A0300|156 165|mood states
P02252953A0300|173 187|eating behaviour
P02253274A0000|3 14|Mauriceville
P02253274A0000|18 23|Varkud
P02253274A0000|37 44|plasmids
P02253274A0000|116 130|characteristics
P02253274A0000|131 142|mtDNA introns
P02253274A0000|153 160|elements
P02253663A0687|12 17|rhythm
P02253663A0687|45 54|difference
P02253663A0687|62 68|minimum
P02253663A0687|80 86|maximum
P02253663A0687|94 112|serum concentrations
P02254282T0000|0 7|Sequence
P02254282T0000|18 29|organization
P02254282T0000|33 59|Zymomonas mobilis gene cluster
P02254282T0000|78 84|enzymes
P02254282T0000|87 103|glucose metabolism
P02254418A0641|4 10|strains
P02254418A0641|17 29|S. lugdunensis
P02254418A0641|38 51|delta hemolysin
P02254418A0641|77 83|species
P02254749A0133|7 11|cDNAs
P02254749A0133|44 54|170K protein
P02254749A0133|58 66|sequences
P02254749A0133|89 101|ATG start codon
P02254749A0133|138 145|sequence
P02254749A0133|158 162|codon
P02254749A0133|194 201|sequence
P02256678A1224|21 40|footprinting analysis
P02256678A1224|54 59|region
P02256678A1224|88 96|HSC82 gene
P02256678A1224|107 114|presence
P02256678A1224|130 145|protein complexes
P02257251T0000|0 14|Pathophysiology
P02257251T0000|17 24|bone loss
P02257251T0000|36 42|animals
P02257899T0000|15 25|interaction
P02257899T0000|31 40|generation
P02257899T0000|43 50|saccades
P02258918A0242|25 30|slices
P02258918A0242|46 54|disectors
P02258918A0242|90 105|sampling fraction
P02259334A0205|11 18|promoter
P02259334A0205|43 50|sequence
P02259334A0205|80 86|protein
P02259334A0205|108 115|function
P02259795A0570|10 20|consumption
P02259795A0570|56 67|calculations
P02259795A0570|81 88|water PO2
P02259795A0570|99 102|mm Hg
P02259795A0570|130 135|uptake
P02261254A0168|0 10|Experiments
P02261254A0168|30 35|arrest
P02261254A0168|47 57|circulation
P02261254A0168|63 72|conditions
P02261254A0168|89 99|circulation
P02261254A0168|115 125|development
P02261254A0168|128 135|ischemia
P02261254A0168|161 166|tissue
P02262439A0508|0 10|MCh infusion
P02262439A0508|41 48|increase
P02262439A0508|51 66|airway resistance
P02264601A0000|0 19|Taste reactivity tests
P02264601A0000|49 57|responses
P02264601A0000|60 66|alcohol
P02264601A0000|89 108|alcohol nonpreferring
P02264601A0000|122 126|taste
P02264601A0000|127 133|alcohol
P02265055A0417|0 19|Plasma concentrations
P02265055A0417|22 31|atracurium
P02265055A0417|35 45|laudanosine
P02265055A0417|58 71|micrograms ml-1
P02265055A0417|83 96|micrograms ml-1
P02265055A0417|109 124|CSF concentration
P02265055A0417|127 137|laudanosine
P02265055A0417|147 152|ng ml-1
P02266679A0740|0 7|Plasma Al
P02266679A0740|29 36|baseline
P02266679A0740|40 49|drug course
P02268461A0224|3 10|survival
P02268461A0224|29 36|patients
P02268461A0224|50 54|years
P02269281A1276|3 12|occurrence
P02269281A1276|13 23|maintenance
P02269281A1276|35 45|involvement
P02269281A1276|61 69|sequences
P02269281A1276|101 110|structures
P02269281A1276|125 132|relation
P02269281A1276|140 147|location
P02269281A1276|153 158|region
P02269281A1276|161 174|control signals
P02269426A0428|13 21|RNA target
P02269426A0428|29 47|Tat trans-activation
P02269426A0428|87 93|factors
P02269426A0428|97 104|activity
P02269426A0428|135 144|RNA targets
P02269426A0428|147 165|Tat trans-activation
P02269426A0428|174 184|requirement
P02269426A0428|204 217|mRNA expression
P02270096T0000|9 16|activity
P02270096T0000|36 46|nitrosamine
P02270587A0000|13 25|treatment need
P02270587A0000|49 53|order
P02270587A0000|56 64|magnitude
P02270834A0123|5 10|method
P02270834A0123|17 25|HML method
P02272095A0832|5 11|results
P02272095A0832|22 32|involvement
P02272095A0832|45 55|enkephalins
P02272095A0832|58 71|pain modulation
P02272095A0832|74 81|patients
P02272095A0832|94 108|cluster headache
P02273690T0001|0 6|Effects
P02273690T0001|9 17|cisapride
P02273690T0001|42 49|motility
P02273690T0001|62 69|hormones
P02274343A0064|6 20|foot pathologies
P02274343A0064|24 31|heel pain
P02274343A0064|32 44|metatarsalgia
P02274343A0064|45 54|hammertoes
P02274343A0064|58 65|clawtoes
P02274343A0064|66 72|bunions
P02274343A0064|73 85|hallux rigidus
P02274343A0064|86 90|corns
P02274343A0064|94 101|calluses
P02274343A0064|102 116|nail pathologies
P02274343A0064|117 125|arthritis
P02274343A0064|129 140|neuropathies
P02274509A0623|0 15|Liver dysfunction
P02274509A0623|21 28|presence
P02274509A0623|47 55|reactions
P02274509A0623|76 83|activity
P02274509A0623|89 98|blood serum
P02274509A0623|101 121|indicator liver enzymes
P02274509A0623|151 158|function
P02276891T0000|0 10|Coenzyme Q10
P02276891T0000|11 21|blood levels
P02276891T0000|34 39|demand
P02277005A0227|3 19|CT characteristics
P02277005A0227|44 53|literature
P02277319A0211|18 30|preservatives
P02277319A0211|66 71|assays
P02277319A0211|87 102|product sterility
P02277319A0211|105 119|bioburden levels
P02277452A0116|4 11|patients
P02277452A0116|16 29|angina pectoris
P02277452A0116|33 39|changes
P02277452A0116|48 52|LVESV
P02277452A0116|55 63|PSP/LVESV
P02277452A0116|87 95|detection
P02277452A0116|114 121|ischemia
P02277452A0116|129 138|appearance
P02277452A0116|141 149|chest pain
P02277452A0116|156 162|changes
P02278217A0372|6 11|groups
P02278217A0372|22 38|management failure
P02278217A0372|41 47|therapy
P02278217A0372|65 74|medication
P02278217A0372|86 96|section lead
P02278217A0372|99 106|delivery
P02278474A0000|0 29|Serum Fibrin Degradation Products
P02278474A0000|57 70|cancer patients
P02278474A0000|81 91|individuals
P02278474A0000|110 118|treatment
P02280777T0000|3 21|uteroglobin promoter
P02280777T0000|43 50|estrogen
P02280777T0000|61 67|element
P02281118A1191|0 31|Prostaglandin synthesis inhibitors
P02281118A1191|52 58|healing
P02281118A1191|82 92|limitations
P02281118A1191|120 129|situations
P02281330A0556|14 32|oxygen concentration
P02281330A0556|51 66|Horowitz quotient
P02281330A0556|94 99|manner
P02281330A0556|127 132|trauma
P02281948A0245|12 30|mineral oil emulsions
P02281948A0245|79 85|sucrose
P02281948A0245|103 111|ingestion
P02282815T0000|0 11|Significance
P02282815T0000|28 44|basement membranes
P02282815T0000|56 63|children
P02283148T0000|0 11|Significance
P02283148T0000|14 31|cytokine production
P02283148T0000|35 51|adhesion molecules
P02283148T0000|62 76|immunopathology
P02283378A0385|9 17|procedure
P02283378A0385|95 113|ultrafiltration tube
P02283378T0000|6 11|method
P02283378T0000|15 27|determination
P02283378T0000|33 52|cephalosporin DQ-2556
P02283378T0000|65 70|fluids
P02283378T0000|95 108|chromatography
P02283873A0308|8 12|group
P02283873A0308|15 25|adolescents
P02283873A0308|63 74|parents smoke
P02283873A0308|83 93|involvement
P02283873A0308|96 112|smoking prevention
P02283873A0308|127 134|enhancer
P02284393A0751|7 14|research
P02284393A0751|41 52|coping styles
P02284393A0751|74 103|EE/low EE research classification
P02284573A0943|27 34|BAL fluid
P02284573A0943|75 93|methenamine staining
P02284573A0943|109 124|brushing material
P02287860T0001|30 34|study
P02287860T0001|47 61|parenchyma cells
P02287860T0001|83 95|X-ray exposure
P02289102A0114|7 23|audiotape cassette
P02289102A0114|27 36|headphones
P02289102A0114|40 47|duration
P02289102A0114|53 66|hallucinations
P02289639A0989|7 12|change
P02289639A0989|42 46|value
P02289639A0989|86 97|control group
P02290216T0001|0 5|Effect
P02290216T0001|15 25|obstruction
P02290216T0001|29 39|cholangitis
P02290216T0001|42 57|serum SPan-1 level
P02291144A0493|8 15|accuracy
P02291144A0493|75 81|machine
P02291144A0493|86 101|reference methods
P02291144A0493|111 115|MCHCH
P02291144A0493|119 131|basophil count
P02291628A0264|21 25|paper
P02291628A0264|41 52|applications
P02291628A0264|63 69|aspects
P02291628A0264|93 100|examples
P02291628A0264|111 120|literature
P02291628A0264|151 163|endocrinology
P02292272T0000|0 20|Interlimb coordination
P02292272T0000|34 43|locomotion
P02293019A0000|0 18|Antileukoproteinase
P02293019A0000|53 59|protein
P02293019A0000|70 76|tissues
P02293019A0000|88 97|activities
P02293019A0000|110 115|serine
P02293019A0000|125 143|proteinases elastase
P02293019A0000|147 157|cathepsin-G
P02293664A0946|14 19|series
P02293664A0946|22 30|deletions
P02293664A0946|36 51|vimentin promoter
P02293664A0946|74 82|sequences
P02293664A0946|87 95|base pairs
P02293664A0946|119 127|base pairs
P02293664A0946|141 151|mRNA cap site
P02294048A0881|18 47|% amino acid sequence similarities
P02294048A0881|66 70|hsp70
P02294048A0881|91 108|Bacillus megaterium
P02295521A0922|8 16|relations
P02295521A0922|37 47|correlation
P02295521A0922|58 62|level
P02295521A0922|65 81|trapezius activity
P02295521A0922|85 94|complaints
P02295521A0922|116 125|individual
P02295521A0922|137 158|muscle activity patterns
P02295521A0922|183 192|risk factor
P02295521A0922|196 206|development
P02295521A0922|225 234|complaints
P02296509A0997|18 33|household members
P02296509A0997|46 57|seronegative
P02296509A0997|80 94|serum p24 antigen
P02298741A0809|0 7|Analysis
P02298741A0809|34 43|antibodies
P02298741A0809|55 59|alpha
P02298741A0809|68 75|gamma PKC
P02298741A0809|96 100|types
P02298741A0809|122 128|JK cells
P02298741A0809|135 143|JKPE cells
P02298741A0809|197 203|protein
P02298741A0809|225 237|alpha antibody
P02299543A0317|43 49|outlook
P02300541A0000|14 20|effects
P02300541A0000|35 41|barrier
P02300541A0000|51 57|surface
P02300541A0000|64 69|agents
P02300541A0000|71 76|series
P02300541A0000|86 97|dose inhalers
P02300541A0000|141 150|surfactant
P02300541A0000|154 160|airways
P02300541A0000|179 186|rat lungs
P02300577A0852|3 11|beta chain
P02300577A0852|41 58|glycosylation sites
P02300577A0852|62 85|endoglycosidase digestion
P02300577A0852|102 110|beta chain
P02300577A0852|128 134|complex
P02300577A0852|147 156|side chains
P02300759A0000|14 22|protocole
P02300759A0000|32 53|Gustave Roussy Institute
P02300759A0000|65 75|epithelioma
P02300759A0000|88 93|cervix
P02300759A0000|109 113|forms
P02300759A0000|114 119|T1B-T2
P02300759A0000|138 146|radiology
P02300759A0000|150 156|surgery
P02303158T0000|19 28|expression
P02303158T0000|51 57|protein
P02303158T0000|69 79|trk oncogene
P02303470A0242|3 9|introns
P02303874A1643|14 28|titration period
P02303874A1643|32 41|adjustment
P02303874A1643|77 81|doses
P02303874A1643|96 111|micrograms/24 hrs
P02303874A1643|121 136|micrograms/24 hrs
P02305014A0226|10 15|series
P02305014A0226|18 28|experiments
P02305014A0226|82 94|guide cannulas
P02305014A0226|111 119|ventricle
P02306539T0000|7 30|Selenastrum capricornutum
P02306539T0000|33 42|Microfeast
P02306539T0000|54 65|Daphnia pulex
P02307067A1348|3 13|persistence
P02307067A1348|16 22|members
P02307067A1348|40 55|families Tydeidae
P02307067A1348|56 69|Nanorchestidae
P02307067A1348|73 84|Tarsonemidae
P02307067A1348|111 133|concentration treatments
P02307067A1348|149 156|evidence
P02307067A1348|159 169|adaptations
P02307067A1348|189 196|habitats
P02307371A0263|11 19|mechanism
P02307371A0263|45 75|transcription elongation blockage
P02307371A0263|87 103|c-myc deregulation
P02307371A0263|106 112|Burkitt
P02307371A0263|114 121|lymphoma
P02307371A0263|132 152|transcription patterns
P02307371A0263|158 165|transfer
P02307371A0263|177 183|Burkitt
P02307371A0263|185 204|lymphoma c-myc alleles
P02307371A0263|215 219|cells
P02307371A0263|223 235|Xenopus oocyte
P02307371A0263|244 251|vesicles
P02307613A0783|0 37|Erythrocyte protoporphyrin concentration
P02307613A0783|177 182|groups
P02307613A0783|184 192|remainder
P02307613A0783|198 202|study
P02307848A0347|9 17|sequences
P02307848A0347|23 30|Crry gene
P02307848A0347|74 82|sequences
P02307848A0347|111 124|Eco-R1 fragment
P02307848T0042|28 37|complexity
P02307848T0042|59 63|genes
P02307850A0000|6 29|RNK-16 lambda-gt11 library
P02307850A0000|62 82|cDNA rat NK cell protease
P02307850A0000|84 89|RNKP-1
P02307850A0000|97 111|characteristics
P02307850A0000|120 134|serine proteases
P02307850A1197|3 11|induction
P02307850A1197|14 29|RNKP-1 expression
P02307850A1197|50 60|spleen cells
P02307850A1197|75 83|increases
P02307850A1197|117 142|killer lymphocyte activities
P02308496A0000|3 7|paper
P02308496A0000|34 39|change
P02308496A0000|44 53|blood level
P02308496A0000|72 79|cortisol
P02308496A0000|81 87|insulin
P02308496A0000|87 95|C-peptide
P02308496A0000|112 118|session
P02308496A0000|121 131|respiration
P02308496A0000|152 158|mixture
P02308496A0000|164 170|% oxygen
P02308496A0000|171 176|GHM-10
P02310261A0115|3 9|abscess
P02310261A0115|27 32|septum
P02310261A0115|54 58|layer
P02310261A0115|71 81|pericardium
P02310300A0298|3 15|% lymphography
P02310350A0221|10 14|study
P02310350A0221|26 31|effect
P02310350A0221|34 42|intensity
P02310350A0221|52 59|polarity
P02310350A0221|72 78|content
P02310350A0221|105 112|subjects
P02310496X0000|7 23|memory impairments
P02310496X0000|68 72|Broca
P02310496X0000|75 88|nucleus basalis
P02310496X0000|106 118|memory defects
P02310496X0000|127 147|nucleus basalis lesions
P02310496X0000|160 165|degree
P02310496X0000|191 198|cell loss
P02310496X0000|235 242|function
P02310496X0000|245 258|nucleus basalis
P02310496X0000|303 307|Broca
P02310496X0000|306 312|MS-VDBB
P02310496X0000|316 334|place navigation task
P02310496X0000|344 358|reference memory
P02311544A0086|0 6|Studies
P02311544A0086|25 36|relationship
P02311544A0086|47 54|MSMR cyst
P02311544A0086|65 69|signs
P02311544A0086|72 79|symptoms
P02311544A0086|82 88|disease
P02312470A0774|3 15|BAL-to-plasma
P02312470A0774|24 31|activity
P02312470A0774|209 219|circulation
P02312470A0774|227 232|lavage
P02312689A0360|3 18|kappa coefficient
P02312689A0360|21 29|agreement
P02312689A0360|40 49|Patho Dx Kit
P02312689A0360|56 69|standard method
P02315151T0020|6 12|systems
P02315151T0020|21 26|health
P02315151T0020|30 36|illness
P02315472A0583|17 27|imaging time
P02315472A0583|31 40|parameters
P02315472A0583|86 93|unit time
P02317413A0364|0 7|Patients
P02317413A0364|27 36|infarction
P02317413A0364|46 65|plasma concentrations
P02317413A0364|68 85|neutrophil elastase
P02317413A0364|104 108|diene
P02317413A0364|119 124|isomer
P02317413A0364|151 160|volunteers
P02317413A0364|162 169|patients
P02317413A0364|189 200|heart disease
P02317554T0000|0 12|Determination
P02317554T0000|32 48|imaging properties
P02317554T0000|57 72|microscope system
P02318208A0817|13 19|element
P02318208A0817|32 42|CACGTGACCCG
P02318208A0817|73 99|transcription initiation site
P02318208A0817|113 124|core sequence
P02318208A0817|138 153|promoter sequence
P02318208A0817|156 161|Ad2MLP
P02319610A1527|11 19|relevance
P02319610A1527|27 34|findings
P02319610A1527|54 64|observation
P02319610A1527|76 82|results
P02319610A1527|99 103|P.HCl
P02319610A1527|127 131|route
P02320008A0651|0 5|TMBr-1
P02320008A0651|27 49|muscle alpha-tropomyosin
P02320008A0651|54 63|amino acids
P02320008A0651|105 110|region
P02320008A0651|115 124|amino acids
P02320999A0606|3 11|procedure
P02320999A0606|33 41|materials
P02320999A0606|42 54|particle board
P02320999A0606|59 64|carpet
P02320999A0606|65 75|gypsum board
P02320999A0606|80 88|wallpaper
P02320999A0606|92 98|plywood
P02320999A0606|103 121|polyurethane lacquer
P02320999A0606|145 159|emission factors
P02320999A0606|160 167|mg m-2 h-1
P02320999A0606|177 185|compounds
P02322535A0658|0 5|Intron
P02322535A0658|33 37|sizes
P02322535A0658|39 45|introns
P02323517A0557|9 15|lesions
P02323517A0557|40 46|stomach
P02323517A0557|66 89|prostaglandin E2 synthesis
P02323517A0557|114 145|prostaglandin generation technique
P02324102A1157|0 9|Comparison
P02324102A1157|12 24|transmembrane
P02324102A1157|39 45|domains
P02324102A1157|66 77|proteoglycan
P02324102A1157|93 107|lung fibroblasts
P02324102A1157|107 113|Marynen
P02324102A1157|118 122|Zhang
P02324102A1157|126 133|Cassiman
P02324102A1157|137 148|Vanden Berghe
P02324102A1157|155 159|David
P02324104A0151|41 66|phosphotransferase activity
P02324104A0151|90 98|fractions
P02324104A0151|101 111|homogenates
P02324104A0151|136 146|populations
P02324104A0151|149 157|C. elegans
P02324104A0516|4 9|levels
P02324104A0516|12 20|C subunits
P02324104A0516|65 70|stages
P02324104A0516|73 83|development
P02324104A0929|12 19|C subunit
P02324104A0929|20 29|CeCAT alpha
P02324104A0929|33 40|residues
P02324104A0929|78 83|region
P02324104A0929|115 122|splicing
P02324104A0929|128 136|C pre-mRNA
P02324104A1195|38 53|carboxyl terminus
P02324104A1195|60 80|translation stop signal
P02324104A1195|119 126|sequence
P02324104A1195|149 156|residues
P02324104A1195|159 168|CeCAT alpha
P02324104A1195|185 195|nucleotides
P02325208A0209|0 5|French
P02325895T0000b|21 44|mechanoreceptor discharge
P02325895T0000b|47 54|function
P02325895T0000b|64 68|force
P02325895T0000b|82 93|displacement
P02325895T0000b|112 118|raccoon
P02325895T0000b|121 138|squirrel monkey hand
P02326716A0139|0 6|Methods
P02326716A0139|18 26|Cobb angle
P02326716A0139|40 49|evaluation
P02326716A0139|50 55|T7-T12
P02326716A0139|64 69|convex
P02326716A0139|73 97|concave rib-vertebra angles
P02326716A0139|116 131|angle differences
P02326716A0139|131 135|RVADs
P02326716A0139|145 152|rotation
P02326716A0139|162 173|displacement
P02326946T0000|0 40|Plasma lecithin/cholesterol acyltransferase
P02326946T0000|47 54|activity
P02326946T0000|70 75|donors
P02326946T0000|77 85|predictor
P02326946T0000|88 105|allograft viability
P02326946T0000|116 135|liver transplantation
P02328328A0419|13 18|status
P02328328A0419|19 50|tumour progesterone receptor status
P02328328A0419|54 59|season
P02328328A0419|62 76|tumour detection
P02328328A0419|100 107|survival
P02328328A0419|162 169|patients
P02329840A0383|3 13|application
P02329840A0383|21 35|microelectrodes
P02329840A0383|41 51|measurement
P02329840A0383|68 74|changes
P02330041A0335|0 9|Expression
P02330041A0335|18 29|localization
P02330041A0335|40 59|transcription studies
P02330041A0335|102 107|factor
P02330041A0335|141 154|control element
P02330041A0335|169 184|rRNA gene promoter
P02330041A0335|194 206|transcription
P02330041A0335|210 216|binding
P02330041A0335|231 236|manner
P02330110A1085|17 33|laboratory studies
P02330110A1085|41 45|value
P02330110A1085|73 79|outcome
P02330333A0325|0 12|Accumulations
P02330333A0325|21 30|202Tl label
P02330333A0325|34 38|times
P02330333A0325|60 64|brain
P02330333A0325|67 73|muscles
P02330333A0325|79 83|times
P02330333A0325|86 91|plasma
P02331361A0268|16 23|increase
P02331361A0268|29 43|myocyte diameter
P02331361A0268|65 70|biopsy
P02331361A0268|73 88|autopsy specimens
P02332018A0538|10 16|absence
P02332018A0538|35 40|asthma
P02332018A0538|60 64|WH air
P02332018A0538|73 80|patients
P02332018A0538|108 123|mean GH increments
P02332018A0538|134 141|subjects
P02332018A0538|150 154|ng/ml
P02332798A0725|3 11|afferents
P02332798A0725|12 16|phase
P02332798A0725|19 26|response
P02332798A0725|52 65|EVS stimulation
P02333239T0000|17 23|problem
P02333545A0313|3 14|distribution
P02333545A0313|22 37|fibrinogen levels
P02333545A0313|73 84|distribution
P02333545A0313|96 103|controls
P02333749A0411|19 36|regression analysis
P02333749A0411|47 54|RAST data
P02333749A0411|57 66|occurrence
P02333749A0411|69 86|serum IgE antibodies
P02333749A0411|89 100|P. orbiculare
P02333749A0411|125 129|value
P02333749A0411|140 145|eczema
P02334972A0145|3 13|examination
P02334972A0145|26 35|assessment
P02334972A0145|47 51|types
P02334972A0145|54 59|drusen
P02334972A0145|62 71|evaluation
P02334972A0145|77 87|development
P02334972A0145|91 99|incidence
P02334972A0145|102 112|risk factors
P02334972A0145|122 134|complications
P02334972A0145|153 158|vision
P02335034A0584|33 42|heat stress
P02335034A0584|57 61|suits
P02335034A0584|69 75|minutes
P02335521T0000|13 40|vitellogenin activator element
P02335521T0000|49 61|transcription
P02335521T0000|87 119|Xenopus laevis vitellogenin promoter
P02335713A0905|5 15|correlation
P02335713A0905|46 57|ALAD activity
P02335713A0905|62 76|stearate workers
P02335815A0530|5 20|carboxyl terminus
P02335815A0530|21 28|deletion
P02335815A0530|36 42|residue
P02335815A0530|85 93|C assembly
P02335815A0530|118 125|activity
P02336338A0931|3 9|effects
P02336338A0931|12 24|mean luminance
P02336338A0931|52 61|expression
P02336338A0931|83 89|account
P02339005T0000|0 5|Effect
P02339005T0000|8 20|hyperglycemia
P02339005T0000|23 35|pain threshold
P02339447A0162|17 23|7,7-2H2
P02339447A0162|38 53|deuterium content
P02339447A0162|68 74|7,7-2H2
P02339447A0162|80 87|9,11-2H2
P02339447A0162|86 92|estrone
P02339447A0162|123 127|assay
P02339447A0162|129 144|serum level 19-OHA
P02339447A0162|163 222|gas chromatography/mass spectrometry-mass fragmentography method
P02339447A0162|240 247|subjects
P02339447A0162|258 266|pregnancy
P02340595A0124|0 15|Sequence analysis
P02340595A0124|23 27|genes
P02340595A0124|47 55|sequences
P02340595A0124|93 101|tRNA genes
P02340595A0124|106 122|plant mitochondria
P02341669A0000|0 10|Experiments
P02341669A0000|31 40|brain-stem
P02341669A0000|56 64|responses
P02341669A0000|65 69|BAERs
P02341669A0000|87 91|types
P02341669A0000|94 116|pseudorandom pulse trains
P02341669A0000|117 138|maximum length sequences
P02341669A0000|147 163|Legendre sequences
P02342477A1292|57 64|features
P02342477A1292|82 93|biosynthesis
P02342477A1292|98 108|endometrium
P02342477A1292|109 125|P4-responsiveness
P02342477A1292|129 136|presence
P02342477A1292|142 148|mannose
P02342477A1292|169 185|recognition marker
P02342477A1292|201 218|sequence similarity
P02342477A1292|257 264|function
P02343033A0000|7 11|light
P02343033A0000|15 26|dates infants
P02343033A0000|35 43|placentae
P02343033A0000|70 76|infants
P02343033A0000|85 93|placentae
P02344529T0000|13 19|anaemia
P02344529T0000|40 53|erythropoietin
P02347102A0000|3 24|pseudolymphoma syndrome
P02347102A0000|46 54|condition
P02347102A0000|67 71|fever
P02347102A0000|72 86|lymphadenopathy
P02347407A0217|21 25|field
P02347407A0217|29 35|animals
P02347407A0217|48 56|SE-sector
P02347655A0193|56 62|tissues
P02347655A0193|61 72|gas exchanges
P02347655A0193|88 97|parameters
P02347655A0193|98 117|blood inlet conditions
P02347655A0193|118 130|blood flow rate
P02347655A0193|131 141|temperature
P02347655A0193|142 152|composition
P02347655A0193|158 167|gas mixture
P02347655A0193|175 185|ventilation
P02347655A0193|186 205|blood tissue perfusion
P02347655A0193|208 218|consumption
P02348225A0192|11 22|measurements
P02348225A0192|23 31|clearance
P02348225A0192|51 59|mL/min/m2
P02348225A0192|60 68|half-life
P02348225A0192|84 88|hours
P02348225A0192|92 97|volume
P02348225A0192|100 111|distribution
P02348225A0192|166 173|patients
P02348225A0192|177 184|jaundice
P02348225A0192|201 208|controls
P02348408A0126|0 8|Attitudes
P02348408A0126|49 58|dimensions
P02348408A0126|80 86|samples
P02348728A1153|14 22|DNA ploidy
P02348728A1153|50 55|factor
P02348728A1153|70 80|determinant
P02348728A1153|95 103|carcinoma
P02349827A0193|21 26|system
P02349827A0193|27 35|Videoplan
P02349942A0287|13 19|factors
P02349942A0287|47 53|cohorts
P02349942A0287|82 87|recall
P02349998A0297|0 18|Dopamine SERS spectra
P02349998A0297|28 37|electrodes
P02349998A0297|73 82|electrodes
P02351239A0693|5 12|findings
P02351239A0693|25 40|hypergastrinemia
P02351239A0693|58 64|removal
P02351239A0693|81 86|mucosa
P02351239A0693|107 113|effects
P02351239A0693|131 141|HDC activity
P02351239A0693|142 163|histamine concentration
P02351239A0693|167 180|ECL cell density
P02351239A0693|183 198|hypergastrinemia
P02351239A0693|218 232|gastrin infusion
P02351239A0693|246 254|treatment
P02351239A0693|268 284|antisecretagogues
P02351297A0000|20 35|toxicity research
P02351297A0000|63 96|atmosphere metal corrosion inhibitors
P02351297A0000|156 160|level
P02351297A0000|170 176|percent
P02353453A1249|3 7|order
P02353453A1249|13 25|helicase motif
P02353453A1249|32 49|nsP3 homology region
P02353453A1249|55 63|RUB genome
P02353453A1249|78 84|respect
P02353453A1249|90 105|alphavirus genome
P02353453A1249|128 140|rearrangement
P02353453A1249|161 169|evolution
P02353453A1249|177 183|viruses
P02353875A0800|3 9|results
P02353875A0800|17 26|followings
P02353875A0800|32 42|eosinophils
P02353875A0800|46 56|neutrophils
P02353875A0800|70 83|hypersecretion
P02353875A0800|86 91|type Ib
P02353875A0800|100 104|cases
P02353875A0800|112 122|eosinophils
P02353875A0800|135 139|cases
P02354381A0207|10 19|treatments
P02354381A0207|20 26|control
P02354381A0207|54 59|corner
P02354381A0207|74 91|fiberglass rollaway
P02354381A0207|105 110|corner
P02354381A0207|150 156|nest box
P02355293A0749|18 28|differences
P02355293A0749|41 49|responses
P02355293A0749|52 73|failure characteristics
P02355293A0749|112 117|grafts
P02355293A0749|134 148|bath environment
P02355293A0749|164 170|tissues
P02355293A0749|181 188|strength
P02355293A0749|192 198|modulus
P02355765A0220|3 9|patient
P02355765A0220|24 43|benzathine penicillin
P02355765A0220|53 59|U weekly
P02355765A0220|68 72|weeks
P02355920A0681|1 20|consensus binding site
P02355920A0681|27 48|transcription factor SP1
P02355920A0681|64 69|intron
P02355920A0681|87 120|proenkephalin germ cell cap site region
P02356823A0063|12 17|method
P02356823A0063|29 37|principle
P02356823A0063|43 55|sets technique
P02356823A0063|98 112|alarm properties
P02357537A0451|3 9|effects
P02357537A0451|18 26|latencies
P02357537A0451|35 39|paCO2
P02357537A0451|60 67|naloxone
P02357537A0451|68 72|mg/kg
P02357537A0451|109 115|animals
P02358975A0709|58 65|symptoms
P02358975A0709|91 102|gluten intake
P02358975A0709|118 130|IgA deficiency
P02360336A0574|9 22|personnel costs
P02360336A0574|37 54|batch manufacturing
P02360336A0574|64 77|multidose vials
P02360336A0574|131 135|vials
P02361008T0000|0 6|Changes
P02361008T0000|9 17|prognosis
P02361008T0000|24 29|births
P02361008T0000|36 40|years
P02361575T0000|6 13|toxicity
P02361575T0000|17 31|carcinogenicity
P02361575T0000|55 63|diepoxide
P02361575T0000|66 76|Fischer rats
P02361575T0000|80 89|B6C3F1 mice
P02361812A1110|3 10|kg FFM SMR
P02361812A1110|30 43|baseline values
P02361812A1110|50 56|EX group
P02361812A1110|81 88|subjects
P02361812A1110|109 114|values
P02361812A1110|170 178|treatment
P02362161T0000|0 5|MK-927
P02362161T0000|47 64|anhydrase inhibitor
P02362803A0608|11 19|fragments
P02362803A0608|30 35|probes
P02362803A0608|42 50|isolation
P02362803A0608|56 67|U3 snRNA genes
P02362803A0608|80 86|library
P02362803A0608|89 99|Arabidopsis
P02368931A0587|2 31|addition serum IgE concentrations
P02370571A0663|3 10|findings
P02370571A0663|30 45|iodine deficiency
P02370571A0663|63 67|cause
P02370571A0663|70 75|goiter
P02370571A0663|81 90|immigrants
P02370571A0663|100 105|cohort
P02370571A0663|120 129|population
P02370571A0663|153 157|women
P02370571A0663|177 182|factor
P02371273A0144|41 46|region
P02371273A0144|55 67|kilobase pairs
P02371517A0747|8 15|patients
P02372496A0782|0 16|Co-administration
P02372496A0782|24 34|angiotensin
P02372496A0782|39 50|microspheres
P02372496A0782|64 69|artery
P02372496A0782|79 90|drug exposure
P02372496A0782|104 114|compartment
P02372496A0782|152 156|ratio
P02372496A0782|159 175|5FU administration
P02372496A0782|189 194|artery
P02372712A0002|3 9|effects
P02372712A0002|37 41|water
P02372712A0002|60 67|pressure
P02372712A0002|69 81|carbon dioxide
P02372712A0002|91 103|plasma lactate
P02372712A0002|132 139|broilers
P02373686T0000|9 18|expression
P02373686T0000|29 56|chicken progesterone receptors
P02373686T0000|95 104|initiation
P02373686T0000|127 135|mechanism
P02373686T0000|148 163|receptor isoforms
P02373810A1118|2 9|contrast
P02373810A1118|31 41|risk factors
P02373810A1118|72 76|weeks
P02374886A0305|3 26|Community Adjustment Scale
P02374886A0305|35 45|outcome data
P02374886A0305|58 65|subjects
P02374886A0305|66 71|degree
P02374886A0305|74 85|productivity
P02374886A0305|86 92|ability
P02374886A0305|108 120|relationships
P02374886A0305|124 139|presence/absence
P02374886A0305|142 155|symptomatology
P02374886A0305|158 164|average
P02374886A0305|169 173|years
P02374886A0305|186 194|admission
P02376023A0307|11 16|months
P02376023A0307|43 48|levels
P02376023A0307|108 114|infants
P02376023A0307|180 184|level
P02378615A0807|3 17|protein sequence
P02378615A0807|48 65|glycosylation sites
P02378615A0807|91 96|region
P02378615A0807|123 132|attachment
P02378615A0807|142 153|carbohydrate
P02378945A0487|4 13|adaptation
P02378945A0487|30 35|stress
P02378945A0487|60 65|effect
P02378945A0487|94 102|vagal tone
P02383693A0301|16 21|column
P02383693A0301|53 60|solution
P02383693A0301|71 79|lucigenin
P02383693A0301|83 93|Triton X-100
P02383693A0301|102 113|M KOH solution
P02383693A0301|116 120|pumps
P02383693A0301|136 160|chemiluminescence detector
P02383771A0544|12 22|examination
P02383771A0544|34 43|epithelium
P02383771A0544|55 62|membrane
P02383771A0544|94 103|epithelium
P02383771A0544|114 125|distribution
P02383771A0544|136 141|nuclei
P02383771A0544|157 165|cytoplasm
P02384265A0947|5 11|results
P02384265A0947|48 53|cancer
P02384265A0947|58 70|polyp patients
P02384265A0947|77 87|possibility
P02384265A0947|90 107|prophylactic effect
P02384265A0947|110 120|polypectomy
P02384265A0947|138 143|cancer
P02384389A0854|7 11|trend
P02384389A0854|34 40|heifers
P02384389A0854|78 87|deposition
P02384389A0854|89 95|seam fat
P02384389A0854|98 106|fed cattle
P02386485A0554|3 20|nucleotide sequence
P02386485A0554|52 57|region
P02386485A0554|73 78|region
P02386485A0554|103 108|region
P02386485A0554|120 125|bp poly
P02386895A0496|0 9|Toxicities
P02386895A0496|18 32|nausea/vomiting
P02386895A0496|37 44|headache
P02386895A0496|48 53|chills
P02386895A0496|65 74|tumor sites
P02386895A0496|77 87|hypotension
P02386895A0496|94 105|hypertension
P02388685A0577|3 9|results
P02388685A0577|32 57|oyster shell supplementation
P02388685A0577|76 102|alkaline phosphatase activity
P02388685A0577|103 120|bone mineralization
P02388685A0577|162 173|coefficients
P02388685A0577|176 184|variation
P02388685A0577|217 223|calcium
P02388685A0577|224 240|phosphorus content
P02388685A0577|246 250|femur
P02388685A0577|254 258|tibia
P02390538A0000|7 13|infants
P02390538A0000|30 34|weeks
P02390538A0000|37 45|gestation
P02390538A0000|77 85|anomalies
P02390538A0000|91 97|airways
P02390538A0000|133 142|fiberscope
P02390538A0000|143 154|Olympus PF18 S
P02390633T0000|5 16|encephalitis
P02390633T0000|20 26|patient
P02390633T0000|55 61|disease
P02390989A0745|13 23|counterpart
P02390989A0745|29 35|GPB gene
P02390989A0745|48 54|GPE gene
P02390989A0745|69 82|point mutations
P02390989A0745|85 93|insertion
P02390989A0745|106 114|stop codon
P02390989A0745|130 141|reading frame
P02391344T0000|9 15|cloning
P02391344T0000|33 61|rat NADH-cytochrome b5 reductase
P02392032A0657|3 9|results
P02392032A0657|37 45|structure
P02392032A0657|47 62|relaxation curves
P02392032A0657|71 81|information
P02392032A0657|87 99|distance scale
P02392032A0657|108 119|architecture
P02392032A0657|125 133|pore space
P02392032A0657|171 181|ambiguities
P02392511T0000|0 28|Serotonin 5-HT2 receptor binding
P02392511T0000|31 44|blood platelets
P02392511T0000|48 52|state
P02392511T0000|62 67|marker
P02392511T0000|84 91|disorder
P02393001A0324|71 81|definitions
P02393001A0324|80 86|obesity
P02393001A0324|109 120|densitometry
P02393001A0324|142 148|results
P02393895A0918|3 10|RF values
P02393895A0918|60 64|scale
P02393895A0918|67 74|severity
P02393895A0918|83 95|insufficiency
P02393895A0918|143 149|authors
P02393895A0918|166 180|differentiation
P02393895A0918|205 218|regurgitations
P02394707A0789|0 15|Promoter elements
P02394707A0789|33 39|TATA box
P02394707A0789|49 56|CCAAT box
P02394707A0789|74 87|initiation site
P02394707A0789|100 110|compliments
P02394707A0789|113 117|CCAAT
P02394707A0789|118 122|ATTGG
P02394707A0789|144 162|nucleotide stretches
P02394718A0130|9 13|genes
P02394718A0130|37 45|libraries
P02394718A0130|48 69|hybridization screening
P02394718A0130|79 104|deoxyoligonucleotide probes
P02394718A0130|134 150|amino acid sequence
P02394718A0130|164 169|enzyme
P02395868A0322|3 9|pattern
P02395868A0322|22 30|zinc sites
P02395868A0322|42 48|ligands
P02395868A0322|56 63|sequence
P02395868A0322|81 86|ligand
P02395868A0322|101 112|hydrogen bond
P02395868A0322|123 129|ligands
P02396415T0001|0 6|Results
P02396415T0001|21 31|observation
P02396415T0001|35 43|treatment
P02396415T0001|46 53|patients
P02396415T0001|66 77|hypertension
P02398897A0000|10 29|transcription factors
P02398897A0000|43 55|RNA polymerase
P02398897A0000|73 82|efficiency
P02398897A0000|85 94|elongation
P02398897A0000|128 136|RNA chains
P02399053A0153|43 49|% oxygen
P02399053A0153|52 58|room air
P02399053A1032|22 32|alveoli/mm2
P02399053A1032|42 55|recoil pressure
P02400070T0000|0 9|Comparison
P02400070T0000|12 19|propofol
P02400070T0000|23 33|thiopentone
P02400070T0000|47 52|agents
P02400070T0000|73 79|therapy
P02400457A0469|2 11|Experiment
P02400457A0469|34 46|supine cycling
P02400457A0469|48 54|% VO2 max
P02400457A0469|60 66|minutes
P02400457A0469|79 92|LBNP conditions
P02400457A0469|105 109|women
P02400457A0469|149 155|manners
P02400457A0469|175 185|adjustments
P02400457A0469|197 202|phases
P02400457A0469|210 221|Experiment I.
P02402678A0463|21 32|formulations
P02402678A0463|43 60|% lambdacyhalothrin
P02402678A0463|82 86|water
P02402678A0463|99 119|aerosol space-spraying
P02402678A0463|125 139|diesel/kerosene
P02402678A0463|150 156|fogging
P02402678A0463|170 185|application rates
P02402678A0463|193 198|g ai/ha
P02402678A0463|202 216|mosquito control
P02402678A0463|221 226|g ai/ha
P02402678A0463|230 244|housefly control
P02403035A0621|8 19|reading frame
P02403035A0621|43 51|precursor
P02403035A0621|67 74|fumarase
P02403634A0788|0 15|Sequence analysis
P02403634A0788|31 38|addition
P02403634A0788|51 55|GC box
P02403634A0788|59 64|region
P02403634A0788|73 79|domains
P02403634A0788|107 116|regulation
P02403634A0788|139 143|genes
P02403634A0788|145 151|CArG box
P02403634A0788|200 205|factor
P02403634A0788|206 226|binding site homologies
P02403634A0788|251 278|muscle-CAAT consensus sequence
P02403634A0788|301 307|cap site
P02403926A0000|3 16|trk-2h oncogene
P02403926A0000|37 65|breast carcinoma cell line MDA-MB
P02403926A0000|78 93|DNA-transfection
P02403926A0000|98 108|NIH3T3 cells
P02403926A0000|122 158|trk proto-oncogene receptor kinase domain
P02403926A0000|179 187|amino acid
P02403926A0000|198 205|sequence
P02403926A0000|206 210|Kozma
P02403926A0000|217 223|Redmond
P02403926A0000|223 228|S.M.S.
P02403926A0000|229 238|Xiao-Chang
P02403926A0000|243 248|Saurer
P02403926A0000|254 259|Groner
P02403926A0000|266 270|Hynes
P02403926A0307|0 9|Antibodies
P02403926A0307|43 80|beta gal-trk receptor kinase fusion protein
P02403926A0307|94 109|kd phosphoprotein
P02403926A0307|126 131|serine
P02403926A0307|132 140|threonine
P02403926A0307|144 151|tyrosine
P02403926A0307|154 161|extracts
P02403926A0307|181 191|NIH3T3 cells
P02404451A1532|15 39|scanning-deletion analysis
P02404451A1532|69 74|region
P02404451A1532|78 85|activity
P02404451A1532|90 96|Cys-118
P02404451A1532|104 110|Cys-118
P02404451A1532|132 139|activity
P02404451A1532|157 170|Cys-118 residue
P02404451A1532|191 203|glycosylation
P02404451A1532|222 229|activity
P02404451A1532|232 237|GM-CSF
P02405393T0000|22 37|characterization
P02405393T0000|43 50|promoter
P02405393T0000|67 77|c-ets-2 gene
P02405589A0000|0 10|Information
P02405589A0000|27 42|drug interactions
P02405589A0000|53 63|pharmacists
P02405589A0000|78 94|drug-use decisions
P02405818A0550|0 14|Branch occlusion
P02405818A0550|17 23|Heubner
P02405818A0550|25 30|artery
P02405818A0550|33 43|perforators
P02405818A0550|83 90|arteries
P02405818A0550|105 113|mechanism
P02405818A0550|116 125|infarction
P02406570A0466|15 19|sites
P02406570A0466|32 37|origin
P02406570A0466|83 94|test plasmids
P02406570A0898|2 12|examination
P02406570A0898|18 27|properties
P02406570A0898|30 38|sequences
P02406570A0898|67 77|possibility
P02406570A0898|98 107|initiation
P02406570A0898|109 122|DNA replication
P02406570A0898|148 157|activation
P02406992A0192|34 42|disorders
P02406992A0192|64 77|amaurosis fugax
P02406992A0192|92 100|algorithm
P02406992A0192|104 113|evaluation
P02406992A0192|137 147|examination
P02406992A0192|148 164|laboratory studies
P02406992A0192|179 198|carotid artery studies
P02408248A0414|34 39|action
P02408248A0414|52 67|enzyme inhibitors
P02409297A0984|10 18|antiserum
P02409297A0984|33 45|fusion protein
P02409297A0984|85 96|polypeptides
P02409297A0984|101 114|virus particles
P02409297A0984|119 130|polypeptides
P02409297A0984|153 169|HBsAg determinants
P02411513A0667|5 19|characteristics
P02411513A0667|22 28|N22/P22
P02411513A0667|76 80|event
P02411513A0667|104 109|dipole
P02411513A0667|114 129|dorsal negativity
P02411513A0667|154 163|positivity
P02417023T0001|8 26|superoxide dismutase
P02417023T0001|45 53|processes
P02417023T0001|57 62|method
P02417023T0001|68 80|determination
P02417023T0001|93 101|materials
P02417669A0218|2 24|maximum photosensitivity
P02417669A0218|38 47|amino acids
P02417669A0218|75 81|taurine
P02417669A0218|100 109|asparagine
P02417669A0218|110 119|metabolite
P02417669A0218|135 152|amino acid aspartate
P02417669A0218|174 180|animals
P02418701A0000|14 23|likelihood
P02418701A0000|26 32|tissues
P02418701A0000|64 70|antigen
P02418701A0000|77 85|intensity
P02418701A0000|104 118|antigen staining
P02418701A0000|121 129|specimens
P02418701A0000|139 146|adenomas
P02418701A0000|152 159|polypoid
P02418701A0000|167 174|adenomas
P02418701A0000|183 190|adenomas
P02418701A0000|194 207|diverticulitis
P02418701A0000|241 249|technique
P02419327A0998|3 17|priming activity
P02419327A0998|55 61|enzymes
P02419327A0998|95 104|incubation
P02420432A1060|11 21|conjunction
P02420432A1060|35 47|pregnancy test
P02420432A1060|54 60|patient
P02420432A1060|70 76|history
P02420432A1060|103 118|serum PAPP-A level
P02420432A1060|130 138|diagnosis
P02420432A1060|153 161|pregnancy
P02423533A1314|3 8|levels
P02423533A1314|44 48|mRNAs
P02423533A1314|80 84|brain
P02423533A1314|88 92|level
P02423533A1314|137 148|rat PC12 cells
P02423533A1314|152 159|exposure
P02423533A1314|162 178|nerve growth factor
P02423533A1790|3 7|cDNAs
P02423533A1790|34 42|sequences
P02423533A1790|58 67|chicken DNA
P02423533A1790|104 112|sea urchin
P02423773T0001|12 17|method
P02423773T0001|31 38|glycerin
P02423773T0001|44 48|blood
P02423850A0292|0 15|Deletion analysis
P02423850A0292|55 60|region
P02423850A0292|67 74|homology
P02423850A0292|88 93|region
P02423850A0292|99 111|yeast CYC1 gene
P02424743A0280|30 38|amplitude
P02424743A0280|66 72|periods
P02427024X0000|0 8|Tolerance
P02427024X0000|11 30|fenfluramine anorexia
P02427024X0000|39 45|fiction
P02427024X0000|59 66|findings
P02427024X0000|73 82|laboratory
P02427024X0000|87 92|regard
P02427024X0000|95 103|tolerance
P02427024X0000|106 125|fenfluramine anorexia
P02427024X0000|141 147|respect
P02427024X0000|150 159|generality
P02427024X0000|176 185|phenomenon
P02427797A0199|34 41|pancreas
P02427797A0199|70 75|cavity
P02427797A0199|81 89|cessation
P02427797A0199|92 100|blood flow
P02427797A0199|114 121|ischemia
P02427797A0199|154 162|time point
P02427797A0199|186 192|Ringers
P02427797A0199|193 199|lactate
P02427797A0199|225 231|vessels
P02427812A0865|5 11|results
P02427812A0865|32 40|clonidine
P02427812A0865|43 48|6-OHDA
P02427812A0865|55 62|alpha-MD
P02427812A0865|74 87|pressor actions
P02427812A0865|129 134|action
P02427869A0939|31 41|sensitivity
P02431314A0834|14 19|Hansel
P02431314A0834|50 60|recognition
P02431314A0834|63 76|eosinophiluria
P02431314A0834|91 96|Wright
P02436005A0707|5 11|results
P02436005A0707|43 48|action
P02436005A0707|51 60|nicorandil
P02436005A0707|71 80|inhibition
P02436005A0707|83 90|Ca influx
P02436005A0707|107 118|mobilization
P02437625A0197|3 7|study
P02437625A0197|43 64|histoplasmosis syndrome
P02437625A0197|91 102|degeneration
P02437792T0000|0 9|Comparison
P02437792T0000|12 21|elastase-1
P02437792T0000|26 32|amylase
P02437792T0000|33 38|lipase
P02437792T0000|54 69|immunoreactivity
P02437792T0000|75 83|diagnosis
P02437792T0000|91 102|pancreatitis
P02437895A0000|1 5|probe
P02437895A0000|12 30|potentials procedure
P02437895A0000|57 66|engagement
P02437895A0000|81 91|hemispheres
P02437895A0000|99 110|language task
P02437895A0000|129 134|groups
P02437895A0000|144 149|adults
P02437895A0000|154 163|hemisphere
P02437895A0000|174 181|aphasics
P02437895A0000|195 200|stroke
P02437895A0000|201 211|dysarthrics
P02437895A0000|217 226|hemisphere
P02437895A0000|247 254|patients
P02437895A0000|270 277|subjects
P02438637T0000|0 16|Mucolipidosis type
P02438637T0000|27 34|spectrum
P02438637T0000|45 51|history
P02442837A0060|13 18|groups
P02442837A0060|35 43|dauricine
P02442837A0060|50 70|calcium channel blocker
P02442837A0060|74 82|verapamil
P02442837A0060|105 125|calcium channel blocker
P02442837A0060|144 150|minutes
P02442837A0060|176 190|bypass procedure
P02442837A0060|191 196|period
P02442837A0060|201 207|minutes
P02443028A0695|2 7|reflow
P02443028A0695|33 39|percent
P02443028A0695|45 66|muscle microvasculature
P02443028A0695|71 81|reperfusion
P02443924A0083|6 13|patients
P02443924A0083|70 75|cancer
P02443924A0083|90 97|survival
P02444507A0240|0 15|Lysozyme activity
P02444507A0240|85 92|patients
P02445751A0925|16 27|measurements
P02445751A0925|39 49|state levels
P02445751A0925|52 56|mRNAs
P02445751A0925|60 66|subunit
P02445751A0925|70 86|cytochrome oxidase
P02445751A0925|93 103|beta subunit
P02445751A0925|106 113|F1 ATPase
P02445751A0925|132 141|hem2 mutant
P02446871A1021|10 18|structure
P02446871A1021|45 50|region
P02446871A1021|80 87|LSU rRNAs
P02446871A1021|90 97|contrast
P02446871A1021|109 117|structure
P02446871A1021|145 153|molecules
P02449431A1121|0 18|ATP gamma S inhibition
P02449431A1121|38 51|concentrations
P02449431A1121|65 70|araATP
P02449431A1121|71 75|ddATP
P02451872A0391|3 10|recovery
P02451872A0391|21 35|methoxydextrane
P02452313A0114|0 7|ASL-8123
P02452313A0114|54 69|blocking activity
P02452313A0114|80 98|guinea pig right atria
P02452313A0114|134 141|activity
P02452313A0114|158 163|tissue
P02452313A0114|166 179|concentrations
P02452313A0114|182 189|ASL-8123
P02454390T0000|0 7|Enhancer
P02454390T0000|11 26|promoter elements
P02454390T0000|36 45|activation
P02454390T0000|49 72|glucocorticoid repression
P02454390T0000|78 99|alpha 1-fetoprotein gene
P02454390T0000|102 112|hepatocytes
P02454976A0944|12 18|results
P02454976A0944|21 28|relation
P02454976A0944|39 45|systems
P02454976A0944|84 88|gyrus
P02454976A0944|113 123|possibility
P02454976A0944|127 135|divisions
P02454976A0944|167 171|gyrus
P02454976A0944|192 196|areas
P02454976A0944|224 228|gyrus
P02454976A0944|231 238|primates
P02455821A0099|39 74|AccI-EcoRI restriction fragment mapping
P02455821A0099|109 116|UL region
P02455821A0099|121 131|EHV-1 genome
P02455821A0099|152 156|right
P02456827A0899|17 22|effect
P02456827A0899|32 39|decrease
P02456827A0899|52 59|activity
P02457922A0991|0 12|Hybridization
P02457922A0991|16 20|probe
P02457922A0991|29 34|region
P02457922A0991|52 56|blots
P02457922A0991|83 89|tissues
P02457922A0991|107 118|2.8-kilobase
P02457922A0991|123 129|message
P02457922A0991|148 152|bands
P02458080T0000|0 8|Prognosis
P02458080T0000|31 37|myeloma
P02458234T0000|4 9|method
P02458234T0000|28 35|analysis
P02458234T0000|38 50|sleep spindles
P02458234T0000|76 88|EEG recordings
P02458699A0650|0 7|Svensson
P02459309T0000|10 16|release
P02459309T0000|27 35|serotonin
P02459309T0000|71 85|caudate-putamen
P02459309T0000|120 127|dialysis
P02459309T0000|158 171|chromatography
P02459309T0000|188 196|detection
P02461368A0162|6 11|report
P02461368A0162|57 65|structure
P02461368A0162|67 79|type X collagen
P02461368A0162|87 93|cloning
P02461368A0162|97 106|sequencing
P02462047A0208|6 14|flap areas
P02462047A0208|47 61|pedicle ligation
P02462047A0208|66 72|vessels
P02462047A0208|79 84|artery
P02462047A0208|113 128|flap replantation
P02462047A0208|133 138|island
P02462047A0208|146 150|flaps
P02462305A1071|3 17|size discrepancy
P02462305A1071|28 40|glycosylation
P02462305A1071|43 57|phosphorylation
P02462305A1071|95 102|sequence
P02462305A1071|119 129|polypeptide
P02462523A0394|7 23|KpnI-SalI fragment
P02462523A0394|35 44|DNA changes
P02462523A0394|66 74|mutations
P02462523A0394|114 122|phenotype
P02462523A0394|144 166|germ-line transformation
P02463050A0514|3 44|corticosterone synthesis inhibitor metyrapone
P02463050A0514|47 51|mg/kg
P02463050A0514|86 99|corticosterone
P02463050A0514|102 106|level
P02463050A0514|124 128|males
P02464097T0000|3 9|effects
P02464097T0000|31 41|thromboxane
P02464097T0000|44 78|prostaglandin endoperoxide antagonist
P02464097T0000|81 88|ischemia
P02464097T0000|118 128|arrhythmias
P02466414A0000|27 41|plasma viscosity
P02466414A0000|75 88|blood viscosity
P02466414A0000|118 122|steps
P02466414A0000|124 142|exchange transfusion
P02466414A0000|154 159|plasma
P02466414A0000|163 168|plasma
P02466414A0000|192 204|weight dextran
P02466414A0000|220 226|% wt/vol
P02466665A0202|19 25|protein
P02466665A0202|51 55|fluid
P02468795A1086|0 4|Serum
P02468795A1086|14 34|acid phosphatase levels
P02468795A1086|61 71|correlation
P02468795A1086|76 87|cancer volume
P02468795A1086|126 134|parameter
P02469451A0239|3 15|investigation
P02469451A0239|46 52|fashion
P02469451A0239|77 82|mg dose
P02469451A0239|88 109|MAO-B inhibitor deprenyl
P02469451A0239|119 126|subjects
P02470955A0101|5 11|studies
P02470955A0101|37 44|increase
P02470955A0101|47 59|CSF AP activity
P02470955A0101|70 81|meningitides
P02470955A0101|97 108|meningitides
P02473156A0000|24 52|lymphocyte cell surface molecule
P02473156A0000|92 97|member
P02473156A0000|119 124|family
P02473156A0000|127 142|adhesion proteins
P02473198A0613|0 7|Dopamine
P02473198A0613|24 38|potassium efflux
P02473198A0613|55 60|efflux
P02473198A0613|71 76|glands
P02473198A0613|90 95|effect
P02473198A0613|108 113|glands
P02473619A0202|11 23|sensitization
P02473619A0202|40 48|chemicals
P02473619A0202|52 61|proportion
P02473619A0202|64 77|control animals
P02473619A0202|122 134|sensitization
P02473619A0202|137 144|patients
P02473619A0202|162 170|reactions
P02473619A0202|186 193|blockers
P02473619A0202|201 208|exposure
P02473619A0202|218 230|IgE antibodies
P02473693A0174|4 11|approach
P02473693A0174|40 46|protein
P02473693A0174|47 51|HGB F.
P02473718A0000|3 15|investigation
P02473718A0000|35 46|relationship
P02473718A0000|61 71|metabolites
P02473718A0000|74 82|serotonin
P02473718A0000|86 98|catecholamine
P02473718A0000|99 104|5-HIAA
P02473718A0000|113 119|T-cells
P02473718A0000|125 132|T-helper
P02473718A0000|138 149|T-suppressor
P02473718A0000|158 164|B-cells
P02473718A0000|182 186|cells
P02473718A0000|197 204|subjects
P02473718A0000|206 211|female
P02473718A0000|228 232|years
P02473718A0000|234 239|stress
P02473718A0000|252 259|subjects
P02473718A0000|262 269|subjects
P02473718A0000|271 276|female
P02473718A0000|294 298|years
P02473907A1338|6 9|C mAb
P02473907A1338|66 75|Fc epsilon R
P02473907A1338|152 161|Fc epsilon R
P02473942A1207|16 20|plots
P02473942A1207|65 72|segments
P02473942A1207|99 119|transmembrane segments
P02474093T0000|0 10|Angiotensin
P02474093T0000|21 36|enzyme inhibitors
P02474093T0000|63 70|efficacy
P02474093T0000|73 81|diuretics
P02474093T0000|115 121|effects
P02474110A1039|2 9|addition
P02474110A1039|26 34|reduction
P02474110A1039|37 49|blood pressure
P02474110A1039|53 63|angiotensin
P02474110A1039|74 79|enzyme
P02474110A1039|85 101|inhibitor ramipril
P02474110A1039|119 128|regression
P02474110A1039|156 166|hypertrophy
P02474110A1039|189 204|resonance imaging
P02474110A1039|208 223|echocardiography
P02474204A0105|9 13|cells
P02474204A0105|27 31|means
P02474204A0105|34 42|Grimelius
P02474204A0105|49 56|staining
P02474204A0105|60 73|immunostaining
P02474204A0105|77 88|chromogranin
P02474204A0105|97 102|marker
P02474204A0105|114 118|cells
P02474356A0559|3 7|ratio
P02474356A0559|10 22|radioactivity
P02474356A0559|25 30|tumour
P02474356A0559|49 54|tissue
P02474356A0559|57 62|N ratio
P02474356A0559|103 114|microspheres
P02474356A0559|122 127|portal
P02474356A0559|139 149|circulation
P02474356A0559|156 161|animal
P02475506A0878|46 77|polymerase chain reaction technique
P02475717A0565|0 13|Tissue necrosis
P02475717A0565|31 58|triphenyltetrazolium staining
P02475717A0565|82 99|baseline predictors
P02475717A0565|102 112|infarct size
P02475717A0565|121 132|risk zone size
P02475717A0565|144 157|collateral flow
P02476030A0000|17 23|surface
P02476030A0000|58 63|states
P02476030A0000|69 91|laser scanning tomography
P02476664A0563|23 30|sequence
P02477373A0930|10 16|TATA box
P02477373A0930|28 36|base pairs
P02477373A0930|55 81|transcription initiation site
P02479635A0659|0 13|Cotransfection
P02479635A0659|22 30|construct
P02479635A0659|35 42|plasmids
P02479635A0659|95 101|phorbol
P02479635A0659|117 126|expression
P02479823A0727|0 15|Sequence analysis
P02479823A0727|30 35|region
P02479823A0727|51 57|GC boxes
P02479823A0727|75 81|TATA box
P02480419A0735|13 21|cirrhosis
P02480419A0735|67 76|hepatitis B
P02480419A0735|82 90|infection
P02480959A0470|4 15|P-450scc mRNA
P02480959A0470|28 38|consequence
P02480959A0470|50 54|surge
P02480959A0470|95 99|cells
P02480959A0470|139 145|absence
P02480959A0470|146 158|gonadotropins
P02480959A0470|174 183|modulation
P02480959A0470|186 194|prolactin
P02481230A1258|22 41|bovine alpha transgene
P02481230A1258|56 63|placenta
P02481429T0000|6 22|staining technique
P02481429T0000|26 44|Leishmania parasites
P02481429T0000|62 67|smears
P02481779A0213|0 6|NIK-244
P02481779A0213|25 32|ligation
P02481779A0213|53 63|arrhythmias
P02481779A0213|86 105|plasma concentrations
P02481779A0213|109 119|arrhythmias
P02481779A0213|148 155|ligation
P02481779A0213|159 167|digitalis
P02481779A0213|184 192|mg/kg i.v.
P02481779A0213|205 213|mg/kg i.v.
P02481779A0213|231 239|mg/kg i.v.
P02481779A0213|240 251|microgram/ml
P02482293A1518|15 38|T24 bladder carcinoma cells
P02482293A1518|57 90|EGF-R tyrosine protein kinase activity
P02482293A1518|110 121|phorbol ester
P02482293A1518|152 159|activity
P02482293A1518|165 172|receptor
P02482293A1518|180 184|cells
P02482511A0860|4 30|phosphodiesterase inhibitors
P02482511A0860|66 73|syndrome
P02482511A0860|97 103|stimuli
P02482511A0860|107 116|weight loss
P02482511A0860|134 151|withdrawal syndrome
P02482511A0860|166 175|naltrexone
P02483210A0000|13 17|value
P02483210A0000|20 29|blood serum
P02483210A0000|40 46|amylase
P02483210A0000|47 52|lipase
P02483210A0000|56 62|trypsin
P02483210A0000|65 77|exacerbations
P02483210A0000|87 107|relapsing pancreatitis
P02483438A0498|5 9|basis
P02483438A0498|15 23|mechanism
P02483438A0498|26 31|action
P02483438A0498|35 40|groups
P02483438A0498|43 53|inodilators
P02483438A0498|73 99|phosphodiesterase inhibitors
P02483438A0498|118 123|agents
P02484714T0000|10 21|organization
P02484714T0000|25 34|expression
P02484714T0000|40 60|mouse estrogen receptor
P02484994T0001|11 24|gamma globulins
P02485188A0415|9 24|chondroitinase AC
P02485188A0415|28 39|ABC digestion
P02485188A0415|48 56|reactions
P02485188A0415|80 85|levels
P02485188A0415|88 102|dermatan sulfate
P02485188A0415|112 119|diabetes
P02485188A0415|129 133|group
P02485188A0415|194 201|diabetes
P02485188A0415|218 223|levels
P02485188A0415|226 244|chondroitin sulfates
P02485188A0415|254 261|diabetes
P02485188A0415|267 271|group
P02486634A0632|10 18|perfusion
P02486634A0632|51 55|level
P02486634A0632|61 77|contrast injection
P02486634A0632|84 88|level
P02486634A0632|107 116|morphology
P02486634A0632|120 125|degree
P02486634A0632|128 148|collateral development
P02487898A0315|4 20|NGF administration
P02487898A0315|82 98|NGF administration
P02488148A1156|9 15|program
P02488148A1156|27 37|RSNA meeting
P02488148A1156|40 46|program
P02488148A1156|65 73|diagnosis
P02489032A0000|0 13|Immunoglobulin
P02489032A0000|19 23|chain
P02489032A0000|29 37|diversity
P02489032A0000|53 59|chicken
P02489032A0000|62 74|recombination
P02489032A0000|101 108|variable
P02489032A0000|127 138|gene segments
P02489032A0000|157 171|diversification
P02489032A0000|187 194|VL region
P02489753A0581|3 9|results
P02489753A0581|39 49|EMG activity
P02489753A0581|52 58|FB group
P02489753A0581|93 100|position
P02489753A0581|121 127|GF group
P02489753A0581|137 144|position
P02489753A0581|147 154|position
P02489895T0001|0 11|Muscle action
P02489895T0001|35 40|rhythm
P02489895T0001|70 76|muscles
P02489895T0001|79 86|children
P02489895T0001|90 95|adults
P02492111A0670|20 27|children
P02492111A0670|27 40|bone lead values
P02492111A0670|124 129|adults
P02492111A0868|36 42|effects
P02492111A0868|45 52|children
P02492111A0868|58 63|levels
P02492111A0868|66 73|exposure
P02492111A0868|85 91|results
P02492111A0868|132 137|margin
P02492111A0868|140 145|safety
P02492111A0868|160 165|safety
P02492111A0868|185 198|U.S. guidelines
P02492111A0868|222 243|blood lead concentration
P02492111A0868|248 260|micrograms/dl
P02493644A0588|9 16|3T3 cells
P02493644A0588|17 21|jun-D
P02493644A0588|42 46|level
P02493644A0588|57 61|c-jun
P02493644A0588|65 69|jun-B
P02493644A0588|76 88|transcription
P02493644A0588|115 132|serum growth factors
P02495745T0000|15 21|effects
P02495745T0000|30 60|tissue-type plasminogen activator
P02495745T0000|61 66|AK-124
P02495745T0000|95 104|thrombosis
P02496090A0252|15 30|tracheostomy tube
P02496090A0252|57 72|mass spectrometry
P02496090A0252|109 125|sampling technique
P02496100T0000|26 30|assay
P02496100T0000|43 53|aflatoxin B1
P02496100T0000|56 73|cottonseed products
P02496100T0000|101 105|study
P02496109A0754|7 17|experiments
P02496109A0754|22 30|S1 mapping
P02496109A0754|39 49|transcripts
P02496109A0754|50 64|gene disruptions
P02496109A0754|70 80|alpha region
P02496109A0754|111 122|fusion vector
P02496109A0754|152 160|promoters
P02496109A0754|197 202|growth
P02496109A0754|215 222|promoter
P02496109A0754|229 239|alpha operon
P02496109A0754|258 263|region
P02496109A0754|280 284|genes
P02496109A0754|297 307|L17 interval
P02497340A0989|20 32|antibody genes
P02497340A0989|65 75|chain probes
P02497340A0989|97 107|chain probes
P02498322A0226|22 30|complexes
P02498322A0226|47 66|gel retardation assays
P02498322A0226|72 79|HeLa cell
P02498322A0226|87 94|extracts
P02498322A0226|100 119|oligonucleotide probe
P02498322A0226|142 147|region
P02498652A0460|5 16|transfection
P02498652A0460|25 47|TSH beta promoter activity
P02498652A0460|119 130|cell cultures
P02500432A1416|31 43|CAT expression
P02500432A1416|73 80|kilobase
P02500432A1416|118 124|segment
P02500432A1416|145 155|orientation
P02500432A1416|158 162|front
P02500432A1416|168 174|CAT gene
P02502096A0462|18 26|blood flow
P02502096A0462|56 73|excretion processes
P02502602A0323|0 8|Tonometry
P02502602A0323|11 22|blood samples
P02502602A0323|27 34|patients
P02502602A0323|53 65|determination
P02502602A0323|68 86|acid-base quantities
P02502602A0323|107 114|affinity
P02504603T0000|0 8|Isolation
P02504603T0000|11 25|Weeksella virosa
P02504603T0000|34 44|CDC group IIf
P02504603T0000|57 62|sample
P02505087A1037|14 36|dimerization specificity
P02505087A1037|67 79|leucine zipper
P02506390T0001|0 5|Growth
P02506390T0001|16 26|anastomoses
P02506390T0001|36 42|animals
P02506740A0742|27 31|hours
P02506740A0742|34 41|recovery
P02506740A0742|65 70|effect
P02506740A0742|80 86|hypoxia
P02506740A0742|97 105|blood flow
P02507523A0791|3 13|ORF1 product
P02507523A0791|28 37|competence
P02507523A0791|100 106|protein
P02507523A0791|110 119|amino acids
P02507815A0000|0 7|Kindling
P02507815A0000|26 31|cortex
P02507815A0000|60 67|amygdala
P02508306A0528|8 19|infiltration
P02508306A0528|22 32|lymphocytes
P02508306A0528|36 46|plasma cells
P02508306A0528|75 83|carcinoma
P02508306A0528|113 121|follicles
P02508726A0498|5 15|case reports
P02508726A0498|30 37|evidence
P02508726A0498|42 46|LiCO3
P02508726A0498|59 68|medication
P02508726A0498|74 82|treatment
P02508726A0498|95 102|behavior
P02508726A0498|115 125|instability
P02508726A0498|131 141|brain injury
P02508726A0498|165 173|potential
P02508726A0498|177 189|neurotoxicity
P02508726A0498|196 205|population
P02508726A0498|228 238|conjunction
P02508726A0498|254 259|agents
P02509123A0371|5 12|sessions
P02509123A0371|26 32|latency
P02509123A0371|37 49|P100 component
P02509123A0371|84 101|baseline conditions
P02510242A0313|8 12|cases
P02510242A0313|31 39|hepatitis
P02510242A0313|53 67|hepatitis B virus
P02510242A0313|85 90|search
P02510242A0313|94 98|HBs Ag
P02510242A0313|127 133|viruses
P02510242A0313|168 172|tests
P02510242A0313|186 192|viruses
P02511069A0532|15 23|mutations
P02511069A0532|45 51|failure
P02511069A0532|76 84|lethality
P02511069A0532|99 106|deletion
P02511069A0532|109 117|DRE region
P02511069A0532|134 156|polytene chromosome bands
P02511150T0025|7 12|status
P02511150T0025|22 33|perspectives
P02511430A0000|18 23|region
P02511430A0000|28 36|mouse MOPC
P02511430A0000|39 43|kappa
P02511430A0000|55 80|immunoglobulin gene enhancer
P02511430A0000|107 113|binding
P02511430A0000|145 151|factors
P02511898A0000|4 8|paper
P02511898A0000|20 26|reasons
P02511898A0000|30 38|countries
P02511898A0000|46 58|Chagas disease
P02511898A0000|93 100|research
P02512010A0801|3 19|PETCO2 measurement
P02512010A0801|36 46|compression
P02512010A0801|59 65|success
P02512010A0801|68 81|defibrillation
P02512010A0801|86 91|return
P02512010A0801|105 115|circulation
P02514498A0000|7 14|CO2/HCO3
P02514498A0000|30 36|absence
P02514498A0000|51 60|inhibition
P02514498A0000|63 75|acid secretion
P02514498A0000|78 82|intra
P02514498A0000|98 116|pCO2/pH measurements
P02514498A0000|121 127|persons
P02514498A0000|149 156|equation
P02514498A0000|159 179|Henderson-Hasselbalch
P02514498A0000|242 250|electrode
P02515953A0459|9 13|study
P02515953A0459|31 38|patients
P02515953A0459|42 54|effectiveness
P02517008A0481|8 15|patients
P02517008A0481|28 32|trial
P02517008A0481|48 52|doses
P02517008A0481|55 65|monotherapy
P02518645T0001|8 20|Chagas disease
P02518645T0001|21 39|laboratory diagnosis
P02518691A0251|12 38|IL2R alpha promoter constructs
P02518691A0251|50 61|transfection
P02518691A0251|65 80|DNA binding assays
P02518691A0251|101 109|sequences
P02518691A0251|154 167|kappa B enhancer
P02518691A0251|187 196|regulation
P02518691A0251|199 221|IL2R alpha gene expression
P02519327T0001|11 20|rheumatism
P02519679T0000|0 9|Inefficacy
P02519679T0000|12 30|phosphine fumigation
P02519679T0000|38 42|ticks
P02520622A0200|5 12|patients
P02520622A0200|64 75|transit times
P02520622A0200|89 96|symptoms
P02520622A0200|112 129|cimetropium bromide
P02520622A0200|132 139|mg t.d.s.
P02520622A0200|142 148|placebo
P02520622A0200|153 157|month
P02520622A0200|190 200|group design
P02521217A1035|24 30|protein
P02521217A1035|44 51|ribosome
P02521217A1035|55 71|membrane fractions
P02521217A1035|74 85|mitochondria
P02521674T0000|0 6|Mapping
P02521674T0000|35 41|mutants
P02521674T0000|50 54|virus
P02521674T0000|55 82|complementation group F mutants
P02521674T0000|87 93|lesions
P02522297A0000|3 8|effect
P02522297A0000|14 26|thromboxane A2
P02522297A0000|32 74|prostaglandin endoperoxide receptor antagonist
P02522297A0000|100 107|ischemia
P02523800A1178|23 30|sequence
P02523800A1178|36 43|CHS1 gene
P02523800A1178|48 55|fragment
P02523800A1178|68 74|repeats
P02523800A1178|78 101|TGAAACA consensus sequence
P02523800A1178|149 160|BAR1 promoter
P02523800A1178|161 168|Kronstad
P02525044A1026|3 15|recovery index
P02525044A1026|16 22|T25-T75
P02525044A1026|31 38|infusion
P02525044A1026|58 65|patients
P02525044A1026|77 86|mivacurium
P02525044A1026|106 118|suxamethonium
P02526165X0000|11 22|Leser-Trelat
P02526165X0000|52 63|Leser-Trelat
P02526165X0000|100 105|marker
P02526165X0000|116 125|malignancy
P02527365T0000|0 13|Xenopus homolog
P02527365T0000|19 34|mos protooncogene
P02527365T0000|54 64|fibroblasts
P02527365T0000|75 84|maturation
P02527365T0000|87 100|Xenopus oocytes
P02527745A0865|0 19|Southern blot analyses
P02527745A0865|47 56|copy number
P02527745A0865|73 84|conservation
P02527745A0865|90 95|domain
P02527745A0865|103 113|vertebrates
P02528329A0000|5 19|missense mutants
P02528329A0000|22 28|subunit
P02528329A0000|50 60|F1F0-ATPase
P02528329A0000|94 117|hydroxylamine mutagenesis
P02528329A0000|121 127|plasmid
P02528329A0000|145 151|subunit
P02528730A1073|8 14|exons 2a
P02528730A1073|20 24|share
P02528730A1073|33 40|sequence
P02528730A1073|86 101|donor splice sites
P02529378A0536|0 17|S1 nuclease analysis
P02529378A0536|38 49|transfection
P02529378A0536|56 68|HIV constructs
P02529378A0536|73 81|HeLa cells
P02529378A0536|103 112|adenovirus
P02529378A0536|129 136|enhancer
P02529378A0536|152 158|portion
P02529378A0536|188 194|element
P02529378A0536|238 247|activation
P02529378A0536|253 258|HIV LTR
P02530413A0195|2 15|supine position
P02530413A0195|16 30|plasma ANP levels
P02530413A0195|43 47|pg/ml
P02530413A0195|54 58|pg/ml
P02530413A0195|72 76|level
P02530413A0195|88 92|pg/ml
P02530470A0604|10 19|prevalence
P02530470A0604|22 31|HBV markers
P02530470A0604|46 57|staff members
P02530470A0604|67 77|blood donors
P02531203A0241|12 22|predictions
P02531203A0241|49 57|responses
P02531203A0241|70 78|negatives
P02531203A0241|96 104|SSTS model
P02532032A0385|0 19|Plasma concentrations
P02532032A0385|33 43|aldosterone
P02532032A0385|50 54|renin
P02532032A0385|93 102|parameters
P02532210A0000|3 19|adenovirus E1A gene
P02532210A0000|28 34|protein
P02532210A0000|75 79|genes
P02534067A0316|0 13|Administration
P02534067A0316|16 28|dexamethasone
P02534067A0316|57 61|rises
P02534067A0316|64 69|plasma
P02534067A0316|72 90|alpha OH progesterone
P02534067A0316|93 111|beta-desoxycortisol
P02534067A0316|112 123|DHEA sulphate
P02534067A0316|124 138|androstenedione
P02534067A0316|142 153|testosterone
P02534067A0316|182 190|excretion
P02534067A0316|193 204|androsterone
P02534067A0316|207 224|beta OH androsterone
P02534067A0316|225 239|etiocholanolone
P02534067A0316|251 261|alpha OH DHEA
P02535460A1443|0 13|RNA transcripts
P02536096A0327|2 10|HeLa cells
P02536096A0327|22 34|transcription
P02536096A0327|42 63|herpes simplex virus type
P02536096A0327|65 87|thymidine kinase promoter
P02536096A0327|99 134|chloramphenicol acetyltransferase gene
P02536096A0327|156 166|orientation
P02536096A0327|180 202|thymidine kinase promoter
P02536096A0327|220 255|chloramphenicol acetyltransferase gene
P02536096A0327|262 269|sequence
P02536160A0518|22 30|condition
P02536160A0518|31 35|Ren1d
P02536160A0518|45 52|sequence
P02536160A0518|58 73|sense orientation
P02536160A0518|88 100|CAT expression
P02536160A0518|108 117|TK promoter
P02536160A0518|120 126|pUTKAT1
P02536160A0518|141 148|sequence
P02536160A0518|163 173|orientation
P02537441A0231|32 37|duties
P02537441A0231|46 61|varicella-zoster
P02537441A0231|68 75|globulin
P02537441A0231|87 93|disease
P02537485A0841|5 16|formalin test
P02537485A0841|24 31|naloxone
P02537485A0841|42 58|morphine analgesia
P02537485A0841|69 73|doses
P02537485A0841|83 87|mg/kg
P02537485A0841|102 118|morphine analgesia
P02537485A0841|139 143|mg/kg
P02538450A0000|14 23|cDNA clones
P02538450A0000|28 35|rat brain
P02538450A0000|44 48|liver
P02538450A0000|66 72|isoform
P02538450A0000|78 99|Na,K-ATPase beta subunit
P02538656A0172|27 35|E1 mutants
P02538656A0172|58 65|R regions
P02538656A0172|75 80|mutant
P02538656A0172|104 109|region
P02538656A0172|121 140|transforming activity
P02538656A0172|143 156|mouse C127 cells
P02538656A0172|173 178|genome
P02538720A0582|28 45|polyubiquitin genes
P02538720A0582|72 78|introns
P02538720A0582|94 101|sequence
P02541251A1327|9 14|T2 gene
P02541251A1327|40 44|sites
P02541251A1327|67 88|transcription factor SP1
P02541251A1327|102 115|CCAAT sequences
P02541251A1327|159 166|features
P02541251A1327|191 196|T1 gene
P02541882A0251|0 15|Radiation therapy
P02541882A0251|52 61|metastasis
P02541882A0251|72 79|patients
P02542194A1496|5 11|results
P02542194A1496|24 31|patients
P02542194A1496|55 65|irradiation
P02542194A1496|72 76|grade
P02542194A1496|83 94|astrocytomas
P02542194A1496|113 123|ependymomas
P02542194A1496|140 147|survival
P02542270A0000|3 13|methylation
P02542270A0000|26 40|chloroplast DNAs
P02542270A0000|58 65|relation
P02542270A0000|88 97|expression
P02542270A0000|100 120|C4 photosynthesis genes
P02542270A0000|126 137|bundle sheath
P02542270A0000|141 154|mesophyll cells
P02542270A0000|166 173|greening
P02542270A0000|187 191|maize
P02542612A0530|0 17|S1 nuclease analysis
P02542612A0530|46 55|B95-8 cells
P02542612A0530|62 70|Vero cells
P02542612A0530|88 109|NotI repeat promoter-CAT
P02542612A0530|126 141|Z transactivation
P02542612A0530|153 157|level
P02542612A0530|184 197|RNA transcripts
P02543226A1559|18 27|likelihood
P02543226A1559|39 47|carcinoma
P02543226A1559|58 68|hyperplasia
P02543226A1559|85 106|adipose tissue component
P02543226A1559|122 135|breast biopsies
P02543226A1559|177 182|method
P02543226A1559|185 192|sampling
P02543226A1559|206 219|breast biopsies
P02543226A1559|250 256|maximum
P02543226A1559|261 266|blocks
P02543226A1559|276 285|parenchyma
P02543226A1559|324 329|tissue
P02543226A1559|349 357|carcinoma
P02543226A1559|368 378|hyperplasia
P02543226A1559|396 401|blocks
P02543621A0788|0 7|Analysis
P02543621A0788|24 28|cases
P02543621A0788|49 53|Wilms
P02543621A0788|54 58|tumor
P02543621A0788|74 80|changes
P02543621A0788|98 120|translocation breakpoint
P02543679A1291|13 20|evidence
P02543679A1291|35 41|lambda O
P02543679A1291|45 55|P initiators
P02543679A1291|77 97|DnaK heat shock proteins
P02543679A1291|119 129|propagation
P02543679A1291|131 147|lambda replication
P02543734A0414|9 24|oligonucleotides
P02543734A0414|42 53|bp repeat unit
P02543734A0414|72 79|activity
P02543734A0414|85 106|IE1/2 enhancer/promoter
P02543734A0414|109 128|cotransfection assays
P02543734A0414|143 152|expression
P02544059A0377|0 6|Effects
P02544059A0377|9 16|nitrogen
P02544059A0377|36 41|helium
P02545357A0000|3 29|mustard chloroplast gene rps16
P02545357A0000|44 50|bp group
P02545357A0000|58 63|intron
P02545903A0639|0 9|Antibodies
P02545903A0639|37 48|immunization
P02545903A0639|99 106|BHK cells
P02545903A0639|120 139|BTV-10 virus particles
P02546234A1382|25 35|tachycaydia
P02546234A1382|58 64|efforts
P02546234A1382|100 106|outcome
P02547079A0910|11 24|calcium balance
P02547079A0910|29 48|hyperparathyroidemia
P02547079A0910|76 89|administration
P02547079A0910|127 135|excretion
P02547079A0910|137 143|calcium
P02547611A0318|0 6|Clone 4c
P02547611A0318|25 30|region
P02547611A0318|47 54|clone 22c
P02547611A0318|77 82|intron
P02547706A0928|3 13|application
P02547706A0928|74 87|classification
P02547706A0928|88 97|pneumonias
P02547706A0928|102 107|CMV-IP
P02547706T0001|0 7|Validity
P02547706T0001|10 24|immunohistology
P02547706T0001|34 46|hybridization
P02547706T0001|64 72|diagnosis
P02547706T0001|75 98|cytomegalovirus pneumonia
P02547706T0001|124 132|pneumonia
P02547706T0001|147 171|bone marrow transplantation
P02547778A0786|9 14|nature
P02547778A0786|18 28|arrangement
P02547778A0786|55 69|control elements
P02547778A0786|98 107|expression
P02548683T0001|6 12|account
P02548683T0001|22 28|seminar
P02548683T0001|31 38|Shanghai
P02548683T0001|46 55|hepatitis A
P02549036A0000|3 26|Bacillus subtilis phage phi
P02549036A0000|30 38|repressor
P02549036A0000|40 45|lambda
P02549036A0000|85 91|protein
P02549036A0000|141 151|homogeneity
P02549036A0000|154 158|order
P02549036A0000|189 198|properties
P02549343A1008|2 12|consequence
P02549343A1008|32 36|cells
P02549343A1008|69 83|characteristics
P02549343A1008|120 124|cells
P02549343A1008|143 168|immunoprecipitation pattern
P02549343A1008|189 194|weight
P02549343A1008|201 211|polypeptide
P02549343A1008|227 234|antibody
P02549343A1008|245 251|rabbits
P02549343A1008|275 279|virus
P02549343A1008|288 307|neutralizing activity
P02549343A1008|315 322|reaction
P02549343A1008|339 348|complement
P02549417A0000|12 17|stages
P02549417A0000|37 45|parasites
P02549417A0000|53 73|acristate mitochondria
P02549417A0000|79 87|functions
P02550118A0610|32 44|infiltrations
P02550682A0411|10 18|incidence
P02550682A0411|22 37|type IIc carcinoma
P02551886A0332|0 14|Restriction maps
P02551886A0332|26 33|plasmids
P02551886A0332|62 68|inserts
P02551886A0332|91 99|fragments
P02552143A0748|25 37|capsid protein
P02552143A0748|51 86|chloramphenicol acetyltransferase gene
P02552316A0526|26 35|caretakers
P02552316A0526|49 55|average
P02552316A0526|70 74|woman
P02552316A0526|100 117|seroconversion rate
P02552316A0526|122 128|percent
P02554310A0419|2 9|contrast
P02554310A0419|18 25|fragment
P02554310A0419|48 53|region
P02554310A0419|74 79|effect
P02555177A0488|6 10|pet54
P02555177A0488|55 60|genome
P02555177A0488|73 91|COX1 introns aI5 alpha
P02555177A0488|95 101|aI5 beta
P02555177A0488|119 136|COX3 gene expression
P02555177A0488|145 160|COX1 mRNA splicing
P02555177A0488|163 177|mRNA translation
P02555418A0973|0 6|Insert2
P02555418A0973|39 47|sequences
P02555418A0973|67 74|sequence
P02555519A0798|17 26|variations
P02555519A0798|29 34|length
P02555519A0798|45 52|sequence
P02555519A0798|64 95|complementarity determining region
P02555519A0798|95 102|peptides
P02555519A0798|111 118|H-chains
P02555519A0798|129 140|conservation
P02555519A0798|146 162|D-region structure
P02555519A0798|201 213|hapten binding
P02555703T0000|0 22|Tyrosine kinase oncogenes
P02555703T0000|31 53|interleukin-3 dependence
P02555703T0000|69 73|cells
P02555703T0000|81 97|signaling pathways
P02555703T0000|107 111|c-myc
P02555703T0000|123 132|regulation
P02555703T0000|135 152|c-myc transcription
P02555703T0000|176 180|v-abl
P02556264A0278|4 16|TC-II enhanson
P02556264A0278|38 48|kappa B motif
P02556264A0278|56 73|kappa chain enhancer
P02556264A0278|112 116|cells
P02556264A0278|164 178|cell specificity
P02556264A0278|184 194|kappa B motif
P02556269A0187|3 10|DNA helix
P02556269A0187|32 44|13mer sequence
P02556269A0187|85 100|hypersensitivity
P02556269A0187|125 132|nuclease
P02556269A0187|157 163|plasmid
P02556269A0187|225 242|gel electrophoresis
P02556269A0187|244 254|topoisomers
P02556603A0606|19 29|improvement
P02556603A0606|65 70|cancer
P02556603A0606|71 87|gallbladder cancer
P02556603A0606|102 115|bile duct cancer
P02557217A0000|0 13|Beta-endorphin
P02557217A0000|23 39|cortisol secretion
P02557217A0000|71 75|males
P02557217A0000|86 104|spray administration
P02557217A0000|108 125|IU salmon calcitonin
P02557217A0398|21 30|calcitonin
P02557217A0398|52 59|increase
P02557217A0398|81 110|corticotrophin-cortisol release
P02557350A0632|3 14|DNA sequences
P02557350A0632|22 29|proteins
P02557350A0632|33 39|SRP54sc
P02557350A0632|43 49|SRP54sp
P02557350A0632|79 86|SRP54mam
P02559630A0270|15 20|values
P02559630A0270|50 68|thromboplastin times
P02559630A0270|69 84|prothrombin times
P02559630A0270|85 97|thrombin times
P02559630A0270|98 107|fibrinogen
P02559630A0270|108 121|platelet counts
P02559630A0270|125 160|fibrin/fibrinogen degradation products
P02560415T0012|14 18|tumor
P02560415T0012|23 32|metastasis
P02560415T0012|35 39|mouth
P02560415T0012|48 58|face regions
P02562787A0637|19 25|protein
P02562825A0413|0 13|Responsiveness
P02562825A0413|16 35|beta-2 agonist therapy
P02562825A0413|55 60|agents
P02565405T0000|0 6|Drug use
P02565405T0000|9 21|trauma victims
P02565683A0841|9 17|heart rate
P02565683A0841|46 50|state
P02565683A0841|71 79|instances
P02565683A0841|82 90|reentrant
P02565683A0841|108 118|tachycardia
P02565683A0841|140 150|tachycardia
P02565807A1198|2 9|contrast
P02565807A1198|13 29|neu proto-oncogene
P02565807A1198|40 53|kinase activity
P02565807A1198|68 77|properties
P02565807A1198|100 105|levels
P02565807A1198|108 118|NIH 3T3 cells
P02565807A1198|142 149|ABSTRACT
P02565807A1198|164 168|WORDS
P02566613A0831|8 15|sequence
P02566613A0831|51 58|enhancer
P02566613A0831|64 71|TGACGTCA
P02566613A0831|71 81|nucleotides
P02566613T0000|0 25|Somatostatin gene expression
P02566613T0000|38 47|islet cells
P02566613T0000|73 90|DNA control elements
P02566613T0000|105 112|proteins
P02566680A0820|2 9|contrast
P02566680A0820|26 41|agonists fentanyl
P02566680A0820|42 49|morphine
P02566680A0820|50 60|I-methadone
P02566680A0820|64 74|levorphanol
P02566680A0820|119 123|doses
P02566680A0820|136 140|times
P02566680A0820|175 187|response rates
P02567030A0482|30 43|discrimination
P02567030A0482|47 54|controls
P02567030A0482|70 79|difficulty
P02567030A0482|98 105|reversal
P02568930T0000|0 8|Isolation
P02568930T0000|12 27|characterization
P02568930T0000|54 61|cytokine
P02568930T0000|77 87|stimulation
P02568930T0000|94 105|CD2 structure
P02568930T0000|113 124|T lymphocytes
P02569411A0151|5 15|termination
P02569411A0151|18 27|medication
P02569411A0151|31 37|animals
P02569411A0151|66 80|nucleus amygdala
P02571924A0000|7 11|cells
P02571924A0000|14 24|mating type A
P02571924A0000|45 73|yeast Rhodosporidium toruloides
P02571924A0000|82 96|mating pheromone
P02571924A0000|97 110|rhodotorucine A
P02571924A0000|120 132|undecapeptide
P02571924A0000|143 160|S-farnesyl cysteine
P02571924A0000|166 180|carboxy terminus
P02572777T0000|0 19|Tumour necrosis factor
P02572777T0000|39 54|distress syndrome
P02572928T0000|0 9|Monitoring
P02572928T0000|22 30|arthritis
P02573303A0000|3 10|decrease
P02573303A0000|32 43|stroke volume
P02573303A0000|71 78|pressure
P02573303A0000|135 150|contractile state
P02573336A0000|2 11|experiment
P02573336A0000|53 57|snake
P02573336A0000|72 79|subjects
P02573336A0000|82 86|order
P02573336A0000|115 119|event
P02573336A0000|143 148|retest
P02573336A0000|162 170|magnitude
P02573829T0000|12 23|conservation
P02573829T0000|45 49|sites
P02573829T0000|58 66|sequences
P02573829T0000|92 108|transcription unit
P02573829T0000|124 139|segmentation gene
P02573836A0244|21 30|importance
P02573836A0244|55 77|drug resistance phenotype
P02573836A0244|106 127|amino acid substitutions
P02573836A0244|132 152|core consensus sequence
P02573836A0244|156 172|nucleotide binding
P02573836A0244|173 178|GXGKST
P02574016A0428|55 66|control value
P02574016A0428|65 75|neostigmine
P02574016A0428|89 101|micrograms/kg
P02574016A0428|104 109|adults
P02574016A0428|112 124|micrograms/kg
P02574016A0428|127 133|infants
P02574016A0428|137 144|children
P02574052A0910|13 23|differences
P02574052A0910|35 42|relation
P02574052A0910|45 58|Type A behaviour
P02574052A0910|62 86|beta-adrenoceptor blockade
P02574193A0663|0 8|Selection
P02574193A0663|16 20|items
P02574193A0663|34 78|Institute Withdrawal Assessment-Benzodiazepines
P02574193A0663|79 84|CIWA-B
P02574193A0663|119 129|differences
P02574193A0663|137 144|baseline
P02574193A0663|156 172|withdrawal periods
P02574193A0663|184 191|subjects
P02574193A0663|202 209|symptoms
P02574193A0663|224 230|placebo
P02574193A0663|234 241|diazepam
P02574193A0663|252 259|subjects
P02574193A0663|265 281|contingency tables
P02574193A0663|293 310|regression analysis
P02574551T0000|0 13|Antihistamines
P02574551T0000|16 21|asthma
P02575174A0229|27 34|efficacy
P02575174A0229|38 43|safety
P02575174A0229|46 54|doxazosin
P02575174A0229|80 84|alpha
P02575174A0229|86 92|blocker
P02575174A0229|95 102|patients
P02575174A0229|115 126|hypertension
P02575174A0229|142 158|airflow limitation
P02575490A1021|0 19|Northern blot analysis
P02575490A1021|36 52|oIGF-I transcripts
P02575490A1021|77 87|nucleotides
P02575490A1021|95 105|transcripts
P02575490A1021|123 128|weight
P02575490A1021|131 135|liver
P02575567T0001|0 22|Materials science studies
P02575567T0001|59 63|wires
P02575959A0643|3 13|latency time
P02575959A0643|20 39|lactate concentration
P02575959A0643|53 58|values
P02575959A0643|78 85|training
P02576405A0223|2 9|patients
P02576405A0223|35 43|therapies
P02576405A0223|58 66|melphalan
P02576405A0223|68 81|CBV combination
P02576405A0223|82 108|cyclophosphamide-BCNU-VP-16
P02576405A0223|113 123|EDAP regimen
P02576405A0223|124 128|VP-16
P02576405A0223|129 136|platinum
P02576405A0223|145 153|responses
P02576405A0223|167 174|patients
P02577458A0412|3 12|discussion
P02577458A0412|39 43|drugs
P02577458A0412|48 58|angiotensin
P02577458A0412|69 84|enzyme inhibitors
P02577458A0412|101 116|receptor blockers
P02577458A0412|120 137|calcium antagonists
P02577867T0000|16 22|homolog
P02577867T0000|28 39|oncogene jun.
P02580830A1131|7 14|sequence
P02580830A1131|29 34|region
P02580830A1131|48 54|cap site
P02580830A1131|65 71|AFP gene
P02580830A1131|79 89|% similarity
P02580830A1131|110 115|region
P02580830A1131|121 132|mouse AFP gene
P02582240A1009|4 16|ATP/GTP ratios
P02582240A1009|25 34|initiation
P02582240A1009|37 54|RNA primer synthesis
P02582240A1009|57 66|dCTTT sites
P02582240A1009|77 89|ATP/GTP ratios
P02582240A1009|98 107|initiation
P02582240A1009|110 118|dCCC sites
P02582918A0000|5 33|hepatitis B vaccine immunization
P02582918A0000|34 54|serum antibody response
P02582918A0000|77 81|cases
P02582918A0000|85 92|anti-HBs
P02582918A0000|109 120|S/N Ratio Unit
P02584969A0119|15 20|design
P02584969A0119|42 56|regression model
P02584969A0119|67 76|treatments
P02584969A0119|93 100|end point
P02584969A0119|108 121|protection time
P02585492A1005|13 32|complementation tests
P02585492A1005|46 55|P7 proteins
P02585492A1005|77 82|P1 parA
P02585492A1005|85 95|parB mutants
P02585492A1005|102 111|P1 proteins
P02585492A1005|131 141|P7 mutations
P02586485A0511|0 4|GN101
P02586485A0511|5 11|YC819-9
P02586513A0622|0 7|Analysis
P02586513A0622|34 45|ama-1 product
P02586513A0622|64 71|identity
P02586513A0622|86 92|subunit
P02586513A0622|112 120|organisms
P02586513A0622|132 139|presence
P02586513A0622|143 157|zinc finger motif
P02586513A0622|165 177|amino terminus
P02586513A0622|199 204|domain
P02586513A0622|227 235|heptamers
P02586513A0622|243 257|consensus Tyr Ser
P02586513A0622|261 266|Thr Ser
P02590097A0093|7 17|involvement
P02590097A0093|36 47|infiltration
P02590097A0093|52 57|mucosa
P02590097A0093|72 83|lobe bronchus
P02590097A0093|119 128|gammopathy
P02590097A0093|134 142|Type Kappa
P02590391A0442|19 28|parameters
P02590391A0442|28 40|heart contents
P02590391A0442|50 55|lipids
P02590391A0442|61 73|phospholipids
P02590391A0442|74 92|phosphatidylcholine
P02590391A0442|93 116|phosphatidylethanolamine
P02590391A0442|117 138|diphosphatidylglycerol
P02590391A0442|139 151|sphingomyelin
P02590391A0442|160 174|acid composition
P02590391A0442|181 197|phospholipid class
P02590391A0442|224 230|grading
P02590391A0442|236 242|lesions
P02590540A0741|5 9|women
P02590540A0741|27 35|diagnoses
P02590540A0741|52 57|levels
P02590540A0741|58 63|excess
P02590615A0636|22 26|state
P02590615A0636|30 35|timing
P02590615A0636|91 96|manner
P02590615A0636|99 114|pharmacokinetics
P02590615A0636|117 126|nifedipine
P02590615A0636|147 153|tablets
P02590869A0743|14 19|calves
P02590869A0743|32 39|serum IgG
P02590869A0743|40 48|lavage IgG
P02590869A0743|69 77|LNA titers
P02590869A0743|83 94|lavage fluids
P02590869A0743|98 102|serum
P02590869A0743|115 120|SC dose
P02590869A0743|129 136|bacteria
P02591078A0000|6 19|investigations
P02591078A0000|33 41|Grenz rays
P02591078A0000|64 88|contact dermatitis reaction
P02591078A0000|106 120|Langerhans cells
P02591078A0000|133 146|OKT6 antibodies
P02591078A0000|150 167|electron microscopy
P02591078A0000|184 192|epidermis
P02591969A0961|3 10|elements
P02591969A0961|25 49|glucocorticoid stimulation
P02591969A0961|52 71|ADH gene transcription
P02591969A0961|99 104|region
P02592543A0106|10 16|studies
P02592543A0106|38 52|characteristics
P02592543A0106|53 78|Kanagawa hemolysin reactions
P02592543A0106|82 96|plasmid profiles
P02592543A0106|101 107|patient
P02592543A0106|127 134|isolates
P02592543A0106|140 147|organism
P02592640A0466|4 9|values
P02592640A0466|16 22|retinol
P02592640A0466|26 38|beta-carotene
P02592640A0466|57 63|cheeses
P02592640A0466|75 79|cream
P02592640A0466|89 94|cheese
P02592640A0466|136 140|cream
P02592640A0466|151 156|cheese
P02592640A0466|198 202|cream
P02592640A0466|214 220|retinol
P02592640A0466|229 241|beta-carotene
P02592961A0327|0 5|COGLAB
P02592961A0327|14 21|measures
P02592961A0327|62 83|psychomotor performance
P02595451A1136|20 31|aniridia gene
P02595451A1136|49 72|T-cell leukemia breakpoint
P02595451A1136|83 96|marker sequence
P02595451A1136|106 110|sides
P02595451T0000|15 25|deletion map
P02595451T0000|33 45|chromosome 11p
P02595451T0000|46 53|analysis
P02595451T0000|56 70|J1 series hybrids
P02597484A0624|4 10|respect
P02597484A0624|22 32|diffusivity
P02597484A0624|35 43|platelets
P02597484A0624|54 70|surface reactivity
P02597484A0624|96 106|differences
P02597484A0624|130 138|materials
P02597549A0964|16 23|patients
P02597549A0964|54 65|dipyridamole
P02597549A0964|67 74|mg X 3/day
P02597549A0964|78 84|aspirin
P02597549A0964|87 92|mg/day
P02597549A0964|106 119|recovery period
P02597549A0964|151 161|prothrombin
P02597549A0964|171 189|thromboplastin times
P02598034A0000|0 21|Middle-latency auditory
P02598034A0000|28 37|potentials
P02598034A0000|38 42|MAEPs
P02598034A0000|57 64|controls
P02598034A0000|68 75|patients
P02598034A0000|85 91|lesions
P02598034A0000|116 121|cortex
P02598745A0251|24 37|Sylvius fissure
P02598745A0251|40 44|cases
P02599995A1031|13 27|activity studies
P02599995A1031|46 53|times MBC
P02599995A1031|58 67|penicillin
P02599995A1031|85 92|activity
P02599995A1031|113 125|staphylococci
P02599995A1031|134 141|survival
P02600306A0140|47 55|detection
P02600306A0140|58 79|envelope phase disparity
P02600306A0140|97 106|processing
P02600306A0140|120 126|channel
P02600306A0140|137 143|AM tones
P02601707A0986|0 19|Gel retardation assays
P02601707A0986|32 36|DNase
P02601707A0986|38 49|footprinting
P02601707A0986|53 84|diethyl pyrocarbonate interference
P02601707A0986|103 108|factor
P02601707A0986|127 136|C2 myotubes
P02601707A0986|140 152|BC3H1 myocytes
P02601707A0986|183 190|sequence
P02601707A0986|219 224|region
P02602150A0993|14 19|plants
P02602150A0993|52 59|analysis
P02602150A0993|62 77|sequence elements
P02602150A0993|87 109|replication origin region
P02602150A0993|120 131|construction
P02602150A0993|138 147|generation
P02602150A0993|150 156|vectors
P02602150A0993|160 176|gene amplification
P02602150A0993|179 184|plants
P02602150A0993|200 212|virus replicon
P02603374A0383|7 15|rhinotomy
P02603374A0383|37 51|dorsal rhinotomy
P02603374A0383|59 74|patient morbidity
P02603374A0383|96 108|complications
P02603923A0220|18 30|skin incisions
P02603923A0220|119 130|growth factor
P02603923A0220|129 133|ng/ml
P02603923A0220|143 148|Ringer
P02603923A0220|149 163|lactate solution
P02603923A0220|189 195|fashion
P02604420A0234|6 14|challenge
P02604420A0234|15 22|rebiopsy
P02604420A0234|34 52|reticulin antibodies
P02604420A0234|74 78|years
P02604420A0234|79 83|range
P02604420A0234|112 120|year study
P02605160A0000|3 8|effect
P02605160A0000|11 20|iron intake
P02605160A0000|23 36|59Fe absorption
P02605160A0000|47 55|pregnancy
P02605160A0000|77 84|Fe status
P02605160A0000|102 110|pregnancy
P02605182A0936|10 24|protein sequence
P02605182A0936|75 87|signal peptide
P02605182A0936|124 134|polypeptide
P02605679A0306|0 7|Analysis
P02605679A0306|13 25|rate constants
P02605679A0306|42 61|isomerization rate k12
P02605679A0306|96 110|degradation rate
P02605679A0306|116 120|delta
P02605679A0306|122 130|ester kdeg
P02605679A0306|147 160|hydrolysis rate
P02605679A0306|166 170|delta
P02605679A0306|172 179|ester k24
P02607766A0000|1 8|protocol
P02607766A0000|27 37|preparation
P02607766A0000|41 56|characterization
P02607766A0000|60 81|quality control material
P02607766A0000|106 118|concentration
P02607766A0000|120 126|cadmium
P02607766A0000|134 144|microgram/L
P02607766A0000|161 173|micrograms/dL
P02607766A0000|182 186|blood
P02607766A0000|222 233|micrograms/L
P02607766A0000|232 238|mercury
P02607766A0000|247 258|micrograms/L
P02607766A0000|269 281|micrograms/dL
P02607766A0000|291 295|blood
P02607766A0000|313 329|spiking-solutions
P02607766A0000|342 346|salts
P02609112A0000|0 12|Reagent strips
P02609112A0000|35 42|practice
P02609112A0000|45 62|laboratory medicine
P02609112A0000|93 104|laboratories
P02614668A0971|19 31|concentration
P02614668A0971|38 42|ng/ml
P02614668A0971|48 52|serum
P02615078A0283|13 22|antibodies
P02615078A0283|38 50|actinomycetes
P02617623A0740|0 5|LON-72
P02617623A0740|8 15|isolates
P02617623A0740|16 21|LON-73
P02617623A0740|23 28|LON-71
P02617623A0740|33 38|LON-10
P02617623A0740|51 59|altitudes
P02617623A0740|89 95|village
P02620085A0656|0 5|Animal
P02620085A0656|29 40|applications
P02620085A0656|43 48|plates
P02620085A0656|49 54|screws
P02620085A0656|73 91|replacement implants
P02620085A0656|111 118|material
P02620085A0656|132 138|results
P02621983T0001|0 11|Significance
P02621983T0001|34 45|acid analysis
P02621983T0001|56 60|tests
P02623038A0632|2 8|changes
P02623038A0632|32 42|performance
P02623038A0632|45 52|controls
P02623038A0632|70 85|saline injections
P02627159A0899|19 30|IgG4 antibody
P02627159A0899|42 46|index
P02627159A0899|59 71|immunotherapy
P02629109A0000|11 26|fertility decline
P02629109A0000|37 46|population
P02629109A0000|52 67|Mississippi Delta
P02629109A0000|139 148|population
P02629109A0000|201 210|1880 levels
P02630543A0210|16 31|staining affinity
P02630543A0210|41 50|antibodies
P02630543A0210|63 73|tissue cells
P02630543A0210|117 123|changes
P02630543A0210|125 131|numbers
P02630543A0210|139 153|cell populations
P02630543A0210|167 172|volume
P02630543A0210|195 200|tissue
P02631505A0382|0 9|Ampicillin
P02631505A0382|28 41|aminoglycoside
P02631505A0382|52 60|treatment
P02631505A0382|68 72|cases
P02631566A0151|0 13|Alkoxymetgyl-3
P02631566A0151|14 40|dimethylpyridinium chlorides
P02631566A0151|66 85|3,4-dimethylpyridine
P02631566A0151|90 112|chloromethyl alkyl ethers
P02631566A0151|163 171|chlorides
P02631566A0151|186 194|reactions
P02631566A0151|197 220|1-ethyloxymethylimidazol
P02631566A0151|225 249|chloromethyl alkyl sulfides
P02631743A0275|17 25|incidence
P02631743A0275|38 52|color deficiency
P02631743A0275|58 64|Koreans
P02631743A0275|77 81|H-R-R
P02631743A0275|99 104|plates
P02631887A0000|6 13|patients
P02631887A0000|48 56|lymphomas
P02632904A0619|3 10|relation
P02632904A0619|18 23|VE/VO2
P02632904A0619|27 31|Q/VO2
P02632904A0619|58 68|correlation
P02634490A0186|15 23|diagnosis
P02634490A0186|30 39|affections
P02634490A0186|60 65|course
P02634490A0186|66 76|sialography
P02634490A0186|80 92|CT examination
P02634490A0186|113 124|ATB treatment
P02634490A0186|164 170|therapy
P02634872A0000|0 9|Retrograde
P02634872A0000|34 50|endodontics system
P02634872A0000|89 96|approach
P02636920T0001|13 17|study
P02636920T0001|28 70|Pharmacopoeia Heparin Sodium Reference Standard
P02637597A0362|11 17|studies
P02637597A0362|28 39|relapse stage
P02637597A0362|46 52|disease
P02637597A0362|68 75|serum ANA
P02637597A0362|84 91|IgM level
P02637597A0362|109 116|decrease
P02638964A0372|3 15|maximum stress
P02638964A0372|35 45|examination
P02638964A0372|51 59|composite
P02638964A0372|67 72|kg/mm2
P02638964A0372|75 85|equilibrium
P02638964A0372|91 95|water
P02638964A0372|109 117|composite
P02641762T0001|8 19|heart disease
P02641762T0001|31 56|exercise stress thallium-201
P02641762T0001|67 78|scintigraphy
P02641762T0001|80 89|comparison
P02641762T0001|92 96|SPECT
P02641762T0001|107 116|eye display
P02642466T0000|0 15|Sequence analysis
P02642466T0000|47 63|membrane immunogen
P02642976A1474|9 26|consensus sequences
P02642976A1474|52 59|elements
P02644735A0427|2 9|FP mutant
P02644735A0427|10 18|AcFP875-2
P02644735A0427|30 38|insertion
P02644735A0427|41 55|S. frugiperda DNA
P02644735A0427|76 86|transcripts
P02644735A0427|93 102|S1 analysis
P02644735A0427|131 146|host cell sequence
P02645276T0088|0 11|Construction
P02645276T0088|15 32|RIP1 deletion strain
P02645276T0088|36 44|isolation
P02645276T0088|68 74|mutants
P02645431A1562|22 35|hypocitraturia
P02645431A1562|56 63|acidosis
P02645431A1562|74 79|defect
P02645431A1562|96 103|function
P02646007T0000|29 36|leukemia
P02646007T0000|49 56|leukemia
P02646007T0000|60 69|thrombosis
P02646007T0000|74 91|protein C deficiency
P02647403A0000|11 24|hallucinations
P02647403A0000|37 51|psychopathology
P02647403A0000|85 89|years
P02647918A0423|10 14|group
P02647918A0423|27 45|somatomedin-C levels
P02647918A0423|74 78|error
P02647918A0423|110 114|ng/ml
P02647918A0588|0 10|Application
P02647918A0588|22 29|criteria
P02647918A0588|52 59|patients
P02647918A0588|71 78|GH levels
P02647918A0588|84 88|ng/ml
P02647918A0588|91 98|patients
P02647918A0588|112 130|somatomedin-C values
P02647918A0588|132 139|patients
P02647918A0588|155 167|GH suppression
P02647918A0588|176 180|ng/ml
P02647918A0588|198 205|patients
P02647918A0588|230 237|criteria
P02647918A0588|241 253|disappearance
P02647918A0588|270 279|GH response
P02647918A0588|282 293|TRH/GnRH test
P02647937A0191|11 18|sequence
P02647937A0191|29 36|planning
P02647937A0191|90 97|problems
P02648396A0565|2 12|Rat-1a cells
P02648396A0565|16 25|expression
P02648396A0565|33 41|c-jun mRNA
P02648396A0565|62 68|ability
P02648396A0565|71 75|clone
P02648396A0565|82 88|agarose
P02648396A0565|92 101|form tumors
P02648396A1033|11 19|formation
P02648396A1033|61 71|combination
P02648396A1033|93 139|tumor promoter phorbol 12-tetradecanoate 13-acetate
P02648646A0216|0 23|Platelet activating factor
P02648646A0216|37 41|doses
P02648646A0216|46 60|minute intervals
P02648646A0216|64 77|airway response
P02648646A0216|88 93|change
P02648646A0216|103 116|expiratory flow
P02648646A0216|130 137|capacity
P02648646A0932|21 31|correlation
P02648646A0932|39 62|baseline PC40 methacholine
P02648646A0932|111 120|micrograms
P02648646A0932|138 147|micrograms
P02648646A0932|149 172|platelet activating factor
P02649445A0412|11 27|IRI concentrations
P02649445A0412|57 68|body builders
P02649445A0412|68 73|medium
P02649445A0412|76 83|controls
P02649811T0000|10 22|contraception
P02649811T0000|24 42|family planning study
P02650663A0178|4 9|rating
P02650663A0178|35 42|subjects
P02650663A0178|62 71|impairment
P02650663A0178|83 90|dementia
P02650663A0178|96 108|Alzheimer type
P02650663A0178|141 146|degree
P02650663A0178|157 165|diagnosis
P02650663A0178|176 183|dementia
P02651448A0000|34 42|diffusion
P02651448A0000|56 66|dissolution
P02651448A0000|88 95|material
P02651448A0000|103 118|depolymerization
P02651448A0000|119 123|Type A
P02651448A0000|128 137|bioerosion
P02651448A0000|147 162|depolymerization
P02651448A0000|163 167|Type B
P02651487A0000|25 46|calcium channel blockers
P02651487A0000|59 69|contraction
P02651487A0000|86 91|muscle
P02651487A0000|103 111|knowledge
P02651487A0000|117 122|effect
P02651487A0000|125 153|excitation contraction coupling
P02651487A0000|168 173|glands
P02651487A0000|195 201|insulin
P02651487A0000|205 219|glucagon release
P02655381A0000|4 10|studies
P02655381A0000|28 38|possibility
P02655381A0000|54 60|factors
P02655381A0000|71 79|impotence
P02655381A0000|96 100|means
P02655381A0000|103 126|laboratory investigations
P02655381A0000|131 142|hypogonadism
P02655381A0000|143 160|hyperprolactinemia
P02655381A0000|161 170|occlusions
P02655381A0000|211 218|arteries
P02655381A0000|224 235|incompetence
P02655381A0000|247 258|neuropathies
P02656257A0000|16 36|DNA inversion system Cin
P02656257A0000|49 63|bacteriophage P1
P02656257A0000|75 85|recombinase
P02656257A0000|97 114|crossing-over sites
P02656257A0000|134 141|enhancer
P02657388A1011|3 18|terminator region
P02657388A1011|28 38|termination
P02657388A1011|41 51|transcripts
P02657388A1011|63 76|RNA polymerase I
P02657883A0000|0 9|US-Doppler
P02657883A0000|27 35|attention
P02657883A0000|50 55|method
P02657883A0000|72 81|evaluation
P02657883A0000|97 104|fistulas
P02657883T0001|0 6|Doppler
P02657883T0001|36 43|fistulae
P02657883T0001|47 54|dialysis
P02664229A0138|8 15|cosmesis
P02664229A0138|16 24|extension
P02664229A0138|30 34|scope
P02664229A0138|40 47|problems
P02664229A0138|74 79|repair
P02664229A0138|89 97|treatment
P02664229A0138|123 129|fistula
P02664229A0138|154 166|Arap procedure
P02664229A0138|186 195|advantages
P02664229A0138|204 212|operation
P02664229A0138|238 255|hypospadias repairs
P02666034A1520|12 19|patients
P02666034A1520|27 32|course
P02666034A1520|35 41|therapy
P02666034A1520|56 83|vasodilator calcium antagonist
P02666034A1520|108 119|vasodilation
P02666034A1520|171 183|placebo course
P02666034A1520|186 192|therapy
P02666404A0220|3 22|galactose transporter
P02666404A0220|32 39|sequence
P02666404A0220|53 60|homology
P02666404A0220|66 76|superfamily
P02666404A0220|79 95|sugar transporters
P02666404A0220|117 133|HepG2-erythrocyte
P02666404A0220|142 166|muscle glucose transporters
P02666404A0220|170 177|rat brain
P02666404A0220|181 204|liver glucose transporters
P02666404A0220|223 228|xylose
P02666404A0220|232 249|arabinose permeases
P02666404A0220|268 274|glucose
P02666404A0220|275 281|maltose
P02666404A0220|285 305|galactose transporters
P02666568A0000|24 31|patients
P02666568A0000|48 52|study
P02666568A0000|55 68|protocol TCL821
P02667259A0331|32 40|reactions
P02667259A0331|64 69|nausea
P02667259A0331|68 76|dizziness
P02668691A0570|82 86|genes
P02669199A0000|0 18|Tumor necrosis factor
P02669199A0000|42 54|shock syndrome
P02669199A0000|77 85|endotoxin
P02670457T0000|3 20|calcium requirement
P02670457T0000|35 41|storage
P02670457T0000|54 60|explant
P02674141A1202|10 24|cysteine residue
P02674141A1202|51 73|activation peptide region
P02674141A1202|78 86|proenzyme
P02674327A0493|25 38|codon usage bias
P02674327A0493|76 89|polyhedrin gene
P02674671A0601|20 35|DNA transformants
P02674671A0601|52 62|replacement
P02674671A0601|75 86|met2 mutation
P02674671A0601|110 115|allele
P02674674A1308|3 9|results
P02674674A1308|28 33|notion
P02674674A1308|53 57|sites
P02674674A1308|64 74|OBF1 protein
P02674674A1308|96 106|ARS function
P02674674A1308|111 116|origin
P02674674A1308|119 129|replication
P02674679A1237|5 9|basis
P02674679A1237|12 39|S1 nuclease protection analysis
P02674679A1237|42 56|RNA preparations
P02674679A1237|68 79|mouse tissues
P02674679A1237|102 106|genes
P02674679A1237|119 124|levels
P02674679A1237|127 136|expression
P02674679A1237|151 161|specificity
P02674679A1237|164 183|start site utilization
P02675492A0806|11 18|patients
P02675492A0806|33 43|improvement
P02675492A0806|55 67|Ritchie-Index
P02675492A0806|68 76|pain score
P02677002A0205|29 35|enzymes
P02677002A0205|65 97|equilibrium N-carbamyl-L-aspartate
P02677002A0205|95 99|C-Asp
P02677002A0205|110 126|carbamyl phosphate
P02677002A0205|133 154|equilibrium Pi exchanges
P02677429A0366|0 12|Survival rates
P02677429A0366|27 40|treatment group
P02677429A0366|69 74|months
P02677429A0366|98 111|treatment group
P02677429A0366|136 141|months
P02677429A0366|179 184|months
P02677429A0366|200 207|subjects
P02677429A0366|253 260|subjects
P02677429A0366|274 280|complex
P02677429A0366|294 307|treatment group
P02677666A0356|0 6|Mapping
P02677666A0356|30 49|complementation group
P02677666A0356|67 73|mutants
P02677666A0356|88 94|ag alpha
P02677666A0356|96 103|mutation
P02679804A2000|3 10|products
P02679804A2000|13 22|genes ura10
P02679804A2000|61 70|channeling
P02679804A2000|72 93|orotidine monophosphate
P02680843A0724|8 18|application
P02680843A0724|27 36|REM latency
P02680843A0724|53 58|groups
P02680843A0724|64 76|investigation
P02684159A0870|0 20|Hybridization analysis
P02684159A0870|61 69|kilobases
P02684585T0001|0 23|Agranulocytosis treatment
P02684585T0001|28 35|rhGM-CSF
P02685331A0523|3 24|R. meliloti nifH promoter
P02685331A0523|48 59|nifH promoter
P02685331A0523|65 69|sigma
P02685331A0523|82 102|methylation protection
P02685331A0523|105 119|guanine residues
P02685331A0523|150 160|nucleotides
P02685331A0523|177 181|sigma
P02685331A0523|194 202|promoters
P02685461A0380|13 20|symptoms
P02685461A0380|26 32|disease
P02685461A0380|50 54|group
P02685461A0380|57 64|patients
P02685565A0165|82 86|cells
P02685565A0165|119 128|c-myb genes
P02686588A0592|15 22|analysis
P02686588A0592|36 45|hematocrit
P02686588A0592|49 58|hemoglobin
P02686588A0592|78 96|alkaline phosphatase
P02686588A0592|108 112|group
P02686749A0000|11 28|health significance
P02686749A0000|44 50|changes
P02686749A0000|63 70|exposure
P02686749A0000|73 79|cadmium
P02686749A0000|82 88|workers
P02686749A0000|100 107|exposure
P02686749A0000|120 128|discovery
P02686749A0000|149 157|excretion
P02686749A0000|160 178|beta 2-microglobulin
P02686749A0000|181 201|retinol binding protein
P02686749A0000|242 246|years
P02686980A0000|2 6|order
P02686980A0000|40 51|organization
P02686980A0000|67 75|nucleolus
P02686980A0000|122 131|components
P02686980A0000|137 141|yeast
P02686985A0811|1 33|transcription factor exclusion assay
P02686985A0811|54 65|PCF1 mutation
P02686985A0811|84 89|stages
P02686985A0811|92 104|transcription
P02686985A0811|132 147|complex formation
P02686985A0811|160 166|effects
P02686985A0811|181 189|component
P02686985A0811|201 207|complex
P02688772T0000|0 9|Psychiatry
P02689136A1851|12 18|effects
P02689439A0000|12 36|glutathione S-transferases
P02689439A0000|59 69|superfamily
P02689439A0000|77 86|isoenzymes
P02689439A0000|103 113|conjugation
P02689439A0000|129 138|substrates
P02689439A0000|143 153|glutathione
P02689439A0402|26 32|regions
P02689439A0402|35 40|pmGT10
P02689439A0402|55 60|degree
P02689439A0402|63 70|homology
P02689439A0402|77 82|region
P02689439A0402|88 97|rat Yb1 gene
P02689439A0402|107 112|region
P02689439A0402|115 119|pmGT2
P02689439A0402|134 141|homology
P02689439A0402|160 165|region
P02689439A0402|171 180|rat Yb2 gene
P02689544A0456|0 4|Model
P02689544A0456|14 22|abutments
P02689544A0456|37 43|incisor
P02689544A0456|72 80|abutments
P02691557A0273|3 11|incidence
P02691557A0273|19 36|breathing movements
P02691557A0273|107 120|concentrations
P02691557A0273|121 129|plasma PGE
P02691557A0273|163 168|period
P02691557A0273|171 179|gestation
P02691811A0355|22 29|recovery
P02691811A0355|29 43|plasma potassium
P02691811A0355|57 61|spite
P02691811A0355|79 91|blood acidosis
P02691811A0355|129 141|concentration
P02691998A0672|112 130|bolus administration
P02692881A0354|2 11|comparison
P02692881A0354|30 34|women
P02692881A0354|56 60|women
P02692881A0354|61 65|women
P02692881A0354|83 90|increase
P02692881A0354|92 100|heart rate
P02692881A0354|161 171|derangement
P02692881A0354|178 185|function
P02692881A0354|198 205|increase
P02692881A0354|208 212|serum
P02692881A0354|226 234|reduction
P02692881A0354|236 250|sodium excretion
P02692881A0354|254 258|total
P02692881A0354|272 287|calcium excretion
P02692881A0354|298 302|level
P02692881A0354|305 319|sodium excretion
P02693208A0166|28 40|recombination
P02693208A0166|59 67|mutations
P02693208A0166|77 81|rad52
P02693208A0166|89 107|repeat recombination
P02693208A0166|144 152|sequences
P02693593A0866|10 16|protein
P02693593A0866|21 34|leader sequence
P02693593A0866|39 48|amino acids
P02694731A0241|16 24|knowledge
P02694731A0241|29 40|epidemiology
P02694731A0241|43 51|Parkinson
P02694731A0241|53 59|disease
P02694731A0241|92 101|hypotheses
P02694731A0241|111 120|hypotheses
P02694731A0241|153 159|profile
P02694731A0241|174 180|testing
P02695914T0000|3 19|stereoselectivity
P02695914T0000|22 31|drug action
P02700977A0444|0 9|Scotchbond
P02700977A0444|28 38|penetration
P02700977A0444|69 80|XR bond/Silus
P02700977A0444|85 95|combination
P02702566A0000|1 11|combination
P02702566A0000|14 22|cisplatin
P02702566A0000|26 39|5-fluorouracil
P02702566A0000|77 84|infusion
P02702566A0000|114 123|neck cancer
P02702849A0418|0 28|Metformin plasma concentrations
P02702849A0418|55 62|patients
P02702849A0418|120 147|patients plasma concentrations
P02702849A0418|179 190|micrograms/l
P02703121T0000|0 8|Diagnosis
P02703121T0000|18 38|sclerosing cholangitis
P02703121T0000|42 51|blood donor
P02703121T0000|64 91|serum alanine aminotransferase
P02703925A0359|34 45|subgroupings
P02703925A0359|64 88|sedimentation coefficients
P02703925A0359|92 113|polydispersity profiles
P02703925A0359|135 145|conclusions
P02703925A0359|155 177|proteoglycan aggregation
P02703925A0359|180 194|sedimentability
P02703925A0359|226 251|cartilage matrix degradation
P02703925A0359|258 264|S values
P02703925A0359|268 280|proteoglycans
P02703925A0359|290 295|weight
P02703925A0359|306 310|areas
P02703925A0359|318 323|values
P02703925A0359|340 345|weight
P02703925A0359|356 360|areas
P02703925A0359|372 378|finding
P02703925A0359|387 402|cartilage samples
P02703925A0359|404 412|inversion
P02703925A0359|419 425|pattern
P02703925A0359|441 457|matrix degradation
P02703925A0359|475 483|HW regions
P02703925A0359|516 520|areas
P02703925A0359|532 549|S value distribution
P02703925A0359|556 573|cartilage thickness
P02703925A0359|606 624|proteoglycan content
P02703925A0359|631 638|distance
P02703925A0359|652 658|surface
P02703925A0359|673 686|cartilage layer
P02703925A0359|696 700|cases
P02703925A0359|712 717|amount
P02703925A0359|720 729|aggregates
P02703925A0359|752 766|sedimentability
P02703925A0359|806 812|samples
P02704579A1078|12 23|relationship
P02704579A1078|40 48|evolution
P02704579A1078|54 60|disease
P02704579A1078|68 73|CRS/BW
P02704579A1078|77 97|gas exchange parameters
P02704579A1078|107 116|a/AO2 ratio
P02704579A1078|134 144|gas exchange
P02704579A1078|163 175|lung mechanics
P02705072A0464|0 8|End points
P02705072A0464|50 59|infarction
P02705072A0464|73 77|death
P02705296A0231|21 26|weight
P02705296A0231|32 42|polyprotein
P02705296A0231|62 72|kilodaltons
P02705556A1049|10 15|demand
P02705556A1049|29 34|supply
P02705556A1049|53 63|flow reserve
P02707909A0209|2 18|alternative method
P02707909A0209|59 66|fraction
P02707909A0209|73 85|dialysate flow
P02707909A0209|101 108|dialyses
P02708288A0139|0 19|Liquid chromatography
P02708288A0139|36 44|detection
P02708288A0139|45 49|LC/AD
P02708288A0139|97 106|metabolism
P02708288A0139|108 121|base hydrolysis
P02708288A0139|124 138|fluazifop-butyl
P02708288A0139|141 148|soybeans
P02708288A0139|152 161|soybean oil
P02708288A0621|3 17|dichloromethane
P02708288A0621|33 37|phase
P02708288A0621|55 62|aliquots
P02708288A0621|79 89|PRP-1 liquid
P02708288A0621|105 110|column
P02708288A0621|152 160|compounds
P02708288A0621|182 190|potential
P02708288A0621|235 242|detector
P02708288A0621|247 259|oxidation mode
P02708353A1080|0 25|Primer extension experiments
P02708353A1080|42 68|transcription initiation site
P02708353A1080|78 85|position
P02708353A1080|151 160|P-450e gene
P02708353A1452|16 38|polymerase chain reaction
P02708353A1452|70 80|transcripts
P02708353A1452|105 121|polysome fractions
P02708353A1452|143 153|utilization
P02708353A1452|160 165|tissue
P02709081T0000|0 9|Validation
P02709081T0000|15 20|survey
P02709081T0000|23 32|work styles
P02709081T0000|34 47|profile measure
P02709081T0000|53 73|type A behaviour pattern
P02709819A0495|34 53|ciprofloxacin therapy
P02711145T0000|0 16|HIV infectiousness
P02711167A0818|16 22|turnout
P02711167A0818|25 33|PFB-group
P02711167A0818|55 75|serum pepsinogen levels
P02711167A0818|95 100|degree
P02711167A0818|111 116|damage
P02711167A0818|124 130|animals
P02711601A0601|16 25|inhibition
P02711601A0601|28 50|acid phosphatase activity
P02711601A0601|53 59|control
P02711601A0601|73 82|guinea pigs
P02712246T0042|29 43|characteristics
P02712450A0989|11 15|PACO2
P02712450A0989|19 22|mm Hg
P02712450A0989|34 38|drive
P02712450A0989|81 88|subjects
P02712450A0989|95 102|response
P02712450A0989|132 137|others
P02712450A0989|145 152|response
P02712450A0989|156 166|hypercapnia
P02712450A0989|170 176|changes
P02712450A0989|179 183|drive
P02712450A0989|204 209|groups
P02713310T0000|0 12|Fundus changes
P02713310T0000|40 57|glomerulonephritis
P02713310T0000|67 72|drusen
P02713310T0000|91 96|report
P02713520T0000|7 17|dose effects
P02713520T0000|20 34|methyl parathion
P02713520T0000|37 46|nuthatches
P02713520T0000|47 60|cholinesterase
P02713520T0000|64 78|ptilochronology
P02713994A0482|3 7|titer
P02713994A0482|14 20|HSV type
P02713994A0482|29 35|HSV type
P02713994A0482|37 46|antibodies
P02713994A0482|52 58|mothers
P02713994A0482|62 70|cord blood
P02714525A0529|0 11|Kidney weight
P02714525A0529|29 39|weight ratio
P02714525A0529|77 85|dose level
P02714525A0529|93 97|weeks
P02714525A0529|115 124|dose levels
P02714525A0529|132 136|weeks
P02714525A0529|139 146|exposure
P02714852T0000|7 15|variation
P02714852T0000|18 22|HLA-B
P02714852T0000|26 39|HLA-C sequences
P02714852T0000|46 54|evolution
P02714852T0000|60 71|HLA-B alleles
P02717133T0001|1 6|method
P02717133T0001|28 48|development conditions
P02717133T0001|51 74|summary oxygen consumption
P02717349A0311|39 45|fitness
P02717349A0311|49 53|women
P02718683A0142|0 18|Handgrip dynamometry
P02718683A0142|46 53|patients
P02720966A0455|15 19|fluid
P02720966A0455|36 48|concentration
P02720966A0455|57 63|mu kat/L
P02720966A0455|91 100|meningitis
P02720966A0455|103 110|patients
P02720966A0455|121 125|years
P02720966A0455|126 136|sensitivity
P02720966A0455|141 151|specificity
P02720966A0455|159 168|efficiency
P02721169A0171|0 8|NERVTRACK
P02721169A0171|31 39|data items
P02721169A0171|60 65|manner
P02721169A0171|99 111|relationships
P02723503T0000|0 8|Swim-over
P02723503T0000|11 27|alternative method
P02723503T0000|47 57|spermatozoa
P02724227T0000|0 15|Perfusion washout
P02724227T0000|44 56|flap tolerance
P02724227T0000|59 66|ischemia
P02725495A0929|12 19|sequence
P02725495A0929|25 35|U2 RNA region
P02725495A0929|55 84|pre-mRNA branchpoint recognition
P02725495A0929|87 91|yeast
P02725495A0929|113 126|metazoan U2 RNAs
P02725495A0929|148 159|trypanosomes
P02725513A0617|25 41|CHO spacer promoter
P02725513A0617|81 101|metazoan RNA polymerase
P02725513A0617|102 110|promoters
P02725513A0617|119 126|G residue
P02725513A0617|129 136|position
P02727909A0383|7 15|amplitude
P02727909A0383|21 31|aggregation
P02727909A0383|34 39|plates
P02727909A0383|44 51|decrease
P02727909A0383|57 65|threshold
P02727909A0383|73 83|sensitivity
P02727909A0383|111 117|persons
P02727909A0383|121 128|types IIa
P02727909A0383|132 137|IIb HLP
P02729666A0267|11 31|intergroup differences
P02729666A0267|61 73|dentoskeletal
P02729666A0267|81 102|tissue profile variables
P02731611A0134|3 8|author
P02731611A0134|18 26|rationale
P02731611A0134|89 95|hiccups
P02731611A0134|122 131|principles
P02731611A0134|146 168|Mental Research Institute
P02731671A0000|11 18|toxicity
P02731671A0000|21 31|nickel oxide
P02731671A0000|37 60|nickel sulfate hexahydrate
P02731671A0000|60 64|NiSO4
P02731671A0000|73 88|nickel subsulfide
P02731671A0000|88 92|Ni3S2
P02731671A0000|105 114|F344/N rats
P02731671A0000|118 127|B6C3F1 mice
P02731671A0000|133 150|inhalation exposure
P02731671A0000|155 160|hr/day
P02731671A0000|162 170|days/week
P02731671A0000|176 180|weeks
P02732341A0000|47 53|studies
P02732341A0000|65 72|neoplasm
P02732341A0000|87 91|woman
P02732341A0000|121 128|lymphoma
P02732341A0000|145 152|staining
P02732341A0000|156 176|chloroacetate esterase
P02732341A0000|198 206|diagnosis
P02733116T0000|7 24|National Institutes
P02733116T0000|27 32|Health
P02733690T0000|9 15|cloning
P02733690T0000|19 34|characterisation
P02733690T0000|53 57|genes
P02733690T0000|74 82|reductase
P02733690T0000|85 91|tobacco
P02735364A1330|10 14|model
P02735364A1330|15 19|grade
P02735364A1330|49 55|results
P02735364A1330|65 90|progesterone receptor status
P02735364A1330|120 127|variable
P02735364A1330|176 183|survival
P02736482A0550|2 9|contrast
P02736482A0550|25 40|radiation therapy
P02736482A0550|41 55|brain metastases
P02739739T0000|0 22|COUP transcription factor
P02739739T0000|26 31|member
P02739739T0000|37 62|steroid receptor superfamily
P02740196A0704|2 11|Experiment
P02740196A0704|24 37|classification
P02740196A0704|49 56|standard
P02740196A0704|70 75|center
P02740196A0704|81 85|range
P02740196A0704|88 100|target numbers
P02740347A0644|0 11|Cosmid clones
P02740347A0644|26 38|VNTR sequences
P02740347A0644|56 73|restriction mapping
P02740627A0137|3 14|oxygen uptake
P02740627A0137|20 38|carbon dioxide output
P02740627A0137|65 81|minute ventilation
P02740627A0137|91 101|ventilation
P02740627A0137|113 126|oxygen pressure
P02740627A0137|135 145|VE/VO2 ratio
P02740627A0137|179 184|volume
P02740627A0137|208 212|space
P02740627A0137|231 236|horses
P02740874A0957|10 15|damage
P02740874A0957|35 42|controls
P02740874A0957|54 60|tissues
P02740955A0333|11 18|patients
P02740955A0333|30 42|mortality rate
P02740955A0333|66 73|patients
P02740955A0333|86 95|deliveries
P02743842A0000|10 14|study
P02743842A0000|34 47|prostaglandins
P02743842A0000|48 58|cytoprotect
P02743842A0000|69 74|mucosa
P02743842A0000|100 115|stress ulceration
P02743842A0000|130 138|influence
P02743842A0000|155 169|prostaglandin E2
P02743842A0000|205 219|lesion formation
P02743842A0000|231 238|tissue pH
P02743842A0000|242 255|back-diffusion
P02743842A0000|265 273|blood flow
P02743842A0000|288 293|mucosa
P02743842A0000|318 322|mM HCl
P02743842A0000|339 343|shock
P02743842A0000|346 350|ml/kg
P02743981A0347|0 10|Transcripts
P02743981A0347|74 97|L1e-L10e-L12e transcripts
P02743981A0347|122 129|NAB-L11e
P02743981A0347|146 159|NAB transcripts
P02743981A0347|193 202|transcript
P02744123A0237|16 22|results
P02744123A0237|42 48|species
P02744123A0237|53 64|rhesus monkey
P02744123A0237|96 103|branches
P02744123A0237|175 193|background luminance
P02744490A0894|0 7|Evidence
P02744490A0894|15 23|structure
P02744490A0894|27 32|number
P02744490A0894|35 44|cDNA clones
P02744490A0894|53 62|S1 nuclease
P02744490A0894|66 87|primer extension studies
P02744490A0894|99 108|hypothesis
P02744490A0894|116 124|PTHrP gene
P02744490A0894|143 170|mRNA transcription start points
P02744490A0894|202 208|domains
P02745280A0276|6 10|level
P02745280A0276|41 48|measures
P02745280A0276|67 76|blood gases
P02745280A0276|83 102|lactate concentration
P02745280A0276|106 112|changes
P02745280A0276|126 139|concentrations
P02745280A0276|151 159|phosphate
P02745280A0276|160 174|phosphocreatine
P02745280A0276|208 228|resonance spectroscopy
P02745444A0391|3 29|transcription initiation site
P02745444A0391|45 61|S1 nuclease mapping
P02745666A0000|11 18|biopsies
P02745666A0000|22 37|plasma oestradiol
P02745666A0000|45 56|progesterone
P02745666A0000|60 65|levels
P02745666A0000|69 76|patients
P02745666A0000|98 121|replacement therapy cycles
P02745666A0000|141 147|failure
P02746099A0000|3 10|mobility
P02746099A0000|29 37|premolars
P02746099A0000|66 73|relation
P02746099A0000|91 97|contact
P02746099A0000|109 114|facets
P02747653A0910|19 25|protein
P02747653A0910|50 57|staining
P02747653A0910|60 64|serum
P02747653A0910|67 74|tadpoles
P02747653A0910|84 92|beginning
P02747653A0910|95 107|metamorphosis
P02747653A0910|110 114|stage
P02748188A0091|26 30|group
P02748188A0091|71 75|means
P02748188A0091|104 108|group
P02748188A0091|217 223|studies
P02748595A0492|17 32|baboon liver class
P02748595A0492|59 65|lineage
P02748595A0492|75 82|ADH-beta
P02749215A0000|8 18|proteinuria
P02749215A0000|30 38|hematuria
P02749215A0000|45 50|pyuria
P02749215A0000|62 68|finding
P02751080A0176|22 28|bullets
P02751080A0176|36 42|minutes
P02751080A0176|47 60|intensity level
P02752303A0000|0 12|Lithium delays
P02752303A0000|25 30|rhythm
P02752303A0000|54 61|hamsters
P02752303A0000|64 83|plasma concentrations
P02752303A0000|114 123|weight loss
P02752629A0163|0 6|Dynamic
P02752629A0163|16 26|scintigrams
P02752629A0163|45 66|methylene diphosphonate
P02752629A0163|93 97|weeks
P02752629A0163|103 110|fracture
P02752651A0480|2 10|admission
P02752651A0480|16 25|department
P02752651A0480|28 36|September
P02752651A0480|44 50|patient
P02752651A0480|72 82|paraparesis
P02752651A0480|86 95|impairment
P02752651A0480|108 117|modalities
P02752651A0480|126 130|level
P02752651A0480|149 159|disturbance
P02756731T0001|0 13|Prostaglandins
P02756731T0001|17 26|gallstones
P02756878A0075|3 8|nature
P02756878A0075|14 20|process
P02756878A0075|42 52|occurrences
P02756878A0075|59 68|arrhythmia
P02756878A0075|82 89|patients
P02756878A0075|95 101|history
P02757033A0905|19 24|effect
P02757033A0905|41 45|genes
P02757033A0905|93 107|heterochromatin
P02757033A0905|126 139|position effect
P02757033A0905|142 154|transcription
P02757033A0905|162 166|genes
P02757862T0000|7 16|experience
P02757862T0000|22 35|microprocessor
P02757862T0000|58 70|defibrillator
P02758382A0478|0 6|Obesity
P02758382A0478|35 45|proportions
P02758382A0478|80 88|estradiol
P02758382A0478|115 139|sex hormone binding globulin
P02758382A0478|146 151|levels
P02758382A0478|157 166|proportion
P02758382A0478|179 187|estradiol
P02760922A0000|20 36|ribonucleoprotein
P02760922A0000|37 41|hnRNP
P02760922A0000|42 54|core protein A1
P02760922A0000|63 71|component
P02760922A0000|83 87|hnRNP
P02760922A0000|90 99|S particles
P02761008X0000|0 26|Brain cholinesterase activity
P02761008X0000|42 47|egrets
P02761008X0000|53 58|egrets
P02761008X0000|75 86|night-herons
P02761008X0000|101 110|inhibition
P02761008X0000|113 131|brain cholinesterase
P02761008X0000|137 144|activity
P02761008X0000|146 150|birds
P02761008X0000|172 179|exposure
P02761008X0000|182 186|death
P02761008X0000|191 206|organophosphorus
P02761008X0000|209 227|carbamate pesticides
P02761150A0000|3 8|effect
P02761150A0000|11 24|zinc deficiency
P02761150A0000|27 37|trace metals
P02761150A0000|43 47|liver
P02761150A0000|48 53|spleen
P02761150A0000|54 59|kidney
P02761150A0000|60 67|pancreas
P02761150A0000|71 78|duodenum
P02761150A0000|99 105|control
P02761150A0000|152 160|pregnancy
P02761492A0124|3 10|findings
P02761492A0124|44 50|genesis
P02761492A0124|62 72|involvement
P02761492A0124|81 88|patients
P02761537A0168|0 11|Heating cells
P02761537A0168|16 23|degrees C
P02761537A0168|36 41|amount
P02761537A0168|84 95|control level
P02761537A0168|114 124|% inhibition
P02761537A0168|127 150|transcription termination
P02761537A0168|154 159|region
P02761537A0168|168 178|nucleotides
P02761537A0168|202 208|28S rRNA
P02761537A0168|212 222|readthrough
P02761537A0168|244 260|transcription unit
P02761540A0873|0 15|Deletion analysis
P02761540A0873|29 34|NF-4FA
P02761540A0873|35 40|NF-4FB
P02761540A0873|44 56|AP-1 sequences
P02761540A0873|80 95|enhancer activity
P02762006A0071|28 35|patients
P02762006A0071|55 61|lesions
P02762198T0001|7 14|syndrome
P02762198T0001|14 20|reports
P02762198T0001|24 28|cases
P02762198T0001|34 39|period
P02763467A0903|19 35|polyacrylamide gel
P02763467A0903|51 58|patterns
P02763467A0903|83 90|proteins
P02763467A0903|102 106|cells
P02763467A0903|141 147|viruses
P02763467A0903|229 233|point
P02763467A0903|257 262|N1L ORF
P02764797A0182|0 4|PULSE
P02764797A0182|38 47|parameters
P02764797A0182|52 56|delay
P02764797A0182|60 67|duration
P02764797A0182|92 96|gates
P02764797A0182|96 102|rf phase
P02764797A0182|103 115|sampling times
P02764797A0182|123 139|imaging parameters
P02764797A0182|142 153|rf pulse shape
P02764797A0182|157 173|gradient waveforms
P02765001A0105|16 23|patients
P02765001A0105|35 43|arthritis
P02765001A0105|110 118|arthritis
P02765001A0105|138 145|criteria
P02765001A0105|146 155|dactylitis
P02765001A0105|191 203|family history
P02765001A0105|204 212|psoriasis
P02765214A0486|12 16|Kurti
P02765214A0486|18 23|demand
P02765214A0486|44 53|importance
P02765214A0486|59 67|arguments
P02766330A0779|3 8|author
P02766330A0779|16 22|account
P02766330A0779|75 81|effects
P02766330A0779|88 105|calcium antagonists
P02766330A0779|122 132|application
P02766508A0421|1 22|correlation coefficient
P02766508A0421|45 54|similarity
P02766508A0421|61 70|map pattern
P02766508A0421|84 95|mean IQRST map
P02766745T0000|15 19|study
P02766745T0000|25 36|relationship
P02766745T0000|52 59|placenta
P02766745T0000|63 70|mastitis
P02766745T0000|73 81|dairy cows
P02767166A0368|17 33|lipid peroxidation
P02767166A0368|52 62|development
P02767166A0368|71 78|cataract
P02767166A0368|91 101|consequence
P02767166A0368|111 116|damage
P02767166A0368|126 137|pathogenesis
P02767166A0368|140 147|cataract
P02767166A0368|150 157|diabetes
P02767166A0368|169 174|myopia
P02767733A0690|15 21|grading
P02767733A0690|38 42|cases
P02767733A0690|74 79|spread
P02767733A0690|92 96|cases
P02772495A0641|0 5|Asthma
P02772495A0641|45 52|ASA group
P02772495A0641|84 92|INTR group
P02773507A0750|1 5|value
P02773507A0750|52 66|sample estimates
P02773507A0750|67 75|clearance
P02773507A0750|84 88|value
P02773507A0750|123 137|sample estimates
P02773507A0750|139 147|clearance
P02773507A0750|150 155|plasma
P02773507A0750|169 173|CLunb
P02773930T0000|11 16|kidney
P02773930T0000|18 22|model
P02773930T0000|32 46|hyperfiltration
P02773930T0000|49 54|humans
P02774271A0000|0 8|Halothane
P02774271A0000|35 41|pathway
P02774271A0000|61 71|end products
P02774271A0000|102 108|bromide
P02774271A0000|125 132|pathways
P02774271A0000|149 156|fluoride
P02774808A0194|3 8|values
P02774808A0194|51 56|summer
P02774808A0194|65 80|micrograms/100 ml
P02774808A0194|93 98|winter
P02775136A1151|5 11|results
P02775136A1151|23 30|HAPE-S-S
P02775136A1151|59 75|breathing patterns
P02775136A1151|82 89|altitude
P02775136A1151|114 124|development
P02775136A1151|182 198|breathing patterns
P02775136A1151|202 206|cause
P02775136A1151|211 216|effect
P02775333A1137|0 9|Buflomedil
P02775333A1137|38 45|increase
P02775333A1137|54 59|output
P02775333A1137|70 74|mg/kg
P02775333A1137|83 89|changes
P02775333A1137|103 107|mg/kg
P02775333A1137|118 125|decrease
P02775333A1137|145 152|increase
P02775333A1137|173 177|mg/kg
P02776471A0235|26 32|animals
P02776471A0235|47 56|responders
P02776471A0235|71 77|pattern
P02776471A0235|93 100|response
P02776742A0000|0 8|Heart rate
P02776742A0000|19 29|temperature
P02776742A0000|34 46|blood pressure
P02776742A0000|46 56|temperature
P02776742A0000|68 82|humidity changes
P02776742A0000|89 96|clothing
P02776742A0000|125 131|firemen
P02776742A0000|153 158|VO2 max
P02776742A0000|165 175|ml kg-1 min-1
P02776742A0000|183 193|fire fighter
P02776742A0000|195 202|uniforms
P02776742A0000|245 252|clothing
P02776742A0000|270 287|breathing apparatus
P02776823A0000|11 19|tolerance
P02776823A0000|23 38|pharmacokinetics
P02776823A0000|51 56|sodium
P02776823A0000|67 78|hydroxyethyl
P02776823A0000|76 115|carbamoyloxymethyl-2-penem-3-carboxylate
P02776823A0000|120 124|penem
P02776823A0000|168 175|i.v. dose
P02776823A0000|179 185|mg.kg-1
P02776823A0000|202 211|volunteers
P02777797A0720|0 19|DNA blot hybridization
P02777797A0720|35 43|rat genome
P02777797A0720|79 99|PtdIns transfer protein
P02778237A0585|61 67|problem
P02778237A0585|88 115|maintenance prednisone therapy
P02778873A0761|7 13|segment
P02778873A0761|46 61|enhancer function
P02778873A0761|84 92|sequences
P02778873A0761|93 97|DR-A1
P02778873A0761|101 105|DR-A2
P02779752A0000|0 9|1-Naphthyl
P02779752A0000|9 18|piperazine
P02779752A0000|46 74|serotonin antagonist properties
P02779752A0000|79 90|5-HT2 subtype
P02779752A0000|93 100|receptor
P02779752A0000|135 148|agonist actions
P02779752A0000|154 162|5-HT1 site
P02779752A0776|0 13|m-Chlorophenyl
P02779752A0776|13 22|piperazine
P02779752A0776|35 39|mg/kg
P02779752A0776|42 64|m-trifluoromethylphenyl
P02779752A0776|64 73|piperazine
P02779752A0776|74 78|TFMPP
P02779752A0776|85 89|mg/kg
P02779752A0776|117 126|5-HT1 sites
P02779752A0776|157 162|effect
P02779752A0776|175 186|methysergide
P02779752A0776|206 215|ketanserin
P02780157A0576|17 23|feature
P02780157A0576|26 30|liver
P02780157A0576|34 49|spleen MP function
P02780157A0576|52 59|patients
P02780157A0576|83 98|HBsAg carriership
P02780157A0576|135 142|reaction
P02780157A0576|155 162|spleen MP
P02780157A0576|193 202|overstrain
P02780157A0576|209 216|standing
P02780157A0576|220 228|depletion
P02780157A0576|234 241|MP system
P02780157A0576|265 275|stimulation
P02780157A0576|278 282|HBsAg
P02781495T0001|0 6|Changes
P02781495T0001|9 31|xanthine oxidase activity
P02781495T0001|34 41|patients
P02781495T0001|57 63|failure
P02781567A0544|10 14|water
P02781567A0544|22 29|solution
P02781567A0544|62 75|stratum corneum
P02783181A0000|29 38|activities
P02783181A0000|44 60|antacid magaldrate
P02783181A0000|61 68|ES Riopan
P02783181A0000|80 86|effects
P02783181A0000|103 111|blood flow
P02783181A0000|115 129|mucus secretions
P02784507A0000|8 32|immunodeficiency virus type
P02784507A0000|34 38|HIV-1
P02784507A0000|65 76|T lymphocytes
P02784507A0000|96 103|provirus
P02784507A0000|115 119|cells
P02784507A0000|131 137|periods
P02787430A0124|11 22|panniculitis
P02787430A0124|36 50|biopsy specimens
P02787430A0124|55 70|cytophagocytosis
P02789062A0000|32 36|chain
P02789062A0000|36 40|4F2HC
P02789062A0000|50 60|model system
P02789062A0000|62 68|studies
P02789062A0000|100 105|events
P02789062A0000|135 148|gene expression
P02789062A0000|166 181|T-cell activation
P02789062A1420|18 45|NF-4FB enhancer binding protein
P02789062A1420|70 90|lambda gt11 cDNA library
P02789062A1420|109 123|oligonucleotide
P02789062A1420|142 166|NF-4FB recognition sequence
P02789180A0407|36 46|hypertrophy
P02789180A0407|73 83|hypertrophy
P02789180A0407|87 94|patients
P02789217A1323|6 19|IL6 mRNA species
P02789217A1323|45 59|polyadenylation
P02789217A1323|62 66|sites
P02789217A1323|79 86|distance
P02789217A1323|92 100|kilobases
P02790009A0375|0 17|Sequencing analysis
P02790009A0375|46 54|fragments
P02790009A0375|79 89|nucleotides
P02790009A0375|103 108|region
P02790009A0375|120 127|fragment
P02790009A1052|9 15|protein
P02790009A1052|59 64|region
P02790009A1052|89 112|serine protease inhibitors
P02790009A1052|113 120|residues
P02792270A1220|13 26|EPSP components
P02792270A1220|80 88|responses
P02792270A1220|91 107|flexor motoneurons
P02792270A1220|130 138|amplitude
P02792270A1220|148 159|flexion phase
P02792430A0000|0 10|Experiments
P02792430A0000|31 40|guinea pigs
P02792430A0000|86 95|inhibition
P02792430A0000|98 120|prostaglandins synthesis
P02792430A0000|130 140|development
P02792430A0000|152 157|oedema
P02792430A0000|178 182|serum
P02792430A0000|196 203|vagotomy
P02792430A0000|205 214|guinea pigs
P02793216A0876|24 35|conservation
P02793216A0876|39 64|membrane attachment sequence
P02793216A0876|122 131|importance
P02793620A0214|55 65|parturition
P02793620A0214|67 75|Charolais
P02793620A0214|79 90|Red Poll bulls
P02793620A0214|106 113|pastures
P02793753A0354|19 30|PA dispersion
P02793753A0354|39 43|cmH2O
P02793753A0354|55 59|l/min
P02793753A0354|87 91|sites
P02793753A0354|117 126|dispersion
P02794828A0214|3 8|system
P02794828A0214|35 39|heart
P02794828A0214|52 64|microcomputer
P02794828A0214|103 111|pacemaker
P02795923A0000|2 6|order
P02795923A0000|36 48|CT appearances
P02795923A0000|63 71|pneumonia
P02795923A0000|103 107|study
P02795923A0000|141 145|lungs
P02795923A0000|150 156|autopsy
P02795923A0000|160 166|surgery
P02796216A0063|3 9|disease
P02796216A0063|23 28|course
P02796216A0063|38 53|jaundice syndrome
P02796216A0063|60 72|enterorrhagia
P02796216A0063|80 89|appearance
P02796216A0063|92 98|roseola
P02796988A0735|3 24|transcription factor Sp1
P02796988A0735|37 41|sites
P02796988A0735|58 75|footprinting assays
P02796988A0735|79 94|gel shift analysis
P02797877A0475|3 16|combination PIP
P02797877A0475|19 28|micrograms
P02797877A0475|36 45|micrograms
P02797877A0475|73 80|regrowth
P02797877A0475|91 95|hours
P02797877A0475|103 113|antibiotics
P02798953A0307|5 10|sample
P02798953A0307|13 19|mothers
P02798953A0307|29 35|infants
P02798953A0307|44 52|subscales
P02798953A0307|65 74|instrument
P02798953A0307|75 79|WPL-R
P02798953A0307|93 98|levels
P02798953A0307|109 119|consistency
P02798953A0307|130 143|days postpartum
P02798953A0307|147 155|stability
P02798953A0307|162 176|administrations
P02799892A0154|35 39|cells
P02799892A0154|39 43|WRBCs
P02799892A0154|70 78|hemolysis
P02799892A0154|84 94|transfusion
P02799892A0154|97 104|patients
P02800417A0332|5 9|group
P02800417A0332|12 21|asthmatics
P02800417A0332|46 56|correlation
P02800417A0332|72 84|PC20 PGF2 alpha
P02800417A0332|88 102|histamine values
P02800435A0000|5 15|experiments
P02800435A0000|47 51|mg/kg
P02800435A0000|79 84|effect
P02800435A0000|108 112|field
P02800435A0000|132 137|system
P02802280A0495|13 23|differences
P02805945A0000|3 13|percentages
P02805945A0000|22 26|cysts
P02805945A0000|30 40|growth rates
P02805945A0000|91 97|cosinor
P02805945A0000|108 115|cultures
P02805945A0000|118 143|Scripsiella trochoidea Stein
P02805945A0000|153 157|years
P02805945A0000|163 182|laboratory conditions
P02805945A0000|216 224|view point
P02805945A0000|240 250|temperature
P02805945A0000|255 261|degree C
P02805945A0000|262 269|lighting
P02805945A0000|272 285|microEin m-2 s-1
P02805945A0000|299 306|seawater
P02806916A0000|8 15|DNA clone
P02806916A0000|24 36|oryzacystatin
P02806916A0000|42 68|cysteine proteinase inhibitor
P02806916A0000|68 75|cystatin
P02806916A0000|100 122|lambda EMBL3 phage library
P02806916A0000|137 142|Sau3AI
P02806916A0000|150 156|digests
P02806916A0000|198 203|oc cDNA
P02806916A0000|205 209|probe
P02807780A0143|23 30|solution
P02807780A0143|32 44|methylene blue
P02807780A0143|55 59|M NaCl
P02807780A0143|79 86|staining
P02807780A0143|100 104|areas
P02807780A0143|126 134|diagnosis
P02808232A0681|5 10|limits
P02808232A0681|15 27|micrograms/kg
P02808232A0681|54 64|reliability
P02809116A0237|24 30|effects
P02809116A0237|63 69|effects
P02809116A0237|72 79|husbands
P02809116A0237|80 89|retirement
P02809116A0237|102 113|satisfaction
P02809116A0237|124 128|wives
P02809651A0492|41 53|meta-analysis
P02809651A0492|61 70|clinicians
P02809651A0492|74 85|policy makers
P02809651A0492|100 108|questions
P02809722A0926|16 22|patient
P02809722A0926|29 39|improvement
P02809722A0926|67 77|GH secretion
P02809831A0799|2 9|contrast
P02809831A0799|20 26|DBP side
P02809831A0799|37 43|amounts
P02809831A0799|46 58|bone formation
P02810911A0372|3 12|accuracies
P02810911A0372|15 22|presence
P02810911A0372|25 31|absence
P02810911A0372|34 46|neuroblastoma
P02810911A0372|66 81|131I-MIBG imaging
P02810911A0372|92 103|tumor markers
P02811378A0250|13 17|forms
P02811378A0250|19 23|cases
P02811378A0250|43 49|infants
P02811378A0250|64 69|mucosa
P02811378A0250|96 100|ridge
P02811378A0250|106 112|maxilla
P02811378A0250|118 125|mandible
P02811378A0379|19 25|studies
P02811378A0379|42 49|staining
P02811378A0379|53 63|S100 protein
P02811378A0379|80 89|cell tumors
P02811378A0379|134 145|cell epulides
P02813369A0390|22 26|males
P02813369A0390|46 50|years
P02813369A0390|60 70|territories
P02813369A0390|93 98|harems
P02813369A0390|104 108|years
P02813369A0390|124 132|neighbors
P02813404T0000|13 23|antigen gene
P02813404T0000|69 74|stages
P02813404T0000|77 91|spermatogenesis
P02814182A1211|40 44|4-EPI
P02814182A1211|62 69|ABSTRACT
P02814182A1211|84 88|WORDS
P02814820A0967|9 16|Roux limb
P02814820A0967|36 45|pacemakers
P02814820A0967|61 68|emptying
P02814820A0967|71 77|liquids
P02814820A0967|108 119|Billroth dogs
P02814820A0967|141 147|minutes
P02814820A0967|146 153|Billroth
P02814820A0967|158 164|minutes
P02814820A0967|208 213|solids
P02815229A0139|3 12|treatments
P02815229A0139|19 26|mg t.i.d.
P02815229A0139|33 40|mg t.i.d.
P02815229A0139|55 63|treatment
P02815229A0139|103 111|diltiazem
P02816251A0397|25 35|capillaries
P02816251A0397|97 103|network
P02816251A0397|130 136|surface
P02816251A0397|143 152|ventricles
P02817724A0075|3 13|examination
P02817724A0075|32 42|T2 sequences
P02817724A0075|45 49|scans
P02817724A0075|57 62|planes
P02818122A0000|14 24|information
P02818122A0000|40 49|morphology
P02818122A0000|55 63|claustrum
P02818122A0000|73 85|animal species
P02818122A0000|107 118|distribution
P02818122A0000|122 134|relationships
P02818122A0000|150 155|cortex
P02818122A0000|164 169|nuclei
P02818260T0000|9 14|glioma
P02820128A1333|2 6|terms
P02820128A1333|9 27|sequence repetitions
P02820128A1333|49 54|copies
P02820128A1333|60 79|hexanucleotide ATTGTT
P02820128A1333|96 102|regions
P02820128A1333|105 116|dyad symmetry
P02820128A1333|134 139|ORF T3C
P02820128A1670|3 14|significance
P02820128A1670|33 39|domains
P02820128A1670|66 76|coincidence
P02820128A1670|97 106|palindrome
P02820128A1670|133 147|protein sequence
P02820128A1670|154 161|homology
P02820128A1670|169 174|B chain
P02820128A1670|177 183|insulin
P02820128A1670|199 209|palindromes
P02820128A1670|222 230|T2 protein
P02820128A1670|252 256|units
P02821340A0434|17 24|exercise
P02821340A0434|35 40|UT dogs
P02821340A0434|61 65|value
P02821340A0434|77 91|mm Hg X ml-1 X min-1
P02821340A0434|103 117|mm Hg X ml-1 X min-1
P02821340A0434|121 128|workload
P02821340A0434|139 143|speed
P02821340A0434|146 150|grade
P02824334A0972|25 43|G-protein gene family
P02824334A0972|78 88|chromosomes
P02825139A0661|37 44|homology
P02825139A0661|67 79|acid sequences
P02825750A0260|13 20|patients
P02825750A0260|24 35|response rate
P02825750A0260|58 65|response
P02826127A0709|29 39|interaction
P02826127A0709|50 65|SV40 octamer motif
P02826127A0709|93 105|protein oct-B2
P02826127A0709|131 139|component
P02826127A0709|159 166|extracts
P02826127A0709|186 194|cell lines
P02826717A0179|0 5|Anoxia
P02826717A0179|43 47|water
P02826717A0179|57 62|oxygen
P02826717A0179|77 85|water flow
P02826729A0790|0 5|Growth
P02826729A0790|15 29|14C turnover data
P02826729A0790|59 67|B-6 intake
P02828926A1870|20 26|factors
P02828926A1870|116 123|programs
P02828926A1870|126 144|actin gene expression
P02828926A1870|165 185|muscle differentiation
P02829183A0117|0 18|DNA sequence analysis
P02829183A0117|36 41|clones
P02829183A0117|59 63|forms
P02829183A0117|66 76|translocase
P02830214A0000|3 8|effect
P02830214A0000|11 23|acetazolamide
P02830214A0000|44 53|activities
P02830214A0000|58 65|ear fluid
P02830214A0000|96 116|microelectrode methods
P02830265A0341|0 5|RPA190
P02830265A0341|14 29|polypeptide chain
P02830265A0341|39 45|daltons
P02830265A0341|67 78|reading frame
P02830282A0155|13 21|A1 protein
P02830282A0155|39 46|fragment
P02830282A0155|50 59|UP1 protein
P02830282A0155|94 104|V-8 protease
P02830282A0155|117 128|polypeptides
P02830282A0155|133 142|amino acids
P02831398A0346|0 6|Irmiere
P02831556A0173|5 13|offspring
P02831556A0173|19 27|alpha-MSH
P02831556A0173|35 41|mothers
P02831556A0173|72 77|adults
P02831556A0173|100 107|response
P02831556A0173|110 117|morphine
P02831796A0000|6 26|immunodeficiency virus
P02831796A0000|35 44|lentivirus
P02831796A0000|73 84|similarities
P02831796A0000|92 112|immunodeficiency virus
P02831796A0000|125 129|agent
P02831796A0000|140 163|immunodeficiency syndrome
P02831796A0000|172 177|humans
P02832149A1009|11 16|change
P02832149A1009|21 25|ratio
P02832149A1009|41 48|products
P02832149A1009|120 128|insertion
P02832149A1009|142 151|amino acids
P02832149A1009|163 176|myb transcripts
P02832149A1009|183 193|consequence
P02832149A1009|210 219|activation
P02832149A1009|225 240|mouse myb oncogene
P02832293T0000|10 15|CRF-41
P02832293T0000|32 40|diagnosis
P02832293T0000|43 49|Cushing
P02832293T0000|51 58|syndrome
P02832293T0000|62 68|obesity
P02832744A0403|10 23|mos transcripts
P02832744A0403|26 33|Northern
P02832744A0403|39 46|analyses
P02832744A0403|65 71|chicken
P02832744A0403|74 85|quail ovaries
P02832744A0403|89 94|testes
P02833012A0428|12 16|L mRNA
P02833012A0428|24 34|nucleotides
P02833012A0428|62 73|reading frame
P02833012A0428|91 98|L protein
P02833012A0428|115 124|amino acids
P02833021A1185|3 9|results
P02833021A1185|24 35|organization
P02833021A1185|48 52|units
P02833021A1185|63 68|repeat
P02833021A1185|95 105|enhancement
P02833021A1185|116 123|promoter
P02833021A1185|158 173|promoter function
P02833049A0630|0 9|Variations
P02833049A0630|44 53|insertions
P02833049A0630|56 64|deletions
P02833049A1041|2 9|analysis
P02833049A1041|21 34|state RNA levels
P02833049A1041|47 55|cell lines
P02833049A1041|105 115|transcripts
P02833049A1041|131 138|products
P02833049A1041|148 155|majority
P02833049A1041|167 176|RD-114 mRNA
P02833049A1041|293 301|cell types
P02833101T0000|8 13|crisis
P02833101T0000|22 34|cell disorders
P02833101T0000|35 52|bone marrow necrosis
P02833101T0000|61 79|parvovirus infection
P02833517A0467|24 32|sequences
P02833517A0467|43 50|cleavage
P02833517A0467|60 66|element
P02834478A0000|12 25|weight heparins
P02834478A0000|44 51|interest
P02834478A0000|89 94|action
P02834478A0000|97 104|Xa factor
P02834843A0000|15 22|activity
P02834843A0000|31 50|rifamycin derivatives
P02834843A0000|51 59|rifabutin
P02834843A0000|80 90|rifapentine
P02834843A0000|143 152|rifampicin
P02834843A0000|174 181|log phase
P02834843A0000|212 219|activity
P02834843A0000|236 248|phase cultures
P02834843A0000|251 275|Mycobacterium tuberculosis
P02834843A0000|276 280|H37Rv
P02836623A1094|26 32|animals
P02836623A1094|52 72|months postinoculation
P02836623A1094|80 86|delta Mo
P02836623A1094|109 115|animals
P02836623A1094|136 156|months postinoculation
P02837575A0979|0 12|Sodium dodecyl
P02837575A0979|29 36|cleavage
P02837575A0979|49 61|topoisomerase
P02837575A0979|77 82|enzyme
P02837763A0259|0 16|Amino acid sequence
P02837763A0259|27 36|liver clone
P02837763A0259|37 41|HL-14
P02837763A0259|59 64|rabbit
P02837763A0259|73 95|muscle phosphatase 2A cDNA
P02837763A0259|101 119|% nucleotide identity
P02838246A0225|0 19|Herpes virus infection
P02838246A0225|38 46|inversion
P02838246A0225|52 61|T4/T8 ratio
P02838246A0225|70 80|sensitivity
P02838246A0225|85 95|specificity
P02838246A0225|107 119|proliferation
P02838246A0225|124 138|T8 subpopulation
P02838246A0225|159 166|findings
P02838246A0225|169 176|patients
P02838246A0225|181 195|rejection crises
P02838710A0299|3 8|levels
P02838710A0299|11 16|NPY-ir
P02838710A0299|86 94|treatment
P02839488A1314|12 17|assays
P02839488A1314|28 35|activity
P02839488A1314|50 57|alpha s-1
P02839488A1314|96 114|erythrocyte type-1 Gs
P02839488A1314|134 141|products
P02839488A1314|168 173|margin
P02839488A1314|176 180|error
P02839716A0673|7 11|cells
P02839716A0673|12 21|E2 proteins
P02839716A0673|46 51|effect
P02839716A0673|72 79|activity
P02839716A0673|85 111|HPV-11 enhancer-SV40 promoter
P02839716A1907|3 11|mechanism
P02839716A1907|46 61|enhancer activity
P02839716A1907|79 89|competition
P02839716A1907|166 173|ABSTRACT
P02839716A1907|188 192|WORDS
P02840034A1266|8 17|evaluation
P02840034A1266|23 31|treatment
P02840034A1266|53 70|lung cancer patients
P02840034A1266|98 104|factors
P02840034A1266|109 115|account
P02840376A0461|0 7|anti-IIa
P02840376A0461|11 16|Holmer
P02843495A0544|0 11|Introduction
P02843495A0544|14 18|v-fms
P02843495A0544|24 28|CSF-1
P02843495A0544|44 61|macrophage cell line
P02843495A0544|69 86|factor independence
P02843495A0544|90 103|tumorigenicity
P02843495A0544|119 127|mechanism
P02843694T0001|7 23|E-B virus infection
P02843694T0001|45 52|lymphoma
P02843694T0001|54 63|case report
P02844767A0191|10 18|structure
P02844767A0191|22 36|cotranscription
P02844767A0191|42 51|petCA genes
P02844767A0191|63 72|Rieske-FeS
P02844767A0191|89 94|plants
P02844767A0191|98 110|apocytochrome
P02844767A0191|112 119|proteins
P02844767A0191|146 151|Kallas
P02844767A0191|156 162|Spiller
P02844767A0191|169 174|Malkin
P02844767A0596|3 18|Nostoc petBD genes
P02844767A0596|43 50|psbB gene
P02844767A0596|68 78|photosystem
P02844767A0596|81 91|polypeptide
P02844767A0596|107 113|introns
P02844767A0596|135 150|chloroplast genes
P02844767A1022|0 20|RNA blot hybridizations
P02844767A1022|53 64|cytochrome b6
P02844767A1022|67 73|subunit
P02844767A1022|126 132|subunit
P02844767A1022|134 142|gene probe
P02844797A1225|10 22|muscle isoform
P02844797A1225|36 45|amino acids
P02844797A1225|66 88|sequence Ala-Ile-Leu-Glu
P02844797A1225|98 104|isoform
P02844797A1225|111 120|amino acids
P02844797A1225|123 128|length
P02844797A1225|137 147|replacement
P02844797A1225|160 169|amino acids
P02844797A1225|183 194|acid sequence
P02844797A1225|217 235|transmembrane domain
P02844797A1225|247 263|consensus sequence
P02844797A1225|277 293|glycosylation site
P02845654A0510|0 11|Substitution
P02845654A0510|15 30|threonine residue
P02845654A0510|35 48|alanine residue
P02845654A0510|51 58|position
P02845654A0510|71 82|cleavage site
P02845654A0510|91 98|cleavage
P02845654A0510|106 117|substitution
P02845654A0510|121 135|tyrosine residue
P02845654A0510|139 158|phenylalanine residue
P02845654A0510|161 177|amino acid position
P02845654A0510|189 200|cleavage site
P02845654A0510|215 224|processing
P02846640A0643|24 31|bacteria
P02846640A0643|37 54|indoxyl phosphatase
P02846852A1459|3 8|number
P02846852A1459|11 21|polymerases
P02846852A1459|40 54|E strand promoter
P02846852A1459|70 75|number
P02846852A1459|78 88|polymerases
P02846852A1459|94 108|L strand promoter
P02848842A0643|1 6|family
P02848842A0643|9 20|RNA molecules
P02848842A0643|33 45|kilobase range
P02848842A0643|60 64|probe
P02848842A0643|109 113|cells
P02849100A0441|18 25|sequence
P02849100A0441|57 65|extremity
P02849100A0441|71 78|molecule
P02849100A0441|103 108|anchor
P02849100A0441|114 127|plasma membrane
P02849759A0865|3 14|SV40 enhancer
P02849759A0865|24 34|replication
P02850472A0112|13 22|origin core
P02850472A0112|40 53|DNA replication
P02850967T0000|0 8|Induction
P02850967T0000|11 40|proto-oncogene fos transcription
P02850967T0000|51 73|adenylate cyclase pathway
P02850967T0000|74 89|characterization
P02850967T0000|108 114|element
P02850971A0180|7 26|oligodeoxynucleotide
P02850971A0180|43 48|region
P02850971A0180|54 74|VtHb amino acid sequence
P02850971A0180|85 102|hybridization probe
P02850971A0180|112 123|Vitreoscilla
P02850971A0180|131 137|library
P02850971A0180|167 184|cosmid vector pVK102
P02852805A0216|12 17|solids
P02852805A0216|33 47|characteristics
P02852805A0216|56 64|influence
P02852805A0216|76 85|treatments
P02852894T0000|0 5|Causes
P02852894T0000|8 12|death
P02852894T0000|37 41|study
P02852894T0000|50 57|chickens
P02852894T0000|60 71|Thai villages
P02853799T0001|3 13|progression
P02853799T0001|16 20|non-A
P02853799T0001|26 34|hepatitis
P02853799T0001|44 51|diseases
P02853799T0001|58 71|transformation
P02853799T0001|88 96|carcinoma
P02853922A0596|26 33|patients
P02853922A0596|50 54|study
P02856622T0001|7 37|serum thyroglobulin determination
P02856622T0001|42 50|follow-up
P02856622T0001|67 76|carcinomas
P02856622T0001|82 88|thyroid
P02859434T0000|0 11|Poor response
P02859434T0000|16 25|laboratory
P02859434T0000|37 41|range
P02859434T0000|45 56|serum lithium
P02861067A0000|14 18|study
P02861067A0000|37 43|effects
P02861067A0000|55 65|ipratropium
P02861067A0000|68 75|patients
P02861067A0000|85 90|asthma
P02861067A0000|93 97|order
P02861067A0000|129 148|bronchodilator effect
P02861067A0000|152 166|beta agonist drug
P02861144A0242|7 14|analysis
P02861144A0242|21 31|DNA fragment
P02861144A0242|46 50|genes
P02861144A0242|61 76|encoding proteins
P02861238T0000|7 11|virus
P02862656T0000|0 6|Changes
P02862656T0000|9 35|dopamine receptor sensitivity
P02862656T0000|38 43|humans
P02862656T0000|54 66|alcohol intake
P02863492A0544|13 23|differences
P02863492A0544|37 51|treatment groups
P02863492A0544|69 78|responders
P02863492A0544|122 129|IgG index
P02863492A0544|193 202|responders
P02863747T0000|0 10|Replacement
P02863747T0000|18 29|histone genes
P02863747T0000|48 56|sequences
P02865502T0000|22 26|trial
P02865502T0000|40 70|tissue-type plasminogen activator
P02865502T0000|77 83|placebo
P02865502T0000|101 110|infarction
P02868446A0184|13 19|domains
P02868446A0184|31 46|RPase beta subunit
P02868446A0184|49 58|DNA primase
P02868446A0184|59 69|dnaG protein
P02868446A0184|144 153|RPase alpha
P02868446A0184|170 174|alpha
P02868446A0184|187 192|enzyme
P02868446A0184|224 241|core enzyme subunits
P02868446A0184|245 251|primase
P02868848A0167|7 16|vancomycin
P02868848A0167|20 29|fosfomycin
P02868848A0167|72 79|activity
P02868848A0167|101 111|penicillin G
P02868848A0167|115 122|imipenem
P02868848A0167|153 163|gas gangrene
P02869125A0120|0 7|Fentanyl
P02869125A0120|28 42|receptor agonist
P02869125A0120|75 82|syndrome
P02869125A0120|104 112|analgesia
P02869125A0120|116 135|locomotor stimulation
P02869125A0120|144 154|tachycardia
P02869125A0120|155 164|tachypnoea
P02869125A0120|179 185|arousal
P02870249T0000|12 23|chemotherapy
P02870720A0188|0 9|Bisoprolol
P02870720A0188|33 59|beta-adrenoceptor antagonist
P02870720A0188|63 71|pA2 values
P02870720A0188|89 100|isoprenaline
P02870720A0188|103 116|guinea pig atria
P02870720A0188|120 133|tracheal muscle
P02870851A0349|0 5|Output
P02870851A0349|8 15|99mTcO-4
P02870851A0349|21 32|parotid gland
P02870851A0349|48 59|fluctuations
P02870851A0349|62 82|parotid saliva flow rate
P02872786A0147|19 26|equation
P02872786A0147|44 50|effects
P02872786A0147|61 69|parasites
P02872786A0147|75 81|foregut
P02872786A0147|103 111|sandflies
P02872786A0147|114 122|blood flow
P02873593A0581|86 91|reward
P02873593A0581|121 129|frequency
P02873593A0581|148 153|reward
P02873593A0581|167 184|5-HT uptake blockers
P02873593A0581|202 208|effects
P02874078A0252|13 33|luteal phase deficiency
P02874078A0252|63 70|patients
P02874635T0000|8 15|exposure
P02874635T0000|21 36|fungicide dinocap
P02874635T0000|53 63|torticollis
P02874635T0000|64 73|ballooning
P02874635T0000|77 87|cleft palate
P02874635T0000|110 117|hamsters
P02875224A1059|0 10|Reperfusion
P02875224A1059|21 25|blood
P02875224A1059|31 37|beating
P02875224A1059|45 50|hearts
P02875224A1059|76 81|damage
P02875224A1059|89 94|reflow
P02875224A1059|113 125|contractility
P02875224A1059|131 138|instance
P02875967A0377|3 13|sensitivity
P02875967A0377|32 41|adrenaline
P02875967A0377|67 76|guinea pigs
P02875967A0377|96 108|fertility rate
P02876820A0841|11 18|acidosis
P02876820A0841|34 44|stimulation
P02876899A0568|33 40|subjects
P02876899A0568|64 70|decline
P02876899A0568|73 102|bevantolol plasma concentrations
P02876899A0568|108 122|absorption phase
P02877124A0000|12 16|B6AF1
P02877124A0000|20 29|B6D2F1 mice
P02877124A0000|48 55|tap water
P02877124A0000|58 72|promethazine HCl
P02877124A0000|74 86|phenothiazine
P02877124A0000|91 116|H1 receptor blocking activity
P02877124A0000|117 132|chlorpheniramine
P02877124A0000|135 143|H1 blocker
P02877124A0000|146 160|trifluoperazine
P02877124A0000|162 174|phenothiazine
P02877124A0000|181 198|H1 blocking activity
P02877124A0000|206 218|drinking water
P02877124A0000|225 231|effects
P02877124A0000|239 244|agents
P02877124A0000|247 264|bone mineral content
P02877124A0000|314 326|body retention
P02877124A0000|336 357|methylene diphosphonate
P02877124A0000|371 379|indicator
P02877124A0000|380 393|bone metabolism
P02877124A0000|412 418|studies
P02877124A0000|434 440|weights
P02877124A0000|443 447|femur
P02877124A0000|448 452|ilium
P02877124A0000|456 461|sacrum
P02878100A0674|7 13|results
P02878100A0674|40 49|inhibition
P02878100A0674|62 73|transmission
P02878100A0674|76 84|diltiazem
P02878100A0674|99 107|diltiazem
P02878100A0674|138 145|activity
P02878100A0674|178 189|transmission
P02879906A0000|0 6|Studies
P02879906A0000|40 44|veins
P02879906A0000|52 61|rabbit face
P02879906A0000|74 85|relationship
P02879906A0000|93 127|beta adrenoceptor subtype distribution
P02879906A0000|165 180|nerve innervation
P02879951T0000|0 6|Effects
P02879951T0000|29 33|agent
P02879951T0000|34 41|SGB-1534
P02879951T0000|44 65|rat platelet aggregation
P02880841A0313|8 16|stability
P02880841A0313|43 51|structure
P02880841A0313|93 101|structure
P02880841A0313|105 115|beta subunit
P02880841A0313|133 150|nucleotide sequence
P02880841A0313|174 181|sequence
P02880841A0313|211 220|categories
P02880841A0313|238 246|membranes
P02880841A0313|246 257|chloroplasts
P02880841A0313|261 272|mitochondria
P02882893A0301|0 14|Body temperature
P02882893A0301|25 35|conductance
P02882893A0301|69 81|P. s. campbelli
P02883327A0413|3 22|polyadenylation sites
P02883327A0413|57 62|region
P02883327A0413|106 111|region
P02883871A1075|29 41|beta receptors
P02883871A1075|95 114|drug hypersensitivity
P02883871A1075|116 123|contrast
P02883871A1075|126 131|agents
P02883963A0000|3 10|patients
P02883963A0000|20 25|T-cell
P02883963A0000|38 46|virus type
P02883963A0000|48 53|HTLV-I
P02883963A0000|63 72|myelopathy
P02883963A0000|109 115|methods
P02884860A0329|0 8|Terazosin
P02884860A0329|20 25|analog
P02884860A0329|28 35|prazosin
P02884860A0329|48 52|alpha
P02884860A0329|54 66|adrenoceptors
P02884860A0329|102 108|therapy
P02885517T0000|7 17|blood donors
P02885517T0000|21 25|non-A
P02885517T0000|31 39|hepatitis
P02889352A0000|4 11|patients
P02889352A0000|20 32|blood pressure
P02889352A0000|62 68|classes
P02889352A0000|70 78|compounds
P02889352A0000|88 98|beta blocker
P02889352A0000|109 123|enzyme inhibitor
P02889352A0000|126 142|calcium antagonist
P02889495A0000|25 29|study
P02889495A0000|37 57|episode schizophrenics
P02889495A0000|67 74|pimozide
P02889495A0000|77 88|flupenthixol
P02889495A0000|97 101|weeks
P02889495A0000|137 146|mg pimozide
P02889495A0000|150 163|mg flupenthixol
P02890200T0001|41 45|tumor
P02890200T0001|48 61|Recklinghausen
P02890200T0001|63 79|neurofibromatosis
P02892762A0296|17 30|repeat elements
P02892762A0296|46 56|nucleotides
P02892762A0296|69 80|promoter site
P02894689A0000|27 38|DNA fragments
P02894689A0000|44 48|bases
P02894689A0000|51 64|chromatin loops
P02894689A0000|86 104|extraction procedure
P02894689A0000|111 119|lithium-3
P02894689A0000|120 135|diiodosalicylate
P02894741A0000|24 28|doses
P02894741A0000|31 40|vecuronium
P02894741A0000|52 67|muscle relaxation
P02894741A0000|84 99|NLA II anaesthesia
P02894789A0954|10 24|recovery indexes
P02894789A0954|41 45|times
P02894789A0954|57 61|T1/T0
P02894789A0954|65 69|T4/T1
P02895472A0178|20 27|colonies
P02895472A0178|54 61|plasmids
P02895472A0178|109 123|mRNA translation
P02895566A0187|18 25|increase
P02895566A0187|30 38|intensity
P02895566A0187|55 76|pressure pain components
P02895566A0187|91 106|ischemia duration
P02895566A0187|117 122|effect
P02895566A0187|128 148|pressure pain component
P02895754A0000|8 27|percent isoproterenol
P02895754A0000|33 40|presence
P02895754A0000|46 83|phosphodiesterase inhibitor theophylline
P02895754A0000|99 105|ability
P02895754A0000|135 143|humor flow
P02895754A0000|161 167|chamber
P02895754A0000|228 233|Horner
P02895754A0000|234 241|syndrome
P02897651A0000|0 14|Hyperthyroidism
P02897651A0000|33 38|causes
P02897651A0000|41 51|infertility
P02897651A0000|64 71|abortion
P02898752A0683|7 17|correlation
P02898752A0683|34 40|numbers
P02898752A0683|43 48|CFU-GM
P02898752A0683|73 84|granulocytes
P02898752A0683|87 103|platelets recovery
P02899177A0605|16 24|technique
P02899177A0605|27 47|low-frequency kindling
P02899177A0605|69 73|model
P02899177A0605|88 94|effects
P02899177A0605|125 129|drugs
P02899177A0605|135 146|excitability
P02899177A0605|158 164|regions
P02899792T0000|0 8|Oestrogen
P02899792T0000|16 23|overdose
P02900760A0073|5 20|sequence elements
P02900760A0073|64 87|transcription termination
P02900760A0073|90 103|RNA polymerase I
P02900760A0073|104 107|pol I
P02900760A0073|131 149|transcription system
P02900760A0073|164 175|transfection
P02900760A0073|178 199|rDNA minigene constructs
P02900760A0073|204 211|3T6 cells
P02901498A0354|3 14|biosynthesis
P02901498A0354|18 26|stability
P02901498A0354|43 50|proteins
P02901498A0354|83 93|erbB protein
P02901498A0354|116 122|ability
P02901498A0354|134 157|chicken embryo fibroblasts
P02901763A0977|0 9|Codon usage
P02901763A0977|12 36|C. reinhardtii mitochondria
P02901763A0977|60 65|codons
P02901763A0977|101 105|genes
P02901763A0977|123 132|codon usage
P02901763A0977|158 175|C. reinhardtii mtDNA
P02901763A0977|197 202|number
P02901763A0977|205 209|tRNAs
P02901763A0977|238 253|protein synthesis
P02902615A0000|22 30|treatment
P02902615A0000|44 56|polyarteritis
P02902615A0000|67 74|advances
P02902615A0000|80 88|treatment
P02902615A0000|104 113|hepatitis B
P02902615A0000|126 133|patients
P02902656A0481|11 16|testes
P02902656A0481|28 33|testes
P02902656A0481|38 48|hypointense
P02902656A0481|58 66|sequences
P02902656A0481|76 89|repetition time
P02902656A0481|116 120|cases
P02902656A0481|121 132|hyperintense
P02902656A0481|135 144|isointense
P02902656A0481|158 171|TR/TE sequences
P02902656A0481|182 186|cases
P02902844A1219|63 69|protein
P02902844A1219|100 109|atp operons
P02902844A1219|118 129|bacterium PS3
P02902844A1219|133 145|cyanobacteria
P02902927A0145|17 25|isolation
P02902927A0145|37 54|rat GHF-1 cDNA clones
P02903500A0278|22 31|properties
P02903500A0278|37 43|protein
P02903500A0278|68 77|fusion gene
P02903500A0278|100 105|domain
P02903500A0278|131 137|portion
P02903500A0278|141 154|immunoglobulin
P02903500A0278|160 164|chain
P02904322A0002|21 28|antelope
P02904322A0002|49 61|model ruminant
P02904322A0002|76 82|studies
P02906027A0553|2 19|sequence comparison
P02906027A0553|22 27|blocks
P02906027A0553|30 37|homology
P02906027A0553|61 66|region
P02906027A0553|87 95|CpG island
P02906027A0553|123 138|CpG dinucleotides
P02906027A1156|12 19|features
P02906027A1156|60 68|sequences
P02906027A1156|85 90|intron
P02906249A1195|10 14|group
P02906249A1195|18 26|% Prazosin
P02906249A1195|30 34|mg/kg
P02906249A1195|69 73|hours
P02906249A1195|83 93|application
P02906249A1195|96 101|Oxy-Hb
P02906249A1195|104 112|PGF2 alpha
P02906673T0000|0 7|Efficacy
P02906673T0000|11 25|field evaluation
P02906673T0000|28 48|Bacillus thuringiensis
P02906673T0000|58 69|B. sphaericus
P02906673T0000|76 95|floodwater mosquitoes
P02906673T0000|98 107|California
P02907308T0001|1 5|cases
P02907308T0001|16 26|tyrosinosis
P02907308T0001|26 48|Richner-Hanhart syndrome
P02907533A0362|26 42|drug concentration
P02907533A0362|46 61|correction factor
P02907533A0362|95 115|diazepam concentration
P02907533T0000|0 6|Effects
P02907533T0000|27 41|blood substitute
P02907533T0000|44 58|diazepam binding
P02907533T0000|66 72|albumin
P02909528A1081|7 22|promoter activity
P02909528A1081|41 46|region
P02909528A1081|80 89|start sites
P02910496A0583|1 15|decamer sequence
P02910496A0583|16 28|CGA-CCCCUCC-3
P02910496A0583|54 61|sequence
P02910496A0583|84 95|cleavage site
P02910496A0583|114 125|RNA substrate
P02910496A0583|140 151|RNAase MRP RNA
P02910989T0000|0 6|Effects
P02910989T0000|9 13|aging
P02910989T0000|17 40|beta-adrenergic-blockade
P02910989T0000|59 71|QT/QS2 changes
P02911540A0478|1 7|patient
P02911540A0478|22 26|wound
P02911540A0478|48 52|hands
P02911540A0478|66 73|perineum
P02913368A1037|0 18|Pharmacology studies
P02913368A1037|23 39|potassium chloride
P02913368A1037|43 55|acetylcholine
P02913368A1037|67 73|raveron
P02913368A1037|81 97|calcium antagonist
P02913368A1037|111 116|influx
P02913368A1037|132 138|calcium
P02914422A0409|0 15|Computer analysis
P02914422A0409|31 39|averaging
P02914422A0409|77 90|frequency bands
P02914422A0409|93 97|order
P02914422A0409|112 125|frequency range
P02914422A0409|141 147|notches
P02914422A0409|151 155|slurs
P02914492A0183|2 10|admission
P02914492A0183|24 31|patients
P02914492A0183|33 39|percent
P02914492A0183|43 56|hypomagnesemia
P02914492A0183|57 63|serum Mg
P02914492A0183|75 80|mEq/dl
P02914492A0183|83 90|patients
P02914492A0183|93 99|percent
P02914492A0183|103 117|normomagnesemia
P02914492A0183|126 131|mEq/dl
P02914492A0183|138 145|patients
P02914492A0183|147 153|percent
P02914492A0183|157 171|hypermagnesemia
P02914492A0183|186 191|mEq/dl
P02916764A0253|3 13|risk factors
P02916764A0253|34 45|hypertension
P02916764A0253|45 60|diabetes mellitus
P02916764A0253|61 80|hypercholesterolemia
P02916764A0253|81 96|cigarette smoking
P02916764A0253|106 115|life-style
P02916764A0253|119 131|family history
P02918474A0817|7 15|verapamil
P02918474A0817|19 28|nifedipine
P02918474A0817|36 45|collateral
P02918474A0817|56 64|blood flow
P02918474A0817|83 96|subendocardium
P02918474A0817|109 116|ml/min/g
P02918474A0817|122 134|subepicardium
P02919483A0091|22 26|girls
P02919483A0091|50 58|half years
P02919530A0000|28 38|reperfusion
P02919530A0000|49 58|myocardium
P02919530A0000|84 98|artery occlusion
P02919530A0000|123 128|effect
P02919530A0000|150 159|wall motion
P02919530A0000|184 194|alterations
P02919832A0144|7 13|disease
P02919832A0144|32 37|M-mode
P02919832A0144|73 95|Doppler echocardiography
P02920591A0251|11 20|assessment
P02920591A0251|50 63|administration
P02920591A0251|66 72|digoxin
P02920591A0251|75 87|micrograms/kg
P02920591A0251|92 99|dopamine
P02920591A0251|105 121|micrograms/kg/min
P02923687A0218|17 28|relationship
P02923687A0218|47 55|sinusitis
P02923687A0218|61 69|cleft side
P02923687A0218|72 79|patients
P02923687A0218|94 104|cleft palate
P02925013A1112|24 29|levels
P02925013A1112|37 44|aluminum
P02925013A1112|68 73|tissue
P02925013A1112|85 96|accumulation
P02925013A1112|109 121|citrate ligand
P02925568A0460|7 13|effects
P02925568A0460|16 28|father absence
P02925568A0460|41 50|conditions
P02925568A0460|70 76|samples
P02925568A0460|98 104|effects
P02925568A0460|129 143|family stressors
P02925568A0460|154 168|psychopathology
P02926499A0340|31 41|analog model
P02926499A0340|44 51|heat flow
P02926499A0340|61 65|brain
P02926499A0340|93 102|expression
P02926499A0340|165 169|decay
P02926499A0340|183 189|density
P02926499A0340|191 195|blood
P02927391A0238|21 30|proviruses
P02927391A0238|49 69|founder SWR/J-RF/J mice
P02927391A0238|102 109|germ line
P02927391A0238|134 140|tissues
P02927391A0238|163 173|integration
P02927391A0238|191 198|germ line
P02927391A0238|224 231|lineages
P02928112T0000|9 15|cloning
P02928112T0000|59 65|protein
P02928376A0312|25 29|water
P02928376A0312|48 54|mixture
P02928376A0312|66 70|gases
P02928376A0312|81 90|heat defect
P02929056T0000|17 40|transureteroureterostomy
P02929056T0000|49 68|ureterosigmoidostomy
P02929056T0000|85 91|failure
P02930623A0404|6 20|flexion whiplash
P02930623A0404|24 29|torque
P02930623A0404|44 50|condyle
P02930623A0404|62 70|direction
P02930623A0404|89 94|impact
P02934778A0702|21 28|presence
P02934778A0702|30 34|5-HT2
P02934778A0702|47 55|receptors
P02934778A0702|70 75|artery
P02934778A0702|83 89|species
P02934889A0558|0 10|Oxfendazole
P02934889A0558|65 69|start
P02934889A0558|70 76|grazing
P02934889A0558|99 111|cent reduction
P02934889A0558|113 129|Ostertagia species
P02934889A0558|142 154|cent reduction
P02934889A0558|157 166|D viviparus
P02934891A0845|11 16|method
P02934891A0845|47 54|extracts
P02934891A0845|75 79|cells
P02934891A0845|118 122|sites
P02934891A0845|140 150|nucleotides
P02935638A0000|35 43|structure
P02935638A0000|49 57|Spec1 gene
P02935638A0000|63 99|sea urchin Strongylocentrotus purpuratus
P02936163T0000|0 15|Platelet function
P02936163T0000|56 66|interaction
P02936163T0000|69 76|patients
P02936163T0000|90 117|platelet lipoxygenase activity
P02936284A0357|11 21|degradation
P02936284A0357|24 33|atracurium
P02936284A0357|36 41|plasma
P02936284A0357|52 56|route
P02936284A0357|59 69|elimination
P02936284A0357|99 118|elimination half-life
P02938185A0223|11 19|cell lines
P02938185A0223|51 65|E1b gene products
P02938185A0223|80 86|viruses
P02938185A0223|123 128|growth
P02938185A0223|133 140|degrees C
P02938185A0223|149 156|degrees C
P02938185A0223|180 191|architecture
P02938185A0223|227 235|CREF cells
P02939260A1553|17 41|amino acid sequence analysis
P02939260A1553|63 74|42K T antigens
P02939260A1553|81 90|methionine
P02939260A1553|93 100|residues
P02939260A1553|124 134|DNA sequence
P02939260A1553|144 153|methionine
P02939260A1553|172 182|39K T antigen
P02939260A1553|200 205|cycles
P02939260A1553|208 223|Edman degradation
P02940334A0141|0 5|Group A
P02940334A0141|31 35|doses
P02940334A0141|38 47|hepatitis B
P02940334A0141|54 61|globulin
P02940334A0141|89 97|schedules
P02941237A0160|11 18|instance
P02941237A0160|21 28|addition
P02941237A0160|31 42|serum calcium
P02941237A0160|46 73|phosphorous ion concentrations
P02941237A0160|74 81|tissue pH
P02941237A0160|82 92|blood supply
P02941237A0160|93 100|hormones
P02941237A0160|105 112|vitamin D
P02941237A0160|113 120|vitamin A
P02941237A0160|131 137|enzymes
P02941237A0160|142 160|alkaline phosphatase
P02941237A0160|164 178|pyrophosphatase
P02941237A0160|243 247|roles
P02943562T0000|0 22|Penicillinase production
P02943562T0000|45 51|strains
P02943562T0000|62 71|importance
P02947866A1416|16 23|analysis
P02947866A1416|26 43|thallium-201 uptake
P02947866A1416|47 53|washout
P02947866A1416|71 78|evidence
P02947866A1416|100 108|perfusion
P02947866A1416|122 132|angioplasty
P02949170A0184|4 8|study
P02949170A0184|19 25|effects
P02949170A0184|29 39|preparation
P02949170A0184|46 71|micrograms ethinyl estradiol
P02949170A0184|76 95|mg cyproterone acetate
P02949170A0184|98 110|gonadotropins
P02949170A0184|111 119|prolactin
P02949170A0184|120 131|testosterone
P02949170A0184|132 156|sex hormone binding globulin
P02949170A0184|163 177|androstenedione
P02949170A0184|194 210|testosterone index
P02949170A0184|228 233|months
P02949170A0184|236 244|treatment
P02950216A0084|33 53|laser Doppler flowmetry
P02950216A0084|69 80|output signal
P02950216A0084|80 92|blood cell flux
P02950216A0084|111 115|terms
P02950216A0084|117 121|volts
P02957125A0601|6 13|patients
P02957125A0601|23 29|failure
P02957125A0601|37 49|haemodialysis
P02957125A0601|72 84|cent reduction
P02957125A0601|87 108|plasma ANP concentration
P02958204A0175|16 22|effects
P02958204A0175|25 36|isotretinoin
P02958204A0175|54 58|HDL-C
P02958204A0175|58 73|HDL phospholipids
P02958204A0175|74 79|HDL-PL
P02958204A0175|80 91|apoprotein A1
P02958204A0175|92 97|apo A-1
P02958204A0175|101 117|HDL-C subfractions
P02958204A0175|118 123|HDL2-C
P02958204A0175|127 132|HDL3-C
P02958204A0175|148 155|patients
P02958204A0175|173 178|course
P02958204A0175|181 192|isotretinoin
P02958204A0175|196 204|mg/kg/day
P02958204A0175|208 216|treatment
P02958204A0175|225 236|acne vulgaris
P02958233A0123|11 17|picture
P02958233A0123|21 40|laboratory parameters
P02958233A0123|60 80|serum sickness reaction
P02958660A1094|32 40|existence
P02958660A1094|43 58|conversion factor
P02958660A1094|62 70|LDF signal
P02958660A1094|81 90|flow values
P02958660A1094|95 104|experiment
P02958660A1094|107 116|experiment
P02959089T0000|10 15|effect
P02959089T0000|18 25|ONO-3708
P02959089T0000|28 37|thrombosis
P02959089T0000|41 50|vasospasms
P02960012A0838|3 11|frequency
P02960012A0838|14 24|PPNG strains
P02962859A0276|12 21|antibodies
P02962859A0276|35 65|beta-galactosidase fusion protein
P02962859A0276|74 78|clone
P02962859A0276|111 118|A antigen
P02963517A0453|12 19|analysis
P02963517A0453|33 40|stenosis
P02963517A0453|78 87|dilatation
P02963517A0453|99 106|increase
P02964329A0000|3 14|pathogenesis
P02964329A0000|24 36|Joint Mobility
P02964329A0000|44 51|diabetes
P02964329A0000|66 76|abnormality
P02964329A0000|112 120|incidence
P02964329A0000|123 137|microangiopathy
P02965149A0727|11 15|study
P02965149A0727|16 21|Brandl
P02966671A0151|15 23|end points
P02966671A0151|55 60|tumors
P02966671A0151|68 72|times
P02966671A0151|78 90|treatment size
P02966671A0151|94 101|survival
P02966671A0151|104 112|stem cells
P02966671A0151|126 131|crypts
P02966671A0151|138 150|breathing rate
P02966671A0151|169 173|weeks
P02966671A0151|186 190|weeks
P02966671A0151|196 204|treatment
P02966671A0551|0 7|Schedule
P02966671A0551|19 28|mg/kg c-DDP
P02966671A0551|61 65|X-ray
P02966671A0551|104 109|degree
P02966671A0551|111 121|enhancement
P02966671A0551|124 138|radiation effect
P02966671A0551|161 166|factor
P02966671A0551|185 195|enhancement
P02966671A0551|211 220|mg/kg c-DDP
P02966671A0551|247 251|start
P02966671A0551|270 281|radiotherapy
P02967496A0182|16 25|transcript
P02967496A0182|43 55|reading frames
P02967496A0182|95 107|leader segment
P02967496A0182|120 124|cpc-1
P02967496A0182|131 136|region
P02967915A0000|15 44|hormone 1,25-dihydroxyvitamin D3
P02967915A0000|63 72|expression
P02967915A0000|76 96|calcium binding protein
P02967915A0000|103 116|calbindin-D28K
P02967915A0000|120 126|variety
P02967915A0000|129 141|target tissues
P02967915A0968|2 9|addition
P02967915A0968|13 34|calbindin-D28K promoter
P02967915A0968|48 54|variety
P02967915A0968|71 79|sequences
P02967915A0968|94 103|components
P02967915A0968|124 130|signals
P02968055A0984|30 37|increase
P02969316A0002|11 17|ability
P02969316A0002|23 27|atria
P02969316A0002|46 65|plasma concentrations
P02969316A0002|85 91|peptide
P02969316A0002|108 114|changes
P02969316A0002|116 138|plasma ANP concentrations
P02969316A0002|220 225|pacing
P02969819A0814|0 19|Ig D-JH recombinations
P02969819A0814|30 49|TcR gene recombination
P02969819A0814|62 71|T cell lines
P02969819A0814|102 115|Cmu transcripts
P02970061A0271|3 11|RAD18 gene
P02970061A0271|16 27|reading frame
P02970061A0271|36 42|protein
P02970061A0271|48 57|amino acids
P02970061A0271|82 87|weight
P02970640A0341|6 32|absorption spectrophotometry
P02970640A0341|62 72|E1A proteins
P02970640A0341|97 107|acid protein
P02970640A0341|116 122|zinc ion
P02970640A0341|142 152|acid protein
P02971603A0883|4 11|patients
P02971603A0883|21 27|tablets
P02971603A0883|30 38|injection
P02971710A0734|0 4|Plots
P02971710A0734|22 29|2A weight
P02971710A0734|33 42|hematocrit
P02971710A0734|60 70|inflections
P02971710A0734|77 86|hematocrit
P02971710A0734|127 135|viscosity
P02971710A0734|163 172|hematocrit
P02971957A0287|43 53|improvement
P02971957A0287|62 66|cases
P02971957A0287|84 93|techniques
P02971957A0287|113 120|bleeding
P02973304A0000|12 17|course
P02973304A0000|20 38|Budd-Chiari syndrome
P02973304A0000|53 62|thrombosis
P02973304A0000|109 124|patient suffering
P02973304A0000|143 157|cardiosclerosis
P02975680A0000|8 25|accommodation night
P02975680A0000|26 43|sleep EEG recordings
P02975680A0000|79 84|nights
P02975680A0000|99 108|inpatients
P02975680A0000|130 144|anxiety disorder
P02975680A0000|165 174|depression
P02975680A0000|206 210|group
P02975680A0000|212 219|patients
P02975680A0000|233 237|group
P02975680A0000|261 268|disorder
P02975680A0000|274 281|patients
P02975753A1333|0 25|Oligonucleotide mutagenesis
P02975753A1333|33 46|binding domains
P02975753A1333|61 70|importance
P02975753A1333|91 100|regulation
P02975753A1333|106 115|E3 promoter
P02975753A1333|118 127|yeast cells
P02976332A1277|3 15|concentration
P02976332A1277|48 54|surface
P02979426T0000|0 19|Organ transplantation
P02979426T0000|22 28|Denmark
P02979834T0000|0 6|Effects
P02979834T0000|26 59|maltose tetrapalmitate immunotherapy
P02979834T0000|60 87|cyclophosphamide chemotherapy
P02979834T0000|91 102|radiotherapy
P02979834T0000|105 118|ethyl carbamate
P02979834T0000|137 146|lung cancer
P02979834T0000|149 155|A/J mice
P02981840A0907|9 20|pair sequence
P02981840A0907|62 72|nucleotides
P02981840A0907|96 102|repeats
P02982332T0001|0 4|Phase
P02982332T0001|7 11|study
P02982332T0001|14 18|VP-16
P02982332T0001|19 25|capsule
P02982332T0001|33 38|tumors
P02983316A0310|13 20|segments
P02983316A0310|34 42|framework
P02983316A0310|46 79|complementarity-determining regions
P02983316A0310|87 91|genes
P02983316A0310|104 117|probe sequences
P02983316A0310|137 144|analysis
P02983316A0310|164 174|caiman genes
P02983316A0310|230 237|sequence
P02983316A0310|263 274|preservation
P02983316A0310|277 294|nucleotide sequence
P02983316A0310|309 314|period
P02983331T0000|0 7|Evidence
P02983331T0000|53 58|factor
P02983331T0000|64 68|ether
P02983331T0000|69 82|immobilization
P02983331T0000|95 100|stress
P02985812A0984|9 15|feature
P02985812A0984|34 38|genes
P02985812A0984|82 93|reading frame
P02985820A1287|9 24|sequence elements
P02985820A1287|44 50|vectors
P02985820A1287|57 65|c-myc gene
P02985820A1287|82 88|genesis
P02985820A1287|106 121|retroviruses CMII
P02986279A0000|2 12|milk samples
P02986279A0000|28 33|donors
P02986279A0000|44 49|months
P02986279A0000|54 61|delivery
P02986279A0000|80 89|occurrence
P02986279A0000|92 106|cytomegalovirus
P02987220A0472|0 9|Subcloning
P02987220A0472|12 23|DNA fragments
P02987220A0472|47 52|insert
P02987220A0472|54 58|pAVO4
P02987220A0472|71 81|DNA fragment
P02987220A0472|136 141|region
P02987777A0000|5 9|cases
P02987777A0000|30 42|cell carcinoma
P02987777A0000|48 53|rectum
P02988457A0650|44 55|potentiality
P02988457A0650|57 73|Bestatin treatment
P02988457A0650|82 86|types
P02988457A0650|89 98|malignancy
P02989637A0671|34 43|regulation
P02989637A0671|52 80|zona glomerulosa corticosteroid
P02989637A0671|89 102|renin secretion
P02989637A0671|113 120|patients
P02989637A0671|135 150|cord transections
P02989637A0671|177 184|pathways
P02989637A0671|206 211|system
P02989637A0671|227 251|metoclopramide stimulation
P02989637A0671|254 264|aldosterone
P02989637A0671|268 281|renin secretion
P02989786A0328|5 11|absence
P02989786A0328|14 30|enhancer sequences
P02989786A0328|34 50|adenovirus E1A gene
P02989786A0328|66 80|CATase synthesis
P02991060A0465|5 17|IgG antibodies
P02991060A0465|23 28|babies
P02991060A0465|51 58|delivery
P02991060A0465|83 87|cases
P02991060A0465|96 101|months
P02991060A0465|117 122|babies
P02991060A0465|128 133|months
P02993630A1190|4 11|analysis
P02993630A1190|17 31|nucleotide level
P02993630A1190|42 47|events
P02993630A1190|53 61|digestion
P02993630A1190|66 75|nuclease S1
P02993630A1190|88 100|enzyme attacks
P02993630A1190|118 125|sequence
P02993630A1190|137 143|message
P02993630A1190|156 161|strand
P02994253A0482|5 11|dosages
P02994253A0482|25 39|mean NTE activity
P02994253A0482|81 85|brain
P02994253A0482|110 122|control values
P02994253A0482|130 143|hr postexposure
P02994253A0482|164 176|cord pathology
P02994253A0482|179 194|days postexposure
P02994253A0482|237 243|animals
P02994336A0864|32 39|analogue
P02994336A0864|49 58|plasma ACTH
P02994336A0864|72 76|level
P02994336A0864|81 93|bromocriptine
P02994336A0864|94 99|CB-154
P02994336A0864|119 124|change
P02995967T0000|15 27|protooncogene
P02995967T0000|28 35|c-erbB-2
P02995967T0000|53 60|c-erbB-1
P02995967T0000|69 93|growth factor-receptor gene
P02995967T0000|124 142|gland adenocarcinoma
P02995999A0000|3 18|sequence analysis
P02995999A0000|25 32|products
P02995999A0000|65 83|recombination events
P02995999A0000|98 110|recombination
P02995999A0000|125 134|attachment
P02995999A0000|176 181|joints
P02995999A0000|195 202|position
P02995999A0000|206 223|recombination event
P02995999A0000|241 257|base-pair deletion
P02995999A0000|269 287|recombination events
P02995999A0000|316 337|base-pair substitutions
P02997622A0916|9 16|sequence
P02997622A0916|44 59|SCLC cell line DNAs
P02997622A0916|68 85|SCLC tumour specimen
P02997622A0916|104 110|patient
P02997777A0609|17 27|experiments
P02997777A0609|51 55|cells
P02997777A0609|59 71|delta top1 top2
P02997777A0609|123 134|top2 ts strain
P02997777A0609|156 161|blocks
P02997777A0609|172 178|killing
P02997777A0609|184 189|top2 ts
P02997777A0609|212 222|temperature
P02997777A0609|230 239|treatments
P02997777A0609|266 274|cell death
P02997777A0609|280 294|delta top1 top2 ts
P02998016A0527|3 10|homology
P02998016A0527|13 17|v-mil
P02998016A0527|39 46|sequence
P02998016A0527|85 90|region
P02998016A0527|102 112|nucleotides
P02998016A0527|129 141|nonsense codon
P02998016A0527|165 176|reading frame
P02998016A0527|190 194|c-mil
P02998016A0527|198 202|v-mil
P02998043A1199|0 10|Examination
P02998043A1199|16 23|sequence
P02998043A1199|29 49|Punta Toro M gene product
P02998043A1199|60 67|presence
P02998043A1199|89 97|sequences
P02998043A1199|122 137|carboxy-proximal
P02998043A1199|148 153|region
P02999267A0606|22 32|amyloidosis
P02999267A0606|66 72|uptakes
P02999267A0606|79 87|intensity
P02999267A0606|108 114|sternum
P02999267A0885|3 11|intensity
P02999267A0885|24 29|uptake
P02999267A0885|32 41|Tc-99m-PYP
P02999267A0885|44 51|patients
P02999267A0885|88 98|hypertrophy
P02999267A0885|131 136|echoes
P02999267A0885|163 172|appearance
P02999267A0885|205 212|patients
P02999267A0885|233 243|hypertrophy
P03000457A1554|6 17|kDa precursor
P03000457A1554|59 68|processing
P03000457A1554|80 84|alpha
P03000457A1554|100 106|species
P03000489A0822|8 18|lymphocytes
P03000489A0822|50 57|patients
P03000489A0822|85 89|range
P03000489A0822|118 122|range
P03000489A0822|129 136|criteria
P03000489A0822|138 147|activation
P03000489A0822|166 181|blood lymphopenia
P03001054A0703|25 29|nicks
P03001054A0703|65 69|sites
P03001084A0406|3 10|sequence
P03001084A0406|47 53|segment
P03001084A0406|80 86|cap site
P03001084A0406|88 92|alpha
P03001084A0406|106 113|psi alpha
P03001086A0587|12 28|amino acid sequence
P03001086A0587|43 50|homology
P03001086A0587|70 74|hsp70
P03001086A0587|75 84|trout hsp70
P03001086A0587|85 96|Xenopus hsp70
P03001086A0587|97 106|yeast hsp70
P03001086A0587|114 121|homology
P03001086A0587|141 155|dnaK gene product
P03001110A0546|4 18|phosphorylation
P03001110A0546|30 46|peptide substrates
P03001110A0546|61 68|function
P03001110A0546|71 98|receptor self-phosphorylation
P03001110A0546|99 120|tyrosine kinase activity
P03001110A0546|167 175|phosphate
P03001110A0546|185 192|receptor
P03001353A0146|2 13|temperatures
P03001353A0146|27 40|transformation
P03001353A0146|41 48|6m2 cells
P03001353A0146|56 61|P58gag
P03001353A0146|98 106|RNA genome
P03001353A0146|109 118|P85gag-mos
P03001645A0785|3 7|pet56
P03001645A0785|11 19|his3 genes
P03001645A0785|49 63|initiation sites
P03001705T0000|9 22|transformation
P03001705T0000|32 40|fragments
P03001705T0000|43 64|herpes simplex virus type
P03001705T0000|80 85|region
P03001705T0000|91 101|gene product
P03001952A0958|19 26|patients
P03001952A0958|50 55|herpes
P03001952A0958|90 100|determinant
P03001952A0958|111 121|recurrences
P03001952A0958|140 148|acyclovir
P03001952A0958|158 163|effect
P03001952A0958|176 186|recurrences
P03002501A1327|0 9|Comparison
P03002501A1327|12 20|sequences
P03002501A1327|45 73|guinea-pig alpha s1-casein mRNAs
P03002501A1327|92 99|homology
P03002501A1327|129 135|regions
P03002786A0143|3 7|group
P03002786A0143|32 40|midazolam
P03002786A0143|43 48|mg kg-1
P03002786A0143|52 59|atropine
P03002786A0143|66 71|mg i.m.
P03003695A0395|0 9|Comparison
P03003695A0395|32 45|c-sis cDNA clone
P03003695A0395|46 52|Collins
P03003695A0395|58 63|Nature
P03003695A0395|96 107|kbp DNA region
P03003695A0395|124 132|c-sis exon
P03004364A0775|35 44|activities
P03004364A0775|68 73|FAMLIP
P03004364A0775|83 87|FULIP
P03004364A0775|88 93|ADRLIP
P03004364A0775|97 102|MMCLIP
P03004739A0753|18 30|G transversion
P03004739A0753|40 46|residue
P03004739A0753|52 69|CAT pentanucleotide
P03004739A0753|93 100|activity
P03004739A0753|107 115|promoters
P03004739A0753|133 140|affinity
P03004739A0753|146 162|CAT binding protein
P03004982A0199|3 20|nucleotide sequence
P03004982A0199|39 51|R. sphaeroides
P03004982A0199|94 102|genes fbcF
P03004982A1094|13 20|sequence
P03004982A1094|37 43|peptide
P03004982A1094|49 58|FeS protein
P03004982A1094|91 106|fbcF reading frame
P03005231A0649|20 28|sequences
P03005231A0649|50 58|sequences
P03005231A0649|79 88|initiation
P03005231A0649|92 102|termination
P03005231A0649|105 117|transcription
P03005231A0649|138 146|promoters
P03005231A0649|184 192|sequences
P03006066A0653|6 20|P135gag-myb-ets
P03006066A0653|37 54|translation product
P03006066A0653|56 60|c-myb
P03006066A0653|61 68|P75c-myb
P03006066A0653|84 91|proteins
P03006066A0653|92 99|P54c-ets
P03007281A0905|3 13|Dox-A2 locus
P03007281A0905|45 58|OD15 breakpoint
P03007281A0905|90 96|maximum
P03008094A0697|24 34|polypeptide
P03008094A0697|46 50|types
P03008094A0697|61 69|sequences
P03008405A0532|7 15|outbreaks
P03008405A0532|24 30|disease
P03008405A0532|42 51|deer calves
P03008405A0532|60 64|HVC-1
P03009366A0438|36 42|studies
P03009366A0438|66 76|pneumocytes
P03009366A0438|86 91|target
P03009366A0438|94 102|radiation
P03009366A0438|109 115|release
P03009366A0438|118 127|surfactant
P03009366A0438|155 162|exposure
P03009366A0438|183 187|weeks
P03009826A0201|11 16|clones
P03009826A0201|38 55|base-pair dimer unit
P03009826A0201|61 66|repeat
P03010281A0220|3 8|copies
P03010281A0220|19 24|repeat
P03010281A0220|42 51|activation
P03010281A0220|54 67|gene expression
P03011793A0582|7 19|reading frames
P03011793A0582|49 56|proteins
P03011793A0582|68 84|amino acid residues
P03013477A0000|2 6|order
P03013477A0000|17 25|influence
P03013477A0000|28 39|iron overload
P03013477A0000|62 70|leucocyte
P03013477A0000|76 85|metabolism
P03013477A0000|87 94|patients
P03013477A0000|104 115|hemodialysis
P03013477A0000|116 125|generation
P03013477A0000|128 142|superoxide anion
P03013477A0000|159 163|blood
P03013477A0000|179 184|groups
P03013477A0000|199 206|patients
P03013477A0000|207 211|group
P03013477A0000|234 244|individuals
P03013477A0000|249 267|serum ferritin levels
P03013477A0000|277 281|ng/ml
P03013477A0000|285 290|group B
P03013477A0000|301 311|individuals
P03013477A0000|316 334|serum ferritin levels
P03013477A0000|344 348|ng/ml
P03013841A0207|0 7|Cattaneo
P03014515T0000|5 24|alpha-galactosidase A
P03014515T0000|25 42|nucleotide sequence
P03014515T0000|46 54|cDNA clone
P03014515T0000|72 77|enzyme
P03014593A0681|0 7|Diazepam
P03014593A0681|9 13|mg/kg
P03014593A0681|67 74|Ro 5-4864
P03014593A0681|75 79|mg/kg
P03014593A0681|85 89|mg/kg
P03015611A0331|3 19|amino acid sequence
P03015611A0331|37 44|residues
P03015611A0331|60 72|lysine residue
P03015628A1078|0 10|Osteocalcin
P03015628A1078|21 34|hydroxyproline
P03015628A1078|60 79|hyperphosphatasaemia
P03015628A1078|94 103|mechanisms
P03015628A1078|122 133|bone turnover
P03015628A1078|166 197|serum alkaline phosphatase activity
P03015628A1078|205 212|subjects
P03015953T0000|0 7|Analysis
P03015953T0000|10 23|glucocorticoid
P03015953T0000|36 47|cell variants
P03015953T0000|54 80|mouse glucocorticoid receptor
P03015953T0000|94 101|DNA clone
P03016301A0605|8 18|v-myc codons
P03016301A0605|55 62|terminus
P03016301A0605|74 82|c-myc exon
P03016301A0605|89 94|codons
P03016301A0605|110 114|c-myc
P03016301A0605|121 126|region
P03016506A0611|12 17|vector
P03016506A0611|60 67|fragment
P03016506A0611|67 77|nucleotides
P03016506A0611|97 107|B95-8 strain
P03016506A0611|140 152|antigen EBNA-1
P03016506A0611|166 173|sequence
P03016506A0611|181 195|BamHI-C fragment
P03016506A0611|218 227|marker gene
P03016506A0611|236 250|G-418 resistance
P03016506A0611|253 263|animal cells
P03016883A0000|12 18|history
P03016883A0000|36 57|herpes simplex virus type
P03016883A0000|59 63|HSV-2
P03016883A0000|64 72|infection
P03016883A0000|94 98|weeks
P03016883A0000|103 109|samples
P03016883A0000|122 128|urethra
P03016883A0000|132 145|virus isolation
P03017225A0706|8 16|carcinoma
P03017225A0706|28 40|leather bottle
P03017225A0706|41 59|linitis plastica type
P03017225A0706|65 71|stomach
P03017225A0706|81 90|II c portion
P03017225A0706|96 102|stomach
P03017225A0706|120 125|glands
P03017225A0706|142 150|carcinoma
P03017225A0706|172 176|focus
P03017225A0706|187 194|Nakamura
P03017225A0706|196 201|theory
P03017996A0731|9 20|biosynthesis
P03017996A0731|37 48|polypeptides
P03017996A0731|52 64|signal peptide
P03017996A0731|112 118|protein
P03017996A0731|131 139|mutants X2
P03017996A0731|150 161|cleavage site
P03018491A0840|3 16|hexanucleotide
P03018491A0840|17 24|TGTCCT-3
P03018491A0840|48 58|GRE activity
P03018491A0840|80 87|sequence
P03018491A0840|104 109|region
P03018491A0840|176 190|receptor binding
P03019505A0390|4 11|patients
P03019505A0390|31 36|spread
P03019505A0390|55 59|tumor
P03020001A0781|16 30|mini-Mu elements
P03020001A0781|40 52|kilobase pairs
P03020001A0781|68 74|cloning
P03020001A0781|77 88|DNA fragments
P03020001A0781|99 111|kilobase pairs
P03020001A0781|137 149|kilobase pairs
P03020001A0781|163 168|clones
P03020001A0781|174 183|insertions
P03020001A0781|198 210|kilobase pairs
P03020513T0000|13 19|subunit
P03020513T0000|22 39|T4 DNA topoisomerase
P03020513T0000|57 68|gyrA-protein
P03020513T0000|71 76|gyrase
P03021050A0501|22 26|peaks
P03021050A0501|32 43|quantitation
P03021050A0501|46 54|sulbactam
P03021088A0135|9 15|periods
P03021088A0135|29 37|exclusion
P03021088A0135|43 52|occurrence
P03021088A0135|66 71|ulcers
P03021088A0135|86 96|gastrectomy
P03021088A0135|101 108|Billroth
P03021088A0135|118 131|reconstruction
P03021088A0135|155 159|years
P03021088A0135|165 171|average
P03021088A0135|177 181|years
P03022129A0842|14 19|arrays
P03022129A0842|30 35|MPE X Fe
P03022129A0842|79 84|detail
P03022129A0842|107 119|accessibility
P03022129A0842|123 128|extent
P03022129A0842|164 180|transcription rate
P03023067A0779|0 10|Translation
P03023067A0779|29 33|genes
P03023067A0779|63 73|transcripts
P03023679A0624|12 17|weight
P03023679A0624|34 41|proteins
P03023679A0624|88 95|proteins
P03023679A0624|128 139|modification
P03023682A0271|0 8|Insertion
P03023682A0271|52 83|chloramphenicol acetyltransferase
P03023682A0271|87 96|expression
P03023859A0000|45 60|leukemia patients
P03023859A0000|76 85|breakpoint
P03023859A0000|87 96|chromosome
P03023859A0000|102 114|Ph1 chromosome
P03023859A0000|137 141|probe
P03023859A0000|154 176|breakpoint cluster region
P03023887A0470|0 19|Nuclease footprinting
P03023887A0470|40 61|glucocorticoid receptor
P03023887A0470|85 89|sites
P03023887A0470|104 110|borders
P03023887A0470|132 144|sequence motif
P03023970A0922|8 13|insert
P03023970A0922|24 40|termination signal
P03023970A0922|64 74|termination
P03023970A0922|80 86|protein
P03023970A0922|99 108|generation
P03023970A0922|112 121|p53 product
P03023970A0922|123 132|amino acids
P03024343A0372|3 8|tumors
P03024343A0372|33 46|neuroendocrine
P03024343A0372|49 54|origin
P03024703A1036|9 14|region
P03024703A1036|21 31|nucleotides
P03024703A1036|46 61|polypeptide chain
P03024703A1036|67 76|amino acids
P03024703A1036|93 98|weight
P03024703A1036|113 125|hsp108 protein
P03025606T0000|15 28|control signals
P03025606T0000|32 53|herpes simplex virus type
P03025606T0000|59 63|gamma
P03025606T0000|65 71|gene lie
P03025606T0000|78 82|bases
P03025606T0000|106 113|terminus
P03025655T0000|13 18|domain
P03025655T0000|60 66|kinases
P03025655T0000|78 91|kinase function
P03025655T0000|95 114|transforming activity
P03025655T0000|117 147|Fujinami sarcoma virus P130gag-fps
P03025661A0260|0 6|Gluzman
P03025661A0260|7 12|EMBO J.
P03025862A0860|42 51|amino acids
P03025862A0860|56 63|ssd chain
P03025862A0860|83 88|region
P03025862A0860|118 129|addition site
P03026915A1024|16 24|sequences
P03026915A1024|28 32|parts
P03026915A1024|44 52|sequences
P03026915A1024|62 71|yeast genes
P03026915A1024|104 120|lacZ fusion vectors
P03027661A0000|3 12|activities
P03027661A0000|18 25|D protein
P03027661A0000|31 42|miniF plasmid
P03027779A0000|0 15|SPECT examination
P03027779A0000|34 39|Tc-MDP
P03027779A0000|55 62|patients
P03027779A0000|98 108|dislocation
P03027779A0000|127 133|normals
P03027905A0632|0 18|Plasma renin activity
P03027905A0632|29 50|plasma aldosterone level
P03027905A0632|66 75|lisinopril
P03029111A0155|3 9|mutants
P03029111A0155|14 27|representative
P03029111A0155|39 61|pet complementation group
P03031602A1001|9 13|group
P03031602A1001|26 33|elements
P03031602A1001|56 61|region
P03031602A1001|68 72|genes
P03032143A0218|1 10|centromere
P03032143A0218|36 41|region
P03032143A0218|71 76|length
P03032143A0218|99 114|sequence elements
P03032143A0218|133 140|proteins
P03032143A0218|154 165|conformation
P03032143A0218|171 179|chromatin
P03032143A0218|183 198|yeast kinetochore
P03032964T0000|12 19|function
P03032964T0000|42 49|promoter
P03032964T0000|60 68|sequences
P03032964T0000|81 88|activity
P03033283A0837|56 63|IE68 gene
P03033283A0837|70 74|Towne
P03033283A0837|97 107|DNA sequence
P03033283A0837|109 143|competition filter binding experiments
P03033283A0837|154 160|maximum
P03033283A0837|177 197|consensus binding sites
P03033283A0837|230 235|region
P03033283A1415|62 75|repeat elements
P03033283A1415|132 139|strength
P03033283A1415|150 160|arrangement
P03033283A1415|205 209|sites
P03033283A1415|259 267|host range
P03033283A1415|271 280|expression
P03033283A1415|283 290|SCMV IE94
P03033283A1415|303 310|HCMV IE68
P03034570A0943|10 14|genes
P03034570A0943|17 28|gene segments
P03034570A0943|54 85|chloramphenicol acetyltransferase
P03034570A0943|113 122|resistance
P03034570A0943|129 138|hygromycin
P03034570A0943|145 149|ORF E7
P03034570A0943|160 177|papillomavirus type
P03034570A0943|189 195|vectors
P03034956A0666|2 9|contrast
P03034956A0666|27 40|androgen levels
P03034956A0666|90 97|subjects
P03034956A0666|128 137|prednisone
P03035056T0000|6 11|lambda
P03035056T0000|15 44|kappa antibody gene rearrangement
P03035056T0000|47 53|Abelson
P03035056T0000|60 67|leukemia
P03035056T0000|90 98|cell lines
P03035218T0000|0 13|Identification
P03035218T0000|41 49|sequences
P03035218T0000|64 86|T-cell leukemia virus type
P03035218T0000|100 105|repeat
P03035658A0355|19 28|anesthesia
P03035658A0355|49 57|ml/kg/min
P03035658A0355|74 84|epinephrine
P03035658A0355|103 108|manner
P03035658A0355|110 129|plasma concentrations
P03035658A0355|140 144|ng/ml
P03035658A0355|155 163|ml/kg/min
P03035658A0355|170 174|ng/ml
P03035658A0355|185 193|ml/kg/min
P03036415T0000|0 8|Influence
P03036415T0000|11 35|cyclo-oxygenase inhibition
P03036415T0000|41 67|leukotriene receptor blockade
P03036415T0000|87 120|pressure/cardiac index relationships
P03036817A0213|24 34|mutagenesis
P03036817A0213|52 70|NdeI restriction site
P03036817A0213|93 99|yeast R.
P03036933A0774|0 10|ACTH release
P03036933A0774|40 47|children
P03036933A0774|62 74|ACTH treatment
P03037334A0932|33 47|promoter element
P03037334A0932|53 66|yeast RP39A gene
P03037334A0932|91 104|sequence motifs
P03038643A1374|40 53|alpha-spectrin
P03038643A1374|62 72|duplication
P03038643A1374|81 90|divergence
P03038891A0935|0 15|Northern analyses
P03038891A0935|28 39|mouse tissues
P03038891A0935|42 50|cell lines
P03038891A0935|64 76|p11 mRNA levels
P03039177A0503|3 7|group
P03039177A0503|13 22|cDNA clones
P03039177A0503|55 64|transcript
P03039177A0503|77 92|IR2 repeat element
P03039177A0503|102 128|restriction site polymorphism
P03039177A0503|135 144|enzyme SmaI
P03039387A0920|30 45|cyclophosphamide
P03039387A0920|66 76|enhancement
P03039387A0920|90 95|effect
P03039387A0920|124 134|combination
P03039387A0920|137 148|methotrexate
P03039387A0920|161 176|cyclophosphamide
P03039387A0920|180 189|levamisole
P03040023A0113|0 7|Morphine
P03040023A0113|31 41|bradycardia
P03040023A0113|52 62|tachycardia
P03040403A0155|3 9|PSS gene
P03040403A0155|33 40|fragment
P03040403A0155|46 53|yeast DNA
P03040403A0155|59 69|YEp13 vector
P03041046A0127|6 11|A-MuLV
P03041046A0127|31 37|viruses
P03041046A0127|47 57|Moloney MuLV
P03041046A0127|98 103|A-MuLV
P03041046A0127|124 130|viruses
P03041046A0127|140 145|BALB/c
P03041046A0127|205 213|potential
P03041802A0975|3 10|presence
P03041802A0975|24 41|platelet aggregates
P03041802A0975|53 58|levels
P03041802A0975|61 75|fibrinopeptide A
P03041802A0975|77 91|cleavage product
P03041802A0975|112 129|platelet activation
P03041802A0975|139 148|deposition
P03041802A0975|168 179|pathogenesis
P03041802A0975|185 192|disorder
P03042778A0643|23 27|yeast
P03042778A0643|37 42|growth
P03045117A0936|12 17|values
P03045117A0936|34 40|methods
P03045117A0936|47 55|agreement
P03045117A0936|63 69|species
P03045117A0936|81 92|growth factor
P03045117A0936|107 111|order
P03045117A0936|133 137|Glu24
P03045117A0936|153 157|Asp27
P03045117A0936|200 204|Tyr29
P03045117A0936|220 224|Leu47
P03045725A0872|17 27|suppression
P03045725A0872|38 52|prolactin levels
P03045725A0872|76 95|breast cancer patients
P03045725A0872|121 136|tumor sensitivity
P03045725A0872|139 150|chemotherapy
P03046655A0000|9 23|prevalence study
P03046655A0000|39 44|acuity
P03046655A0000|76 83|patients
P03046655A0000|95 103|keratitis
P03046655A0000|123 128|period
P03046931A0247|13 18|eIF-4A
P03046931A0247|29 38|retroposon
P03046931A0247|82 101|nucleotide difference
P03048024A0418|13 19|culture
P03048024A0418|32 37|tissue
P03048024A0418|65 71|NIB rats
P03049570A1242|5 16|similarities
P03049570A1242|33 42|E2 proteins
P03050147A0896|5 13|infection
P03050147A0896|19 23|cells
P03050147A0896|49 64|E1a-E1b functions
P03050147A0896|69 75|viruses
P03050147A0896|89 95|amounts
P03050147A0896|110 126|mRNA transcription
P03050147A1520|4 14|observation
P03050147A1520|36 48|scanning model
P03050147A1520|61 70|initiation
P03050147A1520|86 94|ribosomes
P03050147A1520|127 134|mRNA site
P03050147A1520|146 162|initiator AUG codon
P03050147A1520|169 176|C protein
P03052327A1474|15 21|results
P03052327A1474|33 62|pancreas-kidney transplantation
P03052327A1474|77 85|treatment
P03052327A1474|88 93|choice
P03052327A1474|112 119|patients
P03052641A0204|14 22|compounds
P03052641A0204|35 42|vehicles
P03052641A0204|59 63|gases
P03053713A0752|0 12|DNA sequencing
P03053713A0752|18 25|DPM1 gene
P03053713A0752|40 51|reading frame
P03053713A0752|57 61|bases
P03057259A0514|3 14|relationship
P03057259A0514|38 45|lymphoma
P03057259A0514|51 57|thyroid
P03057259A0514|68 78|thyroiditis
P03059171A1232|0 13|Administration
P03059171A1232|16 29|anticoagulants
P03059171A1232|34 40|heparin
P03059171A1232|41 55|prostaglandin E1
P03059171A1232|59 69|ticlopidine
P03059171A1232|101 108|symptoms
P03059171A1232|131 143|deterioration
P03060846T0000|10 17|analysis
P03060846T0000|23 35|L1 binding site
P03060846T0000|38 44|23S rRNA
P03060953A0481|0 6|Animals
P03060953A0481|27 37|vaccination
P03060953A0481|48 57|mechanisms
P03060953A0481|78 86|outbreaks
P03061301A0624|0 20|Prostacyclin formation
P03061301A0624|35 47|excretion rate
P03061301A0624|59 95|metabolite 6-keto-prostaglandin F1 alpha
P03061301A0624|109 113|means
P03061301A0624|116 131|radioimmunoassay
P03061301A0624|140 153|urine specimens
P03061301A0624|181 186|period
P03061301A0624|195 206|participants
P03061301A0624|217 221|smoke
P03061301A0624|243 252|cigarettes
P03061301A1409|7 15|excretion
P03061301A1409|38 44|F1 alpha
P03061301A1409|67 73|smokers
P03061301A1409|85 98|contraceptives
P03061301A1409|111 115|ng/gm
P03061301A1409|118 127|creatinine
P03061383A0000|10 17|activity
P03061383A0000|20 29|mecillinam
P03061383A0000|83 89|strains
P03061383A0000|98 112|beta-lactamases
P03061383A0000|118 122|TEM-1
P03061383A0000|123 127|Oxa-1
P03061383A0000|167 171|broth
P03061383A0000|174 194|agar dilution technique
P03062370A0000|29 37|activator
P03062370A0000|39 47|amino acid
P03062370A0000|60 64|genes
P03062370A0384|5 11|results
P03062370A0384|24 34|GCN3 product
P03062370A0384|51 60|repression
P03062370A0384|63 72|activation
P03062370A0384|75 88|GCN4 expression
P03062370A0384|100 120|amino acid availability
P03064524A0160|3 10|efficacy
P03064524A0160|35 39|drugs
P03064811A0485|3 19|amino acid sequence
P03064811A0485|25 39|S. aureus peptide
P03064811A0485|51 65|phosphoryl group
P03065140A0273|5 13|mutations
P03065140A0273|22 28|regions
P03065140A0273|31 41|GAL4 protein
P03065140A0273|45 60|DNA binding domain
P03065140A0273|67 95|transcription activation domain
P03065141A0448|3 9|results
P03065141A0448|26 30|genes
P03065141A0448|58 66|promoters
P03065141A0448|71 78|location
P03065141A0448|84 91|promoter
P03065141A0448|98 105|citB gene
P03065141A0448|111 134|Tn3411 nucleotide sequence
P03065141A0448|157 162|pMS185
P03065610A0375|3 9|rci gene
P03065610A0375|34 44|gene product
P03065610A0375|59 77|Western blot analysis
P03065621T0000|0 8|Structure
P03065621T0000|12 21|regulation
P03065621T0000|76 80|MRP13
P03065621T0000|81 87|protein
P03065621T0000|98 104|subunit
P03065621T0000|123 130|ribosome
P03066131A0000|6 11|survey
P03066131A0000|43 47|basis
P03066131A0000|59 67|treatment
P03066131A0000|70 87|behaviour disorders
P03066131A0000|102 108|lesions
P03066131A0000|114 121|amygdala
P03066131A0000|143 154|hypothalamus
P03066131A0000|158 163|author
P03066131A0000|179 189|experiences
P03066131A0000|197 206|operations
P03066131A0000|210 216|control
P03066131A0000|244 257|aggressiveness
P03066208A0310|12 22|examination
P03066208A0310|73 85|cell carcinoma
P03066625A0756|26 32|studies
P03066625A0756|65 77|contributions
P03066625A0756|88 98|risk factors
P03066625A0756|123 133|risk factors
P03066625A0756|137 143|studies
P03066625A0756|176 184|questions
P03067505A0688|4 15|prostacyclin
P03067505A0688|41 48|property
P03067505A0688|59 68|ear vessels
P03069046A0126|3 8|method
P03069046A0126|27 35|precision
P03069046A0126|47 57|sensitivity
P03069980T0000|0 6|Factors
P03069980T0000|21 32|bond strength
P03069980T0000|40 57|glass polyalkenoate
P03069980T0000|58 64|ionomer
P03069980T0000|65 71|cements
P03069980T0000|75 81|dentine
P03072021A0696|3 20|amino acid sequences
P03072021A0696|26 30|yeast
P03072021A0696|56 73|targeting sequences
P03072021A0696|111 122|polypeptides
P03072580A0455|0 9|Van der Ende
P03073091A0338|6 20|insulin infusion
P03073091A0338|23 39|% dextrose solution
P03073091A0338|53 61|Biostator
P03073091A0338|64 68|order
P03073091A0338|82 88|patient
P03073091A0338|90 97|glycemia
P03073091A0338|102 106|mg/dl
P03073091A0449|0 6|Amounts
P03073091A0449|9 15|glucose
P03073091A0449|50 68|hour insulin infusion
P03073091A0449|106 114|treatment
P03073091A0449|122 127|mmol/l
P03073091A0449|136 144|mg/kg/min
P03073091A0449|150 163|spironolactone
P03073091A0449|171 176|mmol/l
P03073091A0449|186 194|mg/kg/min
P03073091A0449|200 212|indomethacine
P03073091A0449|220 225|mmol/l
P03073091A0449|231 239|mg/kg/min
P03073091A0449|253 257|drugs
P03073091A0449|265 270|mmol/l
P03073091A0449|279 287|mg/kg/min
P03073192T0000|0 49|Mycobacterium avium-intracellulare complex infections
P03073192T0000|63 86|immunodeficiency syndrome
P03075154T0000|0 9|Recurrence
P03075154T0000|12 28|oxalate deposition
P03075154T0000|37 46|transplant
P03075154T0000|53 71|ciclosporin A therapy
P03076124A0496|3 22|bile acid sequestrants
P03076124A0496|23 36|cholestyramine
P03076124A0496|40 49|colestipol
P03076124A0496|65 75|fenofibrate
P03076124A0496|78 87|inhibitors
P03076124A0496|90 119|hydroxymethylglutaryl coenzyme A
P03076124A0496|120 125|HMG CoA
P03076124A0496|126 134|reductase
P03076124A0496|139 148|lovastatin
P03076124A0496|151 161|simvastatin
P03076124A0496|181 185|drugs
P03076124A0496|196 203|patients
P03076124A0496|214 234|hypercholesterolaemia
P03076124A0496|240 245|agents
P03076124A0496|252 271|plasma concentrations
P03076124A0496|274 278|total
P03076124A0496|282 296|LDL-cholesterol
P03078268A0529|28 34|aspects
P03078268A0529|44 56|acidification
P03078268A0529|91 104|acidosis models
P03078268A0529|114 120|maleate
P03078268A0529|124 145|amphotericin B treatment
P03078268A0529|162 171|mechanisms
P03078268A0529|198 205|steroids
P03078268A0529|214 226|acidification
P03079276T0029|0 7|Analysis
P03079276T0029|11 16|groups
P03079276T0029|19 26|patients
P03079276T0029|72 80|flare-ups
P03080793T0000|0 8|Statement
P03080793T0000|14 24|development
P03080793T0000|27 36|guidelines
P03080793T0000|43 52|prevention
P03080793T0000|55 70|AIDS transmission
P03080793T0000|76 84|workplace
P03083441T0000|0 12|Modifications
P03083441T0000|29 43|postcontraction
P03083441T0000|54 59|people
P03088643A0000|30 39|preference
P03088643A0000|70 76|stimuli
P03088643A0000|106 116|control rats
P03090237A0202|10 18|schedules
P03090237A0202|30 40|response run
P03090237A0202|79 83|times
P03090237A0202|89 99|response key
P03090237A0202|100 106|work key
P03090237A0202|137 147|response key
P03090372A0607|11 31|glucose tolerance tests
P03090372A0607|51 59|operation
P03090372A0607|88 92|weeks
P03091849A0000|3 9|effects
P03091849A0000|12 25|glutaraldehyde
P03091849A0000|28 37|dimensions
P03091849A0000|41 54|ultrastructure
P03091849A0000|78 89|rat mesentery
P03091849A0000|105 109|kinds
P03091849A0000|112 121|experiment
P03091849A0000|138 145|fixative
P03091849A0000|162 170|perfusion
P03091849A0000|174 181|pressure
P03091849A0000|186 189|mm Hg
P03091849A0000|195 205|superfusion
P03091849A0000|233 240|membrane
P03097509A0654|16 27|RNA molecules
P03097509A0654|43 49|regions
P03097509A0654|71 79|base pairs
P03097643A1357|7 16|BALB/c gene
P03097643A1357|32 43|substitution
P03097643A1357|56 70|octamer sequence
P03097643A1357|94 104|nucleotides
P03097643A1357|124 129|region
P03097643A1357|149 158|expression
P03098018A0139|8 15|findings
P03098018A0139|20 25|height
P03098018A0139|33 38|weight
P03098018A0139|53 58|length
P03098018A0139|65 69|limbs
P03098018A0139|70 82|P2-A2 pilosity
P03098018A0139|86 95|micropenis
P03102289A0786|50 66|hCG administration
P03102289A0786|68 75|midcycle
P03102289A0786|92 97|number
P03102289A0786|100 108|follicles
P03102289A0786|127 136|ultrasound
P03102289A0786|138 145|cycle day
P03102289A0786|170 182|serum E2 levels
P03102289A0786|197 202|pmol/l
P03102289A0786|206 213|follicle
P03104245A0402|4 11|patients
P03104245A0402|21 25|Ir192
P03104245A0402|35 42|addition
P03104245A0402|53 61|radiation
P03104245A0402|84 91|survival
P03104245A0402|134 139|months
P03104245A0402|140 144|range
P03104245A0402|152 157|months
P03104245A0402|165 170|months
P03104245A0402|171 175|range
P03104245A0402|182 187|months
P03104248A0322|6 12|Stage IA
P03104248A0322|16 23|patients
P03104248A0322|45 49|tumor
P03104248A0322|87 91|tumor
P03104248A0322|100 107|patients
P03104914T0000|0 8|Mechanism
P03104914T0000|30 42|translocation
P03104914T0000|52 59|analysis
P03104914T0000|93 100|partners
P03104982A0690|16 31|hemoglobin levels
P03104982A0690|68 72|women
P03104982A0690|85 97|sex difference
P03104982A0690|115 119|years
P03108171A0088|0 9|Ritanserin
P03108171A0088|16 24|substance
P03108171A0088|44 59|blocking activity
P03108171A0088|62 72|S2 receptors
P03108171A0088|101 106|system
P03109147A0000|0 13|Ethylene glycol
P03109147A0000|17 32|diethylene glycol
P03109147A0000|79 84|groups
P03109147A0000|96 103|NMRI mice
P03109147A0000|107 113|dosages
P03109147A0000|143 147|mouse
P03109147T0127|0 7|Research
P03109147T0127|10 23|ethylene glycol
P03109147T0127|27 42|diethylene glycol
P03109147T0127|58 64|effects
P03109954A0945|3 9|results
P03109954A0945|41 49|influence
P03109954A0945|67 73|ethinyl
P03109954A0945|108 117|inhibition
P03109954A0945|127 147|artery atherosclerosis
P03109954A0945|183 190|lowering
P03109954A0945|193 225|plasma HDL cholesterol concentration
P03109954A0945|248 254|balance
P03109954A0945|269 277|influence
P03109954A0945|283 294|relationship
P03109954A0945|302 313|plasma lipids
P03109954A0945|317 329|atherogenesis
P03110119A0267|13 22|ventilator
P03110119A0267|41 48|bias flow
P03110119A0267|62 66|l/min
P03110119A0267|88 96|side ports
P03110119A0267|105 112|catheter
P03110119A0267|137 146|cm cephalad
P03110119A0267|151 156|carina
P03110678A0702|0 9|Comparison
P03110678A0702|33 39|removal
P03110678A0702|51 70|polysulphone membrane
P03110678A0702|74 86|haemodialysis
P03110678A0702|90 104|haemofiltration
P03110678A0702|114 132|beta 2-microglobulin
P03110678A0702|159 168|convection
P03110678A0702|175 183|diffusion
P03110678A0702|192 205|treatment modes
P03110678A0702|219 227|blood flow
P03110678A0702|231 243|urea clearance
P03110692A0156|60 65|beta 2m
P03110692A0156|93 100|patients
P03110692A0156|105 113|bone cysts
P03110692A0156|149 156|duration
P03110692A0156|158 165|dialysis
P03110692A0156|205 212|patients
P03110692A0156|216 224|bone cysts
P03110692A0156|231 236|months
P03110692A0156|287 292|beta 2m
P03110692A0156|303 310|patients
P03110692A0156|323 330|dialysis
P03110692A0156|365 375|urine volume
P03110692A0156|392 396|litre
P03110746A0146|7 16|percentage
P03110746A0146|38 50|triglycerides
P03110746A0146|67 79|adipose tissue
P03110746A0146|80 85|PLASAT
P03110746A0146|93 100|subjects
P03110746A0146|141 145|group
P03110794A0991|2 10|overdoses
P03110794A0991|16 27|g fluvoxamine
P03110794A0991|42 48|effects
P03110801A0532|20 42|plasma prolactin response
P03110801A0532|49 58|micrograms
P03111946A0309|2 7|effect
P03111946A0309|26 33|behavior
P03112028A0404|15 22|patients
P03112028A0404|68 77|parameters
P03112412A0985|2 9|addition
P03112412A0985|20 25|strain
P03112412A0985|71 88|synthetase mutation
P03112412A0985|104 122|thr operon expression
P03112412A0985|142 152|temperature
P03112412A0985|171 177|mutants
P03112412A0985|186 191|change
P03114188A0907|28 35|problems
P03114188A0907|59 64|decade
P03114188A0907|68 75|patients
P03114188A0907|88 103|chest wall sarcoma
P03114188A0907|114 121|patients
P03114188A0907|148 153|breast
P03114188A0907|169 173|areas
P03114829T0000|21 30|correlates
P03114829T0000|33 43|panic states
P03114995T0000|0 6|Effects
P03114995T0000|28 36|nutrition
P03114995T0000|39 52|gastrin release
P03115087A0515|7 12|weight
P03115087A0515|16 31|height velocities
P03115087A0515|54 61|standard
P03115787A0633|3 10|patients
P03115787A0633|22 37|cyclophosphamide
P03115787A0633|38 55|hexamethylmelamine
P03115787A0633|56 65|adriamycin
P03115787A0633|69 77|cisplatin
P03115787A0633|78 83|CHAP-5
P03115787A0633|98 104|disease
P03115787A0633|120 127|response
P03115787A0633|137 145|responses
P03115787A0633|156 161|months
P03115787A0633|173 181|responses
P03115787A0633|191 196|months
P03117046T0000|0 8|Isolation
P03117046T0000|12 27|characterization
P03117046T0000|31 42|vinculin cDNA
P03117046T0000|59 69|fibroblasts
P03117147A1059|14 18|study
P03117147A1059|31 39|agreement
P03117147A1059|47 53|surface
P03117147A1059|57 71|oesophageal EMGd
P03117147A1059|90 100|surface EMGd
P03117147A1059|139 151|investigation
P03118631A0140|2 12|differences
P03118631A0140|15 29|fixation quality
P03118631A0140|49 56|cochleas
P03118631A0140|77 85|perfusion
P03118631A0140|89 96|cochleas
P03118631A0140|121 129|perfusion
P03119227A0079|3 13|DNA sequence
P03119227A0079|22 28|protein
P03119227A0079|35 44|amino acids
P03119227A0079|49 64|sequence homology
P03119227A0079|75 100|c-abl proto-oncogene product
P03119227A0079|115 127|amino terminus
P03119227A0079|143 152|amino acids
P03119227A0079|163 168|region
P03119227A0079|181 202|tyrosine kinase activity
P03119485A0476|3 13|requirement
P03119485A0476|39 43|acids
P03119485A0476|46 53|patients
P03119485A0476|73 81|nutrition
P03119485A0476|92 97|injury
P03119485A0476|109 116|interest
P03119485A0476|121 127|respect
P03119485A0476|133 143|development
P03119485A0476|147 155|prognosis
P03119485A0476|158 162|shock
P03119485A0476|163 168|sepsis
P03119485A0476|187 202|distress syndrome
P03120334A0893|43 48|origin
P03120334A0893|77 82|system
P03120334A0893|99 103|veins
P03123310A0000|25 32|Gart gene
P03123310A0000|54 63|activities
P03123310A0000|69 75|pathway
P03123310A0000|79 84|purine
P03123310A0000|91 99|synthesis
P03123983T0000|11 25|neuroplasticity
P03123983T0000|30 37|response
P03123983T0000|40 44|drugs
P03125422A0202|3 9|results
P03125422A0202|17 27|experiments
P03125422A0202|58 75|activator sequences
P03125422A0202|95 103|induction
P03125422A0202|105 113|galactose
P03126531T0000|0 7|Reversal
P03126531T0000|13 20|increase
P03126531T0000|42 51|stereotypy
P03126531T0000|55 64|aggression
P03126531T0000|67 74|REM sleep
P03126531T0000|91 118|dopamine agonist pretreatments
P03127034A0591|3 11|heart rate
P03127034A0591|58 67|resistance
P03127463A1017|5 9|rIL-3
P03127463A1017|21 29|COS7 cells
P03127463A1017|47 57|CSF activity
P03127463A1017|69 76|cultures
P03127463A1017|79 93|bone marrow cells
P03127463A1017|118 130|proliferation
P03127463A1017|133 137|My-10
P03127463A1017|138 143|marrow
P03127463A1017|146 159|cord blood cells
P03127463A1017|168 175|cultures
P03132498A0730|4 11|patients
P03132498A0730|17 21|PaCO2
P03132498A0730|53 57|range
P03132498A0730|80 90|asthma score
P03132498A0730|103 107|PaCO2
P03132498A0730|154 158|hours
P03133250A0000|22 26|study
P03133250A0000|55 65|stimulation
P03133250A0000|85 96|gonadotropin
P03133250A0000|130 136|hormone
P03133250A0000|153 165|fertilization
P03133250A0000|168 181|embryo transfer
P03133250A0000|182 187|IVF-ET
P03133250A0000|188 194|program
P03133360A1215|3 10|findings
P03133360A1215|25 34|mtr product
P03133360A1215|45 68|transcription attenuation
P03133360A1215|72 81|inhibition
P03133360A1215|84 94|translation
P03133360A1215|97 104|trpE mRNA
P03134872T0029|0 6|Apropos
P03137105A0146|1 21|prostaglandin analogue
P03137105A0146|34 42|pregnancy
P03137105A0146|60 71|gonadotropin
P03137105A0146|111 115|phase
P03137105A0146|152 156|cycle
P03137105A0146|163 178|oocyte collection
P03137105A0146|198 203|cycles
P03137105A0146|206 217|oocyte donors
P03137105A0146|221 236|embryo recipients
P03137346A0319|3 15|nucleolin gene
P03137346A0319|31 40|base-pairs
P03137346A0319|57 61|exons
P03137346A0319|78 94|amino acid residues
P03137346A0319|100 106|protein
P03137601A0212|8 36|L-threo-dihydroxyphenylserine
P03137601A0212|55 68|norepinephrine
P03137601A0212|72 80|precursor
P03137601A0212|92 101|immobility
P03137601A0212|142 151|immobility
P03137601A0212|184 199|NE neurotoxin DSP4
P03138190A0347|11 17|amounts
P03138190A0347|29 38|ampicillin
P03138190A0347|64 75|Kupffer cells
P03138190A0347|79 89|target cells
P03138190A0347|123 133|inoculation
P03138449A0759|17 21|delta
P03138449A0759|26 30|delta
P03138449A0759|32 53|desaturation activities
P03138449A0759|70 79|conditions
P03138449A0759|93 100|w6 supply
P03139750A0000|10 14|basis
P03139750A0000|21 30|expression
P03139750A0000|40 49|VH allotype
P03139750A0000|55 60|rabbit
P03142875A0366|23 44|6-kilobase cDNA sequence
P03142875A0366|55 59|chain
P03142875A0366|66 75|amino acids
P03142875A0366|94 102|structure
P03143048A1091|0 14|HDL-cholesterol
P03143048A1091|36 52|apolipoprotein A-I
P03143048A1091|69 82|concentrations
P03143485A0366|3 9|Euglena
P03143485A0366|19 36|protein gene cluster
P03143485A0366|62 74|protein operon
P03143485A0366|94 109|gene organization
P03143485A0366|134 138|order
P03143485A0366|153 157|genes
P03143485A0366|163 169|tobacco
P03143485A0366|173 199|liverwort chloroplast genomes
P03144705A0859|3 14|distribution
P03144705A0859|20 24|sites
P03144705A0859|42 51|resolution
P03144705A0859|86 93|gradient
P03144705A0859|96 113|sequence divergence
P03144705A0859|211 226|Alu family repeats
P03146017A0983|3 20|nucleotide sequence
P03146017A0983|26 31|region
P03146017A0983|54 60|ORFtrpA
P03146017A0983|87 94|presence
P03146017A0983|110 120|nucleotides
P03146017A0983|120 126|ORFtrpB
P03146017A0983|139 158|amino acid polypeptide
P03146150T0000|0 11|Potentiation
P03146150T0000|29 36|efficacy
P03146150T0000|51 59|urokinase
P03146150T0000|60 72|Pro-urokinase
P03146150T0000|75 81|heparin
P03146784A0158|4 12|receptors
P03146784A0158|25 29|phase
P03146784A0158|34 44|ventilation
P03146784A0158|91 106|stretch receptors
P03146784A0158|145 160|stretch receptors
P03146784A0158|207 220|chemoreceptors
P03147912A0422|11 26|hyperventilators
P03147912A0422|37 42|number
P03147912A0422|45 49|sighs
P03147912A0422|67 78|fluctuations
P03147912A0422|81 88|baseline
P03147912A0422|128 133|PETCO2
P03149774A0173|5 10|IA task
P03149774A0173|39 48|injections
P03149774A0173|51 60|picrotoxin
P03149774A0173|64 74|bicuculline
P03149774A0173|97 107|enhancement
P03149774A0173|110 118|retention
P03149774A0173|140 147|training
P03149774A0173|152 160|retention
P03149774A0173|177 197|bicuculline methiodide
P03149774A0173|199 220|GABA receptor antagonist
P03149774A0173|258 264|barrier
P03150015T0001|8 15|research
P03150015T0001|18 22|non-A
P03150015T0001|44 52|hepatitis
P03150296A0594|37 55|creatinine clearance
P03150296A0594|78 91|filtration rate
P03150296A0594|105 111|caution
P03150296A0594|117 127|recognition
P03150296A0594|133 143|limitations
P03150296A0594|149 154|method
P03150296A0594|169 178|techniques
P03150296A0594|179 193|serum creatinine
P03150296A0594|215 233|creatinine clearance
P03150296A0594|256 263|practice
P03154072A0862|3 17|protein mixtures
P03154072A0862|20 30|sesame flour
P03154072A0862|34 45|soybean flour
P03159903A0352|20 25|region
P03159903A0352|65 81|amino acid sequence
P03159903A0352|103 119|amino acid sequence
P03166458A1356|1 16|protein footprint
P03166458A1356|38 49|GC box element
P03166458A1356|52 62|nucleotides
P03167060A0000|12 23|growth factor
P03167060A0000|26 30|IGFII
P03167060A0000|43 53|polypeptide
P03167060A0000|57 61|mRNAs
P03167060A0000|89 93|forms
P03167060A0000|101 110|derivation
P03168709A0000|16 21|fields
P03168709A0000|40 51|glaucoma eyes
P03168709A0000|70 78|threshold
P03168709A0000|86 107|suprathreshold strategy
P03171221A0531|3 13|variability
P03171221A0531|27 32|result
P03171221A0531|46 53|splicing
P03171221A0531|56 60|exons
P03171221A0531|75 92|elastin transcripts
P03171279A0158|12 21|conclusion
P03171279A0158|39 44|artery
P03171279A0158|60 64|toe MP
P03171279A0158|70 75|grafts
P03171279A0158|107 112|artery
P03171279A0158|126 131|toe PIP
P03171279A0158|137 142|grafts
P03171279A0158|168 173|dorsal
P03172863T0000|0 5|Effect
P03172863T0000|15 28|undernutrition
P03172863T0000|31 44|susceptibility
P03172863T0000|51 56|stress
P03175942A0706|4 9|effect
P03175942A0706|34 38|doses
P03175942A0706|77 86|experiment
P03175942A0706|105 109|doses
P03178097A0000|3 19|CHARGE association
P03178097A0000|23 32|collection
P03178097A0000|35 45|multisystem
P03178097A0000|56 64|anomalies
P03178097A0000|81 87|atresia
P03178161A0000|10 14|brush
P03178161A0000|26 34|screening
P03178161A0000|51 69|blood concentrations
P03178161A0000|72 85|micronutrients
P03178161A0000|86 93|vitamin A
P03178161A0000|116 125|methionine
P03178161A0000|137 142|adults
P03178161A0000|164 172|carcinoma
P03178161A0000|178 185|Transkei
P03178161A0000|188 193|Ciskei
P03178161A0000|194 207|Southern Africa
P03178626A0137|0 7|Aviators
P03178626A0137|20 29|Attack Wing
P03178626A0137|30 36|Pacific
P03178626A0137|55 61|results
P03178626A0137|79 90|aircraft type
P03179496T0000|0 9|Evaluation
P03179496T0000|26 52|modified-hemoglobin solution
P03179496T0000|70 74|fluid
P03179496T0000|78 99|blood volume replacement
P03180595A1040|7 30|gallbladder visualization
P03180595A1040|34 42|reduction
P03180595A1040|45 60|ejection fraction
P03180595A1040|88 97|indicators
P03180595A1040|107 113|disease
P03181276A0422|2 14|micrograms PAF
P03181276A0422|17 23|placebo
P03181276A0422|47 52|cavity
P03181276A0422|76 92|allergen challenge
P03183103A0000|10 23|MR examinations
P03183103A0000|34 39|cavity
P03183103A0000|52 58|sinuses
P03183103A0000|82 88|h period
P03183103A0000|101 110|volunteers
P03183127A0068|0 9|Comparison
P03183127A0068|43 59|imaging modalities
P03183127A0068|73 83|myelography
P03183127A0068|83 100|CT ventriculography
P03183127A0068|104 124|CT myelocisternography
P03184267A0000|21 35|broiler chickens
P03184267A0000|85 92|serotype
P03184267A0000|122 131|infections
P03184267A0000|152 159|chickens
P03184267A0000|163 175|food poisoning
P03184267A0000|178 183|humans
P03185322A1305|5 15|correlation
P03185322A1305|70 75|result
P03185322A1305|76 80|class
P03185322A1305|104 112|diagnosis
P03185322A1305|119 131|class-2 smears
P03185322A1305|160 168|dysplasia
P03185540T0000|0 6|Factors
P03185540T0000|25 37|transcription
P03185540T0000|49 61|RNA polymerase
P03185540T0000|64 75|purification
P03185540T0000|83 93|specificity
P03185540T0000|97 124|TATA box-promoter interactions
P03185540T0000|127 131|TFIID
P03186091T0000|0 5|Change
P03186091T0000|8 33|plasma cystyl aminopeptidase
P03186091T0000|34 44|oxytocinase
P03186091T0000|57 61|weeks
P03186091T0000|62 70|gestation
P03186091T0000|74 82|predictor
P03186091T0000|102 113|hypertension
P03186270T0001|10 18|diagnosis
P03190481A0292|26 33|esterase
P03190481A0292|36 47|quantitation
P03190481A0292|50 60|macrophages
P03190481A0292|69 74|number
P03190481A0292|78 97|infiltration area unit
P03190481A0292|111 117|abscess
P03190481A0292|132 142|correlation
P03190481A0292|161 166|number
P03190481A0292|169 179|macrophages
P03190481A0292|186 190|width
P03190481A0292|196 202|capsule
P03190914A0149|12 33|migration differentials
P03190914A0149|60 73|responsiveness
P03190914A0149|106 110|group
P03192537A0370|20 28|amino acid
P03192537A0370|35 42|sequence
P03192537A0370|54 58|HMG-I
P03192537A0370|93 109|amino acid sequence
P03192537A0370|115 119|HMG-I
P03192537A0370|147 156|amino acids
P03192537A0370|175 181|protein
P03192724A0000|13 28|style differences
P03192724A0000|34 44|drug abusers
P03192724A0000|84 89|system
P03192724A0000|91 110|FIRO-B interpretation
P03192799T0000|0 8|Statement
P03192799T0000|14 28|American Academy
P03192799T0000|31 46|Implant Dentistry
P03192950A0566|44 48|women
P03192950A0566|55 63|TSH levels
P03192950A0566|79 83|range
P03194410A0771|2 11|UOxase mRNA
P03194410A0771|37 43|tissues
P03194410A0771|61 77|tissue specificity
P03194410A0771|79 88|expression
P03194410A0771|95 104|UOxase gene
P03195167A0104|3 22|platelet adhesion rate
P03195167A0104|30 35|layers
P03195167A0104|59 67|valuation
P03195167A0104|73 90|haemocompatibility
P03195167A0104|96 121|basic-polymers polyurethane
P03195167A0104|127 143|polyvinylchloride
P03195167A0104|151 161|polystyrene
P03195167A0104|185 196|test chambers
P03198436T0000|12 20|treatment
P03198436T0000|23 38|bladder carcinoma
P03198436T0000|48 57|cystectomy
P03198436T0000|73 79|iridium
P03198525A0164|8 19|feedlot trial
P03198525A0164|23 29|heifers
P03198525A0164|44 48|light
P03198525A0164|49 54|medium
P03198525A0164|63 68|weight
P03198525A0164|81 90|treatments
P03198525A0164|105 111|mg.hd-1
P03198525A0164|142 148|control
P03198525A0164|157 164|DEPO-MGA
P03198525A0164|182 186|ml/hd
P03198525A0164|194 201|mg MGA/hd
P03199043A0248|0 8|Existence
P03199043A0248|12 21|uniqueness
P03199043A0248|24 32|solutions
P03199043A0248|49 69|boundary value problems
P03199043A0248|102 125|permeability coefficients
P03199043A0248|128 141|transport rates
P03199043A0248|149 169|diffusion coefficients
P03199043A0248|178 187|resistance
P03199043A0248|194 202|constants
P03199436A1060|9 20|gene clusters
P03199436A1060|29 52|photosynthesis components
P03199436A1060|62 80|psbB-psbH-petB-petD
P03199436A1060|87 103|psbE-psbF clusters
P03200488A0439|3 9|results
P03200488A0439|45 56|turnover rate
P03200488A0439|74 88|dopamine neurons
P03200488A0439|102 115|administration
P03200488A0439|124 129|period
P03200844A1211|10 17|sequence
P03200844A1211|36 51|pore glycoprotein
P03200844A1211|63 72|similarity
P03200844A1211|93 100|proteins
P03200844A1211|124 131|features
P03200844A1211|135 140|member
P03200844A1211|146 151|family
P03200844A1211|161 177|pore glycoproteins
P03207975A0709|11 15|hours
P03207975A0709|21 34|administration
P03207975A0709|37 45|vitamin K1
P03207975A0709|46 65|plasma concentrations
P03207975A0709|71 77|vitamin
P03208493A0849|13 26|filtration rate
P03208493A0849|42 57|lithium clearance
P03209019A0662|14 30|promotion bioassay
P03209019A0662|31 36|groups
P03209019A0662|45 52|CD-1 mice
P03209019A0662|74 83|microliter
P03209019A0662|101 105|mg/ml
P03209019A0662|107 113|acetone
P03209019A0662|124 128|weeks
P03209019A0662|161 172|test material
P03209019A0662|189 193|weeks
P03212551T0001|3 14|pathogenesis
P03212551T0001|17 25|Dupuytren
P03212551T0001|27 37|contracture
P03212929A0000|2 15|ELISA procedure
P03212929A0000|52 62|IgE response
P03212929A0000|73 99|Dirofilaria immitis infection
P03214709A0559|15 21|release
P03214709A0559|25 30|stress
P03214709A0559|42 67|plasma corticosterone levels
P03214709A0559|77 82|stress
P03214709A0559|103 107|group
P03214709A0559|138 142|group
P03216131A0559|7 13|isolate
P03216131A0559|16 34|Aeromonas hydrophila
P03216131A0559|52 62|enterotoxin
P03218714A0000|33 56|Dandy-Walker malformation
P03218714A0000|75 83|tetralogy
P03218714A0000|85 90|Fallot
P03219107A0212|3 11|incidence
P03219107A0212|27 37|convulsions
P03219107A0212|47 52|babies
P03219107A0212|66 71|births
P03220077A0274|9 16|survival
P03220077A0274|60 64|years
P03223123T0001|8 17|evaluation
P03223123T0001|27 33|methods
P03223123T0001|47 53|markers
P03223123T0001|61 68|maturity
P03223123T0001|79 83|fluid
P03227288A0542|7 13|infants
P03227288A0542|55 60|months
P03227568T0001|0 6|Variety
P03227568T0001|18 22|sires
P03227568T0001|33 37|types
P03227568T0001|40 54|dermatoglyphics
P03227568T0001|55 62|patterns
P03227568T0001|79 84|mirror
P03227568T0001|87 92|cattle
P03228518A0339|38 44|samples
P03228518A0339|54 61|Academic
P03228518A0339|62 83|Personal Responsibility
P03228518A0339|107 116|dimensions
P03228785A1047|0 7|Recovery
P03228785A1047|31 41|improvement
P03228785A1047|61 70|parameters
P03228785A1047|152 156|weeks
P03228785A1047|185 191|control
P03228785A1047|229 236|ABSTRACT
P03228785A1047|251 255|WORDS
P03229917A0099|26 34|resection
P03229917A0099|57 72|remnant infection
P03232410A1467|33 37|cases
P03232410A1467|40 49|lung cancer
P03232410A1467|90 96|smoking
P03233862T0000|0 18|Neuromyelitis optica
P03233862T0000|25 32|syndrome
P03233862T0000|50 58|sclerosis
P03234790T0001|0 5|Effect
P03234790T0001|11 17|methods
P03234790T0001|29 42|administration
P03234790T0001|45 64|methyl isobutyl ketone
P03234790T0001|70 77|toxicity
P03235487A0404|0 12|Incorporation
P03235487A0404|23 48|M sodium dihydrogen phosphate
P03235487A0404|54 67|sugar solutions
P03235487A0404|79 86|decrease
P03235487A0404|92 101|shelf-life
P03235487A0404|104 112|diltiazem
P03237446A0377|14 20|history
P03237446A0377|35 44|infections
P03237446A0377|62 72|lymphopenia
P03239106A0856|13 29|phosphorus content
P03239106A0856|52 63|reabsorption
P03239106A0856|65 71|calcium
P03239106A0856|75 83|magnesium
P03243027T0000|20 29|regulation
P03243027T0000|41 61|protein gene expression
P03243027T0000|68 78|development
P03243027T0000|81 103|Dictyostelium discoideum
P03243920A0591|20 58|plasma concentration-effect relationships
P03243920A0591|89 96|modeling
P03243920A0591|106 115|regression
P03246999A0483|3 10|increase
P03246999A0483|13 22|amplitudes
P03246999A0483|28 33|b-wave
P03246999A0483|43 58|adaptation period
P03246999A0483|89 96|subjects
P03246999A0483|103 110|controls
P03249792A0241|8 14|factors
P03249792A0241|21 31|development
P03249792A0241|43 56|symptomatology
P03249792A0241|63 77|group activities
P03249792A0241|92 104|group dynamics
P03249792A0241|112 124|stress factors
P03249792A0241|148 156|psychoses
P03249792A0241|174 187|manifestations
P03249840A0411|0 19|Baseline measurements
P03249840A0411|38 43|volume
P03249840A0411|64 80|airway conductance
P03249840A0411|110 118|carbachol
P03249840A0411|126 135|% reduction
P03249840A0411|155 164|% reduction
P03249840A0411|194 198|entry
P03249840A0411|206 212|subject
P03249840A0411|221 227|smoking
P03251210A0981|4 11|children
P03251210A0981|38 48|development
P03251210A0981|51 64|calcifications
P03251210A0981|96 100|forms
P03251210A0981|113 123|dysfunction
P03253219T0000|6 12|voltage
P03253219T0000|33 37|leads
P03253219T0000|40 66|anthracycline cardiomyopathy
P03253219T0000|76 80|study
P03256150A1866|3 9|results
P03256150A1866|32 43|requirements
P03257146A1037|5 11|results
P03257146A1037|24 28|CSFHU
P03257146A1037|40 55|neutrophil counts
P03257146A1037|71 76|number
P03257146A1037|80 87|maturity
P03257146A1037|93 118|marrow neutrophil precursors
P03257146A1037|125 129|types
P03257146A1037|132 140|childhood
P03257146A1037|148 158|neutropenia
P03258069A0000|3 10|purposes
P03258069A0000|17 21|study
P03258069A0000|39 44|effect
P03258069A0000|51 59|intensity
P03258069A0000|63 71|frequency
P03258069A0000|96 111|nerve stimulation
P03258069A0000|123 139|acupuncture points
P03258069A0000|154 166|pain threshold
P03258069A0000|180 184|wrist
P03258069A0000|203 209|changes
P03258069A0000|212 217|effect
P03259437A0140|13 43|neonates serum alpha-amylase value
P03259437A0140|65 76|starch method
P03259437A0140|101 108|controls
P03259437A0140|115 119|value
P03259437A0140|148 155|neonates
P03259437A0140|201 205|value
P03259437A0140|236 243|neonates
P03261005A0216|0 6|Records
P03261005A0216|11 18|children
P03261005A0216|43 49|complex
P03261005A0216|80 87|care unit
P03261005A0216|107 113|failure
P03261005A0216|133 138|period
P03261223A0644|8 15|patients
P03261223A0644|35 46|disease group
P03261223A0644|63 67|SPECT
P03261331A0563|0 4|SPECT
P03261331A0563|28 36|diagnosis
P03261331A0563|38 56|AIDS dementia complex
P03261331A0563|76 88|understanding
P03261331A0563|112 121|mechanisms
P03261331A0563|128 135|disorder
P03263357A0112|29 40|relationship
P03263357A0112|60 65|rhythm
P03263357A0112|68 82|body temperature
P03263357A0112|90 99|variations
P03263357A0112|102 121|plasma concentrations
P03263357A0112|147 161|leukocyte counts
P03263357A0112|163 179|plasma interleukin
P03263357A0112|187 194|activity
P03263465T0000|9 16|MHC class
P03263465T0000|18 22|genes
P03263465T0000|23 27|H-2Dq
P03263465T0000|31 35|H-2Lq
P03263465T0000|70 74|H-2Ld
P03263465T0000|81 85|genes
P03263465T0000|116 123|antigens
P03264073A0224|9 19|derivatives
P03264073A0224|32 37|series
P03264073A0224|69 76|activity
P03264073A0224|111 120|albino mice
P03264073A0224|135 142|activity
P03264073A0224|145 154|albino rats
P03264299A0679|29 36|activity
P03264299A0679|48 58|macrophages
P03264299A0679|94 104|ip injection
P03264886A0000|6 15|population
P03264886A0000|24 31|children
P03264886A0000|38 42|years
P03264886A0000|52 57|medium
P03264886A0000|62 66|towns
P03264886A0000|75 79|areas
P03264886A0000|95 101|Germany
P03264886A0000|111 115|cases
P03264886A0000|117 121|croup
P03264886A0000|145 156|months period
P03264886A0000|173 182|physicians
P03267732A0788|15 32|Ga-fbg scintigraphy
P03267732A0788|46 51|method
P03267732A0788|106 112|thrombi
P03267732A0788|132 137|effect
P03267732A0788|153 159|therapy
P03268555T0000|7 16|assessment
P03268555T0000|22 37|biocompatibility
P03268555T0000|46 54|materials
P03268555T0000|58 78|millipore filter method
P03270085A0382|0 13|Hypomagnesemia
P03270085A0382|22 37|magnesium wasting
P03270085A0382|43 48|kidney
P03274204A0642|0 11|Dentalplaque
P03274204A0642|42 46|index
P03274204A0642|57 65|dentition
P03274204A0642|92 108|cent alkaline fuxin
P03275867A0187|13 21|sequences
P03275867A0187|44 51|elements
P03275867A0187|52 60|silencers
P03275867A0187|72 89|mating type loci HML E
P03275867A0187|93 96|HMR E
P03275867A0187|123 130|sequence
P03275867A0187|147 159|transcription
P03275867A0187|164 176|MAT alpha genes
P03275873A0379|3 9|effects
P03275873A0379|17 25|mutations
P03275873A0379|28 40|RNA polymerase
P03275873A0379|43 50|activity
P03275873A0379|76 82|ability
P03275873A0379|91 95|genes
P03275873A0379|118 127|resistance
P03275873A0379|133 144|transfection
P03275873A0379|164 168|cells
P03276246A0037|44 50|colloid
P03276246A0037|55 63|blood cell
P03276246A0037|64 70|TAC-WBC
P03276246A0037|80 89|evaluation
P03276246A0037|92 103|appendicitis
P03276924A0090|12 17|tumors
P03276924A0090|29 41|rearrangement
P03276924A0090|56 64|insertion
P03276924A0090|75 88|MoMuLV provirus
P03278829A0082|3 13|indications
P03278829A0082|67 75|candidate
P03278829A0082|81 89|tip grafts
P03278829A0082|107 113|tension
P03278829A0082|121 129|deformity
P03280021A1615|14 21|affinity
P03280021A1615|41 47|buffers
P03280021A1615|63 67|M NaCl
P03280021A1615|83 87|M NaBr
P03280021A1615|90 118|measure alpha log Kobsd/alpha log
P03280021A1615|144 148|value
P03280807A0000|0 8|Mutations
P03280807A0000|14 23|suf12 locus
P03280807A0000|73 83|suppressors
P03280807A0000|88 106|frameshift mutations
P03280807A0000|109 115|glycine
P03280807A0000|124 130|proline
P03280807A0000|135 140|codons
P03280807A0000|156 175|UAG nonsense mutations
P03280807A1447|3 10|behavior
P03280807A1447|13 28|suf12-null/SUF12
P03280807A1447|29 41|heterozygotes
P03280807A1447|55 59|suf12
P03280807A1447|99 103|suf12
P03280807A1447|119 129|suppression
P03280807A1447|169 176|proteins
P03280807A1447|187 195|variation
P03280807A1447|215 219|SUF12
P03280807A1447|220 227|activity
P03280912T0000|0 21|Antituberculosis agents
P03280946A0375|11 25|immunity protein
P03280946A0375|68 75|proteins
P03280946A0375|85 93|minicells
P03280946A0375|118 135|lac promoter control
P03280946A0375|167 183|expression vectors
P03280946A0375|191 197|control
P03280946A0375|201 223|bacteriophage T7 promoter
P03282232A0743|0 9|Antibodies
P03282232A0743|21 33|fusion protein
P03282232A0743|47 55|DP1A clone
P03282232A0743|92 102|immunoblots
P03282813A0794|19 23|range
P03282813A0794|31 46|oxygen extraction
P03282813A0794|58 65|patients
P03282813A0794|86 93|patients
P03282813A0794|116 122|failure
P03282813A0794|135 139|slope
P03282813A0794|159 163|slope
P03283881A0216|6 13|patients
P03283881A0216|24 37|hypersecretion
P03283881A0216|47 54|evidence
P03283881A0216|62 73|inflammation
P03285764A0675|0 18|Hyperprolactinaemia
P03285764A0675|27 38|hypogonadism
P03285764A0675|52 63|neuropathies
P03285764A0675|72 79|stenoses
P03285764A0675|97 104|leakages
P03285764A0675|147 154|cofactor
P03285764A0675|163 174|consequences
P03285764A0675|209 215|factors
P03285764A0675|249 256|failures
P03287597T0000|9 16|function
P03287597T0000|22 34|prostate gland
P03292076A0820|7 17|endotoxemia
P03292076A0820|75 86|permeability
P03292076A0820|91 98|tendency
P03292076A0820|118 128|circulation
P03292076A0820|149 154|degree
P03292076A0820|157 170|refractoriness
P03292076A0820|193 204|hemodynamics
P03292076A0820|208 229|eicosanoid biosynthesis
P03292082A0486|2 9|contrast
P03292082A0486|24 37|concentrations
P03292082A0486|46 53|patients
P03292082A0486|58 63|tumors
P03292082A0486|83 88|system
P03292082A0486|101 110|meningioma
P03292082A0486|114 125|glioblastoma
P03292082A0486|133 141|neurinoma
P03293844T0000|15 20|eczema
P03296019T0000|0 15|Time delay effects
P03296019T0000|28 39|bond strength
P03296019T0000|54 63|Silicoater
P03296212A0603|3 8|future
P03296212A0603|11 18|research
P03296212A0603|23 32|interferon
P03296212A0603|54 58|areas
P03296212A0603|59 65|Efforts
P03296212A0603|115 121|synergy
P03296212A0603|146 150|terms
P03296212A0603|153 157|order
P03296212A0603|177 185|potential
P03296212A0603|193 200|research
P03296212A0603|223 227|agent
P03296212A0603|237 243|disease
P03296212A0603|267 280|tumor debulking
P03296212A0603|295 303|diagnosis
P03296212A0603|314 322|community
P03296212A0603|344 350|history
P03296212A0603|357 364|diseases
P03296212A0603|382 390|potential
P03296212A0603|404 409|agents
P03296212A0603|447 452|agents
P03296254A0556|5 15|differences
P03296254A0556|29 37|latamoxef
P03296254A0556|61 69|elevation
P03296254A0556|72 86|prothrombin time
P03296254A0556|110 119|depression
P03296254A0556|122 127|factor
P03296254A0556|133 141|factor VII
P03297181A0127|14 21|subjects
P03297181A0127|40 44|doses
P03297181A0127|54 60|release
P03297181A0127|65 80|quinidine sulfate
P03297181A0127|89 95|release
P03297181A0127|100 117|quinidine bisulfate
P03297181A0127|140 146|product
P03298134A0000|4 9|report
P03298134A0000|37 53|interferon alfa-2b
P03298134A0000|53 59|Intron A
P03298134A0000|60 74|Schering-Plough
P03298134A0000|80 88|treatment
P03298134A0000|96 107|cell leukemia
P03300118A0392|0 13|Oxygen delivery
P03300118A0392|17 26|base excess
P03304015T0000|8 16|chemistry
P03304866T0001|0 16|Revascularization
P03304866T0001|52 60|osteotomy
P03305875T0000|6 13|orthoses
P03305875T0000|20 29|management
P03305875T0000|32 42|microstomia
P03306340A0537|18 23|spread
P03306340A0537|29 37|carcinoma
P03306340A0537|58 65|invasion
P03306340A0537|68 76|carcinoma
P03306340A0537|77 84|hardness
P03306340A0537|105 115|obstruction
P03306340A0537|148 162|pancreaticogram
P03308909A0485|9 15|enzymes
P03308909A0485|27 35|cartilage
P03309892A0637|13 23|observation
P03309892A0637|46 50|genes
P03309892A0637|73 77|yeast
P03309892A0637|93 111|actin gene transcript
P03309892A0637|125 135|nucleotides
P03309892A0637|149 167|initiation start site
P03309892A0637|187 191|yeast
P03311954A0000|12 16|study
P03311954A0000|34 45|institutions
P03311954A0000|71 78|efficacy
P03311954A0000|82 87|safety
P03311954A0000|90 99|ranitidine
P03311954A0000|103 110|mg b.i.d.
P03311954A0000|114 123|ranitidine
P03311954A0000|127 133|mg nocte
P03311954A0000|139 147|treatment
P03311954A0000|150 167|reflux oesophagitis
P03312033A0501|0 10|Monotherapy
P03312033A0501|15 25|ceftazidime
P03312033A0501|73 90|combination therapy
P03312033A0501|95 103|cefazolin
P03312033A0501|107 116|tobramycin
P03312514A0756|3 8|N3 wave
P03312514A0756|69 76|recovery
P03312514A0756|100 119|preischemia amplitude
P03312514A0756|138 144|animals
P03312514A0756|175 179|group
P03312514A0756|195 208|control animals
P03315359A0732|0 10|Proctoscopy
P03315359A0732|30 36|studies
P03315359A0732|61 70|evaluation
P03315359A0732|82 89|patients
P03315359A0732|112 122|suppuration
P03315359A0732|123 128|masses
P03315359A0732|135 142|fissures
P03317796A0853|5 16|control group
P03317796A0853|32 38|picture
P03317796A0853|48 61|osteoarthritis
P03319621A0707|2 9|contrast
P03319621A0707|28 32|alpha
P03319621A0707|34 47|beta actin mRNAs
P03319621A0707|68 76|myoblasts
P03319621A0707|80 87|myotubes
P03319646T0000|0 18|Plasma renin activity
P03319646T0000|52 59|efficacy
P03319646T0000|62 75|chlorthalidone
P03319912A0000|0 9|Cephradine
P03319912A0000|19 23|night
P03319912A0000|28 33|months
P03319912A0000|45 63|prophylactic measure
P03319912A0000|74 81|patients
P03319912A0000|84 90|mean age
P03319912A0000|95 99|years
P03319912A0000|107 113|history
P03319912A0000|130 135|months
P03319912A0000|155 160|median
P03319912A0000|163 170|episodes
P03319912A0000|173 181|frequency
P03319912A0000|188 194|dysuria
P03320875A2090|23 30|Supramid
P03320875A2090|41 46|record
P03320875A2090|54 72|tissue compatibility
P03320875A2090|76 85|resistance
P03320875A2090|88 96|infection
P03322829A0952|14 18|group
P03322829A0952|36 53|compliance category
P03322829A0952|69 81|digoxin marker
P03322829A0952|105 109|group
P03322829A0952|111 118|patients
P03322829A0952|179 187|deviation
P03322829A0952|208 219|prescription
P03325081A0524|7 17|keratopathy
P03325081A0524|37 42|origin
P03325081A0524|80 90|keratopathy
P03325081A0524|112 116|cause
P03325081A0524|125 135|keratopathy
P03326381A0423|18 25|findings
P03326381A0423|44 61|C-peptide excretion
P03326381A0423|86 92|effects
P03326381A0423|127 132|action
P03326381A0423|138 142|drugs
P03326381A0423|161 168|pancreas
P03329716A0187|3 10|activity
P03329716A0187|16 34|EGF receptor promoter
P03329716A0187|51 60|E1A protein
P03329716A0187|64 80|receptor RNA levels
P03329716A0187|92 102|stimulation
P03329716A0187|107 118|phorbol ester
P03329716A0187|126 134|calf serum
P03330711T0000|19 26|activity
P03330711T0000|35 53|Azadirachta indica A.
P03331525T0001|7 11|study
P03331525T0001|14 27|dentin adhesion
P03331525T0001|30 38|adhesives
P03331525T0001|47 63|urethane molecules
P03331525T0001|72 77|groups
P03331525T0001|80 89|isocyanate
P03331933T0048|2 14|Felix Lagrange
P03332022A1094|8 31|cysteine clustering region
P03332022A1094|46 51|region
P03332022A1094|57 61|c-raf
P03332022A1094|63 69|product
P03332022A1094|84 101|nucleotide sequence
P03332022A1094|109 132|cysteine clustering region
P03332022A1094|188 193|region
P03332022A1094|196 209|protein kinase C
P03332022A1094|229 244|cysteine clusters
P03332848A0000|24 36|Doppler probes
P03332848A0000|61 68|analysis
P03332848A0000|91 111|carotid artery stenosis
P03334950A0000|3 15|German Society
P03334950A0000|18 34|Pediatric Oncology
P03334950A0000|53 68|Cooperative Ewing
P03334950A0000|70 81|Sarcoma Study
P03334950A0000|105 115|combination
P03334950A0000|117 128|chemotherapy
P03334950A0000|151 157|control
P03334950A0000|162 168|surgery
P03334950A0000|175 183|radiation
P03335127A0176|3 9|program
P03335127A0176|34 38|BASIC
P03335127A0176|41 45|order
P03335127A0176|55 63|procedure
P03335398A0568|9 14|levels
P03335398A0568|17 31|immunoglobulin G
P03335398A0568|58 64|surface
P03335398A0568|80 91|immunization
P03335398A0568|91 116|passive transfer experiments
P03335444A0000|1 5|study
P03335444A0000|46 52|mixture
P03335444A0000|54 58|241Am
P03335651A0000|10 15|method
P03335651A0000|30 47|parameter weighting
P03335651A0000|58 66|resonance
P03335651A0000|71 77|imaging
P03335651A0000|101 107|concept
P03335651A0000|120 130|sensitivity
P03335651A0000|163 170|approach
P03335651A0000|196 202|indexes
P03335651A0000|217 233|hydrogen weighting
P03335923A0257|10 17|patients
P03335923A0257|33 38|groups
P03335923A0257|63 74|presentation
P03335923A0257|92 101|volunteers
P03335923A0257|104 111|patients
P03335923A0257|132 148|reflux gastropathy
P03335923A0257|156 163|patients
P03335923A0257|176 181|ulcers
P03335923A0257|211 218|patients
P03335923A0257|221 228|Moynihan
P03335923A0257|230 236|disease
P03337024A0000|10 16|studies
P03337024A0000|34 50|pharmaco-dynamics
P03337024A0000|64 75|procainamide
P03337024A0000|105 109|mg/kg
P03337024A0000|125 130|mg/min
P03337024A0000|140 147|practice
P03337024A0000|174 180|testing
P03338154T0000|4 17|concentrations
P03338154T0000|36 51|trypsin inhibitor
P03338154T0000|66 73|patients
P03340548A1018|5 16|chicken liver
P03340548A1018|17 22|levels
P03340548A1018|25 37|chicken MT mRNA
P03340548A1018|58 63|metals
P03340548A1018|79 93|glucocorticoids
P03340548A1018|94 111|lipopolysaccharide
P03340726A1103|4 12|histology
P03340726A1103|16 20|Evans
P03340726A1103|25 34|injections
P03340726A1103|46 63|barrier alterations
P03340774A0328|10 18|estimates
P03340774A0328|27 32|organs
P03340774A0328|97 104|estimate
P03343730A0486|12 22|association
P03343730A0486|31 43|family history
P03343730A0486|90 109|calcium stone patients
P03344586T0000|0 14|New technologies
P03344586T0000|17 25|diagnosis
P03344586T0000|29 42|classification
P03344586T0000|45 54|malignancy
P03344812A0924|42 55|HR measurements
P03344812A0924|91 97|factors
P03344812A0924|128 134|factors
P03344812A0924|162 166|state
P03344812A0924|184 191|HR values
P03344812A0924|213 217|cycle
P03344812A0924|221 226|animal
P03344812A0924|245 253|influence
P03344812A0924|269 275|ranking
P03344812A0924|281 290|individual
P03344812A0924|299 306|HR levels
P03344812A0924|315 324|population
P03345706A0561|3 13|correlation
P03345706A0561|21 25|PaCO2
P03345706A0561|29 33|PtcO2
P03345706A0561|70 78|judgement
P03346157A0000|14 18|times
P03346157A0000|34 42|ABCC/RERF
P03346157A0000|55 66|examinations
P03346157A0000|70 85|Adult Health Study
P03346157A0000|91 98|subjects
P03346157A0000|131 139|exposures
P03346157A0000|149 154|x-rays
P03346157A0000|172 183|institutions
P03346157A0000|201 205|order
P03346157A0000|218 224|numbers
P03346157A0000|227 238|examinations
P03346157A0000|255 259|doses
P03346210A0000|12 23|growth factor
P03346210A0000|29 36|receptor
P03346210A0000|58 86|protein tyrosine kinase activity
P03346210A0000|116 143|self-phosphorylation reaction
P03346210A0000|153 165|EGF activation
P03348382A0785|13 19|ouabain
P03348382A0785|48 56|secretion
P03351478A0371|8 14|regions
P03351478A0371|44 53|% G residues
P03352254A0203|15 23|structure
P03352254A0203|32 41|prediction
P03352254A0203|64 69|vowels
P03352254A0203|80 88|syllables
P03352439T0000|5 31|cord abduction rehabilitation
P03352439T0000|50 60|anastomosis
P03352727T0000|5 17|biotechnology
P03352727T0000|24 34|specialists
P03352947T0001|21 27|complex
P03352947T0001|27 33|ARC/LAS
P03352947T0001|37 48|health worker
P03354295A0157|7 12|spread
P03354295A0157|25 32|patients
P03354295A0157|48 54|serum Tg
P03354295A0157|67 78|micrograms/l
P03354341A0177|13 26|filtration rate
P03354341A0177|44 53|plasma flow
P03354341A0177|79 93|clearance method
P03354341A0177|113 120|infusion
P03354341A0177|123 128|inulin
P03355122A0238|24 29|potato
P03355122A0238|29 47|plasma glucose levels
P03355122A0238|96 101|levels
P03359860A0000|3 11|relations
P03359860A0000|54 68|characteristics
P03359860A0000|73 82|aggression
P03359860A0000|83 89|anxiety
P03359860A0000|90 104|undercompliance
P03359860A0000|124 133|adjustment
P03359860A0000|183 206|New York Longitudinal Study
P03360667A0000|13 18|effect
P03360667A0000|21 28|altitude
P03360667A0000|41 46|growth
P03360667A0000|50 60|development
P03360667A0000|66 71|groups
P03360667A0000|95 99|youth
P03360667A0000|122 127|status
P03360667A0000|137 144|grouping
P03360667A0000|157 164|sea level
P03360667A0000|173 180|subjects
P03360667A0000|180 191|mid-altitude
P03360667A0000|200 207|subjects
P03360667A0000|214 221|altitude
P03360667A0000|230 237|subjects
P03360948A0477|23 31|variables
P03360948A0477|50 57|behavior
P03360948A0477|70 81|relationship
P03360948A0477|114 120|MHI Loss
P03360948A0477|122 153|Behavioral/Emotional Control scale
P03361653A0459|17 22|system
P03361653A0459|33 51|contour digitization
P03361653A0459|79 89|limitations
P03361653A0459|114 120|objects
P03366720A1335|5 10|change
P03366720A1335|37 47|utilization
P03366720A1335|93 102|metabolism
P03366720A1335|104 110|glucose
P03366720A1335|114 123|glycolysis
P03366864A0099|3 10|skin site
P03366864A0099|45 52|segments
P03366864A0099|58 65|catheter
P03366864A0099|77 81|blood
P03368701A0113|17 27|reliability
P03368701A0113|40 52|arteriography
P03368701A0113|62 66|place
P03368701A0113|69 74|choice
P03368701A0113|90 106|imaging techniques
P03370815T0000|5 13|detection
P03370815T0000|45 53|test serum
P03370815T0000|60 69|radioassay
P03370815T0000|72 81|vitamin B12
P03371139A0829|9 13|group
P03371139A0829|36 43|material
P03371139A0829|63 68|groups
P03371806A0000|10 23|data processing
P03371806A0000|29 44|latex immunoassay
P03371806A0000|66 80|acid phosphatase
P03371806A0000|96 100|serum
P03371806A0000|117 123|species
P03371806A0000|127 145|organ identification
P03371806A0000|160 165|stains
P03371894A0355|0 17|Vimentin positivity
P03371894A0355|62 71|components
P03372422A0558|3 20|maximum deflections
P03372422A0558|23 27|phase
P03372422A0558|60 64|phase
P03372422A0558|66 71|slopes
P03372422A0558|93 100|position
P03372422A0558|122 144|tracer gas concentrations
P03372422A0558|154 158|lungs
P03373755T0001|6 17|developments
P03373755T0001|20 24|drugs
P03373755T0001|39 45|factors
P03373755T0001|59 63|ulcer
P03373755T0001|72 79|efficacy
P03373755T0001|83 90|problems
P03373755T0001|91 115|gastrin receptor blockaders
P03375184A0000|3 23|spermicide nonoxynol-9
P03375184A0000|27 32|member
P03375184A0000|46 51|series
P03375184A0000|54 76|alkylphenol-ethoxylates
P03375184A0000|77 94|polyethoxyethanols
P03375184A0000|104 122|formula C9H19-C6H6-O
P03375184A0000|122 128|CH2CH2O
P03375184A0000|128 138|n-1 CH2CH2OH
P03377864A0000|14 19|fields
P03377864A0000|29 37|diffusion
P03377864A0000|50 58|particles
P03377864A0000|61 69|solutions
P03377864A0000|80 91|Lorentz force
P03377864A0000|95 107|Maxwell stress
P03377891A0652|13 23|disturbance
P03377891A0652|43 57|life stress group
P03377891A0652|82 91|elevations
P03377891A0652|103 115|severity index
P03377891A0652|121 139|Symptom Checklist-90
P03377891A0652|143 152|elevations
P03377891A0652|155 166|somatization
P03377891A0652|199 209|sensitivity
P03377891A0652|210 219|depression
P03377891A0652|220 226|anxiety
P03377891A0652|230 250|psychoticism subscales
P03378994T0000|7 20|administration
P03378994T0000|23 35|sodium cyanate
P03378994T0000|47 61|extraction ratio
P03379058A0188|0 19|Nucleotide sequencing
P03379058A0188|37 52|E1 alpha cDNA clone
P03379058A0188|59 67|base pairs
P03379058A0188|74 79|length
P03379058A0188|89 100|reading frame
P03379058A0188|127 132|region
P03380547A0169|9 16|PAG sites
P03380547A0169|33 40|aversion
P03381039A0364|2 9|contrast
P03381039A0364|39 50|distribution
P03381039A0364|55 59|range
P03381039A0364|82 87|micron
P03381039A0364|92 98|maximum
P03381039A0364|104 109|micron
P03382310A0903|8 19|technetium Tc
P03382310A0903|32 36|scans
P03382310A0903|39 46|patients
P03382310A0903|72 86|polyarthralgias
P03382310A0903|108 118|arthropathy
P03382310A0903|132 150|management decisions
P03382310A0903|175 182|outcomes
P03382772A0319|0 16|Practical interest
P03382772A0319|23 29|studies
P03382772A0319|62 71|parameters
P03382772A0319|111 115|phase
P03382772A0319|116 121|trials
P03382855A0368|3 12|artery cuff
P03382855A0368|71 79|adhesions
P03382855A0368|101 107|picture
P03383897A0189|17 22|action
P03383897A0189|29 44|radiation therapy
P03383897A0189|77 82|effect
P03383897A0189|85 96|leukopoiesis
P03383897A0189|127 136|conditions
P03383897A0189|142 149|patients
P03383897A0189|152 157|course
P03383897A0189|160 168|treatment
P03384033A0155|7 11|units
P03384033A0155|34 39|motion
P03384033A0155|83 94|otolith input
P03384033A0155|129 133|input
P03384033A0155|163 172|modalities
P03384272A0145|14 21|location
P03384272A0145|47 51|range
P03384272A0145|60 72|presentations
P03384272A0145|92 97|lesion
P03387665A0000|3 13|development
P03387665A0000|17 28|distribution
P03387665A0000|31 41|Trypanosoma
P03387665A0000|52 57|T vivax
P03387665A0000|61 67|T brucei
P03387665A0000|81 85|goats
P03387665A0000|104 110|animals
P03387665A0000|131 156|Glossina morsitans centralis
P03390074A0000|0 18|Electroglottography
P03390074A0000|40 48|technique
P03390074A0000|67 76|assessment
P03390074A0000|88 98|dysfunction
P03395009A1750|11 18|analysis
P03395009A1750|24 30|degrees
P03395009A1750|48 62|cord compression
P03395009A1750|77 87|group-1 dogs
P03395009A1750|111 116|ratios
P03395009A1750|145 153|diameters
P03395009A1750|175 186|cord sections
P03395009A1750|191 199|locations
P03395009A1750|230 235|T11-12
P03395009A1750|249 254|region
P03395009A1750|263 274|intervention
P03395164A0000|18 24|effects
P03395164A0000|35 45|compound WEB
P03395249A1044|17 27|examination
P03395249A1044|48 60|proliferation
P03395249A1044|71 81|pneumocytes
P03395249A1044|92 104|proliferation
P03395249A1044|118 122|cells
P03395249A1044|149 159|development
P03395249A1044|162 169|neonates
P03395249A1044|190 197|ABSTRACT
P03395249A1044|212 216|WORDS
P03396437A0321|7 14|problems
P03396437A0321|36 42|strains
P03396628A0207|9 25|observation period
P03396628A0207|34 38|weeks
P03396628A0207|51 55|spots
P03396628A0207|66 74|ventricle
P03396628A0207|77 86|BALB/c mice
P03396628A0207|111 115|weeks
P03396628A0207|144 152|incidence
P03396628A0207|165 169|spots
P03396628A0207|187 191|weeks
P03398433T0001|3 7|state
P03398433T0001|13 17|liver
P03398433T0001|31 35|forms
P03398433T0001|51 59|infection
P03398714A0594|37 45|solvation
P03398714A0594|49 61|peroxy radical
P03398714A0594|84 90|radical
P03398714A0594|106 131|propagation transition state
P03398823A0459|3 9|effects
P03398823A0459|24 37|administration
P03398823A0459|43 55|mg/kg p-xylene
P03398823A0459|58 64|toluene
P03398823A0459|91 96|effect
P03398823A0459|105 112|p-xylene
P03398823A0459|138 144|removal
P03398823A0459|151 158|exposure
P03400694A0245|0 7|PATIENTS
P03400694A0245|11 17|METHODS
P03400694A0245|18 29|Thallium-201
P03400694A0245|40 51|scintigraphy
P03400694A0245|84 88|mg/kg
P03400694A0245|99 110|dipyridamole
P03400694A0245|121 127|minutes
P03400694A0245|132 139|patients
P03400694A0245|144 154|sarcoidosis
P03401060A0000|4 12|melanomas
P03402183A0171|3 10|TA muscle
P03402183A0171|28 32|forms
P03402183A0171|52 63|contractions
P03402183A0171|81 92|contractions
P03402183A0171|108 118|circulation
P03402183A0171|144 155|contractions
P03402183A0171|178 195|voltage stimulation
P03402183A0171|217 228|contractions
P03402183A0171|233 243|circulation
P03403313A0298|17 28|control rates
P03403313A0298|33 37|years
P03403313A0298|49 63|treatment groups
P03403313A0298|85 92|excision
P03403313A0298|110 117|excision
P03403313A0298|134 149|radiation therapy
P03403313A0298|162 169|excision
P03403412A0000|3 9|effects
P03403412A0000|20 27|implants
P03403412A0000|36 46|composition
P03403412A0000|58 67|efficiency
P03403412A0000|70 75|growth
P03403412A0000|98 105|fed diets
P03403412A0000|115 120|forage
P03403412A0000|124 135|grain content
P03403480A0299|9 18|suspension
P03403480A0299|38 43|change
P03403480A0299|58 70|configuration
P03403480A0299|76 92|femur middiaphysis
P03403480A0299|115 122|diameter
P03403480A0299|148 158|alterations
P03403480A0299|174 180|density
P03403480A0299|180 186|mineral
P03403480A0299|190 211|collagen concentrations
P03403826T0000|77 88|measurements
P03403826T0000|91 106|stenosis severity
P03403826T0000|122 131|comparison
P03403826T0000|146 153|analysis
P03403826T0000|167 179|cineangiogram
P03403826T0000|200 210|flow reserve
P03403826T0000|214 260|exercise/redistribution thallium-201 scintigraphy
P03404334T0000|0 11|Water content
P03404334T0000|15 39|equilibrium water partition
P03404334T0000|50 58|cartilage
P03404495A0172|0 19|Thyroid function tests
P03404495A0172|38 47|admissions
P03406054A0351|11 28|line spread function
P03406054A0351|52 56|image
P03406054A0351|83 90|tungsten
P03406054A0351|118 126|isocentre
P03406054A0351|129 133|front
P03406054A0351|137 147|polystyrene
P03407676A0585|7 15|infection
P03407843T0000|0 5|Papers
P03407843T0000|11 17|Society
P03407843T0000|37 43|Surgery
P03413681A0659|8 19|heart disease
P03413681A0659|37 41|years
P03413681A0659|60 66|patient
P03413681A0659|70 74|woman
P03413681A0659|90 99|predictors
P03413681A0659|113 120|function
P03413890T0001|0 8|Prognosis
P03413890T0001|11 15|Bowen
P03413890T0001|17 23|disease
P03413890T0001|49 54|region
P03417104A0536|16 22|results
P03417104A0536|34 49|chlorphentermine
P03417104A0536|77 91|stimulus effects
P03417104A0536|94 100|animals
P03417588T0000|0 5|Liquid
P03417588T0000|21 26|method
P03417588T0000|30 42|determination
P03417588T0000|45 57|citreoviridin
P03417668A1233|5 12|findings
P03417668A1233|25 43|autophosphorylation
P03417668A1233|46 51|Thr286
P03417668A1233|52 63|alpha subunit
P03417668A1233|67 72|Thr287
P03417668A1233|73 83|beta subunit
P03417668A1233|100 109|transition
P03417668A1233|112 123|CaM-kinase II
P03418727A0992|21 31|penetration
P03418727A0992|59 70|chemotherapy
P03418727A0992|79 85|insight
P03418727A0992|93 102|myelopathy
P03418727A0992|120 129|treatments
P03420266A0000|3 13|interaction
P03420266A0000|16 24|radiation
P03420266A0000|28 39|hyperthermia
P03420266A0000|69 81|Dunning R3327G
P03420266A0000|91 104|adenocarcinoma
P03420266A0000|118 128|animal model
P03420266A0000|146 151|cancer
P03420324A0178|35 43|following
P03420324A0178|102 110|pregnancy
P03420324A0178|133 146|h/day beginning
P03420466A0000|3 11|incidence
P03420466A0000|14 30|cryptosporidiosis
P03420466A0000|38 45|children
P03420466A0000|61 68|staining
P03420466A0000|77 85|specimens
P03420466A0000|99 105|Kinyoun
P03421425A0878|5 12|patients
P03421425A0878|16 22|percent
P03421425A0878|32 45|hypothyroidism
P03421425A0878|70 83|determinations
P03423732A0341|0 7|Addition
P03423732A0341|10 19|sucralfate
P03423732A0341|22 27|De-Nol
P03423732A0341|38 47|increments
P03423732A0341|57 69|HCO3 secretion
P03423732A0341|118 129|HCO3 response
P03423732A0341|150 155|dmPGE2
P03427474A0853|14 24|control rats
P03427474A0853|33 39|animals
P03427474A0853|50 57|aversion
P03427474A0853|70 83|concentrations
P03427474A0853|86 103|saccharin solutions
P03427613A0659|29 34|system
P03427613A0659|43 49|vessels
P03427613A0659|74 84|pineal organ
P03427613A0659|93 100|portions
P03427613A0659|106 110|brain
P03428084A0430|4 17|degrees stimuli
P03428084A0430|35 52|scalp distributions
P03428084A0430|59 77|pattern reversal P100
P03428084A0430|84 97|pattern onset C1
P03428084A0430|112 118|striate
P03428084A0430|148 154|origins
P03428274A0000|7 12|factor
P03428274A0000|16 20|NFIII
P03428274A0000|24 30|protein
P03428274A0000|35 43|HeLa cells
P03428274A0000|61 70|initiation
P03428274A0000|73 86|adenovirus type
P03428274A0000|93 106|DNA replication
P03428274A0000|126 143|nucleotide sequence
P03428274A0000|149 154|origin
P03428274A0000|175 180|factor
P03428274A0000|182 196|recognition site
P03429306T0000|1 10|Golgi study
P03429306T0000|21 25|layer
P03429306T0000|39 44|cortex
P03429371A1051|14 33|cephalothin clearance
P03429371A1051|67 76|phagocytes
P03430221A1236|3 10|findings
P03430221A1236|28 34|context
P03430221A1236|42 51|properties
P03430221A1236|66 74|detectors
P03434347A0358|0 7|Mean rCBF
P03434347A0358|23 30|patients
P03434347A0358|34 38|weeks
P03434347A0358|44 50|surgery
P03436119A0000|20 29|tomography
P03436119A0000|51 68|bone mineral content
P03436119A0000|79 89|sensitivity
P03436119A0000|93 107|reproducibility
P03436529A1066|3 11|structure
P03436529A1066|17 24|enhancer
P03436529A1066|80 100|oligodeoxynucleotides
P03436529A1066|119 124|region
P03436529A1066|132 142|nt positions
P03436529A1066|168 175|template
P03436529A1066|190 197|enhancer
P03436877A0950|35 42|lung mass
P03436877A0950|61 70|reductions
P03436877A0950|73 88|lung mass % delta Kf
P03436877A0950|99 103|% mass
P03436877A0950|136 143|% delta CT
P03436877A0950|151 155|% mass
P03436877A0950|186 198|relationships
P03436877A0950|217 235|blocker pretreatment
P03436877A0950|297 304|ABSTRACT
P03436877A0950|319 323|WORDS
P03439248A0000|16 22|methods
P03439248A0000|30 41|dipyridamole
P03439248A0000|45 64|exercise thallium-201
P03439248A0000|75 90|perfusion imaging
P03439248A0000|118 131|artery stenosis
P03439248A0000|148 155|patients
P03439248A0000|177 189|artery disease
P03440780A0779|9 15|results
P03440780A0779|47 71|vasoconstrictor properties
P03440780A0779|99 120|calcium entry mechanisms
P03440780A0779|136 146|differences
P03440780A0779|152 173|vasoconstrictor effects
P03440780A0779|176 180|EDLFs
P03440780A0779|185 191|respect
P03441587A0000|0 7|Research
P03441587A0000|36 42|factors
P03441587A0000|48 52|serum
P03441587A0000|58 65|patients
P03441587A0000|68 72|means
P03441587A0000|78 82|tests
P03441587A0000|91 101|polystyrene
P03441587A0000|112 123|erythrocytes
P03441587A0000|130 136|results
P03441587A0000|163 168|method
P03441587A0000|171 179|reference
P03443144A0409|4 26|aspirin esterase activity
P03443144A0409|45 50|factor
P03443144A0409|71 77|aspirin
P03443144A0409|87 95|reactions
P03443566A0675|6 16|experiments
P03443566A0675|38 54|gain-to-feed ratio
P03443573A0329|7 19|least-squares
P03443573A0329|45 61|longissimus muscle
P03443573A0329|130 135|tissue
P03443609A0000|24 42|fluid chromatography
P03443609A0000|56 64|technique
P03443609A0000|88 95|products
P03443609A0000|138 154|column methodology
P03446332A0831|0 12|Nitrofurazone
P03448035T0000|7 12|tumors
P03448035T0000|15 23|pregnancy
P03449358T0001|15 19|study
P03449358T0001|22 34|polyarteritis
P03450438A0446|0 5|X2 test
P03450438A0446|10 24|Yates correction
P03450438A0446|65 70|method
P03451761A0215|6 18|baseline study
P03451761A0215|19 29|WPW syndrome
P03451761A0215|44 54|stimulation
P03451761A0215|71 75|sites
P03451761A0215|96 105|ventricles
P03452920T0001|8 13|insect
P03457330A0271|3 10|patients
P03457330A0271|24 28|assay
P03457330A0271|74 82|operation
P03459385T0000|0 6|Allergy
P03459385T0000|10 17|Tourette
P03459385T0000|19 26|syndrome
P03459736A0184|3 11|criterion
P03459736A0184|30 37|sessions
P03459736A0184|41 54|generalization
P03459736A0184|58 64|variety
P03459736A0184|67 71|pills
P03459736A0184|75 82|capsules
P03463537T0001|8 13|method
P03463537T0001|20 28|treatment
P03463537T0001|31 35|Class
P03463537T0001|46 54|anomalies
P03463543A1613|0 7|Enoxacin
P03463543A1613|35 43|treatment
P03465957A1008|0 18|Mean fluorosis scores
P03466730A0210|9 20|dysfunctions
P03466730A0210|42 47|pupils
P03473253A0000|28 47|cohort mortality study
P03473253A0000|67 81|chemical workers
P03473253A0000|121 148|chloromethyl ether manufacture
P03473253A0000|157 169|U.S. companies
P03473379A0183|3 11|diagnosis
P03473379A0183|14 24|amyloidosis
P03473379A0183|57 67|gland biopsy
P03476002A0148|9 20|blood samples
P03476002A0148|35 42|vitamin C
P03476002A0148|45 66|placebo supplementation
P03476002A0148|89 97|intervals
P03476002A0148|116 121|months
P03478354A0436|9 13|herds
P03478354A0436|30 40|d postpartum
P03478354A0436|45 56|corpus luteum
P03478354A0436|65 84|prostaglandin F2 alpha
P03479897A0961|29 36|angle ANB
P03479897A0961|62 66|angle
P03479897A0961|78 85|relation
P03479897A0961|88 95|Class III
P03484075T0001|0 17|Emergency treatment
P03484075T0001|49 56|injuries
P03484894A0782|4 8|cases
P03484894A0782|9 16|isolates
P03484894A0782|46 52|biotype
P03484894A0782|63 69|biotype
P03484894A0782|87 94|biotypes
P03485064A0135|1 5|total
P03485064A0135|11 23|EVS treatments
P03485064A0135|41 48|patients
P03486405A0341|19 25|portion
P03486405A0341|31 50|precursor polypeptide
P03486405A0341|74 78|exons
P03486405A0341|99 107|IL-1 alpha
P03486405A0341|135 139|exons
P03487348A0000|11 17|version
P03487348A0000|20 26|Kernell
P03487348A0000|36 40|model
P03487348A0000|55 76|afterhyperpolarization
P03488532A0235|18 23|report
P03488532A0235|41 50|resolution
P03488532A0235|53 67|dermatomal signs
P03488532A0235|71 78|symptoms
P03488532A0235|83 100|acyclovir treatment
P03491190A0233|3 15|detectability
P03491190A0233|21 27|defects
P03491190A0233|37 45|LAD region
P03491190A0233|69 73|scans
P03491190A0233|75 87|stress studies
P03493240T0000|13 22|properties
P03493240T0000|37 42|agents
P03493240T0000|60 64|drugs
P03494649A0472|20 28|challenge
P03494649A0472|42 49|increase
P03494649A0472|62 68|absence
P03494649A0472|73 78|change
P03499608A1054|37 44|reagents
P03499608A1054|47 67|heterozygote detection
P03499608A1054|79 87|diagnosis
P03499608A1054|92 117|beta-hydroxylase deficiency
P03499608A1054|139 143|cause
P03499608A1054|163 173|hyperplasia
P03499657A0000|0 10|Osteocalcin
P03499657A0000|11 30|serum bone-Gla protein
P03499657A0000|37 60|serum alkaline phosphatase
P03499657A0000|75 104|hydroxyproline/creatinine ratio
P03499657A0000|104 122|uOH-Prol/creatinine
P03499657A0000|143 150|patients
P03499657A0000|162 180|hyperparathyroidism
P03499657A0000|196 203|patients
P03499657A0000|207 220|hypercalcaemia
P03499657A0000|223 232|malignancy
P03499822A0182|20 37|regression analysis
P03499822A0182|51 64|seropositivity
P03499822A0182|93 102|prevalence
P03499822A0182|105 114|hepatitis B
P03499822A0182|119 126|employee
P03499822A0182|128 134|country
P03499822A0182|137 141|birth
P03504971A0000|0 5|Hexsyn
P03504971A0000|11 22|Goodyear Tire
P03504971A0000|26 47|Rubber Company tradename
P03504971A0000|52 67|polyolefin rubber
P03504971A0000|97 112|% methylhexadiene
P03504971A0000|118 123|source
P03504971A0000|140 144|bonds
P03504971A0000|148 160|vulcanization
P03507689A0000|8 37|phage-plasmid expression vectors
P03507689A0000|57 72|pUC18/19 plasmids
P03507689A0000|103 107|ssDNA
P03507689A0000|107 112|origin
P03507689A0000|115 125|replication
P03507689A0000|130 144|bacteriophage f1
P03507689A0000|158 180|bacteriophage T7 promoter
P03507689A0000|190 211|beta-galactosidase gene
P03508698A0535|2 6|order
P03508698A0535|25 37|finger flexors
P03508698A0535|49 57|adductors
P03508698A0535|60 74|triceps reflexes
P03508698A0535|107 112|groups
P03510185A0187|0 4|Natl.
P03513989A0580|7 13|ethanol
P03513989A0580|17 24|estrogen
P03513989A0580|44 58|UROD-deficiency
P03513989A0580|61 67|animals
P03513989A1149|20 27|disorder
P03513989A1149|56 66|disturbance
P03513989A1149|69 87|porphyrin metabolism
P03513989A1149|94 102|countries
P03513989A1149|113 119|insight
P03513989A1149|134 145|pathogenesis
P03513989A1149|170 176|effects
P03513989A1149|192 197|agents
P03515840A0000|25 29|cases
P03515840A0000|41 48|symptoms
P03515840A0000|59 67|granuloma
P03515840A0000|93 105|histiocytosis
P03515840A0000|117 123|sarcoma
P03515840A0000|136 141|months
P03515840A0000|145 149|years
P03515840A0000|155 168|generalization
P03515840A0000|172 176|death
P03516189A0406|3 10|patients
P03516189A0406|23 35|suxamethonium
P03516189A0406|39 48|mg kg-1 i.v.
P03517388A0763|23 32|CK-MB level
P03520729A0381|10 16|changes
P03520729A0381|19 27|heart rate
P03520729A0381|28 37|body weight
P03520729A0381|41 52|plasma levels
P03520729A0381|55 67|renin activity
P03520729A0381|71 94|aldosterone concentration
P03522105A1011|4 31|trough serum TOB concentrations
P03522105A1011|50 54|death
P03522105A1011|65 70|levels
P03522105A1011|75 82|recovery
P03526279T0000|14 20|schools
P03526279T0000|23 33|nursing R.N.
P03528748A0414|3 16|maxicell system
P03528748A0414|18 24|protein
P03528748A0414|51 56|weight
P03531317A0930|24 33|recessives
P03531317A0930|57 70|hypergeometric
P03531317A0930|86 90|model
P03531317A0930|93 98|Fisher
P03534581A0976|3 11|incidence
P03534581A0976|29 37|neoplasms
P03534581A0976|56 60|group
P03534581A0976|71 84|5-fluorouracil
P03534581A0976|85 95|doxorubicin
P03534581A0976|99 114|cyclophosphamide
P03534581A0976|134 145|control group
P03536682A0572|0 8|Ovulation
P03536682A0572|28 35|patients
P03537686A0099|17 25|placement
P03537686A0099|30 46|mutagenesis marker
P03537686A0099|50 71|supF suppressor tRNA gene
P03537686A0099|100 105|vector
P03537686A0099|129 137|frequency
P03537686A0099|151 159|mutations
P03537686A0099|181 192|transfection
P03537686A0099|204 208|cells
P03537686A0099|213 222|plasmid DNA
P03537686A0099|238 246|mutations
P03537686A0099|286 295|background
P03537721A0491|6 13|analysis
P03537721A0491|24 47|recombination experiments
P03537721A0491|60 67|PEP4 gene
P03537721A0491|86 98|chromosome XVI
P03537721A0876|10 21|observations
P03537721A0876|32 36|model
P03537721A0876|52 69|precursor molecules
P03537721A0876|85 105|PEP4 gene self-activate
P03537721A0876|115 126|yeast vacuole
P03537721A0876|163 172|hydrolases
P03537727A0243|11 17|segment
P03537727A0243|80 86|protein
P03537727A0243|89 95|protein
P03540591A0330|7 17|translation
P03540591A0330|49 53|cDNAs
P03540591A0330|65 77|P0 transcripts
P03540591A0330|116 122|protein
P03540591A0330|150 161|reading frame
P03540853A0652|13 29|amino acid sequence
P03540853A0652|40 55|sequence homology
P03540853A0652|59 76|DNA binding proteins
P03541263A0368|10 19|techniques
P03541263A0368|45 51|control
P03541263A0368|54 61|diabetes
P03542945T0000|0 12|Ciprofloxacin
P03542945T0000|15 22|overview
P03542945T0000|32 42|experiences
P03543485A0069|20 29|mechanisms
P03543485A0069|43 49|changes
P03543485A0069|52 59|response
P03543485A0069|62 79|space flight effects
P03543936A0000|3 10|rho genes
P03543936A0000|44 49|family
P03543936A0000|65 72|homology
P03543936A0000|78 94|ras oncogene family
P03544858A0374|4 12|component
P03544858A0374|48 54|insulin
P03544858A0374|58 63|VO2 max
P03544858A0374|71 75|sexes
P03544858A0374|88 97|metabolism
P03544858A0374|101 115|HDL-cholesterol
P03544858A0374|119 125|females
P03544858A0374|129 133|males
P03545955A0751|3 14|glucose areas
P03545955A0751|27 35|ingestion
P03545955A0751|41 45|foods
P03545955A0751|50 54|Study
P03545955A0751|56 62|glucose
P03545955A0751|73 77|juice
P03545955A0751|81 87|sucrose
P03545955A0751|91 97|glucose
P03545955A0751|99 106|fructose
P03545955A0751|113 120|fructose
P03545955A0751|124 131|mmol X h/l
P03545955A0751|132 136|Study
P03545955A0751|138 144|glucose
P03545955A0751|155 159|juice
P03545955A0751|163 168|apples
P03545955A0751|175 184|apple juice
P03545955A0751|188 195|mmol X h/l
P03545955A0751|196 200|Study
P03545955A0751|202 208|glucose
P03545955A0751|213 220|ice cream
P03545955A0751|236 242|lactose
P03545955A0751|245 252|mmol X h/l
P03545955A1378|3 22|serum insulin response
P03549045A0878|27 35|verapamil
P03549045A0878|38 48|sinus arrest
P03549045A0878|67 71|group
P03549045A0878|85 89|group
P03549045A0878|91 97|animals
P03550444T0000|0 10|Development
P03550444T0000|14 24|yeast system
P03550444T0000|27 31|assay
P03550444T0000|42 52|specificity
P03552363A0568|11 28|serum insulin levels
P03552363A0568|48 59|correlations
P03552363A0568|83 101|blood pressure levels
P03552363A0568|143 150|subjects
P03552363A0568|161 172|correlations
P03552363A0568|206 223|blood pressure level
P03553149A0299|30 40|mutagenesis
P03553149A0299|85 96|cleavage site
P03553439A0404|3 8|latter
P03553439A0404|44 54|tumor tissue
P03553439A0404|90 99|tumor cells
P03553439A0404|114 124|tumor tissue
P03553439A0404|156 165|tumor cells
P03553439A0404|184 193|tumor cells
P03555318T0000|3 14|pharmacology
P03555318T0000|17 25|carnitine
P03556834T0000|5 22|inhalation toxicity
P03556834T0000|25 36|T-2 mycotoxin
P03559193A0000|10 22|investigation
P03559193A0000|51 60|dimensions
P03559193A0000|66 79|Framingham Type
P03559193A0000|81 85|scale
P03559193A0000|142 151|correlates
P03559232T0000|12 16|study
P03559232T0000|27 35|arthritis
P03559287T0000|0 9|Legionella
P03559287T0000|19 25|ecology
P03559287T0000|42 52|consumption
P03561036T0000|0 9|Lymphatics
P03561036T0000|15 19|aorta
P03561036T0000|48 57|oil extract
P03561036T0000|57 66|lipofundin
P03561622A0659|7 12|resort
P03561622A0659|39 45|patient
P03561622A0659|48 55|dialysis
P03561622A0659|68 73|health
P03561622A0659|79 102|DiaTAP button graft complex
P03561622A0659|163 175|blood cultures
P03561622A0659|185 205|term vancomycin therapy
P03563399A0534|3 17|signal durations
P03563399A0534|51 64|S pi No threshold
P03563399A0534|100 109|difference
P03563604A1075|3 12|spleen rate
P03563604A1075|23 31|villagers
P03563604A1075|62 73|parasite rate
P03563604A1075|87 102|drug intervention
P03567017A0000|8 13|dosing
P03567017A0000|18 22|times
P03567017A0000|40 49|indoprofen
P03567017A0000|103 111|half-life
P03567017A0000|124 139|drug accumulation
P03567017A0000|153 160|subjects
P03568311A0273|4 11|patients
P03568311A0273|31 39|tamponade
P03568311A0273|49 61|wedge pressure
P03568311A0273|101 107|indexes
P03568311A0273|115 122|function
P03568311A1361|12 20|tamponade
P03568311A1361|24 45|pericardiocentesis data
P03568311A1361|61 75|stroke work index
P03568311A1361|90 100|correlation
P03568311A1361|105 109|TMFP1
P03568311A1361|120 124|TMFP2
P03568311A1361|141 145|TMFP3
P03570455A0433|0 6|Rabbits
P03570455A0433|24 35|hypocalcemia
P03570455A0433|40 45|levels
P03570455A0433|74 78|mg/dl
P03570455A0433|87 95|influence
P03570455A0433|98 103|TSST-1
P03571135T0000|6 10|value
P03571135T0000|21 28|features
P03571135T0000|31 38|language
P03571135T0000|75 82|children
P03572706A0329|18 32|interpretations
P03572706A0329|45 53|protocols
P03572706A0329|85 94|therapists
P03572706A0329|118 135|treatment condition
P03572706A0329|139 147|elevation
P03572706A0329|159 168|F-K indices
P03572706A0329|178 188|MMPI profile
P03575656A0120|25 36|chemical form
P03575656A0120|100 106|portion
P03575656A0120|123 128|period
P03577670A0102|3 7|study
P03577670A0102|28 34|atrophy
P03577670A0102|59 77|matter hypodensities
P03577670A0236|3 11|diagnosis
P03577670A0236|27 40|leukodystrophy
P03577670A0236|63 69|finding
P03577670A0236|74 87|arylsulfatase A
P03577670A0236|93 98|levels
P03577670A0236|108 118|fibroblasts
P03577670A0236|125 131|sisters
P03578948A0448|10 20|ventilation
P03578948A0448|44 49|volume
P03578948A0448|54 60|ml X kg-1
P03578948A0448|79 85|c X min-1
P03581160A0583|18 36|heart rate reactivity
P03581160A0583|79 107|artery pulse amplitude responses
P03581160A0583|132 141|TH subjects
P03581160A0583|148 155|controls
P03582149T0001|17 22|survey
P03582149T0001|34 45|valve disease
P03582149T0001|58 62|fever
P03582149T0001|84 97|school students
P03582149T0001|100 114|Jiangxi Province
P03582184A0448|0 4|Drugs
P03582184A0448|26 30|phase
P03582184A0448|33 41|reactions
P03582184A0448|61 76|dosage adjustment
P03582982A0000|1 5|study
P03582982A0000|13 17|genes
P03583001A0111|19 27|procedure
P03583001A0111|39 50|gas injection
P03583001A0111|52 57|bubble
P03583001A0111|120 127|drainage
P03583001A0111|140 144|fluid
P03583001A0111|147 156|vitrectomy
P03584426A0706|16 26|enterotoxin
P03584426A0706|50 62|stool isolates
P03584426A0706|83 90|isolates
P03584426A0706|116 123|activity
P03584426A0706|125 136|suckling mice
P03584426A0706|165 171|strains
P03584426A0706|192 199|material
P03586925T0001|0 10|Development
P03586925T0001|46 63|descriptor language
P03586925T0001|67 98|Roentgenology and Medical Radiology
P03586925T0001|112 126|Medinform system
P03590911T0001|22 31|dermatosis
P03590911T0001|45 60|light sensitivity
P03591464A0840a|38 52|disease activity
P03591464A0840a|58 65|efficacy
P03591464A0840a|68 93|calcium antagonist treatment
P03591464A0840b|38 52|disease activity
P03591464A0840b|58 65|efficacy
P03591464A0840b|68 93|calcium antagonist treatment
P03592297A0138|0 14|Dorsal foot TcpO2
P03592297A0138|47 56|electrodes
P03592297A0138|61 79|surface temperatures
P03592297A0138|84 91|degrees C
P03592297A0138|97 104|degrees C
P03592297A0138|107 112|theory
P03592297A0138|113 119|changes
P03592297A0138|133 140|activity
P03592297A0138|153 165|vasomotor tone
P03592297A0138|169 173|TcpO2
P03592297A0138|191 199|electrode
P03592297A0138|203 210|degrees C
P03592297A0138|221 232|vasodilation
P03592297A0138|243 250|degrees C
P03592297A0138|258 269|vasodilation
P03592297A0679|2 9|subjects
P03592297A0679|19 30|quadriplegia
P03592297A0679|76 85|cord trauma
P03592297A0679|85 89|TcpO2
P03592297A0679|94 101|degrees C
P03592297A0679|105 121|vasodilation index
P03592297A0679|152 156|TcpO2
P03592297A0679|160 167|degrees C
P03595418A0688|3 21|nucleotide sequences
P03595418A0688|41 67|ornithine decarboxylase mRNAs
P03595418A0688|76 84|% homology
P03595418A0688|105 111|regions
P03597218A0901|11 24|concentrations
P03597218A0901|27 31|alpha
P03597218A0901|41 49|inhibitor
P03597218A0901|50 69|alpha 2-macroglobulin
P03597218A0901|73 84|antithrombin
P03597218A0901|101 108|exercise
P03597218A0901|135 148|concentrations
P03597218A0901|169 174|shifts
P03597218A0901|177 187|plasma water
P03597218A0901|194 201|exercise
P03597218A0901|205 212|quantity
P03597218A0901|220 229|inhibitors
P03597269A0409|8 12|model
P03597269A0409|27 37|exponential
P03597269A0409|42 49|constant
P03597269A0409|55 60|form La
P03600705T0000|0 5|Timing
P03600705T0000|8 15|symptoms
P03600705T0000|19 33|oocyst excretion
P03600705T0000|41 57|cryptosporidiosis
P03601275A0601|5 20|dopamine infusion
P03601275A0601|23 27|women
P03601275A0601|47 54|syndrome
P03601275A0601|67 74|controls
P03601275A0601|81 91|state levels
P03601275A0601|94 107|plasma dopamine
P03601275A0601|108 121|norepinephrine
P03601275A0601|128 132|ratio
P03601275A0601|135 157|dopamine/norepinephrine
P03601275A0601|177 182|groups
P03601533T0001|10 19|importance
P03601533T0001|36 57|complement constituents
P03601533T0001|60 67|children
P03601533T0001|82 92|thyroiditis
P03602261A0238|28 36|condition
P03602261A0238|59 70|correlations
P03602261A0238|107 119|blood pressure
P03602261A0238|122 129|dopamine
P03602261A0238|138 151|norepinephrine
P03602261A0238|161 171|epinephrine
P03602261A0238|202 213|correlations
P03602261A0238|220 228|melatonin
P03602261A0238|232 239|dopamine
P03602261A0238|249 262|norepinephrine
P03602261A0238|273 285|growth hormone
P03605895A0888|4 11|patients
P03605895A0888|16 38|carboxyhemoglobin levels
P03605895A0888|41 46|excess
P03605895A0888|71 93|carbon monoxide poisoning
P03605895A0888|99 108|population
P03607109A0370|8 16|processes
P03607109A0370|48 52|month
P03607109A0370|55 63|pregnancy
P03607109A0370|79 85|picture
P03607109A0370|91 98|controls
P03607961T0001|12 17|action
P03607961T0001|27 38|zhuang qi gong
P03607961T0001|45 53|mechanism
P03607961T0001|56 71|diabetes mellitus
P03608916A0790|2 6|cases
P03608916A0790|10 19|degrees HPT
P03608916A0790|23 28|plasma
P03608916A0790|35 41|2D level
P03608916A0790|63 67|cases
P03608916A0790|94 100|pattern
P03608916A0790|105 112|increase
P03608989A0668|4 9|region
P03608989A0668|14 23|amino acids
P03608989A0668|50 61|interactions
P03608989A0668|93 109|filament formation
P03608989A0668|115 123|rod region
P03610663A0201|4 11|approach
P03610663A0201|22 28|sources
P03610663A0201|31 35|error
P03610663A0201|41 51|calculation
P03610663A0201|54 72|nutrient utilization
P03610663A0201|102 107|effect
P03610663A0201|110 118|precision
P03610663A0201|165 170|states
P03610674T0000|3 8|effect
P03610674T0000|18 31|zinc deficiency
P03610674T0000|42 57|fiber zinc content
P03610674T0000|63 76|rat hippocampus
P03612316A0102|35 45|low-protein
P03612316A0102|75 80|saline
P03612316A0102|82 90|thyroxine
P03612648A0085|22 39|lupus anticoagulant
P03612648A0085|67 84|thromboplastin time
P03612648A0085|91 98|antibody
P03612648A0085|101 111|cardiolipin
P03615550A0000|3 9|effects
P03615550A0000|25 32|agonists
P03615550A0000|45 62|antagonist naloxone
P03615550A0000|99 122|fixed-consecutive-number
P03615550A0000|127 134|schedule
P03615550A1094|18 24|effects
P03615550A1094|27 34|morphine
P03615550A1094|38 43|U50488
P03615550A1094|79 87|mg/kg dose
P03615550A1094|90 97|naloxone
P03615763A0170|23 27|women
P03615763A0170|44 54|angiography
P03615763A0170|64 74|opportunity
P03615763A0170|89 100|associations
P03615763A0170|103 110|relation
P03615763A0170|133 139|measure
P03615763A0170|142 156|atherosclerosis
P03615763A0170|186 191|income
P03615763A0170|190 201|hypertension
P03615763A0170|202 217|serum cholesterol
P03615763A0170|218 224|smoking
P03615763A0170|225 230|angina
P03615763A0170|231 238|diabetes
P03615763A0170|239 251|family history
P03615763A0170|254 265|heart disease
P03615763A0170|266 285|Type A behavior pattern
P03615763A0170|289 297|hostility
P03616174A1069|12 17|change
P03616174A1069|20 30|temperature
P03616174A1069|45 52|degrees C
P03616174A1069|83 91|blood flow
P03616174A1069|111 119|blood flow
P03616174A1069|133 139|tissues
P03616174A1069|180 190|circulation
P03616237T0001|10 26|status epilepticus
P03616237T0001|32 39|infusion
P03616237T0001|42 50|cisplatin
P03618039A0126|3 10|presence
P03618039A0126|17 24|patients
P03618039A0126|27 36|antibodies
P03618039A0126|39 48|adrenaline
P03618039A0126|52 64|noradrenaline
P03618039A0126|91 100|disruption
P03618039A0126|103 132|catecholamine biotransformation
P03619249A0428|12 18|markers
P03619249A0428|37 41|serum
P03619249A0428|51 55|liver
P03619249A0428|60 67|patients
P03619249A0428|79 87|hepatitis
P03619249A0428|93 97|HBs Ag
P03619249A0428|100 104|HBe Ag
P03619249A0428|105 112|anti-HBs
P03619249A0428|137 141|serum
P03619249A0428|150 154|HBc Ag
P03619249A0428|159 163|liver
P03619249A0428|191 198|antibody
P03619249A0428|207 212|non-Bc
P03619249A0428|218 222|serum
P03619249A0428|223 227|non-A
P03619249A0428|243 247|liver
P03622423A0000|0 5|Groups
P03622423A0000|23 29|Fischer
P03622423A0000|38 47|B6C3F1 mice
P03622423A0000|50 66|Hartley guinea pigs
P03622423A0000|96 109|concentrations
P03622423A0000|127 133|control
P03622423A0000|141 156|methyl isocyanate
P03622423A0000|161 165|vapor
P03622571A0208|0 16|Radionuclide study
P03622571A0208|34 39|biopsy
P03622571A0208|58 69|degeneration
P03622571A0208|72 81|myocardium
P03625688A0372|0 13|Immobilization
P03625688A0372|19 26|fracture
P03625688A0372|30 35|collar
P03625688A0372|39 47|cuff sling
P03625688A0372|77 83|methods
P03625762A0308|0 9|Comparison
P03625762A0308|12 19|patients
P03625762A0308|29 37|phenytoin
P03625762A0308|80 84|serum
P03625762A0308|114 122|phenytoin
P03625762A0308|147 156|difference
P03625762A0308|167 176|sub-groups
P03625762A0308|181 187|respect
P03625762A0308|190 199|vitamin B12
P03625762A0308|202 223|behaviour problem rating
P03626129T0001|0 6|Effects
P03626129T0001|20 28|laser beam
P03626129T0001|34 38|cells
P03626129T0001|48 53|embryo
P03627720A0196|26 33|features
P03627720A0196|48 54|sac cyst
P03628532A0000|11 16|saliva
P03628532A0000|22 36|taste perception
P03628532A0000|55 60|series
P03628532A0000|64 74|experiments
P03628596A0000|0 6|Samples
P03628596A0000|27 34|patients
P03628596A0000|63 67|value
P03628596A0000|70 92|acid alpha 1-glycoprotein
P03628596A0000|117 121|fluid
P03628713A0961|8 18|experiments
P03628713A0961|35 46|86RbCl uptake
P03628713A0961|48 58|36B-10 cells
P03628713A0961|88 100|Gy irradiation
P03628713A0961|119 131|radiation dose
P03628713A0961|142 149|capacity
P03628713A0961|152 161|tumor cells
P03628713A0961|164 170|trap AIB
P03628794A0648|3 10|patients
P03628794A0648|36 42|disease
P03628794A0648|63 83|I-131 MIBG scintigraphy
P03628794A0648|88 98|examination
P03628794A0648|101 106|choice
P03629974A1468|0 9|Comparison
P03629974A1468|15 31|amino acid sequence
P03629974A1468|37 47|M RNA product
P03629974A1468|50 63|Uukuniemi virus
P03629974A1468|74 82|Punta Toro
P03629974A1468|86 107|Rift Valley fever viruses
P03629974A1468|120 124|cases
P03629974A1468|130 137|homology
P03629974A1468|165 172|proteins
P03629974A1468|208 216|precursor
P03632739T0000|0 20|Cyclosporine treatment
P03632739T0000|35 46|polymyositis
P03635597A0377|2 9|addition
P03635597A0377|15 20|Cohler
P03635597A0377|30 34|scale
P03635597A0377|41 47|mothers
P03635597A0377|68 74|infants
P03635597A0377|81 87|passive
P03635597A0377|112 118|mothers
P03637037T0000|13 27|teaching booklet
P03637037T0000|40 47|patients
P03645733T0001|0 14|Hyperthyroidism
P03649340A1119|30 39|precursors
P03649340A1119|61 66|choice
P03649340A1119|69 79|splice sites
P03649340A1119|89 101|exon sequences
P03649340A1119|136 150|splicing process
P03651330T0000|22 28|lesions
P03651840A0266|6 22|MAO inhibition data
P03651840A0266|32 37|DPGPEA
P03651840A0266|44 52|inhibitor
P03651840A0266|55 59|MAO-B
P03651840A0266|71 76|effect
P03651840A0266|102 116|tranylcypromine
P03651840A0266|119 127|pargyline
P03652083A0720|10 15|region
P03652083A0720|21 38|vessel pyridinoline
P03652083A0720|68 76|crosslink
P03652083A0720|79 86|collagen
P03653226A0833|21 44|tissue-distribution study
P03653226A0833|98 108|perhexiline
P03658866A0081|8 25|lupus erythematosus
P03659603A0797|5 11|evening
P03659603A0797|15 23|amplitude
P03659603A0797|29 37|responses
P03659603A0797|69 76|increase
P03659603A0797|78 91|CO2 sensitivity
P03659805A0404|14 25|significance
P03659805A0404|31 46|prognosis factors
P03659805A0404|81 87|methods
P03659805A0404|101 105|model
P03659805A0404|130 140|IMB computer
P03659994A0150|5 11|changes
P03659994A0150|25 33|injection
P03659994A0150|48 58|abnormality
P03659994A0150|81 88|increase
P03659994A0150|91 105|signal intensity
P03659994A0150|120 125|images
P03659994A0150|145 159|signal intensity
P03659994A0150|174 179|images
P03663789A0568|5 11|results
P03663789A0568|43 50|activity
P03663789A0568|109 118|conversion
P03664038A0000|3 9|purpose
P03664038A0000|16 20|study
P03664038A0000|60 88|Gudjonsson Suggestibility Scale
P03664038A0000|119 131|reliabilities
P03664038A0000|145 158|suggestibility
P03666957A0219|0 8|Organisms
P03666957A0219|29 39|conjunctiva
P03666957A0219|50 54|weeks
P03666957A0219|94 102|infection
P03666957A0219|128 136|infection
P03668003T0000|21 30|microscopy
P03668003T0000|42 52|skin lesions
P03668396A0171|5 24|equilibrium solutions
P03668396A0171|51 58|vertices
P03668396A0171|72 87|convex polyhedron
P03668736A0177|10 19|deviations
P03668736A0177|25 35|X-ray counts
P03668736A0177|49 56|elements
P03668736A0177|64 69|series
P03668736A0177|103 107|count
P03668736A0177|121 127|element
P03668736A0177|134 138|block
P03672532A1111|24 30|effects
P03672532A1111|42 46|doses
P03673640A0533|3 13|MAO subjects
P03673640A0533|21 27|pattern
P03673640A0533|36 41|scores
P03673640A0533|44 59|KSP Impulsiveness
P03673640A0533|60 73|EPQ Neuroticism
P03673640A0533|89 95|Anxiety
P03673640A0533|98 109|Irritability
P03673640A0533|118 123|scores
P03673640A0533|126 141|KSP Socialization
P03673640A0533|154 172|personality profiles
P03673640A0533|179 188|alcoholics
P03673640A0533|189 199|psychopaths
P03673640A0533|203 219|suicide attempters
P03673640A0533|240 258|platelet MAO activity
P03673881A0000|21 28|accuracy
P03673881A0000|58 81|pulse repetition frequency
P03673881A0000|86 92|Doppler
P03673881A0000|124 140|pressure gradients
P03673881A0000|141 159|Doppler examinations
P03673881A0000|168 174|devices
P03673881A0000|202 209|patients
P03673881A0000|220 231|valve disease
P03676054A0865|2 6|group
P03676054A0865|13 18|delta V
P03676054A0865|75 82|pressure
P03676054A0865|123 130|diameter
P03676054A0865|135 149|injector cannula
P03676174A0730|2 7|calves
P03676174A0730|32 36|diets
P03676174A0730|53 58|g DM/kg
P03676174A0730|59 69|milk intakes
P03676174A0730|108 113|calves
P03678269A0633|0 4|Today
P03678269A0633|14 18|doubt
P03678269A0633|31 53|plasma cholesterol levels
P03678269A0633|83 94|modification
P03678269A0633|106 114|childhood
P03678269A0633|139 143|years
P03678372A0170|3 8|number
P03678372A0170|16 22|pellets
P03678372A0170|43 47|weeks
P03678372A0170|53 63|pellets/day
P03678372A0170|98 104|pellets
P03678372A0170|109 113|weeks
P03678372A0170|120 126|pellets
P03678372A0170|132 136|weeks
P03679407A0556|5 11|results
P03679407A0556|23 40|N-nitroso compounds
P03679407A0556|71 77|bladder
P03679407A0556|98 108|association
P03679407A0556|129 138|infections
P03679407A0556|160 172|bladder cancer
P03679756A0830|10 26|nerve fiber defects
P03679756A0830|35 41|absence
P03679756A0830|53 64|architecture
P03679756A0830|85 90|plexus
P03679756A0830|110 118|terminals
P03680791A0230|13 17|grade
P03680791A0230|53 58|hearts
P03680791A0230|83 87|sites
P03680791A0230|97 101|heart
P03682805A0375|0 10|Serum levels
P03682805A0375|13 19|albumin
P03682805A0375|20 27|globulin
P03682805A0375|31 56|coagulation protein activity
P03682805A0375|69 76|preshock
P03682805A0375|77 85|postshock
P03682805A0375|104 118|skin lymph levels
P03684378A0653|38 48|correlation
P03684378A0653|50 58|vitamin K1
P03684378A0653|61 71|cholesterol
P03684378A0653|93 97|lipid
P03684378A0653|131 141|cholesterol
P03684378A0653|146 154|secretion
P03684378A0653|157 165|vitamin K1
P03684517A0462|9 16|training
P03684517A0462|29 36|increase
P03684517A0462|39 47|stiffness
P03684517A0462|63 70|decrease
P03684517A0462|81 86|fibers
P03685073A0200|24 36|physostigmine
P03685073A0200|38 66|acetylcholinesterase inhibitor
P03685073A0200|79 89|combination
P03685073A0200|97 101|range
P03685073A0200|104 116|atropine doses
P03687078T0001|0 9|References
P03687078T0001|25 31|fitness
P03687078T0001|34 44|adolescents
P03687078T0001|49 56|diseases
P03687078T0001|73 77|tract
P03687078T0001|81 85|lungs
P03687148T0187|0 7|Salzburg
P03687148T0187|12 20|September
P03687313A0000|6 26|glucosidase inhibitors
P03687313A0000|27 30|BAY m
P03687313A0000|38 41|BAY o
P03687313A0000|59 68|volunteers
P03687313A0000|80 88|diabetics
P03687313A0000|100 109|conditions
P03688202A0377|3 8|models
P03688202A0377|37 46|boundaries
P03688301A0129|13 17|cases
P03688301A0129|31 36|spread
P03688301A0129|51 58|invasion
P03688301A0129|59 63|type A
P03688301A0129|80 84|cases
P03688301A0129|101 109|extension
P03688301A0129|110 114|type B
P03688301A0129|134 143|carcinomas
P03688301A0129|149 155|bladder
P03688676A0487|7 17|conversions
P03688676A0487|55 60|result
P03688676A0487|69 74|spread
P03688676A0487|77 85|infection
P03690262A0428|3 18|maximum amplitude
P03690262A0428|27 35|responses
P03690262A0428|60 64|trunk
P03690262A0428|92 96|ramus
P03690262A0428|147 157|stimulation
P03691316A0560|17 30|contact allergy
P03692331A0000|3 8|effect
P03692331A0000|29 38|antagonist
P03692331A0000|39 46|pindolol
P03692331A0000|62 67|muscle
P03692331A0000|84 88|women
P03692331A0000|128 132|women
P03693543A0405|35 52|Rhodococcus species
P03693543A0405|74 81|patterns
P03693543A0405|107 118|elution times
P03693543A0405|122 129|patterns
P03693543A0405|132 149|Nocardia asteroides
P03693543A0405|150 167|N. otitidiscaviarum
P03693543A0405|171 184|N. brasiliensis
P03693543A0405|197 202|number
P03693543A0405|205 209|peaks
P03693543A0405|219 225|species
P03693543A0405|230 239|separation
P03693543A0405|250 255|genera
P03694102A0000|3 13|development
P03694102A0000|17 24|data base
P03694102A0000|58 66|reference
P03694102A0000|70 88|ECG computer programs
P03694102A0000|126 130|leads
P03696899T0001|0 28|Blood serum erythropoietin level
P03696899T0001|50 56|indices
P03696899T0001|66 75|adaptation
P03696899T0001|92 98|infants
P03697587T0000|2 23|XXXXY chromosome anomaly
P03697587T0000|33 39|variant
P03697587T0000|42 52|Klinefelter
P03697587T0000|54 61|syndrome
P03697798T0001|0 10|Contraction
P03697798T0001|24 29|muscle
P03697798T0001|36 43|activity
P03697798T0001|46 61|stretch receptors
P03697798T0001|67 73|trachea
P03697971A0311|3 15|selenium level
P03697971A0311|19 47|glutathione peroxidase activity
P03697971A0311|53 57|blood
P03697971A0311|58 62|liver
P03697971A0311|66 78|stomach mucosa
P03697971A0311|120 128|diet group
P03697971A0311|150 158|diet group
P03698251T0000|0 13|Oxygen delivery
P03698251T0000|17 27|consumption
P03698251T0000|38 45|patients
P03698251T0000|64 73|infarction
P03700952A0273|0 6|Infants
P03700952A0273|13 18|sample
P03700952A0273|41 48|acuities
P03700952A0273|75 82|McDonald
P03700952A0273|91 107|laboratory setting
P03701640A1178|5 11|results
P03701640A1178|27 32|effect
P03701640A1178|38 44|isomers
P03701640A1178|81 89|FR30 FI600
P03701640A1178|173 180|ABSTRACT
P03701640A1178|195 199|WORDS
P03703493A0654|3 8|number
P03703493A0654|22 29|deposits
P03703493A0654|57 61|areas
P03703493A0654|67 93|RPE-choriocapillaris complex
P03704087A0394|5 12|subjects
P03704087A0394|34 44|instruments
P03704087A0394|64 73|components
P03704087A0394|76 80|anger
P03704087A0394|84 90|anxiety
P03704087A0394|91 101|Spielberger
P03704087A0394|103 133|State-Trait Personality Inventory
P03704087A0394|137 156|Anger Expression Scale
P03704087A0394|163 185|State Anger Reaction Scale
P03709191A0125|30 35|cortex
P03709191A0125|62 67|volume
P03709191A0125|77 85|asymmetry
P03709191A0125|94 108|side differences
P03709191A0125|114 119|number
P03709191A0125|122 128|neurons
P03709627A0247|3 10|subjects
P03709627A0247|29 34|mg dose
P03709627A0247|37 53|acetaminophen i.v.
P03709627A0247|57 70|concentrations
P03709627A0247|73 78|plasma
P03709627A0247|97 103|minutes
P03709627A0247|109 113|urine
P03709627A0247|124 128|order
P03709627A0247|141 150|production
P03709627A0247|153 163|metabolites
P03710973A0817|14 28|skin temperature
P03710973A0817|65 75|acclimation
P03710973A0817|87 97|acclimation
P03710973A0817|130 147|Tre-to-Tsk gradient
P03712050T0000|0 25|Indium-111 leukocyte imaging
P03712050T0000|28 35|patients
P03712050T0000|50 58|arthritis
P03712106A0000|3 8|effect
P03712106A0000|11 37|L-methionine supplementation
P03712106A0000|43 53|utilization
P03712106A0000|57 73|soy protein isolate
P03712106A0000|103 124|nitrogen balance studies
P03712106A0000|131 135|women
P03712153T0000|15 47|Haemophilus influenzae type b disease
P03712153T0000|65 74|assessment
P03712153T0000|77 87|risk factors
P03713187A0691|7 13|lesions
P03713187A0691|33 45|lamina propria
P03713187A0691|66 74|frequency
P03713187A0691|77 86|occurrence
P03713187A0691|97 103|lesions
P03713187A0691|127 132|muscle
P03713187A0691|140 149|carcinomas
P03713187A0691|168 172|sites
P03713187A0691|187 195|frequency
P03713187A0691|216 222|lesions
P03713187A0691|225 234|comparison
P03713187A0691|252 258|lesions
P03714348A0833|0 6|Factors
P03714348A0833|28 38|correlation
P03714348A0833|74 80|portion
P03714348A0833|85 97|CIC population
P03714348A0833|106 113|NIH score
P03714348A0833|123 132|patient age
P03714348A0833|136 157|peak expiratory flow rate
P03714348A0833|174 181|serum IgG
P03714473A0496|0 8|Induction
P03714473A0496|24 34|transcripts
P03714473A0496|42 50|heat shock
P03717475A0208|18 22|steps
P03717475A0208|36 52|immunodiagnostics
P03717475A0208|53 65|immunotherapy
P03717475A0208|69 85|immunoprophylaxis
P03717475A0208|114 124|infertility
P03717936A0252|0 7|Amikacin
P03717936A0252|27 36|tobramycin
P03717936A0252|54 67|aminoglycoside
P03717936A0252|76 85|conditions
P03720615A0434|30 34|trend
P03720615A0434|48 58|birthweight
P03720615A0434|62 70|gestation
P03720615A0434|80 86|infants
P03720966A1043|16 30|acid N absorption
P03720966A1043|40 46|N intake
P03721594A0000|0 7|Adhesion
P03721594A0000|8 19|phagocytosis
P03721594A0000|40 48|migration
P03721594A0000|58 68|tetrazolium
P03721594A0000|72 80|reduction
P03721594A0000|93 110|exudate neutrophils
P03721594A0000|114 124|macrophages
P03721594A0000|125 139|fibrinogen level
P03721594A0000|140 147|gelation
P03721594A0000|172 199|dilution protamine sulfate test
P03721594A0000|221 230|New Zealand
P03721594A0000|236 242|rabbits
P03721594A0000|268 287|Shwartzman phenomenon
P03721594A0000|293 297|colon
P03721594A0000|310 316|animals
P03721666A0000|0 5|Nickel
P03721666A0000|21 25|cause
P03721666A0000|36 52|contact dermatitis
P03721666A0000|55 63|Singapore
P03721666A0000|83 91|reactions
P03721666A0000|94 103|patch tests
P03722016A0797|3 11|FFA levels
P03722016A0797|45 56|meal interval
P03728230A0104|12 19|hospital
P03732252A0556|14 21|analyses
P03732252A0556|96 101|VO2max
P03732252A0556|138 153|m race performance
P03732252A0556|162 167|extent
P03732252A0556|186 191|amount
P03732252A0556|194 199|change
P03732252A0556|200 204|delta
P03732252A0556|216 223|m run time
P03732252A0556|245 255|combination
P03732252A0556|258 265|delta VO2
P03732252A0556|271 275|delta
P03732252A0556|281 288|m run time
P03733563A0716|12 33|herd X period interaction
P03733563A0716|44 50|liver TG
P03733563A0716|54 65|serum dextran
P03733563A0716|78 102|cholesterol concentrations
P03733563A0820|0 6|Liver TG
P03733563A0820|10 32|serum NEFA concentrations
P03734641A0203|3 9|results
P03734641A0203|18 22|nerve
P03734641A0203|26 30|roots
P03734641A0203|58 62|force
P03734641A0203|80 86|failure
P03734641A0203|100 111|biomechanics
P03736081A0465|15 27|sinus pressure
P03736081A0465|63 70|decrease
P03736081A0465|79 83|index
P03736081A0465|102 109|L/min/m2
P03736081A0465|134 142|blood flow
P03736081A0465|159 164|ml/min
P03736081A0465|212 219|pressure
P03736081A0465|257 264|increase
P03736081A0465|287 296|difference
P03736081A0465|320 330|% saturation
P03738919A0000|0 13|Calcifications
P03738919A0000|27 31|aorta
P03738919A0000|37 41|level
P03738919A0000|69 77|vertebrae
P03738919A0000|94 98|women
P03738919A0000|122 131|tomography
P03743683A0000|3 8|series
P03743683A0000|25 33|autopsies
P03743683A0000|49 55|plaques
P03743683A0000|73 83|individuals
P03743683A0000|90 94|years
P03743702A0158|19 28|cell bodies
P03743702A0158|37 43|neurons
P03743702A0158|58 62|intra
P03743702A0158|74 83|structures
P03743702A0158|102 109|alveolar
P03743702A0158|110 116|lingual
P03743702A0158|132 137|nerves
P03743702A0158|147 151|range
P03743702A0158|168 173|micron
P03743702A0158|216 221|micron
P03743702A0158|227 232|micron
P03743702A0158|241 246|micron
P03743702A0158|258 263|micron
P03744168T0001|15 20|action
P03744168T0001|23 32|eptazocine
P03744168T0001|67 77|hexahydro-1
P03744168T0001|77 100|methano-1H-4-benz azonine
P03745833A0258|2 11|transition
P03745833A0258|25 31|voltage
P03745833A0258|68 75|pressure
P03745833A0258|83 90|increase
P03745833A0258|107 111|areas
P03745833A0258|115 119|brain
P03745833A0258|138 149|arborization
P03745833A0258|164 172|formation
P03745833A0258|189 196|cerebrum
P03745833A0258|200 209|cerebellum
P03746053A0670|0 7|Findings
P03746053A0670|18 27|potentials
P03746053A0670|76 81|matter
P03746053A0670|104 109|column
P03746053A0670|127 138|dorsal column
P03746107A0192|41 47|tumours
P03746508A0390|0 7|Failures
P03746508A0390|22 31|additivity
P03746508A0390|54 63|conditions
P03746601A0299|17 24|problems
P03746601A0299|25 37|extravasation
P03746601A0299|48 53|sepsis
P03746601A0299|58 65|hematoma
P03746601A0299|74 78|total
P03746601A0299|94 101|exposure
P03746896A0890|22 28|results
P03746896A0890|51 61|possibility
P03746896A0890|74 78|means
P03746896A0890|107 120|susceptibility
P03746896A0890|134 140|effects
P03746896A0890|143 155|Type A behavior
P03746906A0000|3 9|studies
P03746906A0000|21 25|types
P03746906A0000|28 38|reliability
P03746906A0000|44 71|student Jenkins Activity Survey
P03746906A0000|78 97|questionnaire measure
P03746906A0000|99 111|Type A behavior
P03747493A0000|14 21|patients
P03747493A0000|73 82|infections
P03749226A0506|4 16|phencyclidine
P03749226A0506|44 55|response rate
P03749226A0506|75 80|errors
P03749226A0506|104 108|doses
P03750700T0001|0 12|Possibilities
P03750700T0001|16 22|outlook
P03750700T0001|26 30|wrist
P03750700T0001|36 49|endoprosthesis
P03751308T0001|0 4|Study
P03751308T0001|10 25|energy metabolism
P03751308T0001|31 46|sensomotor cortex
P03751308T0001|50 60|hippocampus
P03751308T0001|70 89|2-deoxyglucose method
P03751308T0001|98 108|development
P03751308T0001|122 127|states
P03753022A0000|9 16|lymphoma
P03753022A0000|38 42|terms
P03753022A0000|58 65|behavior
P03755623A1233|7 20|investigations
P03755623A1233|74 83|properties
P03755673A0054|11 15|cases
P03757294A0414|5 9|cases
P03757294A0414|41 45|cysts
P03757294A0414|56 60|cases
P03757294A0414|83 92|liver cysts
P03758250A0000|26 34|movements
P03758250A0000|50 58|extremity
P03758250A0000|98 103|bursts
P03758250A0000|106 116|EMG activity
P03758250A0000|131 137|muscles
P03759330A0713|3 13|combination
P03759330A0713|42 50|predictor
P03759330A0713|62 71|population
P03759330A0713|105 118|trunk adiposity
P03759731A0992|5 13|clearance
P03759731A0992|30 37|ml/min/1
P03759731A0992|44 48|group
P03759731A0992|58 65|ml/min/1
P03759731A0992|72 76|group
P03761122T0000|3 11|relations
P03761122T0000|19 31|type A behavior
P03761122T0000|50 57|behavior
P03761122T0000|66 76|achievement
P03761122T0000|86 93|children
P03761523A0000|23 27|study
P03761523A0000|32 38|effects
P03761523A0000|41 46|sepsis
P03761523A0000|52 62|utilization
P03761523A0000|77 84|emulsion
P03763241A0446|16 23|weakness
P03763241A0446|34 44|extremities
P03763836T0001|0 6|Results
P03763836T0001|9 23|electron therapy
P03763836T0001|26 31|tumors
P03763836T0001|43 47|sites
P03765552A0582|3 11|mechanism
P03765552A0582|14 19|action
P03765552A0582|36 41|detail
P03765552A0582|86 91|system
P03765552A0582|97 114|Fc receptor blockade
P03765552A0582|117 127|suppression
P03765552A0582|142 158|antibody synthesis
P03765731A0918|0 9|Incidences
P03765731A0918|20 25|stroke
P03765731A0918|36 45|infarction
P03765731A0918|46 62|angina pectoris und
P03765731A0918|78 88|hypertrophy
P03766370A0546|10 16|r values
P03766370A0546|34 43|deviations
P03766370A0546|90 96|regions
P03768208A0879|5 11|results
P03768208A0879|30 38|pregnancy
P03768208A0879|47 55|increases
P03768208A0879|58 75|bone formation rates
P03768208A0879|93 101|increases
P03769224A0000|22 29|patients
P03769224A0000|41 58|Lupus Erythematosus
P03769224A0000|75 82|biopsies
P03770143A1209|3 13|possibility
P03770143A1209|27 34|disorder
P03770143A1209|50 55|defect
P03770143A1209|65 78|fibre structure
P03770143A1209|119 125|lesions
P03771670T0058|0 9|Prevention
P03771670T0058|13 32|heparin-antithrombin
P03771670T0058|36 46|combination
P03771703A0000|13 36|trimethylsilylcarbamates
P03771703A0000|61 68|reagents
P03771703A0000|92 99|analysis
P03771749A0465|22 27|agents
P03771749A0465|27 42|5-fluorocytosine
P03771749A0465|43 52|miconazole
P03771749A0465|53 64|ketoconazole
P03771749A0465|68 80|amphotericin B
P03771749A0465|94 101|isolates
P03771749A0465|111 124|Candida species
P03771749A0465|151 155|media
P03771749A0465|158 169|agar dilution
P03771749A0465|173 202|microtiter broth dilution systems
P03772471A1054|11 18|patients
P03772471A1054|23 29|Group II
P03772471A1054|30 35|tumors
P03772471A1054|44 54|tumor biopsy
P03772471A1054|93 101|diagnosis
P03772471A1054|115 121|surgery
P03774111T0000|0 7|Evidence
P03774111T0000|18 26|addiction
P03774111T0000|45 52|response
P03776080A0400|15 36|post-mortem examination
P03776080A0400|54 60|animals
P03776080A0400|93 99|animals
P03776080A0400|112 122|CWE antigens
P03776438A0000|0 13|Glucocorticoid
P03776438A0000|21 32|hypertension
P03776438A0000|63 68|sodium
P03776438A0000|75 82|contrast
P03776438A0000|84 100|mineralocorticoid
P03776438A0000|108 119|hypertension
P03776779A0238|21 29|treatment
P03776779A0238|42 49|steroids
P03777398A0156|0 7|Examples
P03777398A0156|32 42|therapy unit
P03779182A0370|10 20|drug problem
P03779182A0370|51 56|number
P03779182A0370|59 63|cases
P03779182A0370|66 75|hepatitis B
P03779182A0370|93 98|deaths
P03779205A0459|9 16|patients
P03779205A0459|41 47|disease
P03779205A0459|65 69|years
P03779205A0459|80 91|presentation
P03779205A0459|96 103|patients
P03779205A0459|116 126|secondaries
P03779205A0459|138 142|years
P03780248A0274|8 18|differences
P03780248A0274|37 43|infants
P03780248A0274|61 65|group
P03780248A0274|73 79|changes
P03780248A0274|106 116|ventilation
P03780248A0274|122 129|settings
P03780248A0274|135 143|transport
P03780248A0274|155 161|infants
P03780248A0274|183 190|hospital
P03780248A0274|212 221|PCO2 values
P03780371A0792|10 18|sequences
P03780371A0792|43 49|introns
P03780371A0792|55 77|cytochrome P-450PBc2 gene
P03780371A0792|86 90|exons
P03780371A0792|104 109|region
P03780704A0573|6 13|increase
P03780704A0573|16 27|serum ketones
P03780704A0573|44 53|conditions
P03780704A0573|60 67|exercise
P03780704A0573|79 86|quotient
P03780704A0573|100 107|increase
P03780704A0573|113 123|utilization
P03781000A0101|12 22|correlation
P03781000A0101|32 41|variations
P03781000A0101|56 63|activity
P03781000A0101|82 89|implants
P03781000A0101|108 113|stages
P03781000A0101|119 125|disease
P03781948T0000|11 20|adaptation
P03781948T0000|30 36|hypoxia
P03783160A0285|0 7|Compound
P03783160A0285|17 29|21-O-angeloyl
P03783160A0285|42 54|R1-barrigenol
P03783160A0285|57 68|21-O-tigloyl
P03783160A0285|82 94|R1-barrigenol
P03785212A0091|15 40|hamster S14 protein sequences
P03785212A0091|55 59|cDNAs
P03785212A1128|0 11|RPS14 introns
P03785212A1128|28 39|Alu sequences
P03788231A0802|20 26|aspects
P03788231A0802|51 58|survival
P03788231A0802|63 68|animal
P03788231A0802|94 105|implantation
P03788231A0802|124 128|heart
P03788231A0802|167 175|placement
P03788231A0802|188 197|ventricles
P03788231A0802|207 211|chest
P03789052A0527|13 26|tissue response
P03789052A0527|40 56|cyanoacrylate site
P03789052A0527|81 88|chemical
P03789052A0527|98 105|reaction
P03789052A0527|117 130|tissue adhesive
P03789052A0527|144 151|evidence
P03789052A0527|170 176|effects
P03791645A1124|5 12|findings
P03791645A1124|35 46|relationship
P03791645A1124|57 68|pathogenesis
P03791645A1124|76 85|narcolepsy
P03795488A0487|18 24|lesions
P03795488A0487|82 93|response rate
P03799323A0501|12 21|hematocrit
P03799323A0501|25 38|flow conditions
P03799323A0501|50 73|oxygen saturation decrease
P03799323A0501|101 111|sickle cells
P03799323A0501|125 129|cells
P03799790A0146|8 15|examiner
P03799790A0146|27 34|interior
P03799790A0146|57 70|ophthalmoscopy
P03799790A0146|73 83|point source
P03799790A0146|86 90|light
P03799790A0146|108 116|light pipe
P03799790A0146|133 139|margins
P03799790A0146|155 160|plaque
P03802195A0481|5 18|fusion proteins
P03802195A0481|33 44|localization
P03802195A0481|65 74|activation
P03802195A0481|78 94|DNA binding domains
P03802195A0481|100 110|ToxR protein
P03802195A0481|148 154|portion
P03805090A0645|14 21|analyses
P03805090A0645|29 36|patients
P03805090A0645|55 63|incidence
P03805090A0645|75 88|chondrosarcoma
P03805090A0645|91 98|patients
P03805090A0645|112 118|disease
P03805090A0645|154 158|years
P03805090A0645|173 184|degeneration
P03805090A0645|194 202|certainty
P03805090A0645|205 212|patients
P03805090A0645|220 235|Maffucci syndrome
P03806696A0000|9 16|toxicity
P03806696A0000|28 32|HgCl2
P03806696A0000|43 49|CH3HgCl
P03806696A0000|50 64|mercury chloride
P03806696A0000|79 86|Coturnix
P03806696A0000|87 99|Japanese quail
P03806696A0000|100 115|Coturnix japonica
P03806696A0000|137 141|hatch
P03806696A0000|148 156|adulthood
P03806696A0000|195 204|injections
P03806696A0000|221 225|trial
P03810361A0576|29 52|plasma cortisol estimation
P03810361A0576|96 119|plasma cortisol estimation
P03810361A0576|136 142|adjunct
P03810361A0576|148 156|diagnosis
P03810361A0576|159 165|Cushing
P03810361A0576|167 174|syndrome
P03810867A0305|9 16|patients
P03810867A0305|35 41|lesions
P03810867A0305|77 85|TNM system
P03810867A0305|84 100|Lederman-Gadeberg
P03810867A0305|101 112|Sisson-Jesse
P03811852A0109|17 29|complications
P03811852A0109|54 60|factors
P03811852A0109|69 77|gestation
P03811852A0109|81 91|combination
P03811852A0109|94 109|magnesium sulfate
P03811852A0109|128 134|agonist
P03811852A0109|148 169|adrenocortico-steroids
P03811852A0109|191 198|maturity
P03814493T0000|0 11|Chlorambucil
P03814493T0000|15 24|interferon
P03814493T0000|31 35|grade
P03814493T0000|48 55|lymphoma
P03818467A0180|0 7|Selenium
P03818467A0180|23 27|IU/kg
P03818467A0180|26 40|supplementation
P03818467A0180|69 84|plasma tocopherol
P03818467A0180|87 102|Se concentrations
P03818467A0180|120 146|plasma glutathione peroxidase
P03818467A0180|147 152|GSH-Px
P03818467A0180|153 160|activity
P03818866A0116|0 13|Framingham Type
P03818866A0116|15 22|behavior
P03818866A0116|59 71|blood pressure
P03818866A0116|103 107|women
P03820222A0203|23 29|potency
P03820222A0203|124 128|group
P03824908A0116|3 15|M reading frame
P03824908A0116|39 46|sequence
P03824908A0116|56 65|nucleotide
P03824908A0116|94 99|lysine
P03824908A0116|102 130|arginine amino acid substitution
P03824908A0116|138 153|carboxy-terminus
P03824908A0116|171 179|M proteins
P03824908A0116|182 196|paramyxoviruses
P03826871A0000|22 27|method
P03826871A0000|45 49|Br ion
P03826871A0000|55 59|urine
P03826871A0000|62 71|Greyhounds
P03828209T0000|14 20|changes
P03828209T0000|42 51|intubation
P03828209T0000|54 59|adults
P03828500T0001|0 14|Intensification
P03828500T0001|32 50|contractile activity
P03828500T0001|63 72|blood serum
P03829848T0001|0 18|Autotransplantation
P03829848T0001|22 32|vein segment
P03829848T0001|37 41|valve
P03829848T0001|47 55|treatment
P03829848T0001|76 88|insufficiency
P03829848T0001|98 106|extremity
P03830147A0000|3 15|relationships
P03830147A0000|25 35|descriptors
P03830147A0000|38 52|lactate increase
P03830147A0000|53 68|lactate threshold
P03830147A0000|88 112|blood lactate concentration
P03830147A0000|142 146|level
P03830147A0000|166 177|exercise test
P03830147A0000|198 209|blood lactate
P03830147A0000|237 241|level
P03830147A0000|261 285|blood lactate concentration
P03830147A0000|297 301|value
P03830147A0000|309 313|onset
P03830147A0000|315 338|blood lactate accumulation
P03830147A0000|360 371|blood lactate
P03830147A0000|378 390|concentration
P03830147A0000|421 428|capacity
P03830147A0000|428 433|VO2max
P03830147A0000|451 461|performance
P03830147A0000|480 487|students
P03830255A0074|55 66|distribution
P03835413A0616|3 13|observation
P03835413A0616|20 26|effects
P03835413A0616|32 43|irradiations
P03835413A0616|51 62|space flights
P03835413A0616|70 81|difficulties
P03835413A0616|113 117|risks
P03835413A0616|128 147|duration space flights
P03836777T0001|0 11|Practical use
P03836777T0001|15 28|interpretation
P03836777T0001|36 52|hepatitis B markers
P03836777T0001|63 68|biopsy
P03836777T0001|71 83|HBs Ag carriers
P03836777T0001|99 112|hepatitis stage
P03836853A0204|10 26|year survival rates
P03836854T0000|0 9|Inhibition
P03836854T0000|38 46|secretion
P03836854T0000|93 97|agent
P03837609T0000|20 24|study
P03837609T0000|42 51|blood cells
P03837609T0000|64 76|mononucleosis
P03838797A0903|0 15|Northern blotting
P03838797A0903|33 47|oligonucleotide
P03838797A0903|63 69|absence
P03838797A0903|81 88|sequence
P03838797A0903|112 122|cDNA library
P03840480T0000|14 21|families
P03840480T0000|46 61|peptide sequences
P03841627T0001|0 11|Chemotherapy
P03841627T0001|27 38|breast cancer
P03843496A0919|8 12|years
P03843496A0919|36 41|models
P03843496A0919|63 69|variety
P03843496A0919|94 102|chemicals
P03843496A0919|111 117|ability
P03843496A0919|130 143|extrapolations
P03843496A0919|152 165|risk assessment
P03843676A0381|6 18|extrapolation
P03843676A0381|104 108|doses
P03848527T0020|0 11|Hisako Minowa
P03848527T0020|38 47|counsellor
P03848527T0020|50 57|industry
P03848527T0020|70 74|years
P03857577A0413|0 21|Deletion mapping studies
P03857577A0413|45 56|DNA sequences
P03857577A0413|96 113|level transcription
P03857577A0413|116 124|HeLa cells
P03857577A0413|149 161|transcription
P03860162A0000|0 12|Incorporation
P03860162A0000|18 24|polyene
P03860162A0000|35 47|amphotericin B
P03860162A0000|55 63|liposomes
P03860162A0000|79 87|reduction
P03860162A0000|90 101|drug toxicity
P03860162A0000|126 132|potency
P03861687A0000|25 29|males
P03861687A0000|89 97|treatment
P03861687A0000|119 129|alterations
P03861687A0000|132 139|response
P03861687A0000|169 185|system stimulation
P03862898A0563|0 7|Serum IgM
P03862898A0563|11 27|IgE concentrations
P03862898A0563|45 53|IgE scores
P03862898A0563|60 73|tumor E2R status
P03862898A0563|109 126|risk classification
P03862898A0563|170 179|components
P03863231A0530|3 12|M-3 subtype
P03863231A0530|35 40|factor
P03863561A0405|9 13|Strep
P03863561A0405|18 28|mutans group
P03863561A0405|56 65|difference
P03863561A0405|73 77|Strep
P03863561A0405|88 99|mutans/Strep
P03863561A0405|102 109|cricetus
P03863561A0405|129 135|respect
P03863561A0405|141 149|clump size
P03865743A0859|5 11|results
P03865743A0859|30 35|LDL-C.
P03865743A0859|35 40|HDL-C.
P03865743A0859|41 47|HDL2-C.
P03865743A0859|48 51|apo B
P03865743A0859|52 64|apo A-I/B ratio
P03865743A0859|68 81|apo A-II/B ratio
P03865743A0859|95 105|risk factors
P03865743A0859|119 130|heart disease
P03866085A0795|26 47|suppository formulation
P03866085A0795|50 54|CZX-S
P03866085A0795|68 76|treatment
P03866085A0795|79 88|infections
P03866085A0795|91 98|children
P03866085A0795|125 133|disorders
P03866085A0795|139 146|children
P03866085A0795|163 167|drugs
P03866085A0795|183 190|vomiting
P03869442A0223|2 9|addition
P03869442A0223|16 27|hypertension
P03869442A0223|43 50|disorder
P03869442A0223|57 69|abnormalities
P03869442A0223|82 93|hypertension
P03869442A0223|128 145|vasopressin therapy
P03871298A0217|6 19|photon emission
P03871298A0217|32 41|tomography
P03871298A0217|42 46|SPECT
P03871298A0217|75 88|representation
P03871298A0217|101 106|Tl-201
P03871298A0217|113 119|promise
P03871298A0217|131 142|localization
P03871445T0000|0 7|Computer
P03871445T0000|16 22|mapping
P03871445T0000|37 44|analysis
P03871445T0000|55 79|positron emission tomograms
P03873141A0304|4 19|patients vagotomy
P03873141A0304|36 43|bleeding
P03873141A0304|65 71|therapy
P03873141A0304|72 77|Visick
P03873141A0304|83 90|patients
P03873141A0304|95 107|mortality rate
P03874921A0862|0 12|Documentation
P03874921A0862|38 50|fertilization
P03874921A0862|55 62|delivery
P03874921A0862|66 73|term baby
P03874921A0862|96 106|feasibility
P03874921A0862|123 133|anovulation
P03874921A0862|146 154|procedure
P03874921A0862|174 181|drawback
P03875231A0627|37 49|abnormalities
P03875231A0627|68 74|kidneys
P03875231A0627|99 113|differentiation
P03875231A0627|123 127|fluid
P03875231A0627|140 147|hematoma
P03875231A0627|149 158|hemorrhage
P03875231A0627|190 202|abnormalities
P03877298A0718|3 9|results
P03877298A0718|59 78|Cremophor formulation
P03877298A0718|94 104|variability
P03877298A0718|107 115|induction
P03877298A0718|119 131|recovery times
P03877298A0718|147 165|emulsion formulation
P03878585A0507|3 24|percentage RFR reduction
P03878585A0507|59 69|correlation
P03878585A0507|73 83|CPB duration
P03878585A0507|93 111|oxygen flow rate index
P03878585A0507|134 155|bubble oxygenator/m2 bsa
P03878585A0507|167 184|blood flow rate index
P03878585A0507|201 206|volume
P03878585A0507|208 212|blood
P03878585A0507|239 262|machine/min CPB time/m2 bsa
P03880838T0000|0 8|Diagnosis
P03880838T0000|26 38|artery lesions
P03880838T0000|44 66|captopril administration
P03881260A0000|1 16|yeast DNA fragment
P03881260A0000|28 35|gene CP A1
P03881260A0000|52 58|subunit
P03881260A0000|64 107|arginine pathway carbamoyl-phosphate synthetase
P03882029A0000|14 18|study
P03882029A0000|64 79|granuloma complex
P03882029A0000|124 133|antibodies
P03882029A0000|134 143|components
P03882029A0000|152 164|cat epithelium
P03883052T0001|2 7|memory
P03883052T0001|10 27|Magdelaine Comtesse
P03883541A0200|3 23|H2 receptor antagonists
P03883541A0200|27 40|sucralfate cost
P03883541A0200|67 73|effects
P03885983A0254|5 11|results
P03885983A0254|23 31|indoramin
P03885983A0254|39 46|Class III
P03885983A0254|61 68|activity
P03887085A0000|5 12|efficacy
P03887085A0000|41 45|doses
P03887085A0000|50 64|pharmaceuticals
P03887085A0000|65 73|cystamine
P03887085A0000|76 80|mg/kg
P03887085A0000|84 91|mexamine
P03887085A0000|94 98|mg/kg
P03887085A0000|107 116|conditions
P03887085A0000|138 144|hypoxia
P03887085A0000|162 170|CBA X C57Bl
P03887085A0000|169 174|F1 mice
P03887769A0093|21 35|micrograms J/g Cr
P03887769A0093|46 60|micrograms J/g Cr
P03887769A0584|5 10|region
P03887769A0584|42 51|population
P03887769A0584|54 69|iodine deficiency
P03887769A0584|90 105|iodine deficiency
P03888621A0185|22 32|hydrogenase
P03888621A0185|40 53|protein product
P03890486A0000|19 38|lymph node enlargement
P03890486A0000|51 55|cause
P03890486A0000|64 69|source
P03890486A0000|72 87|imaging confusion
P03890486A0000|100 109|propensity
P03890486A0000|127 136|malignancy
P03890486A0000|155 165|obstruction
P03891766A1473|0 11|Interference
P03891766A1473|26 31|factor
P03891766A1473|52 56|ELISA
P03891766A1473|95 109|latex adsorbents
P03894482A0549|3 10|patients
P03894482A0549|22 27|levels
P03894482A0549|30 47|serum IgE antibodies
P03894482A0549|58 71|soybean extract
P03894482A0549|72 84|binding values
P03894482A0549|104 108|times
P03894482A0549|124 135|control serum
P03896991T0000|0 12|New techniques
P03896991T0000|19 34|mass spectrometry
P03896991T0000|44 51|products
P03898382A0000|16 33|subtraction imaging
P03898382A0000|39 44|spleen
P03898382A0000|50 60|67Ga citrate
P03898382A0000|64 68|99mTc
P03898382A0000|97 103|lesions
P03898382A0000|137 154|radiogallium survey
P03898382A0000|172 184|sulfur colloid
P03898382A0000|197 201|image
P03904004A1577|26 31|energy
P03904004A1577|34 56|medium energy collimation
P03904004A1577|61 66|window
P03904004A1577|83 98|keV 123I photopeak
P03904004A1577|123 141|breakthrough signals
P03904004A1577|157 170|Compton scatter
P03904004A1577|177 189|energy photons
P03904952T0000|0 15|Nursing education
P03904952T0000|19 36|computer obligation
P03908196T0000|0 16|Shear bond strength
P03908196T0000|29 33|resin
P03908196T0000|44 55|glass ionomer
P03908493A0246|12 20|advantage
P03908493A0246|30 34|resin
P03908493A0246|53 77|immunoperoxidase technique
P03908493A0246|94 101|sections
P03910310A0666|5 11|concept
P03910310A0666|26 38|understanding
P03910310A0666|44 52|pathology
P03911052A0909|14 19|DIL-CP
P03911052A0909|45 55|CABG surgery
P03911052A0909|88 95|patients
P03911052A0909|104 114|CABG surgery
P03911702A0530|34 38|model
P03911702A0530|41 45|means
P03911702A0530|74 94|microembolism syndrome
P03911702A0530|140 145|trauma
P03911702A0530|176 185|anesthesia
P03911702A0530|202 211|conditions
P03911965A0513|21 32|significance
P03911965A0513|76 80|trend
P03911965A0513|87 97|superiority
P03911965A0513|100 110|Galphimia D6
P03911965A0513|119 135|Galphimia dilution
P03911965A0513|175 181|placebo
P03912247A0282|3 8|volume
P03912247A0282|11 15|blood
P03912247A0282|41 46|ml/min
P03912247A0282|46 66|collateral circulation
P03912247A0282|115 120|change
P03912247A0282|134 142|blood flow
P03912247A0282|148 155|flap ages
P03913522A0000|4 8|aging
P03913522A0000|13 19|aspects
P03913522A0000|28 41|function change
P03914875T0001|4 14|candidiasis
P03915540A0863|2 9|addition
P03915540A0863|13 28|gcd1-101 mutation
P03915540A0863|58 67|efficiency
P03915540A0863|70 82|GCN4-lacZ mRNA
P03915540A0863|108 112|cells
P03920700A0491|46 59|responsiveness
P03920700A0491|87 91|alpha
P03920700A0491|93 105|adrenoceptors
P03921727A0523|3 16|concentrations
P03921727A0523|19 24|apo A-I
P03921727A0523|28 34|apo A-II
P03921727A0523|37 46|abstainers
P03921727A0523|97 103|changes
P03921727A0523|106 113|controls
P03922116A0197|3 14|distribution
P03922116A0197|17 24|patients
P03922116A0197|37 41|group
P03922116A0197|50 62|gamma-therapy
P03922116A0197|65 69|cases
P03922116A0197|70 74|group
P03922116A0197|83 95|gamma-therapy
P03922116A0197|105 119|lymphadenectomy
P03922116A0197|122 126|cases
P03922116A0197|130 134|group
P03922116A0197|143 160|radiation treatment
P03922116A0197|165 172|megavolt
P03922116A0197|200 218|luc type installation
P03922116A0197|221 240|iliac lymphadenectomy
P03922116A0197|243 247|cases
P03923828A1031|3 14|availability
P03923828A1031|17 31|cryoprecipitate
P03923828A1031|35 39|DDAVP
P03923828A1031|71 79|treatment
P03923828A1031|95 102|reversal
P03923828A1031|111 118|bleeding
P03923828A1031|121 128|patients
P03923828A1031|153 162|procedures
P03923976T0001|0 15|Thrombophlebitis
P03923976T0001|28 35|embolism
P03923976T0001|48 66|factor XII deficiency
P03925712A0229|0 7|Biopsies
P03925712A0229|20 25|mucosa
P03925712A0229|43 56|enzyme activity
P03925712A0229|59 70|deficiencies
P03925712A0229|73 91|transport mechanisms
P03928357A0340|0 18|Laboratory pyrolyses
P03928357A0340|59 64|yields
P03928357A0340|66 70|PCDFs
P03928357A0340|74 87|chlorobenzenes
P03928357A0340|96 100|PCDFs
P03928357A0340|104 108|PCDDs
P03928442A0463|12 17|degree
P03928442A0463|20 27|homology
P03928442A0463|50 54|genes
P03928442A0463|61 69|Mtase gene
P03928442A0463|79 86|phage SPR
P03928442A0463|102 107|enzyme
P03928442A0463|121 143|modification specificity
P03928678T0000|36 46|contraction
P03928678T0000|49 56|urethral
P03928678T0000|67 72|muscle
P03929486A0309|18 22|trial
P03929486A0309|25 32|patients
P03929486A0309|43 52|NYHA II-III
P03929486A0309|56 66|sinus rhythm
P03929486A0309|86 101|ejection fraction
P03929486A0309|102 106|LV-EF
P03929486A0309|156 162|placebo
P03929486A0309|173 180|releases
P03929486A0309|186 191|mg/d SR
P03929486A0309|198 202|drugs
P03929486A0309|223 227|doses
P03929610A0268|11 20|discomfort
P03929610A0268|35 42|patients
P03930549A0209|3 8|sample
P03930549A0209|32 45|centrifugation
P03930549A0209|65 75|supernatant
P03930549A0209|108 116|injection
P03930549A0209|123 138|gas chromatograph
P03930894T0000|0 6|Changes
P03930894T0000|19 40|acetylcholine receptors
P03930894T0000|59 65|effects
P03930894T0000|67 71|aging
P03930894T0000|72 81|inhalation
P03930894T0000|86 93|allergen
P03930894T0000|94 107|administration
P03930894T0000|110 114|drugs
P03930894T0000|118 125|vagotomy
P03931293A0437|5 11|absence
P03931293A0437|19 29|stabilizers
P03931293A0437|39 45|sucrose
P03931293A0437|65 80|thermoresistance
P03931293A0437|86 90|virus
P03931293A0437|95 102|% albumin
P03931797A0134|10 19|prevalence
P03931797A0134|22 30|psoriasis
P03931797A0134|58 62|women
P03933232T0000|5 14|classicism
P03933232T0000|23 31|structure
P03933232T0000|51 58|pathways
P03933232T0000|61 76|animal morphology
P03933784A0420|11 16|origin
P03933784A0420|28 39|CSF prolactin
P03934667A0124|16 28|crsA mutations
P03934667A0124|29 33|crsA1
P03934667A0124|34 38|crsA4
P03934667A0124|42 47|crsA47
P03934667A0124|68 81|gene conversion
P03934667A0124|82 88|process
P03934667A0124|91 113|B. subtilis plasmid pRPD11
P03934667A0124|159 166|sequence
P03934667A0124|182 186|sigma
P03934667A0124|189 194|factor
P03934667A0124|197 219|B. subtilis RNA polymerase
P03934667A0124|223 228|pUB110
P03935117T0000|9 14|effect
P03935117T0000|26 31|oedema
P03935117T0000|34 64|prostaglandin E2 pharmacokinetics
P03935117T0000|67 73|rat lung
P03935375A0414|4 10|article
P03935375A0414|51 60|morphology
P03935375A0414|60 67|function
P03935375A0414|71 82|biochemistry
P03935375A0414|99 105|medulla
P03935375A0414|112 120|pathology
P03935375A0414|164 170|changes
P03935375A0414|195 206|degeneration
P03935375A0414|218 226|carcinoma
P03935797A0183|60 75|sry messenger RNAs
P03935797A0183|92 98|embryos
P03935797A0183|126 130|sites
P03935797A0183|182 188|regions
P03935797A0183|205 209|order
P03935797A0183|216 220|alpha
P03935797A0183|223 227|delta
P03936828T0000|7 17|thyroiditis
P03936828T0000|21 30|risk factor
P03936828T0000|33 46|B-cell lymphoma
P03936828T0000|52 63|thyroid gland
P03937294A0404|0 19|Plasma secretin levels
P03937294A0404|41 54|administration
P03937294A0404|57 72|ethanol solutions
P03937294A0404|78 82|delay
P03937294A0404|107 111|onset
P03937294A0404|113 125|acid secretion
P03937481T0001|18 30|microanalysis
P03937481T0001|80 91|preparations
P03939317A0352|1 10|comparison
P03939317A0352|28 34|regions
P03939317A0352|61 70|HS promoter
P03939317A0352|76 97|soybean HS-protein genes
P03939317A0352|114 119|region
P03940426A0618|0 6|Results
P03940426A0618|13 17|study
P03940426A0618|42 46|chain
P03940426A0618|51 55|acids
P03940426A0618|66 75|agar medium
P03940426A0618|78 86|anaerobes
P03940426A0618|105 109|tests
P03940426A0618|139 148|morphology
P03940426A0618|178 196|genus identification
P03940426A0618|213 223|agar culture
P03940733A0755|9 14|method
P03940733A0755|25 34|absorption
P03940733A0755|40 44|doses
P03940733A0755|47 54|vitamin A
P03940733A0755|88 95|approach
P03940733A0755|98 107|assessment
P03940733A0755|113 125|malabsorption
P03940818T0000|9 18|hepatitis A
P03940818T0000|28 37|HBV carrier
P03944212A0166|0 13|Tissue pressure
P03944212A0166|23 34|water content
P03944212A0166|54 59|matter
P03944212A0166|94 99|margin
P03944212A0166|104 115|MCA territory
P03944239A0780|19 26|patients
P03944239A0780|49 75|plasma thyroid hormone changes
P03944239A0780|90 106|amiodarone therapy
P03946125T0000|9 28|nutrient interactions
P03952387A0336|6 16|compartment
P03952387A0336|33 39|tissues
P03952387A0336|51 58|reaction
P03952387A0336|64 68|place
P03952387A0336|81 93|oxyhemoglobin
P03953361A0000|13 19|effects
P03953361A0000|22 32|propranolol
P03953361A0000|45 54|metabolism
P03953361A0000|68 78|reperfusion
P03953361A0000|79 96|serial measurements
P03953361A0000|109 122|creatine kinase
P03953361A0000|130 136|calcium
P03953361A0000|140 147|contents
P03953361A0000|157 166|lactic acid
P03953361A0000|170 183|concentrations
P03953361A0000|193 202|sinus blood
P03956647A1063|0 10|Dissolution
P03956647A1063|20 39|%Ir microelectrode tip
P03956647A1063|52 77|scanning electron microscopy
P03956647A1063|80 94|charge densities
P03956647A1063|105 117|microC/cm2 X ph
P03956647A1063|119 123|A/cm2
P03956647A1063|131 137|erosion
P03956647A1063|149 170|iridium microelectrodes
P03956647A1063|195 200|charge
P03956647A1063|211 219|densities
P03956647A1063|224 236|microC/cm2 X ph
P03956647A1063|239 243|A/cm2
P03956695A0617|0 16|Cortisol excretion
P03956695A0617|50 55|season
P03956695A0617|69 75|factors
P03956695A0617|104 109|stress
P03959045A0000|3 9|studies
P03959045A0000|15 26|relationship
P03959045A0000|51 64|coaching course
P03959045A0000|68 78|performance
P03959045A0000|84 110|Medical College Admission Test
P03963860A0137|1 5|total
P03963860A0137|10 17|patients
P03963860A0137|75 79|group
P03964489A1195|6 14|% decrease
P03964855A0254|0 10|Angiography
P03964855A0254|35 43|rCBF study
P03964855A0254|50 55|degree
P03964855A0254|58 66|vasospasm
P03964855A0254|83 92|angiograms
P03965012A0163|3 9|results
P03965012A0163|26 30|years
P03965012A0163|68 76|mortality
P03965012A0163|97 109|heart diseases
P03965012A0163|110 119|ICD A83-A84
P03965012A0163|143 157|reference cohort
P03965012A0163|160 175|paper mill workers
P03966687A0000|12 17|impact
P03966687A0000|20 34|childhood asthma
P03966687A0000|58 62|Vance
P03966687A0000|66 71|Taylor
P03966687A0000|93 98|Annals
P03966687A0000|100 106|Allergy
P03966687A0000|109 113|years
P03967144T0001|0 12|Hypersplenism
P03970191A0275|10 17|activity
P03970191A0275|52 69|electrocorticogram
P03970191A0275|99 107|potential
P03970191A0275|109 113|sites
P03972038A0000|3 12|topography
P03972038A0000|16 27|trajectories
P03972038A0000|33 49|commissural fibers
P03972038A0000|71 76|region
P03972038A0000|116 124|technique
P03972185A0137|11 15|state
P03972185A0137|38 54|insulin deficiency
P03972185A0137|55 66|plasma levels
P03972185A0137|78 85|controls
P03972185A0137|92 104|hyperglycemia
P03972185A0137|119 137|plasma glucose levels
P03972185A0137|143 147|times
P03974790A0053|10 19|CT findings
P03974790A0053|41 52|brain infarct
P03974790A0053|64 69|tumour
P03976323A0821|12 22|correlation
P03976323A0821|30 48|blood pressure change
P03976323A0821|52 61|SCR-change
P03977577T0000|0 21|Shoulder forearm support
P03977577T0000|36 43|shoulder
P03977603A0326|0 8|Piroxicam
P03977603A0326|23 31|incidence
P03977603A0326|41 46|ulcers
P03977603A0326|61 65|doses
P03977603A0326|68 79|indomethacin
P03978045A0857|5 12|findings
P03978045A0857|38 43|stages
P03978045A0857|67 72|stages
P03978045A0857|78 83|stages
P03978045A0857|97 111|hyperreactivity
P03978045A0857|124 130|vessels
P03978045A0857|134 140|Raynaud
P03978045A0857|142 149|syndrome
P03978045A0857|161 169|disorders
P03978045A0857|182 187|origin
P03978045A0857|220 230|alterations
P03978132A0108|2 14|MCCP functions
P03978132A0108|20 33|source emission
P03978132A0108|34 50|surface reflection
P03978132A0108|51 74|photoacceptor sensitivity
P03978132A0108|101 118|distribution curves
P03979084A1019|7 13|kidneys
P03979084A1019|59 67|functions
P03980386A0000|11 17|effects
P03980386A0000|28 34|hypoxia
P03980386A0000|38 48|angiotensin
P03980386A0000|51 58|infusion
P03980386A0000|61 72|distribution
P03980386A0000|75 83|blood flow
P03980386A0000|106 118|perfusion lung
P03980386A0000|159 163|lambs
P03981421A0246|1 8|flow rate
P03981421A0246|45 52|receptor
P03981421A0246|52 57|volume
P03981421A0246|76 82|results
P03981640A0168|47 51|mRNAs
P03981952T0000|3 10|efficacy
P03981952T0000|39 55|chloride titrators
P03981952T0000|61 70|estimation
P03981952T0000|78 87|salt intake
P03982288T0000|0 13|Doctor Berglund
P03982288T0000|19 25|members
P03982288T0000|28 40|union pitfalls
P03984683A0000|5 14|appearance
P03984683A0000|17 27|hemiparesis
P03984683A0000|30 39|hemiplegia
P03984683A0000|57 66|spasticity
P03984683A0000|81 94|stroke patients
P03985849A0221|14 27|rhinosinusitis
P03985849A0221|43 48|groups
P03985849A0221|51 58|patients
P03985849A0221|65 75|development
P03985849A0221|85 98|rhinosinusitis
P03985849A0221|113 120|patients
P03985849A0221|154 159|nature
P03985849A0221|165 173|condition
P03985849A0221|195 207|IgA deficiency
P03987818A0440|55 64|management
P03987818A0440|65 76|heart failure
P03987857A0733|10 16|muscles
P03987857A0733|28 38|floor region
P03987857A0733|86 93|mass unit
P03987857A0733|108 116|intensity
P03987857A0733|119 129|stimulation
P03988001A0227|21 44|rat blood chloroform levels
P03988001A0227|76 84|treatment
P03989827T0000|3 11|frequency
P03989827T0000|14 30|lactase phenotypes
P03989827T0000|33 46|Aymara children
P03992022A0330|0 9|Activities
P03992022A0330|19 28|cytochrome
P03992022A0330|56 62|enzymes
P03992022A0330|69 79|aminopyrine
P03992022A0330|83 98|TMO N-demethylase
P03992022A0330|102 127|aniline hydroxylase activity
P03992022A0330|143 154|pretreatment
P03992022A0330|167 176|cimetidine
P03992022A0330|208 217|ranitidine
P03992022A0330|222 237|enzyme activities
P03995513T0000|0 10|Doxorubicin
P03995513T0000|11 21|dacarbazine
P03995513T0000|22 32|vincristine
P03995513T0000|36 51|cyclophosphamide
P03995513T0000|57 65|treatment
P03995513T0000|92 105|leiomyosarcoma
P03997467A0000|3 8|effect
P03997467A0000|20 37|antagonist naloxone
P03997467A0000|64 71|patients
P03997467A0000|84 91|ischemia
P03998071T0000|0 23|Electrochemical detection
P03998071T0000|46 51|levels
P03998071T0000|54 62|vitamin K1
P03998071T0000|65 76|osteoporosis
P03998813A0406|12 22|experiments
P03998813A0406|64 70|pattern
P03998813A0406|78 85|activity
P03998813A0406|95 102|ontogeny
P03998813A0406|105 119|frequency tuning
P03998813A0406|125 129|mouse
P03998813A0406|145 150|system
P03999219A0463|0 13|Ultrastructure
P03999219A0463|19 23|tumor
P03999219A0463|27 33|patient
P03999219A0463|53 61|resection
P03999219A0463|75 79|weeks
P03999219A0463|85 98|alum irrigation
P03999219A0463|127 135|chromatin
P03999219A0463|162 168|changes
P03999219A0463|179 192|alum irrigation
P04000347A0442|19 26|criteria
P04000347A0442|56 62|persons
P04000347A0442|80 85|groups
P04000347A0442|145 155|individuals
P04000347A0442|161 165|signs
P04000347A0442|174 180|disease
P04001413A0093|7 13|purpose
P04001413A0093|40 45|device
P04001413A0093|76 82|patient
P04001413A0093|92 105|breath-holding
P04001413A0093|122 126|scans
P04001490T0001|3 15|POEMS syndrome
P04001490T0001|16 29|Polyneuropathy
P04001490T0001|30 41|Organomegaly
P04001490T0001|42 55|Endocrinopathy
P04001490T0001|66 74|component
P04002131A0506|7 22|disease remission
P04002131A0506|33 40|increase
P04002131A0506|43 54|GAG secretion
P04002131A0506|59 63|urine
P04002131A0506|74 89|hyperheparinuria
P04002667A0181|17 24|patients
P04002667A0181|32 38|results
P04002667A0181|55 68|tumor diameters
P04002667A0181|96 107|localization
P04002667A0181|109 118|lung tissue
P04002667A0181|130 137|cm tumors
P04002667A0181|148 161|lung parenchyma
P04004168A0000|3 10|siblings
P04004168A0000|24 29|anemia
P04004168A0000|38 71|triosephosphate isomerase deficiency
P04004168A0000|105 112|syndrome
P04004168A0000|130 138|movements
P04004168A0000|139 144|tremor
P04004168A0000|154 163|tract signs
P04004168A0000|167 174|evidence
P04004168A0000|183 204|motor neuron involvement
P04005190A1288|3 9|extract
P04005190A1288|23 32|PCA content
P04011338A0620|7 14|patients
P04011338A0620|30 35|degree
P04011338A0620|38 48|steatorrhea
P04011338A0620|52 59|decrease
P04011338A0620|94 105|relationship
P04011338A0620|145 150|extent
P04011338A0620|159 166|acid loss
P04011338A0620|169 175|placebo
P04011338A0620|182 189|decrease
P04011338A0620|204 210|taurine
P04011466T0000|6 14|diameters
P04011466T0000|17 23|infants
P04011466T0000|32 39|children
P04013576A0981|10 22|investigation
P04013576A0981|41 52|distribution
P04013576A0981|67 71|acids
P04013576A0981|74 96|Leptospira phospholipids
P04013576A0981|113 124|distribution
P04013576A0981|127 136|Leptospira
P04013576A0981|144 149|lipids
P04013576A0981|157 165|exception
P04013576A0981|196 206|carbon atoms
P04013576A0981|223 235|phospholipids
P04013604A0412|12 20|frequency
P04013604A0412|40 49|ulceration
P04013604A0412|61 65|cases
P04013604A0412|75 87|patient-years
P04013604A0412|90 110|slow-release tablet use
P04014833A0400|0 13|Hydrocortisone
P04014833A0400|20 30|lymphopenia
P04014833A0400|57 64|response
P04014833A0400|77 92|blood lymphocytes
P04014833A0400|95 112|phytohemagglutinin
P04014833A0400|116 127|concanavalin
P04014833A0400|129 136|mitogens
P04014861A0000|9 19|feasibility
P04014861A0000|27 35|liposomes
P04014861A0000|56 61|agents
P04014861A0000|67 71|lungs
P04014861A0000|75 80|effect
P04014861A0000|104 122|superoxide dismutase
P04014861A0000|130 137|catalase
P04014861A0000|148 161|oxygen toxicity
P04015988T0000|0 17|Marrow cell necrosis
P04015988T0000|20 34|anorexia nervosa
P04015988T0000|49 58|starvation
P04017295A0139|3 12|comparison
P04017295A0139|25 31|heparin
P04017295A0139|47 54|dialyses
P04017295A0139|64 71|patients
P04018444A0000|22 26|cheno
P04018444A0000|64 84|cholesterol gallstones
P04019066A0000|13 27|field potentials
P04019066A0000|69 77|formation
P04019066A0000|114 119|cortex
P04019066A0000|143 147|doses
P04019066A0000|149 157|halothane
P04021281T0001|0 13|Ultrastructure
P04021281T0001|19 29|heart muscle
P04021281T0001|54 60|infarct
P04021281T0001|78 85|training
P04021305A0530|15 30|desympathization
P04021305A0530|41 51|development
P04021305A0530|54 69|hyper-reactivity
P04021305A0530|79 88|pacemakers
P04021305A0530|91 103|noradrenaline
P04021305A0530|107 114|dopamine
P04021305A0530|129 135|changes
P04021305A0530|141 150|regulation
P04021305A0530|164 171|activity
P04021305A0530|179 183|cells
P04021305A0530|186 199|catecholamines
P04021431A0000|19 24|method
P04021431A0000|34 43|assessment
P04021431A0000|52 62|pulse curves
P04021431A0000|75 87|determination
P04021431A0000|90 103|blood pressures
P04021431A0000|130 135|system
P04021431A0000|161 174|blood pressures
P04021431A0000|209 218|dilatation
P04021431A0000|223 228|pupils
P04021437A0000|5 14|infections
P04021437A0000|49 54|agents
P04021437A0000|58 63|number
P04021437A0000|71 85|ear dysfunctions
P04024685A0650|15 24|parameters
P04024685A0650|42 49|increase
P04024685A0650|50 56|RS index
P04024685A0650|64 68|mVolt
P04024685A0650|78 82|mVolt
P04025178A0126|13 20|analyses
P04025178A0126|27 31|death
P04025178A0126|52 59|decrease
P04025178A0126|97 107|volume index
P04025178A0126|117 121|ml/m2
P04025179A0955|2 6|group
P04025179A0955|8 13|adults
P04025179A0955|25 33|variables
P04026903A0512|0 10|Polysorbate
P04026903A0512|30 38|stimulant
P04026903A0512|41 54|relaxant effect
P04026903A0512|63 76|guinea pig ileum
P04026903A0512|79 87|rat uterus
P04026903A0512|111 122|contractions
P04026903A0512|132 144|acetylcholine
P04026903A0512|145 153|histamine
P04026903A0512|154 159|barium
P04026903A0512|160 178|5-hydroxytryptamine
P04026903A0512|182 190|carbachol
P04026903A0512|208 213|manner
P04026972T0000|10 32|alcohol reaction profiles
P04027182T0000|0 7|Vitiligo
P04027182T0000|10 25|diabetes mellitus
P04028871A0133|3 18|pharmacokinetics
P04028871A0133|25 36|tetracycline
P04028871A0133|39 43|serum
P04028871A0133|60 71|blister fluid
P04028871A0133|95 99|doses
P04028871A0133|105 117|mg lymecycline
P04028871A0133|123 135|mg doxycycline
P04031488A1091|5 10|degree
P04031488A1091|13 23|correlation
P04031488A1091|29 33|sense
P04031488A1091|46 55|conception
P04031488A1091|58 74|brain localization
P04031488A1091|95 103|syndromes
P04032268A0358|7 16|UV detector
P04032268A0358|52 59|detector
P04032268A0358|64 72|potential
P04032268A0358|88 101|Ag/AgCl/3 M NaCl
P04032349A0000|2 9|patients
P04032349A0000|27 36|occlusions
P04032349A0000|42 56|graft thromboses
P04032349A0000|87 94|ischemia
P04032349A0000|120 126|therapy
P04032349A0000|127 135|Urokinase
P04032349A0000|140 152|units/kg/hour
P04032349A0000|156 169|Lys Plasminogen
P04032716A0299|3 20|mean transfer ratios
P04032716A0299|46 52|tissues
P04032716A0299|57 69|concentration
P04032716A0299|90 94|blood
P04032716A0299|110 122|transfer ratio
P04032716A0299|178 183|cervix
P04032716A0299|190 199|myometrium
P04032716A0299|214 220|oviduct
P04033402A1112|24 31|hormones
P04033402A1112|38 66|HDL-cholesterol concentrations
P04033402A1112|73 99|HDL2-cholesterol subfraction
P04033402A1112|126 151|triglyceride lipase activity
P04034220A0205|16 23|spectrum
P04034220A0205|26 33|activity
P04034220A0205|53 62|ampicillin
P04034220A0205|72 78|strains
P04034220A0205|81 92|H. influenzae
P04034220A0205|112 128|tolerance Cefaclor
P04034220A0205|143 151|treatment
P04034220A0205|165 179|tract infections
P04034220A0205|182 189|children
P04034666T0000|5 26|extremity weight bearing
P04034666T0000|39 56|standing conditions
P04034666T0000|82 89|patients
P04034666T0000|94 104|hemiparesis
P04036838A0918|5 10|factor
P04036838A0918|49 53|RV/LV
P04036838A0918|61 74|pressure ratios
P04036838A0918|128 146|pressure differences
P04037809A0964|23 35|dose schedules
P04037809A0964|38 44|KW-2083
P04038454A0984|21 38|plasma retinol level
P04038454A0984|41 51|conjunction
P04038454A0984|86 93|patients
P04038454A0984|97 110|micrograms dl-1
P04038454A0984|114 119|mg dl-1
P04038454A0984|138 153|cancer recurrence
P04038454A0984|190 195|cancer
P04038454A0984|200 213|micrograms dl-1
P04038454A0984|217 222|mg dl-1
P04038702A0768|3 9|results
P04038702A0768|33 40|response
P04038702A0768|43 51|tethering
P04038702A0768|77 83|penning
P04038702A0768|95 104|experience
P04038702A0768|126 131|rhythm
P04038702A0768|134 141|cortisol
P04038702A0768|175 180|estrus
P04038702A0768|185 195|disruptions
P04038702A0768|240 245|stalls
P04038702A0768|267 288|cortisol concentrations
P04038702A0768|291 295|gilts
P04039109A0139|4 8|laser
P04039109A0139|27 31|power
P04039109A0139|44 54|fluid medium
P04039109A0139|73 79|vessels
P04039109A0139|96 103|diameter
P04039109A0139|110 116|seconds
P04039109A0139|120 131|power density
P04039109A0139|138 142|W/cm2
P04039307A0613|8 19|progesterone
P04039307A0613|59 65|heifers
P04039307A0613|76 90|treatment groups
P04039439A0000|12 16|quail
P04039439A0000|45 56|ppm manganese
P04039439A0000|74 87|manganese oxide
P04039439A0000|87 91|Mn3O4
P04039439A0842|4 8|study
P04039439A0842|33 37|quail
P04039439A0842|67 79|Mn3O4 exposure
P04039439A0842|84 90|rodents
P04039525A0475|0 5|Plasma
P04039525A0475|9 36|bladder platinum concentration
P04039525A0475|99 109|examination
P04039525A0475|109 118|urinalysis
P04039525A0475|127 136|blood count
P04039525A0475|140 153|blood chemistry
P04039525A0475|169 173|order
P04039525A0475|183 190|toxicity
P04039667T0000|13 25|visualisation
P04039667T0000|28 46|Walker carcinoma-256
P04039667T0000|49 66|Sprague-Dawley rats
P04039667T0000|69 73|means
P04039667T0000|90 98|monocytes
P04039744A0141|5 11|results
P04039744A0141|43 50|D mothers
P04039744A0141|74 80|mothers
P04039744A0141|86 95|supplement
P04039744A0141|98 114|i.u. vitamin D3/day
P04039744A0141|124 129|period
P04039744A0141|132 140|lactation
P04040083A0000|0 9|Rabbit eyes
P04040083A0000|51 58|chambers
P04040083A0000|75 80|saline
P04040307A0145|6 10|birth
P04040307A0145|46 51|nerves
P04040307A0145|80 87|NE levels
P04040339T0001|0 16|Monitoring changes
P04040339T0001|22 30|heart rate
P04040339T0001|45 49|fetus
P04040339T0001|56 64|tocolysis
P04040339T0001|91 101|partusisten
P04040339T0001|105 111|Pre-par
P04040858A0000|5 13|September
P04040858A0000|45 52|patients
P04040858A0000|63 68|cancer
P04041307A0614|3 9|results
P04041307A0614|24 40|calcium antagonist
P04041307A0614|41 49|diltiazem
P04041307A0614|62 68|effects
P04041307A0614|71 80|isoflurane
P04041307A0614|93 100|function
P04041346T0000|16 26|arrhythmias
P04041346T0000|27 33|digoxin
P04041346T0000|37 45|quinidine
P04043489A0648|0 6|Visidex
P04043489A0648|23 29|storage
P04043489A0648|33 42|re-reading
P04048245A0331|0 8|Treatment
P04048245A0331|13 29|oxyphenylbutazone
P04048245A0331|33 46|hydrocortisone
P04048245A0331|71 84|serum CPN levels
P04050771A0474|20 31|hazards model
P04050771A0474|54 58|order
P04050771A0474|82 88|factors
P04050771A0474|101 108|survival
P04050821A0531|16 25|mechanisms
P04050821A0531|46 53|increase
P04050821A0531|66 77|oxygen demand
P04050821A0531|104 111|episodes
P04050821A0531|131 138|hospital
P04051521T0001|0 7|Duration
P04051521T0001|10 18|remission
P04051521T0001|36 49|cancer patients
P04052919A0205|21 41|progesterone secretion
P04052919A0205|70 80|luteal phase
P04052919A0205|92 100|frequency
P04052919A0205|116 120|phase
P04052919A0205|144 148|phase
P04052919A0205|153 160|subjects
P04052919A0205|164 181|progesterone levels
P04052919A0205|225 234|thresholds
P04052919A0205|252 262|measurement
P04052919A0205|264 275|progesterone
P04052919A0205|291 295|phase
P04052919A0205|316 324|indicator
P04052919A0205|327 335|ovulation
P04052919A0205|337 345|threshold
P04052919A0205|359 364|nmol/l
P04052919A0205|387 392|number
P04052919A0205|408 414|results
P04055593A0523|23 32|processing
P04055593A0523|45 55|flow signals
P04055593A0523|81 92|compensation
P04055593A0523|96 106|corrections
P04055593A0523|113 119|effects
P04055593A0523|122 128|changes
P04055593A0523|131 144|gas composition
P04055593A0523|148 158|temperature
P04056218A0463|4 8|slope
P04056218A0463|41 45|dB/dB
P04056256A0416|0 18|Histamine reactivity
P04056256A0416|50 66|nifedipine aerosol
P04056256A0416|96 108|concentration
P04056256A0416|117 121|% fall
P04056256A0416|132 148|airway conductance
P04056256A0416|168 172|mg/ml
P04056256A0416|175 183|histamine
P04058985A0000|13 17|doses
P04058985A0000|20 28|vitamin B6
P04058985A0000|52 56|women
P04058985A0000|83 97|plasma prolactin
P04061342A0512|30 38|elevation
P04061342A0512|49 54|uptake
P04061342A0512|62 76|min postexercise
P04061342A0512|122 126|state
P04062128T0028|0 17|National Institutes
P04062128T0028|20 64|Health Consensus Development Conference Statement
P04063732A0509|2 9|controls
P04063732A0509|19 24|output
P04063732A0509|32 38|conduit
P04063732A0509|60 67|activity
P04066194A0163|0 17|Greater attenuation
P04066194A0163|23 27|N1-P2
P04066194A0163|31 50|baseline-P2 amplitude
P04066194A0163|56 63|probe EPs
P04066194A0163|82 94|probe stimulus
P04066194A0163|134 141|material
P04066194A0163|183 204|stimulation arrangement
P04066274A0265|11 18|patients
P04066274A0265|34 42|neoplasms
P04066274A0265|75 87|parotidectomy
P04066274A0265|88 93|T.C.P.
P04067540A0413|3 13|comparisons
P04067540A0413|48 59|perpetrators
P04067540A0413|100 106|victims
P04067540A0413|121 125|homes
P04067540A0413|135 139|lover
P04067540A0413|142 149|ex-lover
P04067540A0413|159 163|crime
P04067540A0413|192 202|suicide note
P04067540A0413|210 216|weekend
P04067540A0413|273 279|victims
P04067540A0413|291 296|spouse
P04068663A0452|9 15|rabbits
P04068663A0452|21 34|mouse CRF-flora
P04068663A0452|41 46|values
P04068663A0452|72 78|animals
P04068663A0452|86 95|parameters
P04068663A0452|106 118|unsuitability
P04068663A0452|121 133|mouse CRF flora
P04068663A0452|145 151|rabbits
P04068774A1292|7 19|relationships
P04068774A1292|67 72|effect
P04068774A1292|75 82|contents
P04068774A1292|90 97|elements
P04068969A0300|0 4|L3-L4
P04068969A0300|41 45|model
P04068969A0300|50 56|anatomy
P04068969A0300|62 66|trunk
P04068969A0300|82 87|system
P04069756T0025|0 8|Diagnosis
P04069756T0025|30 48|leukoencephalopathy
P04070725A0442|0 12|Component P100
P04070725A0442|38 47|negativity
P04070725A0442|57 63|latency
P04070725A0442|75 84|hypothesis
P04070725A0442|104 112|generator
P04071063A0863|10 20|differences
P04071063A0863|35 42|decrease
P04071063A0863|45 58|platelet counts
P04071063A0863|72 77|groups
P04071063A0863|78 93|fibrinogen levels
P04071063A0863|97 101|alpha
P04071063A0863|115 120|levels
P04071063A0863|169 173|group
P04073848T0000|0 6|Failure
P04073848T0000|9 29|stapedius reflexometry
P04073848T0000|35 43|diagnosis
P04073848T0000|46 61|myasthenia gravis
P04074214A0000|0 6|Factors
P04074214A0000|18 37|semen characteristics
P04074214A0000|45 49|boars
P04074214A0000|70 80|environment
P04075021T0000|4 22|beta-phenethylamine
P04075021T0000|25 36|distribution
P04075021T0000|42 55|administration
P04075021T0000|65 70|routes
P04075021T0000|85 91|effects
P04075021T0000|93 118|monoamine oxidase inhibitors
P04075061A0355|3 9|runners
P04075061A0355|16 20|total
P04075061A0355|31 35|water
P04079738A0677|3 7|rates
P04079738A0677|15 23|energy use
P04079738A0677|54 61|kJ X min-1
P04079738A0677|103 110|degrees C
P04079738A0677|118 126|degrees C.
P04081425T0016|8 14|aspects
P04081425T0016|18 24|therapy
P04082267A0720|20 29|incubation
P04082267A0720|37 44|degrees C
P04082267A0720|50 57|degrees C
P04082267A0720|76 81|vexans
P04082267A0720|115 119|virus
P04082592T0000|0 15|Blood eosinophils
P04082592T0000|18 25|patients
P04082592T0000|30 35|Taenia
P04084607A0663|3 13|imino proton
P04084607A0663|25 29|O6meG
P04084607A0663|57 61|O6meG
P04084607A0663|74 78|helix
P04084607A0663|103 118|modification site
P04084607A0663|142 146|field
P04084607A0663|170 181|imino protons
P04084607A0663|183 203|Watson-Crick base pairs
P04084896A0569|3 16|recommendation
P04084896A0569|35 44|sub-groups
P04084896A0569|47 56|attempters
P04084896A0569|99 120|intervention strategies
P04085589A0264a|10 20|correlation
P04085589A0264a|28 41|secretor status
P04085589A0264a|53 58|status
P04085589A0264a|59 80|spirometry measurements
P04085589A0264a|92 110|serum lysozyme levels
P04085589A0264a|113 117|rates
P04085589A0264a|131 147|tract colonization
P04085589A0264b|10 20|correlation
P04085589A0264b|28 41|secretor status
P04085589A0264b|53 58|status
P04085589A0264b|59 80|spirometry measurements
P04085589A0264b|92 110|serum lysozyme levels
P04085589A0264b|113 117|rates
P04085589A0264b|131 147|tract colonization
P04086403A1016|0 4|Gains
P04086403A1016|36 49|feed conversion
P04086403A1016|90 96|% AS-VFA
P04086403A1016|115 128|feed conversion
P04086403A1016|133 139|control
P04086657T0000|19 29|development
P04086657T0000|45 50|cortex
P04086993T0000|0 4|Daily
P04086993T0000|16 26|rhythmicity
P04086993T0000|32 42|methylation
P04086993T0000|45 50|pineal
P04086993T0000|58 66|compounds
P04086993T0000|84 91|hamsters
P04086993T0000|108 117|conditions
P04088233A0309|3 13|transit time
P04088396A0145|8 26|patients grades 1-2-3
P04088396A0145|68 78|abnormality
P04088396A0145|86 93|patients
P04088733T0001|0 7|Activity
P04088733T0001|10 23|acid hydrolases
P04088733T0001|36 50|blood leukocytes
P04088733T0001|70 78|pneumonia
P04088733T0001|81 88|children
P04088936T0001|11 17|studies
P04088936T0001|23 34|antithrombin
P04088936T0001|38 42|level
P04088936T0001|46 73|plasminogen activator activity
P04088936T0001|76 83|patients
P04088936T0001|88 103|thrombophlebitis
P04093211A0560|31 37|ability
P04093211A0560|51 59|attitudes
P04093211A0560|63 74|orientations
P04101003T0001|0 8|Relations
P04101003T0001|34 41|activity
P04101003T0001|62 69|activity
P04101003T0001|91 96|rabbit
P04102280T0000|0 8|Treatment
P04102280T0000|11 15|Paget
P04102280T0000|17 23|disease
P04103248T0000|0 10|Improvement
P04103248T0000|16 25|CRT display
P04103248T0000|30 37|averager
P04113011T0000|3 17|desensitization
P04113011T0000|21 35|ragweed hay fever
P04114211T0000|5 13|excretion
P04114211T0000|16 29|sulphadimidine
P04114211T0000|48 55|subjects
P04115870T0000|0 10|Experiences
P04115870T0000|48 65|Urat-I lithotriptor
P04123217T0000|0 8|Formation
P04123217T0000|11 16|hyphae
P04123217T0000|20 33|chlamydospores
P04123217T0000|36 56|Cryptococcus laurentii
P04123662T0000|0 9|Evaluation
P04123662T0000|12 26|thyroid function
P04138224T0095|3 8|effect
P04138224T0095|12 25|tissue emulsion
P04138224T0095|26 33|vitamin A
P04138224T0095|48 61|gamma-globulin
P04138224T0095|67 80|blood clearance
P04138224T0095|83 89|rabbits
P04139081T0001|4 13|antibodies
P04139081T0001|30 37|patients
P04139943T0001|0 12|Demonstration
P04139943T0001|19 27|structure
P04139943T0001|33 46|guinea pig organ
P04139943T0001|49 53|Corti
P04139943T0001|59 66|electron
P04139943T0001|78 91|silver staining
P04140567T0001|0 18|Histamine metabolism
P04140567T0001|44 48|shock
P04143528A0394|26 37|nomenclature
P04145244T0000|0 9|Relaxation
P04145244T0000|12 16|catch
P04145244T0000|35 40|muscle
P04152725T0001|0 6|Studies
P04152725T0001|18 28|liver injury
P04160980T0000|12 18|control
P04160980T0000|29 39|circulation
P04164595T0020|0 7|Evidence
P04164595T0020|64 68|types
P04164595T0020|71 79|infection
P04164669T0000|24 37|kinin formation
P04172166T0000|0 12|Poliomyelitis
P04172166T0000|18 24|vaccine
P04175007T0001|5 11|problem
P04175007T0001|17 27|stimulation
P04175007T0001|33 38|growth
P04175007T0001|55 60|tumors
P04175007T0001|63 69|animals
P04175007T0001|105 115|antibiotics
P04176249T0001|0 9|Assessment
P04176249T0001|20 24|media
P04176249T0001|30 38|diagnosis
P04176249T0001|41 49|diptheria
P04176268T0000|0 13|Aluminium resin
P04176268T0000|20 28|treatment
P04176268T0000|34 45|hyperkalamia
P04176268T0000|53 59|failure
P04176625T0000|0 4|Value
P04176625T0000|20 28|diagnosis
P04176625T0000|31 44|cardiomyopathy
P04176625T0000|68 75|myopathy
P04189158T0000|0 9|Prevention
P04189158T0000|20 34|Rh sensitization
P04189158T0000|48 55|globulin
P04194466T0000|0 14|Serotonin levels
P04194466T0000|17 36|infant hypothyroidism
P04196986T0000|13 28|fluid transferrin
P04196986T0000|31 37|studies
P04196986T0000|48 56|disorders
P04196986T0000|76 81|system
P04213917T0001|4 10|dosages
P04213917T0001|13 27|D-penicillamine
P04213917T0001|39 46|fibroses
P04214345T0000|7 14|relation
P04214345T0000|22 42|serum IgG concentration
P04214345T0000|46 52|glucose
P04214345T0000|56 71|xylose absorption
P04214345T0000|74 93|Zambian African adults
P04226360T0001|0 8|Disorders
P04226360T0001|11 26|platelet function
P04226360T0001|43 51|leukemias
P04239041T0045|3 8|effect
P04239041T0045|11 25|anticonvulsants
P04239041T0045|54 59|ATPase
P04239041T0045|60 65|sodium
P04239041T0045|69 76|potassim
P04239041T0045|79 84|cortex
P04246054T0028|0 5|Effect
P04246054T0028|14 24|lymphocytes
P04246054T0028|30 59|rabbit-anti-lymphocyte globulin
P04246054T0028|60 64|RAMLG
P04246054T0028|75 85|macrophages
P04246054T0028|104 124|incubation temperature
P04247472T0001|6 10|cycle
P04247472T0001|39 47|mountains
P04247472T0001|49 57|Kirghizia
P04247966T0000|0 8|Lactation
P04247966T0000|11 17|baboons
P04247966T0000|25 46|protein maintenance diet
P04262268T0001|0 6|Studies
P04262268T0001|19 24|matrix
P04262268T0001|32 42|ear ossicles
P04263748T0042|21 26|review
P04281856T0001|8 19|sex structure
P04281856T0001|31 40|population
P04281856T0001|43 66|Ornithodoros tatarovski Ol
P04282315T0001|0 12|Sensitization
P04282315T0001|15 29|hyperlactatemia
P04282315T0001|39 48|phenformin
P04282315T0001|62 69|ablation
P04282315T0001|75 82|pancreas
P04284435T0000|0 8|Vitamin D3
P04284435T0000|12 28|calcium absorption
P04284435T0000|34 38|chick
P04289156T0000|3 11|incidence
P04289156T0000|14 20|tumours
P04289156T0000|28 35|chickens
P04291759T0048|0 16|Laboratory aspects
P04291759T0048|31 39|reference
P04291759T0048|42 53|chemotherapy
P04291759T0048|57 63|control
P04295031T0062|5 10|effect
P04295031T0062|16 24|guinea pig
P04305850T0000|0 8|Androgens
P04305850T0000|12 17|growth
P04308979T0000|0 5|Effect
P04308979T0000|8 17|variations
P04308979T0000|20 31|time interval
P04308979T0000|39 47|treatment
P04308979T0000|60 69|quartz dust
P04308979T0000|71 83|translocation
P04308979T0000|86 95|quartz dust
P04308979T0000|103 107|lungs
P04308979T0000|123 132|lymph nodes
P04311951T0001|11 16|action
P04311951T0001|43 53|association
P04311951T0001|61 73|instillations
P04311951T0001|76 82|otology
P04315233T0128|21 30|experiment
P04316696T0001|0 5|Enzyme
P04316696T0001|19 26|findings
P04316696T0001|58 62|horse
P04321861T0001|8 37|glutathione reductase deficiency
P04321861T0001|41 48|disorder
P04321861T0001|51 70|glutathione synthesis
P04321861T0001|76 86|erythrocyte
P04323641T0000|0 6|Studies
P04323641T0000|9 26|swine enteroviruses
P04325736T0001|0 12|Serodiagnosis
P04325736T0001|15 24|ectromelia
P04325736T0001|27 40|laboratory mice
P04328746T0073|0 15|Ultrasound effect
P04328746T0073|21 45|cytochrome oxidase activity
P04335965T0000|0 9|Metastasis
P04335965T0000|12 25|colon carcinoma
P04350410T0000|0 6|Genesis
P04350410T0000|9 17|foam cells
P04350410T0000|18 22|study
P04350410T0000|36 49|administration
P04350410T0000|51 58|Cloforex
P04364369T0000|0 20|Pre-beta-1 lipoprotein
P04364369T0000|29 37|detection
P04364369T0000|40 50|risk factors
P04364369T0000|62 73|heart disease
P04369884T0000|0 9|Conditions
P04369884T0000|21 30|inhibitors
P04369884T0000|54 59|factor
P04371279T0000|0 6|Absence
P04371279T0000|9 24|action potentials
P04371279T0000|37 48|muscle fibres
P04371279T0000|59 72|botulinum toxin
P04377003A0000|11 16|method
P04377003A0000|35 42|analysis
P04377003A0000|48 67|polyamines putrescine
P04377003A0000|68 77|spermidine
P04377003A0000|81 88|spermine
P04377003A0000|104 108|fluid
P04377003A0000|130 139|CSF samples
P04377003A0000|145 152|patients
P04377003A0000|171 176|system
P04377003A0000|182 187|tumors
P04377003A0000|196 203|patients
P04377003A0000|211 216|tumors
P04385060T0000|0 9|Disulfiram
P04385060T0000|28 34|effects
P04385060T0000|37 44|motility
P04387103T0000|0 8|Particles
P04387103T0000|19 29|microbodies
P04387103T0000|59 64|glands
P04392584T0000|17 24|malarias
P04392584T0000|34 50|hemisphere monkeys
P04394290T0000|1 5|study
P04394290T0000|24 32|receptors
P04394290T0000|38 43|rectum
P04394290T0000|63 71|sphincter
P04407649T0000|12 24|arachnoid cyst
P04407649T0000|36 40|fossa
P04407649T0000|63 84|99mTc brainscintigraphy
P04418687T0000|0 6|Effects
P04418687T0000|9 16|estrogen
P04418687T0000|20 34|glucocorticoids
P04418687T0000|47 57|development
P04418687T0000|63 67|fetus
P04423347T0001|0 5|Copper
P04423347T0001|9 28|ceruloplasmin content
P04423347T0001|39 43|women
P04423347T0001|49 53|women
P04423347T0001|78 85|diseases
P04428800T0001|0 5|Effect
P04428800T0001|8 12|noise
P04428800T0001|25 33|increases
P04428800T0001|44 54|GPT activity
P04428800T0001|59 64|plasma
P04428981T0000|0 7|Kinetics
P04428981T0000|10 26|calcium metabolism
P04429269T0000|5 13|transport
P04429269T0000|16 20|mucus
P04429269T0000|36 44|simulants
P04429269T0000|55 61|systems
P04437406T0000|13 23|description
P04437406T0000|36 56|reflection coefficient
P04437406T0000|61 71|application
P04437406T0000|77 86|pore theory
P04437406T0000|103 110|exchange
P04445874T0001|0 8|Pathology
P04445874T0001|11 18|neuritis
P04445874T0001|37 41|horse
P04446923T0001|8 22|characteristics
P04446923T0001|26 39|verticillation
P04446923T0001|42 61|Platynothrus peltifer
P04460692T0000|8 13|topics
P04460692T0000|16 39|laboratory animal medicine
P04468264T0053|0 7|Problems
P04468264T0053|16 25|pediatrics
P04468264T0053|29 42|anesthesiology
P04482661T0001|8 13|course
P04482661T0001|17 27|nursing care
P04482661T0001|30 37|patients
P04482661T0001|42 55|decubitus ulcer
P04482661T0001|63 69|pillows
P04482661T0001|80 93|buckwheat chaff
P04487835T0001|2 8|parents
P04487920T0001|7 33|Icelandic Red Cross activities
P04488232T0001|0 6|Effects
P04488232T0001|9 18|alcoholism
P04488232T0001|24 29|family
P04488271T0001|0 8|Treatment
P04488271T0001|25 40|diabetes mellitus
P04495034T0000|12 24|methylbenzene
P04495034T0000|25 31|toluene
P04495034T0000|35 43|treatment
P04495034T0000|47 65|Ancylostomum caninum
P04506738T0000|0 8|Junctions
P04506738T0000|16 20|cells
P04506738T0000|31 41|enamel organ
P04510102T0000|0 17|Electrocardiograms
P04510102T0000|23 27|month
P04511139T0001|0 9|Composites
P04511139T0001|12 31|restoration materials
P04512496T0000|0 6|Hodgkin
P04512496T0000|8 14|disease
P04515631T0000|0 4|Value
P04515631T0000|7 15|Normotest
P04515631T0000|19 30|antithrombin
P04515631T0000|37 46|assessment
P04515631T0000|49 61|liver function
P04518624T0000|0 20|Glutathione peroxidase
P04518624T0000|31 35|cells
P04518624T0000|38 43|health
P04518624T0000|47 53|disease
P04524081T0000|15 22|response
P04524081T0000|33 39|tissues
P04524081T0000|42 49|hemodent
P04524081T0000|53 77|aluminum chloride solutions
P04524081T0000|80 106|tissue displacement materials
P04533208T0083|0 6|Changes
P04533208T0083|27 33|surgery
P04536964T0000|17 24|H ion flux
P04536964T0000|27 53|H ion permeability coefficient
P04536964T0000|56 72|bullfrog toe muscle
P04539552T0001|13 19|studies
P04539552T0001|22 27|SF-837
P04543036T0001|0 9|Directives
P04544430T0001|0 10|Proceedings
P04544430T0001|29 38|heart block
P04544430T0001|48 54|surgery
P04544430T0001|67 78|heart defects
P04544704T0001|0 5|Method
P04544704T0001|8 16|synthesis
P04544704T0001|32 37|factor
P04544704T0001|61 67|studies
P04546974T0000|0 9|Variations
P04546974T0000|15 20|timing
P04546974T0000|23 33|deflections
P04546974T0000|42 57|bundle recordings
P04547933T0000|13 27|fibril formation
P04547933T0000|40 44|cells
P04547933T0000|63 70|junction
P04548483T0001|0 13|Blood platelets
P04548483T0001|14 31|coagulation factors
P04548483T0001|46 57|organ changes
P04548483T0001|75 79|shock
P04548483T0001|82 94|rhesus monkeys
P04551650T0001|0 12|Cell viability
P04551650T0001|25 31|enzymes
P04552263T0000|14 20|schools
P04552263T0000|23 29|nursing
P04562038T0001|7 19|investigation
P04562038T0001|36 44|influence
P04562038T0001|53 59|hormone
P04562038T0001|62 72|lymphocytes
P04563045T0000|0 6|1,3-bis
P04563045T0000|6 18|2-chloroethyl
P04563045T0000|19 29|nitrosourea
P04563045T0000|44 55|nitrosoureas
P04563045T0000|57 71|cancer treatment
P04563045T0000|73 78|review
P04578686T0000|0 11|Pneumothorax
P04578686T0000|21 31|lung abscess
P04578686T0000|42 58|transplant patient
P04579436T0000|24 36|colour changes
P04579436T0000|39 58|Brevibacterium linens
P04579436T0000|97 103|pigment
P04580044T0047|8 20|relationships
P04580044T0047|27 42|development phase
P04583791T0000|6 12|history
P04583791T0000|15 25|dermatology
P04583791T0000|28 32|Lagos
P04583791T0000|33 39|Nigeria
P04598670T0000|5 20|graft irradiation
P04598670T0000|25 31|adjunct
P04598670T0000|47 63|immunosuppression
P04600603T0001|0 5|Letter
P04600603T0001|16 24|detection
P04613073T0001|8 17|biocenosis
P04613073T0001|22 34|manifestation
P04613073T0001|37 53|Shigella virulence
P04615525T0001|3 8|effect
P04615525T0001|33 41|formation
P04615525T0001|43 57|transplantation
P04615525T0001|75 82|immunity
P04615828T0001|4 11|birthday
P04615828T0001|14 36|colonel prof. e.cerny m.d.
P04621188T0000|0 9|Morphology
P04621188T0000|12 25|bacteriophages
P04621188T0000|28 44|Klebsiella bacilli
P04622430T0000|8 16|afferents
P04622430T0000|32 37|cortex
P04622430T0000|43 54|Rhesus monkey
P04624863T0001|0 8|Mechanism
P04624863T0001|11 23|immunogenesis
P04624863T0001|26 36|vaccination
P04624863T0001|63 69|mutants
P04624863T0001|72 82|salmonellae
P04624863T0001|86 94|shigellae
P04627477T0001|0 16|Resistance pattern
P04627477T0001|19 43|Mycobacterium tuberculosis
P04627477T0001|69 79|lividomycin
P04632967T0000|17 24|pressure
P04632967T0000|28 36|structure
P04632967T0000|42 52|patas monkey
P04632967T0000|67 80|administration
P04632967T0000|83 98|aminorex fumarate
P04638365T0001|0 5|Effect
P04638365T0001|8 16|triftazin
P04638365T0001|20 27|aminazin
P04638365T0001|52 59|activity
P04640155T0045|0 7|Sex ratio
P04640155T0045|10 14|birth
P04645078T0001|12 20|processes
P04645078T0001|26 36|cervix uteri
P04646045T0001|16 21|tumors
P04646045T0001|27 35|esophagus
P04653144T0000|0 14|General formulae
P04653144T0000|28 39|heritability
P04653144T0000|43 52|population
P04653144T0000|64 70|parents
P04654249T0000|0 10|Measurement
P04654249T0000|22 30|responses
P04654249T0000|43 53|stimulation
P04656185T0000|0 23|Glucose disappearance rate
P04656185T0000|27 33|changes
P04656185T0000|36 50|plasma nutrients
P04656185T0000|76 82|glucose
P04656185T0000|126 133|newborns
P04661961T0001|6 11|values
P04661961T0001|28 32|blood
P04661961T0001|36 45|bone marrow
P04661961T0001|63 69|hamster
P04676734T0000|3 14|relationship
P04676734T0000|48 59|plasma levels
P04676734T0000|62 76|corticosteroids
P04679438T0001|10 15|effect
P04679438T0001|30 34|heviz
P04679807T0000|8 24|acid concentration
P04679807T0000|39 57|breathalyzer ampules
P04704137T0001|21 27|studies
P04704137T0001|32 42|prophylaxis
P04704137T0001|56 64|abortions
P04704186T0000|0 12|Range behavior
P04704186T0000|15 22|Hereford
P04704186T0000|23 30|Hereford
P04704186T0000|32 39|Holstein
P04704186T0000|43 50|Holstein
P04704186T0000|64 70|heifers
P04712626T0000|0 19|Chemical constituents
P04712626T0000|25 37|gentianaceae V
P04712626T0000|53 61|xanthones
P04712626T0000|64 86|Swertia chirata Buch.-Ham
P04718233T0000|0 24|Methyl mercury intoxication
P04718233T0000|27 36|rat kidneys
P04727344T0000|0 17|Microdetermination
P04727344T0000|34 41|steroids
P04727344T0000|50 62|isotope method
P04729063T0000|12 18|justice
P04729063T0000|27 36|investment
P04729063T0000|60 66|Koreans
P04730467T0000|0 6|Effects
P04730467T0000|9 17|cortisone
P04730467T0000|18 27|starvation
P04730467T0000|31 37|rickets
P04730467T0000|49 64|enzyme activities
P04730467T0000|67 85|epiphyseal cartilage
P04733391T0000|0 25|Metal coordination compounds
P04733391T0000|28 40|thiabendazole
P04746559T0053|0 9|Estimation
P04746559T0053|12 29|renin secretion rate
P04746559T0053|38 47|plasma flow
P04746559T0053|70 84|vein renin levels
P04752455T0000|0 18|Disability insurance
P04752455T0000|30 37|security
P04753073T0000|0 5|Choice
P04753073T0000|8 13|vessel
P04753286T0000|0 10|Suppression
P04753286T0000|13 22|food intake
P04753286T0000|35 41|tung oil
P04757217T0000|0 6|Studies
P04757217T0000|9 21|lipoprotein-X
P04757217T0000|31 39|bile acids
P04757217T0000|49 62|LCAT deficiency
P04758799T0000|0 11|Pneumothorax
P04758799T0000|32 47|steroid treatment
P04759722T0000|0 16|Polycythemia-1973
P04760826T0000|8 14|anxiety
P04760826T0000|17 32|Vietnam returnees
P04760826T0000|36 49|undergraduates
P04764049T0001|16 31|nephronophthisis
P04766888T0000|5 18|heparin therapy
P04766888T0000|23 30|children
P04766888T0000|40 54|meningococcemia
P04778129T0000|0 16|9,11-Seco steroids
P04778129T0000|28 49|estradiol 3-methyl ether
P04782788T0001|13 24|examinations
P04782788T0001|27 34|patients
P04782788T0001|46 64|kidney insufficiency
P04784432T0001|0 12|Possibilities
P04784432T0001|25 38|administration
P04784432T0001|48 57|substances
P04784432T0001|60 66|animals
P04787472T0001|0 5|Change
P04787472T0001|11 16|makeup
P04787472T0001|22 26|blood
P04787472T0001|52 57|action
P04787472T0001|78 82|field
P04787716T0000|0 11|Observations
P04787716T0000|17 32|flight activities
P04787716T0000|35 54|Chrysops caecutiens L.
P04788701T0001|0 10|Combination
P04788701T0001|47 52|tumors
P04788701T0001|58 64|breasts
P04788701T0001|68 73|uterus
P04789916T0001|0 7|Analysis
P04789916T0001|10 23|clearance curve
P04789916T0001|30 41|bengal-I-131
P04791420T0000|0 10|Proceedings
P04791420T0000|11 17|Barrels
P04791420T0000|21 30|somatotopy
P04791420T0000|37 45|neocortex
P04791420T0000|62 67|possum
P04794218T0001|11 17|K agents
P04796997T0000|6 17|reproduction
P04796997T0000|18 24|effects
P04796997T0000|34 42|injection
P04796997T0000|45 70|medroxyprogesterone acetate
P04796997T0000|88 93|organs
P04796997T0000|99 103|bitch
P04801663T0049|27 36|properties
P04803629T0001|13 18|system
P04803629T0001|34 40|allergy
P04810131T0000|0 5|Letter
P04810131T0000|6 31|Aryl hydrocarbon hydroxylase
P04810131T0000|35 41|smoking
P04813394T0000|0 9|Evaluation
P04813394T0000|12 30|1,10-phenanthroline
P04813394T0000|34 40|reagent
P04813394T0000|50 67|acid determinations
P04820791T0001|41 50|conditions
P04820791T0001|57 64|diseases
P04820791T0001|67 74|children
P04824747T0000|0 16|Nonteratogenicity
P04824747T0000|35 42|potatoes
P04824747T0000|45 53|compounds
P04828587T0000|0 8|Isolation
P04828587T0000|40 44|virus
P04828587T0000|44 50|strain T
P04837183T0000|0 11|Observations
P04837183T0000|14 21|saccules
P04837183T0000|48 59|hypergravity
P04839176T0001|0 5|Effect
P04839176T0001|23 30|SHF field
P04839176T0001|36 57|blood coagulation system
P04843031T0000|3 8|levels
P04843031T0000|11 39|galactosyltransferase activity
P04843031T0000|58 65|children
P04843031T0000|68 75|patients
P04843031T0000|86 93|fibrosis
P04852635T0000|8 13|effect
P04852635T0000|18 43|appetite stimulant pizotifen
P04852635T0000|56 65|absorption
P04852635T0000|67 87|isonicotinylhydrazine
P04863895T0000|0 11|Relationship
P04863895T0000|24 30|lesions
P04863895T0000|49 57|serotypes
P04863895T0000|78 84|disease
P04863895T0000|92 98|poultry
P04871589T0001|7 14|solution
P04871589T0001|17 21|elbow
P04871589T0001|27 35|ankylosis
P04878680T0000|0 6|Effects
P04878680T0000|17 25|radiation
P04878680T0000|40 45|cavity
P04878680T0000|49 58|oropharynx
P04878680T0000|59 65|results
P04878680T0000|69 74|survey
P04884060T0000|3 22|Twentieth Anniversary
P04884060T0000|28 51|Pomeranian Medical Academy
P04890336T0001|20 26|pattern
P04890336T0001|29 44|Wassermann reagin
P04890336T0001|48 57|comparison
P04890336T0001|63 76|appearance time
P04890336T0001|93 105|FTA antibodies
P04909355T0000|15 29|Actinomycetales
P04911925T0001|0 31|Electrocardiographic QRS complexes
P04911925T0001|54 60|QRS loop
P04919613T0001|0 4|Study
P04919613T0001|18 31|autoantibodies
P04919613T0001|34 58|immunofluorescence technic
P04919613T0001|61 76|collagen diseases
P04921762T0000|7 18|preservation
P04941419T0000|0 24|Yusuf Dawood Docrat L.R.C.P.
P04942414T0000|3 12|metabolism
P04942414T0000|16 27|pharmacology
P04942414T0000|30 43|5-fluorouracil
P04947347T0000|0 11|Spleen weight
P04947347T0000|26 37|tumour growth
P04947347T0000|42 59|homograft rejection
P04948325T0000|0 8|Isolation
P04948325T0000|11 17|Proteus
P04948325T0000|26 30|MC-63
P04948325T0000|35 43|carcinoma
P04948325T0000|61 66|effect
P04948325T0000|69 82|Crocker sarcoma
P04948325T0000|89 104|Ehrlich carcinoma
P04959816T0000|13 17|fluid
P04959816T0000|18 26|detection
P04959816T0000|33 41|component
P04967824T0000|0 6|Effects
P04967824T0000|9 19|temperature
P04967824T0000|31 35|cycle
P04967824T0000|38 53|melanin synthesis
P04970131T0001|4 20|reflexions apropos
P04970131T0001|43 47|study
P04970131T0001|61 69|embolisms
P04970918T0069|0 9|LA-3848-MS
P04973523T0000|14 20|studies
P04973523T0000|33 40|antigens
P04975676T0000|26 36|alterations
P04975676T0000|47 52|baboon
P04975676T0000|58 76|allotransplantation
P04976988T0000|0 12|Heterogeneity
P04976988T0000|20 31|serum albumin
P04989251T0000|0 7|Analysis
P04989251T0000|10 24|corticosteroids
P04990556T0000|0 11|Reactivities
P04990556T0000|14 18|horse
P04990556T0000|34 41|globulin
P04992478T0000|0 16|Plasma histaminase
P04992478T0000|19 26|patients
P04992478T0000|38 43|asthma
P04992478T0000|50 55|effect
P04992478T0000|70 83|administration
P04999086T0001|12 16|study
P04999086T0001|48 55|analyzer
P04999086T0001|70 80|ontogenesis
P04999086T0001|88 94|monkeys
P05000171T0000|3 8|effect
P05000171T0000|29 40|distribution
P05000171T0000|42 62|horseradish peroxidase
P05000171T0000|85 90|spaces
P05000171T0000|93 113|toad bladder epithelium
P05005311T0000|0 13|Immunogenicity
P05005311T0000|23 34|mycobacteria
P05005311T0000|54 59|levels
P05005311T0000|62 77|cross-protection
P05005311T0000|94 100|species
P05012220T0000|8 17|experience
P05012220T0000|31 45|proctocolectomy
P05012220T0000|53 61|ileostomy
P05015678T0000|17 27|tautomerism
P05015678T0000|30 39|porphyrins
P05015678T0000|43 50|chlorins
P05020660T0000|0 6|Factors
P05020660T0000|19 28|inhibition
P05020660T0000|31 42|phagocytosis
P05020660T0000|45 58|chlorpromazine
P05021912T0000|16 26|sensitivity
P05021912T0000|67 75|pigeon eye
P05025918T0000|0 10|Angiography
P05025918T0000|23 30|bone cyst
P05027295T0034|0 13|Cholinesterase
P05027799T0000|0 16|Sodium restriction
P05027799T0000|26 32|failure
P05028628T0001|23 34|examinations
P05028628T0001|37 52|occlusion disease
P05028628T0001|73 80|arteries
P05031074T0001|0 16|Serum lipid changes
P05031074T0001|23 31|pregnancy
P05031074T0001|41 61|calcium administration
P05031659T0000|10 18|treatment
P05031659T0000|21 31|candidiasis
P05031659T0000|36 49|transfer factor
P05034373T0000|26 52|function oxidase enzyme system
P05034373T0000|57 67|requirement
P05034373T0000|71 78|selenium
P05045351T0000|8 16|breathing
P05045351T0000|20 24|apnea
P05045351T0000|34 40|infants
P05049711T0000|7 19|session report
P05049711T0000|34 42|screening
P05060388T0000|17 23|studies
P05060388T0000|36 41|tumors
P05060388T0000|47 51|ovary
P05065548T0075|5 16|constituents
P05065548T0075|19 37|Dryopteris polylepis
P05066316T0001|0 7|Relation
P05066316T0001|21 25|ratio
P05066316T0001|31 39|materials
P05066316T0001|43 53|composition
P05066316T0001|56 63|products
P05066316T0001|69 77|synthesis
P05066316T0001|80 95|aluminosilicates
P05068271T0000|0 8|Influence
P05068271T0000|26 37|VMA excretion
P05075857T0000|0 28|Oscilloscope triggering circuit
P05075857T0000|45 54|transients
P05075857T0000|61 71|sweep speeds
P05081814T0000|0 10|Derivatives
P05081814T0000|22 26|acids
P05083872T0000|3 8|status
P05083872T0000|11 19|education
P05083872T0000|23 38|training programs
P05083872T0000|41 55|speech pathology
P05083872T0000|59 67|audiology
P05087496T0000|8 15|arteries
P05091970T0000|9 14|agents
P05093030T0001|0 9|Separation
P05093030T0001|30 38|compounds
P05093030T0001|41 45|urine
P05093030T0001|59 65|methods
P05093030T0001|68 93|medium-tension intophoresis
P05093030T0001|97 119|partition chromatography
P05095988T0001|12 20|treatment
P05095988T0001|37 50|system injuries
P05101762T0000|0 12|Spasmus nutans
P05101762T0000|14 21|syndrome
P05110049T0001|31 37|therapy
P05110049T0001|39 49|scleroderma
P05114515T0000|15 27|enzyme release
P05114515T0000|34 46|normalization
P05114515T0000|49 53|drugs
P05114515T0000|72 84|polyarthritis
P05119546T0001|0 8|Treatment
P05119546T0001|18 26|neoplasms
P05120197T0000|12 23|pancreatitis
P05123884T0000|9 18|metabolism
P05123884T0000|21 42|4-chlorophenoxyacetate
P05124707T0001|0 7|Dynamics
P05124707T0001|10 21|hospital stay
P05124707T0001|30 42|ulcer patients
P05128149T0001|0 16|Surgical treatment
P05128149T0001|29 33|scars
P05128149T0001|46 52|infarct
P05132558T0000|3 13|interaction
P05132558T0000|16 23|caffeine
P05132558T0000|24 35|theophylline
P05132558T0000|39 49|theobromine
P05132558T0000|54 79|monoamine oxidase inhibitors
P05133723T0000|0 5|Effect
P05133723T0000|8 17|phenformin
P05133723T0000|20 34|gluconeogenesis
P05133723T0000|45 52|rat liver
P05135168T0000|0 11|New alkaloids
P05135168T0000|24 44|Erythrophleum ivorense
P05138738T0001|9 23|M hemoglobinosis
P05145925T0000|14 19|nature
P05145925T0000|54 62|potential
P05145925T0000|73 83|spleen cells
P05152314T0001|10 21|oscillations
P05152314T0001|25 44|gas dilution indicator
P05154132T0000|3 7|value
P05154132T0000|19 25|sources
P05154132T0000|28 35|nitrogen
P05154132T0000|38 42|diets
P05162342T0001|9 14|tumors
P05162342T0001|17 25|childhood
P05170106T0034|0 6|Results
P05170106T0034|20 29|inspection
P05170106T0034|62 79|enzyme preparations
P05170106T0034|90 101|chymotrypsin
P05170106T0034|105 111|trypsin
P05170106T0034|114 118|means
P05170106T0034|135 141|methods
P05172320T0001|0 6|Studies
P05172320T0001|22 27|nature
P05172320T0001|34 39|prints
P05172320T0001|51 59|reference
P05172320T0001|62 73|interdigital
P05172320T0001|77 84|triradii
P05172970T0001|3 9|problem
P05172970T0001|12 22|disablement
P05172970T0001|37 48|tuberculosis
P05172970T0001|54 58|basis
P05172970T0001|63 70|analysis
P05172970T0001|76 82|history
P05172970T0001|88 92|cases
P05172970T0001|105 110|Gdansk
P05172970T0001|116 120|years
P05174753T0001|13 22|dysostosis
P05177935T0001|0 8|Proposals
P05177935T0001|11 23|authorization
P05177935T0001|27 31|group
P05177935T0001|34 39|nurses
P05177935T0001|55 63|hospitals
P05203499T0001|19 31|scintillation
P05203499T0001|53 63|description
P05203499T0001|68 79|thyroid gland
P05203499T0001|80 85|kidney
P05203499T0001|89 94|spleen
P05203499T0001|95 104|comparison
P05203499T0001|109 116|131-I-RB
P05210791T0001|0 8|Pneumonia
P05210791T0001|11 18|children
P05253274T0001|0 11|Osteosarcoma
P05253274T0001|20 34|3,4-benzopyrene
P05274128T0001|3 9|content
P05274128T0001|12 22|glucosamine
P05274128T0001|26 38|galactosamine
P05274128T0001|41 46|tartar
P05274526T0000|0 6|Relapse
P05274526T0000|9 16|leukemia
P05274526T0000|31 39|remission
P05276380T0000|0 8|Influence
P05276380T0000|11 26|cigarette smoking
P05276380T0000|33 53|blood coagulation tests
P05284310T0000|13 20|fluoride
P05284310T0000|26 32|control
P05284310T0000|35 47|plasma calcium
P05285978T0076|6 11|report
P05285978T0076|26 38|Cancer Society
P05299993T0000|0 11|Modification
P05299993T0000|17 22|growth
P05299993T0000|25 35|Tetrahymena
P05299993T0000|38 46|compounds
P05299993T0000|71 79|mechanism
P05303700T0066|0 11|SAM-TR-68-54
P05305671T0000|6 15|discussion
P05305671T0000|18 34|color deficiencies
P05309471T0000|0 7|Problems
P05309471T0000|13 25|determination
P05309471T0000|40 46|content
P05309471T0000|49 65|influenza vaccines
P05316745T0000|0 11|Aedes aegypti
P05316745T0000|19 33|Aedes albopictus
P05316745T0000|33 37|Skuse
P05316745T0000|40 52|Singapore City
P05322558T0000|0 16|Homograft response
P05322558T0000|20 42|hemagglutinin production
P05322747T0034|11 15|study
P05322747T0034|27 34|overload
P05322747T0034|40 50|tolbutamide
P05322747T0034|54 63|tolazamide
P05322747T0034|83 90|subjects
P05340801T0000|0 9|Mycotoxins
P05340801T0000|20 24|foods
P05344097T0000|0 6|Factors
P05344097T0000|25 56|skin permeability factor production
P05344097T0000|59 72|Vibrio cholerae
P05353667T0000|6 23|cord representation
P05353667T0000|29 39|micturition
P05356107T0001|10 15|action
P05356107T0001|19 26|kinetics
P05356107T0001|32 42|elimination
P05356107T0001|45 56|tritium oxide
P05357390T0001|9 15|isotopy
P05357390T0001|20 30|conjunctiva
P05359464T0000|0 7|Pitfalls
P05359464T0000|20 47|chromosome aberration analysis
P05359464T0000|60 77|radiation dosimetry
P05362866T0000|0 13|Renin secretion
P05362866T0000|39 50|hypertension
P05363816T0001|36 44|expertise
P05363816T0001|84 90|actions
P05364951T0001|0 13|Histopathology
P05364951T0001|17 28|pathogenesis
P05364951T0001|44 50|viroses
P05368978T0000|0 9|CNS effects
P05368978T0000|17 27|anesthetics
P05368978T0000|60 74|amine mechanisms
P05372511T0105|0 16|Diethylene benzene
P05379901T0000|0 11|Midge control
P05379901T0000|14 26|flood channels
P05388567T0000|3 9|effects
P05388567T0000|12 21|taloximine
P05388567T0000|25 37|aminophylline
P05388567T0000|59 64|muscle
P05389125T0000|14 22|behaviour
P05394352T0000|0 11|Genitography
P05394352T0000|25 30|states
P05394461T0001|0 12|Tolerance test
P05394461T0001|24 40|animal experiments
P05410590T0000|30 39|prevention
P05410590T0000|40 60|bladder tumor formation
P05410641T0000|5 11|percent
P05410641T0000|12 22|Venturi mask
P05410641T0000|36 48|airway disease
P05412122T0000|0 5|Methyl
P05412122T0000|6 13|8-methyl
P05412122T0000|17 35|8-phenyl derivatives
P05412122T0000|54 66|benzomorphans
P05412687T0000|10 17|invasion
P05412687T0000|20 27|impulses
P05412687T0000|40 59|collateral inhibition
P05412687T0000|71 83|tract neurones
P05413428T0000|3 14|distribution
P05413428T0000|17 26|body fluids
P05413428T0000|36 45|hemorrhage
P05413428T0000|49 61|resuscitation
P05413428T0000|64 79|combat casualties
P05414186T0001|8 24|Hong Kong influenza
P05414186T0001|30 40|Netherlands
P05417431T0001|5 14|disagnosis
P05417431T0001|17 22|cancer
P05417431T0001|39 46|patients
P05421537T0001|0 11|Difficulties
P05421537T0001|30 44|sputum viscosity
P05424220T0001|0 17|Lipid concentration
P05424220T0001|21 34|lipase activity
P05424220T0001|40 48|epiphysis
P05424220T0001|101 113|sodium content
P05425195T0001|0 7|Behavior
P05425195T0001|10 34|aspartate aminotransferase
P05425195T0001|49 71|alanine aminotransferase
P05425195T0001|84 91|rat serum
P05425195T0001|100 105|course
P05425195T0001|113 129|radiation syndrome
P05425195T0001|144 160|body X-irradiation
P05437405T0000|10 16|forearm
P05437405T0000|27 41|dilator capacity
P05437405T0000|77 89|salt retention
P05441564T0001|0 6|Studies
P05441564T0001|12 24|pathogenicity
P05441564T0001|40 44|virus
P05441564T0001|49 55|mutants
P05441564T0001|59 70|suckling mice
P05445187T0000|15 26|heat exchange
P05445187T0000|43 50|passages
P05445187T0000|51 56|effect
P05445187T0000|59 63|water
P05445187T0000|67 77|heat balance
P05451324T0000|0 10|Calibration
P05451324T0000|15 24|correction
P05451324T0000|27 31|blood
P05451324T0000|34 40|content
P05451324T0000|59 70|CO saturation
P05456002T0000|0 6|Mae West
P05456002T0000|13 26|doctor shortage
P05460466T0001|0 10|Elimination
P05460466T0001|13 29|gamma-irradiation
P05460466T0001|37 45|oxidation
P05460466T0001|55 70|drug preparations
P05463837T0023|11 23|configuration
P05466177T0001|11 17|effects
P05466177T0001|20 31|actinomycin D
P05471866T0000|3 34|plasma growth hormone concentration
P05472485T0000|7 28|cochlear response curves
P05472485T0000|31 37|rodents
P05474466T0001|4 23|hemagglutination test
P05474466T0001|38 42|assay
P05474466T0001|55 60|factor
P05488121T0000|0 14|CO2 assimilation
P05488121T0000|17 28|chloroplasts
P05488121T0000|42 52|filter paper
P05492285T0000|3 9|biology
P05492285T0000|12 30|Hyostrongylus ruidus
P05496619T0000|7 14|profiles
P05496619T0000|17 45|air pollution control activities
P05497793T0000|0 6|Effects
P05497793T0000|16 35|metaraminol treatment
P05497793T0000|52 59|activity
P05497793T0000|112 123|environments
P05500957T0001|3 13|association
P05500957T0001|16 24|clopamide
P05500957T0001|28 36|hydergine
P05500957T0001|37 45|Brinedine
P05500957T0001|51 59|treatment
P05500957T0001|78 86|syndromes
P05500957T0001|89 97|pregnancy
P05501347T0001|3 8|effect
P05501347T0001|14 28|dosage radiation
P05501347T0001|31 40|metabolism
P05501347T0001|44 51|function
P05501347T0001|57 65|rat kidney
P05501347T0001|75 82|ischemia
P05502054T0000|0 7|Leukemia
P05502054T0000|10 14|twins
P05502054T0000|25 30|review
P05502054T0000|41 45|cases
P05525652T0064|11 16|report
P05529283T0000|0 11|Quantitation
P05529283T0000|34 38|serum
P05529283T0000|40 45|health
P05529283T0000|49 55|disease
P05532854T0001|16 29|manifestations
P05532854T0001|40 48|sclerosis
P05533214T0001|0 15|Iodine metabolism
P05533214T0001|25 35|thyroiditis
P05536803T0001|5 13|body water
P05536803T0001|14 27|rhodanide space
P05536803T0001|44 48|space
P05536803T0001|62 67|effect
P05536803T0001|70 79|furosemide
P05552149T0000|8 22|85Sr scintimetry
P05552149T0000|27 31|study
P05552149T0000|41 53|arthropathies
P05552642T0000|0 10|Propagation
P05552642T0000|14 30|hormone production
P05552642T0000|56 66|trophoblast
P05553261T0000|0 5|Health
P05553261T0000|19 27|reticulum
P05555149T0001|21 26|method
P05555149T0001|48 57|S-S-groups
P05556977T0001|0 12|Morphogenesis
P05556977T0001|18 27|trochanter
P05556977T0001|45 56|regeneration
P05556977T0001|62 86|phasmid Carausius morosus Br
P05560428T0001|27 36|expression
P05560428T0001|46 50|sleep
P05560428T0001|54 64|wakefulness
P05560428T0001|67 74|reptiles
P05567721T0000|0 12|Sensitivities
P05567721T0000|15 29|thromboplastins
P05567721T0000|32 50|factor VII deficiency
P05572662T0000|0 6|Central
P05572662T0000|13 20|catheter
P05572662T0000|49 65|electrocardiogram
P05574818T0000|9 26|computer programmes
P05574818T0000|39 43|study
P05574818T0000|68 93|contractile characteristics
P05574818T0000|104 109|muscle
P05593469T0001|14 21|injuries
P05594277T0051|3 14|modification
P05594277T0051|17 25|P32 uptake
P05594277T0051|33 45|Jensen sarcoma
P05594277T0051|63 70|peroxide
P05594277T0051|85 90|medium
P05595036T0001|0 7|Students
P05595036T0001|8 14|parents
P05595036T0001|15 22|teachers
P05595036T0001|33 41|disorders
P05621339T0001|21 25|doses
P05621339T0001|28 43|Cs137 irradiation
P05627251T0000|8 13|shifts
P05627251T0000|21 34|skin potentials
P05627251T0000|46 50|sleep
P05642051T0000|17 36|department management
P05671267T0000|0 18|Dimethylaminopropyl
P05671267T0000|23 38|dihydro-5H-benzo
P05671267T0000|40 45|pyrido
P05671267T0000|49 55|azepine
P05672903T0001|0 21|Osteogenesis imperfecta
P05683363T0001|0 12|Investigation
P05683363T0001|18 25|exchange
P05683363T0001|69 82|analysis method
P05683809T0000|0 5|Effect
P05683809T0000|35 39|drugs
P05683809T0000|45 72|surface charge characteristics
P05683809T0000|81 92|blood vessels
P05683809T0000|109 115|studies
P05684081T0001|0 11|Measurements
P05684081T0001|14 21|activity
P05684081T0001|44 58|chamber VA-K-254
P05684081T0001|64 77|osimeter VA-J18
P05689427T0052|0 33|N-Alkyl-N-2-chloroethylaminomethyl
P05689427T0052|61 74|hydrochlorides
P05692759T0001|0 10|Nephrectomy
P05692759T0001|20 25|cattle
P05693602T0001|0 9|Evaluation
P05693602T0001|21 37|blood cell counters
P05693605T0001|0 12|Determination
P05693605T0001|15 27|transaminases
P05693605T0001|34 45|autoanalyzer
P05715613T0000|0 6|Sterols
P05715613T0000|9 14|pollen
P05718386T0001|20 27|skin flap
P05718386T0001|32 43|complication
P05718386T0001|49 57|treatment
P05718386T0001|69 74|hernia
P05718500T0001|12 23|observations
P05718500T0001|29 35|decidua
P05718500T0001|55 63|pregnancy
P05718994T0000|11 25|fibro-elastosis
P05718994T0000|32 43|incompetence
P05718994T0000|47 57|coarctation
P05718994T0000|69 73|aorta
P05719031T0000|0 6|Studies
P05719031T0000|12 17|method
P05719031T0000|20 32|size reduction
P05719031T0000|44 52|compounds
P05719746T0001|0 7|Children
P05719746T0001|21 26|vision
P05722341T0000|0 13|Identification
P05722341T0000|17 26|estimation
P05722341T0000|29 43|monosaccharides
P05722341T0000|47 59|disaccharides
P05722341T0000|62 66|urine
P05722341T0000|79 92|chromatography
P05725509T0000|0 7|Steroids
P05725509T0000|10 17|germfree
P05727222T0000|3 9|effects
P05727222T0000|33 37|pumps
P05727222T0000|43 59|oxygen consumption
P05727222T0000|62 76|Callionymus lyra
P05732641T0001|0 5|Trials
P05732641T0001|8 21|sevine activity
P05732641T0001|29 42|mosquito larvae
P05733952T0001|3 14|significance
P05733952T0001|27 35|integrity
P05733952T0001|46 51|tissue
P05733952T0001|55 72|antibody production
P05733952T0001|75 81|culture
P05733953T0001|3 8|effect
P05733953T0001|28 32|field
P05733953T0001|48 55|activity
P05733953T0001|58 66|Paramecia
P05734847T0000|0 6|Studies
P05734847T0000|24 46|Glossina morsitans colony
P05734847T0000|49 54|Lisbon
P05740389T0001|0 8|Relations
P05740389T0001|26 35|mechanisms
P05740389T0001|48 54|effects
P05742879T0000|0 14|Transformations
P05742879T0000|20 33|morphine series
P05749438T0001|12 22|anesthetics
P05749438T0001|23 36|o-chlorophenyl
P05749438T0001|37 62|methyl-amino cyclohexane HCL
P05749438T0001|63 68|CI-581
P05750950T0001|0 5|Estrus
P05750950T0001|19 27|abilities
P05751819T0000|3 9|bearing
P05751819T0000|12 17|season
P05751819T0000|21 28|sequence
P05751819T0000|31 37|calving
P05751819T0000|40 48|frequency
P05751819T0000|71 78|calvings
P05751819T0000|80 90|Hariana cows
P05758469T0001|0 18|Hemodynamics changes
P05758469T0001|32 37|flight
P05760665T0000|0 15|Caries prevention
P05760665T0000|27 32|office
P05763347T0000|8 19|applications
P05763347T0000|22 31|inhibition
P05763347T0000|49 57|receptors
P05763347T0000|62 72|propranolol
P05769307T0000|0 15|Automatic view box
P05774062T0000|0 10|Measurement
P05774062T0000|20 32|acid secretion
P05774062T0000|35 46|conductivity
P05779953T0000|0 5|Effect
P05779953T0000|8 17|castration
P05779953T0000|32 38|serum LH
P05781385T0000|3 14|significance
P05781385T0000|20 48|phenolphthalein sulphatase test
P05781385T0000|55 69|differentiation
P05781385T0000|73 86|identification
P05781385T0000|89 103|Nocardia species
P05782943T0001|0 11|Relationship
P05782943T0001|14 22|mast cells
P05782943T0001|25 44|sarcoidosis granuloma
P05787318T0000|9 15|effects
P05787318T0000|18 27|clofibrate
P05787318T0000|28 36|Atromid-S
P05787318T0000|39 49|serum lipids
P05789870T0001|0 38|Phosphate glucose dehydrogenase deficiency
P05789870T0001|46 63|hyperbilirubinemia
P05792868T0000|0 33|Evidence forthe electroosmosis theory
P05792868T0000|36 44|transport
P05792868T0000|50 55|phloem
P05792911T0000|0 6|Effects
P05792911T0000|24 39|receptor blockade
P05792911T0000|42 58|airway conductance
P05792911T0000|62 71|lung volume
P05792911T0000|92 99|subjects
P05794247T0000|0 5|Effect
P05794247T0000|8 14|heparin
P05794247T0000|20 31|inactivation
P05794247T0000|34 55|serum lipoprotein lipase
P05794247T0000|61 65|liver
P05796272T0000|12 34|chlorpromazine cataracts
P05798063T0000|0 9|Specialist
P05798063T0000|12 25|family practice
P05798063T0000|26 34|prototype
P05798063T0000|38 43|doctor
P05799686T0001|3 13|possibility
P05799686T0001|25 36|chemotherapy
P05799686T0001|66 74|carcinoma
P05799686T0001|89 101|cytodiagnosis
P05799686T0001|104 116|incorporation
P05799686T0001|125 135|idoxuridine
P05805644T0001|0 8|Variation
P05805644T0001|30 41|distribution
P05805644T0001|44 48|228Ra
P05805644T0001|52 56|224Ra
P05805644T0001|81 88|skeleton
P05805644T0001|93 105|incorporation
P05805644T0001|108 120|colloidal ThO2
P05806615T0001|9 19|degradation
P05806615T0001|22 40|adrenaline solutions
P05806615T0001|41 45|study
P05806615T0001|63 68|stages
P05806615T0001|85 89|value
P05806615T0001|96 102|control
P05806615T0001|109 114|solute
P05806936T0000|0 9|Absorption
P05806936T0000|12 23|electrolytes
P05806936T0000|31 35|colon
P05806936T0000|38 42|cases
P05806936T0000|55 61|colitis
P05806936T0000|74 81|subjects
P05807222T0052|0 11|Ion injection
P05810259T0001|0 15|Polyvinyl alcohol
P05810259T0001|19 34|solution mediator
P05819249T0000|0 5|Mining
P05819249T0000|19 25|iron ore
P05822499T0034|3 11|structure
P05822499T0034|14 25|digiprogenin
P05823624T0031|19 26|hospital
P05833022T0001|5 13|character
P05833022T0001|16 22|changes
P05833022T0001|28 41|enzyme activity
P05833022T0001|47 57|brain tissue
P05833022T0001|70 77|epilepsy
P05836483T0000|14 21|teratoma
P05836483T0000|24 28|liver
P05836483T0000|31 39|childhood
P05837169T0001|0 13|Methoxyflurane
P05837169T0001|22 29|function
P05839844T0000|0 13|Histochemistry
P05839844T0000|17 34|electron microscopy
P05839844T0000|42 53|liver lesions
P05839844T0000|63 73|Aflatoxin B1
P05839844T0000|76 84|ducklings
P05847772T0001|10 18|disorders
P05847772T0001|24 29|ureter
P05847772T0001|50 56|surgery
P05850652T0001|0 4|Study
P05850652T0001|10 20|alterations
P05850652T0001|33 42|absorption
P05850652T0001|45 49|means
P05850652T0001|52 65|I-131-triolein
P05857301T0000|0 7|Chemical
P05857301T0000|32 40|responses
P05857301T0000|51 55|CC1-4
P05857301T0000|66 71|routes
P05857301T0000|74 87|administration
P05858571T0000|8 13|trials
P05858571T0000|18 24|1,3-bis
P05858571T0000|24 36|2-chloroethyl
P05858571T0000|37 47|nitrosourea
P05858571T0000|48 57|NSC-409962
P05859016T0000|0 24|Hydroxypropyl methacrylate
P05859016T0000|43 57|embedding medium
P05859016T0000|61 78|electron microscopy
P05879595T0094|0 9|Statistics
P05879595T0094|20 24|years
P05881833T0001|5 13|diagnosis
P05881833T0001|22 29|leucosis
P05881833T0001|36 42|control
P05881833T0001|53 63|Lower Saxony
P05884183T0001|0 9|Experience
P05884183T0001|17 27|restoration
P05884183T0001|30 52|agglutination properties
P05884183T0001|83 90|cultures
P05884183T0001|105 113|Rzhaninov
P05884183T0001|114 119|method
P05890093T0000|0 4|Study
P05890093T0000|7 17|micromelias
P05890093T0000|23 32|mouse fetus
P05890093T0000|41 51|x-radiation
P05890093T0000|52 58|hypoxia
P05890093T0000|59 64|trypan
P05890093T0000|69 77|injection
P05890093T0000|80 97|hypervitaminosis-A
P05890093T0000|102 114|mother animals
P05890093T0000|121 129|pregnancy
P05890351T0001|5 20|antitetanus serum
P05890351T0001|29 34|wealth
P05893495T0001|0 6|Studies
P05893495T0001|26 34|infection
P05893495T0001|37 43|rabbits
P05896996T0001|2 11|catabolism
P05896996T0001|14 25|aminoketones
P05901778T0000|3 8|effect
P05901778T0000|18 25|patterns
P05901778T0000|31 40|deposition
P05902458T0001|0 10|Naphthalene
P05902458T0001|14 32|paradichlorobenzene
P05902458T0001|43 52|toxicology
P05909034T0000|0 6|Studies
P05909034T0000|17 28|preparations
P05917315T0026|1 10|case report
P05917315T0026|36 40|study
P05919308T0001|0 11|Interactions
P05919308T0001|19 29|adrenergics
P05919308T0001|30 41|adrenolytics
P05919308T0001|45 70|monoamine oxidase inhibitors
P05930797T0000|7 13|studies
P05930797T0000|25 43|isoprecipitin system
P05930797T0000|44 59|Australia antigen
P05933228T0000|10 16|rhythms
P05933228T0000|19 28|indicators
P05933228T0000|31 44|neurosecretion
P05938720T0000|0 4|Story
P05938720T0000|8 15|hospital
P05938720T0000|29 54|employee orientation program
P05939748T0000|15 22|Pap smear
P05947377T0001|9 18|test iodine
P05947377T0001|19 23|I-132
P05947377T0001|24 29|uptake
P05947377T0001|35 41|thyroid
P05947377T0001|44 51|children
P05947377T0001|56 71|growth deficiency
P05949971T0000|0 10|Persistence
P05949971T0000|13 21|toxaphene
P05949971T0000|31 35|lakes
P05959588T0000|0 6|Studies
P05959588T0000|9 22|Coxsackie B Type
P05959588T0000|24 38|virus infections
P05960999T0001|0 4|Value
P05960999T0001|10 15|method
P05960999T0001|18 40|passive hemagglutination
P05960999T0001|45 59|polysaccharide C
P05960999T0001|81 87|protein
P05960999T0001|100 112|precipitation
P05960999T0001|115 125|capillaries
P05960999T0001|129 142|slide latex test
P05960999T0001|155 159|serum
P05967610T0000|10 22|nerve function
P05967610T0000|23 40|noradrenaline level
P05967610T0000|44 62|noradrenaline uptake
P05967610T0000|81 88|membrane
P05967610T0000|93 110|reserpine treatment
P05969185T0001|0 9|Concussion
P05982700T0000|0 4|Study
P05982700T0000|10 20|evagination
P05982700T0000|23 43|Cysticercus pisiformis
P05985275T0000|13 21|substance
P05985275T0000|36 47|acorn extract
P05992157T0001|3 15|pathogenicity
P05992157T0001|18 38|Achromobacter puntatum
P05992157T0001|46 52|blooded
P05992157T0001|67 73|animals
P05994421T0045|0 12|Consanguinity
P05994421T0045|16 24|migration
P05994421T0045|30 38|marriages
P05994421T0045|44 49|region
P05994421T0045|52 56|Nunoa
P05994421T0045|57 64|Santiago
P05995140T0001|5 10|amount
P05995140T0001|14 25|significance
P05995140T0001|40 51|glucose level
P05995140T0001|54 59|tumors
P05999607T0001|0 6|Studies
P05999607T0001|9 19|lipogenesis
P05999607T0001|30 39|precursors
P06012827T0000|15 21|studies
P06012827T0000|41 46|system
P06027841T0000|15 19|249Bk
P06027841T0000|26 43|hyperfine structure
P06027841T0000|49 64|emission spectrum
P06035001T0000|7 18|observations
P06035001T0000|21 30|resorption
P06035001T0000|33 42|guinea pigs
P06035001T0000|52 61|injections
P06035001T0000|64 73|trypan blue
P06048505T0000|0 10|Derivatives
P06048505T0000|13 20|fluorene
P06051644T0000|13 18|method
P06051644T0000|32 44|determination
P06051644T0000|47 56|creatinine
P06054411T0000|0 16|Retention behavior
P06054411T0000|19 26|steroids
P06054411T0000|29 45|gas chromatography
P06054411T0000|51 56|series
P06054411T0000|59 76|combination columns
P06065507T0000|17 27|hypertrophy
P06072512T0000|7 16|evaluation
P06072512T0000|31 36|action
P06073427T0001|15 30|characteriaztion
P06073427T0001|46 55|interferon
P06073427T0001|61 65|blood
P06073427T0001|69 73|urine
P06073427T0001|76 82|rabbits
P06074093T0001|9 24|folate deficiency
P06074093T0001|26 34|pregnancy
P06074640T0001|0 8|Symposium
P06074640T0001|26 41|encephalopathies
P06084279A0218|17 24|patients
P06084279A0218|45 56|serum amylase
P06084810A0169|29 43|polysome complex
P06084810A0169|105 111|library
P06084864T0001|16 32|alpha fetoproteins
P06084864T0001|36 46|oligoamnios
P06084864T0001|52 60|prognosis
P06085839A0721|18 28|possibility
P06085839A0721|63 70|etiology
P06088722A0171|0 6|Courses
P06088722A0171|30 37|recovery
P06088722A0171|40 55|myelosuppression
P06089575A0464|0 10|Stimulation
P06089575A0464|50 58|elevation
P06089575A0464|60 68|cGMP level
P06089575A0464|79 88|fmol/gland
P06089575A0464|128 132|level
P06090369A0000|21 28|patients
P06090369A0000|41 47|WR-2721
P06090369A0000|50 54|Phase
P06090369A0000|59 65|studies
P06090458A0407|3 23|PEPCK promoter fragment
P06090458A0407|54 64|orientation
P06090458A0407|68 80|transcription
P06090458A0407|86 91|TK gene
P06090458A0407|107 117|orientation
P06091914A0000|11 16|tumors
P06091914A0000|26 30|mouse
P06091914A0000|38 47|tumor virus
P06091914A0000|62 69|provirus
P06091914A0000|78 83|region
P06091914A0000|98 103|genome
P06091914A0000|113 122|expression
P06091914A0000|142 149|oncogene
P06091914A0000|156 160|int-1
P06092048A1111|7 11|cases
P06092048A1111|12 19|asbestos
P06092048A1111|37 42|burden
P06092048A1111|53 60|fibrosis
P06092588T0000|0 14|Hepatitis B virus
P06092588T0000|18 25|hepatoma
P06093354A0000|16 24|DNA clones
P06093354A0000|43 55|leukemia virus
P06093354A0000|68 79|DNA sequences
P06093354A0000|118 124|library
P06093354A0000|127 140|Balb/c mouse DNA
P06093363A0612|22 29|proteins
P06093363A0612|34 44|% identities
P06093363A0612|52 68|amino acid sequence
P06093363A0612|73 81|alignment
P06094591A0000|3 23|envelope glycoproteins
P06094591A0000|26 41|Rous sarcoma virus
P06094591A0000|78 85|membrane
P06094591A0000|111 116|domain
P06094591A0000|160 165|domain
P06094591A0000|170 184|carboxy terminus
P06095372A0435|63 80|radiation treatment
P06095774T0001|12 18|aspects
P06095774T0001|32 39|nephroma
P06096246T0000|0 5|Effect
P06096246T0000|34 39|stress
P06096246T0000|76 83|hormones
P06096380A0662|24 55|phosphoenolpyruvate carboxykinase
P06096380A0662|60 66|chicken
P06096380A0662|72 80|kilobases
P06096380A0662|83 88|length
P06096380A0662|142 147|enzyme
P06096863T0000|8 22|activation sites
P06096863T0000|28 35|CYC1 gene
P06096863T0000|113 119|TATA box
P06097027A0000|14 21|provirus
P06097027A0000|32 55|erythroblastosis virus E26
P06097027A0000|83 93|comparisons
P06097027A0000|103 121|myeloblastosis virus
P06097027A0000|140 151|tumor viruses
P06097285A1077|17 27|haloperidol
P06097285A1077|49 54|animal
P06097285A1077|56 63|capacity
P06097285A1077|95 108|motor behaviour
P06098719A0369|11 16|effect
P06098719A0369|28 45|laboratory findings
P06098828A0352|3 9|results
P06098828A0352|25 30|report
P06098828A0352|59 67|sequences
P06098828A0352|91 103|RNA polymerase
P06098828A0352|129 136|elements
P06099656T0000|0 11|Construction
P06099656T0000|19 27|cell lines
P06099656T0000|53 83|adenovirus DNA binding protein gene
P06099656T0000|86 101|cotransformation
P06099656T0000|109 119|HSV-1 tk gene
P06101359T0000|0 8|Diagnosis
P06101359T0000|12 20|treatment
P06101359T0000|40 46|tumours
P06108610A0518|0 7|Theories
P06108610A0518|32 50|modality shift effect
P06109017A0000|3 9|effects
P06109017A0000|27 32|beta-1
P06109017A0000|43 49|agonist
P06109017A0000|50 65|4-hydroxyphenoxy
P06109017A0000|65 89|isopropylamino-2-propanol
P06109017A0000|94 104|prenalterol
P06109017A0000|138 149|measurements
P06109017A0000|171 178|pressure
P06109017A0000|178 185|diameter
P06109017A0000|186 190|dP/dt
P06109017A0000|191 198|velocity
P06109017A0000|219 226|pressure
P06109017A0000|232 240|blood flow
P06109017A0000|244 252|heart rate
P06110026T0000|0 9|Endorphins
P06110026T0000|15 22|approach
P06110026T0000|25 29|death
P06111283T0032|0 13|Trial treatment
P06111283T0032|16 28|schizophrenia
P06111283T0032|33 55|des-Tyr-gamma-endorphin
P06113084T0000|7 19|taurine levels
P06113084T0000|34 55|calcium binding activity
P06113084T0000|78 91|cardiomyopathy
P06113443T0000|0 9|Separation
P06113443T0000|28 39|erythrocytes
P06113443T0000|49 53|blood
P06113443T0000|92 110|separation technique
P06119262T0000|3 15|roll-over test
P06119262T0000|25 31|toxemia
P06119262T0000|34 42|pregnancy
P06120429T0000|3 20|thyroglobulin assay
P06120429T0000|35 45|radioiodine
P06120429T0000|53 60|patients
P06120429T0000|79 91|thyroid cancer
P06121577A0280|12 21|reductions
P06121577A0280|41 53|blood pressure
P06121577A0280|75 79|doses
P06121577A0280|152 160|decreases
P06121577A0280|157 165|heart rate
P06121577A0280|169 187|plasma renin activity
P06130348T0000|0 8|Isolation
P06130348T0000|11 19|Aeromonas
P06130348T0000|24 29|faeces
P06131038A0000|0 5|Plasma
P06131038A0000|9 30|erthrocyte lipid profile
P06131038A0000|34 58|lipoprotein lipase activity
P06131038A0000|61 77|postheparin plasma
P06131038A0000|92 98|rabbits
P06131038A0000|120 128|incidence
P06131038A0000|131 145|atherosclerosis
P06131378A0818|44 52|sequences
P06131378A0818|68 75|DHFR cDNA
P06131378A0818|88 109|polyadenylation signals
P06131378A0818|127 134|DHFR cDNA
P06136374A0151|6 22|water temperatures
P06136374A0151|59 74|swimming velocity
P06137028A0624|0 10|Propranolol
P06137028A0624|47 52|tremor
P06138015T0114|5 10|report
P06138313A0948|3 19|distribution phase
P06138313A0948|34 49|elimination phase
P06138313A0948|65 73|half-life
P06138313A0948|74 82|mean value
P06138313A0948|95 100|volume
P06138313A0948|102 113|distribution
P06141764A0339|0 26|Hybrid-selection experiments
P06141764A0339|73 82|plasmid DNA
P06141764A0339|93 98|clones
P06141764A0339|121 131|information
P06142279T0000|8 20|HTLV infection
P06142279T0000|22 29|patients
P06142279T0000|32 44|haemodialysis
P06143734T0000|7 16|metabolism
P06143734T0000|19 30|progesterone
P06143734T0000|52 57|testis
P06147504A0086|3 10|patients
P06147504A0086|23 29|therapy
P06147504A0086|44 50|reasons
P06150069A0422|3 10|patients
P06150069A0422|27 31|mg/m2
P06150069A0422|41 45|weeks
P06150069A0422|50 65|dose modification
P06150069A0422|69 81|neurotoxicity
P06151518A0000|65 74|sodium salt
P06151518A0000|125 134|injections
P06151518A0000|135 142|dexazone
P06151942A0235|0 4|Serum
P06151942A0235|46 56|association
P06151942A0235|68 80|blood pressure
P06151942A0235|89 99|risk factors
P06151942A0235|109 121|blood pressure
P06151942A0235|127 137|cholesterol
P06151942A0235|138 149|triglyceride
P06151942A0235|150 158|gamma-GTP
P06151942A0235|162 168|obesity
P06152670T0000|0 13|Plasma secretin
P06152670T0000|14 25|pancreozymin
P06152670T0000|46 52|hormone
P06152670T0000|67 81|failure patients
P06152844T0000|0 5|Effect
P06152844T0000|8 17|bromazepam
P06152844T0000|20 32|growth hormone
P06152844T0000|36 53|prolactin secretion
P06152844T0000|62 69|subjects
P06153936A0784|9 13|cases
P06153936A0784|43 59|gland examinations
P06153936A0784|76 87|year interval
P06153936A0784|106 114|occasions
P06153936A0784|149 155|changes
P06155967A1132|3 14|radiologists
P06155967A1132|23 29|machine
P06155967A1132|42 58|reporting terminal
P06155967A1132|98 110|abnormalities
P06155967A1132|128 133|effort
P06158844A0000|0 10|Thalamotomy
P06158844A0000|22 33|CM-Pf complex
P06158844A0000|54 69|gamma irradiation
P06158844A0000|89 94|series
P06158844A0000|99 106|patients
P06158844A0000|128 137|malignancy
P06161823A0129|9 16|capsules
P06161823A0129|42 57|ethinyl estradiol
P06161823A0129|110 120|hypertrophy
P06162419A0118|39 45|maximum
P06162419A0118|55 59|doses
P06162419A0118|85 95|development
P06162419A0118|98 115|lymphadenosis NK/Li
P06163433T0000|0 5|Effect
P06163433T0000|8 21|p-chlorophenyl
P06163433T0000|21 36|cyclopropylamine
P06163433T0000|54 66|concentration
P06163433T0000|70 93|monoamine oxidase activity
P06163433T0000|96 103|rat brain
P06165068A0547|18 22|juice
P06165068A0547|40 47|duodenum
P06165132A0000|2 11|experiment
P06165132A0000|34 38|fowls
P06165132A0000|42 49|broilers
P06165132A0000|65 69|farms
P06165132A0000|84 93|spray lento
P06165132A0000|106 113|vaccines
P06165132A0000|129 136|immunity
P06165132A0000|144 153|pseodopest
P06165132A0000|179 190|pseudoplague
P06165132A0000|205 209|virus
P06165551A0793|4 20|inappropriateness
P06165551A0793|31 42|segmentation
P06165551A0793|49 57|isolation
P06165551A0793|60 65|spikes
P06165551A0793|74 78|waves
P06165551A0793|120 127|duration
P06165551A0793|133 142|transients
P06165551A0793|145 152|relation
P06165551A0793|158 163|length
P06165551A0793|169 174|window
P06165551A0793|193 207|autocorrelation
P06165551A0793|229 249|segmentation algorithm
P06167806A0000|3 9|ability
P06167806A0000|19 24|UM-272
P06167806A0000|25 43|dimethylpropranolol
P06167806A0000|44 52|treatment
P06167806A0000|65 73|induction
P06167806A0000|96 111|tachyarrhythmias
P06167806A0000|179 189|stimulation
P06167806A0000|214 223|infarction
P06173032T0000|3 8|effect
P06173032T0000|11 23|echothiophate
P06173032T0000|37 44|response
P06173032T0000|47 52|rabbit
P06173032T0000|59 66|pressure
P06173032T0000|69 78|dipivefrin
P06173860A0000|6 10|cases
P06173860A0000|28 37|infarction
P06173860A0000|53 70|segment depressions
P06173860A0000|81 98|contralateral leads
P06173860A0000|128 144|segment elevations
P06175691T0000|0 28|Bacillus cereus cross-infection
P06175691T0000|32 45|maternity-unit
P06181216A0070|33 40|patients
P06181216A0070|52 73|serum IgA concentrations
P06181216A0070|80 84|years
P06182979A0807|11 18|category
P06182979A0807|29 36|emphasis
P06182979A0807|55 76|anthracycline analogues
P06182979A0807|79 89|doxorubicin
P06182979A0807|93 101|analogues
P06182979A0807|104 132|cisplatinum diammine dichloride
P06184276T0001|7 12|course
P06184276T0001|15 27|plasmocytosis
P06184487A1485|42 64|HindIII-P/EcoRI-B region
P06184487A1485|68 75|AcNPV map
P06184487A1485|87 95|synthesis
P06184487A1485|106 116|30K proteins
P06184487A1485|146 156|30K proteins
P06184487A1485|188 215|HindIII-A/EcoRI-C/SstI-G cDNA
P06185014A0642|19 37|complement factor C3c
P06185014A0642|58 75|alpha 1-antitrypsin
P06185014A0642|98 105|increase
P06185493A0468|1 16|polypeptide chain
P06185493A0468|21 28|residues
P06185493A0468|41 62|yeast amino acid sequence
P06185493A0468|80 94|peptide sequence
P06185493A0468|100 113|ADP binding site
P06185493A0468|122 141|muscle pyruvate kinase
P06189698A0246|3 15|P165 component
P06189698A0246|59 68|components
P06189698A0246|87 95|amplitude
P06189698A0246|109 119|task demands
P06189698A0246|135 146|P3 amplitudes
P06191243T0000|12 22|drawing size
P06191243T0000|47 57|brain damage
P06193351A1010|16 29|administration
P06193351A1010|36 40|drugs
P06193351A1010|59 67|incidence
P06193351A1010|86 92|release
P06193351A1010|109 123|artery occlusion
P06198241A0209|5 11|fusions
P06198241A0209|26 33|plasmids
P06198241A0209|47 51|yeast
P06198241A0209|61 78|replication origins
P06198241A0209|92 98|markers
P06198241A0209|137 141|yeast
P06198241A0209|150 154|cells
P06198532A0982|37 44|tendency
P06198532A0982|63 70|patients
P06198532A0982|126 131|causes
P06198532A0982|152 160|incidence
P06198532A0982|163 177|thromboembolism
P06198532A0982|180 189|comparison
P06199132A0179|0 7|Toxicity
P06199132A0179|32 36|cases
P06199132A0179|42 49|patients
P06199132A0179|98 105|patients
P06199132A0179|113 118|sepsis
P06200300A0409|8 17|electrodes
P06200300A0409|32 44|VEP amplitudes
P06200300A0409|49 53|skull
P06200300A0409|56 70|scalp electrodes
P06203843A0757|0 7|Products
P06203843A0757|16 20|cells
P06203843A0757|27 40|transfer factor
P06203843A0757|44 54|lymphokines
P06203843A0757|91 95|group
P06203843A0757|116 121|agents
P06204120T0001|10 33|immunofluorescence method
P06204120T0001|36 49|identification
P06204120T0001|52 64|enteroviruses
P06204120T0001|67 78|cell cultures
P06208024A0168|4 11|fraction
P06208024A0168|25 34|digestions
P06208024A0168|37 41|DNase
P06208024A0168|46 52|RNase T1
P06208024A0168|86 95|hydrolysis
P06208477A0000|3 14|construction
P06208477A0000|23 29|library
P06208477A0000|32 36|mouse
P06208477A0000|77 83|Pietras
P06208477A0000|95 102|Acids Res
P06209403A0562|8 14|repeats
P06209403A0562|23 32|pseudogene
P06209403A0562|38 46|U2/4 locus
P06209499A0682|9 15|effects
P06209499A0682|18 35|transmitter release
P06209499A0682|76 88|pressor effect
P06209499A0682|98 108|bradycardia
P06209499A0682|124 134|tachycardia
P06212776A0000|2 7|Cabras
P06212776A0000|8 15|Oristano
P06212776A0000|43 51|incidence
P06212776A0000|53 64|thalassaemia
P06212776A0000|68 81|G6PD deficiency
P06212776A0000|97 102|people
P06212776A0000|126 134|knowledge
P06212776A0000|144 151|diseases
P06212776A0000|162 171|prevention
P06214605A0123|3 8|number
P06214605A0123|11 18|elements
P06214605A0123|27 31|sizes
P06214605A0123|45 57|configuration
P06214605A0123|71 76|series
P06214605A0123|83 93|experiments
P06216125A0470|2 9|addition
P06216125A0470|20 25|chance
P06216125A0470|31 37|patient
P06216125A0470|67 71|cycle
P06216125A0470|89 96|follicle
P06216125A0470|131 135|cycle
P06216125A0470|154 161|follicle
P06217859T0000|0 9|Experience
P06217859T0000|17 22|tensor
P06218005A0948|9 16|patients
P06218005A0948|30 36|L-L size
P06218005A0948|47 57|A-P diameter
P06223586A0000|0 17|Immunochemotherapy
P06223586A0000|22 34|schizophyllan
P06223586A0000|68 73|agents
P06223586A0000|99 107|tumor-C3H
P06223586A0000|109 120|mouse systems
P06223586A0460|23 32|mitomycin C
P06223586A0460|51 58|interval
P06223586A0460|72 85|administration
P06223586A0460|118 126|life-span
P06224974A0833|34 45|beta-hydroxy
P06224974A0833|45 54|metabolite
P06224974A0833|96 100|agent
P06225279A0498|12 18|surface
P06225279A0498|57 61|layer
P06225279A0498|84 89|tissue
P06227570A0523|2 9|contrast
P06227570A0523|12 21|LL patients
P06227570A0523|48 65|suppressor response
P06229542T0045|10 25|characterization
P06229542T0045|29 36|fraction
P06229542T0045|52 59|activity
P06229542T0045|69 87|template rescue assay
P06230499A0128|36 46|irradiation
P06230499A0128|63 75|fractionation
P06230499A0128|120 130|summary dose
P06230499A0128|162 168|surgery
P06230499A0128|181 191|irradiation
P06230499A0128|217 227|performance
P06230499A0128|233 238|course
P06230499A0128|257 262|period
P06230499A0128|288 294|results
P06230499A0128|320 336|dose fractionation
P06233924T0000|0 9|Fibrin gels
P06233924T0000|26 36|implication
P06233924T0000|40 58|surface hemorheology
P06233924T0000|61 66|health
P06233924T0000|70 76|disease
P06234369T0000|11 21|vaccination
P06234786A0606|0 18|Radiogallium imaging
P06234786A0606|41 50|evaluation
P06234786A0606|66 75|cell tumors
P06237518A0117|12 26|coupling reagent
P06237518A0117|122 127|system
P06237518A0117|144 153|chloramine
P06238540A0798|11 25|volume stiffness
P06238540A0798|32 57|mean wall stress relationship
P06238540A0798|98 116|wall muscle stiffness
P06238540A0798|122 147|mean wall stress relationship
P06238540A0798|169 173|slope
P06238704T0001|0 8|Synthesis
P06238704T0001|19 34|acid diethylamide
P06239545A0649|0 9|Weight loss
P06239545A0649|25 32|pressure
P06239545A0649|36 43|decrease
P06239545A0649|59 64|volume
P06239545A0649|75 80|output
P06239545A0649|115 122|activity
P06240448A0652|3 8|effect
P06240448A0652|11 19|treatment
P06240448A0652|47 52|phases
P06240448A0652|62 66|phase
P06240448A0652|72 80|reduction
P06240448A0652|83 88|LV mass
P06240448A0652|93 101|reduction
P06240448A0652|111 116|output
P06240448A0652|122 127|change
P06240448A0652|145 154|resistance
P06240448A0652|165 169|phase
P06240448A0652|183 188|LV mass
P06240448A0652|194 201|increase
P06240448A0652|211 216|output
P06240448A0652|222 238|pretreatment level
P06240448A0652|259 266|decrease
P06240448A0652|284 293|resistance
P06241900A0000|4 8|study
P06241900A0000|33 39|effects
P06241900A0000|42 52|hypothermia
P06241900A0000|56 75|chemical cardioplegia
P06241900A0000|91 98|recovery
P06241900A0000|125 133|rat hearts
P06241900A0000|155 160|period
P06241900A0000|169 177|ischaemia
P06241980A0855|0 13|Oxygen profiles
P06241980A0855|30 39|Krogh model
P06241980A0855|53 61|diffusion
P06241980A0855|96 101|models
P06241980A0855|114 122|diffusion
P06242113T0001|0 18|Cultivation technics
P06242113T0001|22 39|Codonopsis pilosula
P06244732T0000|0 15|Radioimmunoassay
P06244732T0000|18 46|serum creatine kinase B isoenzyme
P06244732T0000|52 60|diagnosis
P06244732T0000|78 87|infarction
P06245672T0000|9 28|macrophage inhibition
P06245672T0000|54 62|reduction
P06245672T0000|65 74|metastasis
P06246254A0676|0 16|Restriction enzyme
P06246254A0676|20 39|heteroduplex analyses
P06246254A0676|53 61|sequences
P06246254A0676|76 87|src sequences
P06246254A0676|102 107|center
P06246254A0676|113 122|FeSV genome
P06246254A0676|145 157|kilobase pairs
P06246254A0676|160 165|length
P06251469A0830|17 31|library isolates
P06251469A0830|51 58|IAP units
P06251469A0830|63 78|restriction sites
P06251469A0830|105 110|others
P06251469A0830|123 132|occurrence
P06251469A0830|136 143|position
P06252520T0000|0 13|Catecholamines
P06252520T0000|25 32|learning
P06252520T0000|34 39|review
P06252883A0100|26 31|strain
P06252883A0100|79 85|piglets
P06252883A0100|97 105|rotavirus
P06252883A0100|123 128|number
P06252883A0100|131 139|occasions
P06254403A0000|3 15|antibody titer
P06254403A0000|21 28|chickens
P06254403A0000|31 44|SA-11 rotavirus
P06254403A0000|86 98|blocking assay
P06254973A1757|21 33|calf thymus DNA
P06254973A1757|62 76|polynucleotides
P06254973A1757|94 105|accumulation
P06254973A1757|145 153|molecules
P06254973A1757|212 222|binding site
P06254973A1757|236 247|accumulation
P06254973A1757|266 273|residues
P06258699T0000|13 17|trial
P06258699T0000|33 43|Polybactrin
P06258699T0000|51 69|GU bladder irrigation
P06258699T0000|72 81|cystoscopy
P06258806A0963|17 25|insertion
P06258806A0963|41 47|element
P06258806A0963|56 63|terminus
P06258806A0963|107 116|expression
P06258806A0963|144 149|enzyme
P06259220A0000|4 14|experiments
P06259220A0000|26 34|influence
P06259220A0000|43 53|antagonists
P06259220A0000|82 89|reaction
P06259220A0000|111 118|exposure
P06259220A0000|131 135|shock
P06259220A0000|160 167|reaction
P06259220A0000|182 191|reexposure
P06259220A0000|194 198|shock
P06259220A0000|221 233|shock exposure
P06259220A0464|0 9|Experiment
P06259220A0464|42 49|reaction
P06259220A0464|70 83|administration
P06259220A0464|86 95|naltrexone
P06259220A0464|103 112|reexposure
P06259220A0464|115 119|shock
P06259389A0000|9 14|period
P06259389A0000|26 31|August
P06259389A0000|62 73|mouth disease
P06259389A0000|88 101|Gifu prefecture
P06270347A0740|1 14|22K polypeptide
P06270347A0740|29 46|translation product
P06270347A0740|78 88|DNA fragment
P06272844A0000|17 21|virus
P06272844A0000|30 40|chromosomes
P06272844A0000|77 87|chromosomes
P06272844A0000|106 111|extent
P06272844A0000|124 131|nuclease
P06272844A0000|132 136|MNase
P06272844A0000|137 145|digestion
P06272844A0000|200 212|SV40 chromatin
P06277159T0033|1 10|hypothesis
P06278424A0145|21 32|requirements
P06278424A0145|38 49|CH gene switch
P06278424A0145|80 91|gamma 2b genes
P06278424A0145|97 103|gamma 2b
P06278424A0145|113 124|mouse myeloma
P06278424A0145|125 130|MPC-11
P06278544T0027|0 9|Physiology
P06278544T0027|13 27|Physiopathology
P06279309A0000|3 8|genome
P06279309A0000|16 36|erythroblastosis virus
P06279309A0000|83 88|v-erbA
P06279309A0000|91 96|v-erbB
P06279309A0000|102 111|activities
P06279309A0000|137 147|oncogenesis
P06279309A0000|153 157|virus
P06281759A1086|7 11|RNase
P06281759A1086|15 25|host mutants
P06281759A1086|40 52|sib regulation
P06281759A1086|53 62|processing
P06281759A1086|68 73|PL mRNA
P06281759A1086|87 102|endoribonuclease
P06281759A1086|110 121|int mRNA decay
P06281759A1086|133 144|int synthesis
P06281786A1222|10 14|clone
P06281786A1222|15 23|lambda HHG
P06281786A1222|36 43|addition
P06281786A1222|49 60|histone genes
P06281786A1222|62 67|region
P06281786A1222|119 129|nucleotides
P06281786A1222|131 136|length
P06281891A0399|21 28|pathways
P06281891A0399|54 63|substances
P06281891A0399|68 72|roles
P06281891A0399|78 94|complex modulation
P06281891A0399|97 112|pain transmission
P06286191T0000|0 10|Restoration
P06286191T0000|27 35|functions
P06286191T0000|43 49|animals
P06286443A0498|13 27|serum ACTH levels
P06286549A0000|0 6|WR-2721
P06286549A0000|12 27|aminopropylamino
P06286549A0000|78 84|ability
P06286549A0000|107 112|testis
P06286549A0000|119 130|fibrosarcoma
P06286549A0000|136 147|tumor nodules
P06286549A0000|152 156|lungs
P06286549A0000|169 189|gamma-radiation injury
P06287212A1352|8 15|families
P06287212A1352|17 28|polypeptides
P06287212A1352|43 52|initiation
P06287212A1352|55 65|translation
P06287212A1352|68 76|AUG codons
P06287212A1352|83 91|sequences
P06287212A1352|125 130|result
P06287212A1352|131 159|transcription initiation events
P06287231A0914|2 9|addition
P06287231A0914|10 24|TRP1 RI Circle DNA
P06287231A0914|40 50|nucleosomes
P06287231A0914|65 71|spacing
P06287231A0914|101 118|bulk yeast chromatin
P06287737A0477|3 11|frequency
P06287737A0477|22 32|transfusion
P06287737A0477|42 50|hepatitis
P06287737A0477|51 59|cirrhosis
P06287737A0477|77 85|carcinoma
P06287737A0477|88 95|type NANB
P06287737A0477|138 146|incidence
P06287737A0477|153 176|posttransfusion hepatitis
P06287737A0477|255 267|liver diseases
P06287737A0477|273 279|history
P06287737A0477|282 289|jaundice
P06287737A0477|296 304|hepatitis
P06287737A0477|313 324|transfusions
P06287737A0477|356 363|type NANB
P06287737A0477|372 383|type B disease
P06290859A0426|5 22|hepatitis B patients
P06290859A0426|31 36|months
P06290859A0426|50 72|hepatitis Bs antigenaemia
P06290859A0426|96 105|antibodies
P06290859A0426|129 141|liver function
P06290899T0000|0 5|Survey
P06290899T0000|8 15|antibody
P06290899T0000|23 47|egg drop syndrome-1976 virus
P06290899T0000|53 65|chicken flocks
P06290899T0000|68 72|Japan
P06291369A0000|4 11|patients
P06291369A0000|23 49|equilibrium ventriculography
P06291369A0000|60 74|catheterization
P06291369A0000|96 106|day interval
P06291369A0000|125 132|portions
P06291369A0000|168 183|ejection fraction
P06291369A0000|233 240|pressure
P06295429A0412|3 13|combination
P06295429A0412|25 31|WR-2721
P06295429A0412|49 56|response
P06295429A0412|105 117|sensitization
P06295429A0412|127 131|doses
P06295429A0412|144 153|protection
P06295429A0412|171 175|doses
P06296833A0000|3 11|mutations
P06296833A0000|28 55|cuticle protein gene expression
P06296833A0000|93 98|strain
P06298014A0647|3 11|ensembles
P06298014A0647|37 41|forms
P06298014A0647|44 51|activity
P06298014A0647|91 95|units
P06298014A0647|103 109|columns
P06298720A0893|9 20|conservation
P06298720A0893|42 55|repeat sequence
P06298720A0893|73 92|integration mechanism
P06298720A0893|96 107|VL30 elements
P06298720A0893|111 124|MuLV proviruses
P06300662T0000|1 17|cDNA cloning vector
P06300662T0000|29 38|expression
P06300662T0000|41 51|cDNA inserts
P06300662T0000|63 67|cells
P06300836A0285|0 12|Hybridization
P06300836A0285|49 59|RR1 colonies
P06300836A0285|80 89|genome RNAs
P06300836A0285|105 112|presence
P06300836A0285|115 137|DNA clones representative
P06300836A0285|151 162|reovirus RNAs
P06300836A0285|175 193|constituent segments
P06300836A0285|199 213|rotavirus genome
P06304771A1284|7 14|sequence
P06304771A1284|15 22|GGGXGGAG
P06304771A1284|45 49|times
P06304771A1284|56 69|polyomaviruses
P06304771A1284|73 84|adenoviruses
P06304771A1284|117 130|DNA replication
P06304771A1284|136 148|transcription
P06304771A1284|164 174|JCV sequence
P06306342A1156|2 11|conclusion
P06306342A1156|17 23|studies
P06306342A1156|79 91|acid secretion
P06306342A1156|117 126|disruption
P06306342A1156|146 152|barrier
P06306342A1156|164 178|Heidenhain pouch
P06307099A1005|0 10|Lung density
P06307099A1005|64 70|animals
P06308536T0001|3 25|hepatitis A virus antibody
P06308536T0001|26 33|anti-HAV
P06308536T0001|50 62|liver diseases
P06308607A0375|3 11|junctions
P06308607A0375|35 43|sequences
P06308607A0375|60 78|DNA sequence analysis
P06308607A0375|86 96|nucleotides
P06308607A0375|104 114|p30 sequence
P06308607A0375|123 133|nucleotides
P06308607A0375|141 158|polymerase sequence
P06309020A0473|0 7|Naloxone
P06309020A0473|9 18|mg/kg bolus
P06309020A0473|21 31|mg X kg-1 X h-1
P06309020A0473|55 59|doses
P06309020A0473|65 82|lipopolysaccharide
P06309855T0000|0 18|Gel route preparation
P06309855T0000|24 29|fusing
P06309855T0000|36 48|porcelain frit
P06310159A0000|57 63|protein
P06310159A0000|69 81|retrovirus MH2
P06310457A0000|13 22|recordings
P06310457A0000|46 51|tectum
P06310553T0000|9 17|structure
P06310553T0000|33 38|origin
P06310553T0000|53 67|muscle actin gene
P06310608A0749|3 9|mutants
P06310608A0749|24 35|substitution
P06310608A0749|50 54|clone
P06310608A0749|57 65|M-MuLV DNA
P06310608A0749|99 105|viruses
P06310608A0749|105 115|Ableson MuLV
P06310608A0749|116 122|Ab-MuLV
P06310608A0749|126 132|Moloney
P06310608A0749|139 150|sarcoma virus
P06310608A0749|151 155|M-MSV
P06314276T0000|0 7|Plasmids
P06314276T0000|14 20|cloning
P06314276T0000|24 33|expression
P06314276T0000|62 66|cDNAs
P06314276T0000|72 78|control
P06314276T0000|101 112|gene promoter
P06314312A0359|14 27|soybean protein
P06314312A0359|54 59|levels
P06314312A0359|101 107|sources
P06314312A0359|127 134|purities
P06314312A0359|143 152|weight gain
P06314312A0359|155 160|chicks
P06314312A0359|163 169|average
P06314312A0359|187 200|feed efficiency
P06314312A0359|202 208|average
P06314312A0359|226 231|levels
P06316347A0852|3 11|dnaQ-lacZ
P06316347A0852|18 25|rnh-lacZ
P06316347A0852|31 35|genes
P06316347A0852|60 67|proteins
P06316347A0852|72 97|beta-galactosidase activity
P06316623A0188|7 17|prevalences
P06316623A0188|20 27|antibody
P06316623A0188|45 50|cattle
P06316623A0188|63 67|sheep
P06316623A0188|83 87|goats
P06316623A0188|101 119|immunodiffusion test
P06318078T0000|0 9|Expression
P06318078T0000|12 33|herpes simplex virus beta
P06318078T0000|37 46|gamma genes
P06318078T0000|68 72|cells
P06318078T0000|81 89|induction
P06318078T0000|94 109|alpha gene product
P06318091A0395|3 20|splice acceptor site
P06318322A0350|21 25|model
P06318322A0350|58 70|recombination
P06318322A0350|99 105|sarcoma
P06318322A0350|115 119|virus
P06318322A0350|123 131|proto-sis
P06318322A0350|139 145|introns
P06318322A0350|191 202|messenger RNA
P06319040A1627|34 47|system activity
P06319040A1627|54 73|carotid chemoreceptor
P06319040A1627|80 89|activation
P06319040A1627|109 116|reflexly
P06319040A1627|125 133|reduction
P06319040A1627|144 152|blood flow
P06319040A1627|187 194|increase
P06319040A1627|204 211|pressure
P06319071A0173|6 13|subjects
P06319071A0173|33 40|subjects
P06319071A0173|54 73|calcium stone-formers
P06319071A0173|97 105|AMP levels
P06319071A0173|119 130|counterparts
P06319071A0173|138 147|difference
P06319071A0173|199 210|units mumol/g
P06319071A0173|212 221|creatinine
P06319072A0711|17 26|morning dip
P06319072A0711|46 53|patients
P06319072A0711|78 84|changes
P06319072A0711|87 104|cell receptor number
P06319072A0711|107 114|affinity
P06319072A0711|120 126|results
P06319072A0711|142 147|groups
P06319072A0711|158 182|beta-adrenoceptor function
P06319421A0937|3 8|effect
P06319421A0937|11 21|desipramine
P06319421A0937|40 49|inhibition
P06319421A0937|60 65|uptake
P06319421A0937|75 87|amitriptyline
P06319421A0937|91 107|mianserin blockade
P06319421A0937|118 123|uptake
P06319421A0937|140 161|alpha 2-adrenoreceptors
P06319740A1331|52 61|initiation
P06319740A1331|62 74|amplification
P06319740A1331|87 109|erythroblast hyperplasia
P06319740A1331|142 146|phase
P06319740A1331|149 163|Rauscher disease
P06320380T0001|0 16|Surgical treatment
P06320380T0001|28 37|metastases
P06321505A0401|1 16|promoter sequence
P06321505A0401|17 32|Goldberg-Hogness
P06321505A0401|35 41|TATA box
P06321505A0401|54 62|base pairs
P06321505A0401|78 82|point
P06321505A0401|85 94|initiation
P06321505A0401|97 109|transcription
P06321505A0401|125 141|S1 nuclease mapping
P06321505A0401|176 188|transcription
P06321505A0401|191 200|rat PTH mRNA
P06321634A0123|18 22|mRNAs
P06321634A0123|40 53|leader sequence
P06321634A0123|59 63|bases
P06321634A0123|74 79|intron
P06321634A0123|98 102|bases
P06321634A0123|134 149|TRs/IRs sequences
P06321770A1353|3 12|expression
P06321770A1353|15 46|chloramphenicol acetyltransferase
P06321770A1353|73 81|infection
P06321770A1353|83 87|cells
P06321770A1353|103 107|virus
P06321770A1353|126 131|nature
P06321770A1353|137 145|promoters
P06322183A1070|0 13|NPT II synthesis
P06322183A1070|24 38|agar plate assays
P06322183A1070|41 59|kanamycin resistance
P06322183A1070|65 83|immunoprecipitation
P06322183A1070|89 100|NPT II protein
P06322183A1070|118 125|presence
P06322183A1070|128 135|cysteine
P06322183A1070|155 161|absence
P06323556A0126|9 19|tomographic
P06323556A0126|37 50|EOE-13 infusion
P06323556A0126|70 85|perfusion pattern
P06323556A0126|100 107|catheter
P06324089A0453|10 18|structure
P06324089A0453|39 44|region
P06324089A0453|51 58|features
P06324089A0453|97 101|genes
P06324121A0256|20 30|polypeptide
P06324121A0256|38 45|IEmRNA-5
P06324121A0256|66 70|codon
P06324121A0256|75 86|reading frame
P06324121A0256|120 125|region
P06325415A0757|11 20|difference
P06325415A0757|39 45|Ad5 DBPs
P06325415A0757|50 56|absence
P06325415A0757|62 71|Ad7 protein
P06325415A0757|76 85|amino acids
P06325415A0757|116 122|domains
P06325415A0757|128 137|Ad5 protein
P06325415A0757|138 147|amino acids
P06327039A0743|13 23|correlation
P06327039A0743|46 58|wall thickness
P06327039A0743|61 75|body surface area
P06327039A0743|81 93|blood pressure
P06327039A0743|93 101|heart rate
P06327039A0743|109 114|output
P06327039A0743|130 139|resistance
P06327039A0743|166 175|wall stress
P06327039A0743|213 226|catecholamines
P06327039A0743|244 251|patients
P06327292A0846|13 35|Shine-Dalgarno sequences
P06327292A0846|80 90|start codons
P06327638A0155|3 12|gene cat-86
P06327638A0155|48 79|chloramphenicol acetyltransferase
P06327638A0155|94 105|1.1-kilobase
P06328002A0000|21 32|sarcoma virus
P06328002A0000|51 57|passage
P06328002A0000|59 77|Moloney sarcoma virus
P06328002A0000|78 84|Mo-MuSV
P06328012A0549|13 23|EBNA protein
P06328012A0549|55 66|transfection
P06328012A0549|71 77|BamHI-K
P06328012A0549|81 93|kilobase pairs
P06328012A0549|104 117|I1f subfragment
P06328485A0277|23 40|nucleotide sequence
P06328485A0277|65 72|delta gag
P06328485A0277|109 114|MH2 DNA
P06328485A0277|116 120|order
P06328485A0277|142 150|structure
P06328485A0277|156 160|virus
P06328485A0277|216 222|viruses
P06328485A0277|237 256|chicken proto-myc gene
P06328504A0161|38 53|clone lambda PGK-1
P06328504A0161|64 70|portion
P06328504A0161|84 88|locus
P06328504A0161|92 113|phosphoglycerate kinase
P06330478A0304|3 10|patients
P06330478A0304|19 28|cimetidine
P06330478A0304|32 39|mg q.i.d.
P06330478A0304|85 89|doses
P06331684A0607|24 30|stomach
P06331684A0607|33 45|tumor antigens
P06331684A0607|49 57|screening
P06331684A0607|80 92|stomach cancer
P06333433A0000|6 13|isolates
P06333433A0000|27 41|influenzae type b
P06333433A0000|62 69|outbreak
P06333433A0000|80 103|H. influenzae type b disease
P06333433A0000|141 147|profile
P06333433A0000|155 172|lipopolysaccharide
P06333878T0000|11 22|acid overdose
P06336045A0261a|0 7|Frog type
P06336045A0261a|18 25|frog type
P06336045A0261a|50 54|units
P06336045A0261a|61 66|spikes
P06336045A0261a|76 91|indentation phase
P06336045A0261a|98 119|threshold response phase
P06336045A0261a|167 171|phase
P06336045A0261a|182 186|spike
P06336045A0261b|0 7|Frog type
P06336045A0261b|18 25|frog type
P06336045A0261b|50 54|units
P06336045A0261b|61 66|spikes
P06336045A0261b|76 91|indentation phase
P06336045A0261b|98 119|threshold response phase
P06336045A0261b|167 171|phase
P06336045A0261b|182 186|spike
P06340643A0598|17 25|extension
P06340643A0598|30 42|possibilities
P06340643A0598|70 80|donor organs
P06340703A0324|0 8|Grimelius
P06340703A0324|25 37|Masson Fontana
P06341139A0213|0 11|Blood glucose
P06341139A0213|15 27|plasma insulin
P06341139A0213|85 93|ingestion
P06341139A0213|96 103|g glucose
P06341139A0213|104 111|fructose
P06341139A0213|114 120|lactose
P06341139A0213|125 130|g honey
P06341139A0213|141 145|bread
P06341139A0213|164 171|potatoes
P06341139A0213|173 179|g apples
P06341139A0213|185 192|g carrots
P06341661T0001|37 46|acid suture
P06341661T0001|48 62|Blalock-Taussig
P06341661T0001|64 72|operation
P06342141A0226|31 43|understanding
P06342141A0226|46 66|family pathophysiology
P06342141A0226|72 82|sensitivity
P06342141A0226|86 96|specificity
P06342141A0226|109 118|techniques
P06342141A0226|127 132|safety
P06342141A0226|136 143|efficacy
P06342141A0226|157 166|modalities
P06342141A0226|177 192|family health care
P06342141A0226|281 285|needs
P06342141A0226|289 294|family
P06342141A0226|311 317|members
P06342141A0226|323 337|value judgements
P06342141A0226|360 369|importance
P06342141A0226|415 426|consequences
P06342141A0226|433 456|health care delivery system
P06342141A0226|504 519|literature review
P06342141A0226|530 536|attempt
P06342141A0226|550 556|queries
P06342141A0226|566 574|questions
P06342141A0226|585 589|study
P06345840A0348|2 9|patients
P06345840A0348|12 17|group A
P06345840A0348|35 43|heart rate
P06345840A0348|69 73|fiber
P06345840A0348|83 90|velocity
P06346427A0000|23 35|insulin levels
P06346427A0000|98 107|test-meals
P06349364A1051|5 11|results
P06349364A1051|48 54|passive
P06349364A1051|69 81|serum globulin
P06349364A1051|82 91|antibodies
P06349364A1051|103 128|group B Streptococcus antigen
P06349364A1051|171 179|infection
P06350092A0916|17 21|phase
P06350092A0916|48 57|occurrence
P06350092A0916|102 108|degrees
P06350092A0916|140 146|disease
P06350092A0916|158 168|possibility
P06350092A0916|190 194|death
P06354594A0114|5 11|oranges
P06354594A0114|12 19|mandarin
P06354594A0114|20 29|grapefruit
P06354594A0114|63 72|processing
P06355483A0134|3 7|genes
P06355483A0134|14 18|locus
P06355483A0134|56 64|sequences
P06355483A0134|82 91|base-pairs
P06355483A0134|97 101|locus
P06355483A0134|108 117|base-pairs
P06360426A0501|10 19|hydrolysis
P06360426A0501|36 42|ammonia
P06360426A0501|73 84|colour change
P06360426A0501|90 100|pH indicator
P06361318A0440|11 23|efficacy rates
P06361318A0440|38 42|cases
P06361318A0440|43 52|KS-R1 group
P06361318A0440|57 61|cases
P06361318A0440|66 70|group
P06361318A0440|75 79|cases
P06361318A0440|90 97|criteria
P06361318A0440|100 115|committee members
P06361318A0440|132 141|KS-R1 group
P06361318A0440|160 164|group
P06361318A1127|0 9|Side effect
P06361318A1127|41 48|symptoms
P06361318A1127|75 79|cases
P06361318A1127|80 89|KS-R1 group
P06361318A1127|94 98|cases
P06361318A1127|103 107|group
P06361318A1127|112 116|cases
P06361318A1127|123 135|incidence rate
P06361318A1127|156 165|KS-R1 group
P06361318A1127|184 188|group
P06361318A1127|207 216|difference
P06362143A0565|0 18|Plasma renin activity
P06362143A0565|33 40|response
P06362143A0565|58 77|isoprenaline infusion
P06362143A0565|82 89|patients
P06362239T0001|0 11|Martin Luther
P06362239T0001|18 27|physicians
P06362602T0001|0 10|Enhancement
P06362602T0001|22 29|response
P06362602T0001|41 46|action
P06362602T0001|49 64|vaccine additives
P06362602T0001|79 90|immunization
P06362602T0001|93 97|swine
P06362602T0001|105 109|swine
P06364265T0062|7 27|gamma-ray spectroscopy
P06367414A0000|0 7|Bepridil
P06367414A0000|9 25|calcium antagonist
P06367414A0000|31 39|half-life
P06367414A0000|57 61|hours
P06367414A0000|77 83|placebo
P06367414A0000|109 122|crossover trial
P06369355A0834|0 7|Analysis
P06369355A0834|10 17|proteins
P06369355A0834|31 38|plasmids
P06369355A0834|56 60|forms
P06369355A0834|66 75|trfA region
P06369355A0834|92 100|A2 protein
P06369355A0834|127 144|replication protein
P06369355A0834|147 156|plasmid RK2
P06369954T0000|0 6|Effects
P06369954T0000|24 31|pressure
P06369954T0000|49 60|hemodynamics
P06370553A0444|7 26|plasma norepinephrine
P06370553A0444|34 44|epinephrine
P06370553A0444|47 52|levels
P06370553A0444|73 79|therapy
P06370553A0444|94 103|withdrawal
P06370553A0444|103 112|guanfacine
P06370553A0444|116 122|control
P06370553A0444|123 130|plasma NE
P06370553A0444|148 152|ng/ml
P06370553A0444|153 159|plasma E
P06370553A0444|177 181|ng/ml
P06372563T0000|5 12|response
P06372563T0000|15 23|captopril
P06372563T0000|32 43|heart failure
P06372563T0000|52 61|furosemide
P06372563T0000|63 73|natriuresis
P06372563T0000|77 84|reversal
P06372563T0000|87 98|hyponatremia
P06373409A1163|0 8|Lauciello
P06373409A1163|19 27|technique
P06373409A1163|34 42|placement
P06373409A1163|66 72|amalgam
P06373409A1163|80 91|restorations
P06373409A1163|115 119|teeth
P06373855A0000|6 20|biopsy specimens
P06373855A0000|25 31|papules
P06373855A0000|38 42|dusky
P06373855A0000|52 58|lesions
P06373855A0000|67 74|patients
P06373855A0000|79 99|pityriasis lichenoides
P06373855A0000|115 119|acuta
P06373855A0000|121 125|PLEVA
P06373855A0000|146 163|immunofluorescence
P06373855A0000|167 190|immunoperoxidase technics
P06374369A1112|39 47|reduction
P06374369A1112|48 57|food intake
P06374369A1112|131 136|events
P06374418A0877|3 10|aspirate
P06374418A0877|63 68|amount
P06374418A0877|81 87|hormone
P06376227A0217|20 25|effect
P06376227A0217|27 37|PP secretion
P06376227A0217|60 69|conditions
P06379363A0415|11 15|tests
P06379363A0415|34 39|HDL-2M
P06379363A0415|78 84|therapy
P06379363A0415|104 119|diabetes mellitus
P06379363A0415|130 137|practice
P06381438A1280|0 25|Lung prostacyclin production
P06382374A0206|27 47|insulin administration
P06382374A0206|58 63|change
P06382374A0206|65 77|glucose levels
P06382374A0206|106 113|patients
P06382374A0206|133 140|disorder
P06382374A0206|159 166|patients
P06382374A0206|180 187|disorder
P06382374A0206|199 213|control subjects
P06384983T0000|0 9|Management
P06384983T0000|12 23|hypertension
P06385474T0001|8 16|treatment
P06385474T0001|19 26|children
P06385474T0001|42 48|allergy
P06388189T0001|0 14|Transplantation
P06388189T0001|17 23|kidneys
P06388189T0001|34 39|donors
P06388189T0001|47 56|recipients
P06388818A0000|3 10|patients
P06388818A0000|30 36|Hodgkin
P06388818A0000|53 61|lymphomas
P06388818A0000|108 127|chemotherapy regimens
P06388818A0000|153 164|chemotherapy
P06388818A0000|180 185|rescue
P06388818A0000|209 226|bone marrow infusion
P06391496T0000|0 5|Effect
P06391496T0000|19 25|enzymes
P06391496T0000|29 40|polypeptides
P06391496T0000|46 60|antacid activity
P06391496T0000|63 70|almagate
P06391496T0000|79 86|antacids
P06394228T0073|0 6|Results
P06394228T0073|20 24|study
P06394347A1024|0 11|Hydrallazine
P06394347A1024|29 36|increase
P06394347A1024|39 57|plasma renin activity
P06394347A1024|68 76|excretion
P06394347A1024|79 91|noradrenaline
P06395804A0382|0 13|Urease activity
P06395804A0382|27 35|organisms
P06397009A0204|5 15|description
P06397009A0204|37 47|explanation
P06397009A0204|57 72|conductor Bozzini
P06397009A0204|74 78|merit
P06397009A0204|96 104|invention
P06397009A0204|112 120|physician
P06397009A0204|143 150|medicine
P06397009A0204|171 183|possibilities
P06401749T0000|3 8|effect
P06401749T0000|11 17|lithium
P06401749T0000|23 36|osmoregulation
P06401749T0000|39 66|arginine vasopressin secretion
P06402480A0373|3 16|susceptibility
P06402480A0373|22 32|PPNG strains
P06402480A0373|53 63|antibiotics
P06402480A0373|77 90|plasmid pattern
P06402480A0373|106 114|necessity
P06402480A0373|126 137|surveillance
P06402480A0373|150 159|infections
P06402480A0373|172 181|evaluation
P06402480A0373|187 201|recommendations
P06402480A0373|218 226|treatment
P06402859A0000|0 14|Antithrombin III
P06402859A0000|23 35|plasma protein
P06402859A0000|59 67|inhibitor
P06402859A0000|70 77|thrombin
P06402859A0000|89 97|modulator
P06402859A0000|113 123|coagulation
P06404842A0127|8 15|patients
P06404842A0127|53 61|treatment
P06404842A0127|66 82|depot testosterone
P06404842A0127|113 117|weeks
P06404842A0127|129 136|duration
P06404842A0127|142 146|years
P06406060A0000|14 22|cisplatin
P06406060A0000|82 88|Sarcoma
P06407348A0516|18 22|drugs
P06407348A0516|80 89|situations
P06407348A0516|117 124|blockade
P06407348A0516|137 145|receptors
P06407348A0516|146 150|beta1
P06407348A0516|168 182|muscle receptors
P06407348A0516|183 187|beta2
P06411659A0264|2 11|facilities
P06411659A0264|15 26|measurements
P06411659A0264|31 41|consumption
P06411659A0793|20 31|energy intake
P06411659A0793|42 46|times
P06411659A0793|50 66|energy expenditure
P06411659A0793|72 78|N intake
P06411659A0793|89 97|mg/kg/day
P06412385A0356|7 14|patients
P06412385A0356|22 32|lung disease
P06412385A0356|44 57|muscle weakness
P06412385A0356|85 93|decreases
P06412385A0356|101 108|capacity
P06412385A0356|114 125|lung capacity
P06412385A0356|129 135|maximum
P06412385A0356|145 155|ventilation
P06412385A0356|169 177|increases
P06412385A0356|188 193|volume
P06412385A0356|205 224|carbon dioxide tension
P06412385A0356|225 229|PaCO2
P06412385A0356|240 249|likelihood
P06412385A0356|252 261|dependence
P06412385A0356|264 274|ventilators
P06412385A0356|275 285|atelectasis
P06412385A0356|289 297|pneumonia
P06413492A0990|0 5|Commun
P06414990A0057|14 21|analysis
P06414990A0057|32 38|TRH test
P06414990A0057|41 46|sample
P06414990A0057|58 67|volunteers
P06414990A0057|82 91|evaluation
P06414990A0057|102 107|limits
P06414990A0057|119 137|thyrotropin response
P06415299A0233|15 19|doses
P06415299A0233|22 32|doxorubicin
P06419251T0000|0 18|Movement programming
P06419251T0000|28 40|understanding
P06419251T0000|53 64|requirements
P06426493A0331|24 39|state anaesthesia
P06426493A0331|50 61|measurements
P06426493A0331|77 84|pressure
P06426493A0331|84 92|heart rate
P06426493A0331|99 103|FE'CO
P06426493A0331|126 130|group
P06426493A0331|132 139|patients
P06426493A0331|148 157|atracurium
P06426493A0331|162 167|mg kg-1
P06426493A0331|179 189|pancuronium
P06426493A0331|193 198|mg kg-1
P06428116T0000|33 46|hypothyroidism
P06428116T0000|52 57|course
P06428116T0000|68 78|thyroiditis
P06429992T0000|0 17|Gonadotropin levels
P06429992T0000|20 26|mothers
P06429992T0000|48 54|DZ twins
P06433442T0000|0 7|Freezing
P06433442T0000|10 15|plasma
P06433442T0000|30 34|yield
P06433442T0000|37 42|factor
P06434572A0157|5 12|children
P06434572A0157|42 51|categories
P06434572A0157|63 74|GH deficiency
P06434572A0157|89 103|hypopituitarism
P06434572A0157|121 137|growth retardation
P06434572A0157|160 164|delay
P06434572A0157|166 171|growth
P06434572A0157|191 197|stature
P06434572A0157|222 229|criteria
P06434572A0157|263 267|tests
P06434572A0157|270 278|GH reserve
P06434587A0551|4 10|patient
P06434587A0551|31 39|FSH levels
P06434587A0551|58 66|secretion
P06434587A0551|85 96|FSH responses
P06435565A0648|5 11|changes
P06435565A0648|19 24|result
P06435565A0648|28 35|decrease
P06435565A0648|38 46|afterload
P06435565A0648|57 64|pressure
P06435565A0648|129 138|resistance
P06435565A0648|163 170|dynes/cm
P06437579A0727|0 9|Cimetidine
P06437579A0727|24 28|night
P06437579A0727|69 79|dose regimen
P06437579A0727|89 105|patient compliance
P06437579A0727|122 130|treatment
P06439114A0677|0 10|Ceftazidime
P06439114A0677|16 22|promise
P06439114A0677|37 43|therapy
P06439114A0677|76 85|infections
P06439135A0250|0 10|Regional CBF
P06439135A0250|26 34|clearance
P06439135A0250|37 41|xenon
P06439135A0250|49 56|patients
P06439135A0250|75 80|bypass
P06439135A0250|89 98|procedures
P06441624A0263|3 9|results
P06441624A0263|22 29|serum BGP
P06441624A0263|41 51|measurement
P06441624A0263|54 67|bone metabolism
P06443550T0000|3 12|management
P06443550T0000|25 31|patient
P06443639T0001|0 4|Study
P06443639T0001|16 23|motility
P06443639T0001|35 42|movement
P06443639T0001|54 70|circuit television
P06443714T0001|9 28|Rhodnius prolixus Stal
P06443714T0001|35 50|babassu palm trees
P06444119A0340|13 20|organism
P06444119A0340|41 50|preference
P06444119A0340|54 64|requirement
P06444119A0340|68 78|temperature
P06444119A0340|79 86|salinity
P06444119A0340|99 107|nutrients
P06444119A0340|110 122|growth factors
P06444119A0340|129 142|toxin formation
P06444119A0340|173 179|factors
P06446048A0356|32 38|by-pass
P06446048A0356|48 55|solution
P06446048A0356|101 107|problem
P06451557A0777|0 10|Deformities
P06451557A0777|26 34|olecranon
P06451557A0777|50 56|process
P06451557A0777|73 79|De Palma
P06451557A0777|84 89|Jordan
P06451557A0777|94 100|Ahlberg
P06451557A0777|105 111|Weseloh
P06452461A0930|19 29|correlation
P06452461A0930|32 37|LVM/M2
P06452461A0930|50 56|pre-AVR
P06452461A0930|59 72|post AVR studies
P06452827T0001|17 25|recording
P06452827T0001|28 44|Huntington choreas
P06453290A0000|3 13|development
P06453290A0000|32 43|organization
P06453290A0000|65 69|ducts
P06453290A0000|100 107|material
P06453290A0000|113 117|weeks
P06454625A0000|18 33|animal experiment
P06454625A0000|38 48|alterations
P06454625A0000|59 69|vasculature
P06454625A0000|73 82|parenchyma
P06454625A0000|88 97|hemostasis
P06454625A0000|109 136|Infrared-Contact-Coagulation
P06454625A0000|161 184|magnification angiography
P06454625A0000|185 203|magnification factor
P06459831T0001|0 13|Cardiovascular
P06459831T0001|43 51|reactions
P06459831T0001|59 74|tobacco poisoning
P06460889A0111|11 20|injections
P06460889A0111|23 27|SG-75
P06460889A0111|34 38|mg/kg
P06460889A0111|56 68|blood pressure
P06460889A0111|129 137|blood flow
P06460889A0512|2 6|doses
P06460889A0512|14 24|.3 mg/kg i.v.
P06460889A0512|25 29|SG-75
P06460889A0512|55 67|pulse pressure
P06460889A0512|68 76|heart rate
P06460889A0512|83 91|blood flow
P06460889A0512|107 114|pressure
P06460889A0512|123 132|LVdP/dt max
P06463429A0414|22 26|phase
P06463429A0414|64 68|phase
P06466804A0686|0 7|Exposure
P06466804A0686|10 20|endothelium
P06466804A0686|32 44|shear stresses
P06466804A0686|58 70|tape recording
P06466804A0686|86 98|flow waveforms
P06466804A0686|114 122|flowmeter
P06466804A0686|139 144|injury
P06466804A0686|147 156|denudation
P06466804A0686|169 173|shear
P06466804A0686|186 193|dyne/cm2
P06467241A0000|0 18|Modern cancer therapy
P06467241A0000|30 36|surgery
P06467241A0000|37 48|radiotherapy
P06467241A0000|49 60|chemotherapy
P06467241A0000|76 88|immunotherapy
P06467241A0000|92 103|hyperthermia
P06467797A0233|14 24|correlation
P06467797A0233|32 46|plasma clearance
P06467797A0233|55 70|10-hydroxylation
P06467797A0233|88 92|ratio
P06467797A0233|92 99|D/4-OH-D
P06467797A0233|102 106|urine
P06467797A0233|112 120|Ghanaians
P06467797A0233|149 154|Swedes
P06468565A0000|3 20|response properties
P06468565A0000|38 51|canal afferents
P06468565A0000|81 90|parameters
P06468565A0000|99 111|time constants
P06468565A0000|120 141|frequency gain constants
P06468565A0000|154 175|frequency gain constants
P06468632A0135|0 10|Endothelium
P06468632A0135|23 31|ear artery
P06468632A0135|48 53|rabbit
P06468632A0135|72 84|artery forceps
P06468632A0135|110 115|vessel
P06468673A0358|23 38|E2 concentrations
P06468673A0358|54 64|mucus scores
P06468673A0358|104 108|group
P06468694A0441|0 10|Stimulation
P06468694A0441|16 29|caudate nucleus
P06468694A0441|48 53|system
P06468694A0441|64 68|means
P06468694A0441|70 83|administration
P06468694A0441|86 94|dophamine
P06468694A0441|97 106|micrograms
P06468694A0441|110 118|phenamine
P06468694A0441|124 136|deterioration
P06468694A0441|166 175|components
P06468694A0441|185 193|behaviour
P06473219T0000|0 4|Value
P06473219T0000|7 23|urine glucose tests
P06473219T0000|29 38|management
P06473219T0000|49 64|diabetes mellitus
P06473252A1073|4 13|experiment
P06473252A1073|55 67|egg production
P06473252A1073|82 87|factor
P06473252A1073|104 111|ABSTRACT
P06473252A1073|126 130|WORDS
P06479362A0680|0 13|Hydrocortisone
P06479362A0680|40 61|postdenervation changes
P06479362A0680|67 80|muscle membrane
P06479362A0680|92 96|doses
P06479362A0680|102 108|hormone
P06479362A0680|124 130|changes
P06479362A0680|136 149|muscle membrane
P06479976A0386|19 29|differences
P06479976A0386|40 47|patients
P06479976A0386|84 95|survival time
P06479976A0386|104 112|diagnosis
P06479976A0386|115 121|illness
P06479976A0386|159 168|nerve signs
P06479976A0386|180 187|patients
P06480542A0000|16 20|study
P06480542A0000|23 32|apalcillin
P06480542A0000|49 56|patients
P06482179A0497|0 13|Catch-up growth
P06482179A0497|41 46|period
P06482179A0497|50 57|children
P06482179A0497|63 69|bone age
P06482179A0497|76 80|years
P06482318A0117|0 18|Thrombocyte function
P06482318A0117|35 42|patients
P06482318A0117|69 87|platelet shape change
P06482665A0735|3 10|findings
P06482665A0735|26 43|AMPH administration
P06482665A0735|63 70|increase
P06482665A0735|76 81|height
P06482665A0735|114 127|caudate nucleus
P06482665A0735|129 142|pigtail monkeys
P06482665A0735|180 188|increases
P06482665A0735|242 246|state
P06482665A0735|252 257|animal
P06483863A0000|5 15|experiments
P06483863A0000|30 39|BALB/cCrgl
P06483863A0000|42 59|BALB/cfC3HCrgl mice
P06483863A0000|81 90|injections
P06483863A0000|94 103|micrograms
P06483863A0000|106 119|beta-estradiol
P06483863A0000|217 227|concretions
P06483863A0000|222 232|Experiments
P06483863A0000|241 246|silica
P06483863A0000|247 256|Experiment
P06486932A0000|11 16|deaths
P06486932A0000|21 29|occurring
P06486932A0000|39 44|people
P06486932A0000|62 75|Malumfashi area
P06486932A0000|85 91|Nigeria
P06486932A0000|113 120|symptoms
P06486932A0000|134 138|death
P06487290A0000|8 16|estradiol
P06487290A0000|25 33|E2-17 beta
P06487290A0000|36 47|progesterone
P06487290A0000|72 97|radioimmunoassay techniques
P06487290A0000|109 115|females
P06487290A0000|140 149|trimesters
P06487290A0000|174 181|controls
P06487290A0000|197 201|phase
P06487290A0000|216 220|cycle
P06492188A0615|34 39|effect
P06492188A0615|44 49|number
P06492188A0615|52 59|implants
P06493655A0415|8 23|FHR decelerations
P06493655A0415|26 37|bradycardias
P06493655A0415|57 70|nonstress tests
P06493655A0415|95 102|patients
P06494215A0248|3 15|response chain
P06494215A0248|22 30|component
P06494215A0248|46 61|food presentation
P06494215A0248|79 86|schedule
P06494297A0939|3 9|results
P06494297A0939|19 26|kindling
P06494297A0939|56 61|effect
P06494297A0939|64 74|acquisition
P06494297A0939|77 81|HPC SS
P06494297A0939|103 108|effect
P06494297A0939|114 124|stimulation
P06494766A0241|18 27|dispersion
P06494766A0241|38 56|Hiss bundle fragments
P06494766A0241|77 82|septum
P06494766A0241|104 114|explanation
P06495195A0536|25 29|tests
P06495195A0536|34 41|activity
P06495195A0536|56 74|alkaline phosphatase
P06495195A0536|98 105|patients
P06495195A0536|141 151|liver damage
P06497671T0001|0 6|Changes
P06497671T0001|9 27|plasma cortisol level
P06497671T0001|43 51|responses
P06501086A0165|11 21|alterations
P06501086A0165|49 56|sham rats
P06501086A0165|87 97|hypertrophy
P06501086A0165|98 106|formation
P06501086A0165|119 139|vas deferens granulomas
P06501086A0165|154 165|serum protein
P06501086A0165|187 192|levels
P06501086A0165|202 221|serum electrophoresis
P06501086A0165|234 262|sperm agglutinin antibody titers
P06503329A0588|10 18|birth mass
P06503329A0588|26 33|newborns
P06503329A0588|69 80|control group
P06503885A0342|4 15|machine drift
P06503885A0342|50 54|water
P06503885A0342|61 71|temperature
P06503885A0342|115 127|x-ray tube heat
P06503885A0342|153 166|overestimation
P06503885A0342|185 193|blood flow
P06503885A0342|204 223|xenon/CT rCBF protocol
P06503885A0342|245 249|scans
P06503885A0342|265 282|interscan intervals
P06505014A1192|5 17|uncertainties
P06505014A1192|23 31|dosimetry
P06505014A1192|43 47|Vinca
P06506074A0456|0 11|E2 treatments
P06506074A0456|20 30|hen plasma TG
P06506074A0456|65 72|plasma TG
P06507629A0717|2 9|contrast
P06507629A0717|10 16|kidneys
P06507629A0717|47 54|acidosis
P06507629A0717|97 102|groups
P06507629A0717|111 125|mumol X min-1 X g-1
P06508393T0000|0 12|Serodiagnosis
P06508393T0000|15 29|trypanosomiasis
P06508393T0000|41 46|camels
P06508393T0000|53 76|card agglutination test set
P06508393T0000|77 87|Testryp CATT
P06513456T0001|0 20|Adenyl cyclase activity
P06513456T0001|30 35|mucosa
P06513456T0001|38 45|patients
P06513456T0001|58 62|ulcer
P06513456T0001|77 85|treatment
P06516369T0001|0 10|Proteinuria
P06516369T0001|48 55|problems
P06516847A0393|33 43|pneumococci
P06516847A0393|54 62|mortality
P06516847A0393|67 77|pneumococci
P06516977T0000|0 7|Reaction
P06516977T0000|15 22|organism
P06516977T0000|25 32|exercise
P06517816A0388|46 53|degrees C
P06517816A0388|60 66|b X min-1
P06517816A0388|100 108|g X m-2 X h-1
P06517816A0388|116 132|saline experiments
P06520418A0325|3 9|results
P06520418A0325|40 55|valve orifice area
P06520418A0325|86 93|patients
P06520418A0325|111 133|LVIT flow velocity pattern
P06520418A0325|139 146|patients
P06521802A0251|0 20|Scientific cooperation
P06521802A0251|23 41|CMEA member countries
P06521802A0251|76 86|sponsorship
P06521802A0251|92 114|Cancer Research Institute
P06521802A0251|115 127|Slovak Academy
P06521802A0251|130 137|Sciences
P06521802A0251|138 151|Czechoslovakia
P06521802A0251|161 169|framework
P06521999A0677|23 29|results
P06521999A0677|46 54|melanomas
P06521999A0677|64 74|enucleation
P06524202A0167|4 10|variant
P06524202A0167|16 28|EMG-BFB method
P06524202A0167|29 40|multichannel
P06524202A0167|80 85|method
P06524202A0167|96 103|training
P06524202A0167|112 118|muscles
P06524202A0167|130 139|spasticity
P06524202A0167|147 157|antagonists
P06524202A0167|177 193|motor coordination
P06524727A0601|0 10|Lymphocytes
P06524727A0601|19 25|species
P06524727A0601|40 48|responses
P06524727A0601|61 68|prelabel
P06524727A0601|93 108|incubation period
P06524727A0601|122 134|blood dilution
P06524761A0596|16 25|difference
P06524761A0596|31 37|quality
P06524761A0596|40 47|immunity
P06524761A0596|48 52|fever
P06524761A0596|56 69|body weight loss
P06524761A0596|80 87|hamsters
P06524761A0596|105 128|killed-toxoplasma vaccine
P06524761A0596|142 150|challenge
P06524761A0596|162 170|T-1 strain
P06524761A0596|183 189|changes
P06524761A0596|206 213|hamsters
P06524761A0596|222 243|live-toxoplasma vaccine
P06524761A0596|251 259|challenge
P06524761A0596|271 278|RH strain
P06527379T0044|11 33|proline/alanine sequence
P06527379T0044|36 48|beta B1 subunit
P06527379T0044|74 84|DNA sequence
P06527872T0000|23 33|projections
P06527872T0000|69 74|nerves
P06527872T0000|80 99|substantia gelatinosa
P06527872T0000|139 143|study
P06527872T0000|144 148|means
P06527872T0000|153 167|acid phosphatase
P06527872T0000|173 178|method
P06531286A0382|0 6|Removal
P06531286A0382|9 22|lipid fractions
P06531286A0382|25 40|plant extractions
P06531286A0382|45 50|hexane
P06531286A0382|71 76|damage
P06531286A0382|82 91|HPLC column
P06535384A1115|15 21|subtest
P06535384A1115|30 34|items
P06535384A1115|50 59|difficulty
P06535384A1115|87 91|items
P06535384A1115|107 117|possibility
P06535384A1115|120 126|success
P06535384A1115|133 140|subjects
P06535384A1115|170 177|ABSTRACT
P06535384A1115|192 196|WORDS
P06539738T0000|16 25|evaluation
P06539738T0000|28 45|chlorofluorocarbon
P06541019A0555|3 10|patients
P06541019A0555|27 34|toxicity
P06541019A0555|42 49|response
P06541932A0000|0 6|Methods
P06541932A0000|32 42|algesimetry
P06541932A0000|81 87|effects
P06541932A0000|120 129|analgesics
P06542372A0159|10 14|paper
P06542372A0159|36 48|discrepancies
P06542372A0159|69 79|terminology
P06542372A0159|101 105|terms
P06542372A0159|108 117|additivity
P06542372A0159|118 129|potentiation
P06542372A0159|139 148|similarity
P06542918A1131|25 38|discrimination
P06542918A1131|71 80|evaluation
P06542918A1131|115 125|P3 latencies
P06545651A0346|0 19|Ammonia concentration
P06545651A0346|45 54|treatments
P06545651A0346|56 62|finding
P06545651A0346|87 92|effect
P06545651A0346|95 120|protein nitrogen degradation
P06545651A0346|134 141|nitrogen
P06546392A0542|6 13|respect C
P06546392A0542|22 42|protein concentrations
P06546392A0542|61 69|cell count
P06546392A0542|70 97|erythrocyte sedimentation rate
P06546392A0542|101 111|temperature
P06546392A0542|118 131|concentrations
P06546392A0542|134 146|antiproteases
P06548953T0001|5 21|thyroid stimulator
P06548953T0001|29 43|thyroid diseases
P06555107A1227|14 27|administration
P06555107A1227|33 58|calcium antagonist Verapamil
P06555107A1227|75 79|value
P06555107A1227|91 99|treatment
P06555107A1227|104 116|beta-mimetics
P06568939A0000|0 8|Brainstem
P06568939A0000|23 31|responses
P06568939A0000|32 36|BAERs
P06568939A0000|60 77|eye movement studies
P06568939A0000|85 95|information
P06568939A0000|101 109|integrity
P06568939A0000|112 119|pathways
P06568939A0000|133 141|brainstem
P06571587T0000|0 6|Effects
P06571587T0000|9 16|ketamine
P06571587T0000|33 41|functions
P06571587T0000|45 65|body tissue oxygenation
P06571587T0000|99 108|conditions
P06579147A0060|18 25|features
P06579147A0060|29 36|problems
P06579147A0060|39 48|management
P06579147A0060|61 70|approaches
P06579147A0060|76 89|reconstruction
P06579147A0060|98 108|deformities
P06579147A0060|119 125|disease
P06579152A1061|53 62|activation
P06579152A1061|63 84|velopharyngeal activity
P06579152A1061|100 115|feed-back control
P06582285A0222|24 29|safety
P06582285A0222|73 84|D&E abortions
P06582285A0222|99 103|weeks
P06582285A0222|104 112|gestation
P06584416A0157|5 16|radiologists
P06584416A0157|24 32|knowledge
P06584416A0157|35 42|patients
P06584416A0157|52 60|treatment
P06584416A0157|70 79|angiograms
P06584416A0157|89 100|examinations
P06585277A0000|26 33|leukemia
P06585277A0000|36 46|association
P06585277A0000|67 89|acid phosphatase activity
P06585277A0000|92 96|serum
P06585277A0000|103 110|presence
P06585277A0000|120 130|bone lesions
P06585277A0000|133 147|roentgenography
P06585277A0000|160 168|existence
P06585277A0000|192 200|carcinoma
P06588306A0076|17 37|prophylactic treatment
P06588306A0076|41 47|therapy
P06588306A0076|53 64|meningopathy
P06588306A0076|73 86|AIEOP protocols
P06588501T0059|23 27|study
P06591992A0569|2 13|anisotropism
P06591992A0569|43 50|solution
P06593862T0001|0 16|Hepatitis B vaccine
P06594105A0560|13 18|values
P06594105A0560|21 28|lambda tb
P06594105A0560|33 40|degrees C
P06594105A0560|49 63|cent haematocrit
P06594105A0560|96 101|tongue
P06594105A0560|125 129|gland
P06594105A0560|144 150|gingiva
P06594105A0560|198 205|lambda cp
P06594105A0560|218 225|lambda tp
P06594105A0560|240 250|temperature
P06594105A0560|270 278|degrees C.
P06597709A0596|35 44|asbestosis
P06597709A0596|60 70|lung volumes
P06597709A0596|77 81|ratio
P06597709A0596|84 97|transfer factor
P06597709A0596|117 122|volume
P06597709A0596|126 132|results
P06597709A0596|140 151|measurements
P06597709A0596|173 177|cases
P06599282T0001|11 17|pattern
P06599282T0001|28 40|cell carcinoma
P06599282T0001|56 62|gingiva
P06600533T0000|0 9|Azygos vein
P06600533T0000|58 68|lobe bronchi
P06600533T0000|75 83|CT variant
P06602580A0664|10 16|history
P06602580A0664|30 42|complications
P06602580A0664|47 57|otitis media
P06602580A0664|73 81|frequency
P06602580A0664|89 99|individuals
P06602580A0664|104 131|alpha 1-antitrypsin deficiency
P06602580A0664|144 150|normals
P06602600A0582|3 10|Sarns 51F
P06602600A0582|21 27|cannula
P06602600A0582|49 54|system
P06602600A0582|84 91|cannulas
P06606043A0598|8 14|changes
P06606043A0598|25 35|6-positions
P06606043A0598|47 57|replacement
P06606043A0598|63 73|phenyl group
P06606043A0598|76 83|position
P06606043A0598|98 105|decrease
P06606043A0598|108 115|activity
P06607427A0000|5 15|experiments
P06607427A0000|29 35|effects
P06607427A0000|63 69|lesions
P06607427A0000|98 103|dorsal
P06607427A0000|117 127|projections
P06607427A0000|143 154|hypothalamus
P06607427A0000|158 163|cortex
P06607427A0000|180 196|body weight changes
P06607427A0000|212 220|behaviour
P06607714T0000|0 13|Limb allografts
P06607714T0000|42 54|cyclosporin A.
P06609166A0209|3 8|method
P06609166A0209|31 37|samples
P06609166A0209|45 51|volumes
P06609166A0209|54 65|acetonitrile
P06609166A0209|76 84|injection
P06609166A0209|88 98|microliters
P06609166A0209|130 152|C18 reversed-phase column
P06610347A0581|10 16|periods
P06610347A0581|22 31|AV junction
P06610347A0581|56 62|fashion
P06610347A0581|65 74|conduction
P06610347A0581|85 90|AV node
P06612373A0000|4 8|paper
P06612373A0000|42 48|variety
P06612373A0000|50 56|sources
P06612373A0000|62 67|extent
P06612373A0000|70 81|prescription
P06612373A0000|104 108|drugs
P06612373A0000|117 121|1960s
P06612373A0000|130 134|1970s
P06615053A0202|7 14|patients
P06615053A0202|34 38|hours
P06615053A0202|41 53|resuscitation
P06615053A0202|91 98|ejection
P06615053A0202|135 140|volume
P06615053A0202|140 145|RVEDVI
P06615403A0718|13 24|LAD occlusion
P06615403A0718|34 40|minutes
P06615403A0718|41 46|series
P06615403A0718|55 64|microns TMs
P06615403A0718|91 97|minutes
P06615403A0718|103 110|ligation
P06615403A0718|113 122|microns TMs
P06615403A0718|145 151|minutes
P06625058A0666|3 12|population
P06625058A0666|68 73|capita
P06627123A0000|6 15|Wistar rats
P06627123A0000|36 43|Sustacal
P06627123A0000|57 63|ethanol
P06627123A0000|70 77|calories
P06627123A0000|89 95|sucrose
P06627569T0001|6 29|type oculomotor stimulator
P06629370A0252|4 11|patients
P06629370A0252|12 16|group
P06629370A0252|28 54|basement membrane nephropathy
P06629370A0252|88 98|lamellation
P06629370A0252|104 119|basement membrane
P06629370A0252|123 129|pattern
P06629370A0252|146 151|Alport
P06629370A0252|153 160|syndrome
P06630319A0244|0 6|Brain pH
P06630319A0244|35 42|ischemia
P06630319A0244|60 64|value
P06630319A0244|83 89|animals
P06630319A0244|102 112|barbiturate
P06630319A0244|116 134|halothane anesthesia
P06634712A0557|3 9|results
P06634712A0557|24 33|importance
P06634712A0557|36 44|phosphate
P06634712A0557|48 54|calcium
P06634712A0557|71 79|secretion
P06634712A0557|96 101|uremia
P06643612A0000|25 31|methods
P06643612A0000|62 68|studies
P06643612A0000|71 80|imipramine
P06643612A0000|83 88|plasma
P06643612A0000|92 96|urine
P06648156T0034|12 18|remarks
P06652293A0353|20 24|point
P06652293A0353|36 44|responses
P06652293A0353|57 67|sensitivity
P06652293A0353|89 99|specificity
P06653755A0192|5 26|clofelin administration
P06653755A0192|30 50|autoregulation borders
P06653755A0192|68 71|i. e.
P06653755A0192|85 92|AP levels
P06654047A0694|4 13|phenomenon
P06654047A0694|30 36|variant
P06654047A0694|58 66|cell death
P06654047A0694|88 96|apoptosis
P06654047A0694|150 165|rhabdomyosarcoma
P06654686T0001|0 10|Combination
P06654686T0001|14 30|Shwachman syndrome
P06654686T0001|42 68|granulocyte function disorder
P06655634A0195|9 14|series
P06655634A0195|17 24|patients
P06655634A0195|64 81|cesarean deliveries
P06655634A0195|99 106|delivery
P06655634A0195|135 143|morbidity
P06656249T0000|0 20|Nursing home discharges
P06656249T0000|31 38|practice
P06657559A0489|0 4|Trial
P06657559A0489|6 20|broiler chickens
P06657559A0489|37 47|control feed
P06657559A0489|65 69|weeks
P06657559A0489|145 155|control feed
P06657559A0489|173 186|ppm ochratoxin A
P06657559A0489|189 197|heart rate
P06657559A0489|201 213|blood pressure
P06657559A0489|231 238|half hour
P06658029A0086|3 20|carcinogen bioassay
P06658029A0086|46 54|component
P06658029A0086|60 66|battery
P06658029A0086|82 86|tests
P06658029A0086|93 108|hazard evaluation
P06658445A0140|7 13|effects
P06658445A0140|16 22|animals
P06658445A0140|68 74|amounts
P06658445A0140|76 81|intake
P06658586T0001|0 22|Angionephroscintigraphy
P06658586T0001|28 36|diagnosis
P06658586T0001|39 46|diseases
P06658586T0001|52 57|kidney
P06659982A0231|3 10|analysis
P06659982A0231|16 24|structure
P06659982A0231|30 40|sleep period
P06659982A0231|97 101|stage
P06659982A0231|144 153|parameters
P06659982A0231|152 160|increases
P06659982A0231|180 184|phase
P06659982A0231|187 191|sleep
P06659982A0231|209 214|change
P06659982A0231|250 255|months
P06662623A0124|35 41|samples
P06662623A0124|42 48|Br-MISO
P06662623A0124|52 66|SLOWPOKE reactor
P06662623A0124|84 94|neutron flux
P06662623A0124|99 106|n cm-2 s-1
P06667015A0832|10 17|findings
P06667015A0832|31 41|sensitivity
P06667015A0832|68 76|ischaemia
P06667015A0832|82 88|surgery
P06667015A0832|105 112|recovery
P06667015A0832|131 145|serum CK-MB level
P06667868T0001|16 21|status
P06667868T0001|33 40|elements
P06667868T0001|46 50|blood
P06667868T0001|79 86|variants
P06667868T0001|107 114|exposure
P06667868T0001|117 127|BR-1 benzene
P06668316A0178|18 37|reversed-phase column
P06668316A0178|43 57|phosphate buffer
P06668316A0178|58 69|acetonitrile
P06668316A0178|76 80|phase
P06668316A0178|81 98|baseline separation
P06668316A0178|101 110|antipyrine
P06668316A0178|114 124|metabolites
P06668316A0178|199 206|standard
P06668316A0178|207 216|phenacetin
P06669864T0001|3 7|liver
P06670732A0000|13 17|study
P06670732A0000|23 30|patients
P06670732A0000|47 55|induction
P06670732A0000|57 67|anaesthesia
P06670732A0000|71 77|effects
P06670732A0000|80 87|Fentanyl
P06670732A0000|98 108|combination
P06670732A0000|110 117|Fentanyl
P06670732A0000|128 137|Droperidol
P06670732A0000|142 148|Innovar
P06670732A0000|148 157|Thalamonal
P06670732A0000|161 168|Atropine
P06670732A0000|173 181|mg/kg b.w.
P06670732A0000|206 215|parameters
P06671047A1124|5 11|results
P06671047A1124|29 36|validity
P06671047A1124|65 73|diagnosis
P06671047A1124|100 105|states
P06671047A1124|125 133|responses
P06671047A1124|136 140|CD/LD
P06671047A1124|167 175|existence
P06671047A1124|177 185|sub-group
P06671047A1124|188 200|Prolactinomas
P06671047A1124|236 240|tonus
P06671047A1124|253 263|possibility
P06671047A1124|293 299|factors
P06671047A1124|337 342|states
P06671065A0000|0 10|Serum lipids
P06671065A0000|14 25|lipoproteins
P06671065A0000|30 36|insulin
P06671065A0000|54 61|children
P06671065A0000|104 109|status
P06671065A0000|115 122|patients
P06671385A0856|40 58|plasma renin activity
P06671385A0856|118 134|body sodium content
P06671925T0000|0 21|Amikacin concentrations
P06671925T0000|24 28|serum
P06671925T0000|32 43|blister fluid
P06671925T0000|53 62|volunteers
P06671925T0000|68 75|patients
P06671925T0000|85 94|impairment
P06672094A0390|3 10|subgroup
P06672094A0390|31 36|rectus
P06672094A0390|77 93|oculomotor nucleus
P06672094A0390|107 113|neurons
P06672094A0390|137 146|fasciculus
P06672094A0390|169 175|mammals
P06674374T0000|0 28|Hepatitis B vaccination strategy
P06674374T0000|32 49|health-care workers
P06674374T0000|53 59|country
P06674374T0000|74 93|hepatitis B endemicity
P06674516A0350|13 24|drip infusion
P06674516A0350|42 47|dosage
P06674516A0350|90 97|diseases
P06674516A0350|120 124|field
P06674977A1181|10 17|families
P06674977A1181|35 43|pregnancy
P06674977A1181|43 47|table
P06674977A1181|76 84|diagnosis
P06674977A1181|84 90|table VI
P06675047A0000|3 9|authors
P06675047A0000|23 34|interference
P06675047A0000|40 49|hemoglobin
P06675047A0000|62 68|methods
P06675047A0000|70 78|Berthelot
P06675047A0000|89 97|Berthelot
P06675047A0000|112 124|determination
P06683807A0160|12 19|patients
P06683807A0160|42 51|prevalence
P06683807A0160|54 63|alcohol use
P06683876A0244|5 9|cells
P06683876A0244|20 26|microns
P06683876A0244|29 36|diameter
P06683876A0244|52 58|fission
P06683876A0244|66 73|clusters
P06683876A0244|85 97|daughter cells
P06684624A0298|16 26|mortalities
P06684624A0298|82 88|diet 41B
P06684624A0736|7 37|N-acetylglucosaminidase activity
P06684624A0736|41 52|mg creatinine
P06684624A0736|85 90|groups
P06685004A0000|3 14|associations
P06685004A0000|41 56|globulin capacity
P06685004A0000|68 80|body mass index
P06685004A0000|95 101|fitness
P06685004A0000|130 134|women
P06685177T0000|0 11|Dipetalonema
P06685177T0000|12 21|Alafilaria
P06685177T0000|22 39|hydrochoerus subgen
P06685536A0502|8 12|years
P06685536A0502|32 38|control
P06685536A0502|77 87|enucleation
P06685643A0179|3 16|concentrations
P06685643A0179|26 31|C1-INH
P06685643A0179|53 57|stage
P06685643A0179|60 66|disease
P06685643A0179|85 94|mean values
P06685643A0179|100 105|stages
P06686454A0585|17 24|activity
P06686454A0585|55 61|bacilli
P06686454A0585|77 99|Klebsiella-Enterobacter
P06686454A0585|100 107|Shigella
P06686454A0585|123 140|Serratia marcescens
P06686454A0585|144 150|Proteus
P06687953T0000|10 24|defence capacity
P06687953T0000|43 58|leukocyte enzymes
P06689413A0174|3 11|apparatus
P06689413A0174|24 29|Am-241
P06689413A0174|38 43|source
P06689413A0174|58 67|Ge detector
P06689413A0174|68 71|mm2 X
P06689413A0174|89 94|K alpha
P06689413A0174|105 110|x-rays
P06689413A0174|143 148|iodine
P06689513T0001|15 21|studies
P06689513T0001|24 34|retinopathy
P06689513T0001|46 52|infants
P06691304A0284|3 7|range
P06691304A0284|10 28|serum concentrations
P06691304A0284|33 38|values
P06691304A0284|45 50|values
P06691304A0284|62 71|deviations
P06691304A0284|79 85|analyte
P06691304A0284|100 104|males
P06691304A0284|108 114|females
P06691304A0284|126 134|age groups
P06692517T0000|3 9|effects
P06692517T0000|26 30|drugs
P06692517T0000|33 40|patients
P06692517T0000|60 66|thrombi
P06692517T0000|67 76|assessment
P06692517T0000|81 105|indium-111 platelet imaging
P06692517T0000|124 139|echocardiography
P06692631A0129|7 15|interface
P06692631A0129|32 37|stress
P06692631A0129|41 63|microstress distribution
P06694380A1483|0 7|Plasma NE
P06694380A1483|31 35|group
P06694380A1483|39 46|mg/liter
P06694380A1483|110 117|ABSTRACT
P06694380A1483|132 136|WORDS
P06694778A0000|11 30|hemodialysis patients
P06694778A0000|46 71|redistribution thallium-201
P06694778A0000|82 88|imaging
P06694778A0000|104 109|course
P06694778A0000|112 123|hemodialysis
P06698047A0445|3 17|Prolactin levels
P06698047A0445|44 48|norms
P06698047A0445|52 60|responses
P06698047A0445|99 103|cases
P06700231A0259|12 25|tumor resection
P06700231A0259|49 60|tumor nodules
P06700231A0259|70 74|sizes
P06700231A0259|98 103|months
P06700469T0000|7 27|hospital accreditation
P06702257T0001|0 14|Antithrombin III
P06702257T0001|17 26|hip surgery
P06702643A0000|8 19|infant hearts
P06702643A0000|34 49|arch interruption
P06702643A0000|69 75|carotid
P06702643A0000|93 100|arteries
P06702643A0000|101 105|type B
P06702643A0000|108 114|Celoria
P06702643A0000|118 123|Patton
P06702643A0000|142 147|artery
P06704467A0539|13 23|sensitivity
P06704467A0539|26 36|photoperiod
P06704467A0539|67 73|mammals
P06704467A0539|88 98|pineal gland
P06705456A0346|0 9|Absorption
P06707357A0180|12 23|observations
P06707357A0180|28 35|patients
P06707357A0180|58 70|regurgitation
P06707357A0180|91 106|valve replacement
P06707357A0180|118 128|differences
P06707357A0180|163 167|types
P06707357A0180|170 183|volume overload
P06709310A0000|23 31|nystagmus
P06709310A0000|37 41|onset
P06709700A0230|9 19|compartment
P06709700A0230|22 30|dimension
P06709700A0230|33 40|severity
P06709700A0230|43 52|depression
P06709700A0230|54 61|subscale
P06709700A0230|67 89|Hamilton Depression Scale
P06709700A0230|95 110|Melancholia Scale
P06709700A0230|146 155|perfection
P06709700A0230|164 177|outcome measure
P06709700A0230|194 202|treatment
P06711642A0093|11 28|immunoglobulinuria
P06711642A0093|48 58|development
P06711642A0093|61 68|azotemia
P06711642A0093|91 109|creatinine clearance
P06711642A0093|121 131|proteinuria
P06711642A0093|153 160|dipstick
P06711642A0093|198 212|urine collection
P06711642A0093|214 221|oliguria
P06712314A0148|6 11|number
P06712314A0148|18 22|cases
P06712314A0148|50 61|institutions
P06713200A0630|0 19|Epileptiform activity
P06713200A0630|43 49|laminae
P06713200A0630|59 63|layer
P06713200A0630|77 81|layer
P06713200A0630|91 101|projections
P06713200A0630|139 147|phenytoin
P06713204A0867|3 14|AD components
P06713204A0867|54 58|state
P06713204A0867|79 89|V1 component
P06714298X0000|45 51|preload
P06714298X0000|84 94|nisoldipine
P06714298X0000|97 117|micrograms X kg-1 X min-1
P06714298X0000|119 139|calcium channel blocker
P06714298X0000|161 170|nifedipine
P06714298X0000|201 208|pressure
P06714298X0000|232 241|resistance
P06714298X0000|252 261|maxLVdP/dt
P06714298X0000|286 291|output
P06714354A0194|0 6|Monkeys
P06714354A0194|62 68|removal
P06714354A0194|87 92|cortex
P06715792A0295|0 15|HBB concentration
P06715792A0295|21 27|fetuses
P06715792A0295|48 59|accumulation
P06716977A0136|3 9|samples
P06716977A0136|20 26|decline
P06716977A0136|29 48|ethanol concentration
P06716977A0136|57 62|losses
P06716977A0136|93 100|mg% range
P06718064T0001|0 16|Plasma lactoferrin
P06718064T0001|23 32|blood count
P06718064T0001|46 56|neutrophils
P06719057A0181|3 12|importance
P06719057A0181|29 44|vein phlebography
P06719057A0181|50 59|evaluation
P06719057A0181|73 81|hematuria
P06719057A0181|85 97|filing defects
P06719057A0181|112 118|urogram
P06720371T0000|0 9|Pilot study
P06720371T0000|12 27|blood coagulation
P06720371T0000|30 41|gout patients
P06721188A0200|14 21|analysis
P06721188A0200|34 38|F test
P06721188A0200|49 56|Snedecor
P06721188A0200|59 70|contrast test
P06723849A0197|12 16|tract
P06723849A0197|42 50|Formation
P06723849A0197|87 97|transection
P06726257A1179|10 18|reduction
P06726257A1179|21 39|5-hydroxytryptophan
P06726257A1179|40 44|5-HTP
P06726257A1179|45 56|accumulation
P06726257A1179|78 88|differences
P06726257A1179|90 99|inhibition
P06726257A1179|102 113|methiothepin
P06726257A1179|114 125|hypothalamus
P06726257A1179|137 142|cortex
P06726257A1179|154 161|striatum
P06726257A1179|180 209|autoreceptor antagonist activity
P06726257A1179|212 223|methiothepin
P06726257A1179|268 275|ABSTRACT
P06726257A1179|290 294|WORDS
P06726257T0000|0 6|Effects
P06726257T0000|9 20|methiothepin
P06726257T0000|32 47|acid diethylamide
P06726257T0000|50 65|serotonin release
P06726257T0000|76 93|serotonin synthesis
P06726257T0000|108 115|relation
P06726257T0000|118 146|serotonin autoreceptor function
P06728580A0291|9 15|measles
P06728580A0291|26 31|El Paso
P06728580A0291|44 50|records
P06728580A0291|72 79|criteria
P06728580A0291|86 91|result
P06728580A0291|98 105|students
P06731302A0930|2 8|patient
P06731302A0930|13 27|bradyarrhythmia
P06731302A0930|67 71|block
P06731302A0930|79 89|branch block
P06732946A0281|3 13|measurement
P06732946A0281|19 23|areas
P06732946A0281|34 39|tissue
P06732946A0281|43 54|fibrinolysis
P06732946A0281|74 78|times
P06732946A0281|104 116|magnification
P06732946A0281|126 138|image analyser
P06732946A0281|138 146|Videoplan
P06732946A0281|147 151|scale
P06734713T0000|0 9|Diclofenac
P06734713T0000|30 38|poisoning
P06735247A0803|12 44|plasma enteroglucagon concentration
P06735247A0803|52 58|minutes
P06735247A0803|70 77|patients
P06735247A0803|112 120|excretion
P06738410T0000|0 12|Blood pressure
P06738410T0000|15 22|children
P06740373A0891|6 10|study
P06740373A0891|28 34|captive
P06740373A0891|39 48|cynomolgus
P06740373A0891|83 88|rhesus
P06740373A0891|105 120|drug testing model
P06740697A0318|3 9|results
P06740697A0318|23 33|sensitivity
P06740697A0318|45 60|guinea pig strains
P06740919A0162|5 20|Amblyomma lepidum
P06740919A0162|31 36|nymphs
P06740919A0162|60 69|heartwater
P06743061A0239|10 16|percent
P06743061A0239|24 31|patients
P06743061A0239|45 51|disease
P06743061A0239|85 92|tinnitus
P06744024A0000|0 7|Morphine
P06744024A0000|30 38|ventricle
P06744024A0000|67 75|analgesia
P06744024A0000|80 91|formalin test
P06748227A0423|29 35|maximum
P06748227A0423|57 61|right
P06748227A0423|110 115|thorax
P06749072A0116|7 20|urate excretion
P06749072A0116|26 34|clearance
P06749072A0116|48 56|excretion
P06749072A0116|59 63|urate
P06749072A0116|95 108|water immersion
P06749072A0116|141 154|water immersion
P06750608A1442|0 8|Mutations
P06750608A1442|21 28|lts genes
P06750608A1442|50 58|phenotype
P06751455A0117|26 35|gallstones
P06751455A0117|54 62|remainder
P06751455A0117|65 72|patients
P06751455A0117|81 88|glucagon
P06751455A0117|94 100|placebo
P06753902A0437|5 12|patients
P06753902A0437|26 30|month
P06753902A0437|33 41|captopril
P06753902A0437|68 73|months
P06753902A0437|98 105|class IIM
P06753902A0437|125 129|death
P06754662T0001|7 30|angiolymphoid hyperplasia
P06754662T0001|35 46|eosinophilia
P06755468A0180|0 6|Regions
P06755468A0180|26 38|reading frames
P06755468A0180|58 63|intron
P06755468A0180|68 74|cob gene
P06755468A0180|77 81|yeast
P06755468A0180|90 106|amino acid homology
P06755986A0382|14 20|strains
P06755986A0382|33 38|humans
P06755986A0382|48 64|toxico-infections
P06755986A0382|107 113|strains
P06755986A0382|123 140|hospital infections
P06760394T0001|6 21|tooth replacement
P06760394T0001|44 76|International Team fur Implantologie
P06760394T0001|75 79|type F
P06762025A0171|3 35|13,14-dihydro-15-keto-metabolites
P06762025A0171|47 55|PGF2 alpha
P06762025A0171|98 103|effect
P06762321T0000|0 17|Nucleotide sequence
P06762321T0000|20 43|DNA controlling expression
P06762321T0000|46 50|genes
P06762321T0000|54 79|maltosaccharide utilization
P06762321T0000|82 94|Streptococcus
P06763897A0216|3 14|hypertension
P06763897A0216|56 66|angiotensin
P06763897A0216|73 78|analog
P06764669T0001|12 24|determination
P06764669T0001|52 64|deferoxamine B
P06764669T0001|76 82|reagent
P06767648A0734|0 11|Measurements
P06767648A0734|14 22|perfusion
P06767648A0734|52 57|values
P06767648A0734|69 75|therapy
P06772370A0342|0 5|Volume
P06772370A0342|8 19|distribution
P06772370A0342|33 37|range
P06772370A0342|76 85|correction
P06772370A0342|87 100|protein binding
P06772370A0342|101 105|range
P06772370A0342|130 134|women
P06772612A0000|0 6|Effects
P06772612A0000|9 16|dopamine
P06772612A0000|35 41|blocker
P06772612A0000|42 52|haloperidol
P06772612A0000|58 66|responses
P06772612A0000|69 93|carotid body chemoreceptors
P06772612A0000|96 102|hypoxia
P06772612A0000|106 116|hypercapnia
P06775834A0000|0 4|HLA-A
P06775834A0000|8 18|B phenotypes
P06775834A0000|24 31|patients
P06775834A0000|54 62|melanomas
P06775834A0000|88 93|regard
P06775834A0000|115 121|relapse
P06776918T0000|0 15|Trypanosoma cruzi
P06777229A0243|3 10|subjects
P06777229A0243|16 20|study
P06777229A0243|33 40|subjects
P06777229A0243|46 53|patients
P06777229A0243|72 78|disease
P06781339A0501|4 8|study
P06781339A0501|45 53|follow-up
P06781339A0501|75 83|treatment
P06781339A0501|85 92|patients
P06781339A0501|105 119|hypoventilation
P06781728A0690|3 13|alterations
P06781728A0690|16 30|differentiation
P06781728A0690|33 52|osteoprogenitor cells
P06781728A0690|68 74|failure
P06781728A0690|77 90|mineralization
P06781728A0690|119 123|rates
P06781728A0690|126 138|bone formation
P06781728A0690|151 170|fluorochrome labeling
P06782612A0142|11 17|measure
P06782612A0142|24 33|impairment
P06782612A0142|55 59|ratio
P06782612A0142|62 72|urine volume
P06782612A0142|85 100|lithium clearance
P06782869A0263|0 14|Nitrogen balance
P06782869A0263|38 50|complications
P06782869A0263|81 95|serum creatinine
P06782869A0263|95 113|creatinine clearance
P06782869A0263|114 121|serum CO2
P06782869A0263|134 141|serum LDH
P06782869A0263|143 166|serum alkaline phosphatase
P06784123A0286|0 9|Production
P06784123A0286|12 18|C mu RNAs
P06784123A0286|25 31|mu mRNAs
P06784123A0286|46 58|recombination
P06784123A0286|73 78|region
P06784123A0286|83 87|locus
P06784123A0771|9 14|C mu RNA
P06784123A0771|27 48|sequence characteristic
P06784123A0771|59 65|mu chain
P06784123A0771|82 88|species
P06784123A0771|113 118|mu chin
P06784123T0000|0 10|Transcripts
P06784123T0000|16 36|immunoglobulin C mu gene
P06784123T0000|43 51|structure
P06784123T0000|55 62|splicing
P06784123T0000|77 87|development
P06785113A0337|42 49|activity
P06785113A0337|78 82|mucus
P06785113A0337|92 99|patients
P06786756T0000|11 26|DNA rearrangement
P06786756T0000|40 52|RNA processing
P06786756T0000|58 67|expression
P06786756T0000|70 93|immunoglobulin delta genes
P06788388A0000|11 19|mechanism
P06788388A0000|22 27|action
P06788388A0000|30 37|ICRF-159
P06788388A0000|114 120|studies
P06788388A0000|130 138|compounds
P06788388A0000|144 151|interest
P06790572A0330|5 12|isolates
P06790572A0330|28 37|lincomycin
P06790572A0330|38 45|colistin
P06790572A0330|46 53|nystatin
P06790572A0330|54 66|amphotericin B
P06790572A0330|67 85|trimethoprim lactate
P06790572A0330|86 95|polymyxin B
P06790572A0330|99 108|anisomycin
P06791500A0622|3 12|evaluation
P06791500A0622|23 37|fluid delta OD450
P06791500A0622|57 67|cornerstone
P06791500A0622|78 87|management
P06793764T0001|0 9|Host lipids
P06793764T0001|23 31|infection
P06794480A0785|24 33|difference
P06794480A0785|41 48|age group
P06794480A0785|58 63|others
P06794666A0208|14 35|neuroeffector influence
P06794666A0208|41 50|myocardium
P06794666A0208|76 82|measure
P06794666A0208|87 95|intensity
P06794666A0208|101 128|neurotransmitter biosynthesis
P06794666A0208|132 139|function
P06794666A0208|142 169|cardiomyocyte adrenoreceptors
P06795119T0000|0 18|Lens aldose reductase
P06795119T0000|44 52|cataracts
P06795654A0434|0 11|Fenfluramine
P06795654A0434|14 18|doses
P06795654A0434|39 52|mg/kg/infusion
P06795654A0434|67 93|self-administration behavior
P06795654A0434|106 123|minimum requirement
P06795832A0148|5 10|course
P06795832A0148|13 22|Hepatitis A
P06795832A0148|29 39|HBe-antigen
P06795832A0148|71 84|HBe-antibodies
P06795900A0000|3 8|effect
P06795900A0000|19 58|acid cyclo-oxygenase inhibitor indomethacin
P06795900A0000|69 77|blood flow
P06795900A0000|107 112|oxygen
P06795900A0000|111 115|CMRO2
P06795971A0000|3 12|rat incisor
P06795971A0000|26 36|model system
P06795971A0000|51 61|amelgenesis
P06796300A0759|18 32|prolactin levels
P06796300A0759|35 46|nursing women
P06796300A0759|73 96|oestradiol administration
P06797063A0000|0 5|Factor
P06797063A0000|10 29|procoagulant activity
P06797063A0000|30 49|antigen concentration
P06797063A0000|53 73|von Willebrand activity
P06797063A0000|76 93|ristocetin cofactor
P06797063A0000|115 119|times
P06797063A0000|124 131|patients
P06798609A0000|53 60|protocol
P06798609A0000|75 89|gamma-vinyl GABA
P06798609A0000|106 112|mg/kg IP
P06798609A0000|141 147|periods
P06801778T0001|0 11|Significance
P06801778T0001|26 44|gas exchange reaction
P06801778T0001|55 61|loading
P06801778T0001|77 89|effectiveness
P06801778T0001|98 111|commissurotomy
P06802500T0001|0 16|Thyreoliberin VUFB
P06802500T0001|19 36|thyroid gammagraphy
P06803634A0810|2 10|silicosis
P06803634A0810|22 34|relationships
P06803634A0810|42 49|patients
P06803634A0810|74 80|respect
P06803634A0810|90 111|blood gas determinations
P06803634A0810|126 134|responses
P06803634A0810|144 148|Paco2
P06803634A0810|151 158|patients
P06803634A0810|184 192|responses
P06805504A0629|19 25|N values
P06805504A0629|39 45|mg/kg W0
P06805504A0629|67 72|weight
P06805504A0629|92 101|N excretion
P06805504A0629|132 138|mg/kg W0
P06805537T0001|0 7|Advances
P06805537T0001|10 28|hemophilia treatment
P06805537T0001|44 49|factor
P06805537T0001|54 64|concentrate
P06807149A0222|4 8|study
P06807149A0222|41 47|ability
P06807149A0222|64 68|forms
P06807149T0000|0 9|Comparison
P06807149T0000|26 37|preparations
P06807149T0000|40 59|disodium cromoglycate
P06807149T0000|65 74|prevention
P06807149T0000|93 104|bronchospasm
P06807149T0000|118 122|study
P06807192A0312|24 30|puppies
P06807192A0312|60 77|glucose utilization
P06807192A0312|116 125|conditions
P06807192A0312|125 129|Duffy
P06807659T0001|0 11|Phagocytosis
P06807659T0001|22 28|bacilli
P06807659T0001|31 41|macrophages
P06808287T0001|0 8|Detection
P06808287T0001|11 29|hemophilia A carriers
P06808529A0167|3 11|stability
P06808529A0167|14 31|isoniazid solutions
P06808529A0167|70 86|EDTA concentration
P06808529A0167|91 96|mmol/l
P06809474A1156|0 12|Bile bilirubin
P06809474A1156|39 50|haem infusion
P06809474A1156|51 57|finding
P06809474A1156|78 90|investigation
P06809586T0000|0 25|Autoimmune manipulation aids
P06809586T0000|34 51|diabetes management
P06810070A0502|5 14|properties
P06810070A0502|24 32|Cd-spores
P06810070A0502|52 64|control spores
P06810694A0328|3 10|decrease
P06810694A0328|13 27|HDL-cholesterol
P06810694A0328|42 59|VLDL-triglycerides
P06810694A0328|101 108|decrease
P06810694A0328|111 116|apo A-I
P06810694A1000|0 10|Apo A-I level
P06810694A1000|46 63|ethanol consumption
P06810694A1000|79 87|adiposity
P06812389A0658|0 4|TEMTU
P06812389A0658|31 40|teratogens
P06815368A0203|18 25|mannitol
P06815368A0203|45 52|patients
P06816053A0849|5 12|patients
P06816053A0849|29 41|drug reactions
P06816053A0849|69 76|response
P06816053A0849|81 92|mast cell test
P06816123A0526|0 7|Selenium
P06816123A0526|11 21|constituent
P06816123A0526|24 44|glutathione peroxidase
P06816123A0526|73 86|defense systems
P06816123A0526|114 118|roles
P06816123A0526|121 128|selenium
P06816442T0001|10 14|value
P06816442T0001|17 30|serum myoglobin
P06816442T0001|33 37|cases
P06816442T0001|53 59|disease
P06816609A0639|3 25|% blood pressure reduction
P06816609A0639|48 55|decrease
P06816609A0639|85 91|CBF fall
P06817410A0982|14 19|months
P06817410A0982|25 29|study
P06817410A0982|39 44|change
P06817410A0982|47 58|epidemiology
P06817410A0982|69 78|hepatitis A
P06817410A0982|110 117|increase
P06817410A0982|123 131|incidence
P06817410A0982|146 154|hepatitis
P06817410A0982|159 169|drug addicts
P06818113A0384|9 16|patients
P06818113A0384|30 38|responses
P06818113A0384|45 54|parameters
P06818113A0384|57 66|adrenaline
P06818113A0384|71 78|controls
P06818113A0384|102 124|corticosteroid treatment
P06818113A0384|141 149|responses
P06818113A0384|152 171|plasminogen activator
P06818113A0384|175 188|clotting factor
P06818113A0384|205 212|infusion
P06821147A0468|0 16|Sulphur amino acids
P06821147A0468|41 48|isolates
P06821147A0468|56 61|flours
P06822645T0039|12 39|increase growth hormone release
P06823837A0562|32 41|wavefronts
P06823837A0562|96 101|groove
P06823837A0562|105 116|outflow tract
P06825641A0076|11 28|landfill operations
P06825641A0076|70 78|knowledge
P06825641A0076|107 117|containment
P06825641A0076|123 127|waste
P06826813A0264|0 7|Vesicles
P06826813A0264|38 46|exposures
P06828396A0095|3 7|level
P06828396A0095|10 22|contamination
P06828396A0095|28 32|wound
P06828396A0095|60 82|biopsy fixation technique
P06829082A0187|21 31|hypothermia
P06829082A0187|34 41|degrees C
P06829082A0187|61 68|increase
P06829082A0187|74 104|brain tissues glutaminase activity
P06829082A0187|117 138|incubation temperatures
P06829082A0187|150 157|degrees C
P06829082A0187|197 207|hypothermia
P06830033A0661|7 18|observations
P06830033A0661|41 52|pneumothorax
P06830033A0661|57 61|cmH2O
P06830351A0397|11 17|Sugiura
P06830351A0397|19 32|classification
P06830351A0397|48 53|Type Ia
P06830351A0397|60 65|Type Ib
P06833047A0000|4 8|study
P06833047A0000|33 41|mechanism
P06833047A0000|59 68|inhibition
P06833047A0000|108 118|ventilation
P06833422T0000|0 12|Determination
P06833422T0000|17 35|alpha-hydroxy-9 beta
P06833422T0000|38 51|alpha-pregna-4
P06833422T0000|52 61|dien-3-one
P06833422T0000|64 69|plasma
P06833422T0000|80 92|ion monitoring
P06835516A0000|15 28|epidermoid cyst
P06835516A0000|44 50|cistern
P06835914A0192|0 15|Copper treatments
P06835914A0192|50 55|levels
P06835914A0192|58 69|copper intake
P06835914A0192|89 99|differences
P06835914A0192|107 116|feed intake
P06835914A0192|129 136|practice
P06835914A0192|159 166|industry
P06837312A0000|13 19|intimal
P06837312A0000|62 66|aorta
P06837312A0000|72 76|swine
P06837312A0000|92 103|vitamin D3/kg
P06837312A0000|119 132|months duration
P06837312A0000|141 146|months
P06837312A0000|149 167|vitamin D3 withdrawal
P06837312A0000|183 189|lesions
P06838388A0896|15 25|development
P06838388A0896|41 51|tissue scars
P06838388A0896|64 68|place
P06838388A0896|92 106|parenchyma areas
P06838388A0896|116 128|normalization
P06838388A0896|134 138|organ
P06838388A0896|140 148|structure
P06838388A0896|152 159|function
P06840803A0397|12 16|signs
P06840803A0397|30 37|reaction
P06840803A0397|68 80|i.v. challenge
P06842629A0446|11 24|GMBF reductions
P06842629A0446|40 44|shock
P06842629A0446|51 65|treatment groups
P06848729A0000|5 12|children
P06848729A0000|17 29|neuroblastoma
P06849842T0000|0 30|Penicillin-G degradation products
P06849842T0000|45 58|granulopoiesis
P06851280A0144|0 15|Plasma fibrinogen
P06851280A0144|45 50|method
P06851280A0144|53 57|timol
P06851280A0144|71 75|units
P06851327A0000|4 11|patients
P06851327A0000|40 48|infection
P06851327A0000|65 80|Neisseria species
P06851327A0000|108 113|period
P06853042A0282|13 25|acidification
P06853042A0282|32 40|threshold
P06853042A0282|59 81|bicarbonate reabsorption
P06853042A0282|97 101|urine
P06853042A0282|115 122|capacity
P06854957T0066|0 8|Detection
P06854957T0066|27 34|asynergy
P06854957T0066|43 58|echocardiography
P06856306T0000|3 18|Tullio phenomenon
P06856306T0000|19 29|fistula test
P06856306T0000|33 41|Hennebert
P06856306T0000|57 68|significance
P06856669A1004|5 11|results
P06856669A1004|44 53|metabolism
P06856669A1004|72 77|efflux
P06856669A1004|79 84|5-HIAA
P06856669A1004|95 100|output
P06856669A1004|124 134|circulation
P06858449A0335|0 11|Disturbances
P06858449A0335|23 32|maturation
P06858640A0262|5 9|basis
P06858640A0262|29 36|findings
P06858640A0262|40 45|origin
P06858640A0262|48 54|amyloid
P06858640A0262|86 96|fibroblasts
P06858805A0314|4 9|groups
P06858805A0314|25 29|tests
P06858805A0314|39 54|hypersensitivity
P06858805A0314|59 66|Candidin
P06858805A0314|67 77|Trycophytin
P06858805A0314|81 90|Tuberculin
P06858967A0167|0 24|Serum lactate dehydrogenase
P06858967A0167|28 44|haptoglobin levels
P06858967A0167|63 71|bilirubin
P06863087A0664|65 73|parameter
P06863087A0664|74 80|control
P06864837T0000|0 7|Efficacy
P06864837T0000|18 43|spine immobilization methods
P06868345A0000|3 10|presence
P06868345A0000|13 23|visna-maedi
P06868345A0000|26 30|Italy
P06869215A0347|4 9|levels
P06869215A0347|37 54|hypocomplementemia
P06869986A0000|11 19|platelets
P06869986A0000|57 64|collagen
P06869986A0000|82 88|lesions
P06869986A0000|103 111|ruminants
P06872800T0000|12 20|hepatitis
P06872800T0000|27 34|patients
P06872800T0000|46 57|HBV infection
P06873504T0000|12 24|relationships
P06873504T0000|44 51|acidosis
P06873504T0000|55 81|sodium metabolism alterations
P06873504T0000|84 97|liver cirrhosis
P06875478A0542|1 19|microU/l thyrotropin
P06876006A0930|0 14|Echosismography
P06876006A0930|34 42|diagnosis
P06876006A0930|68 77|sonography
P06876006A0930|91 95|cases
P06876317T0033|0 12|Relationships
P06876317T0033|34 51|deficiency syndrome
P06880563A0516|3 12|prevalence
P06880563A0516|50 57|diabetes
P06880563A0516|67 71|women
P06880563A0516|122 136|administrations
P06880563A0516|154 167|administration
P06880563A0516|170 183|chlorpropamide
P06880604A0167|1 12|reassessment
P06880604A0167|18 31|prevalence data
P06880604A0167|58 65|province
P06880604A0167|68 74|Uusimaa
P06880604A0167|90 97|province
P06880604A0167|100 104|Vaasa
P06880604A0167|108 120|prevalence day
P06880604A0167|126 132|January
P06880650A0316|3 9|results
P06880650A0316|47 57|researchers
P06882578A0464|5 23|ultramarathon runner
P06882578A0464|27 44|testosterone levels
P06882578A0464|61 69|beginning
P06882578A0464|75 89|training session
P06882578A0464|101 105|ng/ml
P06882578A0464|113 117|ng/ml
P06882578A0464|125 132|training
P06882578A0464|162 166|hours
P06882578A0464|171 175|ng/ml
P06882578A0464|195 207|hours training
P06882578A0464|211 215|ng/ml
P06883385A0509|2 9|patients
P06883385A0509|31 39|remission
P06883385A0509|45 49|tumor
P06883385A0509|53 71|neopterine excretion
P06883385A0509|87 92|values
P06884450A0234|9 15|tumours
P06884450A0234|23 29|results
P06886031A0898|5 13|PGE levels
P06886031A0898|24 28|fluid
P06886031A0898|64 75|patient group
P06886031A0898|81 85|hours
P06886031A0898|100 107|test dose
P06886031A0898|110 117|tolmetin
P06886948A0750|6 10|rates
P06886948A0750|13 22|weight gain
P06886948A0750|43 55|energy intakes
P06886948A0750|74 85|requirements
P06890622A0067|34 41|platelet
P06890622A0067|53 59|effects
P06890622A0067|99 106|ischemia
P06890622A0067|107 118|hypertension
P06890622A0067|131 141|coagulation
P06890622A0067|155 167|pre-eclampsia
P06890935T0001|0 5|Behcet
P06890935T0001|7 14|syndrome
P06891051A0587|0 7|Survival
P06891051A0587|38 46|platelets
P06891051A0587|60 67|patients
P06891051A0587|73 82|correction
P06891051A0587|85 97|platelet count
P06891270A0000|3 8|effect
P06891270A0000|28 33|stress
P06891270A0000|51 63|extensibility
P06891270A0000|66 78|contractility
P06891270A0000|101 109|rat atrium
P06895559A0000|0 10|Terbutaline
P06895559A0000|28 34|agonist
P06895559A0000|38 49|aminophyllin
P06895559A0000|51 76|phosphodiesterase inhibitor
P06895559A0000|100 110|combination
P06895559A0000|113 125|rabbit fetuses
P06895559A0000|142 150|gestation
P06895663A0810|6 12|therapy
P06895663A0810|32 42|association
P06895663A0810|87 98|significance
P06897114A0240|13 17|motif
P06897114A0240|49 70|DNA sequence recognition
P06902722T0000|13 17|phase
P06902722T0000|44 53|infarction
P06911559T0000|0 9|Statistics
P06911559T0000|13 25|nurse managers
P06916588A0304|3 15|infection rate
P06916588A0304|23 27|times
P06916588A0304|37 44|patients
P06916588A0304|49 64|Hickman catheters
P06916588A0304|87 95|catheters
P06919347T0001|14 21|planning
P06919347T0001|26 45|Laboratory Assistants
P06919347T0001|46 51|School
P06919347T0001|54 62|Stockholm
P06919347T0001|66 74|education
P06919347T0001|78 97|laboratory assistants
P06928974T0000|3 19|electrocardiogram
P06931124A0109|12 16|place
P06931124A0109|24 39|complex formation
P06931124A0109|42 49|NH4Mg PO4
P06931124A0109|63 71|reactants
P06931124A0109|73 77|water
P06935514A0000|3 9|Authors
P06935514A0000|35 42|research
P06935514A0000|53 63|preparation
P06935514A0000|99 110|desametazone
P06935514A0000|113 117|order
P06935514A0000|131 141|alterations
P06935514A0000|147 160|dentinogenesis
P06935514A0000|181 189|component
P06938948T0001|17 36|serum immunoglobulins
P06938948T0001|38 44|indices
P06938948T0001|55 62|immunity
P06938948T0001|78 83|mucosa
P06938948T0001|91 99|leukemias
P06946314T0000|0 13|Serum IgE levels
P06946314T0000|16 31|Tauranga children
P06946693T0000|7 26|prostaglandin F2 alpha
P06946693T0000|26 34|PGF2 alpha
P06946693T0000|37 42|cattle
P06948398A0523|20 29|management
P06948398A0523|32 36|blood
P06948398A0523|62 71|importance
P06948493T0026|0 4|Range
P06948493T0026|5 14|variations
P06948493T0026|28 36|potential
P06948868A0082|3 8|scores
P06948868A0082|34 44|reliability
P06948868A0082|46 63|faculty evaluations
P06950004T0047|0 4|Study
P06950004T0047|7 18|distribution
P06950004T0047|21 25|metal
P06950004T0047|31 35|teeth
P06950004T0047|45 57|iontophoresis
P06950004T0047|73 81|specimens
P06953957A0503|7 28|creatine kinase activity
P06953957A0503|67 75|myoglobin
P06953957A0503|93 100|episodes
P06953957A0503|133 141|peak value
P06953957A0503|166 176|correlation
P06957125T0000|15 23|blood flow
P06957125T0000|30 35|effect
P06957125T0000|58 73|stimulating drugs
P06957633T0001|0 10|Development
P06957633T0001|23 30|leukemia
P06957633T0001|35 41|trisomy
P06957633T0001|54 69|erythroblastosis
P06957633T0001|73 79|patient
P06957633T0001|85 91|history
P06957633T0001|102 107|anemia
P06957633T0001|110 114|years
P06959130A0996|3 21|arginyl peptide bonds
P06959130A0996|41 50|conversion
P06959130A0996|58 63|factor
P06959130A0996|81 89|factor XIa
P06959130A0996|105 117|Arg145-Ala146
P06959130A0996|121 133|Arg180-Val181
P06962492A0612|8 13|growth
P06962492A0612|36 43|eruption
P06962492A0612|76 85|hypotrophy
P06962492A0612|97 105|bone bases
P06962634A0190|12 18|methods
P06962634A0190|33 43|information
P06962634A0190|49 69|porphyrin binding sites
P06962634A0190|97 114|porphyrin transport
P06962634A0190|118 126|clearance
P06963337T0000|39 49|hyperplasia
P06963337T0000|54 65|hypertension
P06966678A0523|26 34|clearance
P06966678A0523|36 41|tracer
P06966678A0523|57 63|portion
P06966678A0523|86 90|curve
P06966678A0523|101 110|metabolism
P06966678A0523|147 152|lipids
P06966678A0523|181 187|changes
P06966678A0523|202 206|index
P06966678A0523|212 221|injections
P06966678A0523|233 238|atrium
P06966678A0523|258 263|atrium
P06966678A0523|279 285|ear vein
P06969638A0180|4 15|examinations
P06969638A0180|28 37|indicators
P06969638A0180|40 55|CNS abnormalities
P06969638A0180|79 97|meningeal infections
P06969638A0180|113 124|determinants
P06969638A0180|130 136|therapy
P06969638A0180|148 156|prognosis
P06969638A0180|163 175|complications
P06972179A0556|8 16|IgE levels
P06972179A0556|72 76|range
P06972443A0375|15 24|evaluation
P06972443A0375|37 43|carrier
P06972443A0375|60 72|abnormalities
P06972501A0615|0 10|Correlation
P06972501A0615|29 39|involvement
P06972501A0615|51 57|outcome
P06973664A0000|17 32|cleavage syndrome
P06973664A0000|52 58|patient
P06975206A0279|8 21|administration
P06975206A0279|24 36|betamethasone
P06975206A0279|45 49|weeks
P06975206A0279|68 77|absorption
P06975206A0279|80 86|calcium
P06975206A0279|90 98|phosphate
P06975206A0279|110 119|growth rate
P06977605T0000|0 9|Endorphins
P06977605T0000|18 23|issues
P06978566A0197|2 9|necropsy
P06978566A0197|34 41|F344 rats
P06978566A0197|51 61|lung lesions
P06978566A0197|79 89|maximum dose
P06978566A0197|114 118|units
P06978566A0197|120 129|M. pulmonis
P06981991A0756|0 13|Aneurysmectomy
P06981991A0756|20 30|performance
P06981991A0756|86 95|ECG changes
P06981991A0756|102 113|bypass grafts
P06981991A0756|117 123|patient
P06981991A0756|144 148|group
P06981991A0756|166 175|ECG changes
P06981991A0756|198 210|artery disease
P06981991A0756|232 236|group
P06984225A0367|0 3|REV I
P06984225A0367|7 13|vessels
P06984225A0367|35 45|patent graft
P06986168A0304|8 16|sequences
P06986168A0304|53 60|peptides
P06986168A0304|87 94|peptides
P06986168A0304|102 111|V8 protease
P06992600A0405|3 24|extraction measurements
P06992600A0405|55 67|contamination
P06992600A0405|76 82|outflow
P06993660A0000|11 19|responses
P06993660A0000|22 35|norepinephrine
P06993660A0000|36 44|serotonin
P06993660A0000|48 56|potassium
P06993660A0000|63 79|relaxant responses
P06993660A0000|81 93|isoproterenol
P06993660A0000|97 106|papaverine
P06993660A0000|154 159|strips
P06993660A0000|280 287|controls
P06994035T0001|2 16|line calculation
P06994035T0001|19 39|steroid concentrations
P06994035T0001|42 57|radioimmunoassay
P06994049T0001|0 8|Detection
P06994049T0001|21 34|hypothyroidism
P06994049T0001|50 56|infants
P06997203A0325|2 16|rubella patients
P06997203A0325|30 41|confirmation
P06997203A0325|78 82|rises
P06997203A0325|97 104|patients
P06997203A0325|110 116|PHA test
P06997203A0325|125 142|antibody conversion
P06997203A0325|155 162|patients
P07004236A0741|3 9|results
P07004236A0741|22 36|folate compounds
P07004236A0741|45 63|formate accumulation
P07004236A0741|69 76|methanol
P07004236A0741|90 105|formate oxidation
P07004236A0741|108 118|utilization
P07004236A0741|146 152|folates
P07004236A0741|157 165|treatment
P07004236A0741|175 179|cases
P07004236A0741|187 203|methanol poisoning
P07007181T0000|3 8|effect
P07007181T0000|11 25|sodium saccharin
P07007181T0000|45 54|microflora
P07007591A0324|3 18|residue functions
P07007591A0324|27 33|C-11 CPZ
P07007591A0324|35 52|In-113m transferrin
P07007591A0324|88 92|areas
P07007591A0324|94 101|interest
P07007591A0324|126 135|extraction
P07007591A0324|161 165|areas
P07007591A0324|186 192|formula
P07007591A0324|250 265|residue functions
P07007591A0324|267 277|transferrin
P07015018A0395|11 18|extracts
P07015018A0395|38 56|migration inhibition
P07015018A0395|69 74|assays
P07015262A0396|11 27|cefadroxil therapy
P07015262A0396|43 50|children
P07015262A0396|62 75|tract infection
P07015262A0396|79 87|CRP values
P07015262A0396|110 121|microgram/ml
P07015262A0396|134 138|group
P07016141A0238|11 19|blood flow
P07016141A0238|35 43|blood flow
P07016141A0238|61 65|Xenon
P07016141A0238|68 76|clearance
P07018810A0002|0 23|Plasma renin concentration
P07018810A0002|67 73|outflow
P07018810A0002|99 104|cortex
P07018810A0002|124 130|outflow
P07018810A0002|161 166|cortex
P07018810A0002|169 175|medulla
P07018810A0002|181 189|cat kidney
P07021505A0510|5 15|acclimation
P07021505A0510|23 28|supine
P07026328A0369|5 13|diabetics
P07026328A0369|19 27|infusions
P07026328A0369|43 51|plasma Ca2
P07026328A0369|62 67|mmol/1
P07026328A0369|91 98|glucagon
P07026328A0369|128 134|glucose
P07034479A1050|30 41|placebo group
P07034479A1050|68 74|AC group
P07037479T0000|3 15|cracked-tooth
P07037479T0000|16 23|syndrome
P07038189A2301|12 18|results
P07038189A2301|39 46|efficacy
P07038189A2301|49 54|safety
P07038189A2301|106 110|field
P07038684A1050|7 28|peptide map similarities
P07038684A1050|50 61|sequence data
P07038684A1050|78 83|origin
P07038684A1050|127 144|amino acid sequences
P07038684A1050|164 185|p60 initiator methionine
P07038684A1050|186 192|residue
P07040659A0212|3 10|patients
P07040659A0212|16 27|control group
P07040659A0212|46 56|improvement
P07040659A0212|80 87|patients
P07040659A0212|99 103|group
P07040659A0212|112 122|improvement
P07044389T0000|0 4|Facts
P07044389T0000|10 31|Economic Recovery Tax Act
P07044389T0000|56 67|pathologists
P07044389T0000|71 82|audiologists
P07044842A2062|3 14|relationship
P07044842A2062|29 41|complications
P07044842A2062|62 76|pathophysiology
P07044842A2062|79 85|Bartter
P07044842A2062|87 94|syndrome
P07045156A0204|32 36|assay
P07045156A0204|49 56|rat model
P07045156A0204|59 67|GBS sepsis
P07045156A0204|92 105|immunoglobulin
P07045156A0204|129 136|antibody
P07049690T0000|10 16|lesions
P07049690T0000|24 33|allografts
P07053251A0666|29 35|effects
P07053251A0666|36 45|bone marrow
P07053251A0666|62 66|tract
P07053251A0666|70 74|heart
P07053251A0666|92 96|study
P07061263A0293|12 19|pressure
P07061263A0293|54 58|cmH2O
P07061263A0293|60 71|air inflation
P07061350A0042|4 10|Science
P07061350A0042|57 62|bundle
P07061350A0042|81 89|magnitude
P07061350A0042|94 110|distortion product
P07061350A0042|111 115|f2-f1
P07061350A0042|135 142|pressure
P07062036A0072|26 29|% JIB
P07062036A0072|32 44|sham operation
P07062269A0798|34 41|receptor
P07062269A0798|53 60|naloxone
P07062269A0798|63 71|tolerance
P07062269A0798|88 98|l-methadone
P07062269A0798|119 125|effects
P07062269A0798|138 146|mechanism
P07063606T0000|0 8|Microwave
P07063606T0000|40 57|barrier alterations
P07064662A0222|22 28|lesions
P07064662A0222|41 50|occurrence
P07064662A0222|53 64|target fibres
P07064662A0222|81 87|muscles
P07064662A0222|107 116|neurolysis
P07064662A0222|122 132|dorsal roots
P07064923T0000|0 8|Diagnosis
P07064923T0000|11 44|phenylalanine hydroxylase deficiency
P07064923T0000|45 59|phenylketonuria
P07065206A0398|4 15|control sheep
P07065206A0398|20 42|plasma TXB2 concentration
P07065206A0398|60 73|ng/ml prebypass
P07065206A0398|84 88|ng/ml
P07065206A0398|104 109|bypass
P07068493A0414|27 37|breaths/min
P07068493A0414|63 67|cycle
P07068493A0414|74 84|inspiration
P07068493A0414|94 104|CO2 pressure
P07068493A0636|17 24|increase
P07068493A0636|27 43|oxygen consumption
P07068493A0636|53 60|subjects
P07068493A0636|84 92|pressures
P07068496A0000|13 18|volume
P07068496A0000|59 68|water space
P07068496A0000|74 79|sodium
P07068496A0000|83 99|sucrose indicators
P07068496A0000|123 133|rabbit lungs
P07068496A0000|148 157|techniques
P07068887A0000|15 25|reliability
P07068887A0000|26 33|validity
P07068887A0000|37 50|dimensionality
P07068887A0000|53 58|scores
P07068887A0000|85 94|inpatients
P07068887A0000|107 137|Michigan Alcoholism Screening Test
P07068887A0000|152 159|lifetime
P07068887A0000|170 183|symptomatology
P07072635A0000|7 12|method
P07072635A0000|50 63|administration
P07072635A0000|65 79|desferrioxamine
P07073520A0153|18 31|hemofiltration
P07073520A0153|37 53|substitution fluid
P07073520A0153|63 75|concentration
P07073520A0153|80 84|mEq/L
P07073520A0153|86 93|decrease
P07073520A0153|109 119|fluid volume
P07073520A0153|151 161|fluid volume
P07075024A0540|16 20|cases
P07075024A0540|30 34|fever
P07075024A0540|90 94|cases
P07075438T0000|11 31|serial xeroradiography
P07076222A0543|0 14|Recommendations
P07076222A0543|40 45|issues
P07078263T0000|19 30|deferoxamine
P07078263T0000|33 37|child
P07078263T0000|42 56|hemochromatosis
P07078263T0000|98 103|anemia
P07078263T0000|104 109|type I.
P07079595A0848|20 30|correlation
P07079595A0848|45 52|diameter
P07079595A0848|106 125|diameter measurements
P07079595A0848|137 144|sections
P07079595A0848|165 179|sperm production
P07080496A0097|15 27|investigation
P07080496A0097|30 41|lipoproteins
P07080496A0097|74 84|lipoprotein
P07080496A0097|90 98|fractions
P07080496A0097|136 142|respect
P07080496A0097|156 167|lipoproteins
P07080496A0097|183 190|infarcts
P07080496A0097|213 219|attacks
P07081327A0546|21 25|fluid
P07081327A0546|39 52|concentrations
P07081327A0546|55 64|phosphorus
P07081327A0546|79 89|differences
P07081327A0546|120 126|samples
P07084198T0000|0 13|Selenium status
P07084198T0000|16 28|thoroughbreds
P07084198T0000|34 46|United Kingdom
P07084617A0204|12 20|follow-up
P07084617A0204|21 29|parasites
P07084617A0204|44 51|patients
P07084617A0204|89 97|treatment
P07084814T0000|0 10|Preparation
P07084814T0000|20 38|phospholipid reagent
P07084814T0000|42 58|coagulation assays
P07088195T0019|13 24|consequences
P07088195T0019|26 33|UV vision
P07088195T0019|36 40|birds
P07090151A0165|6 12|turnout
P07090151A0165|14 21|morantel
P07090151A0165|31 42|release bolus
P07090151A0165|70 75|animal
P07090151A0165|87 94|category
P07094856A0115|15 19|study
P07094856A0115|30 36|fetuses
P07094856A0115|56 64|intervals
P07094856A0115|71 75|weeks
P07094856A0115|78 86|gestation
P07094905A0644|30 39|injections
P07094905A0644|87 91|cells
P07094905A0644|100 107|CA3 field
P07094905A0644|113 123|hippocampus
P07096587A0267|16 23|patients
P07096587A0267|52 66|training program
P07096587A0267|88 92|month
P07096587A0267|123 130|strategy
P07096587A0267|156 163|material
P07097182A0480|3 10|duration
P07097182A0480|17 25|amplitude
P07097182A0480|39 47|potential
P07097182A0480|95 104|overgrowth
P07105635A0412|0 6|Samples
P07105635A0412|25 34|volunteers
P07105635A0412|50 57|majority
P07105635A0412|63 70|patients
P07105635A0412|89 94|asthma
P07105635A0412|100 105|effect
P07105635A0412|115 121|beating
P07106323A0560|5 11|results
P07106323A0560|24 34|possibility
P07106323A0560|42 46|fetus
P07106323A0560|68 77|production
P07106323A0560|79 85|E3-16-G
P07106323A0560|93 101|pregnancy
P07106534A0160|36 49|growth function
P07106534A0160|65 69|curve
P07106534A0160|75 80|length
P07106534A0160|81 88|increase
P07106534A0160|102 106|curve
P07106534A0160|117 124|increase
P07107287A1083|10 14|doses
P07107287A1083|27 33|drivers
P07107287A1083|53 59|numbers
P07107287A1083|62 75|99Mo generators
P07107462A0202|3 11|steepness
P07107462A0202|27 43|dissociation curve
P07107462A0202|67 80|training period
P07107462A0202|81 88|increase
P07107773A0000|102 107|plasma
P07107773A0000|120 127|subjects
P07107773A0000|140 150|consumption
P07107773A0000|163 171|ingestion
P07107773A0000|173 181|deuterium
P07107773A0000|190 204|amine precursors
P07107773A0000|222 238|gas chromatography
P07107773A0000|243 268|resolution mass spectrometry
P07107773A0000|281 293|ion monitoring
P07107773A0000|301 346|trifluoroethyl-pentafluoropropionyl derivatives
P07109788A0333|2 8|concept
P07109788A0333|13 20|patients
P07109788A0333|45 52|vagotomy
P07109788A0333|56 67|pyloroplasty
P07110999A0160|26 34|disorders
P07110999A0160|35 46|tetraparesis
P07110999A0160|47 58|incontinence
P07110999A0160|62 80|oculomotor paralysis
P07112320A0086|0 28|CSF adenosine deaminase activity
P07112471A0639|0 18|Histamine reactivity
P07112471A0639|47 53|workers
P07112471A0639|77 85|factories
P07112471A0639|98 103|worker
P07112471A0639|132 138|factory
P07112654A0388|38 47|difference
P07112654A0388|58 67|prevalence
P07112654A0388|75 82|carriage
P07112654A0388|103 115|hospital staff
P07112654A0388|122 129|patients
P07113365A0737|0 4|Ficat
P07113365A0737|8 12|Bizou
P07113365A0737|22 31|depth index
P07113365A0737|52 63|surface angle
P07113365A0737|66 75|Brattstrom
P07113365A0737|110 116|methods
P07113365A0737|119 129|measurement
P07113897A0285|22 32|differences
P07113897A0285|52 58|studies
P07113897A0285|109 116|exercise
P07113897A0285|165 175|correlation
P07113897A0285|193 198|groups
P07113897A0285|201 206|values
P07113897A0285|207 211|rest r
P07113897A0285|217 225|exercise r
P07114083A0153|5 15|MOPP therapy
P07114083A0153|24 32|remission
P07114083A0153|35 41|Hodgkin
P07114083A0153|43 49|disease
P07114083A0153|66 78|normalization
P07114083A0153|84 106|glucocerebrosidase level
P07114083A0153|110 122|disappearance
P07114083A0153|125 131|Gaucher
P07114083A0153|133 137|cells
P07116298A1079|33 39|therapy
P07116298A1079|60 67|interval
P07116298A1079|71 78|survival
P07116298A1079|83 90|stage IVA
P07116298A1079|96 103|patients
P07116298A1079|113 133|Corynebacterium parvum
P07116298A1079|146 151|months
P07116298A1079|157 164|patients
P07116298A1079|184 189|months
P07116298A1079|194 199|months
P07116298A1079|205 212|patients
P07116298A1079|246 251|months
P07116298A1079|274 281|patients
P07116298A1079|291 296|months
P07116962A0299|3 18|COP-PAWP gradient
P07116962A0299|45 49|shock
P07116962A0299|62 69|patients
P07116962A0299|83 87|edema
P07119890T0000|15 20|method
P07119890T0000|31 38|labeling
P07119890T0000|44 53|blood cells
P07119890T0000|58 63|Tc-99m
P07124743A1223|8 12|study
P07124743A1223|16 31|glassware factory
P07124743A1223|32 44|As2O3 exposure
P07124743A1223|57 67|measurement
P07124743A1223|83 89|arsenic
P07124743A1223|93 105|determination
P07124743A1223|115 121|arsenic
P07124743A1223|128 137|evaluation
P07124743A1223|149 166|mouth contamination
P07124743A1223|168 174|arsenic
P07124743A1223|192 200|workshift
P07124743A1223|234 239|levels
P07124743A1223|243 263|microgram/g creatinine
P07124743A1223|305 310|intake
P07124743A1223|327 331|hands
P07124743A1223|349 358|absorption
P07124743A1223|366 370|lungs
P07125064T0000|30 37|findings
P07125064T0000|48 54|monkeys
P07125064T0000|67 86|Schistosoma japonicum
P07125064T0000|89 106|Schistosoma mansoni
P07125238T0000|3 10|pia mater
P07125238T0000|27 31|entry
P07125238T0000|33 44|blood vessels
P07125238T0000|66 71|system
P07126067T0000|12 23|reproduction
P07126067T0000|44 48|fever
P07126067T0000|51 60|Bali cattle
P07126413A0000|9 22|delivery system
P07126413A0000|57 61|drugs
P07126413A0000|67 71|colon
P07126413A0000|100 106|coating
P07126413A0000|124 128|resin
P07126413A0000|129 137|Eudragit S
P07130335A1081|0 13|Administration
P07130335A1081|19 46|dopamine agonist bromocriptine
P07130335A1081|59 63|times
P07130335A1081|112 129|plasma 18-OHB levels
P07130335A1081|149 153|ng/dl
P07132408A0387|32 52|magnesium cardioplegia
P07134924A0640|13 17|types
P07134924A0640|20 32|malformations
P07134924A0640|37 46|eye defects
P07134924A0640|54 60|coeloms
P07135112T0000|0 5|Repair
P07135112T0000|17 22|defect
P07136524A0180|14 23|literature
P07136524A0180|49 55|tumours
P07136524A0180|61 68|contrast
P07136524A0180|82 88|tumours
P07136524A0180|95 106|osteosarcoma
P07136524A0180|117 139|retinoblastoma survivors
P07136569A0000|2 6|Malmo
P07136569A0000|7 12|Sweden
P07136569A0000|19 32|school children
P07136569A0000|42 46|years
P07136569A0000|71 79|scoliosis
P07136569A0000|115 119|years
P07137927A0000|11 20|immunology
P07137927A0000|22 30|Singapore
P07137927A0000|50 57|serology
P07137927A0000|64 72|diagnosis
P07137927A0000|92 99|diseases
P07140060T0000|15 25|dislocation
P07140060T0000|31 37|patella
P07140493A1045|4 8|study
P07140493A1045|21 29|secretion
P07140493A1045|32 42|bicarbonate
P07140493A1045|53 59|stomach
P07140493A1045|100 112|acid secretion
P07141130A0615|12 21|evaluation
P07141130A0615|46 53|increase
P07141130A0615|59 64|number
P07141130A0615|93 97|cells
P07141130A0615|122 127|number
P07141130A0615|139 154|cells/100 microns
P07141130A0615|164 169|mucosa
P07141130A0615|176 185|mean height
P07141130A0615|201 205|cells
P07141130A0615|226 231|groups
P07143347T0000|0 5|Cramps
P07143347T0000|22 30|disorders
P07147622T0000|13 26|storage disease
P07147622T0000|29 34|cattle
P07149047A0260|10 19|dog vessels
P07149047A0260|55 62|Torr/cm2
P07149303T0000|14 19|action
P07149303T0000|22 30|lidocaine
P07149303T0000|48 55|activity
P07149303T0000|58 65|behavior
P07154928T0001|0 11|Modification
P07154928T0001|21 30|resorption
P07154928T0001|43 49|therapy
P07155579T0001|12 26|bacteriospermia
P07155579T0001|30 38|fertility
P07158726T0001|0 6|Triumph
P07158726T0001|25 30|policy
P07160491A0547|13 18|effect
P07160491A0547|66 73|increase
P07160491A0547|76 82|LD50/30
P07160491A0547|89 107|dose reduction factor
P07162146A0000|3 13|application
P07162146A0000|16 30|ultrafiltration
P07162146A0000|33 49|sample preparation
P07162146A0000|55 63|detection
P07162146A0000|67 80|quantification
P07162146A0000|83 96|ethylene glycol
P07162146A0000|99 104|plasma
P07162146A0000|107 123|gas chromatography
P07165767T0000|0 11|Mastocytosis
P07168531T0001|4 20|Onchocerca species
P07168531T0001|22 29|parasite
P07168531T0001|40 45|cattle
P07168531T0001|48 54|Senegal
P07169630A0983|21 27|absence
P07169630A0983|40 50|differences
P07169630A0983|58 67|conditions
P07169630A0983|87 96|complexity
P07172690A0547|9 14|factor
P07172690A0547|19 30|disturbances
P07172690A0547|36 41|system
P07172690A0547|44 58|energy transport
P07172690A0547|59 75|creatine phosphate
P07172690A0547|76 96|creatine phosphokinase
P07172690A0547|105 115|calcium pump
P07172690A0547|119 124|ATPase
P07172690A0547|141 149|reticulum
P07172690A0547|175 182|decrease
P07172690A0547|196 205|properties
P07172690A0547|211 220|myocardium
P07172690A0547|224 235|% restriction
P07172690A0547|246 254|blood flow
P07173729A0000|7 22|penetration tests
P07173729A0000|30 34|sperm
P07173729A0000|47 51|mucus
P07173729A0000|68 72|order
P07173729A0000|83 93|interaction
P07173729A0000|101 105|sperm
P07173729A0000|117 121|mucus
P07174046T0000|0 14|Vibrio fluvialis
P07174046T0000|15 26|group F vibrio
P07174046T0000|29 39|Maharashtra
P07174122A0000|0 18|Serum creatine kinase
P07174122A0000|40 47|subjects
P07174122A0000|52 61|laboratory
P07174122A0000|79 89|performance
P07174122A0000|92 107|bicycle ergometry
P07174122A0000|112 122|lifting task
P07174437A0181|0 8|Organisms
P07174437A0181|30 36|bobcats
P07174437A0181|52 59|counties
P07175474A0102|3 7|cause
P07175474A0102|10 14|death
P07175474A0102|70 77|findings
P07175474A0102|88 93|manner
P07175474A0102|96 100|death
P07175474A0102|123 130|official
P07175474A0102|135 144|difficulty
P07179412A1131|33 42|population
P07180901A0539|25 33|blood flow
P07180901A0539|62 84|prostaglandin synthetase
P07180901A0539|95 101|effects
P07180901A0539|104 112|ibuprofen
P07180901A0539|130 137|necrosis
P07181985A0107|8 23|mg mitomycin/20 ml
P07181985A0107|33 37|water
P07181985A0107|42 48|mg/40 ml
P07181985A0107|58 62|water
P07181985A0107|89 95|bladder
P07181985A0107|101 108|catheter
P07182523A0462|4 9|groups
P07182523A0462|54 58|times
P07182523A0462|60 75|SOA concentration
P07183576A0157|16 28|concentration
P07183576A0157|31 44|flucloxacillin
P07183576A0157|55 63|operation
P07183576A0157|71 83|micrograms/ml
P07183576A0157|102 106|fluid
P07183576A0157|109 120|micrograms/g
P07183576A0157|131 138|synovium
P07183576A0157|141 152|micrograms/g
P07183576A0157|185 196|micrograms/g
P07184375T0001|12 16|study
P07184375T0001|19 29|vincristine
P07184375T0001|30 41|methotrexate
P07184375T0001|45 56|prednisolone
P07184375T0001|63 85|combination chemotherapy
P07184375T0001|112 119|lymphoma
P07184598T0001|8 16|secretion
P07184598T0001|19 33|hyperthyroidism
P07184774T0000|0 13|Re-examination
P07184774T0000|19 27|ED01 study
P07184795A0517|10 23|determinations
P07184795A0517|27 33|control
P07184795A0517|38 53|serum CPK activity
P07184795A0517|69 73|liter
P07190627T0000|8 12|study
P07190627T0000|15 41|plasminogen activator release
P07190627T0000|54 59|agents
P07190627T0000|81 86|dog leg
P07190869A0316|23 27|agent
P07190869A0316|41 48|lymphoma
P07191183A0505|0 8|Treatment
P07191183A0505|11 20|meat muscle
P07191183A0505|80 91|autoxidation
P07191183A0505|91 96|lipids
P07191804A0000|11 18|response
P07191804A0000|34 52|bicycle exercise test
P07191804A0000|71 76|cadets
P07191804A0000|87 92|course
P07191804A0000|113 120|activity
P07191804A0000|133 138|h sleep
P07191972A0391|11 21|temperature
P07191972A0391|26 33|degrees C
P07191972A0391|37 45|responses
P07191972A0391|54 60|cooling
P07191972A0391|84 88|phase
P07192369T0000|1 6|method
P07192369T0000|41 48|toxicity
P07192369T0000|65 78|administration
P07192369T0000|81 102|l-alpha-acetylmethadol
P07192722A0682|23 39|parathyroidectomy
P07192722A0682|52 59|decrease
P07192722A0682|62 76|serum iPTH levels
P07192722A0682|90 94|group
P07192722A0682|107 113|ability
P07192722A0682|115 119|group
P07194905A0332|40 49|indication
P07194905A0332|51 64|tissue necrosis
P07194905A0332|95 104|hemorrhage
P07194905A0332|115 129|brain maturation
P07195615A0087|3 8|number
P07195615A0087|39 46|increase
P07195615A0087|51 58|duration
P07195615A0087|61 76|Cd administration
P07195615A0087|79 89|association
P07195615A0087|101 112|accumulation
P07195615A0087|153 158|region
P07195615A0087|162 166|brain
P07195880A0621|39 43|means
P07195880A0621|50 56|leprosy
P07202224A0452|3 13|preferences
P07202224A0452|27 35|vis-a-vis
P07202224A0452|45 49|males
P07202224A0452|56 65|injections
P07202224A0452|83 91|castrates
P07202224A0452|91 104|attractiveness
P07202224A0452|110 116|females
P07202525A0200|4 8|trial
P07202525A0200|20 24|light
P07202525A0200|28 33|buzzer
P07202525A0200|41 47|seconds
P07202525A0200|61 67|stimuli
P07202525A0200|79 83|shock
P07202525A0200|91 97|seconds
P07202525A0200|115 122|stimulus
P07202919A0142|0 4|Ulcer
P07202919A0142|18 24|angulus
P07202919A0142|30 36|stomach
P07202919A0142|65 73|ulcer scar
P07202919A0142|78 85|42nd week
P07203410T0000|0 11|Family visits
P07203410T0000|15 25|involvement
P07203410T0000|28 36|treatment
P07203410T0000|39 46|patients
P07203410T0000|50 62|state hospital
P07205120T0000|12 18|overlay
P07205120T0000|31 39|amplitude
P07205120T0000|42 53|ECG wave forms
P07205967T0000|7 14|reaction
P07205967T0000|37 43|partner
P07205967T0000|46 53|response
P07205967T0000|56 66|improvement
P07205967T0000|92 98|partner
P07208984A0000|0 4|Brain
P07208984A0000|42 48|albumin
P07208984A0000|49 56|MAA brain
P07208984A0000|72 88|tomography studies
P07208984A0000|110 117|patients
P07208984A0000|133 140|diseases
P07214230T0000|0 9|Inhibition
P07214230T0000|12 33|Fusarium moniliforme var
P07214230T0000|40 51|subglutinans
P07214230T0000|61 65|agent
P07214230T0000|72 82|pitch canker
P07214230T0000|88 114|soil bacterium Arthrobacter sp
P07214665A0000|12 22|combination
P07214665A0000|25 56|fluorouracil imidazole carboxamide
P07214665A0000|65 72|triazeno
P07214665A0000|73 83|vincristine
P07214665A0000|84 109|bis-chloroethyl nitrosourea
P07214665A0000|113 122|prednisone
P07214665A0000|146 150|women
P07214665A0000|163 174|breast cancer
P07217329A0000|1 6|method
P07217329A0000|36 48|determination
P07217329A0000|52 71|alpha-acetylmethadol
P07217329A0000|91 101|metabolites
P07217329A0000|101 117|noracetylmethadol
P07217329A0000|118 136|dinoracetylmethadol
P07217329A0000|137 144|methadol
P07217329A0000|145 155|normethadol
P07217329A0000|159 171|dinormethadol
P07217329A0000|174 182|biofluids
P07217329A0000|207 220|chromatography
P07217329A0000|239 244|column
P07217329A0000|249 258|UV detector
P07217523A0364|0 6|Results
P07217523A0364|12 26|recognition task
P07217523A0364|46 52|effects
P07217523A0364|64 70|voicing
P07217523A0364|71 78|position
P07217523A0364|82 93|vowel context
P07217523A0364|104 114|recognition
P07218008T0000|6 23|response properties
P07218008T0000|26 32|neurons
P07218008T0000|57 61|areas
P07218008T0000|67 75|owl monkey
P07218008T0000|76 91|Aotus trivirgatus
P07218008T0000|105 114|comparison
P07218008T0000|163 167|areas
P07219297T0000|8 15|approach
P07219297T0000|21 35|standardization
P07219297T0000|38 46|allergens
P07219821T0028|21 34|considerations
P07221179A0156|23 33|GABA content
P07221179A0156|44 55|GABA decrease
P07221179A0156|81 94|administration
P07221179A0156|104 108|nadir
P07221179A0156|137 143|minutes
P07221354T0000|0 5|Theory
P07221354T0000|9 20|applications
P07221354T0000|23 33|pulse dosing
P07221354T0000|35 41|summary
P07221354T0000|47 55|symposium
P07225300A0968|5 11|results
P07225300A0968|23 29|neonate
P07225300A0968|44 48|adult
P07225300A0968|51 57|respect
P07225300A0968|67 72|nature
P07225300A0968|75 81|effects
P07225300A0968|96 106|sensitivity
P07225540A0193|33 62|electron capture detection method
P07225540A0193|80 92|plasma samples
P07225540A0193|115 124|techniques
P07226440T0000|3 14|hemodynamics
P07226440T0000|45 51|failure
P07228955A0000|7 13|authors
P07228955A0000|34 45|interference
P07228955A0000|48 67|theophylline analysis
P07228955A0000|70 81|paraxanthine
P07228955A0000|82 101|1,7-dimethylxanthine
P07228955A0000|113 122|metabolite
P07228955A0000|125 132|caffeine
P07234308A0121|5 16|drug regimens
P07234308A0121|21 26|C-MOPP
P07234308A0121|36 40|BACOP
P07234308A0121|49 62|remission rates
P07234308A0121|72 76|cases
P07234308A0121|103 109|disease
P07234755A0838|3 11|monocytes
P07234755A0838|27 34|Hematrak
P07234974T0000|13 20|features
P07234974T0000|23 34|Jat dentition
P07235317T0000|8 15|accuracy
P07235317T0000|25 31|version
P07235317T0000|37 52|Phadebas RAST test
P07235355A0462|11 18|subjects
P07235355A0462|48 55|sequence
P07235355A0462|57 61|tests
P07235355A0462|92 97|change
P07235355A0462|99 107|flow rates
P07235355A0462|110 126|density dependence
P07236351A0812|17 24|recovery
P07236351A0812|82 89|areas CA3
P07237123T0000|24 36|unit responses
P07237123T0000|48 59|nerve volleys
P07237123T0000|73 78|turtle
P07237560A1038|8 16|deletions
P07237560A1038|26 33|sequence
P07237560A1038|63 72|inactivity
P07237560A1038|84 88|genes
P07237560A1038|89 100|substitution
P07237560A1038|113 119|portion
P07237560A1038|134 147|Hind III linkers
P07237560A1038|156 164|gene units
P07237560A1038|173 185|transcription
P07237817T0000|0 14|Cross reactivity
P07237817T0000|17 34|theophylline RIA kit
P07240343A0000|0 11|Strontium-90
P07240343A0000|54 67|post conception
P07242929T0001|0 8|Recording
P07242929T0001|29 36|activity
P07242929T0001|47 57|extremities
P07242929T0001|101 107|methods
P07243380A0327|11 18|acidosis
P07243380A0327|51 58|decrease
P07247059A0775|0 14|Catheter transit
P07247059A0775|23 30|response
P07247059A0775|34 45|step increase
P07247059A0775|48 60|concentration
P07247059A0775|84 90|cent-90
P07247059A0775|113 123|transit time
P07247059A0775|133 140|catheter
P07249497A0688|5 9|women
P07249497A0688|36 46|estrogen PPI
P07249497A0688|69 73|women
P07249497A0688|79 83|risks
P07249497A0688|95 105|estrogen use
P07249497A0688|142 149|patients
P07249497A0688|163 169|courses
P07249544A0343|7 17|temperature
P07249544A0343|28 52|serum creatine kinase levels
P07249544A0343|68 75|patients
P07249660T0000|0 12|Determination
P07249660T0000|21 34|distensibility
P07249660T0000|41 50|variations
P07249660T0000|61 72|hypertension
P07249895A0177|20 33|prostaglandins
P07249895A0177|47 57|esophagitis
P07249895A0177|74 87|LES hypotension
P07249895A0177|102 110|treatment
P07249895A0177|117 123|animals
P07249895A0177|128 139|indomethacin
P07249895A0177|143 155|micrograms/kg
P07249895A0177|176 184|inhibitor
P07249895A0177|187 208|prostaglandin synthesis
P07249895A0177|221 230|production
P07249895A0177|233 243|esophagitis
P07249895A0177|252 259|recovery
P07251564A0569|18 23|sample
P07251564A0569|57 65|diagnosis
P07251564A0569|81 92|ASDC nosology
P07252346A0223|9 17|technique
P07252346A0223|35 41|problem
P07253335T0000|0 6|Effects
P07253335T0000|9 31|prostaglandin inhibitors
P07253335T0000|37 41|onset
P07253335T0000|44 54|proteinuria
P07253335T0000|58 63|stroke
P07253335T0000|66 77|stroke-prone
P07256543A0814|6 10|study
P07256543A0814|29 36|criteria
P07256543A0814|40 55|inhalation injury
P07256543A0814|56 63|presence
P07256543A0814|87 91|burns
P07256543A0814|92 114|carboxyhemoglobin levels
P07256543A0814|127 132|sputum
P07256543A0814|141 151|space injury
P07256543A0814|171 178|patients
P07256543A0814|183 194|airway injury
P07256543A0814|223 228|injury
P07259325A0394|0 7|Survival
P07259325A0394|40 44|onset
P07259325A0394|62 70|diagnosis
P07260389A0221|0 11|Methisergide
P07260389A0221|15 19|mg/kg
P07260389A0221|25 31|blocker
P07260389A0221|34 51|serotonin receptors
P07260389A0221|64 74|development
P07260389A0221|95 100|effect
P07260389A0221|103 111|serotonin
P07260987A0336|3 17|plasma half-life
P07260987A0336|24 47|disposition phase t1/2 beta
P07260987A0336|73 79|rabbits
P07260987A0336|94 101|function
P07260987A0336|108 112|hours
P07260987A0336|115 121|rabbits
P07260987A0336|137 146|impairment
P07262239T0000|0 6|Effects
P07262239T0000|23 33|deprivation
P07262239T0000|36 46|development
P07262239T0000|67 77|projections
P07262625A0000|0 20|Corticosteroid therapy
P07262625A0000|43 50|patients
P07262625A0000|55 69|occult infection
P07262625A0000|76 84|mechanism
P07262625A0000|95 118|host parasite relationship
P07262625A0000|130 137|steroids
P07262625A0000|198 214|protozoal parasite
P07262625A0000|215 226|Giardia muris
P07262625A0000|239 245|effects
P07262625A0000|248 262|corticosteroids
P07262625A0000|268 273|number
P07262625A0000|276 284|parasites
P07262625A0000|290 298|intestine
P07262625A0000|304 309|course
P07262625A0000|320 328|infection
P07263374T0000|6 17|lung function
P07263374T0000|20 26|puppies
P07263374T0000|32 44|pneumonectomy
P07263421A0351|27 34|capacity
P07263421A0351|53 59|control
P07263745T0000|9 28|Charnley arthroplasty
P07263745T0000|38 46|procedure
P07264787A0351|8 15|patients
P07264787A0351|40 47|evidence
P07264787A0351|57 67|thyroiditis
P07264787A0351|96 110|hyperthyroidism
P07266969A0246|3 14|relationship
P07266969A0246|32 41|properties
P07266969A0246|44 52|Tamoxifen
P07266969A0246|56 77|breast cancer management
P07267675A0000|24 36|cephalosporin
P07267675A0000|71 76|number
P07267675A0000|90 97|patients
P07267675A0000|109 118|infections
P07268828A0000|1 17|fluoroimmunoassay
P07268828A0000|24 36|determination
P07268828A0000|39 43|serum
P07268828A0000|46 57|plasma levels
P07268828A0000|60 70|propranolol
P07268828A0000|88 97|antibodies
P07268828A0000|100 110|propranolol
P07268828A0000|132 151|solid-phase particles
P07268828A0000|174 184|propranolol
P07268828A0000|187 192|tracer
P07270163A0684|24 34|projections
P07270163A0684|85 93|structure
P07270163A0684|111 115|layer
P07270163A0684|121 125|villi
P07270163A0684|132 137|lining
P07270163A0684|159 165|vessels
P07270163A0684|189 196|controls
P07270991A0149|4 17|pollen allergen
P07270991A0149|27 38|grass species
P07270991A0149|59 65|results
P07270991A0149|91 96|values
P07274042A0249|16 29|concentrations
P07274042A0249|53 57|group
P07274042A0249|73 80|patients
P07274428A0000|16 26|experiments
P07274428A0000|61 66|anions
P07274428A0000|82 94|contrast agent
P07274428A0000|100 108|bilignost
P07274428A0000|114 129|cholecystography
P07274428A0000|133 142|Bengal pink
P07274428A0000|149 156|affinity
P07274428A0000|176 187|RCA triombrin
P07274428A0000|205 218|indigo-carmine
P07274428A0000|234 242|membranes
P07274428A0000|249 258|liver cells
P07274482A0000|9 15|neurons
P07274482A0000|59 69|selectivity
P07274482A0000|75 89|afterdischarges
P07274482A0000|92 99|movement
P07274482A0000|102 106|sound
P07274482A0000|111 118|velocity
P07274482A0000|124 131|movement
P07274482A0000|150 154|deg/s
P07274505A0660|2 9|controls
P07274505A0660|20 30|differences
P07276210T0000|0 4|Assay
P07276210T0000|7 11|serum
P07276210T0000|26 32|trypsin
P07276210T0000|40 49|blood spots
P07276210T0000|61 69|detection
P07276210T0000|78 85|fibrosis
P07277222A1391|7 11|waves
P07277222A1391|40 48|motor unit
P07277222A1391|65 74|oscillator
P07277222A1391|94 103|occurrence
P07277222A1391|136 144|existence
P07277222A1391|159 170|interactions
P07278104T0001|0 22|Leukocyte enzyme activity
P07278104T0001|26 59|blood lymphocyte blast transformation
P07278104T0001|69 78|bronchitis
P07278578T0001|7 12|status
P07278578T0001|15 26|chemotherapy
P07278578T0001|30 36|Hodgkin
P07278578T0001|38 44|disease
P07280654A0000|2 11|literature
P07280654A0000|38 48|application
P07280654A0000|53 67|averaging method
P07282444A0075|10 14|cases
P07282444A0075|37 44|approach
P07282444A0075|50 55|tumour
P07282444A0075|64 68|cases
P07282444A0075|89 93|shunt
P07282552A0990|2 7|Group V
P07282552A0990|19 24|tissue
P07282552A0990|88 93|tissue
P07282552A0990|93 97|ratio
P07282552A0990|108 120|subepicardium
P07282552A0990|131 144|subendocardium
P07282943A0097|27 35|decreases
P07282943A0097|38 54|superfusate oxygen
P07282943A0097|62 69|pressure
P07282943A0097|79 85|control
P07282943A0097|91 98|aeration
P07282943A0097|141 147|changes
P07282943A0097|173 179|tension
P07283110A0000|13 22|deficiency
P07283110A0000|42 47|values
P07283110A0000|57 64|exercise
P07286057A0159|7 25|AUC infinity analyses
P07286057A0159|29 44|pharmacokinetics
P07286057A0159|47 56|buflomedil
P07286057A0159|124 132|injection
P07286057A0159|152 165|administration
P07293100T0001|0 15|Gastrin secretion
P07293100T0001|22 36|food stimulation
P07293100T0001|48 61|system diseases
P07293327T0001|0 22|Fibrinogen determination
P07293327T0001|31 40|KZM-1 meter
P07295033A0513|5 10|period
P07295033A0513|63 68|faeces
P07295033A0513|79 83|urine
P07295417A0092|30 36|regions
P07295417A0092|46 54|ventricle
P07295417A0092|90 98|technique
P07295417A0092|99 110|phase imaging
P07296303A0418|0 8|Responses
P07296303A0418|11 19|brainstem
P07296303A0418|22 27|nuclei
P07296303A0418|36 43|dorsalis
P07296303A0418|44 61|lateralis posterior
P07296303A0418|86 92|latency
P07296997A0125|8 15|patients
P07296997A0125|34 44|gallbladder
P07296997A0125|69 95|Tc-99m-PyG cholescintigraphy
P07297576A0454|18 39|drinking water ad libitum
P07297576A0454|62 68|Aludrox
P07297576A0454|76 88|drinking water
P07297978A0570|32 42|case history
P07297978A0570|42 54|smoking habits
P07298209A0291|3 15|determination
P07298209A0291|26 44|performance capacity
P07298209A0291|80 85|VO2 max
P07298209A0291|118 125|work load
P07298209A0291|129 144|bicycle ergometer
P07298259T0000|0 12|Determination
P07298259T0000|23 27|blood
P07298523T0000|0 5|Effect
P07298523T0000|8 19|indomethacin
P07298523T0000|23 42|prostaglandin F2 alpha
P07298523T0000|45 55|parturition
P07298523T0000|58 62|swine
P07299857A0294|0 9|LD50 values
P07299857A0294|12 16|terms
P07299857A0294|29 33|mg/kg
P07299857A0294|51 55|mg/kg
P07299857A0294|73 78|KP-CMC
P07299857A0294|112 116|mg/kg
P07299857A0294|130 134|mg/kg
P07299857A0294|136 141|female
P07299857A0294|146 151|KP-T10
P07299857A0294|167 180|intrarectally.
P07299857A0294|193 206|administration
P07299857A0294|209 214|KP-CMC
P07299857A0294|221 230|LD50 values
P07299857A0294|235 239|mg/kg
P07299857A0294|242 246|males
P07299857A0294|252 256|mg/kg
P07299857A0294|259 265|females
P07299857A0294|268 272|terms
P07304905A0336|0 14|Autotransfusion
P07304905A0336|36 48|Heparin-ACD-B
P07304905A0336|49 59|Heparin-DPD
P07304905A0336|60 76|Heparin-ACD-B etc.
P07306839T0001|0 7|Electron
P07306839T0001|19 25|picture
P07306839T0001|39 44|cortex
P07306839T0001|63 70|degrees C
P07308849A0817|12 22|differences
P07308849A0817|43 62|sham operation animals
P07308849A0817|110 115|weight
P07309562T0000|36 48|determination
P07309562T0000|82 86|acids
P07310206A0154|3 14|architecture
P07310206A0154|17 32|microvasculature
P07310206A0154|43 49|regions
P07310206A0154|67 92|scanning electron microscopy
P07310206A0154|101 118|resin casting method
P07311881T0000|0 10|MSMS Council
P07311881T0000|25 38|health director
P07312707T0000|0 7|Chordoma
P07312707T0000|28 34|F344 rat
P07320153T0000|0 4|Micro
P07320153T0000|21 26|liquid
P07320153T0000|42 47|system
P07320153T0000|57 65|precolumn
P07320153T0000|88 95|detector
P07320153T0000|105 121|injection analysis
P07320153T0000|124 137|catecholamines
P07320153T0000|140 149|body fluids
P07323063A0000|157 177|mg/kg dl-isoproterenol
P07323063A0000|188 193|degree
P07323063A0000|197 206|time course
P07323063A0000|228 234|failure
P07323063A0000|248 255|recovery
P07323573A0644|28 39|dissociation
P07326596A0061|3 15|IgA deficiency
P07327097A0647|2 7|PB mice
P07327097A0647|26 32|deficit
P07327097A0647|38 43|number
P07327097A0647|69 75|neurons
P07327097A0647|86 93|controls
P07327097A0647|118 124|deficit
P07327097A0647|128 139|granule cells
P07328000T0000|0 19|Nutritional cataracts
P07328000T0000|22 33|timber wolves
P07330073T0000|0 9|Prevention
P07330073T0000|12 31|transfusion reactions
P07330073T0000|44 49|saline
P07330073T0000|58 67|blood cells
P07337609A0531|45 58|antibody titers
P07337609A0531|110 117|chickens
P07337609A0531|137 145|intervals
P07337609A0531|162 173|immunization
P07337609A0531|183 194|immunization
P07337609A0531|198 206|challenge
P07340196T0001|15 27|determination
P07340196T0001|30 34|HBSAG
P07340196T0001|64 77|infectiousness
P07340196T0001|79 101|hepatitis B virus carriers
P07341346A0174|17 28|shunt vessels
P07341346A0174|64 71|arteries
P07341346A0174|96 101|system
P07345217A0000|10 22|complications
P07345217A0000|51 59|treatment
P07345217A0000|75 84|malignancy
P07347728T0000|0 12|Arachnoid cyst
P07349416A0337|16 25|summer coat
P07354367A0162|0 10|Hypotension
P07355527A0467|12 20|procedure
P07355527A0467|23 34|Lich-Gregoir
P07355527A0467|57 62|adults
P07356273T0022|24 37|cell carcinomas
P07356273T0022|48 54|tissues
P07365183A0000|6 13|patients
P07365183A0000|34 42|diagnosis
P07365183A0000|55 64|depression
P07365183A0000|80 84|terms
P07365183A0000|87 92|safety
P07365183A0000|96 103|efficacy
P07365183A0000|111 118|response
P07365183A0000|155 161|therapy
P07365183A0000|162 166|MMECT
P07365183A0000|196 202|therapy
P07369183T0000|6 14|artifacts
P07369183T0000|26 43|coagulation testing
P07369458A0606|38 46|technique
P07369458A0606|62 78|muscle temperature
P07369458A0606|97 103|adjunct
P07369458A0606|117 131|amputation level
P07372433A0000|24 36|relationships
P07372433A0000|39 53|guinea pig ureter
P07372433A0000|74 80|animals
P07372433A0000|82 86|weeks
P07372433A0000|88 93|months
P07372433A0000|98 102|years
P07372928A0105|0 4|Tests
P07372928A0105|10 15|method
P07372928A0105|28 42|Mossbauer source
P07372928A0105|66 73|membrane
P07372928A0105|92 120|signal-transmission properties
P07372928A0105|126 132|cochlea
P07372928A0105|140 145|source
P07372928A0105|165 172|membrane
P07375836T0000|12 18|work-up
P07375836T0000|22 28|patient
P07375836T0000|44 53|metastasis
P07375836T0000|64 72|carcinoma
P07375864A0431|3 9|authors
P07375864A0431|22 35|nonspecificity
P07375864A0431|41 51|platelet MAO
P07375864A0431|63 71|correlate
P07375864A0431|90 97|disorder
P07375864A0431|106 118|schizophrenia
P07375864A0431|131 136|burden
P07375864A0431|139 143|proof
P07375864A0431|159 166|findings
P07375864A0431|172 182|platelet MAO
P07376165T0001|0 6|Ecthyma
P07376165T0001|13 19|disease
P07377378A0143|0 18|Estrogen replacement
P07377378A0143|29 42|beta-estradiol
P07377378A0143|45 69|beta-estradiol-3-benzoate
P07377378A0143|93 100|capsules
P07377378A0143|126 130|rates
P07377378A0143|133 146|heat production
P07377378A0143|153 160|heat loss
P07377378A0143|194 201|controls
P07377954A0117|12 18|aspects
P07377954A0117|35 40|effect
P07377954A0117|60 65|system
P07377954A0117|68 72|terms
P07377954A0117|91 98|pressure
P07377954A0117|99 107|pulse rate
P07377954A0117|111 127|oxygen consumption
P07377954A0117|139 146|exercise
P07377954A0117|149 164|health volunteers
P07377954A0117|166 176|emg activity
P07377954A0117|182 189|tibialis
P07377954A0117|201 220|gastrocnemius muscles
P07377954A0117|227 234|exercise
P07377954A0117|245 254|volunteers
P07377954A0117|259 290|postexercise ankle pressure changes
P07377954A0117|295 302|subjects
P07377954A0117|346 353|diseases
P07377954A0117|364 374|extremities
P07379334A0503|0 6|Changes
P07379334A0503|20 29|reactivity
P07379334A0503|32 39|subjects
P07379334A0503|49 62|transfer factor
P07379334A0503|97 104|subjects
P07379334A0503|114 120|placebo
P07380615A0478|31 41|possibility
P07380615A0478|49 54|nature
P07380615A0478|61 70|collar jobs
P07380615A0478|107 112|tissue
P07380615A0478|159 172|work efficiency
P07380615A0478|204 213|efficiency
P07380615A0478|245 257|collar workers
P07385543T0001|0 9|Importance
P07385543T0001|26 46|blood sulfhydryl groups
P07385543T0001|49 57|fractures
P07385543T0001|74 78|bones
P07385543T0001|92 100|infection
P07385920A0189|3 9|results
P07385920A0189|27 40|blood lead level
P07385920A0189|64 79|blood haemoglobin
P07385920A0189|99 107|excretion
P07385920A0189|110 119|delta amino
P07385933A0085|9 19|iv injection
P07385933A0085|25 34|g galactose
P07385933A0085|38 49|kg body weight
P07385933A0085|63 66|mu Ci
P07385933A0085|88 96|galactose
P07385933A0085|97 101|14CO2
P07385933A0085|122 130|intervals
P07386500A0174|8 27|clotting factor assays
P07386500A0174|44 53|deficiency
P07386500A0174|56 62|factor X
P07386500A0174|95 108|determinations
P07386864T0000|20 27|dialysis
P07387242A0236|0 13|Blood variables
P07387242A0236|29 37|intervals
P07387242A0236|58 66|operation
P07387242A0236|85 98|plasma proteins
P07387242A0236|103 112|hemoglobin
P07387242A0236|119 126|elements
P07387242A0236|130 146|clotting functions
P07392519T0001|7 13|changes
P07392519T0001|26 36|retinopathy
P07392519T0001|39 46|children
P07393856A0314|3 8|result
P07393856A0314|9 18|beta-apo-8
P07393856A0314|28 41|acid ethyl ester
P07393856A0314|42 47|apo-EE
P07393856A0314|58 74|reference standard
P07393856A0314|77 87|Experiments
P07393976A0000|3 9|ability
P07393976A0000|12 30|sodium phenobarbital
P07393976A0000|33 37|mg/kg
P07393976A0000|41 54|sodium barbital
P07393976A0000|57 61|mg/kg
P07393976A0000|72 84|taste aversion
P07393976A0000|89 95|hr fluid
P07393976A0000|127 140|discrimination
P07393976A0000|145 167|bottle taste aversion task
P07393976A0000|172 195|% sodium saccharin solution
P07393976A0000|198 202|water
P07394364A0738|25 45|gas exchange parenchyma
P07394364A0738|61 67|mammals
P07394364A0738|91 98|organism
P07394364A0738|123 128|levels
P07394364A0738|159 163|rates
P07394364A0738|185 194|adaptation
P07395750A0294|0 15|Underestimations
P07395750A0294|46 53|problems
P07395750A0294|66 78|methodologies
P07396545A0217|0 11|Chemotherapy
P07396545A0217|45 50|course
P07396545A0217|56 63|disorder
P07397066T0000|0 13|Drug inhibition
P07397066T0000|21 40|blood aspirin esterase
P07401318A0823|14 24|temperature
P07401318A0823|36 44|staircase
P07401318A0823|73 81|staircase
P07405701T0000|20 28|responses
P07405701T0000|32 55|platelet monoamine oxidase
P07405701T0000|58 65|patients
P07405701T0000|79 88|alcoholism
P07406527A0212|15 24|experiment
P07406527A0212|34 51|porphyrin excretion
P07406527A0212|58 73|porphyrin content
P07406527A0212|76 81|lijver
P07406527A0212|121 127|animals
P07406527A0212|151 161|HCB controls
P07408970A0706|3 7|hours
P07408970A0706|20 33|administration
P07408970A0706|34 39|uterus
P07408970A0706|49 54|Cv mice
P07408970A0706|58 63|weight
P07408970A0706|102 111|difference
P07410037A0752|8 20|stone-formers
P07410037A0752|45 52|features
P07410037A0752|55 73|magnesium metabolism
P07410037A0752|105 116|control group
P07410037A0752|134 142|excretion
P07410037A0752|145 153|magnesium
P07410037A0752|156 163|relation
P07410037A0752|166 172|calcium
P07410037A0752|179 184|factor
P07410037A0752|214 223|propensity
P07413144T0018|0 7|Analysis
P07413144T0018|19 28|population
P07413242A0000|17 21|study
P07413242A0000|26 36|paraplegics
P07413242A0000|49 55|lesions
P07413242A0000|60 64|T1-L3
P07413441T0070|16 27|localisation
P07413441T0070|41 52|distribution
P07413441T0070|58 63|kidney
P07413781A0169|11 21|stimulation
P07413781A0169|44 62|stimulus preexposure
P07413781A0169|71 81|attenuation
P07413781A0169|90 99|inhibition
P07413781A0169|105 115|stimulation
P07413781A0169|131 142|conditioning
P07413781A0169|148 158|preexposure
P07413806T0000|15 22|amygdala
P07413806T0000|33 41|pathology
P07414817T0001|0 17|Cataract extraction
P07414817T0001|27 34|glaucoma
P07415340A0280|0 5|Number
P07415340A0280|26 35|structures
P07415340A0280|40 53|pneumocytes typ
P07416204A0437|11 16|animal
P07416204A0437|34 45|potentiation
P07416204A0437|64 77|pacing interval
P07416204A0437|88 93|timing
P07416204A0437|98 109|extrasystole
P07416204A0437|156 167|potentiation
P07416204A0437|216 227|potentiation
P07418498A0217|2 6|spite
P07418498A0217|21 33|complications
P07418498A0217|36 50|corticosteroids
P07418498A0217|63 70|recovery
P07418498A0217|84 92|infection
P07418498A0217|102 110|treatment
P07418498A0217|115 127|amphotericin B
P07418498A0217|139 146|excision
P07418498A0217|152 162|lung abscess
P07418829A0191|0 11|Implications
P07418829A0191|18 28|observation
P07418829A0191|32 41|pediatrics
P07419485A0158|6 10|study
P07419485A0158|16 25|transition
P07419485A0158|39 43|waves
P07419485A0158|54 58|waves
P07419485A0158|71 78|solution
P07419485A0158|141 154|simplification
P07423803T0001|0 8|Treatment
P07423803T0001|22 32|peritonitis
P07425838A0182|17 32|pheochromocytoma
P07425838A0182|57 65|trimester
P07425838A0182|68 76|pregnancy
P07426101A0124|7 12|plasma
P07426101A0124|16 45|lipoprotein lipid concentrations
P07426101A0124|46 83|adipose tissue lipoprotein lipase activity
P07426101A0124|84 101|anthropometric data
P07426101A0124|102 119|alcohol consumption
P07426101A0124|120 132|smoking habits
P07426101A0124|139 148|mileage run
P07426101A0124|152 162|performance
P07426101A0124|166 181|bicycle ergometer
P07426101A0124|211 224|training period
P07426604A0397|3 7|C18:1
P07426604A0397|7 14|C10 value
P07426604A0397|28 34|measure
P07426604A0397|42 48|changes
P07426604A0397|109 113|acids
P07426745A0177|12 17|growth
P07426745A0177|20 49|blood erythrocyte membrane injury
P07426745A0177|93 108|gamma-irradiaton
P07428037A0989|20 30|nucleotides
P07428037A0989|34 47|mouse mt 12S rRNA
P07428037A0989|68 85|bp hairpin structure
P07428037A0989|90 97|sequence
P07428037A0989|113 123|nucleotides
P07428037A0989|159 165|subunit
P07428037A0989|170 176|systems
P07428037A0989|197 211|mRNA binding site
P07428037A0989|212 217|ACCUCC
P07428037A0989|234 253|corn chloroplast rRNAs
P07429009T0121|11 17|anatomy
P07429009T0121|21 42|cell population dynamics
P07431059A0000|6 18|cadaver brains
P07431059A0000|44 56|magnification
P07431059A0000|58 62|order
P07431059A0000|87 93|anatomy
P07431059A0000|99 110|pineal region
P07431059A0000|126 137|relationship
P07431059A0000|143 152|pineal body
P07431059A0000|170 175|artery
P07431059A0000|184 199|cerebellar artery
P07431059A0000|208 212|Galen
P07431059A0000|225 233|Rosenthal
P07431059A0000|263 267|sinus
P07431059A0000|304 308|notch
P07431059A0000|337 342|nerves
P07432288A0218|0 17|Serum antibody titre
P07432288A0218|54 67|recurrence rate
P07432288A0218|73 80|duration
P07432288A0218|83 91|infection
P07434431A0203|13 21|refeeding
P07434431A0203|38 46|mechanism
P07434431A0203|50 59|activation
P07434431A0203|74 83|infections
P07434431A0203|106 111|famine
P07434456A0286|16 20|units
P07434456A0286|40 49|blood cells
P07434456A0286|58 65|glycerol
P07434456A0286|95 110|% glycerol content
P07434456A0286|114 125|measurements
P07434456A0286|155 159|fluid
P07434456A0286|172 176|index
P07434456A0286|180 188|osmometry
P07435185A0074|3 10|symptoms
P07435185A0074|23 30|findings
P07435185A0074|53 60|lymphoma
P07435185A0074|67 75|diagnosis
P07435185A0074|95 105|drill biopsy
P07436187A0147|3 7|study
P07436187A0147|27 33|studies
P07436187A0147|66 71|entity
P07436187A0147|105 109|range
P07436187A0147|132 138|factors
P07436187A0147|141 150|disability
P07436459A0245|60 68|acid ratio
P07436459A0245|95 113|vitamin B6 deficiency
P07436459A0245|141 148|response
P07436459A0245|151 170|tryptophan metabolism
P07436459A0245|173 178|stress
P07436702A0156|3 16|control persons
P07436702A0156|27 34|reaction
P07436794A0148|3 14|control group
P07436794A0148|25 39|carotid arteries
P07438346A0381|16 38|lidocaine concentrations
P07438346A0381|80 85|action
P07438346A0381|94 102|amplitude
P07438482A0145|12 16|right
P07438482A0145|44 55|blood samples
P07438482A0145|72 84|determination
P07438482A0145|87 94|oestrone
P07438482A0145|102 111|oestradiol
P07440085T0061|0 15|Arm function tests
P07440430A1074|3 7|lambs
P07440430A1074|12 20|B breeding
P07440430A1074|43 50|Hb levels
P07440430A1074|66 75|experiment
P07440430A1074|82 88|NB lambs
P07440430A1074|115 122|S x B lambs
P07440430A1074|138 145|Hb levels
P07440430A1074|152 159|D x B lambs
P07440430A1074|163 168|B lambs
P07440430A1074|204 227|hemoglobin concentrations
P07445971A0241|7 14|response
P07445971A0241|28 37|acrylamide
P07445971A0241|61 73|nerve ligation
P07449221A0086|3 11|operation
P07449221A0086|25 32|excision
P07449221A0086|75 80|repair
P07449221A0086|84 89|tendon
P07449253A0411|14 18|group
P07449253A0411|27 34|pressure
P07449253A0411|96 103|diuresis
P07449253A0411|111 118|decrease
P07449253A0411|121 131|blood volume
P07450031A0691|6 21|sedative activity
P07450031A0691|67 82|benzothiazepin-6
P07450031A0691|83 89|dioxide
P07450031A0691|135 150|benzothiazepin-6
P07450031A0691|150 156|dioxide
P07450388A0406|2 9|patients
P07450388A0406|13 18|effect
P07450388A0406|21 26|CCK-PZ
P07450388A0406|32 39|movement
P07450388A0406|64 71|bile duct
P07450388A0406|87 100|pressure sensor
P07450388A0406|107 123|duodenofiberscope
P07453919A0000|4 11|patients
P07453919A0000|16 21|Horton
P07453919A0000|23 30|headache
P07453919A0000|44 57|investigations
P07453919A0000|75 88|blood cell count
P07453919A0000|102 115|determinations
P07453919A0000|116 123|alkaline
P07453919A0000|127 141|acid phosphatase
P07453919A0000|154 161|esterase
P07453919A0000|182 186|tests
P07453919A0000|195 204|IgG binding
P07453919A0000|229 244|blood neutrophils
P07453919A0000|347 352|finger
P07455042A0457|22 28|imaging
P07455042A0457|52 59|machines
P07455042A0457|69 95|Dynamic Spatial Reconstructor
P07455042A0457|121 137|density resolution
P07455042A0457|152 160|injection
P07455042A0457|163 175|contrast agent
P07455042A0457|188 193|atrium
P07455042A0457|246 257|measurements
P07455521A0414|20 25|result
P07455521A0414|30 38|NEXT study
P07456774A0448|26 30|drugs
P07457931A0655|6 11|series
P07457931A0655|36 44|injection
P07457931A0655|46 52|5-OH-DA
P07457931A0655|92 96|study
P07458171A0086|17 23|species
P07458171A0086|29 42|Platyhelmintha
P07458171A0086|46 53|Nematoda
P07458171A0086|61 69|Crustacea
P07461226A0958|2 9|symptoms
P07461226A0958|22 26|flush
P07461226A0958|48 58|correlation
P07461226A0958|63 79|plasma epinephrine
P07461226A0958|82 101|norepinephrine levels
P07461848A0230|3 12|mean values
P07461848A0230|18 31|concentrations
P07461848A0230|37 46|components
P07461848A0230|52 63|tobacco smoke
P07461848A0230|105 112|nicotine
P07461848A0230|111 123|micrograms/m3
P07461848A0230|135 140|matter
P07461848A0230|145 157|micrograms/m3
P07462481A0422|10 31|backscatter coefficient
P07462481A0422|52 58|regions
P07462481A0422|60 66|infarct
P07462481A0422|77 81|weeks
P07462481A0422|87 95|occlusion
P07462481A0422|106 112|regions
P07462481A0422|115 121|infarct
P07462481A0422|131 135|weeks
P07462481A0422|141 149|occlusion
P07463294A1216|14 25|tumor relapse
P07463294A1216|39 43|group
P07463294A1216|45 54|responders
P07463294A1216|63 67|group
P07463294A1216|77 81|group
P07463294A1216|95 99|group
P07463294A1216|101 110|responders
P07463294A1216|126 130|group
P07463465A0297|5 13|infection
P07463465A0297|34 45|control women
P07463465A0297|53 57|birth
P07463465A0297|68 73|infant
P07466831A0714|0 16|Pentachlorophenol
P07466831A0714|31 35|onset
P07466831A0714|38 49|HCB porphyria
P07466831A0714|57 61|words
P07466831A0714|88 105|porphyrin excretion
P07466831A0714|124 134|disturbance
P07466831A0714|140 155|porphyrin pattern
P07467975A0316|0 13|Family planning
P07467975A0316|66 73|patients
P07467975A0316|90 103|contraceptives
P07467975A0316|122 128|periods
P07467975A0316|167 177|percentages
P07467975A0316|180 189|primiparae
P07467975A0316|193 204|secundiparae
P07467975A0316|210 215|births
P07467975A0316|231 240|percentage
P07467975A0316|243 256|multigravidity
P07467975A0316|260 269|parameters
P07467975A0316|280 287|approach
P07467975A0316|290 301|reproduction
P07467975A0316|326 342|behaviour patterns
P07467975A0316|345 350|Europe
P07469692A0000|3 23|term osteomesopycnosis
P07469692A0000|48 58|bone disease
P07469692A0000|71 81|inheritance
P07469692A0000|109 115|members
P07469692A0000|131 138|families
P07471210A0384|3 12|87K protein
P07471210A0384|25 32|proteins
P07471210A0384|51 57|daltons
P07471210A0384|102 114|messenger RNAs
P07471210A0384|145 150|genome
P07471210A0384|158 166|positions
P07472582A0993|3 16|identification
P07472582A0993|25 34|myocardium
P07472582A0993|43 59|99mTc-tetrofosmin
P07472582A0993|63 67|201Tl
P07472582A0993|98 103|degree
P07472582A0993|109 116|severity
P07472582A0993|119 127|reduction
P07472582A0993|130 137|activity
P07472582A0993|157 163|defects
P07472736A0278|11 19|component
P07472736A0278|37 41|fossa
P07472736A0278|59 66|eminence
P07473169A0133|0 4|EUK-8
P07473169A0133|57 63|complex
P07473169A0133|80 98|superoxide dismutase
P07473169A0133|102 119|catalase activities
P07473742A0187|3 14|protein ELT-1
P07473742A0187|57 66|GATA family
P07473742A0187|68 97|vertebrate transcription factors
P07473742A0187|139 145|element
P07474078A0838|9 16|contrast
P07474078A0838|45 62|integration studies
P07474078A0838|63 72|alteration
P07474078A0838|93 106|CA dinucleotide
P07474078A0838|118 123|mutant
P07474078A0838|157 175|integration activity
P07474085A0932|12 19|R protein
P07474085A0932|34 39|codons
P07474085A0932|55 68|frameshift site
P07474085A0932|74 81|V protein
P07474085A0932|86 90|codon
P07474124A1360|5 11|results
P07474124A1360|43 52|PI3 viruses
P07474124A1360|67 89|parainfluenza virus genus
P07474124A1360|95 101|viruses
P07474124A1360|112 122|differences
P07474124A1360|127 133|respect
P07474124A1360|146 157|requirements
P07474124A1360|186 198|F glycoprotein
P07474140A1036|15 25|mutagenesis
P07474140A1036|50 54|ICP27
P07474140A1036|65 81|amino acid residues
P07474140A1036|112 124|ICP27 homologs
P07474140A1036|132 144|herpesviruses
P07474140A1036|145 149|D-357
P07474140A1036|150 154|E-358
P07474140A1036|155 159|H-479
P07474140A1036|160 164|C-400
P07474140A1036|165 169|C-483
P07474140A1036|173 177|C-488
P07474140A1036|208 215|activity
P07474451A0000|8 23|resonance imaging
P07474451A0000|69 77|pathology
P07474451A0000|79 89|differences
P07474451A0000|92 106|signal intensity
P07474617A1035|0 7|Patients
P07474617A1035|24 28|drugs
P07474617A1035|54 62|PRL levels
P07474772A0274|3 29|Laser Scanning Ophthalmoscope
P07474772A0274|50 60|examination
P07474772A0274|84 93|comparison
P07474772A0274|112 121|appearance
P07474772A0274|138 145|function
P07475733T0000|0 6|Malaria
P07475733T0000|7 13|anaemia
P07475733T0000|17 33|HIV-1 transmission
P07475733T0000|43 48|Africa
P07475793T0000|8 18|farmworkers
P07476164A1602|2 9|addition
P07476164A1602|40 55|resonance studies
P07476164A1602|102 108|mutants
P07476164A1602|123 131|structure
P07476164A1602|146 156|CspB protein
P07476701A0654|16 21|levels
P07476701A0654|24 36|IgE antibodies
P07476701A0654|65 71|pollens
P07476701A0654|86 99|correspondence
P07476963A0000|0 9|Peroxisome
P07476963A0000|32 40|receptors
P07476963A0000|41 45|PPARs
P07476963A0000|49 66|retinoid X receptors
P07476963A0000|83 98|hormone receptors
P07476963A0000|121 125|acids
P07476971A0381|35 49|SKUT-1B-20 cells
P07476971A0381|57 80|transcription factor Pit-1
P07476975A0492|3 8|number
P07476975A0492|11 21|lactotropes
P07476975A0492|22 33|somatotropes
P07476975A0492|34 44|thyrotropes
P07476975A0492|48 59|gonadotropes
P07476975A0492|85 92|controls
P07476975A0492|117 125|pituitary
P07476975A0492|130 137|products
P07476975A0492|165 176|distribution
P07476975A0492|179 187|cell types
P07477245A0625|4 10|strains
P07477245A0625|13 25|A. parasiticus
P07477245A0625|41 58|aflatoxins B1 B2 G1 G2
P07477245A0625|86 89|AF B1
P07477245A0625|102 115|concentrations
P07477245A0625|117 126|aflatoxins
P07477245A0625|139 143|mg/kg
P07478514A0237|41 45|clone
P07478523A0551|2 9|addition
P07478523A0551|32 45|amino acid forms
P07478523A0551|90 99|amino acids
P07478523A0551|123 139|RET protein isoform
P07478525A1177|4 10|classes
P07478525A1177|13 25|MHBst proteins
P07478525A1177|41 46|dimers
P07478525A1177|78 89|dimerization
P07479004A0421|17 35|mobility shift assays
P07479004A0421|61 69|complexes
P07479004A0421|88 95|proteins
P07479004A0421|102 109|extracts
P07479004A0421|125 129|cells
P07482069A0606|27 33|mg/week
P07482069A0606|39 44|months
P07482069A0606|57 74|vasculitis symptoms
P07483276A0139|0 7|Analysis
P07483276A0139|13 20|sequence
P07483276A0139|39 51|reading frames
P07483276A0139|112 119|homology
P07483276A0139|119 126|proteins
P07483276A0139|129 148|herpes simplex virus-1
P07483276A0139|149 153|HSV-1
P07483276A0139|154 170|pseudorabies virus
P07483276A0139|182 194|herpesvirus-1
P07483276A0139|197 217|varicella-zoster virus
P07483285A0322|5 19|HPV16 E6/E7 cDNAs
P07483285A0322|38 58|SV40 enhancer/promoter
P07483285A0322|65 71|MMTV LTR
P07483285A0322|84 93|activities
P07483285A0322|113 126|transformation
P07483285A0322|130 138|induction
P07483285A0322|149 160|DNA synthesis
P07483285A0322|183 195|E7 gene product
P07483857A0350|0 22|Correlation coefficients
P07483857A0350|33 48|reference methods
P07483857A0350|72 76|water
P07483857A0350|84 90|protein
P07483857A0350|94 133|connective-tissue-protein frei meat protein
P07483857A0350|148 172|connective-tissue-protein
P07487067A0592|3 21|translation products
P07487067A0592|28 33|clones
P07487067A0592|67 75|% identity
P07487067A0592|102 108|lengths
P07487067A0592|118 122|amino
P07487067A0592|131 139|sequences
P07487067A0592|150 164|transit peptides
P07487067A0592|168 186|plastid localization
P07487363A0447|3 13|serum levels
P07487363A0447|24 28|asIgE
P07487363A0447|31 35|IgG-4
P07487363A0447|51 63|food allergens
P07487811A0000|3 13|experiments
P07487811A0000|30 36|effects
P07487811A0000|49 59|spaceflight
P07487811A0000|72 83|bone turnover
P07487811A0000|111 129|Systems Experiment-1
P07487811A0000|130 134|PSE-1
P07487811A0000|146 156|spaceflight
P07487811A0000|160 164|PSE-2
P07487811A0000|170 175|flight
P07487908A0230|4 11|sequence
P07487908A0230|31 43|transcription
P07487908A0230|61 91|chloramphenicol acetyltranferase
P07487908A0230|105 109|cells
P07487908A0230|120 125|origin
P07487908A0230|126 131|AR-42J
P07487908A0230|140 144|cells
P07487908A0230|161 166|origin
P07488247T0000|10 17|analysis
P07488247T0000|20 42|aryl hydrocarbon receptor
P07488247T0000|50 73|translocator interactions
P07488247T0000|78 100|aryl hydrocarbon receptor
P07488247T0000|106 110|yeast
P07488247T0000|121 126|system
P07488291A0934|15 26|observations
P07488291A0934|41 52|somatostatin
P07488291A0934|56 77|triamcinolone acetonide
P07488291A0934|100 104|signs
P07488291A0934|115 124|structures
P07488291A0934|133 154|triamcinolone acetonide
P07488959T0000|2 9|approach
P07488959T0000|28 32|model
P07488959T0000|35 51|lymphocytopoiesis
P07489502A0000|3 26|influenza virus NS1 protein
P07489502A0000|55 63|regulator
P07489502A0000|74 83|activities
P07489502A0000|84 93|inhibition
P07489502A0000|106 111|export
P07489502A0000|132 136|mRNAs
P07489502A0000|139 148|inhibition
P07489502A0000|151 166|pre-mRNA splicing
P07490079A0825|11 17|regions
P07490079A0825|34 40|synteny
P07490079A0825|57 64|evidence
P07490079A0825|90 96|homolog
P07490079A0825|107 114|STEP gene
P07490079T0000|9 15|cloning
P07490079T0000|26 32|homolog
P07490079T0000|53 63|phosphatase
P07490079T0000|90 96|mapping
P07490083A0000|8 17|anhydrase V
P07490083A0000|50 55|matrix
P07490083A0000|56 60|liver
P07490083A0000|76 82|tissues
P07490156A0647|0 8|Vitamin D3
P07490156A0647|13 29|nicotine treatment
P07490156A0647|46 54|increases
P07490156A0647|80 86|modulus
P07490156A0647|102 112|correlation
P07490278A0799|9 14|domain
P07490278A0799|45 49|Num1p
P07490278A0799|55 70|mother cell cortex
P07490742A0636|4 10|finding
P07490742A0636|30 35|notion
P07490742A0636|43 61|dsRNA binding domains
P07490742A0636|98 107|subdomains
P07490766T0000|25 32|parallel
P07490766T0000|44 52|formation
P07490766T0000|72 90|c-Myc leucine zippers
P07490766T0000|91 101|description
P07490766T0000|125 136|interactions
P07490766T0000|154 164|specificity
P07490766T0000|167 184|heterodimerization
P07490770A0267|0 9|Comparison
P07490770A0267|17 25|coxI genes
P07490770A0267|41 45|group
P07490770A0267|47 52|intron
P07490770A0267|65 72|homology
P07490770A0267|87 91|yeast
P07490770A0267|96 104|intron aI4
P07490770A0267|151 165|DNA endonuclease
P07491111A0221|18 28|DMS-79 cells
P07491111A0221|64 77|cell lung cancer
P07491305A0102|4 8|study
P07491305A0102|27 38|localization
P07491305A0102|43 58|accessory pathway
P07491305A0102|85 92|polarity
P07491305A0102|98 107|QRS complex
P07491305A0102|114 124|sinus rhythm
P07491305A0102|130 139|surface ECG
P07491305A0102|152 168|delta wave polarity
P07491305A0102|181 187|reports
P07491791A0263|3 18|promoter mutation
P07491791A0263|42 52|E1A products
P07491791A0263|70 89|helper adenovirus type
P07493327A0507|40 48|integrity
P07493327A0507|62 69|U6 snRNAs
P07493627A0882|0 8|Treatment
P07493627A0882|18 27|aza1R cells
P07493627A0882|47 53|agonist
P07493627A0882|70 79|expression
P07493627A0882|82 89|EC-1 mRNA
P07493627A0882|95 103|treatment
P07493627A0882|123 129|agonist
P07493627A0882|137 150|EC-1 expression
P07494244A0335|5 11|absence
P07494244A0335|14 19|E1A243
P07494244A0335|47 59|transcription
P07494244A0335|61 65|c-fos
P07494244A0335|93 108|ATF/CREB proteins
P07494274A1015|10 20|experiments
P07494274A1015|46 54|reduction
P07494274A1015|57 66|virus yield
P07494274A1015|85 95|temperature
P07494274A1015|107 117|disfunction
P07494274A1015|120 127|alpha TIF
P07494274A1015|134 142|infection
P07494274A1015|155 170|virion maturation
P07494293A0585|5 11|results
P07494293A0585|45 49|stage
P07494293A0585|54 84|T-cell signal transduction cascade
P07494293A0585|136 145|activation
P07494303A0000|5 29|immunodeficiency virus type
P07494303A0000|66 72|protein
P07494303A0000|103 113|replication
P07494303A0000|116 136|monocytes/macrophages
P07494306A0240|16 24|potential
P07494306A0240|49 60|interactions
P07494306A0240|84 88|cells
P07494306A0240|133 140|fraction
P07494306A0240|156 166|polypeptide
P07494306A0240|210 220|protein VP22
P07494314A1287|19 28|regulation
P07494314A1287|29 36|splicing
P07494314A1287|37 58|kinase interaction sites
P07494314A1287|62 84|tyrosine phosphorylation
P07494314A1287|90 102|LMP2A homologs
P07494314A1287|138 159|sequences heterogeneity
P07494314A1287|176 188|repeat regions
P07495059T0078|0 6|Results
P07495059T0078|12 39|ECAT Angina Pectoris Study Group
P07495120A0260|21 25|Phase
P07495120A0260|28 32|trial
P07495120A0260|59 64|safety
P07495120A0260|68 75|efficacy
P07495120A0260|78 88|cryosurgery
P07495120A0260|98 113|radiation therapy
P07495120A0260|130 139|recurrence
P07495726A1189|5 10|motifs
P07495726A1189|19 26|Chi motif
P07495726A1189|39 45|element
P07495726A1189|66 91|recombination hotspot region
P07495726A1189|97 115|Bcl-2 proto-oncogene
P07495726A1189|119 123|close
P07495726A1189|137 147|breakpoints
P07495726A1189|150 159|T-ALL lines
P07496184T0001|6 12|history
P07496184T0001|16 24|prospects
P07496184T0001|35 44|gynecology
P07496184T0001|50 56|Charite
P07496184T0001|63 84|Vienna University Clinic
P07496400A0525|2 9|contrast
P07496400A0525|35 43|HMGR1 mRNA
P07496400A0525|44 53|HMGR1S mRNA
P07496400A0525|75 80|levels
P07496400A0525|86 92|tissues
P07496400A0525|98 102|plant
P07496400A0525|103 112|HMGR1L mRNA
P07496400A0525|137 142|levels
P07496400A0525|149 158|expression
P07496400A0525|179 187|seedlings
P07496400A0525|188 192|roots
P07496400A0525|196 209|inflorescences
P07498727A0724|10 20|requirement
P07498727A0724|35 44|production
P07498727A0724|51 66|T.A transversions
P07498727A0724|70 81|rad18 mutator
P07498727A0724|103 115|substitutions
P07498727A0724|153 167|T.A transversion
P07498791A0680|9 16|mutation
P07498791A0680|55 60|allele
P07498791A0680|102 114|protein kinase
P07498791A0680|135 157|osmolarity stress pathway
P07499242A0898|7 13|tissues
P07499242A0898|47 61|RAFTK expression
P07499252A0150|2 16|hGM-CSF receptor
P07499252A0150|38 54|consensus sequence
P07499252A0150|57 63|binding
P07499252A0150|66 75|PI 3-kinase
P07499252A0150|98 106|mechanism
P07499252A0150|112 122|association
P07499252A0150|130 139|activation
P07499252A0150|142 151|PI 3-kinase
P07499401A0444|3 10|identity
P07499401A0444|18 24|hnRNPs H
P07499409A0367|32 38|regions
P07499409A0367|44 49|region
P07499409A0367|63 68|region
P07499409A0367|84 92|N terminus
P07499409A0367|104 120|targeting sequence
P07499421A0237|12 16|study
P07499421A0237|48 55|cultures
P07499421A0237|58 79|rat hepatocytes plasmids
P07499421A0237|92 97|CYP3A1
P07499421A0237|106 114|sequences
P07499421A0237|123 169|chloramphenicol acetyltransferase reporter plasmid
P07499848A0409|10 20|stimulation
P07499848A0409|37 42|B cells
P07499848A0409|63 70|Sf9 cells
P07499848A0409|78 91|germ-line gamma
P07499848A0409|96 113|epsilon transcripts
P07499848A0409|129 137|cytokines
P07500386A0870|12 32|GapIII protein activity
P07500386A0870|33 42|constructs
P07500386A0870|72 78|domains
P07500386A0870|108 112|yeast
P07500386A0870|137 143|ability
P07500597A0212|62 66|years
P07500597A0212|80 84|years
P07500950A0000|1 16|tobacco homologue
P07500950A0000|17 21|trolC
P07500950A0000|27 34|rolC gene
P07500950A0000|40 72|Agrobacterium rhizogenes Ri-plasmid
P07500950A0000|98 117|Nicotiana tabacum L. cv
P07500953A0305|4 17|ADR1 gene dosage
P07500953A0305|30 42|transcription
P07500953A0305|45 49|genes
P07500953A0305|69 76|proteins
P07500953A0305|103 110|ADR1 gene
P07501016T0000|13 22|giga-maser
P07501016T0000|34 51|galaxy TXFS2226-184
P07501458A0578|15 35|C/EBP family inhibitors
P07501458A0578|36 41|Ig/EBP
P07501458A0578|50 56|CHOP-10
P07501458A0578|60 65|Ig/EBP
P07501700A0000|3 9|effects
P07501700A0000|23 41|pretreatment regimen
P07501700A0000|46 65|monophosphoryl lipid A
P07501700A0000|73 89|micrograms/kg i.v.
P07501700A0000|137 146|occlusions
P07501992A0125|5 12|incisors
P07501992A0125|26 41|scanning electron
P07501992A0125|69 88|spectroscopy analysis
P07501992A0125|89 95|SEM-EDS
P07501992A0125|104 113|microscopy
P07501992A0125|141 145|lines
P07501992A0125|148 156|strontium
P07501992A0125|162 171|rat incisor
P07501992A0125|178 183|dentin
P07504171A0715|17 36|growth factor receptor
P07504171A0715|37 42|PDGF-R
P07504171A0715|43 56|phosphopeptide
P07504171A0715|67 73|Tyr-857
P07504171A0715|101 112|Src SH2 domain
P07504171A0715|133 149|PDGF-R binding site
P07504171A1214|16 28|Src SH2 mutants
P07504171A1214|37 53|binding properties
P07504171A1214|75 81|results
P07504171A1214|84 88|light
P07504171A1214|100 123|crystal structure solution
P07504171A1214|130 141|Src SH2 domain
P07504712A0843|5 16|observations
P07504712A0843|21 39|actin plaque assembly
P07504712A0843|51 71|cell substrate adhesion
P07505349A0702|8 16|lethality
P07505349A0702|32 39|resectio
P07505349A0702|65 72|survival
P07505349A0702|76 81|months
P07505798A0000|22 26|sites
P07505798A0000|32 55|type A influenza A/Japan/57
P07505798A0000|62 74|hemagglutinin
P07505798A0000|99 103|class
P07505798A0000|109 133|histocompatibility complex
P07505798A0000|164 175|T lymphocytes
P07506253A0742|4 11|enhancer
P07506253A0742|45 53|promoters
P07506253A0742|54 62|HeLa cells
P07507187T0000|0 8|Mechanism
P07507187T0000|11 21|enhancement
P07507187T0000|24 36|DNA expression
P07507187T0000|49 65|cointernalization
P07507187T0000|90 99|adenovirus
P07507187T0000|113 122|plasmid DNA
P07507207A0991|16 29|IRF binding site
P07507207A0991|47 59|IRF-2 promoter
P07507207A0991|63 72|expression
P07507207A0991|78 86|IRF-2 gene
P07507207A0991|122 136|IRF-1 expression
P07507458A0250|37 44|patients
P07507458A0250|73 82|prevalence
P07507458A0250|84 98|hepatitis C virus
P07507458A0250|104 113|antibodies
P07507458A0250|121 125|ELISA
P07507458A0250|129 139|RIBA methods
P07508082A0821|10 17|decrease
P07508082A0821|29 36|activity
P07508082A0821|61 69|bleaching
P07508082A0821|89 96|chlorine
P07508140A0448|0 23|Hepatitis B surface antigen
P07508140A0448|38 45|patients
P07508140A0448|58 80|hepatitis C virus antibody
P07508250A0537|30 40|correlation
P07508250A0537|53 66|selenium intake
P07508250A0537|70 95|liver selenium concentration
P07508250A0537|124 132|treatment
P07508250A0537|137 153|time liver selenium
P07508250A0537|182 192|correlation
P07508250A0537|230 242|investigation
P07508441A0487|0 9|Antibodies
P07508441A0487|66 72|protein
P07508441A0487|86 99|56K autoantigen
P07508441A0487|103 117|HeLa cell extract
P07508441A0487|136 149|cDNA sequencing
P07508441A0487|165 177|56K cDNA shares
P07508441A0487|183 188|degree
P07508441A0487|191 198|homology
P07508441A0487|205 214|nucleotide
P07508441A0487|222 238|amino acid sequence
P07508441A0487|254 262|annexin XI
P07508441A0487|279 285|56K cDNA
P07508441A0487|301 309|homologue
P07508441A0487|312 320|annexin XI
P07508441A0487|322 327|member
P07508441A0487|357 376|binding protein family
P07508954A0000|16 32|complex peroxidase
P07508954A0000|33 37|ABC-P
P07508954A0000|38 43|method
P07508954A0000|59 76|Mycobacterium bovis
P07508954A0000|83 89|results
P07508954A0000|124 136|Ziehl-Neelsen
P07508954A0000|141 149|technique
P07509053A0139|16 24|processes
P07509053A0139|39 46|function
P07509053A0139|49 53|c-Myb
P07509053A0139|78 90|establishment
P07509053A0139|109 115|lineage
P07509449A0000|31 46|sarcoma virus CT10
P07509449A0000|54 66|fusion protein
P07509449A0000|67 76|p47gag-crk
P07509449A0000|79 83|v-Crk
P07509449A0000|99 110|Gag sequences
P07509449A0000|126 134|sequences
P07509449A0000|156 173|Src homology regions
P07509449A0000|187 198|SH3 sequences
P07509450A0705|12 29|methylation pattern
P07509450A0705|36 47|inactivation
P07509450A0705|53 61|HSV tk gene
P07509450A0705|67 77|methylation
P07509450A0705|83 98|cytosine residues
P07509450A0705|108 125|nucleotide sequence
P07509450A0705|146 151|effect
P07509450A0705|154 170|HSV tk gene activity
P07509472A1320|0 9|CONCLUSION
P07509472A1320|14 27|study documents
P07509472A1320|32 41|regression
P07509472A1320|53 70|neovascularization
P07509472A1320|87 110|alpha interferon treatment
P07509624T0000|10 16|mapping
P07509624T0000|22 32|11q23 region
P07509624T0000|43 63|chromosome aberrations
P07509624T0000|71 76|tumors
P07509624T0000|91 108|gel electrophoresis
P07509624T0000|114 118|yeast
P07509624T0000|129 138|chromosome
P07509811A1357|14 32|CRE oligonucleotides
P07509811A1357|59 72|protein binding
P07509811A1357|87 95|congeners
P07509811A1357|103 116|protein binding
P07509811A1357|142 157|oligonucleotides
P07509811A1357|189 207|CRE oligonucleotides
P07509811A1357|237 255|CRE oligonucleotides
P07509811A1357|282 289|proteins
P07509811A1357|300 306|members
P07509811A1357|312 318|Jun/Fos
P07509811A1357|370 389|transcription factors
P07509811A1357|390 397|CREB/ATF
P07509811A1357|398 405|families
P07509811A1357|408 427|transcription factors
P07509811A1357|430 444|chromaffin cells
P07510461A0731|3 9|patient
P07510461A0731|20 36|test abnormalities
P07510635A0479|3 10|antibody
P07510635A0479|11 16|mAb1C2
P07510635A0479|30 36|peptide
P07510635A0479|50 56|epitope
P07510635A0479|84 96|transcription
P07510635A0479|135 143|promoters
P07510724A1208|3 12|lymph nodes
P07510724A1208|25 32|patients
P07510724A1208|47 55|arthritis
P07510724A1208|73 79|sarcoid
P07510724A1208|84 94|granulomata
P07510724A1208|121 131|association
P07510724A1208|139 149|sarcoidosis
P07510724A1208|163 171|arthritis
P07511444A0728|0 11|HCV infection
P07511444A0728|57 66|hepatitis C
P07511444A0728|90 99|hepatitis C
P07511444A0728|105 111|patient
P07511444A0728|123 127|years
P07511444T0000|0 23|Hepatitis C virus infection
P07511444T0000|27 36|risk factor
P07511444T0000|40 51|liver failure
P07511444T0000|70 76|disease
P07511444T0000|82 106|bone marrow transplantation
P07511496A1511|4 23|plasma concentrations
P07511496A1511|33 42|E-selectin
P07511496A1511|82 92|dysfunction
P07511496A1511|96 100|death
P07511818A0485|30 44|cell populations
P07511818A0485|73 82|production
P07511818A0485|148 152|cells
P07511818A0485|156 160|cells
P07511818A0485|179 191|control vector
P07511818A0485|206 221|IFN-beta sequence
P07511818A0485|247 253|protein
P07512159A0992|0 10|Improvement
P07512159A0992|16 34|polypyrimidine tract
P07512159A0992|51 68|splicing efficiency
P07512159A0992|75 80|degree
P07512159A0992|116 134|branchpoint mutation
P07512258A0441|0 19|Liver transplantation
P07512258A0441|25 31|patient
P07512258A0441|49 61|complications
P07512258A0441|78 85|PMN count
P07512258A0441|101 106|status
P07512258A0441|112 122|neutropenia
P07512258A0441|137 141|G-CSF
P07513703T0000|0 9|Activation
P07513703T0000|29 54|protein tyrosine phosphatase
P07513703T0000|55 61|SH-PTP2
P07513703T0000|90 97|peptides
P07513703T0000|109 134|insulin receptor substrate-1
P07514295A0000|0 22|Tyrosine phosphorylation
P07514295A0000|33 40|proteins
P07514295A0000|66 70|event
P07514295A0000|80 100|T-cell antigen receptor
P07514295A0000|106 116|stimulation
P07514295A0000|153 170|signaling machinery
P07514301A0000|34 46|protein kinase
P07514301A0000|100 106|defense
P07514301A0000|117 125|infection
P07514301A0000|131 138|addition
P07514301A0000|160 178|tumor suppressor gene
P07514301A0000|209 218|properties
P07516337A1119|51 56|p95Vav
P07516337A1119|62 74|stoichiometry
P07516337A1119|77 83|binding
P07516337A1119|111 121|Jurkat cells
P07516466A1054|2 9|contrast
P07516466A1054|10 18|injection
P07516466A1054|22 28|plasmid
P07516466A1054|43 47|virus
P07516466A1054|55 62|t antigen
P07516466A1054|99 106|activity
P07516466A1054|120 143|phosphoprotein substrates
P07516466A1054|149 154|effect
P07516466A1054|160 179|phosphorylation state
P07516466A1054|214 224|NIH 3T3 cells
P07516469A1025|23 30|proteins
P07516469A1025|65 69|cells
P07516597A1017|17 22|effect
P07516597A1017|36 45|processing
P07516597A1017|69 86|polyprotein segment
P07516597A1017|104 116|proteinase NS3
P07516597A1017|119 135|antigen processing
P07516597A1017|139 150|presentation
P07516597A1017|177 192|T cell determinant
P07516866A0000|12 22|PRL receptor
P07516866A0000|51 57|pigeons
P07516866A0000|78 99|pigeon crop sac libraries
P07516866A0000|112 124|transcription
P07516866A0000|136 158|polymerase chain reaction
P07517544A0515|24 33|regression
P07517544A0515|49 59|alterations
P07517544A0515|90 101|pancreatitis
P07517544A0515|115 122|recovery
P07517544A0515|137 144|function
P07517544A0515|150 157|pancreas
P07517544A0515|181 186|period
P07517544A0515|199 203|L-364
P07517544A0515|239 247|mg/kg/day
P07517869A0411|14 30|dephosphorylation
P07517869A0411|61 67|ability
P07517869A0411|70 80|C/EBP-delta
P07517869A0411|111 119|increases
P07517869A0411|125 132|presence
P07517869A0411|143 163|phosphatase inhibitors
P07517869A0411|186 204|sodium orthovanadate
P07518257A0351|3 11|promoters
P07518257A0351|28 44|S1 nuclease mapping
P07518426A0000|0 12|Interleukin-8
P07518426A0000|40 47|mediator
P07518426A0000|63 68|family
P07518426A0000|71 85|C-X-C chemokines
P07518460A0771|16 20|cells
P07518460A0771|31 35|PTP1C
P07518460A0771|86 96|mutagenesis
P07518460A0771|119 129|phosphatase
P07518561A0496|22 48|p72syk protein tyrosine kinase
P07518561A0496|78 91|TCR/CD3 complex
P07518561A0496|104 111|tyrosine
P07518561A0496|140 157|receptor triggering
P07518561A0496|164 169|T cells
P07518561A0496|177 182|p56lck
P07518578A0000|15 21|protein
P07518578A0000|24 39|Rous sarcoma virus
P07518578A0000|40 48|pp60v-src
P07518578A0000|69 75|homolog
P07518578A0000|76 84|pp60c-src
P07518578A0000|143 154|localization
P07518578A0000|170 183|binding ability
P07518578A0000|219 227|pp60v-src
P07518578A0000|293 298|matrix
P07518578A0000|306 314|pp60c-src
P07519447T0000|0 11|Organization
P07519447T0000|57 69|oxide synthase
P07519463A0000|37 50|work efficiency
P07519463A0000|51 70|segment work/regional
P07519463A0000|73 83|consumption
P07519463A0000|121 126|inflow
P07519481A1275|36 54|follicle development
P07519481A1275|83 87|stage
P07519481A1275|91 96|result
P07519481A1275|106 117|KL expression
P07519481A1275|120 132|follicle cells
P07519481A1275|153 157|c-kit
P07519481A1275|159 170|oocyte growth
P07519606A1269|0 12|Anti-NPROSP-C
P07519606A1269|50 60|appearances
P07519606A1269|71 82|proSP-C forms
P07519606A1269|85 98|lamellar bodies
P07519606A1269|102 112|homogenates
P07520098A0211|25 35|B6.CH-2bm13
P07520098A0211|41 46|strain
P07520098A0211|57 61|class
P07520098A0211|84 89|groove
P07520098A0211|100 104|class
P07520098A0211|116 123|sequence
P07521009A0377|5 11|mutants
P07521009A0377|52 59|MW104-1B
P07521009A0377|93 100|plasmids
P07521009A0377|112 124|DNA mismatches
P07521009A0377|152 157|Kramer
P07521009A0377|159 163|1989a
P07521285A1109|3 10|findings
P07521285A1109|25 33|frequency
P07521285A1109|44 55|nerve lesions
P07521285A1109|113 140|motor conduction abnormalities
P07521285A1109|153 162|assessment
P07521285A1109|173 187|F wave parameters
P07521285A1109|200 215|chronodispersion
P07521285A1109|220 226|latency
P07521285A1109|234 242|amplitude
P07521285A1109|245 252|addition
P07521285A1109|255 261|absence
P07521285A1109|265 278|minimum latency
P07521285A1109|291 295|yield
P07521285A1109|298 309|F wave studies
P07521601A0000|13 25|growth factors
P07521601A0000|53 60|recovery
P07521601A0000|63 74|myelopoiesis
P07521601A0000|93 104|chemotherapy
P07521601A0000|107 120|cancer patients
P07521916T0000|0 6|Effects
P07521916T0000|9 19|alterations
P07521916T0000|36 48|site sequences
P07521916T0000|56 80|immunodeficiency virus type
P07521916T0000|82 92|replication
P07522163T0000|0 11|Presentation
P07522163T0000|15 37|horse cytochrome c peptide
P07522163T0000|48 56|H-2b class
P07522163T0000|63 87|histocompatibility complex
P07522163T0000|93 101|molecules
P07522163T0000|103 109|C57BL/6
P07522163T0000|133 144|T lymphocytes
P07522163T0000|145 152|presence
P07522163T0000|162 177|MHC anchor residue
P07522163T0000|212 225|CTL recognition
P07523363A0440|21 25|HpaII
P07523363A0440|30 43|fragment island
P07523363A0440|68 76|base pairs
P07523363A0440|89 117|USF2 translation initiation site
P07523710T0000|0 8|Diagnosis
P07523710T0000|20 28|carcinoma
P07523710T0000|32 36|yield
P07523710T0000|39 51|serum prostate
P07523710T0000|60 66|antigen
P07523710T0000|80 90|examination
P07523710T0000|105 119|ultrasonography
P07524265T0000|27 43|stimulating factor
P07524265T0000|44 48|G-CSF
P07524265T0000|49 54|levels
P07524265T0000|57 64|neonates
P07524265T0000|78 90|complications
P07525548A1380|3 9|results
P07525548A1380|19 27|hierarchy
P07525548A1380|30 45|ligand affinities
P07525548A1380|71 78|activity
P07525548A1380|79 86|rsVCAM-1
P07525548A1380|88 106|fibronectin variants
P07525548A1380|129 147|fibronectin variants
P07525596A0584|93 98|domain
P07525596A0584|122 135|PPIase activity
P07525843A0859|0 8|Dilutions
P07525843A0859|19 32|H-2d NP peptides
P07525843A0859|58 70|H-2b NP peptide
P07525843A0859|101 111|target cells
P07525843A0859|127 131|lysis
P07525843A0859|158 167|affinities
P07525843A0859|190 223|histocompatibility complex molecules
P07525843A0859|230 237|peptides
P07525843A0859|244 250|account
P07525843A0859|262 268|removal
P07525843A0859|271 275|NP CTL
P07525843A0859|281 288|H-2b mice
P07525843A0859|303 309|removal
P07525843A0859|312 319|H-2d mice
P07526609A0736|7 16|expression
P07526609A0736|19 23|sigma
P07526609A0736|33 38|UTR/S1
P07526609A0736|54 73|PKR activator sequence
P07527168A0524|0 11|Microvessels
P07527168A0524|26 34|x200 field
P07527168A0524|65 76|angiogenesis
P07528028A1192|23 31|cell lines
P07528028A1192|39 63|FGF-1 cell surface receptors
P07528028A1192|86 92|studies
P07528028A1192|105 117|transfectants
P07528028A1192|142 146|FGF-1
P07528028A1192|163 175|transfectants
P07528028A1192|222 229|ABSTRACT
P07528028A1192|244 248|WORDS
P07528325A0165|6 12|studies
P07528325A0165|45 54|GH receptor
P07528325A0165|67 71|Stat1
P07528325A0165|84 102|transcription factor
P07528325A0165|114 121|tyrosine
P07528325A0165|156 162|nucleus
P07528325A0165|193 204|DNA sequences
P07528325A0165|215 228|gene expression
P07528531A0904|7 16|infections
P07528531A0904|17 21|G-CSF
P07528531A0904|50 54|cells
P07528531A0904|77 91|blood cell counts
P07528531A0904|107 117|neutrophils
P07528667A0834|5 19|initiation sites
P07528667A0834|31 39|positions
P07528746A1049|0 23|Phosphoamino acid analysis
P07528746A1049|38 50|ASGPR subunits
P07528746A1049|135 150|phosphoamino acid
P07528746A1049|151 161|polypeptide
P07528746A1049|177 184|presence
P07528772A0616|28 39|requirements
P07528772A0616|43 59|ZAP-70 interaction
P07528772A0616|84 95|binding assay
P07528772A0616|111 148|glutathione S-transferase fusion proteins
P07528772A0616|186 195|SH2 domains
P07528772A0616|197 202|ZAP-70
P07528772A0616|222 229|peptides
P07528772A0616|237 244|sequence
P07528772A0616|261 266|region
P07528772A0616|272 283|TCR zeta chain
P07528772A0616|284 293|TCR zeta cyt
P07528772A0616|306 312|TCR zeta
P07528772A0616|316 334|CD3 epsilon TAM motifs
P07528772A1539|13 20|tyrosine
P07528772A1539|35 45|TAM peptides
P07528772A1539|93 102|SH2 domains
P07528772A1539|105 110|ZAP-70
P07529124A0119|20 28|structure
P07529124A0119|69 79|heterodimer
P07529124A0119|111 118|subunits
P07529124A0119|128 134|weights
P07529124A0119|179 196|amino acid sequences
P07529124A0119|195 202|residues
P07529504A0000|33 47|characteristics
P07529504A0000|71 97|X-ray contrast agent iopromide
P07529504A0000|98 106|Ultravist
P07529504A0000|148 154|studies
P07529516A0474|13 20|patients
P07529516A0474|69 77|mg/m2/day
P07530128A0578|36 43|serum PSA
P07530128A0578|50 54|ng/ml
P07530502A0974|0 7|Addition
P07530502A0974|40 55|SI4-h220 cultures
P07530502A0974|63 71|reduction
P07530502A0974|86 100|c-kit expression
P07530502A0974|107 124|protein degradation
P07530502T0000|14 24|Steel factor
P07530502T0000|46 69|tyrosine kinase activation
P07530502T0000|79 86|life span
P07530502T0000|89 93|c-kit
P07530502T0000|106 112|protein
P07530549A0956|0 7|Analysis
P07530549A0956|13 21|sequences
P07530549A0956|29 33|BLAST
P07530549A0956|37 49|GRAIL programs
P07530549A0956|79 86|evidence
P07530549A0956|102 107|clones
P07530549A0956|121 129|sequences
P07530549A0956|146 151|clones
P07530549A0956|170 178|sequences
P07530549A0956|188 195|portions
P07530549A0956|201 205|genes
P07531321A0369|0 7|Patients
P07531321A0369|23 33|PVC/24 hours
P07531321A0369|49 60|distribution
P07531321A0369|71 82|CI evaluation
P07532278A0833|0 6|Horvath
P07533527A0128|0 8|Cell lines
P07533527A0128|23 28|tumors
P07533527A0128|60 72|hybridization
P07533527A0128|79 84|status
P07533527A0128|106 115|chromosome
P07533527A0128|129 138|marker loss
P07533758A1038|3 20|amino acid sequences
P07533758A1038|44 55|RfbB homologs
P07533758A1038|61 70|identities
P07533758A1038|90 99|similarity
P07533758A1038|118 127|similarity
P07533858A1503|15 34|alanine substitutions
P07533858A1503|37 43|proline
P07533858A1503|63 75|substitutions
P07533858A1503|89 103|oligomerization
P07533858A1503|107 115|transport
P07533858A1503|118 124|GP64 EFP
P07533880T0000|3 13|FinO protein
P07533880T0000|16 27|IncF plasmids
P07533880T0000|59 64|target
P07533880T0000|63 70|traJ mRNA
P07533880T0000|82 96|duplex formation
P07534285A0155|6 10|paper
P07534285A0155|23 35|ligand binding
P07534285A0155|43 65|tyrosine phosphorylation
P07534285A0155|68 76|BaF3 cells
P07534285A0155|105 115|Mpl receptor
P07534285A0155|116 124|BaF3/mMpl
P07534286A0842|1 19|chicken paxillin cDNA
P07534286A0842|56 62|protein
P07534286A0842|96 104|paxil-lin
P07534297A0141|21 42|pair HindIII DNA fragment
P07534297A0141|50 55|region
P07534297A0141|74 91|AP endonuclease gene
P07534297A0141|102 133|chloramphenicol acetyltransferase
P07534306A0444|27 41|GrsA derivatives
P07534306A0444|78 87|properties
P07534306A0444|93 107|deletion mutants
P07534306A0444|133 139|studies
P07534306A0444|162 180|amino acid activation
P07534306A0444|181 206|carboxyl thioester formation
P07534306A0444|213 219|ability
P07534306A0444|248 260|phenylalanine
P07534306A0444|273 280|D-isomer
P07535593A0714|9 24|T-cell precursors
P07535593A0714|30 42|V delta 2D delta
P07535593A0714|44 57|rearrangements
P07535768A1076|0 7|HVH2 mRNA
P07535768A1076|16 32|expression pattern
P07535768A1076|45 49|CL100
P07535768A1076|55 63|homologue
P07535768A1076|66 74|mouse MKP1
P07535768A1076|107 127|MAP kinase phosphatases
P07537267A2094|27 35|sequences
P07537267A2094|59 68|breakpoint
P07537267A2094|74 87|HPFH-3 deletion
P07537267A2094|102 110|structure
P07537267A2094|117 124|function
P07537267A2094|129 136|enhancer
P07537267A2094|165 175|specificity
P07537267A2094|186 202|gamma-globin genes
P07537267A2094|228 237|expression
P07537362A1112|6 16|association
P07537362A1112|24 49|Shb-SH3 domain proteins v-Src
P07537362A1112|72 92|coimmunoprecipitation
P07537736A0453|3 9|results
P07537736A0453|22 32|interaction
P07537736A0453|76 83|sequence
P07537736A0453|87 94|membrane
P07537736A0453|103 108|region
P07537736A0453|114 121|receptor
P07537736A0453|155 161|members
P07537736A0453|167 193|cytokine receptor superfamily
P07537851A0000|0 12|Transcription
P07537851A0000|26 45|cell adhesion molecule
P07537851A0000|47 52|VCAM-1
P07537851A0000|72 76|cells
P07537851A0000|87 104|lipopolysaccharide
P07537851A0000|123 148|cytokines interleukin-1 beta
P07537851A0000|152 175|tumor necrosis factor alpha
P07537851A0000|176 184|TNF-alpha
P07537851A0891|0 10|Experiments
P07537851A0891|26 33|proteins
P07537851A0891|44 50|p50/p65
P07537851A0891|78 84|protein
P07537851A0891|110 116|binding
P07537851A0891|119 123|IRF-1
P07537851A0891|129 136|VCAM1 IRF
P07537851A0891|157 161|IRF-1
P07537851A0891|221 227|protein
P07538068A1094|12 18|results
P07538068A1094|29 42|control element
P07538068A1094|71 78|boundary
P07538068A1094|80 92|Hox expression
P07538068A1094|108 121|Hoxa-7 enhancer
P07538122A0800|6 11|report
P07538122A0800|25 33|isolation
P07538122A0800|37 47|Fab fragment
P07538122A0800|48 52|Fab A8
P07538122A0800|73 80|affinity
P07538122A0800|87 94|receptor
P07538173A0307|0 8|MBP-Rep68
P07538173A0307|23 45|DNA-RNA helicase activity
P07538173A0307|54 66|ATP hydrolysis
P07538173A0307|73 80|presence
P07538173A0307|120 127|strength
P07538818A0197|18 24|regions
P07538818A0197|34 57|growth signal transduction
P07538818A0197|60 66|hG-CSFR
P07538818A0197|67 75|deletions
P07538818A0197|91 112|amino acid substitutions
P07538818A0197|145 150|domain
P07538818A0197|153 159|hG-CSFR
P07538818A0197|172 176|cDNAs
P07538818A0197|205 217|interleukin-3
P07538818A0197|232 236|Ba/F3
P07538818A0197|239 251|FDCP cell lines
P07539119A0291|37 45|mutations
P07539119A0291|51 67|c-abl kinase domain
P07539119A0291|70 81|NH2-terminus
P07539119A0291|85 97|G128R mutation
P07539119A0291|105 118|transformation
P07539119A0291|153 163|G128R mutant
P07539119A0291|184 188|cells
P07539119A0291|199 205|reasons
P07539119A0985|4 12|mutations
P07539119A0985|32 38|binding
P07539119A0985|44 55|Abl SH3 domain
P07539119A0985|70 83|target proteins
P07539119A0985|101 105|assay
P07539314T0000|0 6|Changes
P07539314T0000|19 23|gills
P07539314T0000|40 45|chanos
P07539314T0000|54 64|fingerlings
P07539314T0000|75 82|exposure
P07539314T0000|85 96|nifurpirinol
P07539314T0000|97 104|Furanace
P07539314T0000|105 110|P-7138
P07540607A0709|0 10|Retreatment
P07540607A0709|53 60|response
P07540607A0709|67 80|immunoglobulin
P07540773A0576|3 8|levels
P07540866A1069|13 25|insulin effect
P07540866A1069|36 50|ras GTP formation
P07540866A1069|54 70|MAP kinase activity
P07540866A1069|86 97|A/K1018 cells
P07540866A1069|122 130|Y/F2 cells
P07541589A0652|11 19|variables
P07541589A0652|28 39|cancer volume
P07541589A0652|50 54|grade
P07541589A0652|63 73|penetration
P07541589A0652|81 95|vesicle invasion
P07541589A0652|99 117|lymph node metastasis
P07541912A0485|0 15|Sequence analysis
P07541912A0485|23 29|regions
P07541912A0485|37 43|CAAT box
P07541912A0485|54 59|exon 1a
P07541912A0485|67 83|G-C content regions
P07542577A0438|3 16|fusion proteins
P07542577A0438|29 33|ELISA
P07542577A0438|37 46|reactivity
P07542577A0438|52 56|panel
P07542577A0438|79 83|order
P07542577A0438|94 99|nature
P07542577A0438|105 112|epitopes
P07542616A0313|0 4|GCD10
P07542616A0313|50 58|repressor
P07542616A0486|0 4|GCD10
P07542616A0486|51 58|evidence
P07542616A0486|91 97|subunit
P07542616A0486|100 122|yeast initiation factor-3
P07542616A0486|123 127|eIF-3
P07542616A0486|154 158|eIF-3
P07542616A0486|174 180|complex
P07542616A0486|195 215|translation initiation
P07542616A0486|241 245|steps
P07542698A0137|0 6|Sources
P07542698A0137|9 13|noise
P07542698A0137|21 27|signals
P07542698A0137|43 54|preparations
P07542698A0137|83 93|probe RH-414
P07543592A0624|25 30|mutant
P07543592A0624|47 55|E5 protein
P07543592A0624|64 71|receptor
P07543592A0624|82 112|receptor tyrosine phosphorylation
P07543592A0624|116 130|down-regulation
P07543684A1027|51 59|regulator
P07543684A1027|65 82|CFTR gene expression
P07543684A1027|98 106|induction
P07543684A1027|127 135|cell types
P07543868A0414|11 26|restriction sites
P07543868A0414|62 73|cDNA fragment
P07543868A0414|107 114|sequence
P07544357A0808|4 8|PPC-1
P07544357A0808|12 23|ALVA-31 cells
P07544357A0808|31 43|tumorigenesis
P07544357A0808|47 58|invasiveness
P07544357A0808|78 87|LNCap cells
P07544357A0808|108 116|phenotype
P07544357A0808|128 138|correlation
P07544357A0808|146 156|CD44 variant
P07544357A0808|157 161|CD44v
P07544357A0808|162 171|expression
P07544357A0808|185 205|prostate tumor behavior
P07545510A0735|3 13|gene product
P07545510A0735|49 55|Cot40-2
P07545510A0735|57 64|SDS-PAGE
P07545510A0735|68 81|immunoblotting
P07545510A0735|117 123|plasmid
P07545510A0735|137 146|cotS region
P07545920A1336|7 11|genes
P07545920A1336|22 31|hsiggll150
P07545920A1336|35 44|hsiggll295
P07546256A0000|29 33|study
P07546256A0000|58 65|injuries
P07546256A0000|71 78|children
P07546256A0000|116 125|Casablanca
P07546293A0968|3 9|results
P07546293A0968|21 34|protein binding
P07546293A0968|48 56|sequences
P07546293A0968|71 80|expression
P07546294A0000|3 15|RAD6/UBC2 gene
P07546294A0000|72 77|enzyme
P07546294A0000|88 96|DNA repair
P07546294A0000|104 114|mutagenesis
P07546294A0000|118 128|sporulation
P07546794A0100|0 15|Echocardiography
P07546794A0100|49 56|collapse
P07546794A0100|78 82|signs
P07546794A0100|91 99|tamponade
P07547220A0229|10 28|screening programmes
P07547220A0229|32 45|Haemoccult test
P07547220A0229|59 64|slides
P07547220A0229|107 111|slide
P07547500A0066|23 35|fusion protein
P07547500A0066|36 43|GAL4-p40
P07547500A0066|68 73|domain
P07547500A0066|85 93|sequences
P07547500A0066|95 114|chicken l kappa B-alpha
P07547500A0066|128 133|growth
P07547500A0066|138 142|yeast
P07547510A0261|42 46|sites
P07547510A0261|56 72|HNF-3 beta promoter
P07547510A0261|105 111|factors
P07547510A0261|172 182|binding site
P07547510A0261|199 204|factor
P07547510A0261|205 213|LF-H3 beta
P07547510A0261|242 264|HNF-3 beta gene expression
P07547510A0261|267 277|hepatocytes
P07548425A0000|22 28|effects
P07548425A0000|38 43|inputs
P07548425A0000|65 70|nerves
P07548425A0000|85 89|nerve
P07548425A0000|136 156|tail muscle motoneurons
P07548425A0000|187 195|lesioning
P07548425A0000|198 206|S2-3 level
P07548858A0000|3 10|flow rate
P07548858A0000|13 21|phosphate
P07548858A0000|30 35|saline
P07548858A0000|43 48|dermis
P07548858A0000|63 70|function
P07548858A0000|80 87|pressure
P07549005A0530|7 26|parallax measurements
P07549005A0530|43 50|collapse
P07549005A0530|53 64|Epon sections
P07549005A0530|76 80|place
P07550216A0195|20 25|limits
P07550216A0195|26 32|latency
P07551787A0917|3 9|outcome
P07551787A0917|15 26|optimization
P07551787A0917|59 71|investigation
P07551787A0917|82 88|results
P07551787A0917|126 146|radiotherapy technique
P07552974A0217|8 19|requirements
P07552974A0217|37 46|amino acids
P07552974A0217|47 55|glutamine
P07552974A0217|59 66|arginine
P07553942A0810|3 16|pea rps10 intron
P07553942A0810|31 37|introns
P07553942A0810|40 44|rrn26
P07553942A0810|59 68|Marchantia
P07553942A0810|81 86|genome
P07553942A0810|95 113|Marchantia rps10 gene
P07553942A0810|121 126|intron
P07554541A0587|18 27|CHF patient
P07554541A0587|38 48|recognition
P07554541A0587|52 61|management
P07554541A0587|69 91|electrolyte disturbances
P07555373A0000|0 13|Serum magnesium
P07555373A0000|18 25|patients
P07555373A0000|39 47|neoplasms
P07555373A0000|59 67|cisplatin
P07555373A0000|76 83|controls
P07557091A0314|0 6|METHODS
P07557091A0314|21 32|serum albumin
P07557091A0314|73 82|volunteers
P07557276A0526|0 22|Alanine aminotransferase
P07557276A0526|28 33|levels
P07557276A0526|54 59|months
P07557276A0526|65 72|patients
P07557276A0526|76 85|hepatitis B
P07557276A0526|91 99|infection
P07557387A0241|6 10|study
P07557387A0241|40 48|C/EBP beta
P07557387A0241|73 79|program
P07557387A0241|96 104|C/EBP beta
P07557387A0241|121 138|NIH-3T3 fibroblasts
P07557424A0124|35 45|fusion clone
P07557424A0124|69 81|fusion library
P07557446T0000|7 17|transcripts
P07557446T0000|37 45|VCSA1 gene
P07557446T0000|59 66|splicing
P07557446T0000|78 87|processing
P07557446T0000|109 113|gland
P07557717A0184|7 14|division
P07557717A0184|20 35|chest wall muscles
P07557717A0184|47 55|diathermy
P07557717A0184|87 95|morbidity
P07558263T0000|0 6|Closure
P07558263T0000|29 53|guillotine amputation wound
P07558263T0000|75 80|device
P07558583A0562|3 7|study
P07558583A0562|25 33|synthesis
P07558583A0562|40 50|derivatives
P07558583A0562|57 64|sequence
P07558583A0562|67 71|order
P07558583A0562|84 100|peptide substrates
P07558583A0562|115 123|detection
P07558583A0562|137 158|tyrosine kinase activity
P07558583A0562|181 190|inhibitors
P07558583A0562|206 210|class
P07558583A0562|213 219|enzymes
P07559233A0534|0 22|Citrate synthase activity
P07559233A0534|102 121|triceps brachii muscle
P07559233A0534|118 122|R rats
P07559347A0000|3 12|expression
P07559347A0000|26 36|operon bglPH
P07559347A0000|39 54|Bacillus subtilis
P07559347A0000|98 104|fusions
P07559355A0066|23 27|genes
P07559355A0066|40 53|urease activity
P07559355A0066|98 109|organization
P07559355A0066|113 122|regulation
P07559355A0066|133 137|genes
P07559355A0066|147 164|Proteus gene cluster
P07559355A0066|189 194|detail
P07559356T0000|3 16|hypBFCDE operon
P07559356T0000|21 54|Rhizobium leguminosarum biovar viciae
P07559356T0000|80 87|promoter
P07559356T0000|99 109|mutagenesis
P07559356T0000|115 122|fnrN gene
P07559402A0622|22 28|peptide
P07559402A0622|59 72|protein kinase C
P07559402A0622|93 106|protein kinase A
P07559478A0389|11 17|O'Neill
P07559488A0440|0 17|Control experiments
P07559488A0440|32 44|fusion protein
P07559488A0440|53 71|affinity binding site
P07559488A0440|75 90|estradiol-17 beta
P07559488A0440|122 133|reporter gene
P07559488A0440|136 140|yeast
P07559488A0440|157 162|type ER
P07559510A0000|8 38|Micrococcus luteus UV endonuclease
P07559510A0000|66 71|enzyme
P07559510A0000|84 91|homology
P07559510A0000|103 115|endonuclease V
P07559510A0000|120 134|bacteriophage T4
P07559510A0000|135 140|Gordon
P07559524A0000|16 24|oncogenes
P07559524A0000|28 40|growth factors
P07559524A0000|48 65|G1 phase progression
P07559524A0741|0 23|Cyclin D1 promoter activity
P07559524A0741|39 52|overexpression
P07559524A0741|72 84|protein kinase
P07559524A0741|85 91|p41MAPK
P07559524A0741|94 100|c-Ets-2
P07559524A0741|121 129|base pairs
P07559555A0557|14 18|c-Jun
P07559555A0557|45 51|EBS-CRE
P07559555A0557|82 88|complex
P07559563A0282|7 14|residues
P07559563A0282|51 58|activity
P07559639A0996|2 9|addition
P07559639A0996|13 32|R206S HSF substitution
P07559639A0996|68 77|activation
P07559639A0996|83 94|consensus HSE
P07559640A1230|6 10|bases
P07559640A1230|44 50|element
P07559640A1230|78 85|function
P07559640A1230|89 98|UAS element
P07559640A1230|110 114|bases
P07559640A1230|136 144|core motif
P07559650A0558|5 11|results
P07559650A0558|27 34|PCNA gene
P07559650A0558|44 53|target gene
P07560137T0000|12 22|sensitivity
P07560137T0000|28 49|MMPI-2 depression scales
P07560137T0000|53 61|subscales
P07560662A0496|5 12|recovery
P07560662A0496|24 38|saline challenge
P07562775A0596|3 7|range
P07562775A0596|10 20|eosinophils
P07562775A0596|36 41|number
P07562775A0596|58 67|blood cells
P07562775A0596|72 76|nadir
P07563072A0773|0 10|Comparisons
P07563072A0773|13 33|rrnB P1-lacZ expression
P07563072A0773|45 55|ppGpp levels
P07563072A0773|80 84|P504L
P07563072A0773|106 121|hypersensitivity
P07563072A0773|124 128|ppGpp
P07563076A0766|5 18|intron chimeras
P07563076A0766|37 45|sequences
P07563076A0766|52 59|elements
P07563076A0766|73 83|splice sites
P07563076A0766|111 118|activity
P07563076A0766|136 143|portions
P07563076A0766|166 170|cores
P07563076A0766|203 207|cores
P07563076A0766|218 224|targets
P07563076A0766|230 245|splicing proteins
P07563090A0124|43 54|DNA synthesis
P07563090A0124|60 74|yeast Ty1 element
P07563090A0124|91 95|sites
P07563090A0124|109 116|boundary
P07563090A0124|135 140|repeat
P07563090A0124|157 162|middle
P07563090A0124|167 173|pol gene
P07563090A0124|179 187|integrase
P07563090A0124|194 201|sequence
P07563090A0624|0 15|Characterization
P07563090A0624|44 55|DNA fragments
P07563090A0624|78 85|fragment
P07563090A0624|147 154|majority
P07563090A0624|178 189|DNA fragments
P07563090A0624|218 234|primer binding site
P07563090A0624|236 244|agreement
P07563090A0624|260 264|model
P07563090A0624|284 306|RNA reverse transcription
P07563994A0488|3 10|patients
P07563994A0488|59 63|times
P07563994A0488|135 143|blood loss
P07564004A0292|5 11|minutes
P07564004A0292|17 31|Cr2O3 inhalation
P07564004A0292|32 37|FEV1.0
P07564210A0557|34 40|regimen
P07564210A0557|49 59|anaesthesia
P07564210A0557|63 71|analgesia
P07564210A0557|112 116|signs
P07565031A0454|6 17|food products
P07565031A0454|38 49|V. cholerae O1
P07565031A0454|50 54|Ogawa
P07565031A0454|79 85|strains
P07565031A0454|86 92|yoghurt
P07565031A0454|93 103|cream cheese
P07565031A0454|104 119|apricot marmelade
P07565031A0454|129 137|marmelade
P07565031A0454|137 146|mayonnaise
P07565031A0454|154 158|pasta
P07565031A0454|162 170|empanadas
P07565031A0454|183 193|meat sausage
P07565031A0454|203 216|spinach ravioli
P07565031A0454|216 224|margarine
P07565031A0454|225 235|milk dessert
P07565031A0454|244 248|cocoa
P07565031A0454|249 261|milk confiture
P07565031A0454|262 267|starch
P07565031A0454|271 279|additives
P07565031A0454|280 286|lettuce
P07565031A0454|287 294|tuna fish
P07565031A0454|295 301|ricotta
P07565049A1032|37 43|outline
P07565049A1032|158 163|weight
P07565104A0084|3 12|expression
P07565104A0084|18 26|pilin gene
P07565113A0000|29 44|transposon Tn4451
P07565113A0000|72 79|deletion
P07565113A0000|87 105|parent plasmid plP401
P07565113A0000|108 129|Clostridium perfringens
P07565113A0000|151 158|excision
P07565113A0000|172 179|plasmids
P07565669T0000|0 8|Ras p21Val
P07565669T0000|17 26|myogenesis
P07565669T0000|45 54|DNA binding
P07565669T0000|72 81|activities
P07565669T0000|116 122|factors
P07565672A0798|2 6|cells
P07565672A0798|29 38|expression
P07565672A0798|41 45|arg-2
P07565672A0798|49 53|cpc-1
P07565672A0798|66 75|expression
P07565672A0798|78 82|cox-5
P07565672A0798|121 130|components
P07565685A0420|3 18|peptide sequences
P07565685A0420|32 37|factor
P07565685A0420|48 56|GABP alpha
P07565685A0420|60 67|GABP beta
P07565685A0420|81 91|Notch motifs
P07565688A0797|0 27|Immunofluorescence microscopy
P07565688A0797|31 55|cell fractionation analyses
P07565688A0797|76 82|protein
P07565688A0797|121 127|protein
P07565688A0797|147 155|cytoplasm
P07565688A0797|159 165|nucleus
P07565688A0797|173 177|cells
P07565688T0000|0 9|Expression
P07565688T0000|13 22|regulation
P07565688T0000|25 34|interferon
P07565688T0000|66 83|adenosine deaminase
P07565688T0000|93 97|cells
P07565688T0000|98 105|evidence
P07565688T0000|112 116|forms
P07565688T0000|122 130|deaminase
P07565709A0000|0 15|T-cell hybridomas
P07565709A0000|16 25|thymocytes
P07565709A0000|29 34|T cells
P07565709A0000|65 73|cell death
P07565709A0000|76 85|activation
P07565709A0000|96 109|T-cell receptor
P07565712A0286|0 8|Deletions
P07565712A0286|26 33|LYS2 gene
P07565712A0286|57 63|inserts
P07565712A0286|75 81|inserts
P07565712A0286|96 104|potential
P07565712A0286|117 125|structure
P07565712A0286|137 152|quasipalindromes
P07565713A0634|0 13|Overexpression
P07565713A0634|42 57|HSP60-null allele
P07565713A0634|71 81|suppression
P07565713A0634|107 119|Hsp60 activity
P07565720A0256|3 18|DNA binding domain
P07565720A0256|42 54|fusion protein
P07565720A0256|61 84|glutathione S-transferase
P07565720A0256|87 106|Schistosoma japonicum
P07565723A0200|3 8|kinase
P07565723A0200|35 49|phosphorylation
P07565723A0200|72 77|growth
P07565723A0200|80 94|differentiation
P07565731A1629|8 12|model
P07565731A1629|28 42|mRNA degradation
P07565731A1629|98 115|ribonucleoproteins
P07565731A1629|129 136|proteins
P07565736A2134|24 33|C/EBP alpha
P07565736A2134|50 76|GM-CSF receptor alpha promoter
P07565736A2134|89 93|cells
P07565740T0000|0 10|Endocytosis
P07565740T0000|22 32|degradation
P07565740T0000|38 43|plasma
P07565740T0000|79 86|cassette
P07565740T0000|95 105|transporter
P07565775A1265|10 18|mutations
P07565775A1265|21 26|motifs
P07565775A1265|52 58|effects
P07565775A1265|63 70|affinity
P07565775A1265|73 78|enzyme
P07565775A1265|106 114|catalysis
P07565775A1265|113 124|EpG formation
P07565775A1265|130 137|transfer
P07565775A1265|149 154|enzyme
P07565775T0000|10 17|analysis
P07565775T0000|33 38|enzyme
P07565775T0000|48 57|amino acids
P07565775T0000|68 77|GTP binding
P07565775T0000|94 102|formation
P07565775T0000|106 116|GMP transfer
P07565776A0612|0 9|Disruption
P07565776A0612|24 32|PBS2 genes
P07565776A0612|48 55|decrease
P07565776A0612|61 77|HSP12 inducibility
P07565776A0612|92 96|cells
P07565776A0612|104 117|overproduction
P07565776A0612|143 150|increase
P07565776A0612|168 173|levels
P07565776A0612|179 183|shift
P07565776A0612|191 207|salt concentration
P07565797A0116|0 7|Deletion
P07565797A0116|10 21|inactivation
P07565797A0116|57 62|levels
P07565797A0116|64 71|CRY2 mRNA
P07567079A0014|4 9|method
P07567079A0014|12 21|separation
P07567079A0014|24 41|Cryptosporidium spp
P07567079A0014|52 58|oocysts
P07567079A0014|63 67|feces
P07567079A0014|76 82|percoll
P07567079A0014|96 110|density gradient
P07567079A0014|120 125|method
P07567079A0014|128 133|choice
P07567079A0014|151 157|numbers
P07567079A0014|160 166|oocysts
P07567079A0014|169 176|C. parvum
P07567079A0014|188 200|contamination
P07567300T0000|14 24|enterotoxin
P07567300T0000|26 36|involvement
P07567300T0000|42 48|illness
P07567300T0000|68 74|patient
P07567830A0072|0 6|METHODS
P07567830A0072|59 64|curves
P07567830A0072|79 86|patients
P07567830A0072|100 105|tremor
P07567830A0072|108 112|males
P07567830A0072|115 121|females
P07567830A0072|136 140|years
P07567979A1266|3 10|findings
P07567979A1266|25 29|basis
P07567979A1266|36 46|development
P07567979A1266|49 54|assays
P07567979A1266|69 75|ligands
P07567979A1266|78 91|testis receptor
P07567979A1266|96 100|hERR1
P07567980T0000|20 33|domain peptides
P07567980T0000|56 63|elements
P07568026A0622|3 12|Stat5b mRNA
P07568026A0622|43 49|protein
P07568026A0622|53 62|amino acids
P07568116A0902|3 16|hydropathy plot
P07568116A0902|53 58|region
P07568116A0902|65 71|absence
P07568116A0902|86 98|signal peptide
P07568118A1267|5 11|results
P07568118A1267|23 27|G beta
P07568118A1267|44 61|Shc phosphorylation
P07568118A1267|90 96|pathway
P07568118A1267|105 120|p21ras activation
P07568118A1267|133 141|mechanism
P07568118A1267|152 186|growth factor tyrosine kinase receptors
P07568576A0074|4 9|report
P07568576A0074|22 33|relationship
P07568576A0074|41 53|Type A behavior
P07568576A0074|67 83|emotion dimensions
P07568865A0305|3 11|carcasses
P07568865A0305|22 34|contamination
P07568865A0305|56 63|bacteria
P07568865A0305|69 73|range
P07568865A0305|90 95|CFU/ml
P07568865A0305|132 139|bacteria
P07568865A0305|142 150|threshold
P07568865A0305|164 169|CFU/ml
P07568865A0305|170 175|Figure
P07569075A0585|7 11|stage
P07569075A0585|16 33|lung cancer patients
P07569075A0585|85 92|response
P07569075A0585|110 125|chest radiography
P07569075A0585|135 142|cytology
P07569075A0585|147 155|histology
P07569532T0001|0 8|Pediatric
P07569532T0001|16 26|emergencies
P07569532T0001|38 45|hospital
P07569532T0001|57 62|locale
P07569640A0539|0 21|Protein electrophoresis
P07569640A0539|37 49|albumin levels
P07569640A0539|56 61|groups
P07569640A0539|71 76|values
P07569770A0298|0 6|METHODS
P07569770A0298|17 30|non-responders
P07569770A0298|61 67|vaccine
P07569770A0298|68 73|months
P07569770A0298|86 97|immunization
P07569770A0298|102 112|booster dose
P07569770A0298|131 137|vaccine
P07569770A0298|139 143|years
P07571766A0122|16 25|percentage
P07571766A0122|40 47|patients
P07571766A0122|82 96|catheterization
P07571766A0122|140 160|ST-segment depressions
P07571766A0122|193 200|arteries
P07571953T0000|27 38|mycobacteria
P07571953T0000|59 64|smears
P07572582A0000|0 9|Mibefradil
P07572582A0000|29 45|calcium antagonist
P07572582A0000|53 65|chemical class
P07572582A0000|109 122|calcium channel
P07574064A1416|23 45|concentration anesthesia
P07574064A1416|126 132|l.min-1
P07574064A1416|150 154|shift
P07574064A1416|160 179|response relationship
P07574682T0000|53 71|alkaline phosphatase
P07575416A0000|0 13|Protein kinase C
P07575416A0000|38 43|enzyme
P07575416A0000|58 67|regulation
P07575416A0000|87 95|processes
P07575416A0000|107 112|family
P07575416A0000|128 137|isoenzymes
P07575416A0000|151 168|tissue distribution
P07575416A0000|180 191|localization
P07575416A0000|202 211|properties
P07575416A1970|36 45|importance
P07575416A1970|54 59|choice
P07575416A1970|62 76|oligonucleotide
P07575416A1970|80 89|cDNA probes
P07575416A1970|97 107|PKC zeta mRNA
P07575438A1409|4 9|action
P07575438A1409|39 45|factors
P07575438A1409|56 64|E1 element
P07575947T0000|3 8|debate
P07575947T0000|13 21|electives
P07576178A0000|0 23|Polypeptide growth factors
P07576178A0000|27 35|cytokines
P07576178A0000|59 67|functions
P07576178A0000|90 98|receptors
P07576179A0781|25 33|frequency
P07576179A0781|36 51|CpG dinucleotides
P07576307A0144|48 55|cassette
P07576307A0144|71 83|rat enkephalin
P07576307A0144|113 122|regulation
P07576307A0144|126 144|enkephalin phenotype
P07576307A1654|27 32|motifs
P07576307A1654|75 83|complexes
P07576307A1654|95 102|extracts
P07576307A1654|115 127|tumor cell line
P07577904A0141|13 17|years
P07577904A0141|26 36|persistence
P07577904A0141|78 88|dislocation
P07577904A0141|93 104|camera aquosa
P07577904A0141|117 127|buphthalmos
P07577904A0141|145 158|microphthalmos
P07577904A0141|162 172|dislocation
P07579023A0214|9 20|dose-finding
P07579023A0214|24 31|patients
P07579023A0214|60 69|medication
P07579023A0214|76 82|patient
P07579023A0214|111 116|levels
P07579023A0214|119 130|liver enzymes
P07579164A0409|2 11|comparison
P07579164A0409|30 38|sequences
P07579164A0409|42 57|RNA editing events
P07579164A0409|73 81|atp9 genes
P07579328A0653|0 4|MZF-1
P07579328A0653|14 38|CAT reporter gene expression
P07579328A0653|42 57|GAL4 binding sites
P07579328A0653|79 93|cell lines NIH 3T3
P07579328A1345|21 36|DNA binding domain
P07579328A1345|37 41|MZF-1
P07579328A1345|51 72|reporter gene expression
P07579328A1345|91 99|cell lines
P07579328A1345|112 121|expression
P07579328A1345|137 145|cell lines
P07579683A0660|0 7|Analyses
P07579683A0660|10 31|hGMR beta subunit mutants
P07579683A0660|54 60|regions
P07579683A0660|71 80|activation
P07579683A0660|86 98|c-myc promoter
P07579683A0660|151 158|activity
P07579695A0336|28 37|phenotypes
P07579695A0336|45 53|mutations
P07579695A0336|77 85|mutations
P07579695A0336|97 128|yeast centromere protein genes-CEP1
P07579695A0336|128 136|CBF1/CPF1
P07579695A0336|137 146|NDC10/CBF2
P07579695A0336|150 159|CEP3/CBF3B
P07579695A0693|38 48|Mif2 protein
P07579695A0693|61 65|Cep1p
P07579695A0693|71 80|centromere
P07579695A0693|91 105|yeast centromere
P07579695A0693|127 131|order
P07579695A0693|143 149|complex
P07579704A0085|16 26|actin cables
P07579704A0085|30 36|patches
P07579704A0085|62 70|cell cycle
P07579704A0085|88 97|components
P07579704A0085|111 115|sites
P07579704A0085|119 128|cell growth
P07580058A0000|3 9|effects
P07580058A0000|12 29|Codonopsis pilosula
P07580058A0000|34 39|liquor
P07580058A0000|48 78|tissue-type plasminogen activator
P07580058A0000|87 115|plasminogen activator inhibitor
P07580058A0000|125 130|plasma
P07580058A0000|134 141|patients
P07580058A0000|152 163|heart disease
P07580058A0000|168 178|blood stasis
P07580330A0331|14 20|intakes
P07580330A0331|30 35|person
P07580330A0331|43 51|microgram
P07580330A0331|69 77|microgram
P07580330A0331|80 88|gamma-HCH
P07580330A0331|93 101|microgram
P07580330A0331|105 112|dieldrin
P07580330A0331|117 126|micrograms
P07580330A0331|147 155|microgram
P07580782T0000|0 14|Imaging features
P07580782T0000|24 37|epidermoid cyst
P07580782T0000|52 62|correlation
P07581364A0500|12 16|cases
P07581364A0500|53 61|deletions
P07581364A0500|76 81|Ag1-CA
P07582316A0696|18 22|pairs
P07582316A0696|25 32|isolates
P07582316A0696|67 87|IS6110 banding patterns
P07582316A0696|114 123|MTB strains
P07582592A0545|59 64|damage
P07582592A0545|82 91|dilatation
P07582592A0545|124 137|administration
P07582592A0545|153 175|botulinum toxin injection
P07582592A0545|181 189|treatment
P07582592A0545|192 200|achalasia
P07583190A0306|20 28|processes
P07583190A0306|65 69|parts
P07583190A0306|79 88|hemisphere
P07583190A0306|104 118|brain potentials
P07583190A0306|159 183|phrase structure violations
P07583190A0306|213 219|lesions
P07583190A0306|226 233|area lead
P07583190A0306|238 247|impairment
P07583190A0306|270 279|assignment
P07583562A1826|96 101|models
P07583562A1826|118 122|LDL-C
P07583562A1826|125 136|hypertension
P07585246T0000|0 16|SL1 trans-splicing
P07585246T0000|70 98|Caenorhabditis elegans pre-mRNA
P07585559A0000|19 26|compound
P07585559A0000|27 37|6-methoxy-4
P07585559A0000|37 52|2-hydroxyethoxyl
P07585559A0000|52 56|ethyl
P07585559A0000|56 60|amino
P07585559A0000|61 78|methyl-1M-pyrazo lo
P07585559A0000|79 83|3,4-b
P07585559A0000|83 91|quinoline
P07585559A0000|125 131|ability
P07585559A0000|153 185|muscle alpha-actin promoter activity
P07585559A0000|203 207|cells
P07586403A0765|5 9|basis
P07586403A0765|17 25|relations
P07586403A0765|27 51|risk factor-selection scale
P07586403A0765|58 62|range
P07586403A0765|101 107|weights
P07586403A0765|115 124|risk factor
P07588240A0000|3 46|Caenorhabditis elegans death susceptibility gene
P07588240A0000|47 51|ced-3
P07588240A0000|56 61|number
P07588240A0000|64 71|homologs
P07588240A0000|84 90|species
P07588240A0000|100 116|interleukin-1 beta
P07588240A0000|117 124|IL-1 beta
P07588240A0000|134 139|enzyme
P07588240A0000|157 161|CPP32
P07588245T0000|0 9|Repression
P07588245T0000|12 25|glucocorticoid
P07588245T0000|58 67|activation
P07588245T0000|80 101|thyroid hormone receptor
P07588603A1054|3 9|results
P07588603A1054|30 40|flexibility
P07588603A1054|46 52|spacing
P07588603A1054|74 78|sites
P07588608A1687|0 10|Obstruction
P07588608A1687|16 35|ERF repressor function
P07588608A1687|56 62|members
P07588608A1687|68 76|ets family
P07588608A1687|79 83|genes
P07588608A1687|84 98|i.e.gag-myb-ets
P07588608A1687|119 125|control
P07588608A1687|128 132|genes
P07588608A1687|143 159|cell proliferation
P07588608A1687|194 200|effects
P07588628A0318|0 13|Overexpression
P07588628A0318|41 49|apoptosis
P07588633A0362|10 14|c-Fos
P07588633A0362|18 42|c-fos protooncogene product
P07588633A0362|80 86|protein
P07588633A0362|151 160|efficiency
P07588633A0362|163 173|NIH 3T3 cells
P07588750T0061|0 6|Cloning
P07588750T0061|7 16|sequencing
P07588750T0061|20 29|expression
P07588750T0061|53 62|kinase gene
P07588750T0061|65 80|Pyrococcus woesei
P07588750T0061|101 116|characterization
P07588750T0061|122 128|protein
P07588777A1524|5 16|observations
P07588777A1524|26 33|proposal
P07588777A1524|69 74|target
P07588777A1524|88 94|p42mapk
P07588777A1524|98 114|p44mapk MAP kinases
P07589069A1245|37 41|forms
P07589069A1245|49 55|CD6 cDNA
P07589069A1245|63 71|sequences
P07589069A1245|97 103|regions
P07589069A1245|120 125|domain
P07589069A1245|146 157|reading frame
P07589069A1245|160 166|CD6-PB1
P07590264A0373|30 40|differences
P07590264A0373|43 57|polyadenylation
P07590264A0373|79 84|levels
P07590264A0373|96 100|mRNAs
P07590264A0373|119 124|allele
P07590264A0373|142 146|sense
P07590264A0373|159 169|differences
P07590264A0373|173 188|end RNA processing
P07590264A0373|224 228|sites
P07590264A0373|241 245|level
P07590264A0373|248 261|gene expression
P07590268A0350|56 66|polypeptide
P07590268A0350|81 98|sequence similarity
P07590268A0350|113 121|MAPKAPK-2
P07590268A0740|7 22|MAPKAPK-2 message
P07590268A0740|44 54|development
P07590268A0740|70 80|transcripts
P07590268A0740|132 139|germline
P07590283A0820|3 9|finding
P07590283A0820|29 42|Pol beta protein
P07590283A0820|80 97|polymerase activity
P07590283A0820|120 126|Pol beta
P07590283A0820|139 157|template utilization
P07590283A0820|167 188|polymerization reaction
P07590283A0820|213 219|finding
P07590283A0820|242 247|domain
P07590283A0820|250 256|Pol beta
P07590283A0820|279 286|activity
P07590283A0820|287 291|Kumar
P07590525A0811|10 15|values
P07590525A0811|29 40|revertants/g
P07590525A0811|47 56|hamburgers
P07590657A0624|0 14|Cholangiography
P07590657A0624|32 36|cases
P07590657A0624|60 65|system
P07590657A0624|99 106|patients
P07590744A0829|3 11|integrity
P07590744A0829|17 28|cDNA sequence
P07590744A0829|43 50|analysis
P07590744A0829|78 83|clones
P07590744A0829|95 102|GAR1 gene
P07592072A0217|2 6|Trial
P07592072A0217|30 35|farrow
P07592072A0217|84 89|farrow
P07592072A0217|107 115|injection
P07592072A0217|118 137|prostaglandin F2 alpha
P07592072A0217|148 156|gestation
P07592220A0846|20 24|ratio
P07592220A0846|26 42|minute ventilation
P07592220A0846|45 61|oxygen consumption
P07592220A0846|62 67|VE/VO2
P07592220A0846|82 87|PETCO2
P07592337A0891|5 11|results
P07592337A0891|57 66|expression
P07592439A0000|33 40|myovirus
P07592439A0000|43 63|Listeria monocytogenes
P07592467A0000|3 11|mechanism
P07592467A0000|14 36|peroxisome proliferation
P07592485A0734|15 28|gene expression
P07592485A0734|52 58|pathway
P07592485A0734|95 108|NCR sensitivity
P07592485A0734|118 127|expression
P07592485A0734|147 163|ure2 delta mutation
P07592647A0797|18 46|DNA Pur alpha recognition element
P07592647A0797|60 68|complexes
P07592647T0000|0 10|Association
P07592647T0000|18 25|Pur alpha
P07592647T0000|33 53|retinoblastoma protein
P07592647T0000|94 122|DNA Pur alpha recognition element
P07592658A0309|29 35|complex
P07592658A0309|54 71|p50/p65 heterodimer
P07592676A0466|12 21|conditions
P07592676A0466|35 43|complexes
P07592676A0466|82 90|NIP region
P07592676A0466|120 136|repressor activity
P07592706A1465|0 7|Exchange
P07592706A1465|21 26|HL lids
P07592706A1465|37 44|reversal
P07592706A1465|71 81|lipase ratio
P07592706A1465|118 123|region
P07592706A1465|143 153|specificity
P07592710T0000|23 38|protein kinase PKR
P07592710T0000|66 75|activation
P07592710T0000|78 100|immunoglobulin kappa gene
P07592711T0000|9 13|forms
P07592711T0000|22 33|yeast protein
P07592711T0000|45 53|lethality
P07592711T0000|57 86|G protein alpha subunit deficiency
P07592711T0000|107 117|beta subunit
P07592721A0827|13 20|mutation
P07592721A0827|29 38|amino acids
P07592721A0827|67 74|contacts
P07592723A0814|0 12|Phorbol esters
P07592723A0814|23 37|phosphorylation
P07592723A0814|40 53|CSK 35H proteins
P07592723A0814|73 81|sequences
P07592723A0814|101 118|PKC binding activity
P07592723A0814|133 145|PKC substrates
P07592730A0204|0 5|Levels
P07592730A0204|8 20|TSG-14 protein
P07592730A0204|31 35|PTX-3
P07592730A0204|55 59|serum
P07592730A0204|71 76|humans
P07592730A0204|81 89|injection
P07592730A0204|103 120|lipopolysaccharide
P07592730A0204|126 133|contrast
P07592730A0204|153 165|phase proteins
P07592730A0204|177 191|TSG-14 synthesis
P07592730A0204|202 209|organism
P07592730A0204|226 230|liver
P07592771A0258|3 11|mouse beta
P07592771A0258|34 42|kilobases
P07592771A0258|55 59|exons
P07592771A0258|74 83|homologues
P07592771A0258|102 109|position
P07592771A0258|115 119|alpha
P07592790A1457|49 56|subgroup
P07592790A1457|70 76|serpins
P07592790A1457|97 102|region
P07592790A1457|128 135|activity
P07592790A1457|141 147|protein
P07592946A0261|15 21|cloning
P07592946A0261|33 44|p44 MAP kinase
P07592946A0261|74 79|kinase
P07592946A0261|90 102|determination
P07592946A0261|107 127|intron/exon boundaries
P07592946A0261|134 149|characterization
P07592946A0261|155 162|promoter
P07592946A0997|23 31|TATA boxes
P07592946A0997|52 67|start sites region
P07592946A0997|71 77|AP-1 box
P07592946A0997|81 87|AP-2 box
P07592946A0997|91 97|Malt box
P07592946A0997|101 107|GAGA box
P07592946A0997|133 139|element
P07592946A0997|150 161|binding sites
P07592946A0997|181 193|binding factor
P07592946A0997|197 203|CTF-NF1
P07592946A0997|223 227|Ets-1
P07592946A0997|229 234|NF-IL6
P07592946A0997|247 251|Zeste
P07592946A0997|257 266|hepatocyte
P07592946A0997|274 281|factor-5
P07593266A1174|45 50|region
P07593266A1174|71 87|pair stem structure
P07593896A1053|21 40|measurement technique
P07593896A1053|66 80|P0.1 measurement
P07593896A1053|104 112|equipment
P07593896A1053|126 134|lung model
P07594047T0000|0 6|Effects
P07594047T0000|9 17|verapamil
P07594047T0000|21 31|propranolol
P07594047T0000|39 58|afterdepolarizations
P07594047T0000|73 83|arrhythmias
P07594047T0000|93 103|epinephrine
P07594047T0000|120 129|QT syndrome
P07594592A0755|0 7|Deletion
P07594592A0755|13 41|NF-IL6 beta leucine zipper domain
P07594592A0755|66 76|interaction
P07594592A0755|92 99|proteins
P07595221A0733|5 9|cells
P07595221A0733|35 39|CIITA
P07595221A0733|50 57|MHC class
P07595221A0733|60 64|genes
P07595221A0733|95 102|MHC class
P07595221A0733|105 113|promoters
P07595221A0733|125 136|transfection
P07595221A0733|178 182|cells
P07595374A1215|3 9|domains
P07595374A1215|12 16|EBNA2
P07595374A1215|26 33|deletion
P07595374A1215|36 45|amino acids
P07595374A1215|91 100|activation
P07595374A1215|107 115|promoters
P07595374A1215|133 139|domains
P07595374A1215|155 162|residues
P07595374A1215|201 212|LMP1 promoter
P07595857A0521|3 16|peak velocities
P07595857A0521|36 40|waves
P07595857A0521|46 56|transmitral
P07595857A0521|75 88|flow velocities
P07595857A0521|163 171|durations
P07595857A0521|187 191|waves
P07595857A0521|195 203|amplitude
P07595857A0521|223 228|motion
P07595857A0521|241 247|systole
P07595857A0521|284 296|cardioversion
P07595857A0521|335 347|cardioversion
P07595857A0521|352 359|patients
P07595857A0521|370 377|patients
P07595857A0521|389 402|cardiomyopathy
P07596283A0396|15 20|enzyme
P07596283A0396|26 33|activity
P07596283A0396|41 53|triglycerides
P07596283A0396|73 82|tributyrin
P07596283A0396|100 108|emulsions
P07596287A0183|3 20|nucleotide sequence
P07596287A0183|60 72|reading frames
P07596287A0183|99 113|protein products
P07596287A0183|127 133|members
P07596287A0183|137 147|superfamily
P07596287A0183|161 193|cassette membrane transport proteins
P07596287A0183|231 236|uptake
P07596287A0183|240 252|export systems
P07596287A1724|3 11|ORF3 probe
P07596287A1724|32 43|bp transcript
P07596287A1724|98 112|mutagenesis data
P07596558A0824|5 11|results
P07596558A0824|26 39|concentrations
P07596558A0824|42 49|IL-1 beta
P07596558A0824|75 83|treatment
P07596558A0824|99 108|hemorrhage
P07596697A0971|24 34|polypeptide
P07596697A0971|38 53|motilin responses
P07596697A0971|87 94|children
P07596697A0971|100 107|children
P07596697A0971|113 124|control group
P07597030A0260|15 21|cloning
P07597030A0260|22 31|expression
P07597030A0260|46 61|characterization
P07597030A0260|73 79|subunit
P07597030A0260|90 94|TFIID
P07597030A0260|100 107|hTAFII32
P07597488T0000|9 16|jaundice
P07597488T0000|22 35|G6PD deficiency
P07597488T0000|43 53|kernicterus
P07597804A1007|3 13|transcripts
P07597804A1007|71 90|glycoprotein gene EUS4
P07598106A0709|0 16|Mean growth changes
P07598106A0709|23 27|Class
P07598106A0709|30 35|sample
P07598106A0709|82 89|subjects
P07598106A0709|94 98|Class
P07598106A0709|100 112|malocclusions
P07598106A0709|124 132|age period
P07598106A0709|144 153|similarity
P07598106A0709|168 178|development
P07598106A0709|194 199|groups
P07598303A1728|13 19|studies
P07598303A1728|44 54|prophylaxis
P07598303A1728|57 81|bone marrow transplantation
P07598303A1728|101 115|survival benefit
P07599449A0445|3 16|fracture groups
P07599449A0445|49 53|years
P07599449A0445|59 67|menopause
P07599449A0445|75 87|control groups
P07599653A0898|2 9|addition
P07599653A0898|17 27|differences
P07599653A0898|33 39|binding
P07599653A0898|49 55|factors
P07599653A0898|60 65|shoots
P07599653A0898|76 80|roots
P07599653A0898|83 91|agreement
P07599653A0898|108 117|activities
P07599653A0898|123 130|promoter
P07599653A0898|141 146|organs
P07600111A0000|3 12|prevalence
P07600111A0000|16 24|incidence
P07600111A0000|32 57|immunodeficiency virus types
P07600111A0000|63 67|HIV-1
P07600111A0000|68 72|HIV-2
P07600111A0000|92 101|virus types
P07600111A0000|108 116|HTLV-I/II
P07600111A0000|130 139|infections
P07600111A0000|146 156|association
P07600111A0000|169 178|infections
P07600111A0000|196 201|cohort
P07600111A0000|204 217|police officers
P07600111A0000|220 232|Guinea-Bissau
P07600986A0605|9 28|immunoprecipitations
P07600986A0605|32 45|gel shift assays
P07600986A0605|61 67|classes
P07600986A0605|74 81|affinity
P07600986A0605|99 103|sites
P07600986A0605|138 155|transcription units
P07601078A1003|0 7|Subjects
P07601078A1003|18 33|postexposure time
P07601078A1003|38 49|dioxin burden
P07601078A1003|54 58|pg/m3
P07601078A1003|90 97|hypoergy
P07601078A1003|110 117|subjects
P07601078A1003|118 126|hypoergy I
P07601078A1003|153 160|hypoergy
P07601121A0153|0 7|Analysis
P07601121A0153|14 21|sequence
P07601121A0153|70 75|region
P07601121A0153|97 101|start
P07601121A0153|104 116|transcription
P07601121A0153|150 158|sequences
P07601445A0207|16 37|BAT1 translation product
P07601445A0207|43 49|homolog
P07601445A0207|55 60|rat p47
P07601445A0207|68 74|protein
P07601445A0207|78 101|WM6 Drosophila gene product
P07601445A0207|117 123|Ce08102
P07601445A0207|126 146|Caenorhabditis elegans
P07601445A0207|150 156|members
P07601445A0207|166 178|protein family
P07601445A0207|194 205|RNA helicases
P07601827A0778|7 17|lacZ fusions
P07601827A0778|44 55|DNA sequences
P07601827A0778|80 89|repression
P07601827A0778|119 124|region
P07601828A0095|6 11|report
P07601828A0095|25 40|characterization
P07601828A0095|51 55|class
P07601828A0095|58 71|flagellar genes
P07601828A0095|86 99|orfX-fliP locus
P07603726T0000|10 28|adaptation exercises
P07603726T0000|32 39|recovery
P07603726T0000|45 49|stage
P07603726T0000|63 78|neuroma resection
P07603956A0115|15 20|design
P07603956A0115|44 54|arrangement
P07603956A0115|57 66|treatments
P07603956A0115|83 88|levels
P07603956A0115|91 103|incorporation
P07603956A0115|125 132|chickens
P07604047A0704|1 9|cDNA clone
P07604047A0704|57 64|sequence
P07604047A0704|92 114|transcription-PCR method
P07604047A0704|121 128|identity
P07604047A0704|134 142|cDNA clone
P07604047A0704|169 178|capability
P07604047A0704|184 196|fusion protein
P07604783A0952|22 28|changes
P07604783A0952|45 59|acid composition
P07604783A0952|69 76|lecithin
P07604783A0952|84 102|bile acid composition
P07604794A0958|5 15|cholesterol
P07604794A0958|50 55|mg/day
P07604794A0958|68 73|mg/day
P07604794A0958|100 105|mg/day
P07604794A0958|119 124|mg/day
P07605990A1110|15 21|studies
P07605990A1110|62 66|PEBP2
P07605990A1110|71 92|GM-CSF promoter activity
P07605990A1110|103 110|findings
P07605990A1110|123 132|importance
P07605990A1110|146 150|ratio
P07605990A1110|162 174|PEBP2 isoforms
P07605990A1110|190 195|levels
P07605990A1110|201 216|promoter activity
P07606548T0000|0 7|Benefits
P07606548T0000|19 36|board certification
P07606548T0000|39 53|pharmacotherapy
P07606587A0266|0 22|Piperacillin-tazobactam
P07606587A0266|38 46|treatment
P07606587A0266|49 58|infections
P07606587A0266|112 119|bacteria
P07607197A1048|5 23|plasma renin activity
P07607197A1048|53 60|training
P07607197A1048|81 88|controls
P07607213A0140|23 52|structure/activity relationship
P07607213A0140|68 73|issues
P07607213A0140|93 101|evolution
P07607213A0140|114 121|peptides
P07607213A0140|128 137|mechanisms
P07607213A0140|154 163|expression
P07607233A0186|46 56|epilancin K7
P07607233A0186|104 121|nucleotide sequence
P07607342A0703|4 8|paper
P07607342A0703|34 41|evidence
P07607342A0703|62 67|trials
P07607342A0703|70 94|aldose reductase inhibitors
P07607342A0703|105 112|patients
P07607342A0703|136 142|results
P07607342A0703|154 163|drug trials
P07607342A0703|171 178|patients
P07607537A0954|3 10|spectrum
P07607537A0954|13 22|phenotypes
P07607537A0954|36 44|mutations
P07607537A0954|71 79|mutations
P07607537A0954|85 91|adaptor
P07607537A0954|98 117|VP16 activation domain
P07607607T0000|0 7|Increase
P07607607T0000|17 23|calcium
P07607607T0000|27 33|oxalate
P07607607T0000|39 54|fructose infusion
P07607669A1112|11 16|region
P07607669A1112|45 55|CpG doublets
P07607669A1112|74 85|binding sites
P07608268A0194|21 29|disorders
P07608268A0194|32 45|GnRH deficiency
P07608268A0194|70 95|melatonin secretion profiles
P07608268A0194|120 127|males IGD
P07608268A0194|165 172|controls
P07608649A1429|9 21|blood pressure
P07608649A1429|28 39|CyA treatment
P07608649A1429|67 76|ET-1 levels
P07608968A0836|0 7|Analysis
P07608968A0836|17 26|Tat mutants
P07608968A0836|66 76|core domains
P07608968A0836|83 96|transactivator
P07608968A0836|132 144|transcription
P07609037A0775|2 9|addition
P07609037A0775|10 18|depletion
P07609037A0775|21 25|Oct-1
P07609037A0775|40 46|extract
P07609037A0775|68 76|antiserum
P07609037A0775|97 112|DNA affinity resin
P07609037A0775|129 141|transcription
P07609037A0775|158 169|MMTV promoter
P07609037A0775|173 177|level
P07609037A0775|206 213|promoter
P07609037A0775|244 252|sequences
P07609079A0387|0 14|Transactivation
P07609079A0387|20 27|HIV-1 LTR
P07609079A0387|30 37|T3R alpha
P07609079A0387|48 62|receptor mutants
P07609079A0387|101 109|A/B region
P07609079A0387|112 119|T3R alpha
P07609079A0387|147 170|transcription factor TFIIB
P07609079A0387|184 193|activation
P07609079A0387|241 249|sequences
P07609372A0261|0 5|M.M.C.
P07609372A0261|19 25|minutes
P07609372A0261|30 34|cases
P07609372A0261|37 46|HR patients
P07609372A0261|49 58|LR patients
P07609372A0261|66 72|minutes
P07609372A0261|77 81|cases
P07609372A0261|84 93|HR patients
P07609372A0261|96 105|LR patients
P07610052A1064|17 25|complexes
P07610052A1064|51 62|C35 complexes
P07610052A1064|72 80|rat cortex
P07610052A1064|88 95|extracts
P07610052A1064|102 111|SAA element
P07610052A1064|114 128|EMSA experiments
P07610052A1064|142 150|relevance
P07610052A1064|163 174|observations
P07610052A1064|186 196|functioning
P07610052A1064|202 215|rat APP promoter
P07610324A0319|35 41|aspects
P07610324A0319|94 98|years
P07610324A0319|122 135|reconstruction
P07610324A0319|173 179|centers
P07610716A0117|3 10|analysis
P07610716A0117|16 31|prevalence values
P07610716A0117|57 68|MS-frequency
P07610716A0117|119 126|latitude
P07610735A1471|0 8|Diltiazem
P07610735A1471|26 33|decrease
P07610735A1471|50 57|response
P07610735A1471|65 74|conversion
P07610735A1471|77 87|sinus rhythm
P07612174A1064|8 15|primates
P07612174A1064|68 74|effects
P07612174A1064|87 92|humans
P07612557A0635|13 20|children
P07612557A0635|42 50|pathology
P07612557A0635|60 64|pairs
P07612557A0635|86 93|children
P07614762A0224|15 25|antigen test
P07614762A0224|46 63|latex agglutination
P07615541T0000|10 17|analysis
P07615541T0000|20 26|DNase-I
P07615541T0000|41 45|sites
P07615541T0000|51 88|mouse porphobilinogen deaminase gene locus
P07615634A0535|5 15|transcripts
P07615634A0535|39 44|region
P07615634A0535|60 67|sequence
P07615634A0535|87 93|protein
P07616056A0278|11 17|gamma 2b
P07616056A0278|22 31|chain genes
P07616056A0278|41 58|feedback inhibition
P07616056A0278|66 87|chain gene rearrangement
P07616563A0532|31 48|carAB control region
P07616563A0532|66 70|DNase
P07616563A0532|98 106|stretches
P07616563A0532|144 155|GATC sequence
P07616569A0168|11 15|genes
P07616569A0168|29 36|subunits
P07616569A0168|42 58|cytochrome oxidase
P07616569A0168|68 81|apocytochrome b
P07616569A0168|91 98|subunits
P07616569A0168|103 126|NADH dehydrogenase complex
P07616569A0168|136 140|nad4L
P07616569A0168|143 156|ATPase subunits
P07616569A0168|213 217|tRNAs
P07616569A0168|228 235|proteins
P07616569A0168|242 246|rps11
P07616569A0168|246 250|rps12
P07616569A0168|254 258|rpl16
P07616802A0315|23 30|increase
P07616802A0315|32 44|platelet count
P07616802A0315|71 78|patients
P07616802A0315|90 96|heparin
P07616802A0315|109 114|return
P07616802A0315|126 130|value
P07616802A0315|136 151|heparin cessation
P07616802A0315|162 171|responders
P07618280A0550|22 31|structures
P07618280A0550|53 81|density gradient centrifugation
P07618548T0000|3 23|Babcock Surgical Clinic
P07620491T0000|0 8|Resources
P07620491T0000|19 26|patients
P07620491T0000|33 39|smoking
P07622058A0411|3 20|PEBP2 alpha proteins
P07622058A0411|47 52|region
P07622058A0411|95 114|segmentation gene runt
P07622060A0967|20 24|cells
P07622060A0967|42 51|ME activity
P07622060A0967|89 103|thyroid hormones
P07622521A0418|15 21|mapping
P07622521A0418|27 49|G beta gamma binding region
P07622521A0418|52 58|beta ARK
P07622521A0418|71 78|residues
P07622521A0418|88 95|PH domain
P07622521A0418|114 119|series
P07622521A0418|122 128|mutants
P07622521A0418|134 149|carboxyl terminus
P07622521A0418|152 158|beta ARK
P07622521A0418|161 165|order
P07622521A0418|186 193|residues
P07622521A0418|204 213|G beta gamma
P07622521A0418|217 227|PIP2 binding
P07622932T0000|17 24|features
P07622932T0000|35 41|leprosy
P07623807A0162|14 23|mechanisms
P07623807A0162|42 54|Raf-1 proteins
P07623807A0162|77 82|system
P07623807A0162|95 109|plasma membranes
P07623807A0162|114 118|v-Ras
P07623807A0162|139 143|cells
P07623807A0162|155 163|membranes
P07623814A1040|2 10|CV-1 cells
P07623814A1040|11 24|cotransfection
P07623814A1040|30 37|retinoid
P07623814A1040|41 57|estrogen receptors
P07623814A1040|69 78|inhibition
P07623814A1040|90 97|activity
P07623814A1040|117 126|inhibition
P07623814A1040|129 138|ER activity
P07623814A1040|152 168|breast cancer cells
P07623821A0649|10 16|factors
P07623821A0649|17 21|HRF-1
P07623821A0649|33 42|cis element
P07623821A0649|76 80|motif
P07623821T0000|0 9|Regulation
P07623821T0000|12 39|Gax homeobox gene transcription
P07623821T0000|43 53|combination
P07623821T0000|64 70|factors
P07623821T0000|96 109|enhancer factor
P07623825T0000|20 40|transactivation domain
P07623825T0000|43 57|heat shock factor
P07623825T0000|83 88|stress
P07623840A0352|38 46|sequences
P07623840A0352|67 74|activity
P07623840A0352|79 84|kinase
P07623840A0352|146 164|amino acid limitation
P07623844A0639|13 17|Bcl-2
P07623844A0639|24 37|E1B 19K proteins
P07623844A0639|58 66|apoptosis
P07623844A0639|86 97|growth arrest
P07623844A0639|103 112|expression
P07623844A0639|122 133|DNA synthesis
P07623844A0639|137 153|cell proliferation
P07623844A0639|159 166|presence
P07623844A0639|173 178|levels
P07624119A0528|29 59|PAX3-FKHR transactivation domains
P07624119A0528|76 88|test fragments
P07624119A0528|123 128|domain
P07624119A0528|137 146|activation
P07624119A0528|150 161|reporter gene
P07624119A0528|184 192|cell types
P07624581A0312|3 10|subjects
P07624581A0312|42 67|blood pressure determination
P07624581A0312|89 102|thyroid hormone
P07624581A0312|107 113|glucose
P07624581A0312|113 122|creatinine
P07624581A0312|123 130|nitrogen
P07624581A0312|131 151|glutamine transaminase
P07624581A0312|152 162|cholesterol
P07624581A0312|166 190|triglycerides plasma levels
P07624581A0312|197 203|therapy
P07624581A0312|215 227|treatment days
P07624581A0312|243 253|days washout
P07624615A0267|5 12|decrease
P07624615A0267|15 29|body temperature
P07624615A0267|41 45|PaCO2
P07624615A0267|74 78|mEq/L
P07624615A0267|84 88|mEq/L
P07624615A0267|137 141|ratio
P07624615A0267|158 163|effect
P07624615A0267|196 205|phosphorus
P07624615A0267|220 228|phosphate
P07626378T0000|0 16|Hepatitis B vaccine
P07626378T0000|28 35|problems
P07626469A1341|5 20|promoter activity
P07626469A1341|44 51|M1 domain
P07626469A1341|68 88|mouse Leydig tumor cells
P07626469A1341|117 124|CHO cells
P07626806A1098|3 10|RAT3 gene
P07626806A1098|30 40|acid protein
P07626806A1098|48 57|similarity
P07626806A1098|70 77|proteins
P07627317A1502|10 17|exposure
P07627317A1502|23 27|mg/m3
P07627317A1502|37 41|shift
P07627317A1502|64 76|concentration
P07627317A1502|92 96|shift
P07627317A1502|101 121|microgram/g creatinine
P07628389A0145|0 24|Tumor necrosis factor-alpha
P07628389A0145|25 32|TNF alpha
P07628389A0145|49 56|cytokine
P07628389A0145|80 101|testosterone production
P07628389A0145|104 119|mouse Leydig cells
P07628438T0000|13 34|insulin receptor homolog
P07628438T0000|63 73|development
P07628438T0000|83 98|receptor isoforms
P07628438T0000|112 129|signaling potential
P07628451A0114|32 46|phosphorylation
P07628451A0114|67 76|kDa protein
P07628451A0114|92 106|differentiation
P07628451A0114|108 114|F9 cells
P07628456A0000|18 33|RNA binding domain
P07628456A0000|34 38|dsRBD
P07628456A0000|58 71|amino acid motif
P07628456A0000|86 92|variety
P07628456A0000|95 102|proteins
P07628456A0000|162 166|RNase
P07628456A0000|190 195|kinase
P07629103T0000|22 40|protein isoforms beta
P07629103T0000|44 48|delta
P07629103T0000|80 84|cells
P07629103T0000|102 106|sites
P07629103T0000|112 134|beta-casein gene promoter
P07629113A0726|19 28|inhibitors
P07629113A0726|30 35|serine
P07629113A0726|36 43|aspartyl
P07629113A0726|47 62|metalloproteases
P07629113A0726|82 97|N-ethylmaleimide
P07629122A0323|10 17|analysis
P07629122A0323|39 58|phosphorylation sites
P07629122A0323|72 76|NIM-1
P07629122A0323|86 99|protein kinases
P07629123A0885|15 22|mutation
P07629123A0885|26 39|leucine residue
P07629123A0885|42 49|arginine
P07629123A0885|52 59|position
P07629123A0885|71 80|alteration
P07629123A0885|83 100|heterodimerization
P07629123A0885|101 110|DNA binding
P07629123A0885|128 137|activation
P07629150A0155|0 9|Expression
P07629150A0155|15 25|CYP11A1 gene
P07629150A0155|39 46|hormones
P07629150A0155|53 71|adrenocorticotropin
P07629150A0155|86 92|hormone
P07629150A0155|104 109|number
P07629150A0155|112 124|growth factors
P07629150A0155|142 149|promoter
P07629150A0155|170 177|elements
P07629150A0155|199 224|signal transduction pathways
P07629163A0770|21 36|deletion analysis
P07629163A0770|70 107|guanine nucleotide exchange factor domains
P07629163A0770|124 136|zinc butterfly
P07629163A0770|153 166|transformation
P07629196A0274|18 27|expression
P07629196A0274|46 52|mutants
P07629196A0274|55 59|alpha
P07629196A0274|62 73|alpha 12Q229L
P07629196A0274|76 80|alpha
P07629196A0274|83 94|alpha 13Q226L
P07629196A0274|108 117|activation
P07629196A0274|151 163|protein kinase
P07629196A0274|163 170|JNK/SAPK
P07629196A0274|171 177|pathway
P07630687A0010|3 11|objective
P07630687A0010|17 21|study
P07630687A0010|56 65|conditions
P07630687A0010|64 76|family history
P07630687A0010|83 101|catheter association
P07630687A0010|118 127|evaluation
P07630687A0010|128 138|development
P07630687A0010|150 160|involvement
P07630687A0010|161 170|prevalence
P07630687A0010|173 184|antithrombin
P07630687A0010|188 195|protein C
P07630687A0010|199 218|protein S deficiencies
P07630687A0010|222 240|lupus anticoagulants
P07630687A0010|243 250|children
P07630687A0010|273 277|event
P07630934A0343|0 4|Harel
P07631267T0001|0 11|Radiotherapy
P07631267T0001|20 30|orchiectomy
P07631267T0001|33 39|stage D1
P07631267T0001|49 57|carcinoma
P07633444T0000|10 21|organization
P07633444T0000|38 54|expression pattern
P07633444T0000|60 83|mouse WD-repeat gene DMR-N9
P07633444T0000|116 129|dystrophy locus
P07633756A0690|3 21|ARX2 procedure models
P07633756A0690|33 38|signal
P07633756A0690|56 62|signals
P07633756A0690|66 86|background EEG activity
P07633756A0690|113 119|process
P07633756A0690|134 138|noise
P07633756A0690|149 155|version
P07633756A0690|159 173|reference signal
P07633756A0690|192 202|information
P07633756A0690|218 222|sweep
P07633756A0690|225 230|signal
P07633756A0690|245 263|artefact propagation
P07635140A0172|3 12|expression
P07635140A0172|35 40|enzyme
P07635140A0172|40 44|CYP19
P07635140A0172|81 89|promoters
P07635140A0172|126 135|mechanisms
P07635312A0692|5 15|mutagenesis
P07635312A0692|35 43|mutations
P07635312A0692|68 73|domain
P07635312A0692|96 108|act1 mutations
P07635312A0692|111 118|interest
P07635572A1153|0 8|CIITA mRNA
P07635572A1153|30 38|IFN-gamma
P07635572A1153|41 45|class
P07635572A1153|73 77|lines
P07635572A1153|92 104|re-expression
P07635572A1153|115 120|effect
P07635572A1153|122 145|CIITA mRNA induction levels
P07636179A0000|9 17|cell cycle
P07636179A0000|38 46|molecules
P07636179A0000|72 81|protein pRb
P07636179A0000|85 93|G1 cyclins
P07636179A0000|113 119|kinases
P07636179A0000|128 137|inhibitors
P07636187A0585|17 37|protein expression data
P07636187A0585|38 42|V beta
P07636187A0585|46 60|gene transcripts
P07636187A0585|89 93|lines
P07636187A0585|110 117|promoter
P07636337A0687|5 11|results
P07636337A0687|41 45|doses
P07636337A0687|48 55|hormones
P07636337A0687|70 88|serum estradiol level
P07636337A0687|107 111|women
P07636408T0000|0 9|Comparison
P07636408T0000|15 19|Tesla
P07636408T0000|27 44|Tesla field strength
P07636408T0000|53 68|resonance imaging
P07636408T0000|91 100|evaluation
P07636408T0000|112 133|intervertebral foramina
P07636648A1229|3 7|month
P07636648A1229|16 37|DTaP booster vaccination
P07636648A1229|42 47|groups
P07636648A1229|72 98|serum antibody concentrations
P07636648A1229|104 111|antigens
P07636648A1229|121 134|concentrations
P07636648A1229|150 166|pertussis antigens
P07636648A1229|193 200|children
P07636962A1288|31 41|determinant
P07636962A1288|65 76|HSV-alpha TIF
P07636962A1288|117 124|activity
P07636962A1883b|16 22|fusions
P07636962A1883b|30 45|DNA binding domain
P07636962A1883b|58 65|activity
P07636962A1883b|82 93|BHV-alpha TIF
P07636962A1883b|106 110|amino
P07636962A1883b|114 128|carboxyl termini
P07636962A1883b|140 147|activity
P07636984A1349|55 62|extracts
P07636984A1349|78 82|cells
P07637718A0218|14 26|messenger RNAs
P07637718A0218|35 50|trans-sialidases
P07637718A0218|64 70|repeats
P07637718A0218|86 98|epimastigotes
P07637718A0218|115 129|trypomastigotes
P07638517A0000|25 34|necropsies
P07638517A0000|52 69|Sao Paulo City Morgue
P07638517A0000|72 79|cadavers
P07638517A0000|82 103|individuals AIDS victims
P07638517A0000|118 123|deaths
P07638517A0000|135 154|police investigations
P07639106A0678|1 5|model
P07639106A0678|18 23|weight
P07639106A0678|47 51|TBBMD
P07639106A0678|63 68|weight
P07639106A0678|71 76|height
P07639106A0678|106 114|body TBBMC
P07639703A1703|19 32|thyroid hormone
P07639703A1703|78 86|processes
P07639703A1703|107 113|element
P07639703A1703|133 139|process
P07639703A1703|142 165|islet cell differentiation
P07640309A0000|13 28|peptide sequences
P07640309A0000|62 74|mobility group
P07640309A0000|79 105|box transcription factor TCF-1
P07640309A0000|131 146|splice mechanisms
P07640309A0000|159 163|exons
P07640422A0649|0 12|Thromboxane B2
P07640422A0649|39 43|pg/ml
P07640422A0649|75 81|heparin
P07640422A0649|86 97|hemodialysis
P07640422A0649|108 119|hemodialysis
P07640422A0649|124 130|heparin
P07640422A0649|139 146|Wilcoxon
P07640422A0649|153 157|pairs
P07642490A0318|4 9|vector
P07642490A0318|10 16|pHBK280
P07642490A0318|44 51|analysis
P07642538A0138|12 20|mechanism
P07642538A0138|23 35|RSK activation
P07642538A0138|48 54|RSK cDNA
P07642538A0138|113 122|RSK mutants
P07642538A0138|128 132|N-Lys
P07642538A0138|155 160|mutant
P07642538A0138|161 165|K444A
P07642538A0138|166 170|C-Lys
P07642538A0138|195 200|mutant
P07642538A0138|201 207|N/C-Lys
P07642538A0138|225 230|mutant
P07642538A0138|231 235|T570A
P07642538A0138|236 240|C-Thr
P07642538A0138|241 246|mutant
P07642538A0138|260 282|MAPK phosphorylation site
P07642538A0138|305 312|C-domain
P07642538A0138|312 316|S218A
P07642538A0138|317 321|N-Ser
P07642538A0138|322 327|mutant
P07642538A0138|358 364|residue
P07642538A0744|2 9|contrast
P07642538A0744|14 18|C-Lys
P07642538A0744|22 26|C-Thr
P07642538A0744|39 44|levels
P07642538A0744|47 60|kinase activity
P07642538A0744|89 99|stimulation
P07642544A0868|10 18|treatment
P07642544A0868|42 52|phosphatase
P07642544A0868|73 77|cells
P07642544A0868|82 98|phenylarsine oxide
P07642544A0868|128 144|NF-kappa B activity
P07642633T0000|10 17|promoter
P07642633T0000|28 39|binding sites
P07642633T0000|53 72|transcription factors
P07642633T0000|100 109|regulation
P07642633T0000|123 151|transcription enhancer factor-1
P07642633T0000|151 155|TEF-1
P07644127A0000|15 25|stimulation
P07644127A0000|28 35|neurones
P07644127A0000|54 63|cell bodies
P07644127A0000|79 84|fibres
P07644127A0000|89 93|study
P07644127A0000|141 151|stimulation
P07644127A0000|157 179|rat substantia innominata
P07644127A0000|194 207|microinjection
P07644127A0000|209 217|carbachol
P07644127A0000|221 227|effects
P07644127A0000|234 253|acetylcholine agonist
P07644127A0000|270 278|glutamate
P07644466A0578|23 27|assay
P07644466A0578|36 52|NS3-4A polyprotein
P07644466A0578|61 82|serine proteinase domain
P07644466A0578|98 105|residues
P07644466A0578|119 130|NS4A cofactor
P07644466A0578|153 163|translation
P07644466A0578|176 191|trans-processing
P07644466A0578|206 215|substrates
P07644503A0729|2 9|contrast
P07644503A0729|10 24|over-expression
P07644503A0729|27 33|RAR beta
P07644503A0729|52 66|differentiation
P07644503A0729|89 96|RAR gamma
P07644503A0729|103 112|activation
P07644503A0729|115 125|target genes
P07646439A0535|14 21|proteins
P07646439A0535|31 47|platelet membranes
P07646439A0535|67 80|chromatography
P07646439A0535|91 118|mAb F11 affinity chromatography
P07647303T0000|3 18|homeobox gene ATK1
P07647303T0000|21 39|Arabidopsis thaliana
P07647303T0000|56 64|shoot apex
P07647303T0000|70 77|seedling
P07647303T0000|83 89|flowers
P07647303T0000|93 105|inflorescence
P07647303T0000|119 124|plants
P07647570A0713|13 23|explanation
P07647570A0713|70 81|Kupffer cells
P07647570A0713|89 94|cortex
P07647570A0713|103 107|cells
P07647570A0713|127 136|deiodinase
P07648338A0815|5 11|results
P07648338A0815|32 37|models
P07648338A0815|50 57|ischemia
P07648338A0815|71 86|cytokine profiles
P07648338A0815|102 112|TNF response
P07648338A0815|127 143|SMA occlusion model
P07648338A0815|163 172|laparotomy
P07649098A0676|3 10|evidence
P07649098A0676|36 47|observations
P07649098A0676|50 70|transfection construct
P07649098A0676|88 98|nucleotides
P07649098A0676|105 112|promoter
P07649098A0676|160 177|reporter expression
P07649098A0676|195 212|reporter expression
P07649098A0676|224 231|presence
P07649098A0676|274 280|context
P07649098A0676|281 293|IGF-I promoter
P07649098A0676|296 309|cotransfection
P07649098A0676|312 354|IGF-I promoter-luciferase-reporter constructs
P07649098A0676|360 366|plasmid
P07649098A0676|378 390|alpha-isoform
P07649098A0676|405 411|subunit
P07649098A0676|434 446|protein kinase
P07649098A0676|460 466|results
P07649098A0676|491 503|PGE2 treatment
P07649098A0676|511 524|cotransfection
P07649098A0676|530 536|plasmid
P07649098A0676|562 568|subunit
P07649098A0676|614 631|reporter expression
P07650958A0123|3 9|changes
P07650958A0123|15 23|treatment
P07650958A0123|45 60|electromyography
P07650958A0123|76 91|motor improvement
P07650958A0123|119 128|indicators
P07651131A1407|10 15|assays
P07651131A1407|19 23|DNase
P07651131A1407|25 47|footprinting experiments
P07651131A1407|63 81|kDa repressor isoform
P07651131A1407|119 125|targets
P07651131A1407|128 134|binding
P07651131A1407|141 147|protein
P07651141A0265|3 10|terminus
P07651141A0265|16 27|p-gvpF-M mRNA
P07651141A0265|41 51|nucleotides
P07651141A0265|62 67|p-gvpF
P07651141A0265|74 79|p-gvpE
P07651340A0286|0 15|Retransformation
P07651340A0286|18 30|uvsH77 mutants
P07651340A0286|45 51|cosmids
P07651340A0286|72 84|transformants
P07651340A0286|95 105|restoration
P07651340A0286|119 131|MMS resistance
P07651340A0286|142 147|levels
P07651386A0925|15 21|element
P07651386A0925|29 40|p53 induction
P07651386A0925|68 77|adenovirus
P07651386A0925|87 94|promoter
P07651398A0257|2 6|flies
P07651398A0257|10 20|dShc protein
P07651398A0257|57 66|Drosophila
P07651398A0257|76 102|growth factor receptor homolog
P07651398A0257|138 145|tyrosine
P07651398A0803|10 20|binding site
P07651398A0803|27 39|dShc PTB domain
P07651398A0803|51 58|Tyr-1228
P07651398T0000|14 24|gene product
P07651398T0000|39 47|signaling
P07651398T0000|53 77|DER receptor tyrosine kinase
P07651400A0335|4 13|inhibition
P07651400A0335|57 66|splice site
P07651400A0335|108 124|consensus sequence
P07651424A0487|11 18|analysis
P07651424A0487|28 32|Ssm1p
P07651424A0487|46 52|protein
P07651424A0487|92 98|subunit
P07651424A0487|130 137|proteins
P07651424A0743|11 15|cells
P07651424A0743|16 31|SSM1b transcripts
P07651424A0743|52 56|level
P07651424A0743|59 74|SSM1a transcripts
P07651424A0743|89 93|SSM1b
P07651424A0743|113 120|majority
P07651424A0743|126 134|Ssm1p pool
P07651734A0961|0 19|Northern blot analysis
P07651734A0961|31 40|expression
P07651734A0961|43 52|LIMK-1 mRNA
P07651734A0961|71 75|brain
P07651734A0961|82 91|expression
P07651734A0961|94 103|LIMK-2 mRNA
P07651734A0961|113 119|tissues
P07651835A0652|18 32|binding affinity
P07651835A0652|39 44|motifs
P07652066A0677|5 9|basis
P07652066A0677|24 30|concept
P07652066A0677|47 55|procedure
P07652066A0677|82 90|anchoring
P07652066A0677|96 102|arm flap
P07652066A0677|116 121|fascia
P07652066A0677|155 166|system repair
P07652066A0677|169 177|incisions
P07652066A0677|207 215|migration
P07652066A0677|217 221|scars
P07652066A0677|234 241|contours
P07652575A0435|11 24|microinjection
P07652575A0435|43 47|forms
P07652575A0435|58 62|Cdc42
P07652575A0435|69 93|Rho inhibitor C3 transferase
P07652575A0435|114 125|DNA synthesis
P07652582A0000|0 15|INF-alpha therapy
P07652582A0000|29 39|development
P07652582A0000|45 53|treatment
P07653094A0169|1 6|series
P07653094A0169|9 13|amino
P07653094A0169|22 36|deletion mutants
P07653094A0169|90 99|processing
P07653094A0169|93 113|cell surface expression
P07653094A0169|117 127|maintenance
P07653094A0169|145 154|attributes
P07653094A0169|168 177|expression
P07653094A0169|186 190|genes
P07653094A0169|197 209|plasmid vector
P07653094A0169|210 225|pcDL-SR alpha-296
P07653094A0169|237 245|HeLa cells
P07653812T0000|11 40|acetyl cholinesterase inhibitors
P07653812T0000|48 56|analgesia
P07653812T0000|78 85|morphine
P07653812T0000|89 97|clonidine
P07653892A0306|16 28|isoflurane MAC
P07653892A0306|31 40|triplicate
P07653892A0306|41 45|birds
P07653892A0306|65 71|agonist
P07653892A0306|72 79|morphine
P07653892A0306|100 106|agonist
P07653892A0306|106 112|U50488H
P07654239A0698|45 49|level
P07654239A0698|55 74|cell cycle progression
P07654712A0774|3 13|yeast enzyme
P07654712A0774|45 51|enzymes
P07654712A0774|121 128|analysis
P07654712A0774|133 140|degrees C
P07654740A0563|0 7|Key areas
P07654740A0563|13 28|selection process
P07654740A0563|56 67|alternatives
P07654740A0563|70 84|transplantation
P07654740A0563|88 98|composition
P07654740A0563|104 120|transplant work-up
P07654740A0563|129 145|inclusion criteria
P07654740A0563|174 180|factors
P07654740A0563|192 208|disease etiologies
P07654740A0563|212 225|co-morbidities
P07654740A0563|244 260|contraindications
P07655184A0852|3 11|transport
P07655184A0852|44 63|transmembrane protein
P07655184A0852|79 94|ER leader sequence
P07655184A0852|128 134|protein
P07655184A0852|147 156|ER sequence
P07655505A0527|6 11|shoots
P07655505A0527|15 19|roots
P07655505A0527|20 30|GT-2 protein
P07655505A0527|59 64|tissue
P07655505A0527|91 96|stages
P07655505A0527|107 117|development
P07655505A0527|158 164|pattern
P07655505A0527|166 191|phytochrome A gene expression
P07655509T0000|21 32|motif signals
P07655509T0000|40 48|targeting
P07655509T0000|71 78|proteins
P07655509T0000|104 115|Pisum sativum
P07656588A0101|11 29|DNA sequence analysis
P07656588A0101|39 67|Genethon microsatellite D19S596
P07656588A0101|100 105|region
P07656588A0101|130 136|cluster
P07656588A0101|171 179|FUT2 genes
P07656588A0101|201 207|D19S412
P07656588A0101|207 214|lod score
P07656588A0101|237 243|D19S571
P07656588A0101|243 250|lod score
P07657162A1412|14 36|transcription activation
P07657162A1412|39 43|LEF-1
P07657162A1412|73 79|process
P07657162A1412|103 124|trans-activation domain
P07657162A1412|127 134|addition
P07657162A1412|140 148|HMG domain
P07657668A0642|0 12|TH-SH3 binding
P07657668A0642|47 68|amino acid substitutions
P07657668A0642|78 88|Btk TH domain
P07657668A0642|94 105|Fyn SH3 domain
P07657705A1181|5 11|results
P07657705A1181|24 33|K-glypican
P07657705A1181|79 89|development
P07658262A0944|0 13|Protein S levels
P07658262A0944|52 60|admission
P07658262A0944|80 88|infusions
P07658262A0944|102 107|plasma
P07658262A0944|115 124|correction
P07658262A0944|132 143|procoagulant
P07658262A0944|160 166|factors
P07658471A0000|3 19|plant hormone auxin
P07658471A0000|51 55|genes
P07658777A0400|30 37|patients
P07658777A0400|46 62|contraindications
P07659085A1520|13 50|transcription factor Oct-1 forms complexes
P07659085A1520|57 68|octamer motif
P07659085A1520|90 105|gel shift analysis
P07659085A1520|109 113|liver
P07659085A1520|117 130|kidney extracts
P07659085A1520|137 141|Oct-1
P07659085A1520|154 162|candidate
P07659085A1520|166 176|partnership
P07659085A1520|179 196|androgen regulation
P07659515T0000|11 25|retrotransposon
P07659515T0000|34 41|evidence
P07659515T0000|74 81|elements
P07659515T0000|84 117|Crithidia fasciculata miniexon arrays
P07659529A0135|6 21|deletion analysis
P07659529A0135|25 42|transfection assays
P07659529A0135|47 68|reporter gene constructs
P07659529A0135|81 108|transcription control elements
P07659529A0135|123 128|region
P07659529A0135|139 146|EpoR gene
P07659746A1464|3 30|CVA16.4 proteolipid transcript
P07659746A1464|56 74|proteolipid messages
P07659746A1464|86 91|ovules
P07659746A1464|103 116|d post-anthesis
P07659757A0191|0 9|Incubation
P07659757A0191|23 36|fusion proteins
P07659757A0191|41 49|gamma-32P
P07659757A0191|65 69|assay
P07659757A0191|83 90|proteins
P07659757A0191|104 122|autophosphorylation
P07660712A0118|3 11|character
P07660712A0118|28 35|response
P07660712A0118|50 57|children
P07660712A0118|65 70|adults
P07660712A0118|87 95|risk group
P07660712A0118|100 106|respect
P07663138A0835|5 11|nadolol
P07663138A0835|12 20|heart rate
P07663160A0287|12 22|DNA sequence
P07663160A0287|55 65|base pairing
P07663160A0287|104 112|avoidance
P07663160A0287|130 138|structure
P07663160A0287|149 158|codon usage
P07663160A0287|172 188|protein expression
P07663160A0287|191 196|accord
P07663160A0287|209 219|preferences
P07663963A1588|10 25|system activation
P07663963A1588|37 65|metanephrine/epinephrine ratio
P07663963A1588|93 97|males
P07663963A1588|115 119|month
P07663963A1588|122 133|cohabitation
P07663963A1588|134 141|turnover
P07663963A1588|152 157|levels
P07663963A1588|176 189|control animals
P07663998T0000|14 19|repair
P07663998T0000|53 61|aneurysms
P07665172A0000|0 19|Transcription factors
P07665172A0000|56 60|motif
P07665172A0000|72 81|expression
P07665172A0000|99 103|genes
P07665172A0000|107 112|number
P07665172A0000|133 139|systems
P07665187A0208|0 14|Primer extension
P07665187A0208|18 28|cDNA cloning
P07665187A0208|68 77|Nramp1 mRNA
P07665187A0824|0 14|Primer extension
P07665187A0824|18 45|S1 nuclease mapping experiments
P07665187A0824|65 91|transcription initiation site
P07665187A0824|94 99|Nramp1
P07665187A0824|114 121|presence
P07665187A0824|147 161|initiation sites
P07665477A0901|22 31|expression
P07665477A0901|55 64|expression
P07665567A0495|0 15|Sequence analysis
P07665567A0495|29 34|region
P07665567A0495|40 47|CD69 gene
P07665567A0495|59 66|presence
P07665567A0495|79 89|TATA element
P07665567A0495|92 100|base pairs
P07665567A0495|119 145|transcription initiation site
P07665567A0495|164 179|binding sequences
P07665567A0495|192 211|transcription factors
P07665567A0495|212 220|NF-kappa B
P07665567A0495|221 225|Egr-1
P07665567A0495|261 270|expression
P07665605A1127|41 47|product
P07665605A1127|77 84|DD dimers
P07665633A0284|11 18|isolates
P07665633A0284|44 56|disk diffusion
P07665633A0284|60 81|agar dilution procedures
P07665633A0284|97 113|National Committee
P07665633A0284|125 143|Laboratory Standards
P07665948A0591|0 8|IgE levels
P07665948A0591|21 26|values
P07665948A0591|43 53|individuals
P07665948A0591|57 65|IgE levels
P07665948A0591|78 91|children groups
P07665948A0591|98 103|adults
P07665948A0591|119 127|intensity
P07665948A0591|130 138|infection
P07666414A0614|15 24|expression
P07666414A0614|30 38|tmy-1 gene
P07666414A0614|54 67|microinjection
P07666414A0614|71 93|promoter/lacZ fusion gene
P07666414A0614|101 120|immunohistochemistry
P07666414A0614|160 176|anti-tropomyosins
P07666415A0000|3 20|nucleotide sequence
P07666415A0000|26 36|chloroplast
P07666415A0000|50 54|maize
P07666415A0000|53 59|Zea mays
P07666523T0000|0 12|Investigation
P07666523T0000|18 24|control
P07666523T0000|27 37|coronavirus
P07666523T0000|48 64|mRNA transcription
P07666523T0000|98 111|RNA transcripts
P07666538A0000|0 9|Initiation
P07666538A0000|12 22|translation
P07666538A0000|33 47|hepatitis C virus
P07666538A0000|53 61|RNA genome
P07666538A0000|77 89|ribosome entry
P07666538A0000|107 112|region
P07666538A0000|136 141|manner
P07666966A0207|18 26|extension
P07666966A0207|39 44|lesion
P07666966A0207|60 67|segments
P07667097A0267|3 13|association
P07667097A0267|26 42|splicing complexes
P07667097A0267|58 64|finding
P07667097A0267|69 74|mAb CC3
P07667097A0267|92 99|splicing
P07667097A0267|103 119|immunoprecipitate
P07667097A0267|141 156|splicing products
P07667195A0146|0 4|L-735
P07667195A0146|20 30|sulfate salt
P07667195A0146|53 62|suspension
P07667195A0146|63 70|solution
P07667195A0146|80 90|dosage forms
P07667195A0146|104 113|Beagle dogs
P07667621T0001|0 23|Doppler ultrasound studies
P07667621T0001|35 43|follow-up
P07667621T0001|46 53|children
P07667621T0001|74 81|syndrome
P07668009A0172|11 20|cumlations
P07668009A0172|23 40|hepatitis A diseases
P07669351A1278|3 12|properties
P07669351A1278|25 40|SSB-ssDNA complex
P07670504A0834|41 54|banding pattern
P07670504A0834|57 61|plant
P07670504A0834|69 76|proteins
P07670504A0834|95 99|G-box
P07670504A0834|117 128|binding assay
P07670943A0308|29 36|patients
P07670943A0308|88 95|families
P07670943A0308|117 123|sibling
P07672821A0763|11 17|linkage
P07672821A0763|35 46|factor H genes
P07672821A0763|64 71|evidence
P07672821A0763|81 91|relatedness
P07672821A0763|94 110|complement factor H
P07672821A0763|117 122|factor
P07672821A0763|132 139|proteins
P07672822T0000|7 15|structure
P07672822T0000|30 37|location
P07672822T0000|43 47|mouse
P07672822T0000|58 74|receptor alpha gene
P07673128A0989|8 13|domain
P07673128A0989|20 24|motif
P07673128A0989|28 46|cAMP response element
P07673154A0688|26 30|state
P07673154A0688|33 39|CAK beta
P07673154A0688|55 68|trypsinization
P07673154A0688|82 89|response
P07673154A0688|99 106|3Y1 cells
P07673154A0688|111 121|fibronectin
P07673178A0982|3 9|results
P07673178A0982|30 46|muscle gene E-boxes
P07673178A0982|92 99|spectrum
P07673178A0982|102 123|MDF/bH-L-H heterodimers
P07673178A0982|131 146|MCK-L type E-boxes
P07673178A0982|181 187|factors
P07674649A0508|38 51|baseline design
P07674649A0508|71 92|treatment effectiveness
P07675445A0463|5 10|clones
P07675445A0463|34 39|domain
P07675445A0463|54 61|n repeats
P07675445A0463|67 92|sequence length polymorphism
P07675449A0848|5 24|glioblastoma cell line
P07675449A0848|73 77|PDGFR
P07676492A1000|16 25|comparison
P07676492A1000|28 34|reports
P07676492A1000|44 50|regions
P07676492A1000|68 87|transplant recipients
P07676587T0000|10 22|certification
P07676587T0000|26 40|livestock export
P07676655A0214|3 20|serum concentration
P07676655A0214|33 40|dialysis
P07676655A0214|65 70|mmol/l
P07677573A0000|12 22|correlation
P07677573A0000|31 36|number
P07677573A0000|49 58|parameters
P07677573A0000|68 76|secretion
P07677573A0000|77 85|incretion
P07677573A0000|101 107|changes
P07677573A0000|117 122|mucosa
P07677573A0000|133 140|patients
P07677573A0000|152 160|gastritis
P07677715A1076|3 11|TAF factor
P07677836A1356|12 23|matter injury
P07677836A1356|41 49|radiation
P07677836A1356|79 86|deficits
P07677836A1356|90 108|leukoencephalopathy
P07677836A1356|130 136|absence
P07677836A1356|139 150|chemotherapy
P07678006A0472|0 22|RNase protection analyses
P07678006A0472|47 56|CaM PDE mRNA
P07678006A0472|78 88|transcripts
P07678006A0472|106 119|CaM PDE isoforms
P07678006A0472|150 155|manner
P07678006A0901|10 19|protection
P07678006A0901|43 48|cortex
P07678006A0901|56 62|medulla
P07678006A0901|63 67|liver
P07678006A0901|68 79|kidney cortex
P07678006A0901|80 85|spleen
P07678006A0901|88 99|T-lymphocyte
P07678051A1303|3 14|PDGFR mutants
P07678051A1303|40 47|PLC gamma
P07678051A1303|85 94|production
P07678051A1303|97 114|inositol phosphates
P07678242A0473|14 24|correlation
P07678242A0473|35 40|levels
P07678242A0473|43 55|transcription
P07678242A0473|61 68|acc genes
P07678242A0473|91 96|growth
P07678593A0708|14 18|clone
P07678593A0708|21 32|V. vulnificus
P07678593A0708|62 80|V. cholerae fur mutant
P07678602A0153|22 42|B lymphoblast cell lines
P07678602A0153|47 54|controls
P07678602A0153|63 70|patients
P07678602A0153|113 119|disease
P07678602A0153|132 138|parents
P07678695A0604|10 19|expression
P07678695A0604|22 26|Oct-3
P07678695A0604|29 39|hybrid cells
P07678695A0604|58 65|promoter
P07678695A0604|96 105|activation
P07678695A0604|127 134|promoter
P07679390A0721|0 14|RNase protection
P07679390A0721|18 38|primer extension assays
P07679390A0721|87 98|DDT1 aFGF mRNA
P07679390A0721|111 132|transcription start site
P07679390A0721|179 192|splice junction
P07679836A0387|5 11|results
P07679836A0387|56 60|agent
P07679836A0387|62 82|kidney transplantation
P07680035A0221|3 7|roles
P07680035A0221|10 22|phorbol esters
P07680035A0221|51 62|GnRH response
P07680120A1008|0 5|RT-PCR
P07680120A1008|23 29|primers
P07680120A1008|40 45|kidney
P07680120A1008|46 50|brain
P07680120A1008|54 61|prostate
P07680120A1008|90 94|D mRNA
P07680120A1008|105 110|kidney
P07680120A1008|114 118|brain
P07680120A1008|137 142|source
P07680120A1008|146 156|aFGF protein
P07680629T0000|9 15|cloning
P07680629T0000|19 34|characterization
P07680629T0000|40 44|genes
P07680629T0000|53 57|gp138
P07680629T0000|59 81|cell surface glycoprotein
P07680629T0000|101 110|cell fusion
P07680629T0000|113 135|Dictyostelium discoideum
P07681147A1420|29 36|analyses
P07681147A1420|49 63|phosphorylation
P07681147A1420|66 71|Ser-12
P07681147A1420|75 80|Ser-48
P07681147A1420|95 99|cells
P07681147A1420|119 125|ability
P07681147A1420|141 149|pp60c-src
P07681147A1420|177 186|signalling
P07681513A0000|0 9|Piroximone
P07681513A0000|16 32|phosphodiesterase
P07681513A0000|36 44|inhibitor
P07681513A0000|69 89|vasodilator properties
P07681539A0000|11 17|studies
P07681539A0000|33 43|lymphocytes
P07681539A0000|48 62|hospital workers
P07681539A0000|75 79|doses
P07681539A0000|82 90|radiation
P07682842A0294|10 15|origin
P07682842A0294|27 43|fMLF-R transcripts
P07682842A0294|54 60|linkage
P07682842A0294|74 86|receptor genes
P07682842A0294|93 102|regulation
P07682842A0294|105 124|fMLF-R gene expression
P07682842A0294|140 149|copy number
P07682842A0294|161 168|location
P07682842A0294|179 190|organization
P07682842A0294|202 209|sequence
P07682842A0294|220 229|fMLF-R gene
P07682842A0771|44 51|sequence
P07682842A0771|72 77|coding
P07682842A0771|92 100|sequences
P07683131A0885|10 18|structure
P07683131A0885|25 31|members
P07683131A0885|37 46|SRC-family
P07683131A0885|70 90|exon/intron boundaries
P07683131A0885|109 114|domain
P07683131A0885|121 126|family
P07683375A0000|19 25|effects
P07683375A0000|28 40|growth factors
P07683375A0000|58 66|estradiol
P07683375A0000|72 81|regulation
P07683375A0000|83 92|expression
P07683375A0000|99 103|genes
P07683375A0000|119 134|estrogen receptor
P07683375A0000|155 161|studies
P07683375A0000|185 194|activators
P07683375A0000|197 210|protein kinases
P07683375A0000|237 244|activity
P07685263A0503|8 30|polymerase chain reaction
P07685263A0503|47 58|DNA fragments
P07685263A0503|64 72|base pairs
P07685263A0503|80 85|genome
P07685263A0503|91 106|Whipple bacterium
P07685263A0503|107 125|Tropheryma whippelii
P07685823A1234|0 12|RNA polymerase
P07685823A1234|25 33|A promoter
P07685823A1234|54 70|base-pair sequence
P07685823A1234|75 79|DNase
P07685823A1234|81 89|digestion
P07685823A1234|103 111|start site
P07685874A0258|8 13|sodium
P07685874A0258|14 20|calcium
P07685874A0258|24 46|magnesium concentrations
P07685874A0258|75 85|SLE patients
P07685874A0258|98 115|lupus erythematosus
P07685874A0258|123 131|potassium
P07685874A0258|140 160|protein concentrations
P07685874A0258|164 178|amylase activity
P07685874A0258|211 218|controls
P07687320A0526|11 23|plasmid pFV100
P07687320A0526|52 58|ability
P07687320A0526|61 86|complement B-band expression
P07687541A0200|43 54|fission yeast
P07687541A0200|70 77|mutation
P07687541A0200|120 134|mtr1/prp20/srm1
P07687541A0200|134 140|mutants
P07687541A0200|175 183|degrees C.
P07687541A0992|5 9|RCC1p
P07687541A0992|43 48|GTPase
P07687541A0992|52 65|ras superfamily
P07687541A0992|85 92|homologs
P07687745T0000|20 24|FK506
P07687745T0000|33 47|amino acid import
P07688112A0274|0 7|Prostate
P07688112A0274|16 22|antigen
P07688112A0274|41 45|cases
P07688112A0274|52 61|correction
P07688112A0274|82 96|acid phosphatase
P07689154A0168|0 21|Protein phosphorylation
P07689154A0168|52 68|uPA gene expression
P07689154A0168|75 79|cells
P07689154A0168|80 92|protein kinase
P07689154A0168|105 117|phorbol esters
P07689154A0168|131 139|pp60v-src
P07689154A0168|165 171|uPA mRNA
P07689154A0168|204 210|protein
P07689154A0168|226 231|agents
P07689154A0168|256 268|uPA mRNA levels
P07689501A0420|7 14|carriers
P07691837A1359|19 26|sequence
P07691837A1359|28 40|K3 keratin gene
P07691837A1359|88 95|promoter
P07691837A1359|107 114|clusters
P07691837A1359|137 142|motifs
P07691837A1359|152 172|NFkB consensus sequence
P07691837A1359|188 192|GC box
P07691885T0000|0 13|Identification
P07691885T0000|16 24|mutations
P07691885T0000|36 43|sequence
P07691885T0000|49 67|proto-oncogene c-kit
P07691885T0000|76 99|mast cell leukemia cell line
P07691885T0000|125 134|activation
P07691885T0000|137 148|c-kit product
P07692366A0000|0 9|BACKGROUND
P07692366A0000|10 20|Delineation
P07692366A0000|37 43|aspects
P07692366A0000|64 75|degeneration
P07692366A0000|93 103|correlation
P07692366A0000|118 125|features
P07692366A0000|160 171|pathogenesis
P07692668A0326|142 158|blot hybridization
P07692668A0326|182 202|transcription strategy
P07692668A0326|215 225|arrangement
P07692754T0000|0 10|Risk factors
P07692754T0000|30 43|seroprevalence
P07692754T0000|46 69|hepatitis C virus infection
P07692754T0000|80 90|blood donors
P07693132A0100|7 13|cloning
P07693132A0100|26 33|analysis
P07693132A0100|39 47|Zm-ERabp1
P07693132A0100|48 56|Zm-ERabp4
P07693132A0100|60 73|Zm-ERabp5 genes
P07693372A0115|4 8|agent
P07693372A0115|24 29|fungus
P07693372A0115|58 66|mechanism
P07693372A0115|69 74|action
P07693372A0115|90 101|cyclosporine
P07693672A0259|0 4|DNase
P07693672A0259|6 17|footprinting
P07693672A0259|31 38|promoter
P07693672A0259|51 57|regions
P07693672A0259|60 69|protection
P07693699A0831|10 18|stability
P07693699A0831|24 48|nucleotide binding function
P07693699A0831|57 64|proteins
P07693699A0831|86 96|sensitivity
P07693708A0000|12 17|growth
P07693708A0000|32 40|protein-2
P07693708A0000|41 48|IGF-BP-2
P07693708A0000|49 61|transcription
P07693708A0000|64 71|rat liver
P07693708A0000|103 109|fasting
P07693967A0905|3 10|presence
P07693967A0905|20 29|SL sequence
P07693967A0905|51 56|effect
P07693967A0905|59 69|translation
P07693975A1418|2 9|contrast
P07693975A1418|13 20|proteins
P07693975A1418|35 44|methionine
P07693975A1418|54 60|residue
P07693975A1418|81 89|N terminus
P07693975A1418|116 126|proteolysis
P07693975T0000|7 19|transcriptase
P07693975T0000|23 40|protease activities
P07693975T0000|48 81|leukosis virus Gag-Pol fusion proteins
P07693975T0000|99 103|cells
P07695629A0489|2 9|addition
P07695629A0489|12 23|mck1 mds1 mrk1
P07695629A0489|30 39|disruptant
P07696183A0567|20 29|properties
P07696183A0567|64 70|kinases
P07696183A0567|71 80|expression
P07696183A0567|124 132|cell lines
P07696183A0567|135 141|tissues
P07696183A0567|158 162|liver
P07696183A0567|166 171|kidney
P07696183A0567|175 183|cell lines
P07696183A0567|186 191|breast
P07696183A0567|195 205|colon origin
P07696183A0567|240 246|glycine
P07696183A0567|258 270|myristylation
P07696183A0567|274 293|membrane localization
P07696183A0567|337 354|localization signal
P07696183A0567|359 367|SH2 domain
P07696183A0567|382 401|fractionation studies
P07696183A0567|414 419|p54rak
P07696183A0567|445 451|nucleus
P07696450A0271|0 7|PATIENTS
P07696450A0271|11 17|METHODS
P07696450A0271|29 38|experience
P07696450A0271|48 55|children
P07696450A0271|71 80|bowel Crohn
P07696450A0271|82 88|disease
P07696450A0271|128 135|TGF-beta
P07696450A0271|159 172|Nestle-Clintec
P07696450A0271|172 176|Vevey
P07696450A0271|177 187|Switzerland
P07696450A0271|198 206|nutrition
P07696450A0271|211 215|weeks
P07696878A0222|3 16|leader sequence
P07696878A0222|30 38|cDNA clone
P07696878A0222|63 75|reading frames
P07696878A0222|89 103|initiation codon
P07696878A0222|120 131|reading frame
P07696878A0222|144 161|homeodomain protein
P07697294A0329|6 11|amount
P07697294A0329|14 24|HSP81-1 mRNA
P07697294A0329|42 46|roots
P07698219A0551|0 11|Cell adhesion
P07698219A0551|15 29|migration assays
P07698219A0551|45 49|alpha
P07698219A0551|68 82|laminin receptor
P07698219A0551|100 106|F9 cells
P07698219A0551|125 131|PE cells
P07698727A0386|7 17|destruction
P07698727A0386|20 24|tumor
P07698727A0386|27 35|infection
P07698727A0386|64 75|HIV infection
P07699632A0522|13 23|race persons
P07699632A0522|27 40|Chukcha-Eskimo
P07699632A0522|75 83|arthritis
P07699632A0715|3 16|data complement
P07699632A0715|22 28|studies
P07699632A0715|42 52|populations
P07699632A0715|80 90|prevalences
P07699632A0715|101 107|HLA-B27
P07699632A0715|117 127|populations
P07699845A0537|8 20|studies SY5555
P07699845A0537|40 47|patients
P07699845A0537|69 76|diseases
P07699845A0537|87 97|pharyngitis
P07699845A0537|108 118|tonsillitis
P07699845A0537|124 141|lacunar tonsillitis
P07699845A0537|156 165|bronchitis
P07699845A0537|166 174|pneumonia
P07699845A0537|178 186|pertussis
P07699845A0537|199 203|fever
P07699845A0537|209 226|impetigo contagiosa
P07699845A0537|244 258|tract infections
P07699845A0537|264 278|balanoposthitis
P07699845A0537|299 311|lymphadenitis
P07699845A0537|312 319|S.S.S.S.
P07699845A0537|320 327|vulvitis
P07699845A0537|336 342|colitis
P07699845A0537|350 354|doses
P07699845A0537|368 372|mg/kg
P07699845A0537|373 378|t.i.d.
P07700361A0125|20 31|interactions
P07700361A0125|56 60|types
P07700361A0125|63 71|molecules
P07701266A0808|0 6|RESULTS
P07701266A0808|7 17|Closure time
P07701266A0808|20 27|fistulas
P07701266A0808|30 37|patients
P07701266A0808|53 64|somatostatin
P07702327T0000|12 30|adhesion prophylaxis
P07702327T0000|46 71|tissue plasminogen activator
P07702378A0668|16 20|sleep
P07702378A0668|23 30|children
P07702378A0668|41 50|dermatitis
P07702752A0545|16 24|sequences
P07702752A0545|30 47|rat P450c17 promoter
P07702752A0545|90 106|gene transcription
P07702752A0545|107 124|deletion constructs
P07702752A0545|154 162|base pairs
P07702752A0545|185 198|rat P450c17 gene
P07702752A0545|211 218|plasmids
P07702752A0545|232 253|reporter gene luciferase
P07702752A0545|275 288|mouse cell lines
P07702752A0545|296 303|Y-1 cells
P07702752A0545|317 332|Leydig MA-10 cells
P07702808A0427|14 26|BP differences
P07702808A0427|34 40|fish oil
P07702808A0427|44 59|corn oil treatment
P07702808A0427|74 80|Dinamap
P07702808A0427|94 97|mm Hg
P07702808A0427|126 129|mm Hg
P07704040A0000|27 39|mouse NMO1 cDNA
P07704040A0000|63 85|menadione oxidoreductase
P07704040A0000|101 115|quinone acceptor
P07704040A0000|113 126|oxidoreductase
P07704040A0000|127 142|quinone reductase
P07704040A0000|149 157|reductase
P07704040A0000|158 169|DT diaphorase
P07704273A0000|15 20|JRG582
P07704273A0000|25 50|ampD ampE deletion derivative
P07704273A0000|53 62|strain HfrH
P07704273A0000|95 104|expression
P07704273A0000|125 142|beta-lactamase gene
P07704273A0000|145 163|Citrobacter freundii
P07704273A0000|173 185|plasmid pNU305
P07704456A1014|5 13|mechanism
P07704456A1014|22 33|acceleration
P07704456A1014|53 62|conditions
P07704456A1014|91 100|prevalence
P07704456A1014|107 116|conditions
P07704456A1014|125 135|HMS subjects
P07704689T0000|8 20|thyroid nodule
P07704730T0000|4 16|contraception
P07704730T0000|17 21|ideas
P07704730T0000|28 33|future
P07705476A0292|10 19|food intake
P07705476A0292|59 70|protein level
P07705476A0292|71 81|water intake
P07705476A0292|85 95|urine volume
P07705476A0292|129 135|protein
P07705627A1107|21 25|Medea
P07705627A1107|44 53|components
P07705627A1107|64 74|dpp pathways
P07705627A1107|85 95|development
P07706273T0000|15 24|regulation
P07706273T0000|40 58|ATPase B2 subunit gene
P07706273T0000|75 84|THP-1 cells
P07706287A0698|10 18|inability
P07706287A0698|39 45|nucleus
P07706287A0698|50 58|cytoplasm
P07706287A0698|85 89|phase
P07706287A0698|95 111|cell division cycle
P07706291T0000|2 12|E box element
P07706291T0000|29 38|expression
P07706291T0000|44 52|ad4bp gene
P07706291T0000|63 71|homologue
P07706291T0000|74 83|ftz-f1 gene
P07706291T0000|120 130|development
P07706299A0563|0 15|Inhibition assays
P07706299A0563|87 95|compounds
P07706299A0563|124 129|detail
P07706299A0563|148 155|features
P07706299A0563|166 195|oligosaccharide-protein binding
P07706307A0914|3 19|amino acid sequence
P07706307A0914|25 31|protein
P07706307A0914|37 42|region
P07706307A0914|48 64|specificity pocket
P07706307A0914|93 101|proteases
P07706396T0000|0 8|Mutations
P07706396T0000|14 22|VPS45 gene
P07706396T0000|24 36|SEC1 homologue
P07706396T0000|53 59|protein
P07706396T0000|67 73|defects
P07706396T0000|77 88|accumulation
P07706396T0000|91 106|membrane vesicles
P07707523A0704|5 9|cells
P07707523A0704|10 19|expression
P07707523A0704|25 42|NF-kappa B inhibitor
P07707523A0704|43 55|I kappa B-alpha
P07707523A0704|77 84|activity
P07707531A0550|16 21|design
P07707531A0550|43 48|effect
P07707531A0550|51 62|displacement
P07707531A0550|68 72|alpha
P07707531A0550|76 86|binding site
P07707531A0550|92 101|repression
P07707531A0550|104 108|alpha
P07707531A0550|110 126|gene transcription
P07707544T0000|15 27|transcription
P07707544T0000|35 59|channel catfish virus genome
P07707544T0000|60 75|characterization
P07707544T0000|96 106|transcripts
P07708058A0178|10 19|nucleotide
P07708058A0178|69 86|activator protein-1
P07708058A0178|91 95|motif
P07708058A0178|101 114|c-jun homodimer
P07708058A0178|118 139|c-jun/c-fos heterodimer
P07708488A0151|2 9|contrast
P07708488A0151|16 22|results
P07708488A0151|55 69|sequence variant
P07708497A0000|15 24|activation
P07708497A0000|27 40|thyroid hormone
P07708497A0000|53 64|interactions
P07708497A0000|74 83|T3 receptor
P07708497A0000|91 108|T3 response elements
P07708497A0000|127 132|copies
P07708497A0000|134 142|sequences
P07708497A0000|152 157|AGGTCA
P07711667A0766|13 20|analysis
P07711667A0766|23 33|risk factors
P07711667A0766|37 43|relapse
P07711667A0766|64 72|diagnosis
P07711667A0766|71 80|blast count
P07711667A0766|83 91|diagnosis
P07711667A0766|92 101|percentage
P07711667A0766|104 115|marrow blasts
P07711667A0766|116 125|FAB subtype
P07711667A0766|129 134|number
P07711667A0766|137 161|remission induction courses
P07711667A0766|172 180|remission
P07711667A0766|181 198|maintenance therapy
P07711667A0766|199 218|consolidation therapy
P07711667A0766|219 232|marrow cell dose
P07711667A0766|253 274|GVHD prophylaxis regimen
P07711667A0766|277 285|isolation
P07711667A0766|289 303|decontamination
P07711667A0766|313 324|airflow rooms
P07711730A0000|0 28|Carnitine palmitoyltransferase
P07711730A0000|36 45|deficiency
P07711730A0000|69 76|disorder
P07711730A0000|79 93|lipid metabolism
P07711730A0000|111 116|muscle
P07713421A1435a|20 42|gain-of-function mutants
P07713421A1435a|68 74|ability
P07713421A1435a|86 107|sex determination signal
P07713421A1435a|112 116|SxlM4
P07713421A1435a|137 141|SxlM1
P07713421A1435b|20 42|gain-of-function mutants
P07713421A1435b|68 74|ability
P07713421A1435b|86 107|sex determination signal
P07713421A1435b|112 116|SxlM4
P07713421A1435b|137 141|SxlM1
P07713936A0393|0 6|Binding
P07713936A0393|9 13|meAda
P07713936A0393|35 47|transcription
P07713936A0393|61 73|response genes
P07713936A0393|92 104|transcription
P07713936A0393|129 136|presence
P07713936A0393|138 142|meAda
P07714608A1252|13 23|differences
P07714608A1252|45 50|groups
P07714608A1252|58 62|PaCO2
P07714608A1252|74 81|pressure
P07714608A1252|82 90|heart rate
P07714608A1252|91 106|brain temperature
P07714608A1252|109 121|glucose levels
P07714758A1193|0 12|Blood pressure
P07714758A1193|31 39|lidocaine
P07714758A1193|41 46|mg kg-1
P07715200A0000|0 16|Anesthesiologists
P07715200A0000|45 51|patient
P07715200A0000|61 74|target response
P07715200A0000|89 101|blood pressure
P07715602A1088|17 32|gene cluster codes
P07715602A1088|36 40|parts
P07715602A1088|56 75|cytochrome c haem lyase
P07715922A0188|6 10|paper
P07715922A0188|12 21|comparison
P07715922A0188|32 37|number
P07715922A0188|41 45|shape
P07715922A0188|48 54|corneal
P07715922A0188|66 70|cells
P07715922A0188|91 98|patients
P07715922A0188|109 114|months
P07717823A0328|0 23|Standard reference sources
P07717823A0328|60 64|child
P07717823A0328|77 82|height
P07717823A0328|96 101|kcal/d
P07717823A0328|105 111|support
P07717823A0328|128 136|functions
P07719527T0000|4 16|allergenicity
P07719527T0000|30 39|hirudin CGP
P07719527T0000|45 50|REVASC
P07719527T0000|68 77|volunteers
P07720572A0701|2 9|contrast
P07720572A0701|15 26|myoD promoter
P07720572A0701|30 41|myoD enhancer
P07720572A0701|55 66|conservation
P07720572A0701|74 79|humans
P07720572A0701|98 105|sequence
P07720572A0701|117 124|position
P07720572A1584|13 22|difference
P07720572A1584|36 44|myoblasts
P07720572A1584|48 58|10T1/2 cells
P07720572A1584|77 85|cell types
P07720572A1584|91 108|chromatin structure
P07720572A1584|125 140|myoD core enhancer
P07720572A1584|158 169|myoD enhancer
P07720572A1584|193 202|mechanisms
P07720572A1584|205 215|10T1/2 cells
P07720709A0755|23 30|3T3 cells
P07720709A0755|34 44|model system
P07720709A0755|81 89|retinoids
P07720709A0755|117 133|cell proliferation
P07720709A0755|164 179|growth inhibition
P07720709A0755|194 211|AP1 transrepression
P07720710A0861|11 22|HMG2 proteins
P07721074A0766|6 15|dermatitis
P07721074A0766|31 36|rashes
P07721074A0766|75 97|patient treatment program
P07721074A0766|113 124|multiplicity
P07721074A0766|136 149|trigger factors
P07721074A0766|165 171|itching
P07721422A0241|0 25|Primer extension experiments
P07721422A0241|47 74|transcription initiation sites
P07721422A0241|91 99|mouse type
P07721422A0241|100 111|receptor gene
P07721878A1163|3 13|beta subunit
P07721878A1163|19 29|Fc epsilon R1
P07721878A1163|39 60|tyrosine phosphoprotein
P07721878A1163|84 90|protein
P07721878A1163|111 116|report
P07721878A1163|125 144|Fc epsilon R1 beta chain
P07721878A1163|151 158|identity
P07723247A0187|10 19|mechanisms
P07723247A0187|28 36|magnitude
P07723247A0187|42 62|transmembrane transfer
P07723247A0187|74 81|products
P07723247A0187|89 97|dialysate
P07723247A0187|110 121|computerized
P07723247A0187|129 141|dialysis model
P07723247A0187|165 181|pressure recording
P07723247A0187|212 217|inflow
P07723247A0187|221 232|outflow ports
P07723247A1161|7 20|hour incubation
P07723247A1161|41 46|IL-1Ra
P07723247A1161|50 57|IL-1 beta
P07723247A1161|80 95|radioimmunoassay
P07724452A0344|11 19|treatment
P07724452A0344|52 57|chicks
P07728201A0660|2 9|contrast
P07728201A0660|16 23|evidence
P07728201A0660|36 43|children
P07728201A0660|48 72|sickle-hemoglobin C disease
P07728201A0660|95 102|asplenia
P07728201A0660|113 117|years
P07728201A0660|149 169|penicillin prophylaxis
P07729427A0942|0 15|Deletion analysis
P07729427A0942|37 44|hTAFII18
P07729427A0942|58 64|domains
P07729427A0942|67 74|hTAFII28
P07729427A0942|88 95|hTAFII18
P07729427A0942|148 155|hTAFII28
P07729427A0942|158 165|hTAFII30
P07730273A1309|12 23|NarQ proteins
P07730273A1309|27 48|amino acid substitutions
P07730273A1309|68 84|histidine position
P07730273A1309|116 129|NarL-phosphate
P07730328A0000|19 23|cells
P07730328A0000|39 45|changes
P07730328A0000|58 67|activation
P07730328A0000|77 86|expression
P07730328A0000|90 97|spectrum
P07730328A0000|127 131|genes
P07730336A0606|7 11|ATF-1
P07730336A0606|37 56|cAMP response elements
P07730336A0606|75 82|sequence
P07730336A0606|93 99|kappa E3
P07730337A1439|3 8|Ng/RC3
P07730337A1439|12 25|PKC-gamma genes
P07730337A1439|38 54|expression pattern
P07730337A1439|60 64|brain
P07730337A1439|71 81|development
P07730337T0000|0 8|Structure
P07730337T0000|12 21|regulation
P07730337T0000|59 72|protein kinase C
P07730337T0000|81 91|neurogranin
P07730337T0000|92 101|RC3 protein
P07730795A0104|3 20|amino acid sequences
P07730795A0104|38 45|subunits
P07730795A0104|48 52|DdRPs
P07730795A0104|66 72|species
P07730795A0104|95 101|regions
P07731686A0000|3 11|TTG-2 gene
P07731686A0000|53 66|translocations
P07731686A0000|73 86|T-cell leukemia
P07731686A0000|88 92|T-ALL
P07731898A0823|7 13|studies
P07731898A0823|18 27|blood cells
P07731898A0823|41 47|acetate
P07731898A0823|50 64|bicarbonate ions
P07731898A0823|67 80|concentrations
P07731898A0823|109 120|hemodialysis
P07731898A0823|170 195|superoxide anions generation
P07731898A0823|195 210|erythrocyte SOD-1
P07731898A0823|214 231|catalase activities
P07731898A0823|235 270|erythrocyte membrane lipid peroxidation
P07733075A1200|5 11|therapy
P07733075A1200|16 25|omeprazole
P07733075A1200|44 57|clarithromycin
P07733075A1200|117 127|combination
P07733075A1200|143 158|% eradication rate
P07733075A1200|161 168|H. pylori
P07733075A1200|180 196|ulcer healing rates
P07733075A1200|220 229|omeprazole
P07735590A0990|3 15|concentration
P07735590A0990|22 29|allergen
P07735590A0990|48 57|micrograms
P07735590A0990|61 71|p milligrams
P07735590A0990|78 86|house dust
P07735590A0990|100 110|cat allergen
P07735590A0990|120 124|homes
P07735590A0990|139 162|micrograms Fel d milligrams
P07735590A0990|171 175|homes
P07735590A0990|190 213|micrograms Fel d milligrams
P07735833A1078|0 10|CONCLUSIONS
P07735833A1078|12 21|comparison
P07735833A1078|27 46|LysU crystal structure
P07735833A1078|54 63|structures
P07735833A1078|66 70|seryl
P07735833A1078|87 97|synthetases
P07737024A1003|5 19|bowel irrigation
P07737024A1003|40 48|technique
P07737024A1003|61 67|passage
P07737024A1003|70 74|drugs
P07737024A1003|91 97|pylorus
P07737118A0317|13 24|reading frame
P07737118A0317|56 66|LexA protein
P07737118A0317|72 81|GST protein
P07737118A0317|96 105|constructs
P07737118A0317|116 120|yeast
P07737508A0649|38 46|tRNA genes
P07737508A0649|44 50|tRNAGln
P07737508A0649|54 60|tRNAIle
P07737944A0000|13 25|growth factors
P07737944A0000|50 55|impact
P07737944A0000|58 76|transfusion practice
P07737944A0000|115 135|blood cell transfusions
P07737944A0000|138 144|variety
P07737944A0000|153 158|states
P07737944A0000|194 201|decrease
P07737944A0000|204 217|erythropoietin
P07738026A0216|10 14|mouse
P07738026A0216|55 59|forms
P07738839A0173|6 14|IC breaths
P07738839A0173|34 42|VC breaths
P07738839A0173|59 69|CO2 pressure
P07739382A0457|12 19|analyses
P07739382A0457|24 41|amino acid sequences
P07739382A0457|52 63|protein types
P07739382A0457|92 99|proteins
P07739382A0457|109 116|gelsolin
P07739382A0457|141 148|ancestor
P07739382A0457|169 176|proteins
P07739520A1250|2 9|homologs
P07739520A1250|17 23|members
P07739520A1250|29 46|Surfeit gene cluster
P07739520A1250|66 74|proximity
P07739520A1250|96 101|Surf-3
P07739520A1250|100 108|rpL7a gene
P07739542A1419|19 25|cyclin E
P07739542A1419|28 35|contrast
P07739542A1419|38 45|cyclin D1
P07739542A1419|63 76|G1/S transition
P07739542A1419|83 87|cells
P07739542A1419|95 123|retinoblastoma protein function
P07739544A0364|12 28|amino acid sequence
P07739544A0364|34 48|SGC1 gene product
P07739544A0364|58 63|region
P07739544A0364|79 88|similarity
P07739544A0364|116 121|domain
P07739544A0364|127 135|Myc family
P07739544A0364|149 156|proteins
P07739566A1076|10 33|Pax-6-BSAP fusion proteins
P07739566A1076|60 75|amino acid stretch
P07739566A1076|108 113|domain
P07739566A1076|139 149|differences
P07739566A1076|163 173|specificity
P07740487A0167|20 30|association
P07740487A0167|46 62|dysfibrinogenemia
P07740487A0167|66 78|thrombophilia
P07740487A0167|87 91|cases
P07740487A0167|99 108|affections
P07740487A0167|125 129|study
P07740487A0167|139 147|framework
P07740487A0167|153 167|SSC Subcommittee
P07740487A0167|170 179|Fibrinogen
P07740487A0167|185 204|International Society
P07740487A0167|207 216|Thrombosis
P07740487A0167|220 230|Haemostasis
P07740490T0000|10 18|estrogens
P07740490T0000|42 48|uraemia
P07740490T0000|65 73|serotonin
P07741255A0194|8 16|districts
P07741255A0194|50 59|population
P07742024A0121|11 18|symptoms
P07742024A0121|19 23|signs
P07742024A0121|24 38|imaging features
P07742024A0121|39 55|operation findings
P07742024A0121|67 72|places
P07742024A0121|88 97|directions
P07742024A0121|103 107|tumor
P07742024A0121|139 143|types
P07742024A0121|144 149|sellar
P07742024A0121|150 155|clival
P07742024A0121|176 181|extent
P07742363A0135|12 18|enzymes
P07742363A0135|37 45|repressor
P07742363A0135|85 93|inhibitor
P07742363A0135|111 116|Ser-51
P07742363A0135|121 132|alpha subunit
P07742363A0135|153 160|exchange
P07742363A0135|168 178|nucleotides
P07742363A0135|191 199|recycling
P07742363A0135|202 206|eIF-2
P07742363A0941|31 45|yeast eIF-2 alpha
P07742363A0941|90 94|yeast
P07742363A0941|106 127|casein kinase activities
P07742550A0407|3 7|cases
P07742550A0407|41 49|lymphomas
P07742550A0407|68 77|mixed-cell
P07742550A0407|128 136|lymphomas
P07742550A0407|158 166|lymphomas
P07742550A0407|192 200|lymphomas
P07742550A0407|206 224|mantle cell lymphomas
P07742550A0407|249 261|cell lymphomas
P07742917T0001|0 6|Icterus
P07742917T0001|10 25|beta-thalassemia
P07742917T0001|37 44|children
P07742917T0001|47 57|Brazzaville
P07743472A0181|6 13|patients
P07743472A0181|18 29|breast cancer
P07743472A0181|59 84|Roswell Park Cancer Institute
P07743472A0181|93 99|Buffalo
P07743472A0181|99 105|New York
P07743472A0181|117 127|information
P07743472A0181|135 157|cigarette smoking history
P07743472A0181|176 184|diagnosis
P07743515A0223|4 11|analysis
P07743515A0223|17 34|tissue distribution
P07743515A0223|87 91|cells
P07743515A0223|91 106|cytotrophoblasts
P07743515A0223|130 153|colon adenocarcinoma cells
P07743515A0223|161 170|lymphatics
P07743697A0703|13 18|V-HeFT
P07743697A0703|36 44|follow-up
P07743697A0703|65 84|plasma norepinephrine
P07743697A0703|101 113|treatment arms
P07743697A0703|128 134|disease
P07743697A0703|152 160|treatment
P07743697A0703|195 209|enzyme inhibitor
P07743697A0703|210 218|enalapril
P07743697A0703|221 238|vasodilator therapy
P07743697A0703|243 273|hydralazine/isosorbide dinitrate
P07744763A0514|0 14|Binding activity
P07744763A0514|17 24|rat liver
P07744763A0514|32 39|extracts
P07744763A0514|53 67|orphan receptors
P07744763A0514|80 115|electromobility supershift experiments
P07744763A0514|123 129|results
P07744763A0514|151 159|receptors
P07744763A0514|171 177|element
P07744763A0514|180 186|CYP2C11
P07744763A0514|197 201|HNF-4
P07744776A0617|0 17|Transcript analysis
P07744776A0617|35 53|B block substitutions
P07744776A0617|60 73|U6 RNA synthesis
P07744846A1006|0 7|Analysis
P07744846A1006|10 14|Bcl-2
P07744846A1006|14 34|Bcl-2 homodimerization
P07744846A1006|51 63|binding assays
P07744846A1006|73 77|yeast
P07744846A1006|88 93|method
P07744846A1006|102 109|evidence
P07744846A1006|112 118|support
P07744846A1006|134 138|model
P07744846A1006|142 146|Bcl-2
P07744846A1006|146 166|Bcl-2 homodimerization
P07744846A1006|182 190|sequences
P07744846A1006|212 218|A domain
P07744846A1006|232 240|structure
P07744846A1006|256 263|presence
P07744846A1006|273 281|carboxyl B
P07744846A1006|285 292|C domains
P07744846A1006|295 305|combination
P07744954A0418|3 9|protein
P07744954A0418|43 49|portion
P07744954A0418|62 68|domains
P07744954A0418|83 93|COOH termini
P07744954A0418|99 105|epitope
P07744954A0418|121 128|antibody
P07744954A0418|161 165|stalk
P07745008A0892|0 17|Radioligand binding
P07745008A0892|65 74|constructs
P07745311A0264|0 8|Diagnosis
P07745311A0264|47 54|findings
P07745684T0000|5 22|papillomavirus type
P07745684T0000|30 43|gene expression
P07745684T0000|62 74|protein kinase
P07745684T0000|85 91|changes
P07745684T0000|94 106|RNA processing
P07745685A1442|13 19|virions
P07745685A1442|40 47|proteins
P07745685A1442|63 72|antibodies
P07745685A1442|87 103|accessory proteins
P07745685A1442|119 135|CAT fusion partners
P07745693A0914|0 6|Studies
P07745693A0914|14 22|inhibitor
P07745693A0914|32 43|Lb proteinase
P07745693A0914|57 67|stimulation
P07745693A0914|81 91|translation
P07745693A0914|105 115|proteolysis
P07745693A0914|130 138|component
P07745696A0932|0 25|Restriction mapping analysis
P07745696A0932|50 55|HHV-6A
P07745696A0932|54 58|U1102
P07745696A0932|66 79|BamHI G fragment
P07745696A0932|110 116|segment
P07745696A0932|121 126|genome
P07745696A0932|135 139|SalI L
P07745696A0932|143 156|SalI O fragments
P07745696A0932|194 206|repeat regions
P07745726A0960|3 31|replication reporter constructs
P07745726A0960|81 97|expression vectors
P07745726A0960|96 103|distance
P07745726A0960|114 122|half sites
P07745726A0960|159 171|relationships
P07745726A1496|41 50|palindrome
P07745726A1496|69 97|nucleotide sequence information
P07745726A1496|101 109|E1 binding
P07745726A1496|133 150|E1 recognition motif
P07745726A1496|168 175|half site
P07746397A0233|0 6|METHODS
P07746397A0233|15 22|patients
P07746397A0233|32 46|anticoagulation
P07746397A0233|67 74|December
P07746397A0233|80 87|patients
P07746397A0233|103 111|embolisms
P07746397A0233|120 126|heparin
P07746397A0233|135 139|hours
P07746397A0233|144 148|onset
P07746397A0233|165 182|thromboplastin time
P07746397A0233|192 196|times
P07746397A0233|203 207|value
P07746794A0000|37 47|formulation
P07746794A0000|50 61|Cyclosporin A
P07746794A0000|62 70|Sandimmun
P07746794A0000|87 95|castor oil
P07746794A0000|96 106|Cremophor EL
P07746794A0000|128 132|agent
P07746937A0100|0 16|Lung function tests
P07746937A0100|42 49|patients
P07746937A0100|53 58|period
P07746937A0100|69 74|months
P07747462A0332|0 18|Sequence comparisons
P07747462A0332|32 44|RCR initiators
P07747462A0332|75 80|motifs
P07747462A0332|99 119|metal coordination site
P07747462A0332|145 157|tyrosine motif
P07747462A0332|198 215|replicator proteins
P07748451A0343|17 27|discrepancy
P07748451A0343|40 51|restorations
P07748451A0343|66 77|restorations
P07748451A0343|92 96|stone
P07748451A0343|115 127|vinyl siloxane
P07748451A0343|130 149|medium-viscosity poly
P07748451A0343|149 161|vinyl siloxane
P07748493A1045|16 29|Aplysia Afurin2
P07748493A1045|33 43|candidate PC
P07748493A1045|77 86|processing
P07748493A1045|98 104|hormone
P07748493A1045|116 125|precursors
P07748493A1045|139 143|cells
P07748493A1045|155 159|gland
P07748502A0794|17 25|8-OH-DPAT
P07748502A0794|47 53|ability
P07748502A0794|68 81|discrimination
P07748502A0794|85 93|water maze
P07748848A0263|21 40|papillary haemangioma
P07748952A0462|2 9|addition
P07748952A0462|21 29|promoters
P07748952A0462|30 34|PmiaA
P07748952A0462|38 42|P1hfq
P07748952A0462|77 87|nucleotides
P07748952A0462|113 133|translation start sites
P07748952A1329|5 11|results
P07748952A1329|39 51|hfq expression
P07748952A1329|76 85|mechanisms
P07748952A1329|95 100|degree
P07748952A1329|103 117|cotranscription
P07748952A1329|130 134|genes
P07748952A1329|135 144|modulation
P07748952A1329|155 170|promoter strength
P07748952A1329|176 189|RNase E activity
P07749088A0119|27 32|images
P07749461A0632|18 23|region
P07749461A0632|47 62|sGTH alpha subunit
P07749461A0632|68 73|region
P07749461A0632|101 105|clone
P07749461A0632|106 117|sGTH alpha-G1
P07749461A1022|10 17|analysis
P07749461A1022|23 46|sGTH alpha subunit promoter
P07749461A1022|61 72|transfection
P07749461A1022|82 94|sGTH alpha/CAT
P07749461A1022|103 110|plasmids
P07749461A1022|115 126|rainbow trout
P07749461A1022|136 140|cells
P07749461A1022|174 183|expression
P07750217T0000|0 23|Indium-111 OncoScint CR/OV
P07750217T0000|27 33|F-18 FDG
P07750217T0000|56 75|carcinoma recurrences
P07751848A0222|3 31|carnitine palmitoyltransferase
P07751848A0222|43 52|activities
P07751848A0222|67 84|nmol/min/mg protein
P07751848A0222|104 108|value
P07751848A0222|132 149|nmol/min/mg protein
P07751848A0222|171 178|subjects
P07752223A0960|3 7|Myc LZ
P07752223A0960|36 47|interactions
P07752223A0960|62 73|Myc inability
P07752454A0341|48 62|resistance rates
P07752454A0341|64 74|methicillin
P07752454A0341|75 79|DMPPC
P07752644A1031|19 32|defibrillation
P07752644A1031|71 85|plasma drug level
P07752644A1031|108 117|conduction
P07752886A0595|17 30|FecR derivative
P07752886A0595|42 58|amino acid residues
P07752886A0595|77 84|residues
P07753027A0240|3 20|gene pairs psbB-psbT
P07753027A0240|24 32|psbH-psbN
P07753027A0240|61 67|strands
P07753030A0173|0 19|Hybridization signals
P07753030A0173|53 76|Rhizobium leguminosarum bv
P07753030A0173|88 95|phaseoli
P07753030A0173|96 116|Rhodobacter capsulatus
P07753030A0173|148 170|Xanthomonas campestris pv
P07753030A0173|187 196|campestris
P07753796A0625|12 28|amino acid sequence
P07753796A0625|37 43|regions
P07753796A0625|58 66|sequences
P07753796A0625|69 76|peptides
P07753796A0625|94 116|liver eIF-2B alpha subunit
P07753796A0743|0 9|Expression
P07753796A0743|36 42|peptide
P07753796A0743|68 78|eIF-2B alpha
P07753796A0743|81 102|SDS/polyacrylamide gels
P07753837A0724|20 29|tail domain
P07753837A0724|31 40|desmoglein
P07753837A0724|58 71|plakoglobin RNA
P07753837A0724|90 95|effect
P07753837A0724|106 117|accumulation
P07753837A0724|120 130|plakoglobin
P07754713A0227|15 19|PRP21
P07754713A0227|29 33|SPP91
P07754713A0227|75 84|protein S24
P07754713A0227|116 122|protein
P07754713A0227|127 136|amino acids
P07755884A0000|13 18|grafts
P07755884A0000|37 43|tissues
P07755884A0000|98 102|motor
P07755884A0000|106 125|sensorimotor deficits
P07755884A0000|140 146|lesions
P07755884A0000|165 178|dopamine system
P07755914A0000|0 8|OBJECTIVE
P07755914A0000|23 28|impact
P07755914A0000|34 45|introduction
P07755914A0000|48 61|clarithromycin
P07755914A0000|65 76|azithromycin
P07755914A0000|82 90|treatment
P07755914A0000|94 101|survival
P07755914A0000|104 111|patients
P07755914A0000|137 161|Mycobacterium avium complex
P07757315A1227|13 23|aggregation
P07757315A1227|42 47|% value
P07757315A1227|57 71|drug application
P07757315A1227|88 92|level
P07757315A1227|102 118|observation period
P07757315A1227|143 150|ABSTRACT
P07757315A1227|165 169|WORDS
P07758167A1488|0 11|Growth curves
P07758167A1488|25 37|proliferation
P07758167A1488|40 47|clone CA9
P07758167A1488|53 60|presence
P07758167A1488|64 69|% serum
P07758167A1488|98 106|clone ME10
P07758246A0469|3 9|protein
P07758246A0469|16 21|region
P07758246A0469|49 54|intron
P07758246A0469|61 65|exons
P07758459A1277|13 20|AAC2 gene
P07758459A1277|46 51|motifs
P07758459A1277|81 90|activators
P07758459A1277|126 149|core HAP2/3/4 binding motif
P07758459A1277|170 197|ABF1 consensus binding sequence
P07758837A1118|11 20|complexity
P07758837A1118|37 42|region
P07758837A1118|48 61|GH receptor gene
P07758837A1118|80 90|observation
P07758837A1118|95 100|probes
P07758837A1118|112 117|exon 1B
P07758837A1118|131 144|intron boundary
P07758837A1118|186 194|sequences
P07758837A1118|220 229|P1 promoter
P07759094A0634|12 23|dinucleotide
P07759094A0634|24 28|GT/CA
P07759094A0634|28 34|n repeat
P07759094A0634|49 58|NHE5 cosmid
P07759094A0634|89 111|microsatellite PCR marker
P07759525A0417|3 10|proteins
P07759525A0417|55 73|protein kinase domain
P07759525A0417|103 114|casein kinase
P07759525A0417|115 122|isoforms
P07759525A0417|133 138|region
P07759529A0288|9 18|approaches
P07759529A0288|37 43|CDP/cut
P07759529A0288|53 61|repressor
P07759529A0288|64 86|gp91-phox gene expression
P07760790A0327|0 13|Serum induction
P07760790A0327|17 32|MEF2 reporter gene
P07760790A0327|58 68|NIH 3T3 cells
P07760790A0327|83 105|MEF2 site binding activity
P07760819A0731|10 19|activation
P07760819A0731|49 57|molecules
P07760819A0731|58 83|PDGF beta receptor activation
P07760819A0731|104 109|effect
P07760819A0731|112 128|cell proliferation
P07760819A0731|131 145|differentiation
P07760841A0221|11 21|binding site
P07760841A0221|42 55|regulator Adr1p
P07760841A0647|5 11|context
P07760841A0647|41 46|region
P07760841A0647|70 76|concert
P07760841A0647|94 109|promoter elements
P07760841A0647|123 136|gene activation
P07760841A0647|151 161|orientation
P07760841A0647|162 171|copy number
P07760841A0647|175 184|helix phase
P07760844A0413|0 8|Induction
P07760844A0413|11 24|AP-1 DNA binding
P07760844A0413|51 68|GH trans-activation
P07760844A0413|71 75|c-jun
P07760844A0413|79 88|c-fos genes
P07761091A0294|0 11|Inactivation
P07761091A0294|14 23|MAP kinases
P07761091A0294|42 52|phosphatase
P07761091A0294|53 57|MKP-1
P07761216T0000|12 31|amphotericin B therapy
P07761216T0000|35 44|candidemia
P07761216T0000|56 63|patients
P07761420A0909|23 28|assays
P07761420A0909|41 45|CCaMK
P07761434A1084|24 31|mediator
P07761434A1084|33 51|tumor promoter action
P07761434A1084|57 64|findings
P07761434A1084|98 105|activity
P07761434A1084|116 127|antioxidants
P07761467A0666|9 15|complex
P07761467A0666|41 57|protein components
P07761467A0666|76 82|protein
P07762431A0356|3 9|protein
P07762431A0356|55 67|culture medium
P07762431A0356|70 75|yields
P07762431A0356|91 95|litre
P07762504A0648|3 7|study
P07762504A0648|24 37|administration
P07762504A0648|44 53|amiodarone
P07762504A0648|56 64|mg/kg/day
P07762504A0648|85 89|doses
P07763727A1035|0 13|Plasmids pAMS12
P07763727A1035|14 19|pAMS13
P07763727A1035|23 28|pAMS14
P07763727A1035|49 64|laboratory strain
P07763727A1035|97 102|pAMS15
P07763727A1035|139 154|wine yeast strains
P07765118A0967|3 18|maximum induction
P07765118A0967|21 42|ACC-oxidase transcripts
P07765118A0967|67 74|excision
P07765118A0967|82 102|maximum enzyme activity
P07766885A0405|11 26|polypeptide chain
P07766885A0405|55 62|features
P07766885A0405|74 82|plant CDPK
P07766885A0405|83 88|kinase
P07766885A0405|98 106|sequences
P07766885A0405|144 149|domain
P07766885A0405|158 171|junction region
P07767011A0689|0 5|Repair
P07767011A0689|12 20|insertion
P07767011A0689|33 45|recombination
P07767011A0689|57 64|activity
P07767011A0689|70 78|hprt locus
P07767011A0689|104 111|mutation
P07768824A0167|3 8|timing
P07768824A0167|11 27|fla gene expression
P07768824A0167|33 41|cell cycle
P07768824A0167|67 71|forms
P07768824A0167|74 86|RNA polymerase
P07768824A0167|93 102|appearance
P07768824A0167|109 118|activation
P07768824A0167|131 138|proteins
P07768836A1126|0 25|Primer extension experiments
P07768836A1126|41 67|transcription initiation site
P07768836A1126|101 109|start site
P07768848A1880|0 11|Polypeptides
P07768848A1880|29 33|sizes
P07768848A1880|47 52|spores
P07768848A1880|66 71|mutant
P07768848A1880|78 82|basis
P07768848A1880|97 104|products
P07768848A1880|110 119|cotJ operon
P07768848A1880|143 151|formation
P07768848A1880|162 167|layers
P07768848A1880|204 213|components
P07768898A0492|19 24|values
P07768898A0492|27 36|divergence
P07768898A0492|39 54|apobec1 sequences
P07768898A0492|57 61|terms
P07768898A0492|67 73|numbers
P07768898A0492|103 115|suhstitutions
P07768898A0492|136 142|apobec1
P07768898A0492|166 172|protein
P07768953T0039|41 55|membrane protein
P07768953T0039|64 71|cysteine
P07768953T0039|72 78|fingers
P07768953T0039|109 115|IQ motif
P07770033A0978|0 18|Nucleotide sequences
P07770033A0978|24 29|clones
P07770033A0978|45 49|clone
P07770033A0978|71 82|reading frame
P07770033A0978|131 137|peptide
P07770033A0978|151 158|homology
P07770033A0978|161 197|Neurospora crassa copper metallothionein
P07771671T0000|44 59|carbon electrodes
P07771745A0442|0 8|Elevation
P07771745A0442|14 20|tissues
P07771745A0442|65 72|forehead
P07771745A0442|80 85|region
P07771745A0442|93 102|cheekbones
P07772036A1000|4 9|region
P07772036A1000|35 41|factors
P07772036A1000|42 49|USF/MLTF
P07772036A1000|68 100|transcription factor/nuclear factor
P07772036A1000|102 108|CTF/NF1
P07774137A0000|12 17|impact
P07774137A0000|47 55|Strep A OIA
P07774137A0000|57 65|detection
P07774137A0000|69 77|treatment
P07774137A0000|80 85|group A
P07774137A0000|113 117|GABHS
P07774137A0000|118 128|pharyngitis
P07774137A0000|166 171|clinic
P07774807A0405|7 14|proteins
P07774807A0405|46 55|activators
P07774807A0405|73 77|genes
P07774807A0405|87 98|heterodimers
P07774807A0405|134 146|family members
P07774925A0084|8 20|cosmid contigs
P07774925A0084|31 41|BRCA1 region
P07774925A0084|58 67|cDNA clones
P07774925A0084|72 76|pools
P07774925A0084|79 83|cDNAs
P07774925A0084|100 107|placenta
P07774925A0084|108 116|HeLa cells
P07774925A0084|126 131|T cells
P07775428A0172|11 16|clones
P07775428A0172|17 21|Ash-m
P07775428A0172|31 49|nucleotide sequences
P07775428A0172|62 70|Ash-l cDNA
P07775428A0172|90 95|region
P07776685A0000|4 8|study
P07776685A0000|20 30|feasibility
P07776685A0000|34 41|toxicity
P07776685A0000|52 64|immunotherapy
P07776685A0000|69 73|tumor
P07776685A0000|86 96|lymphocytes
P07776685A0000|111 123|interleukin-2
P07776685A0000|128 135|patients
P07776685A0000|148 156|resection
P07776685A0000|160 164|stage
P07776685A0000|182 191|lung cancer
P07776711A0295|0 7|MATERIAL
P07776711A0295|11 17|METHODS
P07776711A0295|35 39|women
P07776711A0295|52 56|years
P07776711A0295|79 83|motor
P07776711A0295|93 106|neuropathy type
P07776711A0295|136 149|polyneuropathy
P07776882A0000|10 14|study
P07776882A0000|27 44|cell volume dynamics
P07776882A0000|53 61|rat hearts
P07776882A0000|68 75|ischemia
P07776882A0000|84 94|reperfusion
P07776979A0702|2 9|contrast
P07776979A0702|10 16|COUP-TF
P07776979A0702|27 32|effect
P07776979A0702|52 71|reporter gene activity
P07777518A0483|0 12|DNA sequencing
P07777518A0483|16 35|Southern blot analyses
P07777518A0483|54 63|cDNA clones
P07777518A0483|90 94|genes
P07779558T0000|0 19|Muscle GSH-Px activity
P07779558T0000|34 41|exercise
P07779558T0000|42 49|training
P07779558T0000|53 75|selenium supplementation
P07779811A0901|0 7|Mutation
P07779811A0901|13 22|Sp1 element
P07779811A0901|37 46|Sp1 binding
P07779811A0901|66 74|reduction
P07779811A0901|77 92|reporter activity
P07779812A0000|3 11|c-myc gene
P07779812A0000|30 36|variety
P07779812A0000|39 48|tumor types
P07779812A0000|95 100|growth
P07779812A0000|103 108|number
P07779812A0000|111 119|cell types
P07780148A1153|36 40|level
P07780148A1153|52 58|M phases
P07780148A1153|82 86|level
P07780148A1153|89 95|G1 phase
P07780525A0495|0 8|Schooling
P07780525A0495|33 38|health
P07780525A0495|62 72|differences
P07780525A0495|85 96|health inputs
P07780719A0477|25 31|driving
P07780738A0091|26 32|S phases
P07780738A0091|36 44|cell cycle
P07780738A0091|85 91|antigen
P07780738A0091|105 118|DNA replication
P07782087A0559|19 46|transcription initiation sites
P07782087A0559|61 69|positions
P07782087A0559|81 88|position
P07782087A0559|107 117|combination
P07782087A0559|120 141|ribonuclease protection
P07782087A0559|142 156|primer extension
P07782087A0559|161 172|RACE analyses
P07782113A0726|3 20|roxithromycin doses
P07782113A0726|43 49|studies
P07782113A0726|72 82|blood levels
P07782302A0479|24 37|DEDDDL sequence
P07782302A0479|77 82|domain
P07782302A0479|98 116|affinity interaction
P07782302A0479|133 139|protein
P07782302A0479|140 151|HTF9A/RanBP1
P07782775A0889|18 27|components
P07782775A0889|50 57|proteins
P07782775A0889|86 100|BBTV coat protein
P07783064A0452|14 25|strength data
P07783064A0452|30 37|patients
P07783064A0452|60 75|creatinine kinase
P07783064A0452|80 85|levels
P07783641A0591|20 29|homologues
P07783641A0591|34 43|data-bases
P07783822A0000|0 8|OBJECTIVE
P07783822A0000|25 33|incidence
P07783822A0000|37 48|presentation
P07783822A0000|79 86|beriberi
P07783822A0000|97 112|district hospital
P07784061A0894|20 28|G proteins
P07784061A0894|94 98|cells
P07784061A0894|104 115|kb transcript
P07784078A1064|2 12|explanation
P07784078A1064|36 49|gene expression
P07784078A1064|65 70|levels
P07784078A1064|73 80|RAR alpha
P07784078A1064|101 113|APL cell growth
P07784079A1018|0 11|Transfection
P07784079A1018|25 40|expression vector
P07784079A1018|45 55|NIH3T3 cells
P07784079A1018|65 75|acquisition
P07784079A1018|91 98|activity
P07784079A1018|120 135|expression vector
P07784079A1018|150 157|activity
P07784079A1018|167 174|presence
P07784197A0827|9 16|extracts
P07784197A0827|22 28|variety
P07784197A0827|40 48|cell lines
P07784197A0827|49 58|monkey Cos7
P07784197A0827|66 83|mouse fibrosarcomas
P07784197A0827|92 97|HeLa S3
P07784197A0827|117 124|TGF-beta
P07784197A0827|146 155|band shifts
P07784197A0827|158 168|cell extract
P07784197A0827|173 197|BALB/c 3T3 mouse fibroblasts
P07784199A0000|12 18|protein
P07784199A0000|23 35|gene promoters
P07784199A0000|104 108|sites
P07784199A0000|121 138|gene regulator Rap1p
P07784199A0000|173 178|factor
P07784199A0000|178 182|Abf1p
P07784870A0119|14 20|reports
P07784870A0119|50 57|findings
P07784870A0119|73 79|reports
P07784870A0119|90 100|information
P07784870A0119|124 137|investigations
P07784870A0119|144 153|microscopy
P07784870A0119|154 167|histochemistry
P07784870A0119|178 195|electron microscopy
P07784870A0119|196 215|immunohistochemistry
P07784870A0119|222 233|microbiology
P07784942T0001|11 24|thrombomodulin
P07784942T0001|32 40|knowledge
P07784942T0001|50 58|prospects
P07786820A0284|0 5|CPT-11
P07786820A0284|33 44|i.v. infusion
P07786820A0284|59 63|mg/m2
P07786820A0284|85 90|saline
P07786820A0284|96 100|weeks
P07786821A2292|0 9|CONCLUSION
P07786821A2292|21 26|CPT-11
P07786821A2292|42 78|consecutive-days-every-3 weeks schedule
P07786821A2292|85 101|patient population
P07786821A2292|107 115|mg/m2/day
P07787179A0312|3 12|bp fragment
P07787179A0312|13 20|X1 region
P07787179A0312|26 39|PRB-1b promoter
P07787179A0312|54 62|positions
P07787179A0312|95 116|ethylene responsiveness
P07787179A0312|122 133|reporter gene
P07789275A0325|11 18|function
P07789275A0325|34 46|metamorphosis
P07789275A0325|84 108|loss-of-function mutations
P07789275A0325|123 139|transcription unit
P07789342A1352|24 29|domain
P07789342A1352|35 39|TSH-R
P07789342A1352|59 73|affinity binding
P07789342A1352|98 108|hyt mutation
P07789342A1352|119 137|transmembrane domain
P07789342A1352|148 157|TSH binding
P07789396A0504|0 7|Lipiodol
P07789809A1246|8 19|Western blots
P07789809A1246|42 46|types
P07789809A1246|105 122|household functions
P07789809A1246|133 148|vesicle transport
P07789809A1246|170 184|differentiation
P07789971A0758|3 9|absence
P07789971A0758|17 23|regions
P07789971A0758|26 38|hybridization
P07789971A0758|75 83|sequences
P07789971A0758|106 116|pseudogenes
P07789971A0758|139 144|genome
P07789971A0758|176 180|genes
P07789971A0758|204 208|GSTT2
P07790271A1185|10 17|lens dose
P07790271A1185|21 34|Gy/25 fractions
P07790271A1185|62 71|techniques
P07790377A0561|0 9|Antibodies
P07790377A0561|20 24|PTS1R
P07790377A0561|38 44|protein
P07790377A0561|52 57|monkey
P07790377A0561|66 77|hamster cells
P07790719A0098|16 21|effort
P07790719A0098|43 50|patients
P07790719A0098|56 69|family violence
P07791760A0424|0 12|GnRH treatment
P07791760A0424|34 48|phosphorylation
P07791760A0424|51 66|tyrosine residues
P07791760A0424|88 99|MAPK activity
P07791760A0424|121 138|complex kinase assay
P07791763T0000|9 15|cloning
P07791763T0000|29 52|insulin receptor substrate
P07791763T0000|68 78|involvement
P07791763T0000|80 107|phosphatidylinositol 3-kinase
P07791763T0000|125 147|Xenopus oocyte maturation
P07791764A0357|26 37|Jurkat T cells
P07791764A0357|63 70|antibody
P07791764A0357|80 97|adapter protein Grb2
P07791768A0930|3 8|effect
P07791768A0930|16 34|cell cycle regulators
P07791768A0930|53 57|rap1s
P07791768A0930|60 76|hmr delta A mutation
P07791768A0930|97 109|clb5 mutations
P07791768A0930|120 128|mutations
P07791768A0930|165 177|establishment
P07791768A0930|178 186|silencing
P07791769A0826|34 42|complexes
P07791769A0826|79 85|protein
P07791769A0826|88 92|TFIIB
P07791769A0826|112 126|ICP4 binding site
P07791769A0826|130 136|TATA box
P07791776T0000|0 15|Characterization
P07791776T0000|76 83|function
P07791776T0000|92 102|conjugation
P07791783A0000|26 32|protein
P07791783A0000|70 87|leucine zipper motif
P07791783A0000|104 109|SOX-LZ
P07791783A0000|126 154|rainbow trout testis cDNA library
P07793783A0189|0 9|Scalp flaps
P07793783A0189|32 36|point
P07793783A0189|65 69|weeks
P07793783A0189|80 101|scalp flap transposition
P07793783A0189|109 115|closure
P07793783A0189|121 129|donor site
P07794556A0000|5 10|Center
P07794556A0000|19 26|Genetics
P07794556A0000|29 34|Leuven
P07794556A0000|45 55|DNA-testing
P07794556A0000|59 68|Huntington
P07794556A0000|70 76|disease
P07794556A0000|99 105|service
P07794556A0000|111 118|November
P07794556A0000|134 144|DNA-linkage
P07794556A0000|168 183|mutation analysis
P07795104T0000|0 4|Risks
P07795104T0000|7 16|chronicity
P07795104T0000|31 54|hepatitis B virus infection
P07795104T0000|56 61|review
P07795576A0126|0 10|Examination
P07795576A0126|25 31|factors
P07795576A0126|70 75|system
P07795576A0126|81 88|increase
P07795576A0126|91 109|plasma renin activity
P07796935A0284|23 28|effect
P07796935A0284|55 61|hTR beta
P07796935A0284|82 89|hTR alpha
P07796935A0284|91 97|mutants
P07796935A0284|98 108|c-erbA alpha
P07796935A0284|121 130|peroxisome
P07796935A0284|153 160|receptor
P07796935A0284|161 165|hPPAR
P07796935A0284|194 201|elements
P07796935A0284|208 214|TRE-PAL
P07796935A0284|223 229|TRE-LAP
P07797077A0842|28 33|domain
P07797077A0842|54 59|degree
P07797077A0842|61 68|homology
P07797077A0842|85 91|domains
P07797077A0842|94 100|members
P07797077A0842|106 115|interferon
P07797077A0842|126 131|factor
P07797077A0842|137 142|family
P07797077A0842|155 159|IRF-1
P07797077A0842|160 164|IRF-2
P07797077A0842|165 169|ICSBP
P07797077A0842|173 182|ISGF3 gamma
P07797346T0000|2 9|outbreak
P07797346T0000|12 21|hepatitis A
P07797346T0000|44 52|Amsterdam
P07797476A1001|3 14|RAP74 subunit
P07797476A1001|17 21|TFIIF
P07797476A1001|50 57|activity
P07797476A1001|71 76|region
P07797476A1001|90 100|stimulation
P07797476A1001|127 134|residues
P07797583A0222|22 38|base substitutions
P07797583A0222|50 58|deletions
P07797583A0222|75 93|nucleotide positions
P07797583A0222|106 112|respect
P07797583A0222|118 144|transcription initiation site
P07797583A0222|150 157|PCNA gene
P07797583A0222|193 199|effects
P07797583A0222|205 211|binding
P07797583A0222|231 236|factor
P07797583A0222|239 246|PCNA gene
P07797583A0222|254 261|activity
P07797583A0222|272 288|Drosophila Kc cells
P07797583A0222|305 309|flies
P07798134T0000|3 17|hsp70 gene family
P07798134T0000|20 35|Neurospora crassa
P07798134T0000|36 42|cloning
P07798134T0000|43 58|sequence analysis
P07798134T0000|59 68|expression
P07798134T0000|79 85|mapping
P07798134T0000|112 117|member
P07798207A0759|10 27|amino acid sequences
P07798207A0759|39 53|W3A1 ETF subunits
P07798207A0759|79 87|% identity
P07798207A0759|108 115|subunits
P07798207A0759|143 165|Paracoccus denitrificans
P07798207A0759|172 176|group
P07798217T0000|10 24|phosphorylation
P07798217T0000|27 33|CREB341
P07798217T0000|36 41|Ser129
P07798217T0000|71 77|control
P07798217T0000|80 93|gene expression
P07798217T0095|10 33|glycogen synthase kinase-3
P07798217T0095|38 44|control
P07798217T0095|47 60|gene expression
P07798271A0330|8 13|region
P07798271A0330|25 29|sites
P07798271A0330|49 56|proteins
P07798271A0330|66 70|liver
P07798271A0330|78 85|extracts
P07798271A0330|113 124|Ets-1 protein
P07799437A0656|5 10|assays
P07799437A0656|41 51|replication
P07799437A0656|54 63|pNeo.Myc-2
P07799437A0656|82 89|labeling
P07799437A0656|92 106|control plasmids
P07799925A0526|0 13|Reconstitution
P07799925A0526|16 24|complexes
P07799925A0526|46 66|src family kinase p59fyn
P07799925A0526|68 76|HeLa cells
P07799925A0526|93 108|complex formation
P07799925A0526|119 141|tyrosine phosphorylation
P07799925A0526|180 189|SH2 domains
P07799925A0526|190 195|p59fyn
P07799931A0287|50 56|control
P07799931A0287|62 75|L7 gene insights
P07799931A0287|83 92|mechanisms
P07799931A0287|123 134|organization
P07799931A0287|146 151|system
P07799931A1232|2 9|contrast
P07799931A1232|22 28|protein
P07799931A1232|52 63|c-Maf actions
P07799939A0628|10 16|element
P07799939A0628|45 74|serine/threonine phosphoprotein
P07799939A0628|102 108|nucleus
P07799939A0628|123 130|3T3 cells
P07799948A0777|2 9|contrast
P07799948A0777|10 17|deletion
P07799948A0777|55 64|activation
P07799948A0777|66 76|Raf-1 kinase
P07799948A0777|120 124|Raf-1
P07799948A0777|140 149|mechanisms
P07799950A0282|2 8|studies
P07799950A0282|46 50|cells
P07799950A0282|64 87|somatostatin gene promoter
P07799950A0282|90 98|prototype
P07799950A0282|123 129|element
P07800479A0201|55 61|protein
P07800479A0201|78 90|RNA maturation
P07800479A0201|104 112|transport
P07800479A0201|115 122|proteins
P07800479A0201|130 136|nucleus
P07800505T0000|0 15|Characterization
P07800505T0000|21 28|promoter
P07800505T0000|56 74|phospholipase A2 gene
P07801180A0197|4 8|paper
P07801180A0197|21 30|advantages
P07801180A0197|34 44|limitations
P07801180A0197|54 68|study approaches
P07802355T0000|11 15|study
P07802355T0000|38 51|blood cell count
P07802355T0000|71 79|analyzers
P07802355T0000|80 90|Coulter STKS
P07802355T0000|91 98|Sysmex NE
P07802355T0000|106 117|Technicon H-1
P07802655T0000|0 15|Characterization
P07802655T0000|18 25|FIII/YY1
P07802655T0000|27 39|Xenopus laevis
P07802655T0000|60 73|protein binding
P07802655T0000|113 124|protein genes
P07803809A1852|7 13|studies
P07803809A1852|42 49|increase
P07803809A1852|52 66|beta-globin mRNA
P07803809A1852|88 119|tyrosine kinase inhibitor genistein
P07803809A1852|126 156|protein kinase C inhibitor Compound
P07803809A1852|185 192|ABSTRACT
P07803809A1852|207 211|WORDS
P07806492A1162|4 12|structure
P07806492A1162|15 23|cucumisin
P07806492A1162|71 79|precursor
P07806507A0121|9 18|dissection
P07806507A0121|34 47|CD3-TCR complex
P07806507A0121|80 91|polypeptides
P07806507A0121|92 98|CD3 zeta
P07806507A0121|102 111|CD3 epsilon
P07806507A0121|139 154|recognition event
P07806507A0121|169 174|events
P07806507A0121|196 212|activation cascade
P07806532A0659|0 11|Protein cHMGI
P07806532A0659|50 69|half-saturation value
P07806651A0097|4 8|study
P07806651A0097|24 29|degree
P07806651A0097|43 50|identity
P07806651A0097|61 77|Mexican-Americans
P07806651A0097|78 88|performance
P07806651A0097|103 110|MF scales
P07806651A0097|114 119|MMPI-2
P07806820A0091|34 40|pedicle
P07806820A0091|70 75|artery
P07806820A0091|101 110|fascia flap
P07807002A0500|8 15|segments
P07807002A0500|31 35|flank
P07807002A0500|40 54|initiation sites
P07807002A0500|58 75|germline epsilon RNA
P07807002A0500|90 111|luciferase reporter gene
P07807002A0500|133 147|mouse B cell lines
P07808210A1510|21 25|value
P07808210A1510|44 49|NCEP I.
P07809128T0000|9 16|capacity
P07809128T0000|22 29|E2F1 gene
P07809410A0606|11 15|cases
P07809410A0606|26 31|lesion
P07809410A0606|32 45|serum TSH levels
P07809410A0606|46 69|serum thyroglobulin values
P07809410A0606|73 83|131I protein
P07809410A0606|91 96|iodine
P07809410A0606|97 104|131I-PBI
P07809410A0606|142 152|differences
P07809410A0606|185 191|therapy
P07811639A0222|0 16|Endo16 transcripts
P07811639A0222|50 54|plate
P07811639A0222|65 76|stage embryos
P07811639A0222|79 91|gastrula stage
P07811639A0222|126 136|archenteron
P07811639A0222|153 158|midgut
P07811964A1252|22 34|repeat element
P07811964A1252|66 71|domain
P07811964A1252|74 79|EmBP-1
P07811964A1252|121 132|dimerization
P07812450A0849|37 42|strand
P07812450A0849|59 66|nspC gene
P07813466A0074|3 10|U14 genes
P07813466A0074|13 17|mouse
P07813466A0074|31 37|hamster
P07813466A0074|42 48|Xenopus
P07813466A0074|52 56|trout
P07813466A0074|73 79|introns
P07813466A0074|133 143|protein gene
P07813466A0074|144 148|hsc70
P07813786A0641|10 14|cDNAs
P07813786A0641|37 44|proteins
P07813786A0641|61 75|XMyoDa TATA motif
P07814321A0850|0 7|Deletion
P07814321A0850|52 57|growth
P07814321A0850|60 68|reduction
P07814321A0850|71 91|sporulation efficiency
P07814323A0313|0 8|Inclusion
P07814323A0313|15 20|family
P07814323A0313|23 30|proteins
P07814323A0313|76 88|export pathway
P07814323A0313|98 114|flagellum assembly
P07814388A0662|8 22|L-cell membranes
P07814388A0662|51 57|M6P/IGF
P07814388A0662|59 67|receptors
P07814388A0662|70 74|nM IGF
P07814388A0662|98 128|pertussis toxin substrate activity
P07814405A1170|27 34|deletion
P07814405A1170|37 50|point mutations
P07814405A1170|60 79|plasma membrane family
P07814405A1170|82 105|guanylyl cyclase receptors
P07814405A1170|121 129|formation
P07814405A1170|157 164|proteins
P07814717A0669|0 7|Increase
P07814717A0669|10 18|blood NEFA
P07814717A0669|49 65|AA supplementation
P07814717A0669|70 76|changes
P07814717A0669|79 92|concentrations
P07814717A0669|109 113|blood
P07815546A0411|0 4|Virol
P07815811A1487b|8 23|vasoconstriction
P07815811A1487b|32 43|endothelin-1
P07815811A1487b|56 75|ischemia-reperfusion
P07815811A1487b|81 94|norepinephrine
P07815811A1487b|104 117|concentrations
P07815811A1487b|163 168|bypass
P07816025A0196|0 9|Comparison
P07816025A0196|22 38|amino acid sequence
P07816025A0196|41 53|gamma-kafirin
P07816025A0196|70 78|sequences
P07816025A0196|81 95|gamma-prolamins
P07816025A0196|98 102|maize
P07816025A0196|135 141|domains
P07816049A0686|0 5|Atcys1
P07816049A0686|6 11|Athyp1
P07816049A0686|12 17|AKin10
P07816049A0686|73 80|polarity
P07816049A0686|98 104|regions
P07816049A0686|157 164|elements
P07816049A0686|181 190|initiation
P07816049A0686|194 204|termination
P07816049A0686|207 219|transcription
P07816049A1157|0 35|Southern blot hybridization experiments
P07816049A1157|46 53|presence
P07816049A1157|67 72|Atcys1
P07816049A1157|72 77|Athyp1
P07816049A1157|81 86|AKin10
P07816049A1157|90 102|haploid genome
P07816049A1157|106 125|Northern blot analysis
P07816049A1157|150 154|genes
P07816049A1157|183 187|roots
P07816617A0763|5 11|results
P07816617A0763|53 57|genes
P07816619A0000|20 48|Arabidopsis thaliana cDNA clones
P07816619A0000|74 82|phenotype
P07816619A0000|112 121|pde1 mutant
P07816619A0000|140 160|cAMP phosphodiesterase
P07816619A0872|14 27|identification
P07816619A0872|39 45|protein
P07816619A0872|48 57|A.thaliana
P07816619A0872|77 84|ubiquity
P07816619A0872|91 97|protein
P07816619A0872|113 118|genera
P07816619A0872|135 143|mechanism
P07816619A0872|154 176|transcription initiation
P07816630A1333|31 38|sequence
P07816630A1333|53 76|translation terminator TGA
P07816630A1333|82 93|beta-tubulin
P07816630A1333|129 134|region
P07816630A1333|138 145|H4-I gene
P07816808A1102|29 37|STR family
P07816808A1102|39 43|genes
P07816808A1102|60 67|nematode
P07816808A1102|73 80|ancestor
P07816808A1102|130 139|Arthropoda
P07816808A1102|142 149|Chordata
P07818416A0895|22 46|haemoglobin concentrations
P07818416A0895|62 66|group
P07818416A0895|137 145|instances
P07818416A0895|148 158|revision THR
P07819225A1094|3 14|introduction
P07819225A1094|25 31|residue
P07819225A1094|64 74|suppression
P07819225A1094|79 93|Asn-285 mutation
P07819225A1094|101 107|Lys-220
P07819225A1094|111 117|Gln-220
P07819225A1094|129 135|mutants
P07819225A1094|141 153|Asn-285 mutant
P07819225A1094|167 188|tetracycline resistance
P07819225A1094|221 228|ABSTRACT
P07819225A1094|243 247|WORDS
P07820057A0000|0 23|Tumor necrosis factor alpha
P07820057A0000|27 34|cytokine
P07820057A0000|65 77|growth control
P07820057A0000|85 96|cell leukemia
P07820057A0000|122 131|properties
P07821790A1084|10 14|UCRBP
P07821790A1084|60 68|repressor
P07821790A1084|83 87|UCRBP
P07821790A1084|109 122|transactivator
P07821790A1084|126 133|reporter
P07821790A1084|142 152|UCR elements
P07821790A1084|163 183|co-transfection assays
P07822161A1172|3 10|sequence
P07822161A1172|13 23|monkey opsin
P07822161A1172|48 55|sequence
P07822161A1172|61 70|nucleotide
P07822161A1172|77 91|amino acid levels
P07822161A1172|116 126|differences
P07822161A1172|135 142|residues
P07822329A0773|3 9|complex
P07822329A0773|52 56|cells
P07822329A0773|73 79|binding
P07822329A0773|99 104|factor
P07823919A1422|10 19|activation
P07823919A1422|22 26|Oct-3
P07823919A1422|27 34|promoter
P07823919A1422|41 55|RXR heterodimers
P07823919A1422|79 83|EAR-3
P07823919A1422|83 90|COUP-TFI
P07823919A1422|96 100|ARP-1
P07823951A1100|5 11|results
P07823951A1100|49 71|transactivation function
P07823951A1100|74 89|globin expression
P07823951A1100|141 149|regulator
P07823951A1100|150 154|CACCC
P07823951A1100|171 183|transcription
P07823951A1100|195 199|cells
P07823953A0777|6 12|battery
P07823953A0777|15 33|I kappa B alpha mutants
P07823953A0777|46 50|dimer
P07823953A0777|63 82|I kappa B alpha molecule
P07823953A0777|104 109|region
P07823953A0777|112 123|I kappa B alpha
P07823953A0777|155 161|binding
P07823953A0777|188 205|localization signal
P07823953A0777|210 214|dimer
P07823953A0777|235 240|region
P07823953A0777|254 263|inhibition
P07823953A0777|266 275|DNA binding
P07823953A0777|285 294|inhibition
P07823953A0777|320 330|interaction
P07823953A0777|350 355|region
P07823953A0777|373 378|region
P07823953A0777|389 396|subunits
P07823953A0777|402 406|dimer
P07823964A0922|21 28|activity
P07823964A0922|44 49|domain
P07823964A0922|77 83|segment
P07823964A0922|86 91|Pho81p
P07823964A0922|102 106|trans
P07824325A0714|11 15|times
P07824325A0714|29 38|procedures
P07824325A0714|39 51|thorax opening
P07824325A0714|55 61|closure
P07824325A0714|62 67|period
P07824325A0714|85 90|bypass
P07824325A0714|105 112|patients
P07824325A0714|114 118|group
P07824325A0714|123 146|vancomycin concentrations
P07824325A0714|159 165|tissues
P07824325A0714|205 215|microgram/g
P07824325A0714|244 255|micrograms/g
P07824464A0169|18 23|images
P07824464A0169|26 36|tissue flaps
P07824464A0169|50 54|lumen
P07824464A0169|73 79|thrombi
P07824464A0169|80 100|artery wall dissections
P07824464A0169|101 114|plaque ruptures
P07824464A0169|119 130|fissurations
P07824464A0169|145 156|haemorrhages
P07824464A0169|174 179|colour
P07824464A0169|201 210|mechanisms
P07824464A0169|221 234|artery stenosis
P07824657A1456|11 27|cysteine formation
P07824657A1456|31 41|pCSK4F plant
P07824657A1456|54 60|sulfite
P07824657A1456|78 86|leaf discs
P07824726A0454|27 35|subgroups
P07824726A0454|40 44|basis
P07824726A0454|77 84|pancreas
P07824726A0454|96 111|fatty replacement
P07824726A0454|138 153|fatty replacement
P07824726A0454|153 157|type b
P07824726A0454|177 192|fatty replacement
P07825888A0715|10 18|subgroups
P07825888A0715|21 37|dementia disorders
P07825888A0715|60 70|differences
P07825888A0715|78 91|cortisol levels
P07826412T0112|4 13|hypothesis
P07826412T0112|16 25|mechanisms
P07826412T0112|48 55|subunits
P07826412T0112|58 71|gamma-subunits
P07826412T0112|75 84|activation
P07826412T0112|88 97|holoenzyme
P07826412T0112|100 109|transducin
P07826625X0000|5 14|components
P07826625X0000|20 41|transcription apparatus
P07826625X0000|42 54|RNA polymerase
P07826625X0000|69 75|protein
P07826625X0000|83 99|activation domains
P07826625X0000|125 130|domain
P07826625X0000|138 150|RNA polymerase
P07826625X0000|161 174|enhancer domain
P07826625X0000|211 217|Regions
P07826625X0000|224 229|serine
P07826625X0000|230 238|threonine
P07826625X0000|242 256|proline residues
P07826625X0000|284 300|activation domains
P07826625X0000|324 328|parts
P07826625X0000|352 359|proteins
P07826625X0000|385 406|polyglutamine stretches
P07828584A0681|0 10|Mutagenesis
P07828584A0681|29 35|ability
P07828584A0681|37 41|c-Fos
P07828584A0681|54 71|AP1 bearing promoter
P07828600A0095|0 6|Binding
P07828600A0095|19 38|stage selector element
P07828600A0095|56 75|gamma-globin promoter
P07828600A0095|101 109|silencing
P07828600A0095|119 131|beta-promoter
P07828600A0095|149 168|stage erythroleukemia
P07828600A0095|175 179|cells
P07828811A0556|4 10|failure
P07828811A0556|29 38|G1/S arrest
P07828811A0556|63 79|thermosensitivity
P07828811A0556|96 102|ability
P07828824A0307|0 8|Mutations
P07828824A0307|18 43|photoreceptor cell structure
P07828824A0307|47 57|development
P07828824A0307|95 103|deletions
P07828852A0153|19 27|telomeres
P07828852A0153|36 41|nuclei
P07828852A0153|55 63|functions
P07829057A1097|3 14|marker orders
P07829057A1097|32 37|RH maps
P07829057T0000|0 24|Integrated mapping analysis
P07829057T0000|30 49|Werner syndrome region
P07829057T0000|52 61|chromosome
P07829097A0000|3 8|region
P07829097A0000|16 20|DXS52
P07829097A0000|24 29|Factor
P07829097A0000|90 97|isochore
P07829097A0000|105 109|genes
P07829102T0000|0 15|Haplotype mapping
P07829102T0000|19 34|sequence analysis
P07829102T0000|40 53|mouse Nramp gene
P07829102T0000|61 74|susceptibility
P07829102T0000|77 85|infection
P07829102T0000|103 111|parasites
P07829519A1251|4 14|utilization
P07829519A1251|27 45|polyadenylation site
P07829519A1251|64 72|exon usage
P07829519A1251|90 98|mechanism
P07829519A1251|135 139|forms
P07829519A1251|145 160|immunoglobulin mu
P07829519A1251|166 170|chain
P07829519A1251|196 200|locus
P07829554A0257|12 20|knowledge
P07829554A0257|50 63|system response
P07829554A0257|98 114|protein conjugates
P07829554A0257|115 123|corrosion
P07829554A0257|127 138|wear products
P07829554A0257|159 165|devices
P07829554A0257|202 206|assay
P07829554A0257|207 211|ELISA
P07829554A0257|212 217|method
P07829554A0257|221 227|testing
P07829554A0257|231 238|antibody
P07829554A0257|246 253|immunity
P07829554A0257|256 261|metals
P07830112A0532|2 9|contrast
P07830112A0532|58 63|volume
P07830112A0532|68 79|stroke volume
P07830112A0532|99 103|ratio
P07830112A0532|105 114|PFR-to-PER
P07830112A0532|207 215|mass index
P07830112A0532|231 238|patients
P07830112A0532|242 251|acromegaly
P07830112A0532|262 268|normals
P07831310A0000|8 28|complementation system
P07831310A0000|48 63|tobacco etch virus
P07831310A0000|69 78|polymerase
P07831310A0000|102 107|plants
P07831310A0000|109 119|protoplasts
P07831310A0000|151 160|TEV mutants
P07831799T0000|0 17|Nucleotide sequence
P07831799T0000|36 43|analysis
P07831799T0000|49 65|DNA polymerase gene
P07831799T0000|68 73|Bombyx
P07831799T0000|85 101|polyhedrosis virus
P07831829A1324|0 9|Comparison
P07831829A1324|15 21|genomes
P07831829A1324|30 34|BNYVV
P07831829A1324|37 41|SBWMV
P07831829A1324|51 61|furoviruses
P07831829A1324|81 93|heterogeneity
P07831829A1324|96 113|genome organization
P07832086A1023|3 17|drug sensitivity
P07832086A1023|29 38|vancomycin
P07832086A1023|50 57|imipenam
P07832086A1023|68 76|minomycin
P07832086A1023|88 95|amikacin
P07832086A1023|108 117|fosfomycin
P07832779A0719|0 14|Deglycosylation
P07832779A0719|19 34|endoglycosidase H
P07832779A0719|54 62|receptors
P07832779A0719|84 104|oligosaccharide chains
P07834582A0115|7 16|supplement
P07834582A0115|21 27|fish oil
P07834582A0115|38 44|n-3 EFAs
P07834582A0115|84 91|property
P07834582A0115|94 100|animals
P07834582A0115|104 109|humans
P07834582A0115|136 147|hypertension
P07835088A0238|3 8|HSD3B1
P07835088A0238|12 22|HSD3B2 genes
P07835088A0238|34 38|types
P07835088A0238|46 63|beta-HSD isoenzymes
P07835088A0238|110 122|hybridization
P07835088A0238|128 149|chromosome 1p13.1 region
P07835214A0603|12 22|prevalences
P07835214A0603|30 37|diabetes
P07835273A0000|18 33|glucose transport
P07835273A0000|36 45|adipocytes
P07835273A0000|61 75|insulin receptor
P07835273A0411|5 13|selection
P07835273A0411|17 26|conversion
P07835273A0411|29 38|adipocytes
P07835273A0411|42 46|level
P07835273A0411|49 62|EGFR expression
P07835273A0411|85 94|adipocytes
P07835273A0411|148 163|3T3-L1 adipocytes
P07835273A0411|164 172|5000/cell
P07835710T0000|11 19|structure
P07835710T0000|25 38|porcine I kappa B
P07835826A0195|0 7|Fraction
P07835826A0195|23 33|2-vitamin D3
P07835826A0195|33 41|vitamin D3
P07835826A0195|46 54|vitamin D3
P07835826A0195|66 76|3-vitamin D3
P07835886A0894|3 17|kallistatin gene
P07835886A0894|38 50|hybridization
P07835886A0894|58 76|chromosome 14q31-q32
P07835886A0894|88 98|serpin genes
P07835886A0894|107 129|alpha 1-antichymotrypsin
P07835886A0894|130 146|protein C inhibitor
P07835886A0894|147 164|alpha 1-antitrypsin
P07835886A0894|190 197|globulin
P07835888A0402|3 7|locus
P07835888A0402|19 24|XD gene
P07835888A0402|67 81|mouse chromosome
P07835888A0402|84 100|haplotype analysis
P07835888A0402|119 131|backcross mice
P07836218A0128|4 10|studies
P07836218A0128|13 20|exercise
P07836218A0128|35 55|beta-endorphin release
P07836218A0128|69 82|exertion levels
P07836218A0128|91 98|evidence
P07836218A0128|111 118|acidosis
P07836218A0128|134 140|release
P07836218A0128|143 156|beta-endorphin
P07836228A1052|13 25|communication
P07836228A1052|38 47|impairment
P07836228A1052|50 59|LV function
P07836228A1052|105 112|pressure
P07836364A0000|23 30|proteins
P07836364A0000|37 44|peptides
P07836364A0000|48 59|presentation
P07836364A0000|67 91|histocompatibility complex
P07836364A0000|97 101|class
P07836364A0000|102 110|molecules
P07836364A0000|116 122|surface
P07836364A0000|125 146|antigen presenting cells
P07836390A1152|3 17|characteristics
P07836390A1152|43 58|cleavage reaction
P07836390A1152|92 102|relaxosomes
P07836390A1152|105 116|IncP plasmids
P07836390A1152|127 136|initiation
P07836390A1152|139 160|transfer DNA replication
P07836390A1152|176 186|conjugation
P07836406A0884|28 35|peptides
P07836406A0884|49 53|MHC-B
P07836406A0884|72 81|cdc2 kinase
P07836406A0884|98 111|phosphopeptide
P07836406A0884|146 156|performance
P07836406A0884|163 176|chromatography
P07836471A0375|10 24|protein sequence
P07836471A0375|74 90|osteosarcoma cells
P07838156A0789|7 27|cotransfection studies
P07838156A0789|60 72|transcription
P07838156A0789|80 101|hormone response element
P07838156A0789|113 124|reporter gene
P07838156A0789|158 166|repressor
P07838156A0789|169 184|ROR alpha function
P07840643A1006|1 10|comparison
P07840643A1006|16 49|Flavobacterium glycosylasparaginase
P07840643A1006|64 83|glycosylasparaginase
P07840643A1006|106 113|identity
P07840643A1006|127 136|similarity
P07840643A1006|170 174|forms
P07840643A1006|180 185|enzyme
P07841230T0000|0 11|Dissociation
P07841230T0000|15 26|complexation
P07841230T0000|47 60|antimicrobials
P07841663A0685|0 18|Superoxide dismutase
P07841663A0685|24 31|activity
P07841663A0685|55 59|sperm
P07841663A0685|94 103|comparison
P07841663A0685|109 115|control
P07841663A0685|121 126|sample
P07841663A0685|152 157|medium
P07841663A0845|5 11|studies
P07841663A0845|50 60|stimulation
P07841663A0845|77 89|oxygen species
P07841663A0845|99 109|SOD activity
P07841663A0845|149 159|sperm motion
P07841663A0845|162 170|viability
P07844142A0640|9 15|cloning
P07844142A0640|19 28|sequencing
P07844142A0640|46 51|SR beta
P07844142A0640|63 68|SR beta
P07844142A0640|85 91|protein
P07844142A0640|99 105|SR alpha
P07844142A0640|109 113|SRP54
P07844142A0640|117 122|member
P07844142A0640|128 144|GTPase superfamily
P07844155A0327|15 22|function
P07844155A0327|40 59|tyrosine phosphatases
P07844155A0327|68 78|development
P07844155A0327|97 107|LAR isoforms
P07844155A0327|143 148|system
P07844155A0327|160 168|processes
P07844155A0327|195 202|splicing
P07844201T0000|0 11|Sex selection
P07844201T0000|15 28|albumin columns
P07844201T0000|31 35|years
P07844201T0000|38 44|results
P07844425A0289|3 10|students
P07844425A0289|15 19|count
P07844425A0289|32 40|eggs/10 ml
P07844425A0289|53 57|urine
P07844425A0289|76 84|eggs/10ml
P07844555A0406|20 27|E mu pim-1
P07844555A0406|66 84|lymphoma development
P07844555A0406|109 114|M-MuLV
P07844555A0406|117 121|birth
P07845672A0368|0 9|Comparison
P07845672A0368|26 37|blk sequences
P07845672A0368|61 78|% amino acid identity
P07845672A0368|95 100|region
P07845672A0368|118 123|domain
P07845672A0368|125 133|% identity
P07846153A0403|0 9|Chrispeels
P07846153A0403|14 18|EMBO J
P07846163A0422|3 7|mRNAs
P07846163A0422|13 20|GRF genes
P07846163A0422|36 40|exons
P07846163A0422|58 64|introns
P07846199A0000|3 8|effect
P07846199A0000|11 17|ethanol
P07846199A0000|25 46|sensorimotor reactivity
P07846199A0000|80 94|startle response
P07846942A0717|0 18|Digitalis glycosides
P07846942A0717|21 44|beta-receptor antagonists
P07846942A0717|63 69|therapy
P07846942A0717|90 101|fibrillation
P07846942A0717|108 112|class
P07846942A0717|128 132|drugs
P07846942T0001|6 17|fibrillation
P07846942T0001|40 45|system
P07847036A0353|6 10|doses
P07847036A0353|14 18|times
P07847036A0353|42 54|haemophiliacs
P07847036A0353|62 70|inhibitor
P07848358A0254|1 9|reduction
P07848358A0254|15 47|aspartate aminotransferase activity
P07848358A0254|66 74|mg/kg b.w.
P07848358A0254|74 81|d onwards
P07851643A1365|9 15|studies
P07851643A1365|38 44|isoform
P07851643A1365|64 76|proliferation
P07851643A1365|85 97|germline cells
P07851643A1365|111 131|oocyte differentiation
P07851758A0330|8 23|analysis maps SAL6
P07851758A0330|26 38|chromosome XVI
P07851758A0330|55 59|spt14
P07852037A0548|15 29|DCT method yields
P07852361A0868|0 6|Removal
P07852361A0868|22 31|cell medium
P07852361A0868|41 48|reversal
P07852361A0868|54 69|cell cycle changes
P07852361A0868|74 78|cells
P07852361A0868|93 98|S phase
P07852400A0519|0 26|Rho GDP/GTP exchange inhibitor
P07852400A0519|27 32|Rho GDI
P07853448A0601|15 30|sports scientists
P07853448A0601|57 62|nature
P07853448A0601|77 81|model
P07853448A0601|87 100|sport performer
P07853476A0159|0 6|Schnell
P07853488T0000|0 12|Encapsidation
P07853488T0000|15 33|poliovirus replicons
P07853488T0000|58 82|immunodeficiency virus type
P07853488T0000|84 90|gag gene
P07853488T0000|99 119|complementation system
P07853488T0000|136 150|P1 capsid protein
P07853488T0000|153 157|trans
P07853524A1944|0 6|Removal
P07853524A1944|12 20|GST domain
P07853524A1944|25 31|GST-Tax
P07853524A1944|34 41|thrombin
P07853524A1944|56 62|ability
P07853524A1944|80 107|Tax-CREB-21-bp-repeat complex
P07853524A1944|126 133|ABSTRACT
P07853524A1944|148 152|WORDS
P07854130A1387|3 13|requirement
P07854130A1387|24 38|pilus biogenesis
P07854130A1387|80 99|pilE insertion mutants
P07854130A1387|104 108|pilus
P07854130A1387|112 129|twitching-motility
P07854130T0000|3 17|pilE gene product
P07854130T0000|52 66|pilus biogenesis
P07854130T0000|67 97|shares amino acid sequence identity
P07854130T0000|105 113|N-termini
P07854130T0000|123 138|prepilin proteins
P07854324A0281|22 33|conservation
P07854324A0281|36 59|cell cycle control elements
P07854324A0281|63 72|expression
P07854324A0281|76 89|vertebrate wee1
P07854324A0281|92 102|mik1 homolog
P07854324A0281|136 144|mutations
P07854324A0281|147 151|yeast
P07854324A0742|3 12|expression
P07854324A0742|19 23|clone
P07854324A0742|52 57|causes
P07854324A0742|69 81|cell phenotype
P07854324A0742|101 116|growth conditions
P07856102A1616|23 37|phosphorylation
P07856102A1616|39 46|M protein
P07856102A1616|63 67|sites
P07856102A1616|85 97|virus assembly
P07857086A0949|18 24|Insulin
P07857086A0949|52 70|Non Insulin Dependent
P07857086A0949|82 87|H White
P07857086A0949|87 91|Class
P07857163A0551|3 10|activity
P07857163A0551|13 30|6-fluoroquinolones
P07857163A0551|53 63|derivatives
P07857344A0591|5 13|half-life
P07857344A0591|19 26|compound
P07857344A0591|71 76|change
P07857344A0591|77 107|pidotimod administration schedule
P07857762A0611|3 18|MAP kinase cascade
P07857762A0611|41 50|eukaryotes
P07857762A0611|80 88|responses
P07858986A0310|12 16|study
P07858986A0310|30 43|interferometry
P07858986A0310|49 55|porcine
P07858986A0310|69 74|valves
P07858986A0310|80 100|Carpentier-Edwards SAV
P07858986A0310|104 113|BioImplant
P07858986A0310|120 125|Valcor
P07858986A0310|145 150|valves
P07858986A0310|165 187|glutaraldehyde treatment
P07859238A1150|9 19|side effects
P07859301A0325|4 9|region
P07859301A0325|35 40|domain
P07859301A0325|70 89|leucine-zipper motifs
P07859301A0325|90 97|features
P07859301A0325|120 144|transcription factor family
P07859371A1246|8 14|binding
P07859371A1246|60 73|mouse fragments
P07859371A1246|91 98|extracts
P07859665A0498|3 12|mean jitter
P07859665A0498|19 30|fiber density
P07859665A0498|74 85|microseconds
P07859665A0498|110 121|microseconds
P07859739T0000|8 27|cyclin D-Cdk complexes
P07859739T0000|40 44|cells
P07859739T0000|63 68|levels
P07859739T0000|71 109|p16INK4/MTS1 tumour suppressor gene product
P07859777A0000|16 27|serum albumin
P07859777A0000|52 63|fermentation
P07859777A0000|91 103|microcapsules
P07859777A0000|115 121|microns
P07859777A0000|124 131|diameter
P07859777A0000|152 165|technetium-99m
P07859777A0000|175 183|reduction
P07859777A0000|196 203|chloride
P07860208A0000|17 23|release
P07860208A0000|26 42|interleukin-1 beta
P07860208A0000|52 77|tumour necrosis factor-alpha
P07860208A0000|96 104|monocytes
P07860208A0000|107 115|monocytes
P07860208A0000|130 147|lipopolysaccharide
P07860208A0000|178 182|blood
P07860208A0000|187 194|patients
P07860208A0000|221 238|glomerulonephritis
P07860208A0000|256 263|controls
P07860646A1363|6 17|intervention
P07860646A1363|48 56|treatment
P07860646A1363|80 87|diseases
P07860646A1363|97 101|FGF-2
P07862092A0302|17 21|clone
P07862092A0302|44 54|suppressors
P07862092A0302|61 69|ts mutants
P07862092A0302|79 93|mutation pol3-14
P07862092A0302|96 101|sdp5-1
P07862092A0302|105 119|mutation pol3-11
P07862092A0302|149 162|haploid strains
P07862092A0302|179 191|pol3-11 sdp5-1
P07862092A0302|211 219|libraries
P07862092A0302|222 231|singlecopy
P07862092A0302|243 249|vectors
P07862108A0987|0 25|UV cross-linking experiments
P07862129A1391|13 18|livers
P07862129A1391|38 46|reduction
P07862129A1391|49 68|HNF-3 alpha expression
P07862129A1391|89 96|decrease
P07862129A1391|102 111|expression
P07862129A1391|117 126|target gene
P07862129A1391|130 136|TTR gene
P07862141A0317|29 35|alleles
P07862141A0317|38 42|genes
P07862141A0317|54 61|cAPK lead
P07862141A0317|67 75|inability
P07862141A0317|91 105|differentiation
P07862141A1412|3 8|member
P07862141A1412|15 20|family
P07862141A1412|30 48|transcription factor
P07862141A1412|52 58|variety
P07862141A1412|77 81|genes
P07862150A0429|4 9|mutant
P07862150A0429|57 62|vector
P07862150A0429|64 69|series
P07862150A0429|72 79|mink lung
P07862150A0429|90 99|cell clones
P07862150A0429|114 136|TGF-beta binding activity
P07862150A0429|183 191|responses
P07862150A0429|194 201|TGF-beta
P07862154A0340|0 6|Cloning
P07862154A0340|9 23|complementation
P07862154A0340|55 62|analysis
P07862162A0408|5 12|presence
P07862162A0408|15 22|inositol
P07862162A0408|26 32|choline
P07862162A0408|46 52|product
P07862162A0408|58 65|OPI1 gene
P07862162A0408|75 87|transcription
P07862162A0408|101 113|UASINO element
P07862165A0184|10 23|monkey COS cells
P07862165A0184|28 43|oligonucleotides
P07862165A0184|52 59|psoralen
P07862165A0184|83 91|mutations
P07862165A0184|101 105|virus
P07862165A0184|114 119|vector
P07862165A0184|137 141|cells
P07862165A0184|164 177|helix formation
P07862168A0000|3 13|interleukin
P07862168A0000|15 33|receptor alpha-chain
P07862168A0000|34 43|IL-2R alpha
P07862168A0000|79 84|T cells
P07862168A0000|86 93|response
P07862168A0000|105 111|stimuli
P07862533A0000|3 7|Wilms
P07862533A0000|8 30|tumour suppressor protein
P07862533A0000|72 78|protein
P07862533A0000|86 96|zinc fingers
P07862533A0000|129 144|sequence homology
P07862533A0000|155 170|growth response-1
P07862533A0000|171 175|EGR-1
P07862533A0000|176 182|protein
P07863047A0229|0 9|OBJECTIVES
P07863047A0229|22 37|serum ACE activity
P07863047A0229|40 47|patients
P07863047A0229|99 111|oxygen therapy
P07863047A0229|141 151|correlation
P07863047A0229|205 213|parameter
P07863619A0098|2 6|order
P07863619A0098|14 18|shape
P07863619A0098|23 29|contour
P07863619A0098|44 49|system
P07863619A0098|74 82|fragments
P07863619A0098|104 109|object
P07863619A0098|122 130|fragments
P07863619A0098|144 150|objects
P07863992A0908|6 10|group
P07863992A0908|12 19|patients
P07863992A0908|33 38|result
P07863992A0908|58 64|testing
P07863992A0908|70 77|evidence
P07863992A0908|90 101|heart disease
P07863992A0908|102 114|mean follow-up
P07863992A0908|118 122|years
P07863992A0908|141 148|episodes
P07863992A0908|151 157|syncope
P07863992A0908|175 184|medication
P07863992A0908|214 221|exercise
P07864652A0753|0 9|Constructs
P07864652A0753|124 130|numbers
P07864652A0753|132 142|parentheses
P07864652A0753|150 166|amino acid sequence
P07864652A0753|173 180|portions
P07864652A0753|186 196|E2 component
P07864652A0753|214 222|construct
P07864652A1901|24 39|domain constructs
P07864652A1901|77 81|roles
P07864652A1901|135 143|processes
P07864709A0324|0 6|METHODS
P07864709A0324|10 19|influenza A
P07864709A0324|26 32|viruses
P07864709A0324|49 57|outbreaks
P07864709A0324|73 82|resistance
P07864709A0324|85 94|amantadine
P07864709A0324|98 108|rimantadine
P07864709A0324|111 115|means
P07864709A0324|120 136|enzyme immunoassay
P07864709A0324|142 151|sequencing
P07864709A0324|202 207|domain
P07864709A0324|212 220|M2 protein
P07865129A0293|16 22|ATF/CRE
P07865129A0293|26 47|TBP/TATA sequence motifs
P07865129A0293|61 66|region
P07865786A0457|0 13|Gene expression
P07865786A0457|32 37|rhythm
P07865786A0457|50 54|light
P07865786A0457|57 62|leaves
P07865786A0457|77 82|plants
P07865787A1086|3 9|results
P07865787A1086|26 32|hexamer
P07865787A1086|39 51|octamer motifs
P07865787A1086|78 87|regulation
P07865787A1086|140 149|expression
P07865787A1086|155 172|wheat histone H3 gene
P07865876A1292|18 27|expression
P07865876A1292|30 44|DP family members
P07865876A1292|60 70|combination
P07865876A1292|73 90|DP/E2F heterodimers
P07865876A1292|105 113|DRTF1/E2F
P07865876A1292|131 139|phenotype
P07865888A1309|20 29|cells PBP74
P07865888A1309|46 56|pre-protein
P07865888A1309|69 76|membrane
P07865888A1309|96 101|import
P07865888A1309|106 117|mitochondria
P07865888A1309|124 133|maturation
P07865895A0896|9 18|experiment
P07865895A0896|34 51|lung clearance assay
P07865895A0896|88 98|LGL/NK cells
P07865895A0896|113 121|rationale
P07865895A0896|124 134|LGL/NK cells
P07865895A0896|158 162|event
P07865895A0896|174 180|absence
P07865895A0896|185 189|event
P07865917A0191|0 8|Treatment
P07865917A0191|46 53|steroids
P07865917A0191|62 73|cyclosporine
P07865917A0191|79 92|plasmapheresis
P07865917A0191|95 107|ACE inhibitors
P07865917A0191|117 123|results
P07867604A1777|3 9|results
P07867604A1777|30 48|inhibin/activin beta
P07867604A1777|58 62|mRNAs
P07867604A1777|91 105|initiation sites
P07867604A1777|111 119|promoters
P07867604A1777|164 171|elements
P07867604A1777|190 198|promoters
P07867604A1777|225 237|phorbol esters
P07867604A1777|245 254|conditions
P07867622X0000|0 13|Promoter region
P07867622X0000|48 63|alpha 1-chimaerin
P07867622X0000|96 102|protein
P07867622X0000|106 111|p21rac
P07867622X0000|129 144|alpha 1-chimaerin
P07867622X0000|180 186|protein
P07867622X0000|190 195|p21rac
P07867622X0000|197 203|protein
P07867622X0000|227 232|events
P07867944A0365|0 7|Upstream
P07867944A0365|15 37|transcription start point
P07867944A0365|44 61|nucleotide sequence
P07867944A0365|82 103|consensus sequence motif
P07867944A0365|110 114|sigma
P07867944A0365|128 136|promoters
P07869721A0000|6 10|paper
P07869721A0000|13 20|analysis
P07869721A0000|26 33|dynamics
P07869721A0000|39 50|closing phase
P07869721A0000|56 63|occluder
P07869721A0000|88 107|heart valve prosthesis
P07869913A1076|6 19|ISO+AT infusion
P07869913A1076|32 40|blood flow
P07869913A1076|85 97|control values
P07869913A1076|112 119|subjects
P07869937A1142|16 33|kilogram body weight
P07869937A1142|57 63|dF group
P07869937A1142|107 114|decrease
P07869937A1142|135 140|P group
P07870305A1015|2 17|nucleus ventralis
P07870305A1015|26 72|thalami-nucleus ventralis lateralis thalami neurons
P07870305A1015|89 93|input
P07870305A1015|98 120|nucleus entopeduncularis
P07870305A1015|134 143|inhibition
P07870305A1015|185 204|haloperidol influence
P07871718A1132|7 15|inclusion
P07871718A1132|32 43|CGGAAR motifs
P07871718A1132|51 62|ICP4 promoter
P07871718A1132|72 87|factors GABP alpha
P07871718A1132|124 133|activation
P07871721A0000|12 23|reading frame
P07871721A0000|38 53|scorch carlavirus
P07871721A0000|54 58|BBScV
P07871721A0000|59 64|genome
P07871721A0000|103 109|protein
P07871721A0392|4 21|sequence alignments
P07871721A0392|49 55|viruses
P07871721A0392|65 75|tymoviruses
P07871721A0392|118 133|proteinase domain
P07871721A0392|155 165|cysteine994
P07871721A0392|169 181|histidine1075
P07871754A0857|4 10|finding
P07871754A0857|46 54|mechanism
P07871754A0857|62 78|HPV gene expression
P07871754A0857|109 113|model
P07871754A0857|120 124|study
P07871754A0857|142 154|cooperativity
P07871755A0521|9 14|method
P07871755A0521|35 44|quantities
P07871755A0521|64 79|characterization
P07871757A0846|0 7|Analysis
P07871757A0846|13 20|sequence
P07871757A0846|35 49|initiation codon
P07871757A0846|60 67|presence
P07871757A0846|71 86|promotor sequence
P07871891A0227|0 4|SUP46
P07871891A0227|19 37|translation fidelity
P07871891A0227|60 69|protein S13
P07872673A0332|22 33|relationship
P07872673A0332|41 45|c-fos
P07872673A0332|64 80|expression plasmid
P07872673A0332|107 115|c-fos gene
P07872673A0332|121 127|control
P07872673A0332|133 151|SV40 promoter complex
P07872788A1717|7 12|degree
P07872788A1717|15 30|sequence identity
P07872788A1717|42 51|hydrolase B
P07872788A1717|87 92|region
P07872788A1717|107 111|genes
P07872788A1717|128 144|carboxylesterases
P07872788A1717|154 164|duplication
P07872788A1717|168 177|divergence
P07873631A0114|3 9|regions
P07873631A0114|15 27|tooth fracture
P07873831T0000|19 29|involvement
P07873831T0000|32 47|mycosis fungoides
P07873876A1035|3 11|NR2 hybrid
P07873876A1035|35 41|mapping
P07873876A1035|46 51|probes
P07873876A1035|58 63|region
P07873876A1035|98 103|probes
P07873876A1035|118 125|deletion
P07873876A1035|139 145|cloning
P07873876A1035|151 156|region
P07874060A0810|0 4|TDEYA
P07874060A0810|7 11|doses
P07874060A0810|22 26|mg/kg
P07874060A0810|50 64|xanthine oxidase
P07874060A0810|69 76|activity
P07874060A0810|81 93|stomach tissue
P07874060A0810|110 123|administration
P07875595A0910|4 9|humans
P07875595A0910|13 26|PITSLRE PK genes
P07875595A0910|29 36|chickens
P07875595A0910|80 92|hybridization
P07875595A0910|99 110|localization
P07875595A0910|117 121|genes
P07875595A0910|131 152|chicken microchromosome
P07876134A0348|15 30|characterization
P07876134A0348|65 72|AFAP-110
P07876134A0348|98 105|base pair
P07876134A0348|116 127|reading frame
P07876191A0808|0 9|Expression
P07876191A0808|12 16|class
P07876191A0808|19 25|ADH mRNA
P07876191A0808|44 50|stomach
P07876191A0808|57 61|liver
P07876192A0443|2 9|ICE gamma
P07876192A0443|19 28|propeptide
P07876192A0443|29 38|amino acids
P07876192A0443|87 94|catalyst
P07876192A0443|98 114|ICE autoprocessing
P07876194T0000|0 10|Endocytosis
P07876194T0000|23 31|targeting
P07876194T0000|43 63|growth factor receptors
P07876194T0000|85 93|sequences
P07876194T0000|110 129|tyrosine kinase domain
P07876210A0275|59 63|genes
P07876210A0275|77 83|regions
P07876210A0275|126 133|proteins
P07876210A0275|144 159|Barbie box element
P07876210A0751|0 7|Mutation
P07876210A0751|13 29|P450BM-3 Barbie box
P07876210A0751|55 64|expression
P07876210A0751|71 78|P450BM-3
P07876210A0751|82 86|Bm3P1
P07876210A0751|125 136|P450BM-3 gene
P07876210A0751|172 178|protein
P07876210A0751|181 188|response
P07876210A0751|204 212|induction
P07876210A0751|228 233|levels
P07876300A0994|15 20|nuclei
P07876300A0994|55 67|protein import
P07876562A1646|10 16|outcome
P07876562A1646|35 41|effects
P07876562A1646|62 75|responsiveness
P07876562A1646|86 91|T cells
P07876562A1646|103 113|stimulation
P07876562A1646|128 141|HIV-1 infection
P07877308A1175|7 14|protocol
P07877308A1175|31 38|patients
P07877308A1175|53 58|cohort
P07877619A1284|2 9|addition
P07877619A1284|34 44|suppression
P07877619A1284|60 79|zif268 gene expression
P07877619A1284|100 125|base pair nucleotide sequence
P07877619A1284|161 166|region
P07877619A1284|172 181|zif268 gene
P07878029A0721|10 14|CBF-A
P07878029A0721|18 22|CBF-C
P07878029A0721|51 68|CBF-A-CBF-C complex
P07878029A0721|76 80|CBF-B
P07878029A0721|100 104|CBF-A
P07878029A0721|107 111|CBF-C
P07878029A0721|150 167|CBF-A-CBF-C complex
P07878040A0505|20 28|sequences
P07878040A0505|45 57|mouse enhancer
P07878040A0505|93 100|activity
P07879204T0000|0 14|OKT3 prophylaxis
P07879204T0000|37 49|graft survival
P07879204T0000|61 68|patients
P07879204T0000|81 92|cyclosporine
P07879204T0000|101 107|results
P07879204T0000|146 154|US studies
P07880442A0236|8 41|PKC beta transcription initiation site
P07880442A0236|57 71|primer extension
P07880442A0236|75 94|S1 nuclease protection
P07880449A0091|5 10|course
P07880449A0091|14 18|study
P07880449A0091|24 40|dose X-rays effects
P07880449A0091|93 103|suppression
P07880449A0091|112 119|behavior
P07880449A0091|130 144|body irradiation
P07880449A0091|152 160|cGy X-rays
P07880650A0493|13 20|analysis
P07880650A0493|26 45|diffraction intensity
P07880650A0493|48 55|function
P07880650A0493|72 83|electron dose
P07880650A0493|95 105|possibility
P07880650A0493|124 142|diffraction patterns
P07880650A0493|151 160|resolution
P07880650A0493|172 193|crotoxin complex crystal
P07881077A0195|0 29|Supplementary Phase Contraste RSE
P07881077A0195|45 54|Excitation
P07881077A0195|55 63|sequences
P07881077A0195|82 89|patients
P07883167A0157|2 6|yeast
P07883167A0157|10 17|products
P07883167A0157|32 40|UPF3 genes
P07883167A0157|58 69|decay pathway
P07883167A0157|79 84|report
P07883167A0157|97 110|identification
P07883167A0157|114 129|characterization
P07883167A0157|142 148|factors
P07883167A0157|165 169|decay
P07883167A0157|191 195|mRNAs
P07883168A0090|0 8|Mutations
P07883168A0090|11 18|UPF1 lead
P07883168A0090|33 45|stabilization
P07883168A0090|48 52|mRNAs
P07883168A0090|68 84|nonsense mutations
P07883168A0090|104 113|decay rates
P07883168A0090|125 129|mRNAs
P07883193A0000|1 11|DNA fragment
P07883193A0000|34 39|domain
P07883193A0000|40 49|amino acids
P07883193A0000|92 100|regulator
P07883193A0000|117 129|pGEX-KT vector
P07883193A0000|144 148|frame
P07883193A0000|175 198|glutathione S-transferase
P07883754A0993|5 24|gel retardation assays
P07883754A0993|29 33|HepG2
P07883754A0993|41 47|extract
P07883754A0993|65 72|presence
P07883754A0993|84 90|protein
P07883754A0993|106 116|NRE fragment
P07885999A0000|14 20|factors
P07885999A0000|37 45|sequences
P07885999A0000|60 65|region
P07885999A0000|71 89|mouse tyrosinase gene
P07885999A0000|109 117|band shift
P07885999A0000|121 149|methylation interference assays
P07886610A0000|5 14|population
P07886610A0000|46 53|patients
P07886610A0000|58 68|hemophilia A
P07886610A0000|71 75|India
P07886610A0000|85 94|prevalence
P07886610A0000|105 114|population
P07887226A0858|16 28|serum ferritin
P07887226A0858|32 55|hemoglobin determinations
P07887226A0858|59 87|serum transferrin receptor assay
P07887226A0858|99 106|addition
P07887226A0858|122 128|surveys
P07887226A0858|159 165|measure
P07887226A0858|178 191|iron deficiency
P07887226A0858|226 231|anemia
P07887226A0858|240 246|disease
P07887859A0315|21 28|patients
P07887859A0315|42 47|ulcers
P07887859A0315|51 55|tcPO2
P07887859A0315|109 115|indices
P07887859A0998|0 15|TcPO2 measurement
P07887859A0998|36 44|technique
P07887859A0998|70 84|ulcer management
P07888156A0169|12 29|University Hospital
P07888156A0169|32 37|Tromso
P07888156A0169|54 62|hospitals
P07888156A0169|73 78|Norway
P07888156A0169|96 109|section service
P07888156A0169|117 122|access
P07888156A0169|125 140|video conferences
P07888156A0169|147 152|review
P07888156A0169|166 173|findings
P07888156A0169|183 192|discussion
P07888156A0169|210 215|issues
P07888156T0000|7 12|status
P07888156T0000|15 27|telepathology
P07888306A1659|0 9|Expression
P07888306A1659|20 29|COS-1 cells
P07888306A1659|36 45|production
P07888306A1659|64 74|PDE activity
P07888306A1659|106 114|substrate
P07888306A1659|119 126|activity
P07888306A1659|186 199|concentrations
P07888306A1659|199 206|rolipram
P07888306A1659|250 257|ABSTRACT
P07888306A1659|272 276|WORDS
P07888623A0721|0 12|PMEK1 displays
P07888623A0721|19 27|% identity
P07888623A0721|47 57|tobacco NTF3
P07888623A0721|61 84|Arabidopsis ATMPK1 kinases
P07888623A0721|121 140|plant MAP kinase MsERK1
P07888623A0721|144 150|alfalfa
P07888629A0344|0 10|Translation
P07888629A0344|22 28|segment
P07888629A0344|47 52|MsPRP2
P07888629A0344|86 102|Da cell wall protein
P07888629A0344|123 136|signal sequence
P07888629A0344|160 167|sequence
P07888629A0344|202 209|sequence
P07888629A0344|233 253|lipid transfer proteins
P07888788A1010|3 10|presence
P07888788A1010|20 35|hypersensitivity
P07888788A1010|38 45|subgroup
P07888788A1010|48 60|aspergillomas
P07888788A1010|85 93|component
P07888788A1010|100 106|disease
P07888788A1010|149 156|response
P07888788A1010|159 169|Aspergillus
P07888788A1010|176 188|aspergillomas
P07888828A0765|4 10|concept
P07888828A0765|27 40|identification
P07888828A0765|50 54|genes
P07888828A0765|65 72|primates
P07890485A0827|10 21|illumination
P07890485A0827|34 46|photoreceptor
P07890485A0827|78 82|g.min
P07890485A0827|134 138|g.min
P07890599A0132|17 32|mouse cDNA library
P07890599A0132|37 48|MIN6 cell line
P07890599A0132|70 78|beta cells
P07890599A0132|90 96|isoform
P07890599A0132|139 149|acid protein
P07890599A0132|163 171|% identity
P07890599A0132|176 182|munc-18
P07890599A0132|182 187|n-Sec1
P07890599A0132|187 192|rbSec1
P07890599A0132|193 218|Caenorhabditis elegans unc18
P07890599A0132|245 249|Sec1p
P07890674A0916|3 10|catenins
P07890674A0916|25 34|E-cadherin
P07890674A0916|44 50|fashion
P07890674A0916|62 71|E-cadherin
P07890674A0916|109 116|presence
P07890674A0916|119 125|absence
P07890674A0916|128 135|catenins
P07890680A1193|7 14|addition
P07890680A1193|17 33|core DNA polymerase
P07890680A1193|52 58|complex
P07890680A1193|78 87|holoenzyme
P07890680A1193|98 108|replacement
P07890680A1193|111 115|gamma
P07890680A1193|118 122|alpha
P07890680A1193|128 141|primer terminus
P07890740A0997|3 10|PSD2 gene
P07890740A0997|39 47|infection
P07890740A0997|50 64|Sf-9 insect cells
P07890740A0997|80 90|baculovirus
P07890740A0997|110 117|increase
P07890740A0997|120 130|PSD activity
P07891638T0000|12 20|detection
P07891638T0000|31 39|asymmetry
P07891638T0000|49 64|chest radiographs
P07891685A1051|5 11|results
P07891685A1051|36 40|genes
P07891685A1051|59 65|binding
P07891685A1051|68 72|Cat8p
P07891685A1051|78 86|synthesis
P07891685A1051|99 105|release
P07891685A1051|108 112|Cat4p
P07891685A1051|113 117|Mig1p
P07891685A1051|125 136|CAT8 promoter
P07891708A0690|9 13|HNF-4
P07891708A0690|26 31|kidney
P07891708A0690|32 36|liver
P07891708A0690|40 49|Hep3B cells
P07891708A0690|58 66|HeLa cells
P07891708A1192|26 35|expression
P07891708A1192|51 57|Epo gene
P07891708A1192|85 94|Hep3B cells
P07891708A1192|116 127|HNF-4 delta C.
P07891709A1542|5 16|observations
P07891709A1542|45 54|mechanisms
P07891709A1542|74 83|transcript
P07891709A1542|106 118|deadenylation
P07891713T0000|5 15|Maf proteins
P07891713T0000|61 70|repressors
P07891713T0000|75 98|NF-E2 transcription factor
P07891720A0818|17 23|binding
P07891720A0818|54 66|concentration
P07891720A0818|68 78|calcium ions
P07892076A0578|0 7|Survival
P07892076A0578|13 23|development
P07892076A0578|37 45|infection
P07892076A0578|65 80|transmission mode
P07892353A0667|4 10|factors
P07892353A0667|34 45|correlations
P07892353A0667|77 82|cortex
P07892353A0667|97 102|cortex
P07892353A0667|115 120|factor
P07892353A0667|140 147|patterns
P07892353A0667|150 161|correlations
P07892353A0667|175 186|brain regions
P07894021A1130|25 32|function
P07894021A1130|50 59|protection
P07894021A1130|80 90|desiccation
P07894359T0000|10 21|hemodynamics
P07894359T0000|28 35|abortion
P07894359T0000|55 60|sepsis
P07894761A0000|27 31|study
P07894761A0000|60 64|cases
P07894761A0000|85 94|hemorrhage
P07894761A0000|110 116|success
P07894761A0000|125 130|vision
P07894761A0000|169 175|surgery
P07896088A0720|3 10|function
P07896088A0720|34 52|telomere maintenance
P07896088A0720|92 101|factor RIF1
P07896088A0720|101 111|rap1 alleles
P07896088A0720|149 170|RIF1 interaction domains
P07896088A0720|182 188|effects
P07896088A0720|191 204|telomere length
P07896291A0693|68 75|resource
P07896291A0693|81 96|characterization
P07896291A0693|99 103|genes
P07896291A0693|126 137|WAGR syndrome
P07896615A0554|3 14|contribution
P07896615A0554|17 24|skin flow
P07896615A0554|30 36|changes
P07896615A0554|46 57|nm absorption
P07896615A0554|87 97|measurement
P07896615A0554|100 107|skin flow
P07896615A0554|110 125|laser flow Doppler
P07896615A0554|129 141|NIR recordings
P07896615A0554|151 164|water immersion
P07896817A0204|0 7|Proteins
P07896817A0204|30 36|lysates
P07896817A0204|39 45|control
P07896817A0204|74 81|antisera
P07896817A0204|83 102|phospholipase C-gamma
P07896817A0204|103 111|PLC-gamma
P07896817A0204|130 165|SDS-polyacrylamide gel electrophoresis
P07896817A0204|182 192|Immobilon-P
P07896846T0000|22 29|isoforms
P07896846T0000|59 65|protein
P07896846T0000|79 94|suppressor region
P07896846T0000|105 115|beta-myosin
P07896846T0000|121 129|chain gene
P07896852T0000|0 10|Involvement
P07896852T0000|18 42|growth response factor Egr-1
P07896852T0000|45 77|apolipoprotein AI gene transcription
P07897359A0354|22 26|forms
P07897359A0354|32 39|F protein
P07897359A0354|55 60|BHK-21
P07897359A0354|64 74|HeLa T4 cells
P07897359A0354|98 105|vaccinia
P07897359A0354|119 136|T7 polymerase system
P07897696A0000|0 10|Erythrocyte
P07897696A0000|31 45|acid dehydratase
P07897696A0000|52 59|activity
P07897696A0000|59 87|erythrocyte zinc protoporphyrin
P07897696A0000|92 100|heme ratio
P07897696A0000|110 123|coproporphyrin
P07897696A0000|128 140|concentration
P07897696A0000|168 177|indicators
P07897696A0000|201 212|lead exposure
P07897696A0000|228 238|blood levels
P07897696A0000|241 246|excess
P07897696A0000|251 263|micrograms/dl
P07897696A0000|271 278|subjects
P07898178A0849|19 27|graft loss
P07898178A0849|32 41|conversion
P07898178A0849|44 55|azathioprine
P07898178A0849|68 76|graft loss
P07898178A0849|82 91|conversion
P07898178A0849|94 105|azathioprine
P07898178A0849|118 139|cyclosporin maintenance
P07898178A0849|177 188|patient death
P07898275A0254|5 11|classes
P07898275A0254|14 24|test objects
P07898275A0254|57 66|test object
P07898275A0254|70 87|31P MRS measurements
P07898275A0254|116 124|sequences
P07898275A0254|142 151|test object
P07898275A0254|171 175|1H MRS
P07898275A0254|195 205|test objects
P07898275A0254|221 231|performance
P07898275A0254|246 252|systems
P07898275A0254|266 291|volume localization sequence
P07898275A0254|293 299|31P MRS.
P07898589T0000|3 14|tobacco issue
P07898840X0000|0 17|Pregnancy screening
P07898840X0000|27 50|artery Doppler velocimetry
P07898840X0000|56 64|criterion
P07898840X0000|90 98|OBJECTIVE
P07898840X0000|121 134|Doppler studies
P07898840X0000|154 164|circulation
P07898840X0000|171 179|gestation
P07898840X0000|201 205|power
P07898840X0000|235 246|hypertension
P07898840X0000|255 271|growth restriction
P07898840X0000|287 294|analysis
P07898840X0000|302 312|combination
P07898840X0000|341 351|assessments
P07898840X0000|372 380|waveforms
P07898840X0000|396 402|results
P07898840X0000|407 414|analysis
P07899581A0000|3 8|effect
P07899581A0000|14 39|Ca entry blocker nitrendipine
P07899581A0000|54 72|superoxide dismutase
P07899581A0000|82 92|combination
P07899581A0000|94 105|nitrendipine
P07899581A0000|109 127|superoxide dismutase
P07899581A0000|147 154|function
P07899581A0000|171 176|groups
P07899634A0000|0 6|PURPOSE
P07899634A0000|21 25|study
P07899634A0000|45 53|anchorage
P07899634A0000|79 91|surface effect
P07899634A0000|96 106|alloy Ti Al Va
P07900915A0000|30 34|water
P07900915A0000|55 59|tract
P07900915A0000|67 77|restitution
P07900915A0000|80 90|blood volume
P07900915A0000|94 106|plasma protein
P07900915A0000|112 121|hemorrhage
P07900915A0000|163 170|ml.kg-1 x
P07900915A0000|170 184|min-1 hemorrhage
P07900915A0000|188 198|restitution
P07900915A0000|201 211|blood volume
P07900915A0000|225 229|Evans
P07900915A0000|240 247|dilution
P07900915A0000|250 259|hematocrit
P07901121T0000|0 22|Cooperative dimerization
P07901121T0000|31 47|class homeo domains
P07901125A0416|6 14|advantage
P07901125A0416|24 29|degree
P07901125A0416|32 49|aa sequence homology
P07901125A0416|57 62|DAHPSs
P07901125A0416|74 80|species
P07901125A0416|90 103|ARO3 homologues
P07901125A0416|121 140|yeast Candida albicans
P07902532A0312|6 10|study
P07902532A0312|28 33|BOX DNA
P07902532A0312|42 54|transcription
P07902532A0312|62 76|thymidine kinase
P07902532A0312|81 88|promoter
P07902532A0312|97 103|EC cells
P07902532A1655|0 15|Deletion analyses
P07902532A1655|21 29|construct
P07902532A1655|45 57|transcription
P07902532A1655|60 68|BOXF1 gene
P07902532A1655|82 87|BOX DNA
P07902532A1655|120 126|EC cells
P07902532A1655|147 151|cells
P07902583A0545|0 7|Analysis
P07902583A0545|10 28|disassociation rates
P07902583A0545|45 65|Grf10-Swi5-DNA complex
P07902583A0545|76 84|half-life
P07902583A0545|100 108|complexes
P07902583A0545|132 136|Grf10
P07903099A0918|3 10|presence
P07903099A0918|22 31|transcript
P07903099A0918|42 50|IVS2C beta
P07903099A0918|58 65|terminus
P07903099A0918|78 85|cleavage
P07903099A0918|91 104|splice acceptor
P07903670A1202|9 14|allele
P07903670A1202|20 37|alpha 1-tubulin gene
P07903670A1202|51 56|tua1-1
P07905413A0585|13 21|treatment
P07905413A0585|26 45|plasma concentrations
P07905413A0585|67 73|ng.ml-1
P07905413A0585|85 91|ng.ml-1
P07905413A0585|111 127|segment depression
P07905413A0585|153 160|workload
P07905413A0585|204 210|placebo
P07905413A0585|225 230|points
P07905453A0281|0 6|Results
P07905453A0281|18 50|transcription-translation analysis
P07905453A0281|54 72|maxicell experiments
P07906265A0897|11 21|experiments
P07906265A0897|60 70|fasD mutants
P07906265A0897|76 83|products
P07906265A0897|111 116|export
P07906265A0897|120 127|assembly
P07906616A0191|23 30|response
P07906616A0191|53 63|stimulation
P07906616A0191|93 97|goats
P07906616A0191|123 133|anaesthesia
P07907846A0623|0 4|Group
P07907846A0623|14 26|physostigmine
P07907846A0623|30 38|mg/kg i.v.
P07907846A0623|53 77|cholinesterase degradation
P07907846A0623|90 114|bupivacaine administration
P07907846A0623|117 121|Group
P07907846A0623|132 142|combination
P07907846A0623|145 169|physostigmine pretreatment
P07907846A0623|188 198|stimulation
P07908012A0678|12 22|possibility
P07908012A0678|27 41|LNNB performance
P07908012A0678|60 65|groups
P07908012A0678|97 106|medication
P07908012A0678|107 114|analyses
P07908012A0678|133 144|relationship
P07908012A0678|152 167|medication levels
P07908012A0678|171 180|LNNB scores
P07908187T0000|7 19|possibilities
P07908827A1200|18 27|antibodies
P07908827A1200|37 50|identification
P07908827A1200|60 66|RAR beta
P07908827A1200|89 97|complexes
P07908827A1200|113 121|sequences
P07908827A1200|151 158|COS cells
P07908827A1200|226 232|element
P07909936A0672|10 26|treatment strategy
P07909936A0672|40 48|disorders
P07909936A0672|80 85|effect
P07909936A0672|97 113|radiochemotherapy
P07909936A0672|124 147|stem-cell transplantation
P07909936A0672|169 177|cytokines
P07909936A0672|201 207|factors
P07910716A0359|3 14|study cohorts
P07910716A0359|28 35|patients
P07910716A0359|47 53|SC rIL-2
P07910716A0359|56 60|doses
P07910716A0359|77 85|IU/m2/day
P07910716A0359|108 112|total
P07910716A0359|114 118|weeks
P07910716A0359|121 128|patients
P07910716A0359|140 151|rIFN-alpha 2b
P07910716A0359|167 180|U/m2/day thrice
P07910716A0359|191 195|total
P07910716A0359|199 203|weeks
P07910716A0359|209 216|patients
P07910716A0359|229 242|SC rIFN-alpha 2b
P07910716A0359|255 268|U/m2/day thrice
P07910716A0359|279 285|SC rIL-2
P07910716A0359|303 311|IU/m2/day
P07910716A0359|345 353|IU/m2/day
P07910716A0359|384 388|weeks
P07910946A0323|0 7|Analysis
P07910946A0323|18 35|deletion constructs
P07910946A0323|46 63|transfection assays
P07910946A0323|85 96|reporter gene
P07910946A0323|97 106|luciferase
P07910946A0323|107 114|activity
P07910946A0323|148 153|region
P07910946A0323|166 181|promoter activity
P07910946A0323|199 205|L2 cells
P07911736A1715|11 19|mg/m2/day
P07911736A1715|35 42|toxicity
P07911736A1715|49 53|agent
P07911736A1715|56 71|myelosuppression
P07912123A0711|15 37|lymphocyte proliferation
P07913080A0564|1 30|decanucleotide promoter sequence
P07913080A0564|55 60|humans
P07913080A0564|98 103|region
P07913080A0564|108 116|horse gene
P07913891A0174|11 17|targets
P07913891A0174|39 47|molecules
P07913891A0174|67 78|interactions
P07913891A0174|88 99|relationship
P07913891A0174|129 136|Hox genes
P07913891A0174|145 164|transcription factors
P07913891A0174|203 219|tissue specificity
P07913926A0878|0 15|Northern analysis
P07913926A0878|18 27|RNA samples
P07913926A0878|54 61|cultures
P07913926A0878|67 76|ntcA mutant
P07913926A0878|90 96|amounts
P07913926A0878|99 109|glnA message
P07913926A0878|116 122|absence
P07913926A0878|132 141|transcript
P07914192A0211|0 22|HER2 overexpressing cells
P07914192A0211|45 49|DNase
P07914192A0211|108 125|ets response element
P07914192A0211|125 130|GAGGAA
P07914192A0211|140 155|bases down-stream
P07914192A0211|163 169|CAAT box
P07914192A0211|187 193|TATA box
P07914192A0211|204 215|HER2 promoter
P07914192A0844|0 14|Gel-shift assays
P07914192A0844|26 33|extracts
P07914192A0844|37 60|oligonucleotide sequences
P07914192A0844|80 93|promoter region
P07914192A0844|122 128|complex
P07914192A0844|152 156|cells
P07914192A0844|195 201|binding
P07914192A0844|214 234|GAGGAA response element
P07914507A1029|0 9|Comparison
P07914507A1029|12 24|cDNA sequences
P07914507A1029|43 53|mRNA species
P07914507A1029|62 67|result
P07914507A1029|93 105|addition sites
P07914700A0000|28 50|eIF-2 alpha protein kinase
P07914700A0000|70 74|mouse
P07915144A0000|0 13|High-frequency
P07915144A0000|24 34|stimulation
P07915144A0000|40 50|hippocampus
P07915144A0000|60 67|increase
P07915144A0000|78 85|efficacy
P07915144A0000|102 106|hours
P07916003A0688|12 20|mouse gene
P07916003A0688|33 38|region
P07916003A0688|46 54|CD79 alpha
P07916003A0688|61 67|TATA box
P07916003A0688|81 94|mouse CD79 alpha
P07916003A0688|105 116|octamer motif
P07916326A0000|17 28|organization
P07916326A0000|34 39|coding
P07916326A0000|61 67|regions
P07916326A0000|107 111|Msx-1
P07916327A0250|15 21|cloning
P07916327A0250|32 44|goosecoid gene
P07916327A0250|62 68|library
P07916327A0250|74 81|sequence
P07916327A0250|94 100|protein
P07916577A0190|2 6|order
P07916577A0190|24 37|candidate genes
P07916577A0190|50 58|disorders
P07916577A0190|82 95|gene expression
P07916577A0190|121 129|sequences
P07916577A0190|162 166|cDNAs
P07916588A0471|4 8|virus
P07916588A0471|33 38|strain
P07916588A0471|41 66|passion fruit woodiness virus
P07916588A0471|82 91|CP sequence
P07916588A0471|136 142|strains
P07916588A0471|178 185|subgroup
P07916588A0471|186 196|potyviruses
P07916685A0455|3 7|ratio
P07916685A0455|13 20|activity
P07916685A0455|23 44|arogenate dehydrogenase
P07916685A0455|53 75|prephenate dehydrogenase
P07916685A0455|118 129|purification
P07916685A0455|139 148|activities
P07916689A0312|11 20|POT1 clones
P07916689A0312|37 48|kb RNA species
P07916689A0312|88 93|oleate
P07916689A0312|100 111|carbon source
P07916689A1407|3 14|Y. lipolytica
P07916689A1407|22 29|POT1 gene
P07916689A1407|71 78|sequence
P07916689A1407|109 128|Y. lipolytica LEU2 gene
P07916729T0000|1 19|leucine zipper domain
P07916729T0000|25 34|suppressor
P07916729T0000|47 53|protein
P07916729T0000|75 80|effect
P07916729T0000|83 98|enhancer function
P07916983A0623|48 55|patients
P07916983A0623|59 74|N1-N3 neck disease
P07916983A0623|110 121|prescription
P07917016A0581|12 22|DNA-binding
P07917016A0581|23 53|zinc finger domain protein sequence
P07917540A0000|2 9|patients
P07917540A0000|36 40|study
P07917540A0000|50 58|vindesine
P07917540A0000|60 69|mg/m2/week
P07917540A0000|74 91|interferon-alpha 2b
P07917540A0000|100 104|times
P07917540A0000|115 123|vindesine
P07917540A0000|132 141|interferon
P07917540A0000|153 161|treatment
P07917540A0000|183 190|melanoma
P07918097T0000|8 31|Notch homologue mouse Notch
P07918097T0000|55 74|growth factor-repeats
P07918097T0000|104 118|neuroepithelium
P07918128A0000|0 9|BACKGROUND
P07918128A0000|22 26|phase
P07918128A0000|56 72|hydroxytryptamine
P07918128A0000|72 76|5-HT3
P07918128A0000|77 94|receptor antagonist
P07918128A0000|99 106|patients
P07918128A0000|126 137|chemotherapy
P07918494A1163|5 12|presence
P07918494A1163|32 37|system
P07918494A1163|38 48|thioredoxin
P07918494A1163|49 68|thioredoxin reductase
P07918494A1163|72 76|NADPH
P07918494A1163|95 101|mutants
P07918494A1163|114 122|formation
P07918494A1163|135 139|dCTPs
P07918494A1163|151 156|enzyme
P07919540A0240|12 22|alterations
P07919540A0240|34 42|synthesis
P07919540A0240|53 64|c-myc protein
P07919540A0240|98 105|AUG codon
P07919540A1119|2 9|addition
P07919540A1119|44 48|forms
P07919540A1119|52 63|c-Myc protein
P07919540A1119|74 86|transcription
P07919540A1119|108 124|reporter construct
P07919540A1119|135 139|level
P07922709T0000|10 19|activities
P07922709T0000|35 47|growth factors
P07922709T0000|72 82|application
P07925022A0285|0 9|Expression
P07925022A0285|54 59|stages
P07925097A1205|14 22|AR content
P07925097A1205|36 45|COS-1 cells
P07925097A1205|64 71|exposure
P07925097A1205|74 82|8-Br-cAMP
P07925282A0705|0 9|Disruption
P07925282A0705|27 31|genes
P07925282A0705|58 68|SRP proteins
P07925282A0705|82 91|cell growth
P07925282A0705|106 125|protein translocation
P07925282A0705|135 144|ER membrane
P07926729A0000|7 17|alterations
P07926729A0000|20 27|elements
P07926729A0000|36 63|signal transduction mechanisms
P07926729A0000|85 90|events
P07926729A0000|115 124|activation
P07926729A0000|127 134|programs
P07926729A0000|137 153|gene transcription
P07926739A0766|3 19|expression pattern
P07926739A0766|49 61|hybridization
P07926739A0766|104 118|progenitor cells
P07926739A0766|123 128|stages
P07926739A0766|143 161|trichome development
P07926748A0383|49 53|assay
P07926748A0383|54 67|overexpression
P07926748A0383|103 115|not2 mutations
P07926749A0471|7 19|site selection
P07926749A0471|44 51|proteins
P07926749A0471|66 73|ROR alpha
P07926749A0471|78 85|ROR alpha
P07926749A0471|87 94|isoforms
P07926749A0471|106 113|monomers
P07926749A0471|115 137|hormone response elements
P07926749A0471|160 167|sequence
P07926749A0471|187 202|core motif PuGGTCA
P07926774A0652|3 25|p73pct1/p85cdc10 complex
P07926774A0652|71 78|E2F sites
P07926775A0895|15 21|stripes
P07926775A0895|51 57|embryos
P07926775A0895|64 74|slp activity
P07926775A0895|87 97|requirement
P07926775A0895|101 111|maintenance
P07926775A0895|114 125|wg expression
P07926775A0895|145 159|wg transcription
P07926789A0960|3 13|DNA sequence
P07926789A0960|27 34|lacZ gene
P07926789A0960|67 77|fusion genes
P07926789A0960|83 90|products
P07926789A0960|134 140|fusions
P07927130A0625|0 30|CMV hyperimmunoglobulin treatment
P07927130A0625|31 38|Cytotect
P07927130A0625|39 45|Biotest
P07927130A0625|57 63|ml/kg bw
P07927130A0625|80 84|ml/kg
P07927130A0625|111 121|eradication
P07927130A0625|134 143|infiltrate
P07927130A0625|147 153|CMV-DNA
P07927130A0625|159 168|myocardium
P07927267T0000|15 22|drainage
P07927267T0000|37 44|drainage
P07927267T0000|63 74|regeneration
P07927267T0000|88 95|rat liver
P07927267T0000|108 118|hepatectomy
P07927711A0698|36 42|protein
P07927711A0698|87 93|regions
P07927838A0000|7 12|groups
P07927838A0000|15 22|subjects
P07927838A0000|57 61|tools
P07927838A0000|79 83|years
P07927838A0000|87 101|prevalence rates
P07927838A0000|126 131|finger
P07927838A0000|140 147|numbness
P07927838A0000|155 163|stiffness
P07927838A0000|181 191|extremities
P07928954A0545|0 18|DNA sequence analysis
P07928954A0545|77 83|protein
P07928954A0545|96 101|weight
P07928954A0545|138 161|lipoprotein signal peptide
P07928954A0545|165 201|consensus prolipoprotein processing site
P07929165T0000|0 10|DNA sequence
P07929165T0000|14 22|functions
P07929165T0000|28 38|actVI region
P07929165T0000|44 55|actinorhodin
P07929165T0000|68 78|gene cluster
P07929238A0734|4 11|Genomics
P07929411A0087|1 10|comparison
P07929411A0087|25 43|polypeptide sequence
P07929411A0087|49 65|Drosophila protein
P07929411A0087|83 90|subunits
P07929411A0087|95 99|mouse
P07929411A0087|103 107|yeast
P07929411A0087|165 171|regions
P07929411A0087|202 215|enzyme activity
P07929431A0949|0 7|Plasmids
P07929431A0949|30 48|mouse promoter region
P07929431A0949|60 103|reporter gene chloramphenicol acetyltransferase
P07929431A0949|148 157|INS-1 cells
P07929559A0000|11 16|dynein
P07929559A0000|68 73|enzyme
P07929559A0000|106 112|variety
P07929559A0000|128 136|movements
P07929559A0000|164 172|transport
P07929559A0000|175 184|organelles
P07929560T0000|0 13|Identification
P07929560T0000|38 43|domain
P07929560T0000|46 55|desmoglein
P07929560T0000|70 83|plaque assembly
P07929560T0000|98 114|filament anchorage
P07931490A0237|0 7|PATIENTS
P07931490A0237|11 17|METHODS
P07931490A0237|57 64|patients
P07931490A0237|83 91|cisplatin
P07931490A0237|99 103|mg/m2
P07931490A0237|136 151|granisetron doses
P07931490A0237|161 173|micrograms/kg
P07931490A0237|192 203|chemotherapy
P07932095A0000|7 17|naphthalene
P07932095A0000|25 33|compounds
P07932095A0000|40 46|VII-XII
P07932095A0000|67 75|compounds
P07932095A0000|110 117|root bark
P07932095A0000|118 136|Oroxylum indicum Vent
P07932943A0113|16 20|study
P07932943A0113|34 42|influence
P07932943A0113|48 64|awareness strategy
P07932943A0113|80 87|strategy
P07932943A0113|90 114|Five-Step Approach strategy
P07932943A0113|120 135|control condition
P07933066T0000|17 27|interaction
P07933066T0000|33 46|adenovirus E4-6
P07933066T0000|47 53|protein
P07933066T0000|60 84|retinoblastoma gene product
P07933066T0000|97 103|domains
P07933066T0000|106 110|E2F-1
P07933076A0211|17 21|EBNA2
P07933076A0211|39 47|promoters
P07933076A0211|64 79|membrane proteins
P07933095A0000|22 26|v-Rel
P07933095A0000|30 40|oncoprotein
P07933095A0000|51 65|retrovirus Rev-T
P07933095A0000|77 86|expression
P07933095A0000|91 99|promoters
P07933095A0000|117 121|sites
P07933095A0000|136 157|transcription factor Sp1
P07933095A0000|160 183|chicken embryo fibroblasts
P07933101A0131|8 14|studies
P07933101A0131|38 48|TATA element
P07933101A0131|81 99|HIV-1 gene expression
P07933107A0991|1 10|comparison
P07933107A0991|16 33|nucleotide sequence
P07933107A0991|39 45|p54 gene
P07933107A0991|66 76|ASFV strains
P07933107A0991|110 119|virus Ba71V
P07933107A0991|126 136|% similarity
P07933116A0412|3 9|p55 mRNA
P07933116A0412|48 58|T-cell lines
P07933116A0412|77 84|cell line
P07934331T0037|7 18|registration
P07934331T0037|23 31|incentive
P07934331T0037|35 45|improvement
P07934666A0158|13 25|magnetization
P07934666A0158|58 67|components
P07934666A0158|99 107|component
P07935094A0516|0 6|RESULTS
P07935094A0516|20 26|quality
P07935094A0516|29 37|FDG images
P07935094A0516|67 84|Tl-201 counterparts
P07935094A0516|93 107|liver background
P07935094A0516|119 126|FDG study
P07935370A0000|14 23|expression
P07935370A0000|45 61|T-cell development
P07935370A0000|83 97|maturation state
P07935370A0000|103 107|T cell
P07935375A1197|0 9|Expression
P07935375A1197|30 36|ras gene
P07935375A1197|47 65|TIS10/PGS2 induction
P07935375A1197|68 72|v-src
P07935379A0347|23 27|cells
P07935379A0347|60 66|changes
P07935379A0347|83 87|cells
P07935379A0347|98 106|apoptosis
P07935383A0108|7 11|RNase
P07935383A0108|22 37|mapping technique
P07935383A0108|57 63|subunit
P07935383A0108|96 104|pre-mRNAs
P07935383A0108|112 118|regions
P07935383A0108|141 152|cleavage site
P07935383A0108|164 168|virus
P07935383A0108|178 198|adenovirus L3 pre-mRNAs
P07935395A0094|3 9|protein
P07935395A0094|43 58|zinc finger motifs
P07935395A0094|85 92|clusters
P07935395A0094|114 121|molecule
P07935415T0000|15 24|expression
P07935415T0000|46 54|inhibitor
P07935415T0000|79 85|cloning
P07935415T0000|86 94|structure
P07935415T0000|98 109|localization
P07935418A0447|6 16|v-erbA probe
P07935418A0447|66 72|protein
P07935418A0447|72 76|RLD-1
P07935418A0447|106 112|domains
P07935418A0447|122 130|receptors
P07935426A0714|12 19|isoforms
P07935426A0714|40 55|zinc finger domain
P07935426A0714|87 104|TdT promoter binding
P07935447A0972|4 8|study
P07935447A0972|23 30|evidence
P07935447A0972|41 46|member
P07935447A0972|72 90|leucine zipper family
P07935447A0972|104 108|HF-1a
P07935447A0972|111 119|PRE B sites
P07935447A0972|140 148|component
P07935447A0972|151 166|protein complexes
P07935447A0972|196 205|expression
P07935447A0972|208 213|MLC-2v
P07935447A0972|217 228|alpha-myosin
P07935447A0972|240 244|genes
P07935451T0000|5 27|T-cell leukemia virus type
P07935451T0000|29 41|Tax activation
P07935451T0000|44 56|NF-kappa B/Rel
P07935451T0000|65 79|phosphorylation
P07935451T0000|83 93|degradation
P07935451T0000|96 107|I kappa B alpha
P07935451T0000|129 137|induction
P07935451T0000|141 149|c-rel gene
P07935468T0000|0 9|Activation
P07935468T0000|12 30|c-fos gene expression
P07935468T0000|59 78|growth factor receptor
P07935471A0613|33 40|activity
P07935471A0613|58 65|antibody
P07935471A0613|82 91|Xenopus HSF
P07935471A0613|106 111|system
P07935471A0613|115 128|mapping regions
P07935471A0613|131 135|hHSF1
P07935471A0613|157 167|maintenance
P07935471A0613|182 186|state
P07935472A0276|0 8|Enhancers
P07935472A0276|28 32|Ets-1
P07935472A0276|40 44|sites
P07935472A0276|66 81|expression assays
P07935472A0276|93 105|T-cell line EL4
P07935472A0276|128 138|alterations
P07935472A0276|143 152|LVb element
P07935472A0276|173 188|enhancer activity
P07935472A0276|194 201|mutation
P07935472A0276|220 229|LVc element
P07935472A0276|238 244|phorbol
P07935472A0276|258 273|enhancer activity
P07935472A0790|14 28|binding activity
P07935472A0790|35 39|Ets-1
P07935472A0790|74 82|complexes
P07935472A0790|99 117|mobility shift assays
P07935491A0495|5 15|RZR subtypes
P07935491A0495|25 31|members
P07935491A0495|38 43|family
P07935491A0495|59 67|receptors
P07935491A0495|98 111|gene expression
P07935491A1182|18 33|response elements
P07935491A1182|60 67|affinity
P07935491A1182|79 121|acid receptor-retinoid-X receptor heterodimers
P07935577A0305|0 8|Treatment
P07935577A0305|13 25|amphotericin B
P07935577A0305|29 39|flucytosine
P07935577A0305|45 55|improvement
P07935577A0305|61 68|symptoms
P07935577A0305|90 104|micro-organisms
P07935577A0305|125 129|fluid
P07935626A1249|13 20|presence
P07935626A1249|39 52|gene transcript
P07935626A1249|52 63|mitochondria
P07935997A0000|3 12|parameters
P07935997A0000|33 40|immunity
P07935997A0000|41 60|serum immunoglobulins
P07935997A0000|70 78|complexes
P07935997A0000|104 108|group
P07935997A0000|111 118|patients
P07935997A0000|130 144|cervix carcinoma
P07935997A0000|145 153|Stages IIB
P07936635A1134|0 7|Mutation
P07936635A1134|53 63|compartment
P07936635A1134|79 85|protein
P07936635A1134|112 118|nucleus
P07936640A0900|12 18|binding
P07936640A0900|21 27|protein
P07936640A0900|35 39|sites
P07936640A0900|42 46|cells
P07936640A0900|74 93|footprinting analysis
P07936640A0900|100 106|portion
P07936640A0900|112 127|TGF alpha promoter
P07936640A0900|150 157|rat liver
P07936640A0900|168 176|cell lines
P07936640A0900|216 221|levels
P07936650A0656|14 22|subdomain
P07936650A0656|69 84|activating region
P07936650A0656|87 96|p58c-ets-2
P07936650A0656|120 129|Ets-1-beta
P07936650A0656|143 150|sequence
P07936650A1752|22 26|model
P07936650A1752|32 36|ets-1
P07936650A1752|36 44|ets-2 gene
P07936650A1752|46 54|evolution
P07936650A1752|106 114|evidences
P07937106A0100|3 15|v-ets oncogene
P07937106A0100|26 38|retrovirus E26
P07937106A0100|61 80|progenitor p68c-ets-1
P07937106A0100|86 107|amino acid substitutions
P07937106A0100|108 114|alanine
P07937106A0100|121 130|isoleucine
P07937106A0100|136 142|c-ets-1
P07937106A0100|160 165|valine
P07937106A0100|168 172|v-ets
P07937106A0100|173 181|mutations
P07937106A0100|228 236|mutation C
P07937108A0325|22 26|mRNAs
P07937108A0325|52 66|RNA polymerase I.
P07937112A0220|13 20|subunits
P07937112A0220|62 66|cells
P07937112A0220|73 84|denaturation
P07937127A0645|9 14|method
P07937127A0645|52 68|activation domains
P07937127A0645|90 96|regions
P07937127A0645|102 114|herpesviruses
P07937127A0645|121 137|pseudorabies virus
P07937127A0645|147 157|herpesvirus
P07937132A0819|28 34|stretch
P07937132A0819|51 65|complementarity
P07937132A0819|84 91|sequence
P07937132A0819|94 100|28S rRNA
P07937147A0205|8 13|system
P07937147A0205|35 50|pi protein mutants
P07937147A0205|146 155|Filutowicz
P07937656A0182|0 9|Univariate
P07937656A0182|21 28|analysis
P07937656A0182|36 57|Kaplan-Meier-estimates
P07937656A0182|61 73|Log-Rank-Test
P07937656A0182|116 122|factors
P07937656A0182|130 141|disease stage
P07937656A0182|151 163|NSE serum level
P07937656A0182|173 184|micrograms/l
P07937656A0182|194 217|serum alkaline phosphatase
P07937656A0182|248 259|serum albumin
P07937656A0182|270 282|activity index
P07937656A0182|284 290|minimum
P07937841A0790|5 11|results
P07937841A0790|19 26|evidence
P07937841A0790|30 35|bypass
P07937841A0790|67 75|cell cycle
P07937841A0790|86 93|pathways
P07937841A0790|97 102|member
P07937841A0790|108 124|myb oncogene family
P07937954A0612|21 26|levels
P07937954A0612|111 119|MAP kinase
P07937965T0000|8 12|c-myc
P07937965T0000|20 24|virus
P07937965T0000|32 36|tumor
P07937965T0000|52 63|DNA synthesis
P07937965T0000|75 96|3T3-L1 mouse fibroblasts
P07938137A0384|3 8|groups
P07938137A0384|39 46|naloxone
P07938137A0384|50 54|mg/kg
P07938137A0384|71 81|environment
P07938137A0384|100 104|signs
P07938137A0384|113 122|withdrawal
P07941174T0001|0 11|Laser therapy
P07941174T0001|20 28|carcinoma
P07941739A0000|5 14|kb fragment
P07941739A0000|20 30|yeast genome
P07941739A0000|59 64|region
P07941739A0000|67 79|chromosome XIV
P07941739A0000|89 95|mapping
P07941750A0344|34 39|length
P07941750A0344|55 70|hydantoinase HyuA
P07941750A0344|92 106|hydatoinase HyuB
P07942076A0497|14 36|estradiol concentrations
P07942076A0497|50 66|estradiol valerate
P07942076A0497|80 97|estradiol ingestion
P07942076A0497|116 122|patient
P07942448A1227|10 17|patients
P07942448A1227|20 28|NYHA class
P07942448A1227|38 42|class
P07942448A1227|58 65|ABSTRACT
P07942448A1227|80 84|WORDS
P07942722T0000|0 11|Constipation
P07942722T0000|18 27|risk factor
P07942722T0000|31 41|hemorrhoids
P07942722T0000|55 59|study
P07942722T0000|82 87|agents
P07943556A0694|5 11|persons
P07943556A0694|56 65|Og4C3 assay
P07944461A0321|0 5|TG-day
P07944461A0321|9 16|TG-night
P07944542T0000|0 17|Vibrio cholerae O139
P07944542T0000|20 27|Calcutta
P07945134A0079|3 12|volunteers
P07945134A0079|112 117|sounds
P07945134A0079|131 144|head microphone
P07945330A0103|4 18|differentiation
P07945330A0103|41 53|transcription
P07945330A0103|57 65|Rex-1 gene
P07945937A0358|0 15|Sequence analysis
P07945937A0358|21 33|zebrafish egr1
P07945937A0358|40 45|region
P07945937A0358|59 63|level
P07945937A0358|66 73|homology
P07945937A0358|79 83|mouse
P07945937A0358|97 105|Egr1 genes
P07945937A0358|119 127|exception
P07945937A0358|142 172|triplet nucleotide repeat sequence
P07945937A0358|178 183|region
P07945937A0358|196 208|amino terminus
P07945937A0358|214 224|Egr1 protein
P07947930A0499|3 12|fibrinogen
P07947930A0499|13 25|serum proteins
P07947930A0499|26 38|sodium heparin
P07947930A0499|42 49|membrane
P07948129A0297|7 13|vectors
P07948129A0297|37 42|repeat
P07948129A0297|43 47|chLTR
P07948129A0297|57 66|expression
P07948129A0297|72 103|chloramphenicol acetyl transferase
P07948129A0297|109 120|reporter gene
P07948129A0297|146 154|SV40 virus
P07948129A0297|160 173|region promoter
P07948129A0297|185 210|neomycin phosphotransferase
P07948921A0051|0 5|Optima
P07948921A0051|13 19|library
P07948921A0051|53 72|stilbene synthase cDNA
P07948921A0051|76 80|probe
P07949137A0000|1 5|total
P07949137A0000|16 23|leukemia
P07949137A0000|29 36|patients
P07949137A0000|56 65|bone marrow
P07949137A0000|78 88|mafosfamide
P07949137A0000|88 92|ASTA Z
P07949137A0000|102 107|period
P07949137A0000|110 116|January
P07949137A0000|123 129|January
P07949137A0532|16 22|regimen
P07949137A0532|34 49|cyclophosphamide
P07949137A0532|53 57|mg/kg
P07949137A0532|66 80|body irradiation
P07949164A0799|16 23|mutation
P07949164A0799|29 39|kappa B motif
P07949164A0799|47 56|CAT plasmid
P07949164A0799|77 86|abrogation
P07949164A0799|89 108|IL-6 promoter activity
P07949164A0799|116 120|cells
P07949205A0286|9 22|testololactone
P07949205A0286|54 70|aminoglutethimide
P07949205A0286|89 103|breast carcinoma
P07949551A0000|10 17|vena cava
P07949551A0000|47 68|cadaver transplantation
P07949770T0000|21 29|blood flow
P07949770T0000|39 53|prostaglandin E1
P07949770T0000|63 82|liver transplantation
P07951235A0277|74 79|muscle
P07951410A0647|21 29|A549 cells
P07951410A0647|28 40|participation
P07951410A0647|43 47|E2F-1
P07951410A0647|54 60|cyclin A
P07951410A0647|80 88|formation
P07951410A0647|94 102|complexes
P07951410A0647|115 127|participation
P07951410A0647|130 136|factors
P07951410A0647|150 154|E2F-1
P07951410A0647|165 170|others
P07951410A1332|0 16|E1A autoactivation
P07951410A1332|32 36|sites
P07951410A1332|73 82|activation
P07951410A1332|106 116|E1A promoter
P07951874A0320|0 14|Cestode invasion
P07951874A0320|27 38|host organism
P07951874A0320|59 64|effect
P07951874A0320|75 83|radiation
P07951874A0320|89 95|hamster
P07951874A0320|102 107|system
P07953785A0648|6 17|heat exposure
P07953785A0648|18 23|chicks
P07953785A0648|52 63|% restriction
P07953785A0648|104 112|H/L ratios
P07953785A0648|123 132|resistance
P07953785A0648|135 162|marble spleen disease infection
P07954475A0714|0 7|Analyses
P07954475A0714|20 25|tumors
P07954475A0714|58 64|crosses
P07954475A0714|64 76|A/J x C3H/HeJ F1
P07954475A0714|92 96|AC3F1
P07954475A0714|100 112|C3H/HeJ x A/J F1
P07954475A0714|128 132|C3AF1
P07954475A0714|141 148|evidence
P07954475A0714|155 166|inactivation
P07954475A0714|172 177|allele
P07954475A0714|191 200|chromosome
P07954475A0714|202 220|tumor suppressor gene
P07954891T0000|34 38|cycle
P07954891T0000|44 54|maintenance
P07954891T0000|70 76|genomes
P07956578A0851|0 14|Lesion diameters
P07956578A0851|57 70|configurations
P07956578A0851|74 80|factors
P07956578A0851|113 119|removal
P07956869A0000|36 53|breast cancer tissue
P07956869A0000|76 83|archives
P07956869A0000|89 107|Pathology laboratory
P07956869A0000|128 134|storage
P07956869A0000|141 145|years
P07956869A0000|161 173|flow cytometry
P07956869A0000|177 185|DNA ploidy
P07956869A0000|189 203|S-phase fraction
P07957085A0207|19 26|proteins
P07957085A0207|26 30|Cbf3a
P07957085A0207|31 35|Cbf3b
P07957085A0207|39 43|Cbf3c
P07957106A0471|6 16|interaction
P07957106A0471|38 57|GST-POU fusion protein
P07957106A0471|65 88|glutathione-agarose beads
P07957106A0875|5 13|mutations
P07957106A0875|35 40|region
P07957106A0875|49 69|HSV transactivator VP16
P07957106A0875|99 110|VP16 contacts
P07957158A1532|12 25|filtration rate
P07957158A1532|36 40|areas
P07957158A1532|84 92|parameter
P07957158A1532|157 163|control
P07957158A1532|169 182|Starling forces
P07957243A1316|12 19|residues
P07957243A1316|41 47|domains
P07957559A1557|7 15|rapamycin
P07957559A1557|25 37|proliferation
P07957559A1557|40 51|Ba/F3-EpoRgp
P07957559A1557|61 68|MEL cells
P07957559A1557|76 85|inhibition
P07957559A1557|88 106|p70 S6 kinase activity
P07957559A1557|113 117|cells
P07957632A0000|16 24|injection
P07957632A0000|63 69|glycine
P07957632A0000|66 71|DCG-IV
P07957632A0000|79 85|agonist
P07957632A0000|101 118|glutamate receptors
P07957632A0000|154 161|recovery
P07957632A0000|165 183|halothane anesthesia
P07957632A0000|187 195|dose range
P07957632A0000|207 214|pmol/rat
P07958446A0000|3 12|hepatocyte
P07958446A0000|20 27|factor-3
P07958446A0000|28 32|HNF-3
P07958446A0000|32 39|forkhead
P07958446A0000|45 52|proteins
P07958446A0000|72 77|family
P07958446A0000|111 124|gene regulators
P07958446A0000|135 142|homology
P07958446A0000|158 177|helix DNA binding motif
P07958865A1152|14 20|embryos
P07958865A1152|34 46|abnormalities
P07958865A1152|49 64|heart development
P07958865A1152|82 91|conclusion
P07958865A1152|137 148|interactions
P07958865A1152|154 164|development
P07958898A1050|13 22|dTFIIA-L/S
P07958898A1050|70 79|activation
P07958898A1050|90 109|transcription factors
P07958898A1050|133 137|NTF-1
P07958911A0500|7 26|trithorax binding site
P07958911A0500|51 58|location
P07958911A0500|64 75|fork head gene
P07958911A0500|131 137|complex
P07958915A1507|12 18|changes
P07958915A1507|82 88|ability
P07958915A1507|107 119|transcription
P07958915A1507|133 140|presence
P07958915A1507|151 155|forms
P07958915A1507|182 195|protein kinases
P07958920A1157|0 9|Antibodies
P07958920A1157|28 38|SNM1 protein
P07958920A1157|57 67|RNase MRP RNA
P07958920A1157|82 89|extracts
P07958920A1157|147 155|RNase P RNA
P07959011A0379a|0 9|C/EBP alpha
P07959011A0379a|26 33|promoter
P07959011A0379a|39 55|rat class-I ADH gene
P07959011A0379a|76 81|manner
P07959011A0379a|82 87|Potter
P07959011A0379b|0 9|C/EBP alpha
P07959011A0379b|26 33|promoter
P07959011A0379b|39 55|rat class-I ADH gene
P07959011A0379b|76 81|manner
P07959011A0379b|82 87|Potter
P07959015A0478|3 9|results
P07959015A0478|28 32|hAMPK
P07959015A0478|42 51|amino acids
P07959015A0478|91 95|rAMPK
P07959015A0478|98 107|identities
P07959015A0478|133 140|nt levels
P07959734A0194|7 11|brain
P07959734A0194|12 20|contactin
P07959734A0194|41 45|amino
P07959734A0194|57 73|peptide sequencing
P07959734A0194|100 116|glycoprotein Gp135
P07959760A0763|14 22|YAC contig
P07959760A0763|60 65|orders
P07959760A0763|82 86|sites
P07959760A0763|100 106|minimum
P07959760A0763|126 147|Ewing sarcoma breakpoint
P07959760A0763|177 181|c-ets
P07959760A0763|186 190|Fli-1
P07959760A0763|194 200|members
P07959760A0763|206 214|ets family
P07959760A0763|270 275|contig
P07959760A0763|304 317|microsatellite
P07959760A0763|318 324|D11S912
P07959760A0763|360 368|Fli-1 gene
P07959952A1446|26 35|pseudogene
P07959952A1446|54 74|mouse mast cell chymases
P07959952A1446|88 123|polymerase chain reaction amplification
P07959952A1446|129 133|mouse
P07959952A1446|155 166|mast cell line
P07959953A0423|0 4|IFI16
P07959953A0423|18 22|exons
P07959953A0423|41 47|introns
P07959953A0423|65 73|kilobases
P07960608A0228|0 6|Courses
P07960608A0228|28 32|weeks
P07960796A0154|0 9|Peter Elfer
P07960796A0154|21 32|implications
P07960796A0154|38 43|ruling
P07961545A1314|12 17|events
P07961545A1314|22 31|incidences
P07961545A1314|59 65|placebo
P07961545A1314|70 78|dizziness
P07961545A1314|79 90|constipation
P07961545A1314|91 98|sweating
P07961545A1314|99 109|nervousness
P07961545A1314|121 131|ejaculation
P07961755A0474|0 7|Homology
P07961755A0474|41 62|transit peptide sequence
P07961755A0474|65 81|cysteine synthase C
P07961755A0474|113 127|leader sequences
P07961957A1565|34 41|addition
P07961957A1565|43 47|TEF-1
P07961957A1565|68 73|factor
P07961957A1565|94 115|alpha-MHC gene EM element
P07961958T0000|0 24|Rat kidney carboxylesterase
P07963540A0795|11 23|I-kappa B alpha
P07963540A0795|33 50|kappa B motif binding
P07963540A0795|60 73|factor-kappa B1
P07963540A0795|83 87|c-Rel
P07963540A0795|100 106|studies
P07963540A0795|141 153|cross-linking
P07963540A0795|185 205|kappa B oligonucleotide
P07963782A0000|22 30|stability
P07963782A0000|34 44|combination
P07963782A0000|47 51|drugs
P07963782A0000|100 104|space
P07963782A0000|111 119|treatment
P07964162A0941|9 18|mechanisms
P07964162A0941|30 39|activation
P07964162A0941|45 60|MAP kinase cascade
P07964162A0941|100 112|specification
P07964162A0941|123 131|responses
P07964458A0179|1 13|candidate gene
P07964458A0179|60 76|macrophage protein
P07964458A0179|76 80|Nramp
P07964458A0179|137 151|membrane protein
P07964458A0179|179 185|animals
P07964459A0845|4 8|motif
P07964459A0845|38 46|LIM domain
P07964459A0845|53 68|RING finger family
P07964459A0845|105 111|regions
P07964624A0491|3 9|P131 ORF
P07964624A0491|75 85|readthrough
P07964624A0491|90 108|UGA termination codon
P07964624A0491|114 120|P131 ORF
P07964624A0491|131 141|polypeptide
P07964770A0172|15 22|patients
P07964770A0172|49 60|arthroplasty
P07964814T0000|16 29|hallucinations
P07964814T0000|32 39|migraine
P07964814T0000|43 50|epilepsy
P07964918A0000|3 11|influence
P07964918A0000|29 35|factors
P07964918A0000|52 62|variability
P07964918A0000|68 77|evaluation
P07964918A0000|92 96|signs
P07965152A0764|0 7|Segments
P07965152A0764|23 33|BMIPP uptake
P07965152A0764|38 47|MIBI uptake
P07965152A0764|48 58|mismatching
P07965152A0764|77 86|wall motion
P07965152A0764|110 116|reserve
P07965152A0764|123 143|dobutamine stimulation
P07966565A0901|10 15|length
P07966565A0901|32 42|nucleotides
P07966565A0901|47 55|agreement
P07966565A0901|100 115|replication cycle
P07966565A0901|133 138|stages
P07966565A0901|141 149|infection
P07966583A1268|9 21|transfections
P07966583A1268|25 33|construct
P07966583A1268|47 59|RNA transcript
P07966583A1268|69 75|clone B1
P07966583A1268|81 88|D17 cells
P07966583A1268|97 106|expression
P07966583A1268|111 118|Env/Mlvi
P07966583A1268|120 132|fusion protein
P07966602A0130|0 6|Roizman
P07966873A0693|0 7|Articles
P07966873A0693|26 37|heart disease
P07966873A0693|40 51|heart failure
P07966873A0693|78 87|infarction
P07966873A0693|90 95|Chagas
P07966873A0693|96 102|disease
P07967360A1048|32 39|patients
P07967360A1048|43 57|TGBM nephropathy
P07967360A1048|78 91|IgA nephropathy
P07967360A1048|117 134|glomerulonephritis
P07967725A0262|10 18|receptors
P07967725A0262|58 64|domains
P07967725A0262|95 100|domain
P07967725A0262|105 123|ligand binding domain
P07967725A0262|129 144|carboxyl terminus
P07967725A0262|150 157|receptor
P07968409A0123|3 8|sample
P07968409A0123|69 85|Outpatient Service
P07968409A0123|101 108|Diseases
P07968409A0123|116 122|Bologna
P07968409A0123|124 139|Ospedale Maggiore
P07968409A0123|140 154|General Hospital
P07969115A0000|7 32|organello footprint analysis
P07969115A0000|70 81|mitochondria
P07969115A0000|94 98|level
P07969115A0000|112 118|binding
P07969115A0000|136 144|intervals
P07969115A0000|162 167|region
P07969115A0000|189 198|DNA origins
P07969115A0000|205 219|promoter regions
P07969116A0196|3 14|Nur77 protein
P07969116A0196|30 51|transcription activator
P07969116A0196|79 88|expression
P07969116A0196|101 105|genes
P07969116A0196|108 115|response
P07969116A0196|131 137|stimuli
P07969132A0268|3 7|class
P07969132A0268|10 17|plasmids
P07969132A0268|35 39|genes
P07969132A0268|60 70|suppression
P07969132A0268|79 83|cells
P07969132A0268|98 106|histidine
P07969132A0268|112 119|plasmids
P07969132A0268|131 142|gcn2 deletion
P07969132A0268|180 187|gcn2-507
P07969135A0913|7 14|presence
P07969135A0913|20 33|Cln2 PEST domain
P07969135A0913|73 79|protein
P07969136A0273|15 33|mobility shift assays
P07969136A0273|49 57|sequences
P07969136A0273|70 78|complexes
P07969136A0273|83 92|mobilities
P07969136A0273|114 126|NF-kappa B site
P07969136A0273|134 138|kappa
P07969152A0721|46 61|activation domain
P07969152A0721|77 86|activation
P07969152A0721|89 105|CUP1 transcription
P07969152A0721|108 115|response
P07969152A0721|122 136|heat shock stress
P07969152A0721|140 156|glucose starvation
P07969152A0721|161 166|region
P07969152A0721|192 210|heat shock activation
P07969152A0721|223 227|genes
P07969152A0721|236 242|members
P07969152A0721|260 270|hsp70 family
P07969181A0313|26 31|levels
P07969181A0313|34 40|CKB mRNA
P07969181A0313|43 51|HeLa cells
P07969181A0313|61 65|study
P07969181A0313|112 118|amounts
P07969181A0313|121 130|p53 protein
P07969181A0313|140 148|HeLa cells
P07969954T0000|11 29|motor neuron syndrome
P07969954T0000|44 51|serum IgM
P07969954T0000|60 69|antibodies
P07969954T0000|70 80|improvement
P07969954T0000|90 102|immunotherapy
P07969954T0000|114 127|plasma exchange
P07969954T0000|142 157|cyclophosphamide
P07971282A0000|0 9|Regulators
P07971282A0000|62 91|pre-mRNA splicing characteristic
P07971282A0000|94 102|metazoans
P07971709A0907|15 22|response
P07971709A0907|55 61|rhG-CSF
P07971709A0907|69 76|activity
P07971709A0907|87 91|state
P07972012A0956|12 20|cDNA clone
P07972012A0956|34 47|rat lung library
P07972012A0956|75 81|protein
P07972012A0956|97 109|amino terminus
P07972012A0956|120 125|domain
P07972012A0956|140 151|ANP-receptor
P07972012A0956|163 168|domain
P07972012A0956|187 202|carboxyl terminus
P07972012A0956|226 242|phosphatase domain
P07972237A0665|16 29|restriction map
P07972237A0665|70 74|N-myc
P07972237A0665|91 104|subcloning YACs
P07972237A0665|109 115|cosmids
P07972831A0563|0 10|PAI-1 levels
P07972831A0563|35 42|patients
P07972831A0563|54 60|iohexol
P07972831A0563|85 93|ioxaglate
P07973364A0325|12 18|article
P07973364A0325|22 27|causes
P07973364A0325|30 34|death
P07973364A0325|68 89|carcinogenicity studies
P07973364A0325|91 97|studies
P07973364A0325|136 145|Wistar rats
P07973364A0325|149 155|studies
P07973364A0325|172 179|NMRI mice
P07973397T0001|0 12|Determination
P07973397T0001|15 29|potassium iodide
P07973825A0445|3 15|recovery value
P07973825A0445|26 33|pressure
P07973825A0445|56 63|pressure
P07973825A0445|67 79|pulse pressure
P07975763A0000|3 12|importance
P07975763A0000|15 29|hepatitis C virus
P07975763A0000|35 43|infection
P07975763A0000|46 50|cause
P07975763A0000|60 71|liver disease
P07975763A0000|93 104|introduction
P07975763A0000|116 131|detection methods
P07975882T0000|5 18|adenovirus type
P07975882T0000|32 37|fibers
P07977239A1283|0 17|Outflow obstruction
P07977239A1283|30 34|juice
P07977239A1283|47 54|stenosis
P07977239A1283|65 71|papilla
P07977239A1283|101 108|patients
P07977239A1283|121 127|papilla
P07977239A1283|142 149|patients
P07977239A1283|162 168|papilla
P07977239A1283|188 199|pancreatitis
P07977239A1283|217 224|drainage
P07977239A1283|237 241|juice
P07977239A1283|254 261|pressure
P07977239A1283|267 276|dorsal duct
P07977648A0880|0 9|Sequencing
P07977648A0880|15 29|TP53 transcripts
P07977648A0880|34 38|exons
P07977648A0880|63 71|mutations
P07977648A0880|86 91|allele
P07977648A0880|104 109|tumors
P07978229T0000|9 20|complication
P07978229T0000|35 41|patient
P07978406A0998|5 12|ISO group
P07978406A0998|15 21|pre-DEX
P07978406A0998|52 59|mL.min-1
P07978406A0998|69 76|response
P07978406A0998|78 88|hypercapnia
P07978406A0998|145 152|ABSTRACT
P07978406A0998|167 171|WORDS
P07979810A0340|17 26|parameters
P07979810A0340|27 33|density
P07979810A0340|34 41|motility
P07979810A0340|56 70|penetration test
P07979810A0340|121 129|pregnancy
P07979827A0722|0 6|KRN2391
P07979827A0722|10 19|cromakalim
P07979827A0722|43 50|increase
P07979827A0722|70 78|blood flow
P07980440A0138|2 22|H4IIE rat hepatoma cells
P07980440A0138|23 37|glucocorticoids
P07980440A0138|72 101|increase PEPCK gene transcription
P07980440A0138|106 112|insulin
P07980440A0138|116 128|phorbol esters
P07980440A0138|144 149|effect
P07980669A0373|5 19|plasma AVP levels
P07980669A0373|23 32|AVP release
P07980669A0373|46 51|change
P07980669A0373|67 81|plasma NPY levels
P07980669A0373|103 109|samples
P07981143A0633|1 7|stretch
P07981143A0633|12 22|nucleotides
P07981143A0633|40 45|IL-4RE
P07981143A0633|59 74|IL-4 inducibility
P07981143A0633|84 105|nucleoprotein complexes
P07981143A0633|122 128|factors
P07981246A0112|11 15|study
P07981246A0112|29 42|pertussis toxin
P07981246A0112|67 73|protein
P07981246A0112|75 83|G-protein
P07981246A0112|98 104|process
P07981246A0112|107 121|differentiation
P07981246A0112|124 136|hormones/IBMX
P07981246A0112|150 163|c-fos induction
P07982964A1017|44 93|phosphodiesterase substrate p-nitrophenyl thymidine-5
P07982964A1017|90 102|monophosphate
P07982995A0000|3 8|effect
P07982995A0000|24 32|mutations
P07982995A0000|38 42|mouse
P07982995A0000|59 70|growth factor
P07982995A0000|77 89|beta-receptor
P07982995A0000|91 100|activation
P07982995A0000|112 120|exchanger
P07982995A0000|151 155|gland
P07982995A0000|166 170|NMuMG
P07982995A0000|181 192|hamster ovary
P07982995A0000|198 202|cells
P07983011A0617|0 15|Sequence analysis
P07983011A0617|26 31|kinase
P07983011A0617|41 46|domain
P07983011A0617|67 89|serine/threonine kinases
P07983011A0617|93 98|hybrid
P07983011A0617|106 112|members
P07983011A0617|118 123|family
P07983011A0617|148 173|protein kinase kinase kinases
P07983011A0617|180 215|fibroblast growth factor receptor family
P07983011A0617|241 259|leucine zipper motifs
P07983011A0617|305 311|segment
P07983011A0617|340 345|domain
P07983011A0617|390 396|domains
P07983011A0617|409 419|src homology
P07983011A0617|426 445|domain binding regions
P07983704A0330|7 13|genomes
P07983704A0330|27 34|sequence
P07983704A0330|66 74|structure
P07983704A0330|111 129|retrovirus ancestors
P07983704A0330|135 146|HERV-K family
P07983704A0330|160 166|genomes
P07983704A0330|177 184|sequence
P07983712A0914|11 16|domain
P07983712A0914|21 26|domain
P07983712A0914|48 54|plasmid
P07983712A0914|59 64|levels
P07983712A0914|67 77|replication
P07983715A0996|0 13|Point mutations
P07983715A0996|38 44|binding
P07983715A0996|92 99|activity
P07983715A0996|111 120|P4 promoter
P07983715A0996|141 156|complex formation
P07983715A0996|195 210|expression assays
P07983715A0996|218 239|luciferase reporter gene
P07983716A1082|12 19|Northern
P07983716A1082|25 36|blot analysis
P07983716A1082|46 63|transcriptase-PCRs
P07983716A1082|78 89|transfection
P07983716A1082|92 96|COS-7
P07983716A1082|99 107|HeLa cells
P07983716A1082|149 156|Y88L RNAs
P07983716A1082|178 183|levels
P07983744A0920|19 23|forms
P07983744A0920|26 30|IE110
P07983744A0920|66 70|IE175
P07983744A0920|81 98|punctate structures
P07983744A0920|122 126|IE110
P07983744A0920|148 152|forms
P07983744A0920|155 159|IE175
P07983744A0920|173 190|punctate structures
P07984088A0592|0 12|Transcription
P07984088A0592|27 37|ivanolysin O
P07984088A0592|40 49|expression
P07984088A0592|57 61|genes
P07984088A0592|67 86|virulence gene cluster
P07984088A0592|89 98|L. ivanovii
P07984105A1509|10 24|complementation
P07984105A1509|30 41|WA fyuA mutant
P07984105A1509|53 60|fyuA gene
P07984105A1509|61 80|yersiniabactin uptake
P07984105A1509|84 97|mouse virulence
P07984261A0536|23 28|cortex
P07984261A0536|43 51|reduction
P07984261A0536|68 73|centre
P07984261A0536|90 96|tissues
P07985305T0001|3 11|treatment
P07985305T0001|14 27|hydronephrosis
P07985305T0001|30 37|children
P07987924A0670|3 14|inflation hub
P07987924A0670|20 24|probe
P07987924A0670|56 78|USCI Tuohy-Borst Y adaptor
P07987924A0670|110 122|probe hypotube
P07988559A0836|8 14|element
P07988559A0836|20 29|RBP-J kappa
P07988559A0836|37 44|affinity
P07988730A0220|8 23|promoter strength
P07988730A0220|26 35|constructs
P07988730A0220|49 57|deletions
P07988730A0220|63 70|U5 region
P07988730A0220|94 125|chloramphenicol acetyltransferase
P07988730A0220|130 135|assays
P07988730A0220|144 155|transfection
P07988730A0220|158 166|HeLa cells
P07988730A0220|169 181|Jurkat T-cells
P07988730A0220|187 194|presence
P07988730A0220|197 203|absence
P07988730A0220|211 234|transactivator tax protein
P07988731A0002|12 17|number
P07988731A0002|67 75|promoters
P07988731A0002|97 104|presence
P07988731A0002|120 127|elements
P07988731A0002|142 157|promoter activity
P07988731A0002|173 177|G-box
P07988731A0002|178 185|CCACGTGG
P07988731A1301|9 15|protein
P07988731A1301|70 86|GBF protein complex
P07988945T0000|15 24|strategies
P07988945T0000|27 45|lupus anticoagulants
P07988945T0000|65 74|antibodies
P07990136A1124|11 17|ability
P07990136A1124|20 46|selectivity arrest elongation
P07990136A1124|49 54|polIII
P07990136A1124|64 72|positions
P07990136A1124|82 106|tRNA gene transcription unit
P07990136A1124|122 135|identification
P07990136A1124|156 165|properties
P07990136A1124|183 188|polIII
P07990136A1124|196 204|complexes
P07991437A1032|0 10|Propafenone
P07991437A1032|31 38|majority
P07991437A1032|46 53|patients
P07991582A1023b|10 17|analysis
P07991582A1023b|20 28|yeast CEG1
P07991582A1023b|67 72|motifs
P07991582A1023b|95 108|enzyme function
P07992027A0485|1 8|patients
P07992027A0485|27 35|morbidity
P07992027A0485|67 81|transplantation
P07993559A0233|7 11|index
P07993559A0233|12 29|Fluorosis Risk Index
P07993559A0233|41 47|Pendrys
P07993559A0233|72 77|review
P07994021A1223|11 18|splicing
P07994021A1223|66 80|PECAM-1 isoforms
P07994021A1223|95 109|phosphorylation
P07994021A1223|122 132|association
P07994021A1223|136 153|affinity modulation
P07994021A1223|165 171|protein
P07995173A0585|0 7|Transfer
P07995173A0585|42 48|juice pH
P07995910A0119|4 12|technique
P07995910A0119|17 27|sensitivity
P07995910A0119|32 42|specificity
P07995910A0119|97 107|involvement
P07995910A0119|115 124|laparotomy
P07997174A0936|29 43|phosphorylation
P07997174A0936|45 51|His-304
P07997174A0936|82 90|functions
P07997174A0936|93 108|A. vinelandii NifL
P07999066A0238|11 16|HIV tat
P07999066A0238|30 44|enhancing factor
P07999066A0238|63 72|regulation
P07999066A0238|74 94|IL-2 gene transcription
P07999066A0238|127 136|expression
P07999066A0238|142 148|tat gene
P07999066A0238|151 162|phorbol ester
P07999066A0238|166 172|calcium
P07999066A0238|192 202|Jurkat cells
P07999066A0238|248 282|acetyltransferase reporter constructs
P07999363A0000|6 15|variations
P07999363A0000|18 22|genes
P07999363A0000|35 58|transmembrane FGF receptor
P07999363A0000|73 80|isoforms
P07999363A0000|93 102|ectodomain
P07999363A0000|116 134|juxtamembrane domain
P07999363A0000|154 165|kinase domain
P07999604A0139|19 26|patients
P07999604A0139|65 71|lesions
P07999982A0086|9 24|maximum lod scores
P07999982A0086|66 70|D9S15
P07999982A0086|98 118|recombination fraction
P07999982A0086|136 154|recombination events
P07999982A0086|172 177|search
P07999995A0000|14 26|protein kinase
P07999995A0000|27 32|OsPK10
P07999995A0000|56 66|Oryza sativa
P08000074A0162|1 8|sequence
P08000074A0162|51 58|sequence
P08000074A0162|71 81|translation
P08000074A0162|94 106|reading frames
P08000074A0162|120 124|kb DNA
P08000074A0162|132 139|fragment
P08000112T0000|0 10|Goodpasture
P08000112T0000|15 22|syndrome
P08000112T0000|26 31|effect
P08000112T0000|48 72|membrane oxygenator support
P08000427A0000|1 13|cDNA clone pCZ1
P08000427A0000|22 29|kb insert
P08000427A0000|58 79|tobacco cell cDNA library
P08000427A0000|116 125|kDa protein
P08000427A0000|129 138|amino acids
P08000497A0179|0 6|METHODS
P08000497A0179|23 32|spirometry
P08000497A0179|37 63|methacholine provocation test
P08000497A0179|88 94|airways
P08000497A0179|104 109|volume
P08001136T0000|0 11|Relationship
P08001136T0000|28 33|kinase
P08001136T0000|37 49|RNA polymerase
P08001136T0000|52 71|CTD kinase TFIIH/TFIIK
P08001792A0284|36 45|git10 genes
P08001792A0284|54 69|adenylate cyclase
P08001792A0284|90 122|adenylate cyclase activation pathway
P08001966A0563|9 15|regions
P08001966A0563|32 39|homology
P08001966A0563|57 64|proteins
P08001966A0563|73 78|skin-1
P08001966A0563|107 117|development
P08001966A0563|145 165|Caenorhabditis elegans
P08002564A0249|0 18|DNA sequence analysis
P08002564A0249|39 46|mutation
P08002564A0249|67 72|region
P08002564A0249|78 89|alpha subunit
P08002564A0249|99 112|leucine residue
P08002564A0249|115 122|position
P08002564A0249|129 137|histidine
P08002564A0249|138 146|rpoAL290H
P08002857A1070|0 10|CONCLUSIONS
P08002857A1070|16 23|findings
P08002857A1070|41 47|barrier
P08002857A1070|50 70|oesophageal surfactant
P08002857A1070|90 95|degree
P08002857A1070|98 107|protection
P08002857A1070|133 138|reflux
P08002857A1070|171 176|attack
P08003700T0000|12 20|screening
P08003700T0000|36 48|cDNA libraries
P08003700T0000|91 100|sugar-beet
P08003700T0000|108 127|genome rearrangements
P08003700T0000|139 146|atpA loci
P08004442A0265|3 9|effects
P08004442A0265|18 26|isolation
P08004442A0265|45 61|locomotor activity
P08004442A0265|77 83|animals
P08004442A0265|138 144|animals
P08004442A0265|164 186|corticosterone secretion
P08004442A0265|199 211|adrenalectomy
P08005230A0222|9 26|reporter gene system
P08005230A0222|60 69|activation
P08005230A0222|75 87|c-fos promoter
P08005230A0222|126 134|elevation
P08005230A0222|145 162|luciferase activity
P08005412A0608|21 34|gene expression
P08005412A0608|59 67|formation
P08005412A0608|70 83|protein complex
P08005412A0608|114 120|PS sites
P08005412A0608|136 147|interactions
P08005438A1185|0 4|SPP41
P08005438A1185|58 62|spp43
P08005438A1185|97 110|suppressor srn1
P08005438A1185|132 140|regulator
P08005438A1185|143 156|gene expression
P08006101A1142|0 35|Standard curve correlation coefficients
P08006101A1142|70 90|validation experiments
P08006101A1142|94 101|analysis
P08006101A1142|104 115|study samples
P08006772A0000|8 20|pulse oximeter
P08006772A0000|34 38|fetus
P08006772A0000|45 50|labour
P08006772A0000|74 78|women
P08006772A0000|100 105|labour
P08006773A0836|10 19|difference
P08006773A0836|22 41|plasma concentrations
P08006773A0836|50 55|figure
P08006773A0836|67 74|patients
P08006773A0836|84 96|blood pressure
P08006773A0836|101 112|preeclampsia
P08006773A0836|116 126|hypotension
P08006773A0836|142 153|preeclampsia
P08006773A0836|157 175|plasma concentration
P08007835A0538|7 14|analysis
P08007835A0538|26 34|variables
P08007835A0538|48 56|formation
P08007835A0538|59 68|FB memories
P08007835A0538|98 102|level
P08007835A0538|105 114|importance
P08007835A0538|128 132|event
P08007835A0538|136 140|level
P08007835A0538|152 159|response
P08007954A0374|0 14|Deletion studies
P08007954A0374|32 46|response element
P08007954A0374|70 85|cytokine response
P08007954A0374|92 101|properties
P08007954A0374|130 137|enhancer
P08007975A0000|3 10|IPL1 gene
P08007975A0000|24 57|high-fidelity chromosome segregation
P08007975A0000|70 74|yeast
P08011017A0169|10 25|oxygen saturation
P08011017A0169|39 46|evidence
P08011017A0169|85 92|arousals
P08011017A0169|104 124|repeat polysomnography
P08011166A0207|11 26|gene organization
P08011166A0207|52 58|results
P08011166A0207|64 71|sequence
P08011166A0207|79 84|clones
P08011166A0207|98 113|characterization
P08011166A0207|116 130|polymerase chain
P08011166A0207|156 163|segments
P08012448T0000|25 29|yeast
P08012448T0000|40 51|biosynthesis
P08012448T0000|66 76|segregation
P08012448T0000|80 98|bud pattern formation
P08012566A0254|3 29|pentafluorobenzyl derivative
P08012566A0254|32 46|clonidine yields
P08012566A0254|56 66|ion fragment
P08012566A0254|88 92|limit
P08012566A0254|94 102|detection
P08012566A0254|110 114|ng/ml
P08012566A0254|123 134|plasma sample
P08013348A0143|18 22|SHBGs
P08013348A0143|26 36|sex steroids
P08013348A0143|45 52|affinity
P08013348A0143|60 76|binding properties
P08013348A0143|88 94|species
P08013457A0342|0 10|Src homology
P08013457A0342|15 20|domain
P08013457A0342|44 55|interactions
P08013457A0342|70 109|tyrosine kinase receptor signal transduction
P08014228A0278|0 14|Sample treatment
P08014228A0278|29 33|order
P08014228A0278|52 61|extraction
P08014228A0278|64 88|labetalol diastereoisomers
P08014228A0278|99 110|racemization
P08014228A0278|117 126|extraction
P08014377A1277|12 21|conditions
P08014377A1277|22 35|activity levels
P08014377A1277|45 49|vagal
P08014377A1277|64 71|outflows
P08014377A1277|108 115|subjects
P08014377A1277|129 139|interaction
P08014377A1277|172 180|divisions
P08014919A0530|37 41|units
P08014919A0530|49 59|progression
P08014919A0530|71 76|fields
P08014919A0530|111 117|rostral
P08014919A0530|125 133|direction
P08014919A0530|142 147|length
P08015672A1282|2 16|control patients
P08015672A1282|17 30|baseline images
P08015672A1282|130 137|baseline
P08015850A1076|13 20|analysis
P08015850A1076|23 34|dose response
P08015850A1076|52 67|Ga administration
P08015850A1076|66 74|preinjury
P08015850A1076|77 86|postinjury
P08015850A1076|90 101|availability
P08015850A1076|128 134|barrier
P08015850A1076|162 169|efficacy
P08015850A1076|176 183|compound
P08016102A1238|3 10|presence
P08016102A1238|23 31|sequences
P08016102A1238|38 44|binding
P08016102A1238|47 66|transcription factors
P08016102A1238|73 81|NF-kappa B
P08016102A1238|96 105|activation
P08016102A1238|133 140|response
P08016102A1238|156 161|injury
P08016102A1238|168 177|indication
P08016102A1238|218 234|defense mechanisms
P08016102A1238|240 251|tissue injury
P08016189A0741|0 10|Granisetron
P08016189A0741|17 22|saline
P08016189A0741|32 39|vomiting
P08016189A0741|43 48|nausea
P08016189A0741|60 71|intervention
P08016189A0741|95 101|regimen
P08017290A1347|25 39|sinus difference
P08017290A1347|42 48|lactate
P08017290A1347|79 98|potassium differences
P08017290A1347|108 112|group
P08017290A1347|120 125|pacing
P08018361A0636|29 42|neutron fluency
P08018361A0636|50 54|n/cm2
P08020702A0000|0 10|Endotoxemia
P08020702A0000|33 40|bacteria
P08020702A0000|57 61|shock
P08020702A0000|101 109|component
P08020702A0000|130 136|lipid A.
P08020702A0137|3 7|study
P08020702A0137|23 29|ability
P08020702A0137|32 37|lipid A
P08020702A0137|48 57|antibodies
P08020702A0137|78 89|disturbances
P08020702A0137|95 105|endotoxemia
P08020702A0137|108 121|dog experiments
P08020702A0137|131 138|efficacy
P08020702A0137|144 167|antibodies administration
P08020806A0187|21 25|trial
P08020806A0187|43 50|patients
P08020806A0187|61 65|Crohn
P08020806A0187|67 73|disease
P08020806A0187|106 113|outcomes
P08020806A0187|121 129|amino acid
P08020806A0187|151 154|% fat
P08020806A0187|165 175|feeding tube
P08020806A0187|189 195|peptide
P08020806A0187|218 221|% fat
P08020962A1226|13 18|region
P08020962A1226|24 33|V beta locus
P08020962A1226|51 56|number
P08020962A1226|69 79|DNA elements
P08020962A1226|132 139|elements
P08020965A0465|19 24|region
P08020965A0465|71 80|transcript
P08020965A0465|118 127|transcript
P08021175A0486|17 22|region
P08021175A0486|34 44|nucleotides
P08021175A0486|56 64|sequences
P08021175A0486|81 89|consensus
P08021175A0486|99 116|AMP receptor protein
P08021175A0486|120 140|integration host factor
P08021175A0486|148 152|sites
P08021177A0000|3 11|fepA-entD
P08021177A0000|15 29|fes-entF operons
P08021177A0000|35 55|enterobactin synthesis
P08021177A0000|59 73|transport system
P08021177A0000|114 122|promoters
P08021177A0000|147 165|Fur repressor protein
P08021177A0000|183 192|conditions
P08021225A0000|0 15|Sequence analysis
P08021225A0000|33 46|EcoRI-fragment
P08021225A0000|49 68|Alcaligenes eutrophus
P08021225A0000|103 118|dihydrolipoamide
P08021225A0000|141 148|DNA probe
P08022212A0071|25 37|two-frequency
P08022212A0071|38 49|AC excitation
P08022212A0071|65 70|method
P08022212A0071|74 92|admittance locus plot
P08022212A0071|103 121|low-frequency region
P08022212A0071|225 234|parameters
P08022212A0071|233 251|phase angle alpha pi/2
P08022212A0071|252 262|conductance
P08022212A0071|281 291|frequency G0
P08022212A0071|302 321|ion relaxation time tau
P08023662T0000|14 24|measurement
P08023662T0000|43 60|thromboplastin time
P08023662T0000|64 78|prothrombin time
P08023662T0000|94 100|monitor
P08024139A0393|2 9|addition
P08024139A0393|27 36|hypothesis
P08024139A0393|50 56|volumes
P08024139A0393|96 106|differences
P08024139A0393|155 163|solutions
P08024139A0393|179 188|impairment
P08025074A0000|11 15|study
P08025074A0000|20 24|nylon
P08025074A0000|61 78|laser energy density
P08025074A0000|88 98|suture lysis
P08025074A0000|135 140|Dacron
P08025074A0000|146 152|prolene
P08025669A0724|3 10|proteins
P08025669A0724|64 68|sigma
P08025669A0724|70 77|activity
P08028671A0687|16 29|microinjection
P08028671A0687|42 50|antiserum
P08028671A0687|55 65|fibroblasts
P08028671A0687|76 88|transcription
P08028671A0687|110 117|promoter
P08029001A1020|5 11|results
P08029001A1020|28 32|class
P08029001A1020|47 63|activator proteins
P08029001A1020|67 79|RNA polymerase
P08029001A1020|119 127|component
P08029001A1020|155 160|target
P08029001A1020|173 194|transcription machinery
P08029334T0000|0 6|Cloning
P08029334T0000|15 26|plant omega-3
P08029334T0000|32 46|acid desaturases
P08030239A0833|38 48|polypeptide
P08030239A0833|57 73|amino acid residues
P08030239A0833|121 136|activation domain
P08030239A0833|160 174|EHV-1 tk promoter
P08030239A0833|188 194|ability
P08030239A0833|213 227|EHV-1 IE promoter
P08030243A1011|24 38|RNA capture assay
P08030243A1011|42 50|multimers
P08030243A1011|83 90|activity
P08030704A1503|0 9|CONCLUSION
P08030704A1503|22 26|birth
P08030704A1503|61 95|progesterone/17 beta-estradiol ratios
P08030704A1503|107 111|women
P08030704A1503|116 127|preterm labor
P08031424T0000|0 7|Ketamine
P08031424T0000|13 21|treatment
P08031424T0000|24 35|bronchospasm
P08031424T0000|52 62|ventilation
P08033490A0875|2 11|conclusion
P08033490A0875|15 25|disposition
P08033490A0875|28 38|venlafaxine
P08033490A0875|42 63|O-desmethylvenlafaxine
P08033490A0875|88 94|disease
P08033490A0875|104 119|dosage adjustment
P08033490A0875|134 141|patients
P08033490A0875|146 170|creatinine clearance values
P08033490A0875|178 183|ml/min
P08034318A0724|3 14|availability
P08034318A0724|17 24|sequence
P08034318A0724|37 43|species
P08034318A0724|76 82|UBE site
P08034318A0724|91 100|similarity
P08034318A0724|103 108|motifs
P08034318A0724|117 123|members
P08034318A0724|129 138|NF-1 family
P08034318A0724|141 160|transcription factors
P08034486A0579|3 11|incidence
P08034486A0579|14 18|HSV-2
P08034486A0579|27 34|subjects
P08034486A0579|35 39|HSV-2
P08034486A0579|39 56|HSV-1 antibody ratio
P08034486A0579|86 95|population
P08034486A0579|122 126|areas
P08034680A0180|3 11|mechanism
P08034680A0180|19 25|zeta PKC
P08034680A0180|35 43|NF-kappa B
P08034680A0180|67 76|activation
P08034680A0180|88 100|I kappa B kinase
P08034680A0180|171 178|I kappa B.
P08034682T0000|6 15|expression
P08034682T0000|27 69|inositol 1,4,5-trisphosphate receptor subunits
P08034682T0000|72 85|3T3 fibroblasts
P08034708A0000|12 16|basis
P08034708A0000|20 29|commitment
P08034708A0000|32 42|progenitors
P08034708A0000|48 64|eosinophil lineage
P08034708A0000|68 77|mechanisms
P08034708A0000|104 108|genes
P08034708A0000|139 153|differentiation
P08034741A0000|11 24|identification
P08034741A0000|28 43|characterization
P08034741A0000|52 57|myosin
P08034741A0000|83 89|myosin I
P08034741A0000|119 132|border myosin I.
P08035498A0833|2 9|addition
P08035498A0833|10 25|computer analysis
P08035498A0833|38 46|sequences
P08035498A0833|59 70|A stem element
P08035498A0833|95 112|AAV promoter regions
P08035499A0941|16 25|difference
P08035499A0941|28 36|stability
P08035499A0941|45 49|kinds
P08035499A0941|52 60|complexes
P08035499A0941|85 100|dissociation rate
P08035499A0941|105 118|A stem substrate
P08035499A0941|137 145|complexes
P08035505A0586|0 9|Processing
P08035505A0586|20 31|B polyprotein
P08035517A0753|11 18|promoter
P08035517A0753|30 34|IEP86
P08035517A0753|66 73|addition
P08035517A0753|76 80|IEP72
P08035796A0890|0 11|32Pi labeling
P08035796A0890|33 40|analysis
P08035796A0890|43 52|eIF-2 alpha
P08035796A0890|68 79|casein kinase
P08035796A0890|82 88|mutants
P08035796A0890|102 116|phosphorylation
P08035796A0890|119 128|eIF-2 alpha
P08035796A0890|158 162|forms
P08035796A0890|165 174|eIF-2 alpha
P08035796A0890|195 201|strains
P08035796A0890|226 241|growth conditions
P08035833A1556|23 29|homolog
P08035833A1556|54 62|component
P08035833A1556|67 71|yeast
P08035833A1556|85 99|import machinery
P08036004A0292|3 10|R2 region
P08036004A0292|20 24|class
P08036004A0292|26 33|enhancer
P08036004A0292|49 55|element
P08036004A0292|74 78|cells
P08036004A0292|99 113|binding activity
P08036004A0292|159 163|cells
P08036004A0292|184 188|class
P08036004A0292|190 199|expression
P08037338A0000|0 6|PURPOSE
P08037338A0000|20 27|kinetics
P08037338A0000|30 43|erythropoietin
P08037338A0000|49 58|production
P08037338A0000|71 82|pathogenesis
P08037338A0000|85 90|anemia
P08037338A0000|93 103|prematurity
P08037338A0000|114 122|EPO levels
P08037338A0000|125 131|infants
P08039422A0000|3 27|nerve growth factor beta gene
P08039422A0000|61 65|group
P08039422A0000|72 81|chromosome
P08039422A0000|86 100|mouse Chromosome
P08040336A0435|21 27|element
P08040336A0435|28 42|collagen element
P08040336A0435|62 69|homology
P08040336A0435|77 97|LAP binding cis-element
P08040336A0435|103 117|albumin promoter
P08040391T0000|0 5|Number
P08040391T0000|45 52|clusters
P08040391T0000|60 68|seminomas
P08040391T0000|69 79|correlation
P08040391T0000|96 103|features
P08040391T0000|107 121|tumour behaviour
P08040468A0303|15 35|mast cell degranulation
P08040468A0303|54 65|pathogenesis
P08040468A0303|68 78|necrobiosis
P08040468A0303|89 112|fibroblast enzyme activity
P08040468A0303|149 157|reactions
P08041362T0000|9 15|cloning
P08041362T0000|19 38|cysteine synthase cDNA
P08041362T0000|52 59|vulgaris
P08041362T0000|60 69|watermelon
P08041362T0000|79 93|complementation
P08041362T0000|118 126|auxotroph
P08041793A0242|9 15|studies
P08041793A0242|45 52|elements
P08041793A0242|79 88|activation
P08041793A0242|99 108|repression
P08041793A0242|121 125|genes
P08041793A0242|126 130|COX5b
P08043523A0000|16 26|serum levels
P08043523A0000|29 38|antibodies
P08043523A0000|53 73|acetylcholine receptor
P08043523A0000|74 78|nAChR
P08043523A0000|115 122|patients
P08043523A0000|134 143|dyskinesia
P08043523A0000|148 157|antibodies
P08043523A0000|204 211|patients
P08044794A0000|3 17|tumor suppressor
P08044794A0000|36 44|factor p53
P08044794A0000|62 68|protein
P08044800A0550|4 32|DNA containing promoter activity
P08044800A0550|54 61|entirety
P08044800A0550|105 109|sites
P08044802A0462|7 18|Southern blot
P08044802A0462|22 38|karyotype analyses
P08044802A0462|65 71|changes
P08044802A0462|74 83|copy number
P08044802A0462|91 104|rearrangements
P08044802A0462|110 116|p53 gene
P08044802A0462|132 140|cell lines
P08045431A0894|18 25|identity
P08045431A0894|27 36|rubredoxin
P08045431A0894|55 62|proteins
P08045431A0894|76 83|bacteria
P08045834A0783|3 20|PCr resynthesis rate
P08045834A0783|72 83|ATP synthesis
P08046923A0000|2 12|examination
P08046923A0000|29 36|patients
P08046923A0000|62 73|osteomalacia
P08046923A0000|90 98|resection
P08048582A0821|44 49|extent
P08048582A0821|80 94|ml O2.min-1 times
P08048582A0821|108 116|LAD region
P08048582A0821|137 151|ml O2.min-1 times
P08048916A0000|0 3|IGF I
P08048916A0000|7 22|insulin receptors
P08048916A0000|36 43|proteins
P08048916A0000|79 86|pathways
P08049401A0428|0 15|Immunodepression
P08049401A0428|34 41|increase
P08049401A0428|44 65|glucocorticoid activity
P08049401A0428|75 80|cortex
P08049401A0428|99 105|changes
P08049401A0428|108 122|thyroid hormones
P08049444A0351|7 14|cleavage
P08049444A0351|18 40|peptide sequence analysis
P08049444A0351|65 71|protein
P08049444A0351|100 106|protein
P08049444A0351|122 135|binding protein
P08049444A0351|137 141|SATB1
P08049444A0351|197 203|regions
P08049444A0351|211 219|MARs/SARs
P08049521T0000|8 29|protein phosphorylation
P08049521T0000|32 39|tyrosine
P08049521T0000|76 81|action
P08049521T0000|84 92|pp60v-src
P08049521T0000|107 111|yeast
P08049885T0000|5 16|pancreatitis
P08049885T0000|18 35|multisystem disease
P08051019A0365|8 19|biosynthesis
P08051019A0365|52 60|mechanism
P08051059A1000|3 10|sequence
P08051059A1000|24 35|rhlA promoter
P08051059A1000|55 61|repeats
P08051059A1000|81 92|binding sites
P08051059A1000|99 111|RhlR regulator
P08051074A0000|23 34|footprinting
P08051074A0000|36 41|region
P08051074A0000|69 89|immunodeficiency virus
P08051074A0000|97 101|HIV-1
P08051074A0000|101 108|promoter
P08051074A0000|134 138|DNase
P08051074A0000|140 148|digestion
P08051102A0532|0 6|Heparin
P08051102A0532|12 17|effect
P08051102A0532|20 31|rAC-st myosin
P08051102A0532|37 60|chain phosphatase activity
P08051102A0532|90 94|forms
P08051151A0347|11 19|abundance
P08051151A0347|98 110|chain reaction
P08051151A0347|124 130|tissues
P08051151A0347|134 142|cell lines
P08053697A0000|0 9|BACKGROUND
P08053697A0000|13 18|DESIGN
P08053697A0000|67 83|hyperpigmentation
P08053697A0000|128 135|diameter
P08053697A0000|183 192|correlates
P08054281A0731|3 16|retention index
P08054281A0731|19 28|201Tl SPECT
P08054281A0731|38 46|indicator
P08054281A0731|59 67|potential
P08054281A0731|90 99|prediction
P08054281A0731|102 110|prognosis
P08054281A0731|122 128|insight
P08054281A0731|136 147|relationship
P08054281A0731|155 165|201Tl uptake
P08054281A0731|169 178|malignancy
P08055939A0159|18 23|domain
P08055939A0159|46 52|regions
P08055939A0159|62 72|H1 molecules
P08055939A0159|96 101|domain
P08055939A0159|120 135|hexapeptide motif
P08055939A0159|136 143|variants
P08055939A0159|168 178|H1 molecules
P08055939A0707|3 10|location
P08055939A0707|25 30|length
P08055939A0707|36 41|intron
P08055939A0707|63 68|tomato
P08055939A0707|72 87|Arabidopsis genes
P08055939A0707|95 100|intron
P08055939A0707|120 125|region
P08055939A0707|163 168|domain
P08055941A1264|3 10|topology
P08055941A1264|14 18|chain
P08055941A1264|31 42|beta subunits
P08055941A1264|48 62|artifactual beta
P08055941A1264|65 70|capsid
P08055941A1264|92 96|alpha
P08055941A1264|106 111|enzyme
P08057356A0531|36 47|substitution
P08057356A0531|72 88|response regulator
P08057356A0531|88 93|region
P08057356A1824|0 10|Comparisons
P08057356A1824|20 39|operon control regions
P08057356A1824|62 74|NarL heptamers
P08057356A1824|97 108|orientations
P08057356A1824|112 118|spacing
P08057421A1583|6 12|binding
P08057421A1583|16 32|competition assays
P08057421A1583|44 64|oligonucleotide probes
P08057421A1583|90 105|CBF1 binding sites
P08057421A1583|150 161|CD23 promoter
P08057421A1583|167 187|EBV LMP-1 promoter sites
P08057421A1583|197 202|Cp site
P08057762A0878|24 38|reproducibility
P08057762A0878|72 86|reproducibility
P08057833A0573|6 17|ParA proteins
P08057833A0573|36 41|result
P08057833A0573|55 75|translation initiation
P08057833A0573|90 100|start codons
P08057833A0573|118 129|reading frame
P08058326A0463|12 19|insights
P08058326A0463|36 45|mechanisms
P08058326A0463|57 71|tal-1 expression
P08058326A0463|87 95|sequences
P08058326A0463|140 151|counterparts
P08058948A0810|0 9|CONCLUSION
P08058948A0810|21 31|angiography
P08058948A0810|55 63|detection
P08058948A0810|70 76|nodules
P08058948A0810|79 86|patients
P08062824A0626|13 18|domain
P08062824A0626|27 33|FKBP-33
P08062824A0626|73 89|isomerase activity
P08062824A0626|117 126|activities
P08062824A0626|131 137|FKBP-12
P08062833A0000|27 53|transcription initiation site
P08062833A0000|58 72|mouse desmin gene
P08062833A0000|87 90|E box
P08062833A0000|98 108|binding site
P08062833A0000|137 146|regulators
P08062833A0000|171 175|level
P08062833A0000|191 200|expression
P08063108A0109|3 10|acfD gene
P08063108A0109|72 78|protein
P08063766A0595|44 57|envelope lamin B
P08063766A0595|63 67|times
P08063766A0595|79 86|alpha PKC
P08063766A0595|97 103|kinases
P08063766A0595|124 129|lamin B
P08063766A0595|139 143|rates
P08063775T0000|0 9|Regulation
P08063775T0000|38 44|protein
P08063775T0000|45 49|PTHrP
P08063775T0000|50 63|gene expression
P08063791A1370|5 11|results
P08063791A1370|59 72|sequence motifs
P08063791A1370|92 104|modifications
P08063791A1370|121 131|Ras proteins
P08063791A1370|134 138|yeast
P08063836A0904|14 18|c-Abl
P08063836A0904|28 45|c-myc transcription
P08063836A0904|62 72|requirement
P08063836A0904|76 85|DNA binding
P08063836A0904|88 92|c-Abl
P08064351A1020|0 11|Long-latency
P08064351A1020|18 22|units
P08064351A1020|34 39|shocks
P08064351A1020|50 55|jitter
P08064351A1020|63 69|latency
P08065310A1144|23 28|heptad
P08065310A1144|46 63|heterodimerization
P08065310A1144|107 117|interaction
P08065310A1144|135 143|inhibitor
P08065310A1144|154 159|member
P08065310A1144|165 182|receptor gene family
P08065324A0458|17 26|expression
P08065324A0458|29 38|snRNA genes
P08065324A0458|41 45|maize
P08065324A0458|63 67|plant
P08065324A0458|79 90|TATA elements
P08065324A0458|121 133|transcription
P08065327A0000|9 24|DNA rearrangement
P08065327A0000|40 50|development
P08065327A0000|63 74|macronucleus
P08065327A0000|82 101|germ line micronucleus
P08065327A0000|112 121|protozoans
P08065331A0279|16 37|site selection procedure
P08065331A0279|56 67|DNA sequences
P08065331A0279|114 128|E2A-HLF proteins
P08065331A0279|158 166|leukemias
P08065338T0000|3 7|Oct-2
P08065338T0000|37 53|activation domains
P08065338T0000|81 90|duplicates
P08065338T0000|113 125|transcription
P08065365A0000|0 6|Binding
P08065365A0000|25 41|ribonucleoprotein
P08065365A0000|41 45|snRNP
P08065365A0000|51 58|pre-mRNA
P08065365A0000|99 106|assembly
P08065366A0918|33 37|Dbf8p
P08065366A0918|61 81|chromosome segregation
P08065368A0839|0 4|Ariga
P08065368A0839|5 11|Biochem
P08065901A0997|3 9|results
P08065901A0997|25 34|KRAB domain
P08065901A0997|57 62|region
P08065901A0997|69 76|ZFP genes
P08065901A0997|85 97|transcription
P08065901A0997|134 145|interactions
P08065901A0997|156 167|KRAB-A domain
P08065901A0997|171 180|components
P08065901A0997|209 217|apparatus
P08066094T0000|0 9|Marine oils
P08066094T0000|27 36|reactivity
P08067013T0001|13 24|significance
P08067013T0001|27 57|creatine phosphokinase antibodies
P08067013T0001|70 75|muscle
P08067013T0001|105 112|diseases
P08067123A0248|14 20|results
P08067123A0248|23 28|assays
P08067123A0248|51 72|assay systems ORTHO ELISA
P08067123A0248|75 86|ABBOTT HCV EIA
P08067123A0248|95 107|detection rate
P08067123A0248|109 123|anti-HCV-C100-3
P08067123A0248|136 146|blood donors
P08067123A0248|149 154|Moscow
P08067123A0248|195 207|HBsAg carriers
P08067123A0248|220 225|donors
P08067123A0248|229 243|anti-HCV-C100-3
P08067123A0248|249 253|blood
P08067546A0000|13 22|hypothesis
P08067546A0000|38 55|vasomotor responses
P08067546A0000|72 79|propofol
P08067546A0000|85 100|sodium thiopental
P08067546A0000|135 141|effects
P08067546A0000|159 163|oxide
P08067546A0000|176 190|vasodilator tone
P08067546A0000|211 233|vasoconstrictor activity
P08067607A0568|11 21|alterations
P08067607A0568|24 33|CBC results
P08067607A0568|37 57|serum CRP concentration
P08067607A0568|70 83|baseline values
P08067607A0568|108 119|control group
P08069298A0492|16 29|splice variants
P08069298A0492|68 74|sources
P08069298A0492|90 109|leptomeningeal tissue
P08069298A0492|134 152|leptomeningeal cells
P08069427T0000|0 25|Roux-en-Y gastroenterostomy
P08069427T0000|42 49|emptying
P08069427T0000|55 65|gallbladder
P08069481A0736|12 22|experiments
P08069481A0736|25 32|phantoms
P08069481A0736|43 53|calf muscles
P08070004A0782|17 25|variation
P08070004A0782|32 46|PCZ plasma levels
P08070004A0782|54 58|ng/ml
P08070004A0782|73 87|plasma half-life
P08070004A0782|88 96|t1/2 alpha
P08070004A0782|124 131|patients
P08070004A0782|143 150|mg/m2 PCZ
P08070393A0631|10 15|effect
P08070393A0631|28 35|ng/ml EGF
P08070393A0631|41 47|time lag
P08070654A0000|24 32|component
P08070654A0000|37 41|yeast
P08070654A0000|49 56|pole body
P08070654A0000|79 87|karyogamy
P08070654A0000|90 103|SPB duplication
P08070654A0574|0 4|CDC31
P08070654A0574|18 31|SPB duplication
P08070654A0574|58 64|protein
P08070654A0574|91 108|caltractin/centrin
P08070654A0574|110 116|protein
P08070654A0574|134 146|Chlamydomonas
P08071356A0232|6 25|transcript elongation
P08071356A0232|29 33|sizes
P08071356A0232|39 50|DNA footprint
P08071356A0232|72 90|transcription bubble
P08071356A0232|108 129|transcription complexes
P08071356A0232|147 163|template positions
P08071982T0000|32 39|syndrome
P08072352A0567|6 13|patients
P08072352A0567|17 22|polyps
P08072352A0567|32 37|asthma
P08072352A0567|46 63|aspirin sensitivity
P08072352A0567|72 83|eosinophilia
P08072352A0567|108 116|IgE levels
P08072547A0690|31 44|protein kinases
P08072547A0690|61 65|c-Jun
P08072547A0690|68 81|serine residues
P08072547A0690|84 92|positions
P08072547A0690|130 137|activity
P08072547A1009|6 13|sequence
P08072547A1009|33 54|JNK phosphorylation site
P08072547A1009|57 61|c-Jun
P08072547A1009|75 79|c-Fos
P08072547A1009|96 111|activation domain
P08072547A1009|125 129|c-Fos
P08072547T0000|0 4|c-Fos
P08072547T0000|20 27|activity
P08072547T0000|55 67|protein kinase
P08073505T0000|4 13|generation
P08073505T0000|16 40|information retrieval tools
P08073505T0000|44 53|biologists
P08073505T0000|57 63|example
P08073505T0000|69 83|ExPASy WWW server
P08075070A1632|9 16|features
P08075070A1632|23 27|model
P08075070A1632|54 58|helix
P08075070A1632|61 67|contact
P08075070A1632|70 82|operator sites
P08075070A1632|87 102|repressor domains
P08075070A1632|110 127|sequence homologies
P08075070A1632|156 161|motifs
P08075070A1632|179 186|proteins
P08075421A0621a|41 49|C terminus
P08075421A0621a|51 55|HrpJ2
P08075421A0621b|41 49|C terminus
P08075421A0621b|51 55|HrpJ2
P08076631A0000|3 9|binding
P08076631A0000|12 34|transcription factor AP-1
P08076631A0000|38 53|vitamin D receptor
P08076631A0000|103 116|promoter region
P08076631A0000|138 152|osteocalcin gene
P08076631A0000|190 194|MG-63
P08076631A0000|216 221|SaOs-2
P08076631A0000|227 247|osteosarcoma cell lines
P08076937A0851|5 13|detection
P08076937A0851|20 27|mutation
P08076937A0851|40 59|restriction digestion
P08076937A0851|88 101|mismatch primer
P08076937A0851|116 128|point mutation
P08076937A0851|137 156|Tru9I restriction site
P08077236A0243|0 7|Wild type
P08077236A0243|17 24|Epo cDNAs
P08077236A0243|55 60|levels
P08077236A0243|72 80|COS7 cells
P08078167A0000|0 8|OBJECTIVE
P08078167A0000|28 37|hepatitis A
P08078167A0000|52 60|travelers
P08078167A0000|85 92|measures
P08078416A0581|15 20|effect
P08078416A0581|23 35|disinfectants
P08078416A0581|43 54|biofilm cells
P08078416A0581|102 115|concentrations
P08078416A0581|121 133|disinfectants
P08078473A1107|0 9|Expression
P08078473A1107|12 20|ME31B cDNA
P08078473A1107|45 57|ste13 mutation
P08079268T0028|7 27|Medi-Jector EZ dermojet
P08079268T0028|30 39|anesthesia
P08079268T0028|47 53|surgery
P08082215A0230|9 16|response
P08082215A0230|19 32|past-infection
P08082215A0230|35 49|cytomegalovirus
P08082215A0230|55 62|patients
P08082286A0748|0 16|Acupuncture effect
P08082286A0748|23 31|receptors
P08082286A0748|50 54|point
P08082286A0748|91 96|effect
P08082292T0000|7 16|NK activity
P08082292T0000|37 43|disease
P08082292T0000|51 58|patients
P08082292T0000|90 101|tuberculosis
P08082360A0411|0 13|Smoking history
P08082360A0411|22 37|oxygen saturation
P08082440A0339a|11 17|LH/FSH P
P08083011A0584|24 30|weights
P08083011A0584|72 85|R-L brain weight
P08083011A0584|115 128|R-L brain weight
P08083011A0584|142 153|testosterone
P08083011A0584|156 160|males
P08083011A0584|161 168|estrogen
P08083011A0584|171 177|females
P08083220A0988|19 34|complex formation
P08083220A0988|38 45|contrast
P08083220A0988|63 70|promoter
P08083220A0988|76 93|c-fos protooncogene
P08083220A0988|99 107|formation
P08083220A0988|120 126|complex
P08083220A0988|148 155|assembly
P08083220A0988|161 173|serum response
P08083220A0988|190 196|complex
P08083963A0795|14 23|activities
P08083963A0795|31 36|a1/EBP
P08083963A0795|39 44|B-cell
P08083963A0795|52 65|extract protein
P08083963A0795|89 96|gel shift
P08083963A0795|97 101|DNase
P08083963A0795|103 114|footprinting
P08083963A0795|118 146|methylation interference assays
P08083998A1723a|5 11|results
P08083998A1723a|23 39|leader-mRNA fusion
P08083998A1723a|42 65|coronavirus transcription
P08083998A1723a|86 103|RNA-RNA interaction
P08083998A1723a|124 132|sequences
P08083998A1723b|5 11|results
P08083998A1723b|23 39|leader-mRNA fusion
P08083998A1723b|42 65|coronavirus transcription
P08083998A1723b|86 103|RNA-RNA interaction
P08083998A1723b|124 132|sequences
P08083999A0501|0 7|Vaccinia
P08083999A0501|42 47|HPV-16
P08083999A0501|51 65|BPV-1 E2 proteins
P08083999A0501|72 86|consensus E2 site
P08083999A0501|103 112|affinities
P08083999A0501|157 169|transcription
P08084339A0907|24 33|transcript
P08084339A0907|49 60|reading frame
P08084339A0907|85 90|J alpha
P08084339A0907|95 100|region
P08084339A0907|105 115|nucleotides
P08084339A0907|131 139|beginning
P08084339A0907|145 159|TCR C alpha region
P08084339A0907|184 203|amino acid polypeptide
P08084592A0145|9 29|fibroblast cell hybrids
P08084592A0145|32 41|expression
P08084592A0145|56 69|tumorigenicity
P08085228A0000|11 25|characteristics
P08085228A0000|29 42|risk factor data
P08085228A0000|52 58|clients
P08085228A0000|87 98|distribution
P08085228A0000|101 109|infection
P08085228A0000|119 139|immunodeficiency virus
P08085228A0000|158 167|counseling
P08085228A0000|169 185|testing facilities
P08085228A0000|188 194|Houston
P08085609A0384|0 6|Results
P08085609A0384|19 24|KNM-LU
P08085609A0384|51 63|chimpanzee M1s
P08085609A0384|74 82|distances
P08085609A0384|98 107|dimensions
P08085609A0384|115 133|crown fissure termini
P08085782A0164|12 16|cases
P08085782A0164|30 34|tumor
P08086450A0467|0 9|Comparison
P08086450A0467|50 55|region
P08086450A0467|60 68|hATP1 gene
P08086450A0467|85 100|guanine-cytosine
P08086450A0467|109 114|region
P08086450A0467|130 142|binding motifs
P08086450A0467|160 166|factors
P08086453T0000|0 8|Structure
P08086453T0000|9 24|promoter analysis
P08086453T0000|39 48|assignment
P08086453T0000|59 66|APEX gene
P08087887A1067|3 19|polyubiquitin gene
P08087887A1067|47 61|Volvox life cycle
P08087887A1067|66 70|peaks
P08087887A1067|82 91|mRNA levels
P08087887A1067|110 117|cleavage
P08087887A1067|121 134|post-inversion
P08088022A1417|30 36|disease
P08088022A1417|55 66|heart disease
P08088022A1417|86 90|links
P08088022A1417|104 108|heart
P08088022A1417|141 148|ischemia
P08088513A0419|20 27|evidence
P08088513A0419|67 77|interaction
P08088513A0419|88 103|DEAH protein Prp16
P08088513A0419|133 138|snRNAs
P08088777A0754|3 20|consensus gene order
P08088777A0754|53 59|crosses
P08088777A0754|61 66|D2Mit1
P08088777A0754|70 75|Notch1
P08088777A0754|74 79|Col5a1
P08088777A0754|84 92|Spna2-Ab l
P08088777A0754|101 105|Grp78
P08088818A1053|7 11|level
P08088818A1053|39 47|deletions
P08088818A1053|125 130|strain
P08088818A1053|142 150|RAD52 gene
P08089184A0825|2 9|addition
P08089184A0825|13 26|megabase region
P08089184A0825|41 49|dagA locus
P08089834A0561|5 11|mutants
P08089834A0561|15 23|deletions
P08089834A0561|50 57|residues
P08089834A0561|65 80|amino acid residue
P08089887A0742|9 22|OUTCOME MEASURE
P08089887A0742|54 63|evaluation
P08090571T0001|0 10|Elimination
P08090571T0001|20 29|antibodies
P08090571T0001|42 51|xenografts
P08090746A1288|6 13|sequence
P08090746A1288|14 21|ATTTCAAA
P08090746A1288|40 51|region shares
P08090746A1288|63 70|homology
P08090746A1288|75 91|promoter sequences
P08090746A1288|103 124|ethylene responsiveness
P08090746A1288|132 157|tomato fruit-ripening E4 gene
P08090767A0000|9 16|evidence
P08090767A0000|21 38|DNA polymerase delta
P08090767A0000|66 71|enzyme
P08090767A0000|90 98|viability
P08090767A0000|113 123|replication
P08090767A0000|141 158|base excision repair
P08090767A0000|170 189|DNA methylation damage
P08091655A0000|19 23|Marek
P08091655A0000|25 36|Disease Virus
P08091655A0000|42 46|genes
P08091655A0000|55 69|EcoRI-B fragment
P08091655A0000|72 77|MDV-GA
P08091665T0000|0 10|Cowpox virus
P08091665T0000|22 27|copies
P08091665T0000|86 96|TNF receptor
P08091669A0828|39 49|39k promoter
P08091669A0828|54 60|absence
P08091669A0828|80 91|reading frame
P08091669A0828|107 113|control
P08091669A0828|119 129|ie1 promoter
P08093450A0688|0 10|Mutagenesis
P08093450A0688|17 26|NRF-1 motif
P08093450A0688|32 43|ALAS promoter
P08093450A0688|68 73|levels
P08093450A0688|76 117|chloramphenicol acetyltransferase expression
P08093450A0688|125 135|mutagenesis
P08093450A0688|142 152|NRF-1 motifs
P08093450A0688|188 197|expression
P08093616A1214|0 4|DNase
P08093616A1214|6 25|footprinting analysis
P08093616A1214|60 68|DRE region
P08093616A1214|73 94|DNA polymerase alpha gene
P08093616A1214|117 125|sequences
P08093616T0000|5 22|8-base pair sequence
P08093616T0000|57 63|element
P08093616T0000|74 86|binding factor
P08093616T0000|100 109|expression
P08093616T0000|122 126|genes
P08093616T0000|130 147|DNA polymerase alpha
P08093616T0000|177 183|antigen
P08093642A0600|2 9|addition
P08093642A0600|11 42|microsatellite repeat polymorphism
P08093642A0600|48 61|heterozygosity
P08093642A0600|73 80|RET locus
P08093642A0600|84 120|restriction fragment length polymorphism
P08093642A0600|126 139|heterozygosity
P08093642A0600|157 167|lambda clone
P08093642A0600|174 184|D10S94 locus
P08093642A0600|227 240|linkage mapping
P08093642A0600|264 270|testing
P08094464A0869|52 59|promoter
P08094464A0869|86 92|portion
P08094464A2014|17 32|attenuator region
P08094464A2014|57 66|structures
P08094464A2014|84 96|configuration
P08094464A2014|99 103|spots
P08094464A2014|106 127|base-residue divergence
P08094464A2014|153 159|regions
P08094498A0614|23 28|spouse
P08094498A0614|36 40|truth
P08094498A0614|50 58|diagnosis
P08094498A0614|62 70|prognosis
P08094927A0311|8 14|studies
P08094927A0311|25 33|mutations
P08094927A0311|39 47|6K protein
P08094927A0311|60 66|release
P08094927A0311|98 104|virions
P08095698T0000|0 9|Metabolism
P08095698T0000|12 18|calcium
P08095698T0000|22 30|vitamin D3
P08095698T0000|33 40|patients
P08095698T0000|68 76|nephritis
P08095698T0000|78 82|study
P08095698T0000|87 94|patients
P08095698T0000|99 119|nephropathia epidemica
P08095872A1672|15 19|study
P08095872A1672|43 50|inotropy
P08095872A1672|55 61|timolol
P08095872A1672|80 90|contraction
P08095872A1672|116 129|LONG/CIRC ratio
P08095872A1672|131 140|transition
P08095872A1672|157 175|contraction efficacy
P08095875T0000|0 6|Effects
P08095875T0000|17 27|hypercapnia
P08095875T0000|30 40|hypothermia
P08095875T0000|54 58|He-O2
P08096066A0623|3 14|RFLP patterns
P08096066A0623|20 27|isolates
P08096066A0623|42 49|patients
P08096066A0623|81 87|strains
P08096066A0623|123 133|development
P08096066A0623|135 148|drug resistance
P08096944A0951|22 32|stimulation
P08096944A0951|58 67|indication
P08096944A0951|79 88|assessment
P08096944A0951|94 100|ovaries
P08096944A0951|108 112|women
P08096944A0951|130 140|stimulation
P08097666A1135|0 5|A23187
P08097666A1135|21 33|modifications
P08097666A1135|52 60|potential
P08097666A1135|64 71|ampullar
P08097666A1135|90 98|frequency
P08097666A1135|118 123|spikes
P08097732A0000|0 9|Activation
P08097732A0000|38 47|Spec2a gene
P08097732A0000|64 79|sea urchin embryos
P08097732A0000|108 113|region
P08097732A0000|139 153|sequence element
P08097732A0000|175 190|Spec1/Spec2 genes
P08098228A0625|1 10|transcript
P08098842A0660|0 8|Mutations
P08098842A0660|12 17|region
P08098842A0660|57 78|transcription start site
P08098842A0660|91 98|homology
P08098842A0660|102 109|sequence
P08098842A0660|128 132|c-fos
P08098842A0660|163 169|element
P08098842A0660|192 199|increase
P08098842A0660|207 220|gene expression
P08098842A0660|236 245|regulation
P08098882T0001|12 26|desensitization
P08098914A0400|6 13|exercise
P08098914A0400|17 31|Pes-Ves relation
P08098914A0400|63 67|slope
P08098914A0400|79 87|elastance
P08098914A0400|127 133|mmHg/ml
P08099443A0359|18 25|dsRNA-PK
P08099443A0359|38 52|yeast eIF-2 alpha
P08099443A0359|97 107|GCN2 protein
P08099443A0359|119 133|GCN4 translation
P08099443A0359|136 140|yeast
P08100057A0577|45 55|populations
P08100057A0577|71 81|macrophages
P08100057A0577|99 109|dendrocytes
P08100765A0361|23 49|transgene expression patterns
P08100765A0361|59 68|cerebellum
P08100765A0361|74 78|lines
P08100765A0361|119 130|compartments
P08100843A0134|0 15|Southern analysis
P08100843A0134|42 48|tissues
P08100843A0134|51 59|cell lines
P08100843A0134|71 82|mouse strains
P08100843A0134|88 96|mCD22 cDNA
P08100843A0134|116 124|Cd22 locus
P08100843A0134|133 137|mCD22
P08100843A0134|147 154|copy gene
P08101134A0376|3 16|concentrations
P08101134A0376|19 28|plasma ACTH
P08101134A0376|32 39|cortisol
P08101134A0376|67 79|MPTP treatment
P08101171A0924|10 16|results
P08101171A0924|37 51|Pc group products
P08101171A0924|64 69|memory
P08101171A0924|84 93|boundaries
P08101171A0924|139 148|regulators
P08101839A0000|16 25|regulation
P08101839A0000|28 37|expression
P08101839A0000|48 55|mdr1 gene
P08101839A0000|59 66|response
P08101839A0000|72 83|mdr1 promoter
P08101839A0000|86 92|signals
P08101839A0000|103 119|cell proliferation
P08101843A0151|3 25|tyrosine hydroxylase gene
P08101843A0151|54 65|consensus CRE
P08101843A0151|74 81|base pair
P08101843A0151|99 125|transcription initiation site
P08102364A0000|0 6|Tobacco
P08102364A0000|27 33|tobacco
P08102364A0000|34 52|Nicotiana tabacum var
P08103379A0577|8 14|stretch
P08103379A0577|19 28|amino acids
P08103379A0577|44 53|MADS domain
P08103379A0577|60 67|proteins
P08103379A0577|104 125|amino acid substitutions
P08103935T0000|0 8|Isolation
P08103935T0000|12 27|characterization
P08103935T0000|30 49|SRF accessory proteins
P08104189A1168|23 37|proSRIF cleavage
P08104189A1168|66 73|reaction
P08104189A1168|143 148|ATPase
P08105727A0099|0 9|Fenoldopam
P08105727A0099|11 33|dopamine receptor agonist
P08105727A0099|48 64|animal experiments
P08105727A0099|79 87|perfusion
P08105994T0000|8 14|aspects
P08105994T0000|22 29|increase
P08105994T0000|32 61|serum gamma-glutamyl transferase
P08105994T0000|72 81|infarction
P08106087A0139|14 19|region
P08106087A0139|27 37|kDa zein gene
P08106087A0139|56 64|sequences
P08106087A0139|69 76|sequence
P08106087A0139|106 113|sequence
P08106087A0139|133 152|polyadenylation sites
P08106245A0325|9 26|radon concentration
P08106245A0325|32 37|summer
P08106245A0325|42 47|period
P08106245A0325|67 71|Bq m-3
P08106245A0325|82 87|winter
P08106245A0325|120 124|Bq m-3
P08106245A0325|144 155|measurements
P08106245A0325|170 174|Bq m-3
P08106245A0325|180 185|summer
P08106245A0325|190 195|period
P08106245A0325|214 218|Bq m-3
P08106245A0325|224 229|winter
P08106245A0325|259 270|measurements
P08106313A1492|3 9|results
P08106313A1492|22 26|hrpRS
P08106313A1492|58 64|cascade
P08106313A1492|93 102|expression
P08106313A1492|127 137|sigma factor
P08106313A1492|143 152|expression
P08106313A1492|170 174|genes
P08106325A0000|52 58|protein
P08106325A0000|72 82|tox operator
P08106325A0000|100 117|nucleotide sequence
P08106325A0000|140 158|diphtheria toxin gene
P08106369A0000|0 10|Vasopressin
P08106369A0000|31 37|hormone
P08106369A0000|46 56|nonapeptide
P08106369A0000|107 123|membrane receptors
P08106369A0000|156 163|subtypes
P08106369A0000|203 212|messengers
P08106398A1003|5 11|results
P08106398A1003|25 32|cleavage
P08106398A1003|38 50|leader peptide
P08106398A1003|68 82|nisin maturation
P08106398A1003|125 131|peptide
P08106512A0522|7 20|promoter region
P08106512A0522|47 58|reporter gene
P08106512A0522|73 86|promoter region
P08106512A0522|104 114|interferons
P08106512A0522|115 130|interferon-alpha
P08106512A0522|134 138|gamma
P08106512A0522|142 151|interferon
P08106512A0522|162 167|factor
P08107167A0222|0 5|Anti-B
P08107167A0222|29 37|turicatae
P08107167A0222|41 46|anti-B
P08107167A0222|51 67|parkeri antibodies
P08107167A0222|104 108|assay
P08107167A0222|149 160|serum samples
P08107167A0222|179 185|IFA-ABS
P08107208A0673|3 10|approach
P08107208A0673|40 47|strategy
P08107208A0673|57 68|recombinants
P08108099T0000|0 9|Evaluation
P08108099T0000|12 23|desmopressin
P08108099T0000|33 43|extractions
P08108099T0000|46 53|patients
P08108099T0000|68 76|disorders
P08108343A0000|11 18|analysis
P08108343A0000|37 44|niftolid
P08108343A0000|86 93|subjects
P08108343A0000|95 102|patients
P08108343A0000|138 149|hypogonadism
P08108343A0000|155 162|patients
P08108343A0000|175 179|signs
P08108343A0000|189 201|insufficiency
P08108343A0000|212 220|diagnosis
P08108343A0000|223 227|order
P08108343A0000|251 270|gonadotropin reserves
P08108413A0964|50 58|cell lines
P08108413A0964|68 74|tissues
P08108413A0964|90 103|PANG expression
P08108413A0964|116 120|brain
P08108413A0964|146 156|transcripts
P08111035A0098|23 32|properties
P08111035A0098|40 57|bp promoter fragment
P08111035A0098|61 78|B. napus oleosin gene
P08111035A0098|93 100|analysis
P08111035A0098|103 120|beta-glucuronidase
P08111035A0098|126 135|expression
P08111035A0098|147 159|tobacco plants
P08111035A0098|172 190|oleosin promoter-GUS
P08111035A0098|206 211|fusion
P08111974A1034|20 28|mechanism
P08111974A1034|51 61|degradation
P08111974A1034|63 73|tubulin mRNA
P08111974A1034|106 116|translation
P08111974A1034|131 141|involvement
P08111974A1034|153 164|trans-factor
P08112341A1128|4 8|Greer
P08112341A1128|13 18|Carter
P08112526A0443|26 45|calcium concentration
P08112526A0443|54 74|detrusor contractility
P08112526A0443|92 97|manner
P08112526A0443|104 110|control
P08112526A0443|124 131|bladders
P08112601T0000|10 21|organization
P08112601T0000|49 57|lipocalin
P08112601T0000|74 82|synthesis
P08112601T0000|99 105|protein
P08112611A0404|3 10|sequence
P08112611A0404|26 37|reading frame
P08112611A0404|47 53|protein
P08112611A0404|59 68|amino acids
P08112870A0484|0 14|Western blotting
P08112870A0484|15 28|immunoblotting
P08112870A0484|35 43|antiserum
P08112870A0484|96 103|proteins
P08112870A0484|125 130|masses
P08113736A0309|3 18|gene organization
P08113736A0309|21 29|CRSV RNA-1
P08113736A0309|51 56|clover
P08113736A0309|65 70|mosaic
P08113736A0309|71 75|RCNMV
P08113736A0309|84 89|clover
P08113736A0309|98 103|mosaic
P08113736A0309|104 108|SCNMV
P08113736A0309|109 122|dianthoviruses
P08113736A0309|130 138|exception
P08113736A0309|143 151|CRSV RNA-1
P08114702A0000|0 6|Members
P08114702A0000|44 49|factor
P08114702A0000|57 62|family
P08114702A0000|64 83|transcription factors
P08114702A0000|106 113|sequence
P08114702A0000|119 132|control regions
P08114702A0000|158 162|genes
P08114710A0137|25 29|LBP-1
P08114710A0137|39 56|HIV-1 transcription
P08114710A0137|72 78|binding
P08114710A0137|81 85|TFIID
P08114710A0137|91 97|TATA box
P08114745A0953|5 11|results
P08114745A0953|48 60|RNA production
P08114745A0953|77 83|ability
P08114745A0953|94 109|termination sites
P08114745A0953|112 116|class
P08114745A0953|120 128|templates
P08114745A0953|161 182|transcription complexes
P08115744A0462|3 7|films
P08115744A0462|26 33|scanning
P08115744A0462|45 61|laser densitometer
P08115744A0462|72 79|aperture
P08115744A0462|86 92|microns
P08115744A0846|13 18|method
P08115744A0846|50 55|method
P08115744A0846|58 65|analysis
P08115744A0846|99 121|quality assurance program
P08116245A0174|25 33|reactions
P08116245A0174|61 69|specimens
P08116245A0174|80 89|infant rats
P08118044A0318|0 9|GATA-1 mRNA
P08118044A0318|32 37|levels
P08118044A0318|53 61|cell lines
P08118044A0318|71 75|level
P08118044A0318|78 88|FDC-P1 cells
P08119149A0000|0 24|Tumor necrosis factor-alpha
P08119149A0000|25 32|TNF alpha
P08119149A0000|66 72|factors
P08119149A0000|101 107|effects
P08119907A0000|37 49|p21ras protein
P08119907A0000|51 57|insulin
P08119907A0000|73 86|growth factor-I
P08119907A0000|87 91|IGF-I
P08119907A0000|92 108|signaling pathways
P08119958A0273|14 21|C2 domain
P08119958A0273|50 57|presence
P08119958A0273|77 84|sequence
P08119958A0273|99 111|signal peptide
P08119958A0273|129 134|domain
P08119958A0273|146 150|PKC mu
P08119958A0273|159 164|member
P08119958A0273|170 177|subgroup
P08119995A0814|25 32|function
P08119995A0814|35 53|T3R-RXR heterodimers
P08119995A0814|56 71|response elements
P08119995A0814|85 94|half-sites
P08119995A0814|114 124|orientation
P08119995A0814|134 144|nucleotides
P08119995A0814|164 168|parts
P08119995A0814|182 189|sequence
P08119995A0814|203 211|half-site
P08120019A1500|12 21|Hm1 mutants
P08120019A1500|62 71|PI turnover
P08120019A1500|87 99|sequestration
P08120019A1500|118 127|mechanisms
P08120029A0864|18 38|decay reaction mixtures
P08120029A0864|63 80|sense RNA transcript
P08120029A0864|91 103|stabilization
P08120029A0864|106 114|R2 message
P08122364A0954|0 15|Deletion analyses
P08122364A0954|21 30|pCD41 ORF-A
P08122364A0954|44 61|promoter constructs
P08122364A0954|94 101|promoter
P08122364A0954|111 123|pCD41 sequence
P08122364A0954|140 148|synthesis
P08122364A0954|170 176|protein
P08122370A0331|15 26|counterparts
P08122370A0331|38 54|herpes simplex type
P08122370A0331|55 59|HSV-1
P08122370A0331|60 76|pseudorabies virus
P08122370A0331|91 105|herpesvirus type
P08122370A0331|106 110|EHV-1
P08123787A0554|11 27|amino acid sequence
P08123787A0554|47 57|HemB protein
P08123787A0554|79 88|difference
P08123787A0554|94 117|metal cofactor requirement
P08123787A0554|137 143|enzymes
P08123787A0554|163 176|overexpression
P08123787A0554|191 198|analysis
P08124785A0445|0 6|METHODS
P08124785A0445|10 16|RESULTS
P08124785A0445|21 30|open-chest
P08124785A0445|60 83|circumflex artery stenosis
P08124785A0445|99 106|decrease
P08124785A0445|119 124|artery
P08124785A0445|158 168|flow reserve
P08124785A0445|190 212|mean transit time Tmicro-1
P08124912A0456|8 18|correlation
P08124912A0456|37 44|SF levels
P08124912A0456|64 70|lactate
P08124912A0456|75 93|beta 2-microglobulin
P08124912A0456|96 102|glucose
P08124956T0000|43 54|pancreatitis
P08124956T0000|75 85|oxygenation
P08125258A0142|18 22|cells
P08125258A0142|34 43|conditions
P08125258A0142|47 54|CHOP gene
P08125258A0142|75 81|variety
P08125258A0142|92 99|stresses
P08125258A0142|117 127|deprivation
P08125258A0142|140 152|perturbations
P08125319A1085|3 11|ipiO genes
P08125319A1085|43 50|proteins
P08125319A1085|68 75|homology
P08125319A1085|80 88|sequences
P08125319A1085|98 110|data libraries
P08125337A0940|0 13|Sterol analysis
P08125337A0940|28 33|mutant
P08125337A0940|49 60|accumulation
P08125337A0940|63 72|ignosterol
P08125337A0940|92 105|Erg24p activity
P08125949A1162|30 40|translation
P08125949A1162|43 56|spinach L12 mRNA
P08125949A1162|73 81|AUG codons
P08125949A1162|101 110|rpl12 genes
P08125949A1162|113 123|Arabidopsis
P08125949A1162|142 151|mechanisms
P08125949A1162|172 177|copies
P08125949A1162|180 202|L12/chloroplast ribosome
P08125949A1162|245 254|eubacteria
P08126096A0478|7 17|experiments
P08126096A0478|44 52|functions
P08126096A0478|58 62|alpha
P08126096A0478|75 80|domain
P08126096A0478|92 101|homologies
P08126096A0478|125 133|sequences
P08126096A0478|146 152|studies
P08126096A0478|176 190|domain antiserum
P08126096A0478|219 223|forms
P08126096A1071|3 16|alpha 7A form RNA
P08126096A1071|40 50|nucleotides
P08126096A1071|64 68|B form
P08126096A1071|79 90|coding region
P08126096A1071|102 110|B form RNAs
P08126096A1071|127 139|reading frames
P08127950A0000|2 6|order
P08127950A0000|20 27|function
P08127950A0000|83 92|depression
P08127950A0000|94 100|authors
P08127950A0000|114 130|0800h plasma levels
P08127950A0000|137 145|thyroxine
P08127950A0000|155 170|triiodothyronine
P08127950A0000|178 202|thyroid stimulating hormone
P08127950A0000|209 213|means
P08127950A0000|235 240|assays
P08127950A0000|241 248|TSH-IRMA
P08127950A0000|260 267|controls
P08127950A0000|314 321|subjects
P08128629A1164|0 10|CRS function
P08128629A1164|25 43|gene expression assay
P08128629A1164|61 67|ability
P08128629A1164|74 79|p60CRS
P08128629A1164|83 88|p40CRS
P08128629A1164|104 109|LTR RNA
P08129955A0572|6 11|levels
P08129955A0572|14 22|troponin T
P08129955A0572|29 36|activity
P08129955A0572|39 43|CK-MB
P08129955A0572|80 89|unclamping
P08130942A0051|0 14|Regionalization
P08130942A0051|17 28|drug delivery
P08130942A0051|41 46|method
P08130942A0051|58 64|problem
P08131545A0158|22 26|group
P08131545A0158|31 46|community members
P08131545A0158|58 62|women
P08131545A0158|76 80|years
P08131545A0158|80 85|living
P08131545A0158|145 149|tests
P08131545A0158|153 162|Mycoplasma
P08131545A0158|173 193|Legionella pneumophila
P08131545A0158|194 208|cytomegalovirus
P08131545A0158|209 218|adenovirus
P08131545A0158|219 234|Coxiella burnetii
P08131545A0158|238 246|Chlamydia
P08131746A0140|25 45|serine phosphorylation
P08131746A0140|55 70|activator kinases
P08131746A0140|80 84|c-raf
P08131746A0140|93 101|MEK kinase
P08132541A0000|7 15|DNA clones
P08132541A0000|49 55|MAL gene
P08132574A0831|0 6|Members
P08132574A0831|33 48|complement C2 gene
P08132574A0831|62 70|kilobases
P08132574A0831|104 123|cytochrome CYP1A1 gene
P08132667T0000|0 9|Expression
P08132667T0000|22 52|proprotein processing enzyme furin
P08132667T0000|73 81|promoters
P08133502T0105|0 26|European Community Huntington
P08133502T0105|28 57|Disease Collaborative Study Group
P08134108A0277|3 7|c-myc
P08134108A0277|19 42|alpha-actin gene promoters
P08134108A0277|50 64|YY1 binding sites
P08134108A0277|113 120|elements
P08134115A1161|0 5|MSSP-1
P08134115A1161|25 37|fusion protein
P08134115A1161|88 93|TCTTAT
P08134115A1161|110 116|ACT-ATT
P08134115A1161|135 143|consensus
P08134115A1161|166 174|A/TCTA/TA
P08136383A0359|8 12|hours
P08136383A0359|18 29|MR tomography
P08136383A0359|33 40|patients
P08138180A0593|7 11|spt10
P08138180A0593|23 29|alleles
P08138180A0593|37 47|suppressors
P08138180A0593|62 71|growth rate
P08138180A0593|89 100|SPT10 protein
P08138180A0593|119 127|functions
P08138364T0000|0 8|Varieties
P08138364T0000|18 27|experience
P08139001A1235|3 9|results
P08139001A1235|25 29|amino
P08139001A1235|33 46|carboxy termini
P08139001A1235|52 69|NS1 protein molecule
P08139001A1235|76 84|cysteines
P08139001A1235|87 94|residues
P08139001A1235|119 133|tubule formation
P08139004A0278|25 32|hairpins
P08139004A0278|67 78|UGC sequences
P08139017A1465|39 48|initiation
P08139017A1465|67 81|primer extension
P08139017A1465|113 126|Ets-1 cDNA clone
P08139017A1465|154 158|cells
P08139017A1465|162 167|tumors
P08139017A1465|177 184|provirus
P08139017A1465|190 199|Tpl-1 locus
P08139031A1168|51 61|mutagenesis
P08139031A1168|83 98|cysteine residues
P08139031A1168|104 118|ORF4 polypeptide
P08139031A1168|123 127|C-421
P08139031A1168|131 135|C-426
P08139031A1168|151 172|transactivator function
P08139031A1168|192 207|cysteine residues
P08139031A1168|247 258|interactions
P08139031A1168|284 299|acid interactions
P08139031A1168|309 324|ORF4 inducibility
P08139539A0446|2 11|Rat 1a cells
P08139539A0446|12 25|m1R stimulation
P08139539A0446|28 45|phospholipase C beta
P08139539A0446|79 85|calcium
P08139539A0446|112 120|synthesis
P08139539A0446|133 142|activation
P08139539A0446|145 159|protein kinase A.
P08139542A1229|3 11|mutations
P08139542A1229|27 36|repression
P08139542A1229|47 54|arginine
P08139542T0000|1 7|segment
P08139542T0000|27 39|leader peptide
P08139542T0000|44 51|CPA1 gene
P08139542T0000|59 68|repression
P08139542T0000|71 78|arginine
P08139542T0000|94 112|yeast gene transcript
P08139543A0427|11 15|genes
P08139543A0427|35 50|SLK1-SLT2 pathway
P08139543A0427|67 83|suppression screen
P08139543A1520|20 27|analysis
P08139543A1520|41 45|NHP6A
P08139543A1520|49 61|NHP6B function
P08139562A0404|6 11|report
P08139562A0404|24 28|lines
P08139562A0404|31 38|evidence
P08139562A0404|46 54|ribosomes
P08139562A0404|100 104|uORF1
P08139562A0404|111 118|scanning
P08139562A0404|138 150|GCN4 start site
P08139577T0000|9 18|components
P08139577T0000|21 48|yeast transcription factor IIIB
P08139577T0000|76 88|transcription
P08139577T0000|123 127|genes
P08139914A0554|29 43|dnHLH protein Id1
P08139914A0554|52 66|differentiation
P08139914A0554|69 74|muscle
P08139914A0554|85 89|cells
P08139928T0000|10 30|ribonucleoprotein gene
P08139928T0000|35 39|yeast
P08140847X0001|0 4|Crohn
P08140847X0001|6 12|disease
P08140847X0001|24 32|remission
P08140847X0001|64 69|intake
P08140847X0001|89 96|subjects
P08140847X0001|149 153|study
P08140847X0001|177 181|Crohn
P08140847X0001|183 197|disease patients
P08140847X0001|209 217|remission
P08140847X0001|230 234|order
P08140847X0001|249 258|body weight
P08140847X0001|309 314|intake
P08140847X0001|356 363|controls
P08142875A0877|17 26|dissection
P08142875A0877|94 105|intervention
P08142875A0877|115 119|cases
P08143198T0001|0 10|Restoration
P08143198T0001|13 20|opponens
P08143198T0001|33 47|transplantation
P08143198T0001|54 82|composites dorsal pedal skin flap
P08143198T0001|93 116|m. extensor hallucis brevis
P08143236A1055|7 20|ethanol regimen
P08143236A1055|40 50|alternation
P08143236A1055|58 70|g ethanol.kg-1
P08143236A1055|72 83|day-1 regimen
P08143236A1055|96 102|percent
P08143236A1055|112 117|trials
P08143667A0222|29 36|pressure
P08143667A0222|58 73|closure pressures
P08143667A0222|104 108|cmH2O
P08143667A0222|126 130|ratio
P08144035A0387|22 28|regions
P08144035A0387|52 60|N terminus
P08144035A0387|70 78|C terminus
P08144037A0000|0 10|Thioredoxin
P08144037A0000|50 55|enzyme
P08144037A0000|72 79|bacteria
P08144037A0000|83 88|plants
P08144470A0711|3 10|mutation
P08144470A0711|20 32|asgB480 allele
P08144470A0711|56 65|transition
P08144470A0711|100 111|substitution
P08144470A0711|126 139|protein product
P08144497T0000|16 21|region
P08144497T0000|24 34|raf-1 kinase
P08144497T0000|63 71|liposomes
P08144497T0000|87 93|segment
P08144497T0000|103 109|GTP-ras
P08144504T0064|7 14|coupling
P08144504T0064|18 28|requirement
P08144504T0064|32 44|ATP hydrolysis
P08144572A0786|24 41|polypeptide binding
P08144572A0786|43 49|Ssb1/2p
P08144572A0786|53 57|level
P08144572A0786|102 117|Ssa Hsp70 proteins
P08144615A0533|0 8|Digestion
P08144615A0533|11 16|NF-IL6
P08144615A0533|21 37|endoprotease Asp-N
P08144615A0533|47 52|domain
P08144615A0533|72 88|NF-IL6 bZIP domains
P08144615A0533|102 107|domain
P08144615A0533|128 134|absence
P08144615A0533|140 147|presence
P08144631A0000|0 8|Signaling
P08144631A0000|11 25|tyrosine kinases
P08144631A0000|40 51|associations
P08144631A0000|59 66|proteins
P08144631A0000|71 81|Src homology
P08144631A0000|88 94|domains
P08144631A0000|97 101|sites
P08144631A0000|104 126|tyrosine phosphorylation
P08144668A0802|24 28|exon V
P08144668A0802|61 66|exon VI
P08144668A0802|73 77|shift
P08144668A0802|87 98|reading frame
P08144668A0802|151 158|sequence
P08144668A0802|160 176|membrane anchoring
P08144852A0000|3 11|responses
P08144852A0000|17 30|stress hormones
P08144852A0000|31 38|cortisol
P08144852A0000|39 54|11-deoxycortisol
P08144852A0000|61 71|vasopressin
P08144852A0000|79 91|corticotropin
P08144852A0000|100 105|factor
P08144852A0000|131 135|males
P08144852A0000|137 144|response
P08144852A0000|152 169|cortisol deficiency
P08144852A0000|201 209|inhibitor
P08144852A0000|210 219|metyrapone
P08145646T0000|0 8|Structure
P08145646T0000|12 21|expression
P08145646T0000|38 48|sigma factor
P08145646T0000|57 77|Rhodobacter capsulatus
P08145646T0000|90 98|relevance
P08145646T0000|116 136|nifU2-rpoN superoperon
P08145770A1078|7 18|observations
P08145770A1078|63 78|retinoid pathways
P08145770A1078|122 131|activities
P08145770A1078|134 157|differentiation processes
P08148463A0000|21 27|factors
P08148463A0000|58 67|production
P08148463A0000|69 79|neutrophils
P08148463A0000|83 91|monocytes
P08148463A0000|95 108|granulocyte CSF
P08148463A0000|136 148|macrophage CSF
P08148463A0000|151 161|interleukin
P08148756A0358|3 8|degree
P08148756A0358|11 25|lung destruction
P08148756A0358|49 58|hemorrhage
P08148756A0358|81 97|hemoglobin content
P08148756A0358|103 107|fluid
P08148756A0358|120 124|lungs
P08149484A0151|0 17|Expression plasmids
P08149484A0151|40 51|kinase domain
P08149484A0151|54 61|PKC alpha
P08149484A0151|65 72|PKC delta
P08149484A0151|73 81|PKC alpha K
P08149484A0151|85 93|PKC delta K
P08149484A1551|5 11|results
P08149484A1551|28 35|PKC alpha
P08149484A1551|36 42|calcium
P08149484A1551|55 62|PKC delta
P08149484A1551|63 69|calcium
P08149484A1551|94 106|transcription
P08149484A1551|122 126|genes
P08149484A1551|155 163|sequences
P08150970A0434|5 15|cutoff level
P08150970A0434|19 24|TSST-1
P08150970A0434|38 42|pg/ml
P08150970A0434|45 51|samples
P08150970A0434|66 73|patients
P08150970A0434|89 94|TSST-1
P08151787A0355|0 8|Insertion
P08151787A0355|16 31|oligonucleotides
P08151787A0355|48 77|amino acid motifs 726-GRKRKSP-732
P08151787A0355|82 86|IE175
P08151787A0355|90 104|500-VRPRKRR-506
P08151787A0355|109 113|IE110
P08151787A0355|136 140|forms
P08151787A0355|149 156|proteins
P08151787A0355|179 187|phenotype
P08151787A0355|209 214|motifs
P08151787A0355|260 271|localization
P08151787T0000|0 6|Mapping
P08151787T0000|22 40|localization domains
P08151787T0000|44 51|evidence
P08151787T0000|55 80|colocalization interactions
P08151787T0000|91 95|IE110
P08151787T0000|99 103|IE175
P08151787T0000|111 132|transactivator proteins
P08151787T0000|135 152|herpes simplex virus
P08151790A0354|3 20|revertant TATA boxes
P08151790A0354|35 42|kinetics
P08151790A0354|45 58|HIV replication
P08151790A0354|75 81|context
P08151790A0354|102 112|Sp1 mutation
P08151790A0354|112 119|deletion
P08151790A0354|138 143|effect
P08151790A0354|159 169|infectivity
P08151980T0001|10 18|emphysema
P08152800A0357|8 16|ETS domain
P08152800A0357|38 44|carboxy
P08152800A0357|53 58|region
P08152800A0357|71 77|protein
P08152800A0357|149 154|member
P08152800A0357|163 179|Molecule PEA3-like
P08152800A0709|0 15|Gel shift analysis
P08152800A0709|43 52|ERM protein
P08152800A0709|81 95|oligonucleotide
P08152800A0709|109 143|consensus nucleotide core sequence GGAA
P08152800A0709|159 169|Ets proteins
P08153130T0000|0 6|Effects
P08153130T0000|9 17|estradiol
P08153130T0000|20 29|worm burden
P08153130T0000|43 52|leukocytes
P08153146A0327|0 9|Dotarizine
P08153146A0327|26 33|dilation
P08153146A0327|60 70|circulation
P08153146A0327|89 98|resistance
P08153146A0327|116 125|artery flow
P08153146A0327|148 157|artery mean
P08153146A0327|170 178|pressures
P08153146A0327|198 206|pressures
P08154171A0649|5 10|issues
P08154171A0649|28 32|LMWHs
P08154171A0649|34 41|patients
P08154171A0649|54 63|thrombosis
P08154171A0649|76 85|infarction
P08154171A0649|92 102|conjunction
P08154171A0649|119 127|treatment
P08154171A0649|133 140|patients
P08154171A0649|154 161|embolism
P08154182A0955|3 12|usefulness
P08154182A0955|18 27|lambda PG15
P08154182A0955|34 56|lambda AD5 cloning vectors
P08154182A0955|91 119|Neurospora crassa cDNA libraries
P08156332T0000|23 35|sympathectomy
P08156332T0000|46 54|treatment
P08156332T0000|76 84|ischaemia
P08157009A0264|0 18|Sequence comparisons
P08157009A0264|32 36|Aps1p
P08157009A0264|55 66|sigma subunit
P08157009A0264|96 106|AP-1 complex
P08157009A0264|111 115|Aps2p
P08157009A0264|139 168|plasma membrane AP-2 sigma subunit
P08157009T0000|26 33|APS1 gene
P08157009T0000|42 48|homolog
P08157009T0000|59 65|subunit
P08157009T0000|80 98|clathrin AP-1 complex
P08157009T0000|99 106|evidence
P08157009T0000|120 130|interaction
P08157009T0000|135 142|clathrin
P08157009T0000|148 159|Golgi complex
P08157663A0882|5 11|results
P08157663A0882|49 60|organization
P08157663A0882|64 77|vertebrate gene
P08157663A0882|96 110|membrane protein
P08157663A0882|123 130|envelope
P08157663A0882|141 146|member
P08157663A0882|150 155|family
P08157663A0882|158 169|polypeptides
P08157663A0882|181 189|evolution
P08157674T0000|11 26|characterization
P08157674T0000|47 53|protein
P08157674T0000|55 84|protein tyrosine kinase substrate
P08157674T0000|100 104|cells
P08159174A0581|3 10|presence
P08159174A0581|43 58|Southern analysis
P08160054A0224|3 10|patients
P08160054A0224|15 28|deterioriation
P08160054A0224|37 42|status
P08160054A0224|56 63|increase
P08160054A0224|66 77|liver enzymes
P08160054A0224|78 86|aspartate
P08160054A0224|90 114|alanine aminotransaminases
P08160054A0224|124 135|coagulopathy
P08160387T0000|19 29|development
P08160387T0000|53 58|cortex
P08160387T0000|78 87|experience
P08160387T0000|91 97|rearing
P08160387T0000|110 120|deprivation
P08160905A0217|6 13|patients
P08160905A0217|34 57|hepatitis B surface antigen
P08160905A0217|58 62|HBsAg
P08163183T0000|3 8|xylose
P08163183T0000|41 72|Clostridium thermosaccharolyticum
P08163183T0000|71 77|cloning
P08163183T0000|78 87|sequencing
P08163183T0000|91 99|phylogeny
P08163183T0000|102 112|XylA enzymes
P08163498A0789|3 17|phosphopeptides
P08163498A0789|37 50|SGASGLLTSEHHSR
P08163498A0789|58 71|SGASGLLTSEHHSR
P08163498A0789|101 115|phosphorylation
P08163498A0789|119 132|trypsinization
P08163498A0789|138 144|peptide
P08163528T0000|13 38|Mas70p signal anchor sequence
P08163546A1230|32 37|Ypt51p
P08163546A1230|37 42|Ypt52p
P08163546A1230|46 51|Ypt53p
P08163546A1230|66 74|transport
P08163546A1230|89 95|pathway
P08163546A1230|109 115|sorting
P08163546A1230|126 135|hydrolases
P08163546A1230|155 166|intersection
P08163546A1230|196 209|sorting pathway
P08164302A0547|13 24|TPN solutions
P08164302A0547|57 75|nutrient composition
P08164302A0547|88 97|difference
P08164302A0547|100 110|energy level
P08164302A0547|131 137|glucose
P08164661A0414|12 22|TFIIIC alpha
P08164661A0414|28 35|homology
P08164661A0414|46 50|yeast
P08164661A0414|57 64|subunits
P08164661A0414|100 105|degree
P08164661A0414|120 129|divergence
P08164661A0414|133 145|RNA polymerase
P08164661A0414|149 155|factors
P08164679A0809|0 20|Transactivation domain
P08164679A0809|59 76|runt homology region
P08164679A0809|92 101|Runt domain
P08164680A1086|17 32|protease activity
P08164680A1086|64 69|B cells
P08164680A1086|81 85|cells
P08164684A1266|3 8|ligand
P08164684A1266|50 55|effect
P08164684A1266|89 95|complex
P08166402A0631|0 17|Cerebral125 albumin
P08166402A0631|39 49|proportions
P08166402A0631|57 62|groups
P08166402A0631|74 88|hyperosmolality
P08167396A0154|20 26|neurons
P08167396A0154|65 91|substantia nigra pars compacta
P08167555A0972|0 7|Response
P08167555A0972|10 18|treatment
P08167555A0972|30 37|patients
P08167555A0972|46 57|pretreatment
P08167555A0972|70 79|treatments
P08167555A0972|129 136|relation
P08169201A0291|26 33|sequence
P08169201A0291|47 57|carA product
P08169201A0291|89 106|nucleotide sequence
P08169201A0291|113 121|organisms
P08169201A0291|152 161|amino acids
P08169709T0000|10 17|bone cyst
P08169709T0000|29 36|analysis
P08169709T0000|40 44|cases
P08170400T0000|0 7|Location
P08170400T0000|11 21|orientation
P08170400T0000|36 41|region
P08170400T0000|62 80|transcription factor
P08172416A0860|0 9|Moxidectin
P08172416A0860|13 17|times
P08172416A0860|59 65|effects
P08172416A0860|84 94|performance
P08172416A0860|108 123|folliculogenesis
P08172416A0860|124 132|ovulation
P08172416A0860|153 157|phase
P08172416A0860|160 170|development
P08172598A0237|13 20|analysis
P08172598A0237|45 57|N. patriciarum
P08172598A0237|89 101|kb mRNA species
P08172653A1589|11 17|regions
P08172653A1589|38 48|TnT isoforms
P08172653A1589|69 76|addition
P08172653A1589|80 91|modification
P08172653A1589|101 109|sequences
P08172653A1589|124 130|members
P08172653A1589|149 154|family
P08172905A0000|3 7|class
P08172905A0000|25 45|alanine tRNA synthetase
P08172905A0000|59 73|RNA miniduplexes
P08172905A0000|93 103|acceptor end
P08172905A0000|106 116|alanine tRNA
P08172905A0000|135 145|U70 base pair
P08173532A0000|6 17|reaction time
P08173532A0000|41 46|target
P08173532A0000|104 113|S2 location
P08173532A0000|128 138|target onset
P08173532A0000|143 154|facilitation
P08173693A0390|7 16|study group
P08173693A0390|34 44|innervation
P08173693A0390|58 65|patients
P08173693A0390|76 94|angina pectoris class
P08173814A0132|5 11|viruses
P08173814A0132|23 39|host cell machinery
P08173814A0132|48 56|existence
P08173814A0132|60 71|interference
P08173814A0132|81 89|processes
P08173814A0132|127 140|host physiology
P08175031A0566|0 8|Treatment
P08175188A0685|1 13|concentration
P08175188A0685|20 25|ppm SO2
P08175188A0685|34 41|decrease
P08175188A0685|46 59|baseline values
P08176742A0190|23 37|assay conditions
P08176742A0190|46 52|studies
P08176742A0190|58 77|transposition pathway
P08177143T0000|5 17|cell carcinoma
P08177143T0000|20 27|children
P08177143T0000|35 45|institution
P08177143T0000|47 56|experience
P08178446A1160|20 24|ICP10
P08178446A1160|47 57|ras activity
P08178446A1160|64 72|TM segment
P08178446A1160|117 133|signaling pathways
P08178490A0879|22 35|signal function
P08178490A0879|43 56|anchor function
P08178490A0879|64 72|K SA domain
P08178572A1118|4 30|concensus poly A addition sites
P08178572A1118|49 57|base pairs
P08178572A1118|81 87|protein
P08178572A1118|96 101|region
P08179827T0000|0 6|Factors
P08179827T0000|34 45|transmission
P08179827T0000|48 71|hepatitis B virus infection
P08179827T0000|74 78|Korea
P08180129A1256|0 7|Exposure
P08180129A1256|16 32|TPA concentrations
P08180129A1256|45 51|content
P08180129A1256|59 69|transcripts
P08181755A0989|0 15|Northern analysis
P08181755A0989|28 42|pcbAB transcript
P08181755A0989|59 68|transcript
P08182041A1067|3 9|results
P08182041A1067|32 43|requirements
P08182041A1067|47 55|induction
P08182041A1067|58 62|PEPCK
P08182041A1067|73 82|inhibition
P08182041A1067|84 90|insulin
P08182041A1067|102 121|CREB activation domain
P08182041A1067|126 142|PEPCK TATA sequence
P08182041A1067|165 177|hepatoma cells
P08182056A0695|7 12|degree
P08182056A0695|15 26|conservation
P08182056A0695|43 62|NQO1 gene organization
P08182056A0695|65 72|sequence
P08182056A0695|86 93|NQO2 gene
P08182056A0695|111 116|member
P08182056A0695|122 134|NQO gene family
P08182171A0000|3 10|efficacy
P08182171A0000|14 42|Propionibacterium acnes product
P08182171A0000|46 54|treatment
P08182171A0000|57 72|coliform mastitis
P08182171A0000|106 113|infusion
P08183552T0000|8 16|eps15 gene
P08183552T0000|26 48|tyrosine kinase substrate
P08183552T0000|62 70|evolution
P08183915A0000|27 33|protein
P08183915A0000|39 47|precursor
P08183915A0000|52 61|p50 subunit
P08183915A0000|64 91|transcription factor NF-kappa B
P08183915A0000|104 120|p70 I kappa B protein
P08183915A0000|121 132|I kappa B gamma
P08183915A0000|167 176|amino acids
P08183915T0000|11 18|splicing
P08183915T0000|21 34|RNA transcripts
P08183915T0000|53 69|p105 NF-kappa B gene
P08183915T0000|79 98|I kappa B gamma isoforms
P08183915T0000|122 131|activities
P08184923A0829|7 11|L-NNA
P08184923A0829|36 43|increase
P08184923A0829|88 95|exposure
P08185288A0106|3 12|experiment
P08185288A0106|45 52|subjects
P08185288A0106|80 98|respiration chambers
P08185288A0106|112 118|morning
P08185288A0106|122 130|afternoon
P08185288A0106|133 142|min cycling
P08185288A0106|168 171|kg m.
P08187085A0086|5 18|rearrangements
P08187085A0086|30 38|formation
P08187085A0086|49 53|genes
P08187085A0086|64 83|tyrosine kinase domain
P08187085A0086|104 115|end sequences
P08187085A0086|126 130|genes
P08187088A0530|16 29|heterozygosity
P08187088A0530|57 61|cases
P08187088A0530|73 85|chromosomes 3p
P08187177A0405|7 21|amino acid change
P08187177A0405|40 52|sorting signal
P08187177A0405|64 74|interaction
P08188258A0000|13 22|synthetase
P08188258A0000|26 46|prolyl-tRNA synthetase
P08188258A0000|64 70|classes
P08188258A0000|87 97|synthetases
P08188258A0000|153 160|pathways
P08188290A0544|8 19|sequence data
P08188290A0544|40 56|TCRAC/TCRDC region
P08188290A0544|72 86|polymerase chain
P08188290A0544|101 105|assay
P08188290A0544|118 127|expression
P08188290A0544|143 159|TCRAJ gene segments
P08188603A0230|4 11|analysis
P08188603A0230|52 57|degree
P08188603A0230|58 65|homology
P08188603A0230|96 103|CPA2 gene
P08188603A0230|120 126|subunit
P08188603A0230|148 157|synthetase
P08188603A0230|158 162|CPS-A
P08188606A1034|0 18|Restriction analysis
P08188606A1034|22 42|Southern hybridization
P08188606A1034|54 61|presence
P08188606A1034|64 69|Tn5422
P08188606A1034|126 132|strains
P08188606A1034|147 153|strains
P08188606A1034|162 178|cadmium resistance
P08188606A1034|184 193|chromosome
P08188978A0822|13 19|latency
P08188978A0822|27 35|ECG R-wave
P08188978A0822|51 63|MSNA burst peak
P08188978A0822|103 107|sleep
P08188978A0822|121 139|pulse-synchronicity
P08189174A0148|0 5|DESIGN
P08189174A0148|17 21|study
P08189174A0148|39 43|women
P08189174A0148|53 57|years
P08189174A0148|76 96|breast cancer screening
P08189174A0148|100 105|living
P08189174A0148|119 125|Utrecht
P08189498T0000|0 13|Identification
P08189498T0000|44 48|Marek
P08189498T0000|49 60|disease virus
P08189498T0000|73 84|repeat region
P08189498T0000|117 127|polypeptide
P08189503A0000|22 30|cDNA clone
P08189503A0000|34 61|mouse hepatitis virus strain A59
P08189503A0000|89 95|pMIDI-C
P08189503A0000|98 116|cassette mutagenesis
P08189503A0000|127 135|mechanism
P08189503A0000|138 148|coronavirus
P08189503A0000|159 171|mRNA synthesis
P08189533A0203|40 46|product
P08189533A0203|64 68|forms
P08189533A0203|108 134|baculovirus expression system
P08189533A0203|149 164|vaccinia virus/T7
P08189533A0203|165 170|vTF7-3
P08189533A0203|171 186|expression system
P08189533A0919|0 17|Gel electrophoresis
P08189533A0919|28 45|immunoblot analyses
P08189533A0919|61 69|fractions
P08189533A0919|89 93|cells
P08189533A0919|111 117|amounts
P08189533A0919|142 148|cytosol
P08189533A0919|153 163|association
P08189533A0919|183 188|matrix
P08190633A0000|3 25|transcription factor AP-2
P08190633A0000|53 62|chromosome
P08190633A0000|70 77|HLA locus
P08190633A0273|9 16|AP-2 mRNA
P08190633A0273|31 35|exons
P08190633A0273|52 57|region
P08191910A0228|0 8|San Martin
P08191910A0228|23 28|traits
P08191910A0228|58 63|lodges
P08191910A0228|89 97|abilities
P08191910A0228|100 109|strategist
P08191910A0228|122 126|ruler
P08192140A0209|3 14|participants
P08192140A0209|36 58|hepatitis B vaccine trials
P08192140A0209|60 68|Amsterdam
P08192140A0209|75 85|New York City
P08192140A0209|95 106|San Francisco
P08192451A0885|8 16|treatment
P08192451A0885|28 35|decrease
P08192451A0885|51 56|uptake
P08192451A0885|59 63|Rh123
P08192451A0885|69 76|increase
P08192451A0885|79 87|NAO uptake
P08192795T0000|26 32|purpura
P08192795T0000|43 60|lupus erythematosus
P08193147A0831|0 9|Comparison
P08193147A0831|17 32|crystal structure
P08193147A0831|35 52|Desulfovibrio gigas
P08193147A0831|61 69|Kissinger
P08193147A0831|103 110|topology
P08193147A0831|145 152|elements
P08193147A0831|180 183|Dg Fd
P08194139A0498|0 10|CONCLUSIONS
P08194139A0498|11 38|Serum prolactin concentrations
P08194139A0498|55 64|variations
P08194549A0000|22 29|kayakers
P08194549A0000|55 66|relationship
P08194549A0000|82 86|power
P08194549A0000|97 101|onset
P08194549A0000|103 126|blood lactate accumulation
P08194753A0157|19 26|sequence
P08194753A0157|29 33|rhp51
P08194753A0157|59 63|boxes
P08194753A0157|97 103|element
P08194753A0157|116 121|region
P08194970A0000|0 4|Women
P08194970A0000|6 18|opportunities
P08194970A0000|84 88|carer
P08194970A0000|95 100|family
P08194970A0000|107 116|Trudy Wynne
P08195186A0000|8 19|cDNA sequence
P08195186A0000|36 46|T lymphocyte
P08195186A0000|82 88|protein
P08195186A0000|121 130|retrovirus
P08195186A0000|148 167|amino acid transporter
P08195186A0000|168 176|ecoR/CAT1
P08195186A0000|180 187|RNA blots
P08195186A0000|204 216|Tea expression
P08195186A0000|219 230|T lymphocytes
P08195186A0000|234 238|liver
P08195186A0000|239 245|MacLeod
P08195186A0000|252 257|Finley
P08195186A0000|261 266|Kakuda
P08195216A1022|52 57|subset
P08195216A1022|67 75|sequences
P08195216A1022|87 99|transcription
P08195216A1022|102 112|conjunction
P08195216A1022|117 121|GCN4p
P08195216A1022|144 152|sequences
P08195216A1022|160 174|GCN4p activation
P08195217A0799|20 26|protein
P08195217A0799|45 80|reticulocyte lysate translation product
P08195217A0799|112 118|protein
P08195217A0799|121 133|sodium dodecyl
P08195233A0147|2 9|addition
P08195233A0147|14 19|kinase
P08195233A0147|76 80|genes
P08195233A0147|87 94|position
P08195233A0147|102 111|chromosome
P08195233A0147|139 144|stages
P08195233A0147|147 159|tumorigenesis
P08196607A0280|0 15|Deletion analysis
P08196607A0280|21 32|ICL1 promoter
P08196607A0280|41 54|identification
P08196607A0280|77 91|sequence element
P08196607A0280|92 98|UASICL1
P08196607A0280|100 109|CATTCATCCG
P08196607A0280|146 151|carbon
P08196607A0280|168 177|regulation
P08196607A0280|193 204|reporter gene
P08196616A1112|16 26|interaction
P08196616A1112|29 34|ZAP-70
P08196616A1112|42 46|motif
P08196616A1112|64 71|presence
P08196616A1112|78 93|ZAP-70 SH2 domains
P08196616A1112|106 121|tyrosine residues
P08196616A1112|127 131|motif
P08196616A1112|146 151|ZAP-70
P08196616A1112|168 190|phosphotyrosine residues
P08196616A1112|201 207|binding
P08196616A1112|216 225|SH2 domains
P08196618A0473|0 4|PRL-1
P08196618A0473|28 52|phosphotyrosine substrates
P08196618A0473|56 63|mutation
P08196618A0473|80 94|cysteine residue
P08196618A0473|108 115|activity
P08196624A0593|2 10|Mv1Lu lung
P08196624A0593|21 25|cells
P08196624A0593|26 32|ActR-IB
P08196624A0593|36 49|T beta R-I signal
P08196624A0593|99 107|responses
P08196624A0593|109 119|association
P08196624A0593|142 148|ligands
P08196624A0593|160 168|receptors
P08199204A0746|45 57|PKC activation
P08199204A0746|62 67|effect
P08199204A0746|70 92|tyrosine phosphorylation
P08199204A0746|96 101|PtdIns
P08199204A0746|103 114|P2 production
P08199878T0000|3 9|effects
P08199878T0000|20 39|glucose concentration
P08199878T0000|42 56|brain metabolism
P08199878T0000|74 86|brain ischemia
P08200528A0970|4 11|strategy
P08200528A0970|33 44|Tn903 neo gene
P08200528A0970|51 99|Rhodosporidium toruloides phenylalanine ammonia lyase
P08200528A0970|141 147|control
P08201352A0239|23 40|protein C deficiency
P08201352A0239|40 58|vitamin K antagonists
P08201352A0239|98 109|skin necrosis
P08201758A0125|13 19|patient
P08201758A0125|48 58|obstruction
P08201758A0125|68 77|laparotomy
P08201758A0125|83 87|times
P08201932A0355|10 20|examination
P08201932A0355|37 49|polyarthritis
P08201932A0355|65 70|joints
P08202546A1206|2 9|addition
P08202546A1206|26 49|hUBF-promoter interaction
P08202546A1206|84 90|effects
P08202546A1206|106 112|adducts
P08203260A1204|40 47|neonates
P08203260A1204|54 63|ventilator
P08204348T0000|0 4|VP-16
P08204348T0000|5 14|ifosfamide
P08204348T0000|18 26|cisplatin
P08204348T0000|49 62|cell lung cancer
P08204403A0000|1 5|total
P08204403A0000|10 14|males
P08204403A0000|19 25|females
P08204403A0000|26 33|patients
P08204403A0000|65 69|study
P08204403A0000|84 94|sensitivity
P08204403A0000|97 119|radioimmunoscintigraphy
P08204403A0000|124 128|I-131
P08204403A0000|140 145|CEA/CA
P08204403A0000|160 169|antibodies
P08204426T0001|33 43|ventilation
P08204426T0001|49 63|diaphragm pacing
P08204426T0001|66 74|childhood
P08204426T0001|78 98|implantation technique
P08204426T0001|102 112|indications
P08204824A0000|8 12|clone
P08204824A0000|19 27|cyc07 gene
P08204824A0000|61 66|S phase
P08204824A0000|76 84|cell cycle
P08204824A0000|98 105|cultures
P08204824A0000|108 117|periwinkle
P08204824A0000|118 135|Catharanthus roseus
P08204824A0000|136 140|cells
P08205827A0940|0 10|CONCLUSIONS
P08205827A0940|11 23|Translocation
P08205827A0940|26 33|bacteria
P08205827A0940|36 44|endotoxin
P08205827A0940|68 72|tract
P08205827A0940|80 90|bloodstream
P08205827A0940|105 121|animal experiments
P08205827A0940|129 141|translocation
P08205827A0940|161 168|patients
P08205827A0940|184 188|shock
P08206848A0296|12 20|pyrP genes
P08206848A0296|27 38|polypeptides
P08206848A0296|62 67|masses
P08206867A0874|0 23|Southern blotting analysis
P08206867A0874|34 43|occurrence
P08206867A0874|54 63|COXVb genes
P08206867A0874|69 77|rat genome
P08206991A0466|0 8|Acylation
P08206991A0466|16 30|palmitate analog
P08206991A0466|47 51|Gly-2
P08206991A0466|64 70|alanine
P08206991A0466|83 97|N-myristylation
P08206991A0466|111 123|palmitylation
P08206991A0466|137 141|Cys-3
P08206991A0466|144 148|Cys-6
P08206991A0466|161 166|serine
P08207022T0000|0 17|Subunit composition
P08207022T0000|21 35|domain structure
P08207022T0000|41 75|Spo0A sporulation transcription factor
P08207022T0000|78 93|Bacillus subtilis
P08207232A0503|15 35|mobility shift analysis
P08207232A0503|49 55|NF-IL-6
P08207232A0503|76 82|members
P08207232A0503|89 94|family
P08207232A0503|116 126|NF-IL-6 site
P08207232A0503|132 143|IL-8 promoter
P08207405A0372|5 23|citrus tristeza virus
P08207405A0372|40 49|stunt virus
P08207405A0372|57 65|carnation
P08207405A0372|73 91|fleck virus templates
P08207405A0372|101 123|kb amplification products
P08207405A0372|140 149|sequencing
P08207405A0372|161 169|fragments
P08207405A0372|185 194|HSP70 genes
P08207795A0409|20 27|location
P08207795A0409|33 51|phosphorylation site
P08207795A0409|63 69|protein
P08207795A0409|83 103|mutagenesis procedures
P08207805A0000|3 31|p53 tumor suppressor gene product
P08207805A0000|61 67|protein
P08207805A0000|103 111|activator
P08207805A0000|115 123|repressor
P08208247T0030|10 17|analysis
P08208247T0030|31 41|segment 64AB
P08208247T0030|43 48|region
P08208247T0030|70 90|acid decarboxylase gene
P08208540A0000|0 13|Rearrangements
P08208540A0000|19 27|NFKB2 gene
P08208540A0000|53 64|malignancies
P08208540A0000|81 92|significance
P08208540A0000|100 110|alterations
P08208540A0417|0 6|Cloning
P08208540A0417|10 19|sequencing
P08208540A0417|38 42|cDNAs
P08208540A0417|70 77|splicing
P08208540A0417|91 99|gene codes
P08208540A0417|106 113|proteins
P08208540A0417|127 132|p84/85
P08208540A0417|157 165|rel domain
P08208540A0417|181 194|ankyrin repeats
P08208540A0417|211 226|carboxy-terminus
P08208540A0417|246 258|ankyrin repeat
P08208540A1114|9 29|co-transfection assays
P08208540A1114|39 60|NFKB2 expression vectors
P08208540A1114|64 68|kappa
P08208540A1114|77 92|reporter plasmids
P08208540A1114|105 112|NFKB2 p85
P08208540A1114|138 155|repressor functions
P08208540A1114|171 178|NFKB2 p52
P08208618A1334|4 9|HR21ap
P08208618A1334|18 24|HR21Xap
P08208618A1334|43 52|inhibition
P08208618A1334|55 64|Sp1 binding
P08209051T0000|21 27|therapy
P08209051T0000|36 43|fibrosis
P08209051T0000|46 53|hospital
P08209423T0000|11 16|frames
P08209423T0000|24 41|nucleotide sequence
P08209423T0000|48 70|MDV-1 BamHI-D DNA fragment
P08209423T0000|71 78|evidence
P08209423T0000|82 89|splicing
P08209423T0000|111 126|glycoprotein gene
P08209772A0167|3 9|ns2 gene
P08209772A0167|25 36|reading frame
P08209772A0167|76 82|protein
P08209772A0167|86 95|amino acids
P08212571A0597|0 14|Co-transfection
P08212571A0597|33 39|plasmid
P08212571A0597|48 54|viruses
P08212571A0597|68 82|tat ORF mutations
P08212571A0597|99 104|levels
P08212571A0597|107 121|virus production
P08212571A0597|142 148|effects
P08212571A0597|155 161|mutants
P08212571A0971|0 7|Analysis
P08212571A0971|21 31|rev proteins
P08212571A0971|47 51|cells
P08212571A0971|73 80|proteins
P08212571A0971|100 104|cells
P08212571A0971|123 132|tat mutants
P08212571A0971|165 173|mutations
P08212571A0971|202 220|tat expression vector
P08212897A0404|3 23|hydrophobicity profile
P08212897A0404|29 45|methyltransferase
P08212897A0404|56 63|presence
P08212897A0404|86 105|transmembrane domains
P08213235A1024|0 10|Measurement
P08213235A1024|29 36|altitude
P08213235A1024|78 85|newborns
P08213235A1024|87 93|infants
P08213747A0000|27 36|prevalence
P08213747A0000|44 68|immunodeficiency virus type
P08213747A0000|70 74|HIV-1
P08213747A0000|75 83|infection
P08213747A0000|157 167|differences
P08213747A0000|183 189|factors
P08213747A0000|190 196|history
P08213747A0000|218 225|diseases
P08213747A0000|245 253|behaviors
P08213747A0000|257 263|authors
P08213747A0000|289 296|analysis
P08213747A0000|299 325|baseline HIV-1 seroprevalence
P08213747A0000|329 344|HIV-1 risk factors
P08213747A0000|422 428|centers
P08213747A0000|433 444|United States
P08213747A0000|445 464|Baltimore/Washington
P08213747A0000|469 478|Pittsburgh
P08213747A0000|478 484|Chicago
P08213747A0000|488 497|Los Angeles
P08216115A0158|3 10|patients
P08216115A0158|16 20|group
P08216115A0158|36 44|catheters
P08216115A0158|56 63|oxytocin
P08216115A0158|91 100|percentile
P08216115A0158|110 117|activity
P08216115A0158|145 150|labour
P08216115A0158|162 167|parity
P08217862A1336|9 19|development
P08217862A1336|25 47|rat conditioning paradigm
P08217862A1336|81 87|ability
P08217862A1336|107 119|nerve activity
P08217862A1336|133 140|subjects
P08217862A1336|152 157|number
P08217862A1336|183 189|strains
P08217862A1336|217 222|states
P08218056A0000|3 16|ultrastructure
P08218056A0000|26 32|vessels
P08218056A0000|69 76|patients
P08218056A0000|99 106|subjects
P08218230A1505|13 18|region
P08218230A1505|27 34|sequence
P08218230A1505|47 57|binding site
P08218230A1505|76 94|transcription factor
P08218230A1505|95 104|hepatocyte
P08218230A1505|112 117|factor
P08218230A1505|119 123|HNF-1
P08218230A1505|126 134|positions
P08218230A1920|52 77|glucocorticoid inducibility
P08218230A1920|82 90|HNF-1 site
P08218230A1920|101 108|promoter
P08218230A1920|121 132|determinants
P08218230A1920|150 156|control
P08218230A1920|162 194|Xenopus fibrinogen B beta subunit gene
P08218230A1920|197 201|cells
P08218230A1920|212 222|liver tissue
P08219081A0000|3 12|PRB-1b gene
P08219081A0000|34 42|component
P08219081A0000|68 84|PR-1 protein family
P08219227A0830|0 10|Replacement
P08219227A0830|43 50|AP-1 site
P08219227A0830|59 63|level
P08219227A0830|81 88|activity
P08219227A0830|121 128|sequence
P08219227A0830|132 142|replacement
P08219227A0830|148 155|AP-1 site
P08219227A0830|175 182|activity
P08220494A0231|8 15|promoter
P08220494A0231|35 40|origin
P08220494A0231|51 56|planta
P08220494A0231|65 78|bp cyt-1 element
P08220494A0231|95 100|region
P08220494A0231|124 139|promotor activity
P08220494A0231|157 165|root cells
P08220494A0231|166 178|tobacco plants
P08220621T0000|9 19|manuscripts
P08220621T0000|41 46|system
P08221251A0239|35 43|diagnosis
P08221251A0239|45 50|tumors
P08222384A0455|0 4|SIN-1
P08222384A0455|10 18|influence
P08222384A0455|38 47|parameters
P08222384A0455|53 76|surface electrocardiogram
P08222556T0000|0 5|Effect
P08222556T0000|8 12|aging
P08222556T0000|34 40|muscles
P08222618A0000|8 23|computer programs
P08222618A0000|29 47|logit transformation
P08222618A0000|54 61|analysis
P08222618A0000|72 77|curves
P08223425T0000|3 15|yeast SSS1 gene
P08223425T0000|39 58|protein translocation
P08223425T0000|79 85|protein
P08223425T0000|102 110|reticulum
P08223554A0574|3 9|lengths
P08223554A0574|23 38|polypeptide chain
P08223554A0574|55 60|enzyme
P08223554A0574|67 80|transit peptide
P08223554A0574|92 99|residues
P08223576A1261|3 9|absence
P08223576A1261|12 20|H4PteGlun
P08223576A1261|31 38|T protein
P08223576A1261|56 65|conditions
P08223576A1261|82 90|H4PteGlun
P08223576A1261|117 124|T protein
P08223592A0424|9 18|CCAAT boxes
P08223592A0424|66 87|transcription start site
P08223592A0424|103 108|leader
P08223592A0424|113 123|nucleotides
P08223592A0424|172 191|polyadenylation sites
P08223613A0105|58 64|subunit
P08223613A0105|88 114|synthase/phosphatase complex
P08223613A0105|155 167|cif1 mutations
P08223613A0519|17 24|sequence
P08223613A0519|48 55|products
P08223613A0519|73 81|genes TPS2
P08223613A0519|112 119|subunits
P08223613A0519|124 147|trehalose synthase complex
P08223613A0519|156 168|TSL1 homologue
P08223613A0519|184 191|function
P08223823T0000|0 17|Stroop interference
P08223823T0000|18 29|aging effects
P08223823T0000|45 64|Stroop Color-Word Test
P08223875A0711|0 10|Stimulation
P08223875A0711|16 27|PA production
P08223875A0711|31 46|CD3 cross-linking
P08223875A0711|80 84|cells
P08223875A0711|95 99|cells
P08223875A0711|123 130|activity
P08223875A0711|133 138|p59fyn
P08223875A0711|147 151|cells
P08224260A1248|0 9|CONCLUSION
P08224260A1248|13 17|study
P08224260A1248|46 60|ultrasonography
P08224260A1248|66 75|efficiency
P08224260A1248|99 111|endometriomas
P08224260A1248|127 132|masses
P08224260A1248|138 148|specificity
P08224907A0000|7 26|Southern blot analysis
P08224907A0000|29 35|rat EFIA
P08224907A0000|36 61|gene encoding enhancer factor
P08224907A0000|63 70|subunit A
P08224907A0000|86 96|band pattern
P08224907A0000|101 121|cDNA subfragment probes
P08225657A0000|3 8|effect
P08225657A0000|11 19|ibopamine
P08225657A0000|23 32|furosemide
P08225657A0000|38 45|patients
P08225657A0000|50 59|NYHA Class I
P08225657A0000|63 76|II heart failure
P08225657A0000|91 98|parallel
P08225657A0000|151 155|trial
P08226616A0000|3 11|nit-3 gene
P08226616A0000|28 49|fungus Neurospora crassa
P08226616A0000|64 72|reductase
P08226616A0000|76 81|enzyme
P08226616A0000|119 130|assimilation
P08226776A0990|35 41|process
P08226776A0990|48 52|ratio
P08226776A0990|55 59|delta
P08226776A0990|75 82|delta Hva
P08226777A0936|1 25|Dictyostelium transformant
P08226777A0936|40 45|DdPTPa
P08226780A0160|4 8|motif
P08226780A0160|30 48|protein interactions
P08226780A0160|62 68|ankyrin
P08226780A0160|102 109|proteins
P08226794A0501|0 4|Ala85
P08226794A0501|33 40|activity
P08226798A1124|15 24|CaM binding
P08226798A1124|27 45|HIV envelope proteins
P08226798A1124|78 84|effects
P08226798A1124|91 99|mechanism
P08226798A1124|114 125|cytotoxicity
P08226798A1124|144 153|inhibition
P08226798A1124|176 184|functions
P08226956A1397|18 23|effect
P08226956A1397|26 42|growth temperature
P08226956A1397|60 65|levels
P08226956A1397|68 75|fad7 mRNA
P08226956A1397|82 91|type plants
P08227129T0000|22 27|domain
P08227129T0000|38 49|muscle MyBP-C
P08227129T0000|50 57|C protein
P08227129T0000|83 103|immunoglobulin C2 motif
P08228805A0540|16 23|molecule
P08228805A0540|26 46|TCR signal transduction
P08228805A0540|52 82|guanine nucleotide binding protein
P08228805A0540|83 88|p21ras
P08228805A0540|116 136|protein tyrosine kinase
P08228805A0540|145 153|mechanism
P08228997A0866|3 9|results
P08228997A0866|33 49|lipid accumulation
P08228997A0866|69 79|oxygenation
P08229102A0768|17 33|QLMI questionnaire
P08229102A0768|41 49|potential
P08229102A0768|54 63|instrument
P08229102A0768|90 97|patients
P08229330A0000|4 10|smokers
P08229330A0000|28 34|smoking
P08229826A1145|13 20|response
P08229826A1145|89 96|activity
P08229826A1145|112 118|muscles
P08229826A1145|149 155|objects
P08230418A0812|3 8|action
P08230418A0812|39 48|expression
P08230418A0812|59 64|effect
P08230418A0812|69 76|activity
P08230418A0812|88 92|virus
P08230418A0812|95 99|c-fms
P08230418A0812|100 128|urokinase plasminogen activator
P08230418A0812|138 160|acid phosphatase promoter
P08230418A0812|211 218|activity
P08230418A0812|239 248|frameshift
P08230418A0812|279 288|amino acids
P08230418A0812|294 300|protein
P08230445A0000|3 9|product
P08230445A0000|24 35|reading frame
P08230445A0000|42 66|immunodeficiency virus type
P08230445A0000|68 72|HIV-1
P08230445A0000|95 101|protein
P08230445A0000|117 123|virions
P08230445A0000|131 140|quantities
P08230452A0551|14 21|vaccinia
P08230452A0551|43 56|P1 polyproteins
P08230452A0551|83 99|processing defects
P08230452A0551|102 106|cells
P08230452A0551|133 145|vaccinia virus
P08230452A0551|168 188|poliovirus 3CD protease
P08230452A0551|194 203|processing
P08230452A0551|207 221|assembly defects
P08230452A0551|235 255|complementation system
P08230452A0551|287 301|vaccinia viruses
P08230452A0551|309 323|capsid precursor
P08230452A0551|336 351|poliovirus genome
P08230452A0551|380 393|capsid proteins
P08230452A1489|2 9|contrast
P08230452A1489|10 23|capsid proteins
P08230452A1489|38 48|P1 precursor
P08230452A1489|54 71|valine substitution
P08230452A1489|77 89|amino terminus
P08230452A1489|97 105|VP1-G001V
P08230452A1489|119 133|capsid particles
P08230452A1489|176 182|virions
P08231398A0802|0 6|RESULTS
P08231398A0802|13 22|moth period
P08231398A0802|32 36|total
P08231398A0802|50 62|blood cultures
P08231398A0802|77 86|isolations
P08231398A0802|89 96|episodes
P08231398A0802|99 108|bacteremia
P08231398A0802|111 124|M. tuberculosis
P08231398A0802|140 153|prison patients
P08231398A0802|174 194|immunodeficiency virus
P08231398A0802|215 231|immunosuppression
P08231577A1027|20 25|larynx
P08231577A1027|35 41|rabbits
P08231577A1027|89 93|apnea
P08231816A1473|20 27|extracts
P08231816A1473|49 77|penicillin producing conditions
P08231816A1473|104 111|activity
P08231816A1473|135 150|promoter fragment
P08231816A1473|186 192|IPNS tsp
P08232304A1166|1 6|series
P08232304A1166|9 17|deletions
P08232304A1166|33 40|fragment
P08232304A1166|74 89|promoter activity
P08232304A1166|130 170|chloramphenicol acetyltransferase construct
P08232412A1342|3 12|lemdr1 gene
P08232412A1342|27 49|expression vector pALTNEO
P08232412A1342|77 87|L. enriettii
P08232412A1342|114 118|cells
P08232412A1342|134 144|vinblastine
P08232412A1342|155 160|levels
P08232412A1342|184 188|cells
P08234166A0425|3 17|bioavailability
P08234166A0425|20 27|etodolac
P08234166A0425|32 39|capsules
P08234166A0425|57 66|conditions
P08234166A0425|93 98|humans
P08234166A0425|100 107|capsules
P08234166A0425|116 127|RT conditions
P08234276A0556|18 27|activation
P08234276A0556|44 55|IL-8 promoter
P08234276A0556|77 82|NF-IL6
P08234276A0556|86 106|NF-kappa B binding sites
P08234308T0000|0 5|Notice
P08234308T0000|8 17|retraction
P08237112A0553|2 9|homology
P08237112A0553|28 37|36K protein
P08237112A0553|46 55|structures
P08237112A0553|58 65|proteins
P08237171A0000|27 37|enlargement
P08237171A0000|50 55|recess
P08237171A0000|59 65|patient
P08237171A0000|84 96|hydrocephalus
P08237578A0253|9 23|lipid metabolism
P08237578A0253|27 36|mean values
P08237578A0253|45 57|triglycerides
P08237578A0253|58 68|cholesterol
P08237578A0253|69 83|LDL-cholesterol
P08237578A0253|87 101|HDL-cholesterol
P08237578A0253|122 126|years
P08237578A0253|128 143|Norplant-2 rod use
P08237578A0253|150 155|months
P08237578A0253|183 198|preinsertion mean
P08238626A0248|3 7|PaCO2
P08238626A0248|18 33|baseline brain pHi
P08238626A0248|71 79|blood flow
P08238626A0248|129 133|min-1
P08239164A0551|13 19|isotime
P08239164A0551|41 46|minute
P08239164A0551|49 56|exercise
P08239164A0551|65 71|dyspnea
P08239164A0551|78 85|patients
P08239164A0551|100 110|lung disease
P08239164A0551|119 124|values
P08239164A0551|154 161|patients
P08239164A0551|174 184|lung disease
P08239586T0000|0 6|Effects
P08239586T0000|9 17|diltiazem
P08239586T0000|38 51|nephrotoxicity
P08239586T0000|54 60|rabbits
P08240170A0000|4 8|forms
P08240170A0000|11 23|salmonellosis
P08240170A0000|40 47|feedlots
P08240170A0000|57 65|transport
P08241139A0378|26 35|DNA binding
P08241139A0378|51 58|presence
P08241139A0378|61 66|MgdTDP
P08241139A0378|94 100|absence
P08241139A0378|102 112|nucleotides
P08241656A0189|5 13|knowledge
P08241656A0189|50 60|association
P08241656A0189|67 80|cholelithiasis
P08241656A0189|84 94|Wildervanck
P08241656A0189|96 103|syndrome
P08242861A0368|4 14|4,8-DiMeIQx
P08242861A0368|18 24|A alpha C
P08242861A0368|38 43|p.p.b.
P08243476A1177|5 12|cysteine
P08243476A1177|20 37|tryptophan residues
P08243476A1177|89 98|reductases
P08243476A1177|112 127|Paracoccus enzyme
P08244034T0000|11 43|Leishmania surface glycoprotein GP63
P08244034T0000|59 85|baculovirus expression system
P08244034T0000|95 111|metalloproteinase
P08245013A0000|23 27|basis
P08245013A0000|46 60|destabilization
P08245013A0000|87 95|receptors
P08245013A0000|112 134|receptor down-regulation
P08245013A0000|153 165|understanding
P08245013A0000|177 186|regulation
P08245013A0000|189 197|receptors
P08245013A0000|200 206|agonist
P08245125A0822|0 7|Addition
P08245125A0822|31 43|F-actin nuclei
P08245125A0822|47 56|phalloidin
P08245125A0822|65 74|L266D actin
P08245125A0822|76 82|ability
P08245125A0822|98 106|degrees C.
P08245456A0501|5 9|cells
P08245456A0501|21 25|level
P08245456A0501|73 88|O2-dibutyryl cAMP
P08245456A0501|86 92|Bt2cAMP
P08245456A0501|95 105|combination
P08245456A0501|144 157|IL-5 production
P08245456A0501|174 186|protein levels
P08245461A0700|0 21|Hu-Met-1 mRNA expression
P08245461A0700|30 35|number
P08245461A0700|43 57|T cell tumor lines
P08245461A0700|90 98|phenotype
P08245461A0700|101 105|stage
P08245461A0700|108 118|development
P08245933A0617|7 17|engorgement
P08245933A0617|32 41|treatments
P08246984A0512|0 7|Northern
P08246984A0512|13 20|analysis
P08246984A0512|32 41|expression
P08246984A0512|49 58|PI 3-kinase
P08246984A0512|64 70|tissues
P08246984A0512|74 82|cell lines
P08246984A0923|5 11|results
P08246984A0923|26 34|existence
P08246984A0923|46 63|PI 3-kinase isoforms
P08246984A0923|74 79|family
P08246984A0923|82 86|genes
P08246984A0923|103 112|PI 3-kinase
P08246984A0923|122 129|subunits
P08246987A0260|2 9|addition
P08246987A0260|31 42|kinase domain
P08246987A0260|43 48|p56lck
P08246987A0260|58 68|Src homology
P08246987A0260|87 93|domains
P08246987A0260|117 122|region
P08247005A0584|0 6|Strains
P08247005A0584|17 35|drs2 mutation process
P08247005A0584|39 50|20S precursor
P08247005A0584|62 68|18S rRNA
P08247005A0584|106 113|subunits
P08247043T0000|0 9|Hepatitis B
P08247043T0000|13 32|liver transplantation
P08248246A0838|3 9|complex
P08248246A0838|44 50|complex
P08248246A0838|72 78|binding
P08248246A0838|127 142|R1 gene expression
P08248253A1785|13 24|observations
P08248253A1785|32 39|promoter
P08248253A1785|45 52|enhancer
P08248253A1785|59 74|chicken L-CAM gene
P08248688A0726|18 28|stimulation
P08248688A0726|43 49|nitrate
P08248688A0726|90 101|NO production
P08248688A0726|115 122|molecule
P08249319A0578|26 40|mislocalization
P08249319A0578|46 53|position
P08249319A0578|90 94|field
P08249390A0111|3 10|duration
P08249390A0111|13 28|diabetes mellitus
P08249390A0111|36 43|patients
P08249390A0111|52 57|months
P08249390A0111|61 65|years
P08249390A0111|74 81|patients
P08249390A0111|107 116|infarction
P08251506A0503|10 16|complex
P08251506A0503|55 63|complexes
P08251506A0503|109 116|proteins
P08251506A0503|147 164|DRE oligonucleotide
P08251506A0503|188 196|complexes
P08251506A0503|223 233|cross-links
P08251622A0000|3 10|promoter
P08251622A0000|22 27|region
P08251622A0000|33 69|Brassica napus 2S storage protein napA gene
P08251622A0000|101 109|sequences
P08251622A0000|146 155|expression
P08252067A0917|14 24|comparisons
P08252067A0917|31 37|domains
P08252067A0917|51 61|COOH termini
P08252067A0917|74 79|degree
P08252067A0917|82 91|similarity
P08252067A0917|112 123|conservation
P08252976A0467|0 4|Rinit
P08252976A0467|25 35|resistances
P08252976A0467|39 43|Rdiff
P08252976A0467|83 102|pressure dissipations
P08252976A0467|108 113|system
P08253386A0800|17 25|mechanism
P08253386A0800|28 33|action
P08253386A0800|39 65|fibronectin splicing enhancer
P08253386A0800|81 89|SE element
P08253386A0800|112 119|assembly
P08253386A0800|127 143|splicing complexes
P08253386A0800|166 176|interaction
P08253386A0800|182 188|U2 snRNP
P08253386A0800|193 211|branch site sequences
P08253387A0801|0 9|Inspection
P08253387A0801|12 26|enhancer mutants
P08253387A0801|39 54|trans-activation
P08253387A0801|57 65|hLEF/GAL4
P08253387A0801|89 93|TCF-2
P08253387A0801|118 124|protein
P08253387A0801|136 144|sequences
P08253387A0801|179 186|enhancer
P08253387A1291|14 22|sequences
P08253387A1291|35 44|hLEF HMG box
P08253387A1291|77 86|activation
P08253387A1291|91 106|TCR alpha enhancer
P08253387A1291|123 134|interactions
P08253387A1291|171 177|factors
P08253387A1291|191 198|enhancer
P08253777A0301|1 19|cAMP response element
P08253777A0301|25 39|consensus signal
P08253777A0301|66 71|region
P08253777A0301|108 117|expression
P08253777A0301|147 152|manner
P08253958A0000|1 6|number
P08253958A0000|20 24|tests
P08253958A0000|37 44|presence
P08253958A0000|47 58|Helicobacter
P08253958A0000|74 93|serum immunoglobulin G
P08254738A0428|6 11|series
P08254738A0428|20 28|T antigens
P08254738A0428|51 63|baculoviruses
P08254738A0428|66 73|Sf9 cells
P08254738A0428|87 92|origin
P08254738A0428|102 111|activities
P08254738A0428|118 122|TS677
P08254738A0428|127 131|TS677
P08254738A0428|153 167|T-antigen kinase
P08254738A0428|181 188|T antigen
P08255022A0827|3 8|degree
P08255022A0827|11 23|hypoperfusion
P08255022A0827|80 87|increase
P08255022A0827|97 107|blood volume
P08255022A0827|124 138|blood cell counts
P08255341A0554|3 10|patients
P08255341A0554|39 49|combination
P08255341A0554|52 64|metronidazole
P08255341A0554|66 81|tissue amoebicide
P08255341A0554|85 94|diloxanide
P08255341A0554|103 112|amoebicide
P08255758A0000|34 39|region
P08255758A0000|60 74|retrotransposon
P08255758A0000|91 98|sequence
P08255758A0000|116 125|regulation
P08255758A0000|128 140|homeoproteins
P08257666A0662|12 16|study
P08257666A0662|17 23|lesions
P08257666A0662|29 38|OPT complex
P08257666A0662|50 55|source
P08257666A0662|58 66|afferents
P08257666A0662|98 103|effect
P08257666A0662|118 136|learning performance
P08257754A0711|32 38|results
P08257754A0711|46 56|individuals
P08257754A0711|60 71|HB antibodies
P08257754A0711|87 91|IU/ml
P08257754A0711|125 136|HB antibodies
P08257754A0711|146 150|IU/ml
P08258025A1131|0 10|CONCLUSIONS
P08258025A1131|16 23|patients
P08258025A1131|36 40|range
P08258025A1131|43 60|treatment variables
P08258025A1131|73 86|Karnofsky index
P08258025A1131|106 112|disease
P08258025A1131|132 138|factors
P08258025A1131|155 163|mortality
P08259650A0640|0 25|Nucleotide sequence analysis
P08259650A0640|31 36|HA gene
P08259650A0640|47 53|mutants
P08259650A0640|70 78|phenotype
P08260635A0926|4 9|intron
P08260635A0926|28 35|position
P08260635A0926|57 62|intron
P08260635A0926|69 88|transit peptide region
P08260635A0926|102 111|GAPDH genes
P08260635A0926|135 140|plants
P08261398A0392|17 35|cell lines P388/ADR/3
P08261398A0392|39 48|P388/ADR/7
P08261398A0392|74 92|alpha mRNA transcript
P08261398A0392|94 101|addition
P08261398A0392|113 122|transcript
P08261398A0392|149 162|P388/4 cell line
P08261398A0838|11 23|amplification
P08261398A0838|36 43|strategy
P08261398A0838|55 59|cDNAs
P08261398A0838|75 81|termini
P08261398A0838|106 116|transcripts
P08261398A0838|125 134|P388/ADR/3
P08261398A0838|138 152|P388/ADR/7 cells
P08262041A0727|3 14|phi AP3 factor
P08262041A0727|25 38|phosphoprotein
P08262041A0727|42 47|extent
P08262041A0727|53 67|phosphorylation
P08262041A0727|88 96|cell cycle
P08262054A0565|33 38|domain
P08262054A0565|50 66|membrane protein 2A
P08262054A0565|67 71|LMP2A
P08262054A0565|89 93|virus
P08262054A0565|125 135|Tyr-X-X-Leu
P08262054A0565|147 151|motif
P08262054A0565|183 201|B cell transformation
P08262067A1608|13 20|homology
P08262067A1608|33 37|Cdc43
P08262067A1608|64 70|control
P08262067A1608|73 84|cell polarity
P08262067A1608|123 128|events
P08262067A1608|134 146|establishment
P08262067A1608|149 160|cell polarity
P08262067A1608|164 183|cell wall biosynthesis
P08263933T0000|9 15|cloning
P08263933T0000|25 34|ATPase gene
P08263933T0000|42 70|cyanobacterium Synechocystis sp
P08264579A1209|3 9|cloning
P08264579A1209|36 42|example
P08264579A1209|63 78|characterization
P08264579A1209|92 111|peptide transport gene
P08264582A0750|32 37|domain
P08264582A0750|41 47|mutants
P08264582A0750|79 87|deletions
P08264582A0750|96 104|deletions
P08264582A0750|107 120|point mutations
P08264582A0750|144 160|amino acid residues
P08264582A0750|181 186|region
P08264582A0750|198 206|signaling
P08264583A0520|23 27|basis
P08264583A0520|52 59|extracts
P08264583A0520|80 86|variety
P08264583A0520|98 106|cell lines
P08264583A0520|124 130|ability
P08264583A0520|137 157|test plasmid substrates
P08264591A1190|33 39|subunit
P08264591A1190|41 53|RNA polymerase
P08264591A1190|59 63|TFIIB
P08264591A1190|76 87|determinants
P08264591A1190|90 120|transcription start site selection
P08264591A1190|153 160|function
P08264591A1190|179 189|interaction
P08264591A1190|205 212|proteins
P08264617A0000|11 20|expression
P08264617A0000|32 40|EGFR/ErbB
P08264617A0000|42 49|receptor
P08264617A0000|52 68|NIH 3T3 fibroblasts
P08264617A0000|102 107|events
P08264617A0000|122 145|ErbB-3 signal transduction
P08264617A0000|150 165|ligand activation
P08264628A0418|0 25|Oligonucleotide competitors
P08264628A0418|47 59|accessibility
P08264628A0418|85 90|TIF-IB
P08264628A0418|90 94|TFIID
P08264628A0418|98 103|TFIIIB
P08264631A0746|13 18|region
P08264631A0746|26 37|ADR1 activity
P08264631A0746|76 89|ADR1 DNA binding
P08264631A0746|99 119|ADH2 promoter sequences
P08264650A0925|0 7|Analysis
P08264650A0925|10 16|strains
P08264650A0925|28 43|mds1 null mutation
P08264650A0925|102 107|growth
P08264650A0925|132 138|meiosis
P08264664A0128|0 6|TGF beta
P08264664A0128|8 17|expression
P08264664A0128|42 57|AP-1 binding sites
P08264664A0128|79 87|promoters
P08265602T0000|5 16|Ala mutations
P08265602T0000|43 49|packing
P08265602T0000|55 74|transmembrane segment
P08265602T0000|77 95|phage M13 coat protein
P08265955T0000|9 14|change
P08267658A0391|18 25|solution
P08267658A0391|50 61|lactobionate
P08267658A0391|60 65|KH2PO4
P08267658A0391|66 70|MgSO4
P08267658A0391|74 82|raffinose
P08267658A0391|107 118|preservation
P08267658A0391|121 134|rat hepatocytes
P08267658A0391|147 166|drug transport studies
P08267667A0748|8 21|administration
P08267667A0748|32 36|mg/kg
P08267667A0748|88 95|deficits
P08267667A0748|158 176|learning acquisition
P08267667A0748|219 236|h memory acquisition
P08267667A0748|282 297|h memory retention
P08267667A0748|348 363|h memory retrieval
P08268718A0676|5 15|bcl3 protein
P08268718A0676|46 54|complexes
P08268833T0000|14 19|action
P08268833T0000|22 33|cyclosporin A
P08268833T0000|34 42|Sandimmun
P08268833T0000|46 56|application
P08268833T0000|69 77|arthritis
P08268912A0657|7 28|translation experiments
P08268912A0657|75 81|protein
P08268912A0657|85 92|mobility
P08268912A0657|106 126|SDS polyacrylamide gels
P08269424A0339|15 28|administration
P08269424A0339|48 57|ACTH levels
P08269424A0339|84 92|tumor side
P08269424A0339|98 105|patients
P08269439X0000|11 19|analgesia
P08269439X0000|28 32|niche
P08269439X0000|36 43|Talwin Nx
P08269439X0000|55 65|Pentazocine
P08269439X0000|87 91|agent
P08269439X0000|98 107|management
P08270257A0551|1 24|sequence homology analysis
P08270257A0551|37 43|nm23-H1
P08270257A0551|50 60|homolog gene
P08270257A0551|71 79|NDP-K beta
P08270257A0551|99 108|boundaries
P08270257A0551|140 146|species
P08270580A0155|11 18|response
P08270580A0155|35 45|combination
P08270580A0155|48 60|amphotericin B
P08270580A0155|64 76|cotrimoxazole
P08270985A0590|0 16|Response durations
P08273122A0708|0 6|RESULTS
P08273122A0708|12 20|beginning
P08273122A0708|26 37|QA/QI process
P08273122A0708|38 47|monitoring
P08273122A0708|50 77|blood administration practices
P08273122A0708|91 98|variance
P08273122A0708|116 140|blood administration policy
P08273122A0708|157 163|percent
P08273122A0708|166 170|blood
P08273122A0708|174 194|component transfusions
P08274774A0958|2 9|addition
P08274774A0958|10 20|REP21 plants
P08274774A0958|52 56|range
P08274774A0958|59 71|tobamoviruses
P08274774A0958|81 97|tomato mosaic virus
P08274774A0958|98 104|tobacco
P08274774A0958|114 124|mosaic virus
P08274774A0958|125 130|TMV-U5
P08274774A0958|136 141|tomato
P08274774A0958|150 160|mosaic virus
P08274774A0958|164 182|ribgrass mosaic virus
P08275618A0457|0 9|Drug effect
P08275618A0457|51 58|patients
P08275618A0457|63 71|cirrhosis
P08275618A0457|82 89|subjects
P08275618A0457|102 106|ratio
P08275618A0457|109 118|effect area
P08275618A0457|127 131|curve
P08275618A0457|134 150|concentration area
P08275618A0457|159 163|curve
P08275618A0457|165 171|measure
P08275618A0457|174 184|sensitivity
P08275618A0457|220 227|patients
P08275618A0457|232 240|cirrhosis
P08275618A0457|254 261|subjects
P08276234A0119|9 16|evidence
P08276234A0119|59 65|protein
P08276234A0119|77 84|activity
P08276234A0119|90 102|c-fos promoter
P08276234A0119|121 126|effect
P08276234A0119|129 140|DNA structure
P08276336A0371|16 23|analysis
P08276336A0371|41 53|colonoscopies
P08276336A0371|59 66|patients
P08276336A0371|84 95|relationship
P08276336A0371|129 134|polyps
P08276732A0799|11 19|decrement
P08276732A0799|21 34|DPOAE amplitude
P08276732A0799|50 59|time period
P08276732A0799|74 80|measure
P08276732A0799|83 96|susceptibility
P08276732A0799|110 115|trauma
P08276762T0000|0 5|Effect
P08276762T0000|14 30|base substitutions
P08276762T0000|33 48|glycine-870 codon
P08276762T0000|51 71|gramicidin S synthetase
P08276762T0000|81 97|proline activation
P08276851A0347|12 24|Pay4p sequence
P08276851A0347|55 61|domains
P08276851A0347|80 92|relationships
P08276851A0347|120 127|proteins
P08276851A0347|148 156|processes
P08276851A0347|178 187|biogenesis
P08276851A0347|204 219|protein transport
P08276851A0347|220 235|cell cycle control
P08276851A0347|254 263|regulation
P08276854A1894|3 9|results
P08276854A1894|21 29|structure
P08276854A1894|35 53|decorin gene promoter
P08276854A1894|83 102|proteoglycan promoter
P08276854A1894|139 152|pur/pyr segment
P08276854A1894|170 179|regulation
P08276854A1894|181 197|gene transcription
P08276865A1188|3 30|kinase inhibitor staurosporine
P08276865A1188|32 37|microM
P08276865A1188|70 75|growth
P08276865A1188|90 99|activation
P08276865A1188|102 107|p21ras
P08276865A1188|111 119|MAP kinase
P08276865A1188|148 160|protein kinase
P08276865A1188|171 181|LPA receptor
P08276865A1188|184 199|p21ras activation
P08276871A1001|30 37|identity
P08276871A1001|72 80|% identity
P08276871A1001|100 112|transmembrane
P08276871A1001|127 133|domains
P08277632A0997|3 14|survival rate
P08277632A0997|22 27|months
P08277632A0997|32 39|patients
P08277632A0997|44 52|N2 disease
P08277632A0997|65 76|R2b operation
P08278423A0147|0 6|Mothers
P08278423A0147|27 39|abnormalities
P08278423A0147|80 87|children
P08278423A0147|105 128|disaccharide intolerances
P08278548A0597|24 35|psaL products
P08278548A0597|40 47|isoforms
P08278548A0597|83 92|mobilities
P08278548A0597|95 126|polyacrylamide gel electrophoresis
P08278548A0597|133 143|psaE product
P08278548A0597|151 158|isoforms
P08278929A0866|10 24|SPF type V embryos
P08278929A0866|53 60|% ethanol
P08278929A0866|75 79|ml CRS
P08278929A0866|79 86|controls
P08278929A0866|102 108|embryos
P08278929A0866|116 127|VSD incidence
P08278929A0866|151 160|% incidence
P08278929A0866|165 172|controls
P08279098T0001|29 39|dystrophies
P08279098T0001|42 55|myopia patients
P08280476A0602|5 11|studies
P08280476A0602|22 30|HIV-1 HXB2
P08280476A0602|34 55|HIV-1 Z2Z6 core enhancers
P08280476A0602|66 75|Z2Z6 strain
P08280476A0602|86 98|point mutation
P08280925A0261|36 44|responses
P08280925A0261|51 61|C57Bl/6 mice
P08280925A0261|118 123|groups
P08280925A0261|122 132|differences
P08280925A0261|173 182|antibodies
P08281153A0543|24 29|degree
P08281153A0543|32 43|conservation
P08281153A0543|46 60|intron sequences
P08281153A0543|83 89|species
P08281536A0626|0 12|Interleukin-6
P08281536A0626|34 43|metastasis
P08281536A0626|53 58|myxoma
P08281634A1801|5 14|parameters
P08281634A1801|17 30|iron metabolism
P08281634A1801|40 47|ferritin
P08281740A0000|0 8|Responses
P08281740A0000|14 39|Plowright Rinderpest vaccine
P08281740A0000|44 49|calves
P08281740A0000|60 65|cattle
P08281740A0000|68 73|Uganda
P08281740A0000|90 99|production
P08281740A0000|102 114|IgG antibodies
P08281740A0000|132 136|weeks
P08281740A0000|145 154|ELISA assay
P08282501A0358|17 22|number
P08282501A0358|33 53|angiography procedures
P08282501A0358|77 87|conclusions
P08282501A0358|107 117|differences
P08282501A0358|141 146|agents
P08282501A0358|156 162|grade-2
P08282501A0358|166 172|grade-3
P08282501A0358|180 185|events
P08282576A0297|0 6|Tumours
P08282576A0297|12 20|cavum oris
P08282576A0297|24 33|oropharynx
P08282576A0297|36 43|T1-stage
P08282576A0297|65 69|cases
P08282749A1474|0 5|Thomas
P08282749A1474|6 21|Hospital solution
P08282749A1474|32 35|% CO2
P08282749A1474|54 59|demand
P08282749A1474|74 83|myocardium
P08282749A1474|106 113|duration
P08282749A1474|123 128|arrest
P08283292A0779|0 5|Plasma
P08283292A0779|14 43|liver cholesterol concentrations
P08283292A0779|72 78|control
P08283292A0779|103 109|control
P08283292A0779|123 128|groups
P08283292A0779|132 136|diets
P08283292A0779|147 152|pectin
P08283292A0779|160 164|fiber
P08283292A0779|188 199|control group
P08283531A0700|3 26|Stryker frame modification
P08283531A0700|40 61|Dornier HM3 lithotriptor
P08283531A0700|79 91|visualization
P08283531A0700|101 112|localization
P08283531A0700|129 135|calculi
P08283531A0700|157 162|gantry
P08284227A0336|19 23|cells
P08284227A0336|46 61|kb mRNA transcript
P08284227A0336|75 82|contrast
P08284227A0336|89 104|cell types Id1 mRNA
P08284227A0336|131 142|cycling cells
P08284227A0336|171 178|cultures
P08284337A0825|19 27|screening
P08284337A0825|30 40|IHD patients
P08284337A0825|66 70|means
P08284337A0825|81 93|cardiologists
P08284337A0825|97 106|internists
P08284337A0825|126 131|levels
P08284337A0825|134 141|distress
P08284337A0825|152 159|patients
P08285710A0634|13 26|transcript mRNA
P08285710A0634|40 47|Northern
P08285710A0634|53 64|blot analysis
P08285710A0634|83 90|position
P08285710A0634|119 128|initiation
P08285710A0634|129 144|protein synthesis
P08286035A0587|13 31|sequence information
P08286035A0587|36 40|c11/1
P08286035A0587|100 104|PMNLs
P08286035A0587|110 122|transcription
P08286035A0587|127 137|combination
P08286035A0587|140 162|polymerase chain reaction
P08286035A0587|168 174|methods
P08288240A0304|3 20|sequence similarity
P08288240A0304|37 41|SCG10
P08288240A0304|45 52|stathmin
P08288240A0304|108 112|genes
P08288240A1343|59 67|SCG10 gene
P08288240A1343|75 85|duplication
P08288240A1343|89 100|modification
P08288240A1343|126 143|stathmin/Lap18 gene
P08288554A0295|10 26|amino acid sequence
P08288554A0295|32 44|mouse HO-1 gene
P08288554A0295|105 111|protein
P08288554A0295|113 131|mouse BALBc/3T3 cells
P08288596A0663|42 54|transcription
P08288596A0663|57 63|rGH-TRE
P08288596A0663|67 72|TREpal
P08288596A0663|79 84|ME-TRE
P08288596A0663|88 93|F2-TRE
P08288596A0663|104 112|templates
P08288596A0663|142 146|front
P08288596A0663|163 170|promoter
P08288596A0663|187 207|TATA box binding protein
P08288596A0663|230 243|binding protein
P08288596A0663|244 251|sequence
P08288606A0240|6 20|polymerase chain
P08288606A0240|35 42|approach
P08288606A0240|60 71|pair fragment
P08288606A0240|78 87|sialymotif
P08288606A0240|97 108|placenta mRNA
P08288606A0240|128 132|probe
P08288606A0240|135 139|clone
P08288606A0240|151 164|coding sequence
P08288606A0240|194 204|cDNA library
P08288622A0725|13 20|analysis
P08288622A0725|44 56|heterogeneity
P08288622A0725|62 68|HDC mRNA
P08288622A0725|81 89|insertion
P08288622A0725|102 115|intron sequence
P08288622A0725|140 159|splicing acceptor site
P08288633A0144|34 54|Caenorhabditis elegans
P08288633A0144|66 76|polypeptide
P08288633A0144|83 99|amino acid residues
P08288633A0144|100 104|CeGAP
P08288633A0144|119 124|domain
P08288633A0144|129 146|sequence similarity
P08288633A0144|165 171|segment
P08288633A0144|189 201|protein region
P08288633A0144|239 246|proteins
P08288633A0144|251 262|Rho subfamily
P08289339A0527|10 20|exonuclease
P08289339A0527|24 33|protection
P08289339A0527|54 63|core region
P08289339A0527|78 82|sides
P08289339A0527|125 133|sequences
P08289341A1202|0 9|Repression
P08289341A1202|72 77|copies
P08289341A1202|78 82|E2-RS
P08289342A0931|1 6|mutant
P08289342A0931|25 38|resolution site
P08289342A0931|58 71|DNA replication
P08289342A0931|83 87|assay
P08289357A0724|3 9|results
P08289357A0724|46 53|function
P08289357A0724|73 80|elements
P08289593A1404|49 54|MK-801
P08289593A1404|77 87|cocaine dose
P08289593A1404|96 100|mg/kg
P08289593A1404|110 116|vehicle
P08289593A1404|142 146|mg/kg
P08289593A1404|165 170|MK-801
P08289593A1404|212 219|toxicity
P08289593A1404|222 228|cocaine
P08289593A1404|231 238|urethane
P08289783A0000|3 7|Oct-3
P08289783A0000|8 18|gene product
P08289783A0000|36 44|POU family
P08289783A0000|47 66|transcription factors
P08289783A0000|74 82|candidate
P08289783A0000|103 126|differentiation decisions
P08289783A1476|18 28|mutagenesis
P08289783A1476|42 48|RAREoct
P08289783A1476|80 89|activation
P08289783A1476|92 96|Oct-3
P08289783A1476|97 104|promoter
P08289783A1476|107 114|P19 cells
P08289783A1476|156 165|repression
P08289783A1476|185 191|EC cells
P08289793A1226|37 42|effect
P08289793A1226|45 52|COUP-TFs
P08289793A1226|80 85|effect
P08289793A1226|125 132|enhancer
P08289831A0290|0 7|Analysis
P08289831A0290|10 16|mig/CAT
P08289831A0290|25 34|constructs
P08289831A0290|74 78|mouse
P08289831A0290|87 94|cell line
P08289831A0290|130 136|element
P08289831A0290|137 145|gamma RE-1
P08289834A0341|20 28|test cells
P08289834A0341|29 33|Atr-I
P08289834A0341|48 55|TGF-beta
P08289834A0341|56 62|activin
P08289834A0341|84 90|protein
P08290278A0374|38 48|Myc function
P08290278A0374|53 81|candidate tumor suppressor genes
P08290421A0165|5 13|knowledge
P08290421A0165|34 41|acidosis
P08290421A0165|71 81|association
P08290421A0165|86 91|Alport
P08290421A0165|93 100|syndrome
P08290421A0165|110 116|patient
P08291233A0000|1 9|cDNA clone
P08291233A0000|26 49|chicken embryo cDNA library
P08291233A0000|85 89|probe
P08291233A0000|104 111|U3 region
P08291233A0000|117 135|Rous sarcoma virus LTR
P08291620A0372|8 15|patterns
P08291620A0372|18 34|locomotor behavior
P08291620A0372|51 65|torso morphology
P08291620A0372|82 92|anthropoids
P08291761A0416|0 8|Animal age
P08291761A0416|33 39|effects
P08291761A0416|41 54|CSF composition
P08291761A0416|58 78|serum IgG concentration
P08291886T0024|14 22|expansion
P08293412T0000|22 26|study
P08293412T0000|39 46|efficacy
P08293412T0000|50 61|tolerability
P08293412T0000|64 74|tropisetron
P08293412T0000|79 101|5-HT3 receptor antagonist
P08293412T0000|142 149|cocktail
P08293412T0000|155 164|prevention
P08293412T0000|184 189|emesis
P08293992A0432|4 9|repeat
P08293992A0432|48 55|sequence
P08293992A0432|55 60|K/NPAG
P08293993A0948|24 33|P. pastoris
P08293993A0948|53 85|alpha-factor prepro secretion leader
P08293993A0948|104 126|invertase signal sequence
P08294386A0000|0 9|BACKGROUND
P08294386A0000|24 33|predictors
P08294386A0000|58 67|depression
P08294386A0000|71 77|authors
P08294386A0000|89 95|outcome
P08294386A0000|98 105|patients
P08294386A0000|115 124|depression
P08294386A0000|150 157|hospital
P08294386A0000|172 182|desipramine
P08294386A0000|203 212|blood level
P08294429A0153|0 7|Analysis
P08294429A0153|19 25|hGH gene
P08294429A0153|62 68|hGh cDNA
P08294429A0153|68 99|chloramphenicol acetyltransferase
P08294429A0153|102 116|luciferase genes
P08294429A0153|155 173|hGH promoter activity
P08294459A0446|12 28|amino acid sequence
P08294459A0446|34 42|SAP-1 cDNA
P08294459A0446|59 63|SAP-1
P08294459A0446|79 88|amino acids
P08294459A0446|150 155|domain
P08294459A0446|171 176|region
P08294511A0639|12 19|evidence
P08294511A0639|41 47|protein
P08294511A0639|79 85|protein
P08294511A0639|112 129|snRNP core particles
P08294511A0639|147 157|interaction
P08294865A0236|7 14|features
P08294865A0236|24 28|cells
P08294865A0236|43 50|mutation
P08294865A0236|78 86|formation
P08294865A0236|89 107|peptide/DR complexes
P08294906A1315|4 15|distribution
P08294906A1315|34 59|neurotransmitters glutamate
P08294906A1315|63 71|aspartate
P08294906A1315|103 112|amino acids
P08294906A1315|116 124|substrate
P08294906A1315|128 136|transport
P08296434A1141|3 18|Harleco apparatus
P08296434A1141|48 54|adjunct
P08296434A1141|60 68|diagnosis
P08296434A1141|72 80|treatment
P08296434A1141|103 111|condition
P08297376A0236|0 14|Co-transfection
P08297376A0236|17 33|expression vectors
P08297376A0236|37 64|CCAAT/enhancer binding protein
P08297376A0236|65 69|C/EBP
P08297376A0236|70 74|alpha
P08297376A0236|78 86|C/EBP beta
P08297376A0236|105 136|rat uncoupling protein gene promoter
P08297376A0236|142 150|sequences
P08297376A0236|165 170|region
P08298129A0274|26 30|basis
P08298129A0274|49 58|expression
P08298129A0274|88 99|gene promoter
P08298129T0000|0 8|Isolation
P08298129T0000|12 27|characterization
P08298129T0000|40 47|promoter
P08298129T0000|66 77|integrin gene
P08299181A1148|10 14|fluid
P08299568A1401|23 32|activation
P08299568A1401|39 45|enzymes
P08299568A1401|72 82|stimulation
P08299568A1401|85 100|glucose transport
P08299725A0724|11 16|region
P08299725A0724|34 39|intron
P08299725A0724|42 46|brain
P08299725A0724|50 55|muscle
P08299725A0724|72 85|tumor cell lines
P08299725A0724|95 105|readthrough
P08299725A0724|120 127|residues
P08299896A0626|0 10|Concordance
P08299896A0626|13 22|IBDQ scores
P08299896A0626|43 50|subjects
P08299896A0880|0 19|Regression line slopes
P08299896A0880|22 31|IBDQ scores
P08299896A0880|60 67|patients
P08300463A0581|0 11|Praziquantel
P08300463A0581|15 25|Albendazole
P08300463A0581|49 57|treatment
P08300463A0581|60 77|neurocysticercosis
P08300463A0581|101 107|effects
P08300463A0581|125 129|cases
P08300463A0581|133 137|drugs
P08300463A0581|170 174|cases
P08300527T0000|0 9|Inhibition
P08300527T0000|12 32|erythromycin synthesis
P08300527T0000|35 44|disruption
P08300527T0000|47 84|malonyl-coenzyme A decarboxylase gene eryM
P08300527T0000|87 112|Saccharopolyspora erythraea
P08300601A0745|4 9|region
P08300601A0745|23 32|activation
P08300601A0745|35 44|DNA binding
P08300601A0745|56 68|E12 homodimers
P08300601A0745|71 90|E12/MyoD heterodimers
P08300605A0432|15 22|analysis
P08300605A0432|26 31|series
P08300605A0432|34 48|deletion mutants
P08300605A0432|72 79|extracts
P08300605A0432|100 108|silk gland
P08300605A0432|125 136|instar larvae
P08300605A0432|148 155|presence
P08300605A0432|180 187|elements
P08300605A0432|225 238|initiation site
P08300605A0671|10 17|elements
P08300605A0671|40 46|element
P08300605A0671|77 86|regulation
P08300611A0341|13 23|mutagenesis
P08300611A0341|54 64|application
P08300611A0341|79 90|TraI proteins
P08300611A0341|101 106|assays
P08300611A0341|136 145|importance
P08300611A0341|157 173|amino acid residues
P08300611T0000|9 14|action
P08300611T0000|30 36|domains
P08300611T0000|63 70|reaction
P08300611T0000|81 88|relaxase
P08300611T0000|108 117|plasmid RP4
P08300625A1352|18 23|codons
P08300625A1352|63 77|peptide sequence
P08300625A1352|111 122|slyD function
P08300625A1352|135 139|lysis
P08301702A1083|12 21|antibodies
P08301702A1083|35 55|rat cytochrome P-450 1A1
P08301702A1083|67 73|protein
P08301702A1083|86 95|microsomes
P08301702A1083|115 123|cormorant
P08301702A1083|152 156|heron
P08301702A1083|175 188|immunoblotting
P08301841A0000|15 28|enzyme activity
P08301841A0000|31 35|serum
P08301841A0000|56 65|infarction
P08301841A0000|82 95|angina pectoris
P08302589A1132|14 25|cell motility
P08302589A1132|77 89|protein kinase
P08302589A1132|102 113|phorbol ester
P08302589A1132|127 135|ionophore
P08303233A0313|2 9|addition
P08303233A0313|17 23|priming
P08303233A0313|49 56|identity
P08304301A0331|0 6|METHODS
P08304301A0331|17 21|cases
P08304301A0331|46 52|nodules
P08304301A0331|67 77|examination
P08304342A0605|12 17|report
P08304342A0605|20 42|hemochromatosis families
P08304342A0605|54 79|hemochromatosis chromosomes
P08304342A0605|92 102|chromosomes
P08304342A0605|122 128|battery
P08304342A0605|131 136|probes
P08304342A0605|172 178|markers
P08304342A0605|192 200|HLA-F loci
P08304342A0605|232 236|HLA-A
P08305058T0000|0 11|Pneumothorax
P08305058T0000|30 39|dissection
P08305058T0000|58 63|hiatus
P08306356A0000|17 29|malformations
P08306356A0000|67 72|X-rays
P08306356A0000|107 115|gestation
P08306834A0866|0 8|T2 cancers
P08306834A0866|35 41|benefit
P08306834A0866|56 66|irradiation
P08306959A0278|0 7|IFN alpha
P08306959A0278|11 30|IFN gamma inducibility
P08306959A0278|50 56|element
P08306959A0278|62 69|affinity
P08306959A0278|87 93|version
P08306959A0278|99 120|IFN gamma activation site
P08307338A0227|0 8|Mutations
P08307338A0227|21 28|gene CBP1
P08307338A0227|54 59|result
P08307338A0227|62 72|degradation
P08307338A0227|97 107|cytochrome b
P08307338A0227|125 129|cells
P08307564A0233|27 31|sites
P08307564A0233|57 62|contig
P08307564A0233|63 69|density
P08308008A0201|6 10|paper
P08308008A0201|28 34|binding
P08308008A0201|50 56|protein
P08308008A0201|65 81|ets sequence motifs
P08308008A0201|133 142|activation
P08308008A0201|147 159|COXIV promoter
P08309726A0000|13 19|insight
P08309726A0000|27 38|pathogenesis
P08309726A0000|60 75|distress syndrome
P08309726A0000|85 91|authors
P08309726A0000|106 118|relationships
P08309726A0000|127 142|activation status
P08309726A0000|173 183|neutrophils
P08309726A0000|189 202|cytokine levels
P08309726A0000|208 215|severity
P08309726A0000|218 227|lung injury
P08309726A0000|232 239|patients
P08309726A0000|263 271|pneumonia
P08309726A0000|318 325|patients
P08309726A0000|345 353|pneumonia
P08309912A0306|0 9|Amiodarone
P08309912A0306|32 40|treatment
P08309953A0776|5 11|results
P08309953A0776|27 53|dopamine receptor stimulation
P08309953A0776|65 80|dopamine agonists
P08309953A0776|99 105|pattern
P08309953A0776|108 114|effects
P08309953A0776|120 134|characteristics
P08309953A0776|140 159|reaction time response
P08309957A0000|3 13|experiments
P08309957A0000|44 55|jaw movements
P08309957A0000|78 91|administration
P08309957A0000|115 128|agent reserpine
P08309975A0662|0 8|Depletion
P08309975A0662|11 18|dopamine
P08309975A0662|24 39|nucleus accumbens
P08309975A0662|54 58|shift
P08309975A0662|61 68|behavior
P08309975A0662|96 103|decrease
P08309975A0662|106 110|lever
P08309975A0662|134 141|increase
P08309975A0662|144 154|consumption
P08309975A0662|157 163|lab chow
P08312243A0177|21 29|influence
P08312243A0177|32 36|NaFe3
P08312243A0177|64 69|levels
P08312243A0177|71 77|Na2EDTA
P08312243A0177|91 102|Ca metabolism
P08312243A0177|114 126|Zn-sufficient
P08312243A0177|164 168|diets
P08314163T0000|0 7|Recovery
P08314163T0000|29 43|agranulocytosis
P08314163T0000|86 108|colony stimulating factor
P08314163T0000|109 116|rhGM-CSF
P08314163T0000|117 130|administration
P08314922A0941|7 12|system
P08314922A0941|45 60|perfusion changes
P08314922A0941|68 79|brain surface
P08314922A0941|91 102|tissue damage
P08316100A0586|3 9|neglect
P08316100A0586|12 19|Richards
P08316100A0586|21 26|theory
P08316100A0586|42 46|range
P08316100A0586|49 55|factors
P08316100A0586|121 129|influence
P08316100A0586|157 162|theory
P08316209A0000|24 29|sulfur
P08316209A0000|40 46|protein
P08316209A0000|55 70|Neurospora crassa
P08316209A0000|80 89|expression
P08316209A0000|93 98|family
P08316209A0000|119 123|genes
P08316209A0000|134 140|enzymes
P08316209A0000|143 158|sulfur catabolism
P08316240A1068|0 7|Analysis
P08316240A1068|33 38|region
P08316240A1068|41 45|CHL15
P08316240A1068|57 64|presence
P08316240A1068|70 83|hexamer element
P08316240A1068|84 89|ACGCGT
P08316240A1068|92 110|MluI restriction site
P08316240A1068|137 146|expression
P08316240A1068|160 169|regulation
P08316240A1068|175 191|DNA synthesis genes
P08316240A1068|201 205|yeast
P08317092A0304|13 18|region
P08317092A0304|31 37|protein
P08317092A0304|59 71|helicase motif
P08317092A0304|89 94|region
P08317092A0304|97 114|RNA polymerase motif
P08317092A0304|148 155|proteins
P08317092A0304|165 185|RNA replication complex
P08317092A0304|202 207|tobamo
P08317092A0304|211 222|tobraviruses
P08317094A0778|21 31|transcripts
P08317094A0778|57 64|sequence
P08317094A0778|64 68|TAAAG
P08317094A0778|97 104|promoter
P08317094A0778|128 142|initiation codon
P08319396A0448|14 19|images
P08319396A0448|22 35|intensity areas
P08319396A0448|41 48|thalamus
P08319396A0448|52 59|striatum
P08319396A0448|90 96|capsule
P08319396A0448|99 107|tegmentum
P08319396A0448|122 135|intensity areas
P08319396A0448|144 161|cerebellar peduncle
P08319396A0448|193 199|capsule
P08319396A0448|228 235|peduncle
P08319396A0448|254 259|matter
P08319907A0754|8 19|rap1t alleles
P08319907A0754|39 43|cells
P08319907A0754|59 78|telomere tract lengths
P08319907A0754|93 115|telomere position effects
P08319907A0754|136 142|changes
P08319907A0754|156 164|structure
P08319907A0754|178 182|tract
P08320120A0361|10 24|microangiopathy
P08320120A0361|49 54|fields
P08320120A0361|74 84|capillaries
P08320120A0361|111 119|diffusion
P08320120A0361|122 138|sodium fluorescein
P08320120A0361|177 183|nodules
P08321199T0000|10 18|switching
P08321199T0000|36 41|states
P08321199T0000|62 68|factors
P08321199T0000|77 89|establishment
P08321199T0000|92 100|silencing
P08321199T0000|106 113|HMR locus
P08321203A0840|0 11|NF-kappa B p65
P08321203A0840|50 59|C/EBP alpha
P08321203A0840|58 66|C/EBP beta
P08321203A0840|70 79|C/EBP delta
P08321227A0854|33 45|culture medium
P08321227A0854|64 71|COS cells
P08321741A0396|8 12|group
P08321741A0396|48 55|progress
P08321741A0396|57 69|myelofibrosis
P08321741A0396|115 122|Myelosis
P08321741A0396|161 177|Metaplasia-AMM-in
P08321741A0396|189 196|patients
P08321741A0396|229 240|increase-CML
P08322117A1019|6 12|methods
P08322117A1019|28 35|patients
P08322117A1019|55 63|pressures
P08322117A1019|79 83|cmH2O
P08322117A1019|96 100|cmH2O
P08322117A1019|107 120|Sussett formula
P08322117A1019|142 148|centile
P08322117A1019|149 154|cutoff
P08322823A0839|15 25|correlation
P08322823A0839|47 54|severity
P08322823A0839|59 70|UTS phenotype
P08323294T0000|0 49|Chicken sterol carrier protein 2/sterol carrier protein x
P08323294T0000|50 60|cDNA cloning
P08323294T0000|80 91|conservation
P08323294T0000|94 102|structure
P08323294T0000|115 124|expression
P08324107A0000|12 31|albumin concentration
P08324107A0000|73 85|plasma protein
P08324280A0098|5 11|lesions
P08324280A0098|71 80|ulceration
P08324792T0000|17 22|period
P08324792T0000|36 41|pacing
P08324792T0000|54 64|infarct size
P08324792T0000|76 86|rabbit heart
P08325504A0226|16 32|RD21 mRNA synthesis
P08325504A0226|55 64|heat stress
P08325639A0129|8 14|studies
P08325639A0129|31 43|20S proteasome
P08325639A0129|83 89|complex
P08325639A0129|122 139|proteinase activity
P08325639A0129|176 184|breakdown
P08325639A0129|187 194|proteins
P08325639A0129|204 212|ubiquitin
P08325720A0840|5 11|deficit
P08325720A0840|27 38|blood lactate
P08325720A0840|55 62|exercise
P08325720A0840|63 82|muscle enzyme activity
P08325720A0840|83 97|citrate synthase
P08325720A0840|98 128|3-hydroxyacyl-CoA-dehydrogenase
P08325720A0840|129 148|lactate dehydrogenase
P08325720A0840|149 154|number
P08325720A0840|157 173|muscle capillaries
P08325720A0840|178 183|fibres
P08325720A0840|185 204|muscle buffer capacity
P08325883A0368|3 10|sequence
P08325883A0368|24 34|RBP1 protein
P08325883A0368|46 51|copies
P08325883A0368|56 74|RNA recognition motif
P08325883A0368|78 95|glutamine stretches
P08325883A0368|113 118|region
P08325883A0368|135 140|region
P08325883A0368|160 172|alpha-helixes
P08327488A0839|27 34|deletion
P08327488A0839|50 55|region
P08327488A0839|109 120|helper genome
P08331064A0440|0 6|Release
P08331064A0440|22 29|pressure
P08331064A0440|58 67|resolution
P08331064A0440|83 92|structures
P08331067T0000|8 25|nucleotide sequence
P08331067T0000|31 54|bacteriophage K1F tail gene
P08331067T0000|63 86|endo-N-acylneuraminidase
P08331067T0000|87 92|endo-N
P08331067T0000|96 105|comparison
P08331067T0000|116 122|homolog
P08331067T0000|125 141|bacteriophage PK1E
P08331728A0686|0 6|Binding
P08331728A0686|25 41|ribonucleoprotein
P08332033T0000|14 27|quantification
P08332033T0000|30 39|brain edema
P08332033T0000|69 82|micro-infarcts
P08332033T0000|91 100|assessment
P08332033T0000|102 118|neurotropin effect
P08332492A0145|3 8|member
P08332492A0145|24 29|family
P08332492A0145|30 35|GATA-3
P08332492A0145|63 74|T lymphocytes
P08332492A0145|84 89|target
P08332492A0145|98 122|immunodeficiency virus type
P08332492A0145|124 128|HIV-1
P08332492A0145|129 137|infection
P08332492A0145|141 151|replication
P08332495A0408|17 21|level
P08332495A0408|24 34|CAT activity
P08332495A0408|53 70|lung adenocarcinoma
P08332495A0408|71 76|A549-1
P08332495A0408|77 81|cells
P08332495A0408|108 114|complex
P08332495A0408|117 131|T7 RNA polymerase
P08332495A0408|132 145|pT7-EMC-CAT DNA
P08332495A0408|149 155|DC-chol
P08332495A0408|164 172|liposomes
P08333643A0000|0 12|Pneumoscrotum
P08333643A0000|20 28|condition
P08333643A0000|47 56|discussion
P08333643A0000|67 71|texts
P08333643A0000|74 80|urology
P08334158A0660|8 16|gene codes
P08334158A0660|21 27|protein
P08334158A0660|40 54|cystein residues
P08334158A0660|59 69|arrangement
P08334158A0660|80 91|Fe/S proteins
P08334304A0473|16 20|cells
P08334304A0473|29 36|capacity
P08334304A0473|40 49|activation
P08334304A0473|55 61|pathway
P08334304A0473|68 87|peptide growth factors
P08334304A0473|93 100|addition
P08334304A0473|113 123|p21 rasVal12
P08334989A0070|19 27|mechanism
P08334989A0070|39 48|expression
P08334989A0070|81 90|mouse B-myb
P08334989A0070|99 106|sequence
P08334989A0070|129 135|library
P08334989A0070|167 179|transcription
P08334989A0070|183 204|luciferase reporter gene
P08334989A0070|224 240|NIH3T3 fibroblasts
P08335710A0338|3 11|influence
P08335710A0338|24 31|strength
P08335710A0338|37 46|resolution
P08336012A0632|3 8|number
P08336012A0632|11 18|bacteria
P08336012A0632|45 53|blood cell
P08336012A0632|56 67|BAL fluid cell
P08336012A0632|86 99|administration
P08336543A0243|18 25|families
P08336543A0243|27 36|L1 elements
P08336543A0243|75 79|basis
P08336543A0243|82 89|sequence
P08336543A0243|101 108|terminus
P08336698T0000|28 34|protein
P08336698T0000|39 50|heterodimers
P08336698T0000|86 108|transcription activation
P08336738A1273|3 12|equivalent
P08336738A1273|23 28|ligand
P08336738A1273|48 67|PSTAIRE sequence motif
P08337828A0895|7 13|results
P08337828A0895|24 35|Western blots
P08337828A0895|38 62|Autographa californica MNPV
P08337828A0895|63 68|AcMNPV
P08337828A0895|76 100|Spodoptera frugiperda cells
P08337841A0612|19 23|cells
P08337841A0612|27 30|ARV G
P08337841A0612|34 41|GNS genes
P08337841A0612|114 130|consensus sequence
P08337841A0612|130 134|AACAG
P08337841A0612|140 144|start
P08337841A0612|150 154|G gene
P08337841A0612|174 194|polyadenylation signal
P08337841A0612|213 223|nucleotides
P08337841A0612|237 262|GNS protein termination codon
P08340400T0000|9 15|cloning
P08340400T0000|19 28|expression
P08340400T0000|31 35|RPE65
P08340400T0000|49 55|pigment
P08340400T0000|85 91|protein
P08342703A0966|7 11|power
P08342703A0966|48 55|flow rate
P08342703A0966|72 86|outflow pressure
P08342703A0966|92 98|product
P08342703A0966|104 111|flow rate
P08342703A0966|118 125|pressure
P08342703A0966|144 149|vessel
P08343041A0000|17 26|antibodies
P08343041A0000|44 54|infertility
P08343041A0000|59 78|hospital laboratories
P08343041A0000|96 105|antibodies
P08343216A0883|12 31|IgG subclass responses
P08343216A0883|52 64|IgG subclasses
P08343961A0000|0 18|Anterior body pattern
P08343961A0000|53 64|distribution
P08343961A0000|76 82|protein
P08343961A0000|113 117|genes
P08343961A0000|135 141|domains
P08344248A0910|0 4|GAP-N
P08344248A0910|53 58|growth
P08344248A0910|76 80|cells
P08345191A1140|3 17|peptide sequence
P08345191A1140|27 32|region
P08345191A1140|37 46|amino acids
P08345191A1140|56 65|similarity
P08345191A1140|68 72|bcl-2
P08347677A0308|3 27|phosphorylation efficiency
P08347677A0308|53 58|number
P08347677A0308|71 86|arginine residues
P08347677A0308|101 114|arginyl cluster
P08347677A0308|118 124|residue
P08347677A0308|143 148|serine
P08347677A0308|167 187|4-Ala-Ala-Ser-Val-Ala
P08347677A0308|199 207|substrate
P08347677A0308|224 231|peptides
P08347677A0308|245 250|microM
P08348919T0000|0 13|Botulinum toxin
P08348919T0000|23 31|treatment
P08348919T0000|45 49|spasm
P08349104A0000|35 44|GAL10 genes
P08349104A0000|59 66|response
P08349104A0000|72 83|availability
P08349104A0000|86 94|galactose
P08349104A0000|98 104|glucose
P08349104A0000|138 145|proteins
P08349104A0000|174 178|sites
P08349104A0450|15 21|results
P08349104A0450|31 41|experiments
P08349104A0450|56 63|TSF genes
P08349104A0450|86 92|factors
P08349104A0450|118 130|tsf6 mutations
P08349104A0450|141 150|expression
P08349104A0450|155 159|yeast
P08349104A0450|167 181|hybrid promoters
P08349104A0450|206 212|variety
P08349104A0450|214 230|operator sequences
P08349104A0450|251 257|defects
P08349104A0450|260 269|cell growth
P08349104A0450|270 275|mating
P08349104A0450|279 289|sporulation
P08349499A1169|13 19|variate
P08349499A1169|47 51|width
P08349499A1169|54 59|muzzle
P08349632A0679|0 17|Sequence comparison
P08349632A0679|31 35|exons
P08349632A0679|49 53|PSG12
P08349632A0679|55 62|PSG12 psi
P08349632A0679|92 98|L/N exon
P08349632A0679|103 114|PSG12 psi gene
P08349632A0679|124 132|stop codon
P08350061A0209|3 12|mechanisms
P08350061A0209|26 35|activation
P08350061A0209|38 48|suppression
P08350061A0209|54 60|CD8 gene
P08350061A0209|86 108|T cell development program
P08350398A1616|35 40|domain
P08350398A1616|42 46|gp19K
P08350398A1616|67 75|structure
P08350398A1616|117 121|alpha
P08350398A1616|126 130|alpha
P08350398A1616|132 138|domains
P08350398A1616|141 145|class
P08350398A1616|147 151|heavy
P08350398A1616|152 156|alpha
P08350398A1616|157 162|chains
P08352066A0000|21 34|beta-estradiol
P08352066A0000|56 69|bone resorption
P08352066A0000|86 98|bone formation
P08352268A0000|16 29|erythropoietin
P08352268A0000|30 36|epoetin
P08352268A0000|103 107|route
P08355062A0000|13 20|emission
P08355062A0000|29 38|tomography
P08355062A0000|39 43|SPECT
P08355062A0000|48 82|99mTc-hexamethylpropyleneamine oxime
P08355062A0000|83 87|HMPAO
P08355062A0000|108 114|changes
P08355062A0000|125 133|blood flow
P08355062A0000|141 148|patients
P08355062A0000|167 176|impairment
P08355063A0456|3 11|rCBF ratio
P08355063A0456|37 41|lobes
P08355539A0133|0 6|METHODS
P08355539A0133|17 24|patients
P08355539A0133|52 59|etiology
P08355539A0133|70 74|study
P08355539A0133|88 97|antibodies
P08355539A0133|100 108|diagnosis
P08355539A0133|114 120|disease
P08355539A0133|144 151|etiology
P08355539A0133|184 191|etiology
P08355539A0133|216 220|study
P08355539A0133|247 254|etiology
P08355680A0824|25 29|rises
P08355680A0824|31 46|mRNA accumulation
P08355680A0824|92 106|HIV-1 constructs
P08355680A0824|112 120|increases
P08355680A0824|151 161|gamma-actin
P08355680A0824|163 193|glucose 6-phosphate dehydrogenase
P08355696A0236|3 13|UV induction
P08355696A0236|16 20|c-jun
P08355696A0236|36 53|UV response elements
P08355696A0236|75 83|sequences
P08355696A0236|101 106|region
P08355697A0000|0 26|Protein tyrosine phosphatases
P08355697A0000|45 66|protein tyrosine kinases
P08355697A0000|88 97|regulation
P08355697A0000|99 112|cell activation
P08355697A0000|113 118|growth
P08355697A0000|122 136|differentiation
P08355857A1293|2 10|elevation
P08355857A1293|20 27|patients
P08355857A1293|36 44|subgroup A
P08355857A1293|51 57|patient
P08355857A1293|63 72|subgroup B.
P08356792A1275|12 22|p21X protein
P08356792A1275|33 42|N-terminus
P08356792A1275|69 74|levels
P08356792A1275|166 175|proviruses
P08356792T0000|0 19|HTLV-1 gene expression
P08356792T0000|31 40|proviruses
P08356792T0000|53 62|T-cell line
P08356944A0589|25 49|sodium lauryl sulfate method
P08356944A0589|62 84|hemoglobin concentration
P08356944A0589|100 110|alternative
P08356944A0589|116 138|cyanmethemoglobin method
P08356944A0589|151 160|generation
P08356944A0589|168 173|wastes
P08357834A0285|1 10|comparison
P08357834A0285|25 42|amino acid sequences
P08357834A0285|56 70|PKC-delta clones
P08357834A0285|86 100|mouse homologues
P08357834A0285|117 122|degree
P08357834A0285|125 142|sequence divergence
P08357834A0285|147 155|% homology
P08357834A0285|173 178|degree
P08357834A0285|181 200|sequence conservation
P08357834A0285|223 238|PKC family members
P08357834A0285|256 267|counterparts
P08360180A1041|16 26|barley PSI-K
P08360180A1041|30 34|PSI-G
P08360180A1041|50 62|PSI-K sequence
P08360180A1041|91 96|degree
P08360180A1041|99 108|similarity
P08360180A1041|178 187|progenitor
P08360180A1041|196 209|cyanobacterial
P08361754A0733|19 28|structures
P08361754A0733|38 43|domain
P08361754A0733|81 88|proteins
P08361755A0734|10 19|conditions
P08361755A0734|20 32|transfections
P08361755A0734|37 41|cDNAs
P08361755A0734|47 58|NF-kappa B p50
P08361755A0734|62 80|serum response factor
P08361755A0734|95 100|factor
P08361755A0734|114 123|Tax binding
P08361755A0734|128 140|NF-kappa B site
P08361755A0734|147 153|CArG box
P08361761A0174|14 18|v-Rel
P08361761A0174|40 49|expression
P08361761A0174|55 69|reporter plasmid
P08361761A0174|88 102|Sp1 binding sites
P08361761A0174|125 148|chicken embryo fibroblasts
P08361761A0174|165 169|v-Rel
P08361761A0174|194 198|sites
P08361761A0174|236 240|v-Rel
P08361761A0174|254 263|expression
P08361761A0174|269 283|reporter plasmid
P08361761A0174|300 324|immunodeficiency virus type
P08361761A0174|326 330|HIV-1
P08361761A0174|343 348|repeat
P08361761A0174|364 381|kappa B binding sites
P08361761A0174|420 434|Sp1 binding sites
P08363332A0365|15 23|recording
P08363332A0365|36 43|activity
P08363332A0365|51 74|surface electrocardiogram
P08363332A0365|100 105|bundle
P08363332A0365|114 119|atrium
P08363332A0365|128 132|sinus
P08363332A0365|153 167|mapping catheter
P08363332A0365|204 221|activation sequence
P08363332A0365|227 231|heart
P08365944A1537|0 9|CONCLUSION
P08365944A1537|27 34|analysis
P08365944A1537|52 59|efficacy
P08365944A1537|65 70|course
P08365944A1537|85 95|Mitomycin-C
P08365944A1537|99 112|5-fluorouracil
P08365944A1537|122 132|association
P08365944A1537|146 157|radiotherapy
P08365944A1537|182 186|boost
P08366034A0637|10 18|existence
P08366034A0637|23 38|cysteine residues
P08366034A0637|39 56|carboxymethylation
P08366034A0637|69 77|formation
P08366034A0637|92 105|disulfide bonds
P08366034A0637|134 138|cells
P08367388T0035|27 34|syndrome
P08367388T0035|47 54|syndrome
P08367487A1014|18 25|addition
P08367487A1014|36 46|17S U2 snRNPs
P08367487A1014|55 65|12S U2 snRNPs
P08367487A1014|68 87|HeLa splicing extracts
P08367487A1014|109 116|U2 snRNPs
P08367487A1014|161 170|antibodies
P08367487A1014|187 207|mRNA-splicing activity
P08367487A1014|213 220|extracts
P08369887A0781|0 10|Differences
P08369887A0781|13 20|profiles
P08369887A0781|23 40|viscosity variables
P08369887A0781|48 56|subgroups
P08369887A0781|66 75|RA patients
P08370119A0642|72 80|sequences
P08370119A0642|81 88|addition
P08370119A0642|103 114|reading frame
P08370119A0642|151 177|muscle cell AT1a receptor cDNAs
P08370119A1521|0 7|Deletion
P08370119A1521|21 34|promoter region
P08370119A1521|48 69|transcription start site
P08370119A1521|82 88|TATA box
P08370119A1521|111 117|ability
P08370119A1521|128 135|elements
P08370119A1521|143 155|transcription
P08370119A1521|161 174|luciferase cDNA
P08370275A0290|3 12|chimpanzee
P08370275A0290|38 44|numeral
P08370275A0290|52 58|testing
P08370275A0290|88 93|chimps
P08370275A0290|101 110|preference
P08371650T0000|0 10|Dissipation
P08371650T0000|13 28|claudication pain
P08371650T0000|41 52|implications
P08371650T0000|65 72|training
P08371713T0000|11 20|transcript
P08371713T0000|43 60|endothelin receptor
P08371713T0000|65 72|rat brain
P08371936T0000|13 31|Independence Measure
P08371936T0000|44 48|study
P08371936T0000|51 59|clinician
P08371936T0000|63 73|self ratings
P08373274A0546|0 9|Polymyxin B
P08373274A0546|35 46|week postburn
P08373274A0546|49 53|doses
P08373274A0546|85 95|endotoxemia
P08374753A0335|13 26|relaxation time
P08374753A0335|42 61|diffusion coefficient
P08374753A0335|63 67|water
P08375651T0000|26 34|chain gene
P08375651T0000|35 50|clathrin function
P08375651T0000|78 85|organism
P08376397A0788|3 20|binding specificity
P08376397A0788|27 33|protein
P08376397A0788|69 74|number
P08376397A0788|82 89|E2F sites
P08376397A0788|92 102|competitors
P08376796A0172|12 20|VH regions
P08376796A0172|35 44|antibodies
P08376796A0172|59 67|attention
P08376796A0172|93 98|status
P08376796A0172|152 157|B cells
P08376796A0172|166 172|subject
P08376796A0172|174 180|patient
P08376796A0172|202 217|diabetes mellitus
P08376796A0172|222 228|patient
P08376796A0172|259 270|efficiencies
P08376796A0172|271 276|number
P08377199A1432|19 23|patch
P08377199A1432|43 54|conformation
P08377199A1432|89 99|recognition
P08378082A1031|5 12|findings
P08378082A1031|31 40|cross-talk
P08378082A1031|48 56|RB protein
P08378082A1031|60 65|p21ras
P08378082A1031|82 94|cell phenotype
P08378082A1031|122 127|states
P08380736A0895|33 40|splicing
P08380736A0895|58 64|protein
P08380736A0895|78 90|amino terminus
P08380896A0938|0 7|Kinetics
P08380896A0938|13 22|inhibition
P08380896A0938|40 55|polymerase domain
P08380896A0938|71 81|replication
P08380896A0938|95 112|preinitiation stage
P08381121A0773|8 27|transmembrane regions
P08381121A0773|52 57|domain
P08382296A0766|0 8|McCann III
P08382300A0341|5 13|cell lines
P08382300A0341|28 34|ability
P08382300A0341|47 57|replication
P08382300A0341|82 90|VP5 mutant
P08382300A0341|126 132|mutants
P08382303A0507|14 27|transport motif
P08382303A0507|49 54|animal
P08382303A0507|63 78|papillomaviruses
P08382303A0507|101 106|region
P08382303A0507|119 125|E1 genes
P08382303T0000|3 22|E1 replication protein
P08382303T0000|31 48|papillomavirus type
P08382303T0000|75 92|localization signal
P08382303T0000|106 131|p34cdc2 phosphorylation site
P08382359A0469|2 6|order
P08382359A0469|26 31|extent
P08382359A0469|36 46|interaction
P08382359A0469|64 77|tumor induction
P08382359A0469|83 87|virus
P08382359A0469|116 129|point mutations
P08382359A0469|158 165|sequence
P08382359A0469|173 180|T antigen
P08382359A0469|206 216|experiments
P08382359A0469|235 241|effects
P08382359A0469|265 274|activities
P08382359A0469|285 298|tumor induction
P08382769A0924|17 28|conservation
P08382769A0924|31 41|nucleotides
P08382769A0924|63 73|consequence
P08382769A0924|107 124|recognition element
P08382769A0924|130 141|SRP54 protein
P08382778A0891|1 6|region
P08382778A0891|19 31|protein shares
P08382778A0891|41 48|homology
P08382778A0891|63 68|region
P08382778A0891|71 80|Raf kinases
P08382778A0891|82 88|feature
P08382778A0891|103 107|TFIIE
P08382778A0891|113 132|transcription factors
P08383129A0776|15 36|mass polypeptide complex
P08383129A0776|60 78|antigen presentation
P08383129A0776|89 96|peptides
P08383129A0776|110 124|protein antigens
P08383129A0776|165 177|T-lymphocytes
P08383129A0776|183 193|cell surface
P08383214A0389|9 16|cleavage
P08383214A0389|25 39|Trp-595-Tyr-596
P08383214A0389|88 99|RNase H domain
P08383217A0357|28 37|amino acids
P08383217A0357|40 44|Bel-1
P08383217A0357|69 81|Bel-1 activity
P08383217A0357|127 142|activation domain
P08383287A0611|15 21|element
P08383287A0611|35 42|estrogen
P08383287A0611|46 73|thyroid hormone responsiveness
P08383287A0611|101 122|hormone response element
P08383323A0000|7 16|activation
P08383323A0000|19 24|T cells
P08383323A0000|43 49|signals
P08383492A1205|56 64|aa stretch
P08383492A1205|71 76|region
P08383492A1205|82 92|differences
P08383492A1205|107 111|terms
P08383492A1205|125 132|affinity
P08383492A1205|149 166|cytochrome oxidases
P08383492A1205|176 192|c-type cytochromes
P08383526A0591|12 16|genes
P08383526A0591|29 37|structure
P08383526A0591|45 59|receptor protein
P08383622T0000|0 7|Identity
P08383622T0000|20 24|NRF-2
P08383622T0000|37 45|activator
P08383622T0000|48 74|cytochrome oxidase expression
P08383622T0000|102 119|ETS domain activator
P08383622T0000|126 134|promoters
P08383850A0206|12 16|study
P08383850A0206|17 35|beta-funaltrexamine
P08383850A0206|36 43|beta-FNA
P08383850A0206|47 57|naltrindole
P08383850A0206|63 78|nonequilibrium mu
P08383850A0206|130 139|withdrawal
P08384309A0000|21 43|region/helix-loop-helix
P08384309A0000|48 61|dioxin receptor
P08384309A0000|70 87|signal transduction
P08384309A0000|90 95|dioxin
P08384309A0000|96 130|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08384309A0000|162 178|DNA binding protein
P08384309A0000|202 212|target genes
P08384309A0000|224 245|dioxin response elements
P08385131A0000|3 7|alpha
P08385131A0000|21 28|receptor
P08385131A0000|29 37|alpha 2AAR
P08385131A0000|50 56|variety
P08385131A0000|59 67|effectors
P08385131A0000|71 79|pertussis
P08385131A0000|106 113|proteins
P08385337A0282|1 18|sequence comparison
P08385337A0282|29 56|CCAAT/enhancer binding protein
P08385337A0282|57 61|C/EBP
P08385337A0282|62 79|consensus sequences
P08385337A0282|85 100|DNA binding region
P08385337A0282|104 117|leucine zippers
P08385337A0282|123 127|bZIP1
P08385337A0282|131 135|bZIP2
P08385337A0282|146 151|region
P08385581A0126|10 14|genes
P08385581A0126|15 20|REC114
P08385581A0126|59 64|REC114
P08385581A0126|83 99|recombination gene
P08385581A0126|116 123|function
P08385581A0126|126 132|mitosis
P08386279A1621|3 25|transactivation function
P08386279A1621|28 32|EBNA2
P08386279A1621|69 76|cell line
P08386279A1621|101 114|HIV-1 infection
P08386279A1621|121 125|cells
P08386279A1621|137 159|HIV-1 promoter activation
P08386280T0000|0 7|Mutation
P08386280T0000|13 29|C/EBP binding sites
P08386280T0000|35 50|Rous sarcoma virus
P08386280T0000|63 68|repeat
P08386280T0000|72 83|gag enhancers
P08386317T0000|7 26|protein phosphatase 2A
P08386317T0000|43 55|protein kinase
P08386317T0000|111 121|stimulation
P08386318A1102|25 31|JRE-IL6
P08386318A1102|52 58|pathway
P08386318A1102|77 90|protein kinase C
P08386318A1102|110 115|kinase
P08386318A1102|142 148|kinases
P08386318A1102|153 157|Raf-1
P08386318A1102|159 164|NF-IL6
P08386318A1102|165 173|C/EBP beta
P08386319A1229|0 7|Mutation
P08386319A1229|38 45|tyrosine
P08386319A1229|49 65|threonine residues
P08386319A1229|68 72|Mpk1p
P08386319A1229|87 99|phenylalanine
P08386319A1229|103 109|alanine
P08386319A1229|138 150|Mpk1p function
P08386592A0089|0 22|Growth factor stimulation
P08386592A0089|48 53|change
P08386592A0089|74 81|mobility
P08386592A0089|94 100|complex
P08386592A0089|123 137|phosphorylation
P08386592A0089|143 147|Elk-1
P08386592A0089|158 163|region
P08386592A0089|172 181|activation
P08386592A0089|199 209|Elk-1 kinase
P08386637A1220|2 9|contrast
P08386637A1220|15 23|situation
P08386637A1220|35 39|cells
P08386637A1220|49 56|exposure
P08386637A1220|62 68|agonist
P08386637A1220|93 102|regulation
P08386637A1220|125 133|receptors
P08387155A1248|15 20|effect
P08387155A1248|42 46|c-Jun
P08387155A1248|81 85|c-Fos
P08387155A1248|121 125|assay
P08387507A1015|3 12|regulation
P08387507A1015|15 19|Myf-5
P08387507A1015|23 34|MyoD function
P08387507A1015|52 58|pathway
P08387507A1015|86 92|signals
P08387507A1015|104 108|serum
P08387507A1015|119 138|peptide growth factors
P08387507A1015|159 165|nucleus
P08387507A1015|191 197|factors
P08387507A1015|219 241|myoblast differentiation
P08387519A0000|32 36|level
P08387519A0000|42 57|desmin expression
P08387519A0000|97 104|enhancer
P08387519A0000|129 136|myotubes
P08387519A0000|155 168|gene expression
P08387519A0000|171 179|myoblasts
P08387662A0302|5 11|surgery
P08387662A0302|12 23|patients self
P08387662A0302|66 76|medications
P08387662A0302|90 96|placebo
P08387662A0302|97 103|codeine
P08387662A0302|113 121|ibuprofen
P08387662A0302|167 175|intensity
P08387743A0624|0 10|Replacement
P08387743A0624|35 40|region
P08387743A0624|56 62|mutants
P08387743A0624|83 89|element
P08387743A0624|112 121|expression
P08387743A0624|130 151|Mn-superoxide dismutase
P08387994A0980|3 18|orf61 gene product
P08387994A0980|47 54|promoter
P08387994A0980|76 86|integration
P08387994A0980|103 110|attB site
P08388496A1117|0 9|Expression
P08388496A1117|52 70|virus producer status
P08388496A1117|77 87|consequence
P08388496A1117|106 112|passage
P08388496A1117|137 154|BamHI-A transcripts
P08388496A1117|181 186|B cells
P08388496A1117|218 226|infection
P08388496A1117|242 250|BamHI-C/W
P08388496A1117|300 304|mRNAs
P08388510A0891|0 7|Analysis
P08388510A0891|10 38|cell surface immunofluorescence
P08388510A0891|52 59|UL28 gene
P08388510A0891|76 85|expression
P08388510A0891|93 105|glycoproteins
P08388510A0891|111 117|surface
P08388510A0891|128 132|cells
P08388543A1263|18 25|receptor
P08388543A1263|26 36|Y977F/Y989F
P08388543A1263|55 59|sites
P08388543A1263|94 103|activation
P08388543A1263|105 118|protein kinase C
P08388543A1263|122 140|calcium mobilization
P08388543A1263|152 157|effect
P08388543A1263|163 174|GDP/GTP state
P08388543A1263|188 195|cell line
P08388600A0000|0 16|Estrogen treatment
P08388600A0000|23 27|doses
P08388600A0000|54 60|stature
P08388600A0000|83 87|girls
P08389074A1227|0 8|Mutations
P08389074A1227|21 30|C-terminus
P08389074A1227|33 39|EIAV Tat
P08389074A1227|52 61|RNA binding
P08389074A1227|65 89|activation domain functions
P08389074A1227|100 106|effects
P08389074A1227|128 136|structure
P08389365A1344|4 14|observation
P08389365A1344|45 56|repair system
P08389365A1344|84 91|sequence
P08389365A1344|98 107|correction
P08389453A0193|0 19|Uracil DNA glycosylase
P08389453A0193|50 62|repair pathway
P08389453A0193|93 98|uracil
P08389453A0193|103 111|duplex DNA
P08390120A0785|15 20|trials
P08390120A0785|36 43|question
P08390120A0785|67 73|options
P08390120A0785|81 87|quality
P08390665A0000|0 20|Lithium phthalocyanine
P08390665A0000|30 38|prototype
P08390665A0000|47 56|generation
P08390665A0000|96 107|crystallites
P08390665A0000|147 154|electron
P08390665A0000|167 183|resonance oximetry
P08390747A0586|6 11|report
P08390747A0586|24 31|genetics
P08390747A0586|37 42|region
P08390747A0586|50 61|hep syn gB gene
P08390747A0586|82 90|syncytial
P08390747A0586|104 113|phenotypes
P08390831A0143|0 9|Recipients
P08390831A0143|19 27|leukaemia
P08390831A0143|35 43|remission
P08390831A0143|60 68|leukaemia
P08390831A0143|83 87|phase
P08390831A0143|131 136|stages
P08390831A0143|142 153|risk patients
P08391534A0828|0 6|Elledge
P08391748A0452|0 4|Drugs
P08391748A0452|53 64|contractions
P08391748A0452|69 76|patients
P08391748A0452|100 114|QRS prolongation
P08391748A0452|138 151|QT prolongation
P08391748A0452|160 167|patients
P08391748A0452|184 198|QRS prolongation
P08391748A0452|234 247|QT prolongation
P08391748A0452|285 299|QRS prolongation
P08391748A0452|322 335|QT prolongation
P08392221A0449|0 5|Losses
P08392221A0449|23 31|procedure
P08392221A0449|63 80|estrogen conjugates
P08392221A0449|95 99|steps
P08392221A0449|134 142|standards
P08392221A0449|148 156|compounds
P08392221A0449|165 176|matairesinol
P08392221A0449|177 186|enterodiol
P08392221A0449|187 199|enterolactone
P08392221A0449|200 207|daidzein
P08392221A0449|208 228|O-desmethylangolensin
P08392221A0449|229 233|equol
P08392221A0449|237 245|genistein
P08392623A1374|0 18|IE2-IE2 interactions
P08392623A1374|32 37|domain
P08392623A1374|73 77|motif
P08392623A1374|92 100|C terminus
P08392623A1374|115 124|amino acids
P08393143A1281|3 11|Sp1 region
P08393143A1281|66 74|tat factor
P08394019A0695|0 12|Precipitation
P08394019A0695|18 34|GST fusion proteins
P08394019A0695|45 50|Fyn SH2
P08394019A0695|59 72|SH2/SH3 domains
P08394019A0695|84 93|PI 3-kinase
P08394019A0695|115 123|SH3 domain
P08394255A0000|1 5|sheep
P08394255A0000|16 26|cDNA library
P08394255A0000|40 51|pcDNA1 vector
P08394255A0000|68 72|probe
P08394255A0000|84 106|polymerase chain reaction
P08394255A0000|134 143|kb fragment
P08394255A0000|164 182|hormone receptor cDNA
P08394464A1080|11 21|Rev proteins
P08394464A1080|43 48|masses
P08394464A1080|123 129|species
P08394862A0565|5 9|group
P08394862A0565|11 18|patients
P08394862A0565|28 37|CMV disease
P08394862A0565|39 43|group
P08394862A0565|45 51|patient
P08394862A0565|61 72|CMV hepatitis
P08395004A0141|3 9|ability
P08395004A0141|12 24|spt2 mutations
P08395004A0141|53 64|interference
P08395004A0141|76 111|delta promoter insertion his-4-912 delta
P08395004A0141|128 135|increase
P08395004A0141|147 160|HIS4 mRNA levels
P08395004A0558|7 18|localization
P08395004A0558|22 48|protein sequence similarities
P08395004A0558|65 80|SPT2/SIN1 protein
P08395004A0558|119 129|protein HMG1
P08395010T0000|27 32|heptad
P08395010T0000|35 48|thyroid hormone
P08395010T0000|60 72|acid receptors
P08395010T0000|88 96|responses
P08395010T0000|108 118|heterodimer
P08395010T0000|125 142|homodimer formation
P08395014A1364|7 18|interactions
P08395014A1364|40 56|pathway components
P08395014A1364|69 81|BCK2 functions
P08395014A1364|91 103|pathway branch
P08395654T0000|13 18|factor
P08395654T0000|35 42|receptor
P08395654T0000|55 64|expression
P08395654T0000|70 85|rat aromatase gene
P08395654T0000|95 101|tissues
P08395681A0388|20 30|differences
P08395681A0388|56 62|HPV8 E7s
P08395681A0388|72 78|HPV16 E7
P08395681A0388|104 116|reading frames
P08395681A0388|158 167|activities
P08395681A0388|171 184|binding ability
P08395681A0388|192 199|products
P08395681A0388|204 224|retinoblastoma protein
P08395681A0388|237 259|complementation activity
P08395681A0388|275 293|adenovirus E1A mutant
P08396120A0690|3 28|rhaB transcription start site
P08396120A0690|56 60|start
P08396120A0690|63 73|translation
P08396261A0388|7 11|lines
P08396261A0388|14 21|evidence
P08396261A0388|41 56|growth inhibition
P08396261A0388|71 81|PKA subunits
P08396261A0388|96 104|phenotype
P08396261A0388|142 147|strain
P08396261A0388|162 176|cyclase activity
P08396261A0388|183 192|growth rate
P08396261A0388|200 212|transformants
P08396261A0388|255 260|growth
P08396261A0388|279 284|RI cDNA
P08396261A0388|304 309|RI cDNA
P08396261A0388|319 327|RI protein
P08396261A0388|339 349|cAMP binding
P08396261A0388|375 383|phenotype
P08396261A0388|410 414|cells
P08396261A0388|434 446|C alpha protein
P08396667T0000|0 6|BCR-ABL
P08396667T0000|15 23|oncogenes
P08396667T0000|38 45|patterns
P08396667T0000|54 61|lymphoma
P08396667T0000|80 96|lymphocyte subsets
P08396713A0305|5 15|experiments
P08396713A0305|52 59|receptor
P08396713A0305|78 85|extracts
P08396713A0305|88 92|cells
P08396713A0305|104 138|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08396713A0305|156 172|Ah receptor protein
P08396713A0305|196 211|heat shock protein
P08396749A1112a|0 13|LDL cholesterol
P08396749A1112a|47 52|mmol/l
P08396749A1112a|59 63|weeks
P08396749A1112a|66 76|simvastatin
P08396749A1112a|89 92|apo B
P08396749A1112a|114 118|mg/dl
P08396749A1112b|0 13|LDL cholesterol
P08396749A1112b|47 52|mmol/l
P08396749A1112b|59 63|weeks
P08396749A1112b|66 76|simvastatin
P08396749A1112b|89 92|apo B
P08396749A1112b|114 118|mg/dl
P08396913A1379|12 18|element
P08396913A1379|75 84|expression
P08396913A1379|88 94|DGK gene
P08397123T0000|9 16|activity
P08397123T0000|41 47|element
P08397123T0000|58 91|corticotropin-releasing hormone gene
P08397123T0000|114 121|features
P08397123T0000|140 150|transcripts
P08399970T0000|4 29|bioencapsulation technology
P08399970T0000|42 51|inoculants
P08400240A0166|8 27|hypersensitivity site
P08400240A0166|41 58|locus control region
P08400240A0166|67 82|gamma-globin gene
P08400240A0166|82 88|A gamma*
P08400240A0166|116 125|transcript
P08400240A0166|157 172|gamma-globin mRNA
P08400928A0318|0 12|INTERVENTIONS
P08400928A0318|13 20|Patients
P08400928A0318|32 40|treatment
P08400928A0318|45 79|levodopa/dopa decarboxylase inhibitor
P08400928A0318|91 132|levodopa/decarboxylase inhibitor/selegiline
P08400928A0318|134 144|combination
P08400928A0318|153 165|bromocriptine
P08401570A0828|23 34|binding sites
P08401570A0828|38 59|transcription factor Sp1
P08401570A0828|80 88|sequences
P08401570A0828|120 128|enhancers
P08401570A0828|138 142|sites
P08401570A0828|146 165|transcription factors
P08401614A0187|26 31|family
P08401614A0187|33 37|genes
P08401614A0187|64 68|genes
P08401614A0187|128 136|mRNA level
P08401614A0187|137 147|bean tissues
P08403245A1234|0 24|Plasma thromboxane B2 levels
P08403245A1234|35 39|group
P08403245A1234|69 75|piglets
P08403804A0754|24 41|regression analysis
P08403804A0754|49 57|magnesium
P08403804A0754|83 104|cyclosporin trough level
P08403804A0754|113 123|cholesterol
P08403804A0754|132 146|serum creatinine
P08403804A0754|158 167|transplant
P08403804A0754|180 190|cyclosporin
P08405433A0000|20 31|growth factor
P08405433A0000|34 39|IGF-II
P08405433A0000|58 66|promoters
P08406004A0691|19 36|transfection assays
P08406004A0691|57 74|reporter constructs
P08406004A0691|86 98|JB cis-element
P08406004A0691|105 114|activation
P08406004A0691|153 160|sequence
P08406004A0691|180 186|portion
P08406352A0172|0 11|Army veterans
P08406352A0172|23 34|fever vaccine
P08406352A0172|51 65|hepatitis B virus
P08406352A0172|75 82|controls
P08406352A0172|100 104|study
P08406352A0172|114 121|veterans
P08406352A0172|140 148|carcinoma
P08406352A0172|151 174|Veterans Affairs hospitals
P08406352A0172|186 193|controls
P08406352A0172|198 204|respect
P08406352A0172|207 213|receipt
P08406352A0172|228 234|vaccine
P08406419A0155|32 41|antibodies
P08406419A0155|44 58|hepatitis C virus
P08406419A0155|78 84|testing
P08406419A0155|92 116|Ortho Diagnostic Systems Inc
P08406419A0155|116 123|Westwood
P08406497A0000|0 6|Defects
P08406497A0000|9 17|fibrillin
P08406497A0000|25 45|glycoprotein component
P08406497A0000|63 73|microfibril
P08406497A0000|79 92|Marfan syndrome
P08407784A0850|24 30|strains
P08407784A0850|30 42|srjA mutations
P08407784A0850|84 93|phenotypes
P08408194T0000|14 18|roles
P08408194T0000|24 44|membrane-cytoskeleton
P08408194T0000|48 55|cadherin
P08408194T0000|73 80|adhesion
P08408194T0000|107 125|ATPase distributions
P08408194T0000|135 143|epithelia
P08408825A0000|8 25|lupus erythematosus
P08408825A0000|51 64|autoantibodies
P08408825A0000|79 88|La antigens
P08408841A0281|7 19|abnormalities
P08408841A0281|35 45|mutagenesis
P08408841A0281|64 76|abnormalities
P08408841A0281|91 99|mutations
P08409284A0262|9 18|absorption
P08409284A0262|21 30|amino acids
P08409284A0262|36 45|NBB carrier
P08409284A0262|56 65|amino acids
P08409284A0262|72 77|system
P08409284A0262|87 96|amino acids
P08409284A0262|103 112|PHE carrier
P08409284A0262|154 158|stage
P08409284A0262|167 175|diarrhoea
P08409284A0262|181 187|cholera
P08409593A0357|47 54|activity
P08409593A0357|59 66|H. pylori
P08409593A0357|111 118|activity
P08410042T0000|17 23|disease
P08410042T0000|38 52|dura mater grafts
P08410042T0000|53 58|report
P08410042T0000|64 68|cases
P08410097A0356|5 17|mean intensity
P08410097A0356|20 24|CLTPA
P08410097A0356|49 73|regression coefficient beta
P08410097A0356|104 115|oxygen uptake
P08410097A0356|161 176|plasma fibrinogen
P08410097A0356|203 212|covariates
P08411024T0000|9 14|people
P08411024T0000|32 37|option
P08411024T0000|47 68|fibrosis carrier testing
P08411276A0302|1 7|patient
P08411276A0302|16 25|PIC patient
P08411276A0302|43 51|mechanism
P08411276A0302|54 59|injury
P08411276A0302|67 72|coding
P08411276A0302|82 101|Trauma Score variables
P08411276A0302|102 122|Glascow Coma Scale score
P08411276A0302|131 143|blood pressure
P08411276A0302|182 205|Severity Characterization
P08411276A0302|206 211|Trauma
P08411276A0302|212 216|ASCOT
P08411276A0302|265 279|ASCOT components
P08411276A0302|287 294|injuries
P08412120A0839|9 17|bowel TPO2
P08412620A0688|1 6|region
P08412620A0688|42 64|transcription start point
P08412620A0688|108 117|activation
P08412620A0688|123 130|promoter
P08412662A0333|15 20|cosmid
P08412662A0333|64 82|transposon insertion
P08412662A0333|83 88|257DH4
P08412662A0333|117 131|kb EcoRI fragment
P08412665A0000|3 12|scr regulon
P08412665A0000|15 20|pUR400
P08412665A0000|47 56|scr regulon
P08412665A0000|59 68|Klebsiella
P08412665A0000|79 85|KAY2026
P08412665A0000|124 132|repressor
P08413186A0077|20 29|mechanisms
P08413186A0077|44 53|regulation
P08413186A0077|118 124|factors
P08413186A0077|134 143|expression
P08413186A0077|166 179|reductase genes
P08413186A0077|200 206|enzymes
P08413186A0077|212 218|pathway
P08413186A1199|3 10|Ntl1 gene
P08413186A1199|47 70|N. plumbaginifolia species
P08413205A0733|9 31|transfection experiments
P08413205A0733|44 56|Pax-8 isoforms
P08413205A0733|96 108|transcription
P08413205A0733|111 118|promoter
P08413205A0733|132 137|copies
P08413205A0733|154 172|recognition sequence
P08413209A0159|17 21|third
P08413209A0159|27 33|protein
P08413209A0159|62 80|motif characteristic
P08413209A0159|94 101|proteins
P08413215A0327|17 23|ability
P08413215A0327|33 49|NF-kappa B subunits
P08413215A0327|69 81|transcription
P08413215A0327|89 100|IL-8 promoter
P08413223A0847|12 17|copies
P08413223A0847|23 43|IL-1 beta NF-kappa B site
P08413223A0847|76 80|virus
P08413223A0847|83 90|promoter
P08413223A0847|95 101|element
P08413223A0847|118 129|phorbol ester
P08413223A0847|160 173|gene expression
P08413239A0490|26 35|sequence CA
P08413239A0490|38 48|3-10AGTNNAA
P08413239A0490|59 66|plant Pol
P08413239A0490|78 88|U snRNA genes
P08413239A0490|106 117|end formation
P08413239A0490|120 132|U2 transcripts
P08413239A0490|148 157|vertebrate
P08413239A0490|182 189|mutation
P08413260A1437|5 11|results
P08413260A1437|24 32|Rb protein
P08413260A1437|54 62|component
P08413260A1437|92 100|machinery
P08413260A1437|105 111|G2 phase
P08413274A0452|19 27|Raji cells
P08413274A0452|43 51|complexes
P08413274A0452|56 76|X-box oligonucleotides
P08413274A0452|125 133|MDBP sites
P08413291A1473|28 47|rat TnI-CAT fusion gene
P08413291A1473|59 66|reporter
P08413291A1473|92 97|muscle
P08414410A0270|0 6|METHODS
P08414410A0270|72 77|fields
P08414410A0270|115 126|field defects
P08414410A0270|169 176|measures
P08414410A0270|189 194|damage
P08414410A0270|205 209|nerve
P08414410A0270|213 227|nerve fiber layer
P08414502A0244|17 26|hypothesis
P08414502A0244|54 62|regulator
P08414502A0244|72 81|p53 protein
P08414502A0244|104 116|transcription
P08414502A0244|125 133|promoters
P08415637A0000|3 24|ADP-ribosylation factor
P08415637A0000|30 35|family
P08415637A0000|46 56|subfamilies
P08415637A0000|62 75|RAS superfamily
P08415637A0000|90 95|weight
P08415637A0000|107 114|proteins
P08415637A0000|115 123|G proteins
P08415643A0555|3 8|E1 gene
P08415643A0555|32 37|intron
P08415643A0555|59 65|protein
P08415643A0555|77 81|onset
P08415643A0555|84 90|mitosis
P08415712A1153|7 26|Southern blot analysis
P08415712A1153|30 46|chromosome mapping
P08415712A1153|57 61|GPRK6
P08415712A1153|91 95|genes
P08415712A1153|105 115|chromosomes
P08415712A1153|172 193|Huntington disease locus
P08415712A1153|195 204|chromosome
P08416952A0956|9 23|labeling studies
P08416952A0956|41 53|co-expression
P08416952A0956|56 61|nmt72p
P08416952A0956|73 89|protein substrates
P08416952A0956|92 96|Nmt1p
P08416952A0956|129 133|Leu99
P08416952A0956|137 148|substitution
P08416952A0956|156 164|reduction
P08416952A0956|170 178|acylation
P08416952A0956|194 210|protein substrates
P08416977A0892|5 14|CTD kinases
P08416977A0892|25 29|CTDK1
P08416977A0892|33 37|CTDK2
P08416977A0892|55 68|chromatography
P08416977A0892|71 76|Mono Q.
P08417117A0592|48 56|abundance
P08417330A0149|28 43|promoter fragment
P08417330A0149|44 53|oligo31/32
P08417330A0149|68 88|heat shock inducibility
P08417330A0149|106 126|CYC1-lacZ reporter gene
P08417331A0745|3 10|sequence
P08417331A0745|16 23|HIR1 gene
P08417331A0745|40 46|protein
P08417331A0745|56 62|repeats
P08417331A0745|66 70|motif
P08417331A0745|81 92|G beta subunit
P08417331A0745|102 111|transducin
P08417331A0745|118 122|yeast
P08417331A0745|138 146|repressor
P08417349A1633|27 37|replication
P08417349A1633|49 57|templates
P08417349A1633|96 106|replication
P08417349A1633|116 131|mutation fixation
P08418183A0000|10 16|factors
P08418183A0000|45 56|transmission
P08418183A0000|64 94|T cell leukemia/lymphoma virus type
P08418183A0000|96 101|HTLV-I
P08418183A0000|112 118|couples
P08418183A0000|132 150|Miyazaki Cohort Study
P08418183A0000|158 165|November
P08418183A0000|173 177|April
P08418183A0000|195 201|husband
P08419333A0126|17 26|expression
P08419333A0126|33 47|DNA repair enzyme
P08419333A0126|85 89|clone
P08419338A0273|4 9|Stange
P08419338A0273|13 21|Markovich
P08419338A0273|25 29|Biber
P08419338A0273|33 38|Testar
P08419338A0273|42 48|Zorzano
P08419338A0273|52 58|Palacin
P08419338A0273|65 69|Murer
P08419376A0357|3 20|nucleotide sequence
P08419376A0357|41 51|polypeptide
P08419376A0357|56 65|amino acids
P08419376A0357|107 113|domains
P08420230A0544|0 4|SAECG
P08420230A0544|5 20|echocardiography
P08420230A0544|24 42|thallium-201 imaging
P08420230A0544|66 70|month
P08420230A0544|85 95|angioplasty
P08420571A1880|14 18|PACE4
P08421295A0365|4 17|fusion proteins
P08421295A0365|36 44|complexes
P08421295A0365|55 63|DNA duplex
P08421295A0365|82 103|4ACAG consensus sequence
P08421295A0365|108 120|LexA repressor
P08421687A0397|3 24|selenocysteine residues
P08421823A1041|0 10|CONCLUSIONS
P08421823A1041|15 32|protein S deficiency
P08421823A1041|58 65|patients
P08421823A1041|75 81|absence
P08421823A1041|107 115|condition
P08421897A0000|13 18|decade
P08421897A0000|28 32|types
P08421897A0000|55 63|sequences
P08421897A0000|89 94|genome
P08421897A0000|107 129|stringency hybridization
P08421897A0000|139 147|DNA probes
P08421897A0000|171 191|animal retrovirus genes
P08421910A0599|5 14|components
P08421910A0599|22 30|complexes
P08421910A0599|42 46|TRBPs
P08421910A0599|102 107|TAR RNA
P08421910A0599|120 139|uv cross-linking assay
P08422975A1205|20 28|necessity
P08422975A1205|32 38|editing
P08422975A1205|41 65|kinetoplastid mitochondria
P08422975A1205|71 79|formation
P08422975A1205|94 98|mRNAs
P08423831A0523|14 18|model
P08423831A0523|65 70|issues
P08423831A0523|84 91|diseases
P08423831A0523|130 139|parameters
P08425050A0898|19 24|repeat
P08425050A0898|51 57|repeats
P08425050A0898|80 88|PE operons
P08425050A0898|117 124|sequence
P08425221A0000|27 40|tyrosine kinase
P08425221A0000|52 72|B cell progenitor kinase
P08425221A0000|93 98|stages
P08425221A0000|104 111|B lineage
P08425221A0000|124 128|cells
P08427501A0221|5 15|differences
P08427501A0221|26 31|groups
P08427501A0221|64 77|enzyme activity
P08427501A0221|92 105|enzyme activity
P08427501A0221|150 155|polyps
P08427501A0221|167 171|types
P08427501A0221|180 185|polyps
P08428722A1123|17 24|analysis
P08428722A1123|28 36|variables
P08428722A1123|68 75|survival
P08428722A1123|76 97|blood urea nitrogen level
P08428722A1123|98 132|serum aspartate aminotransferase level
P08428722A1123|171 181|peritonitis
P08428722A1123|197 201|score
P08428722A1123|204 208|ileus
P08428750T0000|0 11|Localization
P08428750T0000|57 66|protein CLP
P08428750T0000|73 91|chromosome 10p13-ter
P08428907A0653|11 21|stage larvae
P08428907A0653|25 37|OBP transcript
P08428940A1763|7 12|mutant
P08428940A1763|41 47|hexamer
P08428940A1763|73 81|occupancy
P08428940A1763|96 108|RNA polymerase
P08428940A1763|117 122|result
P08428940A1763|151 160|initiation
P08428940A1763|163 170|merR mRNA
P08428952A0399|7 15|L-plastin
P08428952A0399|34 38|types
P08428952A0399|55 59|cells
P08428952A0399|77 82|origin
P08428952A0399|100 109|expression
P08428952A0399|131 143|tumorigenesis
P08428952A0399|151 157|tissues
P08428952A1957|16 23|evidence
P08428952A1957|28 34|fimbrin
P08428952A1957|51 64|plastin isoform
P08428952A1957|99 104|levels
P08428952A1957|115 123|intestine
P08428953A1718|4 11|promoter
P08428953A1718|38 47|expression
P08428953A1718|53 78|reporter beta-galactosidase
P08428953A1718|85 93|frequency
P08428953A1718|107 114|colonies
P08428953A1718|128 132|cells
P08428953A1718|144 152|L-plastin
P08428953A1718|169 176|contrast
P08428953A1718|181 188|promoter
P08428953A1718|222 229|colonies
P08428953A1718|238 248|fibroblasts
P08428953A1718|267 275|frequency
P08428953A1718|290 299|activation
P08428953A1718|313 320|colonies
P08428953A1718|346 356|fibroblasts
P08428953A1718|375 393|L-plastin expression
P08428965A1868|3 11|half-life
P08428965A1868|30 50|CBP/tk binding activity
P08428965A1868|79 86|ABSTRACT
P08428965A1868|100 104|WORDS
P08429019A0735|3 7|DNase
P08429019A0735|9 17|footprint
P08429019A0735|32 45|silencer region
P08429019A0735|65 70|repeat
P08429019A0735|88 92|motif
P08429019A0735|93 99|epsilon
P08429019A0735|119 124|shares
P08429019A0735|128 132|bases
P08429019A0735|140 162|GATA-1 consensus sequence
P08429019A2022|11 20|competitor
P08429019A2022|34 53|YY1 consensus sequence
P08429019A2022|65 79|protein B binding
P08429019A2022|87 96|competitor
P08429019A2022|115 141|yeast ABF-1 consensus sequence
P08429019A2022|173 180|ABSTRACT
P08429019A2022|195 199|WORDS
P08429020A0495|22 26|exons
P08429020A0495|32 38|introns
P08429020A0495|48 56|kilobases
P08429020A0495|80 91|reading frame
P08429020A0495|94 105|glycoprotein
P08429568A0000|0 16|Rhizobium meliloti
P08429568A0000|22 36|plasmid pRmeGR4b
P08429568A0000|47 79|nodulation competitiveness locus nfe
P08429568A0000|97 116|nodulation efficiency
P08429568A0000|131 137|ability
P08429568A0000|140 148|strain GR4
P08429568A0000|151 162|alfalfa roots
P08430087A0467|10 16|ability
P08430087A0467|42 52|gamma chains
P08430087A0467|82 87|assays
P08430087A0467|90 106|beta gamma activity
P08430087A0467|121 136|membrane extracts
P08430087A0467|151 159|fractions
P08430087A0467|172 179|Sf9 cells
P08430095A0161|4 9|report
P08430095A0161|22 35|identification
P08430095A0161|54 61|function
P08430095A0161|88 92|PRP38
P08430095A0913|20 24|Smd1p
P08430095A0913|35 43|component
P08430095A0913|57 73|splicing apparatus
P08430095A0913|78 83|factor
P08430095A0913|86 100|snRNA maturation
P08430095A0913|104 112|stability
P08431100A0108|4 8|study
P08431100A0108|32 47|motor performance
P08431100A0108|78 85|children
P08431100A0108|94 98|years
P08431100A0108|114 126|consciousness
P08431100A0108|138 142|hours
P08431100A0108|153 165|children group
P08432137A0000|13 22|parameters
P08432137A0000|30 47|adenosine deaminase
P08432137A0000|69 76|patients
P08432137A0000|79 96|PADA/serum ADA ratio
P08432137A0000|97 102|P/SADA
P08432137A0000|106 110|cases
P08432137A0000|118 125|lysozyme
P08432137A0000|135 139|cases
P08432137A0000|142 159|PLYS/serum LYS ratio
P08432137A0000|160 165|P/SLYS
P08432137A0000|169 173|cases
P08432137A0000|184 198|interferon gamma
P08432137A0000|207 211|cases
P08432137A0000|225 231|ability
P08432137A0000|265 273|effusions
P08432137A0000|278 283|others
P08432526A0580|5 9|exons
P08432526A0580|36 50|sequencing cDNAs
P08432526A0580|61 96|polymerase chain reaction amplification
P08432526A0580|100 120|fibroblast cDNA library
P08432696A1117|0 7|Deletion
P08432696A1117|13 20|apeA gene
P08432696A1117|40 47|deletion
P08432696A1117|55 65|proteinases
P08432696A1117|66 73|protease
P08432696A1117|79 93|aminopeptidase N
P08432696A1117|107 112|effect
P08432696A1117|115 124|cell growth
P08432696A1117|137 141|media
P08435755A0938|2 11|Experiment
P08435755A0938|13 35|scopolamine hydrobromide
P08435755A0938|45 49|mg/kg
P08435755A0938|93 103|stimulation
P08435755A0938|126 139|stage-3 seizure
P08435755A1078|30 34|stage
P08435755A1078|34 41|kindling
P08435755A1078|42 53|kindling rate
P08435755A1078|60 66|stage-3
P08435755A1078|72 79|seizures
P08435755A1078|80 96|seizure parameters
P08435755A1078|107 113|stage-3
P08435755A1078|147 152|values
P08435755A1078|176 180|group
P08435794A0658|0 10|CONCLUSIONS
P08435885A0787|17 27|correlation
P08435885A0787|35 63|pyridinium cross-link excretion
P08435885A0787|67 94|thyroid hormone concentrations
P08437521A0000|0 8|Mutations
P08437521A0000|40 47|residues
P08437521A0000|70 78|activator
P08437521A0000|91 98|areA gene
P08437521A0000|108 135|nitrogen metabolite repression
P08437521A0000|149 156|nidulans
P08437521A0000|184 190|ability
P08437521A0000|196 206|areA product
P08437521A0000|217 226|expression
P08437521A0000|233 237|genes
P08437521A0000|243 253|areA control
P08437737A0100|0 13|Naval personnel
P08437737A0100|23 31|standards
P08438584A0524|4 19|promoter activity
P08438584A0524|37 44|promoter
P08438584A0524|57 62|C2 ORFs
P08438584A0524|62 70|C1-C2 gene
P08438584A0524|80 87|promoter
P08438584A0524|93 97|V1 ORF
P08438584T0000|3 10|activity
P08438584T0000|16 34|coat protein promoter
P08438584T0000|51 61|mosaic virus
P08438584T0000|83 99|C1-C2 gene products
P08439564A0883|3 28|amino acid sequence alignment
P08439564A0883|52 69|Cbl binding proteins
P08439564A0883|83 88|factor
P08439564A0883|93 107|transcobalamin I
P08439564A0883|111 128|porcine haptocorrin
P08439564A0883|152 159|homology
P08439597A0000|9 21|communication
P08439597A0000|58 74|enzyme immunoassay
P08439597A0000|109 125|fluoroimmunoassay
P08439597A0000|131 143|determination
P08439597A0000|146 156|thyrotropin
P08439597A0000|164 173|blood spots
P08439597A0176|3 12|evaluation
P08439597A0176|44 54|study design
P08439597A0176|66 77|blood samples
P08439597A0176|87 102|screening centres
P08440238T0000|1 6|region
P08440238T0000|12 21|C-terminus
P08440238T0000|24 33|adenovirus
P08440238T0000|37 46|E1a protein
P08440238T0000|60 70|association
P08440238T0000|84 97|phosphoprotein
P08440238T0000|124 133|modulation
P08440238T0000|136 142|T24-ras
P08440238T0000|151 164|transformation
P08440238T0000|165 177|tumorigenesis
P08440238T0000|181 190|metastasis
P08440688A1509|5 11|studies
P08440688A1509|31 36|G alpha
P08440688A1509|38 42|genes
P08440688A1509|68 79|LLC-PK1 cells
P08440688A1509|86 91|growth
P08440688A1509|92 106|differentiation
P08440688A1509|110 123|hormone signals
P08440720A1404|0 9|Constructs
P08440720A1404|34 42|PfCPK cDNA
P08440720A1404|84 88|level
P08440720A1404|117 123|protein
P08441379A0912|16 29|proIL-1 beta cap
P08441379A0912|43 48|region
P08441379A0912|79 89|proIL-1 beta
P08441379A0912|102 106|virus
P08441379A0912|109 124|enhancer elements
P08441379A0912|152 160|monocytes
P08441379A0912|167 175|HeLa cells
P08441379A0912|207 224|IL-1 beta expression
P08441394A1297|9 14|PC-PLC
P08441394A1297|18 26|component
P08441394A1297|30 54|signal transduction pathway
P08441394A1297|64 76|transcription
P08441394A1297|79 83|c-fos
P08441394A1297|113 117|c-myc
P08441394A1297|135 143|PKC-delta
P08441394A1297|147 159|Ras activation
P08441411A1260|20 30|splenocytes
P08441411A1260|31 45|Gfi-1 expression
P08441411A1260|70 80|stimulation
P08441411A1260|98 103|levels
P08441411A1260|157 162|events
P08441411A1260|179 189|interaction
P08441411A1260|205 212|receptor
P08441411A1260|228 237|transition
P08441411A1260|254 259|S phase
P08441411A1260|264 272|cell cycle
P08441423A0145|42 50|GCD7 genes
P08441423A0145|67 74|products
P08441423A0145|95 109|GCN4 translation
P08441423A0145|128 137|conditions
P08441869A0334|3 17|plateau MO2 value
P08441869A0334|46 53|relation
P08442384A0430|29 35|protein
P08442384A0430|41 50|amino acids
P08442384A0430|65 76|reading frame
P08442384A0430|93 98|leader
P08442384A0430|123 138|amino acid peptide
P08442384T0000|3 23|SCH9 protein kinase mRNA
P08442384T0000|38 43|leader
P08442384T0000|58 69|reading frame
P08443122A0657|2 9|contrast
P08443122A0657|12 17|T cells
P08443122A0657|20 49|fibroblasts PILOT gene expression
P08443122A0657|65 70|signal
P08443339A1374|13 24|localization
P08443339A1374|40 55|promoter function
P08443339A1374|57 69|leaf epidermis
P08443339A1374|70 78|mesophyll
P08443339A1374|90 96|bundles
P08443339A1374|102 107|cortex
P08443339A1374|119 126|cylinder
P08443340A0522|2 6|order
P08443340A0522|28 45|expression patterns
P08443340A0522|67 81|promoter regions
P08443340A0522|101 113|glucanase gene
P08443340A0522|119 136|beta-glucuronidase
P08443340A0522|142 153|reporter gene
P08443340A0522|164 173|expression
P08443340A0522|181 190|constructs
P08443340A0522|203 215|tobacco plants
P08443341A0384|0 19|Southern blot analysis
P08443341A0384|25 30|probes
P08443341A0384|39 46|portions
P08443341A0384|62 70|B. napus MA
P08443341A0384|74 85|MB cDNA clones
P08443341A0384|96 112|MA type myrosinases
P08443341A0384|139 143|genes
P08443341A0384|149 165|MB type myrosinases
P08443341A0384|188 192|genes
P08443341A0384|195 201|B. napus
P08444184A0245|0 8|Sudomoina
P08444344A0000|0 10|Zinc fingers
P08444344A0000|35 39|motif
P08444344A0000|69 76|proteins
P08444345A0403|22 30|amino acid
P08444345A0403|34 41|sequence
P08444345A0403|58 64|rat EFIA
P08444345A0403|88 99|EFIA/DbpB/YB
P08444345A0403|100 111|family member
P08444345A0403|123 130|protein B
P08445299T0000|0 5|Effect
P08445299T0000|16 27|insufflation
P08445299T0000|30 41|deferoxamine
P08445299T0000|49 61|ozone toxicity
P08445655A1009|0 11|Localization
P08445655A1009|17 30|insertion locus
P08445655A1009|36 46|yeast genome
P08445655A1009|50 71|complementation studies
P08445655A1009|124 132|mutations
P08445729A0657|0 10|Replacement
P08445729A0657|16 29|spacer sequence
P08445729A0657|61 67|stretch
P08445729A0657|69 76|sequence
P08445729A0657|88 97|RNA binding
P08445792A0469|36 40|forms
P08445792A0469|84 90|species
P08445792A0469|104 109|stages
P08445792A0469|119 125|species
P08446579A0784|9 33|transcription factor Gal-ER
P08446579A0784|94 102|variation
P08446579A0784|119 134|activating domain
P08446579A0784|140 161|herpesvirus protein VP16
P08446579A0784|169 177|C terminus
P08446579A1210|12 18|fos gene
P08446579A1210|45 50|levels
P08446579A1210|66 81|estrogen addition
P08447005T0001|0 10|Elimination
P08447005T0001|24 48|influenzae type b meningitis
P08447005T0001|54 65|introduction
P08447005T0001|68 78|vaccination
P08449133A0578|0 13|Endosonography
P08449133A0578|32 45|tumor extension
P08449133A0578|51 58|T2 tumors
P08449133A0578|61 68|T3 tumors
P08449133A0578|77 84|T4 tumors
P08449943A0225|12 16|study
P08449943A0225|38 46|mechanism
P08449943A0225|49 54|action
P08449943A0225|57 65|8-Cl-cAMP
P08449943A0225|71 80|regulation
P08449943A0225|88 101|kinase isozymes
P08449943A0225|104 108|HL-60
P08449943A0225|127 139|leukemia cells
P08449978A0000|0 7|Analysis
P08449978A0000|10 28|cell cycle regulation
P08449978A0000|41 45|yeast
P08449978A0000|99 111|protein kinase
P08449978A0000|112 116|Cdc28
P08449978A0000|126 132|changes
P08449978A0000|135 142|activity
P08449978A0000|153 161|cell cycle
P08449978A0000|187 192|groups
P08449978A0000|195 201|cyclins
P08449978A0000|227 231|times
P08449986A0455|11 16|clones
P08449986A0455|40 44|cDNAs
P08449986A0455|48 55|MMI alpha
P08449986A0455|72 81|mouse brain
P08450015A0175|3 8|method
P08450015A0175|28 36|isolation
P08450015A0175|39 48|oxiracetam
P08450015A0175|60 67|standard
P08450015A0175|72 77|plasma
P08450015A0175|80 100|solid-phase extraction
P08450015A0175|111 119|formation
P08450015A0175|127 154|n-propyl carbamate derivatives
P08451187A0267|22 32|differences
P08451187A0267|49 60|ars sequences
P08451331T0000|0 7|Pathways
P08451331T0000|27 31|bulbs
P08451331T0000|61 72|hypothalamus
P08451331T0000|97 106|aggression
P08453101A0128|0 14|Pokeweed mitogen
P08453101A0128|52 68|c-jun messenger RNA
P08453101A0128|74 79|levels
P08453101A0128|81 86|T cells
P08453950A0498|9 24|seizure induction
P08453950A0498|45 48|mm Hg
P08453950A0498|51 58|brain pHi
P08453950A0498|104 108|level
P08454077A0956|2 9|contrast
P08454077A0956|25 31|U74500A
P08454077A0956|32 48|mg/kg i.v. infusion
P08454077A0956|73 89|revascularisation
P08454077A0956|122 132|reperfusion
P08454077A0956|206 213|controls
P08454077A0956|212 218|normals
P08454077A0956|231 243|muscle salvage
P08454077A0956|269 275|muscles
P08454077A0956|285 292|controls
P08454077A0956|313 319|normals
P08454077A0956|323 332|h ischaemia
P08454077A0956|412 419|ABSTRACT
P08454077A0956|434 438|WORDS
P08454591A0692|0 9|Sequencing
P08454591A0692|25 32|fragment
P08454591A0692|46 51|region
P08454591A0692|57 64|TSG6 gene
P08454591A0692|87 99|CAAT sequences
P08454591A0692|107 128|transcription start site
P08454591A1322|3 8|region
P08454591A1322|20 31|inducibility
P08454591A1322|47 55|positions
P08454591A1322|80 91|binding sites
P08454591A1322|95 99|IRF-1
P08454591A1322|114 120|NF-IL-6
P08454858A0285|0 7|Ig-alpha
P08454858A0285|11 17|Ig-beta
P08454858A0285|44 52|structure
P08454858A0285|60 69|amino acids
P08454858A0285|85 93|associate
P08454858A0285|109 117|effectors
P08454858A0285|157 174|signal transduction
P08455598A0000|7 13|mutants
P08455598A0000|55 65|alpha * cells
P08455598A0000|75 95|a/alpha aar1-6 genotype
P08455598A0000|106 123|alpha mating ability
P08455598A0000|132 144|mating ability
P08455598A0000|148 153|result
P08455598A0000|157 162|defect
P08455598A0000|165 172|a1-alpha
P08455598A0000|174 183|repression
P08455611A0000|22 32|interaction
P08455611A0000|61 74|globin promoter
P08455611A0000|80 90|alpha globin
P08455611A0000|101 107|element
P08455611A0000|108 112|HS-40
P08455611A0000|146 155|globin gene
P08455611A0154|21 35|expression assay
P08455611A0154|40 44|HS-40
P08455611A0154|65 72|enhancer
P08455611A0154|93 114|globin promoter activity
P08455611A0154|116 124|K562 cells
P08455611A0154|136 143|cell line
P08455611A0154|166 171|origin
P08455623A0630|7 13|results
P08455623A0630|30 40|23S pre-rRNA
P08455623A0630|55 61|species
P08455623A0630|72 80|depletion
P08455623A0630|114 125|proteins NOP1
P08455623A0630|142 146|snr10
P08455623A0630|152 157|strain
P08455629A0335|0 8|Breitbart
P08456378A0134|4 8|study
P08456378A0134|21 31|feasibility
P08456378A0134|52 67|lymphangiography
P08456378A0134|83 91|technique
P08456378A0134|101 105|model
P08456879A0000|0 8|OBJECTIVE
P08456879A0000|12 18|purpose
P08456879A0000|48 61|concentrations
P08456879A0000|64 76|serum cotinine
P08456879A0000|99 103|blood
P08457205A0240|8 24|amino acid sequence
P08457205A0240|51 57|protein
P08457205A0240|74 90|% sequence identity
P08457205A0240|95 103|sequences
P08457205A0240|122 127|G alpha
P08457205A0240|133 138|G alpha
P08457205A0240|140 144|cDNAs
P08457291A0170|0 8|Estradiol
P08457291A0170|24 33|expression
P08457291A0170|43 57|proto-oncogenes
P08457291A0170|98 104|regions
P08457291A0170|118 130|c-fos oncogene
P08458660A0855|0 6|Air lead
P08458660A0855|36 43|variable
P08458849A0364|13 22|regulation
P08458849A0364|25 41|flaN transcription
P08458849A0364|58 62|sigma
P08458849A0364|65 72|promoter
P08458849A0364|79 89|ftr elements
P08458849A0364|112 133|transcription start site
P08458906A0827|1 12|micrograms/l
P08458906A0827|26 30|urine
P08458906A0827|64 70|persons
P08459012T0000|7 13|dimelia
P08459012T0000|18 27|deficiency
P08459012T0000|33 37|tibia
P08459465A0257|15 19|study
P08459465A0257|39 56|energy expenditures
P08459465A0257|61 68|patients
P08459465A0257|82 92|calorimetry
P08459465A0257|116 132|energy expenditure
P08459465A0257|162 169|equation
P08459465A0257|187 203|energy expenditure
P08459465A0257|220 241|energy expenditure times
P08459465A0257|244 257|activity factor
P08459465A0257|262 273|stress factor
P08460270A0205|20 29|infections
P08460270A0205|40 45|larvae
P08460346A0350|60 64|study
P08460918A0252|0 4|Group
P08460918A0252|34 41|patients
P08460918A0252|42 46|group
P08460918A0252|81 88|patients
P08460918A0252|104 113|impairment
P08460918A0252|124 132|bilirubin
P08460918A0252|135 146|mumol liter-1
P08460918A0252|147 165|alkaline phosphatase
P08460918A0252|169 177|IU liter-1
P08460918A0252|178 205|gamma-glutamyltranspeptidase
P08460918A0252|209 217|IU liter-1
P08460918A0252|218 222|group
P08460918A0252|269 276|patients
P08460918A0252|303 320|hyperbilirubinemia
P08460918A0252|325 336|mumol liter-1
P08461946A0386|16 21|change
P08461946A0386|26 36|improvement
P08461946A0386|50 57|findings
P08461946A0386|58 65|t1/2 time
P08461946A0386|72 84|split function
P08461946A0386|89 96|patients
P08461981A0882|23 29|animals
P08461981A0882|39 44|months
P08461981A0882|51 55|study
P08461981A0882|63 83|regeneration phenomena
P08463284A1531|24 36|p34cdc2 kinase
P08463284A1531|63 68|lamina
P08463284A1531|79 87|stability
P08463284A1531|94 102|cell cycle
P08463320A1219|6 38|copper-phenanthroline footprinting
P08463320A1219|51 79|gel shift assembly intermediates
P08463320A1219|108 113|G4oric
P08463320A1219|125 136|SSB tetramers
P08463320A1219|159 166|addition
P08463320A1219|173 184|SSB tetramers
P08463320A1219|194 202|formation
P08463320A1219|212 220|structure
P08463485T0000|0 6|Effects
P08463485T0000|21 37|endotoxin infusion
P08463485T0000|55 69|oxytocin release
P08464056A0000|0 5|Finger
P08464056A0000|24 37|finger proteins
P08464056A0000|38 45|FAX-ZFPs
P08464056A0000|57 65|subfamily
P08464056A0000|75 86|C2H2 type ZFPs
P08464056A0000|89 101|Xenopus laevis
P08464056A0510|7 14|evidence
P08464056A0510|28 39|organization
P08464056A0510|42 66|FAX-ZFP transcription units
P08464056A0510|79 98|Southern blot analysis
P08464056A0510|113 132|restriction fragments
P08464056A0510|154 176|field gel electrophoresis
P08464056A0510|188 200|hybridization
P08464056A0510|209 219|chromosomes
P08464924A0243|1 7|rat cDNA
P08464924A0243|19 23|eIF-5
P08464924A0243|95 106|eIF-5 protein
P08466864A0878|10 17|analyses
P08466864A0878|37 46|importance
P08466864A0878|49 57|sequences
P08466864A0878|70 78|bp segment
P08466864A0878|120 140|element binding protein
P08466864A0878|146 156|binding site
P08466864A0878|159 166|TGF-beta
P08466864A0878|171 187|PMA responsiveness
P08466864A0878|208 222|Sp1 binding sites
P08466864A0878|230 245|promoter activity
P08468475A1280|17 37|internalization assays
P08468475A1280|57 65|YT-1 cells
P08468475A1280|69 83|IL-2R alpha chain
P08468475A1280|124 139|IL-2R beta subunit
P08468475A1280|154 163|IL-2R alpha
P08468475A1280|189 209|F42A-IL-2R beta complex
P08468475A1280|223 235|alpha-subunit
P08468475A1280|258 265|affinity
P08468475A1280|271 289|F42A binding reaction
P08469831T0001|19 26|dynamics
P08469831T0001|29 43|prostaglandin E1
P08469831T0001|50 60|nicardipine
P08469831T0001|78 86|reactions
P08469831T0001|92 96|hyper
P08469831T0001|111 115|state
P08469831T0001|124 128|shock
P08469831T0001|132 139|rat model
P08470021A0195|13 22|prevalence
P08470021A0195|25 37|IgG antibodies
P08470021A0195|45 60|Trypanosoma cruzi
P08470021A0195|70 80|blood donors
P08470021A0195|86 102|Instituto Nacional
P08470021A0195|105 115|Cardiologia
P08470021A0195|116 128|Ignacio Chavez
P08470021A0195|131 140|Mexico City
P08470895A1617|0 10|Examination
P08470895A1617|25 32|sequence
P08470895A1617|39 51|mRNA start site
P08470895A1617|61 67|TATA box
P08470895A1617|84 100|enhancer sequences
P08471241T0000|13 21|synthesis
P08471241T0000|41 47|removal
P08471241T0000|67 71|women
P08471629A0816|0 14|Pseudosubstrate
P08471629A0816|33 42|C-terminus
P08471629A0816|57 67|PKC isotypes
P08471629A0816|77 84|beta-PKC
P08471629A0816|91 102|nPKC activity
P08471629A0816|114 124|Histone IIIS
P08471629A0816|127 133|peptide
P08471629A0816|140 148|substrate
P08471796A1654|12 18|results
P08471796A1654|23 27|model
P08471796A1654|34 43|regulation
P08471796A1654|53 66|gene expression
P08471796A1654|69 81|A. caulinodans
P08472750A0999|6 20|oxide inhalation
P08472750A0999|48 59|hypertension
P08472750A0999|62 82|porcine endotoxin shock
P08472750A0999|102 112|oxygenation
P08472750A0999|131 141|attenuation
P08472750A0999|154 163|activation
P08473731A0149|25 32|B29 genes
P08473731A0149|40 59|alpha/beta components
P08473731A0149|79 85|complex
P08473731A0149|100 105|B cells
P08473967T0000|0 9|Bipolarity
P08473967T0000|12 28|Jungian type theory
P08473967T0000|35 59|Myers-Briggs Type Indicator
P08474438A0000|1 7|variety
P08474438A0000|17 34|ribonucleoproteins
P08474438A0000|76 88|RNA polymerase
P08474438A0000|91 101|transcripts
P08474438A0000|144 165|RNA processing reactions
P08474438A0000|175 197|pre-mRNA polyadenylation
P08474438A0000|201 208|splicing
P08474438A0000|234 246|mRNA transport
P08474439A0877|0 8|Mutations
P08474439A0877|16 20|sites
P08474439A0877|31 37|effects
P08474439A0877|40 45|muscle
P08474439A0877|59 63|cells
P08474439A0877|74 85|site mutation
P08474439A0877|100 105|effect
P08474439A0877|120 130|muscle types
P08474439A0877|131 139|mutations
P08474439A0877|156 160|E-box
P08474439A0877|189 198|expression
P08474439A0877|208 213|muscle
P08474439A0877|217 225|mutations
P08474439A0877|231 238|CArG site
P08474439A0877|262 271|expression
P08474439A0877|281 286|muscle
P08474456A1041|9 28|transfection analysis
P08474456A1041|38 46|mutations
P08474456A1041|69 74|region
P08474456A1041|113 129|LyF-1 binding sites
P08474456A1041|141 150|D' activity
P08474464A0348|17 28|relationship
P08474464A0348|38 44|Rev-Erb
P08474464A0348|57 70|TR binding sites
P08475104A0341|22 36|promoter element
P08475104A0341|71 84|G1-S activation
P08475104A0341|95 109|thymidine kinase
P08475104A0341|115 122|promoter
P08475104A0341|141 145|cells
P08475104A0341|157 162|target
P08475104A0341|165 171|cyclin A
P08475104A0341|178 193|p33cdk2 complexes
P08476087A0814|15 24|influences
P08476087A0814|50 54|range
P08476087A0814|64 72|pressures
P08476854A0097|0 4|DNase
P08476854A0097|6 17|footprinting
P08476854A0097|22 29|rat liver
P08476854A0097|37 44|extracts
P08476854A0097|76 82|domains
P08476854A0097|110 128|base pair DNA fragment
P08476854A0097|127 135|base pairs
P08479742A0985|35 41|ability
P08479742A0985|65 81|cell proliferation
P08479742A0985|109 117|processes
P08481004A0321|7 11|clone
P08481004A0321|29 40|endonuclease
P08482539A0913|0 19|Northern blot analysis
P08482539A0913|73 82|transcript
P08482539A0913|97 101|xylan
P08483412A0000|12 24|nifH promoters
P08483412A0000|26 35|Klebsiella
P08483412A0000|71 75|sigma
P08483412A0000|88 96|promoters
P08483412A0000|128 138|NifA protein
P08483479A1056|43 66|collagen promoter activity
P08483479A1056|66 74|calvariae
P08483479A1056|112 116|alpha
P08483479A1056|117 132|collagen promoter
P08483479A1056|146 164|elements down-stream
P08483479A1056|171 179|kilobases
P08483479A1056|199 212|cAMP repression
P08483479A1056|214 235|collagen gene expression
P08484514A1536|24 33|isoflurane
P08484514A1536|44 63|baseline vein diameter
P08484514A1536|70 80|stimulation
P08484689T0000|0 9|Prevalence
P08484689T0000|22 30|arthritis
P08484689T0000|44 49|factor
P08484689T0000|52 56|women
P08484689T0000|57 64|evidence
P08484689T0000|76 82|decline
P08484891A0000|28 39|conditioning
P08484891A0000|92 98|changes
P08484891A0000|124 131|evidence
P08484891A0000|154 161|circuits
P08484891A0000|195 202|memories
P08485317A0000|3 18|fission yeast dsk1
P08485317A0000|35 44|suppressor
P08485317A0000|61 71|dis1 mutants
P08485317A0000|90 102|protein kinase
P08486035T0000|0 6|Closure
P08486035T0000|12 33|patent ductus arteriosus
P08486035T0000|39 46|Ligaclip
P08486035T0000|55 69|minithoracotomy
P08486276A0419|0 17|Sequence comparison
P08486276A0419|47 61|protein database
P08486276A0419|84 102|% aa sequence homology
P08486276A0419|114 126|transmembrane
P08486276A0419|131 138|proteins
P08486276A0419|161 175|chloramphenicol
P08486276A0419|183 194|tetracycline
P08486276A0419|198 207|resistance
P08486276A0419|228 241|symport protein
P08486705A0181|3 11|yeast gene
P08486705A0181|23 27|eIF-5
P08486705A0181|115 126|eIF-5 protein
P08488700A0283|3 12|strategies
P08488700A0283|20 29|hepatitis B
P08488700A0283|33 42|hepatitis D
P08488700A0283|84 95|immunization
P08488700A0283|113 120|exposure
P08488700A0283|132 136|blood
P08488700A0283|139 154|blood derivatives
P08488700A0283|158 166|education
P08488700A0283|179 187|awareness
P08488700A0283|192 201|hepatitis B
P08488700A0283|224 230|disease
P08490002A0620|0 5|Xylose
P08490002A0620|29 36|polymers
P08490002A0620|62 70|cellulose
P08490002A0620|78 83|breads
P08491124A0517|12 23|construction
P08491124A0517|29 43|mouth protectors
P08491124A0517|73 87|instrumentation
P08491124A0517|93 97|costs
P08491124A0517|104 112|materials
P08491124A0517|139 153|mouth protectors
P08491383A0154|3 15|alpha-subunit
P08491383A1291|17 29|alpha-subunit
P08491383A1291|51 57|protein
P08491383A1291|66 85|transcription factors
P08491383A1291|127 144|interaction domains
P08491683A0651|5 12|patients
P08491683A0651|21 28|patients
P08491683A0651|46 53|patients
P08491683A0651|78 91|adenocarcinoma
P08491683A0651|97 104|prostate
P08492164T0000|11 21|burst firing
P08492164T0000|44 49|cortex
P08492164T0000|57 71|depth dependence
P08492164T0000|77 82|effect
P08492164T0000|91 109|interaction measures
P08492290A0306|27 32|method
P08492290A0306|42 47|medium
P08492290A0306|55 64|strength mu
P08492290A0306|72 89|stability constants
P08492290A0306|90 96|log beta
P08492290A0306|106 112|log beta
P08495786A0085|0 21|Cryopreservation straws
P08495786A0085|32 36|media
P08495786A0085|67 73|surface
P08495786A0085|89 93|donor
P08496157A0000|3 11|bcl-2 gene
P08496157A0000|43 50|proteins
P08496157A0000|72 84|carboxyl tails
P08496157A0000|107 123|splicing mechanism
P08496184A0772|13 24|reading frame
P08496184A0772|30 34|clone
P08496184A0772|59 68|chromosome
P08496184A0772|84 91|sequence
P08496184A0772|99 113|type counterpart
P08496185A0484|10 16|cloning
P08496185A0484|20 45|nucleotide sequence analysis
P08496185A0484|60 78|adenylate kinase gene
P08496185A0484|99 104|region
P08496185A0484|109 119|nucleotides
P08496475T0000|0 12|Calcification
P08496475T0000|26 38|Streptococcus
P08496475T0000|44 58|Corynebacterium
P08496475T0000|59 70|Bacterionema
P08496475T0000|71 81|matruchotii
P08496599A0310|3 8|result
P08496599A0310|22 29|splicing
P08496599A0310|33 39|BGP gene
P08496599A0310|77 87|mRNA species
P08496601A1153|1 10|comparison
P08496601A1153|16 24|promoters
P08496601A1153|28 38|muMIP-1 beta
P08496601A1153|42 53|muMIP-1 alpha
P08496601A1153|71 81|CK-1 element
P08496601A1153|94 110|expression studies
P08496601A1153|123 133|macrophages
P08496601A1153|145 153|fragments
P08496601A1153|165 175|muMIP-1 beta
P08496601A1153|181 192|muMIP-1 alpha
P08496601A1153|194 201|promoter
P08496601A1153|215 259|growth hormone reporter gene link LPS-inducibility
P08496601A1153|268 283|promoter segments
P08496601A1153|312 332|consensus CK-1 sequence
P08496848A0692|16 34|contrast differences
P08496848A0692|53 64|FSE sequences
P08496848A0692|94 106|SE counterpart
P08497190T0079|0 15|Sequence analysis
P08497190T0079|19 32|identification
P08497190T0079|53 59|mutants
P08497248A0000|20 27|receptor
P08497248A0000|30 39|macrophage
P08497248A0000|58 63|factor
P08497248A0000|65 69|CSF-1
P08497248A0000|73 90|c-fms protooncogene
P08497248A0000|143 152|phagocytes
P08497248A0000|156 167|trophoblasts
P08497259A0452|3 7|level
P08497259A0452|13 32|SUP4A53T61 transcript
P08497259A0452|56 67|tap1-1 mutant
P08497269A0999|4 21|sequence similarity
P08497269A0999|31 41|possibility
P08497269A0999|65 73|ribosomes
P08497269A0999|75 87|tRNA molecules
P08497269A0999|91 99|functions
P08497269A0999|102 112|conjunction
P08497269A0999|144 153|tRNA levels
P08497269A0999|162 168|process
P08497269A0999|171 191|translation elongation
P08497273T0000|0 4|NF-HB
P08497273T0000|14 22|repressor
P08497273T0000|33 46|immunoglobulin
P08497273T0000|59 71|alpha enhancer
P08497273T0000|79 84|stages
P08497273T0000|87 107|B-cell differentiation
P08497280A0266|8 17|regulation
P08497280A0266|45 64|cell cycle progression
P08497280A0266|103 112|regulators
P08497280A0266|114 130|SWI4 transcription
P08497280A1397|32 38|pathway
P08497280A1397|55 71|SWI4 transcription
P08497280A1397|77 83|absence
P08497280T0000|32 39|elements
P08497280T0000|47 63|SWI4 transcription
P08497280T0000|74 82|cell cycle
P08498570A1118|2 11|conclusion
P08498570A1118|12 18|changes
P08498570A1118|21 43|carotid sinus stimulation
P08498570A1118|50 58|blood flow
P08498570A1118|64 71|hindlimb
P08498570A1118|79 85|changes
P08498570A1118|92 96|Pcrit
P08499376A0000|43 56|predictability
P08499376A0000|70 80|corrections
P08499903A0883|4 11|patients
P08499903A0883|16 24|deletions
P08499903A0883|36 41|origin
P08499903A0883|44 51|deletion
P08499916A0000|3 12|COL7A1 gene
P08499916A0000|25 39|type VII collagen
P08499916A0000|60 72|candidate gene
P08499916A0000|109 113|forms
P08499916A0000|126 145|epidermolysis bullosa
P08500524A0424|7 11|study
P08500524A0424|27 35|gamma gene
P08500524A0424|88 102|splicing signals
P08500524A0424|120 137|intron organization
P08500938A0408|14 18|grade
P08500938A0408|63 70|excision
P08500938A0408|90 97|surfaces
P08500938A0408|112 121|metaphysis
P08501030A0456|13 21|induction
P08501030A0456|29 46|.5 operon expression
P08501030A0456|82 88|strains
P08501678A0498|7 15|knowledge
P08501678A0498|35 45|development
P08501678A0498|59 84|immunoprophylactic strategy
P08501678A0498|99 108|Hib disease
P08503348A0226|3 27|HMG CoA reductase inhibitors
P08503348A0226|67 72|agents
P08504707A0376|3 10|etiology
P08504707A0376|11 19|pathology
P08504707A0376|20 26|brain CT
P08504707A0376|31 38|features
P08504707A0376|47 60|manifestations
P08504707A0376|64 72|treatment
P08504707A0376|80 88|accidents
P08504928T0000|16 27|TFIID subunit
P08504928T0000|39 45|homolog
P08504928T0000|56 75|cell cycle gene product
P08504928T0000|95 104|DNA binding
P08504928T0000|127 133|subunit
P08504928T0000|135 139|TFIID
P08504932A0123|12 17|aspect
P08504932A0123|20 39|GATA factor expression
P08504932A0123|53 64|GATA proteins
P08504932A0123|103 117|site specificity
P08504932A0123|143 147|cells
P08504933A0000|0 4|Pit-1
P08504933A0000|23 37|POU domain factor
P08504933A0000|54 63|appearance
P08504933A0000|71 84|cell phenotypes
P08504933A0000|107 111|gland
P08505075A0236|0 12|Maximum number
P08505075A0236|15 21|strains
P08505075A0236|43 60|S. bareilly serotype
P08505075A0236|99 105|S. typhi
P08505340T0000|0 15|Characterization
P08505340T0000|27 36|regulation
P08505340T0000|42 49|promoter
P08505340T0000|55 90|rat prostaglandin endoperoxide synthase
P08505340T0000|100 113|granulosa cells
P08505495A0253|3 11|retention
P08505495A0253|14 21|75SeHCAT
P08505605A0461|0 21|Patient characteristics
P08505605A0461|40 45|wounds
P08505605A0461|54 60|patient
P08505605A0461|64 83|wound characteristics
P08505605A0461|99 104|extent
P08505605A0461|107 113|healing
P08505605A0461|134 140|healing
P08506317A0000|0 6|Members
P08506317A0000|12 22|C/EBP family
P08506317A0000|25 43|basic-leucine zipper
P08506317A0000|50 69|transcription factors
P08506317A0000|73 84|heterodimers
P08506317A0000|97 103|CAAT box
P08506317A0000|128 141|enhancer motifs
P08506384A0146|11 15|cells
P08506384A0146|16 30|phosphorylation
P08506384A0146|33 42|eIF-2 alpha
P08506384A0146|54 61|activity
P08506384A0146|64 69|eIF-2B
P08506384A0146|73 93|GDP-GTP exchange factor
P08506384A0146|97 101|eIF-2
P08507921A1021|2 11|conclusion
P08507921A1021|17 28|observations
P08507921A1021|45 58|stratification
P08507921A1021|66 75|MI patients
P08507921A1021|78 91|plasma ANF level
P08507921A1021|113 118|method
P08507921A1021|132 140|prognosis
P08507921A1021|158 168|individuals
P08507921A1021|190 194|death
P08508774A0242|0 7|Analysis
P08508774A0242|13 19|binding
P08508774A0242|55 66|DNA fragments
P08508774A0242|73 78|region
P08508778A0112|0 11|Yeast mutants
P08508778A0112|30 37|NOP1 gene
P08508778A0112|62 72|fibrillarin
P08508778A0112|79 89|temperature
P08508778A0112|102 107|growth
P08508778A0112|129 138|processing
P08508861A0294|3 10|patients
P08508861A0294|26 34|ischaemia
P08508861A0294|51 56|groups
P08508861A0294|62 66|basis
P08508861A0294|72 77|change
P08508861A0294|80 101|lactate extraction ratio
P08508861A0294|108 123|balloon inflation
P08509051A0316|12 19|patients
P08509051A0316|31 43|mortality rate
P08509333A0843|7 13|protein
P08509333A0843|35 50|membrane fraction
P08509333A0843|64 72|minicells
P08509333A0843|83 90|plasmids
P08509333A0843|98 105|ftsN gene
P08509333A0843|130 144|membrane protein
P08509335T0000|42 59|1,3-beta-glucanase
P08509419A0785|0 9|Expression
P08509419A0785|16 22|protein
P08509419A0785|47 54|tyrosine
P08509419A0785|76 86|suppression
P08509419A0785|94 98|yeast
P08509419A0785|110 122|TyrRS activity
P08509430A0372|16 30|complementation
P08509430A0372|51 56|mutant
P08509430A0372|59 71|Chlamydomonas
P08509430A0372|72 78|CC-2341
P08509430A0372|79 88|ac-u-g-2.3
P08509430A0372|97 114|frameshift mutation
P08509430A0372|120 127|psaB gene
P08509430A0372|131 139|selection
P08509430A0372|156 168|transformants
P08509430A0372|178 183|medium
P08510320A0000|10 16|strains
P08510320A0000|105 118|concentrations
P08510320A0000|127 131|total
P08510320A0000|148 153|agents
P08510320A0000|163 171|arbekacin
P08510320A1249|34 38|MRSAs
P08510320A1249|50 54|Japan
P08510320A1249|80 89|resistance
P08510320A1249|96 100|drugs
P08510320A1249|135 144|resistance
P08510320A1249|152 163|beta-lactams
P08510647A1347|54 62|variation
P08510647A1347|63 69|storage
P08510647A1347|72 92|utilization properties
P08510647A1347|101 115|barley globulins
P08510924A0490|33 47|transactivation
P08510924A0490|58 70|HSP70 promoter
P08510924A0490|73 83|Myb proteins
P08511994A0000|30 34|carps
P08511994A0000|58 69|ichthiomycin
P08511994A0000|72 85|concentrations
P08511994A0000|99 112|micrograms/dm3
P08512728A0991|0 6|RESULTS
P08512728A0991|31 41|differences
P08512728A0991|61 65|group
P08512728A0991|85 90|number
P08512728A0991|93 100|patients
P08512728A0991|120 131|fibrillation
P08512728A0991|136 145|conduction
P08512728A0991|151 166|accessory pathway
P08513025A0000|12 17|effect
P08513025A0000|28 36|thickness
P08513025A0000|42 52|correlation
P08513025A0000|60 64|serum
P08513025A0000|70 83|bilirubin level
P08513025A0000|101 109|bilirubin
P08513025A0000|115 122|readings
P08514757A1100|4 16|immunophilins
P08514757A1100|33 37|roles
P08514757A1100|40 55|receptor assembly
P08514757A1100|75 82|category
P08514757A1100|85 90|ligand
P08514757A1100|111 120|modulators
P08514757A1100|123 137|protein function
P08514766A0732|3 16|GTPase activity
P08514766A0732|19 25|CDC42Ce
P08514766A0732|55 65|n-chimaerin
P08514766A0732|84 90|protein
P08514766A0732|104 110|p21 rac1
P08515619A0184|0 16|Tl-201 uptake ratio
P08515619A0184|27 35|ventricle
P08515619A0184|54 58|ratio
P08515619A0184|66 71|counts
P08515619A0184|82 90|ventricle
P08515619A0184|93 98|counts
P08515619A0184|124 129|Tl-201
P08515619A0184|167 175|emphysema
P08515619A0184|178 186|B type COPD
P08515619A0184|189 209|Burrows classification
P08515619A0184|216 223|controls
P08515776A0971|18 23|domain
P08515776A0971|48 54|regions
P08515776A0971|85 90|region
P08516301A0080|40 44|exons
P08516301A0080|50 56|introns
P08516308A0669|17 21|cells
P08516308A0669|37 49|microcolonies
P08516308A0669|53 57|cells
P08516308A0669|92 96|cells
P08516324A0000|17 29|translocation
P08516324A0000|50 61|Ewing sarcoma
P08516324A0000|89 93|tumor
P08516324A0000|112 119|molecule
P08516324A0000|152 158|portion
P08516324A0000|164 170|EWS gene
P08516324A0000|204 209|domain
P08516324A0000|222 229|FLI1 gene
P08517737A0889|5 12|findings
P08517737A0889|25 29|range
P08517737A0889|50 59|conditions
P08517737A0889|79 90|water systems
P08517737A0889|108 118|populations
P08517737A0889|121 128|bacteria
P08518797T0000|8 24|liver glycogenosis
P08518797T0000|25 36|localization
P08518797T0000|40 48|isolation
P08518797T0000|52 64|candidate gene
P08519621A0150|4 13|conclusion
P08519621A0150|26 37|observations
P08519621A0150|54 60|changes
P08519621A0150|85 90|stages
P08519621A0150|93 99|illness
P08519621A0150|125 135|association
P08519621A0150|155 162|bacteria
P08519621A0150|168 174|pharynx
P08519621A0150|194 198|tract
P08519862T0001|0 10|Measurement
P08519862T0001|21 33|IgM antibodies
P08520646A0000|0 20|Embryo coculture system
P08520646A0000|49 58|mechanisms
P08520646A0000|72 79|decrease
P08520646A0000|82 90|fertility
P08520646A0000|95 99|aging
P08521414A1384|5 13|cell lines
P08521414A1384|23 33|methylation
P08521414A1384|39 47|CpG island
P08521414A1384|75 82|p16INK4A
P08521414A1384|102 107|levels
P08521414A1384|164 169|E1 beta
P08521414A1384|181 189|cell lines
P08521414A1384|200 212|p16INK4A locus
P08521717A0126|18 25|reaction
P08521717A0126|26 34|PAP method
P08521717A0126|42 50|antiserum
P08521717A0126|53 58|Factor
P08521717A0126|75 82|antibody
P08521717A0126|112 119|biopsies
P08521717A0126|131 136|Factor
P08521717A0126|141 148|activity
P08521717A0126|165 175|endothelium
P08521717A0126|190 198|insertion
P08521717A0126|201 210|LNG-IUD-20
P08521780A0485|0 9|Umweltchem
P08522175A0306|0 4|Egd1p
P08522175A0306|24 28|BTF3b
P08522175A0306|52 62|beta subunit
P08522175A0306|111 117|complex
P08522175A0306|165 178|protein sorting
P08522175A0306|181 193|translocation
P08522175A0306|194 201|Wiedmann
P08522175A0306|207 212|Nature
P08522511A1250|26 38|lyase activity
P08522511A1578|12 18|regions
P08522511A1578|69 90|beta-glucuronidase gene
P08522511A1578|116 119|f. sp
P08522511A1578|150 177|beta-glucuronidase activities
P08522511A1578|182 194|transformants
P08522530A1342|4 11|nifA mRNA
P08522530A1342|18 23|points
P08522530A1342|36 50|primer extension
P08522530A1342|69 78|transcript
P08522530A1342|106 114|anaerobox
P08522530A1342|132 141|transcript
P08522530A1342|167 171|sigma
P08523031A0737|58 62|onset
P08523031A0737|70 77|seizures
P08523031A0737|96 101|stroke
P08523031A0737|105 114|recurrence
P08523545T0000|8 25|papillomavirus type
P08523545T0000|28 36|E7 protein
P08523545T0000|48 61|adenovirus type
P08523545T0000|92 106|transactivation
P08523545T0000|108 121|adenovirus type
P08523545T0000|128 132|genes
P08523545T0000|153 175|Oct-1 DNA binding activity
P08523566A1106|11 19|detergent
P08523566A1106|22 33|% Nonidet P-40
P08523566A1106|50 60|interaction
P08523566A1106|92 97|nature
P08523566A1106|103 113|interaction
P08524036A0747|10 21|expectations
P08524036A0747|43 47|level
P08524036A0747|50 58|variation
P08524036A0747|64 69|stripe
P08524036A0747|71 84|enhancer region
P08524036A0747|94 111|point substitutions
P08524036A0747|115 133|insertion/deletions
P08524036A0747|143 147|sites
P08524036A0747|162 166|level
P08524036A0747|169 177|variation
P08524036A0747|197 203|regions
P08524229T0000|0 10|Degradation
P08524229T0000|16 32|soybean ribulose-1
P08524229T0000|33 72|bisphosphate carboxylase small-subunit mRNA
P08524229T0000|107 114|cleavage
P08524235A0695|0 6|Cloning
P08524235A0695|10 19|sequencing
P08524235A0695|47 54|deletion
P08524235A0695|70 75|region
P08524235A0695|79 83|helix
P08524235A0695|118 123|region
P08524235A0695|136 141|result
P08524235A0695|155 162|splicing
P08524235A0695|165 170|max RNA
P08524241A0212|15 23|induction
P08524241A0212|26 30|HSP82
P08524241A0212|59 67|IME1-IME2
P08524241A0212|83 89|cascade
P08524260A0835|3 17|domain structure
P08524260A0835|26 31|LTBP-2
P08524260A0835|61 66|LTBP-2
P08524260A0835|79 86|examples
P08524260A0835|108 113|growth
P08524260A0835|125 131|repeats
P08524260A0835|148 164|consensus sequence
P08524260A0835|168 181|calcium binding
P08524260A0835|195 202|examples
P08524260A0835|215 220|motifs
P08524260A0835|237 246|fibrillins
P08524260A0835|250 255|LTBP-1
P08524267A1022|9 18|expression
P08524267A1022|53 72|prothymosin alpha gene
P08524267A1022|78 85|reporter
P08524267A1022|103 112|repertoire
P08524267A1022|126 130|genes
P08524267A1022|181 190|myc mutants
P08524272T0000|12 21|regulation
P08524272T0000|27 36|alpha/beta
P08524272T0000|58 72|Jak/Stat pathway
P08524272T0000|100 124|tyrosine phosphatase SHPTP1
P08524284A0309|14 22|isolation
P08524284A0309|26 35|expression
P08524284A0309|38 42|cDNAs
P08524284A0309|51 58|PTF gamma
P08524284A0309|62 69|PTF delta
P08524284A0309|88 94|studies
P08524284A0309|106 115|antibodies
P08524284A0309|138 147|PTF complex
P08524284A0309|150 161|HeLa extracts
P08524292A1022|0 6|Results
P08524292A1022|14 27|mechanism study
P08524292A1022|64 78|transactivation
P08524292A1022|115 121|protein
P08524292A1022|140 147|activity
P08524292A1022|149 158|DNA binding
P08524314A0216|9 27|Ty enhancer activator
P08524314A0216|27 38|gene sequence
P08524314A0216|48 54|protein
P08524314A0216|71 79|N terminus
P08524314A0216|88 98|zinc cluster
P08524314A0216|102 118|dimerization motif
P08524314A0216|140 145|family
P08524314A0216|159 166|proteins
P08525186A0288|0 7|Refugees
P08525186A0288|38 42|Chile
P08525186A0288|57 62|health
P08525186A0288|77 86|proportion
P08525186A0288|103 114|counterparts
P08525186A0288|121 129|odds ratio
P08526620A1344|4 8|study
P08526620A1344|22 31|importance
P08526620A1344|42 64|SC5b-9 complement complex
P08526620A1344|76 81|marker
P08526620A1344|87 96|evaluation
P08526620A1344|99 118|complement activation
P08526620A1344|140 145|bypass
P08528479A0000|0 17|Videonystagmoscopy
P08528479A0000|53 61|responses
P08528479A0000|77 82|system
P08528479A0000|86 95|population
P08528479A0000|98 105|patients
P08528479A0000|120 127|deficits
P08528796A1470|11 20|UA PI values
P08528796A1470|37 45|deviation
P08528796A1470|65 73|parameter
P08529098A0549|8 27|sequence similarities
P08529098A0549|53 57|yeast
P08529098A0549|70 77|proteins
P08529098A0549|127 133|domains
P08529098A0549|156 168|transmembrane
P08529098A0549|176 181|domain
P08529098A0549|199 220|susceptibility mutation
P08529098A0549|249 262|transport motif
P08529630A0840|26 37|P protein mRNA
P08529630A0840|52 56|level
P08529630A0840|59 63|roots
P08529654A0589|3 47|B. germanica cyclophilin amino acid sequence shares
P08529654A0589|49 57|% identity
P08529654A0589|74 91|cyclophilin isoform
P08529654A0589|118 122|Cyp-1
P08529662A0507|43 53|ERp57/GRP58
P08529662A0507|55 69|Western blotting
P08529662A0507|85 92|labeling
P08530105A0308|10 15|region
P08530105A0308|27 57|Langer-Giedion syndrome deletions
P08530105A0308|80 87|analysis
P08530105A0308|92 99|patients
P08530105A0308|121 128|analysis
P08530105A0308|131 138|patients
P08530105A0308|144 152|deletions
P08530105A0308|162 170|endpoints
P08530107A1003|36 45|expression
P08530107A1003|48 56|histidase
P08530107A1003|61 67|finding
P08530107A1003|80 101|histidase transcription
P08530107A1003|123 129|factors
P08530149A0689|0 9|Comparison
P08530149A0689|12 20|promoters
P08530149A0689|32 36|c-myc
P08530149A0689|49 65|consensus sequence
P08530149A0689|71 79|initiator
P08530149A0689|85 91|element
P08530149A0689|96 100|YYYNY
P08530342T0000|8 19|gp39 promoter
P08530345A0880|0 19|Transfection analyses
P08530345A0880|32 39|mutation
P08530345A0880|55 66|TGACCT motifs
P08530345A0880|69 78|truncation
P08530345A0880|90 95|HD PPRE
P08530345A0880|117 126|DR2 element
P08530345A0880|164 171|response
P08530345A0880|174 179|HD PPRE
P08530345A0880|182 204|peroxisome proliferators
P08530369A0099|11 29|autophosphorylation
P08530369A0099|31 36|Tyr397
P08530369A0099|58 89|consensus autophosphorylation site
P08530369A0099|97 120|Src family tyrosine kinases
P08530384A0559|19 29|interaction
P08530384A0559|59 65|binding
P08530384A0559|68 78|Oct proteins
P08530384A0559|93 114|resolution footprinting
P08530384A0559|126 136|interaction
P08530384A0559|148 154|binding
P08530384A0559|199 209|interaction
P08530418A1182|31 47|TR2 orphan receptor
P08530418A1182|53 67|master regulator
P08530418A1182|83 92|activation
P08530418A1182|107 114|RARE beta
P08530418A1182|117 123|CRBPIIp
P08530418A1182|145 173|acid signal transduction pathway
P08530432A0093|6 11|series
P08530432A0093|20 27|proteins
P08530432A0093|47 53|domains
P08530432A0093|68 77|activation
P08530432A0093|80 89|repression
P08530503A1004|14 32|ARP immunoreactivity
P08530503A1004|45 59|plasma membranes
P08530503A1004|68 74|cytosol
P08530503A1004|89 99|3T3-L1 cells
P08531373A0470|37 44|erythema
P08531373A0470|56 72|skin manifestation
P08531373A0470|88 106|SS-A/SS-B antibodies
P08531669A0950|0 10|Competition
P08531669A0950|40 53|Central America
P08531669A0950|57 71|Caribean islands
P08531669A0950|84 88|study
P08531669A0950|111 117|control
P08531669A0950|129 135|species
P08532516A0000|6 10|paper
P08532516A0000|21 30|properties
P08532516A0000|36 49|cdc10-C4 mutant
P08532516A0000|55 66|fission yeast
P08532536A0925|0 13|TIEG expression
P08532536A0925|16 24|hFOB cells
P08532536A0925|43 50|TGF-beta
P08532536A0925|73 81|protein-2
P08532536A0925|81 85|BMP-2
P08532536A0925|99 107|induction
P08532536A0925|119 130|growth factor
P08532536A0925|141 149|induction
P08532536A0925|156 178|growth factors/cytokines
P08532967A0364|12 17|origin
P08532967A0364|62 68|therapy
P08533472A0777|12 26|protein products
P08533472A0777|29 37|ORFs N2417
P08533472A0777|41 45|N2403
P08533472A0777|53 64|similarities
P08533472A0777|69 75|domains
P08533472A0777|80 87|proteins
P08533472A0777|95 103|organisms
P08533472A0777|107 151|Candida maltosa cycloheximide-resistance protein
P08533472A0777|160 170|interleukin
P08533472A0777|187 192|factor
P08533472A0777|193 197|ILF-2
P08533473A0375|30 37|ADH1 gene
P08533473A0375|57 64|database
P08533473A0375|79 90|EST sequences
P08533757A0204|4 11|families
P08533757A0204|14 35|Ashkenazi Jewish descent
P08533757A0204|46 61|185delAG mutation
P08533757A0204|78 86|haplotype
P08533757A0204|105 111|markers
P08533757A0204|142 146|BRCA1
P08534217A0402|3 10|subjects
P08534217A0402|21 27|regions
P08534217A0402|39 52|pollution level
P08534217A0402|69 78|FEV1 values
P08534217A0402|94 106|Viskovo region
P08534367A0984|0 5|PTP-S3
P08534367A0984|17 22|PTP-S4
P08534367A0984|32 39|deletion
P08534367A0984|44 53|amino acids
P08534367A0984|69 74|exon E1
P08534848A0188a|8 17|NR isoforms
P08534848A0188b|8 17|NR isoforms
P08534855A0000|3 21|Arabidopsis FAD7 gene
P08534855A0000|30 47|chloroplast omega-3
P08534855A0000|53 66|acid desaturase
P08534855A0000|83 94|desaturation
P08534855A0000|121 125|acids
P08535138A0857|29 37|leaf cells
P08535138A0857|57 68|cell division
P08535138A0857|71 79|treatment
P08535138A0857|84 96|plant hormones
P08535138A0857|97 115|cycMs4 transcription
P08535138A0857|135 139|onset
P08535138A0857|142 153|DNA synthesis
P08535537A0000|1 6|survey
P08535537A0000|34 44|backgrounds
P08535537A0000|66 78|drug treatment
P08535537A0000|90 101|hypertension
P08536694A0000|0 13|Protein kinases
P08536694A0000|25 29|roles
P08536694A0000|35 41|control
P08536694A0000|56 64|processes
P08537388A0825|25 33|deletions
P08537388A0825|54 61|promoter
P08537388A0825|98 105|activity
P08537388A0825|124 132|base pairs
P08537388A0825|135 140|WNT-5A
P08537388A0825|161 176|promoter activity
P08537403A0336|3 22|protein kinase domains
P08537403A0336|25 29|LIMK1
P08537403A0336|33 37|LIMK2
P08537403A0336|73 108|sequence motif Asp-Leu-Asn-Ser-His-Asn
P08537403A0336|140 145|insert
P08537403A0336|152 164|subdomains VII
P08538052A0000|17 25|cDNA clone
P08538052A0000|40 57|amino acids residues
P08538052A0000|72 78|protein
P08538052A0000|79 85|THZif-1
P08538052A0000|107 117|cDNA library
P08538052A0000|148 164|leukemia HL60 cells
P08538052A0000|178 203|oligodeoxynucleotide probes
P08538052A0000|225 242|amino acid sequences
P08538052A0000|252 259|peptides
P08538052A0000|285 291|protein
P08538052A0000|329 335|element
P08538052A0000|351 359|c-myc gene
P08538382A1012|0 12|Erythrocyte AA
P08538382A1012|15 20|FO+EPO
P08538382A1012|32 38|infants
P08538382A1012|58 63|breast
P08538382A1012|67 73|placebo
P08538382A1012|85 90|levels
P08538483A0207|10 28|consideration weight
P08538483A0207|40 46|changes
P08538483A0207|49 56|bone mass
P08538483A0207|57 61|total
P08538483A0207|62 66|TBBMC
P08538483A0207|78 99|body bone mineral content
P08538483A0207|116 120|women
P08538483A0207|132 143|GnRH agonists
P08538483A0207|148 153|months
P08538483A0207|157 169|endometriosis
P08538483A0207|172 182|leiomyomata
P08538702A0214|10 20|polypeptide
P08538702A0214|32 39|sequence
P08538702A0214|45 57|ABA-1 allergen
P08538702A0214|60 66|Ascaris
P08538702A0214|70 77|gp15/400
P08538702A0214|78 83|ladder
P08538702A0214|84 90|protein
P08538702A0214|93 104|Brugia malayi
P08538702A0214|105 117|Brugia pahangi
P08538702A0214|150 156|antigen
P08538702A0214|159 176|Dirofilaria immitis
P08541499A0306|7 24|transcript patterns
P08541499A0306|27 42|Epifagus plastids
P08541499A0306|78 91|tobacco operons
P08541793A0796|11 18|recovery
P08542026A0792|10 23|kD glycoprotein
P08542026A0792|33 42|complement
P08542026A0792|58 73|consensus repeats
P08542026A0792|103 112|regulation
P08542026A0792|113 132|complement activation
P08542026A0792|138 148|gene cluster
P08542026A0792|150 159|chromosome
P08542027A1471|3 9|XS2 gene
P08542027A1471|41 50|expression
P08542027A1471|53 59|LU genes
P08542027A1471|76 85|expression
P08542746T0000|0 11|Diabetes care
P08542746T0000|13 21|guideline
P08542746T0000|27 36|facilities
P08542746T0000|75 83|standards
P08543173A0314|9 15|TATA box
P08543173A0314|40 50|start points
P08543173A0314|70 92|primer extension analysis
P08543275A0130|14 26|investigation
P08543275A0130|36 40|burst
P08543275A0130|43 60|pseudoterranovosis
P08543275A0130|102 109|presence
P08543275A0130|111 118|sea lions
P08543275A0130|140 151|Arctic region
P08543275A0130|176 183|Japan Sea
P08543275A0130|205 212|host fish
P08543595A1093|2 8|summary
P08543595A1093|12 21|efficacies
P08543595A1093|32 42|carboplatin
P08543595A1093|57 68|radiotherapy
P08543810A0000|19 23|genes
P08543810A0000|48 59|coelomocytes
P08543810A0000|85 90|clones
P08543810A0000|120 130|cDNA library
P08543810A0000|157 168|sequence tags
P08544820T0000|0 15|Characterization
P08544820T0000|20 47|EcR/USP heterodimer target site
P08544820T0000|60 81|ecdysone responsiveness
P08544820T0000|97 105|Lsp-2 gene
P08545502A0914|4 8|SPECT
P08545502A0914|39 52|activation task
P08546707T0000|15 24|activation
P08546707T0000|30 48|chicken lysozyme gene
P08546707T0000|51 62|NF-kappa Bp65
P08546707T0000|72 76|c-Rel
P08546707T0000|84 95|NF-kappa Bp50
P08547205A1060|3 9|results
P08547205A1060|36 50|agents alinidine
P08547205A1060|54 64|zatebradine
P08547205A1060|89 96|efficacy
P08547205A1060|140 149|infarction
P08548291A1059|15 24|activation
P08548291A1059|27 31|SAPKs
P08548291A1059|42 50|formation
P08548291A1059|63 69|complex
P08548291A1059|80 84|Elk-1
P08548291A1059|85 103|serum response factor
P08548291A1059|110 129|serum response element
P08548291A1059|156 168|transcription
P08549706T0000|12 35|hepatitis B virus infection
P08549706T0000|52 60|drug users
P08549706T0000|63 69|Iceland
P08549859A1604|46 57|chromosome 3p
P08549859A1604|58 100|Centre d'Etude du Polymorphisme Humain pedigrees
P08550425A1401|12 19|subunits
P08550425A1401|69 76|archaeon
P08550425A1401|76 96|Halobacterium halobium
P08550425A1401|98 106|% identity
P08550460A0374|88 103|protein precursor
P08550460A0374|121 153|membrane lipoprotein leader sequence
P08550461A0284|0 5|Cheung
P08550462A0815|0 7|Upstream
P08550462A0815|13 19|dra gene
P08550462A0815|26 37|reading frame
P08550462A0815|43 52|amino acids
P08550467A0863|16 25|regulation
P08550467A0863|49 56|deletion
P08550467A0863|77 84|sequence
P08550467A0863|96 104|positions
P08550467A0863|147 155|start site
P08550470A1021|33 40|coupling
P08550470A1021|45 53|receptors
P08550470A1021|59 68|kinase CheA
P08550476A0610|3 10|promoter
P08550476A0610|47 66|activator protein EpiQ
P08550476A0610|89 96|sequence
P08550476A0610|109 123|EpiQ binding site
P08550476A0610|129 140|epiA promoter
P08550564T0000|0 12|CXC chemokines
P08550564T0000|33 55|selectivity determinants
P08550564T0000|117 123|domains
P08550564T0000|131 153|interleukin-8 receptor B.
P08551572A0155|0 20|Oligodeoxynucleotides
P08551572A0155|44 71|translation initiation regions
P08551572A0155|83 91|pp38 mRNAs
P08551572A0155|100 112|proliferation
P08551572A0155|115 123|MSB1 cells
P08551572A0155|130 138|MDCC-CU91
P08551572A0155|145 165|reticuloendotheliosis
P08551572A0155|182 186|cells
P08551577A0000|10 20|replication
P08551577A0000|34 40|portion
P08551577A0000|53 63|transcripts
P08551577A0000|120 134|envelope protein
P08551577A0000|138 153|Rous sarcoma virus
P08551577A0000|156 162|src mRNA
P08552042A1497|15 20|degree
P08552042A1497|22 40|promoter methylation
P08552042A1497|71 77|borders
P08552042A1497|101 109|reduction
P08552042A1497|132 141|mRNA levels
P08552042A1497|151 155|state
P08552042A1497|177 183|meiosis
P08552042A1497|187 198|reactivation
P08552042A1497|212 222|generations
P08552045A0973|7 24|consensus sequences
P08552045A0973|28 48|phosphatase regulation
P08552045A0973|52 62|GCACGTGGG-3
P08552045A0973|66 76|GCACGTTTT-3
P08552045A0973|95 110|binding sequences
P08552045A0973|117 128|Cpflp protein
P08552045A0973|140 152|transcription
P08552045A0973|158 162|genes
P08552045A0973|165 186|methionine biosynthesis
P08552045A0973|193 210|centromere function
P08552082A0480|31 36|region
P08552082A0480|61 70|SH3 domains
P08552082A0480|79 86|proteins
P08552082A0480|99 103|yeast
P08552082A0480|120 131|protein Abp1p
P08552086A0150|33 55|vitamin D response element
P08552086A0150|67 74|promoter
P08552086A0150|76 80|c-fos
P08552092A1678|2 9|addition
P08552092A1678|12 25|protein binding
P08552092A1678|28 36|sequences
P08552092A1678|59 68|regulation
P08552092A1678|71 83|transcription
P08552092A1678|91 102|footprinting
P08552092A1678|114 127|promoter region
P08552092A1678|143 155|protein factor
P08552092A1678|187 192|intron
P08552092A1678|198 205|rep3 gene
P08552093A0657|0 14|Differentiation
P08552093A0657|42 51|expression
P08552093A0657|70 74|forms
P08552093A0657|77 83|alpha i2
P08552093A0657|86 90|alpha
P08552093A0657|102 112|selectivity
P08552093A0657|119 126|Gq family
P08552093A0657|129 137|G proteins
P08552095A0686|31 43|transcription
P08552095A0686|43 47|Paf1p
P08552095A0686|64 70|nucleus
P08552095A0758|14 23|abundances
P08552095A0758|30 45|yeast transcripts
P08552095A0758|80 86|strains
P08552095A0758|102 106|genes
P08552095A0758|112 121|expression
P08552095A1115|0 4|Paf1p
P08552095A1115|53 62|regulation
P08552095A1115|65 71|subsets
P08552095A1115|74 83|yeast genes
P08552096A0151|15 33|suppression strategy
P08552096A0151|51 59|yeast gene
P08552096A0151|79 88|expression
P08552096A0151|112 127|cell cycle defects
P08552096A0151|142 155|cdc34 mutations
P08552387A0000|9 24|characterization
P08552387A0000|36 43|melanoma
P08552387A0000|50 54|parts
P08552387A0000|61 66|tissue
P08552387A0000|72 82|cell sarcoma
P08552387A0000|99 121|chromosome translocation
P08552387A0000|129 134|fusion
P08552387A0000|162 176|factor gene ATF-1
P08552643A0261|0 5|Clones
P08552643A0261|50 58|phenotype
P08552643A0261|82 89|activity
P08552643A0261|106 120|stomatitis virus
P08552643A0261|126 134|infection
P08552643A0261|138 149|IFN treatment
P08552670A0665|35 39|sites
P08552670A0665|58 71|DNA polymer poly
P08552670T0000|0 13|Identification
P08552670T0000|14 25|purification
P08552670T0000|38 44|cloning
P08552670T0000|86 92|protein
P08552670T0000|98 109|fission yeast
P08553580A0102|10 21|reading frame
P08553580A0102|37 44|function
P08553580A0102|58 68|FIV isolates
P08554069A0743|3 9|patient
P08554069A0743|39 46|mutation
P08554069A0743|68 80|T transversion
P08554069A0743|89 106|acceptor splice site
P08554069A0743|114 119|intron
P08554069A0743|147 157|RNA splicing
P08554540A1480|5 11|regions
P08554540A1480|26 52|HIT protein similarity regions
P08554723A0187|56 66|acid lesions
P08554723A0187|136 144|l-alanine
P08554723A0187|162 175|sodium appetite
P08554723A0187|184 202|furosemide treatment
P08554723A0187|215 220|access
P08554723A0187|223 228|sodium
P08555076A0333|9 22|Amphotericin-B
P08555076A0333|34 41|patients
P08555076A0333|60 66|mycosis
P08555076A0333|78 86|infection
P08555076A0333|91 101|Aspergillus
P08555076A0333|110 116|Candida
P08555168A0390|30 34|sites
P08555168A0390|57 64|affinity
P08555289A0207|8 22|storm indicators
P08555289A0207|36 43|medicine
P08555289A0207|46 55|geophysics
P08555289A0207|69 76|purposes
P08555446A0000|10 22|tobacco plants
P08555446A0000|23 27|ppa-1
P08555446A0000|67 81|pyrophosphatase
P08555446A0000|91 105|35S CaMV promoter
P08555446A0000|120 125|levels
P08555446A0000|135 140|sugars
P08555446A0000|148 153|leaves
P08555498A0427|5 9|LAF-4
P08555498A0427|31 35|genes
P08555498A0427|38 42|mouse
P08555498A0427|46 52|chicken
P08555498A0427|72 81|gene family
P08555498A0427|110 128|vertebrate evolution
P08555597A0808|0 7|Hb levels
P08555597A0808|59 64|months
P08555753A0591|18 27|comparison
P08555753A0591|34 46|Wisconsin Card
P08555753A0591|81 94|activation task
P08555753A0591|107 118|neuroimaging
P08555753A0591|131 135|lobes
P08556707A1390|31 36|218leu
P08556707A1390|49 71|transactivation activity
P08556707A1390|75 85|p53 promoter
P08556707A1390|88 92|yeast
P08556707A1390|108 119|temperatures
P08556707A1390|142 152|p53 function
P08556707A1390|158 165|presence
P08556707A1390|175 180|allele
P08556707A1390|183 193|SNU-C5 cells
P08558187A0403|0 5|Cycles
P08558187A0403|24 28|weeks
P08561607A1443|7 11|class
P08561607A1443|19 28|infections
P08561607A1443|38 52|transplantation
P08561893A0100|44 50|factors
P08561893A0100|58 74|gene transcription
P08561893A0100|78 103|E-box DNA consensus sequences
P08561893A0100|104 110|studies
P08561893A0100|117 130|factor function
P08561893A0100|139 148|eukaryotes
P08561893A0100|175 182|presence
P08561893A0100|193 205|family members
P08561897A0604|0 7|Mobility
P08561897A0604|11 26|supershift assays
P08561897A0604|62 67|factor
P08561897A0604|96 103|elements
P08561897A0604|105 126|competition experiments
P08561897A0604|140 147|CREB/ATF
P08561897A0604|166 179|CRE/TRE element
P08562688A0968|0 7|Upstream
P08562688A0968|29 37|sequences
P08562688A0968|43 50|isolates
P08562688A0968|63 68|length
P08562688A0968|72 79|sequence
P08563483A0094|7 11|cases
P08563483A0094|42 53|gonadotropin
P08563483A0094|59 64|levels
P08563483A0094|77 85|TSH levels
P08563483A0094|116 123|activity
P08564488A1359|4 19|fibrinogen levels
P08564488A1359|54 63|thrombosis
P08564588A1318|0 18|Strontium chloride Sr
P08564588A1318|43 50|analysis
P08564588A1318|75 96|management expenditures
P08564588A1318|122 129|ABSTRACT
P08564588A1318|144 148|WORDS
P08565330A1783|23 30|features
P08565330A1783|48 54|control
P08565330A1783|63 69|control
P08565330A1783|79 88|expression
P08565548A0196|4 8|study
P08565548A0196|35 43|potential
P08565548A0196|46 56|silicone gel
P08565548A0196|83 90|collagen
P08565548A0196|111 121|silicone gel
P08565548A0196|128 133|DA rats
P08566747A0756|15 22|promoter
P08566747A0756|32 41|activation
P08566747A0756|44 56|transcription
P08566747A0756|81 95|Cln/Cdc28 kinase
P08566747A0756|107 113|ability
P08566747A0756|146 158|transcription
P08566751A0455|22 29|question
P08566751A0455|37 54|vertebrate Hox genes
P08566751A0455|72 78|control
P08566751A0455|101 109|sequences
P08566751A0455|126 133|function
P08566751A0455|146 153|Hox genes
P08566751A0788|4 11|approach
P08566751A0788|18 24|gHoxb-1
P08566751A0788|61 67|context
P08566754A0783|5 22|splice site sequence
P08566754A0783|45 59|polyadenylation
P08566754A0783|98 115|ribonucleoproteins
P08566754A0783|115 120|snRNPs
P08566754A0783|135 163|splicing factor/splicing factor
P08566754A0783|165 171|ASF/SF2
P08566756A0752|4 11|analysis
P08566756A0752|53 69|SF3a/SF3b subunits
P08566756A0752|69 81|UV cross-links
P08566756A0752|84 91|pre-mRNA
P08566756A0752|108 113|region
P08566773A1023|37 43|members
P08566773A1023|54 60|classes
P08566773A1023|69 78|chitinases
P08566773A1023|81 91|observation
P08566773A1023|123 128|fungus
P08567556A0000|11 21|consumption
P08567556A0000|47 52|stores
P08567556A0000|54 64|seal muscles
P08567556A0000|86 96|seal muscles
P08567556A0000|103 123|laboratory simulations
P08567556A0000|126 131|diving
P08567556A0000|145 151|feature
P08567556A0000|160 170|field diving
P08567556A0000|178 189|measurements
P08567556A0000|192 200|heart rate
P08567556A0000|204 220|lactate production
P08567556A0000|231 241|differences
P08567556A0000|257 270|diving response
P08567556A0000|286 294|immersion
P08567683A0401|8 15|purH cDNA
P08567683A0401|22 30|base pairs
P08567683A0401|33 38|length
P08567683A0401|60 73|acid polypeptic
P08567717T0000|26 59|spindle pole body duplication gene MPS1
P08567717T0000|78 87|checkpoint
P08567847A1005|5 11|opinion
P08567847A1005|15 26|SM-CMA system
P08567847A1005|40 51|shortcomings
P08567847A1005|57 70|user-interface
P08567847A1005|90 99|instrument
P08567847A1005|103 113|examination
P08567847A1005|121 132|semen samples
P08567847A1005|146 153|features
P08569443A0123|3 9|purpose
P08569443A0123|15 19|study
P08569443A0123|55 65|differences
P08569443A0123|86 91|tumors
P08569443A0123|100 110|consequence
P08569443A0123|113 123|differences
P08569443A0123|139 144|volume
P08569443A0123|163 173|compartment
P08569680A0636|7 17|areA product
P08569680A0636|50 56|residue
P08569680A0636|94 99|domain
P08569680A0636|113 120|function
P08569684A0000|0 15|Oligonucleotides
P08569684A0000|29 33|basis
P08569684A0000|53 77|amino acid sequence segments
P08569684A0000|96 101|domain
P08569684A0000|114 127|protein kinase C
P08569684A0000|133 140|proteins
P08569684A0000|150 156|primers
P08569684A0000|160 183|polymerase chain reactions
P08569684A0000|211 221|DNA fragment
P08569684A0000|240 262|fungus Trichoderma reesei
P08570615T0000|0 9|Disruption
P08570615T0000|12 17|RB/E2F
P08570615T0000|19 29|interaction
P08570615T0000|38 51|point mutations
P08570615T0000|54 58|E2F-1
P08570615T0000|67 78|S-phase entry
P08570615T0000|82 90|apoptosis
P08572616A0000|16 37|differentiation markers
P08572616A0000|67 75|neoplasms
P08573083A0645|4 9|region
P08573083A0645|19 23|motif
P08573083A0645|35 42|identity
P08573083A0645|50 60|binding site
P08573083A0645|77 95|transcription factor
P08573083A0645|115 120|factor
P08573083A0645|146 160|insulin promoter
P08573637A0434|3 8|method
P08573637A0434|42 54|determination
P08573637A0434|57 67|paracetamol
P08573637A0434|84 95|formulations
P08573637A0434|109 114|fluids
P08574414A1037|5 11|primers
P08574414A1037|20 29|PCR product
P08574414A1037|47 52|length
P08574414A1037|63 80|Xanthomonas species
P08574414A1037|84 92|pathovars
P08574583A0658|3 12|Clb5 kinase
P08574583A0658|26 31|S phase
P08574583A0658|62 67|arrest
P08574583A0658|70 74|cells
P08574583A0658|88 93|strain
P08574583A0658|100 107|activity
P08574583A0658|125 134|sim mutants
P08575609A0526|3 10|C/D ratio
P08575609A0526|33 37|cases
P08575609A0526|52 57|values
P08575609A0526|101 108|patients
P08575614A0264|0 10|Rad6 mutants
P08575614A0264|40 48|phenotype
P08575614A0264|63 69|protein
P08575614A0264|91 101|mutagenesis
P08575614A0264|101 121|postreplication repair
P08575614A0264|122 131|repression
P08575614A0264|134 151|retrotransposition
P08575614A0264|155 165|sporulation
P08575618A1138|0 20|RNase protection assays
P08575618A1138|30 40|correlation
P08575618A1138|51 56|levels
P08575618A1138|59 64|dorsal
P08575618A1138|75 88|skin expression
P08575618A1138|93 127|pigmentation/phaeomelanin phenotypes
P08575754T0000|9 15|cloning
P08575754T0000|16 32|expression pattern
P08575754T0000|47 58|localization
P08575754T0000|66 77|CDKN2D/INK4d
P08575754T0000|80 88|inhibitor
P08575754T0000|91 96|cyclin
P08575754T0000|108 114|kinases
P08576042A0765|0 13|Overproduction
P08576042A0765|16 26|HrcA protein
P08576042A0765|64 70|plasmid
P08576042A0765|69 73|phrcA
P08576042A0765|76 85|B. subtilis
P08576042A0765|98 113|delta hrcA strains
P08576042A0765|123 140|heat shock induction
P08576042A0765|155 165|groE operons
P08576042A0765|170 174|level
P08576042A0765|177 189|transcription
P08576042A0765|227 233|amounts
P08576042A0765|248 258|temperature
P08576131A0151|20 26|cloning
P08576131A0151|40 55|characterization
P08576131A0151|58 69|USF2 isoforms
P08576131A0151|92 98|subunit
P08576131A0151|99 103|USF2a
P08576131A0151|117 123|subunit
P08576131A0151|124 128|USF2b
P08576131A0151|152 159|splicing
P08576131A0685|15 32|heterodimerization
P08576131A0685|35 45|USF subunits
P08576131A0685|80 90|association
P08576131A0685|105 112|subunits
P08576131A0685|126 136|USF proteins
P08576179A0126|25 29|dimer
P08576179A0126|59 85|translation initiation factor
P08576179A0126|87 98|alpha subunit
P08576179A0126|99 108|cIF-2 alpha
P08576179A0126|118 143|polypeptide chain initiation
P08576245A0000|0 4|GRP78
P08576245A0000|15 23|chaperone
P08576245A0000|49 57|reticulum
P08576245A0000|78 84|protein
P08576245A0000|94 108|stress responses
P08576245A0000|120 126|glucose
P08576245A0000|143 149|calcium
P08576245A0000|168 190|glycoprotein trafficking
P08576262A0160|3 14|IL-8 receptor
P08576262A0160|18 52|seven-transmembrane spanning receptor
P08576262A0160|84 92|G proteins
P08576546A0975|9 14|series
P08576546A0975|17 27|experiments
P08576546A0975|31 38|efficacy
P08576546A0975|41 49|PDC/HDC Ac
P08576546A0975|85 97|dose regiments
P08580083A0259|24 35|significance
P08580083A0259|48 57|expression
P08580083A0259|64 72|promoters
P08580083A0259|87 106|Fyn-expression vector
P08580083A0259|120 134|reporter plasmid
P08580083A0259|148 183|chloramphenicol acetyltransferase gene
P08580083A0259|192 197|HIV LTR
P08580083A0259|208 216|T cell line
P08580083A0259|217 222|Jurkat
P08580671A0137|43 47|trial
P08580671A0137|50 59|metoprolol
P08580671A0137|70 81|beta-blocker
P08580671A0137|85 94|prevention
P08580671A0137|113 120|bleeding
P08580671A0137|131 142|hypertension
P08580671A0137|159 166|patients
P08580671A0137|171 182|liver disease
P08580671A0137|210 217|bleeding
P08581174A0472|20 27|analysis
P08581174A0472|43 53|qutA mutants
P08581174A0472|69 77|mutations
P08581174A0472|128 138|QUTA protein
P08582143A0614|5 11|studies
P08582143A0614|78 100|cephalosporin substrates
P08582143A0614|107 116|nitrocefin
P08582143A0614|146 169|beta-lactamase production
P08582143A0614|182 188|species
P08582633T0000|0 10|Suppressors
P08582633T0000|22 30|silencing
P08582633T0000|33 37|yeast
P08582633T0000|38 44|effects
P08582633T0000|62 71|repression
P08582633T0000|77 84|HMR locus
P08582633T0000|85 94|cell growth
P08582633T0000|98 114|telomere structure
P08583783A0870|37 46|filtration
P08583783A0870|57 66|filtration
P08583846A0121|6 15|literature
P08583846A0121|32 48|beta-2 transferrin
P08583846A0121|73 78|marker
P08583846A0121|82 90|perilymph
P08583846A0807|11 38|methodology beta-2 transferrin
P08583846A0807|73 78|marker
P08583846A0807|82 90|perilymph
P08583846A0807|105 111|setting
P08584026A0115|3 12|hIGF-I gene
P08584026A0115|19 27|promoters
P08584035A0740|0 21|Gel mobility shift assays
P08584035A0740|53 60|proteins
P08584035A0740|87 103|binding properties
P08584035A0740|114 120|ability
P08584035A0740|131 144|beta I-A element
P08584035A0740|169 177|complexes
P08584074A0000|10 17|patients
P08584074A0000|30 34|years
P08584074A0000|36 41|months
P08584074A0000|47 51|years
P08584074A0000|91 102|lobe epilepsy
P08584074A0000|127 132|period
P08584074A0000|136 141|months
P08584074A0000|144 163|Bethel Epilepsy Center
P08584530A0545|11 22|correlations
P08584530A0545|62 67|values
P08584530A0545|74 78|MEF50
P08584530A0545|81 85|MEF25
P08584530A0545|125 135|differences
P08584530A0545|143 153|test results
P08585324A0467|25 32|SSC1 gene
P08585324A0467|33 37|Smith
P08585324A0823|4 9|region
P08585324A0823|48 56|precursor
P08585324A0823|60 66|remnant
P08585324A0823|70 79|tau element
P08585639T0000|12 19|exposure
P08585639T0000|22 36|hepatitis B virus
P08585639T0000|45 65|immunodeficiency virus
P08585639T0000|78 89|risk analysis
P08585883A0381|0 5|Hybrid
P08585883A0381|18 26|C57BL x CBA
P08585883A0381|40 51|breeder males
P08585883A0381|61 70|LNG pellets
P08585883A0381|106 120|copulation plugs
P08585883A0381|161 166|period
P08585957A0101|26 44|transcription factor
P08585957A0101|48 54|regions
P08585957A0101|57 64|homology
P08585957A0101|79 86|proteins
P08585957A0101|99 109|zinc fingers
P08585957A0101|118 124|domains
P08585957A0101|149 159|gene product
P08585957A0101|166 172|AT-hook
P08585957A0101|184 188|motif
P08585957A0101|195 215|mobility group proteins
P08585994A0567|5 19|reference probes
P08585994A0567|30 38|standards
P08585994A0567|52 71|ost transcription unit
P08585994A0567|101 116|band interval 89A1
P08585994A0567|143 152|chromosome
P08585994A0567|177 210|segmentation gene expression patterns
P08585994A0567|216 221|embryo
P08586643A0951|22 27|enzyme
P08586643A0951|45 62|phosphoryl transfer
P08586874T0000|0 6|Studies
P08586874T0000|12 20|life cycle
P08586874T0000|23 39|Haplorchis pumilio
P08586874T0000|40 44|Looss
P08586874T0000|49 53|Looss
P08586874T0000|75 87|redescription
P08586874T0000|104 109|stages
P08587075T0000|10 23|microaneurysms
P08587075T0000|27 31|cases
P08587075T0000|34 48|hepatitis B virus
P08587075T0000|56 74|polyarteritis nodosa
P08588852A0236|18 26|pregnancy
P08588852A0236|43 49|studies
P08588852A0236|59 63|fetus
P08588852A0236|81 89|gestation
P08588852A0236|103 114|micrognathia
P08588852A0236|127 132|thumbs
P08588852A0236|153 158|tibiae
P08589315A1029|16 27|survival rate
P08589315A1029|34 41|survival
P08589315A1029|93 98|groups
P08589315A1029|98 115|tumor lysis syndrome
P08589315A1029|127 144|lupus erythematosus
P08589315A1029|148 155|patients
P08589315A1029|180 187|syndrome
P08589315A1029|190 197|patients
P08589358A0235|10 17|units/kg
P08589358A0235|36 49|erythropoietin
P08589358A0235|50 54|rhEPO
P08589358A0235|78 82|times
P08589358A0235|94 98|weeks
P08589358A0841|7 13|regimen
P08589358A0841|16 29|erythropoietin
P08589358A0841|47 51|donor
P08589358A0841|78 93|blood transfusion
P08589358A0841|107 114|Hb levels
P08589358A0841|127 136|milligrams
P08589735A0577|7 16|constructs
P08589735A0577|17 29|GUS expression
P08589735A0577|41 55|promoter regions
P08589735A0577|70 100|Arabidopsis alcohol dehydrogenase
P08589735A0577|107 120|maize ubiquitin
P08589735A0577|126 134|rice actin
P08589735A0577|143 154|CaMV 35S genes
P08590465A0773|3 14|organization
P08590465A0773|18 27|regulation
P08590465A0773|52 66|URA1 gene product
P08590465A0773|101 115|URA2 gene product
P08591700A0972|3 19|mean body mass index
P08591700A0972|36 40|kg/m2
P08591700A0972|51 55|kg/m2
P08591700A0972|58 62|women
P08592590A0822|5 12|findings
P08592590A0822|28 48|haemodialysis patients
P08592590A0822|60 69|hepatitis C
P08592590A0822|83 101|interferon treatment
P08592590A0822|119 126|response
P08592590A0822|144 153|proportion
P08592590A0822|156 163|patients
P08592713T0001|9 19|enantiomers
P08592713T0001|22 26|drugs
P08593813A0967|8 15|analysis
P08593813A0967|60 67|Sp1 mRNAs
P08593813A0967|96 105|efficiency
P08593813A0967|120 129|transcript
P08595012A0817|2 13|nondiabetics
P08595012A0817|17 24|response
P08595012A0817|27 31|tcPO2
P08595012A0817|63 68|values
P08595184A0407|4 8|study
P08595184A0407|19 27|estimator
P08595184A0407|54 60|effects
P08595184A0407|74 85|correlations
P08595184A0407|98 112|field potentials
P08595414A0000|3 10|assembly
P08595414A0000|13 20|sequence
P08595414A0000|58 69|construction
P08595414A0000|91 97|contigs
P08595414A0000|117 128|model genomes
P08595414A0000|145 157|determination
P08595414A0000|163 168|extent
P08595414A0000|193 198|clones
P08595414A0000|220 230|orientation
P08595627A1513|2 8|opening
P08595627A1513|27 36|inhibition
P08595627A1513|41 47|channel
P08595627A1513|69 80|consequences
P08595627A1513|91 99|occlusion
P08595627A1513|106 116|KATP opening
P08595658A0961|3 14|DNA sequences
P08595658A0961|30 36|termini
P08595658A0961|44 51|homology
P08595658A0961|54 87|plant mitochondrial-processing sites
P08595658A0961|141 153|RNA processing
P08595836T0000|6 14|shrinkage
P08595836T0000|28 34|changes
P08595836T0000|51 62|glass ionomer
P08595836T0000|74 82|materials
P08595878A0201|20 27|evidence
P08595878A0201|42 54|PP2A functions
P08595878A0201|87 108|receptor tyrosine kinase
P08595878A0201|113 137|signal transduction pathway
P08595878A0201|150 172|R7 photoreceptor cell fate
P08595878A0201|188 200|Drosophila eye
P08597108A0642|0 4|QBMDs
P08597108A0642|9 15|% change
P08597108A0642|18 25|response
P08597108A0642|26 31|QBMD05
P08597108A0642|49 55|average
P08597108A0642|76 80|NOAEL
P08597177T0000|0 6|Effects
P08597177T0000|17 25|exposures
P08597177T0000|28 43|hydrogen sulphide
P08597596A0135|29 36|cassette
P08597596A0135|36 49|ABC transporter
P08597636A0000|8 12|motif
P08597636A0000|25 30|family
P08597636A0000|33 37|genes
P08597636A0000|53 60|features
P08597636A0000|64 81|expression patterns
P08597636A0000|94 104|involvement
P08597636A0000|120 133|gene regulation
P08598051T0000|9 16|analysis
P08598051T0000|25 43|schizosaccharomyces
P08598051T0000|68 88|RNP consensus-sequence
P08598051T0000|99 105|domains
P08598359X0000|9 21|treatment time
P08598359X0000|22 30|field size
P08598359X0000|34 57|treatment energy influence
P08598359X0000|63 69|control
P08598359X0000|72 76|T1-T2
P08598359X0000|85 98|cell carcinomas
P08598359X0000|111 116|larynx
P08598359X0000|141 147|PURPOSE
P08598359X0000|158 166|treatment
P08598359X0000|170 176|patient
P08598359X0000|194 200|factors
P08598359X0000|222 228|control
P08598359X0000|234 242|treatment
P08598359X0000|245 249|T1-T2
P08598359X0000|258 270|cell carcinoma
P08598359X0000|283 288|larynx
P08598449A0784|2 9|contrast
P08598449A0784|15 23|signaling
P08598449A0784|35 53|surface Ig engagement
P08598449A0784|56 67|B lymphocytes
P08598449A0784|68 79|CD38 ligation
P08598449A0784|100 122|tyrosine phosphorylation
P08598449A0784|136 160|protein tyrosine kinases lyn
P08598449A0784|207 213|protein
P08598449A0784|235 241|changes
P08598449A0784|258 271|concentrations
P08599945T0000|0 8|Mutations
P08599945T0000|14 27|alpha-amanitin
P08599945T0000|37 42|domain
P08599945T0000|55 61|subunit
P08599945T0000|64 81|yeast RNA polymerase
P08599945T0000|98 108|RNA cleavage
P08599945T0000|127 137|transitions
P08599946A0999|3 10|evidence
P08599946A0999|39 48|p40 complex
P08599946A0999|52 75|ribonucleoprotein complex
P08599946A0999|86 92|L1Hs RNA
P08599946A0999|117 128|interactions
P08599946A0999|146 155|structures
P08599946A0999|170 188|example coiled-coils
P08599946A0999|202 208|complex
P08600028A1129|20 35|trans-activation
P08600028A1129|53 66|intron enhancer
P08600028A1129|78 87|reflection
P08600028A1129|105 114|properties
P08600028A1129|120 129|Myc protein
P08600048T0000|16 29|conjunctivitis
P08600048T0000|39 63|bone marrow transplantation
P08600048T0000|100 104|study
P08601283A0875|13 20|presence
P08601283A0875|22 34|SECIS elements
P08601283A0875|44 56|reading frames
P08601283A0875|74 87|selenoproteins
P08601283A0875|99 105|effects
P08601283A0875|118 127|deiodinase
P08601283A0875|153 164|SECIS element
P08601283A0875|199 211|SECIS function
P08601284A0000|23 28|spacer
P08601284A0000|34 39|region
P08601284A0000|44 51|pre-rRNA
P08601284A0000|86 93|sequence
P08601284A0000|113 127|complementarity
P08601284A0000|132 139|U3 snoRNA
P08601490A0659|5 11|animals
P08601616A0726|4 16|spindle defect
P08601616A0726|19 29|pds1 mutants
P08601616A0726|88 99|G1/S boundary
P08601616A0726|115 129|spindle assembly
P08601806A0875|22 26|RPF-1
P08601806A0875|53 57|steps
P08601806A0875|63 77|differentiation
P08601806A0875|80 87|amacrine
P08601806A0875|91 103|ganglion cells
P08602169A0484|5 15|point mutant
P08602169A0484|32 37|repair
P08602169A0484|40 51|endonuclease
P08602169A0484|82 88|removal
P08602169A0484|100 107|MAT alpha
P08602169A0484|110 121|HML alpha loci
P08602608A1056|22 26|cases
P08602608A1056|30 41|performances
P08602608A1056|47 52|CD3500
P08602608A1056|122 139|reference procedure
P08603921A1346|16 33|Spc110p truncations
P08603921A1346|44 64|calmodulin binding site
P08603921A1346|75 80|growth
P08603921A1346|128 133|manner
P08604338A0198|4 12|EWS-FLI-1
P08604338A0198|16 28|FLI-1 proteins
P08604338A0198|39 58|transcription factors
P08604338A0198|81 92|ets sequences
P08604338A0198|96 103|ets boxes
P08604338A0198|113 128|promoter elements
P08604338A0885|2 27|electromobility shift assays
P08604338A0885|28 43|EWS-FLI-1 binding
P08604338A0885|71 77|absence
P08604338A0885|94 100|binding
P08604338A0885|102 106|FLI-1
P08604338A0885|129 139|interaction
P08604338A0885|178 193|complex formation
P08604338A0885|194 198|FLI-1
P08604708A1086|10 16|studies
P08604708A1086|49 66|cellulose dialyzers
P08604708A1086|91 104|blood flow rates
P08604708A1086|109 115|minutes
P08604708A1086|124 129|change
P08605302A1770|0 13|DNA methylation
P08605302A1770|46 60|deoxyadenosines
P08605302A1770|69 78|GATC motifs
P08605302A1770|119 124|intron
P08605302A1770|129 140|rice CatA gene
P08605302A1770|170 189|CatA promoter activity
P08605302A1770|214 218|assay
P08605324A0434|25 32|promoter
P08605326A0772|11 20|cDNA clones
P08605705A0676|2 11|conclusion
P08605705A0676|12 22|IgM class CIC
P08605705A0676|51 60|hepatitis A
P08605705A0676|77 91|disease activity
P08605931A0777|0 13|Epitope mapping
P08605931A0777|36 41|clones
P08605931A0777|70 82|epitope domain
P08605931A0777|105 112|RNP motif
P08605931A0777|118 127|U1A protein
P08606267A0740|0 8|Variables
P08606267A0740|22 27|number
P08606267A0740|43 48|events
P08606267A0740|69 83|exercise testing
P08606267A0740|119 130|registration
P08606267A0740|147 156|evaluation
P08606267A0740|159 191|Tc-99m 2-methoxy isobutyl isonitrile
P08606267A0740|198 202|scans
P08606267A0740|214 222|variables
P08608126A0811|5 10|length
P08608126A0811|39 53|binding affinity
P08608126A0811|113 124|medium-chain
P08608126A0811|142 152|short-chain
P08608126A0811|169 174|lipids
P08608222T0000|29 34|region
P08608222T0000|42 52|granulocyte
P08608222T0000|71 84|factor receptor
P08608222T0000|98 102|STAT3
P08608222T0000|109 131|STAT1 homodimer formation
P08608447A0806|27 42|codon recognition
P08608447A0806|49 62|TPI transcripts
P08608447A0806|68 72|place
P08608447A0806|87 94|splicing
P08608448A0353|12 19|residues
P08608448A0353|42 57|dimethylsulphate
P08608448A0353|61 68|kethoxal
P08608448A0353|71 77|regions
P08608448A0353|125 138|structure model
P08608448A0353|143 146|S RNA
P08608448A0353|159 168|reactivity
P08608448A0353|181 188|residues
P08608448A0353|199 203|loops
P08610272A0265|16 29|investigations
P08610272A0265|55 62|approach
P08610272A0265|71 77|control
P08610272A0265|88 95|duration
P08610272A0265|98 120|maintenance chemotherapy
P08610272A0265|151 167|response modifiers
P08610272A0265|170 182|growth factors
P08610272A0265|204 210|outcome
P08610272A0265|214 221|patients
P08610272A0265|230 236|disease
P08610328A0228|0 6|SUMMARY
P08610328A0228|9 14|REVIEW
P08610328A0228|27 34|criteria
P08610328A0228|47 53|studies
P08610328A0228|76 86|experiences
P08610328A0228|95 101|studies
P08610328A0228|120 124|world
P08610582A0150|10 17|patients
P08610582A0150|29 35|lesions
P08610582A0150|48 54|CT scans
P08610582A0150|81 89|MR imaging
P08611280A0820|10 16|volumes
P08611280A0820|50 57|subjects
P08611280A0820|70 75|cm3/m2
P08611280A0820|82 87|cm3/m2
P08611280A0820|98 102|onset
P08611280A0820|110 116|systole
P08611280A0820|121 126|cm3/m2
P08611280A0820|133 138|cm3/m2
P08611280A0820|160 165|cm3/m2
P08611280A0820|170 175|cm3/m2
P08612852A0553|0 6|RESULTS
P08612852A0553|12 28|plasma IGF-I levels
P08612852A0553|37 49|body mass index
P08612852A0553|77 84|patients
P08612852A0553|97 104|controls
P08614403A0557|18 23|levels
P08614403A0557|26 42|Rev-erbA alpha mRNA
P08614403A0557|53 66|C2C12 myoblasts
P08614403A0557|93 97|cells
P08614403A0557|141 148|myotubes
P08614403A0989|23 48|GAL4-REV-erbA alpha chimeras
P08614403A0989|67 72|region
P08614403A0989|85 90|region
P08614403A0989|99 111|transcription
P08614403A0989|114 133|GAL4 response elements
P08614403A0989|139 146|presence
P08614403A0989|149 157|8-Br-cAMP
P08614403A0989|179 184|domain
P08614403A0989|221 228|silencer
P08614410A0000|3 19|alpha T3-1 cell line
P08614410A0000|36 54|gonadotroph cell line
P08614410A0000|74 84|oncogenesis
P08614410A0000|117 126|regulation
P08614410A0000|131 162|glycoprotein hormone alpha-subunit
P08614410A0000|165 171|activin
P08615012A0627|0 13|Cotransfection
P08615012A0627|21 27|ie1 gene
P08615012A0627|47 54|increase
P08615012A0627|60 65|amount
P08615012A0627|74 80|enzymes
P08615012A0627|106 110|cells
P08615025A1214|10 22|glycosylation
P08615025A1214|42 48|mutants
P08615025A1214|79 100|glycosylation phenotype
P08615025A1214|109 118|quantities
P08615025A1214|146 161|immunoreactivity
P08615025A1214|180 184|gp160
P08615025A1214|209 213|gp120
P08615025A1214|245 256|cell membrane
P08615025A1214|264 268|gp120
P08615025A1214|284 295|membrane gp41
P08615025A1214|310 323|membrane fusion
P08615025A1214|333 337|cells
P08615183T0000|0 6|Effects
P08615183T0000|23 33|pallidotomy
P08615183T0000|36 44|Parkinson
P08615183T0000|46 52|disease
P08616743T0000|5 9|trail
P08617216A0584|56 62|protein
P08617216A0584|69 77|refolding
P08617216A0584|93 102|luciferase
P08617237A0489|15 26|phosphoforms
P08617237A0489|29 33|STAT5
P08617237A0489|54 74|DNA binding specificity
P08617237A0489|78 87|reactivity
P08617237A0489|92 114|tyrosine phosphopeptides
P08617237A0489|139 150|localization
P08617238A0334|0 11|TNF Treatment
P08617238A0334|32 50|p38 MAP kinase pathway
P08617238A0334|71 85|phosphorylation
P08617238A0334|88 99|p38 MAP kinase
P08617238A0334|106 115|activation
P08617238A0334|121 150|substrate protein MAPKAP kinase-2
P08617238A0334|170 184|phosphorylation
P08617238A0334|190 205|heat shock protein
P08617238A0334|208 212|hsp27
P08617243A0336|20 26|protein
P08617243A0336|48 55|extracts
P08617243A0336|99 104|region
P08617311A0979|15 32|sequence similarity
P08617311A0979|43 55|membrane exons
P08617311A0979|115 124|similarity
P08617311A0979|126 136|Xenopus mIgY
P08617800A0150|0 6|Control
P08617800A0150|9 21|transcription
P08617800A0150|27 36|erbB-2 gene
P08617800A0150|50 60|determinant
P08617800A0150|63 80|receptor expression
P08617800A0675|0 4|DNase
P08617800A0675|6 17|footprinting
P08617800A0675|36 54|mobility shift assays
P08617800A0675|82 90|half-site
P08617800A0675|96 105|palindrome
P08617800A0675|113 141|core recognition sequence TGGGAG
P08617802A0993|5 11|results
P08617802A0993|27 35|sequences
P08617802A0993|41 57|SH2/SH3/SH2 region
P08617802A0993|60 66|p120 GAP
P08617802A0993|94 101|activity
P08618433A0000|21 42|growth factor FLT3 ligand
P08618433A0000|59 64|ligand
P08618433A0000|76 97|tyrosine kinase receptor
P08618433A0000|116 120|FLK-2
P08618433A0000|123 127|STK-1
P08618433A1720|2 9|contrast
P08618433A1720|24 33|expression
P08618433A1720|39 46|receptor
P08618433A1720|47 58|FL expression
P08618433A1720|92 100|cell types
P08618433A1720|102 118|leukemia cell lines
P08618433A1720|139 150|cell lineages
P08618864A0754|7 14|analysis
P08618864A0754|21 26|domain
P08618864A0754|36 46|mutagenesis
P08618864A0754|85 92|residues
P08618864A0754|108 115|activity
P08618882A0343|0 7|Analysis
P08618882A0343|10 24|RAR alpha mutants
P08618882A0343|27 45|transfection studies
P08618882A0343|60 75|DNA binding domain
P08618882A0343|91 100|inhibition
P08618882A0343|103 115|BZLF1 activity
P08619866A0000|10 36|serum hepatocyte growth factor
P08619866A0000|44 51|patients
P08619866A0000|70 79|infarction
P08619866A0000|80 93|angina pectoris
P08619866A0000|102 114|heart diseases
P08619910A0000|9 17|mechanism
P08619910A0000|32 44|motor symptoms
P08619910A0000|49 56|rigidity
P08619910A0000|57 62|tremor
P08619910A0000|66 73|akinesia
P08619910A0000|85 90|result
P08619910A0000|106 123|dopamine deficiency
P08619910A0000|150 161|observations
P08619910A0000|167 172|effect
P08619910A0000|201 209|treatment
P08619910A0000|215 221|disease
P08619910A0000|224 231|relation
P08619910A0000|254 261|findings
P08619910A0000|281 297|nigra zona compacta
P08620003T0000|0 14|Protein splicing
P08620003T0000|15 22|evidence
P08620003T0000|28 47|N-O acyl rearrangement
P08620003T0000|71 85|splicing process
P08620856A1172|2 10|agreement
P08620856A1172|26 47|western blot experiments
P08620856A1172|54 61|antibody
P08620856A1172|96 102|portion
P08620856A1172|108 124|mouse c-kit protein
P08620856A1172|136 146|polypeptide
P08620856A1172|176 187|reading frame
P08620856A1172|210 218|c-kit cDNA
P08620856A1172|241 246|stages
P08620856A1172|249 263|spermatogenesis
P08620856A1172|279 289|spermatozoa
P08620889A0771|24 30|element
P08620889A0771|35 51|aldolase C promoter
P08620889A0771|59 71|transcription
P08620889A0771|103 107|cells
P08621017A1186|0 7|LY290181
P08621017A1186|24 44|uPA promoter activation
P08621017A1186|55 61|phorbol
P08621017A1186|78 84|binding
P08621017A1186|94 101|proteins
P08621017A1186|107 116|uPA PEA3/12
P08621017A1186|117 146|tetradecanoylphorbol 13-acetate
P08621017A1186|157 163|element
P08621384A0935|0 8|Treatment
P08621384A0935|11 23|keratinocytes
P08621384A0935|50 69|growth factor receptor
P08621384A0935|80 87|TGFalpha
P08621384A0935|98 109|growth factor
P08621384A0935|126 156|PKCdelta tyrosine phosphorylation
P08621420A1166|14 18|bands
P08621420A1166|36 43|antibody
P08621420A1166|58 67|antibodies
P08621420A1166|81 97|NF-kappaB proteins
P08621420A1166|102 107|effect
P08621448A0862|35 39|clone
P08621448A0862|44 66|RL95-2 expression library
P08621448A0862|97 103|protein
P08621453A0815|2 9|addition
P08621453A0815|30 39|antibodies
P08621453A0815|58 62|80K-H
P08621453A0815|67 77|cell lysates
P08621453A0815|111 121|fibroblasts
P08621542A0535|8 21|protein kinases
P08621542A0535|22 26|c-Jun
P08621542A0535|39 45|kinases
P08621542A0535|67 80|protein kinases
P08621542A0535|98 106|TNF-alpha
P08621542A0535|116 132|CD28 costimulation
P08621628A1233|4 10|hGRbeta
P08621628A1233|50 58|inhibitor
P08621628A1233|61 76|hGRalpha activity
P08621659A0189|28 36|Gla domain
P08621659A0189|59 64|growth
P08621659A0189|76 82|repeats
P08621659A0189|103 109|domains
P08621661A1035|4 18|P5CDh cDNA clones
P08621661A1035|38 47|transcript
P08621661A1035|50 62|Northern blots
P08621661A1035|78 84|tissues
P08621661A1035|133 138|intron
P08621661A1035|162 171|transcript
P08621664A1430|0 13|Polymerization
P08621664A1430|16 36|neurofilament L protein
P08621664A1430|58 72|phosphorylation
P08621664A1430|75 95|neurofilament L protein
P08621714A0361|3 9|protein
P08621714A0361|31 44|disulfide bonds
P08621714A0361|53 62|thiol group
P08621714A0361|65 69|Cys25
P08621719A0000|5 10|others
P08621719A0000|34 59|c-cbl proto-oncogene product
P08621719A0000|78 84|targets
P08621719A0000|87 109|tyrosine phosphorylation
P08621719A0000|114 137|T cell receptor stimulation
P08621719A0568|12 19|fraction
P08621719A0568|71 81|interaction
P08621719A0568|93 106|Grb2 SH3 domains
P08621730T0000|2 20|AP-1 binding sequence
P08621730T0000|35 44|regulation
P08621730T0000|55 60|alpha2
P08621730T0000|63 70|collagen
P08621730T0000|70 75|COL1A2
P08621730T0000|76 91|promoter activity
P08621730T0000|106 122|growth factor-beta
P08622030A0667|13 23|differences
P08622030A0667|44 52|age groups
P08622030A0667|55 77|baseline characteristics
P08622030A0667|87 103|treatment protocol
P08622030A0667|104 120|performance status
P08622030A0667|124 148|serum lactate dehydrogenase
P08622030A0667|154 158|level
P08622070A0889|7 14|patients
P08622070A0889|31 38|response
P08622070A0889|58 68|progression
P08622645A1026|34 42|vitamin D3
P08622645A1026|57 67|RA induction
P08622645A1026|88 94|element
P08622668A1155|5 11|results
P08622668A1155|44 51|function
P08622668A1155|54 58|U6 RNA
P08622668A1155|62 71|modulation
P08622668A1155|75 112|phosphorylation-dephosphorylation cycle
P08622668A1155|115 128|C1 hnRNP protein
P08622668A1155|146 160|binding affinity
P08622668A1155|167 173|protein
P08622668A1155|177 184|pre-mRNA
P08622675A0587|0 8|Inclusion
P08622675A0587|22 30|N terminus
P08622675A0587|56 62|protein
P08622675A0587|82 91|similarity
P08622675A0587|105 115|factor Lef-1
P08622698T0000|18 23|Notch1
P08622698T0000|53 57|genes
P08622698T0000|61 69|mechanism
P08622698T0000|98 107|virus EBNA2
P08622887A1026|15 33|mobility shift assays
P08622887A1026|34 38|EMSAs
P08622887A1026|52 89|glucocorticoid receptor DNA binding domain
P08622887A1026|115 119|GRE-2
P08622887A1026|124 129|motifs
P08622887A1026|150 186|oligonucleotide competition experiments
P08622887A1026|219 228|affinities
P08622893A0000|8 16|subfamily
P08622893A0000|19 41|receptor tyrosine kinases
P08622893A0000|66 74|prototype
P08622893A0000|83 87|roles
P08622893A0000|103 115|communication
P08622893A0000|137 147|development
P08622893A0000|165 182|signalling pathways
P08622893A0000|197 202|family
P08623554A1058|9 15|protein
P08623554A1058|40 48|infection
P08623554A1058|51 56|plants
P08624445A0257|29 46|sequencing analysis
P08624445A0257|52 78|cytosine methylation patterns
P08624445A0257|84 106|transposase binding sites
P08624445A0257|130 134|wx-m9
P08624445A0257|133 140|Ac allele
P08624445A0257|167 175|tenth exon
P08625806A0263|0 6|Krox-20
P08625806A0263|8 21|zinc finger gene
P08625806A0263|41 47|pattern
P08625806A0263|50 59|expression
P08625806A0263|106 116|maintenance
P08625806A0263|117 128|mouse embryos
P08625900T0000|9 17|adenylate
P08625900T0000|36 46|polypeptide
P08625900T0000|56 80|prolactin promoter activity
P08625900T0000|85 97|protein kinase
P08625900T0000|108 114|pathway
P08625900T0000|152 158|pathway
P08625900T0000|190 196|hormone
P08625924A0411|0 8|Clones 33F
P08625924A0411|33 49|aromatase proteins
P08625924A0411|54 63|amino acids
P08625924A0411|99 124|polyadenylation signal usage
P08625924A0411|143 147|mRNAs
P08625987A1086|8 32|bone marrow cells expression
P08625987A1086|39 48|VpreB genes
P08625987A1086|62 73|pro-B/pre-BI
P08625987A1086|89 93|cells
P08625987A1086|113 123|state levels
P08625987A1086|179 184|B cells
P08626065A0000|32 47|Bacillus subtilis
P08626065A0000|52 62|DNA fragment
P08626065A0000|88 96|citB genes
P08626065A0000|106 112|degrees
P08626065A0000|118 127|chromosome
P08626290T0000|0 19|Aeromonas salmonicida
P08626290T0000|32 36|genes
P08626290T0000|45 52|homologs
P08626290T0000|68 82|membrane protein
P08626313A1037|0 9|Expression
P08626313A1037|46 52|msp gene
P08626325A0543|2 10|agreement
P08626325A0543|83 92|homodimers
P08626325A0543|90 98|UmuD-UmuD
P08626325A0543|117 127|heterodimer
P08626325A0543|126 134|UmuD-UmuD
P08626437A0332|0 8|Lyn kinase
P08626437A0332|31 37|lysates
P08626437A0332|75 98|glutathione S-transferase
P08626437A0332|102 110|Lyn fusion
P08626437A0332|148 154|p34cdc2
P08626437A0332|157 164|tyrosine
P08626493A1468|0 8|Mutations
P08626493A1468|24 29|region
P08626493A1468|57 63|binding
P08626493A1468|74 98|retinoblastoma gene product
P08626493A1468|121 131|stimulation
P08626493A1468|133 145|transcription
P08626493A1468|153 165|PEPCK promoter
P08626493A1468|191 197|type E1A
P08626529A0000|5 18|autoantibodies
P08626529A0000|24 30|Sjogren
P08626529A0000|32 46|syndrome patient
P08626529A0000|91 105|membrane protein
P08626529A0799|24 30|regions
P08626529A0799|31 40|amino acids
P08626529A0799|79 87|frequency
P08626529A0799|89 101|heptad repeats
P08626529A0799|102 115|characteristic
P08626529A0799|118 130|alpha-helices
P08626529A0799|157 166|structures
P08626529A0799|219 236|sequence ESLALEELEL
P08626529A0799|236 245|amino acids
P08626529A0799|254 258|motif
P08626529A0799|269 280|granin family
P08626529A0799|289 296|proteins
P08626529A0799|315 322|granules
P08626529A0799|325 343|neuroendocrine cells
P08626539T0000|0 17|Binding specificity
P08626539T0000|21 30|modulation
P08626539T0000|36 57|ApoA-I promoter activity
P08626539T0000|69 80|heterodimers
P08626539T0000|89 97|receptors
P08626540A1007|35 48|concentrations
P08626540A1007|52 59|turnover
P08626540A1007|85 92|ceramide
P08626540A1007|93 108|glucosylceramide
P08626540A1007|112 127|lactosylceramide
P08626596A0000|14 21|evidence
P08626596A0000|48 60|protein kinase
P08626596A0000|91 95|cells
P08626596A0000|98 105|stresses
P08626596A0000|115 126|ATP depletion
P08626596A0000|166 173|pathways
P08626610A0931|15 25|suppression
P08626610A0931|28 35|cleavage
P08626610A0931|38 44|SREBP-1
P08626610A0931|91 96|region
P08626610A0931|97 103|residue
P08626610A0931|113 124|COOH terminus
P08626610A0931|141 145|forms
P08626610A0931|149 154|result
P08626610A0931|168 175|splicing
P08626667A1372|0 25|EMSA competition experiments
P08626667A1372|36 44|mutations
P08626667A1372|60 66|repeats
P08626667A1372|85 91|binding
P08626667A1372|104 111|proteins
P08626667A1372|125 143|type oligonucleotide
P08626667A1517|0 12|Transcription
P08626667A1517|20 27|promoter
P08626667A1517|54 60|repeats
P08626667A1517|97 106|conclusion
P08626667A1517|116 130|motifs functions
P08626667A1517|146 162|GPT gene expression
P08626698A0989|16 23|increase
P08626698A0989|26 37|ERK3 activity
P08626698A0989|44 62|PKC beta transfectant
P08626698A0989|73 91|immunoprecipitation
P08626698A0989|115 122|antibody
P08626698A0989|145 162|complex kinase assay
P08626698A0989|169 182|gel kinase assay
P08626777A0537|0 15|Sequence analysis
P08626777A0537|28 41|Col2a1 enhancer
P08626777A0537|57 70|sequence motifs
P08626777A0537|80 85|motifs
P08626777A0537|112 117|region
P08626777A0537|123 137|link protein gene
P08626777A0537|145 157|cartilage gene
P08626785A0674|18 27|activation
P08626785A0674|33 62|tissue transglutaminase promoter
P08626785A0674|95 100|region
P08626785A0674|111 119|sequences
P08626785A0674|156 191|mouse tissue transglutaminase promoters
P08626785A0674|202 207|region
P08626785A0674|228 254|pair retinoid response element
P08626785A0674|255 261|mTGRRE1
P08626785A0674|305 311|mTGRRE1
P08626785A0674|325 348|hexanucleotide half-sites
P08626785A0674|383 394|DR7/DR5 motif
P08626785A0674|411 425|RXR heterodimers
P08626785A0674|428 440|RXR homodimers
P08626809A0729|57 61|Ser51
P08626809A0729|73 89|eIF-2alpha peptide
P08626809A0729|94 107|characteristic
P08626809A0729|113 134|eIF-2alpha kinase family
P08627354A0000|10 18|synapsins
P08627354A0000|30 35|family
P08627354A0000|46 53|proteins
P08627354A0000|74 83|regulation
P08627354A0000|86 108|neurotransmitter release
P08627649A0734|15 33|mobility shift assays
P08627649A0734|44 51|extracts
P08627649A0734|56 65|FREJ4 cells
P08627649A0734|77 83|binding
P08627649A0734|87 92|member
P08627649A0734|100 108|Ets family
P08627649A0734|110 129|transcription factors
P08627649A0734|135 139|P4 EBS
P08627649A0734|151 161|interaction
P08627649A0734|167 173|members
P08627649A0734|179 187|Sp1 family
P08627649A0734|216 220|GC box
P08627667A0132|0 4|ZEBRA
P08627667A0132|16 33|AP-1 bZip activators
P08627667A0132|40 44|c-Fos
P08627667A0132|70 76|domains
P08627667A0132|96 108|specificities
P08627688A1520|4 9|result
P08627688A1520|59 66|activity
P08627719A0784|0 25|UV cross-linking experiments
P08627719A0784|42 53|HSV infection
P08627719A0784|68 74|binding
P08627719A0784|77 90|protein factors
P08627719A0784|109 117|component
P08627719A0784|120 144|cleavage stimulation factor
P08627719A0784|161 168|site RNAs
P08627719A0784|170 179|virus genes
P08627719A0784|193 199|classes
P08627719A0784|219 225|binding
P08627719A0784|234 243|expression
P08628251A1455|0 6|CM-ACO3
P08628251A1455|20 26|flowers
P08628251A1455|52 58|stimuli
P08628254A0665|19 33|Jun/eb1 chimeras
P08628254A0665|43 57|transactivators
P08628254A0665|60 67|AP1 sites
P08628254A0665|95 102|c-Ha-Ras
P08628255A0932|14 22|HeLa cells
P08628255A0932|23 32|expression
P08628255A0932|35 52|luciferase activity
P08628255A0932|68 76|beginning
P08628255A0932|79 90|DNA synthesis
P08628255A0932|111 118|presence
P08628255A0932|145 157|H2A.1 promoter
P08628260A0895|18 36|transfection studies
P08628260A0895|39 48|HepG2 cells
P08628260A0895|64 71|deletion
P08628260A0895|77 82|factor
P08628260A0895|87 103|promoter sequences
P08628260A0895|112 121|nucleotide
P08628260A0895|125 131|results
P08628260A0895|154 161|increase
P08628260A0895|164 179|promoter activity
P08628284A0181|14 32|yeast reporter strain
P08628284A0181|46 53|lacZ gene
P08628284A0181|62 68|control
P08628284A0181|74 85|CYC1 promoter
P08628284A0181|105 110|copies
P08628284A0181|113 117|TRE-1
P08628302A0683|2 7|hnRNP K
P08628302A0683|11 29|transcription factor
P08628302A0683|34 45|interactions
P08628302A0683|53 65|RNA polymerase
P08628302A0683|68 89|transcription apparatus
P08628681A0364|28 33|kb mRNA
P08628681A0364|48 60|Northern blots
P08628681A0364|63 71|oocyte RNA
P08628681A0364|80 91|X.laevis cDNA
P08628681A0821|0 19|Sequence conservation
P08628681A0821|33 40|residues
P08628681A0821|61 67|centers
P08628681A0821|81 90|pol domains
P08628681A0821|100 112|DNA polymerase
P08629348A0237|27 33|history
P08629348A0237|79 85|changes
P08629348A0237|135 143|processes
P08629348A0237|157 161|cysts
P08629348A0237|200 207|epilepsy
P08629348A0237|208 220|hydrocephalus
P08630542A1421|5 12|findings
P08630542A1421|27 34|increase
P08630542A1421|54 64|consequence
P08630542A1421|69 76|increase
P08630542A1421|95 102|response
P08630542A1421|107 115|procedure
P08630548A0000|7 15|cytokines
P08630548A0000|28 33|degree
P08630548A0000|44 53|regulation
P08630548A0000|72 78|potency
P08630548A0000|83 95|interleukin-1
P08630548A0000|102 126|tumor necrosis factor-alpha
P08630548A0000|126 134|TNF-alpha
P08630583A1056|37 46|CO2 content
P08630583A1056|48 53|effect
P08630599A0534|2 11|difference
P08630599A0534|14 40|elastin peptide concentration
P08630599A0534|72 79|patients
P08630599A0534|90 97|subjects
P08630599A0534|119 131|micrograms/ml
P08630599A0534|132 139|patients
P08630599A0534|155 167|micrograms/ml
P08630599A0534|170 178|policemen
P08630599A0534|191 203|micrograms/ml
P08630599A0534|206 215|coal miners
P08631667A0851|0 13|Identification
P08631667A0851|20 25|region
P08631667A0851|37 43|tmk gene
P08631667A0851|68 82|complementation
P08631667A0851|86 100|yeast dTMP kinase
P08631667A0851|122 127|mutant
P08631667A0851|140 150|enzyme assay
P08631667A0851|167 180|kinase activity
P08631667A0851|183 194|cell extracts
P08631667A0851|229 236|plasmids
P08631685A0000|22 27|copper
P08631685A0000|52 67|monoamine oxidase
P08631685A0000|86 101|amine oxidase gene
P08631685A0000|147 156|chromosome
P08631760A0609|4 14|interaction
P08631760A0609|30 38|SH2 domain
P08631760A0609|68 81|phosphopeptide
P08631760A0609|94 112|Crk-SH2 binding motif
P08631797A0982|14 19|ErbB-2
P08631797A0982|32 46|receptor subunit
P08631797A0982|50 72|tyrosine phosphorylation
P08631797A0982|103 109|ligands
P08631797A0982|140 145|effect
P08631797A0982|155 164|EGF binding
P08631817T0000|0 13|Identification
P08631817T0000|17 25|consensus
P08631817T0000|42 66|kinase phosphorylation site
P08631817T0000|98 140|deoxyuridine triphosphate nucleotidohydrolase
P08631820A0755|27 34|FPS1 gene
P08631820A0755|57 71|complementation
P08631820A0755|81 91|yeast strain
P08631820A0755|103 113|FPS activity
P08631820A0755|114 121|Delourme
P08631820A0755|126 133|Lacroute
P08631820A0755|140 144|Karst
P08631822A0677|11 26|plasmin fragments
P08631822A0677|51 57|respect
P08631822A0677|59 72|heparin binding
P08631822A0677|73 83|interaction
P08631822A0677|95 107|VEGF receptors
P08631822A0677|111 117|ability
P08631822A0677|138 152|cell mitogenesis
P08631908A0224|0 6|VDR/RXR
P08631908A0224|21 25|VDREs
P08631908A0224|67 84|mobility shift assay
P08631934A0000|3 9|members
P08631934A0000|15 23|Myb family
P08631934A0000|26 45|transcription factors
P08631934A0000|58 65|homology
P08631934A0000|82 87|domain
P08631934A0000|120 127|sequence
P08631934A0000|135 139|A/C/G
P08631944A0663|2 9|contrast
P08631944A0663|17 23|isoform
P08631944A0663|37 51|C epsilon4 domain
P08631944A0663|71 76|M2 exon
P08631944A0663|77 85|IgE grande
P08631944A0663|102 114|J558L cell line
P08631944A0663|173 182|regulation
P08631944A0663|184 192|secretion
P08631958T0000|5 19|cytomegalovirus
P08631958T0000|35 51|protein IE2 tethers
P08631958T0000|68 83|repression domain
P08632009A1067|3 13|specificity
P08632009A1067|16 21|action
P08632009A1067|24 41|C/EBP family members
P08632009A1067|61 75|characteristics
P08632009A1067|82 87|factor
P08632009A1067|100 117|expression profiles
P08632009A1067|121 140|DNA binding affinities
P08632009A1067|144 152|cofactors
P08632009A1067|162 169|addition
P08632009A1067|175 197|DNA binding specificities
P08632015A0879|3 12|antibodies
P08632015A0879|37 49|transcription
P08632015A0879|52 77|DNA polymerase alpha promoter
P08632015A1226|18 25|analysis
P08632015A1226|41 48|presence
P08632015A1226|51 65|DREF polypeptide
P08632015A1226|68 73|nuclei
P08632015A1226|95 107|division cycle
P08632015A1226|129 140|accumulation
P08632015A1226|183 192|expression
P08632015A1226|218 222|genes
P08632015A1226|230 241|DRE sequences
P08632018A0587|1 11|DNA fragment
P08632018A0587|25 35|nucleotides
P08632018A0587|58 63|region
P08632018A0587|69 78|UGT1A1 gene
P08632018A0587|91 101|MC induction
P08632463A1508|4 9|result
P08632463A1508|21 28|argument
P08632463A1508|42 48|subunit
P08632463A1508|86 93|progress
P08632463A1508|95 117|transcription elongation
P08632779A0351|3 12|XPG regions
P08632779A0351|30 38|amino acid
P08632779A0351|53 57|NLS-B
P08632779A0351|73 77|NLS-C
P08632779A0351|129 136|beta-gal
P08632779A0351|157 163|nucleus
P08632779A0351|165 173|HeLa cells
P08633855A1064|3 10|lacS gene
P08633855A1064|24 56|E. coli-Streptococcus shuttle vector
P08633855A1064|79 100|lacS deletion derivative
P08633855A1064|103 116|S. thermophilus
P08633855A1064|134 139|strain
P08633855A1064|148 153|NZ6091
P08634290A0000|3 8|genome
P08634290A0000|14 25|retroviruses
P08634357A0527|3 20|extraction recovery
P08634357A0527|23 35|Amphotericin B
P08634357A0527|56 60|fluid
P08634357A0527|96 100|range
P08634420A1784|0 8|HuEpo-R Ab
P08634420A1784|37 50|UT-7 cell growth
P08634420A1784|63 67|cells
P08634420A1784|70 74|clone
P08634420A1784|94 100|muEpo-R
P08634420A1784|120 140|UT-7 cell proliferation
P08634423A0498|3 11|frequency
P08634423A0498|14 25|integrations
P08634423A0498|35 47|transcription
P08634423A0498|53 60|lacZ gene
P08634423A0498|87 98|integrations
P08634423A0498|128 142|differentiation
P08634423A0498|144 151|32D cells
P08634423A0498|159 169|neutrophils
P08634697A1155|3 10|sequence
P08634697A1155|22 26|cDNAs
P08634697A1155|44 51|reagents
P08634697A1155|66 75|expression
P08634697A1155|78 82|Brca1
P08634697A1155|88 92|mouse
P08634697A1155|109 118|importance
P08634697A1155|147 153|domains
P08635771A0000|1 5|study
P08635771A0000|30 35|ONLINE
P08635771A0000|39 56|EMIT II immunoassays
P08635771A0000|61 96|gas chromatographic/mass spectrometric
P08635771A0000|97 101|GC/MS
P08635771A0000|102 109|analysis
P08635771A0000|112 134|methaqualone metabolites
P08635771A0000|137 141|urine
P08635771A0000|147 153|samples
P08635771A0000|175 179|study
P08636031A1413|0 10|Interaction
P08636031A1413|16 27|Fur repressor
P08636031A1413|39 46|fragment
P08636031A1413|62 73|pvdS promoter
P08636031A1413|100 116|Fur titration assay
P08636031A1413|138 162|gel retardation experiments
P08636031A1413|185 198|Fur preparation
P08636124A0410|4 10|protein
P08636124A0410|47 53|p150TSP
P08636124A0410|81 94|phosphoprotein
P08636124A0410|122 128|nucleus
P08636124A0410|151 159|evolution
P08636149A0220|10 18|receptors
P08636149A0220|37 47|cell surface
P08636149A0220|56 62|insulin
P08636149A0220|96 114|autophosphorylation
P08636149A0220|117 124|response
P08636149A0220|127 133|insulin
P08636211A0983|0 5|EMBO J.
P08636428A1363|16 22|results
P08636428A1363|62 86|smooth muscle proliferation
P08636428A1363|116 125|expression
P08636428A1363|146 153|mitogens
P08637006A0000|0 12|Transcription
P08637006A0000|17 26|adenovirus
P08637006A0000|35 42|promoter
P08637006A0000|64 68|array
P08637006A0000|85 92|elements
P08637006A0000|115 121|TBP site
P08637006A0000|125 132|E2F sites
P08637006A0000|152 162|orientation
P08637006A0000|187 193|ATF site
P08637711A1121|31 45|interferon gamma
P08637711A1121|45 52|IFN gamma
P08637711A1121|53 67|response element
P08637711A1121|73 85|IRF-1 promoter
P08637711A1121|86 91|IR/IRF
P08637711A1121|173 188|binding complexes
P08637711A1121|196 206|JRE-IL6-BCs
P08637717A0817|7 13|peptide
P08637717A0817|14 23|amino acids
P08637717A0817|44 55|p21-activity
P08637717A0817|63 69|peptide
P08637717A0817|85 91|ability
P08637717A0817|113 124|cyclin E/Cdk2
P08637717A1231|1 10|p21 peptide
P08637717A1231|19 28|amino acids
P08637717A1231|59 76|filter binding assay
P08637717A1231|83 89|peptide
P08637717A1231|111 129|p21-PCNA interaction
P08638435A0522|0 6|Results
P08638435A0522|25 43|agar diffusion method
P08638435A0522|47 62|Y. enterocolitica
P08638435A0522|70 87|inhibition activity
P08638435A0522|102 113|A. hydrophila
P08639310A0548|6 14|mg tid days
P08639310A0548|21 32|mg tid prn days
P08639310A0548|57 65|mg qds days
P08639310A0548|102 107|mg i.v.
P08639310A0548|127 132|mg p.r.
P08639521A1032|10 19|properties
P08639521A1032|26 40|protein fragment
P08639521A1032|96 101|models
P08639521A1032|113 118|motion
P08639561T0000|0 8|Adduction
P08639561T0000|19 28|N-ras codon
P08639561T0000|31 38|sequence
P08639561T0000|59 69|dihydroxy-9
P08639561T0000|67 73|epoxy-7
P08639561T0000|79 93|tetrahydrobenzo
P08639561T0000|94 99|pyrene
P08639561T0000|110 119|refinement
P08639561T0000|169 183|tetrahydrobenzo
P08639561T0000|178 184|pyrenyl
P08639561T0000|185 203|deoxyadenosyl adduct
P08639561T0000|208 212|1H NMR
P08639742T0000|0 8|Isolation
P08639742T0000|19 27|cDNA clone
P08639742T0000|31 39|pea petals
P08639742T0000|44 53|similarity
P08639742T0000|56 62|petunia
P08639742T0000|66 88|wheat zinc finger proteins
P08639837A0268|4 11|fragment
P08639837A0268|38 44|factors
P08639837A0268|61 66|GATA-1
P08639837A0268|70 76|members
P08639837A0268|82 90|Ets family
P08640866A0473|0 7|Exposure
P08640866A0473|20 30|blood T cells
P08640866A0473|40 47|subjects
P08640866A0473|87 96|antibodies
P08640866A0473|111 119|increases
P08640866A0473|145 152|activity
P08641705A0986|14 25|observations
P08641705A0986|34 47|heterozygosity
P08641705A0986|58 66|G mutation
P08641705A0986|68 76|codon beta
P08641705A0986|88 95|deletion
P08641705A0986|114 122|Hbs Lepore
P08641705A0986|125 129|Kenya
P08641705A0986|133 158|beta-globin gene duplication
P08641705A0986|162 166|point
P08641705A0986|184 194|inheritance
P08641705A0986|197 207|Hb Costa Rica
P08642282A1009|14 24|description
P08642282A1009|30 38|knowledge
P08642282A1009|51 58|elements
P08642282A1009|70 79|expression
P08642282A1009|115 122|molecule
P08642285A1548|0 16|DNA-STAT complexes
P08642285A1548|53 61|cell lines
P08642285A1548|87 96|antibodies
P08642285A1548|104 108|STAT1
P08642285A1548|112 116|STAT5
P08642313A0770|32 39|cell line
P08642313A0770|40 45|TAN-1C
P08642313A0770|55 59|kappa
P08642313A0770|71 85|transactivation
P08642313A0770|97 114|reporter gene assays
P08642313A0770|118 124|fashion
P08642313A0770|156 162|protein
P08642313A0770|163 167|Bcl-3
P08642313T0000|0 4|T cell
P08642313T0000|59 72|Notch homologue
P08642313T0000|76 81|I kappa
P08642313T0000|88 95|activity
P08642313T0000|129 149|factor-kappa B proteins
P08642313T0000|152 157|T cells
P08642693T0000|0 20|Polyprotein processing
P08642693T0000|23 38|Southampton virus
P08642693T0000|39 52|identification
P08642693T0000|62 82|protease cleavage sites
P08642693T0000|92 102|mutagenesis
P08643111A0855|35 39|chain
P08643111A0855|46 64|region glycosylation
P08643111A0855|74 91|immunoreactivities
P08643111A0855|181 190|properties
P08643111A0855|207 217|counterpart
P08643111A0855|246 261|oligosaccharides
P08643111A0855|293 306|antigen binding
P08643382A0752|20 33|transit peptide
P08643382A0752|45 50|region
P08643382A0752|80 88|cDNA clone
P08643382A0752|103 120|chloroplast protein
P08643513A0361|0 15|Deletion analysis
P08643513A0361|47 73|acetyltransferase constructs
P08643513A0361|104 111|sequence
P08643513A0361|129 136|promoter
P08643513A0361|173 177|level
P08643513A0361|178 202|osteocalcin gene expression
P08643557A0259|13 20|question
P08643557A0259|26 36|HOX proteins
P08643557A0259|61 71|target genes
P08643578A0000|0 8|RAS2val19
P08643578A0000|89 94|growth
P08643578A0000|96 105|expression
P08643578A0000|124 133|reporter FG
P08643578A0000|162 186|mating pathway reporter FUS1
P08643578A0532|11 31|Rho family protein Cdc42
P08643578A0532|55 62|G protein
P08643578A0532|76 84|regulator
P08643578A0532|98 103|growth
P08643578A0532|114 127|lacZ expression
P08643633A1187|4 20|immunoprecipitate
P08643633A1187|31 37|complex
P08643633A1187|43 49|deltaEC
P08643646A0479|4 9|region
P08643646A0479|73 84|biosynthesis
P08643646A0479|111 121|transcripts
P08643646A0479|200 209|conditions
P08643682A0268|11 23|localizations
P08643682A0268|38 44|CBFbeta
P08643682A0268|51 76|CBFbeta-SMMHC fusion protein
P08643682A0268|93 110|immunofluorescence
P08643682A0268|113 123|NIH 3T3 cells
P08643682A0268|150 162|fusion protein
P08643759A0338|15 19|phase
P08643759A0338|45 64|personality variables
P08643759A0338|73 77|group
P08644734A0404|11 19|isolation
P08644734A0404|27 31|cDNAs
P08644734A0404|71 90|segment-polarity gene
P08645214A1052|25 29|plysS
P08645214A1052|50 56|plasmid
P08645214A1052|70 92|catalase-peroxidase gene
P08645214A1052|107 112|amount
P08645214A1052|115 122|proteins
P08645214A1052|140 147|SDS/PAGE
P08645214A1052|161 166|enzyme
P08645219A1377|19 25|binding
P08645219A1377|26 33|S100 beta
P08645219A1377|63 67|MRP14
P08645219A1377|90 100|binding site
P08645219A1377|142 155|binding domains
P08647086A0622|13 19|complex
P08647086A0622|23 30|cyclin D1
P08647086A0622|37 42|system
P08647086A0720|3 23|Cdk2-cyclin-D1 complex
P08647086A0720|52 61|substrates
P08647086A0720|68 76|H1 histone
P08647086A0720|93 100|T antigen
P08647086A0720|104 108|E2F-1
P08647086A0720|111 121|preparation
P08647086A0720|131 138|proteins
P08647086A0720|143 151|HeLa cells
P08647086A0720|154 161|contrast
P08647086A0720|162 174|Cdk2-cyclin-E
P08647086A0720|178 190|Cdk2-cyclin-A
P08647086A0720|210 217|proteins
P08647086T0000|16 23|kinase-2
P08647086T0000|45 51|complex
P08647086T0000|55 62|cyclin D1
P08647086T0000|88 95|cyclin D1
P08647086T0000|116 128|Cdk7-cyclin-H
P08647091A0592|14 19|clones
P08647091A0592|40 48|Adh-2 gene
P08647091A0592|63 67|exons
P08647091A0592|76 81|region
P08647091A0592|89 97|placement
P08647091A0592|100 106|introns
P08647091A0592|143 150|ADH genes
P08647264T0000|0 7|Ligation
P08647264T0000|36 49|lymphoma B cells
P08647264T0000|53 68|calcium ionophore
P08647264T0000|72 78|antigen
P08647264T0000|97 105|apoptosis
P08647264T0000|118 127|activation
P08647264T0000|133 158|cysteine protease CPP32/Yama
P08647264T0000|162 169|cleavage
P08647264T0000|175 187|substrate PARP
P08647434A1124|5 12|T antigen
P08647434A1124|38 47|antibodies
P08647434A1124|119 128|conditions
P08647434A1124|129 138|holo-TFIID
P08647451A0663|0 24|Northern blot hybridization
P08647451A0663|41 47|HEP-COP
P08647451A0663|67 71|range
P08647451A0663|92 98|tissues
P08647802A0000|17 32|signaling protein
P08647802A0000|76 86|arrangement
P08647802A0000|89 106|SH3-SH2-SH3 domains
P08647822T0000|16 21|sterol
P08647822T0000|31 51|element binding protein
P08647822T0000|54 63|activation
P08647822T0000|92 99|coenzyme
P08647822T0000|101 113|reductase gene
P08647884A0547|29 37|reticulum
P08647884A0547|52 59|MHC class
P08647884A0547|61 69|molecules
P08647884A0547|92 100|transport
P08647884A0547|106 116|cell surface
P08648408A0792|15 23|CSA groups
P08648408A0792|35 43|Hyp levels
P08648408A0792|72 77|PHT-GO
P08648408A0792|78 82|group
P08648408A0792|92 97|CSA-GO
P08648408A0792|98 102|group
P08648665A0956|8 19|LE6 deletions
P08648665A0956|38 61|transformation efficiency
P08648665A0956|83 87|cells
P08648665A1320|0 12|ORF E8 colinear
P08648665A1320|17 21|ORF E6
P08648665A1320|54 60|protein
P08648665A1320|77 83|segment
P08648665A1320|99 103|cells
P08648665A1320|121 133|pZipNeo vector
P08648726A0713|0 6|Cloning
P08648726A0713|19 27|ZI domains
P08648726A0713|46 53|promoter
P08648726A0713|86 95|ZID domains
P08648726A0713|103 111|ZIB domain
P08649372A0501|0 15|Clb2/Cdc28 kinase
P08649372A0501|35 44|repression
P08649372A0501|58 63|factor
P08649372A0501|79 86|activity
P08649372A0501|96 101|M phase
P08649372A0755|3 17|carboxy terminus
P08649372A0755|41 51|interaction
P08649372A0755|67 81|carboxy terminus
P08649372A0755|102 112|interaction
P08649373T0000|23 33|cis elements
P08649373T0000|60 68|chromatin
P08649373T0000|79 87|c-myc gene
P08649386A1032|4 24|UASH consensus sequence
P08649386A1032|50 57|analysis
P08649386A1032|73 85|consensus Abf1
P08649389A0000|30 43|CTCF cDNA clones
P08649389A0000|97 106|factor CTCF
P08649389A0000|139 145|protein
P08649389A0000|157 165|% identity
P08649389A0000|186 203|amino acid sequences
P08649389A0692|10 17|analysis
P08649389A0692|34 48|CTCF binding site
P08649389A0692|52 86|transient-cotransfection experiments
P08649389A0692|126 134|repressor
P08649389A0692|144 152|c-myc gene
P08649393A0000|1 30|chromosome transmission fidelity
P08649393A0000|36 41|mutant
P08649393A0000|90 99|centromere
P08649393A0000|119 138|readthrough phenotype
P08649393A0000|157 176|kinetochore integrity
P08649403A0963|3 14|growth defect
P08649403A0963|18 25|reg1 reg2
P08649403A0963|32 37|mutant
P08649403A0963|69 76|mutation
P08649403A0963|94 106|protein kinase
P08649405T0000|13 17|sites
P08649405T0000|22 34|CD11c promoter
P08649405T0000|62 66|cells
P08649405T0000|99 111|transcription
P08649424A0000|0 9|Expression
P08649424A0000|15 42|phenylalanine hydroxylase gene
P08649424A0000|45 50|livers
P08649424A0000|54 60|kidneys
P08649424A0000|63 69|rodents
P08649424A0000|83 87|birth
P08649424A0000|102 116|glucocorticoids
P08649424A0000|136 140|liver
P08649425A0373|23 30|enhancer
P08649425A0373|59 63|DNase
P08649425A0373|85 101|B-cell development
P08649425T0000|25 42|chromatin structure
P08649425T0000|48 71|mouse immunoglobulin kappa
P08649425T0000|73 80|enhancer
P08649427A0689|15 28|identification
P08649427A0689|53 58|member
P08649427A0689|80 86|protein
P08649427A0689|92 97|family
P08649427A0689|99 114|GTPase regulators
P08649428A1227|6 10|study
P08649428A1227|35 44|regulation
P08649428A1227|50 58|synthesis
P08649428A1227|64 83|c-mos oncogene product
P08649428A1227|106 115|activation
P08649440T0000|3 15|heterogeneity
P08649773A1374|3 9|ability
P08649773A1374|12 16|BCL-6
P08649773A1374|45 53|repressor
P08649773A1374|72 78|ability
P08649773A1374|90 101|B lymphocytes
P08649773A1374|116 127|cell lymphoma
P08649841A0956|0 10|Positioning
P08649841A0956|48 61|Kozak sequences
P08649841A0956|81 88|promoter
P08649841A0956|103 117|CAT reporter gene
P08649841A0956|133 142|inhibition
P08649841A0956|145 164|CAT protein production
P08649841A0956|173 180|decrease
P08649841A0956|183 189|CAT mRNA
P08650818A0000|10 15|spread
P08650818A0000|69 74|strain
P08650818A0000|91 98|patients
P08650818A0000|135 139|spite
P08650818A0000|141 149|isolation
P08650818A0000|198 204|arrival
P08650818A0000|210 217|hospital
P08650818A0000|223 239|Mediterranean area
P08651853A0607|14 22|sclerosis
P08651853A0607|74 80|gliosis
P08651853A0607|94 109|CA1/prosubiculum
P08651853A0607|112 119|patients
P08651853A0607|137 148|dentate gyrus
P08651853A0607|150 157|patients
P08651853A0607|170 178|CA4 region
P08651853A0607|180 187|patients
P08651853T0000|14 22|sclerosis
P08652081A1953|19 24|events
P08652081A1953|64 73|toxicities
P08652081A1953|81 91|hypotension
P08652081A1953|108 115|headache
P08652081A1953|117 124|skin rash
P08652081A1953|143 152|congestion
P08652081A1953|169 175|lesions
P08654200A0274|17 32|resonance imaging
P08654200A0274|51 61|liver volume
P08654200A0274|86 93|patients
P08654200A0274|108 116|clearance
P08654200A0274|124 138|model substrates
P08654200A0274|139 147|lorazepam
P08654200A0274|152 156|mg/kg
P08654200A0274|157 166|antipyrine
P08654200A0274|169 173|mg/kg
P08654200A0274|177 187|indocyanine
P08654200A0274|201 205|mg/kg
P08654375A0544|11 18|analysis
P08654375A0544|31 36|region
P08654375A0544|44 53|amino acids
P08654375A0544|54 63|amino acids
P08654375A0544|74 83|N-terminus
P08654375A0544|124 142|DNA binding POU domain
P08654375A0544|144 148|Oct-1
P08654375A0544|151 155|Oct-2
P08654390A0000|0 12|Heme oxygenase
P08654390A0000|27 32|enzyme
P08654390A0000|35 48|heme catabolism
P08654390A0000|72 81|biliverdin
P08654390A0000|90 103|carbon monoxide
P08654435A0540|10 15|analog
P08654435A0540|18 27|wortmannin
P08654435A0540|61 74|Erk2 activation
P08654435A0540|77 86|wortmannin
P08654435A0540|92 97|effect
P08654435A0540|103 110|activity
P08654435A0540|148 153|assays
P08654946A0475|7 12|shares
P08654946A0475|13 21|% identity
P08654946A0475|38 43|region
P08654946A0475|46 62|Xenopus laevis FGF3
P08654946A0475|67 75|% identity
P08654946A0475|83 89|product
P08654946A0986|3 25|transcription start point
P08654946A0986|39 46|promoter
P08654946A0986|61 75|mouse promoter P3
P08654946A0986|99 104|region
P08654946A0986|107 114|sequence
P08654972A0000|0 6|Defects
P08654972A0000|63 67|genes
P08654972A0000|76 95|cell cycle progression
P08654983A0000|14 38|signal recognition particle
P08654983A0000|43 53|SRP receptor
P08654983A0000|58 63|system
P08654983A0000|65 80|Bacillus subtilis
P08654983A0000|96 104|Bs srb gene
P08654983A0000|117 125|homologue
P08654983A0000|140 163|SRP receptor alpha-subunit
P08654983A0000|164 168|Oguro
P08654983A0000|174 179|DNA Res
P08655497A0000|69 78|K-12 genome
P08655497A0000|93 102|resistance
P08655497A0000|105 119|chloramphenicol
P08655497A0000|152 157|vector
P08655555A0772|2 9|addition
P08655555A0772|11 19|deletions
P08655555A0772|53 75|transcription start point
P08655555A0772|95 111|% promoter activity
P08655555A0772|132 138|hexamer
P08655555A0772|157 172|promoter activity
P08655555A1368|3 13|DNA sequence
P08655555A1368|43 49|hexamer
P08655555A1368|62 69|TGn motif
P08655555A1368|94 99|region
P08655555A1368|113 121|promoters
P08656672A0678|10 30|ufo mRNA overexpression
P08656672A0678|60 76|leukemia cell lines
P08656672A0678|112 120|subclones
P08656672A0678|126 152|cervix carcinoma cell line HeLa
P08657135A1444|19 25|studies
P08657135A1444|53 61|regulator
P08657135A1444|63 72|myogenesis
P08657135A1444|85 102|E protein homodimers
P08657135A1444|116 125|muscle gene
P08657135A1444|136 143|elements
P08657150A1049|19 28|regulators
P08657150A1049|70 77|SIN5 gene
P08657150A1049|93 111|promoter specificity
P08657150A1049|124 133|activators
P08657157A0000|15 24|regulators
P08657157A0000|37 45|POU domain
P08657157A0000|57 61|motif
P08657157A0000|94 102|complexes
P08657157A0000|117 125|POU domain
P08657157A0000|146 156|recognition
P08657157A0000|166 188|octamer sequence elements
P08657183A0145|7 12|strand
P08657183A0145|22 27|repair
P08657183A0145|30 41|DNA fragments
P08657183A0145|57 61|genes
P08657918A0360|0 8|MATERIALS
P08657918A0360|12 18|METHODS
P08657918A0360|19 37|Coronal 3D GRE imaging
P08657918A0360|69 82|dorsal portions
P08657918A0360|97 104|patients
P08657918A0360|155 160|wrists
P08657918A0360|189 198|dissection
P08659545A0000|4 9|effort
P08659545A0000|27 39|transcript map
P08659545A0000|47 56|chromosome
P08659545A0000|65 77|understanding
P08659545A0000|83 97|pathophysiology
P08659545A0000|100 106|trisomy
P08659545A0000|119 130|exon trapping
P08659545A0000|141 149|fragments
P08659545A0000|152 161|chromosome
P08659545A0000|164 168|genes
P08660733X0000|11 21|populations
P08660733X0000|28 32|aphid
P08660733X0000|52 61|Puerto Rico
P08660733X0000|64 68|April
P08660748X0000|3 7|model
P08660748X0000|19 25|essence
P08660748X0000|41 48|dynamics
P08660748X0000|68 78|predictions
P08660748X0000|81 98|population patterns
P08660866A0504|11 19|positions
P08660866A0504|45 57|loss phenotype
P08660866A0504|75 81|progeny
P08660866A0504|126 132|neurons
P08660866A0504|135 142|thecogen
P08660866A0504|143 148|sheath
P08660866A0504|149 153|cells
P08660866A0504|166 174|trichogen
P08660866A0504|175 179|shaft
P08660866A0504|183 190|tormogen
P08660866A0504|191 196|socket
P08660866A0504|197 201|cells
P08660892A1044|15 22|blockade
P08660892A1044|36 51|co-transfections
P08660892A1044|64 82|SRF expression vector
P08660892A1044|104 113|expression
P08660892A1044|129 135|factors
P08660892A1044|151 156|Mef-2C
P08660998A0851|3 16|mMIWC1 promoter
P08660998A0851|63 74|AP-2 elements
P08660998A0851|72 86|primer extension
P08660998A0851|95 122|mMIWC transcription initiation
P08660998A0851|147 152|mMIWC1
P08660998A0851|165 178|initiation site
P08661007T0000|5 14|MN/CA9 gene
P08661007T0000|21 26|member
P08661007T0000|40 54|anhydrase family
P08661007T0000|55 63|structure
P08661007T0000|75 100|protein domain relationships
P08661100A0285|14 25|distribution
P08661100A0285|28 32|Cdebp
P08661100A0285|68 74|App gene
P08661100A0285|80 86|regions
P08661100A0285|107 113|domains
P08661100A0285|128 136|structure
P08661100A0285|147 151|parts
P08661101A0396|0 18|DNA sequence analysis
P08661101A0396|47 53|protein
P08661101A0396|71 77|rat CRP1
P08661104A0687|72 84|cells/tissues
P08661104A0687|92 99|prostate
P08661104A0687|106 110|liver
P08661104A0687|113 117|colon
P08661114A0564|11 17|domains
P08661114A0564|30 45|sequence homology
P08661114A0564|76 83|proteins
P08661116A0963|0 15|Promoter activity
P08661116A0963|25 33|cell lines
P08661116A0963|51 56|levels
P08661116A0963|69 74|D3 mRNA
P08661116A0963|88 107|Northern blot analyses
P08661116A0963|141 148|promoter
P08661119A0085|22 44|EP4 receptor gene sequence
P08661119A0085|61 69|structure
P08661119A0085|80 87|EP4R cDNA
P08661119A0085|113 128|blood lymphocytes
P08661613A0691|4 8|users
P08661613A0691|32 49|management measures
P08661613A0691|55 59|users
P08661613A0691|72 79|response
P08661613A0691|82 90|education
P08661613A0691|112 116|group
P08661613A0691|137 157|enforcement activities
P08662193A0404|13 32|activation subdomains
P08662193A0404|54 59|region
P08662193A0404|75 79|yeast
P08662193A0404|113 118|region
P08662499A0484|3 7|front
P08662499A0484|11 21|interaction
P08662617A2051|72 78|protein
P08662617A2051|91 97|surface
P08662617A2051|111 126|uterine epithelia
P08662617A2051|147 155|cell lines
P08662789A0673|40 56|GenBankTM data base
P08662789A0673|58 74|sequence alignment
P08662789A0673|84 89|RPS30A
P08662852A1297|3 10|location
P08662852A1297|30 53|GRK5 phosphoacceptor sites
P08662852A1297|65 80|carboxyl terminus
P08662852A1297|86 92|beta2AR
P08662852A1297|127 141|phosphorylation
P08662852A1297|144 152|rhodopsin
P08662928A1153|4 13|regulation
P08662928A1153|53 62|expression
P08662928A1153|65 76|STAT proteins
P08662928T0000|0 8|Receptors
P08662928T0000|12 22|interleukin
P08662928T0000|41 49|cytokines
P08662928T0000|59 77|signaling mechanisms
P08662928T0000|89 101|transcription
P08662928T0000|109 128|IL-6 response elements
P08662936A0428|22 43|FR-19 amino acid sequence
P08662936A0428|78 85|identity
P08662936A0428|87 99|chicken TEF-1A
P08662936A0428|100 109|mouse TEF-1
P08662936A0428|113 117|mouse
P08662936A0428|149 154|factor
P08662980A0762|4 13|phenomenon
P08662980A0762|27 36|DNA binding
P08662980A0762|53 60|receptor
P08662980A0762|151 158|receptor
P08662980A0762|186 191|effect
P08663000A0000|3 10|receptor
P08663000A0000|14 23|hyaluronan
P08663000A0000|32 39|motility
P08663000A0000|40 44|RHAMM
P08663000A0000|45 58|gene expression
P08663000A0000|79 91|fibrosarcomas
P08663000A0000|113 130|growth factor-beta1
P08663000A0000|131 139|TGF-beta1
P08663120T0000|9 13|Raf-1
P08663120T0000|23 33|p70 S6 kinase
P08663120T0000|55 61|protein
P08663120T0000|80 86|pathway
P08663127A0697|10 17|analysis
P08663127A0697|45 52|homology
P08663127A0697|84 90|domains
P08663127A0697|136 153|glycosylation sites
P08663127A0697|183 189|regions
P08663141T0000|11 20|DNA element
P08663141T0000|35 41|TATA box
P08663141T0000|45 71|transcription initiation site
P08663141T0000|84 91|response
P08663141T0000|104 112|sequences
P08663141T0000|120 138|angiotensinogen gene
P08663172A0311|4 10|protein
P08663172A0311|27 39|amino terminus
P08663172A0311|60 66|protein
P08663219A0246|3 10|promoter
P08663219A0246|16 27|rat PGS-2 gene
P08663219A0246|59 78|protein consensus site
P08663219A0246|78 84|CAAT box
P08663219A0246|99 117|hormone inducibility
P08663219A0246|121 125|PGS-2
P08663219A0246|151 165|CAT reporter gene
P08663219A0246|183 193|E-box region
P08663310A0157|32 40|regulator
P08663310A0157|42 48|members
P08663310A0157|52 56|class
P08663310A0157|67 79|response genes
P08663310A0157|101 105|genes
P08663310A0157|158 167|cell growth
P08663310A0157|170 184|differentiation
P08663326A0000|25 37|DmpR activator
P08663326A0000|47 59|transcription
P08663326A0000|65 73|dmp operon
P08663326A0000|88 94|enzymes
P08663326A0000|98 107|catabolism
P08663326A0000|110 115|methyl
P08663326A0000|115 121|phenols
P08663392A0215|6 10|study
P08663392A0215|31 38|DSG3 gene
P08663392A0215|68 77|regulation
P08663392A0215|83 92|expression
P08664229T0000|8 17|evaluation
P08664229T0000|23 38|Allergan Humphrey
P08664229T0000|42 54|autorefractor
P08664229T0000|61 85|Nidek AR-1000 autorefractor
P08664347A0923|15 43|proprotein processing proteases
P08664347A0923|75 81|pro-LPH
P08664347A0923|127 136|maturation
P08664347A0923|143 148|enzyme
P08664462A1404|5 11|changes
P08664462A1404|20 25|result
P08664462A1404|53 63|sensitivity
P08664462A1404|81 92|transmission
P08664462A1404|108 126|muscle contractility
P08664462A1404|149 154|result
P08664462A1404|164 178|plasma clearance
P08664462A1404|185 195|hypothermia
P08664667A0093|7 11|Delhi
P08664667A0093|17 21|India
P08665853A0228|30 34|cells
P08665853A0228|65 76|ErbB proteins
P08665853A0228|84 95|combinations
P08665853A0228|107 112|ErbB-3
P08665853A0228|136 143|activity
P08665853A0228|151 156|ErbB-1
P08665853A0228|160 165|ErbB-2
P08665853A0228|208 215|activity
P08666102A0820|52 58|methods
P08666238T0000|9 29|translation initiation
P08666238T0000|32 39|ribosome
P08666238T0000|83 87|cells
P08666241A0930|33 38|region
P08666241A0930|44 55|24p3 promoter
P08666241A0930|70 86|Dex responsiveness
P08666383A1252|5 12|findings
P08666383A1252|30 40|cDNA mapping
P08666383A1252|46 57|fluorescence
P08666383A1252|64 76|hybridization
P08666383A1252|103 110|approach
P08666383A1252|116 125|definition
P08666383A1252|155 160|genome
P08666398T0000|8 20|cosmid contigs
P08666398T0000|31 43|Batten disease
P08666398T0000|50 55|region
P08666398T0000|57 69|16p12.1-p11.2
P08666404A0311|0 8|Isolation
P08666404A0311|48 63|brain cDNA library
P08666404A0311|72 105|protein serine-threonine phosphatase
P08666404A0311|111 132|tetratricopeptide motif
P08666404A0311|155 159|PPP5C
P08666404A0311|186 191|rat PPT
P08666913A0000|0 4|Ly-49
P08666913A0000|8 17|family type
P08666913A0000|20 40|transmembrane proteins
P08666913A0000|51 61|gene cluster
P08666913A0000|70 79|chromosome
P08668124A0744|3 11|Dox-A2 ORF
P08668124A0744|23 34|TDH3 promoter
P08668124A0744|50 58|phenotype
P08668124A0744|62 67|strain
P08668142A1048|3 14|introduction
P08668142A1048|17 21|hARF4
P08668142A1048|27 31|cells
P08668142A1048|45 51|balance
P08668142A1048|90 99|Sec7p pools
P08668158A0765|32 36|Rpm1r
P08668158A0765|56 65|substrates
P08668158A0765|79 85|tRNAPro
P08668158A0765|90 97|promoter
P08668158A0765|149 155|portion
P08668158A0765|179 186|promoter
P08668158A1252|11 17|strains
P08668158A1252|28 36|RPM1 genes
P08668158A1252|51 64|precursor Rpm1r
P08668158A1252|79 87|mutations
P08668158A1252|118 134|biogenesis defects
P08668190A1364|8 23|membrane vesicles
P08668190A1364|28 38|hum1 mutants
P08668190A1364|53 68|antiport activity
P08668190A1364|84 88|Hum1p
P08668190A1364|101 108|exchange
P08668190A1364|131 135|yeast
P08668190A1364|142 149|membrane
P08668201A1059|8 18|mutagenesis
P08668201A1059|24 30|element
P08668201A1059|50 65|sequence boundary
P08668201A1059|94 101|activity
P08668201A1059|107 117|MATalpha1 IE
P08668201A1059|143 147|codon
P08668201A1059|153 159|element
P08668201A1059|171 178|interval
P08668203A1230|35 42|pancreas
P08668203A1230|53 76|differentiation functions
P08668203A1230|89 99|sublineages
P08668203A1230|130 136|tissues
P08668209A0406|0 5|Merlie
P08668209A0406|6 25|Cold Spring Harbor Symp
P08668210A0000|11 18|evidence
P08668210A0000|48 57|activation
P08668210A0000|62 66|Raf-1
P08668210A0000|87 106|protein kinase pathway
P08668210A0000|130 143|transformation
P08669274T0000|10 26|chain ossification
P08669274T0000|27 32|choice
P08669274T0000|46 53|approach
P08669676A1644|3 11|incidence
P08669676A1644|21 25|death
P08669676A1644|32 36|group
P08669676A1644|37 43|Q wave MI
P08669676A1644|44 51|propofol
P08669676A1644|57 65|midazolam
P08669676A1644|83 89|Q wave MI
P08669676A1644|88 95|propofol
P08669676A1644|102 110|midazolam
P08669676A1644|143 157|treatment groups
P08670556A0425|4 13|micromol/1
P08670556A0425|37 65|plasma concentration-time curve
P08670556A0425|78 88|infinity AUC
P08670556A0425|89 98|0-infinity
P08670853A0000|0 15|Cluster formation
P08670853A0000|18 27|E-cadherin
P08670853A0000|33 43|cell surface
P08670853A0000|65 74|importance
P08670853A0000|87 94|adhesion
P08670910A0156|0 13|DNA polymerase E
P08670910A0156|14 22|DNA ligase
P08670910A0156|53 73|endonuclease co-purify
P08670910A0156|84 101|polypeptide complex
P08672242A0517|7 28|reporter gene constructs
P08672242A0517|50 58|sequences
P08672242A0517|64 73|P1 promoter
P08672242A0517|88 94|regions
P08672242A0517|110 119|expression
P08673026T0000|3 17|factor structure
P08673026T0000|20 30|schizotypal
P08673026T0000|31 36|traits
P08673026T0000|43 58|replication study
P08675026A0420|52 63|sequence tags
P08675026A0420|78 85|function
P08675026A0420|89 109|Caenorhabditis elegans
P08675026A0420|110 120|Oryza sativa
P08675395A0751|0 6|RESULTS
P08675395A0751|18 22|model
P08675395A0751|61 77|acuity outcome data
P08675608T0000|0 6|Outcome
P08675608T0000|25 38|hypothyroidism
P08675763A0788|0 11|Mean increase
P08675763A0788|14 29|milk protein yield
P08675763A0788|65 72|increase
P08675763A0788|76 89|protein content
P08675769A0158|9 13|rates
P08675769A0158|55 62|measures
P08675769A0158|78 87|efficiency
P08675769A0158|94 107|conception rate
P08675769A0158|111 121|calving rate
P08675769A0158|194 202|fertility
P08675769A0158|216 226|performance
P08675769A0158|230 241|AI technician
P08675821A0657|26 35|glans penis
P08675821A0657|52 57|search
P08675821A0657|68 77|malignancy
P08676266A0838|3 12|mean values
P08676266A0838|15 30|protease activity
P08676266A0838|59 68|test groups
P08676266A0838|78 89|control group
P08676266A0838|92 99|baseline
P08676383A0518|4 15|half molecule
P08676383A0518|28 44|disulfide linkages
P08676383A0518|52 62|cis peptides
P08676454A0731|37 41|ICP35
P08676454A0731|39 43|ICP35
P08676454A0731|57 64|B capsids
P08676454A0731|85 94|precursors
P08676454A0731|103 109|virions
P08676456A0879|9 25|VP16-Tat construct
P08676456A0879|39 54|leucine mutations
P08676456A0879|72 89|AP-1 responsiveness
P08676456A0879|92 101|comparison
P08676456A0879|115 134|VP16 activation domain
P08676495A0129|11 20|splice site
P08676495A0129|30 39|nucleotide
P08676495A0129|60 69|processing
P08676495A0129|75 88|BPV-1 pre-mRNAs
P08676495A0129|108 116|C127 cells
P08676495A0129|141 145|times
P08676495A0129|168 172|warts
P08676858A0309|7 13|cloning
P08676858A0309|17 32|characterization
P08676858A0309|35 46|S-RNase genes
P08676858A0309|54 60|species
P08676858A0309|63 70|Rosaceae
P08676858A0309|71 75|apple
P08676858A0309|76 90|Malus x domestica
P08676858A0309|108 120|Pyrus serotina
P08676858A0309|139 147|sequences
P08676858A0309|182 187|RNases
P08676858A1084|21 27|members
P08676858A1084|32 52|T2/S-RNase superfamily
P08676858A1084|55 60|plants
P08677443A0238|3 22|Hoosier Oncology Group
P08677443A0238|33 37|study
P08677443A0238|64 75|SCLC patients
P08677443A0238|117 122|regard
P08677443A0238|138 148|progression
P08677443A0238|155 160|months
P08677443A0238|167 179|survival times
P08677443A0238|187 192|months
P08677443A0238|206 218|survival rates
P08677678A0258|14 27|administration
P08677678A0258|30 55|immunomodulator neurotropin
P08677678A0258|80 92|consolidation
P08677678A0258|95 103|retention
P08677678A0258|106 112|feeding
P08677678A0258|116 132|avoidance behavior
P08677678A0258|158 167|mechanisms
P08677678A0258|174 182|phenomena
P08678959A0640|0 20|Sestamibi scintigraphy
P08678959A0640|34 41|patients
P08678959A0640|62 76|ultrasonography
P08679131T0000|6 12|allergy
P08679131T0000|21 38|hypersensitivities
P08680702A0548|18 26|lethality
P08680702A0548|44 54|dysfunction
P08680702A0548|66 70|group
P08680702A0548|103 109|animals
P08680702A0548|125 135|differences
P08680702A0548|165 170|Vo2DIR
P08680702A0548|170 178|ml/kg/min
P08680702A0548|263 270|catheter
P08680702A0548|277 284|Vo2INDIR
P08680702A0548|285 293|ml/kg/min
P08680706A0889|11 21|reperfusion
P08680706A0889|21 33|PO2/FlO2 ratio
P08680706A0889|69 75|Therapy
P08680706A0889|82 85|mm Hg
P08680706A0889|95 112|Recipient Instilled
P08680706A0889|119 122|mm Hg
P08680706A0889|126 138|Control groups
P08680706A0889|144 147|mm Hg
P08680706A0889|164 169|values
P08680706A0889|172 187|Donor Aerosol dogs
P08680706A0889|194 197|mm Hg
P08682155A0902|3 25|euglobulin clot lysis time
P08682155A0902|48 54|smokers
P08682155A0902|64 74|non-smokers
P08682155A0902|97 106|situations
P08682155A0902|113 123|differences
P08682317A0900|0 13|HS inducibility
P08682317A0900|45 67|HS transcription factor-1
P08682317A0900|66 70|HSF-1
P08682317A0900|80 87|extracts
P08682317A0900|100 104|cells
P08682868A0738|11 24|DSK2-1 mutation
P08682868A0738|41 47|residue
P08682868A0738|53 57|Dsk2p
P08682868A0738|72 77|domain
P08682868A0738|88 98|differences
P08682868A0738|101 105|Dsk2p
P08682868A0738|108 122|Cdc31p stability
P08683106A0374|17 25|IFN-alpha
P08683106A0374|34 43|STAT1 alpha
P08683106A0374|47 51|STAT5
P08683106A0374|80 84|STAT5
P08683106A0374|89 97|IFN-alpha
P08683106A0374|120 129|STAT1 alpha
P08683108A0965|18 31|interpretation
P08683108A0965|62 88|transcription factor proteins
P08683108A1501|17 23|results
P08683108A1501|35 44|components
P08683108A1501|50 79|protein kinase A signaling pathway
P08683108A1501|107 123|junB transcription
P08683983A0785|3 9|complex
P08683983A0785|23 30|D protein
P08683983A0785|92 104|leukemia cells
P08683983A1163|3 9|results
P08683983A1163|20 32|participation
P08683983A1163|35 40|intron
P08683983A1163|59 68|regulation
P08683983A1163|74 82|c-myb gene
P08683983A1163|85 89|mouse
P08683983A1163|138 147|mechanisms
P08683983A1163|150 159|activation
P08683983A1163|180 194|differentiation
P08683983A1163|206 222|cell growth control
P08684522A0415|0 27|Immunofluorescence microscopy
P08684522A0415|45 54|deposition
P08684522A0415|74 81|matrices
P08684522A0415|92 99|collagen
P08684522A0415|102 108|laminin
P08684742A0000|0 8|OBJECTIVE
P08684742A0000|18 39|pregnancy complications
P08684742A0000|42 46|women
P08684742A0000|60 72|amniocentesis
P08684742A0000|80 84|weeks
P08684742A0000|106 118|amniocentesis
P08684742A0000|126 130|weeks
P08684742A0000|131 139|gestation
P08686381A0527|11 21|9765orfR002
P08686381A0527|21 31|9765orfR011
P08686381A0527|35 45|9765orfR013
P08686381A0527|97 123|polyadenylate binding protein
P08686381A0527|159 165|protein
P08686381A0527|177 182|region
P08686381A0527|185 197|transcription
P08686381A0527|208 218|protein Swi3
P08688190A0000|6 22|flavone glucosides
P08688190A0000|23 52|nevadensin 5-O-beta-D-glucoside
P08688190A0000|56 84|nevadensin 5-O-beta-D-glucosyl
P08688190A0000|85 100|beta-D-glucoside
P08688190A0000|130 134|parts
P08688190A0000|137 157|Lysionotus pauciflorus
P08688556A0242|11 20|laboratory
P08688556A0242|31 36|screen
P08688556A0242|64 74|suppressors
P08688556A0242|94 100|strains
P08688556A0242|103 110|clathrin
P08688556A0242|131 135|yeast
P08688556A0242|142 147|scd1-i
P08688556A0242|149 157|viability
P08689520T0000|0 17|Reproductive period
P08689520T0000|25 35|water intake
P08689520T0000|61 65|goats
P08690118A0845|11 28|regression analysis
P08690118A0845|34 45|manual method
P08690118A0845|46 55|percentage
P08690118A0845|62 71|morphology
P08690118A0845|102 111|predictors
P08690118A0845|113 125|fertilization
P08690198A0346|0 6|METHODS
P08690198A0346|43 50|infusion
P08690198A0346|73 87|supplementation
P08690198A0346|89 95|oatbase
P08690198A0346|96 119|Lactobacillus reuteri R2LC
P08690198A0346|123 147|Lactobacillus plantarum DSM
P08690198A0346|166 177|fermentation
P08690198A0346|185 193|beginning
P08690198A0346|199 203|study
P08691106A0733|7 15|D8 binding
P08691106A0733|29 46|nuclease protection
P08691106A0733|51 60|lactotroph
P08691106A0733|98 104|protein
P08691962T0000|25 33|diagnosis
P08691962T0000|35 41|Whipple
P08691962T0000|43 49|disease
P08691962T0000|64 68|blood
P08691962T0000|80 84|cells
P08692885A0663|3 9|ability
P08692885A0663|24 42|NF-kappaB activation
P08692885A0663|66 81|zinc finger domain
P08692892A0330|3 9|Pro-258
P08692892A0330|15 19|P258L
P08692892A0330|19 26|mutation
P08692892A0330|45 61|receptor signaling
P08692892A0330|95 106|maximum level
P08692892A0330|125 129|cells
P08692892A0330|144 155|alpha-factor
P08692924A0328|8 18|DNA sequence
P08692924A0328|33 39|ability
P08692924A0328|57 61|BCL-6
P08692924A0328|83 87|BCL-6
P08692924A0328|110 118|complexes
P08692924A0328|128 135|extracts
P08692924A0328|147 157|B-cell lines
P08697728A1199|13 17|value
P08698756A1240|0 10|CONCLUSIONS
P08698756A1240|14 21|findings
P08698756A1240|33 45|pre-treatment
P08698756A1240|50 60|coenzyme Q10
P08698756A1240|106 115|procedures
P08698756A1240|139 143|cross
P08698756A1240|168 173|degree
P08698756A1240|188 193|damage
P08700531A1420|7 17|chromosome X
P08700531A1420|50 60|alterations
P08700531A1420|79 90|hamster cells
P08700531A1420|104 122|chemical carcinogens
P08700531A1420|135 141|viruses
P08700531A1420|145 156|localization
P08700531A1420|162 169|cph locus
P08700531A1420|176 185|chromosome
P08700531A1420|197 202|notion
P08700531A1420|210 220|cph oncogene
P08700531A1420|247 256|conversion
P08700531A1420|279 296|hamster fibroblasts
P08702517A0000|3 8|screen
P08702517A0000|12 16|genes
P08702517A0000|59 65|B6SUtA1
P08702517A0000|73 90|progenitor cell line
P08702543A0000|5 9|IP4BP
P08702543A0000|15 20|member
P08702543A0000|45 52|proteins
P08702543A0000|80 112|inositol 1,3,4,5-tetrakisphosphate
P08702543A0000|117 130|binding protein
P08702543A0000|130 135|Cullen
P08702556A0000|24 35|purification
P08702556A0000|58 72|acid phosphatase
P08702556A0000|85 106|porcine thymus membranes
P08702556A0000|106 110|Kanoh
P08702556A0000|121 125|S.-i.
P08702556A0000|124 129|Yamada
P08702556A0000|137 142|Sakane
P08702633A0164|3 11|mechanism
P08702633A0164|20 29|Gbetagamma
P08702633A0164|46 54|increases
P08702633A0164|57 79|tyrosine phosphorylation
P08702633A0164|85 101|Shc adapter protein
P08702633A0164|106 125|Grb2 complex formation
P08702633A0164|128 138|recruitment
P08702633A0164|141 182|Ras guanine nucleotide exchange factor activity
P08702644A0499|44 49|apoB17
P08702644A0499|82 91|amino acids
P08702644A0499|111 116|factor
P08702644A0499|138 143|signal
P08702644A0499|146 189|glycosylphosphatidylinositol anchor attachment
P08702728A1325|41 45|Y317F
P08702728A1325|60 68|HIRc cells
P08702756A0000|8 16|GTPase Rho
P08702756A0000|44 52|functions
P08702756A0000|67 87|actin-myosin filaments
P08702756A0000|94 104|cytokinesis
P08702756A0000|105 116|cell motility
P08702756A0000|126 142|muscle contraction
P08702807A0964|10 19|activation
P08702807A0964|26 41|signaling pathway
P08702807A0964|44 53|expression
P08702807A0964|110 133|cyclin D1 promoter activity
P08702807A0964|136 160|cyclin D1 protein expression
P08702807A0964|164 169|growth
P08702807A0964|188 193|manner
P08702826A0870|19 27|insertion
P08702826A0870|33 52|GSTP1 silencer element
P08702826A0870|68 75|activity
P08702826A0870|91 98|promoter
P08702826A0870|101 109|MCF7 cells
P08702845A0000|2 6|order
P08702845A0000|28 33|motifs
P08702845A0000|53 60|affinity
P08702845A0000|64 74|recognition
P08702845A0000|86 104|dopamine transporter
P08702845A0000|123 144|dopamine uptake kinetics
P08702845A0000|149 173|CFT binding characteristics
P08702845A0000|175 184|COS-7 cells
P08702845A0000|228 239|COOH terminus
P08702936A0168|2 18|expression library
P08702936A0168|61 65|cDNAs
P08702936A0168|109 113|blood
P08702936A0168|125 129|cells
P08702936A0168|144 149|signal
P08702936A0168|166 172|CD4 cDNA
P08702936A0168|189 206|virus shuttle vector
P08702936A0984|48 57|T cell lines
P08702936A0984|70 75|T cells
P08702936A0984|84 92|monocytes
P08702936A0984|95 106|granulocytes
P08703005A0645|13 20|elements
P08703005A0645|32 47|promoter activity
P08703005A0645|62 66|sites
P08703005A0645|70 92|transcription factors Sp1
P08703005A0645|96 103|alphaCbf
P08703005A0645|111 115|CCAAT
P08703005A0645|127 133|protein
P08703010A0905|36 42|element
P08703010A0905|46 52|E1 E-box
P08703010A0905|65 84|GAP-43 promoter region
P08703010A0905|129 138|expression
P08703010A0905|144 153|GAP-43 gene
P08703010A0905|183 190|proteins
P08703908A1814|15 22|findings
P08703908A1814|98 107|expression
P08703908A1814|111 118|StAR gene
P08703959A0659|28 43|proton resonances
P08703959A0659|64 70|segment
P08703959A0659|87 96|lesion site
P08703959A0659|122 131|assignment
P08703959A0659|138 149|sugar protons
P08703959A0659|155 163|C7 residue
P08703959A0659|169 176|spectrum
P08703959A0659|182 193|adduct duplex
P08704124A0420|16 24|fragments
P08704124A0420|25 30|CPK3-8
P08704124A0420|46 51|bp cDNA
P08704124A0420|52 59|VrCDPK-1
P08704124A0420|65 93|Vigna radiata lambda gt11 library
P08704240A1111|9 17|TF-1 cells
P08704240A1111|25 30|GM-CSF
P08704240A1111|37 46|starvation
P08704240A1111|47 65|CREB phosphorylation
P08704240A1111|79 85|minutes
P08704240A1111|91 108|PIXY321 stimulation
P08705056T0000|0 16|Workplace violence
P08705056T0000|17 22|nurses
P08706368A1024|0 6|RESULTS
P08706368A1024|10 28|LV maximum brightness
P08706368A1024|46 50|curve
P08706368A1024|75 86|correlations
P08706368A1024|125 134|brightness
P08706368A1024|159 169|correlation
P08706662A1125|3 9|results
P08706662A1125|26 32|absence
P08706662A1125|35 52|perforin expression
P08706662A1125|68 72|cells
P08706662A1125|86 96|suppression
P08706662A1125|102 110|induction
P08706662A1125|148 158|factor NF-P2
P08706731A1303|37 48|similarities
P08706731A1303|64 81|expression patterns
P08706731A1303|84 93|Ypr10 genes
P08706731A1303|97 113|ribonuclease genes
P08706731A1303|145 162|sequence similarity
P08706731A1303|168 186|ginseng ribonuclease
P08706731A1303|197 206|hypothesis
P08706731A1303|210 229|ribonuclease function
P08706731A1303|233 245|PR-10 proteins
P08706731A1303|257 266|prediction
P08706731A1303|287 291|roles
P08707424A0709|3 12|expression
P08707424A0709|15 25|ERV3 env mRNA
P08707424A0709|72 81|expression
P08707424A0709|99 104|stages
P08707424A0709|116 126|development
P08707516A0194|7 15|estimates
P08707516A0194|34 39|people
P08707516A0194|51 57|receipt
P08707516A0194|78 93|handicap services
P08707825A0063|31 41|muscle cells
P08707825A0063|44 59|Northern blotting
P08707825A0063|82 89|analysis
P08707825A0063|112 121|smoothelin
P08707825A0063|155 171|muscle cDNA library
P08707825A0063|200 210|antibody R4A
P08707825A0063|235 241|protein
P08707840A0753|15 32|electron microscopy
P08707840A0753|44 50|p58/p45
P08707840A0753|77 81|sides
P08707840A0753|93 103|pore complex
P08707846A2308|30 35|uptake
P08707846A2308|52 59|receptor
P08707846A2308|83 96|ubiquitination
P08707846A2308|111 132|receptor ubiquitination
P08707846A2308|165 175|endocytosis
P08707846A2308|181 196|a-factor receptor
P08707846A2308|222 232|endocytosis
P08707922A0334|0 27|Transcription initiation sites
P08707922A0334|46 52|III beta
P08707922A0334|54 70|O beta-globin genes
P08707922A0334|91 99|base pairs
P08707922A0334|117 142|translation initiation codon
P08707922A0334|161 183|primer extension analysis
P08708984T0000|11 17|process
P08708984T0000|27 38|indomethacin
P08708984T0000|55 60|lesion
P08709224T0000|12 16|virus
P08709224T0000|24 30|protein
P08709224T0000|32 36|EBNA2
P08709224T0000|45 53|component
P08709224T0000|64 77|SNF-SWI complex
P08709224T0000|78 87|hSNF5/Ini1
P08709245A1521|3 9|studies
P08709245A1521|25 35|possibility
P08709245A1521|43 57|phosphorylation
P08709245A1521|60 64|Ser-2
P08709245A1521|65 71|Ser-123
P08709245A1521|74 80|Ser-210
P08709245A1521|84 88|roles
P08709245A1521|94 118|trans-suppression activity
P08709245A1521|140 147|assembly
P08709245A1521|164 175|HDAg particle
P08709245A1521|191 199|transport
P08709245A1521|202 206|HDAgs
P08709251A0000|10 22|recombination
P08709251A0000|33 53|Autographa californica
P08709251A0000|61 77|polyhedrosis virus
P08709251A0000|78 82|AcNPV
P08709251A0000|83 88|genome
P08709251A0000|105 115|DNA fragment
P08709251A0000|138 152|DNA helicase gene
P08709251A0000|155 160|Bombyx
P08709251A0000|172 188|polyhedrosis virus
P08709251A0000|198 206|eh2-AcNPV
P08709251A0000|228 238|AcNPV mutant
P08709637A1471|31 46|IL-7R alpha chains
P08709637A1471|70 79|activation
P08709637A1471|91 95|STATs
P08709637A1471|129 137|signaling
P08709637A1471|139 153|precursor B cells
P08709831A0599|14 20|potency
P08709831A0599|23 33|Dacarbacine
P08709831A0599|39 47|treatment
P08709831A0599|59 64|tumors
P08710151A0782|23 27|value
P08710151A0782|42 48|episode
P08710151A0782|50 54|pnx s.
P08710151A0782|57 62|class A
P08710151A0782|88 93|class B
P08710151A0782|108 114|patient
P08710151A0782|116 121|class A
P08710151A0782|143 149|class B.
P08710371A0000|21 31|interaction
P08710371A0000|51 64|polyomavirus BK
P08710371A0000|93 102|protein p53
P08710371A0000|117 123|biology
P08710371A0000|130 134|virus
P08710371A0000|163 172|mechanisms
P08710371A0000|175 192|p53 transactivation
P08710371A0499|0 7|Site S-II
P08710371A0499|20 29|bp sequence
P08710371A0499|49 69|consensus binding sites
P08710371A0499|79 96|base pair mismatches
P08710371A0499|110 125|base pair deletion
P08710377A0577|35 44|SH3 domains
P08710377A0577|57 66|preference
P08710377A0577|86 91|domain
P08710377A0577|128 141|BCR stimulation
P08710504A0995|0 9|Activation
P08710504A0995|20 24|Cat8p
P08710504A0995|49 58|cat1 mutant
P08711631A0989|0 8|Treatment
P08711631A0989|25 34|prednisone
P08711631A0989|38 53|cyclophosphamide
P08712799A0123|7 14|attempts
P08712799A0123|21 27|smoking
P08713933A0606|0 19|Laboratory evaluation
P08713933A0606|32 43|neuroimaging
P08713933A0606|59 69|obstruction
P08713933A0606|89 96|drainage
P08716757T0001|0 22|Microcomputer management
P08716757T0001|32 46|hepatitis B virus
P08716757T0001|59 66|patients
P08717391A0466|5 10|fusion
P08717391A0466|16 25|N-terminus
P08717391A0466|35 40|linker
P08717391A0466|49 55|surface
P08717391A0466|70 75|fusion
P08717391A0466|81 90|N-terminus
P08717391A0466|99 108|C-terminus
P08717391A0466|126 141|particle assembly
P08717391A0466|163 174|antigenicity
P08717391A0466|178 191|immunogenicity
P08717391A0466|194 198|HBcAg
P08717559A0223|11 16|dosage
P08717559A0223|64 70|ampoule
P08717559A0223|83 92|micrograms
P08719155A0105|24 30|cloning
P08719155A0105|50 57|molecule
P08719155A0105|62 73|P. falciparum
P08719155A0105|88 95|sequence
P08719155A0105|109 120|similarities
P08719155A0105|136 150|surface molecule
P08719155A0105|155 164|Plasmodium
P08719155A0105|205 211|protein
P08719155A0105|230 235|extent
P08719155A0105|242 257|circumsporozoite
P08719155A0105|262 268|protein
P08719156A0953|10 16|introns
P08719156A0953|57 68|reading frame
P08719156A0953|86 92|protein
P08719697A0221|0 6|METHODS
P08719697A0221|81 88|subjects
P08719697A0221|92 99|patients
P08719832A0397|3 12|experience
P08719832A0397|25 41|rhinotomy approach
P08719832A0397|59 65|surgery
P08719832A0397|68 77|acromegaly
P08720407A1386|0 9|CONCLUSION
P08720407A1386|13 19|results
P08720407A1386|54 67|disc herniation
P08720407A1386|79 87|cytokines
P08720407A1386|94 111|interleukin-1 alpha
P08720407A1386|137 161|prostaglandin E2 production
P08721526A0000|25 33|allergens
P08721526A0000|52 59|children
P08721526A0000|69 78|pet animals
P08721989A1012|3 9|results
P08721989A1012|44 50|domains
P08721989A1012|58 74|cytokine receptors
P08721989A1012|91 107|signaling pathways
P08721989A1012|118 125|evidence
P08721989A1012|130 134|beta c
P08721989A1012|138 154|IL-2R beta function
P08721989A1012|166 181|signal transducer
P08721999A0432|2 9|addition
P08721999A0432|27 34|features
P08721999A0432|66 74|snoRNA U14
P08721999A0727|29 45|complementarities
P08721999A0727|62 66|tract
P08721999A0727|69 75|28S rRNA
P08722011A0103|4 10|complex
P08722011A0103|25 36|GTPase domain
P08722011A0103|47 57|subunit rRNA
P08722011A0103|72 82|binding site
P08722011A0103|88 94|protein
P08722011A0103|113 123|counterpart
P08722011A0103|147 156|protein L15
P08722011A0103|169 178|protein L12
P08722568A1001|0 18|Chromatin repression
P08722568A1001|26 41|replacement genes
P08722568A1001|89 98|expression
P08722568A1001|101 125|replacement H3 histone genes
P08722568A1001|128 133|plants
P08723352A0084|4 13|transition
P08723352A0084|64 70|kinases
P08723352A0084|95 101|product
P08723352A0084|106 139|retinoblastoma tumour suppressor gene
P08723365T0000|8 19|relationship
P08723365T0000|27 42|hyperinsulinemia
P08723365T0000|56 66|hypertrophy
P08723365T0000|69 83|nephrosclerosis
P08723883A0823|0 18|Blood GSH-Px activity
P08723883A0823|35 51|spectrophotometer
P08723883A0823|58 69|modification
P08723883A0823|92 96|assay
P08723883A1684|3 16|concentrations
P08723883A1684|19 36|vitamin A precursors
P08723883A1684|40 47|vitamin E
P08723883A1684|94 99|levels
P08723883A1684|102 107|llamas
P08723883A1684|111 120|alfalfa hay
P08723883A1684|149 154|source
P08723883A1684|157 164|vitamins
P08723883A1684|178 184|species
P08726024A0244|23 30|H. pylori
P08726024A0244|43 47|study
P08726024A0532|30 36|primers
P08726024A0532|56 62|product
P08726024A0532|66 73|majority
P08726024A0532|89 97|weeks p.t.
P08726024A0532|107 118|fluid samples
P08726024A0532|139 146|H. pylori
P08726024A0532|171 179|weeks p.t.
P08726024A0532|188 193|plaque
P08726024A0532|213 220|H. pylori
P08726247A0175|20 39|concentration changes
P08726247A0175|44 55|measurements
P08726247A0175|63 73|attenuation
P08726247A0175|84 93|path length
P08727192A0000|0 10|STUDY DESIGN
P08727992A0570|12 20|injection
P08727992A0570|23 31|PGF2 alpha
P08727992A0570|32 38|heifers
P08727992A0570|62 66|signs
P08727992A0570|69 74|estrus
P08728040T0000|12 21|activation
P08728040T0000|56 61|kinase
P08728040T0000|62 70|Jun kinase
P08728040T0000|74 97|Janus kinase-Stat pathways
P08728040T0000|100 110|oncostatin M
P08728040T0000|119 140|fibroblast growth factor
P08728040T0000|155 160|Kaposi
P08728040T0000|162 173|sarcoma cells
P08730470A0000|14 22|agreement
P08730470A0000|30 44|hepatitis C virus
P08730470A0000|99 110|transmission
P08730470A0000|114 120|mothers
P08730470A0000|123 128|babies
P08730470A0000|151 166|household contact
P08731155A0499|3 7|weeks
P08731155A0499|13 26|reconstruction
P08731155A0499|42 47|nerves
P08731155A0499|70 75|nerves
P08731222A0000|3 14|distribution
P08731222A0000|18 29|organization
P08731222A0000|32 42|projections
P08731222A0000|64 74|enlargement
P08731222A0000|77 105|subnucleus reticularis dorsalis
P08731222A0000|129 142|Cuneate nucleus
P08731222A0000|179 193|microinjections
P08731222A0000|193 224|Phaseolus vulgaris leucoagglutinin
P08731222A0000|225 229|PHA-L
P08731222A0000|243 249|laminae
P08731222A0000|259 265|C7 level
P08731511A0625|3 8|levels
P08731511A0625|11 20|fibrinogen
P08731511A0625|29 40|antithrombin
P08731511A0625|44 48|ATIII
P08731511A0625|52 66|heparin cofactor
P08731511A0625|75 84|activities
P08731511A0625|119 125|animals
P08732665A0000|0 12|Amplification
P08732665A0000|16 29|overexpression
P08732665A0000|35 46|c-erbB-2 gene
P08732665A0000|49 54|21MT-2
P08732665A0000|58 63|21MT-1
P08732665A0000|69 88|breast carcinoma cells
P08732665A0000|119 124|levels
P08732665A0000|164 173|p185erbB-2
P08732665A0000|216 227|growth factor
P08732665A0000|257 268|growth factor
P08732665A0000|273 284|independence
P08732665A0000|286 292|culture
P08733123A0000|27 35|dystrophy
P08733123A0000|76 83|disorder
P08733123A0000|109 116|weakness
P08733123A0000|119 125|muscles
P08733123A0000|137 144|shoulder
P08733123A0951|9 18|chromosome
P08733123A0951|20 33|FRG1 transcript
P08733123A0951|46 51|length
P08733123A0951|66 70|exons
P08733123A0951|91 97|protein
P08733123A0951|103 119|amino acid residues
P08733874A0000|0 7|Patients
P08733874A0000|24 36|thyroidectomy
P08733874A0000|40 55|thyroid carcinoma
P08733874A0000|80 86|periods
P08733874A0000|102 115|hypothyroidism
P08733874A0000|118 128|preparation
P08733874A0000|143 154|body scanning
P08733874A0000|157 167|measurement
P08733874A0000|170 176|serum TG
P08733881A0343|4 25|thyroid function testing
P08733881A0343|59 65|samples
P08733881A0343|76 84|TSH values
P08733881A0343|94 101|subjects
P08733881A0343|114 122|TSH levels
P08734538A0613|8 17|experiment
P08734538A0613|18 26|crossover
P08734538A0613|46 53|textures
P08734538A0613|100 107|textures
P08738510A0254|11 25|tumor FDG-uptake
P08738510A0254|26 32|Q-MRGlu
P08738510A0254|52 57|cortex
P08738510A0254|63 73|meningiomas
P08739209A0700|0 10|Zatebradine
P08739209A0700|72 76|ratio
P08739209A0700|92 102|arrhythmias
P08739209A0700|129 136|ligation
P08739209A0700|150 157|ligation
P08739260T0000|0 4|Catha
P08739260T0000|12 16|plant
P08739260T0000|24 41|amphetamine effects
P08740416A0239|12 18|protein
P08740416A0239|19 23|Seb1p
P08740416A0239|36 45|amino acids
P08740416A0239|86 91|region
P08740416A0239|97 106|C-terminus
P08740416A0239|122 135|signal sequence
P08740416A0919|3 15|SEB1 homologue
P08740416A0919|42 48|protein
P08740416A0919|63 67|Seb1p
P08741206A1551|26 34|afferents
P08741206A1551|51 58|settings
P08741206A1551|89 100|vasodilation
P08741206A1551|104 114|hypotension
P08741280A0374|84 89|length
P08742135A0000|0 8|Fragments
P08742135A0000|12 18|analogs
P08742135A0000|24 34|hormone ACTH
P08742135A0000|70 75|effect
P08742135A0000|81 87|outcome
P08742135A0000|90 99|head injury
P08742135A0000|113 118|levels
P08742135A0000|121 134|corticosterone
P08742385A0211|15 20|causes
P08742385A0211|26 35|meningitis
P08742385A0211|61 68|drainage
P08742385A0211|101 110|head injury
P08745669A0000|9 16|patients
P08745669A0000|57 64|lymphoma
P08745669A0000|79 86|lymphoma
P08745669A0000|94 100|Hodgkin
P08745669A0000|102 108|disease
P08745669A0000|144 150|regimen
P08745669A0000|151 161|cisplatinum
P08745669A0000|162 170|methyl GAG
P08745669A0000|171 180|bleomocyin
P08745669A0000|181 197|methyl prednisolon
P08746605A0377|24 36|ACE inhibitors
P08746605A0377|39 47|incidence
P08746605A0377|61 67|effects
P08746605A0377|91 102|pancreatitis
P08746981A0154|3 12|treatments
P08746981A0154|51 68|mg probiotic/kg food
P08747078T0000|8 14|aspirin
P08747078T0000|27 37|miscarriage
P08747343A0790|0 11|Protein films
P08747343A0790|46 53|profiles
P08747343A0790|63 67|films
P08747343A0790|79 87|materials
P08748033A0874|17 25|mutations
P08748033A0874|36 43|toxicity
P08748033A0874|58 79|LamB-LacZ hybrid protein
P08748033A0874|94 100|effects
P08748033A0874|106 114|cytoplasm
P08749393A0783|3 14|PI3K_68D cDNA
P08749393A0783|23 29|protein
P08749393A0783|50 58|sequences
P08749393A0783|77 91|p110 PI 3-kinases
P08749393A0783|94 111|p85 adaptor proteins
P08749393A0783|151 158|sequence
P08749393A0783|175 184|SH3 domains
P08749393A0783|205 212|C2 domain
P08749394A0874|7 24|interaction studies
P08749394A0874|30 37|proteins
P08749394A0874|45 69|glutathione-S-transferase
P08749394A0874|80 89|RBP-J kappa
P08749394A0874|116 127|RAM23 regions
P08749394A0874|128 138|mouse Notch1
P08749394A0874|142 156|Drosophila Notch
P08750173A0000|0 11|AIMS/METHODS
P08750173A0000|31 44|system function
P08750173A0000|57 65|clearance
P08750173A0000|81 88|bacteria
P08750173A0000|108 118|liver injury
P08750173A0000|128 142|D-galactosamine
P08750173A0000|176 195|% liver resection model
P08750190A0000|3 12|laboratory
P08750190A0000|16 21|others
P08750190A0000|42 49|splicing
P08750190A0000|59 63|exons
P08750190A0000|124 133|generation
P08750190A0000|135 145|CD44 variant
P08750190A0000|146 150|CD44v
P08750190A0000|151 158|isoforms
P08750702A0183|0 10|Study groups
P08750702A0183|15 21|control
P08750702A0183|71 84|blockers WB4101
P08750702A0183|88 96|mg/kg i.v.
P08750702A0183|99 118|chloroethylclonidine
P08750702A0183|122 130|mg/kg i.v.
P08751635A0135|24 29|damage
P08751635A0135|49 71|hippocampus subfields CA1
P08751635A0135|79 83|hilus
P08752714A0000|3 12|occurrence
P08752714A0000|23 32|malignancy
P08752714A0000|48 55|patients
P08752714A0000|71 82|malignancies
P08752714A0000|104 113|department
P08752714A0000|129 133|years
P08754777A1214|3 7|upTRE
P08754777A1214|17 29|T3R homodimers
P08754777A1214|37 55|T3R-RXR heterodimers
P08754777A1214|63 67|dnTRE
P08754777A1214|97 114|heterodimer binding
P08754777A1214|132 136|upTRE
P08754802T0000|15 21|control
P08754802T0000|65 83|acid oxidation enzyme
P08754802T0000|117 125|receptors
P08754802T0000|141 157|adipose expression
P08754827A0231|0 5|Hoeben
P08754834A1097|13 21|fragments
P08754834A1097|37 52|response elements
P08754834A1097|71 87|transcription unit
P08754834A1097|111 117|NN-84AG
P08754834A1097|136 141|detail
P08754840A0793|8 29|glucan synthase activity
P08754840A0793|48 52|Rho1p
P08754840A0793|81 95|deltabem4 mutant
P08754852A0960|2 21|gel retardation assays
P08754852A0960|42 48|protein
P08754852A0960|72 78|protein
P08754852A0960|94 101|RCS cells
P08754852A0960|112 123|chondrocytes
P08754852A0960|137 144|sequence
P08754852A0960|154 159|18-mer
P08755898A0339|3 9|classes
P08755898A0339|23 31|pathogens
P08755898A0339|39 55|Bs2 host resistance
P08755898A0339|76 82|fitness
P08755898A0339|117 122|avrBs2
P08756332A0000|0 6|Members
P08756332A0000|12 23|Ras subfamily
P08756332A0000|42 49|proteins
P08756332A0000|86 92|variety
P08756332A0000|103 119|effector molecules
P08756332A0000|129 146|protein kinase c-Raf
P08756332A0000|165 195|guanine nucleotide exchange factor
P08756332A0000|196 202|Ral-GEF
P08756433A0282|7 22|characterization
P08756433A0282|28 41|promoter region
P08756433A0282|70 77|elements
P08756433A0282|120 129|expression
P08756433A0282|135 143|MAP1B gene
P08756556A0406|23 29|protein
P08756556A0406|34 43|amino acids
P08756556A0406|62 79|acid signal sequence
P08756597A0854|0 6|Mutants
P08756597A0854|38 47|% reduction
P08756597A0854|53 57|level
P08756597A0854|60 67|psaB mRNA
P08756609A0498|10 26|amino acid sequence
P08756609A0498|58 62|range
P08756609A0498|65 74|eukaryotes
P08756609A0498|75 85|vertebrates
P08756609A0498|86 98|invertebrates
P08756609A0498|99 103|fungi
P08756609A0498|104 109|plants
P08756609A0498|113 120|protozoa
P08756636T0000|12 20|mutations
P08756636T0000|26 42|yeast Rad51 protein
P08756636T0000|51 63|relationships
P08756636T0000|71 82|Srs2 helicase
P08756642A0230|0 10|Alterations
P08756642A0230|24 31|interval
P08756642A0230|55 68|myelodysplasia
P08756642A0230|79 86|leukemia
P08756712A0227|8 14|studies
P08756712A0227|38 46|amino acid
P08756712A0227|53 59|subunit
P08756712A0227|115 121|domains
P08757265A0466|0 6|Neurons
P08757265A0466|49 55|effects
P08757943A0876|25 31|element
P08757943A0876|51 73|thymidine kinase promoter
P08757943A0876|90 101|inducibility
P08759870A1128|3 8|extent
P08759870A1128|14 33|fbpA operator sequence
P08759870A1128|54 73|footprinting analysis
P08759870A1128|88 94|binding
P08759870A1128|100 117|Fur repressor dimers
P08760286A0696|13 22|similarity
P08760286A0696|43 74|guanine nucleotide exchange factors
P08760286A0696|93 100|proteins
P08760286A0696|122 135|identification
P08760286A0696|149 154|routes
P08760286A0696|166 172|members
P08760286A0696|186 194|Rho family
P08760286A0696|196 202|GTPases
P08760286A0696|255 264|components
P08760286A0696|268 287|Vav signaling pathways
P08760776A1559|0 9|CONCLUSION
P08760776A1559|20 28|treatment
P08760776A1559|40 60|fluticasone propionate
P08760776A1559|63 72|micrograms
P08760776A1559|78 87|micrograms
P08760776A1559|121 132|theophylline
P08760776A1559|138 146|treatment
P08760776A1559|165 170|asthma
P08760872A0696|3 9|results
P08760872A0696|18 22|model
P08760872A0696|52 61|repression
P08760872A0696|78 83|stages
P08760872A0696|89 97|cell cycle
P08760872A0696|129 139|CHR elements
P08760889A0170|3 11|cDNA clone
P08760889A0170|32 36|probe
P08760889A0170|63 67|clone
P08760889A0531|0 9|Comparison
P08760889A0531|22 39|amino acid sequences
P08760889A0531|44 59|protein sequences
P08760889A0531|101 111|differences
P08760889A0531|126 130|total
P08760889A0531|136 145|amino acids
P08760889A0531|161 170|amino acids
P08760889A0531|195 199|genes
P08760889A0531|213 222|divergence
P08760889A0531|233 239|species
P08761169T0000|15 25|dysfunction
P08761169T0000|29 33|child
P08761169T0000|46 51|damage
P08761480A0331|0 10|Interaction
P08761480A0331|49 60|splice region
P08761480A0331|63 68|RPDE-6
P08761480A0331|74 84|PDE4A splice
P08761480A0331|92 98|RPDE-39
P08761480A0331|115 120|RPDE-6
P08761480A0331|133 142|N-terminus
P08761480A0331|164 172|v-Src-SH3
P08761480A0331|173 180|met26RD1
P08761480A0331|233 244|splice region
P08761480A0331|270 278|v-Src-SH3
P08761480A0331|285 295|association
P08761480A0331|298 303|RPDE-6
P08761480A0331|307 315|v-Src-SH3
P08761480A0331|329 341|fusion protein
P08761480A0331|365 376|splice region
P08762021A0156|27 34|measures
P08762021A0156|48 58|performance
P08762021A0156|118 124|rabbits
P08762172A0178|5 21|strain differences
P08762172A0178|37 45|variables
P08762172A0178|61 70|proportion
P08762172A0178|82 86|males
P08762172A0178|128 133|number
P08762172A0178|134 144|transitions
P08762172A0178|168 172|boxes
P08762472A0000|3 8|effect
P08762472A0000|11 35|ligustrazine hydrochloride
P08762472A0000|62 79|artery hypertension
P08762472A0000|100 106|studies
P08763207A0402|7 19|oxidation peak
P08763207A0402|26 32|product
P08763207A0402|48 52|media
P08763207A0402|105 116|accumulation
P08763207A0402|117 127|clenbuterol
P08763311A0189|0 12|Phenylephrine
P08763311A0189|20 47|alpha-1 adrenoreceptor agonist
P08763311A0189|76 91|vasoconstriction
P08763311A0189|105 116|hypertension
P08763311A0189|145 155|bradycardia
P08763925A0588|3 12|expression
P08763925A0588|26 30|genes
P08763925A0588|50 55|c-gvpD
P08763925A0588|58 63|c-gvpE
P08763925A0588|82 92|Western blot
P08763925A0588|93 102|immunoblot
P08763925A0588|103 110|analyses
P08763925A0588|116 123|antisera
P08763925A0588|142 149|proteins
P08764136A0000|4 9|effort
P08764136A0000|19 23|genes
P08764136A0000|42 51|expression
P08764136A0000|57 65|mRNA level
P08764136A0000|81 94|transformation
P08764136A0000|119 123|cells
P08764136A0000|152 164|hybridization
P08764136A0000|177 188|MEC strain 76N
P08764136A0000|237 242|76R-30
P08766049A0000|0 9|CASE REPORT
P08766049A0000|33 50|corneal perforation
P08766049A0000|63 70|reaction
P08766049A0000|81 87|chamber
P08766049A0000|89 95|patient
P08766049A0000|139 147|injection
P08766049A0000|162 169|Amikacin
P08766049A0000|183 192|Vancomycin
P08766781A0322|9 14|period
P08766781A0322|29 36|increase
P08766781A0322|39 48|hematocrit
P08768374A0765|12 28|P-rr cDNA sequences
P08768374A0765|50 56|regions
P08768377A1387|10 20|hcf109 locus
P08768377A1387|33 40|distance
P08768377A1387|45 56|centimorgans
P08768377A1387|64 79|phytochrome C gene
P08768377A1387|92 107|characterization
P08768377A1387|120 126|cloning
P08769132A0000|8 23|MSH-2 gene product
P08769132A0000|27 32|member
P08769132A0000|51 56|family
P08769132A0000|59 66|proteins
P08769132A0000|101 114|mismatch repair
P08769132A0000|138 143|hMSH-2
P08769132A0000|210 214|MSH-1
P08769132A0000|217 229|MSH-2 proteins
P08769132A0000|266 270|sites
P08769132A0000|281 294|base mismatches
P08769132A0000|298 306|deletions
P08769132A0000|309 318|insertions
P08769132A0000|324 332|base pairs
P08769132A0000|372 377|hMSH-2
P08769132A0000|421 426|cancer
P08769132A0000|427 431|HNPCC
P08769132A0000|432 451|tumor suppressor genes
P08769132A0000|466 479|chromosome 2p16
P08769409A0114|41 50|expression
P08769409A0114|56 62|RAR beta
P08769409A0114|72 83|mouse embryos
P08769409A0114|112 116|level
P08769409A0114|136 148|reading frames
P08769409A0114|149 153|uORFs
P08769409A0114|171 176|region
P08769409A0114|177 182|Zimmer
P08769566A0000|35 53|transcription factor
P08769566A0000|65 69|Zfhep
P08769566A0000|70 90|zinc finger homeodomain
P08769566A0000|107 113|protein
P08769566A0000|135 151|zinc finger domains
P08769566A0000|190 200|homeodomain
P08769568A0949|3 11|structure
P08769568A0949|19 23|genes
P08769568A0949|39 46|ancestor
P08769568A0949|60 68|PLA2 genes
P08770021T0000|9 23|PTHRP production
P08770021T0000|27 48|tyrosine kinase oncogene
P08770021T0000|49 55|Tpr-Met
P08770021T0000|67 85|Ras signaling pathway
P08770896A1121|17 25|secretion
P08770896A1121|29 34|IGF-II
P08770896A1121|46 53|G11 cells
P08770896A1121|80 85|medium
P08770896A1121|115 121|species
P08770896A1121|126 130|appMr
P08770920A1220|13 24|coexpression
P08770920A1220|78 82|IDX-1
P08770920A1220|89 96|proteins
P08770920A1220|119 123|IDX-1
P08770920A1220|156 166|enhancement
P08770920A1220|169 183|transactivation
P08770920A1220|204 224|TAAT-1 element reporter
P08770981A0328|3 10|patients
P08770981A0328|22 40|von Willebrand factor
P08770981A0328|46 58|fragmentation
P08770981A0328|93 98|weight
P08770981A0328|123 140|weight vWF multimers
P08770981A0328|146 156|circulation
P08771781A0103|4 10|attempt
P08771781A0103|44 49|region
P08771781A0103|60 66|oleosin
P08771781A0103|81 92|reading frame
P08771781A0103|93 97|ORFII
P08771781A0103|100 112|Brassica napus
P08771781A0103|129 136|promoter
P08771781A0103|160 164|ORFII
P08771781A0103|165 174|cDNA clones
P08771781A0103|209 223|leaf cDNA library
P08771781A1103|3 18|ORFII gene product
P08771781A1103|34 44|chloroplast
P08771781A1103|93 100|presence
P08771781A1103|102 113|PMSR activity
P08771781A1103|119 129|chloroplast
P08771787T0000|0 15|Characterization
P08771787T0000|36 41|repeat
P08771787T0000|46 52|protein
P08771787T0000|56 67|tomato plants
P08771787T0000|89 100|pathogenesis
P08774732A0271|21 30|zif268/egr
P08774732A0271|47 51|motif
P08774732A0271|52 71|gel retardation assays
P08775674A0000|0 9|OBJECTIVES
P08775674A0000|23 27|study
P08775674A0000|50 64|characteristics
P08775674A0000|65 73|treatment
P08775674A0000|77 83|outcome
P08775674A0000|89 96|patients
P08775674A0000|101 116|hydatidiform mole
P08776735A0000|22 27|kidney
P08776735A0000|31 35|cells
P08776735A0000|53 72|type rat LH/CG receptor
P08776735A0000|81 89|receptors
P08776735A0000|103 107|tails
P08776735A0000|119 126|residues
P08776735A0000|148 156|rLHR-t653
P08776735A0000|157 165|rLHR-t631
P08776735A0000|169 177|rLHR-t628
P08776735A0000|196 205|importance
P08776735A0000|212 217|region
P08776735A0000|223 232|regulation
P08776735A0000|243 256|responsiveness
P08776748T0000|6 19|P300 amplitudes
P08776748T0000|21 26|marker
P08776748T0000|30 42|schizophrenia
P08776792A0626|0 4|Sleep
P08776792A0626|49 53|hours
P08776793A0811|3 10|patients
P08776793A0811|29 33|males
P08776901A0000|0 17|Chloroplast mutator
P08776901A0000|25 35|Arabidopsis
P08776901A0000|54 61|mutation
P08776901A0000|85 95|variegation
P08776901A0000|98 103|leaves
P08776901A0000|134 140|fashion
P08777374A1471|6 19|concentrations
P08777374A1471|55 68|concentrations
P08777374A1471|87 95|exposures
P08777374A1471|135 148|concentrations
P08778265A0422|19 29|test battery
P08778265A0422|53 65|Wisconsin card
P08778265A0422|79 98|Street completion test
P08778265A0422|98 107|Stroop test
P08778265A0422|117 122|memory
P08778265A0422|148 162|recognition test
P08778700A0476|31 36|rarity
P08778700A0476|53 63|involvement
P08780339A0142|13 24|single-blind
P08780339A0142|30 46|Latin-square study
P08780339A0142|50 60|corrections
P08780339A0142|67 82|carryover effects
P08780339A0142|85 89|males
P08780339A0142|95 101|females
P08780339A0142|110 120|supplements
P08780339A0142|131 137|glucose
P08780339A0142|149 154|starch
P08780339A0142|178 187|cornstarch
P08780339A0142|221 230|cornstarch
P08781119A0723|12 17|region
P08781119A0723|23 40|mouse Met-ase-1 gene
P08781119A0723|63 69|regions
P08781119A0723|72 79|identity
P08781119A0723|96 101|region
P08781119A0723|107 122|rat Met-ase-1 gene
P08781144A1520|7 15|FMISO TMRR
P08781144A1520|43 47|index
P08781144A1520|60 72|tumour hypoxia
P08783180A0000|8 14|methods
P08783180A0000|83 90|fruit bat
P08783180A0000|91 111|Carollia perspicillata
P08783180A0000|143 149|setting
P08783666A0957|2 9|addition
P08783666A0957|21 31|engraftment
P08783666A0957|59 71|amifostine arm
P08783666A0957|78 84|cohorts
P08784787A0383|11 26|thrombin receptor
P08784787A0383|52 62|hexapeptide
P08784787A0383|88 101|ligand sequence
P08784787A0383|115 130|receptor cleavage
P08787110A0981|29 41|investigation
P08787110A0981|46 55|management
P08787110A0981|58 65|patients
P08787110A0981|85 91|disease
P08787110A0981|121 134|investigations
P08787110A0981|154 171|function laboratory
P08789441A0339|5 16|fluorescence
P08789441A0339|23 35|hybridization
P08789441A0339|60 69|breakpoint
P08789441A0339|73 79|patient
P08789441A0339|104 114|sex reversal
P08789441A0339|150 162|translocation
P08789441A0339|177 189|cosmid markers
P08789441A0339|204 209|region
P08790288A0068|22 30|isolation
P08790288A0068|33 37|cDNAs
P08790288A0068|42 48|spinach
P08790288A0068|49 64|Spinacia oleracea
P08790288A0068|68 73|barley
P08790288A0068|74 89|Hordeum vulgare cv
P08790291A1022|67 84|DNA damage tolerance
P08790291A1022|84 93|plant cells
P08790387A0299|5 16|rat rnu allele
P08790387A0299|31 46|nonsense mutation
P08790387A0299|61 67|whn gene
P08792217A1407|6 13|increase
P08792217A1407|41 55|TIMP-2 mRNA level
P08792217A1407|74 79|result
P08792217A1407|84 96|up-regulation
P08792217A1407|99 107|germ cells
P08792217A1407|115 123|germ cells
P08792217A1407|145 149|cells
P08792217A1407|166 173|increase
P08792217A1407|204 218|TIMP-2 mRNA level
P08793029A0246|0 6|Control
P08793029A0246|55 60|groups
P08793693A0237|0 5|DESIGN
P08793693A0237|22 26|study
P08794254A2957|13 23|PTA category
P08794254A2957|34 40|therapy
P08794254A2957|72 80|graft loss
P08794326A0405|37 43|element
P08794326A0405|81 87|gag gene
P08794326A0405|100 106|pol gene
P08794326A0405|109 113|SFV-1
P08794339A1162|11 17|binding
P08794339A1162|65 73|deltaCREB
P08794339A1162|96 104|complexes
P08794339A1162|132 138|protein
P08794339A1162|181 195|adaptor proteins
P08794339A1162|196 207|CREB function
P08794348A1067|11 30|complementation assay
P08794348A1067|66 70|trans
P08794348A1067|109 115|genomes
P08794348A1067|131 141|NIa proteins
P08794363A0259|5 9|basis
P08794363A0259|31 38|homology
P08794363A0259|59 64|member
P08794363A0259|69 85|jun-fos gene family
P08794363A0259|103 108|origin
P08794547A0648|12 21|vasomotion
P08794547A0648|35 56|laser-doppler fluxmetry
P08794547A1403|13 19|vessels
P08794547A1403|49 55|vessels
P08794601A0000|9 19|combination
P08794601A0000|22 31|nizatidine
P08794601A0000|32 45|clarithromycin
P08794601A0000|49 65|bismuth subcitrate
P08794601A0000|78 93|ulcer healing rate
P08794601A0000|105 127|H. pylori eradication rate
P08794869A0274|7 11|lines
P08794869A0274|14 21|evidence
P08794869A0274|46 53|PKC-zeta
P08794869A0274|68 72|alpha
P08794869A0274|73 94|integrin gene expression
P08795304T0000|0 19|Plasma thrombomodulin
P08795304T0000|21 26|marker
P08795304T0000|43 55|complications
P08795304T0000|58 73|diabetes mellitus
P08797362T0037|0 5|Update
P08797362T0037|6 15|diphtheria
P08797362T0037|45 50|states
P08797362T0037|68 74|January
P08798420A0207|3 18|characterization
P08798420A0207|24 37|promoter region
P08798420A0207|74 81|elements
P08798420A0207|99 113|AP-1 binding site
P08798420A0207|122 139|PRDII/kappaB domain
P08798420A0207|143 149|CAAT box
P08798420A0207|166 175|activation
P08798443A0660|0 5|Serine
P08798443A0660|40 48|cell lines
P08798443A0660|52 63|substitution
P08798443A0660|66 71|serine
P08798443A0660|77 83|alanine
P08798443A0660|84 88|S528A
P08798443A0660|110 116|ability
P08798443A0660|149 156|promoter
P08798443A0660|170 175|copies
P08798443A0660|181 186|mim-1A
P08798443A0660|201 207|element
P08798443A0660|219 234|herpes tk promoter
P08798443A1218|3 12|DNA binding
P08798443A1218|16 40|multimerization activities
P08798443A1218|43 47|c-Myb
P08798443A1218|73 89|S528A substitution
P08798443A1218|104 118|phosphorylation
P08798443A1218|121 126|serine
P08798443A1218|143 148|effect
P08798443A1218|154 189|transcription transactivating activity
P08798443A1218|192 196|c-Myb
P08798443A1218|209 220|interactions
P08798443A1218|230 237|proteins
P08798512A1197|3 8|amount
P08798512A1197|16 22|factors
P08798512A1197|35 42|GEO cells
P08798512A1197|53 61|u-PAR gene
P08798610A0843|26 59|phosphatidylcholine carrier vesicles
P08798610A0843|76 82|guanine
P08798610A0843|110 116|Cdc42Hs
P08798610A0843|161 167|protein
P08798610A0843|192 198|Cdc42Hs
P08798610A0843|229 242|Dbl oncoprotein
P08798635A0870|8 16|spleen GAP
P08798635A0870|28 37|hydrolysis
P08798635A0870|92 97|effect
P08798635A0870|107 120|myristoylation
P08798643T0000|29 34|domain
P08798643T0000|50 67|transforming region
P08798643T0000|110 115|ZAP-70
P08798643T0000|117 122|T cells
P08798648A1816|0 6|Cys-757
P08798648A1816|16 20|Fe4S4
P08798648A1816|36 41|domain
P08798648A1816|63 76|enzyme activity
P08798700A0134|3 15|transcription
P08798700A0134|51 58|response
P08798700A0134|61 66|oxygen
P08798700A0134|69 82|heme deficiency
P08798700A0134|98 103|relief
P08798700A0134|105 114|repression
P08798700A0134|124 128|Rox1p
P08798700A0134|142 151|activation
P08798700A0134|171 188|activation sequence
P08798762A1279|13 19|results
P08798762A1279|50 57|activity
P08798762A1279|60 70|Cut proteins
P08798782A0976|50 59|SH3 domains
P08798893A0611|11 18|freezing
P08798893A0611|24 31|presence
P08798893A0611|40 50|lactalbumin
P08798893A0611|66 76|maintenance
P08798893A0611|90 98|viability
P08798893A0611|107 123|CCCD heterogeneity
P08798893A0611|126 132|respect
P08798893A0611|140 144|cells
P08801403T0001|18 25|effusion
P08801403T0001|28 43|presentation form
P08801403T0001|54 60|myeloma
P08803710A0701|9 17|survivals
P08803710A0701|61 66|stages
P08803845A0665|3 10|presence
P08803845A0665|49 56|clusters
P08803845A0665|69 73|cells
P08803845A0665|113 121|insertion
P08803845A0665|123 128|lesion
P08803845A0665|143 149|attempt
P08803845A0665|164 171|excision
P08804012A0662|10 19|categories
P08804012A0662|60 69|recreation
P08804012A0662|71 78|pastimes
P08804012A0662|79 92|home management
P08804012A0662|96 100|sleep
P08804389A0893|0 19|Northern blot analysis
P08804389A0893|41 45|probe
P08804389A0893|59 81|Xanthomonas campestris pv
P08804389A0893|97 107|translucens
P08804389A0893|117 124|increase
P08804389A0893|134 139|levels
P08804389A0893|142 149|Ltp4 mRNA
P08804389A0893|192 199|japonica
P08804389A0893|207 214|decrease
P08805338A1061|8 17|disruption
P08805338A1061|23 30|OGG1 gene
P08805338A1061|33 37|yeast
P08805338A1061|53 78|OG glycosylase/lyase protein
P08805824A1155|21 29|zero-loss
P08805824A1155|40 50|combination
P08805824A1155|55 81|exit wavefront reconstruction
P08805824A1155|122 128|effects
P08805824A1155|158 167|scattering
P08805824A1155|171 180|microscope
P08805824A1155|190 204|lens aberrations
P08805824A1155|215 223|technique
P08806491A0542|0 10|Transcripts
P08806491A0542|18 24|ODV-E18
P08806491A0542|28 35|ODV-EC27
P08806491A0542|57 66|TAAG motifs
P08806491A0542|70 80|transcripts
P08806491A0542|107 112|hr p.i.
P08806693A0584|2 6|order
P08806693A0584|23 31|sequences
P08806693A0584|37 50|GATA-1 promoter
P08806693A0584|64 73|activation
P08806693A0584|90 96|protein
P08806693A0584|102 110|deletions
P08806693A0584|116 123|promoter
P08806693A0584|139 164|luciferase expression vector
P08806693A0584|179 186|activity
P08806693A0584|189 204|mouse fibroblasts
P08806693A0584|222 227|GATA-1
P08806817A0244|0 15|Sequence analysis
P08806817A0244|36 40|clone
P08806817A0244|56 71|DNA binding domain
P08806817A0244|78 91|orphan receptor
P08806817A0244|118 128|TR2 receptor
P08806817A0716|7 22|DNA hybridization
P08806817A0716|35 40|SpSHR2
P08806817A0716|66 83|S. purpuratus genome
P08807245A0843|5 23|retrospective review
P08807245A0843|54 63|undercalls
P08807288T0000|0 8|Isolation
P08807288T0000|12 25|identification
P08807288T0000|28 32|genes
P08807288T0000|57 70|ADH2 expression
P08807408A0524|0 6|METHODS
P08807408A0524|10 16|RESULTS
P08807408A0524|29 33|woman
P08807408A0524|65 75|tachycardia
P08807408A0524|99 105|pathway
P08807408A0524|106 119|AV modification
P08807408A0524|131 155|radiofrequency application
P08808120A0774|0 7|Patients
P08808120A0774|15 25|probability
P08808120A0774|34 49|aluminum overload
P08808120A0774|50 64|serum iron levels
P08808120A0774|68 79|micrograms/L
P08808120A0774|92 103|micrograms/L
P08808120A0774|125 130|values
P08808120A0774|133 141|serum iron
P08808120A0774|142 166|iron transferrin saturation
P08808120A0774|170 188|serum ferritin levels
P08808120A0774|206 213|patients
P08808120A0774|223 233|probability
P08808120A0774|242 257|aluminum overload
P08808120A0774|258 276|serum aluminum levels
P08808120A0774|280 291|micrograms/L
P08808120A0774|304 315|micrograms/L
P08808275A1193|11 26|RAD23 equivalents
P08808275A1193|49 57|evolution
P08808275A1193|70 74|genes
P08808275A1193|103 111|phenotype
P08808275A1193|119 134|yeast counterpart
P08808707A0631|0 8|Ha-RasV12
P08808707A0631|21 28|proteins
P08808707A0631|61 66|kinase
P08808707A0631|94 106|protein kinase
P08808707A0631|129 134|kinase
P08808707A0631|138 145|cascades
P08808707A0631|181 194|gene expression
P08808756A0587|0 15|Sequence analysis
P08808756A0587|97 101|cells
P08808756A0587|115 122|presence
P08808756A0587|142 149|products
P08808756A0587|177 181|bases
P08808756A0587|193 204|accumulation
P08808924A0326|3 19|hydropathy profile
P08808924A0326|46 50|spans
P08808924A0326|66 78|amino terminus
P08808924A0326|97 104|residues
P08808924A0326|121 128|presence
P08808924A0326|176 184|proximity
P08808924A0326|212 218|segment
P08808927A0417|7 13|HindIII
P08808927A0417|21 28|fragment
P08808927A0417|40 47|vspA gene
P08808927A0417|52 62|M. bovis PG45
P08808939A0000|0 25|Carbon catabolite repression
P08808939A0000|31 39|gnt operon
P08808939A0000|42 57|Bacillus subtilis
P08808939A0000|73 100|catabolite control protein CcpA
P08808939A0000|112 132|phosphocarrier protein
P08808939A0000|137 160|phosphotransferase system
P08809680T0000|0 8|Melatonin
P08809680T0000|12 22|seasonality
P08810040A0955|11 16|screen
P08810040A0955|54 70|target locus marker
P08810040A0955|87 97|replacement
P08810040A0955|106 114|frequency
P08810278A0682|36 42|protein
P08810278A0682|51 57|BCR/ABL
P08810278A0682|68 81|CRKL-SH2 domain
P08810278A0682|132 139|tyrosine
P08810278A0682|177 202|BCR/ABL expressing cell lines
P08810278A0682|207 213|samples
P08810278A0682|234 244|ALL patients
P08810278A0682|252 258|samples
P08810278A0682|263 270|controls
P08810323A0735|12 30|polyglutamine motifs
P08810323A0735|61 67|regions
P08812012T0000|3 9|effects
P08812012T0000|22 31|variations
P08812012T0000|45 57|Stroop effects
P08812020A0597|8 17|experiment
P08812020A0597|19 29|Chessmaster
P08812020A0597|51 56|number
P08812020A0597|59 64|boards
P08812020A0597|104 111|accuracy
P08812020A0597|137 142|pieces
P08812106T0000|0 7|PCNA mRNA
P08812106T0000|34 44|crescent RNA
P08812106T0000|77 83|embryos
P08812490A0000|7 15|cDNA clone
P08812490A0000|30 44|gene symbol AQP2L
P08812490A0000|48 55|homology
P08812490A0000|61 70|aquaporins
P08812490A0000|92 108|kidney cDNA library
P08812490A0542|0 23|PCR/Southern blot analysis
P08812490A0542|31 40|kidney cDNA
P08812490A0542|46 52|primers
P08812490A0542|76 83|sequence
P08812490A0542|91 100|expression
P08812490A0542|129 139|transcripts
P08812490A0542|174 182|deletions
P08812490A1509|7 22|sequence homology
P08812490A1509|37 45|structure
P08812490A1509|91 95|AQP-2
P08812490A1509|101 120|MIP family gene cluster
P08812490A1509|123 142|chromosome locus 12q13
P08813766A0605|23 32|transcript
P08813766A0605|52 58|protein
P08813766A0605|63 70|residues
P08813766A0605|88 92|match
P08813766A0605|98 114|consensus sequence
P08813766A0605|118 137|C2H2 zinc finger domain
P08813766A0605|153 160|homology
P08813766A0605|165 174|yeast Mig1p
P08813766A0605|178 182|Cre-A
P08813766A0605|187 197|Aspergillus
P08813766A0605|198 207|Emericella
P08813900A1088|6 12|phytase
P08813900A1088|31 41|orderliness
P08813900A1088|43 53|development
P08813900A1088|54 67|mineralization
P08813900A1088|71 81|arrangement
P08813900A1088|84 92|cartilage
P08813900A1088|96 104|bone cells
P08813900A1088|121 127|effects
P08813900A1088|130 140|P deficiency
P08813900A1088|166 174|structure
P08813900A1088|180 185|tibias
P08814651A0000|3 12|importance
P08814651A0000|23 29|factors
P08814651A0000|35 42|presence
P08814651A0000|46 53|severity
P08814651A0000|56 77|ethanol withdrawal signs
P08814651A0000|106 116|rating scale
P08814651A0000|116 121|tremor
P08814651A0000|140 148|paradigms
P08816052A0238|18 24|brevity
P08816052A0238|29 36|WISC-III
P08816052A0238|71 78|validity
P08816052A0238|87 92|K-FAST
P08816052A0238|99 147|Kaufman Short Neuropsychological Assessment Procedure
P08816052A0238|148 153|K-SNAP
P08816438A0316|12 19|analysis
P08816438A0316|22 37|plasmid loss rates
P08816438A0316|40 54|cdc28-1N strains
P08816438A0316|63 70|plasmids
P08816438A0316|83 100|replication origins
P08816438A0316|114 119|defect
P08816438A0316|132 145|DNA replication
P08816438A0316|164 183|plasmid loss phenotype
P08816443A1674|20 27|ROK alpha
P08816443A1674|49 62|reorganization
P08816443A1674|68 79|cytoskeleton
P08816443A1674|93 100|C termini
P08816443A1674|127 136|regulators
P08816443A1674|154 165|kinase domain
P08816443A1674|171 178|activity
P08816443A1674|191 199|formation
P08816443A1674|202 213|stress fibers
P08816443A1674|222 238|adhesion complexes
P08816452A0936|5 12|findings
P08816452A0936|31 48|tissue distribution
P08816452A0936|78 84|protein
P08816452A0936|100 109|regulation
P08816452A0936|123 130|splicing
P08816452A0936|134 139|tissue
P08816452A0936|162 167|manner
P08816453A0000|3 11|elevation
P08816453A0000|31 36|levels
P08816453A0000|62 69|activity
P08816453A0000|74 84|Raf-1 kinase
P08816459A0090|2 18|interaction screen
P08816459A0090|26 41|repression domain
P08816459A0090|47 66|orphan receptor RevErb
P08816459A0090|77 81|N-CoR
P08816459A0090|85 95|corepressor
P08816459A0090|99 120|thyroid hormone receptor
P08816459A0090|136 147|acid receptor
P08816460A1769|5 11|results
P08816460A1769|24 33|inhibition
P08816460A1769|36 54|Jun kinase activation
P08816460A1769|77 93|Ras transformation
P08816460A1769|103 110|presence
P08816460A1769|122 126|Erk-2
P08816461A0892|3 10|analysis
P08816461A0892|23 27|Upf1p
P08816461A0892|46 52|protein
P08816461A0892|66 75|activities
P08816461A0892|89 100|mRNA turnover
P08816461A0892|104 122|nonsense suppression
P08816472T0000|0 13|Identification
P08816472T0000|34 42|regulator
P08816472T0000|61 75|response pathway
P08816482A0234|17 24|variants
P08816482A0234|27 31|Stat5
P08816482A0234|32 37|Stat5a
P08816482A0234|41 46|Stat5b
P08816482A0234|67 71|genes
P08816483A0869|0 8|Mutations
P08816498A0000|3 29|serine/threonine kinase Raf-1
P08816498A0000|60 84|signal transduction cascade
P08816498A0000|107 113|stimuli
P08816498A0000|121 134|plasma membrane
P08816498A0000|140 146|nucleus
P08816504T0000|16 21|growth
P08816504T0000|38 47|activation
P08816504T0000|50 77|phosphatidylinositol 3-kinase
P08816504T0000|91 105|receptor binding
P08816504T0000|129 136|proteins
P08816504T0000|151 161|Ras activity
P08816507A1125|11 28|cotransfections E1A
P08816507A1125|43 50|activity
P08816507A1125|56 66|p53 promoter
P08816507A1125|74 78|level
P08816507A1125|79 84|12S E1A
P08816507A1125|110 115|13S E1A
P08816507A1125|122 129|activity
P08816507A1125|157 163|element
P08816507A1125|190 198|induction
P08816759A0000|3 23|retinoid Z receptor beta
P08816759A0000|24 30|RZR beta
P08816759A0000|33 46|orphan receptor
P08816759A0000|50 55|member
P08816759A0000|69 80|acid receptor
P08816759A0000|85 106|thyroid hormone receptor
P08816759A0000|110 118|subfamily
P08816759A0000|127 135|receptors
P08816792A0000|13 25|protein kinase
P08816792A0000|26 31|DNA-PK
P08816792A0000|56 62|protein
P08816792A0000|85 91|subunit
P08816792A0000|91 98|DNA-PKcs
P08817323A0714|14 29|sequence identity
P08817323A0714|59 70|DXS6673E gene
P08817323A0714|85 96|sequence tags
P08817323A0714|127 138|DXS6673E gene
P08817324A1070|0 9|Sequencing
P08817324A1070|23 48|Xq28 duplication breakpoints
P08817324A1070|62 69|presence
P08817324A1070|101 122|CAGGG pentamer sequences
P08817324A1070|134 151|paralogy boundaries
P08818436A0557|22 29|analysis
P08818436A0557|46 51|gender
P08818436A0557|63 69|history
P08818436A0557|86 93|diseases
P08818436A0557|100 105|gender
P08818436A0557|139 143|death
P08818718A1229|35 43|injection
P08818718A1229|60 65|vector
P08818718A1229|85 93|liposomes
P08818718A1229|113 120|delivery
P08818718A1229|131 137|GC cDNAs
P08818718A1229|156 161|organs
P08820324A1699|3 8|limits
P08820324A1699|11 19|agreement
P08820324A1699|35 46|TOF responses
P08820642A0173|18 25|hrpZ gene
P08820642A0173|39 44|operon
P08820642A0173|60 88|Hrp secretion pathway components
P08820642A0173|115 121|cluster
P08820642A0173|123 130|hrp genes
P08820642A0173|140 151|cosmid pHIR11
P08820642A0173|174 181|bacteria
P08820642A0173|243 249|tobacco
P08820648A0123|10 17|presence
P08820648A0123|33 55|ribonucleotide reductase
P08820648A0123|72 77|enzyme
P08820648A0123|101 106|growth
P08820648A0123|140 146|mutants
P08820648A0123|152 158|species
P08820648A0123|176 183|presence
P08820648A0123|186 191|oxygen
P08822208A1364|13 19|results
P08822208A1364|41 48|isoforms
P08822208A1364|62 70|responses
P08822208A1364|84 94|differences
P08822208A1364|102 111|regulation
P08822399A0518|12 18|factors
P08822399A0518|29 37|attitudes
P08822399A0518|47 60|susceptibility
P08822399A0518|63 71|pregnancy
P08822399A0518|84 90|factors
P08823163T0000|15 23|structure
P08823163T0000|29 52|diphtheria toxin repressor
P08823163T0000|66 71|cobalt
P08823163T0000|75 83|manganese
P08823163T0000|106 111|domain
P08823163T0000|140 148|phosphate
P08823163T0000|150 163|co-corepressor
P08823187A1020|0 8|Titration
P08823187A1020|22 36|porcine proteins
P08823187A1020|81 99|membrane dipeptidase
P08823187A1020|134 147|disulfide bonds
P08823260A1161|31 38|patients
P08823260A1161|90 97|patients
P08823260A1161|127 135|infection
P08823646A1012|0 13|Administration
P08823646A1012|16 25|adrenaline
P08823646A1012|42 55|overestimation
P08823646A1012|76 87|measurements
P08823709A0220|0 6|Therapy
P08823709A0220|18 29|modification
P08823709A0220|33 57|triglyceride lowering drugs
P08823709A0220|68 77|resolution
P08823709A0220|80 87|symptoms
P08823709A0220|91 97|parotid
P08823709A0220|111 117|patient
P08824201A0270|0 7|Chernoff
P08824201A0270|20 30|publication
P08824585A0260|18 30|protein kinase
P08824585A0260|50 65|progenitor kinase
P08824585A0260|116 120|cells
P08824585A0260|134 148|progenitor cells
P08824798A0761|5 20|ESP1/CRP2 protein
P08824798A0761|27 36|LIM domains
P08824798A0761|44 49|shares
P08824798A0761|76 83|residues
P08824798A0761|104 110|protein
P08824798A0761|119 125|rat CRIP
P08824800A0808|3 11|fragments
P08824800A0808|42 66|agarose gel electrophoresis
P08824805A0832|12 25|exon boundaries
P08824805A0832|41 50|boundaries
P08824805A0832|63 69|domains
P08824805A0832|75 84|p55 protein
P08824881A0133|0 13|Linkage studies
P08824881A0133|23 40|locus heterogeneity
P08824881A0133|48 54|TSC gene
P08824881A0133|63 76|chromosome 9q34
P08824881A0133|89 95|16p13.3
P08824884A0000|14 23|expression
P08824884A0000|29 34|folate
P08824884A0000|57 61|FRAXE
P08824884A0000|71 79|expansion
P08824884A0000|83 91|GCC repeat
P08824884A0000|118 128|X chromosome
P08824884A0000|166 173|handicap
P08825087A0213|0 18|DNA sequence analysis
P08825087A0213|26 45|bp BamHI-ClaI fragment
P08825087A0213|67 79|reading frames
P08825087A0213|106 116|orientation
P08825178A0071|10 28|inpatient experience
P08825178A0071|32 42|individuals
P08825178A0071|79 88|acceptance
P08825178A0071|93 105|participation
P08825178A0071|115 120|TB care
P08825554A0000|0 14|Tristetraprolin
P08825554A0000|25 33|prototype
P08825554A0000|36 40|group
P08825554A0000|52 71|transcription factors
P08825554A0000|99 113|CCCH zinc fingers
P08825556A0522|4 10|element
P08825556A0522|17 23|CREsp-a
P08825556A0522|24 31|TGACCTCA
P08825556A0522|44 53|nucleotide
P08825556A0522|75 80|CREpal
P08825556A0522|80 87|TGACGTCA
P08825556A0522|115 123|homodimer
P08825633A0304|0 7|Analysis
P08825633A0304|46 53|sequence
P08825633A0304|63 70|homology
P08825633A0304|78 83|G alpha
P08825636T0000|22 30|structure
P08825636T0000|47 55|gene NFKB1
P08825636T0000|80 90|p50 proteins
P08825636T0000|92 120|transcription factors NF-kappa B
P08825636T0000|124 136|I kappa B-gamma
P08825636T0000|137 148|implications
P08825636T0000|152 159|NF-kappa
P08825636T0000|170 187|signal transduction
P08825639A0827|10 25|Alu repeat element
P08825639A0827|48 54|repeats
P08825639A0827|77 82|region
P08825639A0827|103 109|cap site
P08827783A0499|23 30|normoxia
P08827783A0499|33 42|monitoring
P08828142A0000|6 20|leukemia viruses
P08828142A0000|21 25|FeLVs
P08828142A0000|55 70|oncoretroviruses
P08828142A0000|84 93|cat species
P08828142A0000|129 140|environments
P08828152A1238|0 9|Comparison
P08828152A1238|15 32|amino acid sequences
P08828152A1238|38 53|RPO1 polypeptides
P08828152A1238|71 75|MCV-1
P08828152A1238|123 130|proteins
P08828152A1238|139 149|differences
P08828152A1238|152 170|amino acid similarity
P08828152A1238|186 198|relationships
P08828152A1825|32 41|similarity
P08828152A1825|78 87|similarity
P08828152A1825|101 111|polymerases
P08828152A1825|147 153|subunit
P08828857A2423|17 23|GE cells
P08828857A2423|53 58|system
P08828857A2423|69 73|study
P08828857A2423|79 87|endocrine
P08828857A2423|88 96|paracrine
P08828857A2423|109 115|factors
P08828857A2423|137 150|gene expression
P08828857A2423|157 165|pregnancy
P08829393A0083|11 26|dipole estimation
P08829393A0083|29 34|spikes
P08829393A0083|38 50|SEP components
P08829393A0083|62 69|patients
P08831364A1252|4 12|verapamil
P08831364A1252|16 26|propranolol
P08831364A1252|45 51|effects
P08831364A1252|56 64|adenosine
P08831364A1252|86 99|conduction time
P08831364A1252|110 118|verapamil
P08831364A1252|139 147|adenosine
P08831364A1252|173 177|block
P08832146A0959|39 61|bone alkaline phosphatase
P08833153A0628|2 9|addition
P08833153A0628|11 20|comparison
P08833153A0628|26 43|hCHLR gene sequences
P08833153A0628|57 65|databases
P08833153A0628|85 91|portion
P08833153A0628|99 103|genes
P08833153A0628|113 117|exons
P08833153A0628|139 145|domains
P08833153A0628|168 173|region
P08833153A0628|181 188|proteins
P08833153A0628|237 250|repeat sequence
P08833153A0628|266 276|chromosomes
P08833653A0304|17 45|LIM domain homeobox protein isl-1
P08833653A0304|58 74|rat amylin promoter
P08833653A0304|81 90|fibroblast
P08833653A0304|94 107|islet cell lines
P08833653A0783|8 12|isl-1
P08833653A0783|27 33|insulin
P08833653A0783|37 62|amylin gene promoter elements
P08833653A0783|75 83|sequences
P08833653A0783|97 107|differences
P08833653A0783|138 147|properties
P08833653A0783|182 189|promoter
P08833653A0783|214 225|G9 islet cells
P08835393A2829|19 26|pathways
P08835393A2829|43 66|signal transduction events
P08835393A2829|71 89|calcium mobilization
P08835393A2829|93 116|promoter response elements
P08835895A1292|3 10|CD4 count
P08835895A1292|18 26|remission
P08835895A1292|49 64|immunodeficiency
P08835895A1292|94 102|infection
P08835969A0000|18 28|laparoscopy
P08835969A0000|57 65|reference
P08835969A0000|71 79|diagnosis
P08835969A0000|89 97|pregnancy
P08835969A0000|135 144|sonography
P08835969A0000|145 155|conjunction
P08835969A0000|171 181|serum assays
P08835969A0000|187 197|beta subunit
P08835969A0000|214 225|gonadotropin
P08835969A0000|226 233|beta-hCG
P08835969A0000|240 248|detection
P08836032T0000|0 14|Bifunctionality
P08836032T0000|20 25|AcMNPV
P08836032T0000|36 49|region sequence
P08836032T0000|55 62|enhancer
P08836032T0000|65 76|ori functions
P08836032T0000|90 109|sequence requirements
P08836172A1382|13 20|function
P08836172A1382|19 25|studies
P08836172A1382|40 54|over-expression
P08836172A1382|74 82|RVR delta E
P08836172A1382|102 107|levels
P08836172A1382|110 121|p21Cip1/Waf1
P08836172A1382|125 137|myogenin mRNAs
P08836172A1382|143 157|serum withdrawal
P08836740A1025|36 45|cell growth
P08836740A1025|54 67|deletion mutant
P08837503A0392|8 19|repeat motifs
P08837503A0392|57 63|pattern
P08837503A0392|70 75|domain
P08837503A0392|93 99|SbHRGP3
P08837503A0392|113 117|group
P08837503A0392|120 127|proteins
P08837503A0392|137 148|repeat motifs
P08837503A0392|162 167|groups
P08837503A0392|170 183|dicot extensins
P08837746A0951|28 40|BrAAP activity
P08837746A0951|54 64|postproline
P08837746A0951|69 89|postglutamate cleavage
P08837746A0951|113 123|specificity
P08838144A0107|22 33|significance
P08838144A0107|41 50|subdomains
P08838144A0107|53 62|PRL binding
P08838144A0107|66 83|signal transduction
P08838144A0107|84 98|deletion mutants
P08838144A0107|101 120|S1 or/and S2 subdomains
P08838148A1218|19 26|cell line
P08838148A1218|40 55|mouse TRH receptor
P08838148A1218|72 83|transfection
P08838148A1218|101 105|cells
P08838148A1218|115 130|L channel activity
P08838314A0129|22 31|expression
P08838314A0129|35 44|regulation
P08838314A0129|79 93|characteristics
P08838314A0129|93 108|tissue expression
P08838314A0129|120 131|localization
P08838314A0129|143 149|mapping
P08838314A0129|160 167|V1aR gene
P08838314A0129|168 173|AVPR1A
P08838585A0968|17 25|structure
P08838585A0968|38 54|backbone deviation
P08838585A0968|71 77|ras-p21
P08838805T0000|7 18|organization
P08838805T0000|29 44|beta-catenin gene
P08838805T0000|45 50|CTNNB1
P08839498A0507|30 41|distribution
P08839498A0507|48 57|tissue mass
P08839498A0507|63 67|trunk
P08839498A0507|118 123|stages
P08839498A0507|134 145|distribution
P08839832A0729|16 27|CD30v protein
P08839832A0729|55 60|region
P08839832A0729|101 107|domains
P08839832A1220|12 26|phosphorylation
P08839832A1220|32 43|CD30v protein
P08839832A1220|68 75|labeling
P08839911A0716|8 13|cycles
P08840501A0345|15 23|discovery
P08840501A0345|55 62|organism
P08840506A0544|79 83|G2850
P08840997A0765|0 8|MVR typing
P08840997A0765|22 28|alleles
P08840997A0765|72 80|sequences
P08840997A0765|105 115|resemblance
P08840997A0765|132 138|alleles
P08842143A0000|0 12|Plasmid pAL618
P08842143A0000|31 42|determinants
P08842143A0000|46 53|H2 uptake
P08842143A0000|102 107|viciae
P08842143A0000|118 124|cluster
P08842143A0000|129 133|genes
P08843411A0801|3 9|classes
P08843411A0801|20 28|receptors
P08843411A0801|72 81|activation
P08843411A0801|85 96|dimerization
P08843411A0801|148 157|activation
P08843412A0543|27 44|40-amino acid region
P08843412A0543|79 94|chicken ovalbumin
P08843412A0543|99 125|promoter transcription factor
P08843412A0543|154 161|identity
P08843412A0543|180 190|interaction
P08843412A0543|210 219|DNA binding
P08843419A1290|8 17|calyculin A
P08843419A1290|30 34|OCFRE
P08843419A1290|46 57|interactions
P08843419A1290|96 107|interactions
P08844448A0000|47 60|crossover study
P08844448A0000|84 93|volunteers
P08844448A0000|108 112|years
P08844448A0000|131 136|effect
P08844448A0000|138 145|orlistat
P08844448A0000|163 177|lipase inhibitor
P08844448A0000|199 208|absorption
P08844448A0000|231 243|weight control
P08844448A0000|246 252|obesity
P08844448A0000|258 267|absorption
P08844448A0000|270 277|vitamins
P08844577A0000|0 9|Tilmicosin
P08844577A0000|18 26|macrolide
P08844577A0000|75 82|medicine
P08844712A0000|0 5|Effect
P08844712A0000|15 19|oxide
P08844712A0000|53 62|C-reflexes
P08844712A0000|125 140|alpha-chloralose
P08844712A0000|143 150|urethane
P08845378A0368|0 23|Restriction enzyme mapping
P08845378A0368|27 42|Southern analysis
P08845378A0368|71 79|MZF-1 gene
P08846775A0110|5 11|absence
P08846775A0110|23 39|Swi6 cell viability
P08846775A0110|70 79|expression
P08846775A0110|85 92|G1 cyclin
P08846775A0110|101 105|genes
P08847138A0609|3 16|detection ratio
P08847138A0609|71 75|years
P08847403T0000|7 13|embryos
P08847403T0000|26 33|patients
P08847723A2351|0 11|IMPLICATIONS
P08847723A2351|37 41|study
P08847723A2351|47 59|inconsistency
P08847723A2351|62 68|results
P08847723A2351|91 97|studies
P08847723A2351|107 112|cancer
P08847723A2351|133 144|associations
P08847723A2351|145 156|replications
P08847723A2351|164 171|findings
P08848013A1469|15 21|TATA box
P08848013A1469|24 32|promoter B
P08848013A1469|60 75|promoter activity
P08848013A1469|82 88|TATA box
P08848013A1469|91 100|promoter A.
P08848052A0733|5 14|properties
P08848052A0733|37 52|RNA-export factor
P08848052A0733|79 87|RNA export
P08848052A0733|101 108|function
P08849208A1022|0 7|Demispan
P08849208A1022|34 40|measure
P08849208A1022|43 49|stature
P08849569A0615|3 12|techniques
P08849569A0615|20 36|assay coefficients
P08849569A0615|39 47|variation
P08849569A0615|90 96|pattern
P08849569A0615|99 106|cortisol
P08849778A0226|15 33|toeprinting analyses
P08849778A0226|36 43|repA mRNA
P08849778A0226|46 54|plasmid R1
P08849778A0226|68 73|duplex
P08849778A0598|30 45|initiator protein
P08849778A0598|44 53|expression
P08849778A0598|67 79|leader peptide
P08849778A0598|79 89|translation
P08849834A0000|1 6|system
P08849834A0000|28 41|volume flow rate
P08849834A0000|44 48|blood
P08849834A0000|52 57|vessel
P08849834A0000|85 114|colour Doppler ultrasound imaging
P08850585A0602|3 18|enzyme activities
P08850585A0602|38 45|elements
P08850585A0602|51 65|pathophysiology
P08850585A0602|74 79|caries
P08850585A0602|103 118|virulence factors
P08851337A1092|0 12|Tonsillectomy
P08851337A1092|26 30|means
P08851337A1092|33 43|prophylaxis
P08851337A1092|63 71|infection
P08851337A1092|82 95|angina patients
P08851434A0383|15 37|fat/water intensity ratio
P08853303A0431|15 24|parameters
P08853303A0431|38 43|values
P08853303A0431|54 63|literature
P08853303A0431|99 116|bolus MMC injections
P08853303A0431|143 151|beginning
P08853303A0431|152 162|MMC infusion
P08853303A0431|187 192|ml/min
P08853303A0431|232 240|T1/2 alpha
P08853303A0431|249 256|T1/2 beta
P08853893A0158|6 10|study
P08853893A0158|35 46|E2F complexes
P08853893A0158|90 100|fibroblasts
P08854459A0000|4 8|paper
P08854459A0000|16 23|overview
P08854459A0000|35 41|pattern
P08854459A0000|44 53|casualties
P08854459A0000|56 66|earthquakes
P08854459A0000|97 102|period
P08854459A0000|108 116|September
P08854459A0000|125 132|February
P08854844A0637|12 18|finding
P08854844A0637|21 37|non-visualization
P08854844A0637|50 63|h post injection
P08854844A0637|68 76|criterion
P08854844A0637|83 91|diagnosis
P08854844A0637|111 118|accuracy
P08855804A1528|5 11|results
P08855804A1528|41 45|study
P08855804A1528|106 110|times
P08855804A1528|117 122|months
P08856077T0000|11 20|processing
P08856077T0000|26 56|tryptophanyl-tRNA synthetase mRNA
P08856077T0000|84 88|cells
P08856132T0000|0 7|Evidence
P08856132T0000|47 58|kinin release
P08856132T0000|63 73|development
P08856132T0000|104 111|abortion
P08858211A0694|4 14|GAP activity
P08858211A0694|28 49|3T3-L1 adipocyte lysates
P08858211A0694|75 84|hydrolysis
P08858211A0694|90 98|alpha-32P
P08858211A0694|110 117|GST-Rab4
P08858211A0694|121 129|alpha-32P
P08858268A1307|0 9|CONCLUSION
P08858268A1307|23 31|treatment
P08858268A1307|47 54|response
P08858268A1307|61 70|cilazapril
P08858268A1307|115 125|improvement
P08858268A1307|128 135|patients
P08858268A1307|189 195|effects
P08858463A0853|16 27|AIDS patients
P08858463A0853|32 45|cryptococcosis
P08858463A0853|46 54|tolerance
P08858463A0853|57 63|ILd-AmB
P08858463A0853|89 94|dosage
P08858463A0853|108 112|mg/kg
P08858463A0853|128 132|mg/kg
P08858463A0853|138 143|dosage
P08858463A0853|183 196|nephrotoxicity
P08861955A0927|26 30|motif
P08861955A0927|43 56|amino-terminus
P08861955A0927|75 99|guanine nucleotide exchange
P08861955A0927|112 118|members
P08861955A0927|130 140|Rab proteins
P08861955A0927|159 176|GTP binding proteins
P08861955A0927|190 195|R-Ras2
P08861963A0375b|16 29|RNA polymerases
P08861963A0375b|43 61|mutant alpha subunits
P08861963A0375b|82 89|response
P08861963A0375b|92 114|transcription activation
P08861963A0375b|117 124|cAMP-CRP
P08861963A0375b|131 145|rrnBP1 UP element
P08861963T0000|0 36|Transcription factor recognition surface
P08861963T0000|42 66|RNA polymerase alpha subunit
P08861963T0000|79 85|contact
P08861963T0000|93 110|DNA enhancer element
P08862522A0690|18 27|similarity
P08862522A0690|31 38|cdc28-P8
P08862522A0690|65 74|precursors
P08862522A0690|91 101|temperature
P08862743A0603|1 8|decrease
P08862743A0603|11 23|erythrocyte Mn
P08862743A0603|44 49|nmol/L
P08863824A0509|0 6|Cloning
P08863824A0509|10 25|sequence analyses
P08863824A0509|57 64|deletion
P08863824A0509|69 74|region
P08863824A0509|132 150|transmembrane domain
P08863824A0509|155 162|5-HT2C-R
P08864061A0000|0 9|Expression
P08864061A0000|12 30|thymidine kinase gene
P08864061A0000|51 55|cells
P08864061A0000|62 70|cell cycle
P08864219A0178|20 33|concentrations
P08864219A0178|42 53|ketoconazole
P08864219A0178|53 62|miconazole
P08864219A0178|63 74|itraconazole
P08864219A0178|75 85|fluconazole
P08864219A0178|89 101|amphotericin B
P08864219A0178|134 145|inoculum size
P08864219A0178|161 170|techniques
P08866485A0125|5 12|bacteria
P08866485A0125|23 36|export proteins
P08866485A0125|54 65|interactions
P08866485A0125|98 106|molecules
P08866485A0125|108 112|order
P08866485A0125|130 138|functions
P08866485A0125|144 148|cells
P08867519A0557|3 12|elevations
P08867519A0557|76 89|administration
P08867519A0557|106 112|periods
P08868473A1287|65 73|cleavages
P08868473A1287|92 102|development
P08868473A1287|130 138|cell cycle
P08868660A0087|17 28|contribution
P08868660A0087|40 44|arena
P08868660A0087|48 57|discussion
P08868660A0087|63 73|Rivista dell
P08868660A0087|73 82|Infermiere
P08868660A0087|114 121|research
P08868660A0087|141 149|strengths
P08868660A0087|153 159|novelty
P08868660A0087|163 172|weaknesses
P08868660A0087|178 198|hypothesis formulation
P08868660A0087|199 205|methods
P08868660A0087|209 219|instruments
P08868660A0087|224 233|discussion
P08868660A0087|236 242|results
P08868954A0648|26 32|effects
P08868954A0648|51 55|drugs
P08868954A0648|87 92|agents
P08868954A0648|97 114|calcium antagonists
P08868954A0648|121 131|angiotensin
P08868954A0648|142 157|enzyme inhibitors
P08868954A0648|170 181|hemodynamics
P08869358A0121|9 15|viruses
P08869358A0121|40 49|strategies
P08869358A0121|62 70|apoptosis
P08869358A0121|87 91|cells
P08869358A0121|109 114|T cells
P08869763A0378|36 44|phenomena
P08869763A0378|47 54|response
P08869763A0378|57 64|morphine
P08869763A0378|81 91|differences
P08869763A0378|94 103|expression
P08869763A0378|107 117|sensitivity
P08869763A0378|130 145|receptor subtypes
P08869763A0378|148 155|migraine
P08869825A0000|8 14|studies
P08869825A0000|51 64|monooxygenases
P08869825A0000|100 105|manner
P08870266A0651|18 29|observations
P08870266A0651|57 66|amino acids
P08870266A0651|83 95|NodO secretion
P08870266A0651|107 112|region
P08870266A0651|127 132|domain
P08870266A0651|148 166|secretion efficiency
P08871542A1352|14 22|potential
P08871542A1352|42 51|mechanisms
P08871542A1352|64 71|evidence
P08871542A1352|100 107|promoter
P08871542A1352|133 151|Thbs3 gene expression
P08871567A0000|0 11|MSSP proteins
P08871567A0000|37 43|binding
P08871567A0000|56 62|element
P08871567A0000|65 69|c-myc
P08871635A0000|0 19|B cell antigen receptor
P08871635A0000|31 39|apoptosis
P08871635A0000|44 68|WEHI-231 B lymphoma cell line
P08872162A0884|4 10|alleles
P08872162A0884|67 78|T cell subsets
P08872671A0573|3 7|model
P08872671A0573|24 45|blood flow shunt fraction
P08872671A0573|46 50|Qs/QT
P08872671A0573|73 78|oxygen
P08872671A0573|88 109|amplitude perturbations
P08872671A0573|165 169|blood
P08872671A0573|185 193|equations
P08873063A0493|10 26|amino acid sequence
P08873063A0493|29 34|LvUSF2
P08873063A0493|54 59|LvUSF1
P08873063A0493|71 78|amino end
P08873063A0875|0 12|ECM disruption
P08873063A0875|15 31|Lytechinus embryos
P08873063A0875|55 78|USF RNA accumulation levels
P08873063A0875|99 112|control embryos
P08873063A0875|117 141|LpS1 RNA accumulation levels
P08873159A0791|16 23|patients
P08873159A0791|26 30|group
P08873159A0791|51 62|chemotherapy
P08874399A0277|19 30|intervention
P08874399A0277|46 53|tensions
P08874399A0277|96 108|concentration
P08874399A0277|120 125|groups
P08874631A1133|0 13|Discrimination
P08874631A1133|21 25|HIV-1
P08874631A1133|29 33|HIV-2
P08874631A1133|40 47|evidence
P08874631A1133|54 61|presence
P08874631A1133|64 68|HIV-1
P08876167A0322|29 35|subunit
P08876167A0322|39 44|HiNF-D
P08876167A0717|3 8|HiNF-D
P08876167A0717|9 15|CDP/cut
P08876167A0717|16 22|complex
P08876167A0717|30 39|H4 promoter
P08876167A0717|60 69|antibodies
P08876167A0717|77 83|CDP/cut
P08876167A0717|121 127|complex
P08876167A0717|141 148|promoter
P08876167A0717|149 157|gp91-phox
P08876167A0717|180 193|p107 antibodies
P08876701A0177|25 36|UmuC-homolog
P08877103A0081|10 19|regulation
P08877103A0081|22 35|mdr2 expression
P08877103A0081|39 46|promoter
P08877103A0081|52 59|mdr2 gene
P08877103A0081|107 114|cell line
P08877103A0081|115 121|J7.V2-1
P08877818A0184|3 15|amplification
P08877818A0184|35 41|primers
P08877818A0184|59 79|TRH progenitor sequence
P08877818A0184|80 94|Lys/Arg-Arg-Gln
P08877818A0184|94 108|His-Pro-Gly-Lys
P08877818A0184|108 114|Arg-Arg
P08878019A0357|24 28|cells
P08878019A0357|40 48|sinusoids
P08878019A0357|54 63|lymph nodes
P08878019A0357|120 124|tumor
P08878037A0000|3 10|gene ccpA
P08878037A0000|22 49|catabolite control protein CcpA
P08878044A1390|2 19|InlC deletion mutant
P08878044A1390|32 40|virulence
P08878044A1390|66 75|mouse model
P08878044A1390|92 102|replication
P08878044A1390|108 113|mutant
P08878044A1390|116 121|Caco-2
P08878044A1390|125 133|J774 cells
P08878044A1390|177 182|strain
P08878045A0606|7 18|N-Nus complex
P08878045A0606|39 46|contacts
P08878045A0606|64 75|alpha subunit
P08878045A0606|77 89|RNA polymerase
P08878045A0606|95 99|group
P08878045A0606|112 119|proteins
P08878045A0606|134 143|initiation
P08878045A0606|146 158|transcription
P08878573A1370|0 13|Administration
P08878573A1370|27 35|mg/kg/day
P08878573A1370|37 47|combination
P08878573A1370|62 70|mg/kg/day
P08878573A1370|87 98|prolongation
P08878573A1370|101 108|survival
P08879080A0265|10 14|ACOAs
P08879080A0265|27 31|order
P08879080A0265|54 58|model
P08879080A0265|71 82|path analysis
P08879080A0265|86 94|LISREL VII
P08879237A0744|10 24|initiation sites
P08879237A0744|39 46|sequence
P08879237A0744|62 83|consensus promoter motif
P08879237A0744|99 107|CRTA motif
P08879237A0744|129 145|rice mitochondrion
P08880405A1170|0 8|Selection
P08880405A1170|14 18|SC EPD
P08880405A1170|49 57|selection
P08880405A1170|75 81|puberty
P08880405A1170|83 91|daughters
P08881036A0351|19 27|VL element
P08881542T0000|0 34|Sodium polystyrene sulfonate treatment
P08881542T0000|38 52|lithium toxicity
P08881542T0000|53 59|effects
P08881542T0000|62 89|serum potassium concentrations
P08882492A0000|12 30|homeodomain proteins
P08882492A0000|40 47|Hox genes
P08882492A0000|80 90|development
P08882492A0000|111 116|queues
P08882492A0000|141 150|identities
P08882492A0000|192 200|organisms
P08882710A0000|0 9|Interferon
P08882710A0000|20 29|gene factor
P08882710A0000|31 35|ISGF3
P08882710A0000|47 65|transcription factor
P08882710A0000|77 85|treatment
P08882710A0000|88 92|cells
P08882710A0000|97 112|interferon-alpha
P08884273A1413|3 17|TYAC/P1 resource
P08884273A1413|37 49|polymorphisms
P08884273A1413|69 76|resource
P08884273A1413|86 92|studies
P08884273A1413|95 111|telomere structure
P08884273A1413|115 122|function
P08884273A1413|127 131|means
P08884273A1413|153 166|map integration
P08884273A1413|170 176|closure
P08884757A0653|12 21|statistics
P08884757A0653|56 65|Impression
P08884757A0653|78 82|score
P08884757A0653|87 92|Sandoz
P08884757A0653|101 119|Assessment Geriatric
P08884757A0653|126 130|scale
P08884757A0653|159 163|nurse
P08884757A0653|164 169|rating
P08884757A0653|181 188|patients
P08884757A0653|189 229|Beurteilungsskala fur geriatrische Patienten
P08884757A0653|246 250|score
P08884757A0653|269 283|Performance Test
P08884757A0653|284 299|Syndrom-Kurztest
P08885270A0428|5 11|mutants
P08885270A0428|41 46|strain
P08886845A1274|28 43|myogenin promoter
P08886845A1274|44 51|presence
P08886845A1274|67 72|copies
P08886845A1274|82 88|vectors
P08886845A1274|100 117|expression activity
P08886845A1274|120 127|myotubes
P08886845A1274|181 189|myoblasts
P08887643A1167|28 34|signals
P08887643A1167|40 49|activation
P08887643A1167|78 99|TC21 controls cell growth
P08887643A1167|134 150|signaling pathways
P08887647T0000|0 15|Fission yeast mal2
P08887647T0000|29 49|chromosome segregation
P08887652A0341|0 8|Selection
P08887652A0341|19 28|expression
P08887652A0341|43 53|DNA fragment
P08887652A0341|92 97|region
P08887652A0341|118 124|segment
P08887652A0341|140 151|reading frame
P08887652A0341|159 163|frame
P08887652A0341|180 208|hygromycin B phosphotransferase
P08887652A0341|225 229|con10
P08887659A0753|0 8|Mutations
P08887659A0753|25 29|sites
P08887659A0753|30 35|serine
P08887659A0753|42 50|threonine
P08887659A0753|68 73|effect
P08887661A0138|0 4|IRF-1
P08887661A0138|27 35|activator
P08887661A0138|41 45|IRF-2
P08887661A0138|53 61|repressor
P08887661A1061|2 9|contrast
P08887661A1061|10 23|cotransfection
P08887661A1061|26 30|TFIIB
P08887661A1061|34 38|IRF-1
P08887661A1061|43 53|NIH 3T3 cells
P08887661A1061|79 88|repression
P08887661A1061|91 108|promoter activation
P08887661A1061|139 144|manner
P08887667A0992|3 13|requirement
P08887667A0992|16 38|Tyr-19 dephosphorylation
P08887667A0992|42 56|spindle assembly
P08887667A0992|76 85|conditions
P08887667A0992|93 108|spindle formation
P08887667A0992|124 130|mitosis
P08887667A0992|148 158|involvement
P08887667A0992|161 175|Cdc28/Clb kinase
P08887667A0992|178 190|SPB separation
P08887674A0630|1 6|subset
P08887674A0630|14 37|DMP1 recognition sequences
P08887674A0630|49 68|GGA trinucleotide core
P08887674A0630|100 107|elements
P08887674A0920|6 13|settings
P08887674A0920|37 42|cyclin
P08887674A0920|54 60|kinases
P08887674A0920|93 100|activity
P08887674A0920|134 143|mechanisms
P08887678A0000|0 9|Expression
P08887678A0000|27 36|protein Bax
P08887678A0000|45 51|control
P08887678A0000|55 67|GAL10 promoter
P08887678A0000|122 130|cell death
P08890537A0355|4 12|technique
P08890537A0355|28 35|patients
P08890537A0355|51 58|bone cyst
P08891131A0000|0 25|Enterococcus faecium strains
P08891131A0000|43 64|glycopeptide resistance
P08891131A0000|79 95|enrichment culture
P08891131A0000|103 112|intestines
P08891131A0000|116 120|feces
P08891131A0000|136 142|species
P08891131A0000|149 154|horses
P08891131A0000|175 182|chickens
P08891337A0614|17 22|region
P08891337A0614|55 68|weight proteins
P08891337A0614|97 115|coactivator function
P08891337A0614|140 158|cAMP response element
P08891337A0614|162 175|binding protein
P08891341A0724|9 26|transfection assays
P08891341A0724|32 53|reporter gene constructs
P08891341A0724|71 77|lengths
P08891341A0724|89 97|sequences
P08891341A0724|113 120|sequence
P08891341A0724|128 138|between-247
P08891341A0724|167 176|expression
P08891341A0724|181 192|reporter gene
P08891341A0724|208 216|cell lines
P08891345A0684|13 29|UTR characteristic
P08891345A0684|47 55|c-mos mRNA
P08891345A0684|73 83|translation
P08891345A0684|97 107|translation
P08891345A0684|110 120|transcripts
P08891345A0684|149 163|beta-globin mRNA
P08891345A0684|190 194|uORFs
P08891346A1217|22 27|effect
P08891346A1217|38 54|isoform expression
P08891346A1217|55 65|NIH3T3 cells
P08891346A1217|96 111|expression vector
P08891346A1217|131 135|FGF8a
P08891346A1217|135 139|FGF8b
P08891346A1217|142 146|FGF8e
P08891474A0667|5 12|findings
P08891474A0667|27 32|F-wave
P08891474A0667|48 57|motoneuron
P08891474A0667|69 91|depolarization threshold
P08891474A0667|121 131|nerve fibers
P08891474A0667|142 150|threshold
P08891474A0667|153 166|depolarization
P08892755A0186|2 9|addition
P08892755A0186|10 17|carp JAK1
P08892755A0186|29 44|sequence homology
P08892755A0186|90 95|kinase
P08892755A0186|99 105|domains
P08892755A0186|119 127|% identity
P08892755A0981|8 18|DNA fragment
P08892755A0981|41 72|chloramphenicol acetyltransferase
P08892755A0981|78 89|reporter gene
P08892755A0981|108 121|carp CF cell line
P08892755A0981|137 145|synthesis
P08892755A0981|148 156|CAT enzyme
P08892755A0981|159 163|times
P08892755A0981|198 207|pCAT-Basic
P08892757T0000|9 15|cloning
P08892757T0000|18 22|Elk-3
P08892757T0000|27 32|member
P08892757T0000|38 46|Ets family
P08892757T0000|62 79|mouse embryogenesis
P08892757T0000|83 90|analysis
P08892757T0000|111 128|repression activity
P08892859A0563|10 16|example
P08892859A0563|52 59|cell line
P08892859A0563|78 83|levels
P08892859A0563|95 106|C-MYB protein
P08892859A0563|110 115|result
P08892859A0563|118 131|RAV integration
P08892859A0563|141 151|c-myb allele
P08893779A0229|21 52|digitorum longus muscle tendon units
P08893779A0229|74 79|values
P08893779A0229|91 97|failure
P08893779A0229|105 110|energy
P08893779A0229|120 126|failure
P08893779A0229|138 143|strain
P08893779A0229|145 151|failure
P08893779A0229|199 206|location
P08893779A0229|239 247|interface
P08893779A0229|294 301|junction
P08893779A0229|311 315|units
P08893822A0560|0 15|Northern analysis
P08893822A0560|27 35|PWP2H cDNA
P08893822A0560|60 69|transcript
P08893822A0560|105 111|tissues
P08894144A0330|89 102|CsA vehicle p.o.
P08894144A0330|105 115|FB vehicle sc
P08894144A0330|124 128|mg/kg
P08894144A0330|138 148|FB vehicle sc
P08894144A0330|149 162|CsA vehicle p.o.
P08894144A0330|174 178|mg/kg
P08894144A0330|193 197|mg/kg
P08894144A0330|213 217|mg/kg
P08894144A1173|28 39|bone turnover
P08894826A0228|0 10|Individuals
P08894826A0228|23 35|GUM Department
P08894826A0228|41 54|Royal Infirmary
P08894826A0228|57 65|Edinburgh
P08894826A0228|91 99|diagnosis
P08894826A0228|102 113|HIV infection
P08894826A0228|121 125|warts
P08894826A0228|133 138|herpes
P08894826A0228|158 166|infection
P08894826A0228|173 182|gonorrhoea
P08894826A0228|185 192|syphilis
P08894826A0228|210 214|study
P08895522T0000|9 18|activation
P08895522T0000|24 43|tyrosine kinase domain
P08895522T0000|54 70|trk proto-oncogene
P08895522T0000|73 78|fusion
P08895522T0000|82 101|cell adhesion molecule
P08895579A0583|0 15|Northern blotting
P08895579A0583|58 64|tissues
P08895579A0583|83 87|mRNAs
P08895997A0336|0 6|Physiol
P08896272A0000|3 20|nucleotide sequence
P08896272A0000|49 58|chromosome
P08896280A0860|36 41|levels
P08896280A0860|53 60|IME2 mRNA
P08896280A0860|76 81|result
P08896280A0860|119 132|acid metabolism
P08896280A0860|144 157|yvh1 disruption
P08896402A0587|7 15|FL protein
P08896402A0587|43 50|cell line
P08896402A0587|100 111|glycoprotein
P08896402A0587|124 133|kD subunits
P08896402A0587|170 175|sugars
P08896473A0282|3 11|objective
P08896473A0282|18 22|study
P08896473A0282|38 46|influence
P08896473A0282|74 80|factors
P08896473A0282|87 97|development
P08896590T0000|7 11|exons
P08896590T0000|14 23|adenovirus
P08896590T0000|48 52|snRNP
P08896590T0000|70 75|domain
P08896795A0166|5 9|Spurr
P08896795A0166|11 15|resin
P08896795A0166|27 32|medium
P08896795A0166|52 60|specimens
P08896795A0166|65 76|oil immersion
P08896795A0166|109 118|coverslips
P08896795A0166|126 135|air bubbles
P08896795A0166|143 150|specimen
P08896804A0000|10 14|study
P08896804A0000|27 40|dose dependence
P08896804A0000|44 60|time course effects
P08896804A0000|66 79|benzodiazepine
P08896804A0000|99 105|agonist
P08896804A0000|105 113|RO19-4603
P08896804A0000|123 127|mg/kg
P08896804A0000|138 148|combination
P08896804A0000|156 187|BDZ receptor antagonists flumazenil
P08896804A0000|211 215|mg/kg
P08896804A0000|231 248|alcohol-preferring
P08896804A0000|277 286|choice test
P08896804A0000|292 298|ethanol
P08896804A0000|306 309|% v/v
P08896804A0000|322 330|saccharin
P08896804A0000|336 339|% g/v
P08896804A0000|340 347|solution
P08897663T0000|9 13|Tower
P08897663T0000|16 20|Babel
P08897663T0000|22 33|nomenclature
P08897663T0000|37 47|suicidology
P08897721A0000|0 8|Infection
P08897721A0000|13 21|Neisseria
P08897721A0000|34 39|group B
P08897721A0000|90 94|group
P08897721A0000|96 109|polysaccharide
P08897721A0000|117 125|immunogen
P08898336A0268|0 22|RNase protection analysis
P08898336A0268|28 40|rRNA fragments
P08898336A0268|46 50|genes
P08898336A0268|70 77|evidence
P08898336A0268|95 104|transcript
P08898336A0268|115 123|sequences
P08898365A0274|0 4|Rss1p
P08898365A0274|27 33|protein
P08898365A0274|39 48|amino acids
P08898365A0274|92 97|domain
P08898365A0274|123 135|pore complexes
P08898365A0274|150 158|cytoplasm
P08898866A0458|19 43|serine phosphorylation site
P08898866A0458|76 91|expression system
P08898866A0458|104 110|annexin
P08898866A0458|120 125|series
P08898866A0458|128 134|annexin
P08898866A0458|137 143|mutants
P08898866A0458|158 170|substitutions
P08898866A0458|182 195|serine residues
P08898866A0458|218 223|domain
P08898893A0202|3 11|PAI-2 gene
P08898893A0202|40 44|genes
P08898893A0202|77 117|phorbol ester phorbol 12-myristate 13-acetate
P08898893A0202|129 148|phosphatase inhibitor
P08898893A0202|167 185|HT-1080 fibrosarcoma
P08898893A0202|188 192|U-937
P08898893A0202|204 208|cells
P08899719A0318|8 14|contigs
P08899719A0318|23 27|total
P08899719A0318|37 49|reading frames
P08899719A0318|71 77|operons
P08899719A0318|116 124|certainty
P08900164A0188|4 8|Patel
P08900190A0430|0 12|Growth factors
P08900190A0430|22 31|expression
P08900190A0430|51 84|gene products MAP kinase phosphatase-1
P08900190A0430|85 89|MKP-1
P08900190A0430|90 94|c-Fos
P08900190A0430|98 102|c-Jun
P08900296A0000|3 15|up-regulation
P08900296A0000|18 27|E-selectin
P08900296A0000|36 52|adhesion molecules
P08900296A0000|58 68|endothelium
P08900296A0000|82 86|event
P08900296A0000|92 100|mediation
P08900296A0000|118 125|response
P08901135A1132|3 13|NIT2 protein
P08901135A1132|27 32|nuclei
P08901135A1132|70 77|fraction
P08901135A1132|80 84|cells
P08901135A1132|96 115|nitrogen derepression
P08901135A1132|118 135|nitrogen repression
P08901135A1132|160 165|import
P08901635A0000|2 6|spite
P08901635A0000|13 18|effort
P08901635A0000|69 74|enzyme
P08901635A0000|90 98|synthesis
P08901635A0000|100 108|cellulose
P08901635A0000|117 131|cell wall polymer
P08901635A0000|134 139|plants
P08901658A0498|8 16|responses
P08901658A0498|27 35|hyperemia
P08901658A0498|40 51|flow increase
P08901658A0498|82 89|dilation
P08901658A0498|105 122|glyceryl trinitrate
P08901658A0498|151 158|dilation
P08902214A1486|10 15|period
P08902214A1486|16 29|administration
P08902214A1486|78 87|activation
P08902214A1486|87 93|binding
P08902214A1486|99 109|Stat factors
P08902548A0144|15 28|administration
P08902548A0144|31 51|L-5-hydroxytryptophan
P08902548A0144|52 58|L-5-HTP
P08902548A0144|61 65|doses
P08902548A0144|75 79|mg/kg
P08902548A0144|100 109|defecation
P08902641A0930|5 14|VA-SMV mode
P08902641A0930|18 27|connection
P08902641A0930|45 52|conduits
P08902641A0930|60 65|LV apex
P08902641A0930|66 71|inflow
P08902641A0930|86 90|aorta
P08902641A0930|91 97|outflow
P08902847A1946|3 10|evidence
P08902847A1946|13 19|support
P08902847A1946|56 63|affinity
P08902847A1946|65 75|interaction
P08902847A1946|89 96|subunits
P08902847A1946|129 145|order rate constant
P08902847A1946|148 155|hCG alpha
P08902847A1946|175 179|min-1
P08902847A1946|191 198|degrees C
P08902847A1946|208 212|order
P08902847A1946|215 223|magnitude
P08902847A1946|241 245|rehCG
P08902847A1946|258 262|min-1
P08902988A0258|0 12|Factor V Leiden
P08902988A0258|23 30|disorder
P08902988A0258|70 79|thrombosis
P08903339A0264|14 26|determination
P08903339A0264|49 57|structure
P08903339A0264|77 87|spliceosome
P08905819A0531|3 10|majority
P08905819A0531|16 20|cases
P08905819A0531|32 46|0-III components
P08905819A0531|64 69|cancer
P08906056A1290|5 12|patients
P08906056A1290|48 55|function
P08906056A1290|70 75|status
P08906056A1290|100 105|degree
P08906056A1290|108 128|health care utilization
P08906139A2935|4 14|observation
P08906139A2935|30 39|monitoring
P08906139A2935|42 48|calcium
P08906139A2935|52 76|alkaline phosphatase values
P08906139A2935|88 98|adjustments
P08906139A2935|101 114|vitamin D intake
P08906139A2935|119 128|fortifiers
P08906139A2935|147 153|periods
P08909546A0810|55 61|pattern
P08909546A0810|83 89|protein
P08909546A0810|115 120|domain
P08910292T0000|0 8|Signaling
P08910292T0000|32 43|proteins Rac1
P08910292T0000|47 51|Cdc42
P08910292T0000|57 61|c-Jun
P08910292T0000|95 114|protein kinase pathway
P08910373A0315|0 16|Percent identities
P08910373A0315|22 29|mouse PP2
P08910373A0315|32 38|mouse Y1
P08910373A0315|39 49|mouse Y4/PP1
P08910373A0315|58 68|Y2 receptors
P08910550A0501|26 36|observation
P08910550A0501|41 50|CBF binding
P08910550A0501|56 63|78C1 site
P08910550A0501|104 118|cation chelators
P08910550A0501|151 163|transcription
P08910567A2269|8 19|gene fragment
P08910567A2269|39 65|rat liver glucokinase promoter
P08910567A2269|84 91|enhancer
P08910567A2269|97 124|hepatocyte transfection system
P08912232A0260|56 63|children
P08912232A0260|74 78|girls
P08912807A0411|19 30|deer receptor
P08912807A0411|53 67|tyrosine residue
P08912807A0411|86 91|domain
P08912807A0411|123 132|activation
P08912807A0411|138 156|beta-casein promoter
P08913186A0431|4 9|report
P08913186A0431|25 32|evidence
P08913186A0431|39 43|riMLF
P08913186A0431|49 55|control
P08913186A0431|58 65|downgaze
P08913186A0431|70 79|synkinesis
P08913186A0431|98 108|development
P08913186A0431|114 143|convergence retraction nystagmus
P08913387A1010|0 8|Rifabutin
P08913387A1010|23 30|efficacy
P08913387A1010|52 57|agents
P08913974A0533|11 17|percent
P08913974A0533|49 53|tubes
P08913974A0533|75 81|changes
P08913974A0533|98 108|salpingitis
P08913974A0533|128 138|salpingitis
P08913974A0533|147 152|others
P08914388A1645|3 12|assessment
P08914388A1645|29 34|medium
P08914388A1645|45 50|author
P08914388A1645|72 81|activities
P08914388A1645|88 94|CS-940*
P08914388A1645|97 108|sparfloxacin
P08914388A1645|125 132|AM-1155*
P08914388A1645|131 143|ciprofloxacin
P08914388A1645|150 161|levofloxacin
P08914388A1645|167 176|OPC-17116*
P08914388A1645|175 180|NM-394
P08914388A1645|183 190|sequence
P08914522A0118|3 11|STE20 gene
P08914522A0118|21 33|protein kinase
P08914522A0118|45 71|pheromone signal transduction
P08914522A0118|107 112|screen
P08914522A0118|132 142|suppressors
P08914522A0118|161 173|G beta mutation
P08914532A0598|4 9|enzyme
P08914532A0598|33 57|endohydrolase isoenzyme X-I
P08915051T0000|8 23|resonance imaging
P08915051T0000|38 46|arthritis
P08915508A0000|0 6|Moloney
P08915508A0000|13 25|leukemia virus
P08915508A0000|62 68|vectors
P08915508A0000|109 123|trans-activator
P08915508A0000|125 137|transcription
P08915508A0000|146 155|expression
P08915508A0000|162 180|hammerhead ribozymes
P08915508A0000|211 219|sequences
P08915508A0000|229 240|group antigen
P08915508A0000|246 253|protease
P08915508A0000|263 275|transcriptase
P08915508A0000|288 295|envelope
P08915508A0000|299 311|coding regions
P08915508A0000|318 344|immunodeficiency virus type-1
P08915508A0000|345 349|HIV-1
P08915559A0366|0 18|REM sleep deprivation
P08915559A0366|39 55|platform technique
P08916928A0950|7 13|ligands
P08916928A0950|43 48|effect
P08916928A0950|71 92|thymidine incorporation
P08916928A0950|94 101|PAE cells
P08916928A0950|115 132|PDGF beta-receptors
P08916960A0350|16 30|biopsy specimens
P08916960A0350|40 47|patients
P08916960A0350|68 78|alterations
P08916960A0350|93 101|bcl-2 gene
P08916960A0350|107 116|breakpoint
P08916960A0350|124 135|reading frame
P08916960A0350|141 147|regions
P08916960A1331|10 14|cases
P08916960A1331|29 36|DLL cells
P08916960A1331|42 52|alterations
P08916960A1331|55 72|bcl-2 gene sequences
P08916960A1331|78 93|breakpoint region
P08916960A1331|108 119|conservation
P08916960A1331|125 133|bcl-2 gene
P08916960A1331|150 162|translocation
P08916960A1331|176 189|transformation
P08916960A1331|195 201|FL cells
P08917270A0229|0 9|BACKGROUND
P08917270A0229|38 45|interval
P08917270A0229|50 57|exercise
P08917270A0229|72 77|marker
P08917270A0229|89 95|disease
P08917270A0229|110 118|substrate
P08917270A0229|129 138|QT syndrome
P08917435A0481|19 23|c-Jun
P08917435A0481|26 30|c-Fos
P08917435A0481|55 67|transcription
P08917435A0481|73 81|PAI-1 gene
P08917435A0481|101 107|finding
P08917435A0481|121 125|c-jun
P08917435A0481|129 154|c-fos oligodeoxynucleotides
P08917435A0481|196 209|PAI-1 synthesis
P08917449A0000|19 24|factor
P08917449A0000|33 44|neuropoietin
P08917449A0000|61 75|differentiation
P08917449A0000|82 89|survival
P08917449A0000|96 104|cell types
P08917449A0000|129 139|populations
P08917696A0485|12 20|mechanism
P08917696A0485|23 39|fos/jun activation
P08917696A0485|73 85|mobility shift
P08917696A0485|97 112|expression assays
P08917696A0485|115 136|reporter gene constructs
P08917696A0485|147 162|response elements
P08917696A0485|166 202|12-O-tetradecanoyl-phorbol-13-acetate
P08917696A0485|208 212|serum
P08917696A0485|239 250|hydrocarbons
P08917696A0485|269 276|jun genes
P08917696A0485|292 305|luciferase gene
P08917696A0485|314 320|control
P08917696A0485|339 346|promoter
P08918456A0455|10 17|sequence
P08918456A0455|21 31|interaction
P08918456A0455|57 64|tyrosine
P08918456A0455|67 72|anchor
P08918456A0455|83 90|arginine
P08918456A0455|93 101|position Y
P08918456A0455|107 113|leucine
P08918456A0455|116 124|position Y
P08918464A0225|18 22|Ba/F3
P08918464A0225|28 32|cells
P08918464A0225|33 39|BaF/STK
P08918464A0225|62 67|growth
P08918464A0225|94 119|mouse erythroleukaemia cells
P08918464A0225|149 157|apoptosis
P08918810A0967|7 11|DNase
P08918810A0967|13 24|footprinting
P08918810A0967|35 44|OxyR-C199S
P08918810A0967|81 86|strand
P08918810A0967|98 128|protection pattern characteristic
P08918885A0811|26 39|GST-Dig1 fusion
P08918885A0811|44 50|absence
P08918885A0811|61 72|yeast protein
P08918885A1087|2 9|contrast
P08918885A1087|10 22|dig1 dig2 cells
P08918885A1087|43 52|agar medium
P08918885A1087|61 73|dig1 dig2 ste12
P08918885A1087|80 85|mutant
P08918885A1087|167 179|growth pathway
P08918918T0000|9 18|activation
P08918918T0000|24 39|HIV-1 LTR promoter
P08918918T0000|50 59|Tat protein
P08918918T0000|86 101|trans-activation
P08918934A0424|0 9|Comparison
P08918934A0424|15 23|sequences
P08918934A0424|29 46|xFxFG repeat regions
P08918934A0424|57 61|Nsplp
P08918934A0424|146 152|repeats
P08918934A0424|182 188|linkers
P08919289A0402|14 19|report
P08919289A0402|35 43|resection
P08919289A0402|81 86|tissue
P08919289A0402|113 120|vena cava
P08919907A0763|9 18|expression
P08919907A0763|21 25|VSF-1
P08919907A0763|28 38|protoplasts
P08919907A0763|64 73|activation
P08919907A0763|92 99|promoter
P08919986A1262|25 29|range
P08919986A1262|39 45|dosages
P08919986A1262|45 54|advantages
P08919986A1262|58 70|disadvantages
P08919986A1262|118 124|results
P08919986A1262|147 156|literature
P08920499A0164|0 22|Blood sampling procedures
P08921387A1182|0 7|Analysis
P08921387A1182|36 48|splicing event
P08921387A1182|81 88|gene GPR2
P08921387A1182|109 117|mechanism
P08921387A1182|133 143|EZH1 protein
P08921387A1182|168 173|domain
P08921667A0294|14 26|input function
P08921667A0294|36 40|value
P08921667A0294|43 60|distribution volume
P08921667A0294|75 89|rCBF measurement
P08921667A0294|95 100|method
P08921667A0294|129 133|study
P08921667A0294|145 154|volunteers
P08921865A1293|36 50|DNA binding motif
P08921865A1293|70 86|terminase proteins
P08921865A1293|89 94|T4 gp17
P08921865A1293|132 143|ssDNA regions
P08921865A1293|171 175|T4DNA
P08922344A1539|34 41|subjects
P08922344A1539|55 69|xanthine oxidase
P08922344A1539|84 94|association
P08922344A1539|99 111|blood pressure
P08922344A1539|134 140|factors
P08922344A1539|162 166|cause
P08922344A1539|169 174|effect
P08922344A1539|177 188|hypertension
P08922384A0466|0 13|Immunoblotting
P08922384A0466|36 43|proteins
P08922384A0466|61 71|08L antibody
P08922384A0466|84 93|08L epitope
P08922384A0466|99 109|carboxyl end
P08922384A0466|115 121|protein
P08922385A0622|30 39|inhibition
P08922385A0622|61 71|proteolysis
P08922385A0622|77 102|beta-galactosidase tetramer
P08922385A0622|108 120|fusion subunit
P08922385A0622|124 129|detour
P08922385A0622|135 142|tetramer
P08922385A0622|148 155|lysosome
P08922390A0361|10 14|study
P08922390A0361|25 32|vinculin
P08922390A0361|51 57|domains
P08922390A0361|60 67|paxillin
P08922390A0361|93 100|paxillin
P08922390A0361|106 113|adhesion
P08922390A0361|123 127|motif
P08922390A0793|25 32|presence
P08922390A0793|41 51|binding site
P08922390A0793|55 62|vinculin
P08922390A0793|83 87|sites
P08922390A0793|127 133|stretch
P08922390A0793|138 147|amino acids
P08922390A2076|26 33|paxillin
P08922390A2076|49 57|adhesions
P08922390A2076|71 82|interactions
P08922390A2076|87 94|vinculin
P08922390A2076|137 149|demonstration
P08922390A2076|151 160|LIM domains
P08922390A2076|182 192|determinant
P08922390A2076|195 201|protein
P08922390A2076|213 224|localization
P08922390A2076|232 240|adhesions
P08922391A0304|25 33|structure
P08922391A0304|45 52|entirety
P08922391A0304|59 68|PDZ repeats
P08922391A0304|74 79|PDZ1-2
P08922391A0304|91 97|protein
P08922488A0187|7 12|agents
P08922488A0187|29 37|treatment
P08922488A0187|61 67|effects
P08923258A0353|0 6|Jerseys
P08923258A0353|23 38|Cu concentrations
P08923258A0353|46 54|Holsteins
P08923460A0565|0 9|RUSH-1 beta
P08923460A0565|28 34|version
P08923460A0565|37 47|RUSH-1 alpha
P08923460A0565|74 81|splicing
P08923460A0565|116 122|cloning
P08923469A1391|5 11|results
P08923469A1391|47 54|polarity
P08923469A1391|57 77|RXR heterodimer binding
P08923469A1391|89 111|hormone response elements
P08923469A1391|138 149|half-element
P08923470A0458|0 18|PPAR gamma mRNA levels
P08923470A0458|41 59|nM TNF alpha treatment
P08924211A0941|0 4|Exons
P08924211A0941|33 38|region
P08924211A0941|58 63|region
P08924211A0941|87 91|types
P08924211A0941|101 108|AST cDNAs
P08924381T0000|0 11|Growth factor
P08924381T0000|41 47|regimen
P08924381T0000|58 77|breast cancer patients
P08925545T0001|11 24|erythropoietin
P08925545T0001|25 31|r-HuEPO
P08925545T0001|37 45|treatment
P08925545T0001|48 53|anemia
P08925545T0001|64 70|myeloma
P08927169A0178|16 24|infection
P08927169A0178|29 36|body lice
P08927169A0178|52 56|times
P08927169A0178|61 68|patients
P08927169A0178|74 79|clinic
P08927169A0178|83 90|homeless
P08927169A0178|96 117|Community Health Service
P08927169A0178|120 126|Utrecht
P08927612T0000|9 20|p53 mutations
P08927612T0000|39 52|adenocarcinoma
P08927841A0053|51 55|death
P08927841A0053|78 85|activity
P08927841A0053|104 113|occurrence
P08929089A0231|10 18|ratio M/Pc
P08929089A0231|34 38|index
P08929089A0231|77 82|demand
P08929563T0000|0 15|Rat liver catalase
P08929563T0000|26 36|peroxisomes
P08929563T0000|52 72|tripeptide Ala-Asn-Leu
P08929563T0000|89 104|Ser-Lys-Leu motif
P08931388A0806|3 20|mobility shift assay
P08931388A0806|40 47|fragment
P08931388A0806|58 64|extract
P08931388A0806|84 89|sample
P08931388A0806|139 144|sample
P08931991A1026|24 31|evidence
P08931991A1026|55 73|transcription factor
P08931991A1026|88 97|regulation
P08931991A1026|109 124|myosin expression
P08932363A0807|7 19|E1A N-terminus
P08932363A0807|29 38|competitor
P08932363A0807|41 61|squelshing experiments
P08932363A0807|84 93|activation
P08932363A0807|96 103|E2F1/DP1
P08932363A0807|113 121|E1A mutant
P08932363A0807|129 145|CBP binding ability
P08932385T0000|5 15|Maf proteins
P08932385T0000|36 70|transcription factor TCF11/Nrf1/LCR-F
P08933487A0325|10 22|occasion water
P08933640A0000|3 8|effect
P08933640A0000|19 27|ingestion
P08933640A0000|40 64|energy sweetener erythritol
P08933640A0000|86 93|JW strain
P08933640A0000|101 107|rabbits
P08934533A0784|15 23|mutations
P08934533A0784|32 40|structure
P08934533A0784|69 77|chromatin
P08934540A0673|3 9|nm23-H1
P08934540A0673|9 19|nm23-H2 gene
P08934540A0673|35 47|activity ratio
P08934540A0673|68 75|cell line
P08935931A0787|0 9|CONCLUSION
P08935931A0787|21 42|diazepam administration
P08935931A0787|97 105|procedure
P08935931A0787|133 142|monitoring
P08935991A0844|3 29|nucleotide sequence alignment
P08935991A0844|37 41|mouse
P08935991A0844|56 60|shows
P08935991A0844|61 69|% identity
P08935991A0844|81 86|region
P08935991A0844|109 118|boundaries
P08935991A0844|139 143|sizes
P08935991A0844|149 155|introns
P08936128A0611|0 10|Discordance
P08936128A0611|16 28|cost dimension
P08936128A0611|83 89|control
P08936128A0611|99 110|disagreement
P08936640A0105|0 10|DATA SOURCES
P08936640A0105|24 30|studies
P08936640A0105|31 45|research studies
P08936640A0105|46 59|review articles
P08936640A0105|63 79|government reports
P08936640A0105|92 103|epidemiology
P08936640A0105|106 115|lung cancer
P08937112A0561|0 6|RESULTS
P08937112A0561|10 24|age distribution
P08937112A0561|34 38|years
P08937112A0561|55 59|years
P08937631A1223|12 18|changes
P08937631A1223|36 49|cell involution
P08937631A1223|53 62|hemorrhage
P08937631A1223|89 94|period
P08937631A1223|117 125|relevance
P08937631A1223|131 140|remodeling
P08937631A1223|153 163|vasculature
P08937981A0840|11 23|co-expression
P08937981A0840|38 48|p54 subunits
P08937981A0840|77 88|distribution
P08937981A0840|134 140|nucleus
P08937989A1365|3 9|results
P08937989A1365|52 58|regions
P08937989A1365|60 64|talin
P08937989A1365|69 73|actin
P08937989A1365|77 86|properties
P08937989A1365|97 103|regions
P08937989A1365|109 115|protein
P08938418A0099|7 19|embryo library
P08938420A0862|3 14|accumulation
P08938420A0862|30 38|LHA2 mRNAs
P08938420A0862|52 59|addition
P08938420A0862|71 76|sugars
P08938420A0862|84 92|induction
P08938420A0862|115 125|sugar uptake
P08938420A0862|129 138|metabolism
P08938420A0862|146 153|mannitol
P08938420A0862|157 173|3-O-methylglucose
P08938420A0862|188 203|mRNA accumulation
P08939891A0285|8 12|yeast
P08939891A0285|23 28|screen
P08939891A0285|86 90|clone
P08939966A0816|13 28|protein synthesis
P08939966A0816|47 59|embryogenesis
P08939966A0816|60 65|levels
P08939966A0816|68 72|SEC-1
P08939966A0816|86 96|mRNA decline
P08940132A1120|5 12|findings
P08940132A1120|24 40|fodrin proteolysis
P08940132A1120|60 67|activity
P08940132A1120|86 94|proteases
P08940132A1120|107 117|sensitivity
P08940132A1120|120 127|DEVD-CHO
P08940132A1120|144 155|contribution
P08940132A1120|160 164|CPP32
P08940132A1120|177 184|protease
P08940132A1120|202 206|CPP32
P08940132A1120|209 226|DEVD-CHO inhibition
P08940134A0705|32 42|fibroblasts
P08940134A0705|60 64|PTP1B
P08940134A0705|94 104|co-sediment
P08940134A0705|106 114|membranes
P08940134A0705|145 153|reticulum
P08940298A0962|9 16|residues
P08940298A0962|26 33|delta419
P08940298A0962|50 59|AF-2 domain
P08940298A0962|67 83|vitamin D3 receptor
P08940298A0962|89 104|estrogen receptor
P08940298A0962|115 122|receptor
P08940298A0962|156 163|activity
P08942999T0000|9 26|G-to-A substitution
P08942999T0000|36 40|codon
P08942999T0000|43 47|SREBP
P08942999T0000|67 73|protein
P08942999T0000|86 95|resistance
P08942999T0000|116 136|hamster ovary cell lines
P08943032A0000|18 30|tet-repressor
P08943032A0000|37 50|operator system
P08943032A0000|67 75|variation
P08943032A0000|81 85|yeast
P08943032A0000|96 100|assay
P08943032A0000|108 118|disruptions
P08943032A0000|136 147|interactions
P08943032A0000|174 182|selection
P08943354A0295|6 12|studies
P08943354A0295|30 34|SHP-1
P08943354A0295|47 54|function
P08943354A0295|57 80|Jak family tyrosine kinases
P08943354A0295|105 115|association
P08943354A0295|123 132|Tyk2 kinase
P08943354A0295|139 158|hyperphosphorylation
P08943354A0295|161 170|Jak kinases
P08943354A0295|176 189|motheaten cells
P08943354A0295|208 212|SHP-1
P08943928A1137|0 13|Administration
P08943928A1137|31 37|vaccine
P08943928A1137|46 53|outbreak
P08943934A0604|5 13|Theriault
P08943934A0604|22 33|improvements
P08943934A0604|45 52|exposure
P08943934A0604|95 102|findings
P08945479T0000|10 14|basis
P08945479T0000|18 27|activation
P08945479T0000|35 53|lymphocyte kinase Lck
P08945479T0000|58 80|tyrosine phosphorylation
P08945810T0001|9 18|morphology
P08945810T0001|65 71|mammals
P08946166A0568|9 15|results
P08946166A0568|45 52|FRDS gene
P08946668A0077|0 4|FK506
P08946668A0077|33 44|cyclosporin A
P08946668A0077|57 70|organ rejection
P08946668A0077|76 83|toxicity
P08947028A0992|5 11|results
P08947028A0992|23 27|Rho1p
P08947028A0992|49 62|reorganization
P08947028A0992|77 81|Bni1p
P08947028A0992|85 89|Pkc1p
P08948440A0628|3 22|ERH expression profile
P08948440A0628|64 79|animal hemisphere
P08948440A0628|81 87|oocytes
P08948440A0628|117 122|embryo
P08950144A0172|0 6|Waves N1
P08950144A0172|38 48|CNV paradigm
P08950144A0172|56 71|reaction time task
P08950144A0172|98 105|interval
P08950352A0525|37 43|samples
P08950352A0525|64 68|areas
P08950352A0525|90 94|rates
P08950352A0525|149 160|significance
P08951815A0465|0 9|Regulation
P08951815A0465|21 34|ASN2 expression
P08951815A0465|49 59|lacZ fusions
P08951815A0465|67 71|genes
P08951815A0465|92 96|times
P08951815A0465|115 121|absence
P08951815A0465|127 153|transcription activator Gcn4p
P08952483A0207|17 24|features
P08952483A0207|31 49|polypeptide fragment
P08952483A0207|57 83|hamster lysyl-tRNA synthetase
P08952483A0207|114 121|assembly
P08952483A0207|128 133|enzyme
P08952483A0207|143 164|multisynthetase complex
P08952796A0743|12 16|years
P08952796A0743|22 28|relapse
P08952965A1182|0 9|Comparison
P08952965A1182|15 24|proportion
P08952965A1182|61 73|substitutions
P08952965A1182|96 102|tamarin
P08952965A1182|110 120|region genes
P08952965A1182|134 142|reduction
P08952965A1182|154 169|framework regions
P08952965A1182|198 214|MHC contact regions
P08953340A0000|3 9|effects
P08953340A0000|16 29|vanadyl sulfate
P08953340A0000|30 34|VOSO4
P08953340A0000|38 46|mg/kg/day
P08953340A0000|49 61|anthropometry
P08953340A0000|62 76|body composition
P08953340A0000|80 90|performance
P08953340A0000|147 151|trial
P08953340A0000|161 185|weight-training volunteers
P08954725A1175|7 17|development
P08954725A1175|18 31|Tbx6 expression
P08954725A1175|64 71|mesoderm
P08954725A1175|80 86|tail bud
P08954725A1175|103 108|streak
P08954725A1175|114 119|source
P08954725A1175|122 129|mesoderm
P08955071T0000|0 9|Disruption
P08955071T0000|12 32|re-replication control
P08955071T0000|35 48|overexpression
P08955071T0000|64 75|fission yeast
P08955111A0989|3 9|results
P08955111A0989|28 35|promoter
P08955111A0989|39 53|enhancer regions
P08955111A0989|106 121|promoter activity
P08955111A0989|132 154|activin betaA subunit gene
P08955136A0606|31 41|PIP5KIalpha
P08955136A0606|51 63|PIP5K activity
P08955136A0606|97 112|PIP5KI antibodies
P08955159A0000|5 18|acid ceramidase
P08955159A0000|23 53|N-acylsphingosine amidohydrolase
P08955189A1198|10 27|NheI/BglII promoter
P08955189A1198|37 51|PMA inducibility
P08955189A1198|61 65|cells
P08955189A1198|93 99|element
P08955189A1198|120 144|EGR-1 transcription factors
P08955306A0224|0 7|Northern
P08955306A0224|13 24|blot analyses
P08955306A0224|40 47|cdh genes
P08955306A0224|63 70|subunits
P08955306A0224|80 91|reading frame
P08955306A0224|109 116|function
P08955306A0224|138 143|growth
P08955306A0224|146 152|acetate
P08955402A0288|3 9|classes
P08955402A0288|12 20|mutations
P08955402A0288|59 64|region
P08955402A0288|86 92|ability
P08955402A0288|100 109|histidinol
P08955402A0288|125 133|mutations
P08955402A0288|151 166|HOL1-1 background
P08955402A0288|180 189|expression
P08955402A0288|195 205|Hol1 protein
P08955928A0390|0 5|Damage
P08955928A0390|27 39|extravasation
P08955928A0390|41 49|Evans Blue
P08955928A0390|99 103|onset
P08958137A0534|0 23|Lipid hydroperoxide levels
P08958137A0534|26 31|plasma
P08958137A0534|70 74|study
P08958720A1204|7 12|degree
P08958720A1204|15 22|exercise
P08959062A0372|17 26|vasculitis
P08959062A0372|61 69|discovery
P08959062A0372|82 94|immunodeficit
P08959062A0372|116 122|Purtilo
P08959062A0372|123 130|syndrome
P08959117A0708|36 42|changes
P08959117A0708|60 69|hypoxaemia
P08959117A0708|88 94|disease
P08959117A0708|107 116|influences
P08959117A0708|133 142|ICU setting
P08959117A0708|146 157|measurements
P08959117A0708|197 210|reference group
P08959117A0708|247 256|hypoxaemia
P08959778A0292|22 32|differences
P08959778A0292|35 47|graft survival
P08959778A0292|55 60|groups
P08959778A0292|70 82|graft function
P08959778A0292|109 124|transplantations
P08959778A0292|125 142|retransplantations
P08960827A1169|5 11|results
P08960827A1169|28 35|GG motifs
P08960827A1169|65 77|transcription
P08960827A1169|88 98|insulin gene
P08960827A1169|101 111|association
P08960827A1169|119 125|binding
P08960827A1169|155 160|factor
P08961873T0000|15 34|coproporphyrin levels
P08961873T0000|37 44|patients
P08961873T0000|55 69|hepatitis C virus
P08961873T0000|88 108|immunodeficiency virus
P08962614A0000|3 15|determination
P08962614A0000|18 32|immunoglobulin E
P08962614A0000|38 47|antibodies
P08962614A0000|61 75|laboratory tests
P08962614A0000|78 92|skin-prick tests
P08962614A0000|108 126|challenge procedures
P08962614A0000|157 167|individuals
P08962614A0000|172 188|outcome predictors
P08962614A0000|197 204|children
P08964067A0188|0 9|Thrombosis
P08964067A0188|54 60|failure
P08964172A0221|0 5|Filter
P08964172A0221|9 34|cytocentrifuge preparations
P08964172A0221|40 44|urine
P08964172A0221|62 66|cases
P08964172A0221|93 102|aggregates
P08964172A0221|111 120|tumor cells
P08964172A0221|137 146|background
P08967870A0000|9 17|protocols
P08967870A0000|20 41|postmortem examinations
P08967870A0000|46 61|Moscow hospitals N
P08967963A1735|3 17|promoter segment
P08967963A1735|50 70|rat glioma cell line C6B4
P08967963A1735|92 106|cell line RSMT-A5
P08967963A1735|127 145|beta cell line RIN-5AH
P08967963A1735|180 193|alpha2c-AR gene
P08969495A0256|3 12|sequencing
P08969495A0256|35 48|mutation ts-A13
P08969495A0256|63 73|nrdE cistron
P08969495A0256|80 88|lethality
P08969495A0256|102 110|mutations
P08969495A0256|132 137|region
P08969495A0256|191 195|locus
P08969777A0771|21 26|scores
P08969777A0771|47 57|differences
P08969777A0771|60 67|patients
P08969777A0771|95 118|serum 25-OHD concentration
P08969777A0771|139 144|degree
P08969777A0771|147 155|paralysis
P08970352A0880|54 64|progression
P08970352A0880|71 76|sepsis
P08970951A0823|25 30|levels
P08970951A0823|41 50|hepatitis B
P08970951A0823|52 58|antigen
P08970951A0823|84 89|levels
P08970951A0823|101 111|Pol proteins
P08970951A0823|125 143|HBV DNA intermediates
P08970979A1246|2 9|contrast
P08970979A1246|10 17|extracts
P08970979A1246|29 35|virions
P08970979A1246|56 60|level
P08970979A1246|63 75|transcription
P08970979A1246|91 98|template
P08970979A1246|116 123|promoter
P08970984A0765|3 14|SCMV SNE sites
P08970984A0765|42 69|core recognition binding motifs
P08970984A0765|78 89|Rel/NFkappaB
P08970984A0765|97 124|YY1 class transcription factors
P08970984A0765|148 152|serum
P08970984A0765|155 178|tumor necrosis factor alpha
P08970991A0747|4 18|serum withdrawal
P08970991A0747|34 44|temperature
P08970991A0747|57 65|apoptosis
P08970991A0747|91 95|cells
P08971009A0860|16 22|problem
P08971009A0860|38 45|strategy
P08971009A0860|82 86|sites
P08971009A0860|95 102|sequence
P08971009A0860|156 165|DNA genomes
P08971721A1314|5 9|basis
P08971721A1314|23 29|studies
P08971721A1314|49 54|domain
P08971721A1314|92 97|domain
P08971835A1057|2 6|Group
P08971835A1057|27 35|alpha-MSH
P08971835A1057|45 55|reperfusion
P08971835A1057|56 60|BAEPs
P08971835A1057|105 111|Group II
P08971835A1057|124 140|reperfusion period
P08972182A0000|3 13|Fas receptor
P08972182A0000|23 39|signalling cascade
P08972182A0000|61 69|cell death
P08972182A0000|70 78|apoptosis
P08972182A0000|85 89|hours
P08972182A0000|92 112|receptor cross-linking
P08972182A0527|31 43|interleukin-1
P08972182A0527|57 62|enzyme
P08972182A0527|63 77|family proteases
P08972182A0527|86 94|apoptosis
P08972182A0527|99 105|studies
P08972182A0527|118 146|cowpox ICE inhibitor protein CrmA
P08972182A0527|159 190|tetrapeptide ICE inhibitor YVAD-CMK
P08972182A0527|197 231|tripeptide pan-ICE inhibitor Z-VAD-FMK
P08972211A0059|12 21|expression
P08972211A0059|82 90|transgene
P08972211A0059|116 123|sequence
P08972211A0059|138 145|sequence
P08972211A0059|181 189|enhancers
P08972232A0365|6 11|report
P08972232A0365|29 33|hGCN5
P08972232A0365|60 79|substrate specificity
P08972232A0365|81 85|yGCN5
P08973185T0061|3 8|effect
P08973185T0061|14 30|arginine mutations
P08973185T0061|42 56|phosphorylation
P08973185T0061|60 72|AAC expression
P08973527A0000|34 44|coat protein
P08973527A0000|61 67|regions
P08973527A0000|70 89|Agropyron mosaic virus
P08973527A0000|99 116|Hordeum mosaic virus
P08973630A0923|6 10|cases
P08973630A0923|25 37|Rac activation
P08973630A0923|47 59|Rho activation
P08973630A0923|77 91|Cdc42 activation
P08973630A0923|99 111|Rac activation
P08973630A0923|147 153|changes
P08973917A0632|7 11|cDNAs
P08973917A0632|35 42|PWP2 gene
P08973917T0000|0 8|Isolation
P08973917T0000|19 27|structure
P08973917T0000|36 42|homolog
P08973917T0000|48 52|yeast
P08973917T0000|61 77|tryptophan protein
P08973917T0000|85 95|gene mapping
P08973917T0000|97 103|21q22.3
P08974103A0451|0 7|Patterns
P08974103A0451|17 28|combinations
P08974103A0451|48 64|laboratory results
P08974103A0451|80 89|likelihood
P08974103A0451|103 107|all-2
P08974103A0451|114 120|pattern
P08974135A0052|16 23|thiamine
P08974135A0052|24 32|vitamin B1
P08974135A0052|33 42|deficiency
P08974135A0052|76 85|stomatitis
P08974135A0052|95 109|vitamin B1 levels
P08974135A0052|114 121|patients
P08974135A0052|143 152|stomatitis
P08974135A0052|160 166|members
P08974135A0052|170 181|control group
P08975532T0001|0 12|Liver injuries
P08975713A0454|12 22|cDNA library
P08975713A0454|28 32|probe
P08975713A0454|44 52|sequences
P08975713A0454|68 81|p53p2 start site
P08975713A0454|175 187|p53p2 promoter
P08976253A0637|23 33|correlation
P08976253A0637|41 45|serum
P08976253A0637|56 70|plasma PSA levels
P08977013A0788|3 14|implications
P08977013A0788|18 26|estimates
P08977013A0788|37 49|magnification
P08977013A0788|61 71|differences
P08977013A0788|77 91|specializations
P08977013A0788|94 99|foveal
P08977013A0788|113 118|vision
P08977235A0134|0 4|G-CSF
P08977235A0134|31 39|molecules
P08977235A0134|61 71|JAK2 kinases
P08977235A0134|77 100|STAT transcription factors
P08977235A0588|0 6|Mutants
P08977235A0588|17 32|tyrosine residues
P08977235A0588|49 54|domain
P08977235A0588|68 74|ability
P08977235A0588|85 89|STAT5
P08977235A0588|93 97|STAT1
P08977235A0588|114 118|STAT3
P08977235A0588|131 135|STAT5
P08977235A0588|139 153|STAT1 activation
P08977235A0588|168 198|receptor tyrosine phosphorylation
P08977401A0227|3 13|RI alpha gene
P08977401A0227|36 40|exons
P08977401A0227|50 56|lengths
P08977401A0227|68 74|introns
P08977401A0227|96 101|length
P08977401A0227|152 158|cloning
P08977401A0227|171 187|RI alpha pseudogene
P08977401A0227|202 207|region
P08977401A0227|242 248|RI alpha
P08977401A0227|283 293|RI alpha gene
P08977401A0227|308 318|leader exons
P08977401A0227|351 363|messenger RNAs
P08977401A0227|363 367|mRNAs
P08978690A0262|15 23|Rad3/Mec1
P08978690A0262|42 48|protein
P08978690A0262|73 95|DNA structure checkpoints
P08978690A0262|102 118|yeast model systems
P08978817A0620|2 9|addition
P08978817A0620|16 22|mutants
P08978817A0620|33 42|dim1-delta
P08978817A0620|45 50|dim2-1
P08978817A0620|57 80|endocytosis mutants end4-1
P08978817A0620|83 88|act1-1
P08978817A0620|107 119|growth defects
P08978817A0620|137 151|DIM gene products
P08978817A0620|188 194|pathway
P08978996A0000|3 16|identification
P08978996A0000|22 36|hepatitis C virus
P08978996A0000|47 51|cause
P08978996A0000|54 65|liver disease
P08978996A0000|72 87|dialysis patients
P08978996A0000|93 110|transplant patients
P08978996A0000|121 129|attention
P08978996A0000|135 146|epidemiology
P08978996A0000|153 158|impact
P08978996A0000|171 179|infection
P08978996A0000|187 199|patient groups
P08979089A1197|6 17|transfection
P08979089A1197|23 36|BL cell line Raji
P08979089A1197|41 50|constructs
P08979089A1197|61 81|core promoter mutations
P08979089A1197|106 112|Sp1 site
P08979089A1197|119 125|TATA box
P08979089A1197|144 153|activation
P08979089A1197|156 165|promoter P1
P08979089A1197|171 186|Ig kappa enhancers
P08979828A1561|16 27|interactions
P08979828A1561|47 54|behavior
P08980413A0500|18 23|ppSEPs
P08980413A0500|25 49|phase reversal relationship
P08980522A0280|39 45|protein
P08980533A1160|20 25|region
P08980533A1160|28 32|ENBP1
P08980533A1160|44 51|homology
P08980533A1160|55 61|protein
P08980533A1160|100 111|testis tissue
P08980536A1196|3 14|conservation
P08980536A1196|24 28|G-box
P08980536A1196|32 36|H-box
P08980536A1196|48 59|CHS promoters
P08980536A1196|75 84|importance
P08980536A1196|97 102|motifs
P08980819A0193|0 8|Mortality
P08980819A0193|18 22|ranch
P08980819A0193|66 71|groups
P08980819A0193|74 80|turkeys
P08980819A0193|106 110|birds
P08980819A0193|113 117|birds
P08980819A0193|138 142|event
P08980819A0193|159 170|insemination
P08981371A2049a|10 20|PIP2 content
P08981371A2049a|31 40|kDa protein
P08981371A2049a|63 76|CSF-1 treatment
P08981371A2049b|10 20|PIP2 content
P08981371A2049b|31 40|kDa protein
P08981371A2049b|63 76|CSF-1 treatment
P08985109A1285|32 37|margin
P08985109A1285|57 61|crest
P08985109A1285|80 85|aspect
P08985115A1571|8 21|identification
P08985115A1571|33 45|37LRP/p40 gene
P08985115A1571|61 65|study
P08985115A1571|92 100|isolation
P08985115A1571|135 147|understanding
P08985115A1571|161 170|mechanisms
P08985115A1571|184 196|up-regulation
P08985115A1571|202 211|expression
P08985115A1571|218 230|tumor invasion
P08985115A1571|234 243|metastasis
P08985122A0501|3 16|promoter region
P08985122A0501|43 47|group
P08985122A0501|49 76|transcription initiation sites
P08985122A0501|96 104|CAAT boxes
P08985122A0501|118 129|binding sites
P08985122A0501|136 157|transcription factor SP1
P08985122A0501|189 194|domain
P08985122A0501|197 205|CpG island
P08985122A0501|225 233|promoters
P08985122A0501|271 275|genes
P08985415A1096|3 24|STAT-1 signaling pathway
P08985415A1096|43 51|mechanism
P08985415A1096|55 64|activation
P08985415A1096|70 76|CAEV LTR
P08985415A1096|79 87|IFN-gamma
P08985415A1096|90 98|monocytes
P08986190A0927|0 10|Reperfusion
P08986190A0927|27 35|reduction
P08986190A0927|38 54|lactate production
P08986190A0927|70 77|increase
P08986190A0927|80 89|LDH release
P08986214A0000|32 39|response
P08986214A0000|42 49|patients
P08986214A0000|63 74|liver disease
P08986214A0000|88 95|patients
P08986214A0000|114 122|hepatitis
P08986214A0000|129 137|cirrhosis
P08986214A0000|153 174|hepatocyte growth factor
P08986214A0000|183 199|alpha-fetoprotein
P08986228A0000|0 7|Children
P08986228A0000|32 38|mothers
P08986228A0000|69 75|effects
P08986228A0000|107 119|malformations
P08986692A0306|0 11|INTERVENTION
P08986692A0306|24 43|hemostasis parameters
P08986692A0306|64 71|patients
P08986692A0306|82 87|IVF-ET
P08986770A0268|16 25|expression
P08986770A0268|31 49|I-POU/tI-POU message
P08986770A0268|77 81|phase
P08986770A0268|94 104|development
P08986770A0268|108 112|I-POU
P08986770A0268|127 139|splice variant
P08986812A1214|23 32|delta proAE
P08986812A1214|66 70|tumor
P08986812A1214|77 85|cell lines
P08986812A1214|113 119|effects
P08987009A0400|3 9|patient
P08987009A0400|31 43|prerequisites
P08987009A0400|55 61|freedom
P08987009A0400|83 95|psychoanalyst
P08987225A0675|13 22|risk factor
P08987225A0675|55 69|hepatitis C cases
P08987225A0675|74 80|history
P08987225A0675|92 98|drug use
P08987225A0675|110 119|proportion
P08987225A0675|122 126|cases
P08987225A0675|135 141|history
P08987225A0675|172 181|Queensland
P08988257A1256|0 8|Silencing
P08988257A1256|24 31|creation
P08988257A1256|35 42|telomere
P08988257A1256|58 74|reporter construct
P08988257A1256|78 86|insertion
P08988257A1256|98 102|yeast
P08988257A1256|111 124|repeat sequence
P08988257A1256|155 164|truncation
P08988913A0821|2 9|contrast
P08988913A0821|30 35|models
P08988913A0821|36 45|provisions
P08988913A0821|63 70|turnover
P08988913A0821|80 94|folate excretion
P08988913A0821|119 127|excretion
P08988913A0821|140 148|processes
P08989025A0359|25 32|channels
P08989025A0359|50 59|nifedipine
P08989025A0359|59 67|midazolam
P08989025A0359|70 83|concentrations
P08989025A0359|93 98|microM
P08989025A0359|127 135|responses
P08989763A0605|7 15|artifacts
P08989763A0605|42 54|visualization
P08989763A0605|60 68|diaphragm
P08990168A0688|8 23|p48 gene induction
P08990168A0688|37 41|STAT1
P08990168A0688|60 64|STAT1
P08990194A0000|3 10|syndrome
P08990194A0000|13 22|resistance
P08990194A0000|25 38|thyroid hormone
P08990194A0000|64 68|serum
P08990194A0000|73 87|thyroid hormones
P08990194A0000|88 94|failure
P08990194A0000|114 133|thyrotropin secretion
P08990194A0000|155 168|refractoriness
P08990194A0000|171 183|hormone action
P08990397A1437|24 30|mutants
P08990397A1437|55 65|photosystem
P08990397A1437|88 95|evidence
P08990397A1437|113 125|RNA processing
P08992115A0199|3 13|progression
P08992115A0199|21 30|bronchitis
P08992115A0199|55 73|blood concentrations
P08992115A0199|76 94|acute-phase proteins
P08992115A0199|95 107|KKS activation
P08992115A0199|113 117|blood
P08992115A0199|125 133|serotonin
P08992115A0199|137 153|lactic acid content
P08992115A0199|159 163|humor
P08993393A0498|21 32|implications
P08993393A0498|40 47|findings
P08993393A0498|55 64|physiology
P08993393A0498|76 87|hPACAP-R gene
P08993393T0000|12 20|signaling
P08993393T0000|39 52|gene activation
P08993393T0000|59 72|splice variants
P08993393T0000|92 100|adenylate
P08993393T0000|119 137|polypeptide receptor
P08993393T0000|138 145|hPACAP-R
P08993831A0000|14 30|muscle development
P08993831A0000|40 44|types
P08993831A0000|47 58|muscle fibers
P08993831A0000|92 103|combinations
P08993831A0000|121 132|gene products
P08993836A0699|14 20|results
P08993836A0699|25 31|respect
P08993836A0699|52 60|induction
P08993836A0699|66 79|HNF-3 alpha gene
P08993836A0699|93 102|epithelium
P08993836A0699|109 121|embryogenesis
P08994825A0000|0 9|BACKGROUND
P08994825A0000|10 16|Mitosis
P08994825A0000|35 44|maturation
P08994825A0000|53 58|factor
P08994825A0000|76 99|Cdc2/28-cyclin B complexes
P08994832A0782|7 16|expression
P08994832A0782|19 23|Apo-3
P08994832A0782|26 31|HEK293
P08994832A0782|34 42|HeLa cells
P08994832A0782|56 64|apoptosis
P08994968A0926|25 31|subunit
P08994968A0926|65 70|domain
P08994968A0926|83 89|subunit
P08995054A0618|0 9|Similarity
P08995054A0618|29 45|zinc knuckle region
P08995054A0618|47 52|region
P08995054A0618|69 76|gag genes
P08995054A0618|104 116|retroelements
P08995054A1368|16 20|HeT-A
P08995054A1368|26 34|sequences
P08995054A1368|51 56|region
P08995054A1368|61 80|insertions/deletions
P08995054A1368|87 92|codons
P08995054A1368|100 116|nucleotide changes
P08995410A0000|10 25|initiation factor
P08995410A0000|53 59|complex
P08995410A0000|83 89|complex
P08995410A0000|90 97|eIF2 x GTP
P08995410A0000|120 130|mRNA binding
P08995410A0000|148 154|subunit
P08995410A0000|210 224|ribosome subunit
P08995410A0000|240 245|factor
P08995410A1109|28 34|Hershey
P08995410A1109|37 46|co-workers
P08995410A1109|94 101|subunits
P08995410A1109|113 117|hPrt1
P08995614T0000|0 13|Identification
P08995614T0000|27 33|element
P08995614T0000|39 43|class
P08995614T0000|50 86|histocompatibility complex gene promoter
P08995614T0000|99 108|activation
P08995614T0000|121 129|sequences
P08995652A0812|3 9|results
P08995652A0812|34 40|capsids
P08995652A0812|106 115|amino acids
P08995652A0812|116 128|UL80.5 protein
P08995652A0812|158 167|amino acids
P08995652A0812|173 185|UL80.5 protein
P08995652A0812|216 225|amino acids
P08995652A0812|231 243|UL26.5 protein
P08995652A0812|249 255|capsids
P08995652A0812|273 283|interaction
P08995652A0812|289 301|UL80.5 protein
P08995652A0812|324 331|assembly
P08995652A0812|339 345|capsids
P08995652A0812|368 375|sequence
P08995652A0812|387 396|amino acids
P08995652A0812|402 414|UL80.5 protein
P08995652A0812|428 439|RRIFVA ALNKLE
P08995652A0812|442 453|RRIFVAAMMKLE
P08995652A0812|456 471|self-interaction
P08995652A0812|477 492|scaffold proteins
P08995652A0812|505 514|sequences N
P08995652A0812|528 549|maturation cleavage site
P08995652A0812|557 562|UL26.5
P08995652A0812|565 578|UL80.5 proteins
P08995652A0812|599 616|scaffold structures
P08995659A0563|9 29|region splice junctions
P08995659A0563|66 74|infection
P08995659A0563|90 114|sequencing RNA-PCR products
P08995659A0563|128 134|primers
P08995659A0563|148 159|splice region
P08995681A0518|2 6|ICP27
P08995681A0518|40 44|forms
P08995681A0518|54 60|protein
P08996730A1146|26 46|vibration measurements
P08996730A1146|48 66|employment durations
P08996730A1146|75 85|uncertainty
P08996730A1146|90 99|variations
P08996730A1146|102 115|tool conditions
P08996730A1146|116 128|grinder wheels
P08996730A1146|143 154|difficulties
P08996730A1146|157 167|measurement
P08997490A1127|0 9|C/EBP beta V
P08997490A1127|35 40|subset
P08997490A1127|43 52|C/EBP sites
P08997490A1127|64 71|DBP sites
P08997490A1127|78 93|oligonucleotides
P08997490A1127|113 120|contexts
P08997490A1127|126 132|albumin
P08997490A1127|136 166|cholesterol hydroxylase promoters
P08997532A0116|34 51|IgE immunoglobulins
P08997532A0116|57 64|Toxocara
P08997532A0116|89 96|antigens
P08997532A0116|121 134|ELISA technique
P08998115A0114|0 20|SUMMARY BACKGROUND DATA
P08998115A0114|21 32|Melanoma care
P08998115A0114|70 74|years
P08998115A0114|81 91|controversy
P08998115A0114|102 121|lymph node dissections
P08998115A0114|128 134|disease
P08999414A0819|3 13|differences
P08999414A0819|19 27|subgenera
P08999414A0819|33 48|genus Dermacentor
P08999857A0801|11 15|E-box
P08999857A0801|21 27|context
P08999857A0801|41 46|region
P08999857A0801|78 88|enhancement
P08999857A0801|106 113|activity
P08999857A0801|119 124|alpha1
P08999857A0801|127 146|collagen gene promoter
P08999882T0000|0 9|Expression
P08999882T0000|20 25|traits
P08999882T0000|38 46|beta cells
P09000049A1341|25 33|complexes
P09000049A1341|62 74|Max activities
P09000049A1341|88 104|cell proliferation
P09000108A0330|3 22|transcription product
P09000108A0330|27 32|kb mRNA
P09000108A0330|68 76|consensus
P09000108A0330|86 107|polyadenylation signals
P09000108A0330|139 165|translation termination codon
P09000146T0000|10 16|changes
P09000146T0000|46 55|c-src genes
P09000146T0000|73 91|sequence alterations
P09000589A0000|3 12|resurgence
P09000589A0000|29 35|malaria
P09000589A0000|50 59|evaluation
P09000589A0000|77 82|agents
P09000632A2341|5 14|p51 subunit
P09000632A2341|18 33|Cys181 side-chain
P09000632A2341|54 62|direction
P09000632A2341|68 83|Tyr181 side-chain
P09000632A2341|98 104|complex
P09001213A1111|17 34|level transcription
P09001213A1111|72 85|chromosome ends
P09001213A1111|87 98|P. falciparum
P09001213A1111|158 172|expression sites
P09001213A1111|176 183|var genes
P09001245A0187|0 5|NUP145
P09001245A0187|59 64|screen
P09001313A0000|0 9|Prevalence
P09001313A0000|28 36|breathing
P09001313A0000|74 78|women
P09001667A0312|5 9|cases
P09001667A0312|13 23|antigenemia
P09001667A0312|52 70|day post-vaccination
P09001828A0222|1 5|total
P09001828A0222|27 31|years
P09001828A0222|66 75|physicians
P09001828A0222|114 122|treatment
P09001828A0222|139 143|study
P09002648A0202|0 4|BCL-2
P09002648A0202|7 15|inhibitor
P09002648A0202|18 26|apoptosis
P09002648A0202|34 40|variety
P09002648A0202|43 51|cell types
P09002648A0202|99 107|cell death
P09002672A0439|7 17|translation
P09002672A0439|23 31|mTRF1 cDNA
P09002672A0439|45 54|kDa protein
P09002672A0439|72 83|repeat arrays
P09002672A0439|104 108|mTRF1
P09002672A0439|125 143|sequence specificity
P09002672A0439|146 150|hTRF1
P09002672A0439|161 166|arrays
P09002672A0439|169 181|TTAGGG repeats
P09002672A0439|185 200|binding substrate
P09002672A0439|205 210|TTAGGC
P09002672A0439|214 226|TTGGGG repeats
P09003001A1593|33 39|protein
P09003001A1593|77 83|factors
P09003001A1909|3 15|E-box sequence
P09003001A1909|21 31|SE2 fragment
P09003001A1909|37 55|transferrin promoter
P09003001A1909|59 64|CATCTG
P09003001A1909|80 88|gel shifts
P09003001A1909|94 115|consensus E-box elements
P09003001A1909|116 121|CANNTG
P09003311A0478|7 17|DNA fragment
P09003311A0478|50 58|porin gene
P09003311A0478|64 68|porCa
P09003311A0478|83 89|regions
P09003312A0740|11 17|AT-PHH1
P09003312A0740|25 31|AT-PHH1
P09003312A0740|35 51|AT-PHH1 delta C-513
P09003312A0740|98 112|photolyase genes
P09003312A0740|112 116|cDNAs
P09003312A0740|148 152|yeast
P09003312A0740|171 177|mutants
P09003312A0740|205 209|light
P09003410A0000|8 18|p100 protein
P09003410A0000|43 53|coactivator
P09003410A0000|71 75|virus
P09003410A0000|83 89|antigen
P09003462A0792|14 26|mutation sites
P09003462A0792|48 52|SL196
P09003462A0792|52 56|SL126
P09003462A0792|71 80|nrdB intron
P09003462A0792|91 103|self-splicing
P09003463A0198|4 9|report
P09003463A0198|21 29|isolation
P09003463A0198|33 48|characterization
P09003463A0198|62 67|region
P09003463A0198|95 106|RII alpha gene
P09003617A0000|1 6|cohort
P09003617A0000|16 23|children
P09003617A0000|41 46|months
P09003617A0000|51 55|years
P09004304A0000|14 18|study
P09004304A0000|32 46|reproducibility
P09004304A0000|50 55|number
P09004304A0000|68 83|clearance methods
P09004304A0000|89 114|chromium-51 ethylenediamine
P09004304A0000|132 140|51Cr-EDTA
P09004304A0000|172 191|blood sample technique
P09004504A0000|10 18|structure
P09004504A0000|26 38|bp DNA fragment
P09004504A0000|49 55|pla gene
P09004504A0000|64 83|plasminogen activator
P09004504A0000|90 95|origin
P09004504A0000|98 108|replication
P09004504A0000|123 149|Yersinia pestis plasmid pYP358
P09004987T0001|0 21|Serotonin concentration
P09004987T0001|27 31|blood
P09004987T0001|34 41|patients
P09004987T0001|57 61|fever
P09004987T0001|71 78|syndrome
P09005273A0322|0 18|MAIN OUTCOME MEASURES
P09005273A0322|19 30|Associations
P09005273A0322|33 38|factor
P09005273A0322|55 63|syndromes
P09005273A0322|68 78|risk factors
P09005273A0322|82 101|chemical interactions
P09005273A0322|113 133|butyrylcholinesterase
P09005273A0322|137 160|neuropathy target esterase
P09005273A1558|0 9|CONCLUSION
P09005273A1558|14 28|Gulf War veterans
P09005273A1558|60 68|syndromes
P09005273A1558|80 87|exposure
P09005273A1558|90 101|combinations
P09005273A1558|104 112|chemicals
P09005273A1558|124 144|butyrylcholinesterase
P09005273A1558|148 171|neuropathy target esterase
P09005609A0299|0 17|Control examination
P09005609A0299|46 51|period
P09005836A0977|2 12|correlation
P09005836A0977|33 38|horses
P09005836A0977|44 56|antibody level
P09005979A0841|3 9|GHR mRNA
P09005979A0841|9 21|GHBP mRNA ratio
P09005979A0841|59 73|differentiation
P09006007A0997|3 9|results
P09006007A0997|52 59|UGA codon
P09006007A0997|84 93|conditions
P09006007A0997|112 122|SelB protein
P09006007A0997|152 162|specificity
P09006007A0997|177 187|interaction
P09006007A0997|199 211|compatibility
P09006007A0997|227 233|complex
P09006007A0997|241 248|ribosome
P09006010A0527|3 25|linker-peptide insertion
P09006010A0527|31 43|RsaA C terminus
P09006010A0527|44 52|amino acid
P09006010A0527|61 66|effect
P09006010A0527|69 85|S-layer biogenesis
P09006010A0527|98 106|amino acid
P09006010A0527|119 127|secretion
P09006010A0527|133 139|protein
P09006010A0527|170 184|secretion signal
P09006010A0527|202 210|amino acid
P09006010A0527|228 236|amino acid
P09006022A0252|17 28|gene products
P09006022A0252|32 39|cvaA gene
P09006022A0252|72 78|control
P09006022A0252|81 103|T7 RNA polymerase promoter
P09006051A1162|12 19|homology
P09006051A1162|21 63|carboxyphosphonoenolpyruvate phosphonomutase
P09006051A1162|99 105|homolog
P09006051A1162|111 139|carnation Dianthus caryophyllus
P09006051A1162|165 172|archaeal
P09006051A1162|184 199|citrate synthases
P09006051A1162|212 219|homology
P09006051A1162|221 225|yeast
P09006051A1162|229 252|Bacillus subtilis proteins
P09006051A1162|262 269|function
P09006051A1162|282 289|homology
P09006051A1162|291 316|acetyl coenzyme A synthetases
P09006555A0738|0 18|MAIN OUTCOME MEASURES
P09006555A0738|39 50|hemodynamics
P09006555A0738|59 79|blood gas determination
P09006555A0738|95 107|lavage protein
P09006555A0738|111 127|neutrophil content
P09006555A0738|128 149|neutrophil oxidant burst
P09006555A0738|150 175|lung myeloperoxidase content
P09006555A0738|179 194|scanning electron
P09006555A0738|207 213|studies
P09006902A0370|34 38|MEKK3
P09006910A0000|16 25|mechanisms
P09006910A0000|54 60|control
P09006910A0000|63 79|retinoid X receptor
P09006910A0000|85 98|gene expression
P09006910A0000|109 114|region
P09006910A0000|125 140|RXRgamma2 isoform
P09006914A0812|42 48|nucleus
P09006914A0812|59 63|c-JUN
P09006914A0812|67 71|ATF-2
P09006914A1127|3 9|effects
P09006914A1127|31 35|forms
P09006914A1127|41 63|JNK/p38 signaling pathway
P09006914A1127|79 88|activation
P09006914A1127|96 102|kinases
P09006914A1127|132 155|E-selectin gene expression
P09006935A0590|13 21|CTC repeat
P09006935A0590|27 34|affinity
P09006935A0590|66 79|consensus GC box
P09006936T0000|0 13|Identification
P09006936T0000|19 24|region
P09006936T0000|40 46|protein
P09006936T0000|72 77|domain
P09006936T0000|80 98|glycoprotein IBalpha
P09008301A0193|6 16|enzyme forms
P09008301A0193|50 67|autoprocessing site
P09008301A0193|99 105|protein
P09008301A0193|127 133|studies
P09009208A0337|3 8|primer
P09009208A0337|23 30|cleavage
P09009208A0337|48 52|bases
P09009208A0337|65 71|Tf1 mRNA
P09010223A0667|35 39|SAP1a
P09010223A0667|45 52|EWS-FLI1
P09010223A0667|73 84|PU.1 proteins
P09010223A0667|95 103|complexes
P09010223A0667|118 125|Egr1 SREI
P09010223A1850|4 11|R-domain
P09010223A1850|26 36|interaction
P09010223A1850|56 64|mechanism
P09010223A1850|92 99|EWS-FLI1
P09010223A1850|120 127|function
P09010223A1850|136 158|ETS transcription factors
P09010223A1850|164 173|regulation
P09010223A1850|179 186|Egr1 gene
P09011591A0309|8 13|number
P09011591A0309|16 24|specimens
P09011591A0309|37 46|nonsmokers
P09011591A0309|52 58|smokers
P09011744A0790|20 28|locations
P09011744A0790|38 64|NMDA receptor channel subunits
P09011744A0790|68 74|epsilon
P09011744A0790|76 81|Grin2a
P09011744A0790|82 88|epsilon
P09011744A0790|90 95|Grin2b
P09011744A0790|96 102|epsilon
P09011744A0790|104 109|Grin2c
P09011744A0790|110 116|epsilon
P09011744A0790|118 123|Grin2d
P09011744A0790|134 138|Grinl
P09011744A0790|138 145|subunits
P09011744A0790|180 200|backcross mapping panel
P09011744A0790|212 218|crosses
P09011744A0790|221 230|C57BL/6JxM
P09011744A0790|290 296|spretus
P09011744A0790|297 307|F1xC57BL/6J
P09011745T0000|4 10|cloning
P09011745T0000|13 22|chick brain
P09011745T0000|74 86|acid receptors
P09011745T0000|94 105|conservation
P09011745T0000|108 116|structure
P09011745T0000|117 124|function
P09011745T0000|148 156|processes
P09011745T0000|170 178|receptors
P09012405A0785|14 18|TTD-A
P09012405A0785|22 32|XP-D defects
P09012405A0785|50 57|subunits
P09012405A0785|60 64|TFIIH
P09012405A0785|71 89|transcription factor
P09012405A0785|101 108|function
P09012405A0785|111 119|DNA repair
P09012636A0723|0 9|Adjustment
P09012636A0723|23 33|cholesterol
P09012636A0723|33 46|HDL cholesterol
P09012636A0723|47 59|triglycerides
P09012636A0723|67 73|smoking
P09012636A0723|85 92|pressure
P09012636A0723|111 121|association
P09012636A0723|129 138|fibrinogen
P09012636A0723|142 156|atherosclerosis
P09013499A0198|2 11|Experiment
P09013499A0198|36 44|injection
P09013499A0198|63 106|N-methyl-D-aspartate receptor antagonist MK-801
P09013499A0198|110 114|mg/kg
P09013499A0198|156 167|conditioning
P09013499A0198|224 231|controls
P09013760A0000|0 10|Cholesterol
P09013760A0000|21 42|cleavage cytochrome P450
P09013760A0000|43 48|CYP11A
P09013760A0000|49 55|P450scc
P09013760A0000|56 69|gene expression
P09013760A0000|83 95|gonadotropins
P09013760A0000|110 114|ovary
P09013760A0000|151 155|cells
P09015543A0210|11 18|solution
P09015543A0210|32 38|forearm
P09015757T0000|10 17|analysis
P09015757T0000|21 36|characterization
P09015757T0000|39 44|tissue
P09015757T0000|66 75|expression
P09015757T0000|86 101|bone sialoprotein
P09015799T0000|0 17|Serotonin receptors
P09015799T0000|20 33|suicide victims
P09015799T0000|43 52|depression
P09016566A0655|19 23|motif
P09016566A0655|45 50|number
P09016566A0655|62 69|BiP mRNAs
P09017443A0734|14 25|marker screen
P09017443A0734|46 55|occurrence
P09017443A0734|67 74|syndrome
P09017443A0734|86 91|effect
P09017443A0734|94 100|regimen
P09017443A0734|118 131|stratification
P09018122A1389|3 11|detection
P09018122A1389|14 27|ORF-1 sequences
P09018122A1389|35 40|tumors
P09018122A1389|49 53|proof
P09018122A1389|62 73|prerequisite
P09018122A1389|100 115|tumor development
P09018133A0244|12 19|analysis
P09018133A0244|24 31|evidence
P09018133A0244|53 64|relationship
P09018133A0244|72 77|PhHV-1
P09018133A0244|81 87|members
P09018133A0244|93 111|Varicellovirus genus
P09018133A0244|117 135|alpha-Herpesvirinae
P09018133A0244|144 154|herpesvirus
P09019302A0600|6 11|method
P09019302A0600|19 24|plasma
P09019302A0600|47 57|sensitivity
P09019302A0600|63 76|derivatization
P09019302A0600|81 95|sodium bisulfite
P09019302A0600|107 111|phase
P09020138A0833|29 35|complex
P09020138A0833|48 55|adhesion
P09020138A0833|61 74|tyrosine kinase
P09020138A0833|75 79|RAFTK
P09020138A0833|87 94|tyrosine
P09020138A0833|116 134|adapter molecule CrkL
P09020169A0552|24 33|homodimers
P09020172A0964|0 8|Complexes
P09020172A0964|11 16|qTBP42
P09020172A0964|38 43|strand
P09020172A0964|77 81|forms
P09020172A0964|98 103|strand
P09020172A0964|114 136|nM dissociation constants
P09020172A0964|148 156|complexes
P09020172A0964|210 217|Kd values
P09020856A0560|11 16|effect
P09020856A0560|59 69|MCK promoter
P09021684A1418|41 48|proteins
P09021684A1418|79 85|nucleus
P09021684A1418|112 129|repressor functions
P09021684A1418|145 157|NF-kappa B2p52
P09021684A1418|175 197|transactivation activity
P09022040A0263|7 25|L-plastin expression
P09022040A0263|62 67|humans
P09022040A0263|71 77|rodents
P09022040A0263|99 108|mechanisms
P09022040A0263|126 139|gene expression
P09022040A0263|156 160|cells
P09022040A0263|203 210|function
P09022040A0263|214 232|nucleotide sequences
P09022040A0263|252 273|L-plastin gene promoters
P09022632T0000|35 41|surgery
P09023197T0000|3 12|dnaK operon
P09023197T0000|15 30|Bacillus subtilis
P09023378A0959|8 17|expression
P09023378A0959|28 32|yeast
P09023378A0959|50 62|transcription
P09023378A0959|65 77|reporter genes
P09023378A0959|91 102|C-repeat/DRE
P09023378A0959|115 131|activator sequence
P09023378A0959|144 151|versions
P09023378A0959|157 166|DNA element
P09024039A0247|22 27|status
P09024039A0247|37 44|patients
P09024039A0247|56 62|variety
P09024039A0247|80 89|procedures
P09024039A0247|128 137|desflurane
P09024039A0247|139 148|isoflurane
P09024039A0247|153 163|ventilation
P09024097A0000|0 8|OBJECTIVE
P09024097A0000|57 61|women
P09024097A0000|87 99|complications
P09024097A0000|104 113|postpartum
P09024097A0000|119 126|ligation
P09024793A1325|5 37|electrophoresis mobility shift assay
P09024793A1325|50 57|extracts
P09024793A1325|71 75|cells
P09024793A1325|85 92|myogenin
P09024793A1325|107 111|E-box
P09024793A1325|117 130|enhancer region
P09024793A1325|136 142|MCK gene
P09024793A1325|152 159|presence
P09024793A1325|162 166|BMP-2
P09024805A0905b|13 29|promoter construct
P09024805A0905b|45 51|repeats
P09024805A0905b|55 70|consensus Sp1 site
P09024805A0905b|121 127|element
P09024805A0905b|131 143|BZLF1 promoter
P09024805A0905b|155 172|beta-globin TATA box
P09024805A0905b|182 205|phorbol ester inducibility
P09025122A0374|10 20|experiments
P09025122A0374|38 42|tasks
P09025122A0374|62 68|aspects
P09025122A0374|74 81|COWA task
P09025122A0374|122 132|performance
P09025549A0000|8 12|nurse
P09025549A0000|34 38|level
P09025549A0000|41 50|competence
P09025549A0000|76 88|practitioners
P09025549A0000|94 98|field
P09025549A0000|123 155|Vancouver sex therapist Bianca Rucker
P09025549A0000|179 185|network
P09025549A0000|188 197|colleagues
P09025549A0000|201 207|mentors
P09025549A0000|217 222|fields
P09025549A0000|247 255|continent
P09027346A1957|7 21|antibody binding
P09027346A1957|24 31|site IIIa
P09027346A1957|37 57|hCG-ectodomain complex
P09027346A1957|110 116|peptide
P09027506T0000|0 10|cDNA cloning
P09027506T0000|11 28|expression analysis
P09027506T0000|43 54|localization
P09027506T0000|72 79|homology
P09027506T0000|81 88|wheat eIF
P09027506T0000|108 113|eIF-4G
P09028089A0183|31 42|hypertension
P09028089A0183|66 74|blood flow
P09028089A0183|92 113|transplantation surgery
P09028308A0590|10 17|patients
P09028308A0590|37 49|mitroxantrone
P09028308A0590|69 89|bone marrow suppression
P09028308A0590|112 118|cohorts
P09028308A0590|134 138|G-CSF
P09028308A0590|140 152|micrograms/kg
P09028308A0590|175 184|completion
P09028308A0590|194 198|cycle
P09028308A0590|201 212|chemotherapy
P09028942A0000|45 50|factor
P09028942A0000|51 57|hGM-CSF
P09028942A0000|75 79|genes
P09028942A0000|85 89|c-fos
P09028942A0000|108 125|growth response gene
P09028942A0000|125 129|egr-1
P09028998A0143|2 6|order
P09028998A0143|29 35|control
P09028998A0143|63 69|outcome
P09028998A0143|73 78|amount
P09028998A0143|81 92|breast tissue
P09029091A0881|31 53|tyrosine phosphorylation
P09029091A0881|56 74|phospholipase C gamma
P09029091A0881|94 104|Jurkat cells
P09029091A0881|118 130|A2/HCP chimera
P09029104A0226|6 10|IGLL1
P09029104A0226|31 37|lineage
P09029104A0226|56 61|manner
P09029159A0000|3 12|interferon
P09029159A0000|44 48|dsRNA
P09029159A0000|55 74|Ser/Thr protein kinase
P09029159A0000|126 132|effects
P09029713A1120|42 48|control
P09029713A1120|53 59|amounts
P09029713A1120|65 77|activator SF-1
P09029713A1120|84 99|repressor COUP-TF
P09029713A1120|128 140|transcription
P09029956T0000|6 14|relations
P09029956T0000|21 30|management
P09029956T0000|41 58|structure formation
P09030581A0990|15 24|COS-7 cells
P09030581A0990|25 29|MKP-4
P09030581A0990|36 45|activation
P09030581A0990|48 57|MAP kinases
P09030581A0990|65 78|selectivity ERK
P09030581A0990|86 93|JNK/SAPK
P09030688A0435|2 12|rlf2 mutants
P09030688A0435|22 30|chromatin
P09030688A0435|51 59|silencing
P09030688A0435|72 88|Rap1p localization
P09030781A0734|4 10|kinases
P09030781A0734|41 51|roscovitine
P09030781A0734|61 72|cdc2/cyclin B
P09030781A0734|73 84|cdk2/cyclin A
P09030781A0734|85 96|cdk2/cyclin E
P09030781A0734|100 107|cdk5/p35
P09030781A0734|137 146|IC50 values
P09030781A0734|165 170|microM
P09030781A0734|213 225|cdk4/cyclin D1
P09030781A0734|229 241|cdk6/cyclin D2
P09030781A0734|266 276|roscovitine
P09030781A0734|287 292|microM
P09031639A0474|8 13|kb cDNA
P09031639A0474|28 39|reading frame
P09031639A0474|63 73|polypeptide
P09031639A0474|77 86|amino acids
P09031639A0474|112 119|position
P09031639A0474|119 126|position
P09031639A0474|141 151|U1-C protein
P09032233T0000|0 10|Interaction
P09032233T0000|13 17|Ets-1
P09032233T0000|24 50|POU-homeodomain protein GHF-1
P09032233T0000|50 54|Pit-1
P09032233T0000|86 99|gene expression
P09032248A0239|8 12|Pho85
P09032248A0239|30 38|viability
P09032248A0239|39 65|Pcl1,2-Pho85 kinase complexes
P09032248A0239|84 88|Start
P09032248A0239|94 100|absence
P09032248A0239|103 121|Cln1,2-Cdc28 kinases
P09032250A0257|8 12|yeast
P09032250A0257|23 28|system
P09032250A0257|31 36|screen
P09032250A0257|40 47|proteins
P09032250A0257|84 91|B subunit
P09032250A0257|96 118|CCAAT binding protein NF-Y
P09032250A0257|124 138|HeLa cDNA library
P09032254A0724|0 15|Enhancer activity
P09032254A0724|31 38|AP-1 site
P09032254A0724|55 63|sequences
P09032258A0395|0 6|Studies
P09032258A0395|12 28|HLA-DR-B7-1-LFA-3
P09032258A0395|35 47|transfectants
P09032258A0395|74 96|NF-AT DNA binding activity
P09032258A0395|121 137|B7-1 costimulation
P09032259A0150|12 21|activation
P09032259A0150|56 69|transformation
P09032259A0150|70 80|NIH 3T3 cells
P09032259A0150|89 97|functions
P09032259A0150|118 134|Ras transformation
P09032259A0972|11 24|Rac1 activation
P09032259A0972|41 49|induction
P09032259A0972|50 61|lamellipodia
P09032259A0972|97 120|Rac1 transforming activity
P09032267A0850|0 13|Overexpression
P09032267A0850|19 39|bZip interaction domain
P09032267A0850|79 87|cross talk
P09032267A0850|101 108|p45/NF-E
P09032275A1133|14 19|domain
P09032275A1133|57 74|AHC deletion mutants
P09032304T0000|0 13|Identification
P09032304T0000|34 54|transactivation domain
P09032304T0000|60 77|herpes simplex virus
P09032304T0000|88 98|protein ICP4
P09032328A0650|0 12|DNA sequencing
P09032328A0650|21 27|segment
P09032328A0650|41 56|gammaherpesvirus
P09032328A0650|66 70|locus
P09032328A0650|84 88|ORF11
P09032328A0650|91 95|ORF17
P09032328A0650|107 114|presence
P09032328A0650|145 156|gene products
P09032328A0650|173 180|proteins
P09034337A0251|0 6|Studies
P09034337A0251|18 22|cells
P09034337A0251|37 45|induction
P09034337A0251|58 65|tyrosine
P09034337A0251|73 87|phosphorylation
P09034337A0251|89 95|p34cdc2
P09034337A0251|103 110|response
P09034337A0251|113 121|DNA damage
P09035307A0000|77 83|adenoma
P09035307A0000|95 137|99mTc-methoxyisobutylisonitrile scintigraphy
P09035307A0000|138 147|99mTc-MIBI
P09035612T0000|7 23|endothelin release
P09035612T0000|27 37|infarct size
P09035612T0000|48 56|blood flow
P09035612T0000|71 78|function
P09035612T0000|87 96|infarction
P09035612T0000|100 110|reperfusion
P09036529A0343|3 8|workup
P09036529A0343|17 25|skin tests
P09036529A0343|31 42|microgram/ml
P09036529A0343|43 51|Pharmacia
P09036529A0343|52 62|measurement
P09036529A0343|73 80|serum IgE
P09036529A0343|85 92|RAST-CAP
P09036529A0343|93 101|Pharmacia
P09036529A0343|120 133|concentrations
P09036529A0343|140 152|Apis mellifera
P09036529A0343|161 171|Vespula spec
P09036529A0343|211 215|venom
P09036529A0343|216 225|Aquagen ALK
P09037032T0000|3 15|proliferation
P09037032T0000|40 44|P2P-R
P09037032T0000|55 61|domains
P09037032T0000|89 116|ribonucleoprotein association
P09037032T0000|120 129|Rb1 binding
P09037032T0000|144 153|expression
P09037032T0000|168 182|differentiation
P09037064A0183|6 16|application
P09037064A0183|30 47|canarypox ALVAC/HIV
P09037064A0183|49 55|vectors
P09037064A0183|58 74|vaccine immunogens
P09037064A0183|77 81|HIV-1
P09037064A0183|92 101|volunteers
P09037064A0183|113 124|CTL responses
P09037064A0183|139 144|number
P09037064A0183|147 155|vaccinees
P09037163A1652|3 11|relevance
P09037163A1652|19 26|elements
P09037163A1652|48 56|induction
P09037163A1652|59 76|gpc4 gene expression
P09038166A0818|0 7|Exons A1a
P09038166A0818|58 63|intron
P09038192A0846|13 21|inhibitor
P09038192A0846|22 29|PD098059
P09038192A0846|30 35|Dudley
P09038202A1951|34 51|repression activity
P09038202A1951|52 60|NRSF/REST
P09038202A1951|75 81|species
P09038202A1951|84 91|promoter
P09038202A1951|119 126|proteins
P09038202A1951|142 150|promoters
P09039744T0000|19 26|analysis
P09039744T0000|29 50|electro-encephalograms
P09039744T0000|61 72|sinc function
P09040011A1316|2 8|summary
P09040011A1316|18 25|activity
P09040011A1316|34 47|G1/S transition
P09040011A1316|58 68|thymoblasts
P09040011A1316|81 93|cell viability
P09040011A1316|97 108|transduction
P09040011A1316|123 139|activation signals
P09040011A1316|152 161|components
P09040011A1316|167 185|Ras/Raf/MAPK pathway
P09041123A0195|10 15|action
P09041123A0195|29 34|ligand
P09041123A0195|58 64|factors
P09041123A0195|112 120|responses
P09041123A0195|139 145|complex
P09042078A0202|24 31|incisors
P09042078A0202|37 45|direction
P09042078A0202|53 62|dimensions
P09042078A0202|75 85|jaw openings
P09042078A0202|91 98|subjects
P09042269A1007|5 12|findings
P09042269A1007|48 59|chemotherapy
P09042269A1007|95 100|cancer
P09042683A0492|3 18|FBF questionnaire
P09042683A0492|54 68|symptoms profile
P09042683A0492|86 93|disorder
P09042683A0492|126 133|disorder
P09042683A0492|137 149|schizophrenia
P09042755T0000|14 30|sigma factor sigmaB
P09042755T0000|53 62|regulation
P09042755T0000|68 77|sigB operon
P09042755T0000|80 87|response
P09042755T0000|90 100|growth phase
P09042755T0000|104 112|heat shock
P09042911A0626|7 22|promoter elements
P09042911A0626|35 48|glucocorticoid
P09042911A0626|65 74|regulation
P09042911A0626|85 89|liver
P09042911A0626|119 128|expression
P09042911A0626|157 164|sequence
P09043534A1600|20 28|decreases
P09043534A1600|34 47|alkalinization
P09043534A1600|61 67|minutes
P09043768A0139|16 26|biokinetics
P09043768A0139|45 54|indium-111
P09043768A0139|54 59|In-111
P09045636A0789|0 15|CD3 cross-linking
P09045636A0789|23 45|tyrosine phosphorylation
P09045636A0789|48 52|Sam68
P09045636A0789|65 70|T cells
P09045805A0945|17 26|expression
P09045805A0945|32 44|acoABCD operon
P09045805A0945|71 81|acoK mutants
P09045805A0945|94 100|plasmid
P09045805A0945|134 156|transactivating function
P09045805A0945|161 171|gene product
P09045842T0000|0 8|Mutations
P09045842T0000|14 18|alpha
P09045842T0000|30 37|subunits
P09045842T0000|40 52|RNA polymerase
P09045842T0000|59 68|expression
P09045842T0000|74 82|mer operon
P09045919A1250|22 29|evidence
P09045919A1250|36 44|existence
P09045919A1250|49 57|activator
P09045919A1250|70 80|combination
P09045919A1250|95 107|c-Rel proteins
P09045919A1250|121 148|transcription factor machinery
P09045919A1250|162 177|enhancer activity
P09045919A1250|188 194|control
P09045919A1250|200 207|IgH locus
P09045919A1250|214 235|B lymphocyte development
P09046013A0000|18 25|efficacy
P09046013A0000|63 83|calcium channel blocker
P09046013A0000|84 90|SNX-111
P09046013A0000|169 176|ischemia
P09046013A0000|186 193|ligation
P09046013A0000|210 222|carotid artery
P09046013A0000|235 243|occlusion
P09046013A0000|268 273|artery
P09046090T0000|3 7|genes
P09046090T0000|19 45|transcription factor yTAFII60
P09046090T0000|49 59|G4p1 protein
P09046090T0000|72 89|glucose transporter
P09046090T0000|109 121|kb DNA fragment
P09046090T0000|161 173|chromosome VII
P09046186A0189|3 11|protector
P09046186A0189|31 42|fall distance
P09046186A0189|46 53|fracture
P09046186A0189|59 68|trochanter
P09046384A0403|0 21|Marinol/marijuana usage
P09046384A0403|53 58|counts
P09046384A0403|69 81|amylase levels
P09046384A0403|91 101|DDI subgroup
P09047252A0209|0 6|METHODS
P09047252A0209|18 25|patients
P09047252A0209|54 62|resection
P09047252A0209|91 99|AFP levels
P09047252A0209|106 110|ng/ml
P09047252A0209|130 134|study
P09047344A0000|18 24|peptide
P09047344A0000|31 37|peptide
P09047344A0000|41 50|amino acids
P09047344A0000|62 73|muscle myosin
P09047344A0000|79 89|chain kinase
P09047344A0000|103 112|calmodulin
P09047344A0000|125 132|affinity
P09048617A0648|25 46|tyrosine kinase receptor
P09048617A0648|77 82|nature
P09048617A0648|88 97|cAMP effect
P09049198A0289|6 12|insight
P09049198A0289|28 38|involvement
P09049198A0289|48 62|liver cell growth
P09049198A0289|65 74|expression
P09049198A0289|78 87|regulation
P09049198A0289|93 99|p21 gene
P09049198A0289|120 125|models
P09049198A0289|128 144|liver regeneration
P09049198A0289|148 156|specimens
P09049198A0289|164 176|liver diseases
P09049270A0488|0 19|Northern blot analysis
P09049270A0488|51 61|transcripts
P09049270A0488|71 75|genes
P09049270A0488|94 99|leaves
P09049270A0488|104 108|roots
P09049270A0488|111 122|tomato plants
P09049270A0488|135 142|addition
P09049270A0488|150 158|metal ions
P09049270A0488|160 173|characteristic
P09049304A1193|2 23|co-transfection studies
P09049304A1193|40 60|Egr-1 expression vector
P09049304A1193|69 89|VPF/VEGF transcription
P09049304A1193|108 118|AP-2 protein
P09049304A1193|162 183|VPF/VEGF gene expression
P09049306A0830|3 9|HBP gene
P09049306A0830|27 31|exons
P09049306A0830|65 74|chromosome
P09049313A0116|6 14|instances
P09049313A0116|40 49|expression
P09049313A0116|66 74|proteases
P09049313A0116|89 96|cleavage
P09049313A0116|99 119|initiation factor eIF4G
P09050689A0685|18 25|ablation
P09050689A0685|37 41|SnET2
P09050689A0685|64 77|administration
P09050689A0685|87 95|treatment
P09050689A0685|109 113|hours
P09050847A0180|6 10|class
P09050847A0180|28 43|TBP-TAF complexes
P09050847A0180|60 65|murine
P09050847A0180|74 78|class
P09050847A0180|89 127|transcription initiation factor TIF-IB/SL1
P09050847A0180|147 157|selectivity
P09050847A0180|174 181|promoter
P09050849A0000|0 10|Cytohesin-1
P09050849A0000|12 18|protein
P09050849A0000|29 33|cells
P09050849A0000|45 50|system
P09050849A0000|76 82|homolog
P09050849A0000|111 125|Sec7 gene product
P09050849A0000|142 157|protein transport
P09050849A1459|6 11|regard
P09050849A1459|55 61|ARF-GEP
P09050849A1459|79 84|domain
P09050861A0903|16 29|identification
P09050861A0903|49 58|pets factor
P09050867A0542|5 12|elements
P09050867A0542|22 32|binding site
P09050867A0542|36 47|Krox proteins
P09050867A0542|61 66|factor
P09050867A0542|70 81|octamer motif
P09050867A0542|91 113|POU-homeodomain proteins
P09050867A0542|123 138|TN control element
P09051656A0390|0 12|Tissue samples
P09051656A0390|67 76|withdrawal
P09051656A0390|91 109|day morphine infusion
P09051656A0390|132 139|subjects
P09053309A1103|20 40|floor plate development
P09053309A1103|43 52|oep mutants
P09053309A1103|69 75|absence
P09053309A1103|81 100|floor plate inducer shh
P09053494A0612|0 6|RESULTS
P09053494A0612|10 16|medians
P09053494A0612|37 46|cell yields
P09053494A0612|49 56|patients
P09053494A0612|68 77|paclitaxel
P09053494A0612|102 106|G-CSF
P09053494A0612|169 182|reference group
P09053494A0612|201 205|G-CSF
P09053835A0865|9 19|p53 activity
P09053835A0865|51 57|p53 mRNA
P09053835A0865|62 74|protein levels
P09053973A1252|0 9|CONCLUSION
P09053973A1252|17 30|administration
P09053973A1252|33 43|misoprostol
P09053973A1252|77 82|effect
P09053973A1252|94 101|patients
P09053973A1252|106 112|ascites
P09055221A0288|3 11|intensity
P09055221A0288|17 21|SSTEs
P09055221A0288|26 30|order
P09055221A0288|33 41|magnitude
P09055221A0288|83 96|signal contrast
P09055221A0288|102 108|effects
P09056761A0000|12 16|cells
P09056761A0000|26 36|termination
P09056761A0000|39 49|translation
P09056761A0000|60 65|codons
P09056761A0000|88 92|cause
P09056761A0000|96 102|variety
P09056761A0000|124 129|events
P09056761A0000|144 152|mRNA decay
P09056761A0000|158 166|cytoplasm
P09056761A0000|172 178|nucleus
P09056761A0000|186 204|splice site selection
P09057325A0177|3 8|region
P09057325A0177|11 21|plasmid pCM2
P09057325A0177|33 55|pathogenicity locus pat-1
P09057325A0177|67 82|deletion analysis
P09057325A0177|86 107|complementation studies
P09057325A0177|117 137|Bg/II/SmaI DNA fragment
P09057648A0422|9 22|cotransfection
P09057648A0422|25 31|tat cDNA
P09057648A0422|34 49|sense orientation
P09057648A0422|50 54|tat/S
P09057648A0422|68 74|plasmid
P09057648A0422|88 100|c-fos promoter
P09057648A0422|121 125|front
P09057648A0422|139 170|chloramphenicol acetyltransferase
P09057648A0422|203 213|CAT activity
P09057648A0422|214 224|Jurkat cells
P09057648A0422|239 246|addition
P09057648A0422|258 266|calf serum
P09057648A0422|274 304|micrograms/mL phytohemagglutinin
P09057648A0422|311 338|mol/L phorbol myristate acetate
P09057648A0422|347 355|U937 cells
P09057648A0422|367 370|% FCS
P09057648A0422|376 383|mol/L PMA
P09057703A1389|0 13|Snail mortality
P09057703A1389|41 59|treatment conditions
P09057840A0946|14 20|protein
P09057840A0946|34 44|homogeneity
P09057840A0946|51 68|2SO4-precipitation
P09057840A0946|71 92|affinity chromatography
P09057840A0946|96 108|AMP-Sepharose
P09057841T0000|0 11|Derepression
P09057841T0000|14 27|gene expression
P09057841T0000|50 55|region
P09057841T0000|61 79|isocitrate lyase gene
P09057841T0000|82 98|Candida tropicalis
P09057841T0000|134 141|pathways
P09058002T0000|45 54|lobe damage
P09058250A0128|7 19|complications
P09058250A0128|40 47|analysis
P09058250A0128|83 89|therapy
P09058323A1287|3 9|results
P09058323A1287|25 35|cis elements
P09058323A1287|56 60|alpha
P09058323A1287|78 84|regions
P09058323A1287|132 142|CNS patterns
P09058323A1287|151 155|alpha
P09058323A1287|159 163|alpha
P09058323A1287|165 181|gene transcription
P09058373A0670|0 25|RNase protection experiments
P09058373A0670|38 45|presence
P09058373A0670|51 65|GHR1-279 variant
P09058373A0670|68 76|IM-9 cells
P09058373A0670|85 89|liver
P09058373A1620|10 14|tests
P09058373A1620|21 32|reporter gene
P09058373A1620|56 63|elements
P09058373A1620|134 141|function
P09058373A1620|157 164|receptor
P09058378A1134|19 41|glucocorticoid receptors
P09058378A1134|55 77|transactivation function
P09058378A1134|90 104|transrepression
P09059039A0850|0 10|99mTc-HMPAO
P09059039A0850|30 40|territories
P09059039A0850|67 74|patients
P09059039A0850|104 111|infusion
P09059039A0850|114 123|papaverine
P09059039A0850|131 139|C4 segment
P09059039A0850|166 174|territory
P09059039A0850|191 198|patients
P09059039A0850|229 236|infusion
P09059039A0850|239 248|papaverine
P09059039A0850|256 264|C1 segment
P09059039A0850|268 273|ml/min
P09060045A0576|9 22|review analyses
P09060045A0576|28 39|interactions
P09060045A0576|58 65|settings
P09060045A0576|89 104|endotoxin release
P09060444A0557|4 18|promoter segment
P09060444A0557|29 38|expression
P09060444A0557|42 63|luciferase reporter gene
P09060444A0557|97 106|initiation
P09060444A0557|112 119|reporter
P09060444A0557|137 154|EGF-responsiveness
P09060622A1679|14 19|report
P09060622A1679|45 57|alphavirus RNA
P09060622A1679|91 99|infection
P09060622A1679|127 132|genome
P09060623A0961|8 17|coreceptor
P09060623A0961|43 50|SIV entry
P09060676A1634|5 11|changes
P09060676A1634|14 31|virus entry features
P09060676A1634|43 55|coronaviruses
P09060676A1634|75 84|properties
P09060971A0982|0 6|RESULTS
P09060971A0982|12 16|women
P09060971A0982|31 37|decline
P09060971A0982|67 71|sites
P09060971A0982|118 124|decline
P09060971A0982|153 159|g/cm2/y
P09060971A0982|186 195|trochanter
P09060971A0982|211 217|g/cm2/y
P09061697A0629|14 21|patients
P09061697A0629|51 67|99Tcm-tetrofosmin
P09061697A0629|114 119|stress
P09061697A0629|120 130|day protocol
P09061697A0629|144 151|patients
P09061697A0629|163 182|stress imaging studies
P09061697A0629|234 250|99Tcm-tetrofosmin
P09061697A0629|253 260|occasion
P09061697A0629|265 275|day protocol
P09061697T0000|10 20|SPET imaging
P09061697T0000|25 41|99Tcm-tetrofosmin
P09061697T0000|52 59|practice
P09061697T0000|60 69|comparison
P09061697T0000|84 101|day imaging protocol
P09061698A0177|0 12|99Tcm-DMP-HSA
P09061698A0177|36 44|behaviour
P09061698A0177|65 74|blood cells
P09061698A0177|111 127|reference standard
P09061698A0177|130 144|blood pool agents
P09062130A0116|0 5|Relief
P09062130A0116|10 23|autoinhibition
P09062130A0116|48 55|increase
P09062130A0116|85 105|N-SH2 domain engagement
P09062130A0116|115 134|phosphotyrosyl ligand
P09062130A0116|141 148|deletion
P09062130A0116|154 163|SH2 domains
P09062130A0116|183 194|PTPase domain
P09064659A1055|37 43|homolog
P09064659A1055|46 54|yeast UPF1
P09064659A1055|56 62|protein
P09064659A1055|76 81|levels
P09064659A1055|84 95|nonsense mRNA
P09064659A1055|120 126|protein
P09064659A1055|132 136|HUPF1
P09064659A1055|145 151|homolog
P09064868T0001|1 11|miracle cure
P09064868T0001|18 25|solution
P09065170A0853|3 10|addition
P09065170A0853|13 22|zidovudine
P09065170A0853|42 49|transfer
P09065463A1012|0 16|DNA strand exchange
P09065463A1012|28 39|Rad51 protein
P09065690A0463|0 4|Ume6p
P09065690A0463|25 34|expression
P09065690A0463|49 53|genes
P09065690A0463|63 76|CAR1 expression
P09065690A0463|85 92|sequence
P09065690A0463|107 114|function
P09065690A0463|116 135|nitrogen availability
P09065768A0862|9 13|class
P09065768A0862|37 48|kb transcript
P09065768A0862|95 105|lactase mRNA
P09067577A0307|2 10|cell lines
P09067577A0307|24 30|BCR/ABL
P09067577A0307|40 47|tyrosine
P09067577A0721|15 19|cells
P09067577A0721|30 37|proteins
P09067577A0721|87 91|c-ABL
P09068989T0000|0 5|Effect
P09068989T0000|8 24|Azadirachta indica
P09068989T0000|39 49|leaf extract
P09068989T0000|69 74|system
P09071308A0376|0 6|RESULTS
P09071308A0376|14 22|opacities
P09071308A0376|44 55|distribution
P09071308A0376|73 79|finding
P09071308A0376|103 110|patients
P09071407T0000|11 18|oxytocin
P09071407T0000|25 34|guinea pigs
P09071407T0000|54 65|cohabitation
P09071407T0000|81 89|condition
P09072361A0357|21 28|fraction
P09072361A0357|29 33|SHRSP
P09072361A0357|41 48|decrease
P09072361A0357|51 59|magnesium
P09072361A0357|66 72|tissues
P09072361A0357|78 86|elevation
P09072361A0357|92 98|calcium
P09072361A0357|101 114|magnesium ratio
P09072361A0357|148 152|SHRSR
P09073074T0000|9 21|transcription
P09073074T0000|31 46|FGFR-3 psuedogene
P09073074T0000|58 69|developement
P09073582A0444|9 14|report
P09073582A0444|35 52|BglII-SmaI fragment
P09073582A0444|58 68|SSO activity
P09073582A0444|75 81|Kataoka
P09074508A0397|8 15|CD38 gene
P09074508A0397|27 31|exons
P09074508A0397|66 71|genome
P09075739A0827|8 20|splice pattern
P09075739A0827|30 35|exon U3
P09075739A0827|56 61|kidney
P09075739A0827|64 68|ovary
P09076336A0281|0 11|GH deficiency
P09076336A0281|44 52|diagnosis
P09076336A0281|72 84|constellation
P09076336A0281|106 113|findings
P09076336A0281|127 134|spectrum
P09076336A0281|148 160|GH sufficiency
P09076336A0281|169 179|GH secretion
P09077076A0219|8 14|CRP test
P09077108A0458|16 21|period
P09077108A0458|22 32|pleocytosis
P09077108A0458|54 59|levels
P09077108A0458|73 81|TNF-alpha
P09077108A0458|107 111|fluid
P09077437T0000|0 20|Recognition mechanisms
P09077437T0000|38 43|origin
P09077437T0000|46 52|phage f1
P09077437T0000|70 82|RNA polymerase
P09077438A0076|3 9|minimum
P09077438A0076|22 29|subunits
P09077438A0076|33 44|RNA synthesis
P09079625A0935|0 9|Syndecan-4
P09079625A0935|18 34|adhesion component
P09079625A0935|42 52|interaction
P09079625A0935|86 93|activity
P09079625A0935|95 99|sites
P09079625A0935|109 117|adhesions
P09079638A0883|3 13|3ASubE cells
P09079638A0883|24 28|CXCR2
P09079638A0883|33 40|mutation
P09079638A0883|43 49|Ser-346
P09079638A0883|63 69|alanine
P09079638A0883|76 83|mutation
P09079638A0883|93 98|serine
P09079638A0883|105 110|domain
P09079638A0883|139 146|response
P09079638A0883|149 154|ligand
P09079638A0883|199 213|ligand challenge
P09079650A0136|0 6|Members
P09079650A0136|12 21|MAPK family
P09079650A0136|45 59|response kinases
P09079650A0136|68 73|p42/44
P09079650A0136|81 85|c-Jun
P09079650A0136|99 105|kinases
P09079650A0136|118 124|p38/Hog
P09079650A0136|125 138|protein kinases
P09079689A0472|32 40|PAS domain
P09079689A0472|52 60|C terminus
P09079689A0472|99 104|domain
P09079689A0472|120 131|reading frame
P09079817A0928|10 21|NO production
P09079817A0928|29 33|cells
P09079817A0928|54 59|levels
P09079817A0928|79 90|NO synthetase
P09079878A0000|16 44|Lactobacillus sake plasmid pCIM1
P09079878A0000|90 102|reading frames
P09079902A0713|49 62|pyruvate kinase
P09079902A0713|86 92|complex
P09079902A0713|150 157|affinity
P09079902A0713|174 180|complex
P09079904A0995|9 22|iron regulation
P09079904A0995|23 36|sodA expression
P09079904A0995|50 56|changes
P09079904A0995|59 69|DNA topology
P09079904A0995|79 90|coumermycin A
P09079904A0995|108 116|virulence
P09079904A0995|127 135|Bvg system
P09079915T0000|9 24|characterization
P09079915T0000|52 65|motility operon
P09079915T0000|85 108|consensus sigma70 promoter
P09079928A0525|0 11|M. leprae OxyR
P09079928A0525|44 50|binding
P09079928A0525|56 64|oxyR-ahpC
P09079928A0525|75 80|region
P09079928A0525|83 90|M. leprae
P09079928A1319|3 13|binding site
P09079928A1319|33 38|P1oxyR
P09079928A1319|68 72|loops
P09079928A1319|84 93|expression
P09079928A1319|111 118|bacteria
P09079928A1319|121 134|characteristic
P09079928A1319|140 154|LysR superfamily
P09080250A0212|12 16|study
P09080250A0212|50 70|p15E cDNA gene fragments
P09080250A0212|82 86|means
P09080250A0212|89 111|polymerase chain reaction
P09080250A0212|149 157|P815/DTIC
P09080250A0212|156 166|tumour cells
P09080517A0215|11 18|patients
P09081389A1088|0 4|Grade
P09081389A1088|8 16|mucositis
P09081389A1088|38 43|cycles
P09081392A0174|31 45|salvage regimens
P09082335A0730|20 33|manifestations
P09082335A0730|61 65|means
P09083291A1378|5 13|TGF-beta1
P09083291A1378|44 53|expression
P09083291A1378|57 65|abundance
P09083291A1378|68 82|G1 phase cyclin D1
P09083291A1378|114 124|cyclin E-cdk
P09083291A1378|124 131|activity
P09083291A1378|162 176|phosphorylation
P09083291A1378|180 191|inactivation
P09083291A1378|201 207|G1 phase
P09083291A1378|210 219|transition
P09083291A1378|222 227|S phase
P09083345A0851|10 14|range
P09083345A0851|17 22|values
P09083345A0851|67 75|districts
P09083345A0851|90 95|values
P09083345A0851|98 102|SYPLR
P09083345A0851|107 113|respect
P09083345A0851|119 137|inter-relationships
P09083345A0851|161 175|characteristics
P09083345A0851|176 183|duration
P09083345A0851|186 193|symptoms
P09083345A0851|202 213|presentation
P09083345A0851|217 233|treatment efficacy
P09083563A0971|12 18|lesions
P09083563A0971|44 55|surface layer
P09083563A0971|59 78|leptomeningeal tissue
P09083563A0971|91 106|arachnoid vessels
P09083563A0971|143 147|fluid
P09083563A0971|177 182|toxins
P09083563A0971|205 209|fluid
P09083563A0971|215 222|B. cereus
P09084174A0667|4 11|fragment
P09084174A0667|36 46|nucleotides
P09084174A0667|80 92|dehydrogenase
P09084174A0667|105 144|aspartate-beta-semialdehyde dehydrogenase
P09084174A0667|163 169|product
P09084174A0667|174 183|similarity
P09084174A0667|189 199|Asd proteins
P09084174A0667|204 212|Vibrio spp
P09084176A0601|15 22|activity
P09084176A0601|36 57|slot-blot hybridization
P09084176A0601|97 113|M. smegmatis clones
P09084227A0833|0 9|Hovenitin I
P09084227A0833|13 22|ampelopsin
P09084227A0833|47 57|ingredients
P09084227A0833|69 77|fractions
P09084227A0833|93 100|medicine
P09084227A0833|128 135|activity
P09084227A0833|156 171|muscle relaxation
P09084621A0374|0 11|Movement time
P09084621A0374|24 38|characteristics
P09084621A0374|66 74|magnitude
P09084621A0374|85 93|blood flow
P09084621A0374|104 108|areas
P09084621A0374|111 136|brain activity proportionate
P09084621A0374|148 164|movement variables
P09084621A2567|0 4|Areas
P09084621A2567|58 68|motor cortex
P09084621A2567|85 90|sulcus
P09084621A2567|98 104|caudate
P09085842A0181|6 12|studies
P09085842A0181|36 42|U1 snRNP
P09085842A0181|60 69|splice site
P09085842A0181|72 98|protein/protein interactions
P09085842A0181|113 119|domains
P09085842A0181|125 137|U1-70K protein
P09085842A0181|141 147|SF2/ASF
P09085842A1559|25 34|27K protein
P09085842A1559|81 107|protein/protein interactions
P09085842A1559|126 145|phosphorylation state
P09085842A1559|159 174|pre-mRNA splicing
P09086268A0611|32 40|particles
P09086268A0611|54 62|particles
P09086268A0611|77 89|RNA polymerase
P09087430A1046|14 23|U1A peptide
P09088371T0000|0 11|Plasma levels
P09088371T0000|14 21|protein C
P09088371T0000|22 29|protein S
P09088371T0000|33 44|antithrombin
P09088371T0000|50 57|patients
P09088371T0000|74 84|haemorrhage
P09088416A0000|28 33|branch
P09088416A0000|49 57|occlusion
P09088416A0000|58 64|IBRBRAO
P09088416A0000|72 79|syndrome
P09088416A0000|95 111|migraine headaches
P09088416A0000|112 119|tinnitus
P09088416A0000|120 126|vertigo
P09088416A0000|127 137|hearing loss
P09088416A0000|150 155|branch
P09088416A0000|163 177|artery occlusion
P09088416A0000|187 194|etiology
P09088737T0000|20 40|thickness measurements
P09088737T0000|57 66|microscopy
P09089093A0373|0 8|Sequences
P09089093A0373|32 38|CA genes
P09089093A0373|67 82|enhancer elements
P09089653A0615|11 18|plasmids
P09089653A0615|68 76|nt segment
P09089653A0615|85 92|sequence
P09089653A0615|103 120|luciferase activity
P09089653A0615|129 133|times
P09089653A0615|157 170|control plasmid
P09089653A1112|0 7|Analysis
P09089653A1112|22 33|interactions
P09089653A1112|43 61|DNase-I footprinting
P09089653A1112|78 83|region
P09089653A1112|86 95|protection
P09090050A0419|25 37|sugar carriers
P09090050A0419|47 51|mouse
P09090054A0186|52 56|genes
P09090054A0186|59 67|regulator
P09090054A0186|68 75|permease
P09090054A0186|79 95|alpha-glucosidase
P09090054A0186|129 149|alpha-glucosidase gene
P09090054A0186|183 189|cluster
P09090054A0186|196 200|genes
P09090592A0175|8 14|methods
P09090592A0175|25 31|control
P09090592A0175|35 53|activation fMR images
P09090592A0175|85 89|error
P09090592A0175|149 159|orientation
P09091010A1003|5 9|women
P09091010A1003|45 52|cytology
P09091010A1003|73 79|disease
P09091125A0161|19 23|cells
P09091125A0161|47 54|activity
P09091125A0161|57 64|alkaline
P09091125A0161|68 83|acid phosphatases
P09091125A0161|90 103|NBT-test values
P09091403T0001|0 7|Analysis
P09091403T0001|20 31|DNA sequences
P09091403T0001|46 51|intron
P09091403T0001|57 61|mouse
P09091403T0001|70 78|mts1 genes
P09091403T0001|95 111|microsatellite DNA
P09092493A0861|3 13|integration
P09092493A0861|19 25|VIP CyRE
P09092493A0861|31 38|Jak-Stat
P09092493A0861|42 62|AP-1 signaling pathways
P09092493A0861|84 91|proteins
P09092493A0861|109 117|mechanism
P09092493A0861|147 155|signaling
P09092580A1354|5 11|studies
P09092580A1354|22 32|involvement
P09092580A1354|38 53|MAP kinase pathway
P09092580A1354|59 68|activation
P09092580A1354|80 84|cells
P09092580A1354|91 104|transmigration
P09092580A1354|119 123|sites
P09092636A0802|3 9|results
P09092636A0802|42 54|rad54-3 allele
P09092636A0802|68 80|recombination
P09092636A0802|104 125|DYZ3 satellite sequences
P09092636A0802|184 191|YAC clone
P09092675A0283|1 16|P22 R17 derivative
P09092675A0283|23 31|OcRNA site
P09092675A0283|32 37|P22 R17
P09092675A0283|71 79|infection
P09092675A0283|85 91|strains
P09093867T0000|12 27|Ac/Ds transposons
P09093867T0000|28 36|formation
P09093867T0000|37 45|structure
P09094093A0578|27 33|TATA box
P09094093A0578|46 50|cells
P09094315A0541|6 10|study
P09094315A0541|28 37|regulation
P09094315A0541|45 52|activity
P09094315A0541|55 65|cyclin-Cdks
P09094671A1192|0 28|Candidate tumor suppressor genes
P09094671A1192|35 42|p16INK4a
P09094671A1192|51 58|p15INK4b
P09094671A1192|78 83|region
P09094671A1192|89 108|Southern blot analysis
P09094671A1192|121 129|deletions
P09096229T0000|0 13|Excision repair
P09096229T0000|19 23|level
P09096229T0000|29 38|nucleotide
P09096229T0000|67 74|MFA2 gene
P09096229T0000|75 81|mapping
P09096229T0000|97 102|repair
P09096229T0000|119 124|strand
P09096229T0000|140 153|identification
P09096229T0000|168 172|rad16
P09096229T0000|202 217|control sequences
P09096234T0000|18 28|interaction
P09096234T0000|36 43|subunits
P09096234T0000|56 77|DNA sequence specificity
P09096234T0000|78 103|operator site discrimination
P09096234T0000|106 127|phage lambda cI repressor
P09096958A0000|20 24|panel
P09096958A0000|38 47|antibodies
P09096958A0000|66 78|platelet talin
P09096958A0000|81 95|Western blotting
P09096958A0000|102 114|precipitation
P09096958A0000|118 135|immunofluorescence
P09096958A0000|148 162|antibodies TA205
P09096958A0000|179 195|actin stress fibers
P09096958A0000|203 211|adhesions
P09096958A0000|222 233|cell motility
P09096958A0000|260 270|fibroblasts
P09098066A0119|4 8|locus
P09098066A0119|41 45|genes
P09098066A0119|76 87|proteins HMW1
P09098066A0119|103 112|insertions
P09098066A0119|140 147|proteins
P09098066A0119|175 183|phenotype
P09098066A0119|196 206|designation
P09098066A0119|230 234|locus
P09098899A0000|0 8|Coliphage
P09098899A0000|26 36|acid protein
P09098899A0000|50 58|Ogr family
P09098899A0000|70 89|transcription factors
P09098899A0000|106 110|phage
P09098899A0000|160 175|zinc-finger motif
P09098899A0435|3 22|UV absorption spectrum
P09098899A0435|32 39|shoulder
P09098899A0435|49 62|characteristic
P09098899A0435|64 70|CysS-Cd
P09098899A0435|87 112|charge-transfer transitions
P09098899A0435|119 149|difference absorption coefficient
P09098899A0435|155 167|acidification
P09098899A0435|168 179|delta epsilon
P09098899A0435|185 192|mM-1 cm-1
P09098899A0435|205 212|presence
P09098899A0435|219 223|Cys-S
P09098899A0435|223 228|center
P09099683A0000|0 19|Diacylglycerol kinase
P09099683A0000|35 40|levels
P09099683A0000|48 70|messenger diacylglycerol
P09099683A0000|73 77|cells
P09099683A0000|104 112|messenger
P09099702A0000|25 31|cloning
P09099702A0000|63 84|orphan receptor germ cell
P09099702A0000|91 96|factor
P09099702A0692|10 17|sequence
P09099702A0692|23 29|conRTRE
P09099702A0692|66 70|P2-RE
P09099702A0692|93 98|region
P09099702A0692|104 117|mouse protamine
P09099702A0692|152 156|stage
P09099702A0692|158 172|spermatogenesis
P09099743A0585|15 26|purification
P09099743A0585|69 76|particle
P09099743A0585|88 94|mRNP3+4
P09099743A0585|111 122|polypeptides
P09099743A0585|144 155|polypeptides
P09099743A0585|174 180|doublet
P09099743A0585|208 216|nucleolin
P09099745A1446|6 14|complexes
P09099745A1446|39 44|weight
P09099745A1446|57 65|complexes
P09099745A1446|139 147|threonine
P09099745A1446|148 162|phosphorylation
P09099745A1446|178 186|mechanism
P09099745A1446|189 198|activation
P09099745A1446|201 212|cyclin E-Cdk2
P09099745A1446|233 255|CDK inhibitor association
P09099745A1446|288 302|phosphorylation
P09100202A0000|6 10|Class
P09100202A0000|15 31|Class II recessions
P09100202A0000|36 43|patients
P09100202A0000|91 110|tissue graft procedure
P09101085A0686|3 13|derivatives
P09101085A0686|28 36|cell lines
P09101085A0686|52 61|expression
P09101085A0686|67 80|p27Kip1 protein
P09101085A0686|84 93|inhibition
P09101085A0686|96 105|cell growth
P09101910A0394|16 24|mortality
P09101910A0394|30 37|patients
P09101910A0394|49 57|mortality
P09101910A0394|59 66|patients
P09101910A0394|78 82|years
P09102113A0739|12 26|failure patients
P09102113A0739|59 64|causes
P09102113A0739|71 79|frequency
P09102113A0739|91 97|disease
P09102113A0739|112 116|death
P09103382T0000|6 19|FIGO definition
P09103382T0000|30 42|cancer stage IA
P09103382T0000|44 51|critique
P09104816A0610|3 8|effect
P09104816A0610|18 22|class
P09104816A0610|23 32|biogenesis
P09104816A0610|50 55|detail
P09104816A0610|87 99|vaccinia virus
P09105042A1497|4 8|study
P09105042A1497|25 33|phenotype
P09105042A1497|36 55|myofibrillar disarray
P09105042A1497|62 72|HCM patients
P09105042A1497|100 108|mutations
P09105042A1497|133 139|failure
P09105042A1497|151 156|myosin
P09105042A1497|162 173|chain protein
P09105042A1497|197 206|sarcomeres
P09105042A1497|231 236|effect
P09105042A1497|268 273|stress
P09105042A1497|285 299|beta MHC function
P09105363A0636|18 23|plasma
P09105363A0636|30 49|emission spectroscopy
P09105363A0636|72 96|tissue silicon measurements
P09105530A0000|2 11|egg protein
P09105530A0000|12 19|lysozyme
P09105530A0000|60 76|cheese preparation
P09106057A0000|1 6|method
P09106057A0000|25 37|determination
P09106057A0000|41 48|N-methyl
P09106057A0000|48 56|N-ethyl-8
P09106057A0000|58 76|anhydroerythromycin
P09106057A0000|92 96|EM523
P09106057A0000|109 119|metabolites
P09106057A0000|127 132|plasma
P09106057A0000|136 140|urine
P09106057A0000|184 197|chromatography
P09106057A0000|208 224|chemiluminescence
P09106057A0000|228 236|detection
P09108029A0399|23 30|activity
P09108029A0399|33 48|activator protein
P09108029A0399|69 83|DNA repair enzyme
P09108029A0399|83 93|redox factor
P09108029A0399|95 99|Ref-1
P09108029A0399|119 133|DNA repair enzyme
P09108029A0399|134 147|AP endonuclease
P09108038A1128|8 16|LRR domain
P09108038A1128|33 38|domain
P09108038A1128|39 45|Acan125
P09108038A1128|52 69|C. elegans homologue
P09108038A1128|82 87|family
P09108038A1128|102 116|binding proteins
P09108207A0306|10 22|participation
P09108207A0306|41 63|oropharyngeal irritation
P09108279A0431|3 10|capacity
P09108279A0431|19 24|8-OxoG
P09108279A0431|51 58|extracts
P09108279A0431|73 83|ogg1 strains
P09108279A0431|90 105|34mer DNA fragment
P09108279A0431|123 135|8-OxoG residue
P09108279A0431|147 154|cytosine
P09108279A0431|155 162|8-OxoG/C
P09108279A0431|166 174|substrate
P09108451A0160|0 6|Results
P09108451A0160|22 33|laboratories
P09108451A0160|51 56|UCN-01
P09108451A0160|76 95|G1-phase accumulation
P09108451A0160|110 123|tumor cell lines
P09110176A0890|0 7|Northern
P09110176A0890|11 24|RT-PCR analysis
P09110176A0890|27 41|Ube3a expression
P09110176A0890|44 55|mouse tissues
P09110176A0890|60 66|animals
P09110176A0890|99 104|disomy
P09110176A0890|147 156|expression
P09110176A0890|174 180|animals
P09110176A0890|200 207|evidence
P09110176A0890|228 237|expression
P09110176A0890|246 250|locus
P09111004A0732|14 20|effects
P09111004A0732|34 43|Xaa residue
P09111004A0732|53 83|phosphorylation motif Thr-Xaa-Tyr
P09111004A0732|95 100|length
P09111004A0732|103 137|L12 influence p38 substrate specificity
P09111004A0732|146 151|length
P09111004A0732|189 207|autophosphorylation
P09111048X0000|21 34|mRNA transcript
P09111048X0000|66 85|nitric-oxide synthase
P09111048X0000|99 111|mRNA diversity
P09111048X0000|128 132|theme
P09111048X0000|143 162|nitric-oxide synthase
P09111048X0000|169 182|gene expression
P09111048X0000|191 203|cells/tissues
P09111059A0327|20 25|domain
P09111059A0327|29 39|homeodomain
P09111059A0327|73 83|specificity
P09111309A0674|0 13|Cotransfection
P09111309A0674|16 20|Ets-2
P09111309A0674|46 52|protein
P09111309A0674|57 79|kinase expression vectors
P09111309A0674|98 121|HB-EGF promoter activation
P09111309A0674|124 131|response
P09111309A0674|134 143|deltaRaf-1
P09111314A0970|0 7|Cyclin D1
P09111314A0970|51 69|184A1L5R cell lysates
P09111314A1243|3 12|importance
P09111314A1243|32 41|regulation
P09111314A1243|44 51|p15INK4B
P09111314A1243|54 61|TGF-beta
P09111314A1243|79 89|observation
P09111314A1243|114 121|184A1L5R
P09111314A1243|133 145|p15 transcript
P09111314A1243|155 169|p15INK4B protein
P09111314A1243|208 230|cyclin D1-cdk association
P09111314A1243|234 249|kinase activation
P09111331A0119|3 13|Rlm1 protein
P09111331A0119|15 20|member
P09111331A0119|26 38|MADS box family
P09111331A0119|41 60|transcription factors
P09111331A0119|61 69|functions
P09111331A0119|93 99|pathway
P09111340A0240|20 27|elements
P09111340A0240|38 46|c-myc mRNA
P09111340A0240|50 63|downregulation
P09111340A0240|70 79|myogenesis
P09111340A0240|99 108|C2C12 cells
P09111340A0240|119 126|myc genes
P09111340A0240|137 141|genes
P09111340A0240|156 167|myc sequences
P09111340A0240|187 201|beta-globin gene
P09111340A0240|218 249|chloramphenicol acetyltransferase
P09111367A1098|11 21|experiments
P09111367A1098|52 59|p53 cells
P09111367A1098|79 93|tal-1 expression
P09111367A1098|109 119|temperature
P09111367A1098|146 151|effect
P09111367A1098|173 181|apoptosis
P09111367A1098|189 193|tal-1
P09111367A1098|207 212|effect
P09111367A1098|225 233|integrity
P09111367A1098|239 258|cell cycle checkpoints
P09111367A1098|264 271|host cell
P09111367A1098|285 289|c-myc
P09111367A1098|298 306|oncogenes
P09111367A1098|362 366|tal-1
P09111367A1098|373 383|experiments
P09111367A1098|403 414|tal-1 effects
P09111367A1098|452 476|heterodimerization domains
P09111367A1098|485 496|N-terminally
P09111367A1098|506 517|tal-1 variant
P09111367A1098|533 537|T-ALL
P09111367A1098|546 550|cells
P09111367A1098|560 566|effects
P09111367A1098|581 587|protein
P09111863A0743|3 12|likelihood
P09111863A0743|24 29|region
P09111863A0743|32 40|deletions
P09111863A0743|54 68|tumor suppressor
P09111863A0743|89 99|coincidence
P09111863A0743|106 111|region
P09111863A0743|117 134|chromosome fragment
P09111863A0743|146 159|tumorigenicity
P09111863A0743|164 175|introduction
P09111863A0743|178 187|tumor cells
P09112400A1155|11 18|activity
P09112400A1155|39 46|addition
P09112400A1155|49 57|forskolin
P09112400A1155|74 78|cells
P09112589A0078|25 31|pattern
P09114972A1366|4 12|induction
P09114972A1366|20 28|viability
P09115242A0934|19 28|supershift
P09115242A0934|32 55|promoter deletion analyses
P09115242A0934|97 108|protein-beta
P09115242A0934|108 117|C/EBP-beta
P09115242A0934|118 128|binding site
P09115242A0934|161 173|transcription
P09115242A0934|176 188|collagenase-1
P09115242A0934|200 204|cells
P09115247A2069|0 24|11-Aminoundecanoyl-SK-NH2
P09115247A2069|28 52|11-aminoundecanoyl-SH-NH2
P09115247A2069|73 85|alkyl backbone
P09115247A2069|110 117|distance
P09115247A2069|130 137|elements
P09115247A2069|149 159|recognition
P09115247A2069|171 176|enzyme
P09115247A2069|220 229|amino group
P09115247A2069|230 242|beta-hydroxyl
P09115247A2069|248 265|epsilon-amino group
P09115247A2069|270 278|imidazole
P09115265A1160|20 29|CCCC module
P09115265A1160|67 72|domain
P09115265A1160|87 111|transcription factor GATA-1
P09115279A0345|0 18|Cdc2 co-precipitates
P09115279A0345|40 50|cell lysates
P09115279A0345|88 94|partner
P09115279A0345|97 106|Pch1 kinase
P09115357A0073|21 29|mechanism
P09115357A0073|36 47|availability
P09115357A0073|61 66|assays
P09115357A0073|80 106|immunoglobulin hypermutation
P09115357A0073|125 135|development
P09115357A0073|138 151|culture systems
P09115357A0073|155 173|hypermutating B cells
P09115357A0073|185 193|screening
P09115357A0073|197 207|individuals
P09115357A0073|222 228|process
P09115365A0000|0 9|Expression
P09115365A0000|20 35|heat shock protein
P09115365A0000|44 48|hsp70
P09115365A0000|66 70|kinds
P09115365A0000|73 78|stress
P09115365A0000|84 92|oncogenes
P09115395A0478|7 14|proteins
P09115395A0478|66 72|mitosis
P09115395A0478|73 94|epithelial-microtubule
P09115395A0478|105 115|protein-115
P09115395A0478|116 120|Oct91
P09115395A0478|121 142|Elongation factor 1gamma
P09115395A0478|161 171|protein L18A
P09115395A0478|187 194|proteins
P09115395A0478|211 215|roles
P09115395A0478|218 224|mitosis
P09115395A0478|225 246|epithelial-microtubule
P09115395A0478|257 267|protein-115
P09115395A0478|298 319|innercentrosome protein
P09115395A0478|331 344|RNA helicase WM6
P09115395A0478|363 382|transcription factors
P09115395A0478|397 411|co-factor 2alpha
P09115395A0478|411 415|Oct91
P09115395A0478|431 435|HoxD1
P09115395A0478|440 444|Vent2
P09115395A0478|450 457|isoforms
P09115395A0478|460 464|Xbr1b
P09115989A0993|20 27|location
P09115989A0993|28 46|psoralen cross-links
P09115989A0993|64 68|steps
P09115989A0993|74 90|initiation process
P09117345A0945|0 9|Activation
P09117345A0945|12 16|alpha
P09117345A0945|29 34|TS2/16
P09117345A0945|57 67|protrusions
P09117345A0945|71 83|cell migration
P09117345A0945|102 108|pattern
P09117345A0945|111 125|phosphorylation
P09118196A0281|0 10|Performance
P09118196A0281|34 46|National Adult
P09118196A0281|66 71|NART-R
P09118196A0281|78 94|Vocabulary subtest
P09118196A0281|102 139|Wechsler Adult Intelligence Scale-Revised
P09118196A0281|140 145|WAIS-R
P09118196A0281|157 168|correlations
P09118196A0281|173 177|level
P09118196A0281|180 188|education
P09118664A1734|0 11|L-canavanine
P09118664A1734|22 30|inhibitor
P09118664A1734|51 63|oxide synthase
P09118664A1734|88 102|filling pressure
P09118664A1734|125 130|return
P09118664A1734|141 150|conditions
P09118704A0771|0 6|RESULTS
P09118704A0771|14 21|patients
P09118704A0771|43 54|chemotherapy
P09118704A0771|58 62|G-CSF
P09118704A0771|71 89|% confidence interval
P09118704A0771|144 160|bleomycin toxicity
P09119031A1036|12 35|holoenzyme RNA polymerases
P09119031A1036|68 74|mutants
P09119031A1036|92 108|core RNA polymerase
P09119031A1036|109 122|alpha2beta beta
P09119031A1036|154 161|activity
P09119031A1036|164 173|comparison
P09119031A1036|179 184|enzyme
P09119031A1036|204 214|sigma factor
P09119112A1350|29 33|model
P09119112A1350|40 45|GATA-5
P09119112A1350|93 100|function
P09119112A1350|115 119|heart
P09119391A0870|9 16|sequence
P09119391A0870|25 31|protein
P09119391A0870|37 46|amino acids
P09119391A0870|91 105|protein sequence
P09119391A0870|113 117|GPT-1
P09121424A0296|32 42|Swi3 homolog
P09121424A0296|59 66|evidence
P09121424A0296|85 91|complex
P09121424A0296|101 107|homolog
P09121430A0132|36 48|protein kinase
P09121430A0132|69 75|complex
P09121430A0132|104 111|tyrosine
P09121430A0132|114 120|residue
P09121430A1075|2 9|contrast
P09121430A1075|10 21|Y239/240F Shc
P09121430A1075|28 35|Y317F Shc
P09121430A1075|57 68|c-myc message
P09121432A0000|3 12|Ras guanine
P09121432A0000|31 37|protein
P09121432A0000|59 64|switch
P09121432A0000|67 76|signalling
P09121432A0000|105 111|kinases
P09121433A0463|52 64|specificities
P09121433A0463|85 95|specificity
P09121433A0463|146 162|consensus sequence
P09121433A0463|158 164|ACTACTA
P09121435A1183|0 6|Domains
P09121435A1183|31 38|assembly
P09121435A1183|43 59|TFIIIB-DNA complex
P09121435A1183|74 92|protein footprinting
P09121452A0538|0 22|Domain switch experiments
P09121452A0538|33 49|C/EBP beta proteins
P09121452A0538|69 81|leucine zipper
P09121452A0538|87 102|activation domain
P09121452A0538|105 114|C/EBP alpha
P09121452A0538|138 148|2D5 promoter
P09121452A0538|196 203|promoter
P09121452A0538|225 233|C/EBP site
P09121454A1328|10 19|phenotypes
P09121454A1328|43 51|mutations
P09121454A1328|60 64|Bur6p
P09121454A1328|68 72|Mot1p
P09121454A1328|99 107|functions
P09121454A1328|123 130|activity
P09121454A1328|143 164|transcription machinery
P09121476T0000|0 4|PRH75
P09121476T0000|26 31|member
P09121476T0000|37 57|DEAD-box protein family
P09121476T0000|68 73|plants
P09121774A0611|5 14|activities
P09121774A0611|32 42|stimulation
P09121774A0611|45 54|cell growth
P09121774A0611|76 82|members
P09121774A0611|88 102|MAP kinase family
P09121774T0000|18 26|GTPase Rac
P09121774T0000|28 39|polyomavirus
P09121774T0000|64 73|activation
P09121774T0000|79 98|serum response element
P09121774T0000|104 121|cell transformation
P09121998A0663|13 18|curves
P09121998A0663|33 38|region
P09121998A0663|41 48|interest
P09121998A0663|62 71|subjection
P09121998A0663|95 104|procedures
P09121998A0663|132 142|transit time
P09121998A0663|155 162|fraction
P09121998A0663|167 174|test meal
P09121998A0663|188 194|stomach
P09122168A1427|4 8|study
P09122168A1427|24 36|demonstration
P09122168A1427|49 58|G betagamma
P09122168A1427|90 102|translocation
P09122168A1427|138 143|system
P09122168A1427|157 174|isoform specificity
P09122168A1427|180 190|interaction
P09122168A1427|198 207|components
P09122176A0970|3 9|results
P09122176A0970|33 42|repression
P09122176A0970|48 55|hMGP gene
P09122176A0970|63 69|binding
P09122176A0970|80 86|RAR/RXR
P09122176A0970|103 119|RA response element
P09122198A0478|0 13|Point mutations
P09122198A0478|23 38|tyrosine residues
P09122198A0478|55 60|domain
P09122198A0478|66 73|receptor
P09122198A0478|106 116|conclusions
P09122215A0335|16 21|method
P09122215A0335|80 88|mutations
P09122215A0335|102 109|interest
P09123055T0000|14 19|injury
P09123055T0000|26 37|preservation
P09123055T0000|45 50|livers
P09123055T0000|62 72|HTK solution
P09123787A0486|32 40|responses
P09123787A0486|59 68|R1 response
P09123787A0486|74 106|orbicularis oculi muscle ipsilateral
P09123787A0486|120 130|stimulation
P09123787A0486|144 151|response
P09123787A0486|196 205|R3 response
P09123787A0486|220 241|orbicularis oculi muscle
P09124054A1164|3 11|prognosis
P09124054A1164|19 26|patients
P09124054A1164|38 42|ABSCT
P09124054A1164|77 84|patients
P09124054A1164|108 114|therapy
P09126622A0466|3 18|pigment intensity
P09126622A0466|34 41|colonies
P09126622A0466|45 55|appressoria
P09126622A0466|58 73|CAL transformants
P09128730A0000|8 22|decarboxylation
P09128730A0000|25 40|Malonomonas rubra
P09128730A0000|52 60|formation
P09128730A0000|63 71|malonyl-S
P09128730A0000|71 89|acyl-carrier protein
P09128730A0000|94 101|acetyl-S
P09128730A0000|101 119|acyl-carrier protein
P09128730A0000|123 130|malonate
P09128730A0000|131 146|carboxyltransfer
P09128730A0000|150 162|biotin protein
P09128730A0000|169 183|decarboxylation
P09128730A0000|199 207|delta mu Na
P09128730A0000|208 217|generation
P09129147A0644|3 20|Jem peptide sequence
P09129147A0644|27 40|leucine-zipper
P09129147A0644|53 57|motif
P09129147A0644|69 76|homology
P09129147A0644|79 85|Fos/Jun
P09129147A0644|89 104|ATF/CREB proteins
P09129147A0644|123 142|phosphorylation sites
P09130595A0478|15 21|cloning
P09130595A0478|27 33|protein
P09130595A0478|45 56|enhancer site
P09130700A0676|7 13|support
P09130700A0676|24 34|interaction
P09130700A0676|37 41|Tub4p
P09130700A0676|42 47|Spc98p
P09130700A0676|51 56|Spc97p
P09130700A0676|69 76|toxicity
P09130700A0676|85 103|SPC97 overexpression
P09130700A0676|123 139|co-overexpression
P09130700A0676|150 154|SPC98
P09130718A0497|0 8|Sequences
P09130718A0497|32 41|expression
P09130718A0497|69 76|bp region
P09130720A0417|8 13|screen
P09130720A0417|23 29|mutants
P09130720A0417|35 50|branch site region
P09130720A0417|63 71|positions
P09130720A0417|86 100|TACTAAC sequence
P09130720A0417|116 132|intron recognition
P09131139T0000|0 10|Implication
P09131139T0000|21 35|acetylhydrolase
P09131139T0000|35 40|PAF-AH
P09131139T0000|41 48|activity
P09131139T0000|62 68|disease
P09132011A0298|0 9|Comparison
P09132011A0298|15 25|p50 sequence
P09132011A0298|39 46|proteins
P09132011A0298|56 64|% homology
P09132011A0298|95 101|protein
P09132011A0298|106 114|% homology
P09132011A0298|119 151|Drosophila cell cycle control protein
P09132057A0559|1 11|polypeptide
P09132057A0559|35 46|reading frame
P09132057A0559|49 66|sequence similarity
P09132057A0559|81 86|domain
P09132057A0559|96 117|receptor protein kinases
P09132057A0559|122 127|plants
P09132057A0559|140 156|S-receptor kinases
P09132057A0559|172 180|rejection
P09132057A0559|183 193|self-pollen
P09132057A0559|196 210|Brassica species
P09132057A0559|217 230|Pto gene product
P09132057A0559|233 238|tomato
P09132057A0559|251 260|resistance
P09132057A0559|273 280|pathogen
P09132061A0828|18 22|types
P09132061A0828|23 35|cDNA sequences
P09132061A0828|75 88|isoperoxidases
P09132061A0828|112 121|peroxidase
P09133122A0656|10 20|information
P09133122A0656|47 55|sequences
P09133122A0656|69 82|video sequences
P09133122A0656|83 95|x-ray analysis
P09133122A0656|96 105|angiograms
P09133122A0656|128 134|program
P09135066A0653|55 61|p96h2bk
P09135066A0653|66 72|absence
P09135149A0000|29 36|activity
P09135149A0000|58 67|Cdc2/Cdc13
P09135149A0000|84 89|kinase
P09135149A0000|112 130|Mik1 tyrosine kinases
P09135149A0000|144 148|Cdc25
P09135149A0000|152 175|Pyp3 tyrosine phosphatases
P09135772T0000|8 15|response
P09135772T0000|33 38|roller
P09135772T0000|61 65|foods
P09135772T0000|74 81|subjects
P09135928A0912|9 14|mmol/l
P09135928A0912|34 44|BP responses
P09135928A0912|57 70|norepinephrine
P09135928A0912|74 84|angiotensin
P09135928A0912|112 124|glibenclamide
P09135928A0912|131 139|metformin
P09136015A0529|3 12|sequencing
P09136015A0529|23 28|copies
P09136015A0529|57 63|cluster
P09136015A0529|80 86|pattern
P09136015A0529|89 103|diversification
P09136080A1469|3 9|results
P09136080A1469|22 35|DNA methylation
P09136080A1469|36 53|chromatin structure
P09136080A1469|57 71|transactivation
P09136080A1469|76 82|Sp1 site
P09136080A1469|114 123|expression
P09136080A1469|144 150|lineage
P09138076A1099|2 23|gel mobility shift assays
P09138076A1099|24 30|factors
P09138076A1099|47 54|extracts
P09138076A1099|80 89|osteoblast
P09138076A1099|97 117|oligonucleotide probes
P09138076A1099|131 135|E-box
P09138076A1099|140 144|E-box
P09138076A1099|146 153|elements
P09138492A0806|0 13|Laboratory exam
P09138492A0806|24 33|tuberculin
P09138492A0806|48 63|chest radiography
P09138492A0806|83 96|calcifications
P09138492A0806|97 103|ORL exam
P09138492A0806|110 114|tumor
P09138492A0806|131 140|epiglottis
P09138492A0806|190 208|epidermoid carcinoma
P09139665A0784|17 29|PhLP complexes
P09139665A0784|50 59|Gbetagamma
P09139694A0789|0 8|CTF1alpha
P09139694A0789|61 70|palindrome
P09139694A0789|72 82|DNA fragment
P09139694A0789|91 100|palindrome
P09139694A0789|110 119|palindrome
P09139694A0789|121 132|DNA fragments
P09139694A0789|151 157|binding
P09139694A0789|160 168|CTF1alpha
P09139694A0789|171 180|palindrome
P09139721A0183|0 7|Cyclin G2
P09139721A0183|36 41|system
P09139721A0183|58 74|tolerance subjects
P09139721A0183|88 98|lymphocytes
P09139721A0183|109 117|selection
P09139721A0183|127 134|deletion
P09139721A0183|138 146|apoptosis
P09139737A0000|17 24|protease
P09139737A0000|34 40|release
P09139737A0000|58 65|segments
P09139737A0000|68 73|sterol
P09139737A0000|99 106|proteins
P09139737A0000|107 112|SREBPs
P09139737A0000|117 129|cell membranes
P09139737A0000|159 165|nucleus
P09139737A0000|180 192|transcription
P09139737A0000|195 199|genes
P09139737A0000|213 218|uptake
P09139737A0000|222 230|synthesis
P09139737A0000|233 243|cholesterol
P09139737A0000|252 256|acids
P09139892A1150|28 39|vfr promoters
P09139892A1150|65 75|orientation
P09139892A1150|101 111|orientation
P09139892A1150|126 137|crp promoters
P09139910A0350|0 15|Sequence analysis
P09139910A0350|24 34|PCR products
P09139910A0350|47 54|presence
P09139910A0350|78 89|DNA fragments
P09139910A0350|139 144|probes
P09139910A0350|158 175|clone XbaI fragments
P09139910A0350|186 190|pOST4
P09139910A0350|201 205|pOST2
P09139910A1572|2 9|contrast
P09139910A1572|13 26|Anabaena strain
P09139910A1572|31 38|leuA gene
P09139910A1572|58 69|nifV mutation
P09139910A1572|72 76|R229I
P09140079A2528|5 10|effect
P09140474T0000|2 14|leishmaniasis
P09140474T0000|27 32|island
P09140474T0000|35 41|Minorca
P09140474T0000|42 46|Spain
P09140474T0000|92 96|years
P09140474T0000|98 104|Minorca
P09142146A0887|0 6|RESULTS
P09142146A0887|19 29|PAF blockade
P09142146A0887|39 47|mortality
P09142146A0887|53 58|trauma
P09142146A0887|64 78|WEB-2086 animals
P09142146A0887|89 102|vehicle animals
P09142146A0887|130 134|index
P09142146A0887|139 146|delivery
P09142146A0887|151 155|hours
P09143328A1002|4 10|finding
P09143328A1002|21 27|example
P09143328A1002|30 40|utilization
P09143328A1002|59 76|dinucleotide primer
P09143328A1002|81 93|RNA polymerase
P09143465A0838|11 23|dual-T1 images
P09143465A0838|47 58|image quality
P09143465A0838|76 80|scale
P09144165A0614|3 7|model
P09144165A0614|20 26|complex
P09144165A0614|30 36|segment
P09144165A0614|63 77|Rel insert region
P09144165A0614|82 88|feature
P09144165A0614|107 122|hypervariability
P09144165A0614|136 143|sequence
P09144165A0614|150 156|members
P09144165A0614|162 189|Rel transcription factor family
P09144165A1275|21 27|NFAT RIR
P09144165A1275|56 69|DNA recognition
P09144165A1275|83 89|binding
P09144165A1275|92 121|AP-1 family transcription factors
P09144195A1051|7 17|association
P09144195A1051|20 31|PS1 fragments
P09144195A1051|53 58|cycles
P09144195A1051|61 93|phosphorylation/dephosphorylation
P09144195A1051|99 104|PS1 CTF
P09144770A0906|4 12|conformer
P09144770A0906|29 37|beta-turn
P09144770A0906|63 70|contacts
P09144770A0906|78 97|FKBP12 binding surface
P09144958A0047|4 10|protein
P09144958A0047|21 26|region
P09144958A0047|32 39|promoter
P09144958A0047|44 54|Arabidopsis
P09144958A0047|71 95|chlorophyll a/b protein gene
P09144958A0047|96 100|Lhcb1
P09144958A0047|123 132|regulation
P09144958A0047|135 145|phytochrome
P09146027A0809|1 7|patient
P09146027A0809|10 15|Group B
P09146027A0809|25 34|athetoid CP
P09146027A0809|39 48|spasticity
P09146027A0809|70 74|trunk
P09146071T0001|8 15|movement
P09146071T0001|55 71|pontine hemorrhage
P09147420A0623|28 38|HCMV IE1/IE2
P09147420A0623|68 75|HIV-1 LTR
P09147420T0000|23 37|transactivation
P09147420T0000|56 61|repeat
P09147420T0000|66 75|Tat protein
P09147420T0000|81 88|presence
P09147420T0000|96 117|cytomegalovirus IE1/IE2
P09147788A0458|11 29|chain enzyme activity
P09147832A0174|0 7|Children
P09147832A0174|9 19|temperament
P09147832A0174|31 43|socialization
P09147832A0174|67 71|years
P09147832A0174|84 93|predictors
P09147832A0174|102 111|conscience
P09147832A0174|153 160|measures
P09148770A0977|37 51|phosphoproteins
P09148770A0977|84 95|Csk SH2 domain
P09148903A1715|7 13|studies
P09148903A1715|36 45|activation
P09148903A1715|48 63|HIV-1 LTR activity
P09148903A1715|88 100|translocation
P09148903A1715|106 133|NF-kappaB transcription factor
P09148903A1715|151 183|IkappaBalpha serine phosphorylation
P09148903A1715|187 197|degradation
P09148903A1715|243 249|pathway
P09148929A0372|14 18|clone
P09148929A0372|34 49|plasmid subclones
P09148929A0372|90 101|organization
P09148929A0372|107 115|Ctpct gene
P09148935A0805|13 28|c-Src PTK activity
P09148935A0805|46 62|type FAK expression
P09148935A0805|83 92|activation
P09148935A0805|113 122|expression
P09148935A0805|127 155|c-Src binding site Phe-397 mutant
P09149825A0151|13 18|cement
P09149825A0151|19 32|4-META/MMA-TBB
P09149825A0151|39 43|resin
P09149825A0151|70 79|properties
P09149825A0151|83 92|bone cement
P09149929A0750|22 32|predictions
P09149929A0750|48 55|children
P09149929A0750|68 74|control
P09149929A0750|79 90|homesickness
P09149929A0750|94 103|separation
P09149929A0750|127 133|control
P09150334A0559|4 9|sample
P09150334A0559|70 77|sampling
P09150566A0316|23 28|grains
P09150566A0316|33 41|formation
P09150566A0316|44 59|complex molecules
P09150566A0316|83 88|clouds
P09150595A0225|7 15|elicitors
P09150595A0225|35 42|reaction
P09150595A0225|57 70|E. chrysanthemi
P09150595A0225|70 78|HarpinEch
P09150595A0225|82 92|E. amylovora
P09150595A0225|93 100|HarpinEa
P09150595A0225|117 123|protein
P09150595A0225|146 159|signal sequence
P09150595A0225|199 204|domain
P09150595T0000|9 24|characterization
P09150595T0000|28 37|expression
P09150595T0000|43 70|Erwinia carotovora hrpNEcc gene
P09150595T0000|85 92|elicitor
P09150595T0000|112 119|reaction
P09150728A0596|73 77|heart
P09150728A0596|86 91|muscle
P09150774A0616|0 9|Anesthesia
P09150774A0616|27 36|isoflurane
P09150774A0616|48 57|inhalation
P09151152A0174|21 36|protein C activity
P09151152A0174|103 114|hemodialysis
P09151152A0174|119 125|factor X
P09151152A0174|129 137|factor VII
P09151152A0174|170 183|heparinization
P09151152A0174|194 199|amount
P09151152A0174|202 217|serum lipoprotein
P09151376A0000|26 49|hyperbetalipoproteinemia
P09151376A0000|51 57|patient
P09151376A0000|63 71|diagnosis
P09151376A0000|150 158|arthritis
P09151806A1125|18 25|evidence
P09151806A1125|47 52|intron
P09151806A1125|57 68|mLAT pre-mRNA
P09151806A1125|80 90|branch point
P09151828A0919|10 26|amino acid residues
P09151828A0919|43 59|9ORF1 polypeptides
P09151828A0919|88 94|regions
P09151828A0919|107 112|region
P09151828A0919|114 121|residues
P09151828A0919|128 133|region
P09151828A0919|136 143|residues
P09151828A0919|163 168|region
P09151828A0919|172 179|residues
P09151837A0723|7 24|protein interaction
P09151837A0723|51 82|coimmunoprecipitation experiments
P09151837A0723|136 148|fusion protein
P09151837A0723|151 161|combination
P09151837A0723|188 192|Rep78
P09151837A0723|220 250|transcription-translation system
P09151925A0479|3 7|C-LIP
P09151925A0479|27 37|transcather
P09151925A0479|46 57|embolization
P09151925A0479|63 67|C-LIP
P09151925A0479|77 89|gelatin sponge
P09151925A0479|105 127|ethanol injection therapy
P09152656A0149|8 15|patients
P09152656A0149|20 47|New York Heart Association class
P09152656A0149|60 71|heart failure
P09152656A0149|109 113|study
P09153010A0499|7 16|advantages
P09153010A0499|28 35|analysis
P09153010A0499|45 55|acquisition
P09153010A0499|81 90|collection
P09153010A0499|126 136|possibility
P09153010A0499|154 166|threshold MUPs
P09153010A0499|183 191|selection
P09153010A0499|206 220|reproducibility
P09153010A0499|225 231|results
P09153010A0499|248 262|reference values
P09153010A0499|282 293|laboratories
P09153319A0844|30 38|triplexes
P09153319A0844|73 79|ethanol
P09153319A0844|96 100|water
P09153319A1332|0 22|Transfection experiments
P09153319A1332|37 45|triplexes
P09153319A1332|51 65|reporter plasmid
P09153319A1332|79 102|collagen promoter sequence
P09153319A1332|120 129|inhibition
P09153319A1332|132 144|transcription
P09153319A1332|162 187|control phosphorothioate ODN
P09153348A0647|6 13|increase
P09153348A0647|16 24|plasma TBG
P09153348A0647|29 33|shift
P09153348A0647|45 52|androgen
P09153348A0647|56 88|mineralocorticoid steroid secretion
P09153348A0647|96 112|cortisol secretion
P09153348A0647|127 133|markers
P09153348A0647|137 147|progression
P09153348A0647|153 159|disease
P09153348A0647|162 169|patients
P09153348A0647|174 186|HIV-infection
P09153795A0298|9 15|studies
P09153795A0298|33 40|evidence
P09153795A0298|42 52|reliability
P09153795A0298|56 63|validity
P09154283A0307|0 10|Latanoprost
P09154283A0307|31 39|reduction
P09154283A0307|53 60|pressure
P09154283A0307|76 86|combination
P09154283A0307|90 96|timolol
P09154283A0307|97 107|pilocarpine
P09154283A0307|108 120|acetazolamide
P09154283A0307|124 133|dipivefrin
P09154621A1475|5 11|results
P09154621A1475|30 51|safflower phospholipids
P09154621A1475|66 75|ingredient
P09154621A1475|78 83|layers
P09154621A1475|95 112|liver triglycerides
P09154621A1475|116 131|serum cholesterol
P09154621A1475|149 155|effects
P09154795A0628|12 21|techniques
P09154795A0628|49 56|analysis
P09154795A0628|83 99|DNA polymerase beta
P09154795A0628|100 107|beta-pol
P09154795A0628|108 119|gene promoter
P09154797A0777|9 27|spermidine transport
P09154797A0777|35 45|lacZ mutants
P09154797A0777|77 84|affinity
P09154797A0777|124 129|strain
P09154819A0501|9 22|overexpression
P09154819A0501|25 29|c-Jun
P09154819A0501|37 56|tenascin-C expression
P09154819A0501|76 80|FR3T3
P09154819A0501|93 110|fibroblast cell line
P09154822T0000|0 9|Inhibition
P09154822T0000|15 25|Raf-1 kinase
P09154822T0000|34 44|AMP agonists
P09154822T0000|51 59|apoptosis
P09154822T0000|79 83|cells
P09154827A0158|8 14|studies
P09154827A0158|33 47|hamster cell line
P09154827A0158|59 71|point mutation
P09154827A0158|81 88|250/CCG1
P09154827A0158|128 137|expression
P09154827A0158|139 144|subset
P09154827A0158|147 151|genes
P09154827A0158|155 161|arrests
P09154827A0158|178 186|degrees C.
P09155015A0140|17 34|protein kinase MEKK1
P09155015A0140|44 65|reporter gene expression
P09155015A0140|90 95|factor
P09155015A0140|101 108|promoter
P09155015A0140|116 121|marker
P09155015A0140|149 159|hypertrophy
P09155024A0955|0 13|Overexpression
P09155024A0955|24 33|C. albicans
P09155024A0955|59 64|growth
P09155024A0955|86 97|pseudohyphae
P09155024A0955|99 104|liquid
P09155024A0955|115 119|media
P09156883A0294|8 17|parameters
P09156883A0294|18 26|heart rate
P09156883A0294|39 51|blood pressure
P09156883A0294|69 78|saturation
P09156883A0294|95 106|pulsoximetry
P09156883A0294|127 135|procedure
P09157100A0583|13 19|signing
P09157100A0583|78 87|extinction
P09157337A0545|3 9|husband
P09157337A0545|27 33|couples
P09157337A0545|47 55|hepatitis
P09157337A0545|70 77|etiology
P09157337A0545|82 102|Infectology Department
P09157337A0545|107 111|years
P09157760A0000|30 37|analysis
P09157760A0000|67 79|peculiarities
P09157760A0000|82 88|Meynart
P09157760A0000|90 96|nucleus
P09157760A0000|134 140|nucleus
P09157760A0000|142 149|thalamus
P09157760A0000|178 188|individuals
P09159111A0437|16 23|proposal
P09159111A0437|45 53|dichroism
P09159111A0437|61 74|NMR experiments
P09159111A0437|79 87|Skn domain
P09159111A0437|104 111|proteins
P09159160A0000|10 16|cloning
P09159160A0000|38 46|sequences
P09159160A0000|64 68|genes
P09159160A0000|91 98|diseases
P09159183A0119|0 4|Genes
P09159183A0119|8 31|ocs element binding factors
P09159183A0119|58 62|class
P09159183A0119|64 88|basic-region leucine zipper
P09159183A0119|95 114|transcription factors
P09159183A0119|133 138|number
P09159183A0119|141 146|plants
P09160361A0858|9 17|mortality
P09160361A0858|23 30|CPB group
P09160361A0858|44 48|group
P09160881A0491|18 40|co-precipitation studies
P09160881A0491|44 48|yeast
P09160881A0491|59 64|screen
P09160881A0491|93 104|interactions
P09162084A0956|4 14|association
P09162084A0956|36 48|Src-SH2 domain
P09162084A0956|56 62|PECAM-1
P09162084A0956|83 107|GST-Src-SH2 affinity matrix
P09162092A0675|0 22|MKK3 autophosphorylation
P09162092A0675|26 35|activation
P09162092A0675|67 78|coexpression
P09162092A0675|90 94|MEKK3
P09162092A0675|104 108|MEKK2
P09162097A0776|22 36|MAdCAM-1 variant
P09162097A0776|77 87|mucin domain
P09162097A0776|100 116|leukocyte adhesion
P09162097A0776|119 124|LPAM-1
P09162097A0776|132 139|adhesion
P09162097A0776|154 161|receptor
P09162097A0776|162 171|L-selectin
P09162097A1258|2 8|summary
P09162097A1258|57 68|MAdCAM-1 cDNA
P09162097A1258|92 100|homologue
P09162097A1258|103 115|mouse MAdCAM-1
P09162097A1258|128 142|dissimilarities
P09162097A1258|148 155|MAdCAM-1
P09162097A1258|166 175|structures
P09163332A0275|24 42|mutagenesis approach
P09163332A0275|66 72|hydroxy
P09163332A0275|72 78|Ser/Thr
P09163332A0275|79 95|amino acid residues
P09163332A0275|98 104|sequons
P09163332A0275|132 141|efficiency
P09164543A0219|0 7|MATERIAL
P09164543A0219|11 17|METHODS
P09164543A0219|21 27|authors
P09164543A0219|38 44|persons
P09164543A0219|64 70|surgery
P09164543A0219|77 81|years
P09164543A0219|86 91|months
P09164543A0219|120 127|vagotomy
P09164543A0219|152 159|vagotomy
P09164543A0219|178 185|drainage
P09164856A0980|4 9|region
P09164856A0980|38 48|TATA element
P09164856A0980|63 75|transcription
P09164856A0980|81 95|glutaminase gene
P09164856A0980|116 123|promoter
P09165004A1700|0 10|SRE activity
P09165004A1700|29 38|activation
P09165004A1700|41 55|phosphorylation
P09165004A1700|66 78|complex factor
P09165004A1700|102 115|complex factors
P09165004A1700|118 122|Elk-1
P09165035A0842|0 31|Serum alkaline phosphatase activity
P09165035A0842|32 51|bone mass measurements
P09165035A0842|56 66|energy x-ray
P09165035A0842|81 88|analysis
P09165035A0842|91 104|mineral density
P09165035A0842|118 130|testing values
P09165035A0842|133 141|vertebrae
P09165035A0842|145 150|femora
P09165035A0842|162 168|animals
P09165035A0842|210 216|animals
P09165039A0728|3 15|monkey LHR cDNA
P09165039A0728|39 54|sequence homology
P09165039A0728|75 82|LHR cDNAs
P09165039A1372|2 11|conclusion
P09165039A1372|12 28|marmoset monkey LHR
P09165039A1372|43 50|sequence
P09165039A1372|79 85|LHR gene
P09165039A1372|101 107|species
P09165118A0311|7 13|mutants
P09165118A0311|14 27|VA motor neurons
P09165118A0311|37 43|pattern
P09165118A0311|54 58|input
P09165118A0311|89 99|sister cells
P09165118A0311|103 116|VB motor neurons
P09165118A0311|134 138|input
P09165118A0311|176 189|movement defect
P09167421A0234|13 23|irradiation
P09167421A0234|42 58|microSelectron HDR
P09167421A0234|71 76|device
P09167421A0234|110 118|fractions
P09168083A0987|2 8|patient
P09168083A0987|11 15|group
P09168083A0987|46 50|group
P09168134A0858|0 17|Sequence comparison
P09168134A0858|27 44|kb promoter sequence
P09168134A0858|52 60|promoters
P09168134A0858|66 73|Sm-E gene
P09168134A0858|77 88|U1 snRNA genes
P09168134A0858|114 119|motifs
P09168134A0858|134 138|genes
P09168134A0858|150 164|snRNP components
P09168218A0216|0 6|METHODS
P09168218A0216|10 18|responses
P09168218A0216|33 37|woman
P09168218A0216|57 72|pain syndrome type
P09168218A0216|91 99|dystrophy
P09168218A0216|110 114|grill
P09168218A0216|150 162|ganglion block
P09168511A0640|20 25|number
P09168511A0640|28 39|developments
P09168511A0640|76 92|steroid budesonide
P09168511A0640|99 111|dexamethasone
P09168511A0640|129 136|argument
P09168511A0640|145 152|steroids
P09168623A0614|22 27|fusion
P09168623A0614|40 51|mxbD promoter
P09168623A0614|67 76|expression
P09168623A0614|88 92|cells
P09168623A0614|100 109|one-carbon
P09168623A0614|114 122|compounds
P09168623A0614|137 146|expression
P09168623A0614|149 153|cells
P09168623A0614|161 169|succinate
P09168879A0219|17 24|Sf9 cells
P09168879A0219|29 51|transcription initiation
P09168879A0219|81 89|TAAG sites
P09168879A0219|115 123|TAAG sites
P09168892A1016|0 7|Mutation
P09168892A1016|10 20|nucleotides
P09168892A1016|52 59|elements
P09168892A1016|64 69|effect
P09168892A1016|72 87|trans-activation
P09169127A0371|8 16|proximity
P09169127A0371|25 50|neuropeptide Y receptor genes
P09169127A0371|83 102|gene duplication event
P09169127A0371|115 120|intron
P09169127A0371|142 149|sequence
P09169127A0371|155 160|y1 gene
P09169127A0371|190 197|sequence
P09169127A0371|207 212|y5 gene
P09169127A0371|241 248|sequence
P09169127A0371|297 302|y1 gene
P09169420A0000|12 36|phosphoinositide 3-kinases
P09169420A0000|37 41|PI3Ks
P09169420A0000|42 50|p110alpha
P09169420A0000|60 80|delta form heterodimers
P09169420A0000|84 94|Src homology
P09169420A0000|118 125|adaptors
P09169420A0000|131 138|p85alpha
P09169475A0272|5 11|studies
P09169475A0272|35 40|region
P09169475A0272|51 59|gp130 gene
P09169475A0272|77 104|transcription initiation sites
P09169475A0772|0 11|Localization
P09169475A0772|17 39|cytokine response element
P09169475A0772|42 57|deletion analysis
P09169475A0772|74 84|mutagenesis
P09169475A0772|104 114|binding site
P09169475A0772|127 139|STAT complexes
P09169593T0000|0 16|Insulin regulation
P09169593T0000|36 54|protein kinase kinase
P09169593T0000|77 89|protein kinase
P09169593T0000|92 103|casein kinase
P09169593T0000|109 119|cell nucleus
P09169593T0000|140 149|regulation
P09169593T0000|151 164|gene expression
P09169852A0235|0 9|Sequencing
P09169852A0235|20 31|pag-3 alleles
P09169852A0235|57 63|alleles
P09169852A0235|71 86|nonsense mutation
P09169852A0235|96 106|zinc fingers
P09169852A0235|111 126|missense mutation
P09169852A0235|138 147|zinc finger
P09169852A0235|172 180|histidine
P09169852A0235|184 191|tyrosine
P09169853A0000|0 4|Pax-3
P09169853A0000|19 30|homeobox gene
P09169853A0000|63 68|dorsal
P09170159A0348|29 33|cells
P09170159A0348|56 69|marker proteins
P09170159A0348|76 85|tyrosinase
P09170159A0348|107 113|protein
P09170159A0721|5 13|mutations
P09170159A0721|24 29|codons
P09170159A0721|83 90|proteins
P09170159A0721|97 103|HLH-Zip
P09170159A0721|106 117|Zip structure
P09171038A0219|13 19|Sjogren
P09171038A0219|20 27|syndrome
P09171038A0219|79 88|complaints
P09171038A0219|101 109|treatment
P09171038A0219|112 118|Sjogren
P09171038A0219|120 127|patients
P09171081T0000|0 6|Cloning
P09171081T0000|10 25|characterization
P09171081T0000|62 74|RNA polymerase
P09171081T0000|87 107|plant Chenopodium album
P09171235A0851|9 22|overexpression
P09171235A0851|35 47|concentration
P09171235A0851|50 57|COUP-TFI
P09171235A0851|64 78|COUP-TFI delta35
P09171235A0851|92 108|silencing activity
P09171235A0851|124 129|TRbeta
P09171239A1118|8 17|amino acids
P09171239A1118|42 46|helix
P09171239A1118|79 94|hormone receptors
P09171239A1118|109 118|core domain
P09171239A1118|140 162|transactivation function
P09171239A2146|27 32|ligand
P09171239A2146|60 66|binding
P09171239A2146|68 72|SRC-1
P09171239A2146|78 89|RXR component
P09171239A2146|104 114|heterodimer
P09171363A0149|2 9|ciliates
P09171363A0149|14 23|mechanisms
P09171389A0549|10 19|occurrence
P09171389A0549|29 48|transcription signals
P09171389A0549|54 77|Thermus pyr promoter region
P09171389A0549|87 113|amino acid sequence identities
P09171389A0549|130 140|Thermus PyrR
P09171389A0549|146 168|PyrR attenuation proteins
P09171389A0549|174 184|Bacillus sp.
P09171389A0549|205 213|mechanism
P09171389A0549|238 248|attenuation
P09171389A0549|258 274|pyr gene expression
P09171389A0549|277 283|Thermus
P09171468T0000|0 4|Diver
P09171468T0000|16 24|responses
P09171468T0000|49 66|breathing apparatus
P09171969A1165|0 10|Measurement
P09171969A1165|40 50|oxygen pulse
P09171969A1165|63 78|work rate exercise
P09171969A1165|103 112|evaluation
P09171969A1165|118 131|training effect
P09171969A1165|134 141|patients
P09172312T0000|0 15|Characterization
P09172312T0000|18 26|CR1 repeat
P09172312T0000|33 42|PCR markers
P09172312T0000|56 68|chicken genome
P09172414A0000|58 63|method
P09172414A0000|69 81|determination
P09172414A0000|84 101|cocaine metabolites
P09172414A0000|119 123|serum
P09172414A0000|127 140|liver esterases
P09172641A0181|10 16|studies
P09172641A0181|24 31|evidence
P09172641A0181|61 70|side chains
P09172641A0181|72 80|subdomain
P09172641A0181|96 103|contacts
P09172641A0181|111 121|nucleotides
P09172812A0660|17 27|fludarabine
P09172812A0660|43 47|agent
P09173733A0404|14 23|techniques
P09173733A0404|26 35|EA analysis
P09173733A0404|49 53|study
P09173733A0404|59 79|Fourier transformation
P09173733A0404|130 135|method
P09173733A0404|147 155|expansion
P09173733A0404|161 169|EEG curves
P09173733A0404|192 196|shape
P09173733A0404|198 211|factor analysis
P09173733A0404|229 237|densities
P09174049A1788|13 42|p34CDC2 histone H1 kinase activity
P09174049A1788|80 88|cell lines
P09174049A1788|118 124|protein
P09174049A1788|143 151|cell death
P09175708A1526|5 9|PRL-R
P09175708A1526|47 53|regions
P09175708A1526|65 72|receptor
P09175708A1526|84 94|possibility
P09175708A1526|105 112|fragment
P09175708A1526|158 164|nucleus
P09175858A1449|7 15|B-S mutant
P09175858A1449|55 60|GAPDHs
P09175858A1449|92 98|effects
P09175858A1449|129 138|inspection
P09175858A1449|158 167|structures
P09175858A1449|185 191|account
P09175858A1449|227 232|mutant
P09175858A1449|244 248|GAPDH
P09176340A1194|0 12|Transcription
P09176340A1194|20 24|genes
P09176340A1194|62 69|freezing
P09176340A1194|71 80|mRNA levels
P09176340A1194|88 94|tissues
P09176340A1194|110 114|liver
P09176837A0211|0 15|Computer software
P09176837A0211|61 64|PN Ca
P09176837A0211|63 73|P solubility
P09176837A0211|118 132|P administration
P09177169A0935|8 14|chimera
P09177169A0935|37 42|halves
P09177169A0935|48 55|molecule
P09177169A0935|86 93|bacteria
P09177857A0000|3 12|conditions
P09177857A0000|25 39|titanium dioxide
P09177857A0000|47 77|substrates titanium tetrachloride
P09177857A0000|81 86|oxygen
P09177857A0000|122 126|steel
P09177857A0000|147 152|plasma
P09177857A0000|160 189|chemical vapour deposition method
P09178269A0107|6 10|genes
P09178491A0262|13 19|regions
P09178491A0262|30 53|preS2/S gene transcription
P09178491A0262|59 71|HBV adw subtype
P09178491A0262|83 89|TATA box
P09178491A0262|102 117|initiator element
P09178494A1123|46 52|regions
P09178494A1123|61 68|patterns
P09178494A1123|80 93|loop structures
P09178494A1123|118 129|flaviviruses
P09178494A1123|150 158|selection
P09178494A1123|162 173|preservation
P09178494A1123|199 208|structures
P09178494A1123|243 249|control
P09178494A1123|253 263|replication
P09178752A0574|20 24|means
P09178752A0574|26 50|transactivation domain AF-1
P09178752A0574|71 95|transactivation domain AF-2
P09180687A0096|16 21|region
P09180687A0096|47 56|inhibition
P09180687A0096|58 69|cell division
P09180687A0096|84 89|series
P09180687A0096|115 123|deletions
P09180687A0096|136 141|series
P09180687A0096|143 168|alanine substitution mutants
P09181130A1067|17 23|Krox-20
P09181130A1067|36 48|recombination
P09181130A1067|51 57|ES cells
P09181130A1067|80 87|mutation
P09181130A1067|98 105|deletion
P09181130A1587a|32 39|analysis
P09181130A1587a|58 68|populations
P09181130A1587a|82 89|mutation
P09181130A1587a|102 106|light
P09181130A1587a|120 126|Krox-20
P09181130A1587a|131 142|segmentation
P09181130A1587a|164 175|consequences
P09181130A1587a|181 192|inactivation
P09182281A0197|30 41|Cyclosporin A
P09182527A0443|25 41|p53 ubiquitination
P09182527A0443|41 46|mE6-AP
P09182527A0443|64 70|nucleus
P09182527A0443|74 80|cytosol
P09182527A0443|86 91|Nedd-4
P09182527A0443|109 115|cytosol
P09182707A0254|25 47|tyrosine phosphorylation
P09182707A0254|54 67|adhesion kinase
P09182707A0254|88 101|tyrosine kinase
P09182707A0254|120 128|adhesions
P09182707A0254|160 174|protein paxillin
P09182990A0245|30 35|allele
P09182990A0245|38 42|SUP45
P09182990A0245|43 49|sup45-2
P09182990A0245|54 64|combination
P09182990A0245|83 92|approaches
P09182990A0245|113 119|product
P09182990A0245|125 133|SUP45 gene
P09182990A0245|134 139|Sup45p
P09182990A0245|151 156|factor
P09182990A0245|167 188|translation termination
P09182990A0245|191 195|yeast
P09183145T0001|0 9|Evaluation
P09183145T0001|22 30|perfusion
P09183145T0001|50 54|SPECT
P09183145T0001|109 119|angioplasty
P09183145T0001|138 147|infarction
P09183406A0637|19 34|thrombocytopenia
P09183406A0637|41 46|HPA-3a
P09183406A0637|53 67|incompatibility
P09185183A0089|27 31|years
P09185183A0089|58 66|worsening
P09185183A0089|68 81|motor abilities
P09185183T0000|0 6|Merosin
P09185183T0000|33 41|dystrophy
P09185183T0000|52 61|deficiency
P09185183T0000|62 69|epilepsy
P09185183T0000|73 82|MRI changes
P09185183T0000|101 106|matter
P09185586A0000|14 18|mRNAs
P09185586A0000|35 50|scanning ribosome
P09185586A0000|51 59|mechanism
P09185645T0000|0 9|Comparison
P09185645T0000|12 42|Tc-99m sestamibi perfusion imaging
P09185645T0000|46 61|echocardiography
P09185645T0000|69 86|arbutamine infusion
P09185645T0000|93 101|detection
P09185645T0000|112 124|artery disease
P09186056A0514|13 26|overexpression
P09186056A0514|33 39|protein
P09186056A0514|42 51|C2C12 cells
P09186056A0514|62 74|transcription
P09186056A0514|78 89|CAT-reporter
P09186056A0514|103 110|E12/MyoD
P09186056A0514|117 124|enhancer
P09186430A0341|37 44|albinism
P09186507A0882|46 53|sequence
P09186507A0882|82 93|cDNA sequence
P09186507A0882|112 120|CpG island
P09186507A0882|136 144|CAAT boxes
P09186507A0882|161 170|G+C content
P09186507A0882|185 200|CpG dinucleotides
P09187136A0000|0 5|SSeCKS
P09187136A0000|16 20|essex
P09187136A0000|34 56|protein kinase C substrate
P09187136A0000|60 69|expression
P09187136A0000|124 134|fibroblasts
P09187136A0000|163 173|fibroblasts
P09187277A0118|7 31|position-vestibular-pause
P09187277A0118|31 34|PVP I
P09187277A0118|58 64|neurons
P09187277A0118|79 84|number
P09187277A0118|129 135|neurons
P09187371A0450|15 25|mRNA species
P09187371A0450|44 48|heart
P09187371A0450|61 67|species
P09187371A0450|81 85|heart
P09187371A0450|86 91|kidney
P09187371A0450|95 99|brain
P09187371A0450|116 121|muscle
P09187371A0450|124 128|liver
P09187637A1199|0 16|Taurine deficiency
P09187637A1199|42 50|amplitude
P09188094A0934|21 25|cells
P09188094A0934|39 48|activation
P09188094A0934|59 66|response
P09188094A0934|75 79|forms
P09188094A0934|82 87|stress
P09188699A1388|11 25|rat SP-A isoforms
P09188699A1388|77 87|SP-A species
P09188699A1388|99 110|SDS-PAGE gels
P09188863A0954|11 18|splicing
P09188863A0954|21 26|CDC25B
P09188863A0954|54 60|control
P09188863A0954|63 79|cell proliferation
P09189783A0000|4 16|investigation
P09189783A0000|69 76|feedings
P09189783A0000|90 101|carbohydrate
P09189783A0000|124 128|bolus
P09189783A0000|139 150|blood glucose
P09189783A0000|154 169|insulin responses
P09189783A0000|185 192|exercise
P09189896A0611|3 10|findings
P09189896A0611|22 31|ERP effects
P09189896A0611|42 56|memory processes
P09189896A0611|97 108|instructions
P09190202A0166|4 14|coat protein
P09190202A0166|25 29|Sar1p
P09190202A0166|33 52|Sec23p protein complex
P09190202A0166|63 68|Sec23p
P09190202A0166|72 77|Sec24p
P09190202A0166|84 103|Sec13p protein complex
P09190202A0166|114 119|Sec13p
P09190202A0166|136 142|protein
P09190821A0707|50 55|change
P09190821A0707|58 65|position
P09190821A0707|69 73|P243L
P09190940A0127|0 8|Induction
P09190940A0127|27 45|germline transcripts
P09190940A0127|66 77|switch region
P09190940A0127|81 93|recombination
P09190940A0127|97 105|switching
P09191052A0850|18 32|Pbx dimer partner
P09191052A0850|49 53|Class
P09191052A0850|55 65|Hox proteins
P09192732A1384|26 32|portion
P09192732A1384|38 46|homologue
P09192732A1384|77 84|membrane
P09192769T0000|9 15|cloning
P09192769T0000|19 34|characterization
P09192769T0000|44 49|CHEMR1
P09192769T0000|58 74|chemokine receptor
P09192769T0000|80 87|homology
P09192769T0000|98 117|C-C chemokine receptor
P09192769T0000|118 122|CCR-4
P09192786T0000|0 11|Organization
P09192786T0000|22 27|LU gene
P09192786T0000|40 44|basis
P09192786T0000|59 80|blood group polymorphism
P09192842A0988|23 29|hybrids
P09192842A0988|33 44|FISH analysis
P09192842A0988|48 55|PE-2 gene
P09192842A0988|74 90|chromosome 19q13.2
P09192842A0988|91 96|region
P09192842A0988|107 120|translocations
P09192842A0988|124 132|deletions
P09192842A0988|135 143|leukemias
P09192842A0988|159 164|tumors
P09192842A0988|188 196|ETS factor
P09192842A0988|213 226|carcinogenesis
P09192998A0356|16 22|enzymes
P09192998A0356|49 58|terminator
P09192998A0356|61 65|T7 DNA
P09192998A0356|76 81|rrnB T2
P09192998A0356|109 124|termination sites
P09192998A0356|127 132|rrnB T1
P09192998A0356|166 174|CJ signals
P09193072A0199|31 40|transgenes
P09193072A0199|54 62|nucleolus
P09193077A0000|79 88|activation
P09193077A0000|92 107|chalcone synthase
P09193077A0000|120 127|promoter
P09193077A0000|129 147|Petroselinum crispum
P09193080A0904|0 17|Sequence divergence
P09193080A0904|42 48|regions
P09193080A0904|63 72|definition
P09193080A0904|88 93|probes
P09193671A0347|9 13|state
P09193671A0347|28 37|hydrolysis
P09193671A0347|67 73|ARF-GDP
P09194250A0708|25 35|World Summit
P09194250A0708|39 46|Children
P09194250A0708|58 72|mortality target
P09194250A0708|102 108|targets
P09194250A0708|128 139|inequalities
P09194250A0708|152 160|mortality
P09195923A0125|3 14|immunophilin
P09195923A0125|30 34|FK506
P09195923A0125|37 61|cyclosporin A-binding class
P09195923A0125|69 73|hsp90
P09195923A0125|80 102|tetratricopeptide repeat
P09195923A0125|108 113|domain
P09195923A0125|125 147|receptor heterocomplexes
P09195923A0125|171 182|immunophilin
P09195923A0125|205 210|region
P09195923A0125|213 217|hsp90
P09197241A0770|10 20|macrophages
P09197241A0770|21 27|absence
P09197241A0770|44 63|hyperphosphorylation
P09197241A0770|66 80|hyperactivation
P09197241A0770|83 88|p56/59
P09197241A0770|96 101|p53/56
P09197241A0770|117 121|c-fgr
P09197342T0000|0 8|Secretion
P09197342T0000|34 41|transfer
P09197342T0000|59 68|Lipiodol UF
P09197342T0000|71 77|Oriodol
P09197342T0000|80 86|rabbits
P09197408A0126|0 9|Sequencing
P09197408A0126|15 22|facB gene
P09197408A0126|45 51|protein
P09197408A0126|89 93|2Cys6
P09197408A0126|95 100|C6 zinc
P09197408A0126|110 116|cluster
P09197408A0126|120 129|DNA binding
P09197408A0126|130 136|leucine
P09197408A0126|148 165|heptad repeat motifs
P09197408A0126|208 214|regions
P09197408A0126|230 237|function
P09197408A0126|267 275|activator
P09199167A0942|0 13|Overexpression
P09199167A0942|16 20|Sed5p
P09199167A0942|28 33|growth
P09199167A0942|39 45|absence
P09199167A0942|48 52|Vti1p
P09199286A0086|9 14|region
P09199286A0086|78 84|protein
P09199292A0536|24 34|association
P09199292A0536|61 72|cyclin E-cdk2
P09199292A0536|73 84|cyclin A-cdk2
P09199292A0536|95 104|activities
P09199292A0536|112 118|kinases
P09199318A1147|27 39|actin gelation
P09199318A1147|61 79|muscle alpha-actinin
P09199322T0000|0 11|Denaturation
P09199322T0000|23 27|virus
P09199322T0000|30 35|origin
P09199322T0000|38 48|replication
P09199322T0000|64 83|replication protein A.
P09199327A1250|4 9|effect
P09199327A1250|29 35|EM motif
P09199327A1250|58 66|construct
P09199327A1250|109 131|transactivation function
P09199327A1250|137 145|TEF-1-Max
P09199327A1250|157 163|complex
P09199327A1250|181 187|binding
P09199327A1250|193 199|complex
P09199327A1250|205 211|EM motif
P09199328T0000|14 21|residues
P09199328T0000|34 39|region
P09199328T0000|60 64|Oct-1
P09199348A0156|38 52|U14 interactions
P09199348A0156|62 67|domain
P09199348A0156|79 86|activity
P09199348A0156|112 118|U14 RNAs
P09199348A0156|122 128|Y domain
P09199348A0156|166 173|analysis
P09199353A1924|12 18|results
P09199353A1924|29 33|Cdc68
P09199353A1924|54 62|regulator
P09199353A1924|65 82|chromatin structure
P09199353A1924|98 112|polymerase alpha
P09199353A1924|133 140|proteins
P09199353A1924|147 152|access
P09199353A1924|158 165|template
P09199353A1924|170 176|origins
P09199353A1924|179 189|replication
P09199413A0518|11 22|inoculum size
P09199413A0518|48 56|CFU/mouse
P09199413A0518|81 87|animals
P09199626A0613|4 8|cases
P09199626A0613|15 20|change
P09199626A0613|22 26|stage
P09199932A1357|0 28|Promoter recognition algorithms
P09199932A1357|48 63|promoter elements
P09199932A1357|73 81|CpG island
P09199932A1357|109 121|E14/NPAT genes
P09199932A1357|131 138|evidence
P09199932A1357|157 167|ATM promoter
P09199932A1357|181 186|intron
P09199970A1101|34 46|transmembrane
P09199970A1101|60 66|domains
P09199970A1101|70 75|factor
P09199970A1101|77 92|cofactor activity
P09199970A1101|95 105|C3b cleavage
P09200029A0211|25 29|signs
P09200029A0211|50 56|setting
P09200029A0211|63 71|diagnosis
P09200029A0211|92 99|features
P09200029A0211|106 126|bone marrow examination
P09200498T0000|7 11|zones
P09200498T0000|15 32|muscle coactivation
P09200498T0000|39 45|control
P09200498T0000|56 64|stability
P09200530A0411|0 5|Liquid
P09200530A0411|21 30|separation
P09200530A0411|45 54|Zorbax RX C8
P09200530A0411|65 70|column
P09200530A0411|76 90|gradient elution
P09200811T0000|9 20|plasmid pDHL1
P09200811T0000|53 59|protein
P09200811T0000|81 106|pGKL1-plasmid DNA polymerase
P09201946A0000|24 41|helicase activities
P09201946A0000|62 94|transcription termination factor rho
P09201946A0000|127 138|RNA molecules
P09201946A0000|155 172|nucleotide residues
P09201946A0000|175 180|length
P09201946A0000|198 201|trp t
P09201946A0000|215 233|termination sequence
P09201980A0910|3 15|p20-CGGBP gene
P09201980A0910|32 38|mammals
P09201980A0910|49 56|homology
P09201980A0910|73 79|species
P09202147A0866|26 30|yeast
P09202147A0866|32 37|plants
P09202147A0866|46 54|subfamily
P09202147A0866|100 110|degradation
P09202147A0866|120 127|proteins
P09202147A0866|130 135|result
P09202147A0866|138 143|stress
P09202669A0614|3 8|pWP-19
P09202669A0614|44 50|repeats
P09202669A0614|53 63|integration
P09202669A0614|67 77|replication
P09202669A0614|84 109|herpes virus thymidine kinase
P09202669A0614|134 151|neomycin resistance
P09202669A1530|29 46|gene transfer system
P09202669A1530|53 68|rat preproinsulin
P09202859A0091|3 13|serum levels
P09202859A0091|16 25|beta-human
P09202859A0091|35 46|gonadotropin
P09202859A0091|64 82|alkaline phosphatase
P09203585A0660|9 15|feature
P09203585A0660|32 40|H19 allele
P09203585A0660|46 55|occurrence
P09203585A0660|67 73|imprint
P09203585A0660|82 103|neo replacement cassette
P09203586A1197|17 27|recruitment
P09203586A1197|35 42|T antigen
P09203586A1197|48 59|rRNA promoter
P09203586A1197|97 113|activation process
P09203731A0497|8 30|International Commission
P09203731A0497|37 49|Certification
P09203731A0497|52 62|Eradication
P09203731A0497|65 88|Poliomyelitis Eradication
P09203731A0497|89 93|ICCPE
P09203731A0497|113 141|Pan American Health Organization
P09203731A0497|165 176|transmission
P09204566T0000|23 30|analysis
P09204566T0000|39 44|copies
P09204566T0000|50 62|fixNOQP operon
P09204566T0000|65 96|Rhizobium leguminosarum strain VF39
P09204570A0110|4 8|study
P09204570A0110|22 32|MADS box gene
P09204570A0110|33 37|nmhC5
P09205113A0587|9 13|TG3B1
P09205113A0587|22 31|ES cell line
P09205113A0587|47 57|mouse genome
P09205113A0587|66 73|HPRT gene
P09205113A0587|77 91|selection marker
P09205113A0587|98 109|transmission
P09205113A0587|117 125|frequency
P09205113A0587|133 145|mouse germ line
P09205677A0577|21 26|damage
P09205677A0577|35 44|indicators
P09205677A0577|51 57|outcome
P09205677A0577|75 81|disease
P09205965A1249|3 9|results
P09205965A1249|35 45|micturition
P09205965A1249|60 73|bladder filling
P09205965A1249|77 82|L-dopa
P09205965A1249|102 108|pathway
P09205965A1249|114 125|transmission
P09205965A1249|144 169|spinal alpha 1-adrenoceptors
P09206230A0000|0 8|OBJECTIVE
P09206230A0000|13 17|study
P09206230A0000|47 51|cause
P09206230A0000|54 63|asthenopia
P09206230A0000|69 79|astigmatism
P09206968A0000|0 10|Disturbance
P09206968A0000|13 24|regeneration
P09206968A0000|47 55|condition
P09206968A0000|70 75|damage
P09206968A0000|78 90|tunica propria
P09206968A0000|105 112|function
P09206968A0000|118 124|support
P09206968A0000|137 147|homeostasis
P09208214A0572|0 18|Sternocleidomastoid
P09208214A0572|33 39|muscles
P09208214A0572|66 70|cases
P09208930T0000|0 13|Identification
P09208930T0000|23 27|genes
P09208930T0000|47 63|interleukin-1beta
P09208930T0000|74 83|enzyme gene
P09208930T0000|109 117|proteases
P09209031A0350|19 24|region
P09209031A0350|49 71|serine carboxypeptidases
P09209312A0968|3 14|RNA construct
P09209312A0968|34 44|nucleotides
P09209312A0968|89 95|complex
P09209312A0968|124 134|nucleotides
P09209372A0345|21 25|AML1a
P09209372A0345|42 48|effects
P09209372A0345|67 75|regulator
P09209372A0345|111 120|activation
P09209372A0345|123 127|AML1b
P09209372A0345|135 139|AML1a
P09209372A0345|157 164|affinity
P09209372A0345|183 187|AML1b
P09209406A1021|34 40|regions
P09209406A1021|45 76|guanine nucleotide exchange factors
P09209406A1021|96 103|proteins
P09209406A1021|109 117|c-cbl gene
P09209438A0994|12 18|ATL-16T
P09209438A0994|26 32|extract
P09209438A0994|51 56|GATA-4
P09209438A0994|78 84|protein
P09209438A0994|113 119|complex
P09209438A0994|130 137|GATA site
P09210012A0000|3 8|impact
P09210012A0000|17 23|support
P09210012A0000|29 41|relationships
P09210012A0000|51 57|couples
P09210478A0000|41 48|factor-1
P09210478A0000|49 53|HIF-1
P09210478A0000|66 75|expression
P09210478A0000|84 89|number
P09210478A0000|108 112|genes
P09211354A0000|0 12|Stromelysin-1
P09211354A0000|13 37|matrix metalloproteinase-3
P09211354A0000|38 42|MMP-3
P09211354A0000|56 68|endopeptidase
P09211354A0000|98 102|cells
P09211354A0000|105 116|organ tissues
P09211605A0478|0 5|Tendon
P09211605A0478|16 21|degree
P09211605A0478|24 36|extensibility
P09211675A0392|0 11|Surveillance
P09211675A0392|15 26|preeclampsia
P09211675A0392|41 49|personnel
P09211675A0392|74 84|assignments
P09211675A0392|102 113|measurements
P09211675A0392|116 128|blood pressure
P09211675A0392|139 154|protein excretion
P09211675A0392|183 188|visits
P09211675A0392|189 197|protocols
P09211675A0392|216 227|measurements
P09211675A0392|237 251|hospitalization
P09211675A0392|255 262|delivery
P09211675A0392|266 272|reviews
P09211675A0392|282 288|records
P09211675A0392|302 317|outpatient visits
P09211675A0392|324 339|hospitalizations
P09211913A0000|0 22|Aryl hydrocarbon receptor
P09211913A0000|30 41|translocator
P09211913A0000|51 59|component
P09211913A0000|64 83|transcription factors
P09211913A0000|84 106|aryl hydrocarbon receptor
P09211913A0000|132 137|factor
P09211913A0000|161 171|target genes
P09211913A0000|178 183|CYP1A1
P09211913A0000|187 200|erythropoietin
P09211913A0000|203 210|response
P09211913A0000|231 242|hydrocarbons
P09211913A0000|253 265|concentration
P09211934A0722|0 4|DNase
P09211934A0722|6 22|footprint analysis
P09211934A0722|43 48|region
P09211981A0526|13 20|evidence
P09211981A0526|81 86|kinase
P09211981A0526|112 119|extracts
P09211981A0526|153 160|activity
P09211981A0526|187 192|kinase
P09212059A1356|20 51|metal affinity chromatography assay
P09212059A1356|52 67|self-association
P09212059A1356|119 123|DhLBD
P09212059A1356|125 138|hLBD constructs
P09212059A1856|10 16|results
P09212059A1856|23 27|paper
P09212059A1856|48 57|conclusion
P09212059A1856|114 127|PR dimerization
P09212059A1856|142 148|regions
P09212059A1856|161 165|hinge
P09212059A1856|183 191|sequences
P09212059A1856|230 245|homodimerization
P09212063A0425|28 34|A-phage
P09212063A0425|38 49|cosmid clones
P09212063A0425|107 113|VDR gene
P09214274T0001|10 18|carcinoma
P09214274T0001|30 37|approach
P09214274T0001|40 47|patients
P09214274T0001|66 84|metastasis resection
P09215525A0581|18 24|effects
P09215525A0581|27 35|cell cycle
P09215525A0581|40 46|changes
P09215525A0581|49 63|E2F/DP complexes
P09215525A0581|67 74|activity
P09215525A0581|92 104|C2C12 myocytes
P09215891A0000|3 10|products
P09215891A0000|54 62|CIN4 genes
P09215891A0000|87 93|pathway
P09215891A0000|111 129|microtubule function
P09216017A0621|0 9|Vitrectomy
P09216017A0621|30 39|risk factor
P09216017A0621|51 55|holes
P09216936T0000|7 15|editorial
P09216936T0000|33 39|effects
P09216936T0000|42 49|exercise
P09216936T0000|52 63|leptin levels
P09216936T0000|66 71|humans
P09218436A0443|4 12|promoters
P09218436A0443|18 24|TATA box
P09218436A0443|46 55|MED-1 class
P09218436A0443|57 65|promoters
P09218436A0443|79 91|transcription
P09218436A0443|102 106|sites
P09218459A0000|0 18|Serum response factor
P09218459A0000|25 30|member
P09218459A0000|41 46|family
P09218459A0000|60 67|proteins
P09218459A0000|101 119|transcription factor
P09218459A0000|140 145|growth
P09218459A0000|163 167|genes
P09218520A0075|15 21|studies
P09218520A0075|32 57|candidate signal transducers
P09218520A0075|87 92|domain
P09218520A0075|102 106|IL-1R
P09218599A0184|6 10|study
P09218599A0184|29 38|mechanisms
P09218599A0184|74 80|effects
P09218775A0000|21 27|strains
P09218775A0000|37 44|patients
P09218775A0000|55 62|fibrosis
P09218775A0000|81 89|phenotype
P09218775A0000|94 107|overproduction
P09218775A0000|110 117|alginate
P09218775A1229|0 7|Activity
P09218775A1229|10 14|palgD
P09218775A1229|20 29|cysB mutant
P09218775A1229|55 63|strain PAO
P09218775A1229|102 116|algD-xylE fusion
P09219526A0383|19 29|specificity
P09219526A0383|35 47|cDNA construct
P09219526A0383|64 74|observation
P09219526A0383|82 97|peptide sequences
P09219526A0383|153 160|fragment
P09219526A0383|185 190|region
P09220158A0537|14 20|protein
P09220158A0537|53 62|processing
P09220158A0537|83 90|sequence
P09220158A0537|93 102|amino acids
P09220158A0537|113 117|ORF-2
P09220158A0537|121 147|baculovirus expression vector
P09220158A0537|172 176|virus
P09220158A0537|185 192|Sf9 cells
P09220177A0564|3 17|CPK-MB isoenzyme
P09220177A0564|26 43|percentage increase
P09220177A0564|98 102|shock
P09220177A0564|116 121|number
P09220177A0564|124 131|attempts
P09220177A0564|134 146|cardioversion
P09222057A0176|0 4|Serum
P09222057A0176|18 30|dialysis fluid
P09222057A0176|52 56|assay
P09222057A0176|69 74|course
P09222057A0176|80 84|study
P09222115A0545|0 6|Results
P09222115A0545|17 26|hypothesis
P09222115A0545|64 69|factor
P09222115A0545|96 106|binding site
P09222115A0545|136 157|response characteristic
P09222115A0545|180 184|phase
P09222115A0545|186 194|isolation
P09222115A0545|202 213|surroundings
P09223042A0000|0 4|Liver
P09223042A0000|13 23|blood volume
P09223042A0000|48 60|disease states
P09223042A0000|70 74|drugs
P09223122A0774|7 23|matter NAA/mI ratio
P09223122A0774|46 51|groups
P09223229A0565|23 31|mb-1 genes
P09223229A0565|36 41|region
P09223229A0565|53 60|mb-1 gene
P09223229A0565|68 74|TATA box
P09223475A0898|0 37|Chloramphenicol acetyltransferase assays
P09223475A0898|50 56|ability
P09223475A0898|74 81|activity
P09223475A0898|101 108|promoter
P09223475A0898|132 139|promoter
P09223475A0898|151 155|class
P09223475A0898|189 197|integrity
P09223475A0898|202 212|IE86 protein
P09223479A1193|0 4|ORF M1
P09223479A1193|16 23|homology
P09223479A1193|26 40|poxvirus serpins
P09223479A1193|46 51|ORF M11
P09223479A1193|69 75|homolog
P09223479A1193|88 96|molecules
P09223479A1193|111 128|gammaherpesviruses
P09223479A1193|159 167|BHRF1 gene
P09223506T0000|0 30|Transcription factor binding sites
P09223506T0000|51 75|immunodeficiency virus type
P09223506T0000|77 98|transcription start site
P09223506T0000|114 129|virus infectivity
P09223647T0000|0 15|Crystal structure
P09223647T0000|20 27|oligomer
P09223647T0000|41 48|zymogens
P09223647T0000|71 78|analysis
P09223647T0000|97 103|complex
P09223647T0000|107 118|implications
P09223647T0000|127 136|activation
P09223667A0139|16 27|transfection
P09223667A0139|30 50|NIH3T3 fibroblast cells
P09223667A0139|54 75|gel mobility shift assays
P09223667A0139|89 99|binding site
P09223667A0139|120 125|region
P09223667A0139|147 168|transcription start site
P09223667A0139|177 189|CTCCC sequence
P09223880A1147|17 30|injection speed
P09223880A1147|35 42|.2 ml.s-1
P09223880A1147|62 71|anesthesia
P09224655T0000|11 18|splicing
P09224655T0000|21 25|ClC-6
P09224655T0000|27 32|member
P09224655T0000|38 62|CIC chloride-channel family
P09224655T0000|63 73|transcripts
P09224655T0000|97 104|isoforms
P09224655T0000|115 120|ClC-6c
P09224811A0000|10 14|study
P09224811A0000|43 55|transcription
P09224811A0000|61 65|NADPH
P09224811A0000|65 92|cytochrome P450 oxidoreductase
P09224811A0000|93 97|P450R
P09224811A0000|120 126|thyroid
P09224811A0000|134 139|status
P09224811A0000|145 150|animal
P09224811A0000|197 204|pathways
P09224811A0000|242 255|P450R mRNA level
P09225151T0000|3 10|behavior
P09225151T0000|22 26|types
P09225151T0000|29 51|polytetrafluoroethylene
P09225151T0000|58 67|prostheses
P09225151T0000|82 96|scarring process
P09225151T0000|108 118|wall defects
P09225506A0462|3 14|control group
P09225506A0462|42 47|levels
P09225506A0462|50 67|coagulation factors
P09225506A0462|95 104|index group
P09225682A0579|3 11|frequency
P09225682A0579|30 43|antibody titers
P09225682A0579|63 78|syndrome patients
P09225682A0579|90 97|isolates
P09225682A0579|133 140|syndrome
P09225682A0579|144 149|Fisher
P09225682A0579|151 166|syndrome patients
P09225682A0579|181 188|isolates
P09225686A0683|12 34|radiofrequency lesioning
P09225686A0683|40 48|hamartoma
P09225686A0683|59 74|seizure remission
P09225686A0683|82 94|complications
P09225686A0683|97 102|months
P09225686A0683|108 114|surgery
P09225998A0000|0 32|NF-kappa B/Rel transcription factors
P09225998A0000|49 58|activation
P09225998A0000|69 73|genes
P09225998A0000|90 112|regulation/inflammation
P09225998A0000|122 130|cytokines
P09225998A0000|131 150|cell surface receptors
P09225998A0000|151 167|adhesion molecules
P09225998A0000|176 188|phase proteins
P09226113A0857|22 38|source water sample
P09226113A0857|42 49|borehole
P09226113A0857|73 80|borehole
P09226345A0436|11 20|food intake
P09226345A0436|27 32|% group
P09226345A0436|49 56|ACT group
P09226345A0436|101 108|SEP group
P09226345A0436|120 126|amounts
P09226345A0436|150 160|requirement
P09227099A0106|12 20|technique
P09227099A0106|31 42|modification
P09227099A0106|46 62|bar superstructure
P09227099A0106|78 87|advantages
P09227099A0106|90 100|convenience
P09227099A0106|101 108|security
P09227099A0106|166 175|angulation
P09227099A0106|178 185|implants
P09227099A0106|193 200|accuracy
P09227332A1798|2 8|summary
P09227332A1798|21 29|receptors
P09227332A1798|38 42|panel
P09227332A1798|45 53|cytokines
P09227332A1798|58 66|receptors
P09227332A1798|70 78|cytokines
P09227332A1798|84 90|effects
P09227799A0254|49 60|surveillance
P09227799A0254|73 82|comparison
P09227799A0254|107 111|tests
P09227799A0254|112 127|stool examination
P09227799A0254|128 132|ELISA
P09227799A0254|144 153|egg antigen
P09227799A0254|175 188|precipitin test
P09228042A0109|16 42|dermatan sulfate proteoglycan
P09228042A0109|43 51|epiphycan
P09228042A0109|56 62|decorin
P09228042A0109|66 73|biglycan
P09228042A0109|93 102|extraction
P09228042A0109|116 134|epiphyseal cartilage
P09228042A0109|155 166|ion-exchange
P09228042A0109|167 179|gel permeation
P09228042A0109|199 205|chelate
P09228042A0109|220 224|steps
P09228092A1779|5 12|analyses
P09228092A1779|31 45|dUTPase isoforms
P09228092A1779|91 101|transcripts
P09228092A1779|137 141|exons
P09228202A0581|12 45|5-HT3 receptor antagonists ramosetron
P09228202A0581|46 50|YM060
P09228202A0581|51 55|YM114
P09228202A0581|56 62|KAE-393
P09228202A0581|63 73|granisetron
P09228202A0581|77 87|ondansetron
P09228202A0581|105 114|benzamides
P09228202A0581|115 139|5-HT4 receptor agonist/5-HT
P09228202A0581|140 158|receptor antagonists
P09228202A0581|159 176|cisapride mosapride
P09228202A0581|180 187|SC-53116
P09228202A0581|219 226|emptying
P09229420A0158|0 12|Re-evaluation
P09229420A0158|18 31|biopsy specimen
P09229420A0158|77 85|operation
P09229420A0158|90 94|areas
P09229420A0158|97 110|chondrosarcoma
P09229420A0158|123 132|background
P09229420A0158|143 156|chondromatosis
P09229595A0618|3 16|corneal buttons
P09229595A0618|51 58|electron
P09229595A0618|70 76|studies
P09230129A0039|19 29|homogeneity
P09230129A0039|36 41|% yield
P09230129A0039|44 65|affinity chromatography
P09230129A0039|75 87|DNA-cellulose
P09230129A0039|91 96|purity
P09230129A0039|107 117|preparation
P09230129A0039|131 138|SDS/PAGE
P09230129A0039|147 159|contamination
P09230129A0039|166 174|nucleases
P09230129A0039|178 187|production
P09230129A0039|203 210|antibody
P09230129A0039|221 226|enzyme
P09230216T0000|16 30|glycosylase maps
P09230216T0000|33 51|chromosome 12q22-q24
P09230216T0000|54 59|region
P09230216T0000|74 87|heterozygosity
P09230216T0000|96 101|cancer
P09230307A0329|22 27|GATA-1
P09230307A0329|42 52|development
P09230307A0329|84 88|cells
P09230384A0725|7 11|times
P09230384A0725|14 22|detection
P09230384A0725|28 39|mycobacteria
P09230384A0725|44 49|BACTEC
P09230384A0725|61 66|BACTEC
P09230384A1056|9 14|BACTEC
P09230384A1056|19 26|MB system
P09230384A1056|54 62|specimens
P09230384A1056|111 118|recovery
P09230384A1056|121 132|mycobacteria
P09230384A1056|145 153|specimens
P09230384A1056|179 183|sites
P09230894A0422|18 24|KmMig1p
P09230945A0089|16 24|deformity
P09230986A0000|0 20|Autoimmune neutropenia
P09230986A0000|37 41|cause
P09230986A0000|50 60|neutropenia
P09230986A0000|81 88|children
P09232593A0946|4 9|regard
P09232593A0946|29 45|expression pattern
P09232593A0946|48 56|DJ protein
P09232593A0946|74 84|repeat units
P09232593A0946|103 107|roles
P09233487A1386|6 13|analysis
P09233487A1386|25 39|outcome measures
P09233487A1386|42 52|performance
P09233487A1386|90 96|benefit
P09233487A1386|99 110|ear selection
P09233487A1386|119 127|Prom-EABR
P09233772A0136|4 10|protein
P09233772A0136|55 60|weight
P09233772A0136|60 64|EMBO J
P09233772A0136|101 107|domains
P09233772A0136|120 126|regions
P09233772A0136|142 148|repeats
P09233772A0136|167 188|cell cycle regulator RCC1
P09233772A0136|190 220|guanine nucleotide exchange factor
P09233772A0136|243 252|protein Ran
P09233772A0136|269 275|domains
P09233772A0136|295 305|beta subunit
P09233772A0136|322 330|G proteins
P09233772A0136|344 358|SH3 binding sites
P09233772A0136|368 381|leucine-zipper
P09233772A0136|402 425|HECT domain characteristic
P09233772A0136|428 453|E3 ubiquitin-protein ligases
P09233801A1180|7 17|L45 sequence
P09233801A1180|25 40|kinase subdomains
P09233801A1180|58 79|TGF-beta responsiveness
P09233801A1180|91 98|receptor
P09233809A0381|6 15|mouse lines
P09233809A0381|39 51|Hnf3g-lacZ YAC
P09233809A0381|118 127|expression
P09233809A0381|150 159|Hnf3g locus
P09233809A0381|169 176|elements
P09233809A0381|191 200|regulation
P09233809A0381|203 207|Hnf3g
P09233809A0815|21 30|transgenes
P09233809A0815|34 46|gene targeting
P09233809A0815|62 75|Hnf3g gene locus
P09233809A0815|112 117|region
P09233809A0815|161 182|reporter gene expression
P09233809A0815|184 188|liver
P09233809A0815|189 196|pancreas
P09233809A0815|197 203|stomach
P09233809A0815|212 220|intestine
P09233811A0072|4 13|regulation
P09233811A0072|25 39|HMG-box proteins
P09233811A0072|53 76|Ste11 transcription factor
P09233811A0072|102 115|protein Mat1-Mc
P09234677A0770|19 28|hypothesis
P09234677A0770|41 51|transcripts
P09234677A0770|54 61|proteins
P09234677A0770|84 94|transcripts
P09234677A0770|113 123|respiration
P09234690A0242|0 7|Upstream
P09234690A0242|18 26|sequences
P09234690A0242|65 69|genes
P09234690A0242|153 163|binding site
P09234690A0242|172 178|protein
P09234696A0238|9 29|protein kinase cascades
P09234696A0238|67 73|protein
P09234696A0238|79 85|kinases
P09234703A0192|44 55|G proteins Rac
P09234703A0192|58 62|Cdc42
P09234713A0754|6 10|study
P09234713A0754|23 28|notion
P09234713A0754|69 77|formation
P09234713A0754|122 140|double-strand breaks
P09234713A0754|156 162|Ddelta3
P09234713A0754|167 173|Jdelta1
P09234717A0000|6 12|studies
P09234717A0000|48 61|protein product
P09234717A0000|66 84|c-cbl proto-oncogene
P09234717A0000|94 102|substrate
P09234717A0000|106 111|number
P09234717A0000|130 144|tyrosine kinases
P09234717A0000|148 161|forms complexes
P09234717A0000|196 203|proteins
P09234717A0000|223 240|signal transduction
P09234720A1015|43 48|MEK-2E
P09234720A1015|51 55|v-Src
P09234720A1015|99 108|H19-7 cells
P09234720A1015|109 120|coexpression
P09234720A1015|154 158|v-Src
P09234720A1015|165 180|neurite outgrowth
P09234723A0846|4 12|mechanism
P09234723A0846|17 24|contrast
P09234723A0846|32 36|cases
P09234723A0846|39 56|splicing regulation
P09234723A0846|74 80|protein
P09234723A0846|92 101|splice site
P09234725A1892|33 47|transactivation
P09234725A1892|52 69|interaction surface
P09234725A1892|93 107|transrepression
P09234725A1892|110 121|AP-1 activity
P09234727A0770|8 20|fusion protein
P09234727A0770|30 42|transcription
P09234727A0770|46 57|reporter gene
P09234727A0770|67 74|promoter
P09234727A0770|99 109|DNA elements
P09234736A0999|6 26|hybridization analysis
P09234736A0999|34 42|rat tissue
P09234736A0999|54 64|correlation
P09234736A0999|73 79|pattern
P09234736A0999|96 102|drm mRNA
P09234736A0999|164 168|cells
P09234736A0999|175 181|neurons
P09234736A0999|189 197|lung cells
P09234736A0999|200 210|goblet cells
P09234743A0475|14 21|proteins
P09234743A0475|55 66|alpha-globin
P09234743A0475|119 133|binding proteins
P09234743A0475|137 149|alpha-complex
P09235073A0000|2 6|years
P09235073A0000|11 16|months
P09235073A0000|26 32|patient
P09235073A0000|40 48|diagnosis
P09235073A0000|51 64|Weaver syndrome
P09235424A1200|10 17|measures
P09235424A1200|24 29|nurses
P09235424A1200|54 58|women
P09235424A1200|74 79|effect
P09235618A0000|3 8|series
P09235618A0000|11 18|patients
P09235618A0000|23 36|neuroinfection
P09235618A0000|37 47|Lyme disease
P09235618A0000|48 68|Guillain Barre syndrome
P09235618A0000|69 83|demyelinization
P09235618A0000|104 111|epilepsy
P09235618A0000|146 155|antibodies
P09235618A0000|166 176|IgM subtypes
P09235618A0000|201 207|factors
P09235618A0000|208 213|member
P09235618A0000|216 227|thrombocytes
P09235618A0000|228 244|sedimentation rate
P09235618A0000|247 258|erythrocytes
P09235995A0339|0 4|1996a
P09235995A0339|5 16|Biochemistry
P09235998A0788|9 26|membrane expression
P09235998A0788|29 33|alpha
P09235998A0788|37 48|beta subunits
P09235998A0788|62 72|cholesterol
P09235998A0788|76 93|17-ketocholesterol
P09235998A0788|112 127|HMG-CoA reductase
P09236118A1455|3 9|results
P09236118A1455|92 97|groove
P09236118A1455|101 109|DNA target
P09236118A1455|127 132|dimers
P09236118A1455|147 151|sites
P09236118A1455|159 188|nucleoprotein activation complex
P09236224A0939|9 18|activation
P09236224A0939|21 33|p21 expression
P09236224A0939|63 69|feature
P09236224A0939|75 82|activity
P09236224A0939|107 122|PC12 growth arrest
P09236224A0939|128 142|differentiation
P09236441A0639|14 21|patients
P09236441A0639|31 40|recordings
P09236441A0639|68 83|oxygen saturation
P09236441A0639|92 102|respiration
P09236441A0639|136 144|breathing
P09236656A0124|17 25|cell count
P09236656A0124|40 47|baseline
P09237695A0000|25 29|study
P09237695A0000|57 66|indicators
P09237695A0000|80 93|virus infection
P09237862A0782|38 46|reduction
P09237862A0782|63 69|absence
P09237862A0782|82 87|nerves
P09238467A0763|5 11|lesions
P09238467A0763|26 36|propranolol
P09238467A0763|39 50|phentolamine
P09238850A0785|54 61|promoter
P09238850A0785|76 87|feedback loop
P09238850A2042|13 23|oscillation
P09238850A2042|47 51|clock
P09238850A2042|79 85|nucleus
P09238860A0175|16 22|nucleus
P09238860A0175|28 32|cells
P09238860A0175|92 128|AMP response element binding proteins CREB
P09238860A0175|132 138|CREM tau
P09238860A0175|142 147|manner
P09238860A0175|159 173|protein kinase A.
P09238860A1974|5 9|cells
P09238860A1974|27 33|signals
P09238860A1974|87 107|cytokine Interleukin-2
P09238860A1974|115 122|response
P09238860A1974|124 129|agents
P09238860A1974|140 147|increase
P09238860A1974|180 194|protein kinase C.
P09239635A0477|23 30|serum IgG
P09239635A0477|38 42|mg/ml
P09239635A0477|55 64|littermate
P09239635A0477|79 86|serum IgA
P09239635A0477|97 101|mg/ml
P09241092A1108|0 10|CONCLUSIONS
P09241092A1108|11 19|Valproate
P09241092A1108|39 53|glucuronidation
P09241092A1108|56 71|carbamazepine-10
P09241092A1108|73 82|trans-diol
P09241092A1108|109 118|conversion
P09241092A1108|121 136|carbamazepine-10
P09241092A1108|138 144|epoxide
P09241092A1108|151 170|trans-diol derivative
P09241092A1108|206 213|reaction
P09241232A0653|3 13|Ogg1 protein
P09241232A0653|33 41|DNA duplex
P09241232A0653|57 62|AP site
P09241232A0653|80 87|cytosine
P09241232A1154|1 17|consensus sequence
P09241232A1154|43 55|lysine residue
P09241232A1154|64 75|endonuclease
P09242375A1313|12 19|findings
P09242375A1313|35 48|mutations E768D
P09242375A1313|52 56|V804L
P09242375A1313|60 84|gain-of-function mutations
P09242375A1313|104 113|RET isoform
P09242375A1313|117 124|capacity
P09242375A1313|143 148|effect
P09242375A1313|162 170|mutations
P09242375A1313|201 205|MEN2A
P09242375A1313|209 222|MEN2B mutations
P09242499A0505|0 9|Volunteers
P09242499A0505|31 35|backs
P09242499A0505|73 83|application
P09242499A0505|87 96|sunscreens
P09242499A0505|105 114|base lotion
P09242499A0505|126 130|sites
P09242506A1033|21 27|complex
P09242506A1033|39 54|E2F family members
P09242506A1033|61 70|DP proteins
P09242551A0653|0 8|EBER1 mRNA
P09242551A0653|20 25|marker
P09242551A0653|33 39|latency
P09242551A0653|56 63|PEL cases
P09242551A0653|79 84|levels
P09242551A0653|101 108|controls
P09242551A0653|114 128|EBER1 expression
P09242551A0653|144 149|subset
P09242551A0653|152 164|lymphoma cells
P09243267A0401|0 6|METHODS
P09243267A0401|23 30|patients
P09243267A0401|38 46|diagnosis
P09243267A0401|57 69|cell carcinoma
P09243267A0401|79 84|cavity
P09243267A0401|105 113|treatment
P09243267A0401|116 138|Roswell Park Cancer Center
P09243385A1314|16 28|presaturation
P09243385A1314|54 66|motion studies
P09243385A1314|76 89|PC velocity data
P09243505A1194|2 9|addition
P09243505A1194|24 34|experiments
P09243505A1194|60 70|MADS domains
P09243505A1194|74 78|dimer
P09243505A1194|124 134|specificity
P09243505A1194|140 146|complex
P09243505A1194|154 162|sequences
P09243505A1194|192 197|region
P09243505A1194|203 212|MADS domain
P09243505A1194|222 226|cases
P09243505A1194|253 263|specificity
P09243505A1194|269 276|proteins
P09243587A0000|0 17|PURPOSE/OBJECTIVES
P09243587A0000|30 37|question
P09243587A0000|68 76|pregnancy
P09243587A0000|98 109|breast cancer
P09243587A0000|119 130|interruption
P09243587A0000|136 144|pregnancy
P09243587A0000|158 190|abortion increases breast cancer risk
P09243840A0663|10 16|studies
P09243840A0663|35 44|week period
P09243840A0663|61 68|HLA-DQA1
P09243840A0663|91 101|autopsy room
P09243840A0663|112 134|DNA Laboratory structures
P09244100A0194|35 40|groups
P09244282A1371|0 10|Mutagenesis
P09244282A1371|32 37|region
P09244282A1371|48 55|presence
P09244282A1371|61 65|sites
P09244282A1371|73 82|insertions
P09244282A1371|96 109|pec-1 phenotype
P09244350A0000|0 4|BRCA1
P09244350A0000|14 19|breast
P09244350A0000|30 53|cancer susceptibility gene
P09244350A0000|68 82|phosphoproteins
P09244350A0000|97 112|tumor suppressors
P09244350A0000|120 136|breast cancer cells
P09244430A0693|14 24|splice sites
P09244430A0693|39 52|adducin isoform
P09244430A0693|53 58|beta-3
P09244430A0693|73 77|donor
P09244430A0693|81 93|acceptor sites
P09244430A0693|100 104|exons
P09246343T0000|0 10|Proteinuria
P09246585T0000|6 13|blockade
P09246585T0000|26 35|cancer pain
P09247645A0000|27 33|alleles
P09247645A0000|58 65|SEC genes
P09247645A0000|87 92|fusion
P09247645A0000|114 121|vesicles
P09247645A0000|127 140|plasma membrane
P09247645A0000|181 186|screen
P09247645A0000|220 226|mutants
P09247645A0000|257 262|sec4-8
P09248639A0152|4 14|cell strains
P09248639A0152|28 38|fibroblasts
P09248639A0152|63 69|samples
P09248639A0152|76 87|blister fluid
P09248639A0152|94 99|effect
P09248639A0152|123 133|contraction
P09248639A0152|147 156|fibroblast
P09248639A0152|166 181|collagen lattices
P09249039A0124|19 25|enzymes
P09249039A0124|64 70|control
P09249039A0124|73 78|growth
P09249039A0124|79 93|differentiation
P09249039A0124|102 111|metabolism
P09249039A0124|114 124|vertebrates
P09249710A0331|62 97|plaque reduction neutralization testing
P09250554A0402|0 7|Patients
P09250554A0402|22 32|diltiazem CD
P09250554A0402|42 56|placebo once/day
P09250554A0402|58 68|combination
P09250554A0402|92 98|therapy
P09251843A0189|16 26|hyperplasia
P09251843A0189|39 43|cases
P09251843A0189|45 49|cases
P09251843A0189|76 86|hyperplasia
P09251843A0189|89 97|Castleman
P09251843A0189|99 105|disease
P09251843A0189|122 132|hyperplasia
P09251843A0189|154 161|lymphoma
P09251843A0189|176 180|cases
P09251843A0189|193 200|lymphoma
P09251843A0189|228 232|cases
P09252397A0081|23 33|repair rates
P09252397A0081|36 62|cyclobutane pyrimidine dimers
P09252397A0081|65 84|nucleotide resolution
P09252397A0081|98 104|JUN gene
P09252397A0081|113 123|fibroblasts
P09252397A0081|145 150|repair
P09252397A0081|153 161|sequences
P09252397A0081|169 195|transcription initiation site
P09252397A0081|203 208|repair
P09252397A0081|217 224|promoter
P09252406A0511|0 7|Tyrosine
P09252406A0511|32 42|binding site
P09252406A0511|58 75|Shc adaptor proteins
P09252406A0511|78 87|p85 subunit
P09252406A0511|90 109|phosphatidylinositol
P09252406A0511|110 115|kinase
P09252406A0511|116 134|phospholipase Cgamma
P09252406A0511|139 149|phosphatase
P09252879A0470|16 27|HRCT findings
P09252879A0470|43 50|features
P09252879A0470|60 68|functions
P09252879A0470|72 87|methacholine PC20
P09252879A0470|88 92|PC20M
P09252879A0470|116 127|significance
P09254678A0106|0 6|Gtx mRNA
P09254678A0106|20 27|parallel
P09254678A0106|67 74|proteins
P09254678A0106|93 99|protein
P09254678A0106|108 125|proteolipid protein
P09254678A0106|145 160|brain development
P09254678A0106|160 166|Gtx mRNA
P09254678A0106|178 185|parallel
P09254678A0106|198 205|PLP mRNAs
P09254678A0106|210 215|brains
P09254678A0106|250 262|point mutation
P09254678A0106|267 273|PLP gene
P09254709T0000|0 7|Contacts
P09254709T0000|15 40|Bacillus subtilis catabolite
P09254709T0000|51 61|protein CcpA
P09254709T0000|65 78|amyO target site
P09255349A0836|20 25|GTPase
P09255349A0836|36 43|proteins
P09256973A0455|31 35|group
P09256973A0455|52 66|itraconazole/kg
P09256973A0455|64 71|capsules
P09256973A0455|86 90|weeks
P09256973A0673|0 6|RESULTS
P09256973A0673|14 48|itraconazole plasma drug concentration
P09256973A0673|90 102|micrograms/ml
P09256973A0673|108 120|residence time
P09256973A0673|134 138|hours
P09257651T0000|8 17|U4/U6 snRNP
P09257651T0000|31 42|90kD proteins
P09257651T0000|77 101|yeast splicing factors Prp4p
P09257651T0000|105 109|Prp3p
P09257887A0457|0 4|G-CSF
P09257887A0457|29 33|cycle
P09257887A0457|34 46|microg/kg/day
P09257887A0457|81 89|apheresis
P09257887A0457|103 117|neutrophil count
P09258439A1001|7 22|expression system
P09258439A1001|49 53|forms
P09258439A1001|56 61|SsEF-2
P09258439A1001|72 82|mutagenesis
P09258606A0822|0 8|Crosstalk
P09258606A0822|17 24|pathways
P09258606A0822|42 46|forms
P09258606A0822|49 54|stress
P09258606A0822|73 83|development
P09258606A0822|87 96|malignancy
P09259052A0568|0 15|Supershift assays
P09259052A0568|29 37|Fos family
P09259052A0568|52 61|antibodies
P09259052A0568|72 87|protein complexes
P09259052A0568|96 105|AtT-20 cell
P09259052A0568|113 120|extracts
P09259052A0568|131 143|c-jun AP-1 site
P09259052A0568|159 174|Jun family members
P09259313A0950|3 10|majority
P09259313A0950|13 28|PI kinase activity
P09259313A0950|60 73|PRL stimulation
P09259315A0809|0 7|Mutation
P09259315A0809|38 45|enhanson
P09259315A0809|50 56|context
P09259315A0809|68 75|enhancer
P09259315A0809|85 100|silencer activity
P09259315A0809|116 130|GT-IIC enhansons
P09259315A0809|145 175|CSEn enhancer/silencer activities
P09259315A0809|187 193|GC cells
P09259320A0830|20 33|chromatography
P09259320A0830|34 44|discordance
P09259320A0830|55 61|pattern
P09259320A0830|64 78|O-glycosylation
P09259328A0440|0 25|Deletion mapping experiments
P09259328A0440|43 51|sequences
P09259328A0440|67 74|activity
P09259328A0440|77 86|MSC-1 cells
P09259328A0440|117 125|start site
P09259328A0440|145 151|regions
P09259328A0440|177 194|luciferase activity
P09259328A0440|250 256|regions
P09261155A0833|21 30|PTB domains
P09261155A0833|83 107|insulin receptor substrates
P09261155A0833|113 117|IRS-1
P09261155A0833|118 122|IRS-2
P09261155A0833|126 130|IRS-3
P09261178T0000|3 7|mouse
P09261178T0000|37 42|kinase
P09261184A0170|16 39|gel mobility shift analysis
P09261184A0170|43 63|supershift experiments
P09261184A0170|64 68|FIRE1
P09261200T0001|0 8|MR imaging
P09261200T0001|20 31|head injuries
P09261200T0001|37 50|FLAIR technique
P09261397A0509|0 23|Gag protein sequence motifs
P09261397A0509|29 36|NC domain
P09261397A0509|51 57|viruses
P09261397A0509|79 97|genome encapsidation
P09263010T0000|0 8|Induction
P09263010T0000|11 24|B cell apoptosis
P09263010T0000|73 82|regulation
P09263010T0000|83 87|c-myc
P09263010T0000|104 108|bcl-2
P09263094A0799|0 11|MEASUREMENTS
P09263094A0799|15 25|MAIN RESULTS
P09263094A0799|26 38|Lung elastance
P09263094A0799|46 55|resistance
P09263094A0799|77 88|measurements
P09263094A0799|90 103|airway pressure
P09263094A0799|114 121|pressure
P09263094A0799|125 134|airway flow
P09263094A0799|202 219|mean airway pressure
P09263094A0799|223 227|cmH2O
P09263094A0799|235 239|range
P09263094A0799|242 261|breathing frequencies
P09263094A0799|276 284|intervals
P09263094A0799|297 303|volumes
P09263856A0563|23 28|models
P09263856A0563|43 54|EGF-1 modules
P09263856A0563|81 91|prothrombin
P09263856A0563|94 100|factor X
P09263856A0563|113 122|structures
P09264466A0947|3 13|Cut9 subunit
P09264466A0947|27 32|target
P09264466A0947|60 67|function
P09264466A0947|89 100|interactions
P09264466A0947|104 118|phosphorylation
P09265534A0455|14 34|Gy/20 fractions/5 weeks
P09265642A0668|22 28|pathway
P09265642A0668|34 40|vacuole
P09265642A0668|67 73|pathway
P09265642A0668|74 88|internalization
P09265642A0668|96 103|membrane
P09265642A0668|113 120|marker FM
P09265642A0668|140 149|sop mutants
P09265932A0575|6 10|women
P09265932A0575|32 42|bupivacaine
P09265932A0575|57 65|injection
P09265932A0575|71 84|L2-3 interspace
P09267306A0381|35 45|measurement
P09267306A0381|47 50|apo B
P09267306A0381|72 79|standard
P09267306A0381|82 100|laboratory precision
P09267306A0381|104 114|reliability
P09267306A0381|135 146|introduction
P09267306A0381|157 168|laboratories
P09267431A0000|3 19|soybean cDNA clones
P09267431A0000|20 24|SPK-3
P09267431A0000|28 32|SPK-4
P09267431A0000|49 62|protein kinases
P09267439A0000|0 4|Genes
P09267439A0000|19 32|ras superfamily
P09267439A0000|74 81|proteins
P09267439A0000|110 116|variety
P09267439A0000|119 127|organisms
P09267542A0126|0 9|Naltrexone
P09267542A0126|47 64|Drug Administration
P09267542A0126|70 78|treatment
P09267542A0126|81 97|alcohol dependence
P09268298T0000|0 18|Ent-kaurene synthase
P09268298T0000|26 46|fungus Phaeosphaeria sp
P09268387A0293|6 11|report
P09268387A0293|66 72|domains
P09268387A0293|85 95|interaction
P09268387A0293|100 112|RNA polymerase
P09268387A0293|128 144|elongation complex
P09268578A0225|12 24|cDNA sequences
P09268578A0225|52 58|message
P09268578A0225|77 81|death
P09268631A0316|3 10|position
P09268631A0316|11 34|transcription orientation
P09268631A0316|47 52|status
P09268631A0316|58 62|genes
P09268631A0316|82 86|Igf2r
P09268638A0332|25 48|chromosome walking studies
P09268638A0332|61 66|D8S260
P09268638A0332|75 80|D8S285
P09268652A0116|16 32|zinc finger protein
P09268652A0116|33 41|dsRBP-ZFa
P09268652A0116|63 79|expression library
P09268652A0116|84 88|dsRNA
P09268661A1405|3 9|results
P09268661A1405|25 36|retroplasmid
P09268661A1405|44 56|transcriptase
P09268661A1405|84 96|cDNA synthesis
P09268661A1405|112 122|CCA sequence
P09269879A0266|5 14|absorption
P09269879A0266|28 42|bioavailability
P09269879A0266|68 86|elimination profiles
P09269900A1035|13 19|results
P09269900A1035|31 41|EGF/Ras/Raf
P09269900A1035|49 61|transcription
P09269900A1035|73 82|activation
P09269900A1035|85 94|ATF3/c-Jun
P09269900A1035|112 117|factor
P09269900A1035|138 146|repressor
P09269900A1035|152 159|response
P09271393A1333|27 31|model
P09271393A1333|38 50|Tax anchors CBP
P09271393A1333|56 69|HTLV-1 promoter
P09271393A1333|95 104|activation
P09271393A1333|135 144|activities
P09271393A1333|157 166|remodeling
P09271393A1333|170 180|recruitment
P09271393A1333|193 214|transcription machinery
P09271394A0558|0 4|DNase
P09271394A0558|35 46|footprinting
P09271394A0558|49 68|MURA-Mu1 TIR complexes
P09271394A0558|122 127|region
P09271397A1596|18 22|model
P09271397A1596|33 41|construct
P09271397A1596|63 68|copies
P09271397A1596|80 99|LDL receptor SREBP site
P09271397A1596|115 121|Sp1 site
P09271397A1596|176 182|fashion
P09271400A0475|7 12|assays
P09271400A0475|24 39|promoter activity
P09271400A0475|46 53|sequence
P09271400A0475|77 83|control
P09271400A0475|86 99|E2F2 expression
P09271400A0475|107 123|growth stimulation
P09271417A0585|10 14|mouse
P09271417A0585|15 22|ERR alpha
P09271417A0585|46 51|kidney
P09271417A0585|52 56|heart
P09271417A0585|65 74|adipocytes
P09271417A0585|75 81|tissues
P09271417A0585|116 120|acids
P09271417A1011|16 38|receptor response element
P09271417A1011|39 44|NRRE-1
P09271417A1011|65 72|ERR alpha
P09271417A1011|84 93|COS-7 cells
P09271496T0000|0 14|Mapping features
P09271496T0000|17 30|HIV-1 integrase
P09271496T0000|43 47|sites
P09271496T0000|58 75|target DNA molecules
P09271496T0000|96 102|complex
P09271496T0000|105 123|photo-cross-linking
P09272108A1295a|0 7|Analysis
P09272108A1295a|22 27|region
P09272108A1295a|54 61|presence
P09272108A1295a|80 92|CAAT sequences
P09272108A1295b|0 7|Analysis
P09272108A1295b|22 27|region
P09272108A1295b|54 61|presence
P09272108A1295b|80 92|CAAT sequences
P09272138A1153|11 18|response
P09272138A1153|51 62|rhG-CSF group
P09272138A1153|82 86|group
P09272138A1153|94 101|survival
P09272138A1153|112 116|weeks
P09272138A1153|136 141|groups
P09275159T0000|20 38|ribonucleoprotein A1
P09275159T0000|73 78|region
P09275159T0000|81 102|mouse hepatitis virus RNA
P09275164A0000|3 21|m7GpppN cap structure
P09275164A0000|82 87|action
P09275164A0000|94 100|enzymes
P09275164A0000|101 117|RNA triphosphatase
P09275164A0000|118 139|RNA guanylyltransferase
P09275164A0000|148 156|guanine-7
P09275164A0000|155 171|methyltransferase
P09275990A0938|21 25|study
P09275990A0938|35 46|mutagenicity
P09275990A0938|60 69|TA98 strain
P09275990A0938|86 95|activation
P09275990A0938|120 141|mutagenicity prevalence
P09275990A0938|144 149|diesel
P09276882A0479|3 10|addition
P09276882A0479|13 19|culture
P09276882A0479|35 47|SW by-products
P09276882A0479|56 63|pH values
P09276882A0479|93 99|culture
P09276882A0479|115 136|% carbohydrate treatment
P09276882A0479|169 181|% carbohydrate
P09277472A1070|22 26|edema
P09277472A1070|49 57|mechanism
P09277472A1070|69 79|dysfunction
P09277472A1070|85 92|DC shocks
P09277629A0268|3 13|experiments
P09277629A0268|50 55|nature
P09277629A0268|57 71|ERP negativities
P09277629A0268|87 96|memory task
P09277629A0268|119 128|memory task
P09278441A1160|3 9|pattern
P09278441A1160|13 18|timing
P09278441A1160|21 38|CARP mRNA expression
P09278441A1160|57 66|expression
P09278441A1160|72 77|tongue
P09278441A1160|133 139|homolog
P09278441A1160|139 144|tinman
P09278441A1160|197 207|development
P09278441A1777|0 13|Overexpression
P09278441A1777|24 37|cardiomyocytes
P09278441A1777|54 62|troponin C
P09278441A1777|83 101|factor transcription
P09278445T0000|0 19|Substrate specificity
P09278445T0000|25 37|RNase activity
P09278445T0000|40 57|yeast RNA polymerase
P09278450A1338|15 33|mobility shift assays
P09278450A1338|37 58|competition experiments
P09278450A1338|69 73|site A
P09278450A1338|90 99|NF1 protein
P09278454A1261|0 10|Examination
P09278454A1261|16 31|MMP-2 RE1 sequence
P09278454A1261|52 64|Y-box sequence
P09278454A1261|65 76|CTGCTGGGCAAG
P09278454A1261|127 159|DMS protection footprinting analysis
P09278475A0465|5 9|scs32
P09278475A0465|36 46|ts phenotype
P09278475A0465|72 84|Ino-phenotype
P09278475A0465|87 94|rpo26-31
P09278494A0762|2 9|contrast
P09278494A0762|22 32|ETS proteins
P09278494A0762|59 74|promoter activity
P09278494A0762|80 94|Surf-1 direction
P09278758A1636|0 9|CONCLUSION
P09278758A1636|10 20|Patients wit
P09278758A1636|39 49|neck disease
P09278758A1636|68 75|evidence
P09278758A1636|92 98|disease
P09278758A1636|112 117|spread
P09278758A1636|140 149|lymph nodes
P09278758A1636|180 186|failure
P09278758A1636|195 199|sites
P09279379A0310|19 24|pBR322
P09279379A0310|52 60|sequences
P09279379A0310|83 88|region
P09279379A0310|93 98|spacer
P09279379A0310|105 110|spacer
P09279379A0310|116 129|H2B histone gene
P09279889A1124|38 43|curves
P09279889A1124|42 50|AUC0-24 hr
P09279889A1124|92 97|% Azone
P09279889A1124|104 116|% Azone systems
P09280747A0195|3 13|combination
P09280747A0195|16 39|hydralazine hydrochloride
P09280747A0195|43 61|isosorbide dinitrate
P09280747A0195|74 81|survival
P09280747A0195|91 100|comparison
P09280747A0195|107 114|regimens
P09280747A0195|123 130|evidence
P09280747A0195|149 154|effect
P09280747A0195|168 180|ACE inhibitors
P09282329A0527|9 18|mechanisms
P09282329A0527|29 40|interactions
P09282329A0527|61 67|factors
P09282329A0527|75 97|cell cycle control element
P09282329A0527|121 132|determinants
P09282329A0527|150 159|regulation
P09282329A0527|165 183|G1/S phase transition
P09282329A0527|186 191|FDC-P1
P09282329A0527|205 219|progenitor cells
P09282911A0277|15 19|study
P09282911A0277|40 51|cell cultures
P09282911A0277|63 77|RC3/neurogranin
P09282911A0277|129 137|mechanism
P09282911A0277|139 148|regulation
P09282985A0961|9 19|differences
P09282985A0961|27 31|males
P09282985A0961|52 66|characteristics
P09283828A0484|14 22|responses
P09285715A1257|55 67|export pathway
P09285715A1257|168 174|factors
P09285715A1257|198 207|mRNA export
P09285789A0712|19 49|guanine nucleotide exchange factor
P09285789A0712|54 59|domain
P09285789A0712|89 106|pleckstrin homology
P09285789A0712|111 116|domain
P09285789A0712|132 142|repeat units
P09286115T0000|31 36|factor
P09286115T0000|59 65|element
P09286115T0000|95 103|RPL21 gene
P09286981A0147|19 23|dimer
P09286981A0147|33 40|subunits
P09287036A0457|0 25|Plasma leptin concentrations
P09287036A0457|38 42|women
P09287036A0457|64 73|adjustment
P09287036A0457|76 86|differences
P09287036A0457|102 106|ng/ml
P09287036A0457|109 113|women
P09287352A0930|14 20|effects
P09287352A0930|23 36|STAT activation
P09287352A0930|44 58|SHP-1 expression
P09287352A0930|82 91|activation
P09287352A0930|114 133|protein kinase pathway
P09287352A0930|134 143|expression
P09287352A0930|146 150|SHP-1
P09287352A0930|171 178|activity
P09287352A0930|210 219|expression
P09287352A0930|220 224|SHP-1
P09287352A0930|250 258|% increase
P09287362A0589|4 14|interaction
P09287362A0589|26 34|SH3 region
P09287362A0589|62 67|region
P09287362A0589|66 82|PPPLPERTPESFVLADM
P09287362A0589|102 107|region
P09287362A0589|110 117|PTP-PEST
P09288848A0780|16 26|HbO2 changes
P09288916T0000|9 18|expression
P09288916T0000|70 82|acid hydrolase
P09288916T0000|88 93|meprin
P09288916T0000|94 98|alpha
P09288916T0000|102 113|beta subunits
P09288916T0000|116 126|Madin-Darby
P09288916T0000|133 143|kidney cells
P09290207A0731|22 33|derepression
P09290207A0731|45 58|mating type loci
P09290571A0420|7 14|patients
P09290571A0420|72 76|study
P09290571A0420|93 100|patients
P09290571A0799|3 13|cycle length
P09291077T0000|9 23|hyperammonaemia
P09291077T0000|39 49|shepherd dog
P09291098A0452|23 31|kb mRNA V-1
P09291098A0452|41 52|kb GGT mRNA V-2
P09291098A0452|70 77|splicing
P09291098A0452|90 99|transcript
P09291098A0452|118 125|promoter
P09291098A0452|131 140|rat GGT gene
P09291098T0000|15 22|promoter
P09291098T0000|31 72|gamma-glutamyl transpeptidase gene expression
P09291098T0000|107 116|liver cells
P09292499A0887|5 18|repressor sites
P09292499A0887|22 31|pyrimidine
P09292499A0887|54 86|polypyrimidine tract binding protein
P09292499A0887|107 114|extracts
P09292499A0887|127 158|UV crosslinking/competition assays
P09293006A1412|9 18|expression
P09293006A1412|29 38|S. lividans
P09293006A1412|71 83|aphII promoter
P09294139A0729|13 30|core homology region
P09294139A0729|39 51|HS12 enhancers
P09294139A0729|92 98|homolog
P09294139A0729|115 120|motifs
P09294139A0729|159 166|function
P09294139A0729|178 185|enhancer
P09294139A0729|196 203|segments
P09294139A0729|210 229|sequence conservation
P09294139A0729|240 250|possibility
P09294139A0729|285 290|motifs
P09294161A0650|2 9|contrast
P09294161A0650|24 30|protein
P09294161A0650|31 40|expression
P09294161A0650|43 50|p45 NF-E2
P09294161A0650|62 77|activation domain
P09294161A0650|82 86|NF-E2
P09294161A0650|91 98|cell line
P09294161A0650|131 143|transcription
P09294161A0650|155 160|assays
P09294161A1103|5 12|findings
P09294161A1103|32 40|mechanism
P09294161A1103|50 60|recruitment
P09294161A1103|79 85|regions
P09294161A1103|91 100|globin loci
P09294161A1103|116 124|promoters
P09294262A0885|3 16|promoter region
P09294262A0885|25 40|consensus TATA box
P09294262A0885|54 58|CCAAT
P09294262A0885|62 70|CreA boxes
P09294262A0885|94 99|stress
P09294262A0885|120 129|regulation
P09294262A0885|138 146|promoters
P09294422A1223|6 21|cysteine residues
P09294422A1223|45 50|region
P09294422A1223|69 77|formation
P09294422A1223|81 95|disulfide bridge
P09294422A1223|113 129|activation process
P09294422A1223|144 151|activity
P09294422A1376|3 9|por gene
P09294422A1376|135 145|tac promoter
P09294422A1376|159 168|production
P09294452A2107|17 24|operator
P09294452A2107|52 60|reduction
P09294452A2107|63 82|reporter enzyme levels
P09294453A0949|3 12|ORF3 mutant
P09294453A0949|28 33|levels
P09294453A0949|36 43|tabtoxin
P09294453A0949|80 97|T beta L biosynthesis
P09294471A1198|7 15|Cox models
P09294471A1198|22 29|CD4 count
P09294471A1198|32 41|150/microL
P09294471A1198|52 61|200/microL
P09294471A1198|104 108|model
P09296251A0163|19 25|reports
P09296251A0163|41 46|number
P09296251A0163|49 56|patients
P09297698A0933|5 15|transcripts
P09297698A0933|41 51|UbCRBP mRNAs
P09297698A0933|64 69|UbCRBP
P09297698A0933|89 94|region
P09297698A0933|110 117|distance
P09297698A0933|126 136|enolase gene
P09299696A1074|3 14|distribution
P09299696A1074|17 30|cryptosporidia
P09299696A1074|36 44|intestine
P09299696A1074|48 53|number
P09299696A1074|56 69|cryptosporidia
P09299696A1074|78 83|villus
P09299696A1074|128 143|characterization
P09299696A1074|148 156|infection
P09299696A1074|168 172|model
P09299696A1074|187 203|cryptosporidiosis
P09300323A1182|3 8|result
P09300323A1182|40 53|blood flow ratio
P09300323A1182|54 61|ENDO/EPI
P09300323A1182|90 104|control stenosis
P09300697A0000|0 10|Proteasomes
P09300697A0000|29 36|protease
P09300697A0000|50 59|generation
P09300697A0000|62 69|peptides
P09300697A0000|81 88|MHC class
P09300697A0000|90 98|molecules
P09300698A1219|2 8|support
P09300698A1219|15 28|interpretation
P09300698A1219|109 116|peptides
P09301114A0573|0 8|Takahashi
P09301350A0946|3 21|sputum interleukin-8
P09301350A0946|45 69|treatment median difference
P09301350A0946|75 79|pg/ml
P09301350A0946|81 99|% confidence interval
P09301350A0946|111 115|pg/ml
P09301350A0946|117 122|favour
P09301350A0946|125 131|placebo
P09301350A0946|147 160|expiratory flow
P09301350A0946|194 201|capacity
P09301350A0946|220 225|height
P09301350A0946|236 251|percentage points
P09301350A0946|272 294|mean treatment difference
P09301350A0946|293 298|favour
P09301350A0946|301 307|placebo
P09303437A0875|15 22|deletion
P09303437A0875|35 44|hCRBP1 gene
P09303437A0875|60 70|CAT activity
P09303437A0875|104 111|function
P09303437A0875|125 131|element
P09303437A0875|135 143|insertion
P09303437A0875|167 174|promoter
P09303437A0875|203 213|stimulation
P09303437A0875|216 232|CAT gene expression
P09303635A0000|0 6|Gaucher
P09303635A0000|8 14|disease
P09303635A0000|31 38|disorder
P09303635A0000|88 93|enzyme
P09304123A0079|5 17|discoloration
P09304123A0079|59 72|tooth structure
P09304123A0079|102 107|manner
P09304123A0079|110 114|order
P09304123A0079|160 167|material
P09305592A0000|16 42|translocation characteristic
P09305592A0000|65 75|bcr/abl gene
P09305592A0000|88 100|fusion protein
P09305592A0000|101 111|p210bcr/abl
P09305631A0770|0 13|Overexpression
P09305631A0770|16 20|BAG-1
P09305631A0770|41 49|cell lines
P09305631A0770|73 81|cell death
P09305755A0540|12 17|region
P09305755A0540|35 46|binding sites
P09305755A0540|62 68|protein
P09305755A0540|81 86|factor
P09305755A0540|92 113|CAAT-box binding protein
P09305755A0540|113 117|C/EBP
P09305755A0540|118 127|hepatocyte
P09305755A0540|135 141|factors
P09305755A0540|162 178|activator proteins
P09305870A0894|3 24|recognition specificity
P09305870A0894|30 41|p55 PDZ domain
P09305870A0894|72 81|PDZ domains
P09305870A0894|95 113|lymphocyte homologue
P09305870A0894|128 132|discs
P09305870A0894|138 152|tumor suppressor
P09305870A0894|176 181|domain
P09305870A0894|184 196|glycophorin C.
P09305944A0621|14 27|RanGAP activity
P09305944A0621|31 36|series
P09305944A0621|61 82|rna1p mutant derivatives
P09305944A0621|108 115|sequence
P09305944A0621|131 136|domain
P09305944A0621|143 155|yeast proteins
P09305944A0621|196 208|GTP hydrolysis
P09307065A0553|5 11|absence
P09307065A0553|14 21|MHC class
P09307065A0553|39 44|D10 TCR
P09307065A0553|72 84|enterotoxin C2
P09307065A0553|91 105|association rate
P09307065A0553|132 147|dissociation rate
P09307065A0553|172 191|dissociation constant
P09307065A0553|196 201|microM
P09307312A0172|0 7|Evidence
P09307312A0172|19 24|shifts
P09307312A0172|42 50|responses
P09307312A0172|61 71|nerve fibers
P09307312A0172|80 91|microphonics
P09307312A0172|98 106|responses
P09307312A0172|114 122|hair cells
P09307312A0172|136 140|cells
P09307312A0172|146 152|cochlea
P09307312A0172|170 198|membrane vibration measurements
P09308234A0225|4 15|Max complexes
P09308234A0225|51 60|activation
P09308234A0225|72 79|promoter
P09308738A1216|5 16|United States
P09308738A1216|119 126|decrease
P09308738A1216|127 162|factor VIII/von Willebrand factor levels
P09309457A0680|0 5|Assays
P09309457A0680|13 23|cholesterol
P09309457A0680|51 63|triglycerides
P09309457A0680|61 72|endothelin-1
P09309457A0680|73 83|lipoprotein
P09309457A0680|85 93|estradiol
P09309457A0680|120 127|baseline
P09309457A0680|156 161|months
P09310836A1019|9 15|repeats
P09310836A1019|21 28|P element
P09310836A1019|40 51|SV40 promoter
P09310836A1019|63 91|phorbol 12-myristate 13-acetate
P09310836A1019|108 115|elements
P09311164A0245|21 28|density J
P09311164A0245|50 55|volume
P09311164A0245|68 76|motor unit
P09311568A0595|3 20|cleavage dipeptides
P09311568A0595|23 38|C1YVV NIa protease
P09311796A0218|13 19|studies
P09311796A0218|35 44|activation
P09311796A0218|68 79|IEP86 binding
P09311796A0218|89 110|TATA-box binding protein
P09311796A0218|122 140|transcription factor
P09311808A0341|30 39|p4 molecule
P09311810A0814|5 16|accumulation
P09311810A0814|19 33|cyclin D3 protein
P09311810A0814|36 44|Vero cells
P09311810A0814|59 78|alpha0 deletion mutant
P09311810A0814|105 109|cells
P09311810A0814|131 135|virus
P09311810A0814|150 154|virus
P09311810A0814|172 186|alpha0 sequences
P09311835A0147|33 48|characterization
P09311835A0147|54 62|T antigens
P09311835A0147|77 87|SV40 mutants
P09311835A0147|125 132|residues
P09311835A0147|148 163|ATP binding pocket
P09312025A0373|5 11|effects
P09312025A0373|27 39|co-expression
P09312025A0373|58 64|PKC zeta
P09312025A0373|68 77|inhibition
P09312025A0373|80 120|phosphatidylinositol 3-kinase p85alpha-p110
P09312025A0373|123 132|wortmannin
P09312025A0373|133 140|LY294002
P09312025A0373|162 167|mutant
P09312025A0373|170 177|p85alpha
P09312025T0000|0 19|Protein phosphatase 2A
P09312025T0000|31 39|regulator
P09312025T0000|42 68|protein kinase C zeta signaling
P09312025T0000|102 111|cell growth
P09312025T0000|113 131|NF-kappaB activation
P09312028A0975|16 28|RXRalphaF318A
P09312028A0975|41 48|activity
P09312028A0975|64 75|heterodimers
P09312028A0975|81 88|presence
P09312028A0975|91 96|BMS614
P09312028A0975|108 116|integrity
P09312028A0975|131 144|RAR AF-2 domains
P09312032A0165|5 11|introns
P09312032A0165|29 39|snoRNA genes
P09312032A0165|48 57|processing
P09312032A0165|80 86|release
P09312032A0165|92 97|snoRNA
P09312032A0165|112 124|intron lariats
P09312087A0000|6 12|studies
P09312087A0000|29 41|Src homology-2
P09312087A0000|80 90|phosphatase
P09312087A0000|90 94|SHP-2
P09312087A0000|123 128|domain
P09312087A0000|131 137|PECAM-1
P09312087A0000|178 196|platelet aggregation
P09312087A0000|198 204|process
P09312087A0000|246 260|phosphopeptides
P09312087A0000|289 294|domain
P09312087A0000|297 303|PECAM-1
P09312087A0000|316 338|tyrosine residues Tyr-663
P09312087A0000|341 347|Tyr-686
P09313755A0816|13 22|clustering
P09313755A0816|30 42|risk variables
P09313755A0816|52 58|factors
P09314306A0571|0 14|Supplementation
P09314306A0571|29 34|pl-ALB
P09314487T0000|0 8|Detection
P09314487T0000|19 43|Mycobacterium tuberculosis
P09314487T0000|46 58|air filtration
P09314487T0000|62 84|polymerase chain reaction
P09314537A1600|5 12|findings
P09314537A1600|21 25|EBP50
P09314537A1600|52 70|ezrin binding protein
P09314554A0149|35 45|translation
P09314554A0149|83 94|reading frame
P09314554A0149|131 142|presentation
P09314554A0149|152 159|epitopes
P09314554A0149|175 187|reading frames
P09314554A0149|197 230|influenza A PR/8/34 nucleoprotein gene
P09314570A0153|4 9|family
P09314570A0153|12 19|proteins
P09314570A0153|32 37|motifs
P09314570A0153|57 69|gene promoters
P09314570A0153|89 98|activation
P09314570A0153|101 110|repression
P09314570A0153|128 137|activities
P09315631A1064|0 7|Deletion
P09315631A1064|13 20|POR2 gene
P09315631A1064|41 49|phenotype
P09315631A1064|55 60|yeasts
P09315631A1064|65 73|deletions
P09315631A1064|92 100|POR2 genes
P09315631A1064|125 132|glycerol
P09315631A1064|137 144|degrees C
P09315631A1064|165 173|delta por1
P09315631A1064|180 186|mutants
P09315632A1137|19 29|observation
P09315632A1137|34 43|expression
P09315632A1137|62 78|FGFR3 kinase domain
P09315632A1137|111 121|fibroblasts
P09315632A1137|134 146|dysregulation
P09315632A1137|149 153|FGFR3
P09315632A1137|189 197|neoplasia
P09315633A0333|10 26|amino acid sequence
P09315633A0333|52 59|homology
P09315633A0333|64 73|interferon
P09315633A0333|84 90|factors
P09315651T0000|0 10|Involvement
P09315651T0000|21 30|regulation
P09315651T0000|35 44|R-FABP gene
P09315651T0000|60 70|chick retina
P09315678A0278|7 11|Cbf5p
P09315678A0278|73 84|protein NAP57
P09315678A0278|113 119|Nopp140
P09315678A0278|175 183|shuttling
P09316937A0133|18 25|organism
P09316937A0133|53 65|discrepancies
P09316937A0133|76 80|Vitek
P09316937A0133|84 110|API 20E identification systems
P09317131A0000|9 27|chain class switching
P09317131A0000|39 47|cytokines
P09317131A0000|56 68|transcription
P09317131A0000|85 91|CH genes
P09317131A1332|32 60|NF kappa B2 nucleoprotein complex
P09317131A1332|85 89|STAT6
P09317131A1332|113 122|activation
P09317131A1332|133 147|IgE germline gene
P09317757T0000|0 7|EXERCISE
P09317757T0000|24 63|CHRISTMAS ISLAND RED CRAB GECARCOIDEA NATALIS
P09317757T0000|65 74|ENERGETICS
P09317757T0000|77 86|LOCOMOTION
P09317830T0000|12 24|SONG FREQUENCY
P09317830T0000|27 33|CICADAS
P09321406T0000|3 26|pheromone response pathway
P09321406T0000|36 48|transcription
P09321406T0000|51 69|Ty5 retrotransposons
P09321406T0000|89 97|chromatin
P09321657A0439|6 10|study
P09321657A0439|27 35|mutations
P09321657A0439|56 63|elements
P09321657A0439|69 81|cox3 promoters
P09321657A0439|101 111|core element
P09321657A0439|126 145|cox3 promoter activity
P09321657A0439|154 169|element mutations
P09321657A0439|184 189|effect
P09321930A0567|19 38|tumor suppressor genes
P09321930A0567|63 67|BRCA1
P09321930A0567|67 75|WAF1/CIP1
P09321930A0567|102 112|frequencies
P09321930A0567|123 132|mechanisms
P09321930A0567|145 158|heterozygosity
P09321930A0567|171 180|expression
P09321930A0567|184 191|mutation
P09321930A0567|194 205|inactivation
P09321930A0567|216 229|binding protein
P09322738A0510|25 31|rpoCHIS
P09322738A0510|59 64|allele
P09322738A0510|70 79|chromosome
P09322738A0510|82 93|S. coelicolor
P09322738A0510|97 106|S. lividans
P09322872A0745|10 17|deletion
P09322872A0745|29 34|TK gene
P09322872A0745|35 43|selection
P09322872A0745|48 58|gancyclovir
P09322872A0745|66 70|cells
P09322872A0745|89 101|recombination
P09323366A0000|3 20|malate synthase gene
P09323366A0000|32 36|yeast
P09323366A0000|92 103|carbon source
P09323366A0000|109 120|growth medium
P09323366A0299|2 17|deletion analysis
P09323366A0299|23 39|MLS1 control region
P09323366A0299|55 59|sites
P09323366A0299|98 109|derepression
P09323612A0374|29 35|studies
P09323612A0374|37 62|sleep electroencephalograms
P09323612A0374|81 90|medication
P09323612A0374|91 98|children
P09323612A0374|116 124|dysphasia
P09323612A0374|143 161|treatment strategies
P09323612A0374|164 171|children
P09323612A0374|195 200|speech
P09323612A0374|204 220|language disorders
P09324720A0317|7 11|meals
P09324720A0317|16 20|times
P09324720A0317|29 39|tablespoons
P09324720A0317|42 47|Alzoon
P09324878A0952|38 58|ultrasound examination
P09324878A0952|82 90|diagnosis
P09324878A0952|115 129|type B dissection
P09324922T0065|0 18|Fermentation process
P09324922T0065|24 38|supplementation
P09324922T0065|61 72|acid bacteria
P09324988X0000|0 9|Substrates
P09324988X0000|30 37|proteins
P09324988X0000|43 48|lamins
P09324988X0000|53 58|series
P09324988X0000|68 75|proteins
P09325022A0192|0 6|Ovaries
P09325022A0192|11 17|animals
P09325022A0192|21 25|group
P09325022A0192|32 38|studies
P09325022A0192|41 48|CD-1 mice
P09325022A0192|53 57|study
P09325022A0192|72 82|C57BL/6 mice
P09325022A0192|106 111|microm
P09325135A0737|9 21|fusion protein
P09325135A0737|74 80|protein
P09325273A1240|5 11|results
P09325273A1240|23 27|UBP41
P09325273A1240|57 65|recycling
P09325273A1240|67 75|ubiquitin
P09325273A1240|78 87|hydrolysis
P09325273A1240|98 117|poly-ubiquitin chains
P09325273A1240|132 137|action
P09325273A1240|142 152|S proteasome
P09325273A1240|173 189|protein substrates
P09325273A1240|203 212|production
P09325273A1240|219 227|ubiquitin
P09325273A1240|238 257|poly-ubiquitin chains
P09325273A1240|279 286|proteins
P09325273A1240|291 313|ubiquitin fusion proteins
P09325278A0458|1 22|data base homology search
P09325278A0458|47 66|ER1 amino acid sequence
P09325278A0458|80 86|regions
P09325278A0458|89 98|similarity
P09325278A0458|117 124|proteins
P09325278A0458|175 181|regions
P09325278A0458|182 191|similarity
P09325278A0458|197 225|Caenorhabditis elegans sequence
P09325284A0469|36 46|acid protein
P09325284A0469|66 80|progelatinase B.
P09325322A1293|3 12|inhibition
P09325322A1293|41 48|decrease
P09325322A1293|50 62|cooperativity
P09325322A1293|69 73|shift
P09325322A1293|94 112|InsP3 concentrations
P09326163A0942|0 6|RESULTS
P09326163A0942|22 35|mortality ratio
P09326163A0942|56 64|neoplasms
P09326246A0567|0 15|Sequence analysis
P09326246A0567|22 27|region
P09326246A0567|59 66|elements
P09326246A0567|70 77|deletion
P09326246A0567|102 107|levels
P09326246A0567|110 127|luciferase activity
P09326246A0567|136 152|bp reporter plasmid
P09326263A0410|21 37|transcription-PCR
P09326263A0410|37 42|RT-PCR
P09326263A0410|43 55|methodologies
P09326263A0410|69 77|sequences
P09326263A0410|82 86|brain
P09326263A0410|90 97|placenta
P09326263A0410|110 117|material
P09326263A0410|152 156|exons
P09326317A0372|14 18|study
P09326317A0372|26 42|mutation screening
P09326317A0372|78 86|EXT2 genes
P09326317A0372|96 110|linkage analysis
P09326727T0000|3 15|regurgitation
P09326727T0000|31 40|injections
P09327881T0000|0 37|Positron emission tomography radioligands
P09327881T0000|41 60|dopamine transporters
P09327881T0000|64 70|studies
P09327881T0000|89 96|primates
P09328341A1449|0 10|Attenuation
P09328341A1449|18 34|vit A2 consensus ERE
P09328341A1449|62 71|DNA binding
P09328341A1449|77 99|TR alpha DNA binding mutant
P09328341A1449|132 146|transactivation
P09328343A0181|0 9|Expression
P09328343A0181|18 24|element
P09328343A0181|50 63|protein complex
P09328343A0181|110 117|proteins
P09328343A0181|134 140|members
P09328343A0181|150 155|family
P09328349A1679|7 14|CCAAT box
P09328349A1679|37 51|characteristics
P09328349A1679|73 82|expression
P09328349A1679|88 104|alpha-subunit gene
P09328349A1679|107 118|trophoblasts
P09328476A0068|0 9|U4/U6 snRNP
P09328476A0068|42 58|ribonucleoprotein
P09328476A0068|59 63|snRNP
P09328476A0068|64 72|particles
P09328476A0068|88 92|U4/U6
P09328476A0068|102 112|spliceosome
P09328476A0374|0 5|Hprp3p
P09328476A0374|11 20|kDa protein
P09328476A0374|66 84|splicing factor Prp3p
P09328824A0000|19 28|properties
P09328824A0000|44 57|v-erbA oncogene
P09328824A0000|72 78|version
P09328824A0000|84 112|chicken thyroid hormone receptor
P09328824A0000|117 121|alpha
P09328824A0000|161 170|repression
P09328824A0000|189 193|roles
P09328824A0000|211 223|acid receptors
P09328833A0588|44 59|MCF-7 cDNA library
P09331119A0659|13 17|grade
P09331119A0659|19 26|toxicity
P09331119A0659|30 40|neutropenia
P09331119A0659|41 56|thrombocytopenia
P09331119A0659|60 71|parasthesias
P09331119A0659|88 93|cycles
P09331864A0230|0 18|Serum concentrations
P09331864A0230|88 94|heifers
P09331864A0230|116 125|treatments
P09331864A0230|127 133|control
P09331864A0230|149 154|heifer
P09331864A0230|159 167|Revalor-H
P09331864A0230|171 175|mg TBA
P09331864A0230|179 182|mg E2
P09331864A0230|184 192|Revalor-H
P09331864A0230|200 209|Finaplix-H
P09331864A0230|212 216|mg TBA
P09331864A0230|221 230|Finaplix-H
P09331864A0848|0 20|Serum E2 concentrations
P09331864A0848|71 78|controls
P09331864A0848|98 105|controls
P09333018A0000|0 9|Interferon
P09333018A0000|20 25|Factor
P09333018A0000|65 70|growth
P09333018A0000|99 117|transcription factor
P09333026A0397|10 18|structure
P09333026A0397|37 41|exons
P09333026A0397|46 55|boundaries
P09333026A0397|88 103|PTK family members
P09333026A0397|143 152|divergence
P09333026A0851|28 37|expression
P09333026A0851|41 46|tumour
P09333026A0851|54 60|brk cDNA
P09333026A0851|63 67|mouse
P09333026A0851|77 87|fibroblasts
P09333026A0851|113 117|cells
P09333026A0851|126 134|anchorage
P09333026A0851|146 151|growth
P09333026A0851|189 196|response
P09333026A0851|208 219|growth factor
P09333168A0310|0 19|Anti-hepatitis A virus
P09333168A0310|25 29|titer
P09333168A0310|34 44|vaccination
P09333231T0018|3 7|skull
P09333231T0018|16 22|species
P09334264A0540|12 25|calf thymus CstF
P09334264A0540|69 75|subunit
P09334330A0252|4 12|mutations
P09334330A0252|15 19|daf-3
P09334330A0252|28 36|mutations
P09334330A0252|39 43|genes
P09334330A0252|56 69|TGF-beta signal
P09334330A0252|73 81|receptors
P09334330A0252|95 124|Smad signal transduction proteins
P09334330A0252|148 152|daf-3
P09334330A0252|161 171|Smad protein
P09334330A0252|237 247|development
P09334330A0252|258 264|tissues
P09334330A0252|287 302|dauer development
P09334331A0910|3 9|results
P09334331A0910|18 28|possibility
P09334331A0910|46 64|EGF receptor DER/Egfr
P09334331A0910|79 86|EMA cells
P09334331A0910|99 106|receptor
P09334475A0327|0 7|PATIENTS
P09334475A0327|11 17|METHODS
P09334475A0327|34 41|patients
P09334475A0327|56 71|National Registry
P09334475A0327|89 98|Infarction
P09334475A0327|112 121|resolution
P09334475A0327|124 132|chest pain
P09334475A0327|138 153|segment elevation
P09334475A0327|189 194|CK rise
P09334475A0327|206 219|T wave inversion
P09334475A0327|221 227|infarct
P09334475A0327|269 280|thrombolysis
P09335267A0142|12 26|operon structure
P09335267A0142|33 40|organism
P09335267A0142|52 58|methods
P09335267A0142|76 86|mutagenesis
P09335267A0142|117 123|effects
P09335267A0142|135 139|genes
P09335267A0142|159 167|mutations
P09335267A0142|182 187|genome
P09335298A0529|24 35|parCBA operon
P09335298A0529|44 68|plasmid partitioning system
P09335298A1227|14 22|insertion
P09335298A1227|28 39|ColE1 cer site
P09335298A1227|47 56|RK2 plasmid
P09335298A1227|73 78|region
P09335298A1227|99 105|plasmid
P09335298A1227|111 123|MC1061K strain
P09335298A1227|141 166|multimer resolution activity
P09335298A1227|176 181|parCBA
P09335298A1227|212 232|stabilization activity
P09335298A1227|248 253|operon
P09335298A2129|12 16|basis
P09335298A2129|31 41|differences
P09335298A2129|61 67|killing
P09335298A2129|87 93|strains
P09335298A2129|94 113|transformation assays
P09335298A2129|150 162|sensitivities
P09335298A2129|168 174|strains
P09335298A2129|180 195|ParE toxin protein
P09335608T0000|15 22|elements
P09335608T0000|34 42|sequences
P09335608T0000|62 69|splicing
P09335608T0000|85 90|myosin
P09335608T0000|96 114|chain gene transcript
P09335619A0583|0 25|Nucleotide sequence analysis
P09335619A0583|42 53|similarities
P09335619A0583|58 66|R1 plasmid
P09335619A0583|91 100|maize races
P09335619A0583|105 115|RU cytoplasm
P09335619A0583|121 129|M1 plasmid
P09335619A0583|140 145|source
P09335619A0583|162 169|teosinte
P09335619A0583|214 221|sequence
P09335619A0583|230 235|region
P09335619A0583|242 251|orf221 gene
P09336455A0000|17 24|kinetics
P09336455A0000|30 37|recovery
P09336455A0000|40 52|mRNA synthesis
P09336455A0000|67 71|GAL10
P09336455A0000|75 83|RNR3 genes
P09336455A0000|89 96|exposure
P09336455A0000|99 108|yeast cells
P09336455A0000|111 121|ultraviolet
P09336455A0000|126 134|radiation
P09337861T0000|0 6|Cloning
P09337861T0000|15 38|phosphoinositide 3-kinase
P09337861T0000|44 51|C2 domain
P09337861T0000|71 81|sensitivity
P09337861T0000|87 105|inhibitor wortmannin
P09338414A0430|0 6|Ea value
P09338414A0430|25 29|ratio
P09338414A0430|65 72|pressure
P09338414A0430|81 92|stroke volume
P09338414A0430|92 105|thermodilution
P09339900A0939|10 17|analysis
P09339900A0939|20 35|promoter activity
P09339900A0939|49 54|region
P09339900A0939|57 64|cyclin D2
P09339900A0939|81 86|region
P09339900A0939|108 112|C/EBP
P09339900A0939|130 134|c-Myc
P09339900A0939|171 178|activity
P09339900A0939|181 190|expression
P09339900A0939|193 200|cyclin D2
P09340641T0001|0 5|Effect
P09340641T0001|8 14|alcohol
P09340641T0001|33 45|nCPAP pressure
P09341139A0690|2 9|contrast
P09341139A0690|10 24|resensitization
P09341139A0690|50 62|beta2AR mutant
P09341139A0690|63 67|Y326A
P09341139A0690|96 109|overexpression
P09341139A0690|126 138|beta-arrestin
P09341158A0167|3 14|medium chains
P09341158A0167|22 30|complexes
P09341158A0167|67 71|types
P09341158A0167|72 82|interaction
P09341158A0167|83 90|assembly
P09341158A0167|98 102|beta1
P09341158A0167|106 116|beta2 chains
P09341158A0167|135 143|complexes
P09341158A0167|147 157|recognition
P09341158A0167|174 187|sorting signals
P09341182A0605|58 70|BTB/POZ domain
P09341182A0605|81 92|PLZF-BTB/POZ
P09341192T0000|7 11|shock
P09341192T0000|22 39|GLUT4 translocation
P09341192T0000|42 56|3T3L1 adipocytes
P09341192T0000|65 85|tyrosine kinase pathway
P09341193A0362|29 38|NGFI-A/Egr
P09341193A0362|57 76|transcription factors
P09341193A0362|104 120|Tax responsiveness
P09343208A1405|13 19|segment
P09343208A1405|53 62|copy number
P09343208A1405|65 69|genes
P09343208A1405|79 86|segment W
P09343208A1405|118 129|organization
P09343208A1405|168 176|functions
P09343208A1405|182 186|virus
P09343208A1405|211 221|association
P09343208A1405|235 239|wasps
P09343210A1112|11 18|deletion
P09343210A1112|22 37|mutation analyses
P09343210A1112|43 56|VCAM-1 promoter
P09343210A1112|70 111|chloramphenicol acetyltransferase constructs
P09343210A1112|150 163|VCAM-1 promoter
P09343210A1112|169 182|NF-kappaB sites
P09343210A1112|210 227|VCAM-1 gene promoter
P09343210A1112|271 280|expression
P09343210A1112|287 302|adhesion molecule
P09343222A0415|11 36|NIH/Swiss mouse CCR5 proteins
P09343222A0415|79 85|protein
P09343398A1193|0 11|Processivity
P09343398A1193|14 25|DNA synthesis
P09343398A1193|37 46|holoenzyme
P09343398A1193|57 63|pcna-79
P09343398A1193|132 139|template
P09343398A1193|150 158|structure
P09343426A0456|0 27|Alanine substitution mutations
P09343426A0456|33 51|Zta activation domain
P09343426A0456|69 75|ability
P09343426A0456|97 106|D-A complex
P09343432A0209|11 20|ph proteins
P09343432A0209|26 39|homology domain
P09343432A0209|45 53|% identity
P09343432A0209|59 64|length
P09343432A0209|69 78|amino acids
P09343432A0209|88 96|SPM domain
P09343432A0209|127 134|C termini
P09343433A0000|28 32|genes
P09343433A0000|46 58|RNA polymerase
P09343433A0000|89 105|effect variegation
P09343433A0000|120 133|yeast telomeres
P09343433A0360|8 17|rad6-delta
P09343433A0360|25 33|silencing
P09343433A0360|75 83|genes URA3
P09343982A0890|3 11|amplitude
P09343982A0890|14 33|detrusor contractions
P09343982A0890|44 48|hours
P09343982A0890|68 77|difference
P09343982A0890|91 98|controls
P09344650A0967|14 32|transmembrane domain
P09344650A0967|33 40|Casr-rs2
P09344650A0967|44 51|Casr-rs3
P09344650A0967|70 77|Casr-rs1
P09345037A0886|8 12|roles
P09345037A0886|47 64|trans-factor GATA-1
P09345037A0886|77 103|progenitor cell proliferation
P09345495A0000|0 19|PET activation studies
P09345495A0000|50 62|brain function
P09346238T0000|5 12|proteins
P09346238T0000|16 24|receptors
P09346238T0000|50 59|substrates
P09346238T0000|65 90|SCF ubiquitin-ligase complex
P09346621A1181|5 11|context
P09346621A1181|14 35|liver allograft shortage
P09346621A1181|39 45|results
P09346621A1181|86 93|patients
P09346621A1181|104 110|failure
P09346621A1181|131 138|APACHE II
P09346925A0660|3 12|SH3 domains
P09346925A0660|55 60|motifs
P09346925A0660|65 72|HPK1 tail
P09346925A0660|118 124|binding
P09346925A0660|154 162|Cos1 cells
P09346935A0459|13 20|analysis
P09346935A0459|24 51|coimmunoprecipitation studies
P09346935A0459|69 73|ZNF74
P09346935A0459|89 104|zinc finger domain
P09346935A0459|138 144|subunit
P09346935A0459|147 159|RNA polymerase
P09346935A0459|162 167|pol IIo
P09346935A0927|4 23|ZNF74 sublocalization
P09346935A0927|33 39|domains
P09346935A0927|50 74|pre-mRNA maturating factors
P09346935A0927|78 95|RNA binding activity
P09346935A0927|124 134|interaction
P09346935A0927|142 147|pol IIo
P09346935A0927|160 172|RNA polymerase
P09346935A0927|201 214|mRNA processing
P09346935A0927|236 241|member
P09346935A0927|246 273|KRAB multifinger protein family
P09346935A0927|276 288|RNA processing
P09346938A1680|0 30|Ki-ras4BVal-12 transfectant cells
P09346938A1680|54 66|protein levels
P09346938A1680|81 106|cysteine protease cathepsin B
P09346938A1680|127 150|cathepsin B mRNA expression
P09346953A0000|32 57|heparan sulfate proteoglycan
P09346953A0000|57 63|HSPGact
P09346953A0000|64 73|generation
P09346953A0000|91 95|level
P09346953A0000|128 135|activity
P09346953A0000|136 158|HSact conversion activity
P09346953A0000|202 249|heparan sulfate D-glucosaminyl 3-O-sulfotransferase
P09346953A0000|250 254|3-OST
P09346953A0000|255 261|Shworak
P09348226A0852|24 30|insulin
P09348226A0852|40 62|tyrosine phosphorylation
P09348226A0852|65 69|c-cbl
P09348226A0852|76 86|association
P09348226A0852|91 96|Crk-II
P09348931T0000|12 18|lottery
P09349501A0196|35 41|portion
P09349501A0196|65 75|MLL products
P09349501A0196|86 93|MLL-LTG9
P09349501A0196|97 105|MLL-LTG19
P09349501A0196|120 125|nuclei
P09349501A0196|181 194|leukemogenesis
P09349967A0653|3 9|results
P09349967A0653|24 30|pattern
P09349967A0653|33 43|blood supply
P09349967A0653|69 80|organisation
P09349967A0653|89 100|lamellar bone
P09351242A0719|0 8|Induction
P09351242A0719|11 33|AtP5CS1 mRNA accumulation
P09351242A0719|48 56|seedlings
P09351242A0719|96 103|response
P09351242A0719|115 127|ABA signalling
P09351242A0719|148 160|cycloheximide
P09351242A0719|178 187|deficiency
P09351242A0719|190 204|ABA biosynthesis
P09351242A0719|210 230|aba1 Arabidopsis mutant
P09351823A0414|17 29|MAPK functions
P09351823A0414|39 48|maturation
P09351823A0414|112 122|development
P09352016A1110|4 15|AF G-CSF level
P09352016A1110|46 54|predictor
P09352127A0953|9 19|correlation
P09352127A0953|27 40|serum myoglobin
P09352127A0953|44 62|CA III concentrations
P09352127A0953|107 114|patients
P09352127A0953|129 135|failure
P09353247A0922|14 38|over-replication phenotype
P09353247A0922|59 66|p65cdc18
P09353247A0922|96 113|cyclin/CDK activity
P09353247A0922|120 128|inhibitor
P09353247A0922|131 146|over-replication
P09353255A0159|0 4|Rip1p
P09353255A0159|39 51|pore complexes
P09353255A0159|79 98|FG-nucleoporin family
P09353255A0159|101 112|pore proteins
P09353296A0510|3 12|CNXA domain
P09353296A0510|27 40|amino acid level
P09353296A0510|61 75|moaA gene product
P09353296A0510|107 117|moaC product
P09353296A0510|131 138|products
P09353296A0510|157 164|cistrons
P09353304A0732|0 8|Deletions
P09353304A0732|22 28|regions
P09353304A0732|36 55|membrane localization
P09353304A0732|58 62|Tiam1
P09353304A0732|66 81|membrane ruffling
P09353328A0736|17 22|kinase
P09353328A0736|32 37|domain
P09353328A0736|65 71|zippers
P09353328A0736|93 100|homology
P09353328A0736|110 117|proteins
P09353343A0919|0 12|RNA polymerase
P09353343A0919|15 24|inhibition
P09353343A0919|37 43|binding
P09353343A0919|49 60|AUBP activity
P09353343A0919|71 79|Sepharose
P09353343A0919|91 97|hnRNP A1
P09353343A0919|110 123|hnRNP A1 binding
P09353343T0000|0 9|Modulation
P09353343T0000|12 38|AUUUA response element binding
P09353343T0000|61 79|ribonucleoprotein A1
P09353343T0000|87 98|T lymphocytes
P09354349A0338|12 17|slides
P09354349A0338|23 28|biopsy
P09354349A0338|35 41|patient
P09354349A0338|100 105|Giemsa
P09354349A0338|113 126|Warthin-Starry
P09354349A0338|154 159|method
P09354349A0338|187 203|H. pylori antiserum
P09354349A0338|203 210|DAKO B471
P09354644A0124|5 16|biosynthesis
P09354644A0124|34 43|precursors
P09354644A0124|64 89|beta1,6-GlcNAc transferases
P09354644A0124|90 94|IGnT6
P09354644A0124|95 100|GlcNAc
P09354676A1714|5 12|findings
P09354676A1714|32 36|p16.3
P09354676A1714|76 88|translocation
P09354676A1714|111 119|FGFR3 gene
P09354676A1714|127 132|target
P09354676A1714|139 149|abnormality
P09354676A1714|169 181|tumorigenesis
P09354684A1158|2 9|addition
P09354684A1158|10 17|mutation
P09354684A1158|23 29|Sp1 site
P09354684A1158|54 69|promoter activity
P09354757A1444|0 16|Amino acid residues
P09354757A1444|26 31|alpha A
P09354757A1444|31 36|alpha B
P09354757A1444|59 64|His539
P09354757A1444|69 80|RNase H domain
P09354757A1444|96 107|primer strand
P09354757A1444|113 117|dsDNA
P09356645A0672|13 19|patient
P09356645A0672|25 31|sarcoma
P09356645A0672|56 64|procedure
P09356645A0672|74 89|nerve enlargement
P09358045A0000|7 24|length cDNA sequence
P09358045A0000|47 63|growth factor-beta
P09358045A0000|63 70|TGF-beta
P09358045A0000|71 78|receptor
P09358045A0000|118 138|nematode Brugia pahangi
P09358055A0590|4 11|sequence
P09358055A0590|21 28|homology
P09358055A0590|55 69|promoter element
P09358055A0590|95 99|mouse
P09358055A0590|113 123|A-particles
P09358069T0000|0 16|Codon optimization
P09358069T0000|30 39|expression
P09358069T0000|47 60|erythropoietin
P09358069T0000|77 81|cells
P09358837T0000|26 38|albumin levels
P09358837T0000|43 51|treatment
P09358837T0000|63 74|hypertension
P09359844A0674|11 24|HSL transcripts
P09359844A0674|43 52|adipocytes
P09359887A1168|33 45|Rat7p/Nup159p
P09359887A1168|90 95|region
P09359887A1168|106 114|sequences
P09360422A0135|3 7|group
P09360422A0135|12 19|patients
P09360422A0135|36 49|arteriopathies
P09360422A0135|60 64|limbs
P09360422A0135|68 79|plasma levels
P09360422A0135|82 95|thrombomodulin
P09360422A0135|100 118|betathromboglobulin
P09360422A0135|118 124|beta-TG
P09360422A0135|125 131|D-dimer
P09360422A0135|139 168|plasminogen activator-inhibitor
P09360422A0135|168 172|pAI-1
P09360422A0135|201 206|values
P09360422A0135|228 237|volunteers
P09360953A1057|5 12|residues
P09360953A1057|13 18|Ile244
P09360953A1057|57 61|helix
P09360953A1057|65 70|Tyr318
P09360953A1057|89 95|portion
P09360953A1057|149 161|PTH-1 receptor
P09360956A0840|24 38|phosphorylation
P09360956A0840|58 69|CKIalpha site
P09360956A0840|69 75|Thr-233
P09360956A0840|98 104|binding
P09360956A0840|107 111|c-Raf
P09360956A0840|143 160|signal transduction
P09360993T0000|0 20|Mouse mast cell protease
P09360993T0000|28 33|member
P09360993T0000|39 48|chromosome
P09360993T0000|51 56|family
P09360993T0000|59 73|serine proteases
P09360993T0000|109 117|mast cells
P09361007A0922|1 5|DNase
P09361007A0922|58 75|pair enhancer region
P09362105X0422|17 26|resistance
P09362105X0422|39 45|% O2-PVR
P09362105X0422|52 58|% O2/PVR
P09362105X0422|102 117|vasoconstriction
P09362473A1540|11 17|results
P09362473A1540|26 31|tinman
P09362473A1540|48 52|array
P09362473A1540|63 78|enhancer elements
P09362473A1540|128 133|inputs
P09362473A1540|157 165|activator
P09362473A1540|169 189|repressor binding sites
P09362473A1540|210 217|enhancer
P09362473A1540|231 243|twist activity
P09362473A1540|254 258|areas
P09362473A1540|268 288|twist expression domain
P09362480A0452|9 23|cysteine triplet
P09362480A0452|38 46|sequences
P09362480A0452|49 57|TB domains
P09362480A0452|96 105|C-terminus
P09362499A0000|3 12|Fis protein
P09362499A0000|35 46|DNA inversion
P09362499A0000|59 64|family
P09362499A0000|67 79|DNA invertases
P09362499A0000|117 124|enhancer
P09363759A0000|0 18|Protein phosphatases
P09363759A0000|43 52|regulation
P09363759A0000|67 75|cell cycle
P09363759A0000|79 96|signal transduction
P09364211A0319|24 45|transcription factor E2F
P09364211A0319|71 77|binding
P09364440A2206|3 7|study
P09364440A2206|29 37|structure
P09364440A2206|43 57|FSH receptor gene
P09364440A2206|67 72|motifs
P09364440A2206|83 90|coupling
P09364440A2206|102 110|effectors
P09364750T0000|15 24|regulation
P09364750T0000|27 31|SUP35
P09364750T0000|35 39|SUP45
P09365201A2018|5 11|studies
P09365201A2018|22 26|basis
P09365201A2018|40 55|characterization
P09365201A2018|71 79|mechanism
P09365201A2018|82 100|aromatase expression
P09365201A2018|108 119|breast cancer
P09365272T0000|0 6|Xenopus
P09365272T0000|18 24|protein
P09365272T0000|35 46|interactions
P09365272T0000|50 56|effects
P09365272T0000|66 73|assembly
P09365272T0000|76 93|Xenopus egg extracts
P09365431A0314|16 26|combination
P09365431A0314|29 43|benzodiazepines
P09365431A0314|50 91|acetylcholinesterase inhibitor physostigmine
P09366456A0234|0 6|METHODS
P09366456A0234|12 26|muscle paralysis
P09366456A0234|49 58|anesthesia
P09366456A0234|62 66|group
P09366456A0234|74 80|persons
P09366456A0234|86 98|body mass index
P09366456A0234|113 117|group
P09366456A0234|127 133|persons
P09366456A0234|139 150|body mas index
P09366517A0835|26 32|Ser-365
P09366517A0835|34 40|Ser-393
P09366517A0835|68 72|sites
P09366517A0835|80 94|phosphorylation
P09366517A0835|118 125|activity
P09366517A1828|3 10|findings
P09366517A1828|26 33|evidence
P09366517A1828|41 48|function
P09366517A1828|75 89|phosphorylation
P09366628T0000|16 24|direction
P09366628T0000|26 34|causality
P09366628T0000|52 58|studies
P09367288A0115|36 43|decrease
P09367288A0115|58 71|unit rest length
P09367288A0115|91 104|immobilisation
P09367288A0115|117 124|position
P09367288A0115|146 156|adaptations
P09367288A0115|162 167|muscle
P09367288A0115|170 175|tendon
P09367392A0567|3 10|presence
P09367392A0567|25 32|sequence
P09367392A0567|35 45|nucleotides
P09367392A0567|82 100|template recognition
P09367392A0567|117 128|accumulation
P09367392A0567|153 158|levels
P09367426A1354|46 53|polarity
P09367426A1354|69 84|compartment cells
P09367426A1354|99 112|interpretation
P09367426A1354|136 147|polarization
P09367676A0275|0 23|Restriction enzyme mapping
P09367676A0275|24 33|subcloning
P09367676A0275|37 57|DNA sequencing analysis
P09367676A0275|71 81|phage lambda
P09367676A0275|85 92|P1 clones
P09367676A0275|105 109|exons
P09367676A0275|127 137|mouse TS mRNA
P09367676A1115|0 19|Transfection analyses
P09367676A1115|36 45|expression
P09367676A1115|48 53|Tbxas1
P09367676A1115|97 104|sequence
P09367676A1115|133 140|elements
P09368006A1332|3 9|results
P09368006A1332|16 20|study
P09368006A1332|32 48|NF-kappaB activity
P09368006A1332|68 78|interaction
P09368006A1332|86 94|cell cycle
P09368006A1332|105 111|protein
P09368006A1332|112 116|E2F-1
P09368014A0740|3 17|lysozyme FEF site
P09368026A0000|0 10|Osteocalcin
P09368026A0000|18 23|matrix
P09368026A0000|38 44|protein
P09368026A0000|56 66|osteoblasts
P09368026A0000|70 81|odontoblasts
P09368026A0000|92 105|mineralization
P09368026A0435|6 10|study
P09368026A0435|23 29|effects
P09368026A0435|32 45|Msx2 expression
P09368026A0435|48 67|OC promoter activation
P09368026A0435|68 85|luciferase reporter
P09368026A0435|88 95|FGF2/FSK
P09368026A0435|99 108|calcitriol
P09368026A0435|111 129|MC3T3-E1 osteoblasts
P09368057A1083|15 22|proteins
P09368057A1083|40 50|SRF activity
P09368057A1083|54 70|repressor activity
P09368057A1083|95 101|element
P09368057A1083|138 147|inhibition
P09368057A1083|150 159|SRF binding
P09368058A0969|28 51|phosphopeptide comigrates
P09368058A0969|76 89|phosphopeptide
P09368100A1354|3 13|mHIF-1 alpha
P09368100A1354|44 48|exons
P09368190A1053|34 41|sequence
P09368190A1053|63 79|DNA binding pattern
P09368190A1053|108 115|exposure
P09368190A1053|118 126|IFN-gamma
P09368190A1053|157 167|stimulation
P09368190A1053|176 184|IFN-alpha
P09368190A1053|188 196|IFN-gamma
P09368419A0000|2 12|Arabidopsis
P09368419A0000|16 24|induction
P09368419A0000|104 122|protein biosynthesis
P09368419A0000|135 148|gene expression
P09368419A0628|27 43|DNA binding protein
P09368419A0628|56 81|DNA-ligand binding screening
P09368419A0628|95 100|region
P09368419A0628|104 108|probe
P09368419A0628|122 128|rd22BP1
P09368760A0665|28 57|Drosophila protein kinase DSTPK61
P09368760A0665|84 93|regulation
P09368760A0665|96 113|sex differentiation
P09368760A0665|114 122|oogenesis
P09368760A0665|126 140|spermatogenesis
P09369450A1358|18 24|effects
P09369450A1358|27 35|HNF-1beta
P09369450A1358|72 87|promoter activity
P09369450A1358|115 123|HNF-1 site
P09369450A1358|175 186|interactions
P09369450A1358|196 215|transcription factors
P09369450A1358|240 261|transcription machinery
P09369450A1358|265 290|steroid receptor coactivator
P09369451A0693|10 17|analysis
P09369451A0693|43 50|sequence
P09369451A0693|57 66|TGAATCATCA
P09369451A0693|80 100|myocyte enhancer factor
P09369451A0693|111 118|sequence
P09369451A0693|125 137|TTAAAAATAAAAA
P09369451A0693|148 153|region
P09369451A0693|172 181|OP-1 effect
P09369453A0273|15 21|members
P09369453A0273|27 37|Bcl-2 family
P09369453A0273|43 52|Bcl-xL/Bcl
P09369453A0273|63 75|death promoter
P09369453A0273|77 89|death enhancer
P09369453A0273|105 123|transmembrane domain
P09369453A0273|159 166|membrane
P09369453A0273|177 184|envelope
P09369482A0690|0 19|Electromobility shift
P09369482A0690|23 42|cotransfection assays
P09369482A0690|59 67|HNF1alpha
P09369482A0690|120 139|G6Pase gene expression
P09370276A0781|6 17|reading frame
P09370276A0781|40 55|amino acid protein
P09370307A0093|12 20|AACA motif
P09370307A0093|46 54|regulator
P09370307A0093|65 71|tissues
P09370307A0093|79 88|similarity
P09370307A0093|94 110|barley gibberellin
P09370307A0093|121 127|element
P09370307A0093|148 165|DNA binding proteins
P09371431A1172|0 11|Strain CFN037
P09371431A1172|16 27|R. etli mutant
P09371431A1172|44 58|Tn5mob insertion
P09371431A1172|64 77|promoter region
P09371431A1172|83 100|thiCOGE gene cluster
P09371431T0000|0 9|Expression
P09371431T0000|31 35|genes
P09371431T0000|36 42|thiCOGE
P09371431T0000|46 55|production
P09371431T0000|67 85|terminal oxidase cbb3
P09371431T0000|88 100|Rhizobium etli
P09371455A0000|25 30|region
P09371455A0000|40 51|lipase operon
P09371455A0000|89 103|metalloprotease
P09371455A0000|106 121|Vibrio cholerae O1
P09371564A0713|14 19|amount
P09371564A0713|69 75|viruses
P09371564A0713|121 125|virus
P09371566A1384|4 10|protein
P09371566A1384|39 46|extracts
P09371566A1384|49 60|S100 extracts
P09371566A1384|76 94|protein preparations
P09371566A1384|128 134|protein
P09371596T0000|12 21|regulation
P09371596T0000|27 31|pre-C
P09371596T0000|45 53|promoters
P09371596T0000|61 75|hepatitis B virus
P09371596T0000|78 84|members
P09371596T0000|97 115|receptor superfamily
P09371622A0779|0 7|Chimeras
P09371622A0779|18 28|IE1 peptides
P09371622A0779|50 62|transcription
P09371622A0779|73 80|promoter
P09371622A0779|89 108|lac operator sequences
P09371626A1345|3 9|results
P09371626A1345|12 26|replicase assays
P09371626A1345|62 69|deletion
P09371626A1345|85 90|domain
P09371626A1345|131 141|replication
P09371626A1345|153 159|protein
P09371626A1345|161 167|ability
P09371626A1345|177 188|mRNA template
P09371626A1345|204 212|synthesis
P09371657A0165|24 46|alanine cluster mutations
P09371657A0165|71 81|E192A-E194A
P09371657A0165|108 130|triphosphatase component
P09371698A1254|0 11|Transfection
P09371698A1254|14 18|HepG2
P09371698A1254|22 33|SK-N-MC cells
P09371698A1254|38 47|constructs
P09371698A1254|75 83|fragments
P09371698A1254|96 105|definition
P09371698A1254|119 136|bp promoter fragment
P09371698A1254|150 163|pseudo-TATA box
P09371698A1254|189 193|sites
P09371731A0627|4 10|inserts
P09371731A0627|29 38|homologues
P09371731A0627|41 57|eIF-2alpha kinases
P09372287A0296|14 23|electrodes
P09372287A0296|77 81|tract
P09372287A0296|112 116|tract
P09372287A0296|127 135|C1 segment
P09372287A0296|149 155|pathway
P09372287A0296|158 162|axons
P09372451T0000|0 7|Epitopes
P09372451T0000|39 48|antibodies
P09372451T0000|81 86|domain
P09372451T0000|92 103|integrin beta
P09372451T0000|105 111|subunit
P09372908A1068|24 31|Sex Combs
P09372908A1068|75 83|mechanism
P09372908A1068|103 116|gene repression
P09372908A1068|127 135|inclusion
P09372908A1068|138 152|Polycomb protein
P09372908A1068|158 164|complex
P09372908A1068|186 194|silencing
P09372924A0758|15 28|rhHR23 proteins
P09372924A0758|47 55|NER system
P09372924A0758|81 88|proteins
P09372924A0758|105 115|involvement
P09372924A0758|118 130|hHR23 proteins
P09372924A0758|136 152|DNA repair reaction
P09372924A0758|156 166|interaction
P09372937T0000|3 7|yeast
P09372937T0000|14 45|information regulator Sir4p anchors
P09372937T0000|49 66|partitions plasmids
P09372950A1283|5 11|results
P09372950A1283|51 59|structure
P09372950A1283|69 77|sequences
P09372950A1283|84 88|sides
P09372950A1283|100 111|cleavage site
P09372950A1283|118 127|processing
P09372950A1283|135 139|U2 RNA
P09372960A0456|0 15|Polysome analyses
P09372960A0456|40 51|fal1-1 mutant
P09372960A0456|70 75|strain
P09372960A0456|83 90|decrease
P09372960A0456|96 101|number
P09372960A0456|118 125|subunits
P09372968A0532|0 15|Sequence analysis
P09372968A0532|37 46|cDNA clones
P09372968A0532|49 53|Dlc-1
P09372968A0532|55 62|sequence
P09372968A0532|87 93|homolog
P09372968A0532|108 113|dynein
P09372968A0532|125 131|protein
P09372968A0996|25 29|cells
P09372968A0996|54 64|kappaB alpha
P09372968A0996|111 115|Dlc-1
P09373140A0000|3 17|mouse M-lysozyme
P09373140A0000|28 35|enhancer
P09373140A0000|75 80|levels
P09373140A0000|83 96|gene regulation
P09373155T0000|0 13|Identification
P09373155T0000|16 21|dynein
P09373155T0000|27 36|chain genes
P09373155T0000|56 66|mouse testis
P09373155T0000|78 89|localization
P09373155T0000|102 111|dynein gene
P09373651A0255|6 12|cassava
P09373651A0255|31 40|glycosides
P09373651A0255|41 50|processing
P09373651A0255|67 84|acetone cyanohydrin
P09373651A0255|88 102|hydrogen cyanide
P09374082A0504|11 19|mechanism
P09374082A0504|22 33|effect states
P09374082A0504|41 52|2-ethylhexyl
P09374082A0504|53 61|phthalate
P09374082A0504|78 94|hydrolysis product
P09374082A0504|119 132|prostaglandins
P09374082A0504|141 146|9alpha
P09374082A0504|146 153|betaPGF2
P09374082A0504|157 165|PGF2alpha
P09374082A0504|169 180|thromboxanes
P09374082A0504|186 190|lungs
P09374082A0504|227 238|inflammation
P09374082A0504|243 249|airways
P09374082A0504|258 271|characteristic
P09374082A0504|274 279|asthma
P09374541A0277|9 27|protein binding sites
P09374541T0000|12 21|protection
P09374541T0000|24 46|E2F recognition sequences
P09374541T0000|57 79|thymidine kinase promoter
P09374541T0000|86 105|cell cycle progression
P09376325A0167|0 9|Comparison
P09376325A0167|19 26|sequence
P09376325A0167|39 45|ph locus
P09376325A0167|97 114|transcription units
P09376626A0737|0 8|Radiation
P09376626A0737|21 26|levels
P09376626A0737|54 59|group C
P09376626A0737|58 63|group A
P09376626A0737|73 78|group B
P09376626A0737|82 94|h postexposure
P09376782A0328|17 26|experience
P09376782A0328|47 54|practice
P09376782A0328|58 72|hepatitis C virus
P09376782A0328|78 86|infection
P09377355A0362|3 8|author
P09377355A0362|42 46|study
P09377355A0362|60 67|features
P09377355A0362|84 92|disorders
P09377355A0362|107 117|impairement
P09377355A0362|151 155|tools
P09377374A0000|6 10|paper
P09377374A0000|11 26|characterization
P09377374A0000|58 65|features
P09377374A0000|68 76|VH B course
P09377374A0000|87 96|background
P09377374A0000|99 108|narcomania
P09379301A2036|3 9|microns
P09379301A2036|13 27|A. microcephalum
P09379301A2036|34 40|microns
P09379301A2036|44 50|A. wedli
P09379301A2036|59 64|testes
P09379301A2036|68 77|proglottis
P09380504A1255|3 11|ZnF20 cDNA
P09380504A1255|32 42|transcripts
P09380504A1255|46 66|thyroid cancer cell line
P09380504A1255|99 120|cycloheximide treatment
P09380504A1255|139 146|addition
P09380504A1255|148 160|actinomycin D.
P09380507A0514|0 23|Glutathione S-transferase
P09380507A0514|36 55|GST-DP fusion proteins
P09380507A0514|93 100|E2F sites
P09380507A0514|106 135|DNA polymerase alpha gene promoter
P09380697T0000|3 8|sterol
P09380697T0000|31 39|sequences
P09380697T0000|47 59|up-regulation
P09380697T0000|62 86|caveolin gene transcription
P09380697T0000|89 96|response
P09380697T0000|102 119|density lipoprotein
P09380697T0000|124 134|cholesterol
P09380707A0714|20 28|LAZ3/BCL6
P09380707A0714|69 76|proteins
P09381261A0970|0 10|CONCLUSIONS
P09381261A0970|27 35|EPO levels
P09381261A0970|39 45|mothers
P09381261A0970|49 56|newborns
P09381950A0209|0 8|Ischaemia
P09381950A0209|25 32|flow rate
P09381950A0209|38 44|mL min-1
P09381950A0209|81 91|reperfusion
P09382498A0618|24 32|electrode
P09382498A0618|81 85|tumor
P09382498A0618|105 113|electrode
P09382498A0618|174 178|tumor
P09382850A0000|0 9|BACKGROUND
P09382850A0000|10 27|Checkpoint pathways
P09382850A0000|45 55|progression
P09382850A0000|61 65|event
P09382850A0000|68 77|DNA lesions
P09382886A1061|6 10|proof
P09382886A1061|41 49|apoptosis
P09382886A1061|106 112|matings
P09382924A0131|11 18|evidence
P09382924A0131|36 46|stimulation
P09382924A0131|51 66|interferon-gamma
P09382924A0131|67 75|IFN-gamma
P09382924A0131|90 97|subunits
P09382924A0131|123 128|PSMB10
P09382924A0131|149 161|20S proteasome
P09382924A0131|198 205|subunits
P09382924A0131|216 220|PSMB6
P09382924A0131|221 225|PSMB5
P09382924A0131|229 233|PSMB7
P09383156A0691|8 28|RNase E cleavage product
P09383156A0691|36 41|pSok-6
P09383156A0691|61 87|polynucleotide phosphorylase
P09383156A0691|88 93|PNPase
P09383188A0654|4 13|difference
P09383188A0654|35 39|match
P09383188A0654|45 59|ARG box consensus
P09385169T0000|10 16|experts
P09385169T0000|24 45|productivity indicators
P09386074A0694|31 43|LV dysfunction
P09386074A0694|53 70|LV ejection fraction
P09387333T0001|3 10|progress
P09387333T0001|26 33|research
P09387333T0001|51 57|nucleus
P09387999A1053|3 12|amplitudes
P09387999A1053|15 19|DPOAE
P09387999A1053|43 48|extent
P09387999A1053|57 70|hair cell losses
P09388198A1396|16 23|evidence
P09388198A1396|31 55|signal transduction pathway
P09388198A1396|82 93|p38 MAP kinase
P09388198A1396|109 117|induction
P09388198A1396|137 142|stress
P09388198A1396|164 177|autoregulation
P09388199A0948|4 9|effort
P09388199A0948|20 26|domains
P09388199A0948|46 55|DNA binding
P09388199A0948|55 66|dimerization
P09388199A0948|70 82|ligand binding
P09388199A0948|91 104|protein fusions
P09388199A0948|115 130|DNA binding domain
P09388199A0948|151 157|regions
P09388200A0639|0 9|Inhibition
P09388200A0639|29 37|titration
P09388200A0639|47 66|transcription factors
P09388200A0639|74 91|MDM2 overexpression
P09388200A0639|100 104|c-fos
P09388200A0639|118 126|promoters
P09388200A0639|141 153|transcription
P09388201A1027|38 47|CAAT motifs
P09388246A0903|22 58|electron microscopy immunocytochemistry
P09388246A0903|63 73|amphiphysin
P09388246A0903|91 95|nerve
P09388246A0903|104 113|cytomatrix
P09388246A0903|151 163|intermediates
P09388271A1243|3 15|mobility shift
P09388271A1243|29 36|proteins
P09388271A1243|50 58|treatment
P09388271A1243|63 72|inhibitors
P09388271A1243|99 105|protein
P09388271A1243|139 150|kinase kinase
P09389137A0763|3 14|prescription
P09389137A0763|18 25|apoplexy
P09389198A0363|9 17|aftermath
P09389198A0363|20 29|excitation
P09389198A0363|52 56|nerve
P09389198A0363|64 74|arithmetics
P09389198A0363|79 89|A delta units
P09389198A0363|111 115|state
P09389198A0363|139 147|threshold
P09389492A0520|10 16|fashion
P09389492A0520|33 37|cells
P09389492A0520|38 42|serum
P09389492A0520|57 64|response
P09389492A0520|67 79|dexamethasone
P09389492A0520|88 93|effect
P09389492A0520|96 102|phorbol
P09389492A0520|119 126|activity
P09389666A0538|4 16|Hex expression
P09389666A0538|53 76|anteroposterior asymmetry
P09389666A0538|82 92|mouse embryo
P09389666A0538|138 143|embryo
P09389666A0538|155 164|conversion
P09389666A0538|181 189|asymmetry
P09389666A0538|215 229|endoderm lineage
P09389669A1009|28 44|dorsal leg cell fate
P09389669A1009|79 90|leg disc cells
P09389982A1383|0 10|CONCLUSIONS
P09389982A1383|16 28|INR correction
P09389982A1383|55 61|methods
P09389982A1383|74 88|log reference INR
P09389982A1383|99 113|prothrombin time
P09389982A1383|122 139|regression analysis
P09390125A0379|0 6|RESULTS
P09390125A0379|82 89|quarters
P09390183A1027|0 18|Western blot analysis
P09390183A1027|34 40|tissues
P09390183A1027|50 67|NMT peptide antibody
P09390183A1027|161 167|tissues
P09391173A0811|0 22|Transcription start sites
P09391173A0811|28 45|plastid ACCase genes
P09391173A0811|73 82|cDNA clones
P09391173A0811|104 116|amplification
P09391173A0811|118 125|cDNA ends
P09392979T0000|24 37|histoplasmosis
P09392979T0000|40 51|San Francisco
P09392979T0000|52 61|California
P09393706A1171|41 49|activator
P09393706A1171|57 64|promoter
P09393717A1517|5 16|observations
P09393717A1517|30 36|support
P09393717A1517|53 62|expression
P09393717A1517|86 101|mutator phenotype
P09393717A1517|129 137|phenotype
P09393717A1517|157 165|mutC cells
P09393771A1659|0 16|TNF-alpha exposure
P09393771A1659|34 41|activity
P09393771A1659|62 69|proteins
P09393771A1659|113 119|protein
P09393875A0873|23 36|papillomavirus
P09393875A0873|41 45|mRNAs
P09393875A0873|72 77|copies
P09393875A0873|83 93|virus genome
P09393875A0873|111 115|cells
P09393875A0873|130 139|c-fos mRNAs
P09393875A0873|164 170|factors
P09393875A0873|199 214|Fos protein levels
P09393875A0873|222 235|papillomavirus
P09393875A0873|244 248|cells
P09393966A0190|30 40|region genes
P09394650A0121|14 18|study
P09394650A0121|64 73|lymph nodes
P09395456A0424|23 33|chain motifs
P09395456A0424|35 54|substrate recognition
P09395456A0424|63 70|variants
P09395456A0424|90 107|proenteropeptidase
P09395456A0424|137 155|transmembrane domain
P09395456A0424|161 173|signal peptide
P09395470A0294|0 11|CKbeta4GT-II
P09395470A0294|40 64|transmembrane glycoprotein
P09395470A0294|98 115|glycosylation sites
P09395525A0395|42 48|protein
P09395525A0395|49 53|C/EBP
P09395525A0395|54 58|delta
P09395525A0395|67 75|component
P09395525A0395|105 111|complex
P09395525A0395|138 147|C/EBPdelta
P09395525A0395|161 173|IGF-I promoter
P09396402A0264|0 7|PATIENTS
P09396402A0264|11 17|METHODS
P09396402A0264|18 30|Semen analyses
P09396402A0264|48 55|patients
P09396402A0264|60 65|stages
P09396402A0264|95 106|chemotherapy
P09396402A0264|117 126|sperm count
P09396402A0264|143 149|effects
P09396402A0264|161 172|radiotherapy
P09396402A0264|190 201|chemotherapy
P09396427A1488|7 13|absence
P09396427A1488|24 44|infarct-zone viability
P09396427A1488|58 65|patients
P09396427A1488|102 109|dilation
P09396427A1488|171 178|geometry
P09396437A0878|5 13|BMI cutoff
P09396437A0878|29 39|NE spillover
P09396437A0878|62 69|subjects
P09396437A0878|92 99|subjects
P09396722A0185|9 13|ApxII
P09396722A0185|38 66|ascorbate peroxidase isoenzymes
P09396722A0185|84 95|organization
P09396796A1173|17 26|conclusion
P09396796A1173|31 35|CDF-1
P09396796A1173|43 57|E2F family member
P09396796A1173|61 66|points
P09396796A1173|77 87|differences
P09396796A1173|93 111|cell cycle regulation
P09396796A1173|114 118|CDF-1
P09396823T0000|15 20|domain
P09396823T0000|38 50|DNA polymerase
P09396823T0000|71 91|RNA exonuclease domains
P09397261A0940|0 18|Interleukin-1 levels
P09397261A0940|43 48|course
P09397723T0001|0 20|Responsibility matters
P09397723T0001|38 44|council
P09398267A0440|0 19|Southern blot analysis
P09398267A0440|66 87|chick embryo fibroblasts
P09398267A0440|147 153|species
P09398332A0732|0 8|Sequences
P09398332A0732|20 30|interaction
P09398332A0732|41 46|CTLA-4
P09398332A0732|61 68|residues
P09398332A0732|69 76|161TTGVY
P09398332A0732|79 84|CTLA-4
P09398332A0732|89 96|sequence
P09398332A0732|147 161|SH2 binding motif
P09398332A0732|162 168|165YVKM
P09398332A0732|179 193|CTLA-4 signaling
P09398598A0256|35 46|hamster ovary
P09398598A0256|52 59|cell line
P09398598A0256|76 86|CD4 fragment
P09398598A0256|118 124|domains
P09398598A0256|146 154|molecules
P09398598A0256|174 182|multimers
P09398855A0438|0 4|SCID V
P09398855A0438|6 19|J recombination
P09398855A0438|39 51|T-lymphocytes
P09398855A0438|72 77|agents
P09398855A0438|78 94|gamma-irradiation
P09398855A0438|98 106|bieomycin
P09398855A0438|114 121|mutation
P09398855A0438|127 133|p53 gene
P09398855A0438|170 186|DNA repair activity
P09398855A0438|189 196|response
P09398855A0438|199 207|DNA damage
P09398855A0438|219 227|apoptosis
P09398855A0438|233 239|absence
P09400613A0594|0 11|Coexpression
P09400613A0594|14 21|mouse PKR
P09400613A0594|47 58|domain fusion
P09400613A0594|104 114|K296R mutant
P09400613A0594|151 160|K64E/K296R
P09400613A0594|183 190|mouse PKR
P09400613A0594|209 239|PKR-Gal4 activation domain fusions
P09400613A0594|250 259|activation
P09400613A0594|274 286|lacZ reporters
P09400613A1209|5 31|GST-PKR fusion chromatography
P09400613A1209|46 56|interaction
P09400613A1209|67 71|mouse
P09400613A1209|80 90|PKR homologs
P09400738A1046|25 32|response
P09400738A1046|62 73|instillation
P09400738A1046|93 106|CB instillation
P09402029A1632|25 35|strain H37Ra
P09402029A1632|46 58|hybridization
P09402029A1632|71 76|probes
P09402029A1632|96 100|genes
P09402029A1632|135 140|strain
P09402029A1632|162 172|copy numbers
P09402029A1632|202 212|strain H37Rv
P09402088A2250|5 11|defects
P09402088A2250|14 18|doubt
P09402088A2250|38 50|configuration
P09402088A2250|69 78|processing
P09402088A2250|84 99|AVP gene precursor
P09402139A1121|0 11|Similarities
P09402139A1121|22 29|hIGFBP-1
P09402139A1121|33 57|phosphoenolpyruvate kinase
P09402139A1121|58 62|PEPCK
P09402139A1121|63 71|promoters
P09402139A1121|81 87|regions
P09402139A1121|98 104|insulin
P09402139A1121|105 118|glucocorticoid
P09402139A1121|151 159|responses
P09402139A1121|188 197|hypothesis
P09402139A1121|202 208|IGFBP-1
P09402139A1121|221 230|regulation
P09402139A1121|233 249|glucose metabolism
P09403059A0209|10 15|repeat
P09403059A0209|34 44|DNA elements
P09403059A0209|56 60|LINES
P09403059A0209|61 65|SINES
P09403059A0209|66 98|medium reiteration frequency repeats
P09403059A0209|118 124|element
P09404725A0644|13 18|amount
P09404725A0644|20 31|gangliosides
P09404725A0644|51 57|females
P09404725A0644|64 68|males
P09404725A0644|83 91|exception
P09405195A0320|12 21|constructs
P09405195A0320|46 50|locus
P09405195A0320|63 75|recombination
P09405195A0320|91 99|sequences
P09405195A0320|111 119|stretches
P09405195A0320|149 162|intron excision
P09405195A0320|215 227|recombination
P09405380A0800|3 11|existence
P09405380A0800|22 31|categories
P09405380A0800|34 40|strains
P09405380A0800|58 63|system
P09405380A0800|74 83|properties
P09405380A0800|108 117|retrovirus
P09405536A0777|9 29|conditioning procedure
P09405536A0777|33 39|C-fiber
P09405536A0777|88 94|fashion
P09405536A0777|115 121|animals
P09405536A0777|131 141|application
P09405536A0777|157 175|conditioning stimuli
P09405536A0777|189 197|magnitude
P09405536A0777|203 211|responses
P09405536A0777|220 226|plateau
P09405685A0113|20 48|DNA binding transcription factor
P09405685A0113|79 92|consensus motif
P09405685A0113|92 98|PuPuPuC
P09405685A0113|107 120|GPyPyPyPuPuPuC
P09405685A0113|126 134|GPyPyPy-3
P09407026A0426|0 11|TSA treatment
P09407026A0426|40 60|enhancer factor binding
P09407026A0426|66 76|positioning
P09407026A0426|79 83|nuc-1
P09407026A0426|89 96|majority
P09407026A0426|102 119|chromatin templates
P09407026A0426|134 151|protein acetylation
P09407026A0426|155 173|chromatin remodeling
P09407026A0426|187 191|steps
P09407026A0426|233 241|templates
P09407026A0426|248 257|remodeling
P09407026A0426|260 264|nuc-1
P09407026A0426|283 289|factors
P09407031A0557|4 11|UV damage
P09407031A0557|73 78|timing
P09407031A0557|80 94|phosphorylation
P09407031A0557|97 106|Chk1 kinase
P09407031A0557|132 145|Cdc2 activation
P09407031A0974|16 29|overexpression
P09407031A0974|51 60|phenotypes
P09407031A0974|71 81|crb2 mutants
P09407036T0000|0 10|Tcn1p/Crz1p
P09407036T0000|33 51|transcription factor
P09407036T0000|79 92|gene expression
P09407090T0000|0 8|Structure
P09407090T0000|12 23|localization
P09407090T0000|48 56|SR-BI/CLA
P09407642A0305|15 26|gel technique
P09407642A0305|37 41|assay
P09407642A0305|45 61|antibody detection
P09407642A0305|65 78|identification
P09408516T0000|0 8|Stability
P09408516T0000|11 23|pyrimethamine
P09408516T0000|33 49|dosage formulation
P09408516T0000|64 69|months
P09408796A0648|8 25|regression analyses
P09408796A0648|38 74|WAIS-R factor scores Verbal Comprehension
P09408796A0648|78 84|Freedom
P09408796A0648|89 103|Distractibility
P09408796A0648|129 136|variance
P09408796A0648|138 142|WMS-R
P09408796A0648|146 156|CVLT indices
P09409416A0111|14 21|arteries
P09409416A0111|52 59|approach
P09409416A0111|77 93|Doppler instrument
P09409416A0111|93 102|TC-2 64B EME
P09409774A0214|12 16|level
P09409774A0214|20 28|sequences
P09409774A0214|34 40|members
P09409774A0214|47 52|family
P09409774A0214|66 84|rat Rattus norvegicus
P09409774A0214|88 96|VCSA1 gene
P09409774A0214|123 137|polypeptide SMR1
P09409774A0214|144 152|VCSB1 gene
P09409774A0214|178 188|polypeptide
P09409821T0000|26 34|RAD30 gene
P09409821T0000|36 44|homologue
P09409821T0000|79 87|DNA damage
P09409821T0000|98 106|functions
P09409821T0000|125 154|postreplication repair mechanism
P09411459A0729|13 22|experiment
P09411459A0729|33 44|deletion task
P09411459A0729|60 69|puppet game
P09411459A0729|77 87|pretraining
P09411459A0729|91 99|selection
P09411459A0729|102 114|vowel deletion
P09411459A0729|135 139|level
P09411459A0729|142 148|success
P09411459A0729|165 172|children
P09411459A0729|187 198|CVCC material
P09412079T0001|0 10|Diet therapy
P09412079T0001|15 25|soy proteins
P09412079T0001|36 48|stomach ulcers
P09413375A1486|2 12|ICU patients
P09413375A1486|54 62|IL-6 level
P09413375A1486|86 105|plasma concentrations
P09413375A1486|107 115|cytokines
P09414074A0827|0 17|Resistance training
P09414074A0827|27 36|power curve
P09414074A0827|48 56|direction
P09414074A0827|64 75|measurements
P09414074A0827|101 105|loads
P09414074A0827|121 125|power
P09414074A0827|157 171|performance task
P09414287A0637|0 14|Gel-shift assays
P09414287A0637|28 42|Sp1 binding sites
P09414287A0637|53 59|element
P09414319A1442|0 5|Y15170
P09414319A1442|6 11|Surf-2
P09414319A1442|12 17|Surf-4
P09414319A1442|18 23|Y15171
P09414319A1442|24 29|Surf-3
P09414319A1442|30 35|Surf-1
P09414319A1442|36 41|Surf-6
P09414319A1442|45 50|Y15172
P09414319A1442|51 56|Surf-5
P09415711A1348|0 15|Gel mobility shift
P09415711A1348|30 35|assays
P09415711A1348|41 45|liver
P09415711A1348|53 60|extracts
P09415711A1348|71 78|rat liver
P09415711A1348|81 93|DDT1MF-2 cells
P09415711A1348|123 136|alpha 1B-AR gene
P09415711A1348|141 157|CRE binding protein
P09416467A0959|5 11|results
P09416467A0959|41 45|model
P09416467A0959|46 58|ACE inhibitors
P09416467A0959|67 77|arrhythmias
P09416467A0959|87 106|ischemia-reperfusion
P09416467A0959|121 136|scavenging action
P09416467A0959|144 148|drugs
P09416467A0959|201 206|effect
P09416898A1798|3 12|mean values
P09416898A1798|28 37|components
P09416898A1798|69 80|ARVD patients
P09416898A1798|91 98|subjects
P09417082A0127|10 25|signaling cascade
P09417082A0127|39 55|urokinase receptor
P09417108A0000|9 21|Htf9-a/RanBP1
P09417108A0000|25 35|Htf9-c genes
P09417108A0000|81 88|promoter
P09417493A0823|2 11|accordance
P09417493A0823|24 34|improvement
P09417493A0823|43 50|decrease
P09417493A0823|53 72|laboratory indicators
P09417493A0823|75 86|inflammation
P09417493A0823|97 103|protein
P09417493A0823|104 119|alpha 2-globuline
P09417493A0823|120 134|prostaglandin E2
P09417870A0105|28 36|depletion
P09417870A0105|39 52|protein kinase C
P09417870A0105|64 72|treatment
P09417870A0105|75 95|B16 mouse melanoma cells
P09417870A0105|100 116|phorbol dibutyrate
P09417870A0105|155 167|melanogenesis
P09417928A0980|0 10|Replacement
P09417928A0980|13 20|residues
P09417928A0980|23 31|positions
P09417928A0980|34 42|His128Asn
P09417928A0980|50 58|Gln155Lys
P09417928A0980|63 76|reading helices
P09417928A0980|79 85|fingers
P09417928A0980|112 118|binding
P09417941A1287|3 19|disulphide bridges
P09417941A1287|42 62|spermadhesin molecules
P09417941A1287|70 79|CUB domains
P09417941A1287|89 94|loop LA
P09417941A1287|98 107|strand beta
P09417941A1287|112 118|loops LE
P09417941A1287|148 152|edges
P09417941A1287|172 177|domain
P09418040T0000|0 11|Mg-chelatase
P09418040T0000|14 20|tobacco
P09418040T0000|21 34|identification
P09418040T0000|38 53|Chl D cDNA sequence
P09418040T0000|68 74|subunit
P09418040T0000|75 82|analysis
P09418040T0000|88 98|interaction
P09418040T0000|109 116|subunits
P09418040T0000|124 128|yeast
P09418040T0000|139 144|system
P09418040T0000|148 161|reconstitution
P09418040T0000|167 180|enzyme activity
P09418040T0000|183 195|co-expression
P09418040T0000|209 212|CHL D
P09418040T0000|213 216|CHL H
P09418040T0000|220 224|CHL I.
P09418057A0684|3 7|R-EST
P09418057A0684|22 29|sequence
P09418057A0684|45 53|locations
P09418861A0623|14 22|structure
P09418861A0623|45 49|motif
P09418861A0623|67 80|protein kinase C
P09418861A0623|84 94|n-chimaerin
P09418861A0623|107 130|pleckstrin homology domain
P09418871A0620|3 13|interaction
P09418871A0620|54 85|coimmunoprecipitation experiments
P09418882A0760|12 21|antibodies
P09418882A0760|53 59|version
P09418882A0760|62 67|Prp42p
P09418882A0760|91 97|U1 snRNA
P09418882A0760|102 114|yeast extracts
P09418905A1396|5 11|results
P09418905A1396|26 33|addition
P09418905A1396|49 58|activation
P09418905A1396|85 97|DAG production
P09418905A1396|130 141|S-phase entry
P09418905A1396|144 157|gene expression
P09418905A1396|173 182|activation
P09419415A0236|6 10|study
P09419415A0236|25 38|STAT activation
P09419415A0236|42 46|panel
P09419415A0236|55 73|fibroblast cell lines
P09419415A0236|105 116|oncoproteins
P09419421A0385|18 22|cells
P09419421A0385|26 32|binding
P09419421A0385|35 42|NF-Y/CBF
P09419421A0385|78 84|plateau
P09419421A0385|89 94|S phase
P09419680A1112|0 9|CONCLUSION
P09419680A1112|15 25|animal model
P09419680A1112|37 53|barrier disruption
P09419680A1112|78 84|finding
P09419680A1112|87 101|single-fraction
P09419680A1112|111 127|irradiation injury
P09420219A0284|15 27|investigation
P09420219A0284|30 39|parameters
P09420219A0284|59 64|export
P09420219A0284|86 90|cells
P09420219A0284|116 133|beta-actin minigene
P09420219A0284|142 148|control
P09420219A0284|178 194|enhancer-promoter
P09420219A0284|197 201|mouse
P09420219A0284|209 218|tumor virus
P09420219A0284|255 268|adenovirus type
P09420219A0284|274 279|genome
P09420220A0070|31 42|interactions
P09420220A0070|78 87|expression
P09420234A0654|0 7|MpB GroEL
P09420234A0654|20 37|sequence similarity
P09420234A0654|61 65|GroEL
P09420234A0654|73 79|members
P09420234A0654|85 103|chaperonin-60 family
P09420239A1937|11 19|mutations
P09420239A1937|69 78|elongation
P09420239A1937|91 108|Nef coding sequences
P09420239A1937|108 114|changes
P09420239A1937|117 130|RNA splice donor
P09420239A1937|134 146|acceptor sites
P09420239A1937|147 158|TATA box sites
P09420239A1937|162 169|Sp1 sites
P09420239A1937|178 184|changes
P09420239A1937|190 197|V2 region
P09420239A1937|214 243|consensus neutralization epitope
P09420239A1937|261 278|glycosylation sites
P09420252A0092|23 28|repeat
P09420252A0092|34 41|promoter
P09420252A0092|55 64|expression
P09420252A0092|85 92|proteins
P09420252A0092|111 118|promoter
P09420252A0092|147 153|env gene
P09420252A0092|164 173|expression
P09420252A0092|184 200|auxiliary proteins
P09420269A0000|28 39|rubella virus
P09420269A0000|84 89|leader
P09420269A0000|88 96|ss-leader
P09420269A0000|121 129|structure
P09420269A0000|147 156|complement
P09420269A0000|227 234|promoter
P09420269A0000|235 243|synthesis
P09420269A0000|257 263|strands
P09420275A0682|16 27|requirements
P09420275A0682|31 41|CBF2 binding
P09420275A0682|56 61|series
P09420275A0682|64 79|oligonucleotides
P09420275A0682|94 114|transversion mutations
P09420275A0682|139 150|core sequence
P09420275A0682|169 177|sequences
P09420275A1111|2 9|addition
P09420275A1111|13 22|affinities
P09420275A1111|46 50|LMP-1
P09420275A1111|50 54|LMP-2
P09420275A1111|58 70|CD23 promoters
P09420671A1190|0 10|CONCLUSIONS
P09420671A1190|24 29|uptake
P09420671A1190|32 45|99mTc sestamibi
P09420671A1190|54 61|subjects
P09420671A1190|65 72|patients
P09420671A1190|85 97|artery disease
P09420671A1190|115 122|exercise
P09420671A1190|123 134|dipyridamole
P09420671A1190|138 152|adenosine stress
P09421507A0000|5 17|protein family
P09421507A0000|54 69|pre-mRNA splicing
P09421507A0000|122 130|organisms
P09421508A0696|16 23|activity
P09421508A0696|26 30|TCF11
P09421508A0696|73 80|presence
P09421508A0696|108 124|transfection assay
P09421511A0827|13 23|comparisons
P09421511A0827|41 49|evolution
P09421511A0827|57 81|RNA-polymerase specificity
P09421511A0827|84 110|telomerase RNA-gene promoters
P09421511A0827|129 136|position
P09421511A0827|142 157|template sequence
P09421511A0827|163 175|telomerase RNA
P09421516A1516|0 12|Deadenylation
P09421516A1516|16 20|decay
P09421516A1516|23 37|beta-globin mRNA
P09421516A1516|40 48|K562 cells
P09421516A1516|82 92|NIH 3T3 cells
P09421516A1516|119 127|stability
P09421516A1516|136 150|beta-globin mRNA
P09421516A1516|153 161|K562 cells
P09421516A1516|185 201|deadenylation step
P09421521T0000|0 24|Holliday junction resolvase
P09421521T0000|63 82|endonuclease activity
P09421521T0000|88 104|CCE1 homologue YDC2
P09422351A0000|24 36|protein kinase
P09422351A0000|64 92|serine/threonine protein kinase
P09422351A0000|105 115|ion channels
P09422351A0000|125 131|enzymes
P09422351A0000|144 151|proteins
P09422351A0000|163 182|transcription factors
P09422727A0196|36 43|TGACGTGA
P09422727A0196|44 59|promoter sequence
P09422727A0196|64 93|protein kinase A signaling pathway
P09422727A0196|111 119|induction
P09422727A0196|123 132|activation
P09422727A0196|139 155|CRE binding protein
P09422727A0196|175 195|transcription factor-2
P09422727A0196|195 199|ATF-2
P09422727A0196|220 226|process
P09423123A0000|18 24|acronym
P09423123A0000|40 49|oxygenator
P09423310A0251|0 18|Histopathologically
P09423310A0251|26 37|lymphangioma
P09423310A0251|75 82|features
P09423310A0251|108 116|stainings
P09423310A0251|128 133|Factor
P09423310A0251|144 150|antigen
P09423310A0251|176 184|reactions
P09423310A0251|198 202|cells
P09423310A0251|208 212|cysts
P09423856A1098|0 17|Protease activities
P09423856A1098|20 27|cultures
P09423856A1098|46 52|strains
P09423856A1098|71 77|species
P09423856A1098|98 103|masses
P09423856A1098|155 164|processing
P09423856A1098|175 180|result
P09423856A1098|183 197|autoproteolysis
P09423856A1098|212 223|peptide bonds
P09423856A1098|239 243|parts
P09423856A1098|249 257|molecules
P09423968A0039|3 11|mechanism
P09423968A0039|26 34|analgesia
P09423968A0039|63 73|interaction
P09423968A0039|124 130|systems
P09423968A0039|131 137|defense
P09423968A0039|200 205|course
P09423968A0039|208 214|defense
P09423968A0039|218 228|nociception
P09423968A0039|234 242|processes
P09423968A0039|266 273|ontogeny
P09424012A1774|10 29|field placement errors
P09424012A1774|33 40|patients
P09424012A1774|56 66|mm distances
P09424012A1774|94 102|isocenter
P09424012A1774|121 127|patient
P09424012A1774|134 139|degree
P09424012A1774|150 154|error
P09424012A1774|186 191|errors
P09425036A0649|2 9|addition
P09425036A0649|32 38|version
P09425036A0649|44 58|Src family member
P09425036A0649|72 81|cell kinase
P09425036A0649|116 127|Csk substrate
P09425038A0752|4 8|Swift
P09425676A0000|8 17|mechanisms
P09425676A0000|28 44|stimulus-response
P09425676A0000|50 61|associations
P09425676A0000|63 83|S-R compatibility tasks
P09425676A0000|101 111|experiments
P09425676A0000|116 122|monkeys
P09426068A0826|3 21|c-myc/TGF-alpha HCCs
P09426068A0826|64 73|expression
P09426068A0826|76 84|TGF-alpha
P09426068A0826|104 108|index
P09426068A0826|111 118|contrast
P09426068A0826|125 130|levels
P09426068A0826|133 141|apoptosis
P09426068A0826|156 162|tissues
P09426068A0826|166 174|c-myc HCCs
P09426143A1358|48 54|effects
P09426143A1358|75 84|expression
P09426143A1358|88 104|pectinolysis genes
P09426143A1358|121 130|mechanisms
P09426143A1358|146 156|competition
P09426143A1358|170 179|regulators
P09426143A1358|192 200|repressor
P09426143A1358|204 216|RNA polymerase
P09426143A1358|223 232|occupation
P09426143A1358|242 250|DNA region
P09426143A1358|256 266|target genes
P09426183A0000|13 31|Rel/NF-kappaB family
P09426183A0000|34 63|vertebrate transcription factors
P09426183A0000|74 79|number
P09426183A0000|112 119|proteins
P09426183A0000|135 140|dimers
P09426183A0000|148 155|activity
P09426183A0000|180 187|location
P09426239A0386|3 11|cglIM gene
P09426239A0386|34 39|operon
P09426239A0386|55 62|addition
P09426239A0386|66 70|genes
P09426239A0386|95 112|restriction enzymes
P09426595T0000|20 28|reductase
P09426595T0000|32 56|saccharopine dehydrogenase
P09426595T0000|61 79|Arabidopsis thaliana
P09426595T0000|80 97|nucleotide sequence
P09426595T0000|101 116|characterization
P09426907A0391|3 9|purpose
P09426907A0391|16 28|investigation
P09426907A0391|46 56|formulation
P09426907A0391|59 76|silver sulfadiazine
P09426907A0391|80 84|water
P09426907A0391|97 105|poloxamer
P09426958A0110|3 12|study goals
P09426958A0110|38 42|clone
P09426958A0110|51 55|CO-Ag
P09426958A0110|67 84|corneal cDNA library
P09426958A0110|101 105|clone
P09427544A0000|3 9|pel gene
P09427544A0000|16 26|Amycolata sp
P09427544A0000|44 55|pectate lyase
P09427544A0000|80 87|activity
P09427544A0000|104 113|DNA library
P09427551A0501|20 24|exons
P09427551A0501|41 49|kb introns
P09427551A0501|80 89|chromosome
P09427551A0501|93 107|linkage analysis
P09427627A0802|2 15|Xenopus embryos
P09427627A0802|29 47|PDGF receptor protein
P09427627A0802|58 66|formation
P09427627A0802|69 76|mesoderm
P09427627A0802|92 99|explants
P09427627A0802|120 125|manner
P09427627A0930|10 16|variant
P09427627A0930|22 28|protein
P09427627A0930|47 66|transphosphorylation
P09427627A0930|114 122|MAP kinase
P09427627A0930|130 138|treatment
P09427627A0930|143 148|FK1012
P09427627T0000|14 20|control
P09427627T0000|23 29|insulin
P09427627T0000|33 53|PDGF receptor signaling
P09427627T0000|68 85|membrane attachment
P09427844A0739|21 30|dAK subunit
P09427844A0739|58 68|association
P09427844A0739|81 90|dCK subunit
P09427844A0739|131 136|affect
P09427844A0739|171 177|subunit
P09428389A1805|0 10|CONCLUSIONS
P09428389A1805|30 41|bicalutamide
P09428389A1805|64 74|combination
P09428389A1805|81 85|agent
P09428389A1805|93 98|LHRH-A
P09428389A1805|109 125|serum testosterone
P09428389A1805|135 139|doses
P09428389A1805|142 153|bicalutamide
P09428389A1805|187 197|monotherapy
P09428787A0138|8 12|clone
P09428787A0138|58 63|region
P09428787A0138|85 108|p69/71 2-5A synthetase gene
P09428799A0897|51 55|genes
P09428799A0897|76 82|enzymes
P09428799A0897|86 108|intron/exon organization
P09428799A0897|140 146|P450scc
P09429913A0528|0 6|RESULTS
P09429913A0528|19 26|question
P09429913A0528|32 39|benefits
P09429913A0528|82 88|studies
P09429913A0528|102 109|efficacy
P09429913A0528|127 135|disorders
P09429913A0528|157 164|disorder
P09430461A0742|13 17|study
P09430461A0742|21 30|defect size
P09430461A0742|38 49|BMIPP imaging
P09430461A0742|84 91|infarcts
P09430461A0742|125 132|risk area
P09430461A0742|142 165|contrast ventriculography
P09430461A0742|184 193|CONCLUSION
P09430461A0742|237 241|group
P09430461A0742|243 250|patients
P09430461A0742|273 284|BMIPP imaging
P09430461A0742|303 316|quantification
P09430461A0742|319 328|defect size
P09430461A0742|331 335|means
P09430461A0742|345 362|threshold technique
P09430461A0742|379 383|phase
P09430461A0742|391 403|determination
P09430461A0742|409 414|amount
P09430461A0742|417 426|myocardium
P09430461A0742|455 464|infarction
P09430661A0796|9 22|overexpression
P09430661A0796|31 44|EphB1 receptors
P09430661A0796|45 49|Y594F
P09430661A0796|57 70|Nck recruitment
P09430661A0796|73 77|EphB1
P09430661A0796|98 110|JNK activation
P09430661A0796|121 143|cell attachment responses
P09430668A0172a|3 10|promoter
P09430668A0172a|14 28|HMG-CoA synthase
P09430668A0172a|47 51|sites
P09430668A0172a|58 63|sterol
P09430668A0172a|89 96|proteins
P09430668A0172a|97 102|SREBPs
P09430730A0374|7 12|Walter
P09431812A0576|28 34|Patched
P09431812A0576|54 67|Ci binding sites
P09431812A0576|80 84|level
P09431812A0576|114 123|activation
P09431812A0576|126 132|S2 cells
P09431828A1472|20 27|increase
P09431828A1472|30 45|cyclosporine DR/C
P09431828A1472|45 52|SS trough
P09431828A1472|58 61|l h-1
P09431828A1472|72 75|l h-1
P09431828A1472|89 93|range
P09432752A0109|0 7|Patients
P09432752A0109|16 24|relatives
P09432752A0109|65 86|treatment possibilities
P09432752A0109|103 108|moment
P09432752A0109|117 127|application
P09432752A0109|142 148|patient
P09434160A0767|7 13|PTPases
P09434160A0767|54 72|bone marrow stem cells
P09434160A2078|0 9|Expression
P09434160A2078|12 16|PTPRO
P09434160A2078|45 59|bone marrow cells
P09434160A2078|89 97|stem cells
P09434185A0902|3 14|organization
P09434185A0902|17 25|SPP1 genes
P09434185A0902|39 49|replication
P09434185A0902|50 61|DNA packaging
P09434185A0902|65 85|phage assembly proteins
P09434185A0902|98 109|organization
P09434185A0902|112 116|genes
P09434185A0902|129 135|regions
P09434185A0902|168 176|DNA phages
P09434979A0790|3 9|results
P09434979A0790|40 52|photon fluence
P09434979A0790|67 79|photon fluence
P09434979A0790|94 103|collimator
P09434979A0790|120 125|filter
P09434979A0790|142 150|isocenter
P09434979A0790|192 197|filter
P09435056A0128|19 24|domain
P09435056A0128|27 37|pediocin AcH
P09435056A0128|79 87|machinery
P09435056A0128|102 110|periplasm
P09435056A0128|136 140|frame
P09435056A0128|145 156|COOH terminus
P09435056A0128|171 177|protein
P09435056A0128|193 199|protein
P09435116A0437|0 6|Isomers
P09435116A0437|35 43|MS-MS data
P09435116A0437|49 85|trofluoroacetyl-biphenylol derivatives
P09435789A0961a|8 12|RAD17
P09435789A0961a|13 17|RAD24
P09435789A0961a|44 58|cell cycle arrest
P09435789A0961a|62 67|S phase
P09435789A0961a|81 91|hydroxyurea
P09435789A0961a|117 125|viability
P09435789A0961a|127 136|yeast cells
P09435789A0961a|147 154|presence
P09435789A0961a|197 202|repair
P09435789A0961a|214 222|DNA damage
P09435806T0001|8 12|value
P09435806T0001|18 27|estimation
P09435806T0001|30 43|growth kinetics
P09435806T0001|60 76|cancer recurrences
P09435806T0001|79 83|CA125
P09436657A0303|4 9|review
P09436657A0303|29 35|disease
P09436657A0303|45 52|pathways
P09436657A0303|55 68|carcinogenesis
P09436657A0303|108 118|risk factors
P09436657A0303|139 143|basis
P09436657A0303|154 162|knowledge
P09436706A0168|3 9|patient
P09436706A0168|38 57|sperm injection cycles
P09436706A0168|78 88|spermatozoa
P09436706A0168|102 111|pharmacist
P09436706A0168|113 119|mistake
P09436706A0168|127 137|stimulation
P09436706A0168|154 164|combination
P09436706A0168|178 214|gonadotrophin-releasing hormone agonist
P09436706A0168|215 229|leuprolide depot
P09436706A0168|233 246|gonadotrophins
P09436795A0350|0 17|Protein C deficiency
P09436795A0350|20 37|protein S deficiency
P09436795A0350|58 67|risk factor
P09436795A0350|77 84|patients
P09436795A0350|94 101|patients
P09436795A0350|122 129|children
P09436989A1011|9 16|addition
P09436989A1011|43 50|function
P09436989A1011|56 62|mitosis
P09436989A1011|83 104|cell cycle reset function
P09436989A1011|119 128|initiation
P09436989A1011|134 159|spindle pole body duplication
P09437001A0769|2 9|contrast
P09437001A0769|10 23|overproduction
P09437001A0769|26 30|Der3p
P09437001A0769|42 54|sec61-2 strain
P09437001A0769|70 80|temperature
P09437001A0769|85 93|degrees C.
P09438165A0405|6 13|baseline
P09438165A0405|14 18|day-8
P09438165A0405|19 26|PC levels
P09438165A0405|61 68|patients
P09438165A0405|81 96|VOD manifestation
P09438427A0727|24 33|CE2 element
P09438427A0727|45 59|Hoxa1 expression
P09438427A0727|108 142|Hoxa1 beta-galactosidase reporter gene
P09438427A0727|155 162|mutation
P09438427A0727|168 177|CE2 element
P09438427T0000|23 29|element
P09438427T0000|44 49|somite
P09438427T0000|72 81|expression
P09438427T0000|87 95|Hoxa1 gene
P09440166A0857|0 6|RESULTS
P09440166A0857|16 33|cDNA insert sequence
P09440166A0857|40 50|nucleotides
P09440166A0857|53 58|length
P09440166A0857|83 88|region
P09440166A0857|91 101|nucleotides
P09440166A0857|120 125|region
P09440166A0857|128 138|nucleotides
P09440166A0857|157 162|region
P09440616A0422|12 16|phase
P09440616A0422|20 29|activities
P09441664A0377|41 59|transcription factor
P09441664A0377|60 64|HNF-6
P09441664A0377|83 107|HNF-3 beta promoter activity
P09441664A0377|138 143|region
P09441664A0377|173 177|genes
P09441746A0546|1 9|cDNA clone
P09441746A0546|57 61|GPR39
P09442017A0435|4 10|Science
P09442024A0236|4 9|Peyron
P09442024A0708|1 14|hybridoma clone
P09442024A0708|36 41|fusion
P09442024A0708|48 56|CEMLAI/NP
P09442024A0708|74 93|fibroblasts MRC5 cells
P09442024A0708|111 117|amounts
P09442024A0708|145 157|Jacalin lectin
P09442024A0708|168 176|O-glycans
P09442031A0586|4 14|information
P09442031A0586|27 36|estimation
P09442031A0586|68 74|subunit
P09442031A0586|85 90|series
P09442031A0586|112 133|TSHR ectodomain variants
P09442031A0586|134 151|places cleavage Site
P09442031A0586|158 165|vicinity
P09442031A0586|187 193|residue
P09442072A0716|7 11|DNase
P09442072A0716|13 24|footprinting
P09442072A0716|44 49|region
P09442072A0716|55 62|promoter
P09442072A0716|96 102|extract
P09442072A0716|115 123|footprint
P09442072A0716|127 132|region
P09442072A0716|171 178|fVII gene
P09442072A0716|192 203|liver factors
P09442072A0716|220 225|region
P09442080A0856|11 22|binding assay
P09442080A0856|28 36|IM-9 cells
P09442080A0856|40 45|source
P09442080A0856|48 52|SHP-1
P09442080A0856|56 60|SHP-2
P09442080A0856|77 87|association
P09442080A0856|90 94|SHP-2
P09442080A0856|101 105|SHP-1
P09442080A0856|111 140|glutathione S-transferase fusion
P09442080A0856|170 183|domain residues
P09442080A0856|202 207|fusion
P09442172A0908|77 93|gonadotrophin dose
P09442172A0908|102 107|number
P09442172A0908|110 116|oocytes
P09442172A0908|129 141|pregnancy rate
P09443948A0000|12 16|study
P09443948A0000|67 75|technique
P09443948A0000|96 104|diagnosis
P09443948A0000|111 124|trichinellosis
P09443948A0000|139 160|immunofluorescence test
P09443948A0000|185 193|outbreaks
P09443948A0000|199 212|trichinellosis
P09443948A0000|215 223|Argentina
P09443972A1145|3 9|results
P09443972A1145|45 63|transcription factor
P09443972A1145|79 88|regulation
P09443972A1145|91 100|expression
P09443972A1145|113 117|genes
P09443973A1028|18 24|plasmid
P09443973A1028|43 51|tif1-A79V
P09443978A0262|26 30|cells
P09443978A0262|87 99|transcription
P09443978A0262|112 120|promoters
P09443978A0262|131 139|TATA boxes
P09443978A0262|150 158|promoters
P09443978A0262|172 180|initiator
P09443978A0262|191 197|TATA box
P09444316A0388|18 22|signs
P09444316A0388|43 50|toxicity
P09444316A0388|75 83|F1 animals
P09445056A0215|27 47|chemical cross-linking
P09445056A0215|56 72|sulfosuccinimidyl
P09445056A0215|71 78|suberate
P09445056A0215|100 111|architecture
P09445056A0215|116 127|gp41 oligomer
P09445488A0230|4 9|effort
P09445488A0230|23 38|USH1C disease gene
P09445488A0230|56 61|region
P09445488A0230|74 80|markers
P09445488A0230|83 87|yeast
P09445488A0230|98 108|chromosomes
P09445488A0230|121 131|combination
P09445488A0230|133 149|STS content mapping
P09445488A0230|153 172|Alu-PCR hybridization
P09445488A1169|0 17|PowerBLAST analysis
P09445488A1169|31 38|clusters
P09445488A1169|50 61|sequence tags
P09445488A1169|76 80|genes
P09445488A1169|113 118|region
P09445488A1169|155 162|gene NEFA
P09445488A1169|163 175|DNA binding/EF
P09446600A0260|1 13|fusion protein
P09446600A0260|24 41|beta-galactosidase
P09446600A0260|80 88|cytoplasm
P09446600A0260|93 99|nucleus
P09446600A0260|119 124|manner
P09446616A0780|0 13|Reconstitution
P09446616A0780|16 28|Raf-1 activity
P09446616A0780|48 53|kinase
P09446616A0780|72 80|cell lines
P09446815A1021|2 9|addition
P09446815A1021|30 35|region
P09447917A0000|3 12|hypothesis
P09447917A0000|15 21|Geisler
P09447917A0000|22 29|Brain Res
P09447962A0452|9 18|transcript
P09447962A0452|19 24|rhis4l
P09447962A1027|18 31|interpretation
P09447962A1027|68 78|exonuclease
P09447962A1027|104 113|suppressor
P09447962A1027|130 138|half-life
P09447962A1027|141 149|rhis4 mRNA
P09447962A1027|167 174|increase
P09447962A1027|189 198|mRNA levels
P09447962A1027|221 233|HIS4 mRNA level
P09447963A0223|30 35|virtue
P09447963A0223|40 50|interaction
P09447963A0223|62 75|splicing factor
P09447963A0223|82 87|family
P09447973A0168|22 28|reports
P09447973A0168|29 36|addition
P09447973A0168|40 59|myristoylation signal
P09447973A0168|62 66|mSos1
P09447973A0168|67 73|MyrSos1
P09447973A0168|99 109|NIH 3T3 cells
P09447973A0168|113 120|deletion
P09447973A0168|126 138|mSos C terminus
P09447973A0168|139 152|MyrSos1-deltaC
P09447973A0168|176 183|activity
P09447979A1430|4 12|mutations
P09447979A1430|43 51|phenotype
P09447979A1430|54 66|sequestration
P09447979A1430|72 102|guanine nucleotide exchange factor
P09447994A0000|7 13|studies
P09447994A0000|52 57|region
P09447994A0000|60 64|c-fos
P09447994A0000|88 95|elements
P09447994A0000|122 137|response elements
P09447994A0000|160 177|c-fos transcription
P09447994A0000|179 186|response
P09447994A0000|190 196|variety
P09447994A0000|212 218|stimuli
P09448268A0186|13 18|kinase
P09448268A0186|37 43|homolog
P09448574A0964|3 10|findings
P09448574A0964|50 54|RACLO
P09448574A0964|78 85|measures
P09448574A0964|96 103|function
P09448574A0964|128 135|patients
P09448574A0964|148 160|system atrophy
P09449018T0000|0 19|Childhood misbehavior
P09449018T0000|43 49|drug use
P09450932A0142|7 14|analysis
P09450932A0142|40 50|subpathways
P09450932A0142|56 78|DNA structure checkpoints
P09450932A0142|101 106|arrest
P09450932A0142|109 120|DNA synthesis
P09451003A0894|4 20|Esigma54 promoters
P09451003A0894|42 48|protein
P09451003A0894|59 75|sigma54 activators
P09451003A0894|82 91|repression
P09451003A0894|110 115|result
P09451003A0894|120 130|interaction
P09451003A0894|138 145|Esigma54
P09451003A0894|152 166|CRP-cAMP complex
P09451016A1037|0 5|GlcNAc
P09451016A1037|9 39|GlcNAc2-PP-Dolichol biosynthesis
P09451016A1037|75 83|membranes
P09451016A1037|88 92|cells
P09451016A1037|116 122|plasmid
P09451016A1037|133 139|glucose
P09451016A1037|155 167|transcription
P09451857T0001|0 12|Demonstration
P09451857T0001|15 27|tissue lesions
P09451857T0001|46 54|injection
P09451857T0001|57 69|determination
P09451857T0001|72 85|creatine kinase
P09451857T0001|88 92|blood
P09452421A1042|0 9|Antibodies
P09452421A1042|23 31|GST mSH2-B
P09452421A1042|51 57|protein
P09452444A0000|0 12|Interleukin-6
P09452444A0000|33 40|cytokine
P09452444A0000|78 86|responses
P09452444A0000|92 105|phase reactions
P09452444A0000|109 121|hematopoiesis
P09452444A0450|4 11|analysis
P09452444A0450|21 28|deletion
P09452444A0450|45 52|variants
P09452444A0450|63 78|IL-6 gene promoter
P09452444A0450|89 100|reporter gene
P09452444A0450|133 152|transcription factors
P09453537A0863|4 9|region
P09453537A0863|26 34|CCAATC box
P09453537A0863|47 56|complement
P09453537A0863|67 73|GC boxes
P09453537A0863|81 96|recognition sites
P09453689A0000|3 9|purpose
P09453689A0000|46 57|pin sensation
P09453689A0000|65 79|bulbocavernosus
P09453689A0000|114 123|cord injury
P09453689A0000|142 164|bladder function recovery
P09454719A0181|10 20|termination
P09454719A0181|33 43|transcripts
P09454719A0181|50 64|LTR R/U5 junction
P09454719A0181|99 125|AAUAAA polyadenylation signal
P09454719A0181|145 150|effect
P09454719A0181|164 193|polyadenylation signal sequences
P09454719A0181|199 208|properties
P09454719A0181|238 243|vector
P09454735A1782|0 5|Levels
P09454735A1782|11 29|MEK inhibitor PD98059
P09454735A1782|50 60|mitogenesis
P09454735A1782|64 87|MAP kinase phosphorylation
P09454735A1782|116 134|adhesion disassembly
P09454735A1782|138 149|cell motility
P09455695A0762|0 8|ALT levels
P09455695A0762|11 20|responders
P09455695A0762|41 49|AST levels
P09455695A0762|73 77|weeks
P09455695A0762|79 95|vitamin E treatment
P09456312A1064|28 33|domain
P09456312A1064|36 42|RanGAP1
P09456312A1064|71 88|localization signal
P09458021A1373|33 41|AZA groups
P09458030A0192|3 7|study
P09458030A0192|35 40|effect
P09458030A0192|56 76|bone mineral metabolism
P09459241A0707|38 41|mm Hg
P09459241A0707|61 64|mm Hg
P09459685T0001|7 20|configurations
P09459685T0001|35 47|stress factors
P09459685T0001|76 83|children
P09459685T0001|87 97|adolescents
P09459835A0297|27 32|dosage
P09459835A0297|35 49|mg/kg body weight
P09459835A0297|68 72|FPMPA
P09459835A0297|75 80|dosage
P09459835A0297|85 99|mg/kg body weight
P09460171T0000|0 9|Resistance
P09460171T0000|12 25|thyroid hormone
P09460171T0000|26 37|implications
P09460171T0000|59 66|research
P09460171T0000|72 78|effects
P09460171T0000|81 104|thyroid hormone disruptors
P09461594A0000|13 20|evidence
P09461594A0000|25 32|exposure
P09461594A0000|35 52|DT40 lymphoma B cells
P09461594A0000|58 63|energy
P09461594A0000|79 83|field
P09461594A0000|99 106|tyrosine
P09461594A0000|122 131|activation
P09461594A0000|134 153|phospholipase Cgamma2
P09461594A0000|154 163|PLC-gamma2
P09461594A0000|182 209|inositol phospholipid turnover
P09463174A0670|23 29|results
P09463174A0670|42 49|patients
P09463174A0670|75 80|period
P09463174A0670|85 90|months
P09463380A1050|8 14|xTAK1KN
P09463380A1050|28 37|expression
P09463380A1050|47 65|mesoderm marker genes
P09463380A1050|75 79|Smad1
P09463560A0124|0 7|PATIENTS
P09463560A0124|11 16|METHOD
P09463560A0124|28 35|patients
P09463964A0243|3 7|assay
P09463964A0243|24 28|range
P09463964A0243|38 50|micrograms l-1
P09463964A0243|67 74|antibody
P09463964A0243|92 104|micrograms l-1
P09463964A0243|109 113|mg l-1
P09463964A0243|140 148|antiserum
P09463991T0000|11 15|audit
P09464248A0289|10 16|TATA box
P09464525T0000|0 9|Expression
P09464525T0000|13 28|characterization
P09464525T0000|61 71|Fv fragments
P09464525T0000|99 108|antibodies
P09465035A1032|9 17|inhibitor
P09465035A1032|50 57|fraction
P09465035A1032|73 77|alpha
P09465035A1032|77 84|activity
P09465783A0449|0 18|Platelet aggregation
P09465783A0449|21 28|response
P09465783A0449|33 53|micrograms collagen/ml
P09465783A0449|68 75|parallel
P09465783A0449|81 89|treatment
P09466267A1192|5 15|himA mutants
P09466267A1192|72 81|regulation
P09466267A1192|82 100|dmsA-lacZ expression
P09466931T0000|0 12|Cross-talking
P09466931T0000|35 43|receptors
P09466931T0000|60 74|response element
P09466931T0000|89 106|ng-2 intermolt genes
P09467044A0973|14 35|breast tumor relapse rate
P09467044A0973|65 75|MGDET groups
P09467707T0000|0 17|Sibling aggregation
P09467707T0000|38 59|lipoprotein cholesterol
P09467707T0000|63 78|apolipoproteins B
P09467707T0000|82 90|A-I levels
P09467707T0000|106 113|children
P09467707T0000|117 134|Bogalusa Heart Study
P09467900A0701|3 15|CAPLC1 protein
P09467900A0701|42 49|features
P09467900A0701|65 71|stretch
P09467900A0701|79 95|amino acid residues
P09467900A0701|105 111|X domain
P09467900A0701|130 139|N-terminus
P09467900A0701|171 179|EF-hand Ca
P09467900A0701|179 191|binding domain
P09467955A0468|4 13|hypothesis
P09467955A0468|33 42|occurrence
P09467955A0468|45 60|PEA3 binding sites
P09467955A0468|66 77|PEA3 promoter
P09467955A0468|88 94|ability
P09467955A0468|122 129|promoter
P09468386A0594|0 4|Pet-1
P09468386A0594|27 33|PEA3 ETS
P09468386A0594|45 49|motif
P09468386A0594|64 76|transcription
P09468386A0594|88 105|promoter constructs
P09468386A0594|126 131|manner
P09468509A0463|3 9|protein
P09468509A0463|21 29|F2771 cDNA
P09468509A0463|43 50|COS cells
P09468509A0463|67 75|cytoplasm
P09468514A1065|0 15|Northern analysis
P09468514A1065|37 46|expression
P09468514A1065|49 54|tissue
P09468514A1065|66 75|expression
P09468514A1065|81 85|heart
P09468515A0621|13 20|deletion
P09468515A0621|26 39|promoter region
P09468515A0621|42 51|nucleotide
P09468515A0621|76 90|SF-1 binding site
P09468515A0621|107 113|ability
P09469415A1337|3 13|observation
P09469415A1337|18 23|beta 2m
P09469415A1337|46 52|peptide
P09469415A1337|73 91|CTL target structures
P09469415A1337|108 120|possibilities
P09469415A1337|133 141|induction
P09469415A1337|160 171|CTL responses
P09469415A1337|180 194|DNA immunization
P09469415A1337|197 205|injection
P09469415A1337|233 238|beta 2m
P09469820A0151|3 7|mRNAs
P09469820A0151|15 19|genes
P09469820A0151|42 49|YAP1 uORF
P09469820A0151|56 64|YAP2 uORF1
P09469820A0151|68 72|uORF2
P09469820A0151|85 97|reading frames
P09469820A0151|136 145|modulation
P09469820A0151|164 169|events
P09469820A0151|187 192|region
P09469820A0151|217 223|control
P09469820A0151|232 242|translation
P09469820A0151|252 260|mRNA decay
P09469833A0533|23 28|nature
P09469833A0533|34 48|site specificity
P09469833A0533|57 71|deletion mutants
P09469833A0533|79 88|bp sequence
P09469933A1060|5 11|tissues
P09469933A1060|24 28|brain
P09469933A1060|32 38|message
P09469933A1060|42 49|CLIP-170
P09469933A1060|76 81|Restin
P09471984A0000|0 9|BACKGROUND
P09471984A0000|10 18|Chemicals
P09471984A0000|51 57|ability
P09471984A0000|73 89|contact dermatitis
P09472038T0000|12 23|polarization
P09472038T0000|26 31|T cells
P09472038T0000|47 60|immunoreceptor
P09472038T0000|75 84|activation
P09472038T0000|100 108|mechanism
P09472608A0253|21 27|ability
P09472608A0253|41 51|protein YB-1
P09472608A0253|62 74|transcription
P09472608A0253|80 92|HIV-1 promoter
P09472608A0253|111 118|cell line
P09472608A0253|119 124|U-87MG
P09472608A0253|134 141|cell line
P09472608A0253|142 148|SK-N-MC
P09472608A0253|160 164|cells
P09472608A0253|165 170|Jurkat
P09472608A0253|173 189|transfection assay
P09472616A1004|14 23|amino acids
P09472616A1004|38 44|regions
P09472616A1004|102 109|lineages
P09473040A1303a|9 16|alcR gene
P09473040A1303a|45 71|siderophore system activities
P09473040A1303a|77 83|mutants
P09473040A1303b|9 16|alcR gene
P09473040A1303b|45 71|siderophore system activities
P09473040A1303b|77 83|mutants
P09473317X2131|0 8|Copyright
P09473317X2131|13 25|Academic Press
P09473483A0953|76 84|Rev mutant
P09473483A0953|114 120|therapy
P09473483A0953|128 141|HIV-I infection
P09473483A0953|144 154|individuals
P09473483A0953|171 175|HIV-I
P09473483A0953|179 184|HTLV-1
P09473755A0318|0 7|PATIENTS
P09473755A0318|11 17|METHODS
P09473755A0318|25 31|January
P09474001A0825|3 11|frequency
P09474001A0825|46 51|groups
P09474001A0825|83 90|patients
P09474001A0825|102 106|MMFCV
P09474001A0825|136 140|MMFCV
P09474648A0298|13 19|P-SAECG
P09474648A0298|34 48|frequency domain
P09474648A0298|52 59|patients
P09474648A0298|74 81|controls
P09475378A1449|18 54|transcription-polymerase chain reaction
P09475378A1449|58 69|HPLC analysis
P09475378A1449|80 90|RUSH-1alpha
P09475378A1449|118 130|splice variant
P09475724T0000|26 42|signaling pathways
P09475724T0000|53 62|cell growth
P09475898T0000|13 25|amnioinfusion
P09476399A0141|8 15|division
P09476399A0141|24 36|tea plantation
P09476399A0141|39 43|Kandy
P09476520A1326|6 11|models
P09476520A1326|25 35|interaction
P09476520A1326|67 74|profiles
P09476520A1326|98 107|antibodies
P09476520A1326|114 120|hybrids
P09476520A1326|128 137|complexity
P09476520A1326|150 158|existence
P09476520A1326|176 188|heterogeneity
P09476520A1326|196 204|molecules
P09477316A0140|2 6|order
P09477316A0140|20 26|pathway
P09477316A0140|38 53|Hox gene induction
P09477316A0140|80 95|Hox gene regulator
P09477316A0140|99 137|leucine zipper transcription factor MafB/Kr
P09477316A0140|190 196|signals
P09478921A0126|0 9|Substrates
P09478921A0126|18 24|bcr-abl
P09478921A0126|50 61|pathogenesis
P09478971A1896|0 17|Reporter constructs
P09478971A1896|37 42|manner
P09478971A1896|112 121|expression
P09478971A1896|122 127|Cyp1B1
P09478971A1896|130 151|mouse embryo fibroblasts
P09478976A0718|0 18|Transfection studies
P09478976A0718|33 40|deletion
P09478976A0718|43 51|sequences
P09478976A0718|82 90|start site
P09478976A0718|119 127|induction
P09478976T0000|0 10|Oncostatin M
P09478976T0000|21 25|c-Fos
P09478976T0000|60 70|AP-1 element
P09478976T0000|80 94|tissue inhibitor
P09478976T0000|97 123|metalloproteinase-1 promoter
P09479498A0000|23 37|RING-finger gene
P09479498A0000|70 76|protein
P09480831A0272|24 32|mechanism
P09480831A0272|42 55|gene expression
P09480831A0272|66 73|elements
P09480831A0272|84 89|region
P09480831A0272|92 97|AM gene
P09480831A0272|133 137|cells
P09480843A0848|16 21|region
P09480843A0848|27 37|transcripts
P09480843A0848|54 67|triplet repeats
P09480843A0848|73 79|alanine
P09480843A0848|81 90|nucleotide
P09480843A0848|140 146|rat RL14
P09480929T0000|27 32|domain
P09480929T0000|42 51|production
P09480929T0000|60 65|fusion
P09480929T0000|90 97|proteins
P09480929T0000|106 133|baculovirus/insect cell system
P09481826T0000|0 6|Control
P09481826T0000|14 26|liver syndrome
P09481826T0000|30 39|Jersey herd
P09481826T0000|43 48|change
P09481826T0000|87 99|somatotrophin
P09482107A0551|3 12|inhibition
P09482107A0551|15 28|focus formation
P09482107A0551|42 49|presence
P09482107A0551|73 79|effects
P09482107A0551|81 93|cell viability
P09482107A0551|110 117|C3G cells
P09482107A0551|134 141|survival
P09482107A0551|145 155|growth rates
P09482107A0551|171 181|NIH3T3 cells
P09482107A0551|184 188|cells
P09482107A0551|204 216|plasmid vector
P09482902A0423|0 7|C.D2-Chr
P09482902A0423|17 23|strains
P09482902A0423|33 44|DBA/2 alleles
P09482902A0423|62 71|Pctr1 locus
P09482902A0423|81 85|DBA/2
P09482902A0423|95 101|alleles
P09482902A0423|107 128|CDK4/CDK6 inhibitors p16
P09482902A0942|23 27|DBA/2
P09482902A0942|37 41|A134C
P09482902A0942|44 48|G232A
P09482902A0942|64 71|variants
P09482902A0942|101 107|ability
P09482902A0942|119 126|activity
P09482902A0942|129 141|cyclin D2/CDK4
P09482902A0942|144 155|kinase assays
P09482902A0942|160 180|retinoblastoma protein
P09482902A0942|213 218|allele
P09482902A0942|253 266|susceptibility
P09482902A0942|268 277|BALB/c mice
P09482902A0942|281 301|plasmacytoma induction
P09482902A0942|313 317|INK4a
P09482902A0942|326 334|candidate
P09482902A0942|341 350|Pctr1 locus
P09483596A0626|21 30|difference
P09483596A0626|46 55|conditions
P09483596A0626|61 66|minute
P09483596A0626|73 83|excellent/5
P09483596A0626|93 110|suxamethonium group
P09483596A0626|116 126|excellent/3
P09483596A0626|136 150|rocuronium group
P09484463T0000|0 6|Cloning
P09484463T0000|10 19|expression
P09484463T0000|25 29|genes
P09484463T0000|51 58|proteins
P09484463T0000|63 69|tobacco
P09484781A1233|17 27|association
P09484781A1233|32 55|D3 phosphatidylinositides
P09484781A1233|77 86|activation
P09484781A1233|89 95|PKB/Akt
P09485308A1165|3 11|FMN moiety
P09485308A1165|21 26|3Fe-4S
P09485308A1165|27 33|cluster
P09485308A1165|39 45|subunit
P09485308A1165|72 79|reaction
P09485790T0000|0 22|Alison Bell Memorial Award
P09486035A0051|0 6|METHODS
P09486035A0051|8 23|population survey
P09486035A0051|45 55|individuals
P09486035A0051|68 77|prevalence
P09486035A0051|92 97|causes
P09486035A0051|100 108|blindness
P09486035A0051|111 117|Lebanon
P09486531A0638|6 18|organogenesis
P09486531A0638|19 33|HFH-8 expression
P09486531A0638|56 63|mesoderm
P09486531A0638|71 80|apposition
P09486531A0638|86 96|gut endoderm
P09486531A0638|138 146|induction
P09486531A0638|157 172|gut morphogenesis
P09486890A0234|7 17|laparoscopy
P09486890A0234|35 47|inoperability
P09486890A0234|53 57|cases
P09486890A0234|60 74|carcinoma spread
P09486890A0234|77 81|areas
P09486890A0234|109 121|visualization
P09487130A0383|2 11|difference
P09487130A0383|14 27|telomere length
P09487130A0383|37 43|mutants
P09487130A0383|57 66|regulation
P09487130A0383|91 106|DNA repair mutants
P09487130A0383|131 139|telomeres
P09487590A0657|3 14|mean duration
P09487590A0657|17 26|pain relief
P09487590A0657|33 37|weeks
P09487841A0132|45 61|sample preparation
P09487841A0132|90 96|changes
P09488441A0615|16 28|transcription
P09488441A0615|35 48|immunoglobulin
P09488441A0615|60 67|enhancer
P09488441A0615|70 101|P-selectin promoter NF-kappaB sites
P09488441A0615|115 127|p50 homodimers
P09488441A0615|147 164|P-selectin promoter
P09488441A0615|173 187|site competition
P09488441A0615|226 235|expression
P09488441A0615|240 246|concert
P09488441A0615|251 255|Bcl-3
P09488441A0615|265 274|expression
P09488466A0695|4 11|fragment
P09488466A0695|64 74|actinomycin
P09488466A0695|83 87|cells
P09488466A0695|99 127|precursor-product relationship
P09488486A0000|20 26|protein
P09488486A0000|55 67|transcription
P09488486A0000|93 106|RNA polymerases
P09488486A0000|107 117|polymerases
P09488486A0906|19 23|R231E
P09488486A0906|24 28|R235E
P09488486A0906|30 34|R239S
P09488486A0906|52 59|activity
P09488486A0906|63 91|yeast U6 snRNA gene transcription
P09488486A0906|127 139|transcription
P09488491A0000|0 10|E2F activity
P09488491A0000|35 54|retinoblastoma family
P09488491A0000|56 78|tumor suppressor proteins
P09488713A0886|23 32|inhibition
P09488713A0886|35 48|Site-1 cleavage
P09488713A0886|77 90|overexpression
P09488725A0904|27 34|identity
P09488725A0904|60 71|polypeptides
P09488725T0000|9 24|characterization
P09488725T0000|41 48|subunits
P09488725T0000|68 77|proton pump
P09489670A1157|2 11|C. albicans
P09489670A1157|49 54|levels
P09489670A1157|68 76|cell types
P09489670A1157|85 89|yeast
P09489670A1157|90 95|hyphae
P09489670A1157|127 143|HST6 transcription
P09489670A1157|171 175|yeast
P09489670A1157|232 239|function
P09489670A1157|246 261|Hst6p transporter
P09489670A1157|264 273|C. albicans
P09490676A0800|11 17|binding
P09490676A0800|39 50|Ets-2 protein
P09490676A0800|57 65|fragments
P09490676A0800|87 92|excess
P09490676A0800|109 129|oligodeoxynucleotides
P09490676A0800|180 184|sites
P09490727A1041|4 25|structure interconnects
P09490727A1041|34 41|triplets
P09490727A1041|52 57|bodies
P09490727A1041|77 83|bundles
P09490727A1041|106 114|apparatus
P09491074A0104|25 33|mechanism
P09491074A0104|48 57|expression
P09491074A0104|63 73|temperature
P09491074A0104|77 90|promoter region
P09492038A0352|12 16|study
P09492038A0352|20 24|roles
P09492038A0352|48 55|elements
P09492038A0352|73 78|region
P09492038A0352|93 108|promoter activity
P09492038A0352|126 136|mutagenesis
P09492038A0352|158 170|binding assays
P09494078A1362|6 18|5HT5A receptor
P09494078A1362|22 29|addition
P09494078A1362|32 40|yohimbine
P09494078A1362|69 74|effect
P09495283A0000|14 25|reporter gene
P09495283A0000|26 33|beta-gal
P09495283A0000|34 43|expression
P09495283A0000|59 87|heat shock transcription factors
P09495283A0000|110 118|HeLa cells
P09495283A0000|122 126|yeast
P09495771A0379|9 20|fluorescence
P09495771A0379|40 44|cells
P09495771A0379|63 81|midcell constriction
P09495771A0379|136 140|stage
P09495771A0379|142 150|septation
P09498553A0702|2 8|TATA box
P09498553A0702|30 43|promoter region
P09498553A0702|55 61|GC boxes
P09498553A0702|80 87|cap sites
P09498553A0702|131 136|nature
P09498553A0702|139 147|CYP51 gene
P09498553A0702|154 162|existence
P09498553A0702|176 203|transcription initiation sites
P09498553T0000|25 31|studies
P09498553T0000|34 39|sterol
P09498553T0000|60 64|CYP51
P09498553T0000|80 96|P450 monooxygenase
P09498769A0095|3 19|expression pattern
P09498769A0095|22 35|representative
P09498769A0095|58 65|proteins
P09498769A0095|85 100|B cell development
P09498769A0095|104 113|activation
P09498769A0095|139 144|B cells
P09498769A0095|175 185|plasma cells
P09499031A0000|17 29|gene junctions
P09499031A0000|41 55|stomatitis virus
P09499031A0000|77 92|sequence elements
P09499031A0000|111 125|polyadenylation
P09499031A0000|129 152|transcription termination
P09499031A0000|163 172|transcript
P09499031A0000|181 192|reinitiation
P09499031A0000|195 207|transcription
P09499031A0000|220 229|transcript
P09499048A1003|16 27|virus progeny
P09499048A1003|71 75|cells
P09499048A1003|108 115|function
P09499048A1003|120 135|replication cycle
P09499061A0000|0 7|Cleavage
P09499061A0000|23 31|reactions
P09499061A0000|48 72|immunodeficiency virus type
P09499061A0000|74 78|HIV-1
P09499061A0000|79 87|integrase
P09499061A0000|119 127|insertion
P09499061A0000|130 137|HIV-1 DNA
P09499061A0000|145 154|host genome
P09499254A1309|3 12|DSF regimen
P09499254A1309|37 44|activity
P09499254A1309|47 54|patients
P09499254A1309|82 100|islet-cell carcinoma
P09499254A1309|104 119|patient tolerance
P09499254A1309|125 131|regimen
P09499254A1309|164 176|investigation
P09501093A0071|0 9|Activation
P09501093A0071|15 21|mitogen
P09501093A0071|31 37|protein
P09501093A0071|43 48|kinase
P09501093A0071|58 68|consequence
P09501093A0071|71 83|Ras activation
P09501093A0071|113 133|Ras signal transduction
P09501169A0000|0 23|Histone acetylation levels
P09501169A0000|26 30|cells
P09501169A0000|49 59|equilibrium
P09501169A0000|76 92|histone acetylases
P09501169A0000|96 107|deacetylases
P09501982A1178|0 10|CONCLUSIONS
P09501982A1178|11 15|XCoe2
P09501982A1178|57 63|cascade
P09501982A1178|83 89|neurons
P09501982A1178|92 105|Xenopus embryos
P09501982A1178|119 139|Delta-Notch signalling
P09501982A1178|140 144|XCoe2
P09501982A1178|170 178|potential
P09501982A1178|189 203|progenitor cells
P09501982A1178|215 222|X-ngnr-1
P09501982A1178|234 243|transition
P09501982A1178|257 266|competence
P09501982A1178|282 291|commitment
P09501982A1178|328 342|differentiation
P09501982A1178|354 370|XNeuroD expression
P09502627A0705|0 6|RESULTS
P09502627A0705|7 14|Patients
P09502627A0705|17 22|Group A
P09502627A0705|33 41|incidence
P09502627A0705|58 80|wall motion abnormalities
P09502627A0705|104 119|ventriculography
P09502627A0705|126 136|infarct area
P09502627A0705|156 179|peak creatine kinase levels
P09502627A0705|212 227|ejection fraction
P09502627A0705|235 251|hospital discharge
P09502627A0705|271 277|Group B.
P09502720A0214|0 17|CyIIa transcription
P09502720A0214|61 73|specification
P09502720A0214|90 96|domains
P09502720T0000|26 46|cell type specification
P09502720T0000|61 67|element
P09502720T0000|79 95|complex expression
P09502720T0000|101 109|CyIIa gene
P09502720T0000|112 127|sea urchin embryos
P09503017A1021|13 20|evidence
P09503017A1021|30 34|HYAL1
P09503017A1021|91 96|others
P09503017A1021|100 115|chromosome 3p21.3
P09503017A1021|159 180|lung carcinoma cell lines
P09503526A0614|2 9|patients
P09503526A0614|14 20|myalgia
P09503526A0614|21 27|Raynaud
P09503526A0614|29 36|syndrome
P09503526A0614|37 50|skin vasculitis
P09503526A0614|62 87|diseases WFAg concentrations
P09503526A0614|104 111|patients
P09504423A0114|11 20|expression
P09504423A0114|26 35|4E-BP1 gene
P09504423A0114|117 126|fusion gene
P09504423A0114|131 155|glutathione-S-transferase
P09504423A0114|184 199|gene fusion vector
P09504423A0114|198 206|pGEX-4T-2
P09504423A0114|221 232|gene sequence
P09504423A0114|242 253|cleavage site
P09504423A0114|266 273|protease
P09504423A0114|274 287|alpha-thrombin
P09504514T0000|10 19|comparison
P09504514T0000|22 29|addition
P09504514T0000|42 67|bone-marrow transplantation
P09504514T0000|79 90|chemotherapy
P09504514T0000|106 114|leukaemia
P09504514T0000|122 130|remission
P09504514T0000|131 137|results
P09504514T0000|140 145|MRC AML
P09504514T0000|148 152|trial
P09504553T0000|18 25|cannabis
P09504906A0099|0 7|Analysis
P09504906A0099|20 29|revertants
P09504906A0099|43 50|function
P09504906A0099|63 71|amino acid
P09504906A0099|89 103|cysteine residue
P09504906A0099|120 125|domain
P09504906A0099|128 132|Hap1p
P09505135A0182|16 22|stimuli
P09505135A0182|43 49|stimuli
P09505135A0182|60 66|targets
P09505733A0246|1 6|review
P09505733A0246|9 15|studies
P09505733A0246|43 47|shows
P09505733A0246|70 76|factors
P09505733A0246|102 109|distress
P09505733A0246|132 142|limitations
P09505733A0246|147 151|group
P09505733A0246|154 161|patients
P09506439A2179|0 8|PKC-gamma
P09506439A2179|28 40|keratinocytes
P09506439A2179|62 75|gene expression
P09506439A2179|94 99|manner
P09506439A2179|118 126|SVHK cells
P09506959T0000|0 13|Identification
P09506959T0000|17 32|characterization
P09506959T0000|54 62|complexes
P09506959T0000|73 79|members
P09506959T0000|85 102|Myc/Max/Mad network
P09506959T0000|120 129|regulators
P09506962A1000|28 36|targeting
P09506962A1000|39 45|calpain
P09506962A1000|54 63|proteasome
P09506962A1000|91 98|elements
P09506983A0304|0 6|Primers
P09506983A0304|20 25|rounds
P09506983A0304|70 81|RACE products
P09506990T0000|5 15|ZFM1 protein
P09506990T0000|34 42|repressor
P09506990T0000|63 91|transcription activation domain
P09506990T0000|108 123|activator protein
P09507032A1144|15 30|CSF1R/IRDelta960
P09507032A1144|50 57|CSF1R/IR
P09507032A1144|69 83|CSF-1 protection
P09507032A1144|86 90|cells
P09507032A1144|116 124|apoptosis
P09508119A0498|0 10|CONCLUSIONS
P09508119A0498|29 40|presentation
P09508119A0498|62 68|Gardner
P09508119A0498|69 76|syndrome
P09508377A0863|5 11|results
P09508377A0863|33 45|UV sensitivity
P09508377A0863|66 77|phaeomelanin
P09508377A0863|84 98|eumelanin levels
P09508377A0863|102 106|point
P09508377A0863|112 138|eumelanin/phaeomelanin ratio
P09508377A0863|147 163|chemical parameter
P09508377A0863|192 202|individuals
P09508377A0863|218 227|skin cancer
P09508377A0863|230 237|melanoma
P09508511A0588|2 8|ferrets
P09508511A0588|30 39|H. mustelae
P09508511A0588|55 59|mg/kg
P09508511A0588|68 79|fluorofamide
P09508511A0588|107 112|urease
P09508775A0293|26 32|pathway
P09508775A0293|77 99|protein kinase activation
P09508775A0293|114 119|growth
P09508775A0293|136 143|pathways
P09508775A0293|149 153|level
P09508775A0293|159 168|expression
P09508775A0293|178 212|protooncogenes/transcription factors
P09509226A1235|0 10|CONCLUSIONS
P09509226A1235|26 31|method
P09509226A1235|49 57|reduction
P09509226A1235|63 74|time patients
P09509226A1235|99 106|transfer
P09509226A1235|124 130|savings
P09509226A1235|132 142|nursing time
P09509226A1235|152 158|methods
P09509226A1235|190 197|outcomes
P09510189A0192|30 41|organization
P09510189A0192|58 65|CD58 gene
P09510189A0192|91 99|kilobases
P09510398A1138|3 13|risk factors
P09510398A1138|17 25|hematuria
P09510398A1138|28 35|patients
P09510398A1138|45 56|hypouricemia
P09510398A1138|63 71|elevation
P09510398A1138|81 98|urate concentration
P09510398A1138|105 112|subtypes
P09510398A1138|124 132|Secretion
P09510582A0157|20 27|patients
P09510582A0157|93 98|geG-25
P09510582A0157|111 116|geG-50
P09510582A0157|139 143|agent
P09510925A0389|5 28|haemoglobin concentration
P09510925A0389|46 50|g dL-1
P09510925A0389|68 77|week course
P09510925A0389|87 94|sulphate
P09511724A0483|5 9|cells
P09511724A0483|13 24|accumulation
P09511724A0483|31 46|Dsg protein levels
P09511724A0483|55 61|calcium
P09511724A0483|84 90|calcium
P09511724A0483|103 107|media
P09511760A0221|7 31|restriction enzyme analysis
P09511760A0221|32 44|Southern blots
P09511760A0221|45 75|polymerase chain reaction analysis
P09511760A0221|79 91|DNA sequencing
P09511760A0221|129 134|clones
P09511760A0221|157 165|cHO-1 gene
P09511760A0221|206 212|regions
P09512416A0460|0 6|RESULTS
P09512416A0460|12 22|information
P09512416A0460|28 40|dbEST database
P09512416A0460|52 63|sequence tags
P09512416A0460|76 98|Arabidopsis thaliana gene
P09512416A0460|117 123|protein
P09512416A0460|158 164|domains
P09512416A0460|173 180|features
P09512416A0460|197 208|7TM receptors
P09512550T0000|14 45|apolipoprotein AI enhancer activity
P09512550T0000|47 56|liver cells
P09512550T0000|88 94|pathway
P09512559T0000|20 29|expression
P09512559T0000|38 77|nerve growth factor-luciferase reporter gene
P09512559T0000|87 91|yeast
P09512559T0000|102 117|chromosome vector
P09513759A0716|0 16|Calcitriol therapy
P09513759A0716|35 42|decrease
P09513759A0716|45 59|serum iPTH levels
P09514156A1147|0 10|Alterations
P09514156A1147|13 17|DNase
P09514156A1147|19 28|reactivity
P09514156A1147|45 57|element region
P09514156A1147|84 92|complexes
P09514156A1147|116 121|manner
P09514156A1147|129 136|promoter
P09514156A1147|169 173|state
P09514159A0562|13 39|hormone-coding gene promoters
P09514260A1083|15 21|inteins
P09514260A1083|40 51|pseudo intein
P09514260A1083|70 76|results
P09514260A1083|92 103|architecture
P09514260A1083|107 113|inteins
P09514260A1083|126 131|origin
P09514260A1083|135 146|relationship
P09514260A1083|154 168|protein families
P09514260A1083|196 203|findings
P09514260A1083|219 223|roles
P09514260A1083|226 232|intein N
P09514260A1083|239 246|EN motifs
P09514272A0482|0 11|Purification
P09514272A0482|34 45|polypeptides
P09514962A0841|25 31|protein
P09514962A0841|53 66|T-cell lymphoma
P09515031A1020|5 11|results
P09515031A1020|24 32|TGF-betaf
P09515031A1020|47 54|c-fos SRE
P09515031A1020|81 94|SRF binding site
P09515032A1230|0 5|RT-PCR
P09515032A1230|19 25|p21 mRNA
P09515032A1230|92 97|stages
P09515032A1230|134 138|stage
P09515665T0000|0 10|Ganciclovir
P09515665T0000|14 30|foscarnet efficacy
P09515665T0000|45 64|CMV polyradiculopathy
P09515858A0000|0 9|BACKGROUND
P09515858A0000|10 18|Defensins
P09515858A0000|35 52|neutrophil peptides
P09515858A0000|69 76|peptides
P09515858A0000|89 105|azurophil granules
P09515858A0000|108 118|neutrophils
P09515921A1662|14 21|mutation
P09515921A1662|30 46|pca gene expression
P09515921A1662|62 69|promoter
P09515921A1662|76 84|pca operon
P09515924A0104|12 16|cells
P09515924A0104|33 42|PDH complex
P09515924A0104|55 62|activity
P09515924A0104|77 83|protein
P09515924A0553|24 28|genes
P09515924A0553|44 67|hybridization experiments
P09515924A0553|71 86|sequence analysis
P09515924A0553|100 110|gene regions
P09515924A0553|116 121|genome
P09515924A0553|124 132|Z. mobilis
P09516472A0292|29 36|elements
P09516472A0292|65 73|TATA motif
P09516472A0292|85 103|Id4 promoter activity
P09517646A0149|0 11|Azithromycin
P09517646A0149|18 36|generation macrolide
P09517646A0149|70 85|pharmacokinetics
P09517646A0149|112 116|agent
P09517646A0149|161 174|pylori regimens
P09517989A0476|3 7|study
P09517989A0476|19 24|people
P09517989A0476|67 74|CD4 count
P09517989A0476|88 94|cells/l
P09518383A0000|0 9|BACKGROUND
P09518383A0000|13 22|OBJECTIVES
P09518383A0000|45 52|diseases
P09518383A0000|58 71|control program
P09518383A0000|80 89|sex workers
P09518383A0000|136 140|tests
P09518383A0000|141 148|syphilis
P09518383A0000|160 165|smears
P09518383A0000|169 177|gonococci
P09518383A0000|184 193|medication
P09518383A0000|204 210|condoms
P09518808T0000|0 20|National certification
P09518808T0000|27 35|component
P09518808T0000|38 53|quality assurance
P09519757A0482|12 20|mutations
P09519757A0482|21 25|D811N
P09519757A0482|39 43|R835C
P09519757A0482|128 133|region
P09519757A0482|144 150|patient
P09519757A0482|158 170|heterozygotes
P09519828A0809|9 24|VP16-E2 molecules
P09519828A0809|72 81|activation
P09519828A0809|87 102|BPV-4 LCR promoter
P09519828A0809|118 140|E2 transactivation domain
P09519830A0282|2 6|order
P09519830A0282|51 59|silencing
P09519830A0282|75 88|HSV-1 infection
P09519830A0282|100 106|viruses
P09519830A0282|144 148|ICP34
P09519830A0282|150 158|promoters
P09519830A0282|173 182|expression
P09519830A0282|186 229|chloramphenicol acetyltransferase reporter gene
P09519830A0282|249 267|thymidine kinase gene
P09519830A0282|278 283|genome
P09520398A0124|5 11|changes
P09520398A0124|35 42|increase
P09520398A0124|48 64|acetylation levels
P09520398A0124|74 85|core histones
P09521907A0190|37 44|Otx genes
P09521907A0190|63 67|terms
P09521907A0190|70 87|expression patterns
P09521907A0190|97 106|phenotypes
P09521909A0081|0 18|APETALA3 transcripts
P09521909A0081|50 55|region
P09521909A0081|77 81|petal
P09521909A0081|85 99|stamen primordia
P09521909A0081|103 112|expression
P09521909A0081|131 136|region
P09521909A0081|153 163|development
P09521909A0081|171 176|organs
P09521913A0400|15 23|mutations
P09521913A0400|29 35|60A gene
P09521913A0400|71 76|factor
P09522297A0744|0 8|Cell lines
P09522297A0744|46 51|tumors
P09522297A0744|76 83|analysis
P09522297A0744|88 96|karyotype
P09522979T0000|20 30|fibronectin
P09522979T0000|36 45|prediction
P09522979T0000|48 60|preterm labour
P09522979T0000|72 81|population
P09523478A0572|2 9|addition
P09523478A0572|28 35|children
P09523478A0572|49 61|toxoplasmosis
P09523478A0572|64 71|subjects
P09523478A0572|85 96|reactivation
P09523551A0367|4 11|variants
P09523551A0367|41 48|topology
P09523551A0367|83 91|receptors
P09524122A0336|13 18|allele
P09524122A0336|41 46|growth
P09524122A0336|49 54|strain
P09524122A0336|66 73|RAS genes
P09524222A0769|3 15|COOH-terminus
P09524222A0769|25 31|isoform
P09524222A0769|63 71|amino acid
P09524222A0769|82 89|sequence
P09524222A0769|113 121|cell alpha
P09524222A0769|137 144|subunits
P09524222A0769|176 181|region
P09524222A0769|184 189|MARCKS
P09524222A0769|202 212|actin-cross
P09524222A0769|220 226|protein
P09524222A0769|238 251|protein kinase C
P09524222A0769|255 272|calcium/calmodulin
P09524222A0769|327 339|beta 4-adducin
P09524222A0769|370 392|calmodulin binding domain
P09524222A1113|0 10|PCR analysis
P09524222A1113|31 49|beta-adducin isoform
P09524222A1113|68 72|brain
P09524222A1113|76 80|liver
P09524222A1113|81 90|bone marrow
P09524222A1113|115 119|cells
P09524222A1113|149 155|tissues
P09524229A0000|3 11|gene lac-1
P09524229A0000|23 35|enzyme laccase
P09524229A0000|61 66|number
P09524229A0000|69 73|genes
P09524229A0000|79 98|chestnut blight fungus
P09524229A0000|99 121|Cryphonectria parasitica
P09524229A0000|140 150|hypoviruses
P09524229A0000|152 156|group
P09524229A0000|180 190|mycoviruses
P09524229A0000|230 234|lac-1
P09524229A0000|286 299|concentrations
P09524229A0000|318 339|inhibitor cycloheximide
P09524229A0000|370 382|cyclosporin A.
P09524250A0767|12 19|elements
P09524259A0301|3 18|hp55 gamma protein
P09524259A0301|52 56|IGFIR
P09524259A0301|85 98|mutant receptor
P09524259A0301|117 125|hp55 gamma
P09524259A0301|146 160|insulin receptor
P09524259A0301|170 174|yeast
P09524259A0301|184 189|system
P09524267A1023|3 14|plant protein
P09524267A1023|40 46|domains
P09524267A1023|62 69|proteins
P09524267A1023|86 103|localization signal
P09524267A1023|115 120|domain
P09524267A1023|124 137|helicase motifs
P09524267A1023|179 203|RNA transcription apparatus
P09524267A1023|211 234|nucleotide excision repair
P09524267A1023|237 246|plant cells
P09524273A0205|4 8|paper
P09524273A0205|28 39|organization
P09524273A0205|42 52|mouse gC1qBP
P09524273A0205|59 74|characterization
P09524273A0205|89 94|region
P09524276A0939|0 11|LysR proteins
P09524276A0939|35 40|urease
P09524276A0939|43 61|Klebsiella aerogenes
P09524276A0939|70 77|catalase
P09524276A0939|127 145|bacterium protection
P09524276A0939|162 167|damage
P09525105A0298|24 33|activities
P09525105A0298|45 51|extract
P09525105A0298|54 68|Buddleia cordata
P09525105A0298|84 99|glycoside linarin
P09525598A0325|0 9|Regulation
P09525598A0325|15 23|Raf kinase
P09525598A0325|26 31|T cells
P09525598A0325|43 50|findings
P09525598A0325|56 62|variety
P09525598A0325|65 73|cell lines
P09525598A0325|90 95|domain
P09525598A0325|107 117|delta26-303
P09525598A0325|123 130|activity
P09525888A1482|11 20|FLAP clones
P09525888A1482|38 42|mouse
P09525888A1482|51 67|muscle cDNA library
P09525891T0000|0 6|Members
P09525891T0000|12 16|meis1
P09525891T0000|20 48|pbx homeodomain protein families
P09525891T0000|82 89|sequence
P09525891T0000|106 110|CYP17
P09527921A1178|27 35|complexes
P09527921A1178|38 55|electron microscopy
P09527921A1178|88 100|WDV Rep protein
P09527921A1178|109 119|core element
P09527921A1178|173 186|initiation site
P09527921A1178|196 204|start site
P09527921A1178|227 239|transcription
P09527921A1178|246 252|TATA box
P09528758T0000|0 4|Rex-1
P09528758T0000|21 39|transcription factor
P09528758T0000|58 63|embryo
P09528758T0000|78 82|Oct-3
P09528758T0000|86 97|Oct-6 binding
P09528758T0000|102 112|octamer site
P09528758T0000|122 128|protein
P09528758T0000|129 133|Rox-1
P09528766A0915|7 16|inhibition
P09528766A0915|26 32|ERK/RSK
P09528766A0915|39 54|p38/MAPKAP kinase
P09528766A0915|56 63|pathways
P09528766A0915|94 119|CREB Ser-133 phosphorylation
P09528768A0000|0 4|Cells
P09528768A0000|17 28|accumulation
P09528768A0000|39 46|proteins
P09528768A0000|63 71|reticulum
P09528768A0000|91 103|transcription
P09528768A0000|108 112|genes
P09528768A0000|132 148|chaperone proteins
P09528770A1379|26 49|protein kinase cAPK pathway
P09528770A1379|61 71|UAS activity
P09528770A1379|85 92|presence
P09528770A1379|94 100|glucose
P09528770A1379|110 121|carbon source
P09528770A1379|145 159|activators Msn2p
P09528770A1379|163 167|Msn4p
P09528770A1379|178 188|UAS activity
P09528770A1379|195 200|repeat
P09528770A1379|206 213|presence
P09528770A1379|216 222|acetate
P09528784A0000|20 31|fission yeast
P09528784A0000|75 89|complementation
P09528792A0000|11 18|splicing
P09528792A0000|21 50|fibroblast growth factor receptor
P09528792A0000|52 57|FGF-R2
P09528792A0000|62 68|example
P09528792A0000|97 104|splicing
P09528792A0000|112 120|exons IIIb
P09528792A0000|161 166|manner
P09528792A0000|177 185|cell types
P09528858A0205|6 10|cases
P09528858A0205|22 32|methylation
P09528858A0205|58 64|regions
P09528858A0205|72 82|suppression
P09528858A0205|85 96|gene activity
P09528950A0716|10 18|fragments
P09528950A0716|41 62|luciferase reporter gene
P09528987A1348|0 21|Cotransfection analyses
P09528987A1348|27 58|T/EBP promoter-reporter constructs
P09528987A1348|64 84|T/EBP expression vector
P09528987A1348|94 103|HepG2 cells
P09528987A1348|121 125|T/EBP
P09528987A1348|139 152|autoregulation
P09528987A1348|196 214|T/EBP gene expression
P09529156A1238|0 7|Deletion
P09529156A1238|20 30|Ser residues
P09529156A1238|43 58|PKC consensus site
P09529156A1238|64 75|receptor tail
P09529156A1238|89 107|phorbol 12-myristate
P09529156A1238|126 140|desensitization
P09529216A0644|0 11|Flap survival
P09529216A0644|24 34|development
P09529216A0644|43 48|number
P09529216A0644|59 69|connections
P09529216A0644|77 83|vessels
P09529216A0644|98 104|pedicle
P09529216A0644|125 131|vessels
P09529649A0307|0 7|Jean Klig
P09529649A0307|21 30|literature
P09529649A0307|52 65|tract infection
P09529649A0307|68 75|children
P09529721A0000|9 18|indicators
P09529721A0000|40 54|classifications
P09529721A0000|71 82|malnutrition
P09529721A0000|88 97|guidelines
P09529721A0000|111 120|management
P09529721A0000|123 138|childhood illness
P09529721A0000|145 156|malnutrition
P09529721A0000|179 186|referral
P09529721A0000|189 196|hospital
P09529721A0000|207 212|weight
P09529721A0000|233 242|assessment
P09529721A0000|254 264|counselling
P09529721A0000|268 276|follow-up
P09530251A0766|54 61|ischemia
P09530251A0766|84 91|duration
P09530251A0766|94 104|reperfusion
P09531538A0983|10 20|requirement
P09531538A0983|42 57|splicing activity
P09531538A0983|68 82|dU2AF38 RS domain
P09531549A0658|7 20|binding studies
P09531549A0658|26 42|GST fusion proteins
P09531549A0658|46 58|yeast extracts
P09531549A0658|81 85|sites
P09531549A0658|88 94|yAP180A
P09531549A0658|98 102|Pan1p
P09531549A0658|106 113|clathrin
P09531549A0658|136 149|yAP180 proteins
P09531549A0658|153 157|Pan1p
P09531549A0658|162 166|actin
P09531549A0658|187 193|patches
P09531549A0658|202 215|plasma membrane
P09531559A1153|7 22|affinity analyses
P09531559A1153|56 62|protein
P09531559A1153|107 112|domain
P09531559A1153|114 121|occludin
P09533030T0000|0 10|Cytochrome b
P09533030T0000|18 24|complex
P09533030T0000|47 60|oxidoreductase
P09533030T0000|61 71|cDNA cloning
P09533030T0000|77 86|components
P09533030T0000|89 105|liver mitochondria
P09533030T0000|109 128|chromosome assignment
P09533030T0000|134 138|genes
P09533030T0000|170 177|subunits
P09533030T0000|187 191|11q23
P09533109A0449|9 16|decrease
P09533109A0449|19 30|theophylline
P09533109A0449|32 37|volume
P09533109A0449|40 51|distribution
P09533109A0449|83 96|administration
P09533109A0449|98 108|chloroquine
P09533109A0449|163 174|significance
P09535082A0537|3 10|addition
P09535082A0537|28 34|extract
P09535082A0537|59 72|protein binding
P09535082A0537|86 100|target sequences
P09535082A0537|106 112|absence
P09535082A0537|135 141|complex
P09535082A0537|181 191|DNA fragment
P09535082A0537|219 225|complex
P09535579A1105|15 25|assumptions
P09535579A1105|46 51|uptake
P09535579A1105|73 86|interpretation
P09535579A1105|89 105|energy expenditure
P09535833A0228|12 28|amino acid sequence
P09535833A0228|31 36|m-Staf
P09535833A0228|76 110|selenocysteine tRNA gene transcription
P09535833A0228|120 125|factor
P09535833A0228|128 140|Xenopus laevis
P09535835A0279|0 5|ROCK-I
P09535835A0279|6 13|Kinectin
P09535835A0279|17 21|mDia2
P09535835A0279|36 44|type forms
P09535835A0279|60 64|Cdc42
P09535835A0279|80 85|manner
P09535851A0591|10 17|isoforms
P09535851A0591|21 31|beta isoform
P09535851A0591|46 54|Vmax value
P09535851A0591|61 66|PtdIns
P09535851A0591|66 80|P kinase activity
P09535851A0591|87 98|gamma isoform
P09535892A0000|3 13|beta subunit
P09535892A0000|33 41|G proteins
P09535892A0000|55 61|signals
P09535892A0000|71 84|plasma membrane
P09535892A0000|124 130|segment
P09535892A0000|155 159|units
P09535892A0000|170 176|Trp-Asp
P09535892A0000|176 182|repeats
P09535892A0000|211 218|proteins
P09535908A0321|26 36|LNX messages
P09535908A0321|54 61|proteins
P09535908A0321|84 89|masses
P09535908A0321|114 118|LNX-b
P09536028A0945|2 9|contrast
P09536028A0945|13 29|contractile action
P09536028A0945|61 81|cyclooxygenase product
P09536028A0945|96 107|contractions
P09536028A0945|155 182|signal pathway probe inhibitors
P09536440A0000|6 12|studies
P09536440A0000|39 45|myosin V
P09536440A0000|81 85|motor
P09536440A0000|105 112|movement
P09536901A0362|11 18|occasion
P09536901A0362|49 56|sagittal
P09536901A0362|75 83|sequences
P09536901A0362|102 109|relation
P09536901A0362|122 131|assessment
P09537295A0951|17 25|start site
P09537295A0951|81 117|transcriptase-polymerase chain reaction
P09537295A0951|127 135|P1 primers
P09537295A0951|136 148|primer walking
P09537295A0951|149 163|primer extension
P09537295A0951|167 177|cDNA cloning
P09537295T0000|0 7|Analysis
P09537295T0000|10 17|promoter
P09537295T0000|21 28|androgen
P09537295T0000|39 47|sequences
P09537295T0000|66 78|transcription
P09537295T0000|105 115|protein gene
P09537361A0149|3 16|iron dependence
P09537361A0149|19 31|transcription
P09537361A0149|35 44|expression
P09537361A0149|66 92|transporter accessory protein
P09537361A0149|111 133|colicin V immunity protein
P09537361A0149|149 158|conditions
P09537361A0149|161 170|iron excess
P09537361A0149|173 181|depletion
P09537375A0198|3 20|gntR deletion mutant
P09537375A0198|24 33|expression
P09537375A0198|53 62|lacZ fusion
P09537375A0198|120 128|regulator
P09537378A1227|14 21|deletion
P09537378A1227|36 45|chromosome
P09537378A1227|50 55|effect
P09537378A1227|58 75|gcv-lacZ expression
P09537651A0366|7 11|sites
P09537651A0366|52 60|induction
P09537651A0366|61 65|v-src
P09537651A0366|85 92|elements
P09537651A0366|111 119|induction
P09537651A0366|125 159|phorbol ester phorbol myristate acetate
P09538156A0130|0 11|BRCA1 protein
P09538156A0130|36 50|zinc finger motif
P09538156A0130|77 82|region
P09538220A0000|26 31|region
P09538220A0000|54 60|tRNAPhe
P09538220A0000|63 74|tRNAPro genes
P09538220A0000|95 99|mtDNA
P09538220A0000|113 122|regulation
P09538220A0000|125 135|replication
P09538220A0000|139 151|transcription
P09538220A0000|170 175|genome
P09538258A0200|6 11|report
P09538258A0200|28 36|mechanism
P09538258A0200|47 59|Ras activation
P09538258A0200|64 74|stimulation
P09538258A0200|85 89|types
P09538258A0200|92 100|receptors
P09538258A0200|116 120|cells
P09539421A0970|4 14|Sir proteins
P09539421A0970|19 26|K. lactis
P09539421A0970|31 35|roles
P09539421A0970|42 50|silencing
P09539421A0970|54 78|telomere length maintenance
P09539421A0970|108 113|themes
P09539721A0599|42 52|beta subunit
P09539721A0599|54 66|RNA polymerase
P09539721A0599|73 82|activation
P09539721A0599|88 97|pR promoter
P09539746A0781|0 9|Expression
P09539746A0781|12 17|Bcl-XL
P09539746A0781|30 40|association
P09539746A0781|43 48|Apaf-1
P09539746A0781|53 61|caspase-9
P09539746A0781|73 77|cells
P09539779A0621|17 29|hybridization
P09539779A0621|37 48|mouse embryos
P09539779A0621|81 87|pattern
P09539779A0621|89 102|Arp1 expression
P09539779A0621|130 139|expression
P09540062A0755|5 11|mutants
P09540062A0755|25 31|ability
P09540062A0755|62 69|proteins
P09540062A0755|96 102|ability
P09540062A0755|130 137|activity
P09540062A0755|150 179|H4 promoter/CAT fusion constructs
P09540062A0755|191 199|cell types
P09541280A0404|9 17|plasma IgE
P09541280A0404|39 44|NC mice
P09541280A0404|48 56|treatment
P09541280A0404|61 73|FK506 ointment
P09541280A0404|84 97|plasma IgE level
P09541636T0000|0 20|Creatine kinase release
P09541636T0000|33 50|artery embolization
P09541636T0000|53 60|patients
P09541636T0000|74 79|tumors
P09541721A0894|16 36|ischemia/angiotension
P09541721A0894|47 54|AHF model
P09541721A0894|97 104|pressure
P09541721A0894|104 108|LVEDP
P09543227A0815|0 5|Group A
P09543227A0815|13 17|years
P09543227A0815|29 36|patients
P09543227A0815|45 55|risk factors
P09543227A0815|66 70|years
P09543227A0815|80 90|risk factors
P09543227A0815|104 108|years
P09543227A0815|124 134|risk factors
P09544987A1583|24 33|RU486-PR-B
P09544991A0483|0 10|PRL receptor
P09544991A0483|24 28|SHP-2
P09544991A0483|39 57|tyrosine phosphatase
P09544991A0750|19 24|mutant
P09544991A0750|27 31|SHP-2
P09544991A0750|52 60|induction
P09544991A0750|63 85|tyrosine phosphorylation
P09544991A0750|100 107|activity
P09544991A0750|110 117|m-Stat5a
P09544991A0750|118 125|m-Stat5b
P09544991A0750|149 156|deletion
P09544991A0750|164 179|m-Stat5adelta749
P09544991A0750|191 214|transactivation potential
P09544991A0750|217 224|m-Stat5a
P09544991A0750|228 235|m-Stat5b
P09545146A0884|0 10|CONCLUSIONS
P09545146A0884|60 68|estimates
P09545146A0884|70 76|changes
P09545146A0884|79 85|CBZ Cl/F
P09545146A0884|91 102|comedication
P09545146A0884|119 126|decrease
P09545146A0884|145 163|regression equations
P09545146A0884|182 195|concentrations
P09545146A0884|207 219|validation set
P09545293A0590|0 4|Sites
P09545293A0590|12 18|lumican
P09545293A0590|22 30|keratocan
P09545293A0590|47 54|location
P09545312A1197|3 14|observations
P09545312A1197|26 32|members
P09545312A1197|38 48|HMG-I family
P09545312A1197|85 97|transcription
P09545312A1197|109 114|effect
P09545312A1197|152 162|interaction
P09545323T0000|13 20|assembly
P09545323T0000|31 37|complex
P09545323T0000|51 61|DNA mismatch
P09545323T0000|68 81|yeast MSH2-MSH6
P09545323T0000|85 109|MLH1-PMS1 protein complexes
P09545332A0137|0 7|Mutation
P09545332A0137|20 25|Tyr497
P09545332A0137|42 64|tyrosine phosphorylation
P09545332A0137|69 92|insulin receptor substrate
P09545332A0137|113 125|proliferation
P09545332A0137|127 134|response
P09545353A1071|27 40|kappaB elements
P09545353A1071|52 104|activating transcription factor/cAMP response element site
P09545353A1071|126 130|sites
P09545353A1071|136 149|E-selectin gene
P09545353A1071|168 176|TNF-alpha
P09545353A1071|192 201|expression
P09545638A0330a|30 56|yeast hnRNP methyltransferase
P09545638A0330b|30 56|yeast hnRNP methyltransferase
P09545638A0836|11 24|HRMT1L2 protein
P09545638A0836|63 87|methyltransferase activity
P09545638A1181|11 15|roles
P09545638A1181|18 24|HRMT1L1
P09545638A1181|28 34|HRMT1L2
P09545638A1181|42 48|disease
P09545638T0000|0 13|Identification
P09545638T0000|17 32|characterization
P09545638T0000|51 76|arginine methyltransferases
P09545638T0000|77 83|HRMT1L1
P09545638T0000|87 93|HRMT1L2
P09546424A1550|25 41|PDGF beta-receptor
P09546424A1550|59 69|Crk proteins
P09547311A1394|11 22|interactions
P09547311A1394|54 63|E-cadherin
P09547311A1394|70 76|chimera
P09547311A1394|90 99|E-cadherin
P09547311A1394|113 118|domain
P09547311A1394|125 134|desmoglein
P09547311A1394|149 154|domain
P09547311A1394|170 177|evidence
P09547311A1394|207 218|interactions
P09547311A1394|221 230|E-cadherin
P09547311A1394|244 250|domains
P09547349A0000|3 72|ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
P09547349A0000|73 82|ET-18-OCH3
P09547349A0000|83 92|edelfosine
P09547349A0000|102 108|inducer
P09547349A0000|111 119|apoptosis
P09547349A0000|127 136|tumor cells
P09548481A0000|2 9|addition
P09548481A0000|36 43|promoter
P09548481A0000|60 68|existence
P09548481A0000|77 84|promoter
P09548481A0000|96 109|IL-5Ralpha gene
P09549179A0774|0 10|Serum levels
P09549179A0774|13 24|testosterone
P09549179A0774|48 54|changes
P09549179A0774|57 64|exposure
P09549179A0774|84 93|conditions
P09549179A0774|97 101|study
P09549398A1463|7 15|agreement
P09549398A1463|23 58|rest/postnitroglycerin technetium-99m
P09549398A1463|70 80|SPET studies
P09549398A1463|84 102|rest/redistribution
P09549398A1463|105 143|rest/reinjection thallium-201 SPET studies
P09549398A1463|156 163|presence
P09549398A1463|176 184|viability
P09549632A1189|21 31|sensitivity
P09549632A1189|41 51|specificity
P09549632A1189|61 66|regard
P09549632A1189|68 81|predictability
P09549632A1189|84 92|ALT levels
P09549632A1189|112 116|trial
P09549660A0782|19 26|data sets
P09549660A0782|32 39|subjects
P09549660A0782|71 82|data scenario
P09549783T0000|7 14|accuracy
P09549783T0000|49 56|saccades
P09549783T0000|72 79|patients
P09550591A0454|10 18|treatment
P09550591A0454|46 59|airway pressure
P09550591A0454|67 71|cmH2O
P09550591A0454|100 107|decrease
P09550591A0454|113 125|blood pressure
P09550919A0365|36 41|manner
P09550919A0365|44 51|response
P09550919A0365|65 73|adenosine
P09550919A0365|105 112|episodes
P09550919A0365|122 129|episodes
P09550919A0365|135 142|episodes
P09550919A0365|148 155|episodes
P09550919A0365|164 171|episodes
P09551096A0108|25 34|components
P09551096A0108|49 56|subunits
P09551096A0108|86 92|factors
P09551096A0108|99 115|particle formation
P09551182A0212|7 24|retinoid signalling
P09551182A0212|27 42|zebrafish embryos
P09551182A0212|60 65|method
P09551182A0212|84 92|retinoids
P09551182A0212|101 107|embryos
P09551182A0212|114 126|fusion protein
P09551182A0212|132 137|ligand
P09551182A0212|147 167|transactivation domain
P09551182A0212|179 190|acid receptor
P09551182A0212|207 222|DNA binding domain
P09551938A0318|27 33|factors
P09551938A0318|78 93|CCR5 gene promoter
P09551972A1033|0 11|Fluorescence
P09551972A1033|18 30|hybridization
P09551972A1033|33 48|metaphase spreads
P09551972A1033|51 60|chromosome
P09551972A1033|72 96|hybrid cell line 706-B6 clone
P09551972A1033|99 103|CL-17
P09551972A1033|108 119|cosmid c101F1
P09551972A1033|133 141|gene close
P09551972A1033|147 154|telomere
P09551972A1033|157 162|8q24.3
P09552469A0225|3 13|interaction
P09552469A0225|21 29|piroxicam
P09552469A0225|33 41|poloxamer
P09552469A0225|54 72|x-ray diffractometry
P09552469A0225|90 101|spectroscopy
P09552469A0225|122 129|analysis
P09552469A0225|145 154|dispersion
P09552469A0225|177 183|mixture
P09553040A0651|0 11|Cell survival
P09553040A0651|32 41|activation
P09553040A0651|53 69|signaling pathways
P09553040A0651|79 88|PI-3 kinase
P09553040A0651|89 97|PLC-gamma
P09553040A0651|105 109|Stats
P09553134A0596|23 38|neurite outgrowth
P09553134A0596|55 89|tyrosine kinase inhibitors herbimycin A
P09553143A0729|8 22|ZAP-70 substrate
P09553143A0729|23 28|SLP-76
P09553143A0729|41 53|Erk activation
P09553143A0729|96 106|Jurkat cells
P09553143A0729|115 123|P116 cells
P09553143A0729|128 136|treatment
P09553686A0000|18 25|patterns
P09553686A0000|28 36|estradiol
P09553686A0000|54 60|estrone
P09553686A0000|92 96|women
P09553686A0000|115 123|menopause
P09553686A0000|133 143|application
P09553686A0000|150 158|estradiol
P09553686A0000|170 174|patch
P09553686A0000|185 190|matrix
P09553686A0000|201 219|absorption enhancers
P09553686A0000|243 254|applications
P09553686A0000|281 287|patch 7D
P09555046A1617|3 9|results
P09555046A1617|28 37|base change
P09555046A1617|43 70|branchpoint consensus sequence
P09555046A1617|75 80|intron
P09555046A1617|94 100|disease
P09555046A1617|113 120|sequence
P09555046A1617|140 146|mammals
P09556557A1238|20 26|regions
P09556561A0671|8 19|H/ACA snoRNAs
P09556561A0671|34 38|Gar1p
P09556561A0671|62 66|group
P09556561A0671|69 75|snoRNAs
P09556561A0671|97 101|yeast
P09556561A0671|112 117|guides
P09556561A0671|121 142|pseudouridine synthesis
P09556561A0671|158 165|molecule
P09556566A0174|9 24|vitamin D receptor
P09556566A0174|44 61|acid Xalpha receptor
P09556566A0174|61 68|RXRalpha
P09556566A0174|79 95|T cell line MT2 cells
P09556573A1062|7 13|studies
P09556573A1062|33 47|PPARalpha ligand
P09556573A1062|98 108|interaction
P09556573A1062|109 117|PPARalpha
P09556573A1062|125 143|co-activator RIP-140
P09556573A1062|159 169|interaction
P09556573A1062|172 180|PPARalpha
P09556861A1018|17 26|literature
P09556861A1018|30 39|mechanisms
P09556861A1018|53 60|toxicity
P09556861A1018|85 91|effects
P09556861A1018|92 101|inhibition
P09556861A1018|117 127|respiration
P09556861A1018|143 151|depletion
P09556861A1018|160 169|inhibition
P09556861A1018|171 185|tRNA-synthetase
P09556861A1018|207 222|protein synthesis
P09556861A1018|235 251|lipid peroxidation
P09557678A0140|33 42|expression
P09557678A0140|54 71|papillomavirus type
P09557678A0140|79 87|E2 protein
P09557678A0140|112 129|carcinoma cell lines
P09557678A0140|150 162|proliferation
P09557678A0140|182 202|G1/S phase growth arrest
P09557682A0490|12 19|isoforms
P09557682A0490|20 29|hGli2 alpha
P09557682A0490|36 40|gamma
P09557682A0490|43 47|delta
P09557682A0490|59 70|combinations
P09557682A0490|98 106|splicings
P09557682A0490|116 123|isoforms
P09557682A0490|136 143|DNA motif
P09557682A0490|144 148|TRE2S
P09557708A1426|0 20|Specialized actin tails
P09557708A1426|31 42|IEV particles
P09557708A1426|48 56|periphery
P09557708A1426|72 81|microvilli
P09557708A1426|112 116|cells
P09557708A1426|129 133|cells
P09557708A1426|146 154|vA33delta
P09557912A0699|41 49|induction
P09557912A0699|49 58|anesthesia
P09557912A0699|89 95|eyelash
P09557912A0699|108 116|injection
P09557912A0699|119 131|methohexitone
P09557912A0699|154 162|cessation
P09557912A0699|163 182|muscle fasciculations
P09557912A0699|192 204|suxamethonium
P09557912A0699|227 235|cessation
P09557912A0699|236 245|convulsion
P09557912A0699|275 284|resumption
P09557912A0699|303 313|respiration
P09560221A0282|7 12|cak1At
P09560221A0282|40 50|CAK mutation
P09560221A0282|60 64|yeast
P09560221A0282|87 107|fission yeast CAK mutant
P09560221A0282|133 138|cak1At
P09560221A0282|147 153|protein
P09560221A0282|163 172|animal CAKs
P09560325A1285|18 30|modifications
P09560325A1285|37 49|glycosylation
P09560325A1285|53 67|phosphorylation
P09560325A1285|94 105|explanations
P09560325A1285|112 131|protein heterogeneity
P09560390A0771|2 9|addition
P09560390A0771|21 37|checkpoint control
P09560390A0771|38 51|overexpression
P09560390A0771|77 93|cell cycle response
P09560390A0771|102 107|stress
P09560430A0000|30 39|initiation
P09560430A0000|40 46|meiosis
P09560430A0000|49 55|a/alpha
P09560430A0000|63 67|cells
P09561560A0579|0 13|Rhesus macaques
P09561560A0579|17 26|BALB/c mice
P09561560A0579|44 68|Mengo virus SIV recombinants
P09561560A0579|84 95|CTL responses
P09561560A0579|106 120|SIV gene products
P09561560A0579|134 152|HIV-Nef recombinants
P09561560A0579|165 175|CTL response
P09561560A0579|196 209|HIV1 Nef peptide
P09561560A0579|217 225|positions
P09561616A0142|0 11|Deltamethrin
P09561616A0142|41 47|surface
P09561616A0142|61 70|% mortality
P09561616A0142|91 108|culicifacies adults
P09561616A0142|115 119|weeks
P09561616A0142|156 160|mg/m2
P09562398A0848|0 16|Trichloroethylene
P09562398A0848|114 119|values
P09562398A0848|119 126|n-hexane
P09562558T0000|0 16|Solution structure
P09562558T0000|22 26|IRF-2
P09562558T0000|38 43|domain
P09562558T0000|50 57|subgroup
P09562558T0000|85 90|family
P09564860A2139|2 9|contrast
P09564860A2139|10 34|receptor/G protein coupling
P09564860A2139|55 64|expression
P09564860A2139|67 79|loop 3i domains
P09564860A2139|94 102|receptors
P09564860A2139|119 126|proteins
P09564860A2139|162 170|receptors
P09564860A2315|55 63|rat GnRH-R
P09564860A2315|74 82|receptor G
P09564860A2315|88 102|protein coupling
P09564860A2315|108 118|selectivity
P09564860A2315|132 139|cell line
P09564860A2315|165 182|signal transduction
P09564860A2315|200 215|Gs protein pathway
P09564917A0900|9 14|levels
P09564917A0900|17 34|alpha2-antiplasmin
P09564917A0900|56 66|mediastinum
P09565576T0000|10 15|domain
P09565576T0000|28 45|DNA topoisomerase I.
P09565584A0770|1 7|cluster
P09565584A0770|15 24|amino acids
P09565584A0770|54 62|sequences
P09565584A0770|143 151|targeting
P09565584A0770|186 204|mutagenesis analysis
P09565606A0520|22 30|structure
P09565606A0520|71 77|rCGCC-3
P09565606A0520|76 83|sequence
P09566731A0458|8 12|genes
P09566731A0458|44 49|region
P09566731A0458|57 79|chromosome 16p12.1-p11.2
P09566731A0458|91 105|mouse chromosome
P09566731A0458|119 129|cell hybrids
P09566731A0458|139 144|clones
P09566871A0343|2 12|fus3 mutants
P09566871A0343|16 21|levels
P09566871A0343|24 29|Ty1 RNA
P09566871A0343|30 45|protein synthesis
P09566871A0343|60 69|processing
P09566871A0343|101 111|FUS3 strains
P09566871A0343|127 132|levels
P09566871A0343|140 148|integrase
P09566871A0343|158 178|transcriptase proteins
P09566871A0343|182 188|Ty1 cDNA
P09566871T0000|17 26|regulation
P09566871T0000|29 49|Ty1 retrotransposition
P09566871T0000|69 85|protein kinase Fus3
P09566876A0000|10 31|transcription factor IIA
P09566876A0000|32 36|TFIIA
P09566876A0000|53 70|TATA binding protein
P09566876A0000|79 89|promoter DNA
P09566876A0000|98 120|transcription activation
P09566882A0693|5 12|function
P09566882A0693|42 49|promoter
P09566882A0693|70 76|binding
P09566918A1115|0 11|Substitution
P09566918A1115|17 28|Ser-Thr sites
P09566918A1115|93 97|IRF-3
P09566918A1115|123 131|activator
P09566918A1115|134 142|promoters
P09566918A1115|153 163|PRDI-PRDIII
P09566918A1115|182 189|elements
P09568445T0000|9 14|angina
P09568445T0000|39 48|infarction
P09568445T0000|73 91|contractile recovery
P09568445T0000|97 108|thrombolysis
P09568549A0188|6 10|study
P09568549A0188|14 19|effect
P09568549A0188|27 40|administration
P09568549A0188|50 54|doses
P09568549A0188|57 65|malathion
P09568549A0188|82 87|routes
P09568549A0188|107 117|serum levels
P09568549A0188|118 126|histamine
P09570030T0000|5 21|growth retardation
P09570030T0000|25 29|cause
P09570030T0000|47 57|development
P09570107A0355|9 24|PCDFs/PCDDs ratio
P09570107A0355|53 58|boiler
P09570133A0474|2 9|addition
P09570133A0474|23 34|interactions
P09570133A0474|50 61|interactions
P09570133A0474|66 80|partner proteins
P09570133A0474|95 99|roles
P09570133A0474|121 128|proteins
P09570133A0474|139 147|promoters
P09570944T0000|0 11|Localization
P09570944T0000|16 20|exons
P09570944T0000|24 32|YAC contig
P09570944T0000|66 85|resistance gene region
P09570944T0000|92 107|chromosome 7q21.1
P09570952A0000|22 33|organization
P09570952A0000|59 67|M-protein
P09570952A0000|78 84|protein
P09570952A0000|97 106|myofibrils
P09571563A0000|0 6|PURPOSE
P09571563A0000|20 32|image analysis
P09571563A0000|38 43|cornea
P09571563A0000|61 71|keratectomy
P09571563A0000|113 125|determination
P09571563A0000|127 133|changes
P09571563A0000|139 147|condition
P09571563A0000|153 158|cornea
P09572428A0526|5 29|SD serum VEGF concentrations
P09572428A0526|63 67|women
P09572428A0526|101 105|ng/ml
P09572428A0526|128 132|women
P09572428A0526|143 149|ovaries
P09572428A0526|156 160|ng/ml
P09572491A1044|15 19|cells
P09572491A1044|28 43|missense mutation
P09572491A1044|49 55|p53 gene
P09572491A1044|58 62|codon
P09572491A1044|89 95|alanine
P09572491A1044|98 104|glycine
P09572511A0148|6 14|algorithm
P09572511A0148|21 27|RBI-MAP
P09572511A0148|48 52|block
P09572511A0148|66 71|RBI-EM
P09572511A0148|71 79|algorithm
P09572965A1235|22 29|homology
P09572965A1235|32 39|gene agrB
P09572965A1235|84 92|mechanism
P09572965A1235|95 104|regulation
P09572965A1235|110 127|virulence phenotype
P09572965A1235|134 140|species
P09572990A0630|2 12|association
P09572990A0630|29 34|Stat-3
P09572990A0630|39 51|MHC-I ligation
P09572990A0630|90 95|Stat-3
P09572990A0630|107 114|extracts
P09572990A0630|131 139|hSIE probe
P09572990A0630|157 163|agarose
P09573187T0000|15 24|repression
P09573187T0000|44 56|regulator CatR
P09573187T0000|72 83|binding sites
P09573202A0900|29 34|levels
P09573202A0900|40 51|alpha subunit
P09573202A0900|65 76|substitution
P09573202A0900|79 85|glycine
P09573202A0900|100 110|acid residue
P09573202A0900|113 120|position
P09573202A0900|139 144|domain
P09573244A0523|8 18|mRNA species
P09573244A0523|44 67|polyadenylation site usage
P09573374A0687|5 24|Southern blot analysis
P09573374A0687|28 45|restriction mapping
P09573374A0687|60 64|yeast
P09573374A0687|74 83|chromosome
P09573374A0687|87 98|cosmid clones
P09573374A0687|116 122|RIL gene
P09573374A0687|148 155|IRF1 gene
P09573374A0687|181 189|structure
P09573378A0761|22 28|D' boxes
P09573378A0761|52 66|complementarity
P09573884A0392|17 24|position
P09573884A0392|25 29|S-N-B
P09573884A0392|33 39|S-N-Pog
P09573884A0392|69 77|retrusive
P09573884A0392|80 84|Class
P09573884A0392|103 107|Class
P09573884A0392|109 116|subjects
P09574799A1072|0 14|Echinostomiasis
P09574799A1072|42 48|factors
P09574799A1072|55 61|poverty
P09574799A1072|62 73|malnutrition
P09574799A1072|103 108|market
P09574799A1072|128 141|food inspection
P09574799A1072|159 168|sanitation
P09574799A1072|174 186|helminthiases
P09574799A1072|207 216|conditions
P09575143A1189|3 14|localization
P09575143A1189|17 22|ZAP-70
P09575143A1189|28 37|cell cortex
P09575143A1189|63 70|activity
P09575143A1189|73 89|SRC-family kinases
P09575143A1189|110 116|ability
P09575143A1189|132 145|immunoreceptor
P09575143A1189|160 175|activation motifs
P09575187A1558|17 25|NF-kappaB
P09575187A1558|37 45|apoptosis
P09575187A1558|55 70|ER calcium release
P09575187A1558|105 113|sAPPalpha
P09575187A1558|141 149|apoptosis
P09575187A1558|152 157|effect
P09575187A1558|167 180|kappaB decoy DNA
P09575217A0000|4 20|cytokine receptors
P09575217A0000|27 53|Janus protein tyrosine kinases
P09575217A0000|63 79|signal transducers
P09575217A0000|82 91|activators
P09575217A0000|94 106|transcription
P09575217A0000|107 111|Stats
P09575217A0000|122 130|signaling
P09575217A0971|14 26|R618K mutation
P09575217A0971|32 45|Stat5 SH2 domain
P09575217A0971|58 72|phosphorylation
P09575217A0971|86 93|deletion
P09575217A0971|98 106|C terminus
P09575217A0971|112 136|Stat5 hyperphosphorylation
P09576230T0000|3 8|effect
P09576230T0000|17 38|oxide synthase inhibitor
P09576230T0000|41 57|reperfusion injury
P09576230T0000|63 67|brain
P09576230T0000|95 100|arrest
P09576915A0269|12 24|recombination
P09576915A0269|48 52|rings
P09576915A0269|72 80|silencers
P09577365A0747|2 15|angiodysplasia
P09577365A0747|23 29|vessels
P09577365A0747|35 40|mucosa
P09577365A0747|62 73|collagen type
P09577365A0747|94 100|vessels
P09577365A0747|106 114|submucosa
P09577365A0747|129 135|vessels
P09577365A0747|150 154|cases
P09577365A0747|161 168|staining
P09577365A0747|174 178|level
P09577365A0747|184 200|muscularis mucosae
P09577395A0000|46 53|response
P09577395A0000|59 66|impulses
P09577395A0000|67 71|brief
P09577395A0000|117 126|degrees/s2
P09577395A0000|127 139|low-amplitude
P09577395A0000|145 151|degrees
P09577395A0000|156 164|rotations
P09578042A0363|30 37|patterns
P09578042A0363|61 74|seizure outcome
P09578042A0363|84 92|SEEG/ECoG
P09578042A0363|103 107|group
P09578042A0363|110 117|patients
P09578042A0363|130 141|lobe epilepsy
P09578570A0200|6 10|study
P09578570A0200|37 44|protein Z
P09578570A0200|47 58|organization
P09578570A0200|62 70|structure
P09578570A0200|88 98|combination
P09578570A0200|101 116|PCR amplification
P09578570A0200|119 130|leukocyte DNA
P09578570A0200|134 142|isolation
P09578570A0200|145 155|phage clones
P09578570A0200|173 179|library
P09579602A1720|5 17|modifications
P09579602A1720|46 60|reproducibility
P09579602A1720|63 80|CD34 determinations
P09579602A1720|89 97|reduction
P09579602A1720|100 113|sample handling
P09579602A1720|117 127|calculation
P09579602A1720|130 136|results
P09579789A0974|10 16|results
P09579789A0974|57 64|remnants
P09579789A0974|95 101|variety
P09579789A0974|103 115|odor detection
P09579789A0974|119 137|discrimination tasks
P09579789A0974|160 167|controls
P09579808A0000|0 9|UDP-GlcNAc
P09579808A0000|9 33|alpha-6-D-mannoside beta-1
P09579808A0000|34 64|N-acetylglucosaminyltransferase
P09579808A0000|110 117|assembly
P09579808A0000|135 141|glycans
P09580062A0100|5 12|patients
P09580062A0100|41 56|cyclophosphamide
P09580062A0100|60 67|steroids
P09580062A0100|99 111|cyclosporine A
P09580062A0100|124 132|mg/kg/day
P09580563A0331|12 28|amino acid sequence
P09580563A0331|62 67|dynein
P09580563A0331|72 76|chain
P09580563A0331|79 94|Neurospora crassa
P09580563A0331|129 136|nidulans
P09580700A0841|3 22|DNA binding activities
P09580700A0841|33 53|repressor preparations
P09580700A0841|70 78|fragments
P09580700A0841|95 103|CIR3-CIR6
P09580700A0841|124 129|region
P09580700A0841|132 140|templates
P09580700A0841|144 148|DNase
P09580700A0841|150 161|footprinting
P09581552A1323|9 17|modelling
P09581552A1323|34 54|tetramerization domain
P09581552A1323|69 74|bundle
P09581552A1323|87 98|interactions
P09581552A1323|123 132|amino acids
P09581775A0185|12 16|study
P09581775A0185|57 73|NF-kappaB activity
P09581775A0185|119 125|U9-IIIB
P09581775A0185|140 146|PLB-985
P09581775A0185|147 154|PLB-IIIB
P09581775A0185|155 159|cells
P09581775A0185|176 184|signaling
P09581834A2578|18 24|results
P09581834A2578|36 44|silymarin
P09581834A2578|76 81|effect
P09581834A2578|105 110|effect
P09581834A2578|127 136|impairment
P09581834A2578|157 172|signaling pathway
P09581834A2578|173 181|induction
P09581834A2578|184 188|CDKIs
P09581834A2578|202 209|G1 arrest
P09581872A0000|12 17|tissue
P09581872A0000|18 30|cell structure
P09581872A0000|51 68|collagen expression
P09582267A0326|12 19|function
P09582267A0326|48 55|proteins
P09582267A0326|55 72|expression plasmids
P09582267A0326|81 87|Siah-1A
P09582267A0326|131 135|cells
P09582267A0326|139 158|GM701 fibroblast cells
P09582267A0326|170 181|growth arrest
P09582267A0326|189 197|induction
P09582267A0326|200 208|apoptosis
P09582306T0000|1 13|point mutation
P09582306T0000|16 22|Galphao
P09582306T0000|26 33|Galphai1
P09582306T0000|40 50|interaction
P09582306T0000|55 63|regulator
P09582306T0000|66 90|G protein signaling proteins
P09582308A1165|32 40|formation
P09582308A1165|59 68|homodimers
P09582308A1165|79 87|formation
P09582308A1165|99 110|heterodimers
P09582326A0151|7 13|Fanning
P09582327A0295|25 32|GH3 cells
P09582327A0295|51 69|rat GnRH receptor cDNA
P09582327A0295|70 75|GGH3-1
P09582327A0295|76 80|cells
P09582327A0295|91 100|expression
P09582327A0295|117 126|fusion gene
P09582327A0295|140 148|base pairs
P09582327A0295|151 163|rat LHbeta gene
P09582327A0295|172 179|sequence
P09582327A0295|192 200|base pairs
P09582327A0295|218 223|region
P09582327A0295|232 249|luciferase reporter
P09582327A0295|254 262|LHbetaLUC
P09582327A0295|276 286|GnRH agonist
P09582327A0295|299 309|stimulation
P09582327A0295|312 319|activity
P09582331A0506|11 16|region
P09582331A0506|21 30|nucleotide
P09582331A0506|66 74|CAAT boxes
P09582331A0506|82 87|GATA-1
P09582331A0506|130 137|elements
P09582343A0000|30 40|cell line SX9
P09582343A0000|52 72|carcinoma cell line FM3A
P09582350A0165|2 9|patients
P09582350A0165|14 41|type IA maple syrup urine disease
P09582350A0165|45 58|E1alpha subunit
P09582350A0165|112 132|ketoacid dehydrogenase
P09582350A0165|140 149|activities
P09582635A0523|0 6|Results
P09582635A0523|20 35|mean bond strength
P09582635A0523|38 52|H.T.V. specimens
P09582635A0523|73 78|kg/cm2
P09582635A0523|87 102|mean bond strength
P09582635A0523|105 119|R.T.V. specimens
P09582635A0523|140 145|kg/cm2
P09582953A0000|0 9|OBJECTIVES
P09582953A0000|19 39|coagulation factor VIII
P09582953A0000|39 47|coagulant
P09582953A0000|48 53|F.VIII
P09582953A0000|58 77|C1-esterase inhibitor
P09582953A0000|77 82|C1-INH
P09582953A0000|104 130|acute-phase reactant proteins
P09582953A0000|134 154|coagulation factors VII
P09582953A0000|155 159|F.VII
P09582953A0000|177 194|hemostasis proteins
P09582953A0000|210 228|acute-phase response
P09582953A0000|238 247|population
P09582953A0000|250 255|horses
P09582953A0000|260 264|colic
P09582953A0000|268 290|hemostasis abnormalities
P09582953A0000|319 325|changes
P09582953A1097|0 6|RESULTS
P09582953A1097|7 12|Horses
P09582953A1097|17 21|colic
P09582953A1097|44 66|fibrinogen concentration
P09582953A1097|74 81|alpha 2AP
P09582953A1097|85 102|protein C activities
P09582953A1097|139 144|horses
P09582953A1670|20 30|plasminogen
P09582953A1670|30 37|alpha 2AP
P09582953A1670|41 46|C1-INH
P09582953A1670|71 89|acute-phase proteins
P09583201A0759|11 18|patients
P09583208A0171|6 14|elevation
P09583208A0171|17 30|creatine kinase
P09583208A0171|47 58|serum albumin
P09583208A0171|59 72|immunoglobulin
P09583208A0171|76 85|complement
P09583592A0263|0 5|DESIGN
P09583592A0263|9 15|METHODS
P09583592A0263|16 24|Case study
P09583823A0238|0 6|METHODS
P09583823A0238|8 12|total
P09583823A0238|39 46|ligation
P09583823A0238|60 67|arteries
P09583823A0238|68 82|infarction group
P09583823A0238|124 130|holmium
P09583823A0238|127 149|yttrium-aluminium garnet
P09583823A0238|158 162|laser
P09583823A0238|161 170|laser group
P09583823A0238|201 205|group
P09584165T0000|0 4|RACK1
P09584165T0000|6 13|receptor
P09584165T0000|26 32|C kinase
P09584165T0000|37 43|homolog
P09584165T0000|49 59|beta subunit
P09584165T0000|62 70|G proteins
P09584165T0000|79 86|activity
P09584165T0000|89 106|src tyrosine kinases
P09584165T0000|110 115|growth
P09584165T0000|118 128|NIH 3T3 cells
P09584179A0673|0 15|Peptide sequences
P09584179A0673|21 40|zinc finger protein Ttk
P09584179A0673|47 70|transcription factor Adf-1
P09584180A0701|21 32|reporter gene
P09584180A0701|78 82|Stat6
P09584180A0701|86 102|NF-kappaB proteins
P09584180A0701|120 139|I.29mu B lymphoma cells
P09584194A0000|19 25|Efs/Sin
P09584194A0000|34 39|family
P09584194A0000|53 67|docking proteins
P09584194A0000|107 116|regulation
P09584194A0000|119 130|cell adhesion
P09584194A1305|2 8|support
P09584194A1305|23 29|spindle
P09584194A1305|39 54|library screening
P09584194A1305|83 89|homolog
P09584194A1305|118 129|protein Dim1p
P09584194A1305|140 149|interactor
P09584194A1305|155 160|region
P09585253A1147|19 28|activation
P09585253A1147|33 46|raf-ERK pathway
P09585253A1147|52 61|activation
P09585253A1147|64 75|TF expression
P09585253A1147|78 97|breast carcinoma cells
P09585253A1147|126 135|activation
P09585253A1147|142 148|pathway
P09585253A1147|160 171|TF expression
P09585253A1147|174 188|MDA-MB-231 cells
P09585540A0440|21 26|enzyme
P09585540A0440|52 59|dialysis
P09585540A0440|87 110|agent 1,10-phenanthroline
P09586285A0551|3 10|patients
P09586285A0551|22 47|H. influenza type b meningitis
P09586285A0551|61 65|years
P09586832A0229|3 7|lines
P09586832A0229|57 65|receptors
P09587549T0001|10 16|seizure
P09587549T0001|24 32|treatment
P09587549T0001|37 51|interferon alpha
P09587549T0001|67 76|hepatitis C
P09588228A0370|21 35|anticytokeratin
P09588228A0370|38 45|antibody
P09588228A0370|60 67|staining
P09588228A0370|98 107|MPM tissues
P09590294A0453|7 13|studies
P09590294A0453|38 51|identification
P09590294A0453|61 70|components
P09590294A0453|76 87|Notch pathway
P09590540A0513|3 10|bZP2 cDNA
P09590540A0513|39 47|sequences
P09590540A0513|65 78|signal sequence
P09590540A0513|109 114|domain
P09590540A0513|135 143|Sac1-Sal1
P09590540A0513|153 160|fragment
P09590540A0513|169 173|frame
P09590540A0513|189 198|T5 promoter
P09590540A0513|207 224|lac operator control
P09590540A0513|228 239|pQE-30 vector
P09591221A0137|0 14|Control subjects
P09591221A0137|21 30|potentials
P09591221A0137|64 73|positivity
P09591221A0137|84 90|ms range
P09592125A0000|0 4|Class
P09592125A0000|6 26|alpha1,2-mannosidases
P09592125A0000|53 63|elaboration
P09592125A0000|65 71|complex
P09592125A0000|75 81|hybrid N
P09592125A0000|82 88|glycans
P09592125A0000|100 104|cells
P09592168T0000|10 17|features
P09592168T0000|30 45|DNA binding domain
P09592168T0000|46 53|M98-F219
P09592168T0000|61 94|nucleotide excision repair protein XPA
P09592208A0470|12 20|qualities
P09592208A0470|31 40|importance
P09592208A0470|93 104|construction
P09592208A0470|142 154|possibilities
P09592208A0470|185 194|statistics
P09592219A0652|3 9|results
P09592219A0652|20 32|effectiveness
P09592219A0652|49 60|intervention
P09593302A1165|14 25|implications
P09593302A1165|36 53|non-responsiveness
P09593302A1165|77 84|A-domain
P09593302A1165|107 113|ability
P09593302A1165|120 125|phenol
P09594299A0468|0 6|RESULTS
P09594299A0468|17 21|index
P09594299A0468|103 111|reduction
P09594299A0468|125 135|dislocation
P09595496A0000|21 26|levels
P09595496A0000|29 40|endothelin-1
P09595496A0000|75 79|fluid
P09595496A0000|81 88|patients
P09595496A0000|106 112|surgery
P09596536A0219|27 44|knee loading changes
P09596536A0219|54 67|ACL transection
P09596536A0219|89 109|cartilage degeneration
P09596542A0542|13 20|surfaces
P09596542A0542|31 45|cartilage matrix
P09596638T0000|11 17|mapping
P09596638T0000|23 42|Brassica S locus region
P09596638T0000|49 56|homeolog
P09596638T0000|59 69|Arabidopsis
P09596738T0000|0 4|Roles
P09596738T0000|10 24|Candida albicans
P09596738T0000|42 61|protein kinase homolog
P09596738T0000|62 66|Cek1p
P09596738T0000|75 85|development
P09596738T0000|97 107|candidiasis
P09598205A0430|10 17|reaction
P09598205A0430|20 34|monosaccharides
P09598205A0430|41 53|disaccharides
P09598205A0430|58 69|beta-alanine
P09598205A0430|83 91|formation
P09598205A0430|94 99|maltol
P09598894A0732|6 13|subjects
P09598894A0732|14 20|markers
P09598894A0732|23 35|bone formation
P09598894A0732|39 48|resorption
P09599102A1191|0 7|Analysis
P09599102A1191|11 21|Mac1p mutant
P09599102A1191|22 31|refractile
P09599102A1191|51 60|repression
P09599102A1191|72 85|transport genes
P09599102A1191|100 106|pattern
P09599102A1191|109 122|CUP1 expression
P09599102A1191|126 142|copper sensitivity
P09599664A0881|3 15|DNA sequencing
P09599664A0881|32 37|clones
P09599664A0881|49 58|expression
P09599664A0881|61 68|RXR alpha
P09599664A0881|72 78|RXR beta
P09599724A0193|17 22|sample
P09599724A0193|33 41|employees
P09599724A0193|47 52|cohort
P09599724A0193|55 77|phenoxy herbicide workers
P09599724A0193|118 130|PCDF congeners
P09599724A0193|132 142|blood lipids
P09599724A0193|154 159|extent
P09599724A0193|175 186|PCDF exposure
P09599724A0193|192 197|cohort
P09599724A0193|212 219|exposure
P09599724A0193|245 258|cancer findings
P09599724A0193|269 274|cohort
P09599897A0000|14 31|laboratory features
P09599897A0000|36 43|children
P09599897A0000|48 70|Henoch-Schonlein purpura
P09599897A0000|110 121|associations
P09599897A0000|131 147|laboratory indices
P09599897A0000|162 170|blood cell
P09599897A0000|182 186|serum
P09599897A0000|196 202|protein
P09599897A0000|208 213|levels
P09599897A0000|213 220|platelet
P09599897A0000|246 259|manifestations
P09601007A0223|9 17|community
P09601007A0223|54 60|changes
P09601007A0223|62 77|CO2 concentration
P09601007A0223|88 102|coral reef waters
P09601007A0223|120 128|processes
P09601007A0223|154 167|photosynthesis
P09601007A0223|168 178|respiration
P09601007A0223|179 191|calcification
P09601007A0223|195 210|CaCO3 dissolution
P09601510A0215|2 9|contrast
P09601510A0215|22 33|retroviruses
P09601510A0215|37 46|FV pol genes
P09601510A0215|69 79|transcripts
P09601516A0695|0 11|Substitution
P09601516A0695|30 37|residues
P09601516A0695|49 56|residues
P09601516A0695|79 92|fusion activity
P09601516A0695|97 104|S protein
P09601516A0695|121 130|processing
P09601516A0695|134 150|surface expression
P09601921A0000|0 10|Tributyltin
P09601921A0000|17 33|breakdown products
P09601921A0000|41 51|di-butyltin
P09601921A0000|68 77|water birds
P09601921A0000|91 99|Lake Huron
P09601921A0000|103 112|Great Lakes
P09601921A0000|126 137|United States
P09601921A0000|144 152|west coast
P09601921A0000|155 169|British Columbia
P09601921A0000|170 175|Canada
P09601940A0280|12 17|region
P09601940A0280|23 29|CD1 gene
P09601940A0280|42 54|binding motifs
P09601940A0280|79 98|transcription factors
P09601940A0280|99 106|NF-IL2-A
P09601940A0280|110 115|NF-IL6
P09602124A0127|0 6|Fregnac
P09603345A1257|0 6|GLRaV-2
P09603345A1257|16 28|closterovirus
P09603345A1257|48 65|genome organization
P09603345A1257|71 80|type member
P09603345A1257|86 90|group
P09603345A1257|144 149|member
P09603345A1257|154 171|genus Closterovirus
P09604052A0166|45 56|control group
P09604052A0166|79 83|women
P09604052A0166|92 97|sample
P09604052A0166|103 107|women
P09604052A0166|112 124|wrist fracture
P09605137A0677|8 17|expression
P09605137A0677|20 24|c-Jun
P09605137A0677|48 60|transcription
P09605137A0677|62 73|IL-2 promoter
P09605137A0677|90 107|reporter constructs
P09605137A0677|114 118|LFA-3
P09605137A0677|139 149|Jurkat cells
P09605930A1428|9 15|results
P09605930A1428|32 44|transfections
P09605930A1428|48 66|mobility shift assays
P09605930A1428|89 102|rat hepatocytes
P09605930A1428|123 129|ALS gene
P09605934A0801|4 15|E box sequence
P09605934A0801|16 21|CACGTG
P09605934A0801|38 51|binding element
P09605934A0801|79 84|factor
P09605934A0801|85 90|member
P09605934A0801|112 117|family
P09605934A0801|120 139|transcription factors
P09606633A0523|0 20|Interferon beta therapy
P09606633A0523|40 44|weeks
P09606924T0000|0 5|Liquid
P09606924T0000|21 26|method
P09606924T0000|30 37|analysis
P09606924T0000|40 70|all-rac-alpha-tocopheryl acetate
P09606924T0000|74 89|retinyl palmitate
P09606924T0000|102 114|infant formula
P09606924T0000|120 146|matrix solid-phase dispersion
P09609342A0000|19 23|types
P09609342A0000|26 35|turbo pumps
P09609342A0000|65 72|flow pump
P09609342A0000|86 93|flow pump
P09609342A0000|121 131|performance
P09609705A0895|0 10|Examination
P09609705A0895|29 54|bc1 complex crystal structure
P09609705A0895|55 59|Zhang
P09609705A0895|64 68|Huang
P09609705A0895|72 82|Shulmeister
P09609720A0357|21 29|fragments
P09609720A0357|57 62|halves
P09609720A0357|67 74|nuclease
P09609720A0357|103 111|proteases
P09609720A0357|126 132|protein
P09609720A0357|142 147|region
P09610755A1731|3 24|side-to-side difference
P09610755A1731|61 69|degrees/s
P09610755A1731|74 82|degrees/s
P09611016A0652|0 9|CONCLUSION
P09611016A0652|12 16|women
P09611016A0652|45 54|management
P09611016A0652|57 61|grade
P09611016A0652|63 70|prolapse
P09611016A0652|98 104|pessary
P09611016A0652|108 116|placement
P09611016A0652|122 130|pessaries
P09611229A1664|3 9|ability
P09611229A1664|20 29|expression
P09611229A1664|40 62|nmt1-451Dino2 Delta cells
P09611229A1664|73 81|existence
P09611229A1664|91 109|transcription factor
P09611229A1664|112 118|factors
P09611229A1664|124 142|expression/activity
P09611229A1664|170 175|levels
P09611229A1664|186 209|protein N-myristoy-lation
P09611234A0098|0 17|Rev-erbAalpha/beta
P09611234A0098|18 22|Mxi-1
P09611234A0098|26 44|Mad bHLH-zip proteins
P09611234A0098|51 66|oncoproteins PLZF
P09611234A0098|70 78|LAZ3/BCL6
P09611234A0098|94 110|corepressors N-CoR
P09611877A0455|13 20|isolates
P09612351A0386|10 17|evidence
P09612351A0386|33 43|oscillation
P09612351A0386|53 59|ULF band
P09612775A0726|3 17|ParaSight-F test
P09612775A0726|39 56|serum antigen levels
P09612775A0726|62 70|treatment
P09612775A0726|75 82|patients
P09613574A0905|22 28|protein
P09613574A0905|45 58|enzyme activity
P09613574A0905|71 78|transfer
P09613574A0905|84 95|methyl groups
P09613574A0905|102 113|substrate DNA
P09613574A0905|119 129|MGMT protein
P09613574A0905|133 140|activity
P09613574A0905|163 170|degrees C
P09613946A0194|1 25|deproteinization procedure
P09613946A0194|55 68|HPLC separation
P09613946A0194|81 86|mm I.D.
P09614065A0966|0 10|Elimination
P09614065A0966|25 32|response
P09614065A0966|53 60|mutation
P09614065A0966|67 75|sequences
P09614065A0966|88 95|presence
P09614065A0966|123 130|AP-1 site
P09614065A0966|144 152|induction
P09614106T0000|9 16|mobility
P09614106T0000|27 35|sequences
P09614106T0000|50 61|pair enhancer
P09614106T0000|67 76|Col2a1 gene
P09614106T0000|109 118|expression
P09617765A0174|3 10|sequence
P09617765A0174|25 36|reading frame
P09617765A0174|63 68|strand
P09617765A0174|82 87|region
P09617807A0929|13 20|analysis
P09617807A0929|33 51|transcriptase domain
P09617807A0929|82 91|assessment
P09617807A0929|96 102|Cyclops
P09617807A0929|120 126|element
P09617807A0929|140 151|relationship
P09617807A0929|186 193|elements
P09617807A0929|198 203|plants
P09618150A0127|15 19|doses
P09618150A0127|38 50|growth factor I
P09618150A0127|51 55|IGF-I
P09618150A0127|58 64|insulin
P09618150A0127|88 100|dibutyryl cAMP
P09618150A0127|101 106|dbcAMP
P09618150A0127|119 143|UCP1 gene transcription rate
P09618150A0127|155 174|UCP1 mRNA accumulation
P09618150A0127|190 195|effect
P09618150A0127|202 209|increase
P09618150A0127|221 229|treatment
P09618150A1464|2 9|addition
P09618150A1464|10 16|insulin
P09618150A1464|24 45|AP-1 DNA binding activity
P09618150A1464|50 55|effect
P09618150A1464|82 89|presence
P09618150A1464|92 105|MEK-1 inhibitor
P09618164A0709|15 40|methyl oligoribonucleotides
P09618164A0709|40 45|OMeRNA
P09618164A0709|64 69|nuclei
P09618164A0709|79 90|mdx myoblasts
P09618164A0709|93 99|culture
P09618475A0747|6 13|deletion
P09618475A0747|30 34|motif
P09618475A0747|41 55|down-regulation
P09618475A0747|84 91|function
P09618481T0000|0 9|Regulation
P09618481T0000|20 40|p21/WAF1/Cip1 promoter
P09618481T0000|50 54|cells
P09618481T0000|67 78|interactions
P09618481T0000|94 110|Smad family members
P09619631A0344|0 6|RESULTS
P09619631A0344|18 30|C. elegans cDNA
P09619631A0344|43 49|protein
P09619631A0344|103 113|p120 Ras-GAP
P09619777A1583|7 22|base ketoconazole
P09619777A1583|37 47|dissolution
P09619777A1583|59 69|formulation
P09619777A1583|88 92|Fluid
P09619777A1583|100 105|pepsin
P09619777A1583|106 110|SGFsp
P09619777A1583|119 125|minutes
P09619777A1583|127 138|% dissolution
P09619777A1583|142 146|hours
P09619777A1583|155 159|state
P09619777A1583|181 190|conditions
P09619777A1583|198 209|% dissolution
P09619777A1583|213 217|hours
P09619777A1583|229 243|state conditions
P09620273A0189|2 8|mammals
P09620273A0189|12 20|Rb protein
P09620273A0189|52 58|cyclins
P09620273A0189|71 87|cell proliferation
P09620273A0189|90 96|binding
P09620273A0189|110 132|E2F transcription factors
P09620606A0000|2 9|addition
P09620606A0000|15 21|signals
P09620606A0000|32 39|ligation
P09620606A0000|50 55|T cells
P09620606A0000|83 89|signals
P09620873A1710|11 21|observation
P09620873A1710|32 58|luteal HSP-27 phosphorylation
P09620873A1710|71 79|pregnancy
P09620873A1710|84 92|PKC-delta
P09620873A1710|130 145|PKC family members
P09620873A1710|158 182|sHSP phosphorylation events
P09620955A0370|18 26|structure
P09620955A0370|33 42|leader mRNA
P09620955A0370|53 64|program Mfold
P09620955A0370|69 79|combination
P09620955A0370|99 107|deletions
P09620955A0370|145 153|lac operon
P09621062A0810|3 12|importance
P09621062A0810|20 24|sites
P09621062A0810|43 52|activation
P09621062A0810|78 88|mutagenesis
P09621062A0810|99 122|promoter function analysis
P09621062A0810|128 134|mutants
P09621062A0810|140 185|chloramphenicol acetyltransferase reporter system
P09621372A0369|7 22|blood examination
P09621372A0369|29 40|leukocytosis
P09621372A0369|41 56|thrombocytopenia
P09621372A0369|91 97|enzymes
P09621893A0000|8 14|studies
P09621893A0000|47 55|increases
P09621893A0000|59 72|responsiveness
P09621893A0000|83 102|alpha2-adrenoceptors
P09622055A0207|3 9|members
P09622055A0207|15 23|Cbl family
P09622055A0207|46 52|mammals
P09622055A0207|53 57|c-Cbl
P09622055A0207|61 65|Cbl-b
P09622055A0207|71 79|C. elegans
P09622055A0207|80 84|Sli-1
P09622055A0207|103 107|D-Cbl
P09622121A0525|8 17|antibodies
P09622121A0525|34 40|binding
P09622121A0525|76 101|supershift RNA-PTB complexes
P09622121T0000|10 19|antibodies
P09622121T0000|24 56|polypyrimidine tract binding protein
P09622121T0000|74 90|protein components
P09622121T0000|124 132|pre-mRNAs
P09622121T0000|147 158|branch points
P09623830A0000|21 34|botulinum toxin
P09623830A0000|34 38|Botox
P09623830A0000|53 62|popularity
P09625762A0426|8 21|oncoprotein E1A
P09625762A0426|44 58|transactivation
P09625762A0426|76 81|manner
P09625807A0000|34 46|display method
P09625807A0000|65 69|mRNAs
P09625807A0000|116 127|cell cultures
P09625807A0000|149 166|carcinoma cell lines
P09626662A1076|7 17|experiments
P09626662A1076|40 47|affinity
P09626662A1076|49 54|RIP140
P09626662A1076|60 69|RXR subunit
P09626662A1076|94 100|partner
P09626662A1076|106 122|TR/RXR heterodimer
P09626662A1076|148 153|ligand
P09627285A0160|0 6|SETTING
P09627285A0160|7 16|University
P09627285A0160|39 59|care infertility center
P09627285A0554|0 5|RESULT
P09627285A0554|10 17|patients
P09627285A0554|29 37|FSH levels
P09627285A0554|40 47|cycle day
P09627285A0554|53 63|oocyte yield
P09627285A0554|92 97|number
P09627285A0554|100 106|ampules
P09627598A0384|0 6|RESULTS
P09627598A0384|12 19|patients
P09627598A0384|53 58|values
P09627598A0384|71 83|preponderance
P09627598A0384|89 96|OVAR test
P09627598A0384|98 104|measure
P09627598A0384|107 128|otolith system imbalance
P09627598A0384|148 155|subjects
P09628375A0700|5 18|ePTFE specimens
P09628375A0700|19 32|tissue coverage
P09628419A0812|25 42|Kristofferson model
P09628419A0812|45 53|durations
P09628821A1194|17 30|KG1a EST dataset
P09628821A1194|34 43|candidates
P09628821A1194|55 59|genes
P09628821A1194|71 75|roles
P09628821A1194|106 116|progression
P09628821A1194|120 136|lineage commitment
P09628890A0455|10 18|following
P09628890A0455|27 35|mutations
P09628890A0455|54 74|carbohydrate structure
P09628890A0455|90 97|HA trimer
P09629449A0540|3 9|results
P09629449A0540|18 30|ROS production
P09629449A0540|39 49|spermatozoa
P09629449A0540|75 87|concentration
P09629449A0540|90 100|PMN elastase
P09629449A0540|107 112|number
P09629449A0540|146 150|cells
P09630245A0102|0 11|Yeast U1 snRNP
P09630245A0102|52 62|counterpart
P09630245A0102|84 94|differences
P09630245A0102|102 106|yeast
P09630245A0102|110 116|metazoa
P09630245A0102|124 137|splicing events
P09630245A0903|0 11|Yeast U1 snRNP
P09630245A0903|40 47|proteins
P09630245A0903|62 78|snRNP core proteins
P09630245A0903|84 93|homologues
P09630245A0903|99 108|metazoan U1
P09630245A0903|123 130|proteins
P09630245A0903|151 165|U1 snRNP proteins
P09631366A0951|13 17|cycle
P09631366A0951|20 24|cases
P09631366A0951|38 46|dose level
P09631366A0951|60 64|cycle
P09631366A0951|67 71|cases
P09631366A0951|85 93|dose level
P09632217A0477|9 28|antagonist naltrexone
P09632217A0477|36 40|mg/kg
P09632217A0477|69 83|stimulus effects
P09632217A0477|86 91|heroin
P09632217A0477|95 104|naltrexone
P09632217A0477|107 111|doses
P09632217A0477|118 122|mg/kg
P09632217A0477|128 133|effect
P09632217A0477|153 167|stimulus effects
P09632217A0477|170 176|cocaine
P09632637A0361|6 10|study
P09632637A0361|36 49|cell regulation
P09632637A0361|52 71|M6P/IGFIIR expression
P09632637A0361|84 113|M6P/IGFIIR mRNA transcript levels
P09632637A0361|133 137|cells
P09632637A0361|157 175|carbon tetrachloride
P09632637A0361|198 206|stimulant
P09632709A0464|3 11|cDNA clone
P09632709A0464|22 28|NCoA-62
P09632709A0464|45 51|protein
P09632709A0464|109 115|protein
P09632709A0464|144 157|gene expression
P09632734A0081|20 27|proteins
P09632734A0081|44 49|region
P09632734A0081|70 85|sequence homology
P09632734A0081|89 93|group
P09632734A0081|96 118|GDP/GTP exchange proteins
P09632734A0081|125 134|Rab3 family
P09632734A0081|142 159|GTP binding proteins
P09632734A0943|7 19|p82 expression
P09632734A0943|25 30|effect
P09632734A0943|33 46|ERK2 activation
P09632734A0943|83 90|activity
P09632785A0000|3 28|pre-mRNA splicing factor U2AF
P09632785A0000|45 69|ribonucleoprotein particle
P09632785A0000|69 73|snRNP
P09632785A0000|83 88|factor
P09632785A0000|112 130|splice site selection
P09633171A0321|3 10|brackets
P09633171A0321|48 55|incisors
P09633171A0321|64 70|storage
P09633171A0321|73 80|tap water
P09633171A0321|83 97|room temperature
P09633171A0321|103 107|hours
P09633171A0321|137 145|shear mode
P09633171A0321|161 174|testing machine
P09633274A0000|0 15|Exercise training
P09633274A0000|51 59|treatment
P09633274A0000|62 81|heart failure patients
P09633630A0740|3 8|growth
P09633630A0740|19 28|hydrophila
P09633630A0740|48 61|lettuce extract
P09633630A0740|130 140|fluorescens
P09633879A0246|17 26|compliance
P09633879A0246|38 47|resurgence
P09633879A0246|50 68|serum ferritin levels
P09633879A0246|82 89|patients
P09633879A0246|95 101|veteran
P09633879A0246|102 106|group
P09633879A0246|115 119|years
P09635149A1148|0 9|Hematocrit
P09635276A1608|0 9|Regulation
P09635276A1608|12 36|myosin phosphatase activity
P09635276A1608|45 51|changes
P09635276A1608|54 72|subunit interactions
P09635276A1608|90 99|mechanisms
P09636119T0000|19 27|generator
P09636119T0000|59 63|plant
P09636119T0000|68 74|pulleys
P09636358A0000|19 24|VAI RNA
P09636358A0000|27 36|adenovirus
P09636358A0000|95 105|translation
P09636358A0000|123 127|mRNAs
P09636358A0000|134 138|times
P09636358A0000|144 152|infection
P09636670T0000|0 8|Structure
P09636670T0000|52 69|kinase inhibitor p18
P09636670T0000|82 89|analysis
P09636670T0000|92 103|breast cancer
P09636708A0460|3 13|YccA protein
P09636708A0460|52 57|manner
P09636708A0460|84 89|YccA11
P09636708A0460|96 102|protein
P09636708A0460|115 131|amino acid residues
P09636708A0460|166 171|domain
P09636708A0460|190 200|degradation
P09637689A0150|22 38|activator proteins
P09637689A0150|71 83|RNA polymerase
P09637689A0150|89 98|holoenzyme
P09637689A0150|121 131|recruitment
P09637689A0150|148 155|promoter
P09638342T0000|60 67|adhesion
P09638342T0000|68 95|membrane cytoskeleton assembly
P09638485A0111|11 17|benzene
P09638485A0111|38 42|tt-MA
P09638485A0111|45 80|leukocyte alkaline phosphatase activity
P09638485A0111|107 118|car mechanics
P09638485A0111|120 136|road tanker drivers
P09638485A0111|152 158|workers
P09638650A0169|20 25|region
P09638650A0169|35 45|nucleotides
P09638650A0169|53 65|reading frames
P09638650A0169|87 94|proteins
P09638650A0169|124 136|RNA polymerase
P09638650A0169|142 159|kDa movement protein
P09638650A0169|168 185|kDa movement protein
P09638650A0169|194 211|kDa movement protein
P09638650A0169|220 233|kDa coat protein
P09638650A0169|253 263|nucleotides
P09638793A1446|25 36|hemodilution
P09638793A1446|45 55|superiority
P09638793A1446|56 59|LV MC
P09638793A1446|76 85|properties
P09638793A1446|107 117|oxygenation
P09638793A1446|132 153|i.v. perflubron emulsion
P09638793A1446|166 172|carrier
P09639074A0707|11 21|Sp3 isoforms
P09639074A0707|53 64|constituents
P09639074A0707|78 86|complexes
P09639410A3282|5 9|genes
P09639410A3282|33 39|targets
P09639410A3282|57 66|strategies
P09639558A0957|31 40|haemolysis
P09639558A0957|69 80|erythrocytes
P09639565A0225|33 48|enhancer activity
P09639565A0225|60 64|cells
P09639565A0225|88 99|SV40 promoter
P09640162A0242|9 15|patient
P09640162A0242|44 56|growth hormone
P09640162A0242|60 68|treatment
P09640162A0242|71 93|growth hormone deficiency
P09640162A0242|111 127|ventricle teratoma
P09640802A0467|34 45|consequences
P09640802A0467|80 92|possibilities
P09640802A0467|97 106|flap choice
P09641167A1359|0 9|CONCLUSION
P09641167A1359|10 17|TNF alpha
P09641167A1359|18 24|TGF beta
P09641167A1359|34 41|IL-1beta
P09641167A1359|50 67|LDLr gene expression
P09641167A1359|124 140|gene transcription
P09642042A0646|0 16|Binding affinities
P09642042A0646|28 41|nucleotide mono
P09642042A0646|47 59|triphosphates
P09642042A0646|79 85|analogs
P09642042A0646|101 120|beta-phosphate moiety
P09642042A0646|134 149|substrate binding
P09642200A0956|49 60|proteolipids
P09642200A0956|64 84|M. thermoautotrophicum
P09642200A0956|88 99|M. jannaschii
P09642200A0956|204 211|membrane
P09642200A0956|230 244|chemical natures
P09642200A0956|247 252|lipids
P09642200A0956|257 263|archaea
P09642200A0956|267 274|bacteria
P09642214A0244|6 11|report
P09642214A0244|48 63|phosphatase SHP-2
P09642214A0244|78 87|activation
P09642214A0244|107 119|protein kinase
P09642214A0244|142 153|SHP-2 mutants
P09642214A0244|155 164|COS-7 cells
P09642227A0000|0 11|Osteoadherin
P09642227A0000|32 47|bone proteoglycan
P09642227A0000|58 71|keratan sulfate
P09642238A0532|0 5|Intron
P09642238A0532|40 55|enhancer activity
P09642238A1285|3 8|intron
P09642238A1285|10 23|enhancer region
P09642238A1285|41 46|GATA-1
P09642238A1285|66 91|transactivation experiments
P09642238A1285|93 102|COS-1 cells
P09642238A1285|116 126|involvement
P09642238A1285|137 146|Sp1 protein
P09642238A1285|179 184|factor
P09642276A0881|3 10|cleavage
P09642276A0881|20 27|caspases
P09642276A0881|60 68|execution
P09642276A0881|73 86|suicide program
P09642276A0881|115 122|function
P09642764A0469|33 43|QCM response
P09642764A0469|53 69|Sauerbrey equation
P09642764A0469|100 105|thanks
P09642764A0469|122 131|techniques
P09642764A0469|154 158|assay
P09643153T0000|0 8|Treatment
P09643153T0000|25 40|T2N breast cancers
P09643546A0436|0 22|Transcription initiation
P09643546A0436|73 80|promoter
P09643546A0436|103 107|cells
P09643546A0436|126 141|stress conditions
P09643548A0000|3 7|genes
P09643548A0000|16 21|2Fe-2S
P09643548A0000|32 42|ferredoxins
P09643548A0000|69 102|cyanobacterium Synechocystis PCC6803
P09645576A0148|7 11|GBV-C
P09645576A0148|30 37|patients
P09645942A1164|14 37|Dsg-plakoglobin complexes
P09645942A1164|69 81|stoichiometry
P09645961A1158|3 9|results
P09645961A1158|25 31|binding
P09645961A1158|34 41|CBF/NF-Y
P09645961A1158|55 62|CCAAT box
P09645961A1158|94 103|activation
P09645961A1158|109 116|nTPH gene
P09647233A0336|2 12|macrophages
P09647233A0336|26 44|HIV-1 gene expression
P09647233A0336|65 71|binding
P09647233A0336|73 81|NF-kappa B
P09647233A0336|99 110|binding sites
P09647233A0336|139 144|repeat
P09647240A0000|3 11|influence
P09647240A0000|39 63|Janus kinase-STAT signaling
P09647240A0000|85 106|hepatoma Hep3B cell lines
P09647240A0000|164 175|Val135 mutant
P09649069A0490|31 49|laryngeal parameters
P09649069A0490|97 108|examinations
P09649265A1575|0 10|CONCLUSIONS
P09649265A1575|44 53|ultrasound
P09649265A1575|66 73|biopsies
P09649265A1575|79 86|prostate
P09649265A1575|105 115|office visit
P09649265A1575|140 153|biopsy strategy
P09649265A1575|199 209|examination
P09649265A1575|223 230|serum PSA
P09649315A0943|0 10|Examination
P09649315A0943|28 36|resonance
P09649315A0943|42 48|spectra
P09649315A0943|51 56|series
P09649315A0943|80 96|MIP-1 beta variants
P09649315A0943|113 120|proteins
P09649315A0943|129 133|range
P09649315A0943|136 142|ability
P09649426A0636|13 23|PKA activity
P09649426A0636|40 45|strain
P09649426A0636|53 57|Msn2p
P09649426A0636|61 73|Msn4p activity
P09649437A1140|26 37|interactions
P09649437A1140|45 50|C/EBPs
P09649437A1140|62 77|Ets family members
P09649437A1140|90 95|GATA-1
P09649437A1140|111 140|eosinophil lineage determination
P09649438A0182|14 48|transcription elongation factor P-TEFb
P09649438A0182|61 70|CDK9 kinase
P09649438A0182|71 77|cyclin T
P09649438A0182|96 102|factors
P09649438A0182|143 155|Tat activation
P09649438A0182|170 176|extract
P09649438A0182|186 191|P-TEFb
P09649501A0358|24 30|repeats
P09649501A0358|36 58|HSF1 trimerization domain
P09649501A0358|64 68|yeast
P09649501A0358|79 101|protein interaction assay
P09649501A0358|112 140|heat shock factor binding protein
P09649501A0358|142 146|HSBP1
P09649501A0358|175 181|protein
P09649501A0358|205 210|arrays
P09649501A0358|224 230|repeats
P09649501A0358|250 266|HSF1 heptad repeats
P09649537A0000|10 19|cDNA clones
P09649537A0000|35 59|yeast GCN2 eIF-2alpha kinase
P09649537A0000|60 64|yGCN2
P09650180A1130|10 22|recombination
P09650180A1130|36 42|voltage
P09650180A1130|67 76|dose-rates
P09650180A1130|87 94|mGy min-1
P09650186A1043|6 11|number
P09650186A1043|19 27|positives
P09650186A1043|44 49|scheme
P09650186A1043|68 78|radiologist
P09650186A1043|97 103|regions
P09650275T0000|26 42|weapons convention
P09650275T0000|46 57|implications
P09650275T0000|80 100|biotechnology industry
P09650299A0000|0 4|VirD2
P09650299A0000|18 49|Agrobacterium tumefaciens proteins
P09650299A0000|65 74|processing
P09650299A0000|78 85|transfer
P09650299A1334|39 43|VirD2
P09650299A1334|48 53|domain
P09650299A1334|82 92|integration
P09650403A0868|3 13|DHEAS levels
P09650403A0868|19 24|stages
P09650403A0868|77 81|group
P09650789A0185|0 10|Orientation
P09650789A0185|23 32|spin system
P09650789A0185|57 71|Overhauser shift
P09650789A0185|86 97|energy levels
P09650789A0185|115 120|degree
P09650789A0185|130 140|orientation
P09651321A0000|0 8|Cystatin A
P09651321A0000|10 36|cysteine proteinase inhibitor
P09651321A0000|47 63|precursor proteins
P09651321A0000|75 86|cell envelope
P09651321A0000|89 101|keratinocytes
P09651321A0000|129 133|stage
P09651321A0000|136 162|keratinocyte differentiation
P09651367T0000|10 15|RalGDS
P09651367T0000|24 34|Ras effector
P09651367T0000|52 61|inhibition
P09651367T0000|72 81|myogenesis
P09651375T0000|0 5|GTPase
P09651375T0000|16 26|specificity
P09651375T0000|29 33|RGS12
P09651375T0000|37 54|binding specificity
P09651375T0000|84 89|PSD-95
P09651375T0000|88 93|Dlg/ZO
P09651375T0000|95 100|domain
P09651383A0967|7 15|mutations
P09651383A0967|21 36|HNF-4 binding site
P09651383A0967|39 49|element CIIB
P09651383A0967|53 62|inhibition
P09651383A0967|65 78|HNF-4 synthesis
P09651383A0967|81 90|HepG2 cells
P09651383A0967|102 116|HNF-4 constructs
P09651383A0967|129 150|apoCII promoter activity
P09651383A0967|165 171|control
P09651383A0967|185 189|HNF-4
P09651383A0967|201 209|regulator
P09651383A0967|215 224|apoCII gene
P09652736A1205|2 9|addition
P09652736A1205|20 24|E2F-1
P09652736A1205|33 41|apoptosis
P09652736A1205|49 59|tumour cells
P09652736A1205|96 107|co-activator
P09652736A1205|113 129|E2F/DP heterodimer
P09652736A1205|150 157|activity
P09652736A1205|160 164|E2F-1
P09652737A1244|23 30|analysis
P09652737A1244|44 66|Fos family member proteins
P09652737A1244|77 81|Fra-1
P09652737A1244|85 89|Fra-2
P09652737A1244|102 112|progression
P09652737A1244|118 124|changes
P09652737A1244|135 157|Jun family member proteins
P09652737A1244|190 206|DNA binding complex
P09652742A0455|77 82|glands
P09652742A0455|94 99|tumors
P09652742A0455|124 129|strain
P09653182A1298|31 39|virus RNAs
P09653182A1298|55 66|primer donors
P09653182A1298|69 76|MStV mRNA
P09653182A1298|93 105|transcription
P09653182A1298|122 127|plants
P09653641A0471|5 12|isoforms
P09653641A0471|51 60|start codon
P09653648A0445|0 9|Comparison
P09653648A0445|28 36|sequences
P09653648A0445|48 57|ZNF189 gene
P09653648A0445|111 115|exons
P09653648A0445|123 129|end exon
P09653648A0445|150 165|zinc finger domain
P09653648A0445|185 190|region
P09653745A0180|0 6|Malaria
P09653745A0180|43 47|1940s
P09653745A0180|55 66|paper queries
P09653745A0180|78 86|reduction
P09653745A0180|98 112|control projects
P09653745A0180|118 125|thirties
P09653745A0180|144 151|projects
P09653745A0180|161 165|model
P09653745A0180|189 193|world
P09653745A0180|199 205|malaria
P09653745A0180|216 227|problem today
P09655248A0000|3 19|gp330/Megalin/LRP
P09655248A0000|21 27|protein
P09655248A0000|51 79|lipoprotein receptor gene family
P09655248A0000|116 123|receptor
P09655248A0000|130 135|uptake
P09655248A0000|138 149|lipoproteins
P09655248A0000|162 168|ligands
P09655916A0415|5 23|DNA recognition helix
P09655916A0415|26 31|finger
P09655916A0415|53 60|position
P09655916A0415|105 113|histidine
P09656414A0220|0 5|Dosage
P09656414A0220|12 16|cases
P09656485A0351|14 19|copies
P09656485A0351|26 33|elements
P09656485A0351|54 73|restriction digestion
P09657003T0000|12 24|relationships
P09657003T0000|51 64|RNA polymerases
P09657003T0000|113 128|elm disease fungus
P09657003T0000|128 146|Ophiostoma novo-ulmi
P09657003T0000|154 160|viruses
P09657003T0000|188 198|Arabidopsis
P09657003T0000|211 216|genome
P09658104T0000|11 42|transcription start site core region
P09658104T0000|45 66|transcription factor YY1
P09658104T0000|69 84|Rous sarcoma virus
P09658104T0000|97 118|repeat promoter activity
P09658122T0000|0 11|Fowlpox virus
P09658122T0000|31 38|homologs
P09658122T0000|49 58|alpha-SNAP
P09658122T0000|81 87|homolog
P09658122T0000|98 112|nematode protein
P09658403A1207|0 7|Addition
P09658403A1207|28 35|exposure
P09658403A1207|36 40|cells
P09658403A1207|43 64|progesterone agonist Org
P09658403A1207|74 79|effect
P09658403A1207|82 90|induction
P09658403A1207|93 103|CAT activity
P09658405A0000|3 11|Dax-1 gene
P09658405A0000|20 26|protein
P09658405A0000|54 60|members
P09658405A0000|66 71|orphan
P09658405A0000|79 97|receptor superfamily
P09658769A0058|28 38|IFN alpha-2b
P09658769A0058|47 55|diagnosis
P09658769A0058|65 75|hepatitis C.
P09660823A0934|7 28|Ser/Thr phosphorylation
P09660823A0934|41 52|molecules Akt
P09660823A0934|56 66|p70 S6 kinase
P09660836A0983|12 21|evaluation
P09660836A0983|33 45|state kinetics
P09660836A0983|48 60|MEK inhibition
P09660836A0983|68 76|compounds
P09660836A0983|88 92|U0126
P09660836A0983|123 130|affinity
P09660836A0983|134 146|deltaN3-S218E
P09660836A0983|146 153|S222D MEK
P09660836A0983|162 169|PD098059
P09660838A0920|0 9|Regulation
P09660838A0920|14 21|degrees C
P09660838A0920|42 47|action
P09660838A0920|55 75|protein kinase cascades
P09660838A0920|100 114|phosphorylation
P09660838A0920|116 129|serine residues
P09660838A0920|155 160|growth
P09660838A0920|177 193|heat shock response
P09661676T0000|8 18|implication
P09661676T0000|21 33|protein levels
P09661676T0000|51 56|sputum
P09661676T0000|67 74|patients
P09662339A0744|7 11|cells
P09662339A0744|23 32|transition
P09662339A0744|55 63|induction
P09662339A0744|78 85|activity
P09662339A0744|104 113|expression
P09662339A0744|116 123|CD44 mRNA
P09662339A0744|127 133|protein
P09662443A0402|39 50|organization
P09662443A0402|67 76|expression
P09662443A0402|82 99|caveolin gene family
P09663062A0175|0 19|Tensile bond strengths
P09663062A0175|27 31|resin
P09663062A0175|50 55|dentin
P09663062A0175|61 66|dentin
P09663062A0175|75 81|systems
P09663062A0175|82 100|Clearfil Liner Bond II
P09663062A0175|107 129|Scotchbond Multi-Purpose
P09663062A0175|133 146|bonding systems
P09663062A0175|158 164|scatter
P09663062A0175|170 177|students
P09663062A0175|181 188|dentists
P09664033A1204|4 15|distribution
P09664033A1204|43 51|precursor
P09664033A1204|69 77|nucleolus
P09664033A1204|102 108|snoRNAs
P09664033A1204|119 124|import
P09664033A1204|127 143|processing pathway
P09664033A1204|158 163|bodies
P09665361T0000|11 17|therapy
P09665361T0000|21 34|thyroid nodules
P09665503A0526|19 28|volunteers
P09665503A0526|41 45|study
P09665720A0325|5 11|absence
P09665720A0325|31 45|exonuclease site
P09665720A0325|61 74|polymerase site
P09665720A0325|78 87|possession
P09665720A0325|93 106|primer terminus
P09665720A1145|23 34|binding sites
P09665720A1145|46 59|primer terminus
P09665720A1145|75 89|exonuclease site
P09665720A1145|111 120|polymerase
P09666103A0496|3 16|missense allele
P09666103A0496|17 21|P236S
P09666103A0496|42 49|function
P09666103A0496|53 60|degreesC
P09666103A0496|68 82|missense alleles
P09666103A0496|83 87|L173F
P09666103A0496|88 92|E225K
P09666103A0496|93 97|S269L
P09666103A0496|101 105|E274K
P09666103A0496|120 130|temperature
P09666103A0496|140 148|phenotype
P09666114A0389|10 17|analysis
P09666114A0389|33 38|region
P09666114A0389|53 65|c-met promoter
P09666114A0389|79 90|CAAT elements
P09666114A0389|111 120|G-C content
P09666114A0389|132 146|Sp1 binding sites
P09667482A0978|3 8|report
P09667482A0978|30 41|contribution
P09667482A0978|44 56|stress factors
P09667482A0978|62 68|context
P09667482A0978|71 77|therapy
P09667482A0978|98 104|disease
P09667482A0978|111 117|results
P09667482A0978|149 155|context
P09667482A0978|159 189|stress system disorder perspective
P09667795A0000|5 16|pancreatitis
P09667795A0000|41 48|disorder
P09668063A0274|29 39|Ets proteins
P09668063A0274|41 57|Ras transformation
P09668063A0274|78 84|effects
P09668063A0274|104 110|variety
P09668063A0274|113 126|Ets2 constructs
P09668063A0274|144 149|NIH3T3
P09668063A0274|154 158|cells
P09668096A0806|41 50|preference
P09668096A0806|60 67|partners
P09668098A0868|18 31|FGF-BP promoter
P09668098A0868|47 62|deletion analysis
P09668098A0868|82 89|elements
P09668098A0868|118 126|base pairs
P09668098A0868|140 161|transcription start site
P09668108A1017|0 11|Manipulation
P09668108A1017|17 36|checkpoint regulators
P09668108A1017|47 61|cell cycle arrest
P09668108A1017|65 73|apoptosis
P09668108A1017|94 101|strategy
P09668108A1017|104 116|cancer therapy
P09668119A0496|15 33|mobility shift assays
P09668119A0496|61 74|protein binding
P09668119A0496|91 104|point mutations
P09668119A0496|123 140|binding nucleotides
P09668119A0496|169 173|bases
P09668119A0496|186 192|CTCCT-3
P09669641A0425|13 20|accuracy
P09669641A0425|23 31|serum PE-1
P09669641A0425|48 54|amylase
P09670034A0340|17 21|Ddc1p
P09670034A0340|51 55|Mec3p
P09670034A0340|63 73|interaction
P09670034A0340|82 87|Rad17p
P09670912T0000|14 21|seizures
P09670943T0000|0 19|B cell antigen receptor
P09670943T0000|32 40|formation
P09670943T0000|43 60|SHP-2-pp120 complex
P09670943T0000|67 76|inhibition
P09670943T0000|79 104|Fc gamma RIIB1-BCR coligation
P09671313A0334|0 4|Chem.
P09671313A0334|24 34|MT Hartsough
P09671464A0316|23 29|meiosis
P09671464A0316|43 47|steps
P09671464A0316|67 73|glucose
P09671464A0316|88 94|glucose
P09671464A0316|101 107|meiosis
P09671496A0557|28 32|c-Cbl
P09671496A0557|34 44|development
P09671496A0557|48 58|homeostasis
P09671496A0557|77 86|disruption
P09671496A0557|91 100|c-Cbl locus
P09671496A0557|178 187|appearance
P09671576A0900|27 34|endoderm
P09671576A0900|50 68|streak morphogenesis
P09671579A1168|13 20|noi/pax2
P09671579A1168|46 63|signaling processes
P09671579A1168|70 79|integrator
P09671579A1168|100 118|boundary development
P09671791T0000|18 27|activation
P09671791T0000|46 65|growth factor receptor
P09671791T0000|78 89|intermediate
P09671791T0000|132 139|activity
P09671791T0000|142 147|L cells
P09673037A0358|0 6|METHODS
P09673037A0358|15 21|changes
P09673037A0358|31 40|bone marrow
P09673037A0358|91 116|reticulin fiber impregnation
P09673037A0358|117 122|method
P09673037A0358|125 130|Gomori
P09673436A0898|26 36|ANP infusion
P09673436A0898|49 57|increases
P09673436A0898|60 74|sodium excretion
P09673436A0898|130 137|infusion
P09673436A0898|181 190|hypocapnia
P09675154A0690|34 41|families
P09675154A0690|46 51|GSD-Ib
P09675154A0690|70 78|mutations
P09675154A0690|106 114|insertion
P09675154A0690|116 128|point mutation
P09675154A0690|136 161|consensus splicing donor site
P09675154A0690|166 181|missense mutation
P09675154A0690|182 186|W118R
P09675896A0959|0 6|Removal
P09675896A0959|12 25|carboxyl region
P09675896A0959|56 65|activation
P09676349A0000|1 6|Level A
P09676349A0000|21 31|correlation
P09676349A0000|59 77|release theophylline
P09676349A0000|90 100|preparation
P09676349A0000|100 112|Bronchoretard
P09676349A0000|118 130|investigation
P09676419A0158|0 5|METHOD
P09676419A0158|19 26|children
P09676419A0158|36 41|months
P09676419A0158|46 50|years
P09676419A0158|70 74|study
P09676419A0158|89 102|questionnaires
P09676419A0158|105 111|patient
P09676419A0158|115 129|family histories
P09676419A0158|141 154|screening tests
P09676419A0158|176 184|allergens
P09676419A0158|185 190|CAP SX1
P09676419A0158|194 206|determination
P09676419A0158|214 233|serum immunoglobulin E
P09676419A0158|258 265|serum IgE
P09676419A0158|267 289|solid-phase immunoassays
P09677330A0584|27 41|linker region LR1
P09677330A0584|81 85|exons
P09677405A0856|0 16|Pol32Delta strains
P09677405A0856|24 35|antimutators
P09677405A0856|68 78|mutagenesis
P09677410A1059|18 24|results
P09677410A1059|106 120|HBV core promoter
P09677410A1059|139 146|enhancer
P09677410A1059|193 200|function
P09678579A0768|6 12|insight
P09678579A0768|20 29|expression
P09678579A0768|35 43|AtCP1 gene
P09678579A0768|52 63|blot analysis
P09678837A0736|13 17|study
P09678837A0736|34 47|responsiveness
P09678837A0736|50 67|bronchoprovocation
P09678837A0736|72 83|methacholine
P09678837A0736|86 93|subjects
P09678837A0736|107 114|rhinitis
P09678837A0736|132 143|pollen season
P09678837A0736|153 160|serum IgE
P09678837A0736|164 179|blood eosinophils
P09679066A1352|5 11|results
P09679066A1352|27 39|demonstration
P09679066A1352|48 54|protein
P09679066A1352|67 74|splicing
P09679066A1352|85 93|pre-mRNAs
P09679750A0304|15 23|potential
P09679750A0304|27 55|prostate cancer chemoprevention
P09679750A0304|90 94|drugs
P09679750A0304|95 119|cyclo-oxygenase inhibitors
P09679750A0304|120 125|NSAIDs
P09679750A0304|143 151|attention
P09680994A0169|4 8|study
P09680994A0169|19 27|isolation
P09680994A0169|31 43|P. hybrida gene
P09680994A0169|44 48|jaf13
P09680994A0169|79 85|protein
P09680994A0169|95 99|basis
P09680994A0169|102 117|sequence homology
P09680994A0169|121 140|intron/exon structure
P09680994A0169|154 172|P. hybrida orthologue
P09680994A0169|178 189|Z. mays r genes
P09681822A0520|9 26|c-erbB3 transcripts
P09681822A0520|61 67|tissues
P09682897A0218|14 18|years
P09682897A0218|30 35|search
P09682897A0218|46 63|electrocardiograms
P09682897A0218|88 97|QRS changes
P09682897A0218|120 132|injury pattern
P09683576A0542|18 29|cleavage site
P09683576A0542|52 65|protease domain
P09683576A0542|66 80|Gln2526-Asp2527
P09683576A0542|91 100|processing
P09685021A0127|0 6|METHODS
P09685021A0127|7 39|Millipore ultrafiltration membranes
P09685021A0127|56 64|pore sizes
P09685021A0127|75 97|model lenticule materials
P09685021A0127|124 140|membrane pore sizes
P09685021A0127|148 153|microm
P09685021A0127|158 163|microm
P09685021A0127|168 173|microm
P09685021A0127|177 192|surface roughness
P09685021A0127|211 215|order
P09685021A0127|219 227|membranes
P09685021A0127|247 251|layer
P09685021A0127|254 262|collagen I
P09685021A0127|286 291|pocket
P09685021A0127|305 310|cornea
P09685021A0127|356 361|extent
P09685021A0127|363 379|epithelialization
P09685021A0127|386 396|persistence
P09685021A0127|409 418|attachment
P09685226A0000|11 20|calcitonin
P09685226A0000|28 35|agonists
P09685226A0000|52 62|cAMP pathway
P09685226A0000|75 87|transcription
P09685226A0000|124 130|protein
P09685226A0000|131 135|PTHrP
P09685226A0000|165 182|lung cancer cell line
P09685346A0419|3 13|combination
P09685346A0419|16 20|Pitx2
P09685346A0419|31 48|homeodomain protein
P09685346A0419|49 53|Pit-1
P09685346A0419|80 89|activation
P09685346A0419|95 111|prolactin promoter
P09685346A0419|114 131|transfection assays
P09686344T0000|26 33|spectrum
P09686344T0000|36 70|ornithine transcarbamylase deficiency
P09686603A0124|40 47|elements
P09686603A0124|64 73|mechanisms
P09686603A0124|109 116|promoter
P09686603A0124|127 144|germline expression
P09686603A0124|147 165|TCR beta gene segments
P09687498A1173|3 9|results
P09687498A1173|42 50|mutations
P09687498A1173|60 65|v-erbA
P09687498A1173|70 77|oncogene
P09687498A1173|88 93|c-ErbA
P09687498A1173|94 100|TRalpha
P09687498A1173|128 139|conformation
P09687498A1173|158 171|overexpression
P09687511A1091|0 13|Downregulation
P09687511A1091|16 28|FUS expression
P09687511A1091|49 59|32Dcl3 cells
P09687511A1091|77 87|suppression
P09687511A1091|90 95|growth
P09687511A1091|114 128|colony formation
P09687511A1091|129 139|restoration
P09687511A1091|167 181|differentiation
P09687511A1091|203 211|potential
P09687514A0521|6 10|study
P09687514A0521|40 58|transcription system
P09687514A0521|91 98|proteins
P09687514A0521|128 136|complexes
P09688264A1029|4 12|repressor
P09688264A1029|48 64|UTR silencer action
P09688264A1029|87 100|rat hepatocytes
P09689047A0253|1 12|prerequisite
P09689047A0253|19 27|synthesis
P09689047A0253|40 54|glycoconjugates
P09689047A0253|69 92|sugar-nucleotide cytidine
P09689047A0253|93 105|monophosphate
P09689047A0253|130 139|CMP-Neu5Ac
P09689047A0253|153 161|substrate
P09689047A0253|165 187|Golgi sialyltransferases
P09689919A1192|13 20|PEDF cDNA
P09689919A1192|67 82|PEDF glycoprotein
P09691031A1050|10 14|model
P09691031A1050|22 33|Sro7 function
P09691031A1050|49 57|targeting
P09691031A1050|63 76|myosin proteins
P09691031A1050|93 100|pathways
P09691037A0355|7 15|sequences
P09691037A0355|29 37|insertion
P09691037A0355|49 55|strains
P09691037A0355|58 65|N. crassa
P09691037A0355|74 90|Neurospora species
P09692965A0904|4 11|cysteine
P09692965A0904|31 37|helices
P09692965A0904|61 68|patterns
P09692965A0904|78 85|exposure
P09692965A0904|89 94|burial
P09693035T0000|17 38|serine/threonine kinase
P09693035T0000|47 58|UNC-51 kinase
P09693035T0000|61 81|Caenorhabditis elegans
P09693035T0000|82 92|cDNA cloning
P09693035T0000|93 102|expression
P09693035T0000|117 126|assignment
P09693134A0782|25 31|markers
P09693134A0782|69 75|domains
P09693134A0782|79 89|neuroblasts
P09693134A0782|102 112|neuroblasts
P09693134A0782|136 142|embryos
P09693134A0782|155 171|column neuroblasts
P09693134A0782|188 204|column neuroblasts
P09693134A0782|217 226|identities
P09693134A0782|248 255|position
P09693134A0782|269 279|neuroblasts
P09693306T0000|19 28|potentials
P09693306T0000|31 38|patients
P09693306T0000|53 63|schwannomas
P09694034A0713|5 11|results
P09694034A0713|16 24|clozapine
P09694034A0713|56 69|antipsychotics
P09694034A0713|95 100|action
P09694034A0713|126 130|value
P09694034A0713|140 148|test model
P09694034A0713|176 184|potential
P09694034A0713|192 196|drugs
P09694514A0000|3 36|complement C3a anaphylatoxin receptor
P09694514A0000|65 73|G-protein
P09694514A0000|80 102|chemoattractant receptor
P09694514A0000|119 134|C3a peptide ligand
P09694514A0000|159 167|responses
P09694514A0000|177 192|histamine release
P09694514A0000|197 205|mast cells
P09694514A0000|245 261|muscle contraction
P09694514A0000|276 284|migration
P09694514A0000|287 297|eosinophils
P09694599A1355|0 10|CONCLUSIONS
P09694599A1355|22 31|elevations
P09694599A1355|34 42|IL-1alpha
P09694599A1355|46 53|IL-1beta
P09694599A1355|61 68|patients
P09694599A1355|82 89|cystitis
P09694599A1355|104 112|hematuria
P09694725A0500|10 15|assays
P09694725A0500|59 65|element
P09694725A0500|66 70|LILRE
P09694725A0500|71 85|oligonucleotide
P09694725A0500|87 111|gamma interferon activation
P09694725A0500|150 165|IL-1beta promoter
P09694860A0498|13 18|region
P09694860A0498|38 43|domain
P09694860A0498|64 69|region
P09694860A0498|77 84|homology
P09694860A0498|104 110|protein
P09694869A0932|2 9|addition
P09694869A0932|15 21|support
P09694869A0932|42 46|STATs
P09694869A0932|51 60|activation
P09694869A0932|66 76|p21 promoter
P09694869A0932|77 90|overexpression
P09694869A0932|93 97|Stat3
P09694869A0932|112 125|cytokine effect
P09694869A0932|131 141|p21 promoter
P09694869A0932|166 170|Stat3
P09694869A0932|174 181|mutation
P09694869A0932|187 205|STAT response element
P09694869A0932|211 218|promoter
P09694869A0932|242 255|cytokine effect
P09694897T0000|23 55|ribonucleoprotein C protein tetramer
P09694897T0000|72 79|U6 snRNAs
P09694897T0000|92 115|affinity RNA binding domain
P09694897T0000|128 132|motif
P09695194T0000|5 14|comparison
P09695194T0000|27 37|proportions
P09696164A0000|14 19|system
P09696164A0000|26 34|detection
P09696164A0000|43 61|infant death syndrome
P09696819A0450|12 18|mutants
P09696819A0450|47 54|vaccinia
P09696819A0450|65 76|vTF7-3 system
P09696819A0450|83 91|formation
P09696819A0450|106 114|reticulum
P09696819A0450|126 134|transport
P09696819A0450|156 162|complex
P09698457A0778|32 46|Cux/CDPDeltaCR1
P09698457A0778|54 62|phenotype
P09698457A0778|83 91|vibrissae
P09698457A0976|9 15|protein
P09698457A0976|27 32|levels
P09698457A0976|79 96|tissue distribution
P09698457A0976|108 114|protein
P09698457A0976|140 147|affinity
P09698457A0976|156 170|target sequences
P09698457A0976|224 232|cut repeat
P09698457A0976|234 240|binding
P09698512A0296|0 6|METHODS
P09698512A0296|54 73|transplant recipients
P09700644T0000|3 10|spectrum
P09700644T0000|27 44|brain abnormalities
P09700644T0000|50 60|measurement
P09700644T0000|81 90|correlates
P09701609A0116|3 12|laboratory
P09701609A0116|51 64|orphan proteins
P09701609A0116|65 70|PhLOP1
P09701609A0116|74 79|PhLOP2
P09701609A0116|91 97|ability
P09701609A0116|112 121|Gbetagamma
P09701616A0108|7 43|transcriptase-polymerase chain reaction
P09701616A0108|44 49|RT-PCR
P09701616A0108|67 74|eyestalk
P09701616A0108|98 123|sand shrimp Metapenaeus ensis
P09701821A1108|2 9|contrast
P09701821A1108|10 22|transcription
P09701821A1108|37 43|opuE P-1
P09701821A1108|44 49|sigma A
P09701821A1108|56 65|proportion
P09701821A1108|79 88|osmolarity
P09701821A1108|111 116|levels
P09701895A0119|19 26|children
P09701895A0119|32 41|months-3 yr
P09701895A0119|59 64|period
P09701895A0119|89 98|prevalence
P09701895A0119|111 117|anaemia
P09703021A0000|2 8|insects
P09703021A0000|9 42|arylalkylamine N-acetyltransferases
P09703021A0000|43 48|AANATs
P09703021A0000|89 97|processes
P09703021A0000|107 120|sclerotization
P09703021A0000|121 132|inactivation
P09703021A0000|142 158|neurotransmitters
P09703021A0000|174 181|function
P09703021A0000|184 194|vertebrates
P09703021A0000|195 203|catalysis
P09703021A0000|230 250|melatonin biosynthesis
P09703213A0280|2 12|experiments
P09703213A0280|20 34|D1 antagonist SCH
P09703213A0280|61 70|depression
P09703213A0280|96 107|facilitation
P09703276A2346|5 11|results
P09703276A2346|25 37|hydroquinones
P09703276A2346|44 55|mutagenicity
P09703276A2346|59 73|carcinogenicity
P09703816A0139|0 4|IA-CT
P09703816A0139|9 17|cisplatin
P09703816A0139|27 37|doxorubicin
P09703816A0139|63 72|shot method
P09703816A0139|91 103|iliac arteries
P09704006A0224|0 8|Arnt3 mRNA
P09704006A0224|23 27|brain
P09704006A0224|36 41|muscle
P09704006A0224|50 56|embryos
P09704006A0224|60 67|P19 cells
P09704296T0000|31 37|purpura
P09704296T0000|53 62|serum level
P09704296T0000|65 79|immunoglobulin E
P09704296T0000|83 94|eosinophilia
P09704296T0000|106 112|patient
P09704569T0000|10 18|structure
P09704569T0000|33 40|location
P09704569T0000|51 67|TR2 orphan receptor
P09704569T0000|69 74|member
P09704569T0000|80 105|steroid receptor superfamily
P09704857T0000|0 10|Correlation
P09704857T0000|13 25|skin disorders
P09704857T0000|30 42|CD4 lymphocyte
P09704857T0000|51 58|patients
P09704857T0000|63 70|HIV/AIDS
P09704927A0479|5 10|shares
P09704927A0479|22 29|homology
P09704927A0479|62 71|DNA binding
P09704927A0479|71 88|heterodimerization
P09704927A0479|98 107|box domains
P09705258A0837|3 16|IE13.1 cell line
P09705258A0837|47 51|virus
P09705258A0837|63 68|copies
P09705258A0837|96 104|insertion
P09705258A0837|124 131|lacZ gene
P09705324A0213|0 4|DNase
P09705324A0213|6 17|footprinting
P09705324A0213|36 56|mobility shift analyses
P09705324A0213|68 77|hepatocyte
P09705324A0213|85 92|factor-1
P09705324A0213|126 132|protein
P09705324A0213|132 136|C/EBP
P09705324A0213|143 151|consensus
P09705324A0213|163 192|thyroid hormone response elements
P09705324A0213|210 218|base pairs
P09705324A0213|228 243|promoter sequence
P09705324A0213|245 250|rat Std
P09705324A1602|9 15|studies
P09705324A1602|18 39|rat Std promoter function
P09705324A1602|62 66|C/EBP
P09705324A1602|83 98|liver specificity
P09705324A1602|104 113|rat Std gene
P09705324A1602|126 135|repression
P09705324A1602|158 165|presence
P09705324A1602|175 179|OCT-1
P09705324A1602|183 195|C/EBP elements
P09705324A1602|203 211|positions
P09705324A1602|262 267|effect
P09705324A1602|299 310|interference
P09705324A1602|313 317|OCT-1
P09705324A1602|321 325|C/EBP
P09705324A1602|350 366|DNA-AR interaction
P09705352A0879|31 35|Cdc19
P09705352A0879|41 47|subunit
P09705352A0879|62 100|minichromosome maintenance protein complex
P09705352A0879|113 124|fission yeast
P09705497A0227|3 15|yeast MMS2 gene
P09705497A0227|30 36|ability
P09705497A0227|52 84|methyl methanesulfonate sensitivity
P09705497A0227|90 101|mms2-1 mutant
P09705497A0227|132 156|DNA post-replication repair
P09705564T0000|0 9|Expression
P09705564T0000|20 37|papillomavirus type
P09705564T0000|40 49|E5A protein
P09705564T0000|62 73|E5 transcript
P09706565A1072|0 9|Anesthesia
P09706565A1072|46 59|immobilization
P09706565A1072|62 72|atipamezole
P09706643A0206|25 29|agent
P09706643A0206|35 41|disease
P09707498A0262|0 19|MK-801 administration
P09707498A0262|39 46|response
P09707498A0262|49 62|seizure latency
P09707577A1047|2 9|contrast
P09707577A1047|13 24|distribution
P09707577A1047|36 42|markers
P09708450A0648|0 7|Toxicity
P09708450A0648|28 33|period
P09708450A0648|56 65|study group
P09708450A0648|91 97|control
P09708450A0648|116 122|regimen
P09708450A0648|130 134|G-CSF
P09708565A0000|3 9|purpose
P09708565A0000|16 22|article
P09708565A0000|37 43|factors
P09708565A0000|57 65|selection
P09708565A0000|68 77|antibodies
P09708565A0000|78 90|radionuclides
P09708565A0000|102 108|methods
P09708565A0000|114 124|development
P09708565A0000|127 144|radioimmunotherapy
P09708565A0000|165 172|lymphoma
P09708565A0000|196 204|study site
P09708565A0000|211 227|multicenter trials
P09708565A0000|231 247|commercialization
P09710131A0374|4 10|methods
P09710131A0374|43 51|distances
P09710131A0374|52 76|image intensifier tube modes
P09710131A0374|80 98|laser printer formats
P09710582A0535|3 8|effect
P09710582A0535|59 78|protein kinase pathway
P09710582A0535|106 117|MEK inhibitor
P09710582A0535|117 123|PD98059
P09710582A0535|147 158|AP-1 activity
P09710589A1111|13 23|mutagenesis
P09710589A1111|26 33|residues
P09710589A1111|40 45|domain
P09710589A1111|83 90|proteins
P09710589A1111|120 128|HTLV-1 LTR
P09710591A0981|0 8|Mutations
P09710591A0981|18 26|C terminus
P09710591A0981|29 33|c-fos
P09710591A0981|36 49|serine residues
P09710591A0981|57 78|phosphorylation targets
P09710591A0981|82 94|growth factors
P09710591A0981|98 106|MAP kinase
P09710591A0981|125 139|transactivation
P09710591A0981|143 159|block potentiation
P09710591A0981|162 170|MAP kinase
P09710599A0310|11 15|cells
P09710599A0310|16 20|ets-2
P09710599A0310|25 29|CSF-1
P09710599A0310|45 56|response gene
P09710599A0310|74 78|ets-2
P09710599A0310|116 125|expression
P09710599A0310|127 138|ets-2 protein
P09710599T0000|10 19|activation
P09710599T0000|39 55|protein kinases p42
P09710599T0000|67 86|ets-2 phosphorylation
P09710599T0000|88 95|response
P09710599T0000|116 121|factor
P09710599T0000|129 137|signaling
P09710614T0000|0 13|Identification
P09710614T0000|29 36|sequence
P09710614T0000|58 63|domain
P09710614T0000|74 83|regulation
P09710614T0000|103 110|adhesion
P09710614T0000|114 123|activation
P09710614T0000|126 149|phosphoinositide 3-kinase
P09710615T0000|0 4|Vam7p
P09710615T0000|18 25|molecule
P09710615T0000|29 33|Vam3p
P09710615T0000|35 49|syntaxin homolog
P09710615T0000|50 57|function
P09710615T0000|68 72|yeast
P09710615T0000|81 98|protein trafficking
P09710621A0598|16 26|possibility
P09710621A0598|53 58|series
P09710621A0598|61 81|cysteine substitutions
P09710621A0598|87 108|Neu juxtamembrane domain
P09710621A0598|111 115|order
P09710621A0598|123 134|dimerization
P09710621A0598|141 146|series
P09710621A0598|149 161|interreceptor
P09710641A0000|35 39|Pax-6
P09710641A0000|47 52|domain
P09710641A0000|56 66|homeodomain
P09710641A0000|70 88|transcription factor
P09710641A0000|99 112|eye development
P09710641A0000|129 138|activation
P09710641A0000|144 149|alphaB
P09710641A0000|150 155|alphaA
P09710641A0000|156 161|delta1
P09710641A0000|165 184|zeta-crystallin genes
P09712037A0470|0 13|Tctex-1 binding
P09712037A0470|32 41|amino acids
P09712037A0470|52 60|integrity
P09712037A0470|65 78|lysine residues
P09712037A0470|89 96|sequence
P09712037A0470|136 150|Fyn interactions
P09712037A0470|158 171|immunoreceptor
P09712037A0470|186 201|activation motifs
P09712037A0470|202 206|ITAMs
P09712037A0470|209 229|lymphocyte Ag receptors
P09712297T0000|3 32|prothrombin gene G20210A mutation
P09712297T0000|56 63|patients
P09712297T0000|72 85|vein thrombosis
P09712297T0000|96 106|individuals
P09712644T0000|15 24|regulation
P09712644T0000|30 38|GluR2 gene
P09712644T0000|54 63|expression
P09712644T0000|72 80|promoters
P09712644T0000|94 101|elements
P09712859A1110|3 9|binding
P09712859A1110|12 17|NF-ATp
P09712859A1110|29 34|NF-AT4
P09712859A1110|41 48|enhancer
P09712859A1110|83 91|infection
P09712859A1110|109 120|blood T-cells
P09712898A0911|4 8|TRAF2
P09712898A0911|27 39|p38 activation
P09712898A0911|59 72|protein kinases
P09712898T0000|0 27|Tumor necrosis factor signaling
P09712898T0000|46 58|protein kinase
P09712898T0000|81 86|kinase
P09712915A0672|3 10|activity
P09712915A0672|23 30|promoter
P09712915A0672|56 66|combination
P09712915A0672|72 81|activities
P09712915A0672|87 109|transcription factors Sp1
P09712919A0307|5 11|studies
P09712919A0307|27 32|report
P09712919A0307|54 69|signaling pathway
P09712919A0307|93 106|CREB activation
P09712919A0307|114 119|T cells
P09713584A1193|0 10|Respondents
P09713584A1193|24 37|spouse/partner
P09713584A1193|75 83|BMI status
P09713584A1193|88 93|people
P09713584A1193|107 112|groups
P09713990T0000|0 8|Isolation
P09713990T0000|17 30|TP53 target gene
P09713990T0000|36 54|colon cancer cell line
P09713990T0000|88 107|TP53 expression system
P09713996A0262|0 13|Overexpression
P09713996A0262|47 53|cancers
P09713996A0262|59 71|patient tumors
P09713996A0262|77 85|cell lines
P09713996A0262|99 105|variety
P09713996A0262|124 129|agents
P09713996T0000|23 38|characterization
P09713996T0000|58 71|rearrangements
P09713996T0000|85 102|drug resistance gene
P09713996T0000|103 121|MDR1/P-glycoprotein
P09713996T0000|137 145|cell lines
P09713996T0000|149 156|patients
P09714109A0000|0 9|BACKGROUND
P09714109A0000|35 41|smoking
P09714109A0000|51 63|blood pressure
P09714109A0000|75 80|muscle
P09714109A0000|92 104|nerve activity
P09714109A0785|7 27|blood pressure increase
P09714109A0785|30 37|response
P09714109A0785|40 46|smoking
P09714109A0785|72 79|infusion
P09714109A0785|97 104|increase
P09714109A0785|107 115|muscle SNA
P09714835A0345|9 14|report
P09714835A0345|15 31|carboxypeptidase D
P09714835A0345|103 119|carboxypeptidase E
P09714835A0345|127 132|enzyme
P09714835A0345|140 154|characteristics
P09714835A0345|167 175|duck gp180
P09714835A0345|186 192|Fricker
P09715278A1079|0 11|RA-treatment
P09715278A1079|19 31|transfectants
P09715278A1079|69 78|maturation
P09715278A1079|79 85|changes
P09715278A1079|100 104|genes
P09715278A1079|109 125|G1 cell cycle arrest
P09715278A1079|129 134|manner
P09715278A1079|152 162|NT2/D1 cells
P09715278A1526|3 16|histopathology
P09715278A1526|20 37|neovascularization
P09715278A1526|68 82|xenograft tumors
P09715278A1526|94 112|FGF4 over-expressing
P09715278A1526|119 138|control transfectants
P09715384A0235|10 16|vessels
P09715384A0235|22 29|diameter
P09715384A0235|39 48|treatments
P09715384A0235|57 61|J/cm2
P09715384A0235|72 78|results
P09715384A0235|105 111|vessels
P09716095T0000|0 13|Pressure ulcers
P09716179A0974|0 18|RXR-gamma expression
P09716179A0974|38 46|reduction
P09716179A0974|49 54|levels
P09716179A0974|70 74|genes
P09716179A0974|103 130|kinase inhibitors p21Cip1/WAF1
P09716179A0974|134 140|p27Kip1
P09716179A0974|170 187|cdk2 kinase activity
P09716179A0974|190 206|RB phosphorylation
P09716183A1036|33 40|extracts
P09716183A1036|42 50|U937 cells
P09716183A1036|93 112|phosphorylation sites
P09716183A1036|124 146|ERK kinase consensus sites
P09716183A1036|171 176|domain
P09716435A1004|9 17|CR/PP diet
P09716435A1004|25 34|HS subjects
P09716435A1004|70 79|depression
P09716435A1004|79 85|decline
P09716435A1004|88 93|vigour
P09716435A1004|97 113|cortisol elevation
P09716435A1004|136 144|PR/CP diet
P09717246A0526|17 26|ILVF values
P09717246A0526|49 60|exposure time
P09717246A0526|65 77|rate constants
P09717246A0526|99 103|day-1
P09717246A0526|110 120|lipid weight
P09717246A0526|142 146|day-1
P09717835A0941|5 20|sequence analyses
P09717835A0941|32 37|xIRS-u
P09717835A0941|46 51|member
P09717835A0941|57 65|IRS family
P09717835A0941|77 90|Xenopus homolog
P09717835A0941|103 108|member
P09717887A0239|10 14|study
P09717887A0239|32 39|equation
P09717887A0239|50 56|VO2peak
P09717887A0239|77 92|occlusive disease
P09717887A0239|99 106|patients
P09717887A0239|122 133|claudication
P09717887A0239|159 168|predictors
P09717887A0239|171 177|VO2peak
P09717887A0239|184 193|population
P09718372T0000|0 7|Evidence
P09718372T0000|35 41|pathway
P09718372T0000|56 61|stress
P09718372T0000|71 88|Sty1/Spc1 MAP kinase
P09718372T0000|91 102|fission yeast
P09718671A0000|14 24|Injury Scale
P09718671A0000|30 48|Injury Severity Scale
P09718671A0000|51 66|TRISS methodology
P09718671A0000|95 100|system
P09718671A0000|107 114|analysis
P09718671A0000|117 124|injuries
P09718671A0000|135 142|patients
P09719636A1134|4 13|hypothesis
P09719636A1134|36 44|mutations
P09719636A1134|61 74|histidine pairs
P09719636A1134|78 93|H382-X2-H385 pair
P09719636A1134|97 112|H411-X2-H414 pair
P09719636A1134|119 134|H430-X5-H436 pair
P09719636A1134|167 172|region
P09719636A1134|180 188|C terminus
P09721207A0637|14 21|analysis
P09721207A0637|26 30|exons
P09721207A0637|53 58|region
P09721207A0637|67 76|Chromosome
P09721207A0637|102 114|vacillans gene
P09721798A1734|12 18|percent
P09721798A1734|21 28|children
P09721798A1734|47 56|transplant
P09721798A1734|60 71|HCV hepatitis
P09721798A1734|90 99|recurrence
P09721798A1734|109 120|liver failure
P09721798A1734|124 128|death
P09722043A2070|11 19|TPN groups
P09722043A2070|33 40|increase
P09722043A2070|43 52|activities
P09722043A2070|55 59|liver
P09722043A2070|69 75|enzymes
P09722161A3065|0 9|Regulation
P09722161A3065|21 26|growth
P09722161A3065|39 47|targeting
P09722161A3065|62 73|Igf2/Mpr gene
P09722508A0953|29 41|Galpha11 Q209L
P09722508A0953|52 74|Src family kinase activity
P09722508A0953|85 107|tyrosine phosphorylation
P09722508A0953|117 124|proteins
P09722508A0953|127 138|HEK-293 cells
P09722766A0706|3 21|micturition pressure
P09722766A0706|56 64|injection
P09722766A0706|69 73|BUP-4
P09723896A0000|0 9|Peroxisome
P09723896A0000|32 40|receptors
P09723896A0000|55 67|transcription
P09723896A0000|86 95|peroxisome
P09723896A0000|117 124|elements
P09723896A0000|138 155|heterodimerization
P09723896A0000|175 186|acid receptor
P09724654A0761|30 36|origins
P09724654A0761|51 56|timing
P09724654A0761|64 74|recruitment
P09724654A0761|79 88|Mcm protein
P09724654A0761|97 102|timing
P09724654A0761|111 121|recruitment
P09724654A1120|9 16|presence
P09724654A1120|25 30|S-CDKs
P09724654A1120|34 42|Dbf4/Cdc7
P09724654A1120|56 62|origins
P09724654A1120|85 91|loading
P09724754A0173|0 7|Tyrosine
P09724754A0173|22 26|STATs
P09724754A0173|56 62|nucleus
P09724754A0173|81 85|genes
P09724763T0000|13 24|substitution
P09724763T0000|27 56|abalone sperm fertilization genes
P09724763T0000|64 75|substitution
P09724763T0000|78 84|introns
P09724772A0840|0 19|Gel retardation assays
P09724772A0840|42 50|complexes
P09724772A0840|65 84|zia operator-promoter
P09724772A0840|88 102|ZiaR-DNA binding
P09724772A0840|116 124|treatment
P09724772A0840|130 143|metal-chelator
P09725292A1473|0 9|CONCLUSION
P09725292A1473|44 51|criteria
P09725292A1473|70 74|liver
P09725651A0077|37 52|Microsoft Windows
P09725651A0077|56 66|environment
P09725651A0077|75 82|versions
P09725651A0077|86 94|computers
P09725651A0077|112 128|Pentium processors
P09725854A1060|16 25|similarity
P09725854A1060|46 51|action
P09725854A1060|57 61|genes
P09725854A1060|80 90|differences
P09725854A1060|101 116|IS1112C Rf3 allele
P09725854A1060|130 136|alleles
P09725854A1060|139 153|maintainer lines
P09725854A1060|159 168|capability
P09725854A1060|183 188|orf107
P09725854A1060|192 217|urf209 processing activities
P09726201T0000|0 4|JCAHO
P09726201T0000|12 25|interpretation
P09726979T0000|9 15|cloning
P09726979T0000|29 44|characterization
P09726979T0000|53 69|sphingosine kinase
P09726987T0000|6 40|SPT3-TAFII31-GCN5-L acetylase complex
P09726987T0000|53 74|transcription factor IID
P09726988A0275|0 5|Oleate
P09726988A0275|25 30|levels
P09726988A0275|33 42|M-CPT I mRNA
P09726991T0000|0 6|Mapping
P09726991T0000|12 27|DNA binding domain
P09726991T0000|50 72|transcription factor Mac1
P09727045A0817|8 16|mechanism
P09727045A0817|35 44|activation
P09727045A0817|48 58|cooperation
P09727045A0817|61 69|receptors
P09727045A0817|117 124|presence
P09727045A0817|133 143|AR N terminus
P09727045A0817|147 165|ligand binding domain
P09727046A0000|37 43|protein
P09727046A0000|44 49|HS2NF5
P09727046A0000|78 83|region
P09727046A0000|126 154|beta-globin locus control region
P09727046A0784|3 10|CBF1 site
P09727046A0784|33 37|sites
P09727046A0784|53 62|regulators
P09727046A0784|69 74|GATA-1
P09727046A0784|75 79|NF-E2
P09729481A0000|3 43|rat branched-chain-2-oxo-acid dehydrogenase
P09729481A0000|50 59|kinase mRNA
P09729481A0000|86 93|promoter
P09729481A0000|108 116|sequences
P09729481A0000|131 145|Sp1 binding sites
P09729481A0000|153 174|transcription start site
P09729481A1177|0 14|Co-transfection
P09729481A1177|20 39|Sp1 expression plasmid
P09729481A1177|49 65|promoter construct
P09729481A1177|80 93|Schneider cells
P09729481A1177|127 132|kinase
P09729481A1177|137 152|promoter activity
P09729481A1177|194 199|region
P09730413A0642|9 22|investigations
P09730413A0642|69 77|treatment
P09730413A0642|98 107|TME surgery
P09730413A0642|124 138|treatment option
P09730413A0642|142 151|Stage T1-T3
P09730413A0642|158 164|cancers
P09731354A0963|13 20|degrees C
P09731354A0963|34 47|surface density
P09731354A0963|49 57|NH2 groups
P09731354A0963|66 72|maximum
P09731513A1090|18 24|results
P09731513A1090|39 49|cooperation
P09731513A1090|52 80|transcription factors NF-kappaB
P09731513A1090|104 118|transactivation
P09731513A1090|120 127|IL-8 gene
P09731513A1090|130 138|HTLV-I Tax
P09731704A0000|4 8|study
P09731704A0000|31 37|effects
P09731704A0000|46 67|estrogen receptor-alpha
P09731704A0000|68 74|ERalpha
P09731704A0000|75 81|isoform
P09731704A0000|84 91|estrogen
P09731704A0000|103 116|gene activation
P09731704A0000|118 139|U2-OS osteosarcoma cells
P09731704A1472|0 11|Transfection
P09731704A1472|24 30|amounts
P09731704A1472|33 61|delta5ERalpha expression vector
P09731704A1472|66 72|ERalpha
P09731704A1472|72 78|OS cells
P09731704A1472|89 100|potentiation
P09731704A1472|116 129|ERELuc activity
P09731704A1472|158 163|manner
P09731705A2126|0 6|Studies
P09731705A2126|15 19|yeast
P09731705A2126|30 35|system
P09731705A2126|53 60|evidence
P09731705A2126|67 75|formation
P09731705A2126|79 84|VDR-TR
P09731705A2126|100 110|interaction
P09733493A0493|3 9|results
P09733493A0493|38 47|standpoint
P09733493A0493|48 56|melatonin
P09733493A0493|76 91|hydroxyl radicals
P09733493A0493|98 103|vacuum
P09733493A0493|116 123|solution
P09733647A1960|4 11|sequence
P09733647A1960|12 46|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe
P09733647A1960|63 68|B-loop
P09733647A1960|89 95|variety
P09733647A1960|98 106|organisms
P09733647A1960|118 125|bacteria
P09733647A1960|126 130|algae
P09733647A1960|134 147|archeabacteria
P09733794A1323|18 24|changes
P09733794A1323|27 31|Bcl-2
P09733794A1323|47 54|proteins
P09733794A1323|55 59|Bcl-x
P09733794A1323|73 79|control
P09733794A1323|98 102|cells
P09733794A1323|116 124|treatment
P09733815T0000|0 7|Tyrosine
P09733815T0000|19 35|membrane protein 2A
P09733815T0000|50 77|protein tyrosine kinase loading
P09733815T0000|81 90|regulation
P09733815T0000|105 116|virus latency
P09733854A0198|20 29|transcript
P09733854A0198|45 51|latency
P09734808A0000|9 22|test efficiency
P09734808A0000|56 77|contrast/color card test
P09734808A0000|99 110|test stimulus
P09734808A0000|125 130|number
P09734808A0000|133 139|stimuli
P09734808A0000|158 163|phases
P09735286A0599|3 8|defect
P09735286A0599|16 23|proteins
P09735286A0599|68 77|Mu B protein
P09735286A0599|82 89|presence
P09735286A0599|100 108|target DNA
P09735366A1180|5 29|homology cloning techniques
P09735366A1180|43 56|mouse homologue
P09735366A1180|78 89|yeast protein
P09735366A1180|134 154|Caenorhabditis elegans
P09735366A1180|162 167|humans
P09735368A0636|43 54|accumulation
P09735368A0636|67 77|transcripts
P09735368A0636|86 93|activity
P09735368A0636|109 121|K box sequences
P09735371A0227|34 51|homeodomain protein
P09735371A0227|64 73|production
P09735371A0227|79 88|touch cells
P09735371A0227|94 98|mec-3
P09735371A0227|115 132|homeodomain protein
P09735371A0227|145 159|differentiation
P09735371A0227|165 174|touch cells
P09736239A0436|11 29|resuscitation period
P09736239A0436|43 51|aspartate
P09736239A0436|55 77|glutamate concentrations
P09736239A0436|91 98|striatum
P09736239A0436|125 137|resuscitation
P09736239A0436|181 193|resuscitation
P09736239A0436|235 246|accumulation
P09736239A0436|253 264|excitotoxins
P09736239A0436|281 293|resuscitation
P09736697A0783|0 9|Expression
P09736697A0783|41 46|kinase
P09736697A0783|67 80|overexpression
P09736697A0783|109 123|Stat3 activation
P09736697A1107|24 37|IL-6 activation
P09736697A1107|38 42|Stat3
P09736697A1107|53 60|mutation
P09736697A1107|63 72|serine-727
P09736697A1107|90 110|serine phosphorylation
P09736697A1107|119 128|inhibition
P09736697A1107|140 144|Stat3
P09736697A1107|157 172|Janus kinases Jak1
P09736697A1107|192 196|Stat3
P09736697A1107|219 225|pathway
P09736715A0729|11 30|phosphatidylinositol
P09736715A0729|34 46|trisphosphate
P09736715A0729|72 79|activity
P09736715A0729|99 106|addition
P09736715A0729|106 113|membrane
P09736770A0351|0 11|Transfection
P09736770A0351|22 35|binding studies
P09736770A0351|52 56|HEFT1
P09736770A0351|58 65|promoter
P09736770A0351|76 83|activity
P09736770A0351|93 97|GC box
P09737453A0557|0 5|Plasma
P09737453A0557|45 51|surgery
P09737453A0557|53 65|IgG antibodies
P09737453A0557|71 77|complex
P09737453A0557|96 101|factor
P09737453A0557|156 160|assay
P09737453A0557|161 165|ELISA
P09737921T0000|0 15|Genome plasticity
P09737921T0000|27 40|tail fiber locus
P09737921T0000|52 64|bacteriophage
P09737921T0000|65 77|recombination
P09737921T0000|94 104|motifs swaps
P09737921T0000|112 122|specificity
P09738010A0305|3 13|FAS promoter
P09738010A0305|31 37|insulin
P09738010A0305|56 78|insulin response sequence
P09738010A0305|91 100|E-box motif
P09738010A0305|108 123|base pair position
P09738087A0583|3 8|effect
P09738087A0583|22 31|predictors
P09738087A0583|34 41|survival
P09738087A0583|56 73|Cox regression model
P09738087A0583|78 87|adjustment
P09738087A0583|99 107|illnesses
P09738693T0000|0 6|Effects
P09738693T0000|9 15|rhG-CSF
P09738693T0000|18 36|neutrophil functions
P09738693T0000|40 47|survival
P09738693T0000|50 55|sepsis
P09739401A0000|0 8|OBJECTIVE
P09739401A0000|12 18|purpose
P09739401A0000|25 31|article
P09739401A0000|42 59|balance instruments
P09739401A0000|84 88|years
P09739401A0000|107 112|clinic
P09739401A0000|115 129|home environment
P09739913A0194|0 9|CASE REPORT
P09739913A0194|31 40|skin defect
P09739913A0194|64 68|trunk
P09741391A0581|28 34|body box
P09741391A0581|35 43|PenH units
P09741391A0581|52 56|Pause
P09741391A0581|64 69|effort
P09741391A0581|72 80|breathing
P09741391A0581|121 125|pause
P09741391A0581|133 143|inspiration
P09741391A0581|147 156|expiration
P09741783A0000|0 10|Anastrozole
P09741783A0000|21 38|aromatase inhibitor
P09741783A0000|57 73|survival advantage
P09741783A0000|87 93|acetate
P09741783A0000|111 115|women
P09741783A0000|128 139|breast cancer
P09743128A0969|0 6|Moritta
P09743128A0969|18 24|Bis-GMA
P09743233A0526|0 7|Mutation
P09743233A0526|30 41|ets component
P09743233A0526|66 81|promoter activity
P09743720A0268|0 6|ANIMALS
P09744095A1016|18 24|mutants
P09744095A1016|30 42|shy2-1D mutant
P09744095A1016|71 80|mutants hy2
P09744095A1016|85 90|phyB-1
P09744095A1016|93 98|fre1-1
P09744095A1016|98 105|phyA-201
P09744095A1016|135 142|response
P09744095A1016|145 152|darkness
P09744095A1016|164 172|hypocotyl
P09744095A1016|180 196|inflorescence stem
P09744095A1016|206 220|level expression
P09744095A1016|226 232|CAB gene
P09744095A1016|240 246|shy2-1D
P09744095A1016|253 258|mutant
P09745797A0943|21 36|underpredictions
P09745797A0943|58 67|disruption
P09745797A0943|76 80|tasks
P09745797A0943|97 102|impact
P09747651A0000|0 12|Laser ablation
P09747651A0000|42 48|measure
P09747651A0000|68 76|emphysema
P09747873T0000|17 35|adapter protein GRB10
P09747873T0000|49 55|BCR-ABL
P09748261A0000|40 58|acyl-CoA synthetases
P09748261A0000|64 85|acid activation proteins
P09748261A0000|86 90|Faaps
P09748286A0000|36 43|enhancer
P09748286A0000|54 61|leukemia
P09748286A0000|72 85|factor receptor
P09748286A0000|116 131|characterization
P09748286A0000|143 154|pair enhancer
P09748286A0000|164 174|nucleotides
P09748513X1360|0 8|Copyright
P09748513X1360|13 31|Elsevier Science B.V.
P09748669A0414|28 36|dichotomy
P09749533A0764|0 4|Clone
P09749533A0764|11 17|homolog
P09749533A0764|20 27|CONSTANS
P09749533A0764|66 78|flowering time
P09749533A0764|80 90|Arabidopsis
P09749988A0000|0 6|Badcock
P09749988A0000|10 19|Westheimer
P09749988A0000|27 32|Vision
P09749988A0000|87 91|zones
P09749988A0000|92 101|attraction
P09749988A0000|105 113|repulsion
P09749988A0000|118 122|study
P09749988A0000|135 141|results
P09749988A0000|188 194|extents
P09749988A0000|200 212|repulsion zone
P09749988A0000|233 239|contour
P09749988A0000|248 256|repulsion
P09750325A0000|3 9|effects
P09750325A0000|16 38|intensity light emissions
P09750325A0000|61 86|power energization technique
P09750325A0000|98 105|survival
P09750325A0000|116 126|populations
P09750325A0000|161 168|serotype
P09750325A0000|179 199|Listeria monocytogenes
P09750325A0000|199 208|serotype 4b
P09750540A0000|8 26|chemical sensitivity
P09750540A0000|35 42|syndrome
P09750540A0000|57 64|symptoms
P09750540A0000|93 108|chemical exposure
P09751061A0000|0 17|POU-domain proteins
P09751061A0000|45 55|factor Pit-1
P09751061A0000|59 65|members
P09751061A0000|71 87|homeodomain family
P09751061A0000|90 97|proteins
P09751061A0000|117 127|development
P09751061A0000|131 141|homeostasis
P09751061A0000|166 173|response
P09751061A0000|176 202|signal-transduction pathways
P09751061A0000|231 240|expression
P09751061A0000|251 255|genes
P09751114A0967|42 46|cells
P09751114A0967|77 82|vector
P09751114A1987|5 11|results
P09751114A1987|23 28|Thr115
P09751114A1987|58 67|regulation
P09751114A1987|69 80|MyoD function
P09751114A1987|86 95|conditions
P09751114A1987|102 112|mitogenesis
P09751166A1460|15 21|results
P09751166A1460|44 50|Sp1 site
P09751166A1460|76 90|TH transcription
P09751166A1460|94 101|promoter
P09751166A1460|119 124|manner
P09751458A0845|0 19|desmethyltrimebutine
P09753241A0524|10 21|examinations
P09753241A0524|37 45|blood cell
P09753241A0524|60 65|assays
P09753241A0524|67 89|myeloperoxidase activity
P09753241A0524|97 107|homogenates
P09753241A0524|109 119|colon mucosa
P09753241A0524|147 155|% DSS model
P09753241A0524|163 167|weeks
P09753241A0524|168 176|% DSS model
P09753730A0881|0 14|T7 transcription
P09753730A0881|51 56|levels
P09753730A0881|71 80|expression
P09753730A0881|98 114|promoter mutations
P09753769A0362|3 9|primers
P09753769A0362|32 47|oligonucleotides
P09753769A0362|63 80|amino acid sequences
P09753769A0362|86 98|PBAN precursor
P09753774A1642|0 5|Plants
P09753774A1642|33 41|construct
P09753774A1642|56 77|oligofructans 1-kestose
P09753774A1642|83 93|1,1-nystose
P09753774A1642|101 122|1,1,1-fructosylnystose
P09753774A2246|10 19|comparison
P09753774A2246|34 51|amino acid sequences
P09753774A2246|54 58|1-sst
P09753774A2246|62 66|1-fft
P09753774A2246|83 112|plant fructosyl transferase genes
P09753774A2246|132 148|plant fructan genes
P09753774A2246|164 182|plant invertase genes
P09753775A0734|42 54|ICK1 induction
P09753775A0734|62 69|decrease
P09753775A0734|81 103|histone H1 kinase activity
P09754571A0169|7 16|transcript
P09754571A0169|42 59|display amplicon 3G1
P09754571A0169|91 108|RAG1 mRNA expression
P09754571A0169|123 131|cell lines
P09754571A1257|3 11|hBRAG gene
P09754571A1257|40 49|chromosome
P09754571A1257|51 55|10q26
P09755191A0553|16 21|swa5-1
P09755191A0553|49 54|allele
P09755191A0553|60 67|clathrin
P09755191A0553|73 81|chain gene
P09755191A0553|82 87|chc1-5
P09755191A0553|101 118|frameshift mutation
P09755191A0553|147 158|reading frame
P09755199A0373|28 34|lesions
P09755199A0373|52 58|alleles
P09755199A0373|81 92|requirements
P09755199A0373|104 110|domains
P09755199A0559|28 39|Scm mutations
P09755199A0559|56 64|mbt repeat
P09755199A0559|77 88|PcG mutations
P09755199A0559|116 122|alleles
P09755478A0366|0 15|Northern analysis
P09755478A0366|36 45|expression
P09755478A0366|51 60|transcript
P09755478A0366|63 70|diapause
P09755478A0366|104 109|larvae
P09755478A0366|117 131|trace expression
P09755478A0366|147 151|pupae
P09756687A0981|10 25|characterization
P09756687A0981|29 38|discussion
P09756687A0981|56 60|setup
P09756687A0981|68 80|rate constants
P09756687A0981|125 130|values
P09756895A0322|7 11|locus
P09756895A0322|14 19|chCTCF
P09756895A0322|78 82|exons
P09756895A0322|89 94|intron
P09757012A0942|3 10|presence
P09757012A0942|21 30|SAM domains
P09757012A0942|35 44|KS5 protein
P09757012A0942|77 83|adaptor
P09757012A0942|104 114|information
P09757012A0942|118 142|signal transduction pathway
P09759180A0000|0 9|BACKGROUND
P09759180A0000|10 25|Fluoroquinolones
P09759180A0000|50 57|children
P09759180A0000|77 91|cartilage damage
P09759691A1051|2 9|analyses
P09759691A1051|14 20|control
P09759691A1051|32 40|variables
P09759691A1051|58 73|microalbuminuria
P09759691A1051|80 95|albumin excretion
P09759691A1051|102 111|microg/min
P09759691A1051|122 126|women
P09759691A1051|158 161|mm Hg
P09759691A1051|181 193|blood pressure
P09759691A1051|220 227|1.0-mmol
P09759691A1051|232 236|mg/dL
P09759691A1051|242 263|plasma cholesterol level
P09759691A1051|290 296|smokers
P09759691A1051|299 308|nonsmokers
P09759691A1051|340 344|kg/m2
P09759691A1051|351 363|body mass index
P09759865A0673|12 19|IL-1beta
P09759865A0673|23 31|TNF-alpha
P09759865A0673|50 56|binding
P09759865A0673|62 75|Rel proteins p50
P09759865A0673|88 120|NF-kappaB consensus oligonucleotide
P09759865A0673|122 135|gel shift assays
P09759865A0673|154 164|degradation
P09759865A0673|167 175|inhibitor
P09759865A0673|178 192|NF-kappaB-alpha
P09759865A0673|193 205|IkappaB-alpha
P09759865A0673|211 219|cytoplasm
P09759865A0673|222 235|myofibroblasts
P09759865A0673|240 247|IL-1beta
P09759865A0673|259 269|PDGF-Ralpha
P09760243A0970|0 14|Cotransfections
P09760243A0970|19 23|ATF-2
P09760243A0970|27 49|HNF-4 expression plasmids
P09760243A0970|68 82|transactivation
P09760243A0970|88 102|apoCIII promoter
P09760341T0000|0 24|Phosphocreatine hydrolysis
P09760341T0000|41 48|exercise
P09760341T0000|52 57|effect
P09761711A0000|0 18|Pseudocontact shifts
P09761711A0000|55 61|average
P09761711A0000|74 81|coupling
P09761711A0000|97 104|electron
P09761711A0000|108 113|nuclei
P09761711A0000|119 126|presence
P09761711A0000|137 160|susceptibility anisotropy
P09761723A0226|0 5|GETS-1
P09761723A0226|23 29|tissues
P09761723A0226|45 50|retina
P09761723A0226|54 58|brain
P09761791A0489|3 13|interaction
P09761791A0489|16 21|U1-70K
P09761791A0489|29 39|SRZ proteins
P09761791A0489|71 86|blot overlay assay
P09763421A1199|8 17|phenotypes
P09763421A1199|31 53|Fab1p kinase inactivation
P09763421A1199|82 87|growth
P09763421A1199|96 115|acidification defects
P09763421A1199|127 135|increases
P09763446A0000|5 11|GTPases
P09763446A0000|17 29|Ypt/Rab family
P09763446A0000|46 55|regulation
P09763446A0000|67 75|transport
P09763446A1234|11 23|GAP activities
P09763446A1234|26 30|Ypt1p
P09763446A1234|60 68|fractions
P09763470A0000|0 23|Dopamine beta-hydroxylase
P09763470A0000|41 50|conversion
P09763470A0000|52 59|dopamine
P09763470A0000|62 74|noradrenaline
P09763470A0000|128 134|neurons
P09763470A0000|138 156|neuroendocrine cells
P09763470A1756|16 20|study
P09763470A1756|48 53|Phox2a
P09763470A1756|74 82|synergism
P09763470A1756|92 111|transcription factors
P09763470A1756|152 161|activation
P09763470A1756|164 170|DBH gene
P09763522A2545|15 22|antibody
P09763522A2545|30 36|N-SMase
P09763522A2545|48 53|Ox-LDL
P09763522A2545|74 82|apoptosis
P09763522A2545|115 121|studies
P09763522A2545|124 132|apoptosis
P09763522A2545|147 153|animals
P09763607A0521|19 28|Ngo strains
P09763607A0521|35 49|phosphorylation
P09763607A0521|53 62|activation
P09763607A0521|78 86|p38 kinase
P09764741A0092|7 11|beams
P09764741A0092|34 41|elements
P09764741A0092|47 67|cell division machinery
P09764741A0092|80 86|beating
P09764741A0092|89 94|hearts
P09764741A0092|106 110|basis
P09765261A0000|8 12|T cell
P09765261A0000|25 38|retrovirus type
P09765261A0000|40 45|HTLV-I
P09765261A0000|46 60|trans-activator
P09765261A0000|94 120|basic-domain/leucine-zipper
P09765261A0000|126 132|protein
P09765261A0000|132 164|cAMP response element binding protein
P09765261A0000|200 206|element
P09765261A0000|239 249|pair repeats
P09765261A0000|259 281|cAMP response element core
P09765261A0000|299 307|sequences
P09765271A1108|4 11|sequence
P09765271A1108|30 52|insulin response sequence
P09765271A1108|73 78|region
P09765271A1108|86 90|genes
P09765271A1108|112 118|insulin
P09765271A1108|138 169|phosphoenolpyruvate carboxykinase
P09765271A1108|170 193|tyrosine aminotransferase
P09765271A1108|209 214|growth
P09765271A1108|229 235|protein
P09765277A0000|21 45|glucose transporter isoform
P09765277A0000|109 115|neurons
P09765277A0000|118 129|trophoblasts
P09765285A0998|18 26|half-site
P09765285A0998|32 54|consensus sequence AGGTCA
P09765285A0998|55 61|IRper-1
P09765285A0998|71 77|binding
P09765285A0998|80 84|AaEcR
P09765285A0998|102 106|AaUSP
P09765285A0998|118 124|IRhsp-1
P09765285A0998|153 162|stringency
P09765285A0998|167 189|spacer length requirement
P09765285A0998|194 200|IRper-0
P09765285A0998|203 209|IRper-5
P09765285A0998|227 233|binding
P09765285A1763|3 8|levels
P09765285A1763|11 25|transactivation
P09765285A1763|56 72|binding affinities
P09765285A1763|78 93|response elements
P09765285A1763|94 100|IRper-1
P09765285A1763|109 115|IRhsp-1
P09765372A0669|7 13|density
P09765372A0669|26 31|spines
P09765372A0669|66 77|distribution
P09765372A0669|86 93|papillae
P09765372A0669|95 107|dorsal surface
P09765372A0669|141 149|C. armatus
P09765388T0000|0 11|Inactivation
P09765388T0000|32 45|adenovirus type
P09765388T0000|83 94|oncoproteins
P09765394A0000|15 36|virus transactivator Zta
P09765394A0000|50 63|gene expression
P09765394A0000|81 91|replication
P09765394A0000|102 107|origin
P09765394A0000|108 113|oriLyt
P09765394A1590|0 13|Cotransfection
P09765394A1590|35 42|proteins
P09765394A1590|76 91|activation domain
P09765394A1590|110 124|superactivation
P09765394A1590|127 139|CAT expression
P09765411A0991|0 18|Sequence comparisons
P09765411A0991|53 61|ubiquitin
P09765411A0991|67 75|sequences
P09765411A0991|86 91|genome
P09765411A0991|94 98|CP Rit
P09765411A0991|140 152|hybrid protein
P09765411A0991|159 190|structure NH2-ubiquitin-S27a-COOH
P09765754A1727|9 13|trend
P09765754A1727|19 25|studies
P09767504A1371|23 27|mg/kg
P09767504A1371|46 58|concentration
P09767504A1371|71 84|administration
P09767575A0657|4 9|domain
P09767575A0657|43 52|SD sequence
P09767575A0657|66 80|ribosome binding
P09767575A0657|107 112|region
P09767575A0657|115 120|domain
P09767593A0130|58 63|subset
P09767593A0130|87 94|proteins
P09767593A0130|97 105|host cells
P09767593A0130|115 121|p130Cas
P09767687T0000|12 19|position
P09767687T0000|25 35|Phacotaceae
P09767687T0000|45 61|Chlamydophyceaeas
P09767687T0000|72 79|analysis
P09767687T0000|82 88|18S rDNA
P09767687T0000|92 104|rbcL sequences
P09769209A0100|15 21|studies
P09769209A0100|30 39|conclusion
P09769209A0100|61 69|induction
P09769209A0100|72 91|nasF operon expression
P09769209A0100|122 145|antitermination mechanism
P09769910A1700|3 12|activation
P09769910A1700|16 21|injury
P09769910A1700|35 39|cells
P09769910A1700|77 85|cytokines
P09769910A1700|104 110|effects
P09769910A1700|118 126|mediators
P09770241A0000|1 9|technique
P09770241A0000|20 26|imaging
P09770241A0000|32 37|animal
P09770241A0000|46 56|brain cortex
P09770241A0000|79 84|system
P09770378A0641|0 9|EGFR levels
P09770415A0139|21 26|THOV NP
P09770415A0139|36 40|motif
P09770415A0139|41 55|KRxxxxxxxxxKTKK
P09770415A0139|58 75|amino acid positions
P09770415A0139|123 140|localization signal
P09770493A0499|15 19|range
P09770493A0499|29 37|functions
P09770493A0499|47 65|cell cycle regulation
P09770493A0499|69 89|cell fate determination
P09770493A0499|120 126|embryos
P09770493A0499|147 162|postimplantation
P09770686A0484|15 24|risk factor
P09770686A0484|40 51|hypertension
P09771555A0499|3 9|results
P09771555A0499|22 44|anthraquinone sennoside B
P09771555A0499|48 52|rhein
P09771967A1052|11 17|LB1 gene
P09771967A1052|26 40|chromosome 13q14
P09771967A1052|42 47|region
P09771967A1052|81 90|breakpoint
P09771985A0238|2 9|subjects
P09771985A0238|14 20|repatch
P09771985A0238|29 48|ethylmercury chloride
P09771985A0238|49 54|EtHgCl
P09771985A0238|60 68|solutions
P09771985A0238|79 84|EtHgCl
P09771985A0238|94 103|L-cysteine
P09771985A0238|107 117|glutathione
P09773975A1873|9 21|AT1A receptors
P09773975A1873|40 56|hamster ovary cells
P09773975A1873|81 96|Ang II stimulation
P09773975A1873|118 122|level
P09773975A1873|123 137|internalization
P09773975A1873|161 169|receptors
P09773975A1873|188 200|substitutions
P09773975A1873|201 205|T332E
P09773975A1873|232 236|S335D
P09773975A1873|259 263|T336E
P09773975A1873|286 290|S338D
P09773981A0415b|12 33|glucocorticoid receptor
P09773981A0415b|40 46|complex
P09773981A0415b|51 55|Stat5
P09773981A0415b|96 104|induction
P09774403A0107|4 11|Mahasneh
P09774444A0351|20 26|portion
P09774444A0351|48 58|zinc fingers
P09774444A0351|63 75|Cys2-His2 type
P09774444A0351|96 105|CACCC motif
P09774444A0351|111 129|beta-globin promoter
P09774444A0351|138 159|Sp1 recognition sequence
P09774450A0000|25 35|mouse enzyme
P09774450A0000|42 68|gamma-glutamyl leukotrienase
P09774450A0000|86 98|leukotriene C4
P09774450A0000|106 118|leukotriene D4
P09774484T0000|0 15|UGA codon position
P09774484T0000|26 35|efficiency
P09774484T0000|38 64|selenocysteine incorporation
P09774484T0000|69 91|glutathione peroxidase-1
P09774641A0824|0 8|Forskolin
P09774641A0824|50 59|expression
P09774641A0824|62 68|cyclin D
P09774641A0824|72 86|phosphorylation
P09774641A0824|92 116|retinoblastoma gene product
P09774662A0958|3 13|ARF promoter
P09774662A0958|48 61|E2F1 expression
P09774662A0958|83 89|results
P09774662A0958|95 102|RNA level
P09776293A0777|0 6|RESULTS
P09776293A0777|10 16|binding
P09776293A0777|19 24|99mTc d
P09776293A0777|25 31|1-HMPAO
P09776293A0777|39 46|placenta
P09776293A0777|99 106|solution
P09776360A0620|21 35|binding activity
P09776360A0620|37 59|transcription factor AP-1
P09776360A1781|0 8|NF-kappaB
P09776360A1781|41 48|activity
P09776360A1781|66 73|promoter
P09776360A1781|101 108|effector
P09776360A1781|117 126|DLD-1 cells
P09777477A0000|0 8|Observers
P09777477A0000|13 23|brain injury
P09777477A0000|27 45|control participants
P09777477A0000|56 68|vigilance task
P09777477A0000|100 105|whiffs
P09777477A0000|140 149|peppermint
P09777600A0000|17 22|method
P09777600A0000|26 34|l-menthol
P09777600A0000|59 72|chromatography
P09777600A0000|98 105|detector
P09777999A0796|0 6|RESULTS
P09777999A0796|17 21|index
P09777999A0796|53 63|PaCO2 levels
P09777999A0796|64 73|hypocapnia
P09777999A0796|78 88|hypercapnia
P09778006A0718|14 25|baseline Vmca
P09778006A0718|36 43|pressure
P09778006A0718|46 58|carbon dioxide
P09778006A0718|69 73|blood
P09778006A0718|74 78|PaCO2
P09778006A0718|106 117|measurements
P09778006A0718|158 180|carbon dioxide reactivity
P09778006A0718|187 191|value
P09778006A0718|217 221|value
P09778006A0718|219 228|percentage
P09778006A0718|231 247|baseline Vmca/mmHg
P09778068A1129|12 30|Cox survival analysis
P09778068A1129|41 50|baseline EF
P09778068A1129|59 66|presence
P09778068A1129|85 97|regurgitation
P09778068A1129|105 112|ablation
P09778068A1129|116 122|failure
P09778068A1129|147 157|performance
P09778068A1129|161 165|month
P09778068A1129|171 178|ablation
P09778068A1129|199 208|predictors
P09778068A1129|211 215|death
P09778191A0000|19 24|method
P09778191A0000|28 37|estimation
P09778191A0000|77 91|reserve capacity
P09778191A0000|107 111|basis
P09778191A0000|114 118|means
P09778191A0000|136 151|resonance imaging
P09778197A0415|0 25|Cost-effectiveness analysis
P09778197A0415|43 47|means
P09778197A0415|67 85|health care resources
P09778197A0415|99 108|comparison
P09778197A0415|114 118|costs
P09778197A0415|135 141|therapy
P09778197A0415|154 160|therapy
P09778197A0415|165 200|beta-hydroxy-beta-methylglutaryl-CoA
P09778197A0415|201 209|coenzyme A
P09778197A0415|210 228|reductase inhibitors
P09778197A0415|229 235|statins
P09778197A0415|243 247|costs
P09778197A0415|250 264|atherosclerosis
P09778197A0415|295 305|cholesterol
P09780002A0996|8 13|E2FBP1
P09780002A0996|22 42|transactivation domain
P09780002A0996|74 86|transcription
P09780002A0996|88 98|cooperation
P09780002A0996|103 107|E2F-1
P09780228A0122|0 9|Sequencing
P09780228A0122|18 27|DNA segment
P09780228A0122|33 48|FK506 gene cluster
P09780228A0613|12 27|domain structures
P09780228A0613|84 102|fatty-acid-synthase
P09780228A0613|107 113|domains
P09780228A0613|124 130|modules
P09780336A0771|0 7|Analysis
P09780336A0771|10 27|Msy2 mRNA expression
P09780336A0771|49 59|mouse testes
P09780336A0771|73 83|populations
P09780336A0771|86 94|germ cells
P09780336A0771|109 118|expression
P09780336A0771|132 146|round spermatids
P09780336A0771|148 155|cell type
P09780336A0771|168 174|amounts
P09780336A0771|183 209|messenger ribonucleoproteins
P09781761A0384|3 15|Ho Chi Minh City
P09781761A0384|28 34|culture
P09781761A0384|38 55|latex agglutination
P09781761A0384|58 62|blood
P09781761A0384|76 80|fluid
P09781761A0384|81 85|urine
P09781761A0384|96 100|fluid
P09781871A0404|0 16|Glycogen synthesis
P09781871A0404|20 29|catabolism
P09781871A0404|30 44|gluconeogenesis
P09781871A0404|45 54|glycolysis
P09781871A0404|55 62|motility
P09781871A0404|63 83|cell surface properties
P09781871A0404|87 95|adherence
P09781871A0404|141 150|production
P09781871A0404|167 182|virulence factors
P09781871A0404|186 190|plant
P09781871A0404|205 224|response elicitor HrpN
P09781871A0404|257 267|metabolites
P09781871A0404|289 305|Erwinia carotovora
P09781874A1061|3 16|cwg2-1 mutation
P09781874A1061|33 39|guanine
P09781874A1061|42 60|adenine substitution
P09781874A1061|63 72|nucleotide
P09781874A1061|87 92|region
P09781874A1061|107 117|change A202T
P09781874A1061|123 127|cwg2p
P09784063A0621|0 15|Deletion analysis
P09784063A0621|40 45|domain
P09784063A0621|52 59|promoter
P09784063A0621|69 97|ORF5/deltaX transcript promoter
P09784063A0621|106 116|nucleotides
P09784192A1027|9 15|peptide
P09784192A1027|15 24|MBP fusions
P09784192A1027|46 68|surface plasmon resonance
P09784245T0000|21 28|protein C
P09784245T0000|29 34|MyBP-C
P09784245T0000|35 48|identification
P09784245T0000|51 64|protein kinase A
P09784245T0000|68 101|protein kinase C phosphorylation sites
P09785114A1026|38 47|CORT levels
P09785114A1026|57 62|groups
P09786197A0322|0 7|Analysis
P09786197A0322|21 31|DNA sequence
P09786197A0322|58 76|transposon insertion
P09786197A0322|94 106|reading frames
P09786197A0322|146 163|sequence similarity
P09786197A0322|196 202|systems
P09786404A0541|6 18|aggregates/ml
P09786926A0095|23 28|region
P09786926A0095|34 59|fatty-acid synthase promoter
P09786926A0095|97 110|overexpression
P09786926A0095|116 133|fatty-acid synthase
P09786926A0095|170 177|activity
P09786926A0095|191 198|promoter
P09786926A0095|224 228|cells
P09786926A1372|19 32|binding studies
P09786926A1372|45 50|SREBP2
P09786926A1372|68 85|ADD1/SREBP1 binding
P09786926A1372|93 98|sterol
P09786926A1372|109 115|element
P09786932A1042|4 8|IRF-7
P09786932A1042|27 36|similarity
P09786932A1042|39 43|IRF-3
P09786932A1042|66 75|expression
P09786932A1042|78 82|IRF-7
P09786932A1042|93 97|cells
P09786932A1042|101 108|cell type
P09786932A1042|140 144|IRF-7
P09786932A1042|181 198|IFNA gene expression
P09787323A0000|0 6|PURPOSE
P09787323A0000|10 26|role interleukin-6
P09787323A0000|38 46|treatment
P09787323A0000|58 74|thrombocytopenias
P09788739A1096|22 33|serine kinase
P09788739A1096|64 71|molecule
P09788739A1096|75 90|signaling cascade
P09788739A1096|104 110|variety
P09788739A1096|121 129|responses
P09788739A1096|132 154|MDA231 breast cancer cells
P09789025A0149|0 6|Galphaq
P09789025A0149|7 14|Galpha12
P09789025A0149|18 25|Galpha13
P09789025A0149|32 38|Galphai
P09789795A0607|19 26|subjects
P09789795A0607|43 55|noradrenaline
P09789795A0607|59 72|concentrations
P09790499A0545|0 19|Northern blot analyses
P09790499A0545|31 44|hBub1 mRNA level
P09790499A0545|68 74|tissues
P09790499A0545|77 81|cells
P09790499A0545|98 102|index
P09790767A0372|31 47|sequence tag clones
P09790767A0372|62 67|contig
P09790767A0372|75 84|chromosome
P09790767A0372|86 92|band q31
P09790768A0621|0 10|Htra2-beta3
P09790768A0621|64 68|brain
P09790768A0621|69 79|liver testis
P09790768A0621|91 96|kidney
P09790771A0956|0 16|Gng3lg transcripts
P09790771A0956|32 38|variety
P09790771A0956|41 47|tissues
P09790771A0956|61 65|brain
P09790771A0956|69 74|testes
P09790771A1032|20 33|backcross panel
P09790771A1032|58 63|Gng3lg
P09790771A1032|72 76|locus
P09790771A1032|79 88|chromosome
P09790986A0689|23 30|antibody
P09790986A0689|41 77|glutathione S-transferase fusion protein
P09790986A0689|105 114|amino acids
P09790986A0689|122 127|NRAMP2
P09792439T0000|0 9|Inhibition
P09792439T0000|15 40|apolipoprotein B mRNA editing
P09792439T0000|57 70|hnRNP C1 protein
P09792439T0000|74 90|40S hnRNP complexes
P09792627A0441|0 4|SRC-1
P09792627A0441|36 45|repression
P09792627A0441|48 57|GR activity
P09792630A1127|10 17|sequence
P09792630A1127|32 57|transcription start site CTCA
P09792630A1127|81 93|consensus CTCA
P09792630A1127|108 117|nucleoside
P09792630A1127|120 135|initiator element
P09792630A1127|151 177|deoxynucleotidyltransferase
P09792630A1127|182 187|number
P09792630A1127|210 214|genes
P09792682A0713|5 11|results
P09792682A0713|32 37|number
P09792682A0713|40 47|subunit c
P09792702A0754|0 9|Expression
P09792702A0754|30 35|mutant
P09792702A0754|58 64|glucose
P09792702A0754|83 96|JNK1 activation
P09792702A0754|105 123|HSP70 gene expression
P09792714A1408|3 13|interaction
P09792714A1408|26 33|proteins
P09792714A1408|53 57|steps
P09792714A1408|60 72|transcription
P09792714A1408|84 92|mechanism
P09792714A1408|107 116|activation
P09792714A1408|119 132|gene expression
P09794414T0000|11 33|protein kinase C signaling
P09794414T0000|44 59|DRA transcription
P09794795A0183|0 12|Ligand binding
P09794795A0183|18 32|receptor complex
P09794795A0183|40 62|tyrosine phosphorylation
P09794795A0183|66 75|activation
P09794795A0183|78 89|Janus kinases
P09794795A0183|95 109|phosphorylation
P09794795A0183|114 142|signal transducing subunit gp130
P09794795A0183|153 163|recruitment
P09794795A0183|167 181|phosphorylation
P09794795A0183|187 202|signal transducer
P09794795A0183|206 214|activator
P09794795A0183|217 241|transcription factors STAT3
P09794795A0183|245 249|STAT1
P09794795A0183|256 272|src homology domain
P09794795A0183|287 312|protein tyrosine phosphatase
P09795130A0742|15 22|increase
P09795130A0742|25 32|distance
P09795130A0742|60 65|effect
P09795130A0742|68 88|translation efficiency
P09795170A0774|13 31|polyadenylation site
P09795170A0774|61 65|codon
P09795170A0774|84 99|kb transcript size
P09795213A0129|0 11|RBP56 protein
P09795213A0129|25 32|hTAFII68
P09795213A0129|64 70|protein
P09795213A0129|81 86|factor
P09795213A0129|97 110|sub-population
P09795213A0129|112 125|TFIID complexes
P09795213A0129|126 137|Bertolotti A.
P09795213A0129|148 152|Heard
P09795213A0129|157 163|Chambon
P09795213A0129|218 225|hTAFII68
P09795213A0129|249 255|protein
P09795213A0129|260 267|homology
P09795213A0129|273 297|proto-oncoproteins TLS/FUS
P09795213A0129|326 330|TFIID
P09795213A0129|333 345|RNA polymerase
P09795341A0806|17 34|mobility shift assay
P09795341A0806|64 78|binding property
P09795341A0806|101 107|isoform
P09797189A0559|12 24|shift analysis
P09797189A0559|47 56|CCAAT motif
P09797456A0000|0 9|BACKGROUND
P09797456A0000|13 31|c-myc proto-oncogene
P09797456A0000|57 61|roles
P09797456A0000|64 80|cell proliferation
P09797456A0000|81 95|differentiation
P09797456A0000|96 109|transformation
P09797456A0000|113 121|apoptosis
P09797456A0883|0 4|AMY-1
P09797456A0883|22 30|cytoplasm
P09797456A0883|33 37|cells
P09797456A0883|48 52|c-myc
P09797456A0883|58 63|levels
P09797456A0883|72 78|nucleus
P09797456A0883|84 88|cells
P09797456A0883|96 110|c-myc expression
P09797456A0883|135 139|cells
P09798068A0290|0 6|RESULTS
P09798068A0290|47 58|reading frame
P09798068A0290|93 99|protein
P09798068A0290|104 113|amino acids
P09798068A0290|136 144|% homology
P09798068A0290|175 179|acid B
P09798068A0290|179 183|GABAB
P09798068A0290|184 191|receptor
P09798100A0705|11 16|CIDR-B
P09798100A0705|32 53|micrograms cloprostenol
P09798263T0000|19 28|properties
P09798263T0000|35 58|serotonin receptor ligands
P09798263T0000|62 86|calcium channel antagonists
P09798263T0000|108 119|swimming test
P09799086A0725|16 30|hotspot mutation
P09799086A0725|41 47|patient
P09799086A0725|49 58|frame shift
P09799086A0725|68 87|G nucleotide insertion
P09799086A0725|101 106|repeat
P09799086A0725|118 125|HPRT exon
P09799086A0725|163 172|LN patients
P09799237A0624|13 19|embryos
P09799237A0624|35 52|gastrulation defect
P09799362A0507|29 36|features
P09799362A0507|56 71|abbreviation AZF1
P09799362A0507|87 103|Zinc Finger protein
P09799362A1463|0 14|Over-expression
P09799362A1463|17 21|Azf1p
P09799362A1463|27 35|yeast cell
P09799362A1463|55 69|expression level
P09799362A1463|88 111|transcription factor Mtf1p
P09799362A1463|129 137|influence
P09799362A1463|140 144|Azf1p
P09799362A1463|150 160|suppression
P09799362A1463|186 204|RNA polymerase mutant
P09799634A0161|16 28|computer model
P09799634A0161|44 49|domain
P09799634A0161|58 66|repressor
P09799634A0161|77 92|crystal structure
P09799634A0161|114 120|protein
P09799793T0000|11 20|sequencing
P09799793T0000|26 32|regions
P09799793T0000|40 53|chromosome 7q22
P09799793T0000|54 61|analysis
P09799793T0000|80 87|sequence
P09799793T0000|104 112|CUTL1 loci
P09799793T0000|121 125|genes
P09800187A0100|7 11|Trp53
P09800187A0100|15 26|mouse homolog
P09800187A0100|60 69|chromosome
P09800187A0100|103 111|responses
P09800187A0100|121 128|exposure
P09800187A0100|131 147|DNA damaging agents
P09800187A0100|174 191|mouse lymphoma cells
P09800187A0100|198 206|mutations
P09800187A0100|209 213|Trp53
P09801156A0220|10 18|fragments
P09801156A0220|34 58|amino acid sequence homology
P09801156A0220|70 77|ecdysone
P09801156A0220|87 93|gene E75
P09801333A0174|14 18|N gene
P09801333A0174|32 43|reading frame
P09801333A0174|69 77|PRRS virus
P09802206A1058|7 22|sequence homology
P09802206A1058|26 30|genes
P09802206A1058|60 93|translation elongation factor-1 alpha
P09802206A1058|119 127|protein S7
P09802902A0225|45 58|plasma membrane
P09802902A0225|87 108|ARF6 nucleotide exchange
P09803081T0000|5 13|pathology
P09803081T0000|26 32|outcome
P09803081T0000|35 46|childhood SLE
P09804779A0000|0 19|Transcription factors
P09804779A0000|25 34|Stat family
P09804779A0000|50 63|protein kinases
P09804779A1163|16 23|pathways
P09804779A1163|32 57|Stat5 serine phosphorylation
P09804779A1163|182 187|Stat5a
P09804836A0000|32 38|protein
P09804836A0000|76 83|response
P09804836A0000|86 109|mouse BAC1.2F5 macrophages
P09804836A0000|110 134|colony stimulating factor-1
P09804836A0000|135 139|CSF-1
P09804836A0000|198 205|fraction
P09804836A0000|217 238|affinity chromatography
P09804836A0000|238 264|size exclusion chromatography
P09804836A0000|279 283|phase
P09804836A0000|287 294|pressure
P09804836A0000|301 314|chromatography
P09805052A0119|37 42|scheme
P09805052A0119|51 56|months
P09805052A0119|59 63|order
P09805052A0119|74 87|immunogenicity
P09805052A0119|114 119|months
P09805977A0143|63 68|origin
P09805977A0143|74 82|sperm fall
P09805977A0143|132 136|class
P09805977A0143|139 148|substances
P09805977A0143|152 164|xenoestrogens
P09806516A1212|4 14|association
P09806516A1212|45 52|patients
P09806516A1212|75 84|recurrence
P09806516A1689|0 9|CONCLUSION
P09806516A1689|15 21|control
P09806516A1689|36 40|Preop
P09806516A1689|43 50|patients
P09806516A1689|79 85|disease
P09806516A1689|93 98|Postop
P09806516A1689|101 108|patients
P09806516A1689|147 154|excision
P09806546A1270|3 13|interaction
P09806546A1270|27 31|RFXAP
P09806546A1270|45 51|binding
P09806546A1270|57 66|RFX complex
P09806546A1270|69 83|MHC-II promoters
P09806826A0244|25 30|defect
P09806826A0244|33 39|RIIIS/J
P09806826A0244|48 55|mouse Chr
P09806826A0244|73 80|Vwf locus
P09806826A1773|26 37|localization
P09806826A1773|44 54|disease loci
P09806826A1773|67 72|region
P09806826A1773|114 121|syndrome
P09806826A1773|131 135|locus
P09806826A1773|139 152|susceptibility
P09806826A1773|173 182|lung injury
P09806830X1174|0 8|Copyright
P09806830X1174|13 25|Academic Press
P09806857A0854|6 17|reading frame
P09806857A0854|27 33|protein
P09806857A0854|55 64|similarity
P09806857A0854|67 76|invertases
P09806857A0854|80 89|resolvases
P09806857A0854|124 138|Pac25I R-M operon
P09806858T0000|0 13|Identification
P09806858T0000|44 54|plasmid pLS1
P09806858T0000|57 64|rnaI gene
P09806919A0447|32 43|instar larvae
P09806919A0447|88 96|responses
P09806919A0447|102 114|ecdysone pulse
P09806919A0447|127 143|puparium formation
P09807755A0146|21 26|supply
P09807755A0146|44 52|viability
P09807755A0146|56 65|muscle flap
P09808155A0813|0 10|Examination
P09808155A0813|17 39|protein binding complexes
P09808155A0813|50 57|analysis
P09808155A0813|78 84|factors
P09808155A0813|124 128|cells
P09808155A0813|139 149|DNA fragment
P09808216A0000|0 9|BACKGROUND
P09808216A0000|10 16|Studies
P09808216A0000|36 45|regulation
P09808216A0000|47 52|energy
P09808216A0000|63 69|balance
P09808216A0000|79 90|manipulation
P09808216A0000|99 104|ratios
P09808366A0828|5 12|apneusis
P09808366A0828|38 47|conditions
P09808366A0828|59 63|apnea
P09808366A0828|87 102|KA microinjection
P09808366A0828|119 125|VRG-Apa
P09808366A0828|126 132|animals
P09808441A0320|12 19|analysis
P09808441A0320|57 65|melanomas
P09808441A0320|79 89|singularity
P09808441A0320|116 124|character
P09808441A0320|129 136|melanoma
P09808441A0320|140 152|lymphotropism
P09808441A0320|159 169|coexistence
P09808441A0320|188 200|cell carcinoma
P09810087A0379|0 6|RESULTS
P09810087A0379|17 30|seroconversion
P09810087A0379|45 52|presence
P09810087A0379|62 79|herpes simplex virus
P09810087A0379|79 82|HSV I
P09810087A0379|90 94|acids
P09810087A0379|117 121|humor
P09811695A1146|5 11|results
P09811695A1146|24 40|HIV-1 Gag sequences
P09811695A1146|72 81|processing
P09811695A1146|87 105|MuLV TM Env protein p15
P09811718A0979a|5 11|results
P09811718A0979a|32 42|association
P09811718A0979a|53 60|HIV-2 nef
P09811718A0979a|66 73|HIV-1 nef
P09811718A0979a|78 84|TCRzeta
P09811730A1396|0 14|Competition EMSA
P09811730A1396|60 67|proteins
P09811730A1396|76 85|KCS element
P09811730A1396|97 121|KCS protein binding activity
P09811730A1396|136 151|promoter activity
P09811730A1396|166 190|transfection reporter assay
P09811730T0000|0 8|Mechanism
P09811730T0000|11 26|interferon action
P09811730T0000|27 40|identification
P09811730T0000|52 60|positions
P09811730T0000|87 96|KCS element
P09811730T0000|123 132|activation
P09811730T0000|151 170|protein kinase pkr gene
P09813041A1122|21 35|phosphorylation
P09813041A1122|37 46|activation
P09813041A1122|64 69|kinase
P09813041A1122|77 86|conditions
P09813063T0000|0 9|Expression
P09813063T0000|24 44|phospholipase D homolog
P09813063T0000|70 80|development
P09813063T0000|86 94|forebrain
P09813093A0624|12 17|effect
P09813093A0624|28 34|YCL024W
P09813093A0624|50 60|combination
P09813093A0624|65 72|deletion
P09813098A0521|0 9|Paralemmin
P09813098A0521|110 115|manner
P09813110A0982|10 26|amino acid sequence
P09813110A0982|29 33|CBP90
P09813110A0982|50 59|similarity
P09813110A0982|70 76|protein
P09813110A0982|98 103|domain
P09813110A0982|119 124|region
P09813203T0000|3 8|effect
P09813203T0000|22 40|serine substitutions
P09813203T0000|46 51|V3 loop
P09813203T0000|54 71|HIV-1 gp120 IIIB/LAI
P09813203T0000|77 90|immunogenicity
P09813203T0000|96 110|envelope protein
P09813207A0434|0 28|Transcription start site mapping
P09813207A0434|42 49|presence
P09813207A0434|79 88|transcript
P09813207A0434|101 109|TAAG motif
P09813207A0434|123 133|nucleotides
P09813207A0434|167 176|transcript
P09813207A0434|193 201|TTGT motif
P09813207A0434|211 221|nucleotides
P09813207A0434|235 241|TATA box
P09813207A0434|248 258|nucleotides
P09813207A0434|263 269|respect
P09813254A0000|9 22|oligoadenylate
P09813254A0000|29 39|synthetases
P09813254A0000|42 48|members
P09813254A0000|52 67|family interferon
P09813254A0000|91 98|proteins
P09813259A1097|3 10|findings
P09813259A1097|37 44|blockade
P09813259A1097|60 70|sensitivity
P09813259A1097|91 96|injury
P09813635A0678|5 14|striations
P09813635A0678|27 33|contact
P09813635A0678|65 70|canine
P09813635A0678|107 113|complex
P09814637A1214|3 15|PbrO2 readings
P09814637A1214|43 58|microhemorrhages
P09814905A0598|3 14|consequences
P09814905A0598|26 40|swine production
P09814905A0598|46 56|environment
P09814905A0598|68 76|solutions
P09814905A0598|79 83|means
P09814905A0598|86 94|nutrition
P09815578A1245|4 8|study
P09815578A1245|25 34|alteration
P09815578A1245|37 41|CDKN2
P09815578A1245|71 83|abnormalities
P09815578A1245|86 99|prostate cancer
P09815578A1245|118 139|prostate carcinogenesis
P09815948A1065|18 27|parameters
P09815948A1065|51 60|toxicities
P09815948A1065|83 87|curve
P09815948A1065|90 104|peak plasma level
P09817131A0296|10 24|SF-36 survey form
P09817131A0296|50 67|translation process
P09817190A0074|17 28|cyclosporin A
P09817190A0074|55 64|prevalence
P09817190A0074|67 78|hypertension
P09817190A0074|81 106|kidney transplant recipients
P09817373A0000|0 6|PURPOSE
P09817373A0000|21 27|effects
P09817373A0000|30 49|hypercholesterolemia
P09817373A0000|101 113|insufficiency
P09817373A0000|132 141|muscle tone
P09817373A0000|148 160|oxide synthase
P09817373A0000|166 173|activity
P09817373A0000|186 200|tissue synthesis
P09817373A0000|203 224|constrictor eicosanoids
P09817601T0000|0 15|Characterization
P09817601T0000|31 37|regions
P09817601T0000|48 56|aromatase
P09817601T0000|57 64|P450arom
P09817601T0000|98 107|expression
P09819038A0448|11 15|FVIIa
P09819038A0448|30 41|infusion pump
P09819038A0448|60 74|room temperature
P09819038A0448|87 101|body temperature
P09819110A0703|0 12|CD4 lymphocyte
P09819110A0703|21 30|load levels
P09819110A0703|49 56|response
P09819110A0703|59 68|ARV therapy
P09819110A0703|74 79|time LD
P09819216A0220|4 15|Biochemistry
P09819288A0578|0 5|Levels
P09819288A0578|8 15|serum IgE
P09819288A0578|64 69|height
P09819288A0578|82 87|season
P09819377A1209|1 8|mutation
P09819377A1209|15 24|C2U4 repeat
P09819377A1209|31 47|underaccumulation
P09819377A1209|50 55|snR13F
P09819377A1209|63 71|mutations
P09819377A1209|78 87|C2U4 repeat
P09819377A1209|96 107|accumulation
P09819377A1209|146 150|range
P09819391A1123|38 52|tyrosine kinases
P09819391A1123|72 81|cell growth
P09819391A1123|97 108|organization
P09819391A1123|109 113|ASAP1
P09819391A1123|129 152|membrane remodeling events
P09819391A1123|162 170|processes
P09819411A0897|2 6|DNase
P09819411A0897|8 24|footprint analysis
P09819411A0897|30 39|PNR element
P09819411A0897|41 50|palindrome
P09819411A0897|80 84|sites
P09819411A0897|85 96|CTTCCCTGGAAG
P09819414A1103|12 17|nexins
P09819414A1103|43 49|isoform
P09819414A1103|55 68|leptin receptor
P09819414A1103|90 103|medium isoforms
P09819421A0000|0 11|Cyclophilins
P09819421A0000|40 49|isomerases
P09819421A0000|97 108|cyclosporin A
P09819422A0768|7 33|protein retention experiments
P09819422A0768|41 60|Hsp90 heterocomplexes
P09819422A0768|87 101|coprecipitation
P09819430A0000|14 20|GTPases
P09819430A0000|39 46|proteins
P09819430A0000|52 56|cycle
P09819430A0000|109 113|state
P09819440A0000|10 22|transcription
P09819440A0000|33 39|factors
P09819440A0000|60 79|transcription factors
P09819440A0000|86 99|RNA polymerases
P09819440A0000|103 109|variety
P09819440A0783|73 85|RNA polymerase
P09819440A0783|95 99|cells
P09819507A0000|6 10|study
P09819507A0000|11 17|rabbits
P09819507A0000|46 58|wound reaction
P09819507A0000|63 67|Dexon
P09819507A0000|70 74|nylon
P09819507A0000|119 139|trabeculectomy surgery
P09819507A0000|161 171|mitomycin-C
P09820163A0565|3 9|mapping
P09820163A0565|26 41|Southern blotting
P09820163A0565|45 63|restriction analysis
P09820205A0000|3 15|zona pellucida
P09820205A0000|36 45|glycocalyx
P09820205A0000|61 66|oocyte
P09820205A0000|97 113|gamete interaction
P09820611T0000|40 47|infusion
P09820611T0000|65 78|erythropoietin
P09820611T0000|93 103|predialysis
P09820611T0000|110 117|patients
P09820611T0000|130 140|nephropathy
P09820621A0067|20 34|thyroid function
P09820621A0067|46 52|changes
P09820621A0067|55 71|energy expenditure
P09820621A0067|75 89|body composition
P09820621A0067|101 109|influence
P09820621A0067|112 123|leptin levels
P09821978A1255|14 21|deficits
P09821978A1255|37 43|animals
P09821978A1255|55 60|MK-801
P09822602A0237|24 32|mechanism
P09822602A0237|35 44|activation
P09822602A0237|47 56|HIF-1alpha
P09822602A0237|70 76|process
P09822602A0237|114 119|import
P09822602A0237|123 132|activation
P09822602A0237|133 144|derepression
P09822602A0237|150 170|transactivation domain
P09822602A0237|182 192|recruitment
P09822602A0237|210 216|protein
P09822602A0237|221 235|p300 coactivator
P09822602A1172|28 33|import
P09822602A1172|37 51|transactivation
P09822602A1172|54 64|recruitment
P09822602A1172|127 131|roles
P09822602A1172|133 150|signal transduction
P09822602A1172|153 162|HIF-1alpha
P09822647A0000|3 18|rat aldolase C gene
P09822647A0000|37 42|enzyme
P09822647A0000|67 71|brain
P09822652A1118|12 17|effect
P09822652A1118|20 38|HCK promoter activity
P09822652A1118|56 69|concentrations
P09822661T0073|15 20|domain
P09822661T0073|24 40|amino acid residues
P09822661T0073|51 64|quinone binding
P09822685A0596|7 14|analyses
P09822685A0596|19 26|antisera
P09822685A0596|40 56|Lu-ECAM-1 peptides
P09822685A0596|78 83|region
P09822685A0596|102 113|reading frame
P09822685A0596|138 149|size proteins
P09822690A0000|9 21|sperm motility
P09822690A0000|36 42|cascade
P09822690A0000|59 86|protein phosphorylation events
P09822690A0000|97 111|protein kinase A.
P09822825A0141|6 10|paper
P09822825A0141|34 43|expression
P09822825A0141|48 55|BAP3 gene
P09822825A0141|84 91|addition
P09822825A0141|108 117|amino acids
P09822825A0141|123 128|medium
P09823014T0000|0 5|Effect
P09823014T0000|26 33|products
P09823014T0000|45 56|carbohydrate
P09823014T0000|67 73|indices
P09823014T0000|75 86|carbohydrate
P09823014T0000|90 104|lipid metabolism
P09823014T0000|107 114|patients
P09823014T0000|119 123|NIDDM
P09823561T0001|16 27|MALT lymphoma
P09823561T0001|31 52|helicobacter heilmannii
P09823561T0001|53 74|Gastrospirillum hominis
P09823775A1122|5 11|studies
P09823775A1122|32 35|HMG I
P09823775A1122|50 57|cofactor
P09823775A1122|60 80|HLA-DRA gene activation
P09823775A1122|83 88|Oct-2A
P09823775A1122|99 106|insights
P09823775A1122|114 122|mechanism
P09823775A1122|125 130|action
P09824001A1665|2 9|contrast
P09824001A1665|43 52|predictors
P09824001A1665|55 62|survival
P09824001A1665|93 102|techniques
P09824021A1263|0 9|CONCLUSION
P09824021A1263|32 39|features
P09824021A1263|42 48|disease
P09824021A1263|90 97|response
P09824021A1263|107 115|NO therapy
P09824021A1263|124 133|parameters
P09824158A1336|10 32|BCL-6 POZ domain mutations
P09824158A1336|47 57|interaction
P09824158A1336|62 66|N-CoR
P09824158A1336|91 103|transcription
P09826434T0000|7 22|characterization
P09826434T0000|45 73|platelet cAMP phosphodiesterase
P09826434T0000|73 77|PDE3A
P09826434T0000|93 103|mutagenesis
P09826658A0691|4 15|core sequence
P09826658A0691|56 66|nucleotides
P09826658A0691|89 99|suppression
P09826658A0691|113 120|assembly
P09826658A0691|124 131|splicing
P09826658A0691|134 147|BPV-1 pre-mRNAs
P09826778A0943|0 14|Over-expression
P09826778A0943|20 31|cofactor p300
P09826778A0943|49 59|coactivator
P09826778A0943|75 87|transcription
P09826778A0943|98 107|repression
P09826778A0943|110 116|COUP-TF
P09827446T0001|18 26|hepatitis
P09827446T0001|30 41|C4 deficiency
P09827724A1362|2 10|mutations
P09827724A1362|32 39|adenomas
P09827878A0091|5 25|glutathione peroxidase
P09827878A0091|34 52|superoxide dismutase
P09827878A0091|81 91|erythrocyte
P09827878A0091|103 109|defence
P09827878A0091|143 150|activity
P09827878A0091|174 180|workers
P09827993A0000|10 29|nucleocapsid proteins
P09827993A0000|48 65|zinc finger proteins
P09827993A0000|76 101|virion RNA binding activities
P09827993A0000|116 133|retrovirus assembly
P09827993A0000|144 159|RNA encapsidation
P09828137A0000|33 62|cell cycle checkpoint control gene
P09828137A0000|75 81|S-phase
P09828137A0000|85 94|G2/M arrest
P09828137A0000|97 104|response
P09828137A0000|111 119|DNA damage
P09828137A0000|133 146|DNA replication
P09829836A0000|26 36|progression
P09829836A0000|57 65|cell cycle
P09829836A0000|80 91|oscillations
P09829836A0000|97 104|activity
P09829836A0000|107 112|cyclin
P09829836A0000|122 128|kinases
P09829836A0815|15 24|selections
P09829836A0815|28 37|inhibition
P09829836A0815|40 57|cyclin/CDK function
P09829836A0815|95 108|yeast LEU2 genes
P09829843A0119|34 40|factors
P09829843A0119|76 83|practice
P09829843A0119|105 112|measures
P09829843A0119|129 137|incidence
P09829843A0119|150 162|complications
P09829843A0119|165 172|patients
P09829843A0119|177 182|cancer
P09829843A0119|186 196|neutropenia
P09829843A0819|3 12|injections
P09829843A0819|37 46|initiation
P09829843A0819|48 58|neutropenia
P09829843A0819|79 88|occurrence
P09829843A0819|101 118|neutrophil recovery
P09829843A0819|140 148|rHu GM-CSF
P09829843A0819|152 159|rHu G-CSF
P09829843A0819|189 195|microg m
P09829843A0819|207 214|microg kg
P09829843A0819|221 225|level
P09829843A0819|261 275|neutrophil count
P09829843A0819|279 296|neutrophil function
P09829843A0819|320 342|chemiluminescence system
P09829916T0000|0 9|Expression
P09829916T0000|25 32|promoter
P09829916T0000|55 60|operon
P09829916T0000|71 77|vectors
P09829916T0000|102 107|fusion
P09832099A0000|35 44|wall motion
P09832099A0000|51 57|systole
P09832099A0000|60 67|patients
P09832099A0000|90 98|tetralogy
P09832099A0000|101 106|Fallot
P09832099A0000|117 135|color kinesis imaging
P09832436A0738|0 13|RT-PCR analysis
P09832436A0738|24 28|PLP-H
P09832436A0738|37 41|PLP-C
P09832436A0738|45 49|PLP-D
P09832436A0738|67 76|rat strains
P09832436A0738|99 110|PLP diversity
P09832436A0738|127 137|differences
P09832436T0000|9 15|cloning
P09832436T0000|19 34|characterization
P09832436T0000|41 46|member
P09832436T0000|66 74|prolactin
P09832436T0000|79 84|family
P09832436T0000|92 100|protein H.
P09832504A0596|26 36|interaction
P09832504A0596|52 57|hCycT1
P09832504A0596|88 103|cysteine residues
P09832504A0596|109 116|proteins
P09832505A0903|22 37|activation target
P09832505A0903|46 54|activator
P09832505A0903|55 59|Oct-1
P09832505A0903|81 100|transcription complex
P09832511A0269|11 22|neurogenesis
P09832511A0269|23 32|Vnd protein
P09832511A0269|54 72|column neuroectoderm
P09832511A0269|76 86|neuroblasts
P09832511A0269|114 120|pattern
P09832511A0269|123 129|neurons
P09832518A0615|3 18|repression domain
P09832518A0615|37 48|Cdc68 protein
P09832518A0615|78 85|sequence
P09832518A0615|91 95|Cdc68
P09832518A0615|106 112|homolog
P09832518A0615|120 124|yeast
P09832518A0615|138 143|lactis
P09832518A0615|149 164|database searches
P09833610A0626|3 11|exodomain
P09833610A0626|27 41|affinity hormone
P09833610A0626|90 95|signal
P09833740A1112|0 25|Pyrrolidine dithiocarbamate
P09833740A1112|48 56|inhibitor
P09833740A1112|84 100|cytokine responses
P09833740A1112|113 122|ACH-2 cells
P09833740A1112|172 180|mechanism
P09833740A1112|188 196|cell types
P09833740A1112|218 222|modes
P09833740A1112|225 239|provirus latency
P09834070A0793|22 31|activation
P09834070A0793|53 59|absence
P09834070A0793|61 67|changes
P09834070A0793|106 115|inhibition
P09834070A0793|117 138|protein kinase C activity
P09834070A0793|161 167|pathway
P09834070A0793|190 202|B cell function
P09834521A0000|15 25|hydatid cyst
P09835615A0574|11 18|analysis
P09835615A0574|45 51|protein
P09835615A0574|79 94|repressor domains
P09836881A0441|10 17|BCH group
P09836881A0441|37 52|motor performance
P09836881A0441|58 80|Bruininks-Oseretsky Test
P09836881A0441|83 98|Motor Proficiency
P09836881A0441|99 107|Bruininks
P09837714A1068|3 9|results
P09837714A1068|18 28|possibility
P09837714A1068|62 74|modifications
P09837714A1068|76 80|DdRPA
P09837714A1068|94 99|events
P09837714A1068|108 124|cell proliferation
P09837714A1068|134 148|differentiation
P09837714A1068|151 163|Dictyostelium
P09837715A0581|28 33|amount
P09837715A0581|55 59|level
P09837715A0581|61 92|chloramphenicol acetyltransferase
P09837715A0581|131 135|cells
P09837715A0581|145 149|HIV-1
P09837715A0581|159 171|leukemia virus
P09837715A0581|177 205|SL3-3 LTR-CAT reporter construct
P09837824A0419|12 26|telSMN mutations
P09837824A0419|55 65|individuals
P09837824A0419|89 94|telSMN
P09837824A0419|109 127|frameshift mutations
P09837824A0419|128 135|800ins11
P09837824A0419|139 146|542delGT
P09837824A0419|155 171|missense mutations
P09837824A0419|177 181|S262I
P09837824A0419|184 188|T274I
P09837907A0857|3 10|decrease
P09837907A0857|13 24|TNF receptors
P09837907A0857|49 63|down-regulation
P09837907A0857|76 85|activities
P09837907A0857|95 106|cytotoxicity
P09837907A0857|107 125|caspase-3 activation
P09837907A0857|126 134|NF-kappaB
P09837907A0857|138 151|AP-1 activation
P09837907A0857|155 159|c-Jun
P09837907A0857|170 184|kinase induction
P09837913A0000|7 16|deiodinase
P09837913A0000|32 43|deiodination
P09837913A0000|45 53|thyroxine
P09837913A0000|64 79|triiodothyronine
P09837913A0419|39 55|sequence tag clones
P09837920A0222|35 46|requirements
P09837920A0222|50 61|consequences
P09837920A0222|74 88|phosphorylation
P09837920A0222|95 105|interaction
P09837920A0222|113 117|c-Jun
P09837933T0000|0 5|P-CIP1
P09837933T0000|12 18|protein
P09837933T0000|48 53|domain
P09837933T0000|56 70|peptidylglycine
P09837933T0000|86 98|monooxygenase
P09837933T0000|115 123|endosomes
P09837945A0820|0 17|Immunolocalization
P09837945A0820|20 24|Sop1p
P09837945A0820|45 56|distribution
P09837945A0820|60 83|cell fractionation studies
P09837945A0820|106 113|fraction
P09837945A0820|116 120|Sop1p
P09837945A0820|148 155|fraction
P09837945A0820|170 177|material
P09837978T0093|9 18|activation
P09837978T0093|21 25|c-Jun
P09837978T0093|59 71|protein kinase
P09837978T0093|72 79|JNK/SAPK
P09838122A0489|26 43|coding cDNA sequence
P09838122A0489|49 62|mouse homologue
P09840822A0462|3 8|method
P09840822A0462|23 29|tagging
P09840822A0462|46 52|concern
P09840822A0462|68 95|magnetization transfer effects
P09840928A0884|45 58|core histones H3
P09840928A0884|81 90|substrates
P09840928A0884|102 110|histone H3
P09840928A0884|113 124|kinase assays
P09840928A0884|136 143|extracts
P09840932A0365|6 10|study
P09840932A0365|20 27|evidence
P09840932A0365|32 36|B-Myb
P09840932A0365|59 64|target
P09840932A0365|68 79|cyclin A/Cdk2
P09840934A0435|7 12|Ha-Ras
P09840934A0435|25 36|Ha-RasV12S35
P09840934A0435|52 71|Rafl signaling pathway
P09840934A0435|75 80|Ha-Ras
P09840934A0435|92 103|Ha-RasV12G37
P09840934A0435|120 132|RalGDS pathway
P09840934A0435|154 160|effects
P09840934A0435|180 188|apoptosis
P09840934A0435|198 202|cells
P09840943A0144|25 30|cyclin
P09840943A0144|31 38|cyclin E2
P09840943A0144|62 69|homology
P09840943A0144|72 79|cyclin E.
P09842517A0497|7 16|experience
P09842517A0497|27 36|technology
P09842517A0497|50 57|SieScape
P09842517A0497|80 86|methods
P09843378A0187|3 20|dopamine D4 receptor
P09843378A0187|55 63|receptors
P09843378A0187|86 102|SH3 binding domains
P09843412A0130|40 44|Abeta
P09843412A0130|44 50|Abeta42
P09843412A0130|61 67|species
P09843572A0944|4 8|model
P09843572A0944|22 32|experiments
P09843572A0944|44 57|Cdr2 associates
P09843572A0944|85 90|domain
P09843572A0944|101 111|cell lysates
P09843577A0000|24 28|cells
P09843577A0000|46 56|deprivation
P09843577A0000|67 85|G2/M cell size control
P09843944A0976|0 7|A-tracts
P09843944A0976|49 55|hexamer
P09843944A0976|130 146|UP element function
P09844106A0835|4 18|phosphorylation
P09844106A0835|32 40|adherence
P09844106A0835|52 56|cells
P09844106A0835|58 68|fibronectin
P09844106A0835|86 90|cells
P09844921A0000|11 39|serine-threonine protein kinase
P09844921A0000|61 72|transmission
P09844921A0000|75 80|growth
P09844921A0000|98 120|differentiation messages
P09845043A0000|3 21|US National Institute
P09845043A0000|24 35|Alcohol Abuse
P09845043A0000|39 48|Alcoholism
P09845043A0000|49 53|NIAAA
P09845043A0000|67 71|forms
P09845043A0000|85 92|drinking
P09845043A0000|100 111|alcohol abuse
P09845043A0000|124 130|problem
P09845043A0000|134 150|alcohol dependence
P09845043A0000|163 170|disorder
P09845043A0000|192 200|component
P09845662A0085|0 7|Collagen
P09845662A0085|56 63|collagen
P09845662A0085|76 80|means
P09845662A0085|83 95|sodium dodecyl
P09845662A0085|118 135|gel electrophoresis
P09845662A0085|136 143|SDS-PAGE
P09845856A0560|0 6|RESULTS
P09845856A0560|22 27|period
P09845856A0560|53 65|ulcer diseases
P09846033A0488|0 6|RESULTS
P09846033A0488|18 24|changes
P09846033A0488|29 40|pretreatment
P09846033A0488|43 55|posttreatment
P09846482A0441|8 15|assembly
P09846482A0441|21 27|complex
P09846482A0441|48 57|activation
P09846482A0441|76 88|protein kinase
P09846482A0441|104 122|actin polymerization
P09846927A0227|13 18|button
P09846927A0227|25 35|perforation
P09846927A0227|50 60|stomach wall
P09846927A0227|70 74|death
P09847371A0000|0 19|Jembrana disease virus
P09847371A0000|49 58|lentivirus
P09847371A0000|89 109|immunodeficiency virus
P09847397A0935|22 29|residues
P09847397A0935|54 62|sequences
P09847397A0935|74 80|viruses
P09847397A0935|93 108|response elements
P09847397A0935|112 126|glucocorticoids
P09847397A0935|151 160|CCAAT boxes
P09847397A0935|185 193|TATA boxes
P09848653A0597|0 4|Nhp2p
P09848653A0597|19 25|protein
P09848653A0597|40 45|family
P09848653A0597|67 74|proteins
P09849421A0332|4 9|survey
P09849421A0332|38 47|Norwegians
P09849421A0332|55 59|years
P09849421A0332|89 100|Organization
P09849421A0332|103 110|Research
P09849421A0332|114 122|Treatment
P09849421A0332|125 141|Cancer Core Quality
P09849421A0332|144 160|Life Questionnaire
P09849421A0332|161 172|EORTC QLQ-C30
P09849722A0797|6 17|presentation
P09849722A0797|31 41|expressions
P09849722A0797|53 66|signal increase
P09849722A0797|97 110|cingulate gyrus
P09849722A0797|129 141|cingulate gyri
P09849722A0797|155 160|cortex
P09849722A0797|182 186|gyrus
P09849722A0797|187 198|brain regions
P09849722A0797|236 257|emotion processing tasks
P09849961A0387|0 14|Down-regulation
P09849961A0387|17 21|IRS-1
P09849961A0387|35 55|serine phosphorylation
P09849961A0387|67 84|PI 3-kinase activity
P09849961A0387|106 120|differentiation
P09849961A0387|130 134|IRS-1
P09849961A0387|193 208|myoblast cell line
P09849965A0000|4 8|study
P09849965A0000|39 44|system
P09849965A0000|65 70|ligand
P09849965A0000|75 86|dimerization
P09849965A0000|94 113|progesterone receptor
P09851614A0109|14 21|features
P09851614A0109|62 68|regions
P09851614A0109|77 87|nucleotides
P09851614A0109|106 112|absence
P09851614A0109|114 126|cap structures
P09851614A0109|134 138|mRNAs
P09851700A0000|22 52|tissue-type plasminogen activator
P09851700A0000|90 95|manner
P09851988A0085|7 14|presence
P09851988A0085|17 24|arginine
P09851988A0085|28 39|anaerobiosis
P09851988A0085|58 66|induction
P09851988A0085|72 78|pathway
P09852005A1287|0 10|Competition
P09852005A1287|24 50|MADS box consensus binding site
P09852005A1287|58 65|promoter
P09852005A1287|113 120|gene PEP1
P09852005A1287|138 164|MADS box consensus binding site
P09852005A1287|167 185|serum response factor
P09852005A1287|215 223|complexes
P09852005A1287|246 256|OP4 sequence
P09852068A0150b|22 29|promoter
P09852068A0150b|42 46|DNase
P09852068A0150b|48 59|footprinting
P09852068A0150b|76 87|significance
P09852068A0150b|102 108|regions
P09852068A0150b|109 115|FP1-FP6
P09852068A0150b|133 140|promoter
P09852068A0150b|158 181|HepG2 hepatoblastoma cells
P09852109A1475|7 17|translation
P09852109A1475|35 49|profile analysis
P09852109A1475|63 74|transcripts C
P09852109A1475|119 130|efficiencies
P09852109A1475|167 177|transcript D
P09852109A1475|204 210|regions
P09852109A1475|237 243|control
P09852136A0174|17 24|mutation
P09852136A0174|25 29|Ser36
P09852136A0174|45 50|domain
P09852136A0174|74 80|ability
P09852136A0174|86 102|guanine nucleotide
P09852136A0174|119 131|hemagglutinin
P09852136A0174|141 147|protein
P09852136A0174|149 156|COS cells
P09852136A0507|0 14|Wild type HA-p190
P09852136A0507|23 31|phenotype
P09852136A0507|41 45|cells
P09852136A0507|60 69|extensions
P09852136A0507|91 101|Rho function
P09852136A0507|115 130|ADP-ribosylation
P09852752A0950|30 39|vasculitis
P09852752A0950|58 69|complication
P09854034A0536|22 29|promoter
P09854034A0536|37 46|G+C content
P09854034A0536|50 55|exon 1b
P09854034A0536|92 102|mRNA species
P09855111A0905|23 36|overexpression
P09855111A0905|55 61|domains
P09855111A0905|95 104|regulation
P09855111A0905|107 121|SREBP processing
P09855111A0905|135 144|disruption
P09855111A0905|180 189|regulation
P09855111A0905|199 203|genes
P09855111A0905|207 216|mRNA levels
P09855111A0905|246 254|coenzyme A
P09855111A0905|255 260|HMG CoA
P09855111A0905|261 268|synthase
P09855111A0905|279 287|cell lines
P09855111A0905|320 325|manner
P09856397A0099|0 14|Dry matter intake
P09856397A0099|23 45|nutrient digestibilities
P09856397A0099|46 67|serum chemistry profiles
P09856397A0099|68 93|sphingolipid concentrations
P09856397A0099|97 107|persistency
P09856397A0099|117 123|tissues
P09856732A0114|9 15|studies
P09856732A0114|77 82|effect
P09856732A0114|85 93|lidocaine
P09857038A1374|4 8|Scott
P09857197A0289|0 4|Yap1p
P09857197A0289|31 40|crm1 mutant
P09857197A0289|44 48|Crm1p
P09857197A0289|64 77|export sequence
P09857197A0289|86 93|sequence
P09857197A0289|95 99|Yap1p
P09857197A0289|105 112|presence
P09857197A0289|115 120|RanGTP
P09857265A0669|0 9|Mean intake
P09857265A0669|12 19|vitamin A
P09857265A0669|39 46|mg RE/day
P09857265A0669|58 62|women
P09857265A0669|77 89|contributions
P09857265A0669|113 122|vegetables
P09857265A0669|123 135|dairy products
P09857265A0669|143 148|intake
P09858094A0583|7 15|amplitude
P09858094A0583|32 41|potentials
P09858094A0583|99 104|period
P09858531A1017|11 29|RING1 overexpression
P09858531A1017|47 56|expression
P09858531A1017|62 81|proto-oncogenes c-jun
P09858531A1017|85 89|c-fos
P09858571T0000|3 15|yeast RER2 gene
P09858571T0000|39 75|reticulum protein localization mutations
P09858571T0000|83 103|cis-prenyltransferase
P09858571T0000|108 113|enzyme
P09858571T0000|116 132|dolichol synthesis
P09858572A0000|3 25|yeast retrotransposon Ty5
P09858572A0000|54 60|regions
P09858572A0000|69 77|chromatin
P09858577A1186|35 48|ENA1 expression
P09858577A1186|50 59|hog1 mutant
P09858577A1186|92 108|stress sensitivity
P09858577A1186|119 123|Sko1p
P09858577A1186|137 144|effector
P09858577A1186|150 159|HOG pathway
P09858581A0183|8 17|expression
P09858581A0183|52 57|SPP381
P09858581A0183|81 86|growth
P09858581A0183|90 104|splicing defects
P09858581A0183|139 145|prp38-1
P09858588A1046|63 67|cells
P09858588A1046|90 94|cells
P09858593A0334|16 33|amino acid sequences
P09858593A0334|48 67|Xenopus NeuroD1/BETA2
P09858593A0334|87 107|insulin gene expression
P09858593A0334|118 129|neurogenesis
P09858599A0392|4 22|NUP98-HOXA9 chimeras
P09858599A0392|34 50|NIH 3T3 fibroblasts
P09858599A0392|58 71|transformation
P09858599A0392|83 94|HOXA9 domains
P09858599A0392|98 107|DNA binding
P09858599A0392|111 124|PBX interaction
P09858619A0356|6 12|studies
P09858619A0356|58 71|ZAP-70 function
P09858713A1174|104 115|transduction
P09858713A1174|117 124|Wg signal
P09858713A1174|144 150|animals
P09858713A1174|164 174|enhancement
P09858713A1174|180 203|gain-of-function activity
P09858713A1174|223 229|mutants
P09858714A1171|12 16|dda.2
P09858714A1171|43 66|shares sequence similarity
P09858714A1171|69 75|sigma70
P09858745A1350|3 10|location
P09858745A1350|55 67|cooperativity
P09858745A1350|75 93|footprinting studies
P09858745A1350|104 110|studies
P09858745A1350|147 157|interaction
P09858745A1350|180 191|binding sites
P09858745A2033|7 25|transcription assays
P09858745A2033|53 64|intermediate
P09858745A2033|65 72|fumarate
P09858745A2033|107 115|formation
P09858745A2033|121 134|clcA transcript
P09858883A1106|0 14|BIAcore analysis
P09858883A1106|46 52|binding
P09858883A1106|61 65|T84.1
P09858883A1106|85 91|binding
P09860979A0521|0 9|Expression
P09860979A0521|33 46|binding protein
P09860979A0521|50 62|Crk SH2-domain
P09860979A0521|74 86|JNK activation
P09861099A1011|8 19|correlations
P09861099A1011|38 49|measurements
P09861099A1011|53 65|protein intake
P09861099A1011|80 91|energy intake
P09861099A1011|113 123|differences
P09861099A1011|127 132|g/kg/d
P09861099A1011|143 153|kcal/kg/day
P09861365A0000|3 7|Og4C3
P09861365A0000|34 38|assay
P09861365A0000|39 43|ELISA
P09861365A0000|82 88|antigen
P09861365A0000|95 100|microL
P09861365A0000|103 107|serum
P09862343A0225|13 29|gp200-MR6 ligation
P09862343A0225|91 99|influence
P09862343A0225|114 119|system
P09862343A0225|127 139|up-regulation
P09862343A0225|156 164|molecules
P09862343A0225|167 178|B lymphocytes
P09862481A0000|3 15|Mig1 repressor
P09862481A0000|19 35|zinc finger protein
P09862481A0000|48 64|glucose repression
P09862481A0000|67 71|yeast
P09862496A0187|0 7|Ethylene
P09862496A0187|20 35|endosperm rupture
P09862496A0187|49 66|betaGLU I expression
P09862496A0187|106 112|pattern
P09862496A0187|115 132|betaGLU I expression
P09863624A0629|3 12|divergence
P09863624A0629|22 30|structure
P09863624A0629|41 49|sheep CRF1
P09863624A0629|70 74|CRF1s
P09863624A0629|113 117|amino
P09863624A0629|126 131|domain
P09863624A0629|137 144|receptor
P09863624A0629|160 167|residues
P09863624A0629|168 172|ovine
P09863624A2301|15 37|receptor internalization
P09863624A2301|53 59|percent
P09863624A2301|62 66|total
P09863624A2301|73 81|Tyr0-oCRF
P09863624A2301|112 119|fraction
P09863624A2301|139 143|cells
P09863624A2301|175 182|degrees C
P09863624A2301|207 211|oCRF1
P09863720T0000|27 33|disease
P09863720T0000|41 45|onset
P09863720T0000|49 66|protein S deficiency
P09864141A0528|12 16|Stat3
P09864141A0528|20 28|Stat3beta
P09864141A0528|33 40|affinity
P09864141A0528|54 68|phosphopeptides
P09864141A0528|119 134|peptide analogues
P09864141A0528|137 151|phosphopeptides
P09864335A1226|16 22|results
P09864335A1226|38 45|FCR1 gene
P09864335A1226|64 72|regulator
P09864335A1226|75 88|drug resistance
P09864335A1226|91 100|C. albicans
P09864335A1226|122 129|evidence
P09864335A1226|134 146|FCZ resistance
P09864335A1226|163 174|inactivation
P09864335A1226|188 193|factor
P09864335A1226|200 204|Fcr1p
P09864689A1408|5 12|findings
P09864689A1408|28 32|MYO/M
P09864689A1408|49 59|washout rate
P09864689A1408|71 76|effect
P09864689A1408|79 87|treatment
P09864689A1408|90 101|heart failure
P09865775A0162|4 8|study
P09865775A0162|35 42|couplers
P09865775A0162|51 59|placement
P09865775A0162|69 73|ALGO2
P09865775A0162|87 96|properties
P09866068A1058|0 10|CONCLUSIONS
P09866068A1058|11 22|Pretreatment
P09866068A1058|48 58|suppression
P09866068A1058|78 82|phase
P09866068A1058|99 111|cyst formation
P09866068A1058|129 134|effect
P09866068A1058|157 167|recruitment
P09866068A1058|170 183|pregnancy rates
P09867159A1444|4 9|regard
P09867159A1444|22 36|threshold values
P09867159A1444|37 47|sensitivity
P09867159A1444|51 61|specificity
P09867159A1444|88 93|FDG PET
P09867253A0229|4 16|c-Jun activity
P09867253A0229|30 34|c-Fos
P09867253A0229|42 57|protooncoprotein
P09867253A0229|77 81|c-Jun
P09867253A0229|91 113|transcription factor AP-1
P09867855T0000|0 16|Dorsal root ganglia
P09867855T0000|32 47|promoter activity
P09867855T0000|53 105|rabbit beta-galactoside alpha1,2-fucosyltransferase gene
P09868412A1628|0 9|CONCLUSION
P09868412A1628|13 17|study
P09868412A1628|33 39|body BMD
P09868412A1628|50 56|neck BMD
P09868412A1628|85 94|study group
P09868412A1628|122 130|exercises
P09868412A1628|144 151|subjects
P09868412A1628|153 168|swimming exercise
P09868412A1628|174 179|effect
P09868412A1628|199 206|swimming
P09868412A1628|225 232|exercise
P09868412A1628|258 265|shoulder
P09868412A1628|273 290|grip muscle strength
P09869297A1807|12 16|roles
P09869297A1807|35 45|CE2 elements
P09869297A1807|57 75|Hoxb1 gene expression
P09869297A1807|82 92|development
P09869356A0926|0 6|CAL gain
P09869356A0926|36 42|defects
P09869356A0926|48 54|CAL gain
P09869400A0203|0 10|Comparisons
P09869400A0203|25 31|germins
P09869400A0203|46 53|proteins
P09869400A0203|71 95|Arabidopsis GLP subfamilies
P09869400A0203|109 119|wheat germin
P09869528T0000|4 11|fixation
P09869528T0000|32 39|RF energy
P09871353A0174|25 32|evidence
P09871353A0174|35 57|A. salmonicida infections
P09871353A0174|70 81|furunculosis
P09872326A0566|34 41|CBF/cdc2
P09872326A0566|87 102|heat shock protein
P09872326A0566|104 111|promoter
P09872337A0000|15 24|absorption
P09872337A0000|27 37|clindamycin
P09872337A0000|61 70|volunteers
P09872337A0000|96 106|clindamycin
P09872337A0000|107 110|% w/v
P09872337A0000|110 118|tretinoin
P09872337A0000|123 126|% w/v
P09872337A0000|143 167|clindamycin phosphate ester
P09872337A0000|170 183|clindamycin HCl
P09872337A0000|207 232|clindamycin phosphate lotion
P09872337A0000|233 244|% clindamycin
P09872337A0000|245 252|Dalacin T
P09872832A1262|3 19|BAL concentrations
P09872832A1262|29 37|cytokines
P09872832A1262|72 76|lungs
P09872832A1262|89 101|interleukin-6
P09872832A1262|114 118|IL-12
P09872832A1262|117 141|tumor necrosis factor-alpha
P09872832A1262|142 150|TNF-alpha
P09872832A1262|154 168|interferon gamma
P09872832A1262|169 177|IFN-gamma
P09872832A1262|195 205|differences
P09873060A0901|0 22|Phosphorylation analyses
P09873060A0901|36 45|inhibition
P09873060A0901|48 52|ERK-1
P09873060A0901|82 96|phosphorylation
P09873291A0620|7 14|analysis
P09873291A0620|17 24|variance
P09873291A0620|59 72|knowledge score
P09873291A0620|86 98|patient groups
P09874803A0000|18 45|bacterium group A Streptococcus
P09874803A0000|69 84|cysteine protease
P09874803A0000|107 115|exotoxin B
P09874803A0000|137 151|virulence factor
P09874803A0000|162 176|disease episodes
P09875541A0210|3 15|orbitofrontal
P09875541A0210|51 69|dorsal premotor areas
P09875541A0210|115 130|hand movement task
P09876794T0000|0 8|Improving
P09876794T0000|12 23|evidence base
P09876794T0000|27 37|anaesthesia
P09877417A0704|0 14|Plasma CCK levels
P09877417A0704|38 46|intervals
P09878256A0000|3 31|peroxisome biogenesis disorders
P09878256A0000|62 69|diseases
P09878256A0000|103 114|deficiencies
P09878256A0000|126 138|abnormalities
P09878256A0000|145 155|retardation
P09878256A0000|168 172|death
P09878437A0967|32 41|triad Asp53
P09878437A0967|52 66|phosphorylation
P09878437A0967|66 70|Asp10
P09878542A1151|19 26|findings
P09878542A1151|56 64|silencing
P09878542A1151|100 114|osteopontin VDRE
P09879766A0402|2 6|PAV-3
P09879766A0402|10 18|E1A region
P09879766A0402|44 51|map units
P09880029A0703|11 27|MDV genome products
P09880029A0703|59 66|proteins
P09880029A0703|84 100|amino acid identity
P09880029A0703|121 133|FBNYV proteins
P09880029A0703|149 159|Rep proteins
P09880029A0703|169 174|MDV-C2
P09880029A0703|225 231|SCSV-C2
P09880103A0387|20 26|mCi 125I
P09880103A0387|29 37|technique
P09880103A0387|40 52|self-labeling
P09880103A0387|58 65|presence
P09880103A0387|71 87|M hydrogen peroxide
P09880327A0322|14 20|variety
P09880327A0322|48 55|proteins
P09880327A0322|64 73|yeast Uso1p
P09880327A0322|85 91|protein
P09880327A0322|102 108|docking
P09880327A0322|139 146|vesicles
P09880512A1251|66 74|receptors
P09880513A1013|4 11|proteins
P09880513A1013|53 59|tubulin
P09880543A0570|22 30|MA protein
P09880543A0570|60 69|yeast cells
P09880544A0693|13 32|DT-40 lymphoma B-cells
P09880544A0693|69 78|disruption
P09880544A0693|84 90|btk gene
P09880544A0693|103 123|recombination knockout
P09880544A0693|133 141|apoptosis
P09880544A0693|147 157|Fas ligation
P09880544A0693|170 179|DT-40 cells
P09880544A0693|195 204|DT-40 cells
P09880544A0693|236 242|btk gene
P09881666A0535|1 5|motif
P09881666A0535|6 13|TGATGTCA
P09881666A0535|27 34|CREB site
P09881666A0535|51 58|AP-1 site
P09881692A0094|34 41|variants
P09881692A0094|105 120|Ckappa1 gene locus
P09881692A1109|11 15|order
P09881692A1109|36 40|genes
P09881692A1109|64 79|oligonucleotides
P09881692A1109|100 108|probe DNAs
P09881692A1109|142 148|rabbits
P09881692A1109|150 165|Southern blotting
P09882303A1413|0 4|TRAF2
P09882303A1413|27 31|TRADD
P09882303A1413|35 44|expression
P09882303A1413|75 93|deletion TRAF2 mutant
P09882303A1413|132 144|JNK activation
P09882303A1413|150 154|cells
P09882303A1984|34 38|TRADD
P09882303A1984|40 44|TRAF2
P09882303A1984|47 59|JNK activation
P09882303A1984|88 107|signalling mechanisms
P09882303A1984|116 137|TNF receptor/CD40 family
P09882303A1984|160 169|activities
P09882303T0000|31 45|membrane protein
P09882303T0000|59 68|JNK pathway
P09882303T0000|86 94|C terminus
P09882303T0000|99 107|mechanism
P09882303T0000|117 121|TRADD
P09882303T0000|125 129|TRAF2
P09882321A0948|2 9|contrast
P09882321A0948|32 36|cells
P09882321A0948|47 52|EBNA-3
P09882321A0948|69 76|increase
P09882321A0948|79 101|EBNA-3 protein expression
P09882321A0948|116 125|EBNA-3 gene
P09882321A0948|136 145|EBNA-3 cDNA
P09882334A0822|13 20|passages
P09882334A0822|28 37|lamb kidney
P09882334A0822|43 47|cells
P09882334A0822|66 74|infection
P09882334A0822|98 109|transfection
P09882334A0822|121 128|mutation
P09882334A0822|138 152|tyrosine residue
P09882334A0822|168 172|motif
P09882334A0822|195 205|propagation
P09882334A0822|211 215|virus
P09882337A0000|0 20|Varicella-zoster virus
P09882337A0000|26 39|glycoprotein gI
P09882337A0000|49 73|transmembrane glycoprotein
P09882337A0000|83 91|component
P09882337A0000|113 131|gI Fc receptor complex
P09882348A0611|24 44|phosphorylation status
P09882348A0611|56 78|tyrosine kinase substrate
P09882348A0611|94 110|Shc adapter protein
P09882348A0611|113 123|fibroblasts
P09882348A0611|142 149|oncogene
P09882451A0195|5 9|genes
P09882451A0195|49 54|mutant
P09882451A0195|75 92|ferrochelatase gene
P09882451A0195|93 97|HEM15
P09882451A0195|118 127|phenotypes
P09882451A0195|133 145|transformants
P09882489A0451|6 10|study
P09882489A0451|11 18|evidence
P09882489A0451|64 77|mef2 expression
P09882489A0451|100 104|array
P09882489A0451|127 133|modules
P09882489A0451|169 175|signals
P09882499A0231|26 40|mouse technology
P09882499A0231|77 84|elements
P09882499A0231|114 123|expression
P09882593A0996|11 20|experiment
P09882593A0996|28 40|nickel isotope
P09882593A0996|57 69|drinking water
P09882593A0996|90 94|women
P09882593A0996|111 118|controls
P09882593A0996|123 128|groups
P09882593A0996|144 153|hand eczema
P09882593A0996|159 171|pompholyx type
P09882638A0235|6 11|tissue
P09882638A0235|22 35|collagen fibers
P09882638A0235|41 55|tunica albuginea
P09882638A0235|65 73|expansion
P09882638A0235|80 87|erection
P09883639A0000|0 5|Number
P09883639A0000|8 15|patients
P09883639A0000|42 53|mycobacteria
P09883639A0000|89 93|years
P09884232A0286|0 9|Comparison
P09884232A0286|15 23|sequences
P09884232A0286|58 70|junctions attL
P09884232A0286|97 108|core sequence
P09884232A0286|112 124|recombination
P09884232A0286|130 134|place
P09884232A0286|153 165|integrase gene
P09884275T0000|0 24|Interferon-alpha treatment
P09884275T0000|60 67|disorder
P09884275T0000|70 79|recipients
P09884275T0000|87 102|organ transplants
P09884747A0477|13 19|testing
P09884747A0477|37 50|brewery workers
P09884747A0477|58 74|control volunteers
P09884747A0477|80 95|skin prick testing
P09884747A0477|104 109|barley
P09884747A0477|113 125|yeast antigens
P09884747A0477|154 162|allergens
P09884747A0477|184 197|serum IgE levels
P09885431A0000|0 8|OBJECTIVE
P09885431A0000|22 29|accuracy
P09885431A0000|47 51|crown
P09885431A0000|55 72|bridge restorations
P09885431A0000|100 107|silicone
P09885431A0000|118 136|impression materials
P09885431A0000|151 155|types
P09885431A0000|158 166|stock tray
P09886602A0000|0 9|OBJECTIVES
P09886602A0000|21 27|ability
P09886602A0000|30 41|pretreatment
P09886602A0000|76 82|antigen
P09886602A0000|88 99|measurements
P09886602A0000|107 116|tumor stage
P09886602A0000|117 126|tumor grade
P09886602A0000|127 136|Gleason sum
P09886602A0000|151 163|radiation dose
P09886602A0000|174 183|recurrence
P09886602A0000|186 199|prostate cancer
P09886602A0000|217 236|beam radiation therapy
P09886602A0000|250 261|introduction
P09886602A0000|271 281|tumor marker
P09886602A0000|294 303|care center
P09886843A0339|38 43|target
P09886843A0339|45 58|thyroid hormone
P09886843A0339|89 96|elements
P09886843A0339|118 126|fragments
P09886850A0145|18 25|activity
P09886850A0145|28 36|PPARgamma
P09886850A0145|60 72|ligand binding
P09886850A0145|97 111|phosphorylation
P09886850A0145|125 147|MEK/ERK signaling pathway
P09887544A0000|0 9|BACKGROUND
P09887544A0000|10 17|Diazepam
P09887544A0000|26 44|benzodiazepine group
P09887544A0000|47 59|tranquilizers
P09887544A0000|89 96|sedation
P09887544A0000|102 107|relief
P09887544A0000|110 116|anxiety
P09887544A0000|122 130|treatment
P09887544A0000|133 140|epilepsy
P09888711A0781|0 20|Bioplastique granuloma
P09888711A0781|56 61|spaces
P09888711A0781|126 131|bodies
P09888711A0781|138 154|Artecoll granuloma
P09888711A0781|168 180|round vacuoles
P09888711A0781|207 211|shape
P09888711A0781|220 224|round
P09888711A0781|281 286|bodies
P09888994A0858|55 71|mesoderm formation
P09888994A0858|74 86|somitogenesis
P09888994A0858|94 99|embryo
P09889202T0000|18 25|analysis
P09889202T0000|44 55|domain Zalpha
P09889202T0000|58 84|dsRNA adenosine deaminase type
P09889202T0000|93 102|similarity
P09889202T0000|108 112|alpha
P09889202T0000|120 125|family
P09889202T0000|143 150|proteins
P09889306A0321|2 9|addition
P09889306A0321|13 22|regulation
P09889306A0321|25 44|Glvr-1 gene expression
P09889306A0321|61 72|applications
P09889306A0321|75 85|gene therapy
P09889306A0321|101 107|vectors
P09889306A0321|122 153|ape leukemia virus envelope proteins
P09889306A0321|164 175|gene delivery
P09889306A0321|189 197|cell types
P09890778T0000|0 12|Carbohydrates
P09890778T0000|16 30|glycoconjugates
P09890778T0000|42 48|methods
P09891009T0000|9 15|cloning
P09891009T0000|18 38|mouse glycolate oxidase
P09891046A0269|7 12|manner
P09891046A0269|35 44|cell growth
P09891046A0269|54 62|apoptosis
P09891046A0269|70 79|disruption
P09891046A0269|88 99|PKR signaling
P09891046A0269|120 129|cell growth
P09891046A0554|20 29|protein L18
P09891046A0554|32 42|interaction
P09891049A0761|0 9|Processing
P09891049A0761|28 36|precursor
P09891049A0761|45 53|nucleases
P09891049A0761|68 81|rRNA processing
P09891049A0761|86 90|Rnt1p
P09891049A0761|94 98|Rat1p
P09891061A0373|26 35|regulators
P09891061A0373|43 50|fragment
P09891061A0373|56 67|SpHE promoter
P09891061A0373|95 102|elements
P09891061A0373|158 167|cis element
P09891061A1240|43 51|regulator
P09891061A1240|54 59|timing
P09891061A1240|62 81|SpEts4 gene expression
P09891061A1240|102 111|expression
P09891061A1240|134 150|sea urchin blastula
P09891065A1493|24 36|SRE activation
P09891065A1493|65 71|mutants
P09891065A1493|74 82|PKC-alpha
P09891065A1493|85 95|PKC-epsilon
P09891085A0815|14 18|cells
P09891085A0815|35 41|defects
P09891085A0815|58 62|cells
P09891085A0815|88 100|27S precursors
P09891092A1000|32 40|stem-loop
P09891092A1000|43 52|structures
P09891092A1000|75 86|end formation
P09891707A0000|13 20|subtypes
P09891707A0000|23 41|spondyloarthropathy
P09892017A2151|7 17|experiments
P09892017A2151|75 93|receptor functioning
P09892021A0712|0 13|Overexpression
P09892021A0712|35 45|NIH 3T3 cells
P09892021A0712|59 68|expression
P09892021A0712|72 80|secretion
P09892021A0712|88 109|fibroblast growth factor
P09892021A0712|125 129|tumor
P09892021A0712|147 152|factor
P09892422A1096|27 38|tissue sheath
P09892422A1096|65 75|contraction
P09892422A1096|81 90|myocardium
P09892422A1096|110 115|spread
P09892422A1096|118 127|conduction
P09892422A1096|143 154|transmission
P09892422A1096|160 166|impulse
P09892422A1096|176 186|termination
P09892422A1096|192 204|purkinje fibre
P09892642A0172|5 15|DNA helicase
P09892642A0172|34 45|HPV E2 protein
P09892642A0172|61 71|replication
P09892662A0334|15 32|mutant alpha subunit
P09892662A0334|75 84|activation
P09892662A0334|105 113|regulator
P09892662A0334|123 129|cyclase
P09892736A0343|7 12|search
P09892736A0343|30 35|region
P09892736A0343|38 46|CDED/LIOR
P09892736A0343|60 70|% similarity
P09892736A0343|80 87|proteins
P09892736A0343|97 114|signal transduction
P09892736A0343|118 132|cell replication
P09893060A0767|0 19|Northern blot analysis
P09893060A0767|45 54|expression
P09893262A1272|13 19|variety
P09893262A1272|32 38|schemes
P09893262A1272|70 80|restriction
P09893262A1272|83 99|TGF-beta responses
P09893913A0656|0 8|Induction
P09893913A0656|11 21|anaesthesia
P09893913A0656|37 44|fentanyl
P09893913A0656|46 58|micrograms/kg
P09893913A0656|59 69|thiopentone
P09893913A0656|71 75|mg/kg
P09893913A0656|76 85|atracurium
P09893913A0656|89 93|mg/kg
P09894962T0000|1 10|comparison
P09894962T0000|24 30|profile
P09894962T0000|42 54|malformations
P09894962T0000|85 97|malformations
P09895323T0000|20 24|roles
P09895323T0000|27 34|kreisler
P09895323T0000|37 46|regulation
P09895323T0000|62 66|Hoxa3
P09895323T0000|70 79|Hoxb3 genes
P09897032T0000|26 37|self-pulsing
P09897032T0000|50 58|resonator
P09900679T0000|0 14|Wave cybernetics
P09900679T0000|22 26|model
P09900679T0000|75 83|phenomena
P09903722T0000|0 18|Autoionization rates
P09903722T0000|22 33|energy levels
P09903722T0000|36 44|triplet nf
P09903722T0000|46 58|Rydberg states
P09904139T0000|13 20|approach
P09904139T0000|37 45|operators
P09911328T0000|8 15|approach
P09911328T0000|18 27|scattering
P09911328T0000|46 52|problem
P09913308T0000|10 15|lasing
P09913308T0000|35 40|Ti ions
P09913308T0000|55 60|energy
P09913308T0000|73 83|laser pulses
P09914156A1496|14 20|regions
P09914156A1496|26 33|promoter
P09914156A1496|53 58|series
P09914156A1496|61 88|tenascin-C promoter constructs
P09914156A1496|94 102|deletions
P09914156A1496|143 158|promoter activity
P09914156A1496|181 191|pair element
P09914156A1496|225 236|RNA start site
P09914500A0000|7 18|factor kappa B
P09914500A0000|19 27|NF-kappaB
P09914500A0000|41 59|transcription factor
P09914500A0000|66 70|genes
P09914500A0000|93 100|proteins
P09914500A0000|128 149|cytokines interleukin-1
P09914500A0000|153 171|tumor necrosis factor
P09914500A0000|176 180|alpha
P09914500A0000|204 213|conditions
P09914518A1217|12 22|enhancement
P09914518A1217|40 49|activation
P09914518A1217|52 59|COUP-TFI
P09914518A1217|83 109|AF-1 transactivation function
P09914518A1217|137 144|presence
P09914518A1217|152 169|4-hydroxytamoxifen
P09914525A0890|27 31|point
P09914525A0890|40 47|degreesC
P09915118T0000|10 23|naris occlusion
P09915118T0000|30 41|rat accessory
P09915798A1077|4 9|region
P09915798A1077|12 16|hsp90
P09915798A1077|40 56|chaperone activity
P09915798A1077|68 90|hsp90 dimerization domain
P09915798A1077|112 119|elements
P09915798A1077|132 157|steroid receptor interaction
P09915860A0000|3 10|promoter
P09915860A0000|16 32|rat pgp2/mdr1b gene
P09915860A0000|44 49|region
P09915860A0000|50 55|pgp2GC
P09915860A0000|79 86|mdr genes
P09915860A0000|100 115|consensus Sp1 site
P09915860A0119|14 28|transactivation
P09915860A0119|32 49|pgp2/mdr1b promoter
P09915860A0119|71 84|Schneider cells
P09916786A0811|0 11|Measurements
P09916786A0811|20 37|bone mineral density
P09916786A0811|49 53|spine
P09916786A0811|65 69|femur
P09916786A0811|83 101|X-ray absorptiometry
P09916786A0811|116 122|markers
P09916786A0811|125 138|bone remodeling
P09916786A0811|139 143|serum
P09916786A0811|157 175|alkaline phosphatase
P09916786A0811|178 188|immunoassay
P09916786A0811|192 213|urine deoxypyridinoline
P09916786A0811|235 248|chromatography
P09916809A0405|39 44|matrix
P09916809A0405|49 55|protein
P09916809A0405|82 88|protein
P09916809A0405|98 123|transmembrane signal peptide
P09917064T0000|4 8|roles
P09917064T0000|19 33|clam CPEB homolog
P09917064T0000|46 60|polyadenylation
P09917064T0000|77 83|masking
P09917387T0000|3 15|RNA polymerase
P09917387T0000|30 41|factor TFIIIB
P09917387T0000|50 56|DNA bend
P09917387T0000|67 73|TATA box
P09917387T0000|95 103|start site
P09917389A1239|3 9|pattern
P09917389A1239|12 26|RNase E digestion
P09917389A1239|29 38|finP305 RNA
P09917389A1239|60 67|GST-FinO
P09917389A1239|80 89|finP305 RNA
P09917389A1239|94 101|cleavage
P09917391A0380|0 23|Transcription readthrough
P09917391A0380|39 45|repeats
P09917391A0380|55 60|effect
P09917391A0380|67 71|event
P09917555T0001|0 7|Analysis
P09917555T0001|23 47|growth factor prescriptions
P09917555T0001|58 70|cancer centers
P09918715A0304|16 26|DNA sequence
P09918715A0304|27 33|MotA box
P09918715A0304|44 51|position
P09918715A1158|66 83|TATA binding protein
P09918715A1158|96 102|factors
P09918715A1158|107 113|binding
P09918715A1158|116 125|TBP results
P09918715A1158|128 140|transcription
P09918715A1158|148 168|core promoter sequences
P09918720A0998|3 14|S229A variant
P09918720A0998|36 40|bases
P09918720A0998|100 105|pocket
P09918720A0998|119 124|Ser229
P09918720A0998|135 141|contact
P09918720A0998|154 160|adenine
P09918842A0184|7 18|conservation
P09918842A0184|25 32|terminus
P09918842A0184|49 54|region
P09918842A0184|65 72|assembly
P09918842A0184|75 82|proteins
P09918842A0184|97 106|initiation
P09918842A0184|109 122|RNA replication
P09920539A0272|3 14|stimulations
P09920539A0272|37 42|GnRH-a
P09920539A0272|68 75|protocol
P09920539A0272|81 103|gonadotropin stimulation
P09920775A0075|3 10|sequence
P09920775A0075|36 57|transcription start site
P09920775A0075|79 100|reporter gene expression
P09920775A0075|125 139|differentiation
P09920775A0075|142 149|P19 cells
P09920896A1230|13 23|differences
P09920896A1230|52 63|type peptides
P09920896A1230|94 105|substitution
P09920896A1230|117 123|protein
P09920896A1230|132 141|disruption
P09920896A1230|165 174|structures
P09920903A1045|5 11|results
P09920903A1045|26 34|c-met gene
P09920903A1045|42 47|target
P09920903A1045|50 66|p53 gene regulation
P09920930A0521|0 6|C3 toxin
P09920930A0521|26 37|RhoA function
P09920930A0521|60 70|Luc activity
P09920930A0521|78 83|effect
P09920930A0521|100 114|c-Fos expression
P09920930A0959|7 13|C3 toxin
P09920930A0959|23 33|combination
P09920930A0959|38 50|growth factors
P09920930A0959|71 81|Luc activity
P09920930A0959|117 126|activation
P09920930A0959|149 156|response
P09920930A0959|157 170|co-stimulation
P09920930A0959|175 187|growth factors
P09920930A0959|191 200|Ro-31-8220
P09920982A0253|20 24|study
P09920982A0253|52 65|susceptibility
P09920982A0253|96 101|agents
P09920982A0253|106 112|strains
P09920982A0253|136 146|acne lesions
P09920982A0253|165 179|Rap ID ANA II panel
P09921179T0001|25 40|echocardiography
P09921179T0001|42 48|surgery
P09921179T0001|54 58|heart
P09921179T0001|67 73|vessels
P09922230A1482|16 22|results
P09922230A1482|65 74|resistance
P09922230A1482|86 99|stress response
P09922230A1482|102 111|C. albicans
P09922856A0459|0 9|Trinipatch
P09922856A0459|47 51|patch
P09922856A0459|58 75|absorption promoter
P09922856A0459|89 102|dose-strengths
P09922856A0459|104 109|mg/24 h
P09922856A0459|115 120|mg/24 h
P09922856A0459|123 144|Laboratoires Synthelabo
P09923245A0482|21 41|interrater reliability
P09923245A0482|71 78|patients
P09924675A0412|11 15|point
P09924675A0412|21 33|consideration
P09924675A0412|41 51|conceptions
P09924675A0412|65 69|ICIDH
P09924675A0412|94 101|mainstay
P09924675A0412|105 109|model
P09924675A0412|113 123|diagnostics
P09924675A0412|126 139|rehabilitation
P09924675A0412|172 186|characteristics
P09924675A0412|202 208|process
P09924675A0412|219 223|basis
P09924675A0412|227 238|intervention
P09924987A0000|0 7|Pokeweed
P09924987A0000|17 23|protein
P09924987A0000|33 51|Phytolacca americana
P09924987A0000|68 80|N-glycosidase
P09924987A0000|89 103|adenine residues
P09924987A0000|104 108|A4324
P09924987A0000|111 117|28S rRNA
P09924987A0000|121 125|A2660
P09924987A0000|128 134|23S rRNA
P09924987A0000|145 153|ribosomes
P09924987A0000|160 169|eukaryotes
P09924987A0000|173 183|prokaryotes
P09925120A0074|0 8|OBJECTIVE
P09925120A0074|13 25|meta-analysis
P09925120A0074|40 45|trials
P09925120A0074|91 96|effect
P09925120A0074|111 116|fibers
P09925372A0458|25 31|ZFP cDNA
P09925372A0458|52 59|heart ZFP
P09925372A0458|63 78|sequence homology
P09925372A1063|17 26|expression
P09925372A1063|37 41|heart
P09925372A1063|56 60|heart
P09925372A1063|73 80|HFHZ mRNA
P09925372A1063|101 107|process
P09925372A1063|110 120|development
P09925777A1195|11 25|affinity hnRNP A1
P09925777A1195|57 75|beta-globin reporter
P09925777A1195|111 116|levels
P09925777A1195|127 131|mRNAs
P09927193A0107|15 22|proteins
P09927193A0107|31 35|LAZ-3
P09927193A0107|34 38|BCL-6
P09927193A0107|59 69|oncogenesis
P09927449A0421|0 13|Overexpression
P09927449A0421|50 57|G1 arrest
P09927449A0421|75 84|repression
P09927449A0421|99 107|CLN2 genes
P09927570A0507|13 25|RNU2 fragility
P09927570A0507|40 51|transfection
P09927570A0507|58 73|expression vector
P09927570A0507|82 88|Ad12 E1B
P09927570A0507|111 118|E1 vector
P09927570A0507|129 138|E1 products
P09927570A0507|140 150|E1A proteins
P09927570A0507|179 189|kDa proteins
P09927585A0796|0 30|Competitionsupershift EMSA assays
P09927585A0796|51 58|proteins
P09927585A0796|73 97|bandshift complex formation
P09927585A0796|132 140|factor Sp1
P09927589T0000|0 9|Similarity
P09927589T0000|12 21|DNA binding
P09927589T0000|40 49|regulation
P09927589T0000|52 77|Caenorhabditis elegans MAB-3
P09927589T0000|116 127|conservation
P09927589T0000|145 154|mechanisms
P09929088A0000|0 6|CONTEXT
P09929088A0000|7 14|ThinPrep
P09929088A0000|15 21|AutoPap
P09929088A0000|25 30|Papnet
P09929088A0000|38 49|technologies
P09929088A0000|65 75|sensitivity
P09929088A0000|95 109|cancer screening
P09929811A0000|0 10|Experiments
P09929811A0000|48 58|derivatives
P09929811A0000|96 105|properties
P09929811A0000|127 132|agents
P09929811A0000|143 148|CM-251
P09929811A0000|149 154|CM-266
P09929811A0000|158 163|CM-345
P09929811A0000|173 180|mean rise
P09929811A0000|183 189|segment
P09929811A0000|202 206|leads
P09929811A0000|222 232|electrogram
P09929811A0000|244 252|occlusion
P09929811A0000|276 281|branch
P09929811A0000|299 304|artery
P09931118A1072|10 15|p42/44
P09931118A1072|22 31|JNK pathway
P09931118A1072|48 53|action
P09931118A1072|56 63|IL-1beta
P09931191A0434|2 9|protocol
P09931191A0434|25 32|subjects
P09931191A0434|50 60|Ecc arm curls
P09931191A0434|62 68|fatigue
P09931191A0434|91 104|muscle ischemia
P09931191A0434|119 128|resistance
P09931191A0434|133 140|protocol
P09931216A0566|0 6|Airflow
P09931216A0566|38 44|turbine
P09931216A0566|49 53|45-ft
P09931216A0566|68 72|cable
P09931216A0566|99 104|module
P09931252A1055|4 12|mutations
P09931252A1055|19 40|amino acid substitutions
P09931252A1055|51 61|coat protein
P09931252A1055|86 94|abilities
P09931252A1055|114 131|scaffolding protein
P09931391A0944|8 15|recovery
P09931391A0944|18 30|liver function
P09931391A0944|40 46|surgery
P09931435A0357|12 22|transcripts
P09931435A0357|40 44|exons
P09931435A0357|55 59|ZIS-2
P09931435A0357|70 74|ZIS-1
P09931435A0357|105 109|ZIS-1
P09932288A0378|0 9|Expression
P09932288A0378|60 65|kidney
P09932288A0378|74 81|sequence
P09932288A0378|103 113|cDNA library
P09933428A0351|0 8|IFN-gamma
P09933428A0351|59 66|controls
P09933428A0351|89 97|treatment
P09933641A0241|11 19|sequences
P09933641A0241|39 51|amplification
P09933641A0241|54 61|cDNA ends
P09933641A0241|67 74|analysis
P09933641A0241|92 96|clone
P09933641A0241|110 118|sequences
P09933641A0241|138 150|amplification
P09933641A0241|153 160|cDNA ends
P09933848A1008|4 17|alloantibodies
P09933848A1008|36 43|analysis
P09933848A1008|76 89|autoantibodies
P09934611A1054|4 13|dependence
P09934611A1054|42 47|extent
P09934611A1054|58 67|min LVdP/dt
P09934611A1054|82 89|pressure
P09935377T0108|0 4|Genoa
P09935377T0108|5 9|Italy
P09935377T0108|15 20|August
P09936001T0000|10 18|structure
P09936001T0000|21 25|delta
P09936001T0000|26 34|plutonium
P09936001T0000|57 68|Sc impurities
P09936001T0000|69 73|delta
P09936001T0000|74 82|plutonium
P09938097T0000|13 20|transfer
P09938097T0000|24 57|photoluminescence undulation spectra
P09938097T0000|61 69|acceptors
P09940132T0000|7 12|theory
P09940132T0000|38 58|charge-transfer solids
P09940132T0000|67 76|properties
P09943651T0000|8 12|modes
P09943651T0000|16 22|soliton
P09945838T0000|17 34|matching conditions
P09945838T0000|51 65|heterojunctions
P09947191T0000|0 28|Neutron scattering measurements
P09947191T0000|39 47|exponents
P09947191T0000|50 56|CsMnBr3
P09947191T0000|67 81|antiferromagnet
P09949160A0600|10 21|32D Epo1 cells
P09949160A0600|34 38|level
P09949160A0600|41 47|bulk PKC
P09949160A0600|57 64|activity
P09949160A0600|74 83|expression
P09949160A0600|86 92|epsilon
P09949160A0600|96 109|eta PKC isoforms
P09949160A0600|132 143|upregulation
P09949160A0600|158 165|isoforms
P09949160A0600|172 176|betaI
P09949160A0600|181 190|readdition
P09949160A0600|200 205|growth
P09949160A0600|219 223|cells
P09949178A0264|6 15|expression
P09949178A0264|33 45|interleukin-6
P09949178A0264|57 62|factor
P09949178A0264|76 81|growth
P09949178A0264|85 94|pre-B-cell
P09949178A0264|108 112|1A9-M
P09949312A0524|0 6|Airflow
P09949312A0524|17 24|dust trap
P09949312A0524|43 52|vacuum pump
P09950213A1660|32 42|goblet cells
P09950213A1660|43 49|TbetaRI
P09950213A1660|53 60|TbetaRII
P09950213A1660|97 104|TGF-beta
P09950213A1660|115 127|participation
P09950213A1660|130 138|TbetaRIII
P09950394A0336|3 9|history
P09950394A0336|12 19|exposure
P09950394A0336|23 45|carboxyhemoglobin levels
P09950394A0336|60 68|physician
P09950394A0336|75 83|diagnosis
P09952378A0529|3 11|odds ratio
P09952378A0529|28 46|% confidence interval
P09952378A0529|68 77|serostatus
P09952378A0529|88 100|IgG antibodies
P09952378A0529|106 115|adjustment
P09952378A0529|119 128|covariates
P09952425A0893|7 11|group
P09952425A0893|35 41|animals
P09952425A0893|53 57|tasks
P09952425A0893|66 71|lesion
P09952425A0893|85 95|impairments
P09952425A0893|151 160|structures
P09952425A0893|175 180|lesion
P09952425A0893|204 214|hippocampus
P09952425A0893|220 225|degree
P09959737T0000|12 20|neutrinos
P09959737T0000|24 30|SN 1987A
P09961326T0000|0 6|Scaling
P09961326T0000|9 20|fluctuations
P09961326T0000|38 46|interface
P09961326T0000|57 62|models
P09961682T0000|0 4|Model
P09961682T0000|21 28|dynamics
P09961682T0000|31 46|stick-slip motion
P09964171T0000|16 20|atoms
P09964171T0000|37 42|medium
P09964171T0000|48 55|presence
P09964171T0000|77 81|field
P09964770T0000|0 13|Microstructure
P09964770T0000|17 28|conductivity
P09964770T0000|43 60|laminate composites
P09965234T0000|11 23|heat transport
P09965234T0000|29 46|octylcyanobiphenyl
P09965234T0000|52 64|liquid crystal
P09965909T0000|6 13|approach
P09965909T0000|19 23|study
P09965909T0000|26 45|soliton perturbations
P09971776A0838|0 8|Mutations
P09971776A0838|22 34|CD4 regulation
P09971776A0838|43 50|residues
P09971776A0838|78 84|binding
P09971776A0838|98 105|receptor
P09971776A0838|149 162|dileucine motif
P09971776A0838|174 182|dipeptide
P09971776A0838|198 203|region
P09971776A0838|209 215|protein
P09971790A0856|7 15|mutations
P09971790A0856|28 39|endonuclease
P09971790A0856|43 60|helicase activities
P09971790A0856|75 102|amino-terminal-charge cluster
P09971790A0856|109 115|protein
P09971790A0856|116 129|D40A-D42A-D44A
P09971790A0856|144 171|AAV hairpin DNA binding activity
P09971806A1585|8 12|cycle
P09971806A1585|44 50|control
P09971806A1585|55 66|KSHV/Rta gene
P09971806A1585|90 106|tumor pathogenesis
P09971815A2094|38 58|candidate latency genes
P09971815A2094|67 75|gammaHV68
P09971815A2094|78 87|expression
P09971815A2094|90 94|genes
P09971815A2094|101 107|latency
P09971815A2094|133 138|organs
P09971815A2094|161 175|latency programs
P09971815A2094|198 202|sites
P09971815A2094|205 211|latency
P09971815A2094|218 224|regions
P09971815A2094|235 240|genome
P09971815A2094|241 251|v-bcl-2 gene
P09971815A2094|252 260|v-GCR gene
P09971815A2094|292 298|latency
P09971815A2094|306 314|gammaHV68
P09971815A2094|325 342|gammaherpesviruses
P09971822A1542|57 74|splicing inhibition
P09973351A1522|19 33|DcuS-DcuR system
P09973351A1522|52 61|substrates
P09973607A0254|17 30|identification
P09973607A0254|34 49|characterization
P09973607A0254|59 69|Sp100 splice
P09973607A0254|77 84|proteins
P09973607A0254|100 108|existence
P09973607A0254|111 121|elucidation
P09973607A0254|137 145|Sp100 gene
P09974642T0000|0 8|Crossover
P09974642T0000|36 42|magnets
P09974642T0000|68 75|dynamics
P09976626T0000|0 6|Erratum
P09976626T0000|7 13|Absence
P09976626T0000|16 31|precursor effects
P09976626T0000|51 64|transformation
P09976626T0000|74 80|crystal
P09976626T0000|83 89|Li metal
P09980944T0000|0 17|Interplane coupling
P09980944T0000|23 47|superconductor Y2Ba4Cu7O15
P09980944T0000|60 71|NQR spin-echo
P09980944T0000|78 86|resonance
P09982923T0000|10 18|structure
P09982923T0000|28 32|NiSi2
P09982923T0000|35 44|CoSi2 layer
P09982923T0000|47 52|bulk Si
P09983871T0000|0 17|Raman investigation
P09983871T0000|20 41|YBa2-xLaxCu3O7 ceramics
P09984526T0000|0 6|Effects
P09984526T0000|9 20|point defects
P09984526T0000|23 39|lattice parameters
P09984526T0000|42 55|semiconductors
P09985302T0000|7 22|electron dynamics
P09985302T0000|54 60|antidot
P09986796A1761|7 15|deletions
P09986796A1761|38 47|amino acids
P09986796A1761|65 71|effects
P09987176A0260|5 10|months
P09987176A0260|26 36|vaccination
P09987176A0260|40 48|vaccinees
P09987176A0260|66 74|follow-up
P09987176A0260|93 98|levels
P09987176A0260|101 108|anti-HAV
P09987634A1265|20 24|weeks
P09987634A1265|38 48|retreatment
P09987634A1265|67 76|regression
P09987634A1265|82 90|PRK effect
P09987961A0093|8 14|lesions
P09987961A0093|34 45|angiomatosis
P09987961A0093|46 57|vasculopathy
P09987961A0093|61 73|proliferation
P09987961A0093|76 87|synoviocytes
P09987961A0093|91 101|fibroblasts
P09988682T0033|9 15|cloning
P09988682T0033|43 81|beta1,6-N-acetylglucosaminyltransferase
P09988767A1496|13 35|mouse back-cross analysis
P09988767A1496|58 71|mouse 3Ost genes
P09988767A1496|82 92|assignments
P09988767A1496|113 119|isologs
P09988767A1496|138 151|identification
P09988767A1496|175 185|site markers
P09988850A0000|3 8|Scales
P09988850A0000|20 29|Impairment
P09988850A0000|52 58|Records
P09988850A0000|59 65|SCIRFIR
P09988850A0000|67 73|battery
P09988850A0000|93 117|dementia rating instruments
P09988850A0000|132 138|records
P09988850A0000|178 198|schizophrenia patients
P09988850A0000|205 211|purpose
P09988850A0000|251 256|course
P09988850A0000|268 273|change
P09988850A0000|276 288|schizophrenia
P09988850A0000|313 328|autopsy materials
P09989334A0964|24 40|processing signals
P09989334A0964|46 55|transcript
P09989334A0964|64 79|donor splice sites
P09989334A0964|86 104|polyadenylation site
P09989334A0964|132 137|intron
P09989339A0968|25 31|product
P09989339A0968|33 43|brain weight
P09989339A0968|47 55|clearance
P09990057T0000|0 12|Recombination
P09990057T0000|16 28|transcription
P09990057T0000|53 62|chain locus
P09990057T0000|86 90|chain
P09990057T0000|98 115|enhancer core region
P09990057T0000|121 127|absence
P09990057T0000|133 155|matrix attachment regions
P09990060A0803|10 15|motifs
P09990060A0803|55 73|dyad symmetry element
P09990060A0803|104 115|IL-2 enhancer
P09990060A0803|122 133|CD18 promoter
P09990060A0937|2 8|concert
P09990060A0937|16 49|coactivator CREB binding protein/p300
P09990060A0937|68 76|GABPalpha
P09990060A0937|80 86|binding
P09990060A0937|89 97|GABPalpha
P09990060A0937|112 130|dyad symmetry element
P09990060A0937|141 149|induction
P09990060A0937|152 164|IL-16 promoter
P09990060A0937|167 172|T cells
P09990315A0205|42 55|protein kinase C
P09990315A0205|102 111|activation
P09990315A0205|132 139|agonists
P09990315A0205|148 155|thrombin
P09990315A0205|159 171|phorbol esters
P09990315A0205|191 203|PKC activation
P09990315A0205|211 218|agonists
P09990507A0000|0 9|BACKGROUND
P09990507A0000|34 51|proteolysis pathway
P09990507A0000|53 67|ubiquitin ligase
P09990507A0000|97 107|selectivity
P09990507A0000|110 115|timing
P09990507A0000|118 128|degradation
P09990507A0763|0 10|CONCLUSIONS
P09990507A0763|11 25|Fission yeast SCF
P09990507A0763|101 123|F-box/WD-repeat proteins
P09994942T0000|3 12|NMR studies
P09994942T0000|31 46|antiferromagnets
P09995847T0000|0 24|Optical-absorption spectra
P09995847T0000|38 49|energy levels
P09995847T0000|53 75|transition line strengths
P09995847T0000|78 84|holmium
P09995897T0000|0 10|Observation
P09995897T0000|20 31|interactions
P09995897T0000|39 48|Pb0 defects
P09995897T0000|57 72|Si/SiO2 interface
P09999256T0000|19 24|theory
P09999256T0000|37 54|transport phenomena
P09999742T0000|8 20|NO interaction
P09999742T0000|32 39|surfaces
P10000253T0000|0 14|Chirality-glass
P10000253T0000|18 39|spin-glass correlations
P10000253T0000|71 77|XY model
P10001333T0038|0 13|Echo modulation
P10001333T0038|20 24|YAlO3
P10001541T0000|0 9|Mechanisms
P10001541T0000|25 32|emission
P10001541T0000|59 65|silicon
P10002245T0000|19 30|conductivity
P10002245T0000|36 44|CuO chains
P10002245T0000|61 69|YBa2Cu3O7
P10002245T0000|70 81|delta crystal
P10006319T0000|0 15|Surface spin waves
P10006319T0000|19 39|Heisenberg ferrimagnet
P10006319T0000|55 64|anisotropy
P10007469T0000|17 23|librons
P10007469T0000|27 33|phonons
P10007564T0000|21 28|geometry
P10007564T0000|42 50|structure
P10007564T0000|59 65|surface
P10008261T0000|0 20|Temperature dependence
P10008261T0000|26 35|sublattice
P10008261T0000|47 59|magnetization
P10008261T0000|62 70|YBa2Cu3O6
P10009565T0000|0 19|GW Gamma approximation
P10009565T0000|23 43|electron self-energies
P10009565T0000|46 59|semiconductors
P10009565T0000|63 72|insulators
P10013227T0000|0 19|Precision measurement
P10013227T0000|25 45|pion mass difference m pi
P10019841T0000|7 13|gravity
P10019841T0000|36 40|order
P10019841T0000|54 61|approach
P10021333A0674|7 17|experiments
P10021333A0674|23 29|mutants
P10021333A0674|51 55|bruno
P10021333A0674|73 83|interaction
P10021333A0674|96 100|genes
P10021350A0093|12 16|model
P10021350A0093|29 34|signal
P10021350A0093|45 66|Armadillo/beta-catenin
P10021350A0093|89 94|nuclei
P10021350A0093|103 123|TCF/LEF family proteins
P10021350A0093|140 159|transcription factors
P10021350A0093|173 185|transcription
P10021350A0093|188 199|Wingless/Wnt
P10021350A0093|210 214|genes
P10022032A0000|2 8|support
P10022032A0000|30 36|studies
P10022032A0000|40 60|vasodilator nicorandil
P10022032A0000|99 128|receptor antagonists propranolol
P10022032A0000|134 141|atenolol
P10022032A0000|157 186|calcium channel blocker diltiazem
P10022032A0000|239 250|interactions
P10022210A0620|0 6|Factors
P10022210A0620|18 33|direct-immersion
P10022210A0620|37 47|SPME process
P10022850A0929|2 9|contrast
P10022850A0929|26 33|fragment
P10022850A0929|47 56|C/H1 domain
P10022850A0929|73 84|coactivation
P10022850A0929|87 102|Zta transcription
P10022850A0929|111 130|reactivation function
P10022858A0985|2 9|addition
P10022858A0985|17 40|splicing enhancer sequence
P10022858A0985|54 62|selection
P10022858A0985|89 95|protein
P10022867A1069a|0 10|Elimination
P10022867A1069a|21 31|apn1 strains
P10022867A1069a|55 67|mutation rates
P10022867A1069a|115 123|reversion
P10022867A1069a|125 131|adenine
P10022867A1069a|134 150|lysine prototrophy
P10022867A1069b|0 10|Elimination
P10022867A1069b|21 31|apn1 strains
P10022867A1069b|55 67|mutation rates
P10022867A1069b|115 123|reversion
P10022867A1069b|125 131|adenine
P10022867A1069b|134 150|lysine prototrophy
P10022875A1265|27 38|Ras effectors
P10022875A1265|56 65|PI 3-kinase
P10022880A0000|9 35|Ras GTPase-activating protein
P10022880A0000|41 51|p120 Ras-GAP
P10022880A0000|75 87|downregulator
P10022880A0000|91 98|effector
P10022880A0000|101 111|Ras proteins
P10022880A0000|145 170|signal transduction pathways
P10022905A0446|5 16|mog-1 alleles
P10022905A0446|33 42|stop codons
P10022905A0446|63 69|alleles
P10022905A0446|79 94|missense mutation
P10022905A0446|122 129|activity
P10022905A0446|159 167|mog-1 mRNA
P10022905A0446|185 192|germ line
P10022905A0446|203 209|tissues
P10022921A0608|16 23|SIN3 gene
P10022921A0608|69 81|cell viability
P10022925A0870|3 21|Nmd3 protein sequence
P10022925A0870|55 60|motifs
P10022925A0870|68 75|function
P10022978A1261|3 14|distribution
P10022978A1261|27 33|repeats
P10022978A1261|45 56|organization
P10022978A1261|91 97|regions
P10022978A1261|121 134|chromosome arms
P10024383T0000|0 9|Calcitonin
P10024383T0000|47 58|hyperostosis
P10024383T0000|72 81|osteopenia
P10024383T0000|105 109|mouse
P10024383T0000|110 116|twy/twy
P10024498A0783|29 34|assays
P10024498A0783|51 56|HNF-3 X
P10024498A0783|60 65|Y sites
P10024498A0783|86 90|sites
P10024498A0783|110 119|HNF-3alpha
P10024498A0783|123 131|HNF-3beta
P10024882A0541|2 9|addition
P10024882A0541|65 70|domain
P10024882A0541|77 82|RNA pol
P10024882A0541|89 95|absence
P10024882A0541|98 112|promoter opening
P10025050A1052|3 9|therapy
P10025050A1052|26 35|antagonist
P10025050A1052|64 72|therapies
P10025050A1052|77 86|omeprazole
P10025050A1052|89 100|lansoprazole
P10025506A0079|2 7|humans
P10025506A0079|28 42|plastin isoforms
P10025506A1078|10 20|Inr sequence
P10026146A0680|3 12|inhibition
P10026146A0680|18 31|RIalpha subunit
P10026146A0680|44 51|addition
P10026146A0680|63 76|concentrations
P10026146A0680|152 164|protein kinase
P10026146A0680|182 199|cAMP concentrations
P10026146A0680|207 216|holoenzyme
P10026146A0680|224 236|Calpha subunit
P10026146A0680|253 265|protein kinase
P10026211A0136|0 7|Proteins
P10026211A0136|22 29|PEPCK CRE
P10026211A0136|51 57|protein
P10026211A0136|67 73|members
P10026211A0136|100 106|protein
P10026211A0136|107 111|C/EBP
P10026211A0136|112 117|family
P10026211A0543|4 12|construct
P10026211A0543|19 32|pDeltaCREC/EBP
P10026211A0543|38 47|C/EBPalpha
P10026211A0543|96 117|glucocorticoid response
P10026211A0543|146 166|H4IIE rat hepatoma cells
P10026229A0950|2 9|addition
P10026229A0950|17 27|mutagenesis
P10026229A0950|34 42|Engrailed
P10026229A0950|46 54|Pbx1 sites
P10026229A0950|85 89|sites
P10026229A0950|125 135|enhancement
P10026229A0950|159 166|fragment
P10026275A0549|16 32|structure elements
P10026784A0331|6 13|evidence
P10026784A0331|34 42|functions
P10026784A0331|48 53|family
P10026784A0331|56 75|transcription factors
P10026784A0331|94 111|POU DNA binding motif
P10026784A0331|118 122|roles
P10026784A0331|134 144|development
P10026784A0929|26 35|DNA binding
P10026784A0929|38 66|POU domain transcription factors
P10026784A0929|100 114|POU-homeodomain
P10026784A2166|5 16|Oct-1 crystal
P10026784A2166|32 37|domain
P10026784A2166|49 61|GCAT half-site
P10026784A2166|83 90|sequence
P10026784A2166|106 110|Pit-1
P10026784A2166|123 128|domain
P10026784A2166|150 155|strand
P10026824A0309|20 27|analysis
P10026824A0309|30 50|V1a/V2 hybrid receptors
P10026824A0309|94 104|V1a receptor
P10026824A0309|139 146|coupling
P10026824A0309|149 153|Gq/11
P10026824A0309|193 202|V2 receptor
P10026824A0309|228 235|coupling
P10027498A0536|9 17|end points
P10027498A0536|42 46|death
P10027498A0536|73 83|U.S. program
P10027904A0768|50 55|region
P10029337A0406|3 17|fatigue exercise
P10029337A0406|38 62|blood lactate concentration
P10029337A0406|90 97|increase
P10029337A0406|97 115|serum creatine kinase
P10029337A0406|120 127|activity
P10029860A0605|17 23|aspects
P10029860A0605|44 53|categories
P10029860A0605|91 97|filling
P10029917A0366|0 6|Results
P10029917A0366|26 33|presence
P10029917A0366|36 49|myofibroblasts
P10029917A0366|113 132|muscle cell dispersion
P10029917A0366|169 186|portal vein branches
P10031854T0000|0 19|New Langevin equations
P10032519T0000|9 19|corrections
P10032519T0000|22 30|beta decay
P10032519T0000|37 47|possibility
P10032519T0000|57 66|generation
P10032581T0000|16 43|grazing-incidence diffraction
P10032581T0000|46 56|synchrotron
P10032581T0000|58 66|radiation
P10033973T0000|11 18|exchange
P10033973T0000|21 25|atoms
P10033973T0000|33 37|traps
P10033973T0000|48 62|Bose condensates
P10034615T0000|0 21|Structure determination
P10034615T0000|53 66|reconstruction
P10035841T0000|8 15|trapping
P10035841T0000|38 45|hydrogen
P10036181A0603|0 11|Northern blot
P10036181A0603|21 41|hybridization analyses
P10036181A0603|50 69|GPR34 mRNA transcripts
P10036181A0603|87 101|rat brain regions
P10036191A0000|3 20|microphthalmia-TFE
P10036191A0000|26 34|subfamily
P10036191A0000|57 69|leucine zipper
P10036191A0000|70 77|bHLH-ZIP
P10036191A0000|78 97|transcription factors
P10036191A0000|156 165|regulation
P10036191A0000|179 192|gene expression
P10036191A0000|202 213|cell lineages
P10037004A0000|11 18|patients
P10037004A0000|26 30|years
P10037004A0000|53 60|leukemia
P10037004A0000|81 90|bone marrow
P10037004A0000|94 100|relapse
P10037004A0000|124 130|therapy
P10037004A0000|165 169|study
P10037378A0176|3 14|dorsal nerves
P10037378A0176|20 24|penis
P10037378A0176|56 64|lidocaine
P10037460A0221|5 9|brain
P10037460A0221|20 28|receptors
P10037460A0221|36 40|motor
P10037460A0221|44 57|memory function
P10037460A0221|60 70|interaction
P10037460A0221|80 98|ligand acetylcholine
P10037576T0000|18 25|necrosis
P10037576T0000|31 36|iodine
P10037576T0000|41 58|plaque radiotherapy
P10037576T0000|76 83|melanoma
P10037681A0494|10 20|interaction
P10037681A0494|31 39|PKC-alpha
P10037681A0494|77 84|fragment
P10037681A0494|131 136|mutant
P10037681A0494|143 152|RhoAVal-14
P10037774A0366|6 10|study
P10037774A0366|28 53|signal transduction pathways
P10037774A0366|81 97|LDLR transcription
P10041728T0000|0 18|Vacuum Rabi splitting
P10041728T0000|22 28|feature
P10041728T0000|31 53|linear-dispersion theory
P10041728T0000|54 61|Analysis
P10041728T0000|77 88|observations
P10043466T0000|13 19|effects
P10043466T0000|42 49|kinetics
P10043466T0000|52 59|excitons
P10043466T0000|62 81|polydiacetylene 4BCMU
P10044519T0000|4 12|reduction
P10044519T0000|24 28|flows
P10044519T0000|31 38|polymers
P10046849T0000|5 9|scale
P10046849T0000|20 40|structure calculations
P10047970T0013|7 21|world literature
P10049357A0608|5 11|results
P10049357A0608|28 36|component
P10049357A0608|41 51|HDAC complex
P10049357A0608|95 104|repression
P10049357A0608|118 124|complex
P10049359A1073|66 76|translation
P10049359A1073|89 102|rhinovirus IRES
P10049742T0000|0 7|Analysis
P10049742T0000|13 36|consensus binding sequence
P10049742T0000|54 59|domain
P10049775T0000|0 6|Mapping
P10049775T0000|34 53|Anion Channel isoforms
P10049912T0000|0 13|Identification
P10049912T0000|16 21|RNase T
P10049912T0000|34 43|suppressor
P10049912T0000|49 61|UV sensitivity
P10049912T0000|89 112|DNA exonuclease deficiency
P10050883A0967|0 9|Inhibition
P10050883A0967|12 39|phosphatidylinositol-3 kinase
P10050883A0967|62 67|effect
P10050883A0967|70 84|p53 conformation
P10050883A0967|114 119|effect
P10050883A0967|134 142|viability
P10051030A1080|2 11|difference
P10051030A1080|14 23|percentage
P10051030A1080|26 30|males
P10051030A1080|33 47|semen production
P10051030A1080|63 69|strains
P10051030A1080|70 77|CP levels
P10051030A1080|87 94|regimens
P10051400A0000|3 9|Lp mouse
P10051400A0000|25 29|model
P10051400A0000|53 62|tube defect
P10051400A0000|68 86|cranio-rachischisis
P10051488A1293|7 14|analysis
P10051488A1293|17 40|AP-1 DNA binding activities
P10051488A1293|52 58|culture
P10051488A1293|82 90|discovery
P10051488A1293|96 116|mobility AP-1 complexes
P10051488A1293|117 122|HMAP-1
P10051488A1610|0 8|Mutations
P10051488A1610|14 21|AP-1 site
P10051488A1610|27 40|TIMP-1 promoter
P10051488A1610|54 62|formation
P10051488A1610|65 70|HMAP-1
P10051488A1610|79 83|% loss
P10051488A1610|86 93|activity
P10052371A0171|0 10|STUDY DESIGN
P10052371A0171|19 39|immunoglobulin A levels
P10052371A0171|50 57|subjects
P10052371A0171|75 83|occasions
P10052371A0171|97 103|subject
P10052371A0171|112 118|smoking
P10052371A0171|137 145|cessation
P10052371A0171|147 153|smoking
P10052371A0171|178 186|cessation
P10052878A0135|13 26|set-up accuracy
P10052878A0135|30 44|reproducibility
P10053852T0000|25 33|Schwinger
P10053852T0000|35 63|Gerasimov-Drell-Hearn sum rules
P10054976T0000|0 11|Spectroscopy
P10054976T0000|48 57|detachment
P10054976T0000|60 78|Raman coupling regime
P10055173T0000|0 19|Band structure effects
P10055173T0000|22 40|transport properties
P10055173T0000|54 66|quasicrystals
P10059496T0000|8 26|transmission spectra
P10059496T0000|32 45|Penrose lattice
P10063122T0000|0 22|Two-Channel Kondo Lattice
P10063122T0000|35 39|Metal
P10063739A0601|23 49|esophageal sphincter pressure
P10063739A0601|65 74|study group
P10063739A0601|101 108|controls
P10063739A0601|122 129|pressure
P10064604A0824|18 22|sites
P10064604A0824|42 47|TFIIIA
P10064604A0824|68 73|repair
P10065176A0657|10 19|difference
P10065176A0657|25 45|hormone receptor status
P10065176A0657|56 60|cases
P10065176A0657|68 86|lymph node metastases
P10065176A0657|94 112|lymph node metastases
P10065176A0657|126 140|macrometastases
P10065684A0916|16 23|subjects
P10065684A0916|27 37|air trapping
P10065684A0916|46 51|volume
P10065684A0916|60 71|lung capacity
P10065684A0916|132 140|mt x microm
P10065684A0916|154 163|sarcomeres
P10065684A0916|174 181|subjects
P10065684A0916|201 211|abnormality
P10065684A0916|230 235|microm
P10066790A0497|0 12|Gel filtration
P10066790A0497|13 33|sedimentation velocity
P10066790A0497|37 66|immunoprecipitation experiments
P10066790A0497|79 83|beta4
P10066790A0497|87 95|component
P10066790A0497|111 117|complex
P10066790A0497|143 159|sigma4 polypeptide
P10066790A0497|175 196|adaptor subunit homologs
P10066790A0497|207 213|mu-ARP2
P10066790A0497|216 222|epsilon
P10066798A0391|0 5|Cyclin
P10066798A0391|19 32|kinase activity
P10066798A0391|36 48|protein levels
P10066798A0391|71 76|tumors
P10066798A0391|94 108|tumor virus-pp60
P10066798A0391|108 116|c-src527F
P10066815T0000|25 32|inositol
P10066815T0000|32 42|phosphatase
P10066815T0000|60 69|p85 subunit
P10066815T0000|71 94|phosphoinositide 3-kinase
P10066815T0000|122 131|inhibition
P10066815T0000|134 155|B cell receptor signaling
P10068040A0136|13 23|mouse genome
P10068040A0136|36 41|copies
P10068040A0136|47 55|ubc-9 gene
P10068418A1194|2 9|increase
P10068418A1194|12 29|bone mineral density
P10068418A1194|35 39|spine
P10068418A1194|83 92|raloxifene
P10068418A1194|123 130|estrogen
P10068418A1194|133 150|alendronate therapy
P10068446A0124|14 20|studies
P10068446A0124|29 36|presence
P10068446A0124|39 49|thiol agents
P10068446A0124|55 69|PKC preparations
P10068446A0124|82 89|reaction
P10068446A0124|113 128|cysteine residues
P10068637A1320|13 20|Csx/Nkx2
P10068674A0644|44 49|Lyp RNA
P10068834A0713|3 7|costs
P10069815A0285|12 19|evidence
P10069815A0285|44 54|interaction
P10069815A0285|74 83|proteasome
P10070158A0573|11 24|splicing events
P10070158A0573|56 68|cassette exons
P10070158A0573|109 127|transmembrane domain
P10071205A0833|11 15|genes
P10071205A0833|81 89|AUG codons
P10071205A0833|99 105|cistron
P10071212A0399|18 32|O. australiensis
P10071761A2374|2 9|addition
P10071761A2374|10 16|mapping
P10071761A2374|22 35|promoter region
P10071761A2374|42 55|identification
P10071761A2374|66 73|promoter
P10071761A2374|84 92|sequences
P10071761A2374|103 109|insight
P10071761A2374|132 141|regulation
P10071761A2374|144 157|UCP2 expression
P10071761A2374|172 177|anyone
P10071761A2374|197 203|factors
P10071806A0377|11 23|resectability
P10071806A0377|37 44|survival
P10072205A0167|2 6|order
P10072205A0167|30 41|distribution
P10072205A0167|51 62|MAP estimates
P10072205A0167|72 81|conditions
P10072205A0167|91 108|point approximation
P10072205A0167|111 123|density values
P10072205A0167|140 151|distribution
P10072205A0167|158 166|estimates
P10072774A0537|0 5|RT-PCR
P10072774A0537|51 72|oligonucleotide primers
P10072774A0537|78 96|ligand binding domain
P10072774A0537|109 128|beta integrin subunits
P10072774A0537|131 137|Bge cDNA
P10073899A0740|9 26|culture failure rate
P10073940A0335|7 16|expression
P10073940A0335|19 24|d-axin
P10073940A0335|42 50|signaling
P10073947A1110|16 26|differences
P10073947A1110|29 33|FVIIa
P10073947A1110|37 41|PAI-1
P10074135T0000|29 36|elements
P10074135T0000|48 56|synthesis
P10074135T0000|59 64|barley
P10074135T0000|71 80|dwarf virus
P10074282A0236|50 54|L-NNA
P10074282A0236|53 73|NO-synthesis inhibitor
P10074282A0236|76 88|methylene blue
P10074282A0236|96 111|cGMPase inhibitor
P10074282A0236|115 121|changes
P10074425A0729|12 23|inactivation
P10074425A0729|29 47|cyclin E-Cdk2 complex
P10074425A0729|50 57|response
P10074425A0729|60 76|mitogen starvation
P10074425A0729|118 125|deletion
P10074425A0729|130 136|p27 gene
P10074520T0000|0 13|Identification
P10074520T0000|17 32|characterization
P10074520T0000|35 40|IS2404
P10074520T0000|44 49|IS2606
P10074520T0000|69 77|sequences
P10074520T0000|81 89|detection
P10074520T0000|92 112|Mycobacterium ulcerans
P10074903A0915|18 24|results
P10074903A0915|45 55|possibility
P10074903A0915|60 70|p202 protein
P10074903A0915|87 115|cell growth retardation activity
P10074903A0915|154 169|p21 protein levels
P10074921A1169|7 13|results
P10074921A1169|35 61|HepG2 hepatoblastoma cell line
P10075415A1178|7 16|sequencing
P10075415A1178|22 27|region
P10075415A1178|40 46|ORF-Pto
P10075415A1178|55 62|homology
P10075415A1178|68 77|ru/AB genes
P10075415A1178|88 99|UV resistance
P10075415A1178|104 115|plasmid pPSR1
P10076007A0656|19 24|kinase
P10076007A0656|29 40|casein kinase
P10076007A0656|45 50|kinase
P10076007A0656|74 80|mRNP3+4
P10076007A0656|82 88|oocytes
P10076007A0656|108 113|kinase
P10077188A1172|29 33|genes
P10077188A1172|52 63|biosynthesis
P10077188A1172|73 77|acids
P10077188A1172|81 88|proteins
P10077188A1172|99 103|genes
P10077188A1172|137 145|heat shock
P10077188A1172|173 181|synthesis
P10077188A1172|193 199|protein
P10077533A0976|30 34|tools
P10077533A0976|45 58|identification
P10077533A0976|75 82|MUL genes
P10078734A0480|11 23|recovery curve
P10078734A0480|40 50|stimulation
P10078734A0480|62 66|nerve
P10078734A0480|72 76|elbow
P10078734A0480|80 88|recording
P10078734A0480|96 114|flexor carpi radialis
P10078876A0000|3 9|origins
P10078876A0000|26 32|changes
P10078876A0000|55 62|activity
P10078876A0000|70 76|signals
P10078876A0000|95 116|rat somatosensory cortex
P10078876A0000|128 134|imaging
P10078876A0000|135 156|microspectrophotometry
P10078876A0000|173 181|flowmetry
P10078876A0000|192 198|changes
P10078876A0000|206 228|hemoglobin concentration
P10078876A0000|232 242|oxygenation
P10079173A0000|22 29|proteins
P10079173A0000|50 69|RNA recognition motifs
P10080436T0000|0 9|Comparison
P10080436T0000|12 22|frequencies
P10080436T0000|31 42|fibrillation
P10080436T0000|56 67|artery bypass
P10080436T0000|115 120|bypass
P10080875A0772|3 9|results
P10080875A0772|12 29|supershift analysis
P10080875A0772|43 52|antibodies
P10080875A0772|60 79|transcription factors
P10080875A0772|104 112|complexes
P10080875A0772|125 146|NF-kappaB components p50
P10080875A0772|176 192|NF-kappaB proteins
P10080875A0772|197 201|c-Rel
P10080875A0772|201 204|Rel B
P10080875A0772|205 216|AP-1 proteins
P10080875A0772|217 221|c-Fos
P10080875A0772|222 226|C-Jun
P10080875A0772|235 243|C/EBPbeta
P10080875A0772|243 248|NF-IL6
P10080901A0271|8 15|peptides
P10080901A0271|43 50|elements
P10080901A0271|62 70|structure
P10080901A0271|95 100|domain
P10080901A0271|115 123|protein L9
P10082137A0262|3 9|results
P10082137A0262|20 28|IFN-gamma
P10082137A0262|47 58|accumulation
P10082137A0262|61 70|interferon
P10082137A0262|80 85|factor
P10082137A0262|133 142|inhibition
P10082137A0262|143 148|alpha1
P10082137A0262|151 175|procollagen mRNA expression
P10082137A0262|177 191|skin fibroblasts
P10082137A0262|212 217|donors
P10082554T0000|10 16|domains
P10082554T0000|19 45|c-myc promoter binding protein
P10082554T0000|72 81|repression
P10082554T0000|85 104|cell growth regulation
P10082570A0440|24 32|gene UBP43
P10082573A1015|5 11|results
P10082573A1015|32 41|hypothesis
P10082573A1015|105 127|globin gene transcription
P10082573A1015|127 137|holocomplex
P10082573A1015|174 182|formation
P10082573A1015|186 190|DNase
P10082573A1015|206 216|holocomplex
P10082573A1015|259 281|globin gene transcription
P10082585A0512|27 33|factors
P10082585A0512|44 56|rDNA silencing
P10082585A0512|76 81|screen
P10082585A0512|99 107|mutations
P10082585A0512|121 130|expression
P10082585A0512|133 145|reporter genes
P10084294A0219|62 72|progenitors
P10084294A0219|88 100|serum ferritin
P10084294A0219|104 130|transferrin saturation levels
P10084294A0219|156 167|microg/liter
P10085088A0918|5 11|results
P10085088A0918|27 36|p33 subunit
P10085088A0918|72 86|initiation phase
P10085088A0918|87 102|protein synthesis
P10085088A0918|124 129|domain
P10085088A0918|150 157|activity
P10085120A0000|6 10|study
P10085120A0000|22 38|signaling pathways
P10085120A0000|60 66|therapy
P10085120A0000|76 84|hypericin
P10085140A1004|5 11|results
P10085140A1004|24 28|ATF-2
P10085140A1004|50 66|TGF-beta signaling
P10085140A1004|90 95|target
P10085140A1004|111 122|TAK1 pathways
P10085383A1367|3 7|WORDS
P10085383A1367|8 16|Melaleuca
P10085383A1367|17 30|Lake Okeechobee
P10085383A1367|31 42|Littoral zone
P10085383A1367|43 52|Water level
P10085383A1367|53 70|Regulation schedule
P10085505A1184|76 80|cases
P10085605A0239|0 8|Specimens
P10085605A0239|23 39|alpha-fetoprotein
P10085605A0239|52 58|estriol
P10085605A0239|63 70|alpha hCG
P10085697T0000|0 39|FASEB Federal Funding Consensus Conference FY
P10086544A0504|32 38|arrival
P10086544A0504|52 59|care unit
P10086544A0504|70 74|hours
P10086544A0504|80 90|termination
P10086544A0504|98 106|heart rate
P10086544A0504|106 118|blood pressure
P10086544A0504|129 136|pressure
P10086544A0504|155 175|temperature difference
P10086544A0504|198 223|oxygen saturation difference
P10086544A0504|224 234|urine output
P10086544A0504|235 249|serum creatinine
P10086544A0504|250 256|lactate
P10086544A0504|260 283|neutrophil elastase levels
P10086544A0504|287 293|Doppler
P10086544A0504|311 317|factors
P10086544A0504|328 335|fraction
P10086544A0504|339 349|preejection
P10086544A0504|373 384|ejection time
P10086544A0504|398 402|doses
P10086544A0504|405 418|catecholamines
P10086544A0504|419 429|epinephrine
P10086544A0504|430 438|enoximone
P10086544A0504|442 451|furosemide
P10086725A0000|0 8|MDS1/EVI1
P10086725A0000|18 27|chromosome
P10086725A0000|29 35|band q26
P10086725A0000|66 87|transcription activator
P10086725A0000|120 124|cells
P10086725A0000|152 158|tissues
P10087213A0878|0 7|Analysis
P10087213A0878|13 28|protein sequences
P10087213A0878|39 48|replicases
P10087213A0878|84 117|H. pylori plasmid replication proteins
P10087213A0878|129 137|formation
P10087213A0878|149 153|class
P10087213A0878|156 178|H. pylori plasmid proteins
P10087549A0720|3 10|JTc delta
P10087549A0720|24 29|groups
P10087549A0720|48 55|JTc delta
P10087549A0720|61 67|VT group
P10087549A0720|87 94|JTc delta
P10087549A0720|98 105|PVC group
P10087549A0720|132 139|JTc delta
P10087549A0720|143 154|control group
P10087993A0782|2 9|contrast
P10087993A0782|10 17|deletion
P10087993A0782|31 37|portion
P10087993A0782|43 55|delta promoter
P10087993A0782|68 75|decrease
P10087993A0782|78 87|expression
P10087993A1352|13 23|mutagenesis
P10087993A1352|33 37|sites
P10087993A1352|44 63|repressor proteins BP1
P10087993A1352|85 91|portion
P10087993A1352|96 109|beta globin gene
P10087993A1352|118 123|region
P10087993A1352|137 144|increase
P10087993A1352|147 162|promoter activity
P10090125A0750|14 37|alpha1 antagonist prazosin
P10090125A0750|53 62|relaxation
P10090146T0000|12 21|expression
P10090146T0000|24 32|AP-2alpha
P10090146T0000|36 43|AP-2beta
P10090146T0000|59 69|chick retina
P10090146T0000|70 79|repression
P10090146T0000|82 103|R-FABP promoter activity
P10090535A1194|3 11|algorithm
P10090535A1194|89 94|groups
P10090943A1426|7 11|value
P10090943A1426|17 21|CD79b
P10090943A1426|27 31|CD79b
P10090943A1426|49 53|ratio
P10090943A1426|78 83|donors
P10090943A1426|101 105|B-CLL
P10090943A1976|8 13|B cells
P10090943A1976|29 35|variant
P10090943A1976|39 47|mechanism
P10090943A1976|50 54|CD79b
P10090943A1976|74 83|regulation
P10090943A1976|99 113|activation stage
P10090943A1976|125 129|B cell
P10090943A1976|139 143|B-CLL
P10091594A0284|14 20|studies
P10091594A0284|39 58|structure predictions
P10091594A0284|66 80|NMR spectroscopy
P10091594A0284|92 102|ELISA assays
P10091594A0284|128 137|propensity
P10091594A0284|143 149|epitope
P10091594A0284|153 166|helix formation
P10091594A0284|181 191|recognition
P10091594A0284|194 202|anti-K159
P10091619A0104|0 5|Schwab
P10091619A0104|9 24|England ADL scores
P10091619A0104|33 37|state
P10091619A0104|66 70|state
P10091619A0104|73 78|scores
P10092132A0285|10 14|gains
P10092132A0285|33 50|gene amplifications
P10092132A0285|66 70|11q13
P10092132A0285|76 80|cases
P10092132A0285|127 133|7q21-22
P10092132A0285|132 138|11p11.2
P10092132A0285|138 147|12p11.2-12
P10092132A0285|151 155|13q34
P10092847A0455|4 10|respect
P10092847A0455|16 27|distribution
P10092847A0455|49 62|promoter region
P10092847A0455|65 75|hMT-IIA gene
P10092847A0455|101 126|mouse metallothionein-I gene
P10092847A0455|141 154|MRE arrangement
P10092847A0455|171 176|factor
P10092847A0455|180 194|metal regulation
P10092856A0798|54 60|control
P10092856A0798|65 69|yeast
P10092856A0798|76 101|phosphate isomerase promoter
P10094314A0935|16 27|RNA sequences
P10094314A0935|48 68|zinc knuckle 9G8 variant
P10094314A0935|95 99|SRp20
P10094314A0935|102 110|agreement
P10094314A0935|146 150|SRp20
P10094396A0000|0 14|Topoisomerase II
P10094396A0000|23 28|target
P10094396A0000|34 58|protein kinase casein kinase
P10094396A0000|60 64|PK CK2
P10094701A0000|18 27|laboratory
P10094701A0000|57 69|acetate kinase
P10094701A0000|77 97|Sinorhizobium meliloti
P10094701A0000|113 120|response
P10094701A0000|123 141|phosphate limitation
P10095059A1003|3 9|numbers
P10095059A1003|17 35|nucleotide positions
P10095059A1003|50 64|HIV-1 transcript
P10095061A0592|0 15|Sequence analysis
P10095061A0592|31 41|MEMA protein
P10095061A0592|73 78|domain
P10095061A0592|84 90|serines
P10095061A0592|96 102|protein
P10095061A0592|120 130|nucleoplasm
P10095061A0592|156 165|structures
P10095062A0558|23 31|structure
P10095062A0558|42 65|topoisomerase IIalpha gene
P10095062A0558|83 87|exons
P10096469T0000|12 21|modulation
P10096469T0000|37 44|activity
P10096469T0000|47 54|cat motor
P10096469T0000|63 69|neurons
P10096573A0207|8 14|studies
P10096573A0207|64 69|factor
P10096573A0207|73 94|kappaB consensus element
P10096573A0207|119 124|region
P10096573A0207|130 147|MGSA/GRO-alpha gene
P10097120T0000|20 28|transport
P10097932A0915|15 22|patients
P10097932A0915|61 66|mg/24 h
P10097932A0915|75 90|microalbuminuria
P10097932A0915|120 127|patients
P10097932A0915|146 151|mg/24 h
P10097932A0915|157 161|years
P10097932A0915|164 172|follow-up
P10098601A1320|10 17|analysis
P10098601A1320|43 47|JEG-3
P10098601A1320|54 61|proteins
P10098601A1320|106 117|SF-1 sequence
P10098744A0630|2 9|contrast
P10098744A0630|12 17|change
P10098744A0630|34 42|phenotype
P10098744A0630|55 60|clones
P10098744A0630|65 71|respect
P10098744A0630|91 100|parameters
P10098744A0630|101 117|proliferation rate
P10098744A0630|120 128|monolayer
P10098744A0630|129 144|serum-dependence
P10098744A0630|148 160|proliferation
P10098744A0630|163 170|survival
P10098744A0630|171 184|tumorigenicity
P10098744A0630|193 202|morphology
P10098744A0630|220 241|differentiation markers
P10099247A1051|5 13|reactor pH
P10099247A1051|27 39|retention time
P10099247A1051|55 62|presence
P10099247A1051|76 88|SRB population
P10099247A1051|94 101|inoculum
P10099576A0666|12 17|valves
P10099576A0666|42 47|effect
P10099576A0666|49 53|shear
P10099576A0666|57 65|parameter
P10099576A0666|83 90|geometry
P10099576A0666|96 100|valve
P10099576A0666|115 124|conditions
P10100605A0392|21 25|burst
P10100605A0392|68 81|transformation
P10100605A0392|84 99|dihydrorhodamine
P10100605A0392|122 130|rhodamine
P10100605A0392|137 149|flow cytometry
P10101159A0742|1 8|mutation
P10101159A0742|20 27|SOC1 gene
P10101159A0742|56 64|mutations
P10101159A0742|77 89|cbp1 ts alleles
P10101159A0742|119 123|mRNAs
P10101198A0632|1 24|deletion mutation analysis
P10101198A0632|41 47|protein
P10101198A0632|73 78|region
P10101198A0632|88 101|leucine zippers
P10101198A0632|120 126|binding
P10101198A0946|1 14|database search
P10101198A0946|48 55|homology
P10101198A0946|57 61|match
P10101198A0946|87 116|transcription termination factor
P10101198A0946|117 121|mTERF
P10101198A0946|123 129|protein
P10101198A0946|151 157|monomer
P10101198A0946|173 186|leucine zippers
P10101198A0946|208 219|interactions
P10101744A0917|5 10|trials
P10101744A0917|11 26|antigen challenge
P10101744A0917|51 59|treatment
P10102000A1206|8 15|patients
P10102000A1206|30 40|ERA-II group
P10102000A1206|50 61|ERA-III group
P10102000A1206|71 83|mortality rate
P10102136A0220|39 48|cyst fluids
P10102136A0646|7 11|cysts
P10102136A0646|27 31|ratio
P10102136A0646|68 72|cysts
P10102627A0217|11 28|DNA binding activity
P10102627A0217|29 48|AP-1 reporter activity
P10102627A0217|69 73|cells
P10103002A0705|7 25|N-glycosylation site
P10103002A0705|35 45|chicken gp42
P10103002A0705|76 83|proteins
P10103002A0705|84 103|carbohydrate analysis
P10103002A0705|123 130|presence
P10103002A0705|140 154|type glycan chain
P10103057A0251|17 28|optimization
P10103057A0251|32 47|characterization
P10103057A0251|62 69|fragment
P10103057A0251|83 92|Runt domain
P10103057A0251|129 135|studies
P10119827T0000|0 11|Judge OKs docs
P10119827T0000|20 34|Chicago hospital
P10120952T0000|0 4|HANYS
P10120952T0000|27 47|gall bladder guidelines
P10125354T0000|0 11|Groups dicker
P10125354T0000|15 25|price breaks
P10132730T0000|8 18|CareNetwork
P10132730T0000|40 51|teacher union
P10134977T0000|0 4|JCAHO
P10134977T0000|12 20|hospitals
P10134977T0000|21 28|patience
P10146207A0223|0 14|Ultrasonography
P10146207A0223|46 55|evaluation
P10146207A0223|64 73|cord injury
P10153759A0360|18 29|organization
P10153759A0360|47 66|NHBC organ procurement
P10171173A0955|9 16|concerns
P10171173A0955|26 30|blood
P10171173A0955|62 68|disease
P10171173A0955|85 102|deficiency syndrome
P10171173A0955|106 110|non-A
P10171173A0955|116 124|hepatitis
P10171173A0955|147 160|research effort
P10171173A0955|178 187|hemorrhage
P10171173A0955|212 217|bypass
P10171173A0955|236 246|circulation
P10181397A0641|12 17|trends
P10181397A0641|20 28|fertility
P10181397A0641|29 48|life expectancy ratios
P10181397A0641|52 68|gender differences
P10181397A0641|76 84|countries
P10181397A0641|100 109|population
P10181397A0641|115 126|United States
P10184191T0045|0 5|Holger
P10187317T0000|0 7|Hospital
P10187317T0000|20 34|AHERF physicians
P10187798A1098|0 13|Overexpression
P10187798A1098|22 26|DAP-1
P10187798A1098|29 35|sentrin
P10187798A1098|42 50|apoptosis
P10187798A1098|66 87|L929 fibroblast cell line
P10187798A1098|109 128|osteosarcoma cell line
P10187842A1155|8 15|contrast
P10187842A1155|18 27|PPARgamma2
P10187842A1155|87 91|motif
P10187842A1155|115 119|sites
P10187842A1155|134 142|PPARalpha
P10187864A1372|5 11|results
P10187864A1372|31 36|member
P10187864A1372|41 49|KCC family
P10187864A1372|69 78|regulation
P10190324A0000|17 27|elastin gene
P10190324A0000|31 39|mutations
P10190324A0000|73 80|stenosis
P10190324A0000|119 126|families
P10191090A0000|14 23|expression
P10191090A0000|29 36|PAX3 gene
P10191090A0000|61 71|development
P10192134A1088|0 7|25-OH-D3
P10192134A1088|35 40|health
P10192134A1088|54 61|use level
P10192134A1088|66 82|micrograms/kg feed
P10192134A1088|96 104|vitamin D3
P10192134A1088|107 119|turkey rations
P10192432A0214|11 15|names
P10192432A0214|21 27|disease
P10192432A0214|43 50|criteria
P10192432A0214|66 79|Consensus Panel
P10192432A0214|91 97|experts
P10192432A0214|113 117|order
P10192432A0214|133 139|core set
P10192432A0214|142 149|criteria
P10192638T0000|0 22|Methanesulfonyl fluoride
P10192638T0000|59 63|study
P10192638T0000|65 70|safety
P10192638T0000|74 81|efficacy
P10192638T0000|87 95|treatment
P10192638T0000|104 111|dementia
P10192638T0000|117 129|Alzheimer type
P10193950A0478|0 6|METHODS
P10193950A0478|14 19|August
P10193950A0478|82 98|prostate carcinoma
P10193950A0478|133 152|lymph node involvement
P10193950A0478|175 183|pendetide
P10193950A0478|195 216|staging lymphadenectomy
P10194225A1132|9 13|wheel
P10194225A1132|57 63|alanine
P10194225A1132|66 77|pyruvate Gneo
P10194225A1132|88 97|glycerol Ra
P10194230A0817|16 22|surgery
P10194230A0817|23 35|dialysate PGE2
P10194230A0817|39 61|adenosine concentrations
P10194451A0000|26 37|relationship
P10194451A0000|62 68|bcr/abl
P10194451A0000|68 96|protein tyrosine kinase activity
P10194451A0000|100 113|manifestations
P10194451A0000|147 154|leukemia
P10194451A0000|167 175|expansion
P10194451A0000|205 218|p210 substrates
P10194451A0000|227 242|chronic-phase CML
P10194451A0000|256 270|progenitor cells
P10194762A0648|7 19|precipitation
P10194762A0648|25 63|glutathione-S-transferase-fusion protein
P10194762A0648|87 107|transactivation domain
P10194762A0648|110 115|STAT5a
P10194762A0648|134 144|association
P10194762A0648|147 152|ERK1/2
P10194762A0648|160 172|fusion protein
P10194762A0648|196 201|serine
P10194762A0648|207 212|STAT5a
P10194762A0648|225 231|alanine
P10194769A0146|7 13|element
P10194769A0146|31 35|clone
P10194769A0146|54 74|cDNA expression library
P10194769A0146|80 101|417-amino acid WD protein
P10194769A0146|133 146|element binding
P10194769A0146|145 151|protein
P10195425T0000|0 15|Characterization
P10195425T0000|21 44|transcription factor MTF-1
P10195425T0000|60 69|pufferfish
P10195425T0000|70 81|Fugu rubripes
P10195425T0000|101 112|conservation
P10195425T0000|120 138|metal stress response
P10195690A0000|3 12|peroxisome
P10195690A0000|35 43|receptors
P10195690A0000|44 48|PPARs
P10195690A0000|52 58|members
P10195690A0000|71 96|hormone receptor superfamily
P10195697A0456|7 19|F-SRC-1 mutant
P10195697A0456|42 47|domain
P10195697A0456|62 78|enhancing activity
P10196127A1059|23 30|S1 pocket
P10196127A1059|59 66|residues
P10196127A1059|83 101|pyroglutamyl residue
P10196248A0482|19 27|TTV genome
P10196248A0482|43 50|sequence
P10196248A0482|126 132|stretch
P10196248A0482|130 138|GC content
P10196266A0000|8 24|mouse Mus castaneus
P10196266A0000|38 46|infection
P10196266A0000|62 83|mink cell focus-inducing
P10196266A0000|89 96|subgroup
P10196266A0000|104 118|leukemia viruses
P10196266A0000|119 123|MuLVs
P10196316A0715|14 21|function
P10196316A0715|24 28|VZV gK
P10196316A0715|31 41|virus growth
P10196316A0715|43 48|series
P10196316A0715|51 67|gK deletion mutants
P10196316A0715|117 125|Oka strain
P10196318T0000|0 23|CCAAT displacement protein
P10196318T0000|58 75|papillomavirus type
P10196318T0000|88 98|E1 promoters
P10196597A0510|9 16|findings
P10196597A0510|32 38|studies
P10196597A0510|68 82|characteristics
P10196597A0510|85 96|drink drivers
P10197763A0580|27 35|mutations
P10197763A0580|47 64|AMP response element
P10197763A0580|79 101|nerve growth factor effect
P10197985A0145|7 27|RNase H protection assay
P10197985A0145|47 62|oligonucleotides
P10197985A0145|73 83|recognition
P10197985A0145|108 126|branchpoint sequence
P10197985A0145|131 138|elements
P10197985A0145|148 156|U12 snRNPs
P10197985A0145|182 194|cooperativity
P10197985A0145|208 212|sites
P10197985A0145|218 234|pre-mRNA substrate
P10197985A0145|247 262|complex formation
P10198003A1505|0 7|Analysis
P10198003A1505|31 37|fusions
P10198003A1505|61 65|sites
P10198003A1505|85 94|expression
P10198056A0000|14 32|cell surface proteins
P10198056A0000|49 60|lipid bilayer
P10198056A0000|68 95|glycosylphosphatidylinositol
P10198061A0339|14 24|import assay
P10198061A0339|25 36|beta-catenin
P10198061A0339|59 65|nucleus
P10198061A0339|85 92|addition
P10198061A0339|95 101|cytosol
P10198061A0339|109 115|ATP/GTP
P10199539A1353|20 26|hypoxia
P10199539A1353|34 44|correlation
P10199539A1353|65 80|a3 oxidation level
P10199539A1353|112 118|hypoxia
P10200473A0171|21 29|regulator
P10200473A0171|36 42|process
P10200473A0171|48 54|Usurpin
P10200473A0171|72 78|aliases
P10200473A0171|82 88|Usurpin
P10200473A0171|102 107|Casper
P10200473A0171|107 111|CLARP
P10200473A0171|112 118|FLAME-1
P10200473A0171|125 131|I-FLICE
P10201468A0297|0 12|Plasma glucose
P10201468A0297|27 33|insulin
P10201468A0297|39 47|C-peptide
P10201468A0297|47 54|glucagon
P10201468A0297|58 68|GLP-1 levels
P10201468A0297|75 83|time point
P10202006A0546|15 21|product
P10202006A0546|26 38|fusion protein
P10202006A0546|44 50|B domain
P10202006A0546|67 74|protein A
P10202006A1266|0 13|Polypyrimidine
P10202006A1266|17 28|ssDNA binding
P10202006A1266|42 49|VH domain
P10202006A1266|98 105|activity
P10202006A1266|114 127|autoantibodies
P10202006A1266|155 161|binding
P10202006A1266|165 170|ligand
P10202006A1266|181 195|polypyrimidines
P10202006A1266|212 225|B cell selection
P10202006A1266|231 242|immunization
P10202006A1266|247 251|Z-DNA
P10203611T0000|0 52|Technetium-99m methylene diphosphonate scintimammography
P10203611T0000|56 65|evaluation
P10203611T0000|76 87|breast masses
P10205099A0377|0 12|INTERVENTIONS
P10205099A0377|13 25|Study patients
P10205099A0377|61 66|groups
P10205099A0377|82 92|terbinafine
P10205099A0377|115 119|weeks
P10205099A0377|118 126|groups T12
P10205099A0377|137 148|itraconazole
P10205099A0377|179 183|weeks
P10205099A0377|190 194|weeks
P10205099A0377|195 202|groups I3
P10205176A0000|7 15|receptors
P10205176A0000|49 63|transregulators
P10205176A0000|81 90|yeast cells
P10205176A0000|114 121|features
P10205176A0000|139 145|control
P10205176A0000|173 181|evolution
P10205176A0704|38 43|domain
P10205176A0704|61 73|transcription
P10205588A0000|0 8|OBJECTIVE
P10205588A0000|33 40|patients
P10205588A0000|45 53|arthritis
P10205588A0000|59 67|infection
P10205588A0000|87 98|streptococci
P10205588A0000|101 116|Lancefield group A
P10205588A0000|117 123|beta HSA
P10205588A0000|128 135|emphasis
P10205588A0000|146 160|characteristics
P10205588A0000|175 182|features
P10205933A0699|0 7|Bacteria
P10205933A0699|21 33|labyrinthitis
P10205933A0699|73 90|Treponemas Pallidum
P10205933A0699|91 101|spirochaete
P10205933A0699|113 120|syphilis
P10205933A0699|144 154|spirochaete
P10205933A0699|165 175|Lyme Disease
P10206152A1024|14 23|expression
P10206152A1024|29 35|protein
P10206152A1024|39 45|maximum
P10206152A1024|48 54|mitosis
P10206152A1024|58 64|minimum
P10206152A1024|93 102|expression
P10206152A1024|107 118|messenger RNA
P10206698A2041|5 12|findings
P10206698A2041|44 54|mutagenesis
P10206698A2041|64 71|approach
P10206698A2041|91 95|genes
P10206698A2041|113 119|ability
P10206698A2041|138 142|tract
P10206959A0368|0 5|Pathol
P10207041A0065|13 21|cell cycle
P10207041A0065|53 65|transcription
P10207041A0065|67 77|cyclin genes
P10207041A0065|83 97|protein products
P10207041A0065|151 157|kinases
P10207049A0693|3 10|GAC1 gene
P10207049A0693|31 37|subunit
P10207049A0693|49 89|serine/threonine phosphoprotein phosphatase
P10207049A1001|3 9|results
P10207049A1001|28 42|Glc7 phosphatase
P10207049A1001|65 75|subunit play
P10207049A1001|83 87|roles
P10207049A1001|90 102|HSF activation
P10207049A1001|105 121|CUP1 transcription
P10207087A0956|8 12|AML1B
P10207087A0956|43 53|interleukin
P10207087A0956|55 83|promoter reporter gene construct
P10207087A0956|90 107|activating activity
P10207087A0956|154 161|AML1/ETO
P10207090A0801|18 25|presence
P10207090A0801|56 66|degradation
P10207090A0801|90 97|molecule
P10207092A0924|4 18|phosphorylation
P10207092A0924|75 95|protein kinase activity
P10207092A0924|103 118|sea urchin nucleus
P10207115A0389|29 33|level
P10207115A0389|84 92|mechanism
P10208865A1246|22 39|osteoclast cultures
P10208865A1246|40 46|mrIhh-N
P10208865A1246|68 76|formation
P10208865A1246|79 92|resorption pits
P10208865A1246|95 107|dentine slices
P10208893A0839|10 16|results
P10208893A0839|37 45|genotypes
P10208893A0839|59 75|WAD goat population
P10209021A0212|12 20|mechanism
P10209021A0212|28 32|Gle2p
P10209021A0212|52 70|interaction function
P10209021A0212|73 82|mRNA export
P10209031A0832|3 16|Fyn NH2 terminus
P10209031A0832|48 58|interaction
P10209031A0832|76 84|Fyn kinase
P10209031A0832|87 96|SH2 domains
P10209031A0832|118 132|phosphorylation
P10209031A0832|135 151|zeta ITAM tyrosines
P10209031A0832|164 187|zeta ITAM phosphotyrosines
P10209119A0076|9 13|yeast
P10209119A0076|17 28|protein Skp1p
P10209119A0076|45 56|member Cdc53p
P10209119A0076|63 89|F-box/WD-repeat protein Cdc4p
P10209119A0076|97 126|SCFCdc4p ubiquitin ligase complex
P10209119A0076|158 163|kinase
P10209119A0076|169 182|inhibitor Sic1p
P10209119A0076|185 195|proteolysis
P10209119A0594|49 60|similarities
P10209119A0594|73 81|pop2 genes
P10209119A0594|107 124|deletion phenotypes
P10209119A0594|191 199|functions
P10209119A0594|202 212|proteolysis
P10209759T0000|0 14|Antithrombin III
P10209759T0000|44 68|ischemia reperfusion injury
P10210952A0261|2 11|retrospect
P10210952A0261|15 23|diagnoses
P10210952A0261|54 61|criteria
P10211329A0457|5 16|observations
P10211329A0457|27 37|serum lipase
P10211329A0457|41 47|serum CA
P10211329A0457|54 60|Sjogren
P10211329A0457|62 69|syndrome
P10211329A0457|77 84|evidence
P10211329A0457|87 96|malignancy
P10211329A0457|117 127|involvement
P10211329A0457|134 141|disorder
P10211422T0000|5 16|pancreatitis
P10211422T0000|20 31|complication
P10211422T0000|34 52|polyarteritis nodosa
P10211919A0846|20 30|improvement
P10211919A0846|44 58|sertraline group
P10211919A0846|101 106|Y-BOCS
P10211919A0846|111 129|CGI Improvement scale
P10211919A0846|145 149|weeks
P10211919A0846|180 195|CGI Severity scale
P10212278A0387|16 29|protein kinases
P10212278A0387|49 63|c-jun expression
P10212278A0387|87 105|protein kinase/c-Jun
P10212278A0387|116 128|protein kinase
P10212278A0387|129 136|SAPK/JNK
P10212278A0387|140 149|p38 members
P10212278A0387|172 184|protein kinase
P10212278A0387|191 201|superfamily
P10212278A0387|212 220|molecules
P10212284A0000|12 23|growth factor
P10212284A0000|28 32|beta1
P10212284A0000|52 67|matrix deposition
P10212284A0000|71 83|proliferation
P10212284A0000|97 101|cells
P10212332T0000|0 17|Chronotherapeutics
P10212332T0000|34 40|disease
P10212426A1067|0 4|Group
P10212426A1067|17 25|functions
P10212426A1067|29 37|listeners
P10212426A1067|42 52|hearing loss
P10212426A1067|63 70|decrease
P10212426A1067|73 83|performance
P10212426A1067|96 101|values
P10212426A1067|104 108|delta
P10212426A1067|124 128|study
P10212969A0470|0 11|Uroflowmetry
P10212969A0470|21 27|dysuria
P10212969A0470|71 78|subjects
P10214610A0900|12 20|variation
P10214610A0900|34 44|percentiles
P10215485A0837|11 22|correlations
P10215485A0837|36 41|status
P10215485A0837|68 83|State Examination
P10215485A0837|87 91|NA/mI
P10215485A0837|92 96|mI/Cr
P10215594A1728|0 7|Glucagon
P10215594A1728|19 29|LUC activity
P10215594A1728|58 66|CRE2 sites
P10215594A1728|78 86|induction
P10215594A1728|102 120|2SV40-LUC constructs
P10215608A0161|6 10|study
P10215608A0161|22 30|isolation
P10215608A0161|34 49|characterization
P10215608A0161|61 68|rat GSTA3
P10215608A0161|69 75|rGST Yc1
P10215608A0161|76 86|subunit gene
P10215803T0000|35 42|infusion
P10215803T0000|45 60|calcium gluconate
P10215811A0635|7 13|control
P10215811A0635|16 23|bleeding
P10215811A0635|36 46|eradication
P10215811A0635|64 71|sessions
P10215850A0754|29 40|organization
P10215850A0754|51 59|TrxR2 gene
P10215850A0754|77 81|exons
P10215850A0754|118 129|localization
P10215850A0754|131 145|position 22q11.2
P10216052A0105|15 19|study
P10216052A0105|44 52|frequency
P10216052A0105|75 84|disability
P10216052A0105|91 95|tasks
P10216052A0105|107 122|glaucoma patients
P10216052A0105|135 147|interrelation
P10216052A0105|155 166|disabilities
P10216052A0105|172 185|factor analysis
P10216052A0105|196 203|relation
P10216052A0105|226 235|difficulty
P10216052A0105|240 246|measure
P10216052A0105|252 259|severity
P10216052A0105|268 276|field loss
P10216052A0105|287 294|glaucoma
P10216052A0105|303 310|subgroup
P10216052A0105|313 321|questions
P10216052A0105|335 342|validity
P10216052A0105|346 356|reliability
P10216052A0105|363 370|subgroup
P10216052A0105|373 381|questions
P10216052A1682|14 21|validity
P10216052A1682|31 36|subset
P10216052A1682|39 47|questions
P10216052A1682|90 100|correlation
P10216052A1682|107 113|measure
P10216052A1682|119 126|severity
P10216052A1682|144 152|field loss
P10216052A1682|163 167|score
P10216052A1682|173 181|variables
P10216052A1682|191 198|glaucoma
P10216052A1682|207 214|subgroup
P10216052A1682|217 225|questions
P10216161A1530|0 17|Sequence comparison
P10216161A1530|20 32|cytochromes bd
P10216161A1530|41 48|homologs
P10216161A1530|60 68|organisms
P10216161A1530|88 95|proteins
P10216161A1530|118 128|subfamilies
P10216161A1530|213 238|B. stearothermophilus enzyme
P10217683A0509|0 20|Canalith repositioning
P10217683A0509|26 33|mainstay
P10217683A0509|36 44|treatment
P10218109T0000|0 16|Solution structure
P10218109T0000|20 28|mechanism
P10218109T0000|34 57|MutT pyrophosphohydrolase
P10218200A0534|39 48|micrograms
P10218200A0534|61 86|tissue plasminogen activator
P10218357A0486|0 6|RESULTS
P10218357A0486|10 20|CONCLUSIONS
P10218357A0486|21 26|Brandt
P10218357A0486|34 43|cuff-tubes
P10218357A0486|77 84|increase
P10218357A0486|86 98|cuff-pressure
P10218357A0486|105 115|anaesthesia
P10219091A0246|27 34|gene CTL1
P10219091A0246|42 47|enzyme
P10220275A0694|3 9|binding
P10220275A0694|12 20|PH domains
P10220275A0694|23 32|Gbetagamma
P10220275A0694|47 59|preincubation
P10220275A0694|62 71|Gbetagamma
P10220275A0694|114 120|Gialpha
P10220364A0087|5 14|afterglows
P10220364A0087|30 39|supernovae
P10220364A0087|61 70|hypernovae
P10221467T0000|12 23|pericarditis
P10221467T0000|42 48|disease
P10221467T0000|62 83|dopamine agonist therapy
P10221467T0000|84 94|cabergoline
P10221467T0000|98 106|Parkinson
P10221467T0000|108 114|disease
P10221820A0902|81 90|clinicians
P10221820A0902|112 122|coexistence
P10223338A1601|2 9|addition
P10223338A1601|47 59|fusion protein
P10223338A1601|72 79|HIV-2 gag
P10223338A1601|84 92|V3 domains
P10223338A1601|95 103|HIV-1IIIB
P10223338A1601|104 110|HIV-1MN
P10223338A1601|111 118|HIV-1SF2
P10223338A1601|122 128|HIV-1RF
P10223338A2186|3 9|results
P10223338A2186|22 31|V3 peptides
P10223338A2186|44 49|clades
P10223338A2186|52 56|HIV-1
P10223338A2186|66 73|HIV-2 gag
P10223338A2186|95 109|HIV/AIDS vaccine
P10223498A0479|0 7|Efficacy
P10223498A0479|23 31|responses
P10223498A0479|43 49|ability
P10223498A0479|61 68|erection
P10223498A0479|72 79|question
P10223498A0479|81 87|ability
P10223498A0479|100 107|erection
P10223498A0479|113 137|15-item International Index
P10223498A0479|140 155|Erectile Function
P10224244T0000|0 7|Evidence
P10224244T0000|14 24|involvement
P10224244T0000|30 49|Glc7-Reg1 phosphatase
P10224244T0000|56 70|Snf1-Snf4 kinase
P10224244T0000|76 85|regulation
P10224244T0000|88 104|INO1 transcription
P10224257A0079|2 8|XO males
P10224257A0079|12 21|her-1 mRNAs
P10224257A0079|22 27|her-1a
P10224257A0079|31 36|her-1b
P10224257A0079|66 74|promoters
P10224257A0079|99 104|region
P10224257A0079|134 139|intron
P10224289T0000|0 8|Induction
P10224289T0000|11 29|Fas ligand expression
P10224289T0000|48 58|interaction
P10224289T0000|72 93|T cell receptor zeta chain
P10224293A0000|0 34|Receptor protein tyrosine phosphatases
P10224293A0000|35 39|RPTPs
P10224293A0000|49 54|family
P10224293A0000|57 64|proteins
P10224293A0000|89 106|phosphatase domains
P10224293A0000|112 121|ectodomain
P10224293A0000|148 153|motifs
P10224293A2021|23 34|brain regions
P10224293A2021|46 50|basis
P10224293A2021|60 66|studies
P10224293A2021|69 86|RPTP-kappa function
P10224513A0240|12 20|stressors
P10224513A0240|30 40|arithmetics
P10224513A0240|41 51|speech tasks
P10224513A0240|55 64|Stroop test
P10224513A0240|65 80|videogame playing
P10224513A0240|81 85|films
P10224513A0240|88 97|videotapes
P10224513A0240|101 110|interviews
P10224758A0202|3 14|control group
P10224758A0202|24 40|afterbirth samples
P10224758A0202|67 77|pregnancies
P10225279A0450|36 43|MDV2 UL54
P10225279A0450|46 54|UL55 genes
P10225279A0450|59 66|homology
P10225279A0450|82 86|ORF-1
P10225279A0450|94 108|herpesvirus type
P10225279A0450|144 160|pseudorabies virus
P10225945A0436|2 9|contrast
P10225945A0436|21 32|MAD2 staining
P10225945A0436|34 40|meiosis
P10225945A0436|68 88|microtubule attachment
P10225945A0436|110 116|measure
P10225945A0436|119 125|tension
P10225945A0436|129 136|distance
P10225945A0436|162 173|kinetochores
P10225945A0436|176 182|meiosis
P10226029A0905|12 16|cells
P10226029A0905|20 27|PH domain
P10226029A0905|30 36|Akt/PKB
P10226029A0905|48 52|sites
P10226029A0905|78 84|contact
P10226029A0905|102 109|contacts
P10226029A0905|119 125|absence
P10226029A0905|128 132|serum
P10226074A0637|25 31|regions
P10226074A0637|52 56|exons
P10226074A0637|64 83|translation start site
P10226838A1011|3 10|motility
P10226838A1011|13 17|sperm
P10226838A1011|46 55|electrodes
P10226838A1011|73 83|stimulation
P10226838A1011|114 119|energy
P10228009A0600|0 8|Induction
P10228009A0600|14 25|CINC promoter
P10228009A0600|28 32|IL-17
P10228009A0600|35 44|IEC-6 cells
P10228009A0600|72 79|factor-6
P10228009A0600|79 83|TRAF6
P10228009A0600|90 94|TRAF2
P10228155A1293|0 6|SCFFWD1
P10228155A1293|23 38|tumor development
P10228155A1293|42 52|suppression
P10228155A1293|60 69|regulation
P10228155A1293|72 99|beta-catenin protein stability
P10228157T0000|16 39|spindle checkpoint pathway
P10228157T0000|52 62|Dbf2p kinase
P10228157T0000|72 76|yeast
P10228561A0539|20 31|organization
P10228561A0539|34 50|DNA polymerase beta
P10228561A0539|63 70|residues
P10228561A0539|77 83|contact
P10228561A0539|88 100|DNA phosphates
P10228561A0539|120 126|modules
P10228795A0842|0 6|RESULTS
P10228795A0842|18 23|nerves
P10228795A0842|46 55|regulation
P10228795A0842|65 78|nerve responses
P10229084A0000|15 32|gel electrophoresis
P10229084A0000|46 63|immunoprecipitates
P10229084A0000|103 114|T lymphocytes
P10229084A0000|128 141|identification
P10229084A0000|156 169|protein complex
P10229084A0000|229 243|phosphoproteins
P10229084A0000|264 288|protein tyrosine kinase Pyk2
P10229084A0000|314 328|adaptor proteins
P10229084A0000|329 334|SKAP55
P10229084A0000|338 345|SLAP-130
P10229668A0190|15 26|cdc33 mutants
P10229668A0560|1 13|cdc33-1 strain
P10229668A0560|36 40|Cln3p
P10229668A0560|41 47|Cln3-1p
P10229668A0560|51 60|hybrid UBI4
P10229668A0560|61 68|CLN3 mRNA
P10229668A0560|74 84|translation
P10229668A0560|102 111|dependence
P10229668A0560|114 118|eIF4E
P10229668A0560|140 148|cell cycle
P10229682A1151|10 15|motifs
P10229682A1151|19 32|gene expression
P10229682A1151|78 85|sequence
P10229682A1151|86 95|kappaB site
P10229682A1151|145 152|sequence
P10229682A1151|153 163|NF-IL-6 site
P10229682A1151|196 201|region
P10231026A0253|3 15|gene structure
P10231026A0253|55 59|exons
P10231026A0253|64 70|introns
P10231454A0731|5 16|serum calcium
P10231454A0731|27 31|mg/dl
P10231454A0731|46 52|calcium
P10231454A0731|63 67|mg/dl
P10231454A0731|68 77|phosphorus
P10231454A0731|85 89|mg/dl
P10231454A0731|93 111|alkaline phosphatase
P10231454A0731|120 126|U/liter
P10231485A0342|0 15|Sequence analysis
P10231485A0342|43 82|molybdopterin guanine dinucleotide cofactor
P10231485A0342|86 91|4Fe-4S
P10231485A0342|92 98|cluster
P10231485A0342|118 123|4Fe-4S
P10231485A0342|123 130|clusters
P10231485A0342|156 170|membrane protein
P10231485A0342|181 199|quinol oxidation site
P10231513T0000|13 23|differences
P10231513T0000|26 51|granulation tissue formation
P10231513T0000|66 70|study
P10231581A1125|13 23|mutagenesis
P10231581A1125|45 52|SP1 sites
P10231581A1125|107 122|promoter activity
P10231862A1117|17 23|infants
P10231862A1117|67 71|acids
P10231862A1117|113 124|contribution
P10231862A1117|135 143|synthesis
P10231862A1117|154 159|plasma
P10232078A0552|0 7|Ischemia
P10232078A0552|11 21|reperfusion
P10232078A0552|42 48|release
P10232078A0552|51 66|6-keto-PGF1 alpha
P10232600T0000|17 23|antigen
P10232600T0000|62 71|expression
P10232600T0000|73 93|sodium iodide symporter
P10232600T0000|96 118|prostate cancer cell lines
P10232872A0081|50 57|subgroup
P10232872A0081|68 77|population
P10233147A0218|0 4|Ras2p
P10233147A0218|22 27|growth
P10233147A0218|54 70|signaling pathways
P10233147A0218|74 90|filamentation MAPK
P10233147A0218|91 108|Cdc42p/Ste20p/MAPK
P10233147A0218|109 115|cascade
P10233147A0218|135 147|protein kinase
P10233147A0218|148 161|Cyr1p/cAMP/PKA
P10233147A0218|162 168|pathway
P10233885A0899|18 27|prediction
P10233885A0899|28 40|transfections
P10233885A0899|61 74|cell line Jurkat
P10233885A0899|96 105|activation
P10233885A0899|111 123|mim-1 promoter
P10233885A0899|137 147|p30 isoforms
P10233946A0000|26 44|spleen necrosis virus
P10233946A0000|61 67|repeats
P10233946A0000|127 136|expression
P10233946A0000|144 159|leukemia virus RNA
P10233946A0000|174 183|hypothesis
P10233946A0000|188 193|SNV RNA
P10233946A0000|213 219|element
P10233946A0000|253 260|proteins
P10234698A0728|29 35|effects
P10234698A0728|38 51|CNS development
P10234698A0728|53 58|number
P10234698A0728|61 73|animal studies
P10234698A0728|87 98|pretreatment
P10234698A0728|103 117|corticosteroids
P10234698A0728|140 144|brain
P10234698A0728|165 170|injury
P10234698A0728|192 200|treatment
P10235265A0197|5 13|mechanism
P10235265A0197|56 61|system
P10235265A0197|84 103|proteolysis machinery
P10235265A0197|127 139|cyclin subunit
P10236651T0000|0 9|Predictors
P10236651T0000|12 18|success
P10236651T0000|21 34|pharmacy school
P10236651T0000|49 65|admission criteria
P10240361T0000|8 13|survey
P10240361T0000|31 45|dissatisfaction
P10240361T0000|51 60|physicians
P10243927A0000|3 8|series
P10243927A0000|23 31|fire tests
P10243927A0000|32 44|investigators
P10243927A0000|50 69|IIT Research Institute
P10243927A0000|96 106|door control
P10243927A0000|120 129|fire origin
P10243927A0000|154 159|spread
P10243927A0000|167 171|smoke
P10243927A0000|175 179|gases
P10271171A0458|6 10|LATCH
P10271171A0458|24 28|shift
P10271171A0458|31 44|identification
P10271171A0458|50 56|library
P10271171A0458|90 103|resource center
P10281637A0000|0 8|Reporting
P10281637A0000|18 23|events
P10281637A0000|47 52|trials
P10281637A0000|70 74|drugs
P10281637A0000|78 84|complex
P10281637A0000|101 105|issue
P10304090T0000|0 18|Medicare SNF benefits
P10308312A0203|6 10|paper
P10308312A0203|21 26|status
P10308312A0203|32 44|understanding
P10308312A0203|50 70|interaction mechanisms
P10308312A0203|73 82|ultrasound
P10308312A0203|97 101|media
P10308312A0203|108 114|factors
P10308312A0203|144 150|effects
P10318806A0000|0 6|Members
P10318806A0000|12 18|mitogen
P10318806A0000|28 34|protein
P10318806A0000|40 51|kinase family
P10318806A0000|80 85|kinase
P10318806A0000|102 116|protein kinase-1
P10318806A0000|116 120|c-Jun
P10318806A0000|133 138|kinase
P10318806A0000|157 164|elements
P10318806A0000|180 185|signal
P10318806A0000|197 209|growth factors
P10318806A0000|210 218|cytokines
P10318806A0000|231 236|agents
P10318806A0476|12 16|study
P10318806A0476|64 73|MAP kinases
P10318806A0476|96 104|responses
P10318806A0918|0 7|Analyses
P10318806A0918|10 17|tyrosine
P10318806A0918|33 45|PDGF receptors
P10318806A0918|54 64|Src homology
P10318806A0918|83 90|proteins
P10318806A0918|100 115|Src family kinases
P10318806A0918|116 143|phosphatidylinositol 3-kinase
P10318806A0918|164 170|protein
P10318806A0918|181 191|Src homology
P10318806A0918|209 224|phosphatase SHP-2
P10318806A0918|225 244|phospholipase C-gamma
P10318806A0918|300 309|activation
P10318859A0535|14 22|calpeptin
P10318859A0535|31 50|tyrosine phosphatases
P10318859A0535|60 82|tyrosine phosphorylation
P10318859A0535|97 104|paxillin
P10318900A0637|27 33|studies
P10318900A0637|39 60|electron cryomicroscopy
P10318900A0637|74 80|binding
P10318900A0637|91 96|8H2/G5
P10318900A0637|112 123|conformation
P10318900A0637|129 134|capsid
P10318900A0637|141 150|efficiency
P10318900A0637|153 166|mRNA production
P10318900A0637|201 208|particle
P10318918A0824|17 24|analysis
P10318918A0824|55 60|region
P10318918A0824|75 79|motif
P10318918A0824|106 117|HCV genotypes
P10319320A1022|18 25|findings
P10319320A1022|34 40|16K hPRL
P10319320A1022|64 76|Ras activation
P10319320A1022|81 90|antagonism
P10319320A1022|130 138|mechanism
P10319320A1022|145 151|control
P10319320A1022|154 165|angiogenesis
P10319327A1237|0 7|Analysis
P10319327A1237|10 49|SRE oligonucleotide gel mobility shift assays
P10319327A1237|61 68|extracts
P10319327A1237|80 84|cells
P10319327A1237|100 107|presence
P10319327A1237|153 166|protein E12/E47
P10319955A0941|12 22|differences
P10319955A0941|29 42|occlusion rates
P10319955A0941|54 63|chi-square
P10319955A0941|82 92|differences
P10320177A0487|0 27|Baseline electrocorticography
P10320177A0487|35 41|surface
P10320177A0487|64 87|depth electrode recordings
P10320177A0487|92 99|amygdala
P10320177A0487|103 113|hippocampus
P10320177A0487|145 153|recording
P10320177A0487|170 187|i.v. administration
P10320177A0487|194 203|alfentanil
P10320177A0487|206 214|microg/kg
P10320177A0487|218 225|fentanyl
P10320177A0487|228 236|microg/kg
P10320480A0451|18 23|system
P10320480A0451|69 78|C-terminus
P10320480A0451|83 93|beta subunit
P10320480A0451|102 114|RNA polymerase
P10320579A1831|49 67|flagellar chaperones
P10320579A1831|77 91|oligomerization
P10320579A1831|126 132|domains
P10320579A1831|138 143|export
P10321158T0000|9 23|core fabrication
P10321158T0000|35 40|canals
P10321158T0000|46 53|cast post
P10321158T0000|80 84|dowel
P10322022A0263|0 5|Rep63A
P10322022A0263|9 18|amino acids
P10322022A0263|62 71|similarity
P10322022A0263|71 79|% identity
P10322022A0263|85 103|replication proteins
P10322022A0263|108 123|plasmids pAMbeta1
P10322022A0263|124 129|pIP501
P10322022A0263|133 140|pSM19035
P10322022A0263|158 170|pAW63 replicon
P10322022A0263|183 196|pAMbeta1 family
P10322022A0263|229 236|plasmids
P10322629A0198|15 21|cloning
P10322629A0198|25 40|characterization
P10322629A0198|43 54|Xenopus Pax-5
P10322629A0198|58 62|Pax-8
P10322629A0198|66 76|orthologues
P10322629A0198|82 86|Pax-2
P10322629A0198|89 98|gene family
P10323225A0244|0 7|Km values
P10323225A0244|11 18|ammonium
P10323225A0244|19 32|2-oxoglutarate
P10323225A0244|39 47|glutamate
P10323463T0000a|0 15|Interferon-alpha
P10323463T0000a|61 74|manifestations
P10323463T0000a|84 89|effect
P10323463T0000a|128 135|activity
P10323463T0000b|0 15|Interferon-alpha
P10323463T0000b|61 74|manifestations
P10323463T0000b|84 89|effect
P10323463T0000b|128 135|activity
P10323863A0852|2 9|addition
P10323863A0852|30 39|production
P10323863A0852|59 68|telomerase
P10323863A0852|78 83|factor
P10323863A0852|86 109|rabbit reticulocyte lysate
P10323863A0852|122 146|ribonucleoprotein assembly
P10325413A1211|11 17|binding
P10325413A1211|20 24|c-Abl
P10325413A1211|27 63|DNA containing 5-methylcytosine residues
P10325413A1211|88 97|propensity
P10325413A1211|109 113|helix
P10325413A1211|158 166|reduction
P10325413A1211|186 196|interaction
P10326221A0531|10 17|mutation
P10326221A0531|23 30|children
P10326221A0531|36 45|amputation
P10326221A0531|66 74|fulminans
P10326654A0351|11 26|pilot experiments
P10326654A0351|49 57|durations
P10326654A0351|73 80|ischemia
P10326654A0351|98 104|minutes
P10326654A0351|108 116|durations
P10326654A0351|140 144|study
P10326654A0351|147 153|minutes
P10326654A0351|154 158|group
P10326654A0351|179 190|fibrillation
P10326654A0351|220 230|arrhythmias
P10326654A0351|234 240|minutes
P10326654A0351|241 245|group
P10326654A0351|258 267|prevalence
P10326654A0351|305 314|difference
P10326654A0351|319 326|duration
P10326654A0351|329 336|ischemia
P10326856T0000|12 33|pancreaticojejunostomy
P10326856T0000|50 67|purse-string device
P10327051A0688|27 57|Stress-Activated-Protein-Kinase
P10327051A0688|64 74|target sites
P10327051A0688|82 86|Thr69
P10327051A0688|89 93|Thr71
P10327051A0688|114 122|formation
P10327051A0688|128 139|p300/CBP-ATF
P10327051A0688|152 158|complex
P10328351A0443|0 11|Blood samples
P10328351A0443|39 59|supplementation period
P10329135A1326|5 11|results
P10329135A1326|36 47|presequences
P10329135A1326|63 70|mt-hsp70
P10329135A1326|97 109|protein import
P10329566A0610|4 11|terminus
P10329566A0610|17 22|genome
P10329566A0610|57 65|structure
P10329566A0610|74 88|valine anticodon
P10329566A0610|101 109|structure
P10329566A0610|116 125|pseudoknot
P10329566A0610|131 143|aminoacyl stem
P10329566A0610|145 151|feature
P10329566A0610|164 169|genera
P10329566A0610|172 183|tetraviruses
P10329574A1733|13 17|RNA-7
P10329574A1733|96 107|OnuMV4-Ld RNA
P10329574A1733|124 132|deletions
P10329586A0414|13 23|fibronectin
P10329586A0414|58 69|LNCaP-r cells
P10329586A0414|101 114|overexpression
P10329586A0414|123 136|prostate cancer
P10329625A0715|18 31|cell surface CD4
P10329625A0715|40 44|cells
P10329625A0715|57 64|TCR genes
P10329625A0715|125 129|cells
P10329736A0681|23 27|yeast
P10329736A0681|38 43|system
P10329736A0681|44 48|mIRS3
P10329736A0681|67 76|p85 subunit
P10329736A0681|79 106|phosphatidylinositol 3-kinase
P10329736A1106|0 17|Insulin stimulation
P10329736A1106|29 39|association
P10329736A1106|42 46|mIRS3
P10330134A0765|3 16|mRNA expression
P10330134A0765|68 95|transient-transfection assays
P10330134A0765|105 119|RFX binding sites
P10330134A0765|122 126|front
P10330134A0765|135 142|promoter
P10330134A0765|167 172|tissue
P10330134A0765|192 197|manner
P10330146A0730|28 33|intron
P10330146A0730|33 42|repression
P10330146A0730|45 64|luciferase expression
P10330146A0730|94 102|sequences
P10330146A0730|108 127|luciferase expression
P10330146A0730|142 149|deletion
P10330146A0730|157 161|sites
P10330159A1258|32 41|components
P10330159A1258|52 61|activation
P10330159A1258|68 84|promoter/enhancer
P10330159A1258|99 103|NFAT1
P10330159A1258|161 167|Jun-Fos
P10330168A0135|26 32|kinases
P10330168A0135|36 42|cyclin B
P10330168A0135|63 68|kinase
P10330168A0135|68 77|Cdk/Cdc28p
P10330168A0135|81 85|Cdc7p
P10330168A0135|109 119|factor Dbf4p
P10330168A0135|151 164|DNA replication
P10330396A0387|3 22|RanQ69L preincubation
P10330396A0387|30 41|accumulation
P10330396A0387|66 74|periphery
P10330396A0387|86 96|pore complex
P10330396A0387|104 114|association
P10330396A0387|121 130|p62 complex
P10330396A0387|134 143|Can/Nup214
P10331276A0298|8 15|elements
P10331276A0298|33 41|structure
P10331646A0595|2 9|contrast
P10331646A0595|20 36|amino acid sequence
P10331646A0595|46 51|family
P10331646A0595|60 71|transferases
P10331646A0595|87 99|lymphoma cells
P10331646A0595|118 126|abundance
P10331646A0595|129 134|testis
P10331646A0595|155 167|amino terminus
P10331646A0595|183 196|signal sequence
P10331646A0595|217 230|signal sequence
P10331646A0595|236 251|carboxyl terminus
P10331646A0595|269 275|protein
P10331646A0595|289 294|export
P10331730A0504|0 6|RESULTS
P10331730A0504|32 36|cases
P10331730A0504|41 48|Sardinia
P10331730A0504|76 83|patients
P10331730A0504|100 110|study period
P10331730A0504|141 147|centres
P10331875A0523|4 17|dimer interface
P10331875A0523|62 72|specificity
P10331875A0523|76 83|affinity
P10331875A0523|131 143|cooperativity
P10331875A0523|157 163|trimers
P10332733A0000|3 21|paramyxovirus fusion
P10332733A0000|25 31|protein
P10332733A0000|39 52|membrane fusion
P10333481A1102|12 27|deletion analysis
P10333481A1102|52 61|constructs
P10333481A1102|84 89|region
P10333481A1102|103 118|promoter activity
P10333481A1102|164 171|enhancer
P10333481A1102|199 212|promoter region
P10333526A0459|3 11|hTERT gene
P10333526A0459|50 54|exons
P10333529A0277|4 14|betaAPP mRNA
P10333529A0277|18 28|Abeta levels
P10333529A0277|43 49|trisomy
P10334888A0960|2 13|reperfusion B
P10334888A0960|29 33|group
P10334888A0960|58 65|increase
P10334888A0960|68 85|IL-8 concentrations
P10334888A0960|109 120|nondiabetics
P10336495A0547|4 13|repression
P10336495A0547|25 32|agonists
P10336495A0547|41 48|receptor
P10336495A0547|73 83|interaction
P10336495A0547|100 108|PPARalpha
P10336495A0547|123 130|RXRalpha
P10336495A0547|144 152|complexes
P10336495A0547|164 168|cells
P10339552A0361|12 16|study
P10339552A0361|27 36|SRm160/300
P10339552A0361|79 86|splicing
P10339552A0361|89 96|pre-mRNA
P10339566A0602|0 5|Spc42p
P10339566A0602|26 34|component
P10339566A0602|49 61|SPB subcomplex
P10339566A0602|72 83|Spc94p/Nud1p
P10339566A0602|84 89|Cnm67p
P10339566A0602|93 98|Spc42p
P10340447A0424|10 21|coefficients
P10340447A0424|24 34|correlation
P10340447A0424|71 79|QIT system
P10340883A1266|16 24|stage IIIB
P10340883A1266|51 55|stage
P10341219A0481|11 31|heparin lyase treatment
P10341219A0481|34 41|extracts
P10341219A0481|44 48|cells
P10341219A0481|70 85|YD-repeat protein
P10341219A0481|98 104|protein
P10341219A0481|122 135|mass aggregates
P10342511A0909|3 13|coefficient
P10342511A0909|16 28|determination
P10342511A0909|43 48|scores
P10342536A0954|5 17|determination
P10342536A0954|23 36|protein content
P10342536A0954|42 49|formulae
P10342536A0954|61 71|information
P10342536A0954|72 90|RAST/EAST inhibition
P10342536A0954|148 158|whey formula
P10342536A0954|176 193|whey/casein formula
P10342536A0954|194 216|soy/pork collagen formula
P10342536A0954|223 238|amino acid formula
P10342829A0236|2 6|light
P10342829A0236|12 21|importance
P10342829A0236|24 28|GnRHR
P10342829A0236|41 50|mechanisms
P10342829A0236|79 88|regulation
P10342829A0236|99 103|GnRHR
P10342829A0236|104 109|hGnRHR
P10342829A0236|126 130|issue
P10342829A0236|150 161|reproduction
P10342829A1370|11 29|mobility shift assays
P10342829A1370|41 49|alphaT3-1
P10342829A1370|57 63|extract
P10342829A1370|77 87|SF-1 protein
P10342829A1370|150 159|GSE element
P10343189A0911|0 4|Grade
P10343189A0911|6 14|mucositis
P10343189A0911|29 35|patient
P10344736A0796|0 19|CDK4 kinase activities
P10344736A0796|43 48|levels
P10344736A0796|54 72|CDK inhibitor p21Cip1
P10344736A0796|82 103|cyclin E immunocomplexes
P10347144A0516|22 28|protein
P10347144A0516|43 59|baculovirus system
P10347144A0516|116 123|sequence
P10347144A0516|124 128|AVQGP
P10347197A0502|0 8|Induction
P10347197A0502|14 30|urokinase promoter
P10347197A0502|33 38|HGF/SF
P10347197A0502|45 55|Met receptor
P10347197A0502|68 80|co-expression
P10347197A0502|110 132|Sos1 expression construct
P10347203A0832|0 20|Serine phosphorylation
P10347203A0832|23 27|STAT3
P10347203A0832|48 68|somatostatin treatment
P10347203A0832|86 99|pertussis toxin
P10347203A0832|136 144|increases
P10347203A0832|146 158|proliferation
P10347220A1477|53 57|yeast
P10347220A1477|65 73|apparatus
P10347220A1477|91 104|triphosphatase
P10347220A1477|104 108|Cet1p
P10347220A1477|109 130|RNA guanylyltransferase
P10347220A1477|131 135|Ceg1p
P10347220A1477|139 143|Abd1p
P10347220A1477|192 200|apparatus
P10347220A1477|226 264|triphosphatase-guanylyltransferase Mce1p
P10347220A1477|271 291|methyltransferase Hcm1
P10347839A0434|3 12|IC50 values
P10347839A0434|36 42|bladder
P10348859A0292|25 36|binding sites
P10348859A0292|48 60|MerR homodimer
P10348859A0292|92 96|Cys82
P10348859A0292|102 108|monomer
P10348859A0292|112 117|Cys117
P10348859A0292|121 126|Cys126
P10349084T0000|3 11|influence
P10349084T0000|26 44|virus seropositivity
P10349084T0000|50 57|efficacy
P10349084T0000|77 84|globulin
P10349084T0000|87 94|children
P10349084T0000|121 127|purpura
P10349443A0358|3 9|results
P10349443A0358|23 32|field tests
P10349443A0358|43 48|levels
P10349443A0358|51 61|infestation
P10349443A0358|64 69|larvae
P10349443A0358|74 79|values
P10350027A0942|0 10|Amisulpride
P10350027A0942|35 41|effects
P10350027A0942|43 53|psychomotor
P10350027A0942|86 96|performance
P10350454A0000|21 31|glycosylase
P10350454A0000|35 45|specificity
P10350454A0000|49 58|mismatches
P10350454A0000|68 79|8-oxoguanine
P10350454A0000|97 103|guanine
P10350484A0346|3 10|kinetics
P10350484A0346|13 26|kinase activity
P10350484A0346|38 46|complexes
P10350484A0346|91 99|% decrease
P10350484A0346|128 135|increase
P10350638A0000|0 6|Latexin
P10350638A0000|8 33|carboxypeptidase A inhibitor
P10350638A0000|67 72|manner
P10350638A0000|105 111|systems
P10353073A0118|0 17|Regression analyses
P10353073A0118|49 55|factors
P10353880A0257|48 54|infants
P10353880A0257|69 74|births
P10353880A0257|79 87|diagnosis
P10355085A1119|0 6|Subsets
P10355085A1119|9 16|patients
P10355085A1119|44 51|severity
P10355085A1119|54 59|trauma
P10355085A1119|98 110|injury pattern
P10355085A1119|113 121|survivors
P10355085A1119|128 139|nonsurvivors
P10355536A0172|19 23|years
P10355536A0172|23 27|range
P10355536A0172|33 37|years
P10355910A0369|13 21|follow-up
P10355910A0369|30 34|years
P10357751A0866|10 14|group
P10357751A0866|25 32|children
P10357751A0866|48 52|score
P10357751A0866|59 64|weight
P10357751A0866|125 129|death
P10357751A0866|194 201|children
P10357751A0866|213 219|disease
P10357751A0866|239 243|score
P10357751A0866|247 252|weight
P10358031A0303|2 9|addition
P10358031A0303|15 19|cells
P10358031A0303|45 50|nuclei
P10358031A0303|64 72|G2/M delay
P10358031A0303|82 89|division
P10358031A0303|98 103|defect
P10358031A0303|106 116|cytokinesis
P10358031A0303|123 136|cell separation
P10358075A0984|0 4|DAF16
P10358075A0984|17 25|component
P10358075A0984|29 44|signaling pathway
P10358075A0984|96 105|homologues
P10358075A0984|111 121|insulin/IGF
P10358075A0984|123 130|receptor
P10358075A0984|131 144|PtdIns 3-kinase
P10358079A0391|7 24|neu differentiation
P10358079A0391|39 50|heterodimers
P10358079A0391|53 57|ErbB2
P10358079A0391|61 65|ErbB4
P10358079A0391|75 79|Stat5
P10358080A1114|8 20|linker regions
P10358080A1114|23 42|transcription factors
P10358080A1114|61 81|DNA binding specificity
P10358080A1114|85 91|studies
P10358080A1114|111 120|HSF1 linker
P10358080A1114|147 168|HSF1 binding preferences
P10358080A1114|188 198|determinant
P10358080A1114|214 242|HSF1 monomer-trimer equilibrium
P10358080T0000|0 9|Modulation
P10358080T0000|17 44|heat shock factor trimerization
P10358080T0000|50 61|linker domain
P10358083A0263|14 21|analyses
P10358083A0263|57 63|F9 cells
P10358083A0263|67 82|characterization
P10358083A0263|96 104|complexes
P10358083A0263|129 148|sequence motifs GTGACT
P10358083A0263|151 155|ATTGT
P10358083A0263|172 190|transcription factor
P10358083A0263|197 201|sites
P10358138A0672|5 11|results
P10358138A0672|26 34|phenotype
P10358138A0672|64 72|signaling
P10358138A0672|104 123|cell surface molecules
P10358138A0672|142 164|signaling adaptor protein
P10359014A1077|18 42|Fra-2 phosphorylation sites
P10359014A1077|58 66|threonine
P10359014A1077|74 87|serine residues
P10359014A1077|106 111|region
P10359014A1077|114 118|means
P10359014A1077|134 144|mutagenesis
P10359014A1077|161 177|threonine residues
P10359575A0317|45 53|FcalphaRI
P10359575A0317|93 97|bIgG2
P10359575A0317|102 111|bFcgamma2R
P10359575A0317|117 121|bIgG2
P10359603A0430|0 4|Vac1p
P10359603A0430|22 41|Sec1p homologue Vps45p
P10359663A0425|30 35|system
P10359663A0425|54 60|regions
P10359663A0425|63 69|oIFNtau
P10359663A0425|84 88|front
P10359663A0425|97 101|virus
P10359663A0425|110 117|promoter
P10359663A0425|120 126|regions
P10359663A0425|134 138|bases
P10359663A0425|174 187|enhancer region
P10359663A0425|199 229|oIFNtau-SV40-CAT transactivation
P10359663A1280|2 23|co-transfection studies
P10359663A1280|27 36|expression
P10359663A1280|39 43|c-Jun
P10359663A1280|48 52|c-Fos
P10359663A1280|64 78|transactivation
P10359663A1280|81 91|oIFNtau-CAT
P10359663A1280|98 107|expression
P10359663A1280|110 115|GATA-1
P10359663A1280|116 121|GATA-2
P10359663A1280|124 129|GATA-3
P10359664A0579|15 19|sites
P10359664A0579|39 44|MARCKS
P10359664A0579|60 76|lysyl endoprotease
P10359664A0579|90 104|electrospray MS.
P10359673A0000|3 15|yeast LPD1 gene
P10359673A0000|24 45|lipoamide dehydrogenase
P10359673A0000|67 73|control
P10359673A0000|76 96|amino acid biosynthesis
P10359673A0000|110 132|GCN4 transcription factor
P10359792A0610|17 23|defects
P10359792A0610|34 44|Rpd3 mutants
P10359792A0610|77 83|Groucho
P10359792A0610|87 110|dCtBP corepressor proteins
P10359792A0610|140 150|recruitment
P10359792A0610|153 171|histone deacetylases
P10360454A0916|10 32|serum TNF-a concentration
P10360454A0916|57 64|patients
P10360454A0916|74 87|pentoxifylline
P10360454A0916|99 103|pg/ml
P10360454A0916|107 111|month
P10360454A0916|118 122|pg/ml
P10360454A0916|142 153|control group
P10360839A1338|2 9|addition
P10360839A1338|23 32|expression
P10360839A1338|45 51|members
P10360839A1338|57 65|subfamily
P10360839A1338|68 86|KRAB zinc finger genes
P10360839A1338|122 133|cell lineages
P10360947A1113|9 32|fluorescence spectroscopy
P10360947A1113|44 52|dichroism
P10360947A1113|68 74|binding
P10360947A1113|84 88|ALG-2
P10360947A1113|120 126|changes
P10360947A1113|159 165|domains
P10360947A1113|171 177|protein
P10361038A0281|22 30|locations
P10361038A0281|36 44|promoters
P10361038A0281|68 79|protein genes
P10362652A0350|4 12|carbachol
P10362652A0350|16 21|microM
P10362652A0350|43 55|Ras activation
P10362652A1456|33 52|carbachol stimulation
P10362652A1456|54 60|HA-ERK2
P10362652A1456|87 92|effect
P10362897A0545|0 6|RESULTS
P10362897A0545|21 27|passage
P10362897A0545|30 37|contrast
P10362897A0545|58 64|amounts
P10362897A0545|77 85|intensity
P10362897A0545|91 103|Doppler signal
P10362897A0545|123 130|duration
P10362897A0545|137 142|effect
P10363517A0401|6 10|paper
P10363517A0401|15 21|lesions
P10363517A0401|27 31|cases
P10363517A0401|47 61|ultrasonography
P10364076A0429|5 11|regions
P10364076A0429|27 31|E-box
P10364076A0429|51 62|repeat motifs
P10364076A0429|70 76|SREBP-1
P10364076A0429|90 99|affinities
P10364159A0813|14 22|questions
P10364159A0813|35 50|FRAP/mTOR protein
P10364159A0813|55 80|FRAP/mTOR immunoprecipitate
P10364159A0813|102 113|kinase assays
P10364159A0813|129 134|4E-BP1
P10364163A0092|21 36|zinc finger domain
P10364163A0092|57 76|phosphatidylinositol
P10364163A0092|76 84|phosphate
P10364163A0092|108 115|proteins
P10364163A0092|135 141|traffic
P10364202A0646|3 14|coexpression
P10364202A0646|28 47|expression constructs
P10364202A0646|70 83|leukemia factor
P10364202A0646|102 109|increase
P10364202A0646|112 121|activation
P10364202A0646|135 156|GAL4-DBP fusion proteins
P10364202A0646|170 180|involvement
P10364202A0646|193 203|coactivator
P10364202A0646|210 216|process
P10364314A0919|5 14|subgenomes
P10364314A0919|34 44|nucleotides
P10364314A0919|71 77|NS2 gene
P10364319A0109|21 28|promoter
P10364319A0109|31 48|EBNA mRNA initiation
P10364319A0109|64 69|EBNA3C
P10364319A0109|106 116|control loop
P10364425A0610|5 15|indications
P10364425A0610|29 38|signalling
P10364425A0610|44 50|absence
P10364425A0610|53 60|tyrosine
P10364425A0610|92 101|activation
P10364425A0610|104 108|STAT3
P10364523A0826|4 15|exon trapping
P10364523A0826|43 47|exons
P10364523A0826|55 63|YAC 946E12
P10364523A0826|76 81|region
P10364523A0826|111 116|contig
P10364523A0826|122 129|vicinity
P10364523A0826|135 145|breakpoints
P10364523T0000|10 42|dysplasia translocation breakpoints
P10364523T0000|80 87|evidence
P10364523T0000|99 111|control region
P10365883A1355|13 27|characteristics
P10365883A1355|30 40|VRE patients
P10365883A1355|56 68|vancomycin use
P10365883A1355|103 111|infection
P10365883A1355|112 122|coinfection
P10365883A1355|141 149|pathogens
P10365883A1355|169 177|infection
P10366446A0893|12 17|domain
P10366446A0893|44 50|protein
P10366446A0893|69 84|interaction motif
P10366446A0893|88 93|FLI LRR
P10366503A0812|0 16|Binding affinities
P10366503A0812|35 40|phages
P10366503A0812|58 66|retention
P10366503A0812|74 79|phages
P10366503A0812|83 89|His-tag
P10366503A0812|101 110|gp17 column
P10366503A0812|116 137|co-immunoprecipitation
P10366503A0812|150 158|terminase
P10366503A0812|179 184|nature
P10366503A0812|196 202|protein
P10366503A0812|206 230|terminase interaction sites
P10366503A1506|11 19|terminase
P10366503A1506|59 65|peptide
P10366503A1506|75 82|antibody
P10366503A1506|99 105|peptide
P10366503A1506|121 126|access
P10366503A1506|140 148|structure
P10366503A1506|167 177|association
P10366503A1506|215 230|terminase regions
P10366503A1506|238 243|portal
P10366503A1506|249 264|packasome complex
P10366559A0605|3 15|hybrid viruses
P10366559A0605|43 48|levels
P10366559A0605|59 64|plants
P10366559A0605|77 83|virions
P10366722T0000|19 30|organization
P10366722T0000|35 43|gene Pole1
P10366722T0000|50 74|mouse DNA polymerase epsilon
P10366722T0000|84 90|subunit
P10367240A1354|12 27|cryopreservation
P10367240A1354|30 40|spermatozoa
P10367240A1354|44 49|medium
P10367240A1354|84 93|substances
P10367240A1354|115 128|cryoprotection
P10367240A1354|131 141|spermatozoa
P10367240A1354|160 182|fertilization procedures
P10367240A1354|212 225|sperm injection
P10367385A0000|22 27|method
P10367385A0000|42 49|analysis
P10367385A0000|52 64|beta-carotene
P10367460A0191|3 16|FCMS conditions
P10367460A0191|31 39|kW maximum
P10367460A0191|50 65|power consumption
P10367460A0191|69 92|V maximum capacitor voltage
P10367460A0191|96 107|microseconds
P10367460A0191|121 132|microseconds
P10367460A0191|150 160|Hz frequency
P10367646A0569|6 14|hemolysis
P10367646A0569|49 55|changes
P10367646A0569|61 70|mean values
P10367646A0569|81 88|analytes
P10367646A0569|91 98|addition
P10367646A0569|113 121|increases
P10367646A0569|122 144|alanine aminotransferase
P10367646A0569|145 151|calcium
P10367646A0569|155 168|serum globulins
P10367646A0569|181 187|albumin
P10367646A0569|195 201|protein
P10369418A0644|22 29|extracts
P10369418A0644|45 55|stimulation
P10369418A0644|60 64|CD40L
P10369418A0644|77 85|induction
P10369418A0644|88 105|NF-kappaB complexes
P10369418A0644|130 143|NF-kappaB sites
P10369418A0644|194 198|c-Rel
P10369625A0942|7 16|monitoring
P10369757A0000|8 27|transcription factors
P10369757A0000|39 56|arginine metabolism
P10369757A0000|77 92|Bacillus subtilis
P10369757A0000|143 150|proteins
P10369757A0000|189 197|complexes
P10369757A0000|216 228|transcription
P10369757A0000|246 250|genes
P10369757A0000|265 277|transcription
P10369757A0000|289 293|genes
P10369757A0000|318 339|plasmid dimer resolution
P10369775A0178|10 25|protein fragments
P10369775A0178|35 55|residues Arg183-His267
P10369775A0178|73 93|residues Lys438-Gln520
P10369775A0178|98 102|rat GR
P10369926A0251|8 22|intron structure
P10369926A0251|24 33|chicken IL8
P10369926A0251|116 132|CXC chemokine genes
P10369965A0000|3 13|Aa-Pri2 gene
P10369965A0000|41 66|basidiocarp differentiation
P10369965A0000|72 95|mushroom Agrocybe aegerita
P10370675A0649|7 12|causes
P10370675A0649|15 26|liver disease
P10370675A0649|32 39|patients
P10370675A0649|53 67|hepatitis C virus
P10370675A0649|76 87|alcohol abuse
P10370675A0649|96 106|combination
P10370675A0649|116 127|alcohol abuse
P10370778A0000|8 26|aromatase inhibitors
P10370778A0000|48 52|phase
P10370778A0000|56 65|evaluation
P10370778A0000|68 76|treatment
P10370778A0000|89 100|breast cancer
P10370778A0000|118 122|women
P10370778A0000|128 134|disease
P10370778A0000|155 170|tamoxifen therapy
P10370778A0000|171 181|anastrozole
P10370778A0000|182 189|ARIMIDEX
P10370778A0000|190 195|Zeneca
P10370778A0000|196 204|letrozole
P10370778A0000|205 210|FEMARA
P10370778A0000|211 218|Novartis
P10370778A0000|222 229|vorozole
P10370778A0000|230 236|RIVIZOR
P10370778A0000|237 243|Janssen
P10371097A0963|0 10|CONCLUSIONS
P10371097A0963|11 19|Turbutest
P10371097A0963|48 55|patients
P10371097A0963|55 62|training
P10371097A0963|71 84|identification
P10371097A0963|88 98|improvement
P10371097A0963|113 131|inhalation technique
P10371097A0963|136 145|Turbuhaler
P10372627A0530|7 14|injuries
P10372627A0530|18 22|cases
P10372627A0530|27 35|snowboard
P10372627A0530|49 53|cases
P10373029A0204|10 20|artery/vein
P10373029A0204|27 32|soleus
P10373029A0204|36 55|gastrocnemius muscles
P10373029A0204|86 95|volunteers
P10373507A0680|0 8|SRFDelta5
P10373507A0680|60 65|mutant
P10373507A0680|97 107|alpha-actin
P10373507A0680|115 125|alpha-actin
P10373507A0680|132 142|alpha-actin
P10373507A0680|143 151|SM22alpha
P10373507A0680|155 194|SRF promoter-luciferase reporter activities
P10373523A0924|12 16|media
P10373523A0924|17 22|p50E4F
P10373523A0924|45 53|apoptosis
P10374632A0818|3 9|potency
P10374632A0818|15 20|effect
P10374632A0818|31 37|mg.kg-1
P10374632A0818|66 72|mg.kg-1
P10374632A0897|0 9|CONCLUSION
P10374632A0897|10 25|NBP pre-treatment
P10374632A0897|69 76|striatum
P10374632A0897|78 86|RMCAO rats
P10375107A1138|0 10|Progression
P10375107A1138|26 37|chemotherapy
P10375107A1138|73 80|survival
P10375107A1138|84 91|patients
P10375107A1138|96 105|metastasis
P10375638A0859|0 8|Mutations
P10375638A0859|34 48|NRF-1 expression
P10375638A0859|84 93|efficiency
P10375638A0859|106 110|cells
P10375638A0859|125 141|translation system
P10375640A0153|18 35|nucleotide sequence
P10375640A0153|47 51|CBS-1
P10375640A0153|65 76|reading frame
P10375640A0153|92 101|amino acids
P10375640A0153|116 121|weight
P10375694T0000|36 45|input zones
P10375694T0000|69 77|motor area
P10375694T0000|90 95|monkey
P10375694T0000|96 105|comparison
P10375694T0000|113 122|input zones
P10375694T0000|143 151|motor area
P10375718A0000|5 26|fibroblast growth factor
P10375718A0000|53 64|angiogenesis
P10375718A0000|73 84|animal models
P10375718A0000|91 97|methods
P10375718A0000|100 113|administration
P10376065A0881|4 10|filters
P10376065A0881|31 39|elevation
P10376065A0881|53 60|pressure
P10376065A0881|61 66|median
P10376065A0881|76 79|mm Hg
P10376065A0881|92 103|spring filter
P10376065A0881|106 115|RF02 filter
P10376446A0000|9 13|women
P10376446A0000|24 28|years
P10376446A0000|48 53|2-hour
P10376446A0000|55 60|method
P10376446A0000|105 110|luteal
P10376446A0000|112 117|phases
P10376446A0000|134 138|cycle
P10376873A0706|4 9|sgRNA2
P10376874A0759|21 27|defects
P10376874A0759|33 52|eRF1-eRF3 interaction
P10376874A0759|85 96|protein eRF3C
P10376874A0759|118 129|eRF1 proteins
P10376874A0759|153 159|protein
P10376874A0759|176 182|support
P10376874A0759|189 196|presence
P10376874A0759|210 220|interaction
P10376877A0611|0 6|Removal
P10376877A0611|30 37|segments
P10376877A0611|84 92|formation
P10376877A0611|96 101|Ss rRNA
P10376877A0611|138 143|region
P10376877A0611|148 154|protein
P10376877A0611|168 177|production
P10376877A0611|180 186|18S rRNA
P10376991A0977|27 34|tegument
P10377345A0740|0 4|Green
P10377345A0740|30 36|UNC-49B
P10377345A0740|40 54|UNC-49C subunits
P10377345A0740|71 81|muscle cells
P10377345A0740|109 115|regions
P10377438A0647|11 17|protein
P10378989A0000|14 18|study
P10378989A0000|48 54|reports
P10378989A0000|73 85|drug reactions
P10378989A0000|103 110|patients
P10378989A0000|117 121|years
P10378989A0000|131 136|Sicily
P10378989A0000|136 140|Italy
P10378989A0000|150 155|period
P10378989A0000|161 167|January
P10378989A0000|176 183|December
P10379547A0000|0 8|Molecules
P10379547A0000|46 54|radiation
P10379547A0000|54 58|MASER
P10379899A0446|8 15|findings
P10379899A0446|21 27|studies
P10379899A0446|61 67|signals
P10379899A0446|89 97|follicles
P10379899A0446|108 128|theca cell layer markers
P10379942A0956|26 33|residues
P10379942A0956|89 103|MDV2 UL10 protein
P10379942T0000|0 13|Identification
P10379942T0000|17 25|structure
P10379942T0000|31 35|Marek
P10379942T0000|37 56|disease virus serotype
P10379942T0000|58 74|glycoprotein M gene
P10379942T0000|75 84|comparison
P10379942T0000|89 106|glycoprotein M genes
P10379942T0000|109 127|Herpesviridae family
P10380232A0000|0 8|OBJECTIVE
P10380232A0000|19 44|cost-effectiveness analysis
P10380232A0000|76 97|regimen-chlorpromazine
P10380232A0000|98 110|dexamethasone
P10380232A0000|111 117|CPM-DEX
P10380232A0000|122 156|5-HT3 receptor antagonist-tropisetron
P10380232A0000|168 174|control
P10380232A0000|181 186|emesis
P10380232A0000|212 223|chemotherapy
P10380232A0000|226 233|children
P10380232A0000|256 267|perspectives
P10380232A0000|268 275|hospital
P10380232A0000|279 286|patients
P10380659A0545|0 11|Baseline data
P10380659A0545|30 35|adults
P10380800A0194|1 10|comparison
P10380800A0194|16 25|nucleotide
P10380800A0194|36 53|amino acid sequences
P10380800A0194|59 69|core regions
P10380800A0194|88 107|RNA polymerase domains
P10380800A0194|125 130|dsRNAs
P10380800A0194|149 154|dsRNAs
P10380800A0194|193 201|host plant
P10380800A0194|213 220|ancestor
P10380878A0542|18 28|possibility
P10380878A0542|37 42|region
P10380878A0542|74 91|repression function
P10380878A0542|116 133|histone deacetylase
P10380890A0619|11 19|sequences
P10381257A0000|18 24|protein
P10381257A0000|25 31|metaxin
P10381257A0000|42 50|component
P10381257A0000|54 76|preprotein import complex
P10381257A0000|87 94|membrane
P10381257A0000|109 121|mitochondrion
P10381377T0000|9 15|cloning
P10381377T0000|37 55|inositol phosphatase
P10381377T0000|56 60|SHIP2
P10381377T0000|78 87|regulation
P10381377T0000|89 104|insulin signaling
P10381570A1355|15 27|transcription
P10381570A1355|34 44|binding site
P10381570A1355|47 56|yeast cells
P10381570A1355|89 97|repressor
P10381570A1355|99 108|ftz stripes
P10381570A1355|111 128|interstripe regions
P10381570A1355|139 144|stages
P10381570A1355|147 159|embryogenesis
P10383764A1809|3 9|results
P10383764A1809|17 23|studies
P10383764A1809|32 36|model
P10383764A1809|44 54|VirB4 dimers
P10383764A1809|57 69|homomultimers
P10383764A1809|90 100|information
P10383764A1809|107 114|assembly
P10383764A1809|118 137|transenvelope channel
P10383764A1809|163 173|DNA transfer
P10383764A1809|196 203|activity
P10383764A1809|232 238|channel
P10383764A1809|251 263|export machine
P10383966A0000|3 27|penicillin binding proteins
P10383966A0000|54 66|peptidoglycan
P10383966A0000|79 87|component
P10383966A0000|102 109|cell wall
P10384129A0000|0 7|TCR alpha
P10384129A0000|14 23|expression
P10384129A0000|36 45|RNA samples
P10384129A0000|67 77|populations
P10384129A0000|94 99|T cells
P10384129A0000|111 121|individuals
P10385384A0654|7 13|results
P10385384A0654|30 36|xylitol
P10385384A0654|39 47|activator
P10385384A0654|53 75|pentose phosphate pathway
P10385395A0000|7 24|density lipoprotein
P10385395A0000|30 37|receptor
P10385395A0000|48 53|uptake
P10385395A0000|56 66|cholesterol
P10385395A0000|70 86|cholesteryl esters
P10385395A0000|87 96|substrates
P10385395A0000|100 114|steroidogenesis
P10385395A0000|121 131|HDL particle
P10385395A0000|144 148|gland
P10385395A0000|152 157|gonads
P10385915A1341|0 6|D3S1261
P10385915A1341|37 45|MITF locus
P10385915A1341|51 57|D3S2465
P10385915A1341|61 67|D3S1766
P10385915A1341|82 86|locus
P10385915A1341|109 116|distance
P10388670A1976|3 13|percentages
P10388670A1976|16 23|recovery
P10388670A1976|37 47|storage time
P10388670A1976|59 66|addition
P10388670A1976|69 78|dispersant
P10388670A1976|97 103|storage
P10388670A1976|130 137|adhesion
P10390158A1150|0 13|Point mutations
P10390158A1150|39 50|Pit-1 binding
P10390158A1150|69 88|tiGH promoter activity
P10390538T0000|20 37|zinc-finger protein
P10390538T0000|58 66|sequences
P10391075A0000|16 26|autopsy case
P10391075A0000|51 59|sclerosis
P10391075A0000|96 105|brain tumor
P10391075A0000|108 118|MRI findings
P10391246A0756|11 15|MOM-4
P10391246A0756|36 43|proteins
P10391246A0756|59 74|kinase activities
P10391277A0000|0 9|BACKGROUND
P10391277A0000|13 20|MAZE-III
P10391277A0000|34 42|treatment
P10391277A0000|45 50|choice
P10391277A0000|79 90|fibrillation
P10391903T0000|10 27|pleckstrin homology
P10391903T0000|44 57|adapter protein
P10391903T0000|72 80|signaling
P10391903T0000|85 93|ERK kinase
P10391903T0000|96 100|Elk-1
P10392266A0111|3 10|presence
P10392266A0111|22 30|xanthomas
P10392266A0111|41 56|serum lipid levels
P10392266A0111|86 93|activity
P10392266A0111|109 122|immunoglobulin
P10392669A0935|4 10|attempt
P10392669A0935|22 30|incidence
P10392669A0935|62 68|lesions
P10392669A0935|81 90|approaches
P10392669A0935|118 149|prostaglandin analogue misoprostol
P10392669A0935|211 220|prevention
P10392669A0935|253 258|ulcers
P10392669A0935|266 274|reduction
P10392669A0935|305 317|complications
P10392669A0935|320 349|histamine H2 receptor antagonists
P10392669A0935|350 362|H2 antagonists
P10392669A0935|367 376|ranitidine
P10392669A0935|377 386|cimetidine
P10392669A0935|390 399|famotidine
P10392669A0935|419 428|prevention
P10392669A0935|452 457|ulcers
P10392669A0935|468 480|term treatment
P10392669A0935|492 501|prevention
P10392669A0935|524 529|ulcers
P10392669A0935|533 552|proton pump inhibitors
P10392669A0935|556 565|omeprazole
P10392669A0935|569 580|pantoprazole
P10392669A0935|586 593|efficacy
P10392669A0935|622 627|ulcers
P10392669A0935|660 672|barrier agents
P10392669A0935|712 729|prophylactic agents
P10392669A0935|752 762|gastropathy
P10392710A1000|0 13|Lung mesenchyme
P10392710A1000|23 30|compleat
P10392710A1000|31 37|inducer
P10392710A1000|40 56|lung morphogenesis
P10392710A1000|75 94|peptide growth factors
P10392900A1020|3 12|activation
P10392900A1020|18 28|HIV promoter
P10392900A1020|47 58|localization
P10392900A1020|61 65|c-Abl
P10392900A1020|99 121|tyrosine phosphorylation
P10392900A1020|124 136|RNA polymerase
P10392903A0000|9 31|papillomavirus E2 protein
P10392903A0000|45 57|proliferation
P10392903A0000|60 68|HT-3 cells
P10392903A0000|90 106|carcinoma cell line
P10392903A0000|132 149|papillomavirus type
P10392903A0889|0 13|E2 point mutants
P10392903A0889|29 38|cell growth
P10392903A0889|52 57|cdc25A
P10392903A0889|61 76|cdc25B expression
P10392903A0889|86 115|cell cycle inhibitors hydroxyurea
P10392903A0889|119 126|mimosine
P10392914A0000|0 17|BACKGROUND/PURPOSE
P10392914A0000|27 37|arrangement
P10392914A0000|67 71|AAPBD
P10392914A0000|106 115|dilatation
P10392914A0000|150 164|tract malignancy
P10393192A0792|0 21|Neurospora crassa CYT-18
P10393192A0792|49 61|intron mutants
P10393192A0792|82 87|defect
P10393197A0543|21 35|heterochromatin
P10393197A0543|37 52|interphase nuclei
P10393197A0543|61 71|neuroblasts
P10393201A0654|21 35|DNA repair system
P10393201A0654|46 62|DNA polymerase beta
P10393201A0654|66 83|DNA ligase III-XRCC1
P10393201A0654|115 125|base residue
P10393201A0654|142 146|break
P10393201A0654|160 167|addition
P10393201A0654|173 183|exonuclease
P10393251A0283|3 10|PAC clone
P10393251A0283|17 26|insert size
P10393251A0283|29 33|120kb
P10393251A0283|56 74|restriction analysis
P10393251T0000|0 7|Sequence
P10393251T0000|10 19|10q24 locus
P10393251T0000|34 46|HOX11 oncogene
P10393251T0000|58 65|gene HUG1
P10393251T0000|78 90|T-ALL cell line
P10393422A0476|21 25|LAMB2
P10393422A0476|82 91|pseudogene
P10393422A0476|91 96|LAMB2L
P10393910A0705|13 23|mutagenesis
P10393910A0705|29 37|R2 protein
P10393910A0705|54 61|evidence
P10393910A0705|70 74|motif
P10393910A0705|109 120|endonuclease
P10393910A0705|132 138|element
P10393969A0000|11 24|cell protein no.
P10393969A0000|34 51|herpes simplex virus
P10393969A0000|66 79|transactivator
P10393969A0000|97 106|expression
P10393969A0000|109 113|genes
P10393969A0000|129 133|cells
P10393969A0000|136 144|infection
P10393969A0000|147 158|transfection
P10394116T0000|0 15|Wrist measurement
P10394116T0000|18 30|blood pressure
P10394116T0000|43 49|remarks
P10394116T0000|52 63|oscillometry
P10394900A1166|14 23|expression
P10394900A1166|26 31|leaves
P10394900A1166|43 50|presence
P10394900A1166|55 68|enhancer region
P10394900A1166|76 97|cauliflower mosaic virus
P10394900A1166|104 114|35S promoter
P10394919A1058|7 13|element
P10394919A1058|39 47|amplitude
P10394919A1058|53 63|oscillation
P10395199A0792|28 34|control
P10395199A0792|36 46|experiments
P10395199A0792|73 80|Y259 scFv
P10395199A0792|114 123|mAb Y13-259
P10395199A0792|134 143|Ras pathway
P10395199A0792|159 173|tumor regression
P10395199A0792|181 190|mouse model
P10395199A0792|191 196|Cochet
P10395199A0792|201 210|Kenigsberg
P10395199A0792|214 221|Delumeau
P10395199A0792|225 236|Virone-Oddos
P10395199A0792|240 245|Multon
P10395199A0792|251 257|Fridman
P10395199A0792|263 275|Schweighoffer
P10395199A0792|279 286|Teillaud
P10395199A0792|292 297|Tocque
P10395283A0960|10 20|competition
P10395283A0960|28 35|activin A
P10395283A0960|48 59|availability
P10395283A0960|61 65|Smad4
P10395283A0960|83 95|concentration
P10395283A0960|108 123|signal transducer
P10395283A0960|171 179|responses
P10395378A1198|55 76|HA envelope glycoprotein
P10395378A1198|84 90|ligands
P10395378A1198|134 147|fusion activity
P10395827A1297|17 38|parallel beta helix model
P10395827A1297|77 87|beta strands
P10395827A1297|97 113|parallel beta sheet
P10395908A0236|35 41|protein
P10395908A0236|75 81|regions
P10395908A0236|88 115|amino acid motif characteristic
P10395908A0236|121 129|R7G family
P10395908A0236|132 140|G-protein
P10395908A0236|162 170|receptors
P10395911A0288|0 15|Characterisation
P10395911A0288|21 48|chicken apolipoprotein A-I gene
P10395911A0288|57 62|region
P10395920A1424|5 11|results
P10395920A1424|23 29|members
P10395920A1424|35 43|ATF family
P10395920A1424|84 93|regulation
P10395920A1424|99 105|KGF gene
P10395920A1424|108 115|response
P10395920A1424|131 137|stimuli
P10395920A1424|162 168|element
P10396343A0754|13 22|proportion
P10396343A0754|25 36|blood samples
P10396343A0754|48 53|sample
P10396343A0754|70 77|suspects
P10396343A0754|135 147|T. b. gambiense
P10396343A0754|157 171|T. b. rhodesiense
P10396343T0000|13 22|evaluation
P10396343T0000|42 58|agglutination test
P10396343T0000|61 75|trypanosomiasis
P10396343T0000|76 88|TrypTect CIATT
P10396793A0815|0 6|Results
P10396793A0815|30 35|drinks
P10396793A0815|59 76|dependence criteria
P10396793A0815|87 96|reductions
P10396793A0815|102 111|prevalence
P10396793A0815|122 131|indicators
P10396793A0815|134 150|alcohol dependence
P10397257A1142|0 10|Mutagenesis
P10397257A1142|16 30|CDE/CHR elements
P10397257A1142|34 41|Sp1 sites
P10397257A1142|48 53|region
P10397257A1142|63 73|combination
P10397257A1142|96 103|activity
P10397257A1142|136 140|cells
P10397257A1142|152 171|cell cycle periodicity
P10397257A1142|191 195|cells
P10398286A0678|5 11|Scheffe
P10398286A0678|13 21|procedure
P10398286A0678|26 37|illustration
P10398286A0678|38 48|comparisons
P10398286A0678|63 79|sample size methods
P10398286A0678|114 119|nature
P10398682A0365|3 18|crystal structure
P10398682A0365|24 31|VP16 core
P10398682A0365|55 64|resolution
P10399136A0389|0 6|Ozagrel
P10399136A0389|7 16|ifenprodil
P10399136A0389|17 27|cinnarizine
P10399136A0389|31 37|dilazep
P10399136A0389|59 72|pentoxifylline
P10400032A0304|9 14|method
P10400032A0304|40 47|vena cava
P10400032A0304|62 72|hypotension
P10400032A0304|100 109|management
P10400593A1084|2 9|contrast
P10400593A1084|10 14|PvirE
P10400593A1084|17 38|Plac promoter constructs
P10400593A1084|56 60|VirE2
P10400593A1084|67 71|virE1
P10400593A1084|90 94|virE2
P10400712A0000|6 23|parainfluenza virus
P10400712A0000|33 41|prototype
P10400712A0000|46 66|Paramyxoviridae family
P10400712A0000|95 104|RNA viruses
P10400712A0577|16 24|functions
P10400712A0577|38 48|GS sequences
P10400712A0577|49 61|transcription
P10400712A0577|75 82|plasmids
P10400712A0577|93 97|cDNAs
P10400712A0577|114 122|SV5 genome
P10400712A0577|133 153|gene junction sequences
P10400712A0577|165 175|GS sequences
P10400712A0577|191 217|hemagglutinin-neuraminidase
P10400712A0577|228 237|polymerase
P10400712A0577|240 244|genes
P10400712A0577|263 282|counterpart sequences
P10400712A0577|292 304|gene junctions
P10400757A0000|0 4|CXCR4
P10400757A0000|8 24|chemokine receptor
P10400757A0000|29 38|coreceptor
P10400757A0000|89 113|immunodeficiency virus type
P10400757A0000|113 117|HIV-1
P10400757A0000|118 125|isolates
P10400757A1498|29 34|detail
P10400757A1498|37 41|CXCR4
P10400757A1498|52 63|requirements
P10400757A1498|84 95|HIV-1 strains
P10400757A1498|116 133|mutagenesis efforts
P10400757A1498|158 164|domains
P10400757A1498|167 171|CXCR4
P10400757A1498|185 189|HIV-1
P10400757A1498|202 214|fusion process
P10400760A0663|3 9|results
P10400760A0663|17 24|analyses
P10400760A0663|40 49|proteinase
P10400760A0663|59 84|amino acid residues E960-A961
P10400760A0663|85 95|E1071-S1072
P10400760A0663|96 106|E1345-T1346
P10400760A0663|110 120|E1419-G1420
P10400760A0663|131 148|cleavage efficiency
P10400785A0912|44 53|components
P10400785A0912|64 76|export pathway
P10400785A0912|93 101|GTPase Ran
P10400785A0912|108 128|nucleoporin CAN/Nup214
P10400794T0000|0 13|Identification
P10400794T0000|34 39|Kaposi
P10400794T0000|58 68|herpesvirus
P10400794T0000|78 84|protein
P10400794T0000|89 100|similarities
P10400794T0000|109 124|membrane proteins
P10400794T0000|147 151|virus
P10402022A0432|8 13|clicks
P10402467T0000|0 5|Myosin
P10402467T0000|11 21|chain kinase
P10402467T0000|43 49|Ras/ERK
P10402467T0000|59 67|migration
P10402467T0000|84 94|plasminogen
P10402467T0000|115 119|cells
P10402467T0000|142 147|manner
P10403575A1401|3 12|inhibition
P10403575A1401|15 35|StAR gene transcription
P10403575A1401|38 42|DAX-1
P10403575A1401|68 80|transcription
P10403575A1401|88 100|control levels
P10403690A0000|24 28|study
P10403690A0000|32 39|patients
P10403690A0000|61 74|cell lung cancer
P10403690A0000|75 79|NSCLC
P10403690A0000|80 88|stage IIIb
P10403690A0000|97 117|ECOG performance status
P10403690A0000|210 232|combination chemotherapy
P10403690A0000|229 238|IEP regimen
P10403690A0000|239 248|ifosfamide
P10403690A0000|250 254|gm/m2
P10403690A0000|261 278|mesna uroprotection
P10403690A0000|279 288|epirubicin
P10403690A0000|291 295|mg/m2
P10403690A0000|309 317|cisplatin
P10403690A0000|319 323|mg/m2
P10403690A0000|336 345|MVP regimen
P10403690A0000|345 355|mitomycin-C
P10403690A0000|357 361|mg/m2
P10403690A0000|362 370|cisplatin
P10403690A0000|374 378|mg/m2
P10403690A0000|389 399|vinblastine
P10403690A0000|400 404|mg/m2
P10403839A0140|5 23|sequence information
P10403839A0140|33 37|BMAL1
P10403839A0140|38 43|hBMAL1
P10403839A0140|44 48|cDNAs
P10403839A0140|72 81|laboratory
P10403839A0140|112 116|cDNAs
P10403839A0140|130 143|splice variants
P10403839A0140|149 158|mouse BMAL1
P10403839A0140|159 164|mBMAL1
P10403839A1459|0 9|Comparison
P10403839A1459|17 35|bHLH/PAS family genes
P10403839A1459|51 74|intron/exon splice pattern
P10403839A1459|77 82|mBMAL1
P10403839A1459|133 137|BMAL1
P10403839A1459|160 167|subclass
P10405635A0374|18 27|activities
P10405635A0374|44 51|promoter
P10405635A0374|71 88|deletion constructs
P10405635A0374|150 154|cells
P10406047A1244|29 39|differences
P10406047A1244|60 67|capacity
P10406047A1244|79 84|weight
P10406047A1244|87 92|height
P10406047A1244|96 105|compliance
P10406047A1244|122 127|system
P10406047A1244|139 144|weight
P10406047A1244|147 156|lung volume
P10406047A1244|162 171|ILD infants
P10406047A1244|192 199|controls
P10406047A1244|202 208|infants
P10406047A1244|284 295|lung function
P10406047A1244|300 307|age group
P10406122T0000|20 26|element
P10406122T0000|32 42|LTR promoter
P10406122T0000|48 73|tobacco retrotransposon Tto1
P10406122T0000|86 99|responsiveness
P10406122T0000|102 114|tissue culture
P10406122T0000|123 137|methyl jasmonate
P10406122T0000|147 155|elicitors
P10406459A0000|6 10|study
P10406459A0000|41 52|growth factor
P10406459A0000|59 92|12-O-tetradecanoyl-phorbol-acetate
P10406459A0000|100 108|forskolin
P10406459A0000|151 157|protein
P10406459A0000|157 178|Ser-133 phosphorylation
P10406459A0000|193 201|magnitude
P10406459A0000|205 212|kinetics
P10406459A0000|215 225|NIH 3T3 cells
P10406462A1127|15 22|evidence
P10406462A1127|42 46|SRC-1
P10406462A1127|68 77|activation
P10406462A1127|80 91|OR1/RXRalpha
P10406464A0687|2 9|contrast
P10406464A0687|10 31|mTRAP100 coprecipitates
P10406464A0687|49 57|component
P10406464A0687|63 73|TRAP complex
P10406464A0687|74 80|TRAP220
P10406464A0687|94 103|contacts TR
P10406464A0687|110 125|vitamin D receptor
P10406464A0687|145 150|manner
P10406465A0589|4 11|sequence
P10406465A0589|31 52|vitamin D responsiveness
P10406465A0589|67 74|promoter
P10406466A0000|32 40|receptors
P10406466A0000|45 66|thyroid hormone receptor
P10406466A0000|75 86|acid receptor
P10406466A0000|100 108|receptors
P10406843A1265|0 9|Expression
P10406843A1265|12 24|GlcNAc-TI mRNA
P10406843A1265|27 33|tobacco
P10406843A1265|56 61|RT-PCR
P10406954A0715|0 21|Chemical stability tests
P10406954A0715|38 48|mutagenesis
P10406954A0715|59 72|amino acids H219
P10406954A0715|129 136|residues
P10407184A0149|2 15|overexpression
P10407184A0149|21 31|betaAPP gene
P10407184A0149|41 45|areas
P10407184A0149|51 57|AD brain
P10407184A0149|89 94|factor
P10407184A0149|100 113|neuropathology
P10407184A0520|13 19|studies
P10407184A0520|23 37|promoter regions
P10407184A0520|61 72|reporter gene
P10407184A0520|73 104|chloramphenicol acetyl transferase
P10407184A0520|111 119|phbetaE-B
P10407184A0520|123 129|plasmid
P10407184A0520|153 166|promoter region
P10407184A0520|196 205|prhbetaE-B
P10407184A0520|209 215|plasmid
P10407184A0520|231 236|rhesus
P10407184A0520|241 254|promoter region
P10407184A0520|281 288|bp region
P10407184A0520|293 308|hbetaAPP promoter
P10407269A0000a|40 51|markers cdc18
P10407269A0000a|53 57|cdc14
P10407269A0000a|75 96|fission yeast chromosome
P10407269A0000a|127 139|European Union
P10407269A0000a|163 185|genome sequencing project
P10407269A0000b|40 51|markers cdc18
P10407269A0000b|53 57|cdc14
P10407269A0000b|75 96|fission yeast chromosome
P10407269A0000b|127 139|European Union
P10407269A0000b|163 185|genome sequencing project
P10407985A0574|0 4|G-CSF
P10407985A0574|8 17|micrograms
P10407985A0574|53 58|GM-CSF
P10407985A0574|61 74|micrograms s.c.
P10407985A0574|95 100|cycles
P10409656A1016|0 13|Overexpression
P10409656A1016|16 23|H411 cDNA
P10409656A1016|39 56|macrophage cell line
P10409656A1016|75 84|growth rate
P10409656A1016|99 108|expression
P10409656A1016|143 154|cell response
P10409699A0292|14 30|sequence tag clones
P10409699A0292|47 64|sequence similarity
P10409699A0292|79 83|yeast
P10409699A0292|110 121|mannosidases
P10409699A0292|139 150|coding region
P10409699A0292|164 181|mannosidase homolog
P10409699A0292|196 206|combination
P10409699A0292|214 226|amplification
P10409699A0292|229 236|cDNA ends
P10409699A0292|246 268|polymerase chain reaction
P10409724A1021|0 9|Activation
P10409724A1021|12 17|ERK1/2
P10409724A1021|34 42|induction
P10409724A1021|63 75|response genes
P10409730A0597|3 15|transcription
P10409730A0597|22 28|RP genes
P10409730A0597|45 61|Rap1p binding sites
P10409730A0597|89 98|initiation
P10409730A0597|100 112|transcription
P10409741A0382|25 31|alleles
P10409741A0382|40 46|cdc4-10
P10409741A0382|46 52|cdc4-11
P10409741A0382|56 62|cdc4-16
P10409741A0382|86 99|division defect
P10409741A0382|102 113|cdc20-1 cells
P10409749T0000|17 25|structure
P10409749T0000|27 40|discrimination
P10409749T0000|72 81|activators
P10409755A1846|2 8|summary
P10409755A1846|21 30|activation
P10409755A1846|32 43|NO production
P10409755A1846|52 60|apoptosis
P10409755A1846|66 75|TG exposure
P10409755A1846|78 88|JT/Neo cells
P10411139A0887|0 11|Accumulation
P10411139A0887|17 27|U4/U6 duplex
P10411139A0887|41 54|overexpression
P10411139A0887|66 71|Prp44p
P10411139A1344|3 9|results
P10411139A1344|52 58|results
P10411139A1344|82 87|Prp44p
P10411139A1344|103 112|U4/U6 helix
P10411140A0499|44 57|RNase E cleavage
P10411140A0499|72 77|region
P10411140A0499|83 87|mRNAs
P10411140A0499|98 107|terminator
P10411160T0000|3 11|mysteries
P10411160T0000|24 34|variability
P10411160T0000|48 66|skin cancer incidence
P10413604A0063|42 48|kinases
P10413604A0063|73 78|growth
P10413604A0063|108 116|mechanism
P10413604A0063|137 148|DNA synthesis
P10413607A0085|27 34|contrast
P10413607A0085|55 69|matrix molecules
P10413607A0085|88 97|collagen VI
P10413607A0085|115 126|DNA synthesis
P10413607A0085|146 154|cell types
P10413607A0085|195 212|signal transduction
P10413662A0193|34 56|pMJ101 replication region
P10413662A0193|88 94|plasmid
P10413662A0193|107 127|iron acquisition system
P10413662A0193|142 150|virulence
P10413662A0193|153 165|V. anguillarum
P10413662A0193|185 192|pathogen
P10413662A0193|203 211|vibriosis
P10413676A0000|16 20|sites
P10413676A0000|22 60|transmembrane integrin receptor clustering
P10413676A0000|88 102|signaling events
P10413676A0595|0 9|Expression
P10413676A0595|19 28|FAK mutants
P10413676A0595|39 43|cells
P10413676A0595|53 69|FAK kinase activity
P10413676A0595|73 79|Tyr-397
P10413676A0595|79 87|SH2 domain
P10413676A0595|124 139|SH3 binding region
P10413676A0595|159 164|domain
P10413676A0595|216 228|cell migration
P10413676A0595|247 261|paxillin binding
P10413676A1193|21 26|effect
P10413676A1193|49 61|point mutation
P10413676A1193|61 68|Leu-1034
P10413676A1193|90 105|FRNK localization
P10413676A1193|112 123|contact sites
P10414451A0093|13 20|patients
P10414451A0093|77 84|presence
P10414451A0093|84 93|resistance
P10414451A0093|105 112|protein C
P10414451A0093|113 117|APC-R
P10414451A0093|118 135|lupus anticoagulant
P10414451A0093|155 164|antibodies
P10414451A0093|167 178|deficiencies
P10414451A0093|181 188|protein C
P10414451A0093|189 196|protein S
P10414451A0093|197 211|ATIII activities
P10416429A0221|0 5|DESIGN
P10416429A0221|6 15|Comparison
P10416429A0221|18 23|number
P10416429A0221|26 30|women
P10416429A0221|49 53|years
P10416429A0221|58 71|NSW PKU database
P10416429A0221|80 85|number
P10416429A0221|98 103|number
P10416429A0221|115 128|population data
P10416558A0000|0 6|PURPOSE
P10416558A0000|10 17|purposes
P10416558A0000|30 34|study
P10416558A0000|50 56|effects
P10416558A0000|65 74|laboratory
P10416558A0000|87 101|exercise program
P10416558A0000|119 126|function
P10416558A0000|127 138|CD4 cell count
P10416558A0000|160 171|health status
P10416558A0000|208 218|individuals
P10416558A0000|239 244|degree
P10416558A0000|254 259|health
P10416558A0000|277 291|exercise relapse
P10417331A1008|3 8|enzyme
P10417331A1008|24 31|activity
P10417331A1008|42 51|mM pantoate
P10417703A1326|18 24|results
P10417703A1326|54 66|20S proteasome
P10417703A1326|109 118|eukaryotes
P10417703A1326|137 152|plant RPT subunits
P10417703A1326|162 178|yeast counterparts
P10417703A1326|196 204|functions
P10419006A0378|13 20|evidence
P10419006A0378|34 59|estrogen replacement therapy
P10419006A0378|65 73|menopause
P10419006A0378|83 98|breast cancer risk
P10419521A0136|2 9|addition
P10419521A0136|15 32|elongation activity
P10419521A0136|60 72|RNA polymerase
P10419521A0136|73 89|interaction domain
P10419521A0136|115 132|polymerase activity
P10419521A0136|152 164|transcription
P10422291A0572|1 9|diagnosis
P10422291A0572|12 20|IgA lambda
P10422291A0572|29 35|myeloma
P10422291A0572|50 60|involvement
P10422342A0535|3 17|radiation burden
P10422342A0535|35 42|majority
P10422342A0535|45 56|examinations
P10422342A0535|66 73|medicine
P10422342A0535|122 136|radiation burden
P10422342A0535|153 164|examinations
P10422342A0535|174 187|administration
P10422342A0535|190 201|preparations
P10422342A0535|212 216|201Tl
P10422342A0535|225 229|111In
P10422468A0524|19 30|malformation
P10422468A0524|32 39|children
P10422468A0524|110 122|abnormalities
P10422468A0524|153 165|sex chromosome
P10422468A0524|165 178|microdeletions
P10422468A0524|184 194|Y chromosome
P10422468A0524|222 230|mutations
P10422468A0524|240 251|fibrosis gene
P10423156A0265|0 11|TaV particles
P10423156A0265|24 30|density
P10423156A0265|38 42|g/cm3
P10423156A0265|66 79|capsid proteins
P10423193A1309|0 9|CONCLUSION
P10423193A1309|15 21|results
P10423193A1309|56 66|involvement
P10423193A1309|100 109|neuropathy
P10423292A0782|22 27|region
P10423292A0782|29 33|Spam1
P10423292A0782|71 89|transcription factor
P10423292A0782|97 101|sites
P10423292A0782|132 138|element
P10425094A1006|10 19|relaxivity
P10425094A1006|25 31|complex
P10425445T0000|0 8|Structure
P10425445T0000|12 21|expression
P10425445T0000|27 84|mouse growth hormone receptor/growth hormone binding protein gene
P10426450A1458|9 16|recovery
P10426450A1458|30 41|liver/spleen
P10426450A1458|52 57|tonsil
P10426450A1458|60 72|contact poults
P10426450A1458|84 96|contact chicks
P10426450A1458|159 171|contact poults
P10426450A1458|174 179|chicks
P10426878A0367|3 9|results
P10426878A0367|15 25|ISIS-2 trial
P10426878A0367|57 65|Trialists
P10426878A0367|65 77|Collaboration
P10426878A0367|91 97|aspirin
P10426878A0367|111 118|patients
P10426878A0367|138 147|infarction
P10426878A0367|163 172|prevention
P10427654A0000|4 8|study
P10427654A0000|60 70|laparoscopy
P10427654A0000|87 93|staging
P10427654A0000|96 103|patients
P10427654A0000|108 121|adenocarcinoma
P10427654A0000|127 135|esophagus
P10427654A0000|143 148|cancer
P10427654A0000|162 167|cancer
P10427654A0000|191 197|surgery
P10428091A0322|4 9|report
P10428091A0322|70 80|disparities
P10428091A0322|90 98|mortality
P10428091A0322|119 123|women
P10428294A0227|0 21|Preheparin LPL mass level
P10428294A0227|49 59|individuals
P10428294A0227|70 74|years
P10428294A0227|93 97|women
P10428759A0743|1 8|decrease
P10428759A0743|26 47|receptor kinase activity
P10428759A0743|81 89|receptors
P10428811A0628|0 4|Cat-1
P10428811A0628|39 52|binding partner
P10428811A0628|74 87|receptor kinase
P10428811A0628|88 94|betaARK
P10428811A0628|97 101|GRK-2
P10428811A0628|128 135|activity
P10428811A1067|0 10|Cat proteins
P10428811A1067|55 59|cells
P10428811A1067|72 88|adhesion kinase Fak
P10428862A0834|0 29|Immunoprecipitation experiments
P10428862A0834|48 57|antibodies
P10428862A0834|68 78|interaction
P10428862A0834|113 119|protein
P10428862A0834|164 173|BaF/3 cells
P10429184A0000|0 8|Expansins
P10429184A0000|13 18|family
P10429184A0000|21 28|proteins
P10429184A0000|50 58|extension
P10429184A0000|69 82|plant cell walls
P10429184A0000|113 121|mechanism
P10429740A0000|4 9|review
P10429740A0000|31 38|evidence
P10429740A0000|55 63|therapies
P10429740A0000|75 87|bowel syndrome
P10429946A0473|13 18|region
P10429946A0473|24 28|alpha
P10429946A0473|32 43|collagen gene
P10429946A0473|58 65|fragment
P10429946A0473|89 96|promoter
P10429946A0473|115 123|sequences
P10429946A0473|147 154|elements
P10429946A0988|11 18|addition
P10429946A0988|21 65|B-Myb-glutathionine S-transferase fusion protein
P10429946A0988|75 90|complex formation
P10430421T0000|0 17|APOE-epsilon4 count
P10430421T0000|35 44|prevalence
P10430421T0000|46 56|AD increases
P10430421T0000|72 87|Cache County Study
P10430580A0000|0 5|Repair
P10430580A0000|8 26|double-strand breaks
P10430580A0000|66 76|end-joining
P10430580A0000|108 112|yeast
P10430583A0000|4 16|DNA repair gene
P10430583A0000|49 56|homology
P10430883A0000|20 24|cells
P10430883A0000|35 39|gland
P10430883A0000|46 50|cells
P10430883A0000|51 57|Brunner
P10430883A0000|59 64|glands
P10430883A0000|74 79|glands
P10430883A0000|100 104|tract
P10430883A0000|118 122|ducts
P10430883A0000|140 149|metaplasia
P10430883A0000|176 180|class
P10430883A0000|184 188|mucin
P10430883A0000|218 225|staining
P10430883A0000|244 252|oxidation
P10430883A0000|253 278|sodium borohydride reduction
P10430883A0000|279 282|Con A
P10430883A0000|286 314|horseradish peroxidase reaction
P10430886A0838|13 19|mutants
P10430886A0838|75 89|heteromultimers
P10430886A0838|105 113|activator
P10430890A1059|4 11|elongin C
P10430890A1059|34 41|solution
P10430890A1059|75 88|rearrangements
P10430890A1059|93 99|binding
P10430890A1059|114 128|partner proteins
P10430944A1298|18 34|JAK/STAT signaling
P10430944A1298|60 71|malignancies
P10430980A0465|22 26|women
P10433729A1559|4 9|Bowers
P10433729A1559|17 24|Matthews
P10433970A0279|0 5|Spfkh1
P10433970A0279|28 39|reading frame
P10433970A0279|55 70|DNA binding domain
P10433970A0279|78 95|localization signal
P10433970A0279|99 119|transactivation domain
P10435595A0203|12 20|mechanism
P10435595A0203|35 50|trans-activation
P10436016A0337|0 12|Gel filtration
P10436016A0337|16 45|co-immunoprecipitation analyses
P10436016A0337|56 60|Mad2p
P10436016A0337|89 114|spindle checkpoint component
P10436016A0337|115 119|Mad1p
P10437043A0164|0 6|METHODS
P10437043A0164|19 23|cases
P10437043A0164|44 51|biopsies
P10438540A1185|31 43|domain mutants
P10438540A1185|55 63|tolerance
P10438540A1185|74 79|strain
P10438540A1185|83 99|transport activity
P10438540A1185|105 111|protein
P10438593A0000|8 34|immunodeficiency virus type-1
P10438593A0000|35 39|HIV-1
P10438593A0000|40 49|Tat protein
P10438593A0000|59 71|transcription
P10438593A0000|85 109|RNA polymerase processivity
P10438607A0330|10 14|SEBPs
P10438607A0330|15 19|SEBP2
P10438607A0330|35 41|product
P10438607A0330|55 66|gene fork head
P10438627A0885|0 15|Identity elements
P10438627A0885|49 57|reactions
P10438627A0885|72 78|pfTrm1p
P10438627A0885|105 117|T7 transcripts
P10438627A0885|122 129|variants
P10438627A0885|157 161|yeast
P10438924A1009|20 24|cells
P10438924A1009|61 106|serine/threonine kinase glycogen synthase kinase-3
P10438924A1009|106 110|GSK-3
P10438924T0000|3 22|B cell antigen receptor
P10438924T0000|40 53|protein kinase B
P10438924T0000|52 91|glycogen synthase kinase-3 signaling pathway
P10438924T0000|95 122|phosphatidylinositol 3-kinase
P10438941A1197|5 23|recombination events
P10438941A1197|56 65|T cell lines
P10438941A1197|81 99|switch recombination
P10438941A1197|117 121|genes
P10438950A0580|9 41|TNF increase AND-34 transcript levels
P10438950A0580|72 76|nurse
P10438950A0580|80 98|fibroblast cell lines
P10439040A0658|15 23|role eIF4E
P10439040A0658|35 49|c-myc expression
P10439040A0658|53 57|c-myc
P10439040A0658|71 76|region
P10439040A0658|100 111|CAT reporters
P10439040A0658|135 144|constructs
P10440923A0684|0 7|Analysis
P10440923A0684|10 26|cell cycle proteins
P10440923A0684|44 62|lovastatin treatment
P10440923A0684|67 78|control cells
P10440923A0684|87 95|elevation
P10440923A0684|101 106|levels
P10440923A0684|128 145|kinase inhibitor p27
P10440923A0684|151 160|inhibition
P10440923A0684|166 172|cyclin E
P10440923A0684|176 181|cyclin
P10440923A0684|193 206|kinase activity
P10440923A0684|219 224|levels
P10440923A0684|246 266|retinoblastoma protein
P10441243A0443|0 6|RESULTS
P10441243A0443|18 37|leptin concentrations
P10441243A0443|64 68|ng/ml
P10441243A0443|78 85|subjects
P10441449X1212|0 8|Copyright
P10441449X1212|13 25|Academic Press
P10441483A0454|0 20|Oligonucleotide probes
P10441483A0454|54 66|EpRE sequences
P10441483A0454|100 107|analyses
P10441483A0454|118 125|proteins
P10441506A0098|0 6|PKNbeta
P10441506A0098|14 29|sequence homology
P10441506A0098|34 41|PKNalpha
P10441506A0098|80 86|repeats
P10441506A0098|95 99|amino
P10441506A0098|109 114|region
P10441506A0098|119 132|leucine-zipper
P10441506A0098|137 145|sequences
P10441506A0098|146 157|CZ region/HR1
P10441506A0098|189 194|domain
P10441506A0098|216 231|amino acid stretch
P10441506A0098|232 242|D region/HR2
P10441506A0098|257 268|CZ region/HR1
P10441506A0098|284 289|domain
P10442493A0815|2 9|baseline
P10442493A0815|10 20|serum levels
P10442493A0815|23 30|lycopene
P10442493A0815|61 69|serum FLOP
P10442493A0815|99 122|plasma cyclosporine levels
P10443990A0000|0 9|BACKGROUND
P10443990A0000|17 34|alcohol consumption
P10443990A0000|71 80|bone health
P10444597A0586|22 30|induction
P10444597A0586|33 38|stress
P10444597A0586|41 49|heat shock
P10444597A0586|62 68|ethanol
P10444597A0586|68 77|conditions
P10444597A0586|92 101|mRNA export
P10444597A0586|111 115|Npl3p
P10444597A0586|138 144|nucleus
P10444813A0448|14 19|relief
P10444813A0448|23 32|inhibition
P10444813A0448|38 43|growth
P10444813A0448|49 70|metastases interferon-a
P10444813A0448|74 94|somatostatin analogues
P10445161A1565|2 8|summary
P10445161A1565|42 46|study
P10445161A1565|89 98|weight gain
P10445161A1565|123 140|organ weight changes
P10445161A1565|146 150|sexes
P10445506A0073|25 29|sperm
P10445506A0073|37 41|times
P10445506A0073|54 63|body length
P10445945T0000|0 16|John leonard dawson
P10446131A0132|0 16|PDGF A-chain levels
P10446131A0132|43 59|smooth muscle cells
P10446149A0809|24 28|yeast
P10446149A0809|39 43|assay
P10446149A0809|56 67|Ras effectors
P10446149A0809|77 83|c-Raf-1
P10446149A0809|84 88|A-Raf
P10446149A0809|89 93|B-Raf
P10446149A0809|94 121|phosphoinositol-3 kinase delta
P10446149A0809|122 127|RalGDS
P10446206A0000|0 14|Deletion mapping
P10446206A0000|25 36|presenilin-1
P10446206A0000|42 49|promoter
P10446206A0000|72 79|fragment
P10446206A0000|96 103|relation
P10446206A0000|109 130|transcription start site
P10446206A0000|143 147|study
P10446206A0000|159 178|neuroblastoma SK-N-SH
P10446206A0000|182 199|hepatoma HepG2 cells
P10446833T0000|16 26|oxygenation
P10446833T0000|30 37|shunting
P10446833T0000|40 45|sepsis
P10446833T0000|49 53|shock
P10446910A0147|0 7|Analysis
P10446910A0147|13 28|E2F1 gene promoter
P10446910A0147|51 56|region
P10446910A0147|71 87|E2-responsiveness
P10446910A0147|99 116|transfection assays
P10446910A0147|130 154|deletion/mutation analysis
P10446910A0147|216 220|sites
P10446910A0147|236 250|transactivation
P10446912A0883|5 10|course
P10446912A0883|29 38|mechanisms
P10446912A0883|68 87|CYP11A1 transcription
P10446912A0883|130 139|JEG-3 cells
P10446998A0375|2 9|contrast
P10446998A0375|13 27|differentiation
P10446998A0375|55 59|cells
P10446998A0375|83 96|responsiveness
P10446998A0375|107 123|c-fos inducibility
P10446998A0955|0 23|Adipocyte differentiation
P10446998A0955|40 44|cells
P10446998A0955|69 75|ability
P10446998A0955|94 100|junB SRE
P10446998A0955|103 110|c-fos SRE
P10446998A0955|139 151|mobility shift
P10446998A0955|154 172|gel supershift assays
P10446998A0955|192 216|DNA binding characteristics
P10446998A0955|229 239|protein SP-1
P10446998T0000|0 13|Transformation
P10446998T0000|43 52|inhibition
P10446998T0000|55 85|serum response factor interactions
P10446998T0000|90 110|serum response elements
P10447593A0144|3 12|core enzyme
P10447593A0144|34 49|bacteriophages T3
P10447593A0144|72 88|specificity factor
P10447593A0144|92 103|similarities
P10447593A0144|117 128|sigma factors
P10447597A1004|3 14|Cr.psbA-4 ORF
P10447597A1004|30 34|motif
P10447597A1004|47 58|GIY-YIG motif
P10448036A0748|3 13|interaction
P10448036A0748|16 20|zf4-6
P10448036A0748|37 40|S RNA
P10448036A0748|74 96|competitor concentration
P10448036A0748|107 111|zf4-7
P10448036A0748|113 127|S RNA interaction
P10448036A0748|142 147|finger
P10448036A0748|170 177|affinity
P10448036A0748|181 191|specificity
P10448036A0748|198 204|protein
P10448036A0748|204 217|RNA interaction
P10448095A0865|3 25|STAT protein accumulation
P10448095A0865|39 53|C/EBP expression
P10448095A0865|89 98|conversion
P10448095A0865|101 111|fibroblasts
P10448095A0865|114 123|adipocytes
P10448095A0865|139 155|expression profile
P10448095A0865|188 197|adipocytes
P10448285A1035|9 17|durations
P10448285A1035|21 28|response
P10448285A1035|32 43|survival time
P10448285A1035|53 57|phase
P10448285A1035|60 64|trial
P10448285A1035|72 77|months
P10448285A1035|84 89|months
P10448440T0020|21 30|psychiatry
P10448440T0020|32 52|understanding patients
P10448440T0020|64 76|schizophrenia
P10448440T0020|85 103|personality disorder
P10448902A0921|21 27|enzymes
P10448902A0921|28 35|catalase
P10448902A0921|36 56|glutathione peroxidase
P10448902A0921|60 78|superoxide dismutase
P10449072A0560|43 53|arrangement
P10449899A0881|12 18|results
P10449899A0881|50 57|PERV copy
P10449899A0881|61 75|integration site
P10450815A0180|10 22|investigation
P10450815A0180|35 44|population
P10450815A0180|63 73|individuals
P10450815A0180|79 86|age range
P10450815A0180|92 96|years
P10450815A0180|123 134|relationship
P10450815A0180|142 155|tobacco smoking
P10450815A0180|172 179|calculus
P10450815A0180|190 196|account
P10450815A0180|216 222|factors
P10450815A0180|234 239|gender
P10450815A0180|243 249|hygiene
P10450815A0180|261 272|inflammation
P10451209A0000|0 8|OBJECTIVE
P10451209A0000|27 40|administration
P10451209A0000|43 53|misoprostol
P10451209A0000|69 78|hemorrhage
P10451209A0000|109 113|doses
P10451209A0000|115 147|methylprednisolone sodium succinate
P10452306A0502|0 7|Patients
P10452306A0502|30 39|MIBG uptake
P10452306A0502|51 77|norepinephrine concentration
P10452306A0502|84 90|peak Vo2
P10452306A0502|90 94|x-ray
P10452306A0502|109 113|ratio
P10452306A0502|114 119|M-mode
P10452306A0502|144 151|diameter
P10452306A0502|166 195|heart catheterization parameters
P10452951A0000|7 22|hormone receptors
P10452951A0000|47 66|transcription factors
P10452951A0000|85 93|functions
P10452951A0000|100 106|species
P10452991A0331|5 9|cells
P10452991A0331|27 49|influenza virus particles
P10452991A0331|70 80|T cell clones
P10453006A0000|0 9|Sequencing
P10453006A0000|12 20|zebrafish
P10453006A0000|21 30|Danio rerio
P10453006A0000|50 59|chromosome
P10453006A0000|77 86|chromosome
P10453006A0000|93 106|clone fragments
P10453006A0000|112 121|cDNA clones
P10453006A0000|133 146|identification
P10453006A0000|171 182|beta subunits
P10453006A0000|184 194|proteasomes
P10453006A0478|2 9|addition
P10453006A0478|12 21|homologues
P10453006A0478|32 41|genes PSMB5
P10453006A0478|49 53|PSMB9
P10453006A0478|60 64|genes
P10453006A0478|65 70|PSMB11
P10453006A0478|74 79|PSMB12
P10453006A0478|129 133|genes
P10453006A0478|136 141|humans
P10453248A0094|25 35|perspective
P10453248A0094|87 92|models
P10453248A0094|126 134|behaviour
P10453371A0640|0 5|Weight
P10453371A0640|9 22|height z-scores
P10453371A0640|54 64|BMD z-scores
P10453721A0445|8 23|sampling strategy
P10453721A0445|47 74|parameter estimation algorithm
P10453721A0445|92 113|ADAPT II software package
P10454533A0859|0 10|Interaction
P10454533A0859|22 26|Hsc70
P10454533A0859|43 56|transformation
P10454533A0859|69 83|Hsc70 antagonist
P10454533A0859|145 156|conformation
P10454540A0392|3 23|amino acid changes D206A
P10454540A0392|27 31|D208A
P10454540A0392|49 59|combination
P10454540A0392|63 81|exonuclease activity
P10454550A0960|20 27|evidence
P10454550A0960|76 85|substrates
P10454550A0960|93 109|Snf1 kinase complex
P10454557A0000|12 16|yeast
P10454557A0000|40 50|replicators
P10454557A0000|72 81|chromosome
P10454557A0000|107 114|sequence
P10454557A0000|120 127|elements
P10454557A0000|140 149|chromosome
P10454557A0000|196 207|HML locus show
P10454557A0000|209 233|replication origin activity
P10454557A0975|5 11|results
P10454557A0975|29 41|HML ARS cluster
P10454557A0975|42 47|ARS303
P10454557A0975|48 53|ARS320
P10454557A0975|57 62|ARS302
P10454557A0975|63 72|inactivity
P10454557A0975|75 81|origins
P10454557A0975|117 125|silencing
P10454557A0975|136 142|origins
P10454557A0975|146 154|silencers
P10454557A0975|183 192|components
P10454561A0594|12 16|study
P10454561A0594|34 43|expression
P10454561A0594|46 60|TD-IkappaBalpha
P10454561A0594|68 109|phorbol myristate acetate-phytohemagglutinin
P10454561A0594|112 130|tumor necrosis factor
P10454561A0594|144 172|IkappaBalpha gene transcription
P10454561A0594|185 211|NF-kappaB DNA binding activity
P10454561A0594|240 252|sequestration
P10454561A0594|267 281|TD-IkappaBalpha
P10454568A0815|9 23|Grb10 expression
P10454568A0815|67 82|expression system
P10454568A0815|92 98|PDGF-BB
P10454568A0815|99 103|IGF-I
P10454568A0815|107 113|insulin
P10454568A0815|129 140|growth factor
P10454568A0815|152 163|DNA synthesis
P10454568A0815|167 174|ecdysone
P10454568A0815|190 196|fashion
P10454570A0846|3 10|analysis
P10454570A0846|41 61|protein kinase pathways
P10454570A0846|87 103|protein kinase-Jun
P10454570A0846|114 129|kinase activation
P10454570A0846|144 158|phosphorylation
P10454570A0846|161 165|ATF-2
P10454570A0846|166 170|c-Jun
P10454570A0846|235 243|induction
P10454570A0846|277 282|kinase
P10454570A0846|284 288|ERK-1
P10454570A0846|292 306|ERK-2 activation
P10454570A0846|352 362|stimulation
P10454570A0846|367 377|uPA enhancer
P10455087A1400|0 10|CONCLUSIONS
P10455087A1400|20 30|individuals
P10455087A1400|36 57|body insulin sensitivity
P10455087A1400|91 99|threshold
P10455143T0000|0 19|Interdomain signaling
P10455143T0000|33 40|fragment
P10455143T0000|51 72|glucocorticoid receptor
P10455183A0530|2 9|contrast
P10455183A0530|13 17|xtRNA
P10455183A0530|36 42|binding
P10455183A0530|51 65|Staf zinc fingers
P10455183A0530|72 76|Oct-1
P10455183A0530|102 109|capacity
P10455183A0930|17 23|results
P10455183A0930|47 57|utilization
P10455183A0930|60 73|Staf zinc finger
P10455183A0930|97 107|determinant
P10455183A0930|128 146|activation mechanism
P10455183A0930|153 163|Xenopus tRNA
P10455183A0930|176 187|U6 snRNA genes
P10455189A0104|2 7|B cells
P10455189A0104|55 63|mechanism
P10455189A0104|80 95|integrin ligation
P10455189A0427|21 43|tyrosine phosphorylation
P10455189A0427|87 92|manner
P10457075A1198|0 36|Independent protrudor muscle stimulation
P10457075A1198|58 65|increase
P10457075A1198|89 93|Pcrit
P10457075A1198|108 119|peak decrease
P10458905A0000|11 22|construction
P10458905A0000|60 77|YAC/BAC clone contig
P10458905A0000|80 87|8p22-p23
P10458907A0543|8 13|RAD30B
P10458907A0543|17 42|mouse Rad30b mRNA transcripts
P10458907A0543|51 64|repair proteins
P10458907A0543|88 93|testis
P10458914A0674|0 7|Analysis
P10458914A0674|13 25|mouse STAP gene
P10458914A0674|48 54|library
P10458914A0674|70 77|STAP gene
P10458914A0674|84 89|region
P10458914A0674|119 123|exons
P10459809A1262|8 25|matrix distribution
P10459809A1262|37 47|cell density
P10459809A1262|65 71|biofilm
P10460015A0465|7 12|months
P10460015A0465|15 23|treatment
P10460015A0465|41 48|estrogen
P10460015A0465|56 61|height
P10460015A0465|65 70|weight
P10460015A0465|77 87|improvement
P10460015A0465|96 113|bone mineral density
P10460015A0465|117 123|bone age
P10460171A0842|0 19|Viscosity experiments
P10460171A0842|34 55|fragment kinase reaction
P10460171A0842|75 82|chemical
P10460171A0842|83 100|phosphoryl transfer
P10460172A0823|0 20|Velocity sedimentation
P10460172A0823|21 33|cross-linking
P10460172A0823|37 63|immunoprecipitation analyses
P10460172A0823|87 94|rat brain
P10460172A0823|117 131|kDa polypeptides
P10460172A0823|144 158|heterotetramers
P10463057A0534|7 22|expression levels
P10463057A0534|37 44|plasmids
P10463242A0316|21 25|waves
P10463242A0316|42 47|region
P10464185T0000|9 24|characterization
P10464185T0000|48 78|polysaccharide biosynthesis genes
P10464185T0000|81 109|Streptococcus agalactiae type Ia
P10464250A0275|4 10|FASEB J.
P10464291A0597|0 7|IL-1beta
P10464291A0597|10 14|ng/ml
P10464291A0597|39 48|PDGFalphaR
P10464291A0597|74 85|protein delta
P10464291A0597|86 95|C/EBPdelta
P10464291A0597|96 105|mRNA levels
P10464291A0597|124 129|manner
P10464302A1109b|3 13|recruitment
P10464302A1109b|78 92|pathway proteins
P10464302A1109b|119 133|interaction site
P10464302A1109b|151 155|model
P10464302A1109b|173 180|assembly
P10464302A1109b|195 201|pathway
P10464302A1109b|209 220|transmission
P10464302A1109b|223 240|growth factor signal
P10464302A1109b|246 257|cytoskeleton
P10464310A0218|9 31|tyrosine phosphorylation
P10464310A0218|41 56|fibroblast growth
P10464310A0218|86 90|cells
P10464310A0218|108 135|juxtamembrane tyrosine residue
P10464310A0218|141 146|FGFR-1
P10464310A0218|151 162|Crk SH2 domain
P10464310A0218|175 180|FGFR-1
P10464310A0218|198 204|Tyr-463
P10464310A0218|221 236|complex formation
P10464310A0218|252 257|FGFR-1
P10466306A0000|19 46|Technetium-99m sestamibi SPECT
P10466306A0000|56 64|technique
P10466306A0000|84 92|perfusion
P10466306A0000|96 103|function
P10466825T0000|24 29|region
P10466825T0000|31 48|baculovirus p10 mRNA
P10466825T0000|61 70|expression
P10466825T0000|80 84|genes
P10467004A0116|3 11|intron RNA
P10467004A0116|26 36|nucleotides
P10467004A0116|67 75|structure
P10467004A0116|94 107|sequence motifs
P10467004A0116|123 129|introns
P10467004A0116|130 135|Michel
P10467004A0683|3 8|intron
P10467004A0683|20 27|splicing
P10467004A0683|55 63|EBS1/IBS1
P10467004A0683|69 91|EBS2/IBS2 sequence motifs
P10467004A0683|122 129|splicing
P10467403A0000|3 31|Trk/Nerve Growth Factor receptor
P10467403A0000|48 57|activation
P10467403A0000|61 66|number
P10467403A0000|82 98|signaling proteins
P10467403A0000|108 135|phosphatidylinositol 3-kinase
P10467403A0000|136 145|PI 3-kinase
P10467465T0000|3 13|controversy
P10467465T0000|16 34|significance testing
P10467465T0000|35 48|misconceptions
P10467465T0000|52 63|alternatives
P10468033T0000|0 13|Chemical uptake
P10468033T0000|23 36|stratum corneum
P10468033T0000|70 77|solvents
P10468585A0980|4 13|DNA binding
P10468585A0980|29 39|enhancement
P10468585A0980|76 92|amino acid residues
P10468585A0980|119 125|portion
P10468585A0980|128 132|Hap46
P10468585A0980|153 168|hsp70 interaction
P10469140A0336|15 22|function
P10469140A0336|51 55|sites
P10469140A0336|68 72|PAI-2
P10469140A0336|81 88|promoter
P10469140A0336|92 105|responsiveness
P10469140A0336|108 115|TNFalpha
P10469140A0336|121 172|chloramphenicol acetyl transferase reporter gene deletion
P10469140A0336|176 191|mutation analyses
P10469174A0678|10 25|sequence analysis
P10469174A0678|29 43|NMR measurements
P10469174A0678|60 67|fragment
P10469174A0678|97 104|residues
P10469174A0678|145 150|domain
P10469174A0678|158 164|MBF1CTD
P10469656T0000|14 21|response
P10469656T0000|51 63|gene induction
P10469656T0000|88 104|MAP kinase cascades
P10469656T0000|123 135|histone H3/HMG
P10469656T0000|137 142|kinase
P10470220A1011|3 13|arrangement
P10470220A1011|21 33|cutoff-levels
P10470220A1011|42 52|sensitivity
P10470220A1011|62 72|specificity
P10470220A1011|81 91|Protein S100
P10470220A1011|116 126|sensitivity
P10470220A1011|135 145|specificity
P10471587A0239|7 13|strains
P10471587A0239|16 28|C. trachomatis
P10471587A0239|31 46|triplicate assays
P10471587A0239|57 68|RT-PCR method
P10471587A0239|113 121|technique
P10471587A0239|133 146|antimicrobials
P10471587A0239|184 189|RT-PCR
P10471587A0239|214 225|erythromycin
P10471587A0239|242 252|amoxicillin
P10471696A0734|4 10|alleles
P10471696A0734|50 65|Abf1p binding site
P10471696A0734|68 80|HMR-E silencer
P10471696A0734|108 123|Rap1p binding site
P10471721A0141|15 22|analysis
P10471721A0141|41 46|S locus
P10471721A0141|84 88|genes
P10471721A0141|125 135|pollen S gene
P10471721A0141|150 154|genes
P10471743A0000|35 45|DNA helicase
P10471743A0000|63 94|Arabidopsis thaliana cDNA libraries
P10471746A1102|24 38|tryptophan motif
P10471746A1102|45 63|chromatin remodeling
P10471746A1102|69 84|Myogenin promoter
P10471746A1102|98 118|Myogenin transcription
P10472314A0717|0 6|RESULTS
P10472314A0717|10 16|Periods
P10472314A0717|59 63|women
P10472836A0189|0 9|Feed intake
P10472836A0189|13 19|BW gains
P10472836A0189|50 59|treatments
P10473589A0189|3 11|N terminus
P10473589A0189|40 44|alpha
P10473589A0189|50 64|integrase domain
P10473589A0189|78 86|C terminus
P10473598A0691|0 5|Skn-1a
P10473598A0691|26 31|region
P10473598A0691|46 67|transactivation ability
P10473598A0691|85 92|promoter
P10473598A0691|116 130|transactivation
P10473598A0691|139 144|Skn-1a
P10473598A0691|147 163|competition assays
P10473623A0081|7 20|Xenopus embryos
P10473623A0081|36 65|growth factor-beta member activin
P10473623A0081|76 84|gene Mix.2
P10473623A0081|100 108|formation
P10473623A0081|124 130|complex
P10473623A0081|149 154|factor
P10474898A0629|24 32|structure
P10474898A0629|48 56|synthesis
P10474898A0629|62 76|CMT1A-REP repeat
P10474898A0629|94 106|hybridization
P10474898A0629|113 120|analysis
P10474898A0629|144 149|assays
P10474898A0629|168 173|series
P10474898A0629|176 183|primates
P10475610A1289|0 4|Natl.
P10475972A0269|16 23|outbreak
P10475972A0269|32 36|delay
P10475972A0269|43 53|vaccination
P10475972A0269|67 72|deaths
P10476970A0542|20 26|isoform
P10476970A0542|52 58|protein
P10476970A0542|64 72|rap1GAPII
P10476970A0542|95 108|alpha-subunits
P10476970A0542|117 122|family
P10476970A0542|138 147|G-proteins
P10477545T0000|3 12|B-oligomer
P10477545T0000|15 28|pertussis toxin
P10477545T0000|40 58|CC chemokine receptor
P10477545T0000|69 73|entry
P10477545T0000|84 95|HIV-1 strains
P10477583A0000a|16 30|B cell Ag receptor
P10477583A0000a|45 55|Fc receptors
P10477583A0000a|63 70|Fc gamma R
P10477583A0000a|85 95|progression
P10477583A0000a|99 107|mechanism
P10477583A0000b|16 30|B cell Ag receptor
P10477583A0000b|45 55|Fc receptors
P10477583A0000b|63 70|Fc gamma R
P10477583A0000b|85 95|progression
P10477583A0000b|99 107|mechanism
P10477597A0126|0 4|TRAF2
P10477597A0126|14 22|activator
P10477597A0126|32 53|serine/threonine kinase
P10477597A0126|68 79|center kinase
P10477597A0126|127 136|activation
P10477597A0126|140 150|SAPK pathway
P10477599T0000|23 29|element
P10477599T0000|38 45|C motif-1
P10477599T0000|45 64|lymphotactin promoter
P10477599T0000|111 122|interactions
P10477599T0000|138 143|factor
P10477599T0000|155 159|T cell
P10477620A0580|16 42|NF-kappa B DNA binding activity
P10477620A0580|56 68|translocation
P10477620A0580|68 90|I kappa B alpha degradation
P10477620A0580|91 103|I kappa B serine
P10477620A0580|106 120|phosphorylation
P10477620A0580|124 136|I kappa B kinase
P10477620A0580|142 149|activity
P10477620A0580|162 178|curcumin treatment
P10477748A1076|1 7|portion
P10477748A1076|49 55|spindle
P10478275A1230|7 12|issues
P10478275A1230|35 40|number
P10478275A1230|54 63|mechanisms
P10478275A1230|137 141|foods
P10478275A1230|156 165|technology
P10478275A1230|183 190|contrast
P10478844A1604|0 13|Cotransfection
P10478844A1604|19 29|coactivator
P10478844A1604|42 48|protein
P10478844A1604|75 84|repression
P10478844A1604|87 97|PPARalphawt
P10478844A1604|100 110|PPARalphatr
P10478844A1604|144 149|effect
P10478844A1604|152 162|PPARalphatr
P10478844A1604|180 190|competition
P10478844A1604|203 214|coactivators
P10478848A0331|29 37|AF1 domain
P10479025A0528|13 21|locations
P10479025A0528|24 30|sources
P10479025A0528|38 54|TF-MUSIC algorithm
P10479025A0528|68 79|target region
P10479025A0528|85 95|spectrogram
P10479025A0528|114 122|responses
P10479382A1098|14 20|results
P10479382A1098|23 27|terms
P10479382A1098|33 41|influence
P10479382A1098|66 76|constraints
P10479382A1098|89 107|development patterns
P10479382A1098|111 117|fitness
P10479492A0000|0 8|OBJECTIVE
P10479492A0000|13 24|Surveillance
P10479492A0000|25 36|Epidemiology
P10479492A0000|40 49|End Results
P10479492A0000|84 95|survival rate
P10479492A0000|96 129|corpus uteri adenocarcinoma FIGO stage
P10480937A0000|6 35|Drosophila A kinase anchor protein
P10480937A0000|46 65|A kinase anchor protein
P10480937A0000|69 76|DAKAP200
P10480937A0000|132 138|signals
P10480937A0000|161 174|diacylglycerol
P10480937A0000|181 185|Rossi
P10482516A1158|7 26|transcription results
P10482516A1158|44 61|structure functions
P10482516A1158|67 86|attenuation mechanism
P10482516A1158|92 99|deletion
P10482516A1158|105 113|stem-loop
P10482516A1158|122 129|increase
P10482516A1158|132 155|transcription readthrough
P10482516T0000|2 13|RNA stem-loop
P10482516T0000|31 63|transcription attenuation mechanism
P10482516T0000|76 85|expression
P10482516T0000|91 121|Bacillus subtilis trpEDCFBA operon
P10482565A0469|27 35|mutations
P10482565A0469|51 57|effects
P10482565A0469|81 86|fusion
P10482620A1009|28 40|transcription
P10482620A1009|79 85|absence
P10482620A1009|86 91|Stat5a
P10482620A1009|93 111|transcription factor
P10482620A1009|153 165|transcription
P10482620A1009|173 179|MMTV LTR
P10483124T0000|0 7|Regional
P10483124T0000|19 29|mutagenesis
P10483124T0000|40 44|genes
P10483124T0000|50 68|CIC5F11/CIC2B9 locus
P10483124T0000|71 99|Arabidopsis thaliana chromosome
P10483124T0000|109 123|Ac/Ds transposon
P10483124T0000|126 136|combination
P10483124T0000|144 161|cDNA scanning method
P10483945A0641|0 6|RESULTS
P10483945A0641|7 20|CK-MB elevation
P10483945A0641|37 44|patients
P10483945A0641|104 111|patients
P10484695A0791|4 20|NART-R performance
P10484695A0791|35 42|estimate
P10484695A0791|45 54|baseline IQ
P10484695A0791|58 65|patients
P10484695A0791|80 88|disorders
P10484695A0791|102 119|language impairment
P10484818A0292|9 13|areas
P10484818A0292|34 38|means
P10484818A0292|41 65|cross-correlation analysis
P10485353T0000|7 32|Haemophilus influenzae type b
P10485353T0000|41 64|polysaccharide antibodies
P10485353T0000|70 76|infants
P10485353T0000|80 87|children
P10485353T0000|92 101|West Africa
P10485353T0000|102 113|Burkina-Faso
P10485353T0000|117 122|France
P10485353T0000|139 148|serosurvey
P10485470A0242|6 10|study
P10485470A0242|43 49|factors
P10485470A0242|60 67|Sp1 sites
P10485470A0242|73 93|p21/WAF1/Cip1 promoter
P10485470A0242|96 104|MG63 cells
P10485470A0242|127 145|mobility shift assays
P10485470A0242|159 170|TSA treatment
P10485470A0242|188 204|binding activities
P10485585A0175|0 6|Galoyan
P10485585A0175|23 29|results
P10485585A0175|35 43|discovery
P10485585A0175|58 70|neurohormones
P10486210A0126|10 19|regulation
P10486210A0126|25 34|expression
P10486210A0126|43 63|aldehyde reductase gene
P10486210A0126|67 74|promoter
P10487040A0453|19 26|staining
P10487040A0453|31 35|MIB-1
P10487040A0453|39 51|p53 antibodies
P10487040A0453|76 83|reaction
P10487217A0735|3 9|C2C-Prx
P10487217A0735|22 31|preprotein
P10487217A0735|37 46|amino acids
P10487217A0735|87 92|signal
P10487217A0735|97 106|amino acids
P10487217A0735|112 121|N-terminus
P10487307A0768|17 31|surgery patients
P10487307A0768|57 70|hydrocortisone
P10487307A0768|80 86|placebo
P10487307A0768|106 110|order
P10487744T0000|15 27|sorting signal
P10487744T0000|33 45|beta2 integrin
P10487744T0000|57 62|domain
P10487744T0000|74 82|recycling
P10487744T0000|88 101|plasma membrane
P10487744T0000|134 142|migration
P10487753A0788|3 11|injection
P10487753A0788|14 25|XDRP1 protein
P10487753A0788|40 50|Xenopus eggs
P10487753A0788|67 78|cell division
P10487759A0630|15 28|Xenopus embryos
P10487759A0630|49 57|integrity
P10487759A0630|68 76|sequences
P10487759A0630|105 114|expression
P10487759A0630|118 122|Xbra2
P10487759A0630|138 149|reporter gene
P10487760A0336|2 6|order
P10487760A0336|9 14|screen
P10487760A0336|22 30|cofactors
P10487760A0336|67 72|mutant
P10487760A0336|75 86|Xenopus MEF2D
P10487760A0336|90 94|yeast
P10487760A0336|105 110|screen
P10487921A0132|0 16|ATF1 transcription
P10487921A0132|56 60|acids
P10487921A0132|64 69|oxygen
P10487953A0765|3 10|patients
P10487953A0765|24 29|tumors
P10487953A0765|37 52|S-phase fractions
P10487953A0765|75 83|specimens
P10487953A0765|109 117|operation
P10488087A0340|0 7|Mutation
P10488087A0340|23 27|sites
P10488087A0340|41 51|combination
P10488087A0340|83 90|activity
P10488087A0340|123 149|acetyltransferase constructs
P10488087A0340|159 175|SP-A gene sequences
P10488088T0000|12 25|growth factor-I
P10488088T0000|33 45|bcl-2 promoter
P10488088T0000|56 74|transcription factor
P10488088T0000|103 109|protein
P10488129T0058|0 8|Synthesis
P10488129T0058|46 52|binding
P10488129T0058|53 64|E2F complexes
P10488129T0058|67 72|intron
P10488147A1176|0 13|Identification
P10488147A1176|16 24|eotaxin-3
P10488147A1176|46 58|understanding
P10488147A1176|64 70|control
P10488147A1176|73 93|eosinophil trafficking
P10488147A1176|125 133|phenomena
P10488148A0111|0 8|NF-kappaB
P10488148A0111|31 40|activation
P10488148A0111|42 60|HIV-1 gene expression
P10488148A0111|63 71|cytokines
P10488148A0111|80 86|stimuli
P10488148A0111|93 118|signal transduction pathways
P10488148A0111|134 139|switch
P10488148A0111|162 170|infection
P10488148A1267|5 11|studies
P10488148A1267|87 97|interaction
P10488148A1267|108 116|NF-kappaB
P10488148A1267|128 134|complex
P10488148A1267|171 178|HIV-1 LTR
P10488148T0000|0 31|ERK MAP kinase links cytokine signals
P10488148T0000|34 43|activation
P10488148T0000|52 65|HIV-1 infection
P10488148T0000|91 101|interaction
P10488148T0000|113 121|NF-kappaB
P10488337T0000|23 31|chaperone
P10488337T0000|45 56|dimerization
P10488337T0000|57 66|DNA binding
P10488337T0000|85 92|activity
P10488337T0000|95 106|bZIP proteins
P10488875A0000|8 22|differentiation
P10488875A0000|25 32|patients
P10488875A0000|57 61|palsy
P10488875A0000|79 88|toe walking
P10489680A0927|0 9|Sputum IL-8
P10489680A0927|68 83|grain dust-asthma
P10489822T0000|0 10|Montelukast
P10489822T0000|18 23|airway
P10489822T0000|36 47|inflammation
P10489822T0000|50 55|asthma
P10489822T0000|77 81|trial
P10490065T0000|0 8|Treatment
P10490065T0000|19 24|angina
P10490065T0000|47 53|therapy
P10490604A0601|21 31|kinase-dead
P10490604A0601|47 51|forms
P10490604A0601|67 80|ZAP-70 block 70Z
P10490604A0601|91 104|NFAT activation
P10490609A0413|0 12|Substitutions
P10490609A0413|15 20|region
P10490609A0413|35 43|sequences
P10490609A0413|64 71|sequence
P10490609A0413|81 87|repeats
P10490609A0413|112 119|adenines
P10490609A0413|122 129|thymines
P10490609A0413|137 148|interruption
P10490609A0413|151 157|guanine
P10490609A0413|160 167|cytosine
P10490609A0413|185 195|ARS activity
P10490639A0000|25 29|PHO85
P10490639A0000|54 66|protein kinase
P10490639A0000|81 87|subunit
P10490639A0000|109 113|roles
P10490639A0000|136 146|association
P10490639A0000|160 173|cyclin partners
P10490662A0431|0 6|Mutants
P10490662A0431|15 25|lace alleles
P10490662A0431|38 43|adults
P10490662A0431|64 75|morphologies
P10490662A0431|81 90|appendages
P10490662A0431|91 101|compound eye
P10490662A0819|8 18|SPT activity
P10490662A0819|87 94|antibody
P10490816A0000|0 8|Mutations
P10490816A0000|14 20|RET gene
P10490816A0000|30 51|receptor tyrosine kinase
P10490816A0000|86 105|cancer syndromes MEN 2A
P10490816A0000|109 113|MEN 2B
P10490822A1167|5 11|results
P10490822A1167|20 28|targeting
P10490822A1167|31 37|Ras-GAP
P10490822A1167|68 75|approach
P10490826T0000|7 42|tyrosine kinase signal transduction gene
P10490826T0000|79 84|subset
P10490826T0000|108 126|oncoprotein E2a-Pbx1
P10490835T0000|0 20|Protein kinase A-Ialpha
P10490835T0000|46 55|inhibition
P10490835T0000|65 80|cancer cell growth
P10490835T0000|81 89|crosstalk
P10490835T0000|94 123|tyrosine kinase signaling pathway
P10490843A0159|14 32|POZ/Zn finger protein
P10490843A0159|33 41|structure
P10490843A0159|84 93|regulators
P10490843A0159|106 112|protein
P10490843A0159|142 151|malignancy
P10490955T0000|7 14|integrin
P10490955T0000|38 48|stimulation
P10490955T0000|51 71|T lymphoma cell adhesion
P10490955T0000|92 113|protein kinase signaling
P10490955T0000|116 131|thrombospondin-1
P10490955T0000|135 158|thrombospondin-1 peptides
P10491133A0365|0 8|Optical CD
P10491133A0365|23 38|activity analyses
P10491133A0365|56 65|reactivity
P10491133A0365|68 77|HO isozymes
P10491133A0365|82 90|NO species
P10491133A0365|101 108|NO donors
P10491187T0000|3 26|phosphotransferase system
P10491187T0000|56 69|identification
P10491187T0000|83 90|analysis
P10491187T0000|94 126|histidine phosphocarrier protein HPr
P10491187T0000|139 146|gene ptsH
P10491213A0263|0 18|Serum concentrations
P10491213A0263|35 53|alkaline phosphatase
P10491213A0263|62 72|osteocalcin
P10491213A0263|72 85|bone Gla protein
P10491213A0263|98 103|levels
P10491213A0263|105 116|pyridinoline
P10491213A0263|125 141|deoxypyridinoline
P10491213A0263|158 167|tomography
P10491213A0263|171 182|measurements
P10491213A0263|202 206|areas
P10491213A0263|212 220|vertebrae
P10491213A0263|227 232|femurs
P10491213A0263|244 250|density
P10491213A0263|274 282|vertebrae
P10491213A0263|288 293|volume
P10491213A0263|300 314|material density
P10491213A0263|336 341|femurs
P10491213A0263|372 376|girls
P10491213A0263|386 390|years
P10492127A0914|9 13|study
P10492127A0914|25 38|administration
P10492127A0914|41 50|devazepide
P10492127A0914|60 94|cholecystokinin-A receptor antagonist
P10492127A0914|109 116|mg/kg/hr
P10492127A0914|149 160|saline intake
P10492169A0939|4 10|cluster
P10492169A0939|57 61|genes
P10492169A0939|81 95|plasma protein-A
P10492169A0939|96 101|PAPP-A
P10492169A0939|133 139|EST-YD1
P10493203T0000|10 14|value
P10493203T0000|18 39|treadmill exercise score
P10493203T0000|53 60|patients
P10493203T0000|80 92|abnormalities
P10493575T0000|10 16|changes
P10493575T0000|22 31|C-terminus
P10493575T0000|43 50|rat S100B
P10493575T0000|50 57|beta beta
P10493575T0000|72 78|peptide
P10493575T0000|113 118|domain
P10493580A1126|13 17|Gly84
P10493580A1126|37 48|oxyanion hole
P10493580A1126|61 73|stabilization
P10493580A1126|79 93|transition state
P10493580A1126|106 111|C group
P10493580A1126|117 137|esterase/lipase family
P10493876A0000|3 19|solution structure
P10493876A0000|25 30|adduct
P10493876A0000|53 59|bonding
P10493876A0000|65 75|fjord region
P10493876A0000|96 107|stereoisomer
P10493876A0000|115 126|dihydroxy-13
P10493876A0000|128 135|epoxy-11
P10493876A0000|160 167|chrysene
P10493876A0000|197 206|amino group
P10493876A0000|215 224|residue dA6
P10493876A0000|236 245|trans-anti
P10493876A0000|267 274|opposite
P10493876A0000|272 289|thymine residue dT17
P10493876A0000|295 313|DNA sequence context d
P10493876A0000|313 326|C1-T2-C3-T4-C5
P10493876A0000|332 350|A6-C7-T8-T9-C10-C11
P10493876A0000|449 483|G12-G13-A14-A15-G16-T17-G18-A19-G20
P10493876A0000|483 489|A21-G22
P10493876A0000|531 536|duplex
P10493876A0000|565 575|information
P10493876A0000|587 593|NMR data
P10493876A0000|596 606|combination
P10493876A0000|620 627|dynamics
P10493876A0000|632 643|calculations
P10495573A0365|5 14|sildenafil
P10495573A0365|24 29|market
P10495573A0365|44 48|place
P10495573A0365|84 90|studies
P10495573A0365|100 106|results
P10495573A0365|110 119|sildenafil
P10495573A0365|145 150|course
P10495573A0365|159 168|acceptance
P10496161A0503|0 14|Serum antibodies
P10496161A0503|53 62|guinea pigs
P10496284A0115|24 31|episodes
P10496284A0115|32 41|CSF protein
P10496284A0115|45 59|immunoglobulin G
P10496284A0115|65 70|levels
P10496284A0115|100 107|IgG index
P10496284A0115|110 125|IgG synthesis rate
P10496303A1968|0 10|CONCLUSIONS
P10496303A1968|16 22|results
P10496303A1968|44 57|valganciclovir
P10496303A1968|68 76|exposures
P10496303A1968|79 89|ganciclovir
P10496303A1968|90 94|AUC24
P10496303A1968|133 143|ganciclovir
P10496303A1968|146 150|mg/kg
P10496388A1956a|9 20|nonperfusion
P10496388A1956a|42 48|vessels
P10496388A1956a|68 72|J/cm2
P10496388A1956a|86 91|events
P10496388A1956a|98 104|concern
P10496388A1956b|9 20|nonperfusion
P10496388A1956b|42 48|vessels
P10496388A1956b|68 72|J/cm2
P10496388A1956b|86 91|events
P10496388A1956b|98 104|concern
P10496553A1004|3 13|healing rate
P10496553A1004|28 35|patients
P10496553A1004|41 47|percent
P10496553A1004|55 59|weeks
P10496553A1004|66 72|percent
P10496553A1004|80 84|weeks
P10496553A1004|101 107|figures
P10496553A1004|111 118|patients
P10496553A1004|131 154|immunodeficiency syndrome
P10496553A1004|165 171|percent
P10497117A0358|3 7|P mRNA
P10497117A0358|37 44|V protein
P10497199A0559|8 13|screen
P10497199A0559|16 20|yeast
P10497199A0559|64 76|factor binding
P10497199A0559|95 110|chicken ovalbumin
P10497199A0559|140 145|factor
P10497199A0559|148 156|COUP-TFII
P10497262A0000|38 42|trans
P10497262A0000|54 60|U5 snRNA
P10497262A0000|68 106|trypanosomatid species Leptomonas seymouri
P10497262A0000|112 133|U5 RNA affinity selection
P10497262A0000|137 147|cDNA cloning
P10497800A0000|3 8|MMPI-A
P10497800A0000|9 15|Butcher
P10497800A0000|43 50|Hathaway
P10497800A0000|51 58|McKinley
P10497800A0000|83 90|anorexia
P10497800A0000|94 100|bulimia
P10497874A0925|16 35|phosphatidyl inositol
P10497874A0925|38 49|bisphosphate
P10497874A0925|56 65|hydrolysis
P10497874A0925|79 93|phosphorylation
P10497874A0925|96 110|tyrosine residue
P10497874A0925|116 132|PLC-gamma1 isozyme
P10498616A0157|1 10|G22V mutant
P10498616A0157|13 17|M-Ras
P10498616A0157|47 56|expression
P10498616A0157|61 73|interleukin-3
P10498616A0157|88 117|mast cell/megakaryocyte cell line
P10498616A0157|136 143|survival
P10498616A0157|149 155|absence
P10498616A0157|173 178|growth
P10498616A0157|195 210|expression levels
P10498616A0157|230 235|growth
P10498616A1280|9 13|M-Ras
P10498616A1280|18 38|Caenorhabditis elegans
P10498616A1280|49 55|exhibit
P10498616A1280|75 82|features
P10498616A1280|109 118|activation
P10498616A1280|132 145|signaling paths
P10498616A1280|160 167|parallel
P10498616A1280|187 192|p21 Ras
P10498706A1219|58 71|pelE expression
P10498706A1219|92 100|repressor
P10498717A1048|5 16|observations
P10498717A1048|55 71|rsmB transcription
P10498717A1048|91 104|RsmA production
P10499121A0542|18 32|hearing aid users
P10499121A0542|46 62|Class D instruments
P10499121A0542|67 82|input compression
P10499121A0542|109 118|enrollment
P10499121A0542|124 128|study
P10499357A0439|0 10|SCOB testing
P10499357A0439|28 34|animals
P10499357A0439|54 58|ratio
P10499357A0439|67 74|interval
P10499357A0439|78 85|schedule
P10499357A0439|90 94|FI120
P10499357A0439|117 124|exposure
P10499357A0439|145 152|behavior
P10499357A0439|166 170|Weeks
P10499357A0439|195 202|evidence
P10499357A0439|205 217|neurotoxicity
P10501034A0839|0 27|Ribonuclease protection assays
P10501034A0839|121 126|manner
P10501034A0839|131 143|morphogenesis
P10501034A0839|177 189|pigment glands
P10501034A0839|192 198|embryos
P10501656A1415|12 21|expression
P10501656A1415|36 55|Northern blot analysis
P10501656A1415|82 95|tumor cell lines
P10501936T0000|0 11|Inactivation
P10501936T0000|17 32|Neurospora crassa
P10501936T0000|51 70|membrane protein TOM70
P10501936T0000|87 99|point mutation
P10501936T0000|111 117|defects
P10501936T0000|132 144|protein import
P10501936T0000|148 157|morphology
P10501965A0879|7 11|genes
P10501965A0879|29 33|units
P10501965A0879|77 84|s6 kinase
P10501965A0879|124 128|genes
P10501965A0879|131 135|Gpr31
P10501965A0879|156 164|G-protein
P10501965A0879|172 179|receptor
P10501969A1329|3 9|results
P10501969A1329|21 26|GATA-5
P10501969A1329|52 58|targets
P10501969A1329|66 71|GATA-4
P10501969A1329|119 131|cardiogenesis
P10502216A0289|4 8|study
P10502216A0289|32 39|efficacy
P10502216A0289|42 50|efegatran
P10502216A0289|55 67|streptokinase
P10502216A0289|74 80|heparin
P10502216A0289|96 121|tissue plasminogen activator
P10502216A0289|137 147|reperfusion
P10502402A0129|20 24|TRAIL
P10502402A0129|69 85|mouse T lymphocytes
P10502402A0129|96 106|possibility
P10502402A0129|111 115|TRAIL
P10502402A0129|149 160|cytotoxicity
P10502402A0129|172 181|regulation
P10502402A0533|1 5|panel
P10502402A0533|21 30|inhibitors
P10502402A0533|54 79|signal transduction pathways
P10502402A0533|90 107|TRAIL gene induction
P10502402A0533|117 137|T lymphocyte activation
P10502434A0367|4 11|February
P10502434A0367|18 23|August
P10502434A0367|31 38|patients
P10502434A0367|54 62|carcinoma
P10502434A0367|114 131|vault brachytherapy
P10502434A0367|149 157|treatment
P10502434A0604|6 13|patients
P10502434A0604|17 25|stage IBG3
P10502434A0604|54 64|ICG3 disease
P10502522A0000|9 23|provirus genomes
P10502522A0000|31 53|T-cell leukemia virus type
P10502522A0000|78 88|lymphocytes
P10502522A0000|101 111|individuals
P10502522A0000|125 133|cell lines
P10503540A0602|1 5|total
P10503540A0602|11 21|primer pairs
P10503540A0602|39 53|banding patterns
P10503540A0602|86 92|alleles
P10503540A0602|100 117|polyacrylamide gels
P10503812A1450|1 10|population
P10503812A1450|26 30|study
P10503812A1450|33 43|cyclosporin
P10503812A1450|46 68|organ transplant patients
P10503812A1450|85 103|allograft recipients
P10503812A1450|110 114|years
P10503812A1450|165 191|cyclosporin pharmacokinetics
P10504332A0701|0 20|Immunofluoresence data
P10504332A0701|54 61|receptor
P10504332A0701|102 108|markers
P10504332A0701|122 128|pathway
P10504332A0701|138 142|cells
P10504332A0701|165 172|receptor
P10504332A0701|173 187|RAP fluorescence
P10504332A0701|213 219|markers
P10505694A0000|0 13|Interleukin-12
P10505694A0000|14 18|IL-12
P10505694A0000|22 29|cytokine
P10505694A0000|50 54|blood
P10505694A0000|66 70|cells
P10505694A0000|87 102|interferon-gamma
P10505694A0000|102 110|IFN-gamma
P10505694A0000|111 120|production
P10505694A0000|124 134|enhancement
P10505694A0000|150 161|cytotoxicity
P10505694A0739|0 14|IL-12 production
P10505694A0739|32 47|C3a concentration
P10505694A0739|61 66|outlet
P10505694A0739|69 80|hemodialyzer
P10505694A0739|95 102|dialysis
P10506143A0610|2 10|HeLa cells
P10506143A0610|14 36|JNKK2-JNK1 fusion protein
P10506143A0610|54 64|JNK activity
P10506143A0610|114 120|stimuli
P10506143A0610|123 132|activators
P10506143A0610|147 155|TNF-alpha
P10506143A0610|155 164|anisomycin
P10506143A0610|165 177|UV irradiation
P10506143A0610|178 182|MEKK1
P10506143A0610|191 212|GTP binding proteins Rac1
P10506143A0610|216 222|Cdc42Hs
P10508522A1598|3 9|results
P10508522A1598|19 29|TGF-beta RII
P10508522A1598|39 44|target
P10508522A1598|47 54|EWS-FLI1
P10509768A1118|3 11|reduction
P10509768A1118|28 38|acids intake
P10509768A1118|55 59|group
P10509768A1118|76 81|mmol/l
P10509768A1118|87 95|reduction
P10509768A1118|102 122|serum cholesterol level
P10510295A0606|10 40|ethanol repression autoregulation
P10510295A0606|56 63|TA repeat
P10510295A0606|68 83|repressor element
P10510295A0606|105 118|promoter region
P10510295A0606|124 131|GLK1 gene
P10510379A0105|8 26|transcription factor
P10510379A0105|33 39|process
P10510379A0105|42 46|STAT6
P10510379A0105|68 77|DNA element
P10510379A0105|82 99|cytokine activation
P10511216A0654|0 10|CONCLUSIONS
P10511216A0654|55 59|cause
P10511554T0000|35 49|polymorphism map
P10511554T0000|56 86|clone Caenorhabditis elegans cdf-1
P10512699A0364|4 12|machinery
P10512699A0364|31 39|structure
P10512699A0364|40 51|SECIS element
P10512699A0364|94 116|selenocysteine insertion
P10512699A0364|121 128|position
P10512699A0364|144 148|codon
P10512699A0364|165 175|termination
P10512699A0364|178 188|translation
P10512699T0000|10 19|expression
P10512699T0000|64 86|rat thioredoxin reductase
P10512699T0000|96 106|gene fusions
P10512699T0000|135 147|SECIS elements
P10512699T0000|151 163|co-expression
P10512699T0000|186 194|selC genes
P10512857A0000|2 13|Wnt signaling
P10512857A0000|14 25|beta-catenin
P10512857A0000|29 39|plakoglobin
P10512857A0000|49 55|signals
P10512857A0000|61 67|nucleus
P10512857A0000|75 86|interactions
P10512857A0000|99 118|transcription factors
P10512882A0137|0 7|Assembly
P10512882A0137|11 17|complex
P10512882A0137|33 42|Src kinases
P10512882A0137|74 85|localization
P10512882A0137|101 108|activity
P10512882A0137|111 117|members
P10512882A0137|123 131|Src family
P10512882A0137|134 140|kinases
P10513756A0584|50 65|8-predictor model
P10513756A0584|92 109|selection criterion
P10513756A0584|117 121|alpha
P10513922A1237|3 7|study
P10513922A1237|35 43|increases
P10513922A1237|49 54|number
P10513922A1237|73 78|fibers
P10513922A1237|90 99|repair site
P10513922A1237|102 111|comparison
P10513922A1237|135 140|groups
P10514493A0199|19 33|differentiation
P10514493A0199|36 60|N1E-115 neuroblastoma cells
P10514493A0199|77 86|expression
P10514493A0199|102 110|Ntr-1 gene
P10514493A0199|114 126|reporter genes
P10514493A0199|135 156|NTR-1 promoter sequences
P10514808T0000|8 17|dysplasias
P10514808T0000|18 25|genetics
P10514808T0000|29 43|epileptogenesis
P10516011A0471|29 42|peptide mapping
P10516011A0471|42 57|mass spectrometry
P10516011A0471|74 84|mutagenesis
P10516011A0471|106 128|pAP phosphorylation sites
P10516026A0270|4 13|HERV-K type
P10516026A0270|19 24|clones
P10516738A0925|5 15|time-points
P10516738A0925|20 27|patients
P10516738A0925|45 59|irbesartan/HCTZ
P10516878T0000|0 11|Modification
P10516878T0000|14 39|dopamine D2 receptor activity
P10516878T0000|42 50|pergolide
P10516878T0000|53 61|Parkinson
P10516878T0000|63 69|disease
P10516878T0000|78 82|study
P10517666A1069|13 24|binding sites
P10517666A1069|39 56|AP-1 nucleoproteins
P10517666A1069|80 87|elements
P10517672A1417|12 19|fragment
P10517672A1417|32 65|alpha1-globin promoter-CAT construct
P10517672A1417|86 109|CCAAT transcription factor
P10517672A1417|125 157|Drosophila Schneider SL2 insect cells
P10517672A1417|173 180|proteins
P10517672A1417|181 196|trans-activation
P10517672A1417|199 209|CAT activity
P10517675A0809|0 18|Western blot analysis
P10517675A0809|44 51|increase
P10517675A0809|54 72|p21WAF1/CIP1 protein
P10517675A0809|80 92|protein levels
P10517675A0809|102 107|member
P10517675A0809|129 149|kinase inhibitor family
P10517675A0809|150 156|p27kip1
P10518496A0952|0 10|Aggregation
P10518496A0952|37 45|stem cells
P10518496A0952|69 75|embryos
P10518496A0952|118 124|tissues
P10518496A0952|132 156|periimplantation lethality
P10518496A0952|166 176|development
P10518496A0952|194 206|organogenesis
P10518502T0000|0 4|nos-1
P10518502T0000|8 12|nos-2
P10518502T0000|16 20|genes
P10518502T0000|63 81|germ cell development
P10518502T0000|85 92|survival
P10518502T0000|95 115|Caenorhabditis elegans
P10518561A0261|16 25|regulators
P10518561A0261|28 43|Tec family kinases
P10518561A0261|102 110|effectors
P10518561A0261|118 124|enzymes
P10518561A0885|9 23|phosphorylation
P10518561A0885|26 30|BRDG1
P10518561A0885|56 65|SH2 domains
P10518561A0885|75 86|kinase domain
P10518822A1037|0 9|CONCLUSION
P10518822A1037|15 22|findings
P10518822A1037|32 38|eotaxin
P10518822A1037|77 82|asthma
P10518822A1037|94 102|biomarker
P10518822A1037|106 113|activity
P10518822A1037|119 142|CCR3 receptor ligand system
P10518822A1037|170 175|asthma
P10518937A0572|3 20|expression analysis
P10518937A0572|26 35|KlHIS4 gene
P10518937A0572|41 59|phosphate starvation
P10518937A0572|66 78|adenine supply
P10518937A0572|88 94|factors
P10518937A0572|133 139|control
P10518937A0572|171 178|K. lactis
P10518956A0137|5 25|thyroid hormone changes
P10518956A0137|49 57|cytokines
P10518956A0137|76 84|mediators
P10518956A0137|96 100|level
P10518956A0137|106 117|hypothalamus
P10518956A0137|130 134|gland
P10518956A0137|138 149|thyroid gland
P10518956A0137|163 178|deiodinase system
P10518956A1212|0 6|ESS type
P10520800A0307|0 6|METHODS
P10520800A0307|29 36|patients
P10520800A0307|68 72|years
P10520800A0307|90 98|reduction
P10520800A0307|104 119|echocardiography
P10520800A0307|123 139|electrocardiogram
P10521345A0202|30 42|Laurentian Fan
P10521345A0202|49 53|proxy
P10521345A0202|57 77|sea surface temperature
P10521345A0202|88 110|surface slope waters north
P10521345A0202|116 125|Gulf Stream
P10521345A0202|159 164|Ice Age
P10521345A0202|180 188|centuries
P10521345A0202|202 207|notion
P10521345A0202|229 234|system
P10521443A0486|4 9|effect
P10521443A0486|19 30|IR activation
P10521443A0486|52 61|IR mutation
P10521443A0486|64 72|tyrosines
P10521443A0486|89 107|NF-kappaB activation
P10521443A0486|129 142|overexpression
P10521443A0486|162 174|IkappaB-alpha
P10521443A0486|174 179|A32/36
P10521443A0486|193 206|overexpression
P10521443A0486|212 232|NF-kappaB c-Rel subunit
P10521447A0606|3 8|factor
P10521447A0606|49 62|sequence TGTGGT
P10521447A0606|63 71|core motif
P10521447A0606|84 90|members
P10521447A0606|96 132|AML/CBFalpha transcription factor family
P10521447A1190|11 24|overexpression
P10521447A1190|27 40|AML3/CBFalpha1
P10521447A1190|55 72|AML1-ETO repression
P10521450A0437|10 22|Akt activation
P10521450A0437|51 59|DT40 cells
P10521450A0437|61 66|B cells
P10521509A0000|0 9|Regulators
P10521509A0000|12 28|G protein signaling
P10521509A0000|34 41|proteins
P10521509A0000|67 72|EGL-10
P10521509A0000|72 81|pleckstrin
P10521509A0000|90 102|G protein gamma
P10521509A0000|114 120|domains
P10521509A0000|126 134|subfamily
P10521509A0000|159 173|RGS proteins RGS6
P10521509A0000|189 193|RGS11
P10521544T0000|0 6|Cloning
P10521544T0000|10 19|expression
P10521544T0000|36 55|alpha 1,2-mannosidase
P10521544T0000|65 75|Man9GlcNAc2
P10521544T0000|78 95|Man8GlcNAc2 isomer B
P10521544T0000|110 121|biosynthesis
P10521796A0872|64 80|baseline diagnoses
P10521796A0872|100 109|metaplasia
P10521796A0872|146 154|dysplasia
P10521796A0872|177 183|atrophy
P10521796A0872|185 199|neck hyperplasia
P10521796A0872|254 261|subjects
P10521796A0872|276 284|gastritis
P10521796A0872|306 314|gastritis
P10521796A0872|321 328|baseline
P10523319A0209|16 20|Dbp5p
P10523319A0209|24 28|Rat7p
P10523319A0209|58 64|domains
P10523520A0986|7 19|nematode genes
P10523520A0986|30 37|homologs
P10523520A0986|40 50|Hh molecules
P10523520A0986|58 62|phyla
P10523634A1404|1 6|subset
P10523634A1404|9 17|mutations
P10523634A1404|23 39|Psi synthase domain
P10523634A1404|47 57|association
P10523634A1404|70 82|Cbf5p proteins
P10523634A1404|95 109|box H/ACA snoRNAs
P10523634A1404|146 151|domain
P10523634A1404|170 180|interaction
P10523640A0367|11 27|Src tyrosine kinase
P10523640A0367|47 66|Stat3 phosphorylation
P10523640A0367|69 76|tyrosine
P10523640A0367|77 86|activation
P10523640A0367|103 116|gene regulation
P10523640A0367|129 136|tyrosine
P10523640A0367|140 160|serine phosphorylation
P10523640A0367|163 167|Stat3
P10523647A0000|3 25|transcription factor CHOP
P10523647A0000|26 30|C/EBP
P10523647A0000|41 47|protein
P10523647A0000|53 63|bZIP protein
P10523647A0000|74 80|variety
P10523647A0000|83 89|stimuli
P10523647A0000|107 121|stress responses
P10523647A0000|145 154|cell growth
P10523647A0000|177 185|cell death
P10523647A1001|39 47|regulator
P10523647A1001|49 64|C/EBP target genes
P10523647A1001|86 96|AP-1 factors
P10523647A1001|108 122|AP-1 target genes
P10523663A0404|4 8|motif
P10523663A0404|39 61|homeobox activator DEAF-1
P10523663A0404|82 86|group
P10523663A0404|112 121|modulators
P10523674A0000|0 7|RNase MRP
P10523674A0000|11 43|ribonucleoprotein endoribonuclease
P10523674A0000|66 70|roles
P10523674A0000|90 103|DNA replication
P10523674A0000|116 130|S rRNA processing
P10524258A0286|17 26|regulation
P10524258A0286|32 41|FGFR-1 gene
P10524258A0286|42 46|cek-1
P10524258A0286|62 69|cultures
P10524258A0286|72 90|immunocytochemistry
P10524258A0286|94 113|Northern blot analysis
P10524258T0000|0 9|Regulation
P10524258T0000|17 46|fibroblast growth factor receptor
P10524258T0000|48 53|FGFR-1
P10524258T0000|54 67|gene expression
P10524258T0000|82 102|muscle differentiation
P10525413A1408|3 18|backbone dynamics
P10525413A1408|21 28|residues
P10525413A1408|65 69|R122A
P10525413A1408|105 120|N NMR spectroscopy
P10526670A0236|11 19|uncapping
P10526670A0236|21 34|actin filaments
P10526670A0236|35 41|F-actin
P10526670A0236|47 55|plus-ends
P10526670A0236|63 82|phosphatidylinositol
P10526670A0236|86 97|bisphosphate
P10526670A0236|124 139|membrane ruffling
P10526670A1828|16 26|ICE/caspase
P10526670A1828|28 36|inhibitor
P10526670A1828|43 47|N1445
P10526670A1828|80 88|apoptosis
P10526670A1828|140 150|suppression
P10526670A1828|152 168|Ras transformation
P10527106A0384|0 8|OBJECTIVE
P10527106A0384|20 32|preponderance
P10527106A0384|35 42|findings
P10527106A0384|48 54|support
P10527106A0384|131 137|deficit
P10527106A0384|163 171|depiction
P10527106A0384|176 182|deficit
P10527158T0000|3 9|AL-R8 SI
P10527158T0000|17 42|generation staging container
P10527158T0000|46 58|plutonium pits
P10527158T0000|64 79|USDOE Pantex Plant
P10527180A0869|0 6|RESULTS
P10527180A0869|7 13|Factors
P10527180A0869|63 78|treatment failure
P10527180A0869|97 104|analysis
P10527180A0869|128 132|years
P10527180A0869|140 145|hazard
P10527180A0869|151 169|% confidence interval
P10527180A0869|182 206|Karnofsky performance score
P10527180A0869|237 243|absence
P10527180A0869|243 258|hormone receptors
P10527180A0869|298 309|chemotherapy
P10527180A0869|345 360|survival interval
P10527180A0869|372 380|treatment
P10527180A0869|395 400|months
P10527180A0869|420 429|metastases
P10527180A0869|433 437|liver
P10527180A0869|473 478|system
P10527180A0869|496 517|approaches significance
P10527180A0869|522 527|tissue
P10527180A0869|549 553|sites
P10527180A0869|564 570|disease
P10527180A0869|603 610|response
P10527180A0869|619 626|response
P10527180A0869|642 653|chemotherapy
P10527426A0521|14 31|SBEI gene transcript
P10527426A0521|42 48|kernels
P10527426A0521|61 83|exon I+II+III combination
P10527426A0521|107 111|forms
P10527426A0521|121 129|inclusion
P10527426A0521|132 137|intron
P10527426A0521|141 149|exclusion
P10527426A0521|160 168|sequences
P10527475A0643|10 14|MNGCs
P10527475A0643|29 38|inclusions
P10527475A0643|42 48|grooves
P10528035A1102|2 8|percent
P10528035A1102|28 40|normalization
P10528035A1102|42 75|serum alanine aminotransferase levels
P10528035A1102|78 84|percent
P10529198A0068|22 27|domain
P10529198A0068|60 73|homologues p140
P10529198A0068|73 79|ras-GRF
P10529354A0375|3 12|proteasome
P10529354A0375|21 27|complex
P10529354A0375|55 64|structures
P10529354A0375|80 84|PA700
P10529354A0375|85 96|P28 complexes
P10529354A0375|117 128|26S particles
P10531334A0525|2 7|assays
P10531334A0525|20 26|enzymes
P10531334A0525|42 50|PTPS-S19A
P10531334A0525|63 71|substrate
P10531334A0525|92 104|protein kinase
P10531340A1275|4 14|Fleischmann
P10531340A1275|18 23|Venter
P10531342A0348|13 18|domain
P10531342A0348|60 75|amino acid repeats
P10531342A0348|87 94|homology
P10531342A0348|97 128|promastigote surface glycoproteins
P10531342A0348|134 149|psa2/gp46 complex
P10531342A1111|2 9|contrast
P10531342A1111|35 54|proteophosphoglycans
P10531342A1111|58 72|ppg1 gene product
P10531342A1111|128 150|promastigote cell surface
P10531360A0958|13 21|infection
P10531360A0958|27 31|cells
P10531360A0958|48 56|construct
P10531360A0958|89 97|induction
P10531360A0958|100 107|VEGF mRNA
P10531360A0958|113 122|conditions
P10531360A0958|132 138|hypoxia
P10531446A0203|0 9|Neuregulin
P10531446A0203|20 24|ErbB2
P10531446A0203|25 29|ErbB3
P10531446A0203|33 37|ErbB4
P10531446A0203|38 44|members
P10531446A0203|50 59|ErbB family
P10531446A0203|62 84|receptor tyrosine kinases
P10532354A1374|3 9|results
P10532354A1374|21 25|Anu2p
P10532354A1374|31 44|yeast homologue
P10532354A1374|56 66|epsilon-COP
P10532354A1374|79 90|accumulation
P10532354A1374|96 105|ER membrane
P10532354A1374|115 122|blockage
P10532354A1374|133 155|protein transport pathway
P10532354A1374|163 172|alteration
P10532354A1374|182 191|morphology
P10532354A1374|204 213|yeast cells
P10532805A0792|2 10|PC12 cells
P10532805A0792|11 27|nerve growth factor
P10532805A0792|43 57|differentiation
P10532805A0792|70 79|expression
P10532805A0792|82 86|nrg-1
P10532805A1084|3 16|PC12 cell mutant
P10532805A1084|34 55|protein kinase A activity
P10532805A1084|85 90|agents
P10532805A1084|115 123|nrg-1 mRNA
P10533066A0758|0 12|TSC1 mutations
P10533066A0758|31 39|mutations
P10533066A0758|44 53|insertions
P10533066A0758|62 76|splice mutations
P10533066A1197|6 13|patients
P10533066A1197|21 33|abnormalities
P10533066A1197|62 78|missense mutations
P10534048A0297|8 16|algorithm
P10534048A0297|17 24|FOREPROJ
P10534048A0297|40 58|projection algorithm
P10534048A0297|69 79|calculation
P10534048A0297|88 115|attenuation correction factors
P10534048A0297|153 164|transmission
P10534048A0297|197 210|attenuation map
P10534048A0297|239 248|projection
P10534402A0126|37 45|mouse gene
P10534402A0126|53 59|protein
P10534402A0126|75 92|sequence similarity
P10534402A0126|104 110|domains
P10534402A0126|118 125|proteins
P10534402A0126|131 142|Spo11p family
P10534402A0659|0 5|RT-PCR
P10534402A0659|15 35|hybridization analyses
P10534402A0659|39 48|time course
P10534402A0659|59 75|testis development
P10534402A0659|88 102|Spo11 expression
P10534402A0659|123 130|Prophase
P10534402A0659|142 155|pachytene stage
P10534402A0659|170 181|accumulation
P10534402A0659|200 213|pachytene stage
P10534691A0542|0 6|Animals
P10534691A0542|16 20|death
P10534691A0542|22 26|weeks
P10534691A0542|38 43|grafts
P10534691A0542|93 99|culture
P10534691A0542|121 130|procedures
P10534691A0542|134 141|evidence
P10534691A0542|144 152|infection
P10535715A0268|30 34|phase
P10535715A0268|88 93|kJ/24 h
P10535715A0268|99 104|luteal
P10535715A0268|109 114|kJ/24 h
P10535715A0268|115 120|phases
P10536125A0093|0 10|Oseltamivir
P10536125A0093|11 16|GS4104
P10536125A0093|50 56|prodrug
P10536125A0093|59 64|GS4071
P10536125A0093|84 92|inhibitor
P10536125A0093|95 122|influenzavirus neuraminidases
P10536369A0662|2 23|gel mobility shift assays
P10536369A0662|33 40|evidence
P10536369A0662|44 71|VDR-TR heterodimer interaction
P10536369A0662|85 91|element
P10536369A1280|11 20|importance
P10536369A1280|31 40|mechanisms
P10536369A1280|52 59|response
P10536369A1280|76 81|manner
P10536788A0931|12 22|overfeeding
P10536788A0931|29 38|PL profiles
P10536788A0931|60 65|breeds
P10536788A0931|84 96|control livers
P10540015A0664|0 11|C-SP duration
P10540015A0664|37 47|ALS patients
P10540015A0664|58 65|controls
P10540015A0664|71 90|stimulation intensity
P10540015A0664|108 119|MEP threshold
P10540292A1179|22 38|spv virulence genes
P10540292A1179|67 74|regulons
P10540292A1179|96 106|possibility
P10540292A1179|110 122|spv expression
P10540292A1179|140 147|response
P10540292A1179|171 176|inputs
P10540553A0980|9 17|synthesis
P10540553A0980|30 34|cells
P10540553A0980|85 92|activity
P10540553A0980|98 106|synthesis
P10540553A0980|131 137|ability
P10540553A0980|140 152|proliferation
P10540553A0980|162 167|growth
P10540915A0697|8 19|transsection
P10540915A0697|37 44|ligation
P10540915A0697|45 49|TL&PL
P10540915A0697|59 67|reduction
P10541432A0185|16 27|erbB proteins
P10541432A0185|44 55|growth factor
P10541432A0185|67 89|tyrosine phosphorylation
P10541432A0185|101 111|Shc proteins
P10541432A0185|158 174|ERK MAPK activities
P10541432A0185|182 198|glioblastoma cells
P10541432A0185|212 228|ERK MAPK activities
P10541550A0487|5 22|immunolocalization
P10541550A0487|49 62|chorion element
P10541550A0487|74 84|information
P10541550A0487|102 114|amplification
P10541550A0487|122 138|DmORC localization
P10541550A0487|141 153|follicle cells
P10541865A1301|19 30|co-deletions
P10541865A1301|33 38|CDKN2A
P10541865A1301|42 47|CDKN2B
P10541865A1301|58 66|mutations
P10541865A1301|86 96|transcripts
P10541865A1301|128 133|tumors
P10542237A0357|20 27|explants
P10542237A0357|80 87|response
P10542237A0357|101 107|stimuli
P10542237A0357|114 131|lipopolysaccharide
P10542237A0357|162 174|IL-6 secretion
P10542249A0415|0 16|Albumin expression
P10542249A0415|34 38|liver
P10542249A0415|42 52|combination
P10542249A0415|69 88|transcription factors
P10542249A0415|117 123|protein
P10542249A0415|123 127|C/EBP
P10542249A0415|127 131|alpha
P10542249A0415|135 143|C/EBPbeta
P10542260A0832|3 13|requirement
P10542260A0832|28 35|activity
P10542260A0832|42 46|FVIIa
P10542260A0832|85 93|receptors
P10542269A0000|0 18|Amyloid beta-protein
P10542269A0000|19 23|Abeta
P10542269A0000|33 43|constituent
P10542269A0000|46 59|amyloid fibrils
P10542269A0000|73 79|plaques
P10542269A0000|91 97|vessels
P10542269A0000|100 108|Alzheimer
P10542269A0000|110 116|disease
P10542269A0000|135 145|proteolysis
P10542269A0000|152 179|beta-amyloid precursor protein
P10542274A1376|14 23|activation
P10542274A1376|26 39|protein kinase A
P10542274A1376|45 53|signaling
P10542274A1376|80 106|caveolin-1 protein expression
P10542274A1376|110 125|promoter activity
P10542277A0000|3 15|importin alpha
P10542277A0000|19 33|beta heterodimer
P10542277A0000|49 54|import
P10542277A0000|57 64|proteins
P10542277A0000|91 109|localization signals
P10542281A0382|12 16|G1-G2
P10542281A0382|28 37|hyaluronan
P10542281A0382|41 51|link protein
P10542281A0382|88 92|motif
P10542281A0382|96 107|proteoglycan
P10542281A0382|114 124|repeat loops
P10542281A0382|130 137|G1 domain
P10542281A2021|3 9|results
P10542281A2021|24 31|presence
P10542281A2021|34 40|absence
P10542281A2021|48 61|keratan sulfate
P10542281A2021|70 74|G1-G2
P10542281A2021|91 98|activity
P10542281A2021|101 110|atrolysin C
P10542281A2021|123 127|sites
P10543270A1054|7 24|i.v. steroid therapy
P10543270A1054|25 29|NOexh
P10543270A1054|56 63|recovery
P10543270A1054|88 96|discharge
P10543727A0282|17 21|sites
P10543727A0282|32 51|transcription factors
P10543727A0282|55 61|example
P10543727A0282|82 92|binding site
P10543727A0282|96 128|rel/NF-kappaB transcription factors
P10543727A0282|142 146|H2TF1
P10543727A0282|148 161|kappaB1 element
P10543727A0282|171 180|kappaB site
P10543727A0282|184 197|kappaB2 element
P10543727A0282|237 248|H2TF1 element
P10543727A0282|271 278|p65/relA
P10543727A0282|289 297|HLA system
P10543727A0282|311 332|ATF recognition sequence
P10543727A0282|343 349|EnA-TRE
P10543728A0358|20 31|cHa-ras cells
P10543728A0358|68 87|DNA binding activities
P10543728A0358|98 105|contrast
P10543728A0358|121 125|cells
P10543728A0358|132 139|E1A cells
P10543730A0000|3 7|yeast
P10543730A0000|14 31|cyclin Ume3p/Srb11p
P10543730A0000|54 59|kinase
P10543730A0000|65 69|Ume5p
P10543730A0000|90 99|repression
P10543730A0000|102 106|genes
P10543730A0000|120 133|stress response
P10543730A0000|136 142|meiosis
P10543949A0686|19 33|specificity site
P10543949A0686|60 65|cavity
P10544037A0617|29 33|FZD10
P10544037A0617|42 58|amino acid identity
P10544037A0617|98 102|FZD10
P10544037A0617|113 117|FZD10
P10544088A0308|3 11|NF-kappaB
P10544088A0308|22 38|reporter construct
P10544088A0308|39 43|PRDII
P10544088A0308|64 76|transcription
P10544088A0308|89 97|NF-kappaB
P10544089A1208|3 16|RNA transcripts
P10544089A1208|42 47|sgRNAs
P10544089A1208|50 54|TMV U1
P10544089A1208|58 62|crTMV
P10544089A1208|77 92|hairpin structure
P10544089A1208|140 146|MP-CP-3
P10544089A1208|158 164|MP-CP-3
P10544089A1208|186 191|MP gene
P10544113A0293|0 25|EIAV LTR sequence variability
P10544113A0293|50 56|portion
P10544113A0293|62 69|enhancer
P10544113A0293|79 87|U3 segment
P10545192T0000|0 38|Phosphatidylinositol 3-kinase requirement
P10545192T0000|41 50|activation
P10545192T0000|56 64|ras/C-raf
P10545192T0000|65 71|MEK/ERK
P10545192T0000|84 99|signaling cascade
P10545192T0000|118 136|agent vanadyl sulfate
P10545248A0567|15 22|enhancer
P10545248A0567|56 67|binding sites
P10545248A0567|74 97|homeodomain protein Tinman
P10545248A0567|149 162|muscle lineages
P10545281A0836|3 9|example
P10545281A0836|10 21|introduction
P10545281A0836|38 61|purification tag sequences
P10545281A0836|79 90|coding region
P10545281A0836|113 123|bop gene mRNA
P10545281A0836|127 145|protein accumulation
P10548434A1549|22 28|ability
P10548434A1549|31 37|polyoma
P10548434A1549|44 52|T antigens
P10548434A1549|82 96|differentiation
P10548434A1549|124 130|JNK/SPK
P10548434A1549|132 143|p38 signaling
P10548622A0906|27 31|block
P10548622A0906|36 45|lignocaine
P10548622A0906|60 70|conjunction
P10548622A0906|75 96|i.v. sedation/analgesia
P10548622A0906|103 115|egg collection
P10548622A0906|147 151|route
P10548622A0906|157 174|ultrasound guidance
P10548622A0906|175 179|TUGOR
P10548622A0906|202 210|procedure
P10548722A0099|21 32|organization
P10548722A0099|61 73|TcP2beta genes
P10548722A0099|118 125|sequence
P10548722A0099|164 170|element
P10549354A1782|1 10|proportion
P10549354A1782|27 41|colon carcinomas
P10549354A1782|44 52|melanomas
P10549354A1782|84 88|Tcf-4
P10549354A1782|88 108|beta-catenin complexes
P10549354A1782|112 117|result
P10549354A1782|128 136|mutations
P10549354A1782|142 150|N terminus
P10549354A1782|153 164|beta-catenin
P10549354A1782|190 203|downregulation
P10549354A1782|211 218|GSK3 beta
P10549354A1782|221 234|Axin/Conductin
P10549354A2371|7 16|mechanisms
P10549354A2371|26 37|deregulation
P10549354A2371|40 60|Tcf target gene activity
P10549354A2371|84 91|melanoma
P10549354A2371|100 104|forms
P10549354A2371|107 112|cancer
P10549912A0136|4 9|report
P10549912A0136|20 26|patient
P10549912A0136|63 72|infarction
P10549912A0136|101 110|infarction
P10549912A0136|142 157|segment elevation
P10549912A0136|157 161|V1-V4
P10549912A0136|205 212|branches
P10549912A0136|227 237|angioplasty
P10549912A0136|256 261|artery
P10550139A0191|0 7|PATIENTS
P10550139A0191|11 17|METHODS
P10550139A0191|42 54|prostatectomy
P10550139A0191|55 73|bone marrow aspirates
P10550139A0191|82 86|sides
P10550139A0191|97 101|crest
P10550139A0191|118 125|patients
P10550571A0000|0 6|PURPOSE
P10550571A0000|15 21|WR-2721
P10550571A0000|42 48|studies
P10550571A0000|62 73|plasma levels
P10550571A0000|76 83|patients
P10550571A0000|107 115|compounds
P10550571A0000|136 142|effects
P10550571A0000|144 150|WR-2721
P10550571A0000|163 168|thiols
P10550574A1038|4 9|regard
P10550574A1038|26 35|toxicities
P10550574A1038|36 43|diarrhea
P10550574A1038|44 52|infection
P10550574A1038|64 87|serum alkaline phosphatase
P10550574A1038|90 94|grade
P10550574A1038|121 126|cycles
P10551788A0229|0 5|LHbeta
P10551788A0229|28 43|gonadotrope cells
P10551788A0229|47 52|CGbeta
P10551788A0229|75 90|trophoblast cells
P10551796T0000|0 9|Regulation
P10551796T0000|12 29|HIV-1 transcription
P10551816A0162|5 10|LTBP-1
P10551816A0162|36 40|forms
P10551848A0000|11 15|study
P10551848A0000|16 21|Kimura
P10551848A0000|26 37|Kurzydlowski
P10551848A0000|54 62|MacLennan
P10551867A0350|16 32|amino acid residues
P10551867A0350|43 60|9-kilobase pair mRNA
P10551867A0350|68 81|splice variants
P10551867A0350|108 123|rat cDNA libraries
P10551879T0000|19 38|protein kinase binding
P10551879T0000|41 65|A-kinase anchoring proteins
P10551879T0000|68 78|living cells
P10551879T0000|81 115|fluorescence resonance energy transfer
P10551879T0000|134 154|protein fusion proteins
P10552357A1936|0 10|CONCLUSIONS
P10552357A1936|13 20|addition
P10552357A1936|26 36|superiority
P10552357A1936|63 74|microspheres
P10552357A1936|87 98|microspheres
P10552357A1936|102 116|LV opacification
P10552357A1936|120 127|efficacy
P10552357A1936|168 177|LV function
P10552357A1936|202 208|effects
P10552357A1936|215 226|echogenicity
P10553551A0000|0 17|Factor XI deficiency
P10553551A0000|43 50|disorder
P10553551A0000|72 78|pathway
P10553959A0812|3 16|Ishasha samples
P10553959A0812|22 26|range
P10553959A0812|51 56|levels
P10554946A0082|18 22|SERMS
P10554946A0082|23 39|clomiphene citrate
P10554946A0082|43 51|tamoxifen
P10554946A0082|85 89|drugs
P10554946A0082|92 101|raloxifene
P10554946A0082|105 112|faslodex
P10554946A0082|117 124|emphasis
P10554946A0082|134 140|actions
P10554946A0082|143 148|breast
P10554946A0082|149 154|uterus
P10554946A0082|164 169|lipids
P10555079A0254|26 35|morphology
P10555285A1065|4 15|organization
P10555285A1065|28 44|duplication events
P10555285A1065|72 92|FUT3-FUT5-FUT6 cluster
P10555285A1065|157 165|mechanism
P10555285A1065|204 216|globin cluster
P10556028A0292|3 11|cop region
P10556028A0292|24 29|region
P10556028A0292|32 53|plasmid incompatibility
P10556028A0292|81 89|structure
P10556028A0292|92 103|repA promoter
P10556028A0292|129 144|RepA binding sites
P10556029A0852|0 11|WA constructs
P10556029A0852|38 48|topoisomers
P10556029A0852|52 70|cyclization kinetics
P10556029A0852|84 98|interconversion
P10556029A0852|101 110|precursors
P10556029A0852|119 129|topoisomers
P10556033A0000|3 18|RFX protein family
P10556033A0000|27 33|members
P10556033A0000|38 42|yeast
P10556033A0000|45 50|humans
P10556033A0000|83 89|systems
P10556033A0000|110 115|domain
P10556033A0000|139 144|region
P10556044A0913|0 6|Binding
P10556044A0913|9 19|sulphatides
P10556044A0913|26 51|alpha-dystroglycan receptor
P10556044A0913|88 96|LG modules
P10556046A0328|53 68|signaling pathway
P10556046A0328|98 110|Xenopus embryo
P10556063A0092|5 11|kinases
P10556063A0092|24 32|subfamily
P10556063A0092|45 56|Trk subfamily
P10556089A0901|21 25|etr-1
P10556089A0901|39 55|muscle development
P10556089A0901|58 66|C. elegans
P10556089A0901|112 121|processing
P10556089A0901|127 141|muscle component
P10556089A0901|168 179|conservation
P10556089A0901|182 193|gene function
P10556089A0901|203 208|CUG-bp
P10556145A1034|0 9|Gentamicin
P10556145A1034|55 70|sputum Psa density
P10556145A1034|88 92|order
P10556145A1034|94 102|magnitude
P10556263A1035|0 10|CONCLUSIONS
P10556263A1035|21 25|value
P10556263A1035|36 40|space
P10556263A1035|83 87|space
P10556595A0391|2 9|analysis
P10556595A0391|12 19|sequence
P10556595A0391|31 38|recN gene
P10556595A0391|58 69|transversion
P10556595A0391|91 96|region
P10556751A0758|34 50|transmission rates
P10556751A0758|80 91|immunization
P10556751A0758|135 140|hazard
P10556751A0758|159 163|staff
P10557008T0000|0 8|Detection
P10557008T0000|11 19|poisoning
P10557008T0000|22 27|Impila
P10557008T0000|49 54|mother
P10557008T0000|58 62|child
P10557072A0127|26 30|mouse
P10557072A0127|39 43|cDNAs
P10557072A0127|63 68|kinase
P10557072A0418|9 14|UNC-51
P10557072A0418|27 41|domain structure
P10557072A0418|60 71|kinase domain
P10557072A0418|80 93|proline/serine
P10557072A0418|102 107|domain
P10557072A0418|130 135|domain
P10557072A1218|5 11|results
P10557072A1218|67 82|signaling pathway
P10557072A1218|93 97|cells
P10557308A0000|0 16|Connector enhancer
P10557308A0000|43 49|protein
P10557308A0000|59 70|RAS signaling
P10559207A0207|9 17|organisms
P10559207A0207|21 34|ATP sulfurylase
P10559207A0207|38 55|APS kinase reactions
P10559207A0207|78 84|enzymes
P10559207A0207|104 108|genes
P10559207A0207|124 129|fusion
P10559207A0207|140 144|genes
P10559207A0207|154 159|course
P10559207A0207|162 170|evolution
P10559207A0207|195 200|enzyme
P10559303A0000|12 16|virus
P10559303A0000|28 42|membrane protein
P10559303A0000|75 88|transformation
P10559303A0000|97 108|B lymphocytes
P10559320A0080|39 45|homolog
P10559320A0080|46 55|alphavirus
P10559320A0080|69 79|protein nsP1
P10559324A0716|34 44|Ad5 E4orf6/7
P10559324A0716|51 59|apoptosis
P10559324A0716|62 69|rat cells
P10559364A0846|7 11|Towne
P10559364A0846|18 24|HF cells
P10559364A0846|74 99|DNA replication compartments
P10559364A0846|111 138|polymerase processivity factor
P10559364A0846|163 179|DNA binding protein
P10559364A0846|193 217|UL112-113 accessory protein
P10559364A0846|236 252|bromodeoxyuridine
P10560014A0000|23 42|heart vascularization
P10560014A0000|63 79|angioarchitecture
P10560014A0000|95 100|system
P10560014A0000|127 136|myocardium
P10560997A1072|0 9|CONCLUSION
P10560997A1072|28 35|LH levels
P10560997A1072|48 53|method
P10560997A1072|68 76|ovulation
P10561095A2141|7 17|reoperation
P10561095A2141|34 40|disease
P10561095A2141|41 45|group
P10561095A2141|68 83|calcitonin levels
P10561095A2141|108 116|incidence
P10561095A2141|128 145|hypoparathyroidism
P10561153A0225|18 26|carcinoma
P10561153A0225|31 36|breast
P10561153A0225|119 125|failure
P10561153A0225|132 136|month
P10561251A0000|0 6|PURPOSE
P10561251A0000|32 39|survival
P10561251A0000|55 62|survival
P10561251A0000|76 82|factors
P10561251A0000|102 110|mortality
P10561251A0000|113 117|women
P10561251A0000|122 130|stage IIIB
P10561251A0000|143 154|breast cancer
P10561251A0000|179 193|modality therapy
P10561251A0000|210 221|chemotherapy
P10561251A0000|241 264|stem-cell transplantation
P10561460A0615|3 17|GPI anchor moiety
P10561460A0615|51 55|level
P10561460A0615|61 71|polypeptide
P10561460A0615|114 126|signal peptide
P10561460A0615|129 146|GPI signal sequences
P10561546A0000|34 40|protein
P10561546A0000|75 82|antibody
P10561546A0000|117 134|localization signal
P10561546A0000|137 155|NF-kappaB p65 subunit
P10562418A0238|17 22|events
P10562418A0238|40 44|cells
P10562456T0000|10 16|regions
P10562456T0000|22 29|promoter
P10562456T0000|38 43|intron
P10562456T0000|49 65|growth hormone gene
P10562456T0000|68 79|rainbow trout
P10562456T0000|80 91|Oncorhynchus
P10562456T0000|98 104|walbaum
P10562495A0188|12 19|SFV genes
P10562495A0188|24 31|homologs
P10562495A0188|46 61|Chordopoxvirinae
P10562495A0188|65 73|SFV genome
P10562495A0188|103 112|production
P10562495A0188|136 140|virus
P10563212A0514|21 38|SF-36 questionnaire
P10563212A0514|108 115|controls
P10563605A0773|9 13|trend
P10563605A0773|22 32|association
P10563605A0773|54 58|nerve
P10563605A0773|70 83|fiber densities
P10563789A1951|2 9|addition
P10563789A1951|10 14|media
P10563789A1951|25 41|F beta alpha/CG beta
P10563789A1951|84 95|FSH receptors
P10563836A1234|2 9|contrast
P10563836A1234|10 28|AP-2 binding activity
P10563836A1234|54 62|T47D cells
P10563836A1234|66 77|Western blots
P10563836A1234|96 112|AP-2 protein levels
P10563836A1234|120 124|cells
P10564231A0315|0 8|N. van Hoek
P10564280A0140|45 51|protein
P10564280A0140|52 58|YT521-B
P10564280A0140|111 144|component scaffold attachment factor B
P10564280A0140|157 168|Src substrate
P10564280A0140|185 191|mitosis
P10564280A0140|192 196|Sam68
P10564472A0853|5 11|mutants
P10564472A0853|38 47|TraR fusion
P10564472A0853|63 68|system
P10564474T0000|9 18|homologues
P10564474T0000|50 59|expression
P10564474T0000|65 89|outer-membrane protein OprH
P10564474T0000|93 112|polymyxin B resistance
P10564479A0384|0 7|Deletion
P10564479A0384|39 44|effect
P10564479A0384|57 65|fds operon
P10564479A0384|90 98|activator
P10564479A0384|104 111|presence
P10564479A0384|114 120|formate
P10564479A0384|125 133|repressor
P10564479A0384|139 145|absence
P10564479A0384|148 154|formate
P10564484A0859|4 13|constructs
P10564484A0859|27 37|binding site
P10564484A0859|59 66|promoter
P10564484A0859|107 118|requirements
P10564484A0859|123 130|function
P10564484A0859|163 170|promoter
P10564495A0444|2 9|addition
P10564495A0444|18 28|Opa proteins
P10564495A0444|54 62|HeLa cells
P10564495A0444|110 116|antigen
P10564495A0444|121 125|CD66e
P10564495A0444|125 132|subgroup
P10564495A0444|138 147|CD66 family
P10564495A0444|163 169|tropism
P10564495A0444|179 183|CD66d
P10564495A0444|191 195|CD66c
P10564495A0444|204 208|cells
P10564593A0428|17 26|chromosome
P10564593A0428|27 31|paint
P10564593A0428|52 65|rearrangements
P10564593A0428|75 84|chromosome
P10564593A0428|88 100|MCF-7 AdVp3000
P10564593A0428|104 110|MCF-7 MX
P10564593A0428|116 123|S1-M1-80
P10564593A0428|154 166|translocation
P10564593A1618|3 9|MXR gene
P10564593A1618|18 33|half-transporter
P10564593A1618|40 46|absence
P10564593A1618|60 67|evidence
P10564593A1618|70 84|coamplification
P10564593A1618|92 98|regions
P10564593A1618|112 118|partner
P10564593A1618|153 171|MXR half-transporter
P10564593A1618|194 206|drug transport
P10564939A0981|3 8|effect
P10564939A0981|11 17|smoking
P10564939A0981|38 42|study
P10566630A0371|0 4|Serum
P10566630A0371|17 29|growth factor I
P10566630A0371|30 34|IGF-I
P10566630A0371|35 41|SD score
P10566630A0371|76 80|women
P10566630A0371|107 112|months
P10566630A0371|130 135|months
P10566862A0000|0 9|BACKGROUND
P10566862A0000|10 20|Measurement
P10566862A0000|23 34|stereoacuity
P10566862A0000|44 52|distances
P10566862A0000|70 91|depth stereoacuity tests
P10566862A0000|106 115|evaluation
P10566862A0000|118 125|patients
P10566862A0000|139 147|imbalance
P10566862A0000|150 159|strabismus
P10567430A0785|10 16|studies
P10567430A0785|35 45|brain Galpha
P10567430A0785|78 86|construct
P10567430A0785|101 107|binding
P10567430A0785|109 114|Galpha
P10567430A0785|120 125|Galpha
P10567430A0785|127 132|Galpha
P10567430A0785|134 139|Galpha
P10567430A0785|156 165|constructs
P10567524T0000|3 21|elm1 kinase functions
P10567524T0000|32 47|signaling network
P10567524T0000|57 61|yeast
P10567533A0818|7 19|transcription
P10567533A0818|23 33|PCR products
P10567533A0818|65 71|primers
P10567533A0818|95 100|motifs
P10567533A0818|110 124|tyrosine kinases
P10567538A1028|2 9|addition
P10567538A1028|13 37|acetyltransferase activity
P10567538A1028|92 109|activation function
P10567538A1028|137 142|region
P10567581A0119|25 29|HNF-3
P10567581A0119|29 54|fork head homolog-11B protein
P10567581A0119|55 61|HFH-11B
P10567581A0119|73 79|Trident
P10567581A0119|91 102|family member
P10567581A0119|123 146|head transcription factors
P10567581A0119|164 168|liver
P10567581A0119|172 181|expression
P10567581A0119|202 216|hepatocyte entry
P10567581A0119|221 234|DNA replication
P10567581A0119|235 240|S phase
P10567582A1334|5 9|mouse
P10567582A1334|10 14|CtBP1
P10567582A1334|30 35|embryo
P10567582A1334|46 50|CtBP2
P10567582A1334|74 86|embryogenesis
P10567589A1268|11 19|functions
P10567589A1268|22 26|Pmt3p
P10567589A1268|65 72|proteins
P10567589A1268|87 102|Pmt3p conjugation
P10568275A0679|11 19|transport
P10568275A0679|21 26|sea ice
P10568275A0679|34 40|Kara Sea
P10568275A0679|48 58|Arctic Ocean
P10568275A0679|78 85|subgroup
P10568275A0679|88 93|GEOMAR
P10568455A0000|26 34|injection
P10568455A0000|37 64|slow-release estradiol-17beta
P10568455A0000|82 96|pseudopregnancy
P10568455A0000|98 102|gilts
P10568455A0000|113 121|PGF2alpha
P10568455A0000|137 148|corpora lutea
P10568455A0000|155 169|pseudopregnancy
P10568728A1445|3 7|level
P10568728A1445|10 28|serum creatine kinase
P10568728A1445|61 65|ESWIB
P10568744A0728|19 23|sites
P10568744A0728|35 43|promoters
P10568744A0728|65 69|genes
P10568744A0728|81 85|sites
P10568744A0728|135 143|direction
P10568744A0728|145 163|mating type switching
P10570262A0000|0 9|Activation
P10570262A0000|12 17|T cells
P10570262A0000|50 58|receptors
P10570262A0000|67 72|number
P10570262A0000|75 91|signaling cascades
P10570996A1213|13 20|analysis
P10570996A1213|28 36|TK domains
P10570996A1213|46 54|sequences
P10570996A1213|75 86|scavenger RTK
P10570996A1213|90 96|domains
P10570996A1213|108 116|signature
P10570996A1213|123 129|TK class
P10570996A1213|132 140|receptors
P10570996A1213|179 185|insulin
P10570996A1213|201 209|receptors
P10571047A1009|24 32|sequences
P10571047A1009|52 58|spacers
P10571047A1009|89 104|HindIII fragments
P10571474A0571|0 6|Results
P10571474A0571|20 25|stress
P10571474A0571|48 54|atrophy
P10571474A0571|57 66|tianeptine
P10572087A0326|15 28|binding partner
P10572087A0326|42 60|anemia group C protein
P10572087A0326|61 65|FANCC
P10572087A0326|68 72|yeast
P10572087A0326|83 91|screening
P10572130A1623|5 11|results
P10572130A1623|27 49|transcription activators
P10572130A1623|81 88|subunits
P10572130A1623|91 103|RNA polymerase
P10572130A1623|125 133|formation
P10572130A1623|141 151|DNA geometry
P10572131A0000|0 16|Klebsiella oxytoca
P10572131A0000|54 60|enzymes
P10572131A0000|73 87|nasFEDCBA operon
P10572866A0481|6 14|hemolysis
P10572866A0481|37 48|plasma values
P10572866A0481|51 59|potassium
P10572866A0481|60 69|phosphorus
P10572866A0481|75 81|protein
P10572866A0481|85 109|aspartate aminotransferase
P10573781A0631|0 6|Studies
P10573781A0631|27 37|involvement
P10573781A0631|63 73|chromosomes
P10573781A0631|75 80|excess
P10573781A0631|85 95|chromosomes
P10574913A1108|34 56|receptor phosphorylation
P10574913A1108|79 87|processes
P10574913A1108|94 107|Src recruitment
P10574913A1108|128 142|internalization
P10574913A1108|175 187|ERK activation
P10574913A1108|220 232|ERK activation
P10574929A0583|18 30|fractionation
P10574929A0583|40 52|P-CIP2 protein
P10574982A1075|0 14|Supershift EMSAs
P10574982A1075|48 55|factor-1
P10574982A1075|61 65|USF-1
P10574982A1075|88 96|complexes
P10574992A0901|10 19|E1A binding
P10574992A0901|26 33|p300/CBP
P10574992A0901|45 52|increase
P10574992A0901|55 72|PARP enzyme activity
P10574992A0901|90 112|cell death susceptibility
P10574992A0901|115 125|irradiation
P10574992A0901|161 197|PARP chemical inhibitor 3-aminobenzamide
P10575231A0355|0 7|Analysis
P10575231A0355|20 25|region
P10575231A0355|46 53|Cdc6 gene
P10575231A0355|69 73|exons
P10575231A0355|78 84|introns
P10575545A0147|15 19|CACCC
P10575545A0147|23 32|CAAT motifs
P10575642T0000|0 12|Skin pH changes
P10575642T0000|27 39|iontophoresis
P10576177A0308|4 14|distinction
P10576177A0308|37 45|diagnosis
P10576177A0308|70 74|range
P10576177A0308|77 85|prognoses
P10576177A0308|107 117|implication
P10576545A0926|3 14|availability
P10576545A0926|33 44|DNA cassettes
P10576545A0926|63 77|D1A gene promoter
P10576545A0926|113 122|expression
P10576545A0926|125 134|transgenes
P10578528A0730|18 25|location
P10578528A0730|29 33|focus
P10578528A0730|63 71|character
P10578528A0730|74 86|manifestation
P10578528A0730|120 133|symptomatology
P10579331A1225|3 9|results
P10579331A1225|17 23|studies
P10579331A1225|42 68|rat HDL receptor SR-BI promoter
P10579331A1225|80 101|sterol response elements
P10579331A1225|129 136|SREBP-1a
P10579331A1225|153 165|transcription
P10579722T0000|0 14|Phosphorylation
P10579722T0000|31 37|subunit
P10579722T0000|45 61|myosin phosphatase
P10579722T0000|63 72|Rho-kinase
P10580071A0436|7 14|patients
P10580071A0436|50 64|transplantation
P10580071A0436|99 108|transplant
P10580438A0508|17 34|mobility shift assay
P10580438A0508|45 65|GLUT4 repressor element
P10580438A0508|88 92|bands
P10580438A0508|103 110|extracts
P10580438A0508|115 127|preadipocytes
P10580438A0508|138 147|adipocytes
P10582831T0000|0 8|Syndromes
P10582831T0000|22 35|redistribution
P10582831T0000|48 60|complications
P10582831T0000|75 82|patients
P10584138T0001|0 13|Cytoprotection
P10584138T0001|18 27|amifostine
P10584138T0001|30 41|radiotherapy
P10584138T0001|44 61|radio-chemotherapy
P10584138T0001|73 82|neck tumors
P10584704A0913|19 26|staining
P10584704A0913|41 45|S-100
P10584704A0913|52 56|cases
P10584704A0913|75 80|HMB-45
P10584704A0913|106 116|cytokeratin
P10584704A0913|122 126|cases
P10584704A0913|140 147|melanoma
P10584704A0913|161 165|block
P10584704A0913|179 186|sections
P10585311A0494|0 7|Patients
P10585311A0494|12 16|types
P10585311A0494|59 63|onset
P10585311A0494|69 77|diagnosis
P10585311A0494|79 86|interval
P10585311A0494|99 103|onset
P10585311A0494|106 113|symptoms
P10585311A0494|116 124|diagnosis
P10585311A0494|125 130|biopsy
P10585311A1542|15 27|abnormalities
P10585311A1542|59 66|patients
P10585417A1412|13 23|differences
P10585417A1412|26 34|signaling
P10585417A1412|38 53|tissue expression
P10585417A1412|130 137|function
P10585440A0204|37 48|FAK homologue
P10585440A0204|49 54|DFak56
P10585440A0204|66 72|band 56D
P10585440A0204|99 108|chromosome
P10585453A1029|10 19|Pit-1 sites
P10585453A1029|25 41|hGH-N gene promoter
P10585453A1029|64 77|gene activation
P10585453A1029|151 155|Pit-1
P10585453A1029|159 164|hGH LCR
P10585463A0859|11 29|prenylcysteine lyase
P10585463A0859|44 74|baculovirus-Sf9 expression system
P10585480A0157|22 30|SH3 domain
P10585480A0157|44 74|guanine nucleotide exchange factor
P10585480A0265|0 13|Point mutations
P10585480A0265|24 32|SH3 domain
P10585480A0265|56 66|interaction
P10585491A0945|2 23|gel mobility shift assays
P10585491A0945|27 41|binding activity
P10585491A0945|63 82|AtpC promoter sequence
P10585491A0945|104 111|extracts
P10585491A0945|116 121|tissue
P10585491A0945|129 148|AtpC expression levels
P10585491A0945|153 160|extracts
P10585491A0945|190 198|seedlings
P10585491A0945|210 224|binding activity
P10585491A0945|242 249|extracts
P10585491A0945|254 260|tissues
P10585491A0945|269 288|AtpC expression levels
P10585491A0945|293 300|extracts
P10585491A0945|316 324|seedlings
P10585491A0945|337 345|seedlings
P10585491A0945|357 365|cytokinin
P10585808A0000|0 26|Mycoplasma hominis infections
P10585808A0000|61 67|methods
P10585808A0000|80 88|detection
P10586074A0129|7 13|purpose
P10586074A0129|21 26|series
P10586074A0129|29 45|plasmid constructs
P10586074A0129|63 67|forms
P10586074A0129|73 93|envelope glycoprotein E
P10586074A0129|99 108|flavivirus
P10586074A0129|119 135|encephalitis virus
P10586107A0160|24 28|types
P10586107A0160|41 60|transduction pathways
P10586107A0160|73 92|cell surface receptors
P10586115A0477|45 53|cytokines
P10586115A0477|62 70|IL-1alpha
P10586115A0477|71 78|IL-1beta
P10586115A0477|79 87|TNF-alpha
P10586115A0477|132 137|PKCeta
P10586115A0477|146 150|cells
P10586115A0477|171 177|inducer
P10586115A0477|198 205|cultures
P10586115A0477|207 210|% FCS
P10586626A0607|13 20|diseases
P10586626A0607|37 42|matter
P10586626A0607|75 82|presence
P10586626A0607|104 114|involvement
P10586626A0607|117 124|patients
P10587460A0302|18 34|VDRE binding domain
P10587460A0302|55 60|series
P10587460A0302|82 92|hVDR mutants
P10587460A0302|93 100|Delta134
P10587460A0302|101 108|Delta113
P10587460A0302|109 116|Delta102
P10587460A0302|117 123|Delta90
P10587460A0302|124 130|Delta84
P10587460A0302|131 137|Delta80
P10587460A0302|141 147|Delta60
P10587460A0302|174 181|bacteria
P10587461A0341|15 23|mechanism
P10587461A0341|24 31|contacts
P10587461A0341|39 47|anticodon
P10587461A0341|59 67|formation
P10587461A0341|77 91|transition state
P10587576A0596|13 20|clusters
P10587576A0596|54 59|harbor
P10587576A0596|89 103|SH3GL pseudogene
P10588946A0432|13 19|minimum
P10588946A0432|42 49|proteins
P10588946A0432|60 64|ORP-1
P10588946A0432|67 71|ORP-6
P10589562A1208|11 16|result
P10589562A1208|21 29|inability
P10589562A1208|56 66|BB resonator
P10589562A1208|82 100|RF power requirements
P10589711A1228|2 9|addition
P10589711A1228|10 23|narZ expression
P10589711A1228|71 81|Madin-Darby
P10589711A1228|88 93|kidney
P10589711A1228|104 108|cells
P10589711A1228|134 144|salts medium
P10589711A1228|183 188|milieu
P10590092A0124|7 16|mechanisms
P10590092A0124|27 45|HIV-1 gene expression
P10590368X0000|9 21|trachelectomy
P10590368X0000|27 37|alternative
P10590368X0000|47 58|hysterectomy
P10590368X0000|62 69|patients
P10590368X0000|74 91|stage IA-B carcinoma
P10590368X0000|97 102|cervix
P10590368X0000|122 131|BACKGROUND
P10590368X0000|135 143|prognosis
P10590368X0000|158 166|lymph node
P10590368X0000|180 193|stage carcinoma
P10590368X0000|199 204|cervix
P10590368X0000|226 238|survival rates
P10591633A0138|4 8|event
P10591633A0138|15 21|process
P10591633A0138|36 46|recognition
P10591633A0138|52 65|target membrane
P10591633A0138|71 77|vesicle
P10591633A0138|103 126|SNARE protein interactions
P10591633A0138|166 176|recognition
P10591633A0138|181 194|membrane fusion
P10591933A0798|20 32|configuration
P10591933A0798|50 55|values
P10591933A0798|76 80|angle
P10591933A0798|84 91|coracoid
P10591933A0798|150 157|distance
P10591976A0317|0 11|Measurements
P10591976A0317|17 23|LWS p.a.
P10591976A0317|25 30|LWS lat
P10591976A0317|52 59|triangle
P10591976A0317|70 74|total
P10591976A0317|80 87|patients
P10591990A0178|1 5|group
P10591990A0178|10 15|DSM-IV
P10591990A0178|37 47|in-patients
P10591990A0178|65 69|times
P10592791A0370|2 11|conclusion
P10592791A0370|13 20|TECRA kit
P10592791A0370|65 71|strains
P10592791A0370|73 80|SET-RPLA
P10592791A0370|84 97|RIDASCREEN kits
P10592791A0370|127 139|investigation
P10592791A0370|142 148|SE types
P10592791A0370|163 169|ability
P10592791A0370|205 211|testing
P10592791A0370|215 225|SET-RPLA kit
P10592791A0370|233 242|background
P10592791A0370|252 264|RIDASCREEN kit
P10592791A0370|308 321|test procedures
P10592791A0370|336 342|ability
P10592791A0370|360 371|practicality
P10592791A0370|374 383|SET-EIA kit
P10592791A0370|386 394|screening
P10592791A0370|413 428|research purposes
P10592791T0001|0 9|Comparison
P10592791T0001|12 26|immunoassay kits
P10592791T0001|30 38|detection
P10592791T0001|55 66|enterotoxins
P10592824A1157|14 22|frequency
P10592824A1157|32 40|infection
P10592824A1157|56 60|rates
P10592824A1157|63 73|JEV antibody
P10592824A1157|108 114|vaccine
P10592824A1157|171 178|children
P10592824A1157|199 208|JE vaccines
P10592824A1157|230 239|Chi-square
P10592824A1157|242 250|trend test
P10593939A0747|42 63|interaction experiments
P10593939A0747|77 87|SR33 protein
P10593939A0747|114 124|SR45 protein
P10593939A0747|143 149|members
P10593939A0747|150 154|SRZ21
P10593939A0747|158 162|SRZ22
P10593939A0747|170 175|family
P10593939A0747|205 215|Arabidopsis
P10593939A0747|227 231|U-70K
P10593950A1113|2 8|summary
P10593950A1113|34 47|chromatography
P10593950A1113|51 56|U2AF65
P10593950A1113|90 100|protein p116
P10593950A1113|103 109|hnRNP A1
P10594130A0652|11 16|hearts
P10594130A0652|39 45|infants
P10594130A0652|59 65|degrees
P10594130A0652|76 83|staining
P10594239A0614|0 7|Tih1 maps
P10594239A0614|16 23|mouse Chr
P10594239A0614|33 39|Chr 1q31
P10594239A0614|51 57|regions
P10594239A0614|74 81|evidence
P10594239A0614|100 107|contrast
P10594239A0614|155 161|alleles
P10594239T0000|6 15|pleckstrin
P10594239T0000|32 41|gene family
P10594239T0000|51 59|Ipl/Tssc3
P10594239T0000|60 65|TDAG51
P10594239T0000|90 99|expression
P10594239T0000|110 117|location
P10594903A0000|3 11|potential
P10594903A0000|29 41|nanoparticles
P10594903A0000|95 104|substances
P10594903A0000|113 127|warfare agents GA
P10594903A0000|167 176|laboratory
P10595315A0344|24 30|effects
P10595315A0344|46 55|parameters
P10595315A0344|65 70|status
P10595315A0344|74 83|blood gases
P10596955A1032|18 32|failure patients
P10596955A1032|36 43|troponin
P10596955A1032|52 59|microg/l
P10596955A1032|65 75|Axsym method
P10596955A1032|83 88|levels
P10596955A1032|99 106|microg/l
P10596955A1032|112 117|Immuno
P10597222A1371|45 52|molecule
P10597222A1371|54 66|HMBA signaling
P10597223A0339|19 32|Ras-expression
P10597223A0339|55 64|activation
P10597223A0339|90 95|region
P10597223A0339|97 107|p21 promoter
P10597223A0339|130 156|transcription initiation site
P10597223A0339|166 177|binding sites
P10597223A0339|191 210|transcription factors
P10597232A0000|3 23|RET/PTC3 rearrangement
P10597232A0000|34 39|fusion
P10597232A0000|54 61|RET genes
P10597232A0000|123 139|thyroid carcinomas
P10597317A1156|0 8|Apoptosis
P10597317A1156|16 20|cells
P10597317A1156|41 55|co-transfection
P10597317A1156|77 84|addition
P10597317A1156|96 106|HD-MyZ cells
P10597317A1156|128 133|masses
P10597317A1156|169 178|inhibition
P10597317A1156|197 205|apoptosis
P10597317A1156|220 226|RS cells
P10598101A0000|2 9|addition
P10598101A0000|15 32|bZIP protein Opaque2
P10598101A0000|48 61|maize endosperm
P10598101A0000|69 76|proteins
P10598101A0000|104 123|kDa zein gene promoters
P10598101A0754|3 16|mEmBP-1 protein
P10598101A0754|28 40|transcription
P10598101A0754|55 62|promoter
P10598101A0754|74 81|pentamer
P10598101A0754|97 106|yeast cells
P10598101A0754|133 145|transcription
P10598101A0754|151 165|kDa zein promoter
P10598101A0754|178 192|expression assay
P10598101A0754|206 224|maize endosperm cells
P10598316A1534|35 44|substances
P10599013A0505|11 16|deaths
P10599727A1567|15 38|estrogen treatment regimen
P10599727A1567|42 46|girls
P10599727A1567|82 91|conformity
P10599727A1567|107 111|peers
P10600171A1066|23 36|responsiveness
P10600171A1066|39 44|CYP3A2
P10600171A1066|50 55|result
P10600171A1066|70 76|binding
P10600171A1066|79 85|COUP-TF
P10600171A1066|91 107|CYP3A2 DexRE-1 site
P10600171A1432|6 12|CYP3A23
P10600171A1432|18 25|activity
P10600171A1432|44 48|E-box
P10600171A1432|51 59|3A23SiteA
P10600171A1432|94 130|bHLH/leucine zipper transcription factor
P10601280A0674|28 34|element
P10601280A0674|59 77|ST3 promoter activity
P10601280A0674|100 109|activation
P10601290A0742|15 19|basis
P10601290A0742|35 54|cell surface stability
P10601290A0742|76 82|peptide
P10601290A0742|101 111|differences
P10601290A0742|114 129|T cell recognition
P10601290A0742|165 186|x-ray crystal structures
P10601290A0742|193 197|class
P10601290A0742|199 218|MHC-peptide complexes
P10601335A0892|0 13|Redistribution
P10601335A0892|16 26|mannosidase
P10601335A0892|45 49|cells
P10601335A0892|63 71|degrees C.
P10601344A1653|2 9|addition
P10601344A1653|26 39|activity assays
P10601344A1653|51 57|GTPases
P10601344A1653|71 80|expression
P10601344A1653|83 88|beta1A
P10601344A1653|89 94|beta1D
P10601344A1653|97 107|IL2R-beta1A
P10601344A1653|118 126|GD25 cells
P10601344A1653|134 143|activation
P10601344A1653|173 177|Cdc42
P10601410A0977|2 11|conclusion
P10601410A0977|54 66|remyelination
P10601410A0977|80 95|sclerosis lesions
P10601410A0977|115 128|conduction time
P10601606A0152|3 21|rhabdomyosarcoma R1H
P10601606A0152|39 43|flank
P10601606A0152|50 60|WAG/Rij rats
P10601606A0152|85 92|degrees C
P10601606A0152|96 104|degrees C.
P10601747A0482|18 29|control words
P10601747A0482|71 79|anomalies
P10601747A0482|94 103|N400 effect
P10601747A0482|139 147|word onset
P10602419A1253|16 22|effects
P10602502A0422|7 16|Tob protein
P10602502A0422|32 51|cell cycle progression
P10602502A0422|58 62|G0/G1
P10602502A0422|65 71|S phases
P10602507A0652|13 20|increase
P10602507A0652|23 30|cyclin D1
P10602507A0652|45 50|effect
P10602507A0652|87 94|activity
P10602507A0652|97 109|cyclin D1/cdk4
P10602507A0652|156 169|CSF-1 induction
P10602507A0652|208 220|p53 expression
P10602516A0182|2 9|addition
P10602516A0182|27 34|homology
P10602516A0182|36 46|microtubule
P10602516A0182|67 73|protein
P10602516A0182|74 78|M-NAP
P10602516A0182|82 87|AT1-46
P10602516A0182|101 108|function
P10602838A0127|6 10|study
P10602838A0127|13 20|patients
P10602838A0127|23 29|females
P10602838A0127|34 38|males
P10603349A1667|3 25|signalling molecules Wnt1
P10603349A1667|34 41|hedgehog
P10603349A1667|57 66|activation
P10603349A1667|85 99|progenitor cells
P10603349A1667|104 109|somite
P10603349A1667|130 138|viscinity
P10603349A1667|144 163|Myf5 expression domain
P10603349A1667|169 181|mesencephalon
P10604246A0523|0 10|STUDY DESIGN
P10604246A0523|14 20|METHODS
P10604246A0523|22 26|study
P10604246A0523|51 60|collection
P10604246A0523|63 67|PBPCs
P10604246A0523|78 83|device
P10604246A0523|87 94|AutoPBSC
P10604246A0523|95 101|version
P10604246A0523|111 127|AutoPBSC tubing set
P10604246A0523|163 171|procedure
P10604246A0523|184 196|cell tubing set
P10604246A0523|199 206|patients
P10604246A0523|217 222|donors
P10604583T0000|0 14|Albumin dialysis
P10604583T0000|24 30|removal
P10604583T0000|33 38|copper
P10604583T0000|42 48|patient
P10604583T0000|62 74|Wilson disease
P10604583T0000|98 117|liver transplantation
P10604583T0000|122 132|possibility
P10604583T0000|139 149|elimination
P10604583T0000|165 170|toxins
P10604945A0731|14 31|promoter constructs
P10604945A0731|50 57|Sp1 sites
P10604945A0731|80 86|ethanol
P10604945A0731|90 95|others
P10604945A0731|120 131|organization
P10604945A0731|145 158|promoter region
P10604945A0731|174 179|factor
P10604945A0731|195 209|ethanol response
P10606245A0906|0 13|Overexpression
P10606245A0906|16 22|CDP/cut
P10606245A0906|35 51|osteosarcoma cells
P10606245A0906|60 69|repression
P10606245A0906|72 89|OC promoter activity
P10606245A0906|94 103|repression
P10606245A0906|125 131|OC box I.
P10606272A1241|0 8|Injection
P10606272A1241|35 43|C. elegans
P10606272A1241|61 69|lethality
P10606272A1241|77 83|SF1 gene
P10606272A1241|104 108|yeast
P10606272A1241|128 135|metazoan
P10606515A0389|4 10|domains
P10606515A0389|34 43|DNA binding
P10606515A0389|62 80|acid receptor element
P10606515A0389|91 95|DNase
P10606515A0389|97 105|footprint
P10606515A0389|130 135|strand
P10606664A0000|0 18|Snail family proteins
P10606664A0000|22 31|zinc finger
P10606664A0000|47 56|regulators
P10606664A0000|101 105|roles
P10606664A0000|108 128|cell fate determination
P10607566A0880|18 24|finding
P10607566A0880|25 36|beta-catenin
P10607566A0880|62 71|RA receptor
P10607566A0880|98 103|manner
P10607566A0880|116 132|retinoid X receptor
P10607566A0880|166 184|beta-catenin binding
P10607899A0605|0 15|Sequence analysis
P10607899A0605|21 34|promoter region
P10607899A0605|43 49|TATA box
P10607899A0605|63 84|consensus binding motifs
P10607899A0605|102 110|half sites
P10607899A0605|114 140|estrogen receptor binding site
P10607900T0000|0 21|Sak kinase gene structure
P10607900T0000|40 49|regulation
P10608053A0923|0 11|Thrombolysis
P10608053A0923|33 40|increase
P10608053A0923|43 58|platelet activity
P10608053A0923|70 75|values
P10608053A0923|103 108|groups
P10608053A0923|114 118|IU/ml
P10608053A0923|121 125|Group
P10608053A0923|138 142|Group
P10608053A0923|151 167|001versus baseline
P10608053A0923|186 191|groups
P10608893A0727|9 13|Hp140
P10608893A0727|50 57|strength
P10608893A0727|63 73|specificity
P10610716A1127|15 31|missense mutations
P10610716A1127|32 36|E138V
P10610716A1127|37 41|R254G
P10610716A1127|45 49|P362R
P10610716A1127|74 79|AC gene
P10610716A1127|84 93|FD patients
P10611225A1127|26 36|interaction
P10611225A1127|38 42|eIF4A
P10611225A1127|56 61|region
P10611225A1127|64 69|eIF4GI
P10611225A1127|84 94|translation
P10611225A1127|105 115|interaction
P10611225A1127|118 122|eIF4A
P10611225A1127|140 145|region
P10611228A1388|3 10|DAP5/p86
P10611228A1388|43 50|DAP5/p97
P10611228A1388|67 72|assays
P10611235A1927|31 35|model
P10611235A1927|40 49|activation
P10611235A1927|55 63|MAPK Fus3p
P10611235A1927|76 84|betagamma
P10611235A1927|92 105|relocalization
P10611235A1927|111 127|Ste5p-MAPK cascade
P10611235A1927|133 146|plasma membrane
P10611242A0541|18 24|finding
P10611242A0541|48 57|TBP binding
P10611242A0541|62 73|HIS3 promoter
P10611320A0816|65 71|CAK gene
P10611320A0816|105 116|Cak1p protein
P10611353A0458|0 11|Northern blot
P10611353A0458|22 46|transcription-PCR analyses
P10611353A0458|54 64|mRNA samples
P10611353A0458|112 117|retina
P10611353A0458|121 131|transcripts
P10611353A0458|199 218|Northern blot analysis
P10612044A1180|26 37|conservation
P10612044A1180|42 56|AP-4 binding site
P10612044A1180|66 76|nucleotides
P10612044A1180|90 116|transcription initiation site
P10612044A1180|123 131|Aal-rpL34
P10612044A1180|135 147|Aal-rpL8 genes
P10612505A1317|15 19|error
P10612505A1317|28 32|study
P10612505A1317|37 41|power
P10612505A1317|74 89|group differences
P10612505A1317|91 105|treatment effect
P10612773A1210|0 10|CONCLUSIONS
P10612773A1210|11 21|Serum levels
P10612773A1210|24 32|S-100beta
P10612773A1210|44 50|markers
P10612773A1210|71 78|outcomes
P10612773A1210|91 97|surgery
P10612805A0716|16 25|alteration
P10612805A0716|47 53|cancers
P10612918A0318|3 10|problems
P10612918A0318|44 49|screws
P10613816X0000|0 6|Statins
P10613816X0000|12 17|lipids
P10613816X0000|27 31|bones
P10613816X0000|48 54|statins
P10613816X0000|90 94|drugs
P10613816X0000|102 106|study
P10613816X0000|124 132|compounds
P10613816X0000|145 151|effects
P10613816X0000|186 195|treatments
P10613816X0000|213 224|bone diseases
P10613816X0000|231 242|osteoporosis
P10613843A0107|14 21|products
P10613843A0107|31 47|duplication events
P10613843A0107|76 80|genes
P10613843A0107|110 120|ion channels
P10613863T0000|3 23|VirR response regulator
P10613863T0000|28 49|Clostridium perfringens
P10613863T0000|88 94|repeats
P10613863T0000|115 126|pfoA promoter
P10613874A0663|0 6|Cloning
P10613874A0663|10 19|sequencing
P10613874A0663|33 38|region
P10613874A0663|58 65|presence
P10613874A0663|122 129|proteins
P10613874A0663|136 143|homology
P10613874A0663|155 166|GlnA proteins
P10614676A0000|0 8|Objective
P10614676A0000|30 38|thickness
P10614676A0000|45 53|incidence
P10614676A0000|63 70|bleeding
P10614676A0000|87 91|women
P10614676A0000|103 110|tibolone
P10614676A0000|139 149|mg estradiol
P10614676A0000|153 175|mg norethisterone acetate
P10614676A0000|176 181|E+NETA
P10614676A0000|189 213|hormone replacement therapy
P10614857A0584|0 16|Leukocyte cultures
P10614857A0584|29 33|blood
P10614857A0584|50 57|children
P10614857A0584|61 66|months
P10614857A0584|87 92|yields
P10614857A0584|124 131|children
P10614857A0584|149 158|adenovirus
P10614857A0584|167 177|coronavirus
P10614857A0584|186 195|rhinovirus
P10616948A0998|5 14|BF ECT group
P10616948A0998|76 96|seizure threshold level
P10617126A1005|12 19|analysis
P10617126A1005|64 68|group
P10617126A1005|136 147|dentate gyrus
P10617126A1005|222 226|group
P10617144A0386|3 9|extents
P10617144A0386|12 26|phosphorylation
P10617144A0386|29 33|Ser44
P10617144A0386|37 41|Ser64
P10617144A0386|75 79|sites
P10617232A0393|0 11|Serum HBV-DNA
P10617232A0393|17 24|serology
P10617232A0393|28 39|liver enzymes
P10617232A0393|64 77|liver histology
P10617232A0393|101 109|treatment
P10617232A0393|114 121|patients
P10618645A0750|0 15|Maximum induction
P10618645A0750|37 49|concentration
P10618645A0750|54 59|nmol/L
P10619062T0000|0 23|Haycocknema perplexum n. g.
P10619062T0000|24 27|n. sp
P10619169A0411|20 29|testis size
P10619169A0411|43 52|orchimetry
P10619169A0411|59 68|time period
P10619254A1055|0 12|Animal studies
P10619254A1055|23 38|beam equalization
P10619254A1055|87 98|image quality
P10619353T0000|8 29|estrogen receptor ligand
P10619353T0000|32 62|estrogen response element sequence
P10619353T0000|65 75|interaction
P10619353T0000|80 95|chicken ovalbumin
P10619353T0000|104 130|promoter transcription factor
P10619353T0000|131 137|COUP-TF
P10620010A1155|0 9|CONCLUSION
P10620010A1155|42 50|cell cycle
P10620010A1155|50 72|tyrosine phosphorylation
P10620010A1155|90 99|activation
P10620010A1155|102 107|kinase
P10620010A1155|118 132|phosphorylation
P10620010A1155|135 143|threonine
P10620010A1155|149 154|T-loop
P10620010A1155|169 178|activation
P10620335A0749|34 40|COUP-TF
P10620335A0749|53 61|CV-1 cells
P10620777A1399|0 7|AB004534
P10622574A0000|3 12|prevalence
P10622574A0000|15 29|hepatitis C virus
P10622574A0000|35 43|infection
P10622574A0000|60 68|childhood
P10622574A0000|81 95|prevalence rates
P10622574A0000|118 122|world
P10622576A0552|23 33|information
P10622576A0552|52 59|patients
P10622576A0552|67 71|means
P10622576A0552|74 83|prevention
P10622576A0552|95 103|attention
P10622576A0552|116 125|risk groups
P10622576A0552|134 144|drug abusers
P10623758A0947|6 12|latency
P10623758A0947|26 32|neurons
P10623758A0947|34 40|ganglia
P10623758A0947|57 63|footpad
P10623758A0947|73 90|beta-galactosidase
P10623758A0947|98 103|number
P10623758A0947|114 118|cells
P10623758A0947|147 152|months
P10623804A0808|15 22|approach
P10623804A0808|29 36|question
P10623804A0808|53 59|effects
P10623804A0808|88 92|SHP-1
P10623804A0808|94 98|SHP-2
P10623804A0808|113 125|decoy proteins
P10623804A0808|128 148|Fc gamma RIIB1 signaling
P10624787A0432|30 38|functions
P10624787A0432|44 51|patients
P10624787A0432|96 109|blood pressures
P10624787A0432|167 179|body mass index
P10624787A0432|188 201|waist-hip ratio
P10625438A1429|5 11|tissues
P10625438A1429|24 34|transcripts
P10625438A1429|46 51|insert
P10625438A1429|57 67|bp insertion
P10625438A1429|70 75|repeat
P10625438A1429|100 109|conditions
P10625438A1429|119 124|% level
P10625438A1429|127 132|insert
P10625438A1429|142 151|transcript
P10625438A1429|195 208|control samples
P10625494A1059|5 11|results
P10625494A1059|23 33|CAAT-region
P10625494A1059|61 72|MDR1 promoter
P10625494A1059|75 87|HL60/VCR cells
P10625683A0091|4 12|receptors
P10625683A0091|20 41|protein tyrosine kinases
P10625683A0091|54 68|phosphorylation
P10625683A0091|86 94|molecules
P10625683A0091|96 102|process
P10625683A0091|123 130|function
P10625683A0091|137 145|receptors
P10625721T0101|0 10|Hypothermia
P10625721T0101|23 28|Arrest
P10625721T0101|35 44|Study Group
P10627518A0544|14 19|effect
P10627518A0544|30 40|cooperation
P10627518A0544|83 95|contributions
P10627532A0739|49 54|stress
P10627532A0739|70 76|protein
P10627532A0739|82 88|kinases
P10627532A0739|112 126|phosphorylation
P10627532A0739|128 137|activation
P10627532A0739|151 173|transcription factor ATF2
P10627834A0178|17 25|cultivars
P10627834A0178|25 30|Tehama
P10627834A0178|63 71|cultivars
P10627834A0178|71 79|Esterhazy
P10627834A0178|96 115|New Zealand selections
P10627834A0178|120 125|Dublin
P10627834A0178|126 130|Glory
P10627834A0178|131 136|Meyric
P10627834A0178|137 145|McKinster
P10627834A0178|146 152|Stanley
P10628490T0000|0 6|Anatomy
P10628490T0000|19 24|artery
P10628748A0344|7 16|activation
P10628748A0344|22 32|cAMP pathway
P10628748A0344|55 76|inhibin alpha expression
P10628748A0344|95 101|actions
P10628748A0746|0 7|Deletion
P10628748A0746|24 34|mutagenesis
P10628748A0746|66 72|element
P10628748A0746|72 80|TCA GGGCCA
P10628748A0746|109 128|cAMP-response element
P10628750A0298|34 41|cytokine
P10628750A0298|41 65|tumor necrosis factor-alpha
P10628750A0298|66 73|TNFalpha
P10628750A0298|83 90|enhancer
P10628750A0298|123 135|factor-kappaB
P10628750A0298|136 144|NF-kappaB
P10628750A0298|158 168|x NF-kappaB1
P10628750T0000|0 10|Angiotensin
P10628750T0000|27 32|factor
P10628750T0000|36 50|kappaB1 isoforms
P10628750T0000|59 103|angiotensinogen gene acute-phase response element
P10628750T0000|122 128|pathway
P10628750T0000|132 150|NF-kappaB activation
P10628755A0000|9 15|ligands
P10628755A0000|56 60|cycle
P10628755A0000|72 82|GH secretion
P10628755A0000|103 131|orphan GH-secretagogue receptor
P10628755A0000|132 136|GHS-R
P10628971A0824|3 12|collection
P10628971A0824|15 21|mutants
P10628971A0824|44 50|defects
P10628971A0824|58 64|members
P10628971A0824|69 77|mutations
P10628971A0824|108 126|protein sorting genes
P10628971A0824|144 166|dynamin family member VPS1
P10628971A1165|9 16|spectrum
P10628971A1165|19 25|mutants
P10628971A1165|42 48|defects
P10628971A1165|51 58|isolates
P10628971A1165|63 71|mutations
P10628971A1165|77 85|following
P10628971A1165|101 107|product
P10628971A1165|140 157|ribosome biogenesis
P10628971A1165|173 179|product
P10628971A1165|200 206|vacuole
P10628971A1165|210 232|microtubule organization
P10628971A1165|236 240|INP53
P10628971A1165|267 300|inositol polyphosphate 5-phosphatase
P10629035A0827|9 20|strandedness
P10629035A0827|44 52|extension
P10629035A0827|64 69|strand
P10629035A0827|70 75|G tails
P10629035A0827|103 112|telomerase
P10629035A0827|127 143|cdc17/pol1 mutants
P10629035A0827|151 157|defects
P10629035A0827|183 191|synthesis
P10629176A0887|2 9|addition
P10629176A0887|10 15|CaMig1
P10629176A0887|30 38|complexes
P10629176A0887|46 55|URS1 region
P10629176A0887|73 80|FBP1 gene
P10629938A1352|18 29|distribution
P10629938A1352|35 49|GFP-POLO protein
P10629938A1352|55 66|compartments
P10629938A1352|79 87|apparatus
P10629938A1352|120 126|studies
P10629938A1352|128 136|cell cycle
P10629938A1352|143 153|development
P10630471T0000|2 10|ASIC-chip
P10630471T0000|26 38|depth analysis
P10630471T0000|77 88|cell behavior
P10630630A0614|7 17|calphostin C
P10630630A0614|27 35|inhibitor
P10630630A0614|66 73|increase
P10630630A0614|75 87|CFI mRNA levels
P10633075A1111|23 34|Fab fragments
P10633075A1111|44 51|polymers
P10633075A1111|64 82|N-acetylglucosamine
P10633075A1111|88 93|effect
P10633499A1306|0 22|Arhythmacanthus Yamaguti
P10633499A1306|42 48|synonym
P10633499A1306|73 83|distinction
P10633499A1306|102 110|hook types
P10633499A1306|133 142|transition
P10633499A1306|171 175|hooks
P10634007A0202|19 39|acetaminophen overdose
P10634007A0202|61 72|hemodialysis
P10634007A0202|96 107|intoxication
P10634007A0202|113 125|drug clearance
P10635209A0419|9 20|conditioning
P10635209A0419|36 43|adhesive
P10637149A0806|15 28|G-A anastomosis
P10637149A0806|47 55|loop areas
P10637230A0332|7 16|expression
P10637230A0332|19 23|c-myc
P10637230A0332|49 61|proliferation
P10637230A0332|74 78|cells
P10637230A0332|81 88|response
P10637238A0291|0 40|Eastern Cooperative Oncology Group trial E3186
P10637238A0291|66 73|question
P10637337A0545|15 23|DNA repair
P10637337A0545|53 61|mutations
P10638607A0000|5 12|articles
P10638607A0000|26 32|results
P10638607A0000|64 68|phase
P10638607A0000|70 75|trials
P10638607A0000|82 90|treatment
P10638607A0000|93 100|patients
P10638607A0000|118 123|N0-1 M0
P10638607A0000|124 133|esophageal
P10638607A0000|142 154|cell carcinoma
P10638607A0000|172 185|adenocarcinoma
P10639585A0157|0 6|Studies
P10639585A0157|9 25|MPO gene regulation
P10639585A0157|47 55|mechanism
P10639585A0157|82 96|differentiation
P10640683A0204|0 11|NDRF/NeuroD2
P10640683A0204|46 51|lysate
P10640683A0204|53 62|COS-7 cells
P10640683A0204|82 101|expression constructs
P10640683A0204|105 116|NDRF/NeuroD2
P10640683A0670|9 26|transfection assays
P10640683A0670|32 39|P19 cells
P10640683A0670|52 61|expression
P10640683A0670|64 75|NDRF/NeuroD2
P10640683A0670|88 102|transactivation
P10640683A0670|108 132|rat insulin promoter element
P10640683A0670|134 138|RIPE3
P10640683A0670|139 146|enhancer
P10640683A0670|178 190|co-expression
P10640683A0670|247 256|derivative
P10640683A0670|282 289|increase
P10640683A0670|313 325|transcription
P10640701T0000|19 23|sites
P10640701T0000|26 35|Engrailed2
P10640701T0000|56 65|initiation
P10640701T0000|91 100|expression
P10640734A0190|4 26|tyrosine phosphorylation
P10640734A0190|32 36|ITIMs
P10640734A0190|42 50|molecules
P10640734A0190|80 91|phosphatases
P10640734A0190|111 131|tyrosine phosphatase-1
P10640734A0190|153 164|cell activity
P10641037A1371|0 7|AF154055
P10641688A0341|0 8|Alignment
P10641688A0341|22 26|spine
P10641688A0341|36 48|abnormalities
P10641688A0341|52 62|disc changes
P10642524A0156|14 24|interaction
P10642524A0156|27 31|mSTI1
P10642524A0156|36 40|hsp70
P10642524A0156|44 48|hsp90
P10642524A0156|96 118|tetratricopeptide repeat
P10642524A0156|123 128|motifs
P10642524A0156|135 141|regions
P10642531A2322|0 21|Competition experiments
P10642531A2322|52 63|relationship
P10642531A2322|76 94|RGD recognition sites
P10642889A0393|0 15|Sequence analysis
P10642889A0393|37 42|region
P10642889A0393|56 63|ATG codon
P10642889A0393|90 96|TATA box
P10643313A0345|5 22|i.v. administration
P10643313A0345|28 42|mg acetazolamide
P10643313A0345|46 57|disinfection
P10643313A0345|63 73|conjunctiva
P10643313A0345|76 90|micrograms rt-PA
P10643313A0345|111 115|ml SF6
P10644357A0935|5 11|results
P10644357A0935|58 64|nucleus
P10644357A0935|99 105|regions
P10644414T0000|12 21|expression
P10644414T0000|25 34|regulation
P10644414T0000|37 54|20-hydroxyecdysone
P10644414T0000|57 85|mosquito ultraspiracle isoforms
P10644753A0725|8 15|isoforms
P10644753A0725|37 58|antibody affinity column
P10644753A0725|70 76|sulfate
P10644753A0725|79 92|heparan sulfate
P10644753A0725|96 102|heparin
P10644753A0725|116 133|glycosaminoglycans
P10644760A0000|3 17|differentiation
P10644760A0000|21 31|maintenance
P10644760A0000|35 59|neurotransmitter phenotype
P10644760A0000|73 83|interaction
P10644760A0000|121 129|machinery
P10644760A0956|0 7|Analysis
P10644760A0956|20 26|domains
P10644760A0956|54 69|activation domain
P10644760A0956|83 98|repression domain
P10645921A0000|0 9|BACKGROUND
P10645921A0000|25 35|hypertrophy
P10645921A0000|52 59|disorder
P10645921A0000|72 83|morphologies
P10645921A1320|12 21|predictors
P10645921A1320|36 45|remodeling
P10645921A1320|54 62|odds ratio
P10645921A1320|81 96|ejection fraction
P10645921A1320|141 157|circumflex disease
P10645921A1320|164 172|odds ratio
P10646820T0000|25 39|lymphadenectomy
P10646820T0000|51 60|lymph nodes
P10646820T0000|82 93|hysterectomy
P10646820T0000|105 113|carcinoma
P10646863A0838|0 13|Overexpression
P10646863A0838|16 21|ICBP90
P10646863A0838|41 45|cells
P10646863A0838|63 72|expression
P10646863A0838|85 104|topoisomerase IIalpha
P10647177A0599|3 12|RNA aptamer
P10647177A0599|59 64|bulges
P10647177A0599|115 119|sites
P10647177A0599|149 157|formation
P10647633A1685|3 7|study
P10647633A1685|19 26|presence
P10647633A1685|41 49|sphincter
P10647633A1685|83 89|passage
P10647633A1685|91 96|stools
P10647633A1685|111 115|colon
P10647633A1685|121 126|rectum
P10647817T0000|0 8|Isolation
P10647817T0000|11 15|cDNAs
P10647817T0000|24 29|gibbon
P10647817T0000|33 46|monkey platelet
P10647817T0000|50 71|T cell activation antigen
P10647859A0000|33 38|effect
P10647859A0000|66 84|pressure ventilation
P10647859A0000|104 111|activity
P10647859A0000|116 124|diaphragm
P10647859A0000|157 164|subjects
P10647859A0000|170 178|occasions
P10647859A0000|192 196|rates
P10647859A0000|211 219|breathing
P10647859A0000|234 239|levels
P10647859A0000|248 255|pressure
P10647859A0000|256 260|Pappl
P10647859A0000|268 272|cmH2O
P10647859A0000|283 292|hypocapnia
P10647859A0000|320 327|eucapnia
P10648020A0151|0 6|METHODS
P10648020A0151|7 25|Von Willebrand factor
P10648020A0151|49 81|factors tissue plasminogen activator
P10648020A0151|96 106|tPA capacity
P10648020A0151|109 137|plasminogen activator inhibitor
P10648020A0151|139 143|PAI-1
P10648020A0151|144 152|platelets
P10648020A0151|153 162|fibrinogen
P10648020A0151|178 184|markers
P10648020A0151|201 208|patients
P10648211A0000|8 26|signaling properties
P10648211A0000|52 59|quantity
P10648211A0000|63 73|combination
P10648211A0000|76 86|ion channels
P10648489A1117|0 8|Treatment
P10648489A1117|45 53|reduction
P10648489A1117|67 83|segment depression
P10648489A1117|89 94|trough
P10648489A1117|98 115|peak concentrations
P10648619A0000|21 32|contribution
P10648619A0000|55 61|protein
P10648619A0000|66 81|TATA interactions
P10648619A0000|86 101|promoter activity
P10648619A0000|128 139|silkworm tRNA
P10648619A0000|193 212|interactions accounts
P10648619A0000|218 233|promoter activity
P10649449A0413|3 11|sequences
P10649449A0413|27 36|homologies
P10649449A0413|41 61|squalene synthase genes
P10649449A0413|65 71|enzymes
P10649449A0413|77 82|number
P10649449A0413|90 98|organisms
P10649449A0413|109 129|amino acid conservation
P10649449A0413|139 145|binding
P10649449A0413|158 164|domains
P10649456A1061|3 8|clones
P10649456A1061|12 18|strains
P10649456A1061|49 55|EUROFAN
P10649456A1061|63 73|stock centre
P10649456A1061|74 82|EUROSCARF
P10649456A1061|83 91|Frankfurt
P10649738A0953|3 10|episodes
P10649738A0953|13 23|peritonitis
P10649738A0953|40 46|patient
P10649738A0953|62 70|episode/3
P10649738A0953|71 84|patient-months
P10650104X0284|0 8|Copyright
P10650104X0284|16 27|Royal College
P10650104X0284|30 41|Radiologists
P10650938T0000|3 18|estrogen receptor
P10650938T0000|23 30|isoforms
P10650938T0000|43 62|estrogen dependencies
P10650938T0000|82 92|trout ER gene
P10650939A0789|0 8|Induction
P10650939A0789|22 33|coexpression
P10650939A0789|36 40|A-Fos
P10650939A1542|21 28|isoforms
P10650939A1542|33 52|progesterone receptor
P10650939A1542|91 100|activation
P10650939A1542|101 109|PGDH-2368
P10650958A1315|0 7|Element B
P10650958A1315|29 37|% homology
P10650958A1315|41 61|consensus c-myb element
P10650958A1315|82 90|complexes
P10650958A1315|113 117|c-myb
P10650958A1315|138 155|mobility shift assay
P10651076T0000|4 13|resolution
P10651076T0000|22 31|tomography
P10651076T0000|37 41|lungs
P10651076T0000|44 51|patients
P10651076T0000|66 74|arthritis
P10651805A1600|6 17|transfection
P10651805A1600|45 55|carrier cDNA
P10651805A1600|60 82|mouse L1210 leukemia cells
P10651805A1600|92 109|folate accumulation
P10651805A1600|124 133|leucovorin
P10651805A1600|142 163|acid growth requirements
P10651805A1600|181 191|sensitivity
P10651805A1600|194 205|methotrexate
P10651805T0000|0 15|Characterization
P10651805T0000|66 72|carrier
P10651805T0000|83 100|folate accumulation
P10651805T0000|111 123|leukemia cells
P10652093A0139|0 7|Electron
P10652093A0139|31 38|analyses
P10652093A0139|54 63|A118 genome
P10652093A0139|110 119|collection
P10652093A0139|137 148|DNA molecules
P10652102A0620|21 26|dosage
P10652102A0620|58 67|inhibition
P10652102A0620|73 88|Ty1 transposition
P10652102A0620|100 105|growth
P10652228A0759|12 21|activation
P10652228A0759|24 28|c-Jun
P10652228A0759|39 44|kinase
P10652228A0759|57 65|Rho family
P10652228A0759|77 84|proteins
P10652324A0177|10 22|participation
P10652324A0177|25 39|collagen binding
P10652362A0933|33 48|carboxyl terminus
P10652362A0933|79 99|internalization signal
P10652362A0933|128 145|adaptor complex AP-2
P10652362A0933|167 171|entry
P10652362A0933|199 206|vesicles
P10652800A0984|3 23|insulin therapy regimen
P10652800A0984|39 47|evolution
P10652800A0984|53 60|patients
P10652800A0984|77 88|relationship
P10652800A0984|113 121|diagnosis
P10652800A0984|121 128|duration
P10652800A0984|131 138|diabetes
P10652800A0984|144 156|insulin dosage
P10652800A0984|168 174|control
P10652800A0984|178 183|height
P10653359A1297|0 8|Scmh1 maps
P10653359A1297|11 18|4D1-D2.1
P10653400A0000|3 15|applicability
P10653400A0000|30 45|donor nephrectomy
P10653400A0000|79 83|donor
P10653550A1120|0 18|Hyaluronan treatment
P10653550A1120|29 46|collagen remodeling
P10653550A1120|62 67|region
P10653550A1120|93 100|meniscus
P10653550A1120|119 124|region
P10653693A0429|20 25|issues
P10653693A0429|67 87|KAP-1-RBCC interaction
P10653693A0429|100 109|components
P10653693A0903|3 12|RING finger
P10653693A0903|13 17|B2 box
P10653693A0903|32 37|region
P10653693A0903|52 66|oligomerization
P10653693A0903|69 78|KAP-1-RBCC
P10653693A0903|82 92|KRAB binding
P10653693A0903|95 103|mutations
P10653693A0903|111 117|domains
P10653693A0903|145 153|functions
P10653697A0133|0 5|Actins
P10653697A0133|22 26|forms
P10653697A0133|39 48|processing
P10653697A0133|75 82|sequence
P10653733A0596|7 13|domains
P10653733A0596|49 56|peptides
P10654032A1133|20 35|compression ratio
P10654032A1133|71 81|performance
P10655164A0546|35 47|uncertainties
P10655164A0546|73 83|Li abundance
P10655164A0546|104 109|limits
P10655164A0546|114 118|parl0
P10655164A0546|125 129|solm0
P10655164A0546|134 138|parr0
P10655164A0546|150 155|x10-10
P10655230A0685|9 24|yeast counterpart
P10655230A0685|28 44|mouse GCN2 isoforms
P10655230A0685|65 73|sequences
P10655230A0685|89 94|kinase
P10655230A0685|104 109|domain
P10656154A0722|4 8|women
P10656154A0722|18 25|criteria
P10656161A0316|27 36|Cmax values
P10656161A0316|69 73|serum
P10656161A0316|109 117|AUC values
P10656802A1724|11 19|insertion
P10656802A1724|25 51|cathepsin X amino acid sequence
P10657238A0541|0 22|Transfection experiments
P10657238A0541|50 55|region
P10657238A0541|71 79|mStaf gene
P10657238A0541|86 98|transcription
P10657238A0541|101 115|mouse NMuMG cells
P10657238A0541|124 132|construct
P10657238A0541|144 151|fragment
P10657238A0541|196 203|activity
P10657658A0165|7 13|studies
P10657658A0165|16 24|T-24 cells
P10657658A0165|41 51|HA fragments
P10657658A0165|63 89|I kappa B alpha phosphorylation
P10657658A0165|93 103|degradation
P10657658A0165|104 108|kappa
P10657658A0165|117 138|reporter gene expression
P10657658A0165|142 163|ICAM-1 promoter activity
P10657658A0165|168 175|NF-kappa
P10657658A0165|187 192|manner
P10657899A0685|0 11|Pretreatment
P10657899A0685|14 18|cells
P10657899A0685|21 29|mouse skin
P10657899A0685|43 58|oligonucleotides
P10657899A0685|61 67|PKCzeta
P10657899A0685|86 95|activation
P10657899A0685|106 113|JB6 cells
P10658425A1567|3 7|level
P10658425A1567|21 29|infection
P10658445A0208|0 6|METHODS
P10658445A0208|16 20|group
P10658445A0208|29 36|patients
P10658445A0208|69 91|PGE1 alpha-ciclodestrina
P10658445A0208|102 116|treatment cycles
P10658445A0208|134 139|latter
P10658445A0208|153 166|reference group
P10658445A0208|181 194|prostaglandins
P10658588A0304|0 26|Desmethylferrochloroquine 1a
P10658588A0304|30 56|didesmethylferrochloroquine
P10658588A0304|82 95|schizontocides
P10658588A0304|121 127|strains
P10658588A0304|142 161|Plasmodium falciparum
P10660069A0819|3 19|rrd1,2delta mutant
P10660069A0819|39 50|inactivation
P10660069A0819|79 89|interaction
P10660069A0819|98 105|RRD genes
P10660069A0819|112 141|Hog1p signal transduction pathway
P10660304A0522|0 6|Members
P10660304A0522|12 24|JAK/Tyk family
P10660304A0522|27 41|tyrosine kinases
P10660304A0522|49 63|phosphorylation
P10660304A0522|66 70|STAT3
P10660304A0522|73 78|Tyr705
P10660304A0522|85 97|CNTF signaling
P10660304A0522|108 113|kinase
P10660304A0522|128 142|phosphorylation
P10660304A0522|145 155|STAT3 Tyr727
P10660304A0522|193 200|stimulus
P10660304A0522|215 221|context
P10660604A0748|6 21|CARbeta/RXRalpha
P10660604A0748|31 43|transcription
P10660604A0748|50 83|HD-PPRE luciferase reporter construct
P10660676A0000|0 15|Zebrafish cyclops
P10660676A0000|41 56|Growth Factor beta
P10660676A0000|56 62|TGFbeta
P10660676A0000|63 77|signaling factor
P10660676A0000|94 103|mouse Nodal
P10662550A0679|17 29|candidate gene
P10662550A0679|52 71|retardation phenotype
P10662550A0679|78 91|ATR-16 patients
P10662614A0000|3 20|genome organization
P10662614A0000|42 63|wheat streak mosaic virus
P10662614A0000|93 99|members
P10662614A0000|104 114|Potyviridae
P10662614A0000|130 136|genomes
P10662614A0000|159 182|amino acid dissimilarities
P10662614A0000|201 212|polyproteins
P10662614A0972|13 17|assay
P10662614A0972|50 54|genes
P10662614A0972|61 66|HC-Pro
P10662614A0972|98 109|interactions
P10663558T0000|17 27|light chains
P10663558T0000|40 65|basement membrane reactivity
P10663558T0000|123 127|chain
P10664876A0000|0 8|Patch test
P10664876A0000|28 41|corticosteroid
P10664876A0000|50 57|patients
P10664876A0000|74 93|corticosteroid series
P10664876A0000|113 126|classification
P10664876A0000|129 151|corticosteroid molecules
P10664876A0000|158 163|groups
P10664876A0000|180 188|molecules
P10664876A0000|193 198|group A
P10664876A0000|199 216|hydrocortisone type
P10664876A0000|217 222|group B
P10664876A0000|223 232|acetonides
P10664876A0000|233 238|group C
P10664876A0000|239 259|betamethasone type-non
P10664876A0000|273 278|group D
P10664876A0000|279 284|esters
P10665308T0001|0 9|Mechanisms
P10665308T0001|12 24|tachyphylaxis
P10665308T0001|35 44|anesthesia
P10665308T0001|51 58|duration
P10665798A0598|2 9|increase
P10665798A0598|15 19|level
P10665798A0598|22 33|serum enzymes
P10665798A0598|40 60|aspartate transaminase
P10665798A0598|61 79|alkaline phosphatase
P10665798A0598|80 100|creatine phosphokinase
P10665798A0598|101 120|lactate dehydrogenase
P10665798A0598|126 149|D. russelli venom injection
P10665798A0598|152 161|albino rats
P10665798A0598|184 195|tissue damage
P10665949A1131|10 19|farm budget
P10665949A1131|34 43|importance
P10665949A1131|66 72|lesions
P10665949A1131|76 82|feedlot
P10666222A0330|30 47|survivin cDNA clones
P10666222A0330|73 81|existence
P10666222A0330|93 108|survivin proteins
P10666238A1322|7 15|induction
P10666238A1322|18 27|E2F binding
P10666238A1322|33 45|E2F-1 promoter
P10666238A1322|57 63|protein
P10666238A1322|92 106|transactivation
P10666238A1322|109 129|E2F-1 promoter activity
P10666253A1291|10 22|stabilization
P10666253A1291|28 34|hairpin
P10666253A1291|45 50|amount
P10666253A1291|53 62|tRNA primer
P10666509A0494|24 34|arrhythmias
P10666509A0494|55 65|zatebradine
P10666509A0494|69 85|propranolol groups
P10667597A0668|8 17|HZF16 genes
P10667597A0668|30 43|splice variants
P10668701A1311|0 9|CONCLUSION
P10668701A1311|10 17|Presence
P10668701A1311|20 31|APOE epsilon4
P10668701A1311|59 66|dementia
P10668701A1311|91 96|effect
P10668701A1311|98 109|dyslipidemia
P10668701A1311|113 125|atherogenesis
P10669319A1722|10 20|conclusions
P10669319A1722|49 54|number
P10669319A1722|57 64|patients
P10669319A1722|79 83|phase
P10669319A1722|86 90|trial
P10669594A0000|21 28|fimbrins
P10669594A0000|69 81|fimbriae SEF17
P10669594A0000|83 87|SEF14
P10669594A0000|156 190|16-amino acid Leishmania T-cell epitope
P10669594A0000|204 222|metalloprotease gp63
P10669594A0969|8 15|contrast
P10669594A0969|43 54|SefA proteins
P10669594A0969|81 88|fimbriae
P10669596A0430|10 15|growth
P10669596A0430|18 25|phage P22
P10669596A0430|75 82|presence
P10669596A0430|120 124|level
P10669596A0430|139 154|nuclease activity
P10669596A0430|177 182|change
P10669596A0430|188 193|nature
P10669596A0430|209 230|RecBCD nuclease activity
P10669596A0430|250 255|enzyme
P10669633A0391|6 10|study
P10669633A0391|37 46|mechanisms
P10669633A0391|69 78|expression
P10669633A0391|84 92|flt-1 gene
P10669633A0391|102 111|activation
P10669633A0391|114 123|THP-1 cells
P10669736A0903|17 26|difference
P10669736A0903|51 61|transcripts
P10669736A0903|63 71|HeLa cells
P10669736A0903|99 107|abundance
P10669751T0000|25 54|protein kinase signaling pathways
P10669751T0000|65 78|cot oncoprotein
P10669751T0000|84 96|c-jun promoter
P10669751T0000|110 123|transformation
P10670358A0143|0 10|Dermatology
P10670358A0143|15 23|exception
P10671224A0254|12 16|study
P10671224A0254|48 56|mechanism
P10671224A0254|60 74|CD95L expression
P10671519A0641|0 22|Protein sequence analysis
P10671519A0641|34 43|MAN1 shares
P10671519A0641|62 67|domain
P10671519A0641|85 94|amino acids
P10671519A0641|109 117|LEM module
P10671519A0641|134 149|membrane proteins
P10671519A0641|167 177|polypeptide
P10671519A0641|182 187|emerin
P10671520T0000|9 15|cloning
P10671520T0000|29 33|I-mfa
P10671520T0000|51 57|protein
P10671520T0000|87 109|T-cell leukemia virus type
P10671520T0000|114 128|HIV-1 expression
P10671554A0492|10 27|amino acid sequences
P10671554A0492|44 49|bovine
P10671554A0492|53 64|porcine cDNAs
P10671554A0492|93 109|amino acid residues
P10671554A0492|144 151|sequence
P10671554A0492|164 179|Edman degradation
P10671606A0884|4 23|chemical shift imaging
P10671606A0884|27 41|signal intensity
P10671606A0884|68 73|images
P10671606A0884|90 97|patients
P10671606A0884|126 133|patients
P10672433A0199|7 11|night
P10672433A0199|15 19|diary
P10672433A0199|40 50|measurement
P10672433A0199|53 59|bedtime
P10672433A0199|60 67|wake time
P10672433A0199|91 100|efficiency
P10672433A0199|98 103|number
P10672433A0199|106 112|minutes
P10672433A0199|126 135|sleep onset
P10672433A0199|141 149|alertness
P10672433A0199|151 159|awakening
P10672433A0199|163 172|percentage
P10672433A0199|175 181|morning
P10672433A0199|191 195|alarm
P10672433A0199|199 204|person
P10673335X0782|0 8|Copyright
P10673335X0782|13 25|Academic Press
P10673426A0168|13 18|domain
P10673426A0168|50 57|activity
P10673426A0168|81 86|domain
P10673426A0168|94 106|translocation
P10673426A0168|110 116|process
P10673426A0168|146 151|domain
P10673426A0168|172 179|receptor
P10673426A0168|196 207|cytotoxicity
P10674395A0262|32 41|expression
P10674395A0262|71 82|neuropeptide
P10674395A0262|134 158|signal transduction pathway
P10674395A0262|177 189|protein kinase
P10674395A0262|229 241|cell line GT1-7
P10674484A0633|30 36|lesions
P10674484A0633|64 70|neurons
P10674484A0633|76 83|rat brain
P10674484A0633|103 112|perception
P10674484A0633|134 139|memory
P10675154T0000|7 13|potency
P10675154T0000|16 29|botulinum toxin
P10675331A0600|2 9|contrast
P10675331A0600|10 14|c-Src
P10675331A0600|26 38|isoproterenol
P10675331A0600|44 66|tyrosine phosphorylation
P10675331A0600|87 99|Erk activation
P10675331A0600|105 127|tyrosine phosphorylation
P10675331A0600|130 138|cortactin
P10675331A0600|141 145|Stat3
P10675610A0279|0 4|MSSPs
P10675610A0279|26 39|DNA replication
P10675610A0279|40 52|transcription
P10675610A0279|53 62|apopotosis
P10675610A0279|66 85|cell cycle progression
P10675610A0279|106 117|C-MYC protein
P10677214A1045|7 14|type MutT
P10677214A1045|30 40|E44D mutants
P10677214A1045|40 44|plots
P10677214A1045|86 90|slope
P10677214A1045|143 149|maximum
P10677214A1045|168 174|plateau
P10677214A1045|194 199|values
P10677214A1045|254 265|acid catalyst
P10677214A1045|298 304|MutT-Mg
P10677214A1045|304 310|dGTP-Mg
P10677214A1045|311 317|complex
P10677214A2842|10 16|changes
P10677214A2842|69 80|N HSQC spectra
P10677214A2842|102 112|loop I-helix
P10677214A2842|114 118|motif
P10677214A2842|133 138|Glu-44
P10677214A2842|158 167|site region
P10677297A0933|7 16|expression
P10677297A0933|50 57|nonsense
P10677297A0933|61 77|missense mutations
P10677297A0933|117 124|location
P10677297A0933|130 136|protein
P10677297A0933|147 151|cells
P10678968A1096|0 7|Immunity
P10678968A1096|30 41|I. scapularis
P10678968A1096|48 55|activity
P10678968A1096|63 68|summer
P10678968A1096|85 94|proportion
P10678968A1096|100 114|mouse population
P10678968A1096|130 145|E. phagocytophila
P10678968A1096|155 160|period
P10678968A1096|169 176|activity
P10678968A1096|187 192|season
P10679015A0216|24 30|studies
P10679015A0216|32 36|yeast
P10679015A0216|47 51|class
P10679015A0216|54 60|snoRNPs
P10679015A0216|87 94|proteins
P10679065A0711|0 15|BCR cross-linking
P10679065A0711|48 70|protein kinase-2 activity
P10679065A0711|73 78|enzyme
P10679065A0711|112 118|p38 MAPK
P10679065A0711|133 147|protein kinase-2
P10679065A0711|154 162|complexes
P10679065A0711|178 193|peptide substrate
P10679065A0711|207 216|CREB serine
P10679065A0711|220 239|phosphoacceptor motif
P10679065A1217|0 9|Activation
P10679065A1217|26 70|junB promoter/chloramphenicol acetyltransferase
P10679065A1217|76 87|reporter gene
P10679065A1217|113 120|SB203580
P10679190A0693|9 16|evidence
P10679190A0693|36 47|reading frame
P10679190A0693|66 76|translation
P10679190A0693|100 111|reading frame
P10679649A0311|0 6|METHODS
P10679649A0311|7 21|TBN measurements
P10679649A0311|45 55|outpatients
P10679649A0311|60 74|breast carcinoma
P10679649A0311|100 115|cyclophosphamide
P10679649A0311|116 127|methotrexate
P10679649A0311|131 144|5-fluorouracil
P10679649A0311|154 165|chemotherapy
P10679649A0311|165 173|median age
P10679649A0311|176 180|years
P10679649A0311|181 185|range
P10679649A0311|190 194|years
P10679781A1183|4 31|bp Glucocorticoid Response Unit
P10679781A1183|55 77|glucocorticoid induction
P10679781A1183|90 103|dibutyryl-cAMP
P10679781A1183|116 128|phorbol esters
P10679922A1110|9 17|mutations
P10679922A1110|37 43|samples
P10679922A1110|70 94|tumor suppressor gene target
P10679922A1110|105 114|neck cancer
P10681520A0525|0 7|Ras-GRF1
P10681520A0525|32 36|v-Src
P10681520A0525|83 93|GEF activity
P10681520A0525|119 123|Cdc42
P10681520A0525|157 166|Gbetagamma
P10681562A0263|12 31|PPARgamma antagonists
P10681562A0263|92 105|mutant receptor
P10681562A0263|124 138|PPARgamma action
P10681588A0899a|23 30|proteins
P10681588A0899a|52 60|Rat2 cells
P10681588A0899a|74 80|complex
P10681588A0899a|100 118|transcription factor
P10681588A0899a|128 132|CCAAT
P10681588A0899a|148 158|protein beta
P10681588A0899a|177 182|C6 cell
P10681588A0899a|189 196|extracts
P10681588A0899a|215 223|CCAAT-box
P10681588A0899a|227 233|complex
P10681588A0899a|251 258|factor Y.
P10681588A0899b|23 30|proteins
P10681588A0899b|52 60|Rat2 cells
P10681588A0899b|74 80|complex
P10681588A0899b|100 118|transcription factor
P10681588A0899b|128 132|CCAAT
P10681588A0899b|148 158|protein beta
P10681588A0899b|177 182|C6 cell
P10681588A0899b|189 196|extracts
P10681588A0899b|215 223|CCAAT-box
P10681588A0899b|227 233|complex
P10681588A0899b|251 258|factor Y.
P10681679A0220|7 16|resolution
P10681679A0220|27 33|portion
P10681679A0220|39 43|tumor
P10681679A0220|44 52|serial MRI
P10681679A0220|59 69|enlargement
P10681679A0220|80 88|tumor cyst
P10681679A0220|90 94|years
P10681679A0220|111 119|diagnosis
P10682570A0453|8 16|SOD levels
P10682570A0453|34 39|points
P10682570A0453|58 66|operation
P10683072T0000|20 30|tachycardia
P10683072T0000|47 57|prophylaxis
P10683072T0000|73 97|bolus interleukin-2 therapy
P10683072T0000|116 128|cell carcinoma
P10683244A0939|18 25|R protein
P10683244A0939|28 38|NBF2 protein
P10683244A0939|43 49|mixture
P10683244A0939|58 65|proteins
P10683244A0939|108 125|sieve chomatography
P10683244A0939|129 135|mixture
P10683244A1860|17 27|experiments
P10683244A1860|55 61|R region
P10683244A1860|66 75|NBF2 domain
P10683244A1860|108 112|units
P10683244A1860|124 133|propensity
P10683244A1860|155 165|interaction
P10683244A1860|179 185|absence
P10683244A1860|193 203|nucleotides
P10683244A1860|224 238|phosphorylation
P10683244X2359|0 8|Copyright
P10683244X2359|13 25|Academic Press
P10683259A0774|0 18|Sulfhydryl titration
P10683259A0774|23 35|iodoacetamide
P10683259A0774|70 75|thiols
P10683259A0774|81 88|reaction
P10683259A0774|94 112|maleimide derivative
P10683259A0774|115 120|biotin
P10683259A0774|138 147|difference
P10683259A0774|165 170|values
P10683259A0774|175 183|cysteines
P10683259A0774|192 206|splice junctions
P10683989A0251|11 25|oxide inhalation
P10683989A0251|29 35|results
P10683989A0251|50 58|increases
P10683989A0251|99 106|decrease
P10683989A0251|106 117|Qs/Q tau ratio
P10684069A0508|3 9|results
P10684069A0508|36 40|Wimax
P10684069A0508|47 63|minute ventilation
P10684069A0508|97 110|administration
P10684069A0508|112 127|methylphenidatum
P10684069A0508|131 143|aminophylline
P10684097A0175|58 63|groups
P10684097A0175|68 80|sham operation
P10684097A0175|90 100|ovariectomy
P10684097A0175|101 111|ovariectomy
P10684097A0175|129 144|ethinyl estradiol
P10684111A1411|23 29|variety
P10684111A1411|45 51|factors
P10684111A1411|70 76|MAPK p44
P10684111A1411|79 85|MAPK p42
P10684111A1411|88 104|MAPK family members
P10684265T0000|8 19|modification
P10684265T0000|25 52|transactivator protein IE2-p86
P10684265T0000|60 74|cytomegalovirus
P10684265T0000|77 87|conjugation
P10684265T0000|113 126|proteins SUMO-1
P10684265T0000|130 135|hSMT3b
P10684304A1242|3 13|interaction
P10684534A0634|0 8|Protamine
P10684534A0634|12 23|heparin doses
P10684534A0634|34 43|Sigma-dose
P10684534A0634|68 72|doses
P10684534A0634|85 97|clotting times
P10684646A0224|6 10|study
P10684646A0224|18 26|mechanism
P10684646A0224|59 64|growth
P10684646A0224|80 89|expression
P10684646A0224|92 99|caveolin
P10684660A1266|0 9|Comparison
P10684660A1266|15 19|plant
P10684660A1266|34 49|processing enzyme
P10684660A1266|56 60|plant
P10684660A1266|93 102|activities
P10684660A1266|115 121|enzymes
P10684941A0722|3 13|requirement
P10684941A0722|17 31|complementarity
P10684941A0722|36 51|ligation reaction
P10684941A0722|66 72|results
P10684941A0722|78 89|nt insertions
P10684967A0000|0 5|NKX2.1
P10684967A0000|8 13|member
P10684967A0000|19 27|NK2 family
P10684967A0000|52 71|transcription factors
P10684967A0000|85 94|disruption
P10684967A0000|97 101|mouse
P10684967A0000|114 120|absence
P10684967A0000|123 135|thyroid tissue
P10684967A0000|156 168|lung phenotype
P10687366A0000|0 19|National abortion laws
P10687366A0000|37 44|abortion
P10687366A0000|50 55|foetus
P10687366A0000|111 115|weeks
P10687855A1197|0 9|Expression
P10687855A1197|26 34|pituitary
P10687855A1197|57 61|cells
P10687855A1197|74 78|Zn-16
P10687855A1197|106 116|development
P10687855A1197|134 148|differentiation
P10687855T0000|0 41|Mouse growth hormone transcription factor Zn-16
P10687855T0000|57 65|structure
P10687855T0000|92 108|zinc finger domains
P10687855T0000|122 129|rat Zn-15
P10687862A1980|3 26|CCAAT core sequence mutants
P10687862A1980|47 52|CI/CII
P10687862A1980|81 96|promoter activity
P10687945A0000|0 10|Deglutition
P10687945A0000|37 43|infants
P10688639A1310|4 13|repression
P10688639A1310|31 49|PU.1 transactivation
P10688639A1310|51 61|PEST domains
P10688639A1310|82 95|p300 expression
P10688646A0535|19 27|K562 cells
P10688646A0535|55 69|HS-40 mutants cis
P10688646A0535|84 95|alpha-globin
P10688646A0535|111 127|hormone hybrid gene
P10688646A0535|149 160|footprinting
P10688646A0535|164 181|expression analysis
P10688660A0992|13 20|addition
P10688660A0992|48 55|extracts
P10688660A0992|57 65|T47D cells
P10688660A0992|84 95|progesterone
P10688660A0992|111 123|transcription
P10688660A0992|144 170|progesterone response element
P10688660A0992|181 199|reporter DNA template
P10688661A0237|10 23|binding protein
P10688661A0237|24 32|REST/NRSF
P10688661A0237|46 64|transcription factor
P10688661A0237|72 80|mutations
P10688661A0237|98 106|lethality
P10688661A0237|129 135|mutants
P10688661A0237|151 160|expression
P10688661A0237|178 182|genes
P10688663A0207|0 6|Removal
P10688663A0207|12 33|core histone tail domains
P10688663A0207|43 60|trypsin proteolysis
P10688663A0207|63 73|acetylation
P10688663A0207|79 94|core histone tails
P10688663A0207|120 129|inhibition
P10688663A0207|139 144|TFIIIA
P10688666A1010|10 18|mechanism
P10688666A1010|21 34|ASK1 activation
P10688666A1010|51 70|homo-oligomerization
P10690702A0065|0 6|OUTCOME
P10690702A0065|7 37|Acetylcholine receptor antibodies
P10690702A0065|53 66|electromyogram
P10690702A0065|82 90|diagnosis
P10690702A0065|93 108|myasthenia gravis
P10690725A1037|8 15|patients
P10690866A0783|3 12|variations
P10690866A0783|33 38|shifts
P10690866A0783|41 64|TSH frequency distribution
P10690866A0783|67 73|mothers
P10690866A0783|77 84|neonates
P10691972T0000|0 15|Characterization
P10691972T0000|29 34|region
P10691972T0000|54 70|resistance protein
P10691972T0000|90 99|regulation
P10691972T0000|100 116|comparison withthe
P10691972T0000|126 142|resistance protein
P10692167A0364|12 20|mechanism
P10692167A0364|48 59|observations
P10692167A0364|62 71|M. synoviae
P10692374A1873|5 11|results
P10692374A1873|26 37|M. jannaschii
P10692374A1873|61 74|20S proteasomes
P10692374A1873|83 101|nucleotidase complex
P10692374A1873|141 150|hydrolysis
P10692374A1873|168 175|proteins
P10692374A1873|198 214|amino acid residues
P10692374A1873|253 260|reaction
P10692433A0000|3 24|transcription factor E2F
P10692433A0000|54 69|S phase transition
P10692433A0000|89 97|cell cycle
P10693246A0252|16 25|dissection
P10693246A0252|29 38|components
P10693246A0252|103 112|dissection
P10693246A0252|132 151|laryngeal nerve chains
P10693246A0252|162 172|mediastinum
P10693314A0521|8 15|patients
P10693314A0521|23 34|CK-MB results
P10693314A0521|55 62|patients
P10693314A0521|88 95|patients
P10694189A0469|3 8|effect
P10694189A0469|34 38|curve
P10694189A0469|57 69|noradrenaline
P10694210A0385|11 18|blockade
P10694210A0385|74 90|cingulate cortices
P10694210A0385|107 120|administration
P10694210A0385|123 140|d-chlorpheniramine
P10694210A0385|200 207|cortices
P10694511A0570|3 12|expression
P10694511A0570|47 51|cells
P10694511A0570|74 82|phenotype
P10694511A0570|103 110|increase
P10694511A0570|117 130|uptake activity
P10694605A1327|17 30|infection rates
P10694605A1327|31 52|events/100 patient-days
P10694605A1327|88 98|double-lung
P10694605A1327|110 115|months
P10694609A0309|16 25|compliance
P10694609A0309|42 50|induction
P10694609A0309|53 62|anesthesia
P10694609A0309|88 97|filtration
P10694609A0309|103 118|operating theater
P10694609A0309|131 136|return
P10694609A0309|159 166|care unit
P10694609A0309|172 176|hours
P10694609A0309|185 193|operation
P10695685T0000|11 17|therapy
P10695685T0000|29 37|rationale
P10695685T0000|48 59|implications
P10695685T0000|71 82|consequences
P10696007A1325|9 19|correlation
P10696007A1325|27 45|C2-C3 disk morphology
P10696007A1325|76 83|response
P10698516T0000|16 21|kinase
P10698516T0000|46 55|capability
P10698516T0000|69 83|SAPK/JNK pathway
P10698937T0000|0 4|TIP30
P10698937T0000|19 32|kinase activity
P10698937T0000|44 56|up-regulation
P10698937T0000|60 65|subset
P10698937T0000|77 81|genes
P10698974A0951|20 28|STAG3 gene
P10698974A0951|38 43|region
P10698974A0951|46 55|chromosome
P10698974A0951|78 82|genes
P10698974A0951|180 190|breakpoints
P10698974A0951|230 237|syndrome
P10698974A0951|243 250|deletion
P10699354A0557|0 11|Reaction time
P10699653A0967|2 11|experiment
P10699653A0967|29 34|access
P10699653A0967|39 45|bottles
P10699653A0967|65 72|tap water
P10699653A0967|101 107|ethanol
P10699653A0967|114 120|sucrose
P10699653A0967|123 130|solution
P10699684A0661|11 15|Zelen
P10699684A0661|17 22|method
P10699684A0661|41 46|number
P10699684A0661|49 56|patients
P10699684A0661|74 79|groups
P10699684A0661|90 100|institution
P10699896A0455|0 6|RESULTS
P10699896A0455|13 17|group
P10699896A0455|20 27|patients
P10699896A0455|32 37|gender
P10700262A0000|15 23|attention
P10700262A0000|39 47|interplay
P10700262A0000|66 79|control systems
P10700262A0000|90 104|brain structures
P10701534A0164|3 9|patient
P10701534A0164|32 50|low-frequency tremor
P10701534A0164|54 65|hemidystonia
P10701534A0164|78 87|head trauma
P10701534A0164|101 105|years
P10702241A0357|10 18|a1 isoform
P10702241A0357|43 47|brain
P10702241A0357|51 55|heart
P10702241A0357|62 66|liver
P10702241A0357|69 74|kidney
P10702241A0357|84 88|liver
P10702241A0357|94 98|heart
P10702241A0357|98 102|brain
P10702241A0357|103 108|spleen
P10702241A0357|112 117|kidney
P10702253A0357|9 15|cloning
P10702253A0357|25 61|transcriptase-polymerase chain reaction
P10702253A0357|72 88|HIF-1alpha subunit
P10702253A0357|102 111|cDNA clones
P10702253A0357|142 149|splicing
P10702253A0357|155 168|HIF-1alpha gene
P10702285A0855|11 22|relationship
P10702285A0855|38 45|function
P10702285A0855|50 77|phosphatidylinositol 3-kinase
P10702285A0855|87 93|pathway
P10702285A0855|94 103|expression
P10702285A0855|142 148|subunit
P10702285A0855|156 174|wortmannin treatment
P10702285A0855|228 250|GLUT4-EGFP translocation
P10702389A1148|16 27|RB2/p130 gene
P10702389A1148|47 51|cases
P10702389A1148|58 64|protein
P10702389A1148|82 90|cytoplasm
P10702794A1495|53 58|target
P10702794A1495|59 63|HePTP
P10702794A1495|85 89|model
P10702794A1495|97 101|HePTP
P10702794A1495|121 132|ERK2 activity
P10702794A1495|144 160|feedback mechanism
P10702926T0089|0 13|Cross-reaction
P10702926T0089|32 39|antibody
P10702926T0089|46 68|alpha beta T cell receptors
P10703633A0747|0 15|Strontium nitrate
P10703633A0747|41 50|comparison
P10703633A0747|99 106|duration
P10703633A0747|110 128|irritation sensation
P10703633A0747|210 222|mean magnitude
P10703633A0747|221 239|irritation sensation
P10703633A0747|245 254|time points
P10704196A1051|17 32|sulfhydryl groups
P10704196A1051|80 93|plasma membrane
P10704196A1051|119 123|model
P10704196A1051|146 152|helices
P10704283A0649a|0 7|Analysis
P10704283A0649a|26 33|sequence
P10704283A0649a|40 45|region
P10704283A0649a|57 63|synteny
P10704283A0649a|71 88|chromosome 5q31-q33
P10704283A0649a|101 114|gene candidates
P10704283A0649a|135 139|genes
P10704283A0649a|150 172|IL-4 cytokine gene cluster
P10704285A0536|5 11|AP-2rep
P10704285A0536|25 42|reporter expression
P10704285A0536|70 86|AP-2alpha promoter
P10704285A0536|103 115|AP-2alpha gene
P10704285A0536|152 160|AP-2alpha
P10704338A0354|2 6|order
P10704338A0354|19 25|insight
P10704338A0354|58 63|domain
P10704338A0354|76 82|protein
P10704338A0354|92 102|replication
P10704338A0354|123 137|proline residues
P10704338A0354|152 156|turns
P10704338A0354|171 183|alpha-helices
P10704338A0354|206 214|structure
P10704338A0354|229 242|leucine residue
P10704338A0354|243 254|P-position-L
P10704410T0000|0 15|Clb/Cdc28 kinases
P10704410T0000|30 35|export
P10704410T0000|41 74|replication initiator proteins Mcm2-7
P10704499A0682|13 24|PC12-E2 cells
P10704499A0682|40 48|treatment
P10704499A0682|53 62|antibodies
P10704499A0682|68 89|fibroblast growth factor
P10704499A0682|95 102|receptor
P10704499A0682|102 111|inhibitors
P10704499A0682|128 144|tyrosine kinase p59
P10704499A0682|172 180|activator
P10704499A0682|184 214|phorbol-12-myristate-13-acetate
P10704853T0000|0 15|Cooperative roles
P10704853T0000|18 31|Bozozok/Dharma
P10704853T0000|48 55|proteins
P10704853T0000|61 69|formation
P10704853T0000|75 89|dorsal organizer
P10704853T0000|92 100|zebrafish
P10704975A0479|0 16|Thiopentone sodium
P10704975A0479|69 76|exposure
P10704975A0479|77 81|NOC-5
P10704975A0479|131 143|neurotoxicity
P10704975A0479|156 163|controls
P10705380A0629|34 51|Xretpos transcripts
P10705380A0629|91 97|regions
P10705380A0629|110 123|UV-irradiation
P10705380A0629|127 145|BMP-4 overexpression
P10705380A0629|199 205|genesis
P10705783A0433|10 14|cases
P10705783A0433|25 34|neurectomy
P10705783A0433|37 44|chemical
P10705783A0433|55 69|labyrinthectomy
P10705783A0433|72 76|means
P10705783A0433|95 117|concentration gentamicin
P10705783A0433|120 124|mg/mL
P10706513A0843|11 19|prognosis
P10706513A0843|25 34|% mortality
P10706513A0843|38 43|months
P10706513A0843|61 71|ventilation
P10706688A0376|11 22|TCR signaling
P10706688A0376|30 40|AP-1 binding
P10706688A0376|68 87|fasl promoter function
P10706688A0376|90 96|fashion
P10706688A0376|108 123|NF-kappaB binding
P10706736A1091|4 11|patients
P10706736A1091|26 33|melanoma
P10706736A1091|69 77|detection
P10706736A1091|84 89|T cells
P10706736A1091|108 112|HLA-A
P10706736A1091|140 147|epitopes
P10706887A0281|19 23|ALCLs
P10706887A0281|83 95|abnormalities
P10706887A0281|113 125|ALK expression
P10706887A1457|2 9|addition
P10706887A1457|18 26|decreases
P10706887A1457|44 51|function
P10706887A1457|72 80|lymphomas
P10706887A1457|95 100|tumors
P10706887A1457|126 130|drugs
P10706887A1457|137 148|methotrexate
P10708243A0000|12 22|observation
P10708243A0000|45 54|antibodies
P10708243A0000|69 81|pregnancy loss
P10708243A0000|85 96|preeclampsia
P10708243A0000|122 131|antibodies
P10708424A0800|40 58|autophosphorylation
P10708424A0800|60 64|BGLF4
P10708424A0800|68 76|magnesium
P10708424A0800|92 99|activity
P10708769A0433|18 23|region
P10708769A0433|63 69|element
P10708769A0433|89 97|induction
P10708769A0433|100 110|tunicamycin
P10709705T0000|5 28|point feature registration
P10709705T0000|40 50|information
P10710499A0000|0 11|Methysergide
P10710499A0000|15 33|serotonin antagonist
P10710499A0000|64 77|wound blood flow
P10710499A0000|81 94|edema formation
P10710742T0000|0 24|Serum leptin concentrations
P10710742T0000|27 31|women
P10710742T0000|38 66|gonadotropin stimulation cycles
P10710985T0000|7 14|families
P10710985T0000|21 32|work practice
P10710985T0000|37 44|families
P10710985T0000|50 69|strengths perspective
P10711674A0000|0 6|PURPOSE
P10711674A0000|45 50|family
P10711674A0000|73 77|Leber
P10711674A0000|88 96|amaurosis
P10711674A0000|117 127|keratoconus
P10712512A0506|0 5|Ste18p
P10712512A0506|22 35|plasma membrane
P10712512A0506|45 51|absence
P10712512A0506|54 64|prenylation
P10712512A0506|67 79|thioacylation
P10712599A0349|14 18|IRF-1
P10712599A0349|55 61|pathway
P10712618A0181|12 29|sequence comparison
P10712618A0181|42 64|Bacillus YM55-1 aspartase
P10712618A0181|72 80|% homology
P10712618A0181|85 109|Bacillus subtilis aspartase
P10712618A0181|161 170|aspartases
P10713083A0170|12 17|system
P10713083A0170|21 28|activity
P10713083A0560|20 24|assay
P10713083A0560|50 59|DNA binding
P10713083A0560|75 86|TraR function
P10713083A0560|103 121|transcription factor
P10713083A0560|135 152|DNA recognition site
P10713155A0151|14 33|IIIa pre-mRNA splicing
P10713155A0151|70 77|extracts
P10713155A0151|113 117|cells
P10713155A0151|118 122|Ad-NE
P10713155A0151|143 150|HeLa cell
P10713155A0151|158 165|extracts
P10713155A0151|166 172|HeLa-NE
P10713161A0985|0 11|Inactivation
P10713161A0985|50 56|defects
P10713161A0985|91 112|Smt3-protein conjugates
P10713161A0985|129 134|mutant
P10713175A1399|15 21|results
P10713175A1399|33 42|ARF binding
P10713175A1399|73 78|change
P10713175A1399|102 107|import
P10713175A1399|113 127|ARF-Mdm2 complex
P10713175A1399|144 158|cell cycle arrest
P10713176A0422|0 16|Cyclin A expression
P10713176A0422|39 43|cells
P10713176A0422|59 69|conjunction
P10713176A0422|76 98|pocket protein partners Rb
P10713176A0422|121 125|v-Jun
P10713176A0422|137 143|control
P10713176A0422|194 210|E2F-p107 complexes
P10713176A0422|224 240|mitogen withdrawal
P10713176A0885|0 19|D-cyclin-cdk activity
P10713176A0885|33 49|Rb phosphorylation
P10713176A0885|69 73|cells
P10713176A0885|86 95|expression
P10713176A0885|123 134|inhibitor p16
P10713176A0885|133 137|INK4A
P10713176A0885|150 161|DNA synthesis
P10713176A0885|165 181|cell proliferation
P10713239A0988|0 9|CONCLUSION
P10713239A0988|21 29|mechanism
P10713239A0988|41 56|capsulorhexis rim
P10713239A0988|78 85|IOL optic
P10713453A0172|3 9|protein
P10713453A0172|40 50|antibody Q18
P10713453A0172|85 103|polytene chromosomes
P10713453A0172|129 134|Hrb57A
P10714985A1057|1 22|RNA boundary experiments
P10714985A1057|39 47|structure
P10714985A1057|58 63|number
P10714985A1057|70 78|AG repeats
P10714985A1057|103 122|leader RNA association
P10715322A0000|0 12|Gene silencing
P10715322A0000|35 46|DNA sequences
P10715322A0000|69 78|eukaryotes
P10715322A0000|88 93|plants
P10715325A0834|3 12|AtERF genes
P10715325A0834|42 49|ethylene
P10715325A0834|62 77|stress conditions
P10715325A0834|84 91|wounding
P10715325A0834|100 107|salinity
P10715325A0834|110 116|drought
P10715325A0834|120 140|ETHYLENE-INSENSITIVE2
P10715325A0834|168 175|pathways
P10715602A0149|0 6|Animals
P10715602A0149|24 36|dexamethasone
P10715602A0149|38 42|mg/kg
P10715602A0149|69 96|surfactant preparation Exosurf
P10715602A0149|101 113|phospholipids
P10715602A0149|124 133|surfactant
P10715602A0149|134 145|Wellcome GmbH
P10715602A0149|146 154|Burgwedel
P10715602A0149|155 161|Germany
P10715602A0149|166 170|rSP-C
P10715602A0149|176 185|surfactant
P10717612A0000|0 9|BACKGROUND
P10717612A0000|24 28|study
P10717612A0000|45 57|response rates
P10717612A0000|61 68|toxicity
P10717612A0000|74 81|regimens
P10717612A0000|121 137|stimulating factor
P10717612A0000|138 143|GM-CSF
P10717612A0000|146 156|combination
P10717612A0000|161 173|interleukin-2
P10717612A0000|185 193|treatment
P10717612A0000|195 202|patients
P10717612A0000|222 234|cell carcinoma
P10720434A0291|8 16|injection
P10720434A0291|28 32|mRNAs
P10720434A0291|50 58|sequences
P10720434A0291|73 82|repression
P10720434A0291|85 96|cyclin B1 mRNA
P10721698A1195|23 31|expansion
P10721698A1195|36 50|dodecamer repeat
P10721698A1195|71 78|promoter
P10721698A1195|106 113|function
P10721698A1195|118 125|promoter
P10721698A1195|143 155|transcription
P10721704A1155|19 30|organization
P10721704A1155|70 76|members
P10721704A1155|81 90|Elav family
P10721704A1155|94 108|promoter element
P10721704A1155|135 150|sequence analysis
P10721704A1155|169 176|activity
P10721704A1155|189 197|cell types
P10721704X0000|0 7|Analysis
P10721704X0000|24 34|mouse Elavl1
P10721704X0000|79 85|element
P10721704X0000|87 94|evidence
P10721704X0000|114 125|organization
P10721704X0000|155 160|Elavl1
P10721704X0000|185 190|family
P10721704X0000|193 197|genes
P10721704X0000|217 224|proteins
P10721704X0000|243 252|cell growth
P10721704X0000|256 268|proliferation
P10721704X0000|279 288|regulation
P10721704X0000|291 303|mRNA stability
P10721714A1087|15 33|mobility shift assays
P10721714A1087|70 76|regions
P10721714A1087|89 96|promoter
P10721714A1087|105 111|Sp1 site
P10721714A1087|139 144|region
P10721717A0676|25 30|degree
P10721717A0676|31 46|sequence identity
P10721717A0676|69 85|amino acid residues
P10721726T0000|9 15|cloning
P10721726T0000|18 43|mouse thioredoxin reductases
P10722063A0328|3 12|HPLC method
P10722063A0328|23 43|octadecylsilane column
P10722063A0328|48 55|degrees C
P10722063A0328|57 63|mixture
P10722063A0328|128 132|phase
P10722063A0328|134 142|detection
P10722509A0392|5 12|patients
P10722509A0392|38 46|dipivoxil
P10722509A0392|55 64|body weight
P10722509A0392|70 77|patients
P10722509A0392|103 111|dipivoxil
P10722661A0146|20 26|protein
P10722661A0146|33 48|sequence identity
P10722661A0146|54 74|Neurospora crassa PREG1
P10722661A0146|93 103|PHO80 cyclin
P10722661A0406|29 35|complex
P10722661A0406|59 69|trypanosome
P10722661A0406|82 88|kinases
P10722661A0406|98 105|CYC2 gene
P10722661A0406|118 129|TY epitope tag
P10722661A0406|147 163|trypanosome genome
P10722661A0406|190 196|control
P10722737A1726|5 12|findings
P10722737A1726|24 34|involvement
P10722737A1726|71 80|regulation
P10722737A1726|95 113|transcription factor
P10722737A1726|140 149|regulation
P10722737A1726|158 162|S gene
P10722969A0510|12 19|progress
P10723723A0781|15 27|mouse promoter
P10723723A0781|38 43|copies
P10723723A0781|47 74|CT dinucleotide repeat sequence
P10723727A0713|15 20|region
P10723727A0713|31 36|intron
P10723727A0713|74 103|polyadenylation signal sequences
P10724436A0085|33 50|reference materials
P10724436A0085|72 77|system
P10724483A0540|20 30|cAMP control
P10724483A0540|52 61|HEM13 genes
P10724483A0540|80 89|HOG pathway
P10724519A1185|69 76|elements
P10725017A0673|4 8|paper
P10725017A0673|35 42|approach
P10725017A0673|52 57|CEN ENV
P10725017A0673|71 84|specialisation
P10725017A0673|100 115|healthcare record
P10725017A0673|123 128|CEN ENV
P10725017A0673|144 171|Healthcare Record Architecture
P10725382A0398|0 15|Sequence analyses
P10725382A0398|30 36|alleles
P10725382A0398|72 77|domain
P10725382A0398|104 109|domain
P10725433A0543|1 8|mutation
P10725433A0543|26 32|binding
P10725433A0543|40 46|factors
P10725433A0543|54 71|Wp reporter activity
P10725433A0543|86 95|B cell lines
P10725433A0543|104 111|mutation
P10725433A0543|137 145|consensus
P10725433A0543|157 164|sequence
P10725433A0543|183 198|promoter function
P10727247A0461|17 23|cloning
P10727247A0461|39 55|expression pattern
P10727247A0461|69 84|characterization
P10727247A0461|95 107|TEF-1 isoforms
P10727247A0461|108 116|TEF-1beta
P10727247A0461|120 129|TEF-1gamma
P10727413A1244|12 23|binding sites
P10727413A1244|41 47|factors
P10727413A1244|60 72|hamster CYP7A1
P10727413A1244|81 88|promoter
P10727413A1244|96 103|vicinity
P10727413A1244|123 129|species
P10727413A1244|181 190|expression
P10727413A1244|193 209|tissue restriction
P10727413A1244|215 220|action
P10727413A1244|223 230|hormones
P10727413A1244|237 243|insulin
P10727426A1280|3 16|kinase activity
P10727426A1280|19 23|PfPK6
P10727426A1280|37 49|CDK inhibitors
P10727426A1280|56 65|olomoucine
P10727426A1280|69 79|roscovitine
P10727428A0000|30 36|protein
P10727428A0000|36 42|kinases
P10727428A0000|58 74|cell proliferation
P10727428A0000|78 92|differentiation
P10727428A0000|99 107|cell types
P10727428A0000|119 128|MAP kinases
P10727428A0000|137 147|hypertrophy
P10727433A0560|0 11|Transfection
P10727433A0560|17 39|CSF-1R expression plasmid
P10727433A0560|64 73|activation
P10727433A0560|79 95|signalling pathway
P10727433A0560|107 113|Ets/AP1
P10727433A0560|114 129|activator protein
P10727433A0560|131 137|element
P10727433A0560|143 153|uPA promoter
P10727433A0560|185 190|target
P10727433A0560|210 231|protein kinase C pathways
P10727433T0000|0 9|Regulation
P10727433T0000|12 57|urokinase plasminogen activator gene transcription
P10727433T0000|63 68|RAW264
P10727433T0000|75 92|macrophage cell line
P10727433T0000|95 104|macrophage
P10727433T0000|123 128|factor
P10727433T0000|129 133|CSF-1
P10727433T0000|152 156|level
P10727433T0000|171 178|receptor
P10727511A0294|0 7|Molecule
P10727511A0294|28 35|cultures
P10727511A0294|51 59|induction
P10727511A0294|62 66|GLT-1
P10727511A0294|91 107|signaling pathways
P10727511A0294|121 130|regulation
P10727515A1202|0 11|Coactivation
P10727515A1202|46 54|receptors
P10727515A1202|72 79|receptor
P10727515A1202|94 105|stimulations
P10727515A1202|108 114|PLCbeta
P10727515A1202|122 130|responses
P10727515A1202|156 169|pertussis toxin
P10728945A0233|0 7|Patients
P10728945A0233|21 30|Integrilin
P10728945A0233|41 59|Platelet Aggregation
P10728945A0233|71 83|Thrombosis-II
P10728945A0233|84 92|IMPACT-II
P10728945A0233|93 97|trial
P10728986A0000|3 21|Wnt signaling pathway
P10728986A0000|50 66|animal development
P10728986A0000|76 92|cell fate decisions
P10729151A1160|4 11|mutation
P10729151A1160|32 37|HPV-11
P10729151A1160|73 90|reporter expression
P10729155A0653|17 26|MVMi capsid
P10729155A0653|31 38|sequence
P10729155A0653|47 56|carboxy end
P10729155A0653|73 84|beta-strand I
P10729155A0653|85 89|betaI
P10729155A0653|104 111|residues
P10729155A0653|168 174|subunit
P10729220A0000|39 50|growth factor
P10729220A0000|55 62|H19 genes
P10729220A0000|101 105|mouse
P10729220A1569|13 23|methylation
P10729220A1569|56 65|disruption
P10729220A1569|97 101|brain
P10729221A0798|3 12|comparison
P10729221A0798|18 35|expression patterns
P10729221A0798|46 61|Kv4 family members
P10729221A0798|67 84|subtype specificity
P10730292T0000|5 22|treatment mechanics
P10730292T0000|28 42|Class II division
P10730292T0000|44 55|malocclusion
P10730763A1491|21 49|Nottingham Eczema Severity Score
P10730763A1491|68 78|development
P10730763A1491|82 93|research tool
P10730763A1491|104 113|assessment
P10730763A1491|116 130|disease severity
P10730763A1491|163 169|studies
P10731411A0958|3 11|consensus
P10731411A0958|25 34|importance
P10731411A0958|37 44|residues
P10731411A0958|62 67|motifs
P10731411A0958|94 113|DEAD-box RNA helicases
P10731411A0958|139 148|importance
P10731411A0958|157 163|residue
P10731411A0958|178 182|motif
P10731926A0775|0 14|Advanced adenoma
P10731926A0775|29 35|adenoma
P10731926A0775|56 62|adenoma
P10731926A0775|84 92|component
P10731926A0775|102 110|dysplasia
P10731926A0775|121 129|carcinoma
P10732669A0510|11 16|assays
P10732669A0510|47 51|cells
P10732669A0510|64 82|particle bombardment
P10732669A0510|105 110|Oshox1
P10732669A0510|141 148|activity
P10732669A0510|151 172|reporter gene constructs
P10732669A0510|185 202|HD-Zip binding sites
P10732669A1336|0 6|Results
P10732669A1336|19 24|assays
P10732669A1336|43 61|mobility shift assays
P10732669A1336|90 97|proteins
P10732669A1336|100 107|families
P10732669A1336|121 130|homodimers
P10732669A1336|138 149|heterodimers
P10732669A1336|163 170|proteins
P10732669A1336|180 185|family
P10733569A0364|54 63|regulation
P10733569A0364|79 98|stress gene expression
P10733569A0364|109 116|function
P10733569A0364|127 140|stress response
P10733581A1391|22 31|expression
P10733581A1391|63 71|V12N38 Ras
P10733581A1391|102 114|TTF-1 activity
P10733591A0146|23 29|targets
P10733591A0146|39 48|remodeling
P10733591A0146|54 70|actin cytoskeleton
P10733591A0146|71 80|activation
P10733591A0146|91 96|kinase
P10733591A0146|98 102|c-jun
P10733591A0146|113 118|kinase
P10733591A0146|127 136|regulation
P10733591A0146|138 150|transcription
P10733591A0146|154 170|cell proliferation
P10733591A0533|0 9|Expression
P10733591A0533|21 32|Cdc42 results
P10733591A0533|38 50|translocation
P10733591A0533|53 61|PKClambda
P10733591A0533|69 75|nucleus
P10733591A0533|83 89|cytosol
P10733591A0533|93 97|Cdc42
P10733591A0533|101 109|PKClambda
P10733591A0533|125 138|plasma membrane
P10733591A0533|147 155|cytoplasm
P10733880X1783|0 8|Copyright
P10733880X1783|13 25|Academic Press
P10734312A0503|19 33|Shc localization
P10734312A0503|36 48|membrane rafts
P10734312A0503|71 81|Shc function
P10734312A0503|96 105|Shc chimera
P10734312A0503|119 146|Ras membrane localization motif
P10734312A0503|152 161|C-terminus
P10735272A0649|0 15|Southern blotting
P10735272A0649|25 62|strand conformation polymorphism analyses
P10735272A0649|87 97|alterations
P10735272A0649|112 118|gliomas
P10735272A0649|121 133|RT-PCR studies
P10735272A0649|140 149|expression
P10735272A0649|152 166|glioma cell lines
P10735272A0649|181 185|ANOVA
P10735272A0649|194 231|chromosome 19q glioma tumor suppressor gene
P10735848A1440|32 40|regulator
P10735848A1440|42 59|tol-oprL expression
P10736161T0000|0 6|Enzyme I
P10736161T0000|12 30|phosphoenolpyruvate
P10736161T0000|30 58|sugar phosphotransferase system
P10736223A1227|32 44|transcription
P10736223A1227|70 79|Qa promoter
P10736223A1227|112 124|transcription
P10736223A1227|155 165|readthrough
P10736223A1227|178 190|mRNA stability
P10737366A0280|76 84|threshold
P10737366A0280|97 103|stimuli
P10737366A0280|109 120|formalin test
P10738139A0681|9 15|mimicry
P10738139A0681|23 30|cytokine
P10738139A0681|34 61|cytokine response pathway genes
P10739408A0896|0 16|Family environment
P10739408A0896|31 39|influence
P10739408A0896|55 67|relationships
P10739408A0896|68 79|substance use
P10739408A0896|89 95|support
P10739671A0136|2 35|electrophoresis mobility shift assays
P10739671A0136|41 46|probes
P10739671A0136|71 78|segments
P10739671A0136|97 107|c-myb intron
P10739671A0136|109 132|transcription pause region
P10739671A0136|143 150|extracts
P10739671A0136|162 171|leukemia HL
P10739671A0136|177 188|fibroblast WI
P10739671A0136|191 195|cells
P10739671A0136|232 238|complex
P10739671A0136|250 257|fragment
P10739671A0136|268 279|binding sites
P10739671A0136|286 295|interferon
P10739671A0136|306 312|factors
P10739671A0136|326 333|proteins
P10740602A0141|0 10|STUDY DESIGN
P10740602A0141|11 30|Fine needle aspiration
P10740602A0141|40 45|smears
P10740602A0141|52 56|cases
P10740602A0141|74 82|carcinoma
P10740602A0141|90 95|breast
P10740602A0141|133 140|analysis
P10741850A0452|0 27|Electrophile Response Elements
P10741850A0452|28 32|EpREs
P10741850A0452|50 58|sequences
P10741850A0452|77 92|GCSl subunit genes
P10741850A0452|132 144|gene induction
P10741850A0452|164 171|exposure
P10741947T0000|4 12|technique
P10741947T0000|33 40|stenosis
P10741947T0000|63 70|hemoclip
P10742114A0486|33 37|mouse
P10742114A0486|43 47|pudgy
P10742114A0486|60 66|variety
P10742114A0486|82 88|defects
P10742114A0486|98 109|SD phenotypes
P10742216A0555|0 7|Schlegel
P10743608A1154|0 15|TbRAB31 behaviour
P10743608A1154|39 47|cell cycle
P10743608A1154|48 54|TbRAB31
P10743608A1154|81 89|structure
P10743608A1154|115 121|mitosis
P10743608A1154|136 148|daughter cells
P10743608A1154|162 167|manner
P10743608A1154|189 199|kinetoplast
P10743608A1154|212 222|involvement
P10743608A1154|225 236|microtubules
P10743719A0223|16 24|rejection
P10743719A0223|43 51|rejection
P10743719A0223|63 72|management
P10743719A0223|107 126|rejection nephropathy
P10744026A0000|0 9|Invertases
P10744026A0000|30 38|breakdown
P10744026A0000|41 47|sucrose
P10744026A0000|50 57|fructose
P10744026A0000|61 67|glucose
P10744749A0315|25 34|mechanisms
P10744749A0315|53 62|inhibition
P10744749A0315|76 81|effect
P10744749A0315|102 109|activity
P10744749A0315|123 133|MyoD protein
P10744749A0315|149 156|paradigm
P10744749A0315|163 169|factors
P10744749T0000|8 12|T cell
P10744749T0000|34 42|virus type
P10744749T0000|44 53|Tax protein
P10744749T0000|77 89|transcription
P10744749T0000|119 127|KIX domain
P10744974T0000|0 14|Phosphorylation
P10744974T0000|18 44|spindle pole body localization
P10744974T0000|50 55|Cdc15p
P10744974T0000|73 85|protein kinase
P10744974T0000|95 99|yeast
P10745563A0409|11 21|hyperplasia
P10745563A0409|35 47|complications
P10745563A0409|99 108|gold stents
P10745563A0409|126 133|capacity
P10745563A0409|138 142|steel
P10745563A0409|166 180|neo-endothelium
P10747053A1102|3 11|cell cycle
P10747053A1102|30 36|defects
P10747053A1102|45 49|taf17
P10747053A1102|49 54|slm7-1
P10747053A1102|91 100|modulators
P10747053A1102|116 125|activation
P10747053A1102|149 153|TAF17
P10747053A1102|165 174|activation
P10747099A0507|23 28|kinase
P10747099A0507|34 43|activation
P10747099A0507|55 62|coupling
P10747099A0507|68 86|adaptor proteins p130
P10747099A0507|101 109|substrate
P10747099A0507|118 124|c-CrkII
P10747099A0507|149 156|pathways
P10747099A0507|166 177|cell invasion
P10747099A0507|188 192|cells
P10747099A0507|197 205|apoptosis
P10747099A0507|226 239|collagen matrix
P10747782A0390|0 10|Proteolysis
P10747782A0390|39 47|complexes
P10747782A0390|60 65|extent
P10747782A0390|73 81|sequences
P10747782A0390|105 113|molecules
P10747782A0390|139 156|DNA binding activity
P10747782A0390|170 180|core domains
P10747879A0607|3 11|evolution
P10747879A0607|37 42|region
P10747879A0607|55 66|reading frame
P10747879A0607|89 95|domains
P10747879A0607|105 116|reading frame
P10747890A1096|5 11|results
P10747890A1096|24 30|residue
P10747890A1096|43 55|protein sensor
P10747890A1096|70 87|groove interactions
P10747890A1096|106 125|base pair interactions
P10747890A1096|143 149|lesions
P10747987A0658|14 20|enzymes
P10747987A0658|28 35|monomers
P10748054T0048|1 7|pathway
P10748054T0048|11 20|regulation
P10748054T0048|23 40|B lymphocyte antigen
P10748054T0048|57 67|calcium flux
P10748113A0187|20 29|RIM protein
P10748113A0187|99 103|brain
P10748125A0000|0 10|Inhibitor-1
P10748125A0000|19 29|inhibitor-2
P10748125A0000|59 93|protein serine/threonine phosphatases
P10748164A1284|0 16|Scanning mutations
P10748164A1284|30 38|AC element
P10748164A1284|53 61|induction
P10748164A1284|97 101|sites
P10748164A1284|115 121|factors
P10748164A1284|139 144|probes
P10748164A1284|163 169|factors
P10748175A0000|3 12|substrates
P10748175A0000|16 30|glycan synthesis
P10748175A0000|36 40|lumen
P10748175A0000|46 50|Golgi
P10748175A0000|64 69|sugars
P10748175A0000|98 104|cytosol
P10748175A0000|129 140|transporters
P10748194T0000|8 16|targeting
P10748194T0000|34 53|density protein PSD-95
P10748194T0000|79 95|trafficking signal
P10748672A0130|0 4|Bites
P10748672A0130|10 16|species
P10748672A0130|19 24|adders
P10748672A0130|25 35|Vipera aspis
P10748672A0130|39 49|Vipera berus
P10748672A0130|90 96|failure
P10749145T0000|25 36|PCPH proteins
P10749145T0000|50 70|diphosphatase activity
P10749145T0000|81 91|oncoprotein
P10749145T0000|152 161|kinase ERK1
P10749166A0991|5 11|results
P10749166A0991|44 48|genes
P10749166A0991|75 85|arrangement
P10749166A0991|119 128|B. henselae
P10749166A0991|150 157|bacteria
P10749166A0991|164 176|A. tumefaciens
P10749849A0000|11 19|mechanism
P10749849A0000|30 47|tumor suppressor p53
P10749849A0000|64 72|stability
P10749849A0000|83 97|cell cycle arrest
P10749849A0000|105 114|activation
P10749849A0000|136 153|kinase inhibitor p21
P10749849A0000|153 161|WAF1/Cip1
P10749932A0000|0 7|Paxillin
P10749932A0000|16 30|adaptor molecule
P10749932A0000|33 49|integrin signaling
P10750020A0843|4 25|growth factor activation
P10750020A0843|42 56|transactivation
P10750020A0843|58 70|ER/Sp1 binding
P10750020A0843|80 84|sites
P10750020A0843|104 110|pathway
P10750020A0843|132 139|ER action
P10750021A0728|11 18|analysis
P10750021A0728|21 55|deletion promoter-reporter constructs
P10750021A0728|73 80|activity
P10750021A0728|107 112|region
P10750524A0724|0 6|RESULTS
P10750524A0724|15 24|thresholds
P10750524A0724|51 55|tests
P10750524A0724|76 85|proportion
P10750524A0724|122 126|group
P10751398A1135|2 9|addition
P10751398A1135|13 25|transcription
P10751398A1135|28 41|c-IAP2 promoter
P10751398A1135|89 93|virus
P10751398A1135|99 113|membrane protein
P10752450A0288|1 7|variety
P10752450A0288|37 52|fluoride products
P10752450A0288|71 93|fluoride delivery systems
P10752450A0288|116 121|market
P10752475A1376|5 11|studies
P10752475A1376|32 56|signal-transduction events
P10752475A1376|70 78|apoptosis
P10752475A1376|90 95|B cells
P10752475A1376|118 125|ligation
P10752475A1376|145 154|antibodies
P10752475A1376|159 166|presence
P10752475A1376|191 195|cells
P10752475A1376|217 223|mouse Ig
P10752475A1376|223 232|antibodies
P10752475A1376|259 274|tumor regressions
P10752475A1376|285 295|mouse models
P10752475A1376|307 312|trials
P10752807A1598|0 9|CONCLUSION
P10752807A1598|10 18|Treatment
P10752807A1598|21 26|sepsis
P10752807A1598|53 74|factor antagonist BB-882
P10752807A1598|83 91|advantage
P10752807A1598|96 102|placebo
P10752807A1598|105 112|survival
P10752807A1598|124 129|status
P10752807A1598|141 148|function
P10752807A1598|151 168|organ failure scores
P10753553T0000|0 8|Phenazone
P10753553T0000|39 44|effect
P10753553T0000|47 55|lidocaine
P10754312A0798|3 12|solubility
P10754312A0798|28 35|proteins
P10756007A0575|17 28|RBE sequences
P10756007A0575|54 62|locations
P10756007A0575|73 78|genome
P10756007A1512|0 9|EM analysis
P10756007A1512|40 46|complex
P10756007A1512|58 71|ch-19 target DNA
P10756020A0571|3 9|protein
P10756020A0571|35 56|vaccinia virus particles
P10756020A0571|64 72|membranes
P10756020A0571|92 98|virions
P10756020A0571|119 136|electron microscopy
P10756020A0571|147 151|cells
P10756032A0599|6 32|dimethyl sulfate footprinting
P10756032A0599|38 52|cyclin E promoter
P10756032A0599|68 74|regions
P10756032A0599|77 86|protection
P10756032A0599|90 105|hypersensitivity
P10756032A0599|130 134|cells
P10756094A0671|1 5|total
P10756094A0671|26 33|interval
P10756094A0671|55 70|marker resolution
P10756100A0457|9 16|mutation
P10756100A0457|22 35|amino-terminus
P10756100A0457|60 67|diabetes
P10756225A1464|0 9|CONCLUSION
P10756225A1464|24 31|patients
P10756225A1464|44 51|rhinitis
P10756225A1464|77 83|surgery
P10756225A1464|84 91|response
P10756225A1464|116 120|cells
P10756225A1464|131 138|IL-5 mRNA
P10756225A1464|144 157|ethmoid sinuses
P10757983A0733|5 9|basis
P10757983A0733|21 31|CRS sequence
P10757983A0733|60 73|identification
P10757983A0733|77 93|zinc finger protein
P10757983A0733|94 102|Adx factor
P10757983A0733|135 151|zinc finger protein
P10757983A0733|153 172|mouse ZBP-89 homologue
P10758289A0141|0 6|METHODS
P10758289A0141|20 31|muscle fibres
P10758289A0141|57 69|finger flexors
P10758289A0141|95 106|pisiform bone
P10758289A0141|120 128|specimens
P10758489A0206|17 25|isolation
P10758489A0206|60 66|Cdc2aAt
P10758489A0206|92 102|Arabidopsis
P10758489A0206|102 108|Cdc2bAt
P10758726T0000|8 13|impact
P10758726T0000|28 39|arrangements
P10759693A0201|0 6|METHODS
P10759693A0201|21 29|odds ratio
P10759693A0201|37 43|measure
P10759693A0201|88 98|interaction
P10759693A0201|131 140|antagonist
P10759693A0201|140 149|cimetidine
P10759693A0201|177 192|agents ranitidine
P10759693A0201|193 202|famotidine
P10759693A0201|206 215|nizatidine
P10759693A0201|218 222|users
P10759693A0201|226 233|nonusers
P10759693A0201|236 243|warfarin
P10759693A0201|244 252|phenytoin
P10759693A0201|256 267|theophylline
P10760109A1050|3 12|prevalence
P10760109A1050|15 26|malnutrition
P10760109A1050|41 48|patients
P10760109A1050|105 112|patients
P10760109A1050|146 156|plasma IGF-1
P10760109A1050|154 168|serum creatinine
P10760109A1050|177 191|blood hemoglobin
P10760132A1169|33 43|temperature
P10760132A1169|59 63|level
P10760132A1169|69 86|protein prenylation
P10760132A1169|111 129|vesicle polarization
P10760169A1142|27 35|CreA sites
P10760169A1142|57 84|transcription initiation sites
P10760950A1133|9 23|staining pattern
P10760950A1133|30 39|N-utrophin
P10760950A1133|92 108|actin stress fibers
P10761263A1108|3 11|Newcastle
P10761263A1108|12 16|model
P10761263A1108|31 39|Hotelling
P10761263A1108|41 51|T2 statistic
P10761263A1108|98 109|displacement
P10761263A1108|118 133|prostate patients
P10762254A0954|16 36|TMA methyltransferases
P10762254A0954|41 48|homologs
P10762254A0954|63 86|MMA methyltransferase gene
P10762254A0954|90 94|genes
P10762254A0954|114 134|TMA methyltransferases
P10762254A0954|160 169|amber codon
P10762348A0269|5 19|phosphorylation
P10762348A0269|20 31|STAT proteins
P10762348A0269|53 59|nucleus
P10762348A0269|85 92|activity
P10763823A0824|0 13|Overexpression
P10763823A0824|16 20|mcl-1
P10763823A0824|49 57|apoptosis
P10763823A0824|63 74|transfection
P10763823A0824|78 82|mcl-1
P10763823A0824|92 98|plasmid
P10763823A0824|105 113|cell death
P10763827A1158|20 37|senescence pathways
P10763827A1158|52 59|response
P10763827A1158|63 73|ras oncogene
P10763827A1158|74 85|inactivation
P10763827A1158|88 104|TGFbeta1 secretion
P10763827A1158|107 114|response
P10763827A1158|137 153|senescence program
P10764150A0000|6 10|study
P10764150A0000|14 22|abilities
P10764150A0000|51 55|forms
P10764150A0000|66 75|Raf kinases
P10764150A0000|89 106|cytokine dependency
P10764150A0000|109 119|FDC-P1 cells
P10764574A0718|0 10|Application
P10764574A0718|16 21|method
P10764574A0718|53 57|genes
P10764574A0718|61 79|Arabidopsis thaliana
P10764574A0718|97 107|improvement
P10764574A0718|110 127|prediction accuracy
P10764574A0718|153 168|alignment methods
P10764729A1846|11 22|cDNA sequence
P10764729A1846|30 42|betaV spectrin
P10764729A1846|58 64|GenBank
P10764729A1846|70 84|accession number
P10764760T0000|0 14|Transactivation
P10764760T0000|35 39|HIV-1
P10764760T0000|52 58|repeats
P10764760T0000|64 82|JNK signaling pathway
P10764802A1258|33 38|domain
P10764802A1258|71 85|Cip/Kip proteins
P10764802A1258|113 123|interaction
P10764802A1258|153 161|mechanism
P10764802A1258|190 197|activity
P10764802A1258|218 230|family members
P10764802A1258|252 266|differentiation
P10764970A1009|11 20|resistance
P10764970A1009|22 46|quinupristin/dalfopristin
P10764970A1009|88 92|cases
P10764970A1009|105 113|existence
P10764970A1009|139 146|isolates
P10764970A1009|156 167|introduction
P10764970A1009|187 191|class
P10764970A1009|209 216|practice
P10765095A0308|4 8|study
P10765095A0308|31 42|PRL secretion
P10765095A0308|55 76|prostate cancer patients
P10765095A0308|88 97|conditions
P10765095A0308|103 110|response
P10765095A0308|113 118|L-Dopa
P10765095A0308|122 135|metoclopramide
P10765095A0308|191 195|tests
P10765095A0308|199 210|PRL secretion
P10766246A0000|0 24|Integrin adhesion receptors
P10766246A0000|34 40|signals
P10766246A0000|59 71|cell functions
P10766246A0000|87 96|regulation
P10766246A0000|99 112|gene expression
P10766246A0000|119 131|proliferation
P10766246A0000|132 146|differentiation
P10766246A0000|150 157|survival
P10766493T0000|0 12|Recombination
P10766493T0000|13 23|replication
P10766493T0000|24 29|repair
P10766493T0000|34 43|complexity
P10766493T0000|46 52|harmony
P10766556T0000|3 21|somatoform conundrum
P10766556T0000|23 30|question
P10766556T0000|44 49|valves
P10767091A0133|15 24|ultrasound
P10767091A0133|52 58|attempt
P10767091A0133|73 84|difficulties
P10767091A0133|117 122|nature
P10767091A0133|123 143|inter-user variability
P10767091A0133|147 163|image obliteration
P10767091A0133|189 198|techniques
P10767251A1046|0 10|CONCLUSIONS
P10767251A1046|25 29|study
P10767251A1046|39 46|Vivostat
P10767251A1046|53 59|sealant
P10767251A1046|83 92|air leakage
P10767251A1046|103 116|lung resections
P10767251A1046|146 154|pressures
P10767338T0000|13 19|disease
P10767338T0000|30 38|mutations
P10767338T0000|41 46|ATP2C1
P10767553A0100|31 35|liver
P10767553A0100|67 90|helix transcription factor
P10767553A0100|91 100|Hepatocyte
P10767553A0100|108 118|Factor 3beta
P10767553A0100|119 126|HNF3beta
P10767560A0105|4 12|extension
P10767560A0105|28 43|characterization
P10767560A0105|60 71|organization
P10767560A0105|77 88|mouse Pkr gene
P10767560A0105|125 146|mouse Pkr promoter region
P10767560A0105|171 183|transcription
P10769144A0000|8 17|TGACGTCA-3
P10769144A0000|38 54|consensus sequence
P10769144A0000|61 71|cis-element
P10769144A0000|97 110|gene expression
P10770041A0731|0 11|Kidney length
P10770041A0731|44 48|right
P10770041A0731|63 73|kidney width
P10770041A0731|82 90|thickness
P10770065A0264|11 15|stage
P10770065A0264|20 25|T1N0M0
P10770065A0264|29 49|S2 sleeve segmentectomy
P10770065A0264|54 72|lymph node dissection
P10770471T0000|0 10|Benztropine
P10770471T0000|33 43|night sweats
P10771528T0036|1 5|cause
P10771528T0036|8 15|increase
P10771528T0036|18 36|alkaline phosphatase
P10771528T0036|39 46|children
P10771709A0291|3 12|physicians
P10771709A0291|15 20|charge
P10771709A0291|26 33|patients
P10771709A0291|38 45|evidence
P10771709A0291|53 58|Q fever
P10771709A0291|59 72|seroconversion
P10771709A0291|79 86|presence
P10771709A0291|103 108|Q fever
P10771709A0291|117 123|disease
P10771709A0291|130 145|IgG antibody titer
P10771709A0291|148 153|phase I
P10771709A0291|156 171|Coxiella burnetii
P10771709A0291|199 211|questionnaire
P10772856X1492|0 8|Copyright
P10772856X1492|13 25|Academic Press
P10772977A0222|17 24|movement
P10772977A0222|27 37|PVX CP mutant
P10772977A0222|55 72|Nicotiana tabacum cv
P10773351A0672|0 8|Induction
P10773351A0672|11 24|CD86 expression
P10773351A0672|27 37|stimulation
P10773351A0672|40 48|U937 cells
P10773351A0672|53 61|IFN-gamma
P10773351A0672|73 80|presence
P10773351A0672|101 130|gamma-interferon activation site
P10773351A0672|130 137|elements
P10773455A1268|38 42|sites
P10773455A1268|62 67|region
P10773455A1268|99 116|mouse ALAS2 promoter
P10773455A1268|147 156|activation
P10773455A1268|180 194|differentiation
P10773455A1268|197 204|MEL cells
P10773455A1268|218 227|importance
P10773455A1268|249 259|specificity
P10773455A1268|265 269|ALAS2
P10773455A1268|285 294|activation
P10773458A0000|0 6|SNAP-23
P10773458A0000|34 43|regulation
P10773458A0000|45 62|vesicle trafficking
P10773458A0000|74 78|cells
P10773667A0351|3 11|HMG domain
P10773667A0351|18 30|HMG20 proteins
P10773667A0351|52 61|yeast NHP6A
P10773951A0000|27 41|B antibody status
P10773951A0000|53 65|O group mothers
P10773951A0000|75 88|O group husbands
P10775038A0142|4 10|attempt
P10775038A0142|23 36|Wee1 regulation
P10775038A0142|43 51|cell cycle
P10775038A0142|52 56|yeast
P10775038A0142|67 75|screening
P10775038A0142|105 111|protein
P10775267A0363|10 21|transduction
P10775267A0363|68 74|disease
P10775267A0363|82 101|bone marrow transplant
P10775267A0363|107 111|model
P10775267A0363|132 143|long-latency
P10775267A0363|142 151|pre-B-cell
P10775267A0363|165 172|lymphoma
P10775585A0754|0 12|Ab-MLV strains
P10775585A0754|23 28|P70/S2
P10775585A0754|46 56|NIH 3T3 cells
P10775585A0754|87 94|capacity
P10775585A0754|104 118|signaling events
P10775585A0754|166 172|protein
P10775585A0754|178 190|kinase pathway
P10775623A0120|3 12|codon usage
P10775623A0120|52 59|env genes
P10777217A0536|3 20|p53-homolog p73beta
P10777217A0536|37 48|PIG3 promoter
P10777217A0536|54 61|contrast
P10777217A0536|84 89|domain
P10777217A0536|91 97|p73beta
P10777217A0536|98 105|residues
P10777217A0536|137 148|PIG3 promoter
P10777499A0883|0 6|Results
P10777499A0883|20 25|assays
P10777499A0883|36 42|mutants
P10777499A0883|69 75|signals
P10777499A0883|79 90|phytochromes
P10777499A0883|119 125|element
P10777499A0883|150 156|element
P10777586A1022|0 21|Co-immunoprecipitation
P10777586A1022|25 49|DNA affinity chromatography
P10777586A1022|83 88|ZBP-89
P10777586A1022|102 116|silencer element
P10777586A1022|136 142|complex
P10777586A1022|148 155|mobility
P10777586A1022|207 213|extract
P10777586A1022|215 229|band shift assays
P10777669A0582|3 12|ZNF274 gene
P10777669A0582|29 39|marker RP S28
P10777669A0582|51 72|chromosome 19qter region
P10777669A0582|75 83|RH mapping
P10778740A1493|13 27|Cdk2 truncations
P10778740A1493|60 66|strains
P10778740A1493|86 93|activity
P10778740A1493|99 103|pho85
P10778740A1493|110 115|region
P10778740A1493|140 144|pho85
P10778740A1493|161 165|locus
P10778757A0000|26 31|nature
P10778757A0000|47 52|mutant
P10778757A0000|53 58|mn1-89
P10778757A0000|77 82|allele
P10778757A0000|88 97|Miniature1
P10778757A0000|103 111|seed locus
P10778757A0000|136 152|cell wall invertase
P10778757A0000|153 157|INCW2
P10779313A1842|26 33|myocytes
P10779313A1842|39 52|Xenopus oocytes
P10779313A1842|68 78|stimulation
P10779313A1842|103 114|GIRK channels
P10779313A1842|119 125|pathway
P10779313A1842|151 165|phosphorylation
P10779329T0000|39 46|function
P10779329T0000|72 92|cell morphology changes
P10779352T0000|0 13|Identification
P10779352T0000|22 32|E2F3 product
P10779352T0000|42 50|mechanism
P10779352T0000|65 75|specificity
P10779352T0000|78 87|repression
P10779352T0000|90 99|Rb proteins
P10779508A0452|2 6|DNase
P10779508A0452|8 37|footprinting protection analysis
P10779508A0452|51 60|ERE regions
P10779508A0452|75 121|glutathione S-transferase-ERRalpha1 fusion protein
P10779508A0897|17 27|coactivator
P10779508A0897|28 32|SRC1a
P10779508A0897|35 39|GRIP1
P10779508A0897|87 94|activity
P10779508T0000|0 7|Estrogen
P10779508T0000|24 36|receptor alpha
P10779508T0000|51 61|coactivator
P10779508T0000|91 114|estrogen response elements
P10779508T0000|125 139|lactoferrin gene
P10780018A0539|16 21|models
P10780018A0539|27 33|effects
P10780018A0539|36 40|aging
P10780018A0539|47 58|response time
P10780518A1270|3 9|effects
P10780518A1270|17 25|mutations
P10780518A1270|28 42|protein function
P10780518A1270|57 67|examination
P10780764A0722|9 14|levels
P10780764A0722|17 25|particles
P10780764A0722|52 60|diameters
P10780764A0722|76 81|microm
P10780764A0722|94 98|range
P10780764A0722|110 114|range
P10780764A0722|126 129|x m-3
P10780883T0000|0 5|Kaposi
P10780883T0000|25 35|herpesvirus
P10780883T0000|41 50|interferon
P10780883T0000|61 66|factor
P10780883T0000|74 83|resistance
P10780883T0000|106 111|effect
P10780883T0000|114 129|interferon-alpha
P10781109T0000|27 38|interference
P10781109T0000|63 81|Arabidopsis thaliana
P10781423A0993|0 9|Comparison
P10781423A0993|12 20|sequences
P10781423A0993|47 67|consensus binding sites
P10781423A0993|73 130|homeodomain transcription factor thyroid transcription factor-1
P10781423A0993|131 135|TTF-1
P10781541A1063|23 31|sequences
P10781541A1063|50 55|region
P10781541A1063|61 69|promoters
P10781541A1063|109 117|sequences
P10781541A1063|132 141|regulation
P10781541A1063|144 156|transcription
P10781541A1063|166 174|promoters
P10781552A0000|0 5|Purple
P10781552A0000|20 27|bacteria
P10781552A0000|58 63|energy
P10781552A0000|75 81|sources
P10781552A0000|91 104|photosynthesis
P10781552A0000|105 115|respiration
P10781552A0000|122 130|oxidation
P10781604A0827|2 9|analysis
P10781604A0827|21 28|peptides
P10781604A0827|45 55|CTD sequence
P10781604A0827|89 100|Rsp5 WW domain
P10781604A0827|101 107|Rsp5 WW2
P10781604A0827|120 124|yeast
P10781604A0827|135 140|assays
P10781611A1023|31 41|macrophages
P10781611A1023|90 99|efficiency
P10781611A1023|101 110|comparison
P10781611A1023|116 126|macrophages
P10781990A0455|78 96|hyperintense lesions
P10781990A0455|100 113|globus pallidus
P10782640A0444|3 8|method
P10782640A0444|29 47|aberration constants
P10782640A0444|51 71|CM300 FEG/UT microscope
P10782640A0444|76 85|correction
P10782640A0444|101 111|astigmatism
P10782989A0575|3 13|interaction
P10782989A0575|32 39|presence
P10782989A0575|66 81|DNA binding domain
P10782989A0575|87 104|amino acid sequences
P10782989A0575|115 130|DNA binding domain
P10782989A0575|144 153|amino acids
P10784367A0133|0 5|METHOD
P10784367A0133|9 14|sample
P10784367A0133|17 24|subjects
P10784367A0133|40 71|Suffolk County Mental Health Project
P10784367A0133|98 102|study
P10784367A0133|123 130|subjects
P10784367A0133|144 152|disorders
P10784367A0133|163 167|study
P10784367A0133|177 184|patients
P10784367A0133|202 210|disorders
P10784393A0000|0 14|Marrow dysplasia
P10784393A0000|23 36|characteristic
P10784393A0000|39 46|patients
P10784393A0000|66 73|syndrome
P10784393A0000|88 102|marrow blastosis
P10784393A0000|102 110|cytopenia
P10784393A0000|125 133|anomalies
P10785294A0720|24 36|inlays/onlays
P10785294A0720|55 66|restorations
P10785294A0720|114 127|resin composite
P10785668A0000|3 8|plants
P10785668A0000|18 23|attack
P10785668A0000|29 33|range
P10785668A0000|36 45|herbivores
P10785668A0000|49 57|pathogens
P10785668A0000|79 83|field
P10785668A0000|89 95|subject
P10785668A0000|110 117|research
P10785668A0000|133 142|biologists
P10785668A0000|146 155|ecologists
P10785880A0947|0 9|CONCLUSION
P10785880A0947|13 23|probability
P10785880A0947|41 53|complications
P10785880A0947|80 87|patients
P10785880A0947|95 99|class
P10785880A0947|101 113|HELLP syndrome
P10786671A0182|25 42|telomerase activity
P10786671A0182|54 63|expression
P10786671A0182|78 84|subunit
P10786671A0182|90 95|enzyme
P10786671A0182|113 122|telomerase
P10786671A0182|130 142|transcriptase
P10786671A0182|143 147|hTERT
P10786742A0670|5 16|control group
P10786742A0670|17 31|platelet markers
P10786742A0670|50 56|surgery
P10787437A1616|10 16|element
P10787437A1616|30 51|transcription start site
P10787437A1616|68 72|SRE-1
P10787804T0000|11 15|paper
P10788320A1034|5 12|proteins
P10788320A1034|23 33|TPR elements
P10788320A1034|79 90|interactions
P10788320A1034|107 118|102kD protein
P10788320A1034|137 145|tri-snRNP
P10788320A1034|164 174|U4/U6 snRNPs
P10788320A1034|192 200|particles
P10788476A0891|0 9|Antibodies
P10788476A0891|34 40|portion
P10788476A0891|43 67|Sec31A co-precipitate Sec13
P10788476A0891|78 94|ER-Golgi transport
P10788476A0891|126 143|stomatitis G protein
P10788476A0891|158 166|cell assay
P10788480T0000|0 9|Regulation
P10788480T0000|51 76|protein gene expression links
P10788480T0000|100 113|DNA replication
P10788480T0000|116 125|drosophila
P10790390X0000|19 28|complexity
P10790390X0000|34 69|position effect variegation modifier mod
P10790390X0000|129 133|3-93D
P10790390X0000|143 149|variety
P10790390X0000|152 160|processes
P10790390X0000|167 179|gene silencing
P10790390X0000|182 206|position effect variegation
P10790390X0000|215 221|control
P10790390X0000|223 245|gypsy insulator sequences
P10790390X0000|246 255|regulation
P10790390X0000|266 279|gene expression
P10790390X0000|293 301|cell death
P10791251A0110|20 24|kinds
P10791251A0110|33 38|things
P10791251A0110|47 55|functions
P10791251A0110|73 78|humans
P10791819A0771|4 11|tendency
P10791819A0771|34 54|nucleotide composition
P10791819A0771|60 74|asparagus genome
P10791819A0771|103 111|selection
P10791819A0771|123 128|codons
P10791901A0609|0 11|Transduction
P10791901A0609|30 41|cell line K562
P10791901A0609|57 77|MRP1-PG13 supernatants
P10791901A0609|98 105|MRP1 gene
P10791901A0609|127 141|target K562 cells
P10791901A0609|193 200|presence
P10791901A0609|217 230|concentrations
P10791901A0609|233 241|etoposide
P10792583A0000|0 9|Regulation
P10792583A0000|21 43|vasopressin V1b receptors
P10792583A0000|104 110|hormone
P10792583A0000|116 124|secretion
P10792583A0000|130 139|adaptation
P10792583A0000|142 147|stress
P10792718T0000|0 13|Identification
P10792718T0000|18 30|AfsA homologue
P10792718T0000|76 84|regulator
P10792718T0000|95 119|autoregulator biosynthesis
P10792718T0000|120 144|virginiamycin biosynthesis
P10792718T0000|148 172|virginiamycin M1 resistance
P10793143A1533|27 36|DNA binding
P10793143A1533|57 64|Abf1 ARS1
P10793143A1533|76 83|activity
P10793143A1533|87 93|results
P10793143A1533|122 129|activity
P10793143A1533|155 164|initiation
P10793143A1533|166 179|DNA replication
P10793991A0569|16 24|longevity
P10793991A0569|35 48|TIE researchers
P10793991A0569|65 72|position
P10793991A0569|82 87|trends
P10793991A0569|90 101|telemedicine
P10794405A0000|13 17|study
P10794405A0000|20 27|peptides
P10794405A0000|50 56|domains
P10794405A0000|59 67|histone H1
P10794405A0000|101 113|understanding
P10794405A0000|118 125|function
P10794405A0000|134 142|chromatin
P10794936A0241|3 15|recovery rates
P10794936A0241|22 28|MB/BacT
P10794936A0241|46 50|media
P10794936A0241|89 100|mycobacteria
P10794936A0241|103 115|recovery rates
P10794936A0241|152 172|M. tuberculosis complex
P10794936A0241|229 240|mycobacteria
P10795098A0253|8 17|vasculitis
P10795098A0253|29 33|Crohn
P10795098A0253|35 41|disease
P10795098A0253|60 69|phenomenon
P10796465A0373|0 16|SELECTION CRITERIA
P10796465A0373|48 53|trials
P10796465A0373|59 69|acupuncture
P10796465A0373|77 82|asthma
P10796465A0373|97 104|symptoms
P10796486A0817|0 16|SELECTION CRITERIA
P10796486A0817|27 32|trials
P10796486A0817|42 49|children
P10796486A0817|70 76|therapy
P10796486A0817|90 95|family
P10796486A0817|98 108|conjunction
P10796486A0817|113 128|asthma medication
P10796486A0817|133 140|children
P10796486A0817|147 162|asthma medication
P10797125A0000|9 18|hypothesis
P10797125A0000|41 49|increases
P10797125A0000|59 73|core temperature
P10797125A0000|80 103|core temperature threshold
P10797125A0000|107 119|sweating onset
P10797125A0000|137 144|estrogen
P10797125A0000|159 163|women
P10797125A0000|176 187|degrees C rest
P10797125A0000|202 215|passive heating
P10797125A0000|217 224|degrees C
P10797125A0000|243 250|exercise
P10797125A0000|254 262|degrees C.
P10797586A0402|3 8|models
P10797586A0402|34 41|response
P10797586A0402|44 55|disturbances
P10797586A0402|69 74|signal
P10797586A0402|82 88|bladder
P10798607A1359|31 37|killing
P10798607A1359|39 50|meningococci
P10798607A1359|76 80|assay
P10798607A1359|85 103|antibody titer levels
P10798607A1359|124 131|immunity
P10798607A1359|157 164|patients
P10799501A1391|5 11|studies
P10799501A1391|31 39|component
P10799501A1391|50 60|environment
P10799501A1391|74 87|SPRK activation
P10799501A1391|90 94|Cdc42
P10799590A0431|0 5|Jkappa
P10799590A0431|17 21|sites
P10799590A0431|44 53|activation
P10799590A0431|64 77|EBNA-3C protein
P10799590A0431|90 95|Jkappa
P10799590A0431|105 117|transcription
P10799590A0431|142 148|EBNA-3C
P10799590A0431|163 169|EBNA-3C
P10799590A0431|181 193|transcription
P10799590A0431|202 210|mechanism
P10799590A0431|230 235|Jkappa
P10799595A1454|39 48|regulators
P10799595A1454|75 89|HPV-6 E1 promoter
P10799595A1454|103 114|HPV life cycle
P10799863T0000|10 17|cleavage
P10799863T0000|20 36|metallopeptidases
P10799863T0000|40 50|proteasomes
P10799863T0000|73 87|HIV-1 ENV epitope
P10799863T0000|101 108|MHC class
P10799863T0000|110 128|antigen presentation
P10799879T0000|0 6|Cloning
P10799879T0000|10 25|characterization
P10799879T0000|40 53|adaptor protein
P10799879T0000|57 74|pleckstrin homology
P10799879T0000|78 88|Src homology
P10799879T0000|90 96|domains
P10799879T0000|111 125|T cell activation
P10801244A0578|0 13|Vancomycin data
P10801244A0578|57 61|model
P10801244A0578|73 88|NONMEM population
P10801244A0578|103 110|software
P10801330A1714|27 33|cytosol
P10801330A1714|36 64|membrane cytoskeleton fractions
P10801330A1714|77 81|state
P10801330A1714|108 126|platelet aggregation
P10801330A1714|165 172|fraction
P10801482A0968|31 37|targets
P10801482A0968|52 59|affinity
P10801482A0968|76 83|residues
P10801482A0968|96 100|roles
P10801482A0968|119 131|kappaB targets
P10801809T0000|15 24|regulation
P10801809T0000|30 46|yeast PHO8 promoter
P10801809T0000|49 58|comparison
P10801809T0000|75 86|PHO5 promoter
P10801860A0000|3 9|Siglecs
P10801860A0000|14 22|subfamily
P10801860A0000|31 37|lectins
P10801860A0000|38 70|immunoglobulin superfamily proteins
P10801860A0000|79 84|sugars
P10801860A0000|116 120|acids
P10802669A1434|28 38|explanation
P10802669A1434|44 53|similarity
P10802669A1434|56 64|phenotype
P10802909A0478|0 9|PATIENTS OR
P10802909A0478|15 26|PARTICIPANTS
P10802909A0478|33 40|children
P10802909A0478|47 54|criteria
P10804379T0001|0 5|Update
P10804379T0001|22 31|infections
P10804379T0001|34 43|hepatitis C
P10804379T0001|52 66|cytomegalovirus
P10805286A0233|12 16|study
P10805286A0233|32 43|cis-elements
P10805286A0233|54 60|PCI gene
P10805286A0233|72 81|expression
P10805286A0233|103 110|cell line
P10805286A0233|111 120|HepG2 cells
P10805286A0233|137 156|rat PCI mRNA expression
P10805286A0233|174 179|effect
P10805286A0233|182 189|androgen
P10805286A0233|209 215|tissues
P10805286A0914|5 9|study
P10805286A0914|12 28|PCI mRNA expression
P10805286A0914|46 51|organs
P10805286A0914|65 74|rat PCI cDNA
P10805286A0914|94 99|effect
P10805286A0914|102 109|androgen
P10805286A0914|115 131|PCI mRNA expression
P10805390A0340|15 25|performance
P10805390A0340|26 37|measurements
P10805390A0340|40 56|photoluminescence
P10805390A0340|59 85|GaAs/AlGaAs heterostructures
P10805729A0987|3 15|stoichiometry
P10805729A0987|21 29|complexes
P10805729A0987|59 65|C strand
P10805729A0987|102 110|KH domains
P10805729A0987|150 168|acid binding surfaces
P10805737T0000|10 17|analysis
P10805737T0000|29 55|translation initiation factor
P10805737T0000|71 81|interaction
P10805737T0000|90 100|beta subunit
P10805737T0000|120 131|eIF5 function
P10805738A0799|4 11|evidence
P10805738A0799|34 42|activator
P10805738A0799|51 67|p38 kinase activity
P10805738A0799|83 92|expression
P10805738A0799|110 114|genes
P10805738A0799|125 133|induction
P10805738A0799|169 176|activity
P10805738A0799|179 200|Gal4-MyoD fusion protein
P10805738A0799|219 228|activation
P10805738A0799|251 259|reporters
P10805738A0799|296 305|conversion
P10805738A0799|316 320|mouse
P10805738A0799|330 340|fibroblasts
P10805738A0799|352 359|p38alpha
P10805738A0799|360 366|embryos
P10805739A0343|4 11|activity
P10805739A0343|26 41|complex formation
P10805739A0343|54 66|eIF2B subunits
P10805739A0640|3 10|analysis
P10805739A0640|13 29|nonsense mutations
P10805739A0640|46 54|C terminus
P10805739A0640|57 68|eIF2Bepsilon
P10805739A0640|69 76|residues
P10805739A0640|111 118|activity
P10805739A0640|122 132|interaction
P10805747A0633|2 9|contrast
P10805747A0633|10 18|mutations
P10805747A0633|52 58|kinases
P10805747A0633|73 77|Hsl1p
P10805747A0633|81 85|Kcc4p
P10805747A0633|105 110|effect
P10805747A0633|113 130|septin organization
P10805823A1920|0 10|CONCLUSIONS
P10805823A1920|22 27|pacing
P10805823A1920|42 48|benefit
P10805823A1920|64 69|pacing
P10805823A1920|76 85|prevention
P10805823A1920|88 93|stroke
P10805823A1920|96 100|death
P10805823A1920|120 125|causes
P10807900A0933|5 18|non-cirrhotics
P10807900A0933|33 49|vein visualisation
P10807900A0933|54 65|% sensitivity
P10807900A0933|67 78|% specificity
P10807900A0933|101 105|value
P10807900A0933|130 134|value
P10807900A0933|139 147|diagnosis
P10807900A0933|170 181|hypertension
P10807903A0362|0 4|D5/D1
P10807903A0362|10 15|D5/D1D
P10807903A0362|18 40|tail substitution mutants
P10807903A0362|50 58|rank order
P10807903A0362|61 67|potency
P10807903A0362|71 87|agonist affinities
P10807903A0362|117 127|D1 receptors
P10807903A0362|143 155|ligand binding
P10807903A0362|178 199|cAMP accumulation assays
P10807903A0362|214 224|D1 receptors
P10807903A0362|231 245|exhibit receptor
P10807903A0362|258 265|activity
P10807903A0362|268 281|responsiveness
P10807903A0362|291 298|agonists
P10809233A0606|0 7|Modeling
P10809233A0606|36 42|surface
P10809233A0606|51 57|absence
P10809233A0606|73 80|residues
P10810083A1283|19 28|kinase gene
P10810083A1283|57 71|zinc finger motif
P10810294A0730|0 13|Stat activation
P10810294A0730|16 23|response
P10810294A0730|54 74|reporter gene induction
P10810745A0677|0 6|HFA 134a
P10810745A0677|18 25|tendency
P10810745A0677|34 41|moisture
P10810745A0677|49 59|environment
P10811079A0555|0 6|RESULTS
P10811079A0555|15 29|color perception
P10811079A0555|49 64|epilepsy patients
P10811079A0555|75 95|vigabatrin monotherapy
P10811079A0555|108 123|epilepsy patients
P10811079A0555|134 157|carbamazepine monotherapy
P10811079A1277|5 21|SPP2 screening test
P10811079A1277|26 31|plates
P10811079A1277|49 54|groups
P10811804A0000|17 23|protein
P10811804A0000|29 47|kinase phosphatase-3
P10811804A0000|47 51|MKP-3
P10811804A0000|59 80|specificity phosphatase
P10811804A0000|125 130|kinase
P10811804A0000|136 145|MAP kinases
P10811804A0800|28 35|peptides
P10811804A0800|48 59|docking sites
P10811804A0800|69 89|target substrates Elk-1
P10811804A0800|122 131|activation
P10811804A0800|132 136|MKP-3
P10811908A0938|0 24|HPLC phosphopeptide mapping
P10811908A0938|25 43|amino acid sequencing
P10811908A0938|60 70|mutagenesis
P10812294X0000|44 53|feed intake
P10812294X0000|97 102|ponies
P10812294X0000|118 127|ingredient
P10814989T0000|0 23|Hepatitis C virus infection
P10814989T0000|46 53|diseases
P10814989T0000|56 61|France
P10814989T0000|71 75|study
P10815410A0000|9 14|system
P10815410A0000|41 60|neuroendocrine system
P10815410A0000|81 89|increases
P10815410A0000|92 100|cytokines
P10815410A0000|139 145|effects
P10815410A0000|162 167|system
P10815807A1271|23 35|transcription
P10815807A1271|53 65|c-Myb promoter
P10815807A1271|86 91|HTLV-I
P10815807A1271|103 113|T-cell lines
P10817754T0000|25 34|expression
P10817754T0000|93 98|region
P10819327T0000|0 14|C. elegans KLP-11
P10819327T0000|14 18|OSM-3
P10819327T0000|18 22|KAP-1
P10819327T0000|23 31|orthologs
P10819327T0000|37 55|sea urchin kinesin-II
P10819327T0000|59 94|mouse KIF3A/KIFB/KAP3 kinesin complexes
P10820829T0000|0 9|Flavonoids
P10820829T0000|14 32|Brosimum acutifolium
P10820904A0000|0 9|BACKGROUND
P10820904A0000|17 30|encephalopathy
P10820904A0000|50 57|syndrome
P10820904A0000|77 88|liver failure
P10820904A0000|107 118|liver disease
P10820904A0000|135 145|anastomosis
P10821836A0842|21 32|S transcripts
P10821836A0842|64 80|sense S transcripts
P10822117A1386|9 18|adjustment
P10822117A1386|43 47|model
P10822117A1386|69 80|observations
P10822117A1386|96 106|information
P10822117A1386|114 127|subject-models
P10823630A1124|10 17|presence
P10823630A1124|20 29|effacement
P10823630A1124|64 72|parameter
P10823630A1124|98 107|prediction
P10823837A1213|39 54|YLL031c transfers
P10823837A1213|56 76|ethanolaminephosphate
P10823837A1213|102 108|mannose
P10823837A1213|116 120|group
P10823837A1213|133 146|GPI lipid anchor
P10823837A1213|149 156|proteins
P10823837A1213|164 168|Mcd4p
P10823837A1213|172 205|Gpi7p transfer ethanolaminephosphate
P10823837A1213|213 220|alpha1-4
P10823837A1213|239 246|mannoses
P10823837A1213|252 260|GPI anchor
P10823961A0664|3 11|C terminus
P10823961A0664|27 34|CBP/p300
P10823961A0664|37 43|DRIP130
P10823961A0664|45 53|component
P10823961A0664|59 78|DRIP/TRAP/ARC complex
P10823961A0664|113 125|transcription
P10823961A0664|127 131|means
P10823961A0664|138 149|interactions
P10824485A0393|3 10|patients
P10824485A0393|40 46|disease
P10824485A0393|62 78|T lymphocyte counts
P10824485A0393|108 116|illnesses
P10824958A1109|16 21|energy
P10824958A1109|96 110|broiler breeders
P10825000A1245|3 24|gene amplification model
P10825000A1245|27 34|Coquelle
P10825200T0000|0 8|Hierarchy
P10825200T0000|11 32|protein tyrosine kinases
P10825200T0000|35 47|interleukin-2
P10825200T0000|54 62|signaling
P10825200T0000|62 71|activation
P10825200T0000|147 160|STAT activation
P10825293T0000|11 16|dimers
P10825293T0000|19 38|N-cadherin-Fc chimera
P10825293T0000|61 80|cell contact formation
P10825293T0000|81 92|contribution
P10825293T0000|122 128|signals
P10825294A0473|11 20|OC promoter
P10825294A0473|35 43|C terminus
P10825294A0473|53 58|manner
P10825294A0473|75 86|BSP promoters
P10825294A0473|112 121|mechanisms
P10825294A0473|155 166|AML C terminus
P10825294A0473|204 220|pentapeptide VWRPY
P10826861A0000|13 34|immunoglobulin products
P10826861A0000|37 54|plasma cell neoplasm
P10826861A0000|69 75|variety
P10826861A0000|78 91|manifestations
P10826861A0000|101 114|hyperviscosity
P10826861A0000|115 125|amyloidosis
P10826861A0000|126 141|cryoglobulinemia
P10826861A0000|142 151|neuropathy
P10826861A0000|160 166|failure
P10826946A1198|0 12|Investigation
P10826946A1198|28 32|basis
P10826946A1198|38 48|interaction
P10826946A1198|69 73|gp120
P10826946A1198|90 97|gp120 SAg
P10826946A1198|118 123|subset
P10827885T0059|30 34|trial
P10827952A0158|17 24|TAFII250
P10827952A0158|35 41|subunit
P10827952A0158|44 48|TFIID
P10827952A0158|66 83|bromodomain modules
P10827952A0158|123 139|histone H4 peptides
P10828022A0877|0 18|Endostatin treatment
P10828022A0877|24 30|minutes
P10828022A0877|35 39|hours
P10828022A0877|47 69|tyrosine phosphorylation
P10828022A0877|80 88|formation
P10828022A0877|102 110|complexes
P10828319A0342|9 15|analogs
P10828319A0342|18 26|vitamin D3
P10828319A0342|50 55|number
P10828319A0342|58 63|trials
P10828319A0342|71 81|improvement
P10828319A0342|84 92|psoriasis
P10828591A0080|3 12|transcript
P10828591A0080|45 56|cDNA sequence
P10828591A0080|62 67|course
P10828591A0080|83 95|transcript map
P10828591A0080|101 106|region
P10828591A0080|114 128|markers D11S1765
P10828591A0080|132 142|uteroglobin
P10828591A0080|179 185|disease
P10828751A2258|7 15|challenge
P10828751A2258|22 27|future
P10828751A2258|37 46|management
P10828751A2258|49 56|patients
P10828751A2258|84 92|treatment
P10829973T0000|0 24|Iodine deficiency disorders
P10829973T0000|27 36|Bangladesh
P10830395A0408|3 18|network evolution
P10830395A0408|37 44|approach
P10830395A0408|55 64|Flory model
P10831972A0744|0 6|RESULTS
P10831972A0744|14 23|CD23 levels
P10831972A0744|49 53|women
P10831972A0744|58 70|endometriosis
P10831972A0744|77 85|treatment
P10831972A0744|101 108|controls
P10831972A1091|0 9|CONCLUSION
P10831972A1091|13 20|findings
P10831972A1091|32 44|endometriosis
P10831972A1091|61 70|CD23 levels
P10831972A1091|101 107|danazol
P10831972A1091|110 135|leuprolide acetate injection
P10833461A0603|35 44|chromosome
P10833461A0603|48 54|library
P10833461A0603|74 90|length UGT2B7 probe
P10833461A0603|95 99|clone
P10833461A0603|124 129|length
P10833486A0598|8 12|years
P10833486A0598|12 20|odds ratio
P10833486A0598|50 62|triglycerides
P10833486A0598|63 68|mmol/L
P10833486A0598|77 99|alanine aminotransferase
P10833486A0598|153 160|fibrosis
P10834707A1533|23 29|amounts
P10834707A1533|32 55|platelet activating factor
P10834707A1533|73 79|sorbent
P10834707A1533|95 107|treatment time
P10834781A0693|17 21|group
P10834781A0693|51 64|residence times
P10834781A0693|79 93|plasma clearance
P10834781A0693|95 103|lidocaine
P10834781A0693|113 118|period
P10834781A0693|139 143|group
P10835355A0225|17 37|zinc finger protein Gis1
P10835355A0225|61 70|suppressor
P10835355A0225|76 91|rim15Delta defect
P10835355A0225|94 101|nutrient
P10835355A0225|135 146|derepression
P10835485A0941|17 23|segment
P10835485A0941|28 39|linker domain
P10835485A0941|42 49|contrast
P10835485A0941|71 86|sequence identity
P10835485A0941|98 114|amino acid residues
P10835485A0941|121 127|factors
P10835485A0941|130 135|cattle
P10835485A0941|144 148|mouse
P10835732A0911|2 12|differences
P10835732A0911|20 36|cholesterol levels
P10835732A0911|56 63|mapuches
P10835732A0911|67 73|aymaras
P10836542A0363|18 27|UV exposure
P10836542A0363|42 53|UV-A waveband
P10836786A0516|35 45|RNA subunits
P10836786A0516|47 60|enzyme function
P10836786A0516|64 83|substrate specificity
P10836786A0516|96 112|hairpin structures
P10836786A0516|133 143|RNase MRP RNA
P10836786A0516|145 153|RNase P RNA
P10837126A1004|5 9|genes
P10837126A1004|24 34|pMesogenin1
P10837126A1004|37 42|Xwnt-8
P10837126A1004|44 58|signaling factor
P10837126A1004|78 87|repertoire
P10837126A1004|90 100|marker genes
P10837126A1004|120 128|phenotype
P10838139A1447|13 23|Ha-ras codon
P10838139A1447|26 34|mutations
P10838139A1447|67 72|tumors
P10838399A0525|13 18|PET FDG
P10838399A0525|33 45|lung infection
P10838399A0525|58 68|bone disease
P10838399A0525|72 93|reconstruction artifact
P10838531A0675|0 10|Tumor stages
P10838531A0675|20 23|T3 N0
P10838531A0675|58 65|patients
P10839470A1148|9 18|comparison
P10839470A1148|21 40|percentage reductions
P10839470A1148|43 51|heart rate
P10839470A1148|54 59|supine
P10839470A1148|70 77|exercise
P10839470A1148|88 102|measure analysis
P10839470A1148|112 117|Malays
P10839470A1148|143 148|change
P10839547A0978|17 21|model
P10839547A0978|22 32|CTCF binding
P10839547A0978|46 59|DNA methylation
P10839593A0000|0 8|OBJECTIVE
P10839593A0000|23 30|efficacy
P10839593A0000|34 39|safety
P10839593A0000|42 54|amphotericin B
P10839593A0000|59 68|suspension
P10839593A0000|81 89|treatment
P10839593A0000|91 101|fluconazole
P10839593A0000|116 126|candidiasis
P10839593A0000|129 135|persons
P10839593A0000|140 151|HIV infection
P10840001A0188|0 18|Mucin gene expression
P10840001A0188|58 65|diseases
P10840001A0188|79 85|cancers
P10840001A0188|107 111|tract
P10841537A0669|23 29|regions
P10841537A0669|53 64|interactions
P10841537A0669|115 124|structures
P10841593A0780|3 7|model
P10841593A0780|26 35|% reduction
P10841593A0780|38 57|cigarette consumption
P10841593A0780|77 88|availability
P10841593A0780|91 105|nicotine patches
P10841601T0000|0 9|Paper alert
P10843716A0406|3 15|tryptase locus
P10843716A0406|52 62|pseudogenes
P10843716A0406|72 77|mastin
P10843716A0406|110 115|humans
P10843810A0802|35 39|clone
P10843810A0802|55 62|homology
P10843810A0802|83 101|tyrosine phosphatase
P10843810A0802|138 146|direction
P10845522A0000|0 8|OBJECTIVE
P10845522A0000|13 17|study
P10845522A0000|49 53|roles
P10845522A0000|56 87|99mTc-sestamibi scintimammography
P10845522A0000|91 100|sonography
P10845522A0000|106 115|evaluation
P10845522A0000|118 130|breast lesions
P10845522A0000|165 175|mammography
P10845522A0000|186 196|examination
P10846054A0573|10 17|analyses
P10846054A0573|40 45|codons
P10846054A0573|95 106|accumulation
P10846054A0573|107 120|progeny LIYV RNA
P10846054A0573|163 170|proteins
P10846054A0573|181 198|LIYV RNA replication
P10846069T0000|28 34|domains
P10846069T0000|38 45|P protein
P10846069T0000|53 74|parainfluenza virus type
P10846069T0000|78 90|transcription
P10846069T0000|94 104|replication
P10848605T0000|0 14|Phosphorylation
P10848605T0000|17 32|tyrosine residues
P10848605T0000|38 49|kinase domain
P10848605T0000|53 71|juxtamembrane region
P10848605T0000|106 115|activities
P10848605T0000|118 129|Eph receptors
P10848848A0413|0 6|RESULTS
P10848848A0413|7 14|Fournier
P10848848A0413|16 23|gangrene
P10848993A0000|7 19|DNA sequencing
P10848993A0000|25 32|vicinity
P10848993A0000|35 61|methylmalonyl-CoA mutase gene
P10848993A0000|62 66|mutAB
P10848993A0000|72 80|rifamycin
P10848993A0000|93 120|Amycolatopsis mediterranei U32
P10848993A0000|132 136|clone
P10848993A0000|137 144|sequence
P10848993A0000|177 205|serine/threonine protein kinase
P10850329A0248|27 35|treatment
P10850329A0248|48 58|combination
P10850329A0248|63 74|chemotherapy
P10850329A0248|77 86|biotherapy
P10850329A0248|92 101|management
P10850329A0248|114 121|melanoma
P10850329A0248|140 152|cell carcinoma
P10850453A0713|8 17|expression
P10850453A0713|29 34|Ha-Ras
P10850453A0713|53 57|Raf-1
P10850453A0713|79 84|effect
P10850453A0713|87 95|TGF-beta1
P10850453A0713|98 104|TSU-Pr1
P10850453A0713|111 129|TGF-beta1 inhibition
P10850453A0713|132 136|DU145
P10850453A0713|150 160|stimulation
P10850453A0713|163 183|V12Ha-Ras transfection
P10850453A1292|33 50|prostate carcinomas
P10850453A1292|57 81|Ras/MAPK pathway activation
P10850453A1292|101 115|growth advantage
P10850453A1292|127 145|TGF-beta1 production
P10850719A0680|0 12|Vbeta segments
P10850719A0680|26 45|DJbeta rearrangements
P10850719A0680|66 70|Vbeta
P10850719A0680|73 77|Jbeta
P10850719A0680|97 109|compatibility
P10850719A0680|112 123|Vbeta 23-RSSs
P10850719A0680|127 138|Jbeta12-RSSs
P10850849A0730|7 20|administration
P10850849A0730|21 33|AUC0-infinity
P10850849A0730|48 58|microg x h/ml
P10850849A0730|59 66|t1/2beta
P10850849A0730|80 84|hours
P10850849A0730|85 104|maximum concentration
P10850849A0730|124 132|microg/ml
P10850849A0730|158 162|hours
P10850849A0730|165 178|absorption time
P10850849A0730|191 195|hours
P10850849A0730|199 213|bioavailability
P10850942A0989|2 11|experiment
P10850942A0989|15 24|difference
P10850942A0989|34 41|emptying
P10850942A0989|45 52|% peptone
P10850942A0989|56 63|% glucose
P10850942A0989|128 136|nutrition
P10850997A1016|2 9|contrast
P10850997A1016|24 33|regulation
P10850997A1016|50 56|absence
P10851089A1248|25 44|cell cycle progression
P10851089A1248|46 50|yeast
P10851089A1248|62 75|ubiquitination
P10851089A1248|79 89|degradation
P10851089A1248|92 100|cell cycle
P10851089A1248|111 118|proteins
P10851267A0000|10 28|transcription factor
P10851267A0000|41 60|cell cycle progression
P10851267A0000|65 71|S-phase
P10851745A0624|13 19|fatigue
P10851745A0624|28 32|moods
P10851745A0624|44 49|health
P10851745A0624|50 54|sleep
P10851745A0624|55 60|safety
P10851745A0624|71 78|capacity
P10852221A0422|20 28|treatment
P10852221A0422|34 38|graft
P10852221A0422|67 72|period
P10852221A0422|87 93|surgery
P10852221A0422|107 112|effect
P10852221A0422|118 125|survival
P10852221A0422|147 153|neurons
P10852460A0170|3 15|relationships
P10852460A0170|21 39|blood concentrations
P10852460A0170|42 56|thyroid hormones
P10852460A0170|60 67|selenium
P10852460A0170|74 80|retinol
P10852460A0170|83 98|alpha-tocopherol
P10852460A0170|121 128|Northern
P10852460A0170|146 153|subjects
P10852460A0170|154 161|age range
P10852460A0170|185 192|criteria
P10852460A0170|197 211|SENIEUR protocol
P10852485A0477|7 12|Spring
P10852485A0477|28 32|Q gene
P10852485A0477|42 63|chromosome deletion line
P10852485A0477|113 117|Q gene
P10852953A0000|0 13|Investigations
P10852953A0000|30 35|slices
P10852953A0000|73 78|bursts
P10852953A0000|92 106|field potentials
P10852953A0000|112 130|gamma frequency range
P10852953A0000|160 170|oscillation
P10852953A0000|182 186|range
P10853059X0751|0 7|Karger AG
P10853059X0751|8 12|Basel
P10853778A0316|6 21|surgery bone cysts
P10853778A0316|44 53|bone grafts
P10853850A1103|31 40|challenges
P10853850A1103|85 105|inhalation provocation
P10854004A0788|57 68|FVR responses
P10854004A0788|67 79|noradrenaline
P10854004A0788|80 90|angiotensin
P10854004A0788|93 105|acetylcholine
P10854004A0788|109 121|nitroprusside
P10854699A0424|5 15|FGF-AS cDNAs
P10854699A0424|42 51|FGF-AS mRNA
P10854699A0424|69 82|splice variants
P10854699A0424|99 103|exons
P10854699A0424|113 126|FGF-AS sequence
P10855690A0870|18 24|results
P10855690A0870|37 45|MAP kinase
P10855690A0870|59 71|hPL-B enhancer
P10855690A0870|93 99|pathway
P10855793A1418|0 15|Characterization
P10855793A1418|54 58|genes
P10855793A1418|105 118|identification
P10855793A1418|123 132|candidates
P10855793A1418|136 140|genes
P10855793A1418|168 176|disorders
P10855796A1160|13 35|RNA hybridization studies
P10855796A1160|57 63|pattern
P10855796A1160|66 84|EphA8 gene expression
P10855796A1160|107 112|region
P10855796A1160|123 128|tectum
P10855796A1160|144 154|development
P10856298A0798|0 11|Transfection
P10856298A0798|14 18|cDNAs
P10856298A0798|33 39|enzymes
P10856298A0798|60 76|hamster ovary cells
P10856298A0798|93 97|level
P10856298A0798|106 111|growth
P10856298A0798|120 124|T339I
P10856298A0798|140 145|growth
P10856298A0798|149 153|level
P10856298A0798|184 189|enzyme
P10856491A0178|0 6|SETTING
P10856491A0178|7 16|University
P10856491A0178|19 34|Paris VII hospital
P10856491A0178|42 48|Patient
P10856491A0178|55 59|women
P10856491A0178|62 73|embolization
P10856491A0178|88 92|myoma
P10856491A0178|99 109|pregnancies
P10856805T0000|0 29|Improving fissure sealant quality
P10856805T0000|40 50|preparation
P10856805T0000|61 65|level
P10857215A0000|3 24|Menopause-Rating-Scale
P10857215A0000|25 28|MRS I
P10857215A0000|46 53|practice
P10857215A0806|3 7|MRS II
P10857215A0806|32 39|standard
P10857215A0806|44 53|instrument
P10857215A0806|71 80|population
P10857262A0186|3 9|protein
P10857262A0186|22 35|fruA transcript
P10857262A0186|74 85|type A protein
P10857262A0186|128 133|domain
P10857262A0186|149 153|exons
P10857751A0304|2 9|addition
P10857751A0304|13 25|mouse ortholog
P10857751A0304|26 39|Mharp/Smarcal1
P10857751A0304|55 83|Caenorhabditis elegans ortholog
P10857751A0304|84 89|CEHARP
P10857751A0304|108 122|GenBank database
P10858355A0920|0 11|Sparfloxacin
P10858355A0920|15 27|clinafloxacin
P10858355A0920|48 72|Enterococcus faecium SF2149
P10858355A0920|76 100|Enterococcus faecalis WH245
P10858988A0786|8 21|tryptase levels
P10858988A0786|23 27|serum
P10858988A0786|65 73|challenge
P10860131A0847|0 15|Tolterodine users
P10860131A0847|23 27|times
P10860196A0876|17 23|program
P10860196A0876|27 31|costs
P10860196A0876|88 92|years
P10860752A1601|3 10|presence
P10860752A1601|31 43|binding domain
P10860752A1601|52 60|mechanism
P10860752A1601|75 88|autoregulation
P10860752A1601|91 127|bacteriophage T4 DNA polymerase synthesis
P10860827A0399|0 7|Deletion
P10860827A0399|21 28|analyses
P10860827A0399|62 69|elements
P10860827A0399|76 81|region
P10860827A0399|101 114|CSX1 expression
P10860827A0399|117 130|cardiomyocytes
P10860846A0480|10 16|studies
P10860846A0480|33 40|mutation
P10860846A0480|46 65|AP2 core binding region
P10860846A0480|74 98|cotransfection experiments
P10860846A0480|106 124|AP2 expression vector
P10860846A0480|170 192|HGF gene promoter activity
P10861080A0433|15 22|transfer
P10861080A0433|25 36|IkappaBalpha
P10861080A0433|37 62|IkappaBalpha overexpression
P10861080A0433|66 75|production
P10861080A0433|78 86|TNF-alpha
P10861086A0259|2 26|reconstitution experiments
P10861086A0259|44 53|expression
P10861086A0259|69 76|cell line
P10861086A0259|88 96|Src kinase
P10861086A0259|138 156|gain-of-function Csk
P10861086A0259|168 174|Fc gamma
P10861086A0259|185 193|signaling
P10861086A0259|205 216|phagocytosis
P10861086A0259|236 241|manner
P10861086A0904|2 9|contrast
P10861086A0904|23 31|construct
P10861086A0904|32 36|a-Src
P10861086A0904|75 83|membranes
P10861086A0904|102 107|series
P10861086A0904|110 130|phagocytosis signaling
P10861906A0999|3 20|delta srb10 mutation
P10861906A0999|40 55|transcript levels
P10861906A0999|74 78|genes
P10861906A0999|103 110|mutation
P10861906A0999|120 134|transcript level
P10861906A0999|183 189|defects
P10861906A0999|200 211|DNA synthesis
P10861906A0999|215 221|meiosis
P10861906A1479|28 37|conditions
P10861906A1479|41 47|meiosis
P10861906A1479|65 80|transcript levels
P10861906A1479|83 87|KIN28
P10861906A1479|105 122|nitrogen starvation
P10861906A1479|152 163|alkalization
P10861906A1479|166 171|medium
P10861909A0502|3 12|pJR vectors
P10861909A0502|44 49|marker
P10861909A0502|147 151|genes
P10861909A0502|169 180|nmt1 promoter
P10861909A0502|228 250|transcription efficiency
P10861909A0502|275 285|cloning site
P10861909A0502|304 308|sites
P10861909A0502|315 330|restriction sites
P10862289A0289|14 20|montoux
P10862289A0289|34 39|adults
P10862289A0289|40 46|age/sex
P10862289A0289|65 71|control
P10862289A0289|92 97|bodies
P10862289A0289|99 108|A60 antigen
P10863048A0000|3 8|effect
P10863048A0000|34 44|cord lesions
P10863048A0000|64 71|activity
P10863048A0000|98 105|stimulus
P10863048A0000|116 125|distension
P10863352T0001|0 12|Franz Schubert
P10863352T0001|22 26|music
P10863352T0001|29 36|diseases
P10864271A0504|3 9|results
P10864271A0504|32 44|S. argyrostoma
P10864271A0504|49 61|dissemination
P10864271A0504|64 80|Trichinella larvae
P10864271A0504|83 88|nature
P10864271A0504|100 109|comparison
P10864271A0504|129 135|mammals
P10864271A0504|139 147|scavenger
P10864271A0504|164 171|behavior
P10864496A0401|3 32|equilibrium dissociation binding
P10864496A0401|47 57|interaction
P10864496A0401|73 93|nrgAB promoter fragment
P10864496A0401|111 120|conditions
P10864641A1400|5 11|results
P10864641A1400|27 35|N-glycans
P10864641A1400|74 83|HA molecule
P10864641A1400|92 101|regulators
P10864641A1400|104 123|influenza virus growth
P10864641A1400|131 136|glycan
P10864641A1400|139 144|Asn149
P10864641A1400|167 172|Asn123
P10864989A0484|0 6|RESULTS
P10864989A0484|10 21|introduction
P10864989A0484|62 70|reduction
P10864989A0484|90 95|median
P10864989A0484|108 114|numbers
P10864989A0484|128 133|median
P10864989A0484|161 178|separation efficacy
P10864989A0484|186 199|separation time
P10865422A0138|16 28|serum ferritin
P10865422A0138|33 42|hemoglobin
P10865422A0138|46 50|level
P10865422A0138|69 77|histories
P10865422A0138|80 88|donations
P10865422A0138|92 110|iron supplementation
P10865838A0000|19 30|growth factor
P10865838A0000|44 50|agonist
P10865838A0000|72 76|cells
P10865838A0000|85 93|migration
P10865838A0000|97 104|division
P10865838A0000|126 130|cells
P10865940A0000|14 44|agent pyrrolidine dithiocarbamate
P10865940A0000|83 87|cells
P10865940A0000|141 159|NF-kappaB activation
P10866323A0666|19 25|effects
P10866323A0666|28 48|SIE-1 hypermethylation
P10866323A0666|51 66|p21WAF1 induction
P10866323A0666|69 82|STAT activation
P10866677A1839|28 35|peptides
P10866677A1839|57 61|mouse
P10866677A1839|88 95|extracts
P10866689A0295|10 23|SAOS-2 cell line
P10866689A0295|50 64|reporter plasmid
P10866689A0295|78 93|tal-1 binding site
P10866689A0295|125 132|activity
P10866689A0295|134 147|tal-1-E12-Lmo2
P10866689A0295|151 178|tal-1-E12-Lmo2-Ldb1 complexes
P10866689A0295|192 211|tal-1-E12 heterodimer
P10866886A1277|4 9|effect
P10866886A1277|22 32|conjunction
P10866886A1277|37 45|oxycodone
P10866886A1277|60 77|mu-receptor agonist
P10867199A0230|2 9|contrast
P10867199A0230|28 35|criteria
P10867199A0230|67 73|studies
P10867199A0230|85 89|level
P10867199A0230|131 142|insect orders
P10867496T0001|0 16|Neurofibromatosis
P10867496T0001|22 27|breast
P10867496T0001|31 37|patient
P10867496T0001|42 64|Morbus von Recklinghausen
P10868488A0921|14 19|period
P10868488A0921|32 41|aggression
P10868488A0921|74 90|testosterone level
P10869076A1384|5 11|results
P10869076A1384|22 31|hypothesis
P10869076A1384|41 48|presence
P10869076A1384|51 60|tryptophan
P10869076A1384|64 71|ribosome
P10869076A1384|101 106|access
P10869076A1384|119 126|rut sites
P10869076A1384|143 166|transcription termination
P10869465A1054|6 18|hybridization
P10869465A1054|35 43|RNA probes
P10869465A1054|63 79|expression changes
P10869465A1054|90 95|clones
P10869465A1054|111 117|changes
P10869465A1054|128 141|germ cell stages
P10869465A1054|155 163|cell types
P10869465A1054|164 170|Sertoli
P10869465A1054|197 201|cells
P10870043A0621|3 16|administration
P10870043A0621|22 32|GnRH agonist
P10870043A0621|43 60|bone mineral density
P10870043A0621|71 75|femur
P10870043A0621|95 106|control group
P10870391T0034|0 9|Prevention
P10870391T0034|22 30|diagnosis
P10870391T0034|34 40|therapy
P10870391T0034|43 56|travel diarrhea
P10871045A1221|4 8|study
P10871045A1221|18 26|C/EBPbeta
P10871045A1221|43 54|C/EBP isoform
P10871045A1221|71 83|stellate cells
P10871045A1221|100 115|C/EBPbeta protein
P10871045A1221|119 134|C/EBPbeta binding
P10871045A1221|146 161|C/EBP binding site
P10871045A1221|167 174|promoter
P10871045A1221|196 201|effect
P10871045A1221|204 215|acetaldehyde
P10871347A0477|0 15|Mutation analysis
P10871347A0477|35 45|motif TCCCCT
P10871347A0477|59 74|PyRo1 interaction
P10871379A0261|15 37|transactivation function
P10871379A0261|39 43|Luman
P10871412A0369|18 23|rounds
P10871412A0369|26 34|selection
P10871412A0369|37 55|focus formation assay
P10871412A0369|69 76|ribozyme
P10871412A0369|77 81|Rz007
P10871842A0988|3 9|results
P10871842A0988|21 40|proteasome inhibition
P10871842A0988|48 59|upregulation
P10871842A0988|70 76|members
P10871842A0988|79 105|transcription factor families
P10871842A0988|125 138|stress response
P10871842A0988|142 154|proliferation
P10872473A2286|3 15|ATR-X syndrome
P10872473A2286|27 35|mutations
P10872473A2286|41 47|XH2 gene
P10872473A2286|60 70|X chromosome
P10872473A2286|71 76|Xq13.3
P10872473A2286|100 105|factor
P10872473A2286|120 133|gene expression
P10872535A0000|53 59|factors
P10872535A0000|74 85|birthweights
P10872535A0000|88 92|twins
P10872535A0000|106 119|susceptibility
P10872535A0000|122 129|diabetes
P10872535A0000|154 162|responses
P10872535A0000|172 191|glucose tolerance test
P10872535A0000|218 228|association
P10872535A0000|241 262|birthweight differences
P10872535A0000|275 287|abnormalities
P10872756A1325|2 10|NASCIS III
P10872756A1325|12 33|randomization imbalance
P10872756A1325|72 77|number
P10872756A1325|80 87|patients
P10872756A1325|94 105|motor deficit
P10872756A1325|120 125|chance
P10872756A1325|129 136|recovery
P10872756A1325|147 162|dose control group
P10872827A0000|0 16|Penicillin acylase
P10872827A0000|40 48|ATCC11105
P10872827A0000|62 72|heterodimer
P10872827A0000|98 104|subunit
P10872827A0000|120 126|subunit
P10872831A0000|16 26|sequence tag
P10872831A0000|39 46|homology
P10872831A0000|50 71|erythropoietin receptor
P10872831A0000|96 106|EST database
P10872851A0714|46 56|tachycardia
P10872851A0714|120 124|LVEDP
P10873158A0000|0 9|Activation
P10873158A0000|19 24|factor
P10873158A0000|28 33|kappaB
P10873158A0000|61 74|gene expression
P10873158A0000|82 87|airway
P10873158A0000|98 102|cells
P10873158A0000|125 130|stress
P10873286X0000|0 11|GAP JUNCTIONS
P10873286X0000|17 21|BRAIN
P10873286X0000|22 28|PREFACE
P10873386A0000|45 53|mouse gene
P10873386A0000|60 68|C2 subunit
P10873386A0000|74 86|20S proteasome
P10873387A0816|43 57|Cacna1f gene maps
P10873387A0816|83 104|mouse synaptophysin gene
P10873387A0816|106 111|region
P10873388A0623|12 23|Rhotekin cDNA
P10873388A0623|27 31|probe
P10873388A0623|32 52|Northern hybridization
P10873388A0623|72 81|transcript
P10873388A0623|101 105|level
P10873388A0623|108 115|prostate
P10873388A0623|128 132|level
P10873388A0623|141 147|tissues
P10873388A0623|178 182|liver
P10873388A0623|186 196|lung tissues
P10874044A0647|9 21|co-expression
P10874044A0647|42 47|mutant
P10874044A0647|50 57|p38alpha
P10874044A0647|122 136|pE1-luc activity
P10874151A0000|0 9|BACKGROUND
P10874151A0000|10 31|Gamma knife radiosurgery
P10874151A0000|56 66|alternative
P10874151A0000|68 74|surgery
P10874151A0000|90 96|lesions
P10878398A0542|14 21|patients
P10878398A0542|37 41|group
P10878398A0542|41 52|leptin levels
P10878398A0542|90 101|CAPD patients
P10878398A0542|117 121|group
P10878606A0876|29 38|structures
P10878606A0876|54 59|organs
P10878606A0876|97 108|interactions
P10878675A1278|0 9|CONCLUSION
P10878675A1278|30 47|antagonist idazoxan
P10878675A1278|83 90|activity
P10878675A1278|97 113|energy expenditure
P10878675A1278|121 128|subjects
P10878944A0000|8 37|diphtheria toxin polymer particle
P10878944A0000|48 52|agent
P10878944A0000|67 74|DiaMed AG
P10878944A0000|75 85|Switzerland
P10878944A0000|111 120|laboratory
P10878944A0000|123 131|Institute
P10878944A0000|134 152|Childhood Infections
P10880486A0790|28 36|mutations
P10880486A0790|77 82|zipper
P10880486A0790|97 105|RhoA locus
P10880702A0966|12 18|results
P10880702A0966|39 46|exposure
P10880702A0966|49 59|amphetamine
P10880702A0966|62 72|apomorphine
P10880702A0966|102 110|component
P10880702A0966|113 125|sensitization
P10880702A0966|128 138|amphetamine
P10880702A0966|171 178|behavior
P10881275T0000|10 24|serum IgM binding
P10881275T0000|27 40|GM1 ganglioside
P10881275T0000|51 58|practice
P10882163A1077|0 17|Objective responses
P10882163A1077|32 38|studies
P10882163A1077|68 77|exemestane
P10882163A1077|82 88|failure
P10882163A1077|91 107|aminoglutethimide
P10882163A1077|116 125|exemestane
P10882163A1077|128 133|mg/day
P10882163A1077|153 171|aromatase inhibitors
P10882163A1077|181 190|exemestane
P10882163A1077|192 197|mg/day
P10882213A0163|0 5|Topics
P10882213A0163|44 54|association
P10882213A0163|56 63|myositis
P10882213A0163|68 73|cancer
P10882213A0163|91 101|evaluations
P10882213A0163|105 114|malignancy
P10882213A0163|118 132|myositis patient
P10882213A0163|135 142|approach
P10882213A0163|148 157|assessment
P10882213A0163|160 167|patients
P10882213A0163|172 198|dermatomyositis sine myositis
P10882213A0163|202 211|usefulness
P10882213A0163|250 264|classifications
P10882213A0163|266 275|discussion
P10882213A0163|285 293|childhood
P10882213A0163|302 309|myositis
P10882213A0163|331 338|entities
P10882213A0163|340 345|review
P10882213A0163|363 369|factors
P10882213A0163|393 402|management
P10882213A0163|405 420|myositis patients
P10882213A0163|428 437|approaches
P10882213A0163|446 456|limitations
P10882213A0163|469 483|disease activity
P10882213A0163|487 492|damage
P10882462T0000|3 9|science
P10882462T0000|12 28|tissue engineering
P10882850A0000|0 11|Endonuclease
P10882850A0000|40 53|DNA glycosylase
P10882850A0000|68 74|removal
P10882850A0000|85 106|pyrimidine base residues
P10884978A0633|3 10|duration
P10884978A0633|21 29|hyperemia
P10884978A0633|43 47|aging
P10884978A0633|54 63|difference
P10884978A0633|71 75|males
P10884978A0633|79 85|females
P10885708T0000|8 23|bile duct blockage
P10885708T0000|24 28|entry
P10885708T0000|44 48|agent
P10885708T0000|67 73|abscess
P10885731A0915|15 19|study
P10885731A0915|30 35|impact
P10885731A0915|38 56|synthesis conditions
P10885731A0915|59 69|block length
P10885731A0915|73 85|crystallinity
P10885731A0915|92 97|impact
P10885731A0915|117 129|crystallinity
P10885731A0915|133 142|solubility
P10885731A0915|148 155|polymers
P10885750A0236|40 47|function
P10885750A0236|50 55|CREB-2
P10885750A0236|67 77|development
P10885750A0236|80 94|organ physiology
P10886067A0520|8 15|diameter
P10886067A0520|22 30|thickness
P10886067A0520|36 40|rotor
P10887912A0740|19 36|maximum EMG activity
P10887912A0740|46 53|masseter
P10887912A0740|72 88|temporalis muscles
P10887912A0740|121 130|muscle pain
P10887912A0740|138 148|subjects bit
P10887921A0718|0 10|CONCLUSIONS
P10887921A0718|19 26|relation
P10887921A0718|32 41|topography
P10887921A0718|54 63|field areas
P10887921A0718|112 118|rim area
P10887921A0718|142 150|diagnosis
P10887921A0718|153 161|follow-up
P10887921A0718|173 180|glaucoma
P10888570A0678|8 16|alkaloids
P10888570A0678|39 45|Atzimba
P10888570A0678|45 49|Lopez
P10888570A0678|50 57|Marciana
P10888570A0678|58 65|Montsama
P10888570A0678|66 70|Murca
P10888570A0678|74 79|Puebla
P10888570A0678|95 100|limits
P10888570A0678|115 124|food safety
P10889399A0243|3 22|detection success rate
P10889399A0243|48 54|markers
P10890911A0470|16 20|Smad3
P10890911A0470|47 58|HMG box domain
P10890911A0470|74 80|TGFbeta
P10890911A0470|83 93|Wnt pathways
P10890911A0470|113 125|transcription
P10890911A0470|131 153|Xenopus homeobox gene twin
P10891093A0000|3 23|transmembrane topology
P10891093A0000|32 44|exchanger NHE3
P10891093A0000|69 93|transcription/translation
P10891093A0000|99 103|types
P10891093A0000|106 118|fusion vectors
P10891093A0000|133 159|membrane insertion properties
P10891093A0000|162 174|cDNA sequences
P10891093A0000|191 202|NHE3 membrane
P10891093A0000|211 217|domains
P10891266A0421|0 4|ACE-2
P10891266A0421|20 28|C terminus
P10891266A0421|31 35|H type
P10891286A0000|0 6|Members
P10891286A0000|12 23|titin/myosin
P10891286A0000|29 45|chain kinase family
P10891286A0000|72 83|organization
P10891286A0000|88 111|actin/myosin cytoskeleton
P10891286A0000|133 140|assembly
P10891286A0000|144 151|function
P10891399A1185|15 24|activation
P10891399A1185|27 33|c-fosER
P10891399A1185|57 66|inhibition
P10891399A1185|73 81|Cip1/WAF1
P10891399A1185|114 121|AP-1 site
P10891399A1185|151 155|c-fos
P10891399A1185|165 171|control
P10891399A1185|174 182|cell cycle
P10891399A1185|193 197|genes
P10891441A0871|12 35|pTyr317 Shc phosphopeptide
P10891441A0871|81 90|p85 subunit
P10891441A0871|90 109|phosphatidylinositol
P10891441A0871|111 116|kinase
P10891441A0871|121 129|mast cells
P10891441A0871|147 162|mass spectrometry
P10891489A0152|17 26|expression
P10891489A0152|32 46|HMG-I/Y proteins
P10891489A0152|71 83|proliferation
P10891489A0152|94 107|transformation
P10891489A0152|123 129|cancers
P10891489A0152|146 153|proteins
P10891489A0152|158 169|pathogenesis
P10891489A0152|172 181|malignancy
P10891632A0435|3 34|naltrexone/lofexidine combination
P10891632A0435|62 71|resolution
P10891632A0435|83 100|withdrawal syndrome
P10891632A0435|126 142|treatment schedule
P10891632A0435|161 169|increases
P10891632A0435|172 189|withdrawal symptoms
P10891632A0435|203 214|side-effects
P10892300A0268|8 15|symptoms
P10892300A0268|26 35|calcinosis
P10892300A0268|47 51|March
P10892300A0268|84 105|locomotor abnormalities
P10892823A1040|0 8|Screening
P10892823A1040|9 18|counseling
P10892823A1040|22 30|treatment
P10892823A1040|34 40|alcohol
P10892823A1040|51 57|drug use
P10892823A1040|75 84|components
P10892823A1040|100 106|HBP care
P10893243T0000|15 24|regulation
P10893243T0000|30 34|mouse
P10893243T0000|44 89|chaperonin subunit gene Ccta/t-complex polypeptide
P10893243T0000|93 127|selenocysteine tRNA gene transcription
P10893243T0000|138 167|factor family zinc finger proteins
P10893258T0000|11 25|protein response
P10893258T0000|43 49|aspects
P10893258T0000|64 88|membrane protein biogenesis
P10893258T0000|103 125|reticulum quality control
P10894149T0000|26 33|receptor
P10894149T0000|45 51|protein
P10894149T0000|80 89|activation
P10894149T0000|107 115|receptors
P10894149T0000|125 142|orphan receptors SF1
P10894149T0000|156 161|factor
P10894149T0000|166 174|ERRalpha1
P10894149T0000|175 182|estrogen
P10894149T0000|190 204|receptor alpha-1
P10894816A0836|0 6|Studies
P10894816A0836|13 27|reporter plasmid
P10894816A0836|71 77|element
P10894816A0836|111 118|response
P10894886A0375|20 25|subset
P10894886A0375|28 33|tumors
P10894886A0375|49 55|changes
P10894886A0375|63 67|genes
P10895417A0000|31 38|delivery
P10895417A0000|40 47|morphine
P10895417A0000|76 84|liposomes
P10895417A0000|85 110|DepoFoam drug delivery system
P10895417A0000|129 137|clearance
P10895417A0000|140 147|morphine
P10895417A0000|161 169|analgesia
P10895417A0669|9 17|EPI-C0401
P10895417A0669|24 29|saline
P10895417A0669|32 46|DepoFoam vehicle
P10895417A0669|83 97|food consumption
P10895417A0669|97 103|arousal
P10895417A0669|104 121|hindlimb muscle tone
P10895417A0669|125 139|body temperature
P10895851A0696|0 16|Bailey Instruments
P10895851A0696|20 39|Owen Mumford filaments
P10896008A0531|0 11|PARTICIPANTS
P10896008A0531|23 28|sample
P10896008A0531|41 51|outpatients
P10896008A0531|66 70|motor
P10896008A0531|81 90|neuropathy
P10896008A0531|119 127|dystrophy
P10896008A0531|146 153|controls
P10896859A0000|3 8|effect
P10896859A0000|11 26|water deprivation
P10896859A0000|42 52|Na excretion
P10896859A0000|84 88|sheep
P10896859A0000|120 127|infusion
P10896859A0000|130 140|aldosterone
P10896859A0000|144 151|cortisol
P10896859A0000|164 175|steroid sheep
P10896859A0838|17 21|cause
P10896859A0838|48 58|Na retention
P10897233A1057|0 9|CONCLUSION
P10897233A1057|19 23|fever
P10897233A1057|29 40|Nazareth area
P10897973T0001|0 24|Antithrombin III deficiency
P10897973T0001|29 38|substitute
P10897973T0001|43 49|heparin
P10897973T0001|60 72|Thrombosis ABC
P10897973T0001|85 96|antithrombin
P10898795A0527|8 12|class
P10898795A0527|19 37|histone deacetylases
P10898795A0527|38 42|HDACs
P10898795A0527|114 120|classes
P10898795A0527|121 125|HDACs
P10899128A0661|14 20|example
P10899128A0661|34 59|transcription factor complex
P10899128A0661|75 82|MADS-box
P10899128A0661|87 101|forkhead protein
P10899128A0661|119 130|implications
P10899128A0661|137 146|regulation
P10899128A0661|158 171|gene expression
P10899142A0000|17 24|Berkeley
P10899142A0000|35 55|Genome Project database
P10899142A0000|60 68|sequences
P10899142A0000|139 146|receptor
P10899142A0000|165 170|DLGR-1
P10899142A0000|213 218|DLGR-2
P10900129A0138|0 16|Degenerate primers
P10900129A0138|44 50|regions
P10900129A0138|58 71|CYP3A sequences
P10900129A0138|90 96|RT-PCRs
P10900269A0396|4 8|cells
P10900269A0396|58 71|polypurine site
P10900269A0396|92 98|TK genes
P10900269A0396|99 111|recombination
P10900269A0396|125 135|frequencies
P10900269A0396|141 145|range
P10900269A0396|169 178|background
P10901133A0381|0 15|Methyllevamisole
P10901133A0381|36 43|standard
P10902348A0566|0 15|Resistance ratios
P10902348A0566|27 38|field strains
P10902348A0566|49 58|comparison
P10902348A0566|66 73|R5 strain
P10902348A0566|103 113|application
P10902348A0566|135 148|glass jar method
P10903440A0515|4 14|transcripts
P10903440A0515|26 31|TSGF-2
P10903440A0515|45 49|ovary
P10903440A0515|53 65|testes tissues
P10903440A0515|68 73|adults
P10903440A0515|84 90|puparia
P10903440A0515|148 153|stages
P10903495A0533|3 21|gel retardation assay
P10903495A0533|27 31|HepG2
P10903495A0533|39 46|extracts
P10903495A0533|59 66|sequence
P10903583T0000|0 10|Reliability
P10903583T0000|21 25|range
P10903583T0000|28 33|motion
P10903583T0000|42 46|OSI CA
P10903583T0000|51 69|spine motion analyser
P10903583T0000|98 105|subjects
P10903733A0540|0 31|Coimmunoprecipitation experiments
P10903733A0540|54 58|cells
P10903733A0540|104 109|factor
P10903733A0540|116 120|TRAF2
P10903733A0540|123 142|TRAF3 adaptor proteins
P10903837A1208|8 15|RINX gene
P10903837A1208|26 33|ortholog
P10903837A1208|39 54|goldfish Vsx1 gene
P10903837A1208|85 109|Gene Nomenclature Committee
P10903843A0447|14 25|localization
P10903843A0447|34 43|chromosome
P10903843A0447|56 62|cluster
P10903843A0447|74 78|genes
P10903843A0447|110 114|Tapa1
P10903843A0447|118 127|Kcnq1 genes
P10903877A0879|0 9|Activation
P10903877A0879|40 48|forskolin
P10903877A0879|50 59|inhibition
P10903877A0879|69 79|calphostin C
P10903877A0879|101 108|decrease
P10903877A0879|111 121|3TP activity
P10903877A0879|137 153|ERK kinase activity
P10904191A0000|10 14|study
P10904191A0000|39 49|sensitivity
P10904191A0000|53 63|specificity
P10904191A0000|66 70|AMP CT
P10904191A0000|71 91|Gen-Probe Incorporated
P10904191A0000|92 99|San Diego
P10904191A0000|121 129|specimens
P10904191A0000|148 155|patients
P10904191A0000|166 174|void urine
P10904191A0000|180 188|specimens
P10904191A0000|204 211|patients
P10905349A0329|0 5|Mus81p
P10905349A0329|16 23|homology
P10905349A0329|28 33|motifs
P10905349A0329|44 69|XPF endonuclease superfamily
P10905349A0609|12 19|analysis
P10905349A0609|32 37|Rad54p
P10905349A0609|41 46|Mus81p
P10905349A0609|55 61|pathway
P10905349A0609|68 73|repair
P10905349A0609|78 86|tolerance
P10905349A0609|99 107|DNA damage
P10905352A0000|9 20|plasmid pCLU1
P10905352A0000|28 32|yeast
P10905352A0000|46 51|lactis
P10905352A0000|75 83|cytoplasm
P10905352A0000|101 106|helper
P10905352A0000|112 123|plasmid pGKL2
P10905352A0000|137 143|protein
P10905352A0000|151 156|primer
P10906176A0000|23 32|transposon
P10906176A0000|32 37|family
P10906176A0000|40 48|sequences
P10906176A0000|73 79|mutagen
P10906176A0000|85 95|mouse genome
P10906317A0351|22 30|variables
P10906317A0351|46 54|hemifield
P10906317A0351|63 67|right
P10906317A0351|73 82|proportion
P10906317A0351|85 90|trials
P10906317A0351|101 105|shift
P10906317A0351|116 124|hemifield
P10906999T0000|3 13|measurement
P10906999T0000|32 38|systems
P10906999T0000|43 59|chemiluminescence
P10907348A0508|11 22|examinations
P10907348A0508|43 52|metabolism
P10907348A0508|70 86|PTH concentrations
P10907348A0508|88 97|blood serum
P10907348A0508|104 111|activity
P10907348A0508|114 126|bone isoenzyme
P10907971A0806|0 11|Atorvastatin
P10907971A0806|36 60|HMG-CoA reductase inhibitor
P10907971T0000|16 25|assessment
P10907971T0000|28 59|HMG-CoA reductase inhibitor therapy
P10907971T0000|62 69|analysis
P10907971T0000|80 90|CURVES study
P10908317A1459|21 28|E domains
P10908317A1459|39 47|receptors
P10908317A1459|68 78|replacement
P10908317A1459|85 90|domain
P10908317A1459|109 119|counterpart
P10908317A1459|135 154|estradiol sensitivity
P10908317A1459|160 167|increase
P10908317A1459|173 181|magnitude
P10908317A1459|184 198|transactivation
P10908364A0000|0 4|G-DNA
P10908364A0000|21 32|DNA structure
P10908364A0000|62 66|roles
P10908462A3159|3 15|effectiveness
P10908462A3159|57 65|intensity
P10908462A3159|77 83|support
P10908462A3159|97 102|smoker
P10908478A0717|0 16|SELECTION CRITERIA
P10908478A0717|30 35|trials
P10908478A0717|41 46|adults
P10908478A0717|51 63|schizophrenia
P10908478A0717|73 81|illnesses
P10908478A0717|98 107|quetiapine
P10908478A0717|108 114|placebo
P10908478A0717|133 137|drugs
P10908478A0717|164 171|outcomes
P10909973A1508|2 9|contrast
P10909973A1508|13 18|action
P10909973A1508|21 25|GLP-1
P10909973A1508|51 64|cotransfection
P10909973A1508|68 74|M1-CREB
P10909973A1508|77 83|isoform
P10909973A1508|94 115|consensus serine residue
P10909973A1508|125 133|substrate
P10909973A1508|149 163|phosphorylation
P10910073A0876|10 25|PDGFbetaR fusions
P10910073A0876|50 57|splicing
P10910073A0876|101 113|amplification
P10910073A0876|131 140|patient RNA
P10910439A1196|0 10|CONCLUSIONS
P10910439A1196|22 33|hypertension
P10910439A1196|41 51|protein load
P10910439A1196|60 67|decrease
P10910439A1196|112 120|treatment
P10910908A0767|4 10|finding
P10910908A0767|27 51|PI3K-Akt activation pathway
P10910908A0767|85 90|effect
P10913094A0424|4 15|DNA fragments
P10913094A0424|92 97|cycles
P10913094A0424|100 125|gel mobility shift-PCR method
P10913172A0442|32 36|motif
P10913172A0442|51 63|Rad24 function
P10913172A0442|85 90|lysine
P10913172A0442|93 99|residue
P10913172A0442|106 110|motif
P10913276A0510|32 37|domain
P10913276A0510|61 71|interaction
P10913276A0510|78 96|PLC-gamma1 SH3 domain
P10913276A0684|13 29|expression studies
P10913276A0684|55 63|SH3 domain
P10913276A0684|66 75|PLC-gamma1
P10913276A0684|93 103|association
P10913304A0894|11 18|Ets mRNAs
P10913304A0894|45 53|GABPalpha
P10913304A1180|2 13|kb transcript
P10913304A1180|29 33|brain
P10913304A1180|61 70|kDa protein
P10913304A1180|83 89|protein
P10913304A1180|116 124|Ets domain
P10913304A1180|151 156|domain
P10913304A1180|170 177|homology
P10915728A0216|14 21|patients
P10915728A0216|26 34|cirrhosis
P10915728A0216|56 61|groups
P10915728A0216|64 71|patients
P10915728A0216|91 95|units
P10915728A0216|105 112|IFN-beta
P10915728A0216|130 135|months
P10915728A0216|140 147|patients
P10915728A0216|155 164|IFN therapy
P10915780A1063|0 18|Wnt-1 overexpression
P10915780A1063|38 42|cells
P10915780A1063|50 61|cyclin D1 mRNA
P10915780A1063|73 86|overexpression
P10915780A1063|89 93|Wnt-1
P10915780A1063|106 110|gland
P10915780A1063|142 152|ILK activity
P10915780A1063|155 168|cyclin D1 levels
P10917402T0000|21 34|administration
P10917402T0000|37 49|amitriptyline
P10917402T0000|52 59|patients
P10917402T0000|69 78|depression
P10918059A0569|0 7|Deletion
P10918059A0569|13 21|RVH domain
P10918059A0569|52 61|activation
P10918164A0878|8 25|regression analysis
P10918164A0878|38 47|physicians
P10918164A0878|55 59|times
P10918164A0878|82 88|lesions
P10918164A0878|121 129|detectors
P10918164A0878|130 148|% confidence interval
P10918440T0000|0 28|Erythema exsudativum multiforme
P10918440T0000|38 48|granulocyte
P10918440T0000|67 72|factor
P10918440T0000|97 114|blood stem cell donor
P10918572A0794|39 43|ErbB2
P10918572A0794|52 56|ErbB1
P10918572A0794|57 61|ErbB3
P10918572A0794|64 68|ErbB4
P10918572A1547|5 16|interactions
P10918572A1547|33 41|TGF-alpha
P10918572A1547|48 52|ErbBs
P10918572A1547|64 78|ErbB2 activation
P10918572A1547|109 120|consequences
P10918572A1547|145 163|TGF-alpha precursors
P10918572A1547|186 198|ErbB signaling
P10918596A0000|26 38|p53 C-terminus
P10918596A0000|74 81|activity
P10918596A0000|95 102|molecule
P10918599A0071|2 9|contrast
P10918599A0071|23 27|E2F-3
P10918599A0071|53 64|G1/S boundary
P10918599A0071|65 70|E2F-3B
P10918599A0071|94 102|cell cycle
P10918599A0071|111 116|levels
P10918612A0000|3 24|transcription factor Jun
P10918612A0000|25 29|c-Jun
P10918612A0000|66 78|growth signals
P10918612A0000|98 105|patterns
P10918612A0000|108 121|gene expression
P10918943T0000|13 20|toxicity
P10918943T0000|26 30|class
P10918943T0000|48 62|agent almokalant
P10918948A0110|4 11|compound
P10918948A0110|30 39|metabolite
P10918948A0110|42 52|trimebutine
P10918948A0110|55 62|Debridat
P10918948A0110|116 123|diseases
P10919971A0606|2 9|addition
P10919971A0606|15 20|effect
P10919971A0606|36 53|neutrophil response
P10919971A0606|65 72|exercise
P10919971A0606|73 80|vitamin E
P10919971A0606|95 102|increase
P10919971A0606|116 137|creatine kinase activity
P10919971A0606|172 183|muscle repair
P10920186A0528|14 22|formation
P10920186A0528|34 42|templates
P10920186A0528|50 60|fusion point
P10920186A0528|74 83|transcript
P10920186A0528|108 117|MLL primers
P10920906A0759|0 9|CONCLUSION
P10920906A0759|13 19|authors
P10920906A0759|43 52|management
P10920906A0759|102 107|margin
P10921197A0179|0 11|Measurements
P10921197A0179|43 66|treatment planning systems
P10921197A0179|85 99|ADAC Pinnacle3 V4
P10924061A0588|0 9|Activation
P10924061A0588|52 60|treatment
P10925159A1353|7 12|MARTA1
P10925159A1353|39 45|lysates
P10925159A1353|76 84|fractions
P10925159A1353|97 104|extracts
P10925159A1353|105 110|MARTA2
P10925159A1353|146 165|salt-wash preparation
P10925207A0634|12 16|exons
P10925207A0634|29 40|kb transcript
P10925207A0634|98 104|regions
P10926776A0731|9 20|PDP1 isoforms
P10926776A0731|32 43|substitution
P10926776A0731|46 54|insertion
P10926776A0731|57 66|amino acids
P10926776A0731|93 99|protein
P10928179A0101|10 18|technique
P10928179A0101|37 47|examination
P10928179A0101|50 67|sentinel lymph nodes
P10928179A0101|86 91|debate
P10928337A0590|7 16|correction
P10928337A0590|19 24|anemia
P10928337A0590|45 58|erythropoietin
P10928337A0590|96 101|volume
P10928477A0764|4 8|study
P10928477A0764|28 42|PFA-100 analyzer
P10928477A0764|75 90|platelet function
P10928477A0764|105 119|platelet defects
P10928477A0764|129 139|shear stress
P10928477A0764|149 166|patient populations
P10930526A0174|30 36|cloning
P10930526A0174|40 51|PL scramblase
P10930526A0174|59 66|HuPLSCR1
P10930526A0174|70 80|mouse origin
P10931524A0313|22 29|activity
P10931524A0313|75 82|sequence
P10931524A0313|107 111|assay
P10931927A0655|7 20|oligomer duplex
P10931927A0655|23 28|GGGTTA
P10931927A0655|28 33|TAACCC
P10931927A0655|41 55|template-primer
P10931927A0655|72 85|Klenow fragment
P10931927A0655|103 115|DNA polymerase
P10931927A0655|132 144|transcriptase
P10931927A0655|155 174|telomere DNA sequences
P10931927A0655|187 194|products
P10931927A0655|220 230|template DNA
P10931950A0869|40 51|tumor lysates
P10931950A0869|98 108|T187A mutant
P10931960A0630|11 28|avirulence activity
P10931960A0630|37 45|mutations
P10931960A0630|72 87|activation domain
P10931960A0630|101 108|addition
P10931960A0630|114 129|activation domain
P10931960A0630|137 149|herpes simplex
P10931960A0630|155 165|protein VP16
P10932196A0359|0 8|Mutations
P10932196A0359|14 21|RP2 locus
P10932196A0359|24 29|Xp11.3
P10932196A0359|57 68|XLRP patients
P10932196A0359|83 96|linkage studies
P10932329A0597|3 7|limit
P10932329A0597|18 22|cecum
P10932329A0597|38 42|colon
P10932329A0597|67 91|sulcus cecocolicus dorsalis
P10932329A0597|95 103|ventralis
P10932527A0947|25 31|healing
P10932527A0947|60 76|epithelialization
P10932527A0947|96 107|inflammation
P10932527T0000|3 15|effectiveness
P10932527T0000|21 44|haemodialysate Solcoseryl
P10932527T0000|64 75|wound healing
P10932527T0000|78 83|horses
P10932527T0000|87 92|ponies
P10932679A0049|21 28|evidence
P10932679A0049|33 47|diet composition
P10932679A0049|84 93|absorption
P10932679A0049|95 105|expenditure
P10932679A0049|108 113|energy
P10932679A0049|141 150|food intake
P10933154A1118|5 12|findings
P10933154A1118|31 38|analysis
P10933154A1118|64 79|donor transplants
P10933154A1118|92 100|rejection
P10933728A1398|5 11|results
P10933728A1398|63 82|EBNA2 transactivation
P10933728A1398|96 111|hnRNP protein AUF1
P10933728A1398|120 128|component
P10933728A1398|155 162|evidence
P10933728A1398|175 182|sequence
P10933728A1398|193 210|CBF1 binding element
P10933728A1398|229 242|responsiveness
P10933728A1398|245 249|EBNA2
P10933732A0000|3 8|genome
P10933732A0000|19 29|herpesvirus
P10933732A0000|31 35|HHV-8
P10933732A0000|45 51|cluster
P10933732A0000|58 70|reading frames
P10933732A0000|85 92|proteins
P10933732A0000|96 103|homology
P10933732A0000|117 136|transcription factors
P10933732A0000|142 151|interferon
P10933732A0000|162 167|factor
P10933732A0000|173 178|family
P10934073A1433|12 22|limitations
P10934073A1433|26 37|CHIME monitor
P10934073A1433|48 58|opportunity
P10934310A0698|0 12|DATA SYNTHESIS
P10934310A0698|26 35|ultrasound
P10934310A0698|73 82|weaknesses
P10934310A0698|93 103|angiography
P10934640A1114|0 9|TB bone area
P10934640A1114|19 24|height
P10934640A1114|32 36|years
P10934640A1114|45 50|colony
P10934640A1114|62 67|menses
P10934640A1114|84 88|TB BMC
P10934751T0001|0 12|CREST syndrome
P10934751T0001|30 41|significance
P10935488A1033|0 11|Troglitazone
P10935488A1033|35 53|PPARgamma target gene
P10935488A1033|56 63|T24 cells
P10935488A1033|83 100|acid binding protein
P10935488A1033|101 106|A-FABP
P10935488A1033|110 119|expression
P10935488A1033|141 168|bladder cancer differentiation
P10935880A1049|0 6|Viruses
P10935880A1049|24 28|lungs
P10935880A1049|34 38|PI-3V
P10935880A1049|44 54|NCP BVDV type
P10935880A1049|68 73|BVHV-1
P10936051T0000|3 7|RS447
P10936051T0000|13 25|megasatellite
P10936051T0000|42 49|sequence
P10936051T0000|79 84|enzyme
P10936051T0000|100 107|promoter
P10936920A0105|8 17|experience
P10936920A0105|49 56|elements
P10936920A0105|61 70|generation
P10936920A0105|84 93|prediction
P10938102A0265|18 23|effect
P10938102A0265|35 41|targets
P10938102A0265|44 67|NS1 influenza virus protein
P10938102A0265|81 98|translation factors
P10938102A1359|53 57|model
P10938102A1359|75 80|eIF4GI
P10938102A1359|110 115|region
P10938102A1359|164 174|translation
P10938102A1359|178 201|influenza virus messengers
P10938102T0000|10 39|translation initiation factor 4GI
P10938102T0000|51 56|target
P10938102T0000|60 69|NS1 protein
P10938102T0000|84 92|activator
P10938102T0000|95 108|influenza virus
P10938105A0000|0 7|Splicing
P10938105A0000|40 69|fibroblast growth factor receptor
P10938105A0000|105 116|sequence IAS1
P10938105A0000|150 159|splice site
P10938109A1361|10 14|cells
P10938109A1361|15 21|PKCbeta
P10938109A1361|66 72|insulin
P10938109A1361|90 101|growth factor
P10938109A1361|110 116|signals
P10938113A0388|47 58|isoforms Vav2
P10938113A0388|112 118|classes
P10938113A0388|120 128|receptors
P10938113A0388|151 161|Vav isoforms
P10938113A0388|188 197|activities
P10938120A1093|15 24|regulation
P10938120A1093|27 48|fbp1 promoter constructs
P10938120A1093|100 113|MAPK regulation
P10938120A1093|127 131|sites
P10938130A0338|0 4|X-ray
P10938130A0338|38 54|PLZF BTB/POZ domain
P10938130A0338|69 77|homodimer
P10938130A0338|92 100|interface
P10938135A0259|3 9|ability
P10938135A0259|38 57|transcription factors
P10938135A0259|76 85|repression
P10938135A0259|107 116|activation
P10938135A0259|119 149|tyrosine kinase signaling pathways
P10938135A0259|185 204|growth factor receptor
P10938556A0248|2 9|addition
P10938556A0248|42 48|neurons
P10938556A0248|56 60|cells
P10938556A0248|75 84|ventricles
P10939030A0986|3 13|differences
P10939030A0986|37 49|response rate p
P10939030A0986|56 60|power
P10939030A0986|79 87|survival p
P10939030A0986|94 98|grade
P10939030A0986|101 117|granulocytopenia p
P10939030A0986|135 146|neutropenia p
P10939785A0540|0 7|Patients
P10939785A0540|30 38|treatment
P10939785A0540|46 68|ACE inhibitor perindopril
P10939785A0540|83 92|indapamide
P10939785A0540|115 124|indication
P10939785A0540|130 145|contraindication
P10939785A0540|148 156|treatment
P10939785A0540|180 186|placebo
P10940413A1153|3 9|results
P10940413A1153|37 42|effect
P10940413A1153|64 72|stiffness
P10940413A1153|76 101|stress concentration effects
P10940413A1153|122 129|strength
P10940413A1153|160 165|defect
P10940553A0912|5 11|regions
P10940553A0912|41 58|tissue-specificity
P10940553A0912|74 83|regulation
P10940553A0912|94 115|hPer1 gene transcription
P10940557A1687|20 26|CF1/USP
P10940557A1687|30 70|Broad Complex Z2 transcription factor elements
P10940557A1687|93 99|regions
P10940557A1687|115 119|genes
P10940562A0379|0 15|Sequence analysis
P10940562A0379|45 53|oasA2 gene
P10940562A0379|65 74|pseudogene
P10940562T0000|20 35|characterization
P10940562T0000|41 53|oas gene family
P10940562T0000|62 75|O-acetylserine
P10940562T0000|76 80|thiol
P10940562T0000|81 86|lyases
P10940562T0000|87 93|enzymes
P10940562T0000|120 139|cysteine biosynthesis
P10940562T0000|141 159|Arabidopsis thaliana
P10940892A0573|20 37|susceptibility loci
P10940892A0573|41 50|vasculitis
P10940892A0573|63 72|chromosome
P10940892A0573|81 87|D4Mit89
P10940892A0573|90 97|D4Mit147
P10940892A0573|104 112|progenies
P10942587A0981|6 14|treatment
P10942587A0981|18 37|phosphorylation state
P10942587A0981|100 112|HPV E6/E7 genes
P10942587A0981|139 145|changes
P10942587A0981|151 159|E7 protein
P10942587A0981|189 194|levels
P10942587A0981|230 239|antibodies
P10942599A1298|7 22|characterization
P10942599A1298|38 54|Hoxa-1 target genes
P10942599A1298|78 86|functions
P10942599A1298|92 104|Hoxa-1 protein
P10942599A1298|110 133|differentiation processes
P10942599A1298|150 162|embryogenesis
P10943891A1062|3 9|ability
P10943891A1062|12 24|U6-U57 mutants
P10943891A1062|39 46|fidelity
P10943891A1062|53 62|branch site
P10943891A1062|67 87|splice site recognition
P10943891A1062|104 113|nucleotide
P10943891A1062|133 141|formation
P10943891A1062|166 176|spliceosome
P10944466A0451|19 27|structure
P10944466A0451|33 42|WNT-2B gene
P10945010T0001|11 22|daunorubicin
P10945010T0001|24 39|induction therapy
P10945010T0001|60 67|leukemia
P10945781A0412|9 24|Aeromonas strains
P10945781A0412|33 47|V cholerae non-O1
P10945781A0412|63 81|enterotoxin activity
P10946303A0000|0 8|TNF-alpha
P10946303A0000|40 47|increase
P10946303A0000|49 64|cyclooxygenase-2
P10946303A0000|65 69|COX-2
P10946303A0000|70 79|expression
P10946303A0000|83 95|PGE2 formation
P10946303A0000|103 110|NCI-H292
P10946303A0000|121 125|cells
P10947274A0839|3 13|therapy time
P10947274A0839|55 61|RBE-cGy
P10947274A0839|64 68|times
P10947274A0839|79 83|157Gd
P10947840A0762|20 28|formation
P10947840A0762|30 43|18S ribosome RNA
P10947840A0762|64 68|level
P10947840A0762|71 78|proteins
P10947840A0762|93 100|coupling
P10950398T0100|0 19|Losartan Intervention
P10950398T0100|23 30|Endpoint
P10950415A0866|0 9|CONCLUSION
P10950415A0866|10 19|Vitrectomy
P10950415A0866|31 40|hemorrhage
P10950415A0866|43 56|Terson syndrome
P10950415A0866|76 84|procedure
P10950415A0866|111 121|improvement
P10950415A0866|124 129|vision
P10950924A0393|11 23|hybridization
P10950924A0393|25 37|brain sections
P10950924A0393|51 57|embryos
P10950924A0393|73 80|labeling
P10950924A0393|93 97|areas
P10950924A0393|111 116|cortex
P10950935A0111|12 23|manipulation
P10950935A0111|38 46|sequences
P10950935A0111|59 64|method
P10950935A0111|106 116|chromosomes
P10950935A0111|126 130|yeast
P10950935A0111|140 150|chromosomes
P10951579A1238|5 21|gamma-irradiation
P10951579A1238|25 32|majority
P10951579A1238|35 41|F9 cells
P10951579A1238|49 57|apoptosis
P10951579A1238|70 75|wt-p53
P10951579A1238|82 89|triggers
P10951579A1238|103 116|gene expression
P10951579A1238|131 135|cells
P10951848A0230|0 11|Mobilization
P10951848A0230|16 31|cyclophosphamide
P10951848A0230|53 69|stimulating factor
P10951848A0230|84 88|terms
P10951848A0230|97 105|cell shift
P10951848A0230|117 121|blood
P10951848A0230|132 147|quality autograft
P10951848A0230|174 181|recovery
P10951848A0230|187 202|megachemotherapy
P10952828A2638|38 46|resonance
P10952828A2638|61 69|technique
P10952828A2638|73 78|volume
P10952828A2638|82 107|ejection fraction estimation
P10952828A2638|110 129|heart failure patients
P10952828A2638|142 151|3D approach
P10952828A2638|168 177|ventricles
P10952828A2638|189 200|image quality
P10954093A0000|11 23|DNA transposon
P10954093A0000|47 53|genomes
P10954093A0000|71 77|strains
P10954093A0000|94 116|fungus Podospora anserina
P10954525A1161|10 17|presence
P10954525A1161|38 43|extent
P10954525A1161|56 62|profile
P10954525A1161|65 72|proteins
P10954525A1161|80 84|TRE-2
P10954564A1262|31 36|domain
P10954564A1262|49 55|protein
P10954564A1262|72 82|gene product
P10954913A0152|18 26|cDNA clone
P10954913A0152|31 51|Atlantic halibut Mx gene
P10954913A0152|68 83|liver cDNA library
P10955313A0000|0 5|PLUS-3
P10955313A0000|19 26|protocol
P10955313A0000|36 41|speech
P10955313A0000|54 61|children
P10955913A0827|4 8|HIT II
P10955913A0827|20 26|heparin
P10955913A0827|50 57|heparins
P10955998A1124|10 19|efficiency
P10955998A1124|25 43|glycosylase activity
P10955998A1124|69 75|ability
P10955998A1124|78 86|S120K MutY
P10955998A1124|96 107|DNA mutations
P10958271A0365|0 6|METHODS
P10958271A0365|10 16|RESULTS
P10958271A0365|52 63|measurements
P10958271A0365|81 96|ejection fraction
P10958271A0365|106 112|volumes
P10958271A0365|134 143|Technetium
P10958271A0365|147 151|Tc99m
P10958271A0365|152 165|perfusion SPECT
P10958271A0365|170 209|equilibrium radionuclide angiocardiography
P10958271A0365|220 227|patients
P10958271A0365|233 242|assessment
P10958271A0365|253 260|function
P10958271A0365|265 280|echocardiography
P10958271A0365|285 292|patients
P10958456A0529|4 8|cDNAs
P10958456A0529|22 27|length
P10958456A0529|58 64|regions
P10958456A0529|142 162|polyadenylation signal
P10958673A0142|17 25|signaling
P10958673A0142|44 58|protein response
P10958673A0142|89 111|ER stress response element
P10958673A0142|119 125|mammals
P10958688A0265|1 23|Y. lipolytica Kar2p mutant
P10958688A0265|47 57|interaction
P10958688A0265|64 74|Sls1p mutant
P10958688A0265|92 102|interaction
P10958688A0265|107 111|Sls1p
P10958688A0265|119 128|nucleotide
P10958688A0265|135 146|conformation
P10958698A0280|43 53|mutagenesis
P10958698A0280|59 72|Cse4p N terminus
P10958698A0280|85 92|function
P10958698A0485|3 9|spacing
P10958698A0485|34 39|domain
P10958698A0485|105 110|effect
P10958698A0485|111 123|Cse4p function
P10959676A0200|3 7|bases
P10959676A0200|14 23|comparison
P10959838A0153|2 14|invertebrates
P10959838A0153|33 45|fusion protein
P10959838A0153|55 60|member
P10959838A0153|65 84|nitrilase superfamily
P10961046A0342|0 13|Platelet counts
P10961046A0342|17 24|function
P10961046A0342|33 42|fibrinogen
P10961046A0342|46 64|von Willebrand factor
P10961046A0342|70 75|levels
P10961046A0342|95 100|sample
P10961585A0273|3 16|manifestations
P10961585A0273|38 53|thrombocytopenia
P10961585A0273|69 77|hemolysis
P10962564A0883|1 26|beta2 RARE reporter construct
P10962564A0883|60 68|cytosines
P10962564A0883|74 84|sense strand
P10962564A0883|99 105|thymine
P10962564A0883|129 136|activity
P10962564A0883|168 173|manner
P10962593A0580|17 23|AFP rate
P10962738A0000|0 12|Consciousness
P10962738A0000|28 36|attention
P10962738A0000|44 49|memory
P10962738A0000|53 62|perception
P10962881A0900|0 10|Multiparity
P10962881A0900|25 30|effect
P10963577T0016|0 6|Picture
P10963577T0016|10 14|smell
P10963735A0193|13 17|study
P10963735A0193|33 37|level
P10963735A0193|49 54|stress
P10963735A0193|64 71|controls
P10963735A0193|97 106|HD patients
P10963735A0193|135 149|dialysis session
P10963735A0193|180 208|polyacrylonitrile membrane AN69
P10963735A0651|8 23|plasma parameters
P10963735A0651|30 37|vitamin E
P10963735A0651|38 42|thiol
P10963735A0651|50 59|acid levels
P10964833A1696|11 22|participants
P10964995A2152|34 40|concern
P10964995A2152|45 49|women
P10964995A2152|58 64|cancers
P10964995A2152|103 111|treatment
P10964995A2152|117 122|tumors
P10964995A2152|138 142|HER-2
P10965135A0735|0 15|Promoter activity
P10965135A0735|46 59|cotransfection
P10965135A0735|77 88|mos oncogenes
P10965135A0735|91 108|oncogene inhibition
P10965135A0735|133 140|activity
P10965135A0735|154 158|cells
P10965135A0735|177 191|MAP kinase kinase
P10965135A0735|197 212|inhibitor PD98059
P10965135A1207|3 9|results
P10965135A1207|25 34|expression
P10965135A1207|37 44|Cktsf1b1
P10965135A1207|71 81|development
P10965135A1207|84 101|cell transformation
P10965135A1207|115 123|MKK levels
P10965135A1207|152 179|transcription factor complexes
P10965830A0305|0 12|INTERVENTIONS
P10965830A0305|25 33|tissue PO2
P10965830A0305|37 48|PCO2 tensions
P10965830A0305|71 78|patients
P10965830A0305|94 102|fasciitis
P10965830A0305|115 124|volunteers
P10965830A0305|154 163|conditions
P10965905A1618|17 29|Akt activation
P10965905A1618|58 62|cells
P10965905A1618|72 84|concentration
P10965905A1618|87 94|LY294002
P10965905A1618|100 107|findings
P10965905A1618|123 143|wortmannin sensitivity
P10965905A1618|192 210|MAP kinase activation
P10965905A1618|224 231|activity
P10965905A1618|261 266|target
P10965905A1618|271 278|addition
P10965905A1618|288 296|mediation
P10965905A1618|308 326|MAP kinase activation
P10965905A1618|334 338|cells
P10965905T0000|0 14|Insulin receptor
P10965905T0000|35 45|enhancement
P10965905T0000|48 53|growth
P10965905T0000|86 108|protein kinase activation
P10967361A0000|18 33|resonance imaging
P10967361A0000|78 90|brain function
P10967361A0000|110 116|feature
P10967361A0000|131 140|resolution
P10967531A1025|20 24|aorta
P10967531A1025|44 48|edema
P10967531A1025|54 66|fibre necrosis
P10967531A1025|70 77|adhesion
P10967531A1025|80 89|leucocytes
P10967531A1025|97 112|muscle fibre areas
P10967531A1025|135 140|microm
P10967531A1025|165 170|microm
P10967890A1120|3 9|results
P10967890A1120|25 36|relationship
P10967890A1120|44 56|comprehension
P10967890A1120|60 69|production
P10967890A1120|92 97|stages
P10967890A1120|100 110|development
P10970048A0352|14 21|increase
P10970048A0352|27 33|RH level
P10970048A0352|50 55|values
P10970048A0352|61 66|orders
P10970048A0352|69 77|magnitude
P10970048A0352|78 89|contrariwise
P10970048A0352|93 105|voltage values
P10970048A0352|122 126|times
P10972688A1272|11 19|follow-up
P10972688A1272|41 50|difference
P10972688A1272|56 64|incidence
P10972688A1272|67 82|hospitalizations
P10972894A0488|7 15|libraries
P10972894A0488|34 41|cultures
P10972894A0488|52 57|format
P10972894A0488|96 103|colonies
P10972894A0488|106 111|plates
P10972894A0488|120 126|library
P10972894A0488|145 151|library
P10972894A0488|167 173|library
P10972980A0295|9 17|cell lines
P10972980A0295|39 45|targets
P10972980A0295|61 80|phosphatidylinositol
P10972980A0295|85 92|3-kinase
P10972980A0295|92 106|protein kinases A
P10972980A0295|130 139|G-proteins
P10972980A0295|156 161|kinase
P10972980A0295|164 170|calcium
P10972980A0295|181 190|amino acids
P10972990A0196|19 28|protein p53
P10972990A0196|59 67|stability
P10972990A0526|0 9|Abrogation
P10972990A0526|12 22|p53 function
P10972990A0526|41 48|increase
P10972990A0526|64 82|mutation frequencies
P10972990A0526|100 114|thymidine kinase
P10972990A0526|119 123|locus
P10972990A0526|144 180|hypoxanthine phosphoribosyl transferase
P10972990A0526|187 191|locus
P10972990A0966|11 18|analysis
P10972990A0966|21 30|LOH mutants
P10972990A0966|33 50|chromosome painting
P10972990A0966|61 66|mosaic
P10972990A0966|80 90|aberrations
P10972990A0966|100 109|chromosome
P10972990A0966|126 144|chromosome deletions
P10972990A0966|145 158|amplifications
P10972990A0966|170 183|translocations
P10972990A0966|216 221|mutant
P10972990A1518|5 11|results
P10972990A1518|20 24|model
P10972990A1518|32 41|p53 protein
P10972990A1518|58 68|maintenance
P10972990A1518|78 86|integrity
P10972990A1518|109 114|repair
P10973151A0883|3 12|importance
P10973151A0883|37 43|profile
P10973151A0883|46 60|schistosomiasis
P10973151A0883|66 70|State
P10973151A0883|73 82|Pernambuco
P10973151A0883|137 148|interference
P10973151A0883|153 163|environment
P10973385A1423|2 9|patients
P10973385A1423|22 27|tumors
P10973385A1423|30 36|pattern
P10973385A1423|48 53|spread
P10973385A1423|100 108|curvature
P10973385A1423|123 133|artery nodes
P10973385A1423|134 146|esophagectomy
P10973385A1423|156 170|survival benefit
P10973385A1423|183 193|gastrectomy
P10973385A1423|201 208|patients
P10973400A0664|0 6|RESULTS
P10973400A0664|20 30|deformation
P10973400A0664|42 51|artery flow
P10973400A0664|65 88|flexion-distraction Stage
P10973400A0664|90 97|injuries
P10973400A0664|118 122|range
P10973400A0664|133 139|flexion
P10974541A0389|11 25|K562 cDNA library
P10974541A0389|44 54|transcripts
P10974541A0389|55 59|MZF1B
P10974541A0389|63 67|MZF1C
P10975465A0134|8 21|cDNA clone NFBD1
P10975465A0134|42 49|KIAA0170
P10975465A0134|63 69|protein
P10975465A0134|74 83|amino acids
P10975465A0134|86 91|length
P10975465A0134|139 149|BRCT domains
P10975465A0134|153 167|carboxy terminus
P10975465A0134|168 184|amino acid residues
P10976413A0514|0 6|RESULTS
P10976413A0514|19 26|FSH level
P10976413A0514|40 47|FSH level
P10976413A0514|81 90|predictors
P10976413A0514|93 102|IVF success
P10976413A0514|112 118|patient
P10976413A0514|130 137|FSH level
P10976413A0514|142 147|mIU/ml
P10976413A0514|168 175|FSH level
P10976413A0514|180 185|mIU/ml
P10976413A0514|206 214|pregnancy
P10980416T0000|11 27|hormone regulation
P10980416T0000|30 45|bone sialoprotein
P10980416T0000|51 67|gene transcription
P10980416T0000|103 123|transcription factor-1
P10980416T0000|124 128|Pit-1
P10980416T0000|129 133|motif
P10980416T0000|139 156|rat BSP gene promoter
P10981094A0779|6 18|target BP goals
P10981094A0779|35 45|Sixth Report
P10981094A0779|53 74|Joint National Committee
P10981094A0779|75 79|JNC VI
P10981094A0779|93 99|premise
P10981094A0779|107 115|intensity
P10981094A0779|118 126|treatment
P10981094A0779|151 159|magnitude
P10981094A0779|162 177|pretreatment risk
P10982076A0000|32 49|morbidity recording
P10982076A0000|66 72|illness
P10982076A0000|93 100|sampling
P10982076A0000|124 128|value
P10982076A0000|147 156|indicators
P10982076A0000|170 186|influenza activity
P10982143A0346|3 8|muskox
P10982143A0346|15 24|host record
P10982143A0346|28 35|T. gondii
P10982391A0425|12 21|NPF repeats
P10982391A0425|23 29|leucine
P10982391A0425|36 41|repeat
P10982391A0425|59 66|residues
P10982391A0425|136 141|domain
P10982391A0425|158 169|membrane core
P10982391A0425|192 209|transmembrane spans
P10982391A0425|229 236|segments
P10982391A0425|276 283|elements
P10982825A0363|18 27|difference
P10982825A0363|38 45|presence
P10982825A0363|49 63|Mot3 binding site
P10983344A0000|3 9|article
P10983344A0000|22 31|diagnosing
P10983344A0000|35 44|correction
P10983344A0000|57 64|ischemia
P10983344A0000|70 78|intestine
P10983857A0923|7 17|application
P10983857A0923|20 27|NCX-4016
P10983857A0923|46 56|PD reduction
P10983857A0923|94 102|hyperemia
P10983857A0923|114 119|damage
P10983857A0923|125 131|stomach
P10983979T0000|10 20|recognition
P10983979T0000|24 33|splice site
P10983979T0000|36 40|U4/U6
P10983979T0000|50 60|U5 tri-snRNP
P10983979T0000|100 118|spliceosome assembly
P10984122A0911|2 8|control
P10984122A0911|12 16|cells
P10984122A0911|36 46|DNA mixtures
P10984122A0911|57 68|vector mU6-C1
P10984122A0911|71 76|mU6-C2
P10987280A0604|3 19|amino acid sequence
P10987280A0604|22 33|matrilysin-2
P10987280A0604|47 62|threonine residue
P10987280A0604|121 127|feature
P10987280A0604|129 138|matrilysin
P10987301A0332|6 11|regard
P10987301A0332|77 84|receptor
P10987301A0332|102 107|Kaposi
P10987301A0332|126 136|herpes virus
P10987301A0332|147 157|herpes virus
P10987301A0332|182 193|angiogenesis
P10987301A0332|209 217|secretion
P10987301A0332|239 250|growth factor
P10987301A0332|278 287|stimulator
P10987301A0332|299 305|mitogen
P10987301A0332|312 322|development
P10987301A0332|325 330|Kaposi
P10987301A0332|332 338|sarcoma
P10989777A1286|10 17|subgroup
P10989777A1286|20 26|clients
P10989777A1286|69 73|study
P10989777A1286|88 97|assignment
P10989777A1286|137 141|group
P10991383A0289|5 11|lattice
P10991383A0289|21 25|sites
P10991383A0289|45 49|atoms
P10991383A0289|63 68|energy
P10991383A0289|77 84|sublevel
P10991383A0289|121 125|state
P10991648T0000|38 50|half syndromes
P10992299A0745|17 23|members
P10992299A0745|29 42|gene expression
P10992299A0745|58 70|tumorigenesis
P10992299A0745|71 84|PI12 expression
P10992299A0745|113 129|tumor brain tissues
P10992299A0745|138 157|brain cancer cell lines
P10992299A0745|158 163|U-87 MG
P10992983T0000|12 19|relation
P10992983T0000|33 43|orientation
P10992983T0000|47 56|penile size
P10993773A0717|4 8|slope
P10993773A0717|44 54|min ischemia
P10993773A0717|64 74|microm/mmHg
P10993773A0717|92 104|control values
P10993773A0717|128 137|myocardium
P10993773A0717|142 152|min ischemia
P10993773A0717|162 172|microm/mmHg
P10993787A0369|19 30|MSNA increase
P10993787A0369|44 53|transition
P10993787A0369|96 104|reduction
P10993787A0369|122 130|elevation
P10993787A0369|150 159|separation
P10993787A0369|166 172|factors
P10995121A0569|0 7|Analysis
P10995121A0569|10 38|Standard Reference Material 1846
P10995121A0569|39 51|Infant Formula
P10995121A0569|61 65|value
P10995121A0569|78 90|mg vitamin K/kg
P10995121A0569|136 146|coefficient
P10995121A0569|148 156|variation
P10995751A0093|51 62|protein-beta
P10995751A0093|63 72|C/EBP-beta
P10995751A0093|80 96|gene transcription
P10995751A0093|110 127|IFN response element
P10995751A0093|171 177|element
P10997330A0361|0 19|Northern blot analysis
P10997330A0361|39 47|STORP gene
P10997330A0361|62 68|pattern
P10997330A0361|71 80|expression
P10997330A0361|99 105|PML gene
P10997863A0753|5 15|TLE patients
P10997863A0753|27 32|ratios
P10997863A0753|48 59|seizure focus
P10997863A0753|70 80|FLE patients
P10997863A0753|110 121|seizure focus
P10997904A1258|3 15|Spo0F residues
P10997904A1258|38 42|patch
P10997904A1258|62 79|response regulators
P10997904A1258|97 103|binding
P10997904A1258|129 136|residues
P10997904A1258|153 181|response regulator-kinase pairs
P10998679A0500|14 20|factors
P10998679A0500|43 49|illness
P10998679A0500|57 65|prognoses
P10998679A0500|87 94|scenario
P10999205A0607|19 28|resolution
P10999205A0607|45 52|interest
P10999205A0607|111 121|acquisition
P10999205A0607|137 143|spectra
P10999301A0000|12 21|evaluation
P10999301A0000|39 48|parameters
P10999301A0000|62 66|order
P10999301A0000|74 81|scanning
P10999301A0000|99 108|microscope
P10999301A0000|115 124|technology
P10999301A0000|129 133|study
P10999301A0000|136 144|magnetism
P10999301A0000|160 164|scale
P10999369A0192|14 22|amplitude
P10999369A0192|42 51|potentials
P10999369A0192|52 60|amplitude
P10999369A0192|66 74|N2/P2 peak
P10999369A0192|95 100|microV
P10999369A0192|118 123|microV
P11000203A0752|5 13|mutations
P11000203A0752|16 20|K-Rev
P11000203A0752|48 57|properties
P11000203A0752|91 99|RNA export
P11000203A0752|107 118|K-Rev mutants
P11000203A0752|179 188|activities
P11000203A0752|215 223|RNA export
P11000250A0200|0 4|LMP-1
P11000250A0200|20 33|plasma membrane
P11000250A0200|52 56|TRADD
P11000250A0200|59 70|JAK molecules
P11000250A0200|81 89|NF-kappaB
P11000250A0200|113 120|pathways
P11000266T0000|0 13|Identification
P11000266T0000|18 25|enhancer
P11000266T0000|42 49|promoter
P11000266T0000|60 65|intron
P11000266T0000|71 91|alpha-fetoprotein gene
P11000521A0588|21 37|signaling pathways
P11000521A0588|67 80|transformation
P11000521A0588|100 110|NIH3T3 cells
P11000521A0588|145 159|phosphorylation
P11000521A0588|162 187|insulin receptor substrate-2
P11000521A0588|188 192|IRS-2
P11000521A0588|208 217|activation
P11000521A0588|220 247|phosphatidylinositol 3-kinase
P11000521A0588|248 257|PI 3-kinase
P11000521A0588|261 274|protein kinase B
P11000521A0588|275 281|PKB/AKT
P11002236A0328|0 6|METHODS
P11002236A0328|19 23|study
P11002236A0328|27 33|authors
P11002236A0328|44 51|PPB cases
P11002236A0328|65 83|retrospective search
P11002236A0328|104 115|Associations
P11002236A0328|119 137|Pediatric Hematology
P11002236A0328|141 155|Oncology centers
P11003471A1149|12 19|analysis
P11003471A1149|33 45|ToLCV isolates
P11003471A1149|50 58|Bangalore
P11003471A1149|70 74|group
P11003471A1149|77 83|viruses
P11003471A1149|112 116|India
P11003641A0811|24 33|motif KEFGK
P11003641A0811|39 43|RAP74
P11003641A0811|44 48|Tfg1p
P11003641A0811|49 55|subunit
P11003641A0811|58 62|TFIIF
P11003641A0811|88 97|phenotypes
P11003641A0811|107 114|fcp1 tfg1
P11003641A0811|121 127|mutants
P11003641A0811|139 145|ability
P11003641A0811|148 152|Fcp1p
P11003641A0811|163 175|transcription
P11003641A0811|207 214|promoter
P11003652A0961|5 11|results
P11003652A0961|23 28|Cdc42p
P11003652A0961|50 66|pheromone response
P11003652A0961|73 83|interaction
P11003652A0961|91 99|PAK Ste20p
P11003653A0198|0 7|Deletion
P11003653A0198|46 52|complex
P11003653A0198|62 86|beta-globin locus construct
P11003653A0198|108 112|gamma
P11003653A0198|115 134|beta-globin switching
P11003653A0198|170 179|PYR complex
P11003653A0198|198 203|switch
P11003669A0000|3 9|product
P11003669A0000|12 18|rat gene
P11003669A0000|56 62|protein
P11003669A0000|76 81|screen
P11003669A0000|94 112|ErbB-2 juxtamembrane
P11003669A0000|116 128|kinase domains
P11003805A0443|0 6|Studies
P11003805A0443|34 43|acid reflux
P11003805A0443|54 61|symptoms
P11003805A0443|71 80|acid reflux
P11003805A0443|118 129|oesophagitis
P11003807A0303|0 7|Symptoms
P11003807A0303|42 53|oesophagitis
P11003807A0303|65 72|symptoms
P11003807A0303|100 116|oesophageal damage
P11004369A0000|0 8|OBJECTIVE
P11004369A0000|22 33|relationship
P11004369A0000|41 49|blood flow
P11004369A0000|55 59|tumor
P11004369A0000|70 91|color Doppler ultrasound
P11004369A0000|92 109|microvessel density
P11004369A0000|132 149|growth factor levels
P11004369A0000|163 171|carcinoma
P11005808A1082|5 11|results
P11005808A1082|46 62|ERK MAPK activation
P11005808A1082|71 83|cell viability
P11005808A1082|93 101|heat shock
P11005831A0242|5 9|cDNAs
P11005831A0242|23 35|leucine zipper
P11005831A0242|59 66|proteins
P11005831A0242|87 91|yeast
P11005831A0242|102 107|system
P11005831A0242|125 129|AREB1
P11005831A0242|130 134|AREB2
P11005831A0242|138 142|AREB3
P11005831A0242|157 177|element binding protein
P11006283A1180|11 18|AROM-p64
P11006283A1180|32 38|binding
P11006283A1180|72 83|homopolymers
P11006283A1180|99 105|protein
P11006283A1180|124 148|mRNA maturation/metabolism
P11006284T0000|19 27|kinase fer
P11006284T0000|51 59|complexes
P11006284T0000|70 95|insulin receptor substrate-1
P11006284T0000|99 126|phosphatidylinositol 3-kinase
P11006331A0319|11 19|phenotype
P11006331A0319|25 39|allotetraploids
P11006331A0319|72 84|abnormalities
P11007509A1271|5 17|PMR target area
P11007509A1271|47 57|improvement
P11007509A1271|77 87|flow reserve
P11007509A1271|96 107|wall segments
P11007509A1271|148 162|stress perfusion
P11007777A0813|0 7|Analysis
P11007777A0813|10 30|intron/exon boundaries
P11007777A0813|43 51|BAC clones
P11007777A0813|67 73|junctin
P11007777A0813|74 81|junctate
P11007777A0813|85 108|aspartyl beta-hydroxylase
P11007777A0813|130 137|splicing
P11007949A1395|20 38|inactivation mutants
P11007949A1395|63 67|forms
P11007949A1395|73 78|tumors
P11007949A1607|25 32|activity
P11007949A1607|78 82|cells
P11007954A0170|3 14|growth factor
P11007954A0170|29 35|protein
P11007954A0170|43 49|adaptor
P11007954A0170|90 103|exchange factor
P11007954A0170|119 124|signal
P11007954A0170|133 140|tyrosine
P11007954A0170|157 164|receptor
P11007954A0170|194 201|membrane
P11007954A0170|208 217|activation
P11007961A0930|0 8|Mutations
P11007961A0930|11 15|genes
P11007961A0930|24 37|PR65/A subunits
P11007961A0930|79 85|cancers
P11007961A0930|92 104|PP2A inhibitor
P11007961A0930|111 120|fostriecin
P11007968A0255|7 13|purpose
P11007968A0255|15 21|segment
P11007968A0255|98 113|oligonucleotides
P11007968A0255|123 129|regions
P11008139T0000|10 17|learning
P11008139T0000|22 46|pattern discrimination task
P11008420A0580|3 10|detector
P11008420A0580|17 25|advantage
P11008420A0580|41 57|segment deviations
P11008420A0580|71 84|complex changes
P11008420A0580|107 122|characterization
P11008420A0580|145 150|events
P11011139A0000|32 46|SIN4 gene product
P11011139A0000|50 58|component
P11011139A0000|62 76|mediator complex
P11011139A0000|91 103|RNA polymerase
P11011139A0000|113 119|studies
P11011139A0000|130 140|involvement
P11011139A0000|154 163|alteration
P11011139A0000|177 194|chromatin structure
P11012568A0192|14 29|hypersensitivity
P11012568A0192|32 40|ACTH drive
P11012568A0192|43 49|obesity
P11012671A0576|2 9|addition
P11012671A0576|51 69|Gadd45gamma promoter
P11012671A0576|74 82|C/EBPbeta
P11012671A0576|86 95|C/EBPdelta
P11012671A0576|135 152|mobility shift assay
P11012671A0576|162 181|reporter gene analysis
P11012680A0676|0 12|Src activation
P11012680A0676|43 51|SH2 domain
P11012680A0676|75 83|inhibitor
P11012680A1020|13 20|PLCgamma
P11012680A1020|30 36|peptide
P11012680A1020|37 44|neomycin
P11012680A1020|51 73|calcium chelator BAPTA-AM
P11012680A1020|76 82|oocytes
P11012680A1020|93 97|FGFR1
P11012680A1020|103 113|stimulation
P11012680A1020|116 122|PDGF-BB
P11012680A1020|125 131|oocytes
P11012680A1020|142 152|PDGFR-FGFR1
P11012680A1020|165 183|PLCgamma binding site
P11012680A1020|202 220|ERK2 phosphorylation
P11013079A0927|8 30|transcription start sites
P11013079A0927|45 67|primer extension analysis
P11013079A0927|73 81|mouse gene
P11013079A0927|85 106|transfection constructs
P11013079A0927|131 138|promoter
P11013079A0927|163 170|activity
P11013079A0927|192 203|SV40 promoter
P11014197A0339|7 24|inhibitor scaffolds
P11014197A0339|59 68|inhibitors
P11014197A0339|82 88|kinases
P11014197A0339|105 115|subfamilies
P11014213A1019|18 28|interaction
P11014213A1019|31 38|arsenite
P11014213A1019|61 66|domain
P11014213A1019|76 93|receptor activation
P11014213A1019|94 103|COS-1 cells
P11014213A1019|147 161|receptors GAL-ER
P11014213A1019|193 198|domain
P11014213A1019|201 207|ERalpha
P11014213A1019|225 230|domain
P11014213A1019|236 258|transcription factor GAL4
P11014213A1019|278 292|CAT reporter gene
P11014215A1092|13 27|deletion studies
P11014215A1092|51 61|DNA fragment
P11014215A1092|86 105|translation start site
P11014215A1092|119 124|region
P11014215A1092|135 143|GnRHR gene
P11014215A1092|181 195|down-regulation
P11014215A1092|203 223|GnRHR promoter activity
P11014465A0479|14 22|diagnosis
P11014465A0479|39 51|echodensities
P11014465A0479|64 68|range
P11014465A0479|104 108|range
P11014821T0000|3 21|LAMMER protein kinase
P11014821T0000|34 41|Doa locus
P11014821T0000|44 53|Drosophila
P11014821T0000|80 92|germline cells
P11014821T0000|134 141|isoforms
P11014821T0000|152 162|development
P11015197A0310|15 22|cysteine
P11015197A0310|48 55|residues
P11016014A0181|0 9|HYPOTHESIS
P11016014A0181|24 28|study
P11016014A0181|56 69|susceptibility
P11016014A0181|72 85|apolipoprotein
P11016014A0181|98 109|lipoproteins
P11016014A0181|124 129|status
P11016014A0181|132 139|patients
P11016014A0181|157 165|syndromes
P11016014A0181|182 195|angina pectoris
P11016724A0536|2 7|group B
P11016724A0536|20 25|microL
P11016724A0536|27 46|99mTc-HSA nanocolloid
P11016724A0536|94 100|surgery
P11016724A0536|103 110|aliquots
P11016737A0275|24 30|outcome
P11016737A0275|65 70|status
P11016850A0423|9 19|DNA fragment
P11016850A0423|50 56|protein
P11016850A0423|71 80|similarity
P11016850A0423|83 89|members
P11016850A0423|95 104|LysR family
P11016850A0423|122 131|regulators
P11016850A0423|132 136|LTTRs
P11016954A0438|17 21|QDE-2
P11016954A0438|43 47|RDE-1
P11017876A0787|13 31|localization studies
P11017876A0787|40 45|mDAP-3
P11017876A0787|45 61|EGFP fusion protein
P11017876A0787|62 78|cell fractionation
P11017876A0787|82 110|protease protection experiments
P11017876A0787|120 125|mDAP-3
P11017876A0787|144 149|matrix
P11018028A0263|21 31|involvement
P11018028A0263|48 60|protein kinase
P11018028A0263|71 85|phosphorylation
P11018028A0263|87 93|CDC25Mm
P11018028A0263|96 106|fibroblasts
P11018028A0263|125 130|RasGEF
P11018028A0263|141 150|mouse brain
P11018028A0263|163 171|membranes
P11018264A0397|0 29|Reporter gene expression analyses
P11018264A0397|46 58|WASP promoters
P11018264A0397|67 72|levels
P11018264A0397|75 84|expression
P11018264A0397|109 117|cell lines
P11019257A0159|10 16|3T1-3T2
P11019257A0159|37 42|effect
P11019257A0159|48 56|line shape
P11019257A0159|69 77|decay rate
P11019257A0159|80 87|emission
P11019257A0159|95 102|3T2 state
P11019257A0159|113 118|extent
P11019257A0159|149 157|magnitude
P11019257A0159|174 184|distortions
P11020375A0134|1 5|total
P11020375A0134|20 36|Ross broiler chicks
P11020375A0134|52 66|treatment groups
P11020375A0134|88 94|control
P11020375A0134|116 120|parts
P11020375A0134|138 142|ppb AF
P11020375A0134|153 157|ppb AF
P11020375A0134|160 164|ppb AF
P11023074A1105|49 53|PACE2
P11023832A1038|15 21|results
P11023832A1038|35 43|KG1a cells
P11023832A1038|44 51|TNFalpha
P11023832A1038|74 79|PC-PLC
P11023832A1038|93 105|lipid products
P11023832A1038|138 150|protein kinase
P11023832A1038|150 158|MAP kinase
P11023832A1038|162 180|NF-kappaB signalling
P11023853A0188|23 39|weather conditions
P11023853A0188|60 69|budget data
P11023853A0188|83 87|birds
P11023853A0188|91 104|laboratory data
P11023853A0188|153 162|laboratory
P11023853A0188|167 175|estimates
P11023853A0188|182 198|energy expenditure
P11023853A0188|210 218|partition
P11023853A0188|221 227|verdins
P11023853A0188|228 239|energy budget
P11023853A0188|260 267|activity
P11023853A0188|276 285|components
P11023934A0855|39 52|filling pattern
P11023934A0855|78 87|predictors
P11023934A0855|88 93|events
P11024026A0133|7 17|selectivity
P11024026A0133|20 28|arrestins
P11024026A0133|64 71|receptor
P11024026A0133|89 95|binding
P11024026A0133|99 110|dissociation
P11024036A0984|19 29|fibroblasts
P11024036A0984|35 60|C/EBP alpha expression vector
P11024036A0984|61 82|reporter gene expression
P11024036A0984|116 125|constructs
P11024047A0626|0 9|Expression
P11024047A0626|29 33|Smad2
P11024047A0626|57 61|level
P11024047A0626|64 89|luciferase reporter activity
P11024047A0626|104 112|treatment
P11024182A0781|6 11|alpha1
P11024182A0781|14 25|collagen mRNA
P11024182A0781|44 52|reduction
P11024182A0781|86 106|pHbetaAPr-1-neo vector
P11024182A0781|135 143|reduction
P11024182A0781|153 160|ribozyme
P11024182A0781|218 226|neo vector
P11024300A1579|0 5|Nature
P11024300A1579|23 40|amino acid sequences
P11024300A1579|43 58|peptide fragments
P11024300A1579|72 82|polypeptide
P11024300A1579|91 97|complex
P11024300A1579|100 107|proteins
P11024300A1579|118 135|chromatin structure
P11024300A1579|155 162|portions
P11024300A1579|178 189|reading frame
P11024300A1579|192 200|TIG-1 mRNA
P11025367A1009|0 12|Abnormalities
P11025367A1009|15 35|plasma cholecystokinin
P11025367A1009|54 61|patients
P11025367A1009|80 87|emptying
P11027027A0061|1 15|Sunset Yellow FCF
P11027027A0061|41 71|chromatography/mass spectrometry
P11027027A0061|72 76|LC/MS
P11027027A0061|81 102|electrospray ionization
P11027267A0752|0 7|Polysome
P11027267A0752|11 30|40S ribosome fractions
P11027267A0752|57 66|krr1 mutant
P11027267A0752|84 88|cells
P11027274A1682|29 38|PI 3-kinase
P11027274A1682|48 55|activity
P11027274A1682|70 76|extents
P11027274A1682|107 115|structure
P11027274A1682|122 128|isoform
P11027280A0536|0 8|Cam kinase
P11027280A0536|24 38|phosphorylation
P11027280A0536|41 45|Smad2
P11027280A0536|49 53|Smad4
P11027280A0536|66 71|extent
P11027280A0536|72 76|Smad3
P11027289A0000|25 34|suppressor
P11027289A0000|79 95|RNA binding protein
P11027289A0000|123 137|RNA accumulation
P11027289A0000|146 152|alleles
P11027289A0000|160 164|genes
P11027289A0000|173 192|transposon insertions
P11027289A0000|210 215|region
P11027289A0321|3 8|result
P11027289A0321|38 43|motifs
P11027289A0321|73 90|RNA binding activity
P11027294A0483|4 14|interaction
P11027294A0483|26 57|histone acetyltransferase activity
P11027294A0483|84 92|reduction
P11027294A0483|105 122|histone acetylation
P11027294A0483|126 135|alteration
P11027294A0483|138 155|chromatin structure
P11027724A0335|11 17|BRI1-KD
P11027724A0335|38 43|serine
P11027724A0335|52 60|threonine
P11027724A0335|65 72|residues
P11027724A0335|76 80|p-Ser
P11027833A0362|0 11|Flow cytomery
P11027833A0362|22 38|cell cycle analysis
P11028131A1374|7 14|research
P11028131A1374|33 55|measure treatment effects
P11028131A1374|56 67|modification
P11028131A1374|81 87|history
P11028131A1374|101 105|costs
P11028131A1374|108 117|IFN beta-1b
P11028131T0000|0 17|Cost-effectiveness
P11028131T0000|20 36|interferon beta-1b
P11028131T0000|54 83|sclerosis disability progression
P11028944A1020|16 24|AUC values
P11029045A0000|0 14|Hyperactivation
P11029045A0000|25 36|fission yeast
P11029045A0000|42 46|cells
P11029045A0000|72 78|mitosis
P11029045A0000|92 102|catastrophe
P11029262T0000|0 4|Diary
P11029458A0000|0 4|Cells
P11029458A0000|20 27|response
P11029458A0000|50 56|stimuli
P11029459A0000|12 29|growth factor-beta1
P11029459A0000|30 38|TGF-beta1
P11029459A0000|48 62|tumor suppressor
P11029459A0000|66 78|tumor promoter
P11029459A0000|93 107|characteristics
P11029467T0000|20 26|peptide
P11029467T0000|39 47|adenylate
P11029467T0000|66 76|polypeptide
P11029467T0000|91 102|factor-kappa
P11029467T0000|114 127|gene activation
P11029467T0000|138 143|levels
P11029467T0000|163 175|cell line THP-1
P11029656A0640|21 35|junction binding
P11029656A0640|46 55|activities
P11029656A0640|67 74|proteins
P11029700A0295|44 50|tissues
P11029700A0295|58 68|transcripts
P11029700A0295|100 104|cells
P11029700A0746|26 30|assay
P11029700A0746|86 93|rice CDKs
P11029704A0378|11 18|analysis
P11029704A0378|24 42|particle bombardment
P11029704A0378|45 63|tobacco leaf sections
P11029704A0378|65 72|tetramer
P11029704A0378|78 86|distB ABRE
P11029704A0378|110 116|element
P11029704A0378|125 139|transactivation
P11029704A0378|165 172|response
P11029704A0378|187 194|tetramer
P11029704A0378|208 218|RY/G complex
P11029704A0378|229 237|RY repeats
P11029704A0378|242 246|G-box
P11029704A0378|274 288|transactivation
P11030066A0142|20 33|manifestations
P11030066A0142|36 46|brain injury
P11030066A0142|54 59|babies
P11030066A0142|70 82|motor deficits
P11030476A0685|0 5|Spores
P11030476A0685|10 27|Rhizopus stolonifer
P11030476A0685|52 56|water
P11030476A0685|61 69|spores/mL
P11030744A0763|0 13|Overexpression
P11030744A0763|16 21|Trdpm1
P11030744A0763|30 38|his7/dpm1
P11030744A0763|70 77|increase
P11030744A0763|87 105|DPM synthase activity
P11031252A0646|3 10|LMW FGF-2
P11031252A0646|26 41|PKC epsilon levels
P11031252A0646|54 61|contrast
P11031252A0646|65 74|HMW isoform
P11031252A0646|92 96|level
P11031252A0646|103 112|PKC isotype
P11031252A0646|141 146|amount
P11031252A0646|149 156|PKC delta
P11031366T0001|0 17|Helicobacter pylori
P11031366T0001|21 35|stomach diseases
P11031366T0001|47 51|point
P11031773A0174|7 13|purpose
P11031773A0174|31 39|capsaicin
P11031773A0174|42 61|formalin induced-pain
P11032599T0000|12 26|recommendations
P11032599T0000|71 77|factors
P11032599T0000|99 116|practice guidelines
P11032677A0230|9 16|findings
P11032677A0230|28 39|pancreatitis
P11032677A0230|59 63|plugs
P11032677A0230|105 113|steatitis
P11032677A0230|126 133|myopathy
P11032677A0230|144 150|atrophy
P11032677A0230|151 161|candidiasis
P11032677A0230|185 193|glossitis
P11034392A1072|42 57|survival pathways
P11034392A1072|76 83|receptor
P11034392A1072|91 103|NF-kappaB/Rel
P11034392A1072|107 111|PI-3K
P11034392A1072|137 149|proliferation
P11034547A0674|16 21|NBPhox
P11034547A0674|40 48|multimers
P11034547A0674|70 76|binding
P11034547A0674|97 103|element
P11034547A0674|119 145|homeodomain recognition sites
P11034547A1355|18 22|study
P11034547A1355|36 41|NBPhox
P11034547A1355|104 113|properties
P11034547A1355|119 129|DBH promoter
P11034933A0389|0 6|METHODS
P11034933A0389|10 16|RESULTS
P11034933A0389|17 23|Studies
P11034933A0389|49 63|guinea pig hearts
P11034933A0389|101 112|prolongation
P11034933A0389|122 135|repolarization
P11034933A0389|141 157|nmol/L domperidone
P11035037A0183|18 24|segment
P11035037A0183|27 37|yeast TAF145
P11035037A0183|38 44|yTAF145
P11035037A0183|75 85|TBP function
P11035867A0000|0 8|OBJECTIVE
P11035867A0000|29 39|performance
P11035867A0000|59 83|wrist blood pressure monitor
P11035867A0000|84 103|Braun PrecisionSensor
P11035867A0000|104 112|Braun GmbH
P11035867A0000|113 120|Kronberg
P11035867A0000|121 127|Germany
P11035867A0000|142 169|ANSI/AAMI SP10-1992 guidelines
P11035867A0000|206 214|selection
P11035867A0000|219 227|algorithm
P11035867A0000|242 260|blood pressure values
P11035867A0000|281 299|blood pressure curves
P11036786A0628|12 18|results
P11036786A0628|34 44|experiments
P11036786A0628|50 62|target animals
P11036786A0628|76 97|Drinking Water Standards
P11036786A0628|101 107|Animals
P11036938A1162|2 9|increase
P11036938A1162|24 33|expression
P11036938A1162|51 63|erbB receptors
P11036938A1162|92 103|augmentation
P11036938A1162|113 128|steroid secretion
P11036938A1162|175 179|surge
P11036938A1162|181 193|gonadotropins
P11036939A2149|30 37|pathways
P11036939A2149|40 49|Wnt pathway
P11036939A2149|53 73|planar polarity pathway
P11037759T0000|0 13|Catch-up growth
P11037759T0000|29 38|dimensions
P11037759T0000|48 61|administration
P11037759T0000|81 96|agent vincristine
P11037823A1134|0 10|CONCLUSIONS
P11037823A1134|11 26|LSCC malformation
P11037823A1134|41 56|ear malformations
P11037823A1134|78 85|aqueduct
P11037823A1134|102 109|deafness
P11037823A1134|123 128|gusher
P11037823A1134|167 173|hearing
P11038042A0948|0 9|Escalation
P11038042A0948|15 19|mg/m2
P11038042A0948|44 62|blood cell nadir count
P11038042A0948|78 95|platelet nadir count
P11038118A0000|0 12|Methyl formate
P11038118A0000|47 57|oligoesters
P11038118A0000|64 74|fabrication
P11038118A0000|77 88|microspheres
P11038118A0000|111 122|serum albumin
P11038317A0000|28 35|proteins
P11038317A0000|41 52|RAB subfamily
P11038317A0000|69 76|elements
P11038317A0000|82 90|machinery
P11038317A0000|103 117|membrane traffic
P11038317A0000|130 134|cells
P11038366A1322|19 29|methylation
P11038366A1322|50 60|association
P11038366A1322|70 74|yeast
P11038366A1322|81 87|subunit
P11038366A1322|88 92|Rts1p
P11038366A1417|4 14|methylation
P11038366A1417|17 22|Pph21p
P11038366A1417|37 45|formation
P11038366A1417|72 80|complexes
P11038366A1417|98 109|PP2A function
P11039341A0180|3 9|purpose
P11039341A0180|16 20|study
P11039341A0180|44 58|characteristics
P11039341A0180|72 78|mapping
P11039341A0180|95 104|components
P11039780A0770|3 9|authors
P11039780A0770|27 33|studies
P11039780A0770|68 79|animal models
P11039780A0770|82 95|osteoarthritis
P11039780A0770|101 111|gene therapy
P11039780A0770|124 131|overview
P11039780A0770|141 150|strategies
P11039780A0770|157 167|development
P11039780A0770|170 180|gene therapy
P11039780A0770|183 205|osteoarthritis treatment
P11039780A0770|211 216|future
P11040101A1180|13 19|results
P11040101A1180|32 39|IL-1 beta
P11040101A1180|47 64|VEGF gene expression
P11040101A1180|109 114|levels
P11040101A1180|118 125|IL-1 beta
P11040101A1180|132 138|p38 MAPK
P11040101A1180|142 154|JNK signalings
P11040101A1180|180 192|transcription
P11040101A1180|197 204|VEGF gene
P11040101A1180|223 227|sites
P11040219A0548|0 6|Binding
P11040219A0548|27 34|presence
P11040219A0548|35 39|alpha
P11040219A0548|69 84|S1 homology region
P11041308A0156|3 10|subjects
P11041308A0156|29 33|basis
P11041308A0156|36 41|DSM-IV
P11041308A0156|54 69|gambling criteria
P11041308A0156|92 98|Version
P11041308A0156|101 123|South Oaks Gambling Screen
P11042197A0386|68 79|dimerization
P11042199A0572|0 8|Elevation
P11042199A0572|28 33|levels
P11042199A0572|55 63|treatment
P11042199A0572|87 93|protein
P11042199A0572|94 103|nifedipine
P11042199A0572|104 108|MK801
P11042199A0572|109 115|removal
P11042199A0572|129 134|medium
P11042199A0572|137 146|dantrolene
P11042199A0572|165 180|calcium elevation
P11042199A0572|196 205|activation
P11042204A0186|10 14|study
P11042204A0186|24 43|phosphatidylinositol
P11042204A0186|62 80|p38 kinase activation
P11042204A0186|90 107|Akt phosphorylation
P11042204A0186|111 118|activity
P11042204A0186|126 136|neutrophils
P11042703A0875|23 31|reference
P11042703A0875|31 40|W/A Z scores
P11042703A0875|65 74|increments
P11042703A0875|79 83|birth
P11042703A0875|86 90|girls
P11043469A0440|13 27|border sequences
P11043469A0440|64 72|T-regions
P11043469A0440|89 96|T-region
P11043469A0440|99 106|pTiChry5
P11043469A0440|113 119|T-right
P11043469A0440|135 144|production
P11043469A0440|149 161|Amadoriopines
P11044097A0422|73 77|sites
P11044097A0422|98 116|transcription factor
P11044097A0422|124 128|sites
P11044097T0000|19 25|protein
P11044097T0000|38 44|binding
P11044097T0000|47 66|transcription factors
P11044097T0000|72 79|U5 region
P11044097T0000|90 114|immunodeficiency virus type
P11044097T0000|124 131|promoter
P11044105A0616|17 23|element
P11044105A0616|30 47|splicing suppressor
P11044105A0616|83 92|splice site
P11045180A1892|0 10|Leptinaemia
P11045180A1892|46 65|blood pressure reading
P11045180A1892|73 77|stage
P11045180A1892|80 91|hypertension
P11045180A1892|109 122|classification
P11045607A0239|0 11|RACE analysis
P11045607A0239|28 54|transcription initiation site
P11045607A0239|90 98|start site
P11046146A1202|4 19|diamide treatment
P11046146A1202|29 36|extracts
P11046146A1202|55 61|binding
P11046146A1202|64 74|NFI proteins
P11046146A1202|81 88|addition
P11046146A1202|97 110|concentrations
P11046146A1202|113 126|dithiothreitol
P11046146A1202|136 143|extracts
P11046146A1202|158 162|cells
P11046146A1202|171 184|NFI-DNA binding
P11046146A1202|187 192|levels
P11046146A1202|195 202|extracts
P11046146A1202|216 220|cells
P11046148A0716|0 4|LMP2A
P11046148A0716|21 37|Syk ubiquitination
P11046148A0716|46 52|fashion
P11046148A0716|69 76|activity
P11046148A0716|79 96|Nedd4 family members
P11046148A0716|114 128|destabilization
P11046148A0716|134 150|Lyn tyrosine kinase
P11046153A1052|19 27|apoptosis
P11046153A1052|60 69|expression
P11046153A1052|75 89|p300 coactivator
P11046517A0619|3 9|results
P11048832A0271|0 5|Fisher
P11048832A0271|20 26|Pearson
P11048832A0271|27 34|chi2 test
P11048832A0271|57 64|analysis
P11049241A0659|0 6|RESULTS
P11049241A0659|20 24|group
P11049241A0659|25 47|serum PP14 concentrations
P11049241A0659|93 102|difference
P11049241A0659|120 124|group
P11049241A0659|142 146|group
P11049889A1271|0 18|Thromboelastography
P11049889A1271|64 69|degree
P11049889A1271|71 85|anticoagulation
P11049889A1271|108 120|weight heparin
P11050084A0000|4 13|expression
P11050084A0000|19 28|peroxisome
P11050084A0000|51 63|receptor alpha
P11050084A0000|64 72|PPARalpha
P11050084A0000|127 134|capacity
P11050084A0000|136 149|lipid oxidation
P11050084A0888|13 19|element
P11050084A0888|25 33|PPARalpha
P11050084A0888|37 45|PPARgamma
P11050084A0888|58 63|nuclei
P11050168A1185|5 11|results
P11050168A1185|25 32|evidence
P11050168A1185|48 61|susceptibility
P11050168A1185|85 93|mRNA decay
P11050168A1185|122 129|affinity
P11050168A1185|144 150|protein
P11050168A1185|164 184|stability determinants
P11051364A0890|0 6|RESULTS
P11051364A0890|21 28|patients
P11051364A0890|42 47|group A
P11051364A0890|75 93|variceal eradication
P11051364A0890|92 97|group B
P11051370A1906|0 7|Response
P11051370A1906|33 41|Americans
P11051370A1906|54 64|HCV genotype
P11053009A0000|0 6|Aspirin
P11053009A0000|19 24|ulcers
P11053009A0000|62 75|cyclooxygenase
P11053009A0000|81 88|activity
P11053009A0000|91 112|prostaglandin synthesis
P11053263A0200|1 5|total
P11053263A0200|12 17|clones
P11053263A0200|41 50|sequencing
P11053370A0708|0 9|Expression
P11053370A0708|13 25|hybrid protein
P11053370A0708|81 104|glutathione S-transferase
P11053370A0708|126 137|Uhp signaling
P11054011A1685|0 10|CONCLUSIONS
P11054011A1685|37 45|treatment
P11054011A1685|70 88|locoregional control
P11054011A1685|106 113|survival
P11054011A1685|115 120|series
P11054011A1685|123 130|patients
P11054011A1685|143 160|oncology department
P11054011A1685|171 178|hospital
P11054011A1685|181 185|Quito
P11054011A1685|186 192|Ecuador
P11054341A0599|0 6|RESULTS
P11054341A0599|7 22|Glaucoma suspects
P11054341A0599|41 46|groups
P11054341A0599|90 106|SWAP abnormalities
P11054341A0599|127 136|SWAP result
P11054539A0114|28 32|exons
P11054539A0114|44 50|introns
P11054539A0114|61 72|reading frame
P11054539A0114|87 95|base pairs
P11054539A0114|118 128|polypeptide
P11054539A0114|134 150|amino acid residues
P11054565A0654|7 16|p190-B exon
P11054565A0654|33 38|p190-A
P11054565A0654|63 68|length
P11054565A0654|83 88|GTPase
P11054565A0654|98 104|domains
P11054565A0654|105 112|residues
P11054565A0654|137 145|GAP domain
P11054565A0654|161 172|conservation
P11054565A0654|182 190|structure
P11054565A0654|201 209|p190 genes
P11054571A0230|14 23|teneurin-1
P11054571A0230|54 62|PAC clones
P11054571A0230|95 103|locus Xq25
P11054970A0282|3 23|plexiform neurofibroma
P11054970A0282|44 56|neurofibromas
P11055513A0564|9 16|lookback
P11055513A0564|20 27|patients
P11055513A0564|39 43|blood
P11055513A0564|64 73|hepatitis C
P11055513A0564|93 99|testing
P11055786A0306|11 19|algorithm
P11055786A0306|37 41|steps
P11056007A0224|21 30|amino acids
P11056007A0224|33 39|FVVLNLQ
P11056007A0224|49 55|stretch
P11056007A0224|63 70|sequence
P11056007A0224|117 124|Suvar3-9
P11056007A0224|122 138|Enhancer-of-zeste
P11056007A0224|139 147|Trithorax
P11056007A0224|159 164|domain
P11056019A0926|14 32|glycosylase activity
P11056019A0926|46 51|adduct
P11056019A0926|54 67|ethenocytosine
P11056019A0926|68 77|metabolite
P11056019A0926|80 92|vinyl chloride
P11056019A0926|96 109|ethyl carbamate
P11058008A0159|11 19|instances
P11058008A0159|27 38|flap necrosis
P11058008A0159|50 54|flaps
P11058008A0159|61 72|tip ischaemia
P11058119A0957|5 11|results
P11058119A0957|48 53|GTPase
P11058119A0957|70 81|localization
P11058120A0256|10 16|factors
P11058120A0256|17 21|IRF-2
P11058120A0256|56 66|counterpart
P11058120A0256|69 73|IRF-1
P11058120A0256|87 95|potential
P11058132A0264|21 35|% match sequences
P11058132A0264|37 44|proteins
P11058132A0264|56 71|Bacillus subtilis
P11058132A0264|101 110|comparison
P11058132A0264|117 124|proteins
P11058132A0264|134 142|organisms
P11058132A0264|152 161|B.subtilis
P11058406A0447|56 70|circulation time
P11058406A0447|100 117|tobramycin solution
P11059492A0376|0 8|Bacteriol
P11059777A0813|8 23|deoxynucleotidyl
P11059777A0813|44 64|nick end labeling assays
P11059777A0813|85 94|activation
P11059777A0813|100 113|PAX3 repressors
P11059777A0813|130 138|apoptosis
P11059777A0813|157 171|down-regulation
P11059777A0813|174 178|BCL-X
P11059777A0813|181 190|expression
P11059786A0682|0 19|VEGF promoter activity
P11059786A0682|31 43|transfections
P11059786A0682|88 97|inhibition
P11059786A0682|113 132|phosphatidylinositol
P11059786A0682|131 136|kinase
P11059786A0682|141 146|kinase
P11059786T0000|9 28|growth factor receptor
P11059786T0000|77 98|growth factor expression
P11059786T0000|106 122|glioblastoma cells
P11059786T0000|127 133|pathway
P11059786T0000|143 162|phosphatidylinositol
P11059786T0000|163 168|kinase
P11059786T0000|197 203|hypoxia
P11062047A1208|4 8|IHHNV
P11062047A1208|27 38|densoviruses
P11062047A1208|44 63|genus Brevidensovirus
P11062047A1208|69 86|family Parvoviridae
P11062047A1208|120 153|virus Penaeus stylirostris densovirus
P11062047A1208|154 159|PstDNV
P11062067A0000|16 28|protein kinase
P11062067A0000|30 34|SAPK1
P11062067A0000|45 49|c-Jun
P11062067A0000|60 65|kinase
P11062067A0000|95 102|response
P11062067A0000|120 128|cytokines
P11062067A0000|139 146|stresses
P11062068T0000|9 18|activation
P11062068T0000|38 44|protein
P11062068T0000|50 68|kinase phosphatase-1
P11062068T0000|79 90|p38 MAP kinase
P11062068T0000|125 130|domain
P11062068T0000|142 151|regulation
P11062257A0977|7 23|class C-Vps complex
P11062257A0977|39 47|reactions
P11062257A0977|57 63|docking
P11062257A0977|67 72|fusion
P11062257A0977|75 82|vesicles
P11062257A0977|90 96|vacuole
P11062257A0977|131 141|specificity
P11062257A0977|145 154|efficiency
P11062257A0977|161 176|transport process
P11062274T0000|47 72|tissue plasminogen activator
P11062274T0000|88 93|stroke
P11062705A0658|44 48|ATF-2
P11062705A0658|56 69|cancer cell line
P11063127A0000|0 17|Signal transduction
P11063127A0000|21 30|modulation
P11063127A0000|33 47|phosphorylation
P11063127A0000|62 71|inhibition
P11063127A0000|74 91|protein phosphatase
P11063127A0000|155 161|effects
P11063169T0000|0 14|Botulinum toxin A
P11063169T0000|20 28|treatment
P11063169T0000|48 55|foot drop
P11063169T0000|77 84|outcomes
P11063252A0437|0 4|Exon A
P11063252A0437|38 60|HSL translation start site
P11063742A0000|0 8|NF-kappaB
P11063742A0000|27 45|transcription factor
P11063742A0000|75 80|stress
P11063742A0000|89 96|chemical
P11063742A0000|110 119|reductants
P11064829T0058|0 24|Cardiovascular risk factors
P11064829T0058|44 52|treatment
P11066245T0000|20 35|compliance review
P11066245T0000|44 51|mistakes
P11067797A1306|0 10|CONCLUSIONS
P11067797A1306|11 24|EBCT technology
P11067797A1306|48 57|evaluation
P11067797A1306|91 98|function
P11067797A1306|109 118|assessment
P11067797A1306|134 147|BV distribution
P11067797A1306|169 178|components
P11067928A0532|38 49|gene segments
P11067928A0532|60 65|Vkappa
P11067928A0532|68 78|Jkappa genes
P11069011A0224|0 13|SSF experiments
P11069011A0224|41 51|bioreactors
P11069011A0224|87 91|traps
P11069011A0224|102 108|mixture
P11069011A0224|126 134|materials
P11069011A0224|151 159|pesticide
P11069075T0000|0 15|Characterization
P11069075T0000|19 51|Xenopus laevis CXC chemokine receptor
P11069075T0000|53 64|implications
P11069075T0000|81 95|cell development
P11069075T0000|101 116|vertebrate embryo
P11069223A0593|0 7|Patients
P11069223A0593|25 29|liver
P11069223A0593|38 52|marrow functions
P11069307A0546|0 9|Inhibition
P11069307A0546|12 26|RNA2 translation
P11069307A0546|45 50|effect
P11069307A0546|68 78|translation
P11069307A0546|81 91|translation
P11069307A0546|111 129|replication factor 1a
P11069307A0546|162 171|antagonist
P11069307A0546|173 184|DED1 function
P11069307A0546|187 197|translation
P11069756A2618|0 12|Abbreviations
P11069756A2618|32 40|substrate
P11069756A2618|61 66|domain
P11069756A2618|81 89|SRC kinase
P11069756A2618|93 115|Papillomavirus E6 protein
P11069756A2618|125 138|adhesion kinase
P11069756A2618|143 155|GRK interacter
P11069756A2618|193 200|receptor
P11069756A2618|205 236|G-protein-coupled-receptor kinase
P11069756A2618|259 271|protein kinase
P11069756A2618|304 309|kinase
P11069756A2618|327 335|subdomain
P11069756A2618|355 368|exchange factor
P11069756A2618|373 392|paxillin kinase linker
P11069756A2618|398 404|partner
P11069756A2618|415 427|phosphoserine
P11069756A2618|430 445|phosphothreonine
P11069756A2618|449 463|phosphotyrosine
P11069756A2618|468 501|growth factor receptor tyrosine kinase
P11069756A2618|517 522|domain
P11069788A0531|47 54|patients
P11069788A0531|68 81|difference PEEP
P11069788A0531|95 99|decay
P11069788A0531|147 152|dyn ref
P11069791A0226|13 20|subjects
P11069791A0226|83 90|Regimen A
P11069791A0226|140 147|Regimen B
P11069791A0226|195 202|Regimen C
P11069825A0530|12 16|cases
P11069825A0530|19 30|tuberculosis
P11069825A0530|54 62|follow-up
P11069825A0530|73 81|incidence
P11069897A1112|5 11|results
P11069897A1112|25 30|BACH1t
P11069897A1112|39 43|BACH1
P11069897A1112|49 55|nucleus
P11069897A1112|83 93|interaction
P11069999A1602|3 9|U17/U16
P11069999A1602|21 32|gene products
P11069999A1602|49 54|HIV LTR
P11070007A0136|0 12|Transcription
P11070007A0136|21 29|EBNA genes
P11070007A0136|72 77|B cells
P11070007A0136|96 104|promoters
P11070007A0136|149 154|genome
P11070056A0704|3 17|Cili-2 sequences
P11070056A0704|25 34|similarity
P11070056A0704|40 51|RNaseH domain
P11070056A0704|54 61|Lian-Aa1
P11070056A0704|63 70|mosquito
P11070056A0704|78 92|retrotransposon
P11070078A1153|11 18|response
P11070078A1153|50 74|Rb tumor suppressor pathways
P11070078A1153|85 93|HeLa cells
P11070078A1153|101 110|repression
P11070078A1153|113 117|HPV E6
P11070078A1153|139 146|pathways
P11070078A1153|157 163|fashion
P11070078A1153|173 178|growth
P11070078A1153|189 195|signals
P11070078A1153|201 205|cells
P11071651A1308|32 38|pathway
P11071651A1308|57 71|differentiation
P11071651A1308|91 107|retinoid induction
P11071651A1308|110 126|FR-beta expression
P11071789T0000|21 30|dose levels
P11071789T0000|33 45|ACE inhibitors
P11071789T0000|55 66|heart failure
P11071852A0297|18 23|SOCS-3
P11071852A0297|38 42|IGFIR
P11071852A0297|56 61|SOCS-3
P11071852A0297|95 107|chain reaction
P11071852A0297|125 134|muscle mRNA
P11071924A0588|1 7|protein
P11071924A0588|26 42|RING finger domains
P11071924A0588|47 54|activity
P11071924A0588|67 73|protein
P11071924A0588|89 105|RING finger domains
P11071924A0588|107 111|SLI-1
P11071924A0588|135 141|domains
P11071924A0588|144 148|c-Cbl
P11071924A0588|152 159|activity
P11071974A0155|13 19|effects
P11071974A0155|34 40|factors
P11071974A0155|56 62|disease
P11071974A0155|69 76|patients
P11071974A0155|90 96|changes
P11071974A0155|99 110|lipid profile
P11071974A0155|111 121|coagulation
P11071974A0155|125 143|fibrinolysis markers
P11071974A0155|147 170|plasma homocysteine levels
P11071974A0155|176 184|treatment
P11072155A0764|24 34|correlation
P11072155A0764|42 48|TGF beta
P11072155A0764|50 55|levels
P11072155A0764|65 84|cell radiosensitivity
P11072155A0764|85 97|lymphocyte SF2
P11072388T0000|5 15|feasibility
P11072388T0000|19 24|safety
P11072388T0000|28 51|smoking reduction strategy
P11072388T0000|55 61|smokers
P11072388T0000|66 78|schizophrenia
P11073163A0131|25 35|degradation
P11073163A0131|38 45|proteins
P11073163A0131|57 72|cell cycle control
P11073163A0131|92 101|proteasome
P11073163A0131|114 130|cell proliferation
P11073163A0131|134 145|cell survival
P11073218A0800|8 17|nucleotide
P11073218A0800|51 57|U.G pair
P11073218A0800|78 83|region
P11073539A0866|10 17|analysis
P11073539A0866|29 34|desmin
P11073539A0866|48 52|cells
P11073539A0866|57 67|aggregation
P11073539A0866|84 89|clumps
P11073539A0866|106 113|material
P11073539A0866|136 144|cytoplasm
P11073870A0375|0 7|Patients
P11073870A0375|12 18|lesions
P11073870A0375|57 64|patients
P11073870A0375|67 73|lesions
P11073870A0375|111 120|oculomotor
P11073870A0375|126 137|response task
P11073870A0375|161 172|memory delays
P11073919A0631|2 9|addition
P11073919A0631|12 28|amino acid residues
P11073919A0631|185 201|mouse ODC numbering
P11073919A0631|204 212|formation
P11073919A0631|244 249|domain
P11073919A0631|273 278|domain
P11073919A0631|284 301|dimer stabilization
P11073919A0631|344 359|S. ruminantium LDC
P11073954A0337|3 10|Psc2 cDNA
P11073954A0337|26 37|reading frame
P11073954A0337|50 66|CP2 family proteins
P11074003A0741|3 9|results
P11074003A0741|44 50|cycling
P11074003A0741|73 77|CGNPs
P11074210A0623|3 12|QT interval
P11074210A0623|32 41|components
P11074210A0623|47 71|insulin resistance syndrome
P11074210A0623|88 105|insulin sensitivity
P11075678A0298|3 13|wavenumbers
P11075678A0298|38 42|modes
P11075678A0298|45 53|vibration
P11075678A0298|81 87|B3LYP/6
P11075678A0298|92 104|approximation
P11075678A0298|112 120|agreement
P11075678A0298|136 141|values
P11075678A0298|177 186|force field
P11075929A1657|22 29|evidence
P11075929A1657|54 63|metabolism
P11075929A1657|85 93|formation
P11075929A1657|116 123|function
P11075944A0691|2 9|addition
P11075944A0691|53 65|MMTV insertion
P11075944A0691|83 91|androgens
P11075944A0691|94 102|SC-3 cells
P11076860A0872|0 10|Experiments
P11076860A0872|29 36|proteins
P11076860A0872|45 49|UEV1A
P11076860A0872|60 66|protein
P11076860A0872|86 92|Kua-UEV
P11076860A0872|113 122|structures
P11076860A0872|140 148|Kua domain
P11076860A0872|173 184|localization
P11076860A0872|187 193|Kua-UEV
P11078726X0000|14 28|phosphorylation
P11078726X0000|43 48|Ser315
P11078726X0000|71 83|transcription
P11078726X0000|94 111|p53 protein activity
P11078726X0000|115 133|transcription factor
P11078726X0000|156 165|antibodies
P11078726X0000|207 212|domain
P11078726X0000|235 241|enzymes
P11078726X0000|256 261|domain
P11078726X0000|302 315|gene expression
P11080796A0883|23 30|cell line
P11080796A0883|36 45|expression
P11080796A0883|66 72|protein
P11080796A0883|72 79|IKKgamma
P11080796A1277|3 25|Tax/IKKgamma interaction
P11080796A1277|65 72|subunits
P11080796A1277|71 78|IKKalpha
P11080796A1277|82 88|IKKbeta
P11080796A1277|96 106|recruitment
P11080796A1277|129 137|mechanism
P11080796A1277|163 170|activity
P11081962T0000|54 58|Avena
P11082185A0415|2 9|addition
P11082185A0415|46 51|domain
P11082185A0415|68 77|amino acids
P11082185A0415|80 84|IRF-1
P11082185A0415|124 131|activity
P11082587X0000|0 6|Effects
P11082587X0000|27 35|smoothing
P11082587X0000|48 66|brillouin scattering
P11082587X0000|92 101|model limit
P11082587X0000|105 113|influence
P11082587X0000|116 133|laser beam smoothing
P11082587X0000|146 168|Brillouin backscattering
P11082587X0000|201 205|limit
P11082587X0000|224 232|spot model
P11082715X0001|12 24|determination
P11082715X0001|27 38|theophylline
P11082715X0001|45 55|metabolites
P11082715X0001|69 79|performance
P11082715X0001|85 98|chromatography
P11082715X0001|105 110|method
P11082715X0001|144 156|determination
P11082715X0001|159 170|theophylline
P11082715X0001|177 187|metabolites
P11082715X0001|192 199|caffeine
P11082715X0001|206 216|metabolites
P11083154A0881|3 7|males
P11083154A0881|21 34|test conditions
P11083154A0881|38 52|oxygen uptake VO2
P11083154A0881|53 61|heart rate
P11083154A0881|62 80|minute ventilation VE
P11083154A0881|90 97|exertion
P11083154A0881|107 115|shrinkage
P11083358A1071|0 9|CONCLUSION
P11083358A1071|53 60|patients
P11083358A1071|72 81|aspiration
P11083432A0332|7 12|groups
P11083432A0332|27 33|control
P11083868A0386|0 9|DNA binding
P11083868A0386|13 36|glutathione S-transferase
P11083868A0386|46 51|assays
P11083868A0386|67 73|binding
P11083868A0386|82 86|Elk-1
P11083868A0386|110 130|transactivation domain
P11084022A1178|12 24|ALK7 signaling
P11084022A1178|44 49|change
P11084022A1178|52 65|cell morphology
P11084022A1178|81 94|cell flattening
P11084022A1178|98 108|elaboration
P11084022A1178|121 133|cell processes
P11084334A0590|3 14|swa2-1 allele
P11084334A0590|39 44|screen
P11084334A0590|53 65|point mutation
P11084334A0590|71 93|tetratricopeptide repeat
P11084334A0590|99 104|domain
P11084334A0590|105 109|motif
P11084334A0590|120 126|auxilin
P11084334A0590|142 149|proteins
P11084334A0590|159 169|interaction
P11084334A0590|184 191|proteins
P11084556T0000|0 10|Association
P11084556T0000|13 18|stress
P11084556T0000|25 32|delivery
P11084556T0000|46 52|numbers
P11084556T0000|64 68|cells
P11084556T0000|85 99|progenitor cells
P11084556T0000|111 119|cord blood
P11084649A0497|15 21|embryos
P11084649A0497|25 34|expression
P11084649A0497|60 65|embryo
P11084649A0497|80 84|onset
P11084649A0497|86 97|gastrulation
P11084649A0497|98 107|expression
P11084649A0497|120 127|epiblast
P11084649A0497|136 143|endoderm
P11084649A0497|151 158|mesoderm
P11084649A0497|174 179|streak
P11085267A0562|0 13|Transformation
P11085267A0562|19 30|sconC3 mutant
P11085267A0562|35 39|sconB
P11085267A0562|60 68|phenotype
P11085600A0123|3 9|authors
P11085600A0123|41 46|inputs
P11085600A0123|62 67|cortex
P11085600A0123|80 85|region
P11085600A0123|137 147|information
P11086872A0000|0 8|Influence
P11086872A0000|11 22|oil emulsions
P11086872A0000|26 33|diphenyl
P11086872A0000|66 72|changes
P11086872A0000|75 84|Kagzi limes
P11086872A0000|85 102|Citrus aurantifolia
P11087141A0977|8 15|analysis
P11087141A0977|18 23|alpha1
P11087141A0977|24 36|GT transcripts
P11087141A0977|64 79|splicing patterns
P11087141A0977|97 102|region
P11087141A0977|111 118|evidence
P11087141A0977|126 141|splicing activity
P11087141A0977|170 175|manner
P11088635A0200|8 37|Kubo-Martin-Schwinger condition
P11088635A0200|52 59|coupling
P11088635A0200|63 70|computer
P11088635A0200|88 93|source
P11088635A0200|117 129|usage patterns
P11088635A0200|135 140|system
P11089911A1267|17 25|sequences
P11089911A1267|44 50|regions
P11089911A1267|75 87|transcription
P11089911A1267|94 111|retrotransposition
P11089911A1267|117 128|ATLN elements
P11090172A0612|3 12|time course
P11090172A0612|15 29|RNA1 replication
P11090172A0612|33 45|RNA3 synthesis
P11090172A0612|55 59|yeast
P11090172A0612|76 80|yeast
P11090172A0612|103 114|FHV virion RNA
P11090272A1240|3 15|transcription
P11090272A1240|30 37|splicing
P11090762A0527|0 6|RESULTS
P11090762A0527|14 19|effect
P11090762A0527|22 31|muscle pain
P11090762A0527|53 63|stimulation
P11090762A0527|94 101|increase
P11090762A0527|104 108|delta
P11090762A0527|116 120|power
P11090762A0527|125 131|alpha-1
P11090762A0527|140 152|power increase
P11090762A0527|172 184|parietal locus
P11092770A0238|3 12|extraction
P11092770A0238|81 86|class C
P11092770A0238|90 98|predictor
P11092770A0238|111 120|extraction
P11092770A0238|121 131|specificity
P11092770A0238|142 152|sensitivity
P11092809A0823|2 9|addition
P11092809A0823|13 19|results
P11092809A0823|37 41|PI3Ks
P11092809A0823|62 69|ectoderm
P11092809A0823|74 81|mesoderm
P11092850A1023|7 33|16S rRNA gene sequence analysis
P11092850A1023|39 45|species
P11092850A1023|55 62|tuf genes
P11092850A1023|77 84|ancestor
P11092850A1023|96 102|species
P11092850A1023|149 155|lineage
P11092850A1023|171 178|ancestor
P11092886A0341|12 36|protein kinase A stimulation
P11092886A0341|44 52|CREMalpha
P11092886A0341|66 72|complex
P11092886A0341|79 86|promoter
P11092886A0341|92 123|phosphoenolpyruvate carboxykinase
P11092886A0341|124 128|PEPCK
P11093745A0563|15 22|HNF3 site
P11093745A0563|30 39|apposition
P11093745A0563|43 53|NF1/CTF site
P11093745A0563|92 98|element
P11094066A0505|19 28|regulation
P11094066A0505|42 51|modulation
P11094066A0505|57 90|forkhead transcription factor FKHR-L1
P11094066A0505|109 123|FKHR-L1 activity
P11094066A0505|140 145|manner
P11094066A1194|18 29|observations
P11094066A1194|42 51|inhibition
P11094066A1194|64 76|transcription
P11094066A1194|94 115|FKHR-L1 phosphorylation
P11094066A1194|130 138|mechanism
P11094066A1194|168 175|survival
P11094066A1194|179 191|proliferation
P11094072A0842|0 4|DNase
P11094072A0842|13 24|footprinting
P11094072A0842|40 48|c-Myb site
P11094072A0842|77 83|fashion
P11094072A1234|14 18|c-Myb
P11094072A1234|31 43|RAG-2 promoter
P11094072A1234|46 51|T cells
P11094072A1234|67 80|consensus c-Myb
P11094073A0000|20 25|member
P11094073A0000|31 47|Vav family proteins
P11094073A0000|74 105|Ros receptor protein tyrosine kinase
P11094073A0000|122 128|protein
P11094073A0000|130 134|yeast
P11094073A0000|145 153|screening
P11094075A0257|25 36|reexpression
P11094075A0257|42 53|r-PTPeta gene
P11094075A0257|71 85|rat thyroid cells
P11094075A0257|99 110|retroviruses
P11094075A0257|122 126|v-mos
P11094075A0257|130 146|v-ras-Ki oncogenes
P11094075A0257|171 179|phenotype
P11094087T0000|7 16|expression
P11094087T0000|41 54|transformation
P11094087T0000|75 79|cells
P11094087T0000|122 134|kinase pathway
P11094091A0000|3 10|activity
P11094091A0000|16 38|transcription factor CREB
P11094091A0000|65 71|stimuli
P11094091A0000|87 101|phosphorylation
P11094091A0000|113 125|serine residue
P11094091A0000|126 131|Ser133
P11094109A0600|0 6|RESULTS
P11094109A0600|21 32|symptom onset
P11094109A0600|39 43|years
P11094590A0617|6 11|fields
P11094590A0617|31 42|relationship
P11094590A0617|61 68|presence
P11094590A0617|71 78|bacteria
P11094590A0617|81 92|Gram staining
P11094590A0617|104 112|diagnosis
P11094590A0617|148 158|sensitivity
P11094590A0617|165 175|specificity
P11094590A0617|203 207|value
P11094590A0617|235 239|value
P11095248A0423|18 25|proteins
P11095248A0423|26 30|XFGF3
P11095248A0423|65 76|glycoprotein
P11095248A0423|107 114|cleavage
P11095248A0423|148 154|product
P11095248A1523|22 28|Xenopus
P11095248A1523|41 45|FGF3s
P11095248A1523|61 72|prerequisite
P11095248A1523|92 99|activity
P11095981A0254|21 32|cis-elements
P11095981A0254|44 54|replication
P11095981A0254|67 76|bp promoter
P11095981A0254|105 112|plasmids
P11095981A0254|128 136|mutations
P11095981A0254|140 148|deletions
P11096662T0000|0 8|Tranilast
P11096662T0000|14 20|Therapy
P11096662T0000|31 43|Artery Disease
P11097040A0000|3 12|objectives
P11097040A0000|25 29|study
P11097040A0000|47 53|effects
P11097040A0000|62 66|Equex
P11097040A0000|70 82|TRIS-extender
P11097040A0000|94 98|semen
P11097040A0000|105 109|steps
P11097040A0000|110 117|freezing
P11097040A0000|130 136|methods
P11097040A0000|147 151|rates
P11097040A0000|158 169|interactions
P11097040A0000|182 191|treatments
P11097040A0000|206 213|survival
P11097040A0000|216 229|dog spermatozoa
P11097040A0000|234 242|degrees C.
P11097079A0525|4 8|study
P11097079A0525|35 44|validation
P11097079A0525|50 58|clinician
P11097079A0525|64 73|NIMH-LCM-p
P11098217A0674|3 11|Aie1 locus
P11098217A0674|23 43|mouse chromosome 7A2-A3
P11098217A0674|63 75|hybridization
P11098420A0175|11 19|disorders
P11098420A0175|22 29|children
P11098420A0175|33 43|adolescents
P11098420A0175|61 69|morbidity
P11098420A0175|76 86|development
P11098420A0175|107 115|mortality
P11098420A0175|118 124|suicide
P11099377T0000|9 15|cloning
P11099377T0000|19 28|expression
P11099377T0000|36 47|UDP-d-Xylose
P11099377T0000|47 94|proteoglycan core protein beta-d-xylosyltransferase
P11099377T0000|106 117|isoform XT-II
P11100515A0282|0 13|Thyrotoxicosis
P11100515A0282|19 28|amiodarone
P11100515A0282|89 97|potential
P11100515A0282|100 113|thyrotoxicosis
P11100515A0282|140 145|effect
P11100515A0282|151 170|amiodarone withdrawal
P11101008A0649|0 14|Chaperones/HSPs
P11101008A0649|32 36|roles
P11101008A0649|43 60|cell cycle processes
P11101847A0159|9 18|signalling
P11101847A0159|50 62|stabilization
P11101847A0159|65 74|activation
P11101847A0159|80 98|tumour suppressor p53
P11102367A1170|4 8|study
P11102367A1170|23 33|conclusions
P11102367A1170|42 49|identity
P11102367A1170|52 59|proteins
P11102367A1170|74 84|development
P11102367A1170|97 102|system
P11102367A1170|105 114|Drosophila
P11102367A1170|128 134|example
P11102367A1170|147 154|approach
P11102367A1170|171 175|masse
P11102367A1170|193 201|mutations
P11102367A1170|221 227|screens
P11102458A0000|13 26|identification
P11102458A0000|37 52|characterization
P11102458A0000|55 66|neurobeachin
P11102458A0000|94 100|protein
P11102458A0000|177 183|subunit
P11102458A0000|180 193|protein kinase A
P11102458A0000|194 199|PKA RII
P11103472A0802|0 7|Children
P11103472A0802|42 55|CNV-1 amplitude
P11103472A0802|59 63|trend
P11103472A0802|80 84|CNV-1
P11103472A0802|88 92|CNV-2
P11103472A0802|102 111|amplitudes
P11103601T0025|5 9|UMDNJ
P11103792A0755|0 13|Overexpression
P11103792A0755|16 20|c-Myc
P11103792A0755|43 47|mouse
P11103792A0755|57 61|cells
P11103792A0755|69 77|apoptosis
P11103792A0755|110 117|presence
P11103792A0755|120 125|growth
P11103792A0755|143 147|serum
P11103792A0755|186 194|apoptosis
P11103792A0755|217 224|bax-null
P11103792A0755|252 256|mouse
P11103792A0755|266 276|fibroblasts
P11105129T0000|13 26|Susceptibility
P11105129T0000|29 38|Klebsiella
P11105129T0000|49 88|Producing Extended-Spectrum beta-lactamase
P11105129T0000|105 113|Hospitals
P11105129T0000|115 120|Brazil
P11105716A0782|0 9|CONCLUSION
P11105716A0782|13 19|results
P11105716A0782|31 47|AIF peak saturation
P11105716A0782|77 81|error
P11105716A0782|87 99|determination
P11105716A0782|110 118|CBF values
P11105716A0782|148 154|account
P11105716A0782|182 199|MR perfusion studies
P11105717A0123|0 6|METHODS
P11105717A0123|48 53|images
P11105717A0123|88 111|susceptibility difference
P11105717A0123|144 153|hemoglobin
P11105717A0123|159 169|vasculature
P11105717A0123|173 188|microvasculature
P11106216A0918|5 16|COPD patients
P11106216A0918|20 30|variability
P11106216A0918|72 77|FOT Rrs
P11106428A0635|34 41|proteins
P11106428A0635|63 68|domain
P11106428A0635|71 75|FAP-1
P11106428A0635|89 98|amino acids
P11106428A0635|118 124|Cys2408
P11106428A0635|136 160|glutathione-S-transferase
P11106667A1061|4 10|Pet111p
P11106667A1061|24 28|roles
P11106667A1061|35 54|membrane localization
P11106667A1061|58 67|regulation
P11106667A1061|70 83|Cox2p synthesis
P11106667A1061|90 101|mitochondria
P11106668A0875|11 22|transfection
P11106668A0875|25 29|cells
P11106668A0875|37 53|spacer-RING domain
P11106668A0875|85 92|function
P11106668A0875|108 116|BIR domain
P11106668A0875|119 124|c-IAP1
P11106668A0875|135 143|apoptosis
P11107637X0001|3 15|determination
P11107637X0001|27 32|bounds
P11107637X0001|35 50|blood serum lipids
P11107637X0001|53 61|titration
P11107637X0001|66 70|ozone
P11107637X0001|74 88|pathophysiology
P11107637X0001|102 113|significance
P11107637X0001|120 126|article
P11107637X0001|130 135|method
P11107637X0001|138 147|definition
P11107637X0001|156 162|binders
P11107637X0001|165 170|lipids
P11107637X0001|173 182|blood serum
P11107637X0001|185 192|patients
P11107637X0001|206 213|diseases
P11107637X0001|223 237|atherosclerosis
P11107637X0001|249 260|heart disease
P11107637X0001|265 276|use titration
P11107637X0001|279 283|ozone
P11108151A0560|15 29|fibronectin mRNA
P11108151A0560|45 57|PKC inhibitors
P11108151A0560|60 71|PKC depletion
P11108151A0560|87 96|inhibition
P11108151A0560|99 111|EGF-R function
P11108151A0560|131 141|EGF-R mutant
P11108151A0560|145 160|tyrphostin AG1478
P11108151A0560|170 178|induction
P11108151A0560|181 195|fibronectin mRNA
P11108374A1466|0 5|Acoust
P11108523A0326|0 10|Video images
P11108523A0326|16 23|nostrils
P11108523A0326|60 68|perimeter
P11108523A0326|68 75|centroid
P11108523A0326|91 97|moments
P11108523A0326|134 143|anisometry
P11108523A0326|141 149|bulkiness
P11108523A0326|163 179|internostril angle
P11108523A0326|193 197|angle
P11108548A0710|0 16|MS characteristics
P11108548A0710|19 27|coumarins
P11108548A0710|28 36|psoralens
P11108548A0710|56 63|flavones
P11108548A0710|77 96|substitution patterns
P11108548A0710|116 120|basis
P11108548A0710|126 133|response
P11108548A0710|149 161|APcI interface
P11108616A0000|0 8|Young fish
P11108616A0000|9 30|Oreochromis mossambicus
P11108616A0000|44 55|microgravity
P11108616A0000|84 102|space missions STS-55
P11108616A0000|104 109|STS-84
P11108616A0000|114 125|hypergravity
P11108720A0124|37 46|core kinase
P11108720A0124|48 53|linker
P11108720A0124|64 70|domains
P11108720A0124|112 118|regions
P11108720A0124|156 162|nucleus
P11108720A0124|190 207|localization signal
P11108720A1130|0 11|Pretreatment
P11108720A1130|14 18|cells
P11108720A1130|80 91|kinase kinase
P11108720A1130|97 110|inhibitor U0126
P11108720A1130|119 132|S6K2 activation
P11108720A1130|143 148|extent
P11108839A0401|0 5|T cells
P11108839A0401|16 23|isoforms
P11108839A0401|51 56|kinase
P11108839A0401|62 71|kDa isoform
P11108839A0401|94 105|localisation
P11110040A0000|0 9|Ketanserin
P11110040A0000|32 54|5-HT2 receptor antagonism
P11110040A0000|79 86|infusion
P11110040A0000|93 104|% w/v solution
P11110040A0000|107 113|corneal
P11110040A0000|124 135|applications
P11110040A0000|162 169|pressure
P11110040A0000|178 182|times
P11110040A0000|187 194|activity
P11110040A0000|202 211|metabolite
P11110040A0000|212 223|ketanserinol
P11110528A0414|28 35|sequence
P11110528A0414|39 54|velocity encoding
P11110528A0414|72 80|direction
P11110528A0414|94 99|region
P11110528A0414|109 116|velocity
P11111051A0051|26 30|Tip60
P11111051A0051|34 57|histone acetyltransferase
P11111051A0051|63 70|activity
P11112417A1126|25 40|MLSN1 transcripts
P11112417A1126|108 120|melanoma cells
P11112417A1126|135 149|MLSN1 expression
P11112417A1126|169 173|level
P11112417A1126|180 192|transcription
P11112417A1126|196 209|mRNA processing
P11112438X0847|0 8|Copyright
P11112438X0847|13 25|Academic Press
P11112700A1936|0 6|Plectin
P11112700A1936|10 20|desmoplakin
P11112700A1936|39 45|domains
P11112700A1936|53 61|C-termini
P11112700A1936|106 111|domain
P11112700A1936|114 120|plectin
P11112700A1936|127 137|desmoplakin
P11112700T0000|0 15|Characterization
P11112700T0000|21 44|microtubule binding domain
P11112700T0000|47 80|microtubule actin crosslinking factor
P11112700T0000|87 100|identification
P11112700T0000|108 112|group
P11112700T0000|115 125|microtubule
P11112700T0000|136 143|proteins
P11112790A0989|5 11|results
P11112790A0989|26 36|involvement
P11112790A0989|49 56|elements
P11113179A0541|12 19|contrast
P11113179A0541|34 40|binding
P11113179A0541|52 67|estrogen receptor
P11113179A0541|87 99|SRC1 functions
P11113179A0541|113 119|adaptor
P11113179A1020|11 19|construct
P11113179A1020|35 42|residues
P11113179A1020|71 81|LXXLL motifs
P11113179A1020|88 96|AD1 region
P11113179A1020|119 137|coactivator activity
P11113179A1020|142 147|assays
P11113199A0800|28 33|anchor
P11113199A0800|57 70|MEK interaction
P11113199A0800|97 108|localization
P11113199A0800|111 132|ERK2-Delta19-25 mutants
P11113199A0800|148 152|cells
P11113201A1114|9 14|member
P11113201A1114|17 33|six-protein family
P11113201A1114|36 40|yeast
P11113201A1114|70 83|O mannosylation
P11113201A1114|85 98|target proteins
P11113546A0728|5 11|samples
P11113546A0728|30 38|beginning
P11113546A0728|53 63|trial period
P11113546A0728|97 108|nematode eggs
P11113546A0728|112 122|Giardia cyst
P11113692A0169|14 18|study
P11113692A0169|35 45|risk factors
P11113692A0169|49 58|background
P11113692A0169|67 77|retinopathy
P11113692A0169|113 120|patients
P11113692A0169|141 148|diabetes
P11113692A0169|165 169|years
P11113692A0169|177 183|mean age
P11113692A0169|189 201|blood pressure
P11113692A0169|204 208|entry
P11113692A0169|215 218|mm Hg
P11113822A0999|7 15|quadrants
P11113822A0999|29 36|controls
P11113822A0999|75 85|jaw pathoses
P11113823A0197|4 8|cases
P11113823A0197|19 32|chondromatosis
P11114294A0075|8 14|studies
P11114294A0075|47 79|cytokines tumor necrosis factor alpha
P11114294A0075|83 97|interferon gamma
P11114294A0075|107 116|expression
P11114294A0075|128 168|fibrosis transmembrane conductance regulator
P11114294A0075|189 193|HT-29
P11114294A0075|194 201|T84 cells
P11114521A0282|0 9|Regulation
P11114521A0282|38 45|adhesion
P11114521A0282|57 61|cells
P11114521A0282|82 94|cell spreading
P11114521A0282|98 106|migration
P11114718A0349|12 27|mouse fibroblasts
P11114718A0349|47 51|v-Src
P11114718A0349|65 77|protein levels
P11114718A0349|84 92|WAF1/CIP1
P11114718A0349|92 99|cyclin D1
P11114718A0349|103 109|cyclin E
P11114924A0808|60 82|primer extension analysis
P11116084A0000|0 10|Mouse Impact
P11116084A0000|72 78|protein
P11116084A0000|87 94|function
P11116131A0863|5 9|cells
P11116131A0863|36 42|culture
P11116148A0741|0 18|Coexpression studies
P11116148A0741|31 37|insulin
P11116148A0741|54 68|transactivation
P11116148A0741|70 78|C/EBPbeta
P11116148A0741|85 94|C/EBPalpha
P11116148A0741|112 133|transactivation domains
P11116148A0741|136 144|C/EBPbeta
P11117263A0570|22 28|species
P11117263A0570|35 48|Ids3 expression
P11117263A0570|78 82|roots
P11117263A0570|85 93|H. vulgare
P11117263A0570|103 109|cereale
P11117263A0570|228 233|epiHMA
P11117263A0570|229 237|H. vulgare
P11117263A0570|269 277|S. cereale
P11117523A0650|2 9|contrast
P11117523A0650|14 31|COUP-TFI expression
P11117523A0650|50 64|differentiation
P11117523A0650|67 74|P19 cells
P11117523A0650|101 112|cell cultures
P11117523A0650|119 125|neurons
P11117826A0788|30 41|pretreatment
P11117826A0788|44 62|follow-up evaluation
P11117826A0788|97 104|patients
P11117826A0788|122 131|comparison
P11118062A1691|21 25|model
P11118062A1691|29 40|localization
P11118062A1691|46 53|mutation
P11118062A1691|59 67|K-ras gene
P11118062A1691|91 95|level
P11118062A1691|98 111|aggressiveness
P11118062A1691|129 137|phenotype
P11118438A0411|17 25|isolation
P11118438A0411|28 33|MdPin1
P11118438A0411|35 47|Pin1 homologue
P11118438A0411|55 71|plant species apple
P11118438A0411|72 85|Malus domestica
P11118438A0411|133 152|substrate specificity
P11118438A0411|172 178|juglone
P11118440T0000|12 22|association
P11118440T0000|25 32|products
P11118440T0000|35 56|alternative transcripts
P11118440T0000|62 89|candidate tumor suppressor ING1
P11118440T0000|97 107|mSin3/HDAC1
P11118440T0000|123 140|corepressor complex
P11118619A0835|46 51|models
P11118619A0835|50 77|host cell transcription factors
P11118619A0835|101 109|infection
P11118619A0835|128 132|event
P11118619A0835|158 171|transformation
P11118712A1296|4 22|sensitivity analysis
P11118712A1296|45 50|limits
P11118712A1296|56 63|accuracy
P11118712A1296|101 110|estimation
P11118712A1296|119 132|herd prevalence
P11118712A1296|149 164|confidence limits
P11118712A1296|175 188|within-herd PTB
P11118712A1296|193 202|prevalence
P11118712A1296|252 257|reason
P11118712A1296|272 286|herd specificity
P11118712A1296|290 294|herds
P11118712A1296|310 317|herd size
P11119611A0428|0 5|ORFK10
P11119611A0428|15 21|protein
P11119611A0428|47 53|antigen
P11119611A0428|55 59|LANA2
P11119611A0428|104 110|tissues
P11119611A0428|138 146|KS lesions
P11120441A1193|14 22|believers
P11120441A1193|61 70|activation
P11120441A1193|92 100|asymmetry
P11120441A1193|113 122|complexity
P11121043A0074|2 8|Xenopus
P11121043A0074|29 36|inducers
P11121043A0074|53 62|regulators
P11121043A0074|65 76|neurogenesis
P11121118A0075|19 26|variants
P11121118A0075|43 54|GAF sequences
P11121118A0075|70 75|region
P11121118T0000|7 18|organization
P11121118T0000|29 55|phosphodiesterase PDE11A gene
P11121397A0587|10 17|findings
P11121397A0587|33 44|rib-2 protein
P11121397A0587|55 94|alpha1,4-N-acetylglucosaminyltransferase
P11121397A0587|120 129|initiation
P11121397A0587|133 142|elongation
P11121397A0587|145 158|heparan sulfate
P11121434A0915|0 9|Inhibition
P11121434A0915|15 28|Mek/Erk pathway
P11121434A0915|31 43|Rat1/ras cells
P11121434A0915|52 63|Mek inhibitor
P11121434A0915|64 70|PD98059
P11121434A0915|101 108|recovery
P11121490A0000|3 37|transcription factor CHOP/GADD153 gene
P11121490A0000|57 62|stress
P11121490A0000|87 95|apoptosis
P11122381A0908|0 7|Addition
P11122381A0908|42 49|peptides
P11122381A0908|77 85|tyrosines
P11122381A0908|93 109|GM-CSF stimulation
P11122381A0908|129 138|activation
P11122381A0908|141 145|STAT5
P11122588A0549|0 18|MAIN OUTCOME MEASURES
P11122588A0549|19 34|Percentage change
P11122588A0549|54 58|index
P11122588A0549|64 74|apnea events
P11122588A0549|75 88|hypopnea events
P11122588A0549|100 104|sleep
P11122588A0549|169 174|events
P11122588A0549|183 187|sleep
P11122588A0549|191 197|respect
P11122588A0549|208 213|weight
P11123054T0000|23 31|syndromes
P11123089A0362|4 10|article
P11123089A0362|24 34|information
P11123089A0362|40 48|frequency
P11123089A0362|49 63|characteristics
P11123089A0362|85 94|mechanisms
P11123089A0362|100 111|vasculitides
P11123089A0362|123 130|patients
P11123089A0362|152 165|tissue diseases
P11123316T0000|0 17|Tec kinase signaling
P11123316T0000|20 25|T cells
P11123316T0000|39 66|phosphatidylinositol 3-kinase
P11123316T0000|73 99|Tec pleckstrin homology domain
P11123701A0442|7 14|evidence
P11123701A0442|72 79|coupling
P11123701A0442|101 110|activities
P11123701A0442|113 121|promoters
P11123701A0442|143 155|DNA constructs
P11123701A0442|171 190|transcription complex
P11123701A0442|225 237|DNA supercoils
P11123701A0442|255 263|diffusion
P11123701A0442|277 285|DNA duplex
P11123912A0306|3 11|structure
P11123912A0306|21 29|SH2 domain
P11123912A0306|95 101|peptide
P11123912A0306|112 123|polyomavirus
P11123912A0306|130 137|T antigen
P11124024A1098|28 32|sites
P11124024A1098|36 51|protein complexes
P11124024A1098|53 62|palindrome
P11124024A1098|70 75|repeat
P11124024A1098|80 90|C+T sequence
P11124024A1098|113 122|GAGA motifs
P11124024A1098|139 144|strand
P11124902X1337|0 8|Copyright
P11124902X1337|13 25|Academic Press
P11125151T0000|0 17|Nucleotide sequence
P11125151T0000|18 35|genome organization
P11125151T0000|51 58|analysis
P11125151T0000|61 77|pineapple mealybug
P11125151T0000|93 99|virus-2
P11125363A0525|0 7|Patients
P11125363A0525|17 38|pretreatment cystoscopy
P11125363A0525|50 61|tumor mapping
P11125363A0525|104 112|cisplatin
P11125363A0525|142 155|5-fluorouracil
P11125363A0525|180 191|radiotherapy
P11125411A0857|13 20|patients
P11125411A0857|30 40|laparoscopy
P11125411A0857|92 97|testes
P11125411A0857|110 115|testis
P11125411A0857|129 133|canal
P11125872A0133|4 13|philosophy
P11125872A0133|33 42|compound RP
P11125872A0133|57 73|phosphodiesterase
P11125872A0133|76 84|inhibitor
P11125872A0133|123 130|delivery
P11125872A0133|153 158|routes
P11125872A0133|161 174|administration
P11126275A1068|9 14|levels
P11126275A1068|17 46|anticardiolipin immunoglobulin G
P11126275A1068|59 66|bleeding
P11126353A0582|0 6|RESULTS
P11126353A0582|7 16|Prevalence
P11126353A0582|19 25|obesity
P11126353A0582|26 31|BMI SDS
P11126353A0582|42 50|diagnosis
P11126806A0206|8 15|sequelae
P11126806A0206|21 47|antiphospholipid-antibodies
P11126806A0206|74 84|circulation
P11127161T0000|0 8|Bupropion
P11127161T0000|14 29|smoking cessation
P11127200A1024|53 60|activity
P11127200A1024|72 76|cells
P11127200A1024|92 115|AP-1 transcription factors
P11127200A1024|124 132|TGF-beta1
P11127200A1024|151 160|expression
P11127200A1024|166 171|alpha1
P11127200A1024|172 184|collagen I gene
P11127200A1024|212 221|expression
P11127200A1024|238 244|hormone
P11127200A1024|260 266|peptide
P11127200A1024|266 270|PTHrP
P11127200A1024|271 278|receptor
P11127250A1111|10 14|mg/kg
P11127250A1111|118 125|patients
P11127250A1111|131 135|Bihar
P11127250A1111|135 139|India
P11127955X0001|8 14|therapy
P11127955X0001|18 28|colon cancer
P11127955X0001|29 35|Surgery
P11127955X0001|67 72|number
P11127955X0001|90 101|colon cancers
P11128312A1238|20 30|differences
P11128312A1238|47 54|fracture
P11128312A1238|68 73|groups
P11128312A1238|84 91|femur BMD
P11128312A1238|122 127|radius
P11128312A1238|142 150|dimension
P11128312A1238|155 165|radiographs
P11128925A0000|0 9|BACKGROUND
P11128925A0000|24 28|study
P11128925A0000|52 64|interleukin-6
P11128925A0000|71 76|levels
P11128925A0000|96 100|fluid
P11128925A0000|128 135|findings
P11128925A0000|137 144|patients
P11128925A0000|159 167|arthritis
P11128925A0000|180 192|periodontitis
P11129515A0000|25 29|trial
P11129515A0000|33 40|efficacy
P11129515A0000|45 70|Vitex agnus castus L extract Ze
P11129515A0000|93 100|patients
P11129515A0000|118 125|syndrome
P11129724A0904|0 6|Studies
P11129724A0904|30 35|source
P11129724A0904|38 50|contamination
P11129724A0904|99 110|transmission
P11129724A0904|119 126|neonates
P11131321T0000|0 6|Effects
P11131321T0000|9 24|Trypanosoma vivax
P11131321T0000|27 35|pregnancy
P11131321T0000|38 49|Yankasa sheep
P11131321T0000|56 62|results
P11131321T0000|65 91|homidum chloride chemotherapy
P11131634A0955|0 7|NF kappa B
P11131634A0955|34 39|extent
P11131634A0955|42 52|roscovitine
P11131634A0955|60 64|cells
P11131634A0955|71 77|Y8 cells
P11132063A0250|11 28|treatment exposures
P11132063A0250|40 49|population
P11132063A0250|83 89|effects
P11132063A0250|96 104|cirrhosis
P11132063A0250|116 125|hepatitis C
P11132063A0250|159 172|cardiomyopathy
P11132063A0250|192 198|effects
P11132063A0250|214 224|dysfunction
P11132148A0162|3 10|presence
P11132148A0162|27 34|residues
P11132148A0162|54 67|promoter region
P11132148A0162|98 105|HLA class
P11132195A0000|10 15|number
P11132195A0000|18 27|parameters
P11132195A0000|39 52|Volterra series
P11132195A0000|76 81|length
P11132195A0000|87 92|memory
P11132195A0000|99 103|order
P11132195A0000|109 120|nonlinearity
P11132195A0000|121 127|methods
P11132195A0000|147 152|models
P11132195A0000|157 168|measurements
P11132195A0000|171 186|input/output data
P11132195A0000|208 214|systems
P11132195A0000|234 241|memories
P11132790A0609|11 16|method
P11132790A0609|43 47|score
P11132790A0609|68 75|subtests
P11132790A0609|83 87|score
P11132790A0609|152 163|risk children
P11133741A0617|12 25|MCP-1 synthesis
P11133741A0617|33 42|activation
P11133741A0617|45 53|NF-kappaB
P11133741A0617|59 66|mutation
P11133741A0617|86 90|sites
P11133741A0617|96 103|promoter
P11133741A0617|139 154|promoter activity
P11133830A0174|0 9|Engagement
P11133830A0174|33 37|pairs
P11133830A0174|59 81|tyrosine phosphorylation
P11133830A0174|84 89|number
P11133830A0174|105 112|proteins
P11133830A0174|126 142|kDa phosphoprotein
P11133830A0174|162 180|proto-oncogene c-Cbl
P11133927T0000|0 7|Validity
P11133927T0000|10 24|NIR spectroscopy
P11133927T0000|51 56|muscle
P11133927T0000|83 90|exercise
P11133986A0350|8 14|studies
P11133986A0350|52 71|transcription factors
P11133986A0350|90 111|PU.1 interaction partner
P11133986A0350|114 121|function
P11133986A0350|140 144|c-Fos
P11133986A0350|149 153|c-Jun
P11133986A0350|168 174|kappaE3
P11133986A0350|174 181|enhancer
P11133986A0350|184 191|3T3 cells
P11134033A0000|9 18|int-6 locus
P11134033A0000|40 54|integration site
P11134033A0000|57 61|mouse
P11134033A0000|69 80|tumor viruses
P11134033A0000|97 108|eIF3e subunit
P11134033A0000|111 141|translation initiation factor eIF3
P11134033A0639|2 13|int6 deletion
P11134033A0639|14 22|int6Delta
P11134033A0639|23 28|mutant
P11134033A0639|60 65|medium
P11134351A1405|12 17|MIP-2A
P11134351A1405|29 38|cell growth
P11134351A1405|57 61|MBP-1
P11134508A0317|20 25|plants
P11134508A0317|48 60|Arabidopsis HD
P11134508A0317|61 65|AtHD1
P11134822A0629|20 38|accelerations/30 min
P11137296A0923|4 31|transcription initiation sites
P11137296A0923|88 100|amplification
P11137296A0923|102 109|cDNA ends
P11137296A0923|110 117|RLM-RACE
P11137296A0923|145 170|translation initiation codon
P11137296A0923|204 228|transcription-PCR analysis
P11137296A0923|241 245|PFK-A
P11137296A0923|246 250|PFK-B
P11137296A0923|254 263|PFK-C genes
P11137296A0923|282 293|mouse tissues
P11137296A0923|309 314|levels
P11137296A1216|0 8|PFK-A mRNA
P11137296A1216|40 46|tissues
P11137296A1216|58 62|PFK-B
P11137296A1216|66 75|PFK-C genes
P11137367A0297|9 25|Toshiba IIDR system
P11137367A0297|45 57|X-ray TV system
P11137367A0297|69 73|image
P11137367A0297|82 88|circuit
P11137551A0437|7 13|sardine
P11137551A0437|39 44|levels
P11137551A0437|75 79|limit
P11138009A1032|2 9|addition
P11138009A1032|25 33|mutations
P11138009A1032|34 43|Delta M1281
P11138009A1032|47 51|IVS51
P11138009A1032|65 75|USH1 patient
P11138231T0000|0 6|Closeup
P11138231T0000|8 15|resource
P11138231T0000|19 24|nurses
P11138694A0000|5 26|fluorobenzyltrozamicol
P11138694A0000|66 89|acetylcholine transporter
P11138694A0000|116 121|neuron
P11138694A0000|155 160|ligand
P11138694A0000|167 171|study
P11138694A0000|193 199|density
P11138694A0000|210 216|ganglia
P11139148A0421|20 26|protein
P11139148A0421|36 44|homologue
P11139148A0421|47 51|SAF-A
P11139148A0421|129 136|activity
P11139148A0421|156 164|fractions
P11139336A0257|12 23|associations
P11139336A0257|33 46|INCENP behavior
P11139336A0257|53 59|mitosis
P11139469A0402|0 4|Ang II
P11139469A0402|25 45|Ang2 mRNA accumulations
P11139469A0402|70 83|Tie2 expression
P11139469A0402|102 125|protein kinase C inhibitors
P11139469A0402|157 162|agents
P11139473A0696|0 15|Promoter analysis
P11139473A0696|35 42|sequence
P11139473A0696|54 62|consensus
P11139473A0696|78 84|element
P11139473A0696|108 120|SMemb promoter
P11139473A0696|134 150|Hex responsiveness
P11139567A1440|0 22|LH/CG receptor activation
P11139567A1440|46 55|activation
P11139567A1440|57 84|phosphatidylinositol 3-kinase
P11139567A1440|85 94|PI 3-kinase
P11139567A1440|99 123|G protein beta gamma subunits
P11139605A0811|0 15|Deletion analysis
P11139605A0811|35 42|sequence
P11139605A0811|78 93|promoter activity
P11139605A0811|97 111|auto-activation
P11139605A0811|130 148|mobility shift assays
P11139605A0811|162 172|interaction
P11139605A0811|175 180|C/EBPs
P11139605A0811|195 200|region
P11139974A0762|0 10|Termination
P11139974A0762|34 40|attempt
P11139974A0762|57 64|BV pacing
P11139974A0762|77 84|RV pacing
P11140472A0497|12 18|results
P11140472A0497|25 33|algorithm
P11140472A0497|41 47|results
P11140472A0497|68 77|algorithms
P11140472A0497|88 96|algorithm
P11140472A0497|100 110|monochannel
P11140472A0497|125 129|noise
P11140472A0497|143 151|algorithm
P11140472A0497|175 179|noise
P11140472A0497|199 214|cases improvement
P11141003T0000|0 6|Changes
P11141003T0000|9 25|stimulation levels
P11141003T0000|38 44|nucleus
P11141003T0000|46 53|cochlear
P11141003T0000|61 65|users
P11142380A0389|0 7|Nuclease
P11142380A0389|36 46|mutagenesis
P11142380A0389|72 76|TE105
P11142380A0389|100 108|structure
P11142380A0389|123 129|helices
P11142380A0389|156 162|regions
P11143384A0267|0 8|Tele-Talk
P11143384A0267|20 29|capability
P11143384A0267|32 40|operating
P11143384A0267|47 66|conference situations
P11143384A0267|72 86|microphone input
P11145562A0000|7 14|decrease
P11145562A0000|39 50|growth factor
P11145562A0000|55 62|receptor
P11145562A0000|62 67|IGF-IR
P11145562A0000|76 83|prostate
P11145562A0000|94 98|cells
P11145562A0000|105 118|transformation
P11145562A0000|147 151|state
P11145562A0468|3 13|P69 cell line
P11145562A0468|26 40|immortalization
P11145562A0468|55 62|prostate
P11145562A0468|73 77|cells
P11145562A0468|96 103|T antigen
P11145563A0202|27 38|StAR promoter
P11145563A0202|53 58|sterol
P11145563A0202|84 91|proteins
P11145563A0202|92 97|SREBPs
P11145563A0303|0 9|Expression
P11145563A0303|12 19|SREBP-1a
P11145563A0303|30 49|StAR promoter activity
P11145563A0303|55 61|context
P11145563A0303|64 73|COS-1 cells
P11145563A0303|82 102|granulosa-lutein cells
P11145566A0000|22 40|lipoprotein receptor
P11145566A0000|41 45|HDL-R
P11145566A0000|52 58|element
P11145566A0000|61 82|cholesterol homeostasis
P11145566A0000|107 112|target
P11145566A0000|136 140|drugs
P11145566A0000|143 155|understanding
P11145566A0000|158 172|HDL-R regulation
P11145571A0788|14 25|gene factor-3
P11145571A0788|29 43|STAT1 homodimers
P11145571A0788|74 88|response element
P11145571A0788|113 120|sequence
P11145571A0788|125 131|element
P11145590A0217|34 43|mechanisms
P11145590A0217|46 60|TGF-beta1 action
P11145590A0217|63 75|thyroglobulin
P11145590A0217|80 93|gene expression
P11145590A0217|106 114|attention
P11145590A0217|117 135|TGF-beta1 regulation
P11145590A0217|154 173|transcription factors
P11145717A0936|20 25|lysine
P11145717A0936|47 57|TPO fragment
P11145717A0936|73 82|sequencing
P11145743A0170|24 33|regulation
P11145743A0170|41 45|genes
P11145743A0170|48 59|thyroid cells
P11145743A0170|63 68|effect
P11145743A0170|71 96|thyroid transcription factor
P11145743A0170|98 102|TTF-1
P11145743A0170|132 138|protein
P11145743A0170|140 144|Pax-8
P11145743A0170|165 172|activity
P11145743A0170|178 196|deiodinase promoters
P11145813A0668|0 16|Regional blood blow
P11145813A0668|30 34|means
P11145813A0668|37 48|microspheres
P11145813A0668|61 67|regions
P11145813A0668|85 95|L6 vertebrae
P11145887A1393|0 9|Activation
P11145887A1393|12 24|transcription
P11145887A1393|35 42|AP-1 site
P11145887A1393|45 55|Jurkat cells
P11145887A1393|70 74|Fra-2
P11145887A1393|97 101|c-Jun
P11145887A1393|111 125|c-Fos activation
P11145887A1393|146 150|level
P11145955A0189|3 11|mechanism
P11145955A0189|30 50|estrogen receptor alpha
P11145955A0189|51 57|ERalpha
P11145955A0189|66 75|activation
P11145955A0189|78 91|gene expression
P11145955A0189|132 139|analysis
P11145955A0189|144 151|promoter
P11145955A0189|152 159|analysis
P11145955A0189|179 191|protein kinase
P11145955A0189|198 214|pathway activation
P11145955A0189|235 251|growth factor alpha
P11145955A0189|251 259|TGF-alpha
P11145955A0189|271 277|control
P11146961T0000|0 17|Perfusion technique
P11146961T0000|53 64|artery bypass
P11146961T0000|65 70|PADCAB
P11148042A1258|6 13|mixtures
P11148042A1258|34 41|chain PEs
P11148042A1258|71 80|variations
P11148042A1258|91 110|peptide immiscibility
P11148042A1258|120 135|gel state bilayers
P11148589A1124|0 10|CONCLUSIONS
P11148589A1124|23 43|immunization practices
P11148589A1124|47 53|authors
P11148589A1124|86 108|Pacific Islander children
P11148589A1124|120 136|United States today
P11148589A1124|169 174|future
P11148589A1124|196 215|liver carcinoma deaths
P11149472A1257|10 30|NP/NMP4/CIZ expression
P11149472A1257|33 42|osteocytes
P11149472A1257|43 53|osteoblasts
P11149472A1257|57 68|chondrocytes
P11149472A1257|71 77|rat bone
P11150114T0000|0 8|Chlamydia
P11150114T0000|20 25|cancer
P11150114T0000|31 41|association
P11150315A0226|6 13|approach
P11150315A0226|40 68|transcription factor activities
P11150315A0226|115 123|signaling
P11150315A0226|135 155|oligonucleotide clones
P11150315A0226|161 181|DNA recognition library
P11150315A0226|199 216|DNA binding proteins
P11150315A0226|234 241|extracts
P11150315A0844|36 53|ERK phosphorylation
P11150315A0844|84 90|reports
P11150315A1126|32 36|bands
P11150315A1126|64 68|Fra-2
P11150439A0701|0 16|Energy expenditure
P11150439A0701|46 53|infusion
P11150439A0701|65 70|breath
P11150439A0701|74 96|enrichment determination
P11150439A0701|98 125|isotope ratio mass spectroscopy
P11150439A0701|132 142|application
P11150439A0701|154 171|regression equation
P11151826T0000|0 7|Workload
P11152070A0573|3 10|actA gene
P11152070A0573|40 45|genome
P11152070A0573|47 59|A. chrysogenum
P11152070A0573|66 80|expression level
P11152070A0573|100 117|cefEF cephalosporin
P11152070A0573|129 133|genes
P11152070A0573|149 173|cephalosporin fermentation
P11152070A0573|194 203|transcript
P11152081A0413|8 16|mmol SDS/l
P11152081A0413|31 40|inhibition
P11152081A0413|43 55|acidification
P11152081A0413|56 74|metal solubilization
P11152081A0413|78 92|sulfur oxidation
P11152283A0223|46 62|gene transcription
P11152283A0223|72 81|INS-1 cells
P11152283A0223|83 87|order
P11152283A0223|119 123|genes
P11152344A0416|4 10|animals
P11152344A0416|26 32|animals
P11152344A0416|42 48|animals
P11152344A0416|63 75|arachnoid scar
P11152344A0416|78 82|C1-C2
P11152344A0416|101 109|placement
P11152344A0416|132 137|sponge
P11152344A0416|152 158|surface
P11152451A0529|3 29|Schistosoma mansoni homologue
P11152451A0529|30 36|SmSmad2
P11152451A0529|55 62|bacteria
P11152451A0529|66 86|Sj26-GST fusion protein
P11152451A0529|109 118|antibodies
P11152451A1580|26 32|SmSmad2
P11152451A1580|45 59|TGF-beta signals
P11152451A1580|62 72|interaction
P11152451A1580|77 85|receptor I
P11152451A1580|137 143|nucleus
P11152451A1580|164 186|target gene transcription
P11152451A1580|217 230|TGF-beta effect
P11152521A0181|17 31|protein products
P11152521A0181|65 81|expression vectors
P11152521A0181|93 110|ORF40/41 transcript
P11152521A0181|136 144|component
P11152521A0181|173 178|intron
P11152963A0000|0 9|Expression
P11152963A0000|15 25|src homology
P11152963A0000|61 70|astrocytes
P11152963A0000|98 120|astrocyte transformation
P11152963A0000|121 127|culture
P11152963A0000|131 136|tumors
P11152963A0000|147 151|brain
P11153302A0000|0 22|Naltrexone hydrochloride
P11153302A0000|35 58|opioid receptor antagonist
P11153302A0000|73 79|efforts
P11153302A0000|100 113|detoxification
P11154491A0322|0 6|METHODS
P11154491A0322|36 43|patients
P11154491A0322|55 59|years
P11154491A0322|78 83|masses
P11154491A0322|107 113|EUS-FNA
P11154491A0322|133 145|echoendoscope
P11154491A0322|157 163|needles
P11155096A0222|0 6|METHODS
P11155096A0222|7 19|Thyroid status
P11155096A0222|33 40|baseline
P11155096A0222|55 64|assessment
P11155096A0222|67 81|serum antibodies
P11155096A0222|84 100|thyroid peroxidase
P11155096A0222|101 107|TPO-Abs
P11155096A0222|118 122|IU/ml
P11155096A0222|123 136|serum TSH levels
P11155096A0222|174 192|serum thyroxin levels
P11156303A1098|30 37|shunting
P11156303A1098|70 80|alternative
P11156303A1098|93 100|drainage
P11156303A1098|103 110|children
P11156303A1098|130 138|adhesions
P11156303A1098|146 152|history
P11156303A1098|171 179|infection
P11156413T0000|0 9|Derivation
P11156413T0000|20 35|characterization
P11156413T0000|39 43|mouse
P11156413T0000|51 63|tumor cell line
P11156413T0000|75 86|polyomavirus
P11156413T0000|93 100|T antigen
P11156413T0000|101 107|utility
P11156413T0000|113 123|development
P11156413T0000|131 148|cancer therapeutics
P11156484A0223|0 10|TBARS levels
P11156484A0223|34 46|capacity assay
P11156484A0223|50 59|AFR release
P11156484A0223|70 77|electron
P11156484A0223|90 98|resonance
P11156484A0223|124 132|existence
P11156484A0223|143 148|stress
P11156484A0223|151 158|diabetes
P11156618T0000|10 19|comparison
P11156618T0000|30 41|mouse SCL loci
P11156618T0000|51 57|regions
P11156618T0000|60 70|sensitivity
P11156618T0000|73 96|restriction endonucleases
P11156618T0000|120 124|peaks
P11156618T0000|145 153|sequences
P11156789A1669|16 26|observation
P11156789A1669|40 45|causes
P11156789A1669|62 73|CSF pulsation
P11156789A1669|76 83|children
P11156789A1669|92 105|motion artifact
P11156789A1669|106 112|changes
P11156789A1669|123 141|oxygen concentration
P11156789A1669|153 160|propofol
P11156789A1669|187 192|oxygen
P11156789A1669|215 221|changes
P11156789A1669|224 239|CSF protein levels
P11156789A1669|249 263|propofol binding
P11156789A1669|266 273|proteins
P11156789A1669|277 282|uptake
P11157035A1405|3 11|utilities
P11157035A1405|25 29|study
P11157035A1405|67 80|determinations
P11157035A1405|91 96|trials
P11157035A1405|107 117|IFN alpha-2b
P11157035A1405|133 139|benefit
P11157035A1405|142 148|therapy
P11157334A1107|0 7|Serum PTH
P11157334A1107|29 35|WL group
P11157334A1107|47 53|WM group
P11157763T0000|0 8|Structure
P11157763T0000|14 25|EMAPII domain
P11157763T0000|33 63|aminoacyl-tRNA synthetase complex
P11157763T0000|83 94|dimer mimicry
P11157774A0789|11 22|dSLBP alleles
P11157774A0789|37 47|development
P11157774A0789|62 70|sterility
P11157784A0141|11 19|DGCR6 gene
P11157784A0141|22 36|chromosome 22q11
P11157784A0141|47 56|copy repeat
P11157784A0141|107 112|DGCR6L
P11157784A0141|128 132|locus
P11157879A0192|0 6|METHODS
P11157879A0192|10 16|passive
P11157879A0192|26 34|transport
P11157879A0192|37 47|fluorescein
P11157879A0192|87 97|fluorometry
P11158236A0000|0 16|Nerve growth factor
P11158236A0000|57 63|actions
P11158236A0000|63 71|PC12 cells
P11158288T0000|0 10|Recruitment
P11158288T0000|15 27|RNA polymerase
P11158288T0000|30 36|complex
P11158288T0000|64 79|activation domain
P11158288T0000|103 121|CREB phosphorylation
P11158290A0728|3 8|region
P11158290A0728|23 29|serines
P11158290A0728|57 70|destruction box
P11158290A0728|73 84|IkappaBalpha
P11158290A0728|94 100|epsilon
P11158295A0158|4 11|function
P11158295A0158|30 41|kinase domain
P11158295A0158|59 69|Src homology
P11158295A0158|78 87|SH2 regions
P11158310A0993|47 55|ATF6alpha
P11158324A1073|11 20|phenotypes
P11158324A1073|48 57|disruption
P11158324A1073|76 95|lipoprotein secretion
P11158324A1073|110 119|expression
P11158324A1073|122 126|genes
P11158324A1073|135 149|apolipoprotein B
P11158324A1073|163 189|triglyceride transfer protein
P11158324A1073|194 201|increase
P11158324A1073|211 227|cholesterol uptake
P11158324A1073|242 251|expression
P11158324A1073|274 292|lipoprotein receptor
P11158324A1073|293 311|scavenger receptor BI
P11158324A1073|319 326|decrease
P11158324A1073|329 342|bile acid uptake
P11158324A1073|348 352|liver
P11158324A1073|358 372|down-regulation
P11158324A1073|394 451|bile acid transporters sodium taurocholate cotransporter protein
P11158324A1073|462 484|anion transporter protein
P11158326A1032|5 11|effects
P11158326A1032|27 31|SHIP2
P11158326A1032|43 50|mutation
P11158326A1032|56 64|SH2 domain
P11158337A0000|35 44|expression
P11158337A0000|50 61|GnRH receptor
P11158337A0000|62 67|GnRH-R
P11158337A0000|95 114|transcription factors
P11158337A0000|145 150|GnRH-R
P11158337A0000|161 168|sequence
P11158337A0000|178 195|activator protein-1
P11158337A0000|201 207|element
P11158337A0000|226 233|factor-1
P11158337A0000|240 250|binding site
P11158456A0223|0 6|METHODS
P11158456A0223|18 26|interview
P11158456A0223|60 71|consultation
P11158456A0223|92 100|intervals
P11158456A0223|123 131|frequency
P11158456A0223|132 137|spells
P11158456A0223|148 157|phenomenon
P11158456A0223|158 165|sequelae
P11158456A0223|166 178|family history
P11158456A0223|189 199|termination
P11158456A0223|201 206|spells
P11159081A1155|7 11|cases
P11159081A1155|21 29|MR imaging
P11159081A1155|67 71|tumor
P11159081A1155|86 91|seroma
P11159081A1155|94 103|reexcision
P11159363A1251|0 10|Methylation
P11159363A1251|17 32|cytosine residues
P11159363A1251|38 47|E2F element
P11159363A1251|106 112|complex
P11160096A1067|5 13|mutations
P11160096A1067|36 49|fliF background
P11160096A1067|61 69|phenotype
P11160280A1275|23 32|expression
P11160280A1275|35 39|IRF-1
P11160280A1275|46 52|binding
P11160280A1275|58 67|IRF element
P11160307A0394|4 11|molecule
P11160307A0394|12 20|wH22xeGFP
P11160307A0394|63 68|mAb H22
P11160307A0394|121 129|CH3 domain
P11160307A0394|152 160|wH22xeGFP
P11160307A0394|189 194|region
P11160307A0394|200 204|Fc end
P11160307A0394|237 242|region
P11160307A0394|277 285|FcgammaRI
P11160656A0000|0 9|Inactivity
P11160656A0000|20 34|cytomegalovirus
P11160656A0000|71 76|region
P11160656A0000|76 80|MIERR
P11160656A0000|98 105|promoter
P11160656A0000|106 113|enhancer
P11160656A0000|120 125|region
P11160656A0000|129 137|modulator
P11160656A0000|156 170|HCMV replication
P11160656A0000|188 192|cells
P11160656A0000|216 224|cell types
P11160656A0000|248 262|NTera2 carcinoma
P11160656A0000|268 272|cells
P11160683A1220|4 14|interaction
P11160683A1220|32 48|C/EBP dimer binding
P11160683A1220|58 66|C/EBP site
P11160683A1220|82 98|CREB-1 recruitment
P11160683A1220|101 113|ATF/CREB sites
P11160688A1726|12 17|events
P11160688A1726|39 47|structure
P11160688A1726|60 67|cyclin D3
P11160688A1726|76 88|translocation
P11160688A1726|102 110|cytoplasm
P11160721A0932|9 21|transfections
P11160721A0932|39 46|mutation
P11160721A0932|62 81|TBLV enhancer activity
P11160721A0932|109 119|T-cell lines
P11160732A0464|0 11|Vector stocks
P11160732A0464|22 37|envelope proteins
P11160732A0464|56 67|SIVmac clones
P11160732A0464|74 82|SIVmac239
P11160732A0464|83 100|T-lymphocyte tropic
P11160732A0464|109 117|SIVmac316
P11160732A0464|118 133|macrophage tropic
P11160732A0464|145 154|SIVmac1A11
P11160732A1199|12 21|PCR studies
P11160732A1199|35 43|synthesis
P11160732A1199|47 55|transport
P11160732A1199|58 66|vector DNA
P11160732A1199|74 80|nucleus
P11160732A1199|95 105|macrophages
P11160732A1199|121 125|clone
P11160732A1199|135 145|pseudotypes
P11160732A1199|163 173|restriction
P11160732A1199|177 194|SIVmac239 infection
P11160732A1199|209 221|transcription
P11160732A1199|232 237|import
P11160738A1414|22 30|functions
P11160738A1414|33 38|vIRF-2
P11160738A1414|57 69|establishment
P11160738A1414|88 96|infection
P11160742A0696|10 20|R expression
P11160742A0696|30 42|PML dispersion
P11160742A0696|57 61|cells
P11160860A0662|16 23|activity
P11160860A0662|26 38|IkappaB kinase
P11160860A0662|39 46|IKK-beta
P11160860A0662|76 94|NF-kappaB activation
P11160860A0662|101 122|IkappaB phosphorylation
P11160860A0662|161 165|cells
P11160860A0662|176 202|IkappaBalpha phosphorylation
P11160896A0713|0 24|Immunofluorescence studies
P11160896A0713|27 39|C2C12 myotubes
P11160896A0713|48 52|Smad2
P11160896A0713|56 71|MEF2A co-localise
P11160896A0713|77 83|nucleus
P11160896A0713|98 105|myotubes
P11160896A0713|112 126|differentiation
P11160902A0962|40 48|potential
P11160902A0962|73 82|expression
P11160902A0962|85 110|c-sis/PDGF-B proto-oncogene
P11160902A0962|130 137|settings
P11160902A0962|155 164|expression
P11160929T0000|5 13|evolution
P11160929T0000|38 46|LAGLIDADG
P11160929T0000|52 64|endonucleases
P11161455A1286|0 19|Southern blot analysis
P11161455A1286|45 55|cell hybrids
P11161455A1286|89 96|cDNA maps
P11161455A1286|99 108|chromosome
P11161720X1294|0 8|Copyright
P11161720X1294|13 25|Academic Press
P11161793A1033|3 10|presence
P11161793A1033|22 37|receptor isoforms
P11161793A1033|47 53|species
P11161793A1033|71 78|proteins
P11161793A1033|105 109|roles
P11161793A1033|122 133|EGFR activity
P11161816A0851|16 27|similarities
P11161816A0851|35 52|endophilin proteins
P11161816A0851|67 74|sequence
P11161816A0851|80 91|SH3GLB family
P11161816A0851|143 148|action
P11162278A0629|6 13|rotation
P11162278A0629|22 28|figures
P11162278A0629|39 48|activation
P11162278A0629|74 79|lobule
P11162278A0629|104 108|gyrus
P11162576A0213|17 30|identification
P11162576A0213|51 61|alternative
P11162576A0213|67 71|exons
P11162576A0213|85 92|promoter
P11162576A0213|103 111|PDE5A gene
P11162666A0442|3 28|glucose/insulin stimulation
P11162666A0442|46 53|addition
P11162666A0442|76 80|acids
P11162936A2727|13 23|development
P11162936A2727|26 32|ligands
P11162936A2727|56 64|estrogens
P11162936A2727|67 79|antiestrogens
P11162936A2727|83 89|ERalpha
P11162936A2727|92 97|ERbeta
P11162936A2727|118 134|tissue selectivity
P11162936A2727|142 147|agents
P11162936A2727|161 185|hormone replacement therapy
P11162936A2727|192 200|treatment
P11162936A2727|204 213|prevention
P11162936A2727|216 227|breast cancer
P11163932A0000|11 15|tests
P11163932A0000|23 30|specimen
P11163932A0000|36 65|roman garden snail Helix pomatia L.
P11163932A0000|81 85|order
P11163932A0000|105 121|thermopreferendum
P11163932A0000|128 136|pulmonate
P11163932A0000|161 171|temperature
P11163932A0000|177 186|substratum
P11163932A0000|196 209|air temperature
P11163968A0152|29 43|genome sequences
P11163968A0152|45 64|Pyrococcus horikoshii
P11163968A0152|68 83|Pyrococcus abyssi
P11163968A0152|87 93|species
P11163968A0152|97 101|genus
P11163968A0152|121 128|archaeon
P11163968A0152|129 143|archaebacterium
P11163968A0152|169 187|genome polymorphisms
P11163968A0152|198 233|restriction-modification gene homologs
P11164078A0833|4 14|animal model
P11164078A0833|17 24|dystonia
P11164078A0833|37 41|model
P11164078A0833|63 71|viewpoint
P11164078A0833|72 89|treatment-response
P11166478T0000|29 43|antinociception
P11166478T0000|47 51|mouse
P11166478T0000|60 68|pain model
P11166863A0167|28 35|patients
P11166863A0167|46 50|grade
P11166863A0167|57 64|toxicity
P11167019A1249|8 12|motif
P11167019A1249|38 46|GABPalpha
P11167019A1249|49 80|ATPsynCF6 transcription start sites
P11167111A0957|19 40|lung function parameters
P11167111A0957|64 73|recipients
P11167111A0957|90 95|grafts
P11167111A0957|96 100|weeks
P11167778T0000|8 29|antithrombin deficiency
P11167778T0000|32 37|sepsis
P11168366A0569|2 9|addition
P11168366A0569|32 39|fragment
P11168366A0569|64 72|sequences
P11168366A0569|83 89|GGT mRNA
P11168366A0569|92 101|HepG2 cells
P11168422A0248|4 9|Nature
P11168422A0248|36 52|metal fluoride ions
P11168422A0248|61 69|phosphate
P11168422A0248|89 93|sites
P11168422A0248|99 109|iron protein
P11168446T0000|9 31|erythropoietin synthesis
P11168446T0000|34 41|patients
P11168446T0000|56 67|heart failure
P11168446T0000|79 89|alterations
P11168446T0000|97 109|haemodynamics
P11168588T0000|0 9|Expression
P11168588T0000|12 33|herpes simplex virus type
P11168588T0000|50 65|Cdc42/Rac pathway
P11168588T0000|78 82|c-Jun
P11168588T0000|93 108|kinase activation
P11169080T0000|10 18|education
P11169080T0000|33 41|ignorance
P11169113A0555|31 41|phi29 mutant
P11169113A0555|63 70|mutation
P11169149A0097|14 22|knowledge
P11169149A0097|23 27|SNTCS
P11170476A1546|16 24|stability
P11170476A1546|27 33|peptide
P11170476A1546|34 46|gp96 complexes
P11170476A1546|53 62|plasticity
P11170476A1546|83 88|pocket
P11170476A1546|107 111|relay
P11170476A1546|121 128|peptides
P11170476A1546|147 155|molecules
P11170476A1546|167 177|recognition
P11171118A0836|13 19|binding
P11171118A0836|30 34|PSE-B
P11171118A0836|42 46|PSE-A
P11171118A0836|61 71|competition
P11171118A0836|85 96|interactions
P11171118A0836|104 118|NF-1 DNA elements
P11171118A0836|122 131|antibodies
P11171320A0894|0 11|Coexpression
P11171320A0894|27 33|protein
P11171320A0894|48 55|deletion
P11171320A0894|84 111|tyrosine phosphorylation sites
P11171320A0894|117 123|protein
P11171320A0894|135 155|amino acid substitution
P11171320A0894|156 163|tyrosine
P11171320A0894|171 183|phenylalanine
P11171320A0894|196 203|increase
P11171320A0894|209 219|aggregation
P11171320A0894|246 258|EalphaCL cells
P11172610A0508|43 48|number
P11172610A0508|66 74|promoters
P11172944A0548|0 6|RESULTS
P11172944A0548|14 21|patients
P11172944A0548|26 30|Grade
P11172944A0548|32 42|pneumonitis
P11172944A0548|51 55|Grade
P11172944A0548|57 67|pneumonitis
P11172944A0826|2 9|contrast
P11172944A0826|36 46|correlation
P11172944A0826|54 67|plasma TNFalpha
P11172944A0826|71 90|radiation pneumonitis
P11175333A0336|19 41|co-precipitation methods
P11175333A0336|63 70|proteins
P11176098A0342|0 6|METHODS
P11176098A0342|52 62|shock groups
P11176290T0000|0 13|Identification
P11176290T0000|25 36|vein stenosis
P11176290T0000|42 63|radiofrequency ablation
P11176290T0000|73 84|fibrillation
P11177538A0655|0 13|Tumor cell lines
P11177538A0655|52 74|% gene transfer efficiency
P11177686A0243|0 8|Treatment
P11177686A0243|39 45|options
P11177686A0243|57 63|therapy
P11177686A0243|113 120|dilation
P11178248A1042|32 50|screening techniques
P11178248A1042|53 57|terms
P11178248A1042|60 70|sensitivity
P11178248A1042|71 80|efficiency
P11178248A1042|84 93|occurrence
P11178248A1042|101 109|positives
P11178696A0301|6 13|US images
P11178696A0301|84 92|injection
P11178696A0301|100 112|contrast agent
P11178696A0301|140 143|PD US
P11178765A0642|16 22|effects
P11178765A0642|53 63|development
P11178765A0642|74 83|metastasis
P11178765A0642|100 118|mouse adenocarcinoma
P11178765A0642|128 132|colon
P11178765A0642|135 139|cells
P11179272T0000|0 14|Cytomegalovirus
P11179272T0000|15 23|Chlamydia
P11179272T0000|37 67|Helicobacter pylori IgG antibodies
P11179272T0000|71 80|restenosis
P11179272T0000|91 102|implantation
P11179272T0000|133 147|ultrasound study
P11179400T0000|0 8|Responses
P11179400T0000|22 46|carotid body chemoreceptors
P11179664T0000|0 11|Architecture
P11179664T0000|15 21|anatomy
P11179664T0000|34 38|locus
P11179664T0000|74 102|transcription factor RUNX1/AML1
P11179668A0869|28 35|proteins
P11179668A0869|52 61|PLTP family
P11179687A0280|6 10|paper
P11179687A0280|14 21|tyrosine
P11179687A0280|39 45|enzymes
P11179687A0280|65 76|phosphatases
P11179687A0280|117 127|subfamilies
P11179687A0280|149 160|receptor PTPs
P11179687A0280|160 164|RPTPs
P11179687A1118|20 27|metazoan
P11179687A1118|28 33|module
P11179687A1118|51 60|disulphide
P11179687A1118|68 76|Ig members
P11179687A1118|113 118|member
P11179687A1118|125 129|group
P11179689A0000|3 15|Sox gene family
P11179689A0000|25 34|HMG box gene
P11179689A0000|61 71|DNA sequence
P11179689A0000|81 86|domain
P11179689A0000|104 113|amino acids
P11179689A0000|135 142|sequence
P11179689A0000|151 160|DNA binding
P11179956A1818|10 16|results
P11179956A1818|52 58|effects
P11179956A1818|74 79|domain
P11179956A1818|82 98|nucleotide binding
P11179956A1818|122 133|interactions
P11179956A1818|151 157|domains
P11179956A1818|179 193|proton transport
P11180027A1306|11 20|parameters
P11180027A1306|62 71|depression
P11180027A1306|75 82|morphine
P11180255A0776|20 28|arguments
P11180255A0776|35 47|improbability
P11180255A0776|60 66|effects
P11180255A0776|69 82|UHF frequencies
P11180255A0776|90 98|mechanism
P11180255A0776|124 129|energy
P11180255A0776|143 147|space
P11180688A0000|11 29|maximum oxygen uptake
P11180688A0000|41 48|Hong Kong
P11180688A0000|54 61|children
P11180688A0000|77 87|association
P11180688A0000|103 111|illnesses
P11180688A0000|136 146|Fitness Test
P11180688A0000|157 163|shuttle
P11180688A0000|179 192|schoolchildren
P11180688A0000|207 211|years
P11181516A0119|11 52|deletion insulin promoter-reporter constructs
P11181516A0119|64 76|transfections
P11181516A0119|85 99|INS-1 beta-cells
P11181516A0119|132 138|regions
P11181516A0119|148 166|rat insulin I promoter
P11181516A0119|197 204|elements
P11181516A0119|221 225|A2/A3
P11181525T0000|3 18|androgen receptor
P11181525T0000|23 36|amino-terminus
P11181525T0000|60 69|regulation
P11181525T0000|72 87|AR gene expression
P11181525T0000|99 106|enhancer
P11181531A0464|6 14|mechanism
P11181531A0464|22 30|estrogens
P11181531A0464|38 49|osteoporosis
P11181531A0464|59 68|repression
P11181531A0464|71 83|transcription
P11181531A0464|86 105|NF-kappa B target genes
P11181531A0464|136 157|cytokines interleukin-6
P11181531A0464|161 173|interleukin-1
P11181548A0214|39 45|element
P11181548A0214|61 66|tissue
P11181548A0214|66 71|region
P11181548A0214|88 97|expression
P11181548A0214|103 113|mE-RABP gene
P11181548A0214|121 131|DNA fragment
P11181564A0733|5 9|mouse
P11181564A0733|14 18|genes
P11181564A0733|38 46|region 8E1
P11181564A0733|49 58|chromosome
P11181995A1093|0 7|Analysis
P11181995A1093|13 26|genome sequence
P11181995A1093|57 67|transcripts
P11181995A1093|103 110|evidence
P11181995A1093|167 171|genes
P11181995A1093|176 187|mouse matches
P11181995A1093|209 216|evidence
P11182520A0889|16 23|genotype
P11182520A0889|42 52|restriction
P11182520A0889|65 69|assay
P11182746A0872|13 20|patients
P11182746A0872|35 40|levels
P11182746A0872|55 65|drug therapy
P11185475T0034|2 8|Caveman
P11187016T0000|10 15|models
P11187016T0000|22 39|A-bomb survivor data
P11187016T0000|40 51|implications
P11187016T0000|67 76|mechanisms
P11188971A0000|19 25|surgery
P11188971A0000|29 37|Parkinson
P11188971A0000|39 45|disease
P11188971A0000|59 68|discussion
P11188971A0000|80 90|methodology
P11188971A0000|102 107|target
P11188993A0298|0 6|Corneal
P11188993A0298|30 35|biopsy
P11188993A0298|72 81|evaluation
P11188993A0298|94 104|acid-Schiff
P11188993A0298|105 110|Giemsa
P11188993A0298|114 119|Gomori
P11188993A0298|121 143|methenamine silver stains
P11189314A1000|5 11|results
P11189314A1000|69 75|effects
P11191208A0000|9 18|resistance
P11191208A0000|64 77|overexpression
P11191208A0000|80 84|genes
P11191208A0000|97 115|membrane efflux pumps
P11191208A0000|124 135|facilitators
P11191208A0000|142 171|ABC binding cassette transporters
P11191208A0000|180 186|control
P11191208A0000|192 214|transcription regulators
P11191208A0000|236 244|PDR3 genes
P11191365A0682|0 13|Susceptibility
P11191365A0682|32 42|arrhythmias
P11191365A0682|59 67|diabetics
P11191365A0682|87 92|hearts
P11191365A0682|112 122|tachycardia
P11191365A0682|143 150|episodes
P11191365A0682|162 173|fibrillation
P11191365A0682|244 256|non-diabetics
P11193045A1193|1 7|picture
P11193045A1193|26 33|gradient
P11193045A1193|36 43|function
P11193045A1193|75 90|tumor suppression
P11193045A1193|90 100|development
P11193666A1269|25 33|outbreaks
P11193666A1269|36 56|Babesia carrier animals
P11193704A0000|16 30|pleuropneumonia
P11193704A0000|39 44|threat
P11193704A0000|48 53|cattle
P11193704A0000|56 61|Africa
P11194101A0532|0 16|Baseline BMD values
P11194101A0532|61 65|group
P11194101A0532|78 83|others
P11194101A0532|89 93|level
P11194101A0532|102 106|spine
P11194101A0532|182 185|g x cm
P11194101A0532|228 237|user groups
P11194101A0532|302 306|femur
P11194147A1496|3 14|distribution
P11194147A1496|20 34|rice cultivation
P11194147A1496|37 44|Sri Lanka
P11194147A1496|64 75|HIDD villages
P11194183A0866|3 10|increase
P11194183A0866|13 18|number
P11194183A0866|29 33|hairs
P11194183A0866|51 55|hairs
P11194183A0866|66 71|microm
P11194183A0866|74 81|diameter
P11194183A0866|106 113|cm square
P11194183A0866|118 124|cm2 area
P11194183A0866|130 156|procyanidin B-2 group subjects
P11194183A0866|172 176|trial
P11194183A0866|213 239|placebo control group subjects
P11194183A0866|240 253|procyanidin B-2
P11194183A0866|282 288|placebo
P11194183A0866|333 337|t test
P11195338A0494|7 16|expression
P11195338A0494|36 44|Lg3 allele
P11195338A0494|65 73|phenotype
P11195401A1030|4 18|plasma AVP levels
P11195401A1030|35 39|cases
P11195401A1030|51 55|SSRIs
P11195401A1030|65 76|AVP secretion
P11195401A1030|91 95|SIADH
P11196191A1789|6 29|T47D breast carcinoma cells
P11196191A1789|42 48|synergy
P11196191A1789|52 79|EGF receptor autocrine activity
P11196191A1789|98 114|MAPK/PI3K pathways
P11196199T0000|5 13|homologue
P11196199T0000|16 33|yeast Rad23 protein A
P11196199T0000|72 85|element binding
P11196199T0000|91 104|binding protein
P11196199T0000|134 141|activity
P11196340A1046|16 22|methods
P11196340A1046|23 36|identification
P11196340A1046|43 50|antigens
P11196340A1046|69 79|variability
P11196340A1046|97 109|aescin analogs
P11196340A1046|121 128|validity
P11197288A0855|4 11|patients
P11197288A0855|21 33|metronidazole
P11197288A0855|61 67|strains
P11197288A0855|113 120|regimens
P11197328T0000|0 6|Binding
P11197328T0000|35 42|proteins
P11197328T0000|55 60|region
P11197328T0000|63 103|maize C4 phosphoenolpyruvate carboxylase gene
P11197328T0000|126 138|transcription
P11197328T0000|141 154|mesophyll cells
P11197549A0748|0 6|RESULTS
P11197549A0748|16 34|stabilization period
P11197549A0748|35 39|PaCO2
P11197549A0748|58 61|mm Hg
P11197549A0748|62 72|arrhythmias
P11197926A0000|0 9|BACKGROUND
P11197926A0000|18 24|studies
P11197926A0000|61 68|versions
P11197926A0000|74 99|General Health Questionnaire
P11197926A0000|122 128|effects
P11197926A0000|162 166|times
P11197926A0000|176 184|intervals
P11198053T0000|5 11|effects
P11198053T0000|21 27|extract
P11198053T0000|29 47|Hypericum perforatum
P11198053T0000|48 53|St John
P11198053T0000|72 83|constituents
P11198053T0000|99 107|responses
P11198289T0000|9 26|serum ceruloplasmin
P11198289T0000|30 41|copper levels
P11198289T0000|52 59|dystonia
P11198385A0000|21 32|algerae Vavra
P11198385A0000|62 67|larvae
P11198385A0000|71 76|adults
P11198385A0000|80 95|laboratory colony
P11198385A0000|98 111|Culex pipiens L.
P11198385A0000|126 143|Gharbia Governorate
P11198424T0000|9 15|cloning
P11198424T0000|19 34|characterization
P11198424T0000|37 41|OsPSK
P11198424T0000|58 66|precursor
P11198424T0000|69 88|phytosulfokine-alpha
P11198424T0000|100 120|rice cell proliferation
P11200568A0830|0 4|Blood
P11200568A0830|34 44|inoculation
P11200568A0830|57 64|necropsy
P11200568A0830|67 77|measurement
P11200568A0830|88 100|IgG antibodies
P11200568A0830|102 111|M. pulmonis
P11201250A0849|0 21|Plasma DHE concentration
P11201250A0849|40 44|ng/ml
P11201250A0849|53 63|application
P11201250A0849|69 75|PSA tape
P11202434T0000|6 27|amino acid substitutions
P11202434T0000|49 54|domain
P11202434T0000|67 86|palmitoyl-CoA binding
P11202434T0000|88 92|ACBP2
P11202434T0000|95 105|Arabidopsis
P11202434T0000|122 128|protein
P11202434T0000|133 146|ankyrin repeats
P11202705A1112|0 11|Implications
P11202705A1112|14 26|biomonitoring
P11202705A1112|40 59|accumulation patterns
P11202705A1112|84 90|tissues
P11202705A1112|93 109|Posidonia oceanica
P11203702A1307|4 9|Xlim-1
P11203702A1307|45 60|activation domain
P11203702A1307|97 102|domain
P11203702A1307|105 113|CT239-403
P11203702A1307|142 150|mechanism
P11203702A1307|181 188|activity
P11203702A1307|191 196|Xlim-1
P11203702A1307|202 210|organizer
P11204897A0797|22 31|absorption
P11204897A0797|31 42|participants
P11204897A0797|53 71|bridge simulator task
P11207216A0296|9 18|PGHS-2 cDNA
P11207216A0296|31 41|combination
P11207216A0296|75 87|chain reaction
P11207216A0296|91 110|cDNA library screening
P11207216A0719|3 12|regulation
P11207216A0719|15 24|PGHS-2 mRNA
P11207216A0719|28 34|protein
P11207216A0719|54 61|cultures
P11207216A0719|84 88|cells
P11207216A0719|103 131|phorbol 12-myristate 13-acetate
P11207261A1421|10 17|analysis
P11207261A1421|40 53|DT40 B cell lines
P11207261A1421|87 114|Fc gamma RIIB1-PECAM-1 receptor
P11207261A1421|139 149|Src homology
P11207261A1421|169 180|phosphatases
P11207261A1421|181 185|SHP-1
P11207261A1421|189 193|SHP-2
P11207261A1421|251 260|regulation
P11207261A1421|265 274|coligation
P11207261A1421|277 286|BCR complex
P11207261A1421|301 308|receptor
P11207269A0745|47 56|properties
P11207269A0745|62 73|p95 component
P11207282A0729|17 26|expression
P11207282A0729|58 70|chicken Notch1
P11207282A0729|72 77|Notch2
P11207282A0729|81 89|B cell line
P11207282A0729|100 114|down-regulation
P11207282A0729|117 136|surface IgM expression
P11207282A0729|160 168|reduction
P11207282A0729|171 188|IgH gene transcripts
P11207288A0897|0 12|Substitutions
P11207288A0897|33 38|region
P11207288A0897|79 86|residues
P11207288A0897|105 111|binding
P11207288A0897|114 123|peptide-Ag
P11207288A0897|129 144|class Ia molecules
P11207308A0999|9 16|curcumin
P11207308A0999|17 33|diferuloylmethane
P11207308A0999|53 57|agent
P11207308A0999|82 101|STAT1 phosphorylation
P11207308A0999|113 120|activity
P11207308A0999|123 127|STAT1
P11207308A0999|131 135|c-Jun
P11207308A0999|146 161|kinase activation
P11207308A0999|196 201|ERK1/2
P11207308A0999|202 219|p38 phosphorylation
P11207609A0994|2 9|contrast
P11207609A0994|13 19|failure
P11207609A0994|25 33|QKTT motif
P11207609A0994|37 41|TGN46
P11207609A0994|79 92|ER localization
P11207609A0994|103 129|stomatitis virus glycoprotein
P11207609A0994|136 143|chimeras
P11207609A0994|154 161|NRK cells
P11207609A0994|185 195|differences
P11207609A0994|212 222|trafficking
P11208017A0070|1 9|cDNA clone
P11208017A0070|18 43|C2H2-type zinc finger protein
P11208017A0070|44 49|SCOF-1
P11208017A0070|65 71|soybean
P11208814A0673|17 27|specificity
P11208814A0673|42 52|interaction
P11208814A0673|55 65|DmCKIIalpha
P11208814A0673|79 86|proteins
P11208814A0673|87 103|sequence alignment
P11208814A0673|143 155|consensus site
P11208814A0673|156 170|phosphorylation
P11208814A0673|186 194|subdomain
P11208814A0673|212 219|proteins
P11209100A0069|22 31|properties
P11209100A0069|87 93|effects
P11209100A0069|94 104|stimulation
P11209100A0069|108 114|release
P11209100A0069|117 135|cytokine antagonists
P11209100A0069|142 172|interleukin-1 receptor antagonist
P11209100A0069|173 178|IL-1ra
P11209814A0243|3 9|purpose
P11209814A0243|16 28|investigation
P11209814A0243|55 69|characteristics
P11209814A0243|82 94|tissue capsule
P11209814A0243|111 122|implantation
P11209814A0243|125 148|aluminum calcium phosphate
P11209814A0243|149 153|ALCAP
P11209814A0243|157 170|hydroxyapetite
P11209814A0243|175 185|bioceramics
P11210401A0000|0 21|Sevelamer hydrochloride
P11210401A0000|22 28|Renagel
P11210401A0000|60 66|polymer
P11210401A0000|81 89|treatment
P11210401A0000|92 108|hyperphosphatemia
P11210401A0000|116 123|patients
P11210401A0000|133 144|hemodialysis
P11210401A0544|18 25|profiles
P11210401A0544|28 34|digoxin
P11210401A0544|38 45|warfarin
P11210401A0544|89 102|administration
P11210401A0544|105 113|sevelamer
P11210839A0282|6 22|PO3 administration
P11210839A0282|48 55|patients
P11210839A0282|85 89|drugs
P11210839A0282|90 100|ethambutole
P11210839A0282|104 114|ethionamide
P11210839A0282|117 127|ethambutole
P11210839A0282|131 142|oprofloxacin
P11210988T0000|3 10|survival
P11210988T0000|25 32|patients
P11210988T0000|54 67|prostate cancer
P11211759A0165|0 7|Patients
P11211759A0165|26 30|group
P11211759A0165|31 43|Control group A
P11211759A0165|52 60|hot-water
P11211759A0165|72 77|system
P11211759A0165|88 93|group B
P11211759A0165|102 121|transtracheal heating
P11211759A0165|125 144|humidification system
P11211759A0165|147 160|ANAMED HUMITUBE
P11211759A0165|181 195|cancer operation
P11211936A1490|42 51|expression
P11211936A1490|68 83|JNK/SAPK activity
P11211936A1490|91 104|SAPK activation
P11211936A1490|140 154|differentiation
P11211936A1490|158 169|growth arrest
P11212249A0993|3 9|effects
P11212249A0993|26 34|receptors
P11212249A0993|53 62|antagonism
P11212249A0993|65 80|activator protein
P11212249A0993|88 95|activity
P11212327A1564|6 12|studies
P11212327A1564|26 38|rat adipocytes
P11212327A1564|63 74|PIG compounds
P11212327A1564|82 110|IRS1/3 tyrosine phosphorylation
P11212327A1564|113 124|p59Lyn kinase
P11212327A1564|138 147|cross-talk
P11212327A1564|158 167|regulation
P11212327A1564|177 187|interaction
P11212327A1564|192 199|caveolin
P11213342A0492|0 6|RESULTS
P11213342A0492|10 22|parameters SF2
P11213342A0492|33 42|efficiency
P11213342A0492|72 81|test period
P11214177A1125|9 13|sense
P11214177A1125|41 46|nt RNAs
P11214177A1125|61 66|satRNA
P11214177A1125|99 107|satellite
P11214354A1104|6 12|animals
P11214354A1104|43 48|levels
P11214354A1104|60 76|lipid peroxidation
P11214354A1104|93 105|protein thiols
P11214354A1104|132 141|CON animals
P11215622A0949|0 7|Grippers
P11215622A0949|36 47|force sensors
P11215622A0949|63 68|strain
P11216247T0000|3 7|child
P11218739A0811|0 9|Transition
P11218739A0811|23 28|H-BPPV
P11218739A0811|39 43|cases
P11220166A0616|14 20|effects
P11220166A0616|35 45|stimulation
P11220166A0616|51 66|motor performance
P11220166A0616|76 82|aspects
P11220166A0616|94 103|processing
P11220166A0616|114 122|existence
P11220166A0616|132 143|interactions
P11220166A0616|168 189|brain dopamine receptors
P11220166A0616|195 206|intervention
P11220166A0616|242 252|cortex loops
P11220166A0616|255 259|motor
P11220166A0616|272 280|behaviour
P11220306A0911|0 5|HexA71
P11220306A0911|34 39|levels
P11220306A0911|56 66|sigma factor
P11220306A0911|108 113|strain
P11220306A1753|8 13|copies
P11220306A1753|61 70|production
P11220306A1753|90 96|effects
P11220486A0686|6 10|IL-12
P11220487T0000|10 15|review
P11220487T0000|28 32|tests
P11220487T0000|43 56|trichomoniasis
P11220857T0000|12 21|Department
P11220857T0000|23 37|Veterans Affairs
P11221836A0981|19 24|fusion
P11221836A0981|48 54|vaccine
P11221836A0981|77 83|potency
P11221836A0981|125 130|tumors
P11221845A0295|23 39|methylation status
P11221845A0295|53 57|liver
P11221845A0295|61 71|liver tumors
P11221845A0295|74 87|SV40 T/t antigen
P11221845A0295|104 112|MT-D2 mice
P11221845A0295|117 135|Restriction Landmark
P11221845A0295|143 150|Scanning
P11221845A0295|154 164|Methylation
P11221845A0295|165 170|RLGS-M
P11221845A0295|191 200|loci/spots
P11221845A0295|239 249|liver tumors
P11221845A0800|3 17|Genescan program
P11221845A0800|33 44|reading frame
P11221845A0800|83 90|B236 spot
P11221845A0800|110 129|493-amino acid protein
P11221845A0800|143 160|SNAG repressor motif
P11221845A0800|178 183|region
P11221845A0800|191 215|C2H2-type zinc finger motifs
P11221845A1370|0 19|Northern blot analysis
P11221845A1370|59 63|brain
P11221845A1370|63 68|spleen
P11221845A1370|69 75|stom ach
P11221845A1370|79 83|liver
P11221845A1713|0 8|Treatment
P11221845A1713|11 22|N18TG-2 cells
P11221845A1713|41 45|agent
P11221845A1713|46 64|5-aza-deoxycytidine
P11221845A1713|77 86|expression
P11221845A1713|112 121|repression
P11221845A1713|145 155|methylation
P11221845A1713|173 182|target gene
P11221845A1713|198 208|methylation
P11221845A1713|215 232|liver tumorigenesis
P11221845A1713|244 255|SV40 T antigen
P11222387A1497|16 23|compound
P11222387A1497|29 37|mechanism
P11222387A1497|40 45|action
P11222387A1497|64 90|ABL tyrosine kinase inhibition
P11222387A1497|91 101|FTI SCH66336
P11222387A1497|107 113|promise
P11222387A1497|120 128|treatment
P11222387A1497|146 153|leukemia
P11222639A1273|5 11|results
P11222639A1273|39 53|tyrosine residue
P11222639A1273|62 71|regulation
P11222639A1273|74 86|L1 endocytosis
P11222720A1699|35 43|regulator
P11222720A1699|45 49|EBNA2
P11222720A1699|53 65|Notch activity
P11222720A1699|76 87|interactions
P11222720A1699|110 127|corepressor complex
P11223131A0000|0 15|Folate metabolism
P11223131A0000|26 60|malaria parasite Plasmodium falciparum
P11223131A0000|74 81|activity
P11223131A0000|85 94|cell growth
P11223131A0000|98 108|replication
P11223131A0000|115 120|target
P11223131A0000|134 138|class
P11223131A0000|152 157|agents
P11223153A0533|3 11|BFA System
P11223153A0533|18 25|text file
P11223153A0533|30 34|flows
P11223153A0533|58 77|microsphere technique
P11223153A0533|81 90|constructs
P11223153A0533|94 104|lung anatomy
P11223153A0533|119 124|pixels
P11223153A0533|135 139|flows
P11223153A0533|145 155|color schema
P11223164A0000|0 8|Retinoids
P11223164A0000|25 29|onset
P11223164A0000|32 46|differentiation
P11223164A0000|47 55|apoptosis
P11223164A0000|62 71|inhibition
P11223164A0000|74 79|growth
P11223164A0000|87 93|variety
P11223164A0000|114 118|cells
P11223186A1095|0 14|Transactivation
P11223186A1095|17 50|oIFNtau enhancer-reporter constructs
P11223186A1095|79 85|regions
P11223186A1095|96 103|AP-1 site
P11223186A1095|114 121|sequence
P11223199A0751|5 11|results
P11223199A0751|24 33|evaluation
P11223199A0751|36 43|exposure
P11223199A0751|46 54|S. neurona
P11223199A0751|57 66|WB analysis
P11223199A0751|69 73|serum
P11223199A0751|96 101|horses
P11223240A0655|10 30|Menin1 gene transcripts
P11223240A0655|45 64|polyadenylation sites
P11223240A0655|86 93|messages
P11223246A0359|0 15|Sequence analysis
P11223246A0359|29 47|RBP21 shares homology
P11223246A0359|79 86|proteins
P11223246A0359|103 112|motif LxCxE
P11223246A0359|128 133|region
P11223255A1034|2 9|addition
P11223255A1034|13 35|consensus amino acid motif
P11223255A1034|39 68|serine threonine receptor kinases
P11223256A1212|41 46|region
P11223256A1212|52 63|pea 33RNP gene
P11223257A0404|0 5|OsBBPI
P11223257A0404|34 49|rice seedling leaf
P11223257A0404|52 59|response
P11223257A0404|104 123|protein phosphatase 2A
P11223257A0404|128 137|inhibitors
P11223257A0404|137 147|cantharidin
P11223257A0404|155 163|endothall
P11223257A0404|170 179|light/dark
P11223257A0404|202 207|manner
P11223257A0404|211 219|induction
P11223257A0404|244 256|cycloheximide
P11223257A0404|273 283|requirement
P11223257A0404|292 307|protein synthesis
P11223257A0404|313 321|induction
P11223938X1218|0 8|Copyright
P11223938X1218|13 21|John Wiley
P11224226A0000|3 9|effects
P11224226A0000|12 27|chlordiazepoxide
P11224226A0000|34 38|mg/kg
P11224226A0000|44 72|benzodiazepine receptor agonist
P11224226A0000|76 85|bretazenil
P11224226A0000|92 96|mg/kg
P11224226A0000|105 133|benzodiazepine receptor agonist
P11224226A0000|174 181|paradigm
P11226228A0899|7 14|plasmids
P11226228A0899|26 30|yeast
P11226752A0750|11 28|tissue culture cells
P11226752A0750|29 42|overexpression
P11226752A0750|57 75|mouse deltex homologs
P11226752A0750|104 111|activity
P11226752A0750|145 151|protein
P11226752A0750|154 159|manner
P11226752A0750|169 179|suppression
P11226752A0750|206 211|Notch1
P11227039A0953|11 15|women
P11227039A0953|72 76|primi
P11227039A0953|87 92|groups
P11227182A1475|3 9|authors
P11227182A1475|36 47|correlations
P11227182A1475|55 64|parameters
P11227182A1475|70 75|lipids
P11227182A1475|78 87|bone marrow
P11227182A1475|91 102|leptin levels
P11227182A1475|105 109|serum
P11227182A1475|113 122|bone marrow
P11227484T0000|12 24|determination
P11227484T0000|27 39|methylmercury
P11227484T0000|44 65|ion-association complex
P11227484T0000|70 79|rhodamine B
P11227484T0000|85 92|presence
P11227484T0000|95 100|iodide
P11228700T0000|3 10|position
P11228700T0000|16 22|analyst
P11228700T0000|25 30|expert
P11228700T0000|31 39|yesterday
P11228700T0000|43 47|today
P11230145A0732|3 9|results
P11230145A0732|42 51|Notch-CBF1
P11230145A0732|50 75|RBP-Jkappa signaling pathway
P11230145A0732|78 94|cell fate decisions
P11230145A0732|117 124|pathways
P11230145A0732|132 142|replication
P11230145A0732|155 164|conversion
P11230169A0480|11 16|method
P11230169A0480|26 53|chromatin immunoprecipitation
P11230169A0480|64 81|array hybridization
P11230169A0480|119 127|DNA domain
P11230169A0480|158 168|20p12 region
P11230169A0480|173 178|invdup
P11230169A0480|189 204|marker chromosome
P11230534A0688|11 15|total
P11230534A0688|20 32|DEAH helicases
P11230534A0688|44 50|species
P11230889A1151|3 7|cases
P11230889A1151|25 38|arm lymphoedema
P11230889A1151|65 76|improvements
P11230889A1151|79 87|arm volume
P11230889A1151|100 105|months
P11230889A1151|111 119|treatment
P11231287A0158|3 13|sensitivity
P11231287A0158|21 45|neuroblastoma cells SK-N-SH
P11231287A0158|55 63|apoptosis
P11231287A0158|73 84|thapsigargin
P11232947A1451|12 30|lymph node dissection
P11232947A1451|33 48|radiation therapy
P11232947A1451|59 63|chain
P11232947A1451|80 89|recurrence
P11232947A1451|125 132|survival
P11233643A0000|62 75|protoporphyrin
P11233643A0000|96 102|therapy
P11233643A0000|121 127|maximum
P11233643A0000|140 146|ALA dose
P11233643A0000|149 153|mg/kg
P11234223A1451|13 23|antibiotics
P11234223A1451|31 36|groups
P11234223A1451|63 70|activity
P11234223A1451|93 97|class
P11234223A1451|100 110|antibiotics
P11234223A1451|129 135|killing
P11234223A1451|200 206|killing
P11235777A0878|2 12|Klinefelter
P11235777A0878|14 21|syndrome
P11235777A0878|22 26|47XXY
P11235777A0878|27 49|serum testosterone levels
P11235777A0878|79 83|range
P11235777A0878|86 110|dihydrotestosterone levels
P11235817A0000|3 32|histamine H1 receptor antagonists
P11235817A0000|33 46|antihistamines
P11235817A0000|61 65|class
P11235817A0000|68 78|medications
P11235817A0000|89 94|relief
P11235817A0000|103 110|symptoms
P11235817A0000|140 149|conditions
P11235817A0000|161 168|children
P11235817A0000|172 177|adults
P11236056A0374|0 9|Conclusion
P11236056A0374|17 22|levels
P11236056A0374|29 36|children
P11237038A0889|1 6|subset
P11237038A0889|9 16|patients
P11237038A0889|42 60|pressure flow studies
P11237038A0889|105 129|bladder outflow obstruction
P11237491A0000|18 25|baseline
P11237491A0000|43 54|fluctuations
P11237491A0000|60 75|tumour markers CEA
P11237491A0000|94 101|patients
P11237491A0000|119 124|cancer
P11237491A0000|137 146|hypothesis
P11237491A0000|151 169|serum concentrations
P11237491A0000|188 199|fluctuations
P11237491A0000|218 231|concentrations
P11237491A0000|245 255|individuals
P11237598A0962|24 32|framework
P11237598A0962|40 46|enzymes
P11237598A0962|59 68|structures
P11237598A0962|87 95|evolution
P11237598A0962|114 122|mechanism
P11238105A0959|0 4|Cells
P11238105A0959|15 27|alpha subunits
P11238105A0959|45 50|domain
P11238105A0959|51 56|term-3
P11238105A0959|85 91|alpha-2
P11238105A0959|98 103|domain
P11238105A0959|127 133|ability
P11238105A0959|143 165|tyrosine phosphorylation
P11238105A0959|168 172|Jak-2
P11238105A0959|179 188|substrates
P11238375A0617|35 47|kinase cascade
P11238375A0617|59 68|activation
P11238375A0617|77 84|p38 gamma
P11238375A0617|103 108|member
P11238375A0617|114 122|p38 family
P11238375A0617|125 129|MAPKs
P11238402A0191|32 41|mechanisms
P11238402A0191|59 79|DAN/TIR gene expression
P11238405A0817|2 8|strains
P11238405A0817|16 20|tup11
P11238405A0817|24 28|tup12
P11238405A0817|32 40|atf1-pcr1
P11238405A0817|56 64|activator
P11238405A0817|96 114|fbp1-lacZ expression
P11238405A0817|121 143|spc1 MAPK phosphorylation
P11238405A0817|177 186|activation
P11238447A0524|7 20|binding studies
P11238447A0524|36 41|eIF-5A
P11238447A0524|64 74|interaction
P11238447A0524|77 83|Rev-NES
P11238447A0524|88 101|CRM1/exportin1
P11238447A0524|109 114|eIF-5A
P11238447A0524|131 152|nucleoporins CAN/nup214
P11238447A0524|153 158|nup153
P11238447A0524|159 163|nup98
P11238447A0524|167 171|nup62
P11238586A0000|10 16|studies
P11238586A0000|30 34|class
P11238586A0000|41 65|histocompatibility complex
P11238586A0000|96 108|T cell receptor
P11238586A0000|112 122|alpha/betas
P11238586A0000|134 141|contacts
P11238586A0000|149 154|alpha1
P11238586A0000|158 170|alpha2 helices
P11238586A0000|216 227|interactions
P11238586A0000|249 255|binding
P11238884A0892|22 32|dlg mutation
P11238884A0892|39 55|growth retardation
P11238884A0892|58 62|utero
P11238884A0892|67 76|hypoplasia
P11238884A0892|82 91|premaxilla
P11238884A0892|95 102|mandible
P11238884A0892|108 112|cleft
P11238884A0892|122 127|palate
P11238916A0838|9 15|complex
P11238916A0838|26 31|PTP phi
P11238916A0838|32 39|paxillin
P11238916A0838|63 76|tyrosine kinase
P11238916A0838|110 126|macrophage lysates
P11238916A0838|141 146|domain
P11238916A0838|149 154|PTP phi
P11238916A0838|171 178|paxillin
P11238947A0636|7 16|base change
P11238947A0636|30 37|sequence
P11238947A0636|44 57|hnRNP A2 binding
P11238947A0636|74 79|A2RE-2
P11238947A0636|87 98|RNA transport
P11239184A1340|0 16|Baseline variables
P11239184A1340|72 78|aspirin
P11239184A1340|87 95|incidence
P11239184A1340|103 111|CT changes
P11239184A1340|114 118|edema
P11239184A1340|121 130|mass effect
P11239184A1340|152 161|artery sign
P11239529A0981|0 7|IL-1beta
P11239529A0981|32 43|endometrioma
P11239529A0981|50 56|lesions
P11239529A0981|64 76|localizations
P11240600A0523|9 19|drug history
P11240600A0523|44 49|amount
P11240600A0523|53 60|duration
P11240600A0523|63 75|VGB medication
P11241166A0677|6 13|analysis
P11241166A0677|16 29|gene expression
P11241166A0677|46 56|FA treatment
P11241166A0677|71 78|decrease
P11241166A0677|84 89|amount
P11241166A0677|92 105|leptin receptor
P11241166A0677|123 130|increase
P11241166A0677|142 151|regulators
P11241166A0677|154 167|STAT signalling
P11241166A0677|168 172|SOCS3
P11241166A0677|173 183|suppressors
P11241166A0677|186 203|cytokine signalling
P11241166A0677|206 213|cytokine
P11241166A0677|223 230|sequence
P11241215A0566|9 17|receptors
P11241215A0566|26 33|sBMPR-IA
P11241215A0566|49 62|fusion proteins
P11241215A0566|67 77|thioredoxin
P11241215A0566|118 122|phase
P11241215A0566|127 137|performance
P11241215A0566|144 157|chromatography
P11241215A0566|158 164|RP-HPLC
P11241215A0566|170 178|digestion
P11241215A0566|183 194|enterokinase
P11241243A0693|3 9|authors
P11241243A0693|33 40|analysis
P11241243A0693|43 51|pathology
P11241243A0693|56 69|quantification
P11241243A0693|75 84|percentage
P11241243A0693|102 110|component
P11241243A0693|111 114|% PSC
P11241243A0693|118 130|p53 expression
P11241332A0393|7 13|purpose
P11241332A0393|50 66|fixation strengths
P11241332A0393|72 81|variations
P11241332A0393|96 112|bone anchor designs
P11241332A0393|120 125|anchor
P11241332A0393|130 140|screw anchor
P11241332A0393|167 171|foams
P11241332A0393|205 213|densities
P11241356T0000|12 26|phosphorylation
P11241356T0000|37 48|localization
P11241356T0000|51 55|Smad3
P11241356T0000|82 106|collagen gene transcription
P11241356T0000|125 137|stellate cells
P11241672T0000|0 6|Cloning
P11241672T0000|10 25|characterization
P11241672T0000|31 40|murine beta
P11241672T0000|41 60|integrin gene promoter
P11241672T0000|61 74|identification
P11241672T0000|79 91|interleukin-4
P11241672T0000|102 108|element
P11241672T0000|112 121|regulation
P11241672T0000|124 129|STAT-6
P11243306A0961|0 10|CONCLUSIONS
P11243306A0961|22 27|levels
P11243306A0961|30 44|oxLDL antibodies
P11243306A0961|67 78|hypertension
P11243306A0961|99 111|artery disease
P11243306A0961|127 134|presence
P11243306A0961|137 148|hypertension
P11243306A0961|172 177|levels
P11243336A0000|10 16|MD-55-2
P11243336A0000|73 84|applications
P11243336A0000|109 130|brachytherapy dosimetry
P11243494A0833|0 6|RESULTS
P11243494A0833|23 28|groups
P11243494A0833|52 57|heroin
P11243494A0833|70 74|rates
P11243494A0833|98 108|performance
P11243777A0000|10 22|CCAAT elements
P11243777A0000|53 67|promoter regions
P11243980A0510|11 18|patients
P11243980A0510|31 45|PET examinations
P11243980A0510|55 71|staging procedures
P11244568A0506|3 8|Gap69C
P11244568A0506|66 76|development
P11244568A0506|81 86|amount
P11244568A0506|100 105|larvae
P11244733A0782|0 4|Cases
P11244733A0782|7 16|lung cancer
P11244733A0782|35 44|metastasis
P11244733A0782|82 86|death
P11245986T0000|27 33|protein
P11245986T0000|50 73|rat aldolase B gene promoter
P11246679A0000|0 8|OBJECTIVE
P11246679A0000|25 35|association
P11246679A0000|61 70|heart block
P11246679A0000|82 86|fetus
P11246679A0000|94 100|disease
P11246887A0000|4 8|study
P11246887A0000|28 51|cholesteryl ester transfer
P11246887A0000|56 86|cholesteryl ester transfer protein
P11246887A0000|92 99|activity
P11246887A0000|114 128|transfer protein
P11246887A0000|135 142|activity
P11246887A0000|156 165|prevalence
P11246887A0000|176 194|artery calcification
P11246887A0000|210 217|subjects
P11246887A0000|240 247|subjects
P11246887A0000|267 279|sex difference
P11246887A0000|288 295|diabetes
P11247663A1447|3 10|families
P11247663A1447|25 35|inheritance
P11247663A1447|38 49|DNAH9 alleles
P11247663A1447|60 70|individuals
P11248463A0187|3 13|blood levels
P11248463A0187|16 22|lactate
P11248463A0187|23 30|pyruvate
P11248463A0187|34 43|amino acids
P11248626T0000|0 7|Efficacy
P11248626T0000|26 33|Cavermap
P11248626T0000|42 49|location
P11248626T0000|53 60|function
P11248626T0000|72 77|nerves
P11248626T0000|91 103|prostatectomy
P11248626T0000|124 133|evaluation
P11248626T0000|147 154|surgeons
P11250196A0455|12 21|domain fold
P11250196A0455|39 57|calcium binding sites
P11250196A0455|104 139|betagamma-crystallin fold family member
P11250196A0455|140 148|Protein S.
P11250942A0626|10 17|analyses
P11250942A0626|38 42|GRIP1
P11250942A0626|67 87|VDR activation function
P11250942A0626|93 98|domain
P11250942A0626|110 120|interaction
P11250942A0626|150 156|regions
P11251083T0000|0 8|Mechanism
P11251083T0000|24 30|control
P11251083T0000|33 46|cell morphology
P11251083T0000|50 60|S phase entry
P11251083T0000|72 83|growth factor
P11251083T0000|100 117|MEK/ERK activations
P11251104A0526|3 12|expression
P11251104A0526|15 27|alpha-amylase
P11251104A0526|52 75|transcription factor GAMyb
P11251252A0494|0 17|3D image-processing
P11251252A0494|34 47|ultrasound data
P11251252A0494|78 83|planes
P11251252A0494|84 94|section mode
P11251252A0494|108 114|3D views
P11251276A0793|8 15|patients
P11251276A0793|27 33|surgery
P11251697T0000|6 33|superoxide scavenging activity
P11251697T0000|65 69|drugs
P11251697T0000|70 82|determination
P11251697T0000|85 105|electron spin resonance
P11251697T0000|114 127|spin trap method
P11251951A0000|0 9|BACKGROUND
P11251951A0000|10 19|Dermoscopy
P11251951A0000|34 42|technique
P11251951A0000|69 76|accuracy
P11251951A0000|88 98|skin lesions
P11251951A0000|123 131|diagnosis
P11251951A0000|134 141|patients
P11251951A0000|155 162|melanoma
P11251951A0000|191 198|melanoma
P11254134A0648|29 48|background activities
P11254134A0648|74 81|sequence
P11254134A0648|105 110|region
P11254134A0648|123 138|background levels
P11254504A0766|10 23|promoter region
P11254504A0766|62 69|elements
P11254504A0766|86 101|growth response-1
P11254504A0766|101 118|activator protein-2
P11254504A0766|138 150|factor-kappaB
P11254504A0766|156 174|zinc finger protein-1
P11254504A0766|189 196|homeobox
P11254504A0766|202 206|gene A
P11254504A0766|209 232|Cdx protein-2 binding sites
P11254713A1029|7 17|interaction
P11254713A1029|32 41|components
P11254713A1029|47 53|rel/AP1
P11254713A1029|65 71|complex
P11254713A1029|111 121|alterations
P11254713A1029|128 134|complex
P11254713A1029|137 146|activation
P11254713A1029|169 176|decrease
P11254713A1029|179 199|IL-2 gene transcription
P11254864T0000|22 30|treatment
P11254864T0000|33 44|breast cancer
P11255035A0331|11 25|progenitor cells
P11255035A0331|31 35|brain
P11255035A0331|36 54|SVZa progenitor cells
P11255035A0331|62 69|capacity
P11255035A0331|108 116|phenotype
P11255252A0961|8 18|ER3 sequence
P11255252A0961|61 66|FXR HRE
P11255252A0961|100 112|yeast extracts
P11255423A0211|0 8|OBJECTIVE
P11255423A0211|23 33|association
P11255423A0211|46 53|symptoms
P11255423A0211|69 77|mortality
P11255423A0211|81 87|decline
P11255423A0211|90 102|CD4 lymphocyte
P11255423A0211|114 118|women
P11256845A0340|10 17|analysis
P11256845A0340|31 61|Scotland Coronary Prevention Study
P11256845A0340|61 67|WOSCOPS
P11256845A0340|68 75|findings
P11256845A0340|89 103|statin treatment
P11256845A0340|125 130|events
P11256845A0340|140 147|patients
P11256845A0340|151 160|population
P11256845A0340|176 182|WOSCOPS
P11256845A0340|224 228|event
P11256845A0340|272 277|pounds
P11256944A1144|21 25|forms
P11256944A1144|40 53|G13 gene product
P11256944A1144|77 88|point mutants
P11256944A1144|104 126|ER stress response element
P11256944A1144|153 160|ER stress
P11256962A0233|0 15|Sequence analysis
P11256962A0233|35 45|differences
P11256962A0233|57 62|region
P11256962A0233|68 82|beta subunit gene
P11256962A0233|102 108|regions
P11256962A0233|124 144|GlyR alpha subunit genes
P11256962A0233|212 218|portion
P11256962A0233|222 233|GlyR beta mRNA
P11257870A0000|10 14|study
P11257870A0000|39 47|potential
P11257870A0000|51 56|hybrid
P11257870A0000|67 73|reactor
P11257870A0000|92 97|filter
P11257870A0000|114 126|sludge process
P11257870A0000|138 147|wastewater
P11257870A0000|157 173|trichloroethylene
P11257870A0000|188 198|temperature
P11257870A0000|218 230|retention time
P11258906A0743|2 27|DNA strand exchange reactions
P11258906A0743|33 48|oligonucleotides
P11258906A0743|76 86|pairing bias
P11259347A0000|9 20|observations
P11259347A0000|43 52|literature
P11259347A0000|70 74|clues
P11259347A0000|87 96|variations
P11259347A0000|99 104|humans
P11259347A0000|105 111|ability
P11259347A0000|127 135|chemicals
P11259503A0212|0 17|Forskolin treatment
P11259503A0212|20 25|microM
P11259503A0212|42 46|cells
P11259503A0212|71 80|luciferase
P11259593A1094|0 7|Analysis
P11259593A1094|10 23|ace2Delta cells
P11259593A1094|35 39|Ace2p
P11259593A1094|53 66|cell separation
P11259593A1094|85 90|growth
P11260468A1179|3 9|results
P11260468A1179|58 67|CAP subunit
P11260468A1179|81 98|papBA transcription
P11260468A1179|108 114|absence
P11260468A1179|132 142|protein H-NS
P11260662X0000|4 10|Slatkin
P11263622A0683|0 6|RESULTS
P11263622A0683|19 29|correlation
P11263622A0683|57 69|wall thickness
P11263622A0683|72 85|vessel wall area
P11263622A0683|101 114|histopathology
P11263664A1085|46 63|XBra gene expression
P11263664A1085|67 74|mesoderm
P11263664T0000|6 27|Smad interacting protein
P11263664T0000|31 38|deltaEF1
P11263664T0000|55 75|enhancer binding factor
P11263664T0000|113 122|repressors
P11264176A0181|0 4|B-myb
P11264176A0181|19 32|G1/S transition
P11264176A0181|71 90|cyclin A2/cdk2 complex
P11264177T0000|0 17|Nucleotide sequence
P11264177T0000|18 33|transcription map
P11264177T0000|37 52|mutation analysis
P11264177T0000|58 62|13q14
P11264177T0000|74 79|region
P11264177T0000|89 94|B-cell
P11264177T0000|113 120|leukemia
P11264182A0000|5 27|T-cell leukemia virus type
P11264182A0000|29 34|HTLV-I
P11264182A0000|64 72|regulator
P11264182A0000|112 116|genes
P11264182A0000|153 166|leukemogenesis
P11264182A0000|174 187|T-cell leukemia
P11264372T0000|0 11|Requirements
P11264372T0000|37 49|translocation
P11264372T0000|52 71|infected-cell protein
P11264372T0000|75 92|herpes simplex virus
P11264375A0000|8 22|cytomegalovirus
P11264375A0000|49 58|protein IE2
P11264375A0000|68 81|phosphoprotein
P11264375A0000|104 112|regulator
P11264375A0000|133 142|infections
P11264561A0167|0 8|OBJECTIVE
P11264561A0167|49 55|anatomy
P11264561A0167|74 82|occlusion
P11265853A0000|3 9|Novacor
P11265853A0000|25 36|Assist System
P11265853A0000|43 53|Novacor Corp
P11265853A0000|53 59|Oakland
P11265853A0000|128 140|configuration
P11266184A0000|0 7|Atheroma
P11266184A0000|25 43|signal intensity area
P11266184A0000|59 72|time-of-flight
P11266184A0000|86 94|resonance
P11266184A0000|98 103|images
P11266184A0000|109 118|components
P11266184A0000|130 146|signal intensities
P11266184A0000|149 157|spin-echo
P11266184A0000|162 167|images
P11266194A0743|9 20|distribution
P11266194A0743|52 61|tomography
P11266227A0295|3 11|flux rates
P11266227A0295|14 24|p-toluidine
P11266227A0295|39 45|pH value
P11266227A0295|51 63|donor solution
P11266540A0328|32 51|Groucho family members
P11266540A0328|60 66|ability
P11266540A0328|103 122|Tcf/Lef family members
P11266558A1470|24 43|transcription extract
P11266558A1470|53 67|binding activity
P11266558A1470|88 103|initiator element
P11266558A1470|127 149|recruiting RNA polymerase
P11266558A1470|157 173|SL RNA gene promoter
P11266615A0258|3 9|protein
P11266615A0258|30 36|domains
P11266615A0258|60 71|linker region
P11266615A0258|76 92|amino acid residues
P11267679A0102|6 20|bp EcoRI fragment
P11267679A0102|39 59|Southern hybridization
P11267679A0102|73 84|reading frame
P11267679A0102|98 104|protein
P11267679A0102|110 119|amino acids
P11268459A0167|21 25|study
P11268459A0167|38 49|relationship
P11268459A0167|60 76|DOX binding ability
P11268459A0167|98 105|response
P11268459A0167|112 119|decrease
P11268459A0167|121 131|tumor volume
P11268459A0167|147 158|tissue tumors
P11268459A0167|176 187|chemotherapy
P11268459A0167|191 199|prognosis
P11268887A1174|7 24|misinterpretations
P11268887A1174|32 46|reference values
P11268887A1174|65 78|preadolescents
P11268887A1174|90 95|regard
P11271297T0000|0 13|Nephrotoxicity
P11271297T0000|29 48|liver transplantation
P11271297T0000|51 62|cyclosporin A
P11271297T0000|81 88|patients
P11273995A1148|25 32|subjects
P11273995A1148|38 48|TOF patients
P11273995A1148|91 100|velocities
P11273995A1148|121 134|relaxation time
P11274109A0129|0 6|Acetoin
P11274109A0129|23 30|bacteria
P11274109A0129|47 51|phase
P11274109A0129|61 73|carbon sources
P11274149A0625|10 17|analysis
P11274149A0625|31 35|U-box
P11274149A0625|43 52|RING finger
P11274149A0625|60 67|proteins
P11274149A0625|84 88|basis
P11274149A0625|95 105|interaction
P11274149A0625|110 118|E2 enzymes
P11274179A0610|7 13|studies
P11274179A0610|20 32|Rac/Cdc42/Pak
P11274179A0610|36 41|module
P11274179A0610|52 56|Raf-1
P11274179A0610|66 75|activation
P11274179A0610|89 98|disruption
P11274184A0000|15 24|expression
P11274184A0000|26 30|genes
P11274184A0000|39 45|enzymes
P11274184A0000|50 60|antioxidant
P11274184A0000|65 79|heme oxygenase-1
P11274184A0000|98 111|detoxification
P11274184A1068|5 11|results
P11274184A1068|59 68|expression
P11274184A1068|72 79|ho-1 gene
P11274184A1068|96 101|manner
P11274184A1068|116 122|complex
P11274357A0724|22 35|overexpression
P11274357A0724|77 82|mutant
P11274357A0724|84 89|nm23H1
P11274357A0724|111 115|forms
P11274357A0724|124 128|Cdc42
P11274357A0724|153 157|forms
P11274357A0724|169 203|nucleoside diphosphate kinase activity
P11274357A0724|207 212|nm23H1
P11274357A0724|266 272|GTPases
P11274368A0469|4 9|effect
P11274368A0469|26 32|absence
P11274368A0469|41 56|protein synthesis
P11274368A0469|76 101|histone deacetylase activity
P11274368A0818|0 7|Deletion
P11274368A0818|22 37|initiator element
P11274368A0818|51 60|repression
P11274368A0818|66 76|p21 promoter
P11274368A0818|79 83|c-Myc
P11274563T0000|5 14|lung volume
P11274563T0000|15 24|estimation
P11274563T0000|46 52|results
P11275986A0091|5 16|gene products
P11275986A0091|42 66|p53 tumor suppressor protein
P11275986A0091|98 108|degradation
P11276426A0501|2 6|mouse
P11276426A0501|7 11|Mmip1
P11276426A0501|12 20|Mad member
P11276426A0501|32 38|protein
P11276426A0501|47 51|share
P11276426A0501|53 69|% sequence identity
P11276426A0501|76 83|products
P11277913T0000|2 8|element
P11277913T0000|31 36|region
P11277913T0000|44 52|Hsp70 mRNA
P11277913T0000|72 79|enhancer
P11277913T0000|82 96|mRNA translation
P11278286A0456|15 19|cells
P11278286A0456|42 56|5-HT1A receptors
P11278286A0456|55 62|deletion
P11278286A0456|65 76|inactivation
P11278286A0456|119 128|regulation
P11278286A0456|132 140|rat 5-HT1A
P11278286A0456|155 163|promoters
P11278286A0456|166 180|corticosteroids
P11278286A0456|191 199|inclusion
P11278286A0456|231 240|inhibition
P11278286A0456|256 263|promoter
P11278286A1083|38 47|inhibition
P11278286A1083|61 65|MR/GR
P11278286A1083|68 78|combination
P11278290A1220|7 11|Smad2
P11278290A1220|38 45|TGF-beta
P11278290A1220|69 78|activation
P11278290A1220|81 93|Agc expression
P11278290A1220|105 109|cells
P11278290A1220|110 124|Smad2 activation
P11278290A1220|160 164|level
P11278290A1220|167 179|Agc expression
P11278310A1516|31 36|mutant
P11278310A1516|62 81|caspase-3 stimulation
P11278310A1516|98 105|decrease
P11278310A1516|108 117|cell number
P11278390A0632|7 49|transcriptase-polymerase chain reaction assays
P11278390A0632|60 69|PKRDeltaE7
P11278390A0632|89 93|range
P11278390A0632|101 107|tissues
P11278390A0632|118 123|levels
P11278400A0668|27 35|cell lines
P11278400A0668|55 60|number
P11278400A0668|68 77|OCT binding
P11278400A0668|77 95|homeodomain proteins
P11278400A0668|121 138|mobility shift assay
P11278440A0095|17 26|acid insert
P11278440A0095|31 51|S1 transmembrane domain
P11278440A0095|79 92|hydrophobicity
P11278440A0095|103 113|S0-S1 linker
P11278461A0637|10 19|antibodies
P11278461A0637|46 55|amino acids
P11278461A0637|83 92|amino acids
P11278461A0637|101 129|rainbow trout HIF-1alpha protein
P11278461A0637|140 151|rainbow trout
P11278461A0637|155 184|chinook salmon HIF-1alpha protein
P11278461A0637|187 205|Western blot analysis
P11278488T0000|3 16|v-Src SH3 domain
P11278488T0000|55 65|association
P11278488T0000|74 87|adhesion kinase
P11278521A0849|8 26|pair oligonucleotide
P11278521A0849|41 47|nonamer
P11278521A0849|55 67|up-regulation
P11278521A0849|70 76|hypoxia
P11278521A0849|80 89|inhibition
P11278521A0849|108 112|acids
P11278521A0849|146 153|promoter
P11278521A0849|157 177|lacZ reporter construct
P11278563A0917|0 15|Deletion analyses
P11278563A0917|41 50|amino acids
P11278563A0917|53 57|Grb14
P11278563A0917|61 74|ankyrin repeats
P11278563A0917|82 90|tankyrase
P11278563A0917|107 117|interaction
P11278583A0873|0 10|Mutagenesis
P11278583A0873|41 47|classes
P11278583A0873|47 60|effector motifs
P11278583A0873|96 108|ERK activation
P11278583A0873|119 133|differentiation
P11278583A0873|139 159|phosphotyrosine motifs
P11278583A0873|171 181|recruitment
P11278583A0873|194 214|phosphotyrosine motifs
P11278583A0873|225 235|recruitment
P11278583A0873|259 263|motif
P11278594A0618|18 27|propeptide
P11278594A0618|34 40|chimera
P11278594A0618|60 64|MIC-1
P11278594A0618|67 85|TGF-beta1 propeptide
P11278594A0618|96 104|secretion
P11278594A0618|130 136|chimera
P11278594A0618|156 166|interaction
P11278594A0618|182 196|MIC-1 propeptide
P11278594A0618|206 212|peptide
P11278604A0300|23 31|N-glycans
P11278604A0300|47 52|5Lec20
P11278604A0300|98 104|species
P11278604A0300|117 124|CHO cells
P11278604A0300|128 144|Lec20 cell extracts
P11278604A0300|164 170|ability
P11278604A0300|206 214|acceptors
P11278610A0902|14 20|SOCS box
P11278610A0902|35 42|Cullin-2
P11278610A0902|54 67|ubiquitination
P11278610A0902|70 77|TEL-JAK2
P11278671T0000|15 27|Bcl-2 homology
P11278671T0000|40 52|splice variant
P11278671T0000|78 84|neurons
P11278671T0000|114 118|cells
P11278713A1054|21 26|region
P11278713A1054|80 98|instability elements
P11278713A1054|112 122|transcripts
P11278713A1054|144 166|coding region determinant
P11278819A0565|0 17|Sequence comparison
P11278819A0565|21 34|binding studies
P11278819A0565|57 61|sites
P11278819A0565|71 76|intron
P11278819A0565|94 107|mouse IRBP genes
P11278819A0565|119 130|half sequence
P11278819A0565|145 155|core element
P11278819A0565|159 169|MOK2 binding
P11278848A1316|11 18|SB203580
P11278848A1316|39 48|activation
P11278848A1316|67 82|promoter activity
P11278848A1316|84 88|cells
P11278848A1316|105 111|plasmid
P11278848A1316|125 144|Sp1 consensus sequence
P11278855A0205|14 24|interaction
P11278855A0205|59 63|assay
P11278855A0205|75 105|coimmunoprecipitation experiment
P11278855A0205|116 126|Western blot
P11278870A0123|0 7|Analysis
P11278870A0123|20 26|regions
P11278870A0123|32 39|promoter
P11278870A0123|51 71|copper transporter gene
P11278870A0123|73 84|fission yeast
P11278870A0123|119 126|identity
P11278870A0123|155 161|element
P11278870A0123|190 212|transcription factor Cuf1
P11278928A1634|34 46|mRNA structure
P11278928A1634|68 73|effect
P11278928A1634|76 88|mRNA structure
P11278928A1634|91 101|translation
P11278928A1634|115 134|C/EBPepsilon isoforms
P11279038A0194|0 10|WRN helicase
P11279038A0194|28 40|DNA structures
P11279038A0194|77 93|Holliday junctions
P11279086A1350|22 30|ADAM-TS12
P11279086A1350|37 41|roles
P11279086A1350|53 57|cells
P11279086A1350|69 79|development
P11279086A1350|84 97|tumor processes
P11279086A1350|119 126|activity
P11279086A1350|132 139|molecule
P11279086A1350|161 170|regulation
P11279086A1350|173 184|cell adhesion
P11279108T0000|0 6|Binding
P11279108T0000|9 27|serum response factor
P11279108T0000|30 45|CArG box sequences
P11279108T0000|83 96|gene expression
P11279108T0000|113 123|muscle cells
P11279207A0904|13 19|results
P11279207A0904|40 48|component
P11279207A0904|50 61|TCR signaling
P11279324A0710|14 20|infarct
P11279324A0710|41 54|creatine kinase
P11279324A0710|63 68|method
P11279385A3917|21 29|technique
P11279385A3917|58 62|M mode
P11279385A3917|89 95|Doppler
P11279385A3917|114 120|ability
P11279385A3917|143 150|pathways
P11279385A3917|161 170|conduction
P11279385A3917|189 194|method
P11279720A0844|0 16|SELECTION CRITERIA
P11279720A0844|37 42|trials
P11279720A0844|45 55|cabergoline
P11279720A0844|62 68|placebo
P11279720A0844|71 78|patients
P11279720A0844|92 100|diagnosis
P11279720A0844|113 121|Parkinson
P11279720A0844|123 129|disease
P11279720A0844|142 154|complications
P11279720A0844|157 171|levodopa therapy
P11280495A1330|0 10|CONCLUSIONS
P11280495A1330|54 61|PD fluids
P11280495A1330|81 89|formation
P11280495A1330|92 105|Amadori albumin
P11280799A1025|2 9|contrast
P11280799A1025|19 27|PTHrP1-34
P11280799A1025|35 42|peptides
P11280799A1025|68 81|IL-8 production
P11280799A1025|108 117|antibodies
P11280799A1025|134 143|production
P11280799A1025|165 169|PTHrP
P11281201T0000|13 19|effects
P11281268A0000|17 31|arginine kinases
P11281268A0000|65 69|times
P11281268A0000|84 92|evolution
P11281268A0000|95 111|phosphagen kinases
P11281268A0000|133 164|sea anemone Anthopleurura japonicus
P11281268A0000|174 203|clam Pseudocardium sachalinensis
P11282029A0075|3 7|mouse
P11282029A0075|24 35|growth factor
P11282029A0075|42 62|beta-receptor promoter
P11282029A0075|71 80|CCAAT motif
P11282029A0075|117 129|transcription
P11282088A0837|0 10|Baseline MBF
P11282088A0837|13 19|females
P11282088A0837|55 59|males
P11282394A0841|14 25|VH/VL-chains
P11282394A0841|59 77|antigen reactivities
P11282394A0841|110 127|cross-reactivities
P11282395A0530|30 43|RAG1/2 proteins
P11282395A0530|53 63|DNA hairpins
P11282395A0530|81 88|activity
P11282395A0530|109 122|protein complex
P11282395A0530|128 160|DNA repair proteins Nbs1/Mre11/Rad50
P11282395A1073|2 9|addition
P11282395A1073|35 45|differences
P11282395A1073|48 60|CDR3 sequences
P11282395A1073|73 81|Ig lambdaL
P11282395A1073|85 103|kappaL chain gene loci
P11282395A1073|124 139|blood lymphocytes
P11282395A1073|144 153|NBS patient
P11282395A1073|166 176|individuals
P11282433T0000|0 4|Phase
P11282433T0000|7 11|study
P11282433T0000|14 23|paclitaxel
P11282433T0000|31 39|etoposide
P11282433T0000|42 49|patients
P11282433T0000|90 103|cell lung cancer
P11282761A0531|4 18|supplementation
P11282761A0531|21 30|L-arginine
P11282761A0531|53 70|plasma L-citrulline
P11282761A0531|85 95|enhancement
P11282761A0531|98 109|NO production
P11283010A0701|4 13|activation
P11283010A0701|30 38|CGS 12066A
P11283014A0921|3 9|results
P11283014A0921|36 48|transcription
P11283014A0921|57 70|TCR stimulation
P11283014A0921|74 79|manner
P11283014A0921|125 143|actin polymerization
P11283168A0738|24 28|lines
P11283168A0738|54 63|expression
P11283168A0738|69 75|Gus gene
P11283168A0738|93 101|endosperm
P11283168A0738|108 122|mid-development
P11283168A0738|149 156|anthesis
P11283256A0258|62 70|complexes
P11283354A0548|27 33|pathway
P11283354A0548|50 69|histone modifications
P11283354A0548|80 90|histone code
P11283354A0548|116 126|inheritance
P11283354A0548|129 151|heterochromatin assembly
P11285054A0781|0 17|Regression analyses
P11285054A0781|28 49|SOREMP dream occurrences
P11285054A0781|79 84|amount
P11285054A0781|87 94|REM sleep
P11285054A0781|100 120|NREMP dream occurrences
P11285054A0781|134 141|arousals
P11285054A0781|146 154|NREM sleep
P11285235A0466|7 11|TRPS1
P11285235A0466|59 68|activation
P11285235A0466|84 94|GATA factors
P11285329A0682|16 25|micromol/L
P11285329A0682|29 33|women
P11286833A0959|5 12|patients
P11286833A0959|31 36|cycles
P11286833A0959|39 52|5-fluorouracil
P11286833A0959|54 63|leucovorin
P11286833A0959|66 88|maintenance chemotherapy
P11286833A0959|103 109|RESULTS
P11286833A0959|116 120|males
P11286833A0959|126 132|females
P11286833A0959|153 157|years
P11286833A0959|157 161|range
P11286833A0959|166 170|years
P11287555A1057|3 16|Delta6CCI virus
P11287555A1057|41 59|replication capacity
P11287555A1057|71 84|infectiousness
P11287555A1057|88 94|CEMx174
P11287555A1057|98 105|MT4 cells
P11287578A1311|0 8|Secretion
P11287578A1311|11 23|interleukin-8
P11287578A1311|24 29|RANTES
P11287578A1311|30 39|macrophage
P11287578A1311|52 64|protein 1alpha
P11287578A1311|97 103|protein
P11287578A1311|134 146|keratinocytes
P11287579A1084|7 12|mutant
P11287579A1084|13 17|T255A
P11287579A1084|25 31|ability
P11287579A1084|38 43|E4orf6
P11287579A1084|64 82|late-gene expression
P11287611A0802|6 14|PPARgamma
P11287611A0802|38 44|15d-PGJ
P11287611A0802|64 70|ligands
P11287611A0802|70 77|BRL49653
P11287611A0802|81 92|troglitazone
P11287611A0802|113 122|expression
P11287611A0802|128 139|cyclin D1 gene
P11287623A0286|74 79|kinase
P11287623A0286|85 100|signaling pathway
P11287623A0286|125 134|expression
P11287623A0286|147 162|integrin subunits
P11287623A0286|166 172|variety
P11287623A0286|183 196|mouse cell lines
P11287654A0150|16 22|protein
P11287654A0150|51 57|domains
P11287654A0150|72 80|C terminus
P11288208A0712|0 7|Children
P11288208A0712|36 50|tract infections
P11288208A0712|70 74|rates
P11288208A0712|76 82|decline
P11288208A0712|85 97|CD4 cell counts
P11288208A0712|113 118|months
P11288930A0000|15 21|effects
P11288930A0000|27 40|administration
P11288930A0000|116 126|generations
P11288930A0000|135 140|mating
P11288930A0000|151 156|mating
P11288930A0000|159 167|gestation
P11288930A0000|171 179|lactation
P11289135A0975|0 9|Coexposure
P11289135A0975|57 66|activation
P11289135A0975|88 100|protein kinase
P11289135A0975|137 156|protein kinase cascade
P11289135A0975|162 173|PMA treatment
P11289135A0975|182 191|disruption
P11289135A0975|198 204|pathway
P11289135A0975|227 245|protein kinase kinase
P11289135A0975|247 260|inhibitor U0126
P11289135A0975|274 285|potentiation
P11289135A0975|288 296|apoptosis
P11289149A0658|7 16|EWS protein
P11289149A0658|27 39|transcription
P11289149A0658|66 86|transactivation domain
P11289149A0658|92 99|cofactor
P11289149A0658|112 118|protein
P11290415A0288|12 16|study
P11290415A0288|36 54|ICBP90 gene structure
P11290415A0288|57 65|screening
P11290415A0288|74 81|placenta
P11290415A0288|89 95|library
P11290415A0288|99 109|PCR analysis
P11290906T0000|10 21|accumulation
P11290906T0000|24 34|Tl-201 SPECT
P11290906T0000|64 73|infarction
P11291552A0156|0 6|METHODS
P11291552A0156|10 17|patients
P11292335A0852|18 24|dnaE173
P11292335A0852|32 46|mutator mutation
P11292335A0852|58 77|sequence substitution
P11292335A0852|97 106|frameshift
P11292335A0852|123 131|frequency
P11292335A0852|145 162|frameshift mutation
P11292839A0531|3 15|transcription
P11292839A0531|48 54|factors
P11292839A0531|59 64|U6 gene
P11292839A0531|77 85|exception
P11292839A0531|101 108|TATA-box
P11292839A0531|115 123|construct
P11292839A0531|154 160|protein
P11292839A0531|166 171|mutant
P11292839A0531|171 177|TBP-DR2
P11292839A0531|202 206|TBPwt
P11292844A0081|18 23|trimer
P11292844A0081|35 41|trimers
P11294895A0292|24 28|spo20
P11294895A0292|29 39|gene product
P11294895A0292|89 93|Sec14
P11294895A0292|102 136|phosphatidylinositol transfer protein
P11294895A0292|146 150|yeast
P11295470A0954|10 17|evidence
P11295470A0954|20 40|linkage disequilibrium
P11295470A0954|73 77|B cell
P11295470A0954|85 92|promoter
P11295523A0218|5 11|numbers
P11295523A0218|42 50|mid-1970s
P11295760A1374|0 20|Specimen mass reduction
P11295760A1374|34 43|irradiance
P11296288A1107|2 9|addition
P11296288A1107|17 26|derivative
P11296288A1107|29 36|pCMVJS21
P11296288A1107|37 51|pCMVJS21DeltaGP
P11296288A1107|75 79|orf-x
P11296288A1107|84 92|sequences
P11296442A0565|2 11|conclusion
P11296442A0565|12 19|tube size
P11296442A0565|38 44|formula
P11296442A0565|86 93|tube size
P11296442A0565|113 122|anesthesia
P11296442A0565|147 153|formula
P11296442A0565|167 174|tube size
P11297419A0894|2 6|F222W
P11297419A0894|6 17|W21F rGST A1-1
P11297419A0894|45 61|fluorescence probe
P11297419A0894|64 70|changes
P11297419A0894|76 86|environment
P11297419A0894|102 108|residue
P11297514A0218|12 23|hos1 mutation
P11297514A0218|38 46|induction
P11297514A0218|52 74|CBF transcription factors
P11297514A0218|80 90|temperature
P11297514A0218|131 135|genes
P11297545A0948|6 17|transfection
P11297545A0948|25 32|CHOP cDNA
P11297545A0948|44 57|carcinoma cells
P11297545A0948|96 103|mediator
P11297545A0948|119 129|mitogenesis
P11297545A0948|150 159|protection
P11297545A0948|164 172|apoptosis
P11297545A0948|210 215|manner
P11297866A0484|2 9|contrast
P11297866A0484|17 27|I. argentina
P11297866A0484|31 40|I. theezans
P11297866A0484|51 56|effect
P11297866A0484|75 84|propulsion
P11298326A0677|1 10|comparison
P11298326A0677|26 36|Vkappa genes
P11298326A0677|53 61|selection
P11298326A0677|94 100|regions
P11298326A0677|116 120|genes
P11298326A0677|123 136|point mutations
P11301189A1396|2 9|contrast
P11301189A1396|23 32|expression
P11301189A1396|39 43|INK4d
P11301189A1396|87 100|B-lineage cells
P11302072A0508|3 9|results
P11302072A0508|27 37|stimulation
P11302072A0508|46 56|performance
P11302072A0508|62 77|Boston Naming Test
P11302072A0508|82 104|Word List Recognition Task
P11302072A0508|113 124|intervention
P11302072A0508|154 165|significance
P11302566A1318|16 25|flattening
P11302566A1318|47 73|dopamine receptor sensitivity
P11302566A1318|77 94|psychomotor slowing
P11302704T0000|0 19|Homo-oligomerisation
P11302704T0000|30 41|localisation
P11302704T0000|44 66|mouse histone deacetylase
P11303027A0954|25 31|network
P11303027A0954|33 44|interactions
P11303027A0954|52 58|GTPases
P11303027A0954|64 72|ARF family
P11303027A0954|81 89|effectors
P11303027A0954|100 108|potential
P11303027A0954|112 121|cross-talk
P11303638A0559|4 20|NEU overexpression
P11303638A0559|26 32|control
P11303890A0996|32 36|doses
P11303890A0996|42 47|values
P11303890A0996|64 71|microg/l
P11305129T0000|0 6|Effects
P11305129T0000|10 20|booster dose
P11305129T0000|23 35|tetanus toxoid
P11305129T0000|57 63|courses
P11305129T0000|66 76|vaccination
P11305129T0000|77 88|implications
P11305129T0000|107 114|globulin
P11306101A0000|5 18|RACE techniques
P11306101A0000|51 62|hamster liver
P11306101A0000|85 98|dehydrogenases
P11306101A0000|125 132|alcohols
P11306101A0000|140 162|17beta-hydroxy-steroids
P11306101A0000|166 187|3alpha-hydroxysteroids
P11306463A0383|1 8|mutation
P11306463A0383|14 20|C domain
P11306463A0383|27 31|L901Q
P11306463A0383|71 92|cdk4/D1 phosphorylation
P11306463A0383|106 112|C domain
P11306511A1476|2 12|association
P11306511A1476|38 47|expression
P11306511A1476|86 94|mdm2 mRNAs
P11306511A1476|107 126|progesterone receptor
P11306845A0168|12 22|examination
P11306845A0168|38 44|changes
P11306845A0168|57 72|blister formation
P11306845A0168|85 97|keratinocytes
P11308851A0333|13 28|response function
P11308851A0333|79 92|frequency range
P11308851A0333|107 124|material parameters
P11308851A0333|146 152|network
P11308877A0213|27 31|input
P11308877A0213|55 62|relation
P11308877A0213|69 79|input phases
P11308877A0213|93 106|discharge times
P11308877A0213|144 173|orientation preserving circle map
P11309077A0953|4 10|strains
P11309077A0953|36 41|jejuni
P11309077A0953|50 55|jejuni
P11309077A0953|88 96|biotype I.
P11309373A0783|0 7|Analysis
P11309373A0783|10 18|mCTR mRNAs
P11309373A0783|53 61|promoters
P11309373A0783|86 97|mCTR isoforms
P11309373A0783|103 108|region
P11309373A0783|143 149|regions
P11309373A0783|164 170|lengths
P11309389A0273|26 36|proteolysis
P11309389A0273|63 103|phorbol ester phorbol 12-myristate 13-acetate
P11309389A0273|119 141|metalloprotease activity
P11309389A0273|218 230|domain remnant
P11309389A0273|242 256|down-regulation
P11309389A0273|259 270|GHR abundance
P11309389A0273|274 284|GH signaling
P11309400T0000|0 6|Effects
P11309400T0000|10 30|terminus modifications
P11309400T0000|49 53|decay
P11309400T0000|66 81|protein synthesis
P11309677A0000|32 38|battery
P11309677A0000|58 65|veterans
P11309677A0000|70 83|Gulf War Illness
P11309677A0000|110 116|fatigue
P11309677A0000|134 141|veterans
P11309678A0489|7 31|transcription-PCR analysis
P11309678A0489|44 51|patients
P11309678A0489|75 83|mutations
P11309678A0489|101 108|splicing
P11310937A0548|0 6|RESULTS
P11310937A0548|15 23|mortality
P11310937A0548|58 63|months
P11310937A0548|90 96|tertile
P11310937A0548|143 149|tertile
P11310937A0548|151 160|fibrinogen
P11310937A0548|164 172|TNF-alpha
P11310937A0548|205 212|tertiles
P11311153T0000|3 14|relationship
P11311153T0000|20 40|factor V Leiden mutation
P11311153T0000|63 74|polymorphism
P11311153T0000|80 90|angiotensin
P11311153T0000|101 106|enzyme
P11311153T0000|122 141|thromboembolic events
P11311153T0000|161 172|arthroplasty
P11311464A0362|5 13|disorders
P11311464A0362|35 50|saddle anesthesia
P11311464A0362|59 66|sciatica
P11311464A0362|71 83|motor weakness
P11311464A0362|94 104|extremities
P11311464A0362|114 123|paraplegia
P11311464A0362|127 144|bladder dysfunction
P11311480A0079|5 15|nerve biopsy
P11311480A0079|41 51|perineurium
P11311480A0079|60 70|alterations
P11311480A0079|87 102|cell infiltration
P11311480A0079|108 118|perineurium
P11311480A0079|163 168|fibers
P11311550A0253|24 33|regulation
P11311550A0253|39 50|rat eIF4E gene
P11311550A0253|63 84|rat eIF4E promoter region
P11311550A0253|99 110|contribution
P11311550A0253|121 128|elements
P11311550A0253|141 153|transcription
P11311550A0253|176 183|cultures
P11311550A0253|186 199|rat cardiocytes
P11311550A0253|218 233|myoblast cell line
P11311563A0423|8 15|CCAAT box
P11311563A0423|44 60|promoter construct
P11311563A0423|61 71|OA induction
P11311563A0423|94 101|CCAAT box
P11311687A0231|3 8|JHRLSS
P11311687A0231|27 33|studies
P11311687A0231|42 52|RLS severity
P11311687A0231|87 94|relation
P11311687A0231|103 110|measures
P11311687A0231|116 124|morbidity
P11311909A0938|23 30|aneurysm
P11311909A0938|75 88|A1 fenestration
P11311980A1049|30 34|brain
P11311980A1049|45 51|tissues
P11312120A1311|0 25|NF-kappaB pathway activation
P11312120A1311|38 51|transformation
P11312120A1311|62 67|number
P11312120A1311|79 87|oncogenes
P11312120A1311|97 103|Bcr/Abl
P11312120A1311|150 158|potential
P11312326A0169|28 34|HIV type
P11312326A0169|35 39|HIV-1
P11312326A0169|49 53|clone
P11312326A0169|56 81|complementation experiments
P11312326A0169|94 99|method
P11312326A0169|111 119|isolation
P11312326A0169|151 158|elements
P11312326A0169|175 180|genome
P11312326A0169|195 200|rescue
P11312326A0169|203 218|virus replication
P11312584X1846|0 8|Copyright
P11312584X1846|13 25|Academic Press
P11313249T0000|24 32|zebrafish
P11313249T0000|55 61|protein
P11313249T0000|88 103|activation domain
P11313342A0224|24 43|alanine substitutions
P11313342A0224|55 73|center cleft residues
P11313342A0224|96 107|depurinating
P11313342A0224|111 118|ribosome
P11313342A0224|129 136|activity
P11313386A0704|0 18|SH2D1A protein levels
P11313386A0704|36 52|CD40 cross-linking
P11313386A0704|72 92|B cell receptor ligation
P11313398A0687|0 20|Cross-linking FcalphaR
P11313398A0687|23 29|wt-ITAM
P11313398A0687|32 44|IIA-ITAM cells
P11313398A0687|86 95|activation
P11313398A0687|97 104|PKBalpha
P11313946A0449|0 7|RPM/RGL3
P11313946A0449|26 30|Nore1
P11313946A0449|75 79|M-Ras
P11313946A0449|83 88|p21 Ras
P11313946T0000|15 22|effector
P11313946T0000|25 29|M-Ras
P11313946T0000|33 38|p21 Ras
P11313946T0000|75 87|gene induction
P11313946T0000|90 99|cell growth
P11313961A1323|58 63|tumors
P11313961A1323|79 86|contrast
P11313961A1323|102 108|strains
P11313961A1323|122 128|p53 gene
P11314030A1264|3 9|results
P11314030A1264|34 39|region
P11314030A1264|73 80|elements
P11314030A1264|118 131|signal pathways
P11314030A1264|140 147|paradigm
P11314030A1264|167 172|region
P11314030A1264|200 208|SH3 domain
P11314046A0000|0 6|Cyclins
P11314046A0000|25 36|determinants
P11314046A0000|47 66|cell cycle progression
P11314373T0000|24 30|formula
P11314373T0000|38 44|problem
P11314428A0651|25 31|ability
P11314428A0651|37 50|hydroxyapatite
P11314428A0651|56 62|sockets
P11314428A0651|81 92|significance
P11314428A0651|101 122|months width differences
P11314428A0651|134 139|region
P11315633A0920|3 14|cleavage site
P11315633A0920|44 56|RNA polymerase
P11315633A0920|71 79|E445-T446
P11315633A0920|90 114|amino acid sequence analysis
P11315633A0920|120 130|polyprotein
P11315633A0920|144 156|sobemoviruses
P11316127A0485|3 8|%SVend
P11316127A0485|10 14|HCM-I
P11316127A0485|53 58|values
P11316127A0485|64 69|HCM-II
P11316127A0485|73 85|Control groups
P11317256A0361|9 16|isolates
P11317256A0361|19 31|S. intermedius
P11317256A0361|39 46|isolates
P11317256A0361|49 62|S. constellatus
P11317256A0361|83 93|S. anginosus
P11317256A0361|111 117|abscess
P11318363A0085|0 5|DESIGN
P11318363A0085|19 23|study
P11318608A0669|5 29|brain cDNA library screening
P11318608A0669|39 51|amplification
P11318608A0669|82 90|DENTT cDNA
P11318608A0669|113 124|reading frame
P11318608A0669|157 163|protein
P11318608A0669|188 206|localization signals
P11318608A0669|230 236|regions
P11318608A1155|0 11|Transfection
P11318608A1155|25 50|DENTT NLS deletion constructs
P11318608A1155|70 74|NLS-1
P11318608A1155|94 102|nucleolus
P11319098A0164|5 9|genes
P11319098A0164|17 32|tryptophanyl tRNA
P11319098A0164|36 66|protein translocase component SecE
P11319098A0164|84 94|protein NusG
P11319098A0164|110 120|proteins L11
P11319098A0164|130 137|addition
P11319098A0164|164 170|protein
P11319098A0164|175 189|LacI-GalR family
P11319880A1108|0 8|Rapamycin
P11319880A1108|9 26|FRAP/mTOR inhibitor
P11319880A1108|34 54|4E-BP1 phosphorylation
P11319880A1108|63 74|predominance
P11319880A1108|80 84|alpha
P11321187A0355|26 35|MS patients
P11321187A0355|59 67|synthesis
P11321187A0355|123 130|controls
P11323411A0505|0 21|Far Western blot analysis
P11323411A0505|44 53|SH2 domains
P11323411A0505|85 95|orientation
P11323411A0505|104 114|N-SH2 domain
P11323411A0505|122 136|phosphotyrosine
P11323411A0505|153 163|C-SH2 domain
P11323419T0000|9 15|cloning
P11323419T0000|23 29|mapping
P11323419T0000|33 42|expression
P11323419T0000|56 70|blood group alpha
P11323419T0000|73 95|fucosyltransferase genes
P11323419T0000|121 142|mouse uterine epithelium
P11323419T0000|162 166|tract
P11323716A0413|3 12|UBA domains
P11323716A0413|15 19|RAD23
P11323716A0413|48 59|interactions
P11324516A0159|25 38|administration
P11324516A0159|47 71|D2 receptor agonist LY171555
P11324516A0159|73 103|D1/D2 receptor agonist apomorphine
P11324516A0159|113 125|pain threshold
P11324516A0159|133 150|potentiating effect
P11325195A0661|35 40|muscle
P11325195A0661|65 79|pork longissimus
P11325391A0498|8 12|doses
P11325391A0498|15 27|d-amphetamine
P11325391A0498|58 66|saline key
P11325391A0498|76 84|schedules
P11325685A1624|11 30|L-carnitine treatment
P11325685A1624|40 68|plasma carnitine concentrations
P11325685A1624|93 99|fatigue
P11325685A1624|116 122|decline
P11325685A1624|129 144|exercise capacity
P11325685A1624|147 166|hemodialysis patients
P11325944A0511|8 17|expression
P11325944A0511|49 61|hybrid protein
P11325944A0511|61 66|GST-Bc
P11325944A0511|74 97|glutathione S-transferase
P11325944A0511|134 140|portion
P11325944A0511|165 172|blockage
P11325944A0511|174 187|uhpT expression
P11325944A0511|196 201|strain
P11327292A0190|10 17|location
P11327292A0190|29 40|malformation
P11327292A0190|86 91|vision
P11327698A0191|22 42|p44/p42MAPK signalings
P11327698A0191|82 89|IGF-II P4
P11327698A0191|105 112|activity
P11327698A0191|119 131|PKC activation
P11327698A0191|141 159|PKC expression vector
P11327698A0191|168 185|Sp1 phosphorylation
P11327698A0191|189 198|P4 activity
P11327698A0191|216 225|HepG2 cells
P11327698A0191|228 240|PKC inhibition
P11327698A0191|243 260|PKC inhibitor Go6976
P11327698A0191|268 285|Sp1 phosphorylation
P11327698A0191|286 295|P4 activity
P11327698A0191|299 308|IGF-II mRNA
P11327698A0191|326 335|HepG2 cells
P11327698A0191|345 354|inhibition
P11327698A0191|357 369|MEK activation
P11327698A0191|372 376|U0126
P11327698A0191|384 401|Sp1 phosphorylation
P11327698A0191|402 411|P4 activity
P11327698A0191|415 424|IGF-II mRNA
P11327698A0191|442 451|HepG2 cells
P11327858A0087|15 24|mechanisms
P11327858A0087|41 55|oncoprotein Hdm2
P11327858A0087|64 72|regulator
P11328699A0000|26 33|test mice
P11328699A0000|62 66|close
P11328699A0000|82 90|container
P11328699A0000|122 134|test situation
P11328853A0644|0 10|Examination
P11328853A0644|20 42|promoter deletion mutants
P11328853A0644|84 97|promoter region
P11328853A0644|108 124|promoter sequences
P11331589A0113|3 12|MSL complex
P11331589A0113|41 55|male X chromosome
P11331589A0113|69 78|expression
P11331596A0710|29 38|EVH1 domain
P11331596A0710|77 83|protein
P11331604A0267|0 4|Srb10
P11331604A0267|21 29|regulator
P11331604A0267|32 44|Gcn4 stability
P11331604A0267|56 70|phosphorylation
P11331604A0267|74 81|turnover
P11331604A0267|105 116|srb10 mutants
P11331613A0827|10 16|effects
P11331613A0827|19 30|pVHL function
P11331613A0827|49 57|mutations
P11331613A0827|68 75|subclass
P11333263A0240|4 9|intron
P11333263A0240|15 23|base pairs
P11333263A0240|37 42|middle
P11333263A0240|60 73|leader sequence
P11333263A0240|105 120|promoter activity
P11333268A1521|11 18|analysis
P11333268A1521|35 46|interactions
P11333268A1521|61 66|switch
P11333268A1521|70 75|switch
P11333268A1521|77 83|regions
P11333268A1521|113 124|consequences
P11333268A1521|127 137|interaction
P11333268A1521|142 147|switch
P11333268A1521|160 168|anchoring
P11333268A1521|193 203|interaction
P11333268A1521|206 211|switch
P11333268A1521|220 229|disruption
P11333268A1521|262 276|GDP dissociation
P11334124A0903|11 23|dose-response
P11334124A0903|48 55|increase
P11334124A0903|72 78|AUC0-6 h
P11334124A0903|99 107|dose range
P11334124A0903|121 128|Respimat
P11335116A1099|0 19|Bandshift experiments
P11335116A1099|35 40|BmHR3A
P11335116A1099|86 114|Orphan receptor Response Element
P11335116A1099|117 125|sequences
P11335116A1099|131 139|promoters
P11335116A1099|146 150|genes
P11335116A1099|181 186|BmHR3A
P11335116A1099|201 210|expression
P11335116A1099|213 222|BmGATAbeta
P11335116A1099|226 233|ESP genes
P11335116A1099|240 253|vitellogenesis
P11335710A0320|37 41|phase
P11335710A0320|44 56|Erk activation
P11336211A0132|12 17|method
P11336211A0132|28 36|Bengtsson
P11336698A0075|23 27|Rsc30
P11336698A0075|34 43|components
P11336698A0075|58 81|yeast remodeler RSC complex
P11337859A0651|11 23|color removals
P11337859A0651|47 51|FeCl3
P11337859A0651|63 73|coagulation
P11337859A0651|74 80|dosages
P11337859A0651|91 101|coagulation
P11337859A0651|119 123|mol/L
P11337859A0651|149 185|hydrogen peroxide oxidation pretreatment
P11337859A0651|189 198|H2O2 dosage
P11337859A0651|205 209|mol/L
P11340048A0432|21 31|correlation
P11340048A0432|42 54|flux densities
P11340048A0432|79 85|sensors
P11340048A0432|97 107|differences
P11340048A0432|113 125|flux densities
P11340048A0432|146 152|sensors
P11340080A0096|10 17|proteins
P11340080A0096|28 46|checkpoint signaling
P11340080A0096|93 111|immunoprecipitation
P11340080A0096|112 116|yeast
P11340080A0096|127 133|studies
P11340085A0211|10 19|hypothesis
P11340085A0211|47 53|regions
P11340085A0211|101 112|coactivators
P11340085A0211|126 142|amino acid sequence
P11340085A0211|145 154|C/EBPalpha
P11340085A0211|168 174|species
P11340085A0211|220 226|regions
P11340085A0211|226 232|CR1-CR4
P11340085A0211|242 262|transactivation domain
P11340516A0509|0 8|Tolerance
P11340516A0509|11 16|ADAL-2
P11340516A0509|35 46|Vicryl suture
P11340516A0509|50 58|tolerance
P11340516A0509|61 66|ADAL-2
P11340516A0509|86 94|Tisuacryl
P11340525A0737|5 12|patients
P11340525A0737|19 25|regimen
P11340525A0737|36 49|study end points
P11340525A0737|66 73|regimen A
P11340525A0737|89 96|regimen B
P11340525A0737|115 122|regimen C
P11340525A0737|128 152|treatment success criterion
P11341349T0000|5 14|indicators
P11341349T0000|20 25|effect
P11341349T0000|29 56|breast cancer screening program
P11341349T0000|70 74|women
P11341405A0146|6 15|POPULATION
P11341405A0146|26 41|racing Greyhounds
P11341405A0146|56 62|reasons
P11341405A0146|74 89|MCB abnormalities
P11341405A1154|0 10|CONCLUSIONS
P11341405A1154|22 30|RELEVANCE
P11341405A1154|48 56|thickness
P11341405A1154|69 78|properties
P11341405A1154|85 90|MCB-IV
P11341405A1154|99 108|Greyhounds
P11341405A1154|127 134|turnover
P11341405A1154|138 148|orientation
P11341405A1154|151 157|osteons
P11341405A1154|163 177|dorsal quadrants
P11341405A1154|213 221|responses
P11341405A1154|251 257|loading
P11341405A1154|261 266|result
P11341405A1154|269 274|racing
P11341405A1154|285 290|tracks
P11341828A0744|25 34|D-peptides
P11341828A0744|63 68|domain
P11341828A0744|80 88|molecules
P11342479A0430|0 6|METHODS
P11342479A0430|10 16|RESULTS
P11342479A0430|17 35|Palmaz-Schatz stents
P11342479A0430|54 63|paclitaxel
P11342479A0430|75 89|microgram/stent
P11342479A0430|92 100|immersion
P11342479A0430|112 121|paclitaxel
P11342479A0430|125 135|evaporation
P11344530A0320|0 10|Percentages
P11344530A0320|13 20|recovery
P11344530A0320|24 31|overload
P11344530A0320|35 47|dilution tests
P11345435A0199|17 29|RNA subdomains
P11345435A0199|90 101|localization
P11345445A0533|11 18|OECD soil
P11345445A0533|27 34|Cd levels
P11345445A0533|64 79|Cd concentrations
P11345445A0533|90 100|springtails
P11345445A0533|124 129|levels
P11345445A0533|161 174|concentrations
P11347201X0001|0 16|Nutritional status
P11347201X0001|19 24|adults
P11347201X0001|59 68|BACKGROUND
P11347201X0001|68 76|Plant food
P11347201X0001|82 91|vitamin B12
P11347201X0001|92 99|vitamin D
P11347201X0001|134 138|acids
P11348318A0940|14 20|adjunct
P11348318A0940|23 33|mammography
P11348318A0940|41 48|patients
P11348318A0940|74 80|breasts
P11348318A0940|87 102|characterization
P11348318A0940|113 118|masses
P11349796A0950|0 11|Measurements
P11349796A0950|46 53|exposure
P11349796A0950|81 91|measurement
P11350038A0459|13 20|evidence
P11350038A0459|72 84|stem structure
P11350038A0459|93 98|hY RNAs
P11350038A0459|128 140|export process
P11350165A1606|0 6|Changes
P11350165A1606|12 21|DB sequence
P11350165A1606|51 63|stem structure
P11350165A1606|76 81|losses
P11350165A1606|84 104|translation efficiency
P11350175A0173|22 28|members
P11350175A0173|35 47|protein family
P11350175A0173|65 73|isomerase
P11350175A0173|77 93|chaperone activity
P11350812A0829|0 9|Inhibition
P11350812A0829|15 34|Raf-1 target ERK kinase
P11350812A0829|67 74|Rp-cAMPS
P11350812A0829|88 100|ERK activation
P11350812A0829|101 124|caldesmon phosphorylation
P11350812A0829|128 147|stress fiber formation
P11350957A0457|0 8|PACAP mRNA
P11350957A0457|38 44|tissues
P11350957A0457|58 62|cells
P11350957A0457|63 67|PACAP
P11350957A0457|94 102|cytoplasm
P11350982A0560|21 28|evidence
P11350982A0560|35 45|involvement
P11350982A0560|48 67|GCN1-GCN2 interaction
P11350982A0560|70 79|activation
P11352423A0084|9 19|forearm flap
P11352423A0084|55 61|arm flap
P11352423A0084|78 83|choice
P11352423A0084|92 101|situations
P11352663A0138|2 11|comparison
P11352663A0138|28 35|Ad5 cells
P11352663A0138|36 40|class
P11352663A0138|42 51|expression
P11352663A0138|73 79|binding
P11352663A0138|82 88|COUP-TF
P11352663A0138|98 104|binding
P11352663A0138|107 115|NF-kappaB
P11352671A0492|4 14|application
P11352671A0492|24 31|genetics
P11352671A0492|47 62|nucleotide change
P11352671A0492|123 127|V gene
P11352671A0492|141 149|hPIV2 cDNA
P11352671A0492|179 185|viruses
P11352671A0492|186 191|rPIV2V
P11353392A1127|3 12|frameshift
P11353392A1127|24 28|ADEx2
P11353392A1127|56 69|coding sequence
P11353392A1127|95 106|ASIP mutation
P11353770A0085|20 27|activity
P11353770A0085|66 86|N-glycosylase activity
P11353770A0085|92 98|removal
P11353770A0085|101 120|8-oxoguanine residues
P11353770A0085|146 150|sites
P11353770A0085|157 162|places
P11353774A0255|15 23|isolation
P11353774A0255|27 42|characterization
P11353774A0255|48 64|forkhead homologue
P11353774A0255|67 82|rhabdomyosarcoma
P11353774A0255|107 112|member
P11353774A0255|117 126|hepatocyte
P11353774A0255|134 149|factor 3/forkhead
P11353774A0255|158 167|gene family
P11353774A0255|178 192|hormone receptor
P11353774A0255|209 215|protein
P11354406A1373|11 31|CSF outflow conductance
P11354406A1373|58 67|compliance
P11354406A1373|97 107|ICP waveform
P11354975A0850|4 10|species
P11354975A0850|13 23|Euspondylus
P11354975A0850|43 48|female
P11354975A0850|61 69|bromeliad
P11354975A0850|79 84|El Humo
P11354975A0850|85 89|Sucre
P11354975A0850|102 110|Venezuela
P11355576A1125|3 9|cyclins
P11355576A1125|47 61|phosphorylation
P11355576A1125|68 77|inhibition
P11355576A1125|83 104|tumor suppressor protein
P11355576A1125|133 153|pRb controls commitment
P11355576A1125|177 182|S phase
P11355576A1125|212 219|activity
P11355576A1125|224 246|E2F transcription factors
P11355576A1125|261 277|cell proliferation
P11355615A0766|10 18|education
P11355615A0766|22 29|research
P11355615A0766|54 62|direction
P11355615A0766|66 77|intervention
P11355615A0766|81 93|incorporation
P11355615A0766|98 105|practice
P11355668T0000|13 24|vasculopathy
P11355668T0000|37 47|hemorrhages
P11355668T0000|50 64|porcine neonates
P11355668T0000|80 86|porcine
P11355668T0000|113 125|syndrome virus
P11356214A0794|3 12|difference
P11356214A0794|15 22|hardness
P11356214A0794|44 52|specimens
P11356214A0794|68 92|Knoop hardness measurements
P11356214A0794|115 122|surfaces
P11356214A0794|125 138|resin specimens
P11356214A0794|146 155|Teflon mold
P11356214A0794|163 172|dimensions
P11356214A0794|178 183|cavity
P11356214A0794|194 199|dentin
P11356716A0372|14 18|clone
P11356716A0372|28 36|sequences
P11356716A0372|54 66|GHS-R variants
P11356835A0000|43 49|network
P11356835A0000|63 69|control
P11356835A0000|105 111|amounts
P11356835A0000|113 129|protein precursors
P11356835A0000|136 154|amino acid starvation
P11356853A0429|2 10|Ka13 cells
P11356853A0429|27 36|expression
P11356853A0429|39 60|luciferase reporter gene
P11356853A0429|69 75|control
P11356853A0429|90 110|pair mouse ho-1 promoter
P11356853A0429|111 118|pHO15luc
P11356853A0554|0 15|Mutation analyses
P11356853A0554|46 54|sequences
P11356853A0554|75 82|elements
P11356853A0554|83 87|StREs
P11356853A0873|0 6|Members
P11356853A0873|12 26|AP-1 superfamily
P11356853A0873|29 54|basic-leucine zipper factors
P11357063A0138|0 11|Descriptions
P11357063A0138|18 22|locus
P11357063A0138|33 42|comparison
P11357063A0138|83 90|features
P11357063A0138|98 104|species
P11357063A0138|149 161|LH/CGbeta gene
P11357063A0138|174 202|LHbeta-CGbeta gene cluster locus
P11357063A1053|7 15|consensus
P11357063A1053|25 34|LHbeta gene
P11357063A1053|46 51|region
P11357063A1053|57 71|gpLH/CGbeta gene
P11357063A1053|87 98|TATA sequence
P11357063A1053|118 138|translation start codon
P11358801A1046|15 24|situations
P11358801A1046|36 41|breaks
P11358801A1046|42 55|NHEJ deficiency
P11358801A1046|70 83|rearrangements
P11358801A1046|86 94|agreement
P11358801A1046|110 116|studies
P11358958A0878|0 9|Expression
P11358958A0878|17 21|RACK1
P11358958A0878|53 68|growth inhibition
P11358958A0878|93 102|tumor cells
P11358958A0878|117 125|apoptosis
P11358962A0344|0 4|Foxp1
P11358962A0344|8 12|Foxp2
P11358962A0344|31 36|levels
P11358962A0344|65 80|mouse development
P11358962A0344|83 97|Foxp2 expression
P11358962A0344|113 128|airway epithelium
P11359568T0000|9 16|analysis
P11359568T0000|22 43|pRA2 partitioning region
P11359568T0000|63 80|parAB transcription
P11359568T0000|89 108|nucleoprotein complex
P11359568T0000|116 135|plasmid partition site
P11359827T0000|27 42|characterization
P11359827T0000|67 75|exotoxins
P11359827T0000|83 87|SPE-I
P11359827T0000|90 94|SPE-J
P11359907A0099|7 23|dozen HIF-1 targets
P11359907A0099|77 88|growth factor
P11360190A0178|36 55|cell cycle progression
P11360190A0178|59 68|G0/G1 phase
P11360190A0178|77 86|G2/M phases
P11360190A0178|93 105|T-cell line Kit
P11360190A0178|109 113|cells
P11361338A0093|4 8|yeast
P11361338A0093|20 33|matrix proteins
P11361338A0093|70 84|targeting signal
P11361338A0093|105 117|tripeptide SKL
P11361338A0447|7 21|PEX5-TPR domains
P11361338A0447|31 37|tobacco
P11361338A0447|41 48|nematode
P11361338A0447|74 78|yeast
P11361338A0447|84 92|construct
P11361338A0447|103 116|Pex5p chimaeras
P11361493T0000|0 4|HIV-1
P11361493T0000|8 32|hepatitis B virus infections
P11361493T0000|35 45|adolescents
P11361493T0000|54 71|security institutes
P11361493T0000|74 84|Buenos Aires
P11367523A1684|0 24|Immunofixation experiments
P11367523A1684|54 62|allotypes
P11367523A1684|69 75|classes
P11367523A1684|78 85|proteins
P11367523A2624|7 17|C4B proteins
P11367523A2624|43 47|genes
P11367523A2624|71 84|concentrations
P11367523A2624|102 109|C4A genes
P11368363A0129|5 10|course
P11368363A0129|25 44|transcription factors
P11368363A0129|70 84|myeloperoxidase
P11368363A0129|90 97|promoter
P11368363A0129|173 196|HMG-Box containing protein
P11368363A0129|195 200|member
P11368363A0129|210 222|mobility group
P11368363A0129|247 254|proteins
P11368363A1103|8 22|protein sequence
P11368363A1103|51 56|domain
P11368363A1103|76 82|rat HBP1
P11368363A1103|91 98|homology
P11368363A1103|106 115|activation
P11368363A1103|119 134|repressor domains
P11368363A1103|162 171|rat protein
P11368787A0180|0 7|Promoter
P11368787A0180|23 30|activity
P11368787A0180|53 59|portion
P11368787A0180|70 82|annexin A5 gene
P11368787A0180|136 159|transcription start points
P11368901A0327|2 9|contrast
P11368901A0327|21 25|mouse
P11368901A0327|30 37|proteins
P11368901A0327|48 57|repeat unit
P11368901A0327|81 87|portion
P11368911T0000|9 22|identification
P11368911T0000|25 29|smg-4
P11368911T0000|41 56|mRNA surveillance
P11368911T0000|59 67|C. elegans
P11368914T0071|19 23|exons
P11368914T0071|33 53|complement C3 gene locus
P11368914T0071|101 107|control
P11368914T0071|122 129|promoter
P11369066A1210|0 10|CONCLUSIONS
P11369066A1210|36 49|corticosteroid
P11369066A1210|62 66|cream
P11369066A1210|121 125|cream
P11369066A1210|146 164|radiation dermatitis
P11369106A0428|6 13|advances
P11369106A0428|35 40|sulfur
P11369106A0428|44 49|result
P11369106A0428|62 73|interactions
P11369106A0428|77 99|transformation processes
P11369106A0428|117 124|food webs
P11369410A0949|8 17|hypothesis
P11369410A0949|35 39|sense
P11369410A0949|44 62|stimulus differences
P11369410A0949|74 82|behaviour
P11369410A0949|118 127|processing
P11369410A0949|136 147|participants
P11369453A1083|10 17|increase
P11369453A1083|20 33|protein binding
P11369453A1083|42 48|element
P11369453A1083|58 73|peptide treatment
P11369700A0074|30 42|chain isotypes
P11369700A0074|44 52|cytokines
P11369700A0074|56 70|B cell activators
P11369700A0074|81 93|transcription
P11369700A0074|115 122|germline
P11369700A0074|132 142|region genes
P11369700A0616|6 15|manuscript
P11369700A0616|42 49|Ets sites
P11369700A0616|55 74|mouse GL alpha promoter
P11369700A0616|82 106|transcription factors Elf-1
P11369700A0616|147 156|expression
P11369700A0616|157 178|luciferase reporter gene
P11369700A0616|190 204|GL alpha promoter
P11370174A0447|7 26|serum creatinine level
P11370174A0447|54 59|months
P11370174A0447|65 74|withdrawal
P11371115A0962|3 12|proportion
P11371115A0962|18 25|biopsies
P11371115A0962|50 59|HBs antigen
P11371115A0962|96 106|MPGN pattern
P11371160A0193|16 26|nucleotides
P11371160A0193|39 53|base-pair C1-G72
P11371160A0193|57 76|discriminator base A73
P11371160A0193|82 86|amino
P11371160A0193|100 105|branch
P11371160A0193|111 118|molecule
P11371160A0854|4 9|domain
P11371160A0854|29 41|anticodon loop
P11371160A0854|47 54|tyrosine
P11371160A0854|74 79|anchor
P11371160A0854|82 97|TyrRS interaction
P11371160A0854|114 123|efficiency
P11371160A0854|126 137|tyrosylation
P11371343A0125|15 23|cell cycle
P11371343A0125|24 31|separase
P11371343A0125|69 75|protein
P11371343A0125|82 88|securin
P11371417A0744|10 20|ventilation
P11371417A0744|23 34|control lungs
P11371417A0744|45 53|% decrease
P11371417A0744|56 70|chord compliance
P11371417A0744|73 80|increase
P11371417A0744|83 98|lung lavage levels
P11371417A0744|101 119|tumor necrosis factor
P11371417A0744|124 128|alpha
P11371417A0744|135 139|pg/ml
P11371417A0744|140 150|interleukin
P11371417A0744|168 172|pg/ml
P11371417A0744|174 183|macrophage
P11371417A0744|196 204|protein-2
P11371417A0744|205 209|MIP-2
P11371417A0744|217 221|pg/ml
P11371417A0744|239 244|levels
P11371417A0744|247 255|cytokines
P11371417A0744|266 283|preventilation data
P11371417A0744|289 294|change
P11371417A0744|297 306|percentage
P11371417A0744|324 333|aggregates
P11372882A1143|20 33|beta-HCH levels
P11372882A1143|60 65|levels
P11372882A1143|69 74|levels
P11372959A1447|8 25|regression analysis
P11372959A1447|63 69|factors
P11372959A1447|80 88|abundance
P11372959A1447|99 103|sites
P11372959A1447|114 125|relationship
P11372959A1447|126 139|R2 coefficients
P11372959A1447|148 162|habitat category
P11372959A1447|184 192|variation
P11372959A1447|194 206|tick abundance
P11373277A0812|2 8|summary
P11373277A0812|36 49|oncoprotein E1A
P11373277A0812|59 71|transcription
P11373277A0812|89 101|AP-2alpha gene
P11373277A0812|104 109|effect
P11373277A0812|137 148|derepression
P11373277A0812|154 170|AP-2alpha promoter
P11373277A0812|173 183|interaction
P11373277A0812|205 220|corepressor CtBP1
P11374051A0437|10 16|factors
P11374051A0437|54 68|corticosteroids
P11374051A0437|69 82|anticoagulants
P11374051A0437|88 105|ulcer complications
P11374051A0437|118 125|diseases
P11374051A0437|155 162|bleeding
P11374559A0103|0 10|SERS spectra
P11374559A0103|25 41|vacuum evaporation
P11374559A0103|45 51|casting
P11374559A0103|54 58|p-NTP
P11374559A0103|69 79|island films
P11374559A0103|91 114|colloidal silver solutions
P11374866X0914|0 8|Copyright
P11374866X0914|13 25|Academic Press
P11375392T0000|3 14|core promoter
P11375392T0000|22 41|thioredoxin reductase
P11375392T0000|43 49|cloning
P11375392T0000|65 72|activity
P11375392T0000|76 80|Oct-1
P11375392T0000|89 98|Sp3 binding
P11375392T0000|122 129|promoter
P11376007A0584|48 68|protein kinase activity
P11376007A0584|70 75|DNA-PK
P11376007A0584|91 98|addition
P11376007A0584|121 127|subunit
P11376007A0584|136 153|protein phosphatase
P11376007A0584|157 176|protein phosphatase 2A
P11376007A0584|194 205|reactivation
P11376007A0584|225 251|protein phosphatase inhibitor
P11376007A0584|252 262|microcystin
P11376119A0346|14 19|exon 1A
P11376119A0346|52 57|region
P11376119A0346|63 71|GHR 1A mRNA
P11376119A0346|109 115|GHR gene
P11376134A1506|5 15|corrections
P11376134A1506|28 36|sequences
P11376134A1506|58 76|transcription factor
P11376134A1506|84 88|sites
P11376165T0000|8 29|Cre recombinase function
P11376165T0000|31 44|Xenopus embryos
P11376279A0000|1 6|method
P11376279A0000|47 55|resonance
P11376279A0000|60 70|angiography
P11376279A0000|80 90|extremities
P11376279A0000|104 120|volume acquisition
P11376687A0344|7 28|nucleotide polymorphism
P11376687A0344|76 86|GTG83/ATG83
P11376687A0344|135 143|MTH1 mRNAs
P11376687A0344|160 174|MTH1 polypeptide
P11376687A0344|218 232|targeting signal
P11376946A0000|11 17|studies
P11376946A0000|31 35|SHP-1
P11376946A0000|75 85|phosphatase
P11376946A0000|105 109|cells
P11376946A0000|125 132|lineages
P11376946A0000|163 167|cells
P11376946A0000|176 182|control
P11376946A0000|213 220|promoter
P11377975A0898|27 35|COS1 cells
P11377975A0898|55 72|proteinase activity
P11377975A0898|93 102|substrates
P11377975A0898|123 132|conditions
P11377975A0898|139 143|study
P11378898A0164|14 25|EMBL databank
P11378898A0164|24 35|Accession No.
P11379106A0372|5 12|meantime
P11379106A0372|42 66|deammonification processes
P11379106A0372|96 105|pilot plant
P11380028A0000|3 9|purpose
P11380028A0000|16 20|study
P11380028A0000|44 50|methods
P11380028A0000|54 63|estimation
P11380028A0000|66 77|Technetium Tc
P11380028A0000|81 85|99mTc
P11380028A0000|85 93|pentetate
P11380028A0000|97 114|orthoiodohippurate
P11380028A0000|119 126|131I-OIH
P11380028A0000|127 141|plasma clearance
P11380028A0000|168 179|blood samples
P11380370A0000|1 7|patient
P11380370A0000|23 33|skin lesions
P11380370A0000|44 49|Kaposi
P11380370A0000|51 57|sarcoma
P11380837A1505|0 12|Interventions
P11380837A1505|33 41|mediators
P11380837A1505|45 53|processes
P11380837A1505|113 117|costs
P11380837A1505|128 144|access dysfunction
P11381094A0797|2 9|addition
P11381094A0797|10 15|stonin
P11381094A0797|27 36|C2B domains
P11381094A0797|39 52|synaptotagmins
P11382701A0688|11 21|transection
P11382701A0688|33 43|vasopressin
P11382701A0688|58 65|response
P11382701A0688|83 107|plasma sodium concentration
P11382948A0793|2 11|conclusion
P11382948A0793|26 32|MRI data
P11382948A0793|58 83|tumor microvessel properties
P11382948A0793|90 106|breast cancer model
P11382948A0793|120 131|permeability
P11382948A0793|147 151|USPIO
P11382948A0793|179 188|tumor grade
P11383860A0661|3 8|images
P11383860A0661|40 48|excretion
P11383860A0661|51 68|99mTc ciprofloxacin
P11383860A0661|84 88|brain
P11383860A0661|98 113|bone marrow uptake
P11383860A0661|119 129|liver uptake
P11383860A0661|133 141|excretion
P11384225A0634|13 30|expression cassette
P11384225A0634|71 77|protein
P11384225A0634|138 146|sequences
P11384229A1669|10 21|N63S mutation
P11384229A1669|36 48|VP5 background
P11384229A1669|61 71|interaction
P11384229A1669|85 110|beta-galactosidase activity
P11384229A1669|114 119|factor
P11384229A1669|140 150|PR7 mutation
P11384576A1132|2 9|addition
P11384576A1132|16 25|vision loss
P11384576A1132|39 48|interferon
P11384576A1132|67 77|retinopathy
P11384880A0719|3 11|mechanism
P11384880A0719|17 25|induction
P11384880A0719|28 40|3beta-HSD type
P11384880A0719|42 55|gene expression
P11384880A0719|81 87|ZR-75-1
P11384880A0719|93 109|breast cancer cells
P11385840A1684|12 23|RTC algorithm
P11385840A1684|35 50|wastewater system
P11385840A1684|66 75|parameters
P11385840A1684|113 132|optimization routines
P11387208T0000|0 33|SKP1-SnRK protein kinase interactions
P11387208T0000|52 58|binding
P11387208T0000|62 84|plant SCF ubiquitin ligase
P11387351A0092|0 7|PATIENTS
P11387351A0092|11 17|METHODS
P11387351A0092|38 45|December
P11387351A0092|76 103|analog 2-chlorodeoxyadenosine
P11387351A0092|104 108|2-CDA
P11387351A0092|113 120|children
P11387351A0092|142 149|children
P11387351A0092|184 191|syndrome
P11387940A0647|3 10|severity
P11387940A0647|23 29|changes
P11387940A0647|46 54|magnitude
P11387940A0647|57 66|percussion
P11387950X0001|12 16|study
P11387950X0001|19 28|ta chengchi
P11387950X0001|33 41|decoction
P11387950X0001|54 63|lung injury
P11387950X0001|86 97|pancreatitis
P11387950X0001|101 110|objectives
P11387950X0001|116 120|study
P11387950X0001|141 147|changes
P11387950X0001|150 170|leukocyte adhesiveness
P11387950X0001|174 192|tumor necrosis factor
P11387950X0001|208 212|stage
P11387950X0001|230 241|pancreatitis
P11387950X0001|265 272|relation
P11387950X0001|279 285|changes
P11387950X0001|288 297|lung injury
P11387950X0001|332 337|effect
P11387950X0001|339 348|ta chengchi
P11387950X0001|353 361|Decoction
P11387950X0001|364 380|leukocyte adhesion
P11387950X0001|384 395|TNF secretion
P11389077A0000|1 7|variety
P11389077A0000|27 43|signaling pathways
P11389077A0000|95 104|regulators
P11389085A0290|0 6|TT cells
P11389085A0290|13 23|MTC cell line
P11389085A0290|34 45|MEN 2A type RET
P11389085A0290|91 97|nucleus
P11389085A1032|0 9|Inhibition
P11389085A1032|24 40|NF-kappaB activity
P11389085A1032|50 58|cell death
P11389085A1032|61 67|TT cells
P11389085A1032|77 90|focus formation
P11389085A1032|109 113|forms
P11389085A1032|123 133|NIH 3T3 cells
P11390395A1018|12 27|HMGI-C expression
P11390395A1018|66 75|repression
P11390395A1018|93 107|transactivation
P11390581A1203|8 14|finding
P11390581A1203|20 33|identification
P11390581A1203|44 51|sequence
P11390581A1203|62 69|Cp region
P11390581A1203|140 147|activity
P11390581A1203|153 160|promoter
P11390650A0562|10 26|deletion mutations
P11390650A0562|62 67|domain
P11390650A0562|89 94|region
P11390650A0562|97 102|SLP-76
P11390650A0562|123 131|P-1 domain
P11390663A1400|7 15|profiling
P11390663A1400|19 27|gcn4Delta
P11390663A1400|56 80|induction pathway operating
P11390663A1400|87 102|Gcn4p target genes
P11390663A1400|122 126|cells
P11390684A1170|0 7|Evidence
P11390684A1170|13 33|Northern hybridization
P11390684A1170|47 60|jadM expression
P11390684A1170|77 95|jadomycin B synthesis
P11391303A0807|10 14|R-LHR
P11391303A0807|29 41|interobserver
P11391303A0807|45 72|intraobserver reproducibility
P11391303A1023|0 10|CONCLUSIONS
P11391303A1023|14 24|methodology
P11391303A1023|27 40|LHR measurement
P11391303A1023|75 86|contribution
P11391303A1023|89 114|Tl-201 lung uptake evaluation
P11391531A1157|0 7|Mutation
P11391531A1157|13 25|NF-kappaB site
P11391531A1157|31 43|Mdr1b promoter
P11391531A1157|55 63|induction
P11391531A1157|66 74|TNF-alpha
P11391793A0856|21 30|complexity
P11391793A0856|43 48|region
P11391793A0856|60 65|tumors
P11391793A0856|130 142|bacteriophage
P11391793A0856|161 170|chromosome
P11391793A0856|176 181|clones
P11392306T0000|6 13|teaching
P11392306T0000|14 19|design
P11392306T0000|23 32|techniques
P11392772A0182|3 13|application
P11392772A0182|19 31|biotechnology
P11392772A0182|37 42|plants
P11392772A0182|46 54|treatment
P11392772A0182|60 77|surface storm waters
P11392772A0182|95 106|zone Telychka
P11392772A0182|139 145|content
P11392772A0182|146 154|petroleum
P11392772A0182|157 161|water
P11392772A0182|174 180|Dnieper
P11392772A0182|208 212|times
P11393463A0274|36 49|student samples
P11393463A0274|61 65|group
P11393463A0274|84 103|NEO-PI-R self-ratings
P11393463A0274|106 114|occasions
P11393463A0274|136 143|interval
P11393463A0274|149 162|informant group
P11393463A0274|181 187|ratings
P11393463A0274|199 205|friends
P11393463A0274|208 216|relatives
P11393463A0274|220 228|occasions
P11393463A0274|242 254|month interval
P11393791A1153|0 19|Northern blot analysis
P11393791A1153|33 38|number
P11393791A1153|40 51|mouse tissues
P11393791A1153|63 67|Atp6i
P11393791A1153|94 104|osteoclasts
P11393791A1153|123 132|expression
P11393791A1153|168 190|polymerase chain reaction
P11393791A1153|191 196|RT-PCR
P11393791A1153|197 201|assay
P11393791A1153|224 231|analysis
P11395469A1373|6 13|mutation
P11395469A1373|26 31|motifs
P11395469A1373|52 61|regulation
P11395469A1373|92 101|regulation
P11396685A0477|12 18|results
P11396685A0477|79 84|amount
P11396685A0477|86 91|sample
P11396685A0477|133 143|information
P11396685A0477|155 160|groups
P11396685A0477|163 171|compounds
P11396685A0477|181 187|cheeses
P11397652A0381|0 9|Guidelines
P11397652A0381|31 41|spiral assay
P11397652A0381|68 78|test methods
P11397652A0381|98 104|variety
P11397652A0381|116 127|difficulties
P11397652A0381|144 161|sample availability
P11397652A0381|162 176|sample viscosity
P11397652A0381|179 188|volatility
P11398134A1565|2 11|conclusion
P11398134A1565|12 18|obesity
P11398134A1565|19 31|alcohol intake
P11398134A1565|49 57|disorders
P11398134A1565|87 96|predictors
P11398134A1565|103 113|development
P11398134A1565|116 128|hyperuricemia
P11398899A1183|8 14|tunnels
P11398899A1183|21 27|windows
P11398899A1183|41 49|locations
P11398899A1183|76 85|likelihood
P11398899A1183|92 108|PH3 concentrations
P11398899A1183|119 123|areas
P11399064T0000|0 13|Autoregulation
P11399064T0000|30 37|pathways
P11399064T0000|47 78|CCAAT/enhancer binding protein beta
P11399064T0000|79 87|C/EBP beta
P11399064T0000|88 100|transcription
P11399834T0000|16 32|HCV seroconversion
P11399834T0000|34 41|Portugal
P11399834T0000|50 61|introduction
P11399834T0000|64 78|HCV NAT screening
P11400644A0435|3 12|reflection
P11400644A0435|15 27|uncertainties
P11400644A0435|33 41|estimates
P11400644A0435|55 61|sources
P11400644A0435|69 79|percentiles
P11400644A0435|82 95|PCDD/F releases
P11400644A0435|116 123|g I-TEQ/y
P11401105T0000|0 9|Gabapentin
P11401105T0000|26 34|myoclonus
P11401105T0000|37 50|cancer patients
P11401611A1703|0 10|CONCLUSIONS
P11401611A1703|14 26|meta-analysis
P11401611A1703|49 54|trials
P11401611A1703|92 100|reduction
P11401611A1703|114 122|fractures
P11402674T0000|0 28|Newcastle disease antibody titre
P11402674T0000|42 66|serum calcium concentration
P11403173A0192|1 5|total
P11403173A0192|10 17|patients
P11403173A0192|31 42|brain tumours
P11403663A0359|34 41|bearings
P11403663A0359|53 60|impeller
P11403663A0359|76 86|predictions
P11403663A0359|94 102|2-D theory
P11403719A1257|3 9|results
P11403719A1257|43 49|control
P11403719A1257|51 65|egr-1 expression
P11403719A1257|77 83|insulin
P11404010A0235|11 19|triplexes
P11404010A0235|31 36|length
P11404010A0235|42 47|repeat
P11404016A1922|3 14|co-existence
P11404016A1922|17 25|TE domains
P11404016A1922|92 96|TE IIs
P11404016A1922|114 119|number
P11404016A1922|129 138|polyketide
P11404016A1922|155 170|peptide synthases
P11404019A0532|8 20|understanding
P11404019A0532|26 41|mGSTM2 regulation
P11404019A0532|72 85|promoter region
P11404312A0660|8 15|pmol/24 h
P11406007A0292|0 16|SELECTION CRITERIA
P11406007A0292|40 45|trials
P11406007A0292|70 74|forms
P11406007A0292|86 99|contraceptives
P11406007A0292|128 135|outcomes
P11406007A0292|138 142|women
P11406007A0292|157 161|years
P11406025A0204|0 9|OBJECTIVES
P11406025A0204|13 21|objective
P11406025A0204|28 33|review
P11406025A0204|49 61|effectiveness
P11406025A0204|62 67|safety
P11406025A0204|71 83|acceptability
P11406025A0204|89 97|diaphragm
P11406025A0204|112 121|spermicide
P11406277A0598|9 18|hypothesis
P11406277A0598|28 35|elements
P11406277A0598|50 65|promoter activity
P11406277A0598|79 104|reporter expression activity
P11406277A0598|107 114|segments
P11406277A0598|125 133|mutations
P11406277A0598|141 148|elements
P11406277A0598|153 160|activity
P11406277A0598|166 190|parent Hlx promoter sequence
P11406642A0792|12 16|cases
P11406642A0792|17 26|expression
P11406642A0792|42 46|genes
P11407289A1507|0 10|CONCLUSIONS
P11407289A1507|39 48|anesthesia
P11407289A1507|77 84|BIS index
P11407289A1507|161 166|agents
P11407448A0815|3 9|results
P11407448A0815|49 56|patients
P11407448A0815|71 95|jejunum flap reconstruction
P11407448A0815|124 144|tract voice restoration
P11407448A0815|172 186|voice prosthesis
P11407448A0815|222 229|puncture
P11407448A0815|251 264|speech training
P11407650A0661|0 12|Hypercalcemia
P11407650A0661|35 55|serum PTH concentration
P11407650A0661|73 91|hyperparathyroidism
P11407650A0661|103 112|BC patients
P11407650A0661|136 140|women
P11407650A0661|141 148|patients
P11407650A0661|153 165|thyroid cancer
P11408099A0518|22 33|correlations
P11408099A0518|53 57|weeks
P11408099A0518|60 68|pregnancy
P11408099A0518|72 79|Se levels
P11408099A0518|82 87|kidney
P11408099A0518|105 109|heart
P11408338A1686|4 8|study
P11408338A1686|94 101|majority
P11408338A1686|103 107|cases
P11408338A1686|133 144|neurologists
P11408575A0000|25 29|entry
P11408575A0000|34 40|mitosis
P11408575A0000|49 58|activation
P11408575A0000|80 90|kinase Cdc28
P11408575A0000|96 102|cyclin B
P11408591A0000|17 26|production
P11408591A0000|29 38|hyaluronan
P11408591A0000|49 54|effect
P11408591A0000|56 67|cell motility
P11408591A0000|70 74|cells
P11408591A0000|88 99|v-src mutants
P11408604A1440|3 9|results
P11408604A1440|34 42|receptors
P11408604A1440|51 66|ERK kinase cascade
P11408604A1440|84 92|signaling
P11408604A1440|98 109|PDGF receptor
P11408604A1440|133 142|activation
P11408604A1440|145 150|ERK1/2
P11408604A1440|153 160|pathways
P11408604A1440|179 200|receptor tyrosine kinase
P11408774X0893|0 7|Karger AG
P11408774X0893|8 12|Basel
P11409425A0000|12 24|plasma samples
P11409425A0000|32 39|patients
P11409425A0000|45 61|National Institute
P11409425A0000|76 83|Diseases
P11409425A0000|87 92|Stroke
P11409425A0000|93 97|NINDS
P11409425A0000|98 123|tissue plasminogen activator
P11409425A0000|130 140|Stroke Trial
P11409425A0000|152 163|relationship
P11409425A0000|173 186|apolipoprotein
P11409425A0000|200 213|Apo E4 phenotype
P11409425A0000|225 231|outcome
P11409425A0000|233 238|months
P11409425A0000|244 249|stroke
P11409425A0000|274 283|hemorrhage
P11409425A0000|289 296|response
P11409425A0000|310 320|t-PA therapy
P11410110A0190|31 41|measurement
P11410110A0190|43 49|muscle O
P11410110A0190|50 60|consumption
P11410110A0190|84 99|forearm blood flow
P11410110A0190|115 122|subjects
P11410563A0363|18 23|factor
P11410563A0363|51 68|regression analysis
P11410563A0363|83 97|body surface area
P11410563A0363|97 105|valve size
P11410563A0363|106 126|shop order fracture rate
P11410563A0363|130 148|manufacturing period
P11410563A0363|151 161|risk factors
P11410664A0963|6 11|report
P11410664A0963|16 24|technique
P11410664A0963|42 70|breast carcinoma MDA-MB231 cells
P11410664A0963|97 101|order
P11410664A0963|116 128|up-regulation
P11410664A0963|163 170|activity
P11410664A0963|189 193|hOGG1
P11410664A0963|196 202|APE/ref
P11410664A0963|212 219|reversal
P11410664A0963|226 241|repair activities
P11410679A0000|12 21|alteration
P11410679A0000|27 32|genome
P11410679A0000|38 51|Cre recombinase
P11410679A0000|63 75|rearrangement
P11410679A0000|78 82|genes
P11410679A0000|92 114|LOX recognition sequences
P11410679A0000|154 163|constructs
P11410679A0000|220 227|interest
P11410679A0000|235 242|LOX sites
P11411198A0711|10 15|cancer
P11411198A0711|54 66|Ashkenazi Jews
P11411198A0711|119 131|stomach cancer
P11411198A0711|146 153|lymphoma
P11411623T0000|0 8|Influence
P11411623T0000|11 28|compression therapy
P11411623T0000|31 38|symptoms
P11411623T0000|52 63|tissue injury
P11411623T0000|84 91|exercise
P11411961A0735|0 24|Keratoconjunctivitis sicca
P11411961A0735|49 60|complication
P11411961A0735|67 74|children
P11411961A0735|123 129|battery
P11411961A0735|131 135|tests
P11413148A0573|0 14|STAT5A mutations
P11413148A0573|20 30|Src homology
P11413148A0573|40 49|SH3 domains
P11413148A0573|75 97|tyrosine phosphorylation
P11413277A1121|2 11|conclusion
P11413277A1121|19 30|chemotherapy
P11413277A1121|42 48|dose MTX
P11413277A1121|52 56|ara-C
P11413277A1121|76 80|PCNSL
P11413310A0148|0 5|RANTES
P11413310A0148|19 28|activation
P11413310A0148|37 42|T-cell
P11413310A0148|76 86|CC chemokine
P11413310A0148|112 120|monocytes
P11413310A0148|121 131|lymphocytes
P11413310A0148|135 145|eosinophils
P11413310A0148|149 157|cell types
P11413310A0148|188 197|infiltrate
P11413310A0148|206 217|RSV infection
P11413319A0000|0 12|Reovirus mRNAs
P11413319A0000|43 51|host cells
P11413319A0000|62 68|absence
P11413319A0000|86 90|tails
P11413641A0373|0 7|Analyses
P11413641A0373|20 31|scale matters
P11413641A0373|49 54|effect
P11413641A0373|57 67|quadrat area
P11413760A0000|0 9|Myasthenia
P11413760A0000|30 36|disease
P11413760A0000|53 62|production
P11413760A0000|65 74|antibodies
P11413760A0000|85 96|ACh receptors
P11413760A0000|115 121|synapse
P11414754X1099|0 8|Copyright
P11414754X1099|13 25|Academic Press
P11415633A1253|19 27|force data
P11415633A1253|30 34|input
P11415633A1253|54 58|model
P11415633A1253|79 89|compression
P11415952A0369|0 5|Angina
P11415952A0369|9 19|persistence
P11415952A0369|31 42|associations
P11415952A0369|65 74|infarction
P11415952A0369|84 89|angina
P11415952A0369|90 114|electrocardiogram ischemia
P11415952A0369|141 158|heart disease events
P11415958A0000|9 14|decade
P11415958A0000|36 43|advances
P11415958A0000|64 74|methodology
P11415958A0000|77 84|analysis
P11415958A0000|133 142|advantages
P11415958A0000|155 162|approach
P11416012A1982|33 41|mediation
P11416012A1982|49 60|contribution
P11416012A1982|78 82|drive
P11416012A1982|86 96|LDL receptor
P11416012A1982|111 125|reporter plasmid
P11416012A1982|159 192|rabbit muscle protein kinase inhibitor
P11416012A1982|198 205|minigene
P11416012A1982|232 251|sarcoma virus promoter
P11416012A2511|37 64|insulin/IGF-I effector pathway
P11416012A2511|83 93|stimulation
P11416012A2511|96 124|LDL receptor promoter expression
P11416012A2511|152 156|cells
P11416012A2511|196 205|inhibitors
P11416012A2511|207 233|phophatidylinositol 3-kinase
P11416012A2511|234 243|wortmannin
P11416012A2511|266 271|microM
P11416012A2511|291 309|protein kinase kinase
P11416012A2511|321 326|microM
P11416012A2511|326 330|U0126
P11416012A2511|333 338|microM
P11416012A2511|344 349|latter
P11416012A2511|359 368|derivative
P11416012A2511|369 373|U0124
P11416012A2511|376 381|microM
P11416012T0000|24 33|activation
P11416012T0000|42 71|density lipoprotein receptor gene
P11416012T0000|74 80|insulin
P11416012T0000|95 101|hormone
P11416012T0000|112 118|porcine
P11416012T0000|135 139|cells
P11416012T0000|148 158|convergence
P11416012T0000|161 173|protein kinase
P11416012T0000|175 202|phosphatidylinositol 3-kinase
P11416012T0000|223 252|protein kinase signaling pathways
P11416132A1351|5 11|studies
P11416132A1351|40 50|recognition
P11416132A1351|56 61|bxd PRE
P11416132A1351|72 94|repeat binding activities
P11416132A1351|113 121|silencing
P11416144A1324|3 10|findings
P11416144A1324|21 33|understanding
P11416144A1324|39 44|ZBP-89
P11416144A1324|54 70|cell proliferation
P11416144A1324|87 95|mechanism
P11416144A1324|106 115|p53 protein
P11416260A0000|13 18|method
P11416260A0000|40 44|point
P11416260A0000|57 64|activity
P11416260A0000|92 99|patients
P11416260A0000|149 160|data analysis
P11416393A0000|4 13|modalities
P11416393A0000|32 41|approaches
P11416393A0000|68 88|lifestyle modification
P11416393A0000|92 98|control
P11416393A0000|109 130|blood pressure elevation
P11416393A0000|132 146|weight reduction
P11416393A0000|154 163|body weight
P11416393A0000|186 197|hypertension
P11416393A0000|226 234|morbidity
P11416393A0000|238 246|mortality
P11416393A0000|255 271|sodium restriction
P11416393A0000|299 307|assurance
P11416393A0000|333 340|pressure
P11416393A0000|364 369|dosage
P11416393A0000|373 379|numbers
P11416393A0000|408 412|drugs
P11416393A0000|414 423|moderation
P11416393A0000|426 443|alcohol consumption
P11416393A0000|455 459|ounce
P11416393A0000|483 497|exercise program
P11416393A0000|501 509|cessation
P11416393A0000|512 529|tobacco consumption
P11416650T0000|16 27|Hypertension
P11416650T0000|30 35|Update
P11416737T0000|0 4|Ga-67
P11416737T0000|8 25|Tl-201 scintigraphy
P11416737T0000|42 53|plasmacytoma
P11416737T0000|55 64|case report
P11416879A1589|8 23|blood gas tensions
P11416879A1589|44 59|ventilation modes
P11418130A0499|20 32|loxP sequences
P11418130A0499|65 77|recombination
P11418662A0917|13 19|portion
P11418662A0917|22 26|Notch
P11418662A0917|39 51|p50 DNA binding
P11418662A0917|80 89|p50 subunit
P11418662A0917|100 108|NF-kappaB
P11419938T0000|14 20|changes
P11419938T0000|32 54|uptake regulation protein
P11419938T0000|59 73|metal activation
P11419938T0000|77 86|DNA binding
P11419938T0000|92 99|evidence
P11419938T0000|112 121|homologies
P11419938T0000|129 152|diphtheria toxin repressor
P11420612A0303|3 12|complement
P11420612A0303|26 32|mapping
P11420612A0303|36 52|sequencing efforts
P11420612A0303|98 109|sequence data
P11420612A0303|120 126|regions
P11420612A0303|129 136|interest
P11422200A0000|0 10|Granulocyte
P11422200A0000|29 34|factor
P11422200A0000|35 39|G-CSF
P11422200A0000|40 53|administration
P11422200A0000|84 100|defence mechanisms
P11422200A0000|108 116|infection
P11422200A0000|128 135|microbes
P11422757A0737|5 15|individuals
P11422757A0737|23 29|changes
P11422757A0737|56 64|ACR levels
P11422757A0737|67 74|baseline
P11423991A1393|7 12|screen
P11423991A1393|21 30|p53 mutants
P11423991A1393|33 37|yeast
P11423991A1393|54 64|p53 variants
P11423991A1393|114 122|responses
P11423991A1393|146 160|cancer therapies
P11424992A0712|28 36|diagnoses
P11424992A0712|95 102|criteria
P11425076A0364|41 45|flows
P11425076A0364|49 54|result
P11425076A0364|61 65|alpha
P11425076A0364|88 93|values
P11425076A0364|99 112|Reynolds number
P11425076A0364|134 140|inertia
P11425076A0364|157 181|perturbation theory results
P11425076A0364|184 193|comparison
P11425076A0364|208 218|integration
P11425076A0364|228 232|model
P11425877A1026|0 4|Cells
P11425877A1026|34 39|defect
P11425877A1026|44 52|formation
P11425877A1026|74 83|structures
P11425877A1026|96 104|reduction
P11425877A1026|118 138|fluid phase pinocytosis
P11425877A1026|150 157|decrease
P11425877A1026|163 172|efficiency
P11425877A1026|186 196|aggregation
P11425877A1026|201 208|decrease
P11425877A1026|219 232|F-actin content
P11427329A1077|3 10|validity
P11427329A1077|16 20|FPS-R
P11427329A1077|56 67|correlations
P11427329A1077|125 130|sample
P11427611A0000|3 16|susceptibility
P11427611A0000|30 38|fumigatus
P11427611A0000|41 53|mulundocandin
P11427611A0000|73 80|compound
P11427611A0000|99 104|agents
P11427611A0000|121 137|National Committee
P11427611A0000|149 167|Laboratory Standards
P11427611A0000|168 172|NCCLS
P11427611A0000|173 183|M38-P method
P11427611A0000|222 233|phenyl-amino
P11427611A0000|233 240|carbonyl
P11427611A0000|241 262|H-tetrazolium hydroxide
P11427611A0000|284 288|assay
P11427611A0000|291 303|determination
P11427611A0000|317 327|alterations
P11427611A0000|330 339|microscopy
P11428276A0352|11 15|Hoeve
P11428276A0352|16 30|syndrome lesions
P11428276A0352|57 67|calcium salt
P11428276A0352|79 86|increase
P11428276A0352|89 98|phosphates
P11428283A0228|12 17|infant
P11428283A0228|42 48|stridor
P11428283A0228|68 75|distress
P11428435A0446|0 5|DESIGN
P11428435A0446|20 30|chart review
P11428435A0446|38 45|patients
P11428435A0446|64 73|procedures
P11428435A0446|79 91|period January
P11428435A0446|98 105|December
P11428487T0000|9 17|vein varix
P11428487T0000|20 30|association
P11428487T0000|53 64|vein stenosis
P11428897A0318|11 21|experiments
P11428897A0318|70 78|target DNA
P11428897A0318|83 89|protein
P11428897A0318|89 97|DNA ratios
P11428897A0318|129 133|turns
P11428897A0318|160 164|helix
P11428897A0318|170 179|directions
P11428897A0318|195 200|repeat
P11428897A0318|232 237|target
P11429702A0917|36 45|conditions
P11429702A0917|46 51|KMS-11
P11429702A0917|55 64|OPM-2 cells
P11429702A0917|83 88|levels
P11429702A0917|105 116|FGFR3 mutants
P11429702A0917|140 149|activation
P11429702A0917|155 159|Y373C
P11429702A0917|163 176|K650E receptors
P11429702A0917|180 187|addition
P11429702A0917|193 202|aFGF ligand
P11429702A0917|222 226|level
P11429702A0917|229 251|receptor phosphorylation
P11430042A0000|0 5|figure
P11430042A0000|18 39|Stille coupling reaction
P11430042A0000|84 100|tetrafluoroborate
P11430042A0000|101 107|BMIM BF4
P11430042A0000|130 135|liquid
P11430976X0000|7 12|issues
P11430976X0000|25 36|biosynthesis
P11430976X0000|39 59|woody plant biopolymers
P11430976X0000|70 79|substances
P11431348A0000|0 11|Interactions
P11431348A0000|22 46|checkpoint abrogator UCN-01
P11431348A0000|72 81|inhibitors
P11431348A0000|104 116|protein kinase
P11431348A0000|123 128|kinase
P11431348A0000|132 142|MAPK pathway
P11431348A0000|161 167|variety
P11431348A0000|175 191|leukemia cell lines
P11431472A0540|3 17|affinity binding
P11431472A0540|20 28|Rab6A-GTP
P11431472A0540|52 57|microm
P11431472A0540|63 67|Rab1B
P11431857A0186|3 10|students
P11431857A0186|25 38|urine screening
P11431857A0186|77 89|urine analysis
P11431857A0186|126 138|urine analysis
P11432112A0000|0 6|PURPOSE
P11432112A0000|10 18|objective
P11432112A0000|25 29|study
P11432112A0000|46 59|embryo cleavage
P11432112A0000|94 107|sperm injection
P11432112A0000|115 123|parameter
P11432112A0000|129 150|embryo selection process
P11432748T0000|0 9|Regulation
P11432748T0000|12 42|laminin beta2 chain gene expression
P11432748T0000|50 64|cancer cell lines
P11432776A0421|0 7|Northern
P11432776A0421|11 29|Western blot analyses
P11432776A0421|46 50|Graf2
P11432776A0421|71 77|tissues
P11432776A0421|92 101|expression
P11432776A0421|112 117|muscle
P11433014A0683|36 41|fusion
P11433014A0683|44 57|core histone H2A
P11433014A0683|138 144|protein
P11433018A0756|34 40|binding
P11433018A0756|42 46|Nhp2p
P11433018A0756|49 60|H/ACA snoRNAs
P11433018A0756|77 84|assembly
P11433018A0756|87 98|H/ACA snoRNPs
P11433018A0756|113 121|stability
P11433018A0756|135 144|components
P11433024A0260|0 9|Telomerase
P11433024A0260|13 36|ribonucleoprotein complex
P11433024A0260|70 80|chromosomes
P11433024A0260|88 99|RNA component
P11433024A0260|102 109|template
P11433379A0000|34 47|adaptor protein
P11433379A0000|81 94|adaptor protein
P11433379A0000|113 123|lymphocytes
P11434084A0508|11 20|patients DD
P11434084A0508|40 54|microlatex tests
P11434084A0508|69 75|d-dimer
P11435428A0000|9 28|acetyl-CoA synthetase
P11435428A0000|29 34|AceCS1
P11435428A0000|44 50|acetate
P11435428A0000|62 66|cells
P11435428A0000|71 80|acetyl-CoA
P11435428A0000|84 97|lipid synthesis
P11435517A0396|5 19|digestibilities
P11435517A0396|46 50|fiber
P11435517A0396|64 69|energy
P11435517A0396|102 106|diets
P11435517A0396|126 130|fiber
P11435517A0396|155 165|control diet
P11435560A1322|31 40|HFV R region
P11435560A1322|49 55|nucleus
P11435560A1322|86 98|target HFV mRNA
P11435578A0760|38 45|elements
P11435578A0760|66 73|TGACGTCA
P11435578A0760|73 81|consensus
P11435578A0760|116 121|strain
P11435578A0760|125 132|AGACGTCA
P11435578A0760|133 140|TGACGGCA
P11435578A0760|141 148|TGACCTCA
P11435578A2231|18 31|reconstitution
P11435578A2231|35 46|consensus CRE
P11435578A2231|61 69|enhancers
P11435578A2231|79 85|binding
P11435578A2231|88 103|CREB/ATF proteins
P11435578A2231|121 130|repression
P11435578A2231|145 157|transcription
P11435605A0587|13 23|mutagenesis
P11435605A0587|43 58|CAR residues Leu73
P11435605A0587|61 66|Lys121
P11435605A0587|73 78|Lys123
P11435605A0587|90 104|contact residues
P11435605A0587|109 113|Tyr80
P11435605A0587|117 121|Tyr83
P11435605A0587|152 169|binding interaction
P11435605A0587|196 210|Ad41L fiber knobs
P11435688A0262|4 12|subfamily
P11435688A0262|15 19|genes
P11435688A0262|45 50|domain
P11435688A0262|56 65|N-terminus
P11435688A0262|93 113|transmembrane segments
P11435983T0000|0 8|Tolerance
P11435983T0000|16 30|transplantation
P11435983T0000|46 55|bone marrow
P11435983T0000|78 86|follow-up
P11437439A0201|3 18|promoter activity
P11437439A0201|32 37|region
P11437439A0201|63 68|subset
P11437439A0201|71 83|prestalk cells
P11437660A1219|0 11|Substitution
P11437660A1219|14 27|serine residues
P11437660A1219|33 42|C-terminus
P11437660A1219|64 83|phosphorylation sites
P11437660A1219|104 109|effect
P11437660A1219|112 124|transcription
P11437660A1219|128 138|replication
P11438651A1365|4 26|replication fork movement
P11438651A1365|51 56|origin
P11438651A1365|75 95|replication initiation
P11438651A1365|116 120|Orc2p
P11438651A1365|122 130|component
P11438651A1365|136 155|replication initiator
P11438654A1237|5 12|findings
P11438654A1237|27 37|adapter Gab1
P11438654A1237|49 62|c-Met signaling
P11438654A1237|85 113|c-Akt/Pak1 cell survival pathway
P11438666A0555|18 29|mouse protein
P11438666A0555|59 74|plant homeodomain
P11438666A0555|78 83|finger
P11438666A0555|104 122|immunoprecipitation
P11438666A0555|137 150|TFIID component
P11438838A0788|8 16|inhibitor
P11438838A0788|27 34|TAR decoy
P11438838A0788|62 72|RNA promoter
P11439343A0785|2 9|contrast
P11439343A0785|39 50|Pc protein M33
P11441163T0000|0 9|Foreigners
P11441311X0001|9 15|results
P11441311X0001|20 26|MACOP-B
P11441311X0001|30 45|radiation therapy
P11441311X0001|59 67|lymphomas
P11441311X0001|68 77|BACKGROUND
P11441311X0001|87 93|results
P11441311X0001|113 132|chemotherapy regimens
P11441311X0001|146 152|factors
P11441311X0001|167 175|lymphomas
P11441952A0414|19 24|months
P11441952A0414|69 78|percentage
P11441952A0414|80 88|avoidance
P11441952A0414|93 100|controls
P11441952A0414|117 126|difference
P11441952A0414|138 151|months post-TBI
P11441952A0414|193 205|avoidance test
P11441974A0320|23 31|migration
P11441974A0320|42 53|hemolymph PO2
P11441974A0320|80 89|hemocyanin
P11441974A0320|124 130|reserve
P11441974A0320|156 161|mmol x l
P11443509A0293|0 5|DESIGN
P11443509A0293|17 27|cohort study
P11443509A0293|47 52|period
P11443509A0293|55 73|First National Health
P11443509A0293|77 93|Examination Survey
P11443509A0293|94 99|NHANES
P11443509A0293|123 127|Study
P11443509A0293|128 132|NHEFS
P11443999A0573|0 19|Mean Hg concentrations
P11443999A0573|25 30|livers
P11443999A0573|45 49|sites
P11443999A0573|51 60|Isle Royale
P11443999A0573|97 112|Hg concentrations
P11443999A0573|128 145|government agencies
P11443999A0573|167 177|consumption
P11444762A0373|21 29|proposals
P11444762A0373|47 54|analysis
P11444762A0373|79 83|onset
P11444762A0373|85 90|action
P11445008A0816|3 7|assay
P11445008A0816|32 41|comparison
P11445008A0816|52 71|FGFR expression levels
P11445008A0816|89 95|RNA pool
P11445008A0816|112 125|RNA pool samples
P11447490A0598|3 8|amount
P11447490A0598|18 25|effusion
P11447490A0598|40 44|fluid
P11447490A0598|65 74|assessment
P11448051A0093|3 8|system
P11448051A0093|52 71|intestine transit time
P11448051A0093|124 129|matrix
P11448051A0093|148 152|agent
P11448051A0093|159 166|mannitol
P11448051A0093|169 173|Emdex
P11448051A0093|184 190|polymer
P11448051A0093|191 203|Eudragit RS100
P11449014A0000|0 13|STUDY OBJECTIVE
P11449014A0000|18 22|study
P11449014A0000|52 58|aspects
P11449014A0000|71 77|quality
P11449014A0000|107 112|trials
P11449014A0000|121 128|relation
P11449014A0000|133 145|participation
P11449014A0000|150 179|epidemiologist/biostatistician
P11450490A0565|41 46|acuity
P11450490A0565|53 70|range hand motions/0
P11450490A0565|90 94|lines
P11450490A0565|142 147|acuity
P11450490A0565|154 158|range
P11450776T0000|20 24|group
P11450776T0000|38 48|peritonitis
P11451447A0205|0 4|Gimpl
P11451682A0190|10 21|chemotherapy
P11451682A0190|40 53|administration
P11451682A0190|55 87|benzimidazole carbamate derivatives
P11451682A0190|94 104|mebendazole
P11451682A0190|108 118|albendazole
P11451995T0000|24 31|analysis
P11451995T0000|57 62|Ste14p
P11451995T0000|71 76|member
P11451995T0000|82 129|isoprenylcysteine carboxyl methyltransferase family
P11454004T0000|8 17|regulation
P11454004T0000|28 36|promoters
P11454004T0000|60 96|glycerol-3-phosphate dehydrogenase gene
P11454004T0000|96 109|identification
P11454004T0000|120 142|hormone-response element
P11454004T0000|158 167|promoter B.
P11454190A0000|0 14|BACKGROUND/AIMS
P11454190A0000|15 24|Hepatitis C
P11454190A0000|40 56|fatty liver disease
P11454190A0000|82 86|forms
P11454190A0000|88 99|liver disease
P11454190A0000|105 116|United States
P11454239A0478|11 18|Analysis
P11454239A0478|27 31|ANOVA
P11454239A0478|35 76|Pearson Product Moment Correlation Coefficient
P11454239A0478|77 103|Principal Components Analysis
P11454239A0478|107 134|Discriminant Function Analysis
P11454239A0478|141 151|calculation
P11454239A0478|154 161|Cronbach
P11454239A0478|163 167|alpha
P11454239A0478|168 172|alpha
P11454239A0478|173 179|RESULTS
P11454239A0478|184 194|Sensitivity
P11454239A0478|198 208|specificity
P11454239A0478|227 235|Chronbach
P11454239A0478|237 241|alpha
P11454239A0478|253 257|scale
P11454703A0000|3 12|telomerase
P11454703A0000|24 30|complex
P11454703A0000|45 55|maintenance
P11454703A0000|74 87|chromosome ends
P11454703A0000|129 133|cells
P11454703A0000|171 185|immortalization
P11454703A0000|195 207|tumorigenesis
P11456259A0142|3 7|titer
P11456259A0142|10 42|TSH binding inhibitor immunoglobulin
P11456259A0142|75 86|presentation
P11456259A0142|100 104|weeks
P11457139A0604|3 9|results
P11457139A0604|58 68|affinity Man
P11457139A0604|67 72|GlcNAc
P11457139A0604|79 88|D1D3 isomer
P11457139A0604|95 100|GlcNAc
P11459048A0485|27 39|uncertainties
P11459048A0485|45 50|models
P11459048A0485|62 68|planets
P11459048A0485|78 87|atmosphere
P11459048A0485|92 96|Venus
P11459048A0485|131 144|rotation states
P11459304T0078|0 19|Enantiomer separation
P11459304T0078|22 32|venlafaxine
P11459304T0078|36 57|O-desmethylvenlafaxine
P11459304T0078|65 70|plasma
P11459794A1172|0 10|TE-671 cells
P11459794A1172|34 52|cAMP response element
P11459794A1172|59 68|constructs
P11459794A1172|97 104|activity
P11459794A1172|110 124|GnRH-II promoter
P11459960A1109|32 41|components
P11459960A1109|68 77|heat labile
P11459962A0785|26 30|genes
P11459962A0785|36 40|Rad52
P11459962A0785|56 68|repair pathway
P11459962A0785|86 93|survival
P11459962A0785|96 112|rad27 Delta strains
P11459962A0785|131 138|degrees C
P11459962A0785|142 155|semipermissive
P11459962A0785|158 165|degrees C
P11459962A0785|166 177|temperatures
P11459962A0785|181 186|growth
P11460035A0548|19 36|hydroxychloroquine
P11460035A0548|36 48|carbamazepine
P11460035A0548|52 62|fluvoxamine
P11460035A0548|73 84|imputability
P11461595A0000|16 31|reaction kinetics
P11461595A0000|48 56|particles
P11461595A0000|61 67|inertia
P11461595A0000|75 89|coalescence type
P11461595A0000|92 99|reaction
P11461595A0000|140 144|flows
P11462004A0886|14 19|Vp1 DBD
P11462004A0886|25 33|infection
P11462004A0886|57 65|advantage
P11462004A0886|83 97|complementation
P11462004A1500|65 71|nucleus
P11462004A1500|139 144|signal
P11462004A1500|159 170|localization
P11462952A1040|7 19|gastrin levels
P11462952A1040|26 30|range
P11463359A0167|17 31|phorbol ester PMA
P11463359A0167|79 88|expression
P11463359A0167|92 105|luciferase gene
P11463359A0167|114 120|control
P11463359A0167|126 139|G6Pase promoter
P11463359A0167|164 181|H4IIE hepatoma cells
P11463834A0606|7 25|deletion mutagenesis
P11463834A0606|36 45|amino acids
P11463834A0606|90 95|region
P11463834A0606|113 118|region
P11463834A0606|121 134|Tax interaction
P11464997A0566|4 12|knowledge
P11464997A0566|25 33|diagnosis
P11464997A0566|37 45|treatment
P11464997A0566|51 57|patient
P11464997A0566|61 70|counseling
P11464997A0566|84 89|family
P11465518A0000|0 9|BACKGROUND
P11465518A0000|27 34|interest
P11465518A0000|48 60|investigators
P11465518A0000|66 71|public
P11465518A0000|111 120|treatments
P11465518A0000|165 175|individuals
P11465518A0000|189 193|risks
P11465655A0439|33 50|antagonist atenolol
P11465655A0439|79 84|mg/day
P11465655A0439|99 104|mg/day
P11465844T0000|8 18|association
P11465844T0000|25 40|Kawasaki syndrome
P11465844T0000|44 52|infection
P11465844T0000|57 73|Rickettsia conorii
P11465844T0000|74 88|Rickettsia typhi
P11465844T0000|89 104|Coxiella burnetii
P11465844T0000|107 134|Ehrlichia phagocytophila group
P11466227A1665|3 10|presence
P11466227A1665|13 20|AS-oligo
P11466227A1665|33 38|effect
P11466227A1665|56 65|activation
P11466227A1665|74 89|mTf-CAT construct
P11466227A1665|112 121|activation
P11467349A0452|39 46|measures
P11467349A0452|48 57|ISF glucose
P11468958A0122|11 17|results
P11468958A0122|29 42|policy analysis
P11468958A0122|64 72|decisions
P11468958A0122|78 83|recall
P11468958A0122|86 90|blood
P11468958A0122|96 100|donor
P11468958A0122|127 134|decision
P11468958A0122|141 149|donations
P11468958A0122|154 164|individuals
P11468958A0122|177 189|travel history
P11468958A0122|222 229|concerns
P11469701A0377|8 15|approach
P11469701A0377|18 38|insulin administration
P11469701A0377|76 89|insulin therapy
P11469701A0377|90 94|CIIIT
P11469701A0377|103 109|insulin
P11469701A0377|122 128|fashion
P11469701A0377|153 172|insulin concentration
P11469737A1791|2 6|visit
P11469737A1791|41 62|muscle function recovery
P11469737A1791|112 119|recovery
P11469853A0702|12 17|system
P11469853A0702|21 35|domain shuffling
P11469853A0702|50 57|function
P11469853A0702|60 68|C1 domains
P11469853A0702|78 86|Raf kinase
P11469853A0702|90 98|rat PKC eta
P11469853A0702|101 105|yeast
P11469853A1053|31 38|evidence
P11469853A1053|42 52|interaction
P11469853A1053|63 68|GTPase
P11469853A1053|88 95|function
P11469853A1053|101 108|C1 domain
P11469853A1053|111 115|yeast
P11469926T0000|0 25|Breast cancer risk assessment
P11469926T0000|42 52|crystal ball
P11469970A0873|0 7|Patients
P11469970A0873|41 52|hyperalgesia
P11469970A0873|52 56|trial
P11469970A0873|59 73|antidepressants
P11469970A0873|88 92|trial
P11469970A0873|97 119|botulinum toxin injection
P11469970A0873|127 133|ampulla
P11469970A0873|181 187|therapy
P11470914A0305|3 10|activity
P11470914A0305|26 43|STAT3 translocation
P11470914A0305|48 54|nucleus
P11470914A0305|84 97|gene expression
P11471077A0382|0 6|RESULTS
P11471077A0382|27 32|amount
P11471077A0382|35 43|variation
P11471077A0382|54 60|results
P11471077A0382|91 97|results
P11471077A0382|126 131|survey
P11471231A0964|2 9|addition
P11471231A0964|15 22|patients
P11471231A0964|57 67|differences
P11471231A0964|100 107|spectrum
P11471231A0964|162 171|procedures
P11472523A0535|0 9|CONCLUSION
P11472523A0535|10 25|Extrusion cooking
P11472523A0535|43 54|inactivation
P11472523A0535|76 80|value
P11472523A0535|95 108|metabisulphite
P11472696A0387|3 13|differences
P11472696A0387|19 23|CPIgG
P11472696A0387|32 47|fibrinogen levels
P11472696A0387|49 56|patients
P11473254A0000|12 26|DNA endonuclease
P11473254A0000|31 43|topoisomerase
P11473254A0000|47 67|recombinase activities
P11473254A0000|73 82|Lys residue
P11473261A0587|38 68|guanine nucleotide exchange factor
P11474642A1451|3 12|decrements
P11474642A1451|30 39|resistance
P11474642A1451|49 61|hexamethonium
P11474642A1451|64 69|mm Hg ml
P11474642A1451|102 108|control
P11478627A0573|3 22|desirability function
P11478627A0573|35 40|search
P11478627A0573|51 57|optimum
P11478627A0573|83 96|transformation
P11478627A0573|106 113|property
P11478627A0573|130 134|scale
P11478627A0573|142 150|criterion
P11479104A0446|45 52|antibody
P11479104A0446|77 84|criteria
P11479104A0446|96 113|lupus erythematosis
P11479104A0446|133 142|CONCLUSION
P11479104A0446|146 153|presence
P11479104A0446|171 177|disease
P11479104A0446|181 185|woman
P11479104A0446|215 223|clinician
P11479104A0446|257 261|cause
P11479501A0744|0 6|RESULTS
P11479501A0744|26 37|distribution
P11479501A0744|45 55|coefficient
P11479501A0744|58 66|variation
P11479501A0744|67 74|SD/mean x
P11479501A0744|92 101|valve sizes
P11479501A0744|127 144|St Jude Medical valve
P11479501A0744|165 179|Omnicarbon valve
P11480490A0443|29 33|signs
P11480490A0443|57 64|blockade
P11480490A0443|73 79|current
P11480490A0443|95 104|occurrence
P11480490A0443|107 116|arrhythmia
P11480497T0000|0 6|Effects
P11480497T0000|22 32|JP-8 jet fuel
P11480497T0000|61 67|battery
P11480497T0000|71 78|learning
P11480497T0000|82 87|memory
P11480555A0928|3 12|production
P11480555A0928|15 22|ceramide
P11480555A0928|36 42|fixture
P11480555A0928|55 63|cell death
P11481625A0202|23 30|subjects
P11481625A0202|80 100|interferon alfa-2b dose
P11481625A0202|126 145|peginterferon alfa-2b
P11481625A0202|155 163|microg/kg
P11484028T0000|2 14|cross purposes
P11484578A1132|0 9|CONCLUSION
P11484578A1132|20 30|differences
P11484578A1132|36 50|measurement data
P11484578A1132|66 71|method
P11484578A1132|81 95|measurement data
P11484578A1132|102 107|object
P11484578A1132|140 152|design program
P11486032A1261|8 27|transcription factors
P11486032A1261|62 68|protein
P11486032A1261|73 77|RUNX1
P11486032A1261|107 113|E2A-HLF
P11486141A0424|4 10|factors
P11486141A0424|36 42|outcome
P11486141A0424|45 52|students
P11486141A0424|72 76|power
P11486141A0424|83 94|meta analysis
P11486141A0424|125 131|sources
P11486141A0424|134 138|error
P11486399A0000|3 13|combination
P11486399A0000|16 25|ifosfamide
P11486399A0000|26 35|epirubicin
P11486399A0000|39 47|etoposide
P11486399A0000|66 79|salvage regimen
P11486399A0000|101 107|disease
P11486476A0147|12 16|trial
P11486476A0147|50 64|characteristics
P11486476A0147|67 74|patients
P11486476A0147|79 87|chest pain
P11486476A0147|89 93|value
P11486476A0147|103 118|markers troponin T
P11486476A0147|119 127|myoglobin
P11486476A0147|131 139|CK-MB mass
P11486476A0147|177 185|chest pain
P11486476A0147|190 199|proportion
P11486476A0147|202 209|patients
P11486476A0147|230 236|markers
P11486476A0147|261 271|information
P11486476A0147|274 282|admission
P11486476A1512|7 22|markers troponin T
P11486476A1512|23 31|CK-MB mass
P11486476A1512|35 43|myoglobin
P11486476A1512|72 80|diagnosis
P11486476A1512|83 91|chest pain
P11489597A0379|2 12|termination
P11489597A0379|37 43|females
P11489597A0379|52 56|group
P11489597A0379|81 86|status
P11489597A0379|101 107|outcome
P11489597A0379|112 118|fetuses
P11489597A0379|161 173|malformations
P11489597A0561|11 15|death
P11489597A0561|23 32|body weight
P11489597A0561|43 52|weight gain
P11489597A0561|86 99|pregnancy rates
P11489597A0561|119 123|group
P11490862A0141|12 22|development
P11490862A0141|25 45|bladder neck suspension
P11490862A0141|57 70|Stamey-Pereyra
P11490862A0141|90 100|bone anchors
P11490862A0141|120 126|support
P11494391A0579|3 9|results
P11494391A0579|42 61|artery-alone ALT graft
P11494391A0579|79 87|structure
P11494391A0579|105 109|month
P11494391A0579|127 139|bile secretion
P11495833T0000|13 18|impact
P11495833T0000|39 43|means
P11495833T0000|67 71|model
P11495833T0000|90 99|properties
P11495920A0504|7 18|pair mismatch
P11495920A0504|41 46|region
P11495920A0504|52 61|CYP3A4 gene
P11495920A0504|91 106|enhancer activity
P11496495A0000|3 9|authors
P11496495A0000|16 23|analysis
P11496495A0000|43 52|conditions
P11496495A0000|64 76|possibilities
P11496495A0000|110 117|children
P11496617A0301|0 6|METHODS
P11496617A0301|9 14|female
P11496617A0301|24 31|patients
P11496617A0301|42 55|thyroid surgery
P11496617A0301|144 150|regimes
P11496617A0301|153 164|mg dolasetron
P11496617A0301|178 184|minutes
P11496617A0301|192 200|induction
P11496617A0301|203 213|anaesthesia
P11496617A0301|214 218|group
P11496617A0301|224 235|mg dolasetron
P11496617A0301|260 268|induction
P11496617A0301|271 281|anaesthesia
P11496617A0301|282 286|group
P11496617A0301|293 297|mg DHB
P11496617A0301|322 330|induction
P11496617A0301|333 343|anaesthesia
P11496617A0301|344 348|group
P11496617A0301|354 360|placebo
P11496617A0301|361 365|group
P11498795A0716|8 18|progression
P11498795A0716|34 41|G1-phase
P11498795A0716|61 75|phosphorylation
P11498795A0716|81 89|RB protein
P11498795A0716|103 107|delay
P11498795A0716|115 130|S phase transition
P11500377A0518|2 8|mammals
P11500377A0518|27 36|repressors
P11500377A0518|42 51|Wnt pathway
P11500512A0000|8 16|ABCG1 gene
P11500512A0000|25 30|member
P11500512A0000|47 54|cassette
P11500512A0000|60 70|superfamily
P11500512A0000|72 90|transporter proteins
P11500512A0000|113 123|macrophages
P11500512A0000|140 149|oxysterols
P11500571A0976|15 24|expression
P11500571A0976|27 44|NtmybAS transcripts
P11500571A0976|53 58|pollen
P11500571A0976|59 74|gPAL1 transcripts
P11500571A0976|94 99|pollen
P11500913A1238|0 11|C/EBPbeta LIP
P11500913A1238|26 34|HC11 cells
P11500913A1238|48 62|beta-casein mRNA
P11500913A1238|80 104|cell differentiation marker
P11500913A1238|107 114|response
P11500913A1238|127 134|hormones
P11502738A1457|9 15|effects
P11502738A1457|32 41|inhibitors
P11502738A1457|61 67|mutants
P11502738A1457|92 99|bp region
P11502738A1457|105 120|cyclin D1 promoter
P11502758A0869|5 12|findings
P11502758A0869|54 58|LAD-1
P11502758A0869|67 79|FGFR signaling
P11502778A0941|36 50|estradiol levels
P11502778A0941|58 63|median
P11502778A0941|66 75|pmol/liter
P11502778A0941|78 82|pg/ml
P11502778A0941|105 109|rates
P11502778A0941|112 119|bone loss
P11502778A0941|123 128|levels
P11502778A0941|131 151|bone resorption markers
P11502778A0941|177 191|estradiol levels
P11502778A0941|198 207|pmol/liter
P11504545A0393|0 10|Competition
P11504545A0393|26 38|mobility shift
P11504545A0393|42 58|immunoshift assays
P11504545A0393|72 81|NF1 factors
P11504545A0393|98 105|extracts
P11504545A0393|117 125|CV-1 cells
P11504545A0393|134 140|BKV-MLP
P11504709A0981|4 8|study
P11504709A0981|34 43|expression
P11504709A0981|46 53|response
P11504709A0981|94 100|Ets site
P11504709A0981|112 119|promoter
P11504709A0981|157 166|activation
P11504709A0981|202 207|kinase
P11505407A0461|0 6|RESULTS
P11505407A0461|18 25|fragment
P11505407A0461|40 47|activity
P11505407A0461|50 54|EpCAM
P11505407A0461|63 67|cells
P11505407A0461|96 119|tumor necrosis factor alpha
P11505407A0461|120 127|TNFalpha
P11509266A0955|19 49|hazards regression adenocarcinoma
P11509266A0955|59 69|development
P11509266A0955|120 124|stage
P11509266A0955|149 158|predictors
P11509266A0955|160 167|survival
P11509615T0000|0 27|Phosphatidylinositol 3-kinase
P11509615T0000|56 73|T cell proliferation
P11509615T0000|87 98|IL-2 receptor
P11509673A0574|11 23|transfectants
P11509673A0574|24 31|BM3 cells
P11509673A0574|58 74|P450 AA epoxygenase
P11509673A0574|75 81|F87V BM3
P11509673A0574|146 154|14,15-EET
P11509673A0574|170 178|apoptosis
P11509673A0574|212 220|apoptosis
P11511544T0000|3 12|loop domain
P11511544T0000|15 42|heat shock transcription factor
P11511544T0000|63 73|specificity
P11511544T0000|77 85|responses
P11511544T0000|88 97|heat stress
P11512925A0000|0 16|EXAFS measurements
P11512925A0000|68 73|alloys
P11512925A0000|111 119|structure
P11512925A0000|126 131|Ge atom
P11513121T0000|11 15|study
P11513121T0000|19 32|robustness test
P11513121T0000|35 43|QSAR model
P11513121T0000|51 75|quantum chemical parameters
P11513121T0000|126 134|compounds
P11513121T0000|134 138|PCOCs
P11513180A1257|8 12|cases
P11513180A1257|24 32|polyposis
P11513180A1257|92 96|bowel
P11513579A0372|18 23|system
P11513579A0372|76 82|Rho-GDI
P11513579A0372|130 140|interaction
P11513579A0372|142 157|complex formation
P11516890A0236|24 38|cytochrome P-450
P11516890A0236|44 49|system
P11516890A0236|49 59|venlafaxine
P11516890A0236|68 73|CYP 2D6
P11516890A0236|94 99|extent
P11516890A0236|108 112|SSRIs
P11517190A0352|0 7|Analysis
P11517190A0352|13 28|promoter sequence
P11517190A0352|40 47|presence
P11517190A0352|71 79|start site
P11517190A0352|90 96|TATA box
P11517190A0352|123 130|elements
P11517190A0352|150 159|expression
P11517190A0352|182 188|element
P11517190T0000|13 20|promoter
P11517190T0000|26 39|rat ER alpha gene
P11517190T0000|66 78|transcription
P11517190T0000|89 96|receptor
P11517269A0472|0 4|Pitx2
P11517269A0472|24 44|differentiation defect
P11517269A0472|67 78|axon guidance
P11517269A0472|92 101|phenotypes
P11517269A0472|110 116|mutants
P11517269A0472|132 137|degree
P11517269A0472|150 161|conservation
P11517269A0472|195 199|genes
P11517399A0858|3 10|patterns
P11517399A0858|27 43|protein expression
P11517399A0858|55 61|mutants
P11517399A0858|91 98|mutation
P11517399A0858|109 120|acceptor site
P11517399A0858|133 143|utilization
P11517399A0858|153 163|splice sites
P11517399A0858|170 179|generation
P11517399A0858|188 194|species
P11517445A0221|9 13|cases
P11517445A0221|16 22|cholera
P11517445A0221|34 45|V. cholerae O1
P11518505A0107|63 69|tissues
P11518505A0107|73 78|organs
P11518868A0559|25 31|history
P11518868A0559|43 54|risk behavior
P11518868A0559|64 72|knowledge
P11518868A0559|78 92|hepatitis C virus
P11518868A0559|96 126|healthcare provider communication
P11519466A0196|39 44|impact
P11520436A0705|4 13|BALB/c mice
P11520436A0705|42 47|strain
P11520436A0705|65 71|studies
P11520436A0705|84 93|connection
P11520436A0705|101 109|infection
P11520436A0705|114 120|T. canis
P11520436A0705|132 137|asthma
P11521191A0000|38 50|12S E1A protein
P11521191A0000|63 83|phosphorylation status
P11521191A0000|116 122|changes
P11521191A0000|126 134|cell cycle
P11521191A0000|144 158|phosphorylation
P11521191A0000|164 184|retinoblastoma protein
P11522431A0673|3 12|prevalence
P11522431A0673|15 31|tobacco dependence
P11522431A0673|55 68|ICD-10 criteria
P11522431A0673|97 107|individuals
P11522431A0673|120 130|nondrinkers
P11522431A0673|138 145|drinkers
P11522584A0882|7 14|myalgias
P11522584A0882|33 40|patients
P11522584A0882|58 66|MMF lesion
P11522584A0882|76 87|muscle biopsy
P11522626A1374|19 28|regulation
P11522626A1374|34 50|gene transcription
P11522626A1374|79 88|activation
P11522626A1374|94 101|Mek-Erk1
P11522626A1374|102 108|pathway
P11522626A1374|111 127|estrogen receptors
P11522658A0086|24 43|ErbB1/ErbB2 signaling
P11522658A0086|61 67|process
P11522658A0086|77 103|ErbB kinase inhibitor AG1478in
P11522658A0086|119 124|BT-474
P11522658A0086|128 133|SKBR-3
P11522658A0086|139 155|breast cancer cells
P11522658A0870|18 32|phosphorylation
P11522658A0870|59 67|stability
P11522658A0870|110 122|stoichiometry
P11522658A0870|136 149|kinase activity
P11523446A0523|10 26|reference solution
P11523446A0523|51 64|time-of-flight
P11523446A0523|108 124|nitrogen detection
P11523446A0523|122 128|LC-CLND
P11524015A0937|6 15|expression
P11524015A0937|18 23|BZAP45
P11524015A0937|42 51|H4 promoter
P11524015A0937|63 85|CAT reporter gene activity
P11524815A0753|5 16|control rates
P11524815A0753|38 47|lung cancer
P11524815A0753|61 70|lung cancer
P11524815A0753|84 93|2N0M0 cases
P11524823X0001|0 6|Utility
P11524823X0001|9 19|OAE screener
P11524823X0001|33 42|evaluation
P11524823X0001|44 60|distortion product
P11524823X0001|72 80|emissions
P11524823X0001|84 90|purpose
P11524823X0001|97 101|study
P11524823X0001|121 127|ability
P11524823X0001|133 146|OAE screener GSI
P11524823X0001|161 175|cochlea function
P11524823X0001|178 185|neonates
P11524823X0001|186 192|infants
P11524823X0001|196 201|adults
P11525102A0970|6 11|sample
P11525102A0970|24 30|reviews
P11525102A0970|40 53|ACP Journal Club
P11525102A0970|64 77|PubMed strategy
P11525102A0970|86 96|sensitivity
P11525486A0350|13 21|CaCO3-CO2
P11525486A0350|33 40|solution
P11525640A0560|0 9|Inhibition
P11525640A0560|21 39|ERK kinase activities
P11525640A0560|47 56|expression
P11525640A0560|94 102|treatment
P11525640A0560|116 132|chemical inhibitor
P11525640A0560|140 147|PD098059
P11525640A0560|172 182|UV induction
P11525640A0560|188 201|GADD45 promoter
P11528127A1402|5 13|GC content
P11528127A1402|26 32|segment
P11528127A1402|72 78|segment
P11528127A1402|101 105|mouse
P11528127A1402|112 116|L1/L2
P11528253X1211|0 8|Copyright
P11528500A0571|2 9|mutation
P11528500A0571|15 21|NRL gene
P11528500A0571|43 50|families
P11529914T0000|0 8|NF-kappaB
P11529914T0000|24 33|regulation
P11529914T0000|36 40|CD154
P11529914T0000|41 50|CD40 ligand
P11529914T0000|51 60|expression
P11529914T0000|75 80|T cells
P11530684A0667|5 15|nerve injury
P11530684A0667|30 38|responses
P11530684A0667|53 59|neurons
P11530684A0667|76 83|C-fibers
P11530684A0667|87 113|drive NK1-receptor mechanisms
P11530684A0667|122 137|pain transmission
P11530684A0667|166 172|changes
P11530684A0667|206 213|C-fibers
P11530684A0667|215 242|drive NMDA receptor-mechanisms
P11530684A0667|300 307|A-fibers
P11530684A0667|309 336|drive NMDA-receptor mechanisms
P11530829A0000|4 10|article
P11530829A0000|21 26|design
P11530829A0000|30 40|development
P11530829A0000|45 56|ECG simulator
P11530829A0000|78 84|testing
P11530829A0000|84 94|calibration
P11530829A0000|98 108|maintenance
P11530829A0000|131 139|equipment
P11532556A0000|20 38|angioencephalopathy
P11532556A0000|60 66|disease
P11532556A0000|75 82|etiology
P11532556A0000|98 104|thalami
P11532856A1175|0 4|Third
P11532856A1175|30 45|N-acetylcysteine
P11532856A1175|66 71|effect
P11532856A1175|81 102|stress kinase activities
P11532856A1175|107 119|p42/44 mitogen
P11532856A1175|129 134|kinase
P11532856A1175|166 176|involvement
P11532856A1175|194 199|kinase
P11532856A1175|208 214|p38 MAPK
P11532856A1175|216 230|HIF-1 activation
P11533238A1137|0 7|Mutation
P11533238A1137|13 26|octamer element
P11533238A1137|54 60|ability
P11533238A1137|63 67|HDAC1
P11533238A1137|76 85|repression
P11533238A1137|97 121|HLA-DRA promoter activation
P11533340A1285|21 30|difference
P11533340A1285|46 51|scores
P11533340A1285|59 64|months
P11533340A1285|73 82|PDF infants
P11533340A1285|97 110|point advantage
P11533340A1285|113 134|Bayley motor score scales
P11533863A0125|20 30|restoration
P11533863A0125|48 54|routine
P11533863A0125|68 81|presupposition
P11533863A0125|95 101|therapy
P11534132A0219|12 24|search engines
P11534132A0219|50 56|results
P11534132A0219|61 66|domain
P11534132A0219|75 81|experts
P11534900A0000|20 31|combinations
P11534900A0000|47 76|molluscicides Azadirachta indica
P11534900A0000|80 95|Cedrus deodara oil
P11534900A0000|100 116|synergists MGK-264
P11534900A0000|117 133|piperonyl butoxide
P11534900A0000|141 151|fruit powder
P11534900A0000|153 164|Embelia ribes
P11534900A0000|183 198|Lymnaea acuminata
P11535014A1157|12 18|results
P11535014A1157|38 48|seizure type
P11535014A1157|64 72|frequency
P11535014A1157|74 80|seizure
P11535014A1157|103 120|precipitate factors
P11535014A1157|132 140|latencies
P11535014A1157|163 170|patients
P11535140T0000|12 19|findings
P11535140T0000|22 30|pregnancy
P11535532A0189|19 29|enzyme DUB-2
P11535532A0189|41 48|response
P11535532A0189|68 75|function
P11535832A0586|3 9|isoform
P11535832A0586|20 25|HDAC9a
P11535832A0586|47 55|C terminus
P11535832A0586|59 63|HDAC9
P11536063A0178|9 19|embolectomy
P11536063A0178|23 41|lung transplantation
P11536063A0178|52 62|indications
P11536063A0178|76 93|heart-lung-machine
P11538437A0568|6 15|conditions
P11538437A0568|35 43|reactions
P11538437A0568|130 146|N2 post-discharges
P11538437A0568|144 151|products
P11538437A0568|213 231|% CH4 post-discharges
P11539522A0612|3 16|NAUSICAA system
P11539522A0612|27 35|knowledge
P11539522A0612|38 47|LET spectra
P11539522A0612|67 80|space dosimetry
P11540991A0127|2 6|order
P11540991A0127|22 28|effects
P11540991A0127|29 33|tests
P11540991A0127|52 83|NASA MSFC Neutral Buoyancy Simulator
P11540991A0127|89 98|NASA KC-135
P11540991A0127|110 115|flight
P11540991A0127|121 125|space
P11540991A0127|133 143|EASE program
P11540991A0127|153 178|Shuttle Atlantis mission 61-B
P11542677A0411|4 10|article
P11542677A0411|37 50|Generic Systems
P11542677A0411|71 82|alternatives
P11542677A0411|85 108|composting facility design
P11542677A0411|112 118|control
P11542780A0086|26 34|detectors
P11542780A0086|64 75|contribution
P11542780A0086|89 111|energy transfer component
P11542780A0086|120 133|keV/micrometer
P11542780A0086|150 163|track detectors
P11542780A0086|186 198|energy tranfer
P11542780A0086|203 211|component
P11543154T0000|0 8|Responses
P11543154T0000|11 20|TLD Mg2SiO4
P11543154T0000|48 52|glass
P11543154T0000|66 74|particles
P11543154T0000|78 91|space radiation
P11543317A0203|30 40|combination
P11543317A0203|56 64|detectors
P11543317A0203|82 90|dosemeter
P11543317A0203|93 99|Mg2SiO4
P11543317A0203|127 139|track detector
P11543662A0562|14 20|mutants
P11543662A0562|65 70|defect
P11543662A0562|74 80|ability
P11543662A0562|87 94|L protein
P11545594A1556|22 31|Myb domains
P11545594A1556|59 66|function
P11545594A1556|73 81|Myb domain
P11545594A1556|94 110|amino acid residues
P11545594A1556|130 136|surface
P11545594A1556|143 149|protein
P11547819A0532|0 6|METHODS
P11547819A0532|7 17|Experiments
P11547819A0532|31 38|catheter
P11547819A0532|66 73|catheter
P11547819A0532|83 93|measurement
P11547819A0532|99 118|laser output beam sizes
P11547819A0532|122 132|divergences
P11547819A0532|134 143|evaluation
P11547819A0532|157 172|matter generation
P11547819A0532|179 186|ablation
P11547819A0532|204 209|tissue
P11547819A0532|211 221|measurement
P11547819A0532|224 240|ablation hole sizes
P11547819A0532|244 265|tissue penetration rates
P11547819A0532|282 292|examination
P11547819A0532|314 329|vessel wall injury
P11548027A0163|1 8|proposal
P11548027A0163|13 33|performance indicators
P11548027A0163|58 63|groups
P11548027A0163|95 104|indicators
P11548027A0163|116 125|indicators
P11548027A0163|126 130|water
P11548027A0163|134 157|service quality indicators
P11548027A0163|158 176|personnel indicators
P11548027A0163|188 197|indicators
P11550795A2583|0 13|Overexpression
P11550795A2583|16 23|RORgamma
P11550795A2583|45 49|T cell
P11550795A2583|67 75|apoptosis
P11550795A2583|78 92|T cell hybridomas
P11550795A2583|108 116|induction
P11550795A2583|119 128|Fas-ligand
P11550795A2583|132 142|interleukin
P11552058A0235|24 29|values
P11552058A0235|31 34|mm Hg
P11552058A0235|35 44|herniation
P11552058A0833|5 13|therapies
P11552058A0833|49 62|saline solution
P11552058A0833|69 100|Tris-hydroxy-methyl-aminomethane
P11552058A0833|100 105|buffer
P11552058A0833|118 129|barbiturates
P11552724A0527|0 10|CONCLUSIONS
P11552724A0527|56 64|blood flow
P11552724A0527|73 83|vessel lumen
P11552724A0527|124 130|disease
P11552724A0527|142 150|blood flow
P11552724A0527|186 198|interventions
P11552724A0527|201 208|patients
P11552724A0527|218 224|failure
P11552724A0527|227 233|allergy
P11552724A0527|252 264|contrast media
P11552922A0361|0 14|CYP2C19 genotype
P11552922A0361|33 99|polymerase chain reaction-restriction fragment length polymorphism method
P11553091A1472|3 9|results
P11553091A1472|41 49|diagnosis
P11553091A1472|60 71|relationship
P11553091A1472|105 114|correction
P11553091A1472|117 121|Class
P11553091A1472|129 140|relationship
P11553704A0674|55 64|EGFR-CD533
P11553704A0674|82 87|Ras N17
P11553704A0674|103 116|MAPK activation
P11554469A1386|5 12|analyses
P11554469A1386|23 30|question
P11554469A1386|44 52|CesA genes
P11554469A1386|59 76|cellulose synthases
P11554469A1386|104 110|members
P11554469A1386|151 159|synthases
P11554469A1386|162 167|plants
P11554566A0668|3 19|hatcher incubators
P11554566A0668|26 34|companies
P11554566A0668|118 125|company A
P11554566A0668|156 164|company B.
P11554566A0833|6 19|companies sites
P11554566A0833|65 69|Tr104
P11554566A0833|109 117|locations
P11554727A0890|3 21|mutation experiments
P11554727A0890|47 54|sequence
P11554727A0890|61 70|repression
P11554727A0890|81 94|GGGGGAGGGGAG-3
P11554727A0890|103 107|PTHSR
P11555516A0639|7 12|output
P11555516A0639|24 32|threshold
P11555516A0639|46 50|L/min
P11555516A0639|60 70|cutoff value
P11555516A0639|104 116|artery disease
P11555669A0464|0 9|Experience
P11555669A0464|25 32|sections
P11555669A0464|47 62|Vrinnevi Hospital
P11555669A0983|21 28|sections
P11555669A0983|30 36|samples
P11555669A0983|39 45|tissues
P11555669A0983|48 53|stains
P11555669A0983|69 73|pairs
P11556809A2085|32 45|enzyme activity
P11556809A2085|72 90|5-epi-aristolochene
P11556809A2085|94 109|1-deoxycapsidiol
P11556809A2085|112 120|capsidiol
P11556809A2085|145 150|notion
P11556809A2085|159 168|P450 enzyme
P11556809A2085|182 195|hydroxylations
P11556809A2085|201 220|hydrocarbon substrate
P11557127A0991|2 11|conclusion
P11557127A0991|21 35|Sp1 binding sites
P11557127A0991|64 73|expression
P11557127A0991|78 88|rat mrp2 gene
P11557127A0991|102 109|MRP2 gene
P11559366T0000|28 37|inhibition
P11559366T0000|43 75|plasminogen activator inhibitor type
P11559547T0000|15 24|regulation
P11559547T0000|48 72|pS2 breast cancer marker gene
P11559547T0000|78 86|ERR family
P11559547T0000|102 110|receptors
P11559564A0459|0 5|NB-506
P11559564A0459|27 34|capacity
P11559564A0459|37 49|topoisomerase
P11559564A0459|81 94|splicing factor
P11559564A0459|108 121|splicing factor
P11559564A0459|122 128|SF2/ASF
P11559789A0314|48 52|virus
P11559789A0314|65 85|ASF/SF2 splicing factor
P11559789A0314|91 102|progesterone
P11559789A0314|123 134|gene cassette
P11559789A0314|151 157|ASF/SF2
P11559789A0314|184 188|level
P11559789A0314|197 212|producer cell line
P11559789A0314|222 228|absence
P11559789A0314|231 237|inducer
P11559821A1315|0 15|DNA binding assays
P11559821A1315|28 39|interference
P11559821A1315|55 62|assembly
P11559821A1315|64 76|CREB-Tax-p300
P11559821A1315|93 101|complexes
P11559821A1315|108 129|repeat oligonucleotides
P11560292A0557|28 36|structure
P11560292A0557|39 49|domain model
P11560292A0557|51 62|prototype DSS
P11560292A0557|66 86|dipslide urine cultures
P11560509T0000|0 13|DNA recognition
P11560509T0000|16 28|F factor TraI36
P11560509T0000|52 58|binding
P11560990A0272|0 15|E47 protein levels
P11560990A0272|61 65|stage
P11560990A0272|73 77|point
P11560990A0272|106 111|levels
P11560990A0272|142 151|transition
P11560990A0272|171 175|stage
P11560992A0000|7 24|specificity kinases
P11560992A0000|42 54|protein kinase
P11560992A0000|61 66|kinase
P11560992A0000|90 98|molecules
P11560992A0000|123 135|stress kinases
P11560992A0000|152 165|protein kinases
P11560992A0000|166 170|SAPKs
P11560992A0000|170 174|c-Jun
P11560992A0000|185 191|kinases
P11560992A0000|200 207|response
P11560992A0000|233 239|stimuli
P11560992A0651|0 17|SAPK/JNK activation
P11560992A0651|45 51|absence
P11560992A0651|70 79|expression
P11560992A0651|117 129|mast cell lines
P11560992A0651|131 145|phosphorylation
P11560992A0651|172 179|response
P11560992A0651|189 201|stress stimuli
P11560992A1184|34 42|regulator
P11560992A1184|58 75|SAPK/JNK activation
P11560992A1184|78 86|mast cells
P11560992A1184|115 126|growth factor
P11560992A1184|129 135|antigen
P11560992A1184|151 163|proliferation
P11560992A1184|179 183|cells
P11561623A0897|8 40|copepod Pseudonychocamptus proximus
P11561623A0897|70 81|Tisbe furcata
P11561623A0897|84 94|sand filters
P11561623A0897|144 151|increase
P11561623A0897|163 169|biomass
P11561623A0897|183 188|spring
P11561626A0197|20 28|solutions
P11561626A0197|31 36|TMT-55
P11561626A0197|44 52|solutions
P11561626A0197|80 86|cadmium
P11561626A0197|92 96|salts
P11561626A0197|119 124|Zn-TMT
P11561626A0197|147 152|Cd-TMT
P11561626A0197|164 169|Pb-TMT
P11561626A0197|173 178|S3C3N3
P11562278A0169|18 22|genes
P11562278A0169|37 48|G1 regulation
P11562278A0169|80 92|proliferation
P11562278A0169|92 106|differentiation
P11562278A0169|119 132|transformation
P11562278A0169|146 154|cell death
P11562278A0169|155 163|apoptosis
P11562870A0892|3 13|probability
P11562870A0892|16 24|treatment
P11562870A0892|29 39|lamotrigine
P11562870A0892|61 66|months
P11562870A0892|83 88|months
P11562870A0892|103 107|years
P11564871A1184|5 11|results
P11564871A1184|23 30|presence
P11564871A1184|45 64|transcription systems
P11564871A1184|79 88|eukaryotes
P11564871A1184|99 105|insight
P11564871A1184|158 167|eukaryotes
P11564871A1184|181 192|TATA elements
P11564871A1184|199 207|promoters
P11564893A1068|12 17|change
P11564893A1068|20 31|conformation
P11564893A1068|36 41|repair
P11564893A1068|47 55|6RG lesion
P11564893A1068|75 89|DNA repair factor
P11564893A1068|92 113|transcription regulator
P11564893A1068|114 119|R-MGMT
P11564893A1068|139 143|sense
P11564893A1068|151 157|respond
P11564893A1068|160 167|mutagens
P11565747A1020|17 30|splicing assays
P11565747A1020|30 43|UV crosslinking
P11565747A1020|58 79|competition experiments
P11565747A1020|96 106|correlation
P11565747A1020|117 133|binding affinities
P11565747A1020|147 160|SELEX sequences
P11565747A1020|168 174|ability
P11565747A1020|185 192|splicing
P11565747A1020|195 206|P element IVS3
P11566874T0000|6 16|motor domain
P11566874T0000|31 36|dynein
P11566948A1217|14 28|nephrosclerosis
P11566948A1217|29 35|therapy
P11566948A1217|63 73|combination
P11566948A1217|96 104|incidence
P11566948A1217|112 117|events
P11566961A0472|0 18|Body weight reduction
P11566961A0472|28 45|insulin sensitivity
P11566961A0472|61 72|blood glucose
P11566961A0472|76 95|blood pressure control
P11566996A1391|29 59|nucleotide excision repair pathway
P11566996A1391|75 80|repair
P11566996A1391|95 103|DNA damage
P11566996A1391|134 143|adaptation
P11566996A1391|146 153|S. mutans
P11568988A0960|7 21|regression model
P11568988A0960|35 41|changes
P11568988A0960|82 88|culture
P11568988A0960|90 102|antibody titer
P11568988A0960|106 115|Pa elastase
P11569800T0000|0 21|Temperature measurement
P11569800T0000|36 42|systems
P11569900A0660|0 13|APC-resistance
P11569900A0660|42 47|method
P11569900A0660|56 66|sensitivity
P11569900A0660|70 80|specificity
P11569900A0660|87 107|factor V Leiden mutation
P11569949A2087|0 4|Zarix
P11569949A2087|13 29|patient enrollment
P11569949A2087|48 52|sites
P11569949A2087|62 67|Spring
P11570735A1097|0 6|RESULTS
P11570735A1097|10 17|subjects
P11570735A1097|32 44|feedback group
P11570735A1097|84 102|ground reaction force
P11570735A1097|117 126|conditions
P11570735A1097|144 152|reduction
P11570735A1097|176 184|reduction
P11570735A1097|226 232|control
P11570735A1097|235 248|feedback groups
P11570820T0000|4 15|casein kinase
P11570820T0000|17 24|isoforms
P11570820T0000|60 66|nucleus
P11570820T0000|70 78|cytoplasm
P11572377T0000|18 29|lithotripter
P11572377T0000|63 77|cavitation field
P11572388A0000|4 8|paper
P11572388A0000|21 27|results
P11572388A0000|39 43|study
P11572388A0000|49 59|application
P11572388A0000|68 95|solvation energy relationships
P11572388A0000|96 100|LSERs
P11572388A0000|106 115|prediction
P11572388A0000|134 142|compounds
P11572388A0000|186 202|method development
P11572467A0658|7 15|blood clot
P11572467A0658|37 42|cavity
P11572467A0658|55 63|injection
P11572467A0658|82 92|plasminogen
P11572467A0658|94 100|plasmin
P11572467T0000|0 9|Management
P11572467T0000|42 51|hemorrhage
P11572467T0000|56 81|tissue plasminogen activator
P11572467T0000|91 96|volume
P11572467T0000|118 126|exchanger
P11573771T0000|0 5|Effect
P11573771T0000|8 21|heat treatments
P11573771T0000|27 37|meltability
P11573771T0000|40 46|cheeses
P11573891A0525|0 6|RESULTS
P11573891A0525|30 38|Americans
P11573891A0525|49 66|community outbreaks
P11573891A0525|104 109|whites
P11573891A0525|127 135|exposures
P11574088A1687|34 51|pancreas transplant
P11574088A1687|85 97|PAK recipients
P11574105A0727|0 7|Patients
P11574105A0727|12 24|antibody peaks
P11574105A0727|50 57|increase
P11574105A0727|60 72|antibody titer
P11574105A0727|92 104|antibody titer
P11574105A0727|112 117|course
P11574105A0727|134 149|disability scores
P11574105A0727|166 170|weeks
P11574105A0727|195 201|outcome
P11574105A0727|226 241|IgM antibody peaks
P11574105A0727|250 255|damage
P11574105A0727|265 280|IgM antibody peaks
P11574105A0727|291 298|patients
P11574105A0727|310 323|antibody titers
P11575109A0214|9 16|baseline
P11575109A0214|25 35|examination
P11575109A0214|57 63|therapy
P11575109A0214|66 73|patients
P11575109A0214|94 100|surgery
P11575109A0214|117 122|grafts
P11575109A0214|126 134|treatment
P11575109A0214|157 163|gingiva
P11575977A1133|7 14|patients
P11575977A1133|27 44|office hypertension
P11575977A1133|75 87|complications
P11576158A1371|5 16|TVD-patients
P11576158A1371|28 40|skin blood flow
P11576158A1371|74 81|controls
P11576776T0081|11 16|moduli
P11576776T0081|19 43|microcrystalline cellulose
P11577094A1226|5 12|findings
P11577094A1226|44 55|HSAL2 pathway
P11577094A1226|71 81|development
P11577094A1226|84 96|hematopoiesis
P11578685A0077|0 5|ICAM-1
P11578685A0077|23 31|predictor
P11578685A0077|37 41|onset
P11579100T0000|0 21|Phosphotyrosyl peptides
P11579100T0000|41 58|DNA binding activity
P11579100T0000|59 72|gene regulation
P11579100T0000|76 93|cell transformation
P11580173A0181|0 16|Plane wave geometry
P11580173A0181|52 58|results
P11580173A0181|101 115|P3 approximation
P11580173A0181|128 135|geometry
P11580173A0181|151 155|paper
P11580301A1161|3 11|diagnosis
P11580301A1161|14 25|HCV arthritis
P11580301A1161|28 35|patients
P11580301A1161|58 63|factor
P11580301A1161|86 98|polyarthritis
P11580757A0304|0 6|METHODS
P11580757A0304|34 45|TFCD patients
P11580757A0304|58 64|surgery
P11580757A0304|79 86|epilepsy
P11580757A0304|120 128|resonance
P11580757A0304|141 146|lesion
P11580757A0304|212 221|recordings
P11580941A0815|0 6|RESULTS
P11580941A0815|15 25|examination
P11580941A0815|30 36|UPDRS II
P11580941A0815|40 48|III scores
P11580941A0815|68 78|stimulation
P11580941A0815|81 87|therapy
P11580941A0815|99 108|% reduction
P11583621A0301|24 30|stimuli
P11583621A0301|40 49|expression
P11583621A0301|70 77|cleavage
P11583621A0301|88 92|delta
P11583621A0301|117 121|delta
P11583621A0301|151 157|complex
P11583880T0000|12 25|aneurysm repair
P11583880T0000|33 49|AneuRx stent-graft
P11584107T0000|18 25|diseases
P11584107T0000|38 43|origin
P11584107T0000|46 55|assessment
P11584107T0000|66 70|field
P11584328A0532|0 15|Drug interactions
P11584328A0532|33 37|drugs
P11584328A0532|59 74|CYP450 isoenzymes
P11584328A0532|77 83|statins
P11585856A0285|0 6|METHODS
P11585856A0285|27 33|benefit
P11585856A0285|75 92|scanning line source
P11585856A0285|94 110|scatter correction
P11585856A0285|111 130|photon energy recovery
P11585856A0285|156 169|backprojection
P11586096A0699|9 19|differences
P11586096A0699|22 43|patient characteristics
P11586096A0699|44 62|control measurements
P11586096A0699|85 90|muscle
P11586096A0699|96 103|patients
P11587514A0758|10 26|abi1-1 gene product
P11587514A0758|32 37|effect
P11587514A0758|43 56|ABA suppression
P11587514A0758|73 89|alpha-amylase gene
P11587980A1039|2 9|children
P11587980A1039|41 49|maneuvers
P11587980A1039|61 68|contrary
P11587980A1039|72 91|interrupter technique
P11587980A1039|110 117|subgroup
P11587980A1039|125 132|children
P11587980A1039|141 156|resistance values
P11587980A1039|159 166|baseline
P11587980A1039|193 207|bronchodilation
P11589568A0744|9 13|yeast
P11589568A0744|24 41|checkpoint response
P11589568A0744|53 64|proteins Mad1
P11589568A0744|97 108|counterparts
P11589568A0744|127 138|kinetochores
P11589779T0000|0 5|HTLV-1
P11589779T0000|15 21|Th2 type
P11589779T0000|30 37|response
P11589779T0000|40 47|patients
P11589779T0000|52 67|strongyloidiasis
P11590364A1056|10 28|beta5L splice variant
P11590364A1056|46 51|retina
P11592315A0325|0 8|PROCEDURE
P11592315A0325|9 16|Cannulas
P11592315A0325|70 75|antrum
P11592532A0188|0 6|METHODS
P11592532A0188|7 32|Humphrey Field Analyzer model
P11592532A0188|42 48|program
P11592532A0188|69 75|degrees
P11592532A0188|78 88|degrees grid
P11592532A0188|123 128|method
P11593394A0000|12 28|growth factor-beta
P11593394A0000|29 36|TGF-beta
P11593394A0000|44 55|growth arrest
P11593394A0000|58 62|cells
P11593394A0000|71 80|regulation
P11593394A0000|86 95|activities
P11593394A0000|114 134|cyclin kinase complexes
P11593394A0000|167 176|regulation
P11593394A0000|183 187|Ink4b
P11593394A0000|200 221|cyclin kinase inhibitors
P11595170A0582|0 8|Alignment
P11595170A0582|20 24|cDNAs
P11595170A0582|30 34|NR5A2
P11595170A0582|61 68|sequence
P11595170A0582|81 91|delineation
P11595170A0582|107 118|organization
P11595170A0582|158 162|exons
P11595170A0582|180 186|introns
P11595176T0000|10 18|structure
P11595176T0000|29 37|SPEC1 gene
P11595176T0000|52 59|splicing
P11595176T0000|63 84|close promoter proximity
P11595176T0000|90 110|AF1q translocation gene
P11595478A1014|12 20|relatives
P11595478A1014|29 34|cancer
P11595478A1014|53 62|prevalence
P11595478A1014|65 71|atrophy
P11595478A1014|85 96|Hp negativity
P11595478A1014|104 118|cancer relatives
P11595813A0633|10 19|metabolism
P11595813A0633|22 30|androgens
P11595813A0633|36 40|place
P11595813A0633|50 54|areas
P11595813A0633|101 111|differences
P11595813A0633|116 125|activities
P11595813A0633|128 136|aromatase
P11595813A0633|137 152|5alpha-reductase
P11595813A0633|166 173|presence
P11595813A0633|179 195|androgen receptors
P11595840A0000|3 8|uptake
P11595840A0000|22 39|fluorodeoxyglucose
P11595840A0000|40 46|F-18 FDG
P11595840A0000|59 63|tumor
P11595840A0000|76 92|blood glucose level
P11596104A0614|0 19|Northern blot analysis
P11596104A0614|32 37|PARNAs
P11596104A0614|61 66|signal
P11596104A0614|85 93|kilobases
P11596104A0614|110 118|cell lines
P11596838A1357|4 11|analysis
P11596838A1357|30 50|fluticasone propionate
P11596838A1357|52 57|microg
P11596838A1357|80 88|treatment
P11596838A1357|91 98|patients
P11596838A1357|113 118|asthma
P11596838A1357|152 164|beta2-agonist
P11597185A0477|32 45|metapopulation
P11597185A0477|53 58|models
P11597185A0477|62 80|computer simulations
P11597185A0477|124 130|regimes
P11597185A0477|133 154|metapopulation dynamics
P11597936A0570|5 15|CAD patients
P11597936A0570|42 49|patients
P11597936A0570|60 64|years
P11597936A0570|64 71|baseline
P11597936A0570|75 92|density lipoprotein
P11597936A0570|95 99|mg/dL
P11597936A0570|103 115|triglycerides
P11597936A0570|119 123|mg/dL
P11597936A0570|167 171|drugs
P11597936A0570|186 193|controls
P11599079A1040|16 30|orifice voltages
P11599079A1040|42 52|instruments
P11599797A0732|0 6|RESULTS
P11599840A0813|3 8|moduli
P11599840A0813|11 20|elasticity
P11599840A0813|38 43|matter
P11599840A0813|74 82|deviation
P11599840A0813|105 111|section
P11599840A0813|146 152|section
P11599840A0813|192 198|section
P11600252A0795|65 70|series
P11600252A0795|109 114|change
P11600252A0795|117 125|mortality
P11600314A0000|13 24|polarography
P11600314A0000|40 44|pulse
P11600314A0000|58 64|methods
P11600314A0000|119 126|analysis
P11600314A0000|129 137|vitamin B1
P11600365A0471|20 28|organisms
P11600365A0471|29 34|E-4767
P11600365A0471|38 43|E-5065
P11600365A0471|87 98|tosufloxacin
P11600365A0471|124 141|reference compounds
P11600467A1436|30 39|alteration
P11600467A1436|57 68|permeability
P11602353A0770|13 21|HNF-3 beta
P11602353A0770|22 26|HFH-1
P11602353A0770|27 31|HFH-2
P11602353A0770|32 36|HFH-3
P11602353A0770|37 41|C/EBP
P11602353A0770|45 53|C/EBP beta
P11602353A0770|99 116|expression profiles
P11603271T0001|8 14|vertigo
P11603271T0001|18 33|vertigo syndromes
P11604152A0526|12 23|MCBFV signals
P11604152A0526|27 34|bandpass
P11604152A0526|65 69|range
P11604152A0526|88 105|low-frequency range
P11604152A0526|137 141|range
P11604152A0526|181 187|purpose
P11604152A0526|198 203|effect
P11604152A0526|215 224|bandwidths
P11604152A0526|239 246|mean CCFs
P11605207T0001|0 8|Treatment
P11605207T0001|19 30|heart disease
P11605598A0785|0 9|Hepatitis B
P11605598A0785|13 32|C seroprevalence rates
P11605598A0785|47 57|adolescents
P11605598A0785|68 73|El Paso
P11605598A0785|92 104|US populations
P11605598A0785|122 128|climate
P11605598A0785|132 149|prevention programs
P11606538A1002|8 16|insertion
P11606538A1002|28 32|genes
P11606538A1002|52 73|receptor tyrosine kinase
P11606538A1002|94 107|neuropeptidase
P11614398T0000|9 14|people
P11614398T0000|31 37|aspects
P11614398T0000|40 48|Mormonism
P11639485A0478|82 90|languages
P11639485A0478|95 101|benefit
P11639485A0478|114 124|day students
P11639485A0478|128 135|scholars
P11642687T0000|0 9|Comparison
P11642687T0000|18 33|language versions
P11642687T0000|39 44|QWB-SA
P11642687T0000|48 52|SF-36
P11642687T0000|63 70|outcomes
P11642687T0000|74 81|patients
P11642687T0000|86 100|prostate disease
P11653491T0000|12 17|action
P11653491T0000|21 32|DNA violation
P11669281A0653|10 21|cytotoxicity
P11669281A0653|32 42|antibiotics
P11669281A0653|60 67|evidence
P11669281A0653|70 80|competition
P11669281A0653|83 91|synergism
P11669476A0346|16 23|cytokine
P11669476A0346|24 48|tumor necrosis factor-alpha
P11669476A0346|49 57|TNF-alpha
P11669476A0346|77 83|tissues
P11669476A0346|91 98|subjects
P11669476A0346|140 156|insulin resistance
P11675912A0131|8 14|alcohol
P11675912A0131|60 70|preparation
P11675912A0131|80 86|aspirin
P11675912A0131|90 102|acetaminophen
P11675912A0131|106 116|alleviation
P11675912A0131|119 127|headaches
P11676899A0704|16 26|risk factors
P11676899A0704|51 55|virus
P11676899A0704|66 78|mononucleosis
P11676899A0704|101 116|immunodeficiency
P11676899A0704|130 137|exposure
P11676899A0704|141 152|wood industry
P11677363A0775|16 22|finding
P11677363A0775|37 45|IMT values
P11677363A0775|63 66|h SBP
P11677363A0775|81 89|deviation
P11677363A0775|99 105|measure
P11677363A0775|121 133|PP variability
P11677839A0876|3 12|difference
P11677839A0876|23 30|patients
P11677839A0876|37 44|controls
P11678437A0000|3 8|effect
P11678437A0000|16 26|oil spillage
P11678437A0000|29 34|growth
P11678437A0000|35 46|productivity
P11678437A0000|50 63|nutrient uptake
P11678437A0000|66 70|maize
P11678437A0000|71 79|Zea mays L.
P11678437A0000|94 106|pot experiment
P11678437A0000|121 134|manifold sample
P11678437A0000|138 164|petroleum development company
P11678437A0000|182 188|gravity
P11679441A0429|0 12|NO metabolites
P11679441A0429|32 42|measurement
P11679441A0429|45 59|nitrate/nitrite
P11679441A0429|65 87|micromol/mmol creatinine
P11679441A0429|96 117|guanosine monophosphate
P11679441A0429|124 142|nmol/mmol creatinine
P11679441A0429|144 149|plasma
P11679441A0429|153 157|urine
P11680835A0756|14 21|analysis
P11680835A0756|33 37|costs
P11680835A0756|41 47|patient
P11680835A0756|83 93|pamidronate
P11683558A0446|11 18|migrants
P11683558A0446|36 49|macronutrients
P11683558A0446|61 74|micronutrients
P11683558A0446|75 85|differences
P11684665A0000|0 21|C. elegans embryogenesis
P11684665A0000|44 51|sequence
P11684665A0000|64 76|cell divisions
P11684665A0000|120 135|nematode body plan
P11685047A0301|19 24|method
P11685047A0301|39 56|thrombin inhibition
P11685047A0301|63 77|substrate S-2238
P11685284X0000|0 11|Diabetologia
P11685284X0000|18 22|Suppl
P11685284X0000|24 30|B37-B44
P11686239A0464|12 19|sequence
P11686239A0464|25 30|3B gene
P11686239A0464|75 83|stretches
P11686239A0464|121 138|sequence similarity
P11686239A0464|144 149|G boxes
P11686239A0464|194 211|Dictyostelium genes
P11686378A0326|18 24|reactor
P11686378A0326|52 60|discharge
P11686378A0326|78 83|values
P11686378A0326|111 124|concentrations
P11686378A0326|130 134|range
P11686378A0326|145 155|E coli/cfu mL
P11686378A0326|191 197|Pn decay
P11686378A0326|219 226|colonies
P11686378A0326|239 248|phenomenon
P11686378A0326|262 266|cells
P11686378A0326|296 302|numbers
P11686378A0326|311 315|cells
P11687083A0218|0 9|OBJECTIVES
P11687083A0218|13 21|objective
P11687083A0218|28 33|review
P11687083A0218|48 54|effects
P11687083A0218|57 84|prophylactic prostaglandin use
P11687083A0218|95 99|stage
P11687083A0218|102 107|labour
P11687180A3209|15 23|questions
P11687180A3209|58 63|rHu EPO
P11687180A3209|70 75|speeds
P11687180A3209|80 85|delays
P11687180A3209|89 93|onset
P11687180A3209|96 103|dialysis
P11687352A0215|0 6|METHODS
P11687352A0215|24 29|review
P11687352A0215|56 60|LASIK
P11687352A0215|67 75|September
P11687352A0215|83 91|September
P11687517A1619|2 6|ISREs
P11687517A1619|29 41|mouse promoter
P11687737A0000|0 9|BACKGROUND
P11687737A0000|18 29|heart disease
P11687737A0000|42 46|cause
P11687737A0000|49 57|morbidity
P11687737A0000|61 69|mortality
P11687737A0000|75 83|diabetics
P11687869A0000|12 16|woman
P11687869A0000|31 37|colitis
P11687869A0000|59 69|sarcoidosis
P11689217T0000|0 30|Cholesteryl ester transfer protein
P11689217T0000|34 48|atherosclerosis
P11689217T0000|59 66|subjects
P11689217T0000|68 72|study
P11689217T0000|88 98|angiography
P11691585A1174|15 33|mobility shift assays
P11691585A1174|37 64|coimmunoprecipitation studies
P11691585A1174|85 102|heterodimerization
P11691585A1174|115 132|cKrox family members
P11691585T0000|3 18|hcKrox gene family
P11691585T0000|49 59|matrix genes
P11692004A1200|1 6|review
P11692004A1200|12 21|literature
P11692004A1200|54 60|studies
P11692004A1200|90 101|relationship
P11692004A1200|129 137|aneurysms
P11693461A1649|5 19|utilisation data
P11693461A1649|31 39|drug costs
P11693461A1649|45 49|range
P11693461A1649|81 94|TNF antagonists
P11693461A1649|111 120|population
P11695481A0310|8 17|conditions
P11695481A0310|21 36|combination O3/UV
P11695481A0310|53 67|degradation rate
P11695481A0310|78 86|ozonation
P11697760A0000|4 8|study
P11697760A0000|28 32|boron
P11697760A0000|48 54|ability
P11697760A0000|57 72|17beta-estradiol
P11697760A0000|90 96|hormone
P11697760A0000|110 120|bone quality
P11697760A0000|136 142|OVX rats
P11703464A0560|19 30|subjects rCBF
P11703464A0560|42 48|regions
P11703464A0560|100 107|circuits
P11703464A0560|110 117|response
P11703464A0560|132 137|reward
P11703464A0560|152 164|reinforcement
P11703558A0000|0 10|Doxorubicin
P11703558A0000|36 44|treatment
P11703558A0000|67 72|tumors
P11704380A1608|3 11|event rate
P11704380A1608|14 21|patients
P11704380A1608|33 40|Irr-rMFP
P11704380A1608|43 50|Un-nrMFP
P11704380A1608|88 95|Rev-rMFP
P11704380A1608|98 106|Sta-nrMFP
P11704829A0312|0 23|Subtraction hybridization
P11704829A0312|34 56|melanoma differentiation
P11704829A0312|67 72|gene-7
P11704829A0312|73 77|mda-7
P11704829A0312|118 124|changes
P11704829A0312|131 143|melanoma cells
P11705093A2016|9 26|vitamin D3 analogues
P11705093A2016|56 61|effect
P11706668A0000|0 9|Hydrocoele
P11706668A0000|54 58|areas
P11706668A0000|61 69|treatment
P11706668A0000|97 108|intervention
P11706949T0000|0 12|Growth hormone
P11706949T0000|28 49|growth factor I receptors
P11706949T0000|72 76|joint
P11707977A0750|31 45|infusion therapy
P11707977A0750|56 63|survival
P11707977A0750|66 75|H3 patients
P11708032A0183|2 9|addition
P11708032A0183|48 55|infusion
P11708032A0183|58 69|levoforinate
P11708032A0183|86 99|5-fluorouracil
P11708032A0183|137 146|metastases
P11708032A0183|183 193|medications
P11708032A0183|215 219|hours
P11708032A0183|232 242|infuser pump
P11708362A0889|3 15|astronaut crew
P11708362A0889|27 33|payload
P11708362A0889|49 57|operation
P11708431A0904|8 15|patients
P11708431A0904|19 30|introduction
P11708431A0904|42 49|category
P11708431A0904|58 71|oligoarthritis
P11708431A0904|74 78|onset
P11708431A0904|118 130|patient groups
P11708761A1388|23 28|number
P11708761A1388|31 39|arguments
P11708761A1388|59 71|ACE inhibitors
P11708761A1388|82 89|patients
P11708761A1388|94 109|diabetes mellitus
P11709561T0000|0 4|Phase
P11709561T0000|7 11|trial
P11709561T0000|36 46|antibody 3F8
P11709561T0000|89 94|factor
P11709561T0000|98 110|neuroblastoma
P11709890T0000|0 9|Hepatitis A
P11709890T0000|18 28|food handler
P11709890T0000|33 40|Edmonton
P11709890T0000|41 47|Alberta
P11709890T0000|54 65|food facility
P11709890T0000|72 97|health protection strategies
P11710233T0000|0 8|Hydrogels
P11710233T0000|12 28|tissue engineering
P11710685A0994a|14 19|subset
P11710685A0994a|22 26|ASCUS
P11710685A0994a|37 50|ASCUS/SIL ratio
P11710685A0994a|84 94|sensitivity
P11710685A0994a|100 115|Papanicolaou test
P11710685A0994b|14 19|subset
P11710685A0994b|22 26|ASCUS
P11710685A0994b|37 50|ASCUS/SIL ratio
P11710685A0994b|84 94|sensitivity
P11710685A0994b|100 115|Papanicolaou test
P11711701A0602|10 27|medicine physicians
P11711701A0602|48 55|findings
P11711701A0602|79 84|images
P11711701A0602|95 121|Tc-99m MIBI image combinations
P11711701A0602|126 132|minutes
P11711701A0602|140 146|minutes
P11711701A0602|151 155|hours
P11711701A0602|158 164|minutes
P11711701A0602|169 173|hours
P11711701A0602|179 185|minutes
P11711701A0602|194 198|hours
P11711701A0602|228 254|pertechnetate thyroid imaging
P11714429X0000|2 12|clopidogrel
P11714429X0000|23 29|aspirin
P11714429X0000|41 50|prevention
P11714429X0000|61 67|disease
P11714429X0000|83 93|cornerstone
P11714429X0000|104 111|evidence
P11714429X0000|125 132|efficacy
P11714429X0000|135 149|thienopyridines
P11714429X0000|150 160|clopidogrel
P11714429X0000|161 171|ticlopidine
P11714429X0000|178 184|aspirin
P11714429X0000|199 208|prevention
P11714429X0000|219 225|disease
P11714429X0000|231 241|Clopidogrel
P11714429X0000|248 254|Aspirin
P11714429X0000|257 264|Patients
P11714429X0000|284 294|Events trial
P11715079A1016|17 30|proprioception
P11715079A1016|54 66|efference copy
P11715079A1016|73 83|development
P11715079A1016|89 96|response
P11715079A1016|99 111|perturbations
P11715079A1016|132 141|mismatches
P11715079A1016|149 170|eye movement information
P11715079A1016|193 199|command
P11715079A1016|212 217|motion
P11715079A1016|257 262|organs
P11716043A0380|21 28|patients
P11716043A0380|38 44|surgery
P11716043A0380|65 74|Department
P11716043A0380|76 82|Surgery
P11716043A0380|83 115|Helsinki University Central Hospital
P11716441A0585|16 25|physiology
P11716441A0585|35 50|health evaluation
P11716441A0585|51 56|APACHE
P11716441A0585|71 79|admission
P11718197A1282|3 11|procedure
P11722993A0276|0 10|Paul Monagle
P11722993A0276|23 34|epidemiology
P11722993A0276|45 54|thrombosis
P11722993A0276|81 86|system
P11722993A0276|110 118|locations
P11722993A0276|138 142|utero
P11723500X0000|26 40|characteristics
P11723500X0000|51 63|cell carcinoma
P11723500X0000|73 78|cavity
P11723500X0000|81 85|women
P11723500X0000|86 95|BACKGROUND
P11723500X0000|104 116|cell carcinoma
P11723500X0000|131 136|cavity
P11723500X0000|157 166|population
P11723511A0780|31 35|drugs
P11723511A0780|53 65|category A risk
P11723511A0780|78 86|category B
P11723511A0780|99 107|category C
P11723511A0780|117 125|category D
P11723511A0780|137 146|category X.
P11723675A1022|3 10|severity
P11723675A1022|21 26|course
P11723675A1022|41 45|means
P11723675A1022|48 56|SOFA score
P11723675A1022|57 62|group A
P11723675A1022|69 75|.3 point
P11723675A1022|76 81|group B
P11723675A1022|91 95|point
P11723675A1022|96 101|group C
P11723675A1022|113 117|point
P11723675A1022|120 132|APACHE II score
P11723675A1022|133 138|group A
P11723675A1022|148 152|point
P11723675A1022|153 158|group B
P11723675A1022|170 174|point
P11723675A1022|175 180|group C
P11723675A1022|195 199|point
P11723928A0294|3 9|process
P11723928A0294|29 44|river reclamation
P11723928A0294|47 60|Yangpu District
P11723928A0294|63 74|Shanghai City
P11723928A0294|75 79|China
P11724510T0000|8 17|principles
P11724510T0000|31 39|apheresis
P11726022A0909|5 11|results
P11726022A0909|31 39|estimates
P11726022A0909|42 52|penetration
P11726022A0909|69 80|calculations
P11726022A0909|95 110|time calculations
P11726022A0909|143 147|model
P11726068A0539|12 16|study
P11726068A0539|21 31|conclusions
P11726164A0215|7 13|concern
P11726164A0215|16 29|food processors
P11726164A0215|46 58|cross-contact
P11726164A0215|61 72|food products
P11726164A0215|87 94|residues
P11726164A0215|140 148|reactions
P11726164A0215|161 171|food allergy
P11726262A0692|0 22|Lactate accumulation peak
P11726262A0692|38 52|supplementation
P11726413A1756|12 20|clearance
P11726413A1756|36 42|infants
P11726413A1756|47 54|contrast
P11726413A1756|62 68|opioids
P11726574A1304|5 11|results
P11726574A1304|24 30|changes
P11726574A1304|36 54|baseline assumptions
P11726574A1304|60 64|model
P11727073A0842|0 9|CONCLUSION
P11727073A0842|13 20|training
P11727073A0842|23 29|novices
P11727073A0842|35 47|MIST-VR yields
P11727073A0842|60 66|changes
P11727073A0842|69 73|skill
P11727073A0842|130 136|results
P11727073A0842|160 167|training
P11727209A0502|3 10|patients
P11727209A0502|19 26|families
P11727209A0502|63 73|examination
P11727209A0502|92 102|orthostasia
P11728771A0187|36 43|reaction
P11728771A0187|50 65|contrast material
P11730182A0984|33 43|correlation
P11730182A0984|76 87|pollen levels
P11730182A0984|90 101|Philadelphia
P11730182A0984|107 116|Cherry Hill
P11730182A0984|134 140|Quercus
P11730182A0984|149 154|Betula
P11730182A0984|164 168|Pinus
P11730182A0984|178 189|Cupressaceae
P11730182A0984|199 205|Poaceae
P11730182A0984|215 222|Ambrosia
P11730182A0984|235 239|Rumex
P11730262A0874|18 22|study
P11730262A0874|28 46|etidronate/fluoride
P11730262A0874|66 77|osteoporosis
P11730262A0874|90 99|pilot study
P11730262A0874|137 148|osteoporosis
P11730262A0874|164 173|etidronate
P11730262A0874|195 202|fluoride
P11730262A0874|206 221|calcium/vitamin D
P11730712A0416|0 16|Treadmill training
P11730712A0416|28 32|weeks
P11730712A0416|45 58|infarction size
P11730712A0416|62 66|edema
P11730712A0416|75 86|MCA occlusion
P11732088A0471|2 6|order
P11732088A0471|33 40|readings
P11732088A0471|58 75|sphincter manometry
P11732088A0471|91 98|secretin
P11732088A0471|119 128|ultrasound
P11732088A0471|129 133|SSEUS
P11732088A0471|159 166|response
P11732088A0471|181 186|method
P11732088A0471|208 216|diagnosis
P11732417A0571|10 34|percentage positivity value
P11732417A0571|103 114|serum samples
P11732417A0571|128 136|reference
P11732417A0571|142 151|sample data
P11732417A0571|168 175|ELISA kit
P11736254A0000|2 9|analysis
P11736254A0000|15 22|dynamics
P11736254A0000|51 56|models
P11736254A0000|76 82|glasses
P11736254A0000|96 107|partitioning
P11736254A0000|124 132|landscape
P11736254A0000|143 152|structures
P11736792A0204|9 20|semen samples
P11736792A0204|39 43|study
P11736792A0204|89 119|World Health Organization criteria
P11736792A0204|127 136|morphology
P11736792A0204|171 178|criteria
P11737056A0680|6 14|timepoint
P11737056A0680|19 28|leucocytes
P11737056A0680|41 48|ET mucosa
P11737056A0680|94 100|subsets
P11737158A1517|17 21|areas
P11737158A1517|31 38|Wernicke
P11737158A1517|43 55|fusiform gyrus
P11737158A1517|56 64|Broca BA44
P11737158A1517|78 82|gyrus
P11737158A1517|102 113|computations
P11737158A1517|130 136|contact
P11737158A1517|158 167|dimensions
P11737900A0700|9 19|correlation
P11737900A0700|27 35|plasma COP
P11737900A0700|39 48|body weight
P11738404A0120|5 22|chemical structures
P11738404A0120|40 44|alpha
P11738404A0120|46 81|alpha-diacetoxy-8 beta-isobutanoyloxy
P11738404A0120|83 101|alpha-benzoyloxy-13
P11738404A0120|101 112|alpha-methyl
P11738404A0120|112 128|butanoyloxy-4 beta
P11738404A0120|130 166|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|169 173|alpha
P11738404A0120|175 195|alpha-diacetoxy-8 beta
P11738404A0120|201 216|furancarbonyloxy
P11738404A0120|217 256|alpha-benzoyloxy-13-isobutanoyloxy-4 beta
P11738404A0120|258 294|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|300 304|alpha
P11738404A0120|313 389|alpha,13-tetraacetoxy-9 alpha-benzoyloxy-2 alpha-hydroxy-beta-dihydroagarofuran
P11738404A0120|398 408|analyses NMR
P11740571A0114|4 9|toxins
P11740571A0114|39 45|maximum
P11740571A0114|56 68|concentration
P11740571A0114|78 85|activity
P11740571A0114|88 108|glutathione peroxidase
P11740571A0114|111 121|brain tissue
P11740571A0114|130 136|toluene
P11740571A0114|146 171|chemiluminescence intensity
P11740571A0114|187 196|activation
P11740571A0114|210 218|processes
P11740806X0810|0 14|Saunders Company
P11741259A1233|3 13|performance
P11741259A1233|28 36|particles
P11741259A1233|56 62|ability
P11741259A1233|113 121|intestine
P11741554T0000|0 9|Comparison
P11741554T0000|24 43|lipoprotein particles
P11741554T0000|60 64|women
P11741554T0000|87 99|artery disease
P11741554T0000|122 134|artery disease
P11742432A0798|7 13|results
P11742432A0798|32 37|trials
P11742432A0798|53 60|efficacy
P11742432A0798|73 86|MAC prophylaxis
P11742432A0798|89 96|patients
P11742432A0798|115 125|combination
P11742432A0798|140 146|therapy
P11742432A0798|162 170|incidence
P11742432A0798|201 212|colonization
P11742432A0798|229 233|tract
P11742432A0798|240 244|trial
P11742432A0798|256 270|discontinuation
P11742432A0798|273 292|macrolide prophylaxis
P11742432A0798|298 309|AIDS patients
P11742432A0798|315 323|CD4 counts
P11742432A0798|341 352|cells/microL
P11743360A2491|5 10|stress
P11743360A2491|36 45|mean amount
P11743360A2491|66 70|urine
P11743612A1179|0 7|Patients
P11743612A1179|19 31|meconium ileus
P11743612A1179|56 61|status
P11743612A1179|64 72|diagnosis
P11743612A1179|82 93|survival rate
P11743612A1179|114 125|CF population
P11744290T0045|0 8|Cactaceae
P11744290T0045|9 19|waste matter
P11744953A0878|0 10|Skin cancers
P11744953A0878|37 41|tract
P11744953A0878|56 61|system
P11744953A0878|81 91|age patients
P11752821A1365|0 9|CONCLUSION
P11752821A1365|18 22|g/day
P11752821A1365|42 46|signs
P11752821A1365|62 80|Adamantiades-Behcet
P11752821A1365|82 88|disease
P11755894A0466|5 13|treatment
P11755894A0466|27 34|patients
P11755894A0466|47 53|surgery
P11755894A0466|65 71|opioids
P11755894A0466|119 128|management
P11755894A0466|141 145|ileus
P11755894A0466|187 199|bowel function
P11755894A0466|211 222|hospital stay
P11760398A0553|0 6|METHODS
P11760398A0553|21 28|patients
P11760398A0553|43 50|patients
P11760398A0553|74 83|conditions
P11760398A0553|102 109|presence
P11760398A0553|112 118|absence
P11760398A0553|124 131|features
P11760398A0553|140 144|means
P11760398A0553|192 202|ISG criteria
P11760796A0698|0 7|Evidence
P11760796A0698|20 33|PHACES syndrome
P11760796A0698|46 56|association
P11760796A0698|65 76|phakomatosis
P11760796A0698|84 90|studies
P11760796A0698|107 111|light
P11760796A0698|130 139|background
P11761601A0133|1 15|computer program
P11761601A0133|16 25|ACCESS-IAQ
P11761601A0133|50 63|airflow pattern
P11761601A0133|67 77|time history
P11761601A0133|83 107|contaminant concentrations
P11761601A0133|133 151|inhalation exposures
P11763176A0918|15 22|decrease
P11763176A0918|25 44|antithrombin activity
P11763176A0918|68 78|experiments
P11763176A0918|83 92|experiment
P11764062A0000|3 29|Penn State Worry Questionnaire
P11764062A0000|33 40|Children
P11764062A0000|41 46|PSWQ-C
P11764062A0000|57 80|self-report questionnaire
P11764062A0000|104 111|tendency
P11764062A0000|114 121|children
P11764062A0000|169 173|worry
P11764062A0000|174 181|Chorpita
P11764062A0000|187 191|Behav
P11764226A0798|0 13|Classification
P11764226A0798|28 39|ILAR criteria
P11764226A0798|56 63|patients
P11764226A0798|67 74|patients
P11764226A0798|79 93|disease duration
P11764226A0798|99 104|months
P11764226A0798|136 148|EULAR criteria
P11765448A0588|9 23|X-ray projection
P11765448A0588|41 48|patients
P11766747A0000|33 38|review
P11766747A0000|45 52|patients
P11766747A0000|72 79|teratoma
P11768467A0000|0 21|Pyrethroid insecticides
P11768467A0000|37 47|agriculture
P11768467A0000|58 67|households
P11769229A0357|3 20|sorption mechanisms
P11769229A0357|32 41|adsorption
P11769229A0357|44 52|partition
P11769229A0357|58 64|process
P11769229A0357|78 85|sorption
P11771979A1141|29 39|variability
P11771979A1141|42 51|LDF signals
P11771979A1141|75 83|microflow
P11771979A1141|95 99|range
P11771979A1141|111 117|methods
P11771979A1141|128 133|organs
P11771979A1141|154 160|mapping
P11771979A1141|200 212|heterogeneity
P11771979A1141|233 243|vasculature
P11773168A0915|16 23|survival
P11773168A0915|47 54|survival
P11773168A0915|59 63|rates
P11773168A0915|85 88|arm A
P11773168A0915|108 111|arm B
P11773921A0397|0 6|METHODS
P11773921A0397|7 26|P-selectin expression
P11773921A0397|59 67|platelets
P11773921A0397|108 118|clopidogrel
P11773921A0397|158 165|patients
P11773921A0397|176 188|artery disease
P11773921A0397|191 198|patients
P11773921A0397|201 205|group
P11773921A0397|224 234|clopidogrel
P11773921A0397|244 255|implantation
P11773921A0397|261 268|patients
P11773921A0397|271 275|group
P11773921A0397|300 310|clopidogrel
P11773921A0397|356 366|clopidogrel
P11773921A0397|371 376|groups
P11775180A0379|19 29|exploration
P11775180A0379|43 48|survey
P11775180A0379|54 73|gamma-detecting probe
P11775301A0797|2 7|effect
P11775301A0797|13 24|intervention
P11775301A0797|27 42|depression scores
P11776922A0830|12 20|sclerosis
P11776922A0830|24 33|resorption
P11776922A0830|39 47|skull base
P11776922A0830|49 53|cases
P11776922A0830|55 59|group
P11776922A0830|61 67|lesions
P11776922A0830|72 76|group
P11776922A0830|79 85|lesions
P11777575A0363|3 10|quantity
P11777575A0363|17 26|population
P11777575A0363|29 38|bulgaricus
P11777575A0363|39 52|S. thermophilus
P11777575A0363|74 79|pellet
P11777575A0363|130 137|networks
P11777632A1678|35 41|pattern
P11777632A1678|43 52|expression
P11777632A1678|89 97|component
P11777632A1678|109 114|breast
P11777632A1678|124 130|lesions
P11777632A1678|158 169|AF expression
P11777632A1678|196 207|breast cancer
P11777632A1678|218 223|stroma
P11778044A0000|13 43|probability density distributions
P11778044A0000|64 73|properties
P11778044A0000|79 91|climate system
P11778044A0000|106 127|fingerprinting approach
P11778044A0000|137 147|simulations
P11778044A0000|164 185|complexity climate model
P11778044A0000|203 213|diagnostics
P11778044A0000|222 240|climate observations
P11778804A0179|0 8|Frequency
P11778804A0179|17 22|curves
P11778804A0179|41 46|method
P11781615A0000|24 30|disease
P11781615A0000|31 35|cGVHD
P11781615A0000|44 55|complication
P11781615A0000|81 99|cell transplantation
P11782218A0349|10 23|white-on-white
P11782218A0349|29 37|perimetry
P11782218A0349|71 81|variability
P11782218A0349|98 107|estimation
P11782218A0349|110 118|threshold
P11782218A0349|125 139|media absorption
P11782218A0349|149 167|examination duration
P11782218A0349|183 196|learning effect
P11783457A0000|0 12|Preservatives
P11783457A0000|27 35|component
P11783457A0000|48 59|preparations
P11783457A0000|82 89|activity
P11783457A0000|95 100|bottle
P11783457A0000|114 126|decomposition
P11785085X0001|11 18|analysis
P11785085X0001|28 37|techniques
P11785085X0001|49 56|drainage
P11785085X0001|59 66|patients
P11785085X0001|89 99|prostatitis
P11785085X0001|103 110|efficacy
P11785085X0001|122 129|drainage
P11785085X0001|148 163|vacuum aspiration
P11785085X0001|164 175|Introl-4 unit
P11785085X0001|190 207|pneumovibromassage
P11785085X0001|208 215|PVM-R-01
P11785085X0001|233 240|patients
P11785085X0001|263 273|prostatitis
P11785827A0986|3 9|results
P11785827A0986|24 31|relation
P11785827A0986|44 49|models
P11785827A0986|57 67|propagation
P11785827A0986|71 80|physiology
P11785827A0986|117 127|degradation
P11785827A0986|135 140|forest
P11785827A0986|154 170|selection pressure
P11785827A0986|174 189|transmissibility
P11785827A0986|197 209|communication
P11786248A1162|0 10|Consumption
P11786248A1162|13 20|% sucrose
P11786248A1162|48 54|lesions
P11786248A1162|122 129|% sucrose
P11786248A1162|130 141|sham controls
P11786945A0958|9 15|freedom
P11786945A0958|31 41|arrhythmias
P11786945A0958|50 58|follow-up
P11786945A0958|74 79|group A
P11787041A0167|6 16|development
P11787322X0001|0 8|Influence
P11787322X0001|20 26|methods
P11787322X0001|29 48|chemical disinfection
P11787322X0001|62 71|properties
P11787322X0001|85 91|V gypsum
P11787322X0001|102 112|instruments
P11787322X0001|116 124|materials
P11787322X0001|141 154|prosthodontics
P11787322X0001|161 165|stone
P11787322X0001|177 187|impressions
P11787322X0001|201 207|records
P11787322X0001|232 241|literature
P11787322X0001|244 251|vehicles
P11787322X0001|254 265|transmission
P11787322X0001|278 285|diseases
P11787720A1313|33 40|decrease
P11787746A0374|0 9|Vitrectomy
P11787746A0374|13 19|removal
P11787746A0374|30 42|lens fragments
P11787746A0374|61 66|acuity
P11787746A0374|86 93|glaucoma
P11787746A0374|99 106|majority
P11787746A0374|109 116|patients
P11789206A1182|0 10|CONCLUSIONS
P11789206A1182|14 22|mechanism
P11789206A1182|33 44|Qi deficiency
P11789206A1182|47 57|blood stasis
P11789206A1182|76 85|principles
P11789206A1182|120 130|blood stasis
P11789216T0001|0 6|Effects
P11789216T0001|19 34|blood circulation
P11789216T0001|43 53|blood stasis
P11789216T0001|56 68|barrier action
P11789216T0001|101 109|gastritis
P11790897T0000|9 16|patterns
P11790897T0000|19 24|nipple
P11790897T0000|33 38|fluids
P11790897T0000|49 57|SELDI-TOF
P11790897T0000|58 66|potential
P11790897T0000|73 82|biomarkers
P11790897T0000|93 101|diagnosis
P11790897T0000|104 115|breast cancer
P11791292A0193|14 23|laboratory
P11791292A0193|34 44|application
P11791292A0193|53 59|network
P11791292A0193|71 77|problem
P11791571T0000|1 48|high-efficiency cross-flow micronebulizer interface
P11791571T0000|61 75|electrophoresis
P11791571T0000|97 118|plasma mass spectrometry
P11791585A0287|3 12|electrodes
P11791585A0287|123 129|surface
P11791853A0532|15 21|results
P11791853A0532|35 69|coagulation-electrooxidation process
P11791853A0532|95 99|color
P11791853A0532|130 139|wastewater
P11792586A0290|6 12|loading
P11792586A0290|38 45|activity
P11792586A0290|55 63|formation
P11792586A0290|66 76|microcracks
P11792586A0290|86 97|tissue matrix
P11793172A0545|17 23|surface
P11793172A0545|29 34|PE head
P11793172A0545|75 93|friction coefficient
P11793172A0545|135 140|PE head
P11793614A0000|0 8|OBJECTIVE
P11793614A0000|31 36|effect
P11793614A0000|50 63|concentrations
P11793614A0000|66 75|cilomilast
P11793614A0000|84 100|phosphodiesterase
P11793614A0000|102 110|inhibitor
P11793614A0000|117 125|treatment
P11793614A0000|155 161|disease
P11793614A0000|180 194|anticoagulation
P11796977T0000|0 7|Postdocs
P11796977T0000|12 19|hardship
P11796977T0000|26 39|mainland Europe
P11800119A0814|3 17|design principle
P11800119A0814|33 45|vibration mode
P11800586A1090|10 17|DPPD gene
P11800586A1090|47 53|bacilli
P11800586A1090|59 65|results
P11800586A1090|81 88|molecule
P11800586A1090|128 136|diagnosis
P11800586A1090|138 149|tuberculosis
P11800878T0000|0 13|Dynamic imaging
P11800878T0000|23 35|wave functions
P11800878T0000|40 62|ultrashort UV laser pulses
P11801459T0000|0 7|Efficacy
P11801459T0000|11 16|safety
P11801459T0000|19 25|aspirin
P11801459T0000|40 49|management
P11801459T0000|52 67|atherothrombosis
P11802580A0000|3 33|General Practice Research Database
P11802580A0000|45 49|world
P11802580A0000|57 76|computerized database
P11802580A0000|101 114|patient records
P11802580A0000|126 133|practice
P11802580A0000|152 169|health research tool
P11802601A0107|4 8|paper
P11802601A0107|19 25|results
P11802601A0107|29 43|laboratory study
P11802601A0107|46 53|aldicarb
P11802601A0107|64 74|metabolites
P11802601A0107|75 89|aldicarb sulfone
P11802601A0107|93 109|aldicarb sulfoxide
P11803325A0868|7 21|DC cardioversion
P11803325A0868|38 45|HBS group
P11803325A0868|63 70|CBC group
P11803325A0868|88 95|GIK group
P11804081A0552|5 10|August
P11804081A0552|89 98|Everglades
P11804100A0365a|17 29|disappearance
P11804100A0365a|41 45|NH3-N
P11804100A0365a|80 87|kinetics
P11804100A0365a|94 101|kinetics
P11804100A0365a|104 112|TP removal
P11804100A0365b|17 29|disappearance
P11804100A0365b|41 45|NH3-N
P11804100A0365b|80 87|kinetics
P11804100A0365b|94 101|kinetics
P11804100A0365b|104 112|TP removal
P11804510A0730|0 5|Losses
P11804510A0730|8 20|dichlofluanid
P11804510A0730|25 36|chlozolinate
P11804510A0730|43 53|etridiazole
P11804510A0730|95 104|processing
P11804510A0730|106 111|apples
P11804510A0730|142 147|levels
P11804510A0730|182 191|processing
P11806132A0253|3 13|TB incidence
P11806132A0253|19 23|AIRIN
P11806132A0253|41 51|% TB patients
P11810685A0147|16 39|displacement distribution
P11810685A0147|76 87|displacement
P11810685A0147|105 119|long-wavelength
P11810685A0147|131 136|limits
P11810685A0147|157 180|displacement distribution
P11810685A0147|189 194|DT-MRI
P11811743A0800|3 11|procedure
P11811743A0800|26 34|retention
P11811743A0800|58 67|Class III FI
P11811743A0800|71 76|manner
P11811743A0800|96 102|patient
P11811743A0800|109 117|clinician
P11811825A0972|3 9|results
P11811825A0972|23 49|cross-validation experiments
P11811825A0972|63 69|average
P11811825A0972|73 78|system
P11811825A0972|91 101|specificity
P11811825A0972|127 142|sensitivity level
P11815644A0081|11 25|characteristics
P11815644A0081|33 37|calls
P11815644A0081|47 53|species
P11815644A0081|64 73|variations
P11815644A0081|87 92|timing
P11815644A0081|96 103|patterns
P11815644A0081|117 133|muscle recruitment
P11815644A0081|140 151|echolocation
P11816458A0319|10 17|Examples
P11816458A0319|21 32|Explanations
P11816458A0319|35 41|APA Form
P11816458A0319|51 60|help system
P11816458A0319|65 72|examples
P11816458A0319|85 92|sections
P11816458A0319|96 108|review article
P11816458A0319|109 122|journal article
P11816458A0319|133 142|experiment
P11816458A0319|145 158|journal article
P11816458A0319|175 185|experiments
P11816779A0343|3 13|drug packets
P11816779A0343|23 35|acetyl aspirin
P11816779A0343|36 48|acetaminophen
P11816779A0343|52 66|chloramphenicol
P11818675X0897|0 7|Karger AG
P11818675X0897|8 12|Basel
P11819326A0000|38 43|status
P11819326A0000|53 60|patients
P11819326A0000|90 103|encephalopathy
P11819326A0000|124 130|METHODS
P11819326A0000|152 159|patients
P11819326A0000|164 172|cirrhosis
P11819326A0000|233 242|volunteers
P11821098A0269|0 17|MAIN OUTCOME MEASURE
P11821098A0269|20 30|Serum levels
P11821098A0269|44 51|inhibin A
P11822790A0907|3 10|instance
P11822790A0907|17 24|SIP score
P11822790A0907|39 45|patient
P11822790A0907|70 76|example
P11822790A0907|88 92|score
P11822790A0907|98 112|study population
P11822790A0907|159 163|items
P11822790A0907|172 182|improvement
P11822790A0907|189 208|reproducibility noise
P11822811A0319|0 4|Group
P11822811A0319|21 27|Collies
P11822811A0319|50 72|microg/kg ivermectin p.o.
P11822811A0319|101 105|hours
P11822811A0319|110 121|intoxication
P11824701A0894|0 7|Patients
P11824701A0894|29 33|event
P11824701A0894|54 69|behavior patterns
P11824701A0894|78 90|Bortner scores
P11824701A0894|95 102|patients
P11824701A0894|127 131|event
P11824801A0661|13 24|continuation
P11824801A0661|30 46|interferon therapy
P11824801A0661|52 59|presence
P11824801A0661|79 90|exacerbation
P11824801A0661|93 103|sarcoidosis
P11824801A0661|116 123|minority
P11824801A0661|126 133|patients
P11824801A0661|149 164|organ involvement
P11825801A1212|24 32|mortality
P11825801A1212|54 62|follow-up
P11825801A1212|67 72|months
P11826141T0000|11 17|effects
P11826141T0000|20 40|lidocaine inactivation
P11826141T0000|46 52|rostral
P11826141T0000|73 80|amygdala
P11826141T0000|86 96|maintenance
P11826141T0000|100 112|reinstatement
P11826141T0000|130 137|behavior
P11828186A0239|3 12|population
P11828186A0239|45 49|women
P11828186A0239|58 62|years
P11828186A0239|78 89|heart disease
P11828186A0239|96 110|CRP measurements
P11828186A0239|116 134|Third National Health
P11828186A0239|138 163|Nutrition Examination Survey
P11828186A0239|164 172|NHANES III
P11830544A0335|0 8|Herceptin
P11830544A0335|27 31|HER-2
P11830544A0335|31 40|neu antigen
P11830544A0335|69 75|1B4M-Gd
P11830544A0335|107 118|WIBC-9 tumors
P11830544A0335|139 155|control MC-5 tumors
P11830544A0335|178 189|angiogenesis
P11831512A0468|80 89|treatments
P11831512A0468|88 94|control
P11831512A0468|99 105|lactose
P11831512A0468|111 128|carbohydrate source
P11831512A0468|130 136|lactose
P11831512A0468|169 186|dextrose equivalent
P11831512A0468|194 200|lactose
P11831512A0468|212 216|DE-42
P11832019A0668|0 10|CONCLUSIONS
P11832019A0668|44 59|emergency disease
P11833863A0987|10 19|difference
P11833863A0987|22 34|apnea duration
P11833863A0987|45 50|supine
P11833863A0987|59 67|positions
P11834476A1187|17 27|animal model
P11834476A1187|44 51|ischemia
P11834476A1187|59 69|transfusion
P11834476A1187|88 95|ischemia
P11834476A1187|117 137|hemoglobin transfusion
P11834476A1187|148 162|oxygen transport
P11834476A1187|176 181|cortex
P11834476A1187|188 195|increase
P11834476A1187|232 241|protection
P11835109A0000|40 48|awareness
P11835109A0000|54 63|importance
P11835109A0000|91 97|quality
P11835109A0000|114 121|patients
P11835109A0000|142 150|disorders
P11835109A0000|169 174|trials
P11836046A0549|49 64|calcium carbonate
P11836046A0549|82 88|calcium
P11836046A0549|112 116|times
P11836046A0549|121 126|group A
P11836046A0549|132 147|calcium carbonate
P11836046A0549|156 161|manner
P11836046A0549|171 176|mg/day
P11836046A0549|195 202|estrogen
P11836046A0549|207 227|mg medrogestone acetate
P11836046A0549|245 249|month
P11836046A0549|249 254|group B
P11836303A0518|0 7|TNFalpha
P11836303A0518|11 20|IL-6 levels
P11836303A0518|40 58|culture supernatants
P11836303A1191|13 17|study
P11836303A1191|45 55|disturbance
P11836303A1191|73 78|change
P11836303A1191|81 95|cytokine biology
P11836303A1191|136 140|stage
P11837409A0584|20 44|National Longitudinal Study
P11837409A0584|47 62|Adolescent Health
P11837409A0584|68 74|measure
P11837409A0584|87 100|symptomatology
P11837409A0584|116 123|interval
P11838058A0084|0 6|METHODS
P11838058A0084|8 12|cases
P11838058A0084|39 53|tissue expansion
P11838058A0084|64 68|cases
P11838058A0084|99 113|tissue expansion
P11838058A0084|136 140|study
P11838102T0001|0 6|Wegener
P11838102T0001|8 21|granulomatosis
P11840365A0949|20 25|effect
P11840365A0949|28 37|hematocrit
P11840365A0949|43 60|General Health scale
P11840365A0949|66 70|SF-36
P11842037A0327|15 24|precisions
P11842037A0327|27 49|% urine-plasma difference
P11842037A0327|68 72|value
P11842728X0001|18 32|schistosomiasis
P11842728X0001|33 46|Schistosomosis
P11842728X0001|59 66|diseases
P11842728X0001|75 85|blood flukes
P11842728X0001|91 106|Schistosoma genus
P11843252A0907|7 18|response rate
P11843252A0907|27 45|% confidence interval
P11843252A0907|78 85|survival
P11843252A0907|87 92|months
P11844591A0329|17 25|parameter
P11844591A0329|30 34|angle
P11844591A0329|44 53|peak torque
P11844812A0915|12 21|ng/mL model
P11844812A0915|35 45|ANN ROC curve
P11844812A0915|83 92|percentage
P11844812A0915|111 116|PSA-TZ
P11844812A0915|126 135|PSA density
P11844812A0915|143 156|prostate volume
P11845547A0449|9 18|treatments
P11845547A0449|26 35|dobutamine
P11845547A0449|36 56|KATP channel activators
P11845547A0449|60 75|21-aminosteroids
P11846167A0000|0 7|Selenium
P11846167A0000|21 27|element
P11846167A0000|31 36|humans
P11846167A0000|37 43|animals
P11846167A0000|51 57|species
P11846167A0000|60 73|microorganisms
P11846187A0894|3 21|GT-foreign-pictures
P11846187A0894|35 42|judgment
P11846187A0894|50 57|subjects
P11846187A0894|81 102|permeability directions
P11847580T0000|13 25|cholecystitis
P11847580T0000|37 44|findings
P11849417A0900|27 32|groups
P11849417A0900|67 73|RESULTS
P11849417A0900|79 88|initiation
P11849417A0900|91 108|dialysis PD patients
P11849417A0900|127 131|years
P11849417A0900|153 162|HD patients
P11849796A0452|0 6|RESULTS
P11849796A0452|10 19|target dose
P11849796A0452|38 43|3D-CRT
P11849796A0452|47 55|IMRT plans
P11849796A0452|64 75|improvements
P11849796A0452|100 109|IMRT fields
P11851941A0372|32 49|serumalbumin method
P11851941A0372|61 71|blood volume
P11851941A0372|77 89|haemodilution
P11851941A0372|117 127|haemoglobin
P11851941A0372|130 139|comparison
P11851941A0372|145 161|reference solution
P11851941A0372|164 181|hydroxyethyl starch
P11852907A0871|3 30|equilibrium phosphorus content
P11852907A0871|39 49|surface soil
P11852907A0871|74 83|SRP content
P11852907A0871|86 98|drainage water
P11852907A0871|113 117|order
P11852907A0871|119 127|magnitude
P11853943A0122|12 21|prediction
P11853943A0122|33 41|algorithm
P11853943A0122|45 65|R-R interval estimation
P11858256A0102|19 26|research
P11858256A0102|29 39|explanation
P11858256A0102|46 51|effect
P11858548A0241|3 11|structure
P11858548A0241|33 37|study
P11858548A0241|65 74|NMR spectra
P11858548A0241|77 92|mass spectrometry
P11858635A0896|27 34|property
P11858635A0896|37 46|QSAR models
P11858635A0896|61 79|LOO cross-validation
P11859400A0229|13 20|efficacy
P11859400A0229|24 28|costs
P11859400A0229|31 42|valacyclovir
P11859400A0229|55 69|HSV reactivation
P11859400A0229|102 130|progenitor cell transplantation
P11859400A0229|136 143|patients
P11859400A0229|157 164|controls
P11859400A0229|182 190|acyclovir
P11859400A0229|195 208|HSV prophylaxis
P11859943A0150|3 8|adults
P11859943A0150|21 37|outpatient clinics
P11859943A0150|55 62|hospital
P11859943A0150|103 128|General Health Questionnaire
P11860097A1695|8 20|prosthesis use
P11860097A1695|52 56|study
P11860097A1695|91 97|outcome
P11860097A1695|101 115|prosthesis users
P11860097A1695|119 127|non-users
P11860723A0182|1 10|mail survey
P11860723A0182|13 26|Georgia members
P11860723A0182|32 46|American College
P11860723A0182|49 61|Obstetricians
P11860723A0182|65 77|Gynecologists
P11860876A0409|0 12|HIV-1 C subtype
P11861092A0730|5 11|plateau
P11861092A0730|14 24|enhancement
P11861092A0730|42 47|lesion
P11861092A0730|54 60|patient
P11861092A0730|98 110|scanning modes
P11861092A0730|126 130|scale
P11861092A0730|147 159|colour Doppler
P11861092A0730|175 186|power Doppler
P11861092A0730|209 213|scale
P11861092A0730|226 238|inversion mode
P11861092A0730|250 263|HDI5000 scanner
P11861092A0730|266 274|C5-2 probe
P11861092A0730|280 286|Bothell
P11862350T0000|12 16|study
P11862350T0000|22 28|effects
P11862350T0000|31 43|carbamazepine
P11862350T0000|50 81|NMDA receptor antagonist remacemide
P11862350T0000|84 95|road tracking
P11862350T0000|112 122|performance
P11862350T0000|131 137|traffic
P11863811A0259|21 33|Nusselt number
P11863811A0259|59 63|range
P11863811A0259|81 90|experiment
P11864173T0000|16 24|pathogens
P11864173T0000|27 32|causes
P11864173T0000|47 59|exacerbations
P11864173T0000|68 77|bronchitis
P11865218A0069|0 8|Treatment
P11865218A0069|16 24|condition
P11865218A0069|46 57|wax softening
P11865218A0069|69 73|agent
P11866130A0419|2 9|addition
P11866130A0419|10 19|benzocaine
P11866130A0419|23 38|2-phenoxyethanol
P11866130A0419|48 65|complement activity
P11866130A0419|69 80|phagocytosis
P11866130A0419|86 90|MS222
P11866130A0419|94 111|quinaldine sulphate
P11867388A0502|11 21|suppression
P11867388A0502|32 37|memory
P11867388A0502|41 53|concentration
P11867388A0502|64 69|memory
P11867388A0502|78 93|fear conditioning
P11867388A0502|95 101|context
P11867388A0502|154 169|fear conditioning
P11870646A0668|3 9|utility
P11870646A0668|16 23|analyses
P11870646A0668|29 34|design
P11870646A0668|37 67|ceramic/substrate bilayer systems
P11870646A0668|78 87|resistance
P11870646A0668|110 115|damage
P11872359A0000|21 37|insulin resistance
P11872359A0000|52 58|cluster
P11872359A0000|74 80|disease
P11872359A0000|86 96|risk factors
P11872359A0000|118 125|syndrome
P11872359A0000|167 171|cause
P11872359A0000|182 190|mortality
P11872359A0000|206 216|Australians
P11872570T0000|0 7|Dementia
P11873003X0000|0 13|HIV-1 infection
P11873003X0000|21 26|Africa
P11873003X0000|35 44|difference
P11873003X0000|70 77|survival
P11873003X0000|108 116|countries
P11873003X0000|139 148|OBJECTIVES
P11873003X0000|162 177|progression times
P11873003X0000|180 193|HIV-1 infection
P11873003X0000|198 211|seroconversion
P11873003X0000|225 229|death
P11873003X0000|265 269|death
P11873003X0000|275 280|Uganda
P11874637A0212|36 42|therapy
P11874637A0212|42 46|HAART
P11874637A0212|71 82|improvements
P11874637A0212|88 96|treatment
P11874637A0212|99 110|HIV infection
P11874637A0212|121 128|decrease
P11874637A0212|134 142|incidence
P11874637A0212|146 153|severity
P11874637A0212|177 194|deficiency syndrome
P11874637A0212|207 218|malignancies
P11875695A0718|8 18|progression
P11875695A0718|22 27|months
P11875695A0718|31 36|months
P11875695A0718|48 55|survival
P11875695A0718|60 71|registration
P11875695A0718|77 82|months
P11875695A0718|94 99|months
P11876937A0261|0 6|Heparin
P11876937A0261|70 75|H group
P11876937A0261|85 90|saline
P11876937A0261|100 105|N group
P11879108A0719|0 17|MAIN OUTCOME MEASURE
P11879108A0719|29 38|test result
P11879108A0719|63 71|infection
P11879108A0719|77 100|ligase chain reaction assay
P11879108A0719|110 123|outcome measure
P11879108A0719|136 145|test result
P11879108A0719|154 174|immunodeficiency virus
P11881268A0000|3 9|purpose
P11881268A0000|16 20|study
P11881268A0000|65 98|exercise self-efficacy questionnaire
P11881268A0000|122 126|women
P11881923A1256|0 9|Neutrophil
P11881923A1256|9 23|lymphocyte ratio
P11881923A1256|24 40|plasma haptoglobin
P11881923A1256|44 52|CBG levels
P11881923A1256|88 93|period
P11881923A1256|113 123|POST periods
P11881923A1256|145 154|treatments
P11882054A0568|15 21|lesions
P11882054A0568|50 59|structures
P11882054A0568|60 69|FMZ binding
P11882054A0568|87 91|pairs
P11882054A0568|108 114|regions
P11882054A0568|117 124|interest
P11882054A0568|159 164|slices
P11882054A0568|189 200|lesion volume
P11882054A0568|207 218|mirror region
P11882054A1250|13 23|correlation
P11882054A1250|39 47|decreases
P11882054A1250|50 59|FMZ binding
P11882054A1250|63 77|spiking activity
P11882054A1250|114 123|epilepsies
P11882054A1250|145 154|FMZ binding
P11882054A1250|166 173|relation
P11882054A1250|179 188|mechanisms
P11882054A1250|191 205|epileptogenesis
P11882054A1250|219 228|epilepsies
P11882747A0354|25 44|Farnsworth D-15 method
P11883682A0162|18 27|monitoring
P11883682A0162|43 47|spill
P11883682A0162|58 69|distribution
P11883682A0162|77 82|metals
P11883682A0162|88 105|estuarine sediments
P11883763A1062|8 13|fluxes
P11883763A1062|59 67|transport
P11883763A1062|69 77|particles
P11883763A1062|104 108|slope
P11883763A1062|125 129|layer
P11883763A1062|171 181|Pu transport
P11883763A1062|198 202|slope
P11883763A1062|208 219|East China Sea
P11884014A0665|8 25|treatment protocols
P11884014A0665|29 40|diet delivery
P11884014A0665|66 72|effects
P11885053A1897|29 34|Volkan
P11885053A1897|36 41|groups
P11885053A1897|51 57|objects
P11885053A1897|109 115|objects
P11885053A1897|133 146|memorial shrine
P11885737A1713|3 7|range
P11885737A1713|25 42|spermatozoa/microl
P11885737A1713|66 75|compromise
P11885737A1713|83 90|criteria
P11886473A0796|0 13|Gastritis score
P11886473A0796|47 54|children
P11886473A0796|122 127|corpus
P11886473A0796|122 127|antrum
P11887803A1455|3 15|mean thickness
P11887803A1455|29 38|peritoneum
P11887803A1455|58 63|groups
P11887803A1455|66 72|animals
P11887803A1455|101 108|fibrosis
P11887803A1455|122 131|peritoneum
P11887803A1455|170 176|animals
P11887803A1455|193 199|Balance
P11888183A0541|8 15|analysis
P11888183A0541|40 45|series
P11888183A0541|48 63|maximum intensity
P11888183A0541|72 79|duration
P11888183A0541|106 111|maxima
P11888867A0000|0 9|BACKGROUND
P11888867A0000|44 53|serum level
P11888867A0000|56 62|TA90-IC
P11888867A0000|71 77|complex
P11888867A0000|103 109|antigen
P11888867A0000|116 123|antibody
P11888867A0000|145 155|correlation
P11888867A0000|160 169|recurrence
P11888867A0000|173 180|survival
P11888867A0000|183 190|patients
P11888867A0000|207 215|melanomas
P11890354A0000|0 16|Genetics Institute
P11890354A0000|40 49|oprelvekin
P11890354A0000|50 56|rhIL-11
P11890354A0000|57 63|Neumega
P11890354A0000|89 93|IL-11
P11890438A0838|0 7|Patients
P11890438A0838|33 38|clinic
P11890438A0838|60 65|wounds
P11890438A0838|75 83|dressings
P11893403A0252|0 7|Elements
P11893403A0252|31 46|safety evaluation
P11893403A0252|49 65|flavor ingredients
P11893403A0252|73 80|exposure
P11893403A0252|91 97|analogy
P11893403A0252|98 107|metabolism
P11893403A0252|108 123|pharmacokinetics
P11893403A0252|127 136|toxicology
P11893767A0356|23 39|minute ventilation
P11893767A0356|60 69|equivalent
P11893767A0356|118 133|breathing pattern
P11894605A1429|0 13|INTERPRETATION
P11894605A1429|42 51|dissonance
P11894605A1429|65 81|health information
P11894605A1429|84 90|smoking
P11894605A1429|116 125|motivation
P11894605A1429|145 150|result
P11894605A1429|162 168|changes
P11894605A1429|174 179|amount
P11894605A1429|183 189|content
P11894605A1429|192 202|advertising
P11895024A1054|4 8|cases
P11895024A1054|48 62|AFP surveillance
P11895024A1054|78 93|hospital searches
P11895184A0000|3 9|ability
P11895184A0000|22 28|control
P11895184A0000|41 47|lesions
P11895184A0000|57 68|object-place
P11895184A0000|69 78|odor-place
P11895184A0000|128 151|cheeseboard maze apparatus
P11897449A0566|3 7|shift
P11897449A0566|21 34|activation site
P11897449A0566|40 53|administration
P11897449A0566|56 62|esmolol
P11897449A0566|81 85|shift
P11897449A0566|113 119|RESULTS
P11897449A0566|123 131|heart rate
P11897449A0566|154 158|state
P11897449A0566|179 187|beats/min
P11897449A0566|199 207|beats/min
P11897888A0590|0 11|Urine samples
P11897888A0590|29 42|administration
P11897888A0590|50 60|supplements
P11897950A0617|0 10|CONCLUSIONS
P11897950A0617|11 28|Lymphoscintigraphy
P11897950A0617|34 56|cynomolgus monkey eyelids
P11897950A0617|81 96|drainage pathways
P11897950A0617|116 122|eyelids
P11897950A0617|131 137|pathway
P11897950A0617|156 161|eyelid
P11898018T0000|0 13|Data management
P11898018T0000|30 37|research
P11898797A0124|31 36|levels
P11898797A0124|39 70|choline acetyltransferase activity
P11898797A0124|84 89|cortex
P11898797A0124|92 99|patients
P11898797A0124|113 122|head injury
P11898797A0124|175 185|innervation
P11899479A0122|11 16|smears
P11899479A0122|21 27|lesions
P11899479A0122|37 42|mucosa
P11899479A0122|43 48|tongue
P11899479A0122|49 54|cheeks
P11899479A0122|55 60|palate
P11899479A0122|77 90|denture surface
P11899479A0122|93 107|cotton wool swabs
P11899479A0122|139 149|glucose agar
P11899479A0122|153 168|CHROMagar Candida
P11899479A0122|179 190|yeast species
P11899479A0122|208 215|germ tube
P11899479A0122|230 246|assimilation tests
P11899479A0122|269 280|kit AuxaColor
P11899489A0119|3 9|effects
P11899489A0119|27 35|treatment
P11899489A0119|60 66|support
P11899489A0119|80 87|dementia
P11899489A0119|107 111|stage
P11900770T0000|19 28|incentives
P11900770T0000|29 39|attenuation
P11900770T0000|54 59|impact
P11900770T0000|66 91|dopamine receptor antagonism
P11902068T0000|3 12|CKD patient
P11902068T0000|14 20|journey
P11902738A0185|0 7|PATIENTS
P11902738A0185|11 17|METHODS
P11902738A0185|22 26|study
P11902738A0185|43 53|cohort study
P11902738A0185|59 66|children
P11902738A0185|71 76|cancer
P11902738A0185|94 104|institution
P11902738A0185|109 113|fever
P11902738A0185|117 127|neutropenia
P11902738A0185|147 161|neutrophil count
P11902738A0185|166 174|cells/mm3
P11902738A0185|184 189|period
P11902781A0550|0 13|Concentrations
P11902781A0550|37 45|Deoprayag
P11902781A0550|102 107|season
P11904017A0000|26 32|process
P11904017A0000|49 57|blood flow
P11904017A0000|128 133|region
P11904017A0000|151 156|system
P11907691A0214|3 14|orientations
P11907691A0214|20 34|contact surfaces
P11907691A0214|43 51|locations
P11907691A0214|65 70|object
P11907691A0214|72 77|center
P11908529A0553|3 9|results
P11908529A0553|26 31|number
P11908529A0553|33 37|stars
P11908529A0553|46 51|charge
P11908529A0553|62 71|comparison
P11908529A0553|80 88|detectors
P11908529A0553|89 96|plastics
P11908529A0553|97 108|AgCl crystals
P11908529A0553|114 123|energy loss
P11908529A0553|126 131|region
P11908529A0553|147 153|objects
P11909404A0000|5 11|domains
P11909404A0000|15 21|regions
P11909404A0000|28 35|function
P11910310A0279|0 5|DESIGN
P11910310A0279|49 53|trial
P11910344A1119|0 10|CONCLUSIONS
P11910344A1119|40 44|study
P11910344A1119|56 63|patients
P11910344A1119|113 120|function
P11910344A1119|137 144|increase
P11910344A1119|147 154|survival
P11911552A0776|2 9|patients
P11911552A0776|22 31|quetiapine
P11911552A0776|32 38|therapy
P11911552A0776|87 95|remission
P11911552A0776|104 108|range
P11912261A0284|12 17|agents
P11912261A0284|33 44|PTH secretion
P11912261A0284|75 82|receptor
P11912261A0284|99 104|glands
P11912261A0284|116 125|experience
P11912677A0281|8 15|analysis
P11912677A0281|26 35|hypotheses
P11912677A0281|44 52|structure
P11912677A0281|61 71|variability
P11912677A0281|84 90|data set
P11913427A0290|3 10|subjects
P11913427A0290|55 59|value
P11913427A0290|62 74|accelerations
P11913427A0290|96 100|error
P11915436A0491|11 24|incidence rates
P11915436A0491|47 51|rates
P11915436A0491|64 73|population
P11917061A0922|7 15|predictor
P11917061A0922|18 25|response
P11917061A0922|28 37|tacrolimus
P11917061A0922|50 57|response
P11917061A0922|60 70|cyclosporin
P11917061A0922|74 83|prednisone
P11917061A0922|110 118|remission
P11917061A0922|119 131|remission rate
P11917882A0326|21 25|study
P11917882A0326|44 52|interface
P11917882A0326|59 67|selection
P11917882A0326|70 76|dentine
P11917882A0326|85 91|systems
P11917882A0326|119 135|adhesion-strategy
P11920455X1195|0 8|Copyright
P11920455X1195|13 33|American Cancer Society
P11920455X1195|53 58|.10318
P11920896A0298|6 10|study
P11920896A0298|70 79|population
P11920896A0298|101 105|women
P11921126A1196|15 20|PDQ-39
P11921126A1196|21 27|STN-DBS
P11921126A1196|58 64|aspects
P11921126A1196|74 81|patients
